This classification denotes a therapeutic glucocorticoid with the molecular formula C21H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WDT5SLP0HQ, chemically known as 17,21-dihydroxyprogesterone but generally known as 11-desoxy-17-hydroxycorticosterone, which bears US NIH Compound Identifier 9050. European Medicines Agency schedules Cortodoxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06810MIG. The term 11-DESOXY-17-HYDROXYCORTICOSTERONE is an International Non-Proprietary Name. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)C(=O)CO.
This classification denotes a steroidal estrogen with the molecular formula C18H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8XZ32LI44K, chemically known as 3,16beta,17beta-trihydroxy-1,3,5(10)-estratriene but generally known as 16-epiestriol, which bears US NIH Compound Identifier 3269. European Medicines Agency schedules Epiestriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06565MIG. The term EPIESTRIOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). SMILES: CC12CCC3C(C1CC(C2O)O)CCC4=C3C=CC(=C4)O.
This classification denotes an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but generally known as codeine, which bears US NIH Compound Identifier 223652. European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification. 3-methylmorphine or codeine bears US NLM identifiers UMLS ID C0009214 and NCI Concept Code C383. SMILES: S(=O)(=O)(O)O.O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)C=CC2O.
This classification denotes a dermatologic agent and sunscreen with the molecular formula C7H7NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TL2TJE8QTX, chemically known as 4-aminobenzoic acid but generally known as Aminobenzoic acid, which bears US NIH Compound Identifier 978. European Medicines Agency schedules Para-aminobenzoic in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21105. World Health Organization schedules aminobenzoic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1=CC(=CC=C1C(=O)O)N.
This classification denotes a topical anti-infective agent with the molecular formula C9H5Br2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UK4C618C8T, chemically known as 5,7-dibromooxine but generally known as broxyquinoline, which bears US NIH Compound Identifier 2453. European Medicines Agency schedules Broxyquinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05940MIG. The term BROXYQUINOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules broxyquinoline in its Anatomical Therapeutic Chemical (ATC) Classification. BROXYQUINOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: BRC1C2C(NCCC2)C(O)C(BR)C1.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but generally known as abacavir, which bears US NIH Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine. European Medicines Agency schedules Abacavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07356MIG. The term ABACAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). World Health Organization schedules abacavir in its Anatomical Therapeutic Chemical (ATC) Classification. ABACAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abacavir under HS 29335995 and SITC 51576. As of Q4 2014, ABACAVIR remains the US FDA Preferred Term for this commodity. Abacavir bears US NLM identifiers UMLS ID C0663655 and NCI Concept Code C61523. SMILES: OCC1CC(N2C3NC(NC(NC4CC4)C3NC2)N)C=C1.
This classification denotes a combination drug for treatment of HIV. The first component, ABACAVIR, has US FDA Unique Ingredient Identifier of WR2TIP26VS. The second component, DOLUTEGRAVIR, has US FDA Unique Ingredient Identifier of DKO1W9H7M1. The third component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS. The first component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but more generally known as abacavir, which bears U.S. National Institutes of Health Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine. The European Medicines Agency schedules Abacavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07356MIG. The term ABACAVIR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 3 1997, List 38). The World Health Organization schedules abacavir in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but more generally known as lamivudine, which bears U.S. National Institutes of Health Compound Identifier 60825. The European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG. The term LAMIVUDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). The World Health Organization schedules lamivudine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS. The first component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but more generally known as abacavir, which bears U.S. National Institutes of Health Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine. The European Medicines Agency schedules Abacavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07356MIG. The term ABACAVIR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 3 1997, List 38). The World Health Organization schedules abacavir in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but more generally known as lamivudine, which bears U.S. National Institutes of Health Compound Identifier 60825. The European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG. The term LAMIVUDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). The World Health Organization schedules lamivudine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a reverse transcriptase inhibitor, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4B9XT59T7S. The European Medicines Agency schedules Zidovudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00153MIG. Zidovudine generally arises in the molecular formula C10H13N5O4. The term ZIDOVUDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 1, no. 4, 1987, list 27.)
This classification denotes a reverse transcriptase inhibitor, in succinate form, with the molecular formula C14H18N6O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40FH6D8CHK, chemically known as butanedoic acid, compd. with (1s,4r)-4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol (1:1) but more generally known as abacavir succinate, which bears US NIH Compound Identifier 65139. The base compound, abacavir, also appears in sulfate form, and is sometimes combined with lamivudine and zidovudine. European Medicines Agency schedules Abacavir succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25392. Most nations, for tariff and trade purposes, schedule abacavir succinate under HS 29335995 and SITC 51576. As of Q4 2014, ABACAVIR SUCCINATE remains US FDA's Preferred Term for this commodity. Abacavir succinate bears US NLM identifiers UMLS ID C2346706 and NCI Concept Code C71608. SMILES: C1NC2C(NC(NC2N1[C@@H]3C[C@@H](C=C3)CO)N)NC4CC4.C(CC(=O)O)C(=O)O.
This classification denotes a reverse transcriptase inhibitor, in sulfate form, with the molecular formula 2C14H18N6O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J220T4J9Q2, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, sulfate (salt)(2:1), (1s,4r)- but more generally known as abacavir sulfate, which bears US NIH Compound Identifier 65141. The base compound, abacavir, also appears in succinate form, and is sometimes combined with lamivudine and zidovudine. European Medicines Agency schedules Abacavir sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00231MIG. Most nations, for tariff and trade purposes, schedule abacavir sulfate under HS 29335995 and SITC 51576. As of Q4 2014, ABACAVIR SULFATE remains US FDA's Preferred Term for this commodity. Abacavir sulfate bears US NLM identifiers UMLS ID C0724515 and NCI Concept Code C28804. SMILES: C1NC2C(NC(NC2N1[C@@H]3C[C@@H](C=C3)CO)N)NC4CC4.C1NC2C(NC(NC2N1[C@@H]3C[C@@H](C=C3)CO)N)NC4CC4.OS(=O)(=O)O.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C22H25N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F738MWY53L, chemically known as 4-quinolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)-6,7-dimethoxy-, monomethanesulfonate but generally known as abanoquil, which bears US NIH Compound Identifier 164088. Abanoquil also appears in mesilate or mesylate form. European Medicines Agency schedules Abanoquil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07358MIG. The term ABANOQUIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). ABANOQUIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abanoquil under HS 29334990 and SITC 51575. As of Q4 2014, ABANOQUIL remains the US FDA Preferred Term for this commodity. Abanoquil bears US NLM identifiers UMLS ID C0165215 and NCI Concept Code C72566. SMILES: S(=O)(=O)(O)C.O(C1CC2CCN(CC2CC1OC)C1NC2C(C(N)C1)CC(OC)C(OC)C2)C.
This classification denotes an antipsychotic agent with the molecular formula C25H25FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40755Z8956, chemically known as 7-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3-(hydroxymethyl)-4h-1-benzopyran-4-one but generally known as abaperidone, which bears US NIH Compound Identifier 3037308. Abaperidone most often appears in forms base and hydrochloride. European Medicines Agency schedules Abaperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00232MIG. The term ABAPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule abaperidone under HS 29349990 and SITC 51579. As of Q4 2014, ABAPERIDONE remains the US FDA Preferred Term for this commodity. Abaperidone bears US NLM identifiers UMLS ID C0762225 and NCI Concept Code C73280. SMILES: FC1CC2ONC(C3CCN(CC3)CCCOC3CC4OCC(C(=O)C4CC3)CO)C2CC1.
This classification denotes a gonadotropin releasing hormone inhibitor with the molecular formula C72H95ClN14O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W486SJ5824, chemically known as d-alaninamide, n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-n-methyl-l-tyrosyl-d-asparaginyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl- 10 but generally known as abarelix, which bears US NIH Compound Identifier 16131215. European Medicines Agency schedules Abarelix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07359MIG. The term ABARELIX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules abarelix in its Anatomical Therapeutic Chemical (ATC) Classification. ABARELIX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abarelix under HS 29371900 and SITC 54154. As of Q4 2014, ABARELIX remains the US FDA Preferred Term for this commodity. Abarelix bears US NLM identifiers UMLS ID C1174732 and NCI Concept Code C2015. SMILES: CLC1CCC(CC(NC(=O)C(NC(=O)C)CC2CC3C(CC2)CCCC3)C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(C)C(=O)N)CCCCNC(C)C)CC(C)C)CC(=O)N)CC2CCC(O)CC2)C)CO)CC2CCCNC2)CC1.
This classification denotes an immunosuppressant with the molecular formula C1965H3080N479O695S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D0YB67S97, more generally known as abatacept. European Medicines Agency schedules abatacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20635. The term ABATACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, list 53. Most nations, for tariff and trade purposes, schedule Abatacept under HS 30021095 and SITC 54163 (for the most current information on WCO designations on abatacept and salts thereof, please see Committee proceedings HSC/37, NC1059B2b Ann. O/3, 2006). As of Q4 2014, ABATACEPT remains US FDA's Preferred Term for this commodity. Abatacept bears US NLM identifiers UMLS ID C1619966 and NCI Concept Code C28898.
This classification denotes a monoclonal antibody with the molecular formula C2101H3229N551O673S15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X85G7936GV, more generally known as abciximab. European Medicines Agency schedules abciximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00233MIG. The term ABCIXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 13 no. 1, 1999, list 41. ABCIXIMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abciximab under HS 30021091 and SITC 54163. As of Q4 2014, ABCIXIMAB remains the US FDA Preferred Term for this commodity. Abciximab bears US NLM identifiers UMLS ID C0288672 and NCI Concept Code C76128. SMILES: NONE.
This classification denotes an anxiolytic with the molecular formula C24H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IZM1PNJ3JL, chemically known as 9h-pyrido(3,4-b)indole-3-carboxylic acid, 1-(methoxymethyl)-6-(phenylmethoxy)-, 1-methylethyl ester but generally known as abecarnil, which bears US NIH Compound Identifier 65914. European Medicines Agency schedules Abecarnil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07360MIG. The term ABECARNIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). ABECARNIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abecarnil under HS 29339990 and SITC 51577. As of Q4 2014, ABECARNIL remains the US FDA Preferred Term for this commodity. Abecarnil bears US NLM identifiers UMLS ID C0050360 and NCI Concept Code C76501. SMILES: O(C1CC2C3C([NH]C2CC1)CNC(C3COC)C(=O)OC(C)C)CC1CCCCC1.
Abemaciclib is a drug for the treatment of advanced or metastatic breast cancers.
This classification denotes an immunosuppressant, a biological preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F5Y7739G6U. World Health Organization schedules abetimus in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule abetimus under HS 29349990 and SITC 51579. As of Q4 2014, ABETIMUS remains US FDA's Preferred Term for this commodity. For the most current information on WCO designations on abetimus and salts thereof, please see Committee proceedings HSC/53, NC2004B1b Ann. O/6 (2014).
This classification denotes a natural product and a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K304VI98I3, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 18032 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Gymnospermae, Class Pinopsida, Order Pinales, Family Pinaceae, Genus Abies Mill., and Species Abies balsamea but generally known as ABIES BALSAMEA and secretions thereof. Abies balsamea bears the USDA PLANTS Identifiers ABBA, ABBAB, ABBAP, and ABLAL. European Medicines Agency schedules abies in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30006.
This classification denotes an anti-androgen with the molecular formula C24H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G819A456D0, chemically known as 17-(3-pyridyl)androsta-5,16-dien-3beta-ol but generally known as abiraterone, which bears US NIH Compound Identifier 132971. Abiraterone most often appears in forms base and acetate. European Medicines Agency schedules Abiraterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07361MIG. The term ABIRATERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10 No. 3, 1996, List 36). ABIRATERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abiraterone under HS 29372900 and SITC 54153. As of Q4 2014, ABIRATERONE remains the US FDA Preferred Term for this commodity. Abiraterone bears US NLM identifiers UMLS ID C0754011 and NCI Concept Code C77333. SMILES: OC1CC2=CCC3C(C2(CC1)C)CCC1(C3CC=C1C1CCCNC1)C.
This classification denotes an anti-asthmatic agent with the molecular formula C28H34O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 000TKM5BBQ, chemically known as 2h-1-benzopyran-2-carboxylic acid, 6-acetyl-7-((5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl)oxy)-3,4-dihydro-, (+-)- but generally known as ablukast, which bears US NIH Compound Identifier 57109. Ablukast most often appears in sodium form. European Medicines Agency schedules Ablukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07363MIG. The term ABLUKAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). ABLUKAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ablukast under HS 29329985 and SITC 51569. As of Q4 2014, ABLUKAST remains the US FDA Preferred Term for this commodity. Ablukast bears US NLM identifiers UMLS ID C0073512 and NCI Concept Code C74132. SMILES: O1C(CCC2C1CC(OCCCCCOC1C(CCC)C(O)C(CC1)C(=O)C)C(C2)C(=O)C)C(=O)O.
This classification denotes an anti-asthmatic agent with the molecular formula C28H33O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37BXZ0J2RT, chemically known as 2h-1-benzopyran-2-carboxylic acid, 6-acetyl-7-((5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl)oxy)-3,4-dihydro-, monosodium salt, ( -); but more generally known as ablukast sodium, which bears US NIH Compound Identifier 57108. Most nations, for tariff and trade purposes, schedule ablukast sodium under HS 29329985 and SITC 51569. As of Q4 2014, ABLUKAST SODIUM remains US FDA's Preferred Term for this commodity. Ablukast sodium bears US NLM identifiers UMLS ID C2827073 and NCI Concept Code C83514. SMILES: CCCC1C(CCC(C1O)C(=O)C)OCCCCCOC2CC3C(CC2C(=O)C)CCC(O3)C(=O)[O-].[NA+].
This classification denotes a peripherally-acting muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E211KPY694.
This classification denotes a natural product and plant extract, also known as absinth sagewort, absinth wormwood, absinthium, and common sagewort, which the Integrated Taxonomic Information System classifies and recognizes under Taxonomic Serial Number 35445. European Medicines Agency schedules absinthium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12702MIG. SMILES: n/a.
This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6EH821150I. European Medicines Agency schedules Abunidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07364MIG. Abunidazole generally arises in the molecular formula C15H19N3O4. The term ABUNIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) ABUNIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abunidazole under HS 29332990 and SITC 51573. As of Q4 2014, ABUNIDAZOLE remains the US FDA Preferred Term for this commodity. Abunidazole bears US NLM identifiers UMLS ID C2346715 and NCI Concept Code C73009. SMILES: OC(C1CC(C(C)(C)C)CCC1O)C1N(C([N](=O)O)CN1)C.
This classification denotes a purine antagonist with the molecular formula C9H14N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53IEF47846, chemically known as 1h-imidazole-4-carboxamide, 5-amino-1-beta-d-ribofuranosyl- but generally known as acadesine, which bears US NIH Compound Identifier 17513. Acadesine most often appears in base and phosphate form. European Medicines Agency schedules Acadesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07365MIG. The term ACADESINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules acadesine in its Anatomical Therapeutic Chemical (ATC) Classification. ACADESINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acadesine under HS 29349990 and SITC 51579. As of Q4 2014, ACADESINE remains the US FDA Preferred Term for this commodity. Acadesine bears US NLM identifiers UMLS ID C0051027 and NCI Concept Code C71537. SMILES: O1C(N2C(N)C(NC2)C(=O)N)C(O)C(O)C1CO.
Medication used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma. Specifically, it is for people who had previously been treated with another therapy.
This classification denotes a neuroprotective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N4K14YGM3J. European Medicines Agency schedules Acamprosate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07366MIG. Acamprosate generally arises in the molecular formula C5H11NO4S. The term ACAMPROSATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) ACAMPROSATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acamprosate under HS 29241900 and SITC 51471. As of Q4 2014, ACAMPROSATE remains the US FDA Preferred Term for this commodity. Acamprosate bears US NLM identifiers UMLS ID C0284941 and NCI Concept Code C81691. SMILES: S(=O)(=O)(O)CCCNC(=O)C.
This classification denotes a neuroprotective agent with the molecular formula 2C5H10NO4S.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59375N1D0U, chemically known as 1-propanesulfonic acid, 3-(acetylamino)-, calcium salt (2:1) but more generally known as acamprosate calcium, which bears US NIH Compound Identifier 155434. European Medicines Agency schedules Acamprosate calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00239MIG. Most nations, for tariff and trade purposes, schedule acamprosate calcium under HS 29241900 and SITC 51471. As of Q4 2014, ACAMPROSATE CALCIUM remains US FDA's Preferred Term for this commodity. Acamprosate calcium bears US NLM identifiers UMLS ID C0592789 and NCI Concept Code C65209. SMILES: CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[CA+2].
This classification denotes a glucosidase inhibitor and anti-diabetic agent with the molecular formula C25H43NO18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) T58MSI464G, chemically known as o-4,6-dideoxy-4-(((1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-d-glucopyranosyl-(1->4)-o-alpha-d-glucopyranosyl-(1->4)-d-glucose but more generally known as acarbose, which bears US NIH Compound Identifier 41774. Acarbose most often comes in forms base, hexasaccharide, pentasaccharide, and trisaccharide. European Medicines Agency schedules Acarbose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07368MIG. The term ACARBOSE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19) WHO schedules acarbose in its Anatomical Therapeutic Chemical (ATC) Classification. ACARBOSE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule acarbose under HS 29329970 and SITC 51569. As of Q4 2014, ACARBOSE remains US FDA's Preferred Term for this commodity. Acarbose bears US NLM identifiers UMLS ID C0591572 and NCI Concept Code C983. SMILES: O(C1C(O)C(O)C(OC1CO)OC1C(O)C(O)C(OC1CO)O)C1OC(C(NC2C(O)C(O)C(O)C(=C2)CO)C(O)C1O)C.
This classification denotes a sedative and hypnotic with the molecular formula C29H48Br2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7XZB016MY5, chemically known as 5,6beta-dibromo-5alpha-cholestan-3beta-ol acetate but generally known as acebrochol, which bears US NIH Compound Identifier 170366. European Medicines Agency schedules Acebrochol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07369MIG. The term ACEBROCHOL is an International Non-Proprietary Name. ACEBROCHOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acebrochol under HS 29153980 and SITC 51372. As of Q4 2014, ACEBROCHOL remains the US FDA Preferred Term for this commodity. Acebrochol bears US NLM identifiers UMLS ID C2699521 and NCI Concept Code C77240. SMILES: BRC1C2C(C3C(C4C(C(CC4)C(CCCC(C)C)C)(CC3)C)C1)(CCC(OC(=O)C)C2BR)C.
This classification denotes an industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F777XEP0LL. European Medicines Agency schedules Aceburic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07370MIG. Aceburic acid generally arises in the molecular formula C6H10O4. The term ACEBURIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) Most nations schedule aceburic acid under HS 29181985 and SITC 51392. As of Q4 2014, ACEBURIC ACID remains the US FDA Preferred Term for this commodity. Aceburic acid bears US NLM identifiers UMLS ID C2346942 and NCI Concept Code C72093. SMILES: CC(=O)OCCCC(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H28N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67P356D8GH, chemically known as butanamide, n-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-,monohydrochloride,( -)- but generally known as acebutolol, which bears US NIH Compound Identifier 1978. Acebutolol most often comes in forms base, azide, hydrochloride, and methylboronate. European Medicines Agency schedules Acebutolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07371MIG. The term ACEBUTOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules acebutolol in its Anatomical Therapeutic Chemical (ATC) Classification. ACEBUTOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acebutolol under HS 29242995 and SITC 51479. As of Q4 2014, ACEBUTOLOL remains the US FDA Preferred Term for this commodity. Acebutolol bears US NLM identifiers UMLS ID C0000946 and NCI Concept Code C61525. SMILES: O(CC(O)CNC(C)C)C1C(CC(NC(=O)CCC)CC1)C(=O)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H28N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B025Y34C54, chemically known as m&b 17,803a but more generally known as acebutolol hydrochloride, which bears US NIH Compound Identifier 36816. The base preparation, Acebutolol, also comes in forms base, azide, and methylboronate. European Medicines Agency schedules Acebutolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00240MIG. Most nations, for tariff and trade purposes, schedule acebutolol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, ACEBUTOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Acebutolol hydrochloride bears US NLM identifiers UMLS ID C0543447 and NCI Concept Code C28806. SMILES: CCCC(=O)NC1CCC(C(C1)C(=O)C)OCC(CNC(C)C)O.CL.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C15H23N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 910Q707V6F, chemically known as benzamide, 4-(acetylamino)-n-(2-(diethylamino)ethyl)- but more generally known as acecainide, which bears US NIH Compound Identifier 4342. Acecainide most often appears in forms base and hydrochloride. European Medicines Agency schedules Acecainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07372MIG. The term ACECAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). ACECAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule acecainide under HS 29242995 and SITC 51479. As of Q4 2014, ACECAINIDE remains US FDA's Preferred Term for this commodity. Acecainide bears US NLM identifiers UMLS ID C0001061 and NCI Concept Code C75125. SMILES: O=C(NCCN(CC)CC)C1CCC(NC(=O)C)CC1.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C15H23N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B9K738KX14, chemically known as benzamide, 4-(acetylamino)-n-(2-(diethylamino)ethyl)-, monohydrochloride but more generally known as acecainide hydrochloride, which bears US NIH Compound Identifier 71417. The base compound, acecainide, also comes in base form. Most nations, for tariff and trade purposes, schedule acecainide hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, ACECAINIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Acecainide hydrochloride bears US NLM identifiers UMLS ID C0282038 and NCI Concept Code C75126. SMILES: CCN(CC)CCNC(=O)C1CCC(CC1)NC(=O)C.CL.
This classification denotes a sedative and hypnotic with the molecular formula C9H15BrN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E47C56IGOY, chemically known as urea, 1-acetyl-3-(2-bromo-2-ethylbutyryl)- but generally known as acecarbromal, which bears US NIH Compound Identifier 6489. European Medicines Agency schedules Acecarbromal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05198MIG. The term ACECARBROMAL is an International Non-Proprietary Name. ACECARBROMAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acecarbromal under HS 29241900 and SITC 51471. As of Q4 2014, ACECARBROMAL remains the US FDA Preferred Term for this commodity. Acecarbromal bears US NLM identifiers UMLS ID C0050402 and NCI Concept Code C76932. SMILES: BRC(CC)(CC)C(=O)NC(=O)NC(=O)C.
This classification denotes a cholinergic agonist with the molecular formula C9H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0578K3ELIO, chemically known as 3-quinuclidinol, acetate (ester) but generally known as aceclidine, which bears US NIH Compound Identifier 1979. Aceclidine most often comes in forms base, hydrochloride, and salicylate. European Medicines Agency schedules Aceclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05199MIG. The term ACECLIDINE is an International Non-Proprietary Name. World Health Organization schedules aceclidine in its Anatomical Therapeutic Chemical (ATC) Classification. ACECLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aceclidine under HS 29333999 and SITC 51574. As of Q4 2014, ACECLIDINE remains the US FDA Preferred Term for this commodity. Aceclidine bears US NLM identifiers UMLS ID C0000948 and NCI Concept Code C81044. SMILES: O(C1C2CCN(C1)CC2)C(=O)C.
This classification denotes the hydrochloride form of a cholinergic agonist with the molecular formula C9H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0578K3ELIO, chemically known as 3-quinuclidinol, acetate (ester) but more generally known as aceclidine, which bears US NIH Compound Identifier 1979. Aceclidine most often comes in forms base, hydrochloride, and salicylate. European Medicines Agency schedules Aceclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05199MIG. The term ACECLIDINE is an International Non-Proprietary Name. World Health Organization schedules aceclidine in its Anatomical Therapeutic Chemical (ATC) Classification. ACECLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule aceclidine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, ACECLIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Aceclidine hydrochloride bears US NLM identifiers UMLS ID C1529400 and NCI Concept Code C96880. SMILES: CC(=O)OC1CN2CCC1CC2.CL.
This classification denotes the salicylate form of a cholinergic agonist with the molecular formula C9H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0578K3ELIO, chemically known as 3-quinuclidinol, acetate (ester) but more generally known as aceclidine, which bears US NIH Compound Identifier 1979. Aceclidine most often comes in forms base, hydrochloride, and salicylate. European Medicines Agency schedules Aceclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05199MIG. The term ACECLIDINE is an International Non-Proprietary Name. World Health Organization schedules aceclidine in its Anatomical Therapeutic Chemical (ATC) Classification. ACECLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule aceclidine salicylate under HS 29333999 and SITC 51574. As of Q4 2014, ACECLIDINE SALICYLATE remains US FDA's Preferred Term for this commodity. Aceclidine salicylate bears US NLM identifiers UMLS ID C3273097 and NCI Concept Code C96882. SMILES: CC(=O)OC1CN2CCC1CC2.C1CCC(C(C1)C(=O)O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RPK779R03H, chemically known as 2-(o-(2,6-dichloranilino)phenylacetoxy)essigsaeure but generally known as aceclofenac, which bears US NIH Compound Identifier 71771. European Medicines Agency schedules Aceclofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05200MIG. The term ACECLOFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules aceclofenac in its Anatomical Therapeutic Chemical (ATC) Classification. ACECLOFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aceclofenac under HS 29224995 and SITC 51465. As of Q4 2014, ACECLOFENAC remains the US FDA Preferred Term for this commodity. Aceclofenac bears US NLM identifiers UMLS ID C0050403 and NCI Concept Code C80534. SMILES: CLC1C(NC2C(CC(=O)OCC(=O)O)CCCC2)C(CL)CCC1.
This classification denotes a sulfone anti-infective agent with the molecular formula C16H16N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0GZ72U84TN, chemically known as 4,4-sulphonyldianiline but more generally known as acedapsone, which bears US NIH Compound Identifier 2955. European Medicines Agency schedules Acedapsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05201MIG. The term ACEDAPSONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). ACEDAPSONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(C1CCC(N)CC1)C1CCC(N)CC1.
This classification denotes an antibiotic with the chemical formula C14H14N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30YP2YHH8W, chemically known as n-[4-[(4-aminophenyl)sulfonyl]phenyl]glycine, but which is more commonly know as acediasulfone. European Medicines Agency schedules Acediasulfone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00242MIG. The term ACEDIASULFONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) As of Q4 2014, ACEDIASULFONE remains the US FDA Preferred Term for this commodity. Acediasulfone bears US NLM identifiers UMLS ID C1958507 and NCI Concept Code C77129. SMILES: C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)NCC(=O)O.
This classification denotes an antiestrogen with the molecular formula C25H26F2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K0BN50QXD, chemically known as 4,4-((1rs,2sr)-1-ethyl-2-methylethylene)bis(6-fluoropyrocatechol)tetraacetate but generally known as acefluranol, which bears US NIH Compound Identifier 170368. European Medicines Agency schedules Acefluranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05204MIG. The term ACEFLURANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). ACEFLURANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acefluranol under HS 29153980 and SITC 51372. As of Q4 2014, ACEFLURANOL remains the US FDA Preferred Term for this commodity. Acefluranol bears US NLM identifiers UMLS ID C2699522 and NCI Concept Code C78029. SMILES: FC1CC(C(C(C2CC(OC(=O)C)C(OC(=O)C)C(F)C2)C)CC)CC(OC(=O)C)C1OC(=O)C.
This classification denotes a bronchodilator with the molecular structure C9H10N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, M494UE2YEP chemically known as 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurine-7-acetic a but generally known as acefylline, which bears US NIH Compound Identifier 69550. European Medicines Agency schedules Acefylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00243MIG. The term ACEFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21). As of Q4 2014, ACEFYLLINE remains the US FDA Preferred Term for this commodity. Acefylline bears US NLM identifiers UMLS ID C0050405 and NCI Concept Code C96200. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O.
This classification denotes a bronchodilator with the molecular formula C19H21ClN4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WY672D78VW, chemically known as 7h-purine-7-acetic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-, 2-(4-chlorophenoxy)-2-methylpropyl ester but more generally known as acefylline clofibrol, which bears US NIH Compound Identifier 68898. European Medicines Agency schedules Acefylline clofibrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05206MIG. The term ACEFYLLINE CLOFIBROL is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule acefylline clofibrol under HS 29395900 and SITC 54145. As of Q4 2014, ACEFYLLINE CLOFIBROL remains US FDA's Preferred Term for this commodity. Acefylline clofibrol bears US NLM identifiers UMLS ID C2699524 and NCI Concept Code C74216. SMILES: CC(C)(COC(=O)CN1CNC2C1C(=O)N(C(=O)N2C)C)OC3CCC(CC3)CL.
This classification denotes a bronchodilator with the molecular formula 2C9H10N4O4.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 12I91IOS6Z chemically known as 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid;piperazine but generally known as acefylline, which bears US NIH Compound Identifier 87819. European Medicines Agency schedules Acefylline piperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12706MIG. The term ACEFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21). Most nations schedule acefylline piperazine under HS 29395900 and SITC 54145. As of Q4 2014, ACEFYLLINE PIPERAZINE remains the US FDA Preferred Term for this commodity. Acefylline piperazine bears US NLM identifiers UMLS ID C0771707 and NCI Concept Code C74218. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O.CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O.C1CNCCN1.
This classification denotes a glucuronidase inhibitor with the molecular formula C10H10O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 347Q3OOJ13, chemically known as 2,5-di-o-acetyl-d-glucosaccharo-1,4:6,3-dilactone but more generally known as aceglatone, which bears US NIH Compound Identifier 1980. European Medicines Agency schedules Aceglatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05207MIG. The term ACEGLATONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). ACEGLATONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ACEGLATONE remains US FDA's Preferred Term for this commodity. Aceglatone bears US NLM identifiers UMLS ID C0050406 and NCI Concept Code C984. SMILES: CC(=O)OC1C2C(C(C(=O)O2)OC(=O)C)OC1=O.
This classification denotes a cns stimulant with the molecular formula C7H12N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01J18G9G97, chemically known as l-glutamine, n2-acetyl- but generally known as aceglutamide, which bears US NIH Compound Identifier 25561. Aceglutamide most often arises in forms base and aluminium. European Medicines Agency schedules Aceglutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05208MIG. The term ACEGLUTAMIDE is an International Non-Proprietary Name. ACEGLUTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aceglutamide under HS 29241900 and SITC 51471. As of Q4 2014, ACEGLUTAMIDE remains the US FDA Preferred Term for this commodity. Aceglutamide bears US NLM identifiers UMLS ID C0050407 and NCI Concept Code C77843. SMILES: OC(=O)C(NC(=O)C)CCC(=O)N.
This classification denotes an anti-ulcer agent with the molecular structure 5C7H11N2O4.3AL.4HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, R7QTG0PMPX chemically known as aluminium, pentakis(n(sup 2)-acetyl-l-glutaminato)tetrahydroxytri-, but more commonly known as aceglutamide aluminium, which bears US NIH Compound Identifier 25560. European Medicines Agency schedules Aceglutamide aluminium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00244MIG. Most nations, for tariff and trade purposes, schedule aceglutamide aluminium under HS 29241900 and SITC 51471. SMILES: CC(=O)N[C@@H](CCC(=O)N)C(=O)[O-].CC(=O)N[C@@H](CCC(=O)N)C(=O)[O-].CC(=O)N[C@@H](CCC(=O)N)C(=O)[O-].CC(=O)N[C@@H](CCC(=O)N)C(=O)[O-].CC(=O)N[C@@H](CCC(=O)N)C(=O)[O-].[OH-].[OH-].[OH-].[OH-].[AL+3].[AL+3].[AL+3].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H18ClNO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V141XK28X, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester but generally known as acemetacin, which bears US NIH Compound Identifier 1981. European Medicines Agency schedules Acemetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05209MIG. The term ACEMETACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules acemetacin in its Anatomical Therapeutic Chemical (ATC) Classification. ACEMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acemetacin under HS 29339990 and SITC 51577. As of Q4 2014, ACEMETACIN remains the US FDA Preferred Term for this commodity. Acemetacin bears US NLM identifiers UMLS ID C0050409 and NCI Concept Code C73068. SMILES: CLC1CCC(C(=O)N2C(C(C3C2CCC(OC)C3)CC(=O)OCC(=O)O)C)CC1.
This classification denotes an anticoagulant agent with the molecular formula C19H15NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I6WP63U32H, chemically known as 2h-1-benzopyran-2-one, 4-hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)- but generally known as acenocoumarol, which bears US NIH Compound Identifier 9052. European Medicines Agency schedules Acenocoumarol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05211MIG. The term ACENOCOUMAROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules acenocoumarol in its Anatomical Therapeutic Chemical (ATC) Classification. ACENOCOUMAROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ACENOCOUMAROL remains the US FDA Preferred Term for this commodity. Acenocoumarol bears US NLM identifiers UMLS ID C0000956 and NCI Concept Code C75152. SMILES: O1C(O)C(C(CC(=O)C)C2CCC([N](=O)O)CC2)C(=O)C2C1CCCC2.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C24H29FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S69KXZ59AB, chemically known as acetamide, n-((1-(4-(4-fluorophenyl)-4-oxobutyl)-4-phenyl-4-piperidinyl)methyl)- (9ci) but generally known as aceperone, which bears US NIH Compound Identifier 13122. European Medicines Agency schedules Aceperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05212MIG. The term ACEPERONE is an International Non-Proprietary Name. ACEPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aceperone under HS 29333999 and SITC 51574. As of Q4 2014, ACEPERONE remains the US FDA Preferred Term for this commodity. Aceperone bears US NLM identifiers UMLS ID C0649938 and NCI Concept Code C72567. SMILES: FC1CCC(C(=O)CCCN2CCC(CC2)(CNC(=O)C)C2CCCCC2)CC1.
This classification denotes a dopamine antagonist with the molecular formula C19H22N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 54EJ303F0R, chemically known as promazine, acetyl- but generally known as acepromazine, which bears US NIH Compound Identifier 6077. Acepromazine most often comes in forms base, hydrogen maleate, or maleate. European Medicines Agency schedules Acepromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05213MIG. The term ACEPROMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules acepromazine in its Anatomical Therapeutic Chemical (ATC) Classification. ACEPROMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acepromazine under HS 29343090 and SITC 51578. As of Q4 2014, ACEPROMAZINE remains the US FDA Preferred Term for this commodity. Acepromazine bears US NLM identifiers UMLS ID C0000959 and NCI Concept Code C77568. SMILES: S1C2C(N(CCCN(C)C)C3C1CCCC3)CC(CC2)C(=O)C.
This classification denotes a dopamine antagonist with the molecular formula C19H22N2OS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37862HP2OM, chemically known as 2-acetyl-10-(3-(dimethylamino)propyl)phenothiazine, maleate but more generally known as acepromazine maleate, which bears US NIH Compound Identifier 5476753. The base compound, Acepromazine, also comes in base form. European Medicines Agency schedules Acepromazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21524. Most nations, for tariff and trade purposes, schedule acepromazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, ACEPROMAZINE MALEATE remains US FDA's Preferred Term for this commodity. Acepromazine maleate bears US NLM identifiers UMLS ID C1257654 and NCI Concept Code C76652. SMILES: CC(=O)C1CCC2C(C1)N(C3CCCCC3S2)CCCN(C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antidepressant agent with the molecular formula C19H22N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 984N9YTM4Y, chemically known as ketone, 10-(2-(dimethylamino)propyl)phenothiazin-2-yl methyl but generally known as aceprometazine, which bears US NIH Compound Identifier 26035. European Medicines Agency schedules Aceprometazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05214MIG. The term ACEPROMETAZINE is an International Non-Proprietary Name. ACEPROMETAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aceprometazine under HS 29343090 and SITC 51578. As of Q4 2014, ACEPROMETAZINE remains the US FDA Preferred Term for this commodity. Aceprometazine bears US NLM identifiers UMLS ID C0608826 and NCI Concept Code C72678. SMILES: S1c2c(N(CC(N(C)C)C)c3c1cccc3)cc(cc2)C(=O)C.
This classification denotes the maleate form of an antidepressant agent with the molecular formula C19H22N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 984N9YTM4Y, chemically known as ketone, 10-(2-(dimethylamino)propyl)phenothiazin-2-yl methyl but more generally known as aceprometazine, which bears US NIH Compound Identifier 26035. European Medicines Agency schedules Aceprometazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05214MIG. The term ACEPROMETAZINE is an International Non-Proprietary Name. ACEPROMETAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule aceprometazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, ACEPROMETAZINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CN1C2CCCCC2SC3C1CC(CC3)C(=O)C)N(C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an astringent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 80EHD8I43D. The European Medicines Agency schedules Aluminium acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12809MIG. Aluminum acetate generally arises in the molecular formula 3C2H3O2.AL. The term 'aluminum acetate' is a U.S. Pharmacopeial Convention designation. The third component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules chlorphenamine (in maleate form, the most common form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine generally arises in the molecular formula C16H19ClN2. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The fourth component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a common antacid with the molecular formula Al.3HO, a compound that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 5QB0T2IUN0, which is chemically known as aluminium(3+) trioxidanide but which is more generally known as aluminum hydroxide, which bears U.S. National Institutes of Health Compound Identifier 115283. The European Medicines Agency schedules aluminum hydroxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11700MIG. The third component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fifth component of this combination drug is an antacid with the molecular formula Mg.2HO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier NBZ3QY004S, chemically known as magnesium ion, 2 waters coordinated but more generally known as magnesium hydroxide, which bears U.S. National Institutes of Health Compound Identifier 14791. The European Medicines Agency schedules Magnesium hydroxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14429MIG. The World Health Organization schedules magnesium hydroxide in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a common antacid with the molecular formula Al.3HO, a compound that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 5QB0T2IUN0, which is chemically known as aluminium(3+) trioxidanide but which is more generally known as aluminum hydroxide, which bears U.S. National Institutes of Health Compound Identifier 115283. The European Medicines Agency schedules aluminum hydroxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11700MIG. The third component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an electrolyte replacement agent with the molecular formula 2C6H11O7.Ca, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier SQE6VB453K, chemically known as gluconic acid, calcium salt but more generally known as calcium gluconate, which bears U.S. National Institutes of Health Compound Identifier 9290. The European Medicines Agency schedules Calcium gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13176MIG. The World Health Organization schedules calcium gluconate in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but more generally known as codeine, which bears U.S. National Institutes of Health Compound Identifier 223652. The European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. The World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fifth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 6YKS4Y3WQ7, chemically known as 4,5-epoxy-3-methoxy-17-methylmorphinan-6-one but more generally known as hydrocodone, which bears U.S. National Institutes of Health Compound Identifier 5284569. The European Medicines Agency schedules Hydrocodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08063MIG. The term HYDROCODONE is an International Non-Proprietary Name. The World Health Organization schedules hydrocodone in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a nutritional supplement with the molecular formula CO3.Ca, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier H0G9379FGK, chemically known as carbonic acid, calcium salt (1:1) but more generally known as calcium carbonate, which bears U.S. National Institutes of Health Compound Identifier 10112. The European Medicines Agency schedules Calcium carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13166MIG. The World Health Organization schedules calcium carbonate in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but more generally known as codeine, which bears U.S. National Institutes of Health Compound Identifier 223652. The European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. The World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears U.S. National Institutes of Health Compound Identifier 2244. The European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. The World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C16H19BrN2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier H57G17P2FN, chemically known as 3-(p-bromophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but more generally known as brompheniramine, which bears U.S. National Institutes of Health Compound Identifier 6834. Brompheniramine most often comes in base and maleate forms. The European Medicines Agency schedules Brompheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05924MIG. The term BROMPHENIRAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). The World Health Organization schedules brompheniramine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier KHS0AZ4JVK, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but more generally known as butalbital, which bears U.S. National Institutes of Health Compound Identifier 2481. Butalbital most often comes in base and sodium forms. The European Medicines Agency schedules Butalbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05999MIG. The term BUTALBITAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9).
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier KHS0AZ4JVK, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but more generally known as butalbital, which bears U.S. National Institutes of Health Compound Identifier 2481. Butalbital most often comes in base and sodium forms. The European Medicines Agency schedules Butalbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05999MIG. The term BUTALBITAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). The third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier KHS0AZ4JVK, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but more generally known as butalbital, which bears U.S. National Institutes of Health Compound Identifier 2481. Butalbital most often comes in base and sodium forms. The European Medicines Agency schedules Butalbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05999MIG. The term BUTALBITAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). The third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but more generally known as codeine, which bears U.S. National Institutes of Health Compound Identifier 223652. The European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. The World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier KHS0AZ4JVK, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but more generally known as butalbital, which bears U.S. National Institutes of Health Compound Identifier 2481. Butalbital most often comes in base and sodium forms. The European Medicines Agency schedules Butalbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05999MIG. The term BUTALBITAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). The third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 6YKS4Y3WQ7, chemically known as 4,5-epoxy-3-methoxy-17-methylmorphinan-6-one but more generally known as hydrocodone, which bears U.S. National Institutes of Health Compound Identifier 5284569. The European Medicines Agency schedules Hydrocodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08063MIG. The term HYDROCODONE is an International Non-Proprietary Name. The World Health Organization schedules hydrocodone in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier KHS0AZ4JVK, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but more generally known as butalbital, which bears U.S. National Institutes of Health Compound Identifier 2481. Butalbital most often comes in base and sodium forms. The European Medicines Agency schedules Butalbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05999MIG. The term BUTALBITAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). The third component of this combination drug is an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but more generally known as codeine, which bears U.S. National Institutes of Health Compound Identifier 223652. The European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. The World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (under maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine generally arises in the molecular formula C16H19ClN2. The term 'chlorpheniramine maleate' is a European Pharmacopoeia designation. The fourth component of this combination drug is an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 6YKS4Y3WQ7, chemically known as 4,5-epoxy-3-methoxy-17-methylmorphinan-6-one but more generally known as hydrocodone, which bears U.S. National Institutes of Health Compound Identifier 5284569. The European Medicines Agency schedules Hydrocodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08063MIG. The term HYDROCODONE is an International Non-Proprietary Name. The World Health Organization schedules hydrocodone in its Anatomical Therapeutic Chemical (ATC) Classification. The fifth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. TRUNCATED
Acetaminophen, chlorpheniramine, and phenylephrine is a combination medicine used to treat headache, fever, body aches, runny or stuffy nose, sneezing, itching, watery eyes, and sinus congestion caused by allergies, the common cold, or the flu.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (under maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine generally arises in the molecular formula C16H19ClN2. The term 'chlorpheniramine maleate' is a European Pharmacopoeia designation. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification. The fifth component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears U.S. National Institutes of Health Compound Identifier 4992.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (under maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine generally arises in the molecular formula C16H19ClN2. The term 'chlorpheniramine maleate' is a European Pharmacopoeia designation. The fourth componeny of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but more generally known as codeine, which bears U.S. National Institutes of Health Compound Identifier 223652. The European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. The World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combinaation drug is an opioid receptor agonist and opioid with the molecular formula C18H23NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier N9I9HDB855, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine, which bears U.S. National Institutes of Health Compound Identifier 3063. The European Medicines Agency schedules Dihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07138MIG. The term DIHYDROCODEINE is an International Non-Proprietary Name. The World Health Organization schedules dihydrocodeine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combination drug is an expectorant with the molecular formula C10H14O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears U.S. National Institutes of Health Compound Identifier 3516. The European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG. The term GUAIFENESIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). The World Health Organization schedules guaifenesin in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combination drug is a natural product known to US FDA as an active ingredient or moiety under Unique Ingredient Identifier 32IT7G8BAW, and is more generally known as hyoscyamus. The European Medicines Agency schedules hyoscyamus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14163MIG.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combination drug is an adrenergic agent with the molecular formula C9H19N, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Y7L24THH6T, chemically known as 5-hepten-2-amine, n,6-dimethyl-, hydrochloride but more generally known as isometheptene, which bears U.S. National Institutes of Health Compound Identifier 22297. The European Medicines Agency schedules Isometheptene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08324MIG. The term ISOMETHEPTENE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). The World Health Organization schedules isometheptene in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE900. This VA Drug Class (RE900) classifies this compound as belonging to the group RESPIRATORY AGENTS, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears U.S. National Institutes of Health Compound Identifier 4992.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K65LB6598J, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine but more generally known as phenyltoloxamine, which bears U.S. National Institutes of Health Compound Identifier 7077. The European Medicines Agency schedules Phenyltoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09791MIG. The term PHENYLTOLOXAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). The fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears U.S. National Institutes of Health Compound Identifier 4992.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears U.S. National Institutes of Health Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. The European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. The third component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug a nutritional supplement with the molecular formula CO3.Ca, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier H0G9379FGK, chemically known as carbonic acid, calcium salt (1:1) but more generally known as calcium carbonate, which bears U.S. National Institutes of Health Compound Identifier 10112. The European Medicines Agency schedules Calcium carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13166MIG. The World Health Organization schedules calcium carbonate in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a nutritional supplement with the molecular formula CO3.Ca, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier H0G9379FGK, chemically known as carbonic acid, calcium salt (1:1) but more generally known as calcium carbonate, which bears U.S. National Institutes of Health Compound Identifier 10112. The European Medicines Agency schedules Calcium carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13166MIG. The World Health Organization schedules calcium carbonate in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an electrolyte replacement agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 0E53J927NA. The European Medicines Agency schedules Magnesia carbonica in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34276. Magnesium carbonate generally arises in the molecular formula CO3.MG.H2O. The term 'magnesium carbonate' is a United States Homeopathic Pharmacopoeia Name designation. The fourth component of this combination drug is a nutritional supplement and laxative, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3A3U0GI71G. The European Medicines Agency schedules Magnesium oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14436MIG. Magnesium oxide generally arises in the molecular formula MGO. The term 'magnesium oxide' is a United States Homeopathic Pharmacopoeia Name designation.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component os this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (as maleate) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but more generally known as codeine, which bears U.S. National Institutes of Health Compound Identifier 223652. The European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. The World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE509. This VA Drug Class (RE509) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component os this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (as maleate) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component os this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (as maleate) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component os this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (as maleate) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of thiss combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component os this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (as maleate) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (n maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (n maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears U.S. National Institutes of Health Compound Identifier 4992.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (n maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (in maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (in maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth compone of this combination druug is a histamine-1 receptor antagonist with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K65LB6598J, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine but more generally known as phenyltoloxamine, which bears U.S. National Institutes of Health Compound Identifier 7077. The European Medicines Agency schedules Phenyltoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09791MIG. The term PHENYLTOLOXAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3).
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (in maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification. The forth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U. The European Medicines Agency schedules Chlorphenamine (in maleate form) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine' is a European Pharmacopoeia designation. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class MS200. This VA Drug Class (MS200) classifies this compound as belonging to the group SKELETAL MUSCLE RELAXANTS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a muscle relaxant with the molecular formula C7H4ClNO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier H0DE420U8G, chemically known as 2-benzoxazolinone, 5-chloro- but more generally known as chlorzoxazone, which bears U.S. National Institutes of Health Compound Identifier 2733. The European Medicines Agency schedules Chlorzoxazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06215MIG. The term CHLORZOXAZONE is an International Non-Proprietary Name. The World Health Organization schedules chlorzoxazone in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an adrenergic agonist with the molecular formula C19H23NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Y1245J8012, chemically known as benzenemethanol, alpha-(1-(methyl(3-phenyl-2-propenyl)amino)ethyl)- but more generally known as cinnamedrine, which bears U.S. National Institutes of Health Compound Identifier 5370611. The European Medicines Agency schedules Cinnamedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06301MIG. The term CINNAMEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). The third component of this combination drug is a diuretic with the molecular formula C7H7BrN4O2.C4H11NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier UA8U0KJM72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but more generally known as pamabrom, which bears U.S. National Institutes of Health Compound Identifier 11806. The European Medicines Agency schedules Pamabrom in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14745MIG.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but more generally known as codeine, which bears U.S. National Institutes of Health Compound Identifier 223652. The European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. The World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but more generally known as codeine, which bears U.S. National Institutes of Health Compound Identifier 223652. The European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. The World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an expectorant with the molecular formula C10H14O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears U.S. National Institutes of Health Compound Identifier 3516. The European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG. The term GUAIFENESIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). The World Health Organization schedules guaifenesin in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE515. This VA Drug Class (RE515) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C16H19BrN2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 75T64B71RP, chemically known as 3-(4-bromophenyl)-n,n-dimethyl-3-pyridin-2-yl-propan-1-amine but more generally known as dexbrompheniramine, which bears U.S. National Institutes of Health Compound Identifier 16960. The European Medicines Agency schedules Dexbrompheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07021MIG. The World Health Organization schedules dexbrompheniramine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 8GTS82S83M, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but more generally known as diphenhydramine, which bears U.S. National Institutes of Health Compound Identifier 3100. The European Medicines Agency schedules Diphenhydramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG. The term DIPHENHYDRAMINE is an International Non-Proprietary Name. The World Health Organization schedules diphenhydramine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE509. This VA Drug Class (RE509) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H22N2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 95QB77JKPL, chemically known as pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)- but more generally known as doxylamine, which bears U.S. National Institutes of Health Compound Identifier 3162. The European Medicines Agency schedules Doxylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06394MIG. The term DOXYLAMINE is an International Non-Proprietary Name. The World Health Organization schedules doxylamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H22N2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 95QB77JKPL, chemically known as pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)- but more generally known as doxylamine, which bears U.S. National Institutes of Health Compound Identifier 3162. The European Medicines Agency schedules Doxylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06394MIG. The term DOXYLAMINE is an International Non-Proprietary Name. The World Health Organization schedules doxylamine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an adrenergic agent with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier GN83C131XS, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as ephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Ephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13683MIG. The World Health Organization schedules ephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H22N2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 95QB77JKPL, chemically known as pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)- but more generally known as doxylamine, which bears U.S. National Institutes of Health Compound Identifier 3162. The European Medicines Agency schedules Doxylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06394MIG. The term DOXYLAMINE is an International Non-Proprietary Name. The World Health Organization schedules doxylamine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an expectorant with the molecular formula C10H14O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears U.S. National Institutes of Health Compound Identifier 3516. The European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG. The term GUAIFENESIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). The World Health Organization schedules guaifenesin in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE514. This VA Drug Class (RE514) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an expectorant with the molecular formula C10H14O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears U.S. National Institutes of Health Compound Identifier 3516. The European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG. The term GUAIFENESIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). The World Health Organization schedules guaifenesin in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE514. This VA Drug Class (RE514) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an expectorant with the molecular formula C10H14O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears U.S. National Institutes of Health Compound Identifier 3516. The European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG. The term GUAIFENESIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). The World Health Organization schedules guaifenesin in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE514. This VA Drug Class (RE514) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an expectorant with the molecular formula C10H14O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears U.S. National Institutes of Health Compound Identifier 3516. The European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG. The term GUAIFENESIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). The World Health Organization schedules guaifenesin in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification. The fourth component of this combination drug is The fifth component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears U.S. National Institutes of Health Compound Identifier 4992.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE515. This VA Drug Class (RE515) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE515. This VA Drug Class (RE515) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/ANALGESIC. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears U.S. National Institutes of Health Compound Identifier 3008. The European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. The World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a sedative and hypnotic with the molecular formula C11H12N2O.2C2H3Cl3O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier YYX637R279, chemically known as 1,2-dihydro-1,5-dimethyl-2-phenyl-3h-pyrazol-3-one, compound with 2,2,2-trichloroethane-1,1-diol (1:2) but more generally known as dichloralphenazone, which bears U.S. National Institutes of Health Compound Identifier 10188. The European Medicines Agency schedules Dichloralphenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13563MIG. The World Health Organization schedules dichloralphenazone in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an adrenergic agent with the molecular formula C9H19N, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Y7L24THH6T, chemically known as 5-hepten-2-amine, n,6-dimethyl-, hydrochloride but more generally known as isometheptene, which bears U.S. National Institutes of Health Compound Identifier 22297. The European Medicines Agency schedules Isometheptene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08324MIG. The term ISOMETHEPTENE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). The World Health Organization schedules isometheptene in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C18H23NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier N9I9HDB855, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine, which bears U.S. National Institutes of Health Compound Identifier 3063. The European Medicines Agency schedules Dihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07138MIG. The term DIHYDROCODEINE is an International Non-Proprietary Name. The World Health Organization schedules dihydrocodeine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 8GTS82S83M, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but more generally known as diphenhydramine, which bears U.S. National Institutes of Health Compound Identifier 3100. The European Medicines Agency schedules Diphenhydramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG. The term DIPHENHYDRAMINE is an International Non-Proprietary Name. The World Health Organization schedules diphenhydramine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 8GTS82S83M, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but more generally known as diphenhydramine, which bears U.S. National Institutes of Health Compound Identifier 3100. The European Medicines Agency schedules Diphenhydramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG. The term DIPHENHYDRAMINE is an International Non-Proprietary Name. The World Health Organization schedules diphenhydramine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 8GTS82S83M, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but more generally known as diphenhydramine, which bears U.S. National Institutes of Health Compound Identifier 3100. The European Medicines Agency schedules Diphenhydramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG. The term DIPHENHYDRAMINE is an International Non-Proprietary Name. The World Health Organization schedules diphenhydramine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes an analgesic and antipyretic with the molecular formula C14H17NO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8BE7G9R76X, chemically known as .beta.-d-glucopyranosiduronic acid, 4-(acetylamino)phenyl, but more generally known as acetaminophen glucuronide, which bears US NIH Compound Identifier 83944. European Medicines Agency schedules acetaminophen glucuronide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. Most nations, for tariff purposes, schedule acetaminophen glucuronide under HS 29242990. SMILES: CC(=O)NC1CCC(CC1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 6YKS4Y3WQ7, chemically known as 4,5-epoxy-3-methoxy-17-methylmorphinan-6-one but more generally known as hydrocodone, which bears U.S. National Institutes of Health Compound Identifier 5284569. The European Medicines Agency schedules Hydrocodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08063MIG. The term HYDROCODONE is an International Non-Proprietary Name. The World Health Organization schedules hydrocodone in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist with the molecular formula C15H21NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 9E338QE28F, chemically known as 4-piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester, hydrochloride but more generally known as meperidine, which bears U.S. National Institutes of Health Compound Identifier 4058. The European Medicines Agency schedules Pethidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09738MIG. The term MEPERIDINE is an International Non-Proprietary Name. The World Health Organization schedules meperidine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes an analgesic and antipyretic with the molecular formula C13H16N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R86SEU3G6U, chemically known as l-cysteine, n-acetyl-s-(5-(acetylamino)-2-hydroxyphenyl)-, but more generally known as acetaminophen mercapturate, which bears US NIH Compound Identifier 83967. European Medicines Agency schedules acetaminophen mercapturate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. Most nations, for tariff purposes, schedule acetaminophen mercapturate under HS 29242990. SMILES: CC(=O)NC1CCC(C(C1)SC[C@@H](C(=O)O)NC(=O)C)O.
This classification denotes an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but generally known as acetaminophen, which bears US NIH Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule acetaminophen under HS 29242990 and SITC 51479. As of Q4 2014, ACETAMINOPHEN remains the US FDA Preferred Term for this commodity. Acetaminophen bears US NLM identifiers UMLS ID C0000970 and NCI Concept Code C198. SMILES: OC1CCC(NC(=O)C)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combinaation drug is an opioid receptor agonist and opioid with the molecular formula C18H21NO4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier CD35PMG570, chemically known as 4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one but more generally known as oxycodone, which bears U.S. National Institutes of Health Compound Identifier 5284603. The European Medicines Agency schedules Oxycodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09562MIG. The term OXYCODONE is an International Non-Proprietary Name. The World Health Organization schedules oxycodone in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a diuretic with the molecular formula C7H7BrN4O2.C4H11NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier UA8U0KJM72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but more generally known as pamabrom, which bears U.S. National Institutes of Health Compound Identifier 11806. The European Medicines Agency schedules Pamabrom in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14745MIG.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a diuretic with the molecular formula C7H7BrN4O2.C4H11NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier UA8U0KJM72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but more generally known as pamabrom, which bears U.S. National Institutes of Health Compound Identifier 11806. The European Medicines Agency schedules Pamabrom in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14745MIG. The third component of this combination drug is a b vitamin with the molecular formula C8H11NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier KV2JZ1BI6Z, chemically known as 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol but more generally known as pyridoxine, which bears U.S. National Institutes of Health Compound Identifier 1054. The European Medicines Agency schedules Pyridoxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10168MIG. The term PYRIDOXINE is an International Non-Proprietary Name. The World Health Organization schedules pyridoxine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a diuretic with the molecular formula C7H7BrN4O2.C4H11NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier UA8U0KJM72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but more generally known as pamabrom, which bears U.S. National Institutes of Health Compound Identifier 11806. The European Medicines Agency schedules Pamabrom in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14745MIG. The third component of this combination drug is The fifth component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears U.S. National Institutes of Health Compound Identifier 4992.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an opioid receptor agonist and opioid with the molecular formula C19H27NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier RP4A60D26L, chemically known as 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol but more generally known as pentazocine, which bears U.S. National Institutes of Health Compound Identifier 4736. The European Medicines Agency schedules Pentazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09688MIG. The term PENTAZOCINE is an International Non-Proprietary Name. The World Health Organization schedules pentazocine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a barbiturate and anticonvulsant agent with the molecular formula C12H12N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier YQE403BP4D, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl- but more generally known as phenobarbital, which bears U.S. National Institutes of Health Compound Identifier 4763. The European Medicines Agency schedules Phenobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09770MIG. The term PHENOBARBITAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). The World Health Organization schedules phenobarbital in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but more generally known as phenylephrine, which bears U.S. National Institutes of Health Compound Identifier 6041. The European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). The World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine, which bears U.S. National Institutes of Health Compound Identifier 4786. The European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). The World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K65LB6598J, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine but more generally known as phenyltoloxamine, which bears U.S. National Institutes of Health Compound Identifier 7077. The European Medicines Agency schedules Phenyltoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09791MIG. The term PHENYLTOLOXAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3).
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K65LB6598J, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine but more generally known as phenyltoloxamine, which bears U.S. National Institutes of Health Compound Identifier 7077. The European Medicines Agency schedules Phenyltoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09791MIG. The term PHENYLTOLOXAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3).
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H21NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K65LB6598J, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine but more generally known as phenyltoloxamine, which bears U.S. National Institutes of Health Compound Identifier 7077. The European Medicines Agency schedules Phenyltoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09791MIG. The term PHENYLTOLOXAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). The third component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears U.S. National Institutes of Health Compound Identifier 5032. The European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a histamine-1 receptor antagonist, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 2L8T9S52QM. The European Medicines Agency schedules Triprolidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11323MIG. Triprolidine generally arises in the molecular formula C19H22N2. The term TRIPROLIDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 13, no. 12, 1959, list 3.)
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is The fifth component of this combination drug is a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears U.S. National Institutes of Health Compound Identifier 4992.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. The European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN.
This classification denotes an analgesic and antipyretic with the molecular formula C8H9NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S6002H6J9F, chemically known as acetamide, n-(4-(sulfooxy)phenyl)-, but more generally known as acetaminophen sulfate, which bears US NIH Compound Identifier 83939. European Medicines Agency schedules acetaminophen sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. Most nations, for tariff purposes, schedule acetaminophen sulfate under HS 29242990. SMILES: CC(=O)NC1CCC(CC1)OS(=O)(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS. The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. The European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. The World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is an analgesic agent with the molecular formula C16H25NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 39J1LGJ30J, chemically known as cyclohexanol, 2-((dimethylamino)methyl)-1-(m-methoxyphenyl)- but more generally known as tramadol, which bears U.S. National Institutes of Health Compound Identifier 33741. The European Medicines Agency schedules Tramadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11210MIG. The term TRAMADOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). The World Health Organization schedules tramadol in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes an analgesic and antipyretic with the molecular formula C15H13NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3J7H54KMD, chemically known as 2-hydroxybenzoic acid, 4-(acetylamino)phenyl-, ester but generally known as acetaminosalol, which bears US NIH Compound Identifier 1984. European Medicines Agency schedules Acetaminosalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05217MIG. The term ACETAMINOSALOL is an International Non-Proprietary Name. ACETAMINOSALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acetaminosalol under HS 29242995 and SITC 51479. As of Q4 2014, ACETAMINOSALOL remains the US FDA Preferred Term for this commodity. Acetaminosalol bears US NLM identifiers UMLS ID C2346946 and NCI Concept Code C72101. SMILES: O(C1CCC(NC(=O)C)CC1)C(=O)C1C(O)CCCC1.
This classification denotes an antihelminthic agent with the molecular formula C8H10AsNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 806529YU1N, chemically known as m-arsanilic acid, n-acetyl-4-hydroxy- but generally known as acetarsol, which bears US NIH Compound Identifier 1985. Acetarsol comes in many forms, including base, diethylaminsalz, natrium, and sodium. European Medicines Agency schedules Acetarsol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05218MIG. The term ACETARSOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules acetarsol in its Anatomical Therapeutic Chemical (ATC) Classification. ACETARSOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Acetarsol or acetarsone bears US NLM identifiers UMLS ID C0050436 and NCI Concept Code C61621. SMILES: [AS](=O)(O)(O)C1CC(NC(=O)C)C(O)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a diuretic and carbonic anhydrase inhibitor with the molecular formula C4H6N4O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3FX965V0I, chemically known as 1,3,4-thiadiazole-2-sulfonamide, 5-acetamido- but generally known as acetazolamide, which bears US NIH Compound Identifier 1986. Acetazolamide comes in many forms, including adipate ethyl ester, methyl, sodium, and tri-methyl. European Medicines Agency schedules Acetazolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05219MIG. The term ACETAZOLAMIDE is an International Non-Proprietary Name. World Health Organization schedules acetazolamide in its Anatomical Therapeutic Chemical (ATC) Classification. ACETAZOLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Acetazolamide under HS 29350090 and SITC 51580. As of Q4 2014, ACETAZOLAMIDE remains the US FDA Preferred Term for this commodity. Acetazolamide bears US NLM identifiers UMLS ID C0000981 and NCI Concept Code C28809. SMILES: CC(=O)NC1NNC(S1)S(=O)(=O)N.
This classification denotes a diuretic and carbonic anhydrase inhibitor with the molecular formula C4H5N4O3S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 429ZT169UH, chemically known as 1,3,4-thiadiazole-2-sulfonamide, 5-acetamido- but more generally known as acetazolamide sodium, which bears US NIH Compound Identifier 1986. The base compound, Acetazolamide, also comes in forms adipate ethyl ester, methyl, and tri-methyl. European Medicines Agency schedules Acetazolamide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00251MIG. Most nations, for tariff and trade purposes, schedule acetazolamide sodium under HS 29350090 and SITC 51580. As of Q4 2014, ACETAZOLAMIDE SODIUM remains US FDA's Preferred Term for this commodity. Acetazolamide sodium bears US NLM identifiers UMLS ID C0304713 and NCI Concept Code C61622. SMILES: CC(=O)NC1NNC(S1)S(=O)(=O)[NH-].[NA+].
This classification denotes an anti-infective agent with the molecular formula C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q40Q9N063P, chemically known as ethanoic acid but generally known as Acetic Acid, which bears US NIH Compound Identifier 176. European Medicines Agency schedules Acetic Acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12711MIG. As of Q4 2014, ACETIC ACID remains the US FDA Preferred Term for this commodity. Acetic acid bears US NLM identifiers UMLS ID C0000983 and NCI Concept Code C61623. SMILES: CC(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT109. This VA Drug Class (OT109) classifies this compound as belonging to the group ANTI-INFECTIVES, TOPICAL OTIC OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT109. This VA Drug Class (OT109) classifies this compound as belonging to the group ANTI-INFECTIVES, TOPICAL OTIC OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT109. This VA Drug Class (OT109) classifies this compound as belonging to the group ANTI-INFECTIVES, TOPICAL OTIC OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT109. This VA Drug Class (OT109) classifies this compound as belonging to the group ANTI-INFECTIVES, TOPICAL OTIC OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT109. This VA Drug Class (OT109) classifies this compound as belonging to the group ANTI-INFECTIVES, TOPICAL OTIC OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT109. This VA Drug Class (OT109) classifies this compound as belonging to the group ANTI-INFECTIVES, TOPICAL OTIC OTHER.
This classification denotes an anti-diabetic agent with the molecular formula C15H20N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) QGC8W08I6I, chemically known as urea, 1-((p-acetylphenyl)sulfonyl)-3-cyclohexyl- but more generally known as acetohexamide, which bears US NIH Compound Identifier 1989. European Medicines Agency schedules Acetohexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05223MIG. The term ACETOHEXAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5) WHO schedules acetohexamide in its Anatomical Therapeutic Chemical (ATC) Classification. ACETOHEXAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule acetohexamide under HS 29350090 and SITC 51580. As of Q4 2014, ACETOHEXAMIDE remains US FDA's Preferred Term for this commodity. Acetohexamide bears US NLM identifiers UMLS ID C0733364 and NCI Concept Code C47380. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CCC(CC1)C(=O)C.
This classification denotes a chelating agent with the molecular formula C2H5NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4RZ82L2GY5, chemically known as hydroxylamine, n-acetyl- but generally known as acetohydroxamic acid, which bears US NIH Compound Identifier 1990. European Medicines Agency schedules Acetohydroxamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05224MIG. The term ACETOHYDROXAMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules acetohydroxamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule acetohydroxamic acid under HS 29280090 and SITC 51486. As of Q4 2014, ACETOHYDROXAMIC ACID remains the US FDA Preferred Term for this commodity. Acetohydroxamic acid bears US NLM identifiers UMLS ID C0050451 and NCI Concept Code C47381. SMILES: CC(=O)NO.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K9958V90M. European Medicines Agency schedules Alcohol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15995MIG. Alcohol generally arises in the molecular formula C2H6O. The term 'alcohol' is an FDA designation. Acetone or alcohol based antiseptics bears US NLM identifiers UMLS ID C0001002 and NCI Concept Code C29807. SMILES: CCO.
This classification denotes an antipsychotic agent with the molecular formula C23H29N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8620H6K4QH, chemically known as ketone, 10-(3-(4-(2-hydroxyethyl-1-piperazinyl)propyl)phenothiazin-2-yl methyl but generally known as acetophenazine, which bears US NIH Compound Identifier 17676. Acetophenazine comes in forms base, dimaleate, and maleate. European Medicines Agency schedules Acetophenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05225MIG. The term ACETOPHENAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules acetophenazine in its Anatomical Therapeutic Chemical (ATC) Classification. ACETOPHENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acetophenazine under HS 29343090 and SITC 51578. As of Q4 2014, ACETOPHENAZINE remains the US FDA Preferred Term for this commodity. Acetophenazine bears US NLM identifiers UMLS ID C0050458 and NCI Concept Code C81085. SMILES: S1C2C(N(CCCN3CCN(CC3)CCO)C3C1CCCC3)CC(CC2)C(=O)C.
This classification denotes an antipsychotic agent with the molecular formula C23H29N3O2S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3P5HNU5JTC, chemically known as ethanone, 1-(10-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl)-10h-phenothiazin-2-yl)-, (z) 2-butenedioate (1:2) (salt), but more generally known as acetophenazine dimaleate, which bears US NIH Compound Identifier 5281082. European Medicines Agency schedules acetophenazine dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05225MIG. Most nations, for tariff purposes, schedule acetophenazine dimaleate under HS 29343090. SMILES: CC(=O)C1CC2C(CC1)SC3C(CCCC3)N2CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes a phenothiazine and antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3P5HNU5JTC. European Medicines Agency schedules Acetophenazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00255MIG. Acetophenazine maleate generally arises in the molecular formula C23H29N3O2S.2C4H4O4. The term 'acetophenazine maleate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule acetophenazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, ACETOPHENAZINE MALEATE remains US FDA's Preferred Term for this commodity. Acetophenazine maleate bears US NLM identifiers UMLS ID C0304378 and NCI Concept Code C65210. SMILES: CC(=O)C1CC2C(CC1)SC3C(CCCC3)N2CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an analgesic agent with the molecular formula C27H35NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OGQ81529L, chemically known as 6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine 3-acetate but generally known as acetorphine, which bears US NIH Compound Identifier 62795. European Medicines Agency schedules Acetorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05226MIG. The term ACETORPHINE is an International Non-Proprietary Name. ACETORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acetorphine under HS 29391900 and SITC 54141. As of Q4 2014, ACETORPHINE remains the US FDA Preferred Term for this commodity. Acetorphine bears US NLM identifiers UMLS ID C2699531 and NCI Concept Code C79929. SMILES: O1C2C34C5(C(N(CC3)C)CC3C4C1C(OC(=O)C)CC3)CC(C2(OC)C=C5)C(O)(CCC)C.
This classification denotes an analgesic agent C27H35NO5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60E212GZCG, chemically known as (.alpha.r,5.alpha.,7.alpha.)-4,5-epoxy-3-hydroxy-6-methoxy-.alpha.,17-dimethyl-.alpha.-propyl-6,14-ethenomorphinan-7-methanol, but more generally known as acetorphine hydrochloride, which bears US NIH Compound Identifier 71587068. Most nations, for tariff and trade purposes, schedule acetorphine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, ACETORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCC[C@](C)([C@H]1C[C@@]23C=C[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6C5C(C(CC6)OC(=O)C)O4)C)OC)O.CL.
This classification denotes a sulfone anti-infective agent with the molecular formula C14H14N3O5S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQ3M2Y4BU3, chemically known as 4, 4-diaminodiphenylsulfone-2-n-acetylsulfonamide, but more generally known as acetosulfone, which bears US NIH Compound Identifier 31400. European Medicines Agency schedules Sulfadiasulfone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04621MIG. The term SULFADIASULFONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). SMILES: S(=O)(=O)(C1C(S(=O)(=O)NC(=O)C)CC(N)CC1)C1CCC(N)CC1.
This classification denotes a peptic ulcer drug with the molecular formula C32H48O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CWW961Q19K, chemically known as acetylglycyrrhetic acid or (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-acetoxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid, and which bears US NIH Compound Identifier 94320. European Medicines Agency schedules acetoxolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21866. As of Q4 2014, ACETOXOLONE remains the US FDA Preferred Term for this commodity. Acetoxolone bears US NLM identifiers UMLS ID C0050521 and NCI Concept Code C98247. SMILES: CC(=O)OC1CCC2(C(C1(C)C)CCC3(C2C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C.
This classification denotes a contrast agent with the molecular formula C9H6I3NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24256BQV7M, chemically known as 3-(acetylamino)-2,4,6-triiodobenzoic acid but more generally known as acetrizoic acid, which bears U.S. National Institutes of Health Compound Identifier 6806. The European Medicines Agency schedules Acetrizoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00256MIG. The World Health Organization schedules acetrizoic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Acetrizoic acid under HS 29242995. SMILES: IC1C(NC(=O)C)C(I)CC(I)C1C(=O)O.
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DH1W9VH8Q. European Medicines Agency schedules Acetylcarnitine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12716MIG. Acetylcarnitine generally arises in the molecular formula C8H16CLNO4. The term 'acetylcarnitine' is a Hazardous Substances Data Bank designation. As of Q4 2014, ACETYLCARNITINE remains the US FDA Preferred Term for this commodity. Acetylcarnitine bears US NLM identifiers UMLS ID C0001040 and NCI Concept Code C87329. SMILES: O(C(C[N](C)(C)C)CC(=O)O)C(=O)C.
This classification denotes a cholinergic agonist with the molecular formula C7H16NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9YNS0M02X, chemically known as 2-acetyloxy-n,n,n-trimethylethanaminium but generally known as acetylcholine, which bears US NIH Compound Identifier 187. Acetylcholine comes in many forms including base, bromhydrate, bromide, chloride, hydrobromide, hydrochloride, iodide, mustard, mustard aziridinium, and perchlorate. European Medicines Agency schedules Acetylcholine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00261MIG. World Health Organization schedules acetylcholine in its Anatomical Therapeutic Chemical (ATC) Classification. ACETYLCHOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ACETYLCHOLINE remains the US FDA Preferred Term for this commodity. Acetylcholine bears US NLM identifiers UMLS ID C0001041 and NCI Concept Code C77840. SMILES: O(CC[N](C)(C)C)C(=O)C. .
This classification denotes a cholinergic agonist with the molecular formula C7H16NO2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AF73293C2R, chemically known as 2-acetyloxy-n,n,n-trimethylethanaminium chloride but more generally known as acetylcholine chloride, which bears US NIH Compound Identifier 6060. The base preparation, Acetylcholine, also comes in forms base, bromide, hydrobromide, hydrochloride, iodide, mustard, mustard aziridinium, and perchlorate. European Medicines Agency schedules Acetylcholine chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05228MIG. The term ACETYLCHOLINE CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations, for tariff and trade purposes, schedule acetylcholine chloride under HS 29239000 and SITC 51481. As of Q4 2014, ACETYLCHOLINE CHLORIDE remains US FDA's Preferred Term for this commodity. Acetylcholine chloride bears US NLM identifiers UMLS ID C0055389 and NCI Concept Code C47382. SMILES: CC(=O)OCC[N+](C)(C)C.[CL-].
This classification denotes a mucolytic agent and antioxidant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WYQ7N0BPYC. European Medicines Agency schedules Acetylcysteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05229MIG. Acetylcysteine generally arises in the molecular formula C5H9NO3S. The term ACETYLCYSTEINE is an International Nomenclature of Cosmetic Ingredients designation. ACETYLCYSTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule acetylcysteine under HS 29309016 and SITC 51549. As of Q4 2014, ACETYLCYSTEINE remains US FDA's Preferred Term for this commodity. Acetylcysteine bears US NLM identifiers UMLS ID C0699252 and NCI Concept Code C200. SMILES: SCC(NC(=O)C)C(=O)O.
This classification denotes a glycoside and antiarrhythmic agent with the molecular formula C43H66O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0ZV4Q4L2FU, chemically known as digitoxin, alpha-acetyl- but generally known as acetyldigitoxin, which bears US NIH Compound Identifier 68949. European Medicines Agency schedules Acetyldigitoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05230MIG. The term ACETYLDIGITOXIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules acetyldigitoxin in its Anatomical Therapeutic Chemical (ATC) Classification. ACETYLDIGITOXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acetyldigitoxin under HS 29389010 and SITC 54161. As of Q4 2014, ACETYLDIGITOXIN remains the US FDA Preferred Term for this commodity. Acetyldigitoxin bears US NLM identifiers UMLS ID C0520442 and NCI Concept Code C65212. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(O)C(OC(=O)C)C6)C)C(O)C5)C)C(O)C3)C)CC4)C)CCC1(C(CC2)C1=CC(=O)OC1)C.
This classification denotes a digoxin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7K44M64CW. European Medicines Agency schedules Acetyldigoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12718MIG. Acetyldigoxin generally arises in the molecular formula C43H66O15. The term 'acetyldigoxin' is a European Pharmacopoeia designation. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(OC(=O)C)C(O)C6)C)C(O)C5)C)C(O)C3)C)CC4)C)CC(O)C1(C(CC2)C1=CC(=O)OC1)C.
This classification denotes an opioid receptor agonist with the molecular formula C20H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SGY1T84P34, chemically known as 7,8-dihydrocodeine acetate but generally known as acetyldihydrocodeine, which bears US NIH Compound Identifier 5463874. European Medicines Agency schedules Acetyldihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12719MIG. World Health Organization schedules acetyldihydrocodeine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule acetyldihydrocodeine under HS 29391900 and SITC 54141. As of Q4 2014, ACETYLDIHYDROCODEINE remains the US FDA Preferred Term for this commodity. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)CCC2OC(=O)C.
This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C20H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SGY1T84P34, chemically known as 7,8-dihydrocodeine acetate but more generally known as acetyldihydrocodeine, which bears US NIH Compound Identifier 5463874. European Medicines Agency schedules Acetyldihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12719MIG. World Health Organization schedules acetyldihydrocodeine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule acetyldihydrocodeine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, ACETYLDIHYDROCODEINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)O[C@H]1CC[C@H]2[C@H]3CC4CCC(C5C4[C@]2([C@H]1O5)CCN3C)OC.CL.
This classification denotes the acetylglycinamide form of an adjuvant analgesic with the molecular formula C2H3Cl3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 418M5916WG, chemically known as 2,2,2-trichloroethane-1,1-diol but generally known as chloral hydrate, which bears US NIH Compound Identifier 2707. European Medicines Agency schedules Chloral hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13324MIG. World Health Organization schedules chloral hydrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ACETYLGLYCINAMIDE CHLORAL HYDRATE remains the US FDA Preferred Term for this commodity. SMILES: none.
This classification denotes an amino acid derivative with the molecular formula C8H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K76S41V71X, chemically known as (r,s)-n-acetylleucin but generally known as acetylleucine, which bears US NIH Compound Identifier 1995. European Medicines Agency schedules Acetylleucine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05231MIG. The term ACETYLLEUCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules acetylleucine in its Anatomical Therapeutic Chemical (ATC) Classification. ACETYLLEUCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acetylleucine under HS 29241900 and SITC 51471. As of Q4 2014, ACETYLLEUCINE remains the US FDA Preferred Term for this commodity. Acetylleucine bears US NLM identifiers UMLS ID C0256552 and NCI Concept Code C72679. SMILES: OC(=O)C(NC(=O)C)CC(C)C.
This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L59OC40KWJ, chemically known as 6-(dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester) but more generally known as acetylmethadol, which bears US NIH Compound Identifier 10517. Acetylmethadol comes in forms base and hydrochloride. European Medicines Agency schedules Acetylmethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05232MIG. The term ACETYLMETHADOL is an International Non-Proprietary Name. ACETYLMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule acetylmethadol hydrochloride under HS 29221980. SMILES: CCC(C(CC(C)N(C)C)(C1CCCCC1)C2CCCCC2)OC(=O)C.CL.
This classification denotes an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L59OC40KWJ, chemically known as 6-(dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester) but generally known as acetylmethadol, which bears US NIH Compound Identifier 10517. Acetylmethadol comes in forms base and hydrochloride. European Medicines Agency schedules Acetylmethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05232MIG. The term ACETYLMETHADOL is an International Non-Proprietary Name. ACETYLMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Acetylmethadol or methadyl acetate bears US NLM identifiers UMLS ID C0025607 and NCI Concept Code C91045. SMILES: O(C(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC)C(=O)C.
Clopidogrel/Acetylsalicylic acid Teva is used following initiation of therapy with clopidogrel and ASA given separately. - In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction)
This classification denotes a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but generally known as acetylsalicylic acid, which bears US NIH Compound Identifier 2244. European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O(C1C(CCCC1)C(=O)O)C(=O)C.
Acetylsalicylic acid/ramipril/simvastatin is a fixed-dose triple combination therapy of an antiplatelet (aspirin), statin (simvastatin) and ACE inhibitor (ramipril) used for secondary prevention of cardiovascular disease and treatment of hypertension.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IC4BO7D3R. European Medicines Agency schedules Acexamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05234MIG. Acexamic acid generally arises in the molecular formula C8H15NO3. The term ACEXAMIC ACID is an International Nomenclature of Cosmetic Ingredients designation. Most nations schedule acexamic acid under HS 29241900 and SITC 51471. As of Q4 2014, ACEXAMIC ACID remains the US FDA Preferred Term for this commodity. Acexamic acid bears US NLM identifiers UMLS ID C0049477 and NCI Concept Code C80535. SMILES: OC(=O)CCCCCNC(=O)C.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C8H11N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X4HES1O11F, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)- but generally known as aciclovir, which bears US NIH Compound Identifier 2022. Aciclovir, also known as acyclovir, most often comes in forms natrium and sodium. European Medicines Agency schedules Aciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05235MIG. The term ACICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules aciclovir in its Anatomical Therapeutic Chemical (ATC) Classification. ACICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Aciclovir or acyclovir bears US NLM identifiers UMLS ID C0001367 and NCI Concept Code C205. SMILES: O(CN1C2[NH]C(NC(=O)C2NC1)N)CCO.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C8H10N5O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 927L42J563, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-, monosodium salt but more generally known as aciclovir sodium, which bears US NIH Compound Identifier 50600. The base compound, Aciclovir, also known as acyclovir, also comes in base and natrium forms. European Medicines Agency schedules Aciclovir sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00284MIG. Most nations, for tariff and trade purposes, schedule aciclovir sodium under HS 29335995. SMILES: C1NC2C(=O)[N-]C(NC2N1COCCO)N.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes an anti-lipidemic agent with the molecular formula C12H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B1X701S0MV, chemically known as 4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylic acid but generally known as acifran, which bears US NIH Compound Identifier 51576. European Medicines Agency schedules Acifran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05236MIG. The term ACIFRAN is an International Non-Proprietary Name. ACIFRAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acifran under HS 29321900 and SITC 51569. As of Q4 2014, ACIFRAN remains the US FDA Preferred Term for this commodity. Acifran bears US NLM identifiers UMLS ID C0052730 and NCI Concept Code C81534. SMILES: CC1(C(=O)C=C(O1)C(=O)O)C2=CC=CC=C2.
This classification denotes an anti-lipidemic agent with the molecular formula C6H6N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K9AY9IR2SD, chemically known as 2-pyrazinecarboxylic acid, 5-methyl-, 4-oxide but more generally known as acipimox, which bears U.S. NIH Compound Identifier 39880. European Medicines Agency schedules Acipimox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05237MIG. The term ACIPIMOX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules acipimox in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. ACIPIMOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an anti-asthmatic agent with the molecular formula C9H7N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99Y8VJ356G, chemically known as oxanilic acid, 3-(1h-tetrazol-5-yl)- but generally known as acitazanolast, which bears US NIH Compound Identifier 2006. Acitazanolast comes in base and hydrate forms. European Medicines Agency schedules Acitazanolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05238MIG. The term ACITAZANOLAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ACITAZANOLAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acitazanolast under HS 29339990 and SITC 51577. As of Q4 2014, ACITAZANOLAST remains the US FDA Preferred Term for this commodity. Acitazanolast bears US NLM identifiers UMLS ID C0642373 and NCI Concept Code C74133. SMILES: O=C(NC1CC(CCC1)C1N[NH]NN1)C(=O)O.
This classification denotes an anti-asthmatic agent with the molecular structure C9H7N5O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, U6SU9ZSU4K chemically known as acetic acid, 2-oxo-2-((3-(2h-tetrazol-5-yl)phenyl)amino)-, hydrate (1:1), but more commonly known as acitazanolast hydrate, which bears US NIH Compound Identifier 11954321. European Medicines Agency schedules Acitazanolast hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33524. Most nations, for tariff and trade purposes, schedule acitazanolast hydrate under HS 29339990. SMILES: C1CC(CC(C1)NC(=O)C(=O)O)C2[NH]NNN2.O.
This classification denotes a retinoic acid agent with the molecular formula C21H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LCH760E9T7, chemically known as 2,4,6,8-nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-e)- but generally known as acitretin, which bears US NIH Compound Identifier 5284513. European Medicines Agency schedules Acitretin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05240MIG. The term ACITRETIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules acitretin in its Anatomical Therapeutic Chemical (ATC) Classification. ACITRETIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acitretin under HS 29189900 and SITC 51396. As of Q4 2014, ACITRETIN remains the US FDA Preferred Term for this commodity. Acitretin bears US NLM identifiers UMLS ID C0678135 and NCI Concept Code C985. SMILES: O(C1C(C(C(C(C1)C)/C=C/C(=C/C=C/C(=C/C(=O)O)C)C)C)C)C.
This classification denotes a glutamine amidotransferase inhibitor with the molecular formula C5H7ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0X60K76I6, chemically known as 5-isoxazoleacetic acid, alpha-amino-3-chloro-4,5-dihydro-, (s-(r*,r*))- but generally known as acivicin, which bears US NIH Compound Identifier 2007. European Medicines Agency schedules Acivicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05241MIG. The term ACIVICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). ACIVICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acivicin under HS 29349990 and SITC 51579. As of Q4 2014, ACIVICIN remains the US FDA Preferred Term for this commodity. Acivicin bears US NLM identifiers UMLS ID C0050560 and NCI Concept Code C986. SMILES: CLC1=NOC(C(N)C(=O)O)C1.
This classification denotes an aclacinomycin antibiotic with the molecular formula C42H53NO15.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 501948RI66, chemically known as 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-, methyl ester, hydrochloride, (1r-(1alpha,2beta,4beta))- but more generally known as aclarubicin hydrochloride, which bears US NIH Compound Identifier 153751. The base compound, Aclarubicin, arises in both base and hydrochloride forms. European Medicines Agency schedules Aclarubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00285MIG. Most nations, for tariff and trade purposes, schedule aclarubicin hydrochloride under HS 29419000. As of Q4 2014, ACLARUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Aclarubicin hydrochloride bears US NLM identifiers UMLS ID C0591033 and NCI Concept Code C95830. SMILES: CC[C@]1(C[C@@H](C2C(CC3C(C2O)C(=O)C4C(CCCC4O)C3=O)[C@H]1C(=O)OC)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O.CL.
This classification denotes an aclacinomycin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74KXF8I502. European Medicines Agency schedules Aclarubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05243MIG. Aclarubicin generally arises in the molecular formula C42H53NO15. The term ACLARUBICIN is an International Non-Proprietary Name or INN. ACLARUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1CC(O)(C(C2C1C(O)C1C(C2)C(=O)C2C(C1=O)C(O)CCC2)C(=O)OC)CC)C1OC(C(OC2OC(C(OC3OC(C(=O)CC3)C)C(O)C2)C)C(N(C)C)C1)C.
This classification denotes a cholinergic agonist with the molecular formula 2C10H20NO4.C10H6O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX23434YHQ, chemically known as 2-(2-(acetyloxy)-1-oxopropoxy)-n,n,n-trimethylethanaminium, 1,5-naphthalenedisulfonate (2:1) but generally known as aclatonium napadisilate, which bears US NIH Compound Identifier 41315. European Medicines Agency schedules Aclatonium napadisilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05244MIG. The term ACLATONIUM NAPADISILATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). Most nations schedule aclatonium napadisilate under HS 29239000 and SITC 51481. As of Q4 2014, ACLATONIUM NAPADISILATE remains the US FDA Preferred Term for this commodity. Aclatonium napadisilate bears US NLM identifiers UMLS ID C0076758 and NCI Concept Code C91037. SMILES: CC(C(=O)OCC[N+](C)(C)C)OC(=O)C.CC(C(=O)OCC[N+](C)(C)C)OC(=O)C.C1=CC2=C(C=CC=C2S(=O)(=O)[O-])C(=C1)S(=O)(=O)[O-].
This classification denotes an intercalating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8M28A9O41G. European Medicines Agency schedules Acodazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05245MIG. Acodazole generally arises in the molecular formula C20H19N5O. The term ACODAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) ACODAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acodazole under HS 29339990 and SITC 51577. As of Q4 2014, ACODAZOLE remains the US FDA Preferred Term for this commodity. Acodazole bears US NLM identifiers UMLS ID C0050565 and NCI Concept Code C988. SMILES: CL.O=C(N(C1CCC(NC2C3C4NC[NH]C4CCC3NC(C2)C)CC1)C)C.
This classification denotes a selective estrogen receptor modulator with the molecular formula C29H31NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 815LJ9X0D1, chemically known as 2h-1-benzopyran-7-ol, 3-(4-hydroxyphenyl)-4-methyl-2-(4-(2-(1-piperidinyl)ethoxy)phenyl)-, (2s) but generally known as acolbifene, which bears US NIH Compound Identifier 155435. Acolbifene most often comes in base and hydrochloride forms. Acolbifene also comes in hydrochloride form. The term ACOLBIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3, 2002, List 48). Most nations schedule acolbifene under HS 29349990 and SITC 51579. As of Q4 2014, ACOLBIFENE remains the US FDA Preferred Term for this commodity. Acolbifene bears US NLM identifiers UMLS ID C1122255 and NCI Concept Code C64183. SMILES: CC1=C([C@@H](OC2=C1C=CC(=C2)O)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O.
This classification denotes an antitubercular agent with the molecular formula C15H13N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8OKQ9NS8MO, chemically known as 4-pyridinecarboxylic acid, ((2-(carboxymethoxy)phenyl)methylene)hydrazide but more generally known as aconiazide, which bears US NIH Compound Identifier 5391612. European Medicines Agency schedules Aconiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05246MIG. The term ACONIAZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). ACONIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(CCCC1)/C=N\NC(=O)C1CCNCC1)CC(=O)O.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers U0NQ8555JD and KPD2N7348X, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 18174 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Ranunculanae, Order Ranunculales, Family Ranunculaceae, Genus Aconitum, commonly known as MONKSHOOD or WOLFSBANE or as here, ACONITUM NAPELUS. European Medicines Agency schedules aconitum napelus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB45854, SUB45855, SUB45856, SUB45857, SUB45858, SUB45859, SUB45860, SUB45861, and SUB49093.
This classification denotes an antiemetic agent with the molecular formula C21H30N4O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D42OWK5383. The term ACOTIAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53. ). Most nations schedule acotiamide under HS 29341000 and SITC 51579. As of Q4 2014, ACOTIAMIDE remains the US FDA Preferred Term for this commodity. Acotiamide bears US NLM identifiers UMLS ID C1879544 and NCI Concept Code C65214. SMILES: CC(C)N(CCNC(=O)C1=CSC(=N1)NC(=O)C2=CC(=C(C=C2O)OC)OC)C(C)C.
This classification denotes a vasodilating agent with the molecular formula C23H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IGS0KX75Q, chemically known as 2-(4-(acetamidomethyl)-4-phenyl-1-piperidyl)methyl-1,4-benzodioxane but generally known as acoxatrine, which bears US NIH Compound Identifier 68938. European Medicines Agency schedules Acoxatrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05247MIG. The term ACOXATRINE is an International Non-Proprietary Name. ACOXATRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acoxatrine under HS 29349990 and SITC 51579. As of Q4 2014, ACOXATRINE remains the US FDA Preferred Term for this commodity. Acoxatrine bears US NLM identifiers UMLS ID C2699761 and NCI Concept Code C74418. SMILES: O1C(CN2CCC(CC2)(CNC(=O)C)c2ccccc2)COc2c1cccc2.
This classification denotes an anti-asthmatic agent with the molecular formula C15H14ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84DZ9RW4WK, chemically known as 3,5-bis(acetoxyacetylamino)-4-chlorobenzonitrile but generally known as acreozast, which bears US NIH Compound Identifier 129991. European Medicines Agency schedules Acreozast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05248MIG. The term ACREOZAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). ACREOZAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acreozast under HS 29269095 and SITC 51484. As of Q4 2014, ACREOZAST remains the US FDA Preferred Term for this commodity. Acreozast bears US NLM identifiers UMLS ID C2347176 and NCI Concept Code C74131. SMILES: CLC1C(NC(=O)COC(=O)C)CC(CC1NC(=O)COC(=O)C)C#N.
This classification denotes an anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7SGV5HQH8B. European Medicines Agency schedules Acridorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05249MIG. Acridorex generally arises in the molecular formula C24H24N2. The term ACRIDOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, no. 10 1969, list 9.) ACRIDOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule acridorex under HS 29339990 and SITC 51577. As of Q4 2014, ACRIDOREX remains US FDA's Preferred Term for this commodity. Acridorex bears US NLM identifiers UMLS ID C2699762 and NCI Concept Code C77326. SMILES: N(C(CC1CCCCC1)C)CCC1C2C(NC3C(C2)CCCC3)CCC1.
This classification denotes a dye with the molecular formula C13H11N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1T3A50395T, chemically known as acridine-3,6-diamine, but generally known as acriflavine, and which bears US NIH Compound Identifier 443101. European Medicines Agency schedules acriflavine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00292MIG. The term ACRIFLAVINE is an International Non-Proprietary Name or INN. Acriflavine or acriflavinium bears US NLM identifiers UMLS ID C0001187 and NCI Concept Code C76253. SMILES: C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.
This classification denotes a dye with the molecular formula C13H11N3/C14H15N3.HCL, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1S73VW819C, more generally known as acriflavinium chloride. European Medicines Agency schedules acriflavinium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00292MIG. The term ACRIFLAVINE HYDROCHLORIDE is an International Non-Proprietary Name or INN.
This classification denotes an antifungal agent with the molecular formula C13H10N2.C12H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2U918O4BEV, chemically known as 1,3-benzenediol, 4-hexyl-, compd. with 9-acridinamine (1:1) but generally known as acrisorcin, which bears US NIH Compound Identifier 24144. European Medicines Agency schedules Acrisorcin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05251MIG. The term ACRISORCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). ACRISORCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acrisorcin under HS 29339990 and SITC 51577. As of Q4 2014, ACRISORCIN remains the US FDA Preferred Term for this commodity. Acrisorcin bears US NLM identifiers UMLS ID C0301311 and NCI Concept Code C65215. SMILES: OC1C(CCCCCC)CCC(O)C1.N1C2C(C(N)C3C1CCCC3)CCCC2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A20F9XAI7W, chemically known as 2-propenoic acid, 3-(6-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-2-pyridinyl)-, (e,e)- but generally known as acrivastine, which bears US NIH Compound Identifier 5284514. European Medicines Agency schedules Acrivastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05252MIG. The term ACRIVASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules acrivastine in its Anatomical Therapeutic Chemical (ATC) Classification. ACRIVASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acrivastine under HS 29333999 and SITC 51574. As of Q4 2014, ACRIVASTINE remains the US FDA Preferred Term for this commodity. Acrivastine bears US NLM identifiers UMLS ID C0054340 and NCI Concept Code C47383. SMILES: OC(=O)/C=C/C1NC(C(=C\CN2CCCC2)\C2CCC(CC2)C)CCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H29FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67N58AU0IZ, chemically known as 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acrolein but generally known as acrocinonide, which bears US NIH Compound Identifier 176868. European Medicines Agency schedules Acrocinonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05253MIG. The term ACROCINONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). ACROCINONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acrocinonide under HS 29372200 and SITC 54153. As of Q4 2014, ACROCINONIDE remains the US FDA Preferred Term for this commodity. Acrocinonide bears US NLM identifiers UMLS ID C2699763 and NCI Concept Code C77405. SMILES: FC12C(C3C(C4(OC(OC4C3)C=C)C(=O)CO)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes an antiarrhythmic agent with the molecular formula C23H35N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) IJQ29N87NR, chemically known as 3h-pyrido(1,2-c)pyrimidin-3-one, 4-(2-(bis(1-methylethyl)amino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-, cis-(+-)- but more generally known as actisomide, which bears US NIH Compound Identifier 57147. European Medicines Agency schedules Actisomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05257MIG. The term ACTISOMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). ACTISOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule actisomide under HS 29335995 and SITC 51576. As of Q4 2014, ACTISOMIDE remains US FDA's Preferred Term for this commodity. Actisomide bears US NLM identifiers UMLS ID C0074107 and NCI Concept Code C90662. SMILES: O=C1N=C(N2C(C1(CCN(C(C)C)C(C)C)C1CCCCC1)CCCC2)C.
This classification denotes an element or isotope with the molecular formula C, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2P3VWU3H10, chemically known as 1,3-dichloro-propan-2-one but generally known as activated charcoal, which bears US NIH Compound Identifier 297. European Medicines Agency schedules Carbon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13242MIG. World Health Organization schedules activated charcoal in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C.
This classification denotes an antidepressant agent with the molecular formula C20H26ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B8VQU4C05J, chemically known as 2-(1-tricyclo(3.3.1.1(3,7))decylamino)ethyl (4-chlorphenoxy)acetat but generally known as adafenoxate, which bears US NIH Compound Identifier 64517. European Medicines Agency schedules Adafenoxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05259MIG. The term ADAFENOXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). ADAFENOXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adafenoxate under HS 29221980 and SITC 51461. As of Q4 2014, ADAFENOXATE remains the US FDA Preferred Term for this commodity. Adafenoxate bears US NLM identifiers UMLS ID C0050721 and NCI Concept Code C72680. SMILES: Clc1ccc(OCC(=O)OCCNC23CC4CC(C3)CC(C2)C4)cc1.
This classification denotes a monoclonal antibody and biological response modifier with the molecular formula C6428H9912N1694O1987S46, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) FYS6T7F842, more generally known as adalimumab. European Medicines Agency schedules adalimumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20016. The term ADALIMUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). As of Q4 2014, ADALIMUMAB remains US FDA's Preferred Term for this commodity. Adalimumab bears US NLM identifiers UMLS ID C1122087 and NCI Concept Code C65216. Most nations, for tariff and trade purposes, schedule adalimumab under HS 30021091 and SITC 54163. For the most current information on WCO designations on adalimumab and salts thereof, please see Committee proceedings HSC/27, NC0430B2 Ann. Q/1 (I) (2001). SMILES: none.
This classification denotes a retinoic acid agent with the molecular formula C28H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1L4806J2QF, chemically known as 2-naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo(3.3.1.1(sup 3,7))dec-1-ylphenyl)- but generally known as adapalene, which bears US NIH Compound Identifier 60164. European Medicines Agency schedules Adapalene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05261MIG. The term ADAPALENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules adapalene in its Anatomical Therapeutic Chemical (ATC) Classification. ADAPALENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adapalene under HS 29189900 and SITC 51396. As of Q4 2014, ADAPALENE remains the US FDA Preferred Term for this commodity. Adapalene bears US NLM identifiers UMLS ID C0165631 and NCI Concept Code C28989. SMILES: O(C1C(C23CC4CC(C3)CC(C2)C4)CC(CC1)C1CC2C(CC1)CC(CC2)C(=O)O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C26H39NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XP9911I1WL, chemically known as (+/-)-2-(1-adamantyl)ethyl (p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetate, but generally known as adaprolol, which bears US NIH Compound Identifier 60732. European Medicines Agency schedules adaprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05262MIG. Most nations schedule adaprolol under HS 29221980 and SITC 51461. As of Q4 2014, ADAPROLOL remains the US FDA Preferred Term for this commodity. Adaprolol bears US NLM identifiers UMLS ID C0645354 and NCI Concept Code C77938. SMILES: CC(C)NCC(COC1=CC=C(C=C1)CC(=O)OCCC23CC4CC(C2)CC(C4)C3)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C26H39NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2I8RV6WL9A, chemically known as benzeneacetic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, 2-tricyclo(3.3.1.1(sup 3,7))dec-1-ylethyl ester, (+-)-, (z)-2-butenedioate (1:1) (salt) but more generally known as adaprolol maleate, which bears US NIH Compound Identifier 6435805. Most nations, for tariff and trade purposes, schedule adaprolol maleate under HS 29221980 and SITC 51461. As of Q4 2014, ADAPROLOL MALEATE remains US FDA's Preferred Term for this commodity. Adaprolol maleate bears US NLM identifiers UMLS ID C0645353 and NCI Concept Code C79960. SMILES: CC(C)NCC(COC1CCC(CC1)CC(=O)OCCC23CC4CC(C2)CC(C4)C3)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes a serotonin antagonist with the molecular formula C21H31N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5U6WQM26H, chemically known as tricyclo(3.3.1.1(3,7))decane-1-carboxamide, n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)- but generally known as adatanserin, which bears US NIH Compound Identifier 130918. Adatanserin comes in base and hydrochloride form. European Medicines Agency schedules Adatanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05263MIG. The term ADATANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). ADATANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adatanserin under HS 29335995 and SITC 51576. As of Q4 2014, ADATANSERIN remains the US FDA Preferred Term for this commodity. Adatanserin bears US NLM identifiers UMLS ID C0216334 and NCI Concept Code C75981. SMILES: O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(C1)CC(C2)C3.
This classification denotes a serotonin antagonist with the molecular formula C21H31N5O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48BX75B06D. The term adatanserin hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule adatanserin hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ADATANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Adatanserin hydrochloride bears US NLM identifiers UMLS ID C2700163 and NCI Concept Code C76070. SMILES: C1CNC(NC1)N2CCN(CC2)CCNC(=O)[C@]34C[C@@H]5C[C@H](C3)CC(C5)C4.CL.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H12N5O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6GQP90I798, chemically known as phosphonic acid, ((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)- but generally known as adefovir, which bears US NIH Compound Identifier 60172. Adefovir most often comes in dipivoxil and pivoxil forms. European Medicines Agency schedules Adefovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05264MIG. The term ADEFOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ADEFOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adefovir under HS 29335995 and SITC 51576. As of Q4 2014, ADEFOVIR remains the US FDA Preferred Term for this commodity. Adefovir bears US NLM identifiers UMLS ID C0050175 and NCI Concept Code C61526. SMILES: C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O.
This classification denotes an acyclic nucleotide adenine antiviral with the molecular formula C20H32N5O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6Q8Z01514, chemically known as propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester but more generally known as adefovir dipivoxil, which bears US NIH Compound Identifier 60871. European Medicines Agency schedules Adefovir dipivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12454MIG. World Health Organization schedules adefovir dipivoxil in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule adefovir dipivoxil under HS 29335995 and SITC 51576. As of Q4 2014, ADEFOVIR DIPIVOXIL remains US FDA's Preferred Term for this commodity. Adefovir dipivoxil bears US NLM identifiers UMLS ID C0540694 and NCI Concept Code C28811. SMILES: CC(C)(C)C(=O)OCOP(=O)(COCCN1CNC2C1NCNC2N)OCOC(=O)C(C)(C)C.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C20H32N5O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6Q8Z01514, chemically known as adefovir di(pivaloyloxymethyl) ester [mi], but more generally known as adefovir pivoxil, which bears US NIH Compound Identifier 60871. European Medicines Agency schedules adefovir pivoxil or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05264MIG. Most nations, for tariff purposes, schedule adefovir pivoxil under HS 29335995. SMILES: CC(C)(C)C(=O)OCOP(=O)(COCCN1CNC2C1NCNC2N)OCOC(=O)C(C)(C)C.
This classification denotes an amino acid with the molecular formula C15H22N6O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LP2MPO46S, chemically known as methionine, s-adenosyl- (6ci) active methionine but generally known as ademetionine, which bears US NIH Compound Identifier 34755. European Medicines Agency schedules Ademetionine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05266MIG. The term ADEMETIONINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules ademetionine in its Anatomical Therapeutic Chemical (ATC) Classification. ADEMETIONINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ademetionine under HS 29349990 and SITC 51579. As of Q4 2014, ADEMETIONINE remains the US FDA Preferred Term for this commodity. Ademetionine bears US NLM identifiers UMLS ID CL434401 and NCI Concept Code C100098. SMILES: [S](CC1OC(N2C3NCNC(N)C3NC2)C(O)C1O)(CCC(N)C(=O)O)C.
This classification denotes a purine with the molecular formula C5H5N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JAC85A2161, chemically known as 3,6-dihydro-6-iminopurine but generally known as adenine, which bears US NIH Compound Identifier 190. Adenine comes in many forms, including arabinoside, deoxyribonucleoside, deoxyribose, dihydroiodide, hemisulfate, hydrochloride, nucleoside, octosyl acid, phosphate, propenal, riboside, sulfate, and xyloside. European Medicines Agency schedules Adenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12455MIG. Most nations schedule adenine under HS 29335990 and SITC 51576. As of Q4 2014, ADENINE remains the US FDA Preferred Term for this commodity. Adenine bears US NLM identifiers UMLS ID C0001407 and NCI Concept Code C206. SMILES: [NH]1C2C(NC1)NCNC2N.
This classification denotes a nucleoside with the molecular formula C10H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) K72T3FS567, chemically known as 9h-purin-6-amine, 9-beta-d-xylofuranosyl- (9ci) but more generally known as adenosine, which bears US NIH Compound Identifier 191. Adenosine comes in many forms, including arabinose, arabinoside-5-phosphate, cyclic 3,5-phosphate, dialdehyde, diphosphate, diphosphoglucose, diphosphopyridoxal, diphosphoribose, diphosphoric acid, monophosphofluoridate, oxide, phosphate, phosphonoacetic acid, phosphosulfate, sulfatophosphate, tetraphosphate, tetraphosphate pyridoxal, thiamine triphosphate, and triphosphate. European Medicines Agency schedules Adenosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00297MIG. World Health Organization schedules adenosine in its Anatomical Therapeutic Chemical (ATC) Classification. ADENOSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule adenosine under HS 29349990 and SITC 51579. As of Q4 2014, ADENOSINE remains US FDA's Preferred Term for this commodity. Adenosine bears US NLM identifiers UMLS ID C0001443 and NCI Concept Code C207. SMILES: C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CO)O)O.
This classification denotes a nucleoside C10H15N5O10P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61D2G4IYVH, chemically known as adenosine, 5'-(trihydrogen pyrophosphate), but more generally known as adenosine diphosphate, which bears US NIH Compound Identifier 6022. European Medicines Agency schedules Adenosine diphosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12740MIG. Most nations, for tariff and trade purposes, schedule adenosine diphosphate under HS 29349990 and SITC 51579. As of Q4 2014, ADENOSINE DIPHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N.
This classification denotes an aprt gene, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 415SHH325A. European Medicines Agency schedules Adenosine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05267MIG. Adenosine phosphate generally arises in the molecular formula C10H14N5O7P. The term ADENOSINE PHOSPHATE is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule adenosine phosphate under HS 29349990 and SITC 51579. As of Q4 2014, ADENOSINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Adenosine phosphate bears US NLM identifiers UMLS ID C0001413 and NCI Concept Code C83606. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N.
This classification denotes a nucleotide with the molecular formula C10H16N5O13P3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8L70Q75FXE. European Medicines Agency schedules adenosine triphosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12741MIG. The term adenosine triphosphate is an International Nomenclature of Cosmetic Ingredients designation. Most nations, for tariff and trade purposes, schedule adenosine triphosphate under HS 29349990 and SITC 51579. As of Q4 2014, ADENOSINE TRIPHOSPHATE remains US FDA's Preferred Term for this commodity. Adenosine triphosphate bears US NLM identifiers UMLS ID C0001480 and NCI Concept Code C209. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C16H14N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E87N3L27KX, chemically known as 5,7-dihydro-7,7-dimethyl-2-(4-pyridyl)pyrrolo(2,3-f)benzimidazol-6(3h)-one but generally known as adibendan, which bears US NIH Compound Identifier 65867. European Medicines Agency schedules Adibendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05268MIG. The term ADIBENDAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ADIBENDAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adibendan under HS 29337900 and SITC 51561. As of Q4 2014, ADIBENDAN remains the US FDA Preferred Term for this commodity. Adibendan bears US NLM identifiers UMLS ID C0050840 and NCI Concept Code C74350. SMILES: O=C1NC2C(C1(C)C)CC1[NH]C(NC1C2)C1CCNCC1.
This classification denotes a penicillin antibiotic with the molecular formula C14H21N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NOF9U9EYQ4, chemically known as 6-(5-amino-5-carboxyvaleramido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as adicillin, which bears US NIH Compound Identifier 71724. European Medicines Agency schedules Adicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05269MIG. The term ADICILLIN is an International Non-Proprietary Name. ADICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Adicillin or penicillin n bears US NLM identifiers UMLS ID C0070233 and NCI Concept Code C72659. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)CCCC(N)C(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C25H29N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6CJY5K2ST, chemically known as (rs)-2,3-dihydro-1-(3-(2-hydroxy-3-(naphthyloxy)propylamino)-3-methylbutyl)-1h-2-benzimidazolon but generally known as adimolol, which bears US NIH Compound Identifier 71227. Adimolol most often comes in forms base, hydrochloride, and hydrate. European Medicines Agency schedules Adimolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05270MIG. The term ADIMOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). ADIMOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adimolol under HS 29339990 and SITC 51577. As of Q4 2014, ADIMOLOL remains the US FDA Preferred Term for this commodity. Adimolol bears US NLM identifiers UMLS ID C0050843 and NCI Concept Code C73013. SMILES: OC(CNC(CCN1C2C([NH]C1=O)CCCC2)(C)C)COC1C2C(CCC1)CCCC2.
This classification denotes a benzodiazepine with the molecular formula C19H18ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KN08449444, chemically known as 8-chloro-1-((dimethylamino)methyl)-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine but generally known as adinazolam, which bears US NIH Compound Identifier 37632. Adinazolam most often comes in forms mesylate and monomethanesulfonate. European Medicines Agency schedules Adinazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05271MIG. The term ADINAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules adinazolam in its Anatomical Therapeutic Chemical (ATC) Classification. ADINAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adinazolam under HS 29339940 and SITC 51577. As of Q4 2014, ADINAZOLAM remains the US FDA Preferred Term for this commodity. Adinazolam bears US NLM identifiers UMLS ID C0050844 and NCI Concept Code C76531. SMILES: Clc1cc2c(n3c(nnc3CN=C2c2ccccc2)CN(C)C)cc1.
This classification denotes a benzodiazepine with the molecular formula C19H18CLN5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NT8S62A727. The term adinazolam mesilate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule adinazolam mesylate under HS 29339940. As of Q4 2014, ADINAZOLAM MESYLATE remains US FDA's Preferred Term for this commodity. Adinazolam mesylate bears US NLM identifiers UMLS ID C0167214 and NCI Concept Code C76532. SMILES: CN(C)CC1NNC2N1-C3CCC(CC3C(=NC2)C4CCCCC4)CL.CS(=O)(=O)O.
This classification denotes an antimuscarinic agent with the molecular formula C20H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42B4PDY0AV, chemically known as trasentine, hydrochloride but more generally known as adiphenine hydrochloride, which bears US NIH Compound Identifier 2031. European Medicines Agency schedules Adiphenine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00305MIG. Most nations, for tariff and trade purposes, schedule adiphenine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, ADIPHENINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Adiphenine hydrochloride bears US NLM NCI C75271. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)C2CCCCC2.CL.
This classification denotes an antispasmotic agent with the molecular formula C21H28NO2.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OVU84VI37, chemically known as acetic acid, diphenyl-, ester with diethyl(2-hydroxyethyl)methylammonium bromide, but more generally known as adiphenine methyl bromide, which bears US NIH Compound Identifier 197841. European Medicines Agency schedules adiphenine methyl bromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05272MIG. Most nations, for tariff purposes, schedule adiphenine methyl bromide under HS 29221980. SMILES: CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2CCCCC2.[BR-].
This classification denotes an antispasmotic agent with the molecular formulas C20H25NO2 or C20H25NO2.ClH or C21H28NO2.Br, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers YKG6OR043Q, 42B4PDY0AV, 2OVU84VI37, the base of which is chemically known as 2-(diethylamino)ethyl diphenylacetate but that is generally known as adiphenine, which bears US NIH Compound Identifier 2031. Adiphenine most often comes in forms chloride, hydrochloride, and methyl bromide. European Medicines Agency schedules Adiphenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05272MIG (base) and SUB00305MIG (hydrochloride). The term ADIPHENINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). ADIPHENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adiphenine, adiphenine hydrochloride, and adiphenine methyl bromide under HS 29221980 and SITC 51461. As of Q4 2014, ADIPHENINE remains the US FDA Preferred Term for this commodity. Adiphenine bears US NLM NCI Concept Codes C75271 and C76456. SMILES: O(CCN(CC)CC)C(=O)C(C1CCCCC1)C1CCCCC1 (BASE), CCN(CC)CCOC(=O)C(C1CCCCC1)C2CCCCC2.CL (CHLORIDE and HYDROCHLORIDE), and CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2CCCCC2.[BR-] (METHYL BROMIDE).
This classification denotes an iodinated contrast dye (especially used in liver CT studies) with the molecular formula C20H14I6N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TKQ858A3VW, chemically known as 3,3-(adipoyldiimino)bis(2,4,6-triiodobenzoic acid) but more generally known as adipiodone, which bears U.S. National Institutes of Health Compound Identifier 3739. Adipiodone most often comes in forms base and meglumine. European Medicines Agency schedules Adipiodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05273MIG. The term ADIPIODONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules adipiodone in its Anatomical Therapeutic Chemical (ATC) Classification. ADIPIODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Adipiodone or iodipamide under HS 29242995. Adipiodone or iodipamide bears US NLM identifiers UMLS ID C0021971 and NCI Concept Code C61791. SMILES: IC1C(NC(=O)CCCCC(=O)NC2C(I)C(C(I)CC2I)C(=O)O)C(I)CC(I)C1C(=O)O.
This classification denotes a diuretic with the molecular formula C13H17N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L4F80M873G, chemically known as 2,4-diamino-5-(4-amino-3,5-dimethoxybenzyl)pyrimidine but generally known as aditeren, which bears US NIH Compound Identifier 176875. European Medicines Agency schedules Aditeren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05274MIG. The term ADITEREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). ADITEREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aditeren under HS 29335995 and SITC 51576. As of Q4 2014, ADITEREN remains the US FDA Preferred Term for this commodity. Aditeren bears US NLM identifiers UMLS ID C2700367 and NCI Concept Code C74259. SMILES: O(C1CC(CC2C(NC(NC2)N)N)CC(OC)C1N)C.
This classification denotes a dihydrofolate reductase inhibitor and anti-infective agent with the molecular formula C15H21N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z81WDX2ZH, chemically known as 2,4-pyrimidinediamine, 5-((4-(dimethylamino)-3,5-dimethoxyphenyl)methyl)- but more generally known as aditoprim, which bears US NIH Compound Identifier 68755. European Medicines Agency schedules Aditoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05275MIG. The term ADITOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). ADITOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(N(C)C)C(OC)CC(CC2C(NC(NC2)N)N)C1)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C15H15NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BI81Z4542G, chemically known as acetohydroxamic acid, 2-((diphenylmethyl)sulfinyl)- but generally known as adrafinil, which bears US NIH Compound Identifier 3033226. European Medicines Agency schedules Adrafinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05278MIG. The term ADRAFINIL is an International Non-Proprietary Name. World Health Organization schedules adrafinil in its Anatomical Therapeutic Chemical (ATC) Classification. ADRAFINIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adrafinil under HS 29309085 and SITC 51549. As of Q4 2014, ADRAFINIL remains the US FDA Preferred Term for this commodity. Adrafinil bears US NLM identifiers UMLS ID C0101700 and NCI Concept Code C81369. SMILES: S(=O)(C(c1ccccc1)c1ccccc1)CC(=O)NO.
This classification denotes a catecholamine and adrenergic agonist with the molecular formula C9H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YKH834O4BH, chemically known as 3,4-dihydroxy-alpha-(methylaminomethyl)benzyl alcohol but generally known as adrenaline, which bears US NIH Compound Identifier 838. Adrenaline comes in various forms, including acid tartrate, bitartrate, borate, carboxylic acid, chloride, hydrochloride, hydrogen tartrate, and sulfate. European Medicines Agency schedules Adrenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15951MIG. The term EPINEPHRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules adrenaline in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: OC(C1CC(O)C(O)CC1)CNC.
This classification denotes an adrenergic agent with the molecular formula C9H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EGU41QL329, chemically known as 3,4-dihydroxy-alpha-methylaminoacetophenone but generally known as adrenalone, which bears US NIH Compound Identifier 7436. Adrenalone comes in forms base and hydrochloride. European Medicines Agency schedules Adrenalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05279MIG. The term ADRENALONE is an International Non-Proprietary Name. World Health Organization schedules adrenalone in its Anatomical Therapeutic Chemical (ATC) Classification. ADRENALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adrenalone under HS 29225000 and SITC 51467. As of Q4 2014, ADRENALONE remains the US FDA Preferred Term for this commodity. Adrenalone bears US NLM identifiers UMLS ID C0050876 and NCI Concept Code C81339. SMILES: O=C(C1CC(O)C(O)CC1)CNC.
This classification denotes a dopamine agonist with the molecular formula C22H25NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YC3281G42A, chemically known as (5ar, 11bs) 4,5,5a,6,7,11b-hexahydro-2-propylbenzo(f)thienol(2,3c)quinoline-9,10-diol diacetate (ester) but generally known as adrogolide, which bears US NIH Compound Identifier 176876. Adrogolide comes in both base and hydrochloride forms. The term ADROGOLIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule adrogolide under HS 29349990 and SITC 51579. As of Q4 2014, ADROGOLIDE remains the US FDA Preferred Term for this commodity. Adrogolide bears US NLM identifiers UMLS ID C0381061 and NCI Concept Code C73308. SMILES: CCCC1=CC2=C(S1)CNC3C2C4=CC(=C(C=C4CC3)OC(=O)C)OC(=O)C.
This classification denotes a dopamine agonist with the molecular formula C22H25NO4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69MG3OZA0H, chemically known as benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), hydrochloride, (5ar-trans)- but more generally known as adrogolide hydrochloride, which bears US NIH Compound Identifier 166543. Most nations, for tariff and trade purposes, schedule adrogolide hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ADROGOLIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Adrogolide hydrochloride bears US NLM identifiers UMLS ID C2347538 and NCI Concept Code C72681. SMILES: CCCC1CC2C(S1)CN[C@H]3[C@H]2C4CC(C(CC4CC3)OC(=O)C)OC(=O)C.CL.
This classification denotes a natural product, derivations of which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U76MXL14N and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 28714 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Sapindales, Family Sapindaceae, and Genus Aesculus L., more commonly known as AESCULUS. Aesculus bears the USDA PLANTS Identifier AESCU. European Medicines Agency schedules aesculus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33806.
This classification denotes a quinazoline and antineoplastic agent and tyrosine kinase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41UD74L59M. European Medicines Agency schedules Afatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32268. As of Q4 2014, AFATINIB remains the US FDA Preferred Term for this commodity. Afatinib bears US NLM identifiers UMLS ID C1879772 and NCI Concept Code C66940. SMILES: CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4.
This classification denotes an immunosuppressant, a biological preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SC756X51V. As of Q4 2014, AFELIMOMAB remains US FDA's Preferred Term for this commodity. Most nations, for tariff and trade purposes, schedule afelimomab under HS 30021000 and SITC 54163 (For the most current information on WCO designations on afelimomab and salts thereof, please see Committee proceedings HSC/18, 40.600 Ann. D, par. 6, 1996).
Aflibercept injection is a prescription medicine administered by injection into the eye. It is a vascular endothelial growth factor (VEGF) inhibitor. https://www.eylea.us/
This classification denotes a muscle relaxant with the molecular formula C16H14FN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CO4U2C8ORZ, chemically known as 6-amino-3,4-dihydro-2-fluoromethyl-3-(2-methylphenyl)-4-chinazolinon but generally known as afloqualone, which bears US NIH Compound Identifier 2040. European Medicines Agency schedules Afloqualone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05281MIG. The term AFLOQUALONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). AFLOQUALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule afloqualone under HS 29335995 and SITC 51576. As of Q4 2014, AFLOQUALONE remains the US FDA Preferred Term for this commodity. Afloqualone bears US NLM identifiers UMLS ID C0050939 and NCI Concept Code C83522. SMILES: FCC1N(C2C(CCCC2)C)C(=O)C2C(N1)CCC(N)C2.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WQ1WRV49R9. European Medicines Agency schedules Afurolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05283MIG. Afurolol generally arises in the molecular formula C15H21NO4. The term AFUROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) AFUROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, AFUROLOL remains the US FDA Preferred Term for this commodity. Afurolol bears US NLM identifiers UMLS ID C2348000 and NCI Concept Code C72970. SMILES: O(CC(O)CNC(C)(C)C)C1C2C(COC2=O)CCC1.
Agalsidase alfa is a recombinant human ?-galactosidase indicated in the treatment of Fabry disease.
A drug indicated for use in patients with Fabry disease.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H10Cl2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 670P9AQR46, chemically known as guanidine, (4,7-dichloro-2-isoindolinyl)- but generally known as aganodine, which bears US NIH Compound Identifier 176878. European Medicines Agency schedules Aganodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05284MIG. The term AGANODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). AGANODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aganodine under HS 29339990 and SITC 51577. As of Q4 2014, AGANODINE remains the US FDA Preferred Term for this commodity. Aganodine bears US NLM identifiers UMLS ID C2697894 and NCI Concept Code C74229. SMILES: C1C2=C(C=CC(=C2CN1N=C(N)N)Cl)Cl.
This classification denotes an anti-progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0UT4JLE1CM. European Medicines Agency schedules Aglepristone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05285MIG. Aglepristone generally arises in the molecular formula C29H37NO2. The term AGLEPRISTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) AGLEPRISTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aglepristone under HS 29225000 and SITC 51467. As of Q4 2014, AGLEPRISTONE remains the US FDA Preferred Term for this commodity. Aglepristone bears US NLM identifiers UMLS ID C0963581 and NCI Concept Code C78092. SMILES: OC1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)C(C2)c2ccc(N(C)C)cc2)CC1)C)/C=C\C.
This classification denotes a serotonin antagonist and anxiolytic with the molecular formula C15H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 137R1N49AD, chemically known as acetamide, n-(2-(7-methoxy-1-naphthalenyl)ethyl)- but generally known as agomelatine, which bears US NIH Compound Identifier 82148. European Medicines Agency schedules Agomelatine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05286MIG. The term AGOMELATINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). World Health Organization schedules agomelatine in its Anatomical Therapeutic Chemical (ATC) Classification. AGOMELATINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule agomelatine under HS 29242995 and SITC 51479. As of Q4 2014, AGOMELATINE remains the US FDA Preferred Term for this commodity. Agomelatine bears US NLM identifiers UMLS ID C0971637 and NCI Concept Code C72684. SMILES: O(c1cc2c(CCNC(=O)C)cccc2cc1)C.
This classification denotes an antiarrhythmic agent with the molecular formula C20H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1PON08459R, chemically known as ajmalan-17,21-diol, (17r,21.alpha.)- but more generally known as ajmaline, which bears US NIH Compound Identifier 2073. Ajmaline comes in many forms, including aspartate, ethanolate, ethylphenylbarbiturate, n-oxide, and phenylbarbiturate. European Medicines Agency schedules Ajmaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12754MIG. World Health Organization schedules ajmaline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, AJMALINE remains US FDA's Preferred Term for this commodity. Ajmaline bears US NLM identifiers UMLS ID C0001888 and NCI Concept Code C83524. SMILES: OC1C23C(N(C4C3CCCC4)C)C3N4C(C1C(C3)C(C4O)CC)C2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes an antidepressant agent with the molecular formula C13H18ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4R42570ZO, chemically known as 4-chlor-alpha,alpha-dimethylphenethyl (rs)-2-aminopropionat but generally known as alaproclate, which bears US NIH Compound Identifier 2081. Alaproclate comes in base and hydrochloride forms. European Medicines Agency schedules Alaproclate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05292MIG. The term ALAPROCLATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules alaproclate in its Anatomical Therapeutic Chemical (ATC) Classification. ALAPROCLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alaproclate under HS 29224995 and SITC 51465. As of Q4 2014, ALAPROCLATE remains the US FDA Preferred Term for this commodity. Alaproclate bears US NLM identifiers UMLS ID C0051086 and NCI Concept Code C72685. SMILES: Clc1ccc(CC(OC(=O)C(N)C)(C)C)cc1.
This classification denotes a quinolone antibiotic and antimicrobial solution with the molecular formula C26H25F3N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7QVV6I50DT, chemically known as l-alaninamide, l-alanyl-n-(3-(6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5,8-dihydro-5-oxo-1,8-naphthyridin-2-yl)-3-azabicyclo(3.1.0)hex-6-yl)-, (1alpha,5alpha,6alpha)- but generally known as alatrofloxacin, which bears US NIH Compound Identifier 3086677. Alatrofloxacin most often comes in base and mesylate forms. European Medicines Agency schedules Alatrofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05293MIG. The term ALATROFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). ALATROFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alatrofloxacin under HS 29339990 and SITC 51577. As of Q4 2014, ALATROFLOXACIN remains the US FDA Preferred Term for this commodity. Alatrofloxacin bears US NLM identifiers UMLS ID C0540776 and NCI Concept Code C79898. SMILES: FC1C(N2CC3C(C3NC(=O)C(NC(=O)C(N)C)C)C2)NC2N(CC(C(=O)C2C1)C(=O)O)C1C(F)CC(F)CC1.
This classification denotes an antifungal agent with the molecular formula C20H16ClF2N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YDW24Y8IAB, chemically known as 7-chloro-3-((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)quinazolin-4(3h)-one but generally known as albaconazole, which bears US NIH Compound Identifier 208952. European Medicines Agency schedules Albaconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32139. The term ALBACONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 2, 2003, List 49). Most nations schedule albaconazole under HS 29335995 and SITC 51576. As of Q4 2014, ALBACONAZOLE remains the US FDA Preferred Term for this commodity. Albaconazole bears US NLM identifiers UMLS ID C0675272 and NCI Concept Code C72952. SMILES: CLC1CC2NCN(C(C(O)(CN3NCNC3)C3C(F)CC(F)CC3)C)C(=O)C2CC1.
This classification denotes an antihelminthic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4216019LN. European Medicines Agency schedules Albendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05295MIG. Albendazole generally arises in the molecular formula C12H15N3O2S. The term ALBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) ALBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule albendazole under HS 29339990 and SITC 51577. As of Q4 2014, ALBENDAZOLE remains the US FDA Preferred Term for this commodity. Albendazole bears US NLM identifiers UMLS ID C0591462 and NCI Concept Code C47384. SMILES: CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC.
This classification denotes an antihelminthic agent with the molecular formula C12H15N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J39B52TV34, chemically known as carbamic acid, (5-propylsulfinyl)-1h-benzimidazol-2-yl)-, methyl ester but more generally known as albendazole oxide, which bears US NIH Compound Identifier 83969. European Medicines Agency schedules Albendazole oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05296MIG. The term ALBENDAZOLE OXIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). Most nations, for tariff and trade purposes, schedule albendazole oxide under HS 29339990 and SITC 51577. As of Q4 2014, ALBENDAZOLE OXIDE remains US FDA's Preferred Term for this commodity. Albendazole oxide bears US NLM identifiers UMLS ID C2348240 and NCI Concept Code C72157. SMILES: CCC[S+](C1CCC2C(C1)NC([NH]2)NC(=O)OC)[O-].
This classification denotes an antihelminthic agent with the molecular formula C12H15N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UIC88380G, chemically known as methyl n-(5-(propane-1-sulfonyl)-1h-1,3-benzodiazol-2-yl)carbamate, but more generally known as albendazole sulfone, which bears US NIH Compound Identifier 53174. European Medicines Agency schedules albendazole sulfone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05295MIG. Most nations, for tariff purposes, schedule albendazole sulfone under HS 29339990. SMILES: CCCS(=O)(=O)C1CCC2C(C1)NC([NH]2)NC(=O)OC.
This classification denotes an antihelminthic agent with the molecular formula C12H15N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J39B52TV34, chemically known as methyl (5-(propylsulfinyl)-1h-benzo(d)imidazol-2-yl)carbamate, but more generally known as albendazole sulfoxide, which bears US NIH Compound Identifier 83969. European Medicines Agency schedules albendazole sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05295MIG. Most nations, for tariff purposes, schedule albendazole sulfoxide under HS 29339990. SMILES: CCC[S+](C1CCC2C(C1)NC([NH]2)NC(=O)OC)[O-].
This classification denotes a peptide fragment derived from human blood plasma, or that residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZIF514RVZR. European Medicines Agency schedules albumin human in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB12026MIG, SUB12761MIG, SUB50207, and SUB62389. As of Q4 2014, ALBUMIN HUMAN remains the US FDA Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX201. This VA Drug Class (DX201) classifies this compound as belonging to the group IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QF8SVZ843E, chemically known as 1,3-benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy- but generally known as albuterol, which bears US NIH Compound Identifier 2083. Albuterol comes in many forms, including adipate diethanolate, di-methylboronate, n-butylboronate, and sulfate. European Medicines Agency schedules Albuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10422MIG. The term SALBUTAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules albuterol in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule albuterol under HS 29225090 and SITC 51467. As of Q4 2014, ALBUTEROL remains the US FDA Preferred Term for this commodity. Albuterol bears US NLM identifiers UMLS ID C0001927 and NCI Concept Code C215. SMILES: OC(CNC(C)(C)C)C1CC(C(O)CC1)CO.
This classification denotes an anticonvulsant agent with the molecular formula C10H16N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 475NGR2DC1, chemically known as 4-imidazolidinone, 5-(2-methylpropyl)-3-(2-propenyl)-2-thioxo- but generally known as albutoin, which bears US NIH Compound Identifier 3032361. European Medicines Agency schedules Albutoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05298MIG. The term ALBUTOIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). ALBUTOIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule albutoin under HS 29332990 and SITC 51573. As of Q4 2014, ALBUTOIN remains the US FDA Preferred Term for this commodity. Albutoin bears US NLM identifiers UMLS ID C0051108 and NCI Concept Code C90706. SMILES: CC(C)CC1C(=O)N(C(=S)N1)CC=C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z8O94ECSX. European Medicines Agency schedules alcaftadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37833. The term ALCAFTADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56). Most nations schedule alcaftadine under HS 29333990 and SITC 51574. As of Q4 2014, ALCAFTADINE remains the US FDA Preferred Term for this commodity. Alcaftadine bears US NLM identifiers UMLS ID C2348241 and NCI Concept Code C72686. SMILES: CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1.
This classification denotes an anti-inflammatory agent with the molecular formula C11H11ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M9CP5H21N8, chemically known as benzeneacetic acid, 3-chloro-4-(2-propenyloxy)- but generally known as alclofenac, which bears US NIH Compound Identifier 30951. Alclofenac comes in many forms, including epoxide, monoethanolamine complex, and sodium. European Medicines Agency schedules Alclofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05299MIG. The term ALCLOFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules alclofenac in its Anatomical Therapeutic Chemical (ATC) Classification. ALCLOFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alclofenac under HS 29189900 and SITC 51396. As of Q4 2014, ALCLOFENAC remains the US FDA Preferred Term for this commodity. SMILES: C=CCOC1=C(C=C(C=C1)CC(=O)O)CL.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 136H45TB7B. European Medicines Agency schedules Alclometasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05300MIG. Alclometasone generally arises in the molecular formula C22H29CLO5. The term ALCLOMETASONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) ALCLOMETASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alclometasone under HS 29372200 and SITC 54153. As of Q4 2014, ALCLOMETASONE remains the US FDA Preferred Term for this commodity. Alclometasone bears US NLM identifiers UMLS ID C0360534 and NCI Concept Code C65219. SMILES: CLC1C2C3C(C(OC(=O)CC)(C(C3)C)C(=O)COC(=O)CC)(CC(O)C2C2(C(=CC(=O)C=C2)C1)C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H37ClO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S56PQL4N1V, chemically known as pregna-1,4-diene-3,20-dione, 7-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (7.alpha.,11.beta.,16.alpha.)- but more generally known as alclometasone dipropionate, which bears US NIH Compound Identifier 2085. The base compound, Alclometasone, comes in forms base and dipropionate. European Medicines Agency schedules Alclometasone dipropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12765MIG. Most nations, for tariff and trade purposes, schedule alclometasone dipropionate under HS 29372200 and SITC 54153. As of Q4 2014, ALCLOMETASONE DIPROPIONATE remains US FDA's Preferred Term for this commodity. Alclometasone dipropionate bears US NLM identifiers UMLS ID C0051113 and NCI Concept Code C47385. SMILES: CCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2[C@@H](CC4=CC(=O)C=C[C@]34C)CL)O)C)C)OC(=O)CC.
This classification denotes an astringent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18B8O9DQA2. European Medicines Agency schedules Alcloxa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05301MIG. Alcloxa generally arises in the molecular formula C4H5N4O3.2AL.CL.4HO. The term ALCLOXA is an International Non-Proprietary Name or INN. ALCLOXA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alcloxa under HS 29332100 and SITC 51572. As of Q4 2014, ALCLOXA remains the US FDA Preferred Term for this commodity. Alcloxa bears US NLM identifiers UMLS ID C0771150 and NCI Concept Code C76518. SMILES: C1(C(=O)NC(=O)N1)NC(=O)N[Al]Cl.O.O.O.O.[Al].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS900. This VA Drug Class (RS900) classifies this compound as belonging to the group RECTAL, LOCAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a nicotinic antagonist with the molecular formula C44H50N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8U3J5W06N. European Medicines Agency schedules Alcuronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12766MIG. The term ALCURONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) As of Q4 2014, ALCURONIUM remains the US FDA Preferred Term for this commodity. SMILES: OC/C=C1/C2CC3[N](CCC43C3N(C=C5C6N(C=C23)c2c(C36C6[N](CC3)(CC(=C\CO)\C5C6)CC=C)cccc2)c2c4cccc2)(C1)CC=C.
This classification denotes a nicotinic antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 490DW6501Y. European Medicines Agency schedules Alcuronium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05302MIG. Alcuronium chloride generally arises in the molecular formula C44H50N4O2.2CL. The term ALCURONIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 no. 12 1967, list 7.) Most nations, for tariff and trade purposes, schedule alcuronium chloride under HS 29399900 and SITC 54149. As of Q4 2014, ALCURONIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Alcuronium chloride bears US NLM identifiers UMLS ID C0205658 and NCI Concept Code C79728. SMILES: C=CC[N@@+]12[C@@H]3[C@@]4([C@H]/5N(C6C4CCCC6)/C=C/7\[C@@H]8N(C9C(CCCC9)[C@]84[C@H]6[N@+](C/C(=C/CO)/[C@@H]7C6)(CC4)CC=C)/C=C5/[C@@H](C3)/C(=C\CO)/C1)CC2.[CL-].[CL-].
This classification denotes a therapeutic interleukin-2 with the molecular formula C690H1115N177O202S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M89N0Q7EQR, more generally known as aldesleukin. European Medicines Agency schedules aldesleukin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05303MIG. The term ALDESLEUKIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 5, no. 3 1991, list 31. Most nations schedule aldesleukin under HS 35040000 and SITC 59225. As of Q4 2014, ALDESLEUKIN remains the US FDA Preferred Term for this commodity. Aldesleukin bears US NLM identifiers UMLS ID C0218986 and NCI Concept Code C1498. SMILES: NONE.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C14H16N2O6S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G3C18OH4D, chemically known as methanesulfinic acid, (sulfonylbis(4,1-phenyleneimino))bis- but generally known as sulfoxone, which bears US NIH Compound Identifier 5351. Aldesulfone sodium or sulfoxone bears US NLM identifiers UMLS ID C0075606 and NCI Concept Code C72856. SMILES: C1=CC(=CC=C1NCS(=O)O)S(=O)(=O)C2=CC=C(C=C2)NCS(=O)O.
This classification denotes a mineralocorticoid with the molecular formula C21H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4964P6T9RB, chemically known as 18-formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione but generally known as aldosterone, which bears US NIH Compound Identifier 5839. Aldosterone comes in forms 18-glucuronide, 21-sulfate, hemiacetal, and monoacetate. European Medicines Agency schedules Aldosterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05306MIG. The term ALDOSTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules aldosterone in its Anatomical Therapeutic Chemical (ATC) Classification. ALDOSTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aldosterone under HS 29372900 and SITC 54153. As of Q4 2014, ALDOSTERONE remains the US FDA Preferred Term for this commodity. Aldosterone bears US NLM identifiers UMLS ID C0002006 and NCI Concept Code C219. SMILES: OC1C2C(C3C(C1)(C(CC3)C(=O)CO)C=O)CCC1=CC(=O)CCC21C.
Alectinib is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC).
This classification denotes an immunosuppressant with the molecular formula C2306H3594N610O694S26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) ELK3V90G6C, more generally known as alefacept. European Medicines Agency schedules alefacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20562. The term ALEFACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46). Most nations, for tariff and trade purposes, schedule alefacept under HS 30021095 and SITC 54163 (for the most current information on WCO designations on alefacept and salts thereof, please see Committee proceedings HSC/37, NC1059B2b Ann. O/3, 2006). As of Q4 2014, ALEFACEPT remains US FDA's Preferred Term for this commodity. Alefacept bears US NLM identifiers UMLS ID C0962603 and NCI Concept Code C65220. SMILES: C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)CL.
Drug prescribed and approved by the U.S. Food and Drug Administration for the HIV infection treatment in adults and 6-year children. It is always used in combination with other drugs against the HIV. Atazanavir is a type of drug against the HIV protease inhibitor (PI). It works by blocking the protease, an enzyme produced by the HIV. This prevents HIV multiplication and reduces the virus concentration in blood.
This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C4H13NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1J18R4W8P, chemically known as 4-amino-1-hydroxybutylidene-1,1-bis(phosphonic acid) but generally known as alendronate, which bears US NIH Compound Identifier 2088. Alendronate comes in forms hydrate, sodium, and trihydrate. European Medicines Agency schedules Alendronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05307MIG. The term ALENDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules alendronate in its Anatomical Therapeutic Chemical (ATC) Classification. Alendronic acid or alendronate sodium bears US NLM identifiers UMLS ID C0700482 and NCI Concept Code C973. SMILES: C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN.
This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6G1M06TPO. European Medicines Agency schedules Alepride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05309MIG. Alepride generally arises in the molecular formula C22H30CLN3O2. The term ALEPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) ALEPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alepride under HS 29333999 and SITC 51574. As of Q4 2014, ALEPRIDE remains the US FDA Preferred Term for this commodity. Alepride bears US NLM identifiers UMLS ID C2697984 and NCI Concept Code C74450. SMILES: CLC1CC(C(=O)NC2CCN(CC3CCC=CC3)CC2)C(OCC=C)CC1N.
This classification denotes an analgesic agent with the molecular formula C21H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XBD99QNI42, chemically known as 6-dimethylamino-4,4-diphenyl-3-heptanol, hydrochloride but generally known as alphamethadol, which bears US NIH Compound Identifier 28397. European Medicines Agency schedules Alphamethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05365MIG. The term ALPHAMETHADOL is an International Non-Proprietary Name. ALPHAMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Alfametadol or alphamethadol bears US NLM identifiers UMLS ID C2346722 and NCI Concept Code C72135. SMILES: OC(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC.
This classification denotes a therapeutic progestin with the molecular formula C21H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3JEB53B3WT, chemically known as 16alpha,17-Dihydroxypregn-4-ene-3,20-dione but generally known as algestone, which bears US NIH Compound Identifier 11687. European Medicines Agency schedules Algestone acetophenide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05321MIG. SMILES: CC(=O)C1(C(CC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)O)O.
This classification denotes an aromatase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VQ38D63M7. European Medicines Agency schedules Alfatradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12672MIG. Alfatradiol generally arises in the molecular formula C18H24O2. The term ALFATRADIOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.) Most nations schedule alfatradiol under HS 29072900 and SITC 51243. As of Q4 2014, ALFATRADIOL remains the US FDA Preferred Term for this commodity. Alfatradiol bears US NLM identifiers UMLS ID C1957081 and NCI Concept Code C81622. SMILES: CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O.
This classification denotes an anesthetic agent with the molecular formula C21H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BD07M97B2A, chemically known as 5-alpha-pregnane-11,20-dione, 3-alpha-hydroxy- but generally known as alfaxalone, which bears US NIH Compound Identifier 104845. European Medicines Agency schedules Alfaxalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05316MIG. The term ALFAXALONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules alfaxalone in its Anatomical Therapeutic Chemical (ATC) Classification. ALFAXALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alfaxalone under HS 29144090 and SITC 51629. As of Q4 2014, ALFAXALONE remains the US FDA Preferred Term for this commodity. Alfaxalone bears US NLM identifiers UMLS ID C0051482 and NCI Concept Code C72161. SMILES: O=C1C2C(C3C(C(CC3)C(=O)C)(C1)C)CCC1C2(CCC(O)C1)C.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H32N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1N74HM2BS7, chemically known as propanamide, n-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)-4-piperidinyl)-n-phenyl- but generally known as alfentanil, which bears US NIH Compound Identifier 51263. Alfentanil most often comes in base and hydrochloride forms. European Medicines Agency schedules Alfentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05317MIG. The term ALFENTANIL is an International Non-Proprietary Name. World Health Organization schedules alfentanil in its Anatomical Therapeutic Chemical (ATC) Classification. ALFENTANIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alfentanil under HS 29333300 and SITC 51574. As of Q4 2014, ALFENTANIL remains the US FDA Preferred Term for this commodity. Alfentanil bears US NLM identifiers UMLS ID C0002026 and NCI Concept Code C61626. SMILES: O(CC1(N(C2CCCCC2)C(=O)CC)CCN(CC1)CCN1NNN(C1=O)CC)C.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H32N6O3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11S92G0TIW, chemically known as propanamide, n-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)-4-piperidinyl)-n-phenyl-, monohydrochloride but more generally known as alfentanil hydrochloride, which bears US NIH Compound Identifier 64761. Alfentanil also comes in base form. European Medicines Agency schedules Alfentanil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00339MIG. Most nations, for tariff and trade purposes, schedule alfentanil hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, ALFENTANIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Alfentanil hydrochloride bears US NLM identifiers UMLS ID C0700562 and NCI Concept Code C220. SMILES: CCC(=O)N(C1CCCCC1)C2(CCN(CC2)CCN3C(=O)N(NN3)CC)COC.O.CL.
This classification denotes the anhydrous form of an opioid receptor agonist and opioid with the molecular formula C21H32N6O3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11S92G0TIW, chemically known as propanamide, n-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)-4-piperidinyl)-n-phenyl-, monohydrochloride but more generally known as alfentanil hydrochloride, which bears US NIH Compound Identifier 64761. Alfentanil also comes in base form. European Medicines Agency schedules Alfentanil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00339MIG. Most nations, for tariff and trade purposes, schedule alfentanil hydrochloride anhydrous under HS 29333300. As of Q4 2014, ALFENTANIL HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)N(C1CCCCC1)C2(CCN(CC2)CCN3C(=O)N(NN3)CC)COC.CL.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H32N6O3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11S92G0TIW, chemically known as n-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)-ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide monohydrochloride monohydrate, but more generally known as alfentanil hydrochloride monohydrate, which bears US NIH Compound Identifier 64762. European Medicines Agency schedules alfentanil hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05317MIG. Most nations, for tariff purposes, schedule alfentanil hydrochloride monohydrate under HS 29333300. SMILES: CCC(=O)N(C1CCCCC1)C2(CCN(CC2)CCN3C(=O)N(NN3)CC)COC.O.CL.
This classification denotes a cns stimulant with the molecular formula C11H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Q3V87119BP, chemically known as 1-phenylpent-4-en-2-amine but more generally known as Alfetamine, which bears US NIH Compound Identifier 20254. European Medicines Agency schedules Amfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05318MIG. ALFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule alfetamine under HS 29214980 and SITC 51454. SMILES: C=CCC(CC1=CC=CC=C1)N.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90347YTW5F, chemically known as 2-furancarboxamide, n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro- but generally known as alfuzosin, which bears US NIH Compound Identifier 2092. Alfuzosin comes in base and hydrochloride forms. European Medicines Agency schedules Alfuzosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05319MIG. The term ALFUZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules alfuzosin in its Anatomical Therapeutic Chemical (ATC) Classification. ALFUZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alfuzosin under HS 29349990 and SITC 51579. As of Q4 2014, ALFUZOSIN remains the US FDA Preferred Term for this commodity. Alfuzosin bears US NLM identifiers UMLS ID C0051150 and NCI Concept Code C61627. SMILES: O1C(CCC1)C(=O)NCCCN(C1NC2C(C(N1)N)CC(OC)C(OC)C2)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75046A1XTN, chemically known as 2-furancarboxamide, n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, monohydrochloride (+-)- but more generally known as alfuzosin hydrochloride, which bears US NIH Compound Identifier 71764. The base coompound, Alfuzosin, also comes in simple form. European Medicines Agency schedules Alfuzosin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00340MIG. Most nations, for tariff and trade purposes, schedule alfuzosin hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ALFUZOSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Alfuzosin hydrochloride bears US NLM identifiers UMLS ID C0102130 and NCI Concept Code C53408. SMILES: CN(CCCNC(=O)C1CCCO1)C2NC3CC(C(CC3C(N2)N)OC)OC.CL.
This classification denotes a vaccine adjuvant with the molecular formula Al.3HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5QB0T2IUN0, chemically known as aluminum hydroxide, dried (jp15/usp) but generally known as aluminium hydroxide, which bears US NIH Compound Identifier 6328211. European Medicines Agency schedules Aluminium hydroxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11700MIG. World Health Organization schedules aluminium hydroxide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule aluminium hydroxide under HS 28183000 and SITC 52266. SMILES: O.O.O.[AL].
This classification denotes a therapeutic progestin with the molecular formula C24H34O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WXD8I4Y1IH, chemically known as 16,17-((1-methylethylidene)bis(oxy))(16 deltaalpha)-pregn-4-ene-3,20-dione but more generally known as algestone acetonide, which bears US NIH Compound Identifier 21075. Most nations, for tariff and trade purposes, schedule algestone acetonide under HS 29372900. As of Q4 2014, ALGESTONE ACETONIDE remains US FDA's Preferred Term for this commodity. Algestone acetonide bears US NLM identifiers UMLS ID C2983959 and NCI Concept Code C90967. SMILES: CC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)OC(O2)(C)C.
This classification denotes a therapeutic progestin with the molecular formula C29H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OL7KC2O3OT, chemically known as 16alpha,17-((r)-1-phenylethylidendioxy-4-pregnen-3,20-dion but more generally known as algestone acetophenide, which bears US NIH Compound Identifier 32327. European Medicines Agency schedules Algestone acetophenide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12773MIG. Most nations, for tariff and trade purposes, schedule algestone acetophenide under HS 29372900. As of Q4 2014, ALGESTONE ACETOPHENIDE remains US FDA's Preferred Term for this commodity. Algestone acetophenide bears US NLM identifiers UMLS ID C0002039 and NCI Concept Code C90968. SMILES: CC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)O[C@@](O2)(C)C6CCCCC6.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA109. This VA Drug Class (GA109) classifies this compound as belonging to the group MAGNESIUM/SODIUM BICARBONATE CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes an enzyme replacement preparation with the molecular formula C2532H3854N672O711S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27T56C7KK0, more generally known as alglucerase. European Medicines Agency schedules alglucerase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05322MIG. The term ALGLUCERASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33. ALGLUCERASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Alglucerase under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, ALGLUCERASE remains the US FDA Preferred Term for this commodity. . Alglucerase bears US NLM identifiers UMLS ID C0102139 and NCI Concept Code C74208.
This classification denotes an enzyme replacement preparation with the molecular formula C4758H7262N1274O1369S35, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DTI67O9503, more generally known as alglucosidase alfa. European Medicines Agency schedules alglucosidase alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21275. The term ALGLUCOSIDASE ALFA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53. Most nations schedule Alglucosidase alfa under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, ALGLUCOSIDASE ALFA remains the US FDA Preferred Term for this commodity. . Alglucosidase alfa bears US NLM identifiers UMLS ID C1703294 and NCI Concept Code C65221.
This classification denotes a cholagogue or choleretic agent with the molecular formula C13H17NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8CO1VZK2Z, chemically known as m-anisamide, 5-allyl-2-hydroxy-n-(2-hydroxyethyl)- (8ci) but generally known as alibendol, which bears US NIH Compound Identifier 71916. European Medicines Agency schedules Alibendol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05323MIG. The term ALIBENDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). ALIBENDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alibendol under HS 29242995 and SITC 51479. As of Q4 2014, ALIBENDOL remains the US FDA Preferred Term for this commodity. Alibendol bears US NLM identifiers UMLS ID C0771472 and NCI Concept Code C74231. SMILES: O(C1C(O)C(CC(CC=C)C1)C(=O)NCCO)C.
This classification denotes a beta-adrenergic agonist with the molecular formula C18H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2PM66M0VQ, chemically known as 1-propanone, 1-cyclohexyl-3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-, (r-(r*,s*))- but generally known as alifedrine, which bears US NIH Compound Identifier 51719. Alifedrine comes in base and hydrochloride forms. European Medicines Agency schedules Alifedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05325MIG. The term ALIFEDRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). ALIFEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alifedrine under HS 29225000 and SITC 51467. As of Q4 2014, ALIFEDRINE remains the US FDA Preferred Term for this commodity. Alifedrine bears US NLM identifiers UMLS ID C0051158 and NCI Concept Code C77931. SMILES: CC(C(C1=CC=CC=C1)O)NCCC(=O)C2CCCCC2.
This classification denotes an anesthetic agent with the molecular formula C4H3ClF4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q1069WKM8G, chemically known as 2-chloro-1,2,3,3-tetrafluorocyclopropyl methyl ether but generally known as aliflurane, which bears US NIH Compound Identifier 41967. European Medicines Agency schedules Aliflurane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05326MIG. The term ALIFLURANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). ALIFLURANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aliflurane under HS 29092000 and SITC 51616. As of Q4 2014, ALIFLURANE remains the US FDA Preferred Term for this commodity. Aliflurane bears US NLM identifiers UMLS ID C0051159 and NCI Concept Code C75082. SMILES: CLC1(F)C(F)(OC)C1(F)F.
This classification denotes a sedative and hypnotic with the molecular formula C18H22N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76H78MJJ52, chemically known as 10h-phenothiazine-10-propanamine, n,n,beta-trimethyl- but generally known as alimemazine, which bears US NIH Compound Identifier 5574. Alimemazine most often comes in base, s-dioxide, and tartrate forms. European Medicines Agency schedules Alimemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05328MIG. The term ALIMEMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules alimemazine in its Anatomical Therapeutic Chemical (ATC) Classification. ALIMEMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Alimemazine or trimeprazine bears US NLM identifiers UMLS ID C0041031 and NCI Concept Code C72677. SMILES: CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C.
This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula 2C18H22N2S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362NW1LD6Z, chemically known as 10h-phenothiazine-10-propanamine n,n,beta-trimethyl-, (r-(r*,r*))-2,3-dihydroxybutanedioate (2:1) but more generally known as alimemazine tartrate, which bears US NIH Compound Identifier 78032. The base compound, Alimemazine, also comes in base and s-dioxide forms. European Medicines Agency schedules Alimemazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00343MIG. Most nations, for tariff and trade purposes, schedule alimemazine tartrate under HS 29343000. SMILES: CC(CN1C2CCCCC2SC3C1CCCC3)CN(C)C.CC(CN1C2CCCCC2SC3C1CCCC3)CN(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H13Cl2N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7IDJ8DS1D, chemically known as 2-(n-allyl-n-(2,6-dichlorophenyl)amino)-2-imidazoline but generally known as alinidine, which bears US NIH Compound Identifier 36354. Alinidine most often comes in base and hydrobromide forms. European Medicines Agency schedules Alinidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05330MIG. The term ALINIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). ALINIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alinidine under HS 29332990 and SITC 51573. As of Q4 2014, ALINIDINE remains the US FDA Preferred Term for this commodity. Alinidine bears US NLM identifiers UMLS ID C0102151 and NCI Concept Code C72571. SMILES: C=CCN(C1=C(C=CC=C1Cl)Cl)C2=NCCN2.
This classification denotes a diuretic with the molecular formula C9H12ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PE8925K9EY, chemically known as 4-chloro-3-sulfamoylbenzoic acid 2,2-dimethylhydrazide but generally known as alipamide, which bears US NIH Compound Identifier 18520. European Medicines Agency schedules Alipamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05331MIG. The term ALIPAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). ALIPAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alipamide under HS 29350090 and SITC 51580. As of Q4 2014, ALIPAMIDE remains the US FDA Preferred Term for this commodity. Alipamide bears US NLM identifiers UMLS ID C2825440 and NCI Concept Code C81071. SMILES: CLC1C(S(=O)(=O)N)CC(CC1)C(=O)NN(C)C.
Alirocumab is a PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C)
This classification denotes an antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 502FWN4Q32. European Medicines Agency schedules Aliskiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21380. Aliskiren generally arises in the molecular formula C30H53N3O6. The term ALISKIREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule aliskiren under HS 29242995 and SITC 51479. As of Q4 2014, ALISKIREN remains the US FDA Preferred Term for this commodity. Aliskiren bears US NLM identifiers UMLS ID C0915224 and NCI Concept Code C65222. SMILES: OC(C(N)CC(C(C)C)Cc1cc(OCCCOC)c(OC)cc1)CC(C(C)C)C(=O)NCC(C)(C)C(=O)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an antihypertensive agent with the molecular formula 2C30H53N3O6.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8A0P8G029. European Medicines Agency schedules aliskiren fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25393. The term aliskiren fumarate is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule aliskiren fumarate under HS 29242995 and SITC 51479. SMILES: CC(C)[C@@H](CC1CCC(C(C1)OCCCOC)OC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.CC(C)[C@@H](CC1CCC(C(C1)OCCCOC)OC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C(=C/C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a retinoic acid agent with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UA8E65KDZ, chemically known as 2,4,6,8-nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-e)- but more generally known as alitretinoin, which bears US NIH Compound Identifier 444795. European Medicines Agency schedules Alitretinoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00344MIG. The term ALITRETINOIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules alitretinoin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule alitretinoin under HS 29362100 and SITC 54112. As of Q4 2014, ALITRETINOIN remains US FDA's Preferred Term for this commodity. Alitretinoin bears US NLM identifiers UMLS ID C0281666 and NCI Concept Code C1574. SMILES: OC(=O)/C=C(/C=C/C=C(/C=C/C1=C(CCCC1(C)C)C)C)C.
This classification denotes an antiemetic agent with the molecular formula C16H21N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P55703ZRZY, chemically known as 1h-benzotriazole-5-carboxamide, 6-methoxy-n-((1-(2-propenyl)-2-pyrrolidinyl)methyl)- but generally known as alizapride, which bears US NIH Compound Identifier 43008. Alizapride most often comes in base and hydrochloride forms. European Medicines Agency schedules Alizapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05332MIG. The term ALIZAPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules alizapride in its Anatomical Therapeutic Chemical (ATC) Classification. ALIZAPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alizapride under HS 29339990 and SITC 51577. As of Q4 2014, ALIZAPRIDE remains the US FDA Preferred Term for this commodity. Alizapride bears US NLM identifiers UMLS ID C0051162 and NCI Concept Code C995. SMILES: O=C(NCC1N(CCC1)CC=C)C1C(OC)CC2N[NH]NC2C1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.
This classification denotes an astringent and anti-psoriatic agent with the molecular formula C4H6N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 344S277G0Z, chemically known as 5-ureido-2,4-imidazolidindion but generally known as allantoin, which bears US NIH Compound Identifier 204. Allantoin comes in various forms, including acetyl methionine, ascorbate, biotin, glycyrrhetinic acid, n-acetyl-dl-methionine, and sodium succinate. European Medicines Agency schedules Allantoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12779MIG. Most nations schedule allantoin under HS 29332100 and SITC 51572. As of Q4 2014, ALLANTOIN remains the US FDA Preferred Term for this commodity. Allantoin bears US NLM identifiers UMLS ID C0002083 and NCI Concept Code C74277. SMILES: O=C1NC(=O)NC1NC(=O)N.
This classification denotes an astringent and anti-psoriatic agent with the molecular formula C7H13NO3S.C4H6N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C554034748, chemically known as allantoin, compd. with dl-n-acetylmethionine (1:1), but more generally known as allantoin acetyl methionine, which bears US NIH Compound Identifier 168975. European Medicines Agency schedules allantoin acetyl methionine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12779MIG. Most nations, for tariff purposes, schedule allantoin acetyl methionine under HS 29332100. SMILES: CC(=O)NC(CCSC)C(=O)O.C1(C(=O)NC(=O)N1)NC(=O)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.
This classification denotes an astringent and anti-psoriatic agent with the molecular formula C6H8O6.C4H6N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76WX3J5GER, chemically known as l-ascorbic acid, compd. with n-(2,5-dioxo-4-imidazolidinyl)urea (1:1), but more generally known as allantoin ascorbate, which bears US NIH Compound Identifier 171592. European Medicines Agency schedules allantoin ascorbate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12779MIG. Most nations, for tariff purposes, schedule allantoin ascorbate under HS 29332100. SMILES: C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O.C1(C(=O)NC(=O)N1)NC(=O)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an astringent and anti-psoriatic agent with the molecular formula C10H16N2O3S.C4H6N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8445SU9RKR, chemically known as allantoin, compd. with biotin (1:1), but more generally known as allantoin biotin, which bears US NIH Compound Identifier 6452010. European Medicines Agency schedules allantoin biotin or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12779MIG. Most nations, for tariff purposes, schedule allantoin biotin under HS 29332100. SMILES: C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2.C1(C(=O)NC(=O)N1)NC(=O)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes combination drugs that treat a genetically-determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches, a disorder called Psoriasis, hence the term ANTIPSORIATICS
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes an astringent and anti-psoriatic agent with the molecular formula C7H7NO2.C4H6N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NAA1SZ9N2, chemically known as benzoic acid, 4-amino-, compd. with (2,5-dioxo-4-imidazolidinyl)urea, but more generally known as allantoin paba, which bears US NIH Compound Identifier 3083839. European Medicines Agency schedules allantoin paba or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12779MIG. Most nations, for tariff purposes, schedule allantoin paba under HS 29332100. SMILES: C1CC(CCC1C(=O)O)N.C1(C(=O)NC(=O)N1)NC(=O)N.
This classification denotes an opioid receptor agonist with the molecular formula C27H35NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4UWR086NOA, chemically known as 6,14-ethenotetrahydrooripavine, 17-allyl-17-demethyl-7alpha-((r)-1-hydroxy-1-methylbutyl)- but generally known as alletorphine, which bears US NIH Compound Identifier 72090. European Medicines Agency schedules Alletorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05333MIG. The term ALLETORPHINE is an International Non-Proprietary Name. ALLETORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alletorphine under HS 29391900 and SITC 54141. As of Q4 2014, ALLETORPHINE remains the US FDA Preferred Term for this commodity. Alletorphine bears US NLM identifiers UMLS ID C0604904 and NCI Concept Code C77275. SMILES: O1C2C34C5(C(N(CC3)CC=C)CC3C4C1C(O)CC3)CC(C2(OC)C=C5)C(O)(CCC)C.
This classification denotes a barbiturate with the molecular formula C10H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NT43GG2HA, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-di-2-propenyl- but generally known as allobarbital, which bears US NIH Compound Identifier 5842. Allobarbital comes in forms base, epoxide, and sodium. European Medicines Agency schedules Allobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05334MIG. The term ALLOBARBITAL is an International Non-Proprietary Name. World Health Organization schedules allobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. ALLOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule allobarbital under HS 29335390 and SITC 51576. As of Q4 2014, ALLOBARBITAL remains the US FDA Preferred Term for this commodity. Allobarbital bears US NLM identifiers UMLS ID C0002132 and NCI Concept Code C76522. SMILES: C=CCC1(C(=O)NC(=O)NC1=O)CC=C.
This classification denotes an antitussive agent with the molecular formula C16H23ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H7B263Z7AQ, chemically known as benzamide, 4-chloro-n-(2-(diethylamino)ethyl)-2-(2-propenyloxy)- (9ci) but more generally known as alloclamide, which bears US NIH Compound Identifier 71837. Alloclamide comes in forms base and hydrochloride. European Medicines Agency schedules Alloclamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05335MIG. The term ALLOCLAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). ALLOCLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule alloclamide under HS 29242995 and SITC 51479. As of Q4 2014, ALLOCLAMIDE remains US FDA's Preferred Term for this commodity. Alloclamide bears US NLM identifiers UMLS ID C0051206 and NCI Concept Code C73184. SMILES: CLC1CC(OCC=C)C(C(=O)NCCN(CC)CC)CC1.
This classification denotes a xanthine oxidase inhibitor and uricosuric agent with the molecular formula C5H4N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63CZ7GJN5I, chemically known as 1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidine-4-one but generally known as allopurinol, which bears US NIH Compound Identifier 2094. Allopurinol comes in various forms, including di-methyl, ribonucleoside, riboside, riboside 5-monophosphate, and sodium. European Medicines Agency schedules Allopurinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05338MIG. The term ALLOPURINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules allopurinol in its Anatomical Therapeutic Chemical (ATC) Classification. ALLOPURINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule allopurinol under HS 29335995 and SITC 51576. As of Q4 2014, ALLOPURINOL remains the US FDA Preferred Term for this commodity. Allopurinol bears US NLM identifiers UMLS ID C0002144 and NCI Concept Code C224. SMILES: C1=C2C(=NC=NC2=O)NN1.
This classification denotes a xanthine oxidase inhibitor and uricosuric agent with the molecular formula C10H12N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WZS8452SEC, chemically known as 4h-pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-1-.beta.-d-ribofuranosyl-, but more generally known as allopurinol riboside, which bears US NIH Compound Identifier 85337. European Medicines Agency schedules allopurinol riboside or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05338MIG. Most nations, for tariff purposes, schedule allopurinol riboside under HS 29335995. SMILES: C1C2C(=O)[NH]CNC2N(N1)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O.
This classification denotes a xanthine oxidase inhibitor and uricosuric agen with the molecular formula C5H3N4O.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 428673RC2Z, chemically known as 1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidine-4-one but more generally known as allopurinol sodium, which bears US NIH Compound Identifier 2094. The base compound, Allopurinol, comes in other forms, including di-methyl, ribonucleoside, riboside, riboside, and 5-monophosphate. European Medicines Agency schedules Allopurinol sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30291. Most nations, for tariff and trade purposes, schedule allopurinol sodium under HS 29335995 and SITC 51576. As of Q4 2014, ALLOPURINOL SODIUM remains US FDA's Preferred Term for this commodity. Allopurinol sodium bears US NLM identifiers UMLS ID C0278766 and NCI Concept Code C2564. SMILES: C1C2C(=O)[NH]CNC2[N-]N1.[NA+].
This classification denotes a therapeutic progestin with the molecular formula C21H32O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I47VB5DZ8O, chemically known as 19-nor-17-alpha-preg-4-en-17-ol, 21-methylene- but generally known as allylestrenol, which bears US NIH Compound Identifier 9896. European Medicines Agency schedules Allylestrenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05339MIG. The term ALLYLESTRENOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules allylestrenol in its Anatomical Therapeutic Chemical (ATC) Classification. ALLYLESTRENOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule allylestrenol under HS 29372300 and SITC 54153. As of Q4 2014, ALLYLESTRENOL remains the US FDA Preferred Term for this commodity. Allylestrenol bears US NLM identifiers UMLS ID C0002158 and NCI Concept Code C80270. SMILES: OC1(C2(C(C3C(CC2)C2C(=CCCC2)CC3)CC1)C)CC=C.
This classification denotes an analgesic agent with the molecular formula C18H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4343OEZ18O, chemically known as 4-piperidinol, 3-allyl-1-methyl-4-phenyl-, propionate (ester), hydrochloride, dl but generally known as allylprodine, which bears US NIH Compound Identifier 32938. European Medicines Agency schedules Allylprodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05340MIG. The term ALLYLPRODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). ALLYLPRODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule allylprodine under HS 29333999 and SITC 51574. As of Q4 2014, ALLYLPRODINE remains the US FDA Preferred Term for this commodity. Allylprodine bears US NLM identifiers UMLS ID C2348426 and NCI Concept Code C72102. SMILES: O(C1(C(CN(CC1)C)CC=C)C1CCCCC1)C(=O)CC.
This classification denotes a pharmacologic substance and antacid with the molecular formula CO3.Al.3Mg.7HO.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 568Z59H7ZJ, chemically known as magnesium, (carbonato(2-))heptahydroxy(aluminum)tri-, dihydrate but generally known as almagate, which bears US NIH Compound Identifier 71749. European Medicines Agency schedules Almagate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05343MIG. The term ALMAGATE is an International Non-Proprietary Name. World Health Organization schedules almagate in its Anatomical Therapeutic Chemical (ATC) Classification. ALMAGATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule almagate under HS 28429080 and SITC 52389. As of Q4 2014, ALMAGATE remains the US FDA Preferred Term for this commodity. SMILES: [ALH3].[MG].[MG].[MG].OC(=O)O.O.O.O.O.O.O.O.O.O.
This classification denotes an aluminum silicates and antacid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OZQ8O62H53. European Medicines Agency schedules Almasilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05344MIG. Almasilate generally arises in the molecular formula 2AL.MG.8O.2SI.H2O. The term ALMASILATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) ALMASILATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule almasilate under HS 28421000 and SITC 52389. As of Q4 2014, ALMASILATE remains the US FDA Preferred Term for this commodity. SMILES: O.O[Si](=O)O.O[Si](=O)O.[Mg+2].[Al+3].[Al+3].
This classification denotes a steroidal estrogen with the molecular formula C19H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N18A31MTB0, chemically known as 3-hydroxy-7alpha-methylestra-1,3,5(10)-trien-17-one but generally known as almestrone, which bears US NIH Compound Identifier 65601. European Medicines Agency schedules Almestrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05346MIG. The term ALMESTRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). ALMESTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule almestrone under HS 29372300 and SITC 54153. As of Q4 2014, ALMESTRONE remains the US FDA Preferred Term for this commodity. Almestrone bears US NLM identifiers UMLS ID C2698055 and NCI Concept Code C74404. SMILES: O=C1C2(C(C3C(CC2)c2c(CC3C)cc(O)cc2)CC1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0255AHR9GJ, chemically known as propionic acid, 2-(4-(methallylamino)phenyl)- but generally known as alminoprofen, which bears US NIH Compound Identifier 2097. European Medicines Agency schedules Alminoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05347MIG. The term ALMINOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules alminoprofen in its Anatomical Therapeutic Chemical (ATC) Classification. ALMINOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alminoprofen under HS 29224995 and SITC 51465. As of Q4 2014, ALMINOPROFEN remains the US FDA Preferred Term for this commodity. Alminoprofen bears US NLM identifiers UMLS ID C0051247 and NCI Concept Code C73070. SMILES: OC(=O)C(C1CCC(NCC(=C)C)CC1)C.
This classification denotes a cns stimulant with the molecular formula C26H29F2N7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9A1222NBG4, chemically known as 1,3,5-triazine-2,4-diamine, 6-(4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n-di-2-propenyl- but generally known as almitrine, which bears US NIH Compound Identifier 33887. Almitrine comes in various forms, including bismesylate, bismethane sulfonate, dimesylate, dimethanesulfonate, and mesylate. European Medicines Agency schedules Almitrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05348MIG. The term ALMITRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules almitrine in its Anatomical Therapeutic Chemical (ATC) Classification. ALMITRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule almitrine under HS 29336980 and SITC 51576. As of Q4 2014, ALMITRINE remains the US FDA Preferred Term for this commodity. Almitrine bears US NLM identifiers UMLS ID C0002164 and NCI Concept Code C74241. SMILES: FC1CCC(C(N2CCN(CC2)C2NC(NC(N2)NCC=C)NCC=C)C2CCC(F)CC2)CC1.
This classification denotes a cns stimulant with the molecular formula C26H29F2N7.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6RY6V6XM8T, chemically known as 6-4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-1,3,5-triazine-2,4-diamine dimethanesulfonate, but more generally known as almitrine bismesylate, which bears US NIH Compound Identifier 115048. European Medicines Agency schedules almitrine bismesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05348MIG. Most nations, for tariff purposes, schedule almitrine bismesylate under HS 29336980. SMILES: CS(=O)(=O)O.CS(=O)(=O)O.C=CCNC1NC(NC(N1)N2CCN(CC2)C(C3CCC(CC3)F)C4CCC(CC4)F)NCC=C.
This classification denotes a cns stimulant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6RY6V6XM8T. European Medicines Agency schedules Almitrine dimesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00363MIG. Almitrine dimesilate generally arises in the molecular formula C26H29F2N7.2CH4O3S. The term 'almitrine dimesilate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule almitrine dimesilate under HS 29336980 and SITC 51576. SMILES: CS(=O)(=O)O.CS(=O)(=O)O.C=CCNC1NC(NC(N1)N2CCN(CC2)C(C3CCC(CC3)F)C4CCC(CC4)F)NCC=C.
This classification denotes a cns stimulant with the molecular formula C26H29F2N7.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6RY6V6XM8T, chemically known as 6-4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-1,3,5-triazine-2,4-diamine dimethanesulfonate, but more generally known as almitrine mesylate, which bears US NIH Compound Identifier 6918543. European Medicines Agency schedules almitrine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05348MIG. Most nations, for tariff purposes, schedule almitrine mesylate under HS 29336980. As of Q4 2014, ALMITRINE MESYLATE remains US FDA's Preferred Term for this commodity. Almitrine mesylate bears US NLM identifiers UMLS ID C0002165 and NCI Concept Code C79962. SMILES: CS(=O)(=O)O.CS(=O)(=O)O.C=CCNC1NC(NC(N1)N2CCN(CC2)C(C3CCC(CC3)F)C4CCC(CC4)F)NCC=C.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C18H28N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I9NG89L275, chemically known as benzonitrile, 4-(3-(ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)- but more generally known as almokalant, which bears US NIH Compound Identifier 3033962. European Medicines Agency schedules Almokalant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05349MIG. The term ALMOKALANT is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, List 31). ALMOKALANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule almokalant under HS 29309085 and SITC 51549. As of Q4 2014, ALMOKALANT remains US FDA's Preferred Term for this commodity. Almokalant bears US NLM identifiers UMLS ID C0167716 and NCI Concept Code C77828. SMILES: S(=O)(CCCN(CC(O)COC1CCC(CC1)C#N)CC)CCC.
Almond oil is used directly over body and face as humectants oil. It is used in its natural state or it is mixed with other oils which need to be diluted such as rose hip, castor oil (for the body), wheat germ, borage, etc. It can also be used with some drops of Vitamin E. It can be used over stretch marks or serious areas. It is used over the hair in its natural state or with other oils. You can transform your bath into an original beauty treatment by adding a small dose of almond oil to hot water, your skin gets soft and silky.
This classification denotes a serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1O4XL5SN61. European Medicines Agency schedules Almotriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05350MIG. Almotriptan generally arises in the molecular formula C17H25N3O2S. The term ALMOTRIPTAN is an International Non-Proprietary Name or INN. ALMOTRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule almotriptan under HS 29350090 and SITC 51580. As of Q4 2014, ALMOTRIPTAN remains the US FDA Preferred Term for this commodity. Almotriptan bears US NLM identifiers UMLS ID C0914729 and NCI Concept Code C65224. SMILES: S(=O)(=O)(N1CCCC1)CC1CC2C(CCN(C)C)C[NH]C2CC1.
This classification denotes a serotonin agonist with the molecular formula C17H25N3O2S.C4H6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PJP312605E, chemically known as 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1) but more generally known as almotriptan malate, which bears US NIH Compound Identifier 123607. The base compound, Almotriptan, comes in base and malate forms. European Medicines Agency schedules Almotriptan malate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20534. Most nations, for tariff and trade purposes, schedule almotriptan malate under HS 29350090 and SITC 51580. As of Q4 2014, ALMOTRIPTAN MALATE remains US FDA's Preferred Term for this commodity. Almotriptan malate bears US NLM identifiers UMLS ID C0937898 and NCI Concept Code C61628. SMILES: CN(C)CCC1C[NH]C2C1CC(CC2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O.
This classification denotes a monoamine oxidase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85V47MCE4Z. European Medicines Agency schedules Almoxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05351MIG. Almoxatone generally arises in the molecular formula C18H19CLN2O3. The term ALMOXATONE is an International Non-Proprietary Name or INN. ALMOXATONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule almoxatone under HS 29349990 and SITC 51579. As of Q4 2014, ALMOXATONE remains the US FDA Preferred Term for this commodity. Almoxatone bears US NLM identifiers UMLS ID C2348428 and NCI Concept Code C72688. SMILES: Clc1cc(COc2ccc(N3CC(OC3=O)CNC)cc2)ccc1.
This classification denotes a serotonin agonist and anxiolytic with the molecular formula C26H38N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34E28BM822, chemically known as 8-azaspiro(4.5)decane-7,9-dione, 8-(4-((3,4-dihydro-5-methoxy-2h-1-benzopyran-3-yl)propylamino)butyl)-, monohydrochloride, (s)- but generally known as alnespirone, which bears US NIH Compound Identifier 121851. European Medicines Agency schedules Alnespirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05353MIG. The term ALNESPIRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). ALNESPIRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alnespirone under HS 29349990 and SITC 51579. As of Q4 2014, ALNESPIRONE remains the US FDA Preferred Term for this commodity. Alnespirone bears US NLM identifiers UMLS ID C0753579 and NCI Concept Code C72689. SMILES: Cl.O=C1N(C(=O)CC2(CCCC2)C1)CCCCN(C1Cc2c(OC1)cccc2OC)CCC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA204. This VA Drug Class (GA204) classifies this compound as belonging to the group STIMULANT LAXATIVES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) JHC049LO86. European Medicines Agency schedules Alogliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32564. Alogliptin generally arises in the molecular formula C18H21N5O2. The term ALOGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21, no. 3, 2007, list 58.) Most nations, for tariff and trade purposes, schedule alogliptin under HS 29335990 and SITC 51576. As of Q4 2014, ALOGLIPTIN remains US FDA's Preferred Term for this commodity. Alogliptin bears US NLM identifiers UMLS ID C1958126 and NCI Concept Code C76906. SMILES: CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N.
This classification denotes an anti-diabetic agent C18H21N5O2.C7H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EEN99869SC, chemically known as benzonitrile, 2-((6-((3r)-3-amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl)methyl)-, monobenzoate, but more generally known as alogliptin benzoate, which bears US NIH Compound Identifier 16088021. European Medicines Agency schedules Alogliptin benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32165. Most nations, for tariff and trade purposes, schedule alogliptin benzoate under HS 29335990 and SITC 51576. As of Q4 2014, ALOGLIPTIN BENZOATE remains US FDA's Preferred Term for this commodity. Alogliptin benzoate bears US NLM identifiers UMLS ID C1958127 and NCI Concept Code C75186. SMILES: CN1C(=O)CC(N(C1=O)CC2CCCCC2C#N)N3CCC[C@H](C3)N.C1CCC(CC1)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a laxative with the molecular formula C21H22O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W41H6S09F4, chemically known as 1,8-dihydroxy-3-hydroxymethyl-10-(6-hydroxymethyl-3,4,5-trihydroxy-2-pyranyl)anthrone but generally known as aloin, which bears US NIH Compound Identifier 14989. European Medicines Agency schedules Aloin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12795MIG. Most nations schedule aloin under HS 29389000 and SITC 54161. As of Q4 2014, ALOIN remains the US FDA Preferred Term for this commodity. Aloin bears US NLM identifiers UMLS ID C0051209 and NCI Concept Code C76760. SMILES: O1C(C2C3C(C(=O)C4C2CCCC4O)C(O)CC(C3)CO)C(O)C(O)C(O)C1CO.
This classification denotes a sedative and hypnotic with the molecular formula C14H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 14144823D4, chemically known as 1,2,3,4-tetrahydronaphthalin-1-spiro-3-piperidin-4,2,6-dion but generally known as alonimid, which bears US NIH Compound Identifier 17928. European Medicines Agency schedules Alonimid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05356MIG. The term ALONIMID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). ALONIMID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alonimid under HS 29251995 and SITC 51482. As of Q4 2014, ALONIMID remains the US FDA Preferred Term for this commodity. Alonimid bears US NLM identifiers UMLS ID C2828217 and NCI Concept Code C87203. SMILES: O=C1NC(=O)CCC21CCC(=O)C1C2CCCC1.
This classification denotes a neuroprotective agent with the molecular formula C11H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U0RKZ75D0T, chemically known as n-(2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl)acetamide but generally known as aloracetam, which bears US NIH Compound Identifier 178134. European Medicines Agency schedules Aloracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05357MIG. The term ALORACETAM is an International Non-Proprietary Name. ALORACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aloracetam under HS 29339990 and SITC 51577. As of Q4 2014, ALORACETAM remains the US FDA Preferred Term for this commodity. Aloracetam bears US NLM identifiers UMLS ID C2698059 and NCI Concept Code C74324. SMILES: CC1=CC(=C(N1CCNC(=O)C)C)C=O.
This classification denotes a 5-ht3 receptor antagonist with the molecular formula C17H18N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13Z9HTH115, chemically known as 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1h-imidazol-4-yl)methyl)-1h-pyrido(4,3-b)indol-1-one but generally known as alosetron, which bears US NIH Compound Identifier 2099. Alosetron comes in base and hydrochloride forms. European Medicines Agency schedules Alosetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05358MIG. The term ALOSETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules alosetron in its Anatomical Therapeutic Chemical (ATC) Classification. ALOSETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alosetron under HS 29337900 and SITC 51561. As of Q4 2014, ALOSETRON remains the US FDA Preferred Term for this commodity. Alosetron bears US NLM identifiers UMLS ID C0291772 and NCI Concept Code C73100. SMILES: O=C1N(CCC2N(C3C(C12)CCCC3)C)CC1NC[NH]C1C.
This classification denotes a 5-ht3 receptor antagonist with the molecular formula C17H18N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2F5R1A46YW, chemically known as 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1h-pyrido(4,3-b)indol-1-one monohydrochloride but more generally known as alosetron hydrochloride, which bears US NIH Compound Identifier 60758. The base compound, Alosetron, comes in base and hydrochloride forms. European Medicines Agency schedules Alosetron hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12461MIG. Most nations, for tariff and trade purposes, schedule alosetron hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, ALOSETRON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Alosetron hydrochloride bears US NLM identifiers UMLS ID C0291771 and NCI Concept Code C47386. SMILES: CC1C(NC[NH]1)CN2CCC3C(C4CCCCC4N3C)C2=O.CL.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H13FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PG53R0DWDQ, chemically known as thymidine, 3-deoxy-3-fluoro- but generally known as alovudine, which bears US NIH Compound Identifier 33039. European Medicines Agency schedules Alovudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05359MIG. The term ALOVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). ALOVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alovudine under HS 29349990 and SITC 51579. As of Q4 2014, ALOVUDINE remains the US FDA Preferred Term for this commodity. Alovudine bears US NLM identifiers UMLS ID C0206795 and NCI Concept Code C65226. SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)F.
This classification denotes a pharmacologic substance and aluminium acetylsalicylate and unclear, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6QT214X4XU. European Medicines Agency schedules Aloxiprin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00370MIG. Aloxiprin generally arises in the molecular formula C9H8O4.2AL.3O. The term ALOXIPRIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) ALOXIPRIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(=O)OC1=CC=CC=C1C(=O)[O-].CC(=O)OC1=CC=CC=C1C(=O)[O-].[OH-].[Al+3].
This classification denotes an antipsychotic agent with the molecular formula C25H31N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KYT38QTB4K, chemically known as 1h-indole-2-carboxylic acid, 5,6-dimethoxy-3-(2-(4-phenyl-1-piperazinyl)ethyl)-,ethyl ester but generally known as alpertine, which bears US NIH Compound Identifier 166547. European Medicines Agency schedules Alpertine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05362MIG. The term ALPERTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). Most nations schedule alpertine under HS 29335995 and SITC 51576. As of Q4 2014, ALPERTINE remains the US FDA Preferred Term for this commodity. Alpertine bears US NLM identifiers UMLS ID C2348431 and NCI Concept Code C73300. SMILES: O(C(=O)C1[NH]C2C(C1CCN1CCN(CC1)C1CCCCC1)CC(OC)C(OC)C2)CC.
Alpha keto amino acid analogs are essential amino acid used in the treatment of chronic kidney disease or in acute kidney injury to reduce the production of metabolites of nitrogen degradation, improve the glomerular filtration rate, and delay the need for substitution treatment.
This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 001O2254AC, chemically known as 1,3-dimethyl-4-phenyl-4-propionoxypiperidine but generally known as alphaprodine, which bears US NIH Compound Identifier 6471. Alphaprodine comes in base and hydrochloride forms. European Medicines Agency schedules Alphaprodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05366MIG. The term ALPHAPRODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). ALPHAPRODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alphaprodine under HS 29333999 and SITC 51574. As of Q4 2014, ALPHAPRODINE remains the US FDA Preferred Term for this commodity. Alphaprodine bears US NLM identifiers UMLS ID C0002327 and NCI Concept Code C83528. SMILES: O(C1(C(CN(CC1)C)C)C1CCCCC1)C(=O)CC.
This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CO51Q2EI5Z, chemically known as 1,3-dimethyl-4-phenyl-4-piperidyl propionate hydrochloride but more generally known as alphaprodine hydrochloride, which bears US NIH Compound Identifier 120737. The base compound, Alphaprodine, comes in base and hydrochloride forms. European Medicines Agency schedules Alphaprodine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00376MIG. Most nations, for tariff and trade purposes, schedule alphaprodine hydrochloride under HS 29333990 and SITC 51574. As of Q4 2014, ALPHAPRODINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Alphaprodine hydrochloride bears US NLM identifiers UMLS ID C0028114 and NCI Concept Code C61630. SMILES: CCC(=O)O[C@@]1(CCN(C[C@@H]1C)C)C2CCCCC2.CL.
This classification denotes a sedative and hypnotic with the molecular formula C21H23Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I93SC245QZ, chemically known as 6-chloro-2-(p-chlorophenyl)-n,n-dipropylimidazo(1,2-a)pyridine-3-acetamide but generally known as alpidem, which bears US NIH Compound Identifier 54897. European Medicines Agency schedules Alpidem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05367MIG. The term ALPIDEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). ALPIDEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alpidem under HS 29339990 and SITC 51577. As of Q4 2014, ALPIDEM remains the US FDA Preferred Term for this commodity. Alpidem bears US NLM identifiers UMLS ID C0051484 and NCI Concept Code C80669. SMILES: CLC1CN2C(CC(=O)N(CCC)CCC)C(NC2CC1)C1CCC(CL)CC1.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D5H25D039V. European Medicines Agency schedules Alprafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05369MIG. Alprafenone generally arises in the molecular formula C25H35NO4. The term ALPRAFENONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 4, No. 3 1990, list 30.) ALPRAFENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule alprafenone under HS 29221980 and SITC 51461. As of Q4 2014, ALPRAFENONE remains US FDA's Preferred Term for this commodity. Alprafenone bears US NLM identifiers UMLS ID C0170980 and NCI Concept Code C72572. SMILES: OC(CNC(CC)(C)C)COC1CC(CCC(=O)C2CCC(CC2)C)CCC1OC.
This classification denotes a benzodiazepine with the molecular formula C17H13ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YU55MQ3IZY, chemically known as 8-chloro-1-methyl-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine but generally known as alprazolam, which bears US NIH Compound Identifier 2118. Alprazolam most often comes in base and dihydrate forms. European Medicines Agency schedules Alprazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05370MIG. The term ALPRAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules alprazolam in its Anatomical Therapeutic Chemical (ATC) Classification. ALPRAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alprazolam under HS 29339190 and SITC 51577. As of Q4 2014, ALPRAZOLAM remains the US FDA Preferred Term for this commodity. Alprazolam bears US NLM identifiers UMLS ID C0699034 and NCI Concept Code C227. SMILES: CLC1CC2C(N3C(NNC3C)CN=C2C2CCCCC2)CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 877K5MQ27W, chemically known as 2-propanol, 1-(o-allylphenoxy)-3-(isopropylamino)- but generally known as alprenolol, which bears US NIH Compound Identifier 2119. Alprenolol most often comes in glucuronide and hydrochloride forms. European Medicines Agency schedules Alprenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05371MIG. The term ALPRENOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules alprenolol in its Anatomical Therapeutic Chemical (ATC) Classification. ALPRENOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alprenolol under HS 29221980 and SITC 51461. As of Q4 2014, ALPRENOLOL remains the US FDA Preferred Term for this commodity. Alprenolol bears US NLM identifiers UMLS ID C0002334 and NCI Concept Code C81653. SMILES: O(CC(O)CNC(C)C)C1C(CC=C)CCCC1.
This classification denotes a beta-adrenergic blocking agent C15H23NO2.C7H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3H696761C, chemically known as benzoic acid, compd. with 1-((1-methylethyl)amino)-3-(2-(2-propenyl)phenoxy)-2-propanol (1:1), but more generally known as alprenolol benzoate, which bears US NIH Compound Identifier 9951320. European Medicines Agency schedules Alprenolol benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00377MIG. Most nations, for tariff and trade purposes, schedule alprenolol benzoate under HS 29221980 and SITC 51461. As of Q4 2014, ALPRENOLOL BENZOATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NCC(COC1CCCCC1CC=C)O.C1CCC(CC1)C(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2502C2OIRK, chemically known as 2-propanol, 1-(o-allylphenoxy)-3-(isopropylamino)-, hydrochloride but more generally known as alprenolol hydrochloride, which bears US NIH Compound Identifier 66368. European Medicines Agency schedules Alprenolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00378MIG. Most nations, for tariff and trade purposes, schedule alprenolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, ALPRENOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Alprenolol hydrochloride bears US NLM identifiers UMLS ID C0282044 and NCI Concept Code C81651. SMILES: CC(C)NCC(COC1CCCCC1CC=C)O.CL.
This classification denotes a prostaglandin analogue with the molecular formula C20H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5TD010360, chemically known as 11.alpha., 15.alpha.-dihydroxy-9-oxo-13-trans-prostenoic acid but generally known as alprostadil, which bears US NIH Compound Identifier 214. Alprostadil most often comes in alfadex and prostoglandinalfadex and prostoglandin forms. European Medicines Agency schedules Alprostadil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05372MIG. The term ALPROSTADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules alprostadil in its Anatomical Therapeutic Chemical (ATC) Classification. ALPROSTADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alprostadil under HS 29375000 and SITC 54156. As of Q4 2014, ALPROSTADIL remains the US FDA Preferred Term for this commodity. Alprostadil bears US NLM identifiers UMLS ID C0592016 and NCI Concept Code C28816. SMILES: OC1C(C(CCCCCCC(=O)O)C(=O)C1)/C=C/C(O)CCCCC.
This classification denotes a prostaglandin analogue with the molecular formula C20H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5TD010360, chemically known as prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11a,13e,15s)-, but more generally known as alprostadil alfadex, which bears US NIH Compound Identifier 11954014. European Medicines Agency schedules alprostadil alfadex or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05372MIG. Most nations, for tariff purposes, schedule alprostadil alfadex under HS 29375000. SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O.
This classification denotes an aldose reductase inhibitor with the molecular formula C14H9NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 515DHK15LG, chemically known as 2,3-dihydro-1,3-dioxo-1h-benz(de)isochiolin-2-essigsaeure but more generally known as alrestatin, which bears US NIH Compound Identifier 2120. Alrestatin most often comes in natrium and sodium forms. European Medicines Agency schedules Alrestatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05373MIG. The term ALRESTATIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). ALRESTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule alrestatin under HS 29251995 and SITC 51482. As of Q4 2014, ALRESTATIN remains US FDA's Preferred Term for this commodity. Alrestatin bears US NLM identifiers UMLS ID C0051486 and NCI Concept Code C72917. SMILES: O=C1N(C(=O)C2C3C1CCCC3CCC2)CC(=O)O.
This classification denotes an aldose reductase inhibitor with the molecular structure C14H8NO4.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 018XNU6812 chemically known as 1h-benz(de)isoquinoline-2(3h)acetic acid, 1,3-dioxo-, sodium salt, but more commonly known as alrestatin sodium, which bears US NIH Compound Identifier 40158. European Medicines Agency schedules Alrestatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00380MIG. Most nations, for tariff and trade purposes, schedule alrestatin sodium under HS 29251995 and SITC 51482. As of Q4 2014, ALRESTATIN SODIUM remains US FDA's Preferred Term for this commodity. Alrestatin sodium bears US NLM identifiers UMLS ID C2346724 and NCI Concept Code C72691. SMILES: C1CC2CCCC3C2C(C1)C(=O)N(C3=O)CC(=O)[O-].[NA+].
This classification denotes an amino acid, peptide, or protein with the molecular formula C99H155N29O21S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J0K70H3420, chemically known as 1-beta-alanine-17-(l-2,6-diamino-n-(4-aminobutyl)hexanamide)-alpha(sup 1-17)-corticotropin but generally known as alsactide, which bears US NIH Compound Identifier 16129705. European Medicines Agency schedules Alsactide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05374MIG. The term ALSACTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules alsactide in its Anatomical Therapeutic Chemical (ATC) Classification. ALSACTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alsactide under HS 29371900 and SITC 54154. As of Q4 2014, ALSACTIDE remains the US FDA Preferred Term for this commodity. SMILES: S(CCC(NC(=O)C(NC(=O)C(NC(=O)CCN)CC1CCC(O)CC1)CO)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NCCCCN)CCCCN)CC1C2C([NH]C1)CCCC2)CCCNC(=N)N)CC1CCCCC1)CC1[NH]CNC1)CCC(.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a serotonin antagonist with the molecular formula C22H22FN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5015H744JQ chemically known as 3-(2-(4-(p-fluorobenzoyl)piperidino)ethyl)-2-thio-2,4(1h,3h)-quinazolinedione but generally known as altanserin, which bears US NIH Compound Identifier 3033677. European Medicines Agency schedules Altanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05375MIG. The term ALTANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24. ). Most nations schedule altanserin under HS 29335995 and SITC 51576. As of Q4 2014, ALTANSERIN remains the US FDA Preferred Term for this commodity. Altanserin bears US NLM identifiers UMLS ID C0102811 and NCI Concept Code C77258. SMILES: C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=S.
This classification denotes a serotonin antagonist with the molecular formula C22H22FN3O2S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P204CHE8J, chemically known as 4(1h)-quinazolinone, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-2,3-dihydro-2-thioxo-, (r-(r*,r*))-2,3-dihydroxybutanedioate but more generally known as altanserin tartrate, which bears US NIH Compound Identifier 3033676. Most nations, for tariff and trade purposes, schedule altanserin tartrate under HS 29335995 and SITC 51576. As of Q4 2014, ALTANSERIN TARTRATE remains US FDA's Preferred Term for this commodity. Altanserin tartrate bears US NLM identifiers UMLS ID C2698070 and NCI Concept Code C79965. SMILES: C1CCC2C(C1)C(=O)N(C(=S)[NH]2)CCN3CCC(CC3)C(=O)C4CCC(CC4)F.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a vasodilating agent with the molecular formula C24H28N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SW3OJS6TOD, chemically known as 4-phenyl-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1-piperidinepropionanilide but generally known as altapizone, which bears US NIH Compound Identifier 178135. European Medicines Agency schedules Altapizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05376MIG. The term ALTAPIZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). ALTAPIZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule altapizone under HS 29333999 and SITC 51574. As of Q4 2014, ALTAPIZONE remains the US FDA Preferred Term for this commodity. Altapizone bears US NLM identifiers UMLS ID C2698071 and NCI Concept Code C74423. SMILES: O=C(Nc1ccc(C2=NNC(=O)CC2)cc1)CCN1CCC(CC1)c1ccccc1.
This classification denotes an antifungal agent with the molecular formula C17H12Cl3N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EA590X615B, chemically known as cis-1-(2-(p-chlorophenyl)-3-(2,4-dichlorophenyl)-2,3-epoxypropyl)-1h-1,2,4-triazole but generally known as alteconazole, which bears US NIH Compound Identifier 172289. European Medicines Agency schedules Alteconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05377MIG. The term ALTECONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). ALTECONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alteconazole under HS 29339990 and SITC 51577. As of Q4 2014, ALTECONAZOLE remains the US FDA Preferred Term for this commodity. Alteconazole bears US NLM identifiers UMLS ID C2698072 and NCI Concept Code C78031. SMILES: CLC1C(C2OC2(CN2NCNC2)C2CCC(CL)CC2)CCC(CL)C1.
This classification denotes a differentiation inducer with the molecular formula C2569H3894N746O781S40, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1RXS4UE564, more generally known as alteplase. European Medicines Agency schedules alteplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05378MIG. The term ALTEPLASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 3, no. 3, 1989, list 29. ALTEPLASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alteplase under HS 35079090 and SITC 51691. As of Q4 2014, ALTEPLASE remains the US FDA Preferred Term for this commodity. Alteplase bears US NLM identifiers UMLS ID C0032143 and NCI Concept Code C39607. SMILES: none.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B3911G2Q52 and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 21609 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Malvales, Family Malvaceae, and Genus Althaea L., more commonly known as MARSHMALLOW. Althaea bears the USDA PLANTS Database Identifiers ALRO3, ALRO4, ALOF2, and ALTHA (common variety) and ALCA25 and ALHI2 (palm-leaf and hairy varieties). European Medicines Agency schedules althaea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB12803MIG, SUB12804MIG, SUB12805MIG, SUB12806MIG, SUB33430, and SUB35172.
This classification denotes a thiazide diuretic with the molecular formula C11H14ClN3O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GI8CB72B0D, chemically known as 6-chloro-3,4-dihydro-3-((2-propenylthio)methyl)-2h-1,2,4-benzothiadiazine-7-sulfonamide but generally known as althiazide, which bears US NIH Compound Identifier 2122. European Medicines Agency schedules Althiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05379MIG. Althiazide or altizide bears US NLM identifiers UMLS ID C0051500 and NCI Concept Code C80838. SMILES: C=CCSCC1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)CL.
This classification denotes a cholinergic agonist with the molecular formula C12H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RJ9V9V09VM, chemically known as pyridine, 3-ethynyl-5-((2s)-1-methyl-2-pyrrolidinyl)- but generally known as altinicline, which bears US NIH Compound Identifier 3036156. Altinicline most often comes in base and maleate forms. The term ALTINICLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule altinicline under HS 29339990 and SITC 51577. As of Q4 2014, ALTINICLINE remains the US FDA Preferred Term for this commodity. Altinicline bears US NLM identifiers UMLS ID C2698073 and NCI Concept Code C77841. SMILES: CN1CCCC1C2=CN=CC(=C2)C#C.
This classification denotes a nicotinic agonist with the molecular formula C12H14N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PCL7Q9Q62Q, chemically known as pyridine, 3-ethynyl-5-((2s)-1-methyl-2-pyrrolidinyl)-, (2z)-2-butenedioate(1:1) but more generally known as altinicline maleate, which bears US NIH Compound Identifier 6442277. Most nations, for tariff and trade purposes, schedule altinicline maleate under HS 29339990 and SITC 51577. As of Q4 2014, ALTINICLINE MALEATE remains US FDA's Preferred Term for this commodity. Altinicline maleate bears US NLM identifiers UMLS ID C2983930 and NCI Concept Code C90896. SMILES: CN1CCC[C@H]1C2CC(CNC2)C#C.C(=C\C(=O)O)\C(=O)O.
This classification denotes a progestagen with the molecular formula C21H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2U0X0JA2NB, chemically known as 17-alpha-allyl-estratriene-4,9,11,17-beta-ol-3-one but generally known as altrenogest, which bears US NIH Compound Identifier 13324. European Medicines Agency schedules Altrenogest in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05381MIG. The term ALTRENOGEST is an International Non-Proprietary Name. ALTRENOGEST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule altrenogest under HS 29372300 and SITC 54153. As of Q4 2014, ALTRENOGEST remains the US FDA Preferred Term for this commodity. Altrenogest bears US NLM identifiers UMLS ID C0102819 and NCI Concept Code C83529. SMILES: OC1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C)CC=C.
This classification denotes an ethylenimine compound with the molecular formula C9H18N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q8BIH59O7H, chemically known as 2,4,6-tris(dimethylamino)-s-triazine but more generally known as altretamine, which bears US NIH Compound Identifier 2123. European Medicines Agency schedules Altretamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05382MIG. The term ALTRETAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules altretamine in its Anatomical Therapeutic Chemical (ATC) Classification. ALTRETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule altretamine under HS 29336980 and SITC 51576. As of Q4 2014, ALTRETAMINE remains US FDA's Preferred Term for this commodity. Altretamine bears US NLM identifiers UMLS ID C0019453 and NCI Concept Code C544. SMILES: N(C1NC(N(C)C)NC(N(C)C)N1)(C)C.
This classification denotes an ethylenimine compound with the molecular formula C9H18N6.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30FQ7QG6VM. Most nations, for tariff and trade purposes, schedule altretamine hydrochloride under HS 29336980. As of Q4 2014, ALTRETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)C1NC(NC(N1)N(C)C)N(C)C.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an anti-lipidemic agent with the molecular formula 2C10H10ClO3.Al.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56203T2K2X, chemically known as propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, aluminum complex but generally known as aluminium clofibrate, which bears US NIH Compound Identifier 16683028. European Medicines Agency schedules Aluminium clofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12820MIG. The term ALUMINIUM CLOFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules aluminium clofibrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule aluminium clofibrate under HS 29189900 and SITC 51396. SMILES: CC(C)(C(=O)O[Al]OC(=O)C(C)(C)OC1=CC=C(C=C1)Cl)OC2=CC=C(C=C2)Cl.O
This classification denotes an anti-ulcer agent with the molecular formula C2H4NO2.Al.2HO.(H2O)mix, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DO250MG0W6, chemically known as (glycinato-n,o)dihydroxyaluminum but generally known as aluminium glycinate, which bears US NIH Compound Identifier 16683036. European Medicines Agency schedules Aluminium glycinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12823MIG. World Health Organization schedules aluminium glycinate in its Anatomical Therapeutic Chemical (ATC) Classification. Aluminium glycinate or dihydroxyaluminum aminoacetate bears US NLM identifiers UMLS ID C0058134 and NCI Concept Code C81600. SMILES: [Al](OC(=O)CN)([OH2])[OH2].
This classification denotes an industrial aid, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier F92V3S521O. European Medicines Agency schedules Aluminium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12462MIG. Aluminium phosphate generally arises in the molecular formula AL.O4P. The term 'aluminium phosphate' is a U.S. Pharmacopeial Convention designation.
This classification denotes an astringent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80EHD8I43D. European Medicines Agency schedules Aluminium acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12809MIG. Aluminum acetate generally arises in the molecular formula 3C2H3O2.AL. The term 'aluminum acetate' is a U.S. Pharmacopeial Convention designation. As of Q4 2014, ALUMINUM ACETATE remains the US FDA Preferred Term for this commodity. Aluminum acetate bears US NLM identifiers UMLS ID C0051510 and NCI Concept Code C47387. SMILES: CC(=O)O[AL]OC(=O)C.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an antacid with the molecular formula 3CO3.2Al, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1GA689N629, chemically known as carbonic acid, aluminum salt (3:2) but generally known as aluminum carbonate, which bears US NIH Compound Identifier 16205141. As of Q4 2014, ALUMINUM CARBONATE remains the US FDA Preferred Term for this commodity. SMILES: C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[Al+3].[Al+3].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA102. This VA Drug Class (GA102) classifies this compound as belonging to the group ALUMINUM/CALCIUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN410. This VA Drug Class (TN410) classifies this compound as belonging to the group IRON.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA103. This VA Drug Class (GA103) classifies this compound as belonging to the group ALUMINUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA103. This VA Drug Class (GA103) classifies this compound as belonging to the group ALUMINUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA103. This VA Drug Class (GA103) classifies this compound as belonging to the group ALUMINUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA103. This VA Drug Class (GA103) classifies this compound as belonging to the group ALUMINUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an antispasmotic agent and anticholinergic agent with the molecular formula C20H27N.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9JFB58YK1E, chemically known as n,n-bis(3-phenylpropyl)ethylamine but more generally known as alverine citrate, which bears US NIH Compound Identifier 3678. European Medicines Agency schedules Alverine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00421MIG. Most nations, for tariff and trade purposes, schedule alverine citrate under HS 29214980 and SITC 51454. As of Q4 2014, ALVERINE CITRATE remains US FDA's Preferred Term for this commodity. Alverine citrate bears US NLM NCI C72692. SMILES: CCN(CCCC1CCCCC1)CCCC2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an anticholinergic agent with the molecular formula C20H27N.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8K3R1YUZ4I. Most nations, for tariff and trade purposes, schedule alverine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, ALVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Alverine hydrochloride bears US NLM NCI C97966. SMILES: CCN(CCCC1CCCCC1)CCCC2CCCCC2.CL.
This classification denotes an anticholinergic agent with the molecular formulas C20H27N, C20H27N.C6H8O7, or C20H27N.C4H6O6, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 46TIR1560O, 9JFB58YK1E, 8K3R1YUZ4I, and 943CL334OB, the base compound being n,n-bis(3-phenylpropyl)ethylamine but it generally known as alverine, which bears US NIH Compound Identifier 3678. Alverine most often comes in citrate and dihydrogen citrate forms. European Medicines Agency schedules Alverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05384MIG (base), SUB00421MIG (citrate), or SUB26963 (tartrate). The term ALVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules alverine in its Anatomical Therapeutic Chemical (ATC) Classification. ALVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alverine, alverine citrate, and alverine tartrate under HS 29214980 and SITC 51454. As of Q4 2014, ALVERINE remains the US FDA Preferred Term for this commodity. Alverine bears US NLM NCI C76387, C72692, and C97966. SMILES: N(CCCC1CCCCC1)(CCCC1CCCCC1)CC (base), CCN(CCCC1CCCCC1)CCCC2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O (citrate), CCN(CCCC1CCCCC1)CCCC2CCCCC2.CL (hydrochloride), CCN(CCCC1CCCCC1)CCCC2CCCCC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O (tartrate).
This classification denotes an anticholinergic agent C20H27N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 943CL334OB, chemically known as dipropylamine, n-ethyl-3,3'-diphenyl-, tartrate, but more generally known as alverine tartrate, which bears US NIH Compound Identifier 72941455. European Medicines Agency schedules Alverine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26963. Most nations, for tariff and trade purposes, schedule alverine tartrate under HS 29214980 and SITC 51454. As of Q4 2014, ALVERINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CCCC1CCCCC1)CCCC2CCCCC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an opiate antagonist with the molecular formula C25H32N2O4.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 677C126AET, chemically known as glycine, n-((2s)-2-(((3r,4r)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-, dihydrate but generally known as alvimopan, which bears US NIH Compound Identifier 5488547. Alvimopan most often comes in simple, anhydrous, and hyrdate forms. European Medicines Agency schedules Alvimopan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20585. World Health Organization schedules alvimopan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule alvimopan under HS 29333999 and SITC 51574. As of Q4 2014, ALVIMOPAN remains the US FDA Preferred Term for this commodity. Alvimopan bears US NLM identifiers UMLS ID C1508750 and NCI Concept Code C49096. SMILES: OC1CC(C2(C(CN(CC2)CC(CC2CCCCC2)C(=O)NCC(=O)O)C)C)CCC1.O.O.
This classification denotes the anhydrous form of an opiate antagonist with the molecular formula C25H32N2O4.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 677C126AET, chemically known as glycine, n-((2s)-2-(((3r,4r)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-, dihydrate but more generally known as alvimopan, which bears US NIH Compound Identifier 5488547. Alvimopan most often comes in simple, anhydrous, and hyrdate forms. European Medicines Agency schedules Alvimopan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20585. World Health Organization schedules alvimopan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule alvimopan anhydrous under HS 29333999. As of Q4 2014, ALVIMOPAN ANHYDROUS remains US FDA's Preferred Term for this commodity. Alvimopan anhydrous bears US NLM identifiers UMLS ID C2698078 and NCI Concept Code C77377. SMILES: C[C@H]1CN(CC[C@@]1(C)C2CCCC(C2)O)C[C@H](CC3CCCCC3)C(=O)NCC(=O)O.
This classification denotes a diuretic with the molecular formula C9H9N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X43W7JDA8L, chemically known as 1,3,5-triazine-2,4-diamine, n-phenyl-, monohydrochloride but generally known as amanozine, which bears US NIH Compound Identifier 10832. Amanozine most often comes in base and hydrochloride forms. European Medicines Agency schedules Amanozine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05388MIG. The term AMANOZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). AMANOZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amanozine under HS 29336980 and SITC 51576. As of Q4 2014, AMANOZINE remains the US FDA Preferred Term for this commodity. Amanozine bears US NLM identifiers UMLS ID C2698079 and NCI Concept Code C74253. SMILES: N(C1CCCCC1)C1NC(NCN1)N.
This classification denotes an antiviral agent and cation channel blocker with the molecular formula C10H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BF4C9Z1J53, chemically known as 1-aminotricyclo(3.3.1.1(sup 3,7))decane but generally known as amantadine, which bears US NIH Compound Identifier 2130. Amantadine most often comes in base and hydrochloride\tforms and is often combined with ribavirin and interferon (alpha). European Medicines Agency schedules Amantadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05389MIG. The term AMANTADINE is an International Non-Proprietary Name. World Health Organization schedules amantadine in its Anatomical Therapeutic Chemical (ATC) Classification. AMANTADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amantadine under HS 29213099 and SITC 51453. As of Q4 2014, AMANTADINE remains the US FDA Preferred Term for this commodity. Amantadine bears US NLM identifiers UMLS ID C0002403 and NCI Concept Code C61632. SMILES: C1C2CC3CC1CC(C2)(C3)N.
This classification denotes an antiviral agent and cation channel blocker with the molecular formula C10H17N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M6Q1EO9TD0, chemically known as 1-aminotricyclo(3.3.1.1(sup 3,7))decane but more generally known as amantadine hydrochloride, which bears US NIH Compound Identifier 2130. European Medicines Agency schedules Amantadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00422MIG. Most nations, for tariff and trade purposes, schedule amantadine hydrochloride under HS 29213000 and SITC 51453. As of Q4 2014, AMANTADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amantadine hydrochloride bears US NLM identifiers UMLS ID C0723562 and NCI Concept Code C28818. SMILES: C1[C@@H]2CC3C[C@H]1C[C@](C2)(C3)N.CL.
This classification denotes a miscellaneous antiviral agent and cation channel blocker with the molecular formula 2C10H17N.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9921T5P019. European Medicines Agency schedules amantadine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00423MIG. The term amantadine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule amantadine sulfate under HS 29213099 and SITC 51453. As of Q4 2014, AMANTADINE SULFATE remains US FDA's Preferred Term for this commodity. Amantadine sulfate bears US NLM identifiers UMLS ID C0002404 and NCI Concept Code C90781. SMILES: C1C2CC3CC1CC(C2)(C3)N.OS(=O)(=O)O.
This classification denotes a penicillin antibiotic with the molecular formula C19H27N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, GV5ZHU20H9 chemically known as 6-(3-amino-1-adamantanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as amantocillin, which bears US NIH Compound Identifier 168908. European Medicines Agency schedules Amantocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05391MIG. The term AMANTOCILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7. ). Most nations schedule amantocillin under HS 29411090 and SITC 54131. As of Q4 2014, AMANTOCILLIN remains the US FDA Preferred Term for this commodity. Amantocillin bears US NLM identifiers UMLS ID C2346728 and NCI Concept Code C72693. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C12CC3(N)CC(C1)CC(C2)C3.
This classification denotes a nitrogen mustard compound with the molecular formula C29H39Cl2FN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IB1H345F24, chemically known as n-(3-(m-(bis(2-chloroethyl)amino)phenyl)-n-(3-(p-fluorophenyl)-l-alanyl)-l-alanyl)-l-methionine, ethyl ester but more generally known as ambamustine, which bears US NIH Compound Identifier 178137. Ambamustine most often comes in base and hydrochloride forms. European Medicines Agency schedules Ambamustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05392MIG. The term AMBAMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). AMBAMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ambamustine under HS 29309085 and SITC 51549. As of Q4 2014, AMBAMUSTINE remains US FDA's Preferred Term for this commodity. Ambamustine bears US NLM identifiers UMLS ID C0244456 and NCI Concept Code C73320. SMILES: CLCCN(C1CC(CC(NC(=O)C(N)CC2CCC(F)CC2)C(=O)NC(CCSC)C(=O)OCC)CCC1)CCCL.
This classification denotes an antiarrhythmic agent with the molecular formula C21H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 012LYD6KXM, chemically known as 3-(p-aminobenzoyl)-7-benzyl-3,7-diazabicyclo(3.3.1)nonane but more generally known as ambasilide, which bears US NIH Compound Identifier 71270. European Medicines Agency schedules Ambasilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05393MIG. The term AMBASILIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). AMBASILIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ambasilide under HS 29333999 and SITC 51574. As of Q4 2014, AMBASILIDE remains US FDA's Preferred Term for this commodity. Ambasilide bears US NLM identifiers UMLS ID C0169222 and NCI Concept Code C72573. SMILES: O=C(N1CC2CC(CN(C2)CC2CCCCC2)C1)C1CCC(N)CC1.
This classification denotes an antineoplastic antibiotic with the molecular formula C8H11N7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BYK4592A3Q, chemically known as 1,4-benzoquinone guanylhydrazone thiosemicarbazone but generally known as ambazone, which bears US NIH Compound Identifier 1549158. European Medicines Agency schedules Ambazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12841MIG. The term AMBAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules ambazone in its Anatomical Therapeutic Chemical (ATC) Classification. AMBAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambazone under HS 29309085 and SITC 51549. As of Q4 2014, AMBAZONE remains the US FDA Preferred Term for this commodity. Ambazone bears US NLM identifiers UMLS ID C0043983 and NCI Concept Code C72627. SMILES: S=C(/N=N/C1CCC(N/N=C(/N)N)CC1)N.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C28H42Cl2N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L16PUN799N, chemically known as benzenemethanaminium, n,n-((1,2-dioxo-1,2-ethanediyl)bis(imino-2,1-ethanediyl))bis(2-chloro-n,n-diethyl- but generally known as ambenonium, which bears US NIH Compound Identifier 2131. Ambenonium most often comes in base, chloride, and dichloride forms. European Medicines Agency schedules Ambenonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00425MIG. World Health Organization schedules ambenonium in its Anatomical Therapeutic Chemical (ATC) Classification. AMBENONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, AMBENONIUM remains the US FDA Preferred Term for this commodity. Ambenonium bears US NLM identifiers UMLS ID C0002412 and NCI Concept Code C76136. SMILES: CLC1C(C[N](CCNC(=O)C(=O)NCC[N](CC2C(CL)CCCC2)(CC)CC)(CC)CC)CCCC1.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C28H42Cl2N4O2.2Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51FOB87G3I, chemically known as n,n-bis(2-diethylaminoethyl)oxamide bis(2-chlorobenzyl chloride) but more generally known as ambenonium chloride, which bears US NIH Compound Identifier 8288. European Medicines Agency schedules Ambenonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05394MIG. The term AMBENONIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations, for tariff and trade purposes, schedule ambenonium chloride under HS 29242995 and SITC 51479. As of Q4 2014, AMBENONIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Ambenonium chloride bears US NLM identifiers UMLS ID C1448379 and NCI Concept Code C47388. SMILES: CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1CCCCC1CL)CC2CCCCC2CL.[CL-].[CL-].
This classification denotes an endothelin-1 protein receptor antagonist and antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HW6NV07QEC. European Medicines Agency schedules Ambrisentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25424. Ambrisentan generally arises in the molecular formula C22H22N2O4. The term AMBRISENTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations schedule ambrisentan under HS 29335995 and SITC 51576. As of Q4 2014, AMBRISENTAN remains the US FDA Preferred Term for this commodity. Ambrisentan bears US NLM identifiers UMLS ID C1176329 and NCI Concept Code C72694. SMILES: O(C(C(Oc1nc(cc(n1)C)C)C(=O)O)(c1ccccc1)c1ccccc1)C.
This classification denotes a mucolytic agent and expectorant with the molecular formula C13H18Br2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 200168S0CL, chemically known as trans-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol but more generally known as ambroxol, which bears US NIH Compound Identifier 2132. Ambroxol most often comes in base and hydrochloride forms. European Medicines Agency schedules Ambroxol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG. The term AMBROXOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules ambroxol in its Anatomical Therapeutic Chemical (ATC) Classification. AMBROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ambroxol under HS 29221980 and SITC 51461. As of Q4 2014, AMBROXOL remains US FDA's Preferred Term for this commodity. Ambroxol bears US NLM identifiers UMLS ID C0002421 and NCI Concept Code C74262. SMILES: BRC1C(N)C(CNC2CCC(O)CC2)CC(BR)C1.
This classification denotes a combination drug composed of two constituents: a mucolytic and an aminopenicillin, as more fully appears. The first constituent, ambroxol (51162702) is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90]. European Medicines Agency schedules AMBROXOL in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG (base), SUB12842MIG (acefyllinate), and SUB00427MIG (hydrochloride). The term AMBROXOL is an International Non-Proprietary Name or INN. World Health Organization schedules ambroxol in its Anatomical Therapeutic Chemical (ATC) Classification (R05CB06) and in its WHO Drug Dictionary. AMBROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambroxol under HS 29221980 and SITC 51461. US Census, for industry purposes, classifies ambroxol under NAICS 325199. The second constituent in this preparation is amoxicillin {51281702}, a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 804826J2HU. Amoxicillin comes in forms anhydrous, hydrate, sodium, and trihydrate {51281710, 51281711, 51281712, 51281713}. European Medicines Agency schedules Amoxicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05481MIG. Amoxicillin generally arises in the molecular formula C16H19N3O5S. The term AMOXICILLIN is a European Pharmacopoeia designation. AMOXICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amoxicillin under HS 29411010 and SITC 54131. As of Q4 2014, AMOXICILLIN remains the US FDA Preferred Term for this commodity. Amoxicillin bears US NLM identifiers UMLS ID C0002645 and NCI Concept Code C237. Practitioners typically use this combination drug in treatment of chronic bronchitis and similar maladies.
This classification denotes a combination drug composed of two constituents: a mucolytic and a cephalosporin antibiotic, as more fully appears. The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90]. European Medicines Agency schedules AMBROXOL in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG (base), SUB12842MIG (acefyllinate), and SUB00427MIG (hydrochloride). The term AMBROXOL is an International Non-Proprietary Name or INN. World Health Organization schedules ambroxol in its Anatomical Therapeutic Chemical (ATC) Classification (R05CB06) and in its WHO Drug Dictionary. AMBROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambroxol under HS 29221980 and SITC 51461. US Census, for industry purposes, classifies ambroxol under NAICS 325199. The second constituent, Cefadroxil (51282502), is a cephalosporin antibiotic with the molecular formula C16H17N3O5S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 280111G160, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6r-(6-alpha,7-beta(r*)))- but generally known as cefadroxil, which bears US NIH Compound Identifier 2610. Cefadroxil most often comes in base, hydrate, and hemihydrate forms. European Medicines Agency schedules Cefadroxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06164MIG. World Health Organization schedules cefadroxil in its Anatomical Therapeutic Chemical (ATC) Classification. CEFADROXIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefadroxil under HS 29419000 and SITC 54139. As of Q4 2014, CEFADROXIL remains the US FDA Preferred Term for this commodity. Cefadroxil bears US NLM identifiers UMLS ID C0007538 and NCI Concept Code C28912.
This classification denotes a combination drug composed of two constituents: a mucolytic and a macrolide antibiotic, as more fully appears. The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90]. European Medicines Agency schedules AMBROXOL in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG (base), SUB12842MIG (acefyllinate), and SUB00427MIG (hydrochloride). The term AMBROXOL is an International Non-Proprietary Name or INN. World Health Organization schedules ambroxol in its Anatomical Therapeutic Chemical (ATC) Classification (R05CB06) and in its WHO Drug Dictionary. AMBROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambroxol under HS 29221980 and SITC 51461. US Census, for industry purposes, classifies ambroxol under NAICS 325199. The second component of this combination drug, clarithromycin(51282302), is a macrolide antibiotic with the molecular formula C38H69NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1250JIK0A, chemically known as erythromycin, 6-o-methyl- but generally known as clarithromycin {51282302}, which bears US NIH Compound Identifier 54688. European Medicines Agency schedules Clarithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06641MIG. The term CLARITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules clarithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. CLARITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clarithromycin under HS 29415000 and SITC 54139. As of Q4 2014, CLARITHROMYCIN remains the US FDA Preferred Term for this commodity. Clarithromycin bears US NLM identifiers UMLS ID C0055856 and NCI Concept Code C1054.
This classification denotes a combination drug composed of two constituents: a mucolytic and an opioid receptor agonist and opioid, as more fully appears. The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90]. European Medicines Agency schedules AMBROXOL in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG (base), SUB12842MIG (acefyllinate), and SUB00427MIG (hydrochloride). The term AMBROXOL is an International Non-Proprietary Name or INN. World Health Organization schedules ambroxol in its Anatomical Therapeutic Chemical (ATC) Classification (R05CB06) and in its WHO Drug Dictionary. AMBROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambroxol under HS 29221980 and SITC 51461. US Census, for industry purposes, classifies ambroxol under NAICS 325199. The second component of this combination drug, dextromethorphan (51162626), is an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears US NIH Compound Identifier 3008. Dextromethorphan {51162626} comes in forms base, hydriodide, hydrobromide, hydrobromide anhydrous, hydrochloride, salicylate, and tannate ([086F8ZEM77], [9D2RTI9KYH], [351KFH969D], [B2F298X1AJ], [554R584P9K]); it further serves in many other combination drugs with doxylamine, dyphylline, glycerol, guaifenesin, ipecac, phenylephrine, phenylpropanolamine, potassium, promethazine, pseudoephedrine, quinidine, terpin hydrate ({51143708}, {51162018}, {51162401}, {51162408}, {51162409}, {51162410}, {51162411}, {51162412}, {51162510}, {51162511}, {51314363}, {51314364}, {51314365}, {51314366}, {51314367}, {51314368}). European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. DEXTROMETHORPHAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dextromethorphan under HS 29334930 and SITC 51575. As of Q4 2014, DEXTROMETHORPHAN remains US FDA's Preferred Term for this commodity. Dextromethorphan bears US NLM identifiers UMLS ID C0011816 and NCI Concept Code C62022.
This classification denotes a combination drug composed of two constituents: a mucolytic and bronchodilator and beta-adrenergic agonist, as more fully appears. The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90]. European Medicines Agency schedules AMBROXOL in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG (base), SUB12842MIG (acefyllinate), and SUB00427MIG (hydrochloride). The term AMBROXOL is an International Non-Proprietary Name or INN. World Health Organization schedules ambroxol in its Anatomical Therapeutic Chemical (ATC) Classification (R05CB06) and in its WHO Drug Dictionary. AMBROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambroxol under HS 29221980 and SITC 51461. US Census, for industry purposes, classifies ambroxol under NAICS 325199. The second component of this combination drug, salbutamol (51391703), is a bronchodilator and beta-adrenergic agonist with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QF8SVZ843E, chemically known as 1,3-benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy- but generally known as albuterol, which bears US NIH Compound Identifier 2083. Albuterol comes in many forms, including adipate diethanolate, di-methylboronate, n-butylboronate, and sulfate. European Medicines Agency schedules Albuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10422MIG. The term SALBUTAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules albuterol in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule albuterol under HS 29225090 and SITC 51467. As of Q4 2014, ALBUTEROL remains the US FDA Preferred Term for this commodity. Albuterol bears US NLM identifiers UMLS ID C0001927 and NCI Concept Code C215.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X794618736. European Medicines Agency schedules Ambruticin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05398MIG. Ambruticin generally arises in the molecular formula C28H42O6. The term AMBRUTICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) AMBRUTICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambruticin under HS 29419000 and SITC 54139. As of Q4 2014, AMBRUTICIN remains the US FDA Preferred Term for this commodity. Ambruticin bears US NLM identifiers UMLS ID C0051555 and NCI Concept Code C75987. SMILES: O1C(/C=C/C2C(C2/C=C/C(/C=C(/C2OC(C(=CC2)C)CC)C)C)C)C(O)C(O)CC1CC(=O)O.
This classification denotes an anesthetic agent with the molecular formula C17H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M7G4B57ZCB, chemically known as benzoic acid, 4-amino-2-butoxy-, 2-(diethylamino)ethyl ester but generally known as ambucaine, which bears US NIH Compound Identifier 8387. European Medicines Agency schedules Ambucaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05399MIG. The term AMBUCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). AMBUCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambucaine under HS 29225000 and SITC 51467. As of Q4 2014, AMBUCAINE remains the US FDA Preferred Term for this commodity. Ambucaine bears US NLM identifiers UMLS ID C2346730 and NCI Concept Code C72165. SMILES: O(CCN(CC)CC)C(=O)C1C(OCCCC)CC(N)CC1.
This classification denotes an antispasmotic agent with the molecular formula C17H28N2O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M010V3MAJ. European Medicines Agency schedules ambucetamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00428MIG. Most nations, for tariff and trade purposes, schedule ambucetamide hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, AMBUCETAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCCN(CCCC)C(C1CCC(CC1)OC)C(=O)N.CL.
This classification denotes an antispasmotic agent with the molecular formulas C17H28N2O2 and C17H28N2O2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 131B408RZI and 2M010V3MAJ, the base compound being chemically known as benzeneacetamide, alpha-(dibutylamino)-4-methoxy- (9ci) but generally known as ambucetamide, which bears US NIH Compound Identifier 10616. European Medicines Agency schedules Ambucetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05400MIG and SUB00428MIG. The term AMBUCETAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). AMBUCETAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambucetamide and its salts under HS 29242995 and SITC 51479. As of Q4 2014, AMBUCETAMIDE remains the US FDA Preferred Term for this commodity. Ambucetamide bears US NLM NCI C80975. SMILES: O=C(N)C(N(CCCC)CCCC)C1CCC(OC)CC1 (base) and CCCCN(CCCC)C(C1CCC(CC1)OC)C(=O)N.CL (hydrochloride).
This classification denotes a bronchodilator with the molecular formula C7H8N4O2.C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VOU5V0B772, chemically known as 3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione, compound with 2-amino-2-methylpropan-1-ol (1:1) but generally known as ambuphylline, which bears US NIH Compound Identifier 21850. European Medicines Agency schedules Ambuphylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12843MIG. World Health Organization schedules ambuphylline in its Anatomical Therapeutic Chemical (ATC) Classification. Ambuphylline or bufylline bears US NLM identifiers UMLS ID C0602745 and NCI Concept Code C76572. SMILES: CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC=N2.
This classification denotes an antimuscarinic agent with the molecular formula C20H27N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O677EQ77U, chemically known as 4-dimethylamino-2,2-diphenylbutyramide but generally known as ambutonium, which bears US NIH Compound Identifier 8276. European Medicines Agency schedules Ambutonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12844MIG. As of Q4 2014, AMBUTONIUM remains the US FDA Preferred Term for this commodity. Ambutonium bears US NLM identifiers UMLS ID C0301368 and NCI Concept Code C79895. SMILES: CC[N+](C)(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N.
This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F0Q1D55E29, chemically known as s! 15,112 but generally known as amcinafide, which bears US NIH Compound Identifier 23747. European Medicines Agency schedules Amcinafide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05403MIG. The term AMCINAFIDE is an International Non-Proprietary Name. AMCINAFIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amcinafide under HS 29372200 and SITC 54153. As of Q4 2014, AMCINAFIDE remains the US FDA Preferred Term for this commodity. Amcinafide bears US NLM identifiers UMLS ID C2825338 and NCI Concept Code C80807. SMILES: FC12C(C3C(C4(OC(OC4C3)(C)C3CCCCC3)C(=O)CO)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 423W026MA9. European Medicines Agency schedules Amcinonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05404MIG. Amcinonide generally arises in the molecular formula C28H35FO7. The term AMCINONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) AMCINONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amcinonide under HS 29372200 and SITC 54153. As of Q4 2014, AMCINONIDE remains the US FDA Preferred Term for this commodity. Amcinonide bears US NLM identifiers UMLS ID C0051556 and NCI Concept Code C47389. SMILES: FC12C(C3C(C4(OC5(OC4C3)CCCC5)C(=O)COC(=O)C)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes a penicillin antibiotic with the molecular formula C15H23N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V10579P3QZ, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((hexahydro-1h-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (2s-(2alpha,5alpha,6beta))- but generally known as amdinocillin, which bears US NIH Compound Identifier 36272. Amdinocillin most often comes in mecillinam and pivoxil forms. European Medicines Agency schedules Amdinocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08675MIG. The term MECILLINAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules amdinocillin in its Anatomical Therapeutic Chemical (ATC) Classification. Amdinocillin or mecillinam bears US NLM identifiers UMLS ID C0002435 and NCI Concept Code C65229. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2/N=C/N1CCCCCC1.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C9H12N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 54I81H0M9C, chemically known as 2,6-diaminopurine dioxolane but generally known as amdoxovir, which bears US NIH Compound Identifier 124088. European Medicines Agency schedules Amdoxovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20547. The term AMDOXOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). Most nations schedule amdoxovir under HS 29349990 and SITC 51579. As of Q4 2014, AMDOXOVIR remains the US FDA Preferred Term for this commodity. Amdoxovir bears US NLM identifiers UMLS ID C1528970 and NCI Concept Code C76927. SMILES: O1C(n2c3nc(nc(N)c3nc2)N)COC1CO.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H40O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7YRF8G0G0F, chemically known as 11 beta,17,21-trihydroxy-6 alpha-methylpregn-4-ene-3,20-dione 21-acetate 17-butyrate but generally known as amebucort, which bears US NIH Compound Identifier 3086167. European Medicines Agency schedules Amebucort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05405MIG. The term AMEBUCORT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). AMEBUCORT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amebucort under HS 29372900 and SITC 54153. As of Q4 2014, AMEBUCORT remains the US FDA Preferred Term for this commodity. Amebucort bears US NLM identifiers UMLS ID C2698081 and NCI Concept Code C74406. SMILES: O(C1(C2(C(C3C(C4(C(=CC(=O)CC4)C(C3)C)C)C(O)C2)CC1)C)C(=O)COC(=O)C)C(=O)CCC.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OWK6X9N16. European Medicines Agency schedules Amedalin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05406MIG. Amedalin generally arises in the molecular formula C19H22N2O. The term AMEDALIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) AMEDALIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amedalin under HS 29337900 and SITC 51561. As of Q4 2014, AMEDALIN remains the US FDA Preferred Term for this commodity. Amedalin bears US NLM identifiers UMLS ID C2698082 and NCI Concept Code C79852. SMILES: CC1(C2=CC=CC=C2N(C1=O)C3=CC=CC=C3)CCCNC.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OWK6X9N16. European Medicines Agency schedules Amedalin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05406MIG. Amedalin generally arises in the molecular formula C19H22N2O. The term AMEDALIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) AMEDALIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amedalin hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, AMEDALIN HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Amedalin hydrochloride bears US NLM identifiers UMLS ID C2825651 and NCI Concept Code C81477. SMILES: CC1(C2=CC=CC=C2N(C1=O)C3=CC=CC=C3)CCCNC.Cl.
This classification denotes an anticonvulsant agent with the molecular formula C15H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F83240ZOVE, chemically known as 4-amino-n-(2,6-dimethylphenyl)benzamide but generally known as ameltolide, which bears US NIH Compound Identifier 13086. European Medicines Agency schedules Ameltolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05408MIG. The term AMELTOLIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). AMELTOLIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ameltolide under HS 29242995 and SITC 51479. As of Q4 2014, AMELTOLIDE remains the US FDA Preferred Term for this commodity. Ameltolide bears US NLM identifiers UMLS ID C0065310 and NCI Concept Code C81472. SMILES: O=C(NC1C(CCCC1C)C)C1CCC(N)CC1.
This classification denotes an anesthetic agent with the molecular formula C15H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0619F35CGV, chemically known as p-(butylamino)benzoic acid, 2-(dimethylamino)ethyl ester but generally known as tetracaine, which bears US NIH Compound Identifier 5411. European Medicines Agency schedules Tetracaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10940MIG. The term TETRACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules tetracaine in its Anatomical Therapeutic Chemical (ATC) Classification. TETRACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Amethocaine or tetracaine bears US NLM identifiers UMLS ID C0039629 and NCI Concept Code C66590. SMILES: O(CCN(C)C)C(=O)C1CCC(NCCCC)CC1.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H12N3O.CH3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03NR868ICX, chemically known as pyridazinium, 4-amino-6-methoxy-1-phenyl-, methyl sulfate but generally known as amezinium methyl sulfate, which bears US NIH Compound Identifier 71926. European Medicines Agency schedules Amezinium metilsulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05412MIG. The term AMEZINIUM METILSULFATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules amezinium methyl sulfate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule amezinium metilsulfate under HS 29339990 and SITC 51577. As of Q4 2014, AMEZINIUM METILSULFATE remains the US FDA Preferred Term for this commodity. Amezinium metilsulfate bears US NLM identifiers UMLS ID C0771147 and NCI Concept Code C72918. SMILES: COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2.COS(=O)(=O)[O-].
This classification denotes a cns stimulant and anorexiant with the molecular formula C11H12Cl3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6015XOA0BI, chemically known as 1-phenyl-n-(2,2,2-trichlorethyliden)-2-propylamin but more generally known as amfecloral, which bears US NIH Compound Identifier 21759. European Medicines Agency schedules Amfecloral in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05414MIG. The term AMFECLORAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). AMFECLORAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Amfecloral or amphecloral bears US NLM identifiers UMLS ID C2983798 and NCI Concept Code C90610. SMILES: CC(CC1=CC=CC=C1)N=CC(CL)(CL)CL.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28O5C1J38A. European Medicines Agency schedules Amfenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05415MIG. Amfenac generally arises in the molecular formula C15H13NO3. The term AMFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) AMFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amfenac under HS 29225000 and SITC 51467. As of Q4 2014, AMFENAC remains the US FDA Preferred Term for this commodity. Amfenac bears US NLM identifiers UMLS ID C0051572 and NCI Concept Code C73071. SMILES: O=C(C1C(N)C(CC(=O)O)CCC1)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PPF9V8J28Y. European Medicines Agency schedules Amfenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00433MIG. Amfenac sodium generally arises in the molecular formula C15H12NO3.NA.H2O. The term 'amfenac sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule amfenac sodium under HS 29225000 and SITC 51467. As of Q4 2014, AMFENAC SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(=O)C2CCCC(C2N)CC(=O)[O-].O.[NA+].
This classification denotes an anorexiant with the molecular formula C15H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) OPE7BD4AAA, chemically known as phenethylamine, n,alpha-dimethyl-p-pentyl- but more generally known as amfepentorex, which bears US NIH Compound Identifier 71877. European Medicines Agency schedules Amfepentorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05416MIG. The term AMFEPENTOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). AMFEPENTOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule amfepentorex under HS 29214980 and SITC 51454. As of Q4 2014, AMFEPENTOREX remains US FDA's Preferred Term for this commodity. Amfepentorex bears US NLM identifiers UMLS ID C2346735 and NCI Concept Code C72178. SMILES: N(C(CC1CCC(CCCCC)CC1)C)C.
This classification denotes a cns stimulant and anorexiant with the molecular formula C13H19NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19V2PL39NG, chemically known as 1-propanone, 2-(diethylamino)-1-phenyl- but more generally known as amfepramone hydrochloride, which bears US NIH Compound Identifier 7029. European Medicines Agency schedules Amfepramone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00434MIG. Most nations, for tariff and trade purposes, schedule amfepramone hydrochloride under HS 29223100. SMILES: CCN(CC)C(C)C(=O)C1CCCCC1.CL.
This classification denotes a serotonin agonist with the molecular formula C12H16F3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E35R3G56OV, chemically known as phenethylamine, n-ethyl-alpha-methyl-m-(trifluoromethyl)-, (s)- but generally known as dexfenfluramine, which bears US NIH Compound Identifier 3337. European Medicines Agency schedules Dexfenfluramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07028MIG. The term DEXFENFLURAMINE is an International Non-Proprietary Name. World Health Organization schedules dexfenfluramine in its Anatomical Therapeutic Chemical (ATC) Classification. DEXFENFLURAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCNC(C)CC1=CC(=CC=C1)C(F)(F)F.
This classification denotes a cns stimulant with the molecular formula C9H13N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CK833KGX7E, chemically known as phenethylamine, d-.alpha.-methyl- but more generally known as amfetamine, which bears US NIH Compound Identifier 3007. European Medicines Agency schedules Amfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05418MIG. The term AMPHETAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules amfetamine in its Anatomical Therapeutic Chemical (ATC) Classification. AMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Amfetamine or amphetamine bears US NLM identifiers UMLS ID C0002658 and NCI Concept Code C62006. SMILES: NC(CC1CCCCC1)C.
This classification denotes a cns stimulant with the molecular formula C17H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0XU0V77JVE, chemically known as benzeneacetonitrile, alpha-((1-methyl-2-phenylethyl)amino)- (9ci) but more generally known as amfetaminil, which bears US NIH Compound Identifier 28615. European Medicines Agency schedules Amfetaminil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05419MIG. The term AMFETAMINIL is an International Non-Proprietary Name. AMFETAMINIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Amfetaminil or amphetaminil bears US NLM identifiers UMLS ID C2698084 and NCI Concept Code C74237. SMILES: CC(CC1=CC=CC=C1)NC(C#N)C2=CC=CC=C2.
This classification denotes a xanthine oxidase inhibitor with the molecular formula C11H7F3N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83N680M457, chemically known as 5-isothiazolecarboxylic acid, 4-amino-3-(3-(trifluoromethyl)phenyl)- but generally known as amflutizole, which bears US NIH Compound Identifier 54833. European Medicines Agency schedules Amflutizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05420MIG. The term AMFLUTIZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). AMFLUTIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amflutizole under HS 29341000 and SITC 51579. As of Q4 2014, AMFLUTIZOLE remains the US FDA Preferred Term for this commodity. Amflutizole bears US NLM identifiers UMLS ID C0051573 and NCI Concept Code C91009. SMILES: C1=CC(=CC(=C1)C(F)(F)F)C2=NSC(=C2N)C(=O)O.
This classification denotes an antitussive agent with the molecular formula C22H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 741ZW9MD1G, chemically known as 1-(2-(1h-azepin-1-yl)ethyl)-2-oxocyclohexane carboxylic acid, benzyl ester but more generally known as amicibone, which bears US NIH Compound Identifier 31793. European Medicines Agency schedules Amicibone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05423MIG. The term AMICIBONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). AMICIBONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule amicibone under HS 29339990 and SITC 51577. As of Q4 2014, AMICIBONE remains US FDA's Preferred Term for this commodity. Amicibone bears US NLM identifiers UMLS ID C2983871 and NCI Concept Code C90773. SMILES: O(C(=O)C1(CCN2CCCCCC2)CCCCC1=O)CC1CCCCC1.
This classification denotes an antihelminthic agent with the molecular formula C13H19N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C67IS11N0O, chemically known as acetanilide, 4-((1-(dimethylamino)ethylidene)amino)-2-methoxy- but generally known as amidantel, which bears US NIH Compound Identifier 39521. Amidantel most often comes in base and hydrochloride forms. European Medicines Agency schedules Amidantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05425MIG. The term AMIDANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). AMIDANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amidantel under HS 29252900 and SITC 51482. As of Q4 2014, AMIDANTEL remains the US FDA Preferred Term for this commodity. Amidantel bears US NLM identifiers UMLS ID C0051580 and NCI Concept Code C72152. SMILES: O(CC(=O)NC1CCC(/N=C(/N(C)C)C)CC1)C.
This classification denotes an antiviral agent and antimicrobial with the molecular formula C13H13N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8N5BE1I42E, chemically known as urea, (p-sulfanilylphenyl)- (8ci) but generally known as amidapsone, which bears US NIH Compound Identifier 66267. European Medicines Agency schedules Amidapsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05426MIG. The term AMIDAPSONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). AMIDAPSONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amidapsone under HS 29309085 and SITC 51549. As of Q4 2014, AMIDAPSONE remains the US FDA Preferred Term for this commodity. Amidapsone bears US NLM identifiers UMLS ID C2346737 and NCI Concept Code C73196. SMILES: S(=O)(=O)(C1CCC(NC(=O)N)CC1)C1CCC(N)CC1.
This classification denotes a decongestant and an alpha-adrenergic agonist with the molecular formula C10H16N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E2P22546V, chemically known as 3-(1-hydroxy-2-(methylamino)ethyl)methanesulfonanilide, but more generally known as amidephrine, which bears US NIH Compound Identifier 15010. As of Q4 2014, AMIDEPHRINE remains US FDA's Preferred Term for this commodity. Amidephrine bears US NLM identifiers UMLS ID C0051584 and NCI Concept Code C79522. SMILES: CNCC(C1=CC(=CC=C1)NS(=O)(=O)C)O.
This classification denotes a contrast agent that practitioners often use (along with this commodity's ester) in x-ray and/or computed tomography (ct) liver studies, an agent with the molecular formula C11H9I3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5UVC90J1LK, chemically known as 2,4,6-triiodo-3,5-diacetamidobenzoic acid but more generally known as diatrizoate, which bears U.S. National Institutes of Health Compound Identifier 2140. Most nations schedule Amidotrizoic acid or diatrizoate or diatrizoic acid under HS 29242995. SMILES: CC(=O)NC1C(C(C(C(C1I)NC(=O)C)I)C(=O)[O-])I.[NA+].
This classification denotes a cation channel blocker with the molecular formula C5H7N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RU4S6E2G0J, chemically known as 3,4 DIAMINOPYRIDINE, but generally known as amifampridine. European Medicines Agency schedules amifampridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB28846. As of Q4 2014, AMIFAMPRIDINE remains the US FDA Preferred Term for this commodity. Amifampridine bears US NLM identifiers UMLS ID C0046948 and NCI Concept Code C82687. SMILES: none.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C12H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NE25WV9C8S, chemically known as benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-, (s) but generally known as amiflamine, which bears US NIH Compound Identifier 71221. European Medicines Agency schedules Amiflamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05428MIG. The term AMIFLAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). AMIFLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amiflamine under HS 29215990 and SITC 51455. As of Q4 2014, AMIFLAMINE remains the US FDA Preferred Term for this commodity. Amiflamine bears US NLM identifiers UMLS ID C0102947 and NCI Concept Code C72695. SMILES: N(c1cc(c(CC(N)C)cc1)C)(C)C.
This classification denotes an antispasmotic agent with the molecular formula C16H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X154DLC3EY, chemically known as 2-(3,5-diethoxyphenoxy)triethylamine but generally known as amifloverine, which bears US NIH Compound Identifier 168913. European Medicines Agency schedules Amifloverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05429MIG. The term AMIFLOVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). AMIFLOVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amifloverine under HS 29221980 and SITC 51461. As of Q4 2014, AMIFLOVERINE remains the US FDA Preferred Term for this commodity. Amifloverine bears US NLM identifiers UMLS ID C2346738 and NCI Concept Code C73165. SMILES: O(CCN(CC)CC)C1CC(OCC)CC(OCC)C1.
This classification denotes a quinolone antibiotic with the molecular formula C16H19FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5TU5227KYQ, chemically known as 6-fluoro-1,4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid but generally known as amifloxacin, which bears US NIH Compound Identifier 55492. Amifloxacin most often comes in mesylate and n-oxide forms. European Medicines Agency schedules Amifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05430MIG. The term AMIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). AMIFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amifloxacin under HS 29335995 and SITC 51576. As of Q4 2014, AMIFLOXACIN remains the US FDA Preferred Term for this commodity. Amifloxacin bears US NLM identifiers UMLS ID C0051596 and NCI Concept Code C72696. SMILES: FC1C(N2CCN(CC2)C)CC2N(NC)CC(C(=O)C2C1)C(=O)O.
This classification denotes a cytoprotective agent with the molecular formula C5H15N2O3PS.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M487QF2F4V, chemically known as 2-((3-aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester (9ci) but more generally known as amifostine, which bears US NIH Compound Identifier 2141. Amifostine most often comes in base, ethiofos, and hyrdate forms. European Medicines Agency schedules Amifostine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12846MIG. World Health Organization schedules amifostine in its Anatomical Therapeutic Chemical (ATC) Classification. AMIFOSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule amifostine under HS 29309085 and SITC 51549. As of Q4 2014, AMIFOSTINE remains US FDA's Preferred Term for this commodity. Amifostine bears US NLM identifiers UMLS ID C0591467 and NCI Concept Code C488. SMILES: S(P(=O)(O)O)CCNCCCN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN700. This VA Drug Class (AN700) classifies this compound as belonging to the group PROTECTIVE AGENTS.
This classification denotes a cytoprotective agent with the molecular formula C5H15N2O3PS.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L693H6MM64, chemically known as ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester), monohydrate, but more generally known as amifostine monohydrate, which bears US NIH Compound Identifier 83996. European Medicines Agency schedules amifostine monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12846MIG. Most nations, for tariff and trade purposes, schedule amifostine monohydrate under HS 29309085. SMILES: C(CN)CNCCSP(=O)(O)O.O.
This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84319SGC3C. European Medicines Agency schedules Amikacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05431MIG. Amikacin generally arises in the molecular formula C22H43N5O13. The term AMIKACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, no. 10 1974, list 14.) AMIKACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amikacin under HS 29419000 and SITC 54139. As of Q4 2014, AMIKACIN remains the US FDA Preferred Term for this commodity. Amikacin bears US NLM identifiers UMLS ID C0002499 and NCI Concept Code C61615. SMILES: O(C1C(NC(=O)C(O)CCN)CC(N)C(OC2OC(C(O)C(O)C2O)CN)C1O)C1OC(C(O)C(N)C1O)CO.
This classification denotes an aminoglycoside antibiotic with the molecular formula C22H43N5O13.2H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N6M33094FD, chemically known as d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->6)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1->4))-n(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)- but more generally known as amikacin sulfate, which bears US NIH Compound Identifier 37768. The base compound, Amikacin, most often comes in dihydrate, disulfate, hydrate, and sulfate forms. European Medicines Agency schedules Amikacin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00444MIG. Most nations, for tariff and trade purposes, schedule amikacin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, AMIKACIN SULFATE remains US FDA's Preferred Term for this commodity. Amikacin sulfate bears US NLM identifiers UMLS ID C0700949 and NCI Concept Code C230. SMILES: C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N.OS(=O)(=O)O.OS(=O)(=O)O.
This classification denotes an antispasmotic agent with the molecular formula C18H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BD9T227F6M, chemically known as 9(2-(diethylamino)ethoxy)-4-hydroxy-7-methyl-5h-furo(3,2-g)(1)benzopyran-5-one but generally known as amikhelline, which bears US NIH Compound Identifier 71198. European Medicines Agency schedules Amikhelline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05432MIG. The term AMIKHELLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). AMIKHELLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amikhelline under HS 29329985 and SITC 51569. As of Q4 2014, AMIKHELLINE remains the US FDA Preferred Term for this commodity. Amikhelline bears US NLM identifiers UMLS ID C2346740 and NCI Concept Code C73160. SMILES: O(CCN(CC)CC)C1C2OC(CC(=O)C2C(O)C2C1OCC2)C.
This classification denotes a potassium-sparing diuretic and intercalating agent with the molecular formula C6H8ClN7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7DZO8EB0Z3, chemically known as 3,5-diamino-n-(aminoiminomethyl)-6-chloropyrazinecarboxamide but generally known as amiloride, which bears US NIH Compound Identifier 16231. Amiloride most often comes in caproate, chloride, hydrochloride, hydrochloride dihydrate, and hydrochloride-hydrochlorothiazide forms. European Medicines Agency schedules Amiloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05433MIG. The term AMILORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules amiloride in its Anatomical Therapeutic Chemical (ATC) Classification. AMILORIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Amiloride under HS 29339990 and SITC 51577. As of Q4 2014, AMILORIDE remains the US FDA Preferred Term for this commodity. Amiloride bears US NLM identifiers UMLS ID C0002502 and NCI Concept Code C61633. SMILES: C1(C(NC(C(N1)CL)N)N)C(=O)NC(=N)N.
This classification denotes a potassium-sparing diuretic and intercalating agent with the molecular formula C6H8ClN7O.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZJ37245UC, chemically known as pyrazinecarboxamide, n-amidino-3,5-diamino-6-chloro-, monohydrochloride but more generally known as amiloride hydrochloride, which bears US NIH Compound Identifier 16230. European Medicines Agency schedules Amiloride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00445MIG. Most nations, for tariff and trade purposes, schedule amiloride hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, AMILORIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amiloride hydrochloride bears US NLM identifiers UMLS ID C0026054 and NCI Concept Code C47390. SMILES: C1(C(NC(C(N1)CL)N)N)C(=O)NC(=N)N.O.O.CL.
This classification denotes the anhydrous form of a potassium-sparing diuretic and intercalating agent with the molecular formula C6H8ClN7O.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZJ37245UC, chemically known as pyrazinecarboxamide, n-amidino-3,5-diamino-6-chloro-, monohydrochloride but more generally known as amiloride hydrochloride, which bears US NIH Compound Identifier 16230. European Medicines Agency schedules Amiloride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00445MIG. Most nations, for tariff and trade purposes, schedule amiloride hydrochloride anhydrous under HS 29339990. As of Q4 2014, AMILORIDE HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. SMILES: C1(C(NC(C(N1)CL)N)N)C(=O)NC(=N)N.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV704. This VA Drug Class (CV704) classifies this compound as belonging to the group POTASSIUM SPARING/COMBINATIONS DIURETICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.
This classification denotes a topical anti-infective agent with the molecular formula C13H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78OY3Z0P7Z, chemically known as 9-acridinamine, monohydrochloride but generally known as aminacrine, which bears US NIH Compound Identifier 7019. Aminacrine most often comes in base and hydrochloride forms. European Medicines Agency schedules Aminoacridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05437MIG. The term AMINOACRIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules aminacrine in its Anatomical Therapeutic Chemical (ATC) Classification. Aminacrine or aminoacridine bears US NLM identifiers UMLS ID C0002503 and NCI Concept Code C77023. SMILES: C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)N.
This classification denotes an antidepressant agent with the molecular formula C22H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27T1I13L6G, chemically known as 7-((10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yl)amino)heptanoic acid but generally known as amineptine, which bears US NIH Compound Identifier 34870. Amineptine most often comes in base and hydrochloride forms. European Medicines Agency schedules Amineptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05435MIG. The term AMINEPTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules amineptine in its Anatomical Therapeutic Chemical (ATC) Classification. AMINEPTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amineptine under HS 29224995 and SITC 51465. As of Q4 2014, AMINEPTINE remains the US FDA Preferred Term for this commodity. Amineptine bears US NLM identifiers UMLS ID C0051607 and NCI Concept Code C74142. SMILES: OC(=O)CCCCCCNC1C2C(CCC3C1CCCC3)CCCC2.
This classification denotes an antidepressant agent with the molecular formula C22H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A5P604A12R, chemically known as 7-((10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yl)amino)heptanoic acid hydrochloride but more generally known as amineptine hydrochloride, which bears US NIH Compound Identifier 34869. European Medicines Agency schedules Amineptine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00447MIG. Most nations, for tariff and trade purposes, schedule amineptine hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, AMINEPTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)CCC3CCCCC3C2NCCCCCCC(=O)O.CL.
This classification denotes an antidepressant agent with the molecular formula C22H26NO2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6BYR55117P. European Medicines Agency schedules amineptine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00448MIG. Most nations, for tariff and trade purposes, schedule amineptine sodium under HS 29224995 and SITC 51465. As of Q4 2014, AMINEPTINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)CCC3CCCCC3C2NCCCCCCC(=O)[O-].[NA+].
Amino acids solutions
This classification denotes a topical anti-infective agent with the molecular formula C13H10N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OR5RM3Q5QL, chemically known as 9-acridinamine, monohydrochloride but more generally known as aminacrine hydrochloride, which bears US NIH Compound Identifier 7019. European Medicines Agency schedules Aminacrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00450MIG. Most nations, for tariff and trade purposes, schedule aminoacridine hydrochloride under HS 29339990. SMILES: C1CCC2C(C1)C(C3CCCCC3N2)N.CL.
This classification denotes a neurotransmitter, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2ACZ6IPC6I. European Medicines Agency schedules Gamma-aminobutyric acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13946MIG. Gamma-aminobutyric acid generally arises in the molecular formula C4H9NO2. The term 'gamma-aminobutyric acid' is an International Nomenclature of Cosmetic Ingredients designation. SMILES: OC(=O)CCCN.
This classification denotes a hemostatic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6F3787206. European Medicines Agency schedules Aminocaproic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05438MIG. Aminocaproic acid generally arises in the molecular formula C6H13NO2. The term AMINOCAPROIC ACID is a Japanese Accepted Name designation. Most nations schedule aminocaproic acid under HS 29224995 and SITC 51465. As of Q4 2014, AMINOCAPROIC ACID remains the US FDA Preferred Term for this commodity. Aminocaproic acid bears US NLM identifiers UMLS ID C0000608 and NCI Concept Code C47391. SMILES: C(CCC(=O)O)CCN.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S1IA7R2J48. European Medicines Agency schedules Aminoethyl nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05439MIG. Aminoethyl nitrate generally arises in the molecular formula C2H6N2O3. The term AMINOETHYL NITRATE is an International Non-Proprietary Name or INN. Most nations schedule aminoethyl nitrate under HS 29225000 and SITC 51467. As of Q4 2014, AMINOETHYL NITRATE remains the US FDA Preferred Term for this commodity. Aminoethyl nitrate bears US NLM identifiers UMLS ID C2698088 and NCI Concept Code C74414. SMILES: O([N](=O)O)CCN.
This classification denotes a non-steroidal aromatase inhibitor and anti-adrenal with the molecular formula C13H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O54ZQ14I9, chemically known as 2,6-piperidinedione, 3-(4-aminophenyl)-3-ethyl- but generally known as aminoglutethimide, which bears US NIH Compound Identifier 2145. Aminoglutethimide most often comes in base, phosphate, and racemic forms. European Medicines Agency schedules Aminoglutethimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05440MIG. The term AMINOGLUTETHIMIDE is an International Non-Proprietary Name. World Health Organization schedules aminoglutethimide in its Anatomical Therapeutic Chemical (ATC) Classification. AMINOGLUTETHIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aminoglutethimide under HS 29251995 and SITC 51482. As of Q4 2014, AMINOGLUTETHIMIDE remains the US FDA Preferred Term for this commodity. Aminoglutethimide bears US NLM identifiers UMLS ID C0002555 and NCI Concept Code C233. SMILES: O=C1NC(=O)CCC1(CC)C1CCC(N)CC1.
This classification denotes a nitric oxide synthetase inhibitor with the molecular formula CH6N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SCQ4EZQ113, chemically known as guanidine, amino- but more generally known as aminoguanidine, which bears US NIH Compound Identifier 2146. Aminoguanidine comes in various forms, including bicarbonate, hemisulfate, hydrocarbonate, hydrochloride, hydrogencarbonate, monohydrochloride, nitrate, and sulfate. European Medicines Agency schedules Pimagedine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09835MIG. The term PIMAGEDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 8 No. 3 1994, List 34). Aminoguanidine or pimagedine bears US NLM identifiers UMLS ID C0282774 and NCI Concept Code C84059. SMILES: C(=NN)(N)N.
This classification denotes a diagnostic reagent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier Y79XT83BJ9. The European Medicines Agency schedules Aminohippuric acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12852MIG. Aminohippuric acid generally arises in the molecular formula C9H10N2O3. The term 'aminohippuric acid' is a U.S. Pharmacopeial Convention designation. SMILES: C1=CC(=CC=C1C(=O)NCC(=O)O)N.
This classification denotes a photosensitizing agent with the molecular formula C5H9NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88755TAZ87, chemically known as pentanoic acid, 5-amino-4-oxo-, hydrochloride but generally known as aminolevulinic acid, which bears US NIH Compound Identifier 137. European Medicines Agency schedules Aminolevulinic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12853MIG. World Health Organization schedules aminolevulinic acid in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, AMINOLEVULINIC ACID remains the US FDA Preferred Term for this commodity. Aminolevulinic acid bears US NLM identifiers UMLS ID C0002563 and NCI Concept Code C234. SMILES: O=C(CCC(=O)O)CN.
This classification denotes an antifibrinolytic with the molecular formula C8H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68WG9JKC7L, 4-aminomethylbenzoic acid or 4-Carboxybenzylamine, but generally known as aminomethylbenzoic acid, and which bears US NIH Compound Identifier 65526. European Medicines Agency schedules aminomethylbenzoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12854MIG. As of Q4 2014, AMINOMETHYLBENZOIC ACID remains the US FDA Preferred Term for this commodity. SMILES: C1=CC(=CC=C1CN)C(=O)O.
This classification denotes a diuretic with the molecular formula C9H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PPM8SX5Q3V, chemically known as 6-amino-3-ethyl-1-(2-propenyl)-2,4(1h,3h-)-pyrimidinedione but generally known as aminometradine, which bears US NIH Compound Identifier 12551. European Medicines Agency schedules Aminometradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05441MIG. The term AMINOMETRADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). AMINOMETRADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aminometradine under HS 29335995 and SITC 51576. As of Q4 2014, AMINOMETRADINE remains the US FDA Preferred Term for this commodity. Aminometradine bears US NLM identifiers UMLS ID C0301544 and NCI Concept Code C76645. SMILES: O=C1N(CC)C(=O)CC(N1CC=C)N.
This classification denotes an analgesic and antipyretic with the molecular formula C13H17N3O.C6H13NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RM5BP192F9, chemically known as 4-dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one cyclohexylsulfamate but more generally known as aminophenazone cyclamate, which bears US NIH Compound Identifier 170322. European Medicines Agency schedules Aminophenazone cyclamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05443MIG. The term AMINOPHENAZONE CYCLAMATE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule aminophenazone cyclamate under HS 29331190. As of Q4 2014, AMINOPHENAZONE CYCLAMATE remains US FDA's Preferred Term for this commodity. Aminophenazone cyclamate bears US NLM identifiers UMLS ID C2346742 and NCI Concept Code C72104. SMILES: CC1C(C(=O)N(N1C)C2CCCCC2)N(C)C.C1CCC(CC1)NS(=O)(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01704YP3MO, chemically known as 1,5-dimethyl-2-phenyl-4-aminopyrazoline but generally known as aminophenazone, which bears US NIH Compound Identifier 2151. Aminophenazone most often comes in base, 2,5-dihydroxybenzoate, cyclamate, and salicylate forms. European Medicines Agency schedules Aminophenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05442MIG. The term AMINOPHENAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules aminophenazone in its Anatomical Therapeutic Chemical (ATC) Classification. AMINOPHENAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Aminophenazone or aminopyrine bears US NLM identifiers UMLS ID C0002586 and NCI Concept Code C76792. SMILES: O=C1N(N(C(C1N)C)C)C1CCCCC1.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula 2C7H8N4O2.C2H8N2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7E0LU9ZMS. European Medicines Agency schedules aminophylline hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00461MIG. Most nations schedule aminophylline under HS 29395900 and SITC 54145. As of Q4 2014, AMINOPHYLLINE remains the US FDA Preferred Term for this commodity. Aminophylline bears US NLM identifiers UMLS ID C0002575 and NCI Concept Code C47393. SMILES: CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes the dihydrate form of a phosphodiesterase inhibitor and bronchodilator with the molecular formula 2C7H8N4O2.C2H8N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27Y3KJK423, chemically known as 3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione but more generally known as aminophylline, which bears US NIH Compound Identifier 2153. Aminophylline most often comes in base, anhydrous, and dihydrate forms. European Medicines Agency schedules Aminophylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05444MIG. The term AMINOPHYLLINE is an International Non-Proprietary Name. World Health Organization schedules aminophylline in its Anatomical Therapeutic Chemical (ATC) Classification. AMINOPHYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule aminophylline dihydrate under HS 29395900 and SITC 54145. As of Q4 2014, AMINOPHYLLINE DIHYDRATE remains US FDA's Preferred Term for this commodity. Aminophylline dihydrate bears US NLM identifiers UMLS ID C3472162 and NCI Concept Code C76313. SMILES: CN1C2C(C(=O)N(C1=O)C)[NH]CN2.CN1C2C(C(=O)N(C1=O)C)[NH]CN2.C(CN)N.O.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula 2C7H8N4O2.C2H8N2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7E0LU9ZMS. European Medicines Agency schedules aminophylline hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00461MIG. Most nations, for tariff and trade purposes, schedule aminophylline hydrate under HS 29395900. SMILES: CN1C2C(C(=O)N(C1=O)C)[NH]CN2.CN1C2C(C(=O)N(C1=O)C)[NH]CN2.C(CN)N.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE104. This VA Drug Class (RE104) classifies this compound as belonging to the group BRONCHODILATORS, XANTHINE-DERIVATIVE.
This classification denotes an antispasmotic agent with the molecular formula C19H25N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9SDD93U5U, chemically known as 1,2-propanediamine, n,n,n,n-tetramethyl-3-(10h-phenothiazin-10-yl)- but generally known as aminopromazine, which bears US NIH Compound Identifier 19392. Aminopromazine most often comes in base and fumarate forms. European Medicines Agency schedules Aminopromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05445MIG. The term AMINOPROMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). AMINOPROMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aminopromazine under HS 29343090 and SITC 51578. As of Q4 2014, AMINOPROMAZINE remains the US FDA Preferred Term for this commodity. Aminopromazine bears US NLM identifiers UMLS ID C0521944 and NCI Concept Code C76457. SMILES: S1C2C(N(CC(N(C)C)CN(C)C)C3C1CCCC3)CCCC2.
This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C19H20N8O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JYB41CTM2Q, chemically known as folic acid, 4-amino- but generally known as aminopterin, which bears US NIH Compound Identifier 2154. aminopterin most often comes in base, hydrate, n-hydroxysuccinimide ester, and sodium forms. European Medicines Agency schedules Aminopterin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00464MIG. AMINOPTERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, AMINOPTERIN remains the US FDA Preferred Term for this commodity. Aminopterin bears US NLM identifiers UMLS ID C0002583 and NCI Concept Code C235. SMILES: OC(=O)C(NC(=O)C1CCC(NCC2NC3C(NC2)NC(NC3N)N)CC1)CCC(=O)O.
This classification denotes an anorexiant with the molecular formula C9H10N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2SH16612I9, chemically known as 4,5-dihydro-5-phenyl-2-oxazolamine but more generally known as aminorex, which bears US NIH Compound Identifier 16630. Aminorex most often comes in base and fumarate forms. European Medicines Agency schedules Aminorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05448MIG. The term AMINOREX is an International Non-Proprietary Name. AMINOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule aminorex under HS 29349100 and SITC 51579. As of Q4 2014, AMINOREX remains US FDA's Preferred Term for this commodity. Aminorex bears US NLM identifiers UMLS ID C0002589 and NCI Concept Code C72180. SMILES: O1C(CN=C1N)C1CCCCC1.
This classification denotes an antitubercular agent with the molecular formula C7H6NO3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S38B9W6AXW, chemically known as 4-amino,2-hydroxy-benzoic acid but more generally known as aminosalicylate sodium, which bears U.S. National Institutes of Health Compound Identifier 4649. European Medicines Agency schedules Aminosalicylate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12861MIG. World Health Organization schedules aminosalicylate sodium in its Anatomical Therapeutic Chemical (ATC) Classification. as of Q4 2014, AMINOSALICYLATE SODIUM remains US FDA's Preferred Term for this commodity. Aminosalicylate sodium bears US NLM identifiers UMLS ID C0301336 and NCI Concept Code C47958. Most nations, for tariff and trade purposes, schedule Aminosalicylate sodium under HS 29225010 and SITC 51467. SMILES: C1CC(C(CC1N)O)C(=O)[O-].[NA+].
This classification denotes an antitubercular agent with the molecular formula C7H7NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5B2658E0N2, chemically known as 6018-19-5 (monosodium, dihydrate) but generally known as aminosalicylic acid, which bears US NIH Compound Identifier 4649. European Medicines Agency schedules Aminosalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12862MIG. World Health Organization schedules aminosalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, AMINOSALICYLIC ACID remains the US FDA Preferred Term for this commodity. Aminosalicylic acid bears US NLM identifiers UMLS ID C0030125 and NCI Concept Code C47394. SMILES: Oc1c(ccc(N)c1)C(=O)O.
This classification denotes a vasodilating agent and antiarrhythmic agent with the molecular formula C26H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VO63T4936, chemically known as 2,3,3-tris(p-methoxyphenyl)-n,n-dimethylallylamine but generally known as aminoxytriphene, which bears US NIH Compound Identifier 11283. European Medicines Agency schedules Aminoxytriphene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05450MIG. The term AMINOXYTRIPHENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). AMINOXYTRIPHENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Aminoxytriphene or amotriphene bears US NLM identifiers UMLS ID C2983808 and NCI Concept Code C90628. SMILES: O(c1ccc(C(=C(\c2ccc(OC)cc2)c2ccc(OC)cc2)\CN(C)C)cc1)C.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C25H29I2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) N3RQ532IUT, chemically known as 2-n-butyl-3,5-diiodo-4-n-diethylaminoethoxy-3-benzoylbenzofuran but more generally known as amiodarone, which bears US NIH Compound Identifier 2157. Amiodarone most often comes in base and hydrochloride forms. European Medicines Agency schedules Amiodarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05451MIG. The term AMIODARONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules amiodarone in its Anatomical Therapeutic Chemical (ATC) Classification. AMIODARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule amiodarone under HS 29329985 and SITC 51569. As of Q4 2014, AMIODARONE remains US FDA's Preferred Term for this commodity. Amiodarone bears US NLM identifiers UMLS ID C0002598 and NCI Concept Code C62002. SMILES: IC1C(OCCN(CC)CC)C(I)CC(C(=O)C2C(OC3C2CCCC3)CCCC)C1.
This classification denotes an antipsychotic agent with the molecular formula C24H28ClFN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FTX5V7543O, chemically known as 4-piperidinecarboxamide, 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-n,n-dimethyl- (9ci) but generally known as amiperone, which bears US NIH Compound Identifier 71101. European Medicines Agency schedules Amiperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05452MIG. The term AMIPERONE is an International Non-Proprietary Name. AMIPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amiperone under HS 29333999 and SITC 51574. As of Q4 2014, AMIPERONE remains the US FDA Preferred Term for this commodity. Amiperone bears US NLM identifiers UMLS ID C2346745 and NCI Concept Code C74172. SMILES: CLC1CCC(C2(CCN(CC2)CCCC(=O)C2CCC(F)CC2)C(=O)N(C)C)CC1.
This classification denotes a cns stimulant with the molecular formula C9H9N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZJ8PWY0XD, chemically known as 2,4-thiazolediamine, 5-phenyl- but generally known as amiphenazole, which bears US NIH Compound Identifier 10275. Amiphenazole most often comes in base and hydrochloride forms. European Medicines Agency schedules Amiphenazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05453MIG. The term AMIPHENAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). AMIPHENAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amiphenazole under HS 29341000 and SITC 51579. As of Q4 2014, AMIPHENAZOLE remains the US FDA Preferred Term for this commodity. Amiphenazole bears US NLM identifiers UMLS ID C0051684 and NCI Concept Code C74238. SMILES: S1C(C2CCCCC2)C(NC1N)N.
This classification denotes a cns stimulant with the molecular formula C9H9N3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W6W4748LIO, chemically known as 2,4-thiazolediamine, 5-phenyl- but more generally known as amiphenazole hydrochloride, which bears US NIH Compound Identifier 10275. European Medicines Agency schedules Amiphenazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00473MIG. Most nations, for tariff and trade purposes, schedule amiphenazole hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, AMIPHENAZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C2C(NC(S2)N)N.CL.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C14H16ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7OT95Q2G4E, chemically known as 6-(p-(2-chloropropionylamino)phenyl)-5-methyl-4,5-dihydropyridazin-3-one but generally known as amipizone, which bears US NIH Compound Identifier 68889. European Medicines Agency schedules Amipizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05454MIG. The term AMIPIZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). AMIPIZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amipizone under HS 29339990 and SITC 51577. As of Q4 2014, AMIPIZONE remains the US FDA Preferred Term for this commodity. Amipizone bears US NLM identifiers UMLS ID C2698092 and NCI Concept Code C74345. SMILES: CLC(C(=O)NC1CCC(C2=NNC(=O)CC2C)CC1)C.
This classification denotes an antihypertensive agent with the molecular formula C11H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85HK85C137, chemically known as 4-amino-6,7-dimethoxyquinoline but generally known as amiquinsin, which bears US NIH Compound Identifier 23510. Amiquinsin most often comes in base and hydrochloride forms. European Medicines Agency schedules Amiquinsin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05456MIG. The term AMIQUINSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). AMIQUINSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amiquinsin under HS 29334990 and SITC 51575. As of Q4 2014, AMIQUINSIN remains the US FDA Preferred Term for this commodity. Amiquinsin bears US NLM identifiers UMLS ID C0610917 and NCI Concept Code C79900. SMILES: COC1=CC2=C(C=CN=C2C=C1OC)N.
This classification denotes an antihypertensive agent with the molecular formula C11H12N2O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EZ270U8Z9W, chemically known as 4-quinolinamine, 6,7-dimethoxy-, monohydrochloride, monohydrate but more generally known as amiquinsin hydrochloride, which bears US NIH Compound Identifier 23509. Most nations, for tariff and trade purposes, schedule amiquinsin hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, AMIQUINSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amiquinsin hydrochloride bears US NLM identifiers UMLS ID C0953995 and NCI Concept Code C75237. SMILES: COC1CC2C(CCNC2CC1OC)N.O.CL.
This classification denotes a diuretic with the molecular formula C9H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30973N61ZF, chemically known as 2,4(1h,3h)-pyrimidinedione, 6-amino-3-methyl-1-(2-methyl-2-propenyl)- (9ci) but generally known as amisometradine, which bears US NIH Compound Identifier 11071. European Medicines Agency schedules Amisometradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05457MIG. The term AMISOMETRADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). AMISOMETRADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amisometradine under HS 29335995 and SITC 51576. As of Q4 2014, AMISOMETRADINE remains the US FDA Preferred Term for this commodity. Amisometradine bears US NLM identifiers UMLS ID C0301545 and NCI Concept Code C76646. SMILES: O=C1N(CC(=C)C)C(N)CC(=O)N1C.
This classification denotes a dopamine antagonist with the molecular formula C17H27N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8110R61I4U, chemically known as benzamide, 4-amino-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy- but generally known as amisulpride, which bears US NIH Compound Identifier 2159. European Medicines Agency schedules Amisulpride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05458MIG. The term AMISULPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules amisulpride in its Anatomical Therapeutic Chemical (ATC) Classification. AMISULPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amisulpride under HS 29339990 and SITC 51577. As of Q4 2014, AMISULPRIDE remains the US FDA Preferred Term for this commodity. Amisulpride bears US NLM identifiers UMLS ID C0103045 and NCI Concept Code C83533. SMILES: S(=O)(=O)(C1CC(C(=O)NCC2N(CCC2)CC)C(OC)CC1N)CC.
This classification denotes an antitubercular agent with the molecular formula C10H12N4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MMG78X7SSR, chemically known as acetanilide, 4-formyl-, thiosemicarbazone but generally known as amithiozone, which bears US NIH Compound Identifier 2733749. Amithiozone most often comes in base and thiacetazone forms. The term AMITHIOZONE is an International Non-Proprietary Name. Amithiozone or thiacetazone bears US NLM identifiers UMLS ID C0878231 and NCI Concept Code C90769. SMILES: CC(=O)NC1=CC=C(C=C1)C=NNC(=S)N.
This classification denotes a tricyclic antidepressant with the molecular formula C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1806D8D52K, chemically known as 10,11-dihydro-n,n-dimethyl-5h-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine but generally known as amitriptyline, which bears US NIH Compound Identifier 2160. Amitriptyline most often comes in base, chloride, hydrochloride, n-glucuronide, and n-oxide forms. European Medicines Agency schedules Amitriptyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05462MIG. The term AMITRIPTYLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules amitriptyline in its Anatomical Therapeutic Chemical (ATC) Classification. AMITRIPTYLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amitriptyline under HS 29214980 and SITC 51454. As of Q4 2014, AMITRIPTYLINE remains the US FDA Preferred Term for this commodity. Amitriptyline bears US NLM identifiers UMLS ID C0002600 and NCI Concept Code C62005. SMILES: N(CC/C=C1\c2c(CCc3c1cccc3)cccc2)(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a tricyclic antidepressant with the molecular formula C20H23N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26LUD4JO9K, chemically known as 10,11-dihydro-n,n-dimethyl-5h-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine but more generally known as amitriptyline hydrochloride, which bears US NIH Compound Identifier 2160. European Medicines Agency schedules Amitriptyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00474MIG. Most nations, for tariff and trade purposes, schedule amitriptyline hydrochloride under HS 29214900 and SITC 51454. As of Q4 2014, AMITRIPTYLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amitriptyline hydrochloride bears US NLM identifiers UMLS ID C0733667 and NCI Concept Code C28819. SMILES: CN(C)CCC=C1C2CCCCC2CCC3C1CCCC3.CL.
This classification denotes a tricyclic antidepressant with the molecular formula C23H16O6.2C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX6VNM127F. Most nations, for tariff and trade purposes, schedule amitriptyline pamoate under HS 29214980 and SITC 51454. As of Q4 2014, AMITRIPTYLINE PAMOATE remains US FDA's Preferred Term for this commodity. Amitriptyline pamoate bears US NLM identifiers UMLS ID C0770882 and NCI Concept Code C96201. SMILES: CN(C)CCC=C1C2CCCCC2CCC3C1CCCC3.CN(C)CCC=C1C2CCCCC2CCC3C1CCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes an antidepressant agent with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TYR2U59WMA, chemically known as 10,11-dihydro-n,n-dimethyl-5h-dibenzo(a,d)cycloheptene-delta(sup 5,gamma)-propylamine n-oxide but generally known as amitriptylinoxide, which bears US NIH Compound Identifier 20313. European Medicines Agency schedules Amitriptylinoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05463MIG. The term AMITRIPTYLINOXIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). AMITRIPTYLINOXIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amitriptylinoxide under HS 29299000 and SITC 51489. As of Q4 2014, AMITRIPTYLINOXIDE remains the US FDA Preferred Term for this commodity. Amitriptylinoxide bears US NLM identifiers UMLS ID C0051694 and NCI Concept Code C72698. SMILES: O[N](CC/C=C1/c2c(CCc3c1cccc3)cccc2)(C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7UL287YTPJ, chemically known as pyrrolidine, n-(2-phenyl-2-isoamyloxy)ethyl- but generally known as amixetrine, which bears US NIH Compound Identifier 71911. Amixetrine most often comes in base and hydrochloride forms. European Medicines Agency schedules Amixetrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05464MIG. The term AMIXETRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). AMIXETRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amixetrine under HS 29339990 and SITC 51577. As of Q4 2014, AMIXETRINE remains the US FDA Preferred Term for this commodity. Amixetrine bears US NLM identifiers UMLS ID C0051695 and NCI Concept Code C73072. SMILES: O(C(CN1CCCC1)C1CCCCC1)CCC(C)C.
This classification denotes a nonsteroidal antiinflammatory drug C17H27NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJB5017RC5, chemically known as pyrrolidine, 1-(2-(3-methylbutoxy)-2-phenylethyl)-, hydrochloride (1:1), but more generally known as amixetrine hydrochloride, which bears US NIH Compound Identifier 170333. Most nations, for tariff and trade purposes, schedule amixetrine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, AMIXETRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)CCOC(CN1CCCC1)C2CCCCC2.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BRL1C2459K, chemically known as 5h-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid, 2-amino-7-(1-methylethyl)-5-oxo- but generally known as amlexanox, which bears US NIH Compound Identifier 2161. European Medicines Agency schedules Amlexanox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05465MIG. The term AMLEXANOX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules amlexanox in its Anatomical Therapeutic Chemical (ATC) Classification. AMLEXANOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amlexanox under HS 29349990 and SITC 51579. As of Q4 2014, AMLEXANOX remains the US FDA Preferred Term for this commodity. Amlexanox bears US NLM identifiers UMLS ID C0103049 and NCI Concept Code C47395. SMILES: O1C2C(CC(C(C)C)CC2)C(=O)C2C1NC(N)C(C2)C(=O)O.
This classification denotes a calcium channel blocker with the molecular formula C20H25ClN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1J444QC288, chemically known as 3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester but generally known as amlodipine, which bears US NIH Compound Identifier 2162. Amlodipine most often comes in base, benzenesulfonate, besilate, besylate, and maleate forms. European Medicines Agency schedules Amlodipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05467MIG. The term AMLODIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules amlodipine in its Anatomical Therapeutic Chemical (ATC) Classification. AMLODIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amlodipine under HS 29333999 and SITC 51574. As of Q4 2014, AMLODIPINE remains the US FDA Preferred Term for this commodity. Amlodipine bears US NLM identifiers UMLS ID C0051696 and NCI Concept Code C61635. SMILES: Clc1c(C2C(=C(NC(=C2C(=O)OC)C)COCCN)C(=O)OCC)cccc1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV200. This VA Drug Class (CV200) classifies this compound as belonging to the group CALCIUM CHANNEL BLOCKERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a calcium channel blocker with the molecular formula C20H25ClN2O5.C6H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 864V2Q084H, chemically known as 3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester but more generally known as amlodipine besilate, which bears US NIH Compound Identifier 2162. European Medicines Agency schedules Amlodipine besilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12864MIG. Most nations, for tariff and trade purposes, schedule amlodipine besilate under HS 29333999 and SITC 51574. SMILES: CCOC(=O)C1=C(NC(=C(C1C2CCCCC2CL)C(=O)OC)C)COCCN.C1CCC(CC1)S(=O)(=O)O.
Irbesartan/amlodipine is an angiotensin-receptor blocker/calcium-channel blocker fixed-dose single-pill combination.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
Perindopril/indapamide/amlodipine is a triple-drug therapy incorporating an ACE inhibitor for the treatment of hypertension.
This classification denotes a calcium channel blocker with the molecular formula C20H25ClN2O5.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CQ27G2BZJM, chemically known as 3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (+-)-, (z)-2-butenedioate (1:1) but more generally known as amlodipine maleate, which bears US NIH Compound Identifier 6435922. European Medicines Agency schedules Amlodipine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00476MIG. Most nations, for tariff and trade purposes, schedule amlodipine maleate under HS 29333999 and SITC 51574. As of Q4 2014, AMLODIPINE MALEATE remains US FDA's Preferred Term for this commodity. Amlodipine maleate bears US NLM identifiers UMLS ID C0886700 and NCI Concept Code C65230. SMILES: CCOC(=O)C1=C(NC(=C(C1C2CCCCC2CL)C(=O)OC)C)COCCN.C(=C\C(=O)O)\C(=O)O.
This classification denotes the hydrate form of a calcium channel blocker with the molecular formula C20H25CLN2O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 291Y33EZHA. European Medicines Agency schedules amlodipine mesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22129. Most nations, for tariff and trade purposes, schedule amlodipine mesylate hydrate under HS 29333999. SMILES: CCOC(=O)C1=C(NC(=C(C1C2CCCCC2CL)C(=O)OC)C)COCCN.CS(=O)(=O)O.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
Perindopril arginine and amlodipine combination tablets are indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a local anti-infective agent with the molecular formula Cl.Hg.H2N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JD546Z56F0, chemically known as mercury, ammonobasic (hgnh2cl) but generally known as ammoniated mercury, which bears US NIH Compound Identifier 3032553. European Medicines Agency schedules Ammoniated mercury in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12868MIG. SMILES: [NH2-].[Cl-].[Hg+2].
This classification denotes an alum compound with the molecular formula Al.2O4S.12H2O.H4N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5C36DRL9ZN, chemically known as vanadium sulfate, vso4 but generally known as ammonium alum, which bears US NIH Compound Identifier 1118. As of Q4 2014, AMMONIUM ALUM remains the US FDA Preferred Term for this commodity. SMILES: [NH4+].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[AL+3].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes an antiseptic with the molecular formula CO3S.H4N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQ14646378. European Medicines Agency schedules ichthammol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14178MIG. SMILES: none.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE504. This VA Drug Class (RE504) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a barbiturate with the molecular formula C11H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GWH6IJ239E, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)- but generally known as amobarbital, which bears US NIH Compound Identifier 2164. amobarbital most often arises in base, natrium, and sodium forms. European Medicines Agency schedules Amobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05468MIG. The term AMOBARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules amobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. AMOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Amobarbital or amylobarbitone bears US NLM identifiers UMLS ID C0002640 and NCI Concept Code C76523. SMILES: CCC1(C(=O)NC(=O)NC1=O)CCC(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN301. This VA Drug Class (CN301) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS.
This classification denotes a barbiturate with the molecular formula C11H17N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G0313KNC7D, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)-, monosodium salt but more generally known as amobarbital sodium, which bears US NIH Compound Identifier 6149. European Medicines Agency schedules Amobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00498MIG. Most nations, for tariff and trade purposes, schedule amobarbital sodium under HS 29335300. As of Q4 2014, AMOBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Amobarbital sodium bears US NLM identifiers UMLS ID C0037479 and NCI Concept Code C76524. SMILES: CCC1(C(=O)NC(=O)[N-]C1=O)CCC(C)C.[NA+].
This classification denotes an antihelminthic agent with the molecular formula C18H21N5O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99807U412Y, chemically known as 1-piperazinecarbothioamide, 4-methyl-n-(4-((4-nitrophenyl)amino)phenyl)- but generally known as amocarzine, which bears US NIH Compound Identifier 5464102. European Medicines Agency schedules Amocarzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05469MIG. The term AMOCARZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). AMOCARZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amocarzine under HS 29335995 and SITC 51576. As of Q4 2014, AMOCARZINE remains the US FDA Preferred Term for this commodity. Amocarzine bears US NLM identifiers UMLS ID C0164697 and NCI Concept Code C72145. SMILES: S=C(N1CCN(CC1)C)NC1CCC(NC2CCC([N](=O)O)CC2)CC1.
This classification denotes an antimalarial agent with the molecular formula C20H22ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 220236ED28, chemically known as 6398-98-7(dihydrochloride, dihydrate) but generally known as amodiaquin, which bears US NIH Compound Identifier 2165. Amodiaquin most often arises in simple, dihydrochloride, and dihyrdate forms. European Medicines Agency schedules Amodiaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05470MIG. The term AMODIAQUINE is an International Non-Proprietary Name. World Health Organization schedules amodiaquin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule amodiaquine under HS 29334990 and SITC 51575. As of Q4 2014, AMODIAQUINE remains the US FDA Preferred Term for this commodity. Amodiaquine bears US NLM identifiers UMLS ID C0002641 and NCI Concept Code C65231. SMILES: CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)CL)O.
This is a combination therapy used for seasonal malaria chemoprevention. The first component, AMODIAQUINE, has a US FDA Unique Ingredient Identifier of 220236ED28. The second component, PYRIMETHAMINE, has a US FDA Unique Ingredient Identifier of Z3614QOX8W. The third component, SULFADOXINE, has a US FDA Unique Ingredient Identifier of 88463U4SM5.
This classification is for a combination antimalarial drug. The first component, AMODIAQUINE, has a US FDA Unique Ingredient Identifier of 220236ED28. The second component, ARTESUNATE, has a US FDA Unique Ingredient Identifier of 60W3249T9M.
This classification denotes an anesthetic agent with the molecular formula C20H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1ALL724WB1, chemically known as 3-(2-(diethylamino)ethyl)-2-oxo-3-phenyl-2,3-dihydrobenzofuran but generally known as amolanone, which bears US NIH Compound Identifier 6453. Amolanone most often arises in base and hydrochloride forms. European Medicines Agency schedules Amolanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05472MIG. The term AMOLANONE is an International Non-Proprietary Name. AMOLANONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, AMOLANONE remains the US FDA Preferred Term for this commodity. Amolanone bears US NLM identifiers UMLS ID C0301286 and NCI Concept Code C75083. SMILES: O1C(=O)C(CCN(CC)CC)(C2C1CCCC2)C1CCCCC1.
This classification denotes an anesthetic agent with the molecular formula C20H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M36927R46E, chemically known as 2(3h)-benzofuranone, 3-(2-(diethylamino)ethyl)-3-phenyl-, hydrochloride but more generally known as amolanone hydrochloride, which bears US NIH Compound Identifier 22336. Most nations, for tariff and trade purposes, schedule amolanone hydrochloride under HS 29322985. As of Q4 2014, AMOLANONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amolanone hydrochloride bears US NLM identifiers UMLS ID C2698096 and NCI Concept Code C75084. SMILES: CCN(CC)CCC1(C2CCCCC2OC1=O)C3CCCCC3.CL.
This classification denotes a topoisomerase-ii inhibitor and intercalating agent with the molecular formula C16H17N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q8D39N37L, chemically known as 3-amino-n-(2-(dimethylamino)ethyl)-1,8-naphthalindicarboximid but generally known as amonafide, which bears US NIH Compound Identifier 50515. Amonafide most often comes in base and dihydrochloride forms. European Medicines Agency schedules Amonafide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05473MIG. The term AMONAFIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). AMONAFIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amonafide under HS 29251995 and SITC 51482. As of Q4 2014, AMONAFIDE remains the US FDA Preferred Term for this commodity. Amonafide bears US NLM identifiers UMLS ID C0126606 and NCI Concept Code C71628. SMILES: O=C1N(CCN(C)C)C(=O)C2C3C1CC(N)CC3CCC2.
This classification denotes an antimalarial agent with the molecular formula C20H20ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SV6L22Y9QF, chemically known as 4-((7-chloro-4-quinolyl)amino)-alpha-1-pyrrolidinyl-o-cresol or 4-[(7-chloranylquinolin-4-yl)amino]-2-(pyrrolidin-1-ylmethyl)phenol, but generally known as amopyroquine, which bears US NIH Compound Identifier 25194. European Medicines Agency schedules amopyroquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05475MIG. Most nations schedule amopyroquine under HS 29334990 and SITC 51575. As of Q4 2014, AMOPYROQUINE remains the US FDA Preferred Term for this commodity. Amopyroquine bears US NLM identifiers UMLS ID C0051735 and NCI Concept Code C73000. SMILES: C1CCN(C1)CC2=C(C=CC(=C2)NC3=C4C=CC(=CC4=NC=C3)Cl)O.
This classification denotes an enzyme inhibitor and antifungal agent with the molecular formula C21H35NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AB0BHP2FH0, chemically known as morpholine, 4-(3-(4-(1,1-dimethylpropyl)phenyl)-2-methylpropyl)-2,6-dimethyl-, cis-, (+-)- but generally known as amorolfine, which bears US NIH Compound Identifier 54260. Amorolfine most often comes in base and hydrochloride forms. European Medicines Agency schedules Amorolfine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05476MIG. The term AMOROLFINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules amorolfine in its Anatomical Therapeutic Chemical (ATC) Classification. AMOROLFINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amorolfine under HS 29349990 and SITC 51579. As of Q4 2014, AMOROLFINE remains the US FDA Preferred Term for this commodity. Amorolfine bears US NLM identifiers UMLS ID C0051736 and NCI Concept Code C81332. SMILES: O1C(CN(CC(CC2CCC(C(CC)(C)C)CC2)C)CC1C)C.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 741YH7379H. European Medicines Agency schedules Amorolfine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00500MIG. Amorolfine hydrochloride generally arises in the molecular formula C21H35NO.CLH. The term 'amorolfine hydrochloride' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule amorolfine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, AMOROLFINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amorolfine hydrochloride bears US NLM identifiers UMLS ID C0956137 and NCI Concept Code C81507. SMILES: CCC(C)(C)C1CCC(CC1)CC(C)CN2C[C@H](O[C@H](C2)C)C.CL.
This classification denotes an adrenergic antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C69JI1BAU8. European Medicines Agency schedules Amosulalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05478MIG. Amosulalol generally arises in the molecular formula C18H24N2O5S. The term AMOSULALOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) AMOSULALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amosulalol under HS 29350090 and SITC 51580. As of Q4 2014, AMOSULALOL remains the US FDA Preferred Term for this commodity. Amosulalol bears US NLM identifiers UMLS ID C0103116 and NCI Concept Code C72916. SMILES: S(=O)(=O)(N)C1CC(C(O)CNCCOC2C(OC)CCCC2)CCC1C.
This classification denotes an adrenergic antagonist with the molecular formula C18H24N2O5S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O4S698PEE, chemically known as benzenesulfonamide, 5-(1-hydroxy-2-((2-(2-methoxyphenoxy)ethyl)amino)ethyl)-2-methyl-, monohydrochloride but more generally known as amosulalol hydrochloride, which bears US NIH Compound Identifier 123707. The base compound, Amosulalol, most often comes in base and hydrochloride forms. European Medicines Agency schedules Amosulalol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00502MIG. Most nations, for tariff and trade purposes, schedule amosulalol hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, AMOSULALOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC(CC1S(=O)(=O)N)C(CNCCOC2CCCCC2OC)O.CL.
This classification denotes an adrenergic antagonist with the molecular formula C18H24N2O5S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O4S698PEE, chemically known as benzenesulfonamide, 5-(1-hydroxy-2-((2-(2-methoxyphenoxy)ethyl)amino)ethyl)-2-methyl-, hydrochloride (1:1), but more generally known as amosulalol monohydrochloride, which bears US NIH Compound Identifier 123707. European Medicines Agency schedules amosulalol monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05478MIG. Most nations, for tariff purposes, schedule amosulalol monohydrochloride under HS 29350090. SMILES: CC1CCC(CC1S(=O)(=O)N)C(CNCCOC2CCCCC2OC)O.CL.
This classification denotes a tricyclic antidepressant with the molecular formula C17H16ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R63VQ857OT, chemically known as 2-chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine but generally known as amoxapine, which bears US NIH Compound Identifier 2170. Amoxapine most often comes in base and acetate forms. European Medicines Agency schedules Amoxapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05479MIG. The term AMOXAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules amoxapine in its Anatomical Therapeutic Chemical (ATC) Classification. AMOXAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amoxapine under HS 29349990 and SITC 51579. As of Q4 2014, AMOXAPINE remains the US FDA Preferred Term for this commodity. Amoxapine bears US NLM identifiers UMLS ID C0700992 and NCI Concept Code C47397. SMILES: Clc1cc2C(=Nc3c(Oc2cc1)cccc3)N1CCNCC1.
This classification denotes a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 804826J2HU. European Medicines Agency schedules Amoxicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05481MIG. Amoxicillin generally arises in the molecular formula C16H19N3O5S. The term AMOXICILLIN is a European Pharmacopoeia designation. AMOXICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amoxicillin under HS 29411010 and SITC 54131. As of Q4 2014, AMOXICILLIN remains the US FDA Preferred Term for this commodity. Amoxicillin bears US NLM identifiers UMLS ID C0002645 and NCI Concept Code C237. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(N)C1CCC(O)CC1.
This classification denotes a penicillin antibiotic with the molecular formula C16H19N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9EM05410Q9, chemically known as amoxicillin (anhydrous), but more generally known as amoxicillin anhydrous, which bears US NIH Compound Identifier 33613. European Medicines Agency schedules amoxicillin anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05481MIG. Most nations, for tariff purposes, schedule amoxicillin anhydrous under HS 29411010. Amoxicillin anhydrous bears US NLM identifiers UMLS ID C2828282 and NCI Concept Code C87367. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCC(CC3)O)N)C(=O)O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA303. This VA Drug Class (GA303) classifies this compound as belonging to the group H. PYLORI AGENTS.
This classification denotes a penicillin antibiotic with the molecular formula C16H19N3O5S.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 804826J2HU, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, trihydrate(2s-(2.alpha.,5.alpha.,6.beta.(s*)))-, but more generally known as amoxicillin hydrate, which bears US NIH Compound Identifier 62883. European Medicines Agency schedules amoxicillin hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05481MIG. Most nations, for tariff purposes, schedule amoxicillin hydrate under HS 29411010. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCC(CC3)O)N)C(=O)O)C.O.O.O.
This classification denotes a penicillin antibiotic with the molecular formula C16H18N3O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 544Y3D6MYH, chemically known as sodium (2s-(2alpha,5alpha,6beta(s*)))-6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate but more generally known as amoxicillin sodium, which bears US NIH Compound Identifier 91616. amoxicillin most often comes in base, anhydrous, hydrate, natrium, sodium, and trihydrate forms and is often combined with clavulinic acid. European Medicines Agency schedules Amoxicillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00503MIG. Most nations, for tariff and trade purposes, schedule amoxicillin sodium under HS 29411010 and SITC 54131. As of Q4 2014, AMOXICILLIN SODIUM remains US FDA's Preferred Term for this commodity. Amoxicillin sodium bears US NLM identifiers UMLS ID C0887551 and NCI Concept Code C72700. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCC(CC3)O)N)C(=O)[O-])C.[NA+].
This classification denotes a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 804826J2HU. European Medicines Agency schedules Amoxicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05481MIG. Amoxicillin generally arises in the molecular formula C16H19N3O5S. The term 'amoxicillin' is a European Pharmacopoeia designation. AMOXICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule amoxicillin trihydrate under HS 29411010 and SITC 54131. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCC(CC3)O)N)C(=O)O)C.O.O.O.
The combination of amoxicillin and clavulanic acid is used to treat certain infections caused by bacteria, including infections of the ears, lungs, sinus, skin, and urinary tract. Amoxicillin is in a class of medications called penicillin-like antibiotics.
This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C23H29F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M2W3TAG39, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-n-ethyl-1-piperazinecarboxamide but generally known as amperozide, which bears US NIH Compound Identifier 73333. Amperozide most often comes in base and hydrochloride forms. European Medicines Agency schedules Amperozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05483MIG. The term AMPEROZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). AMPEROZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amperozide under HS 29335995 and SITC 51576. As of Q4 2014, AMPEROZIDE remains the US FDA Preferred Term for this commodity. Amperozide bears US NLM identifiers UMLS ID C0051747 and NCI Concept Code C74191. SMILES: FC1CCC(C(CCCN2CCN(CC2)C(=O)NCC)C2CCC(F)CC2)CC1.
This classification denotes a serotonin antagonist with the molecular formula C23H29F2N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8V2171U69N, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-n-ethyl-1-piperazinecarboxamide but more generally known as amperozide hydrochloride, which bears US NIH Compound Identifier 73333. Most nations, for tariff and trade purposes, schedule amperozide hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, AMPEROZIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amperozide hydrochloride bears US NLM identifiers UMLS ID C0957053 and NCI Concept Code C77259. SMILES: CCNC(=O)N1CCN(CC1)CCCC(C2CCC(CC2)F)C3CCC(CC3)F.CL.
This classification denotes a sedative and hypnotic with the molecular formula C11H10N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M61FM2VCSV, chemically known as 2(1h)-pyridone, 1-(m-aminophenyl)- but generally known as amphenidone, which bears US NIH Compound Identifier 8641. European Medicines Agency schedules Amphenidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05484MIG. The term AMPHENIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). AMPHENIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amphenidone under HS 29337900 and SITC 51561. As of Q4 2014, AMPHENIDONE remains the US FDA Preferred Term for this commodity. Amphenidone bears US NLM identifiers UMLS ID C2698099 and NCI Concept Code C76934. SMILES: C1=CC(=O)N(C=C1)C2=CC(=CC=C2)N.
This classification denotes a cns stimulant with the molecular formula C9H13N.C6H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z58RH02W4M. The term amphetamine adipate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule amphetamine adipate under HS 29214600. As of Q4 2014, AMPHETAMINE ADIPATE remains US FDA's Preferred Term for this commodity. Amphetamine adipate bears US NLM identifiers UMLS ID C0982017 and NCI Concept Code C87425. SMILES: CC(CC1CCCCC1)N.C(CCC(=O)O)CC(=O)O.
This classification denotes a cns stimulant with the molecular formula 2C9H13N.C4H7NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H527KAP6L5, chemically known as l-aspartic acid, compd. with alpha-methylbenzeneethanamine (1:2) but more generally known as amphetamine aspartate, which bears US NIH Compound Identifier 32892. European Medicines Agency schedules Amphetamine aspartate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33384. Most nations, for tariff and trade purposes, schedule amphetamine aspartate under HS 29214600. As of Q4 2014, AMPHETAMINE ASPARTATE remains US FDA's Preferred Term for this commodity. Amphetamine aspartate bears US NLM identifiers UMLS ID C0724524 and NCI Concept Code C61636. SMILES: CC(CC1CCCCC1)N.CC(CC1CCCCC1)N.C([C@@H](C(=O)O)N)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN801. This VA Drug Class (CN801) classifies this compound as belonging to the group AMPHETAMINES.
This classification denotes a cns stimulant with the molecular formula C9H13N.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70DMY940ZG. Most nations, for tariff and trade purposes, schedule amphetamine hydrochloride under HS 29214600. As of Q4 2014, AMPHETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amphetamine hydrochloride bears US NLM identifiers UMLS ID C2698101 and NCI Concept Code C77844. SMILES: CC(CC1CCCCC1)N.CL.
This classification denotes a cns stimulant with the molecular formula C9H13N.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 163DO59R3J. European Medicines Agency schedules amfetamine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB36020. Most nations, for tariff and trade purposes, schedule amphetamine phosphate under HS 29214600. As of Q4 2014, AMPHETAMINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCCC1)N.OP(=O)(O)O.
This classification denotes a cns stimulant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DPV8NK46S. European Medicines Agency schedules Amfetamine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00438MIG. Amphetamine sulfate generally arises in the molecular formula 2C9H13N.H2O4S. The term 'amphetamine sulfate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule amphetamine sulfate under HS 29214600. As of Q4 2014, AMPHETAMINE SULFATE remains US FDA's Preferred Term for this commodity. Amphetamine sulfate bears US NLM identifiers UMLS ID C0282051 and NCI Concept Code C28822. SMILES: CC(CC1CCCCC1)N.CC(CC1CCCCC1)N.OS(=O)(=O)O.
This classification denotes a cns stimulant with the molecular formula C9H13N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30G976P30X. European Medicines Agency schedules amfetamine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00439MIG. Most nations, for tariff and trade purposes, schedule amphetamine tartrate under HS 29214600. As of Q4 2014, AMPHETAMINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCCC1)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an antifungal agent with the molecular formula C47H73NO17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7XU7A7DROE. European Medicines Agency schedules amphotericin b in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05486MIG. The term AMPHOTERICIN B is an International Non-Proprietary Name or INN. Most nations schedule amphotericin b under HS 29419000 and SITC 54139. As of Q4 2014, AMPHOTERICIN B remains the US FDA Preferred Term for this commodity. Amphotericin b bears US NLM identifiers UMLS ID C0002679 and NCI Concept Code C238. SMILES: CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.
This classification denotes a penicillin antibiotic with the molecular formula C16H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C782967RD, chemically known as penicillin, (aminophenylmethyl)- but generally known as ampicillin, which bears US NIH Compound Identifier 2174. Ampicillin comes in various forms, including a, acid, anhydrate, anhydrous, base, benzathine, hydrate, natrium, n,n-dibenzylethylenediamine salt, pivaloyloxymethyl ester, pivaloyloxymethyl ester hydrochloride, potassium, sodium, and trihydrate and is often combined with cloxacillin and dicloxacillin sodium. European Medicines Agency schedules Ampicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05487MIG. The term AMPICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules ampicillin in its Anatomical Therapeutic Chemical (ATC) Classification. AMPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ampicillin under HS 29411020 and SITC 54131. As of Q4 2014, AMPICILLIN remains the US FDA Preferred Term for this commodity. Ampicillin bears US NLM identifiers UMLS ID C0002680 and NCI Concept Code C239. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(N)C1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C16H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C782967RD, chemically known as penicillin, (aminophenylmethyl)- but more generally known as ampicillin, which bears US NIH Compound Identifier 2174. Ampicillin comes in various forms, including a, acid, anhydrate, anhydrous, base, benzathine, hydrate, natrium, n,n-dibenzylethylenediamine salt, pivaloyloxymethyl ester, pivaloyloxymethyl ester hydrochloride, potassium, sodium, and trihydrate and is often combined with cloxacillin and dicloxacillin sodium. European Medicines Agency schedules Ampicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05487MIG. The term AMPICILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules ampicillin in its Anatomical Therapeutic Chemical (ATC) Classification. AMPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ampicillin anhydrous under HS 29411020. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)O)C.
This classification denotes a penicillin antibiotic with the molecular structure C16H20N2.2C16H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E1TD7AM884 chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2r)-2-amino-2-phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2s,5r,6r)-, compd. with n,n'-bis(phenylmethyl)-1,2-ethanediamine (2:1), but more commonly known as ampicillin benzathine, which bears US NIH Compound Identifier 94447. European Medicines Agency schedules Ampicillin benzathine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00506MIG. Most nations, for tariff and trade purposes, schedule ampicillin benzathine under HS 29411020 and SITC 54131. As of Q4 2014, AMPICILLIN BENZATHINE remains US FDA's Preferred Term for this commodity. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)O)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)O)C.C1CCC(CC1)CNCCNCC2CCCCC2.
This classification denotes a penicillin antibiotic with the molecular formula C16H18N3O4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JFN36L5S8K, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as ampicillin sodium, which bears US NIH Compound Identifier 6248. The base compound also comes in various forms, including a, acid, anhydrate, anhydrous, base, benzathine, hydrate, natrium, n,n-dibenzylethylenediamine salt, pivaloyloxymethyl ester, pivaloyloxymethyl ester hydrochloride, potassium, and trihydrate and is often combined with cloxacillin and dicloxacillin sodium. European Medicines Agency schedules Ampicillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00508MIG. Most nations, for tariff and trade purposes, schedule ampicillin sodium under HS 29411020 and SITC 54131. As of Q4 2014, AMPICILLIN SODIUM remains US FDA's Preferred Term for this commodity. Ampicillin sodium bears US NLM identifiers UMLS ID C0282052 and NCI Concept Code C47959. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)[O-])C.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM113. This VA Drug Class (AM113) classifies this compound as belonging to the group EXTENDED SPECTRUM PENICILLINS.
This classification denotes a penicillin antibiotic with the molecular formula C16H19N3O4S.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HXQ6A1N7R6. European Medicines Agency schedules ampicillin trihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00509MIG. The term ampicillin trihydrate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule ampicillin trihydrate under HS 29411020 and SITC 54131. As of Q4 2014, AMPICILLIN TRIHYDRATE remains US FDA's Preferred Term for this commodity. Ampicillin trihydrate bears US NLM identifiers UMLS ID C0700443 and NCI Concept Code C47960. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)O)C.O.O.O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H21N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PV32JZB1J, chemically known as carbonic acid, ethyl 1-((2-methyl-3-((2-pyridinylamino)carbonyl)-2h-1,2-benzothiazin-4-yl)oxy)ethyl ester, s,s-dioxide but generally known as ampiroxicam, which bears US NIH Compound Identifier 2176. European Medicines Agency schedules Ampiroxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05488MIG. The term AMPIROXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). AMPIROXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ampiroxicam under HS 29349990 and SITC 51579. As of Q4 2014, AMPIROXICAM remains the US FDA Preferred Term for this commodity. Ampiroxicam bears US NLM identifiers UMLS ID C0246289 and NCI Concept Code C73073. SMILES: S1(=O)(=O)N(C(=C(OC(OC(=O)OCC)C)C2C1CCCC2)C(=O)NC1NCCCC1)C.
This classification denotes a protease inhibitor with the molecular formula C25H35N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S0W860XNR, chemically known as 4-amino-n-((2 syn,3s)-2-hydroxy-4-phenyl-3-((s)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-n-isobutyl-benzenesulfonamide but generally known as amprenavir, which bears US NIH Compound Identifier 65016. Amprenavir most often comes in base, phosphate, and phosphate calcium forms. European Medicines Agency schedules Amprenavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00511MIG. The term AMPRENAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 1, 1999, List 41). World Health Organization schedules amprenavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule amprenavir under HS 29350090 and SITC 51580. As of Q4 2014, AMPRENAVIR remains the US FDA Preferred Term for this commodity. Amprenavir bears US NLM identifiers UMLS ID C0754188 and NCI Concept Code C28824. SMILES: S(=O)(=O)(N(CC(O)C(NC(=O)OC1CCOC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1.
This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95CO6N199Q. European Medicines Agency schedules Amprolium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05489MIG. Amprolium generally arises in the molecular formula C14H19CLN4. The term AMPROLIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) AMPROLIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amprolium under HS 29335995 and SITC 51576. As of Q4 2014, AMPROLIUM remains the US FDA Preferred Term for this commodity. Amprolium bears US NLM identifiers UMLS ID C0002686 and NCI Concept Code C76388. SMILES: [N]1(CC2C(NC(NC2)CCC)N)C(CCCC1)C.
This classification denotes an antiprotozoal agent with the molecular formula C18H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21N28Z70CI, chemically known as 3-quinolinecarboxylic acid, 7-(diethylamino)-4-hydroxy-6-propyl-, methyl ester but generally known as amquinate, which bears US NIH Compound Identifier 28414. European Medicines Agency schedules Amquinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05492MIG. The term AMQUINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). AMQUINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amquinate under HS 29334910 and SITC 51575. As of Q4 2014, AMQUINATE remains the US FDA Preferred Term for this commodity. Amquinate bears US NLM identifiers UMLS ID C0601306 and NCI Concept Code C90754. SMILES: O=C1C2C([NH]CC1C(=O)OC)CC(N(CC)CC)C(CCC)C2.
This classification denotes a calcium channel blocker with the molecular formula C10H9N3O.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I229274Y5B. European Medicines Agency schedules amrinone lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00512MIG. The term amrinone lactate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule amrinone lactate under HS 29337900. SMILES: CC(C(=O)O)O.C1CNCCC1C2CC(C(=O)[NH]C2)N.
This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C10H9N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JUT23379TN, chemically known as 5-amino-(3,4-bipyridin)-6(1h)-one but generally known as amrinone, which bears US NIH Compound Identifier 3698. European Medicines Agency schedules Amrinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05493MIG. The term AMRINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules amrinone in its Anatomical Therapeutic Chemical (ATC) Classification. AMRINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Amrinone or inamrinone bears US NLM identifiers UMLS ID C0002697 and NCI Concept Code C61789. SMILES: C1=CN=CC=C1C2=CNC(=O)C(=C2)N.
This classification denotes an anthracycline antibiotic with the molecular formula C25H25NO9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 93N13LB4Z2, chemically known as ( -)-(7s,9s)-9-acetyl-9-amino-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione but generally known as amrubicin, which bears US NIH Compound Identifier 178149. Amrubicin most often comes in base and hydrochloride forms. European Medicines Agency schedules Amrubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05494MIG. The term AMRUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules amrubicin in its Anatomical Therapeutic Chemical (ATC) Classification. AMRUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amrubicin under HS 29419000 and SITC 54139. As of Q4 2014, AMRUBICIN remains the US FDA Preferred Term for this commodity. Amrubicin bears US NLM identifiers UMLS ID CL405282 and NCI Concept Code C80089. SMILES: O(C1CC(N)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)CCCC2)C(=O)C)C1OCC(O)C(O)C1.
This classification denotes an anthracycline antibiotic with the molecular formula C25H25NO9.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EUL6MP8FZW, chemically known as 5,12-naphthacenedione, 9-acetyl-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-, hydrochloride, (7s,9s)- but more generally known as amrubicin hydrochloride, which bears US NIH Compound Identifier 114897. European Medicines Agency schedules Amrubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20586. Most nations, for tariff and trade purposes, schedule amrubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, AMRUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amrubicin hydrochloride bears US NLM identifiers UMLS ID C0762659 and NCI Concept Code C47948. SMILES: CC(=O)[C@@]1(CC2C(C(C3C(C2O)C(=O)C4CCCCC4C3=O)O)[C@H](C1)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N.CL.
This classification denotes an intercalating agent with the molecular formula C21H19N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00DPD30SOY, chemically known as methansulfon-m-aniside, 4-(9-acridinylamino)-, monohydrochloride but generally known as amsacrine, which bears US NIH Compound Identifier 2179. Amsacrine most often comes in hydrochloride and lactate forms. European Medicines Agency schedules Amsacrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05495MIG. The term AMSACRINE is an International Non-Proprietary Name. World Health Organization schedules amsacrine in its Anatomical Therapeutic Chemical (ATC) Classification. AMSACRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amsacrine under HS 29350090 and SITC 51580. As of Q4 2014, AMSACRINE remains the US FDA Preferred Term for this commodity. Amsacrine bears US NLM identifiers UMLS ID C0591085 and NCI Concept Code C240. SMILES: S(=O)(=O)(NC1CC(OC)C(NC2C3C(NC4C2CCCC4)CCCC3)CC1)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05W904P57F. European Medicines Agency schedules Amylmetacresol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05497MIG. Amylmetacresol generally arises in the molecular formula C12H18O. The term AMYLMETACRESOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) AMYLMETACRESOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amylmetacresol under HS 29071990 and SITC 51243. As of Q4 2014, AMYLMETACRESOL remains the US FDA Preferred Term for this commodity. Amylmetacresol bears US NLM identifiers UMLS ID C0771502 and NCI Concept Code C80846. SMILES: CCCCCC1=C(C=C(C=C1)C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD200. This VA Drug Class (AD200) classifies this compound as belonging to the group CYANIDE ANTIDOTES.
This classification denotes an anesthetic agent with the molecular formula C14H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QRW683O56T, chemically known as 2-butanol, 1-(dimethylamino)-2-methyl-, benzoate (ester) but generally known as amylocaine, which bears US NIH Compound Identifier 10767. Amylocaine most often comes in base and hydrochloride forms. European Medicines Agency schedules Amylocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12893MIG. As of Q4 2014, AMYLOCAINE remains the US FDA Preferred Term for this commodity. Amylocaine bears US NLM identifiers UMLS ID C0081580 and NCI Concept Code C72170. SMILES: O(C(CN(C)C)(CC)C)C(=O)C1CCCCC1.
This classification denotes a therapeutic progestin with the molecular formula C22H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8FB38IU3G, chemically known as 17-hydroxy-6.alpha.-methylpregn-4-en-20-one but generally known as anagestone, which bears US NIH Compound Identifier 160650. European Medicines Agency schedules Anagestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05498MIG. Most nations schedule anagestone under HS 29372300 and SITC 54153. As of Q4 2014, ANAGESTONE remains the US FDA Preferred Term for this commodity. Anagestone bears US NLM identifiers UMLS ID C0051808 and NCI Concept Code C79752. SMILES: CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CCCC4)C.
This classification denotes a therapeutic progestin with the molecular formula C24H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GNT396G9QT, chemically known as pregn-4-en-20-one, 17-hydroxy-6alpha-methyl-, acetate (8ci) but more generally known as anagestone acetate, which bears US NIH Compound Identifier 18443. European Medicines Agency schedules Anagestone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00522MIG. Most nations, for tariff and trade purposes, schedule anagestone acetate under HS 29372300 and SITC 54153. As of Q4 2014, ANAGESTONE ACETATE remains US FDA's Preferred Term for this commodity. Anagestone acetate bears US NLM identifiers UMLS ID C2698107 and NCI Concept Code C76302. SMILES: C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CCCC4)C.
This classification denotes an antiplatelet agent with the molecular formula C10H7Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9X45X0051, chemically known as 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3h)-one but generally known as anagrelide, which bears US NIH Compound Identifier 2182. Anagrelide most often comes in base and hydrochloride forms. European Medicines Agency schedules Anagrelide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05499MIG. The term ANAGRELIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules anagrelide in its Anatomical Therapeutic Chemical (ATC) Classification. ANAGRELIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anagrelide under HS 29335995 and SITC 51576. As of Q4 2014, ANAGRELIDE remains the US FDA Preferred Term for this commodity. Anagrelide bears US NLM identifiers UMLS ID C0051809 and NCI Concept Code C28825. SMILES: C1C2=C(C=CC(=C2CL)CL)NC3=NC(=O)CN31.
This classification denotes an antiplatelet agent with the molecular formula C10H7Cl2N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VNS4435G39, chemically known as 6,7-dichloro-1,5-dihydroimidazo(2,1-b)-quinazolin-2(3h)-one monohydrochloride but generally known as anagrelide hydrochloride, which bears US NIH Compound Identifier 42786. European Medicines Agency schedules Anagrelide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00523MIG. Most nations schedule anagrelide hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ANAGRELIDE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Anagrelide hydrochloride bears US NLM identifiers UMLS ID C0771907 and NCI Concept Code C28826. SMILES: C1C2=C(C=CC(=C2CL)CL)NC3=NC(=O)CN31.CL.
This classification denotes the monohydrate form of an antiplatelet agent with the molecular formula C10H7Cl2N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VNS4435G39, chemically known as 6,7-dichloro-1,5-dihydroimidazo(2,1-b)-quinazolin-2(3h)-one monohydrochloride but more generally known as anagrelide hydrochloride, which bears US NIH Compound Identifier 42786. European Medicines Agency schedules Anagrelide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00523MIG. Most nations, for tariff and trade purposes, schedule anagrelide hydrochloride monohydrate under HS 29335995. As of Q4 2014, ANAGRELIDE HYDROCHLORIDE MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(C(C2C1NC3=NC(=O)CN3C2)CL)CL.O.CL.
This classification denotes an interleukin-1 receptor antagonist with the molecular formula C759H1186N208O232S10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9013DUQ28K, more generally known as anakinra. European Medicines Agency schedules anakinra in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05500MIG. The term ANAKINRA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 9, no. 3, 1995, list 35. ANAKINRA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anakinra under HS 30021095 and SITC 54163. As of Q4 2014, ANAKINRA remains the US FDA Preferred Term for this commodity. Anakinra bears US NLM identifiers UMLS ID C0245109 and NCI Concept Code C38717. SMILES: none.
This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H19N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z07MYW1AZ, chemically known as 1,3-benzenediacetonitrile, alpha,alpha,alpha,alpha-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)- but more generally known as anastrozole, which bears US NIH Compound Identifier 2187. European Medicines Agency schedules Anastrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05502MIG. The term ANASTROZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules anastrozole in its Anatomical Therapeutic Chemical (ATC) Classification. ANASTROZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule anastrozole under HS 29339990 and SITC 51577. As of Q4 2014, ANASTROZOLE remains US FDA's Preferred Term for this commodity. Anastrozole bears US NLM identifiers UMLS ID C0290883 and NCI Concept Code C1607. SMILES: N1(NCNC1)CC1CC(C(C)(C)C#N)CC(C(C)(C)C#N)C1.
This classification denotes an opioid receptor agonist with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2S5VMM2SG, chemically known as 4-beta-methoxy-1-methyl-4-alpha-phenyl-3-alpha,5-alpha-propanopiperidine but generally known as anazocine, which bears US NIH Compound Identifier 27213. European Medicines Agency schedules Anazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05504MIG. The term ANAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). ANAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anazocine under HS 29333999 and SITC 51574. As of Q4 2014, ANAZOCINE remains the US FDA Preferred Term for this commodity. Anazocine bears US NLM identifiers UMLS ID C2698110 and NCI Concept Code C77276. SMILES: O(C1(C2CCCC1CN(C2)C)C1CCCCC1)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00EED65INL, chemically known as (r,s)-2-(3-(tert-butylamino)-2-hydroxypropoxy-2-furanilid but generally known as ancarolol, which bears US NIH Compound Identifier 170339. European Medicines Agency schedules Ancarolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05506MIG. The term ANCAROLOL is an International Non-Proprietary Name. ANCAROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ancarolol under HS 29321900 and SITC 51569. As of Q4 2014, ANCAROLOL remains the US FDA Preferred Term for this commodity. Ancarolol bears US NLM identifiers UMLS ID C2346780 and NCI Concept Code C73014. SMILES: OC(CNC(C)(C)C)COC1C(NC(=O)C2OCCC2)CCCC1.
This classification denotes a therapeutic stem cell factor with the molecular formula C1662H2650N422O512S18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PYB4Q6JG41, more generally known as ancestim. European Medicines Agency schedules ancestim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00524MIG. The term ANCESTIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 1, 1999, list 41. Most nations schedule Ancestim under HS 30021095 and SITC 54163. SMILES:. As of Q4 2014, ANCESTIM remains the US FDA Preferred Term for this commodity. . Ancestim bears US NLM identifiers UMLS ID C0538777 and NCI Concept Code C1646.
This classification denotes a pyrimidine antagonist with the molecular formula C9H11N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DO2D32W0VC, chemically known as 2,2-o-cyclocytidine but generally known as ancitabine, which bears US NIH Compound Identifier 25051. Ancitabine most often comes in base and hydrochloride forms. European Medicines Agency schedules Ancitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05507MIG. The term ANCITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). ANCITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ancitabine under HS 29349990 and SITC 51579. As of Q4 2014, ANCITABINE remains the US FDA Preferred Term for this commodity. Ancitabine bears US NLM identifiers UMLS ID CL406826 and NCI Concept Code C80636. SMILES: O1C2N3C(OC2C(O)C1CO)NC(=N)CC3.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EL55307L15. European Medicines Agency schedules Ancrod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00525MIG. The term Ancrod is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). Most nations schedule Ancrod under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, ANCROD remains the US FDA Preferred Term for this commodity. . Ancrod bears US NLM identifiers UMLS ID C0002823 and NCI Concept Code C95255.
This classification denotes an anabolic steroid with the molecular formula C19H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08J2K08A3Y, chemically known as 4,5alpha-dihydrotestosterone but generally known as androstanolone, which bears US NIH Compound Identifier 10635. European Medicines Agency schedules Androstanolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05509MIG. The term ANDROSTANOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules androstanolone in its Anatomical Therapeutic Chemical (ATC) Classification. ANDROSTANOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1C2(C(C3C(C4(C(CC3)CC(=O)CC4)C)CC2)CC1)C.
This classification denotes an anabolic steroid with the molecular formula C19H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95PS51EMXY, chemically known as 3beta,17beta-dihydroxyandrost-5-ene but generally known as androstenediol, which bears US NIH Compound Identifier 10634. European Medicines Agency schedules Androstenediol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12899MIG. As of Q4 2014, ANDROSTENEDIOL remains the US FDA Preferred Term for this commodity. Androstenediol bears US NLM identifiers UMLS ID C0524764 and NCI Concept Code C95979. SMILES: OC1C2(C(C3C(C4(C(=CC3)CC(O)CC4)C)CC2)CC1)C. .
This classification denotes an anabolic steroid with the molecular formula C19H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 409J2J96VR, chemically known as 3,17-dioxoandrost-4-ene but generally known as androstenedione, which bears US NIH Compound Identifier 6128. European Medicines Agency schedules Androstenedione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12900MIG. As of Q4 2014, ANDROSTENEDIONE remains the US FDA Preferred Term for this commodity. Androstenedione bears US NLM identifiers UMLS ID CL026907 and NCI Concept Code C2300. SMILES: O=C1C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C. .
This classification denotes a therapeutic androgen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 459AG36T1B. European Medicines Agency schedules Dehydroepiandrosterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10002MIG. Prasterone generally arises in the molecular formula C19H28O2. The term PRASTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) PRASTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C1C2(C(C3C(C4(C(=CC3)CC(O)CC4)C)CC2)CC1)C.
This classification denotes an angiogenesis inhibitor with the molecular formula C21H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5Y8O51589, chemically known as 17-alpha,21-dihydroxypregna-4,9(11)-diene-3,20-dione 21-acetate but generally known as anecortave, which bears US NIH Compound Identifier 111332. anecortave most often comes in base and acetate forms. World Health Organization schedules anecortave in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule anecortave under HS 29372900 and SITC 54153. As of Q4 2014, ANECORTAVE remains the US FDA Preferred Term for this commodity. SMILES: CC(=O)OCC(=O)C1(CCC2C1(CC=C3C2CCC4=CC(=O)CCC43C)C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT900. This VA Drug Class (NT900) classifies this compound as belonging to the group NASAL AND THROAT, TOPICAL, OTHER.
This classification denotes a phase ii enzymes inducer with the molecular formula C10H8OS3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QUY32964DJ, chemically known as 5-(p-methoxyphenyl)-3h-1,2-dithiole-3-thione but generally known as anethole trithione, which bears US NIH Compound Identifier 2194. European Medicines Agency schedules Anethole trithione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12902MIG. World Health Organization schedules anethole trithione in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: COC1=CC=C(C=C1)C2=CC(=S)SS2.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 885452N0GZ and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29431 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Apiaceae, and Genus Angelica L., more commonly known as WILD CELERY or, as here, CELERY ROOT. Angelica bears the USDA PLANTS Database Identifier ANGEL. European Medicines Agency schedules angelica root in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD explicitly under Index SUB11711MIG and additionally, in severak varities implicitly under Indices SUB32803, SUB32493, and SUB32493. The United Nations Common Coding System (UNCCS) codifies angelica seeds under UNCCS 015432.
This classification denotes a therapeutic hormone with the molecular formula C49H70N14O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7WAL1X78KV, chemically known as l-phenylalanine, n-(1-(n-(n-(n-(n-(n2-l-asparaginyl-l-arginyl)-l-valyl)-l-tyrosyl)-l-valyl)-l-histidyl)-l-prolyl)- but generally known as angiotensin amide, which bears US NIH Compound Identifier 5890. European Medicines Agency schedules Angiotensinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05511MIG. The term ANGIOTENSINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules angiotensin amide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule angiotensinamide under HS 29332990 and SITC 51573. SMILES: O=C(N1C(CCC1)C(=O)NC(CC1CCCCC1)C(=O)O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC(=O)N)CCC/N=C(/N)N)C(C)C)CC1CCC(O)CC1)C(C)C)CC1[NH]CNC1.
This classification is for a product used in the treatment of dehydration in patients with severe diarrhea. This is for a combination of electrolytes.
This classification is for a product used in the treatment of dehydration in patients with severe diarrhea. This is for a combination of electrolytes and zinc supplementation.
This classification denotes an antifungal agent with the molecular formula C58H73N7O17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9HLM53094I, chemically known as echinocandin b, 1-((4r,5r)-4,5-dihydroxy-n2-((4-(pentyloxy)(1,1:4,1-terphenyl)-4-yl)carbonyl)-l-ornithine) but generally known as anidulafungin, which bears US NIH Compound Identifier 166548. European Medicines Agency schedules Anidulafungin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22240. The term ANIDULAFUNGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules anidulafungin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule anidulafungin under HS 29419000 and SITC 54139. As of Q4 2014, ANIDULAFUNGIN remains the US FDA Preferred Term for this commodity. Anidulafungin bears US NLM identifiers UMLS ID C1142738 and NCI Concept Code C38716. SMILES: OC1C(CN2C1C(=O)NC(O)C(O)CC(NC(=O)C1CCC(CC1)C1CCC(CC1)C1CCC(OCCCCC)CC1)C(=O)NC(C(=O)N1C(CC(O)C1)C(=O)NC(C(=O)NC(C2=O)C(O)C)C(O)C(O)C1CCC(O)CC1)C(O)C)C.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71Q1A3O279, chemically known as 4-piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester but generally known as anileridine, which bears US NIH Compound Identifier 8944. Anileridine most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Anileridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05514MIG. The term ANILERIDINE is an International Non-Proprietary Name. World Health Organization schedules anileridine in its Anatomical Therapeutic Chemical (ATC) Classification. ANILERIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anileridine under HS 29333300 and SITC 51574. As of Q4 2014, ANILERIDINE remains the US FDA Preferred Term for this commodity. Anileridine bears US NLM identifiers UMLS ID C0051908 and NCI Concept Code C65234. SMILES: O(C(=O)C1(CCN(CC1)CCC1CCC(N)CC1)C1CCCCC1)CC.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H28N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 915Q054DLC, chemically known as 4-piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester, dihydrochloride but more generally known as anileridine hydrochloride, which bears US NIH Compound Identifier 31338. European Medicines Agency schedules Anileridine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00532MIG. Most nations, for tariff and trade purposes, schedule anileridine hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, ANILERIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Anileridine hydrochloride bears US NLM identifiers UMLS ID C0770427 and NCI Concept Code C65235. SMILES: CCOC(=O)C1(CCN(CC1)CCC2CCC(CC2)N)C3CCCCC3.CL.CL.
This classification denotes an opioid receptor agonist with the molecular formula C22H28N2O2.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3584484N8V. European Medicines Agency schedules anileridine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00533MIG. The term anileridine phosphate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule anileridine phosphate under HS 29333990 and SITC 51574. As of Q4 2014, ANILERIDINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Anileridine phosphate bears US NLM identifiers UMLS ID C0770428 and NCI Concept Code C87352. SMILES: CCOC(=O)C1(CCN(CC1)CCC2CCC(CC2)N)C3CCCCC3.OP(=O)(O)O.
This classification denotes a calcium channel blocker, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Y54WZV1CJ. European Medicines Agency schedules Anipamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05516MIG. Anipamil generally arises in the molecular formula C34H52N2O2. The term ANIPAMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) ANIPAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anipamil under HS 29269095 and SITC 51484. As of Q4 2014, ANIPAMIL remains the US FDA Preferred Term for this commodity. Anipamil bears US NLM identifiers UMLS ID C0051916 and NCI Concept Code C76578. SMILES: O(c1cc(C(CCCCCCCCCCCC)(CCCN(CCc2cc(OC)ccc2)C)C#N)ccc1)C.
This classification denotes a neuroprotective agent with the molecular formula C12H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5L16LKN964, chemically known as 2-pyrrolidinone, 1-(4-methoxybenzoyl)- but more generally known as aniracetam, which bears US NIH Compound Identifier 2196. European Medicines Agency schedules Aniracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05517MIG. The term ANIRACETAM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules aniracetam in its Anatomical Therapeutic Chemical (ATC) Classification. ANIRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule aniracetam under HS 29337900 and SITC 51561. As of Q4 2014, ANIRACETAM remains US FDA's Preferred Term for this commodity. Aniracetam bears US NLM identifiers UMLS ID C0051917 and NCI Concept Code C65236. SMILES: COC1=CC=C(C=C1)C(=O)N2CCCC2=O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9B9E35WUX, chemically known as 1h-pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-(4-methoxybenzoyl)-, (+-)- but generally known as anirolac, which bears US NIH Compound Identifier 47975. European Medicines Agency schedules Anirolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05518MIG. The term ANIROLAC is an International Non-Proprietary Name. ANIROLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anirolac under HS 29339990 and SITC 51577. As of Q4 2014, ANIROLAC remains the US FDA Preferred Term for this commodity. Anirolac bears US NLM identifiers UMLS ID C0631258 and NCI Concept Code C80536. SMILES: OC(=O)C1CCN2C1CCC2C(=O)C1CCC(OC)CC1.
This classification denotes an anti-lipidemic agent and anorexiant with the molecular formula C22H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5TB1FV429Z, chemically known as 2-propenoic acid, 3,3-diphenyl-2-(o-methoxyphenyl)- but generally known as anisacril, which bears US NIH Compound Identifier 21203. European Medicines Agency schedules Anisacril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05519MIG. The term ANISACRIL is an International Non-Proprietary Name. ANISACRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ANISACRIL remains the US FDA Preferred Term for this commodity. Anisacril bears US NLM identifiers UMLS ID C2983983 and NCI Concept Code C91010. SMILES: O(c1c(/C(=C(/c2ccccc2)c2ccccc2)C(=O)O)cccc1)C.
This classification denotes an anticoagulant agent with the molecular formula C16H12O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S747T1ERAJ, chemically known as 1,3-indanedione, 2-(4-methoxyphenyl)- but generally known as anisindione, which bears US NIH Compound Identifier 2197. European Medicines Agency schedules Anisindione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05520MIG. The term ANISINDIONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). ANISINDIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anisindione under HS 29145000 and SITC 51629. As of Q4 2014, ANISINDIONE remains the US FDA Preferred Term for this commodity. Anisindione bears US NLM identifiers UMLS ID C0051919 and NCI Concept Code C47398. SMILES: O=C1C(C(=O)C2C1CCCC2)C1CCC(OC)CC1.
This classification denotes an antimuscarinic agent with the molecular formula C16H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MJJ5G1G8OM. As of Q4 2014, ANISOTROPINE remains the US FDA Preferred Term for this commodity. Anisotropine bears US NLM identifiers UMLS ID C0301369 and NCI Concept Code C87426. SMILES: CCCC(CCC)C(=O)OC1CC2CCC(C1)[N+]2(C)C.[BR-]. .
This classification denotes an immunosuppressant with the molecular formula C18H39N7O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0514P112G. The term ANISPERIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, list 44). As of Q4 2014, ANISPERIMUS remains US FDA's Preferred Term for this commodity. Anisperimus bears US NLM identifiers UMLS ID C2698118 and NCI Concept Code C77593. Most nations, for tariff and trade purposes, schedule Anisperimus under HS 29252900 and SITC 51482 (for the most current information on WCO designations on anisperimus and salts thereof, please see Committee proceedings HSC/53, NC2004B1b Ann. O/6, 2014). SMILES: C[C@H](CCNCCCCNC(=O)OCC(=O)NCCCCCCNC(=N)N)N.
This classification denotes an acylated inactive complex of streptokinase and human lysine-plasminogen; after injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5O8V541HJ6. European Medicines Agency schedules Anistreplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00538MIG. The term ANISTREPLASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29.) Most nations schedule Anistreplase under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, ANISTREPLASE remains the US FDA Preferred Term for this commodity. .
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3LY71185IQ. European Medicines Agency schedules Ansoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05524MIG. Ansoxetine generally arises in the molecular formula C26H25NO3. The term ANSOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) ANSOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ansoxetine under HS 29329985 and SITC 51569. As of Q4 2014, ANSOXETINE remains the US FDA Preferred Term for this commodity. Ansoxetine bears US NLM identifiers UMLS ID C2346789 and NCI Concept Code C72702. SMILES: O(C(CCN(C)C)c1ccccc1)c1cc2c(oc(cc2=O)c2ccccc2)cc1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DHA8014SS1, chemically known as 4,5-dihydro-n-phenyl-n-phenylmethyl-1h-imidazole-2-methanamine but generally known as antazoline, which bears US NIH Compound Identifier 2200. Antazoline most often comes in base, 7-theophyllineacetate, hydrochloride, mesylate, methanesulfonate, nitrate, and phosphate forms. European Medicines Agency schedules Antazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05526MIG. The term ANTAZOLINE is an International Non-Proprietary Name. World Health Organization schedules antazoline in its Anatomical Therapeutic Chemical (ATC) Classification. ANTAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule antazoline under HS 29332990 and SITC 51573. As of Q4 2014, ANTAZOLINE remains the US FDA Preferred Term for this commodity. Antazoline bears US NLM identifiers UMLS ID C0003143 and NCI Concept Code C61638. SMILES: N(CC1=NCCN1)(CC1CCCCC1)C1CCCCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FP8Q8F72JH, chemically known as 2-(n-benzylanilino)methyl-2-imidazoline, hydrochloride but more generally known as antazoline hydrochloride, which bears US NIH Compound Identifier 17275. European Medicines Agency schedules Antazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00539MIG. Most nations, for tariff and trade purposes, schedule antazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, ANTAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Antazoline hydrochloride bears US NLM identifiers UMLS ID C0282053 and NCI Concept Code C76668. SMILES: C1CCC(CC1)CN(CC2=NCCN2)C3CCCCC3.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KU470J7TY6. European Medicines Agency schedules antazoline mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00540MIG. The term antazoline mesilate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule antazoline mesylate under HS 29332990. As of Q4 2014, ANTAZOLINE MESYLATE remains US FDA's Preferred Term for this commodity. Antazoline mesylate bears US NLM identifiers UMLS ID C0771474 and NCI Concept Code C95311. SMILES: CS(=O)(=O)O.C1CCC(CC1)CN(CC2=NCCN2)C3CCCCC3.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VPR5FPH326, chemically known as 1h-imidazole-2-methanamine, 4,5-dihydro-n-phenyl-n-(phenylmethyl)-, phosphate (1:1) but more generally known as antazoline phosphate, which bears US NIH Compound Identifier 158798. European Medicines Agency schedules Antazoline phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00541MIG. Most nations, for tariff and trade purposes, schedule antazoline phosphate under HS 29332990 and SITC 51573. As of Q4 2014, ANTAZOLINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Antazoline phosphate bears US NLM identifiers UMLS ID C0003144 and NCI Concept Code C47399. SMILES: C1CCC(CC1)CN(CC2=NCCN2)C3CCCCC3.OP(=O)(O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula 2C17H19N3.2H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T74I07212. European Medicines Agency schedules antazoline sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00542MIG. The term antazoline sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule antazoline sulfate under HS 29332990 and SITC 51573. As of Q4 2014, ANTAZOLINE SULFATE remains US FDA's Preferred Term for this commodity. Antazoline sulfate bears US NLM identifiers UMLS ID C0770941 and NCI Concept Code C95310. SMILES: C1CCC(CC1)CN(CC2=NCCN2)C3CCCCC3.OS(=O)(=O)O.
This classification denotes an anti-psoriatic agent with the molecular formula C14H10O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U8CJK0JH5M, chemically known as 1,8,9-anthracenetriol but generally known as anthralin, which bears US NIH Compound Identifier 2202. Anthralin most often comes in base and triacetate forms. European Medicines Agency schedules Dithranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06332MIG. The term DITHRANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules anthralin in its Anatomical Therapeutic Chemical (ATC) Classification. Anthralin or dithranol bears US NLM identifiers UMLS ID C0003166 and NCI Concept Code C28827. SMILES: O=C1C2C(CC3C1C(O)CCC3)CCCC2O.
This classification is a chemical compound and an ortho-aminobenzoate (which evinces anticonvulsant activity and properties, see US MeSH Unique Identifier C031385) with the molecular formula C7H7NO2, a compound which US FDA regulates as an active or moiety under Unique Ingredient Identifier 0YS975XI6W, chemically known as 2-aminobenzoic acid, which bears US National Library of Medicine Compound Identifier 227 and European Inventory of Existing Commercial Chemical Substances number 204-287-5. European Medicines Agency schedules Safrole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12908MIG. Under the World Customs Organization Harmonised System, anthranilic acid is scheduled in 29224300, and anthranilic acid bears US Drug Enforcement Administration Number 8530. The United Nations International Drug Control Programme's Technical Services Branch, in accordance with and support of the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, and Article 12 thereof, in conjunction with scientific findings Clandestine Manufacture of Substances under International Control (ST/NAR/10), has determined that this commodity (anthranilic acid) is a precursor in manufacture of Methaqualone (See Scientific and Technical Note SCITEC/11). Under EU regulations, anthranilic acid is governed by Regulation (EC) No 273/2004 (rules for the monitoring of trade between the Community and third countries in drug precursors) and Official Journal L 022, 26/01/2005 P. 0001-0010. Under US regulations, anthranilic acid is governed by Title 21 Code of Federal Regulations, §§ 1309, 1310.02, and 1313. Under Canadian regulations, anthranilic acid is governed by Controlled Drugs and Substances Act subsection 55(1) (S.C. 1996, c. 19) and Precursor Control Regulations (SOR/2002-359), P.C. 2002-1615 2002-09-24. Most nations schedule anthranilic acid under HS 29224300 and SITC 51465. As of Q4 2014, ANTHRANILIC ACID remains the US FDA Preferred Term for this commodity. SMILES: C1=CC=C(C(=C1)C(=O)O)N.
This clasification denotes preparations recognized by the immune system and which induce an immune reaction to an acute infection caused by the spore-forming bacteria bacillus anthracis, an infection called anthrax. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.
This classification denotes antibacterials made of carbamide, or CO(NH2)2.
This classification denotes an anticoagulant agent with the molecular formula C12H23O17P, chemically known as 2-hydroxypropane-1,2,3-tricarboxylic acid;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid but generally known as anticoagulant citrate phosphate dextrose solution, which bears US NIH Compound Identifier 123830. European Medicines Agency schedules anticoagulant citrate phosphate dextrose solution in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25621 and SUB25620. SMILES:C(C(C(C(C(C=O)O)O)O)O)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.OP(=O)(O)O.
This classification denotes an antihelminthic agent with the molecular formula C9H8N2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50Z1JVP72H, chemically known as imidazo(2,1-b)thiazole, 5,6-dihydro-6-(2-thienyl)-, ( -)- but generally known as antienite, which bears US NIH Compound Identifier 170351. European Medicines Agency schedules Antienite in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05529MIG. The term ANTIENITE is an International Non-Proprietary Name. ANTIENITE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule antienite under HS 29349990 and SITC 51579. As of Q4 2014, ANTIENITE remains the US FDA Preferred Term for this commodity. Antienite bears US NLM identifiers UMLS ID C2346831 and NCI Concept Code C74151. SMILES: S1C2=NC(CN2CC1)C1SCCC1.
The F8 gene provides instructions for making a protein called coagulation factor VIII. Coagulation factors are a group of related proteins that are essential for the formation of blood clots.
This classification denotes coagulation factor VIII, a procoagulant component,a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 839MOZ74GK. European Medicines Agency schedules Antihemophilic Factor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13813MIG.
This classification denotes a serum containing gamma-globulins which are antibodies for lymphocyte antigens.
This classification denotes a combination drug. The arug consists of two components. The first is PHENAZONE or PHENAZON or ANTIPYRINE or ANALGESINE, a nonsteroidal antiinflammatory drug with the molecular formula C11H12N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3CHA1B51H, chemically known as 2,3-dimethyl-1-phenylpyrazol-5-one but generally known as antipyrine, which bears US NIH Compound Identifier 2206. Antipyrine most often comes in base, iodide, and salicylate forms. European Medicines Agency schedules Phenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09753MIG. The term PHENAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules antipyrine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CC1=CC(=O)N(N1C)C2=CC=CC=C2. The second component of this drug is BENZOCAINE, an anesthetic agent with the molecular formula C9H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3RSY48JW5, chemically known as 4-aminobenzoic acid, ethyl ester but generally known as benzocaine, which bears US NIH Compound Identifier 2337. Benzocaine most often comes in base, oxalate, silicon, and succinate forms. European Medicines Agency schedules Benzocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05755MIG. The term BENZOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules benzocaine in its Anatomical Therapeutic Chemical (ATC) Classification. BENZOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C(=O)C1CCC(N)CC1)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT400. This VA Drug Class (OT400) classifies this compound as belonging to the group ANALGESICS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT400. This VA Drug Class (OT400) classifies this compound as belonging to the group ANALGESICS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H12N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3CHA1B51H, chemically known as 2,3-dimethyl-1-phenylpyrazol-5-one but generally known as antipyrine, which bears US NIH Compound Identifier 2206. Antipyrine most often comes in base, iodide, and salicylate forms. European Medicines Agency schedules Phenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09753MIG. The term PHENAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules antipyrine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CC1=CC(=O)N(N1C)C2=CC=CC=C2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.
Klebsiella pneumoniae is one of a coliform bacteria that causing mastitis. This disease were founded in dairy cows and can be prevented by vaccination.
Antithrombin (AT) is a small protein molecule that inactivates several enzymes of the coagulation system. Antithrombin is a glycoprotein produced by the liver and consists of 432 amino acids. It contains three disulfide bonds and a total of four possible glycosylation sites.
This classification denotes an immunosuppressant.
This classification denotes antisera used to counteract poisoning by animal venoms, especially snake venoms.
This classification denotes an anesthetic agent with the molecular formula C30H26F6N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21FS93Y6OE, chemically known as 2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl n-(7-(trifluoromethyl)-4-quinolyl)anthranilate but generally known as antrafenine, which bears US NIH Compound Identifier 68723. European Medicines Agency schedules Antrafenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05530MIG. The term ANTRAFENINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). ANTRAFENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule antrafenine under HS 29335995 and SITC 51576. As of Q4 2014, ANTRAFENINE remains the US FDA Preferred Term for this commodity. Antrafenine bears US NLM identifiers UMLS ID C0052135 and NCI Concept Code C72107. SMILES: FC(F)(F)C1CC(N2CCN(CC2)CCOC(=O)C2C(NC3C4C(NCC3)CC(CC4)C(F)(F)F)CCCC2)CCC1.
This classification denotes an antiplatelet agent with the molecular formula C22H22ClN5O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J613NI05SV, chemically known as 4-(3-(4-(o-chlorophenyl)-9-methyl-6h-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine but generally known as apafant, which bears US NIH Compound Identifier 65889. European Medicines Agency schedules Apafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05533MIG. The term APAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). APAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule apafant under HS 29349990 and SITC 51579. As of Q4 2014, APAFANT remains the US FDA Preferred Term for this commodity. Apafant bears US NLM identifiers UMLS ID C0245118 and NCI Concept Code C77989. SMILES: CLC1C(C2=NCC3N(C4SC(CCC(=O)N5CCOCC5)CC24)C(NN3)C)CCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C25H23N5O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3373RT9U7A, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((((4-hydroxy-1,5-naphthyridin-3-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2-alpha,5-alpha,6-beta(s*)))- but generally known as apalcillin, which bears US NIH Compound Identifier 107947. Apalcillin most often comes in base and sodium forms. European Medicines Agency schedules Apalcillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05535MIG. The term APALCILLIN is an International Non-Proprietary Name. APALCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule apalcillin under HS 29411090 and SITC 54131. As of Q4 2014, APALCILLIN remains the US FDA Preferred Term for this commodity. Apalcillin bears US NLM identifiers UMLS ID C0052145 and NCI Concept Code C76217. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(NC(=O)C1C(=O)C2NCCCC2[NH]C1)C1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C25H22N5O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XQ12NYC0Q, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((((4-hydroxy-1,5-naphthyridin-3-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as apalcillin sodium, which bears US NIH Compound Identifier 42834. European Medicines Agency schedules Apalcillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00556MIG. Most nations, for tariff and trade purposes, schedule apalcillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, APALCILLIN SODIUM remains US FDA's Preferred Term for this commodity. Apalcillin sodium bears US NLM identifiers UMLS ID C0771721 and NCI Concept Code C76218. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)NC(=O)C4CNC5CCCNC5C4O)C(=O)[O-])C.[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2VOT966ZI, chemically known as 1,2-dihydro-3-dimethylamino-7-methyl-1,2-(propylmalonyl)-1,2,4-benzotriazine but generally known as apazone, which bears US NIH Compound Identifier 26098. Apazone most often comes in base and dihydrate forms. European Medicines Agency schedules Azapropazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05638MIG. The term AZAPROPAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules apazone in its Anatomical Therapeutic Chemical (ATC) Classification. Apazone or azapropazone bears US NLM identifiers UMLS ID C0003524 and NCI Concept Code C73074. SMILES: CCCC1C(=O)N2C3=C(C=CC(=C3)C)N=C(N2C1=O)N(C)C.
This classification denotes a tetracycline antibiotic with the molecular formula C30H38N4O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T1Y573BS7H, chemically known as alpha-(4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)-4-(2-hydroxyethyl)-1-piperazineacetic acid but generally known as apicycline, which bears US NIH Compound Identifier 5490216. European Medicines Agency schedules Apicycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05537MIG. The term APICYCLINE is an International Non-Proprietary Name. APICYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule apicycline under HS 29413000 and SITC 54133. As of Q4 2014, APICYCLINE remains the US FDA Preferred Term for this commodity. Apicycline bears US NLM identifiers UMLS ID C2698165 and NCI Concept Code C76235. SMILES: OC12C(CC3C(O)(C4C(C(=C3C1=O)O)C(O)CCC4)C)C(N(C)C)C(=O)C(=C(\O)NC(N1CCN(CC1)CCO)C(=O)O)\C2=O.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Z9Y7UWC1J. European Medicines Agency schedules Apixaban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25425. Apixaban generally arises in the molecular formula C25H25N5O4. The term APIXABAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55.) APIXABAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule apixaban under HS 29337900 and SITC 51561. As of Q4 2014, APIXABAN remains the US FDA Preferred Term for this commodity. Apixaban bears US NLM identifiers UMLS ID C1831808 and NCI Concept Code C61308. SMILES: O=C1N(CCC2C1N(NC2C(=O)N)C1CCC(OC)CC1)C1CCC(N2CCCCC2=O)CC1.
This classification denotes a dopamine agonist and antiparkinsonian agent C21H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1USW70QZGV, chemically known as (6ar)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(de,g)quinoline-10,11-diol diacetate (ester), but more generally known as apomorphine diacetate, which bears US NIH Compound Identifier 201536. Most nations, for tariff and trade purposes, schedule apomorphine diacetate under HS 29391900 and SITC 54141. As of Q4 2014, APOMORPHINE DIACETATE remains US FDA's Preferred Term for this commodity. Apomorphine diacetate bears US NLM identifiers UMLS ID C2827080 and NCI Concept Code C83535. SMILES: CC(=O)OC1CCC2C(C1OC(=O)C)-C3CCCC4C3[C@@H](C2)N(CC4)C.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula 2C17H17NO2.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F39049Y068, chemically known as 6a.beta.-noraporphine-10,11-diol, 6-methyl-, hydrochloride but more generally known as apomorphine hydrochloride, which bears US NIH Compound Identifier 2215. European Medicines Agency schedules Apomorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12924MIG. Most nations, for tariff and trade purposes, schedule apomorphine hydrochloride under HS 29391900. As of Q4 2014, APOMORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Apomorphine hydrochloride bears US NLM identifiers UMLS ID C0237406 and NCI Concept Code C47400. SMILES: CN1CCC2CCCC-3C2[C@H]1CC4C3C(C(CC4)O)O.CN1CCC2CCCC-3C2[C@H]1CC4C3C(C(CC4)O)O.O.CL.CL.
This classification denotes a dopamine agonist and antiparkinsonian agent C17H17NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9K13MD7A0D, chemically known as (6ar)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(de,g)quinoline-10,11-diol hydrochloride, but more generally known as apomorphine hydrochloride anhydrous, which bears US NIH Compound Identifier 9410. Most nations, for tariff and trade purposes, schedule apomorphine hydrochloride anhydrous under HS 29391900 and SITC 54141. As of Q4 2014, APOMORPHINE HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. Apomorphine hydrochloride anhydrous bears US NLM identifiers UMLS ID C0887720 and NCI Concept Code C80572. SMILES: CN1CCC2CCCC-3C2[C@H]1CC4C3C(C(CC4)O)O.CL.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C17H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N21FAR7B4S, chemically known as 6a.beta.-noraporphine-10,11-diol, 6-methyl-, hydrochloride but generally known as apomorphine, which bears US NIH Compound Identifier 2215. Apomorphine most often comes in base, chloride, diacetate, hydrochloride, and hydrochloride hemihydrate forms. European Medicines Agency schedules Apomorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12923MIG. World Health Organization schedules apomorphine in its Anatomical Therapeutic Chemical (ATC) Classification. Apomorphine or apomorphinum bears US NLM identifiers UMLS ID C0003596 and NCI Concept Code C61639. SMILES: OC1C2C3C4C(N(CCC4CCC3)C)CC2CCC1O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H10Cl2N4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2VW67N38H, chemically known as 2,6-dichloro-n-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,4-diamine but more generally known as apraclonidine hydrochloride, which bears US NIH Compound Identifier 2216. European Medicines Agency schedules Apraclonidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12926MIG. Most nations, for tariff and trade purposes, schedule apraclonidine hydrochloride under HS 29332990. As of Q4 2014, APRACLONIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Apraclonidine hydrochloride bears US NLM identifiers UMLS ID C0304657 and NCI Concept Code C47401. SMILES: C1C(CC(C(C1CL)NC2=NCCN2)CL)N.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H10Cl2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 843CEN85DI, chemically known as 2,6-dichloro-n-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,4-diamine but generally known as apraclonidine, which bears US NIH Compound Identifier 2216. Apraclonidine most often comes in base and hydrochloride forms. European Medicines Agency schedules Apraclonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05539MIG. The term APRACLONIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules apraclonidine in its Anatomical Therapeutic Chemical (ATC) Classification. APRACLONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Apraclonidine or iopidine bears US NLM identifiers UMLS ID C0048038 and NCI Concept Code C61640. SMILES: CLC1C(NC2=NCCN2)C(CL)CC(N)C1.
This classification denotes an antibiotic with the molecular formula C21H41N5O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 388K3TR36Z, chemically known as 4-o-((8r)-2-amino-8-o-(4-amino-4-deoxy-alpha-d-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-d-glycero-alpha-d-allo-octodialdo-1,5:8,4-dipyranos-1-yl)-2-deoxy-d-streptamine but generally known as apramycin, which bears US NIH Compound Identifier 71428. Apramycin most often comes in base and sulphate forms. European Medicines Agency schedules Apramycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05540MIG. The term APRAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). APRAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule apramycin under HS 29419000 and SITC 54139. As of Q4 2014, APRAMYCIN remains the US FDA Preferred Term for this commodity. Apramycin bears US NLM identifiers UMLS ID C0052231 and NCI Concept Code C78789. SMILES: O1C2C(OC(OC3OC(C(N)C(O)C3O)CO)C(NC)C2O)CC(N)C1OC1C(N)CC(N)C(O)C1O.
This classification denotes an antibiotic with the molecular formula C21H41N5O11.(H2O4S)MOD, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8UYL6NAZ3Q. The term apramycin sulfate is a U.S. FDA Green Book designation. Most nations, for tariff and trade purposes, schedule apramycin sulfate under HS 29419000. SMILES:. As of Q4 2014, APRAMYCIN SULFATE remains US FDA's Preferred Term for this commodity. . Apramycin sulfate bears US NLM identifiers UMLS ID C0521895 and NCI Concept Code C79973.
This classification denotes an antiemetic agent with the molecular formula C23H21F7N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1NF15YR6UY, chemically known as 3h-1,2,4-triazol-3-one, 5-(((2r,3s)-2-((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro- but generally known as aprepitant, which bears US NIH Compound Identifier 151165. European Medicines Agency schedules Aprepitant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20017. The term APREPITANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). World Health Organization schedules aprepitant in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule aprepitant under HS 29349990 and SITC 51579. As of Q4 2014, APREPITANT remains the US FDA Preferred Term for this commodity. Aprepitant bears US NLM identifiers UMLS ID C1176306 and NCI Concept Code C49173. SMILES: FC1CCC(C2N(CCOC2OC(C2CC(CC(C2)C(F)(F)F)C(F)(F)F)C)CC2[NH][NH]C(=O)N2)CC1.
This classification denotes an antihypertensive agent with the molecular formula C12H16N2OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 374BH4KVRG, chemically known as 2h-thiopyran-2-carbothioamide, tetrahydro-n-methyl-2-(3-pyridinyl)-, 1-oxide but generally known as aprikalim, which bears US NIH Compound Identifier 3034038. European Medicines Agency schedules Aprikalim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05541MIG. The term APRIKALIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). APRIKALIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aprikalim under HS 29349990 and SITC 51579. As of Q4 2014, APRIKALIM remains the US FDA Preferred Term for this commodity. Aprikalim bears US NLM identifiers UMLS ID C0209261 and NCI Concept Code C77145. SMILES: CNC(=S)[C@@]1(CCCCS1=O)C2=CN=CC=C2.
This classification denotes an antiarrhythmic agent with the molecular formula C22H30N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5Y48085P9Q, chemically known as 1,3-propanediamine, n-(2, 3-dihydro-1h-inden-2-yl)-n,n-diethyl-n-phenyl-, monohydrochloride but more generally known as aprindine, which bears US NIH Compound Identifier 2218. Aprindine most often comes in base and hydrochloride forms. European Medicines Agency schedules Aprindine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05542MIG. The term APRINDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules aprindine in its Anatomical Therapeutic Chemical (ATC) Classification. APRINDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule aprindine under HS 29215990 and SITC 51455. As of Q4 2014, APRINDINE remains US FDA's Preferred Term for this commodity. Aprindine bears US NLM identifiers UMLS ID C0003639 and NCI Concept Code C77975. SMILES: N(C1CC2C(C1)CCCC2)(CCCN(CC)CC)C1CCCCC1.
This classification denotes an antiarrhythmic agent with the molecular formula C22H30N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PB5EKT7Q2V, chemically known as 1,3-propanediamine, n-(2, 3-dihydro-1h-inden-2-yl)-n,n-diethyl-n-phenyl-, monohydrochloride but more generally known as aprindine hydrochloride, which bears US NIH Compound Identifier 2218. European Medicines Agency schedules Aprindine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00565MIG. Most nations, for tariff and trade purposes, schedule aprindine hydrochloride under HS 29215990 and SITC 51455. As of Q4 2014, APRINDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Aprindine hydrochloride bears US NLM identifiers UMLS ID C0771404 and NCI Concept Code C77976. SMILES: CCN(CC)CCCN(C1CCCCC1)C2CC3CCCCC3C2.CL.
This classification denotes a barbiturate with the molecular formula C10H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q0YKG9L6RF, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-, monosodium salt but generally known as aprobarbital, which bears US NIH Compound Identifier 6464. Aprobarbital most often comes in base, o,o-dimethyl-epoxide, natrium, and sodium forms. European Medicines Agency schedules Aprobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05543MIG. The term APROBARBITAL is an International Non-Proprietary Name. World Health Organization schedules aprobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. APROBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aprobarbital under HS 29335400 and SITC kg. As of Q4 2014, APROBARBITAL remains the US FDA Preferred Term for this commodity. Aprobarbital bears US NLM identifiers UMLS ID C0051241 and NCI Concept Code C76525. SMILES: CC(C)C1(C(=O)NC(=O)NC1=O)CC=C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN301. This VA Drug Class (CN301) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS.
This classification denotes a barbiturate C10H13N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T90V76R18, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-methylethyl)-5-(2- propenyl)-, monosodium salt, but more generally known as aprobarbital sodium, which bears US NIH Compound Identifier 23662380. Most nations, for tariff and trade purposes, schedule aprobarbital sodium under HS 29335400 and SITC kg. As of Q4 2014, APROBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C1(C(=O)NC(=O)[N-]C1=O)CC=C.[NA+].
This classification denotes a urea analog with the molecular formula C9H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V18J24E25E, chemically known as 4-pentenamide, n-(aminocarbonyl)-2-(1-methylethyl)- but generally known as apronal, which bears US NIH Compound Identifier 10715. European Medicines Agency schedules Apronal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12929MIG. World Health Organization schedules apronal in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O=C(NC(=O)N)C(C(C)C)CC=C.
This classification denotes an anticoagulant agent with the molecular formula C27H34N2O70S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X94B38CQOM, chemically known as n,n-trimethylenebis(actobionamide) hexadecakis sulfate (ester) but generally known as aprosulate, which bears US NIH Compound Identifier 72125. European Medicines Agency schedules Aprosulate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05545MIG. The term APROSULATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). As of Q4 2014, APROSULATE remains the US FDA Preferred Term for this commodity. Aprosulate bears US NLM identifiers UMLS ID C0103894 and NCI Concept Code C87428. SMILES: C(CNC(=O)C(C(C(C(COS(=O)(=O)[O-])OS(=O)(=O)[O-])OC1C(C(C(C(O1)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])CNC(=O)C(C(C(C(COS(=O)(=O)[O-])OS(=O)(=O)[O-])OC2C(C(C(C(O2)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].
This classification denotes a protease inhibitor with the molecular formula C284H432N84O79S7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04XPW8C0FL. European Medicines Agency schedules aprotinin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05546MIG. The term APROTININ is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24. ). APROTININ is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aprotinin under HS 29349990 and SITC 51579. As of Q4 2014, APROTININ remains the US FDA Preferred Term for this commodity. Aprotinin bears US NLM identifiers UMLS ID C0003641 and NCI Concept Code C47402. SMILES: S1SCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C3NC(=O)CNC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=.
Aprotinin, calcium chloride, fibrinogen, and thrombin combination is used to help control bleeding during surgery when other procedures to close a wound or incision.
This classification denotes an antidepressant agent with the molecular formula C16H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 240J927J1R chemically known as (+/-)-1,3,4,14b-tetrahydro-2-methyl-2h,10h-pyrazino(1,2-a)pyrrolo(2,1-c)(1,4)benzodiazepine but generally known as aptazapine, which bears US NIH Compound Identifier 51355. European Medicines Agency schedules Aptazapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05547MIG. The term APTAZAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24. ). Most nations schedule aptazapine under HS 29335995 and SITC 51576. As of Q4 2014, APTAZAPINE remains the US FDA Preferred Term for this commodity. Aptazapine bears US NLM identifiers UMLS ID C0052237 and NCI Concept Code C79525. SMILES: CN1CCN2C(C1)C3=CC=CN3CC4=CC=CC=C42.
This classification denotes the maleate form of an antidepressant agent with the molecular structure C16H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 240J927J1R chemically known as (+/-)-1,3,4,14b-tetrahydro-2-methyl-2h,10h-pyrazino(1,2-a)pyrrolo(2,1-c)(1,4)benzodiazepine, but more commonly known as aptazapine, which bears US NIH Compound Identifier 51355. European Medicines Agency schedules Aptazapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05547MIG. The term APTAZAPINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, no. 6, 1984, list 24. ). Most nations, for tariff and trade purposes, schedule aptazapine maleate under HS 29335995 and SITC 51576. As of Q4 2014, APTAZAPINE MALEATE remains US FDA's Preferred Term for this commodity. Aptazapine maleate bears US NLM identifiers UMLS ID C2698177 and NCI Concept Code C79726. SMILES: CN1CCN2C3CCCCC3CN4CCCC4C2C1.C(=C\C(=O)O)\C(=O)O.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08K838NNTE. European Medicines Agency schedules Aptocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05549MIG. Aptocaine generally arises in the molecular formula C14H20N2O. The term APTOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) APTOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aptocaine under HS 29339990 and SITC 51577. As of Q4 2014, APTOCAINE remains the US FDA Preferred Term for this commodity. Aptocaine bears US NLM identifiers UMLS ID C0052238 and NCI Concept Code C72172. SMILES: O=C(NC1C(CCCC1)C)C(N1CCCC1)C.
Mistletoe (Viscum album) is a parasitic plant of trees: apple trees, poplars, firs or pines, among others. It is primarily used in preparations made from standardized purified aqueous extracts which possess immunomodulatory and cytotoxic activity.
A type of herbal analgesic
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T90W4582DU, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29372 ss a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Araliaceae, Genus Aralia L., more commonly known as SPIKENARD or, as here, ARALIA. Aralia bears the USDA PLANTS Database Identifier ARALI. European Medicines Agency schedules the most commonly-used aralia variety [in medicine] in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB40581, SUB46029, and SUB46030.
This classification denotes an antiviral agent with the molecular formula C20H18N2O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H56CKB2FFV, chemically known as 5,5a,13,13a-tetrahydro-5,13-dihydroxy-8h,16h-7a,15a-epidithio-7h,15h-bisoxepino(3,4:4,5)pyrrolo(1,2-a:1,2-d)pyrazine-7,15-dione 5-acetate but generally known as aranotin, which bears US NIH Compound Identifier 29844. European Medicines Agency schedules Aranotin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05551MIG. The term ARANOTIN is an International Non-Proprietary Name. ARANOTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aranotin under HS 29349990 and SITC 51579. As of Q4 2014, ARANOTIN remains the US FDA Preferred Term for this commodity. Aranotin bears US NLM identifiers UMLS ID C0052306 and NCI Concept Code C81609. SMILES: S1SC23N(C4C(=COC=CC4O)C2)C(=O)C21N(C1C(=COC=CC1OC(=O)C)C2)C3=O.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BIQ52YQ7VG. European Medicines Agency schedules Araprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05552MIG. Araprofen generally arises in the molecular formula C16H15NO4. The term ARAPROFEN is an International Non-Proprietary Name or INN. ARAPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule araprofen under HS 29224995 and SITC 51465. As of Q4 2014, ARAPROFEN remains the US FDA Preferred Term for this commodity. Araprofen bears US NLM identifiers UMLS ID C2346851 and NCI Concept Code C73075. SMILES: OC(=O)C(C1CCC(NC2C(CCCC2)C(=O)O)CC1)C.
This classification denotes an aminoglycoside antibiotic with the molecular formula C22H44N6O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7V6SLI20L, chemically known as o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1->6))-n-((2s)-4-amino-2-hydroxybutyryl)-2-deoxy-l-streptamine but generally known as arbekacin, which bears US NIH Compound Identifier 68682. Arbekacin most often comes in base and sulfate forms. European Medicines Agency schedules Arbekacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05554MIG. The term ARBEKACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules arbekacin in its Anatomical Therapeutic Chemical (ATC) Classification. ARBEKACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule arbekacin under HS 29419000 and SITC 54139. As of Q4 2014, ARBEKACIN remains the US FDA Preferred Term for this commodity. Arbekacin bears US NLM identifiers UMLS ID C0062073 and NCI Concept Code C76145. SMILES: O(C1C(NC(=O)C(O)CCN)CC(N)C(OC2OC(CCC2N)CN)C1O)C1OC(C(O)C(N)C1O)CO.
This classification denotes an aminoglycoside antibiotic with the molecular formula C22H44N6O10.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7395HZ992, chemically known as d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1-4))-n-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)-, sulfate (salt) but more generally known as arbekacin sulfate, which bears US NIH Compound Identifier 175989. European Medicines Agency schedules Arbekacin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12932MIG. Most nations, for tariff and trade purposes, schedule arbekacin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, ARBEKACIN SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N.OS(=O)(=O)O.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B07L15YAEV. European Medicines Agency schedules Arbutamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05555MIG. Arbutamine generally arises in the molecular formula C18H23NO4. The term ARBUTAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) Most nations schedule arbutamine under HS 29225000 and SITC 51467. As of Q4 2014, ARBUTAMINE remains the US FDA Preferred Term for this commodity. Arbutamine bears US NLM identifiers UMLS ID C0172021 and NCI Concept Code C65238. SMILES: OC(CNCCCCC1CCC(O)CC1)C1CC(O)C(O)CC1.
This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0NF2CPJ7F, chemically known as 1,2-benzenediol, 4-(1-hydroxy-2-((4-(4-hydroxyphenyl)butyl)amino)ethyl)-, (r)-, hydrochloride but more generally known as arbutamine hydrochloride, which bears US NIH Compound Identifier 166551. The base compound, Arbutamine, most often comes in base and hydrochloride forms. European Medicines Agency schedules Arbutamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00570MIG. Most nations, for tariff and trade purposes, schedule arbutamine hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, ARBUTAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Arbutamine hydrochloride bears US NLM identifiers UMLS ID C0772148 and NCI Concept Code C65239. SMILES: C1CC(CCC1CCCCNC[C@@H](C2CCC(C(C2)O)O)O)O.CL.
This classification denotes a low molecular weight heparin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N3927D01PB. European Medicines Agency schedules Ardeparin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00574MIG. Ardeparin sodium generally arises in the molecular formula (C14H18NO11)N.2(C12H15NO13S)N.3NA.3O3S. The term ARDEPARIN SODIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33.) As of Q4 2014, ARDEPARIN remains the US FDA Preferred Term for this commodity. SMILES: C(C1C(C(C(C(O1)O)NS(=O)(=O)[O-])O)OC2C(C(C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-].
This classification denotes an angiotensin ii receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E6SP93I57. European Medicines Agency schedules Arfalasin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05557MIG. Arfalasin generally arises in the molecular formula C48H67N13O11. The term ARFALASIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) ARFALASIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule arfalasin under HS 29332990 and SITC 51573. As of Q4 2014, ARFALASIN remains the US FDA Preferred Term for this commodity. Arfalasin bears US NLM identifiers UMLS ID C0624820 and NCI Concept Code C87430. SMILES: O=C(N1C(CCC1)C(=O)NC(c1ccccc1)C(=O)O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCC(=O)N)CCC/N=C(/N)N)C(C)C)Cc1ccc(O)cc1)C(C)C)Cc1[nH]cnc1.
This classification denotes a beta-adrenergic agonist with the molecular formula C19H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, F91H02EBWT chemically known as formamide, n-(2-hydroxy-5-((1r)-1-hydroxy-2-(((1r)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1) but generally known as arformoterol, which bears US NIH Compound Identifier 3083544. European Medicines Agency schedules Arformoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35021. The term ARFORMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 3, 2004, list 52). Most nations schedule arformoterol under HS 29242995 and SITC 51479. As of Q4 2014, ARFORMOTEROL remains the US FDA Preferred Term for this commodity. Arformoterol bears US NLM identifiers UMLS ID C0969589 and NCI Concept Code C61641. SMILES: CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IY90U61Z3S. European Medicines Agency schedules Argatroban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05559MIG. Argatroban generally arises in the molecular formula C23H36N6O5S. The term ARGATROBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 1 1998, list 39.) ARGATROBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule argatroban under HS 29350090 and SITC 51580. As of Q4 2014, ARGATROBAN remains the US FDA Preferred Term for this commodity. Argatroban bears US NLM identifiers UMLS ID C0048470 and NCI Concept Code C28833. SMILES: CC1CCN(C(C1)C(=O)O)C(=O)C(CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C.O.
This classification denotes the anhydrous form of an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IY90U61Z3S. European Medicines Agency schedules Argatroban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05559MIG. Argatroban generally arises in the molecular formula C23H36N6O5S. The term ARGATROBAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 no. 1 1998, list 39.) ARGATROBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule argatroban anhydrous under HS 29350090. As of Q4 2014, ARGATROBAN ANHYDROUS remains US FDA's Preferred Term for this commodity. Argatroban anhydrous bears US NLM identifiers UMLS ID C2698183 and NCI Concept Code C75153. SMILES: C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)C2CCCC3C2NCC(C3)C.
This classification denotes an anticoagulant agent with the molecular formula C23H36N6O5S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IY90U61Z3S, chemically known as 2-piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, monohydrate, but more generally known as argatroban monohydrate, which bears US NIH Compound Identifier 92721. European Medicines Agency schedules argatroban monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05559MIG. Most nations, for tariff purposes, schedule argatroban monohydrate under HS 29350090. SMILES: C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)C2CCCC3C2NCC(C3)C.O.
This classification denotes a nutritional supplement, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier F7LTH1E20Y. European Medicines Agency schedules Arginine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00579MIG. Arginine hydrochloride generally arises in the molecular formula C6H14N4O2.CLH. The term 'arginine hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation.
This classification denotes antidiuretic hormones released by the neurohypophysis of all vertebrates (structure varies with species) to regulate water balance and osmolarity, most especially arginine vasopressin, which typically arises in the molecular formula C46H65N15O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y87Y826H08, chemically known as 1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide but generally known as vasopressin, which bears US NIH Compound Identifier 8230. European Medicines Agency schedules Vasopressin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20776. The term VASOPRESSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7.). World Health Organization schedules vasopressin in its Anatomical Therapeutic Chemical (ATC) Classification. Argipressin or vasopressin bears US NLM identifiers UMLS ID C0003779 and NCI Concept Code C926. SMILES: C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N.
This classification denotes an antipsychotic agent with the molecular formula C23H27Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82VFR53I78, chemically known as 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1h)-quinolinone but generally known as aripiprazole, which bears US NIH Compound Identifier 60795. European Medicines Agency schedules Aripiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05564MIG. The term ARIPIPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). World Health Organization schedules aripiprazole in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule aripiprazole under HS 29337900 and SITC 51561. As of Q4 2014, ARIPIPRAZOLE remains the US FDA Preferred Term for this commodity. Aripiprazole bears US NLM identifiers UMLS ID C0299792 and NCI Concept Code C47403. SMILES: Clc1c(N2CCN(CC2)CCCCOc2cc3NC(=O)CCc3cc2)cccc1Cl.
This classification denotes an antipsychotic agent C30H39Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SE284EQRL, chemically known as (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2h)-yl)methyl hexanoate, but more generally known as aripiprazole cavoxil, which bears US NIH Compound Identifier 49831462. Most nations, for tariff and trade purposes, schedule aripiprazole cavoxil under HS 29337900 and SITC 51561. As of Q4 2014, ARIPIPRAZOLE CAVOXIL remains US FDA's Preferred Term for this commodity. SMILES: CCCCCC(=O)OCN1C2CC(CCC2CCC1=O)OCCCCN3CCN(CC3)C4CCCC(C4CL)CL.
This classification denotes an antipsychotic agent C36H51Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B786J7A343, chemically known as (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2h)-yl)methyl dodecanoate, but more generally known as aripiprazole lauroxil, which bears US NIH Compound Identifier 49831411. Most nations, for tariff and trade purposes, schedule aripiprazole lauroxil under HS 29337900 and SITC 51561. As of Q4 2014, ARIPIPRAZOLE LAUROXIL remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCC(=O)OCN1C2CC(CCC2CCC1=O)OCCCCN3CCN(CC3)C4CCCC(C4CL)CL.
This classification denotes a cns stimulant with the molecular formula C15H15NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V63XWA605I, chemically known as acetamide, 2-((diphenylmethyl)sulfinyl)- but generally known as armodafinil, which bears US NIH Compound Identifier 4236. European Medicines Agency schedules Armodafinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32249. The term ARMODAFINIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). Armodafinil or modafinil bears US NLM identifiers UMLS ID C0066677 and NCI Concept Code C26661. SMILES: S(=O)(C(C1CCCCC1)C1CCCCC1)CC(=O)N.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MUE8Y11327, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 36554 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Asterales, Family Asteraceae, Genus Arnica L., more commonly known as ARNICA or the SUNFLOWER genus. The US FDA additionally recognizes many varieties of arnica as active ingredients or moieties under Unique Ingredient Identifiers F8YB51A2HV, JB1W7X8DQ6, JCG1OSZ7A8, K181IYA8PH, K75056Q7TX, MFH47KBD23, MO43N06ZEN, NG0U89QRD8, O80TY208ZW, OZ0E5Y15PZ, U664526L2A, U7L2JP51PR, W6150S0KM6, 82CNE9JKJI, and 88WK5I8R3L. Arnica bears the USDA PLANTS Database Identifier ARNIC, and USDA classifies an additional 43 arnica varieties. Most arnica-based preparations aim to exploit the molecular structre C15H18O4, known to US FDA as an active ingredient or moiety under Unique Ingredient Identifier 4GUY9L896T, more commonly known as HELENALIN, or chemically known as 6.alpha.,8.beta.-dihydroxy-4-oxoambrosa-2,11(13)-dien-12-oic acid 12,8-lactone, which the US National Library of Medicine characterizes as having anti-inflammatory action. European Medicines Agency schedules the most commonly-used arnica varieties [in medicine] in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB11719MIG, SUB12938MIG, SUB12939MIG, SUB12940MIG, SUB20592, SUB31799, SUB34588, SUB40582, SUB40583, SUB40584, SUB45898, SUB45899, SUB45900, SUB45901, SUB45902, SUB45903, SUB45904, SUB45905, SUB50970, and SUB63691. The United Nations Common Coding System (UNCCS) codifies arnica, in its various forms, under UNCCS 014310 (seed source) and UNCCS 216551 (oil). SMILES: NONE.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98HS077RUP, chemically known as 2-butanol, 3-amino-1-(4-(2-methoxyethyl)phenoxy)-3-methyl- but generally known as arnolol, which bears US NIH Compound Identifier 65653. European Medicines Agency schedules Arnolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05565MIG. The term ARNOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ARNOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule arnolol under HS 29221980 and SITC 51461. As of Q4 2014, ARNOLOL remains the US FDA Preferred Term for this commodity. Arnolol bears US NLM identifiers UMLS ID C0641873 and NCI Concept Code C73015. SMILES: OC(C(N)(C)C)COC1CCC(CCOC)CC1.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C14H13ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87L38AY71R, chemically known as 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1h-purine-2,6-dione but generally known as arofylline, which bears US NIH Compound Identifier 166553. European Medicines Agency schedules Arofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05566MIG. The term AROFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). Most nations schedule arofylline under HS 29395900 and SITC 54145. As of Q4 2014, AROFYLLINE remains the US FDA Preferred Term for this commodity. Arofylline bears US NLM identifiers UMLS ID C2698184 and NCI Concept Code C74223. SMILES: CLC1CCC(N2C3NC[NH]C3C(=O)N(CCC)C2=O)CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H21N3O2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 394E3P3B99, chemically known as 5-(2-((3-((1,1-dimethylethyl)amino)-2-hydroxypropyl)thio)-4-thiazolyl)-2-thiophenecarboxamide but generally known as arotinolol, which bears US NIH Compound Identifier 2239. Arotinolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Arotinolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05568MIG. The term AROTINOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). AROTINOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule arotinolol under HS 29341000 and SITC 51579. As of Q4 2014, AROTINOLOL remains the US FDA Preferred Term for this commodity. Arotinolol bears US NLM identifiers UMLS ID C0104221 and NCI Concept Code C72609. SMILES: S(CC(O)CNC(C)(C)C)C1SCC(N1)C1SC(CC1)C(=O)N.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H21N3O2S3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9DOI1HT306, chemically known as 2-thiophenecarboxamide, 5-(2-((3-((1,1-dimethylethyl)amino)-2-hydroxypropyl)thio)-4-thiazolyl)-, monohydrochloride, (+-)- but more generally known as arotinolol hydrochloride, which bears US NIH Compound Identifier 155032. European Medicines Agency schedules Arotinolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00590MIG. Most nations, for tariff and trade purposes, schedule arotinolol hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, AROTINOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)NCC(CSC1NC(CS1)C2CCC(S2)C(=O)N)O.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25FN6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85713MT0EH, chemically known as guanidine, n-(3-(4-fluorophenyl)-3-(2-pyridinyl)propyl)-n-(3-(1h-imidazol-4-yl)propyl)- but generally known as arpromidine, which bears US NIH Compound Identifier 65895. European Medicines Agency schedules Arpromidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05570MIG. The term ARPROMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). Most nations schedule arpromidine under HS 29333999 and SITC 51574. As of Q4 2014, ARPROMIDINE remains the US FDA Preferred Term for this commodity. Arpromidine bears US NLM identifiers UMLS ID C0052410 and NCI Concept Code C72108. SMILES: FC1CCC(C(CCN/C(=N/CCCC2[NH]CNC2)N)C2NCCCC2)CC1.
This classification denotes an antihelminthic agent with the molecular formula C11H12AsNO5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VMF4ELY9TZ, chemically known as acetic acid, mercapto-, p-carbamoyldithiobenzenearsonite (2:1) but generally known as arsenamide, which bears US NIH Compound Identifier 10749. Arsenamide or thiacetarsamide bears US NLM identifiers UMLS ID C0003815 and NCI Concept Code C66595. SMILES: [AS](SCC(=O)O)(SCC(=O)O)C1CCC(CC1)C(=O)N.
This classification denotes a differentiation inducer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S7V92P67HO. European Medicines Agency schedules Arsenic trioxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12467MIG. Arsenic trioxide generally arises in the molecular formula AS2O3. The term ARSENIC TRIOXIDE is a United States Adopted Name designation. Most nations schedule arsenic trioxide under HS 28112990 and SITC 52239. As of Q4 2014, ARSENIC TRIOXIDE remains the US FDA Preferred Term for this commodity. Arsenic trioxide bears US NLM identifiers UMLS ID C0052416 and NCI Concept Code C1005. SMILES: O1[As]2O[As]1O2.
This classification denotes an antiprotozoal agent with the molecular formula C11H14AsNO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QNT09A162Y, chemically known as 2-hydroxy-5-(4-hydroxymethyl-1,3,2-dithiarsolan-2-yl)acetanilid but generally known as arsthinol, which bears US NIH Compound Identifier 8414. European Medicines Agency schedules Arsthinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05572MIG. The term ARSTHINOL is an International Non-Proprietary Name. World Health Organization schedules arsthinol in its Anatomical Therapeutic Chemical (ATC) Classification. ARSTHINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule arsthinol under HS 29349990 and SITC 51579. As of Q4 2014, ARSTHINOL remains the US FDA Preferred Term for this commodity. Arsthinol bears US NLM identifiers UMLS ID C0301341 and NCI Concept Code C76411. SMILES: CC(=O)NC1=C(C=CC(=C1)[AS]2SCC(S2)CO)O.
This classification denotes an antimalarial agent with the molecular formula C19H18F6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PE5HV9NF0, chemically known as 2,3-dioxabicyclo(3.3.1)nonan-7-one, 4-(2-(2,4-bis(trifluoromethyl)phenyl)ethenyl)-4,8-dimethyl-(1s-(1alpha,4beta(z),5alpha,8beta))- but generally known as arteflene, which bears US NIH Compound Identifier 6436134. European Medicines Agency schedules Arteflene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05573MIG. The term ARTEFLENE is an International Non-Proprietary Name. Most nations schedule arteflene under HS 29329985 and SITC 51569. As of Q4 2014, ARTEFLENE remains the US FDA Preferred Term for this commodity. Arteflene bears US NLM identifiers UMLS ID C0291500 and NCI Concept Code C75263. SMILES: FC(F)(F)C1C(/C=C\C2(OOC3CC2CC(=O)C3C)C)CCC(C1)C(F)(F)F.
This classification denotes an antimalarial agent with the molecular formula C16H26O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7D6T3H22J, chemically known as 3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12ar)-, (+)- but generally known as artemether, which bears US NIH Compound Identifier 68911. European Medicines Agency schedules Artemether in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05574MIG. The term ARTEMETHER is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules artemether in its Anatomical Therapeutic Chemical (ATC) Classification. ARTEMETHER is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule artemether under HS 29329970 and SITC 51569. As of Q4 2014, ARTEMETHER remains the US FDA Preferred Term for this commodity. Artemether bears US NLM identifiers UMLS ID C0052429 and NCI Concept Code C73001. SMILES: O1OC2(OC3OC(OC)C(C4C13C(C(CC4)C)CC2)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.
This classification denotes an antiprotozoal agent with the molecular formula C15H22O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9RMU91N5K2, chemically known as 3,12-epoxy-12h-pyranol(4,3-j)-1,2-benzodioxepin-10(3h)-one, octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12ar*)-(+)- but generally known as artemisinin, which bears US NIH Compound Identifier 68827. artemisinin most often comes in base, type a, and type b forms. European Medicines Agency schedules Artemisinin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05575MIG. The term ARTEMISININ is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules artemisinin in its Anatomical Therapeutic Chemical (ATC) Classification. ARTEMISININ is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule artemisinin under HS 29329985 and SITC 51569. As of Q4 2014, ARTEMISININ remains the US FDA Preferred Term for this commodity. Artemisinin bears US NLM identifiers UMLS ID C0052430 and NCI Concept Code C78093. SMILES: O1OC2(OC3OC(=O)C(C4C13C(C(CC4)C)CC2)C)C.
This classification denotes an antimalarial agent with the molecular formula C17H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XGL7GFB9YI, chemically known as 3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-ethoxy-3,6,9-trimethyl-, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12ar*))- but generally known as arteether, which bears US NIH Compound Identifier 72416. European Medicines Agency schedules Artemotil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00596MIG. The term ARTEMOTIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules arteether in its Anatomical Therapeutic Chemical (ATC) Classification. Artemotil or beta-arteether bears US NLM identifiers UMLS ID C0052427 and NCI Concept Code C73002. SMILES: CCOC1C(C2CCC(C3C24C(O1)OC(CC3)(OO4)C)C)C.
This classification denotes an antimalarial agent with the molecular formula C15H24O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6A9O50735X, chemically known as (3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3,-j)-1,2-benzodioxepin-10-ol but generally known as artenimol, which bears US NIH Compound Identifier 179336. European Medicines Agency schedules Artenimol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30709. The term ARTENIMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules artenimol in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule artenimol under HS 29329985 and SITC 51569. As of Q4 2014, ARTENIMOL remains the US FDA Preferred Term for this commodity. Artenimol bears US NLM identifiers UMLS ID C0058108 and NCI Concept Code C87432. SMILES: O1OC2(OC3OC(O)C(C4C13C(C(CC4)C)CC2)C)C.
Definition: This classification is for a combination antimalarial drug. The first component, ARTENIMOL, has a US FDA Unique Ingredient Identifier of 6A9O50735X. The second component, PIPERAQUINE, has a US FDA Unique Ingredient Identifier of A0HV2Q956Y.
This classification denotes an antiprotozoal agent with the molecular formula C19H28O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60W3249T9M, chemically known as 4-oxo-4-(((3r,5as,6r,8as,9r,10s,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate but generally known as artesunate, which bears US NIH Compound Identifier 65664. European Medicines Agency schedules Artesunate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05576MIG. The term ARTESUNATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 1, 2006, List 55). World Health Organization schedules artesunate in its Anatomical Therapeutic Chemical (ATC) Classification. ARTESUNATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule artesunate under HS 29329970 and SITC 51569. As of Q4 2014, ARTESUNATE remains the US FDA Preferred Term for this commodity. Artesunate bears US NLM identifiers UMLS ID C0052432 and NCI Concept Code C73005. SMILES: O1OC2(OC3OC(OC(=O)CCC(=O)O)C(C4C13C(C(CC4)C)CC2)C)C.
Definition: This classification is for a combination antimalarial drug. The first component, ARTESUNATE, has a US FDA Unique Ingredient Identifier of 60W3249T9M. The second component, MEFLOQUINE, has a US FDA Unique Ingredient Identifier of TML814419R.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QS9014Q792, chemically known as 2-thiophenecarboxylic acid, 4-methyl-3-(2-(propylamino)propionamido)-, methyl ester, monohydrochloride but more generally known as articaine hydrochloride, which bears US NIH Compound Identifier 32169. European Medicines Agency schedules Articaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00597MIG. Most nations, for tariff and trade purposes, schedule articaine hydrochloride under HS 29349990. As of Q4 2014, ARTICAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Articaine hydrochloride bears US NLM identifiers UMLS ID C0007300 and NCI Concept Code C47404. SMILES: CCCNC(C)C(=O)NC1C(CSC1C(=O)OC)C.CL.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D3SQ406G9X, chemically known as 4-methyl-3-(2-(propylamino)propionamido)-2-thiophenecarboxylic acid, methyl ester but generally known as articaine, which bears US NIH Compound Identifier 32170. Articaine most often comes in base and hydrochloride forms. European Medicines Agency schedules Articaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05577MIG. The term ARTICAINE is an International Non-Proprietary Name. World Health Organization schedules articaine in its Anatomical Therapeutic Chemical (ATC) Classification. ARTICAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Articaine or carticaine bears US NLM identifiers UMLS ID C1608295 and NCI Concept Code C72173. SMILES: CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC.CL.
This classification denotes preparations designed to lubricate the eyes, or to remedy dryness thereof.
This classification denotes a selective estrogen receptor modulator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E569WG6E60. European Medicines Agency schedules Arzoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00599MIG. Arzoxifene generally arises in the molecular formula C28H29NO4S. The term ARZOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule arzoxifene under HS 29349990 and SITC 51579. As of Q4 2014, ARZOXIFENE remains the US FDA Preferred Term for this commodity. Arzoxifene bears US NLM identifiers UMLS ID C0677791 and NCI Concept Code C1805. SMILES: s1c(c(Oc2ccc(OCCN3CCCCC3)cc2)c2c1cc(O)cc2)c1ccc(OC)cc1.
This classification denotes a selective estrogen receptor modulator with the molecular formula C28H29NO4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FU88PI0433, chemically known as benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)ethoxy)phenoxy)-, hydrochloride but more generally known as arzoxifene hydrochloride, which bears US NIH Compound Identifier 179338. The base compound, Arzoxifene, most often comes in base and hydrochloride forms. Most nations, for tariff and trade purposes, schedule arzoxifene hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ARZOXIFENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Arzoxifene hydrochloride bears US NLM identifiers UMLS ID C0950979 and NCI Concept Code C2460. SMILES: COC1CCC(CC1)C2C(C3CCC(CC3S2)O)OC4CCC(CC4)OCCN5CCCCC5.CL.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9FZA51AS1 and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 505943 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Apiaceae, Genus Ferula L., Species Ferula assa-foetida L., more commonly known as ASAFOETIDA or ASAFETIDA. European Medicines Agency schedules asafetida in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12947MIG. As of Q4 2014, ASAFETIDA remains the US FDA Preferred Term for this commodity. Asafetida bears US NLM identifiers UMLS ID C0003946 and NCI Concept Code C83538. SMILES: NONE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes an immunosuppressant and a biological preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AUF4U5NSJK, chemically known as (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-17-ethyl-1,14-dihydroxy-12-[(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0?,?]octacos-18-ene-2,3,10,16-tetrone but more generally known as ascomycin, which bears US NIH Compound Identifier 5282071. Most nations, for tariff and trade purposes, schedule ASCOMYCIN under HS 29349990 and SITC 51579. SMILES: CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT801. This VA Drug Class (VT801) classifies this compound as belonging to the group MULTIVITAMINS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT801. This VA Drug Class (VT801) classifies this compound as belonging to the group MULTIVITAMINS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT400. This VA Drug Class (VT400) classifies this compound as belonging to the group VITAMIN C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX202. This VA Drug Class (DX202) classifies this compound as belonging to the group NON-IMAGING AGENTS RADIOPHARMACEUTICALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT801. This VA Drug Class (VT801) classifies this compound as belonging to the group MULTIVITAMINS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT400. This VA Drug Class (VT400) classifies this compound as belonging to the group VITAMIN C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JKZ19V908O. European Medicines Agency schedules Asenapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30497. Asenapine generally arises in the molecular formula C17H16CLNO. The term ASENAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule asenapine under HS 29349990 and SITC 51579. As of Q4 2014, ASENAPINE remains the US FDA Preferred Term for this commodity. Asenapine bears US NLM identifiers UMLS ID C2000088 and NCI Concept Code C72705. SMILES: CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24.
This classification denotes an antipsychotic agent with the molecular formula C17H16ClNO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU9463U2E2, chemically known as 1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-,(3ar,12br)-rel-, (2z)-2-butenedioate (1:1) but more generally known as asenapine maleate, which bears US NIH Compound Identifier 6440510. The base compound, Asenapine, most often comes in base and maleate forms. European Medicines Agency schedules Asenapine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30493. Most nations, for tariff and trade purposes, schedule asenapine maleate under HS 29349990 and SITC 51579. As of Q4 2014, ASENAPINE MALEATE remains US FDA's Preferred Term for this commodity. Asenapine maleate bears US NLM identifiers UMLS ID C2719618 and NCI Concept Code C79727. SMILES: CN1C[C@H]2C3CCCCC3OC4CCC(CC4[C@@H]2C1)CL.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antispasmotic agent with the molecular formula C26H30FN3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2M24F1I2A, chemically known as (2r,4r)-3-(n-((3-((s)-1-carboxyethyl)phenyl)carbamoyl)glycyl)-2-(o-fluorophenyl)-4-thiazolidinecarboxylic acid, 4-tert-butylester but generally known as aseripide, which bears US NIH Compound Identifier 179339. European Medicines Agency schedules Aseripide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05580MIG. The term ASERIPIDE is an International Non-Proprietary Name. Most nations schedule aseripide under HS 29341000 and SITC 51579. As of Q4 2014, ASERIPIDE remains the US FDA Preferred Term for this commodity. Aseripide bears US NLM identifiers UMLS ID C2346860 and NCI Concept Code C73172. SMILES: S1CC(N(C1C1C(F)CCCC1)C(=O)CNC(=O)NC1CC(C(C)C(=O)O)CCC1)(C(C)(C)C)C(=O)O.
This classification denotes an antiarrhythmic agent with the molecular formula C27H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) J40338OKKT, chemically known as (+-)-6,7,8,9-tetrahydro-2,12-dimethoxy-7-methyl-6-phenethyl-5h-dibenz(d,f)azonin-1-ol but more generally known as asocainol, which bears US NIH Compound Identifier 71161. Asocainol most often comes in base and hydrochloride forms. European Medicines Agency schedules Asocainol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05583MIG. The term ASOCAINOL is an International Non-Proprietary Name. ASOCAINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule asocainol under HS 29339990 and SITC 51577. As of Q4 2014, ASOCAINOL remains US FDA's Preferred Term for this commodity. Asocainol bears US NLM identifiers UMLS ID C0052513 and NCI Concept Code C72574. SMILES: OC1C2C(CC(N(CCC3C2CC(OC)CC3)C)CCC2CCCCC2)CCC1OC.
This classification denotes an antiarrhythmic agent with the molecular formula C27H31NO3.HCL, a preparation chemically known as 6,7,8,9-Tetrahydro-2,12-dimethoxy-7-methyl-6-phenethyl-5H-dibenz(d,f)azonin-1-ol hydrochloride but more generally known as asocainol hydrochloride. Most nations, for tariff and trade purposes, schedule asocainol hydrochloride under HS 29339990 and SITC 51577. SMILES: OC1C2C(CC(N(CCC3C2CC(OC)CC3)C)CCC2CCCCC2)CCC1OC.CL.
This classification denotes a natural antineoplastic product hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1. with the molecular formula C1377H2208N382O442S17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4FQ3CKY5R, chemically known as E. coli L-asparagine amidohydrolase but generally known as asparaginase. European Medicines Agency schedules asparaginase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12950MIG. World Health Organization schedules asparaginase in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ASPARAGINASE remains the US FDA Preferred Term for this commodity.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C9H7O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E62HT5S2E9, and which bears US NIH Compound Identifier 23666729. Most nations schedule aspirin under HS 29182200 and SITC 51393. As of Q4 2014, ASPIRIN remains the US FDA Preferred Term for this commodity. Aspirin bears US NLM identifiers UMLS ID C0004057 and NCI Concept Code C287. SMILES: CC(=O)OC1=CC=CC=C1C(=O)[O-].
This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C9H7O4.Al.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E33TS05V6B, chemically known as aluminium, bis(2-(acetyloxy)benzoato-.kappa.o)hydroxy-, but more generally known as aspirin aluminium, which bears US NIH Compound Identifier 3032790. European Medicines Agency schedules aspirin aluminium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435. Most nations, for tariff purposes, schedule aspirin aluminium under HS 29182200. SMILES: CC(=O)OC1CCCCC1C(=O)[O-].CC(=O)OC1CCCCC1C(=O)[O-].[OH-].[AL+3].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class MS200. This VA Drug Class (MS200) classifies this compound as belonging to the group SKELETAL MUSCLE RELAXANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C9H7O4.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WOD7W0DGZS, chemically known as 2-(acetyloxy)benzoic acid calcium salt, but more generally known as aspirin calcium, which bears US NIH Compound Identifier 6247. European Medicines Agency schedules aspirin calcium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435. Most nations, for tariff purposes, schedule aspirin calcium under HS 29182200. Aspirin calcium bears US NLM identifiers UMLS ID C2006111 and NCI Concept Code C83539. SMILES: CC(=O)OC1CCCCC1C(=O)[O-].CC(=O)OC1CCCCC1C(=O)[O-].[CA+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class MS200. This VA Drug Class (MS200) classifies this compound as belonging to the group SKELETAL MUSCLE RELAXANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA110. This VA Drug Class (GA110) classifies this compound as belonging to the group SODIUM BICARBONATE CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class BL117. This VA Drug Class (BL117) classifies this compound as belonging to the group PLATELET AGGREGATION INHIBITORS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C9H7O4.C2H4NO2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NK259942HJ, chemically known as calcium, (glycinato)(salicylato)-, acetate (ester), but more generally known as aspirin glycine calcium, which bears US NIH Compound Identifier 30987. European Medicines Agency schedules aspirin glycine calcium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435. Most nations, for tariff purposes, schedule aspirin glycine calcium under HS 29182200. SMILES: CC(=O)OC1CCCCC1C(=O)[O-].C(C(=O)[O-])N.[CA+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C9H7O4.Mg, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4995924SMK, chemically known as magnesium 2-(acetyloxy)benzoate, but more generally known as aspirin magnesium, which bears US NIH Compound Identifier 8591. European Medicines Agency schedules aspirin magnesium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435. Most nations, for tariff purposes, schedule aspirin magnesium under HS 29182200. SMILES: CC(=O)OC1CCCCC1C(=O)[O-].CC(=O)OC1CCCCC1C(=O)[O-].[MG+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class MS200. This VA Drug Class (MS200) classifies this compound as belonging to the group SKELETAL MUSCLE RELAXANTS.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C10H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FX481V180, chemically known as benzoic acid, 2-(acetyloxy)-, methyl ester, but more generally known as aspirin methyl ester, which bears US NIH Compound Identifier 68484. European Medicines Agency schedules aspirin methyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435. Most nations, for tariff purposes, schedule aspirin methyl ester under HS 29182200. SMILES: CC(=O)OC1CCCCC1C(=O)OC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV350. This VA Drug Class (CV350) classifies this compound as belonging to the group ANTILIPEMIC AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a penicillin antibiotic with the molecular formula C21H27N5O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0745KNO26J, chemically known as glycinamide, n-methyl-d-asparaginyl-n-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-d-2-(4-hydroxyphenyl)-, (2s-(2-alpha,5-alpha,6-beta))- but generally known as aspoxicillin, which bears US NIH Compound Identifier 71961. European Medicines Agency schedules Aspoxicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05585MIG. The term ASPOXICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). ASPOXICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aspoxicillin under HS 29411090 and SITC 54131. As of Q4 2014, ASPOXICILLIN remains the US FDA Preferred Term for this commodity. Aspoxicillin bears US NLM identifiers UMLS ID C0104449 and NCI Concept Code C72706. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(NC(=O)C(N)CC(=O)NC)C1CCC(O)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H31FN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7HU6337315, chemically known as 1h-benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-n-(1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)- but generally known as astemizole, which bears US NIH Compound Identifier 2247. European Medicines Agency schedules Astemizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05586MIG. The term ASTEMIZOLE is an International Non-Proprietary Name. World Health Organization schedules astemizole in its Anatomical Therapeutic Chemical (ATC) Classification. ASTEMIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule astemizole under HS 29333999 and SITC 51574. As of Q4 2014, ASTEMIZOLE remains the US FDA Preferred Term for this commodity. Astemizole bears US NLM identifiers UMLS ID C0699606 and NCI Concept Code C28834. SMILES: FC1CCC(CN2C(NC3CCN(CC3)CCC3CCC(OC)CC3)NC3C2CCCC3)CC1.
This classification denotes an aminoglycoside antibiotic with the molecular formula C17H35N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JHD84H15J, chemically known as 2-amino-N-[(1S,2R,3R,4S,5S,6R)-4-amino-3-[(2R,3R,6S)-3-amino-6-(1-aminoethyl)tetrahydropyran-2-yl]oxy-2,5-dihydroxy-6-methoxy-cyclohexyl]-N-methyl-acetamide but generally known as astromicin, which bears US NIH Compound Identifier 65345. European Medicines Agency schedules Astromicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05587MIG. Most nations schedule astromicin under HS 29419000 and SITC 54139. As of Q4 2014, ASTROMICIN remains the US FDA Preferred Term for this commodity. Astromicin bears US NLM identifiers UMLS ID C0060685 and NCI Concept Code C76146. SMILES: CC(C1CCC(C(O1)OC2C(C(C(C(C2O)N(C)C(=O)CN)OC)O)N)N)N.
This classification denotes an aminoglycoside antibiotic with the molecular formula C17H35N5O6.2H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier POY3S0T3BD, chemically known as 4-amino-1-(2-amino-n-methylacetamido)-1,4-dideoxy-3-o-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-l-lyxo-heptopyranosyl)-6-o-methyl-l-chiro-inositol sulfate (1:2) (salt) but more generally known as astromicin sulfate, which bears US NIH Compound Identifier 51565. European Medicines Agency schedules Astromicin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00614MIG. Most nations, for tariff and trade purposes, schedule astromicin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, ASTROMICIN SULFATE remains US FDA's Preferred Term for this commodity. Astromicin sulfate bears US NLM identifiers UMLS ID C2698188 and NCI Concept Code C76147. SMILES: C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N.OS(=O)(=O)O.OS(=O)(=O)O.
This classification denotes a protease inhibitor with the molecular formula C38H52N6O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QZU4H47A3S, chemically known as 2,5,6,10,13-pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3s,8s,9s,12s)- but generally known as atazanavir, which bears US NIH Compound Identifier 148192. Atazanavir most often comes in base and sulfate forms. European Medicines Agency schedules Atazanavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16398MIG. The term ATAZANAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules atazanavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule atazanavir under HS 29333999 and SITC 51574. As of Q4 2014, ATAZANAVIR remains the US FDA Preferred Term for this commodity. Atazanavir bears US NLM identifiers UMLS ID C1145759 and NCI Concept Code C66872. SMILES: OC(C(NC(=O)C(NC(=O)OC)C(C)(C)C)Cc1ccccc1)CN(NC(=O)C(NC(=O)OC)C(C)(C)C)Cc1ccc(cc1)c1ncccc1.
Definition: This classification denotes a combination drug for treatment of HIV. The first component, ATAZANAVIR is a protease inhibitor with a US FDA Unique Ingredient Identifier of QZU4H47A3S. ATAZANAVIR is an International Non-Proprietary Name or INN. The second component, RITONAVIR, is a pharmacokinetic booster with a US FDA Unique Ingredient Identifier of O3J8G9O825. RITONAVIR is an International Non-Proprietary Name or INN.
This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, ATAZANAVIR, has a US FDA Unique Ingredient Identifier of QZU4H47A3S. The second component, RITONAVIR, has a US FDA Unique Ingredient Identifier of O3J8G9O825. The third component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The fourth component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.
This classification denotes a protease inhibitor with the molecular formula C38H52N6O7.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4MT4VIE29P, chemically known as 2,5,6,10,13-pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3s,8s,9s,12s)-, sulfate (1:1) (salt) but more generally known as atazanavir sulfate, which bears US NIH Compound Identifier 158550. European Medicines Agency schedules Atazanavir sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20595. Most nations, for tariff and trade purposes, schedule atazanavir sulfate under HS 29333999 and SITC 51574. As of Q4 2014, ATAZANAVIR SULFATE remains US FDA's Preferred Term for this commodity. Atazanavir sulfate bears US NLM identifiers UMLS ID C1176383 and NCI Concept Code C28835. SMILES: CC(C)(C)[C@@H](C(=O)N[C@@H](CC1CCCCC1)[C@H](CN(CC2CCC(CC2)C3CCCCN3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC.OS(=O)(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50VV3VW0TI, chemically known as ici 66,082 but generally known as atenolol, which bears US NIH Compound Identifier 2249. Atenolol comes in many forms, including base, acetate, acid, diacetate, hydrochloride, methylboronate, and n-butylboronate. European Medicines Agency schedules Atenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05590MIG. The term ATENOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules atenolol in its Anatomical Therapeutic Chemical (ATC) Classification. ATENOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atenolol under HS 29242995 and SITC 51479. As of Q4 2014, ATENOLOL remains the US FDA Preferred Term for this commodity. Atenolol bears US NLM identifiers UMLS ID C0004147 and NCI Concept Code C28836. SMILES: O(CC(O)CNC(C)C)C1CCC(CC1)CC(=O)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DI0UT7U1Q, chemically known as benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, monohydrochloride but more generally known as atenolol hydrochloride, which bears US NIH Compound Identifier 119274. European Medicines Agency schedules Atenolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00615MIG. Most nations, for tariff and trade purposes, schedule atenolol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, ATENOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NCC(COC1CCC(CC1)CC(=O)N)O.CL.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C21H25N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N24015WC6D chemically known as piperazine, 1-(3-(ethylamino)-2-pyridinyl)-4-((5-methoxy-1h-indol-2-yl)carbonyl)-, monomethanesulfonate but generally known as atevirdine, which bears US NIH Compound Identifier 60848. European Medicines Agency schedules Atevirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05591MIG. The term ATEVIRDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34. ). Most nations schedule atevirdine under HS 29335995 and SITC 51576. As of Q4 2014, ATEVIRDINE remains the US FDA Preferred Term for this commodity. Atevirdine bears US NLM identifiers UMLS ID C0210243 and NCI Concept Code C73840. SMILES: CCNC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)OC.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C21H25N5O2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A948D8673W. The term atevirdine mesilate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule atevirdine mesylate under HS 29335995. As of Q4 2014, ATEVIRDINE MESYLATE remains US FDA's Preferred Term for this commodity. Atevirdine mesylate bears US NLM identifiers UMLS ID C0210242 and NCI Concept Code C73148. SMILES: CCNC1CCCNC1N2CCN(CC2)C(=O)C3CC4CC(CCC4[NH]3)OC.CS(=O)(=O)O.
Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC).
This classification denotes an antidepressant agent with the molecular formula C17H18N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PZV3P03F1U, chemically known as 7-((5-isopropyl-1,3,4 thiadiazol-2-yl)methoxy)-3,4-dimethylcoumarin but generally known as atibeprone, which bears US NIH Compound Identifier 179342. European Medicines Agency schedules Atibeprone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05593MIG. The term ATIBEPRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). Most nations schedule atibeprone under HS 29349990 and SITC 51579. As of Q4 2014, ATIBEPRONE remains the US FDA Preferred Term for this commodity. Atibeprone bears US NLM identifiers UMLS ID C2346868 and NCI Concept Code C72707. SMILES: s1c(nnc1COc1cc2oc(=O)c(c(c2cc1)C)C)C(C)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03N9U5JAF6, chemically known as 1h-imidazole, 4-(2-ethyl-2,3-dihydro-1h-inden-2-yl)- but generally known as atipamezole, which bears US NIH Compound Identifier 71310. European Medicines Agency schedules Atipamezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05594MIG. The term ATIPAMEZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). Most nations schedule atipamezole under HS 29332990 and SITC 51573. As of Q4 2014, ATIPAMEZOLE remains the US FDA Preferred Term for this commodity. Atipamezole bears US NLM identifiers UMLS ID C0052593 and NCI Concept Code C72921. SMILES: [NH]1C(C2(CC3C(C2)CCCC3)CC)CNC1.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2W4279571X. The term atipamezole hydrochloride is a U.S. FDA Green Book designation. Most nations, for tariff and trade purposes, schedule atipamezole hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, ATIPAMEZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Atipamezole hydrochloride bears US NLM identifiers UMLS ID C1289965 and NCI Concept Code C80011. SMILES: CCC1(CC2CCCCC2C1)C3CNC[NH]3.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H29N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, ALS52889WF chemically known as pyrazino(2',3':3,4)pyrido(1,2-a)indole, 1-ethyl-1,2,3,4,4a,5,6,12b-octahydro-12-methyl-4-(1-methylethyl)-, trans, (z)-2-butenedioate but generally known as atiprosin, which bears US NIH Compound Identifier 3034029. European Medicines Agency schedules Atiprosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05596MIG. The term ATIPROSIN is an International Non-Proprietary Name or INN. Most nations schedule atiprosin under HS 29335995 and SITC 51576. As of Q4 2014, ATIPROSIN remains the US FDA Preferred Term for this commodity. Atiprosin bears US NLM identifiers UMLS ID C0052594 and NCI Concept Code C77299. SMILES: CCN1CCN(C2C1C3=C(C4=CC=CC=C4N3CC2)C)C(C)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H29N3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50SZ4782J0, chemically known as pyrazino(2,3:3,4)pyrido(1,2-a)indole, 1-ethyl-1,2,3,4,4a,5,6,12b-octahydro-12-methyl-4-(1-methylethyl)-, trans- but more generally known as atiprosin maleate, which bears US NIH Compound Identifier 3034029. Most nations, for tariff and trade purposes, schedule atiprosin maleate under HS 29335995 and SITC 51576. As of Q4 2014, ATIPROSIN MALEATE remains US FDA's Preferred Term for this commodity. Atiprosin maleate bears US NLM identifiers UMLS ID C0104775 and NCI Concept Code C87434. SMILES: CCN1CCN([C@H]2[C@H]1C3C(C4CCCCC4N3CC2)C)C(C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes a monoclonal antibody with the molecular formula C6428H9976N1720O2018S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I031V2H011, more generally known as tocilizumab. European Medicines Agency schedules tocilizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20313. The term TOCILIZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 18, no. 3, 2004, list 52. Atlizumab or tocilizumab bears US NLM identifiers UMLS ID C1609165 and NCI Concept Code C84217.
This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OBN5I4B08W. European Medicines Agency schedules Atolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05599MIG. Atolide generally arises in the molecular formula C18H23N3O. The term ATOLIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) ATOLIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atolide under HS 29242995 and SITC 51479. As of Q4 2014, ATOLIDE remains the US FDA Preferred Term for this commodity. Atolide bears US NLM identifiers UMLS ID C2698194 and NCI Concept Code C77997. SMILES: O=C(NC1C(CC(N(CC)CC)CC1)C)C1C(N)CCCC1.
This classification denotes an antidepressant agent with the molecular formula C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ASW034S0B8, chemically known as benzenepropanamine, n-methyl-gamma-(2-methylphenoxy)-, (gammar)- but generally known as atomoxetine, which bears US NIH Compound Identifier 54841. Atomoxetine most often comes in base and hydrochloride forms. The term ATOMOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3, 2002, List 48). World Health Organization schedules atomoxetine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ATOMOXETINE remains the US FDA Preferred Term for this commodity. Atomoxetine bears US NLM identifiers UMLS ID C0076823 and NCI Concept Code C74141. SMILES: CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C33H35FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0JWA85V8F, chemically known as 1h-pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (r-(r*,r*))- but generally known as atorvastatin, which bears US NIH Compound Identifier 60823. Atorvastatin most often comes in base, calcium, and lactone forms. European Medicines Agency schedules Atorvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05600MIG. The term ATORVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules atorvastatin in its Anatomical Therapeutic Chemical (ATC) Classification. ATORVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atorvastatin under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN remains the US FDA Preferred Term for this commodity. Atorvastatin bears US NLM identifiers UMLS ID C0286651 and NCI Concept Code C61527. SMILES: FC1CCC(C2N(C(C(C)C)C(C2C2CCCCC2)C(=O)NC2CCCCC2)CCC(O)CC(O)CC(=O)O)CC1.
Atorvastatin , Aspirin and Ramipril, which prevents heart attack and stroke. Atorvastatin is a lipid-lowering medication that blocks an enzyme required in the body to make cholesterol.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula 2C33H34FN2O5.Ca.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48A5M73Z4Q, chemically known as 1h-pyrrole-1-heptanoic acid, beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (r-(r*,r*))- but more generally known as atorvastatin calcium, which bears US NIH Compound Identifier 60822. European Medicines Agency schedules Atorvastatin calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12958MIG. Most nations, for tariff and trade purposes, schedule atorvastatin calcium under HS 29339990 and SITC 51577. Atorvastatin calcium bears US NLM identifiers UMLS ID C0286650 and NCI Concept Code C28837. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.O.O.O.[CA+2].
This classification denotes a hmg-coa reductase inhibitor with the molecular formula 2C33H34FN2O5.Ca.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48A5M73Z4Q, chemically known as atorvastatin calcium (trihydrate), but more generally known as atorvastatin calcium hydrate, which bears US NIH Compound Identifier 656846. European Medicines Agency schedules atorvastatin calcium hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05600MIG. Most nations, for tariff purposes, schedule atorvastatin calcium hydrate under HS 29339990. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.O.O.O.[CA+2].
This classification denotes a hmg-coa reductase inhibitor with the molecular formula 2C33H34FN2O5.Ca.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48A5M73Z4Q, chemically known as 1h-pyrrole-1-heptanoic acid, beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (r-(r*,r*))- but more generally known as atorvastatin calcium, which bears US NIH Compound Identifier 60822. European Medicines Agency schedules Atorvastatin calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12958MIG. Most nations, for tariff and trade purposes, schedule atorvastatin calcium trihydrate under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN CALCIUM TRIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.O.O.O.[CA+2].
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C33H33FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7876IL7J2N, chemically known as (+)-atorvastatin lactone, but more generally known as atorvastatin lactone, which bears US NIH Compound Identifier 6483036. European Medicines Agency schedules atorvastatin lactone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05600MIG. Most nations, for tariff purposes, schedule atorvastatin lactone under HS 29339990. SMILES: CC(C)C1C(C(C(N1CC[C@@H]2C[C@H](CC(=O)O2)O)C3CCC(CC3)F)C4CCCCC4)C(=O)NC5CCCCC5.
This classification denotes a hmg-coa reductase inhibitor 2C33H34FN2O5.Mg, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IVW98J023E, chemically known as magnesium, bis((.beta.r,.delta.r)-2-(4-fluorophenyl)-.beta.-(hydroxy-.kappa.o)-.delta.-hydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoato-.kappa.o1)-, (t-4)-, but more generally known as atorvastatin magnesium, which bears US NIH Compound Identifier 11651062. European Medicines Agency schedules Atorvastatin magnesium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB51445. Most nations, for tariff and trade purposes, schedule atorvastatin magnesium under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN MAGNESIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.[MG+2].
This classification denotes a hmg-coa reductase inhibitor 2C33H34FN2O5.Mg.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S40X654V9C, chemically known as magnesium, bis((.beta.r,.delta.r)-2-(4-fluorophenyl)-.beta.-(hydroxy-.kappa.o)-.delta.-hydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoato-.kappa.o1)-, hydrate (1:3), (t-4)-, but more generally known as atorvastatin magnesium trihydrate, which bears US NIH Compound Identifier 24849182. European Medicines Agency schedules Atorvastatin magnesium trihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37423. Most nations, for tariff and trade purposes, schedule atorvastatin magnesium trihydrate under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN MAGNESIUM TRIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.O.O.O.[MG+2].
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C33H34FN2O5.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DN43058TIV. European Medicines Agency schedules atorvastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35008. Most nations, for tariff and trade purposes, schedule atorvastatin sodium under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN SODIUM remains US FDA's Preferred Term for this commodity. Atorvastatin sodium bears US NLM identifiers UMLS ID C2698196 and NCI Concept Code C78676. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.[NA+].
This classification denotes a hmg-coa reductase inhibitor 2C33H34FN2O5.Sr, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AMJ4WWI6NM, chemically known as h-pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, strontium salt (2:1), (.beta.r,.delta.r)-, but more generally known as atorvastatin strontium, which bears US NIH Compound Identifier 24875347. Most nations, for tariff and trade purposes, schedule atorvastatin strontium under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN STRONTIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.[SR+2].
This classification denotes a hormone antagonist with the molecular formula C43H67N11O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 081D12SI0Z, chemically known as oxytocin, 1-(3-mercaptopropanoic acid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l-ornithine- but generally known as atosiban, which bears US NIH Compound Identifier 68613. European Medicines Agency schedules Atosiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05601MIG. The term ATOSIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules atosiban in its Anatomical Therapeutic Chemical (ATC) Classification. ATOSIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atosiban under HS 29349990 and SITC 51579. As of Q4 2014, ATOSIBAN remains the US FDA Preferred Term for this commodity. Atosiban bears US NLM identifiers UMLS ID C0164398 and NCI Concept Code C84815. SMILES: S1SCCC(=O)NC(C(=O)NC(C(CC)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CCCN)C(=O)NCC(=O)N)C1)CC(=O)N)C(O)C)CC1CCC(OCC)CC1.
This classification denotes the acetate form of a hormone antagonist with the molecular formula C43H67N11O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 081D12SI0Z, chemically known as oxytocin, 1-(3-mercaptopropanoic acid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l-ornithine- but generally known as atosiban, which bears US NIH Compound Identifier 68613. European Medicines Agency schedules Atosiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05601MIG. The term ATOSIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules atosiban in its Anatomical Therapeutic Chemical (ATC) Classification. ATOSIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. The base compound, atosiban, is a hormone antagonist with the molecular formula C43H67N11O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 081D12SI0Z, chemically known as oxytocin, 1-(3-mercaptopropanoic acid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l-ornithine- but generally known as atosiban, which bears US NIH Compound Identifier 68613. European Medicines Agency schedules Atosiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05601MIG. The term ATOSIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules atosiban in its Anatomical Therapeutic Chemical (ATC) Classification. ATOSIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atosiban acetate under HS 29349990 and SITC 51579. As of Q4 2014, ATOSIBAN ACETATE remains the US FDA Preferred Term for this commodity. Atosiban acetate bears US NLM identifiers UMLS ID C0873206 and NCI Concept Code C97706. SMILES: S1SCCC(=O)NC(C(=O)NC(C(CC)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CCCN)C(=O)NCC(=O)N)C1)CC(=O)N)C(O)C)CC1CCC(OCC)CC1.
This classification denotes an antimalarial and anti-infective agent with the molecular formula C22H19ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y883P1Z2LT, chemically known as 1,4-naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy- but generally known as atovaquone, which bears US NIH Compound Identifier 74989. Atovaquone most often comes in base form and is sometimes combined with proguanil. European Medicines Agency schedules Atovaquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05602MIG. The term ATOVAQUONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules atovaquone in its Anatomical Therapeutic Chemical (ATC) Classification. ATOVAQUONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atovaquone under HS 29147000 and SITC 51629. As of Q4 2014, ATOVAQUONE remains the US FDA Preferred Term for this commodity. Atovaquone bears US NLM identifiers UMLS ID C0165603 and NCI Concept Code C28838. SMILES: CLC1CCC(C2CCC(CC2)C2=C(O)C3C(C(=O)C2=O)CCCC3)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.
This classification denotes a neuromuscular blocking agent with the molecular formula C65H82N2O18S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40AX66P76P, chemically known as benzenesulfonate;5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate but generally known as atracurium besylate, which bears US NIH Compound Identifier 47320. European Medicines Agency schedules Atracurium Besylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29313. The term ATRACURIUM BESYLATE is an International Non-Proprietary Name or INN. ATRACURIUM BESYLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ATRACURIUM remains the US FDA Preferred Term for this commodity. Atracurium bears US NLM identifiers UMLS ID C0004234 and NCI Concept Code C76068. SMILES: C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-].
This classification denotes a nitrogen mustard compound and immunosuppressant with the molecular formula C41H47Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XC0K09B7K4, chemically known as estradiol 3-benzoate 17-glycolate, 4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate but more generally known as atrimustine, which bears US NIH Compound Identifier 53181. European Medicines Agency schedules Atrimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05605MIG. The term ATRIMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). ATRIMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule atrimustine under HS 29224995 and SITC 51465. As of Q4 2014, ATRIMUSTINE remains US FDA's Preferred Term for this commodity. Atrimustine bears US NLM identifiers UMLS ID C0105764 and NCI Concept Code C1348. SMILES: CLCCN(C1CCC(CCCC(=O)OCC(=O)OC2C3(C(C4C(CC3)C3C(CC4)CC(OC(=O)C4CCCCC4)CC3)CC2)C)CC1)CCCL.
This classification denotes an antimuscarinic agent with the molecular formula C17H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C0697DR9I, chemically known as 1alphah,5alphah-tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate but generally known as atropine, which bears US NIH Compound Identifier 3661. Atropine comes in many forms, including acetylsalicylic acidhydrobromide, hydrochloride, iodomethylate, isopropyl bromide, methobromide, methonitrate, methylbromide, methyl nitrate, metonitrate, nitrate, n-octyl bromide, n-oxide, n-oxide hydrochloride, octabromide, oxide, oxide hydrochloride, propionate ester, salicylate, and sulfate. European Medicines Agency schedules Atropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00621MIG. World Health Organization schedules atropine in its Anatomical Therapeutic Chemical (ATC) Classification. ATROPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atropine under HS 29399990 and SITC 54149. As of Q4 2014, ATROPINE remains the US FDA Preferred Term for this commodity. Atropine bears US NLM identifiers UMLS ID C0004259 and NCI Concept Code C28840. SMILES: O(C1CC2N(C(CC2)C1)C)C(=O)C(C1CCCCC1)CO.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AU300. This VA Drug Class (AU300) classifies this compound as belonging to the group PARASYMPATHOMIMETICS (CHOLINERGICS).
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN205. This VA Drug Class (CN205) classifies this compound as belonging to the group ANESTHETIC ADJUNCTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN205. This VA Drug Class (CN205) classifies this compound as belonging to the group ANESTHETIC ADJUNCTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD900. This VA Drug Class (AD900) classifies this compound as belonging to the group ANTIDOTES/DETERRENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes an antidiarrheal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6V729APAM. European Medicines Agency schedules Attapulgite in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12962MIG. Attapulgite generally arises in the molecular formula AL.MG.10O.4SI.HO.4H2O. The term 'attapulgite' is an FDA designation. As of Q4 2014, ATTAPULGITE remains the US FDA Preferred Term for this commodity. Attapulgite bears US NLM identifiers UMLS ID C0052657 and NCI Concept Code C28841. SMILES: O.O.O.O.O.O.O.O.O.O.O.O.O.O.[OH-].[MG].[MG].[AL].[AL].[SI].[SI].[SI].[SI]. .
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes an immunosuppressant with the molecular formula C20H34AuO9PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3H04W2810V, chemically known as gold, (2,3,4, 6-tetra-o-acetyl-1-thio-.beta.-d-glucopyranosato-s)(triethylphosph ine)- but more generally known as auranofin, which bears US NIH Compound Identifier 6333901. European Medicines Agency schedules Auranofin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05610MIG. The term AURANOFIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules auranofin in its Anatomical Therapeutic Chemical (ATC) Classification. AURANOFIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule auranofin under HS 28433000 and SITC 52432. As of Q4 2014, AURANOFIN remains US FDA's Preferred Term for this commodity. Auranofin bears US NLM identifiers UMLS ID C0699923 and NCI Concept Code C65242. SMILES: [AU](SC1OC(C(OC(=O)C)C(OC(=O)C)C1OC(=O)C)COC(=O)C)P(CC)(CC)CC.
This classification denotes an immunosuppressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2P2V9Q0E78. European Medicines Agency schedules Aurothioglucose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12965MIG. Aurothioglucose generally arises in the molecular formula C6H11AUO5S. The term 'aurothioglucose' is a U.S. Pharmacopeial Convention designation. As of Q4 2014, AUROTHIOGLUCOSE remains the US FDA Preferred Term for this commodity. Aurothioglucose bears US NLM identifiers UMLS ID C0018033 and NCI Concept Code C87435. SMILES: [AU]SC1OC(C(O)C(O)C1O)CO.
This classification denotes an antirheumatic agent with the molecular formula C3H6O4S2.Au.Na, , a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7097J63E9, chemically known as 1-propanesulfonic acid, 2-hydroxy-3-mercapto-, gold complex but more generally known as aurotioprol, which bears US NIH Compound Identifier 44144564. European Medicines Agency schedules aurotioprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12966MIG. As of Q4 2014, AUROTIOPROL remains US FDA's Preferred Term for this commodity. SMILES: C(C(CS(=O)(=O)O)O)S.[Na+].[Au+].
This classification denotes a cgmp phosphodiesterase inhibitor with the molecular structure C23H26CLN7O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, DR5S136IVO chemically known as 5-pyrimidinecarboxamide, 4-(((3-chloro-4-methoxyphenyl)methyl)amino)-2-((2s)-2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-, but more commonly known as avanafil, which bears U.S. NIH Compound Identifier 9869929. European Medicines Agency schedules Avanafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34916. The term AVANAFIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 19, no. 3, 2005, list 54).
This classification denotes an anti-lipidemic agent with the molecular formula C29H43NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28LQ20T5RC, chemically known as 2,6-diisopropylphenyl ((2,4,6-triisopropylphenyl)acetyl)sulfamate but generally known as avasimibe, which bears US NIH Compound Identifier 166558. European Medicines Agency schedules Avasimibe in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00632MIG. The term AVASIMIBE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule avasimibe under HS 29299000 and SITC 51489. As of Q4 2014, AVASIMIBE remains the US FDA Preferred Term for this commodity. Avasimibe bears US NLM identifiers UMLS ID C0965226 and NCI Concept Code C75252. SMILES: S(=O)(=O)(Oc1c(C(C)C)cccc1C(C)C)NC(=O)Cc1c(C(C)C)cc(cc1C(C)C)C(C)C.
This clasification denotes vaccines or candidate vaccines used to prevent or treat infection with a species of coronavirus causing infections in chickens and possibly pheasants.
This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C22H27ClN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65NK71K78P, chemically known as 2-benzoyl-4-chloro-2-((s)-2,6-diaminohexanamido)-n-methylacetanilide but generally known as avizafone, which bears US NIH Compound Identifier 71968. European Medicines Agency schedules Avizafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05616MIG. The term AVIZAFONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). AVIZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule avizafone under HS 29242995 and SITC 51479. As of Q4 2014, AVIZAFONE remains the US FDA Preferred Term for this commodity. Avizafone bears US NLM identifiers UMLS ID C0246215 and NCI Concept Code C72708. SMILES: CLC1CC(C(N(C(=O)CNC(=O)C(N)CCCCN)C)CC1)C(=O)C1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes an antipsychotic agent with the molecular formula C21H22ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MCG9O55T6K, chemically known as ( -)-1-(1-(1,4-benzodioxan-2-ylmethyl)-4-piperidyl)-5-chloro-2-benzimidazolinone but generally known as axamozide, which bears US NIH Compound Identifier 170359. European Medicines Agency schedules Axamozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05621MIG. The term AXAMOZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). AXAMOZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule axamozide under HS 29349990 and SITC 51579. As of Q4 2014, AXAMOZIDE remains the US FDA Preferred Term for this commodity. Axamozide bears US NLM identifiers UMLS ID C2346888 and NCI Concept Code C73281. SMILES: CLC1CC2[NH]C(=O)N(C3CCN(CC3)CC3OC4C(OC3)CCCC4)C2CC1.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H18N4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C9LVQ0YUXG. European Medicines Agency schedules axitinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25427. The term AXITINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. ). Most nations schedule axitinib under HS 29333990 and SITC 51574. As of Q4 2014, AXITINIB remains the US FDA Preferred Term for this commodity. Axitinib bears US NLM identifiers UMLS ID C1700874 and NCI Concept Code C38718. SMILES: S(C1CC2[NH]NC(C2CC1)/C=C/C1NCCCC1)C1C(CCCC1)C(=O)NC.
This classification denotes an anti-lipidemic agent with the molecular formula C25H24FNO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V477CK910J, chemically known as ethyl ( -)-((4-(3-((4-fluorophenyl)hydroxymethyl)-4-hydroxyphenoxy)-3,5-dimethylphenyl)amino)oxoacetate but generally known as axitirome, which bears US NIH Compound Identifier 166559. The term AXITIROME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule axitirome under HS 29242995 and SITC 51479. As of Q4 2014, AXITIROME remains the US FDA Preferred Term for this commodity. Axitirome bears US NLM identifiers UMLS ID C2698282 and NCI Concept Code C75992. SMILES: CCOC(=O)C(=O)NC1=CC(=C(C(=C1)C)OC2=CC(=C(C=C2)O)C(C3=CC=C(C=C3)F)O)C.
This classification denotes an antipsychotic agent with the molecular formula C17H23FN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9P043590EX chemically known as 4'-fluoro-4-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)butyrophenone but generally known as azabuperone, which bears US NIH Compound Identifier 18484. European Medicines Agency schedules Azabuperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05623MIG. The term AZABUPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16. ). Most nations schedule azabuperone under HS 29335995 and SITC 51576. As of Q4 2014, AZABUPERONE remains the US FDA Preferred Term for this commodity. Azabuperone bears US NLM identifiers UMLS ID C0052743 and NCI Concept Code C73282. SMILES: FC1CCC(C(=O)CCCN2CC3N(CCC3)CC2)CC1.
This classification denotes a pyrimidine antagonist with the molecular formula C8H12N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M801H13NRU, chemically known as 1,3,5-triazin-2 (1h)-one, 4-amino-1-.beta.-d-ribofuranosyl- but generally known as azacitidine, which bears US NIH Compound Identifier 1805. European Medicines Agency schedules Azacitidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05624MIG. The term AZACITIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules azacitidine in its Anatomical Therapeutic Chemical (ATC) Classification. AZACITIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azacitidine under HS 29349990 and SITC 51579. As of Q4 2014, AZACITIDINE remains the US FDA Preferred Term for this commodity. Azacitidine bears US NLM identifiers UMLS ID C0004475 and NCI Concept Code C288. SMILES: O1C(C(O)C(O)C1N1C(=O)NC(NC1)N)CO.
This classification denotes a vasodilating agent with the molecular formula C22H24ClN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7N4BHX8N3L, chemically known as 10h-phenothiazine, 2-chloro-10-(3-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)-1-oxopropyl)- but generally known as azaclorzine, which bears US NIH Compound Identifier 39526. Azaclorzine most often comes in base and hydrochloride forms. European Medicines Agency schedules Azaclorzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05625MIG. The term AZACLORZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). AZACLORZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azaclorzine under HS 29343090 and SITC 51578. As of Q4 2014, AZACLORZINE remains the US FDA Preferred Term for this commodity. Azaclorzine bears US NLM identifiers UMLS ID C0028295 and NCI Concept Code C74421. SMILES: Clc1cc2N(C(=O)CCN3CC4N(CCC4)CC3)c3c(Sc2cc1)cccc3.
This classification denotes a vasodilating agent with the molecular formula C22H24ClN3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7531I37BK3, chemically known as 10h-phenothiazine, 2-chloro-10-(3-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)-1-oxopropyl)-, dihydrochloride but more generally known as azaclorzine hydrochloride, which bears US NIH Compound Identifier 39525. Most nations, for tariff and trade purposes, schedule azaclorzine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, AZACLORZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Azaclorzine hydrochloride bears US NLM identifiers UMLS ID C2346890 and NCI Concept Code C72709. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)CL)C(=O)CCN4CCN5CCCC5C4.CL.CL.
This classification denotes an anti-lipidemic agent with the molecular formula C25H44N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EPT876J73A, chemically known as 20,25-diazacholesterol but more generally known as azacosterol, which bears US NIH Compound Identifier 9402. Azacosterol most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Azacosterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05627MIG. The term AZACOSTEROL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). AZACOSTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1CC2=CCC3C4C(C(N(CCCN(C)C)C)CC4)(CCC3C2(CC1)C)C.
This classification denotes an enzyme inhibitor and anti-lipidemic agent with the molecular formula C25H44N2O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B32804UAUQ, chemically known as 20,25-diazacholesterol dihydrochloride but more generally known as azacosterol hydrochloride, which bears US NIH Compound Identifier 14729.
This classification denotes an anxiolytic with the molecular formula C18H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2MMR990PEM, chemically known as 4-piperidinemethanol, alpha,alpha-diphenyl- but generally known as azacyclonol, which bears US NIH Compound Identifier 15723. Azacyclonol most often comes in base and hydrochloride forms. European Medicines Agency schedules Azacyclonol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05628MIG. The term AZACYCLONOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). AZACYCLONOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azacyclonol under HS 29333999 and SITC 51574. As of Q4 2014, AZACYCLONOL remains the US FDA Preferred Term for this commodity. Azacyclonol bears US NLM identifiers UMLS ID C0175156 and NCI Concept Code C76502. SMILES: OC(C1CCNCC1)(C1CCCCC1)C1CCCCC1.
This classification denotes an anxiolytic with the molecular formula C18H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4BXX0XNP9R, chemically known as 4-piperidinemethanol, alpha,alpha-diphenyl-, hydrochloride but more generally known as azacyclonol hydrochloride, which bears US NIH Compound Identifier 15722. European Medicines Agency schedules Azacyclonol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00635MIG. Most nations, for tariff and trade purposes, schedule azacyclonol hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, AZACYCLONOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Azacyclonol hydrochloride bears US NLM identifiers UMLS ID C0959907 and NCI Concept Code C76503. SMILES: C1CCC(CC1)C(C2CCCCC2)(C3CCNCC3)O.CL.
This classification denotes an anti-lipidemic agent with the molecular formula C22H24CLN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 2NL79NI1WS chemically known as 1-(((2s,4s)-4-(((p-aminophenyl)thio)methyl)-2-(p-chlorophenethyl)-1,3-dioxolan-2-yl)methyl)imidazole, but more commonly known as azalanstat, which bears US NIH Compound Identifier 60876. European Medicines Agency schedules Azalanstat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05630MIG. The term AZALANSTAT is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule azalanstat under HS 29349990 and SITC 51579. As of Q4 2014, AZALANSTAT remains US FDA's Preferred Term for this commodity. Azalanstat bears US NLM identifiers UMLS ID C0218596 and NCI Concept Code C79817. SMILES: C1[C@H](O[C@@](O1)(CCC2=CC=C(C=C2)CL)CN3C=CN=C3)CSC4=CC=C(C=C4)N.
This classification denotes an anti-lipidemic agent with the molecular formula C22H24ClN3O2S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X30J960B4D, chemically known as 1-(((2s,4s)-4-(((p-aminophenyl)thio)methyl)-2-(p-chlorophenethyl)-1,3-dioxolan-2-yl)methyl)imidazole but more generally known as azalanstat dihydrochloride, which bears US NIH Compound Identifier 60876. Most nations, for tariff and trade purposes, schedule azalanstat dihydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, AZALANSTAT DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Azalanstat dihydrochloride bears US NLM identifiers UMLS ID C2698284 and NCI Concept Code C80126. SMILES: C1CC(CCC1CC[C@@]2(OC[C@H](O2)CSC3CCC(CC3)N)CN4CCNC4)CL.CL.CL.
This classification denotes an antidepressant agent with the molecular formula C18H25N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O653FA999, chemically known as (s)-1-(1-(2-(1,4-benzodioxan-2-yl)-ethyl)-4-piperidyl)-2-imidazolidinone but generally known as azaloxan fumarate, which bears US NIH Compound Identifier 6328465. European Medicines Agency schedules azaloxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05631MIG. Most nations schedule azaloxan under HS 29349990 and SITC 51579. As of Q4 2014, AZALOXAN remains the US FDA Preferred Term for this commodity. Azaloxan bears US NLM identifiers UMLS ID C2698285 and NCI Concept Code C75051. SMILES: C1CN(CCC1N2CCNC2=O)CCC3COC4=CC=CC=C4O3.
This classification denotes an antidepressant agent with the molecular formula C18H25N3O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8605L38D80, chemically known as (s)-1-(1-(2-(1,4-benzodioxan-2-yl)ethyl)-4-piperidyl)-2-imidazolidinon fumarat but more generally known as azaloxan fumarate, which bears US NIH Compound Identifier 6435451. Most nations, for tariff and trade purposes, schedule azaloxan fumarate under HS 29349990 and SITC 51579. As of Q4 2014, AZALOXAN FUMARATE remains US FDA's Preferred Term for this commodity. Azaloxan fumarate bears US NLM identifiers UMLS ID C2346892 and NCI Concept Code C72710. SMILES: C1CCC2C(C1)OC[C@@H](O2)CCN3CCC(CC3)N4CCNC4=O.C(=C/C(=O)O)\C(=O)O.
This classification denotes an antihypertensive agent with the molecular formula C13H33N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43XK6AW58D, chemically known as ((methylimino)diethylene)bis(ethyldimethylammonium) but generally known as azamethonium, which bears US NIH Compound Identifier 9383. European Medicines Agency schedules Azamethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21910. The term AZAMETHONIUM is an International Non-Proprietary Name. As of Q4 2014, AZAMETHONIUM remains the US FDA Preferred Term for this commodity. Azamethonium bears US NLM identifiers UMLS ID C2346893 and NCI Concept Code C73610. SMILES: CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC.
This classification denotes an antihypertensive agent with the molecular formula C13H33N3.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4K6NEI0MSR, chemically known as 3,3,6,9,9-pentamethyl-6-aza-3,9-diazoniaundecan dibromid but more generally known as azamethonium bromide, which bears US NIH Compound Identifier 9382. European Medicines Agency schedules Azamethonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05632MIG. The term AZAMETHONIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule azamethonium bromide under HS 29239000 and SITC 51481. As of Q4 2014, AZAMETHONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Azamethonium bromide bears US NLM identifiers UMLS ID C0104798 and NCI Concept Code C72971. SMILES: CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC.[BR-].[BR-].
This classification denotes an antimicrobial with the molecular formula C24H38N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 875AQ866X1, chemically known as ((5-amino-s-triazol-3-yl)thio)acetic acid, 8-ester with (3as,4r,5s,6r,8r,9ar,10r)-6-ethyloctahydro-5,8-dihydroxy-4,6,9,10-tetramethyl-3a,9-propano-3ah-cyclopentacycloocten-1(4h)-one but more generally known as azamulin, which bears US NIH Compound Identifier 3086060. European Medicines Agency schedules Azamulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05633MIG. The term AZAMULIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). AZAMULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(CC(=O)OC1C2(C3C(C(C(O)C(C1)(CC)C)C)(CCC2C)CCC3=O)C)C1NC([NH]N1)N.
This classification denotes a bronchodilator with the molecular formula C18H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 699725286I chemically known as 5-(1-methyl-4-piperidylidene)-5h-(1)benzopyrano(2,3-b)pyridine but generally known as azanator, which bears US NIH Compound Identifier 38298. European Medicines Agency schedules Azanator in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05634MIG. The term AZANATOR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15). Most nations schedule azanator under HS 29349990 and SITC 51579. As of Q4 2014, AZANATOR remains the US FDA Preferred Term for this commodity. Azanator bears US NLM identifiers UMLS ID C0052750 and NCI Concept Code C72711. SMILES: CN1CCC(=C2C3=C(N=CC=C3)OC4=CC=CC=C42)CC1.
This classification denotes a bronchodilator with the molecular formula C18H18N2O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63ISF1PDWX. The term azanator maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule azanator maleate under HS 29349990 and SITC 51579. As of Q4 2014, AZANATOR MALEATE remains US FDA's Preferred Term for this commodity. Azanator maleate bears US NLM identifiers UMLS ID C2698286 and NCI Concept Code C74219. SMILES: CN1CCC(=C2C3CCCCC3OC4C2CCCN4)CC1.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antiprotozoal agent with the molecular formula C10H10N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YP2Y0DRX4S, chemically known as 2-pyrimidinamine, 4-(2-(1-methyl-5-nitro-1h-imidazol-2-yl)ethenyl)-, (e)- but generally known as azanidazole, which bears US NIH Compound Identifier 6436171. European Medicines Agency schedules Azanidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05635MIG. The term AZANIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules azanidazole in its Anatomical Therapeutic Chemical (ATC) Classification. AZANIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azanidazole under HS 29335995 and SITC 51576. As of Q4 2014, AZANIDAZOLE remains the US FDA Preferred Term for this commodity. Azanidazole bears US NLM identifiers UMLS ID C0052751 and NCI Concept Code C73274. SMILES: CN1C(=CN=C1/C=C/C2=NC(=NC=C2)N)[N+](=O)[O-].
Used for cataracts.
This classification denotes an antipsychotic agent with the molecular formula C19H22FN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19BV78AK7W, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-(2-pyridinyl)-1-piperazinyl)- but generally known as azaperone, which bears US NIH Compound Identifier 15443. Azaperone most often comes in base and dimaleate forms. European Medicines Agency schedules Azaperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05636MIG. The term AZAPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). AZAPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azaperone under HS 29335995 and SITC 51576. As of Q4 2014, AZAPERONE remains the US FDA Preferred Term for this commodity. Azaperone bears US NLM identifiers UMLS ID C0004477 and NCI Concept Code C74187. SMILES: FC1CCC(C(=O)CCCN2CCN(CC2)C2NCCCC2)CC1.
This classification denotes an antipsychotic agent with the molecular formula C19H22FN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19BV78AK7W, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-(2-pyridinyl)-1-piperazinyl)- but more generally known as azaperone, which bears US NIH Compound Identifier 15443. Azaperone most often comes in base and dimaleate forms. European Medicines Agency schedules Azaperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05636MIG. The term AZAPERONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). AZAPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule azaperone for veterinary use under HS 29335995. SMILES: C1CCNC(C1)N2CCN(CC2)CCCC(=O)C3CCC(CC3)F.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TTR0UA2KC, chemically known as 6-allyl-6,7-dihydro-5h-dibenz(c,e)azepine but generally known as azapetine, which bears US NIH Compound Identifier 8966. azapetine most often comes in base, hydrochloride, and phosphate forms. European Medicines Agency schedules Azapetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12970MIG. World Health Organization schedules azapetine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, AZAPETINE remains the US FDA Preferred Term for this commodity. Azapetine bears US NLM identifiers UMLS ID C0052752 and NCI Concept Code C83540. SMILES: N1(CC2C(C3C(C1)CCCC3)CCCC2)CC=C.
This classification denotes an antipsychotic agent with the molecular formula C12H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3H6486135, chemically known as 1,3,4,6,7,11b-hexahydro-2h-pyrazino(2,1-a)isoquinoline but generally known as azaquinzole, which bears US NIH Compound Identifier 179345. European Medicines Agency schedules Azaquinzole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05639MIG. The term AZAQUINZOLE is an International Non-Proprietary Name. Most nations schedule azaquinzole under HS 29335995 and SITC 51576. As of Q4 2014, AZAQUINZOLE remains the US FDA Preferred Term for this commodity. Azaquinzole bears US NLM identifiers UMLS ID C2346894 and NCI Concept Code C74173. SMILES: .
This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C17H20ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77HC7URR9Z, chemically known as 2h-1,4-benzoxazine-8-carboxamide, n-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride but generally known as azasetron, which bears US NIH Compound Identifier 2264. Azasetron most often comes in base and hydrochloride forms. European Medicines Agency schedules Azasetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05642MIG. The term AZASETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). AZASETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azasetron under HS 29349990 and SITC 51579. As of Q4 2014, AZASETRON remains the US FDA Preferred Term for this commodity. Azasetron bears US NLM identifiers UMLS ID C0378974 and NCI Concept Code C73101. SMILES: CLC1CC(C(=O)NC2C3CCN(C2)CC3)C2OCC(=O)N(C2C1)C.
This classification denotes a 5-ht3 receptor antagonist with the molecular formula C17H20ClN3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BSS7XL60S, chemically known as 2h-1,4-benzoxazine-8-carboxamide, n-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride but generally known as azasetron hydrochloride, which bears US NIH Compound Identifier 115000. European Medicines Agency schedules Azasetron hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00639MIG. Most nations schedule azasetron hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, AZASETRON HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Azasetron hydrochloride bears US NLM identifiers UMLS ID C2698288 and NCI Concept Code C77260. SMILES: Clc1cc(C(=O)NC2C3CCN(C2)CC3)c2OCC(=O)N(c2c1)C.Cl.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94Z39NID6C, chemically known as 6,11-dihydro-11-(1-methyl-4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine but generally known as azatadine, which bears US NIH Compound Identifier 19861. Azatadine most often comes in base, dimaleate, and maleate forms. European Medicines Agency schedules Azatadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05645MIG. The term AZATADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules azatadine in its Anatomical Therapeutic Chemical (ATC) Classification. AZATADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azatadine under HS 29333999 and SITC 51574. As of Q4 2014, AZATADINE remains the US FDA Preferred Term for this commodity. Azatadine bears US NLM identifiers UMLS ID C0052759 and NCI Concept Code C77430. SMILES: N1(CC/C(=C2/C3C(CCC4C2NCCC4)CCCC3)CC1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22N2.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F3Q391WTX7, chemically known as 5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-, (z)-2-butenedioate (1:2), but more generally known as azatadine dimaleate, which bears US NIH Compound Identifier 5281066. European Medicines Agency schedules azatadine dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05645MIG. Most nations, for tariff purposes, schedule azatadine dimaleate under HS 29333999. SMILES: CN1CCC(=C2C3NCCCC3CCC4C2CCCC4)CC1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22N2.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F3Q391WTX7, chemically known as 6,11-dihydro-11-(1-methyl-4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine but more generally known as azatadine maleate, which bears US NIH Compound Identifier 19861. European Medicines Agency schedules Azatadine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00640MIG. Most nations, for tariff and trade purposes, schedule azatadine maleate under HS 29333999 and SITC 51574. As of Q4 2014, AZATADINE MALEATE remains US FDA's Preferred Term for this commodity. Azatadine maleate bears US NLM identifiers UMLS ID C0149304 and NCI Concept Code C61642. SMILES: CN1CCC(=C2C3NCCCC3CCC4C2CCCC4)CC1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes an ethylenimine compound with the molecular formula C8H14N5OPS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D57I4Z650L, chemically known as p,p-bis(1-aziridinyl)-n-ethyl-n-1,3,4-thiadiazol-2-ylphosphinic amide but more generally known as azatepa, which bears US NIH Compound Identifier 31321. European Medicines Agency schedules Azatepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05646MIG. The term AZATEPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). AZATEPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule azatepa under HS 29349990 and SITC 51579. SMILES: CCN(C1=NN=CS1)P(=O)(N2CC2)N3CC3.
This classification denotes a purine antagonist and immunosuppressant with the molecular formula C9H6N7O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) AM94R510MS, chemically known as 6-1-methyl,4-nitro,5-imidazolyl mercaptopurine but more generally known as azathioprine sodium, which bears US NIH Compound Identifier 2265. European Medicines Agency schedules Azathioprine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00641MIG. Most nations, for tariff and trade purposes, schedule azathioprine under HS 29335995 and SITC 51576. As of Q4 2014, AZATHIOPRINE remains US FDA's Preferred Term for this commodity. Azathioprine bears US NLM identifiers UMLS ID C0004482 and NCI Concept Code C290. SMILES: CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-].
This classification denotes an anti-infective agent with the molecular formula C9H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F2VW3D43YT, chemically known as 1,9-nonanedioic acid but more generally known as azelaic acid, which bears US NIH Compound Identifier 2266. European Medicines Agency schedules Azelaic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05648MIG. The term AZELAIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules azelaic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule azelaic acid under HS 29171390 and SITC 51389. As of Q4 2014, AZELAIC ACID remains US FDA's Preferred Term for this commodity. Azelaic acid bears US NLM identifiers UMLS ID C0052761 and NCI Concept Code C47407. SMILES: C(CCCC(=O)O)CCCC(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H24ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZQI909440X, chemically known as 1(2h)-phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)- but generally known as azelastine, which bears US NIH Compound Identifier 2267. Azelastine most often comes in base and hydrochloride forms. European Medicines Agency schedules Azelastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05649MIG. The term AZELASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules azelastine in its Anatomical Therapeutic Chemical (ATC) Classification. AZELASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azelastine under HS 29339930 and SITC 51577. As of Q4 2014, AZELASTINE remains the US FDA Preferred Term for this commodity. Azelastine bears US NLM identifiers UMLS ID C0052762 and NCI Concept Code C61643. SMILES: CLC1CCC(CC2NN(C3CCCN(CC3)C)C(=O)C3C2CCCC3)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H24ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0L591QR10I, chemically known as 1(2h)-phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)-, monohydrochloride but more generally known as azelastine hydrochloride, which bears US NIH Compound Identifier 54360. European Medicines Agency schedules Azelastine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00642MIG. Most nations, for tariff and trade purposes, schedule azelastine hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, AZELASTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Azelastine hydrochloride bears US NLM identifiers UMLS ID C0771004 and NCI Concept Code C47408. SMILES: CN1CCCC(CC1)N2C(=O)C3CCCCC3C(N2)CC4CCC(CC4)CL.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H15N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DGB112538O, chemically known as 4h-oxazolo(4,5-d)azepin-2-amine, 6-ethyl-5,6,7,8-tetrahydro-, dihydrochloride but generally known as azepexole, which bears US NIH Compound Identifier 2277. Azepexole most often comes in base and hydrochloride forms. European Medicines Agency schedules Azepexole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05651MIG. The term AZEPEXOLE is an International Non-Proprietary Name. AZEPEXOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azepexole under HS 29349990 and SITC 51579. As of Q4 2014, AZEPEXOLE remains the US FDA Preferred Term for this commodity. Azepexole bears US NLM identifiers UMLS ID C0104808 and NCI Concept Code C72919. SMILES: O1C2CCN(CCC2NC1N)CC.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H15N3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O596V52O42, chemically known as 4h-oxazolo(4,5-d)azepin-2-amine, 6-ethyl-5,6,7,8-tetrahydro-, hydrochloride (1:2), but more generally known as azepexole dihydrochloride, which bears US NIH Compound Identifier 169743. European Medicines Agency schedules azepexole dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05651MIG. Most nations, for tariff purposes, schedule azepexole dihydrochloride under HS 29349990. SMILES: CCN1CCC2C(OC(N2)N)CC1.CL.CL.
This classification denotes an antidepressant agent with the molecular formula C12H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6BB6FW9T8J, chemically known as 2,3,4,5-tetrahydro-1h-(1,4)diazepino(1,2-a)indol but generally known as azepindole, which bears US NIH Compound Identifier 33471. European Medicines Agency schedules Azepindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05652MIG. The term AZEPINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). AZEPINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azepindole under HS 29339940 and SITC 51577. As of Q4 2014, AZEPINDOLE remains the US FDA Preferred Term for this commodity. Azepindole bears US NLM identifiers UMLS ID C2827083 and NCI Concept Code C83542. SMILES: C1=CC2=C(NC=C2)N=C1.
This classification denotes a thyrotropin-releasing hormone analogue with the molecular formula C15H20N6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70J5AWG54Q, chemically known as l-prolinamide, n-((4-oxo-2-azetidinyl)carbonyl)-l-histidyl-, (s)- but generally known as azetirelin, which bears US NIH Compound Identifier 65841. Azetirelin most often comes in base and dihydrate forms. European Medicines Agency schedules Azetirelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05653MIG. The term AZETIRELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). AZETIRELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azetirelin under HS 29371900 and SITC 54154. As of Q4 2014, AZETIRELIN remains the US FDA Preferred Term for this commodity. Azetirelin bears US NLM identifiers UMLS ID C0285719 and NCI Concept Code C74408. SMILES: O=C(N1C(CCC1)C(=O)N)C(NC(=O)C1NC(=O)C1)CC1[NH]CNC1.
This classification denotes an antibiotic with the molecular formula C11H13N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40257685LM, chemically known as acetamide, 2-azido-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, d-threo-(-)- but generally known as azidamfenicol, which bears US NIH Compound Identifier 62858. European Medicines Agency schedules Azidamfenicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05654MIG. The term AZIDAMFENICOL is an International Non-Proprietary Name. World Health Organization schedules azidamfenicol in its Anatomical Therapeutic Chemical (ATC) Classification. AZIDAMFENICOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azidamfenicol under HS 29414000 and SITC 54139. As of Q4 2014, AZIDAMFENICOL remains the US FDA Preferred Term for this commodity. Azidamfenicol bears US NLM identifiers UMLS ID C0771992 and NCI Concept Code C72712. SMILES: C1=CC(=CC=C1C(C(CO)NC(=O)CN=[N+]=[N-])O)[N+](=O)[O-].
This classification denotes a penicillin antibiotic with the molecular formula C16H17N5O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8XDP7L3SL, chemically known as 6-(2-azido-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-4-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as azidocillin, which bears US NIH Compound Identifier 71886. Azidocillin most often comes in base, natrium, and sodium forms. European Medicines Agency schedules Azidocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05655MIG. The term AZIDOCILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules azidocillin in its Anatomical Therapeutic Chemical (ATC) Classification. AZIDOCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azidocillin under HS 29411090 and SITC 54131. As of Q4 2014, AZIDOCILLIN remains the US FDA Preferred Term for this commodity. Azidocillin bears US NLM identifiers UMLS ID C0052772 and NCI Concept Code C76853. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(N=[N]=N)C1CCCCC1.
This classification denotes a penicillin antibiotic C16H16N5O4S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7932098147, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((azidophenylacetyl)amino)-3,3-dimethyl-7-oxo-, monopotassium salt, (2s-(2.alpha.,5.alpha.,6.beta.(s*)))-, but more generally known as azidocillin potassium, which bears US NIH Compound Identifier 71587048. European Medicines Agency schedules Azidocillin potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00643MIG. Most nations, for tariff and trade purposes, schedule azidocillin potassium under HS 29411090 and SITC 54131. As of Q4 2014, AZIDOCILLIN POTASSIUM remains US FDA's Preferred Term for this commodity. Azidocillin potassium bears US NLM identifiers UMLS ID C2986960 and NCI Concept Code C95169. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N=[N+]=[N-])C(=O)[O-])C.[K+].
This classification denotes a penicillin antibiotic with the molecular formula C16H16N5O4S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0XPT6W6670. European Medicines Agency schedules azidocillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00644MIG. The term azidocillin sodium is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule azidocillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, AZIDOCILLIN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N=[N+]=[N-])C(=O)[O-])C.[NA+].
This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B9XT59T7S. European Medicines Agency schedules Zidovudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00153MIG. Zidovudine generally arises in the molecular formula C10H13N5O4. The term ZIDOVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) ZIDOVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Azidothymidine or zidovudine bears US NLM identifiers UMLS ID C0043474 and NCI Concept Code C947. SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-].
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C25H20N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F9NUX55P23, chemically known as 2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid but generally known as Azilsartan, which bears US NIH Compound Identifier 9825285. European Medicines Agency schedules Azilsartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31561. The term AZILSARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, No. 1, 2007, List 57). Most nations schedule azilsartan under HS 29349990 and SITC 51579. As of Q4 2014, AZILSARTAN remains the US FDA Preferred Term for this commodity. Azilsartan bears US NLM identifiers UMLS ID C1958569 and NCI Concept Code C75107. SMILES: CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NC(=O)ON5)C(=O)O.
This classification denotes a cholagogue or choleretic agent with the molecular formula C10H14ClN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ACZ6L64B41, chemically known as 2-((6-chloro-3-pyridazinyl)thio)-n,n-diethylacetamide but generally known as azintamide, which bears US NIH Compound Identifier 71105. European Medicines Agency schedules Azintamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05658MIG. The term AZINTAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). AZINTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azintamide under HS 29339990 and SITC 51577. As of Q4 2014, AZINTAMIDE remains the US FDA Preferred Term for this commodity. Azintamide bears US NLM identifiers UMLS ID C1321999 and NCI Concept Code C74232. SMILES: CCN(CC)C(=O)CSC1=NN=C(C=C1)CL.
This classification denotes a macrolide antibiotic with the molecular formula C38H72N2O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2KLZ20U1M, chemically known as 11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-trihydroxy-13-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one but generally known as azithromycin, which bears US NIH Compound Identifier 55185. Azithromycin most often comes in base and hydrate forms. European Medicines Agency schedules Azithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05660MIG. The term AZITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules azithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. AZITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azithromycin under HS 29419000 and SITC 54139. Azithromycin bears US NLM identifiers UMLS ID C0678143 and NCI Concept Code C28844. SMILES: O(C1C(C(OC2OC(C(O)C(OC)(C2)C)C)C(C(=O)OC(C(O)(C(O)C(N(CC(CC1(O)C)C)C)C)C)CC)C)C)C1OC(CC(N(C)C)C1O)C.
This classification denotes a macrolide antibiotic with the molecular formula C38H72N2O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2KLZ20U1M, chemically known as 11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-trihydroxy-13-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one but more generally known as azithromycin, which bears US NIH Compound Identifier 55185. Azithromycin most often comes in base and hydrate forms. European Medicines Agency schedules Azithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05660MIG. The term AZITHROMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules azithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. AZITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule azithromycin anhydrous under HS 29419000. As of Q4 2014, AZITHROMYCIN ANHYDROUS remains US FDA's Preferred Term for this commodity. Azithromycin anhydrous bears US NLM identifiers UMLS ID C2698292 and NCI Concept Code C76213. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C38H72N2O12.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5FD1131I7S, chemically known as 11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-trihydroxy-13-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one but more generally known as azithromycin dihydrate, which bears US NIH Compound Identifier 55185. European Medicines Agency schedules Azithromycin dihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16399MIG. Most nations, for tariff and trade purposes, schedule azithromycin dihydrate under HS 29419000 and SITC 54139. As of Q4 2014, AZITHROMYCIN DIHYDRATE remains US FDA's Preferred Term for this commodity. Azithromycin dihydrate bears US NLM identifiers UMLS ID C0795582 and NCI Concept Code C76214. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O.O.O.
This classification denotes a penicillin antibiotic with the molecular formula C20H23N5O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HUM6H389W0, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(((((2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-, (2s-(2alpha,5alpha,6beta(s*)))- but generally known as azlocillin, which bears US NIH Compound Identifier 37625. Azlocillin most often comes in base and sodium forms. European Medicines Agency schedules Azlocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05661MIG. The term AZLOCILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules azlocillin in its Anatomical Therapeutic Chemical (ATC) Classification. AZLOCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azlocillin under HS 29411090 and SITC 54131. As of Q4 2014, AZLOCILLIN remains the US FDA Preferred Term for this commodity. Azlocillin bears US NLM identifiers UMLS ID C0004499 and NCI Concept Code C293. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(NC(=O)N1CCNC1=O)C1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C20H22N5O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DWV1EFW947, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(((((2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-, monosodium salt, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as azlocillin sodium, which bears US NIH Compound Identifier 37623. European Medicines Agency schedules Azlocillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00645MIG. Most nations, for tariff and trade purposes, schedule azlocillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, AZLOCILLIN SODIUM remains US FDA's Preferred Term for this commodity. Azlocillin sodium bears US NLM identifiers UMLS ID C0701436 and NCI Concept Code C65243. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)NC(=O)N4CCNC4=O)C(=O)[O-])C.[NA+].
This classification denotes a diuretic with the molecular formula C10H11N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DES29595KX, chemically known as 4-imidazolidinone, 2-imino-3-methyl-1-phenyl- but generally known as azolimine, which bears US NIH Compound Identifier 38684. European Medicines Agency schedules Azolimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05662MIG. The term AZOLIMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). AZOLIMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azolimine under HS 29332990 and SITC 51573. As of Q4 2014, AZOLIMINE remains the US FDA Preferred Term for this commodity. Azolimine bears US NLM identifiers UMLS ID C0604541 and NCI Concept Code C77555. SMILES: CN1C(=O)CN(C1=N)C2=CC=CC=C2.
This classification denotes an antineoplastic antibiotic with the molecular formula C17H23N7O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6TQY580E8M, chemically known as l-norleucine, 6-diazo-n-(6-diazo-n-l-gamma-glutamyl-5-oxo-l-norleucyl)-5-oxo- but generally known as azotomycin, which bears US NIH Compound Identifier 24281. Azotomycin most often comes in base and sodium forms. The term AZOTOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). AZOTOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azotomycin under HS 29419000 and SITC 54139. As of Q4 2014, AZOTOMYCIN remains the US FDA Preferred Term for this commodity. Azotomycin bears US NLM identifiers UMLS ID C0052821 and NCI Concept Code C28803. SMILES: C(CC(=O)NC(CCC(=O)C1N=N1)C(=O)NC(CCC(=O)C2N=N2)C(=O)O)C(C(=O)O)N.
This classification denotes a beta-lactam antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2B4VE5GH8. European Medicines Agency schedules Aztreonam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05664MIG. Aztreonam generally arises in the molecular formula C13H17N5O8S2. The term AZTREONAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) AZTREONAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aztreonam under HS 29419000 and SITC 54139. As of Q4 2014, AZTREONAM remains the US FDA Preferred Term for this commodity. Aztreonam bears US NLM identifiers UMLS ID C0699281 and NCI Concept Code C28845. SMILES: S(=O)(=O)(O)N1C(C(NC(=O)/C(=N\OC(C)(C)C(=O)O)C2NC(SC2)[NH3])C1=O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM119. This VA Drug Class (AM119) classifies this compound as belonging to the group BETA-LACTAMS ANTIMICROBIALS, OTHER.
This classification denotes a beta-lactam antibiotic with the molecular formula C13H17N5O8S2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XNM7LT65NP. European Medicines Agency schedules aztreonam lysine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30777. The term aztreonam lysine is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule aztreonam lysine under HS 29419000 and SITC 54139. As of Q4 2014, AZTREONAM LYSINE remains US FDA's Preferred Term for this commodity. Aztreonam lysine bears US NLM identifiers UMLS ID C2698293 and NCI Concept Code C76021. SMILES: C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2CSC(N2)N.C(CCN)C[C@@H](C(=O)O)N.
This classification denotes a penicillin antibiotic with the molecular formula C21H27N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8GM2J22278, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, 1-((ethoxycarbonyl)oxy)ethyl ester, (2s-(2alpha,5alpha,6beta(s*)))- but generally known as bacampicillin, which bears US NIH Compound Identifier 39849. Bacampicillin most often comes in base and hydrochloride forms. European Medicines Agency schedules Bacampicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05666MIG. The term BACAMPICILLIN is an International Non-Proprietary Name. World Health Organization schedules bacampicillin in its Anatomical Therapeutic Chemical (ATC) Classification. BACAMPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bacampicillin under HS 29411090 and SITC 54131. As of Q4 2014, BACAMPICILLIN remains the US FDA Preferred Term for this commodity. Bacampicillin bears US NLM identifiers UMLS ID C0052865 and NCI Concept Code C65245. SMILES: S1C2N(C(C1(C)C)C(=O)OC(OC(=O)OCC)C)C(=O)C2NC(=O)C(N)C1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C21H27N3O7S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PM034U953T, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, 1-((ethoxycarbonyl)oxy)ethyl ester, monohydrochloride, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as bacampicillin hydrochloride, which bears US NIH Compound Identifier 71429. European Medicines Agency schedules Bacampicillin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00649MIG. Most nations, for tariff and trade purposes, schedule bacampicillin hydrochloride under HS 29411090 and SITC 54131. As of Q4 2014, BACAMPICILLIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bacampicillin hydrochloride bears US NLM identifiers UMLS ID C1122338 and NCI Concept Code C65246. SMILES: CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3CCCCC3)N)(C)C.CL.
This clasification denotes vaccines to treat the bovine variety of the tubercle bacillus, also called Mycobacterium tuberculosis var. bovis or more generally, Calmette-Guerin Bacillus.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58H6RWO52I. European Medicines Agency schedules Bacitracin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00652MIG. Bacitracin generally arises in the molecular formula C66H103N17O16S. The term BACITRACIN is an International Non-Proprietary Name or INN. BACITRACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bacitracin under HS 29419000 and SITC 54139. As of Q4 2014, BACITRACIN remains the US FDA Preferred Term for this commodity. Bacitracin bears US NLM identifiers UMLS ID C0004599 and NCI Concept Code C295. SMILES: CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN)CCCCNC(=O)C(C(C)CC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C2CSC(=N2)C(C(C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4.
This classification denotes an antibiotic with the molecular formula C66H103N17O16S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DDA3RRX0P7, chemically known as l-asparagine, n-(((4r)-2-((1s,2s)-1-amino-2-methylbutyl)-4,5-dihydro-4-thiazolyl)carbonyl)-l-leucyl-d-.alpha.-glutamyl-l-isoleucyl-l-lysyl-d-ornithyl-l-isoleucyl-d-phenylalanyl-l-histidyl-d-.alpha.-aspartyl-, (10->4)-lactam, but more generally known as bacitracin a, which bears US NIH Compound Identifier 65281. European Medicines Agency schedules bacitracin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00652MIG. Most nations, for tariff purposes, schedule bacitracin a under HS 29419000. SMILES:. Bacitracin a bears US NLM identifiers UMLS ID C0052882 and NCI Concept Code C76238.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an antibiotic with the molecular formula C81H117N17O23S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGV6OJ52FT, chemically known as bacitracin methylenebis(2-hydroxybenzoate) (salt), but more generally known as bacitracin methylenedisalicylate, which bears US NIH Compound Identifier 11980094. European Medicines Agency schedules bacitracin methylenedisalicylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00652MIG. Most nations, for tariff purposes, schedule bacitracin methylenedisalicylate under HS 29419000. SMILES:.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes an antibiotic with the molecular formula C66H103N17O16SZn, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89Y4M234ES, chemically known as bacitracins, zinc complex, but more generally known as bacitracin zinc, which bears US NIH Compound Identifier 3083711. European Medicines Agency schedules bacitracin zinc or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00652MIG. Most nations, for tariff purposes, schedule bacitracin zinc under HS 29419000. SMILES:. Bacitracin zinc bears US NLM identifiers UMLS ID C0043483 and NCI Concept Code C28857.
This classification denotes a muscle relaxant with the molecular formula C10H12ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H789N3FKE8, chemically known as hydrocinnamic acid, beta-(aminomethyl)-p-chloro- but generally known as baclofen, which bears US NIH Compound Identifier 2284. European Medicines Agency schedules Baclofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05667MIG. The term BACLOFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules baclofen in its Anatomical Therapeutic Chemical (ATC) Classification. BACLOFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule baclofen under HS 29224995 and SITC 51465. As of Q4 2014, BACLOFEN remains the US FDA Preferred Term for this commodity. Baclofen bears US NLM identifiers UMLS ID C0004609 and NCI Concept Code C28858. SMILES: C1=CC(=CC=C1C(CC(=O)O)CN)CL.
This classification denotes a muscle relaxant with the molecular formula C10H12CLNO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64OSE3996V. Most nations, for tariff and trade purposes, schedule baclofen hydrochloride under HS 29224995. As of Q4 2014, BACLOFEN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Baclofen hydrochloride bears US NLM identifiers UMLS ID C2983921 and NCI Concept Code C90887. SMILES: C1CC(CCC1C(CC(=O)O)CN)CL.CL.
This classification denotes bacterial antibodies.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VMS3A207FA, chemically known as propionic acid, 2-(m-benzoylphenoxy)- but generally known as bakeprofen, which bears US NIH Compound Identifier 179346. European Medicines Agency schedules Bakeprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06089MIG. The term BAKEPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). BAKEPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BAKEPROFEN remains the US FDA Preferred Term for this commodity. Bakeprofen bears US NLM identifiers UMLS ID C2346955 and NCI Concept Code C73077. SMILES: O(C1CC(C(=O)C2CCCCC2)CCC1)C(C)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes a quinolone antibiotic with the molecular formula C20H24FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q022B63JPM, chemically known as 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)-1-piperidinyl)-4-oxo- but generally known as balofloxacin, which bears US NIH Compound Identifier 65958. Balofloxacin most often comes in base and hydrate forms. European Medicines Agency schedules Balofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06091MIG. The term BALOFLOXACIN is an International Non-Proprietary Name. BALOFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule balofloxacin under HS 29334910 and SITC 51575. As of Q4 2014, BALOFLOXACIN remains the US FDA Preferred Term for this commodity. Balofloxacin bears US NLM identifiers UMLS ID C0173239 and NCI Concept Code C72631. SMILES: FC1C(N2CC(NC)CCC2)C(OC)C2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P80AL8J7ZP. European Medicines Agency schedules Balsalazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06092MIG. Balsalazide generally arises in the molecular formula C17H15N3O6. The term BALSALAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) BALSALAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule balsalazide under HS 29270000 and SITC 51485. As of Q4 2014, BALSALAZIDE remains the US FDA Preferred Term for this commodity. Balsalazide bears US NLM identifiers UMLS ID C0052940 and NCI Concept Code C65247. SMILES: O=C(NCCC(=O)O)C1CCC(N/N=C2/C=C(C(=O)C=C2)C(=O)O)CC1.
This classification denotes an anti-infective agent with the molecular formula C17H13N3O6.2NA.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XL6BJI034. European Medicines Agency schedules balsalazide disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35314. The term balsalazide disodium is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule balsalazide disodium under HS 29270000. As of Q4 2014, BALSALAZIDE DISODIUM remains US FDA's Preferred Term for this commodity. Balsalazide disodium bears US NLM identifiers UMLS ID C0595398 and NCI Concept Code C47409. SMILES: C1CC(CCC1C(=O)NCCC(=O)[O-])/N=N/C2CCC(C(C2)C(=O)[O-])O.O.O.[NA+].[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H13N3O6.2Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XL6BJI034, chemically known as benzoic acid, 5-((1e)-(4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt, dihydrate, but more generally known as balsalazide sodium, which bears US NIH Compound Identifier 6504526. European Medicines Agency schedules balsalazide sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06092MIG. Most nations, for tariff purposes, schedule balsalazide sodium under HS 29270000. SMILES: C1CC(CCC1C(=O)NCCC(=O)[O-])/N=N/C2CCC(C(C2)C(=O)[O-])O.O.O.[NA+].[NA+].
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers 8P5F881OCY (basic) and DIK0395679 (the viscous chemically-neutral liquid thereof), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 530967 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Fabales, Family Fabaceae, Genus Myroxylon L. f., Species Myroxylon balsamum (L.), Variety Myroxylon balsamum var. pereirae, more commonly known as MYROXYLON or, as here, BALSAM OF PERU. Balsam peru bears the USDA PLANTS Database Identifier MYBAP. European Medicines Agency schedules balsam peru in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB12210MIG, SUB14818MIG, and SUB61023. As of Q4 2014, BALSAM PERU remains the US FDA Preferred Term for this commodity. Balsam peru bears US NLM identifiers UMLS ID C0070477 and NCI Concept Code C66361. SMILES: NONE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a polysaccharide antibiotic with the molecular formula C70H109N4O35P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PP922A42V2, chemically known as (2S,3S,4R,5R,6R)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-methyl-5-[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopenten-1-yl)carbamoyl]oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-4-carbamoyloxy-3-hydroxy-6-[hydroxy-[(2R)-2-hydroxy-3-oxo-3-[(3E,7E,14E)-4,9,9,15,19-pentamethyl-12-methylideneicosa-3,7,14,18-tetraenoxy]propoxy]phosphoryl]oxy-3-methyloxane-2-carboxylic acid but generally known as Bambermycin, which bears US NIH Compound Identifier 6433554. BAMBERMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bambermycin under HS 29419000 and SITC 54139. SMILES: CC1C(C(C(C(O1)OC2C(OC(C(C2O)NC(=O)C)OC3C(C(C(OC3OP(=O)(O)OCC(C(=O)OCCC=C(C)CCC=CC(C)(C)CCC(=C)CC=C(C)CCC=C(C)C)O)C(=O)O)(C)O)OC(=O)N)COC4C(C(C(C(O4)CO)O)O)O)NC(=O)C)O)OC5C(C(C(C(O5)C(=O)NC6=C(CCC6=O)O)O)O)O.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y1850G1OVC. European Medicines Agency schedules Bambuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06095MIG. Bambuterol generally arises in the molecular formula C18H29N3O5. The term BAMBUTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) BAMBUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bambuterol under HS 29242995 and SITC 51479. As of Q4 2014, BAMBUTEROL remains the US FDA Preferred Term for this commodity. Bambuterol bears US NLM identifiers UMLS ID C0052944 and NCI Concept Code C81692. SMILES: OC(CNC(C)(C)C)C1CC(OC(=O)N(C)C)CC(OC(=O)N(C)C)C1.
This classification denotes a beta-adrenergic agonist with the molecular formula C12H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y08ZFJ9TFK, chemically known as benzyl alcohol, alpha-((butylamino)methyl)-p-hydroxy- but generally known as bamethan, which bears US NIH Compound Identifier 2292. Bamethan most often comes in base and sulfate forms. European Medicines Agency schedules Bamethan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06096MIG. The term BAMETHAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules bamethan in its Anatomical Therapeutic Chemical (ATC) Classification. BAMETHAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bamethan under HS 29225000 and SITC 51467. As of Q4 2014, BAMETHAN remains the US FDA Preferred Term for this commodity. Bamethan bears US NLM identifiers UMLS ID C0004718 and NCI Concept Code C76116. SMILES: CCCCNCC(C1=CC=C(C=C1)O)O.
This classification denotes a beta-adrenergic agonist with the molecular formula 2C12H19NO2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W2L3E1W827, chemically known as benzyl alcohol, alpha-((butylamino)methyl)-p-hydroxy-, sulfate (2:1) (salt) but more generally known as bamethan sulfate, which bears US NIH Compound Identifier 21955. European Medicines Agency schedules Bamethan sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00660MIG. Most nations, for tariff and trade purposes, schedule bamethan sulfate under HS 29225000 and SITC 51467. As of Q4 2014, BAMETHAN SULFATE remains US FDA's Preferred Term for this commodity. Bamethan sulfate bears US NLM identifiers UMLS ID C0350190 and NCI Concept Code C76117. SMILES: CCCCNCC(C1CCC(CC1)O)O.CCCCNCC(C1CCC(CC1)O)O.OS(=O)(=O)O.
This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTY15D026H. European Medicines Agency schedules Bamifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06097MIG. Bamifylline generally arises in the molecular formula C20H27N5O3. The term BAMIFYLLINE is an International Non-Proprietary Name or INN. BAMIFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bamifylline under HS 29395900 and SITC 54145. As of Q4 2014, BAMIFYLLINE remains the US FDA Preferred Term for this commodity. Bamifylline bears US NLM identifiers UMLS ID C0052945 and NCI Concept Code C76573. SMILES: O=C1N(C(=O)N(C2NC(N(CCN(CCO)CC)C12)CC1CCCCC1)C)C.
This classification denotes a bronchodilator with the molecular formula C20H27N5O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66466QLM3S, chemically known as 1h-purine-2,6-dione, 7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)-3,7-dihydro-1,3-dimethyl-8-(phenylmethyl)-, monohydrochloride but more generally known as bamifylline hydrochloride, which bears US NIH Compound Identifier 68549. The base compound, Bamifylline, most often comes in base and hydrochloride forms. European Medicines Agency schedules Bamifylline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12981MIG. Most nations, for tariff and trade purposes, schedule bamifylline hydrochloride under HS 29395900 and SITC 54145. As of Q4 2014, BAMIFYLLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bamifylline hydrochloride bears US NLM identifiers UMLS ID C0771398 and NCI Concept Code C76574. SMILES: CCN(CCN1C(NC2C1C(=O)N(C(=O)N2C)C)CC3CCCCC3)CCO.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y6BHZ28O92, chemically known as 4-piperidinamine, 1-methyl-n-phenyl-n-(phenylmethyl)- but generally known as bamipine, which bears US NIH Compound Identifier 72075. Bamipine most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Bamipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06098MIG. The term BAMIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules bamipine in its Anatomical Therapeutic Chemical (ATC) Classification. BAMIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bamipine under HS 29333999 and SITC 51574. As of Q4 2014, BAMIPINE remains the US FDA Preferred Term for this commodity. Bamipine bears US NLM identifiers UMLS ID C0052946 and NCI Concept Code C76058. SMILES: N1(CCC(N(CC2CCCCC2)C2CCCCC2)CC1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RG2UZ22FEZ, chemically known as 4-piperidinamine, 1-methyl-n-phenyl-n-(phenylmethyl)-, dihydrochloride, but more generally known as bamipine dihydrochloride, which bears US NIH Compound Identifier 109130. European Medicines Agency schedules bamipine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06098MIG. Most nations, for tariff purposes, schedule bamipine dihydrochloride under HS 29333999. Bamipine dihydrochloride bears US NLM identifiers UMLS ID C0953071 and NCI Concept Code C103224. SMILES: CN1CCC(CC1)N(CC2CCCCC2)C3CCCCC3.CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4K9380352I, chemically known as piperidine, 4-(n-benzyl-n-phenylamino)-1-methyl-, dihydrochloride but more generally known as bamipine hydrochloride, which bears US NIH Compound Identifier 109130. European Medicines Agency schedules Bamipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00662MIG. Most nations, for tariff and trade purposes, schedule bamipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BAMIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCC(CC1)N(CC2CCCCC2)C3CCCCC3.CL.
This classification denotes a histamine-1 receptor antagonist C19H24N2.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K8KNJ07D8, chemically known as propanoic acid, 2-hydroxy-, compd. with 1-methyl-n-phenyl-n-(phenylmethyl)-4-piperidinamine (1:1), but more generally known as bamipine lactate, which bears US NIH Compound Identifier 11462853. European Medicines Agency schedules Bamipine lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00663MIG. Most nations, for tariff and trade purposes, schedule bamipine lactate under HS 29333999 and SITC 51574. As of Q4 2014, BAMIPINE LACTATE remains US FDA's Preferred Term for this commodity. Bamipine lactate bears US NLM identifiers UMLS ID C0771814 and NCI Concept Code C97686. SMILES: CC(C(=O)O)O.CN1CCC(CC1)N(CC2CCCCC2)C3CCCCC3.
This classification denotes a histamine-1 receptor antagonist C19H24N2.C7H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2D7769LY0R, chemically known as benzoic acid, 2-hydroxy-, compd. with 1-methyl-n-phenyl-n-(phenylmethyl)-4-piperidinamine, but more generally known as bamipine salicylate, which bears US NIH Compound Identifier 6453348. European Medicines Agency schedules Bamipine salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12982MIG. Most nations, for tariff and trade purposes, schedule bamipine salicylate under HS 29333999 and SITC 51574. As of Q4 2014, BAMIPINE SALICYLATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCC(CC1)N(CC2CCCCC2)C3CCCCC3.C1CCC(C(C1)C(=O)O)O.
This classification denotes an antiprotozoal agent with the molecular formula C17H20N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DE766VIG6, chemically known as 5-((2,4-diamino-5-pyrimidinyl)methyl)-8-(dimethylamino)-7-methylquinoline but more generally known as baquiloprim, which bears US NIH Compound Identifier 72121. European Medicines Agency schedules Baquiloprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06100MIG. The term BAQUILOPRIM is an International Non-Proprietary Name. BAQUILOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an anticonvulsant agent with the molecular formula C12H12N2O3.C10H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 291GX1YB65, chemically known as 1,1-cyclohexyl-2-methylaminopropane-5,5-phenylethylbarbiturate but generally known as barbexaclon, which bears US NIH Compound Identifier 71196. European Medicines Agency schedules Barbexaclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06101MIG. The term BARBEXACLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules barbexaclon in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule barbexaclone under HS 29335400 and SITC kg. As of Q4 2014, BARBEXACLONE remains the US FDA Preferred Term for this commodity. Barbexaclone bears US NLM identifiers UMLS ID C0105205 and NCI Concept Code C77998. SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2.CC(CC1CCCCC1)NC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN309. This VA Drug Class (CN309) classifies this compound as belonging to the group SEDATIVES/HYPNOTICS, OTHER.
This classification denotes a barbiturate with the molecular formula C8H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5WZ53ENE2P, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl- (9ci) but generally known as barbital, which bears US NIH Compound Identifier 2294. Barbital most often comes in base, n-glucoside, and sodium forms. European Medicines Agency schedules Barbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06102MIG. The term BARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules barbital in its Anatomical Therapeutic Chemical (ATC) Classification. BARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Barbital or barbitone bears US NLM identifiers UMLS ID C0004743 and NCI Concept Code C76526. SMILES: O=C1NC(=O)NC(=O)C1(CC)CC.
This classification denotes a barbiturate with the molecular formula C8H11N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 275L5M93QS, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl-, monosodium salt (9ci) but more generally known as barbital sodium, which bears US NIH Compound Identifier 8943. European Medicines Agency schedules Barbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06103MIG. The term BARBITAL SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations, for tariff and trade purposes, schedule barbital sodium under HS 29335310. As of Q4 2014, BARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Barbital sodium bears US NLM identifiers UMLS ID C0770386 and NCI Concept Code C77627. SMILES: CCC1(C(=O)NC(=O)[N-]C1=O)CC.[NA+].
Baricitinib is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
A substance that is introduced into or around a structure and, because of the difference in absorption of X-rays by the contrast medium and the surrounding tissues, allows radiographic visualisation of the structure. Brand Name Liqui-Coat HD, Readi-Cat, e
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX101. This VA Drug Class (DX101) classifies this compound as belonging to the group NON-IONIC CONTRAST MEDIA.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C27H29N7O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UIF43N1HSV, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-((3-(2-furanylmethyl)-3h-imidazo(4,5-b)pyridin-2-yl)amino)-1-piperidinyl)ethyl)-2-methyl-;(2) 3-(2-(4-((3-furfuryl-3h-imidazo(4,5-b)pyridin-2-yl)amino)piperidino)ethyl)-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one but generally known as barmastine, which bears US NIH Compound Identifier 71300. European Medicines Agency schedules Barmastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06104MIG. The term BARMASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). BARMASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule barmastine under HS 29349990 and SITC 51579. As of Q4 2014, BARMASTINE remains the US FDA Preferred Term for this commodity. Barmastine bears US NLM identifiers UMLS ID C2346963 and NCI Concept Code C73043. SMILES: O=C1N2C(NC(C1CCN1CCC(NC3N(C4NCCCC4N3)CC3OCCC3)CC1)C)CCCC2.
This classification denotes a calcium channel blocker with the molecular formula C27H29N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2VBY96ASWJ, chemically known as (+)-(3s,4s)-1-benzyl-3-pyrrolidinyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate but generally known as barnidipine, which bears US NIH Compound Identifier 65884. Barnidipine most often comes in base and hydrochloride forms. European Medicines Agency schedules Barnidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06105MIG. The term BARNIDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules barnidipine in its Anatomical Therapeutic Chemical (ATC) Classification. BARNIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule barnidipine under HS 29333999 and SITC 51574. As of Q4 2014, BARNIDIPINE remains the US FDA Preferred Term for this commodity. Barnidipine bears US NLM identifiers UMLS ID C0078703 and NCI Concept Code C73024. SMILES: O(C1CCN(C1)Cc1ccccc1)C(=O)C1=C(NC(=C(C1c1cc([N](=O)O)ccc1)C(=O)OC)C)C.
This classification denotes a calcium channel blocker with the molecular formula C27H29N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LZ6R3AEM1, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-pyrrolidinyl ester, monohydrochloride, (s-(r*,r*))- but more generally known as barnidipine hydrochloride, which bears US NIH Compound Identifier 163733. European Medicines Agency schedules Barnidipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00671MIG. Most nations, for tariff and trade purposes, schedule barnidipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BARNIDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1=C([C@@H](C(=C(N1)C)C(=O)O[C@H]2CCN(C2)CC3CCCCC3)C4CCCC(C4)[N+](=O)[O-])C(=O)OC.CL.
This classification denotes an antiarrhythmic agent with the molecular formula C22H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 14NFL30YOH, chemically known as 4-((1,3-dihydro-6-methyl-4-benzylfuro(3,4-c)pyridin-7-yl)oxy)-n-isopropylbutylamine monohydrochloride but more generally known as barucainide, which bears US NIH Compound Identifier 146794. European Medicines Agency schedules Barucainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06106MIG. The term BARUCAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). BARUCAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule barucainide under HS 29349990 and SITC 51579. As of Q4 2014, BARUCAINIDE remains US FDA's Preferred Term for this commodity. Barucainide bears US NLM identifiers UMLS ID C0052988 and NCI Concept Code C72575. SMILES: CL.O1CC2C(C1)C(NC(C2OCCCCNC(C)C)C)CC1CCCCC1.
This classification denotes an antifungal agent with the molecular formula C60H92N8O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VV0USO6I6U, chemically known as valine, 3-hydroxy-n-(n-(n-(n-(1-(n-(n-(n-(2-hydroxy-3-methyl-1-oxopentyl)-n-methylvalyl)phenylalanyl)-n-methylphenylalanyl)prolyl)alloisoleucyl)-n-methylvalyl)leucyl)-n-methyl-, alpha-1-lactone but generally known as basifungin, which bears US NIH Compound Identifier 72050. European Medicines Agency schedules Basifungin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06107MIG. The term BASIFUNGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). BASIFUNGIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule basifungin under HS 29419000 and SITC 54139. As of Q4 2014, BASIFUNGIN remains the US FDA Preferred Term for this commodity. Basifungin bears US NLM identifiers UMLS ID C0382347 and NCI Concept Code C90723. SMILES: O=C1NC(C(CC)C)C(=O)N(C(C(C)C)C(=O)NC(CC(C)C)C(=O)N(C(C(O)(C)C)C(=O)OC(C(CC)C)C(=O)N(C(C(C)C)C(=O)NC(C(=O)N(C(C(=O)N2C1CCC2)CC1CCCCC1)C)CC1CCCCC1)C)C)C.
This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6378H9844N1698O1997S48, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9927MT646M, more generally known as basiliximab. European Medicines Agency schedules basiliximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12468MIG. The term BASILIXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 11, No. 3 1997, list 38. BASILIXIMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule basiliximab under HS 30021091 and SITC 54163. As of Q4 2014, BASILIXIMAB remains US FDA's Preferred Term for this commodity. Basiliximab bears US NLM identifiers UMLS ID C0676831 and NCI Concept Code C52186. SMILES: NONE.
This classification denotes an antiemetic agent with the molecular formula C17H26ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1AT99K728N, chemically known as benzamide, 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-(1-methyl-2-oxopropoxy)- but generally known as batanopride, which bears US NIH Compound Identifier 59692. Batanopride most often comes in base and hydrochloride forms. European Medicines Agency schedules Batanopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06108MIG. The term BATANOPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). BATANOPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule batanopride under HS 29242995 and SITC 51479. As of Q4 2014, BATANOPRIDE remains the US FDA Preferred Term for this commodity. Batanopride bears US NLM identifiers UMLS ID C0053879 and NCI Concept Code C1021. SMILES: CLC1CC(C(=O)NCCN(CC)CC)C(OC(C)C(=O)C)CC1N.
This classification denotes an antipsychotic agent with the molecular formula C16H20N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, P71TE299SG chemically known as 11h-(1,2,4)triazolo(1,5-c)(1,3)benzodiazepine, 2-methyl-5-(4-methyl-1-piperazinyl)- but generally known as batelapine, which bears US NIH Compound Identifier 60717. European Medicines Agency schedules Batelapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06110MIG. The term BATELAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31. ). Most nations schedule batelapine under HS 29335995 and SITC 51576. As of Q4 2014, BATELAPINE remains the US FDA Preferred Term for this commodity. Batelapine bears US NLM identifiers UMLS ID C0165561 and NCI Concept Code C76436. SMILES: CC1=NN2C(=N1)CC3=CC=CC=C3N=C2N4CCN(CC4)C.
This classification denotes the maleate form of an antipsychotic agent with the molecular structure C16H20N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, P71TE299SG chemically known as 11h-(1,2,4)triazolo(1,5-c)(1,3)benzodiazepine, 2-methyl-5-(4-methyl-1-piperazinyl)-, but more commonly known as batelapine, which bears US NIH Compound Identifier 60717. European Medicines Agency schedules Batelapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06110MIG. The term BATELAPINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, no. 3 1991, list 31. ). Most nations, for tariff and trade purposes, schedule batelapine maleate under HS 29335995 and SITC 51576. As of Q4 2014, BATELAPINE MALEATE remains US FDA's Preferred Term for this commodity. Batelapine maleate bears US NLM identifiers UMLS ID C2698335 and NCI Concept Code C76437. SMILES: CC1NC2N(N1)C(=NC3CCCCC3C2)N4CCN(CC4)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EZY3PL8Q0M. European Medicines Agency schedules Batoprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05670MIG. Batoprazine generally arises in the molecular formula C13H14N2O2. The term BATOPRAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) BATOPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule batoprazine under HS 29349990 and SITC 51579. As of Q4 2014, BATOPRAZINE remains the US FDA Preferred Term for this commodity. Batoprazine bears US NLM identifiers UMLS ID C2346967 and NCI Concept Code C73283. SMILES: O1C2C(N3CCNCC3)CCCC2CCC1=O.
This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47RYF40GA9. European Medicines Agency schedules Batroxobin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00675MIG. The term BATROXOBIN is an International Non-Proprietary Name (see WHO INN reference publication, Volume 27, No. 10 1973, List 13.). World Health Organization schedules camostat in its Anatomical Therapeutic Chemical (ATC) Classification. BATROXOBIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Batroxobin under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, BATROXOBIN remains the US FDA Preferred Term for this commodity. . Batroxobin bears US NLM identifiers UMLS ID C0035158 and NCI Concept Code C79483.
This classification denotes a selective estrogen receptor modulator with the molecular formula C30H34N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q16TT9C5BK, chemically known as 1h-indol-5-ol, 1-((4-(2-(hexahydro-1h-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl- but generally known as bazedoxifene, which bears US NIH Compound Identifier 154257. Bazedoxifene most often comes in basic and acetate forms. European Medicines Agency schedules Bazedoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26694. World Health Organization schedules bazedoxifene in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule bazedoxifene under HS 29339990 and SITC 51577. As of Q4 2014, BAZEDOXIFENE remains the US FDA Preferred Term for this commodity. Bazedoxifene bears US NLM identifiers UMLS ID C2346970 and NCI Concept Code C73598. SMILES: O(CCN1CCCCCC1)C1CCC(CN2C(C(C3C2CCC(O)C3)C)C2CCC(O)CC2)CC1.
This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C17H19N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NU8Y4C529J, chemically known as 4-pyridazinecarbonitrile, 3-((2-(4-morpholinyl)ethyl)amino)-6-phenyl- but generally known as bazinaprine, which bears US NIH Compound Identifier 72119. European Medicines Agency schedules Bazinaprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05672MIG. The term BAZINAPRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). BAZINAPRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bazinaprine under HS 29349990 and SITC 51579. As of Q4 2014, BAZINAPRINE remains the US FDA Preferred Term for this commodity. Bazinaprine bears US NLM identifiers UMLS ID C2346971 and NCI Concept Code C72719. SMILES: O1CCN(CC1)CCNc1nnc(cc1C#N)c1ccccc1.
This classification denotes an antiparasitic agent with the molecular formula C22H28N2O2S, chemically known as 1-((2-(Ethyl(2-hydroxy-2-methylpropyl)amino)ethyl)amino)-4-methylthioxanthen-9-one but generally known as becanthone, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A6P8OYN3G5. The term becanthone is a United States Adopted Name designation. As of Q4 2014, BECANTHONE remains the US FDA Preferred Term for this commodity. Becanthone bears US NLM identifiers UMLS ID C2698337 and NCI Concept Code C79918. SMILES: CCN(CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O)CC(C)(C)O.
This classification denotes a platelet-derived growth factor with the molecular formula C532H892N162O153S9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B56C968OA, more generally known as becaplermin. European Medicines Agency schedules becaplermin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00680MIG. The term BECAPLERMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36. BECAPLERMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Becaplermin under HS 29371900 and SITC 54154. SMILES:. As of Q4 2014, BECAPLERMIN remains the US FDA Preferred Term for this commodity. . Becaplermin bears US NLM identifiers UMLS ID C0379135 and NCI Concept Code C1668.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K90ZOR23P1. European Medicines Agency schedules Beciparcil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05674MIG. Beciparcil generally arises in the molecular formula C12H13NO3S2. The term BECIPARCIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) BECIPARCIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule beciparcil under HS 29349990 and SITC 51579. As of Q4 2014, BECIPARCIL remains the US FDA Preferred Term for this commodity. Beciparcil bears US NLM identifiers UMLS ID C0761070 and NCI Concept Code C73225. SMILES: C1C(C(C(C(S1)SC2=CC=C(C=C2)C#N)O)O)O.
This classification denotes an anticonvulsant agent with the molecular formula C10H12ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5N0ALI65V, chemically known as propionamide, n-benzyl-3-chloro- but generally known as beclamide, which bears US NIH Compound Identifier 10391. European Medicines Agency schedules Beclamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05675MIG. The term BECLAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules beclamide in its Anatomical Therapeutic Chemical (ATC) Classification. BECLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule beclamide under HS 29242995 and SITC 51479. As of Q4 2014, BECLAMIDE remains the US FDA Preferred Term for this commodity. Beclamide bears US NLM identifiers UMLS ID C0053067 and NCI Concept Code C75160. SMILES: C1=CC=C(C=C1)CNC(=O)CCCL.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5361814USE. European Medicines Agency schedules Becliconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05676MIG. Becliconazole generally arises in the molecular formula C18H12CL2N2O. The term BECLICONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) BECLICONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule becliconazole under HS 29349990 and SITC 51579. As of Q4 2014, BECLICONAZOLE remains the US FDA Preferred Term for this commodity. Becliconazole bears US NLM identifiers UMLS ID C2346978 and NCI Concept Code C72954. SMILES: CLC1C(C(N2CCNC2)C2OC3C(C2)CC(CL)CC3)CCCC1.
Beclometasone dipropionate/formoterol fumarate is an inhalable fixed-dose combination drug used to treat chronic obstructive pulmonary disease and asthma.
Beclomethasone/formoterol/glycopyrronium combination at 100:6:12.5 combination ratio was a balanced drug mixture leading to very strong synergistic effect on relaxation of medium bronchi and middle to very strong synergy in small airways.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29ClO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KGZ1SLC28Z, chemically known as 9-chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione but generally known as beclometasone, which bears US NIH Compound Identifier 20469. Beclometasone most often comes in base, 17,21-dipropionate, and propionate forms. European Medicines Agency schedules Beclometasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05678MIG. The term BECLOMETASONE is an International Non-Proprietary Name. World Health Organization schedules beclometasone in its Anatomical Therapeutic Chemical (ATC) Classification. BECLOMETASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC12C(C3C(C(O)(C(C3)C)C(=O)CO)(CC1O)C)CCC1=CC(=O)C=CC21C.
Beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide is an inhalable fixed-dose combination drug used to treat chronic obstructive pulmonary disease
Definition: This classification is for a diarylquinolone used in the treatment of multi-drug resistant tuberculosis. BEDAQUILINE has a US FDA Unique Ingredient Identifier of 78846I289Y.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C15H18F3NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4H75PAD8M3, chemically known as 2-oxazolidinone, 5-(methoxymethyl)-3-(4-(4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-, (r,(r*,r*))- but generally known as befloxatone, which bears US NIH Compound Identifier 60824. European Medicines Agency schedules Befloxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05681MIG. The term BEFLOXATONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). BEFLOXATONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule befloxatone under HS 29349990 and SITC 51579. As of Q4 2014, BEFLOXATONE remains the US FDA Preferred Term for this commodity. Befloxatone bears US NLM identifiers UMLS ID C0289919 and NCI Concept Code C77519. SMILES: FC(F)(F)C(O)CCOc1ccc(N2CC(OC2=O)COC)cc1.
This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C16H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 418546MT3A, chemically known as ketone, 7-(2-hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl but generally known as befunolol, which bears US NIH Compound Identifier 2309. Befunolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Befunolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05682MIG. The term BEFUNOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules befunolol in its Anatomical Therapeutic Chemical (ATC) Classification. BEFUNOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule befunolol under HS 29329985 and SITC 51569. As of Q4 2014, BEFUNOLOL remains the US FDA Preferred Term for this commodity. Befunolol bears US NLM identifiers UMLS ID C0053071 and NCI Concept Code C73021. SMILES: O(CC(O)CNC(C)C)C1C2OC(CC2CCC1)C(=O)C.
This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C16H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B03Z2VY37I, chemically known as ethanone, 1-(7-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)-, hydrochloride but more generally known as befunolol hydrochloride, which bears US NIH Compound Identifier 38286. European Medicines Agency schedules Befunolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00686MIG. Most nations, for tariff and trade purposes, schedule befunolol hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, BEFUNOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NCC(COC1CCCC2C1OC(C2)C(=O)C)O.CL.
This classification denotes a phosphodiesterase inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 787AQ35GHR. European Medicines Agency schedules Befuraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05683MIG. Befuraline generally arises in the molecular formula C20H20N2O2. The term BEFURALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) BEFURALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule befuraline under HS 29349990 and SITC 51579. As of Q4 2014, BEFURALINE remains the US FDA Preferred Term for this commodity. Befuraline bears US NLM identifiers UMLS ID C0053072 and NCI Concept Code C72720. SMILES: o1c(C(=O)N2CCN(CC2)Cc2ccccc2)cc2c1cccc2.
This classification denotes a phosphodiesterase inhibitor and antidepressant agent with the molecular formula C20H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AF205SN5K, chemically known as piperazine, 1-(2-benzofuranylcarbonyl)-4-(phenylmethyl)-, monohydrochloride but more generally known as befuraline hydrochloride, which bears US NIH Compound Identifier 73346. The base compound, Befuraline, most often comes in base and hydrochloride forms. Most nations, for tariff and trade purposes, schedule befuraline hydrochloride under HS 29349990. As of Q4 2014, BEFURALINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)CN2CCN(CC2)C(=O)C3CC4CCCCC4O3.CL.
This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 15JT14C3GI chemically known as (1r,2s,3s,4r,6s)-4,6-diamino-3-((3-amino-3-deoxy-.alpha.-d-glucopyranosyl)oxy)-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranoside but generally known as bekanamycin, which bears US NIH Compound Identifier 816. European Medicines Agency schedules Bekanamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05684MIG. The term BEKANAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11. ). Most nations schedule bekanamycin under HS 29419000 and SITC 54139. As of Q4 2014, BEKANAMYCIN remains the US FDA Preferred Term for this commodity. Bekanamycin bears US NLM identifiers UMLS ID C0053076 and NCI Concept Code C65248. SMILES: C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)N)N.
This classification denotes the sulfate form of an aminoglycoside antibiotic with the molecular structure C18H37N5O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 15JT14C3GI chemically known as (1r,2s,3s,4r,6s)-4,6-diamino-3-((3-amino-3-deoxy-.alpha.-d-glucopyranosyl)oxy)-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranoside, but more commonly known as bekanamycin, which bears US NIH Compound Identifier 816. European Medicines Agency schedules Bekanamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05684MIG. The term BEKANAMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , no. 10 1971, list 11. ). Most nations, for tariff and trade purposes, schedule bekanamycin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, BEKANAMYCIN SULFATE remains US FDA's Preferred Term for this commodity. Bekanamycin sulfate bears US NLM identifiers UMLS ID C0888075 and NCI Concept Code C76153. SMILES: C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N.OS(=O)(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C22H22FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DN0TK4892, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(2-((1s,5r,6s)-6-(4-fluorophenyl)-3-azabicyclo(3.2.0)hept-3-yl)ethyl)- but generally known as belaperidone, which bears US NIH Compound Identifier 184841. European Medicines Agency schedules Belaperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05685MIG. The term BELAPERIDONE is an International Non-Proprietary Name. BELAPERIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule belaperidone under HS 29335995 and SITC 51576. As of Q4 2014, BELAPERIDONE remains the US FDA Preferred Term for this commodity. Belaperidone bears US NLM identifiers UMLS ID C2698342 and NCI Concept Code C78794. SMILES: FC1CCC(C2C3C(C2)CN(C3)CCN2C(=O)C3C([NH]C2=O)CCCC3)CC1.
This classification denotes an immunosuppressant with the molecular formula C3508H5440N922O1096S32, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E3B2GI648A, more generally known as belatacept. European Medicines Agency schedules belatacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20603. The term BELATACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 1, 2008, list 59. BELATACEPT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule Belatacept under HS 30021095 and SITC 54163. SMILES:. As of Q4 2014, BELATACEPT remains US FDA's Preferred Term for this commodity. . Belatacept bears US NLM identifiers UMLS ID C1619962 and NCI Concept Code C80255.
This classification denotes a calcium channel blocker with the molecular formula C27H50O7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W91CMS1V7Z, chemically known as phosphonic acid, (2-(2-phenoxyethyl)-1,3-propanediyl)bis-, tetrabutyl ester but generally known as belfosdil, which bears US NIH Compound Identifier 72122. European Medicines Agency schedules Belfosdil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05687MIG. The term BELFOSDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). BELFOSDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BELFOSDIL remains the US FDA Preferred Term for this commodity. Belfosdil bears US NLM identifiers UMLS ID C0053078 and NCI Concept Code C76023. SMILES: P(=O)(OCCCC)(OCCCC)CC(CP(=O)(OCCCC)OCCCC)CCOc1ccccc1.
This classification denotes a monoclonal antibody with the molecular formula C6714H10428O2102S52, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73B0K5S26A, more generally known as belimumab. European Medicines Agency schedules belimumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25607. The term BELIMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 1, 2004, list 51. Most nations, for tariff and trade purposes, schedule Belimumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, BELIMUMAB remains US FDA's Preferred Term for this commodity. . Belimumab bears US NLM identifiers UMLS ID C1723401 and NCI Concept Code C91385.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes an anti-lipidemic agent with the molecular formula C18H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S4YR4X39CA, chemically known as acetamide, n-(phenylmethoxy)-n-(3-phenylpropyl)- but generally known as beloxamide, which bears US NIH Compound Identifier 27155. European Medicines Agency schedules Beloxamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05688MIG. The term BELOXAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). BELOXAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule beloxamide under HS 29280090 and SITC 51486. As of Q4 2014, BELOXAMIDE remains the US FDA Preferred Term for this commodity. Beloxamide bears US NLM identifiers UMLS ID C0053081 and NCI Concept Code C78050. SMILES: O(N(CCCc1ccccc1)C(=O)C)Cc1ccccc1.
This classification denotes an antidepressant agent with the molecular formula C19H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G905IN29U4, chemically known as ( -)-cis-1,3,4,13b-tetrahydro-2,10-dimethyldibenz(2,3:6,7)oxepino(4,5-c)pyridin-4a(2h)-ol but generally known as beloxepin, which bears US NIH Compound Identifier 166560. European Medicines Agency schedules Beloxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05689MIG. The term BELOXEPIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). BELOXEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule beloxepin under HS 29349990 and SITC 51579. As of Q4 2014, BELOXEPIN remains the US FDA Preferred Term for this commodity. Beloxepin bears US NLM identifiers UMLS ID C2698343 and NCI Concept Code C78007. SMILES: OC12C(CN(CC1)C)c1c(Oc3c2cccc3)c(ccc1)C.
This classification denotes a cardiotonic agent with the molecular formula C11H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29J330V3XV, chemically known as 2(1h)-quinazolinone, 5,6-dimethoxy-4-methyl- but generally known as bemarinone, which bears US NIH Compound Identifier 58575. Bemarinone most often comes in base and hydrochloride forms. European Medicines Agency schedules Bemarinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05690MIG. The term BEMARINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). BEMARINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bemarinone under HS 29335995 and SITC 51576. As of Q4 2014, BEMARINONE remains the US FDA Preferred Term for this commodity. Bemarinone bears US NLM identifiers UMLS ID C0634220 and NCI Concept Code C76025. SMILES: CC1=C2C(=NC(=O)N1)C=CC(=C2OC)OC.
This classification denotes a cns stimulant with the molecular formula C8H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57DQA39DO2, chemically known as 3,3-methylethylilotarimide but generally known as bemegride, which bears US NIH Compound Identifier 2310. Bemegride most often comes in base or methyl forms. European Medicines Agency schedules Bemegride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05691MIG. The term BEMEGRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules bemegride in its Anatomical Therapeutic Chemical (ATC) Classification. BEMEGRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bemegride under HS 29251995 and SITC 51482. As of Q4 2014, BEMEGRIDE remains the US FDA Preferred Term for this commodity. Bemegride bears US NLM identifiers UMLS ID C0004960 and NCI Concept Code C76617. SMILES: O=C1NC(=O)CC(C1)(CC)C.
This classification denotes a 5-ht3 receptor antagonist with the molecular formula C15H17Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O98T3677PA, chemically known as 3-tropanyl-3,5-dichlorobenzoate but generally known as bemesetron, which bears US NIH Compound Identifier 1683. European Medicines Agency schedules Bemesetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05692MIG. The term BEMESETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). BEMESETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bemesetron under HS 29399900 and SITC 54149. As of Q4 2014, BEMESETRON remains the US FDA Preferred Term for this commodity. Bemesetron bears US NLM identifiers UMLS ID C0164151 and NCI Concept Code C80766. SMILES: CLC1CC(C(=O)OC2CC3N(C(CC3)C2)C)CC(CL)C1.
This classification denotes a diuretic with the molecular formula C15H17N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LT9004D9N0, chemically known as 8-(2-ethoxyethyl)-7-phenyl-(1,2,4)triazolo(1,5-c)pyrimidin-5-amine but generally known as bemitradine, which bears US NIH Compound Identifier 55784. European Medicines Agency schedules Bemitradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05694MIG. The term BEMITRADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). BEMITRADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bemitradine under HS 29335995 and SITC 51576. As of Q4 2014, BEMITRADINE remains the US FDA Preferred Term for this commodity. Bemitradine bears US NLM identifiers UMLS ID C0165297 and NCI Concept Code C77556. SMILES: O(CCC1C(NC(N2NCNC12)N)C1CCCCC1)CC.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2S2V1ETBQ, chemically known as 7-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2h-1,4-benzoxazin-3(4h)-one but generally known as bemoradan, which bears US NIH Compound Identifier 5362399. European Medicines Agency schedules Bemoradan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05695MIG. The term BEMORADAN is an International Non-Proprietary Name. BEMORADAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bemoradan under HS 29349990 and SITC 51579. As of Q4 2014, BEMORADAN remains the US FDA Preferred Term for this commodity. Bemoradan bears US NLM identifiers UMLS ID C0053085 and NCI Concept Code C76314. SMILES: O1C2CC(C3=NNC(=O)CC3C)CCC2NC(=O)C1.
This classification denotes an anticholinergic agent with the molecular formula C20H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 595EG71R3F, chemically known as ethanol, 2-(diethylamino)-, benzilate hydrochloride but generally known as benactyzine, which bears US NIH Compound Identifier 9330. benactyzine most often comes in base, chloride, hydrochloride, or methyl bromide forms. European Medicines Agency schedules Benactyzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05696MIG. The term BENACTYZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). BENACTYZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benactyzine under HS 29221980 and SITC 51461. As of Q4 2014, BENACTYZINE remains the US FDA Preferred Term for this commodity. Benactyzine bears US NLM identifiers UMLS ID C0004962 and NCI Concept Code C81454. SMILES: O(CCN(CC)CC)C(=O)C(O)(C1CCCCC1)C1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C23H27N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DXB7KMD1F, chemically known as 4-(1,2,3,4,4qbeta,10bbeta-hexahydro-8,9-dimethoxy-2-methylbenzo(c)(1,6)naphthyridin-6-yl)acetanilid but generally known as benafentrine, which bears US NIH Compound Identifier 3084603. European Medicines Agency schedules Benafentrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05697MIG. The term BENAFENTRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). BENAFENTRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benafentrine under HS 29339990 and SITC 51577. As of Q4 2014, BENAFENTRINE remains the US FDA Preferred Term for this commodity. Benafentrine bears US NLM identifiers UMLS ID C0050999 and NCI Concept Code C74346. SMILES: O(C1CC2C3C(N=C(C2CC1OC)C1CCC(NC(=O)C)CC1)CCN(C3)C)C.
This classification denotes a proton pump inhibitor with the molecular formula C16H18N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RE0689TX2K, chemically known as 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1h-imidazo(4,5-b)pyridine but generally known as tenatoprazole, which bears US NIH Compound Identifier 636411. European Medicines Agency schedules Tenatoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04717MIG. The term TENATOPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Benatoprazole or tenatoprazole bears US NLM identifiers UMLS ID C1455363 and NCI Concept Code C90934. SMILES: S(=O)(CC1NCC(C(OC)C1C)C)C1[NH]C2C(N1)NC(OC)CC2.
This classification denotes an ace inhibitor with the molecular formula C24H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UDM7Q7QWP8, chemically known as 1h-1-benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (s-(r*,r*))- but generally known as benazepril, which bears US NIH Compound Identifier 5362124. Benazepril most often comes in base and hydrochloride forms. European Medicines Agency schedules Benazepril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05700MIG. The term BENAZEPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules benazepril in its Anatomical Therapeutic Chemical (ATC) Classification. BENAZEPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benazepril under HS 29337900 and SITC 51561. As of Q4 2014, BENAZEPRIL remains the US FDA Preferred Term for this commodity. Benazepril bears US NLM identifiers UMLS ID C0053091 and NCI Concept Code C61645. SMILES: O=C1N(c2c(CCC1NC(CCc1ccccc1)C(=O)OCC)cccc2)CC(=O)O.
This classification denotes an ace inhibitor with the molecular formula C22H24N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JRM708L703, chemically known as 1h-1-benzazepine-1-acetic acid, 3-(((1s)-1-carboxy-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (3s)- but generally known as benazeprilat, which bears US NIH Compound Identifier 5463984. European Medicines Agency schedules Benazeprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05701MIG. The term BENAZEPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). BENAZEPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benazeprilat under HS 29337900 and SITC 51561. As of Q4 2014, BENAZEPRILAT remains the US FDA Preferred Term for this commodity. Benazeprilat bears US NLM identifiers UMLS ID C0105523 and NCI Concept Code C72907. SMILES: O=C1N(c2c(CCC1NC(CCc1ccccc1)C(=O)O)cccc2)CC(=O)O.
This classification denotes an ace inhibitor with the molecular formula C24H28N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N1SN99T69T, chemically known as 1h-1-benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, monohydrochloride, (s-(r*,r*))- but more generally known as benazepril hydrochloride, which bears US NIH Compound Identifier 5362123. European Medicines Agency schedules Benazepril hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13003MIG. Most nations, for tariff and trade purposes, schedule benazepril hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, BENAZEPRIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Benazepril hydrochloride bears US NLM identifiers UMLS ID C0770917 and NCI Concept Code C28862. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]2CCC3CCCCC3N(C2=O)CC(=O)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an antihypertensive agent with the molecular formula C16H13Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1999398A3P, chemically known as 4,5-dihydro-1-benzoyl-n-(2,6-dichlorophenyl)-1h-imidazol-2-amine but generally known as benclonidine, which bears US NIH Compound Identifier 68774. European Medicines Agency schedules Benclonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05704MIG. The term BENCLONIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). BENCLONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benclonidine under HS 29332990 and SITC 51573. As of Q4 2014, BENCLONIDINE remains the US FDA Preferred Term for this commodity. Benclonidine bears US NLM identifiers UMLS ID C2346992 and NCI Concept Code C72972. SMILES: Clc1c(NC2=NCCN2C(=O)c2ccccc2)c(Cl)ccc1.
This classification denotes a calcium channel blocker with the molecular formula C19H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6I97Z6S135, chemically known as 3-((1-benzylcycloheptyl)oxy)-n,n-dimethylpropylamin but generally known as bencyclane, which bears US NIH Compound Identifier 2312. Bencyclane most often comes in base and fumarate forms. European Medicines Agency schedules Bencyclane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05705MIG. The term BENCYCLANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules bencyclane in its Anatomical Therapeutic Chemical (ATC) Classification. BENCYCLANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bencyclane under HS 29221980 and SITC 51461. As of Q4 2014, BENCYCLANE remains the US FDA Preferred Term for this commodity. Bencyclane bears US NLM identifiers UMLS ID C0004969 and NCI Concept Code C74226. SMILES: O(C1(CCCCCC1)Cc1ccccc1)CCCN(C)C.
This classification denotes a calcium channel blocker with the molecular structure C19H31NO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, OZN2MG334O chemically known as 3-((1-benzylcycloheptyl)oxy)-n,n-dimethylpropylamine fumarate, but more commonly known as bencyclane fumarate, which bears US NIH Compound Identifier 5282403. European Medicines Agency schedules Bencyclane fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00695MIG. Most nations, for tariff and trade purposes, schedule bencyclane fumarate under HS 29221980 and SITC 51461. As of Q4 2014, BENCYCLANE FUMARATE remains US FDA's Preferred Term for this commodity. Bencyclane fumarate bears US NLM identifiers UMLS ID C0813193 and NCI Concept Code C73828. SMILES: CN(C)CCCOC1(CCCCCC1)CC2CCCCC2.C(=C/C(=O)O)\C(=O)O.
This classification denotes a nitrogen mustard compound with the molecular formula C16H21Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9266D9P3PQ, chemically known as 2-benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride but more generally known as bendamustine, which bears US NIH Compound Identifier 65628. Bendamustine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bendamustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05707MIG. The term BENDAMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules bendamustine in its Anatomical Therapeutic Chemical (ATC) Classification. BENDAMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bendamustine under HS 29339990 and SITC 51577. As of Q4 2014, BENDAMUSTINE remains US FDA's Preferred Term for this commodity. Bendamustine bears US NLM identifiers UMLS ID C0525079 and NCI Concept Code C73261. SMILES: CLCCN(C1CC2NC(N(C2CC1)C)CCCC(=O)O)CCCL.
This classification denotes a nitrogen mustard compound with the molecular formula C16H21Cl2N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 981Y8SX18M, chemically known as 2-benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride but more generally known as bendamustine hydrochloride, which bears US NIH Compound Identifier 77082. The base compound, Bendamustine, most often comes in base and hydrochloride forms. European Medicines Agency schedules Bendamustine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00696MIG. As of Q4 2014, BENDAMUSTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bendamustine hydrochloride bears US NLM identifiers UMLS ID C1529660 and NCI Concept Code C61565. Most nations, for tariff and trade purposes, schedule bendamustine hydrochloride under HS 29339990 and SITC 51577. SMILES: CN1C2CCC(CC2NC1CCCC(=O)O)N(CCCL)CCCL.CL.
This classification denotes the lysine-dihydrate form of a nonsteroidal antiinflammatory drug with the molecular formula C16H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4AG71204O, chemically known as acetic acid, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)- but more generally known as bendazac, which bears US NIH Compound Identifier 2313. Bendazac most often comes in base, lysine, methyl ester, and sodium forms. European Medicines Agency schedules Bendazac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05708MIG. The term BENDAZAC is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules bendazac in its Anatomical Therapeutic Chemical (ATC) Classification. BENDAZAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bendazac lysine dihydrate under HS 29339990. As of Q4 2014, BENDAZAC LYSINE DIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)CN2C3CCCCC3C(N2)OCC(=O)O.C(CCN)C[C@@H](C(=O)O)N.O.O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4AG71204O, chemically known as acetic acid, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)- but generally known as bendazac, which bears US NIH Compound Identifier 2313. Bendazac most often comes in base, lysine, methyl ester, and sodium forms. European Medicines Agency schedules Bendazac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05708MIG. The term BENDAZAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules bendazac in its Anatomical Therapeutic Chemical (ATC) Classification. BENDAZAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Bendazac or bendazolic acid bears US NLM identifiers UMLS ID C0053097 and NCI Concept Code C80537. SMILES: O(C1NN(C2C1CCCC2)CC1CCCCC1)CC(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4SW243Q44Z, chemically known as sodium, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)acetate but more generally known as bendazac sodium, which bears US NIH Compound Identifier 31020. European Medicines Agency schedules Bendazac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00698MIG. Most nations, for tariff and trade purposes, schedule bendazac sodium under HS 29339990. As of Q4 2014, BENDAZAC SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)CN2C3CCCCC3C(N2)OCC(=O)[O-].[NA+].
This classification denotes a vasodilating agent with the molecular formula C14H12N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26601THN1D, chemically known as 1h-benzimidazole, 2-(phenylmethyl)- (9ci) but generally known as bendazol, which bears US NIH Compound Identifier 12132. Bendazol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bendazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05709MIG. The term BENDAZOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BENDAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bendazol under HS 29339990 and SITC 51577. As of Q4 2014, BENDAZOL remains the US FDA Preferred Term for this commodity. Bendazol bears US NLM identifiers UMLS ID C2698355 and NCI Concept Code C74427. SMILES: [nH]1c(nc2c1cccc2)Cc1ccccc1.
This classification denotes a vasodilating agent C14H12N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ME751TL810, chemically known as 1h-benzimidazole, 2-(phenylmethyl)-, hydrochloride (1:1), but more generally known as bendazol hydrochloride, which bears US NIH Compound Identifier 164798. European Medicines Agency schedules Bendazol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32247. Most nations, for tariff and trade purposes, schedule bendazol hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BENDAZOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)CC2[NH]C3CCCCC3N2.CL.
This classification denotes a thiazide diuretic with the molecular formula C15H14F3N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Q52X6ICJI, chemically known as 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as bendroflumethiazide, which bears US NIH Compound Identifier 2315. European Medicines Agency schedules Bendroflumethiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05711MIG. The term BENDROFLUMETHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules bendroflumethiazide in its Anatomical Therapeutic Chemical (ATC) Classification. BENDROFLUMETHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bendroflumethiazide under HS 29350090 and SITC 51580. As of Q4 2014, BENDROFLUMETHIAZIDE remains the US FDA Preferred Term for this commodity. Bendroflumethiazide bears US NLM identifiers UMLS ID C0701080 and NCI Concept Code C47410. SMILES: S1(=O)(=O)NC(NC2C1CC(S(=O)(=O)N)C(C2)C(F)(F)F)CC1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV701. This VA Drug Class (CV701) classifies this compound as belonging to the group THIAZIDES/RELATED DIURETICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an antimalarial agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F38R0JR742. European Medicines Agency schedules Lumefantrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08618MIG. Lumefantrine generally arises in the molecular formula C30H32CL3NO. The term LUMEFANTRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 1 1998, list 39.) LUMEFANTRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Benflumetol or lumefantrine bears US NLM identifiers UMLS ID C0531104 and NCI Concept Code C81541. SMILES: CLC1CC(C(O)CN(CCCC)CCCC)C2C(/C(=C/C3CCC(CL)CC3)C3C2CCC(CL)C3)C1.
This classification denotes an anti-lipidemic agent and anorexiant with the molecular formula C19H20F3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 403FO0NQG3, chemically known as phenethylamine, n-(2-hydroxyethyl)-alpha-methyl-m-trifluoromethyl-, benzoate but more generally known as benfluorex, which bears US NIH Compound Identifier 2318. Benfluorex most often comes in base and hydrochloride forms. European Medicines Agency schedules Benfluorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05714MIG. The term BENFLUOREX is an International Non-Proprietary Name WHO schedules benfluorex in its Anatomical Therapeutic Chemical (ATC) Classification. BENFLUOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule benfluorex under HS 29221980 and SITC 51461. As of Q4 2014, BENFLUOREX remains US FDA's Preferred Term for this commodity. Benfluorex bears US NLM identifiers UMLS ID C0053105 and NCI Concept Code C72936. SMILES: FC(F)(F)C1CC(CC(NCCOC(=O)C2CCCCC2)C)CCC1.
This classification denotes an anti-lipidemic agent and anorexiant with the molecular formula C19H20F3NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7O165XZ00, chemically known as phenethylamine, n-(2-hydroxyethyl)-alpha-methyl-m-trifluoromethyl-, benzoate but more generally known as benfluorex hydrochloride, which bears US NIH Compound Identifier 2318. European Medicines Agency schedules Benfluorex hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00701MIG. Most nations, for tariff and trade purposes, schedule benfluorex hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, BENFLUOREX HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCC(C1)C(F)(F)F)NCCOC(=O)C2CCCCC2.CL.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 49030P3C8S. European Medicines Agency schedules Benfosformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05715MIG. Benfosformin generally arises in the molecular formula C9H12N5O3P.2NA.H2O. The term BENFOSFORMIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, no. 10 1973, list 13.) BENFOSFORMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule benfosformin under HS 29299000 and SITC 51489. As of Q4 2014, BENFOSFORMIN remains US FDA's Preferred Term for this commodity. Benfosformin bears US NLM identifiers UMLS ID C2346994 and NCI Concept Code C72721. SMILES: P(=O)(O)(O)/N=C(/N/C(=N/CC1CCCCC1)N)N.[NA].[NA].O.
This classification denotes the anhydrous form of an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49030P3C8S. European Medicines Agency schedules Benfosformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05715MIG. Benfosformin generally arises in the molecular formula C9H12N5O3P.2NA.H2O. The term BENFOSFORMIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, no. 10 1973, list 13.) BENFOSFORMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule benfosformin anhydrous under HS 29299000. As of Q4 2014, BENFOSFORMIN ANHYDROUS remains US FDA's Preferred Term for this commodity. Benfosformin anhydrous bears US NLM identifiers UMLS ID C2698357 and NCI Concept Code C79537. SMILES: C1CCC(CC1)CNC(=N)NC(=N)NP(=O)([O-])[O-].[NA+].[NA+].
This classification denotes a calcium channel blocker with the molecular formula C28H31N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G9T91JS7E, chemically known as (+-)-(r*)-3-((r*)-1-benzyl-3-piperidyl) methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate but generally known as benidipine, which bears US NIH Compound Identifier 60065. Benidipine most often comes in base and hydrochloride forms. European Medicines Agency schedules Benidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05719MIG. The term BENIDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules benidipine in its Anatomical Therapeutic Chemical (ATC) Classification. BENIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benidipine under HS 29333999 and SITC 51574. As of Q4 2014, BENIDIPINE remains the US FDA Preferred Term for this commodity. Benidipine bears US NLM identifiers UMLS ID C0053108 and NCI Concept Code C81680. SMILES: O(C1CCCN(C1)CC1CCCCC1)C(=O)C1=C(NC(=C(C1C1CC([N](=O)O)CCC1)C(=O)OC)C)C.
This classification denotes a calcium channel blocker with the molecular formula C28H31N3O6.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A6746FWDL. European Medicines Agency schedules benidipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13004MIG. The term benidipine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule benidipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BENIDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Benidipine hydrochloride bears US NLM identifiers UMLS ID C0088341 and NCI Concept Code C81677. SMILES: CC1=C([C@H](C(=C(N1)C)C(=O)O[C@@H]2CCCN(C2)CC3CCCCC3)C4CCCC(C4)[N+](=O)[O-])C(=O)OC.CL.
This classification denotes a sedative and hypnotic with the molecular formula C19H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7RE4N644YF, chemically known as 1,2,3,4,4a,6,7,11b,12,13a-decahydro-9, 10-dimethoxy-13h-dibenzo(a,f)quinolizin-13-one oxime but more generally known as benolizime, which bears US NIH Compound Identifier 9578100. European Medicines Agency schedules Benolizime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05721MIG. The term BENOLIZIME is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). BENOLIZIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benolizime under HS 29339990 and SITC 51577. As of Q4 2014, BENOLIZIME remains the US FDA Preferred Term for this commodity. Benolizime bears US NLM identifiers UMLS ID C2698362 and NCI Concept Code C77242. SMILES: O/N=C1/C2C(N3C(C1)C1C(CC3)CC(OC)C(OC)C1)CCCC2.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H15NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W1QX9DV96G, chemically known as salicylic acid, acetate, ester with 4-hydroxyacetanilide but generally known as benorilate, which bears US NIH Compound Identifier 21102. European Medicines Agency schedules Benorilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05722MIG. The term BENORILATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules benorilate in its Anatomical Therapeutic Chemical (ATC) Classification. BENORILATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benorilate under HS 29242995 and SITC 51479. As of Q4 2014, BENORILATE remains the US FDA Preferred Term for this commodity. Benorilate bears US NLM identifiers UMLS ID C0005011 and NCI Concept Code C80538. SMILES: CC(=O)NC1=CC=C(C=C1)OC(=O)C2=CC=CC=C2OC(=O)C.
This classification denotes an anti-androgen with the molecular formula C19H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J339Q7IM54, chemically known as b-norandrost-4-en-3-one, 17-hydroxy-17-methyl-, (17beta)- but generally known as benorterone, which bears US NIH Compound Identifier 19126. European Medicines Agency schedules Benorterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05723MIG. The term BENORTERONE is an International Non-Proprietary Name. BENORTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benorterone under HS 29372900 and SITC 54153. As of Q4 2014, BENORTERONE remains the US FDA Preferred Term for this commodity. Benorterone bears US NLM identifiers UMLS ID C0053110 and NCI Concept Code C74121. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)C3)C)CC2)CC1)C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H12ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17SZX404IM, chemically known as 5-benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl, (+-)- but generally known as benoxaprofen, which bears US NIH Compound Identifier 39941. Benoxaprofen most often comes in base and glucuronide forms. European Medicines Agency schedules Benoxaprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05725MIG. The term BENOXAPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules benoxaprofen in its Anatomical Therapeutic Chemical (ATC) Classification. BENOXAPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benoxaprofen under HS 29349990 and SITC 51579. As of Q4 2014, BENOXAPROFEN remains the US FDA Preferred Term for this commodity. Benoxaprofen bears US NLM identifiers UMLS ID C0053111 and NCI Concept Code C76796. SMILES: CLC1CCC(C2OC3C(N2)CC(C(C)C(=O)O)CC3)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes an anesthetic agent with the molecular formula C17H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AXQ0JYM303, chemically known as benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7ci,8ci,9ci) but generally known as benoxinate, which bears US NIH Compound Identifier 4633. Benoxinate most often comes in base and hydrochloride forms. European Medicines Agency schedules Oxybuprocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09557MIG. The term OXYBUPROCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules benoxinate in its Anatomical Therapeutic Chemical (ATC) Classification. Benoxinate or oxybuprocaine bears US NLM identifiers UMLS ID C0053114 and NCI Concept Code C72176. SMILES: CCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N.
This classification denotes a dopamine antagonist with the molecular formula C22H24FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97O6X78C53, chemically known as 2h-benzimidazol-2-one, 1-(1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidinyl)-1,3-dihydro- but generally known as benperidol, which bears US NIH Compound Identifier 16363. Benperidol most often comes in base and hydrochloride forms. European Medicines Agency schedules Benperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05727MIG. The term BENPERIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules benperidol in its Anatomical Therapeutic Chemical (ATC) Classification. BENPERIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benperidol under HS 29333999 and SITC 51574. As of Q4 2014, BENPERIDOL remains the US FDA Preferred Term for this commodity. Benperidol bears US NLM identifiers UMLS ID C0005013 and NCI Concept Code C81086. SMILES: FC1CCC(C(=O)CCCN2CCC(N3C4C([NH]C3=O)CCCC4)CC2)CC1.
This classification denotes an antitussive agent with the molecular formula C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3AA6IZ48YK, chemically known as piperidine, 1-(1-methyl-2-((alpha-phenyl-o-tolyl)oxy)ethyl)- but more generally known as benproperine, which bears US NIH Compound Identifier 2326. Benproperine most often comes in basem, embonate, pamoate, phosphate, and trihydrogen phosphate forms. European Medicines Agency schedules Benproperine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05728MIG. The term BENPROPERINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules benproperine in its Anatomical Therapeutic Chemical (ATC) Classification. BENPROPERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule benproperine under HS 29333999 and SITC 51574. As of Q4 2014, BENPROPERINE remains US FDA's Preferred Term for this commodity. Benproperine bears US NLM identifiers UMLS ID C0772056 and NCI Concept Code C78103. SMILES: O(CC(N1CCCCC1)C)C1C(CC2CCCCC2)CCCC1.
This classification denotes an antitussive agent with the molecular formula C23H16O6.2C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 370C8CB2K3, chemically known as piperidine, 1-(1-methyl-2-(2-(phenylmethyl)phenoxy)ethyl)-, 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (2:1), but more generally known as benproperine embonate, which bears US NIH Compound Identifier 11979739. European Medicines Agency schedules benproperine embonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05728MIG. Most nations, for tariff purposes, schedule benproperine embonate under HS 29333999. SMILES: CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an antitussive agent with the molecular formula C23H16O6.2C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 370C8CB2K3. Most nations, for tariff and trade purposes, schedule benproperine pamoate under HS 29333999. As of Q4 2014, BENPROPERINE PAMOATE remains US FDA's Preferred Term for this commodity. SMILES: CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an antitussive agent with the molecular formula C21H27NO.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S831Z48C5W, chemically known as piperidine, 1-(1-methyl-2-((alpha-phenyl-o-tolyl)oxy)ethyl)-, phosphate but more generally known as benproperine phosphate, which bears US NIH Compound Identifier 167811. European Medicines Agency schedules Benproperine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00705MIG. Most nations, for tariff and trade purposes, schedule benproperine phosphate under HS 29333999 and SITC 51574. As of Q4 2014, BENPROPERINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.OP(=O)(O)O.
This classification denotes an antitussive agent with the molecular formula C21H27NO.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S831Z48C5W, chemically known as 1-(2-(2-benzylphenoxy)-1-methylethyl)piperidine monophosphate, but more generally known as benproperine trihydrogen phosphate, which bears US NIH Compound Identifier 167811. European Medicines Agency schedules benproperine trihydrogen phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05728MIG. Most nations, for tariff purposes, schedule benproperine trihydrogen phosphate under HS 29333999. SMILES: CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.OP(=O)(O)O.
This classification denotes an antiarrhythmic agent with the molecular formula C19H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 58NL35I27K, chemically known as 4-benzyl-1-piperidinecarboxylic acid, 2-(diethylamino)ethyl ester but more generally known as benrixate, which bears US NIH Compound Identifier 184848. European Medicines Agency schedules Benrixate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05729MIG. The term BENRIXATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). BENRIXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule benrixate under HS 29333999 and SITC 51574. As of Q4 2014, BENRIXATE remains US FDA's Preferred Term for this commodity. Benrixate bears US NLM identifiers UMLS ID C2346995 and NCI Concept Code C74126. SMILES: O(C(=O)N1CCC(CC1)CC1CCCCC1)CCN(CC)CC.
This classification denotes an anti-infective agent with the molecular formula C14H10Br3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22T0M6CICV, chemically known as 3,5-dibromo-n-(p-bromobenzyl)salicylamide but generally known as bensalan, which bears US NIH Compound Identifier 27449. European Medicines Agency schedules Bensalan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05730MIG. The term BENSALAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). BENSALAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bensalan under HS 29242995 and SITC 51479. As of Q4 2014, BENSALAN remains the US FDA Preferred Term for this commodity. Bensalan bears US NLM identifiers UMLS ID C2827107 and NCI Concept Code C83604. SMILES: BRC1C(O)C(C(=O)NCC2CCC(BR)CC2)CC(BR)C1.
This classification denotes an antifungal agent with the molecular formula C12H14N2O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8L0T98P0J, chemically known as 5-benzyldihydro-6-thioxo-2h-1,3,5-thiadiazine-3(4h)-acetic acid but generally known as bensuldazic acid, which bears US NIH Compound Identifier 71462. European Medicines Agency schedules Bensuldazic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05732MIG. The term BENSULDAZIC ACID is an International Non-Proprietary Name. Most nations schedule bensuldazic acid under HS 29349990 and SITC 51579. As of Q4 2014, BENSULDAZIC ACID remains the US FDA Preferred Term for this commodity. Bensuldazic acid bears US NLM identifiers UMLS ID C2346996 and NCI Concept Code C72090. SMILES: C1N(CSC(=S)N1CC2=CC=CC=C2)CC(=O)O.
This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C17H16N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66JKK43S1Z, chemically known as 1,3,6,7,8,9-hexahydro-5-phenyl-2h-(1)benzothieno(2,3-e)-1,4-diazepin-2-one but generally known as bentazepam, which bears US NIH Compound Identifier 34592. European Medicines Agency schedules Bentazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05733MIG. The term BENTAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). BENTAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bentazepam under HS 29349990 and SITC 51579. As of Q4 2014, BENTAZEPAM remains the US FDA Preferred Term for this commodity. Bentazepam bears US NLM identifiers UMLS ID C0053117 and NCI Concept Code C74189. SMILES: S1C2C(CCCC2)C2=C(NCC(=O)N=C12)C1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an enzyme inhibitor with the molecular formula C9H9ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9RA9A22Z0W, chemically known as benzamide, 4-chloro-n-(2-(hydroxyamino)-2-oxoethyl)- but more generally known as benurestat, which bears US NIH Compound Identifier 38000. European Medicines Agency schedules Benurestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05738MIG. The term BENURESTAT is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). BENURESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1CCC(C(=O)NCC(=O)NO)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a surface-active agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5UM2KM3W7. European Medicines Agency schedules Benzalkonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00714MIG. Benzalkonium chloride generally arises in the molecular formula C22H40CLN. The term BENZALKONIUM CHLORIDE is an International Non-Proprietary Name or INN. Most nations schedule benzalkonium chloride under HS 34021200 and SITC 55421. As of Q4 2014, BENZALKONIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Benzalkonium chloride bears US NLM identifiers UMLS ID C0005026 and NCI Concept Code C82282. SMILES: C[NH+](C)CC1=CC=CC=C1.[Cl-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE101. This VA Drug Class (DE101) classifies this compound as belonging to the group ANTIBACTERIAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes an antidepressant agent with the molecular formula C20H20ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8J11WBM781, chemically known as 1-propanamine, 3-(1-chloro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-n,n-dimethyl-, n-oxide but generally known as benzaprinoxide, which bears US NIH Compound Identifier 6436093. European Medicines Agency schedules Benzaprinoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05739MIG. The term BENZAPRINOXIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). BENZAPRINOXIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzaprinoxide under HS 29299000 and SITC 51489. As of Q4 2014, BENZAPRINOXIDE remains the US FDA Preferred Term for this commodity. Benzaprinoxide bears US NLM identifiers UMLS ID C2607957 and NCI Concept Code C79853. SMILES: Clc1c2c(/C(=C\CC[N](O)(C)C)c3c(C=C2)cccc3)ccc1.
This classification denotes a thrombolytic agent with the molecular formula C17H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23ZW4BG89C, chemically known as methanone, (2-ethyl-3-benzofuranyl)(4-hydroxyphenyl)- but generally known as benzarone, which bears US NIH Compound Identifier 255968. European Medicines Agency schedules Benzarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05740MIG. The term BENZARONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BENZARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzarone under HS 29329985 and SITC 51569. As of Q4 2014, BENZARONE remains the US FDA Preferred Term for this commodity. Benzarone bears US NLM identifiers UMLS ID C0053152 and NCI Concept Code C74411. SMILES: O1C(C(C2C1CCCC2)C(=O)C1CCC(O)CC1)CC.
This classification denotes a uricosuric agent with the molecular formula C17H12Br2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4POG0RL69O, chemically known as 3,5-dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone but generally known as benzbromarone, which bears US NIH Compound Identifier 2333. European Medicines Agency schedules Benzbromarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05743MIG. The term BENZBROMARONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules benzbromarone in its Anatomical Therapeutic Chemical (ATC) Classification. BENZBROMARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzbromarone under HS 29329985 and SITC 51569. As of Q4 2014, BENZBROMARONE remains the US FDA Preferred Term for this commodity. Benzbromarone bears US NLM identifiers UMLS ID C0005035 and NCI Concept Code C74412. SMILES: BRC1CC(C(=O)C2C3C(OC2CC)CCCC3)CC(BR)C1O.
This classification denotes a therapeutic estrogen with the molecular formula C20H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A27512LR47, chemically known as 4,4-(1,2-diethyl-3-methyltrimethylene)diphenol but generally known as benzestrol, which bears US NIH Compound Identifier 6827. European Medicines Agency schedules Benzestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05744MIG. The term BENZESTROL is an International Non-Proprietary Name. BENZESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzestrol under HS 29072900 and SITC 51243. As of Q4 2014, BENZESTROL remains the US FDA Preferred Term for this commodity. Benzestrol bears US NLM identifiers UMLS ID C0053173 and NCI Concept Code C76994. SMILES: Oc1ccc(C(C(C(c2ccc(O)cc2)C)CC)CC)cc1.
This classification denotes a topical anti-infective agent with the molecular formula C27H42NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1VU15B70BP. European Medicines Agency schedules benzethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00719MIG. BENZETHONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BENZETHONIUM remains the US FDA Preferred Term for this commodity. Benzethonium bears US NLM identifiers UMLS ID C0005041 and NCI Concept Code C87255. SMILES: O(CC[N](CC1CCCCC1)(C)C)CCOC1CCC(C(CC(C)(C)C)(C)C)CC1. .
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT400. This VA Drug Class (OT400) classifies this compound as belonging to the group ANALGESICS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a topical anti-infective agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier PH41D05744. European Medicines Agency schedules Benzethonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05746MIG. Benzethonium chloride generally arises in the molecular formula C27H42NO2.CL. The term BENZETHONIUM CHLORIDE is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE101. This VA Drug Class (DE101) classifies this compound as belonging to the group ANTIBACTERIAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes an antimuscarinic agent with the molecular formula C22H28NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GY56LQX77B, chemically known as 1,1-diethyl-3-hydroxypyrrolidinium bromide benzilate but generally known as benzilone, which bears US NIH Compound Identifier 66247. European Medicines Agency schedules Benzilonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00722MIG. World Health Organization schedules benzilone in its Anatomical Therapeutic Chemical (ATC) Classification. Benzilone or benzilonium bears US NLM identifiers UMLS ID C2828307 and NCI Concept Code C87444. SMILES: CC[N+]1(CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)CC.[BR-].
This classification denotes an antiarrhythmic agent with the molecular formula C17H12I2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75CL65GTYR, chemically known as 3,5-diiodo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl ketone but generally known as benziodarone, which bears US NIH Compound Identifier 6237. European Medicines Agency schedules Benziodarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05751MIG. The term BENZIODARONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules benziodarone in its Anatomical Therapeutic Chemical (ATC) Classification. BENZIODARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benziodarone under HS 29329985 and SITC 51569. As of Q4 2014, BENZIODARONE remains the US FDA Preferred Term for this commodity. Benziodarone bears US NLM identifiers UMLS ID C0053185 and NCI Concept Code C74127. SMILES: Ic1cc(C(=O)c2c3c(oc2CC)cccc3)cc(I)c1O.
This classification denotes an anti-lipidemic agent with the molecular formula C20H19Cl2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6ET4K804XA, chemically known as n-(2,3-bis(p-chlorophenyl)-1-methylpropyl)maleamic acid (alpha-form) but generally known as benzmalecene, which bears US NIH Compound Identifier 6436094. European Medicines Agency schedules Benzmalecene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05752MIG. The term BENZMALECENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). BENZMALECENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzmalecene under HS 29242995 and SITC 51479. As of Q4 2014, BENZMALECENE remains the US FDA Preferred Term for this commodity. Benzmalecene bears US NLM identifiers UMLS ID C0701040 and NCI Concept Code C79818. SMILES: Clc1ccc(C(C(NC(=O)/C=C/C(=O)O)C)Cc2ccc(Cl)cc2)cc1.
This classification denotes an antiprotozoal agent with the molecular formula C12H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YC42NRJ1ZD, chemically known as 1h-imidazole-1-acetamide, 2-nitro-n-(phenylmethyl)- (9ci) but generally known as benznidazole, which bears US NIH Compound Identifier 31593. European Medicines Agency schedules Benznidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05753MIG. The term BENZNIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules benznidazole in its Anatomical Therapeutic Chemical (ATC) Classification. BENZNIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benznidazole under HS 29332990 and SITC 51573. As of Q4 2014, BENZNIDAZOLE remains the US FDA Preferred Term for this commodity. Benznidazole bears US NLM identifiers UMLS ID C0053230 and NCI Concept Code C1013. SMILES: C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-].
This classification denotes a barbiturate with the molecular formula C19H16N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YNJ78BD0AH, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-benzoyl-5-ethyl-5-phenyl- (9ci) but generally known as benzobarbital, which bears US NIH Compound Identifier 12938. European Medicines Agency schedules Benzobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05754MIG. The term BENZOBARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). BENZOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzobarbital under HS 29335400 and SITC kg. As of Q4 2014, BENZOBARBITAL remains the US FDA Preferred Term for this commodity. Benzobarbital bears US NLM identifiers UMLS ID C0053215 and NCI Concept Code C77628. SMILES: O=C1N(C(=O)NC(=O)C1(CC)C1CCCCC1)C(=O)C1CCCCC1.
This classification denotes an anesthetic agent with the molecular formula C9H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3RSY48JW5, chemically known as 4-aminobenzoic acid, ethyl ester but generally known as benzocaine, which bears US NIH Compound Identifier 2337. Benzocaine most often comes in base, oxalate, silicon, and succinate forms. European Medicines Agency schedules Benzocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05755MIG. The term BENZOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules benzocaine in its Anatomical Therapeutic Chemical (ATC) Classification. BENZOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzocaine under HS 29224995 and SITC 51465. As of Q4 2014, BENZOCAINE remains the US FDA Preferred Term for this commodity. Benzocaine bears US NLM identifiers UMLS ID C0005059 and NCI Concept Code C28923. SMILES: O(C(=O)C1CCC(N)CC1)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS201. This VA Drug Class (RS201) classifies this compound as belonging to the group HEMORRHOIDAL PREPARATIONS WITHOUT STEROID.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS201. This VA Drug Class (RS201) classifies this compound as belonging to the group HEMORRHOIDAL PREPARATIONS WITHOUT STEROID.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS300. This VA Drug Class (RS300) classifies this compound as belonging to the group LAXATIVES, RECTAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an anesthetic agent with the molecular formula C9H11NO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OG625Z9LEO. Most nations, for tariff and trade purposes, schedule benzocaine hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, BENZOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Benzocaine hydrochloride bears US NLM identifiers UMLS ID C0887581 and NCI Concept Code C97306. SMILES: CCOC(=O)C1CCC(CC1)N.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes an anxiolytic with the molecular formula C18H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 734MM7Y191, chemically known as 9,10-ethanoanthracene-9(10h)-methylamine, n-methyl-, 9,10-dihydro but generally known as benzoctamine, which bears US NIH Compound Identifier 28425. Benzoctamine most often comes in base and hydrochloride forms. European Medicines Agency schedules Benzoctamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05757MIG. The term BENZOCTAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules benzoctamine in its Anatomical Therapeutic Chemical (ATC) Classification. BENZOCTAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzoctamine under HS 29214980 and SITC 51454. As of Q4 2014, BENZOCTAMINE remains the US FDA Preferred Term for this commodity. Benzoctamine bears US NLM identifiers UMLS ID C0053217 and NCI Concept Code C83545. SMILES: N(CC12CCC(C3C1CCCC3)C1C2CCCC1)C.
This classification denotes an anxiolytic with the molecular formula C18H19N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1C280S920Q, chemically known as 9,10-ethanoanthracene-9(10h)-methanamine, n-methyl-, hydrochloride but more generally known as benzoctamine hydrochloride, which bears US NIH Compound Identifier 66275. European Medicines Agency schedules Benzoctamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00723MIG. Most nations, for tariff and trade purposes, schedule benzoctamine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, BENZOCTAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Benzoctamine hydrochloride bears US NLM identifiers UMLS ID C0960020 and NCI Concept Code C83546. SMILES: CNCC12CCC(C3C1CCCC3)C4C2CCCC4.CL.
This classification denotes an ethylenimine compound with the molecular formula C12H16N3O3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q30T24YM3F, chemically known as carbamic acid, (bis(1-aziridinyl)phosphinyl)-, phenylmethyl ester but more generally known as benzodepa, which bears US NIH Compound Identifier 16111. European Medicines Agency schedules Benzodepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05758MIG. The term BENZODEPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BENZODEPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule benzodepa under HS 29339990 and SITC 51577. As of Q4 2014, BENZODEPA remains US FDA's Preferred Term for this commodity. Benzodepa bears US NLM identifiers UMLS ID C0608440 and NCI Concept Code C1759. SMILES: C1CN1P(=O)(NC(=O)OCC2=CC=CC=C2)N3CC3.
This classification denotes a topical anti-infective agent with the molecular formula C21H38N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N0BN0O8CSL, chemically known as n-dodecyl-n, n-dimethylbenzenemethanaminium chloride but generally known as benzododecinium, which bears US NIH Compound Identifier 8754. Benzododecinium most often comes in base, bromatum, bromide, and chloride forms. European Medicines Agency schedules Benzododecinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00724MIG. World Health Organization schedules benzododecinium in its Anatomical Therapeutic Chemical (ATC) Classification. BENZODODECINIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BENZODODECINIUM remains the US FDA Preferred Term for this commodity. Benzododecinium bears US NLM identifiers UMLS ID C0058263 and NCI Concept Code C79723. SMILES: [N](CCCCCCCCCCCC)(CC1CCCCC1)(C)C. .
This classification denotes an anti-infective agent with the molecular formula C21H38N.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y5A751G47H, chemically known as n,n-dimethyl-n-dodecylbenzenemethanaminium chloride but more generally known as benzododecinium chloride, which bears US NIH Compound Identifier 8753. European Medicines Agency schedules Benzododecinium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05759MIG. The term BENZODODECINIUM CHLORIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule benzododecinium chloride under HS 29239000 and SITC 51481. As of Q4 2014, BENZODODECINIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Benzododecinium chloride bears US NLM identifiers UMLS ID C2698366 and NCI Concept Code C79712. SMILES: CCCCCCCCCCCC[N+](C)(C)CC1CCCCC1.[CL-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes an anti-infective agent with the molecular formula C14H12O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L7J6A1NE81, chemically known as 2-hydroxy-1,2-diphenylethanone but generally known as benzoin, which bears US NIH Compound Identifier 8400. Benzoin comes in many forms, including base, acetate, cyclic butaneboronate, ethyl ether, gum, isobutyl ether, isopropyl ether, methyl ester, methyl ether, n-methylcarbamate, oxime, phenylhydrazone, resin, and tincture. European Medicines Agency schedules Benzoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13016MIG. Most nations schedule benzoin under HS 29144000 and SITC 51629. Benzoin bears US NLM identifiers UMLS ID C0005070 and NCI Concept Code C77026. SMILES: OC(C1CCCCC1)C(=O)C1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes an antitussive agent with the molecular formula C12H17NO2(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5P4DHS6ENR, chemically known as 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl p-(butylamino)benzoate but more generally known as benzonatate, which bears US NIH Compound Identifier 7699. European Medicines Agency schedules Benzonatate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05760MIG. The term BENZONATATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules benzonatate in its Anatomical Therapeutic Chemical (ATC) Classification. BENZONATATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule benzonatate under HS 34021300 and SITC 55421. As of Q4 2014, BENZONATATE remains US FDA's Preferred Term for this commodity. Benzonatate bears US NLM identifiers UMLS ID C0053229 and NCI Concept Code C28863. SMILES: CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes an anti-infective agent with the molecular formula C16H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GRE0P19C3Z, chemically known as 8-quinolinol, benzoate (ester) but generally known as benzoxiquine, which bears US NIH Compound Identifier 6855. European Medicines Agency schedules Benzoxiquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05763MIG. The term BENZOXIQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). BENZOXIQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzoxiquine under HS 29334990 and SITC 51575. As of Q4 2014, BENZOXIQUINE remains the US FDA Preferred Term for this commodity. Benzoxiquine bears US NLM identifiers UMLS ID C0982042 and NCI Concept Code C77027. SMILES: O(C1C2NCCCC2CCC1)C(=O)C1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an anti-infective agent with the molecular formula C23H42NO2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12IMO9R11X, chemically known as n-dodecyl-n,n-bis(2-hydroxyethyl)benzenemethanaminium chloride but generally known as benzoxonium chloride, which bears US NIH Compound Identifier 29563. European Medicines Agency schedules Benzoxonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05764MIG. The term BENZOXONIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules benzoxonium chloride in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule benzoxonium chloride under HS 29239000 and SITC 51481. As of Q4 2014, BENZOXONIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Benzoxonium chloride bears US NLM identifiers UMLS ID C0105668 and NCI Concept Code C73251. SMILES: Cl.OCC[N](CCCCCCCCCCCC)(CCO)Cc1ccccc1.
This classification denotes an anti-infective agent with the molecular formula C14H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9WZN9A0GM, chemically known as peroxide, dibenzoyl but generally known as benzoyl peroxide, which bears US NIH Compound Identifier 7187. European Medicines Agency schedules Benzoyl peroxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13020MIG. World Health Organization schedules benzoyl peroxide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule benzoyl peroxide under HS 29163200 and SITC 51379. As of Q4 2014, BENZOYL PEROXIDE remains the US FDA Preferred Term for this commodity. Benzoyl peroxide bears US NLM identifiers UMLS ID C0005088 and NCI Concept Code C47411. SMILES: C1=CC=C(C=C1)C(=O)OOC(=O)C2=CC=CC=C2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a cns stimulant and anorexiant with the molecular formula C17H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M3S43XK27, chemically known as (r,s)-n-benzyl-alpha,n-dimethylphenethylamin but more generally known as benzfetamine, which bears US NIH Compound Identifier 2341. European Medicines Agency schedules Benzfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05748MIG. The term BENZPHETAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). BENZFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BENZPHETAMINE remains US FDA's Preferred Term for this commodity. Benzphetamine bears US NLM identifiers UMLS ID C0005096 and NCI Concept Code C61647. SMILES: CC(CC1=CC=CC=C1)N(C)CC2=CC=CC=C2.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NHY63BKIV, chemically known as 1,2-dihydro-2-(1-methyl-4-piperidinyl)-4-phenyl-5-(phenylmethyl)-3h-pyrazol-3-one but generally known as benzpiperylon, which bears US NIH Compound Identifier 24039. European Medicines Agency schedules Benzpiperylone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05765MIG. The term BENZPIPERYLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). As of Q4 2014, BENZPIPERYLON remains the US FDA Preferred Term for this commodity. Benzpiperylon bears US NLM identifiers UMLS ID C1957227 and NCI Concept Code C83547. SMILES: CN1CCC(CC1)N2C(=O)C(=C(N2)CC3=CC=CC=C3)C4=CC=CC=C4.
This classification denotes a cholinergic agonist with the molecular formula C15H17N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P00DM5T7ZS, chemically known as 1-benzyl-3-hydroxypyridinium dimethylcarbamate but generally known as benzpyrinium, which bears US NIH Compound Identifier 11481. European Medicines Agency schedules Benzpyrinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05766MIG. The term BENZPYRINIUM is an International Non-Proprietary Name. As of Q4 2014, BENZPYRINIUM remains the US FDA Preferred Term for this commodity. Benzpyrinium bears US NLM identifiers UMLS ID C0599261 and NCI Concept Code C87446. SMILES: CN(C)C(=O)OC1=C[N+](=CC=C1)CC2=CC=CC=C2.
This classification denotes a cholinergic agonist with the molecular formula C15H17N2O2.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X0L78YB79M, chemically known as pyridinium, 3-((dimethylaminocarbonyl)oxy)-1-(phenylmethyl)-, bromide but more generally known as benzpyrinium bromide, which bears US NIH Compound Identifier 11481. European Medicines Agency schedules Benzpyrinium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05766MIG. The term BENZPYRINIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule benzpyrinium bromide under HS 29333999 and SITC 51574. As of Q4 2014, BENZPYRINIUM BROMIDE remains US FDA's Preferred Term for this commodity. Benzpyrinium bromide bears US NLM identifiers UMLS ID C2698369 and NCI Concept Code C76611. SMILES: CN(C)C(=O)OC1CCC[N+](C1)CC2CCCCC2.[BR-].
This classification denotes an antiemetic agent with the molecular formula C22H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0475EA27Q3, chemically known as 3-diethylcarbamoyl-2,3,4,6,7,11b-hexahydro-9,10-dimethoxy-1h-benzo(a)chinolizin-2-yl acetat but generally known as benzquinamide, which bears US NIH Compound Identifier 2342. Benzquinamide most often comes in base and hydrochloride forms. European Medicines Agency schedules Benzquinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05768MIG. The term BENZQUINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BENZQUINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzquinamide under HS 29339990 and SITC 51577. As of Q4 2014, BENZQUINAMIDE remains the US FDA Preferred Term for this commodity. Benzquinamide bears US NLM identifiers UMLS ID C0053284 and NCI Concept Code C65253. SMILES: O(C1C(CN2C(C1)C1C(CC2)CC(OC)C(OC)C1)C(=O)N(CC)CC)C(=O)C.
This classification denotes a thiazide diuretic with the molecular formula C15H14ClN3O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1TD8J48L61, chemically known as 6-chloro-7-sulfamoyl-3-benzylthiomethyl-2h-1,2,4-benzothiadiazine 1,1-dioxide but generally known as benzthiazide, which bears US NIH Compound Identifier 2343. European Medicines Agency schedules Benzthiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05769MIG. The term BENZTHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). BENZTHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzthiazide under HS 29350090 and SITC 51580. As of Q4 2014, BENZTHIAZIDE remains the US FDA Preferred Term for this commodity. Benzthiazide bears US NLM identifiers UMLS ID C0053245 and NCI Concept Code C65254. SMILES: CLC1C(S(=O)(=O)N)CC2S(=O)(=O)N=C(NC2C1)CSCC1CCCCC1.
This classification denotes an antimuscarinic agent with the molecular formula C21H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1NHL2J4X8K, chemically known as 8-azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo- (9ci) but generally known as benzatropine, which bears US NIH Compound Identifier 6832. Benzatropine most often comes in base and methanesulfonate forms. European Medicines Agency schedules Benzatropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05742MIG. The term BENZATROPINE is an International Non-Proprietary Name. World Health Organization schedules benzatropine in its Anatomical Therapeutic Chemical (ATC) Classification. BENZATROPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BENZTROPINE remains the US FDA Preferred Term for this commodity. Benztropine bears US NLM identifiers UMLS ID C0005098 and NCI Concept Code C61649. SMILES: O(C1CC2N(C(CC2)C1)C)C(C1CCCCC1)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O21U048EF, chemically known as 1-propanamine, n,n-dimethyl-3-((1-(phenylmethyl)-1h-indazol-3-yl)oxy)- but generally known as benzydamine, which bears US NIH Compound Identifier 12555. Benzydamine most often comes in base, hydrochloride, n-oxide, and salicylate forms. European Medicines Agency schedules Benzydamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05770MIG. The term BENZYDAMINE is an International Non-Proprietary Name. World Health Organization schedules benzydamine in its Anatomical Therapeutic Chemical (ATC) Classification. BENZYDAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benzydamine under HS 29339990 and SITC 51577. As of Q4 2014, BENZYDAMINE remains the US FDA Preferred Term for this commodity. Benzydamine bears US NLM identifiers UMLS ID C0005099 and NCI Concept Code C83548. SMILES: O(C1NN(C2C1CCCC2)CC1CCCCC1)CCCN(C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H23N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2GI407R4Q, chemically known as 3-((1-benzyl-1h-indazol-3-yl)oxy)-n,n-dimethylpropylamine monohydrochloride but more generally known as benzydamine hydrochloride, which bears US NIH Compound Identifier 65464. European Medicines Agency schedules Benzydamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00737MIG. Most nations, for tariff and trade purposes, schedule benzydamine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BENZYDAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Benzydamine hydrochloride bears US NLM identifiers UMLS ID C1511108 and NCI Concept Code C1581. SMILES: CN(C)CCCOC1C2CCCCC2N(N1)CC3CCCCC3.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This clasification denotes an ester of benzyl alcohol and benzoic acid, with the formula C6H5CH2O2CC6H5 called benzyl benzoate. This easily prepared compound with a mild balsamic odor has a variety of uses. Most nations schedule Benzyl benzoate under HS 29163100 and SITC 51379. As of Q4 2014, BENZYL BENZOATE remains the US FDA Preferred Term for this commodity. Benzyl benzoate bears US NLM identifiers UMLS ID C0053289 and NCI Concept Code C65255. SMILES: C1CCC(CC1)COC(=O)C2CCCCC2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS201. This VA Drug Class (RS201) classifies this compound as belonging to the group HEMORRHOIDAL PREPARATIONS WITHOUT STEROID.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS201. This VA Drug Class (RS201) classifies this compound as belonging to the group HEMORRHOIDAL PREPARATIONS WITHOUT STEROID.
This classification denotes a penicillin antibiotic with the molecular formula C16H18N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q42T66VG0C, chemically known as penicillin, (phenylmethyl)- but generally known as benzylpenicillin, which bears US NIH Compound Identifier 2349. Benzylpenicillin comes in many forms, including base, benzathine, benzathine hydrate, beta-diethylaminoethyl ester, dibenzylethylenediamine salt, g, novocaine salt, potassium, procaine, procaine monohydrate, and sodium. European Medicines Agency schedules Benzylpenicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05772MIG. The term BENZYLPENICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules benzylpenicillin in its Anatomical Therapeutic Chemical (ATC) Classification. BENZYLPENICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Benzylpenicillin or penicillin g bears US NLM identifiers UMLS ID C0030827 and NCI Concept Code C61883. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)CC1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C16H17N2O4S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VL775ZTH4C. European Medicines Agency schedules benzylpenicillin potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13036MIG. The term benzylpenicillin potassium is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule benzylpenicillin potassium under HS 29411090. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3CCCCC3)C(=O)[O-])C.[K+].
This classification denotes a penicillin antibiotic with the molecular formula C16H17N2O4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YS5LY7JF4N, chemically known as penicillin, (phenylmethyl)- but more generally known as benzylpenicillin sodium, which bears US NIH Compound Identifier 2349. European Medicines Agency schedules Benzylpenicillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13038MIG. Most nations, for tariff and trade purposes, schedule benzylpenicillin sodium under HS 29411090. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3CCCCC3)C(=O)[O-])C.[NA+].
Benzylpenicillin sodium/procaine benzylpenicillin or procaine penicillin G is an antibiotic used to treat infections caused by susceptible bacteria.
This classification denotes a topical anti-infective agent with the molecular formula C13H14N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AI9WDT80FQ, chemically known as sulfanilamide, n(sup 4)-benzyl- but more generally known as benzylsulfamide, which bears US NIH Compound Identifier 66909. European Medicines Agency schedules Benzylsulfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05773MIG. The term BENZYLSULFAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). BENZYLSULFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(NCC1CCCCC1)C1CCC(N)CC1.
This classification denotes a uridine phosphorylase antagonist and inhibitor with the molecular formula C11H10N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PZ35LUM333, chemically known as uracil, benzylthio- but generally known as benzylthiouracil, which bears US NIH Compound Identifier 198125. European Medicines Agency schedules Benzylthiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13040MIG. World Health Organization schedules benzylthiouracil in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BENZYLTHIOURACIL remains the US FDA Preferred Term for this commodity. SMILES: C1C=CC=CC1CC23C(=NC=NC2=O)S3.
This classification denotes an antiplatelet agent with the molecular formula C23H22ClN5O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CKS724B66O, chemically known as 4-((6-(o-chlorophenyl)-8,9-dihydro-1-methyl-4h,7h-cyclopenta(4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-8-yl)carbonyl)morpholine but generally known as bepafant, which bears US NIH Compound Identifier 65923. European Medicines Agency schedules Bepafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05774MIG. The term BEPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). Most nations schedule bepafant under HS 29349990 and SITC 51579. As of Q4 2014, BEPAFANT remains the US FDA Preferred Term for this commodity. Bepafant bears US NLM identifiers UMLS ID C0378528 and NCI Concept Code C77947. SMILES: CLC1C(C2=NCC3N(C4SC5CC(CC5C24)C(=O)N2CCOCC2)C(NN3)C)CCCC1.
This classification denotes an antinematodal agent with the molecular formula C17H22NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PXO9B4983I, chemically known as n,n-dimethyl-n-(2-phenoxyethyl)-benzenemethanaminium but generally known as bephenium, which bears US NIH Compound Identifier 19667. Bephenium most often comes in chloride and hydroxynaphthoate forms. World Health Organization schedules bephenium in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BEPHENIUM remains the US FDA Preferred Term for this commodity. SMILES: C[N+](C)(CCOC1=CC=CC=C1)CC2=CC=CC=C2.
This classification denotes an antihelminthic agent with the molecular formula C17H22NO.C11H7O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47RU9546DX, chemically known as benzenemethanaminium, n,n-dimethyl-n-(2-phenoxyethyl)-, salt with 3-hydroxy-2-naphthalenecarboxylic acid (1:1) but more generally known as bephenium hydroxynaphthoate, which bears US NIH Compound Identifier 19666. European Medicines Agency schedules Bephenium hydroxynaphthoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05776MIG. The term BEPHENIUM HYDROXYNAPHTHOATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). Most nations, for tariff and trade purposes, schedule bephenium hydroxynaphthoate under HS 29239000 and SITC 51481. As of Q4 2014, BEPHENIUM HYDROXYNAPHTHOATE remains US FDA's Preferred Term for this commodity. Bephenium hydroxynaphthoate bears US NLM identifiers UMLS ID C0053335 and NCI Concept Code C75210. SMILES: C[N+](C)(CCOC1CCCCC1)CC2CCCCC2.C1CCC2CC(C(CC2C1)C(=O)[O-])O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H17N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35QK773Y96, chemically known as 6-(2-(dimethylamino)ethyl)pyrido(2,3-b)(1,5)benzothiazepin-5(6h)-one but generally known as bepiastine, which bears US NIH Compound Identifier 185456. European Medicines Agency schedules Bepiastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05777MIG. The term BEPIASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). BEPIASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bepiastine under HS 29349990 and SITC 51579. As of Q4 2014, BEPIASTINE remains the US FDA Preferred Term for this commodity. Bepiastine bears US NLM identifiers UMLS ID C2347002 and NCI Concept Code C73044. SMILES: S1C2C(N(CCN(C)C)C(=O)C3C1NCCC3)CCCC2.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HYD2U48IAS. European Medicines Agency schedules Bepotastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05778MIG. Bepotastine generally arises in the molecular formula C21H25CLN2O3. The term BEPOTASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) Most nations schedule bepotastine under HS 29333999 and SITC 51574. As of Q4 2014, BEPOTASTINE remains the US FDA Preferred Term for this commodity. Bepotastine bears US NLM identifiers UMLS ID C2698371 and NCI Concept Code C77431. SMILES: C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25CLN2O3.C6H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6W18MO1QR3. European Medicines Agency schedules bepotastine besilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05778MIG. The term bepotastine besilate is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule bepotastine besilate under HS 29333999 and SITC 51574. As of Q4 2014, BEPOTASTINE BESILATE remains US FDA's Preferred Term for this commodity. Bepotastine besilate bears US NLM identifiers UMLS ID C1723019 and NCI Concept Code C83550. SMILES: C1CCC(CC1)S(=O)(=O)O.C1CCNC(C1)[C@H](C2CCC(CC2)CL)OC3CCN(CC3)CCCC(=O)O.
This classification denotes a calcium channel blocker with the molecular formula C24H34N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 755BO701MA, chemically known as 1-pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-n-phenyl-n-(phenylmethyl)- but generally known as bepridil, which bears US NIH Compound Identifier 2351. Bepridil most often comes in base and hydrochloride forms. European Medicines Agency schedules Bepridil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13041MIG. The term BEPRIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules bepridil in its Anatomical Therapeutic Chemical (ATC) Classification. BEPRIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bepridil under HS 29339990 and SITC 51577. As of Q4 2014, BEPRIDIL remains the US FDA Preferred Term for this commodity. Bepridil bears US NLM identifiers UMLS ID C0005116 and NCI Concept Code C87448. SMILES: O(CC(N1CCCC1)CN(CC1CCCCC1)C1CCCCC1)CC(C)C.
This classification denotes a calcium channel blocker with the molecular formula C24H34N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W2P15D93M, chemically known as 1-pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-n-phenyl-n-(phenylmethyl)-, monohydrochloride but more generally known as bepridil hydrochloride, which bears US NIH Compound Identifier 50088. European Medicines Agency schedules Bepridil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13042MIG. Most nations, for tariff and trade purposes, schedule bepridil hydrochloride under HS 29339990. As of Q4 2014, BEPRIDIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bepridil hydrochloride bears US NLM identifiers UMLS ID C0770909 and NCI Concept Code C47412. SMILES: CC(C)COCC(CN(CC1CCCCC1)C2CCCCC2)N3CCCC3.O.CL.
This classification denotes a calcium channel blocker with the molecular formula C24H34N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W2P15D93M, chemically known as 1-(2-(n-benzylanilino)-1-(isobutoxymethyl)ethyl)-pyrrolidine monohydrochloride monohydrate, but more generally known as bepridil hydrochloride monohydrate, which bears US NIH Compound Identifier 91725. European Medicines Agency schedules bepridil hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13041MIG. Most nations, for tariff purposes, schedule bepridil hydrochloride monohydrate under HS 29339990. SMILES: CC(C)COCC(CN(CC1CCCCC1)C2CCCCC2)N3CCCC3.O.CL.
This classification denotes a respiratory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S866O45PIG.The European Medicines Agency schedules Beractant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13043MIG. As of Q4 2014, BERACTANT remains the US FDA Preferred Term for this commodity.
This classification denotes a prostaglandin analogue with the molecular formula C24H30O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35E3NJJ4O6, chemically known as 2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1h-cyclopenta(b)benzofuran-5-butanoic acid but generally known as beraprost, which bears US NIH Compound Identifier 5282428. Beraprost most often comes in base and sodium forms. European Medicines Agency schedules Beraprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05779MIG. World Health Organization schedules beraprost in its Anatomical Therapeutic Chemical (ATC) Classification. BERAPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule beraprost under HS 29375000 and SITC 54156. As of Q4 2014, BERAPROST remains the US FDA Preferred Term for this commodity. Beraprost bears US NLM identifiers UMLS ID C0053336 and NCI Concept Code C76896. SMILES: O1C2C(C(C(O)C2)/C=C/C(O)C(CC#CC)C)C2C1C(CCC2)CCCC(=O)O.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4MYE3XA3GV. European Medicines Agency schedules Berlafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05781MIG. Berlafenone generally arises in the molecular formula C19H25NO2. The term BERLAFENONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, list 31.) BERLAFENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule berlafenone under HS 29221980 and SITC 51461. As of Q4 2014, BERLAFENONE remains US FDA's Preferred Term for this commodity. Berlafenone bears US NLM identifiers UMLS ID C0165557 and NCI Concept Code C72576. SMILES: O(CC(O)CNC(C)(C)C)C1C(C2CCCCC2)CCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CWU66767HF, chemically known as 10,11-dihydro-alpha,8-dimethyl-11-oxo-dibenz(b,f)oxepin-2-acetic acid but generally known as bermoprofen, which bears US NIH Compound Identifier 54204. European Medicines Agency schedules Bermoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05782MIG. The term BERMOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). BERMOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bermoprofen under HS 29329985 and SITC 51569. As of Q4 2014, BERMOPROFEN remains the US FDA Preferred Term for this commodity. Bermoprofen bears US NLM identifiers UMLS ID C0053340 and NCI Concept Code C73078. SMILES: O1C2C(CC(C(C)C(=O)O)CC2)C(=O)CC2C1CCC(C2)C.
This classification denotes a dopamine antagonist with the molecular formula C19H19BrClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 420895MAOC, chemically known as (+)-(5s)-5-(5-bromo-2,3-dihydro-7-benzofuranyl)-8-chloro-2,3,4,5-tetrahydro-3-methyl-1h-3-benzazepin-7-ol but generally known as berupipam, which bears US NIH Compound Identifier 66002. European Medicines Agency schedules Berupipam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05784MIG. The term BERUPIPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). Most nations schedule berupipam under HS 29349990 and SITC 51579. As of Q4 2014, BERUPIPAM remains the US FDA Preferred Term for this commodity. Berupipam bears US NLM identifiers UMLS ID C0384052 and NCI Concept Code C81087. SMILES: BRC1CC(C2CN(CCC3C2CC(O)C(CL)C3)C)C2OCCC2C1.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C28H31FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 057SF9C1UZ, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)spiro(2h-1-benzopyran-2,1-cyclopentan)-3-yl)-3,5-dihydroxy-, ethyl ester, (3r,5s,6e)-rel- but generally known as bervastatin, which bears US NIH Compound Identifier 6436003. European Medicines Agency schedules Bervastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05785MIG. The term BERVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). Most nations schedule bervastatin under HS 29329985 and SITC 51569. As of Q4 2014, BERVASTATIN remains the US FDA Preferred Term for this commodity. Bervastatin bears US NLM identifiers UMLS ID C2698372 and NCI Concept Code C77441. SMILES: Fc1ccc(C2=C(C3(Oc4c2cccc4)CCCC3)/C=C/C(O)CC(O)CC(=O)OCC)cc1.
This classification denotes a quinolone antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BFE2NBZ7NX. European Medicines Agency schedules Besifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33064. Besifloxacin generally arises in the molecular formula C19H21CLFN3O3. The term BESIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 3, 2008, list 60.) Most nations schedule besifloxacin under HS 29334900 and SITC 51575. As of Q4 2014, BESIFLOXACIN remains the US FDA Preferred Term for this commodity. Besifloxacin bears US NLM identifiers UMLS ID C2351042 and NCI Concept Code C83553. SMILES: C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F.
This classification denotes a quinolone antibiotic with the molecular formula C19H21CLFN3O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7506A6J57T. The term besifloxacin hydrochloride is a United States Adopted Name designation. Most nations schedule besifloxacin hydrochloride under HS 29334900 and SITC 51575. As of Q4 2014, BESIFLOXACIN HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Besifloxacin hydrochloride bears US NLM identifiers UMLS ID C2710017 and NCI Concept Code C76228. SMILES: C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F.Cl.
This classification denotes a diuretic with the molecular formula C15H16ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 048UJ2MM65, chemically known as 1-((4-chloro-3-sulfamoylbenzoyl)amino)-2,4,6-trimethylpyridinium hydroxide, inner salt but generally known as besulpamide, which bears US NIH Compound Identifier 9571085. European Medicines Agency schedules Besulpamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05789MIG. The term BESULPAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). BESULPAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule besulpamide under HS 29350090 and SITC 51580. As of Q4 2014, BESULPAMIDE remains the US FDA Preferred Term for this commodity. Besulpamide bears US NLM identifiers UMLS ID C0053356 and NCI Concept Code C74254. SMILES: CLC1C(S(=O)(=O)N)CC(C(=N\[N]2C(CC(CC2C)C)C)\O)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT050. This VA Drug Class (VT050) classifies this compound as belonging to the group VITAMIN A.
This classification denotes an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 905GLN509G, chemically known as 3-heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3r,6r)-(-)- but generally known as betacetylmethadol, which bears US NIH Compound Identifier 62710. European Medicines Agency schedules Betacetylmethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05792MIG. The term BETACETYLMETHADOL is an International Non-Proprietary Name. BETACETYLMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule betacetylmethadol under HS 29221980 and SITC 51461. As of Q4 2014, BETACETYLMETHADOL remains the US FDA Preferred Term for this commodity. Betacetylmethadol bears US NLM identifiers UMLS ID C2698377 and NCI Concept Code C77278. SMILES: O(C(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC)C(=O)C.
This classification denotes a vasodilating agent with the molecular formula C8H12N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X32KK4201D, chemically known as 2-pyridineethanamine, n-methyl- but generally known as betahistine, which bears US NIH Compound Identifier 2366. Betahistine most often comes in base, dihydrochloride, hydrochloride, and mesylate forms. European Medicines Agency schedules Betahistine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05794MIG. The term BETAHISTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules betahistine in its Anatomical Therapeutic Chemical (ATC) Classification. BETAHISTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule betahistine under HS 29333999 and SITC 51574. As of Q4 2014, BETAHISTINE remains the US FDA Preferred Term for this commodity. Betahistine bears US NLM identifiers UMLS ID C0005301 and NCI Concept Code C83554. SMILES: N(CCC1NCCCC1)C.
This classification denotes a vasodilating agent with the molecular formula C8H12N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49K58SMZ7U, chemically known as 2-pyridineethanamine, n-methyl-, dihydrochloride but more generally known as betahistine dihydrochloride, which bears US NIH Compound Identifier 68643. The base compound, Betahistine, most often comes in base, dihydrochloride, hydrochloride, and mesylate forms. European Medicines Agency schedules Betahistine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00772MIG. Most nations, for tariff and trade purposes, schedule betahistine dihydrochloride under HS 29333999. SMILES: CNCCC1CCCCN1.CL.CL.
This classification denotes a vasodilating agent with the molecular formula C8H12N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49K58SMZ7U, chemically known as 2-pyridineethanamine, n-methyl-, dihydrochloride but more generally known as betahistine dihydrochloride, which bears US NIH Compound Identifier 68643. The base compound, Betahistine, most often comes in base, dihydrochloride, hydrochloride, and mesylate forms. European Medicines Agency schedules Betahistine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00772MIG. Most nations, for tariff and trade purposes, schedule betahistine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BETAHISTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Betahistine hydrochloride bears US NLM identifiers UMLS ID C0282071 and NCI Concept Code C73794. SMILES: CNCCC1CCCCN1.CL.CL.
This classification denotes a vasodilating agent with the molecular formula C8H12N2.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1L0E3R43Y, chemically known as 2-pyridineethanamine, n-methyl-, dimethanesulfonate but more generally known as betahistine mesilate, which bears US NIH Compound Identifier 198334. The base compound, Betahistine, most often comes in base, dihydrochloride, hydrochloride, and mesylate forms. European Medicines Agency schedules Betahistine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00773MIG. Most nations, for tariff and trade purposes, schedule betahistine mesilate under HS 29333999 and SITC 51574. As of Q4 2014, BETAHISTINE MESILATE remains US FDA's Preferred Term for this commodity. SMILES: CNCCC1CCCCN1.CS(=O)(=O)O.CS(=O)(=O)O.
This classification denotes a nutritional supplement with the molecular formula C5H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3SCV180C9W, chemically known as 2-(trimethylammonio)ethanoic acid, hydroxide, inner salt but generally known as betaine, which bears US NIH Compound Identifier 247. Betaine comes in many forms, including base, aldehyde, aldehyde chloride, aldehyde hydrate, alpha-d-glucofuranuronate, amide, aspartate, cephaloridine, chloride, choline citrate, citrate, d-galacturonate, d-gluconate, hydrate, hydrazide hydrochloride, hydrochloride, l-ascorbate, lauryldimethylaminoacetate, methyl ester, monohydrate, nicotinate, solution, and tartrate. European Medicines Agency schedules Betaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13055MIG. World Health Organization schedules betaine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Betaine under HS 29239000 and SITC 51481. As of Q4 2014, BETAINE remains the US FDA Preferred Term for this commodity. Betaine bears US NLM identifiers UMLS ID C1166065 and NCI Concept Code C81038. SMILES: C[N+](C)(C)CC(=O)[O-].
This classification denotes a nutritional supplement with the molecular formula C5H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3SCV180C9W, chemically known as 2-(trimethylammonio)ethanoic acid, hydroxide, inner salt but more generally known as betaine, which bears US NIH Compound Identifier 247. Betaine comes in many forms, including base, aldehyde, aldehyde chloride, aldehyde hydrate, alpha-d-glucofuranuronate, amide, aspartate, cephaloridine, chloride, choline citrate, citrate, d-galacturonate, d-gluconate, hydrate, hydrazide hydrochloride, hydrochloride, l-ascorbate, lauryldimethylaminoacetate, methyl ester, monohydrate, nicotinate, solution, and tartrate. European Medicines Agency schedules Betaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13055MIG. World Health Organization schedules betaine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule betaine anhydrous under HS 29239000. SMILES: C[N+](C)(C)CC(=O)[O-].
This classification denotes a nutritional supplement with the molecular formula C5H11NO2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TPU0ITR2BR, chemically known as 1-carboxy-n,n,n-trimethylmethanaminium, chloride but more generally known as betaine hydrate, which bears US NIH Compound Identifier 248. The base compound, Betaine, comes in many forms, including base, aldehyde, aldehyde chloride, aldehyde hydrate, alpha-d-glucofuranuronate, amide, aspartate, cephaloridine, chloride, choline citrate, citrate, d-galacturonate, d-gluconate, hydrate, hydrazide hydrochloride, hydrochloride, l-ascorbate, lauryldimethylaminoacetate, methyl ester, monohydrate, nicotinate, solution, and tartrate. Most nations, for tariff and trade purposes, schedule betaine hydrate under HS 29239000. As of Q4 2014, BETAINE HYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C[N+](C)(C)CC(=O)[O-].O.
This classification denotes a nutritional supplement with the molecular formula C5H12NO2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JK8U8K4D6K, chemically known as 1-carboxy-n,n,n-trimethylmethanaminium, chloride but more generally known as betaine hydrochloride, which bears US NIH Compound Identifier 248. The base compound, Betaine, comes in many forms, including base, aldehyde, aldehyde chloride, aldehyde hydrate, alpha-d-glucofuranuronate, amide, aspartate, cephaloridine, chloride, choline citrate, citrate, d-galacturonate, d-gluconate, hydrate, hydrazide hydrochloride, hydrochloride, l-ascorbate, lauryldimethylaminoacetate, methyl ester, monohydrate, nicotinate, solution, and tartrate. European Medicines Agency schedules Betaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13059MIG. World Health Organization schedules betaine hydrochloride in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule betaine hydrochloride under HS 29239000 and SITC 51481. As of Q4 2014, BETAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Betaine hydrochloride bears US NLM identifiers UMLS ID C0282072 and NCI Concept Code C82301. SMILES: C[N+](C)(C)CC(=O)O.[CL-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes an opioid receptor agonist with the molecular formula C21H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57ANR1Z628, chemically known as 6-dimethylamino-4,4-diphenyl-3-heptanol, hydrochloride but generally known as betamethadol, which bears US NIH Compound Identifier 28397. European Medicines Agency schedules Betamethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05796MIG. The term BETAMETHADOL is an International Non-Proprietary Name. BETAMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Betametadol or betamethadol bears US NLM identifiers UMLS ID C2698379 and NCI Concept Code C77279. SMILES: OC(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9842X06Q6M, chemically known as 9-fluoro-11.beta.,17, 21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione but generally known as betamethasone, which bears US NIH Compound Identifier 3003. Betamethasone comes in many forms, including base, acetate, acetate phosphate, acibutate, alcohol, benzoate, butyrate propionate, dihydrogen phosphate, dipropionate, disodium phosphate, phosphate, sodium, sodium phosphate, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate. European Medicines Agency schedules Betamethasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05797MIG. The term BETAMETHASONE is an International Non-Proprietary Name. World Health Organization schedules betamethasone in its Anatomical Therapeutic Chemical (ATC) Classification. BETAMETHASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule betamethasone under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE remains the US FDA Preferred Term for this commodity. Betamethasone bears US NLM identifiers UMLS ID C0005308 and NCI Concept Code C303. SMILES: FC12C(C3C(C(O)(C(C3)C)C(=O)CO)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TI05AO53L7, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.beta.)- but more generally known as betamethasone acetate, which bears US NIH Compound Identifier 3680. Betamethasone comes in many other forms, including base, acetate phosphate, acibutate, alcohol, benzoate, butyrate propionate, dihydrogen phosphate, dipropionate, disodium phosphate, phosphate, sodium, sodium phosphate, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate. European Medicines Agency schedules Betamethasone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00780MIG. Most nations, for tariff and trade purposes, schedule betamethasone acetate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE ACETATE remains US FDA's Preferred Term for this commodity. Betamethasone acetate bears US NLM identifiers UMLS ID C0005310 and NCI Concept Code C65256. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H37FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90I96070LY, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregnpa-1,4-diene-3,20-dione 21-acetate 17-isobutyrate but more generally known as betamethasone acibutate, which bears US NIH Compound Identifier 111080. Betamethasone comes in many other forms, including base, acetate, acetate phosphate, alcohol, benzoate, butyrate propionate, dihydrogen phosphate, dipropionate, disodium phosphate, phosphate, sodium, sodium phosphate, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate. European Medicines Agency schedules Betamethasone acibutate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05798MIG. The term BETAMETHASONE ACIBUTATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). Most nations, for tariff and trade purposes, schedule betamethasone acibutate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE ACIBUTATE remains US FDA's Preferred Term for this commodity. Betamethasone acibutate bears US NLM identifiers UMLS ID C2698380 and NCI Concept Code C74405. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C(C)C)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 877K0XW47A, chemically known as pregna-1,4-diene-3,20-dione, 17-(benzoyloxy)-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.beta.)- but more generally known as betamethasone benzoate, which bears US NIH Compound Identifier 571358. The base compound, Betamethasone, comes in many other forms, including base, acetate, acetate phosphate, acibutate, alcohol, butyrate propionate, dihydrogen phosphate, dipropionate, disodium phosphate, phosphate, sodium, sodium phosphate, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate. European Medicines Agency schedules Betamethasone benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00781MIG. Most nations, for tariff and trade purposes, schedule betamethasone benzoate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE BENZOATE remains US FDA's Preferred Term for this commodity. Betamethasone benzoate bears US NLM identifiers UMLS ID C0005311 and NCI Concept Code C65257. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)OC(=O)C5CCCCC5)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C29H39FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50FH5AG9RW, chemically known as 9-fluoro-11-hydroxy-16-methyl-17-(1-oxobutoxy)-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione (11beta,16beta)- but more generally known as betamethasone butyrate propionate, which bears US NIH Compound Identifier 71470. The base compound, Betamethasone comes in many other forms, including base, acetate, acetate phosphate, acibutate, alcohol, benzoate, dihydrogen phosphate, dipropionate, disodium phosphate, phosphate, sodium, sodium phosphate, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate. European Medicines Agency schedules Betamethasone butyrate propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13061MIG. Most nations, for tariff and trade purposes, schedule betamethasone butyrate propionate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE BUTYRATE PROPIONATE remains US FDA's Preferred Term for this commodity. Betamethasone butyrate propionate bears US NLM identifiers UMLS ID C2698381 and NCI Concept Code C78755. SMILES: CCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)COC(=O)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30FO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJO1F9W10R, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, (11.beta.,16.beta.)-, but more generally known as betamethasone dihydrogen phosphate, which bears US NIH Compound Identifier 107782. European Medicines Agency schedules betamethasone dihydrogen phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05797MIG. Most nations, for tariff purposes, schedule betamethasone dihydrogen phosphate under HS 29372200. As of Q4 2014, BETAMETHASONE DIHYDROGEN PHOSPHATE remains US FDA's Preferred Term for this commodity. Betamethasone dihydrogen phosphate bears US NLM identifiers UMLS ID C2698382 and NCI Concept Code C77406. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H37FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 826Y60901U, chemically known as 16-beta-methyl-1,4-pregnadiene-9-alpha-fluoro-11-beta,17-alpha,21-triol-3,20-dione but more generally known as betamethasone dipropionate, which bears US NIH Compound Identifier 9782. The base compound, Betamethasone, comes in many other forms, including base, acetate, acetate phosphate, acibutate, alcohol, benzoate, butyrate propionate, dihydrogen phosphate, disodium phosphate, phosphate, sodium, sodium phosphate, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate. European Medicines Agency schedules Betamethasone dipropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00783MIG. Most nations, for tariff and trade purposes, schedule betamethasone dipropionate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE DIPROPIONATE remains US FDA's Preferred Term for this commodity. Betamethasone dipropionate bears US NLM identifiers UMLS ID C0053523 and NCI Concept Code C47963. SMILES: CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)OC(=O)CC.
Definition: This classification is for a combination analgesic and antiinflammatory therapy. The first component, BETAMETHASONE, has US FDA Unique Ingredient Identifier of 9842X06Q6M. The second component, LIDOCAINE, has US FDA Unique Ingredient Identifier of 98PI200987. The third component, PHENYLEPHRINE, has US FDA Unique Ingredient Identifier of 1WS297W6MV.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30FO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJO1F9W10R, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-(hydrogen phosphonate) but more generally known as betamethasone dihydrogen phosphate, which bears US NIH Compound Identifier 107782. The base compound, Betamethasone comes in many other forms, including base, acetate, acetate phosphate, acibutate, alcohol, benzoate, butyrate propionate, dipropionate, disodium phosphate, phosphate, sodium, sodium phosphate, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate. European Medicines Agency schedules Betamethasone dihydrogen phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32576. Most nations, for tariff and trade purposes, schedule betamethasone phosphate under HS 29372200 and SITC 54153. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28FO8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BK02SCL3W, chemically known as 9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl dihydrogen phosphate but more generally known as betamethasone sodium phosphate, which bears US NIH Compound Identifier 2367. The base compound, Betamethasone, comes in many other forms, including base, acetate, acetate phosphate, acibutate, alcohol, benzoate, butyrate propionate, dihydrogen phosphate, dipropionate, phosphate, sodium, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate. European Medicines Agency schedules Betamethasone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00784MIG. Most nations, for tariff and trade purposes, schedule betamethasone sodium phosphate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE SODIUM PHOSPHATE remains US FDA's Preferred Term for this commodity. Betamethasone sodium phosphate bears US NLM identifiers UMLS ID C0700603 and NCI Concept Code C47964. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[NA+].[NA+].
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H33FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LMR652FZVK. European Medicines Agency schedules betamethasone succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00785MIG. Most nations, for tariff and trade purposes, schedule betamethasone succinate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE SUCCINATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)CCC(=O)O)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9IFA5XM7R2, chemically known as 16-beta-methyl-1,4-pregnadiene-9-alpha-fluoro-11-beta,17-alpha,21-triol-3,20-dione but more generally known as betamethasone valerate, which bears US NIH Compound Identifier 9782. The base compound, Betamethasone, comes in many other forms, including base, acetate, acetate phosphate, acibutate, alcohol, benzoate, butyrate propionate, dihydrogen phosphate, dipropionate, disodium phosphate, phosphate, sodium, sodium phosphate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, and 21-phosphate disodium. European Medicines Agency schedules Betamethasone valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00786MIG. Most nations, for tariff and trade purposes, schedule betamethasone valerate under HS 29372200 and SITC 54153. As of Q4 2014, BETAMETHASONE VALERATE remains US FDA's Preferred Term for this commodity. Betamethasone valerate bears US NLM identifiers UMLS ID C0750848 and NCI Concept Code C47962. SMILES: CCCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CO.
This classification denotes an aminoglycoside antibiotic with the molecular formula C19H38N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 67W9DGG4C7 chemically known as d-streptamine, o-6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6))-2-deoxy- but generally known as betamicin, which bears US NIH Compound Identifier 37569. European Medicines Agency schedules Betamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05799MIG. The term BETAMICIN is an International Non-Proprietary Name or INN. Most nations schedule betamicin under HS 29419000 and SITC 54139. As of Q4 2014, BETAMICIN remains the US FDA Preferred Term for this commodity. Betamicin bears US NLM identifiers UMLS ID C0061208 and NCI Concept Code C81375. SMILES: O(C1C(O)C(OC2OC(C(O)C(O)C2O)CN)C(N)CC1N)C1OCC(O)(C(NC)C1O)C.
This classification denotes the sulfate form of an aminoglycoside antibiotic with the molecular structure C19H38N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 67W9DGG4C7 chemically known as d-streptamine, o-6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6))-2-deoxy-, but more commonly known as betamicin, which bears US NIH Compound Identifier 37569. European Medicines Agency schedules Betamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05799MIG. The term BETAMICIN is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule betamicin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, BETAMICIN SULFATE remains US FDA's Preferred Term for this commodity. Betamicin sulfate bears US NLM identifiers UMLS ID C0953456 and NCI Concept Code C79527. SMILES: C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N)N)O.OS(=O)(=O)O.
This classification denotes an artificial sweetener with the molecular formula C10H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3W0M245736, chemically known as beta-alanine, n-benzoyl- but more generally known as betamipron, which bears US NIH Compound Identifier 71651. European Medicines Agency schedules Betamipron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05800MIG. The term BETAMIPRON is an International Non-Proprietary Name. BETAMIPRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule betamipron under HS 29242995 and SITC 51479. As of Q4 2014, BETAMIPRON remains the US FDA Preferred Term for this commodity. Betamipron bears US NLM identifiers UMLS ID C0208283 and NCI Concept Code C72565. SMILES: C1=CC=C(C=C1)C(=O)NCCC(=O)O.
This classification denotes an adrenergic antagonist with the molecular formula C10H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8S3YM7AUU, chemically known as 2-benzyl-1,3-dimethylguanidine but generally known as betanidine, which bears US NIH Compound Identifier 2368. Betanidine most often comes in base and sulfate forms. European Medicines Agency schedules Betanidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05801MIG. The term BETANIDINE is an International Non-Proprietary Name. World Health Organization schedules betanidine in its Anatomical Therapeutic Chemical (ATC) Classification. BETANIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Betanidine or bethanidine bears US NLM identifiers UMLS ID C0005324 and NCI Concept Code C81343. SMILES: CNC(=NC)NCC1=CC=CC=C1.
This classification denotes an antihypertensive agent and adrenergic antagonist with the molecular formula 2C10H15N3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4THI5N7O2, chemically known as 2-benzyl-1,3-dimethylguanidine but more generally known as betanidine sulfate, which bears US NIH Compound Identifier 2368. European Medicines Agency schedules Betanidine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00787MIG. Most nations, for tariff and trade purposes, schedule betanidine sulfate under HS 29252900. SMILES: CNC(=NCC1CCCCC1)NC.CNC(=NCC1CCCCC1)NC.OS(=O)(=O)O.
This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C18H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X97D2XT0O, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (+-)- but more generally known as betaxolol hydrochloride, which bears US NIH Compound Identifier 107952. European Medicines Agency schedules Betaxolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13062MIG. Most nations, for tariff and trade purposes, schedule betaxolol hydrochloride under HS 29221980. As of Q4 2014, BETAXOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Betaxolol hydrochloride bears US NLM identifiers UMLS ID C0699055 and NCI Concept Code C47413. SMILES: CC(C)NCC(COC1CCC(CC1)CCOCC2CC2)O.CL.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0ZR1R6RZ2, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)- but generally known as betaxolol, which bears US NIH Compound Identifier 2369. Betaxolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Betaxolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05804MIG. The term BETAXOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules betaxolol in its Anatomical Therapeutic Chemical (ATC) Classification. BETAXOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Betaxolol or levobetaxolol bears US NLM identifiers UMLS ID C0005320 and NCI Concept Code C61652. SMILES: O(CC1CC1)CCC1CCC(OCC(O)CNC(C)C)CC1.
This classification denotes a diagnostic reagent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1C065P542O. European Medicines Agency schedules Betazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05805MIG. Betazole generally arises in the molecular formula C5H9N3. The term BETAZOLE is an International Non-Proprietary Name or INN. BETAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule betazole under HS 29331990 and SITC 51571. As of Q4 2014, BETAZOLE remains the US FDA Preferred Term for this commodity. Betazole bears US NLM identifiers UMLS ID C0005321 and NCI Concept Code C65258. SMILES: C1=C(NN=C1)CCN.
This classification denotes a diagnostic reagent with the molecular formula C5H9N3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66ABP6C83F, chemically known as 3-(2-aminoethyl)pyrazole dihydrochloride, but more generally known as betazole dihydrochloride, which bears US NIH Compound Identifier 67412. European Medicines Agency schedules betazole dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05805MIG. Most nations, for tariff purposes, schedule betazole dihydrochloride under HS 29331990. SMILES: C1C[NH]NC1CCN.CL.CL.
This classification denotes a diagnostic reagent with the molecular formula C5H9N3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66ABP6C83F, chemically known as 3,5-beta-pyrazoleethylamine dihydrochloride but more generally known as betazole hydrochloride, which bears US NIH Compound Identifier 67412. The base compound, betazole, most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Betazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00789MIG. Most nations, for tariff and trade purposes, schedule betazole hydrochloride under HS 29331990 and SITC 51571. As of Q4 2014, BETAZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Betazole hydrochloride bears US NLM identifiers UMLS ID C1879837 and NCI Concept Code C65259. SMILES: C1C[NH]NC1CCN.CL.CL.
This classification denotes an antimuscarinic agent with the molecular formula C7H17N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 004F72P8F4, chemically known as 2-((aminocarbonyl)oxy)-n,n,n-trimethyl-1-propanaminium but generally known as bethanechol, which bears US NIH Compound Identifier 2370. European Medicines Agency schedules Bethanechol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13063MIG. World Health Organization schedules bethanechol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BETHANECHOL remains the US FDA Preferred Term for this commodity. Bethanechol bears US NLM identifiers UMLS ID C0053526 and NCI Concept Code C76039. SMILES: O(C(C[N](C)(C)C)C)C(=O)N.
This classification denotes an anesthetic agent with the molecular formula C19H32N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03DB58Y9DO, chemically known as ethanol, 2-(2-(diethylamino)ethoxy)-, 3-amino-4-butoxybenzoate but generally known as betoxycaine, which bears US NIH Compound Identifier 19668. Betoxycaine most often comes in base, q, and hydrochloride forms. European Medicines Agency schedules Betoxycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05807MIG. The term BETOXYCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BETOXYCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule betoxycaine under HS 29225000 and SITC 51467. As of Q4 2014, BETOXYCAINE remains the US FDA Preferred Term for this commodity. Betoxycaine bears US NLM identifiers UMLS ID C2347003 and NCI Concept Code C72175. SMILES: O(CCN(CC)CC)CCOC(=O)C1CC(N)C(OCCCC)CC1.
This classification denotes an anesthetic agent with the molecular formula C19H32N2O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8II47759Z3. Most nations, for tariff and trade purposes, schedule betoxycaine hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, BETOXYCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Betoxycaine hydrochloride bears US NLM identifiers UMLS ID C2347004 and NCI Concept Code C73801. SMILES: CCCCOC1CCC(CC1N)C(=O)OCCOCCN(CC)CC.CL.
This classification denotes a monoclonal antibody anti-vegf with the molecular formula C6638H10160N1720O2108S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S9ZZM9Q9V, more generally known as bevacizumab. European Medicines Agency schedules bevacizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16402MIG. The term BEVACIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45. Most nations schedule Bevacizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, BEVACIZUMAB remains the US FDA Preferred Term for this commodity. . Bevacizumab bears US NLM identifiers UMLS ID C0796392 and NCI Concept Code C2039.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H27NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34ZXW6ZV21, chemically known as 2-propanol, 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)- but generally known as bevantolol, which bears US NIH Compound Identifier 2372. Bevantolol most often comes in base, hydrochloride, and metabolite forms. European Medicines Agency schedules Bevantolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05808MIG. The term BEVANTOLOL is an International Non-Proprietary Name. World Health Organization schedules bevantolol in its Anatomical Therapeutic Chemical (ATC) Classification. BEVANTOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bevantolol under HS 29225000 and SITC 51467. As of Q4 2014, BEVANTOLOL remains the US FDA Preferred Term for this commodity. Bevantolol bears US NLM identifiers UMLS ID C0053532 and NCI Concept Code C79556. SMILES: O(CC(O)CNCCC1CC(OC)C(OC)CC1)C1CC(CCC1)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H27NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VB9HU07BC, chemically known as 2-propanol, 1-((3,4-dimethoxyphenethyl)amino)-3-(m-tolyloxy)-, monohydrochloride but more generally known as bevantolol hydrochloride, which bears US NIH Compound Identifier 39324. European Medicines Agency schedules Bevantolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00793MIG. Most nations, for tariff and trade purposes, schedule bevantolol hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, BEVANTOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCCC(C1)OCC(CNCCC2CCC(C(C2)OC)OC)O.CL.
This classification denotes an anticholinergic agent with the molecular formula C22H28NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34B0471E08, chemically known as 2-(hydroxymethyl)-n,n-dimethylpiperidinium methyl sulfate benzilate but generally known as bevonium, which bears US NIH Compound Identifier 31800. bevonium most often comes in base and methyl sulfate forms, also called methylsulfate, methylsulphate, or even metilsulfate. European Medicines Agency schedules Bevonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00794MIG. World Health Organization schedules bevonium in its Anatomical Therapeutic Chemical (ATC) Classification. BEVONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BEVONIUM remains the US FDA Preferred Term for this commodity. Bevonium bears US NLM identifiers UMLS ID C0053533 and NCI Concept Code C73804. SMILES: O(CC1[N](CCCC1)(C)C)C(=O)C(O)(C1CCCCC1)C1CCCCC1. .
This classification denotes a retinoic acid agent with the molecular formula C24H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A61RXM4375, chemically known as 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid but generally known as bexarotene, which bears US NIH Compound Identifier 82146. European Medicines Agency schedules Bexarotene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00795MIG. The term BEXAROTENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules bexarotene in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule bexarotene under HS 29163900 and SITC 51379. As of Q4 2014, BEXAROTENE remains the US FDA Preferred Term for this commodity. Bexarotene bears US NLM identifiers UMLS ID C0765273 and NCI Concept Code C1635. SMILES: OC(=O)C1CCC(C(=C)C2CC3C(CCC(C3CC2C)(C)C)(C)C)CC1.
This classification denotes an anti-lipidemic agent with the molecular formula C19H20ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y9449Q51XH, chemically known as propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl- but generally known as bezafibrate, which bears US NIH Compound Identifier 39042. European Medicines Agency schedules Bezafibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05810MIG. The term BEZAFIBRATE is an International Non-Proprietary Name. World Health Organization schedules bezafibrate in its Anatomical Therapeutic Chemical (ATC) Classification. BEZAFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bezafibrate under HS 29242995 and SITC 51479. As of Q4 2014, BEZAFIBRATE remains the US FDA Preferred Term for this commodity. Bezafibrate bears US NLM identifiers UMLS ID C0005330 and NCI Concept Code C87449. SMILES: Clc1ccc(C(=O)NCCc2ccc(OC(C)(C)C(=O)O)cc2)cc1.
This classification denotes an analgesic agent with the molecular formula C31H32N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3KXW0Y310I, chemically known as 2-benzimidazolinone, 1-(1-(3-cyano-3,3-diphenylpropyl)-4-piperidyl)-3-propionyl- but generally known as bezitramide, which bears US NIH Compound Identifier 61791. European Medicines Agency schedules Bezitramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05811MIG. The term BEZITRAMIDE is an International Non-Proprietary Name. World Health Organization schedules bezitramide in its Anatomical Therapeutic Chemical (ATC) Classification. BEZITRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bezitramide under HS 29333300 and SITC 51574. As of Q4 2014, BEZITRAMIDE remains the US FDA Preferred Term for this commodity. Bezitramide bears US NLM identifiers UMLS ID C0053535 and NCI Concept Code C72109. SMILES: O=C1N(C2CCN(CC2)CCC(C2CCCCC2)(C2CCCCC2)C#N)C2C(N1C(=O)CC)CCCC2.
This classification denotes an antiprotozoal agent with the molecular formula C28H40N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TA5NM093QJ, chemically known as 5,5-diallyl-alpha,alpha-bis(diethylamino)-n,n-bitolyl-4,4-diol but generally known as bialamicol, which bears US NIH Compound Identifier 10304. Bialamicol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bialamicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05812MIG. The term BIALAMICOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). BIALAMICOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bialamicol under HS 29222900 and SITC 51462. As of Q4 2014, BIALAMICOL remains the US FDA Preferred Term for this commodity. Bialamicol bears US NLM identifiers UMLS ID C0301342 and NCI Concept Code C83555. SMILES: OC1C(CN(CC)CC)CC(C2CC(CN(CC)CC)C(O)C(C2)CC=C)CC1CC=C.
This classification denotes a beta-lactam antibiotic with the molecular formula C15H18N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YR5U3L9ZH1, chemically known as 6-(((4r,5s,6s)-2-carboxy-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-en-3-yl)thio)-6,7-dihydro-5h-pyrazolo(1,2-a)-s-triazol-4-ium hydroxide, inner salt but generally known as biapenem, which bears US NIH Compound Identifier 71339. European Medicines Agency schedules Biapenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05813MIG. The term BIAPENEM is an International Non-Proprietary Name. World Health Organization schedules biapenem in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule biapenem under HS 29419000 and SITC 54139. As of Q4 2014, BIAPENEM remains the US FDA Preferred Term for this commodity. Biapenem bears US NLM identifiers UMLS ID C0209475 and NCI Concept Code C72620. SMILES: S(C1=C(N2C(C(C2=O)C(O)C)C1C)C(=O)O)C1C[N]2N(C1)CNC2.
This classification denotes an antitussive agent with the molecular structure C19H26NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 34YTZ517S2 chemically known as (2-(1,2-diphenylethoxy)ethyltrimethyl)ammonium, but more commonly known as bibenzonium, which bears US NIH Compound Identifier 71954. European Medicines Agency schedules Bibenzonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00798MIG. As of Q4 2014, BIBENZONIUM remains US FDA's Preferred Term for this commodity. Bibenzonium bears US NLM identifiers UMLS ID C2347006 and NCI Concept Code C73821. SMILES: O(CC[N](C)(C)C)C(CC1CCCCC1)C1CCCCC1.
This classification denotes an antitussive agent with the molecular formula C19H26NO.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4455J9277Q, chemically known as (2-(1,2-diphenylethoxy)ethyltrimethyl)ammonium bromide but more generally known as bibenzonium bromide, which bears US NIH Compound Identifier 85001. European Medicines Agency schedules Bibenzonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05815MIG. The term BIBENZONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules bibenzonium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule bibenzonium bromide under HS 29239000 and SITC 51481. As of Q4 2014, BIBENZONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Bibenzonium bromide bears US NLM identifiers UMLS ID C2347007 and NCI Concept Code C73180. SMILES: C[N+](C)(C)CCOC(CC1CCCCC1)C2CCCCC2.[BR-].
This classification denotes an antimicrobial with the molecular formula C6Br4O2.Bi.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0KJ20H1BLJ, chemically known as 4,5,6,7-tetrabrom-1,3,2-benzodioxabismol-2-ol but generally known as bibrocathol, which bears US NIH Compound Identifier 16683103. European Medicines Agency schedules Bibrocathol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05816MIG. The term BIBROCATHOL is an International Non-Proprietary Name. World Health Organization schedules bibrocathol in its Anatomical Therapeutic Chemical (ATC) Classification. BIBROCATHOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bibrocathol under HS 29081900 and SITC 51244. As of Q4 2014, BIBROCATHOL remains the US FDA Preferred Term for this commodity. Bibrocathol bears US NLM identifiers UMLS ID C0602838 and NCI Concept Code C74156. SMILES: [BI]1(OC2C(O1)C(BR)C(BR)C(BR)C2BR)[OH2].
This classification denotes an anti-androgen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0Z3NAU9DP. European Medicines Agency schedules Bicalutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05817MIG. Bicalutamide generally arises in the molecular formula C18H14F4N2O4S. The term BICALUTAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) BICALUTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bicalutamide under HS 29309085 and SITC 51549. As of Q4 2014, BICALUTAMIDE remains the US FDA Preferred Term for this commodity. Bicalutamide bears US NLM identifiers UMLS ID C0285590 and NCI Concept Code C1599. SMILES: S(=O)(=O)(CC(O)(C)C(=O)NC1CC(C(CC1)C#N)C(F)(F)F)C1CCC(F)CC1.
This classification denotes an analgesic agent with the molecular formula C12H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B0SV3N7J3H, chemically known as 3-azabicyclo(3.1.0)hexane, 1-(4-methylphenyl)-, (+-)- but generally known as bicifadine, which bears US NIH Compound Identifier 47953. Bicifadine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bicifadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05818MIG. The term BICIFADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). BICIFADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bicifadine under HS 29339990 and SITC 51577. As of Q4 2014, BICIFADINE remains the US FDA Preferred Term for this commodity. Bicifadine bears US NLM identifiers UMLS ID C0053551 and NCI Concept Code C79930. SMILES: CC1=CC=C(C=C1)C23CC2CNC3.
This classification denotes a neuroprotective agent with the molecular formula C12H15N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OE6G20P68T, chemically known as 3-azabicyclo(3.1.0)hexane, 1-(4-methylphenyl)-, hydrochloride, (+-)- but more generally known as bicifadine hydrochloride, which bears US NIH Compound Identifier 47952. European Medicines Agency schedules Bicifadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32896. Most nations, for tariff and trade purposes, schedule bicifadine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BICIFADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bicifadine hydrochloride bears US NLM identifiers UMLS ID C0106275 and NCI Concept Code C81047. SMILES: CC1CCC(CC1)[C@@]23C[C@@H]2CNC3.CL.
This classification denotes an anti-lipidemic agent with the molecular formula C20H21Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73U81R979T, chemically known as bis(p-chlorophenoxy)-acetic acid, 1-methyl-2-pyrrolidinylmethyl ester but generally known as biclofibrate, which bears US NIH Compound Identifier 185458. European Medicines Agency schedules Biclofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05820MIG. The term BICLOFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). BICLOFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule biclofibrate under HS 29339990 and SITC 51577. As of Q4 2014, BICLOFIBRATE remains the US FDA Preferred Term for this commodity. Biclofibrate bears US NLM identifiers UMLS ID C2347008 and NCI Concept Code C72990. SMILES: Clc1ccc(OC(Oc2ccc(Cl)cc2)C(=O)OC(C2NCCC2)C)cc1.
This classification denotes an anti-infective agent with the molecular formula C21H26Cl2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W4K0AE8XW9, chemically known as 6,6-dichlor-2,2-methylendithymol but generally known as biclotymol, which bears US NIH Compound Identifier 71878. European Medicines Agency schedules Biclotymol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05821MIG. The term BICLOTYMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). BICLOTYMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule biclotymol under HS 29081900 and SITC 51244. As of Q4 2014, BICLOTYMOL remains the US FDA Preferred Term for this commodity. Biclotymol bears US NLM identifiers UMLS ID C0771526 and NCI Concept Code C73252. SMILES: CLC1C(C(CC2C(O)C(C(C)C)CC(CL)C2C)C(O)C(C(C)C)C1)C.
This classification denotes an antihelminthic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2D4432ZP6M. European Medicines Agency schedules Bidimazium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05823MIG. Bidimazium iodide generally arises in the molecular formula C26H25N2S.I. The term BIDIMAZIUM IODIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, no. 10 1972, list 12.) Most nations schedule bidimazium iodide under HS 29341000 and SITC 51579. As of Q4 2014, BIDIMAZIUM IODIDE remains the US FDA Preferred Term for this commodity. Bidimazium iodide bears US NLM identifiers UMLS ID C2825733 and NCI Concept Code C81724. SMILES: I.s1c([n](c(c2ccc(cc2)c2ccccc2)c1)C)/C=C\c1ccc(N(C)C)cc1.
This classification denotes an antispasmotic agent with the molecular formula C19H30N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XWH8UR3OX, chemically known as bietamiverine dihydrochloride, (+/-)-, but more generally known as bietamiverine dihydrochloride, which bears US NIH Compound Identifier 197773. European Medicines Agency schedules bietamiverine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05825MIG. Most nations, for tariff purposes, schedule bietamiverine dihydrochloride under HS 29333999. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)N2CCCCC2.CL.CL.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C19H30N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 646WTQ0G3E, chemically known as 1-piperidineacetic acid, alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride but more generally known as bietamiverine hydrochloride, which bears US NIH Compound Identifier 72063. Most nations, for tariff and trade purposes, schedule bietamiverine hydrochloride under HS 29333999. As of Q4 2014, BIETAMIVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bietamiverine hydrochloride bears US NLM NCI C73602. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)N2CCCCC2.CL.
This classification denotes an antispasmotic agent with the molecular formulas C19H30N2O2, C19H30N2O2.2ClH, and C19H30N2O2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 4MGI916O6Y, 3XWH8UR3OX, 646WTQ0G3E, the base compound being chemically known as 1-piperidineacetic acid, alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride but generally known as bietamiverine, which bears US NIH Compound Identifier 72063. European Medicines Agency schedules Bietamiverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05825MIG. The term BIETAMIVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). BIETAMIVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bietamiverine and its salts under HS 29333999 and SITC 51574. As of Q4 2014, BIETAMIVERINE remains the US FDA Preferred Term for this commodity. Bietamiverine bears US NLM NCI C79555 and C73602. SMILES: CL.O(C(=O)C(N1CCCCC1)C1CCCCC1)CCN(CC)CC (base), CCN(CC)CCOC(=O)C(C1CCCCC1)N2CCCCC2.CL.CL (dihydrochloride) and CCN(CC)CCOC(=O)C(C1CCCCC1)N2CCCCC2.CL (hydrochloride).
This classification denotes an antihypertensive agent with the molecular formula C39H53N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0P5B94FVD5, chemically known as 3-beta,20-alpha-yohimban-16-beta-carboxylic acid, 1-(2-(diethylamino)ethyl)-18-beta-hydroxy-11,17-alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) but generally known as bietaserpine, which bears US NIH Compound Identifier 65518. Bietaserpine most often comes in base and bitartrate forms. European Medicines Agency schedules Bietaserpine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05826MIG. The term BIETASERPINE is an International Non-Proprietary Name. World Health Organization schedules bietaserpine in its Anatomical Therapeutic Chemical (ATC) Classification. BIETASERPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bietaserpine under HS 29399900 and SITC 54149. As of Q4 2014, BIETASERPINE remains the US FDA Preferred Term for this commodity. Bietaserpine bears US NLM identifiers UMLS ID C0053565 and NCI Concept Code C72973. SMILES: O(C1C(C2C(CN3C(C2)c2n(c4c(c2CC3)ccc(OC)c4)CCN(CC)CC)CC1OC(=O)c1cc(OC)c(OC)c(OC)c1)C(=O)OC)C.
This classification denotes an antidepressive agent with the molecular formula C18H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z4501GN13G, chemically known as 1-butanamine, n-methyl-4-(2-(phenylmethyl)phenoxy)-, hydrochloride but generally known as bifemelane, which bears US NIH Compound Identifier 2377. Bifemelane most often comes in base and hydrochloride forms. European Medicines Agency schedules Bifemelane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05827MIG. World Health Organization schedules bifemelane in its Anatomical Therapeutic Chemical (ATC) Classification. BIFEMELANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bifemelane under HS 29221980 and SITC 51461. As of Q4 2014, BIFEMELANE remains the US FDA Preferred Term for this commodity. SMILES: O(CCCCNC)c1c(Cc2ccccc2)cccc1.
This classification denotes the hydrochloride form of an antidepressive agent with the molecular formula C18H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z4501GN13G, chemically known as 1-butanamine, n-methyl-4-(2-(phenylmethyl)phenoxy)-, hydrochloride but more generally known as bifemelane, which bears US NIH Compound Identifier 2377. Bifemelane most often comes in base and hydrochloride forms. European Medicines Agency schedules Bifemelane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05827MIG. World Health Organization schedules bifemelane in its Anatomical Therapeutic Chemical (ATC) Classification. BIFEMELANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bifemelane hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, BIFEMELANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CNCCCCOC1CCCCC1CC2CCCCC2.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9973I7EX5X, chemically known as ( -)-2-chloro-alpha-methyl-4-biphenylacetic acid, ester with 1-glycoloyl-4-methyllpiperazine but generally known as bifeprofen, which bears US NIH Compound Identifier 185459. European Medicines Agency schedules Bifeprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05829MIG. The term BIFEPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). Most nations schedule bifeprofen under HS 29335995 and SITC 51576. As of Q4 2014, BIFEPROFEN remains the US FDA Preferred Term for this commodity. Bifeprofen bears US NLM identifiers UMLS ID C2347011 and NCI Concept Code C73079. SMILES: CLC1C(C2CCC(C(C(=O)OCC(=O)N3CCN(CC3)C)C)CC2)CCCC1.
This classification denotes an anti-androgen with the molecular formula C17H18F2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47602X79JF, chemically known as phenol, 4,4-(1-ethyl-2-methyl-1,2-ethanediyl)bis(2-fluoro-, (r*,s*)- but generally known as bifluranol, which bears US NIH Compound Identifier 71713. European Medicines Agency schedules Bifluranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05830MIG. The term BIFLURANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). BIFLURANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bifluranol under HS 29081900 and SITC 51244. As of Q4 2014, BIFLURANOL remains the US FDA Preferred Term for this commodity. Bifluranol bears US NLM identifiers UMLS ID C0053569 and NCI Concept Code C77332. SMILES: FC1CC(C(C(C2CC(F)C(O)CC2)C)CC)CCC1O.
This classification denotes an antifungal agent with the molecular formula C22H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QYJ305Z91O, chemically known as 1-(p,alpha-diphenylbenzyl)imidazole but generally known as bifonazole, which bears US NIH Compound Identifier 2378. European Medicines Agency schedules Bifonazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05831MIG. The term BIFONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules bifonazole in its Anatomical Therapeutic Chemical (ATC) Classification. BIFONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bifonazole under HS 29332990 and SITC 51573. As of Q4 2014, BIFONAZOLE remains the US FDA Preferred Term for this commodity. Bifonazole bears US NLM identifiers UMLS ID C0053570 and NCI Concept Code C87450. SMILES: N1(C(C2CCC(CC2)C2CCCCC2)C2CCCCC2)CCNC1.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PA1123N395. European Medicines Agency schedules Bilastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37845. Bilastine generally arises in the molecular formula C28H37N3O3. The term BILASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule bilastine under HS 29333999 and SITC 51574. As of Q4 2014, BILASTINE remains the US FDA Preferred Term for this commodity. Bilastine bears US NLM identifiers UMLS ID C1101148 and NCI Concept Code C73045. SMILES: O(CCN1C(NC2C1CCCC2)C1CCN(CC1)CCC1CCC(C(C)(C)C(=O)O)CC1)CC.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P2U39H18W and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 23591 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Ericales, Family Ericaceae, Genus Vaccinium L., and more commonly known as the simple BILBERRY, of which there are several varieties. Bilberry bears the USDA PLANTS Database Identifiers VABR3, VACA13, and VADE (sea, dwarf, and cascade, respectively). European Medicines Agency schedules bilberry in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB11745MIG, SUB11746MIG, SUB33683, and SUB33685. The United Nations Common Coding System codifies bilberry under UNCCS 013444. As of Q4 2014, BILBERRY remains the US FDA Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a prostaglandin analogue and anti-glaucoma agent with the molecular formula C25H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QXS94885MZ, chemically known as 5-heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (1r-(1alpha(z),2beta(1e,3s*),3alpha,5alpha))- but generally known as bimatoprost, which bears US NIH Compound Identifier 5311027. European Medicines Agency schedules Bimatoprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12470MIG. The term BIMATOPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules bimatoprost in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule bimatoprost under HS 29375000 and SITC 54156. As of Q4 2014, BIMATOPROST remains the US FDA Preferred Term for this commodity. Bimatoprost bears US NLM identifiers UMLS ID C0937917 and NCI Concept Code C47414. SMILES: OC1C(C(C(O)C1)/C=C/C(O)CCC1CCCCC1)C/C=C\CCCC(=O)NCC.
This classification denotes an antidepressant agent with the molecular formula C19H23N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3AVG9P140R, chemically known as 1,2-ethanediamine, n,n,n-trimethyl-n-(3-phenyl-1h-indol-1-yl)- but generally known as binedaline, which bears US NIH Compound Identifier 42510. Binedaline most often comes in base and hydrochloride forms. European Medicines Agency schedules Binedaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05835MIG. The term BINEDALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BINEDALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule binedaline under HS 29339990 and SITC 51577. As of Q4 2014, BINEDALINE remains the US FDA Preferred Term for this commodity. Binedaline bears US NLM identifiers UMLS ID C0053611 and NCI Concept Code C72722. SMILES: n1(N(CCN(C)C)C)c2c(c(c1)c1ccccc1)cccc2.
This classification denotes an antidepressant agent with the molecular formula C19H23N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WEK9FVT37G, chemically known as n,n,n-trimethyl-n-(3-phenyl-1h-indol-1-yl)ethylenediamine monohydrochloride but more generally known as binedaline hydrochloride, which bears US NIH Compound Identifier 42509. European Medicines Agency schedules Binedaline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25841. Most nations, for tariff and trade purposes, schedule binedaline hydrochloride under HS 29339990. As of Q4 2014, BINEDALINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCN(C)N1CC(C2C1CCCC2)C3CCCCC3.CL.
This classification denotes a quinolone antibiotic with the molecular formula C19H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78VM28ZA2H, chemically known as 7-(1,4-diazabicyclo(3.2.2)non-4-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid but generally known as binfloxacin, which bears US NIH Compound Identifier 166565. European Medicines Agency schedules Binfloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05836MIG. The term BINFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). BINFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule binfloxacin under HS 29334990 and SITC 51575. As of Q4 2014, BINFLOXACIN remains the US FDA Preferred Term for this commodity. Binfloxacin bears US NLM identifiers UMLS ID C2347020 and NCI Concept Code C72632. SMILES: FC1C(N2C3CCN(CC3)CC2)CC2N(CC)CC(C(=O)C2C1)C(=O)O.
This classification denotes an anti-asthmatic agent with the molecular formula C18H23N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W2KGP0434Y, chemically known as 1-(piperidinomethyl)-4-propyl-s-triazolo(4,3-a)quinazolin-5(4h)-one but generally known as binizolast, which bears US NIH Compound Identifier 185461. European Medicines Agency schedules Binizolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05838MIG. The term BINIZOLAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). BINIZOLAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule binizolast under HS 29335995 and SITC 51576. As of Q4 2014, BINIZOLAST remains the US FDA Preferred Term for this commodity. Binizolast bears US NLM identifiers UMLS ID C2347021 and NCI Concept Code C74130. SMILES: O=C1N(C2N(C(NN2)CN2CCCCC2)C2C1CCCC2)CCC.
This classification denotes an insecticide with the molecular formula C19H26O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier G79DM7O471, chemically known as 2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylic acid, ester with 2-allyl-4-hydroxy-3-methyl-2-cyclopenten-1-one but more generally known as bioallethrin, which bears U.S. NIH Compound Identifier 11442. Bioallethrin most often comes in base and s-cyclopentenyl forms. European Medicines Agency schedules Bioallethrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13071MIG. World Health Organization schedules bioallethrin in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a serotonin agonist with the molecular formula C14H15NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49DCB7156W, chemically known as [2-[2-(aminomethyl)phenyl]sulfanylphenyl]methanol but generally known as cericlamine, which bears US NIH Compound Identifier 43961. European Medicines Agency schedules Bipenamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05842MIG. The term BIPENAMOL is an International Non-Proprietary Name (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25.) Most nations schedule bipenamol under HS 29309085 and SITC 51549. As of Q4 2014, BIPENAMOL remains the US FDA Preferred Term for this commodity. Bipenamol bears US NLM identifiers UMLS ID C2698511 and NCI Concept Code C79854. SMILES: C1=CC=C(C(=C1)CN)SC2=CC=CC=C2CO.
This classification denotes an antidepressant agent with the molecular formula C14H15NOS.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65FL7UEP0F. The term bipenamol hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule bipenamol hydrochloride under HS 29309085 and SITC 51549. As of Q4 2014, BIPENAMOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(C(C1)CN)SC2CCCCC2CO.CL.
This classification denotes an antiparkinsonian agent and antimuscarinic agent with the molecular formula C21H29NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K35N76CUHF, chemically known as 5-norbornene-2-methanol, alpha-phenyl-alpha-(2-piperidinoethyl)- but generally known as biperiden hydrochloride, which bears US NIH Compound Identifier 2381. European Medicines Agency schedules Biperiden hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00807MIG. Most nations schedule biperiden under HS 29333999 and SITC 51574. As of Q4 2014, BIPERIDEN remains the US FDA Preferred Term for this commodity. Biperiden bears US NLM identifiers UMLS ID C0005578 and NCI Concept Code C65263. SMILES: OC(C1C2CC(C1)C=C2)(CCN1CCCCC1)C1CCCCC1.
This classification denotes an astringent with the molecular formula C19H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65X88IL51X, chemically known as (1,1-biphenyl)-3-carboxylic acid, 2-hydroxy-, 2-(diethylamino)ethyl ester but generally known as biphenamine, which bears US NIH Compound Identifier 21720. Biphenamine most often comes in base, hydrochloride, and q forms. European Medicines Agency schedules Xenysalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00108MIG. The term XENYSALATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules biphenamine in its Anatomical Therapeutic Chemical (ATC) Classification. Biphenamine or xenysalate bears US NLM identifiers UMLS ID C0302226 and NCI Concept Code C79881. SMILES: CCN(CC)CCOC(=O)C1=CC=CC(=C1O)C2=CC=CC=C2.
This classification denotes an anxiolytic with the molecular formula C24H26FN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5776HBV7UD, chemically known as pyrazino(1,2:1,6)pyrido(3,4-b)indole, 1,2,3,4,6,7,12,12a-octahydro-2-(3-(p-fluorobenzoyl)propyl)-, dl- but generally known as biriperone, which bears US NIH Compound Identifier 68663. European Medicines Agency schedules Biriperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05845MIG. The term BIRIPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BIRIPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule biriperone under HS 29335995 and SITC 51576. As of Q4 2014, BIRIPERONE remains the US FDA Preferred Term for this commodity. Biriperone bears US NLM identifiers UMLS ID C2698513 and NCI Concept Code C76438. SMILES: FC1CCC(C(=O)CCCN2CC3N(CC2)CC2[NH]C4C(C2C3)CCCC4)CC1.
This classification denotes a laxative with the molecular formula C22H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10X0709Y6I, chemically known as 4,4-diacetoxydiphenylpyridyl-2-methane but generally known as bisacodyl, which bears US NIH Compound Identifier 2391. Bisacodyl most often comes in base and tannex forms. European Medicines Agency schedules Bisacodyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05846MIG. The term BISACODYL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules bisacodyl in its Anatomical Therapeutic Chemical (ATC) Classification. BISACODYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bisacodyl under HS 29333999 and SITC 51574. As of Q4 2014, BISACODYL remains the US FDA Preferred Term for this commodity. Bisacodyl bears US NLM identifiers UMLS ID C0005632 and NCI Concept Code C28870. SMILES: O(C1CCC(C(C2CCC(OC(=O)C)CC2)C2NCCCC2)CC1)C(=O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a laxative C76H52O46.C22H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T0I8L1B7J6, chemically known as er-soluble complex of bisacodyl and tannic acid. (1) phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester), complex with tannic acid, but more generally known as bisacodyl tannex, which bears US NIH Compound Identifier 2391. Most nations, for tariff and trade purposes, schedule bisacodyl tannex under HS 29333999 and SITC 51574. SMILES: As of Q4 2014, BISACODYL TANNEX remains US FDA's Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS300. This VA Drug Class (RS300) classifies this compound as belonging to the group LAXATIVES, RECTAL.
This classification denotes an anthraquinone compound with the molecular formula C22H22N8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39C34M111K, chemically known as 9,10-anthracenedicarboxaldehyde, bis((4,5-dihydro-1h-imidazol-2-yl)hydrazone)- but generally known as bisantrene, which bears US NIH Compound Identifier 5351322. Bisantrene most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Bisantrene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05847MIG. The term BISANTRENE is an International Non-Proprietary Name. BISANTRENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bisantrene under HS 29332990 and SITC 51573. As of Q4 2014, BISANTRENE remains the US FDA Preferred Term for this commodity. Bisantrene bears US NLM identifiers UMLS ID C0053776 and NCI Concept Code C1019. SMILES: N1CCN=C1N/N=C/C1C2C(C(C3C1CCCC3)/C=N/NC1=NCCN1)CCCC2.
This classification denotes an antiarrhythmic agent with the molecular formula C17H23ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) FVT2ESG270, chemically known as syn-3-ethyl-7-methyl-3,7-diazabicyclo(3.3.1)non-9-yl p-chlorobenzoate but more generally known as bisaramil, which bears US NIH Compound Identifier 3033742. Bisaramil most often comes in base and hydrochloride forms. European Medicines Agency schedules Bisaramil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05848MIG. The term BISARAMIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). BISARAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bisaramil under HS 29333999 and SITC 51574. As of Q4 2014, BISARAMIL remains US FDA's Preferred Term for this commodity. Bisaramil bears US NLM identifiers UMLS ID C0106533 and NCI Concept Code C81430. SMILES: CLC1CCC(C(=O)OC2C3CN(CC2CN(C3)C)CC)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H29N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3OA32ZIB31, chemically known as 3-(((2,3-dimethyl-5-oxo-1-phenyl-3-pyrzolin-4-yl)amino)methyl)-4-isopropyl-2-methyl-1-phenyl-3-pyrazolin-5-one but generally known as bisfenazone, which bears US NIH Compound Identifier 189866. European Medicines Agency schedules Bisfenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05851MIG. The term BISFENAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). BISFENAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bisfenazone under HS 29331190 and SITC 51571. As of Q4 2014, BISFENAZONE remains the US FDA Preferred Term for this commodity. Bisfenazone bears US NLM identifiers UMLS ID C2698516 and NCI Concept Code C77334. SMILES: O=C1N(N(C(C1C(C)C)CNC1C(N(N(C1=O)C1CCCCC1)C)C)C)C1CCCCC1.
This classification denotes an anti-ulcer agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JB5Y63JDHJ. European Medicines Agency schedules Bismuth aluminate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13079MIG. Bismuth aluminate generally arises in the molecular formula AL6BI2O12. The term 'bismuth aluminate' is a United States Adopted Name designation.This classification denotes an anti-ulcer agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JB5Y63JDHJ. European Medicines Agency schedules Bismuth aluminate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13079MIG. Bismuth aluminate generally arises in the molecular formula AL6BI2O12. The term 'bismuth aluminate' is a United States Adopted Name designation. SMILES: [O-][Al]=O.[O-][Al]=O.[O-][Al]=O.[Bi+3].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA303. This VA Drug Class (GA303) classifies this compound as belonging to the group H. PYLORI AGENTS.
This classification denotes an anti-ulcer agent with the molecular formula CO3.2Bi.2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M41L2IN55T, chemically known as carbonic acid, bismuth salt but generally known as bismuth carbonate, which bears US NIH Compound Identifier 161253. European Medicines Agency schedules Bismuth carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13088MIG. As of Q4 2014, BISMUTH SUBCARBONATE remains the US FDA Preferred Term for this commodity. Bismuth subcarbonate bears US NLM identifiers UMLS ID C0053789 and NCI Concept Code C76480. SMILES: C(=O)(O[Bi]=O)O[Bi]=O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a cytoprotective agent and anti-ulcer agent with the molecular formula 2C6H5O7.Bi.3K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HS813P8QPX, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, bismuth(3+) potassium salt (2:1:3) but generally known as bismuth subcitrate, which bears US NIH Compound Identifier 6335486. European Medicines Agency schedules Bismuth subcitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13089MIG. World Health Organization schedules bismuth subcitrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BISMUTH SUBCITRATE remains the US FDA Preferred Term for this commodity. Bismuth subcitrate bears US NLM identifiers UMLS ID C0106556 and NCI Concept Code C1351. SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3].
Treatment for helicobacter pilori
This classification denotes a topical anti-infective agent with the molecular formula C7H4O5.Bi.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YIW503MI7V, chemically known as 1,3,2-benzodioxabismole-5-carboxylic acid, 2,7-dihydroxy- but generally known as bismuth subgallate, which bears US NIH Compound Identifier 16682999. European Medicines Agency schedules Bismuth subgallate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13091MIG. As of Q4 2014, BISMUTH SUBGALLATE remains the US FDA Preferred Term for this commodity. Bismuth subgallate bears US NLM identifiers UMLS ID C0053790 and NCI Concept Code C77029. SMILES: [Bi]1(Oc2c(O1)cc(cc2O)C(=O)O)[OH2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS201. This VA Drug Class (RS201) classifies this compound as belonging to the group HEMORRHOIDAL PREPARATIONS WITHOUT STEROID.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes an anti-ulcer agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H19J064BA5. European Medicines Agency schedules Bismuth subnitrate, heavy in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11748MIG. Bismuth subnitrate generally arises in the molecular formula 5BI.4NO3.O.9HO. The term 'bismuth subnitrate' is a European Pharmacopoeia designation. As of Q4 2014, BISMUTH SUBNITRATE remains the US FDA Preferred Term for this commodity. Bismuth subnitrate bears US NLM identifiers UMLS ID C0053791 and NCI Concept Code C76481. SMILES: [NH+](O)([O-])O[Bi](O[N+](=O)[O-])O[N+](=O)[O-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a cytoprotective agent and antidiarrheal agent with the molecular formula C7H4O3.Bi.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62TEY51RR1, chemically known as salicylic acid, bismuth(3+) salt (3:1) but generally known as bismuth salicylate, which bears US NIH Compound Identifier 197976. European Medicines Agency schedules Bismuth subsalicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13093MIG. As of Q4 2014, BISMUTH SUBSALICYLATE remains the US FDA Preferred Term for this commodity. Bismuth subsalicylate bears US NLM identifiers UMLS ID C0053792 and NCI Concept Code C1020. SMILES: C1=CC=C2C(=C1)C(=O)O[Bi]O2.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA303. This VA Drug Class (GA303) classifies this compound as belonging to the group H. PYLORI AGENTS.
This classification denotes a topical anti-infective agent with the molecular formula 3C6H2Br3O.Bi, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5K96Y7WG8T, chemically known as phenol, 2,4,6-tribromo-, bismuth(3+) salt but generally known as bismuth tribromophenate, which bears US NIH Compound Identifier 78852. European Medicines Agency schedules Bismuth tribromophenate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13095MIG. As of Q4 2014, BISMUTH TRIBROMOPHENATE remains the US FDA Preferred Term for this commodity. Bismuth tribromophenate bears US NLM identifiers UMLS ID C0106555 and NCI Concept Code C87256. SMILES: C1=C(C=C(C(=C1Br)[O-])Br)Br.C1=C(C=C(C(=C1Br)[O-])Br)Br.C1=C(C=C(C(=C1Br)[O-])Br)Br.[Bi+3].
This classification denotes a cytoprotective agent and anti-ulcer agent with the molecular formula 2C6H5O7.Bi.3K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HS813P8QPX, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, bismuth(3+) potassium salt (2:1:3) but generally known as bismuth subcitrate, which bears US NIH Compound Identifier 6335486. European Medicines Agency schedules Bismuth subcitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13089MIG. World Health Organization schedules bismuth subcitrate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)[O-].[K].[K].[K].[Bi+3].
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H31NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y41JS2NL6U, chemically known as 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)- but generally known as bisoprolol, which bears US NIH Compound Identifier 2405. Bisoprolol most often comes in base and fumarate forms. European Medicines Agency schedules Bisoprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13096MIG. The term BISOPROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules bisoprolol in its Anatomical Therapeutic Chemical (ATC) Classification. BISOPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bisoprolol under HS 29221980 and SITC 51461. As of Q4 2014, BISOPROLOL remains the US FDA Preferred Term for this commodity. Bisoprolol bears US NLM identifiers UMLS ID C0053799 and NCI Concept Code C61653. SMILES: O(CC(O)CNC(C)C)C1CCC(COCCOC(C)C)CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C18H31NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR59KN573L, chemically known as 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)- but more generally known as bisoprolol fumarate, which bears US NIH Compound Identifier 2405. European Medicines Agency schedules Bisoprolol fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00832MIG. Most nations, for tariff and trade purposes, schedule bisoprolol fumarate under HS 29221980 and SITC 51461. As of Q4 2014, BISOPROLOL FUMARATE remains US FDA's Preferred Term for this commodity. Bisoprolol fumarate bears US NLM identifiers UMLS ID C0543473 and NCI Concept Code C28871. SMILES: CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C18H31NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR59KN573L, chemically known as 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+/-)-, (e)-2-butenedioate (2:1) (salt), but more generally known as bisoprolol hemifumarate, which bears US NIH Compound Identifier 2405. European Medicines Agency schedules bisoprolol hemifumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13096MIG. Most nations, for tariff purposes, schedule bisoprolol hemifumarate under HS 29221980. SMILES: CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H31NO4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2EX58570NP. Most nations, for tariff and trade purposes, schedule bisoprolol hydrochloride under HS 29221980. As of Q4 2014, BISOPROLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an oxazine with the molecular formula C20H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C75N0L7FP, chemically known as 2,2-bis(p-hydroxyphenyl)-3-oxo-dihydrobenzoxazin-(1,4) but generally known as bisoxatin, which bears US NIH Compound Identifier 28689. bisoxatin most often comes in base and acetate forms. European Medicines Agency schedules Bisoxatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05856MIG. World Health Organization schedules bisoxatin in its Anatomical Therapeutic Chemical (ATC) Classification. BISOXATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bisoxatin under HS 29349990 and SITC 51579. As of Q4 2014, BISOXATIN remains the US FDA Preferred Term for this commodity. SMILES: O1C(C2CCC(O)CC2)(C2CCC(O)CC2)C(=O)NC2C1CCCC2.
This classification denotes an oxazine C24H19NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 79W5LFS83K, chemically known as 2h-1,4-benzoxazin-3(4h)-one, 2,2-bis(4-(acetyloxy)phenyl)-, but more generally known as bisoxatin acetate, which bears US NIH Compound Identifier 26391. European Medicines Agency schedules Bisoxatin acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00833MIG. Most nations, for tariff and trade purposes, schedule bisoxatin acetate under HS 29349990 and SITC 51579. As of Q4 2014, BISOXATIN ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OC1CCC(CC1)C2(C(=O)NC3CCCCC3O2)C4CCC(CC4)OC(=O)C.
This classification denotes an anti-infective agent with the molecular formula C12H6Cl4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AMT77LS62O, chemically known as 2,2-thiobis(4,6-dichlorophenol) but generally known as bithionol, which bears US NIH Compound Identifier 2406. Bithionol most often comes in base, sulfide, sulfone, and sulfoxide forms. European Medicines Agency schedules Bithionol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05857MIG. The term BITHIONOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules bithionol in its Anatomical Therapeutic Chemical (ATC) Classification. BITHIONOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bithionol under HS 29309085 and SITC 51549. As of Q4 2014, BITHIONOL remains the US FDA Preferred Term for this commodity. Bithionol bears US NLM identifiers UMLS ID C0005661 and NCI Concept Code C77030. SMILES: CLC1C(O)C(SC2C(O)C(CL)CC(CL)C2)CC(CL)C1.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C28H31NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9KY0QXD6LI, chemically known as 4-(2-(tert-butylamino)-1-hydroxyethyl-1,2-phenylen di-4-toluat but generally known as bitolterol, which bears US NIH Compound Identifier 35330. Bitolterol most often comes in base and mesylate forms. European Medicines Agency schedules Bitolterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05860MIG. The term BITOLTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules bitolterol in its Anatomical Therapeutic Chemical (ATC) Classification. BITOLTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bitolterol under HS 29225000 and SITC 51467. As of Q4 2014, BITOLTEROL remains the US FDA Preferred Term for this commodity. Bitolterol bears US NLM identifiers UMLS ID C0053817 and NCI Concept Code C65267. SMILES: OC(CNC(C)(C)C)C1CC(OC(=O)C2CCC(CC2)C)C(OC(=O)C2CCC(CC2)C)CC1.
This classification denotes an anticoagulant agent with the molecular formula C98H138N24O33, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TN9BEX005G, chemically known as l-leucine, d-phenylalanyl-l-prolyl-l-arginyl-l-prolylglycylglycylglycylglycyl-l-asparaginylglycyl-l-alpha-aspartyl-l-phenylalanyl-l-alpha-glutamyl-l-alpha-glutamyl-l-isoleucyl-l-prolyl-l-alpha-glutamyl-l-alpha-glutamyl-l-tyrosyl- but generally known as bivalirudin, which bears US NIH Compound Identifier 16129704. European Medicines Agency schedules Bivalirudin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05862MIG. The term BIVALIRUDIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules bivalirudin in its Anatomical Therapeutic Chemical (ATC) Classification. BIVALIRUDIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bivalirudin under HS 29339990 and SITC 51577. As of Q4 2014, BIVALIRUDIN remains the US FDA Preferred Term for this commodity. Bivalirudin bears US NLM identifiers UMLS ID C0168273 and NCI Concept Code C47415. SMILES: O=C(N1C(CCC1)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC1CCC(O)CC1)C(=O)NC(CC(C)C)C(=O)O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C1N(CCC1)C(=O)C(NC(=O)C1N(CCC1)C(=O)C(N)CC1CCCCC1)CCCNC(=N)N)CC(=O)N)CC(=O)O)CC1CC.
This classification denotes an antineoplastic alkylating agent with the molecular formula C43H36Cl2N8O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0O9OBI87E, chemically known as 1,3-bis(2-(((s)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo(1,2-b:4,3-b)dipyrrol-3(2h)-yl)carbonyl)indol-5-yl)urea but more generally known as bizelesin, which bears US NIH Compound Identifier 60794. European Medicines Agency schedules Bizelesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05863MIG. The term BIZELESIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). BIZELESIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bizelesin under HS 29339990 and SITC 51577. As of Q4 2014, BIZELESIN remains US FDA's Preferred Term for this commodity. Bizelesin bears US NLM identifiers UMLS ID C0209891 and NCI Concept Code C1472. SMILES: CLCC1C2C(N(C1)C(=O)C1[NH]C3C(C1)CC(NC(=O)NC1CC4CC([NH]C4CC1)C(=O)N1CC(C4C1CC(O)C1[NH]CC(C41)C)CCL)CC3)CC(O)C1[NH]CC(C21)C.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K73E24S6X9 and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 821148 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivis ion Angiospermae, Class Magnoliopsida, Superorder Ranunculanae, Order Ranunculales, Family Ranunculaceae, Genus Actaea L. (baneberry) Species Actaea racemosa L., more commonly known as BLACK BANEBERRY, BLACK SNAKEROOT, or as here, BLACK COHOSH. Black cohosh bears the USDA PLANTS Database Identifier ACRA7. European Medicines Agency schedules black cohosh in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31742. As of Q4 2014, BLACK COHOSH remains the US FDA Preferred Term for this commodity.
For the active immunisation of cattle and sheep against disease associated with infections caused by Clostridium chauvoei (black leg).
This classification denotes a bleomycin antibiotic with the molecular formula C55H84N17O21S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40S1VHN69B, more generally known as bleomycin. European Medicines Agency schedules bleomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00842MIG. The term BLEOMYCIN is an International Non-Proprietary Name or INN. Most nations schedule bleomycin under HS 29419000 and SITC 54139. As of Q4 2014, BLEOMYCIN remains the US FDA Preferred Term for this commodity. Bleomycin bears US NLM identifiers UMLS ID C0005740 and NCI Concept Code C313. SMILES: CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN200. This VA Drug Class (AN200) classifies this compound as belonging to the group ANTINEOPLASTIC ANTIBIOTICS.
A bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory Bcell precursor acute lymphoblastic leukemia.
This classification denotes a serotonin antagonist with the molecular formula C23H30FN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, AQ316B4F8C chemically known as 2-(4-ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine but generally known as blonanserin, which bears US NIH Compound Identifier 125564. European Medicines Agency schedules Blonanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05864MIG. The term BLONANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, no. 3 1997, list 38. ). Most nations schedule blonanserin under HS 29335995 and SITC 51576. As of Q4 2014, BLONANSERIN remains the US FDA Preferred Term for this commodity. Blonanserin bears US NLM identifiers UMLS ID C0287983 and NCI Concept Code C95920. SMILES: CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F.
This classification denotes an aminoglycoside antibiotic with the molecular formula C21H39N5O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LWV7PWE57U, chemically known as d-scyllo-inositol, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1=>2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1=>2)-1-((aminoiminomethyl)amino)-1-deoxy-, 5-carbamate but generally known as bluensomycin, which bears US NIH Compound Identifier 65603. Bluensomycin most often comes in base and sulfate forms. The term BLUENSOMYCIN is an International Non-Proprietary Name. BLUENSOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bluensomycin under HS 29412080 and SITC 54132. As of Q4 2014, BLUENSOMYCIN remains the US FDA Preferred Term for this commodity. Bluensomycin bears US NLM identifiers UMLS ID C0053859 and NCI Concept Code C90636. SMILES: CC1C(C(C(O1)OC2C(C(C(C(C2O)O)OC(=O)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(CO)O.
This classification denotes a protease inhibitor and antiviral with the molecular formula C27H45N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89BT58KELH, chemically known as (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide but generally known as Boceprevir, which bears US NIH Compound Identifier 10324367. Boceprevir most often comes in base and sulfate forms. European Medicines Agency schedules Boceprevir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31579. The term BOCEPREVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 1, 2008, List 59.). As of Q4 2014, BOCEPREVIR remains the US FDA Preferred Term for this commodity. SMILES: CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C.
This classification denotes a nitrogen mustard compound with the molecular formula C18H21ClN4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P52D0J76B, chemically known as 1-(2-chloroethyl)-3-(2,3-o-isopropylidene-d-ribofuranosyl)-1-nitrosourea 5-(p-nitrobenzoate) but more generally known as bofumustine, which bears US NIH Compound Identifier 100269. European Medicines Agency schedules Bofumustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05865MIG. The term BOFUMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). BOFUMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bofumustine under HS 29329970 and SITC 51569. As of Q4 2014, BOFUMUSTINE remains US FDA's Preferred Term for this commodity. Bofumustine bears US NLM identifiers UMLS ID C2825244 and NCI Concept Code C80533. SMILES: CLCCN(N=O)C(=O)NC1OC(C2OC(OC12)(C)C)COC(=O)C1CCC([N](=O)O)CC1.
This classification denotes an anabolic steroid with the molecular formula C18H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49SD6G16U5, chemically known as 3.beta.,17.beta.-dihydroxyestr-4-ene but generally known as bolandiol, which bears US NIH Compound Identifier 70691434. European Medicines Agency schedules bolandiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05866MIG. Most nations schedule bolandiol under HS 29061900 and SITC 51231. As of Q4 2014, BOLANDIOL remains the US FDA Preferred Term for this commodity. SMILES: CCC(=O)OC1CCC2C3CCC4(C(C3CCC2=C1)CCC4OC(=O)CC)C.
This classification denotes an anabolic steroid with the molecular formula C24H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 595CNE7RHB, chemically known as 4-estrene-3-beta,17-beta-diol 3,17-dipropionate but more generally known as bolandiol dipropionate, which bears US NIH Compound Identifier 16141. Most nations, for tariff and trade purposes, schedule bolandiol dipropionate under HS 29061900 and SITC 51231. As of Q4 2014, BOLANDIOL DIPROPIONATE remains US FDA's Preferred Term for this commodity. Bolandiol dipropionate bears US NLM identifiers UMLS ID C3266850 and NCI Concept Code C87452. SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@@H]4OC(=O)CC)C.
This classification denotes an anabolic steroid with the molecular formula C21H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T7ZM08F7FU, chemically known as 17beta-hydroxy-7alpha,17-dimethylandrost-4-en-3-one but generally known as bolasterone, which bears US NIH Compound Identifier 102146. European Medicines Agency schedules Bolasterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05867MIG. The term BOLASTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BOLASTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bolasterone under HS 29372900 and SITC 54153. As of Q4 2014, BOLASTERONE remains the US FDA Preferred Term for this commodity. Bolasterone bears US NLM identifiers UMLS ID C0368780 and NCI Concept Code C74111. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3C)C)CC2)CC1)C)C.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers DG4F8T839X and M9VVZ08EKQ (leaf and root), and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 35980 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Asterales, Family Asteraceae, Genus Eupatorium L. (thoroughwort), Species Eupatorium perfoliatum L., more commonly known as common BONESET. Boneset bears the USDA PLANTS Database Identifiers EUPE3, EUPEC, and EUPEP. European Medicines Agency schedules boneset in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13779MIG, SUB34756, SUB40652, SUB40653, SUB46075, SUB55050, and SUB63369.
This classification denotes an adrenergic beta-antagonist with the molecular formula C23H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KT304VZO57, chemically known as 2-propanol, 1-((1,1-dimethylethyl)amino)-3-((2-methyl-1h-indol-4-yl)oxy)-, benzoate (ester), (+-)- but generally known as bopindolol, which bears US NIH Compound Identifier 44112. Bopindolol most often comes in base and malonate forms. European Medicines Agency schedules Bopindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05873MIG. World Health Organization schedules bopindolol in its Anatomical Therapeutic Chemical (ATC) Classification. BOPINDOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bopindolol under HS 29339990 and SITC 51577. As of Q4 2014, BOPINDOLOL remains the US FDA Preferred Term for this commodity. SMILES: O(C(CNC(C)(C)C)COC1C2C([NH]C(C2)C)CCC1)C(=O)C1CCCCC1.
This classification denotes an adrenergic beta-antagonist C23H28N2O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GM76OF8LS3, chemically known as 2-propanol, 1-((1,1-dimethylethyl)amino)-3-((2-methyl-1h-indol-4-yl)oxy)-, 2-benzoate, 2-butenedioate (1:1), but more generally known as bopindolol fumarate, which bears US NIH Compound Identifier 13302095. Most nations, for tariff and trade purposes, schedule bopindolol fumarate under HS 29339990 and SITC 51577. As of Q4 2014, BOPINDOLOL FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C([NH]1)CCCC2OCC(CNC(C)(C)C)OC(=O)C3CCCCC3.C(=C/C(=O)O)\C(=O)O.
This classification denotes an adrenergic beta-antagonist with the molecular formula C23H28N2O3.C3H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S3UWR70991, chemically known as propanedioic acid, compd. with (+/-)-2-((1,1-dimethylethyl)amino)-1-(((2-methyl-1h-indol-4-yl)oxy)methyl)ethyl benzoate (1:1), but more generally known as bopindolol hydrogen malonate, which bears US NIH Compound Identifier 636368. European Medicines Agency schedules bopindolol hydrogen malonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05873MIG. Most nations, for tariff purposes, schedule bopindolol hydrogen malonate under HS 29339990. SMILES: CC1CC2C([NH]1)CCCC2OCC(CNC(C)(C)C)OC(=O)C3CCCCC3.C(C(=O)O)C(=O)O.
This classification denotes an adrenergic beta-antagonist C23H28N2O3.C3H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S3UWR70991, chemically known as propanedioic acid, compd. with (+/-)-2-((1,1-dimethylethyl)amino)-1-(((2-methyl-1h-indol-4-yl)oxy)methyl)ethyl benzoate (1:1), but more generally known as bopindolol malonate, which bears US NIH Compound Identifier 636368. European Medicines Agency schedules Bopindolol malonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00852MIG. Most nations, for tariff and trade purposes, schedule bopindolol malonate under HS 29339990 and SITC 51577. As of Q4 2014, BOPINDOLOL MALONATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C([NH]1)CCCC2OCC(CNC(C)(C)C)OC(=O)C3CCCCC3.C(C(=O)O)C(=O)O.
This classification denotes a topical anti-infective agent with the molecular formula BH3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R57ZHV85D4, chemically known as boric acid, crude natural, containing not more than 85 per cent ofh3bo3 calculated on the dry weight but generally known as boric acid, which bears US NIH Compound Identifier 7628. European Medicines Agency schedules Boric acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12471MIG. World Health Organization schedules boric acid in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BORIC ACID remains the US FDA Preferred Term for this commodity. Boric acid bears US NLM identifiers UMLS ID C0006020 and NCI Concept Code C47416. SMILES: B(O)(O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an antimuscarinic agent with the molecular formula C21H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9M363FGA7J, chemically known as 2-phenylbicyclo(2.2.1)heptane-2-carboxylic acid, 3-(diethylamino)propyl ester but generally known as bornaprine, which bears US NIH Compound Identifier 30160. European Medicines Agency schedules Bornaprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05874MIG. The term BORNAPRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules bornaprine in its Anatomical Therapeutic Chemical (ATC) Classification. BORNAPRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bornaprine under HS 29221980 and SITC 51461. As of Q4 2014, BORNAPRINE remains the US FDA Preferred Term for this commodity. Bornaprine bears US NLM identifiers UMLS ID C0053947 and NCI Concept Code C90742. SMILES: O(C(=O)C1(C2CC(C1)CC2)C1CCCCC1)CCCN(CC)CC.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66STS87GEY. European Medicines Agency schedules Bornaprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05875MIG. Bornaprolol generally arises in the molecular formula C19H29NO2. The term BORNAPROLOL is an International Non-Proprietary Name or INN. BORNAPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bornaprolol under HS 29221980 and SITC 51461. As of Q4 2014, BORNAPROLOL remains the US FDA Preferred Term for this commodity. Bornaprolol bears US NLM identifiers UMLS ID C0106915 and NCI Concept Code C90794. SMILES: O(C1C(C2C3CC(C2)CC3)CCCC1)CC(O)CNC(C)C.
This classification denotes a proteasome inhibitor with the molecular formula C19H25BN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69G8BD63PP, chemically known as boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (s-(r*,s*))- but generally known as bortezomib, which bears US NIH Compound Identifier 93860. European Medicines Agency schedules Bortezomib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20020. The term BORTEZOMIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules bortezomib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule bortezomib under HS 29339990 and SITC 51577. As of Q4 2014, BORTEZOMIB remains the US FDA Preferred Term for this commodity. Bortezomib bears US NLM identifiers UMLS ID C1176309 and NCI Concept Code C1851. SMILES: O=C(NC(CC(C)C)[B](O)O)C(NC(=O)C1NCCNC1)CC1CCCCC1.
This classification denotes an endothelin receptor antagonist with the molecular formula C27H29N5O6S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q326023R30, chemically known as 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2-bipyrimidin)-4-yl)benzenesulfornamide but generally known as bosentan, which bears US NIH Compound Identifier 104865. Bosentan most often comes in basic and hydrate forms. European Medicines Agency schedules Bosentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05877MIG. World Health Organization schedules bosentan in its Anatomical Therapeutic Chemical (ATC) Classification. BOSENTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bosentan under HS 29350090 and SITC 51580. As of Q4 2014, BOSENTAN remains the US FDA Preferred Term for this commodity. Bosentan bears US NLM identifiers UMLS ID C0252643 and NCI Concept Code C47417. SMILES: S(=O)(=O)(NC1NC(NC(OCCO)C1OC1C(OC)CCCC1)C1NCCCN1)C1CCC(C(C)(C)C)CC1.
This classification denotes an endothelin receptor antagonist with the molecular formula C27H29N5O6S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q326023R30, chemically known as benzenesulfonamide, 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'bipyrimidin)-4-yl)-, monohydrate, but more generally known as bosentan hydrate, which bears US NIH Compound Identifier 185462. European Medicines Agency schedules bosentan hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05877MIG. Most nations, for tariff purposes, schedule bosentan hydrate under HS 29350090. SMILES: CC(C)(C)C1CCC(CC1)S(=O)(=O)NC2C(C(NC(N2)C3NCCCN3)OCCO)OC4CCCCC4OC.O.
This classification denotes an endothelin receptor antagonist with the molecular formula C27H29N5O6S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q326023R30, chemically known as 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2-bipyrimidin)-4-yl)benzenesulfornamide but more generally known as bosentan, which bears US NIH Compound Identifier 104865. Bosentan most often comes in basic and hydrate forms. European Medicines Agency schedules Bosentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05877MIG. World Health Organization schedules bosentan in its Anatomical Therapeutic Chemical (ATC) Classification. BOSENTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bosentan monohydrate under HS 29350090 and SITC 51580. SMILES: CC(C)(C)C1CCC(CC1)S(=O)(=O)NC2C(C(NC(N2)C3NCCCN3)OCCO)OC4CCCCC4OC.O.
This classification denotes a tyrosine kinase inhibitor with the molecular structure C26H29CL2N5O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, 5018V4AEZ0 chemically known as 3-quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methyl-1-piperazinyl)propoxy)-, but more commonly known as bosutinib, which bears U.S. National Institutes of Health Compound Identifier 5328940. European Medicines Agency schedules Bosutinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29176. The term BOSUTINIB is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 20, no. 3, 2006, list 56).
This classification denotes a peripherally-acting muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E211KPY694.
This classification denotes an anti-lipidemic agent with the molecular formula C19H20F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8MJ40K4117, chemically known as pyrrolidine, 1-(2-((4-(trifluoromethyl)(1,1-biphenyl)-4-yl)oxy)ethyl)- but generally known as boxidine, which bears US NIH Compound Identifier 31742. Boxidine most often comes in base and hydrochloride forms. European Medicines Agency schedules Boxidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05879MIG. The term BOXIDINE is an International Non-Proprietary Name. BOXIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule boxidine under HS 29339990 and SITC 51577. As of Q4 2014, BOXIDINE remains the US FDA Preferred Term for this commodity. Boxidine bears US NLM identifiers UMLS ID C0663338 and NCI Concept Code C91025. SMILES: FC(F)(F)c1ccc(c2ccc(OCCN3CCCC3)cc2)cc1.
This classification denotes an anti-lipidemic agent with the molecular formula C19H20F3NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L4BF478JK, chemically known as pyrrolidine, 1-(2-((4-(trifluoromethyl)(1,1-biphenyl)-4-yl)oxy)ethyl)- but more generally known as boxidine hydrochloride, which bears US NIH Compound Identifier 31742. Most nations, for tariff and trade purposes, schedule boxidine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BOXIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Boxidine hydrochloride bears US NLM identifiers UMLS ID C0959899 and NCI Concept Code C91026. SMILES: C1CC(CCC1C2CCC(CC2)OCCN3CCCC3)C(F)(F)F.CL.
This classification denotes a barbiturate with the molecular formula C10H11BrN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0N7A2M3MU, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-bromo-2-propenyl)-5-(2-propenyl)- but generally known as brallobarbital, which bears US NIH Compound Identifier 68416. European Medicines Agency schedules Brallobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05880MIG. The term BRALLOBARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). BRALLOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brallobarbital under HS 29335400 and SITC kg. As of Q4 2014, BRALLOBARBITAL remains the US FDA Preferred Term for this commodity. Brallobarbital bears US NLM identifiers UMLS ID C0054022 and NCI Concept Code C74380. SMILES: C=CCC1(C(=O)NC(=O)NC1=O)CC(=C)BR.
This classification denotes a barbiturate 2C10H10BrN2O3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L214YQB674, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-bromo-2-propenyl)-5-(2-propenyl)-, calcium salt (2:1), but more generally known as brallobarbital calcium, which bears US NIH Compound Identifier 71301214. European Medicines Agency schedules Brallobarbital calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00865MIG. Most nations, for tariff and trade purposes, schedule brallobarbital calcium under HS 29335400 and SITC kg. As of Q4 2014, BRALLOBARBITAL CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: C=CCC1(C(=O)NC(=O)[N-]C1=O)CC(=C)BR.C=CCC1(C(=O)NC(=O)[N-]C1=O)CC(=C)BR.[CA+2].
This classification denotes an antiparkinsonian agent with the molecular formula C16H20Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1YP2S94RVH, chemically known as 3-beta-(3,4-dichlorophenyl)-1-alpha-h, 5-alpha-h-tropane-2-alpha-carboxaldehyde (e)-(o-methyloxime). but generally known as brasofensine, which bears US NIH Compound Identifier 9554198. Brasofensine most often comes in base, maleate, and sulfate forms. European Medicines Agency schedules Brasofensine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05881MIG. The term BRASOFENSINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). BRASOFENSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brasofensine under HS 29333999 and SITC 51574. As of Q4 2014, BRASOFENSINE remains the US FDA Preferred Term for this commodity. Brasofensine bears US NLM identifiers UMLS ID C0965394 and NCI Concept Code C76391. SMILES: CLC1CC(C2C(C3N(C(C2)CC3)C)/C=N/OC)CCC1CL.
This classification denotes the brasofensine form of an antiparkinsonian agent with the molecular formula C16H20Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1YP2S94RVH, chemically known as 3-beta-(3,4-dichlorophenyl)-1-alpha-h, 5-alpha-h-tropane-2-alpha-carboxaldehyde (e)-(o-methyloxime). but more generally known as brasofensine, which bears US NIH Compound Identifier 9554198. Brasofensine most often comes in base, maleate, and sulfate forms. European Medicines Agency schedules Brasofensine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05881MIG. The term BRASOFENSINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 3 1997, List 38). BRASOFENSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule brasofensine maleate under HS 29333999 and SITC 51574. As of Q4 2014, BRASOFENSINE MALEATE remains US FDA's Preferred Term for this commodity. Brasofensine maleate bears US NLM identifiers UMLS ID C2698558 and NCI Concept Code C76392. SMILES: CN1[C@H]2CC[C@@H]1[C@@H]([C@H](C2)C3CCC(C(C3)CL)CL)/C=N/OC.C(=C\C(=O)O)\C(=O)O.
This classification denotes a vasodilating agent and adrenergic antagonist with the molecular formula C22H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DVO6SSG9S3, chemically known as (+-)-6-(2-((1,1-dimethyl-3-phenylpropyl)amino)-1-hydroxyethyl)-3,4-dihydrocarbostyril but generally known as brefonalol, which bears US NIH Compound Identifier 65880. European Medicines Agency schedules Brefonalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05883MIG. The term BREFONALOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). BREFONALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brefonalol under HS 29337900 and SITC 51561. As of Q4 2014, BREFONALOL remains the US FDA Preferred Term for this commodity. Brefonalol bears US NLM identifiers UMLS ID C2347204 and NCI Concept Code C72653. SMILES: OC(CNC(CCC1CCCCC1)(C)C)C1CC2CCC(=O)NC2CC1.
This classification denotes an opioid receptor agonist with the molecular formula C20H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ISF76M2DBE, chemically known as 2,6-methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl- but generally known as bremazocine, which bears US NIH Compound Identifier 1223. European Medicines Agency schedules Bremazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05884MIG. The term BREMAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). BREMAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bremazocine under HS 29333999 and SITC 51574. As of Q4 2014, BREMAZOCINE remains the US FDA Preferred Term for this commodity. Bremazocine bears US NLM identifiers UMLS ID C0054038 and NCI Concept Code C91041. SMILES: OC1(CN2C3C(C(CC2)(C2C(C3)CCC(O)C2)CC)(C)C)CC1.
Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).
This classification denotes a pyrimidine antagonist and dihydroorotate dehydrogenase inhibitor with the molecular formula C23H15F2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5XL19F49H6 chemically known as 4-quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro(1,1'-biphenyl)-4-yl)-3-methyl- but generally known as brequinar, which bears US NIH Compound Identifier 57030. European Medicines Agency schedules Brequinar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05885MIG. The term BREQUINAR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28). Most nations schedule brequinar under HS 29334990 and SITC 51575. As of Q4 2014, BREQUINAR remains the US FDA Preferred Term for this commodity. Brequinar bears US NLM identifiers UMLS ID C0280509 and NCI Concept Code C1560. SMILES: CC1=C(N=C2C=CC(=CC2=C1C(=O)O)F)C3=CC=C(C=C3)C4=CC=CC=C4F.
This classification denotes an anxiolytic and anticonvulsant agent with the molecular formula C19H20BrN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OSZ0E9DGOJ, chemically known as 9h-imidazo(1,5-a)pyrrolo(2,1-c)(1,4)benzodiazepine-1-carboxylic acid, 8-bromo-11,12,13,13a-tetrahydro-9-oxo-, 1,1-dimethylethyl ester, (s)- but generally known as bretazenil, which bears US NIH Compound Identifier 107926. European Medicines Agency schedules Bretazenil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05886MIG. The term BRETAZENIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). BRETAZENIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bretazenil under HS 29339940 and SITC 51577. As of Q4 2014, BRETAZENIL remains the US FDA Preferred Term for this commodity. Bretazenil bears US NLM identifiers UMLS ID C0073482 and NCI Concept Code C72111. SMILES: BRC1C2C(=O)N3C(CCC3)C3N(C2CCC1)CNC3C(=O)OC(C)(C)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C11H17BrN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RZR75EQ2KJ, chemically known as benzenemethanaminium, 2-bromo-n-ethyl-n,n-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1) but generally known as bretylium, which bears US NIH Compound Identifier 2431. Bretylium most often comes in base, bromide, p-toluenesulfonate, and tosylate forms. European Medicines Agency schedules Bretylium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00867MIG. BRETYLIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BRETYLIUM remains the US FDA Preferred Term for this commodity. Bretylium bears US NLM identifiers UMLS ID C0054040 and NCI Concept Code C77300. SMILES: CC[N+](C)(C)CC1=CC=CC=C1BR.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV300. This VA Drug Class (CV300) classifies this compound as belonging to the group ANTIARRHYTHMICS.
This classification denotes an antiarrhythmic agent with the molecular formula C11H17BrN.C7H7O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78ZP3YR353, chemically known as 2-bromo-n-ethyl-n,n-dimethylbenzenemethanaminium 4-methylbenzenesulfonate but more generally known as bretylium tosilate, which bears US NIH Compound Identifier 6100. European Medicines Agency schedules Bretylium tosilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05887MIG. The term BRETYLIUM TOSYLATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules bretylium tosilate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule bretylium tosilate under HS 29239000 and SITC 51481. SMILES: CC[N+](C)(C)CC1CCCCC1BR.CC1CCC(CC1)S(=O)(=O)[O-].
This classification denotes a monoclonal antibody with the molecular formula C6376H9874N1722O1992S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 978I8M0P8X, more generally known as briakinumab. European Medicines Agency schedules briakinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31454. The term BRIAKINUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 24, No. 1, 2010 list 63. As of Q4 2014, BRIAKINUMAB remains US FDA's Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes an anti-glaucoma agent and alpha-adrenergic agonist with the molecular formula C11H10BrN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E6GNX3HHTE, chemically known as 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)- (9ci) but generally known as brimonidine, which bears US NIH Compound Identifier 2435. Brimonidine most often comes in base and tartrate forms. European Medicines Agency schedules Brimonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05889MIG. The term BRIMONIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules brimonidine in its Anatomical Therapeutic Chemical (ATC) Classification. BRIMONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brimonidine under HS 29332990 and SITC 51573. As of Q4 2014, BRIMONIDINE remains the US FDA Preferred Term for this commodity. Brimonidine bears US NLM identifiers UMLS ID C0525227 and NCI Concept Code C65269. SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)BR.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H10BrN5.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4S9CL2DY2H, chemically known as 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)- (9ci) but generally known as brimonidine tartrate, which bears US NIH Compound Identifier 2435. European Medicines Agency schedules Brimonidine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13122MIG. Most nations schedule brimonidine tartrate under HS 29332990 and SITC 51573. As of Q4 2014, BRIMONIDINE TARTRATE remains the US FDA Preferred Term for this commodity. Brimonidine tartrate bears US NLM identifiers UMLS ID C0077768 and NCI Concept Code C47419. SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP105. This VA Drug Class (OP105) classifies this compound as belonging to the group ANTIGLAUCOMA COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a carbonic anhydrase inhibitor and anti-glaucoma agent with the molecular formula C12H21N3O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9451Z89515, chemically known as 2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (r)- but generally known as brinzolamide, which bears US NIH Compound Identifier 68844. European Medicines Agency schedules Brinzolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05892MIG. The term BRINZOLAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). World Health Organization schedules brinzolamide in its Anatomical Therapeutic Chemical (ATC) Classification. BRINZOLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brinzolamide under HS 29350090 and SITC 51580. As of Q4 2014, BRINZOLAMIDE remains the US FDA Preferred Term for this commodity. Brinzolamide bears US NLM identifiers UMLS ID C0673966 and NCI Concept Code C47420. SMILES: S1(=O)(=O)N(CC(NCC)C2C1SC(S(=O)(=O)N)C2)CCCOC.
This classification denotes a neuroprotective agent and anticonvulsant agent with the molecular formula C11H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, U863JGG2IA chemically known as 1-pyrrolidineacetamide, .alpha.-ethyl-2-oxo-4-propyl (.alpha.s,4r)- but generally known as brivaracetam, which bears US NIH Compound Identifier 9837243. European Medicines Agency schedules Brivaracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25397. The term BRIVARACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55). Most nations schedule brivaracetam under HS 29337900 and SITC 51561. As of Q4 2014, BRIVARACETAM remains the US FDA Preferred Term for this commodity. Brivaracetam bears US NLM identifiers UMLS ID C1699861 and NCI Concept Code C65270. SMILES: CCCC1CC(=O)N(C1)C(CC)C(=O)N.
This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C11H13BrN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M3055079H, chemically known as uridine, 5-(2-bromovinyl)-2-deoxy-, (e)- but generally known as brivudine, which bears US NIH Compound Identifier 446727. European Medicines Agency schedules Brivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05893MIG. The term BRIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules brivudine in its Anatomical Therapeutic Chemical (ATC) Classification. BRIVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brivudine under HS 29349990 and SITC 51579. As of Q4 2014, BRIVUDINE remains the US FDA Preferred Term for this commodity. Brivudine bears US NLM identifiers UMLS ID C0163272 and NCI Concept Code C67088. SMILES: C1C(C(OC1N2C=C(C(=O)NC2=O)C=CBr)CO)O.
This classification denotes a diuretic with the molecular formula C15H9BrFNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6ESF2Z39VZ, chemically known as acetic acid, ((7-bromo-3-(2-fluorophenyl)-1,2-benzisoxazol-6-yl)oxy)- but generally known as brocrinat, which bears US NIH Compound Identifier 51603. European Medicines Agency schedules Brocrinat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05897MIG. The term BROCRINAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BROCRINAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brocrinat under HS 29349990 and SITC 51579. As of Q4 2014, BROCRINAT remains the US FDA Preferred Term for this commodity. Brocrinat bears US NLM identifiers UMLS ID C2825442 and NCI Concept Code C81073. SMILES: BRC1C2ONC(C2CCC1OCC(=O)O)C1C(F)CCCC1.
This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C13H15BrN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1YC7T6LLI, chemically known as 2,4-pyrimidinediamine, 5-((4-bromo-3,5-dimethoxyphenyl)methyl)- but more generally known as brodimoprim, which bears US NIH Compound Identifier 68760. European Medicines Agency schedules Brodimoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05898MIG. The term BRODIMOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). The World Health Organization schedules brodimoprim in its Anatomical Therapeutic Chemical (ATC) Classification. BRODIMOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: BRC1C(OC)CC(CC2C(NC(NC2)N)N)CC1OC.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C14H16BrNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WV4B8Q07H, chemically known as piperidine, 4-(7-bromo-5-methoxy-2-benzofuranyl)-, hydrochloride but generally known as brofaromine, which bears US NIH Compound Identifier 44571. Brofaromine most often comes in base and hydrochloride forms. European Medicines Agency schedules Brofaromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05899MIG. The term BROFAROMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). BROFAROMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brofaromine under HS 29349990 and SITC 51579. As of Q4 2014, BROFAROMINE remains the US FDA Preferred Term for this commodity. Brofaromine bears US NLM identifiers UMLS ID C0054085 and NCI Concept Code C72723. SMILES: Brc1c2oc(C3CCNCC3)cc2cc(OC)c1.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6CHG505391. European Medicines Agency schedules Brolaconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05902MIG. Brolaconazole generally arises in the molecular formula C17H15BRN2. The term BROLACONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) BROLACONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brolaconazole under HS 29332990 and SITC 51573. As of Q4 2014, BROLACONAZOLE remains the US FDA Preferred Term for this commodity. Brolaconazole bears US NLM identifiers UMLS ID C2347212 and NCI Concept Code C72957. SMILES: BRC1CCC(C(CN2CCNC2)C2CCCCC2)CC1.
This classification denotes a sedative and hypnotic with the molecular formula C11H15BrN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GC4N5H35P2, chemically known as 3-(p-bromoanilino)-n,n-dimethylpropionamide but generally known as bromamid, which bears US NIH Compound Identifier 68839. European Medicines Agency schedules Bromamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05906MIG. The term BROMAMIDE is an International Non-Proprietary Name. Most nations schedule bromamide under HS 29242995 and SITC 51479. SMILES: BRC1CCC(NCCC(=O)N(C)C)CC1.
This classification denotes a benzodiazepine with the molecular formula C14H10BrN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X015L14V0O, chemically known as 1,3-dihydro-7-bromo-5-(2-pyridyl)-2h-1,4-benzodiazepin-2-one but generally known as bromazepam, which bears US NIH Compound Identifier 2441. European Medicines Agency schedules Bromazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05907MIG. The term BROMAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules bromazepam in its Anatomical Therapeutic Chemical (ATC) Classification. BROMAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromazepam under HS 29333300 and SITC 51574. As of Q4 2014, BROMAZEPAM remains the US FDA Preferred Term for this commodity. Bromazepam bears US NLM identifiers UMLS ID C0006213 and NCI Concept Code C87454. SMILES: BRC1CC2C(NC(=O)CN=C2C2NCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H20BrNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 202J683U97, chemically known as ethanamine, 2-((4-bromophenyl)phenylmethoxy)-n,n-dimethyl- but more generally known as bromazine hydrochloride, which bears US NIH Compound Identifier 2444. European Medicines Agency schedules Bromazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00871MIG. Most nations, for tariff and trade purposes, schedule bromazine hydrochloride under HS 29221980. SMILES: CN(C)CCOC(C1CCCCC1)C2CCC(CC2)BR.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H20BrNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T032BI7727, chemically known as ethanamine, 2-((4-bromophenyl)phenylmethoxy)-n,n-dimethyl- but generally known as bromazine, which bears US NIH Compound Identifier 2444. Bromazine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05908MIG. The term BROMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules bromazine in its Anatomical Therapeutic Chemical (ATC) Classification. BROMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Bromazine or bromodiphenhydramine bears US NLM identifiers UMLS ID C0054120 and NCI Concept Code C61654. SMILES: BRC1CCC(C(OCCN(C)C)C2CCCCC2)CC1.
This classification denotes a dopamine antagonist with the molecular formula C20H25BrN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HX58M2377W, chemically known as 3-(2-bromo-9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea but generally known as bromerguride, which bears US NIH Compound Identifier 71266. European Medicines Agency schedules Bromerguride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05911MIG. The term BROMERGURIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BROMERGURIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromerguride under HS 29396900 and SITC 54146. As of Q4 2014, BROMERGURIDE remains the US FDA Preferred Term for this commodity. Bromerguride bears US NLM identifiers UMLS ID C0054092 and NCI Concept Code C73311. SMILES: BRC1[NH]C2C3C1CC1N(CC(NC(=O)N(CC)CC)C=C1C3CCC2)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H12BrNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 864P0921DW, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- but generally known as bromfenac, which bears US NIH Compound Identifier 60725. Bromfenac most often comes in base and sodium forms. European Medicines Agency schedules Bromfenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05913MIG. The term BROMFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules bromfenac in its Anatomical Therapeutic Chemical (ATC) Classification. BROMFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromfenac under HS 29225000 and SITC 51467. As of Q4 2014, BROMFENAC remains the US FDA Preferred Term for this commodity. Bromfenac bears US NLM identifiers UMLS ID C0054094 and NCI Concept Code C65271. SMILES: BRC1CCC(C(=O)C2C(N)C(CC(=O)O)CCC2)CC1.[NA].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H11BrNO3.2Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ECV571Y37, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, sesquihydrate but more generally known as bromfenac sodium, which bears US NIH Compound Identifier 60725. European Medicines Agency schedules Bromfenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00874MIG. Most nations, for tariff and trade purposes, schedule bromfenac sodium under HS 29225000 and SITC 51467. As of Q4 2014, BROMFENAC SODIUM remains US FDA's Preferred Term for this commodity. Bromfenac sodium bears US NLM identifiers UMLS ID C0107211 and NCI Concept Code C65272. SMILES: C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].O.O.O.[NA+].[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H11BrNO3.2Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ECV571Y37, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, sesquihydrate, but more generally known as bromfenac sodium hydrate, which bears US NIH Compound Identifier 11954316. European Medicines Agency schedules bromfenac sodium hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05913MIG. Most nations, for tariff purposes, schedule bromfenac sodium hydrate under HS 29225000. SMILES: C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].O.O.O.[NA+].[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H11BrNO3.2Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ECV571Y37, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, sesquihydrate but more generally known as bromfenac sodium, which bears US NIH Compound Identifier 60725. European Medicines Agency schedules Bromfenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00874MIG. Most nations, for tariff and trade purposes, schedule bromfenac sodium sesquihydrate under HS 29225000. SMILES: C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].O.O.O.[NA+].[NA+].
This classification denotes an expectorant with the molecular formula C14H20Br2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Q1J152VB1P, chemically known as 3,5-dibromo-nalpha-cyclohexyl-nalpha-methyltoluene-alpha-2-diamine but more generally known as bromhexine, which bears US NIH Compound Identifier 2442. Bromhexine most often comes in base, chloride, and hydrochloride forms. European Medicines Agency schedules Bromhexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05914MIG. World Health Organization schedules bromhexine in its Anatomical Therapeutic Chemical (ATC) Classification. BROMHEXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bromhexine under HS 29215990 and SITC 51455. As of Q4 2014, BROMHEXINE remains US FDA's Preferred Term for this commodity. SMILES: BRC1C(N)C(CN(C2CCCCC2)C)CC(BR)C1.
This classification denotes a sedative and hypnotic with the molecular formula C6H11BrN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 469GW8R486, chemically known as urea, (2-bromo-3-methylbutyryl)- but generally known as bromisoval, which bears US NIH Compound Identifier 2447. European Medicines Agency schedules Bromisoval in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05916MIG. The term BROMISOVAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules bromisoval in its Anatomical Therapeutic Chemical (ATC) Classification. BROMISOVAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Bromisoval or bromvalerylurea bears US NLM identifiers UMLS ID C0006226 and NCI Concept Code C76935. SMILES: BRC(C(C)C)C(=O)NC(=O)N.
This classification denotes a neuroprotective agent with the molecular formula C32H40BrN5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3A64E3G5ZO, chemically known as ergotaman-3,6,18-trione, 2-bromo-12-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-, (5.alpha.)- but generally known as bromocriptine, which bears US NIH Compound Identifier 2443. Bromocriptine most often comes in base and mesilate (mesylate) forms. European Medicines Agency schedules Bromocriptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05918MIG. The term BROMOCRIPTINE is an International Non-Proprietary Name. World Health Organization schedules bromocriptine in its Anatomical Therapeutic Chemical (ATC) Classification. BROMOCRIPTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromocriptine under HS 29396900 and SITC 54146. As of Q4 2014, BROMOCRIPTINE remains the US FDA Preferred Term for this commodity. Bromocriptine bears US NLM identifiers UMLS ID C0006230 and NCI Concept Code C62010. SMILES: BRC1[NH]C2C3C(C4=CC(C(=O)NC5(OC6(O)N(C(C(=O)N7C6CCC7)CC(C)C)C5=O)C(C)C)CN(C4CC13)C)CCC2.
This classification denotes a neuroprotective agent with the molecular formula C32H40BrN5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFP983J3OD, chemically known as 2-bromo-alpha-ergocryptine, methanesulfonate but more generally known as bromocriptine mesilate, which bears US NIH Compound Identifier 31100. European Medicines Agency schedules Bromocriptine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00878MIG. Most nations, for tariff and trade purposes, schedule bromocriptine mesylate under HS 29396900. As of Q4 2014, BROMOCRIPTINE MESYLATE remains US FDA's Preferred Term for this commodity. Bromocriptine mesylate bears US NLM identifiers UMLS ID C0546852 and NCI Concept Code C317. SMILES: CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6C7C(CCCC7[NH]C6BR)C5=C4)C)O.CS(=O)(=O)O.
This classification denotes a neuroprotective agent with the molecular formula C32H40BrN5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFP983J3OD, chemically known as ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'.alpha.)-, but more generally known as bromocriptine methanesulfonate, which bears US NIH Compound Identifier 31100. European Medicines Agency schedules bromocriptine methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05918MIG. Most nations, for tariff purposes, schedule bromocriptine methanesulfonate under HS 29396900. SMILES: CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6C7C(CCCC7[NH]C6BR)C5=C4)C)O.CS(=O)(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a dopamine antagonist and antiemetic agent with the molecular formula C14H22BrN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75473V2YZK, chemically known as o-anisamide, 4-amino-5-bromo-n-(2-(diethylamino)ethyl)- but generally known as bromopride, which bears US NIH Compound Identifier 2446. Bromopride most often comes in base and hydrochloride forms. European Medicines Agency schedules Bromopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05921MIG. The term BROMOPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules bromopride in its Anatomical Therapeutic Chemical (ATC) Classification. BROMOPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromopride under HS 29242995 and SITC 51479. As of Q4 2014, BROMOPRIDE remains the US FDA Preferred Term for this commodity. Bromopride bears US NLM identifiers UMLS ID C0054129 and NCI Concept Code C73035. SMILES: BRC1CC(C(=O)NCCN(CC)CC)C(OC)CC1N.
This classification denotes an antihelminthic agent with the molecular formula C19H18BrF3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9MM438AA0G, chemically known as 4-bromo-3-tert-butyl-alpha,alpha,alpha-trifluoro-5-nitro-2,6-cresoto-o-toluidide but generally known as bromoxanide, which bears US NIH Compound Identifier 166570. European Medicines Agency schedules Bromoxanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05922MIG. The term BROMOXANIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). BROMOXANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromoxanide under HS 29242995 and SITC 51479. As of Q4 2014, BROMOXANIDE remains the US FDA Preferred Term for this commodity. Bromoxanide bears US NLM identifiers UMLS ID C2347217 and NCI Concept Code C72148. SMILES: BRC1CC(C(NC(=O)C2C(O)C(C(C)(C)C)CC([N](=O)O)C2C)CC1)C(F)(F)F.
This classification denotes an antipsychotic agent with the molecular formula C21H23BrFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LYH6F7I22E, chemically known as 1-butanone, 4-(4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as bromperidol, which bears US NIH Compound Identifier 2448. Bromperidol most often comes in base and decanoate forms. European Medicines Agency schedules Bromperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05923MIG. The term BROMPERIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules bromperidol in its Anatomical Therapeutic Chemical (ATC) Classification. BROMPERIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromperidol under HS 29333999 and SITC 51574. As of Q4 2014, BROMPERIDOL remains the US FDA Preferred Term for this commodity. Bromperidol bears US NLM identifiers UMLS ID C0054138 and NCI Concept Code C76439. SMILES: BRC1CCC(C2(O)CCN(CC2)CCCC(=O)C2CCC(F)CC2)CC1.
This classification denotes an antipsychotic agent C31H41BrFNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73LG72M4LV, chemically known as decanoic acid, 4-(4-bromophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidinyl ester, but more generally known as bromperidol decanoate, which bears US NIH Compound Identifier 156321. European Medicines Agency schedules Bromperidol decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00880MIG. Most nations, for tariff and trade purposes, schedule bromperidol decanoate under HS 29333999 and SITC 51574. As of Q4 2014, BROMPERIDOL DECANOATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2CCC(CC2)F)C3CCC(CC3)BR.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19BrN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H57G17P2FN, chemically known as 3-(p-bromophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but generally known as brompheniramine, which bears US NIH Compound Identifier 6834. Brompheniramine most often comes in base and maleate forms. European Medicines Agency schedules Brompheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05924MIG. The term BROMPHENIRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules brompheniramine in its Anatomical Therapeutic Chemical (ATC) Classification. BROMPHENIRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brompheniramine under HS 29333999 and SITC 51574. As of Q4 2014, BROMPHENIRAMINE remains the US FDA Preferred Term for this commodity. Brompheniramine bears US NLM identifiers UMLS ID C0006246 and NCI Concept Code C61655. SMILES: BRC1CCC(C(CCN(C)C)C2NCCCC2)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19BrN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IXA7C9ZN03, chemically known as 3-(p-bromophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but more generally known as brompheniramine maleate, which bears US NIH Compound Identifier 6834. European Medicines Agency schedules Brompheniramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00881MIG. Most nations, for tariff and trade purposes, schedule brompheniramine maleate under HS 29333999 and SITC 51574. As of Q4 2014, BROMPHENIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Brompheniramine maleate bears US NLM identifiers UMLS ID C0012385 and NCI Concept Code C47422. SMILES: CN(C)CCC(C1CCC(CC1)BR)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C76H52O46.C16H19BRN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQD5087V38. European Medicines Agency schedules brompheniramine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20623. Most nations, for tariff and trade purposes, schedule brompheniramine tannate under HS 29333999 and SITC 51574. SMILES: As of Q4 2014, BROMPHENIRAMINE TANNATE remains US FDA's Preferred Term for this commodity.
This classification denotes a therapeutic estrogen with the molecular formula C22H19Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U06D381UQ, chemically known as 2-brom-1-(4-ethylphenyl)-1,2-diphenylethylen but generally known as broparestrol, which bears US NIH Compound Identifier 3032769. European Medicines Agency schedules Broparestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05926MIG. The term BROPARESTROL is an International Non-Proprietary Name. BROPARESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BROPARESTROL remains the US FDA Preferred Term for this commodity. Broparestrol bears US NLM identifiers UMLS ID C0054148 and NCI Concept Code C76995. SMILES: Br/C(=C(/c1ccc(CC)cc1)c1ccccc1)c1ccccc1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H18BrN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G5MIG3753N, chemically known as piperidine, 1-(3-(5-(3-bromophenyl)-2h-tetrazol-2-yl)-1-oxopropyl)- but generally known as broperamole, which bears US NIH Compound Identifier 36341. European Medicines Agency schedules Broperamole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05927MIG. The term BROPERAMOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). BROPERAMOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule broperamole under HS 29333999 and SITC 51574. As of Q4 2014, BROPERAMOLE remains the US FDA Preferred Term for this commodity. Broperamole bears US NLM identifiers UMLS ID C0054149 and NCI Concept Code C76797. SMILES: BRC1CC(C2NN(NN2)CCC(=O)N2CCCCC2)CCC1.
This classification denotes an immunostimulant with the molecular formula C10H8BrN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J57CTF25XJ, chemically known as 4-pyrimidinol, 2-amino-5-bromo-6-phenyl- but generally known as bropirimine, which bears US NIH Compound Identifier 65457. European Medicines Agency schedules Bropirimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05928MIG. The term BROPIRIMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). BROPIRIMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bropirimine under HS 29335995 and SITC 51576. As of Q4 2014, BROPIRIMINE remains the US FDA Preferred Term for this commodity. Bropirimine bears US NLM identifiers UMLS ID C0054150 and NCI Concept Code C1024. SMILES: C1=CC=C(C=C1)C2=C(C(=O)N=C(N2)N)BR.
This classification denotes a benzodiazepine with the molecular formula C15H10BrClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XZM1R3DKF, chemically known as 8-bromo-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine but generally known as brotizolam, which bears US NIH Compound Identifier 2451. European Medicines Agency schedules Brotizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05933MIG. The term BROTIZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules brotizolam in its Anatomical Therapeutic Chemical (ATC) Classification. BROTIZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brotizolam under HS 29349100 and SITC 51579. As of Q4 2014, BROTIZOLAM remains the US FDA Preferred Term for this commodity. Brotizolam bears US NLM identifiers UMLS ID C0054151 and NCI Concept Code C87057. SMILES: BRC1SC2N3C(NNC3C)CN=C(C2C1)C1C(CL)CCCC1.
This classification denotes a mucolytic agent with the molecular formula C24H28Br2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Y00SD533IW, chemically known as 4-acetoxy-2,4-dibrom-6-((n-cyclohexylmethylamino)methyl)-3-methoxybenzanilid but more generally known as brovanexine, which bears US NIH Compound Identifier 162137. Brovanexine most often comes in base and hydrochloride forms. European Medicines Agency schedules Brovanexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05934MIG. The term BROVANEXINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). BROVANEXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule brovanexine under HS 29242995 and SITC 51479. As of Q4 2014, BROVANEXINE remains US FDA's Preferred Term for this commodity. Brovanexine bears US NLM identifiers UMLS ID C0054152 and NCI Concept Code C74261. SMILES: BRC1C(NC(=O)C2CC(OC)C(OC(=O)C)CC2)C(CN(C2CCCCC2)C)CC(BR)C1.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AYN5T18K5R. European Medicines Agency schedules Brovincamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05935MIG. Brovincamine generally arises in the molecular formula C21H25BRN2O3. The term BROVINCAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) BROVINCAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brovincamine under HS 29399900 and SITC 54149. As of Q4 2014, BROVINCAMINE remains the US FDA Preferred Term for this commodity. Brovincamine bears US NLM identifiers UMLS ID C0044725 and NCI Concept Code C74419. SMILES: Brc1cc2n3c4C5N(CCCC5(CC3(O)C(=O)OC)CC)CCc4c2cc1.
This classification denotes a vasodilating agent C21H25BrN2O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3SNC78UTU, chemically known as eburnamenine-14-carboxylic acid, 14,15-dihydro-11-bromo-14-hydroxy-, methyl ester, (3-.alpha.,14-.beta.,16-.alpha.)-, (e)-2-butenedioate (1:1) (salt), but more generally known as brovincamine fumarate, which bears US NIH Compound Identifier 5282434. European Medicines Agency schedules Brovincamine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00883MIG. Most nations, for tariff and trade purposes, schedule brovincamine fumarate under HS 29399900 and SITC 54149. As of Q4 2014, BROVINCAMINE FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@@]12CCCN3[C@@H]1C4C(C5CCC(CC5N4[C@](C2)(C(=O)OC)O)BR)CC3.C(=C/C(=O)O)\C(=O)O.
This classification denotes a beta-adrenergic agonist with the molecular formula C9H15BrN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZE4IRB4DUC, chemically known as 3-bromo-alpha-(((1,1-dimethylethyl)amino)methyl)isoxazole-5-methanol but generally known as broxaterol, which bears US NIH Compound Identifier 71149. European Medicines Agency schedules Broxaterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05937MIG. The term BROXATEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BROXATEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule broxaterol under HS 29349990 and SITC 51579. As of Q4 2014, BROXATEROL remains the US FDA Preferred Term for this commodity. Broxaterol bears US NLM identifiers UMLS ID C0054156 and NCI Concept Code C74195. SMILES: BRC1NOC(C(O)CNC(C)(C)C)C1.
This classification denotes an anti-infective agent with the molecular formula C9H5Br2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UK4C618C8T, chemically known as 5,7-dibromooxine but generally known as broxyquinoline, which bears US NIH Compound Identifier 2453. European Medicines Agency schedules Broxyquinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05940MIG. The term BROXYQUINOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules broxyquinoline in its Anatomical Therapeutic Chemical (ATC) Classification. BROXYQUINOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule broxyquinoline under HS 29334990 and SITC 51575. As of Q4 2014, BROXYQUINOLINE remains the US FDA Preferred Term for this commodity. Broxyquinoline bears US NLM identifiers UMLS ID C0054157 and NCI Concept Code C73253. SMILES: BRC1C2C(NCCC2)C(O)C(BR)C1.
This classification denotes a vaccine against a genus of gram-negative, aerobic bacteria that causes brucellosis. Its cells are nonmotile coccobacilli and are animal parasites and pathogens. The bacterium is transmissible to humans through contact with infected dairy products or tissue.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA204. This VA Drug Class (GA204) classifies this compound as belonging to the group STIMULANT LAXATIVES.
This classification denotes an analgesic agent with the molecular formula C12H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M7CVQ8PF8, chemically known as p-butyrophenetidide, 3-hydroxy- but generally known as bucetin, which bears US NIH Compound Identifier 14130. European Medicines Agency schedules Bucetin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05942MIG. The term BUCETIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules bucetin in its Anatomical Therapeutic Chemical (ATC) Classification. BUCETIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bucetin under HS 29242995 and SITC 51479. As of Q4 2014, BUCETIN remains the US FDA Preferred Term for this commodity. Bucetin bears US NLM identifiers UMLS ID C0054195 and NCI Concept Code C72112. SMILES: CCOC1=CC=C(C=C1)NC(=O)CC(C)O.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C9H13N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G4Z4676IS, chemically known as 6h-purin-6-one, 2-amino-9-(3,4-dihydroxybutyl)-1,9-dihydro-, (r)- but generally known as buciclovir, which bears US NIH Compound Identifier 65648. Buciclovir most often comes in base and triphosphate forms. European Medicines Agency schedules Buciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05943MIG. The term BUCICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). BUCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buciclovir under HS 29335995 and SITC 51576. As of Q4 2014, BUCICLOVIR remains the US FDA Preferred Term for this commodity. Buciclovir bears US NLM identifiers UMLS ID C0050178 and NCI Concept Code C73198. SMILES: OC(CCN1C2[NH]C(NC(=O)C2NC1)N)CO.-.
This classification denotes an antioxidant with the molecular formula C7H13NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) R80LRA5WTF, chemically known as l-cysteine, n-(2-mercapto-2-methyl-1-oxopropyl)- but more generally known as bucillamine, which bears US NIH Compound Identifier 2459. European Medicines Agency schedules Bucillamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05944MIG. The term BUCILLAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules bucillamine in its Anatomical Therapeutic Chemical (ATC) Classification. BUCILLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bucillamine under HS 29309016 and SITC 51549. As of Q4 2014, BUCILLAMINE remains US FDA's Preferred Term for this commodity. Bucillamine bears US NLM identifiers UMLS ID C0073917 and NCI Concept Code C83561. SMILES: SC(C(=O)NC(CS)C(=O)O)(C)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E9UO06K7CE, chemically known as 2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile but generally known as bucindolol, which bears US NIH Compound Identifier 51045. Bucindolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bucindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05945MIG. The term BUCINDOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). BUCINDOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bucindolol under HS 29339990 and SITC 51577. As of Q4 2014, BUCINDOLOL remains the US FDA Preferred Term for this commodity. Bucindolol bears US NLM identifiers UMLS ID C0054196 and NCI Concept Code C79557. SMILES: OC(CNC(CC1C2C([NH]C1)CCCC2)(C)C)COC1C(CCCC1)C#N.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SH683G4QII, chemically known as 2-(2-hydroxy-3-((2-(3-indolyl)-1,1-dimethylethyl)amino)propoxy)benzonitrile hydrochloride but more generally known as bucindolol hydrochloride, which bears US NIH Compound Identifier 51044. European Medicines Agency schedules Bucindolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00886MIG. Most nations, for tariff and trade purposes, schedule bucindolol hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BUCINDOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(CC1C[NH]C2C1CCCC2)NCC(COC3CCCCC3C#N)O.CL.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C18H24N5O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63X7MBT2LQ, chemically known as 16980-89-5 (sodium salt, monohydrate) but generally known as bucladesine, which bears US NIH Compound Identifier 9687. Bucladesine most often comes in base and sodium forms. European Medicines Agency schedules Bucladesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05946MIG. The term BUCLADESINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules bucladesine in its Anatomical Therapeutic Chemical (ATC) Classification. BUCLADESINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bucladesine under HS 29349990 and SITC 51579. As of Q4 2014, BUCLADESINE remains the US FDA Preferred Term for this commodity. Bucladesine bears US NLM identifiers UMLS ID C0012054 and NCI Concept Code C83562. SMILES: P1(=O)(OC2C(OC(=O)CCC)C(OC2CO1)N1C2NCNC(NC(=O)CCC)C2NC1)O.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C18H23N5O8P.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DZN2C97A7, chemically known as sodium dibutyryl cyclic adenosine-3,5-monophosphate but more generally known as bucladesine sodium, which bears US NIH Compound Identifier 28177. European Medicines Agency schedules Bucladesine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00888MIG. Most nations, for tariff and trade purposes, schedule bucladesine sodium under HS 29349990 and SITC 51579. As of Q4 2014, BUCLADESINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC(=O)NC1C2C(NCN1)N(CN2)[C@H]3[C@@H]([C@H]4[C@H](O3)COP(=O)(O4)[O-])OC(=O)CCC.[NA+].
This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H33ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C94V6X681, chemically known as piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-.alpha.-phenylbenzyl)-, dihydrochloride but generally known as buclizine, which bears US NIH Compound Identifier 6729. Buclizine most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Buclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05947MIG. The term BUCLIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules buclizine in its Anatomical Therapeutic Chemical (ATC) Classification. BUCLIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buclizine under HS 29335995 and SITC 51576. As of Q4 2014, BUCLIZINE remains the US FDA Preferred Term for this commodity. Buclizine bears US NLM identifiers UMLS ID C0164386 and NCI Concept Code C65273. SMILES: CLC1CCC(C(N2CCN(CC2)CC2CCC(C(C)(C)C)CC2)C2CCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H33ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58FQD093NU, chemically known as piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-, dihydrochloride, but more generally known as buclizine dihydrochloride, which bears US NIH Compound Identifier 6729. European Medicines Agency schedules buclizine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05947MIG. Most nations, for tariff purposes, schedule buclizine dihydrochloride under HS 29335995. SMILES: CC(C)(C)C1CCC(CC1)CN2CCN(CC2)C(C3CCCCC3)C4CCC(CC4)CL.CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H33ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58FQD093NU, chemically known as piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-.alpha.-phenylbenzyl)-, dihydrochloride but more generally known as buclizine hydrochloride, which bears US NIH Compound Identifier 6729. European Medicines Agency schedules Buclizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00889MIG. Most nations, for tariff and trade purposes, schedule buclizine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, BUCLIZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Buclizine hydrochloride bears US NLM identifiers UMLS ID C0304304 and NCI Concept Code C65274. SMILES: CC(C)(C)C1CCC(CC1)CN2CCN(CC2)C(C3CCCCC3)C4CCC(CC4)CL.CL.CL.
This classification denotes an antifungal agent with the molecular formula C11H14ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O52NM0A9YL, chemically known as benzamide, n-butyl-4-chloro-2-hydroxy- but generally known as buclosamide, which bears US NIH Compound Identifier 68466. European Medicines Agency schedules Buclosamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05948MIG. The term BUCLOSAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). BUCLOSAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buclosamide under HS 29242995 and SITC 51479. As of Q4 2014, BUCLOSAMIDE remains the US FDA Preferred Term for this commodity. Buclosamide bears US NLM identifiers UMLS ID C0162967 and NCI Concept Code C72958. SMILES: CCCCNC(=O)C1=C(C=C(C=C1)CL)O.
This classification denotes an anesthetic agent with the molecular formula C17H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HUC352BGYM, chemically known as 1,2,3,4-tetrahydro-n-butyl-9-acridinamine but generally known as bucricaine, which bears US NIH Compound Identifier 9423. European Medicines Agency schedules Bucricaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05951MIG. The term BUCRICAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BUCRICAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bucricaine under HS 29339990 and SITC 51577. As of Q4 2014, BUCRICAINE remains the US FDA Preferred Term for this commodity. Bucricaine bears US NLM identifiers UMLS ID C2347225 and NCI Concept Code C72141. SMILES: N(C1C2CCCCC2NC2C1CCCC2)CCCC.
This classification denotes an antiarrhythmic agent with the molecular formula C29H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JI688O846T, chemically known as 4h-1-benzopyran-4-one, 2-(4-(3-(dibutylamino)propoxy)-3,5-dimethylbenzoyl)- but generally known as bucromarone, which bears US NIH Compound Identifier 132852. European Medicines Agency schedules Bucromarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05953MIG. The term BUCROMARONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). BUCROMARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bucromarone under HS 29329985 and SITC 51569. As of Q4 2014, BUCROMARONE remains the US FDA Preferred Term for this commodity. Bucromarone bears US NLM identifiers UMLS ID C0054198 and NCI Concept Code C72577. SMILES: O(CCCN(CCCC)CCCC)C1C(CC(CC1C)C(=O)C1OC2C(C(=O)C1)CCCC2)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U8WVJ3501L, chemically known as 8-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-5-methyl-2h-1-benzopyran-2-one but generally known as bucumolol, which bears US NIH Compound Identifier 169787. Bucumolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bucumolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05954MIG. The term BUCUMOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). BUCUMOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BUCUMOLOL remains the US FDA Preferred Term for this commodity. Bucumolol bears US NLM identifiers UMLS ID C0054199 and NCI Concept Code C72611. SMILES: O(CC(O)CNC(C)(C)C)C1C2OC(=O)CCC2C(CC1)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H23NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U2Z7867QU7, chemically known as 5-methyl-8-(2-hydroxy-3-t-butylaminopropoxy)coumarin hydrochloride, dl- but more generally known as bucumolol hydrochloride, which bears US NIH Compound Identifier 169786. European Medicines Agency schedules Bucumolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21960. Most nations, for tariff and trade purposes, schedule bucumolol hydrochloride under HS 29322985. As of Q4 2014, BUCUMOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC(C2C1CCC(=O)O2)OCC(CNC(C)(C)C)O.CL.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3OKS62Q6X. European Medicines Agency schedules Budesonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05955MIG. Budesonide generally arises in the molecular formula C25H34O6. The term BUDESONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) BUDESONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule budesonide under HS 29372900 and SITC 54153. As of Q4 2014, BUDESONIDE remains the US FDA Preferred Term for this commodity. Budesonide bears US NLM identifiers UMLS ID C0054201 and NCI Concept Code C1027. SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a cation channel blocker and antiparkinsonian agent with the molecular formula C21H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L9026OPI2Z, chemically known as 1-tert-butyl-4,4-diphenylpiperidine but generally known as budipine, which bears US NIH Compound Identifier 68778. Budipine most often comes in base and hydrochloride forms. European Medicines Agency schedules Budipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05956MIG. The term BUDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules budipine in its Anatomical Therapeutic Chemical (ATC) Classification. BUDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule budipine under HS 29333999 and SITC 51574. As of Q4 2014, BUDIPINE remains the US FDA Preferred Term for this commodity. Budipine bears US NLM identifiers UMLS ID C0054202 and NCI Concept Code C73271. SMILES: N1(CCC(CC1)(C1CCCCC1)C1CCCCC1)C(C)(C)C.
This classification denotes an antiparkinson agent with the molecular formula C21H27N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NBF4Q9307Q, chemically known as 1-tert-butyl-4,4-diphenylpiperidine hydrochloride but more generally known as budipine hydrochloride, which bears US NIH Compound Identifier 3030419. European Medicines Agency schedules Budipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35026. Most nations, for tariff and trade purposes, schedule budipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BUDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)N1CCC(CC1)(C2CCCCC2)C3CCCCC3.CL.
This classification denotes an antihypertensive agent with the molecular formula C14H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S0177QHV2B, chemically known as 1(2h)-phthalazinone, (1,3-dimethyl-2-butenylidene)hydrazone but generally known as budralazine, which bears US NIH Compound Identifier 6419536. Budralazine most often comes in base and hydrochloride forms. European Medicines Agency schedules Budralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05958MIG. The term BUDRALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). BUDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule budralazine under HS 29339990 and SITC 51577. As of Q4 2014, BUDRALAZINE remains the US FDA Preferred Term for this commodity. Budralazine bears US NLM identifiers UMLS ID C0054203 and NCI Concept Code C79901. SMILES: N(/N=C(/C=C(/C)C)C)c1nncc2c1cccc2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Y0T619B3U, chemically known as 2-((o-tert-butyl-alpha-phenyl-benzyl)oxy)-n,n-dimethylethylamine. but generally known as bufenadrine, which bears US NIH Compound Identifier 21916. European Medicines Agency schedules Bufenadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05959MIG. The term BUFENADRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BUFENADRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bufenadrine under HS 29221980 and SITC 51461. As of Q4 2014, BUFENADRINE remains the US FDA Preferred Term for this commodity. Bufenadrine bears US NLM identifiers UMLS ID C2347227 and NCI Concept Code C73046. SMILES: O(C(C1C(C(C)(C)C)CCCC1)C1CCCCC1)CCN(C)C.
This classification denotes a non-steroidal anti-inflammatory agent with the molecular formula C12H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4T3C38J78L, chemically known as benzeneacetamide, 4-butoxy-n-hydroxy- (9ci) but generally known as bufexamac, which bears US NIH Compound Identifier 2466. European Medicines Agency schedules Bufexamac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05961MIG. World Health Organization schedules bufexamac in its Anatomical Therapeutic Chemical (ATC) Classification. BUFEXAMAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bufexamac under HS 29280090 and SITC 51486. As of Q4 2014, BUFEXAMAC remains the US FDA Preferred Term for this commodity. SMILES: CCCCOC1=CC=C(C=C1)CC(=O)NO.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PUA774J9MP, chemically known as 1-isobutyl-3,4-diphenylpyrazole-5-acetic acid but generally known as bufezolac, which bears US NIH Compound Identifier 68676. European Medicines Agency schedules Bufezolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05962MIG. The term BUFEZOLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). BUFEZOLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bufezolac under HS 29331990 and SITC 51571. As of Q4 2014, BUFEZOLAC remains the US FDA Preferred Term for this commodity. Bufezolac bears US NLM identifiers UMLS ID C2347228 and NCI Concept Code C73081. SMILES: OC(=O)CC1N(NC(C1C1CCCCC1)C1CCCCC1)CC(C)C.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V7I71DQ432, chemically known as 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone but generally known as buflomedil, which bears US NIH Compound Identifier 2467. Buflomedil most often comes in base and hydrochloride forms. European Medicines Agency schedules Buflomedil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05963MIG. The term BUFLOMEDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules buflomedil in its Anatomical Therapeutic Chemical (ATC) Classification. BUFLOMEDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buflomedil under HS 29339990 and SITC 51577. As of Q4 2014, BUFLOMEDIL remains the US FDA Preferred Term for this commodity. Buflomedil bears US NLM identifiers UMLS ID C0054207 and NCI Concept Code C80610. SMILES: O=C(CCCN1CCCC1)c1c(OC)cc(OC)cc1OC.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H25NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J944AFS8S, chemically known as 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone but more generally known as buflomedil hydrochloride, which bears US NIH Compound Identifier 2467. European Medicines Agency schedules Buflomedil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00891MIG. Most nations, for tariff and trade purposes, schedule buflomedil hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BUFLOMEDIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CC(C(C(C1)OC)C(=O)CCCN2CCCC2)OC.CL.
This classification denotes an enzyme inhibitor with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K654P2M4J, chemically known as 14,15beta-epoxy-3beta-hydroxy-5beta-bufa-20,22-dienolide but generally known as bufogenin, which bears US NIH Compound Identifier 10063. European Medicines Agency schedules Bufogenin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05964MIG. The term BUFOGENIN is an International Non-Proprietary Name. BUFOGENIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Bufogenin or resibufogenin bears US NLM identifiers UMLS ID C0054208 and NCI Concept Code C77829. SMILES: CC12CCC(CC1CCC3C2CCC4(C35C(O5)CC4C6=COC(=O)C=C6)C)O.
This classification denotes an anti-diabetic agent with the molecular formula C6H15N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W2115E9C7B, chemically known as imidodicarbonimidic diamide, n-butyl- but more generally known as buformin, which bears US NIH Compound Identifier 2468. Buformin most often comes in base and hydrochloride forms. European Medicines Agency schedules Buformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05965MIG. The term BUFORMIN is an International Non-Proprietary Name WHO schedules buformin in its Anatomical Therapeutic Chemical (ATC) Classification. BUFORMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule buformin under HS 29252900 and SITC 51482. As of Q4 2014, BUFORMIN remains US FDA's Preferred Term for this commodity. Buformin bears US NLM identifiers UMLS ID C0006359 and NCI Concept Code C95328. SMILES: N(=C(\N=C(\N)N)N)/CCCC.
This classification denotes an anti-diabetic agent with the molecular formula C6H15N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D947SXO87P, chemically known as imidodicarbonimidic diamide, n-butyl- but more generally known as buformin hydrochloride, which bears US NIH Compound Identifier 2468. European Medicines Agency schedules Buformin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00892MIG. Most nations, for tariff and trade purposes, schedule buformin hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, BUFORMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Buformin hydrochloride bears US NLM identifiers UMLS ID C2987056 and NCI Concept Code C95329. SMILES: CCCCNC(=N)NC(=N)N.CL.
This classification denotes a mast cell stabilizer with the molecular formula C18H16N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46C1PX266N, chemically known as 6-butyl-1,4,7,10-tetrahydro-4,10-dioxo-1,7-phenanthroline-2,8-dicarboxylic acid but generally known as bufrolin, which bears US NIH Compound Identifier 72103. European Medicines Agency schedules Bufrolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05966MIG. The term BUFROLIN is an International Non-Proprietary Name. BUFROLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bufrolin under HS 29339990 and SITC 51577. As of Q4 2014, BUFROLIN remains the US FDA Preferred Term for this commodity. Bufrolin bears US NLM identifiers UMLS ID C0054211 and NCI Concept Code C72940. SMILES: O=C1C2C([NH]C(C1)C(=O)O)C(CCCC)CC1C2[NH]C(CC1=O)C(=O)O.
This classification denotes an antimalarial agent with the molecular formula C21H27N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TSQ6U39Q3G, chemically known as 2(3h)-furanone, dihydro-3-(1-((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)ethylidene)- but generally known as bulaquine, which bears US NIH Compound Identifier 3036820. European Medicines Agency schedules Bulaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00894MIG. The term BULAQUINE is an International Non-Proprietary Name. Most nations schedule bulaquine under HS 29349990 and SITC 51579. As of Q4 2014, BULAQUINE remains the US FDA Preferred Term for this commodity. Bulaquine bears US NLM identifiers UMLS ID C0082079 and NCI Concept Code C75997. SMILES: O1CC/C(=C(\NCCCC(NC2C3NCCCC3CC(OC)C2)C)C)C1=O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ATD81G944M, chemically known as 2-(2,3-diphenylcarbazoyl)hexansaeure but generally known as bumadizone, which bears US NIH Compound Identifier 19161. Bumadizone most often comes in base and calcium forms. European Medicines Agency schedules Bumadizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05968MIG. The term BUMADIZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules bumadizone in its Anatomical Therapeutic Chemical (ATC) Classification. BUMADIZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bumadizone under HS 29280090 and SITC 51486. As of Q4 2014, BUMADIZONE remains the US FDA Preferred Term for this commodity. Bumadizone bears US NLM identifiers UMLS ID C0054219 and NCI Concept Code C72113. SMILES: O=C(N(NC1CCCCC1)C1CCCCC1)C(CCCC)C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug 4C19H21N2O3.2Ca.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7PSH384AJD, chemically known as calcium 2-(1,2-diphenylhydrazinocarbonyl)hexanoate hemihydrate, but more generally known as bumadizone calcium, which bears US NIH Compound Identifier 36833. European Medicines Agency schedules Bumadizone calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00896MIG. Most nations, for tariff and trade purposes, schedule bumadizone calcium under HS 29280090 and SITC 51486. As of Q4 2014, BUMADIZONE CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCCC(C(=O)N(C1CCCCC1)NC2CCCCC2)C(=O)[O-].CCCCC(C(=O)N(C1CCCCC1)NC2CCCCC2)C(=O)[O-].CCCCC(C(=O)N(C1CCCCC1)NC2CCCCC2)C(=O)[O-].CCCCC(C(=O)N(C1CCCCC1)NC2CCCCC2)C(=O)[O-].O.[CA+2].[CA+2].
This classification denotes an anesthetic agent with the molecular formula C18H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B77K612SPZ, chemically known as 2-pyrrolidinecarboxanilide, 1-butyl-2,4,6-trimethyl- but generally known as bumecaine, which bears US NIH Compound Identifier 65770. Bumecaine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bumecaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05969MIG. The term BUMECAINE is an International Non-Proprietary Name. BUMECAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bumecaine under HS 29339990 and SITC 51577. As of Q4 2014, BUMECAINE remains the US FDA Preferred Term for this commodity. Bumecaine bears US NLM identifiers UMLS ID C2347230 and NCI Concept Code C72171. SMILES: O=C(NC1C(CC(CC1C)C)C)C1N(CCC1)CCCC.
This classification denotes an anesthetic agent C18H28N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PBE1H9OIFQ, chemically known as 1-butyl-2',4',6'-trimethyl-2-pyrrolidinecarboxanilide hydrochloride, but more generally known as bumecaine hydrochloride, which bears US NIH Compound Identifier 167785. Most nations, for tariff and trade purposes, schedule bumecaine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BUMECAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCCN1CCCC1C(=O)NC2C(CC(CC2C)C)C.CL.
This classification denotes a vasodilating agent with the molecular formula C12H17N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9FNZ7TFY4R, chemically known as 8-tert-butyl-7,8-dihydro-5-methyl-6h-pyrrolo(3,2-e)-s-triazolo(1,5-a)pyrimidine but generally known as bumepidil, which bears US NIH Compound Identifier 68813. European Medicines Agency schedules Bumepidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05970MIG. The term BUMEPIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). BUMEPIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bumepidil under HS 29335995 and SITC 51576. As of Q4 2014, BUMEPIDIL remains the US FDA Preferred Term for this commodity. Bumepidil bears US NLM identifiers UMLS ID C0107460 and NCI Concept Code C73108. SMILES: CC1=NC2=NC=NN2C3=C1CCN3C(C)(C)C.
This classification denotes a loop diuretic with the molecular formula C17H20N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Y2S3XUQ5H, chemically known as benzoic acid, 3-(butylamino)-4-phenoxy-5-sulfamoyl- but generally known as bumetanide, which bears US NIH Compound Identifier 2471. European Medicines Agency schedules Bumetanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05971MIG. The term BUMETANIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules bumetanide in its Anatomical Therapeutic Chemical (ATC) Classification. BUMETANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bumetanide under HS 29350090 and SITC 51580. As of Q4 2014, BUMETANIDE remains the US FDA Preferred Term for this commodity. Bumetanide bears US NLM identifiers UMLS ID C0701009 and NCI Concept Code C28875. SMILES: S(=O)(=O)(N)C1C(OC2CCCCC2)C(NCCCC)CC(C1)C(=O)O.
This classification denotes an antiarrhythmic agent with the molecular formula C21H30N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) GH09PRQ3FU, chemically known as 1-naphthalenecarboxamide, n-butyl-n-(2-(diethylamino)ethyl)- but more generally known as bunaftine, which bears US NIH Compound Identifier 36131. European Medicines Agency schedules Bunaftine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05973MIG. The term BUNAFTINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules bunaftine in its Anatomical Therapeutic Chemical (ATC) Classification. BUNAFTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bunaftine under HS 29242995 and SITC 51479. As of Q4 2014, BUNAFTINE remains US FDA's Preferred Term for this commodity. Bunaftine bears US NLM identifiers UMLS ID C0006378 and NCI Concept Code C72578. SMILES: O=C(N(CCN(CC)CC)CCCC)C1C2C(CCC1)CCCC2.
This classification denotes an antiarrhythmic agent with the molecular formula C21H30N2O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A2V53992Z. The term bunaftine citrate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule bunaftine citrate under HS 29242995. As of Q4 2014, BUNAFTINE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCN(CCN(CC)CC)C(=O)C1CCCC2C1CCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antiarrhythmic agent with the molecular formula C21H30N2O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YH47NU604H. European Medicines Agency schedules bunaftine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00897MIG. Most nations, for tariff and trade purposes, schedule bunaftine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, BUNAFTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCCN(CCN(CC)CC)C(=O)C1CCCC2C1CCCC2.CL.
This classification denotes an antihelminthic agent with the molecular formula C25H38N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A9IW1G3P6C, chemically known as 1-naphthamidine, n,n-dibutyl-4-hexyloxy-, monohydrochloride but generally known as bunamidine, which bears US NIH Compound Identifier 13986. Bunamidine base, hydroxynaphthoate, and oxynaphthoate forms. European Medicines Agency schedules Bunamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05974MIG. The term BUNAMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). BUNAMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bunamidine under HS 29252900 and SITC 51482. As of Q4 2014, BUNAMIDINE remains the US FDA Preferred Term for this commodity. Bunamidine bears US NLM identifiers UMLS ID C0054221 and NCI Concept Code C81513. SMILES: O(C1C2C(C(C(=N)N(CCCC)CCCC)CC1)CCCC2)CCCCCC.
This classification denotes an antihelminthic agent with the molecular formula C25H38N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y80LB0Q7CB, chemically known as 1-naphthamidine, n,n-dibutyl-4-hexyloxy-, monohydrochloride but more generally known as bunamidine hydrochloride, which bears US NIH Compound Identifier 13985. Most nations, for tariff and trade purposes, schedule bunamidine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, BUNAMIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bunamidine hydrochloride bears US NLM identifiers UMLS ID C0141753 and NCI Concept Code C75211. SMILES: CCCCCCOC1CCC(C2C1CCCC2)C(=N)N(CCCC)CCCC.CL.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F2613LO055, chemically known as 2-propanol, 3-(tert-butylamino)-1-(m-cyanophenoxy)- but generally known as bunitrolol, which bears US NIH Compound Identifier 2473. Bunitrolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bunitrolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05978MIG. The term BUNITROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). BUNITROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bunitrolol under HS 29269095 and SITC 51484. As of Q4 2014, BUNITROLOL remains the US FDA Preferred Term for this commodity. Bunitrolol bears US NLM identifiers UMLS ID C0006387 and NCI Concept Code C72614. SMILES: OC(CNC(C)(C)C)COC1C(CCCC1)C#N.
This classification denotes a beta-adrenergic blocking agent with the molecular structure C14H20N2O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, A42VUS2X73 chemically known as 2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)benzonitrile, hydrochloride, but more commonly known as bunitrolol hydrochloride, which bears US NIH Compound Identifier 31641. European Medicines Agency schedules Bunitrolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00900MIG. Most nations, for tariff and trade purposes, schedule bunitrolol hydrochloride under HS 29269095 and SITC 51484. As of Q4 2014, BUNITROLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)NCC(COC1CCCCC1C#N)O.CL.
This classification denotes an antiprotozoal agent with the molecular formula C21H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0354RT7LG4, chemically known as 1,4-naphthalenedione, 2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy- but generally known as buparvaquone, which bears US NIH Compound Identifier 71768. European Medicines Agency schedules Buparvaquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05980MIG. The term BUPARVAQUONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BUPARVAQUONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buparvaquone under HS 29146990 and SITC 51629. As of Q4 2014, BUPARVAQUONE remains the US FDA Preferred Term for this commodity. Buparvaquone bears US NLM identifiers UMLS ID C0054224 and NCI Concept Code C73276. SMILES: OC1=C(CC2CCC(C(C)(C)C)CC2)C(=O)C(=O)C2C1CCCC2.
This classification denotes a beta-adrenergic agonist with the molecular formula C19H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EC69E3PW7E, chemically known as benzyl alcohol, p-hydroxy-alpha-(1-((1-methyl-3-phenylpropyl)amino)ethyl)- but more generally known as buphenine hydrochloride, which bears US NIH Compound Identifier 4567. European Medicines Agency schedules Buphenine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00901MIG. Most nations, for tariff and trade purposes, schedule buphenine hydrochloride under HS 29225000. SMILES: CC(CCC1CCCCC1)NC(C)C(C2CCC(CC2)O)O.CL.
This classification denotes a beta-adrenergic agonist with the molecular formula C19H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 695DKH33EI, chemically known as benzyl alcohol, p-hydroxy-alpha-(1-((1-methyl-3-phenylpropyl)amino)ethyl)- but generally known as buphenine, which bears US NIH Compound Identifier 4567. Buphenine most often comes in base and hydrochloride forms. European Medicines Agency schedules Buphenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05981MIG. The term BUPHENINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules buphenine in its Anatomical Therapeutic Chemical (ATC) Classification. BUPHENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Buphenine or nylidrin bears US NLM identifiers UMLS ID C0028735 and NCI Concept Code C81642. SMILES: OC(C(NC(CCc1ccccc1)C)C)c1ccc(O)cc1.
This classification denotes an anesthetic agent with the molecular formula C18H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y8335394RO, chemically known as 2-piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)- but generally known as bupivacaine, which bears US NIH Compound Identifier 2474. Bupivacaine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bupivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05983MIG. The term BUPIVACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules bupivacaine in its Anatomical Therapeutic Chemical (ATC) Classification. BUPIVACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bupivacaine under HS 29333999 and SITC 51574. As of Q4 2014, BUPIVACAINE remains the US FDA Preferred Term for this commodity. Bupivacaine bears US NLM identifiers UMLS ID C0006400 and NCI Concept Code C62011. SMILES: O=C(NC1C(CCCC1C)C)C1N(CCCC1)CCCC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes an anesthetic agent with the molecular formula C18H28N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7TQO7W3VT8, chemically known as 2-piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)- monohydrochloride, monohydrate but more generally known as bupivacaine hydrochloride, which bears US NIH Compound Identifier 64737. European Medicines Agency schedules Bupivacaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00902MIG. Most nations, for tariff and trade purposes, schedule bupivacaine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BUPIVACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bupivacaine hydrochloride bears US NLM identifiers UMLS ID C0699883 and NCI Concept Code C28876. SMILES: CCCCN1CCCCC1C(=O)NC2C(CCCC2C)C.O.CL.
This classification denotes an anesthetic agent with the molecular formula C18H28N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7TQO7W3VT8, chemically known as 2-piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate, but more generally known as bupivacaine hydrochloride monohydrate, which bears US NIH Compound Identifier 64737. European Medicines Agency schedules bupivacaine hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05983MIG. Most nations, for tariff purposes, schedule bupivacaine hydrochloride monohydrate under HS 29333999. SMILES: CCCCN1CCCCC1C(=O)NC2C(CCCC2C)C.O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 858YGI5PIT, chemically known as 2-propanol, 1-(tert-butylamino)-3-((6-chloro-m-tolyl)oxy)- (8ci) but generally known as bupranolol, which bears US NIH Compound Identifier 2475. Bupranolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bupranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05984MIG. The term BUPRANOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules bupranolol in its Anatomical Therapeutic Chemical (ATC) Classification. BUPRANOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bupranolol under HS 29221980 and SITC 51461. As of Q4 2014, BUPRANOLOL remains the US FDA Preferred Term for this commodity. Bupranolol bears US NLM identifiers UMLS ID C0006403 and NCI Concept Code C72615. SMILES: CLC1C(OCC(O)CNC(C)(C)C)CC(CC1)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22ClNO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DTC2G3GDPL, chemically known as 2-propanol, 1-tert-butylamino-3-(6-chloro-m-tolyloxy)-, hydrochloride but more generally known as bupranolol hydrochloride, which bears US NIH Compound Identifier 27072. European Medicines Agency schedules Bupranolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00903MIG. Most nations, for tariff and trade purposes, schedule bupranolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, BUPRANOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC(C(C1)OCC(CNC(C)(C)C)O)CL.CL.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C29H41NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40D3SCR4GZ, chemically known as 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5-alpha,7-alpha-(s))- but generally known as buprenorphine, which bears US NIH Compound Identifier 40400. Buprenorphine most often comes in base and hydrochloride forms. European Medicines Agency schedules Buprenorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05985MIG. The term BUPRENORPHINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules buprenorphine in its Anatomical Therapeutic Chemical (ATC) Classification. BUPRENORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buprenorphine under HS 29391100 and SITC 54141. As of Q4 2014, BUPRENORPHINE remains the US FDA Preferred Term for this commodity. Buprenorphine bears US NLM identifiers UMLS ID C0006405 and NCI Concept Code C61656. SMILES: O1C2C34C5(CC(C2(OC)CC5)C(O)(C(C)(C)C)C)C(N(CC3)CC2CC2)CC2C4C1C(O)CC2.
This classification denotes an opioid receptor agonist and opioid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56W8MW3EN1. European Medicines Agency schedules Buprenorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13133MIG. Buprenorphine hydrochloride generally arises in the molecular formula C29H41NO4.CLH. The term 'buprenorphine hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule buprenorphine hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, BUPRENORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Buprenorphine hydrochloride bears US NLM identifiers UMLS ID C0006404 and NCI Concept Code C47424. SMILES: C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6C5C(C(CC6)O)O4)CC7CC7)OC)(C(C)(C)C)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes an antidepressant agent with the molecular formula C13H18ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01ZG3TPX31, chemically known as 1-propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)- but generally known as bupropion, which bears US NIH Compound Identifier 444. Bupropion most often comes in base and hydrochloride forms. European Medicines Agency schedules Bupropion in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05413MIG. The term BUPROPION is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules bupropion in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BUPROPION remains the US FDA Preferred Term for this commodity. Bupropion bears US NLM identifiers UMLS ID C0085208 and NCI Concept Code C62012. SMILES: Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1.
This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H29N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AWC1VMS3HC, chemically known as 1-butyl-3-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)urea but generally known as buquineran, which bears US NIH Compound Identifier 71953. European Medicines Agency schedules Buquineran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05986MIG. The term BUQUINERAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). BUQUINERAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buquineran under HS 29335995 and SITC 51576. As of Q4 2014, BUQUINERAN remains the US FDA Preferred Term for this commodity. Buquineran bears US NLM identifiers UMLS ID C0107468 and NCI Concept Code C74355. SMILES: O=C(NC1CCN(CC1)c1ncnc2c1cc(OC)c(OC)c2)NCCCC.
This classification denotes a vasodilating agent with the molecular formula C19H29NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4006BCR8NJ, chemically known as 2-(1-pyrrolidinyl)ethyl 4-butoxy-3,5-dimethoxybenzoat but generally known as burodiline, which bears US NIH Compound Identifier 189887. European Medicines Agency schedules Burodiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05990MIG. The term BURODILINE is an International Non-Proprietary Name. BURODILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule burodiline under HS 29339990 and SITC 51577. As of Q4 2014, BURODILINE remains the US FDA Preferred Term for this commodity. Burodiline bears US NLM identifiers UMLS ID C2698571 and NCI Concept Code C74424. SMILES: O(CCN1CCCC1)C(=O)c1cc(OC)c(OCCCC)c(OC)c1.
This classification denotes a gonadotropin-releasing hormone analog with the molecular formula C60H86N16O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PXW8U3YXDV, chemically known as luteinizing hormone-releasing hormone (pig), 6-(o-(1,1-dimethylethyl)-d-serine)-9-(n-ethyl-l-prolinamide)-10-deglycinamide- but generally known as buserelin, which bears US NIH Compound Identifier 42615. Buserelin most often comes in base and acetate forms. European Medicines Agency schedules Buserelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05991MIG. The term BUSERELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules buserelin in its Anatomical Therapeutic Chemical (ATC) Classification. BUSERELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buserelin under HS 29371900 and SITC 54154. As of Q4 2014, BUSERELIN remains the US FDA Preferred Term for this commodity. Buserelin bears US NLM identifiers UMLS ID C0006456 and NCI Concept Code C320. SMILES: O=C(N1C(CCC1)C(=O)NCC)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1[NH]CNC1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)COC(C)(C)C)CC(C)C)CCC/N=C(/N)N.
This classification denotes the acetate form of a gonadotropin-releasing hormone analog with the molecular formula C60H86N16O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PXW8U3YXDV, chemically known as luteinizing hormone-releasing hormone (pig), 6-(o-(1,1-dimethylethyl)-d-serine)-9-(n-ethyl-l-prolinamide)-10-deglycinamide- but more generally known as buserelin, which bears US NIH Compound Identifier 42615. Buserelin most often comes in base and acetate forms. European Medicines Agency schedules Buserelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05991MIG. The term BUSERELIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules buserelin in its Anatomical Therapeutic Chemical (ATC) Classification. BUSERELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule buserelin acetate under HS 29371900 and SITC 54154. As of Q4 2014, BUSERELIN ACETATE remains US FDA's Preferred Term for this commodity. Buserelin acetate bears US NLM identifiers UMLS ID C0600174 and NCI Concept Code C84460. SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2CCC(CC2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3C[NH]C4C3CCCC4)NC(=O)[C@H](CC5CNC[NH]5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O.
This classification denotes an anxiolytic with the molecular formula C21H31N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TK65WKS8HL, chemically known as 8-azaspiro(4,5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)piperizinyl)butyl)- but generally known as buspirone, which bears US NIH Compound Identifier 2477. Buspirone most often comes in base and hydrochloride forms. European Medicines Agency schedules Buspirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05992MIG. The term BUSPIRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules buspirone in its Anatomical Therapeutic Chemical (ATC) Classification. BUSPIRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buspirone under HS 29335995 and SITC 51576. As of Q4 2014, BUSPIRONE remains the US FDA Preferred Term for this commodity. Buspirone bears US NLM identifiers UMLS ID C0006462 and NCI Concept Code C62013. SMILES: O=C1N(C(=O)CC2(CCCC2)C1)CCCCN1CCN(CC1)C1NCCCN1.
This classification denotes an anxiolytic with the molecular formula C21H31N5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 207LT9J9OC, chemically known as 1,1-cyclopentanediacetimide, n-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, hydrochloride but more generally known as buspirone hydrochloride, which bears US NIH Compound Identifier 36431. European Medicines Agency schedules Buspirone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00906MIG. Most nations, for tariff and trade purposes, schedule buspirone hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, BUSPIRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Buspirone hydrochloride bears US NLM identifiers UMLS ID C0700444 and NCI Concept Code C26641. SMILES: C1CNC(NC1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O.CL.
This classification denotes an alkylsulfonate compound with the molecular formula C6H14O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1LN9045DK, chemically known as 1,4-dimethylsulfonyloxybutane but more generally known as busulfan, which bears US NIH Compound Identifier 2478. Busulfan most often comes in base and mannitol forms. European Medicines Agency schedules Busulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05993MIG. The term BUSULFAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules busulfan in its Anatomical Therapeutic Chemical (ATC) Classification. BUSULFAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule busulfan under HS 29053985 and SITC 51229. As of Q4 2014, BUSULFAN remains US FDA's Preferred Term for this commodity. Busulfan bears US NLM identifiers UMLS ID C0700015 and NCI Concept Code C321. SMILES: S(=O)(=O)(OCCCCOS(=O)(=O)C)C.
This classification denotes a barbiturate with the molecular formula C10H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0078O25A9, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylpropyl)- but generally known as butabarbital, which bears US NIH Compound Identifier 2479. Butabarbital most often comes in base and hydrochloride forms. European Medicines Agency schedules Secbutabarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10465MIG. The term SECBUTABARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Most nations schedule butabarbital under HS 29335300 and SITC 51576. As of Q4 2014, BUTABARBITAL remains the US FDA Preferred Term for this commodity. Butabarbital bears US NLM identifiers UMLS ID C0006464 and NCI Concept Code C61657. SMILES: CCC(C)C1(C(=O)NC(=O)NC1=O)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN301. This VA Drug Class (CN301) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS.
This classification denotes a barbiturate with the molecular formula C10H15N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9WTD50I918, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylpropyl)- but more generally known as butabarbital sodium, which bears US NIH Compound Identifier 2479. European Medicines Agency schedules Secbutabarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04343MIG. Most nations, for tariff and trade purposes, schedule butabarbital sodium under HS 29335300. As of Q4 2014, BUTABARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Butabarbital sodium bears US NLM identifiers UMLS ID C0304358 and NCI Concept Code C65275. SMILES: CCC(C)C1(C(=O)NC(=O)[N-]C1=O)CC.[NA+].
This classification denotes an anesthetic agent with the molecular formula C18H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z84S23CGJJ, chemically known as 1-propanol, 3-(dibutylamino)-, p-aminobenzoate (ester) but generally known as butacaine, which bears US NIH Compound Identifier 2480. Butacaine most often comes in base, acetate, chloride, hydrochloride, and sulfate forms. European Medicines Agency schedules Butacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05994MIG. The term BUTACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). BUTACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butacaine under HS 29224995 and SITC 51465. As of Q4 2014, BUTACAINE remains the US FDA Preferred Term for this commodity. Butacaine bears US NLM identifiers UMLS ID C0006466 and NCI Concept Code C87457. SMILES: O(CCCN(CCCC)CCCC)C(=O)C1CCC(N)CC1.
This classification denotes an anesthetic agent with the molecular formula 2C18H30N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PAU39W3CVB, chemically known as 1-propanol, 3-(dibutylamino)-, p-aminobenzoate (ester), sulfate (2:1) but generally known as butacaine sulfate, which bears US NIH Compound Identifier 120185. European Medicines Agency schedules Butacaine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00907MIG. Most nations schedule butacaine sulfate under HS 29224995 and SITC 51465. As of Q4 2014, BUTACAINE SULFATE remains the US FDA Preferred Term for this commodity. Butacaine sulfate bears US NLM identifiers UMLS ID C0521936 and NCI Concept Code C77320. SMILES: CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N.CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N.OS(=O)(=O)O.
This classification denotes a dopamine antagonist with the molecular formula C25H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A7A2802VNL, chemically known as 1h-benzo(6,7)-cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 3-(1,1-dimethylethyl)-2,3,4,4a,8,9,13b,14-octahydro-, (3alpha,4aalpha,13bbeta)-(+-)- but generally known as butaclamol, which bears US NIH Compound Identifier 37459. Butaclamol most often comes in base and hydrochloride forms. European Medicines Agency schedules Butaclamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05995MIG. The term BUTACLAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). BUTACLAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butaclamol under HS 29339990 and SITC 51577. As of Q4 2014, BUTACLAMOL remains the US FDA Preferred Term for this commodity. Butaclamol bears US NLM identifiers UMLS ID C0006467 and NCI Concept Code C81088. SMILES: OC1(CC2N(CC1)CC1C3C2CCCC3CCC2C1CCCC2)C(C)(C)C.
This classification denotes the hydrochloride form of a dopamine antagonist with the molecular formula C25H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A7A2802VNL, chemically known as 1h-benzo(6,7)-cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 3-(1,1-dimethylethyl)-2,3,4,4a,8,9,13b,14-octahydro-, (3alpha,4aalpha,13bbeta)-(+-)- but more generally known as butaclamol, which bears US NIH Compound Identifier 37459. Butaclamol most often comes in base and hydrochloride forms. European Medicines Agency schedules Butaclamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05995MIG. The term BUTACLAMOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). BUTACLAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule butaclamol hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BUTACLAMOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Butaclamol hydrochloride bears US NLM identifiers UMLS ID C0877814 and NCI Concept Code C81089. SMILES: CC(C)(C)[C@]1(CCN2C[C@@H]3C4CCCCC4CCC5C3C(CCC5)[C@H]2C1)O.CL.
This classification denotes a vasodilating agent with the molecular formula C18H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 140T9JTG43, chemically known as 1,2-ethanediamine, n,n-dibutyl-n-(3-phenyl-1,2,4-oxadiazol-5-yl)- but generally known as butalamine, which bears US NIH Compound Identifier 30949. Butalamine most often comes in base and hydrochloride forms. European Medicines Agency schedules Butalamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05998MIG. The term BUTALAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules butalamine in its Anatomical Therapeutic Chemical (ATC) Classification. BUTALAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butalamine under HS 29349990 and SITC 51579. As of Q4 2014, BUTALAMINE remains the US FDA Preferred Term for this commodity. Butalamine bears US NLM identifiers UMLS ID C0644503 and NCI Concept Code C77071. SMILES: o1nc(nc1NCCN(CCCC)CCCC)c1ccccc1.
This classification denotes a vasodilating agent with the molecular formula C18H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 140T9JTG43, chemically known as 1,2-ethanediamine, n,n-dibutyl-n-(3-phenyl-1,2,4-oxadiazol-5-yl)- but generally known as butalamine, which bears US NIH Compound Identifier 30949. Butalamine most often comes in base and hydrochloride forms. European Medicines Agency schedules Butalamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05998MIG. The term BUTALAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules butalamine in its Anatomical Therapeutic Chemical (ATC) Classification. BUTALAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butalamine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, BUTALAMINE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. SMILES: Cl.o1nc(nc1NCC[NH](CCCC)CCCC)c1ccccc1.
This classification denotes a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KHS0AZ4JVK, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but generally known as butalbital, which bears US NIH Compound Identifier 2481. Butalbital most often comes in base and sodium forms. European Medicines Agency schedules Butalbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05999MIG. The term BUTALBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). BUTALBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butalbital under HS 29335390 and SITC 51576. As of Q4 2014, BUTALBITAL remains the US FDA Preferred Term for this commodity. Butalbital bears US NLM identifiers UMLS ID C0054234 and NCI Concept Code C47425. SMILES: CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C.
This classification denotes a barbiturate with the molecular formula C11H15N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BBH31P2ABJ, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-, monosodium salt but more generally known as butalbital sodium, which bears US NIH Compound Identifier 6464. European Medicines Agency schedules Butalbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00910MIG. Most nations, for tariff and trade purposes, schedule butalbital sodium under HS 29335390 and SITC 51576. As of Q4 2014, BUTALBITAL SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)CC1(C(=O)NC(=O)[N-]C1=O)CC=C.[NA+].
This classification denotes an anesthetic agent with the molecular formula C11H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EFW857872Q, chemically known as p-aminobenzoic acid, butyl ester but generally known as butamben, which bears US NIH Compound Identifier 2482. Butamben most often comes in base and picrate forms. European Medicines Agency schedules Butamben in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13138MIG. As of Q4 2014, BUTAMBEN remains the US FDA Preferred Term for this commodity. Butamben bears US NLM identifiers UMLS ID C0054235 and NCI Concept Code C75086. SMILES: CCCCOC(=O)C1=CC=C(C=C1)N.
This classification denotes an antitussive agent with the molecular formula C18H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) M75MZG2236, chemically known as butyric acid, 2-phenyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, citrate but more generally known as butamirate, which bears US NIH Compound Identifier 28891. Butamirate most often comes in base and citrate forms. European Medicines Agency schedules Butamirate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06000MIG. The term BUTAMIRATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules butamirate in its Anatomical Therapeutic Chemical (ATC) Classification. BUTAMIRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule butamirate under HS 29221980 and SITC 51461. As of Q4 2014, BUTAMIRATE remains US FDA's Preferred Term for this commodity. Butamirate bears US NLM identifiers UMLS ID C0054236 and NCI Concept Code C81596. SMILES: O(CCN(CC)CC)CCOC(=O)C(CC)C1CCCCC1.OC(CC(=O)O)(CC(=O)O)C(=O)O.
This classification denotes an antitussive agent with the molecular formula C18H29NO3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67HP51L98R, chemically known as butyric acid, 2-phenyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, citrate but more generally known as butamirate citrate, which bears US NIH Compound Identifier 28891. European Medicines Agency schedules Butamirate citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00911MIG. Most nations, for tariff and trade purposes, schedule butamirate citrate under HS 29221980 and SITC 51461. As of Q4 2014, BUTAMIRATE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(C1CCCCC1)C(=O)OCCOCCN(CC)CC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antihelminthic agent with the molecular formula C15H19N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XVB7982801, chemically known as propanamide, 2-methyl-n-(3-(2,3,5,6-tetrahydroimidazo(2,1-b)thiazol-6-yl)phenyl)-, (-)- but generally known as butamisole, which bears US NIH Compound Identifier 166572. Butamisole most often comes in base and hydrochloride forms. European Medicines Agency schedules Butamisole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06001MIG. The term BUTAMISOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). BUTAMISOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butamisole under HS 29349990 and SITC 51579. As of Q4 2014, BUTAMISOLE remains the US FDA Preferred Term for this commodity. Butamisole bears US NLM identifiers UMLS ID C0054237 and NCI Concept Code C79921. SMILES: S1C2=NC(CN2CC1)C1CC(NC(=O)C(C)C)CCC1.
This classification denotes an antihelminthic agent with the molecular formula C15H19N3OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QGM18599H5, chemically known as propanamide, 2-methyl-n-(3-(2,3,5,6-tetrahydroimidazo(2,1-b)thizol-6-yl)phenyl)-, monohydrochloride, (-)- but generally known as butamisole hydrochloride, which bears US NIH Compound Identifier 166571. Most nations schedule butamisole hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, BUTAMISOLE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Butamisole hydrochloride bears US NLM identifiers UMLS ID C0700565 and NCI Concept Code C79919. SMILES: CC(C)C(=O)NC1=CC=CC(=C1)C2CN3CCSC3=N2.CL.
This classification denotes an adrenergic antagonist with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7725983GSD, chemically known as 1,4-benzodioxan-2-methylamine, n-butyl- but generally known as butamoxane, which bears US NIH Compound Identifier 20504. European Medicines Agency schedules Butamoxane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06002MIG. The term BUTAMOXANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BUTAMOXANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butamoxane under HS 29329985 and SITC 51569. As of Q4 2014, BUTAMOXANE remains the US FDA Preferred Term for this commodity. Butamoxane bears US NLM identifiers UMLS ID C0606819 and NCI Concept Code C74104. SMILES: O1C(CNCCCC)COC2C1CCCC2.
This classification denotes an adrenergic agent with the molecular formula C10H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M6AY4VCZ0A, chemically known as 4-(2-amino-1-hydroxybutyl)-1,2-benzenediol but generally known as ethylnorepinephrine, which bears US NIH Compound Identifier 18538. European Medicines Agency schedules Ethylnorepinephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13768MIG. Butanefrine or ethylnorepinephrine bears US NLM identifiers UMLS ID C0602107 and NCI Concept Code C75928. SMILES: CCC(C(C1=CC(=C(C=C1)O)O)O)N.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7X3WV51F4N. European Medicines Agency schedules Butanilicaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06003MIG. Butanilicaine generally arises in the molecular formula C13H19CLN2O. The term BUTANILICAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) BUTANILICAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butanilicaine under HS 29242995 and SITC 51479. As of Q4 2014, BUTANILICAINE remains the US FDA Preferred Term for this commodity. Butanilicaine bears US NLM identifiers UMLS ID C0054241 and NCI Concept Code C96327. SMILES: CLC1C(NC(=O)CNCCCC)C(CCC1)C.
This classification denotes an anesthetic agent with the molecular formula C13H19ClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 025O9D1EB7, chemically known as o-acetotoluidide, 2-(butylamino)-6-chloro-, monohydrochloride but more generally known as butanilicaine hydrochloride, which bears US NIH Compound Identifier 22378. butanilicaine most often comes in base, dihydrogen phosphate, hydrochloride, and pentafluorobenzamide forms. Most nations, for tariff and trade purposes, schedule butanilicaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, BUTANILICAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Butanilicaine hydrochloride bears US NLM identifiers UMLS ID C0122257 and NCI Concept Code C97303. SMILES: CCCCNCC(=O)NC1C(CCCC1CL)C.CL.
This classification denotes an anesthetic agent with the molecular formula C13H19CLN2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JOZ20TRV0N. European Medicines Agency schedules butanilicaine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00912MIG. The term butanilicaine phosphate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule butanilicaine phosphate under HS 29242995 and SITC 51479. As of Q4 2014, BUTANILICAINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Butanilicaine phosphate bears US NLM identifiers UMLS ID C0888854 and NCI Concept Code C97305. SMILES: CCCCNCC(=O)NC1C(CCCC1CL)C.OP(=O)(O)O.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZ99TBX0LI. European Medicines Agency schedules Butanixin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06004MIG. Butanixin generally arises in the molecular formula C16H18N2O2. The term BUTANIXIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) BUTANIXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butanixin under HS 29333999 and SITC 51574. As of Q4 2014, BUTANIXIN remains the US FDA Preferred Term for this commodity. Butanixin bears US NLM identifiers UMLS ID C2347238 and NCI Concept Code C73082. SMILES: OC(=O)C1C(NC2CC(CCCC)CCC2)NCCC1.
This classification denotes an anthraquinone compound with the molecular formula C18H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P148IBA8M, chemically known as 10-butyryl-1,8-dihydroxyanthrone but generally known as butantrone, which bears US NIH Compound Identifier 53271. European Medicines Agency schedules Butantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06006MIG. The term BUTANTRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). BUTANTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butantrone under HS 29145000 and SITC 51629. As of Q4 2014, BUTANTRONE remains the US FDA Preferred Term for this commodity. Butantrone bears US NLM identifiers UMLS ID C0044655 and NCI Concept Code C74164. SMILES: O=C(C1C2C(C(=O)C3C1CCCC3O)C(O)CCC2)CCC.
This classification denotes a dopamine antagonist with the molecular formula C24H31N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TXP4T9106S, chemically known as 1-butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)- but generally known as butaperazine, which bears US NIH Compound Identifier 12598. Butaperazine most often comes in base and maleate forms. European Medicines Agency schedules Butaperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06007MIG. The term BUTAPERAZINE is an International Non-Proprietary Name. World Health Organization schedules butaperazine in its Anatomical Therapeutic Chemical (ATC) Classification. BUTAPERAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butaperazine under HS 29343090 and SITC 51578. As of Q4 2014, BUTAPERAZINE remains the US FDA Preferred Term for this commodity. Butaperazine bears US NLM identifiers UMLS ID C0006481 and NCI Concept Code C81090. SMILES: S1C2C(N(CCCN3CCN(CC3)C)C3C1CCCC3)CC(CC2)C(=O)CCC.
This classification denotes a dopamine antagonist with the molecular formula C24H31N3OS.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22VUW43J2H, chemically known as 1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)-1-butanone maleate (1:2), but more generally known as butaperazine dimaleate, which bears US NIH Compound Identifier 6433234. European Medicines Agency schedules butaperazine dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06007MIG. Most nations, for tariff purposes, schedule butaperazine dimaleate under HS 29343090. SMILES: CCCC(=O)C1CC2C(CC1)SC3C(CCCC3)N2CCCN4CCN(CC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C24H31N3OS.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22VUW43J2H, chemically known as 1-butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)-, dimaleate but generally known as butaperazine maleate, which bears US NIH Compound Identifier 6433234. European Medicines Agency schedules Butaperazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00913MIG. Most nations schedule butaperazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, BUTAPERAZINE MALEATE remains the US FDA Preferred Term for this commodity. Butaperazine maleate bears US NLM identifiers UMLS ID C1321935 and NCI Concept Code C76440. SMILES: S1c2c(N(CCCN3CCN(CC3)C)c3c1cccc3)cc(cc2)C(=O)CCC.OC(=O)/C=C\C(=O)O.OC(=O)/C=C\C(=O)O.
This classification denotes a phosphorous supplement with the molecular formula C7H17NO2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q2LQ1149L, chemically known as 2-(butylamino)propan-2-yl-hydroxy-oxophosphanium but generally known as casanthranol, which bears US NIH Compound Identifier 6328684. BUTAPHOSPHAN, as BUTAFOSFAN, is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. European Medicines Agency schedules Butaphosphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05997MIG. SMILES: CCCCNC(C)(C)[P+](=O)O.
This classification denotes an antispasmotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1I5O5WIU8X. European Medicines Agency schedules Butaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06009MIG. Butaverine generally arises in the molecular formula C18H27NO2. The term BUTAVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) BUTAVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butaverine under HS 29333999 and SITC 51574. As of Q4 2014, BUTAVERINE remains the US FDA Preferred Term for this commodity. Butaverine bears US NLM identifiers UMLS ID C0771071 and NCI Concept Code C73169. SMILES: O(C(=O)CC(N1CCCCC1)C1CCCCC1)CCCC.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NM31M53PW, chemically known as benzenemethanol, .alpha.-(1-((1,1-dimethylethyl)amino)ethyl)-2,5-dimethoxy-, (r*,s*)-, (+/-)- but generally known as butoxamine, which bears US NIH Compound Identifier 134495. SMILES: CC(C(C1=C(C=CC(=C1)OC)OC)O)NC(C)(C)C.
This classification denotes a bone resorption inhibitor and biphosphonate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26PB1U68YF. European Medicines Agency schedules Butedronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06011MIG. Butedronic acid generally arises in the molecular formula C5H10O10P2. The term BUTEDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) As of Q4 2014, BUTEDRONIC ACID remains the US FDA Preferred Term for this commodity. Butedronic acid bears US NLM identifiers UMLS ID C2347239 and NCI Concept Code C72092. SMILES: P(=O)(O)(O)C(P(=O)(O)O)C(CC(=O)O)C(=O)O.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91Y494NL0X. European Medicines Agency schedules Butenafine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06012MIG. Butenafine generally arises in the molecular formula C23H27N. The term BUTENAFINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) BUTENAFINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butenafine under HS 29214980 and SITC 51454. As of Q4 2014, BUTENAFINE remains the US FDA Preferred Term for this commodity. Butenafine bears US NLM identifiers UMLS ID C0107497 and NCI Concept Code C72959. SMILES: N(CC1CCC(C(C)(C)C)CC1)(CC1C2C(CCC1)CCCC2)C.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91Y494NL0X. European Medicines Agency schedules Butenafine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06012MIG. Butenafine generally arises in the molecular formula C23H27N. The term BUTENAFINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) BUTENAFINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butenafine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, BUTENAFINE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Butenafine hydrochloride bears US NLM identifiers UMLS ID C0771847 and NCI Concept Code C47426. SMILES: N(CC1CCC(C(C)(C)C)CC1)(CC1C2C(CCC1)CCCC2)C.
This classification denotes a vasodilating agent with the molecular formula C31H38N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N8516V0WOM, chemically known as 1h-benzimidazole, 2-butyl-5-((4-(diphenylmethyl)-1-piperazinyl)methyl)-1-ethyl but generally known as buterizine, which bears US NIH Compound Identifier 189902. European Medicines Agency schedules Buterizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06013MIG. The term BUTERIZINE is an International Non-Proprietary Name. BUTERIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buterizine under HS 29335995 and SITC 51576. As of Q4 2014, BUTERIZINE remains the US FDA Preferred Term for this commodity. Buterizine bears US NLM identifiers UMLS ID C2698575 and NCI Concept Code C74422. SMILES: N1(CCN(CC1)Cc1cc2nc(n(c2cc1)CC)CCCC)C(c1ccccc1)c1ccccc1.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M63DKI91K, chemically known as 2-isobutylaminoethanol hydrochloric acid salt, p-aminobenzoic acid ester but generally known as butethamine hydrochloride, which bears US NIH Compound Identifier 11116. As of Q4 2014, BUTETHAMINE remains the US FDA Preferred Term for this commodity. Butethamine bears US NLM identifiers UMLS ID C0301287 and NCI Concept Code C83566. SMILES: CC(C)CNCCOC(=O)C1=CC=C(C=C1)N.Cl.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H20O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JSS1TEM917, chemically known as butyric acid, 2-(4-isobutylphenyl)- but generally known as butibufen, which bears US NIH Compound Identifier 41643. European Medicines Agency schedules Butibufen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06015MIG. The term BUTIBUFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). BUTIBUFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butibufen under HS 29163900 and SITC 51379. As of Q4 2014, BUTIBUFEN remains the US FDA Preferred Term for this commodity. Butibufen bears US NLM identifiers UMLS ID C0054255 and NCI Concept Code C73083. SMILES: OC(=O)C(C1CCC(CC(C)C)CC1)CC.
This classification denotes an adrenergic antagonist with the molecular formula C16H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N2S0PKP5L5, chemically known as 5,6,7,8-tetrahydro-alpha-(((1-methylpropyl)amino)methyl)-2-naphthalenemethanol hydrochloride but generally known as butidrine, which bears US NIH Compound Identifier 15176. Butidrine most often comes in base and hydrochloride forms. European Medicines Agency schedules Butidrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06016MIG. The term BUTIDRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). BUTIDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butidrine under HS 29221980 and SITC 51461. As of Q4 2014, BUTIDRINE remains the US FDA Preferred Term for this commodity. Butidrine bears US NLM identifiers UMLS ID C2698577 and NCI Concept Code C79710. SMILES: CL.OC(C[NH2]C(CC)C)C1CC2CCCCC2CC1.
This classification denotes an aminoglycoside antibiotic with the molecular formula C22H45N5O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I61243PDCC, chemically known as uk-18,892 but generally known as butikacin, which bears US NIH Compound Identifier 65487. European Medicines Agency schedules Butikacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06017MIG. The term BUTIKACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). BUTIKACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butikacin under HS 29419000 and SITC 54139. As of Q4 2014, BUTIKACIN remains the US FDA Preferred Term for this commodity. Butikacin bears US NLM identifiers UMLS ID C0054256 and NCI Concept Code C90637. SMILES: O(C1C(NCC(O)CCN)CC(N)C(OC2OC(C(O)C(O)C2O)CN)C1O)C1OC(C(O)C(N)C1O)CO.
This classification denotes an antimuscarinic agent with the molecular formula C20H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G216926E9T, chemically known as 1,1-diphenyl-4-pyrrolidino-1-yl but-2-yn-1-ol but generally known as butinoline, which bears US NIH Compound Identifier 68943. European Medicines Agency schedules Butinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06020MIG. The term BUTINOLINE is an International Non-Proprietary Name. BUTINOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butinoline under HS 29339990 and SITC 51577. As of Q4 2014, BUTINOLINE remains the US FDA Preferred Term for this commodity. Butinoline bears US NLM identifiers UMLS ID C0772190 and NCI Concept Code C78064. SMILES: OC(C1CCCCC1)(C1CCCCC1)C#CCN1CCCC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H36O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5D0M4JI29K, chemically known as 11 beta,17-dihydroxy-21-mercaptopregn-4-ene-3,20-dione 17-butyrate. but generally known as butixocort, which bears US NIH Compound Identifier 189904. Butixocort most often comes in base and 21-propionate forms. European Medicines Agency schedules Butixocort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06023MIG. The term BUTIXOCORT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). BUTIXOCORT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butixocort under HS 29372900 and SITC 54153. As of Q4 2014, BUTIXOCORT remains the US FDA Preferred Term for this commodity. Butixocort bears US NLM identifiers UMLS ID C2827091 and NCI Concept Code C83568. SMILES: SCC(=O)C1(OC(=O)CCC)C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)C(O)C2)CC1)C.
This classification denotes a barbiturate with the molecular formula C10H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OHZ8QAW6YC, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-butyl-5-ethyl- (9ci) but generally known as butethal, which bears US NIH Compound Identifier 6473. Butethal most often comes in base and sodium forms. European Medicines Agency schedules Butobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13135MIG. World Health Organization schedules butethal in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCCCC1(C(=O)NC(=O)NC1=O)CC.
This classification denotes an antiarrhythmic agent with the molecular formula C32H48N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) RP2J52327K, chemically known as ( )-(s,s)-ethylenebis-((methylimino)(2-ethylethylene))bis(3,4,5-trimethoxy-benzoate). but more generally known as butobendine, which bears US NIH Compound Identifier 3037620. Butobendine most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Butobendine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06025MIG. The term BUTOBENDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). BUTOBENDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule butobendine under HS 29221980 and SITC 51461. As of Q4 2014, BUTOBENDINE remains US FDA's Preferred Term for this commodity. Butobendine bears US NLM identifiers UMLS ID C2825628 and NCI Concept Code C81433. SMILES: O(C(NC)C(CCC(C(OC(=O)C1CC(OC)C(OC)C(OC)C1)NC)CC)CC)C(=O)C1CC(OC)C(OC)C(OC)C1.
This classification denotes an antifungal agent with the molecular formula C19H17Cl3N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Q771797PH, chemically known as 1h-imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate but generally known as butoconazole, which bears US NIH Compound Identifier 47472. Butoconazole most often comes in base and nitrate forms. European Medicines Agency schedules Butoconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06026MIG. The term BUTOCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules butoconazole in its Anatomical Therapeutic Chemical (ATC) Classification. BUTOCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butoconazole under HS 29332990 and SITC 51573. As of Q4 2014, BUTOCONAZOLE remains the US FDA Preferred Term for this commodity. Butoconazole bears US NLM identifiers UMLS ID C0054259 and NCI Concept Code C79927. SMILES: CLC1C(SC(CCC2CCC(CL)CC2)CN2CCNC2)C(CL)CCC1.
This classification denotes an antifungal agent with the molecular formula C19H17Cl3N2S.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4805237NP5, chemically known as 1h-imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, mononitrate but more generally known as butoconazole nitrate, which bears US NIH Compound Identifier 47471. European Medicines Agency schedules Butoconazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00918MIG. Most nations, for tariff and trade purposes, schedule butoconazole nitrate under HS 29332990 and SITC 51573. As of Q4 2014, BUTOCONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Butoconazole nitrate bears US NLM identifiers UMLS ID C0107509 and NCI Concept Code C47427. SMILES: C1CC(C(C(C1)CL)SC(CCC2CCC(CC2)CL)CN3CCNC3)CL.[N+](=O)(O)[O-].
This classification denotes a beta-adrenergic blocking agent with the molecular formula C19H23NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F63SY70KV0, chemically known as 9-(3-(tert-butylamino)-2-hydroxypropoxyl)-4-hydroxy-7-methyl-5h-furo(3,2-g)(1)benzopyran-5-one. but generally known as butocrolol, which bears US NIH Compound Identifier 189906. European Medicines Agency schedules Butocrolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06027MIG. The term BUTOCROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). BUTOCROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butocrolol under HS 29329985 and SITC 51569. As of Q4 2014, BUTOCROLOL remains the US FDA Preferred Term for this commodity. Butocrolol bears US NLM identifiers UMLS ID C2698579 and NCI Concept Code C77939. SMILES: O(CC(O)CNC(C)(C)C)C1C2OC(CC(=O)C2C(O)C2C1OCC2)C.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6MDC25LQSR. European Medicines Agency schedules Butoctamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06028MIG. Butoctamide generally arises in the molecular formula C12H25NO2. The term BUTOCTAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) BUTOCTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butoctamide under HS 29241900 and SITC 51471. As of Q4 2014, BUTOCTAMIDE remains the US FDA Preferred Term for this commodity. Butoctamide bears US NLM identifiers UMLS ID C0054260 and NCI Concept Code C77244. SMILES: O=C(NCC(CCCC)CC)CC(O)C.
This classification denotes a sedative and hypnotic with the molecular formula C16H29NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F58251NT6M, chemically known as butanedioic acid, 1-(3-((2-ethylhexyl)amino)-1-methyl-3-oxopropyl) ester, but more generally known as butoctamide semisuccinate, which bears US NIH Compound Identifier 2486. European Medicines Agency schedules butoctamide semisuccinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06028MIG. Most nations, for tariff purposes, schedule butoctamide semisuccinate under HS 29241900. SMILES: CCCCC(CC)CNC(=O)CC(C)OC(=O)CCC(=O)O.
This classification denotes the succinate form of a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6MDC25LQSR. European Medicines Agency schedules Butoctamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06028MIG. Butoctamide generally arises in the molecular formula C12H25NO2. The term BUTOCTAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, no. 10 1976, list 16.) BUTOCTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule butoctamide succinate under HS 29241900 and SITC 51471. As of Q4 2014, BUTOCTAMIDE SUCCINATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC(CC)CNC(=O)CC(C)OC(=O)CCC(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H26FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AZC6Y5A8G, chemically known as 1-butanone, 1-(2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-5-fluorophenyl)- but generally known as butofilolol, which bears US NIH Compound Identifier 68838. Butofilolol most often comes in base and maleate forms. European Medicines Agency schedules Butofilolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06029MIG. The term BUTOFILOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). BUTOFILOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butofilolol under HS 29221980 and SITC 51461. As of Q4 2014, BUTOFILOLOL remains the US FDA Preferred Term for this commodity. Butofilolol bears US NLM identifiers UMLS ID C0054262 and NCI Concept Code C77940. SMILES: FC1CC(C(OCC(O)CNC(C)(C)C)CC1)C(=O)CCC.
This classification denotes an antihelminthic agent with the molecular formula C8H14Cl3O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39M9R3Q494, chemically known as 2,2,2-trichloro-1-(dimethoxyphosphoryl)ethyl butyrate but generally known as butonate, which bears US NIH Compound Identifier 31343. European Medicines Agency schedules Butonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06030MIG. The term BUTONATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). BUTONATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BUTONATE remains the US FDA Preferred Term for this commodity. Butonate bears US NLM identifiers UMLS ID C0054264 and NCI Concept Code C75966. SMILES: CLC(CL)(CL)C(P(=O)(OC)OC)OC(=O)CCC.
This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZX7907IE2H, chemically known as benzenemethanol, 4-hydroxy-alpha-(((3-(4-hydroxyphenyl)-1-methylpropyl)amino)methyl)-, (r-(r*,r*)) but generally known as butopamine, which bears US NIH Compound Identifier 68556. European Medicines Agency schedules Butopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06031MIG. The term BUTOPAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). BUTOPAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butopamine under HS 29225000 and SITC 51467. As of Q4 2014, BUTOPAMINE remains the US FDA Preferred Term for this commodity. Butopamine bears US NLM identifiers UMLS ID C0054265 and NCI Concept Code C81649. SMILES: OC(CNC(CCC1CCC(O)CC1)C)C1CCC(O)CC1.
This classification denotes an antiarrhythmic agent with the molecular formula C28H38N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9XWF3530OG chemically known as methanone, (4-(3-(dibutylamino)-propoxy)phenyl)(2-ethyl-3-indolizinyl)-, but more commonly known as butoprozine, which bears US NIH Compound Identifier 71959. European Medicines Agency schedules Butoprozine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06033MIG. The term BUTOPROZINE is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule butoprozine under HS 29339990 and SITC 51577. As of Q4 2014, BUTOPROZINE remains US FDA's Preferred Term for this commodity. Butoprozine bears US NLM identifiers UMLS ID C0054266 and NCI Concept Code C79924. SMILES: CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C2=C(C=C3N2C=CC=C3)CC.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QV897JC36D, chemically known as morphinan-3,14-diol, 17-(cyclobutylmethyl)- but generally known as butorphanol, which bears US NIH Compound Identifier 2487. Butorphanol most often comes in base and tartrate forms. European Medicines Agency schedules Butorphanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06035MIG. The term BUTORPHANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules butorphanol in its Anatomical Therapeutic Chemical (ATC) Classification. BUTORPHANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butorphanol under HS 29334990 and SITC 51575. As of Q4 2014, BUTORPHANOL remains the US FDA Preferred Term for this commodity. Butorphanol bears US NLM identifiers UMLS ID C0006491 and NCI Concept Code C61659. SMILES: OC12C3(CCN(C1CC1C3CC(O)CC1)CC1CCC1)CCCC2.
This classification denotes an opioid analgesic with the molecular formula C21H29NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2L7I72RUHN, chemically known as l-n-cyclobutylmethyl-3,14-dihydroxymorphinan tartrate salt but more generally known as butorphanol tartrate, which bears US NIH Compound Identifier 5462346. European Medicines Agency schedules Butorphanol tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00920MIG. Most nations, for tariff and trade purposes, schedule butorphanol tartrate under HS 29334990 and SITC 51575. As of Q4 2014, BUTORPHANOL TARTRATE remains US FDA's Preferred Term for this commodity. Butorphanol tartrate bears US NLM identifiers UMLS ID C0038119 and NCI Concept Code C61658. SMILES: C1CC2C(CC1O)[C@@]34CCCC[C@]3([C@@H](C2)N(CC4)CC5CCC5)O.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an antidepressant agent with the molecular formula C21H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z22441975X, chemically known as 10,11-dihydro-n,n,beta-trimethyl-5h-dibenzo(a,d)cycloheptene-5-propylamine but generally known as butriptyline, which bears US NIH Compound Identifier 21772. Butriptyline most often comes in base, butriptylene, and hydrochloride forms. European Medicines Agency schedules Butriptyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13137MIG. The term BUTRIPTYLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules butriptyline in its Anatomical Therapeutic Chemical (ATC) Classification. BUTRIPTYLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butriptyline under HS 29214980 and SITC 51454. As of Q4 2014, BUTRIPTYLINE remains the US FDA Preferred Term for this commodity. Butriptyline bears US NLM identifiers UMLS ID C0054270 and NCI Concept Code C79855. SMILES: N(CC(CC1c2c(CCc3c1cccc3)cccc2)C)(C)C.
This classification denotes an antidepressant agent with the molecular formula C21H27N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LIJ2H8658W, chemically known as 5h-dibenzo(a,d)cycloheptene-5-propylamine, 10,11-dihydro-n,n,beta-trimethyl-, hydrochloride, dl- but more generally known as butriptyline hydrochloride, which bears US NIH Compound Identifier 21771. European Medicines Agency schedules Butriptyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00922MIG. Most nations, for tariff and trade purposes, schedule butriptyline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, BUTRIPTYLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Butriptyline hydrochloride bears US NLM identifiers UMLS ID C0117009 and NCI Concept Code C79856. SMILES: CC(CC1C2CCCCC2CCC3C1CCCC3)CN(C)C.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes an antimuscarinic agent with the molecular formula C21H30NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z3E1OF81V, chemically known as 3-oxa-9-azonitricyclo(3.3.1.0(2,4))nonane, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, (7(s)-(1alpha,2beta,4beta,5alpha,7beta))- but generally known as butylscopolamine, which bears US NIH Compound Identifier 160883. Butylscopolamine most often comes in base and bromide forms. European Medicines Agency schedules Butylscopolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20624. World Health Organization schedules butylscopolamine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BUTYLSCOPOLAMINE remains the US FDA Preferred Term for this commodity. Butylscopolamine bears US NLM identifiers UMLS ID C2827093 and NCI Concept Code C83571. SMILES: O1C2C3[N](C(C12)CC(OC(=O)C(CO)C1CCCCC1)C3)(CCCC)C. .
Combination of butyl scopolamine, spasmolytic in the smooth muscle of gastrointestinal, biliary and genitourinary tracts, without anticholinergic effects in CNS, with metamizole, a non-acidic, non-narcotic analgesic pyrazolone with analgesic, antipyretic and spasmolytic effects.
This classification denotes a sedative and hypnotic with the molecular formula C11H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3W58ITX06Q, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethenyl-5-(1-methylbutyl)- but generally known as vinylbital, which bears US NIH Compound Identifier 72135. European Medicines Agency schedules Vinylbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00076MIG. The term VINYLBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules vinylbital in its Anatomical Therapeutic Chemical (ATC) Classification. VINYLBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Butylvinyl or vinylbital bears US NLM identifiers UMLS ID C0054306 and NCI Concept Code C74377. SMILES: CCCC(C)C1(C(=O)NC(=O)NC1=O)C=C.
This classification denotes a taxane compound and taxane-site binding agent with the molecular formula C45H57NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51F690397J. European Medicines Agency schedules cabazitaxel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31282. The term CABAZITAXEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 3, 2008, list 60). Most nations schedule cabazitaxel under HS 29329990 and SITC 51569. As of Q4 2014, CABAZITAXEL remains the US FDA Preferred Term for this commodity. Cabazitaxel bears US NLM identifiers UMLS ID C2830183 and NCI Concept Code C66937. SMILES: CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C26H37N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LL60K9J05T, chemically known as ergoline-8-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)- but generally known as cabergoline, which bears US NIH Compound Identifier 54746. Cabergoline most often comes in base and diphosphate forms. European Medicines Agency schedules Cabergoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06041MIG. The term CABERGOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules cabergoline in its Anatomical Therapeutic Chemical (ATC) Classification. CABERGOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cabergoline under HS 29396900 and SITC 54146. As of Q4 2014, CABERGOLINE remains the US FDA Preferred Term for this commodity. Cabergoline bears US NLM identifiers UMLS ID C0107994 and NCI Concept Code C47428. SMILES: O=C(N(CCCN(C)C)C(=O)NCC)C1CC2C(N(C1)CC=C)CC1C3C2CCCC3[NH]C1.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C26H37N5O2.2H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 477M7SA9N9, chemically known as ergoline-8-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-, (8.beta.)-, phosphate (1:2), but more generally known as cabergoline diphosphate, which bears US NIH Compound Identifier 83879. European Medicines Agency schedules cabergoline diphosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06041MIG. Most nations, for tariff purposes, schedule cabergoline diphosphate under HS 29396900. SMILES: CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2C3CCCC4C3C(C[NH]4)C[C@H]2N(C1)CC=C.OP(=O)(O)O.OP(=O)(O)O.
Cabozantinib is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
This classification denotes an antihypertensive agent with the molecular formula C12H21N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8T96I3U713, chemically known as hydrazinecarboxylic acid, 2-(6-(ethyl(2-hydroxypropyl)amino)-3-pyridazinyl)-, ethyl ester but generally known as cadralazine, which bears US NIH Compound Identifier 2515. European Medicines Agency schedules Cadralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06042MIG. The term CADRALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules cadralazine in its Anatomical Therapeutic Chemical (ATC) Classification. CADRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cadralazine under HS 29339990 and SITC 51577. As of Q4 2014, CADRALAZINE remains the US FDA Preferred Term for this commodity. Cadralazine bears US NLM identifiers UMLS ID C0054422 and NCI Concept Code C81527. SMILES: OC(CN(CC)c1nnc(NNC(=O)OCC)cc1)C.
This classification denotes a quinolone antibiotic with the molecular formula C19H20F3N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1YOQ7J9ACY, chemically known as 128427-55-4 (monohydrochloride, s isomer) but generally known as cadrofloxacin, which bears US NIH Compound Identifier 189912. The term CADROFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). Most nations schedule cadrofloxacin under HS 29335995 and SITC 51576. As of Q4 2014, CADROFLOXACIN remains the US FDA Preferred Term for this commodity. Cadrofloxacin bears US NLM identifiers UMLS ID C1454081 and NCI Concept Code C76229. SMILES: CC1CN(CCN1)C2=C(C=C3C(=C2OC(F)F)N(C=C(C3=O)C(=O)O)C4CC4)F.
This classification denotes a cns stimulant with the molecular formula C18H23N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0UYY5V4U2Q, chemically known as 1h-purine-2,6-dione, 3,7-dihydro-7-(2-((2-hydroxy-1-methyl-2-phenylethyl)amino)ethyl)-1,3-dimethyl- (van) but generally known as cafedrine, which bears US NIH Compound Identifier 71740. European Medicines Agency schedules Cafedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06044MIG. The term CAFEDRINE is an International Non-Proprietary Name. World Health Organization schedules cafedrine in its Anatomical Therapeutic Chemical (ATC) Classification. CAFEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cafedrine under HS 29395900 and SITC 54145. As of Q4 2014, CAFEDRINE remains the US FDA Preferred Term for this commodity. Cafedrine bears US NLM identifiers UMLS ID C0068978 and NCI Concept Code C76026. SMILES: OC(C(NCCN1C2C(N(C(=O)N(C2=O)C)C)NC1)C)C1CCCCC1.
This classification denotes a cns stimulant with the molecular formula C18H23N5O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0N3M64B9R. European Medicines Agency schedules cafedrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00934MIG. The term cafedrine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cafedrine hydrochloride under HS 29395900 and SITC 54145. As of Q4 2014, CAFEDRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@@H](C1CCCCC1)O)NCCN2CNC3C2C(=O)N(C(=O)N3C)C.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
Caffeine/Dihydroergotamine/Paracetamol is a mixture of three drugs used to treat acute migraine attacks.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.
This classification denotes a cns stimulant and bioactive food component with the molecular formula C8H10N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3G6A5W338E, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears US NIH Compound Identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. European Medicines Agency schedules Caffeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13146MIG. World Health Organization schedules caffeine in its Anatomical Therapeutic Chemical (ATC) Classification. Caffeine or trimethylxanthine bears US NLM identifiers UMLS ID C0006644 and NCI Concept Code C328. SMILES: O=C1N(C(=O)N(C2NCN(C12)C)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN809. This VA Drug Class (CN809) classifies this compound as belonging to the group CNS STIMULANTS, OTHER.
This classification denotes a dermatologic agent with the molecular formula Fe2O4Zn, chemically known as zinc;iron(3+);oxygen(2-), weakly acidic but generally known as calamine, which bears US NIH Compound Identifier 23083748. European Medicines Agency schedules calamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13155MIG. SMILES: [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes an industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S4255P4G5M. European Medicines Agency schedules Calcium silicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12473MIG. Calcium silicate generally arises in the molecular formula CA.H2O3SI. The term 'calcium silicate' is a United States Homeopathic Pharmacopoeia Name designation. SMILES: [Ca].[Ca].[Si](O)(O)(O)O.
This classification denotes an anti-psoriatic agent with the molecular formula C27H40O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S7499TYY6G. The term calcipotriene hydrate is a U.S. FDA designation. As of Q4 2014, CALCIPOTRIENE HYDRATE remains the US FDA Preferred Term for this commodity. SMILES: CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C.
This classification denotes an anti-psoriatic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 143NQ3779B. European Medicines Agency schedules Calcipotriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06046MIG. Calcipotriene generally arises in the molecular formula C27H40O3. The term CALCIPOTRIENE is an International Non-Proprietary Name or INN. Calcipotriene or calcipotriol bears US NLM identifiers UMLS ID C0065767 and NCI Concept Code C28900. SMILES: CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C.
This classification denotes a peptide hormone with the molecular formula C145H240N44O48S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DF35I47HCM, more generally known as calcitonin. European Medicines Agency schedules calcitonin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00948MIG. The term CALCITONIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 13 no. 1, 1999, list 41. CALCITONIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule calcitonin under HS 29371900 and SITC 54154. As of Q4 2014, CALCITONIN remains the US FDA Preferred Term for this commodity. Calcitonin bears US NLM identifiers UMLS ID C0006668 and NCI Concept Code C2281. SMILES: CCC(C)C(C(=O)NCC(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)O)NC(=O)C(CC4=CN=CN4)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCSC)NC(=O)C(CS)NC(=O)C(C(C)O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)CNC(=O)C(CS)N.
This classification denotes a peptide hormone with the molecular formula C151H226N40O45S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0IO929019, chemically known as calcitonin (human) [mart.], but more generally known as calcitonin human, which bears US NIH Compound Identifier 16132288. European Medicines Agency schedules calcitonin human or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00948MIG. Most nations, for tariff purposes, schedule calcitonin human under HS 29371900. SMILES:. Calcitonin human bears US NLM identifiers UMLS ID C0770558 and NCI Concept Code C77142.
This classification denotes a peptide hormone with the molecular formula C145H240N44O48S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7SFC6U2VI5, chemically known as calcitonin (salmon) [ep], but more generally known as calcitonin salmon, which bears US NIH Compound Identifier 16129616. European Medicines Agency schedules calcitonin salmon or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00948MIG. Most nations, for tariff purposes, schedule calcitonin salmon under HS 29371900. SMILES:. Calcitonin salmon bears US NLM identifiers UMLS ID C0073994 and NCI Concept Code C329.
This classification denotes a vitamin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FXC9231JVH. European Medicines Agency schedules Calcitriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06047MIG. Calcitriol generally arises in the molecular formula C27H44O3. The term CALCITRIOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) CALCITRIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule calcitriol under HS 29362990 and SITC 54116. As of Q4 2014, CALCITRIOL remains the US FDA Preferred Term for this commodity. Calcitriol bears US NLM identifiers UMLS ID C0592076 and NCI Concept Code C330. SMILES: OC(CCCC(C1C2(C(CC1)/C(=C/C=C1\CC(O)CC(O)C1=C)CCC2)C)C)(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y882YXF34X. European Medicines Agency schedules Calcium acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13160MIG. Calcium acetate generally arises in the molecular formula C4H6CAO4. The term CALCIUM ACETATE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule calcium acetate under HS 29152900 and SITC 51371. As of Q4 2014, CALCIUM ACETATE remains the US FDA Preferred Term for this commodity. Calcium acetate bears US NLM identifiers UMLS ID C0717537 and NCI Concept Code C47429. SMILES: CC(=O)[O-].CC(=O)[O-].[Ca+2].
This classification denotes a cyanide with the molecular formula CN2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZLR270912W, chemically known as cyanamide, lead (2+) salt (1:1) but generally known as calcium carbimide, which bears US NIH Compound Identifier 9864. European Medicines Agency schedules Calcium carbimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06049MIG. World Health Organization schedules calcium carbimide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CALCIUM CARBIMIDE remains the US FDA Preferred Term for this commodity. SMILES: C(#N)N.[Ca].
This classification denotes a nutritional supplement with the molecular formula CO3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H0G9379FGK, chemically known as carbonic acid, calcium salt (1:1) but generally known as calcium carbonate, which bears US NIH Compound Identifier 10112. European Medicines Agency schedules Calcium carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13166MIG. World Health Organization schedules calcium carbonate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CALCIUM CARBONATE remains the US FDA Preferred Term for this commodity. Calcium carbonate bears US NLM identifiers UMLS ID C0006681 and NCI Concept Code C332. SMILES: C(=O)([O-])[O-].[Ca+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
Calcium is a mineral that is found naturally and is necessary for many normal functions especially bone formation and maintenance. Calcium carbonate/calcium gluconate lactate is a combination of inorganic salts used for the prevention and treatment of calcium deficiency, osteoporosis and for the treatment of rickets and osteomalacia.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR200. This VA Drug Class (OR200) classifies this compound as belonging to the group DENTAL PROTECTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA106. This VA Drug Class (GA106) classifies this compound as belonging to the group CALCIUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA105. This VA Drug Class (GA105) classifies this compound as belonging to the group CALCIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA106. This VA Drug Class (GA106) classifies this compound as belonging to the group CALCIUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA106. This VA Drug Class (GA106) classifies this compound as belonging to the group CALCIUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA106. This VA Drug Class (GA106) classifies this compound as belonging to the group CALCIUM/MAGNESIUM CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a nutritional supplement and electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4I0D6VV5M. European Medicines Agency schedules Calcium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11767MIG. Calcium chloride generally arises in the molecular formula CACL2. The term 'calcium chloride' is a United States Homeopathic Pharmacopoeia Name designation. As of Q4 2014, CALCIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Calcium chloride bears US NLM identifiers UMLS ID C0006686 and NCI Concept Code C28901. SMILES: [CL-].[CA+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV900. This VA Drug Class (CV900) classifies this compound as belonging to the group CARDIOVASCULAR AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN420. This VA Drug Class (TN420) classifies this compound as belonging to the group CALCIUM.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a benzenesulfonates and anti-hemorrhagic with the molecular formula 2C6H5O5S.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5921X1560Q, chemically known as 2,5-dihydroxybenzenesulfonic acid calcium salt but generally known as calcium dobesilate, which bears US NIH Compound Identifier 29963. European Medicines Agency schedules Calcium dobesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06051MIG. World Health Organization schedules calcium dobesilate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule calcium dobesilate under HS 29089910 and SITC 51244. As of Q4 2014, CALCIUM DOBESILATE remains the US FDA Preferred Term for this commodity. SMILES: C1=CC(=C(C=C1O)S(=O)(=O)[O-])O.C1=CC(=C(C=C1O)S(=O)(=O)[O-])O.[CA+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
A formyl derivative of tetrahydrofolic acid which is a metabolite and active form of folic acid.
This classification denotes an electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L11651398J. European Medicines Agency schedules Calcium gluceptate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13175MIG. Calcium gluceptate generally arises in the molecular formula C14H26CAO16. The term 'calcium gluceptate' is a European Pharmacopoeia designation. Calcium glucoheptonate or calcium gluceptate bears US NLM identifiers UMLS ID C0108111 and NCI Concept Code C65279. SMILES: C(C(C(C(C(C(C(=O)[O-])O)O)O)O)O)O.C(C(C(C(C(C(C(=O)[O-])O)O)O)O)O)O.[CA+2].
This classification denotes an electrolyte replacement agent with the molecular formula 2C6H11O7.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SQE6VB453K, chemically known as gluconic acid, calcium salt but generally known as calcium gluconate, which bears US NIH Compound Identifier 9290. European Medicines Agency schedules Calcium gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13176MIG. World Health Organization schedules calcium gluconate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CALCIUM GLUCONATE remains the US FDA Preferred Term for this commodity. Calcium gluconate bears US NLM identifiers UMLS ID C0006699 and NCI Concept Code C336. SMILES: C(C(C(C(C(C(=O)[O-])O)O)O)O)O.C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[CA+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN420. This VA Drug Class (TN420) classifies this compound as belonging to the group CALCIUM.
This classification denotes a glycerolphosphates and unclear, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XWV9Z12C1C. European Medicines Agency schedules Calcium glycerophosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13178MIG. Calcium glycerophosphate generally arises in the molecular formula C3H7CAO6P. The term 'calcium glycerophosphate' is a European Pharmacopoeia designation. SMILES: C(C(COP(=O)([O-])[O-])O)O.[Ca+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN475. This VA Drug Class (TN475) classifies this compound as belonging to the group PHOSPHORUS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HA000. This VA Drug Class (HA000) classifies this compound as belonging to the group HERBS/ALTERNATIVE THERAPIES.
This classification denotes a diagnostic reagent with the molecular formula 2C12H12I3N2O2.CA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50S7W5M9ZZ. The term calcium iopodate is a U.S. FDA designation. SMILES: IC1C(CCC(=O)O)C(I)CC(I)C1/N=C/N(C)C.IC1C(CCC(=O)O)C(I)CC(I)C1/N=C/N(C)C.[CA]. Most nations schedule Calcium iopodate under HS 29252900.
This classification denotes a nutritional supplement with the molecular formula 2C3H5O3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2URQ2N32W3, chemically known as propanoic acid, 2-hydroxy-, calcium salt (2:1) but generally known as calcium lactate, which bears US NIH Compound Identifier 13144. European Medicines Agency schedules Calcium lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13184MIG. World Health Organization schedules calcium lactate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule calcium lactate under HS 29181100 and SITC 51391. As of Q4 2014, CALCIUM LACTATE remains the US FDA Preferred Term for this commodity. Calcium lactate bears US NLM identifiers UMLS ID C0108121 and NCI Concept Code C76830. SMILES: CC(C(=O)[O-])O.CC(C(=O)[O-])O.[CA+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a dental material with the molecular formula Ca.O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7X2M0VVNH, chemically known as lime, burned but generally known as calcium oxide, which bears US NIH Compound Identifier 14778. European Medicines Agency schedules Calcium oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13189MIG. Most nations schedule calcium oxide under HS 28259000 and SITC 52269. SMILES: O=[CA].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a synthetic polymer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W25LM17A4W. European Medicines Agency schedules Polycarbophil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03927MIG. Polycarbophil generally arises in the molecular formula (C6H10O2)N.(C3H4O2)N. The term POLYCARBOPHIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) POLYCARBOPHIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CALCIUM POLYCARBOPHIL remains the US FDA Preferred Term for this commodity. Calcium polycarbophil bears US NLM identifiers UMLS ID C0054480 and NCI Concept Code C28902. SMILES: NONE.
This classification denotes a metal chelator with the molecular formula C14H18N3O10.Ca.3Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G79YN26H5B, chemically known as trisodium (n,n-bis(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))calciate(3-) but generally known as calcium trisodium pentetate, which bears US NIH Compound Identifier 6328163. European Medicines Agency schedules Calcium trisodium pentetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13204MIG. The term CALCIUM TRISODIUM PENTETATE is an International Non-Proprietary Name. Most nations schedule calcium trisodium pentetate under HS 29224995 and SITC 51465. SMILES: [Ca]12345OC(=O)CN4(CCN3(CCN5(CC(=O)O2)CC(=O)O)CC(=O)O)CC(=O)O1.[Na].[Na].[Na].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a respiratory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q4K217VGA9. European Medicines Agency schedules Calfactant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13207MIG. As of Q4 2014, CALFACTANT remains the US FDA Preferred Term for this commodity.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C21H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0678G6Q58A, chemically known as 17beta-hydroxy-7beta,17-dimethylandrost-4-en-3-one but generally known as calusterone, which bears US NIH Compound Identifier 28204. European Medicines Agency schedules Calusterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06060MIG. The term CALUSTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). CALUSTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule calusterone under HS 29372900 and SITC 54153. As of Q4 2014, CALUSTERONE remains the US FDA Preferred Term for this commodity. Calusterone bears US NLM identifiers UMLS ID C0006790 and NCI Concept Code C337. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3C)C)CC2)CC1)C)C.
This classification denotes a benzodiazepine tranquilizer and temazepam analog with the molecular formula C19H18ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HZ3XRH03C3, chemically known as 7-chloro-1,3-dihydro-3-(n,n-dimethylcarbamoyl)-1-methyl-5-phenyl-2h-1,4-benzodiazepin-2-one but generally known as camazepam, which bears US NIH Compound Identifier 37367. European Medicines Agency schedules Camazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06061MIG. World Health Organization schedules camazepam in its Anatomical Therapeutic Chemical (ATC) Classification. CAMAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule camazepam under HS 29339190 and SITC 51577. As of Q4 2014, CAMAZEPAM remains the US FDA Preferred Term for this commodity. Camazepam bears US NLM identifiers UMLS ID C0006795 and NCI Concept Code C98123. SMILES: CLC1CC2C(N(C(=O)C(OC(=O)N(C)C)N=C2C2CCCCC2)C)CC1.
This classification denotes an antihelminthic agent with the molecular formula C14H14N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 079X63S3DU, chemically known as 5-benzimidazolecarbamic acid, 2-(4-thiazolyl)-, isopropyl ester but generally known as cambendazole, which bears US NIH Compound Identifier 33309. Cambendazole most often comes in base and methyl ester forms. European Medicines Agency schedules Cambendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06062MIG. The term CAMBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). CAMBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cambendazole under HS 29341000 and SITC 51579. As of Q4 2014, CAMBENDAZOLE remains the US FDA Preferred Term for this commodity. Cambendazole bears US NLM identifiers UMLS ID C0006796 and NCI Concept Code C75212. SMILES: S1CC(NC1)C1[NH]C2C(N1)CCC(NC(=O)OC(C)C)C2.
This classification denotes an antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XM930M133O. European Medicines Agency schedules Camonagrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06065MIG. Camonagrel generally arises in the molecular formula C15H16N2O3. The term CAMONAGREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) Most nations schedule camonagrel under HS 29332990 and SITC 51573. As of Q4 2014, CAMONAGREL remains the US FDA Preferred Term for this commodity. Camonagrel bears US NLM identifiers UMLS ID C0534183 and NCI Concept Code C76006. SMILES: O(C1CC2CCC(C2CC1)C(=O)O)CCN1CCNC1.
This classification denotes a protease inhibitor with the molecular formula C20H22N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0FD207WKDU, chemically known as p-guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with n,n-dimethylglycolamide but generally known as camostat, which bears US NIH Compound Identifier 2536. Camostat most often comes in base and mesilate forms. European Medicines Agency schedules Camostat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06066MIG. The term CAMOSTAT is an International Non-Proprietary Name. World Health Organization schedules camostat in its Anatomical Therapeutic Chemical (ATC) Classification. CAMOSTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule camostat under HS 29252900 and SITC 51482. As of Q4 2014, CAMOSTAT remains the US FDA Preferred Term for this commodity. Camostat bears US NLM identifiers UMLS ID C0129975 and NCI Concept Code C73213. SMILES: O(C(=O)CC1CCC(OC(=O)C2CCC(/N=C(/N)N)CC2)CC1)CC(=O)N(C)C.
This classification denotes a protease inhibitor with the molecular formula C20H22N4O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 451M50A1EQ, chemically known as p-(p-guanidinobenzoyloxy)phenyl acetic acid, n,n-dimethylcarbamoylmethyl ester but more generally known as camostat mesilate, which bears US NIH Compound Identifier 43071. European Medicines Agency schedules Camostat mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01007MIG. Most nations, for tariff and trade purposes, schedule camostat mesylate under HS 29252900. As of Q4 2014, CAMOSTAT MESYLATE remains US FDA's Preferred Term for this commodity. Camostat mesylate bears US NLM identifiers UMLS ID C0060700 and NCI Concept Code C96364. SMILES: CN(C)C(=O)COC(=O)CC1CCC(CC1)OC(=O)C2CCC(CC2)NC(=N)N.CS(=O)(=O)O.
This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DLC36A01X. European Medicines Agency schedules Camphora in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13214MIG. Camphora generally arises in the molecular formula C6H5CLO. The term 'camphora' is an International Nomenclature of Cosmetic Ingredients designation. SMILES: C1=CC(=CC=C1O)CL. SMILES: C1=CC(=CC=C1O)CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE101. This VA Drug Class (DE101) classifies this compound as belonging to the group ANTIBACTERIAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS201. This VA Drug Class (RS201) classifies this compound as belonging to the group HEMORRHOIDAL PREPARATIONS WITHOUT STEROID.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE900. This VA Drug Class (RE900) classifies this compound as belonging to the group RESPIRATORY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE900. This VA Drug Class (RE900) classifies this compound as belonging to the group RESPIRATORY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a topical anti-infective agent with the molecular formula C10H16O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5TJD82A1ET, chemically known as 1,7,7-trimethylnorcamphor but generally known as camphor, which bears US NIH Compound Identifier 2537. Camphor most often comes in base, bromide, oil, quinone, and tar forms. European Medicines Agency schedules Camphor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13214MIG. Camphor or topical camphor preparations bears US NLM identifiers UMLS ID C0006809 and NCI Concept Code C28136. SMILES: CC1(C2CCC1(C(=O)C2)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a parasympatholytic with the molecular formula C19H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 340B6Q764V, chemically known as phenyldiethylaminoethyl-1-aminoacetic acid, isopentyl ester but generally known as camylofin, which bears US NIH Compound Identifier 5902. Camylofin most often comes in base and hydrochloride forms. European Medicines Agency schedules Camylofin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06068MIG. World Health Organization schedules camylofin in its Anatomical Therapeutic Chemical (ATC) Classification. CAMYLOFIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule camylofin under HS 29224995 and SITC 51465. As of Q4 2014, CAMYLOFIN remains the US FDA Preferred Term for this commodity. SMILES: O(CCC(C)C)C(=O)C(NCCN(CC)CC)C1CCCCC1.
This classification denotes a monoclonal antibody with the molecular formula C6452H9958N1722O2010S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37CQ2C7X93, more generally known as canakinumab. European Medicines Agency schedules canakinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30137. The term CANAKINUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 22, No. 1, 2008, list 59. As of Q4 2014, CANAKINUMAB remains US FDA's Preferred Term for this commodity.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C24H20N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8Q36MD2XX, chemically known as 1h-benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)- but generally known as candesartan, which bears US NIH Compound Identifier 2541. Candesartan most often comes in base, celexetil, and hexetil forms. European Medicines Agency schedules Candesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06070MIG. The term CANDESARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules candesartan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule candesartan under HS 29339990 and SITC 51577. As of Q4 2014, CANDESARTAN remains the US FDA Preferred Term for this commodity. Candesartan bears US NLM identifiers UMLS ID C0717550 and NCI Concept Code C65284. SMILES: O(c1n(Cc2ccc(cc2)c2c(cccc2)c2n[nH]nn2)c2c(n1)cccc2C(=O)O)CC.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C33H34N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R85M2X0D68, chemically known as 1h-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- but more generally known as candesartan cilexetil, which bears US NIH Compound Identifier 2540. European Medicines Agency schedules Candesartan cilexetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13222MIG. Most nations, for tariff and trade purposes, schedule candesartan cilexetil under HS 29339990 and SITC 51577. As of Q4 2014, CANDESARTAN CILEXETIL remains US FDA's Preferred Term for this commodity. Candesartan cilexetil bears US NLM identifiers UMLS ID C0527379 and NCI Concept Code C28903. SMILES: CCOC1NC2CCCC(C2N1CC3CCC(CC3)C4CCCCC4C5[NH]NNN5)C(=O)OC(C)OC(=O)OC6CCCCC6.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48N2IYJ202. European Medicines Agency schedules Candicidin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01021MIG. Candicidin generally arises in the molecular formula C59H84N2O18. The term CANDICIDIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) CANDICIDIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule candicidin under HS 29419000 and SITC 54139. As of Q4 2014, CANDICIDIN remains the US FDA Preferred Term for this commodity. Candicidin bears US NLM identifiers UMLS ID C0006834 and NCI Concept Code C87461. SMILES: O1C2(O)CC(O)C(C1CC(OC1OC(C(O)C(N)C1O)C)C=CC=CC=CC=CC=CC=CC=CC(C(OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)C2)C(CC(C(O)CC(=O)C1CCC(N)CC1)C)C)C)C(=O)O.
This classification denotes an antibiotic with the molecular formula C59H84N2O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5190Y348H9, chemically known as candicidin d, (32e)-, but more generally known as candicidin d, which bears US NIH Compound Identifier 441142. European Medicines Agency schedules candicidin d or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01021MIG. Most nations, for tariff purposes, schedule candicidin d under HS 29419000. SMILES: C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@@H]([C@@H]([C@H](CC(=O)C[C@H](C[C@H](C[C@H](CC(=O)CCCC(=O)CC(=O)O[C@@H]1[C@@H](C)C[C@H](C)[C@H](CC(=O)C2CCC(CC2)N)O)O)O)O)O)C(=O)O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O.
This classification denotes an antihypertensive agent with the molecular formula C29H41NO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ACP75508EE, chemically known as (.alpha.s)-1-((cis-4-carboxycyclohexyl)carbamoyl)-.alpha.-((2-methoxyethoxy)methyl)cyclopentanepropionic acid, .alpha.-5-indanyl ester, but generally known as candoxatril, which bears US NIH Compound Identifier 5362417. European Medicines Agency schedules candoxatril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06072MIG. Candoxatril or candoxatrilat bears US NLM identifiers UMLS ID C0077780 and NCI Concept Code C77602. SMILES: COCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3.
This classification denotes an antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6AQ1Y404U7. European Medicines Agency schedules Cangrelor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26448. Cangrelor generally arises in the molecular formula C17H25CL2F3N5O12P3S2. The term CANGRELOR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule cangrelor under HS 29349990 and SITC 51579. As of Q4 2014, CANGRELOR remains the US FDA Preferred Term for this commodity. Cangrelor bears US NLM identifiers UMLS ID C1121991 and NCI Concept Code C76395. SMILES: CLC(CL)(P(=O)(OP(=O)(OCC1OC(N2C3NC(SCCC(F)(F)F)NC(NCCSC)C3NC2)C(O)C1O)O)O)P(=O)(O)O.
FDA approved Schedule V hemp or cannabis derivative
This classification denotes an antiemetic agent with the molecular formula C21H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7UYP6MC9GH, chemically known as 6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol but generally known as cannabinol, which bears US NIH Compound Identifier 2543. Cannabinol most often comes in base, methyl, and tert-butyldimethylsilyl ether forms. European Medicines Agency schedules Cannabinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06074MIG. The term CANNABINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). CANNABINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cannabinol under HS 29329985 and SITC 51569. As of Q4 2014, CANNABINOL remains the US FDA Preferred Term for this commodity. Cannabinol bears US NLM identifiers UMLS ID C0006865 and NCI Concept Code C84510. SMILES: O1C(C2C(C3C1CC(CCCCC)CC3O)CC(CC2)C)(C)C.
This classification denotes a potassium-sparing diuretic with the molecular formula C22H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78O20X9J0U, chemically known as 17-hydroxy-3-oxo-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactone but generally known as canrenone, which bears US NIH Compound Identifier 13789. European Medicines Agency schedules Canrenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06076MIG. The term CANRENONE is an International Non-Proprietary Name. World Health Organization schedules canrenone in its Anatomical Therapeutic Chemical (ATC) Classification. CANRENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CANRENOATE POTASSIUM remains the US FDA Preferred Term for this commodity. Canrenoate potassium bears US NLM identifiers UMLS ID C0006881 and NCI Concept Code C81161. SMILES: O1C2(C3(C(C4C(CC3)C3(C(=CC(=O)CC3)C=C4)C)CC2)C)CCC1=O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a pyrimidine antagonist with the molecular formula C15H22FN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6804DJ8Z9U, chemically known as pentyl 1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate but generally known as capecitabine, which bears US NIH Compound Identifier 60953. European Medicines Agency schedules Capecitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12474MIG. The term CAPECITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules capecitabine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule capecitabine under HS 29349990 and SITC 51579. As of Q4 2014, CAPECITABINE remains the US FDA Preferred Term for this commodity. Capecitabine bears US NLM identifiers UMLS ID C0671970 and NCI Concept Code C1794. SMILES: FC1CN(C2OC(C(O)C2O)C)C(=O)NC1NC(=O)OCCCCC.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C20H20Cl2N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VHC779598X, chemically known as 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(pyridin-4-yl-methyl)-1h-imidazol-2-yl-methyl carbamate but generally known as capravirine, which bears US NIH Compound Identifier 1783. European Medicines Agency schedules Capravirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20328. The term CAPRAVIRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). Most nations schedule capravirine under HS 29333999 and SITC 51574. As of Q4 2014, CAPRAVIRINE remains the US FDA Preferred Term for this commodity. Capravirine bears US NLM identifiers UMLS ID C0755617 and NCI Concept Code C81612. SMILES: Clc1cc(Sc2n(c(nc2C(C)C)COC(=O)N)Cc2ccncc2)cc(Cl)c1.
This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C19H30N12O6(R1)(R2), a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 232HYX66HC, more generally known as capreomycin. European Medicines Agency schedules capreomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. The term CAPREOMYCIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 19 1975, list 5. CAPREOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule capreomycin under HS 29419000 and SITC 54139. As of Q4 2014, CAPREOMYCIN remains the US FDA Preferred Term for this commodity. Capreomycin bears US NLM identifiers UMLS ID C0262964 and NCI Concept Code C72607. SMILES: CC1C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)NC(C(=O)NCC(C(=O)N1)N)C2CCN=C(N2)N)CNC(=O)CC(CCCN)N.C1CN=C(NC1C2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)N2)CNC(=O)CC(CCCN)N)CO)N)N.
This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C25H44N14O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AUQ151IUH, chemically known as cyclo(3-(((3s)-3,6-diamino-1-oxohexyl)amino)-l-alanyl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-(2s)-2-((4r)-2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)glycyl-(2s)-2-amino-.beta.-alanyl-l-seryl), but more generally known as capreomycin ia, which bears US NIH Compound Identifier 3032940. European Medicines Agency schedules capreomycin ia or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. Most nations, for tariff purposes, schedule capreomycin ia under HS 29419000. SMILES: C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N.
This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C25H44N14O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2YP3RYC823, chemically known as cyclo((2s)-2-amino-.beta.-alanyl-l-alanyl-3-(((3s)-3,6-diamino-1-oxohexyl)amino)-l-alanyl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-(2s)-2-((4r)-2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)glycyl), but more generally known as capreomycin ib, which bears US NIH Compound Identifier 3034057. European Medicines Agency schedules capreomycin ib or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. Most nations, for tariff purposes, schedule capreomycin ib under HS 29419000. SMILES: C[C@H]1C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.
This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C19H32N12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38TL5Q9SM7, chemically known as cyclo(3-amino-l-alanyl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-(2s)-2-((4r)-2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)glycyl-(2s)-2-amino-.beta.-alanyl-l-seryl), but more generally known as capreomycin iia, which bears US NIH Compound Identifier 3034236. European Medicines Agency schedules capreomycin iia or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. Most nations, for tariff purposes, schedule capreomycin iia under HS 29419000. SMILES: C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CN)CO)N)N.
This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C19H32N12O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K630580G1N, chemically known as cyclo((2s)-2-amino-.beta.-alanyl-l-alanyl-3-amino-l-alanyl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-(2s)-2-((4r)-2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)glycyl), but more generally known as capreomycin iib, which bears US NIH Compound Identifier 3034237. European Medicines Agency schedules capreomycin iib or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. Most nations, for tariff purposes, schedule capreomycin iib under HS 29419000. SMILES: C[C@H]1C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CN.
This classification denotes an antitubercular agent and aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9H8D3J7V21. European Medicines Agency schedules Capreomycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01029MIG. Capreomycin sulfate generally arises in the molecular formula C25H46N14O12S. The term 'capreomycin sulfate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule capreomycin sulfate under HS 29419000 and SITC 54139. Capreomycin sulfate bears US NLM identifiers UMLS ID C0006920 and NCI Concept Code C73797. SMILES: As of Q4 2014, CAPREOMYCIN SULFATE remains US FDA's Preferred Term for this commodity.
This classification denotes a saturated fatty acid and medium chain fatty acid with the molecular formula C8H16O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OBL58JN025, chemically known as octanoic acid, zinc salt but generally known as caprylic acid, which bears US NIH Compound Identifier 379. European Medicines Agency schedules Caprylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11786MIG. The term OCTANOIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). SMILES: OC(=O)CCCCCCC.
This classification denotes a nonnarcotic analgesic and capsaicinoid with the molecular formula C18H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S07O44R1ZM, chemically known as nonanamide, n-vanillyl- (8ci) but generally known as capsaicin, which bears US NIH Compound Identifier 2998. European Medicines Agency schedules Capsaicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13229MIG. World Health Organization schedules capsaicin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CAPSAICIN remains the US FDA Preferred Term for this commodity. Capsaicin bears US NLM identifiers UMLS ID C0006931 and NCI Concept Code C339. SMILES: O=C(NCC1CC(OC)C(O)CC1)CCCCCCCC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes an anxiolytic with the molecular formula C21H29NS2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I7N9PR9J2, chemically known as 2((p-(butylthio)-alpha-phenylbenzyl)thio)-n,n-dimethylethylamine hydrochloride but more generally known as captodiame hydrochloride, which bears US NIH Compound Identifier 13484. European Medicines Agency schedules Captodiame hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01035MIG. Most nations, for tariff and trade purposes, schedule captodiame hydrochloride under HS 29309085. As of Q4 2014, CAPTODIAME HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Captodiame hydrochloride bears US NLM identifiers UMLS ID C2698983 and NCI Concept Code C76504. SMILES: CCCCSC1CCC(CC1)C(C2CCCCC2)SCCN(C)C.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H29NS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H93K9455DD, chemically known as 2-((p-(butylthio)-alpha-phenylbenzyl)thio)-n,n-dimethylethylamine but generally known as captodiame, which bears US NIH Compound Identifier 10240. Captodiame most often comes in base and hydrochloride forms. European Medicines Agency schedules Captodiame in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06080MIG. The term CAPTODIAME is an International Non-Proprietary Name. World Health Organization schedules captodiame in its Anatomical Therapeutic Chemical (ATC) Classification. CAPTODIAME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Captodiame or captodiamine bears US NLM identifiers UMLS ID C0301409 and NCI Concept Code C81137. SMILES: CCCCSC1=CC=C(C=C1)C(C2=CC=CC=C2)SCCN(C)C.
This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9G64RSX1XD. European Medicines Agency schedules Captopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06081MIG. Captopril generally arises in the molecular formula C9H15NO3S. The term CAPTOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) CAPTOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule captopril under HS 29339990 and SITC 51577. As of Q4 2014, CAPTOPRIL remains the US FDA Preferred Term for this commodity. Captopril bears US NLM identifiers UMLS ID C0006938 and NCI Concept Code C340. SMILES: SCC(C(=O)N1C(CCC1)C(=O)O)C.
This classification denotes an ace inhibitor with the molecular formula C18H28N2O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y21D2C2453, chemically known as l-proline, 1,1'-(dithiobis(2-methyl-1-oxo-3,1-propanediyl))bis-, (s-(r*,r*))-, but more generally known as captopril disulfide, which bears US NIH Compound Identifier 163066. European Medicines Agency schedules captopril disulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06081MIG. Most nations, for tariff purposes, schedule captopril disulfide under HS 29339990. SMILES: C[C@H](CSSC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O)C(=O)N2CCC[C@H]2C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a sedative and hypnotic with the molecular formula C9H18N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3FO9QT93IS, chemically known as urea, (2-ethyl-3-methylvaleryl)- (8ci) but generally known as capuride, which bears US NIH Compound Identifier 231285. European Medicines Agency schedules Capuride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06082MIG. The term CAPURIDE is an International Non-Proprietary Name. CAPURIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule capuride under HS 29241900 and SITC 51471. As of Q4 2014, CAPURIDE remains the US FDA Preferred Term for this commodity. Capuride bears US NLM identifiers UMLS ID C0602078 and NCI Concept Code C83587. SMILES: O=C(NC(=O)N)C(C(CC)C)CC.
This classification denotes a thrombolytic agent with the molecular formula C24H27N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39IWK4M2UW, chemically known as ethyl (s)-beta-(2-((s)-4-(p-amidinophenyl)-4-methyl-2,5-dioxo-1-imidazolidinyl)acetamido)hydrocinnamate. but generally known as carafiban, which bears US NIH Compound Identifier 193944. European Medicines Agency schedules Carafiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06084MIG. The term CARAFIBAN is an International Non-Proprietary Name. Most nations schedule carafiban under HS 29332990 and SITC 51573. As of Q4 2014, CARAFIBAN remains the US FDA Preferred Term for this commodity. Carafiban bears US NLM identifiers UMLS ID C2698985 and NCI Concept Code C76113. SMILES: O=C1N(C(=O)NC1(C1CCC(CC1)C(=N)N)C)CC(=O)NC(CC(=O)OCC)C1CCCCC1.
This classification denotes an antitussive agent with the molecular formula C18H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 97J7NP0XJY, chemically known as cyclopentanecarboxylic acid, 1-phenyl-, 2-(diethylamino)ethyl ester but more generally known as caramiphen, which bears US NIH Compound Identifier 6472. Caramiphen most often comes in base, ethanedisulfonate, hydrochloride, and hydrogen edisilate. European Medicines Agency schedules Caramiphen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06085MIG. The term CARAMIPHEN is an International Non-Proprietary Name. CARAMIPHEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule caramiphen under HS 29221980 and SITC 51461. As of Q4 2014, CARAMIPHEN remains US FDA's Preferred Term for this commodity. Caramiphen bears US NLM identifiers UMLS ID C0054635 and NCI Concept Code C81594. SMILES: O(C(=O)C1(CCCC1)C1CCCCC1)CCN(CC)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE512. This VA Drug Class (RE512) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29PW75S82A, chemically known as 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((1-methylethyl)amino)- but generally known as carazolol, which bears US NIH Compound Identifier 71739. Carazolol most often comes in base, glucuronide, and hydrochloride forms. European Medicines Agency schedules Carazolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06086MIG. The term CARAZOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). CARAZOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carazolol under HS 29339990 and SITC 51577. As of Q4 2014, CARAZOLOL remains the US FDA Preferred Term for this commodity. Carazolol bears US NLM identifiers UMLS ID C0054636 and NCI Concept Code C77941. SMILES: O(C1C2C3C([NH]C2CCC1)CCCC3)CC(O)CNC(C)C.
This classification denotes an anti-glaucoma agent with the molecular formula C6H15N2O2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y164V895Y, chemically known as 2-((aminocarbonyl)oxy)-n,n,n-trimethylethanaminium but generally known as carbachol, which bears US NIH Compound Identifier 2551. Carbachol most often comes in base, chloride, and hydrochloride forms. European Medicines Agency schedules Carbachol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06087MIG. The term CARBACHOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules carbachol in its Anatomical Therapeutic Chemical (ATC) Classification. CARBACHOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbachol under HS 29239000 and SITC 51481. As of Q4 2014, CARBACHOL remains the US FDA Preferred Term for this commodity. Carbachol bears US NLM identifiers UMLS ID C0306489 and NCI Concept Code C47430. SMILES: O(CC[N](C)(C)C)C(=O)N.
This classification denotes an anti-infective agent with the molecular formula C11H10N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M2X04R2E2Y, chemically known as 3-(2-quinoxalinylmethylene)carbazic acid methyl ester n,n′-dioxide but more generally known as carbadox, which bears US NIH Compound Identifier 5353472. European Medicines Agency schedules Carbadox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06088MIG. The term CARBADOX is an International Non-Proprietary Name. CARBADOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: COC(=O)N=N/C=C/1\C=[N+](C2=CC=CC=C2N1O)[O-].
This classification denotes an anti-ulcer agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6931E8LH07. European Medicines Agency schedules Carbaldrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06112MIG. Carbaldrate generally arises in the molecular formula CO3.AL.NA.2HO.H2O. The term CARBALDRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) CARBALDRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbaldrate under HS 28429080 and SITC 52389. As of Q4 2014, CARBALDRATE remains the US FDA Preferred Term for this commodity. Carbaldrate bears US NLM identifiers UMLS ID C2827103 and NCI Concept Code C83588. SMILES: [ALH3].[NA].OC(=O)O.O.
This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33CM23913M, chemically known as 5h-dibenz(b,f)azepine-5-carboxamide but generally known as carbamazepine, which bears US NIH Compound Identifier 2554. Carbamazepine most often comes in base, dihydrate, epoxide, and glucuronide forms. European Medicines Agency schedules Carbamazepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06113MIG. The term CARBAMAZEPINE is an International Non-Proprietary Name. World Health Organization schedules carbamazepine in its Anatomical Therapeutic Chemical (ATC) Classification. CARBAMAZEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbamazepine under HS 29339930 and SITC 51577. As of Q4 2014, CARBAMAZEPINE remains the US FDA Preferred Term for this commodity. Carbamazepine bears US NLM identifiers UMLS ID C0006949 and NCI Concept Code C341. SMILES: O=C(N1C2C(C=CC3C1CCCC3)CCCC2)N.
This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78M1RMW7Q8, chemically known as 5h-dibenz(b,f)azepine-5-carboxamide, hydrate (1:2), but more generally known as carbamazepine dihydrate, which bears US NIH Compound Identifier 158856. European Medicines Agency schedules carbamazepine dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06113MIG. Most nations, for tariff purposes, schedule carbamazepine dihydrate under HS 29339930. SMILES: C1CCC2C(C1)C=CC3CCCCC3N2C(=O)N.O.O.
This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OO7RKH9WL. European Medicines Agency schedules Oxpheneridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09553MIG. Oxpheneridine generally arises in the molecular formula C22H27NO3. The term OXPHENERIDINE is an International Non-Proprietary Name or INN. OXPHENERIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Carbamethidine or oxpheneridine bears US NLM identifiers UMLS ID C2698678 and NCI Concept Code C76844. SMILES: O(C(=O)C1(CCN(CC1)CC(O)C1CCCCC1)C1CCCCC1)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a topical anti-infective agent with the molecular formula CH4N2O.H2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31PZ2VAU81, chemically known as urea, compd. with hydrogen peroxide (h2o2) (1:1) but generally known as carbamide peroxide, which bears US NIH Compound Identifier 31294. European Medicines Agency schedules Carbamide peroxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB44863. As of Q4 2014, CARBAMIDE PEROXIDE remains the US FDA Preferred Term for this commodity. Carbamide peroxide bears US NLM identifiers UMLS ID C0108342 and NCI Concept Code C77033. SMILES: O=C(N)N.OO.
This classification denotes an antiprotozoal agent with the molecular formula C7H9AsN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8PK70TXE1T, chemically known as benzenearsonic acid, p-ureido- but generally known as carbarsone, which bears US NIH Compound Identifier 8480. Carbarsone most often comes in base, oxide, and sodium forms. European Medicines Agency schedules Carbarsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06116MIG. The term CARBARSONE is an International Non-Proprietary Name. CARBARSONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CARBARSONE remains the US FDA Preferred Term for this commodity. Carbarsone bears US NLM identifiers UMLS ID C0054654 and NCI Concept Code C76414. SMILES: [AS](=O)(O)(O)C1CCC(NC(=O)N)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C9H7O4.CH4N2O.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N667F17JP1, chemically known as salicylic acid acetate calcium salt, compound with urea (1:1) complex but generally known as carbasalate calcium, which bears US NIH Compound Identifier 21975. European Medicines Agency schedules Carbasalate calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06117MIG. World Health Organization schedules carbasalate calcium in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule carbasalate calcium under HS 29242995 and SITC 51479. SMILES: CC(=O)OC1=CC=CC=C1C(=O)[O-].CC(=O)OC1=CC=CC=C1C(=O)[O-].C(=O)(N)N.[Ca+2].
This classification denotes a phosphodiesterase inhibitor with the molecular formula C18H24N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0N4I6K95P2, chemically known as 1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidyl ethylcarbamate but generally known as carbazeran, which bears US NIH Compound Identifier 71983. European Medicines Agency schedules Carbazeran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06118MIG. The term CARBAZERAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). CARBAZERAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbazeran under HS 29333999 and SITC 51574. As of Q4 2014, CARBAZERAN remains the US FDA Preferred Term for this commodity. Carbazeran bears US NLM identifiers UMLS ID C0054655 and NCI Concept Code C76027. SMILES: O(C1CCN(CC1)C1NNCC2C1CC(OC)C(OC)C2)C(=O)NCC.
This classification denotes a hemostatic agent with the molecular formula C10H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81F061RQS4, chemically known as 5,6-indolinedione, 3-hydroxy-1-methyl-, 5-semicarbazone but generally known as carbazochrome, which bears US NIH Compound Identifier 5360410. Carbazochrome most often comes in base, salicylate, and sodium sulfonate forms. European Medicines Agency schedules Carbazochrome in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13237MIG. The term CARBAZOCHROME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules carbazochrome in its Anatomical Therapeutic Chemical (ATC) Classification. CARBAZOCHROME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbazochrome under HS 29339990 and SITC 51577. As of Q4 2014, CARBAZOCHROME remains the US FDA Preferred Term for this commodity. Carbazochrome bears US NLM identifiers UMLS ID C0006972 and NCI Concept Code C79939. SMILES: CN1CC(C2=C/C(=N/NC(=O)N)/C(=O)C=C21)O.
This classification denotes a hemostatic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3H4OD401LF. European Medicines Agency schedules Carbazochrome salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06119MIG. Carbazochrome salicylate generally arises in the molecular formula C10H12N4O3.C7H6O3.NA. The term CARBAZOCHROME SALICYLATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, no. 12, 1959, list 3.) Most nations, for tariff and trade purposes, schedule carbazochrome salicylate under HS 30039090 and SITC 54291. As of Q4 2014, CARBAZOCHROME SALICYLATE remains US FDA's Preferred Term for this commodity. Carbazochrome salicylate bears US NLM identifiers UMLS ID C0006973 and NCI Concept Code C76883. SMILES: CN1CC(C2=C/C(=N/NC(=O)N)/C(=O)C=C21)O.C1CCC(C(C1)C(=O)[O-])O.[NA+].
This classification denotes a hemostatic agent with the molecular structure C10H11N4O5S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, J0I08M946E chemically known as sodium salt of 5,6-dihydro-1-methyl-5,6-dioxo-3-indoline sulfonic acid 5-semicarbazone, but more commonly known as carbazochrome sodium sulfonate, which bears US NIH Compound Identifier 6321410. European Medicines Agency schedules Carbazochrome sodium sulfonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06120MIG. The term CARBAZOCHROME SODIUM SULFONATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, no. 3 1962, list 4. ). Most nations, for tariff and trade purposes, schedule carbazochrome sodium sulfonate under HS 29339990 and SITC 51577. As of Q4 2014, CARBAZOCHROME SODIUM SULFONATE remains US FDA's Preferred Term for this commodity. Carbazochrome sodium sulfonate bears US NLM identifiers UMLS ID C0054657 and NCI Concept Code C83589. SMILES: CN1C(CC2=C/C(=N/NC(=O)N)/C(=O)C=C21)S(=O)(=O)[O-].[NA+].
This classification denotes an extended spectrum penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G42ZU72N5G. European Medicines Agency schedules Carbenicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06122MIG. Carbenicillin generally arises in the molecular formula C17H18N2O6S. The term CARBENICILLIN is an International Non-Proprietary Name or INN. CARBENICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbenicillin under HS 29411090 and SITC 54131. As of Q4 2014, CARBENICILLIN remains the US FDA Preferred Term for this commodity. Carbenicillin bears US NLM identifiers UMLS ID C0006976 and NCI Concept Code C343. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(C1CCCCC1)C(=O)O.
This classification denotes an extended spectrum penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TS4B3H261. European Medicines Agency schedules Carbenicillin disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01041MIG. Carbenicillin disodium generally arises in the molecular formula C17H16N2NA2O6S. The term 'carbenicillin disodium' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule carbenicillin disodium under HS 29411090 and SITC 54131. As of Q4 2014, CARBENICILLIN DISODIUM remains US FDA's Preferred Term for this commodity. Carbenicillin disodium bears US NLM identifiers UMLS ID C0813202 and NCI Concept Code C65285. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCCCC3)C(=O)[O-])C(=O)[O-])C.[NA+].[NA+].
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C26H26N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V278481KE, chemically known as 1-(5-indanyl)(2s,5r,6r)-n-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamate, but more generally known as carbenicillin indanyl, which bears US NIH Compound Identifier 93184. European Medicines Agency schedules carbenicillin indanyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06122MIG. Most nations, for tariff purposes, schedule carbenicillin indanyl under HS 29411090. As of Q4 2014, CARBENICILLIN INDANYL remains US FDA's Preferred Term for this commodity. Carbenicillin indanyl bears US NLM identifiers UMLS ID C0054667 and NCI Concept Code C76219. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCCCC3)C(=O)OC4CCC5C(C4)CCC5)C(=O)O)C.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C26H25N2O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4OUL81K2RT, chemically known as 1-(5-indanyl)(2s,5r,6r)-n-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamate monosodium salt, but more generally known as carbenicillin indanyl sodium, which bears US NIH Compound Identifier 33554. European Medicines Agency schedules carbenicillin indanyl sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06122MIG. Most nations, for tariff purposes, schedule carbenicillin indanyl sodium under HS 29411090. As of Q4 2014, CARBENICILLIN INDANYL SODIUM remains US FDA's Preferred Term for this commodity. Carbenicillin indanyl sodium bears US NLM identifiers UMLS ID C0142817 and NCI Concept Code C1409. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCCCC3)C(=O)OC4CCC5C(C4)CCC5)C(=O)[O-])C.[NA+].
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C23H22N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9UU4XDB74X, chemically known as n-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid 1-phenyl ester, but more generally known as carbenicillin phenyl, which bears US NIH Compound Identifier 33672. European Medicines Agency schedules carbenicillin phenyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06122MIG. Most nations, for tariff purposes, schedule carbenicillin phenyl under HS 29411090. As of Q4 2014, CARBENICILLIN PHENYL remains US FDA's Preferred Term for this commodity. Carbenicillin phenyl bears US NLM identifiers UMLS ID C2698988 and NCI Concept Code C79761. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCCCC3)C(=O)OC4CCCCC4)C(=O)O)C.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C23H21N2O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18N5JP36GY, chemically known as n-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid 1-phenyl ester sodium salt, but more generally known as carbenicillin phenyl sodium, which bears US NIH Compound Identifier 30728. European Medicines Agency schedules carbenicillin phenyl sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06122MIG. Most nations, for tariff purposes, schedule carbenicillin phenyl sodium under HS 29411090. As of Q4 2014, CARBENICILLIN PHENYL SODIUM remains US FDA's Preferred Term for this commodity. Carbenicillin phenyl sodium bears US NLM identifiers UMLS ID C0085959 and NCI Concept Code C79421. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCCCC3)C(=O)OC4CCCCC4)C(=O)[O-])C.[NA+].
This classification denotes an extended spectrum penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TS4B3H261. European Medicines Agency schedules Carbenicillin disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01041MIG. Carbenicillin disodium generally arises in the molecular formula C17H16N2NA2O6S. The term 'carbenicillin disodium' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule carbenicillin sodium under HS 29411090. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCCCC3)C(=O)[O-])C(=O)[O-])C.[NA+].[NA+].
This classification denotes a hydroxysteroid dehydrogenase inhibitor with the molecular formula C34H50O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MM6384NG73, chemically known as olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-, hydrogen succinate but generally known as carbenoxolone, which bears US NIH Compound Identifier 21913. Carbenoxolone comes in base, adrenochrome, and sodium forms. European Medicines Agency schedules Carbenoxolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06123MIG. The term CARBENOXOLONE is an International Non-Proprietary Name. World Health Organization schedules carbenoxolone in its Anatomical Therapeutic Chemical (ATC) Classification. CARBENOXOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CARBENOXOLONE remains the US FDA Preferred Term for this commodity. Carbenoxolone bears US NLM identifiers UMLS ID C0006979 and NCI Concept Code C63669. SMILES: O(C1C(C2C(C3C(C4(C(=CC3=O)C3C(CC4)(CCC(C3)(C)C(=O)O)C)C)(CC2)C)(CC1)C)(C)C)C(=O)CCC(=O)O.
This classification denotes a cyclopentane and antitussive agent with the molecular formula C20H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32C726X12W, chemically known as 2-(2-diethylaminoethoxy)ethyl 1-phenylcyclopentane-1-carboxylate; 2-hydroxypropane-1,2,3-tricarboxylic acid but more generally known as pentoxyverine, which bears US NIH Compound Identifier 2562. European Medicines Agency schedules Pentoxyverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09706MIG. World Health Organization schedules pentoxyverine in its Anatomical Therapeutic Chemical (ATC) Classification. PENTOXYVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE504. This VA Drug Class (RE504) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes an oxytocic and uterine stimulant with the molecular formula C45H69N11O12S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88TWF8015Y, chemically known as 1-carboxytocin, 1-butanoic acid-2-(o-methyl-l-tyrosine)- but generally known as carbetocin, which bears US NIH Compound Identifier 71715. European Medicines Agency schedules Carbetocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06125MIG. World Health Organization schedules carbetocin in its Anatomical Therapeutic Chemical (ATC) Classification. CARBETOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbetocin under HS 29371900 and SITC 54154. As of Q4 2014, CARBETOCIN remains the US FDA Preferred Term for this commodity. Carbetocin bears US NLM identifiers UMLS ID C0054670 and NCI Concept Code C96858. SMILES: S1CC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N(C(=O)CCC1)C)CC1CCC(O)CC1)C(CC)C)CCC(=O)N)CC(=O)N)C(=O)N1C(CCC1)C(=O)NC(CC(C)C)C(=O)NCC(=O)N.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C10H14N2O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MNX7R8C5VO, chemically known as hydrocinnamic acid, .alpha.-hydrazino-3,4-dihydroxy-.alpha.-methyl-, l- but generally known as carbidopa, which bears US NIH Compound Identifier 2563. Carbidopa most often comes in base, anhydrous, and hydrate forms, and is often combined with Levodopa. European Medicines Agency schedules Carbidopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06126MIG. CARBIDOPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbidopa under HS 29280090 and SITC 51486. As of Q4 2014, CARBIDOPA remains the US FDA Preferred Term for this commodity. Carbidopa bears US NLM identifiers UMLS ID C0006982 and NCI Concept Code C47431. SMILES: CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C10H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KR87B45RGH, chemically known as benzenepropanoic acid, .alpha.-hydrazino-3,4-dihydroxy-.alpha.-methyl-, (s)-, but more generally known as carbidopa anhydrous, which bears US NIH Compound Identifier 34359. European Medicines Agency schedules carbidopa anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06126MIG. Most nations, for tariff purposes, schedule carbidopa anhydrous under HS 29280090. Carbidopa anhydrous bears US NLM identifiers UMLS ID C1881339 and NCI Concept Code C61803. SMILES: C[C@](CC1CCC(C(C1)O)O)(C(=O)O)NN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN500. This VA Drug Class (CN500) classifies this compound as belonging to the group ANTIPARKINSON AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN500. This VA Drug Class (CN500) classifies this compound as belonging to the group ANTIPARKINSON AGENTS.
This classification denotes an antithyroid agent with the molecular formula C7H10N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KQ660G60G, chemically known as 4-imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester but generally known as carbimazole, which bears US NIH Compound Identifier 31072. European Medicines Agency schedules Carbimazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06127MIG. The term CARBIMAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules carbimazole in its Anatomical Therapeutic Chemical (ATC) Classification. CARBIMAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbimazole under HS 29332990 and SITC 51573. As of Q4 2014, CARBIMAZOLE remains the US FDA Preferred Term for this commodity. Carbimazole bears US NLM identifiers UMLS ID C0006983 and NCI Concept Code C83590. SMILES: S=C1N(CCN1C(=O)OCC)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19ClN2O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02O55696WH, chemically known as pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)- but more generally known as carbinoxamine maleate, which bears US NIH Compound Identifier 2564. European Medicines Agency schedules Carbinoxamine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01044MIG. Most nations, for tariff and trade purposes, schedule carbinoxamine maleate under HS 29333999. As of Q4 2014, CARBINOXAMINE MALEATE remains US FDA's Preferred Term for this commodity. Carbinoxamine maleate bears US NLM identifiers UMLS ID C0304300 and NCI Concept Code C47432. SMILES: CN(C)CCOC(C1CCC(CC1)CL)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 982A7M02H5, chemically known as pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)- but generally known as carbinoxamine, which bears US NIH Compound Identifier 2564. Carbinoxamine most often comes in base and maleate forms. European Medicines Agency schedules Carbinoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06128MIG. The term CARBINOXAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules carbinoxamine in its Anatomical Therapeutic Chemical (ATC) Classification. CARBINOXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Carbinoxamine or rotoxamine bears US NLM identifiers UMLS ID C0054672 and NCI Concept Code C65286. SMILES: CLC1CCC(C(OCCN(C)C)C2NCCCC2)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a mucolytic agent with the molecular formula C5H9NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 740J2QX53R, chemically known as (rs)-cysteine, s-(carboxymethyl)- but more generally known as carbocisteine, which bears US NIH Compound Identifier 1080. European Medicines Agency schedules Carbocisteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11790MIG. World Health Organization schedules carbocisteine in its Anatomical Therapeutic Chemical (ATC) Classification. CARBOCISTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule carbocisteine under HS 29309016 and SITC 51549. SMILES: SCC(N)C(=O)O.
This classification denotes a sedative and hypnotic with the molecular formula C5H8Cl3NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0KA807799, chemically known as ethyl 2,2,2-trichloro-1-hydroxyethylcarbamate but generally known as carbocloral, which bears US NIH Compound Identifier 10944. European Medicines Agency schedules Carbocloral in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06611MIG. The term CARBOCLORAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). CARBOCLORAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbocloral under HS 29241900 and SITC 51471. As of Q4 2014, CARBOCLORAL remains the US FDA Preferred Term for this commodity. Carbocloral bears US NLM identifiers UMLS ID C1879999 and NCI Concept Code C65287. SMILES: CLC(CL)(CL)C(O)NC(=O)OCC.
This classification denotes a vasodilating agent with the molecular formula C20H27NO5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52C937V399, chemically known as acetic acid, ((3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)-, ethyl ester, hydrochloride but more generally known as carbocromen hydrochloride, which bears US NIH Compound Identifier 12603. European Medicines Agency schedules Carbocromen hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01048MIG. Most nations, for tariff and trade purposes, schedule carbocromen hydrochloride under HS 29322985. SMILES: CCN(CC)CCC1C(C2CCC(CC2OC1=O)OCC(=O)OCC)C.CL.
This classification denotes a vasodilating agent with the molecular formula C20H27NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R0C9NIE5JJ, chemically known as acetic acid, ((3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)-, ethyl ester but generally known as carbocromen, which bears US NIH Compound Identifier 12604. Carbocromen most often comes in base and hydrochloride forms. European Medicines Agency schedules Carbocromen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06612MIG. The term CARBOCROMEN is an International Non-Proprietary Name. World Health Organization schedules carbocromen in its Anatomical Therapeutic Chemical (ATC) Classification. CARBOCROMEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Carbocromen or chromonar bears US NLM identifiers UMLS ID C0008593 and NCI Concept Code C79586. SMILES: o1c2c(c(c(CCN(CC)CC)c1=O)C)ccc(OCC(=O)OCC)c2.
Ocular lubricant and humectant. Carbomer is a low-molecular weight hydrophilic polymer, which acts by forming a lubricant and humectant film over the eye, by protecting cornea against drying, and by promoting the epithelial, corneal and conjuntival injuries regression associated to dry eye.
This classification denotes a complex of iron atoms chelated with carbonyl ions, and which generally arises in the molecular formula C5FeO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WQ62TAQ6Z. European Medicines Agency schedules carbonyl iron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14266MIG. SMILES: [C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[Fe].
This classification denotes a platinum compound with the molecular formula C6H6O4.Pt.2H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BG3F62OND5, chemically known as cis-diammine(1,1-cyclobutanedicarboxylato) platinum but more generally known as carboplatin, which bears US NIH Compound Identifier 38904. European Medicines Agency schedules Carboplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06614MIG. The term CARBOPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules carboplatin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule carboplatin under HS 28439090 and SITC 52432. As of Q4 2014, CARBOPLATIN remains US FDA's Preferred Term for this commodity. Carboplatin bears US NLM identifiers UMLS ID C0079083 and NCI Concept Code C1282. SMILES: [Pt]1[OH]C(=O)C2(CCC2)C(=O)[OH]1.N.N.
This classification denotes a prostaglandin analogue with the molecular formula C21H36O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7B5032XT6O, chemically known as 9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid (5z,9alpha,11alpha,13e,15s)- but generally known as carboprost, which bears US NIH Compound Identifier 5281005. Carboprost most often comes in base, methyl, methyl ester, and tromethamine forms. European Medicines Agency schedules Carboprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06615MIG. The term CARBOPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules carboprost in its Anatomical Therapeutic Chemical (ATC) Classification. CARBOPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carboprost under HS 29375000 and SITC 54156. As of Q4 2014, CARBOPROST remains the US FDA Preferred Term for this commodity. Carboprost bears US NLM identifiers UMLS ID C0007047 and NCI Concept Code C61662. SMILES: OC1C(C(C(O)C1)/C=C/C(O)(CCCCC)C)C/C=C\CCCC(=O)O.
This classification denotes a prostaglandin analogue C22H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVV9BU3089, chemically known as prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, methyl ester, (5z,9.alpha.,11.alpha.,13e,15s)-, but more generally known as carboprost methyl, which bears US NIH Compound Identifier 5283105. Most nations, for tariff and trade purposes, schedule carboprost methyl under HS 29375000 and SITC 54156. As of Q4 2014, CARBOPROST METHYL remains US FDA's Preferred Term for this commodity. SMILES: CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC)O)O)O.
This classification denotes a prostaglandin analogue with the molecular formula C22H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVV9BU3089, chemically known as prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, methyl ester, (5z,9.alpha.,11.alpha.,13e,15s)-, but more generally known as carboprost methyl ester, which bears US NIH Compound Identifier 6434195. European Medicines Agency schedules carboprost methyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06615MIG. Most nations, for tariff purposes, schedule carboprost methyl ester under HS 29375000. SMILES: CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC)O)O)O.
This classification denotes a prostaglandin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U4526F86FJ. European Medicines Agency schedules Carboprost trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01053MIG. Carboprost trometamol generally arises in the molecular formula C21H36O5.C4H11NO3. The term 'carboprost trometamol' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule carboprost trometamol under HS 29375000 and SITC 54156. SMILES: CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O.
This classification denotes a prostaglandin analogue with the molecular formula C21H36O5.C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U4526F86FJ, chemically known as prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5z,9.alpha.,11.alpha.,13e,15s)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), but more generally known as carboprost tromethamine, which bears US NIH Compound Identifier 5281074. European Medicines Agency schedules carboprost tromethamine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06615MIG. Most nations, for tariff purposes, schedule carboprost tromethamine under HS 29375000. As of Q4 2014, CARBOPROST TROMETHAMINE remains US FDA's Preferred Term for this commodity. Carboprost tromethamine bears US NLM identifiers UMLS ID C0054721 and NCI Concept Code C47433. SMILES: CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O.
This classification denotes an ethylenimine compound with the molecular formula C15H19N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1CB0HBT12C, chemically known as 2,5-cyclohexadiene-1,4-dione, 2,5-bis(1-aziridinyl)-6 (2-hydroxy-1-methoxyethyl)-3-methyl-, carbamate but more generally known as carboquone, which bears US NIH Compound Identifier 2569. European Medicines Agency schedules Carboquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06616MIG. The term CARBOQUONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules carboquone in its Anatomical Therapeutic Chemical (ATC) Classification. CARBOQUONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule carboquone under HS 29339990 and SITC 51577. As of Q4 2014, CARBOQUONE remains US FDA's Preferred Term for this commodity. Carboquone bears US NLM identifiers UMLS ID C0006971 and NCI Concept Code C342. SMILES: O(C(C1=C(N2CC2)C(=O)C(=C(N2CC2)C1=O)C)COC(=O)N)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a non-current chemotherapy regimen or association, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K679OBS311. European Medicines Agency schedules Carboxymethylcellulose sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01063MIG. Carboxymethylcellulose sodium generally arises in the molecular formula (C6H7O5(H)MOD(C2H2O2)MOD(NA)MOD)N. The term 'carboxymethylcellulose sodium' is a European Pharmacopoeia designation. As of Q4 2014, CARBOXYMETHYLCELLULOSE SODIUM remains the US FDA Preferred Term for this commodity. Carboxymethylcellulose sodium bears US NLM identifiers UMLS ID C0037487 and NCI Concept Code C83596. SMILES: [NA].OC(C(O)C(O)C=O)C(O)CO.OC(=O)C.
This classification denotes a sedative and hypnotic with the molecular formula C7H13BrN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Y299JY9V3, chemically known as urea, (2-bromo-ethylbutyryl)- but generally known as carbromal, which bears US NIH Compound Identifier 6488. European Medicines Agency schedules Carbromal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06617MIG. The term CARBROMAL is an International Non-Proprietary Name. World Health Organization schedules carbromal in its Anatomical Therapeutic Chemical (ATC) Classification. CARBROMAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbromal under HS 29241900 and SITC 51471. As of Q4 2014, CARBROMAL remains the US FDA Preferred Term for this commodity. Carbromal bears US NLM identifiers UMLS ID C0007077 and NCI Concept Code C76936. SMILES: BRC(CC)(CC)C(=O)NC(=O)N.
This classification denotes a sedative and hypnotic with the molecular formula C11H17N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SIW4YR11ST, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-((aminocarbonyl)oxy)ethyl)-5-butyl- (9ci) but generally known as carbubarb, which bears US NIH Compound Identifier 13743. European Medicines Agency schedules Carbubarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06618MIG. The term CARBUBARB is an International Non-Proprietary Name. CARBUBARB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbubarb under HS 29335400 and SITC kg. As of Q4 2014, CARBUBARB remains the US FDA Preferred Term for this commodity. Carbubarb bears US NLM identifiers UMLS ID C2698991 and NCI Concept Code C77245. SMILES: CCCCC1(C(=O)NC(=O)NC1=O)CCOC(=O)N.
This classification denotes an anti-diabetic agent with the molecular formula C11H17N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E3K8P4869P, chemically known as urea, 1-butyl-3-sulfanilyl- but more generally known as carbutamide, which bears US NIH Compound Identifier 9564. European Medicines Agency schedules Carbutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06620MIG. The term CARBUTAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17) WHO schedules carbutamide in its Anatomical Therapeutic Chemical (ATC) Classification. CARBUTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule carbutamide under HS 29350090 and SITC 51580. As of Q4 2014, CARBUTAMIDE remains US FDA's Preferred Term for this commodity. Carbutamide bears US NLM identifiers UMLS ID C0007080 and NCI Concept Code C83597. SMILES: CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)N.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0N12JR32MR. European Medicines Agency schedules Carbuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06621MIG. Carbuterol generally arises in the molecular formula C13H21N3O3. The term CARBUTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) CARBUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carbuterol under HS 29242190 and SITC 51473. As of Q4 2014, CARBUTEROL remains the US FDA Preferred Term for this commodity. Carbuterol bears US NLM identifiers UMLS ID C0054773 and NCI Concept Code C79709. SMILES: OC(CNC(C)(C)C)C1CC(NC(=O)N)C(O)CC1.
This classification denotes an anesthetic agent with the molecular formula C18H22N3O2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SM0DJQ1HBT, chemically known as n,n-dimethyl-2-oxo-n-(2-oxo-2-(phenylamino)ethyl)-2-(phenylamino)ethanaminium, chloride but generally known as carcainium chloride, which bears US NIH Compound Identifier 13966. European Medicines Agency schedules Carcainium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06622MIG. The term CARCAINIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). Most nations schedule carcainium chloride under HS 29242995 and SITC 51479. As of Q4 2014, CARCAINIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Carcainium chloride bears US NLM identifiers UMLS ID C0129907 and NCI Concept Code C81416. SMILES: C[N+](C)(CC(=O)NC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2.[Cl-].
This classification denotes solutions which, on administration, temporarily arrest cardiac activity, solutions typically used in heart surgery.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75DLN707DO, chemically known as benzeneacetic acid, 4-(4-(4-(diphenylmethoxy)-1-piperidinyl)-1-oxobutyl)-alpha,alpha-dimethyl- but generally known as carebastine, which bears US NIH Compound Identifier 65820. European Medicines Agency schedules Carebastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06623MIG. The term CAREBASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). CAREBASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carebastine under HS 29333999 and SITC 51574. As of Q4 2014, CAREBASTINE remains the US FDA Preferred Term for this commodity. Carebastine bears US NLM identifiers UMLS ID C0209013 and NCI Concept Code C77432. SMILES: O(C1CCN(CC1)CCCC(=O)C1CCC(C(C)(C)C(=O)O)CC1)C(C1CCCCC1)C1CCCCC1.
This classification denotes a urinary anti-infective agent and penicillin with the molecular formula C23H22N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9UU4XDB74X, chemically known as 6-((1,3-dioxo-3-phenoxy-2-phenylpropyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid (2s-(2alpha,5alpha,6beta))- but generally known as carfecillin, which bears US NIH Compound Identifier 33672. Carfecillin most often comes in base, phenyl, phenyl sodium, and sodium forms. European Medicines Agency schedules Carfecillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06624MIG. World Health Organization schedules carfecillin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule carfecillin under HS 29411090 and SITC 54131. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(C1CCCCC1)C(=O)OC1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C23H21N2O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18N5JP36GY, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((1,3-dioxo-3-phenoxy-2-phenylpropyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, (2s-(2alpha,5alpha,6beta))- but more generally known as carbenicillin phenyl sodium, which bears US NIH Compound Identifier 30728. The base compound, Carbenicillin, comes in many other forms, including base, disodium, indanyl, indanyl potassium, indanyl sodium, phenyl, phenyl ester, potassium, and sodium. European Medicines Agency schedules Carfecillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01058MIG. Most nations, for tariff and trade purposes, schedule carfecillin sodium under HS 29411090 and SITC 54131. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCCCC3)C(=O)OC4CCCCC4)C(=O)[O-])C.[NA+].
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C24H31N3O2S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0HX1Z0A2MC, chemically known as 1-propanone, 1-(10-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-, maleate (1:2) (salt) but more generally known as carfenazine maleate, which bears US NIH Compound Identifier 6433356. Carfenazine most often comes in base and maleate forms. European Medicines Agency schedules Carfenazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01059MIG. Most nations, for tariff and trade purposes, schedule carfenazine maleate under HS 29343090. SMILES: CCC(=O)C1CC2C(CC1)SC3C(CCCC3)N2CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CLY16Y8Z7E. European Medicines Agency schedules Carfenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06625MIG. Carfenazine generally arises in the molecular formula C24H31N3O2S. The term CARFENAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CARFENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Carfenazine or carphenazine bears US NLM identifiers UMLS ID C0771221 and NCI Concept Code C73285. SMILES: S1C2C(N(CCCN3CCN(CC3)CCO)C3C1CCCC3)CC(CC2)C(=O)CC.
This classification denotes an opioid receptor agonist with the molecular formula C24H30N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, LA9DTA2L8F chemically known as 4-piperidinecarboxylic acid, 4-((1-oxopropyl)phenylamino)-1-(2-phenylethyl)-, methyl ester but generally known as carfentanil, which bears US NIH Compound Identifier 62156. European Medicines Agency schedules Carfentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06626MIG. The term CARFENTANIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18). Most nations schedule carfentanil under HS 29333999 and SITC 51574. As of Q4 2014, CARFENTANIL remains the US FDA Preferred Term for this commodity. Carfentanil bears US NLM identifiers UMLS ID C0054797 and NCI Concept Code C80574. SMILES: CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CC=C3)C(=O)OC.
This classification denotes an opioid receptor agonist with the molecular formula C24H30N2O3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LG286J8GV, chemically known as 4-piperidinecarboxylic acid, 4-((1-oxopropyl)phenylamino)-1-(2-phenylethyl)-, methyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) but more generally known as carfentanil citrate, which bears US NIH Compound Identifier 65496. Most nations, for tariff and trade purposes, schedule carfentanil citrate under HS 29333999 and SITC 51574. As of Q4 2014, CARFENTANIL CITRATE remains US FDA's Preferred Term for this commodity. Carfentanil citrate bears US NLM identifiers UMLS ID C0108502 and NCI Concept Code C77280. SMILES: CCC(=O)N(C1CCCCC1)C2(CCN(CC2)CCC3CCCCC3)C(=O)OC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
A type of proteasome inhibitor
This classification denotes a sedative and hypnotic with the molecular formula C10H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9N1XKR2OS, chemically known as carbamic acid, 1-phenyl-2-propynyl ester but generally known as carfimate, which bears US NIH Compound Identifier 19111. European Medicines Agency schedules Carfimate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06627MIG. The term CARFIMATE is an International Non-Proprietary Name. CARFIMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carfimate under HS 29242995 and SITC 51479. As of Q4 2014, CARFIMATE remains the US FDA Preferred Term for this commodity. Carfimate bears US NLM identifiers UMLS ID C2698998 and NCI Concept Code C76095. SMILES: C#CC(C1=CC=CC=C1)OC(=O)N.
This classification denotes an agent affecting blood and body fluid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5L0HB4V1EW. European Medicines Agency schedules Carglumic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20051. Carglumic acid generally arises in the molecular formula C6H10N2O5. The term CARGLUMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.) Most nations schedule carglumic acid under HS 29241900 and SITC 51471. As of Q4 2014, CARGLUMIC ACID remains the US FDA Preferred Term for this commodity. Carglumic acid bears US NLM identifiers UMLS ID C1318649 and NCI Concept Code C76884. SMILES: C(CC(=O)O)C(C(=O)O)NC(=O)N.
This classification denotes an anti-bacterial agent with the molecular formula C26H26N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V278481KE, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((3-((2,3-dihydro-1h-inden-5-yl)oxy)-1,3-dioxo-2-phenylpropyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2-alpha,5-alpha,6-beta))- but generally known as carindacillin, which bears US NIH Compound Identifier 93184. carindacillin most often comes in base and sodium forms. European Medicines Agency schedules Carindacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06629MIG. World Health Organization schedules carindacillin in its Anatomical Therapeutic Chemical (ATC) Classification. CARINDACILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carindacillin under HS 29411090 and SITC 54131. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(C1CCCCC1)C(=O)OC1CC2CCCC2CC1.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C26H25N2O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4OUL81K2RT, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((3-((2,3-dihydro-1h-inden-5-yl)oxy)-1,3-dioxo-2-phenylpropyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, (2s-(2alpha,5alpha,6beta))- but more generally known as carbenicillin indanyl sodium, which bears US NIH Compound Identifier 33554. The base compound, Carbenicillin, comes in many other forms, including base, disodium, indanyl, indanyl potassium, phenyl, phenyl ester, phenyl sodium, potassium, and sodium. European Medicines Agency schedules Carindacillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01061MIG. Most nations, for tariff and trade purposes, schedule carindacillin sodium under HS 29411090 and SITC 54131. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCCCC3)C(=O)OC4CCC5C(C4)CCC5)C(=O)[O-])C.[NA+].
An atypical antipsychotic drug.
This classification denotes an anticonvulsant agent with the molecular formula C9H10CLNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7725I9V3Z. The term CARISBAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, no. 3, 2007, list 58. ). As of Q4 2014, CARISBAMATE remains the US FDA Preferred Term for this commodity. Carisbamate bears US NLM identifiers UMLS ID C1871983 and NCI Concept Code C75161. SMILES: C1=CC=C(C(=C1)C(COC(=O)N)O)CL. .
This classification denotes a muscle relaxant with the molecular formula C12H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21925K482H, chemically known as 1,3-propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate (ester) but generally known as carisoprodol, which bears US NIH Compound Identifier 2576. European Medicines Agency schedules Carisoprodol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06631MIG. The term CARISOPRODOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules carisoprodol in its Anatomical Therapeutic Chemical (ATC) Classification. CARISOPRODOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carisoprodol under HS 29241900 and SITC 51471. As of Q4 2014, CARISOPRODOL remains the US FDA Preferred Term for this commodity. Carisoprodol bears US NLM identifiers UMLS ID C0702216 and NCI Concept Code C28904. SMILES: O(CC(CCC)(COC(=O)N)C)C(=O)NC(C)C.
It increases the tear viscosity, such as the product retention time also increases.
Relieves anger, anxiety and nervousness . Due to its diverse benefits, Carmen Water is indicated for relieving nervous status, stress, insomnia, gastric disorders and nervous dyspepsia.
This classification denotes a pyrimidine antagonist with the molecular formula C11H16FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HA82M3RAB2, chemically known as 2,4-dioxo-5-fluoro-n-hexyl-3,4-dihydro-1(2h)-pyrimidinecarboxamidme but generally known as carmofur, which bears US NIH Compound Identifier 2577. European Medicines Agency schedules Carmofur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06130MIG. The term CARMOFUR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules carmofur in its Anatomical Therapeutic Chemical (ATC) Classification. CARMOFUR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carmofur under HS 29335995 and SITC 51576. As of Q4 2014, CARMOFUR remains the US FDA Preferred Term for this commodity. Carmofur bears US NLM identifiers UMLS ID C0044401 and NCI Concept Code C955. SMILES: CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F.
This classification denotes an antiasthmatic drug with the molecular formula C21H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9810NUL4D1, chemically known as 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one but generally known as carmoterol, which bears US NIH Compound Identifier 63952. European Medicines Agency schedules Aarmoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25400. The term CARMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53.). Most nations schedule carmoterol under HS 29337900 and SITC 51561. As of Q4 2014, CARMOTEROL remains the US FDA Preferred Term for this commodity. SMILES: CC(CC1=CC=C(C=C1)OC)NCC(C2=C3C=CC(=O)NC3=C(C=C2)O)O.
This classification denotes a nitrosourea compound and dna adduct forming agent with the molecular formula C5H9Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U68WG3173Y, chemically known as 1,3-bis(beta-chloroethyl)-1-nitrosourea but more generally known as carmustine, which bears US NIH Compound Identifier 2578. European Medicines Agency schedules Carmustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06132MIG. The term CARMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules carmustine in its Anatomical Therapeutic Chemical (ATC) Classification. CARMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule carmustine under HS 29241900 and SITC 51471. As of Q4 2014, CARMUSTINE remains US FDA's Preferred Term for this commodity. Carmustine bears US NLM identifiers UMLS ID C0007257 and NCI Concept Code C349. SMILES: CLCCN(N=O)C(=O)NCCCL.
This classification denotes an antiprotozoal agent with the molecular formula C8H12N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RH5KI819JG, chemically known as carbamothioic acid, (2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethyl)-, o-methyl ester but generally known as carnidazole, which bears US NIH Compound Identifier 3032998. European Medicines Agency schedules Carnidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06133MIG. The term CARNIDAZOLE is an International Non-Proprietary Name. CARNIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carnidazole under HS 29332990 and SITC 51573. As of Q4 2014, CARNIDAZOLE remains the US FDA Preferred Term for this commodity. Carnidazole bears US NLM identifiers UMLS ID C0054805 and NCI Concept Code C78095. SMILES: S=C(OC)NCCN1C(NCC1[N](=O)O)C.
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G389FZZ9M. European Medicines Agency schedules Carnitine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06134MIG. Carnitine generally arises in the molecular formula C7H15NO3. The term CARNITINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) CARNITINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carnitine under HS 29239000 and SITC 51481. As of Q4 2014, CARNITINE remains the US FDA Preferred Term for this commodity. Carnitine bears US NLM identifiers UMLS ID C0007258 and NCI Concept Code C82599. SMILES: OC(C[N](C)(C)C)CC(=O)O.
This classification denotes a nutritional supplement with the molecular formula C7H16NO3.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F64264D63N, chemically known as dl-(3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide inner salt hydrochloride, but more generally known as carnitine chloride, which bears US NIH Compound Identifier 5970. European Medicines Agency schedules carnitine chloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06134MIG. Most nations, for tariff purposes, schedule carnitine chloride under HS 29239000. SMILES: C[N+](C)(C)CC(CC(=O)O)O.[CL-].
This classification denotes an antidepressant agent with the molecular formula C10H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 807N226MNL chemically known as 2h-1,3-benzoxazine-3(4h)-acetamide, 2-oxo- but generally known as caroxazone, which bears US NIH Compound Identifier 29083. European Medicines Agency schedules Caroxazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06137MIG. The term CAROXAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13. ). Most nations schedule caroxazone under HS 29349990 and SITC 51579. As of Q4 2014, CAROXAZONE remains the US FDA Preferred Term for this commodity. Caroxazone bears US NLM identifiers UMLS ID C0054820 and NCI Concept Code C72725. SMILES: C1C2=CC=CC=C2OC(=O)N1CC(=O)N.
This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LZ6E4G9827. European Medicines Agency schedules Carperidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06138MIG. Carperidine generally arises in the molecular formula C17H24N2O3. The term CARPERIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CARPERIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carperidine under HS 29333999 and SITC 51574. As of Q4 2014, CARPERIDINE remains the US FDA Preferred Term for this commodity. Carperidine bears US NLM identifiers UMLS ID C2827105 and NCI Concept Code C83600. SMILES: O(C(=O)C1(CCN(CC1)CCC(=O)N)C1CCCCC1)CC.
This classification denotes an anxiolytic with the molecular formula C19H27FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3AP22Z9FJ, chemically known as carbamic acid, isopropyl-, 1-(3-(p-fluorobenzoyl)propyl)piperid-4-yl ester but generally known as carperone, which bears US NIH Compound Identifier 30429. European Medicines Agency schedules Carperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06140MIG. The term CARPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). CARPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carperone under HS 29333999 and SITC 51574. As of Q4 2014, CARPERONE remains the US FDA Preferred Term for this commodity. Carperone bears US NLM identifiers UMLS ID C0602043 and NCI Concept Code C73284. SMILES: FC1CCC(C(=O)CCCN2CCC(OC(=O)NC(C)C)CC2)CC1.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8F97XP38W. European Medicines Agency schedules Carpindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06141MIG. Carpindolol generally arises in the molecular formula C19H28N2O4. The term CARPINDOLOL is an International Non-Proprietary Name or INN. CARPINDOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carpindolol under HS 29339990 and SITC 51577. As of Q4 2014, CARPINDOLOL remains the US FDA Preferred Term for this commodity. Carpindolol bears US NLM identifiers UMLS ID C2699124 and NCI Concept Code C76020. SMILES: O(CC(O)CNC(C)(C)C)C1C2C([NH]C(C2)C(=O)OC(C)C)CCC1.
This classification denotes an antidepressant agent with the molecular formula C28H38N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8AFK6F91EQ, chemically known as 5h-dibenz(b,f)azepine, 10,11-dihydro-5-(3-(4-piperidino-4-carbamoylpiperidino)propyl)- but generally known as carpipramine, which bears US NIH Compound Identifier 2580. Carpipramine most often comes in base, dihydrochloride, hydrochloride, and maleate forms. European Medicines Agency schedules Carpipramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06142MIG. The term CARPIPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). CARPIPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carpipramine under HS 29333999 and SITC 51574. As of Q4 2014, CARPIPRAMINE remains the US FDA Preferred Term for this commodity. Carpipramine bears US NLM identifiers UMLS ID C0054826 and NCI Concept Code C81485. SMILES: O=C(N)C1(N2CCCCC2)CCN(CC1)CCCN1C2C(CCC3C1CCCC3)CCCC2.
This classification denotes an antipsychotic agent with the molecular formula C28H38N4O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53X71X3I1W, chemically known as 1-(3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)-(1,4-bipiperidine)-4-carboxamide dihydrochloride monohydrate but more generally known as carpipramine dihydrochloride, which bears US NIH Compound Identifier 23476. European Medicines Agency schedules Carpipramine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01067MIG. Most nations, for tariff and trade purposes, schedule carpipramine dihydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, CARPIPRAMINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Carpipramine dihydrochloride bears US NLM identifiers UMLS ID C0951571 and NCI Concept Code C80976. SMILES: C1CCC2C(C1)CCC3CCCCC3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5.O.CL.CL.
This classification denotes an antidepressant agent with the molecular formula C28H38N4O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53X71X3I1W, chemically known as 1'-(3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)-(1,4'-bipiperidine)-4'-carboxamide dihydrochloride monohydrate, but more generally known as carpipramine dihydrochloride monohydrate, which bears US NIH Compound Identifier 23476. European Medicines Agency schedules carpipramine dihydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06142MIG. Most nations, for tariff purposes, schedule carpipramine dihydrochloride monohydrate under HS 29333999. SMILES: C1CCC2C(C1)CCC3CCCCC3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5.O.CL.CL.
This classification denotes an antipsychotic agent with the molecular formula C28H38N4O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53X71X3I1W, chemically known as 1-(3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)-(1,4-bipiperidine)-4-carboxamide dihydrochloride monohydrate but more generally known as carpipramine dihydrochloride, which bears US NIH Compound Identifier 23476. European Medicines Agency schedules Carpipramine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01067MIG. Most nations, for tariff and trade purposes, schedule carpipramine hydrochloride under HS 29333999. SMILES: C1CCC2C(C1)CCC3CCCCC3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5.O.CL.CL.
This classification denotes an antidepressant agent C28H38N4O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PT5UOX7GI7, chemically known as (1,4'-bipiperidine)-4'-carboxamide, 1'-(3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)-, (2z)-2-butenedioate (1:1), but more generally known as carpipramine maleate, which bears US NIH Compound Identifier 5282174. Most nations, for tariff and trade purposes, schedule carpipramine maleate under HS 29333999 and SITC 51574. As of Q4 2014, CARPIPRAMINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)CCC3CCCCC3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5.C(=C\C(=O)O)\C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H12CLNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFL0D546HO. The term carpofen is a European Pharmacopoeia designation. SMILES: CC(C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)Cl)C(=O)O.
This classification denotes a vasodilating agent with the molecular formula C12H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O55EMK06L9, chemically known as methyl 5-(3,6-dihydro-1(2h)-pyridyl)-2-oxo-2h-(1,2,4)oxadiazolo(2,3-a)pyrimidine-7-carbamate but generally known as carprazidil, which bears US NIH Compound Identifier 68875. European Medicines Agency schedules Carprazidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06143MIG. The term CARPRAZIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). CARPRAZIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carprazidil under HS 29349990 and SITC 51579. As of Q4 2014, CARPRAZIDIL remains the US FDA Preferred Term for this commodity. Carprazidil bears US NLM identifiers UMLS ID C0108537 and NCI Concept Code C77148. SMILES: COC(=O)NC1=CC(=NC2=NC(=O)ON12)N3CCC=CC3.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H12ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFL0D546HO, chemically known as 9h-carbazole-2-acetic acid, 6-chloro-alpha-methyl- but generally known as carprofen, which bears US NIH Compound Identifier 2581. European Medicines Agency schedules Carprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06144MIG. The term CARPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). CARPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carprofen under HS 29339990 and SITC 51577. As of Q4 2014, CARPROFEN remains the US FDA Preferred Term for this commodity. Carprofen bears US NLM identifiers UMLS ID C0054827 and NCI Concept Code C65290. SMILES: CLC1CC2C3C([NH]C2CC1)CC(C(C)C(=O)O)CC3.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H12CLNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFL0D546HO. The term carpofen is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule carprofen for veterinary use under HS 29339990. SMILES: CC(C1CCC2C3CC(CCC3[NH]C2C1)CL)C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C8H5NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 685H843ULU, chemically known as 1,3-benzoxazine-2,4-dione but generally known as carsalam, which bears US NIH Compound Identifier 16258. European Medicines Agency schedules Carsalam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06146MIG. The term CARSALAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). CARSALAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carsalam under HS 29349990 and SITC 51579. As of Q4 2014, CARSALAM remains the US FDA Preferred Term for this commodity. Carsalam bears US NLM identifiers UMLS ID C0081927 and NCI Concept Code C77338. SMILES: O1C2C(C(=O)[NH]C1=O)CCCC2.
This classification denotes a cardiotonic agent with the molecular formula C25H26F2N6OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 2E3S34L69I chemically known as 1-piperazineethanol, 4-(bis(4-fluorophenyl)methyl)-.alpha.-((9h-purin-6-ylthio)methyl)-, (+/-)- but generally known as carsatrin, which bears US NIH Compound Identifier 72049. European Medicines Agency schedules Carsatrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06147MIG. The term CARSATRIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33). Most nations schedule carsatrin under HS 29335995 and SITC 51576. As of Q4 2014, CARSATRIN remains the US FDA Preferred Term for this commodity. Carsatrin bears US NLM identifiers UMLS ID C0211730 and NCI Concept Code C79875. SMILES: C1CN(CCN1CC(CSC2=NC=NC3=C2NC=N3)O)C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F.
This classification denotes a mucolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E3N11DY0TA. European Medicines Agency schedules Cartasteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06148MIG. Cartasteine generally arises in the molecular formula C9H14N2O4S2. The term CARTASTEINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 9, no. 3, 1995, list 35.) CARTASTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cartasteine under HS 29341000 and SITC 51579. As of Q4 2014, CARTASTEINE remains US FDA's Preferred Term for this commodity. Cartasteine bears US NLM identifiers UMLS ID C2699126 and NCI Concept Code C77597. SMILES: S1CC(N(C1)C(=O)CNC(=O)C(S)C)C(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NF31401XG, chemically known as 2(1h)-quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro- but generally known as carteolol, which bears US NIH Compound Identifier 2583. Carteolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Carteolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06150MIG. The term CARTEOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules carteolol in its Anatomical Therapeutic Chemical (ATC) Classification. CARTEOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carteolol under HS 29337900 and SITC 51561. As of Q4 2014, CARTEOLOL remains the US FDA Preferred Term for this commodity. Carteolol bears US NLM identifiers UMLS ID C0007299 and NCI Concept Code C65291. SMILES: O(CC(O)CNC(C)(C)C)C1C2CCC(=O)NC2CCC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H24N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4797W6I0T4, chemically known as 2(1h)-quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro- but more generally known as carteolol hydrochloride, which bears US NIH Compound Identifier 2583. European Medicines Agency schedules Carteolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13251MIG. Most nations, for tariff and trade purposes, schedule carteolol hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, CARTEOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Carteolol hydrochloride bears US NLM identifiers UMLS ID C0543450 and NCI Concept Code C28905. SMILES: CC(C)(C)NCC(COC1CCCC2C1CCC(=O)N2)O.CL.
This classification denotes an anthracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7437K3983. European Medicines Agency schedules Carubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06151MIG. Carubicin generally arises in the molecular formula C26H27NO10. The term CARUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) CARUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carubicin under HS 29419000 and SITC 54139. As of Q4 2014, CARUBICIN remains the US FDA Preferred Term for this commodity. Carubicin bears US NLM identifiers UMLS ID C0007308 and NCI Concept Code C352. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(O)CCC2)C(=O)C)C1OC(C(O)C(N)C1)C.
This classification denotes the hydrochloride form of an anthracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7437K3983. European Medicines Agency schedules Carubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06151MIG. Carubicin generally arises in the molecular formula C26H27NO10. The term CARUBICIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, no. 10 1979, list 19.) CARUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule carubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CARUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Carubicin hydrochloride bears US NLM identifiers UMLS ID C0282089 and NCI Concept Code C1582. SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3C2C(C4C(C3O)C(=O)C5CCCC(C5C4=O)O)O)(C(=O)C)O)N)O.CL.
This classification denotes a beta-lactam antibiotic with the molecular formula C12H14N6O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 486890PI06 chemically known as acetic acid, (((2-((2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethylidene)amino)oxy)-, (2s-(2.alpha.,3.alpha.(z)))- but generally known as carumonam, which bears US NIH Compound Identifier 9576417. European Medicines Agency schedules Carumonam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06152MIG. The term CARUMONAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24. ). Most nations schedule carumonam under HS 29419000 and SITC 54139. As of Q4 2014, CARUMONAM remains the US FDA Preferred Term for this commodity. Carumonam bears US NLM identifiers UMLS ID C0054835 and NCI Concept Code C79879. SMILES: C1=C(N=C(S1)N)C(=NOCC(=O)O)C(=O)NC2C(N(C2=O)S(=O)(=O)O)COC(=O)N.
This classification denotes a beta-lactam antibiotic with the molecular structure C12H12N6O10S2.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, B4J4M4939D chemically known as acetic acid, (((2-((2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethyliden)amino)oxy)-, disodium salt, (2s-(2.alpha.,3.alpha.(z)))-, but more commonly known as carumonam sodium, which bears US NIH Compound Identifier 9568618. European Medicines Agency schedules Carumonam sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01073MIG. Most nations, for tariff and trade purposes, schedule carumonam sodium under HS 29419000 and SITC 54139. As of Q4 2014, CARUMONAM SODIUM remains US FDA's Preferred Term for this commodity. Carumonam sodium bears US NLM identifiers UMLS ID C1612343 and NCI Concept Code C79905. SMILES: C1C(NC(S1)N)/C(=N/OCC(=O)[O-])/C(=O)N[C@H]2[C@H](N(C2=O)S(=O)(=O)[O-])COC(=O)N.[NA+].[NA+].
This classification denotes a pesticide with the molecular formula C10H14O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9B1J4V995Q, chemically known as phenol, 5-isopropyl-2-methyl- but generally known as carvacrol, which bears US NIH Compound Identifier 10364. Carvacrol most often comes in base, acetate, isobutyrate, and methyl ether forms. European Medicines Agency schedules Carvacrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29258. Carvacrol or cymophenol bears US NLM identifiers UMLS ID C0007309 and NCI Concept Code C83602. SMILES: CC1=C(C=C(C=C1)C(C)C)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C24H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0K47UL67F2, chemically known as 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)- but generally known as carvedilol, which bears US NIH Compound Identifier 2585. Carvedilol most often comes in base and phosphate forms. European Medicines Agency schedules Carvedilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06153MIG. The term CARVEDILOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules carvedilol in its Anatomical Therapeutic Chemical (ATC) Classification. CARVEDILOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carvedilol under HS 29339990 and SITC 51577. As of Q4 2014, CARVEDILOL remains the US FDA Preferred Term for this commodity. Carvedilol bears US NLM identifiers UMLS ID C0719509 and NCI Concept Code C28906. SMILES: O(C1C2C3C([NH]C2CCC1)CCCC3)CC(O)CNCCOC1C(OC)CCCC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C24H26N2O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9A00DJ8CM. Most nations, for tariff and trade purposes, schedule carvedilol hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, CARVEDILOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCCCC1OCCNCC(COC2CCCC3C2C4CCCCC4[NH]3)O.CL.
This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C24H26N2O4.H2O.2H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EQT531S367, chemically known as 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino) , phosphate (salt), hydrate (2:2:1), but more generally known as carvedilol phosphate, which bears US NIH Compound Identifier 11954344. European Medicines Agency schedules carvedilol phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06153MIG. Most nations, for tariff purposes, schedule carvedilol phosphate under HS 29339990. Carvedilol phosphate bears US NLM identifiers UMLS ID C1815010 and NCI Concept Code C65292. SMILES: COC1CCCCC1OCCNCC(COC2CCCC3C2C4CCCCC4[NH]3)O.COC1CCCCC1OCCNCC(COC2CCCC3C2C4CCCCC4[NH]3)O.O.OP(=O)(O)O.OP(=O)(O)O.
This classification denotes an antipsychotic agent with the molecular formula C18H18FN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q63WWP8G5, chemically known as 1h-pyrido(4,3-b)indole, 8-fluoro-2,3,4,5-tetrahydro-2-(2-(4-pyridinyl)ethyl)- but generally known as carvotroline, which bears US NIH Compound Identifier 72038. Carvotroline most often comes in base and hydrochloride forms. European Medicines Agency schedules Carvotroline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06154MIG. The term CARVOTROLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). CARVOTROLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carvotroline under HS 29333999 and SITC 51574. As of Q4 2014, CARVOTROLINE remains the US FDA Preferred Term for this commodity. Carvotroline bears US NLM identifiers UMLS ID C0668910 and NCI Concept Code C79946. SMILES: FC1CC2C3CN(CCC3[NH]C2CC1)CCC1CCNCC1.
This classification denotes an antipsychotic agent C18H18FN3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OGU53DND3M, chemically known as 1h-pyrido(4,3-b)indole, 8-fluoro-2,3,4,5-tetrahydro-2-(2-(4-pyridinyl)ethyl)-, monohydrochloride, but more generally known as carvotroline hydrochloride, which bears US NIH Compound Identifier 72037. Most nations, for tariff and trade purposes, schedule carvotroline hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, CARVOTROLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC2C(CC1F)C3C([NH]2)CCN(C3)CCC4CCNCC4.CL.
This classification denotes a laxative with the molecular formula C21H22O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3SJ3U7J6V2, chemically known as (10R)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2R,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-10H-anthracen-9-one but generally known as casanthranol, which bears US NIH Compound Identifier 51371307. European Medicines Agency schedules Casanthranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13254MIG. As of Q4 2014, CASANTHRANOL remains the US FDA Preferred Term for this commodity. Casanthranol bears US NLM identifiers UMLS ID C0205705 and NCI Concept Code C28907. SMILES: C1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(C=C3C2OC4C(C(C(C(O4)CO)O)O)O)CO)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a natural product which US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4VBP01X99F, a partial distillation from the source product, which US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier E9S376T0H5, the source of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 28582 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Rosales, Family Rhamnaceae, Genus Rhamnus L. (buckthorn), Species Rhamnus purshiana, more commonly known as CASCARA BUCKTHORN, PURSH'S BUCKTHORN, or as here, CARSCARA. Carscara (cascara) bears the USDA PLANTS Database Identifier FRPU7. European Medicines Agency schedules carscara in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB34042, SUB13255MIG, and SUB33908..
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3B03KPM27L. European Medicines Agency schedules Casopitant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32122. Casopitant generally arises in the molecular formula C30H35F7N4O2. The term CASOPITANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56.) Most nations schedule Casopitant under HS 29335990 and SITC 51576. As of Q4 2014, CASOPITANT remains the US FDA Preferred Term for this commodity. Casopitant bears US NLM identifiers UMLS ID C2347566 and NCI Concept Code C71635. SMILES: CC1CC(CCC1[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3CC(CC(C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C)F.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F0XDI6ZL63. European Medicines Agency schedules Caspofungin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16405MIG. Caspofungin generally arises in the molecular formula C52H88N10O15. The term CASPOFUNGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule caspofungin under HS 29419000 and SITC 54139. As of Q4 2014, CASPOFUNGIN remains the US FDA Preferred Term for this commodity. Caspofungin bears US NLM identifiers UMLS ID C0537894 and NCI Concept Code C28910. SMILES: OC1C2N(CC1)C(=O)C(NC(=O)C(NC(=O)C1N(CC(O)C1)C(=O)C(NC(=O)C(NC(=O)CCCCCCCCC(CC(CC)C)C)CC(O)C(NC2=O)NCCN)C(O)C)C(O)C(O)C1CCC(O)CC1)C(O)CCN.
This classification denotes an antifungal agent with the molecular formula C52H88N10O15.2C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VUW370O5QE, chemically known as pneumocandin b0, 1-((4r,5s)-5-((2-aminoethyl)amino)-n2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-l-ornithine)-5-((3r)-3-hydroxy-l-ornithine)-, diacetate (salt) but more generally known as caspofungin acetate, which bears US NIH Compound Identifier 123623. The base compound, Caspofungin, most often comes in base and acetate forms. European Medicines Agency schedules Caspofungin acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12476MIG. Most nations, for tariff and trade purposes, schedule caspofungin acetate under HS 29419000 and SITC 54139. As of Q4 2014, CASPOFUNGIN ACETATE remains US FDA's Preferred Term for this commodity. Caspofungin acetate bears US NLM identifiers UMLS ID C0935942 and NCI Concept Code C1724. SMILES: CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4CCC(CC4)O)O)O)[C@@H](CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O.
This classification denotes a natural product, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D5340Y2I9G. European Medicines Agency schedules Castor oil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13263MIG. Castor oil generally arises in the molecular formula C57H104O9. The term 'castor oil' is a United States Homeopathic Pharmacopoeia Name designation. As of Q4 2014, CASTOR OIL remains the US FDA Preferred Term for this commodity. Castor oil bears US NLM identifiers UMLS ID C0007343 and NCI Concept Code C80990. SMILES: NONE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes an alkaloid with the molecular formula C9H13NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IX73851J3P, chemically known as s,s-norpseudoephedrine hydrochloride but more generally known as cathine hydrochloride, which bears US NIH Compound Identifier 9065. European Medicines Agency schedules Cathine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01089MIG. Most nations, for tariff and trade purposes, schedule cathine hydrochloride under HS 29394300. As of Q4 2014, CATHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@H](C1CCCCC1)O)N.CL.
This classification denotes an alkaloid with the molecular formula C9H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E1L4ZW2F8O, chemically known as (r*,s*)-(1)-alpha-(1-aminoethyl)benzyl alcohol but more generally known as cathine, which bears US NIH Compound Identifier 26934. Cathine most often comes in base and hydrochloride forms. European Medicines Agency schedules Cathine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06158MIG. The term CATHINE is an International Non-Proprietary Name. World Health Organization schedules cathine in its Anatomical Therapeutic Chemical (ATC) Classification. CATHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cathine or norpseudoephedrine bears US NLM identifiers UMLS ID C0069021 and NCI Concept Code C79914. SMILES: CC(C(C1=CC=CC=C1)O)N.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Y51EV0DZW, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 32622 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Lamiales, Family Lamiaceae, Genus Nepeta L. (catnip), commonly known as CATNIP or CATNEP. Catnep bears the USDA PLANTS Database Identifier NEPET, and several varieties thereof also bear USDA PLANTS Database Identifiers NECA2 and NERA2. European Medicines Agency schedules catnip in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13267MIG. As of Q4 2014, CATNIP remains the US FDA Preferred Term for this commodity. SMILES: NONE.
This classification denotes an anti-bacterial agent with the molecular formula C13H13N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FDM21QQ344, chemically known as (6r,7r)-3-acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure but generally known as cefacetrile, which bears US NIH Compound Identifier 91562. Cefacetrile most often comes in base and sodium forms. European Medicines Agency schedules Cefacetrile in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06162MIG. World Health Organization schedules cefacetrile in its Anatomical Therapeutic Chemical (ATC) Classification. CEFACETRILE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cefacetrile or cephacetrile bears US NLM identifiers UMLS ID C0007714 and NCI Concept Code C81037. SMILES: CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)CC#N)SC1)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C13H12N3O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87TH1FJY1N, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-cyanoacetamido)-3-(hydroxymethyl)-8-oxo-, acetate (ester), monosodium salt but more generally known as cefacetrile sodium, which bears US NIH Compound Identifier 31725. European Medicines Agency schedules Cefacetrile sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01094MIG. Most nations, for tariff and trade purposes, schedule cefacetrile sodium under HS 29419000. SMILES: CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C15H14ClN3O4S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69K7K19H4L, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6r-(6-alpha,7-beta(r*)))- but generally known as cefaclor, which bears US NIH Compound Identifier 40958. Cefaclor most often comes in base, anhydrous, and hydrate forms. European Medicines Agency schedules Cefaclor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06163MIG. World Health Organization schedules cefaclor in its Anatomical Therapeutic Chemical (ATC) Classification. CEFACLOR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefaclor under HS 29419000 and SITC 54139. As of Q4 2014, CEFACLOR remains the US FDA Preferred Term for this commodity. Cefaclor bears US NLM identifiers UMLS ID C0007537 and NCI Concept Code C28911. SMILES: CLC1=C(N2C(SC1)C(NC(=O)C(N)C1CCCCC1)C2=O)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C15H14ClN3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Z6FS3IK0K, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2r)-2-amino-2-phenylacetyl)amino)-3-chloro-8-oxo-, (6r,7r)-, but more generally known as cefaclor anhydrous, which bears US NIH Compound Identifier 40958. European Medicines Agency schedules cefaclor anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06163MIG. Most nations, for tariff purposes, schedule cefaclor anhydrous under HS 29419000. Cefaclor anhydrous bears US NLM identifiers UMLS ID C2699131 and NCI Concept Code C76033. SMILES: C1CCC(CC1)[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CL)C(=O)O)N.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N3O5S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 280111G160, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6r-(6-alpha,7-beta(r*)))- but generally known as cefadroxil, which bears US NIH Compound Identifier 2610. Cefadroxil most often comes in base, hydrate, and hemihydrate forms. European Medicines Agency schedules Cefadroxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06164MIG. World Health Organization schedules cefadroxil in its Anatomical Therapeutic Chemical (ATC) Classification. CEFADROXIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefadroxil under HS 29419000 and SITC 54139. As of Q4 2014, CEFADROXIL remains the US FDA Preferred Term for this commodity. Cefadroxil bears US NLM identifiers UMLS ID C0007538 and NCI Concept Code C28912. SMILES: S1C2N(C(=O)C2NC(=O)C(N)C2CCC(O)CC2)C(=C(C1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula 2C16H17N3O5S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J9CMF6461M, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, monohydrate, (6r-(6alpha,7beta(r*)))- but more generally known as cefadroxil hemihydrate, which bears US NIH Compound Identifier 47964. Most nations, for tariff and trade purposes, schedule cefadroxil hemihydrate under HS 29419000 and SITC 54139. As of Q4 2014, CEFADROXIL HEMIHYDRATE remains US FDA's Preferred Term for this commodity. Cefadroxil hemihydrate bears US NLM identifiers UMLS ID C1707321 and NCI Concept Code C47965. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3CCC(CC3)O)N)SC1)C(=O)O.CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3CCC(CC3)O)N)SC1)C(=O)O.O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N3O5S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 280111G160, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6r-(6-alpha,7-beta(r*)))- but more generally known as cefadroxil, which bears US NIH Compound Identifier 2610. Cefadroxil most often comes in base, hydrate, and hemihydrate forms. European Medicines Agency schedules Cefadroxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06164MIG. World Health Organization schedules cefadroxil in its Anatomical Therapeutic Chemical (ATC) Classification. CEFADROXIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefadroxil monohydrate under HS 29419000 and SITC 54139. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3CCC(CC3)O)N)SC1)C(=O)O.O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N3O4S.CLH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6VJE5G3D98. European Medicines Agency schedules cefalexin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01097MIG. The term cefalexin hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cefalexin hydrochloride under HS 29419000. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)SC1)C(=O)O.O.CL.
This classification denotes a cephalosporin antibiotic with the molecular structure C16H17N3O4S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, OBN7UDS42Y chemically known as (6r,7r)-7-((r)-2-amino-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate, but more commonly known as cephalexin, which bears US NIH Compound Identifier 2666. European Medicines Agency schedules Cephalexin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06165MIG. Most nations, for tariff and trade purposes, schedule cefalexin monohydrate under HS 29419000. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)SC1)C(=O)O.O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OBN7UDS42Y. European Medicines Agency schedules Cefalexin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06165MIG. Cefalexin generally arises in the molecular formula C16H17N3O4S. The term CEFALEXIN is an International Non-Proprietary Name or INN. CEFALEXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cefalexin or cephalexin bears US NLM identifiers UMLS ID C0007716 and NCI Concept Code C356. SMILES: S1C2N(C(=O)C2NC(=O)C(N)C2CCCCC2)C(=C(C1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular structure C16H16N3O4S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, F78YJG0WXK chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2r)-2-amino-2-phenylacetyl)amino)-3-methyl-8-oxo-, sodium salt (1:1), (6r,7r)-, but more commonly known as cefalexin sodium, which bears US NIH Compound Identifier 27447. European Medicines Agency schedules Cefalexin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13273MIG. Most nations, for tariff and trade purposes, schedule cefalexin sodium under HS 29419000. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)SC1)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular structure C18H19N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, HD2D469W6U chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid, 3-((acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-, (6r-(6.alpha.,7.beta.(r*))) but generally known as cefaloglycin, which bears US NIH Compound Identifier 19150. European Medicines Agency schedules Cefaloglycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06166MIG. The term CEFALOGLYCIN is an International Non-Proprietary Name or INN. Cefaloglycin or cephaloglycin bears US NLM identifiers UMLS ID C0007721 and NCI Concept Code C65307. SMILES: S1C2N(C(=O)C2NC(=O)C(N)C2CCCCC2)C(=C(C1)COC(=O)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C18H18N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) K3086GQJ9Z, chemically known as (6r,7r)-3-(acetoxymethyl)-8-oxo-7-(2-phenylacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure but more generally known as cefaloram, which bears US NIH Compound Identifier 68940. European Medicines Agency schedules Cefaloram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06168MIG. The term CEFALORAM is an International Non-Proprietary Name. CEFALORAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefaloram under HS 29419000 and SITC 54139. As of Q4 2014, CEFALORAM remains US FDA's Preferred Term for this commodity. Cefaloram bears US NLM identifiers UMLS ID C0637533 and NCI Concept Code C76156. SMILES: S1C2N(C(=O)C2NC(=O)CC2CCCCC2)C(=C(C1)COC(=O)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LVZ1VC61HB, chemically known as pyridinium, 1-((2-carboxy-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6r-trans)- but generally known as cefaloridine, which bears US NIH Compound Identifier 5773. European Medicines Agency schedules Cefaloridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06169MIG. The term CEFALORIDINE is an International Non-Proprietary Name. World Health Organization schedules cefaloridine in its Anatomical Therapeutic Chemical (ATC) Classification. Cefaloridine or cephaloridine bears US NLM identifiers UMLS ID C0007727 and NCI Concept Code C76594. SMILES: S1C2N(C(=O)C2NC(=O)CC2SCCC2)C(=C(C1)C[N]1CCCCC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H16N2O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R72LW146E6, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester) but generally known as cefalotin, which bears US NIH Compound Identifier 6024. European Medicines Agency schedules Cefalotin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06170MIG. The term CEFALOTIN is an International Non-Proprietary Name. World Health Organization schedules cefalotin in its Anatomical Therapeutic Chemical (ATC) Classification. CEFALOTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cefalotin or cephalothin bears US NLM identifiers UMLS ID C0007735 and NCI Concept Code C62021. SMILES: CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C16H15N2O6S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C22G6EYP8B, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate, monosodium salt but more generally known as cefalotin sodium, which bears US NIH Compound Identifier 6023. European Medicines Agency schedules Cefalotin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01100MIG. Most nations, for tariff and trade purposes, schedule cefalotin sodium under HS 29419000. SMILES: CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3CCCS3)SC1)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C18H18N6O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5CKP8C2LLI, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7beta(r*)))- but generally known as cefamandole, which bears US NIH Compound Identifier 36831. European Medicines Agency schedules Cefamandole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07373MIG. The term CEFAMANDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules cefamandole in its Anatomical Therapeutic Chemical (ATC) Classification. CEFAMANDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefamandole under HS 29419000 and SITC 54139. As of Q4 2014, CEFAMANDOLE remains the US FDA Preferred Term for this commodity. Cefamandole bears US NLM identifiers UMLS ID C0007541 and NCI Concept Code C353. SMILES: S1C2N(C(=O)C2NC(=O)C(O)C2CCCCC2)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HDO7941DO. European Medicines Agency schedules Cefamandole nafate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01101MIG. Cefamandole nafate generally arises in the molecular formula C19H17N6NAO6S2. The term 'cefamandole nafate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cefamandole nafate under HS 29419000 and SITC 54139. As of Q4 2014, CEFAMANDOLE NAFATE remains US FDA's Preferred Term for this commodity. Cefamandole nafate bears US NLM identifiers UMLS ID C0054995 and NCI Concept Code C47966. SMILES: CN1C(NNN1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4CCCCC4)OC=O)SC2)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C18H17N6O5S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IY6234ODVR, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-mandelamido-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, monosodium salt, d- but more generally known as cefamandole sodium, which bears US NIH Compound Identifier 34779. European Medicines Agency schedules Cefamandole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35548. Most nations, for tariff and trade purposes, schedule cefamandole sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFAMANDOLE SODIUM remains US FDA's Preferred Term for this commodity. Cefamandole sodium bears US NLM identifiers UMLS ID C1707322 and NCI Concept Code C47967. SMILES: CN1C(NNN1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4CCCCC4)O)SC2)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89B59H32VN. European Medicines Agency schedules Cefapirin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07375MIG. Cefapirin generally arises in the molecular formula C17H17N3O6S2. The term 'cefapirin' is a Hazardous Substances Data Bank designation. CEFAPIRIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cefapirin or cephapirin bears US NLM identifiers UMLS ID C0007737 and NCI Concept Code C61670. SMILES: S1C2N(C(=O)C2NC(=O)CSC2CCNCC2)C(=C(C1)COC(=O)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C17H16N3O6S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 431LFF7I7J, chemically known as 5-thia-1-azabicyclo(4,2,0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester), monosodium salt but more generally known as cefapirin sodium, which bears US NIH Compound Identifier 32325. European Medicines Agency schedules Cefapirin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01103MIG. Most nations, for tariff and trade purposes, schedule cefapirin sodium under HS 29419000. SMILES: CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3CCNCC3)SC1)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C18H18N6O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8P4W949T8K, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-((1h-1,2,3-triazol-4-ylthio)methyl)-, (6r-(6alpha,7beta(r*)))- but generally known as cefatrizine, which bears US NIH Compound Identifier 40073. European Medicines Agency schedules Cefatrizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07376MIG. The term CEFATRIZINE is an International Non-Proprietary Name. World Health Organization schedules cefatrizine in its Anatomical Therapeutic Chemical (ATC) Classification. CEFATRIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefatrizine under HS 29419000 and SITC 54139. As of Q4 2014, CEFATRIZINE remains the US FDA Preferred Term for this commodity. Cefatrizine bears US NLM identifiers UMLS ID C0007545 and NCI Concept Code C81027. SMILES: S1C2N(C(=O)C2NC(=O)C(N)C2CCC(O)CC2)C(=C(C1)CSC1N[NH]NC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C18H18N6O5S2.C3H8O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3731IA5GI9, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2r)-2-amino-2-(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-((1h-1,2,3-triazol-5-ylthio)methyl)-, (6r,7r)-, compd. with 1,2-propanediol (1:1), but more generally known as cefatrizine compd with propylene glycol, which bears US NIH Compound Identifier 6410506. European Medicines Agency schedules cefatrizine compd with propylene glycol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07376MIG. Most nations, for tariff purposes, schedule cefatrizine compd with propylene glycol under HS 29419000. SMILES: CC(CO)O.C1CC(CCC1[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4CNN[NH]4)C(=O)O)N)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C18H18N6O5S2.C3H8O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3731IA5GI9, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2r)-2-amino-2-(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-((1h-1,2,3-triazol-5-ylthio)methyl)-, (6r,7r)-, compd. with 1,2-propanediol (1:1), but more generally known as cefatrizine propylene glycol, which bears US NIH Compound Identifier 6410757. European Medicines Agency schedules cefatrizine propylene glycol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07376MIG. Most nations, for tariff purposes, schedule cefatrizine propylene glycol under HS 29419000. SMILES: CC(CO)O.C1CC(CCC1[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4CNN[NH]4)C(=O)O)N)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C13H13F3N6O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 97I0692RNT chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-7-((((trifluoromethyl)thio)acetyl)amino)-, (6r-trans)- but generally known as cefazaflur, which bears US NIH Compound Identifier 40239. European Medicines Agency schedules Cefazaflur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07377MIG. The term CEFAZAFLUR is an International Non-Proprietary Name or INN. Most nations schedule cefazaflur under HS 29419000 and SITC 54139. As of Q4 2014, CEFAZAFLUR remains the US FDA Preferred Term for this commodity. Cefazaflur bears US NLM identifiers UMLS ID C0054998 and NCI Concept Code C79419. SMILES: CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)NC(=O)CSC(F)(F)F)SC2)C(=O)[O-].[NA+].
This classification denotes the sodium form of a cephalosporin antibiotic with the molecular structure C13H13F3N6O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 97I0692RNT chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-7-((((trifluoromethyl)thio)acetyl)amino)-, (6r-trans)-, but more commonly known as cefazaflur, which bears US NIH Compound Identifier 40239. European Medicines Agency schedules Cefazaflur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07377MIG. The term CEFAZAFLUR is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule cefazaflur sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFAZAFLUR SODIUM remains US FDA's Preferred Term for this commodity. Cefazaflur sodium bears US NLM identifiers UMLS ID C2825417 and NCI Concept Code C81028. SMILES: CN1C(NNN1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CSC(F)(F)F)SC2)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C18H15Cl2N5O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Y86X0D799, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((3,5-dichloro-4-oxo-1(4h)-pyridinyl)acetyl)amino)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-, (6r-trans)- but generally known as cefazedone, which bears US NIH Compound Identifier 71736. European Medicines Agency schedules Cefazedone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07378MIG. The term CEFAZEDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules cefazedone in its Anatomical Therapeutic Chemical (ATC) Classification. CEFAZEDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefazedone under HS 29419000 and SITC 54139. As of Q4 2014, CEFAZEDONE remains the US FDA Preferred Term for this commodity. Cefazedone bears US NLM identifiers UMLS ID C0054999 and NCI Concept Code C76157. SMILES: CLC1CN(CC(=O)NC2C3SCC(=C(N3C2=O)C(=O)O)CSC2SC(NN2)C)CC(CL)C1=O.
This classification denotes a cephalosporin antibiotic with the molecular formula C18H14CL2N5O5S3.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 658X66LF6Y. European Medicines Agency schedules cefazedone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01106MIG. The term cefazedone sodium is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cefazedone sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFAZEDONE SODIUM remains US FDA's Preferred Term for this commodity. Cefazedone sodium bears US NLM identifiers UMLS ID C0140149 and NCI Concept Code C98216. SMILES: CC1NNC(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4CC(C(=O)C(C4)CL)CL)SC2)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic C16H20N2.C14H14N8O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BJN67HUZ04, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-((1h-tetrazol-1-ylacetyl)amino)-, (6r-trans)-, compd. with n,n'-bis(phenylmethyl)-1,2-ethanediamine (2:1), but more generally known as cefazolin benzathine, which bears US NIH Compound Identifier 71300925. Most nations, for tariff and trade purposes, schedule cefazolin benzathine under HS 29419000 and SITC 54139. As of Q4 2014, CEFAZOLIN BENZATHINE remains US FDA's Preferred Term for this commodity. SMILES: CC1NNC(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4CNNN4)SC2)C(=O)O.C1CCC(CC1)CNCCNCC2CCCCC2.
This classification denotes a cephalosporin antibiotic with the molecular formula C14H14N8O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IHS69L0Y4T, chemically known as 7-(1-(1h-)-tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid but generally known as cefazolin, which bears US NIH Compound Identifier 33255. European Medicines Agency schedules Cefazolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07379MIG. The term CEFAZOLIN is an International Non-Proprietary Name. World Health Organization schedules cefazolin in its Anatomical Therapeutic Chemical (ATC) Classification. CEFAZOLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(=O)C2NC(=O)CN2NNNC2)C(=C(C1)CSC1SC(NN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P380M0454Z. European Medicines Agency schedules Cefazolin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01107MIG. Cefazolin sodium generally arises in the molecular formula C14H13N8NAO4S3. The term 'cefazolin sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cefazolin sodium under HS 29419000. As of Q4 2014, CEFAZOLIN SODIUM remains US FDA's Preferred Term for this commodity. Cefazolin sodium bears US NLM identifiers UMLS ID C0700526 and NCI Concept Code C47968. SMILES: CC1NNC(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4CNNN4)SC2)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C22H29N9O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T0785J3X40, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-(((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)-3-hydroxy-1-oxobutyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7alpha,7(2r*,3s*)))- but generally known as cefbuperazone, which bears US NIH Compound Identifier 53522. European Medicines Agency schedules Cefbuperazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07380MIG. The term CEFBUPERAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). CEFBUPERAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefbuperazone under HS 29419000 and SITC 54139. As of Q4 2014, CEFBUPERAZONE remains the US FDA Preferred Term for this commodity. Cefbuperazone bears US NLM identifiers UMLS ID C0055000 and NCI Concept Code C81029. SMILES: S1C2N(C(=O)C2(OC)NC(=O)C(NC(=O)N2CCN(C(=O)C2=O)CC)C(O)C)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular structure C22H28N9O9S2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1VX59V96BS chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-((2,3-dioxo-4-ethyl-1-piperazinyl)formamido)-3-hydroxybutyramido)-7-methoxy- 3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, monosodium salt, (6r-(6-alpha,7-alpha,7(2r*,3s*)))-, but more commonly known as cefbuperazone sodium, which bears US NIH Compound Identifier 127526. European Medicines Agency schedules Cefbuperazone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01109MIG. Most nations, for tariff and trade purposes, schedule cefbuperazone sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFBUPERAZONE SODIUM remains US FDA's Preferred Term for this commodity. Cefbuperazone sodium bears US NLM identifiers UMLS ID C0144299 and NCI Concept Code C98217. SMILES: CCN1CCN(C(=O)C1=O)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]2([C@@H]3N(C2=O)C(=C(CS3)CSC4NNNN4C)C(=O)[O-])OC.[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C19H18N4O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2F5V2R6VX8, chemically known as (6r,7r)-7-((r)-mandelamido)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid but generally known as cefcanel, which bears US NIH Compound Identifier 68666. European Medicines Agency schedules Cefcanel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07381MIG. The term CEFCANEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). CEFCANEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefcanel under HS 29419000 and SITC 54139. As of Q4 2014, CEFCANEL remains the US FDA Preferred Term for this commodity. Cefcanel bears US NLM identifiers UMLS ID C0055001 and NCI Concept Code C76158. SMILES: S1C2N(C(=O)C2NC(=O)C(O)C2CCCCC2)C(=C(C1)CSC1SC(NN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C17H19N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4D5D3422MW, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-(2-amino-4-thiazolyl)-1-oxo-2-pentenyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))- but generally known as cefcapene, which bears US NIH Compound Identifier 6436055. European Medicines Agency schedules Cefcapene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07383MIG. The term CEFCAPENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules cefcapene in its Anatomical Therapeutic Chemical (ATC) Classification. CEFCAPENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefcapene under HS 29419000 and SITC 54139. As of Q4 2014, CEFCAPENE remains the US FDA Preferred Term for this commodity. Cefcapene bears US NLM identifiers UMLS ID C2699134 and NCI Concept Code C76160. SMILES: S1C2N(C(=O)C2NC(=O)/C(=C\CC)C2NC(SC2)N)C(=C(C1)COC(=O)N)C(=O)O.
This classification denotes a cephalosporin antibiotic C23H29N5O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8I8MJ56XFQ, chemically known as 2,2-dimethylpropanoyloxymethyl (6r,7r)-7-(((z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl)amino)-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, but more generally known as cefcapene pivoxil, which bears US NIH Compound Identifier 5282438. European Medicines Agency schedules Cefcapene pivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01110MIG. Most nations, for tariff and trade purposes, schedule cefcapene pivoxil under HS 29419000 and SITC 54139. As of Q4 2014, CEFCAPENE PIVOXIL remains US FDA's Preferred Term for this commodity. Cefcapene pivoxil bears US NLM identifiers UMLS ID C0171230 and NCI Concept Code C98218. SMILES: CC/C=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)OCOC(=O)C(C)(C)C.
This classification denotes a cephalosporin antibiotic C23H29N5O8S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5J77167P9E, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-(2-amino-4-thiazolyl)-1-oxo-2- pentenyl)amino)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester,(6r- (6-.alpha.,7-.beta.(z)))-, monohydrochloride, but more generally known as cefcapene pivoxil hydrochloride, which bears US NIH Compound Identifier 6918126. European Medicines Agency schedules Cefcapene pivoxil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01111MIG. Most nations, for tariff and trade purposes, schedule cefcapene pivoxil hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFCAPENE PIVOXIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC/C=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)OCOC(=O)C(C)(C)C.CL.
This classification denotes a cephalosporin antibiotic with the molecular formula C14H15N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6856HDT30F, chemically known as (+)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(z)-oxime but generally known as cefdaloxime, which bears US NIH Compound Identifier 9571072. European Medicines Agency schedules Cefdaloxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07385MIG. The term CEFDALOXIME is an International Non-Proprietary Name. CEFDALOXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefdaloxime under HS 29419000 and SITC 54139. As of Q4 2014, CEFDALOXIME remains the US FDA Preferred Term for this commodity. Cefdaloxime bears US NLM identifiers UMLS ID C2699135 and NCI Concept Code C76161. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\O)C2NC(SC2)N)C(=C(C1)COC)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CI0FAO63WC. European Medicines Agency schedules Cefdinir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07386MIG. Cefdinir generally arises in the molecular formula C14H13N5O5S2. The term CEFDINIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) CEFDINIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefdinir under HS 29419000 and SITC 54139. As of Q4 2014, CEFDINIR remains the US FDA Preferred Term for this commodity. Cefdinir bears US NLM identifiers UMLS ID C0060405 and NCI Concept Code C28914. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/O)C2NC(SC2)N)C(=C(C1)C=C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H18N6O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81QS09V3YW, chemically known as cefditoren pivoxil, me-1207, meiact but generally known as cefditoren, which bears US NIH Compound Identifier 444006. European Medicines Agency schedules Cefditoren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07387MIG. The term CEFDITOREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules cefditoren in its Anatomical Therapeutic Chemical (ATC) Classification. CEFDITOREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefditoren under HS 29419000 and SITC 54139. As of Q4 2014, CEFDITOREN remains the US FDA Preferred Term for this commodity. Cefditoren bears US NLM identifiers UMLS ID C0287573 and NCI Concept Code C72625. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OC)C2NC(SC2)N)C(=C(C1)/C=C/C1SCNC1C)C(=O)OCOC(=O)C(C)(C)C.
This classification denotes a cephalosporin antibiotic with the molecular formula C25H28N6O7S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78THA212DH, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(((2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-((1z)-2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r,7r)-, but more generally known as cefditoren pivaloyloxymethyl ester, which bears US NIH Compound Identifier 444006. European Medicines Agency schedules cefditoren pivaloyloxymethyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07387MIG. Most nations, for tariff purposes, schedule cefditoren pivaloyloxymethyl ester under HS 29419000. SMILES: CC1C(SCN1)/C=C\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C.
This classification denotes a cephalosporin antibiotic with the molecular formula C25H28N6O7S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78THA212DH, chemically known as cefditoren pivoxil, me-1207, meiact but more generally known as cefditoren pivoxil, which bears US NIH Compound Identifier 444006. European Medicines Agency schedules Cefditoren pivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01112MIG. Most nations, for tariff and trade purposes, schedule cefditoren pivoxil under HS 29419000 and SITC 54139. As of Q4 2014, CEFDITOREN PIVOXIL remains US FDA's Preferred Term for this commodity. Cefditoren pivoxil bears US NLM identifiers UMLS ID C0245519 and NCI Concept Code C47434. SMILES: CC1C(SCN1)/C=C\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H16ClN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) O3TY87KJII, chemically known as (6r,7r)-7-((r)-2-amino-2-(3-chloro-4-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid. but more generally known as cefedrolor, which bears US NIH Compound Identifier 193953. European Medicines Agency schedules Cefedrolor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07388MIG. The term CEFEDROLOR is an International Non-Proprietary Name. CEFEDROLOR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefedrolor under HS 29419000 and SITC 54139. As of Q4 2014, CEFEDROLOR remains US FDA's Preferred Term for this commodity. Cefedrolor bears US NLM identifiers UMLS ID C2699136 and NCI Concept Code C76162. SMILES: CLC1CC(C(N)C(=O)NC2C3SCC(=C(N3C2=O)C(=O)O)C)CCC1O.
This classification denotes a cephalosporin antibiotic with the molecular formula C22H21N7O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3YUZ4494BQ, chemically known as 1-(((6r,7r)-7-(2-(2-amino-5-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azacicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt, 7,2-(e)-(o-(2-oxo-3-pyrrolidinyl)oxime). but more generally known as cefempidone, which bears US NIH Compound Identifier 9578269. European Medicines Agency schedules Cefempidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07389MIG. The term CEFEMPIDONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). CEFEMPIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefempidone under HS 29419000 and SITC 54139. As of Q4 2014, CEFEMPIDONE remains the US FDA Preferred Term for this commodity. Cefempidone bears US NLM identifiers UMLS ID C2699137 and NCI Concept Code C76163. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OC2CCNC2=O)C2SC(NC2)N)C(=C(C1)C[N]1CCCCC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H24N6O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 807PW4VQE3, chemically known as 1-(((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(z)-(o-methyloxime) but generally known as cefepime, which bears US NIH Compound Identifier 5479537. European Medicines Agency schedules Cefepime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07390MIG. The term CEFEPIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules cefepime in its Anatomical Therapeutic Chemical (ATC) Classification. CEFEPIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefepime under HS 29419000 and SITC 54139. As of Q4 2014, CEFEPIME remains the US FDA Preferred Term for this commodity. Cefepime bears US NLM identifiers UMLS ID C0055003 and NCI Concept Code C65294. SMILES: S1C2N(C(=C(C[N]3(CCCC3)C)C1)C(=O)O)C(=O)C2NC(=O)/C(=N\OC)C1NC(SC1)N.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H24N6O5S2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2A1O4F5N0C, chemically known as (6r,7r)-7-(((2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl)amino)-3-((1-methylpyrrolidin-1-ium-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid chloride hydrochloride, but more generally known as cefepime dihydrochloride, which bears US NIH Compound Identifier 9571075. European Medicines Agency schedules cefepime dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07390MIG. Most nations, for tariff purposes, schedule cefepime dihydrochloride under HS 29419000. SMILES: C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)[O-].CL.CL.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I8X1O0607P. European Medicines Agency schedules Cefepime dihydrochloride monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26333. Cefepime dihydrochloride monohydrate generally arises in the molecular formula C19H24N6O5S2.2CLH.H2O. The term 'cefepime dihydrochloride monohydrate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule cefepime dihydrochloride monohydrate under HS 29419000. SMILES: C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)[O-].O.CL.CL.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I8X1O0607P. European Medicines Agency schedules Cefepime dihydrochloride monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26333. Cefepime hydrochloride generally arises in the molecular formula C19H24N6O5S2.2CLH.H2O. The term 'cefepime hydrochloride' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule cefepime hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFEPIME HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cefepime hydrochloride bears US NLM identifiers UMLS ID C0771284 and NCI Concept Code C1041. SMILES: C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)[O-].O.CL.CL.
This classification denotes a cephalosporin antibiotic with the molecular formula C14H15N5O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4R5TV783X3, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-8-oxo-, (6r-(6alpha,7beta(z)))- but generally known as cefetamet, which bears US NIH Compound Identifier 5487888. European Medicines Agency schedules Cefetamet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07391MIG. The term CEFETAMET is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules cefetamet in its Anatomical Therapeutic Chemical (ATC) Classification. CEFETAMET is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefetamet under HS 29419000 and SITC 54139. As of Q4 2014, CEFETAMET remains the US FDA Preferred Term for this commodity. Cefetamet bears US NLM identifiers UMLS ID C0055004 and NCI Concept Code C76164. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=C(C1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C20H25N5O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6XA85N260, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r-(6.alpha.,7.beta.(z)))-, but more generally known as cefetamet pivaloyloxymethyl ester, which bears US NIH Compound Identifier 5485222. European Medicines Agency schedules cefetamet pivaloyloxymethyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07391MIG. Most nations, for tariff purposes, schedule cefetamet pivaloyloxymethyl ester under HS 29419000. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3CSC(N3)N)SC1)C(=O)OCOC(=O)C(C)(C)C.
This classification denotes a cephalosporin antibiotic C20H25N5O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6XA85N260, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r-(6.alpha.,7.beta.(z)))-, but more generally known as cefetamet pivoxil, which bears US NIH Compound Identifier 5486182. European Medicines Agency schedules Cefetamet pivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01114MIG. Most nations, for tariff and trade purposes, schedule cefetamet pivoxil under HS 29419000 and SITC 54139. As of Q4 2014, CEFETAMET PIVOXIL remains US FDA's Preferred Term for this commodity. Cefetamet pivoxil bears US NLM identifiers UMLS ID C0055005 and NCI Concept Code C98221. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3CSC(N3)N)SC1)C(=O)OCOC(=O)C(C)(C)C.
This classification denotes a cephalosporin antibiotic C20H25N5O7S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2YE9732GFU, chemically known as (6r,7r)-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester hydrochloride, but more generally known as cefetamet pivoxil hydrochloride, which bears US NIH Compound Identifier 5485221. European Medicines Agency schedules Cefetamet pivoxil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13274MIG. Most nations, for tariff and trade purposes, schedule cefetamet pivoxil hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFETAMET PIVOXIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cefetamet pivoxil hydrochloride bears US NLM identifiers UMLS ID C0140755 and NCI Concept Code C98222. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3CSC(N3)N)SC1)C(=O)OCOC(=O)C(C)(C)C.CL.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H15N5O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61K37E446T, chemically known as (6r,7r)-8-oxo-7-(2-(2-thienyl)acetamido)-3-((s-triazol-3-ylthio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylic acid. but generally known as cefetrizole, which bears US NIH Compound Identifier 193956. European Medicines Agency schedules Cefetrizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07393MIG. The term CEFETRIZOLE is an International Non-Proprietary Name. CEFETRIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefetrizole under HS 29419000 and SITC 54139. As of Q4 2014, CEFETRIZOLE remains the US FDA Preferred Term for this commodity. Cefetrizole bears US NLM identifiers UMLS ID C2699139 and NCI Concept Code C76166. SMILES: S1C2N(C(=O)C2NC(=O)CC2SCCC2)C(=C(C1)CSC1[NH]NCN1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C15H15N7O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 776E09GMHQ, chemically known as (6r,7r)-7-(2-(((z)-2-cyanovinyl)thio)acetamido)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid. but more generally known as cefivitril, which bears US NIH Compound Identifier 6443795. European Medicines Agency schedules Cefivitril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07394MIG. The term CEFIVITRIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). CEFIVITRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefivitril under HS 29419000 and SITC 54139. As of Q4 2014, CEFIVITRIL remains US FDA's Preferred Term for this commodity. Cefivitril bears US NLM identifiers UMLS ID C2699140 and NCI Concept Code C76167. SMILES: S1C2N(C(=O)C2NC(=O)CS/C=C\C#N)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97I1C92E55. European Medicines Agency schedules Cefixime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07395MIG. Cefixime generally arises in the molecular formula C16H15N5O7S2. The term CEFIXIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) CEFIXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefixime under HS 29419000 and SITC 54139. As of Q4 2014, CEFIXIME remains the US FDA Preferred Term for this commodity. Cefixime bears US NLM identifiers UMLS ID C0060400 and NCI Concept Code C1100. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OCC(=O)O)C2NC(SC2)N)C(=C(C1)C=C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H15N5O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XZ7BG04GJX, chemically known as (6r,7r)-7-((2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl)amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, but more generally known as cefixime anhydrous, which bears US NIH Compound Identifier 54362. European Medicines Agency schedules cefixime anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07395MIG. Most nations, for tariff purposes, schedule cefixime anhydrous under HS 29419000. SMILES: C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OCC(=O)O)/C3CSC(N3)N)SC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H15N5O7S2.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97I1C92E55, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, trihydrate, (6r-(6.alpha.,7.beta.(z)))-, but more generally known as cefixime trihydrate, which bears US NIH Compound Identifier 6321411. European Medicines Agency schedules cefixime trihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07395MIG. Most nations, for tariff purposes, schedule cefixime trihydrate under HS 29419000. SMILES: C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OCC(=O)O)/C3CSC(N3)N)SC1)C(=O)O.O.O.O.
This classification denotes a cephalosporin antibiotic with the molecular formula C20H25FN8O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 098633Q42P, chemically known as 2-propen-1-aminium, n-(2-amino-2-oxoethyl)-3-(7-(((5-amino-1,2,4-thiadiazol-3-yl)((fluoromethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)-n-ethyl-n-methyl-, inner salt, (6r-(3(e),6-alpha,7-beta(z)))- but generally known as cefluprenam, which bears US NIH Compound Identifier 6536774. European Medicines Agency schedules Cefluprenam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07396MIG. The term CEFLUPRENAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). CEFLUPRENAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefluprenam under HS 29419000 and SITC 54139. As of Q4 2014, CEFLUPRENAM remains the US FDA Preferred Term for this commodity. Cefluprenam bears US NLM identifiers UMLS ID C0652447 and NCI Concept Code C76034. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OCF)C2NC(SN2)N)C(=C(C1)/C=C/C[N](CC)(CC(=O)N)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C15H17ClN8O6S4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier PA4O9CKP1M, chemically known as (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-(2H-triazol-4-ylsulfanylmethylsulfanyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid but more generally known as cefmatilen, which bears U.S. National Institutes of Health Compound Identifier 9690121. The term CEFMATILEN is an International Non-Proprietary Name or INN. CEFMATILEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(CC1=C(N2C(OC1)C(OC)(NC(=O)CSC(F)F)C2=O)C(=O)O)C1N(NNN1)CCO.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KBZ4844CXN. European Medicines Agency schedules Cefmenoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07397MIG. Cefmenoxime generally arises in the molecular formula C16H17N9O5S3. The term CEFMENOXIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) CEFMENOXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefmenoxime under HS 29419000 and SITC 54139. As of Q4 2014, CEFMENOXIME remains the US FDA Preferred Term for this commodity. Cefmenoxime bears US NLM identifiers UMLS ID C0007549 and NCI Concept Code C65295. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OC)C2NC(SC2)N)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NON736D32W. European Medicines Agency schedules Cefmenoxime hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01117MIG. Cefmenoxime hydrochloride generally arises in the molecular formula 2C16H17N9O5S3.CLH. The term 'cefmenoxime hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cefmenoxime hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFMENOXIME HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cefmenoxime hydrochloride bears US NLM identifiers UMLS ID C0282390 and NCI Concept Code C65296. SMILES: CN1NNNC1SCC2=C(N3C(=O)[C@H]([C@H]3SC2)NC(=O)/C(=N\OC)/C4NC(SC4)N)C(=O)O.CN1NNNC1SCC2=C(N3C(=O)[C@H]([C@H]3SC2)NC(=O)/C(=N\OC)/C4NC(SC4)N)C(=O)O.CL.
This classification denotes a cephalosporin antibiotic with the molecular formula C23H25N6O8S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XLC35939WJ, chemically known as 4-((((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)thio)-1-methylpyridinium 72-(z)-(o-(1-carboxy-1-methylethyl)oxime) s-oxide. but generally known as cefmepidium, which bears US NIH Compound Identifier 9589472. European Medicines Agency schedules Cefmepidium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07398MIG. The term CEFMEPIDIUM is an International Non-Proprietary Name. As of Q4 2014, CEFMEPIDIUM remains the US FDA Preferred Term for this commodity. Cefmepidium bears US NLM identifiers UMLS ID C2827106 and NCI Concept Code C83603. SMILES: CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3=O)CSC4=CC=[N+](C=C4)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C23H25N6O8S3.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 726233N8L3, chemically known as 4-((((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)thio)-1-methylpyridinium chloride 7,2-(z)-(o-(1-carboxy-1-methylethyl)oxime) s-oxide. but more generally known as cefmepidium chloride, which bears US NIH Compound Identifier 9589472. European Medicines Agency schedules Cefmepidium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07398MIG. The term CEFMEPIDIUM CHLORIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule cefmepidium chloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFMEPIDIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Cefmepidium chloride bears US NLM identifiers UMLS ID C2825418 and NCI Concept Code C81030. SMILES: CC(C)(C(=O)O)O/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(C[S+]3[O-])CSC4CC[N+](CC4)C)C(=O)O.[CL-].
This classification denotes a cephalosporin antibiotic with the molecular formula C15H17N7O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J962UJT8H, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((cyanomethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-cis)- but generally known as cefmetazole, which bears US NIH Compound Identifier 42008. European Medicines Agency schedules Cefmetazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07399MIG. The term CEFMETAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules cefmetazole in its Anatomical Therapeutic Chemical (ATC) Classification. CEFMETAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefmetazole under HS 29419000 and SITC 54139. As of Q4 2014, CEFMETAZOLE remains the US FDA Preferred Term for this commodity. Cefmetazole bears US NLM identifiers UMLS ID C0007550 and NCI Concept Code C65297. SMILES: S1C2N(C(=O)C2(OC)NC(=O)CSCC#N)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C15H16N7O5S3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37Y9VR4W7A, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((cyanomethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-cis)- but more generally known as cefmetazole sodium, which bears US NIH Compound Identifier 42008. European Medicines Agency schedules Cefmetazole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01118MIG. Most nations, for tariff and trade purposes, schedule cefmetazole sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFMETAZOLE SODIUM remains US FDA's Preferred Term for this commodity. Cefmetazole sodium bears US NLM identifiers UMLS ID C0700470 and NCI Concept Code C65298. SMILES: CN1C(NNN1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C16H21N7O7S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PW08Y13465, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((2s)-2-amino-2-carboxyethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r,7s)- but generally known as cefminox, which bears US NIH Compound Identifier 71141. European Medicines Agency schedules Cefminox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07400MIG. The term CEFMINOX is an International Non-Proprietary Name. CEFMINOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefminox under HS 29419000 and SITC 54139. As of Q4 2014, CEFMINOX remains the US FDA Preferred Term for this commodity. Cefminox bears US NLM identifiers UMLS ID C0055006 and NCI Concept Code C76169. SMILES: S1C2N(C(=O)C2(OC)NC(=O)CSCC(N)C(=O)O)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes the sodium form of a cephalosporin antibiotic with the molecular formula C16H21N7O7S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PW08Y13465, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((2s)-2-amino-2-carboxyethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r,7s)- but more generally known as cefminox, which bears US NIH Compound Identifier 71141. European Medicines Agency schedules Cefminox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07400MIG. The term CEFMINOX is an International Non-Proprietary Name. CEFMINOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefminox sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFMINOX SODIUM remains US FDA's Preferred Term for this commodity. Cefminox sodium bears US NLM identifiers UMLS ID C1529767 and NCI Concept Code C98223. SMILES: CN1C(NNN1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSC[C@H](C(=O)O)N)OC)SC2)C(=O)[O-].[NA+].
This classification denotes a beta-lactam antibacterial with the molecular formula C20H20N6O7S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC1T51593A, chemically known as (6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(((5-(carboxymethyl)-4-methyl-2-thiazolyl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(z)-(o-methyloxime) but generally known as cefodizime, which bears US NIH Compound Identifier 5361871. Most nations schedule cefodizime under HS 29419000 and SITC 54139. As of Q4 2014, CEFODIZIME remains the US FDA Preferred Term for this commodity. Cefodizime bears US NLM identifiers UMLS ID C0055007 and NCI Concept Code C98224. SMILES: CC1=C(SC(=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O)CC(=O)O.
This classification denotes a beta-lactam antibacterial with the molecular formula C20H18N6O7S4.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC1T51593A, chemically known as (z)-7-(2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)-3-(5-carboxymethyl-4-methylthiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acid, disodium salt, but more generally known as cefodizime disodium, which bears US NIH Compound Identifier 6321412. European Medicines Agency schedules cefodizime disodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07401MIG. Most nations, for tariff purposes, schedule cefodizime disodium under HS 29419000. SMILES: CC1C(SC(N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)[O-])CC(=O)[O-].[NA+].[NA+].
This classification denotes a beta-lactam antibacterial with the molecular formula C20H18N6O7S4.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC1T51593A, chemically known as (z)-7-(2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)-3-(5-carboxymethyl-4-methylthiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acid, disodium salt, but more generally known as cefodizime sodium, which bears US NIH Compound Identifier 9576734. European Medicines Agency schedules cefodizime sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07401MIG. Most nations, for tariff purposes, schedule cefodizime sodium under HS 29419000. Cefodizime sodium bears US NLM identifiers UMLS ID C0122398 and NCI Concept Code C98225. SMILES: CC1C(SC(N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)[O-])CC(=O)[O-].[NA+].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C18H18N6O8S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6532B86WFG, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-8-oxo-3-(((1-sulfomethyl)-1h-tetrazol-5-yl)thio)methyl)-, (6r-(6-alpha,7-beta(r*)))- but generally known as cefonicid, which bears US NIH Compound Identifier 43592. European Medicines Agency schedules Cefonicid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12429MIG. The term CEFONICID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules cefonicid in its Anatomical Therapeutic Chemical (ATC) Classification. CEFONICID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefonicid under HS 29419000 and SITC 54139. As of Q4 2014, CEFONICID remains the US FDA Preferred Term for this commodity. Cefonicid bears US NLM identifiers UMLS ID C0007551 and NCI Concept Code C65299. SMILES: S1C2N(C(=O)C2NC(=O)C(O)C2CCCCC2)C(=C(C1)CSC1N(NNN1)CS(=O)(=O)O)C(=O)O.
This classification denotes a cephalosporin antibiotic C18H17N6O8S3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QD9G66C5UF, chemically known as (6r,7r)-7-((r)-mandelamido)-8-oxo-3-(((1-(sulfomethyl)-1h-tetrazol-5-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, s-sodium salt, but more generally known as cefonicid monosodium, which bears US NIH Compound Identifier 6336979. Most nations, for tariff and trade purposes, schedule cefonicid monosodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFONICID MONOSODIUM remains US FDA's Preferred Term for this commodity. Cefonicid monosodium bears US NLM identifiers UMLS ID CL386475 and NCI Concept Code C76170. SMILES: C1CCC(CC1)[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4NNNN4CS(=O)(=O)[O-])C(=O)O)O.[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C18H16N6O8S3.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F74MFL78A1, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-8-oxo-3-(((1-(sulfomethyl)-1h-tetrazol-5-yl)thio)methyl)disodium salt, (6r-(6alpha,7beta(r*))) but more generally known as cefonicid sodium, which bears US NIH Compound Identifier 43593. Most nations, for tariff and trade purposes, schedule cefonicid sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFONICID SODIUM remains US FDA's Preferred Term for this commodity. Cefonicid sodium bears US NLM identifiers UMLS ID C0886812 and NCI Concept Code C65300. SMILES: C1CCC(CC1)[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4NNNN4CS(=O)(=O)[O-])C(=O)[O-])O.[NA+].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C25H27N9O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U75I1278D, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6-alpha,7-beta(r*)))- but generally known as cefoperazone, which bears US NIH Compound Identifier 44185. European Medicines Agency schedules Cefoperazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07402MIG. The term CEFOPERAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules cefoperazone in its Anatomical Therapeutic Chemical (ATC) Classification. CEFOPERAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefoperazone under HS 29419000 and SITC 54139. As of Q4 2014, CEFOPERAZONE remains the US FDA Preferred Term for this commodity. Cefoperazone bears US NLM identifiers UMLS ID C0007552 and NCI Concept Code C61663. SMILES: S1C2N(C(=O)C2NC(=O)C(NC(=O)N2CCN(C(=O)C2=O)CC)C2CCC(O)CC2)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C25H26N9O8S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5FQG9774WD, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, monosodium salt, (6r-(6alpha,7beta(r*)))- but more generally known as cefoperazone sodium, which bears US NIH Compound Identifier 44186. European Medicines Agency schedules Cefoperazone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01122MIG. Most nations, for tariff and trade purposes, schedule cefoperazone sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFOPERAZONE SODIUM remains US FDA's Preferred Term for this commodity. Cefoperazone sodium bears US NLM identifiers UMLS ID C0733367 and NCI Concept Code C47435. SMILES: CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2CCC(CC2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5NNNN5C)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C20H21N7O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8M1YF8951V, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-trans)- but generally known as ceforanide, which bears US NIH Compound Identifier 43507. European Medicines Agency schedules Ceforanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07403MIG. The term CEFORANIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules ceforanide in its Anatomical Therapeutic Chemical (ATC) Classification. CEFORANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceforanide under HS 29419000 and SITC 54139. As of Q4 2014, CEFORANIDE remains the US FDA Preferred Term for this commodity. Ceforanide bears US NLM identifiers UMLS ID C0055008 and NCI Concept Code C47436. SMILES: S1C2N(C(=O)C2NC(=O)CC2C(CN)CCCC2)C(=C(C1)CSC1N(NNN1)CC(=O)O)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H22N8O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0B50MLU3H1, chemically known as (-)-5-amino-2-(((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-(2-hydroxyethyl)pyrazolium hydroxide, inner salt, 7,2-(z)-(o-methyloxime). but generally known as cefoselis, which bears US NIH Compound Identifier 9589475. European Medicines Agency schedules Cefoselis in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07404MIG. The term CEFOSELIS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). CEFOSELIS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefoselis under HS 29419000 and SITC 54139. As of Q4 2014, CEFOSELIS remains the US FDA Preferred Term for this commodity. Cefoselis bears US NLM identifiers UMLS ID C0965645 and NCI Concept Code C79420. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OC)C2NC(SC2)N)C(=C(C1)C[N]1N(C(N)CC1)CCO)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H22N8O6S2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6EY42207VS, chemically known as 5-amino-2-(((6r,7r)-7-(((z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl)-amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-(2-hydroxyethyl)-1h-pyrazolium hydroxide sulfate, but more generally known as cefoselis sulfate, which bears US NIH Compound Identifier 9690118. European Medicines Agency schedules cefoselis sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07404MIG. Most nations, for tariff purposes, schedule cefoselis sulfate under HS 29419000. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CN4CCC(=N)N4CCO)C(=O)O.OS(=O)(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N2GI8B1GK7. European Medicines Agency schedules Cefotaxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07405MIG. Cefotaxime generally arises in the molecular formula C16H17N5O7S2. The term CEFOTAXIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) CEFOTAXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefotaxime under HS 29419000 and SITC 54139. As of Q4 2014, CEFOTAXIME remains the US FDA Preferred Term for this commodity. Cefotaxime bears US NLM identifiers UMLS ID C0007554 and NCI Concept Code C354. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OC)C2NC(SC2)N)C(=C(C1)COC(=O)C)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 258J72S7TZ. European Medicines Agency schedules Cefotaxime sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13276MIG. Cefotaxime sodium generally arises in the molecular formula C16H16N5NAO7S2. The term 'cefotaxime sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cefotaxime sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFOTAXIME SODIUM remains US FDA's Preferred Term for this commodity. Cefotaxime sodium bears US NLM identifiers UMLS ID C0700445 and NCI Concept Code C2328. SMILES: CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3CSC(N3)N)SC1)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C17H17N7O8S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48SPP0PA9Q, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl)carbonyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7alpha))- but generally known as cefotetan, which bears US NIH Compound Identifier 50614. European Medicines Agency schedules Cefotetan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07406MIG. The term CEFOTETAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules cefotetan in its Anatomical Therapeutic Chemical (ATC) Classification. CEFOTETAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefotetan under HS 29419000 and SITC 54139. As of Q4 2014, CEFOTETAN remains the US FDA Preferred Term for this commodity. Cefotetan bears US NLM identifiers UMLS ID C0007555 and NCI Concept Code C61664. SMILES: S1C2N(C(=O)C2(OC)NC(=O)C2S/C(=C(/C(=O)N)C(=O)O)S2)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C17H15N7O8S4.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0GXP746VXB, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl)carbonyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, disodium salt, (6r-(6alpha,7alpha))- but more generally known as cefotetan disodium, which bears US NIH Compound Identifier 53024. European Medicines Agency schedules Cefotetan disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01124MIG. Most nations, for tariff and trade purposes, schedule cefotetan disodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFOTETAN DISODIUM remains US FDA's Preferred Term for this commodity. Cefotetan disodium bears US NLM identifiers UMLS ID C0007553 and NCI Concept Code C47437. SMILES: CN1C(NNN1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)[O-])S4)OC)SC2)C(=O)[O-].[NA+].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C17H15N7O8S4.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0GXP746VXB, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl)carbonyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, disodium salt, (6r-(6alpha,7alpha))- but more generally known as cefotetan disodium, which bears US NIH Compound Identifier 53024. European Medicines Agency schedules Cefotetan disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01124MIG. Most nations, for tariff and trade purposes, schedule cefotetan sodium under HS 29419000. SMILES: CN1C(NNN1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)[O-])S4)OC)SC2)C(=O)[O-].[NA+].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C18H23N9O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91W6Z2N718, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)acetyl)amino)-3-(((1-(2-(dimethylamino)ethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-trans)- but generally known as cefotiam, which bears US NIH Compound Identifier 43708. European Medicines Agency schedules Cefotiam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07407MIG. The term CEFOTIAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules cefotiam in its Anatomical Therapeutic Chemical (ATC) Classification. CEFOTIAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefotiam under HS 29419000 and SITC 54139. As of Q4 2014, CEFOTIAM remains the US FDA Preferred Term for this commodity. Cefotiam bears US NLM identifiers UMLS ID C0007556 and NCI Concept Code C65301. SMILES: S1C2N(C(=O)C2NC(=O)CC2NC(SC2)N)C(=C(C1)CSC1N(NNN1)CCN(C)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C18H23N9O4S3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H7V12WDZ93, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)acetyl)-amino)-3-(((1-(2-(dimethylamino)ethyl)-1h-tetrazol-5-yl)-thio)methyl)-8-oxo-, hydrochloride, (6r-trans)-, but more generally known as cefotiam dihydrochloride, which bears US NIH Compound Identifier 47896. Cefotiam dihydrochloride is the dihydrochloride salt of cefotiam. European Medicines Agency schedules cefotiam dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07407MIG. Most nations, for tariff purposes, schedule cefotiam dihydrochloride under HS 29419000. SMILES: CN(C)CCN1C(NNN1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4CSC(N4)N)SC2)C(=O)O.CL.CL.
This classification denotes a cephalosporin antibiotic C27H37N9O7S3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3N1X7E8CLE, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-(2-amino-4-thiazolyl)acetyl)amino)-3-(((1-(2-(dimethylamino)ethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, hydrochloride (1:2), (6r,7r)-, but more generally known as cefotiam hexetil hydrochloride, which bears US NIH Compound Identifier 175647. European Medicines Agency schedules Cefotiam hexetil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01125MIG. Most nations, for tariff and trade purposes, schedule cefotiam hexetil hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFOTIAM HEXETIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cefotiam hexetil hydrochloride bears US NLM identifiers UMLS ID C3273886 and NCI Concept Code C98226. SMILES: CC(OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)CC3CSC(N3)N)CSC4NNNN4CCN(C)C)OC(=O)OC5CCCCC5.CL.CL.
This classification denotes a cephalosporin antibiotic with the molecular formula C18H23N9O4S3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H7V12WDZ93, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)acetyl)amino)-3-(((1-(2-(dimethylamino)ethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-trans)- but more generally known as cefotiam hydrochloride, which bears US NIH Compound Identifier 43708. Cefotiam hydrochloride is the hydrochloride salt of cefotiam. European Medicines Agency schedules Cefotiam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01126MIG. Most nations, for tariff and trade purposes, schedule cefotiam hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFOTIAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cefotiam hydrochloride bears US NLM identifiers UMLS ID C0771454 and NCI Concept Code C65302. SMILES: CN(C)CCN1C(NNN1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4CSC(N4)N)SC2)C(=O)O.CL.CL.
This classification denotes a cephalosporin antibiotic with the molecular formula C17H19N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0D1OL46ZIE, che,ically known as (7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-8-oxo-3-[(2S)-tetrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid but generally known cefovecin, as which bears US NIH Compound Identifier 9578573. The term CEFOVECIN is an International Non-Proprietary Name. Most nations schedule cefovecin under HS 29419000 and SITC 54139. As of Q4 2014, CEFOVECIN remains the US FDA Preferred Term for this commodity. Cefovecin bears US NLM identifiers UMLS ID C1869686 and NCI Concept Code C76035. SMILES: CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C4CCCO4)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C17H18N5O6S2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DL8Q24959P. The term cefovecin sodium is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cefovecin sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFOVECIN SODIUM remains US FDA's Preferred Term for this commodity. Cefovecin sodium bears US NLM identifiers UMLS ID C2699141 and NCI Concept Code C76036. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)[C@@H]4CCCO4)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C21H18ClN3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) BN10X2TL6I, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetoxy)methyl)-7-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-8-oxo-, (6r-trans)- but more generally known as cefoxazole, which bears US NIH Compound Identifier 65798. European Medicines Agency schedules Cefoxazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07408MIG. The term CEFOXAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). CEFOXAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefoxazole under HS 29419000 and SITC 54139. As of Q4 2014, CEFOXAZOLE remains US FDA's Preferred Term for this commodity. Cefoxazole bears US NLM identifiers UMLS ID C0055084 and NCI Concept Code C76171. SMILES: CLC1C(C2NOC(C2C(=O)NC2C3SCC(=C(N3C2=O)C(=O)O)COC(=O)C)C)CCCC1.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N3O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6OEV9DX57Y, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6r-cis)- but generally known as cefoxitin, which bears US NIH Compound Identifier 37194. European Medicines Agency schedules Cefoxitin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07409MIG. The term CEFOXITIN is an International Non-Proprietary Name. World Health Organization schedules cefoxitin in its Anatomical Therapeutic Chemical (ATC) Classification. CEFOXITIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefoxitin under HS 29419000 and SITC 54139. As of Q4 2014, CEFOXITIN remains the US FDA Preferred Term for this commodity. Cefoxitin bears US NLM identifiers UMLS ID C0007557 and NCI Concept Code C61665. SMILES: S1C2N(C(=O)C2(OC)NC(=O)CC2SCCC2)C(=CC1COC(=O)N)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H16N3O7S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q68050H03T, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, sodium salt, (6r-cis)- but more generally known as cefoxitin sodium, which bears US NIH Compound Identifier 36551. European Medicines Agency schedules Cefoxitin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13277MIG. Most nations, for tariff and trade purposes, schedule cefoxitin sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFOXITIN SODIUM remains US FDA's Preferred Term for this commodity. Cefoxitin sodium bears US NLM identifiers UMLS ID C0701380 and NCI Concept Code C28915. SMILES: CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)CC3CCCS3.[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N9O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1LG87K28LW, chemically known as imidazo(1,2-b)pyridazinium, 1-((7-(((5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6r-(6alpha,7beta(z)))- but generally known as cefozopran, which bears US NIH Compound Identifier 9571080. European Medicines Agency schedules Cefozopran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07410MIG. The term CEFOZOPRAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules cefozopran in its Anatomical Therapeutic Chemical (ATC) Classification. CEFOZOPRAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefozopran under HS 29419000 and SITC 54139. As of Q4 2014, CEFOZOPRAN remains the US FDA Preferred Term for this commodity. Cefozopran bears US NLM identifiers UMLS ID C0246584 and NCI Concept Code C76172. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SN2)N)C(=C(C1)CN1C2[N](NCCC2)CC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N9O5S2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 060I5C0GRC. European Medicines Agency schedules cefozopran hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13278MIG. The term cefozopran hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cefozopran hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFOZOPRAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cefozopran hydrochloride bears US NLM identifiers UMLS ID C0141689 and NCI Concept Code C92168. SMILES: CO/N=C(/C1NC(SN1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4CCN5C4CCCN5)C(=O)[O-].CL.
This classification denotes a cephalosporin antibiotic with the molecular formula C28H26N6O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24S58UHU7N, chemically known as 1-(((6r,7r)-2-carboxy-7-((r)-2-(5-carboxyimidazole-4-carboxamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)pyridinium hydroxide, inner salt but generally known as cefpimizole, which bears US NIH Compound Identifier 68597. European Medicines Agency schedules Cefpimizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07411MIG. The term CEFPIMIZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). CEFPIMIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefpimizole under HS 29419000 and SITC 54139. As of Q4 2014, CEFPIMIZOLE remains the US FDA Preferred Term for this commodity. Cefpimizole bears US NLM identifiers UMLS ID C0055009 and NCI Concept Code C76173. SMILES: S1C2N(C(=O)C2NC(=O)C(NC(=O)C2NC[NH]C2C(=O)O)C2CCCCC2)C(=C(C1)C[N]1CCC(CC1)CCS(=O)(=O)O)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C28H24N6O10S2.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X4628IMC52, chemically known as 1-(((6r,7r)-2-carboxy-7-((r)-2-(5-carboxyimidazole-4-carboxamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)pyridinium hydroxide, inner salt, monosodium salt but more generally known as cefpimizole sodium, which bears US NIH Compound Identifier 55324. European Medicines Agency schedules Cefpimizole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01129MIG. Most nations, for tariff and trade purposes, schedule cefpimizole sodium under HS 29419000 and SITC 54139. Cefpimizole sodium bears US NLM identifiers UMLS ID C0050383 and NCI Concept Code C81031. SMILES: As of Q4 2014, CEFPIMIZOLE SODIUM remains US FDA's Preferred Term for this commodity.
This classification denotes a cephalosporin antibiotic with the molecular formula C25H24N8O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P936YA152N, chemically known as wy 44,635 but generally known as cefpiramide, which bears US NIH Compound Identifier 53130. European Medicines Agency schedules Cefpiramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07412MIG. The term CEFPIRAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules cefpiramide in its Anatomical Therapeutic Chemical (ATC) Classification. CEFPIRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefpiramide under HS 29419000 and SITC 54139. As of Q4 2014, CEFPIRAMIDE remains the US FDA Preferred Term for this commodity. Cefpiramide bears US NLM identifiers UMLS ID C0055010 and NCI Concept Code C65303. SMILES: S1C2N(C(=O)C2NC(=O)C(NC(=O)C2C(=O)CC([NH]C2)C)C2CCC(O)CC2)C(=C(C1)CSC1N(NNN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C25H23N8O7S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 137KB7GYKB, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-hydroxy-6-methyl-3-pyridinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, monosodium salt, (6r-(6alpha,7beta(r*)))- but more generally known as cefpiramide sodium, which bears US NIH Compound Identifier 53129. European Medicines Agency schedules Cefpiramide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01130MIG. Most nations, for tariff and trade purposes, schedule cefpiramide sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFPIRAMIDE SODIUM remains US FDA's Preferred Term for this commodity. Cefpiramide sodium bears US NLM identifiers UMLS ID C0955901 and NCI Concept Code C65304. SMILES: CC1CC(C(CN1)C(=O)N[C@H](C2CCC(CC2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5NNNN5C)C(=O)[O-])O.[NA+].
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S72Q2F09HY. European Medicines Agency schedules Cefpirome in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07413MIG. Cefpirome generally arises in the molecular formula C22H22N6O5S2. The term CEFPIROME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) CEFPIROME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefpirome under HS 29419000 and SITC 54139. As of Q4 2014, CEFPIROME remains the US FDA Preferred Term for this commodity. Cefpirome bears US NLM identifiers UMLS ID C0062986 and NCI Concept Code C79563. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=C(C1)C[N]1C2CCCC2CCC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C22H22N6O5S2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BA5ALU2ZT9, chemically known as 5h-1-pyrindinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-6,7-dihydro-, hydroxide, inner salt, (6r-(6alpha,7beta(z)))-, sulfate (1:1) but more generally known as cefpirome sulfate, which bears US NIH Compound Identifier 9570928. European Medicines Agency schedules Cefpirome sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01131MIG. Most nations, for tariff and trade purposes, schedule cefpirome sulfate under HS 29419000 and SITC 54139. As of Q4 2014, CEFPIROME SULFATE remains US FDA's Preferred Term for this commodity. Cefpirome sulfate bears US NLM identifiers UMLS ID C0771341 and NCI Concept Code C87463. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4CCCC5C4CCC5)C(=O)[O-].OS(=O)(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7R4F94TVGY. European Medicines Agency schedules Cefpodoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07414MIG. Cefpodoxime generally arises in the molecular formula C15H17N5O6S2. The term CEFPODOXIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) CEFPODOXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefpodoxime under HS 29419000 and SITC 54139. As of Q4 2014, CEFPODOXIME remains the US FDA Preferred Term for this commodity. Cefpodoxime bears US NLM identifiers UMLS ID C0055011 and NCI Concept Code C65305. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=C(C1)COC)C(=O)O.
This classification denotes a cephalosporin antibiotic C21H27N5O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2TB00A1Z7N, chemically known as (+/-)-1-hydroxyethyl (+)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7 (sup 2)-(z)-(o-methyloxime), isopropyl carbonate (ester), but more generally known as cefpodoxime proxetil, which bears US NIH Compound Identifier 6526396. European Medicines Agency schedules Cefpodoxime proxetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01132MIG. Most nations, for tariff and trade purposes, schedule cefpodoxime proxetil under HS 29419000 and SITC 54139. As of Q4 2014, CEFPODOXIME PROXETIL remains US FDA's Preferred Term for this commodity. Cefpodoxime proxetil bears US NLM identifiers UMLS ID C0108938 and NCI Concept Code C28916. SMILES: CC(C)OC(=O)OC(C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N\OC)/C3CSC(N3)N)COC.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W0459ZA4V. European Medicines Agency schedules Cefprozil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07415MIG. Cefprozil generally arises in the molecular formula C18H19N3O5S.H2O. The term CEFPROZIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) CEFPROZIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefprozil under HS 29419000 and SITC 54139. As of Q4 2014, CEFPROZIL remains the US FDA Preferred Term for this commodity. Cefprozil bears US NLM identifiers UMLS ID C0053882 and NCI Concept Code C28917. SMILES: CC=CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C18H19N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1M698F4H4E, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-(1-propenyl)-, (6r-(6.alpha.,7.beta.(r*)))-, but more generally known as cefprozil anhydrous, which bears US NIH Compound Identifier 5281006. European Medicines Agency schedules cefprozil anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07415MIG. Most nations, for tariff purposes, schedule cefprozil anhydrous under HS 29419000. SMILES:. Cefprozil anhydrous bears US NLM identifiers UMLS ID C2699143 and NCI Concept Code C79994.
This classification denotes a cephalosporin antibiotic with the molecular formula C23H24N6O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, Z74S078CWP chemically known as 1-(((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-5,6,7,8-tetrahydroquinolinium hydroxide, inner salt, 72-(z)-(o-methyloxime) but generally known as cefquinome, which bears US NIH Compound Identifier 9571084. European Medicines Agency schedules Cefquinome in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07416MIG. The term CEFQUINOME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29. ). Most nations schedule cefquinome under HS 29419000 and SITC 54139. As of Q4 2014, CEFQUINOME remains the US FDA Preferred Term for this commodity. Cefquinome bears US NLM identifiers UMLS ID C0108939 and NCI Concept Code C79564. SMILES: CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCCC5)C(=O)[O-].
This classification denotes a cephalosporin antibiotic with the molecular formula C23H24N6O5S2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3858K104DQ. The term cefquinome sulfate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cefquinome sulfate under HS 29419000 and SITC 54139. As of Q4 2014, CEFQUINOME SULFATE remains US FDA's Preferred Term for this commodity. Cefquinome sulfate bears US NLM identifiers UMLS ID C2825422 and NCI Concept Code C81032. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4CCCC5C4CCCC5)C(=O)[O-].OS(=O)(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F1BC02I72W. European Medicines Agency schedules Cefradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07417MIG. Cefradine generally arises in the molecular formula C16H19N3O4S. The term CEFRADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, no. 10 1972, list 12.) CEFRADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cefradine or cephradine bears US NLM identifiers UMLS ID C0007738 and NCI Concept Code C47441. SMILES: S1C2N(C(=O)C2NC(=O)C(N)C2=CCC=CC2)C(=C(C1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C20H22N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 44P98H0A27, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-methyl-8-oxo-7-(((4-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl)acetyl)amino)-, (6r,7r)- but more generally known as cefrotil, which bears US NIH Compound Identifier 68692. European Medicines Agency schedules Cefrotil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07418MIG. The term CEFROTIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). CEFROTIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefrotil under HS 29419000 and SITC 54139. As of Q4 2014, CEFROTIL remains US FDA's Preferred Term for this commodity. Cefrotil bears US NLM identifiers UMLS ID C2699148 and NCI Concept Code C76591. SMILES: S1C2N(C(=O)C2NC(=O)CC2CCC(C3=NCCCN3)CC2)C(=C(C1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H19N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B908C4MV2R, chemically known as 7-(d-2-amino-2-(1,4-cyclohexadienyl)acetamide)-3-methoxy-3-cephem-4-carboxylic acid but generally known as cefroxadine, which bears US NIH Compound Identifier 40117. European Medicines Agency schedules Cefroxadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07419MIG. The term CEFROXADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules cefroxadine in its Anatomical Therapeutic Chemical (ATC) Classification. CEFROXADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefroxadine under HS 29419000 and SITC 54139. As of Q4 2014, CEFROXADINE remains the US FDA Preferred Term for this commodity. Cefroxadine bears US NLM identifiers UMLS ID C0108941 and NCI Concept Code C81033. SMILES: S1C2N(C(=O)C2NC(=O)C(N)C2C=CCC=C2)C(=C(OC)C1)C(=O)O.
This classification denotes an anti-bacterial agent with the molecular formula C22H20N4O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OV42LHE42B, chemically known as 4-carbamoyl-1-(((6r,7r)-2-carboxy-8-oxo-7-((2r)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt, monosodium salt but generally known as cefsulodin, which bears US NIH Compound Identifier 40246. European Medicines Agency schedules Cefsulodin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07420MIG. World Health Organization schedules cefsulodin in its Anatomical Therapeutic Chemical (ATC) Classification. CEFSULODIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefsulodin under HS 29419000 and SITC 54139. As of Q4 2014, CEFSULODIN remains the US FDA Preferred Term for this commodity. Cefsulodin bears US NLM identifiers UMLS ID C0007558 and NCI Concept Code C98227. SMILES: S1C2N(C(=O)C2NC(=O)C(S(=O)(=O)O)C2CCCCC2)C(=C(C1)C[N]1CCC(CC1)C(=O)N)C(=O)O.[NA].
This classification denotes the sodium form of an anti-bacterial agent with the molecular formula C22H20N4O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OV42LHE42B, chemically known as 4-carbamoyl-1-(((6r,7r)-2-carboxy-8-oxo-7-((2r)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt, monosodium salt but more generally known as cefsulodin, which bears US NIH Compound Identifier 40246. European Medicines Agency schedules Cefsulodin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07420MIG. World Health Organization schedules cefsulodin in its Anatomical Therapeutic Chemical (ATC) Classification. CEFSULODIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefsulodin sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFSULODIN SODIUM remains US FDA's Preferred Term for this commodity. Cefsulodin sodium bears US NLM identifiers UMLS ID C0887647 and NCI Concept Code C98228. SMILES: C1CCC(CC1)[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4CCC(CC4)C(=O)N)C(=O)[O-])S(=O)(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C17H20N4O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3642W81J7A, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(3-((methylsulfonyl)amino)phenyl)acetyl)amino)-3-methyl-8-oxo-, (6r-(6alpha,7beta(r*)))- but more generally known as cefsumide, which bears US NIH Compound Identifier 68718. European Medicines Agency schedules Cefsumide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07421MIG. The term CEFSUMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). CEFSUMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefsumide under HS 29419000 and SITC 54139. As of Q4 2014, CEFSUMIDE remains US FDA's Preferred Term for this commodity. Cefsumide bears US NLM identifiers UMLS ID C0605109 and NCI Concept Code C76037. SMILES: S1C2N(C(=O)C2NC(=O)C(N)C2CC(NS(=O)(=O)C)CCC2)C(=C(C1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7P6FQA5D21. European Medicines Agency schedules Ceftaroline fosamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31648. Ceftaroline fosamil generally arises in the molecular formula C22H21N8O8PS4. The term CEFTAROLINE FOSAMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 1, 2008, list 59.) As of Q4 2014, CEFTAROLINE FOSAMIL remains the US FDA Preferred Term for this commodity. Ceftaroline fosamil bears US NLM identifiers UMLS ID C1873118 and NCI Concept Code C81034. SMILES: CCO/N=C(/C1=NSC(=N1)NP(=O)(O)O)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)O.CC(=O)[O-].O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9M416Z9QNR. European Medicines Agency schedules Ceftazidime pentahydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01134MIG. Ceftazidime generally arises in the molecular formula C22H22N6O7S2. The term CEFTAZIDIME is a European Pharmacopoeia designation. CEFTAZIDIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceftazidime under HS 29419000 and SITC 54139. As of Q4 2014, CEFTAZIDIME remains the US FDA Preferred Term for this commodity. Ceftazidime bears US NLM identifiers UMLS ID C0007559 and NCI Concept Code C66868. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OC(C)(C)C(=O)O)C2NC(SC2)N)C(=C(C1)C[N]1CCCCC1)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9M416Z9QNR. European Medicines Agency schedules Ceftazidime pentahydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01134MIG. Ceftazidime generally arises in the molecular formula C22H22N6O7S2. The term 'ceftazidime' is a European Pharmacopoeia designation. CEFTAZIDIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ceftazidime pentahydrate under HS 29419000 and SITC 54139. SMILES: [H+].CC(C)(C(=O)[O-])O/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4CCCCC4)C(=O)[O-].O.O.O.O.O.
This classification denotes a cephalosporin antibiotic with the molecular formula C22H21N6O7S2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CMC30V039K. The term ceftazidime sodium is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule ceftazidime sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFTAZIDIME SODIUM remains US FDA's Preferred Term for this commodity. Ceftazidime sodium bears US NLM identifiers UMLS ID C0700860 and NCI Concept Code C355. SMILES: CC(C)(C(=O)[O-])O/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4CCCCC4)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N9O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74CQ4Q3N63, chemically known as (+)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-((5-methyl-2h-tetrazol-2-yl)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(z)-(o-methyloxime) but generally known as cefteram, which bears US NIH Compound Identifier 6537431. European Medicines Agency schedules Cefteram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07423MIG. The term CEFTERAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). CEFTERAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefteram under HS 29419000 and SITC 54139. As of Q4 2014, CEFTERAM remains the US FDA Preferred Term for this commodity. Cefteram bears US NLM identifiers UMLS ID C0108946 and NCI Concept Code C81035. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=C(C1)CN1NC(NN1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C22H27N9O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0OD86RT58C, chemically known as pivaloyloxymethyl (z)-7-(2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)-3-(5-methyl-2h-tetrazol-2-ylmethyl)-3-cephem-4-carboxylate, but more generally known as cefteram pivaloyloxymethyl ester, which bears US NIH Compound Identifier 6917871. European Medicines Agency schedules cefteram pivaloyloxymethyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07423MIG. Most nations, for tariff purposes, schedule cefteram pivaloyloxymethyl ester under HS 29419000. SMILES: CC1NNN(N1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C.
This classification denotes a cephalosporin antibiotic C22H27N9O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0OD86RT58C, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl)amino)-3-((5-methyl-2h-tetrazol-2-yl)methyl)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r,7r)-, but more generally known as cefteram pivoxil, which bears US NIH Compound Identifier 54885. European Medicines Agency schedules Cefteram pivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01135MIG. Most nations, for tariff and trade purposes, schedule cefteram pivoxil under HS 29419000 and SITC 54139. As of Q4 2014, CEFTERAM PIVOXIL remains US FDA's Preferred Term for this commodity. Cefteram pivoxil bears US NLM identifiers UMLS ID C0108947 and NCI Concept Code C98230. SMILES: CC1NNN(N1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C.
This classification denotes a cephalosporin antibiotic with the molecular formula C13H12N8O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z86SYP11W, chemically known as (6r,7r)-8-oxo-7-(2-(1h-tetrazol-1-yl)acetamido)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid but generally known as ceftezole, which bears US NIH Compound Identifier 65755. European Medicines Agency schedules Ceftezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07424MIG. The term CEFTEZOLE is an International Non-Proprietary Name. World Health Organization schedules ceftezole in its Anatomical Therapeutic Chemical (ATC) Classification. CEFTEZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceftezole under HS 29419000 and SITC 54139. As of Q4 2014, CEFTEZOLE remains the US FDA Preferred Term for this commodity. Ceftezole bears US NLM identifiers UMLS ID C0055013 and NCI Concept Code C76038. SMILES: S1C2N(C(=O)C2NC(=O)CN2NNNC2)C(=C(C1)CSC1SCNN1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C13H11N8O4S3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3NHZ4Y117H, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 8-oxo-7-((1h-tetrazol-1-ylacetyl)amino)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-, monosodium salt, (6r-trans)- but more generally known as ceftezole sodium, which bears US NIH Compound Identifier 170470. European Medicines Agency schedules Ceftezole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01136MIG. Most nations, for tariff and trade purposes, schedule ceftezole sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFTEZOLE SODIUM remains US FDA's Preferred Term for this commodity. Ceftezole sodium bears US NLM identifiers UMLS ID C0970035 and NCI Concept Code C98231. SMILES: C1NNNN1CC(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4NNCS4)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IW71N46B4Y. European Medicines Agency schedules Ceftibuten in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07425MIG. Ceftibuten generally arises in the molecular formula C15H14N4O6S2. The term CEFTIBUTEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) CEFTIBUTEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceftibuten under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIBUTEN remains the US FDA Preferred Term for this commodity. Ceftibuten bears US NLM identifiers UMLS ID C0055014 and NCI Concept Code C61666. SMILES: S1C2N(C(=O)C2NC(=O)/C(=C\CC(=O)O)C2NC(SC2)N)C(=CC1)C(=O)O.
This classification denotes a cephalosporin antibiotic C15H14N4O6S2.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62F4443RWP, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl)amino)-8-oxo-, dihydrate, (6r-(6.alpha.,7.beta.(z)))-, but more generally known as ceftibuten dihydrate, which bears US NIH Compound Identifier 5282241. European Medicines Agency schedules Ceftibuten dihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35311. Most nations, for tariff and trade purposes, schedule ceftibuten dihydrate under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIBUTEN DIHYDRATE remains US FDA's Preferred Term for this commodity. Ceftibuten dihydrate bears US NLM identifiers UMLS ID C0591239 and NCI Concept Code C61667. SMILES: C1C(NC(S1)N)/C(=C/CC(=O)O)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O.O.O.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N5O7S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83JL932I1C, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((2-furanylcarbonyl)thio)methyl)-8-oxo, monohydrochloride, (6r,7r) but generally known as ceftiofur, which bears US NIH Compound Identifier 6328657. European Medicines Agency schedules Ceftiofur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07426MIG. The term CEFTIOFUR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). CEFTIOFUR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceftiofur under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIOFUR remains the US FDA Preferred Term for this commodity. Ceftiofur bears US NLM identifiers UMLS ID C0081959 and NCI Concept Code C81036. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=C(C1)CSC(=O)C1OCCC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N5O7S3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6822A07436, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((2-furanylcarbonyl)thio)methyl)-8-oxo, monohydrochloride, (6r,7r) but more generally known as ceftiofur hydrochloride, which bears US NIH Compound Identifier 6328657. Most nations, for tariff and trade purposes, schedule ceftiofur hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIOFUR HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ceftiofur hydrochloride bears US NLM identifiers UMLS ID C0521899 and NCI Concept Code C76174. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4CCCO4)C(=O)O.CL.
This classification denotes a cephalosporin antibiotic with the molecular formula C19H16N5O7S3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NHI34IS56E, chemically known as sodium (6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(mercaptomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 72-(z)-(o-methyloxime), 2-furoate (ester), but more generally known as ceftiofur sodium, which bears US NIH Compound Identifier 9571073. European Medicines Agency schedules ceftiofur sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07426MIG. Most nations, for tariff purposes, schedule ceftiofur sodium under HS 29419000. Ceftiofur sodium bears US NLM identifiers UMLS ID C0108950 and NCI Concept Code C77190. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4CCCO4)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C20H18N8O8S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28TV2P33KF, chemically known as (6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-((e)-2-((4-(formylmethyl)-1,4,5,6-tetrahydro-5,6-dioxo-as-triazin-3-yl)thio)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(z)-(o-methyloxime) but generally known as ceftiolene, which bears US NIH Compound Identifier 6537430. European Medicines Agency schedules Ceftiolene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07427MIG. The term CEFTIOLENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). CEFTIOLENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceftiolene under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIOLENE remains the US FDA Preferred Term for this commodity. Ceftiolene bears US NLM identifiers UMLS ID C2699149 and NCI Concept Code C76175. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=C(C1)/C=C/SC1N(CC=O)C(=O)C(=O)[NH]N1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N5O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Z9DV0V6TG, chemically known as (5s,6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-2-ene-carboxylic acid 7,2-(z)-(o-methyloxime), acetate (ester), 5-oxide but generally known as ceftioxide, which bears US NIH Compound Identifier 9589416. European Medicines Agency schedules Ceftioxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07428MIG. The term CEFTIOXIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). CEFTIOXIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceftioxide under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIOXIDE remains the US FDA Preferred Term for this commodity. Ceftioxide bears US NLM identifiers UMLS ID C2699150 and NCI Concept Code C76176. SMILES: S1(=O)C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=C(C1)COC(=O)C)C(=O)O.
This classification denotes an anti-bacterial agent with the molecular formula C13H13N5O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C43C467DPE, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))- but generally known as ceftizoxime, which bears US NIH Compound Identifier 6533629. European Medicines Agency schedules Ceftizoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07429MIG. The term CEFTIZOXIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules ceftizoxime in its Anatomical Therapeutic Chemical (ATC) Classification. CEFTIZOXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceftizoxime under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIZOXIME remains the US FDA Preferred Term for this commodity. Ceftizoxime bears US NLM identifiers UMLS ID C0007560 and NCI Concept Code C61668. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=CC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C22H28N6O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3MM3320LJN, chemically known as ( )-(pivaloyloxy)methyl (6r,7r)-7-(2-(2-(l-alanylamino)thiazol-4-yl)glyoxylamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate 7,2-(z)-(o)-methyloxime). but more generally known as ceftizoxime alapivoxil, which bears US NIH Compound Identifier 9578661. European Medicines Agency schedules Ceftizoxime alapivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07430MIG. The term CEFTIZOXIME ALAPIVOXIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 No. 1 1998, List 39). Most nations, for tariff and trade purposes, schedule ceftizoxime alapivoxil under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIZOXIME ALAPIVOXIL remains US FDA's Preferred Term for this commodity. Ceftizoxime alapivoxil bears US NLM identifiers UMLS ID C0908922 and NCI Concept Code C90828. SMILES: C[C@@H](C(=O)NC1NC(CS1)/C(=N/OC)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)OCOC(=O)C(C)(C)C)N.
This classification denotes a cephalosporin antibiotic with the molecular formula C13H12N5O5S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26337D5X88, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)-(methoxyimino)acetyl)amino)-8-oxo-, monosodium salt, (6r-(6-alpha,7-beta(z)))- but more generally known as ceftizoxime sodium, which bears US NIH Compound Identifier 9570777. European Medicines Agency schedules Ceftizoxime sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01137MIG. Most nations, for tariff and trade purposes, schedule ceftizoxime sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFTIZOXIME SODIUM remains US FDA's Preferred Term for this commodity. Ceftizoxime sodium bears US NLM identifiers UMLS ID C0282391 and NCI Concept Code C47438. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T97333YZK. European Medicines Agency schedules Ceftobiprole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25723. Ceftobiprole generally arises in the molecular formula C20H22N8O6S2. The term CEFTOBIPROLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations schedule ceftobiprole under HS 29419000 and SITC 54139. As of Q4 2014, CEFTOBIPROLE remains the US FDA Preferred Term for this commodity. Ceftobiprole bears US NLM identifiers UMLS ID C1100584 and NCI Concept Code C65306. SMILES: S1C2N(C(=O)C2NC(=O)C(=C2\[NH]SC(N2)N)\N=O)C(=C(C1)/C=C1\CCN(C2CCNC2)C1=O)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N99027V28J. European Medicines Agency schedules Ceftobiprole medocaril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25721. Ceftobiprole medocaril generally arises in the molecular formula C26H25N8O11S2.NA. The term CEFTOBIPROLE MEDOCARIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations, for tariff and trade purposes, schedule ceftobiprole medocaril under HS 29419000 and SITC 54139. As of Q4 2014, CEFTOBIPROLE MEDOCARIL remains US FDA's Preferred Term for this commodity. Ceftobiprole medocaril bears US NLM identifiers UMLS ID C1622308 and NCI Concept Code C70597. SMILES: CC1C(OC(=O)O1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\O)/C6NC(SN6)N)SC4)C(=O)[O-])/C3=O.[NA+].
Ceftolozane/tazobactam is a combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults. Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75J73V1629. European Medicines Agency schedules Ceftriaxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07431MIG. Ceftriaxone generally arises in the molecular formula C18H18N8O7S3. The term CEFTRIAXONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) CEFTRIAXONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ceftriaxone under HS 29419000 and SITC 54139. As of Q4 2014, CEFTRIAXONE remains the US FDA Preferred Term for this commodity. Ceftriaxone bears US NLM identifiers UMLS ID C0007561 and NCI Concept Code C62020. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OC)C2NC(SC2)N)C(=C(C1)CSC1N([NH]C(=O)C(=O)N1)C)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula 2C18H16N8O7S3.4Na.7H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 023Z5BR09K, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, disodium salt, (6r-(6alpha,7beta(z)))- but more generally known as ceftriaxone sodium, which bears US NIH Compound Identifier 9570832. European Medicines Agency schedules Ceftriaxone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01138MIG. Most nations, for tariff and trade purposes, schedule ceftriaxone sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFTRIAXONE SODIUM remains US FDA's Preferred Term for this commodity. Ceftriaxone sodium bears US NLM identifiers UMLS ID C0035750 and NCI Concept Code C817. SMILES: CN1[N-]C(=O)C(=O)NC1SCC2=C(N3C(=O)[C@H]([C@H]3SC2)NC(=O)/C(=N\OC)/C4NC(SC4)N)C(=O)[O-].CN1[N-]C(=O)C(=O)NC1SCC2=C(N3C(=O)[C@H]([C@H]3SC2)NC(=O)/C(=N\OC)/C4NC(SC4)N)C(=O)[O-].O.O.O.O.O.O.O.[NA+].[NA+].[NA+].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C17H17N3O8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F69EA18270, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((2-furanyl(methylimino)acetyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))- but more generally known as cefuracetime, which bears US NIH Compound Identifier 9571078. European Medicines Agency schedules Cefuracetime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07432MIG. The term CEFURACETIME is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). CEFURACETIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cefuracetime under HS 29419000 and SITC 54139. As of Q4 2014, CEFURACETIME remains US FDA's Preferred Term for this commodity. Cefuracetime bears US NLM identifiers UMLS ID C2699151 and NCI Concept Code C76177. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2OCCC2)C(=C(C1)COC(=O)C)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O1R9FJ93ED. European Medicines Agency schedules Cefuroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07433MIG. Cefuroxime generally arises in the molecular formula C16H16N4O8S. The term CEFUROXIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) CEFUROXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefuroxime under HS 29419000 and SITC 54139. As of Q4 2014, CEFUROXIME remains the US FDA Preferred Term for this commodity. Cefuroxime bears US NLM identifiers UMLS ID C0007562 and NCI Concept Code C61669. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N/OC)C2OCCC2)C(=C(C1)COC(=O)N)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z49QDT0J8Z. European Medicines Agency schedules Cefuroxime axetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01139MIG. Cefuroxime axetil generally arises in the molecular formula C20H22N4O10S. The term 'cefuroxime axetil' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cefuroxime axetil under HS 29419000 and SITC 54139. As of Q4 2014, CEFUROXIME AXETIL remains US FDA's Preferred Term for this commodity. Cefuroxime axetil bears US NLM identifiers UMLS ID C0055015 and NCI Concept Code C28918. SMILES: CC(OC(=O)C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N\OC)/C3CCCO3)COC(=O)N.
This classification denotes a cephalosporin antibiotic C23H28N4O11S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LR90117565, chemically known as 1-hydroxyethyl (6r,7r)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7^2-(z)-(o-methyloxime), 3-carbamate 1-(2-methoxy-2-methylpropionate), but more generally known as cefuroxime pivoxetil, which bears US NIH Compound Identifier 9595289. Most nations, for tariff and trade purposes, schedule cefuroxime pivoxetil under HS 29419000 and SITC 54139. As of Q4 2014, CEFUROXIME PIVOXETIL remains US FDA's Preferred Term for this commodity. Cefuroxime pivoxetil bears US NLM identifiers UMLS ID C2699152 and NCI Concept Code C76178. SMILES: CC(OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N\OC)/C3CCCO3)COC(=O)N)OC(=O)C(C)(C)OC.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8A7M9MY61. European Medicines Agency schedules Cefuroxime sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01140MIG. Cefuroxime sodium generally arises in the molecular formula C16H15N4NAO8S. The term 'cefuroxime sodium' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule cefuroxime sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFUROXIME SODIUM remains US FDA's Preferred Term for this commodity. Cefuroxime sodium bears US NLM identifiers UMLS ID C0701852 and NCI Concept Code C47439. SMILES: CO/N=C(/C1CCCO1)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)[O-].[NA+].
This classification denotes a cephalosporin antibiotic with the molecular formula C16H15N7O5S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 860MT00T7T, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-((1,2,3-thiadiazol-5-ylthio)methyl)-, (6r-(6alpha,7beta(z)))- but generally known as cefuzonam, which bears US NIH Compound Identifier 6336505. European Medicines Agency schedules Cefuzonam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07434MIG. The term CEFUZONAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). CEFUZONAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cefuzonam under HS 29419000 and SITC 54139. As of Q4 2014, CEFUZONAM remains the US FDA Preferred Term for this commodity. Cefuzonam bears US NLM identifiers UMLS ID C0055017 and NCI Concept Code C76179. SMILES: S1C2N(C(=O)C2NC(=O)/C(=N\OC)C2NC(SC2)N)C(=C(C1)CSC1SNNC1)C(=O)O.
This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SOU25L22C. European Medicines Agency schedules Cefuzonam sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01141MIG. Cefuzonam sodium generally arises in the molecular formula C16H14N7O5S4.NA. The term 'cefuzonam sodium' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule cefuzonam sodium under HS 29419000 and SITC 54139. As of Q4 2014, CEFUZONAM SODIUM remains US FDA's Preferred Term for this commodity. Cefuzonam sodium bears US NLM identifiers UMLS ID C0124795 and NCI Concept Code C98232. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4CNNS4)C(=O)[O-].[NA+].
This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H14F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JCX84Q7J1L, chemically known as benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)- but generally known as celecoxib, which bears US NIH Compound Identifier 2662. European Medicines Agency schedules Celecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01143MIG. The term CELECOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules celecoxib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule celecoxib under HS 29350090 and SITC 51580. As of Q4 2014, CELECOXIB remains the US FDA Preferred Term for this commodity. Celecoxib bears US NLM identifiers UMLS ID C0538927 and NCI Concept Code C1728. SMILES: S(=O)(=O)(N)C1CCC(N2NC(CC2C2CCC(CC2)C)C(F)(F)F)CC1.
This classification denotes a glucosidase inhibitor and antiviral agent with the molecular formula C12H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 895VG117HN, chemically known as mdl 28,574a but generally known as celgosivir, which bears US NIH Compound Identifier 60734. European Medicines Agency schedules Celgosivir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07435MIG. The term CELGOSIVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). CELGOSIVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Celgosivir under HS 29339990 and SITC 51577. As of Q4 2014, CELGOSIVIR remains the US FDA Preferred Term for this commodity. Celgosivir bears US NLM identifiers UMLS ID C0287304 and NCI Concept Code C79567. SMILES: CCCC(=O)O[C@H]1CN2CC[C@@H]([C@@H]2[C@H]([C@@H]1O)O)O.
This classification denotes an enzyme inhibitor with the molecular formula C12H21NO5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70U2NQU0FP, chemically known as castanospermine, 6-o-butyrate hydrochloride but more generally known as celgosivir hydrochloride, which bears US NIH Compound Identifier 3033824. Most nations, for tariff and trade purposes, schedule celgosivir hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, CELGOSIVIR HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Celgosivir hydrochloride bears US NLM identifiers UMLS ID C2828312 and NCI Concept Code C87464. SMILES: CCCC(=O)O[C@H]1CN2CC[C@@H]([C@@H]2[C@H]([C@@H]1O)O)O.CL.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H33N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DRB57K47QC, chemically known as urea, n-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-n,n-diethyl- but generally known as celiprolol, which bears US NIH Compound Identifier 2663. European Medicines Agency schedules Celiprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07436MIG. The term CELIPROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules celiprolol in its Anatomical Therapeutic Chemical (ATC) Classification. CELIPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule celiprolol under HS 29242190 and SITC 51473. As of Q4 2014, CELIPROLOL remains the US FDA Preferred Term for this commodity. Celiprolol bears US NLM identifiers UMLS ID C0055021 and NCI Concept Code C79558. SMILES: O(CC(O)CNC(C)(C)C)c1c(cc(NC(=O)N(CC)CC)cc1)C(=O)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H33N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1M3398594, chemically known as 3-(3-acetyl-4-(3-((tert-butyl)amino)-2-hydroxypropoxy)phenyl)-1,1-diethyluronium chloride but more generally known as celiprolol hydrochloride, which bears US NIH Compound Identifier 42373. European Medicines Agency schedules Celiprolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01146MIG. Most nations, for tariff and trade purposes, schedule celiprolol hydrochloride under HS 29242190 and SITC 51473. As of Q4 2014, CELIPROLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Celiprolol hydrochloride bears US NLM identifiers UMLS ID C0700475 and NCI Concept Code C81655. SMILES: CCN(CC)C(=O)NC1CCC(C(C1)C(=O)C)OCC(CNC(C)(C)C)O.CL.
This classification denotes a cation exchange resins and column chromatography, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E6S1NJ4Y5Q. European Medicines Agency schedules Sodium cellulose phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15280MIG. Cellulose sodium phosphate generally arises in the molecular formula (C6H7O5)N.NA.O3P.H. The term 'cellulose sodium phosphate' is a United States Adopted Name designation. As of Q4 2014, CELLULOSE SODIUM PHOSPHATE remains the US FDA Preferred Term for this commodity. SMILES: NONE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a vinca-site binding agent with the molecular formula C35H56N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SQ8M7ZSFV, chemically known as l-prolinamide, n,n-dimethyl-l-valyl-l-valyl-n-methyl-l-valyl-l-prolyl-n-(phenylmethyl)- but generally known as cemadotin, which bears US NIH Compound Identifier 178028. European Medicines Agency schedules Cemadotin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07438MIG. The term CEMADOTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). CEMADOTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cemadotin under HS 29339990 and SITC 51577. As of Q4 2014, CEMADOTIN remains the US FDA Preferred Term for this commodity. Cemadotin bears US NLM identifiers UMLS ID C0754175 and NCI Concept Code C75875. SMILES: O=C(N(C(=O)C1N(CCC1)CC1CCCCC1)C(=O)C(NC(=O)C(N(C)C)C(C)C)C(C)C)C1N(CCC1)C(=O)C(NC)C(C)C.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7M867G6T1U, although the US FDA Substance Registration System (SRS) identifies several varieties and preparations under UNIIs J02K2IV2PB, 8MXU1P42J0, and 6810070TYD, the source product of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29612 Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Apiaceae, Genus Centella L., Species Centella asiatica, more commonly known as SPADELEAF or as here, CENTELLA ASIATICA. Centella asiatica bears the USDA PLANTS Database Identifiers CEAS and CEER2. European Medicines Agency schedules centella asiatica in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13285MIG, SUB13286MIG, SUB34889, SUB44727, SUB44728, SUB44729, and SUB44730. SMILES: NONE.
This classification denotes a neuroprotective agent and nootropic agent with the molecular formula C12H16ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C76QQ2I0RG, chemically known as acetic acid, (p-chlorophenoxy)-, 2-(dimethylamino)ethyl ester, hydrochloride but generally known as meclofenoxate, which bears US NIH Compound Identifier 4039. European Medicines Agency schedules Meclofenoxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08679MIG. World Health Organization schedules meclofenoxate in its Anatomical Therapeutic Chemical (ATC) Classification. MECLOFENOXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CN(C)CCOC(=O)COC1=CC=C(C=C1)CL.
This classification denotes a serotonin agonist with the molecular formula C12H17Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VES82D23IB, chemically known as 2-(3,4-dichlorobenzyl)-2-dimethylamino-1-propanol but generally known as cericlamine, which bears US NIH Compound Identifier 131073. European Medicines Agency schedules Cericlamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07439MIG. The term CERICLAMINE is an International Non-Proprietary Name. CERICLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cericlamine under HS 29221980 and SITC 51461. As of Q4 2014, CERICLAMINE remains the US FDA Preferred Term for this commodity. Cericlamine bears US NLM identifiers UMLS ID C0286710 and NCI Concept Code C76100. SMILES: CC(CC1=CC(=C(C=C1)Cl)Cl)(CO)N(C)C.Cl.
A kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C26H34FNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AM91H2KS67, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))- but generally known as cerivastatin, which bears US NIH Compound Identifier 446156. European Medicines Agency schedules Cerivastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07440MIG. The term CERIVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules cerivastatin in its Anatomical Therapeutic Chemical (ATC) Classification. CERIVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cerivastatin under HS 29333999 and SITC 51574. As of Q4 2014, CERIVASTATIN remains the US FDA Preferred Term for this commodity. Cerivastatin bears US NLM identifiers UMLS ID C0528023 and NCI Concept Code C65308. SMILES: Fc1ccc(c2c(c(nc(c2/C=C/C(O)CC(O)CC(=O)O)C(C)C)C(C)C)COC)cc1.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C26H33FNO5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q18G1060S, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))- but more generally known as cerivastatin sodium, which bears US NIH Compound Identifier 446156. European Medicines Agency schedules Cerivastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13294MIG. Most nations, for tariff and trade purposes, schedule cerivastatin sodium under HS 29333999 and SITC 51574. As of Q4 2014, CERIVASTATIN SODIUM remains US FDA's Preferred Term for this commodity. Cerivastatin sodium bears US NLM identifiers UMLS ID C0724549 and NCI Concept Code C28919. SMILES: CC(C)C1C(C(C(C(N1)C(C)C)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)COC.[NA+].
This classification denotes a monoclonal antibody, which generally arises as C19H30N5O8S(C2H4O)n(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6ADW90R16. European Medicines Agency schedules Certolizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25456. The term CERTOLIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, list 52.) As of Q4 2014, CERTOLIZUMAB remains US FDA's Preferred Term for this commodity. Certolizumab bears US NLM identifiers UMLS ID CL430555 and NCI Concept Code C97947. SMILES: none.
This classification denotes a monoclonal antibody, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UMD07X179E. European Medicines Agency schedules Certolizumab pegol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25423. Certolizumab pegol generally arises in the molecular formula C19H30N5O8S(C2H4O)N(C2H4O)N. The term CERTOLIZUMAB PEGOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, list 52.) Most nations, for tariff and trade purposes, schedule certolizumab pegol under HS 30021091 and SITC 54163. Certolizumab pegol bears US NLM identifiers UMLS ID C1872109 and NCI Concept Code C80972. SMILES: As of Q4 2014, CERTOLIZUMAB PEGOL remains US FDA's Preferred Term for this commodity.
This classification denotes an anti-lipidemic agent with the molecular formula C23H39NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, DTL5W0113X chemically known as benzoic acid, 4-(hexadecylamino)- but generally known as cetaben, which bears US NIH Compound Identifier 47263. European Medicines Agency schedules Cetaben in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07444MIG. The term CETABEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18). Most nations schedule cetaben under HS 29224995 and SITC 51465. As of Q4 2014, CETABEN remains the US FDA Preferred Term for this commodity. Cetaben bears US NLM identifiers UMLS ID C0055140 and NCI Concept Code C73814. SMILES: OC(=O)C1CCC(NCCCCCCCCCCCCCCCC)CC1.
This classification denotes an anti-lipidemic agent with the molecular formula C23H38NO2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 433YPU24B8, chemically known as cl 203,821 but more generally known as cetaben sodium, which bears US NIH Compound Identifier 47262. Most nations, for tariff and trade purposes, schedule cetaben sodium under HS 29224995 and SITC 51465. As of Q4 2014, CETABEN SODIUM remains US FDA's Preferred Term for this commodity. Cetaben sodium bears US NLM identifiers UMLS ID C2347605 and NCI Concept Code C72984. SMILES: CCCCCCCCCCCCCCCCNC1CCC(CC1)C(=O)[O-].[NA+].
This classification denotes an anti-infective agent with the molecular formula C25H46N.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85474O1N9D, chemically known as n-hexadecyl-n,n-dimethylbenzenemethanaminium cl but generally known as cetalkonium chloride, which bears US NIH Compound Identifier 31202. European Medicines Agency schedules Cetalkonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07445MIG. The term CETALKONIUM CHLORIDE is an International Non-Proprietary Name. Most nations schedule cetalkonium chloride under HS 29239000 and SITC 51481. As of Q4 2014, CETALKONIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Cetalkonium chloride bears US NLM identifiers UMLS ID C0109105 and NCI Concept Code C77034. SMILES: Cl.[N](CCCCCCCCCCCCCCCC)(Cc1ccccc1)(C)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, Z0VD1633O8 chemically known as acetamide, 2-(2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenoxy)-n-methyl-, (+/-)- but generally known as cetamolol, which bears US NIH Compound Identifier 53698. European Medicines Agency schedules Cetamolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07446MIG. The term CETAMOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28. ). Most nations schedule cetamolol under HS 29242995 and SITC 51479. As of Q4 2014, CETAMOLOL remains the US FDA Preferred Term for this commodity. Cetamolol bears US NLM identifiers UMLS ID C0055143 and NCI Concept Code C81659. SMILES: CC(C)(C)NCC(COC1=CC=CC=C1OCC(=O)NC)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H26N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5UNK5C6QM5, chemically known as 2-(2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenoxy)-n-methylacetamide monohydrochloride but more generally known as cetamolol hydrochloride, which bears US NIH Compound Identifier 53697. Most nations, for tariff and trade purposes, schedule cetamolol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, CETAMOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cetamolol hydrochloride bears US NLM identifiers UMLS ID C2825713 and NCI Concept Code C81652. SMILES: CC(C)(C)NCC(COC1CCCCC1OCC(=O)NC)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a vasodilating agent with the molecular formula C20H31NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 621RT200TO, chemically known as 3-thiopheneacetic acid, alpha-cyclohexyl-, 2-(hexahydro-1h-azepin-1-yl)ethyl ester but generally known as cetiedil, which bears US NIH Compound Identifier 66384. European Medicines Agency schedules Cetiedil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07450MIG. The term CETIEDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules cetiedil in its Anatomical Therapeutic Chemical (ATC) Classification. CETIEDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cetiedil under HS 29349990 and SITC 51579. As of Q4 2014, CETIEDIL remains the US FDA Preferred Term for this commodity. Cetiedil bears US NLM identifiers UMLS ID C0055146 and NCI Concept Code C79584. SMILES: s1cc(C(C2CCCCC2)C(=O)OCCN2CCCCCC2)cc1.
This classification denotes a vasodilating agent with the molecular formula C20H31NO2S.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IE65P4OE02, chemically known as 3-thiopheneacetic acid, alpha-cyclohexyl-, 2-(hexahydro-1h-azepin-1-yl)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) but more generally known as cetiedil citrate, which bears US NIH Compound Identifier 66383. Most nations, for tariff and trade purposes, schedule cetiedil citrate under HS 29349990 and SITC 51579. As of Q4 2014, CETIEDIL CITRATE remains US FDA's Preferred Term for this commodity. Cetiedil citrate bears US NLM identifiers UMLS ID C0771456 and NCI Concept Code C79585. SMILES: C1CSCC1C(C2CCCCC2)C(=O)OCCN3CCCCCC3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YO7261ME24, chemically known as acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- but generally known as cetirizine, which bears US NIH Compound Identifier 2678. European Medicines Agency schedules Cetirizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07451MIG. The term CETIRIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules cetirizine in its Anatomical Therapeutic Chemical (ATC) Classification. CETIRIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cetirizine under HS 29335995 and SITC 51576. As of Q4 2014, CETIRIZINE remains the US FDA Preferred Term for this commodity. Cetirizine bears US NLM identifiers UMLS ID C0055147 and NCI Concept Code C1042. SMILES: CLC1CCC(C(N2CCN(CC2)CCOCC(=O)O)C2CCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64O047KTOA, chemically known as acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride, (+-)- but more generally known as cetirizine dihydrochloride, which bears US NIH Compound Identifier 55182. European Medicines Agency schedules Cetirizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11803MIG. Most nations, for tariff and trade purposes, schedule cetirizine dihydrochloride under HS 29335995. SMILES: C1CCC(CC1)C(C2CCC(CC2)CL)N3CCN(CC3)CCOCC(=O)O.CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64O047KTOA, chemically known as acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride, (+-)- but more generally known as cetirizine dihydrochloride, which bears US NIH Compound Identifier 55182. European Medicines Agency schedules Cetirizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11803MIG. Most nations, for tariff and trade purposes, schedule cetirizine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, CETIRIZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cetirizine hydrochloride bears US NLM identifiers UMLS ID C0700480 and NCI Concept Code C28920. SMILES: C1CCC(CC1)C(C2CCC(CC2)CL)N3CCN(CC3)CCOCC(=O)O.CL.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a sedative and hypnotic with the molecular formula C6H8N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NS7PP85V4C, chemically known as 4,6-dimethyl-3(2h)-pyridazinone. but generally known as cetohexazine, which bears US NIH Compound Identifier 193965. European Medicines Agency schedules Cetohexazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07454MIG. The term CETOHEXAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). CETOHEXAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cetohexazine under HS 29339990 and SITC 51577. As of Q4 2014, CETOHEXAZINE remains the US FDA Preferred Term for this commodity. Cetohexazine bears US NLM identifiers UMLS ID C2699166 and NCI Concept Code C77246. SMILES: O=C1[NH]NC(CC1C)C.
This classification denotes an anxiolytic with the molecular formula C17H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VPA8CPF0N, chemically known as hydrocinnamic acid, p-hydroxy-, 4-(aminomethyl)cyclohexanecarboxylate, trans- but generally known as cetraxate, which bears US NIH Compound Identifier 2680. European Medicines Agency schedules Cetraxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07457MIG. The term CETRAXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). CETRAXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cetraxate under HS 29224995 and SITC 51465. As of Q4 2014, CETRAXATE remains the US FDA Preferred Term for this commodity. Cetraxate bears US NLM identifiers UMLS ID C0055150 and NCI Concept Code C79885. SMILES: O(C(=O)C1CCC(CC1)CN)C1CCC(CC1)CCC(=O)O.
This classification is for combination irrigation solutions. The first component, CETRIMIDE, has US FDA Unique Ingredient Identifier of 24QSH2NL8N. The second component, CHLORHEXIDINE, has US FDA Unique Ingredient Identifier of R4KO0DY52L.
This classification denotes a topical anti-infective agent with the molecular formula C19H42N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z7FF1XKL7A, chemically known as 1-hexadecanaminium, n,n,n-trimethyl-, chloride but generally known as cetrimonium, which bears US NIH Compound Identifier 2681. European Medicines Agency schedules Cetrimonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01174MIG. World Health Organization schedules cetrimonium in its Anatomical Therapeutic Chemical (ATC) Classification. CETRIMONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CETRIMONIUM remains the US FDA Preferred Term for this commodity. Cetrimonium bears US NLM identifiers UMLS ID C0055151 and NCI Concept Code C79724. SMILES: [N](CCCCCCCCCCCCCCCC)(C)(C)C. .
This classification denotes an anti-infective agent with the molecular formula C19H42N.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L64N7M9BWR, chemically known as 1-hexadecanaminium, n,n,n-trimethyl-, chloride but more generally known as cetrimonium bromide, which bears US NIH Compound Identifier 2681. European Medicines Agency schedules Cetrimonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07458MIG. The term CETRIMONIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule cetrimonium bromide under HS 29239000 and SITC 51481. As of Q4 2014, CETRIMONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Cetrimonium bromide bears US NLM identifiers UMLS ID C0951233 and NCI Concept Code C73149. SMILES: CCCCCCCCCCCCCCCC[N+](C)(C)C.[BR-].
This classification denotes a gonadotropin releasing hormone inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OON1HFZ4BA. European Medicines Agency schedules Cetrorelix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07459MIG. Cetrorelix generally arises in the molecular formula C70H92CLN17O14. The term CETRORELIX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) CETRORELIX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cetrorelix under HS 29371900 and SITC 54154. As of Q4 2014, CETRORELIX remains the US FDA Preferred Term for this commodity. Cetrorelix bears US NLM identifiers UMLS ID C0209366 and NCI Concept Code C2481. SMILES: CLC1CCC(CC(NC(=O)C(NC(=O)C)CC2CC3C(CC2)CCCC3)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(C)C(=O)N)CCCNC(=N)N)CC(C)C)CCCNC(=O)N)CC2CCC(O)CC2)CO)CC2CCCNC2)CC1.
This classification denotes a monoclonal antibody with the molecular formula C6484H10042N1732O2023S36, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PQX0D8J21J, more generally known as cetuximab. European Medicines Agency schedules cetuximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01178MIG. The term CETUXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 14, no. 3, 2000, list 44. Most nations schedule cetuximab under HS 30021091 and SITC 54163. As of Q4 2014, CETUXIMAB remains the US FDA Preferred Term for this commodity. Cetuximab bears US NLM identifiers UMLS ID C0995188 and NCI Concept Code C1723. SMILES: CC(=O)NC1C(C(C(OC1N)CO)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE900. This VA Drug Class (RE900) classifies this compound as belonging to the group RESPIRATORY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
A supplement used for arthritis and joint pain treatment.
This classification denotes a topical anti-infective agent with the molecular formula C21H38N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUB7JI0JV3, chemically known as pyridinium, 1-hexadecyl-, chloride but generally known as cetylpyridinium, which bears US NIH Compound Identifier 2683. European Medicines Agency schedules Cetylpyridinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13306MIG. World Health Organization schedules cetylpyridinium in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CETYLPYRIDINIUM remains the US FDA Preferred Term for this commodity. Cetylpyridinium bears US NLM identifiers UMLS ID C0007906 and NCI Concept Code C83615. SMILES: [N]1(CCCCCCCCCCCCCCCC)CCCCC1. .
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a cholinergic agonist with the molecular formula C10H17NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9V0CDQ56E, chemically known as 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine but generally known as cevimeline, which bears US NIH Compound Identifier 83898. European Medicines Agency schedules Cevimeline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07461MIG. The term CEVIMELINE is an International Non-Proprietary Name. World Health Organization schedules cevimeline in its Anatomical Therapeutic Chemical (ATC) Classification. CEVIMELINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cevimeline under HS 29349990 and SITC 51579. As of Q4 2014, CEVIMELINE remains the US FDA Preferred Term for this commodity. Cevimeline bears US NLM identifiers UMLS ID C0093437 and NCI Concept Code C66873. SMILES: CC1OC2(CN3CCC2CC3)CS1.
This classification denotes a cholinergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P81Q6V85NP. European Medicines Agency schedules Cevimeline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01186MIG. Cevimeline hydrochloride generally arises in the molecular formula 2C10H17NOS.2CLH.H2O. The term 'cevimeline hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cevimeline hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, CEVIMELINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cevimeline hydrochloride bears US NLM identifiers UMLS ID C0874063 and NCI Concept Code C1337. SMILES: C[C@H]1O[C@@]2(CN3CCC2CC3)CS1.C[C@H]1O[C@@]2(CN3CCC2CC3)CS1.O.CL.CL.
This classification denotes a cholinergic agonist with the molecular formula 2C10H17NOS.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P81Q6V85NP, chemically known as (+/-)-cis-2-methylspiro(1,3-oxathiolane-5,3'-quinuclidine)hydrochloride, hemihydrate, but more generally known as cevimeline hydrochloride hemihydrate, which bears US NIH Compound Identifier 83927. European Medicines Agency schedules cevimeline hydrochloride hemihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07461MIG. Most nations, for tariff purposes, schedule cevimeline hydrochloride hemihydrate under HS 29349990. SMILES: C[C@H]1O[C@@]2(CN3CCC2CC3)CS1.C[C@H]1O[C@@]2(CN3CCC2CC3)CS1.O.CL.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD900. This VA Drug Class (AD900) classifies this compound as belonging to the group ANTIDOTES/DETERRENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD900. This VA Drug Class (AD900) classifies this compound as belonging to the group ANTIDOTES/DETERRENTS, OTHER.
This classification denotes a topical anti-infective agent with the molecular formula C48H76N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1S50W1WU8T, chemically known as 4,4-sulfonylbis-(cyclopentanetridecananilide). but more generally known as chaulmosulfone, which bears US NIH Compound Identifier 193966. European Medicines Agency schedules Chaulmosulfone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07462MIG. The term CHAULMOSULFONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). CHAULMOSULFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(C1CC(CC1)CCCCCCCCCCCCC(=O)NC1CCCCC1)C1CC(CC1)CCCCCCCCCCCCC(=O)NC1CCCCC1.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E889U5RNN (and, in top and root form, O9HP59XU7F and FLT36UCF0N), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 501481 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Ranunculanae, Order Ranunculales, Family Papaveraceae, Genus Chelidonium L. (celandine), Species Chelidonium majus L., more commonly known as CELANDINE or as here, CHELIDONIUM MAJUS. Chelidonium majus bears the USDA PLANTS Database Identifier CHMA2. European Medicines Agency schedules chelidonium majus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13315MIG, SUB36234, SUB44902, SUB44903, SUB44904, SUB44905, SUB44906, SUB44907, SUB44908, SUB55438, and SUB63716. As of Q4 2014, CHELIDONIUM MAJUS remains the US FDA Preferred Term for this commodity. Chelidonium majus bears US NLM identifiers UMLS ID C0330281 and NCI Concept Code C72282. SMILES: NONE.
This classification denotes a cholagogue or choleretic agent with the molecular formula C24H40O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0GEI24LG0J, chemically known as cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)- but generally known as chenodeoxycholic acid, which bears US NIH Compound Identifier 5645. European Medicines Agency schedules Chenodeoxycholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07463MIG. The term CHENODEOXYCHOLIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules chenodeoxycholic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule chenodiol under HS 29181900 and SITC 51392. SMILES: OC1C2C3C(C(CC3)C(CCC(=O)O)C)(CCC2C2(C(C1)CC(O)CC2)C)C.
This classification denotes an antimalarial agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 711S8Y0T33. European Medicines Agency schedules Quinine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15093MIG. Quinine hydrochloride generally arises in the molecular formula C20H24N2O2.XCLH. The term 'quinine hydrochloride' is a United States Homeopathic Pharmacopoeia Name designation. SMILES: Cl.OC(C1N2CCC(C1)(CC2)C=C)c1c2c(ncc1)ccc(OC)c2.
This classification denotes an antiprotozoal agent with the molecular formula C9H6INO4S.CHO3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98F8Y85B6W, chemically known as 5-quinolinesulfonic acid, 8-hydroxy-7-iodo- but generally known as chiniofon, which bears US NIH Compound Identifier 11042. European Medicines Agency schedules Chiniofon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12428MIG. The term CHINIOFON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chiniofon in its Anatomical Therapeutic Chemical (ATC) Classification. CHINIOFON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chiniofon under HS 30039010 and SITC 54291. As of Q4 2014, CHINIOFON remains the US FDA Preferred Term for this commodity. Chiniofon bears US NLM identifiers UMLS ID C0008129 and NCI Concept Code C76415. SMILES: IC1CC(S(=O)(=O)O)C2C(NCCC2)C1O.[NA].OC(=O)O.
This classification denotes an anticholinergic agent with the molecular formula C17H20ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42C50P12AP, chemically known as benzhydrol, 2-chloro-alpha-(2-(dimethylamino)ethyl)- but more generally known as chlophedianol, which bears US NIH Compound Identifier 2795. European Medicines Agency schedules Clofedanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06695MIG. The term CLOFEDANOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules chlophedianol in its Anatomical Therapeutic Chemical (ATC) Classification. Chlophedianol or clofedanol bears US NLM identifiers UMLS ID C0055904 and NCI Concept Code C73183. SMILES: CLC1C(C(O)(CCN(C)C)C2CCCCC2)CCCC1.
This classification denotes a vasodilating agent with the molecular formula C19H21ClN2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TZ913SWN6M, chemically known as 10h-phenothiazine, 2-chloro-10-(3-(diethylamino)-1-oxopropyl)- (9ci) but generally known as chloracizine, which bears US NIH Compound Identifier 13113. European Medicines Agency schedules Chloracyzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07464MIG. The term CHLORACYZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Chloracizine or chloracyzine bears US NLM identifiers UMLS ID C0055327 and NCI Concept Code C80874. SMILES: CCN(CC)CCC(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.
This classification denotes an adjuvant analgesic with the molecular formula C2H3Cl3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 418M5916WG, chemically known as 2,2,2-trichloroethane-1,1-diol but generally known as chloral hydrate, which bears US NIH Compound Identifier 2707. European Medicines Agency schedules Chloral hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13324MIG. World Health Organization schedules chloral hydrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CHLORAL HYDRATE remains the US FDA Preferred Term for this commodity. Chloral hydrate bears US NLM identifiers UMLS ID C0008161 and NCI Concept Code C28922. SMILES: C(C(Cl)(Cl)Cl)(O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a hypnotic with the molecular formula C8H15Cl3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8RD4N93R2, chemically known as 2-methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)pentan-2-ol but generally known as chloralodol, which bears US NIH Compound Identifier 19094. European Medicines Agency schedules chloralodol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07465MIG. SMILES: CC(CC(C)(C)O)OC(C(Cl)(Cl)Cl)O.
This classification denotes a nitrogen mustard compound with the molecular formula C14H19Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18D0SL7309, chemically known as p-n,n-di-(beta-chloroethyl)aminophenyl butyric acid but more generally known as chlorambucil, which bears US NIH Compound Identifier 2708. European Medicines Agency schedules Chlorambucil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06172MIG. The term CHLORAMBUCIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chlorambucil in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORAMBUCIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule chlorambucil under HS 29224995 and SITC 51465. As of Q4 2014, CHLORAMBUCIL remains US FDA's Preferred Term for this commodity. Chlorambucil bears US NLM identifiers UMLS ID C0008163 and NCI Concept Code C362. SMILES: CLCCN(C1CCC(CCCC(=O)O)CC1)CCCL.
This classification denotes a topical anti-infective agent with the molecular formula C7H7ClNO2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 328AS34YM6, chemically known as p-toluenesulfonamide, n-chloro-, sodium salt but generally known as chloramine-t, which bears US NIH Compound Identifier 31387. SMILES: CC1=CC=C(C=C1)S(=NCL)(=O)[O-].[NA+]. SMILES: CC1=CC=C(C=C1)S(=NCL)(=O)[O-].[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C11H12Cl2N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66974FR9Q1, chemically known as dl-threo-2,2-dichloro-n-(beta-hydroxy-alpha-hydroxymethyl-4-nitrophenethyl)acetamide but generally known as chloramphenicol, which bears US NIH Compound Identifier 298. European Medicines Agency schedules Chloramphenicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06173MIG. The term CHLORAMPHENICOL is an International Non-Proprietary Name. World Health Organization schedules chloramphenicol in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORAMPHENICOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Chloramphenicol or chloramphenicolum bears US NLM identifiers UMLS ID C0008168 and NCI Concept Code C363. SMILES: C1=CC(=CC=C1C(C(CO)NC(=O)C(CL)CL)O)[N+](=O)[O-].
Chloramphenicol or chloramphenicolum/Sulfacetamide sodium is a combination of two antibiotics to treat bacterial infections of the skin and superficial ocular infections.
This classification denotes an antibiotic with the molecular formula C27H42Cl2N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43VU4207NW, chemically known as palmitic acid, alpha-ester with d-threo-(-)-2,2-dichloro-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)acetamide but more generally known as chloramphenicol palmitate, which bears US NIH Compound Identifier 10736. European Medicines Agency schedules Chloramphenicol palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01206MIG. Most nations, for tariff and trade purposes, schedule chloramphenicol palmitate under HS 29414000. As of Q4 2014, CHLORAMPHENICOL PALMITATE remains US FDA's Preferred Term for this commodity. Chloramphenicol palmitate bears US NLM identifiers UMLS ID C0055337 and NCI Concept Code C65313. SMILES: CCCCCCCCCCCCCCCC(=O)OC[C@H]([C@@H](C1CCC(CC1)[N+](=O)[O-])O)NC(=O)C(CL)CL.
This classification denotes a protein synthesis inhibitor and antibiotic with the molecular structure C15H15CL2N2O8.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 872109HX6B chemically known as butanedioic acid, mono(2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl) ester, monosodium salt, (r-(r*,r*))-, but more commonly known as chloramphenicol sodium succinate, which bears US NIH Compound Identifier 298. European Medicines Agency schedules Chloramphenicol sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01207MIG. Most nations, for tariff and trade purposes, schedule chloramphenicol sodium succinate under HS 29414000. As of Q4 2014, CHLORAMPHENICOL SODIUM SUCCINATE remains US FDA's Preferred Term for this commodity. Chloramphenicol sodium succinate bears US NLM identifiers UMLS ID C0109354 and NCI Concept Code C47972. SMILES: C1CC(CCC1[C@H]([C@@H](COC(=O)CCC(=O)[O-])NC(=O)C(CL)CL)O)[N+](=O)[O-].[NA+].
This classification denotes a protein synthesis inhibitor and antibiotic C29H46Cl2N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DL2A9M9D6X, chemically known as octadecanoic acid, (2r,3r)-2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl ester, but more generally known as chloramphenicol stearate, which bears US NIH Compound Identifier 83945. European Medicines Agency schedules Chloramphenicol stearate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26903. Most nations, for tariff and trade purposes, schedule chloramphenicol stearate under HS 29414000 and SITC 54139. As of Q4 2014, CHLORAMPHENICOL STEARATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCCCCCCCC(=O)OC[C@H]([C@@H](C1CCC(CC1)[N+](=O)[O-])O)NC(=O)C(CL)CL.
This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C15H16Cl2N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZCX619U9A1, chemically known as succinic acid, alpha-monoester with d-threo-(-)-2,2-dichloro-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)acetamide but more generally known as chloramphenicol succinate, which bears US NIH Compound Identifier 2709. Most nations, for tariff and trade purposes, schedule chloramphenicol succinate under HS 29414000. As of Q4 2014, CHLORAMPHENICOL SUCCINATE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1[C@H]([C@@H](COC(=O)CCC(=O)O)NC(=O)C(CL)CL)O)[N+](=O)[O-].
This classification denotes a topical anti-infective agent with the molecular formula C2H4Cl2N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SEF8X7MXO4, chemically known as 1, 1-azobis (chloroformamidine) but generally known as chlorazodin, which bears US NIH Compound Identifier 5354414. European Medicines Agency schedules Chlorazodin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06175MIG. The term CHLORAZODIN is an International Non-Proprietary Name. CHLORAZODIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Chlorazodin or chloroazodin bears US NLM identifiers UMLS ID C2699186 and NCI Concept Code C77038. SMILES: CL/N=C(/N=N/C(=N\CL)N)N.
This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N52918SLYN. European Medicines Agency schedules Chlorbenzoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06176MIG. Chlorbenzoxamine generally arises in the molecular formula C27H31CLN2O. The term CHLORBENZOXAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) CHLORBENZOXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorbenzoxamine under HS 29335995 and SITC 51576. As of Q4 2014, CHLORBENZOXAMINE remains the US FDA Preferred Term for this commodity. Chlorbenzoxamine bears US NLM identifiers UMLS ID C2699179 and NCI Concept Code C79940. SMILES: CLC1C(C(OCCN2CCN(CC2)CC2C(CCCC2)C)C2CCCCC2)CCCC1.
This classification denotes an antiprotozoal agent with the molecular formula C11H11Cl4NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3S489RFX0J, chemically known as 2,2-dichloro-n-2,4-dichlorobenzyl-n-2-hydroxyethyl-acetamide but generally known as chlorbetamide, which bears US NIH Compound Identifier 7330. European Medicines Agency schedules Chlorbetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06177MIG. The term CHLORBETAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). CHLORBETAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorbetamide under HS 29242995 and SITC 51479. As of Q4 2014, CHLORBETAMIDE remains the US FDA Preferred Term for this commodity. Chlorbetamide bears US NLM identifiers UMLS ID C2699182 and NCI Concept Code C76416. SMILES: C1=CC(=C(C=C1CL)CL)CN(CCO)C(=O)C(CL)CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M26C4IP44P, chemically known as piperazine, 1- (p-chloro-.alpha.-phenylbenzyl)-4-methyl-, monohydrochloride but generally known as chlorcyclizine, which bears US NIH Compound Identifier 2710. European Medicines Agency schedules Chlorcyclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06178MIG. The term CHLORCYCLIZINE is an International Non-Proprietary Name. World Health Organization schedules chlorcyclizine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORCYCLIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorcyclizine under HS 29335995 and SITC 51576. As of Q4 2014, CHLORCYCLIZINE remains the US FDA Preferred Term for this commodity. Chlorcyclizine bears US NLM identifiers UMLS ID C0008183 and NCI Concept Code C81138. SMILES: CLC1CCC(C(N2CCN(CC2)C)C2CCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61Y56T95YL, chemically known as piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-, hydrochloride (1:2), but more generally known as chlorcyclizine dihydrochloride, which bears US NIH Compound Identifier 101605. European Medicines Agency schedules chlorcyclizine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06178MIG. Most nations, for tariff purposes, schedule chlorcyclizine dihydrochloride under HS 29335995. SMILES: CN1CCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NPB7A7874U, chemically known as piperazine, 1- (p-chloro-.alpha.-phenylbenzyl)-4-methyl-, monohydrochloride but more generally known as chlorcyclizine hydrochloride, which bears US NIH Compound Identifier 2710. European Medicines Agency schedules Chlorcyclizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01212MIG. Most nations, for tariff and trade purposes, schedule chlorcyclizine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, CHLORCYCLIZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlorcyclizine hydrochloride bears US NLM identifiers UMLS ID C0770863 and NCI Concept Code C76669. SMILES: CN1CCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NPB7A7874U, chemically known as piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-, monohydrochloride, but more generally known as chlorcyclizine monohydrochloride, which bears US NIH Compound Identifier 62413. European Medicines Agency schedules chlorcyclizine monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06178MIG. Most nations, for tariff purposes, schedule chlorcyclizine monohydrochloride under HS 29335995. SMILES: CN1CCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C23H16O6.C18H21ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73R47NSS6P, chemically known as 2-naphthalenecarboxylic acid, 4,4'-methylenebis 3-hydroxy-, compd. with 1-((4-chlorophenyl)phenylmethyl)-4-methylpiperazine, but more generally known as chlorcyclizine pamoate, which bears US NIH Compound Identifier 24296. European Medicines Agency schedules chlorcyclizine pamoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06178MIG. Most nations, for tariff purposes, schedule chlorcyclizine pamoate under HS 29335995. SMILES: CN1CCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an antifungal agent with the molecular formula C11H17Cl3N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W14Z7581PA, chemically known as 1-pentanol, acetate but generally known as chlordantoin, which bears US NIH Compound Identifier 12348. European Medicines Agency schedules Clodantoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06690MIG. The term CLODANTOIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules chlordantoin in its Anatomical Therapeutic Chemical (ATC) Classification. Chlordantoin or clodantoin bears US NLM identifiers UMLS ID C0055903 and NCI Concept Code C75200. SMILES: CCCCC(CC)C1C(=O)N(C(=O)N1)SC(CL)(CL)CL.
This classification denotes a benzodiazepine with the molecular formula C16H14ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6RZ6XEZ3CR, chemically known as 7-chloro-n-methyl-5-phenyl-3h-1,4-benzodiazepin-2-amine 4-oxide but generally known as chlordiazepoxide, which bears US NIH Compound Identifier 2712. European Medicines Agency schedules Chlordiazepoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06179MIG. The term CHLORDIAZEPOXIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules chlordiazepoxide in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORDIAZEPOXIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlordiazepoxide under HS 29339110 and SITC 51577. As of Q4 2014, CHLORDIAZEPOXIDE remains the US FDA Preferred Term for this commodity. Chlordiazepoxide bears US NLM identifiers UMLS ID C0008188 and NCI Concept Code C47443. SMILES: CLC1CC2=C(N(O)CC(=N\C)\N=C2CC1)C1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS300. This VA Drug Class (HS300) classifies this compound as belonging to the group ESTROGENS.
This classification denotes a benzodiazepine with the molecular formula C16H14ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MFM6K1XWDK, chemically known as 7-chloro-n-methyl-5-phenyl-3h-1,4-benzodiazepin-2-amine 4-oxide but more generally known as chlordiazepoxide hydrochloride, which bears US NIH Compound Identifier 2712. European Medicines Agency schedules Chlordiazepoxide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01213MIG. The term CHLORDIAZEPOXIDE HYDROCHLORIDE OR CLIDINIUM BROMIDE COMBINATION is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule chlordiazepoxide hydrochloride under HS 29339110 and SITC 51577. As of Q4 2014, CHLORDIAZEPOXIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlordiazepoxide hydrochloride bears US NLM identifiers UMLS ID C0700528 and NCI Concept Code C47973. SMILES: CNC1=NC2CCC(CC2C(=[N+](C1)[O-])C3CCCCC3)CL.CL.
This classification denotes a benzodiazepine with the molecular formula C15H11ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X1XP5M0SB, chemically known as 5-phenyl-7-chloro-3h-1,4-benzodiazepin-2(1h)-one 4-oxide, but more generally known as chlordiazepoxide lactam, which bears US NIH Compound Identifier 13756. European Medicines Agency schedules chlordiazepoxide lactam or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06179MIG. Most nations, for tariff purposes, schedule chlordiazepoxide lactam under HS 29339110. SMILES: C1CCC(CC1)C2=[N+](CC(=O)NC3C2CC(CC3)CL)[O-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes an anti-infective agent with the molecular formula C22H30Cl2N10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R4KO0DY52L, chemically known as 2,4,11,13-tetraazatetradecanediimidamide, n,n-bis(4-chlorophenyl)-3,12-diimino- but generally known as chlorhexidine, which bears US NIH Compound Identifier 9552079. European Medicines Agency schedules Chlorhexidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06181MIG. World Health Organization schedules chlorhexidine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORHEXIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorhexidine under HS 29252900 and SITC 51482. As of Q4 2014, CHLORHEXIDINE remains the US FDA Preferred Term for this commodity. Chlorhexidine bears US NLM identifiers UMLS ID C0008196 and NCI Concept Code C364. SMILES: CLC1CCC(N/C(=N/C(=N/CCCCCC/N=C(/N=C(/NC2CCC(CL)CC2)N)N)N)N)CC1.
This classification denotes a topical anti-infective agent with the molecular formula C22H30Cl2N10.2C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5908ZUF22Y, chemically known as 1,1'-hexamethylenebis(5-(4-chlorophenyl)biguanide) diacetate, but more generally known as chlorhexidine acetate, which bears US NIH Compound Identifier 9562059. European Medicines Agency schedules chlorhexidine acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06181MIG. Most nations, for tariff purposes, schedule chlorhexidine acetate under HS 29252900. SMILES: CC(=O)O.CC(=O)O.C1CC(CCC1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2CCC(CC2)CL)CL.
This classification is for a combination antiseptic solution. The first component, CHLORHEXIDINE, has US FDA Unique Ingredient Identifier of R4KO0DY52L. The second component, CHLOROCRESOL, has US FDA Unique Ingredient Identifier of 36W53O7109.The third component, HEXAMIDINE, has US FDA Unique Ingredient Identifier of 3483C2H13H.
This classification denotes a topical anti-infective agent with the molecular formula C22H30Cl2N10.2C6H12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MOR84MUD8E, chemically known as 2,4,11,13-tetraazatetradecanediimidamide, n,n-bis(4-chlorophenyl)-3,12-diimino-, di-d-gluconate but more generally known as chlorhexidine digluconate, which bears US NIH Compound Identifier 5360565. European Medicines Agency schedules Chlorhexidine digluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01215MIG. Most nations, for tariff and trade purposes, schedule chlorhexidine digluconate under HS 29252900. SMILES: C1CC(CCC1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2CCC(CC2)CL)CL.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.
This classification denotes a topical anti-infective agent with the molecular structure C22H30CL2N10.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E64XL9U38K chemically known as 1,1'-hexamethylenebis(5-(p-chlorophenyl)biguanide)dihydrochloride, but more commonly known as chlorhexidine dihydrochloride, which bears US NIH Compound Identifier 9571016. European Medicines Agency schedules Chlorhexidine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11811MIG. Most nations, for tariff and trade purposes, schedule chlorhexidine dihydrochloride under HS 29252900. SMILES: C1CC(CCC1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2CCC(CC2)CL)CL.CL.CL.
This classification denotes an anti-infective agent with the molecular formula C22H30Cl2N10.2C6H12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MOR84MUD8E, chemically known as 2,4,11,13-tetraazatetradecanediimidamide, n,n-bis(4-chlorophenyl)-3,12-diimino-, di-d-gluconate but generally known as chlorhexidine gluconate, which bears US NIH Compound Identifier 5360565. European Medicines Agency schedules Chlorhexidine gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01215MIG. Most nations schedule chlorhexidine gluconate under HS 29252900 and SITC 51482. As of Q4 2014, CHLORHEXIDINE GLUCONATE remains the US FDA Preferred Term for this commodity. Chlorhexidine gluconate bears US NLM identifiers UMLS ID C0055361 and NCI Concept Code C47974. SMILES: C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)CL)N)N)CL.C(C(C(C(C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE101. This VA Drug Class (DE101) classifies this compound as belonging to the group ANTIBACTERIAL, TOPICAL.
This classification denotes a topical anti-infective agent with the molecular structure C22H30CL2N10.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E64XL9U38K chemically known as 1,1'-hexamethylenebis(5-(p-chlorophenyl)biguanide)dihydrochloride, but more commonly known as chlorhexidine hydrochloride, which bears US NIH Compound Identifier 9571016. European Medicines Agency schedules Chlorhexidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01216MIG. Most nations, for tariff and trade purposes, schedule chlorhexidine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, CHLORHEXIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlorhexidine hydrochloride bears US NLM identifiers UMLS ID C0008199 and NCI Concept Code C65314. SMILES: C1CC(CCC1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2CCC(CC2)CL)CL.CL.CL.
This classification denotes a topical anti-infective agent with the molecular formula C22H30Cl2N10.2C6H8NO3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I20F29W4EO, chemically known as 1,1'-hexamethylenebis(5-(p-chlorophenyl)biguanide) (p-aminophenyl)phosphonate (1:2), but more generally known as chlorhexidine phosphanilate, which bears US NIH Compound Identifier 9570835. European Medicines Agency schedules chlorhexidine phosphanilate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06181MIG. Most nations, for tariff purposes, schedule chlorhexidine phosphanilate under HS 29252900. SMILES: C1CC(CCC1N)P(=O)(O)O.C1CC(CCC1N)P(=O)(O)O.C1CC(CCC1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2CCC(CC2)CL)CL.
This classification denotes a nicotinic antagonist with the molecular formula C14H20Cl4N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JD3M24F66I, chemically known as 1h-isoindolium, 4,5,6,7-tetrachloro-2,3-dihydro-2-methyl-2-(2- (trimethylammonio)ethyl)- but generally known as chlorisondamine, which bears US NIH Compound Identifier 6243. European Medicines Agency schedules Chlorisondamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06182MIG. The term CHLORISONDAMINE is an International Non-Proprietary Name. As of Q4 2014, CHLORISONDAMINE remains the US FDA Preferred Term for this commodity. Chlorisondamine bears US NLM identifiers UMLS ID C0008211 and NCI Concept Code C83619. SMILES: C[N+]1(CC2=C(C1)C(=C(C(=C2Cl)Cl)Cl)Cl)CC[N+](C)(C)C.[Cl-].
This classification denotes a nicotinic antagonist with the molecular formula C14H20Cl4N2.2Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7B58W7756G, chemically known as 4,5,6,7-tetrachloro-2-(2-dimethylaminoethyl)-isoindoline dimethochloride but more generally known as chlorisondamine chloride, which bears US NIH Compound Identifier 6243. European Medicines Agency schedules Chlorisondamine chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06182MIG. The term CHLORISONDAMINE CHLORIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule chlorisondamine chloride under HS 29339990 and SITC 51577. As of Q4 2014, CHLORISONDAMINE CHLORIDE remains US FDA's Preferred Term for this commodity. Chlorisondamine chloride bears US NLM identifiers UMLS ID C0282099 and NCI Concept Code C76788. SMILES: C[N+]1(CC2C(C(C(C(C2CL)CL)CL)CL)C1)CC[N+](C)(C)C.[CL-].[CL-].
This classification denotes a therapeutic progestin with the molecular formula C21H27ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SDS4N642GG, chemically known as 17.alpha.-acetoxy-6-chloro-4, 6-pregnadiene-3,20-dione but generally known as chlormadinone, which bears US NIH Compound Identifier 2714. European Medicines Agency schedules Chlormadinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06183MIG. World Health Organization schedules chlormadinone in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORMADINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlormadinone under HS 29372300 and SITC 54153. As of Q4 2014, CHLORMADINONE remains the US FDA Preferred Term for this commodity. Chlormadinone bears US NLM identifiers UMLS ID C0262965 and NCI Concept Code C83620. SMILES: ClC1=CC2C3C(C(OC(=O)C)(CC3)C(=O)C)(CCC2C2(C1=CC(=O)CC2)C)C.
This classification denotes a therapeutic progestin with the molecular formula C23H29ClO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0SY050L61N, chemically known as 17.alpha.-acetoxy-6-chloro-4, 6-pregnadiene-3,20-dione but more generally known as chlormadinone acetate, which bears US NIH Compound Identifier 2714. European Medicines Agency schedules Chlormadinone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01219MIG. Most nations, for tariff and trade purposes, schedule chlormadinone acetate under HS 29372300 and SITC 54153. As of Q4 2014, CHLORMADINONE ACETATE remains US FDA's Preferred Term for this commodity. Chlormadinone acetate bears US NLM identifiers UMLS ID C0008214 and NCI Concept Code C365. SMILES: CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)CL)C)OC(=O)C.
This classification denotes a loop diuretic with the molecular formula C5H11ClHgN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99T5TWO621, chemically known as urea, (3-(chloromercurio)-2-methoxypropyl)- but generally known as chlormerodrin, which bears US NIH Compound Identifier 2716. European Medicines Agency schedules Chlormerodrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06184MIG. The term CHLORMERODRIN is an International Non-Proprietary Name. CHLORMERODRIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlormerodrin under HS 28444030 and SITC 52519. As of Q4 2014, CHLORMERODRIN remains the US FDA Preferred Term for this commodity. Chlormerodrin bears US NLM identifiers UMLS ID C0008217 and NCI Concept Code C65315. SMILES: [HG]1(CL)[O]=C(NCC(OC)C1)N.
This classification denotes a nitrogen mustard compound with the molecular formula C5H11Cl2N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0MR697HHI, chemically known as 2,2-dichloro-n-methyldiethylamine but more generally known as chlormethine hydrochloride, which bears US NIH Compound Identifier 4033. European Medicines Agency schedules Chlormethine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01220MIG. Most nations, for tariff and trade purposes, schedule chlormethine hydrochloride under HS 29211980. SMILES: CN(CCCL)CCCL.CL.
This classification denotes a nitrogen mustard compound with the molecular formula C5H11Cl2N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50D9XSG0VR, chemically known as 2,2-dichloro-n-methyldiethylamine but more generally known as chlormethine, which bears US NIH Compound Identifier 4033. European Medicines Agency schedules Chlormethine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06186MIG. The term CHLORMETHINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules chlormethine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORMETHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Chlormethine or mechlorethamine bears US NLM identifiers UMLS ID C0025033 and NCI Concept Code C62056. SMILES: CLCCN(CCCL)C.
This classification denotes an anxiolytic with the molecular formula C11H12ClNO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GP568V9G19, chemically known as 4h-1,3-thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide but generally known as chlormezanone, which bears US NIH Compound Identifier 2717. European Medicines Agency schedules Chlormezanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06187MIG. The term CHLORMEZANONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules chlormezanone in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORMEZANONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlormezanone under HS 29349990 and SITC 51579. As of Q4 2014, CHLORMEZANONE remains the US FDA Preferred Term for this commodity. Chlormezanone bears US NLM identifiers UMLS ID C0008223 and NCI Concept Code C65316. SMILES: CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)CL.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8IKK64FJVX. European Medicines Agency schedules Chlormidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06188MIG. Chlormidazole generally arises in the molecular formula C15H13CLN2. The term CHLORMIDAZOLE is an International Non-Proprietary Name or INN. CHLORMIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlormidazole under HS 29339990 and SITC 51577. As of Q4 2014, CHLORMIDAZOLE remains the US FDA Preferred Term for this commodity. Chlormidazole bears US NLM identifiers UMLS ID C0055375 and NCI Concept Code C78032. SMILES: CLC1CCC(CN2C3C(NC2C)CCCC3)CC1.
This classification denotes an antifungal agent with the molecular formula C15H13ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0RH29TB951, chemically known as benzimidazole, 1-(p-chlorobenzyl)-2-methyl-, hydrochloride but more generally known as chlormidazole hydrochloride, which bears US NIH Compound Identifier 53015. European Medicines Agency schedules Chlormidazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13329MIG. Most nations, for tariff and trade purposes, schedule chlormidazole hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, CHLORMIDAZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1NC2CCCCC2N1CC3CCC(CC3)CL.CL.
This classification denotes an industrial aid with the molecular formula C4H7Cl3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HM4YQM8WRC, chemically known as 1,1,1-trichloro-tert-butyl alcohol but generally known as chlorobutanol, which bears US NIH Compound Identifier 5977. European Medicines Agency schedules Chlorobutanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06190MIG. The term CHLOROBUTANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chlorobutanol in its Anatomical Therapeutic Chemical (ATC) Classification. CHLOROBUTANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorobutanol under HS 29055910 and SITC 51229. As of Q4 2014, CHLOROBUTANOL remains the US FDA Preferred Term for this commodity. Chlorobutanol bears US NLM identifiers UMLS ID C0008232 and NCI Concept Code C65317. SMILES: CLC(CL)(CL)C(O)(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes an industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X4P6271OX. European Medicines Agency schedules Chlorobutanol hemihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11812MIG. Chlorobutanol hemihydrate generally arises in the molecular formula 2C4H7CL3O.H2O. The term 'chlorobutanol hemihydrate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule chlorobutanol hemihydrate under HS 29055910 and SITC 51229. As of Q4 2014, CHLOROBUTANOL HEMIHYDRATE remains US FDA's Preferred Term for this commodity. Chlorobutanol hemihydrate bears US NLM identifiers UMLS ID C0725608 and NCI Concept Code C79995. SMILES: CC(C)(C(CL)(CL)CL)O.CC(C)(C(CL)(CL)CL)O.O.
This classification denotes an anti-infective agent with the molecular formula C7H7ClO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36W53O7109, chemically known as phenol, 4-chloro-3-methyl- but generally known as chlorocresol, which bears US NIH Compound Identifier 1732. European Medicines Agency schedules Chlorocresol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06191MIG. The term CHLOROCRESOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). CHLOROCRESOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorocresol under HS 29081900 and SITC 51244. As of Q4 2014, CHLOROCRESOL remains the US FDA Preferred Term for this commodity. Chlorocresol bears US NLM identifiers UMLS ID C0055402 and NCI Concept Code C77039. SMILES: CC1=C(C=CC(=C1)O)CL.
This classification denotes an industrial aid and carcinogenic chlorinated hydrocarbon with the molecular formula CHCl3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7V31YC746X, chemically known as 1,1,1-trichloromethane but generally known as chloroform, which bears US NIH Compound Identifier 6212. European Medicines Agency schedules Chloroform in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13331MIG. World Health Organization schedules chloroform in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule chloroform under HS 29031300 and SITC 51136. As of Q4 2014, CHLOROFORM remains the US FDA Preferred Term for this commodity. Chloroform bears US NLM identifiers UMLS ID C0008238 and NCI Concept Code C29815. SMILES: CLC(CL)CL.
This classification denotes a dihydrofolate reductase inhibitor and antimalarial agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T04V14CU9. European Medicines Agency schedules Chloroguanide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04062MIG. Chloroguanide hydrochloride generally arises in the molecular formula C11H17CL2N5. The term 'chloroguanide hydrochloride' is a United States Adopted Name designation. SMILES: CLC1CC(N(/C(=N/C(C)C)N)C(=N)N)CCC1CL.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class XA606. This VA Drug Class (XA606) classifies this compound as belonging to the group ODOR CONTROL PRODUCTS, OSTOMY.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H25ClO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 564IBO56IP, chemically known as pregna-1,4-diene-3,11,20-trione, 6.alpha.-chloro-17,21-dihydroxy-, 21-acetate but generally known as chloroprednisone, which bears US NIH Compound Identifier 235970. European Medicines Agency schedules Chloroprednisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06192MIG. CHLOROPREDNISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chloroprednisone under HS 29372200 and SITC 54153. As of Q4 2014, CHLOROPREDNISONE remains the US FDA Preferred Term for this commodity. Chloroprednisone bears US NLM identifiers UMLS ID C2699187 and NCI Concept Code C79755. SMILES: CLC1CC2C3C(C(O)(CC3)C(=O)COC(=O)C)(CC(=O)C2C2(C1=CC(=O)C=C2)C)C.
This classification denotes a therapeutic glucocorticoid C23H27ClO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z243A6BHCS, chemically known as 6.alpha.-chloro-17,21-dihydroxypregna-1,4-diene-3,11,20-trione 21-acetate, but more generally known as chloroprednisone acetate, which bears US NIH Compound Identifier 235970. European Medicines Agency schedules Chloroprednisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01231MIG. Most nations, for tariff and trade purposes, schedule chloroprednisone acetate under HS 29372200 and SITC 54153. As of Q4 2014, CHLOROPREDNISONE ACETATE remains US FDA's Preferred Term for this commodity. Chloroprednisone acetate bears US NLM identifiers UMLS ID C2699188 and NCI Concept Code C76111. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)CL)C)O.
This classification denotes an anesthetic agent with the molecular formula C13H19ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5YVB0POT2H, chemically known as benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester but generally known as chloroprocaine, which bears US NIH Compound Identifier 8612. European Medicines Agency schedules Chloroprocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06193MIG. The term CHLOROPROCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chloroprocaine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLOROPROCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chloroprocaine under HS 29224995 and SITC 51465. As of Q4 2014, CHLOROPROCAINE remains the US FDA Preferred Term for this commodity. Chloroprocaine bears US NLM identifiers UMLS ID C0055443 and NCI Concept Code C72168. SMILES: CLC1C(C(=O)OCCN(CC)CC)CCC(N)C1.
This classification denotes an anesthetic agent with the molecular formula C13H19ClN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LT7Z1YW11H, chemically known as benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester, monohydrochloride but more generally known as chloroprocaine hydrochloride, which bears US NIH Compound Identifier 19727. European Medicines Agency schedules Chloroprocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01232MIG. Most nations, for tariff and trade purposes, schedule chloroprocaine hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, CHLOROPROCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chloroprocaine hydrochloride bears US NLM identifiers UMLS ID C0132182 and NCI Concept Code C47444. SMILES: CCN(CC)CCOC(=O)C1CCC(CC1CL)N.CL.
This classification denotes an anesthetic agent with the molecular formula C13H19ClN2O2.C13H18N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3NVO08Z59, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(((2-propenylthio)acetyl)amino)-, (2s,5r,6r)-, compd. with 2-(diethylamino)ethyl 4-amino-2-chlorobenzoate (1:1), but more generally known as chloroprocaine penicillin o, which bears US NIH Compound Identifier 11329. European Medicines Agency schedules chloroprocaine penicillin o or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06193MIG. Most nations, for tariff purposes, schedule chloroprocaine penicillin o under HS 29224995. SMILES: CCN(CC)CCOC(=O)C1CCC(CC1CL)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CSCC=C)C(=O)O)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2K3L8O9SOV, chemically known as 1,2-ethanediamine, n-((4-chlorophenyl)methyl)-n,n-dimethyl-n-2-pyridinyl- (9ci) but generally known as chloropyramine, which bears US NIH Compound Identifier 25295. European Medicines Agency schedules Chloropyramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06194MIG. The term CHLOROPYRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules chloropyramine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLOROPYRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chloropyramine under HS 29333999 and SITC 51574. As of Q4 2014, CHLOROPYRAMINE remains the US FDA Preferred Term for this commodity. Chloropyramine bears US NLM identifiers UMLS ID C0055445 and NCI Concept Code C81130. SMILES: CLC1CCC(CN(CCN(C)C)C2NCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20ClN3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FWA92Z14NN, chemically known as 1,2-ethanediamine, n-((4-chlorophenyl)methyl)-n,n-dimethyl-n-2-pyridinyl- (9ci) but more generally known as chloropyramine hydrochloride, which bears US NIH Compound Identifier 25295. European Medicines Agency schedules Chloropyramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01233MIG. Most nations, for tariff and trade purposes, schedule chloropyramine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, CHLOROPYRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chloropyramine hydrochloride bears US NLM identifiers UMLS ID C0771732 and NCI Concept Code C97693. SMILES: CN(C)CCN(CC1CCC(CC1)CL)C2CCCCN2.CL.
This classification denotes an antimalarial agent with the molecular formula C18H26ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 886U3H6UFF, chemically known as 1,4-pentanediamine, n(sup 4)-(7-chloro-4-quinolinyl)-n(sup 1),n(sup 1)-diethyl- but generally known as chloroquine, which bears US NIH Compound Identifier 2719. European Medicines Agency schedules Chloroquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06196MIG. The term CHLOROQUINE is an International Non-Proprietary Name. World Health Organization schedules chloroquine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLOROQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chloroquine under HS 29334990 and SITC 51575. As of Q4 2014, CHLOROQUINE remains the US FDA Preferred Term for this commodity. Chloroquine bears US NLM identifiers UMLS ID C0008269 and NCI Concept Code C61671. SMILES: CLC1CC2NCCC(NC(CCCN(CC)CC)C)C2CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H18ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y6068K376I, chemically known as 2-((5-chloro-2-thenyl)(2-(dimethylamino)ethyl)amino)pyridine but generally known as chlorothen, which bears US NIH Compound Identifier 8993. European Medicines Agency schedules chloropyrilene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06195MIG. The term chloropyrilene is a U.S. FDA designation. As of Q4 2014, CHLOROTHEN remains the US FDA Preferred Term for this commodity. Chlorothen bears US NLM identifiers UMLS ID C0164505 and NCI Concept Code C83621. SMILES: CN(C)CCN(CC1=CC=C(S1)Cl)C2=CC=CC=N2.
This classification denotes a thiazide diuretic with the molecular formula C7H6ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77W477J15H, chemically known as 6-chloro-7-sulfamoyl-2h-1,2,4-benzothiadiazine 1,1-dioxide but generally known as chlorothiazide, which bears US NIH Compound Identifier 2720. European Medicines Agency schedules Chlorothiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06198MIG. The term CHLOROTHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules chlorothiazide in its Anatomical Therapeutic Chemical (ATC) Classification. CHLOROTHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorothiazide under HS 29350090 and SITC 51580. As of Q4 2014, CHLOROTHIAZIDE remains the US FDA Preferred Term for this commodity. Chlorothiazide bears US NLM identifiers UMLS ID C0008273 and NCI Concept Code C28924. SMILES: CLC1C(S(=O)(=O)N)CC2S(=O)(=O)N=CNC2C1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a thiazide diuretic with the molecular formula C7H4ClN3O4S2.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SN86FG7N2K, chemically known as 6-chloro-2h-1,2,4-benzothiadiazine-7-sulfonamide, 1,1-dioxide, monosodium salt but more generally known as chlorothiazide sodium, which bears US NIH Compound Identifier 23490. European Medicines Agency schedules Chlorothiazide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21994. Most nations, for tariff and trade purposes, schedule chlorothiazide sodium under HS 29350090 and SITC 51580. As of Q4 2014, CHLOROTHIAZIDE SODIUM remains US FDA's Preferred Term for this commodity. Chlorothiazide sodium bears US NLM identifiers UMLS ID C0304489 and NCI Concept Code C65319. SMILES: C1C2C(CC(C1CL)S(=O)(=O)N)S(=O)(=O)[N-]C=N2.[NA+].
This classification denotes a topical anti-infective agent with the molecular formula C10H13ClO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LJ25TI0CVT, chemically known as thymol, 6-chloro- but generally known as chlorothymol, which bears US NIH Compound Identifier 6982. European Medicines Agency schedules Chlorothymol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13338MIG. As of Q4 2014, CHLOROTHYMOL remains the US FDA Preferred Term for this commodity. Chlorothymol bears US NLM identifiers UMLS ID C0301297 and NCI Concept Code C77040. SMILES: CC1=CC(=C(C=C1CL)C(C)C)O. .
This classification denotes a non-steroidal estrogen with the molecular formula C23H21ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6V5034L121, chemically known as 1,1,1-(1-chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene) but generally known as chlorotrianisene, which bears US NIH Compound Identifier 11289. European Medicines Agency schedules Chlorotrianisene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06199MIG. The term CHLOROTRIANISENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chlorotrianisene in its Anatomical Therapeutic Chemical (ATC) Classification. CHLOROTRIANISENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorotrianisene under HS 29093090 and SITC 51616. As of Q4 2014, CHLOROTRIANISENE remains the US FDA Preferred Term for this commodity. Chlorotrianisene bears US NLM identifiers UMLS ID C0008275 and NCI Concept Code C65320. SMILES: Cl/C(=C(\c1ccc(OC)cc1)c1ccc(OC)cc1)c1ccc(OC)cc1.
This classification denotes an anti-psoriatic agent with the molecular formula C9H5Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2I8BD50I8B, chemically known as 5,7-dichloroxine but generally known as chloroxine, which bears US NIH Compound Identifier 2722. European Medicines Agency schedules Chloroxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13339MIG. As of Q4 2014, CHLOROXINE remains the US FDA Preferred Term for this commodity. Chloroxine bears US NLM identifiers UMLS ID C0055461 and NCI Concept Code C47446. SMILES: CLC1C2C(NCCC2)C(O)C(CL)C1.
This classification denotes an anti-infective agent with the molecular formula C8H9ClO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0F32U78V2Q, chemically known as 3,5-xylenol, 4-chloro- but generally known as chloroxylenol, which bears US NIH Compound Identifier 2723. European Medicines Agency schedules Chloroxylenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06200MIG. The term CHLOROXYLENOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules chloroxylenol in its Anatomical Therapeutic Chemical (ATC) Classification. CHLOROXYLENOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chloroxylenol under HS 29081900 and SITC 51244. As of Q4 2014, CHLOROXYLENOL remains the US FDA Preferred Term for this commodity. Chloroxylenol bears US NLM identifiers UMLS ID C0055463 and NCI Concept Code C76743. SMILES: CLC1C(CC(O)CC1C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1Q0O9OJ9Z. European Medicines Agency schedules Chlorphenamine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorphenamine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorphenamine maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule chlorphenamine maleate under HS 29333999. SMILES: CN(C)CCC(C1CCC(CC1)CL)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U, chemically known as 3-(p-chlorophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but generally known as chlorphenamine, which bears US NIH Compound Identifier 2725. European Medicines Agency schedules Chlorphenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06201MIG. The term CHLORPHENAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chlorphenamine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORPHENAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1CCC(C(CCN(C)C)C2NCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C76H52O46.C16H19CLN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72JT935YTT. European Medicines Agency schedules chlorphenamine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01244MIG. Most nations, for tariff and trade purposes, schedule chlorphenamine tannate under HS 29333999. SMILES:.
This classification denotes an anti-infective agent with the molecular formula C9H11ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I670DAL4SZ, chemically known as 1,2-propanediol, 3-(p-chlorophenoxy)- but generally known as chlorphenesin, which bears US NIH Compound Identifier 7697. European Medicines Agency schedules Chlorphenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06202MIG. World Health Organization schedules chlorphenesin in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORPHENESIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorphenesin under HS 29094990 and SITC 51617. As of Q4 2014, CHLORPHENESIN remains the US FDA Preferred Term for this commodity. Chlorphenesin bears US NLM identifiers UMLS ID C0008280 and NCI Concept Code C77041. SMILES: CLC1CCC(OCC(O)CO)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C10H12ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57U5YI11WP, chemically known as 1,2-propanediol, 3-(p-chlorophenoxy)-, 1-carbamate (8ci) but more generally known as chlorphenesin carbamate, which bears US NIH Compound Identifier 2724. European Medicines Agency schedules Chlorphenesin carbamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01245MIG. Most nations, for tariff and trade purposes, schedule chlorphenesin carbamate under HS 29094990 and SITC 51617. As of Q4 2014, CHLORPHENESIN CARBAMATE remains US FDA's Preferred Term for this commodity. Chlorphenesin carbamate bears US NLM identifiers UMLS ID C0055467 and NCI Concept Code C65322. SMILES: C1CC(CCC1OCC(COC(=O)N)O)CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE507. This VA Drug Class (RE507) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE508. This VA Drug Class (RE508) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE504. This VA Drug Class (RE504) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE504. This VA Drug Class (RE504) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD900. This VA Drug Class (AD900) classifies this compound as belonging to the group ANTIDOTES/DETERRENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19CLN2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S6VUP419V. Most nations, for tariff and trade purposes, schedule chlorpheniramine hydrochloride under HS 29333910. As of Q4 2014, CHLORPHENIRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlorpheniramine hydrochloride bears US NLM identifiers UMLS ID C2828313 and NCI Concept Code C87465. SMILES: CN(C)CCC(C1CCC(CC1)CL)C2CCCCN2.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1Q0O9OJ9Z. European Medicines Agency schedules Chlorphenamine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule chlorpheniramine maleate under HS 29333910. As of Q4 2014, CHLORPHENIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Chlorpheniramine maleate bears US NLM identifiers UMLS ID C0699075 and NCI Concept Code C28925. SMILES: CN(C)CCC(C1CCC(CC1)CL)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE105. This VA Drug Class (RE105) classifies this compound as belonging to the group BRONCHODILATORS, ANTICHOLINERGIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE500. This VA Drug Class (RE500) classifies this compound as belonging to the group COLD REMEDIES, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C76H52O46.C16H19CLN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72JT935YTT. European Medicines Agency schedules chlorphenamine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01244MIG. Most nations, for tariff and trade purposes, schedule chlorpheniramine tannate under HS 29333910. SMILES:. As of Q4 2014, CHLORPHENIRAMINE TANNATE remains US FDA's Preferred Term for this commodity. . Chlorpheniramine tannate bears US NLM identifiers UMLS ID C0724552 and NCI Concept Code C97692.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H22ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3UVD77BP8R, chemically known as 2-(1-(p-chlorophenyl)-1-phenylethoxy)-n,n-dimethylethylamine but generally known as chlorphenoxamine, which bears US NIH Compound Identifier 6475. European Medicines Agency schedules Chlorphenoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06204MIG. The term CHLORPHENOXAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules chlorphenoxamine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORPHENOXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorphenoxamine under HS 29221980 and SITC 51461. As of Q4 2014, CHLORPHENOXAMINE remains the US FDA Preferred Term for this commodity. Chlorphenoxamine bears US NLM identifiers UMLS ID C0055468 and NCI Concept Code C81131. SMILES: CLC1CCC(C(OCCN(C)C)(C2CCCCC2)C)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H22ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5I159322PY, chemically known as 2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)-n,n-dimethylethylamine hydrochloride but more generally known as chlorphenoxamine hydrochloride, which bears US NIH Compound Identifier 11223. European Medicines Agency schedules Chlorphenoxamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01250MIG. Most nations, for tariff and trade purposes, schedule chlorphenoxamine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, CHLORPHENOXAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlorphenoxamine hydrochloride bears US NLM identifiers UMLS ID C1530321 and NCI Concept Code C76671. SMILES: CC(C1CCCCC1)(C2CCC(CC2)CL)OCCN(C)C.CL.
This classification denotes a cns stimulant with the molecular formula C10H14ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) NHW07912O7, chemically known as 4-chloro-.alpha.,.alpha.-dimethylphenethylamine hydrochloride but more generally known as chlorphentermine, which bears US NIH Compound Identifier 10007. European Medicines Agency schedules Chlorphentermine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06205MIG. The term CHLORPHENTERMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). CHLORPHENTERMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule chlorphentermine under HS 29214980 and SITC 51454. As of Q4 2014, CHLORPHENTERMINE remains US FDA's Preferred Term for this commodity. Chlorphentermine bears US NLM identifiers UMLS ID C0008283 and NCI Concept Code C65323. SMILES: CC(C)(CC1=CC=C(C=C1)CL)N.
This classification denotes an anticholinergic agent with the molecular formula C19H23ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 960NX27Z07, chemically known as 10h-phenothiazine-3-propanamine, 2-chloro-n,n-diethyl-, monohydrochloride but generally known as chlorproethazine, which bears US NIH Compound Identifier 65750. European Medicines Agency schedules Chlorproethazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06206MIG. The term CHLORPROETHAZINE is an International Non-Proprietary Name. World Health Organization schedules chlorproethazine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORPROETHAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorproethazine under HS 29343090 and SITC 51578. As of Q4 2014, CHLORPROETHAZINE remains the US FDA Preferred Term for this commodity. Chlorproethazine bears US NLM identifiers UMLS ID C0164858 and NCI Concept Code C79580. SMILES: CLC1CC2N(CCCN(CC)CC)C3C(SC2CC1)CCCC3.
This classification denotes an anticholinergic agent with the molecular formula C19H23ClN2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 520P4U8V2Z, chemically known as 10h-phenothiazine-3-propanamine, 2-chloro-n,n-diethyl-, monohydrochloride but more generally known as chlorproethazine hydrochloride, which bears US NIH Compound Identifier 65750. European Medicines Agency schedules Chlorproethazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01252MIG. Most nations, for tariff and trade purposes, schedule chlorproethazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, CHLORPROETHAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlorproethazine hydrochloride bears US NLM identifiers UMLS ID C0771556 and NCI Concept Code C77983. SMILES: CCN(CC)CCCN1C2CCCCC2SC3C1CC(CC3)CL.CL.
This classification denotes an antiprotozoal agent with the molecular formula C11H15Cl2N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8O3249M729, chemically known as 1-(3,4-dichlorophenyl)-5-isopropylbiguanide but generally known as chlorproguanil, which bears US NIH Compound Identifier 9571037. European Medicines Agency schedules Chlorproguanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06207MIG. The term CHLORPROGUANIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). Most nations schedule chlorproguanil under HS 29252900 and SITC 51482. As of Q4 2014, CHLORPROGUANIL remains the US FDA Preferred Term for this commodity. Chlorproguanil bears US NLM identifiers UMLS ID C0055470 and NCI Concept Code C79941. SMILES: CC(C)N=C(N)/N=C(\N)/NC1=CC(=C(C=C1)CL)CL.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H19ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U42B7VYA4P, chemically known as 10h-phenothiazine-10-propanamine, 2-chloro-n,n-dimethyl-, radical ion(1+) but generally known as chlorpromazine, which bears US NIH Compound Identifier 2726. European Medicines Agency schedules Chlorpromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06208MIG. The term CHLORPROMAZINE is an International Non-Proprietary Name. World Health Organization schedules chlorpromazine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORPROMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorpromazine under HS 29343090 and SITC 51578. As of Q4 2014, CHLORPROMAZINE remains the US FDA Preferred Term for this commodity. Chlorpromazine bears US NLM identifiers UMLS ID C0699065 and NCI Concept Code C367. SMILES: CLC1CC2N(CCCN(C)C)C3C(SC2CC1)CCCC3.
This classification denotes a phenothiazine and antipsychotic agent C17H19ClN2S.C14H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 657G38Q829, chemically known as benzoic acid, 2-(4-hydroxybenzoyl)-, compd. with 2-chloro-n,n-dimethyl-10h-phenothiazine-10-propanamine (1:1), but more generally known as chlorpromazine hibenzate, which bears US NIH Compound Identifier 2726. European Medicines Agency schedules Chlorpromazine hibenzate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22077. Most nations, for tariff and trade purposes, schedule chlorpromazine hibenzate under HS 29343090 and SITC 51578. As of Q4 2014, CHLORPROMAZINE HIBENZATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)CL.C1CCC(C(C1)C(=O)C2CCC(CC2)O)C(=O)O.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H19ClN2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9WP59609J6, chemically known as 10h-phenothiazine-10-propanamine, 2-chloro-n,n-dimethyl-, radical ion(1+) but more generally known as chlorpromazine hydrochloride, which bears US NIH Compound Identifier 2726. European Medicines Agency schedules Chlorpromazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01255MIG. Most nations, for tariff and trade purposes, schedule chlorpromazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, CHLORPROMAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlorpromazine hydrochloride bears US NLM identifiers UMLS ID C0355077 and NCI Concept Code C47975. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)CL.CL.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H19CLN2S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q98X428KKM. European Medicines Agency schedules chlorpromazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01256MIG. Most nations, for tariff and trade purposes, schedule chlorpromazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, CHLORPROMAZINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)CL.C(=C\C(=O)O)\C(=O)O.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C23H16O6.C17H19CLN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85RG9X8ZHE. The term chlorpromazine pamoate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule chlorpromazine pamoate under HS 29343090. As of Q4 2014, CHLORPROMAZINE PAMOATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)CL.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes a phenothiazine and antipsychotic agent C20H16O4.C17H19ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PYC320IMD, chemically known as benzoic acid, 2-(bis(4-hydroxyphenyl)methyl)-, compd. with 2-chloro-n,n-dimethyl-10h-phenothiazine-10-propanamine (1:1), but more generally known as chlorpromazine phenolphthalinate, which bears US NIH Compound Identifier 2726. Most nations, for tariff and trade purposes, schedule chlorpromazine phenolphthalinate under HS 29343090 and SITC 51578. As of Q4 2014, CHLORPROMAZINE PHENOLPHTHALINATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)CL.C1CCC(C(C1)C(C2CCC(CC2)O)C3CCC(CC3)O)C(=O)O.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H19ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6148VKM65V, chemically known as 10h-phenothiazine-10-propanamine, 2-chloro-n,n-dimethyl-, 5,5-dioxide, but more generally known as chlorpromazine sulfone, which bears US NIH Compound Identifier 165214. European Medicines Agency schedules chlorpromazine sulfone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06208MIG. Most nations, for tariff purposes, schedule chlorpromazine sulfone under HS 29343090. SMILES: CN(C)CCCN1C2CCCCC2S(=O)(=O)C3C1CC(CC3)CL.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H19ClN2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 016U10PN9N, chemically known as 2-chloro-10-(3-(dimethylamino)propyl)phenothiazine 5-oxide, but more generally known as chlorpromazine sulphoxide, which bears US NIH Compound Identifier 70413. European Medicines Agency schedules chlorpromazine sulphoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06208MIG. Most nations, for tariff purposes, schedule chlorpromazine sulphoxide under HS 29343090. SMILES: CN(C)CCCN1C2CCCCC2[S+](C3C1CC(CC3)CL)[O-].
This classification denotes an anti-diabetic agent with the molecular formula C10H13ClN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WTM2C3IL2X, chemically known as urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl- but more generally known as chlorpropamide, which bears US NIH Compound Identifier 2727. European Medicines Agency schedules Chlorpropamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06209MIG. The term CHLORPROPAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4) WHO schedules chlorpropamide in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORPROPAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule chlorpropamide under HS 29350090 and SITC 51580. As of Q4 2014, CHLORPROPAMIDE remains US FDA's Preferred Term for this commodity. Chlorpropamide bears US NLM identifiers UMLS ID C0008287 and NCI Concept Code C47447. SMILES: CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)CL.
This classification denotes an antipsychotic agent with the molecular formula C18H18ClNS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9S7OD60EWP, chemically known as 3-(2-chlorothioxanthen-9-ylidene)-n,n-dimethyl-propan-1-amine but generally known as chlorprothixene, which bears US NIH Compound Identifier 2729. European Medicines Agency schedules Chlorprothixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06210MIG. The term CHLORPROTHIXENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules chlorprothixene in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORPROTHIXENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorprothixene under HS 29349910 and SITC 51579. As of Q4 2014, CHLORPROTHIXENE remains the US FDA Preferred Term for this commodity. Chlorprothixene bears US NLM identifiers UMLS ID C0008290 and NCI Concept Code C65325. SMILES: CLC1CC2/C(=C/CCN(C)C)C3C(SC2CC1)CCCC3.
This classification denotes an antipsychotic agent C18H19ClNS.C2H3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K45X4JP9Q1, chemically known as 1-propanamine, 3-(2-chloro-9h-thioxanthen-9-ylidene)-n,n-dimethyl-, (z)-, acetate, but more generally known as chlorprothixene acetate, which bears US NIH Compound Identifier 24892861. European Medicines Agency schedules Chlorprothixene acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35546. Most nations, for tariff and trade purposes, schedule chlorprothixene acetate under HS 29349910 and SITC 51579. As of Q4 2014, CHLORPROTHIXENE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)[O-].C[NH+](C)CC/C=C\1/C2CCCCC2SC3C1CC(CC3)CL.
This classification denotes an antipsychotic agent C18H18ClNS.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 814JN9G41D, chemically known as 1-propanamine, 3-(2-chloro-9h-thioxanthen-9-ylidene)-n,n-dimethyl-, (3z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1), but more generally known as chlorprothixene citrate, which bears US NIH Compound Identifier 24892862. Most nations, for tariff and trade purposes, schedule chlorprothixene citrate under HS 29349910 and SITC 51579. As of Q4 2014, CHLORPROTHIXENE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CC/C=C\1/C2CCCCC2SC3C1CC(CC3)CL.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antipsychotic agent with the molecular formula C18H18ClNS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 268KCR965N, chemically known as 1-propanamine, 3-(2-chloro-9h-thioxanthen-9-ylidene)-n,n-dimethyl-, (z)- but more generally known as chlorprothixene hydrochloride, which bears US NIH Compound Identifier 667466. European Medicines Agency schedules Chlorprothixene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01257MIG. Most nations, for tariff and trade purposes, schedule chlorprothixene hydrochloride under HS 29349910 and SITC 51579. As of Q4 2014, CHLORPROTHIXENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CC/C=C\1/C2CCCCC2SC3C1CC(CC3)CL.CL.
This classification denotes a topical anti-infective agent with the molecular formula C10H7Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D6VHC87LLS, chemically known as 5,7-dichloro-8-quinaldinol but more generally known as chlorquinaldol, which bears US NIH Compound Identifier 6301. European Medicines Agency schedules Chlorquinaldol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06211MIG. The term CHLORQUINALDOL is an International Non-Proprietary Name. The World Health Organization schedules chlorquinaldol in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORQUINALDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=NC2=C(C=C1)C(=CC(=C2O)CL)CL.
This classification denotes a thiazide diuretic with the molecular formula C14H11ClN2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q0MQD1073Q, chemically known as 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)benzenesulfonamide but generally known as chlortalidone, which bears US NIH Compound Identifier 2732. European Medicines Agency schedules Chlortalidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06212MIG. The term CHLORTALIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules chlortalidone in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORTALIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CHLORTHALIDONE remains the US FDA Preferred Term for this commodity. Chlorthalidone bears US NLM identifiers UMLS ID C0008294 and NCI Concept Code C47449. SMILES: CLC1C(S(=O)(=O)N)CC(C2(O)NC(=O)C3C2CCCC3)CC1.
This classification denotes a tetracycline antibiotic with the molecular formula C22H23ClN2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WCK1KIQ23Q, chemically known as 2-(amino-hydroxy-methylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione but generally known as chlortetracycline, which bears US NIH Compound Identifier 5280963. European Medicines Agency schedules Chlortetracycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06213MIG. The term CHLORTETRACYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chlortetracycline in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORTETRACYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlortetracycline under HS 29413000 and SITC 54133. As of Q4 2014, CHLORTETRACYCLINE remains the US FDA Preferred Term for this commodity. Chlortetracycline bears US NLM identifiers UMLS ID C0008293 and NCI Concept Code C61673. SMILES: CLC1C2C(O)(C3CC4C(O)(C(=O)C3=C(O)C2C(O)CC1)C(=O)/C(=C(\O)N)C(=O)C4N(C)C)C.
This classification denotes a tetracycline antibiotic with the molecular formula C22H23ClN2O8.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1D06KZ672I, chemically known as 2-(amino-hydroxy-methylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione but more generally known as chlortetracycline bisulfate, which bears US NIH Compound Identifier 5280963. Most nations, for tariff and trade purposes, schedule chlortetracycline bisulfate under HS 29413000 and SITC 54133. As of Q4 2014, CHLORTETRACYCLINE BISULFATE remains US FDA's Preferred Term for this commodity. Chlortetracycline bisulfate bears US NLM identifiers UMLS ID C0282101 and NCI Concept Code C76989. SMILES: C[C@]1(C2C(CCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)CL)O.OS(=O)(=O)O.
This classification denotes a tetracycline antibiotic C22H23ClN2O8.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NR4B2SX17S, chemically known as 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide calcium salt, but more generally known as chlortetracycline calcium, which bears US NIH Compound Identifier 71458158. Most nations, for tariff and trade purposes, schedule chlortetracycline calcium under HS 29413000 and SITC 54133. As of Q4 2014, CHLORTETRACYCLINE CALCIUM remains US FDA's Preferred Term for this commodity. Chlortetracycline calcium bears US NLM identifiers UMLS ID C2723846 and NCI Concept Code C80800. SMILES: C[C@]1(C2C(CCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)CL)O.[CA+2].
This classification denotes a tetracycline antibiotic with the molecular formula C22H23ClN2O8.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O1GX33ON8R, chemically known as 2-(amino-hydroxy-methylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione but more generally known as chlortetracycline hydrochloride, which bears US NIH Compound Identifier 5280963. European Medicines Agency schedules Chlortetracycline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01258MIG. Most nations, for tariff and trade purposes, schedule chlortetracycline hydrochloride under HS 29413000 and SITC 54133. As of Q4 2014, CHLORTETRACYCLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlortetracycline hydrochloride bears US NLM identifiers UMLS ID C0728748 and NCI Concept Code C47448. SMILES: C[C@]1(C2C(CCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)CL)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C10H10ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KA0B657LV3, chemically known as 4-oxo-2-(beta-chloroethyl)-2,3-dihydrobenzo-1,3-oxazine but generally known as chlorthenoxazine, which bears US NIH Compound Identifier 8602. European Medicines Agency schedules Chlorthenoxazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06214MIG. The term CHLORTHENOXAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). CHLORTHENOXAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorthenoxazine under HS 29349990 and SITC 51579. As of Q4 2014, CHLORTHENOXAZINE remains the US FDA Preferred Term for this commodity. Chlorthenoxazine bears US NLM identifiers UMLS ID CL386772 and NCI Concept Code C77339. SMILES: C1=CC=C2C(=C1)C(=O)NC(O2)CCCL.
This classification denotes a muscle relaxant with the molecular formula C7H4ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H0DE420U8G, chemically known as 2-benzoxazolinone, 5-chloro- but generally known as chlorzoxazone, which bears US NIH Compound Identifier 2733. European Medicines Agency schedules Chlorzoxazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06215MIG. The term CHLORZOXAZONE is an International Non-Proprietary Name. World Health Organization schedules chlorzoxazone in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORZOXAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule chlorzoxazone under HS 29349990 and SITC 51579. As of Q4 2014, CHLORZOXAZONE remains the US FDA Preferred Term for this commodity. Chlorzoxazone bears US NLM identifiers UMLS ID C0008296 and NCI Concept Code C28926. SMILES: CLC1CC2[NH]C(=O)OC2CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
Cholecalciferol/Risedronate sodium or risedronic acid is a fixed-dose combination and is indicated for the treatment and prevention of osteoporosis.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B33BGI082. European Medicines Agency schedules Cholestyramine resin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01427MIG. Colestyramine generally arises in the molecular formula (C12H18CLN)N.(C10H10)N. The term 'colestyramine' is a Hazardous Substances Data Bank designation. COLESTYRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cholestyramine or colestyramine bears US NLM identifiers UMLS ID C0008402 and NCI Concept Code C28929. SMILES: CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C.[Cl-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV350. This VA Drug Class (CV350) classifies this compound as belonging to the group ANTILIPEMIC AGENTS.
This classification denotes a cholagogue or choleretic agent with the molecular formula C24H40O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1JO7801AE, chemically known as 3,7,12-trihydroxycholan-24-oic acid but generally known as cholic acid, which bears US NIH Compound Identifier 303. European Medicines Agency schedules Cholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13348MIG. World Health Organization schedules cholic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cholic acid under HS 29181900 and SITC 51392. As of Q4 2014, CHOLIC ACID remains the US FDA Preferred Term for this commodity. Cholic acid bears US NLM identifiers UMLS ID C0055568 and NCI Concept Code C91035. SMILES: OC1C2(C(C3C(C4(C(CC3O)CC(O)CC4)C)C1)CCC2C(CCC(=O)O)C)C.
This classification denotes a glycerylphosphorylcholine with the molecular formula C8H20NO6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60M22SGW66, chemically known as ethanaminium, 2-(((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)-n,n,n-trimethyl-, hydroxide, inner salt, (r)- but generally known as choline alfoscerate, which bears US NIH Compound Identifier 71920. European Medicines Agency schedules Choline alfoscerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06216MIG. World Health Organization schedules choline alfoscerate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule choline alfoscerate under HS 29231000 and SITC 51481. As of Q4 2014, CHOLINE ALFOSCERATE remains the US FDA Preferred Term for this commodity. SMILES: P(=O)(OCC[N](C)(C)C)(OCC(O)CO)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H5O3.C5H14NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KD510K1IQW, chemically known as 2-hydroxy-n,n,n-trimethylethanaminium salt with 2-hydroxybenzoic acid (1:1) but generally known as choline salicylate, which bears US NIH Compound Identifier 16213. European Medicines Agency schedules Choline salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06219MIG. The term CHOLINE SALICYLATE is an International Non-Proprietary Name. World Health Organization schedules choline salicylate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule choline salicylate under HS 29231000 and SITC 51481. As of Q4 2014, CHOLINE SALICYLATE remains the US FDA Preferred Term for this commodity. Choline salicylate bears US NLM identifiers UMLS ID C0055573 and NCI Concept Code C76798. SMILES: OCC[N](C)(C)C.OC1C(CCCC1)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.
This classification denotes a phosphodiesterase inhibitor and bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K045XR58X. European Medicines Agency schedules Choline theophyllinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06220MIG. Choline theophyllinate generally arises in the molecular formula C7H7N4O2.C5H14NO. The term CHOLINE THEOPHYLLINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) Choline theophyllinate or oxtriphylline bears US NLM identifiers UMLS ID C0055578 and NCI Concept Code C47645. SMILES: OCC[N](C)(C)C.O=C1N(C(=O)N(C2NC[NH]C12)C)C.
This classification denotes a glycosaminoglycan with the molecular formula (C14H21NO14S)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6IC1M3OG5Z. European Medicines Agency schedules chondroitin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13355MIG. The term chondroitin sulfate is a U.S. FDA designation. SMILES: CC(=O)NC1C(C(C(OC1O)CO)O)OC2C(C(C=C(O2)C(=O)O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HA000. This VA Drug Class (HA000) classifies this compound as belonging to the group HERBS/ALTERNATIVE THERAPIES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HA000. This VA Drug Class (HA000) classifies this compound as belonging to the group HERBS/ALTERNATIVE THERAPIES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HA000. This VA Drug Class (HA000) classifies this compound as belonging to the group HERBS/ALTERNATIVE THERAPIES.
This classification denotes a therapeutic gonadotropin with the molecular formula C1105H1770N318O336S26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6413W06WR3, more generally known as chorionic gonadotropin. European Medicines Agency schedules chorionic gonadotropin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12481MIG. The term CHORIOGONADOTROPIN ALFA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 11, no. 11997, list 37. SMILES: NONE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN490. This VA Drug Class (TN490) classifies this compound as belonging to the group ELECTROLYTES/MINERALS, COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HA000. This VA Drug Class (HA000) classifies this compound as belonging to the group HERBS/ALTERNATIVE THERAPIES.
This classification denotes a biological response modifier with the molecular formula C11H13N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 325PG708LF, chemically known as 2-aziridinecarbonitrile, 1-((2-methoxy-6-methyl-3-pyridinyl)methyl)- but more generally known as ciamexon, which bears US NIH Compound Identifier 71759. European Medicines Agency schedules Ciamexon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06224MIG. The term CIAMEXON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). CIAMEXON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ciamexon under HS 29333999 and SITC 51574. As of Q4 2014, CIAMEXON remains US FDA's Preferred Term for this commodity. Ciamexon bears US NLM identifiers UMLS ID C0109748 and NCI Concept Code C76067. SMILES: CC1=NC(=C(C=C1)CN2CC2C#N)OC.
This classification denotes a serotonin antagonist with the molecular formula C20H23N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02MNR4P2PM, chemically known as 5h-dibenz(b,f)azepine-3-carbonitrile, 5-(3-(dimethylamino)propyl)-10,11-dihydro- but generally known as cianopramine, which bears US NIH Compound Identifier 48126. European Medicines Agency schedules Cianopramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06227MIG. The term CIANOPRAMINE is an International Non-Proprietary Name. CIANOPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cianopramine under HS 29339930 and SITC 51577. As of Q4 2014, CIANOPRAMINE remains the US FDA Preferred Term for this commodity. Cianopramine bears US NLM identifiers UMLS ID C0109751 and NCI Concept Code C80767. SMILES: N1(CCCN(C)C)c2c(CCc3c1cccc3)ccc(c2)C#N.
This classification denotes an anti-arrhythmia agent with the molecular formula C18H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Z7489237QT, chemically known as 1h-imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-, (+-)- but more generally known as cibenzoline, which bears US NIH Compound Identifier 2747. European Medicines Agency schedules Cibenzoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06229MIG. World Health Organization schedules cibenzoline in its Anatomical Therapeutic Chemical (ATC) Classification. CIBENZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cibenzoline under HS 29332990 and SITC 51573. SMILES: C1CN=C(N1)C2CC2(C3=CC=CC=C3)C4=CC=CC=C4.
This classification denotes a penicillin antibiotic with the molecular formula C15H23N3O4S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 72ZJ154X86, chemically known as 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but more generally known as ciclacillin, which bears U.S. National Institutes of Health Compound Identifier 19003. The European Medicines Agency schedules Ciclacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06232MIG. The term CICLACILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). CICLACILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C.
This classification denotes an antispasmotic agent with the molecular formula C12H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MYS6082G8G, chemically known as 3,3,5-trimethylcyclohexyl lactate. but generally known as ciclactate, which bears US NIH Compound Identifier 193969. European Medicines Agency schedules Ciclactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06233MIG. The term CICLACTATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). CICLACTATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciclactate under HS 29181100 and SITC 51391. As of Q4 2014, CICLACTATE remains the US FDA Preferred Term for this commodity. Ciclactate bears US NLM identifiers UMLS ID C2825696 and NCI Concept Code C81589. SMILES: O(C1CC(CC(C1)C)(C)C)C(=O)C(O)C.
This classification denotes an antidepressant agent with the molecular formula C17H15ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3I9520J7P, chemically known as 10-(m-chlorophenyl)-2,3,4,10-tetrahydropyrimido(1,2-a)indol-10-ol but generally known as ciclazindol, which bears US NIH Compound Identifier 37825. European Medicines Agency schedules Ciclazindol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06235MIG. The term CICLAZINDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). CICLAZINDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciclazindol under HS 29335995 and SITC 51576. As of Q4 2014, CICLAZINDOL remains the US FDA Preferred Term for this commodity. Ciclazindol bears US NLM identifiers UMLS ID C0055708 and NCI Concept Code C79886. SMILES: Clc1cc(C2(O)C3=NCCCN3c3c2cccc3)ccc1.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S59502J185. European Medicines Agency schedules Ciclesonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06236MIG. Ciclesonide generally arises in the molecular formula C32H44O7. The term CICLESONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) Most nations schedule ciclesonide under HS 29372900 and SITC 54153. As of Q4 2014, CICLESONIDE remains the US FDA Preferred Term for this commodity. Ciclesonide bears US NLM identifiers UMLS ID C0907850 and NCI Concept Code C65326. SMILES: O1C2(C3(C(C4C(C(O)C3)C3(C(=CC(=O)C=C3)CC4)C)CC2OC1C1CCCCC1)C)C(=O)COC(=O)C(C)C.
This classification denotes a diuretic with the molecular formula C14H12ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CHG7QC509W, chemically known as win 90,000 but generally known as cicletanine, which bears US NIH Compound Identifier 54910. European Medicines Agency schedules Cicletanine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06237MIG. The term CICLETANINE is an International Non-Proprietary Name. World Health Organization schedules cicletanine in its Anatomical Therapeutic Chemical (ATC) Classification. CICLETANINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cicletanine under HS 29349990 and SITC 51579. As of Q4 2014, CICLETANINE remains the US FDA Preferred Term for this commodity. Cicletanine bears US NLM identifiers UMLS ID C0056686 and NCI Concept Code C77557. SMILES: CLC1CCC(C2OCC3C2CNC(C3O)C)CC1.
This classification denotes a diuretic with the molecular formula C14H12ClNO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T0SY6373OQ, chemically known as furo(3,4-c)pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, hydrochloride but more generally known as cicletanine hydrochloride, which bears US NIH Compound Identifier 54909. European Medicines Agency schedules Cicletanine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01291MIG. Most nations, for tariff and trade purposes, schedule cicletanine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, CICLETANINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cicletanine hydrochloride bears US NLM identifiers UMLS ID C1530416 and NCI Concept Code C101534. SMILES: CC1C(C2C(CN1)C(OC2)C3CCC(CC3)CL)O.CL.
This classification denotes an antidepressant agent with the molecular formula C14H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CXJ7G6BYD7, chemically known as 2,3,4,9-tetrahydro-n,n-dimethyl-1h-carbazol-3-amine but generally known as ciclindole, which bears US NIH Compound Identifier 36082. European Medicines Agency schedules Ciclindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06238MIG. The term CICLINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). CICLINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ciclindole or cyclindole bears US NLM identifiers UMLS ID C0056704 and NCI Concept Code C81488. SMILES: N(C1Cc2c([nH]c3c2cccc3)CC1)(C)C.
This classification denotes an antihelminthic agent with the molecular formula C13H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JF3KQ40J31, chemically known as 2-benzimidazolecarbamic acid, 5-(cyclopropylcarbonyl)-, methyl ester but generally known as ciclobendazole, which bears US NIH Compound Identifier 35803. European Medicines Agency schedules Ciclobendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06240MIG. The term CICLOBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules ciclobendazole in its Anatomical Therapeutic Chemical (ATC) Classification. CICLOBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ciclobendazole or cyclobendazole bears US NLM identifiers UMLS ID C2699486 and NCI Concept Code C78041. SMILES: COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3CC3.
This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OH4ZJ36RB2. European Medicines Agency schedules Ciclofenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06241MIG. Ciclofenazine generally arises in the molecular formula C23H26F3N3S. The term CICLOFENAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) CICLOFENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ciclofenazine or cyclophenazine bears US NLM identifiers UMLS ID C2825451 and NCI Concept Code C81097. SMILES: C1CC1N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(F)(F)F.
This classification denotes an antilipolytic and a myolytic and nicotinic acid with the molecular formula C15H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7H634NXI03, chemically known as 3-pyridinecarboxylic acid, 3,3,5-trimethylcyclohexyl ester, trans- but generally known as ciclonicate, which bears US NIH Compound Identifier 68703. European Medicines Agency schedules Ciclonicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06243MIG. World Health Organization schedules ciclonicate in its Anatomical Therapeutic Chemical (ATC) Classification. CICLONICATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Ciclonicate under HS 29333999 and SITC 51574. As of Q4 2014, CICLONICATE remains the US FDA Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H](CC(C1)(C)C)OC(=O)C2CCCNC2.
This classification denotes an anticholinergic agent with the molecular structure C22H34NO.BR, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 72R7F44611 chemically known as ethanaminium, 2-(1-bicyclo(2.2.1)hept-5-en-2-yl-1-phenylethoxy)-n,n-diethyl-n-methyl-, bromide (1:1), but more commonly known as ciclonium bromide, which bears US NIH Compound Identifier 34625. European Medicines Agency schedules Ciclonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06244MIG. The term CICLONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, no. 10, 1968, list 8. ). Most nations, for tariff and trade purposes, schedule ciclonium bromide under HS 29239000. As of Q4 2014, CICLONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Ciclonium bromide bears US NLM NCI C90694. SMILES: CC[N+](C)(CC)CCOC(C)(C1CCCCC1)C2CC3CC2C=C3.[BR-].
This classification denotes an anticholinergic agent with the molecular formulas C22H34NO2, C22H34NO.Br, and C22H34NO.I, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 682380CG4N, 72R7F44611, and 682380CG4N, the base compound being chemically known as 2-cyclohexyl-2-phenyl-4-piperidinomethyl-dioxolane-1,3 but generally known as ciclonium, which bears US NIH Compound Identifier 168884. European Medicines Agency schedules Ciclonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01293MIG, SUB06244MIG, and SUB09499MIG. The term CICLONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). Ciclonium bears US NLM NCI C90694. SMILES: C[N+]1(CCCCC1)CC2COC(O2)(C3CCCCC3)C4=CC=CC=C4.[I-] (base) or CC[N+](C)(CC)CCOC(C)(C1CCCCC1)C2CC3CC2C=C3.[BR-] (bromide).
This classification denotes an antifungal agent with the molecular formula C12H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19W019ZDRJ, chemically known as 2(1h)-pyridone, 6-cyclohexyl-1-hydroxy-4-methyl- but generally known as ciclopirox, which bears US NIH Compound Identifier 2749. European Medicines Agency schedules Ciclopirox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06245MIG. The term CICLOPIROX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules ciclopirox in its Anatomical Therapeutic Chemical (ATC) Classification. CICLOPIROX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciclopirox under HS 29337900 and SITC 51561. As of Q4 2014, CICLOPIROX remains the US FDA Preferred Term for this commodity. Ciclopirox bears US NLM identifiers UMLS ID C0055711 and NCI Concept Code C61677. SMILES: CC1=CC(=O)N(C(=C1)C2CCCCC2)O.
This classification denotes an antifungal agent with the molecular formula C12H17NO2.C2H7NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50MD4SB4AP, chemically known as 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1h)-one, compound with 2-aminoethanol (1:1) but more generally known as ciclopirox olamine, which bears US NIH Compound Identifier 38911. European Medicines Agency schedules Ciclopirox olamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01294MIG. Most nations, for tariff and trade purposes, schedule ciclopirox olamine under HS 29337900 and SITC 51561. As of Q4 2014, CICLOPIROX OLAMINE remains US FDA's Preferred Term for this commodity. Ciclopirox olamine bears US NLM identifiers UMLS ID C0126169 and NCI Concept Code C65327. SMILES: CC1CC(N(C(=O)C1)O)C2CCCCC2.C(CO)N.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K2ACH4U3R, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-((1-methylethyl)amino)- but generally known as cicloprolol, which bears US NIH Compound Identifier 146294. European Medicines Agency schedules Cicloprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06248MIG. The term CICLOPROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). CICLOPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cicloprolol under HS 29221980 and SITC 51461. As of Q4 2014, CICLOPROLOL remains the US FDA Preferred Term for this commodity. Cicloprolol bears US NLM identifiers UMLS ID C0055713 and NCI Concept Code C79559. SMILES: O(CC1CC1)CCOC1CCC(OCC(O)CNC(C)C)CC1.
This classification denotes the hydrochloride form of a beta-adrenergic blocking agent with the molecular formula C18H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K2ACH4U3R, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-((1-methylethyl)amino)- but more generally known as cicloprolol, which bears US NIH Compound Identifier 146294. European Medicines Agency schedules Cicloprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06248MIG. The term CICLOPROLOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). CICLOPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cicloprolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, CICLOPROLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cicloprolol hydrochloride bears US NLM identifiers UMLS ID C0074661 and NCI Concept Code C90795. SMILES: CC(C)NCC(COC1CCC(CC1)OCCOCC2CC2)O.CL.
This classification denotes a vasodilating agent and nitric oxide-releasing compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S7P608OW2O. European Medicines Agency schedules Ciclosidomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06249MIG. Ciclosidomine generally arises in the molecular formula C13H20N4O3. The term CICLOSIDOMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) CICLOSIDOMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciclosidomine under HS 29349990 and SITC 51579. As of Q4 2014, CICLOSIDOMINE remains the US FDA Preferred Term for this commodity. Ciclosidomine bears US NLM identifiers UMLS ID C0055714 and NCI Concept Code C77149. SMILES: O1CCN([N]2NOC(/N=C(\O)C3CCCCC3)C2)CC1.
This classification denotes a multidrug resistance modulator and immunosuppressant with the molecular formula C62H111N11O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83HN0GTJ6D, chemically known as cyclosporin a, tolypocladium inflatum but more generally known as ciclosporin, which bears US NIH Compound Identifier 5280754. European Medicines Agency schedules Ciclosporin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06250MIG. The term CICLOSPORIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules ciclosporin in its Anatomical Therapeutic Chemical (ATC) Classification. CICLOSPORIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CYCLOSPORINE remains US FDA's Preferred Term for this commodity. Cyclosporine bears US NLM identifiers UMLS ID C0010592 and NCI Concept Code C406. SMILES: OC(C1N(C(=O)C(N(C(=O)C(N(C(=O)C(N(C(=O)C(NC(=O)C(NC(=O)C(N(C(=O)C(NC(=O)C(N(C(=O)CN(C(=O)C(NC1=O)CC)C)C)CC(C)C)C(C)C)C)CC(C)C)C)C)C)CC(C)C)C)CC(C)C)C)C(C)C)C)C(C/C=C/C)C.
This classification denotes a benzodiazepine with the molecular formula C20H18BrClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JK517QTN4Q, chemically known as 2-bromo-4-(o-chlorophenyl)-9-cyclohexyl-6h-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine but generally known as ciclotizolam, which bears US NIH Compound Identifier 71949. European Medicines Agency schedules Ciclotizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06251MIG. The term CICLOTIZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). CICLOTIZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciclotizolam under HS 29349990 and SITC 51579. As of Q4 2014, CICLOTIZOLAM remains the US FDA Preferred Term for this commodity. Ciclotizolam bears US NLM identifiers UMLS ID C0055715 and NCI Concept Code C77634. SMILES: BRC1SC2N3C(NNC3CN=C(C2C1)C1C(CL)CCCC1)C1CCCCC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C29H37ClFNO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UL947A614K, chemically known as 3-(2-chloroethoxy)-9-fluoro-11beta, 16alpha,17,21-tetrahydroxy-20-oxopregna-3,5-diene-6-carbonitrile, cyclic 16,17-acetal with acetone, 21-acetate. but generally known as cicortonide, which bears US NIH Compound Identifier 193972. European Medicines Agency schedules Cicortonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06255MIG. The term CICORTONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). CICORTONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cicortonide under HS 29372200 and SITC 54153. As of Q4 2014, CICORTONIDE remains the US FDA Preferred Term for this commodity. Cicortonide bears US NLM identifiers UMLS ID C2699209 and NCI Concept Code C77407. SMILES: CLCCOC1=CC2=C(CC3C4C(C5(OC(OC5C4)(C)C)C(=O)COC(=O)C)(CC(O)C3(F)C2(CC1)C)C)C#N.
This classification denotes an antiviral agent with the molecular formula C8H14N3O6P.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, JIL713Q00N chemically known as phosphonic acid, ((2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, dihydrate, (s)- but generally known as cidofovir, which bears US NIH Compound Identifier 60613. European Medicines Agency schedules Cidofovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06257MIG. The term CIDOFOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35. ). Most nations schedule cidofovir under HS 29335995 and SITC 51576. As of Q4 2014, CIDOFOVIR remains the US FDA Preferred Term for this commodity. Cidofovir bears US NLM identifiers UMLS ID C0286079 and NCI Concept Code C1600. SMILES: P(=O)(O)(O)COC(CN1CCC(NC1=O)N)CO.
This classification denotes an antiviral agent with the molecular formula C8H14N3O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 768M1V522C, chemically known as phosphonic acid, ((2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (s)-, but more generally known as cidofovir anhydrous, which bears US NIH Compound Identifier 60613. European Medicines Agency schedules cidofovir anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06257MIG. Most nations, for tariff purposes, schedule cidofovir anhydrous under HS 29335995. Cidofovir anhydrous bears US NLM identifiers UMLS ID C2699210 and NCI Concept Code C77925. SMILES: C1CN(C(=O)NC1N)C[C@@H](CO)OCP(=O)(O)O.
This classification denotes an antiviral agent with the molecular formula C8H12N3O6P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M83JB37U61, chemically known as phosphonic acid, ((2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, disodium salt, (s)-, but more generally known as cidofovir sodium, which bears US NIH Compound Identifier 135406. European Medicines Agency schedules cidofovir sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06257MIG. Most nations, for tariff purposes, schedule cidofovir sodium under HS 29335995. SMILES: C1CN(C(=O)NC1N)C[C@@H](CO)OCP(=O)([O-])[O-].[NA+].[NA+].
This classification denotes an anti-diabetic agent with the molecular formula C18H23NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U8QXS1WU8G, chemically known as 2,4-thiazolidinedione, 5-((4-((1-methylcyclohexyl)methoxy)phenyl)methyl)-, (+-)- but more generally known as ciglitazone, which bears US NIH Compound Identifier 2750. European Medicines Agency schedules Ciglitazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06260MIG. The term CIGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). CIGLITAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ciglitazone under HS 29341000 and SITC 51579. As of Q4 2014, CIGLITAZONE remains US FDA's Preferred Term for this commodity. Ciglitazone bears US NLM identifiers UMLS ID C0055721 and NCI Concept Code C72726. SMILES: S1C(CC2CCC(OCC3(CCCCC3)C)CC2)C(=O)NC1=O.
This classification denotes an antihypertensive agent and analgesic agent with the molecular formula C20H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NLD2X0VD2U, chemically known as 10,11-dihydro-n,n-dimethylspiro(5h-dibenzo(a,d)cycloheptene-5,2-(1,3)dioxolane)-4-methylamine. but generally known as ciheptolane, which bears US NIH Compound Identifier 115697. European Medicines Agency schedules Ciheptolane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06261MIG. The term CIHEPTOLANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). CIHEPTOLANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciheptolane under HS 29329970 and SITC 51569. As of Q4 2014, CIHEPTOLANE remains the US FDA Preferred Term for this commodity. Ciheptolane bears US NLM identifiers UMLS ID C2699211 and NCI Concept Code C77318. SMILES: O1C2(OCC1CN(C)C)c1c(CCc3c2cccc3)cccc1.
This classification denotes a dopamine agonist with the molecular formula C21H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D09L486R3J, chemically known as 2,4,6-cycloheptatrien-1-one, 2-(4-(2-(3,4-dimethoxyphenyl)-2-hydroxyethyl)-1-piperazinyl)-, (s)- but generally known as ciladopa, which bears US NIH Compound Identifier 133371. European Medicines Agency schedules Ciladopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06262MIG. The term CILADOPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). CILADOPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciladopa under HS 29335995 and SITC 51576. As of Q4 2014, CILADOPA remains the US FDA Preferred Term for this commodity. Ciladopa bears US NLM identifiers UMLS ID C0055722 and NCI Concept Code C79568. SMILES: OC(CN1CCN(CC1)C1C(=O)CCCCC1)C1CC(OC)C(OC)CC1.
This classification denotes a dopamine agonist with the molecular formula C21H26N2O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ASR1NR721I. The term ciladopa hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule ciladopa hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, CILADOPA HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC(CC1OC)[C@@H](CN2CCN(CC2)C3CCCCCC3=O)O.CL.
This classification denotes a 5-ht3 receptor antagonist with the molecular formula C20H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2J6DQ1U5B5, chemically known as 4h-pyrido(3,2,1-jk)carbazol-11(8h)-one, 5,6,9,10-tetrahydro-10-((2-methyl-1h-imidazol-1-yl)methyl)-, (r)- but generally known as cilansetron, which bears US NIH Compound Identifier 65939. European Medicines Agency schedules Cilansetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06263MIG. The term CILANSETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules cilansetron in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cilansetron under HS 29332990 and SITC 51573. As of Q4 2014, CILANSETRON remains the US FDA Preferred Term for this commodity. Cilansetron bears US NLM identifiers UMLS ID C0249289 and NCI Concept Code C76106. SMILES: O=C1C(CCC2N3C4C(C12)CCCC4CCC3)CN1C(NCC1)C.
This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 141A6AMN38. European Medicines Agency schedules Cilastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06264MIG. Cilastatin generally arises in the molecular formula C16H26N2O5S. The term CILASTATIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 38, no. 6, 1984, list 24.) CILASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C(N/C(=C\CCC)C(=O)O)C1C(C1)(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM119. This VA Drug Class (AM119) classifies this compound as belonging to the group BETA-LACTAMS ANTIMICROBIALS, OTHER.
This classification denotes a protease inhibitor with the molecular formula C16H24N2O5S.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5428WXZ74M, chemically known as 2-heptenoic acid, 7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-, monosodium salt, (r-(r*,s*-(z)))- but more generally known as cilastatin sodium, which bears US NIH Compound Identifier 5282480. European Medicines Agency schedules Cilastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01295MIG. Most nations schedule cilastatin sodium under HS 29309016. SMILES:. As of Q4 2014, CILASTATIN SODIUM remains the US FDA Preferred Term for this commodity. . Cilastatin sodium bears US NLM identifiers UMLS ID C0282395 and NCI Concept Code C65329.
This classification denotes an ace inhibitor with the molecular formula C22H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Q9454114Q, chemically known as 6h-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, octahydro-9-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-10-oxo-, hydrate, (1s-(1-alpha,9-alpha(r*)))- but generally known as cilazapril, which bears US NIH Compound Identifier 56329. European Medicines Agency schedules Cilazapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06265MIG. The term CILAZAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules cilazapril in its Anatomical Therapeutic Chemical (ATC) Classification. CILAZAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cilazapril under HS 29339940 and SITC 51577. SMILES: O=C1N2N(CCCC2C(=O)O)CCCC1NC(CCc1ccccc1)C(=O)OCC.O.
This classification denotes an ace inhibitor with the molecular formula C22H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Q9454114Q, chemically known as 6h-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, 9-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)octahydro-10-oxo-, monohydrate, (1s-(1.alpha.,9.alpha.(r*))), but more generally known as cilazapril anhydrous, which bears US NIH Compound Identifier 56330. European Medicines Agency schedules cilazapril anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06265MIG. Most nations, for tariff purposes, schedule cilazapril anhydrous under HS 29339940. As of Q4 2014, CILAZAPRIL ANHYDROUS remains US FDA's Preferred Term for this commodity. Cilazapril anhydrous bears US NLM identifiers UMLS ID C0886706 and NCI Concept Code C76134. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O.
This classification denotes an ace inhibitor with the molecular formula C20H27N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WBL76FH528, chemically known as n-((1s,9s)-1-carboxy-10-oxoperhydropyridazino-(1,2-alpha)(1,2)diazepin-9-yl)-4-phenyl-l-homoalanine but generally known as cilazaprilat, which bears US NIH Compound Identifier 64766. European Medicines Agency schedules Cilazaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06266MIG. The term CILAZAPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). CILAZAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cilazaprilat under HS 29339940 and SITC 51577. As of Q4 2014, CILAZAPRILAT remains the US FDA Preferred Term for this commodity. Cilazaprilat bears US NLM identifiers UMLS ID C0055724 and NCI Concept Code C75927. SMILES: O=C1N2N(CCCC2C(=O)O)CCCC1NC(CCc1ccccc1)C(=O)O.
This classification denotes an ace inhibitor with the molecular structure C22H31N3O5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 19KW7PI29F chemically known as (1s,9s)-9-(((s)-1-carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6h-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl ester monohydrate, but more commonly known as cilazapril, which bears US NIH Compound Identifier 56329. European Medicines Agency schedules Cilazapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06265MIG. The term CILAZAPRIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, no. 5, 1985, list 25. ). Most nations, for tariff and trade purposes, schedule cilazapril monohydrate under HS 29339940 and SITC 51577. As of Q4 2014, CILAZAPRIL MONOHYDRATE remains US FDA's Preferred Term for this commodity. Cilazapril monohydrate bears US NLM identifiers UMLS ID C0055723 and NCI Concept Code C76133. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O.O.
This classification denotes a calcium channel blocker with the molecular formula C27H28N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97T5AZ1JIP, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester, (e)-(+-)- but generally known as cilnidipine, which bears US NIH Compound Identifier 5282138. European Medicines Agency schedules Cilnidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06268MIG. World Health Organization schedules cilnidipine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cilnidipine under HS 29333999 and SITC 51574. As of Q4 2014, CILNIDIPINE remains the US FDA Preferred Term for this commodity. SMILES: O(C(=O)C1=C(NC(=C(C1c1cc([N](=O)O)ccc1)C(=O)OC/C=C/c1ccccc1)C)C)CCOC.
This classification denotes an antidepressant agent with the molecular formula C17H23CL2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 067U1T4S30 chemically known as bicyclo(2.2.2)octan-2-ol, 2-(3,4-dichlorophenyl)-3-((1-methylethyl)amino)-, cis- but generally known as cilobamine, which bears US NIH Compound Identifier 50538. European Medicines Agency schedules Cilobamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06269MIG. The term CILOBAMINE is an International Non-Proprietary Name or INN. Most nations schedule cilobamine under HS 29221980 and SITC 51461. As of Q4 2014, CILOBAMINE remains the US FDA Preferred Term for this commodity. Cilobamine bears US NLM identifiers UMLS ID C0621295 and NCI Concept Code C81476. SMILES: CC(C)NC1C2CCC(C1(C3=CC(=C(C=C3)Cl)Cl)O)CC2.
This classification denotes an antidepressant agent with the molecular formula C17H23Cl2NO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SZ83PVQ06I, chemically known as bicyclo(2.2.2)octan-2-ol, 2-(3,4-dichlorophenyl)-3-((1-methylethyl)amino)-, cis-, methanesulfonate (salt), but more generally known as cilobamine mesylate, which bears US NIH Compound Identifier 50537. European Medicines Agency schedules cilobamine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06269MIG. Most nations, for tariff purposes, schedule cilobamine mesylate under HS 29221980. As of Q4 2014, CILOBAMINE MESYLATE remains US FDA's Preferred Term for this commodity. Cilobamine mesylate bears US NLM identifiers UMLS ID C0621294 and NCI Concept Code C78008. SMILES: CC(C)N[C@@H]1C2CCC([C@]1(C3CCC(C(C3)CL)CL)O)CC2.CS(=O)(=O)O.
This classification denotes an antifungal agent with the molecular formula C49H71N7O17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ZJC54A39X, chemically known as 1-((4r,5r)-4,5-dihydroxy-n(sup 2)-(p-(octyloxy)benzoyl)-l-ornithine)echinocandin b but generally known as cilofungin, which bears US NIH Compound Identifier 71762. European Medicines Agency schedules Cilofungin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06271MIG. The term CILOFUNGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). CILOFUNGIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cilofungin under HS 29419000 and SITC 54139. As of Q4 2014, CILOFUNGIN remains the US FDA Preferred Term for this commodity. Cilofungin bears US NLM identifiers UMLS ID C0055726 and NCI Concept Code C83623. SMILES: OC1C(CN2C1C(=O)NC(O)C(O)CC(NC(=O)C1CCC(OCCCCCCCC)CC1)C(=O)NC(C(=O)N1C(CC(O)C1)C(=O)NC(C(=O)NC(C2=O)C(O)C)C(O)C(O)C1CCC(O)CC1)C(O)C)C.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C20H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ATB1C1R6X, chemically known as cyclohexanecarboxylic acid, 4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-, cis- but generally known as cilomilast, which bears US NIH Compound Identifier 151170. European Medicines Agency schedules Cilomilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01296MIG. The term CILOMILAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule cilomilast under HS 29269095 and SITC 51484. As of Q4 2014, CILOMILAST remains the US FDA Preferred Term for this commodity. Cilomilast bears US NLM identifiers UMLS ID C0968887 and NCI Concept Code C95232. SMILES: O(C1CCCC1)C1CC(C2(CCC(CC2)C(=O)O)C#N)CCC1OC.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C20H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45S5605Q18, chemically known as n-cyclohexyl-n-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide but generally known as cilostamide, which bears US NIH Compound Identifier 2753. European Medicines Agency schedules Cilostamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06272MIG. The term CILOSTAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). CILOSTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cilostamide under HS 29337900 and SITC 51561. As of Q4 2014, CILOSTAMIDE remains the US FDA Preferred Term for this commodity. Cilostamide bears US NLM identifiers UMLS ID C0055728 and NCI Concept Code C76315. SMILES: O=C(N(C1CCCCC1)C)CCCOc1cc2c([nH]c(=O)cc2)cc1.
This classification denotes a phosphodiesterase inhibitor and antiplatelet agent with the molecular formula C20H27N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N7Z035406B, chemically known as 3,4-dihydro-6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-2(1h)-quinolinone but generally known as cilostazol, which bears US NIH Compound Identifier 2754. European Medicines Agency schedules Cilostazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06273MIG. The term CILOSTAZOL is an International Non-Proprietary Name. World Health Organization schedules cilostazol in its Anatomical Therapeutic Chemical (ATC) Classification. CILOSTAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cilostazol under HS 29337900 and SITC 51561. As of Q4 2014, CILOSTAZOL remains the US FDA Preferred Term for this commodity. Cilostazol bears US NLM identifiers UMLS ID C0055729 and NCI Concept Code C1051. SMILES: O(CCCCC1N(NNN1)C1CCCCC1)C1CC2CCC(=O)NC2CC1.
This classification denotes a beta-adrenergic agonist with the molecular formula C12H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZPY8VRF0GB, chemically known as benzonitrile, 2-amino-5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (+-)- but generally known as cimaterol, which bears US NIH Compound Identifier 2755. European Medicines Agency schedules Cimaterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06276MIG. The term CIMATEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). CIMATEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cimaterol under HS 29269095 and SITC 51484. As of Q4 2014, CIMATEROL remains the US FDA Preferred Term for this commodity. Cimaterol bears US NLM identifiers UMLS ID C0055730 and NCI Concept Code C76017. SMILES: CC(C)NCC(C1=CC(=C(C=C1)N)C#N)O.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C10H16N6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80061L1WGD, chemically known as guanidine, n-cyano-n-methyl-n-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)- but generally known as cimetidine, which bears US NIH Compound Identifier 2756. European Medicines Agency schedules Cimetidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06279MIG. The term CIMETIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules cimetidine in its Anatomical Therapeutic Chemical (ATC) Classification. CIMETIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cimetidine under HS 29332990 and SITC 51573. As of Q4 2014, CIMETIDINE remains the US FDA Preferred Term for this commodity. Cimetidine bears US NLM identifiers UMLS ID C0008783 and NCI Concept Code C374. SMILES: CC1=C(N=CN1)CSCCNC(=NC)NC#N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA301. This VA Drug Class (GA301) classifies this compound as belonging to the group HISTAMINE ANTAGONISTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA301. This VA Drug Class (GA301) classifies this compound as belonging to the group HISTAMINE ANTAGONISTS.
This classification denotes an anticholinergic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1N3H74AYTK, chemically known as (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-9-(CYCLOPROPYLMETHYL)-7-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9-METHYL-3-OXA-9-AZONIATRICYCLO(3.3.1.0(SUP 2,4))NONANE but generally known as cimetropium, which bears US NIH Compound Identifier 6917944. European Medicines Agency schedules Cimetropium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01298MIG. The term CIMETROPIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) As of Q4 2014, CIMETROPIUM remains the US FDA Preferred Term for this commodity. SMILES: none.
This classification denotes an anticholinergic agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 0C7M5WE60Q. European Medicines Agency schedules Cimetropium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06280MIG. Cimetropium bromide generally arises in the molecular formula C21H28BRNO4. The term CIMETROPIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 38, no. 6, 1984, list 24.)
This classification denotes a monoamine oxidase inhibitor with the molecular formula C19H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6FT1QJ7VL, chemically known as benzonitrile, 3-((4-(5-(methoxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)methyl)- but generally known as cimoxatone, which bears US NIH Compound Identifier 52542. European Medicines Agency schedules Cimoxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06281MIG. The term CIMOXATONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). CIMOXATONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cimoxatone under HS 29349990 and SITC 51579. As of Q4 2014, CIMOXATONE remains the US FDA Preferred Term for this commodity. Cimoxatone bears US NLM identifiers UMLS ID C0109794 and NCI Concept Code C90879. SMILES: O1C(CN(c2ccc(OCc3cc(ccc3)C#N)cc2)C1=O)COC.
This classification denotes a malignancy-associated hypercalcemia inhibitor with the molecular formula C22H22F3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UAZ6V7728S, chemically known as 1-naphthalenemethanamine, a-methyl-n-(3-(3-(trifluoromethyl)phenyl)propyl)-, (ar)- but generally known as cinacalcet, which bears US NIH Compound Identifier 156419. European Medicines Agency schedules Cinacalcet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20068. The term CINACALCET is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules cinacalcet in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cinacalcet under HS 29214980 and SITC 51454. As of Q4 2014, CINACALCET remains the US FDA Preferred Term for this commodity. Cinacalcet bears US NLM identifiers UMLS ID C1337242 and NCI Concept Code C74100. SMILES: FC(F)(F)C1CC(CCCNC(C2C3C(CCC2)CCCC3)C)CCC1.
This classification denotes a malignancy-associated hypercalcemia inhibitor with the molecular formula C22H22F3N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K860WSG25, chemically known as 1-naphthalenemethanamine, a-methyl-n-(3-(3-(trifluoromethyl)phenyl)propyl)-, (ar)-, hydrochloride but more generally known as cinacalcet hydrochloride, which bears US NIH Compound Identifier 156418. European Medicines Agency schedules Cinacalcet hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20068. Most nations, for tariff and trade purposes, schedule cinacalcet hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, CINACALCET HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cinacalcet hydrochloride bears US NLM identifiers UMLS ID C1260199 and NCI Concept Code C47450. SMILES: C[C@H](C1CCCC2C1CCCC2)NCCCC3CCCC(C3)C(F)(F)F.CL.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7531Q8398Y. European Medicines Agency schedules Cinamolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06284MIG. Cinamolol generally arises in the molecular formula C16H23NO4. The term CINAMOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) CINAMOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinamolol under HS 29221980 and SITC 51461. As of Q4 2014, CINAMOLOL remains the US FDA Preferred Term for this commodity. Cinamolol bears US NLM identifiers UMLS ID C2699218 and NCI Concept Code C77942. SMILES: O(CC(O)CNC(C)C)C1C(CCCC1)/C=C/C(=O)OC.
This classification denotes a serotonin antagonist with the molecular formula C20H24N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KI6J9OY7A3, chemically known as 2-propenamide, n-(2-((3-(dimethylamino)propyl)thio)phenyl)-3-phenyl- but generally known as cinanserin, which bears US NIH Compound Identifier 5475158. European Medicines Agency schedules Cinanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06285MIG. The term CINANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). CINANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinanserin under HS 29309085 and SITC 51549. As of Q4 2014, CINANSERIN remains the US FDA Preferred Term for this commodity. Cinanserin bears US NLM identifiers UMLS ID C0008788 and NCI Concept Code C83624. SMILES: S(CCCN(C)C)c1c(NC(=O)/C=C/c2ccccc2)cccc1.
This classification denotes a serotonin antagonist with the molecular formula C20H24N2OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F65Z32KI62, chemically known as 2-propenamide, n-(2-((3-(dimethylamino)propyl)thio)phenyl)-3-phenyl- but more generally known as cinanserin hydrochloride, which bears US NIH Compound Identifier 5475158. Most nations, for tariff and trade purposes, schedule cinanserin hydrochloride under HS 29309085 and SITC 51549. As of Q4 2014, CINANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cinanserin hydrochloride bears US NLM identifiers UMLS ID C0242221 and NCI Concept Code C83625. SMILES: CN(C)CCCSC1CCCCC1NC(=O)/C=C/C2CCCCC2.CL.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1J0E0I69E9. European Medicines Agency schedules Cinaproxen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06286MIG. Cinaproxen generally arises in the molecular formula C19H21NO5S. The term CINAPROXEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) CINAPROXEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinaproxen under HS 29309016 and SITC 51549. As of Q4 2014, CINAPROXEN remains the US FDA Preferred Term for this commodity. Cinaproxen bears US NLM identifiers UMLS ID C2699219 and NCI Concept Code C77340. SMILES: S(C(=O)C(C1CC2C(CC1)CC(OC)CC2)C)CC(NC(=O)C)C(=O)O.
This classification denotes an anesthetic agent with the molecular formula C20H29N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z97702A5DG, chemically known as 4-quinolinecarboxamide, 2-butoxy-n-(2-(diethylamino)ethyl)- but more generally known as cinchocaine hydrochloride, which bears US NIH Compound Identifier 3025. European Medicines Agency schedules Cinchocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01302MIG. Most nations, for tariff and trade purposes, schedule cinchocaine hydrochloride under HS 29334910. SMILES: CCCCOC1CC(C2CCCCC2N1)C(=O)NCCN(CC)CC.CL.
This classification denotes an anesthetic agent with the molecular formula C20H29N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6JW2TJG99, chemically known as 4-quinolinecarboxamide, 2-butoxy-n-(2-(diethylamino)ethyl)- but generally known as cinchocaine, which bears US NIH Compound Identifier 3025. European Medicines Agency schedules Cinchocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06287MIG. The term CINCHOCAINE is an International Non-Proprietary Name. World Health Organization schedules cinchocaine in its Anatomical Therapeutic Chemical (ATC) Classification. CINCHOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cinchocaine or dibucaine bears US NLM identifiers UMLS ID C0012050 and NCI Concept Code C28984. SMILES: CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39Y533Z02M, chemically known as 4-quinolinecarboxylic acid, 2-phenyl- (9ci) but generally known as cinchophen, which bears US NIH Compound Identifier 8593. European Medicines Agency schedules Cinchophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06288MIG. The term CINCHOPHEN is an International Non-Proprietary Name. World Health Organization schedules cinchophen in its Anatomical Therapeutic Chemical (ATC) Classification. CINCHOPHEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinchophen under HS 29334910 and SITC 51575. As of Q4 2014, CINCHOPHEN remains the US FDA Preferred Term for this commodity. Cinchophen bears US NLM identifiers UMLS ID C0008793 and NCI Concept Code C87320. SMILES: OC(=O)C1C2C(NC(C1)C1CCCCC1)CCCC2.
This classification denotes a nonsteroidal antiinflammatory drug C16H10NO2.Li, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17Z71O8Z3D, chemically known as 4-quinolinecarboxylic acid, 2-phenyl-, lithium salt (1:1), but more generally known as cinchophen lithium, which bears US NIH Compound Identifier 71300649. European Medicines Agency schedules Cinchophen lithium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01307MIG. Most nations, for tariff and trade purposes, schedule cinchophen lithium under HS 29334910 and SITC 51575. As of Q4 2014, CINCHOPHEN LITHIUM remains US FDA's Preferred Term for this commodity. SMILES: [LI+].C1CCC(CC1)C2CC(C3CCCCC3N2)C(=O)[O-].
This classification denotes a nonsteroidal antiinflammatory drug C16H11NO2.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O65C9QHG6D, chemically known as 4-quinolinecarboxylic acid, 2-phenyl-, compd. with piperazine (1:1), but more generally known as cinchophen piperazine, which bears US NIH Compound Identifier 71300650. European Medicines Agency schedules Cinchophen piperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01308MIG. Most nations, for tariff and trade purposes, schedule cinchophen piperazine under HS 29334910 and SITC 51575. As of Q4 2014, CINCHOPHEN PIPERAZINE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C2CC(C3CCCCC3N2)C(=O)O.C1CNCCN1.
This classification denotes a vasodilating agent with the molecular formula C29H36N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E052L8N506, chemically known as alpha-(((8-acetyl-1,4-benzodioxan-5-yl)oxy)methyl)-4-(3,4,5-trimethoxycinnamoyl)-1-piperazineethanol but generally known as cinepaxadil, which bears US NIH Compound Identifier 6436099. European Medicines Agency schedules Cinepaxadil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06290MIG. The term CINEPAXADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). CINEPAXADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinepaxadil under HS 29349990 and SITC 51579. As of Q4 2014, CINEPAXADIL remains the US FDA Preferred Term for this commodity. Cinepaxadil bears US NLM identifiers UMLS ID C2983977 and NCI Concept Code C90999. SMILES: OC(CN1CCN(CC1)C(=O)/C=C/c1cc(OC)c(OC)c(OC)c1)COc1c2OCCOc2c(cc1)C(=O)C.
This classification denotes a vasodilating agent with the molecular formula C20H28N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0LC95WWE9Q, chemically known as 4-(1- oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-1-piperazineacetic acid, ethyl ester but generally known as cinepazet, which bears US NIH Compound Identifier 6436156. European Medicines Agency schedules Cinepazet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06291MIG. The term CINEPAZET is an International Non-Proprietary Name. World Health Organization schedules cinepazet in its Anatomical Therapeutic Chemical (ATC) Classification. CINEPAZET is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinepazet under HS 29335995 and SITC 51576. As of Q4 2014, CINEPAZET remains the US FDA Preferred Term for this commodity. Cinepazet bears US NLM identifiers UMLS ID C0055739 and NCI Concept Code C87281. SMILES: O(C(=O)CN1CCN(CC1)C(=O)/C=C\c1cc(OC)c(OC)c(OC)c1)CC.
This classification denotes a vasodilating agent with the molecular formula C20H28N2O6.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F02NGQ0DSF, chemically known as 1-piperazineacetic acid, 4-(1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-, ethyl ester, (z)-2-butenedioate (1:1) but more generally known as cinepazet maleate, which bears US NIH Compound Identifier 6434394. Most nations, for tariff and trade purposes, schedule cinepazet maleate under HS 29335995 and SITC 51576. As of Q4 2014, CINEPAZET MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)CN1CCN(CC1)C(=O)/C=C/C2CC(C(C(C2)OC)OC)OC.C(=C\C(=O)O)\C(=O)O.
This classification denotes a vasodilating agent with the molecular formula C18H24N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OX0J88C7UX, chemically known as 4-(3,4,5-trimethoxycinnamoyl)-1-piperazineacetic acid. but generally known as cinepazic acid, which bears US NIH Compound Identifier 6443799. European Medicines Agency schedules Cinepazic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06292MIG. The term CINEPAZIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). Most nations schedule cinepazic acid under HS 29335995 and SITC 51576. As of Q4 2014, CINEPAZIC ACID remains the US FDA Preferred Term for this commodity. Cinepazic acid bears US NLM identifiers UMLS ID C2983978 and NCI Concept Code C91000. SMILES: O=C(N1CCN(CC1)CC(=O)O)/C=C/c1cc(OC)c(OC)c(OC)c1.
This classification denotes a vasodilating agent with the molecular formula C22H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67Y4P5C84X, chemically known as 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine but generally known as cinepazide, which bears US NIH Compound Identifier 2759. European Medicines Agency schedules Cinepazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06293MIG. The term CINEPAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules cinepazide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cinepazide under HS 29335995 and SITC 51576. As of Q4 2014, CINEPAZIDE remains the US FDA Preferred Term for this commodity. Cinepazide bears US NLM identifiers UMLS ID C0055740 and NCI Concept Code C91001. SMILES: O=C(N1CCCC1)CN1CCN(CC1)C(=O)/C=C/c1cc(OC)c(OC)c(OC)c1.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y35B3VA60V. European Medicines Agency schedules Cinepazide maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01311MIG. Cinepazide maleate generally arises in the molecular formula C22H31N3O5.C4H4O4. The term 'cinepazide maleate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule cinepazide maleate under HS 29335995 and SITC 51576. As of Q4 2014, CINEPAZIDE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: COC1CC(CC(C1OC)OC)/C=C/C(=O)N2CCN(CC2)CC(=O)N3CCCC3.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P26FL0O04P. European Medicines Agency schedules Cinfenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06294MIG. Cinfenine generally arises in the molecular formula C25H27NO. The term CINFENINE is an International Non-Proprietary Name or INN. CINFENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinfenine under HS 29221980 and SITC 51461. As of Q4 2014, CINFENINE remains the US FDA Preferred Term for this commodity. Cinfenine bears US NLM identifiers UMLS ID C2699221 and NCI Concept Code C78009. SMILES: O(C(c1ccccc1)c1ccccc1)CCN(C/C=C/c1ccccc1)C.
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F0XVL451MO. European Medicines Agency schedules Cinflumide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06296MIG. Cinflumide generally arises in the molecular formula C12H12FNO. The term CINFLUMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) CINFLUMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinflumide under HS 29242995 and SITC 51479. As of Q4 2014, CINFLUMIDE remains the US FDA Preferred Term for this commodity. Cinflumide bears US NLM identifiers UMLS ID C1880086 and NCI Concept Code C65330. SMILES: C1CC1NC(=O)/C=C/C2=CC(=CC=C2)F.
This classification denotes a serotonin antagonist and serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8I97I2L24. European Medicines Agency schedules Cinitapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06298MIG. Cinitapride generally arises in the molecular formula C21H30N4O4. The term CINITAPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) CINITAPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinitapride under HS 29333999 and SITC 51574. As of Q4 2014, CINITAPRIDE remains the US FDA Preferred Term for this commodity. Cinitapride bears US NLM identifiers UMLS ID C0055747 and NCI Concept Code C77257. SMILES: O=C(NC1CCN(CC2CCC=CC2)CC1)C1C(OCC)CC(N)C([N](=O)O)C1.
This classification denotes an adrenergic agonist with the molecular formula C19H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y1245J8012, chemically known as benzenemethanol, alpha-(1-(methyl(3-phenyl-2-propenyl)amino)ethyl)- but generally known as cinnamedrine, which bears US NIH Compound Identifier 5370611. European Medicines Agency schedules Cinnamedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06301MIG. The term CINNAMEDRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). CINNAMEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinnamedrine under HS 29221980 and SITC 51461. As of Q4 2014, CINNAMEDRINE remains the US FDA Preferred Term for this commodity. Cinnamedrine bears US NLM identifiers UMLS ID C0055752 and NCI Concept Code C87468. SMILES: OC(C(N(C/C=C/C1CCCCC1)C)C)C1CCCCC1.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S29HWU6QB, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 18174 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Magnolianae, Order Laurales, Family Lauraceae, Genus Cinnamomum Schaeff. (cinnamon), commonly known as CINNAMON or as here, CINNAMOMUM. Cinnamomum bears the USDA PLANTS Database Identifier CINNA2. European Medicines Agency schedules cinnamomum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB30007, SUB32757, SUB35446, SUB35447, SUB44922, SUB44923, SUB44924, SUB44925, and SUB52581. The United Nations Common Coding System codifies the source product under UNCCS 016230.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H28N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DI2E1X18L, chemically known as piperazine, 1- (diphenylmethyl)-4-(3-phenyl-2-propenyl)-, (e)- but generally known as cinnarizine, which bears US NIH Compound Identifier 2761. European Medicines Agency schedules Cinnarizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06302MIG. The term CINNARIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules cinnarizine in its Anatomical Therapeutic Chemical (ATC) Classification. CINNARIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinnarizine under HS 29335995 and SITC 51576. As of Q4 2014, CINNARIZINE remains the US FDA Preferred Term for this commodity. Cinnarizine bears US NLM identifiers UMLS ID C0008803 and NCI Concept Code C76060. SMILES: N1(CCN(CC1)C/C=C/C1CCCCC1)C(C1CCCCC1)C1CCCCC1.
Non-proliferative diabetic retinopathy.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0BI682BR2D, chemically known as 2-pentyl-6-phenyl-1h-pyrazolo(1,2-a)quinoline-1,3-(2h)-dione but generally known as cinnopentazone, which bears US NIH Compound Identifier 16347. European Medicines Agency schedules Cinnopentazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06305MIG. The term CINNOPENTAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). CINNOPENTAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cinnopentazone or cintazone bears US NLM identifiers UMLS ID C2347772 and NCI Concept Code C73084. SMILES: CCCCCC1C(=O)N2C=C(C3=CC=CC=C3N2C1=O)C4=CC=CC=C4.
This classification denotes an anesthetic agent with the molecular formula C19H27NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69J8AO72Q3, chemically known as octahydro-1-(3,4,5-trimethoxycinnamoyl)azocine. but generally known as cinoctramide, which bears US NIH Compound Identifier 6443803. European Medicines Agency schedules Cinoctramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06306MIG. The term CINOCTRAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). CINOCTRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinoctramide under HS 29339990 and SITC 51577. As of Q4 2014, CINOCTRAMIDE remains the US FDA Preferred Term for this commodity. Cinoctramide bears US NLM identifiers UMLS ID C2825618 and NCI Concept Code C81403. SMILES: O=C(N1CCCCCCC1)/C=C/C1CC(OC)C(OC)C(OC)C1.
This classification denotes a benzodiazepine with the molecular formula C18H13ClFN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68P0556B0U, chemically known as 7-chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1h-1,4-benzodiazepine-1-propionitrile but generally known as cinolazepam, which bears US NIH Compound Identifier 3033621. European Medicines Agency schedules Cinolazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06307MIG. The term CINOLAZEPAM is an International Non-Proprietary Name. World Health Organization schedules cinolazepam in its Anatomical Therapeutic Chemical (ATC) Classification. CINOLAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinolazepam under HS 29339940 and SITC 51577. As of Q4 2014, CINOLAZEPAM remains the US FDA Preferred Term for this commodity. Cinolazepam bears US NLM identifiers UMLS ID C0164835 and NCI Concept Code C77635. SMILES: CLC1CC2C(N(CCC#N)C(=O)C(O)N=C2C2C(F)CCCC2)CC1.
This classification denotes a topical anti-infective agent with the molecular formula C13H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5743F6U086, chemically known as n-(2-cyanoethyl)-3-methyl-2-quinoxalinecarboxamide 1,4-dioxide. but more generally known as cinoquidox, which bears US NIH Compound Identifier 193984. European Medicines Agency schedules Cinoquidox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06308MIG. The term CINOQUIDOX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). CINOQUIDOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=[N]1C(C(N(O)C2C1CCCC2)C)C(=O)NCCC#N.
This classification denotes a quinolone antibiotic with the molecular formula C12H10N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LMK22VUH23, chemically known as 1-ethyl-6,7-methylenedioxy-4(1h)-oxocinnoline-3-carboxylic acid but generally known as cinoxacin, which bears US NIH Compound Identifier 2762. European Medicines Agency schedules Cinoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06309MIG. The term CINOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules cinoxacin in its Anatomical Therapeutic Chemical (ATC) Classification. CINOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinoxacin under HS 29349990 and SITC 51579. As of Q4 2014, CINOXACIN remains the US FDA Preferred Term for this commodity. Cinoxacin bears US NLM identifiers UMLS ID C0008806 and NCI Concept Code C65333. SMILES: CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes an anxiolytic and antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 072Z5ZP2FI. European Medicines Agency schedules Cinuperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06318MIG. Cinuperone generally arises in the molecular formula C23H24FN3O. The term CINUPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) CINUPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cinuperone under HS 29335995 and SITC 51576. As of Q4 2014, CINUPERONE remains the US FDA Preferred Term for this commodity. Cinuperone bears US NLM identifiers UMLS ID C2983804 and NCI Concept Code C90621. SMILES: FC1CCC(C(=O)CCCN2CCN(CC2)C2NCC3C(C2)CCCC3)CC1.
This classification denotes an anti-androgen with the molecular formula C16H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1RTH95874Z, chemically known as 1,5-cis-verknupften but generally known as cioteronel, which bears US NIH Compound Identifier 55994. European Medicines Agency schedules Cioteronel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06319MIG. The term CIOTERONEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). CIOTERONEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cioteronel under HS 29372900 and SITC 54153. As of Q4 2014, CIOTERONEL remains the US FDA Preferred Term for this commodity. Cioteronel bears US NLM identifiers UMLS ID C0625429 and NCI Concept Code C74119. SMILES: O=C1CC2C(CCC2CCCCC(OC)CC)C1.
This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8RSD11181G. European Medicines Agency schedules Ciprazafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07466MIG. Ciprazafone generally arises in the molecular formula C19H18CL2N2O2. The term CIPRAZAFONE is an International Non-Proprietary Name or INN. CIPRAZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciprazafone under HS 29242995 and SITC 51479. As of Q4 2014, CIPRAZAFONE remains the US FDA Preferred Term for this commodity. Ciprazafone bears US NLM identifiers UMLS ID C2699233 and NCI Concept Code C78000. SMILES: CLC1CC(C(N(C(=O)CNC2CC2)C)CC1)C(=O)C1C(CL)CCCC1.
This classification denotes an anti-lipidemic agent with the molecular formula C13H14Cl2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8252JGO9S, chemically known as 2-(p-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropionic acid but generally known as ciprofibrate, which bears US NIH Compound Identifier 2763. European Medicines Agency schedules Ciprofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07469MIG. The term CIPROFIBRATE is an International Non-Proprietary Name. World Health Organization schedules ciprofibrate in its Anatomical Therapeutic Chemical (ATC) Classification. CIPROFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciprofibrate under HS 29189900 and SITC 51396. As of Q4 2014, CIPROFIBRATE remains the US FDA Preferred Term for this commodity. Ciprofibrate bears US NLM identifiers UMLS ID C0055775 and NCI Concept Code C87471. SMILES: ClC1(Cl)C(C1)c1ccc(OC(C)(C)C(=O)O)cc1.
This classification denotes a quinolone antibiotic and antitubercular agent with the molecular formula C17H18FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5E8K9I0O4U, chemically known as 86393-32-0 (hydrochloride, monohydrate) but generally known as ciprofloxacin, which bears US NIH Compound Identifier 2764. European Medicines Agency schedules Ciprofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07470MIG. The term CIPROFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules ciprofloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. CIPROFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciprofloxacin under HS 29335995 and SITC 51576. As of Q4 2014, CIPROFLOXACIN remains the US FDA Preferred Term for this commodity. Ciprofloxacin bears US NLM identifiers UMLS ID C0008809 and NCI Concept Code C375. SMILES: FC1C(N2CCNCC2)CC2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.
This classification denotes an antihypertensive agent with the molecular formula C37H55N5O8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, K259Z4O1B3 chemically known as (.alpha.s)-n-((1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-.alpha.-((.alpha.s)-.alpha.-(((1-methyl-1-(morpholinocarbonyl)ethyl)sulfonyl)methyl)hydrocinnamamido)imidazole-4-propionamide but generally known as ciprokiren, which bears US NIH Compound Identifier 64925. European Medicines Agency schedules Ciprokiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07471MIG. The term CIPROKIREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34. ). Most nations schedule ciprokiren under HS 29349990 and SITC 51579. As of Q4 2014, CIPROKIREN remains the US FDA Preferred Term for this commodity. Ciprokiren bears US NLM identifiers UMLS ID C0251321 and NCI Concept Code C79133. SMILES: CC(C)(C(=O)N1CCOCC1)S(=O)(=O)CC(CC2=CC=CC=C2)C(=O)NC(CC3=CN=CN3)C(=O)NC(CC4CCCCC4)C(C(C5CC5)O)O.
This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0D2VUO6DCN. European Medicines Agency schedules Cipropride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07472MIG. Cipropride generally arises in the molecular formula C17H25N3O4S. The term CIPROPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) CIPROPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cipropride under HS 29350090 and SITC 51580. As of Q4 2014, CIPROPRIDE remains the US FDA Preferred Term for this commodity. Cipropride bears US NLM identifiers UMLS ID C0055777 and NCI Concept Code C78026. SMILES: S(=O)(=O)(N)C1CC(C(=O)NCC2N(CC3CC3)CCC2)C(OC)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H18N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8S0GE5Q4I, chemically known as 2(1h)-quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- but generally known as ciproquazone, which bears US NIH Compound Identifier 36489. European Medicines Agency schedules Ciproquazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07473MIG. The term CIPROQUAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). CIPROQUAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciproquazone under HS 29335995 and SITC 51576. As of Q4 2014, CIPROQUAZONE remains the US FDA Preferred Term for this commodity. Ciproquazone bears US NLM identifiers UMLS ID C2347773 and NCI Concept Code C72114. SMILES: O=C1N(CC2CC2)C2C(C(N1)C1CCCCC1)CC(OC)CC2.
This classification denotes an opioid receptor agonist with the molecular formula C15H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9NQ109OW0G, chemically known as phenol, 3-((r)-(dimethylamino)((1r,2r)-2-hydroxycyclohexyl)methyl)- but generally known as ciramadol, which bears US NIH Compound Identifier 44463. European Medicines Agency schedules Ciramadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07477MIG. The term CIRAMADOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). CIRAMADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciramadol under HS 29225000 and SITC 51467. As of Q4 2014, CIRAMADOL remains the US FDA Preferred Term for this commodity. Ciramadol bears US NLM identifiers UMLS ID C0055779 and NCI Concept Code C77282. SMILES: OC1C(CCCC1)C(N(C)C)C1CC(O)CCC1.
This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C15H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9NQ109OW0G, chemically known as phenol, 3-((r)-(dimethylamino)((1r,2r)-2-hydroxycyclohexyl)methyl)- but more generally known as ciramadol, which bears US NIH Compound Identifier 44463. European Medicines Agency schedules Ciramadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07477MIG. The term CIRAMADOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). CIRAMADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ciramadol hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, CIRAMADOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ciramadol hydrochloride bears US NLM identifiers UMLS ID C0890132 and NCI Concept Code C65334. SMILES: CN(C)[C@@H](C1CCCC(C1)O)[C@H]2CCCC[C@H]2O.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QK318GVY3Y, chemically known as 1h-imidazole, 2-((2-cyclopropylphenoxy)methyl)-4,5-dihydro-, monohydrochloride but generally known as cirazoline, which bears US NIH Compound Identifier 2765. European Medicines Agency schedules Cirazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07478MIG. The term CIRAZOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). CIRAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cirazoline under HS 29332990 and SITC 51573. As of Q4 2014, CIRAZOLINE remains the US FDA Preferred Term for this commodity. Cirazoline bears US NLM identifiers UMLS ID C0109817 and NCI Concept Code C77294. SMILES: O(c1c(C2CC2)cccc1)CC1=NCCN1.
This classification denotes an antiemetic agent with the molecular formula C23H29ClFN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVL329170W, chemically known as benzamide, 4-amino-5-chloro-n-(1-(3-(4-fluorophenoxy)propyl)-3-methoxy-4-piperidinyl)-2-methoxy-, cis- but generally known as cisapride, which bears US NIH Compound Identifier 2769. European Medicines Agency schedules Cisapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07479MIG. The term CISAPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules cisapride in its Anatomical Therapeutic Chemical (ATC) Classification. CISAPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cisapride under HS 29333999 and SITC 51574. As of Q4 2014, CISAPRIDE remains the US FDA Preferred Term for this commodity. Cisapride bears US NLM identifiers UMLS ID C0072916 and NCI Concept Code C1210. SMILES: CLC1CC(C(=O)NC2C(OC)CN(CC2)CCCOC2CCC(F)CC2)C(OC)CC1N.
This classification denotes a nicotinic antagonist with the molecular formula C53H72N2O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QX62KLI41N, chemically known as isoquinolinium, 2,2-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1r-(1alpha,2alpha(1r(sup *),2r(sup *))))- but generally known as cisatracurium, which bears US NIH Compound Identifier 62886. European Medicines Agency schedules Cisatracurium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01319MIG. World Health Organization schedules cisatracurium in its Anatomical Therapeutic Chemical (ATC) Classification. CISATRACURIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CISATRACURIUM remains the US FDA Preferred Term for this commodity. Cisatracurium bears US NLM identifiers UMLS ID C1096766 and NCI Concept Code C77365. SMILES: S(=O)(=O)(O)C1CCCCC1.S(=O)(=O)(O)C1CCCCC1.O(C1CC2C([N](CCC2CC1OC)(CCC(=O)OCCCCCOC(=O)CC[N]1(C(C2C(CC1)CC(OC)C(OC)C2)CC1CC(OC)C(OC)CC1)C)C)CC1CC(OC)C(OC)CC1)C.
This classification denotes a nicotinic antagonist with the molecular formula C53H72N2O12.2C6H5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80YS8O1MBS, chemically known as isoquinolinium, 2,2-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1r-(1alpha,2alpha(1r(sup *),2r(sup *))))- but more generally known as cisatracurium besilate, which bears US NIH Compound Identifier 62886. European Medicines Agency schedules Cisatracurium besilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07480MIG. The term CISATRACURIUM BESILATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 10, No. 3, 1996, List 36). Most nations, for tariff and trade purposes, schedule cisatracurium besilate under HS 29334990 and SITC 51575. SMILES: C[N@@+]1(CCC2CC(C(CC2[C@H]1CC3CCC(C(C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5CC(C(CC5[C@H]4CC6CCC(C(C6)OC)OC)OC)OC)C.C1CCC(CC1)S(=O)(=O)[O-].C1CCC(CC1)S(=O)(=O)[O-].
This classification denotes a therapeutic progestin with the molecular formula C21H27ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O00XM1O6TV, chemically known as 6 alpha-chloro-17-hydroxypregna-1,4-diene-3,20-dione. but generally known as cismadinone, which bears US NIH Compound Identifier 193990. European Medicines Agency schedules Cismadinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07482MIG. The term CISMADINONE is an International Non-Proprietary Name. CISMADINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cismadinone under HS 29372300 and SITC 54153. As of Q4 2014, CISMADINONE remains the US FDA Preferred Term for this commodity. Cismadinone bears US NLM identifiers UMLS ID C2699236 and NCI Concept Code C76303. SMILES: ClC1CC2C3C(C(O)(CC3)C(=O)C)(CCC2C2(C1=CC(=O)C=C2)C)C.
This classification denotes a radiosensitizing agent and platinum compound with the molecular formula 2Cl.Pt.2H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q20Q21Q62J, chemically known as platinum(ii), diamminedichloro-, trans- but more generally known as cisplatin, which bears US NIH Compound Identifier 2767. European Medicines Agency schedules Cisplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07483MIG. The term CISPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules cisplatin in its Anatomical Therapeutic Chemical (ATC) Classification. CISPLATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cisplatin under HS 28439000 and SITC 52432. SMILES: N.N.[Cl-].[Cl-].[Pt+2].
This classification denotes a mucolytic agent and expectorant with the molecular formula C50H60Br4N6O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 62VR67FK8E, chemically known as 2-oxa-7,8-dithia-4,11-diazadodecan-12-oic acid, 5,10-bis(((2,4-dibromo-6-((cyclohexylmethylamino)methyl)phenyl)amino)carbonyl)-3-oxo-1-phenyl-, phenylmethyl ester, (r-(r*,r*))- but more generally known as cistinexine, which bears US NIH Compound Identifier 65644. European Medicines Agency schedules Cistinexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07484MIG. The term CISTINEXINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 40, No. 6, 1986, List 26). CISTINEXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cistinexine under HS 29309016 and SITC 51549. As of Q4 2014, CISTINEXINE remains US FDA's Preferred Term for this commodity. Cistinexine bears US NLM identifiers UMLS ID C0627299 and NCI Concept Code C77595. SMILES: BRC1C(NC(=O)C(NC(=O)OCC2CCCCC2)CSSCC(NC(=O)OCC2CCCCC2)C(=O)NC2C(CN(C3CCCCC3)C)CC(BR)CC2BR)C(CN(C2CCCCC2)C)CC(BR)C1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0DHU5B8D6V, chemically known as 1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile but generally known as citalopram, which bears US NIH Compound Identifier 2771. European Medicines Agency schedules Citalopram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07485MIG. The term CITALOPRAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules citalopram in its Anatomical Therapeutic Chemical (ATC) Classification. CITALOPRAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule citalopram under HS 29329985 and SITC 51569. As of Q4 2014, CITALOPRAM remains the US FDA Preferred Term for this commodity. Citalopram bears US NLM identifiers UMLS ID C0008845 and NCI Concept Code C61680. SMILES: Fc1ccc(C2(OCc3c2ccc(c3)C#N)CCCN(C)C)cc1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I1E9D14F36, chemically known as 1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile but more generally known as citalopram hydrobromide, which bears US NIH Compound Identifier 2771. European Medicines Agency schedules Citalopram hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01320MIG. Most nations, for tariff and trade purposes, schedule citalopram hydrobromide under HS 29329985 and SITC 51569. As of Q4 2014, CITALOPRAM HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Citalopram hydrobromide bears US NLM identifiers UMLS ID C0724555 and NCI Concept Code C28932. SMILES: CN(C)CCCC1(C2CCC(CC2CO1)C#N)C3CCC(CC3)F.BR.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DY48G26JY. European Medicines Agency schedules Citalopram hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16412MIG. Citalopram hydrochloride generally arises in the molecular formula C20H21FN2O.CLH. The term 'citalopram hydrochloride' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule citalopram hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, CITALOPRAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCC1(C2CCC(CC2CO1)C#N)C3CCC(CC3)F.CL.
This classification denotes a dopamine antagonist with the molecular formula C20H18N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92S48G7U0W, chemically known as 2,3,4,5-tetrahydro-3-methyl-1h-dibenzo(2,3:6,7)thiepino(4,5-d)azepine-7-carbonitrile. but generally known as citatepine, which bears US NIH Compound Identifier 193991. European Medicines Agency schedules Citatepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07486MIG. The term CITATEPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). CITATEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule citatepine under HS 29349990 and SITC 51579. As of Q4 2014, CITATEPINE remains the US FDA Preferred Term for this commodity. Citatepine bears US NLM identifiers UMLS ID C2699334 and NCI Concept Code C77570. SMILES: S1C2C(C3=C(CCN(CC3)C)C3C1CCCC3)CC(CC2)C#N.
This classification denotes an antiviral agent with the molecular formula C7H6N4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34RU0N173Q, chemically known as 2-thiophenecarbonitrile, 5-formyl-, thiosemicarbazone but generally known as citenazone, which bears US NIH Compound Identifier 3033956. European Medicines Agency schedules Citenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07488MIG. The term CITENAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). CITENAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule citenazone under HS 29349990 and SITC 51579. As of Q4 2014, CITENAZONE remains the US FDA Preferred Term for this commodity. Citenazone bears US NLM identifiers UMLS ID C0602975 and NCI Concept Code C87472. SMILES: S1C(CCC1C#N)/C=N/NC(=S)N.
This classification denotes a nootropic agent with the molecular formula C14H25N4O11P2.H+, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 536BQ2JVC7, chemically known as cytidine 5-(trihydrogen pyrophosphate), monoester with choline hydroxide, inner salt but generally known as citicoline, which bears US NIH Compound Identifier 291. European Medicines Agency schedules Citicoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07489MIG. World Health Organization schedules citicoline in its Anatomical Therapeutic Chemical (ATC) Classification. CITICOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule citicoline under HS 29349990 and SITC 51579. As of Q4 2014, CITICOLINE remains the US FDA Preferred Term for this commodity. Citicoline bears US NLM identifiers UMLS ID C0010725 and NCI Concept Code C96743. SMILES: P(=O)(OCC1OC(N2CCC(NC2=O)N)C(O)C1O)(OP(=O)(OCC[N](C)(C)C)O)O.
This classification denotes the sodium form of a nootropic agent with the molecular formula C14H25N4O11P2.H+, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 536BQ2JVC7, chemically known as cytidine 5-(trihydrogen pyrophosphate), monoester with choline hydroxide, inner salt but more generally known as citicoline, which bears US NIH Compound Identifier 291. European Medicines Agency schedules Citicoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07489MIG. World Health Organization schedules citicoline in its Anatomical Therapeutic Chemical (ATC) Classification. CITICOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule citicoline sodium under HS 29349990 and SITC 51579. As of Q4 2014, CITICOLINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C[N+](C)(C)CCOP(=O)([O-])OP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2CCC(NC2=O)N)O)O.[NA+].
This classification denotes a hepatoprotective agent and expectorant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70JKL15MUH. European Medicines Agency schedules Citiolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06633MIG. Citiolone generally arises in the molecular formula C6H9NO2S. The term CITIOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) CITIOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule citiolone under HS 29349990 and SITC 51579. As of Q4 2014, CITIOLONE remains the US FDA Preferred Term for this commodity. Citiolone bears US NLM identifiers UMLS ID C0055804 and NCI Concept Code C77426. SMILES: S1C(NC(=O)C)C(=O)CC1.
This classification denotes a carboxylic acid with the molecular formula C6H8O7.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2968PHW8QP. European Medicines Agency schedules citric acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12482MIG. The term citric acid monohydrate is a U.S. FDA designation. SMILES: OC(CC(=O)O)(CC(=O)O)C(=O)O.
This classification denotes an alkalinizing agent combination drug. The first component of this drug is a carboxylic acid with the molecular formula C6H8O7.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2968PHW8QPm, and which is called citric acid. European Medicines Agency schedules citric acid monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12482MIG. The term citrate is a U.S. FDA designation. SMILES: OC(CC(=O)O)(CC(=O)O)C(=O)O. The second component of this drug is an an electrolyte replacement agent with the molecular formula C6H5O7.3K.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EE90ONI6FF, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, tripotassium salt but generally known as potassium citrate, which bears US NIH Compound Identifier 13344. European Medicines Agency schedules Potassium citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14973MIG. World Health Organization schedules potassium citrate in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes an alkalinizing agent combination drug. The first component of this drug is a carboxylic acid with the molecular formula C6H8O7.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2968PHW8QPm, and which is called citric acid. European Medicines Agency schedules citric acid monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12482MIG. The term citrate is a U.S. FDA designation. SMILES: OC(CC(=O)O)(CC(=O)O)C(=O)O. The second component of this drug is an electrolyte replacement agent and anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q73Q2JULR. European Medicines Agency schedules Sodium citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12582MIG. Sodium citrate generally arises in the molecular formula C6H5NA3O7. The term 'sodium citrate' is a U.S. Pharmacopeial Convention designation.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN478. This VA Drug Class (TN478) classifies this compound as belonging to the group CITRATES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX900. This VA Drug Class (DX900) classifies this compound as belonging to the group DIAGNOSTICS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a radiosensitizing agent and purine antagonist with the molecular formula C10H12ClN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 47M74X9YT5, chemically known as adenosine, 2-chloro-2-deoxy- but more generally known as cladribine, which bears US NIH Compound Identifier 1546. European Medicines Agency schedules Cladribine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06635MIG. The term CLADRIBINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules cladribine in its Anatomical Therapeutic Chemical (ATC) Classification. CLADRIBINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cladribine under HS 29349990 and SITC 51579. As of Q4 2014, CLADRIBINE remains US FDA's Preferred Term for this commodity. Cladribine bears US NLM identifiers UMLS ID C0092801 and NCI Concept Code C1336. SMILES: C1C(C(OC1N2C=NC3=C2N=C(N=C3N)CL)CO)O.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C19H22CLN3O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 94301K998R. The term CLAMIKALANT is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule clamikalant under HS 29350090 and SITC 51580. As of Q4 2014, CLAMIKALANT remains US FDA's Preferred Term for this commodity. Clamikalant bears US NLM identifiers UMLS ID C2699336 and NCI Concept Code C77831. SMILES: CNC(=S)NS(=O)(=O)C1=C(C=CC(=C1)CCNC(=O)C2=C(C=CC(=C2)CL)OC)OC.
This classification denotes an antiprotozoal agent with the molecular formula C17H24ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JUN13FZ6RF, chemically known as cn-17,900-2b but generally known as clamoxyquin, which bears US NIH Compound Identifier 18029. European Medicines Agency schedules Clamoxyquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06637MIG. The term CLAMOXYQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). As of Q4 2014, CLAMOXYQUIN remains the US FDA Preferred Term for this commodity. Clamoxyquin bears US NLM identifiers UMLS ID C2699337 and NCI Concept Code C78097. SMILES: CCN(CC)CCCNCC1=CC(=C2C=CC=NC2=C1O)CL.
This classification denotes a cholagogue or choleretic agent with the molecular formula C18H18ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W6Y945055S, chemically known as butyric acid, 4-(p-chloro-n-(p-methoxyphenyl)benzamido)- but generally known as clanobutin, which bears US NIH Compound Identifier 35378. European Medicines Agency schedules Clanobutin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06639MIG. The term CLANOBUTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). CLANOBUTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clanobutin under HS 29242995 and SITC 51479. As of Q4 2014, CLANOBUTIN remains the US FDA Preferred Term for this commodity. Clanobutin bears US NLM identifiers UMLS ID C0055854 and NCI Concept Code C77837. SMILES: CLC1CCC(C(=O)N(CCCC(=O)O)C2CCC(OC)CC2)CC1.
This classification denotes a macrolide antibiotic with the molecular formula C38H69NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1250JIK0A, chemically known as erythromycin, 6-o-methyl- but generally known as clarithromycin, which bears US NIH Compound Identifier 54688. European Medicines Agency schedules Clarithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06641MIG. The term CLARITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules clarithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. CLARITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clarithromycin under HS 29415000 and SITC 54139. As of Q4 2014, CLARITHROMYCIN remains the US FDA Preferred Term for this commodity. Clarithromycin bears US NLM identifiers UMLS ID C0055856 and NCI Concept Code C1054. SMILES: O(C1C(C(OC2OC(C(O)C(OC)(C2)C)C)C(C(=O)OC(C(O)(C(O)C(C(=O)C(CC1(OC)C)C)C)C)CC)C)C)C1OC(CC(N(C)C)C1O)C.
This classification denotes a macrolide antibiotic C38H69NO13.C12H22O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4108JKI097, chemically known as erythromycin, 6-o-methyl-, 4-o-.beta.-d-galactopyranosyl-d-gluconate (1:1), but more generally known as clarithromycin lactobionate, which bears US NIH Compound Identifier 178265. European Medicines Agency schedules Clarithromycin lactobionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20333. Most nations, for tariff and trade purposes, schedule clarithromycin lactobionate under HS 29415000 and SITC 54139. SMILES: As of Q4 2014, CLARITHROMYCIN LACTOBIONATE remains US FDA's Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM113. This VA Drug Class (AM113) classifies this compound as belonging to the group EXTENDED SPECTRUM PENICILLINS.
This classification denotes a beta-lactam antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23521W1S24. European Medicines Agency schedules Clavulanic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06642MIG. Clavulanic acid generally arises in the molecular formula C8H9NO5. The term CLAVULANIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) Most nations schedule clavulanic acid under HS 29349990 and SITC 51579. As of Q4 2014, CLAVULANIC ACID remains the US FDA Preferred Term for this commodity. Clavulanic acid bears US NLM identifiers UMLS ID C0055860 and NCI Concept Code C61681. SMILES: O1C2N(C(C\1=C\CO)C(=O)O)C(=O)C2.
This classification denotes a diuretic with the molecular formula C10H10ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C3XSG3DLPA, chemically known as 4-imidazolidinone, 1-(4-chlorophenyl)-2-imino-3-methyl- but generally known as clazolimine, which bears US NIH Compound Identifier 38683. European Medicines Agency schedules Clazolimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06644MIG. The term CLAZOLIMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). CLAZOLIMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clazolimine under HS 29332100 and SITC 51572. As of Q4 2014, CLAZOLIMINE remains the US FDA Preferred Term for this commodity. Clazolimine bears US NLM identifiers UMLS ID C2699341 and NCI Concept Code C77558. SMILES: CN1C(=O)CN(C1=N)C2=CC=C(C=C2)CL.
This classification denotes an antiparasitic agent with the molecular formula C17H10Cl2N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O8W0R05772, chemically known as benzeneacetonitrile, 2-chloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)- but generally known as clazuril, which bears US NIH Compound Identifier 58901. European Medicines Agency schedules Clazuril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06645MIG. The term CLAZURIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). CLAZURIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clazuril under HS 29336980 and SITC 51576. As of Q4 2014, CLAZURIL remains the US FDA Preferred Term for this commodity. Clazuril bears US NLM identifiers UMLS ID C0055867 and NCI Concept Code C82246. SMILES: CLC1C(C(C2CCC(CL)CC2)C#N)CCC(N2NCC(=O)[NH]C2=O)C1.
This classification denotes a dopamine antagonist with the molecular formula C20H24ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0A84520Y9, chemically known as benzamide, 4-amino-5-chloro-2-methoxy-n-(1-(phenylmethyl)-4-piperidinyl)- but generally known as clebopride, which bears US NIH Compound Identifier 2780. European Medicines Agency schedules Clebopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06646MIG. The term CLEBOPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules clebopride in its Anatomical Therapeutic Chemical (ATC) Classification. CLEBOPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clebopride under HS 29333999 and SITC 51574. As of Q4 2014, CLEBOPRIDE remains the US FDA Preferred Term for this commodity. Clebopride bears US NLM identifiers UMLS ID C0055869 and NCI Concept Code C83627. SMILES: CLC1CC(C(=O)NC2CCN(CC2)CC2CCCCC2)C(OC)CC1N.
This classification denotes an antiprotozoal agent with the molecular formula C17H16Cl2N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AZ2V8K4EK, chemically known as 2,2-dichloro-n-(2-hydroxyethyl)-n-(p-(p-nitrophenoxy)benzyl)acetamide but generally known as clefamide, which bears US NIH Compound Identifier 71819. European Medicines Agency schedules Clefamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06647MIG. The term CLEFAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules clefamide in its Anatomical Therapeutic Chemical (ATC) Classification. CLEFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clefamide under HS 29242995 and SITC 51479. As of Q4 2014, CLEFAMIDE remains the US FDA Preferred Term for this commodity. Clefamide bears US NLM identifiers UMLS ID C0610174 and NCI Concept Code C78099. SMILES: CLC(CL)C(=O)N(CC1CCC(OC2CCC([N](=O)O)CC2)CC1)CCO.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95QN29S1ID. European Medicines Agency schedules Clemastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06648MIG. Clemastine generally arises in the molecular formula C21H26CLNO. The term CLEMASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) CLEMASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clemastine under HS 29339990 and SITC 51577. As of Q4 2014, CLEMASTINE remains the US FDA Preferred Term for this commodity. Clemastine bears US NLM identifiers UMLS ID C0008929 and NCI Concept Code C61682. SMILES: CLC1CCC(C(OCCC2N(CCC2)C)(C2CCCCC2)C)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H26ClNO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19259EGQ3D, chemically known as pyrrolidine, 2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methyl-, (r-(r*,r*))- but more generally known as clemastine fumarate, which bears US NIH Compound Identifier 26987. European Medicines Agency schedules Clemastine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01335MIG. Most nations, for tariff and trade purposes, schedule clemastine fumarate under HS 29339990 and SITC 51577. As of Q4 2014, CLEMASTINE FUMARATE remains US FDA's Preferred Term for this commodity. Clemastine fumarate bears US NLM identifiers UMLS ID C0546858 and NCI Concept Code C47454. SMILES: C[C@@](C1CCCCC1)(C2CCC(CC2)CL)OCC[C@H]3CCCN3C.C(=C/C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H26ClNO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19259EGQ3D, chemically known as pyrrolidine, 2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methyl-, (r-(r*,r*))-, (e)-2-butenedioate (1:1), but more generally known as clemastine hydrogen fumarate, which bears US NIH Compound Identifier 5281069. European Medicines Agency schedules clemastine hydrogen fumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06648MIG. Most nations, for tariff purposes, schedule clemastine hydrogen fumarate under HS 29339990. SMILES: C[C@@](C1CCCCC1)(C2CCC(CC2)CL)OCC[C@H]3CCCN3C.C(=C/C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3TC4SEW5A. European Medicines Agency schedules Clemeprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06649MIG. Clemeprol generally arises in the molecular formula C17H20CLNO. The term CLEMEPROL is an International Non-Proprietary Name or INN. CLEMEPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clemeprol under HS 29221980 and SITC 51461. As of Q4 2014, CLEMEPROL remains the US FDA Preferred Term for this commodity. Clemeprol bears US NLM identifiers UMLS ID C0612052 and NCI Concept Code C79858. SMILES: Clc1ccc(C(C(O)CN(C)C)c2ccccc2)cc1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T97CB3796L, chemically known as 1h-benzimidazole, 1-((4-chlorophenyl)methyl)-2-(1-pyrrolidinylmethyl)- but generally known as clemizole, which bears US NIH Compound Identifier 2782. European Medicines Agency schedules Clemizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06650MIG. The term CLEMIZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). CLEMIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clemizole under HS 29339990 and SITC 51577. As of Q4 2014, CLEMIZOLE remains the US FDA Preferred Term for this commodity. Clemizole bears US NLM identifiers UMLS ID C0008931 and NCI Concept Code C81139. SMILES: CLC1CCC(CN2C(NC3C2CCCC3)CN2CCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20ClN3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85W6I13D8M, chemically known as benzimidazole, 1-(p-chlorobenzyl)-2-(1-pyrrolidinylmethyl)-, monohydrochloride but more generally known as clemizole hydrochloride, which bears US NIH Compound Identifier 14412. European Medicines Agency schedules Clemizole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01336MIG. Most nations, for tariff and trade purposes, schedule clemizole hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, CLEMIZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clemizole hydrochloride bears US NLM identifiers UMLS ID C2825478 and NCI Concept Code C81152. SMILES: C1CCC2C(C1)NC(N2CC3CCC(CC3)CL)CN4CCCC4.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20ClN3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AA1G805H0, chemically known as 1h-benzimidazole, 1-((4-chlorophenyl)methyl)-2-(1-pyrrolidinylmethyl)- but more generally known as clemizole sulfate, which bears US NIH Compound Identifier 2782. Most nations, for tariff and trade purposes, schedule clemizole sulfate under HS 29339990 and SITC 51577. As of Q4 2014, CLEMIZOLE SULFATE remains US FDA's Preferred Term for this commodity. Clemizole sulfate bears US NLM identifiers UMLS ID C3273572 and NCI Concept Code C97694. SMILES: C1CCC2C(C1)NC(N2CC3CCC(CC3)CL)CN4CCCC4.OS(=O)(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20ClN3.C11H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K5XAP3A37, chemically known as 1h-benzimidazole, 1-((4-chlorophenyl)methyl)-2-(1-pyrrolidinylmethyl)-, monoundecanoate, but more generally known as clemizole undecylate, which bears US NIH Compound Identifier 656650. European Medicines Agency schedules clemizole undecylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06650MIG. Most nations, for tariff purposes, schedule clemizole undecylate under HS 29339990. Clemizole undecylate bears US NLM identifiers UMLS ID C3273573 and NCI Concept Code C97695. SMILES: CCCCCCCCCCC(=O)O.C1CCC2C(C1)NC(N2CC3CCC(CC3)CL)CN4CCCC4.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C12H18Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XTZ6AXU7KN, chemically known as 4-amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol but generally known as clenbuterol, which bears US NIH Compound Identifier 2783. European Medicines Agency schedules Clenbuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06651MIG. The term CLENBUTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules clenbuterol in its Anatomical Therapeutic Chemical (ATC) Classification. CLENBUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clenbuterol under HS 29221980 and SITC 51461. As of Q4 2014, CLENBUTEROL remains the US FDA Preferred Term for this commodity. Clenbuterol bears US NLM identifiers UMLS ID C0008932 and NCI Concept Code C65335. SMILES: CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O.
This classification denotes a calcium channel blocker with the molecular formula C22H25CLN2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 40DK034DRC chemically known as 1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-8-chloro-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2s-cis)- but generally known as clentiazem, which bears US NIH Compound Identifier 57026. European Medicines Agency schedules Clentiazem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06653MIG. The term CLENTIAZEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30). Most nations schedule clentiazem under HS 29349990 and SITC 51579. As of Q4 2014, CLENTIAZEM remains the US FDA Preferred Term for this commodity. Clentiazem bears US NLM identifiers UMLS ID C0075753 and NCI Concept Code C81679. SMILES: CC(=O)OC1C(SC2=C(C=CC(=C2)CL)N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC.
This classification denotes a calcium channel blocker with the molecular formula C22H25ClN2O4S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YN4F0N5QE0, chemically known as 1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-8-chloro-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2s-cis)-, (z)-2-butenedioate (1:1) but more generally known as clentiazem maleate, which bears US NIH Compound Identifier 6435546. Most nations, for tariff and trade purposes, schedule clentiazem maleate under HS 29349990 and SITC 51579. As of Q4 2014, CLENTIAZEM MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)O[C@@H]1[C@@H](SC2CC(CCC2N(C1=O)CCN(C)C)CL)C3CCC(CC3)OC.C(=C\C(=O)O)\C(=O)O.
This classification denotes a calcium channel blocker with the molecular formula C21H23Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19O2GP3B7Q, chemically known as 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester but generally known as clevidipine, which bears US NIH Compound Identifier 153994. European Medicines Agency schedules Clevidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06655MIG. The term CLEVIDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). World Health Organization schedules clevidipine in its Anatomical Therapeutic Chemical (ATC) Classification. CLEVIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clevidipine under HS 29333999 and SITC 51574. As of Q4 2014, CLEVIDIPINE remains the US FDA Preferred Term for this commodity. Clevidipine bears US NLM identifiers UMLS ID C0766108 and NCI Concept Code C72727. SMILES: Clc1c(C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OCOC(=O)CCC)cccc1Cl.
This classification denotes a calcium channel blocker with the molecular formula C21H23Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19O2GP3B7Q, chemically known as 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester but more generally known as clevidipine, which bears US NIH Compound Identifier 153994. European Medicines Agency schedules Clevidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06655MIG. The term CLEVIDIPINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 11997, List 37). World Health Organization schedules clevidipine in its Anatomical Therapeutic Chemical (ATC) Classification. CLEVIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule clevidipine butyrate under HS 29333999. SMILES: CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2CCCC(C2CL)CL)C(=O)OC)C)C.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H13FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IN51MVP5F1, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-l-arabinofuranosyl)-5-methyl- but generally known as clevudine, which bears US NIH Compound Identifier 73115. European Medicines Agency schedules Clevudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06656MIG. The term CLEVUDINE is an International Non-Proprietary Name. World Health Organization schedules clevudine in its Anatomical Therapeutic Chemical (ATC) Classification. CLEVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clevudine under HS 29349990 and SITC 51579. As of Q4 2014, CLEVUDINE remains the US FDA Preferred Term for this commodity. Clevudine bears US NLM identifiers UMLS ID C0045212 and NCI Concept Code C95210. SMILES: CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)F.
This classification denotes an anesthetic agent with the molecular formula C15H20Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NB2ZOX88RR, chemically known as 2,4-dichloro-beta-piperidinobutyranilide but generally known as clibucaine, which bears US NIH Compound Identifier 65613. European Medicines Agency schedules Clibucaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06657MIG. The term CLIBUCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). CLIBUCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clibucaine under HS 29333999 and SITC 51574. As of Q4 2014, CLIBUCAINE remains the US FDA Preferred Term for this commodity. Clibucaine bears US NLM identifiers UMLS ID C2699344 and NCI Concept Code C77321. SMILES: CLC1C(NC(=O)CC(N2CCCCC2)C)CCC(CL)C1.
This classification denotes a sedative and hypnotic with the molecular formula C9H8Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M04D93C96, chemically known as 2-((2,6-dichlorophenyl)-imino)oxazolidine. but generally known as clidafidine, which bears US NIH Compound Identifier 193994. European Medicines Agency schedules Clidafidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06658MIG. The term CLIDAFIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). CLIDAFIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clidafidine under HS 29349990 and SITC 51579. As of Q4 2014, CLIDAFIDINE remains the US FDA Preferred Term for this commodity. Clidafidine bears US NLM identifiers UMLS ID C2825295 and NCI Concept Code C80662. SMILES: CLC1C(NC2=NCCO2)C(CL)CCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H19ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UA6HM01WAK, chemically known as 6-chloro-5-cyclohexyl-2,3-dihydro-1h-indene-1-carboxylic acid but generally known as clidanac, which bears US NIH Compound Identifier 120108. European Medicines Agency schedules Clidanac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06659MIG. The term CLIDANAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). CLIDANAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clidanac under HS 29163900 and SITC 51379. As of Q4 2014, CLIDANAC remains the US FDA Preferred Term for this commodity. Clidanac bears US NLM identifiers UMLS ID C0055876 and NCI Concept Code C77342. SMILES: CLC1C(C2CCCCC2)CC2C(C(CC2)C(=O)O)C1.
This classification denotes an antimuscarinic agent with the molecular formula C22H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BO76JF850N, chemically known as 1-azoniabicyclo(2.2.2)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl- but generally known as clidinium, which bears US NIH Compound Identifier 2784. European Medicines Agency schedules Clidinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13391MIG. CLIDINIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CLIDINIUM remains the US FDA Preferred Term for this commodity. Clidinium bears US NLM identifiers UMLS ID C0055877 and NCI Concept Code C73138. SMILES: O(C1C2CC[N](C1)(CC2)C)C(=O)C(O)(C1CCCCC1)C1CCCCC1.
This classification denotes a benzodiazepine with the molecular formula C18H13Cl2N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O9KZB9HG1Y, chemically known as 8-chloro-6-(o-chlorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine but generally known as climazolam, which bears US NIH Compound Identifier 68790. European Medicines Agency schedules Climazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06661MIG. The term CLIMAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). CLIMAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule climazolam under HS 29339940 and SITC 51577. As of Q4 2014, CLIMAZOLAM remains the US FDA Preferred Term for this commodity. Climazolam bears US NLM identifiers UMLS ID C0110063 and NCI Concept Code C77636. SMILES: CLC1CC2C(N3C(CN=C2C2C(CL)CCCC2)CNC3C)CC1.
This classification denotes an antifungal agent with the molecular formula C15H17ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9N42CW7I54, chemically known as 2-butanone, 1-(p-chlorophenoxy)-3,3-dimethyl-1-(1-imidazolyl)- but generally known as climbazole, which bears US NIH Compound Identifier 37907. European Medicines Agency schedules Climbazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06662MIG. The term CLIMBAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). CLIMBAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule climbazole under HS 29332990 and SITC 51573. As of Q4 2014, CLIMBAZOLE remains the US FDA Preferred Term for this commodity. Climbazole bears US NLM identifiers UMLS ID C0666079 and NCI Concept Code C78033. SMILES: CLC1CCC(OC(N2CCNC2)C(=O)C(C)(C)C)CC1.
This classification denotes a quinolone antibiotic with the molecular formula C17H17ClFN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8N86XTF9QD, chemically known as 3-quinolinecarboxylic acid, 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, (+-)- but generally known as clinafloxacin, which bears US NIH Compound Identifier 60062. European Medicines Agency schedules Clinafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06664MIG. The term CLINAFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). CLINAFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clinafloxacin under HS 29334910 and SITC 51575. As of Q4 2014, CLINAFLOXACIN remains the US FDA Preferred Term for this commodity. Clinafloxacin bears US NLM identifiers UMLS ID C0070191 and NCI Concept Code C74372. SMILES: CLC1C2N(C3CC3)CC(C(=O)C2CC(F)C1N1CC(N)CC1)C(=O)O.CL.
This classification denotes a lincosamide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3U02EL437C. European Medicines Agency schedules Clindamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06665MIG. Clindamycin generally arises in the molecular formula C18H33CLN2O5S. The term CLINDAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) CLINDAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clindamycin under HS 29419000 and SITC 54139. As of Q4 2014, CLINDAMYCIN remains the US FDA Preferred Term for this commodity. Clindamycin bears US NLM identifiers UMLS ID C0008947 and NCI Concept Code C377. SMILES: CLC(C(NC(=O)C1N(CC(C1)CCC)C)C1OC(SC)C(O)C(O)C1O)C.
This classification denotes a lincosamide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T20OQ1YN1W. European Medicines Agency schedules Clindamycin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01342MIG. Clindamycin hydrochloride generally arises in the molecular formula C18H33CLN2O5S.CLH. The term 'clindamycin hydrochloride' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule clindamycin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CLINDAMYCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clindamycin hydrochloride bears US NLM identifiers UMLS ID C0282105 and NCI Concept Code C47977. SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)CL.CL.
This classification denotes a lincosamide antibiotic with the molecular formula C34H63ClN2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C501Z28AFG, chemically known as methyl (2s-trans)-7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-l-threo-alpha-d-galacto-octopyranoside, monopalmitate (ester) but more generally known as clindamycin palmitate, which bears US NIH Compound Identifier 83855. Most nations, for tariff and trade purposes, schedule clindamycin palmitate under HS 29419000 and SITC 54139. As of Q4 2014, CLINDAMYCIN PALMITATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1SC)[C@@H]([C@H](C)CL)NC(=O)[C@@H]2C[C@H](CN2C)CCC)O)O.
This classification denotes a lincosamide antibiotic with the molecular formula C34H63ClN2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VN9A8JM7M7, chemically known as methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-l-threo-alpha-d-galacto-octopyranoside 2-palmitate monohydrochloride but more generally known as clindamycin palmitate hydrochloride, which bears US NIH Compound Identifier 33030. European Medicines Agency schedules Clindamycin palmitate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01343MIG. Most nations, for tariff and trade purposes, schedule clindamycin palmitate hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, CLINDAMYCIN PALMITATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clindamycin palmitate hydrochloride bears US NLM identifiers UMLS ID C0304311 and NCI Concept Code C61683. SMILES: CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1SC)[C@@H]([C@H](C)CL)NC(=O)[C@@H]2C[C@H](CN2C)CCC)O)O.CL.
This classification denotes a lincosamide antibiotic with the molecular formula C18H34ClN2O8PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EH6D7113I8, chemically known as l-threo-.alpha.-d-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, 2-(dihydrogen phosphate), (2s-trans)-, but more generally known as clindamycin phosphate, which bears US NIH Compound Identifier 29029. European Medicines Agency schedules clindamycin phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06665MIG. Most nations, for tariff purposes, schedule clindamycin phosphate under HS 29419000. Clindamycin phosphate bears US NLM identifiers UMLS ID C0055881 and NCI Concept Code C47978. SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)OP(=O)(O)O)O)O)[C@H](C)CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes an anti-lipidemic agent with the molecular formula C28H36O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0374EZJ8CU, chemically known as 2,2-(cyclohexylidenebis(p-phenyleneoxy))bis(2-methylbutyric acid) but generally known as clinofibrate, which bears US NIH Compound Identifier 2787. European Medicines Agency schedules Clinofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06666MIG. The term CLINOFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). CLINOFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clinofibrate under HS 29189900 and SITC 51396. As of Q4 2014, CLINOFIBRATE remains the US FDA Preferred Term for this commodity. Clinofibrate bears US NLM identifiers UMLS ID C0055883 and NCI Concept Code C78052. SMILES: O(c1ccc(C2(CCCCC2)c2ccc(OC(CC)(C)C(=O)O)cc2)cc1)C(CC)(C)C(=O)O.
This classification denotes an anti-infective agent with the molecular formula C9H5ClINO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BHQ856EJ5, chemically known as 8-quinolinol, 5-chloro-7-iodo- but generally known as clioquinol, which bears US NIH Compound Identifier 2788. European Medicines Agency schedules Clioquinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06669MIG. The term CLIOQUINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules clioquinol in its Anatomical Therapeutic Chemical (ATC) Classification. CLIOQUINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clioquinol under HS 29334990 and SITC 51575. As of Q4 2014, CLIOQUINOL remains the US FDA Preferred Term for this commodity. Clioquinol bears US NLM identifiers UMLS ID C0021978 and NCI Concept Code C65337. SMILES: IC1C(O)C2NCCCC2C(CL)C1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11ClO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BB27ZR25WO, chemically known as benzeneacetic acid, 3-chloro-alpha-methyl-4-(2-thienylcarbonyl)- but generally known as cliprofen, which bears US NIH Compound Identifier 167449. European Medicines Agency schedules Cliprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06671MIG. The term CLIPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). CLIPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cliprofen under HS 29349990 and SITC 51579. As of Q4 2014, CLIPROFEN remains the US FDA Preferred Term for this commodity. Cliprofen bears US NLM identifiers UMLS ID C2699354 and NCI Concept Code C77343. SMILES: CLC1CC(C(C)C(=O)O)CCC1C(=O)C1SCCC1.
This classification denotes an anxiolytic with the molecular formula C16H13ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2MRO291B4U, chemically known as 7-chloro-1-methyl-5-phenyl-1h-1,5-benzodiazepine-2,4(3h,5h)-dione but generally known as clobazam, which bears US NIH Compound Identifier 2789. European Medicines Agency schedules Clobazam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06673MIG. The term CLOBAZAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules clobazam in its Anatomical Therapeutic Chemical (ATC) Classification. CLOBAZAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clobazam under HS 29337200 and SITC 51561. As of Q4 2014, CLOBAZAM remains the US FDA Preferred Term for this commodity. Clobazam bears US NLM identifiers UMLS ID C0055891 and NCI Concept Code C81615. SMILES: CLC1CC2N(C(=O)CC(=O)N(C2CC1)C)C1CCCCC1.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2L2063955H. European Medicines Agency schedules Cloridarol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06757MIG. Cloridarol generally arises in the molecular formula C15H11CLO2. The term CLORIDAROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) CLORIDAROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Clobenfurol or cloridarol bears US NLM identifiers UMLS ID C0055892 and NCI Concept Code C80876. SMILES: C1=CC=C2C(=C1)C=C(O2)C(C3=CC=C(C=C3)Cl)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H18ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O6W0NP518, chemically known as 10,11-dihydro-11-oxo-5h-dibenzo(b,e)(1,4)diazepine, 7-chloro-10-(2-(dimethylamino)ethyl)- but generally known as clobenzepam, which bears US NIH Compound Identifier 14396. European Medicines Agency schedules Clobenzepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06675MIG. The term CLOBENZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). CLOBENZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clobenzepam under HS 29339940 and SITC 51577. As of Q4 2014, CLOBENZEPAM remains the US FDA Preferred Term for this commodity. Clobenzepam bears US NLM identifiers UMLS ID C2699357 and NCI Concept Code C77434. SMILES: CLC1CC2[NH]C3C(C(=O)N(CCN(C)C)C2CC1)CCCC3.
This classification denotes a histamine-1 receptor antagonist C17H18ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 618Q2FLB9R, chemically known as 2-(2-chloro-6-oxo-11h-benzo(b)(1,4)benzodiazepin-5-yl)ethyl-dimethyl-ammonium chloride, but more generally known as clobenzepam hydrochloride, which bears US NIH Compound Identifier 17646. Most nations, for tariff and trade purposes, schedule clobenzepam hydrochloride under HS 29339940 and SITC 51577. As of Q4 2014, CLOBENZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCN1C2CCC(CC2NC3CCCCC3C1=O)CL.CL.
This classification denotes an anorexiant with the molecular formula C16H18ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4A5352XI2A, chemically known as benzeneethanamine, n-((2-chlorophenyl)methyl)-alpha-methyl-, (+)- but more generally known as clobenzorex, which bears US NIH Compound Identifier 71675. European Medicines Agency schedules Clobenzorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06676MIG. The term CLOBENZOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules clobenzorex in its Anatomical Therapeutic Chemical (ATC) Classification. CLOBENZOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule clobenzorex under HS 29214980 and SITC 51454. As of Q4 2014, CLOBENZOREX remains US FDA's Preferred Term for this commodity. Clobenzorex bears US NLM identifiers UMLS ID C0055894 and NCI Concept Code C77327. SMILES: CLC1C(CNC(CC2CCCCC2)C)CCCC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28ClFO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ADN79D536H, chemically known as 21-chloro-9-fluoro-11b,17-dihydroxy-16a-methylpregna-1,4-diene-3,20-dione but generally known as clobetasol, which bears US NIH Compound Identifier 32797. European Medicines Agency schedules Clobetasol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06678MIG. World Health Organization schedules clobetasol in its Anatomical Therapeutic Chemical (ATC) Classification. CLOBETASOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clobetasol under HS 29372200 and SITC 54153. As of Q4 2014, CLOBETASOL remains the US FDA Preferred Term for this commodity. Clobetasol bears US NLM identifiers UMLS ID C0008992 and NCI Concept Code C65339. SMILES: CLCC(=O)C1(O)C2(C(C3C(F)(C(O)C2)C2(C(=CC(=O)C=C2)CC3)C)CC1C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H32ClFO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 779619577M, chemically known as 21-chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione (11beta,16beta)- but more generally known as clobetasol propionate, which bears US NIH Compound Identifier 32798. European Medicines Agency schedules Clobetasol propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01346MIG. Most nations, for tariff and trade purposes, schedule clobetasol propionate under HS 29372200 and SITC 54153. As of Q4 2014, CLOBETASOL PROPIONATE remains US FDA's Preferred Term for this commodity. Clobetasol propionate bears US NLM identifiers UMLS ID C0055895 and NCI Concept Code C28934. SMILES: CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCL.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LT69WY1J6D. European Medicines Agency schedules Clobetasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06679MIG. Clobetasone generally arises in the molecular formula C22H26CLFO4. The term CLOBETASONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, no. 10 1972, list 12.) CLOBETASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clobetasone under HS 29372200 and SITC 54153. As of Q4 2014, CLOBETASONE remains the US FDA Preferred Term for this commodity. Clobetasone bears US NLM identifiers UMLS ID C0360518 and NCI Concept Code C77408. SMILES: CLCC(=O)C1(O)C2(C(C3C(F)(C4(C(=CC(=O)C=C4)CC3)C)C(=O)C2)CC1C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H32ClFO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8U0H6XI6EO, chemically known as 21-chloro-9-fluoro-17-hydroxy-16-methylpregna-1,4-diene-3,11,20-trione 17-butyrate but more generally known as clobetasone butyrate, which bears US NIH Compound Identifier 71386. European Medicines Agency schedules Clobetasone butyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01347MIG. Most nations, for tariff and trade purposes, schedule clobetasone butyrate under HS 29372200 and SITC 54153. As of Q4 2014, CLOBETASONE BUTYRATE remains US FDA's Preferred Term for this commodity. Clobetasone butyrate bears US NLM identifiers UMLS ID C0055896 and NCI Concept Code C77409. SMILES: CCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(CC(=O)[C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)C)C)C(=O)CCL.
This classification denotes an antitussive agent with the molecular formula C14H22ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1NY2IX043A, chemically known as 1-(4-chlorophenyl)-2,3-dimethyl-4-dimethylamino-2-butanol but more generally known as clobutinol, which bears US NIH Compound Identifier 26937. European Medicines Agency schedules Clobutinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06680MIG. The term CLOBUTINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules clobutinol in its Anatomical Therapeutic Chemical (ATC) Classification. CLOBUTINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule clobutinol under HS 29221980 and SITC 51461. As of Q4 2014, CLOBUTINOL remains US FDA's Preferred Term for this commodity. Clobutinol bears US NLM identifiers UMLS ID C0055897 and NCI Concept Code C78105. SMILES: CLC1CCC(CC(O)(C(CN(C)C)C)C)CC1.
This classification denotes an antidepressant agent with the molecular formula C28H37ClN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6EEL1GB72K, chemically known as 3-chloro-5-(3-(4-piperidino-4- carbamoylpiperidino)propyl)-10,11-dihydro-5h- dibenz(b,f)azepine dihydrochloride monohydrate but generally known as clocapramine, which bears US NIH Compound Identifier 2793. European Medicines Agency schedules Clocapramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06683MIG. The term CLOCAPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). CLOCAPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clocapramine under HS 29333999 and SITC 51574. As of Q4 2014, CLOCAPRAMINE remains the US FDA Preferred Term for this commodity. Clocapramine bears US NLM identifiers UMLS ID C0047305 and NCI Concept Code C78010. SMILES: CLC1CC2N(CCCN3CCC(N4CCCCC4)(CC3)C(=O)N)C3C(CCC2CC1)CCCC3.
This classification denotes an antidepressant agent with the molecular structure C28H37CLN4O.2CLH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9NLU6H3LRD chemically known as 1'-(3-(3-chloro-10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)(1,4'-bipiperidine)-4'-carboxamide dihydrochloride monohydrate, but more commonly known as clocapramine hydrochloride, which bears US NIH Compound Identifier 5282503. European Medicines Agency schedules Clocapramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01349MIG. Most nations, for tariff and trade purposes, schedule clocapramine hydrochloride under HS 29333999 and SITC 51574. SMILES: C1CCC2C(C1)CCC3CCC(CC3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5)CL.O.CL.CL.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HQJ711KH8. European Medicines Agency schedules Clocinizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06685MIG. Clocinizine generally arises in the molecular formula C26H27CLN2. The term CLOCINIZINE is an International Non-Proprietary Name or INN. CLOCINIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clocinizine under HS 29335995 and SITC 51576. As of Q4 2014, CLOCINIZINE remains the US FDA Preferred Term for this commodity. Clocinizine bears US NLM identifiers UMLS ID C1322002 and NCI Concept Code C77435. SMILES: CLC1CCC(C(N2CCN(CC2)C/C=C/C2CCCCC2)C2CCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H27CLN2.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AE8KM1QU3Q. European Medicines Agency schedules clocinizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01350MIG. The term clocinizine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule clocinizine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, CLOCINIZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clocinizine hydrochloride bears US NLM identifiers UMLS ID C3273574 and NCI Concept Code C97696. SMILES: C1CCC(CC1)/C=C/CN2CCN(CC2)C(C3CCCCC3)C4CCC(CC4)CL.CL.CL.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N8ZUB7XE0H. European Medicines Agency schedules Clocortolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06686MIG. Clocortolone generally arises in the molecular formula C22H28CLFO4. The term CLOCORTOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) CLOCORTOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clocortolone under HS 29372200 and SITC 54153. As of Q4 2014, CLOCORTOLONE remains the US FDA Preferred Term for this commodity. Clocortolone bears US NLM identifiers UMLS ID C0055899 and NCI Concept Code C61684. SMILES: CLC12C(C3C(C(C(C3)C)C(=O)CO)(CC1O)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid C24H30ClFO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85061HTR8T, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-chloro-6-fluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as clocortolone acetate, which bears US NIH Compound Identifier 3037082. Most nations, for tariff and trade purposes, schedule clocortolone acetate under HS 29372200 and SITC 54153. As of Q4 2014, CLOCORTOLONE ACETATE remains US FDA's Preferred Term for this commodity. Clocortolone acetate bears US NLM identifiers UMLS ID C0770567 and NCI Concept Code C77410. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C)C)O)CL)C)F.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H36ClFO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QBL8IZH14X, chemically known as 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-pivalate but more generally known as clocortolone pivalate, which bears US NIH Compound Identifier 36673. European Medicines Agency schedules Clocortolone pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13393MIG. Most nations, for tariff and trade purposes, schedule clocortolone pivalate under HS 29372200 and SITC 54153. As of Q4 2014, CLOCORTOLONE PIVALATE remains US FDA's Preferred Term for this commodity. Clocortolone pivalate bears US NLM identifiers UMLS ID C0719380 and NCI Concept Code C47455. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C(C)(C)C)C)O)CL)C)F.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H743H7R6YE. European Medicines Agency schedules Clodacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06688MIG. Clodacaine generally arises in the molecular formula C16H26CLN3O. The term CLODACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CLODACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clodacaine under HS 29242995 and SITC 51479. As of Q4 2014, CLODACAINE remains the US FDA Preferred Term for this commodity. Clodacaine bears US NLM identifiers UMLS ID C2699358 and NCI Concept Code C77322. SMILES: CLC1C(NC(=O)CN(CCN(CC)CC)CC)CCCC1.
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96L9G9BL3X. European Medicines Agency schedules Clodanolene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06689MIG. Clodanolene generally arises in the molecular formula C14H9CL2N3O3. The term CLODANOLENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) CLODANOLENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clodanolene under HS 29349990 and SITC 51579. As of Q4 2014, CLODANOLENE remains the US FDA Preferred Term for this commodity. Clodanolene bears US NLM identifiers UMLS ID C0055902 and NCI Concept Code C80981. SMILES: CLC1CC(C2OC(CC2)/C=N/N2CC(=O)NC2=O)CCC1CL.
This classification denotes an antidepressant agent with the molecular formula C18H20ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X82H6JOC4H, chemically known as 2h-benzimidazol-2-one, 5-chloro-1-(3-(dimethylamino)propyl)-1,3-dihydro-3-phenyl- (9ci) but generally known as clodazon, which bears US NIH Compound Identifier 20883. European Medicines Agency schedules Clodazon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06691MIG. The term CLODAZON is an International Non-Proprietary Name. CLODAZON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clodazon under HS 29339990 and SITC 51577. As of Q4 2014, CLODAZON remains the US FDA Preferred Term for this commodity. Clodazon bears US NLM identifiers UMLS ID C2699359 and NCI Concept Code C78011. SMILES: Clc1cc2n(c(=O)n(CCCN(C)C)c2cc1)c1ccccc1.
This classification denotes an antidepressant agent with the molecular formula C18H20ClN3O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FSF9L5AH4G, chemically known as 2h-benzimidazol-2-one, 5-chloro-1(3-(dimethylamino)propyl)-1,3-dihydro-3-phenyl-, monohydrochloride, monohydrate but more generally known as clodazon hydrochloride, which bears US NIH Compound Identifier 167451. Most nations, for tariff and trade purposes, schedule clodazon hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, CLODAZON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clodazon hydrochloride bears US NLM identifiers UMLS ID C2699360 and NCI Concept Code C78012. SMILES: CN(C)CCCN1C2CCC(CC2N(C1=O)C3CCCCC3)CL.O.CL.
This classification denotes an antidepressant agent C18H20ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N0FW29BP3C, chemically known as 2h-benzimidazol-2-one,5-chloro-1-(3-(dimethylamino)propyl)-1,3-dihydro-3-phenyl-, monohydrochloride, but more generally known as clodazon hydrochloride anhydrous, which bears US NIH Compound Identifier 56841979. Most nations, for tariff and trade purposes, schedule clodazon hydrochloride anhydrous under HS 29339990 and SITC 51577. As of Q4 2014, CLODAZON HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. Clodazon hydrochloride anhydrous bears US NLM identifiers UMLS ID C2699361 and NCI Concept Code C78675. SMILES: CN(C)CCCN1C2CCC(CC2N(C1=O)C3CCCCC3)CL.CL.
This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula CH4Cl2O6P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0813BZ6866, chemically known as 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)benzenesulfonamide but generally known as clodronic acid, which bears US NIH Compound Identifier 2732. European Medicines Agency schedules Clodronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06693MIG. The term CLODRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules clodronic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Clodronate or clodronic acid bears US NLM identifiers UMLS ID C0012081 and NCI Concept Code C61685. SMILES: Clc1c(S(=O)(=O)N)cc(C2(O)NC(=O)c3c2cccc3)cc1.
This classification denotes a ribonucleotide reductase inhibitor and purine antagonist with the molecular formula C10H11ClFN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 762RDY0Y2H, chemically known as 9h-purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)- but generally known as clofarabine, which bears US NIH Compound Identifier 119182. European Medicines Agency schedules Clofarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21902. The term CLOFARABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, List 52). World Health Organization schedules clofarabine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule clofarabine under HS 29349990 and SITC 51579. As of Q4 2014, CLOFARABINE remains the US FDA Preferred Term for this commodity. Clofarabine bears US NLM identifiers UMLS ID C0092777 and NCI Concept Code C26638. SMILES: C1=NC2=C(N1C3C(C(C(O3)CO)O)F)N=C(N=C2N)CL.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D959AE5USF. European Medicines Agency schedules Clofazimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06694MIG. Clofazimine generally arises in the molecular formula C27H22CL2N4. The term CLOFAZIMINE is an International Non-Proprietary Name or INN. CLOFAZIMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)CL)C=C1NC5=CC=C(C=C5)CL.
This classification denotes a diuretic with the molecular formula C6H7ClN2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 582ILN204B, chemically known as 1,3-benzenedisulfonamide, 4-chloro- but generally known as clofenamide, which bears US NIH Compound Identifier 69594. European Medicines Agency schedules Clofenamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06697MIG. The term CLOFENAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules clofenamide in its Anatomical Therapeutic Chemical (ATC) Classification. CLOFENAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clofenamide under HS 29350090 and SITC 51580. As of Q4 2014, CLOFENAMIDE remains the US FDA Preferred Term for this commodity. Clofenamide bears US NLM identifiers UMLS ID C2699364 and NCI Concept Code C77559. SMILES: CLC1C(S(=O)(=O)N)CC(S(=O)(=O)N)CC1.
This classification denotes a pesticide and carcinogenic chlorinated hydrocarbon with the molecular formula C14H9Cl5, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier CIW5S16655, chemically known as 1,1,1-tricloro-2, 2-bis (4-cloro-fenil)-etano but more generally known as chlorophenothane, which bears U.S. NIH Compound Identifier 3036. European Medicines Agency schedules Clofenotane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06700MIG. The term CHLOROPHENOTHANE is an International Non-Proprietary Name. World Health Organization schedules chlorophenothane in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes an antifungal agent with the molecular formula C16H12Cl2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B2Z1IL2P8, chemically known as 4,4-oxybis(2-chloroacetophenone). but generally known as clofenoxyde, which bears US NIH Compound Identifier 194699. European Medicines Agency schedules Clofenoxyde in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06701MIG. The term CLOFENOXYDE is an International Non-Proprietary Name. CLOFENOXYDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clofenoxyde under HS 29147000 and SITC 51629. As of Q4 2014, CLOFENOXYDE remains the US FDA Preferred Term for this commodity. Clofenoxyde bears US NLM identifiers UMLS ID C2699368 and NCI Concept Code C78034. SMILES: CLCC(=O)C1CCC(OC2CCC(CC2)C(=O)CCL)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H21ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 071P4J77HF, chemically known as acetamide, 2-(p-chlorophenoxy)-n-(2-(diethylamino)ethyl)- but generally known as clofexamide, which bears US NIH Compound Identifier 28554. European Medicines Agency schedules Clofexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06704MIG. The term CLOFEXAMIDE is an International Non-Proprietary Name. CLOFEXAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clofexamide under HS 29242995 and SITC 51479. As of Q4 2014, CLOFEXAMIDE remains the US FDA Preferred Term for this commodity. Clofexamide bears US NLM identifiers UMLS ID C0055906 and NCI Concept Code C77345. SMILES: CLC1CCC(OCC(=O)NCCN(CC)CC)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O2.C14H21ClN2O2.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TPT3MH65LD, chemically known as 2-(4-chlorophenoxy)-n-(2-(diethylamino)ethyl)acetamide, compound with 4-butyl-1,2-diphenyltetrahydropyrazol-3,5-dione (1:1) but generally known as clofezone, which bears US NIH Compound Identifier 6433695. European Medicines Agency schedules Clofezone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06705MIG. World Health Organization schedules clofezone in its Anatomical Therapeutic Chemical (ATC) Classification. CLOFEZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clofezone under HS 29331990 and SITC 51571. As of Q4 2014, CLOFEZONE remains the US FDA Preferred Term for this commodity. Clofezone bears US NLM identifiers UMLS ID C0650237 and NCI Concept Code C77346. SMILES: CLC1CCC(OCC(=O)NCCN(CC)CC)CC1.O=C1N(N(C(=O)C1CCCC)C1CCCCC1)C1CCCCC1.
This classification denotes the anhydrous form of a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O2.C14H21ClN2O2.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TPT3MH65LD, chemically known as 2-(4-chlorophenoxy)-n-(2-(diethylamino)ethyl)acetamide, compound with 4-butyl-1,2-diphenyltetrahydropyrazol-3,5-dione (1:1) but more generally known as clofezone, which bears US NIH Compound Identifier 6433695. European Medicines Agency schedules Clofezone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06705MIG. World Health Organization schedules clofezone in its Anatomical Therapeutic Chemical (ATC) Classification. CLOFEZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule clofezone anhydrous under HS 29331990. As of Q4 2014, CLOFEZONE ANHYDROUS remains US FDA's Preferred Term for this commodity. SMILES: CCCCC1C(=O)N(N(C1=O)C2CCCCC2)C3CCCCC3.CCN(CC)CCNC(=O)COC1CCC(CC1)CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O2.C14H21ClN2O2.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TPT3MH65LD, chemically known as acetamide, 2-(4-chlorophenoxy)-n-(2-(diethylamino)ethyl)-, compd. with 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione, hydrate (1:1:2), but more generally known as clofezone dihydrate, which bears US NIH Compound Identifier 6443874. European Medicines Agency schedules clofezone dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06705MIG. Most nations, for tariff purposes, schedule clofezone dihydrate under HS 29331990. SMILES: CCCCC1C(=O)N(N(C1=O)C2CCCCC2)C3CCCCC3.CCN(CC)CCNC(=O)COC1CCC(CC1)CL.O.O.
This classification denotes an anti-lipidemic agent with the molecular formula C12H15ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HPN91K7FU3, chemically known as piperazine, 1- (diphenylmethyl)-4-(3-phenyl-2-propenyl)-, (e)- but generally known as clofibrate, which bears US NIH Compound Identifier 2761. European Medicines Agency schedules Clofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06706MIG. The term CLOFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules clofibrate in its Anatomical Therapeutic Chemical (ATC) Classification. CLOFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clofibrate under HS 29189900 and SITC 51396. As of Q4 2014, CLOFIBRATE remains the US FDA Preferred Term for this commodity. Clofibrate bears US NLM identifiers UMLS ID C0009002 and NCI Concept Code C378. SMILES: C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4.
This classification denotes an anti-lipidemic agent with the molecular formula C16H22ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0S9SLS3L93, chemically known as 4-chlorophenoxy isopropionyl 4-hydroxy-n,n-dimethylbutyramide but generally known as clofibride, which bears US NIH Compound Identifier 160134. European Medicines Agency schedules Clofibride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06708MIG. The term CLOFIBRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules clofibride in its Anatomical Therapeutic Chemical (ATC) Classification. CLOFIBRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clofibride under HS 29242995 and SITC 51479. As of Q4 2014, CLOFIBRIDE remains the US FDA Preferred Term for this commodity. Clofibride bears US NLM identifiers UMLS ID C0055909 and NCI Concept Code C78055. SMILES: Clc1ccc(OC(C(=O)OCCCC(=O)N(C)C)(C)C)cc1.
This classification denotes an anti-infective agent with the molecular formula C21H26Cl2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 704083NI0R, chemically known as 2-((2,4-dichlorophenyl)methyl)-4-(1,1,3,3-tetramethylbutyl)phenol but generally known as clofoctol, which bears US NIH Compound Identifier 2799. European Medicines Agency schedules Clofoctol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06711MIG. The term CLOFOCTOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules clofoctol in its Anatomical Therapeutic Chemical (ATC) Classification. CLOFOCTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clofoctol under HS 29081900 and SITC 51244. As of Q4 2014, CLOFOCTOL remains the US FDA Preferred Term for this commodity. Clofoctol bears US NLM identifiers UMLS ID C0055915 and NCI Concept Code C78048. SMILES: CLC1C(CC2CC(C(CC(C)(C)C)(C)C)CCC2O)CCC(CL)C1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H15ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0V7WAB3NV4, chemically known as 5-chloro-6-cyclohexyl-2,3-dihydrobenzofuran-2-one but generally known as clofurac, which bears US NIH Compound Identifier 68806. European Medicines Agency schedules Clofurac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06713MIG. The term CLOFURAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). CLOFURAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CLOFURAC remains the US FDA Preferred Term for this commodity. Clofurac bears US NLM identifiers UMLS ID C2699370 and NCI Concept Code C77347. SMILES: CLC1C(C2CCCCC2)CC2OC(=O)CC2C1.
This classification denotes an antiestrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01L3E93T4C. European Medicines Agency schedules Clometerone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06719MIG. Clometerone generally arises in the molecular formula C22H31CLO2. The term CLOMETERONE is an International Non-Proprietary Name or INN. CLOMETERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Clometerone or clometherone bears US NLM identifiers UMLS ID C2347808 and NCI Concept Code C74147. SMILES: CLC1CC2C3C(C(C(C3)C)C(=O)C)(CCC2C2(C1=CC(=O)CC2)C)C.
This classification denotes a sedative and hypnotic with the molecular formula C6H8ClNS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C5DBZ19HV, chemically known as thiazole, 5-(2-chloroethyl)-4-methyl- but generally known as clomethiazole, which bears US NIH Compound Identifier 10783. European Medicines Agency schedules Clomethiazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06720MIG. The term CLOMETHIAZOLE is an International Non-Proprietary Name. World Health Organization schedules clomethiazole in its Anatomical Therapeutic Chemical (ATC) Classification. CLOMETHIAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clomethiazole under HS 29341000 and SITC 51579. As of Q4 2014, CLOMETHIAZOLE remains the US FDA Preferred Term for this commodity. Clomethiazole bears US NLM identifiers UMLS ID C0008221 and NCI Concept Code C80664. SMILES: CC1=C(SC=N1)CCCL.
This classification denotes a sedative and hypnotic with the molecular formula 2C6H8ClNS.C2H6O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22NJI0W1D2, chemically known as 5-(2-chloroethyl)-4-methylthiazole ethane-1,2-disulphonate, but more generally known as clomethiazole edisylate, which bears US NIH Compound Identifier 15850. European Medicines Agency schedules clomethiazole edisylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06720MIG. Most nations, for tariff purposes, schedule clomethiazole edisylate under HS 29341000. SMILES: CC1C(SCN1)CCCL.CC1C(SCN1)CCCL.C(CS(=O)(=O)O)S(=O)(=O)O.
This classification denotes a penicillin antibiotic with the molecular formula C17H18Cl2N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YI8LL014GF, chemically known as (3,4-dichloro-alpha-methoxybenzyl)penicillin but generally known as clometocillin, which bears US NIH Compound Identifier 71807. European Medicines Agency schedules Clometocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06721MIG. The term CLOMETOCILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules clometocillin in its Anatomical Therapeutic Chemical (ATC) Classification. CLOMETOCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clometocillin under HS 29411090 and SITC 54131. As of Q4 2014, CLOMETOCILLIN remains the US FDA Preferred Term for this commodity. Clometocillin bears US NLM identifiers UMLS ID C0055921 and NCI Concept Code C76221. SMILES: CLC1CC(C(OC)C(=O)NC2C3SC(C(N3C2=O)C(=O)O)(C)C)CCC1CL.
This classification denotes a penicillin antibiotic C17H17Cl2N2O5S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C71K33PDJ, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((2-(3,4-dichlorophenyl)-2-methoxyacetyl)amino)-3,3-dimethyl-7-oxo-, potassium salt (1:1), (2s,5r,6r)-, but more generally known as clometocillin potassium, which bears US NIH Compound Identifier 24892866. European Medicines Agency schedules Clometocillin potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01359MIG. Most nations, for tariff and trade purposes, schedule clometocillin potassium under HS 29411090 and SITC 54131. As of Q4 2014, CLOMETOCILLIN POTASSIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3CCC(C(C3)CL)CL)OC)C(=O)[O-])C.[K+].
This classification denotes an antiestrogen and angiogenesis activator inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B8447E7YI. European Medicines Agency schedules Clomifene citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01360MIG. Clomiphene citrate generally arises in the molecular formula C32H36CLNO8. The term 'clomiphene citrate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule clomifene citrate under HS 29221980. SMILES:.
This classification denotes an antiestrogen and angiogenesis activator inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HRS458QU2. European Medicines Agency schedules Clomifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06722MIG. Clomifene generally arises in the molecular formula C26H28CLNO. The term 'clomifene' is a Hazardous Substances Data Bank designation. CLOMIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Clomifene or clomiphene bears US NLM identifiers UMLS ID C0009008 and NCI Concept Code C61607. SMILES: CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/CL)/C3=CC=CC=C3.
This classification denotes an anorexiant with the molecular formula C9H9ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) O1R2462WA0, chemically known as 5-(4-chlorophenyl)-1,3-oxazolidin-2-imine but more generally known as clominorex, which bears US NIH Compound Identifier 19752. European Medicines Agency schedules Clominorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06724MIG. The term CLOMINOREX is an International Non-Proprietary Name. CLOMINOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule clominorex under HS 29349990 and SITC 51579. As of Q4 2014, CLOMINOREX remains US FDA's Preferred Term for this commodity. Clominorex bears US NLM identifiers UMLS ID C2347809 and NCI Concept Code C72177. SMILES: CLC1CCC(C2OC(=NC2)N)CC1.
This classification denotes a tricyclic antidepressant with the molecular formula C19H23ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NUV44L116D, chemically known as 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5h-dibenz(b,f)azepine but generally known as clomipramine, which bears US NIH Compound Identifier 2801. European Medicines Agency schedules Clomipramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06725MIG. The term CLOMIPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules clomipramine in its Anatomical Therapeutic Chemical (ATC) Classification. CLOMIPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clomipramine under HS 29339990 and SITC 51577. As of Q4 2014, CLOMIPRAMINE remains the US FDA Preferred Term for this commodity. Clomipramine bears US NLM identifiers UMLS ID C0009010 and NCI Concept Code C61608. SMILES: Clc1cc2N(CCCN(C)C)c3c(CCc2cc1)cccc3.
This classification denotes a tricyclic antidepressant with the molecular formula C19H23ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2LXW0L6GWJ, chemically known as 5h-dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-n,n-dimethyl-, monohydrochloride but more generally known as clomipramine hydrochloride, which bears US NIH Compound Identifier 68539. European Medicines Agency schedules Clomipramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01361MIG. Most nations, for tariff and trade purposes, schedule clomipramine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, CLOMIPRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clomipramine hydrochloride bears US NLM identifiers UMLS ID C0282107 and NCI Concept Code C47458. SMILES: CN(C)CCCN1C2CCCCC2CCC3C1CC(CC3)CL.CL.
This classification denotes a tetracycline antibiotic with the molecular formula C23H25ClN2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YP0241BU76, chemically known as 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-n-(hydroxymethyl)-6-methyl-1,11-dioxo-2-naphthacenecarboxamide but generally known as clomocycline, which bears US NIH Compound Identifier 5464321. European Medicines Agency schedules Clomocycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06726MIG. The term CLOMOCYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules clomocycline in its Anatomical Therapeutic Chemical (ATC) Classification. CLOMOCYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clomocycline under HS 29413000 and SITC 54133. As of Q4 2014, CLOMOCYCLINE remains the US FDA Preferred Term for this commodity. Clomocycline bears US NLM identifiers UMLS ID C0055923 and NCI Concept Code C76236. SMILES: CLC1C2C(O)(C3CC4C(O)(C(=O)C3=C(O)C2C(O)CC1)C(=O)/C(=C(\O)NCO)C(=O)C4N(C)C)C.
This classification denotes a tetracycline antibiotic C23H24ClN2O9.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V4JNK46U1U, chemically known as 2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-n-(hydroxymethyl)-6-methyl-1,11-dioxo-, monosodium salt, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, but more generally known as clomocycline sodium, which bears US NIH Compound Identifier 72710627. Most nations, for tariff and trade purposes, schedule clomocycline sodium under HS 29413000 and SITC 54133. As of Q4 2014, CLOMOCYCLINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C[C@]1(C2C(CCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)NCO)[O-])N(C)C)O)O)O)CL)O.[NA+].
This classification denotes a benzodiazepine and anticonvulsant agent with the molecular formula C15H10ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PE9FDE8GB, chemically known as 1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2h-1,4.benzodiazepin-2-one but generally known as clonazepam, which bears US NIH Compound Identifier 2802. European Medicines Agency schedules Clonazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06728MIG. The term CLONAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules clonazepam in its Anatomical Therapeutic Chemical (ATC) Classification. CLONAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clonazepam under HS 29339190 and SITC 51577. As of Q4 2014, CLONAZEPAM remains the US FDA Preferred Term for this commodity. Clonazepam bears US NLM identifiers UMLS ID C0009011 and NCI Concept Code C28935. SMILES: CLC1C(C2=NCC(=O)NC3C2CC([N](=O)O)CC3)CCCC1.
This classification denotes an alpha-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YH9K692U9S. European Medicines Agency schedules Clonazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06729MIG. Clonazoline generally arises in the molecular formula C14H13CLN2. The term CLONAZOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) CLONAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clonazoline under HS 29332990 and SITC 51573. As of Q4 2014, CLONAZOLINE remains the US FDA Preferred Term for this commodity. Clonazoline bears US NLM identifiers UMLS ID C2699373 and NCI Concept Code C77295. SMILES: CLC1C2C(C(CC3=NCCN3)CC1)CCCC2.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H9Cl2N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MN3L5RMN02, chemically known as 2,6-dichloro-n-imidazolidin-2-ylideneaniline but generally known as clonidine, which bears US NIH Compound Identifier 2803. European Medicines Agency schedules Clonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06730MIG. The term CLONIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules clonidine in its Anatomical Therapeutic Chemical (ATC) Classification. CLONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clonidine under HS 29332990 and SITC 51573. As of Q4 2014, CLONIDINE remains the US FDA Preferred Term for this commodity. Clonidine bears US NLM identifiers UMLS ID C0009014 and NCI Concept Code C380. SMILES: CLC1C(NC2=NCCN2)C(CL)CCC1.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H9Cl2N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W76I6XXF06, chemically known as 2-imidazoline, 2-(2,6-dichloroanilino)-, monohydrochloride but more generally known as clonidine hydrochloride, which bears US NIH Compound Identifier 20179. European Medicines Agency schedules Clonidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01362MIG. Most nations, for tariff and trade purposes, schedule clonidine hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, CLONIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clonidine hydrochloride bears US NLM identifiers UMLS ID C0546860 and NCI Concept Code C47979. SMILES: C1CC(C(C(C1)CL)NC2=NCCN2)CL.CL.
This classification denotes an opioid receptor agonist with the molecular formula C20H23ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S90R21A2V2, chemically known as 1h-benzeimidazole-1-ethanamine, 2-((4-chlorophenyl)methyl)-n,n-diethyl-5-nitro- but generally known as clonitazene, which bears US NIH Compound Identifier 62528. European Medicines Agency schedules Clonitazene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06731MIG. The term CLONITAZENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). CLONITAZENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clonitazene under HS 29339990 and SITC 51577. As of Q4 2014, CLONITAZENE remains the US FDA Preferred Term for this commodity. Clonitazene bears US NLM identifiers UMLS ID C2699374 and NCI Concept Code C77283. SMILES: CLC1CCC(CC2N(CCN(CC)CC)C3C(N2)CC([N](=O)O)CC3)CC1.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MIG1YFL8MD. European Medicines Agency schedules Clonitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06732MIG. Clonitrate generally arises in the molecular formula C3H5CLN2O6. The term CLONITRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CLONITRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clonitrate under HS 29209085 and SITC 51639. As of Q4 2014, CLONITRATE remains the US FDA Preferred Term for this commodity. Clonitrate bears US NLM identifiers UMLS ID C2825370 and NCI Concept Code C80875. SMILES: ClCC(O[N](=O)O)CO[N](=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H17CLN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XVF42I68OX, more generally known as clonixeril. European Medicines Agency schedules clonixeril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06733MIG. The term CLONIXERIL is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 24, no. 11 1970, list 10. CLONIXERIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clonixeril under HS 29333999 and SITC 51574. As of Q4 2014, CLONIXERIL remains the US FDA Preferred Term for this commodity. Clonixeril bears US NLM identifiers UMLS ID C2825245 and NCI Concept Code C80540. SMILES: CC1=C(C=CC=C1CL)NC2=C(C=CC=N2)C(=O)OCC(CO)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H11ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V7DXN0M42R, chemically known as 3-pyridinecarboxylic acid, 2-((3-chloro-2-methylphenyl)amino)- but generally known as clonixin, which bears US NIH Compound Identifier 28718. European Medicines Agency schedules Clonixin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06734MIG. The term CLONIXIN is an International Non-Proprietary Name. CLONIXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clonixin under HS 29333999 and SITC 51574. As of Q4 2014, CLONIXIN remains the US FDA Preferred Term for this commodity. Clonixin bears US NLM identifiers UMLS ID C0009018 and NCI Concept Code C65340. SMILES: CLC1C(C(NC2NCCCC2C(=O)O)CCC1)C.
This classification denotes a diuretic with the molecular formula C14H20ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17S83WON0I, chemically known as 4-chloro-n-(2,6-dimethyl-piperidin-1-yl)-3-sulfamoyl-benzamide but generally known as clopamide, which bears US NIH Compound Identifier 2804. European Medicines Agency schedules Clopamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06735MIG. The term CLOPAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules clopamide in its Anatomical Therapeutic Chemical (ATC) Classification. CLOPAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clopamide under HS 29350090 and SITC 51580. As of Q4 2014, CLOPAMIDE remains the US FDA Preferred Term for this commodity. Clopamide bears US NLM identifiers UMLS ID C0009025 and NCI Concept Code C81074. SMILES: CLC1C(S(=O)(=O)N)CC(C(=O)NN2C(CCCC2C)C)CC1.
This classification denotes a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A432D932A. European Medicines Agency schedules Clopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06736MIG. Clopenthixol generally arises in the molecular formula C22H25CLN2OS. The term CLOPENTHIXOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CLOPENTHIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clopenthixol under HS 29349990 and SITC 51579. As of Q4 2014, CLOPENTHIXOL remains the US FDA Preferred Term for this commodity. SMILES: C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)CL)CCO.
This classification denotes a dopamine antagonist , a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2HFX55AF4Y, chemically known as clopenthixol decanoate, (e/z)-, but more generally known as clopenthixol decanoate, which bears US NIH Compound Identifier 6450313. European Medicines Agency schedules Clopenthixol decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01364MIG. Most nations, for tariff and trade purposes, schedule clopenthixol decanoate under HS 29349990 and SITC 51579. SMILES: As of Q4 2014, CLOPENTHIXOL DECANOATE remains US FDA's Preferred Term for this commodity.
This classification denotes a dopamine antagonist with the molecular formula C22H26Cl2N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3BMY435Z0, chemically known as 1-piperazineethanol, 4-(3-(2-chloro-9h-thioxanthen-9-ylidene)propyl)-, hydrochloride (1:2), but more generally known as clopenthixol dihydrochloride, which bears US NIH Compound Identifier 5372683. European Medicines Agency schedules clopenthixol dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06736MIG. Most nations, for tariff purposes, schedule clopenthixol dihydrochloride under HS 29349990. SMILES:.
This classification denotes the hydrochloride form of a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A432D932A. European Medicines Agency schedules Clopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06736MIG. Clopenthixol generally arises in the molecular formula C22H25CLN2OS. The term CLOPENTHIXOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, list 5.) CLOPENTHIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule clopenthixol hydrochloride under HS 29349990 and SITC 51579. SMILES: As of Q4 2014, CLOPENTHIXOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.
This classification denotes an antitussive agent with the molecular formula C20H24ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 69M5L7BXEK, chemically known as piperidine, 1-(2-((p-chloro-alpha-phenylbenzyl)oxy)ethyl)- but more generally known as cloperastine, which bears US NIH Compound Identifier 2805. European Medicines Agency schedules Cloperastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06737MIG. The term CLOPERASTINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules cloperastine in its Anatomical Therapeutic Chemical (ATC) Classification. CLOPERASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cloperastine under HS 29333999 and SITC 51574. As of Q4 2014, CLOPERASTINE remains US FDA's Preferred Term for this commodity. Cloperastine bears US NLM identifiers UMLS ID C0055930 and NCI Concept Code C78106. SMILES: CLC1CCC(C(OCCN2CCCCC2)C2CCCCC2)CC1.
This classification denotes an antitussive agent C20H24ClNO.C20H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M105305SU, chemically known as benzoic acid, 2-((6-hydroxy(1,1'-biphenyl)-3-yl)carbonyl)-, compd. with 1-(2-((4-chlorophenyl)phenylmethoxy)ethyl)piperidine (1:1), but more generally known as cloperastine fendizoate, which bears US NIH Compound Identifier 163446. European Medicines Agency schedules Cloperastine fendizoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01366MIG. Most nations, for tariff and trade purposes, schedule cloperastine fendizoate under HS 29333999 and SITC 51574. As of Q4 2014, CLOPERASTINE FENDIZOATE remains US FDA's Preferred Term for this commodity. Cloperastine fendizoate bears US NLM identifiers UMLS ID C2987012 and NCI Concept Code C95234. SMILES: C1CCC(CC1)C2C(CCCC2O)C(=O)C3CCCCC3C(=O)O.C1CCC(CC1)C(C2CCC(CC2)CL)OCCN3CCCCC3.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8FP5Y6U39R. European Medicines Agency schedules Cloperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06738MIG. Cloperidone generally arises in the molecular formula C21H23CLN4O2. The term CLOPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) CLOPERIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloperidone under HS 29335995 and SITC 51576. As of Q4 2014, CLOPERIDONE remains the US FDA Preferred Term for this commodity. Cloperidone bears US NLM identifiers UMLS ID C2699375 and NCI Concept Code C79578. SMILES: CLC1CC(N2CCN(CC2)CCCN2C(=O)C3C([NH]C2=O)CCCC3)CCC1.
This classification denotes a sedative and hypnotic with the molecular formula C21H23ClN4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17682058OP, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-, monohydrochloride but more generally known as cloperidone hydrochloride, which bears US NIH Compound Identifier 10674. Most nations, for tariff and trade purposes, schedule cloperidone hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, CLOPERIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cloperidone hydrochloride bears US NLM identifiers UMLS ID C2825297 and NCI Concept Code C80665. SMILES: C1CCC2C(C1)C(=O)N(C(=O)[NH]2)CCCN3CCN(CC3)C4CCCC(C4)CL.CL.
This classification denotes a thienopyridine antiplatelet agent with the molecular formula C16H16ClNO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A74586SNO7, chemically known as thieno(3,2-c)pyridine-5(4h)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (s)- but generally known as clopidogrel, which bears US NIH Compound Identifier 60606. European Medicines Agency schedules Clopidogrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13395MIG. World Health Organization schedules clopidogrel in its Anatomical Therapeutic Chemical (ATC) Classification. CLOPIDOGREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clopidogrel under HS 29349990 and SITC 51579. As of Q4 2014, CLOPIDOGREL remains the US FDA Preferred Term for this commodity. Clopidogrel bears US NLM identifiers UMLS ID C0070166 and NCI Concept Code C61686. SMILES: CLC1C(C(N2CCC3SCCC3C2)C(=O)OC)CCCC1.
This classification denotes an antiprotozoal agent with the molecular formula C7H7Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8J763HFF5N, chemically known as 3,5-dichloro-4-hydroxy-2,6-dimethylpyridine but generally known as clopidol, which bears US NIH Compound Identifier 18087. European Medicines Agency schedules Clopidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06739MIG. The term CLOPIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). CLOPIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clopidol under HS 29333999 and SITC 51574. As of Q4 2014, CLOPIDOL remains the US FDA Preferred Term for this commodity. Clopidol bears US NLM identifiers UMLS ID C0009028 and NCI Concept Code C76417. SMILES: CLC1C([NH]C(C(CL)C1=O)C)C.
This classification denotes a dopamine antagonist with the molecular formula C28H28ClF2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C6TA32SD2, chemically known as 5-chloro-1-(4-(4,4-bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone but generally known as clopimozide, which bears US NIH Compound Identifier 65449. European Medicines Agency schedules Clopimozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06740MIG. The term CLOPIMOZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). CLOPIMOZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clopimozide under HS 29333999 and SITC 51574. As of Q4 2014, CLOPIMOZIDE remains the US FDA Preferred Term for this commodity. Clopimozide bears US NLM identifiers UMLS ID C0055934 and NCI Concept Code C77571. SMILES: CLC1CC2[NH]C(=O)N(C3CCN(CC3)CCCC(C3CCC(F)CC3)C3CCC(F)CC3)C2CC1.
This classification denotes an antipsychotic agent with the molecular formula C19H18ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6S9CMY4SE, chemically known as 4-(2-chloroxanthen-9-ylidene)-1-methylpiperidine but generally known as clopipazan, which bears US NIH Compound Identifier 43215. European Medicines Agency schedules Clopipazan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06741MIG. Most nations schedule clopipazan under HS 29349990 and SITC 51579. As of Q4 2014, CLOPIPAZAN remains the US FDA Preferred Term for this commodity. Clopipazan bears US NLM identifiers UMLS ID C2699376 and NCI Concept Code C79944. SMILES: CN1CCC(=C2C3=CC=CC=C3OC4=C2C=C(C=C4)Cl)CC1.
This classification denotes an antipsychotic agent with the molecular formula C19H18ClNO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4ZXX17M1C4, chemically known as piperidine 4-(2-chloro-9h-xanthen-9-ylidene)-1-methyl-, methanesulfonate, but more generally known as clopipazan mesylate, which bears US NIH Compound Identifier 43214. European Medicines Agency schedules clopipazan mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06741MIG. Most nations, for tariff purposes, schedule clopipazan mesylate under HS 29349990. Clopipazan mesylate bears US NLM identifiers UMLS ID C2825692 and NCI Concept Code C81581. SMILES: CN1CCC(=C2C3CCCCC3OC4C2CC(CC4)CL)CC1.CS(=O)(=O)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H25ClO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SYP56O3GJG, chemically known as 6-chloro-11beta,17alpha, 21-trihydroxypregn-1,4,6-triene-3,20-dione but generally known as cloprednol, which bears US NIH Compound Identifier 21320. European Medicines Agency schedules Cloprednol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06744MIG. The term CLOPREDNOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules cloprednol in its Anatomical Therapeutic Chemical (ATC) Classification. CLOPREDNOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloprednol under HS 29372200 and SITC 54153. As of Q4 2014, CLOPREDNOL remains the US FDA Preferred Term for this commodity. Cloprednol bears US NLM identifiers UMLS ID C0055936 and NCI Concept Code C80809. SMILES: CLC1=CC2C3C(C(O)(CC3)C(=O)CO)(CC(O)C2C2(C1=CC(=O)C=C2)C)C.
This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KI24A9FF7S. European Medicines Agency schedules Cloquinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06747MIG. Cloquinate generally arises in the molecular formula C18H26CLN3.2C9H6INO4S. The term CLOQUINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CLOQUINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloquinate under HS 29334990 and SITC 51575. As of Q4 2014, CLOQUINATE remains the US FDA Preferred Term for this commodity. Cloquinate bears US NLM identifiers UMLS ID C2825690 and NCI Concept Code C81577. SMILES: IC1CC(S(=O)(=O)O)C2C(NCCC2)C1O.IC1CC(S(=O)(=O)O)C2C(NCCC2)C1O.CLC1CC2NCCC(NC(CCCN(CC)CC)C)C2CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H19Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3U058H86V, chemically known as 2-propanol, 1-(2,5-dichlorophenoxy)-3-((1,1-dimethylethyl)amino)- but generally known as cloranolol, which bears US NIH Compound Identifier 65814. European Medicines Agency schedules Cloranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06752MIG. The term CLORANOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules cloranolol in its Anatomical Therapeutic Chemical (ATC) Classification. CLORANOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloranolol under HS 29221980 and SITC 51461. As of Q4 2014, CLORANOLOL remains the US FDA Preferred Term for this commodity. Cloranolol bears US NLM identifiers UMLS ID C0076772 and NCI Concept Code C81658. SMILES: CLC1C(OCC(O)CNC(C)(C)C)CC(CL)CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H19Cl2NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 79SQ2WFQ23, chemically known as (+/-)-dichlorophenoxy)-3-tert-butylamino-2-propanol hydrochloride, but more generally known as cloranolol hydrochloride, which bears US NIH Compound Identifier 162743. European Medicines Agency schedules cloranolol hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06752MIG. Most nations, for tariff purposes, schedule cloranolol hydrochloride under HS 29221980. SMILES: CC(C)(C)NCC(COC1CC(CCC1CL)CL)O.CL.
This classification denotes an anti-anxiety agent, anticonvulsant, and gaba modulator with the molecular formula C16H11ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D51WO0G0L4, chemically known as 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1h-1,4-benzodiazepine-3-carboxylic acid but generally known as clorazepate, which bears US NIH Compound Identifier 2809. Most nations schedule clorazepate under HS 29339100 and SITC 51577. SMILES: C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)CL)C(=O)O.
This classification denotes a benzodiazepine with the molecular formula C16H10ClN2O3.2K.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63FN7G03XY, chemically known as 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1h-1,4-benzodiazepine-3-carboxylic acid but more generally known as clorazepate dipotassium, which bears US NIH Compound Identifier 2809. European Medicines Agency schedules Clorazepate dipotassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13397MIG. The term DIPOTASSIUM CLORAZEPATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules clorazepate dipotassium in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule clorazepate dipotassium under HS 29339100 and SITC 51577. As of Q4 2014, CLORAZEPATE DIPOTASSIUM remains US FDA's Preferred Term for this commodity. Clorazepate dipotassium bears US NLM identifiers UMLS ID C0009033 and NCI Concept Code C47459. SMILES: C1CCC(CC1)C2=NC(C(=O)NC3C2CC(CC3)CL)C(=O)[O-].[OH-].[K+].[K+].
This classification denotes a benzodiazepine with the molecular structure C16H10CLN2O3.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, MS63G8NQUI chemically known as 1h-1,4-benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt, but more commonly known as clorazepate monopotassium, which bears US NIH Compound Identifier 22312. European Medicines Agency schedules Clorazepate monopotassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01369MIG. Most nations, for tariff and trade purposes, schedule clorazepate monopotassium under HS 29339100 and SITC 51577. As of Q4 2014, CLORAZEPATE MONOPOTASSIUM remains US FDA's Preferred Term for this commodity. Clorazepate monopotassium bears US NLM identifiers UMLS ID C0009034 and NCI Concept Code C76533. SMILES: C1CCC(CC1)C2=NC(C(=O)NC3C2CC(CC3)CL)C(=O)[O-].[K+].
This classification denotes a sedative and hypnotic with the molecular formula C5H4Cl6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9VY0HXB11T, chemically known as 2,2,2-trichloroethyl carbonate but generally known as cloretate, which bears US NIH Compound Identifier 21851. European Medicines Agency schedules Cloretate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06753MIG. The term CLORETATE is an International Non-Proprietary Name. CLORETATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cloretate or clorethate bears US NLM identifiers UMLS ID C0636116 and NCI Concept Code C80671. SMILES: C(C(CL)(CL)CL)OC(=O)OCC(CL)(CL)CL.
This classification denotes a diuretic with the molecular formula C14H17ClN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2PLT3FS05, chemically known as 6-chloro-2-cyclohexyl-2,3-dihydro-3-oxo-1h-isoindole-5-sulfonamide but generally known as clorexolone, which bears US NIH Compound Identifier 16473. European Medicines Agency schedules Clorexolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06754MIG. The term CLOREXOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules clorexolone in its Anatomical Therapeutic Chemical (ATC) Classification. CLOREXOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clorexolone under HS 29350090 and SITC 51580. As of Q4 2014, CLOREXOLONE remains the US FDA Preferred Term for this commodity. Clorexolone bears US NLM identifiers UMLS ID C0055938 and NCI Concept Code C81075. SMILES: CLC1CC2CN(C3CCCCC3)C(=O)C2CC1S(=O)(=O)N.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H15Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LYJ16FZU9Q, chemically known as 2-propynylamine, n-(3-(2,4-dichlorophenoxy)propyl)-n-methyl- but generally known as clorgiline, which bears US NIH Compound Identifier 4380. European Medicines Agency schedules Clorgiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06755MIG. The term CLORGILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). CLORGILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clorgiline under HS 29221980 and SITC 51461. As of Q4 2014, CLORGILINE remains the US FDA Preferred Term for this commodity. Clorgiline bears US NLM identifiers UMLS ID C0009035 and NCI Concept Code C77522. SMILES: Clc1c(OCCCN(CC#C)C)ccc(Cl)c1.
This classification denotes an antiplatelet agent with the molecular formula C20H26ClNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B9454PE93C, chemically known as acetic acid, ((8-chloro-3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)-, ethyl ester but generally known as cloricromen, which bears US NIH Compound Identifier 68876. European Medicines Agency schedules Cloricromen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06756MIG. The term CLORICROMEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules cloricromen in its Anatomical Therapeutic Chemical (ATC) Classification. CLORICROMEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CLORICROMEN remains the US FDA Preferred Term for this commodity. Cloricromen bears US NLM identifiers UMLS ID C0050066 and NCI Concept Code C78091. SMILES: CLC1C2OC(=O)C(CCN(CC)CC)C(C2CCC1OCC(=O)OCC)C.
This classification denotes an antiplatelet agent with the molecular formula C20H26CLNO5.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 931696CA9T. European Medicines Agency schedules cloricromen hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01371MIG. Most nations, for tariff and trade purposes, schedule cloricromen hydrochloride under HS 29322985. As of Q4 2014, CLORICROMEN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCC1C(C2CCC(C(C2OC1=O)CL)OCC(=O)OCC)C.CL.
This classification denotes an anticoagulant agent with the molecular formula C15H9ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 541C7WS64R, chemically known as 1,3-indandione, 2-(p-chlorophenyl)- but generally known as clorindione, which bears US NIH Compound Identifier 70846. European Medicines Agency schedules Clorindione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06760MIG. The term CLORINDIONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules clorindione in its Anatomical Therapeutic Chemical (ATC) Classification. CLORINDIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clorindione under HS 29147000 and SITC 51629. As of Q4 2014, CLORINDIONE remains the US FDA Preferred Term for this commodity. Clorindione bears US NLM identifiers UMLS ID C0055939 and NCI Concept Code C81463. SMILES: CLC1CCC(C2C(=O)C3C(C2=O)CCCC3)CC1.
This classification denotes an anxiolytic with the molecular formula C22H23CLFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 948IHI495K chemically known as 1-butanone, 4-(4-(4-chlorobenzoyl)-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as cloroperone, which bears US NIH Compound Identifier 41536. European Medicines Agency schedules Cloroperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06763MIG. The term CLOROPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 1, 2000, list 43. ). Most nations schedule cloroperone under HS 29333999 and SITC 51574. As of Q4 2014, CLOROPERONE remains the US FDA Preferred Term for this commodity. Cloroperone bears US NLM identifiers UMLS ID C0055941 and NCI Concept Code C79529. SMILES: C1CN(CCC1C(=O)C2=CC=C(C=C2)CL)CCCC(=O)C3=CC=C(C=C3)F.
This classification denotes an anxiolytic with the molecular formula C22H23ClFNO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95U4NV3X82, chemically known as 1-butanone, 4-(4-(4-chlorobenzoyl)-1-piperidinyl)-1-(4-fluorophenyl)-, hydrochloride but more generally known as cloroperone hydrochloride, which bears US NIH Compound Identifier 41535. Most nations, for tariff and trade purposes, schedule cloroperone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, CLOROPERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cloroperone hydrochloride bears US NLM identifiers UMLS ID C2347810 and NCI Concept Code C72728. SMILES: C1CC(CCC1C(=O)CCCN2CCC(CC2)C(=O)C3CCC(CC3)CL)F.CL.
This classification denotes a dopamine antagonist with the molecular formula C19H21ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E65W20MU7A, chemically known as 1-(8-chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)-4-methylpiperazine but generally known as clorotepine, which bears US NIH Compound Identifier 1238. European Medicines Agency schedules Clorotepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06765MIG. The term CLOROTEPINE is an International Non-Proprietary Name. CLOROTEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clorotepine under HS 29349990 and SITC 51579. As of Q4 2014, CLOROTEPINE remains the US FDA Preferred Term for this commodity. Clorotepine bears US NLM identifiers UMLS ID C0069353 and NCI Concept Code C77572. SMILES: CLC1CC2C(N3CCN(CC3)C)CC3C(SC2CC1)CCCC3.
This classification denotes the maleate form of a dopamine antagonist with the molecular formula C19H21ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E65W20MU7A, chemically known as 1-(8-chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)-4-methylpiperazine but more generally known as clorotepine, which bears US NIH Compound Identifier 1238. European Medicines Agency schedules Clorotepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06765MIG. The term CLOROTEPINE is an International Non-Proprietary Name. CLOROTEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule clorotepine maleate under HS 29349990 and SITC 51579. As of Q4 2014, CLOROTEPINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCN(CC1)C2CC3CCCCC3SC4C2CC(CC4)CL.C(=C\C(=O)O)\C(=O)O.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3W4327W76O. European Medicines Agency schedules Clorprenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06766MIG. Clorprenaline generally arises in the molecular formula C11H16CLNO. The term CLORPRENALINE is an International Non-Proprietary Name or INN. CLORPRENALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clorprenaline under HS 29221980 and SITC 51461. As of Q4 2014, CLORPRENALINE remains the US FDA Preferred Term for this commodity. Clorprenaline bears US NLM identifiers UMLS ID C0055943 and NCI Concept Code C83633. SMILES: CC(C)NCC(C1=CC=CC=C1CL)O.
This classification denotes an antihelminthic agent with the molecular formula C8H8Cl3N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EG1ZDO6LRD, chemically known as 1,3-benzenedisulfonamide, 4-amino-6-(trichloroethenyl)- but generally known as clorsulon, which bears US NIH Compound Identifier 43231. European Medicines Agency schedules Clorsulon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06767MIG. The term CLORSULON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). CLORSULON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clorsulon under HS 29350090 and SITC 51580. As of Q4 2014, CLORSULON remains the US FDA Preferred Term for this commodity. Clorsulon bears US NLM identifiers UMLS ID C0064474 and NCI Concept Code C75213. SMILES: CL/C(=C(\CL)CL)C1C(S(=O)(=O)N)CC(S(=O)(=O)N)C(N)C1.
This classification denotes a cns stimulant with the molecular formula C10H14ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4FA88HM3IX, chemically known as 2-chloro-alpha,alpha-dimethylbenzeneethanamine but more generally known as clortermine, which bears US NIH Compound Identifier 25223. European Medicines Agency schedules Clortermine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06768MIG. The term CLORTERMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). CLORTERMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule clortermine under HS 29214980 and SITC 51454. As of Q4 2014, CLORTERMINE remains US FDA's Preferred Term for this commodity. Clortermine bears US NLM identifiers UMLS ID C0771259 and NCI Concept Code C65344. SMILES: CC(C)(CC1=CC=CC=C1CL)N.
This classification denotes an antihelminthic agent with the molecular formula C22H14Cl2I2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EUL532EI54, chemically known as 5-chloro-alpha(sup 4)-(p-chlorophenyl)-alpha(sup 4)-cyano-3,5-diiodo-2,4-salicyloxylidide but generally known as closantel, which bears US NIH Compound Identifier 42574. European Medicines Agency schedules Closantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06769MIG. The term CLOSANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). CLOSANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule closantel under HS 29269095 and SITC 51484. As of Q4 2014, CLOSANTEL remains the US FDA Preferred Term for this commodity. Closantel bears US NLM identifiers UMLS ID C0055944 and NCI Concept Code C79920. SMILES: IC1C(O)C(C(=O)NC2C(CC(C(C3CCC(CL)CC3)C#N)C(CL)C2)C)CC(I)C1.
This classification denotes an antipsychotic agent with the molecular formula C22H24ClN3OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2V8248111, chemically known as 8-(3-(2-chloro-10-phenothiazinyl)propyl)-1-thia-4,8-diazaspiro(4,5)decan-3-one but generally known as clospirazine, which bears US NIH Compound Identifier 65714. European Medicines Agency schedules Spiclomazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10616MIG. The term SPICLOMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). Clospirazine or spiclomazine bears US NLM identifiers UMLS ID C1883076 and NCI Concept Code C66557. SMILES: C1CN(CCC12NC(=O)CS2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CL.
This classification denotes an anabolic steroid with the molecular formula C19H27ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z7D4G976SH, chemically known as testosterone, 4-chloro-, acetate but generally known as clostebol, which bears US NIH Compound Identifier 13327. European Medicines Agency schedules Clostebol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06771MIG. The term CLOSTEBOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). CLOSTEBOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clostebol under HS 29372900 and SITC 54153. As of Q4 2014, CLOSTEBOL remains the US FDA Preferred Term for this commodity. Clostebol bears US NLM identifiers UMLS ID C0172467 and NCI Concept Code C77306. SMILES: CLC1=C2C(C3C(C4C(CC3)(C(OC(=O)C)CC4)C)CC2)(CCC1=O)C.
This classification denotes an anabolic steroid C22H31ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JJ3052NOU, chemically known as androst-4-en-3-one, 4-chloro-17-(1-oxopropoxy)-, (17.beta.)-, but more generally known as clostebol propionate, which bears US NIH Compound Identifier 71586790. Most nations, for tariff and trade purposes, schedule clostebol propionate under HS 29372900 and SITC 54153. As of Q4 2014, CLOSTEBOL PROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C(C(=O)CC[C@]34C)CL)C.
The first vaccine used to protect against botulinum neurotoxin was a chemically detoxified extract from Clostridium botulinum. A Pentavalent botulinum toxoid (PBT) vaccine in service today is administered under an Investigational New Drug (IND) application held by the CDC.
This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C18H18ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z05HCY0X1T, chemically known as 2-chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)thiazepine but generally known as clothiapine, which bears US NIH Compound Identifier 16351. European Medicines Agency schedules Clotiapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06772MIG. The term CLOTIAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules clothiapine in its Anatomical Therapeutic Chemical (ATC) Classification. Clothiapine or clotiapine bears US NLM identifiers UMLS ID C0009071 and NCI Concept Code C80776. SMILES: CLC1CC2C(=NC3C(SC2CC1)CCCC3)N1CCN(CC1)C.
This classification denotes a sedative and hypnotic with the molecular formula C16H15ClN2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZCN055599V, chemically known as 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2h-thieno(2,3-e)-1,4-diazepin-2-one but generally known as clotiazepam, which bears US NIH Compound Identifier 2811. European Medicines Agency schedules Clotiazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06773MIG. The term CLOTIAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules clotiazepam in its Anatomical Therapeutic Chemical (ATC) Classification. CLOTIAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clotiazepam under HS 29349100 and SITC 51579. As of Q4 2014, CLOTIAZEPAM remains the US FDA Preferred Term for this commodity. Clotiazepam bears US NLM identifiers UMLS ID C0009073 and NCI Concept Code C80672. SMILES: CLC1C(C2=NCC(=O)N(C3SC(CC23)CC)C)CCCC1.
This classification denotes an antifungal agent with the molecular formula C22H17ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G07GZ97H65, chemically known as 1-(o-chloro-alpha,alpha-diphenylbenzyl)imidazole but generally known as clotrimazole, which bears US NIH Compound Identifier 2812. European Medicines Agency schedules Clotrimazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06777MIG. The term CLOTRIMAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules clotrimazole in its Anatomical Therapeutic Chemical (ATC) Classification. CLOTRIMAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clotrimazole under HS 29332990 and SITC 51573. As of Q4 2014, CLOTRIMAZOLE remains the US FDA Preferred Term for this commodity. Clotrimazole bears US NLM identifiers UMLS ID C0009074 and NCI Concept Code C381. SMILES: CLC1C(C(N2CCNC2)(C2CCCCC2)C2CCCCC2)CCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C19H18ClN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6X5QGC2VB, chemically known as 6-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as cloxacillin, which bears US NIH Compound Identifier 6098. European Medicines Agency schedules Cloxacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06780MIG. The term CLOXACILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules cloxacillin in its Anatomical Therapeutic Chemical (ATC) Classification. CLOXACILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloxacillin under HS 29411090 and SITC 54131. As of Q4 2014, CLOXACILLIN remains the US FDA Preferred Term for this commodity. Cloxacillin bears US NLM identifiers UMLS ID C0009077 and NCI Concept Code C61688. SMILES: CLC1C(C2NOC(C2C(=O)NC2C3SC(C(N3C2=O)C(=O)O)(C)C)C)CCCC1.
This classification denotes a penicillin antibiotic with the molecular formula 2C19H18ClN3O5S.C16H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AC79L7PV2G, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2.alpha.,5.alpha.,6.beta.))-, compd. with n,n'-bis(phenylmethyl)-1,2-ethanediamine (2:1), but more generally known as cloxacillin benzathine, which bears US NIH Compound Identifier 64706. European Medicines Agency schedules cloxacillin benzathine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06780MIG. Most nations, for tariff purposes, schedule cloxacillin benzathine under HS 29411090. Cloxacillin benzathine bears US NLM identifiers UMLS ID C0053154 and NCI Concept Code C76854. SMILES: CC1C(C(NO1)C2CCCCC2CL)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O.CC1C(C(NO1)C2CCCCC2CL)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O.C1CCC(CC1)CNCCNCC2CCCCC2.
This classification denotes a penicillin antibiotic with the molecular formula C19H17ClN3O5S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65LCB00B4Y, chemically known as 6-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but more generally known as cloxacillin sodium, which bears US NIH Compound Identifier 6098. European Medicines Agency schedules Cloxacillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13400MIG. Most nations, for tariff and trade purposes, schedule cloxacillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, CLOXACILLIN SODIUM remains US FDA's Preferred Term for this commodity. Cloxacillin sodium bears US NLM identifiers UMLS ID C0037496 and NCI Concept Code C47460. SMILES: CC1C(C(NO1)C2CCCCC2CL)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[NA+].
This classification denotes a penicillin antibiotic C19H17ClN3O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MWQ645MKMF, chemically known as cloxacillin sodium, anhydrous, but more generally known as cloxacillin sodium anhydrous, which bears US NIH Compound Identifier 23675320. Most nations, for tariff and trade purposes, schedule cloxacillin sodium anhydrous under HS 29411090 and SITC 54131. As of Q4 2014, CLOXACILLIN SODIUM ANHYDROUS remains US FDA's Preferred Term for this commodity. Cloxacillin sodium anhydrous bears US NLM identifiers UMLS ID C2699387 and NCI Concept Code C76222. SMILES: CC1C(C(NO1)C2CCCCC2CL)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[NA+].
This classification denotes an anxiolytic with the molecular formula C17H14Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GYL649Z0HY, chemically known as 10-chloro-2,3,5,6,7,11b-hexahydro-11b-(o-chlorophenyl)benzo(6,7)-1,4-diazepino-(5,4-b)-oxazol-6-one but generally known as cloxazolam, which bears US NIH Compound Identifier 2816. European Medicines Agency schedules Cloxazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06781MIG. The term CLOXAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules cloxazolam in its Anatomical Therapeutic Chemical (ATC) Classification. CLOXAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloxazolam under HS 29349100 and SITC 51579. As of Q4 2014, CLOXAZOLAM remains the US FDA Preferred Term for this commodity. Cloxazolam bears US NLM identifiers UMLS ID C0055964 and NCI Concept Code C79883. SMILES: CLC1C(C23OCCN2CC(=O)NC2C3CC(CL)CC2)CCCC1.
This classification denotes a therapeutic estrogen with the molecular formula C20H25Cl3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42R9MZG1DL, chemically known as 17 beta-(2,2,2-trichloro-1-hydroxyethoxy)estra-1,3,5(10)-trien-3-ol. but generally known as cloxestradiol, which bears US NIH Compound Identifier 194705. European Medicines Agency schedules Cloxestradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06782MIG. The term CLOXESTRADIOL is an International Non-Proprietary Name. CLOXESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloxestradiol under HS 29372300 and SITC 54153. As of Q4 2014, CLOXESTRADIOL remains the US FDA Preferred Term for this commodity. Cloxestradiol bears US NLM identifiers UMLS ID C2699388 and NCI Concept Code C79721. SMILES: ClC(Cl)(Cl)C(OC1C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C)O.
This classification denotes an anti-infective agent with the molecular formula C9H6ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BPF36H1G6S, chemically known as 8-quinolinol, 5-chloro- but generally known as cloxiquine, which bears US NIH Compound Identifier 2817. European Medicines Agency schedules Cloxiquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06784MIG. The term CLOXIQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). CLOXIQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cloxiqine or cloxyquin bears US NLM identifiers UMLS ID C0772059 and NCI Concept Code C61689. SMILES: C1=CC2=C(C=CC(=C2N=C1)O)CL.
This classification denotes an anabolic steroid with the molecular formula C21H29Cl3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8422DH508N, chemically known as 17 beta-(2,2,2-tirchloro-1-hydroxyethoxy)androst-4-en-3-one. but generally known as cloxotestosterone, which bears US NIH Compound Identifier 194706. European Medicines Agency schedules Cloxotestosterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06785MIG. The term CLOXOTESTOSTERONE is an International Non-Proprietary Name. CLOXOTESTOSTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloxotestosterone under HS 29372900 and SITC 54153. As of Q4 2014, CLOXOTESTOSTERONE remains the US FDA Preferred Term for this commodity. Cloxotestosterone bears US NLM identifiers UMLS ID C2699389 and NCI Concept Code C79526. SMILES: CLC(CL)(CL)C(OC1C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)O.
This classification denotes an antipsychotic agent with the molecular formula C20H25ClN4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8BK5DLR67A, chemically known as 4-(3-(3-chloro-10h-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)-1-piperazine ethanol but generally known as cloxypendyl, which bears US NIH Compound Identifier 65615. European Medicines Agency schedules Cloxypendyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06786MIG. The term CLOXYPENDYL is an International Non-Proprietary Name. CLOXYPENDYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cloxypendyl under HS 29349990 and SITC 51579. As of Q4 2014, CLOXYPENDYL remains the US FDA Preferred Term for this commodity. Cloxypendyl bears US NLM identifiers UMLS ID C2699390 and NCI Concept Code C78102. SMILES: CLC1CC2SC3C(N(CCCN4CCN(CC4)CCO)C2NC1)CCCC3.
This classification denotes an antipsychotic agent with the molecular formula C20H25ClN4OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JL21P191Z6, chemically known as 1-piperazineethanol, 4-(3-(3-chloro-10h-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)-, dihydrochloride, but more generally known as cloxypendyl dihydrochloride, which bears US NIH Compound Identifier 209399. European Medicines Agency schedules cloxypendyl dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06786MIG. Most nations, for tariff purposes, schedule cloxypendyl dihydrochloride under HS 29349990. SMILES: C1CCC2C(C1)N(C3C(CC(CN3)CL)S2)CCCN4CCN(CC4)CCO.CL.CL.
This classification denotes a 5-ht3 receptor antagonist and antipsychotic agent with the molecular formula C18H19ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J60AR2IKIC, chemically known as 8-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(b,e)(1,4)diazepine but generally known as clozapine, which bears US NIH Compound Identifier 2818. European Medicines Agency schedules Clozapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06787MIG. The term CLOZAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules clozapine in its Anatomical Therapeutic Chemical (ATC) Classification. CLOZAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clozapine under HS 29335995 and SITC 51576. As of Q4 2014, CLOZAPINE remains the US FDA Preferred Term for this commodity. Clozapine bears US NLM identifiers UMLS ID C0009079 and NCI Concept Code C28936. SMILES: CLC1CC2NC(=C3C(=NC2CC1)CCCC3)N1CCN(CC1)C.
This classification denotes an antifibrinolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 382L14738L. European Medicines Agency schedules Coagulation factor ix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12030MIG. Coagulation factor ix bears US NLM identifiers UMLS ID C0015491 and NCI Concept Code C28482.
This classification denotes an antifibrinolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4156XVB4QD. European Medicines Agency schedules Coagulation factor viii in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB32741 and SUB13811MIG. Coagulation factor vii bears US NLM identifiers UMLS ID C0015502 and NCI Concept Code C16570.
This classification denotes an antifibrinolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T6B772R4Q. European Medicines Agency schedules Coagulation factor viii in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13813MIG. Coagulation factor viii bears US NLM identifiers UMLS ID C0015506 and NCI Concept Code C16571.
Coagulation factor VIII/Von Willebrand Factor Human is a multimeric glycoproteins used to treat or prevent bleeding episodes in people with Hemophilia A and Von Willebrand Disease.
This classification denotes an antifibrinolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGH8MYC891. European Medicines Agency schedules Coagulation factor xiv in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12567MIG.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE820. This VA Drug Class (DE820) classifies this compound as belonging to the group ANTIPSORIATICS, TOPICAL.
This classification denotes a cns stimulant with the molecular formula C17H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I5Y540LHVR, chemically known as 8-azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1r-(exo,exo))- but generally known as cocaine, which bears US NIH Compound Identifier 5760. European Medicines Agency schedules Cocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13416MIG. World Health Organization schedules cocaine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cocaine under HS 29399110 and SITC 54149. As of Q4 2014, COCAINE remains the US FDA Preferred Term for this commodity. Cocaine bears US NLM identifiers UMLS ID C0009170 and NCI Concept Code C80153. SMILES: CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC.
This classification denotes a cns stimulant with the molecular formula C17H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XH8T8T6WZH, chemically known as 1.alpha.h,5.alpha.h-tropane-2.beta.-carboxylic acid, 3.beta.-hydroxy-, methyl ester, benzoate (ester), hydrochloride but more generally known as cocaine hydrochloride, which bears US NIH Compound Identifier 2826. European Medicines Agency schedules Cocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13417MIG. Most nations, for tariff and trade purposes, schedule cocaine hydrochloride under HS 29399110 and SITC 54149. As of Q4 2014, COCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cocaine hydrochloride bears US NLM identifiers UMLS ID C0282108 and NCI Concept Code C81016. SMILES: CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3CCCCC3)C(=O)OC.CL.
This classification denotes a cns stimulant with the molecular formula C18H24NO4.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83FKO5XD6J, chemically known as (-)-cocaine methiodide, but more generally known as cocaine methiodide, which bears US NIH Compound Identifier 83828. European Medicines Agency schedules cocaine methiodide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13416MIG. Most nations, for tariff purposes, schedule cocaine methiodide under HS 29399110. SMILES: C[N+]1([C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3CCCCC3)C(=O)OC)C.[I-].
This classification denotes a cns stimulant with the molecular formula C17H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XH8T8T6WZH, chemically known as methyl (1r,2r,3s,5s)-3- (benzoyloxy)-8-methyl-8-azabicyclo(3.2.1) octane-2-carboxylate, hydrochloride, but more generally known as cocaine muriate, which bears US NIH Compound Identifier 2826. European Medicines Agency schedules cocaine muriate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13416MIG. Most nations, for tariff purposes, schedule cocaine muriate under HS 29399110. SMILES: CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3CCCCC3)C(=O)OC.CL.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers LZB7TFX1LT and TZ8Z31B35M, and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 200985 as a member of Kingdom Animalia, Phylum Arthropoda, Subphylum Hexapoda, Class Insecta, Subclass Pterygota, Infraclass Neoptera, Order Hemiptera, Suborder Sternorrhyncha, Superfamily Coccoidea, Family Dactylopiidae (cochineal insects), Genus Dactylopius, more commonly known as COCHINEAL or as here, COCCUS CACTI. European Medicines Agency schedules coccus cacti in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB34748, SUB51162, and SUB55045. SMILES: O1C(C(O)C(O)C(O)C1CO)C1C(O)C2C(C(O)C1O)C(=O)C1C(C2=O)C(C(C(O)C1)C(=O)O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes an opiate with the molecular formula C18H21NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HOK0TIN61, chemically known as morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-, hydrobromide but more generally known as codeine hydrobromide, which bears US NIH Compound Identifier 5464192. European Medicines Agency schedules Codeine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13426MIG. Most nations, for tariff and trade purposes, schedule codeine hydrobromide under HS 29391100. As of Q4 2014, CODEINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.BR.
This classification denotes an opiate with the molecular formula C18H21NO3.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NTZ53GG7XN, chemically known as morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-, hydrochloride but more generally known as codeine hydrochloride, which bears US NIH Compound Identifier 5359615. European Medicines Agency schedules Codeine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01405MIG. Most nations, for tariff and trade purposes, schedule codeine hydrochloride under HS 29391100. As of Q4 2014, CODEINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.O.O.CL.
This classification denotes an opiate with the molecular formula C18H21NO3.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NTZ53GG7XN, chemically known as morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-, hydrochloride but more generally known as codeine hydrochloride, which bears US NIH Compound Identifier 5359615. European Medicines Agency schedules Codeine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01405MIG. Most nations, for tariff and trade purposes, schedule codeine hydrochloride dihydrate under HS 29391100. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.O.O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes an opiate with the molecular formula 2C18H21NO3.H2O.2H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GSL05Y1MN6, chemically known as 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol phosphate (1:1) (salt) hemihydrate but more generally known as codeine phosphate, which bears US NIH Compound Identifier 5359227. European Medicines Agency schedules Codeine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13427MIG. Most nations, for tariff and trade purposes, schedule codeine phosphate hemihydrate under HS 29391100. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.O.OP(=O)(O)O.OP(=O)(O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes an opiate with the molecular formula 2C18H21NO3.3H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11QV9BS0CB, chemically known as morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-, sulfate (2:1) (salt) but more generally known as codeine sulfate, which bears US NIH Compound Identifier 5359613. European Medicines Agency schedules Codeine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01410MIG. Most nations, for tariff and trade purposes, schedule codeine sulfate under HS 29391100. As of Q4 2014, CODEINE SULFATE remains US FDA's Preferred Term for this commodity. Codeine sulfate bears US NLM identifiers UMLS ID C0304352 and NCI Concept Code C53137. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.O.O.O.OS(=O)(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a vasodilating agent with the molecular formula C20H29N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X3S33EX3KW, chemically known as (6aR,9R,10aR)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9,10, 10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid, but generally known as ergoloid mesylates, which bears US NIH Compound Identifier 49800049. SMILES: CC(CO)NC(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)C.CS(=O)(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a colchicine-site binding agent with the molecular formula C22H25NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SML2Y3J35T, chemically known as colchicine, (+)- but generally known as colchicine, which bears US NIH Compound Identifier 2833. European Medicines Agency schedules Colchicine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01420MIG. World Health Organization schedules colchicine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule colchicine under HS 29399990 and SITC 54149. As of Q4 2014, COLCHICINE remains the US FDA Preferred Term for this commodity. Colchicine bears US NLM identifiers UMLS ID C0009262 and NCI Concept Code C385. SMILES: O(C1C2C(CCC(NC(=O)C)C3C2CCC(OC)C(=O)C3)CC(OC)C1OC)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class MS400. This VA Drug Class (MS400) classifies this compound as belonging to the group ANTIGOUT AGENTS.
This classification denotes an anti-lipidemic agent with the molecular formula (C13H27N)n.(C12H27ClN2)n.(C9H18N2O)n.(C3H7N)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XU104G55N, chemically known as 1-hexaminium, n,n,n-trimethyl-6-(2-propenylamino)-, chloride, polymer with (chloromethyl)oxirane, 2-propen-4-amine and n-2-propenyl-1-decanamine, hydrochloride but generally known as colesevelam, which bears US NIH Compound Identifier 160051. European Medicines Agency schedules Colesevelam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01423MIG. The term COLESEVELAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). World Health Organization schedules colesevelam in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule colesevelam under HS 39119099 and SITC 57596. As of Q4 2014, COLESEVELAM remains the US FDA Preferred Term for this commodity. Colesevelam bears US NLM identifiers UMLS ID C0541155 and NCI Concept Code C78056. SMILES: CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-].
This classification denotes an anti-lipidemic agent with the molecular formula (C13H27N)n.(C12H27ClN2)n.(C9H18N2O)n.(C3H7N)n.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P4SG24WI5Q, chemically known as 1-hexaminium, n,n,n-trimethyl-6-(2-propenylamino)-, chloride, polymer with (chloromethyl)oxirane, 2-propen-4-amine and n-2-propenyl-1-decanamine, hydrochloride but more generally known as colesevelam hydrochloride, which bears US NIH Compound Identifier 160051. European Medicines Agency schedules Colesevelam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01424MIG. Most nations, for tariff and trade purposes, schedule colesevelam hydrochloride under HS 39119099 and SITC 57596. Colesevelam hydrochloride bears US NLM identifiers UMLS ID C0541154 and NCI Concept Code C28937. SMILES: As of Q4 2014, COLESEVELAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.
This classification denotes an anti-lipidemic agent with the molecular formula ((C3H5ClO)mon(C4H13N3)mon)co, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K50N755924, chemically known as 1,2-ethanediamine, n-(2-aminoethyl)-n-(2-((2-aminoethyl)amino)ethyl)-, polymer with (chloromethyl)oxirane but generally known as colestipol, which bears US NIH Compound Identifier 62816. European Medicines Agency schedules Colestipol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01425MIG. The term COLESTIPOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules colestipol in its Anatomical Therapeutic Chemical (ATC) Classification. COLESTIPOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule colestipol under HS 39140000 and SITC 57597. As of Q4 2014, COLESTIPOL remains the US FDA Preferred Term for this commodity. Colestipol bears US NLM identifiers UMLS ID C0009279 and NCI Concept Code C81540. SMILES: C1C(O1)CCl.C(CNCCNCCNCCN)N.
This classification denotes an anti-lipidemic agent with the molecular formula ((C3H5ClO)mon(C4H13N3)mon)co.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7D10K905G, chemically known as copolymer of diethylenetriamine and 1-chloro-2,3-epoxypropane, hydrochloride (with approximately 1 out of 5 amine nitrogens protonated) but more generally known as colestipol hydrochloride, which bears US NIH Compound Identifier 3084661. European Medicines Agency schedules Colestipol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13441MIG. Most nations, for tariff and trade purposes, schedule colestipol hydrochloride under HS 39140000 and SITC 57597. Colestipol hydrochloride bears US NLM identifiers UMLS ID C0354648 and NCI Concept Code C28938. SMILES: As of Q4 2014, COLESTIPOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.
This classification denotes an anti-lipidemic agent with the molecular formula C27H44O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5P8396T5XF, chemically known as cl 274,471 but generally known as colestolone, which bears US NIH Compound Identifier 39756. European Medicines Agency schedules Colestolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06796MIG. The term COLESTOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). COLESTOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule colestolone under HS 29144090 and SITC 51629. As of Q4 2014, COLESTOLONE remains the US FDA Preferred Term for this commodity. Colestolone bears US NLM identifiers UMLS ID C2825672 and NCI Concept Code C81532. SMILES: OC1CC2C(C3C(=C4C(C(CC4=O)C(CCCC(C)C)C)(CC3)C)CC2)(CC1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13F3N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier N0V0Q7845W, chemically known as n-(alpha, alpha, alpha-trifluoro-m-tolyl)anthranilic acid, ester with glycolamide. but more generally known as colfenamate, which bears U.S. National Institutes of Health Compound Identifier 198806. The European Medicines Agency schedules Colfenamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06797MIG. The term COLFENAMATE is an International Non-Proprietary Name. COLFENAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: FC(F)(F)C1CC(NC2C(CCCC2)C(=O)OCC(=O)N)CCC1.
This classification denotes an agent affecting respiratory system with the molecular formula C40H80NO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 319X2NFW0A, chemically known as 3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxohexadecyl)oxy)-, inner salt, 4-oxide but generally known as colfosceril palmitate, which bears US NIH Compound Identifier 6138. European Medicines Agency schedules Colfosceril palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06799MIG. The term COLFOSCERIL PALMITATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules colfosceril palmitate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC.
This classification denotes an antimicrobial solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XW0E5YS77G. European Medicines Agency schedules Colistimethate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06801MIG. Colistimethate sodium generally arises in the molecular formula C57H103N16NA5O28S5. The term COLISTIMETHATE SODIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) As of Q4 2014, COLISTIMETHATE remains the US FDA Preferred Term for this commodity. Colistimethate bears US NLM identifiers UMLS ID C0009315 and NCI Concept Code C72729. SMILES: CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.
This classification denotes an antimicrobial solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XW0E5YS77G. European Medicines Agency schedules Colistimethate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06801MIG. Colistimethate sodium generally arises in the molecular formula C57H103N16NA5O28S5. The term COLISTIMETHATE SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, no. 6, 1984, list 24.) Most nations, for tariff and trade purposes, schedule colistimethate sodium under HS 29419000 and SITC 54139. Colistimethate sodium bears US NLM identifiers UMLS ID C0110462 and NCI Concept Code C65349. SMILES: As of Q4 2014, COLISTIMETHATE SODIUM remains US FDA's Preferred Term for this commodity.
This classification denotes a polymyxin antibiotic with the molecular formula C52H98N16O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z67X93HJG1, more generally known as colistin. European Medicines Agency schedules colistin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01429MIG. The term COLISTIN is an International Non-Proprietary Name or INN. COLISTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule colistin under HS 29419000 and SITC 54139. As of Q4 2014, COLISTIN remains the US FDA Preferred Term for this commodity. Colistin bears US NLM identifiers UMLS ID C0009316 and NCI Concept Code C65350. SMILES: CCC(C)CCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)C(C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.
This classification denotes a polymyxin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WP15DXU577. European Medicines Agency schedules Colistin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01431MIG. Colistin sulfate generally arises in the molecular formula C52H102N16O21S2. The term 'colistin sulfate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule colistin sulfate under HS 29419000 and SITC 54139. Colistin sulfate bears US NLM identifiers UMLS ID C0009317 and NCI Concept Code C386. SMILES: As of Q4 2014, COLISTIN SULFATE remains US FDA's Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
Collagen-polyvinylpyrrolidone (C-PVP) is a copolymer that is generated from the ? irradiation of a mixture of type I collagen and low-molecular-weight PVP
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a cytoprotective agent and anti-ulcer agent with the molecular formula 2C6H5O7.Bi.3K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HS813P8QPX, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, bismuth(3+) potassium salt (2:1:3) but generally known as bismuth subcitrate, which bears US NIH Compound Identifier 6335486. European Medicines Agency schedules Bismuth subcitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13089MIG. World Health Organization schedules bismuth subcitrate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3].
This classification denotes a beta-adrenergic agonist with the molecular formula C12H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1WH11068UO chemically known as 1,2-benzenediol, 4-(2-)((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (+/-)- but generally known as colterol, which bears US NIH Compound Identifier 25104. European Medicines Agency schedules Colterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06802MIG. The term COLTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17). Most nations schedule colterol under HS 29225000 and SITC 51467. As of Q4 2014, COLTEROL remains the US FDA Preferred Term for this commodity. Colterol bears US NLM identifiers UMLS ID C0056142 and NCI Concept Code C76018. SMILES: CC(C)(C)NCC(C1=CC(=C(C=C1)O)O)O.
This classification denotes a nootropic with the molecular formula C19H23N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6FL6O5GR7, chemically known as n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide but generally known as coluracetam, which bears US NIH Compound Identifier 214346. Most nations schedule coluracetam under HS 29349990 and SITC 51579. As of Q4 2014, COLURACETAM remains the US FDA Preferred Term for this commodity. Coluracetam bears US NLM identifiers UMLS ID C2699411 and NCI Concept Code C77391. SMILES: CC1=C(OC2=NC3=C(CCCC3)C(=C12)NC(=O)CN4CCCC4=O)C.
This classification denotes a combination drug that treats migraines. The first component of this drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but generally known as acetaminophen (or paracetamol), which bears US NIH Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: OC1CCC(NC(=O)C)CC1. The second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula C9H8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R16CO5Y76E, chemically known as salicylic acid, acetyl- but generally known as acetylsalicylic acid, which bears US NIH Compound Identifier 2244. European Medicines Agency schedules Acetylsalicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12730MIG. World Health Organization schedules acetylsalicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O(C1C(CCCC1)C(=O)O)C(=O)C.
This classification denotes a combination drug that treats migraines. The first component of this drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but generally known as acetaminophen (or paracetamol), which bears US NIH Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: OC1CCC(NC(=O)C)CC1. The second component of this combination drug is a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KHS0AZ4JVK, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but generally known as butalbital, which bears US NIH Compound Identifier 2481. Butalbital most often comes in base and sodium forms. European Medicines Agency schedules Butalbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05999MIG. The term BUTALBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). BUTALBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C.
This classification denotes a combination drug and antiemetic preparation. The first component of this combination drug is a hexose, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6YSS42VSEV. European Medicines Agency schedules Fructose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13925MIG. Fructose generally arises in the molecular formula C6H12O6. The term 'fructose' is an FDA designation. SMILES: C(C1C(C(C(O1)(CO)O)O)O)O. The second component of this combination drug is a hexose with the molecular formula C6H12O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5SL0G7R0OK, chemically known as sugar, grape but generally known as anhydrous dextrose, which bears US NIH Compound Identifier 5793. European Medicines Agency schedules Glucose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13981MIG. World Health Organization schedules anhydrous dextrose in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O1C(C(O)C(O)C(O)C1O)CO. The third component of this combination drug is an acid with the molecular formula H3O4P, chemically known as phosphoric acid, and which bears US NIH Compound Identifier 1004. European Medicines Agency schedules Phosphoric Acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB12212MIG, SUB12213MIG, SUB14854MIG, SUB22394, SUB22400, SUB29997, SUB35788, SUB36455, SUB37010, and SUB42701.
This classification denotes a combination cough and cold and antiallergy drug. The first component of this drug is a histamine-1 receptor antagonist with the molecular formula C16H19ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U, chemically known as 3-(p-chlorophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but generally known as chlorphenamine, which bears US NIH Compound Identifier 2725. European Medicines Agency schedules Chlorphenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06201MIG. The term CHLORPHENAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chlorphenamine in its Anatomical Therapeutic Chemical (ATC) Classification. CHLORPHENAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1CCC(C(CCN(C)C)C2NCCCC2)CC1. The second component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but generally known as acetaminophen (or paracetamol), which bears US NIH Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: OC1CCC(NC(=O)C)CC1.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers JC71GJ1F3L and H74221J5J4, the source product of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 500750 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Sapindales, Family Burseraceae, Genus Commiphora Jacq. (myrrh), commonly known as MYRRH. Myrrh bears the USDA PLANTS Database Identifier COMMI2. European Medicines Agency schedules Myrrh in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB14619MIG (simple) and SUB14620MIG (tincture).
This classification denotes a vasopressin antagonist with the molecular formula C32H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NJ98Y462X, chemically known as (1,1-biphenyl)-2-carboxamide, n-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)- but generally known as conivaptan, which bears US NIH Compound Identifier 151171. European Medicines Agency schedules Conivaptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32706. The term CONIVAPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). World Health Organization schedules conivaptan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule conivaptan under HS 29339930 and SITC 51577. As of Q4 2014, CONIVAPTAN remains the US FDA Preferred Term for this commodity. Conivaptan bears US NLM identifiers UMLS ID C0966107 and NCI Concept Code C74428. SMILES: O=C(N1CCC2[NH]C(NC2C2C1CCCC2)C)C1CCC(NC(=O)C2C(C3CCCCC3)CCCC2)CC1.
This classification denotes a vasopressin antagonist with the molecular formula C32H26N4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75L57R6X36, chemically known as (1,1-biphenyl)-2-carboxamide, n-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)- but more generally known as conivaptan hydrochloride, which bears US NIH Compound Identifier 151171. Most nations, for tariff and trade purposes, schedule conivaptan hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, CONIVAPTAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Conivaptan hydrochloride bears US NLM identifiers UMLS ID C1700196 and NCI Concept Code C65351. SMILES: CC1[NH]C-2C(N1)CCN(C3C2CCCC3)C(=O)C4CCC(CC4)NC(=O)C5CCCCC5C6CCCCC6.CL.
Conjugated estrogens/medroxyprogesterone acetate (CEs/MPA) is a combination product of conjugated estrogens (Premarin), an estrogen, and medroxyprogesterone acetate (Provera), a progestogen, which is used in menopausal hormone therapy for the treatment of menopausal symptoms.
This classification denotes preparations containing substances with antigenic properties administered to activate veterinary or non-human immune systems, thereby inducing immune responses, preparations called vaccines, of which the current commodities address or prevent infectious Contagious bovine pleuropneumonia, a respiratory affliction caused by Mycoplasma mycoides mycoides bacterium of cattle and closely-related livestock, including buffalo, yaks, and zebu, thus the term CONTAGIOUS BOVINE PLEUROPNEUMONIA OR CBPP VACCINES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE751. This VA Drug Class (DE751) classifies this compound as belonging to the group ANTIACNE AGENTS, SYSTEMIC.
This classification denotes a veterinary antihelminthic agent with the molecular formula C22H14CuO4, chemically known as copper;naphthalene-2-carboxylate but generally known as copper napthanate or copper naphthenate, which bears US NIH Compound Identifier 15607801 and EPA Pesticide Codes 023102 and 823102. SMILES: C1=CC=C2C=C(C=CC2=C1)C(=O)[O-].C1=CC=C2C=C(C=CC2=C1)C(=O)[O-].[Cu+2].
This classification denotes an emetic and antidote with the molecular formula Cu.O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KUW2Q3U1VV, chemically known as vanadium sulfate, vso4 but generally known as copper sulfate, which bears US NIH Compound Identifier 1118. European Medicines Agency schedules Copper sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13460MIG. World Health Organization schedules copper sulfate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: [O-]S(=O)(=O)[O-].[CU+2].
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1OV56052IK (though, if in oil form, 7626GC95E5), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29621 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Apiaceae, Genus Coriandrum L. (coriander), and Species Coriandrum sativum, commonly known as CHINESE PARSLEY or as here, CORIANDER. Coriander bears the USDA PLANTS Database Identifiers CORIA and COSA. European Medicines Agency schedules Myrrh in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB11848MIG (simple) and SUB49243 (oil). The United Nations Common Coding System codifies the source product under UNCCS 016263. As of Q4 2014, CORIANDER remains the US FDA Preferred Term for this commodity.
This classification denotes a crh gene with the molecular formula C208H344N60O63S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 305OE8862Y, chemically known as l-alaninamide, l-seryl-l-glutaminyl-l-alpha-glutamyl-l-prolyl-l-prolyl-l-isoleucyl-l-seryl-l-leucyl-l-alpha-aspartyl-l-leucyl-l-threonyl-l-phenylalanyl-l-histidyl-l-leucyl-l-leucyl-l-arginyl-l-alpha-glutamyl-l-valyl-l-leucyl-l-alpha-glutamyl-l-methionyl-l-thronyl-l-lysyl-l-alanyl-l-alpha-aspartyl-l-glutaminyl-l-leucyl-l-alanyl-l-glutaminyl-l-glutaminyl-l-alanyl-l-histidyl-l-seryl-l-asparaginyl-l-arginyl-l-lysyl-l-leucyl-l-leucyl-l-alpha-aspartyl-l-isoleucyl- but generally known as corticorelin, which bears US NIH Compound Identifier 16132344. European Medicines Agency schedules Corticorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27540. The term CORTICORELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules corticorelin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CORTICORELIN remains the US FDA Preferred Term for this commodity. SMILES: S(CCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1N(CCC1)C(=O)C1N(CCC1)C(=O)C(NC(=O)C(NC(=O)C(N)CO)CCC(=O)N)CCC(=O)O)C(CC)C)CO)CC(C)C)CC(=O)O)CC(C)C)C(O)C)CC1CCCCC1)CC1[NH.
This classification denotes a crh gene with the molecular formula C208H344N60O63S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 305OE8862Y, chemically known as l-alaninamide, l-seryl-l-glutaminyl-l-alpha-glutamyl-l-prolyl-l-prolyl-l-isoleucyl-l-seryl-l-leucyl-l-alpha-aspartyl-l-leucyl-l-threonyl-l-phenylalanyl-l-histidyl-l-leucyl-l-leucyl-l-arginyl-l-alpha-glutamyl-l-valyl-l-leucyl-l-alpha-glutamyl-l-methionyl-l-thronyl-l-lysyl-l-alanyl-l-alpha-aspartyl-l-glutaminyl-l-leucyl-l-alanyl-l-glutaminyl-l-glutaminyl-l-alanyl-l-histidyl-l-seryl-l-asparaginyl-l-arginyl-l-lysyl-l-leucyl-l-leucyl-l-alpha-aspartyl-l-isoleucyl- but generally known as corticorelin, which bears US NIH Compound Identifier 16132344. European Medicines Agency schedules Corticorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27540. The term CORTICORELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules corticorelin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CORTICORELIN OVINE TRIFLUTATE remains the US FDA Preferred Term for this commodity. Corticorelin ovine triflutate bears US NLM identifiers UMLS ID C0251515 and NCI Concept Code C47463. SMILES: S(CCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1N(CCC1)C(=O)C1N(CCC1)C(=O)C(NC(=O)C(NC(=O)C(N)CO)CCC(=O)N)CCC(=O)O)C(CC)C)CO)CC(C)C)CC(=O)O)CC(C)C)C(O)C)CC1CCCCC1)CC1[NH.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS701. This VA Drug Class (HS701) classifies this compound as belonging to the group ANTERIOR PITUITARY.
This classification denotes a glucocorticoid with the molecular formula C21H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V27W9254FZ, chemically known as 17,21-dihydroxypregn-4-ene-3,11,20-trione but generally known as cortisone, which bears US NIH Compound Identifier 222786. European Medicines Agency schedules Cortisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06807MIG. The term CORTISONE is an International Non-Proprietary Name. World Health Organization schedules cortisone in its Anatomical Therapeutic Chemical (ATC) Classification. CORTISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cortisone under HS 29372100 and SITC 54153. As of Q4 2014, CORTISONE remains the US FDA Preferred Term for this commodity. Cortisone bears US NLM identifiers UMLS ID C0010137 and NCI Concept Code C2291. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)C(=O)C2)CC1)C)C(=O)CO.
This classification denotes a therapeutic glucocorticoid with the molecular formula C23H30O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 883WKN7W8X, chemically known as 4-pregnene-3,11,20-trione, 17alpha,21-dihydroxy-, 21-acetate but more generally known as cortisone acetate, which bears US NIH Compound Identifier 2863. European Medicines Agency schedules Cortisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01467MIG. Most nations, for tariff and trade purposes, schedule cortisone acetate under HS 29372100 and SITC 54153. As of Q4 2014, CORTISONE ACETATE remains US FDA's Preferred Term for this commodity. Cortisone acetate bears US NLM identifiers UMLS ID C0056391 and NCI Concept Code C1058. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C23H30O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 883WKN7W8X, chemically known as 4-pregnene-3,11,20-trione, 17alpha,21-dihydroxy-, 21-acetate but more generally known as cortisone acetate, which bears US NIH Compound Identifier 2863. European Medicines Agency schedules Cortisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01467MIG. Most nations, for tariff and trade purposes, schedule cortisone aceticum under HS 29372100. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C37H40N2O8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1PA76KJ99Y, chemically known as 11 beta,17,21-trihydroxy-6,16 alpha-dimethyl-2-phenyl-2h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one 21-(m-sulfobenzoate). but generally known as cortisuzol, which bears US NIH Compound Identifier 3037936. European Medicines Agency schedules Cortisuzol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06808MIG. The term CORTISUZOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). CORTISUZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cortisuzol under HS 29372900 and SITC 54153. As of Q4 2014, CORTISUZOL remains the US FDA Preferred Term for this commodity. Cortisuzol bears US NLM identifiers UMLS ID C2699457 and NCI Concept Code C77411. SMILES: S(=O)(=O)(O)C1CC(C(=O)OCC(=O)C2(O)C3(C(C4C(C(O)C3)C3(C(=CC5N(NCC5C3)C3CCCCC3)C(=C4)C)C)CC2C)C)CCC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C32H38N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YM183K0H63, chemically known as 11beta,17alpha,21-trihydroxy-6,16alpha-dimethyl-2-phenylpregna-2,4,6-trieno(3,2-c)pyrazol-20-one 21-acetate but generally known as cortivazol, which bears US NIH Compound Identifier 66249. European Medicines Agency schedules Cortivazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06809MIG. The term CORTIVAZOL is an International Non-Proprietary Name. World Health Organization schedules cortivazol in its Anatomical Therapeutic Chemical (ATC) Classification. CORTIVAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cortivazol under HS 29372900 and SITC 54153. As of Q4 2014, CORTIVAZOL remains the US FDA Preferred Term for this commodity. Cortivazol bears US NLM identifiers UMLS ID C0056396 and NCI Concept Code C80812. SMILES: OC1(C2(C(C3C(C(O)C2)C2(C(=CC4N(NCC4C2)C2CCCCC2)C(=C3)C)C)CC1C)C)C(=O)COC(=O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX900. This VA Drug Class (DX900) classifies this compound as belonging to the group DIAGNOSTICS, OTHER.
This classification denotes a diagnostic reagent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 72YY86EA29. European Medicines Agency schedules Cosyntropin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10941MIG. Tetracosactide generally arises in the molecular formula C136H210N40O31S. The term 'tetracosactide' is a European Pharmacopoeia designation. TETRACOSACTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cosyntropin bears US NLM identifiers UMLS ID C0010192 and NCI Concept Code C28941. SMILES: S(CCC(NC(=O)C(NC(=O)C(NC(=O)C(N)CO)CC1CCC(O)CC1)CO)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(C(=O)N1C(CCC1)C(=O.
This classification denotes a cns stimulant with the molecular formula C10H12N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5161X06LL, chemically known as 2-pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (s)- (9ci) but generally known as cotinine, which bears US NIH Compound Identifier 408. European Medicines Agency schedules Cotinine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06811MIG. The term COTININE is an International Non-Proprietary Name. COTININE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cotinine under HS 29399900 and SITC 54149. As of Q4 2014, COTININE remains the US FDA Preferred Term for this commodity. Cotinine bears US NLM identifiers UMLS ID C0010194 and NCI Concept Code C70941. SMILES: CN1C(CCC1=O)C2=CN=CC=C2.
This classification denotes a cns stimulant with the molecular formula 2C10H12N2O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6ZAF060BHS, chemically known as n-methyl-2-(3-pyridyl)-5-pyrrolidone fumarate, but more generally known as cotinine fumarate, which bears US NIH Compound Identifier 5702029. European Medicines Agency schedules cotinine fumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06811MIG. Most nations, for tariff purposes, schedule cotinine fumarate under HS 29399900. Cotinine fumarate bears US NLM identifiers UMLS ID C2825238 and NCI Concept Code C80524. SMILES: CN1[C@@H](CCC1=O)C2CCCNC2.CN1[C@@H](CCC1=O)C2CCCNC2.C(=C/C(=O)O)\C(=O)O.
This classification denotes an antidepressant agent with the molecular formula C20H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KQJ4QI511C, chemically known as 1-(dimethylamino)-3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-2-propanone but generally known as cotriptyline, which bears US NIH Compound Identifier 71935. European Medicines Agency schedules Cotriptyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06812MIG. The term COTRIPTYLINE is an International Non-Proprietary Name. COTRIPTYLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cotriptyline under HS 29223900 and SITC 51463. As of Q4 2014, COTRIPTYLINE remains the US FDA Preferred Term for this commodity. Cotriptyline bears US NLM identifiers UMLS ID C0600943 and NCI Concept Code C78004. SMILES: O=C(/C=C1/c2c(CCc3c1cccc3)cccc2)CN(C)C.
This classification denotes an antibiotic with the molecular formula C55H59N5O20, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, PCH9QZ1IIH chemically known as 5-methylpyyrole-2-carboxylic acid, diester with 3,3'-((3-methylpyrrole-2,4-diyl)bis(carbonylimino))bis(4-hydroxy-8-methyl-7-((tetrahydro-3,4-dihydroxy-5-methoxy-6,6-dimethylpyran-2-yl)oxy)coumarin) but generally known as coumamycin, which bears US NIH Compound Identifier 20494. European Medicines Agency schedules Coumamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06814MIG. The term COUMAMYCIN is an International Non-Proprietary Name or INN. Most nations schedule coumamycin under HS 29419000 and SITC 54139. SMILES: CC1=CC=C(N1)C(=O)OC2C(C(OC(C2OC)(C)C)OC3=C(C4=C(C=C3)C(=O)C(=C(O4)O)NC(=O)C5=CNC(=C5C)C(=O)NC6=C(OC7=C(C6=O)C=CC(=C7C)OC8C(C(C(C(O8)(C)C)OC)OC(=O)C9=CC=C(N9)C)O)O)C)O.
This classification denotes an alpha-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TR7Y641235. European Medicines Agency schedules Coumazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06815MIG. Coumazoline generally arises in the molecular formula C14H16N2O. The term COUMAZOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, no. 10 1972, list 12.) COUMAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule coumazoline under HS 29349990 and SITC 51579. As of Q4 2014, COUMAZOLINE remains the US FDA Preferred Term for this commodity. Coumazoline bears US NLM identifiers UMLS ID C0602991 and NCI Concept Code C79706. SMILES: O1C(C(CC2=NCCN2)C2C1CCCC2)CC.
The Oxford, AstraZeneca vaccine is a vaccine that aims to protect against COVID-19.
Janssen Ad26.CoV2.S vaccine against coronavirus.
A mRNA vaccine composed of nucleoside-modified mRNA (modRNA) encoding a spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles.
The Pfizer–BioNTech COVID-19 vaccine is used to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus, by eliciting an immune response to the S antigen. The vaccine is used to reduce morbidity and mortality from COVID-19.
The Sputnik V vaccine is a vaccine that aims to protect against COVID-19.
This classification denotes an industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GF3CGH8D7Z. European Medicines Agency schedules Cresol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13490MIG. Cresol generally arises in the molecular formula C7H8O. The term 'cresol' is a Hazardous Substances Data Bank designation. As of Q4 2014, CRESOL remains the US FDA Preferred Term for this commodity. Cresol bears US NLM identifiers UMLS ID C0174883 and NCI Concept Code C80922. SMILES: CC1=CC(=CC=C1)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C14H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2B8XWK36K, more generally known as crilvastatin. European Medicines Agency schedules crilvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06819MIG. The term CRILVASTATIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 5, no. 3 1991, list 31. Most nations schedule crilvastatin under HS 29337900 and SITC 51561. As of Q4 2014, CRILVASTATIN remains the US FDA Preferred Term for this commodity. Crilvastatin bears US NLM identifiers UMLS ID C0217468 and NCI Concept Code C90865. SMILES: CC1CC(CC(C1)(C)C)OC(=O)C2CCC(=O)N2.
This classification denotes an intercalating agent with the molecular formula C23H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 2J71UR51UE chemically known as 1,3-propanediol, 2-((6-chrysenylmethyl)amino)-2-methyl- but generally known as crisnatol, which bears US NIH Compound Identifier 57062. European Medicines Agency schedules Crisnatol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06820MIG. The term CRISNATOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28). Most nations schedule crisnatol under HS 29221980 and SITC 51461. As of Q4 2014, CRISNATOL remains the US FDA Preferred Term for this commodity. Crisnatol bears US NLM identifiers UMLS ID C0056493 and NCI Concept Code C81191. SMILES: CC(CO)(CO)NCC1=CC2=C(C=CC3=CC=CC=C32)C4=CC=CC=C41.
Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC).
This classification denotes an antifungal agent with the molecular formula C18H15CLN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 446254H55G. European Medicines Agency schedules croconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06821MIG. The term CROCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26. ). CROCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule croconazole under HS 29332990 and SITC 51573. As of Q4 2014, CROCONAZOLE remains the US FDA Preferred Term for this commodity. Croconazole bears US NLM identifiers UMLS ID C0056504 and NCI Concept Code C78037. SMILES: C=C(C1=CC=CC=C1OCC2=CC(=CC=C2)CL)N3C=CN=C3.
This classification denotes an antifungal agent with the molecular formula C18H15CLN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 446254H55G. European Medicines Agency schedules croconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06821MIG. The term CROCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26. ). CROCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule croconazole hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, CROCONAZOLE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Croconazole hydrochloride bears US NLM identifiers UMLS ID C0972069 and NCI Concept Code C97991. SMILES: C=C(C1=CC=CC=C1OCC2=CC(=CC=C2)CL)N3C=CN=C3.
This classification denotes an antihypertensive agent with the molecular formula C16H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G4X367WA3, chemically known as 2h-1-benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-, trans-(+-)- but generally known as cromakalim, which bears US NIH Compound Identifier 71191. European Medicines Agency schedules Cromakalim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06822MIG. The term CROMAKALIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). CROMAKALIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cromakalim or levcromakalim bears US NLM identifiers UMLS ID C0056506 and NCI Concept Code C79109. SMILES: O1C(C(O)C(N2CCCC2=O)c2c1ccc(c2)C#N)(C)C.
This classification denotes an anti-asthmatic agent with the molecular formula C20H15N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, W6V355N614 chemically known as benzonitrile, 4-(2-hydroxy-3-((4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-5-yl)oxy)propoxy)-, (+/-)- but generally known as cromitrile, which bears US NIH Compound Identifier 40857. European Medicines Agency schedules Cromitrile in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06823MIG. The term CROMITRILE is an International Non-Proprietary Name or INN. Most nations schedule cromitrile under HS 29349990 and SITC 51579. As of Q4 2014, CROMITRILE remains the US FDA Preferred Term for this commodity. Cromitrile bears US NLM identifiers UMLS ID C2825629 and NCI Concept Code C81437. SMILES: O(CC(O)COC1CCC(CC1)C#N)C1C2C(OC(CC2=O)C2N[NH]NN2)CCC1.
This classification denotes an anti-asthmatic agent with the molecular formula C20H14N5O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z9FYZ8P9ND, chemically known as benzonitrile, 4-(2-hydroxy-3-((4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-5-yl)oxy)propoxy)-,monosodium salt but more generally known as cromitrile sodium, which bears US NIH Compound Identifier 40856. Most nations, for tariff and trade purposes, schedule cromitrile sodium under HS 29349990 and SITC 51579. As of Q4 2014, CROMITRILE SODIUM remains US FDA's Preferred Term for this commodity. Cromitrile sodium bears US NLM identifiers UMLS ID C2825630 and NCI Concept Code C81438. SMILES: C1CC2C(C(C1)OCC(COC3CCC(CC3)C#N)O)C(=O)CC(O2)C4[N-]NNN4.[NA+].
This classification denotes a mast cell stabilizer with the molecular formula C23H16O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0TK0FS77W, chemically known as 5,5-(2-hydroxytrimethylenedioxy)bis(4-oxochromene-2-carboxylic acid) but generally known as cromoglicic acid, which bears US NIH Compound Identifier 27686. European Medicines Agency schedules Cromoglicic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06825MIG. The term CROMOGLICIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules cromoglicic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Cromoglicic acid or cromolyn bears US NLM identifiers UMLS ID C0086073 and NCI Concept Code C61691. SMILES: O(CC(O)COC1C2C(OC(CC2=O)C(=O)O)CCC1)C1C2C(OC(CC2=O)C(=O)O)CCC1.
This classification denotes a calcium channel blocker with the molecular formula C30H32ClN3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7TXJ9MY5V9, chemically known as (8-(p-chlorophenyl)-1,4-dioxa-8-azaspiro(4,5)dec-2-yl)methyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate but generally known as cronidipine, which bears US NIH Compound Identifier 65918. European Medicines Agency schedules Cronidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06826MIG. The term CRONIDIPINE is an International Non-Proprietary Name. Most nations schedule cronidipine under HS 29349990 and SITC 51579. As of Q4 2014, CRONIDIPINE remains the US FDA Preferred Term for this commodity. Cronidipine bears US NLM identifiers UMLS ID C2825728 and NCI Concept Code C81683. SMILES: Clc1ccc(N2CCC3(OC(CO3)COC(=O)C3=C(NC(=C(C3c3cc([N](=O)O)ccc3)C(=O)OC)C)C)CC2)cc1.
This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D6S4O4XD0H. European Medicines Agency schedules Crotamiton in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06828MIG. Crotamiton generally arises in the molecular formula C13H17NO. The term CROTAMITON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) CROTAMITON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule crotamiton under HS 29242995 and SITC 51479. As of Q4 2014, CROTAMITON remains the US FDA Preferred Term for this commodity. Crotamiton bears US NLM identifiers UMLS ID C0056519 and NCI Concept Code C65353. SMILES: CCN(C1=CC=CC=C1C)C(=O)C=CC.
This classification denotes an industrial aid with the molecular formula C2Cl2F4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6B5VVT93AR, chemically known as 1,1,2,2-tetrafluoro-1,2-dichloroethane but generally known as cryofluorane, which bears US NIH Compound Identifier 6429. European Medicines Agency schedules Cryofluorane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06832MIG. The term CRYOFLUORANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). CRYOFLUORANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cryofluorane or dichlorotetrafluoroethane bears US NLM identifiers UMLS ID C0443384 and NCI Concept Code C76747. SMILES: CLC(F)(F)C(CL)(F)F.
This classification denotes an antihypertensive mixture of closely related hypotensive alkaloids from veratrum album. European Medicines Agency schedules Cryptenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13498MIG.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a dermatologic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GV54A213NN. European Medicines Agency schedules crystallized trypsin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12616MIG.
This classification denotes a dye with the molecular formula C25H30N3.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4Z741D6O5, chemically known as pararosaniline, n,n,n,n,n,n-hexamethyl-, chloride but generally known as gentian violet, which bears US NIH Compound Identifier 3468. European Medicines Agency schedules Gentian violet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB40253. The term GENTIAN VIOLET is an International Non-Proprietary Name. SMILES: CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-].
This classification denotes an electrolyte replacement agent with the molecular formula 2CL.CU, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P484053J2Y, chemically known as dichlorocopper but generally known as cupric chloride, which bears US NIH Compound Identifier 24014. The term cupric chloride anhydrous is a Hazardous Substances Data Bank designation. As of Q4 2014, CUPRIC CHLORIDE remains the US FDA Preferred Term for this commodity. Cupric chloride bears US NLM identifiers UMLS ID C0056593 and NCI Concept Code C61692. SMILES: Cl[Cu]Cl.
Cupric sulfate/zinc sulfate/camphor is an antiseptic solution that contains two metal ions as antimicrobial ingredients.
This classification denotes a topical anti-infective agent with the molecular formula 2C13H9N2O4.Cu, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q728680892, chemically known as copper, bis(6-methoxy-1-phenazinol 5,10-dioxidato-o(sup1),o(sup10))- but more generally known as cuprimyxin, which bears US NIH Compound Identifier 421620. European Medicines Agency schedules Cuprimyxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06833MIG. The term CUPRIMYXIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). CUPRIMYXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: COC1=CC=CC2=C1N(C3=CC=CC(=O)C3=[N+]2[O-])O.COC1=CC=CC2=C1N(C3=CC=CC(=O)C3=[N+]2[O-])O.[CU].
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H21N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A2JGV5CNU4, chemically known as 10h-phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)- (9ci) but generally known as cyamemazine, which bears US NIH Compound Identifier 62865. European Medicines Agency schedules Cyamemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06836MIG. The term CYAMEMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules cyamemazine in its Anatomical Therapeutic Chemical (ATC) Classification. CYAMEMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyamemazine under HS 29343090 and SITC 51578. As of Q4 2014, CYAMEMAZINE remains the US FDA Preferred Term for this commodity. Cyamemazine bears US NLM identifiers UMLS ID C0056643 and NCI Concept Code C79120. SMILES: S1C2C(N(CC(CN(C)C)C)C3C1CCCC3)CC(CC2)C#N.
This classification denotes a histamine-1 receptor antagonist C19H21N3S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4ZT3BE459, chemically known as 10h-phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more generally known as cyamemazine tartrate, which bears US NIH Compound Identifier 24892868. European Medicines Agency schedules Cyamemazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01510MIG. Most nations, for tariff and trade purposes, schedule cyamemazine tartrate under HS 29343090 and SITC 51578. As of Q4 2014, CYAMEMAZINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CN1C2CCCCC2SC3C1CC(CC3)C#N)CN(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT109. This VA Drug Class (VT109) classifies this compound as belonging to the group VITAMIN B, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT109. This VA Drug Class (VT109) classifies this compound as belonging to the group VITAMIN B, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT801. This VA Drug Class (VT801) classifies this compound as belonging to the group MULTIVITAMINS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT801. This VA Drug Class (VT801) classifies this compound as belonging to the group MULTIVITAMINS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT109. This VA Drug Class (VT109) classifies this compound as belonging to the group VITAMIN B, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT109. This VA Drug Class (VT109) classifies this compound as belonging to the group VITAMIN B, OTHER.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4139O1OAY2. European Medicines Agency schedules Cyclandelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06841MIG. Cyclandelate generally arises in the molecular formula C17H24O3. The term CYCLANDELATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) CYCLANDELATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclandelate under HS 29181985 and SITC 51392. As of Q4 2014, CYCLANDELATE remains the US FDA Preferred Term for this commodity. Cyclandelate bears US NLM identifiers UMLS ID C0010525 and NCI Concept Code C77072. SMILES: CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O.
This classification denotes a cns stimulant with the molecular formula C12H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O8U55ZRL9K, chemically known as 4(5h)-oxazolone, 2-(cyclopropylamino)-5-phenyl- (9ci) but generally known as cyclazodone, which bears US NIH Compound Identifier 26701. European Medicines Agency schedules Cyclazodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06844MIG. The term CYCLAZODONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). CYCLAZODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclazodone under HS 29349990 and SITC 51579. As of Q4 2014, CYCLAZODONE remains the US FDA Preferred Term for this commodity. Cyclazodone bears US NLM identifiers UMLS ID C2825428 and NCI Concept Code C81049. SMILES: C1CC1NC2=NC(=O)C(O2)C3=CC=CC=C3.
This classification denotes an antitussive agent with the molecular formula C16H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2OU4KS37EO, chemically known as 4(5h)-oxazolone, 2-(cyclopropylamino)-5-phenyl- (9ci) but more generally known as cyclexanone, which bears US NIH Compound Identifier 26701. European Medicines Agency schedules Cyclexanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06845MIG. The term CYCLEXANONE is an International Non-Proprietary Name. CYCLEXANONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cyclexanone under HS 29349990 and SITC 51579. As of Q4 2014, CYCLEXANONE remains US FDA's Preferred Term for this commodity. Cyclexanone bears US NLM identifiers UMLS ID C2699484 and NCI Concept Code C78108. SMILES: O1C(=NC(=O)C1C1CCCCC1)NC1CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H19ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N61YTN00CK, chemically known as 4-(p-chloro-.alpha.-2-pyridylbenzylidene)-1-methylpiperidine but generally known as cycliramine, which bears US NIH Compound Identifier 5357113. The term cycliramine is an International Non-Proprietary Name or INN. European Medicines Agency schedules cycliramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06846MIG. Most nations schedule cycliramine under HS 29333999 and SITC 51574. As of Q4 2014, CYCLIRAMINE remains the US FDA Preferred Term for this commodity. Cycliramine bears US NLM identifiers UMLS ID C2828319 and NCI Concept Code C87479. SMILES: CN1CCC(=C(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CC1.C(=CC(=O)O)C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H19CLN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J542BCR0IQ. The term cycliramine maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cycliramine maleate under HS 29333999 and SITC 51574. As of Q4 2014, CYCLIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Cycliramine maleate bears US NLM identifiers UMLS ID C1880204 and NCI Concept Code C65355. SMILES: CN1CCC(=C(C2CCC(CC2)CL)C3CCCCN3)CC1.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antiemetic agent with the molecular formula C18H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QRW9FCR9P2, chemically known as piperazine, 1- (diphenylmethyl)-4-methyl-, monohydrochloride but generally known as cyclizine, which bears US NIH Compound Identifier 6726. European Medicines Agency schedules Cyclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06847MIG. The term CYCLIZINE is an International Non-Proprietary Name. World Health Organization schedules cyclizine in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclizine under HS 29335995 and SITC 51576. As of Q4 2014, CYCLIZINE remains the US FDA Preferred Term for this commodity. Cyclizine bears US NLM identifiers UMLS ID C0010547 and NCI Concept Code C65356. SMILES: N1(CCN(CC1)C)C(C1CCCCC1)C1CCCCC1.
This classification denotes a sedative and hypnotic with the molecular formula C12H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M8A98AD9H, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-5-ethyl- but generally known as cyclobarbital, which bears US NIH Compound Identifier 5838. European Medicines Agency schedules Cyclobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06848MIG. The term CYCLOBARBITAL is an International Non-Proprietary Name. World Health Organization schedules cyclobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CCCCC2.
This classification denotes a muscle relaxant with the molecular formula C20H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69O5WQQ5TI, chemically known as 10,11-dehydroamitriptyline but generally known as cyclobenzaprine, which bears US NIH Compound Identifier 2895. European Medicines Agency schedules Cyclobenzaprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06849MIG. The term CYCLOBENZAPRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules cyclobenzaprine in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOBENZAPRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclobenzaprine under HS 29214980 and SITC 51454. As of Q4 2014, CYCLOBENZAPRINE remains the US FDA Preferred Term for this commodity. Cyclobenzaprine bears US NLM identifiers UMLS ID C0056732 and NCI Concept Code C28947. SMILES: N(CC/C=C1\C2C(C=CC3C1CCCC3)CCCC2)(C)C.
This classification denotes a muscle relaxant and antidepressant agent with the molecular formula C20H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VE05JYS2P, chemically known as 10,11-dehydroamitriptyline but more generally known as cyclobenzaprine hydrochloride, which bears US NIH Compound Identifier 2895. European Medicines Agency schedules Cyclobenzaprine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13514MIG. Most nations, for tariff and trade purposes, schedule cyclobenzaprine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, CYCLOBENZAPRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cyclobenzaprine hydrochloride bears US NLM identifiers UMLS ID C0125988 and NCI Concept Code C47465. SMILES: CN(C)CCC=C1C2CCCCC2C=CC3C1CCCC3.CL.
This classification denotes a cholagogue or choleretic agent with the molecular formula C10H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8T4L120N6M, chemically known as cyclohexaneacetic acid, alpha-ethyl-1-hydroxy- but generally known as cyclobutyrol, which bears US NIH Compound Identifier 72065. European Medicines Agency schedules Cyclobutyrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06851MIG. The term CYCLOBUTYROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules cyclobutyrol in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOBUTYROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclobutyrol under HS 29181985 and SITC 51392. As of Q4 2014, CYCLOBUTYROL remains the US FDA Preferred Term for this commodity. Cyclobutyrol bears US NLM identifiers UMLS ID C0056739 and NCI Concept Code C81039. SMILES: CCC(C(=O)O)C1(CCCCC1)O.
This classification denotes the sodium form of a cholagogue or choleretic agent with the molecular formula C10H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8T4L120N6M, chemically known as cyclohexaneacetic acid, alpha-ethyl-1-hydroxy- but more generally known as cyclobutyrol, which bears US NIH Compound Identifier 72065. European Medicines Agency schedules Cyclobutyrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06851MIG. The term CYCLOBUTYROL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules cyclobutyrol in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOBUTYROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cyclobutyrol sodium under HS 29181985 and SITC 51392. As of Q4 2014, CYCLOBUTYROL SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CCC(C(=O)[O-])C1(CCCCC1)O.[NA+].
This classification denotes an antiestrogen with the molecular formula C23H24O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J468V64WZ1, chemically known as 4,4-(cyclohexylidenemethylene)diphenol diacetate ester but generally known as cyclofenil, which bears US NIH Compound Identifier 2898. European Medicines Agency schedules Cyclofenil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06852MIG. The term CYCLOFENIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules cyclofenil in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOFENIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclofenil under HS 29153980 and SITC 51372. As of Q4 2014, CYCLOFENIL remains the US FDA Preferred Term for this commodity. Cyclofenil bears US NLM identifiers UMLS ID C0010560 and NCI Concept Code C78030. SMILES: O(C1CCC(C(=C2\CCCCC2)/C2CCC(OC(=O)C)CC2)CC1)C(=O)C.
This classification denotes an antiestrogen with the molecular formula C19H20O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00W4083OML, chemically known as .alpha.-cyclohexylidene-.alpha.-(p-hydroxyphenyl)-p-cresol, but more generally known as cyclofenil diphenol, which bears US NIH Compound Identifier 21260. European Medicines Agency schedules cyclofenil diphenol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06852MIG. Most nations, for tariff purposes, schedule cyclofenil diphenol under HS 29153980. SMILES: C1CC(CCC1C(=C2CCCCC2)C3CCC(CC3)O)O.
This classification denotes an antimalarial and folic acid antagonist with the molecular formula C11H14ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26RM326WVN, chemically known as 1-(4-chlorophenyl)-1,6-dihydro-6,6-dimethyl-1,3,5-triazine-2,4-diamine but generally known as cycloguanil, which bears US NIH Compound Identifier 9049. European Medicines Agency schedules Cycloguanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01526MIG. World Health Organization schedules cycloguanil in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CYCLOGUANIL remains the US FDA Preferred Term for this commodity. Cycloguanil bears US NLM identifiers UMLS ID C0056751 and NCI Concept Code C81015. SMILES: CC1(N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N)C.
This classification denotes an antimalarial and folic acid antagonist with the molecular formula C23H16O6.2C11H14ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TCO0SY4N3D, chemically known as 4,6-diamino-1-(p-chlorophenyl)-1,2-dihydro-2,2-dimethyl-s-triazine pamoate but more generally known as cycloguanil embonate, which bears US NIH Compound Identifier 11870. European Medicines Agency schedules Cycloguanil embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06853MIG. World Health Organization schedules cycloguanil embonate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cycloguanil embonate under HS 29336980 and SITC 51576. SMILES: CC1(N=C(N=C(N1C2CCC(CC2)CL)N)N)C.CC1(N=C(N=C(N1C2CCC(CC2)CL)N)N)C.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O
This classification denotes an anesthetic agent with the molecular formula C22H33NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15E9I74NZ8. European Medicines Agency schedules cyclomethycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06855MIG. The term CYCLOMETHYCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3. ). CYCLOMETHYCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclomethycaine under HS 29333999 and SITC 51574. As of Q4 2014, CYCLOMETHYCAINE remains the US FDA Preferred Term for this commodity. Cyclomethycaine bears US NLM identifiers UMLS ID C0056780 and NCI Concept Code C75088. SMILES: O(C1CCCCC1)C1CCC(C(=O)OCCCN2C(CCCC2)C)CC1.
This classification denotes the hydrochloride form of an anesthetic agent with the molecular formula C22H33NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15E9I74NZ8. European Medicines Agency schedules cyclomethycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06855MIG. The term CYCLOMETHYCAINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, no. 12, 1959, list 3. ). CYCLOMETHYCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cyclomethycaine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, CYCLOMETHYCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cyclomethycaine hydrochloride bears US NLM identifiers UMLS ID C2827120 and NCI Concept Code C83643. SMILES: CC1CCCCN1CCCOC(=O)C2CCC(CC2)OC3CCCCC3.CL.
This classification denotes an anesthetic agent with the molecular formula C22H33NO3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7323N7T136. The term cyclomethycaine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cyclomethycaine sulfate under HS 29333999 and SITC 51574. As of Q4 2014, CYCLOMETHYCAINE SULFATE remains US FDA's Preferred Term for this commodity. Cyclomethycaine sulfate bears US NLM identifiers UMLS ID C2699487 and NCI Concept Code C75089. SMILES: CC1CCCCN1CCCOC(=O)C2CCC(CC2)OC3CCCCC3.CC1CCCCN1CCCOC(=O)C2CCC(CC2)OC3CCCCC3.OS(=O)(=O)O.
This classification denotes an adrenergic agent with the molecular formula C9H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WB9Q6M8O60, chemically known as 2-cyclopentyl-n,1-dimethylethylamine but generally known as cyclopentamine, which bears US NIH Compound Identifier 7608. European Medicines Agency schedules Cyclopentamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06856MIG. The term CYCLOPENTAMINE is an International Non-Proprietary Name. World Health Organization schedules cyclopentamine in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOPENTAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclopentamine under HS 29213099 and SITC 51453. As of Q4 2014, CYCLOPENTAMINE remains the US FDA Preferred Term for this commodity. Cyclopentamine bears US NLM identifiers UMLS ID C0163082 and NCI Concept Code C81341. SMILES: N(C(CC1CCCC1)C)C.
This classification denotes an adrenergic agent with the molecular formula C9H19N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F551446KF3, chemically known as n,alpha-dimethylcyclopentaneethylamine hydrochloride but more generally known as cyclopentamine hydrochloride, which bears US NIH Compound Identifier 92798. European Medicines Agency schedules Cyclopentamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01528MIG. Most nations, for tariff and trade purposes, schedule cyclopentamine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, CYCLOPENTAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cyclopentamine hydrochloride bears US NLM identifiers UMLS ID C0770489 and NCI Concept Code C75030. SMILES: CC(CC1CCCC1)NC.CL.
This classification denotes a thiazide diuretic with the molecular formula C13H18ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VX4S2N85F5, chemically known as 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-2h-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as cyclopenthiazide, which bears US NIH Compound Identifier 2904. European Medicines Agency schedules Cyclopenthiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06857MIG. The term CYCLOPENTHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules cyclopenthiazide in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOPENTHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclopenthiazide under HS 29350090 and SITC 51580. As of Q4 2014, CYCLOPENTHIAZIDE remains the US FDA Preferred Term for this commodity. Cyclopenthiazide bears US NLM identifiers UMLS ID C0010581 and NCI Concept Code C80839. SMILES: CLC1CC2NC(NS(=O)(=O)C2CC1S(=O)(=O)N)CC1CCCC1.
This classification denotes a mydriatic agent and antimuscarinic agent with the molecular formula C17H25NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier I76F4SHP7J, chemically known as benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester but more generally known as cyclopentolate, which bears U.S. NIH Compound Identifier 2905. European Medicines Agency schedules Cyclopentolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06858MIG. The term CYCLOPENTOLATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules cyclopentolate in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. CYCLOPENTOLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP600. This VA Drug Class (OP600) classifies this compound as belonging to the group MYDRIATICS/CYCLOPLEGICS, TOPICAL OPHTHALMIC.
This classification denotes a nitrogen mustard compound and immunosuppressant with the molecular formula C7H15Cl2N2O2P.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8N3DW7272P, chemically known as 2h-1,3,2-oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide but more generally known as cyclophosphamide, which bears US NIH Compound Identifier 2907. European Medicines Agency schedules Cyclophosphamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06859MIG. World Health Organization schedules cyclophosphamide in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOPHOSPHAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cyclophosphamide under HS 29349990 and SITC 51579. As of Q4 2014, CYCLOPHOSPHAMIDE remains US FDA's Preferred Term for this commodity. Cyclophosphamide bears US NLM identifiers UMLS ID C0010583 and NCI Concept Code C405. SMILES: CLCCN(P1(=O)OCCCN1)CCCL.
This classification denotes a nitrogen mustard compound and immunosuppressant with the molecular formula C7H15Cl2N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UXW23996M, chemically known as 2h-1,3,2-oxazaphosphorin-2-amine, n,n-bis(2-chloroethyl)tetrahydro-, 2-oxide, but more generally known as cyclophosphamide anhydrous, which bears US NIH Compound Identifier 2907. European Medicines Agency schedules cyclophosphamide anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06859MIG. Most nations, for tariff purposes, schedule cyclophosphamide anhydrous under HS 29349990. Cyclophosphamide anhydrous bears US NLM identifiers UMLS ID C1880207 and NCI Concept Code C61694. SMILES: C1CNP(=O)(OC1)N(CCCL)CCCL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN100. This VA Drug Class (AN100) classifies this compound as belonging to the group ANTINEOPLASTICS, ALKYLATING AGENTS.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99TB643425. European Medicines Agency schedules Cyclopropane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06861MIG. Cyclopropane generally arises in the molecular formula C3H6. The term CYCLOPROPANE is an International Non-Proprietary Name or INN. CYCLOPROPANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclopropane under HS 29021980 and SITC 51129. As of Q4 2014, CYCLOPROPANE remains the US FDA Preferred Term for this commodity. Cyclopropane bears US NLM identifiers UMLS ID C0010587 and NCI Concept Code C81404. SMILES: C1CC1.
This classification denotes an antitubercular agent with the molecular formula C3H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95IK5KI84Z, chemically known as 3-isoxazolidinone, 4-amino-, (s)- but generally known as cycloserine, which bears US NIH Compound Identifier 401. European Medicines Agency schedules Cycloserine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06863MIG. The term CYCLOSERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules cycloserine in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOSERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cycloserine under HS 29419000 and SITC 54139. As of Q4 2014, CYCLOSERINE remains the US FDA Preferred Term for this commodity. Cycloserine bears US NLM identifiers UMLS ID C0010590 and NCI Concept Code C47466. SMILES: O1NC(=O)C(N)C1.
This classification denotes an antitubercular agent with the molecular formula C4H6O6.C3H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24EZ3L1E6S. Most nations, for tariff and trade purposes, schedule cycloserine tartrate under HS 29419000. As of Q4 2014, CYCLOSERINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C1[C@H](C(=O)NO1)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a thiazide diuretic with the molecular formula C14H16ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P71U09G5BW, chemically known as 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as cyclothiazide, which bears US NIH Compound Identifier 2910. European Medicines Agency schedules Cyclothiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06864MIG. The term CYCLOTHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules cyclothiazide in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOTHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyclothiazide under HS 29350090 and SITC 51580. As of Q4 2014, CYCLOTHIAZIDE remains the US FDA Preferred Term for this commodity. Cyclothiazide bears US NLM identifiers UMLS ID C0056831 and NCI Concept Code C65358. SMILES: CLC1CC2NC(NS(=O)(=O)C2CC1S(=O)(=O)N)C1C2CC(C1)C=C2.
This classification denotes an antiparkinsonian agent and antimuscarinic agent with the molecular formula C19H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 543567RFQQ, chemically known as 1-piperidinepropanol, .alpha.-cyclopentyl-.alpha.-phenyl-, hydrochloride but generally known as cycrimine, which bears US NIH Compound Identifier 2911. European Medicines Agency schedules Cycrimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06867MIG. The term CYCRIMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). CYCRIMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cycrimine under HS 29333999 and SITC 51574. As of Q4 2014, CYCRIMINE remains the US FDA Preferred Term for this commodity. Cycrimine bears US NLM identifiers UMLS ID C0056835 and NCI Concept Code C65359. SMILES: OC(C1CCCC1)(CCN1CCCCC1)C1CCCCC1.
This classification denotes a pesticide with the molecular formula C22H18Cl2FNO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier SCM2QLZ6S0, chemically known as 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylic acid, cyano(4-fluoro-3-phenoxyphenyl)methyl ester but more generally known as cyfluthrin, which bears U.S. National Institutes of Health Compound Identifier 50153. World Health Organization schedules cyfluthrin in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes an anti-arrhythmia agent and cardiotonic agent with the molecular formula C30H44O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UK3LS8435E, chemically known as 5-beta-card-20(22)-enolide, 3-beta-(beta-d-cymarosyloxy)-5,14-dihydroxy-19-oxo- but more generally known as cymarin, which bears US NIH Compound Identifier 10504. World Health Organization schedules cymarin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CYMARIN remains US FDA's Preferred Term for this commodity. SMILES: CC1C(C(CC(O1)OC2CCC3(C4CCC5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)C=O)OC)O.
This classification denotes a cholagogue or choleretic agent with the molecular formula C25H24O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85D81U9JAV, chemically known as 1,5-dicaffeoylqunic acid but generally known as cynarine, which bears US NIH Compound Identifier 5281769. European Medicines Agency schedules Cynarine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06870MIG. The term CYNARINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). Most nations schedule cynarine under HS 29182980 and SITC 51394. As of Q4 2014, CYNARINE remains the US FDA Preferred Term for this commodity. Cynarine bears US NLM identifiers UMLS ID C0056848 and NCI Concept Code C81041. SMILES: C1C(C(C(CC1(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)OC(=O)C=CC3=CC(=C(C=C3)O)O)O)O.
This classification denotes a benzodiazepine with the molecular formula C19H18ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 933N61G4SL, chemically known as 7-chloro-2-((cyclopropylmethyl)amino)-5-phenyl-3h-1,4-benzodiazepine 4-oxide but generally known as cyprazepam, which bears US NIH Compound Identifier 27452. European Medicines Agency schedules Cyprazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06872MIG. The term CYPRAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). Most nations schedule cyprazepam under HS 29339940 and SITC 51577. As of Q4 2014, CYPRAZEPAM remains the US FDA Preferred Term for this commodity. Cyprazepam bears US NLM identifiers UMLS ID C2699536 and NCI Concept Code C76534. SMILES: CLC1CC2=C(N(O)CC(=N\CC3CC3)\N=C2CC1)C1CCCCC1.
This classification denotes an opioid receptor agonist with the molecular formula C26H33NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P6HEG5ZHS, chemically known as 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-methoxy-alpha,alpha-dimethyl-, (5alpha,7alpha)- but generally known as cyprenorphine, which bears US NIH Compound Identifier 20435. European Medicines Agency schedules Cyprenorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06873MIG. The term CYPRENORPHINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). Most nations schedule cyprenorphine under HS 29391900 and SITC 54141. As of Q4 2014, CYPRENORPHINE remains the US FDA Preferred Term for this commodity. Cyprenorphine bears US NLM identifiers UMLS ID C0056851 and NCI Concept Code C87355. SMILES: O1C2C34C5(C(N(CC3)CC3CC3)CC3C4C1C(O)CC3)CC(C2(OC)C=C5)C(O)(C)C.
This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C26H33NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P6HEG5ZHS, chemically known as 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-methoxy-alpha,alpha-dimethyl-, (5alpha,7alpha)- but more generally known as cyprenorphine, which bears US NIH Compound Identifier 20435. European Medicines Agency schedules Cyprenorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06873MIG. The term CYPRENORPHINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). Most nations, for tariff and trade purposes, schedule cyprenorphine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, CYPRENORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cyprenorphine hydrochloride bears US NLM identifiers UMLS ID C2828278 and NCI Concept Code C87356. SMILES: CC(C)([C@H]1C[C@@]23C=C[C@]1([C@H]4[C@@]25CCN([C@@H]3CC6C5C(C(CC6)OC)O4)CC7CC7)OC)O.CL.
This classification denotes a cns stimulant with the molecular formula C13H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I44VIC13P8, chemically known as cyclohexanepropionic acid, 2-(dimethylamino)ethyl ester but generally known as cyprodenate, which bears US NIH Compound Identifier 71875. European Medicines Agency schedules Cyprodenate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06874MIG. The term CYPRODENATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). CYPRODENATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyprodenate under HS 29221980 and SITC 51461. As of Q4 2014, CYPRODENATE remains the US FDA Preferred Term for this commodity. Cyprodenate bears US NLM identifiers UMLS ID C0056852 and NCI Concept Code C76619. SMILES: O(C(=O)CCC1CCCCC1)CCN(C)C.
This classification denotes a cns stimulant C13H25NO2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZOZ0RPZ001, chemically known as cyclohexanepropanoic acid, 2-(dimethylamino)ethyl ester, (2z)-2-butenedioate (1:1), but more generally known as cyprodenate maleate, which bears US NIH Compound Identifier 56843760. Most nations, for tariff and trade purposes, schedule cyprodenate maleate under HS 29221980 and SITC 51461. As of Q4 2014, CYPRODENATE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCOC(=O)CCC1CCCCC1.C(=C\C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2YHB6175DO, chemically known as 5-(1-methylpiperidylidene-4)-5h-dibenzo(a,d)cyclopheptene but generally known as cyproheptadine, which bears US NIH Compound Identifier 2913. European Medicines Agency schedules Cyproheptadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06875MIG. The term CYPROHEPTADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules cyproheptadine in its Anatomical Therapeutic Chemical (ATC) Classification. CYPROHEPTADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyproheptadine under HS 29333999 and SITC 51574. As of Q4 2014, CYPROHEPTADINE remains the US FDA Preferred Term for this commodity. Cyproheptadine bears US NLM identifiers UMLS ID C0010620 and NCI Concept Code C61695. SMILES: N1(CC/C(=C2/C3C(C=CC4C2CCCC4)CCCC3)CC1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula 2C21H21N.2ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NJ82J0F8QC, chemically known as 5-(1-methylpiperidylidene-4)-5h-dibenzo(a,d)cyclopheptene but more generally known as cyproheptadine hydrochloride, which bears US NIH Compound Identifier 2913. European Medicines Agency schedules Cyproheptadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01537MIG. Most nations, for tariff and trade purposes, schedule cyproheptadine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, CYPROHEPTADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cyproheptadine hydrochloride bears US NLM identifiers UMLS ID C0354872 and NCI Concept Code C28949. SMILES: CN1CCC(=C2C3CCCCC3C=CC4C2CCCC4)CC1.CN1CCC(=C2C3CCCCC3C=CC4C2CCCC4)CC1.O.O.O.CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula 2C21H21N.2ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NJ82J0F8QC, chemically known as piperidine, 4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl-, hydrochloride, hydrate (2:2:3), but more generally known as cyproheptadine hydrochloride sesquihydrate, which bears US NIH Compound Identifier 6441505. European Medicines Agency schedules cyproheptadine hydrochloride sesquihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06875MIG. Most nations, for tariff purposes, schedule cyproheptadine hydrochloride sesquihydrate under HS 29333999. SMILES: CN1CCC(=C2C3CCCCC3C=CC4C2CCCC4)CC1.CN1CCC(=C2C3CCCCC3C=CC4C2CCCC4)CC1.O.O.O.CL.CL.
This classification denotes an anti-androgen with the molecular formula C22H27ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E61Q31EK2F, chemically known as 3h-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 6-chloro-1-beta,2-beta-dihydro-17-hydroxy- but generally known as cyproterone, which bears US NIH Compound Identifier 16417. European Medicines Agency schedules Cyproterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06877MIG. World Health Organization schedules cyproterone in its Anatomical Therapeutic Chemical (ATC) Classification. CYPROTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyproterone under HS 29372900 and SITC 54153. As of Q4 2014, CYPROTERONE remains the US FDA Preferred Term for this commodity. Cyproterone bears US NLM identifiers UMLS ID C0010621 and NCI Concept Code C407. SMILES: CLC1=CC2C(C3(C4C(C4)C(=O)C=C13)C)CCC1(C2CCC1(O)C(=O)C)C.
Cyproterone/Estradiol + Estradiol is an oral combination indicated as hormone replacement therapy for the treatment of menopausal syndrome and in the prevention of osteoporosis.
This classification denotes an anti-ulcer agent with the molecular formula C2H7NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5UX2SD1KE2, chemically known as 2-mercaptoethylamine, polymer-bound but generally known as cysteamine, which bears US NIH Compound Identifier 6058. European Medicines Agency schedules Cysteamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08770MIG. The term CYSTEAMINE is an International Non-Proprietary Name. World Health Organization schedules cysteamine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CYSTEAMINE remains the US FDA Preferred Term for this commodity. Cysteamine bears US NLM identifiers UMLS ID C0010648 and NCI Concept Code C61696. SMILES: C(CS)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.
This classification denotes an antimetabolite, antineoplastic, antiviral agent, and immunosuppressive agent with the molecular formula C9H13N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04079A1RDZ, chemically known as 4-amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine but generally known as cytarabine, which bears US NIH Compound Identifier 596. European Medicines Agency schedules Cytarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06880MIG. The term CYTARABINE is an International Non-Proprietary Name. World Health Organization schedules cytarabine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cytarabine under HS 29349990 and SITC 51579. As of Q4 2014, CYTARABINE remains the US FDA Preferred Term for this commodity. Cytarabine bears US NLM identifiers UMLS ID C0010711 and NCI Concept Code C408. SMILES: O1C(N2CCC(NC2=O)N)C(O)C(O)C1CO.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0VM4M70GC. European Medicines Agency schedules Dabigatran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25417. Dabigatran generally arises in the molecular formula C25H25N7O3. The term DABIGATRAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.) Most nations schedule dabigatran under HS 29333999 and SITC 51574. As of Q4 2014, DABIGATRAN remains the US FDA Preferred Term for this commodity. Dabigatran bears US NLM identifiers UMLS ID C2348066 and NCI Concept Code C73224. SMILES: O=C(N(CCC(=O)O)C1NCCCC1)C1CC2NC(N(C2CC1)C)CNC1CCC(CC1)C(=N)N.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2E18WX195X. European Medicines Agency schedules Dabigatran etexilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20521. Dabigatran etexilate generally arises in the molecular formula C34H41N7O5. The term DABIGATRAN ETEXILATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule dabigatran etexilate under HS 29333999 and SITC 51574. As of Q4 2014, DABIGATRAN ETEXILATE remains the US FDA Preferred Term for this commodity. Dabigatran etexilate bears US NLM identifiers UMLS ID C1571583 and NCI Concept Code C87480. SMILES: CCCCCCOC(=O)/N=C(\C1CCC(CC1)NCC2NC3CC(CCC3N2C)C(=O)N(CCC(=O)OCC)C4CCCCN4)/N.
This classification denotes an anticoagulant agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier SC7NUW5IIT. The European Medicines Agency schedules Dabigatran etexilate mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27581. Dabigatran etexilate mesilate generally arises in the molecular formula C34H41N7O5.CH4O3S. The term 'dabigatran etexilate mesilate' is a European Medicines Agency European Public Assessment Report System designation. SMILES: CCCCCCOC(=O)N=C(C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)N.
This classification denotes a triazene compound with the molecular formula C6H10N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7GR28W0FJI, chemically known as 5-(3,3-dimethyltriaz-1-en-1-yl)-1h-imidazole-4-carboxamide but more generally known as dacarbazine, which bears US NIH Compound Identifier 5281007. European Medicines Agency schedules Dacarbazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06882MIG. The term DACARBAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules dacarbazine in its Anatomical Therapeutic Chemical (ATC) Classification. DACARBAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dacarbazine under HS 29332990 and SITC 51573. As of Q4 2014, DACARBAZINE remains US FDA's Preferred Term for this commodity. Dacarbazine bears US NLM identifiers UMLS ID C0010927 and NCI Concept Code C411. SMILES: O=C(N)C1=NC=N/C1=N\NN(C)C.
This classification denotes a triazene compound with the molecular formula C6H10N6O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9UYU348NIF. European Medicines Agency schedules dacarbazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01547MIG. As of Q4 2014, DACARBAZINE CITRATE remains US FDA's Preferred Term for this commodity. Most nations, for tariff and trade purposes, schedule dacarbazine citrate under HS 29332990 and SITC 51573. SMILES: CN(C)/N=N/C1C(NC[NH]1)C(=O)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H16N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88D34UY0QI, chemically known as 10-n,n-dimethylglycylphenothiazine but generally known as dacemazine, which bears US NIH Compound Identifier 68846. European Medicines Agency schedules Dacemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06883MIG. The term DACEMAZINE is an International Non-Proprietary Name. DACEMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dacemazine under HS 29343090 and SITC 51578. As of Q4 2014, DACEMAZINE remains the US FDA Preferred Term for this commodity. Dacemazine bears US NLM identifiers UMLS ID C2348067 and NCI Concept Code C73047. SMILES: S1C2C(N(C3C1CCCC3)C(=O)CN(C)C)CCCC2.
Antiviral for the treatment of Hepatitis C virus infections
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.
This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6394H9888N1696O2012S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUJ2MVI71Y, more generally known as daclizumab. European Medicines Agency schedules daclizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06885MIG. The term DACLIZUMAB is an International Non-Proprietary Name or INN. Dacliximab or daclizumab bears US NLM identifiers UMLS ID C0663182 and NCI Concept Code C1569. Most nations, for tariff and trade purposes, schedule dacliximab or daclizumab under 30021002 and SITC 54163. SMILES: NONE.
This classification denotes an antiplatelet agent with the molecular formula C12H11N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1T03Z1G60, chemically known as (3r)-3-(3-pyridyl)-1h,3h-pyrrolo(1,2-c)thiazole-7-carboxamide. but generally known as dacopafant, which bears US NIH Compound Identifier 205955. European Medicines Agency schedules Dacopafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06886MIG. The term DACOPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DACOPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dacopafant under HS 29349990 and SITC 51579. As of Q4 2014, DACOPAFANT remains the US FDA Preferred Term for this commodity. Dacopafant bears US NLM identifiers UMLS ID C2348068 and NCI Concept Code C73132. SMILES: C1C2=C(C=CN2[C@H](S1)C3=CN=CC=C3)C(=O)N.
This classification denotes an actinomycin antibiotic with the molecular formula C62H86N12O16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1CC1JFE158, chemically known as 4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide but generally known as dactinomycin, which bears US NIH Compound Identifier 2019. European Medicines Agency schedules Dactinomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13528MIG. The term DACTINOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules dactinomycin in its Anatomical Therapeutic Chemical (ATC) Classification. DACTINOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dactinomycin under HS 29419000 and SITC 54139. As of Q4 2014, DACTINOMYCIN remains the US FDA Preferred Term for this commodity. Dactinomycin bears US NLM identifiers UMLS ID C0010934 and NCI Concept Code C412. SMILES: O=C1N2C(CCC2)C(=O)N(CC(=O)N(C(C(C)C)C(=O)OC(C(NC(=O)C2C3NC4C(C(=O)NC5C(=O)NC(C(=O)N6C(CCC6)C(=O)N(CC(=O)N(C(C(C)C)C(=O)OC5C)C)C)C(C)C)CCC(C4OC3C(C(=O)C2N)C)C)C(=O)NC1C(C)C)C)C)C.
This classification denotes a calcium channel blocker with the molecular formula C36H56N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64O87U613H, chemically known as 2-(3-((m-methoxyphenethyl)methylamino)propyl)-2-(3,4,5-trimethoxyphenyl)tetradecanenitrile. but generally known as dagapamil, which bears US NIH Compound Identifier 205957. European Medicines Agency schedules Dagapamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06888MIG. The term DAGAPAMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). DAGAPAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dagapamil under HS 29269095 and SITC 51484. As of Q4 2014, DAGAPAMIL remains the US FDA Preferred Term for this commodity. Dagapamil bears US NLM identifiers UMLS ID C2825727 and NCI Concept Code C81681. SMILES: O(c1cc(C(CCCCCCCCCCCC)(CCCN(CCc2cc(OC)ccc2)C)C#N)cc(OC)c1OC)C.
This classification denotes an antibacterial with the molecular formula C88H100Cl2N10O28, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 808UI9MS5K, chemically known as RISTOMYCIN A AGLYCONE,5,31-DICHLORO-38-DE(METHOXYCARBONYL)-7-DEMETHYL-19-DEOXY-56-O-(2-DEOXY-2-((10-METHYL-1-OXOUNDECYL)AMINO)-.BETA.-D-GLUCOPYRANURONOSYL)-38-(((3-(DIMETHYLAMINO)PROPYL)AMINO)CARBONYL)-42-O-.ALPHA.-D-MANNOPYRANOSYL-N(SUP 15)-METHYL- but generally known as dalbavancin, which bears US NIH Compound Identifier 23724878. The term dalbavancin is an International Non-Proprietary Name or INN SUB26697. Most nations schedule dalbavancin under HS 29419000 and SITC 54139. As of Q4 2014, DALBAVANCIN remains the US FDA Preferred Term for this commodity. SMILES: CC(C)CCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=CC(=CC(=C7C8=C(C=CC(=C8)C(C(=O)N6)NC(=O)C4NC(=O)C9C1=CC(=CC(=C1Cl)O)OC1=C(C=CC(=C1)C(C(=O)NC(CC1=CC=C(O3)C=C1)C(=O)N9)NC)O)O)OC1C(C(C(C(O1)CO)O)O)O)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7GDN12Q42M, chemically known as (- )-1-phenoxy-3-((2-((1,3,5-trimethylpyrazol-4-yl)amino)ethyl)amino)-2-propanol. but generally known as dalbraminol, which bears US NIH Compound Identifier 205958. European Medicines Agency schedules Dalbraminol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06889MIG. The term DALBRAMINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). DALBRAMINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dalbraminol under HS 29331990 and SITC 51571. As of Q4 2014, DALBRAMINOL remains the US FDA Preferred Term for this commodity. Dalbraminol bears US NLM identifiers UMLS ID C2699554 and NCI Concept Code C74200. SMILES: OC(CNCCNC1C(N(NC1C)C)C)COC1CCCCC1.
This classification denotes a cation channel blocker with the molecular formula C5H6N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BH3B64OKL9, chemically known as 4-pyridinamine, monohydrochloride but generally known as fampridine, which bears US NIH Compound Identifier 1727. European Medicines Agency schedules Fampridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07505MIG. The term FAMPRIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules fampridine in its Anatomical Therapeutic Chemical (ATC) Classification. Dalfampridine or fampridine bears US NLM identifiers UMLS ID C0000477 and NCI Concept Code C76777. SMILES: C1=CN=CC=C1N.
This classification denotes an antibiotic with the molecular formula C34H50N4O9S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9M4FJE48E, chemically known as virginiamycin m1, 26-((2-(diethylamino)ethyl)sulfonyl)-26,27-dihydro-, (26r,27s)- but generally known as dalfopristin, which bears US NIH Compound Identifier 6323289. European Medicines Agency schedules Dalfopristin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06892MIG. The term DALFOPRISTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DALFOPRISTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dalfopristin under HS 29349990 and SITC 51579. As of Q4 2014, DALFOPRISTIN remains the US FDA Preferred Term for this commodity. Dalfopristin bears US NLM identifiers UMLS ID C0756085 and NCI Concept Code C47468. SMILES: S(=O)(=O)(C1C2N(CC1)C(=O)C1NC(OC1)CC(=O)CC(O)C=C(C=CCNC(=O)C=CC(C(OC2=O)C(C)C)C)C)CCN(CC)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.
This classification denotes a low molecular weight heparin with the molecular formula (C14H18NO11)N.2(C12H16NO13S)N.3HO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S79O08V79F. European Medicines Agency schedules dalteparin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02475MIG. DALTEPARIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DALTEPARIN remains the US FDA Preferred Term for this commodity. Dalteparin bears US NLM identifiers UMLS ID C0206461 and NCI Concept Code C1453. SMILES: CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.
This classification denotes an anti-lipidemic agent with the molecular formula C24H31FO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZWE0X0IG9D, chemically known as 2h-pyran-2-one, tetrahydro-6-(2-(2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethyl-1-cyclohexen-1-yl)ethenyl)-4-hydroxy-, (4r-(4-alpha,6-beta(e)))- but generally known as dalvastatin, which bears US NIH Compound Identifier 6436001. European Medicines Agency schedules Dalvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06894MIG. The term DALVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DALVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DALVASTATIN remains the US FDA Preferred Term for this commodity. Dalvastatin bears US NLM identifiers UMLS ID C0165939 and NCI Concept Code C75254. SMILES: Fc1c(cc(C2=C(C(CC(C2)(C)C)(C)C)/C=C/C2OC(=O)CC(O)C2)cc1)C.
This classification denotes a low molecular weight heparin with the molecular formula C14H18NO17S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BI6GY4U9CW, more generally known as danaparoid. European Medicines Agency schedules Danaparoid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13531MIG. As of Q4 2014, DANAPAROID remains the US FDA Preferred Term for this commodity. SMILES: NONE.
This classification denotes a therapeutic androgen, gonadotropin releasing hormone inhibitor, and anabolic steroid with the molecular formula C22H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N29QWW3BUO, chemically known as win 17,757 but generally known as danazol, which bears US NIH Compound Identifier 2949. European Medicines Agency schedules Danazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06897MIG. The term DANAZOL is an International Non-Proprietary Name. World Health Organization schedules danazol in its Anatomical Therapeutic Chemical (ATC) Classification. DANAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule danazol under HS 29372900 and SITC 54153. As of Q4 2014, DANAZOL remains the US FDA Preferred Term for this commodity. Danazol bears US NLM identifiers UMLS ID C0010961 and NCI Concept Code C414. SMILES: OC1(C2(C(C3C(C4(C(=CC5ONCC5C4)CC3)C)CC2)CC1)C)C#C.
This classification denotes a serotonin antagonist with the molecular formula C20H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SD507F5T2W, chemically known as 9,10-dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol but generally known as danitracen, which bears US NIH Compound Identifier 35758. European Medicines Agency schedules Danitracen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06900MIG. The term DANITRACEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). DANITRACEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule danitracen under HS 29333999 and SITC 51574. As of Q4 2014, DANITRACEN remains the US FDA Preferred Term for this commodity. Danitracen bears US NLM identifiers UMLS ID C0650227 and NCI Concept Code C72730. SMILES: OC1c2c(/C(=C3/CCN(CC3)C)c3c1cccc3)cccc2.
This classification denotes a quinolone antibiotic with the molecular formula C19H20FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 24CU1YS91D chemically known as 1-cyclopropyl-6-fluoro-1,4-dihydro-7-((1s,4s)-5-methyl-2,5-diazabicyclo(2.2.1)hept-2-yl)-4-oxo-3-quinolinecarboxylic acid but generally known as danofloxacin, which bears US NIH Compound Identifier 71335. European Medicines Agency schedules Danofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06901MIG. The term DANOFLOXACIN is an International Non-Proprietary Name or INN. Most nations schedule danofloxacin under HS 29335995 and SITC 51576. As of Q4 2014, DANOFLOXACIN remains the US FDA Preferred Term for this commodity. Danofloxacin bears US NLM identifiers UMLS ID C0112317 and NCI Concept Code C72731. SMILES: CN1CC2CC1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a carcinogenic anthraquinone with the molecular formula C14H8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z4XE6IBF3V, chemically known as 1,4,5,8-tetroxyantraquinone but generally known as danthron, which bears US NIH Compound Identifier 2950. European Medicines Agency schedules Danthron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06904MIG. The term DANTRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules danthron in its Anatomical Therapeutic Chemical (ATC) Classification. Danthron or dantron bears US NLM identifiers UMLS ID C0057135 and NCI Concept Code C44363. SMILES: O=C1C2C(C(=O)C3C1C(O)CCC3)CCCC2O.
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F64QU97QCR. European Medicines Agency schedules Dantrolene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06903MIG. Dantrolene generally arises in the molecular formula C14H10N4O5. The term DANTROLENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) DANTROLENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dantrolene under HS 29349990 and SITC 51579. As of Q4 2014, DANTROLENE remains the US FDA Preferred Term for this commodity. Dantrolene bears US NLM identifiers UMLS ID C0010976 and NCI Concept Code C61697. SMILES: O1C(C2CCC([N](=O)O)CC2)CCC1/C=N/N1CC(=O)NC1=O.
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 287M0347EV. European Medicines Agency schedules Dantrolene sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01553MIG. Dantrolene sodium generally arises in the molecular formula C14H9N4NAO5. The term DANTROLENE SODIUM is a United States Adopted Name designation. Most nations schedule dantrolene sodium under HS 29349990 and SITC 51579. As of Q4 2014, DANTROLENE SODIUM remains the US FDA Preferred Term for this commodity. Dantrolene sodium bears US NLM identifiers UMLS ID C0010977 and NCI Concept Code C61698. SMILES: C1C(=O)N=C(N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])[O-].[NA+].
This classification denotes a muscle relaxant with the molecular formula C14H9N4O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28F0G1E0VF, chemically known as 1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin sodium salt, but more generally known as dantrolene sodium anhydrous, which bears US NIH Compound Identifier 6604100. European Medicines Agency schedules dantrolene sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06903MIG. Most nations, for tariff purposes, schedule dantrolene sodium anhydrous under HS 29349990. SMILES: C1CC(CCC1C2CCC(O2)/C=N/N3CC(=O)[N-]C3=O)[N+](=O)[O-].[NA+].
Dapagliflozin is a medication used to treat type 2 diabetes and, with certain restrictions, type 1 diabetes. It is also used to treat adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RNZ8GJO7K, chemically known as 5,6,7,8-tetrahydro-3-(2-(4-o-tolyl-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine monohydrochloride but generally known as dapiprazole, which bears US NIH Compound Identifier 91269. European Medicines Agency schedules Dapiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06906MIG. The term DAPIPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules dapiprazole in its Anatomical Therapeutic Chemical (ATC) Classification. DAPIPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dapiprazole under HS 29335995 and SITC 51576. As of Q4 2014, DAPIPRAZOLE remains the US FDA Preferred Term for this commodity. Dapiprazole bears US NLM identifiers UMLS ID C0057143 and NCI Concept Code C83648. SMILES: CL.N12CCCCC1NNC2CCN1CCN(CC1)C1C(CCCC1)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DS9UJN1I0X, chemically known as 5,6,7,8-tetrahydro-3-(2-(4-o-tolyl-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine monohydrochloride but more generally known as dapiprazole hydrochloride, which bears US NIH Compound Identifier 91269. European Medicines Agency schedules Dapiprazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01554MIG. Most nations, for tariff and trade purposes, schedule dapiprazole hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, DAPIPRAZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dapiprazole hydrochloride bears US NLM identifiers UMLS ID C0770916 and NCI Concept Code C47469. SMILES: CC1CCCCC1N2CCN(CC2)CCC3NNC4N3CCCC4.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DS9UJN1I0X, chemically known as 1,2,4-triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-, monohydrochloride, but more generally known as dapiprazole monohydrochloride, which bears US NIH Compound Identifier 91269. European Medicines Agency schedules dapiprazole monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06906MIG. Most nations, for tariff purposes, schedule dapiprazole monohydrochloride under HS 29335995. SMILES: CC1CCCCC1N2CCN(CC2)CCC3NNC4N3CCCC4.CL.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C21H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GB2433A4M3, chemically known as benzenemethanamine, n,n-dimethyl-alpha-(2-(1-naphthalenyloxy)ethyl)-, (+)- but generally known as dapoxetine, which bears US NIH Compound Identifier 71353. European Medicines Agency schedules Dapoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06908MIG. The term DAPOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules dapoxetine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule dapoxetine under HS 29221980 and SITC 51461. As of Q4 2014, DAPOXETINE remains the US FDA Preferred Term for this commodity. Dapoxetine bears US NLM identifiers UMLS ID C0215087 and NCI Concept Code C75168. SMILES: O(CCC(N(C)C)c1ccccc1)c1c2c(ccc1)cccc2.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C21H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U4OHT63MRI, chemically known as (+)-(s)-n,n-dimethyl-alpha-(2-(1-naphthyloxy)ethyl)benzylamine hydrochloride but more generally known as dapoxetine hydrochloride, which bears US NIH Compound Identifier 71352. European Medicines Agency schedules Dapoxetine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30408. Most nations, for tariff and trade purposes, schedule dapoxetine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, DAPOXETINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dapoxetine hydrochloride bears US NLM identifiers UMLS ID C0970823 and NCI Concept Code C76101. SMILES: CN(C)[C@@H](CCOC1CCCC2C1CCCC2)C3CCCCC3.CL.
This classification denotes a sulfone anti-infective agent with the molecular formula C12H12N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8W5C518302, chemically known as 4,4-sulphonyldianiline but more generally known as dapsone, which bears US NIH Compound Identifier 2955. European Medicines Agency schedules Dapsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06909MIG. The term DAPSONE is an International Non-Proprietary Name. The World Health Organization schedules dapsone in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NWQ5N31VKK. European Medicines Agency schedules Daptomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06910MIG. Daptomycin generally arises in the molecular formula C72H101N17O26. The term DAPTOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) DAPTOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule daptomycin under HS 29419000 and SITC 54139. As of Q4 2014, DAPTOMYCIN remains the US FDA Preferred Term for this commodity. Daptomycin bears US NLM identifiers UMLS ID C0057144 and NCI Concept Code C47470. SMILES: O1C(C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCCCCCCCC)CC2C3C([NH]C2)CCCC3)CC(=O)N)CC(=O)O)C(=O)NCC(=O)NC(CCCN)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(CC(=O)O)C)C(=O)NC(CC(=O)C2C(N)CCCC2)C1=O)CO)CC(=O)O)C)C.
A CD38-directed cytolytic antibody.
This classification denotes a gnas gene with the molecular formula C800H1300N228O24S5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15UQ94PT4P, more generally known as darbepoetin alfa. European Medicines Agency schedules darbepoetin alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12486MIG. The term DARBEPOETIN ALFA is an International Non-Proprietary Name or INN. Most nations schedule darbepoetin alfa under HS 30021095 and SITC 54163. As of Q4 2014, DARBEPOETIN ALFA remains the US FDA Preferred Term for this commodity. Darbepoetin alfa bears US NLM identifiers UMLS ID C0937950 and NCI Concept Code C1878. SMILES: NONE.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H24N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72H8H6K34C, chemically known as 5-((z)-3,5-di-tert-butyl-4-hydroxybenzylidene)-2-imino-4-thiazolidinone. but generally known as darbufelone, which bears US NIH Compound Identifier 6444826. European Medicines Agency schedules Darbufelone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26843. The term DARBUFELONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule darbufelone under HS 29341000 and SITC 51579. As of Q4 2014, DARBUFELONE remains the US FDA Preferred Term for this commodity. Darbufelone bears US NLM identifiers UMLS ID C0969365 and NCI Concept Code C81061. SMILES: S1/C(=C\C2CC(C(C)(C)C)C(O)C(C(C)(C)C)C2)C(=O)N=C1N.
This classification denotes the mesylate form of a cyclooxygenase inhibitor with the molecular formula C18H24N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72H8H6K34C, chemically known as 5-((z)-3,5-di-tert-butyl-4-hydroxybenzylidene)-2-imino-4-thiazolidinone. but more generally known as darbufelone, which bears US NIH Compound Identifier 6444826. European Medicines Agency schedules Darbufelone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26843. The term DARBUFELONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations, for tariff and trade purposes, schedule darbufelone mesylate under HS 29341000. As of Q4 2014, DARBUFELONE MESYLATE remains US FDA's Preferred Term for this commodity. Darbufelone mesylate bears US NLM identifiers UMLS ID C2825436 and NCI Concept Code C81062. SMILES: CC(C)(C)C1CC(CC(C1O)C(C)(C)C)/C=C\2/C(=O)NC(=N)S2.CS(=O)(=O)O.
This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CR02EYQ8GV. European Medicines Agency schedules Darifenacin hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21464. Darifenacin hydrobromide generally arises in the molecular formula C28H31BRN2O2. The term 'darifenacin hydrobromide' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule darifenacin hydrobromide under HS 29349990 and SITC 51579. As of Q4 2014, DARIFENACIN HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Darifenacin hydrobromide bears US NLM NCI C78068. SMILES: C1CCC(CC1)C(C2CCCCC2)([C@@H]3CCN(C3)CCC4CCC5C(C4)CCO5)C(=O)N.BR.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C28H30N2O2 and C28H30N2O2.BrH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers APG9819VLM and CR02EYQ8GV, the base compound being chemically known as (s)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide but generally known as darifenacin, which bears US NIH Compound Identifier 72054. European Medicines Agency schedules Darifenacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06913MIG and SUB21464. The term DARIFENACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules darifenacin in its Anatomical Therapeutic Chemical (ATC) Classification. DARIFENACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule darifenacin and its salts under HS 29349990 and SITC 51579. As of Q4 2014, DARIFENACIN remains the US FDA Preferred Term for this commodity. Darifenacin bears US NLM NCI C65363 and C78068. SMILES: O=C(N)C(C1CCN(C1)CCC1CC2C(OCC2)CC1)(C1CCCCC1)C1CCCCC1 (base) or C1CCC(CC1)C(C2CCCCC2)([C@@H]3CCN(C3)CCC4CCC5C(C4)CCO5)C(=O)N.BR (hydrobromide).
This classification denotes a protease inhibitor with the molecular formula C27H37N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YO603Y8113, chemically known as n-((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1s,2r,5r)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide but generally known as darunavir, which bears US NIH Compound Identifier 213039. European Medicines Agency schedules Darunavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25394. The term DARUNAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules darunavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule darunavir under HS 29350090 and SITC 51580. As of Q4 2014, DARUNAVIR remains the US FDA Preferred Term for this commodity. Darunavir bears US NLM identifiers UMLS ID C1435444 and NCI Concept Code C65364. SMILES: S(=O)(=O)(N(CC(O)C(NC(=O)OC1C2C(OC1)OCC2)Cc1ccccc1)CC(C)C)c1ccc(N)cc1.
Darunavir is a protease inhibitor co-formulated with the cobicistat booster that has been shown to be effective under ART for the treatment of HIV.
This classification denotes a protease inhibitor C27H37N3O7S.C2H6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33O78XF0BW, chemically known as ((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)- carbamic acid (3r,3as,6ar)-hexahydrofuro(2,3-b)furan-3-yl ester monoethanolate, but more generally known as darunavir ethanolate, which bears US NIH Compound Identifier 23725083. European Medicines Agency schedules Darunavir ethanolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23573. Most nations, for tariff and trade purposes, schedule darunavir ethanolate under HS 29350090 and SITC 51580. As of Q4 2014, DARUNAVIR ETHANOLATE remains US FDA's Preferred Term for this commodity. Darunavir ethanolate bears US NLM identifiers UMLS ID C1725651 and NCI Concept Code C77389. SMILES: CCO.CC(C)CN(C[C@H]([C@H](CC1CCCCC1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4CCC(CC4)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.
This classification denotes an endothelin receptor antagonist and antihypertensive agent with the molecular formula C22H22N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33JD57L6RW, chemically known as benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (s)- but generally known as darusentan, which bears US NIH Compound Identifier 177236. European Medicines Agency schedules Darusentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32910. The term DARUSENTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule darusentan under HS 29335995 and SITC 51576. As of Q4 2014, DARUSENTAN remains the US FDA Preferred Term for this commodity. Darusentan bears US NLM identifiers UMLS ID C0665087 and NCI Concept Code C75991. SMILES: O(C(C(Oc1nc(OC)cc(OC)n1)C(=O)O)(c1ccccc1)c1ccccc1)C.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H26ClN7O2S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RBZ1571X5H, chemically known as 5-thiazolecarboxamide, n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)- but generally known as dasatinib, which bears US NIH Compound Identifier 3062316. European Medicines Agency schedules Dasatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23322. World Health Organization schedules dasatinib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule dasatinib under HS 29341000 and SITC 51579. As of Q4 2014, DASATINIB remains the US FDA Preferred Term for this commodity. Dasatinib bears US NLM identifiers UMLS ID C1455147 and NCI Concept Code C38713. SMILES: CLC1C(NC(=O)C2SC(NC3NC(NC(N4CCN(CC4)CCO)C3)C)NC2)C(CCC1)C.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H26ClN7O2S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RBZ1571X5H, chemically known as 5-thiazolecarboxamide, n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)- but more generally known as dasatinib, which bears US NIH Compound Identifier 3062316. European Medicines Agency schedules Dasatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23322. World Health Organization schedules dasatinib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule dasatinib hydrate under HS 29341000. SMILES: CC1CCCC(C1NC(=O)C2CNC(S2)NC3CC(NC(N3)C)N4CCN(CC4)CCO)CL.O.
This classification denotes an intercalating agent with the molecular formula C23H28N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L374Y6WE0D, chemically known as 2-(2-(diethylamino)ethyl)-9-hydroxy-5,11-dimethyl-6h-pyrido(4,3-b)carbazolium but generally known as datelliptium, which bears US NIH Compound Identifier 72035. European Medicines Agency schedules Datelliptium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06916MIG. The term DATELLIPTIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). As of Q4 2014, DATELLIPTIUM remains the US FDA Preferred Term for this commodity. Datelliptium bears US NLM identifiers UMLS ID C0057571 and NCI Concept Code C83649. SMILES: CCN(CC)CC[N+]1=CC2=C(C=C1)C(=C3C(=C2C)C4=C(N3)C=CC(=C4)O)C.
This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZS7284E0ZP, chemically known as 5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s-cis)- but generally known as daunorubicin, which bears US NIH Compound Identifier 30323. European Medicines Agency schedules Daunorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06917MIG. The term DAUNORUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules daunorubicin in its Anatomical Therapeutic Chemical (ATC) Classification. DAUNORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule daunorubicin under HS 29419000 and SITC 54139. As of Q4 2014, DAUNORUBICIN remains the US FDA Preferred Term for this commodity. Daunorubicin bears US NLM identifiers UMLS ID C0011015 and NCI Concept Code C62091. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)C)C1OC(C(O)C(N)C1)C.
This classification denotes an anthracycline antibiotic with the molecular formula C21H18O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FN5680X78X, chemically known as 5,12-naphthacenedione, 8-acetyl-7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-1-methoxy-, (8s,10s)-, but more generally known as daunorubicin aglycone, which bears US NIH Compound Identifier 83843. European Medicines Agency schedules daunorubicin aglycone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06917MIG. Most nations, for tariff purposes, schedule daunorubicin aglycone under HS 29419000. SMILES: CC(=O)[C@@]1(CC2C(C(C3C(C2O)C(=O)C4CCCC(C4C3=O)OC)O)[C@H](C1)O)O.
This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5L84T2Z6NP. European Medicines Agency schedules daunorubicin citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22734. The term daunorubicin citrate is a U.S. FDA designation. Most nations schedule daunorubicin citrate under HS 29419000 and SITC 54139. As of Q4 2014, DAUNORUBICIN CITRATE remains the US FDA Preferred Term for this commodity. Daunorubicin citrate bears US NLM identifiers UMLS ID C1289972 and NCI Concept Code C47471. SMILES: CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)C)O)N)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UD984I04LZ, chemically known as 5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, radical ion(1-), (8s,10s)- but generally known as daunorubicin hydrochloride, which bears US NIH Compound Identifier 2958. European Medicines Agency schedules Daunorubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01556MIG. Most nations schedule daunorubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, DAUNORUBICIN HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Daunorubicin hydrochloride bears US NLM identifiers UMLS ID C0701062 and NCI Concept Code C1583. SMILES: O(C1CC(O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)c(OC)ccc2)C(=O)C)C1OC(C(O)C(N)C1)C.
This classification denotes an antidepressant agent with the molecular formula C15H14CLN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9U27285V5R chemically known as 2-pyridinemethanol, .alpha.-(4-chlorophenyl)-.alpha.-(4,5-dihydro-1h-imidazol-2-yl)- but generally known as dazadrol, which bears US NIH Compound Identifier 32940. European Medicines Agency schedules Dazadrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06918MIG. The term DAZADROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13. ). Most nations schedule dazadrol under HS 29333999 and SITC 51574. As of Q4 2014, DAZADROL remains the US FDA Preferred Term for this commodity. Dazadrol bears US NLM identifiers UMLS ID C2827129 and NCI Concept Code C83654. SMILES: C1CN=C(N1)C(C2=CC=C(C=C2)Cl)(C3=CC=CC=N3)O.
This classification denotes an antidepressant agent with the molecular formula C15H14ClN3O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T87PS4H85N, chemically known as 2-pyridinemethanol, alpha-(p-chlorophenyl)-alpha-2-imidazolin-2-yl-, maleate but more generally known as dazadrol maleate, which bears US NIH Compound Identifier 6433894. Most nations, for tariff and trade purposes, schedule dazadrol maleate under HS 29333999 and SITC 51574. As of Q4 2014, DAZADROL MALEATE remains US FDA's Preferred Term for this commodity. Dazadrol maleate bears US NLM identifiers UMLS ID C2827130 and NCI Concept Code C83655. SMILES: C1CCNC(C1)C(C2CCC(CC2)CL)(C3=NCCN3)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antiarrhythmic agent with the molecular formula C17H24ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 92KE01WH2P, chemically known as 8-chloro-3,4,5,6-tetrahydro-6-((1-isopropyl-2-imidazolin-2-yl)methyl)-2h-1,6-benzothiazocine but more generally known as dazolicine, which bears US NIH Compound Identifier 68810. European Medicines Agency schedules Dazolicine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06922MIG. The term DAZOLICINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). DAZOLICINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dazolicine under HS 29349990 and SITC 51579. As of Q4 2014, DAZOLICINE remains US FDA's Preferred Term for this commodity. Dazolicine bears US NLM identifiers UMLS ID C0612580 and NCI Concept Code C75128. SMILES: CLC1CC2N(CC3=NCCN3C(C)C)CCCCSC2CC1.
This classification denotes an anti-asthmatic agent with the molecular formula C11H7N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A16F9MIN3Z, chemically known as imidazo(1,2-a)quinoxaline-2-carboxylic acid but generally known as dazoquinast, which bears US NIH Compound Identifier 71146. European Medicines Agency schedules Dazoquinast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06924MIG. The term DAZOQUINAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). DAZOQUINAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dazoquinast under HS 29339990 and SITC 51577. As of Q4 2014, DAZOQUINAST remains the US FDA Preferred Term for this commodity. Dazoquinast bears US NLM identifiers UMLS ID C2699564 and NCI Concept Code C75138. SMILES: C1=CC=C2C(=C1)N=CC3=NC(=CN23)C(=O)O.
This classification denotes an oxytocin analog, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2N9HM3X95F. European Medicines Agency schedules Demoxytocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06971MIG. Demoxytocin generally arises in the molecular formula C43H65N11O12S2. The term DEMOXYTOCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) DEMOXYTOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Deaminooxytocin or demoxytocin bears US NLM identifiers UMLS ID C0057218 and NCI Concept Code C96860. SMILES: CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N.
This classification denotes an antidepressant agent with the molecular formula C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2N6K9DRA24, chemically known as 2-(n,n-dimethylamino)ethanol but more generally known as deanol, which bears US NIH Compound Identifier 7902. European Medicines Agency schedules Deanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13534MIG. World Health Organization schedules deanol in its Anatomical Therapeutic Chemical (ATC) Classification. DEANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DEANOL remains US FDA's Preferred Term for this commodity. Deanol bears US NLM identifiers UMLS ID C0011064 and NCI Concept Code C72733. SMILES: OCCN(C)C.
This classification denotes a cns stimulant with the molecular formula C7H11NO5.C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2PP737Z523, chemically known as glutamic acid, n-acetyl-, compd. with 2-(dimethylamino)ethanol (1:1), l- but more generally known as deanol aceglumate, which bears US NIH Compound Identifier 71125. European Medicines Agency schedules Deanol aceglumate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06926MIG. The term DEANOL ACEGLUMATE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule deanol aceglumate under HS 29241900 and SITC 51471. As of Q4 2014, DEANOL ACEGLUMATE remains US FDA's Preferred Term for this commodity. Deanol aceglumate bears US NLM identifiers UMLS ID C2699566 and NCI Concept Code C76620. SMILES: CC(=O)N[C@@H](CCC(=O)O)C(=O)O.CN(C)CCO.
This classification denotes an anti-ulcer agent with the molecular formula C12H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QJH0XA6AW9, chemically known as 1h-indole-3-acetamide, n-hydroxy-5-methoxy-2-methyl- but generally known as deboxamet, which bears US NIH Compound Identifier 36660. European Medicines Agency schedules Deboxamet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06927MIG. The term DEBOXAMET is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). DEBOXAMET is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule deboxamet under HS 29339990 and SITC 51577. As of Q4 2014, DEBOXAMET remains the US FDA Preferred Term for this commodity. Deboxamet bears US NLM identifiers UMLS ID C0636219 and NCI Concept Code C76483. SMILES: CC1=C(C2=C(N1)C=CC(=C2)OC)CC(=O)NO.
This classification denotes an adrenergic agent, antihypertensive agent, and sympatholytic with the molecular formula C10H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X31CDK040E, chemically known as 1,2,3, 4-tetrahydro-isoquinoline-2-carboxamidine sulfate but generally known as debrisoquine, which bears US NIH Compound Identifier 2966. European Medicines Agency schedules Debrisoquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06928MIG. World Health Organization schedules debrisoquine in its Anatomical Therapeutic Chemical (ATC) Classification. DEBRISOQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule debrisoquine under HS 29334990 and SITC 51575. SMILES: C1CN(CC2=CC=CC=C21)C(=N)N.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula 2C10H13N3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q94064N9NW, chemically known as 1,2,3, 4-tetrahydro-isoquinoline-2-carboxamidine sulfate but more generally known as debrisoquin sulfate, which bears US NIH Compound Identifier 2966. European Medicines Agency schedules Debrisoquine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01567MIG. Most nations, for tariff and trade purposes, schedule debrisoquine sulfate under HS 29334990 and SITC 51575. SMILES: C1CCC2C(C1)CCN(C2)C(=N)N.C1CCC2C(C1)CCN(C2)C(=N)N.OS(=O)(=O)O.
This classification denotes a muscle relaxant with the molecular formula C16H38N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C1CG1S3T2W, chemically known as 1,10-decanediaminium, n,n,n,n',n',n'-hexamethyl but generally known as decamethonium bromide, which bears US NIH Compound Identifier 2968. European Medicines Agency schedules Decamethonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01568MIG. The term DECAMETHONIUM is an International Non-Proprietary Name. As of Q4 2014, DECAMETHONIUM remains the US FDA Preferred Term for this commodity. Decamethonium bears US NLM identifiers UMLS ID C0057231 and NCI Concept Code C77363. SMILES: C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C.
This classification denotes a muscle relaxant with the molecular formula C16H38N2.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 55C6RK944K, chemically known as 1,10-decanediaminium, n,n,n,n,n,n-hexamethyl-, monobromide but more generally known as decamethonium bromide, which bears US NIH Compound Identifier 2968. European Medicines Agency schedules Decamethonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06930MIG. The term DECAMETHONIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule decamethonium bromide under HS 29239000 and SITC 51481. As of Q4 2014, DECAMETHONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Decamethonium bromide bears US NLM identifiers UMLS ID C0112701 and NCI Concept Code C65365. SMILES: C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C.[BR-].[BR-].
This classification denotes an insecticide, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JTS8R821G, generally arising with the molecular formula C22H19Br2NO3, chemically known as [(S)-cyano-(3-phenoxyphenyl)methyl](1R,3R)-3-(2,2-dibromoethenyl)-2,2-dimethylcyclopropane-1-carboxylate but generally known as Decamethrin or deltamethrin, which bears US NIH Compound Identifier 40585. European Medicines Agency schedules Decamethrin or deltamethrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13539MIG. Decamethrin or deltamethrin bears US NLM identifiers UMLS ID C0057233 and NCI Concept Code C83658. SMILES: CC1(C(C1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C.
This classification denotes an anticonvulsant agent with the molecular formula C19H31NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GAF9GJ18J5, chemically known as 4-n-decyloxy-3,5-dimethoxybenzoic acid amide but generally known as decimemide, which bears US NIH Compound Identifier 26929. European Medicines Agency schedules Decimemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06931MIG. The term DECIMEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). DECIMEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule decimemide under HS 29242995 and SITC 51479. As of Q4 2014, DECIMEMIDE remains the US FDA Preferred Term for this commodity. Decimemide bears US NLM identifiers UMLS ID C2699569 and NCI Concept Code C75162. SMILES: O(CCCCCCCCCC)C1C(OC)CC(CC1OC)C(=O)N.
This classification denotes a fbxw4 gene with the molecular formula C8H12N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 776B62CQ27, chemically known as 1,3,5-triazin-2(1h)-one, 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)- but generally known as decitabine, which bears US NIH Compound Identifier 16886. European Medicines Agency schedules Decitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06932MIG. The term DECITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules decitabine in its Anatomical Therapeutic Chemical (ATC) Classification. DECITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule decitabine under HS 29349990 and SITC 51579. As of Q4 2014, DECITABINE remains the US FDA Preferred Term for this commodity. Decitabine bears US NLM identifiers UMLS ID C0049065 and NCI Concept Code C981. SMILES: O1C(C(O)CC1N1C(=O)NC(NC1)N)CO.
This classification denotes a quinolone antibiotic with the molecular formula C24H35NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 534I52PVWH, chemically known as 3-quinolinecarboxylic acid, 6-(decyloxy)-7-ethoxy-4-hydroxy-, ethyl ester but more generally known as decoquinate, which bears US NIH Compound Identifier 29112. European Medicines Agency schedules Decoquinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06938MIG. The term DECOQUINATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). DECOQUINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(CCCCCCCCCC)C1C(OCC)CC2[NH]CC(C(=O)C2C1)C(=O)OCC.
This classification denotes a protective agent with the molecular formula C18H37N.FH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3B1Y93C1S, chemically known as 9-octadecen-1-amine, hydrofluoride but more generally known as dectaflur, which bears US NIH Compound Identifier 6436136. European Medicines Agency schedules Dectaflur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06939MIG. The term DECTAFLUR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). DECTAFLUR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCCCCCCCC=CCCCCCCCCN.F.
This classification denotes a metal chelator with the molecular formula C21H15N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V8G4MOF2V9, chemically known as 4-(3,5-bis-(hydroxy-phenyl)-1,2,4)triazol-1-yl)-benzoic acid but generally known as deferasirox, which bears US NIH Compound Identifier 5493381. European Medicines Agency schedules Deferasirox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21981. The term DEFERASIROX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3, 2002, List 48). World Health Organization schedules deferasirox in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule deferasirox under HS 29339990 and SITC 51577. As of Q4 2014, DEFERASIROX remains the US FDA Preferred Term for this commodity. Deferasirox bears US NLM identifiers UMLS ID C1619629 and NCI Concept Code C48384. SMILES: O=C1/C(=C2/N([NH]/C(=C3\C(=O)C=CC=C3)[NH]2)C2CCC(CC2)C(=O)O)C=CC=C1.
This classification denotes a cancer tnm vessel invasion finding category with the molecular formula C7H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BTY8KH53L, chemically known as 1,2-dimethyl-3-hydroxypyrid-4-one but generally known as deferiprone, which bears US NIH Compound Identifier 2972. European Medicines Agency schedules Deferiprone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06941MIG. The term DEFERIPRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules deferiprone in its Anatomical Therapeutic Chemical (ATC) Classification. DEFERIPRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule deferiprone under HS 29333999 and SITC 51574. As of Q4 2014, DEFERIPRONE remains the US FDA Preferred Term for this commodity. Deferiprone bears US NLM identifiers UMLS ID C0043832 and NCI Concept Code C73030. SMILES: OC1C(N(CCC1=O)C)C.
This classification denotes a metal chelator with the molecular formula C25H48N6O8, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier J06Y7MXW4D, chemically known as 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy- but more generally known as deferoxamine, which bears U.S. National Institutes of Health Compound Identifier 2973. European Medicines Agency schedules Deferoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06942MIG. World Health Organization schedules deferoxamine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. DEFEROXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an immunosuppessant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 438HCF2X0M, chemically known as sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from bovine lung dna. European Medicines Agency schedules defibrotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01572MIG. Most nations, for tariff and trade purposes, schedule Defibrotide under HS 30012090 and SITC 54162. SMILES:. Defibrotide bears US NLM identifiers UMLS ID C0057257 and NCI Concept Code C1064.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H31NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KR5YZ6AE4B, chemically known as 11beta,21-dihydroxy-2-methyl-5betah-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate but generally known as deflazacort, which bears US NIH Compound Identifier 26709. European Medicines Agency schedules Deflazacort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06943MIG. The term DEFLAZACORT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules deflazacort in its Anatomical Therapeutic Chemical (ATC) Classification. DEFLAZACORT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule deflazacort under HS 29372900 and SITC 54153. As of Q4 2014, DEFLAZACORT remains the US FDA Preferred Term for this commodity. Deflazacort bears US NLM identifiers UMLS ID C0057258 and NCI Concept Code C87230. SMILES: O1C2C(N=C1C)(C1(C(C3C(C(O)C1)C1(C(=CC(=O)C=C1)CC3)C)C2)C)C(=O)COC(=O)C.
This classification denotes a nitrogen mustard compound with the molecular formula C9H20Cl3N2O3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0W33021S30, chemically known as phosphorodiamidic acid, n,n-bis(2-chloroethyl)-n-(3-hydroxypropyl)-, (2-chloroethyl) ester but more generally known as defosfamide, which bears US NIH Compound Identifier 71164. European Medicines Agency schedules Defosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06944MIG. The term DEFOSFAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). DEFOSFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule defosfamide under HS 29299000 and SITC 51489. As of Q4 2014, DEFOSFAMIDE remains US FDA's Preferred Term for this commodity. Defosfamide bears US NLM identifiers UMLS ID C1511757 and NCI Concept Code C2069. SMILES: CLCCN(P(=O)(OCCCL)NCCCO)CCCL.
This classification denotes a gonadotropin releasing hormone inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SX0XJI3A11. European Medicines Agency schedules Degarelix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27748. Degarelix generally arises in the molecular formula C82H103CLN18O16. The term DEGARELIX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3, 2002, list 48.) Most nations schedule degarelix under HS 29371900 and SITC 54154. As of Q4 2014, DEGARELIX remains the US FDA Preferred Term for this commodity. Degarelix bears US NLM identifiers UMLS ID C0971731 and NCI Concept Code C48385. SMILES: CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C.
This classification denotes a fluid used to produce degeneration of nerve function (neurolysis) for control of chronic pain, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K9958V90M. European Medicines Agency schedules Alcohol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15995MIG. Dehydrated alcohol injection generally arises in the molecular formula C2H6O. The term 'dehydrated alcohol injection' is an FDA designation. SMILES: CCO.
This classification denotes a cholagogue or choleretic agent with the molecular formula C24H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NH5000009I, chemically known as cholan-24-oic acid, 3,7,12-trioxo-, (5.beta.)- but generally known as dehydrocholic acid, which bears US NIH Compound Identifier 2975. European Medicines Agency schedules Dehydrocholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06945MIG. The term DEHYDROCHOLIC ACID is an International Non-Proprietary Name. Most nations schedule dehydrocholic acid under HS 29183000 and SITC 51395. As of Q4 2014, DEHYDROCHOLIC ACID remains the US FDA Preferred Term for this commodity. Dehydrocholic acid bears US NLM identifiers UMLS ID C0011182 and NCI Concept Code C76605. SMILES: O=C1C2(C(C3C(C4(C(CC3=O)CC(=O)CC4)C)C1)CCC2C(CCC(=O)O)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes an antiprotozoal agent with the molecular formula C29H38N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7S79QT1T91, chemically known as 2,3-didehydroemetine dihydrochloride (.+-.)- but generally known as dehydroemetine, which bears US NIH Compound Identifier 17558. European Medicines Agency schedules Dehydroemetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06946MIG. The term DEHYDROEMETINE is an International Non-Proprietary Name. DEHYDROEMETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dehydroemetine under HS 29399900 and SITC 54149. As of Q4 2014, DEHYDROEMETINE remains the US FDA Preferred Term for this commodity. Dehydroemetine bears US NLM identifiers UMLS ID C0011184 and NCI Concept Code C418. SMILES: O(C1CC2C3N(CC(=C(C3)CC3NCCC4C3CC(OC)C(OC)C4)CC)CCC2CC1OC)C.
Delamanid (USAN, INN) is a drug for the treatment of multi-drug-resistant tuberculosis. It works by blocking the synthesis of mycolic acids in Mycobacterium tuberculosis, the organism which causes tuberculosis, thus destabilising its cell wall. The drug is approved in the EU under the trade name Deltyba (made by Otsuka Pharmaceutical).
This classification denotes an ace inhibitor with the molecular formula C26H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W77UAL9THI, chemically known as glycine, n-(2,3-dihydro-1h-inden-2-yl)-n-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-, (s)- but generally known as delapril, which bears US NIH Compound Identifier 5362116. European Medicines Agency schedules Delapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06948MIG. The term DELAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules delapril in its Anatomical Therapeutic Chemical (ATC) Classification. DELAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule delapril under HS 29242995 and SITC 51479. As of Q4 2014, DELAPRIL remains the US FDA Preferred Term for this commodity. Delapril bears US NLM identifiers UMLS ID C0057301 and NCI Concept Code C75022. SMILES: O=C(N(C1Cc2c(C1)cccc2)CC(=O)O)C(NC(CCc1ccccc1)C(=O)OCC)C.
This classification denotes an ace inhibitor with the molecular formula C26H32N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2SMM3M5ZMH, chemically known as glycine, n-(2,3-dihydro-1h-inden-2-yl)-n-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-, monohydrochloride, (s)- but more generally known as delapril hydrochloride, which bears US NIH Compound Identifier 5362115. European Medicines Agency schedules Delapril hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01574MIG. Most nations, for tariff and trade purposes, schedule delapril hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, DELAPRIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Delapril hydrochloride bears US NLM identifiers UMLS ID C2348090 and NCI Concept Code C72734. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3CCCCC3C2.CL.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C22H28N6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DOL5F9JD3E, chemically known as piperazine, 1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1h-indol-2-yl)carbonyl)- but generally known as delavirdine, which bears US NIH Compound Identifier 5625. European Medicines Agency schedules Delavirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06949MIG. The term DELAVIRDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules delavirdine in its Anatomical Therapeutic Chemical (ATC) Classification. DELAVIRDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule delavirdine under HS 29350090 and SITC 51580. As of Q4 2014, DELAVIRDINE remains the US FDA Preferred Term for this commodity. Delavirdine bears US NLM identifiers UMLS ID C0288165 and NCI Concept Code C65366. SMILES: S(=O)(=O)(NC1CC2CC([NH]C2CC1)C(=O)N1CCN(CC1)C1NCCCC1NC(C)C)C.
This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 421105KRQE. European Medicines Agency schedules Delavirdine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01575MIG. Delavirdine mesylate generally arises in the molecular formula C22H28N6O3S.CH4O3S. The term 'delavirdine mesylate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule delavirdine mesylate under HS 29350090 and SITC 51580. As of Q4 2014, DELAVIRDINE MESYLATE remains US FDA's Preferred Term for this commodity. Delavirdine mesylate bears US NLM identifiers UMLS ID C0543492 and NCI Concept Code C28974. SMILES: CC(C)NC1CCCNC1N2CCN(CC2)C(=O)C3CC4CC(CCC4[NH]3)NS(=O)(=O)C.CS(=O)(=O)O.
This classification denotes an antidepressant agent with the molecular formula C18H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06YTS68E0H, chemically known as 1-(alpha,alpha-phenyl-2,5-xylyl)pi-perazine. but generally known as delfaprazine, which bears US NIH Compound Identifier 205972. European Medicines Agency schedules Delfaprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06953MIG. The term DELFAPRAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). DELFAPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule delfaprazine under HS 29335995 and SITC 51576. As of Q4 2014, DELFAPRAZINE remains the US FDA Preferred Term for this commodity. Delfaprazine bears US NLM identifiers UMLS ID C2699580 and NCI Concept Code C75169. SMILES: N1(CCNCC1)c1c(Cc2ccccc2)ccc(c1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I9Q51XHI1K, chemically known as 1h-indole-3-acetic acid, 1-benzoyl-2-methyl- (9ci) but generally known as delmetacin, which bears US NIH Compound Identifier 27860. European Medicines Agency schedules Delmetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06955MIG. The term DELMETACIN is an International Non-Proprietary Name. DELMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule delmetacin under HS 29339990 and SITC 51577. As of Q4 2014, DELMETACIN remains the US FDA Preferred Term for this commodity. Delmetacin bears US NLM identifiers UMLS ID C0618634 and NCI Concept Code C76801. SMILES: O=C(N1C(C(C2C1CCCC2)CC(=O)O)C)C1CCCCC1.
This classification denotes a surface-active agent with the molecular formula C16H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) DT67WL708F, chemically known as 4-morpholineethanol, 3-(4-propylheptyl)-, ( -)- but more generally known as delmopinol, which bears U.S. National Institutes of Health Compound Identifier 57337. European Medicines Agency schedules Delmopinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06956MIG. The term DELMOPINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). DELMOPINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule delmopinol under HS 29349990 and SITC 51579. As of Q4 2014, DELMOPINOL remains the US FDA Preferred Term for this commodity. Delmopinol bears US NLM identifiers UMLS ID C0166532 and NCI Concept Code C78112. SMILES: O1CC(N(CC1)CCO)CCCC(CCC)CCC.
This classfication denotes a surface-active agent with the molecular formula C16H33NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SRE423V9Z9, chemically known as 4-morpholineethanol, 3-(4-propylheptyl)-, hydrochloride (1:1), but more generally known as delmopinol hydrochloride, which bears U.S. National Institutes of Health Compound Identifier 57337. European Medicines Agency schedules delmopinol hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06956MIG. Most nations, for tariff purposes, schedule delmopinol hydrochloride under HS 29349990. SMILES: CCCC(CCC)CCCC1COCCN1CCO.CL.
This classification denotes a mucolytic agent with the molecular formula C13H17Br2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F61F502T5, chemically known as 4,6-dibromo-alpha-(trans-4-hydroxycyclohexylamino)-o-cresol but generally known as dembrexine, which bears US NIH Compound Identifier 72009. European Medicines Agency schedules Dembrexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06961MIG. The term DEMBREXINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). DEMBREXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dembrexine under HS 29225000 and SITC 51467. As of Q4 2014, DEMBREXINE remains the US FDA Preferred Term for this commodity. Dembrexine bears US NLM identifiers UMLS ID C0057360 and NCI Concept Code C78114. SMILES: Brc1c(O)c(CNC2CCC(O)CC2)cc(Br)c1.
This classification denotes an anti-glaucoma agent and acetylcholinesterase inhibitor with the molecular formula C32H52N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61D5V4OKTP, chemically known as n,n-bis(3-trimethylammoniumphenoxycarbonyl)-n,n-dimethyldecamethylenediamine dibromide but generally known as demecarium bromide, which bears US NIH Compound Identifier 5965. European Medicines Agency schedules Demecarium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06962MIG. The term DEMECARIUM BROMIDE is an International Non-Proprietary Name. As of Q4 2014, DEMECARIUM remains the US FDA Preferred Term for this commodity. Demecarium bears US NLM identifiers UMLS ID C0360174 and NCI Concept Code C87481. SMILES: BR.BR.O(C1CC([N](C)(C)C)CCC1)C(=O)N(CCCCCCCCCCN(C(=O)OC1CC([N](C)(C)C)CCC1)C)C.
This classification denotes an anti-glaucoma agent and acetylcholinesterase inhibitor with the molecular formula C32H52N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61D5V4OKTP, chemically known as n,n-bis(3-trimethylammoniumphenoxycarbonyl)-n,n-dimethyldecamethylenediamine dibromide but more generally known as demecarium bromide, which bears US NIH Compound Identifier 5965. European Medicines Agency schedules Demecarium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06962MIG. The term DEMECARIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule demecarium bromide under HS 29242995 and SITC 51479. As of Q4 2014, DEMECARIUM BROMIDE remains US FDA's Preferred Term for this commodity. Demecarium bromide bears US NLM identifiers UMLS ID C0057361 and NCI Concept Code C65367. SMILES: CN(CCCCCCCCCCN(C)C(=O)OC1CCCC(C1)[N+](C)(C)C)C(=O)OC2CCCC(C2)[N+](C)(C)C.[BR-].[BR-].
This classification denotes a tetracycline antibiotic with the molecular formula C21H21ClN2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5R5W9ICI6O, chemically known as 7-chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide but generally known as demeclocycline, which bears US NIH Compound Identifier 5281009. European Medicines Agency schedules Demeclocycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06963MIG. The term DEMECLOCYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules demeclocycline in its Anatomical Therapeutic Chemical (ATC) Classification. DEMECLOCYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule demeclocycline under HS 29413000 and SITC 54133. As of Q4 2014, DEMECLOCYCLINE remains the US FDA Preferred Term for this commodity. Demeclocycline bears US NLM identifiers UMLS ID C0011276 and NCI Concept Code C47980. SMILES: CLC1C2C(O)C3CC4C(O)(C(=O)C3=C(O)C2C(O)CC1)C(=O)/C(=C(\O)N)C(=O)C4N(C)C.
This classification denotes a tetracycline antibiotic 2C21H20ClN2O8.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SD6S4YY5HP, chemically known as 2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, calcium salt (2:1), (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, but more generally known as demeclocycline calcium, which bears US NIH Compound Identifier 72941516. Most nations, for tariff and trade purposes, schedule demeclocycline calcium under HS 29413000 and SITC 54133. As of Q4 2014, DEMECLOCYCLINE CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4C(CCC(C4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)[O-])CL)O.CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4C(CCC(C4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)[O-])CL)O.[CA+2].
This classification denotes a tetracycline antibiotic with the molecular formula C21H21ClN2O8.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29O079NTYT, chemically known as 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride but more generally known as demeclocycline hydrochloride, which bears US NIH Compound Identifier 5281008. European Medicines Agency schedules Demeclocycline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01578MIG. Most nations, for tariff and trade purposes, schedule demeclocycline hydrochloride under HS 29413000 and SITC 54133. As of Q4 2014, DEMECLOCYCLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Demeclocycline hydrochloride bears US NLM identifiers UMLS ID C0701198 and NCI Concept Code C28975. SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4C(CCC(C4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)O)CL)O.CL.
This classification denotes a colchicine-site binding agent with the molecular formula C21H25NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z01IVE25KI, chemically known as 6,7-dihydro-1,2,3,10-tetramethoxy-7-(methylamino)-benzo(alpha)heptalen-9(5h)-one but generally known as demecolcine, which bears US NIH Compound Identifier 2832. European Medicines Agency schedules Demecolcine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06964MIG. The term DEMECOLCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules demecolcine in its Anatomical Therapeutic Chemical (ATC) Classification. DEMECOLCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule demecolcine under HS 29399900 and SITC 54149. As of Q4 2014, DEMECOLCINE remains the US FDA Preferred Term for this commodity. Demecolcine bears US NLM identifiers UMLS ID C0011259 and NCI Concept Code C419. SMILES: O(C1C2C(CCC(NC)C3C2CCC(OC)C(=O)C3)CC(OC)C1OC)C.
This classification denotes a tetracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TV240CH11P. European Medicines Agency schedules Demecycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06965MIG. Demecycline generally arises in the molecular formula C21H22N2O8. The term DEMECYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) DEMECYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule demecycline under HS 29413000 and SITC 54133. As of Q4 2014, DEMECYCLINE remains the US FDA Preferred Term for this commodity. Demecycline bears US NLM identifiers UMLS ID C2699585 and NCI Concept Code C76237. SMILES: OC12C(CC3C(=C(O)C4C(C3O)CCCC4O)C1=O)C(N(C)C)C(=O)C(=C(\O)N)/C2=O.
This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6E89AM91SZ, chemically known as 19-norpregna-4,9-diene-3,20-dione, 17-methyl- (8ci)(9ci) but generally known as demegestone, which bears US NIH Compound Identifier 93057. European Medicines Agency schedules Demegestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06966MIG. The term DEMEGESTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules demegestone in its Anatomical Therapeutic Chemical (ATC) Classification. DEMEGESTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule demegestone under HS 29372300 and SITC 54153. As of Q4 2014, DEMEGESTONE remains the US FDA Preferred Term for this commodity. Demegestone bears US NLM identifiers UMLS ID C0057362 and NCI Concept Code C76304. SMILES: O=C(C1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)CC2)CC1)C)C)C.
This classification denotes an antifungal agent with the molecular formula C19H15Cl3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z4E7E087J, chemically known as (e)-1-(2,4-dichloro-beta-(2-(p-chlorophenoxy)ethoxy)styryl)imidazole but generally known as democonazole, which bears US NIH Compound Identifier 3033986. European Medicines Agency schedules Democonazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06969MIG. The term DEMOCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). DEMOCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule democonazole under HS 29332990 and SITC 51573. As of Q4 2014, DEMOCONAZOLE remains the US FDA Preferred Term for this commodity. Democonazole bears US NLM identifiers UMLS ID C0629429 and NCI Concept Code C78038. SMILES: CLC1C(C(=C\N2CCNC2)/OCCOC2CCC(CL)CC2)CCC(CL)C1.
This classification denotes an anticholinergic agent with the molecular formula C24H33NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2AFK8FCD4R, chemically known as benzeneacetic acid, alpha-(2-ethylbutoxy)-alpha-phenyl-, 2-(dimethylamino)ethyl ester, hcl but more generally known as denaverine hydrochloride, which bears US NIH Compound Identifier 18726. European Medicines Agency schedules Denaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01583MIG. Most nations, for tariff and trade purposes, schedule denaverine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, DENAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Denaverine hydrochloride bears US NLM NCI C97976. SMILES: CCC(CC)COC(C1CCCCC1)(C2CCCCC2)C(=O)OCCN(C)C.CL.
This classification denotes an anticholinergic agent with the molecular formulas C24H33NO3 and C24H33NO3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers O14NF38MTL and 2AFK8FCD4R. European Medicines Agency schedules Denaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06973MIG. The term DENAVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) DENAVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule denaverine and its salts under HS 29221980 and SITC 51461. As of Q4 2014, DENAVERINE remains the US FDA Preferred Term for this commodity. Denaverine bears US NLM NCI C77988 and C97976. SMILES: O(CC(CC)CC)C(C1CCCCC1)(C1CCCCC1)C(=O)OCCN(C)C (base) or CCC(CC)COC(C1CCCCC1)(C2CCCCC2)C(=O)OCCN(C)C.CL (hydrochloride).
This classification denotes a phosphodiesterase inhibitor with the molecular formula C16H24N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04B949KO6F, chemically known as 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-1h-purine-2,6-dione but generally known as denbufylline, which bears US NIH Compound Identifier 2984. European Medicines Agency schedules Denbufylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06974MIG. The term DENBUFYLLINE is an International Non-Proprietary Name. DENBUFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule denbufylline under HS 29395900 and SITC 54145. As of Q4 2014, DENBUFYLLINE remains the US FDA Preferred Term for this commodity. Denbufylline bears US NLM identifiers UMLS ID C0057384 and NCI Concept Code C76316. SMILES: O=C1N(C2NCN(C2C(=O)N1CCCC)CC(=O)C)CCCC.
This classification denotes an immunotoxin and fusion toxin with the molecular formula C2560H4042N678O799S17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25E79B5CTM, more generally known as denileukin diftitox. European Medicines Agency schedules denileukin diftitox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06975MIG. The term DENILEUKIN DIFTITOX is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 2 1999, list 40. As of Q4 2014, DENILEUKIN DIFTITOX remains the US FDA Preferred Term for this commodity.
This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T5IBT2ZQS3. European Medicines Agency schedules Denipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06976MIG. Denipride generally arises in the molecular formula C18H26N4O5. The term DENIPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) DENIPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule denipride under HS 29349990 and SITC 51579. As of Q4 2014, DENIPRIDE remains the US FDA Preferred Term for this commodity. Denipride bears US NLM identifiers UMLS ID C2699588 and NCI Concept Code C78027. SMILES: O1C(CN2CCC(NC(=O)C3C(OC)CC(N)C([N](=O)O)C3)CC2)CCC1.
This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V5F60UPD8P, chemically known as (-)-(r)-alpha-(((3,4-dimethoxyphenethyl)amino)methyl)-p-hydroxybenzyl alcohol but generally known as denopamine, which bears US NIH Compound Identifier 71754. European Medicines Agency schedules Denopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06977MIG. The term DENOPAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). DENOPAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule denopamine under HS 29225000 and SITC 51467. As of Q4 2014, DENOPAMINE remains the US FDA Preferred Term for this commodity. Denopamine bears US NLM identifiers UMLS ID C0075749 and NCI Concept Code C77934. SMILES: OC(CNCCC1CC(OC)C(OC)CC1)C1CCC(O)CC1.
This classification denotes a monoclonal antibody with the molecular formula C6404H9912N1724O2004S50, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4EQZ6YO2HI, more generally known as denosumab. European Medicines Agency schedules denosumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29173. The term DENOSUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. Most nations schedule Denosumab under HS 30021020 and SITC 54163. SMILES:. As of Q4 2014, DENOSUMAB remains the US FDA Preferred Term for this commodity. . Denosumab bears US NLM identifiers UMLS ID C1690432 and NCI Concept Code C61313.
This classification denotes a muscle relaxant with the molecular formula C20H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7N3FX2T1J, chemically known as 3,6-pyridazinedione, 1,2-dihydro-4-butyl-5-hydroxy-1,2-diphenyl- but generally known as denpidazone, which bears US NIH Compound Identifier 206004. European Medicines Agency schedules Denpidazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06979MIG. The term DENPIDAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). DENPIDAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule denpidazone under HS 29339990 and SITC 51577. As of Q4 2014, DENPIDAZONE remains the US FDA Preferred Term for this commodity. Denpidazone bears US NLM identifiers UMLS ID C2699589 and NCI Concept Code C77599. SMILES: OC1N(N(C(=O)C(=O)C1CCCC)C1CCCCC1)C1CCCCC1.
This classification denotes an anticonvulsant agent with the molecular formula C19H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9C78O7JATH, chemically known as 1h-imidazole-1-ethanol, alpha-(4-(2-phenylethyl)phenyl)- but generally known as denzimol, which bears US NIH Compound Identifier 53626. European Medicines Agency schedules Denzimol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06980MIG. The term DENZIMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). DENZIMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule denzimol under HS 29332990 and SITC 51573. As of Q4 2014, DENZIMOL remains the US FDA Preferred Term for this commodity. Denzimol bears US NLM identifiers UMLS ID C0057398 and NCI Concept Code C78001. SMILES: OC(C1CCC(CCC2CCCCC2)CC1)CN1CCNC1.
This classification denotes a cholagogue or choleretic agent with the molecular formula C24H40O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 005990WHZZ, chemically known as 3,12-dihydroxycholan-24-oic acid but generally known as deoxycholic acid, which bears US NIH Compound Identifier 2987. European Medicines Agency schedules Deoxycholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13541MIG. The term DEOXYCHOLIC ACID is an International Non-Proprietary Name. Most nations schedule deoxycholic acid under HS 29181900 and SITC 51392. As of Q4 2014, DEOXYCHOLIC ACID remains the US FDA Preferred Term for this commodity. Deoxycholic acid bears US NLM identifiers UMLS ID C0011479 and NCI Concept Code C81042. SMILES: OC1C2(C(C3C(C4(C(CC3)CC(O)CC4)C)C1)CCC2C(CCC(=O)O)C)C.
This classification denotes an adenosine deaminase inhibitor with the molecular formula C11H16N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 395575MZO7, chemically known as (r)-3-(2-deoxy-beta-d-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol but generally known as pentostatin, which bears US NIH Compound Identifier 40926. European Medicines Agency schedules Pentostatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09704MIG. The term PENTOSTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules pentostatin in its Anatomical Therapeutic Chemical (ATC) Classification. PENTOSTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Deoxycoformycin or pentostatin bears US NLM identifiers UMLS ID C0030896 and NCI Concept Code C732. SMILES: C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40GP35YQ49, chemically known as 21-hydroxypregn-4-ene-3,20-dione but generally known as deoxycorticosterone, which bears US NIH Compound Identifier 6166. SMILES: CC12CCC3C(C1CCC2C(=O)CO)CCC4=CC(=O)CCC34C.
This classification denotes an antidepressant agent with the molecular formula C19H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77C3T28736, chemically known as 10,11-dehydroimipramine but generally known as depramine, which bears US NIH Compound Identifier 67534. European Medicines Agency schedules Depramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06981MIG. The term DEPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). DEPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule depramine under HS 29339930 and SITC 51577. As of Q4 2014, DEPRAMINE remains the US FDA Preferred Term for this commodity. Depramine bears US NLM identifiers UMLS ID C0044643 and NCI Concept Code C78014. SMILES: N1(CCCN(C)C)c2c(C=Cc3c1cccc3)cccc2.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, Z380L7N00P chemically known as 11.beta.,17-dihydroxypregna-1,4-diene-3,20-dione but generally known as deprodone, which bears US NIH Compound Identifier 89339. European Medicines Agency schedules Deprodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06982MIG. The term DEPRODONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28. ). Most nations schedule deprodone under HS 29372900 and SITC 54153. As of Q4 2014, DEPRODONE remains the US FDA Preferred Term for this commodity. Deprodone bears US NLM identifiers UMLS ID C2699591 and NCI Concept Code C77412. SMILES: CC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)O.
This classification denotes the propionate form of a therapeutic glucocorticoid with the molecular structure C21H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, Z380L7N00P chemically known as 11.beta.,17-dihydroxypregna-1,4-diene-3,20-dione, but more commonly known as deprodone, which bears US NIH Compound Identifier 89339. European Medicines Agency schedules Deprodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06982MIG. The term DEPRODONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 2, no. 3, 1988, list 28. ). Most nations, for tariff and trade purposes, schedule deprodone propionate under HS 29372900 and SITC 54153. As of Q4 2014, DEPRODONE PROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)C.
This classification denotes a tropane with the molecular formula C23H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AY31301GKG, chemically known as 8-azabicyclo(3.2.1)octane, 3-((10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yl)oxy)-8-methyl-, endo- but generally known as deptropine, which bears US NIH Compound Identifier 16576. European Medicines Agency schedules Deptropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06984MIG. World Health Organization schedules deptropine in its Anatomical Therapeutic Chemical (ATC) Classification. DEPTROPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1CC2N(C(CC2)C1)C)C1C2C(CCC3C1CCCC3)CCCC2.
This classification denotes a quinolone antibiotic with the molecular formula C30H40N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7QC7V26B8, chemically known as quinolinium, 1,1-(1,10-decanediyl)bis(4-amino-2-methyl- but generally known as dequalinium, which bears US NIH Compound Identifier 2993. European Medicines Agency schedules Dequalinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01590MIG. World Health Organization schedules dequalinium in its Anatomical Therapeutic Chemical (ATC) Classification. DEQUALINIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DEQUALINIUM remains the US FDA Preferred Term for this commodity. Dequalinium bears US NLM identifiers UMLS ID C0011588 and NCI Concept Code C83661. SMILES: [n]1(CCCCCCCCCC[n]2c3c(c(N)cc2C)cccc3)c2c(c(N)cc1C)cccc2.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H14F3N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VX29JB5XWV, chemically known as benzenesulfonamide, 4-(3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1h-pyrazol-1-yl)- but generally known as deracoxib, which bears US NIH Compound Identifier 3058754. European Medicines Agency schedules Deracoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01594MIG. The term DERACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule deracoxib under HS 29350090 and SITC 51580. As of Q4 2014, DERACOXIB remains the US FDA Preferred Term for this commodity. Deracoxib bears US NLM identifiers UMLS ID C1174840 and NCI Concept Code C73031. SMILES: S(=O)(=O)(N)C1CCC(N2NC(CC2C2CC(F)C(OC)CC2)C(F)F)CC1.
This classification denotes an antihelminthic agent with the molecular formula C24H30O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KV3495SGKS, chemically known as 3-((5-butyryl-2,4-dihydroxy-3,3-dimethyl-6-oxo-1,4-cyclohexadien-1-yl)methyl)-2,6-dihydroxy-4-methoxybutyrophenone but generally known as desaspidin, which bears US NIH Compound Identifier 8238. European Medicines Agency schedules Desaspidin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06989MIG. The term DESASPIDIN BB is an International Non-Proprietary Name. World Health Organization schedules desaspidin in its Anatomical Therapeutic Chemical (ATC) Classification. DESASPIDIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desaspidin under HS 29145000 and SITC 51629. As of Q4 2014, DESASPIDIN remains the US FDA Preferred Term for this commodity. Desaspidin bears US NLM identifiers UMLS ID C0057515 and NCI Concept Code C81515. SMILES: OC1=C(CC2C(O)C(C(O)CC2OC)C(=O)CCC)C(=C(C(=O)C1(C)C)C(=O)CCC)O.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C8H11N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BHM1XXA2EZ, chemically known as ethanol, 2-((2-amino-9h-purin-9-yl)methoxy)- but generally known as desciclovir, which bears US NIH Compound Identifier 55256. European Medicines Agency schedules Desciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06990MIG. The term DESCICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). DESCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desciclovir under HS 29335995 and SITC 51576. As of Q4 2014, DESCICLOVIR remains the US FDA Preferred Term for this commodity. Desciclovir bears US NLM identifiers UMLS ID C0113168 and NCI Concept Code C73203. SMILES: O(CN1C2NC(NCC2NC1)N)CCO.
This classification denotes an antihypertensive agent with the molecular formula C32H38N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9016E3VB47, chemically known as 3-beta,20-alpha-yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) but generally known as deserpidine, which bears US NIH Compound Identifier 8550. European Medicines Agency schedules Deserpidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06992MIG. The term DESERPIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules deserpidine in its Anatomical Therapeutic Chemical (ATC) Classification. DESERPIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule deserpidine under HS 29399900 and SITC 54149. As of Q4 2014, DESERPIDINE remains the US FDA Preferred Term for this commodity. Deserpidine bears US NLM identifiers UMLS ID C0175158 and NCI Concept Code C61699. SMILES: O(C1C(C2C(CN3C(C2)c2[nH]c4c(c2CC3)cccc4)CC1OC(=O)c1cc(OC)c(OC)c(OC)c1)C(=O)OC)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an anesthetic agent with the molecular formula C3H2F6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CRS35BZ94Q, chemically known as 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane but generally known as desflurane, which bears US NIH Compound Identifier 42113. European Medicines Agency schedules Desflurane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06993MIG. The term DESFLURANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules desflurane in its Anatomical Therapeutic Chemical (ATC) Classification. DESFLURANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desflurane under HS 29091990 and SITC 51616. As of Q4 2014, DESFLURANE remains the US FDA Preferred Term for this commodity. Desflurane bears US NLM identifiers UMLS ID C0063252 and NCI Concept Code C47472. SMILES: FC(OC(F)F)C(F)(F)F.
This classification denotes a tricyclic antidepressant with the molecular formula C18H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TG537D343B, chemically known as 10,11-dihydro-5-(3-methylaminopropyl)-5h-dibenz(b,f)azepine but generally known as desipramine, which bears US NIH Compound Identifier 2995. European Medicines Agency schedules Desipramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06995MIG. The term DESIPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules desipramine in its Anatomical Therapeutic Chemical (ATC) Classification. DESIPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desipramine under HS 29339990 and SITC 51577. As of Q4 2014, DESIPRAMINE remains the US FDA Preferred Term for this commodity. Desipramine bears US NLM identifiers UMLS ID C0011685 and NCI Concept Code C61700. SMILES: N1(c2c(CCc3c1cccc3)cccc2)CCCNC.
This classification denotes a tricyclic antidepressant with the molecular formula C18H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TG537D343B, chemically known as 10,11-dihydro-5-(3-methylaminopropyl)-5h-dibenz(b,f)azepine but generally known as desipramine, which bears US NIH Compound Identifier 2995. European Medicines Agency schedules Desipramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06995MIG. The term DESIPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules desipramine in its Anatomical Therapeutic Chemical (ATC) Classification. DESIPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desipramine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, DESIPRAMINE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Desipramine hydrochloride bears US NLM identifiers UMLS ID C0031232 and NCI Concept Code C28979. SMILES: N1(c2c(CCc3c1cccc3)cccc2)CCCNC.
This classification denotes a tricyclic antidepressant with the molecular formula C18H22N2.C2HF3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T6XJJ77M3, chemically known as acetic acid, trifluoro-, compd. with 10,11-dihydro-n-methyl-5h-dibenz(b,f)azepine-5-propanamine (1:1), but more generally known as desipramine trifluoroacetate, which bears US NIH Compound Identifier 151119. European Medicines Agency schedules desipramine trifluoroacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06995MIG. Most nations, for tariff purposes, schedule desipramine trifluoroacetate under HS 29339990. SMILES: CNCCCN1C2CCCCC2CCC3C1CCCC3.C(=O)(C(F)(F)F)O.
This classification denotes an anticoagulant agent with the molecular formula C287H440N80O110S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U0JZ726775, chemically known as hirudin (hirudo medicinalis isoform hv1), 63-desulfo- but generally known as desirudin, which bears US NIH Compound Identifier 16129703. European Medicines Agency schedules Desirudin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06996MIG. The term DESIRUDIN is an International Non-Proprietary Name. World Health Organization schedules desirudin in its Anatomical Therapeutic Chemical (ATC) Classification. DESIRUDIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desirudin under HS 30019098 and SITC 54162. As of Q4 2014, DESIRUDIN remains the US FDA Preferred Term for this commodity. Desirudin bears US NLM identifiers UMLS ID C1259412 and NCI Concept Code C47473. SMILES: S1SCC2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C3NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)C(C)C)C(C)C)CC4CCC(O)CC4)C(O)C)CC(=O)O)CSSC3)C(O)C)CCC(=O)O)CO)CCC(=O)N)CC(=O)N)C.
This classification denotes a glycoside and cardiotonic agent with the molecular formula C47H74O19, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YGY317RK75, chemically known as 3beta-(o-beta-d-glucopyranosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-beta-d-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid but generally known as deslanoside, which bears US NIH Compound Identifier 28620. European Medicines Agency schedules Deslanoside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06997MIG. The term DESLANOSIDE is an International Non-Proprietary Name. World Health Organization schedules deslanoside in its Anatomical Therapeutic Chemical (ATC) Classification. DESLANOSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule deslanoside under HS 29389010 and SITC 54161. As of Q4 2014, DESLANOSIDE remains the US FDA Preferred Term for this commodity. Deslanoside bears US NLM identifiers UMLS ID C0011689 and NCI Concept Code C65368. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(OC7OC(C(O)C(O)C7O)CO)C(O)C6)C)C(O)C5)C)C(O)C3)C)CC4)C)CC(O)C1(C(CC2)C1=CC(=O)OC1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FVF865388R, chemically known as 5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- but generally known as desloratadine, which bears US NIH Compound Identifier 124087. European Medicines Agency schedules Desloratadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01596MIG. The term DESLORATADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules desloratadine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule desloratadine under HS 29333999 and SITC 51574. As of Q4 2014, DESLORATADINE remains the US FDA Preferred Term for this commodity. Desloratadine bears US NLM identifiers UMLS ID C0908935 and NCI Concept Code C47474. SMILES: CLC1CC2C(/C(=C3/CCNCC3)C3NCCCC3CC2)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a gonadotropin-releasing hormone analog with the molecular formula C64H83N17O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TKG3I66TVE, chemically known as 1-9-luteinizing hormone-releaasing factor (swine), 6-d-tryptophan-9-(n-ethyl-l-prolinamide)- but generally known as deslorelin, which bears US NIH Compound Identifier 16129697. European Medicines Agency schedules Deslorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06998MIG. The term DESLORELIN is an International Non-Proprietary Name. DESLORELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule deslorelin under HS 29371900 and SITC 54154. As of Q4 2014, DESLORELIN remains the US FDA Preferred Term for this commodity. Deslorelin bears US NLM identifiers UMLS ID C0083220 and NCI Concept Code C38709. SMILES: O=C(N1C(CCC1)C(=O)NCC)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1[NH]CNC1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)CC1C2C([NH]C1)CCCC2)CC(C)C)CCCNC(=N)N.
This classification denotes an opioid receptor agonist with the molecular formula C24H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9B1Z1V29C3, chemically known as 1-(4-morpholino-2,2-diphenylbutyryl)pyrrolidine but generally known as desmethylmoramide, which bears US NIH Compound Identifier 206005. European Medicines Agency schedules Desmethylmoramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07000MIG. The term DESMETHYLMORAMIDE is an International Non-Proprietary Name. DESMETHYLMORAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desmethylmoramide under HS 29349990 and SITC 51579. As of Q4 2014, DESMETHYLMORAMIDE remains the US FDA Preferred Term for this commodity. Desmethylmoramide bears US NLM identifiers UMLS ID C2699601 and NCI Concept Code C77285. SMILES: O=C(N1CCCC1)C(CCN1CCOCC1)(C1CCCCC1)C1CCCCC1.
This classification denotes an antidiurectic hormone analogue with the molecular formula C46H64N14O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ENR1LLB0FP, chemically known as vasopressin, 1-(3-mercaptopropanoic acid)-8-d-arginine- but generally known as desmopressin, which bears US NIH Compound Identifier 27991. European Medicines Agency schedules Desmopressin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07001MIG. The term DESMOPRESSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules desmopressin in its Anatomical Therapeutic Chemical (ATC) Classification. DESMOPRESSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desmopressin under HS 29371900 and SITC 54154. As of Q4 2014, DESMOPRESSIN remains the US FDA Preferred Term for this commodity. Desmopressin bears US NLM identifiers UMLS ID C0011701 and NCI Concept Code C61701. SMILES: S1SCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CCC/N=C(/N)N)C(=O)NCC(=O)N)C1)CC(=O)N)CCC(=O)N)CC1CCCCC1)CC1CCC(O)CC1.
This classification denotes an antidiurectic hormone analogue with the molecular formula C46H64N14O12S2.C2H4O2.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XB13HYU18U, chemically known as vasopressin, 1-(3-mercaptopropanoic acid)-8-d-arginine- but more generally known as desmopressin acetate, which bears US NIH Compound Identifier 27991. European Medicines Agency schedules Desmopressin acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01597MIG. Most nations, for tariff and trade purposes, schedule desmopressin acetate under HS 29371900 and SITC 54154. As of Q4 2014, DESMOPRESSIN ACETATE remains US FDA's Preferred Term for this commodity. Desmopressin acetate bears US NLM identifiers UMLS ID C0701195 and NCI Concept Code C47475. SMILES: CC(=O)O.C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N2)CC3CCC(CC3)O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N.O.O.O.
This classification denotes an antidiurectic hormone analogue with the molecular formula C46H64N14O12S2.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K12647SFC, chemically known as 1-(3-mercaptopropionic acid)-8-d-arginine-vasopressin monoacetate (salt), but more generally known as desmopressin acetate anhydrous, which bears US NIH Compound Identifier 64758. European Medicines Agency schedules desmopressin acetate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07001MIG. Most nations, for tariff purposes, schedule desmopressin acetate anhydrous under HS 29371900. SMILES: CC(=O)O.C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N2)CC3CCC(CC3)O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N.
This classification denotes an antidiurectic hormone analogue with the molecular formula C46H64N14O12S2.C2H4O2.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XB13HYU18U, chemically known as vasopressin, 1-(3-mercaptopropanoic acid)-8-d-arginine-, monoacetate (salt), trihydrate, but more generally known as desmopressin acetate trihydrate, which bears US NIH Compound Identifier 64759. European Medicines Agency schedules desmopressin acetate trihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07001MIG. Most nations, for tariff purposes, schedule desmopressin acetate trihydrate under HS 29371900. SMILES: CC(=O)O.C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N2)CC3CCC(CC3)O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N.O.O.O.
This classification denotes a therapeutic progestin with the molecular formula C22H30O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81K9V7M3A3, chemically known as 18,19-dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17alpha)- but generally known as desogestrel, which bears US NIH Compound Identifier 40973. European Medicines Agency schedules Desogestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07003MIG. The term DESOGESTREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules desogestrel in its Anatomical Therapeutic Chemical (ATC) Classification. DESOGESTREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desogestrel under HS 29372300 and SITC 54153. As of Q4 2014, DESOGESTREL remains the US FDA Preferred Term for this commodity. Desogestrel bears US NLM identifiers UMLS ID C0057558 and NCI Concept Code C47476. SMILES: OC1(C2(C(C3C(C4C(=CCCC4)CC3)C(=C)C2)CC1)CC)C#C.
This classification denotes a combination contraceptive drug. The first component of this drug is DESOGESTREL, a therapeutic progestin with the molecular formula C22H30O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81K9V7M3A3, chemically known as 18,19-dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17alpha)- but generally known as desogestrel, which bears US NIH Compound Identifier 40973. European Medicines Agency schedules Desogestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07003MIG. The term DESOGESTREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules desogestrel in its Anatomical Therapeutic Chemical (ATC) Classification. DESOGESTREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1(C2(C(C3C(C4C(=CCCC4)CC3)C(=C)C2)CC1)CC)C#C. The second component of this drug is ethinyl estradiol, a therapeutic estradiol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 423D2T571U. European Medicines Agency schedules Ethinyl estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07277MIG. Ethinylestradiol generally arises in the molecular formula C20H24O2. The term 'ethinylestradiol' is a European Medicines Agency European Public Assessment Report System designation. ETHINYLESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1(C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C)C#C.
This classification denotes an opioid receptor agonist with the molecular formula C17H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7OP86J5E33, chemically known as morphinan-3-ol, 4,5-epoxy-17-methyl-, (5.alpha.)- but generally known as desomorphine, which bears US NIH Compound Identifier 521115. European Medicines Agency schedules Desomorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07004MIG. The term DESOMORPHINE is an International Non-Proprietary Name. DESOMORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desomorphine under HS 29391900 and SITC 54141. As of Q4 2014, DESOMORPHINE remains the US FDA Preferred Term for this commodity. Desomorphine bears US NLM identifiers UMLS ID C2827133 and NCI Concept Code C83663. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(O)CC3)CCC2.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H32O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J280872D1O, chemically known as 16-alpha-hydroxyprednisole-16,17-acetonide but generally known as desonide, which bears US NIH Compound Identifier 12536. European Medicines Agency schedules Desonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07005MIG. The term DESONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules desonide in its Anatomical Therapeutic Chemical (ATC) Classification. DESONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desonide under HS 29372900 and SITC 54153. As of Q4 2014, DESONIDE remains the US FDA Preferred Term for this commodity. Desonide bears US NLM identifiers UMLS ID C0011705 and NCI Concept Code C61702. SMILES: O1C2(C3(C(C4C(C(O)C3)C3(C(=CC(=O)C=C3)CC4)C)CC2OC1(C)C)C)C(=O)CO.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4E07GXB7AU, chemically known as 9-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione but generally known as desoximetasone, which bears US NIH Compound Identifier 9793. European Medicines Agency schedules Desoximetasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07006MIG. The term DESOXIMETASONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules desoximetasone in its Anatomical Therapeutic Chemical (ATC) Classification. DESOXIMETASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule desoximetasone under HS 29372200 and SITC 54153. As of Q4 2014, DESOXIMETASONE remains the US FDA Preferred Term for this commodity. Desoximetasone bears US NLM identifiers UMLS ID C0011707 and NCI Concept Code C47477. SMILES: FC12C(C3C(C(C(C3)C)C(=O)CO)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40GP35YQ49, chemically known as 21-hydroxypregn-4-ene-3,20-dione but generally known as deoxycorticosterone, which bears US NIH Compound Identifier 6166. Desoxycorticosterone or desoxycortone bears US NLM identifiers UMLS ID C0011710 and NCI Concept Code C72737. SMILES: CC12CCC3C(C1CCC2C(=O)CO)CCC4=CC(=O)CCC34C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 16665T4A2X, chemically known as 21-(2,2-dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione but more generally known as desoxycorticosterone pivalate, which bears US NIH Compound Identifier 13126. European Medicines Agency schedules Desoxycortone pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01603MIG. Most nations, for tariff and trade purposes, schedule desoxycortone pivalate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C.
This classification denotes an enzyme replacement preparation with the molecular formula C1321H1995N339O396S9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 953A26OA1Y, more generally known as dornase alfa. European Medicines Agency schedules dornase alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06373MIG. The term DORNASE ALFA is an International Non-Proprietary Name or INN. Most nations schedule dornase alfa under HS 35079090 and SITC 51691. As of Q4 2014, DORNASE ALFA remains the US FDA Preferred Term for this commodity. Dornase alfa bears US NLM identifiers UMLS ID C1135662 and NCI Concept Code C81664. SMILES: NONE.
This classification denotes an antidepressant agent with the molecular formula C16H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NG99554ANW, chemically known as phenol, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)- but generally known as desvenlafaxine, which bears US NIH Compound Identifier 125017. European Medicines Agency schedules Desvenlafaxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25380. The term DESVENLAFAXINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 1, 2004, List 51). World Health Organization schedules desvenlafaxine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule desvenlafaxine under HS 29225000 and SITC 51467. As of Q4 2014, DESVENLAFAXINE remains the US FDA Preferred Term for this commodity. Desvenlafaxine bears US NLM identifiers UMLS ID C1880288 and NCI Concept Code C61703. SMILES: OC1(C(CN(C)C)c2ccc(O)cc2)CCCCC1.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZB22ENF0XR. European Medicines Agency schedules Desvenlafaxine succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27750. Desvenlafaxine succinate generally arises in the molecular formula C16H25NO2.C4H6O4.H2O. The term 'desvenlafaxine succinate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule desvenlafaxine succinate under HS 29225000 and SITC 51467. As of Q4 2014, DESVENLAFAXINE SUCCINATE remains US FDA's Preferred Term for this commodity. Desvenlafaxine succinate bears US NLM identifiers UMLS ID C1871864 and NCI Concept Code C61704. SMILES: CN(C)CC(C1CCC(CC1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y09NU9DS9B, chemically known as salicylic acid, 2-(diethylamino)ethyl ester but generally known as detanosal, which bears US NIH Compound Identifier 160413. European Medicines Agency schedules Detanosal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07009MIG. The term DETANOSAL is an International Non-Proprietary Name. DETANOSAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule detanosal under HS 29221980 and SITC 51461. As of Q4 2014, DETANOSAL remains the US FDA Preferred Term for this commodity. Detanosal bears US NLM identifiers UMLS ID C2699602 and NCI Concept Code C77352. SMILES: O(CCN(CC)CC)C(=O)C1C(O)CCCC1.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7N8K34P2XH, chemically known as 4-(2,3-dimethylbenzyl)imidazole but generally known as detomidine, which bears US NIH Compound Identifier 56032. European Medicines Agency schedules Detomidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07012MIG. The term DETOMIDINE is an International Non-Proprietary Name. DETOMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule detomidine under HS 29332990 and SITC 51573. As of Q4 2014, DETOMIDINE remains the US FDA Preferred Term for this commodity. Detomidine bears US NLM identifiers UMLS ID C0057577 and NCI Concept Code C83664. SMILES: CC1=C(C(=CC=C1)CC2=CN=CN2)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H14N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95K4LKB6QE, chemically known as 4-((2,3-dimethylphenyl)methyl)-1h-imidazole hydrochloride but more generally known as detomidine hydrochloride, which bears US NIH Compound Identifier 56031. European Medicines Agency schedules Detomidine hydrochloride for veterinary use in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11892MIG. Most nations, for tariff and trade purposes, schedule detomidine hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, DETOMIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Detomidine hydrochloride bears US NLM identifiers UMLS ID C0113259 and NCI Concept Code C75038. SMILES: CC1CCCC(C1C)CC2C[NH]CN2.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H14N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95K4LKB6QE, chemically known as 4-((2,3-dimethylphenyl)methyl)-1h-imidazole hydrochloride but more generally known as detomidine hydrochloride, which bears US NIH Compound Identifier 56031. European Medicines Agency schedules Detomidine hydrochloride for veterinary use in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11892MIG. Most nations, for tariff and trade purposes, schedule detomidine hydrochloride for veterinary use under HS 29332990. SMILES: CC1CCCC(C1C)CC2C[NH]CN2.CL.
This classification denotes an anthracycline antibiotic with the molecular formula C33H39NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 822EC3XEJZ, chemically known as glyoxylic acid 3(sup 2)-ester with doxorubicin, 2-(diethyl acetal) but generally known as detorubicin, which bears US NIH Compound Identifier 114806. European Medicines Agency schedules Detorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07013MIG. The term DETORUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). DETORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule detorubicin under HS 29419000 and SITC 54139. As of Q4 2014, DETORUBICIN remains the US FDA Preferred Term for this commodity. Detorubicin bears US NLM identifiers UMLS ID C0057578 and NCI Concept Code C1066. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)COC(=O)C(OCC)OCC)C1OC(C(O)C(N)C1)C.
This classification denotes a calcium channel blocker with the molecular formula C26H36N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M6142PTV7J, chemically known as 2-(3,4-dimethoxyphenyl)-2-isopropyl-5-((m-methoxyphenethyl)methylamino)valeronitrile but generally known as devapamil, which bears US NIH Compound Identifier 65832. European Medicines Agency schedules Devapamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07015MIG. The term DEVAPAMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). DEVAPAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule devapamil under HS 29269095 and SITC 51484. As of Q4 2014, DEVAPAMIL remains the US FDA Preferred Term for this commodity. Devapamil bears US NLM identifiers UMLS ID C0057583 and NCI Concept Code C77823. SMILES: O(c1cc(C(C(C)C)(CCCN(CCc2cc(OC)ccc2)C)C#N)ccc1OC)C.
This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C22H29FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7S5I7G3JQL, chemically known as 9-fluoro-11.beta.,17, 21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione but generally known as dexamethasone, which bears US NIH Compound Identifier 3003. European Medicines Agency schedules Dexamethasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07017MIG. The term DEXAMETHASONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules dexamethasone in its Anatomical Therapeutic Chemical (ATC) Classification. DEXAMETHASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexamethasone under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE remains the US FDA Preferred Term for this commodity. Dexamethasone bears US NLM identifiers UMLS ID C0011777 and NCI Concept Code C422. SMILES: FC12C(C3C(C(O)(C(C3)C)C(=O)CO)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W4N6E1T46B, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-acetate 17-(2-furaoate) but more generally known as dexamethasone acefurate, which bears US NIH Compound Identifier 168903. European Medicines Agency schedules Dexamethasone acefurate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07018MIG. The term DEXAMETHASONE ACEFURATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). Most nations, for tariff and trade purposes, schedule dexamethasone acefurate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE ACEFURATE remains US FDA's Preferred Term for this commodity. Dexamethasone acefurate bears US NLM identifiers UMLS ID C2699606 and NCI Concept Code C77413. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C5CCCO5)C)O)F)C.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E2287TKU04. European Medicines Agency schedules Dexamethasone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01608MIG. Dexamethasone acetate generally arises in the molecular formula C24H31FO6. The term 'dexamethasone acetate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule dexamethasone acetate under HS 29372200 and SITC 54153. Dexamethasone acetate bears US NLM identifiers UMLS ID C0057598 and NCI Concept Code C1067. SMILES: As of Q4 2014, DEXAMETHASONE ACETATE remains US FDA's Preferred Term for this commodity.
This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7V8P532WP, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-, but more generally known as dexamethasone acetate anhydrous, which bears US NIH Compound Identifier 14442. European Medicines Agency schedules dexamethasone acetate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07017MIG. Most nations, for tariff purposes, schedule dexamethasone acetate anhydrous under HS 29372200. Dexamethasone acetate anhydrous bears US NLM identifiers UMLS ID C1658209 and NCI Concept Code C77000. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid and antiemetic agent C29H35FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9T15U399I, chemically known as (11.beta.,16.alpha.)-9-fluoro-3,17-dihydroxy-16-methyl-21(phenylmethoxy)-pregna-1,4-diene-3,20-dione, but more generally known as dexamethasone beloxil, which bears US NIH Compound Identifier 656778. Most nations, for tariff and trade purposes, schedule dexamethasone beloxil under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE BELOXIL remains US FDA's Preferred Term for this commodity. Dexamethasone beloxil bears US NLM identifiers UMLS ID C2699608 and NCI Concept Code C77415. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COCC5CCCCC5)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H37FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3UKR54YXW, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate but more generally known as dexamethasone dipropionate, which bears US NIH Compound Identifier 63049. European Medicines Agency schedules Dexamethasone dipropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01609MIG. Most nations, for tariff and trade purposes, schedule dexamethasone dipropionate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE DIPROPIONATE remains US FDA's Preferred Term for this commodity. Dexamethasone dipropionate bears US NLM identifiers UMLS ID C0245678 and NCI Concept Code C77417. SMILES: CCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)OC(=O)CC.
This classification denotes a therapeutic glucocorticoid with the molecular structure C28H32FNO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8LGC0BOA71 chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-((4-pyridinylcarbonyl)oxy)-,(11.beta.,16.alpha.)-, but more commonly known as dexamethasone isonicotinate, which bears US NIH Compound Identifier 16752. European Medicines Agency schedules Dexamethasone isonicotinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01610MIG. Most nations, for tariff and trade purposes, schedule dexamethasone isonicotinate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE ISONICOTINATE remains US FDA's Preferred Term for this commodity. Dexamethasone isonicotinate bears US NLM identifiers UMLS ID C0011779 and NCI Concept Code C77418. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C5CCNCC5)O)C)O)F)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS051. This VA Drug Class (HS051) classifies this compound as belonging to the group GLUCOCORTICOIDS.
This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C22H29FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7S5I7G3JQL, chemically known as 9-fluoro-11.beta.,17, 21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione but more generally known as dexamethasone, which bears US NIH Compound Identifier 3003. European Medicines Agency schedules Dexamethasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07017MIG. The term DEXAMETHASONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules dexamethasone in its Anatomical Therapeutic Chemical (ATC) Classification. DEXAMETHASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dexamethasone metasulfobenzoate sodium under HS 29372200. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C5CCCC(C5)S(=O)(=O)[O-])O)C)O)F)C.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a therapeutic glucocorticoid and antiemetic agent C38H59FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 601XWN7060, chemically known as 9-fluoro-11,17-dihydroxy-16-methyl-21-((1- oxohexadecyl)oxy)pregna-1,4-diene-3,20-dione (11.beta.,16.alpha.)-, but more generally known as dexamethasone palmitate, which bears US NIH Compound Identifier 63044. European Medicines Agency schedules Dexamethasone palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01611MIG. Most nations, for tariff and trade purposes, schedule dexamethasone palmitate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE PALMITATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30FO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BP70L44PR, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(dihydrogen phosphate) but more generally known as dexamethasone phosphate, which bears US NIH Compound Identifier 9400. European Medicines Agency schedules Dexamethasone phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01612MIG. Most nations, for tariff and trade purposes, schedule dexamethasone phosphate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE PHOSPHATE remains US FDA's Preferred Term for this commodity. Dexamethasone phosphate bears US NLM identifiers UMLS ID C0770565 and NCI Concept Code C77001. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid and antiemetic agent C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K182597N9C, chemically known as pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-, but more generally known as dexamethasone pivalate, which bears US NIH Compound Identifier 63040. European Medicines Agency schedules Dexamethasone pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01613MIG. Most nations, for tariff and trade purposes, schedule dexamethasone pivalate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE PIVALATE remains US FDA's Preferred Term for this commodity. Dexamethasone pivalate bears US NLM identifiers UMLS ID C0057603 and NCI Concept Code C77419. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28FO8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AI9376Y64P, chemically known as 16-alpha-methyl-9-alpha-fluoro-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione but more generally known as dexamethasone sodium phosphate, which bears US NIH Compound Identifier 5743. European Medicines Agency schedules Dexamethasone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01615MIG. Most nations, for tariff and trade purposes, schedule dexamethasone sodium phosphate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE SODIUM PHOSPHATE remains US FDA's Preferred Term for this commodity. Dexamethasone sodium phosphate bears US NLM identifiers UMLS ID C0113286 and NCI Concept Code C1362. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[NA+].[NA+].
This classification denotes a therapeutic glucocorticoid and antiemetic agent C28H39FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8IPA7Z9N7Y, chemically known as 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione 21-(3,3-dimethylbutyrate), but more generally known as dexamethasone tebutate, which bears US NIH Compound Identifier 20055086. European Medicines Agency schedules Dexamethasone tebutate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01618MIG. Most nations, for tariff and trade purposes, schedule dexamethasone tebutate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE TEBUTATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)CC(C)(C)C)O)C)O)F)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K182597N9C, chemically known as pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-, but more generally known as dexamethasone trimethyl acetate, which bears US NIH Compound Identifier 63040. European Medicines Agency schedules dexamethasone trimethyl acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07017MIG. Most nations, for tariff purposes, schedule dexamethasone trimethyl acetate under HS 29372200. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C.
This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OI7CP949NN, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-valerate but more generally known as dexamethasone valerate, which bears US NIH Compound Identifier 63047. European Medicines Agency schedules Dexamethasone valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01619MIG. Most nations, for tariff and trade purposes, schedule dexamethasone valerate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE VALERATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)O.
This classification denotes a cns stimulant with the molecular formula C9H13N, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier TZ47U051FI, chemically known as phenethylamine, alpha-methyl-, d- but more generally known as dexamfetamine, which bears U.S. National Institutes of Health Compound Identifier 5826. European Medicines Agency schedules Dexamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07019MIG. The term DEXAMFETAMINE is an International Non-Proprietary Name. World Health Organization schedules dexamfetamine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. DEXAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an antihelminthic agent with the molecular formula C11H12N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, UMH46V5U01 chemically known as (+)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole but generally known as dexamisole, which bears US NIH Compound Identifier 66374. European Medicines Agency schedules Dexamisole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07020MIG. The term DEXAMISOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, no. 10 1974, list 14. ). Most nations schedule dexamisole under HS 29349990 and SITC 51579. As of Q4 2014, DEXAMISOLE remains the US FDA Preferred Term for this commodity. Dexamisole bears US NLM identifiers UMLS ID C0057604 and NCI Concept Code C78042. SMILES: C1CSC2=NC(CN21)C3=CC=CC=C3.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19BrN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75T64B71RP, chemically known as 3-(4-bromophenyl)-n,n-dimethyl-3-pyridin-2-yl-propan-1-amine but generally known as dexbrompheniramine, which bears US NIH Compound Identifier 16960. European Medicines Agency schedules Dexbrompheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07021MIG. World Health Organization schedules dexbrompheniramine in its Anatomical Therapeutic Chemical (ATC) Classification. DEXBROMPHENIRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexbrompheniramine under HS 29333999 and SITC 51574. As of Q4 2014, DEXBROMPHENIRAMINE remains the US FDA Preferred Term for this commodity. Dexbrompheniramine bears US NLM identifiers UMLS ID C0057605 and NCI Concept Code C61705. SMILES: BRC1CCC(C(CCN(C)C)C2NCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19BrN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BPA9UT29BS, chemically known as 2-pyridinepropanamine, gamma-(4-bromophenyl)-n,n-dimethyl-, (s)-, (z)-2-butenedioate (1:1) but more generally known as dexbrompheniramine maleate, which bears US NIH Compound Identifier 6433334. European Medicines Agency schedules Dexbrompheniramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01626MIG. Most nations, for tariff and trade purposes, schedule dexbrompheniramine maleate under HS 29333999 and SITC 51574. As of Q4 2014, DEXBROMPHENIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Dexbrompheniramine maleate bears US NLM identifiers UMLS ID C0113291 and NCI Concept Code C61706. SMILES: CN(C)CC[C@@H](C1CCC(CC1)BR)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes the tannate form of a histamine-1 receptor antagonist with the molecular formula C16H19BrN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75T64B71RP, chemically known as 3-(4-bromophenyl)-n,n-dimethyl-3-pyridin-2-yl-propan-1-amine but more generally known as dexbrompheniramine, which bears US NIH Compound Identifier 16960. European Medicines Agency schedules Dexbrompheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07021MIG. World Health Organization schedules dexbrompheniramine in its Anatomical Therapeutic Chemical (ATC) Classification. DEXBROMPHENIRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dexbrompheniramine tannate under HS 29333999. SMILES:. As of Q4 2014, DEXBROMPHENIRAMINE TANNATE remains US FDA's Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19ClN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B10YD955QW, chemically known as 3-(p-chlorophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but more generally known as dexchlorpheniramine maleate, which bears US NIH Compound Identifier 2725. European Medicines Agency schedules Dexchlorpheniramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01628MIG. Most nations, for tariff and trade purposes, schedule dexchlorpheniramine maleate under HS 29333999. As of Q4 2014, DEXCHLORPHENIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Dexchlorpheniramine maleate bears US NLM identifiers UMLS ID C0137440 and NCI Concept Code C47478. SMILES: CN(C)CC[C@@H](C1CCC(CC1)CL)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antimuscarinic agent with the molecular formula C23H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43477QYX3D, chemically known as (rs)-3-(1-benzyl-4-piperidyl)-3-phenyl-2,6-piperidindion but generally known as dexetimide, which bears US NIH Compound Identifier 21847. European Medicines Agency schedules Dexetimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07026MIG. The term DEXETIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules dexetimide in its Anatomical Therapeutic Chemical (ATC) Classification. DEXETIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexetimide under HS 29333999 and SITC 51574. As of Q4 2014, DEXETIMIDE remains the US FDA Preferred Term for this commodity. Dexetimide bears US NLM identifiers UMLS ID C0011785 and NCI Concept Code C78069. SMILES: O=C1NC(=O)CCC1(C1CCN(CC1)CC1CCCCC1)C1CCCCC1.
This classification denotes an ibuprofen analog and nonsteroidal anti-inflammatory agent with the molecular formula C13H18O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 671DKG7P5S, chemically known as benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-, (s)- but more generally known as dexibuprofen, which bears U.S. National Institutes of Health Compound Identifier 39912. European Medicines Agency schedules Dexibuprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07030MIG. World Health Organization schedules dexibuprofen in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. DEXIBUPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an ibuprofen analog and nonsteroidal anti-inflammatory agent C13H18O2.C6H14N2O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T179MT9211, chemically known as benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, (s)-, compd. with l-lysine (1:1) monohydrate, but more generally known as dexibuprofen lysine, which bears US NIH Compound Identifier 15009331. Most nations, for tariff and trade purposes, schedule dexibuprofen lysine under HS 29163900 and SITC 51379. As of Q4 2014, DEXIBUPROFEN LYSINE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H](C1CCC(CC1)CC(C)C)C(=O)O.C(CCN)C[C@@H](C(=O)O)N.O.
This classification denotes an antidepressant agent with the molecular formula C11H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1V5135S169, chemically known as 1h-imidazo(1,2-a)imidazole, 2,3,5,6-tetrahydro-3-phenyl-, ( )- but generally known as deximafen, which bears US NIH Compound Identifier 163316. European Medicines Agency schedules Deximafen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07031MIG. The term DEXIMAFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). DEXIMAFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule deximafen under HS 29339990 and SITC 51577. As of Q4 2014, DEXIMAFEN remains the US FDA Preferred Term for this commodity. Deximafen bears US NLM identifiers UMLS ID C2699611 and NCI Concept Code C78015. SMILES: C1CN2C(CN=C2N1)C3=CC=CC=C3.
This classification denotes an anesthetic agent with the molecular formula C15H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QI846AL4NC, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-methyl-, (s)- but generally known as dexivacaine, which bears US NIH Compound Identifier 3032799. European Medicines Agency schedules Dexivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07033MIG. The term DEXIVACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). DEXIVACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexivacaine under HS 29333999 and SITC 51574. As of Q4 2014, DEXIVACAINE remains the US FDA Preferred Term for this commodity. Dexivacaine bears US NLM identifiers UMLS ID C0604558 and NCI Concept Code C65371. SMILES: O=C(NC1C(CCCC1C)C)C1N(CCCC1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6KD9E78X68, chemically known as hydratropic acid, m-benzoyl-, (+)- but generally known as dexketoprofen, which bears US NIH Compound Identifier 667550. European Medicines Agency schedules Dexketoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07034MIG. The term DEXKETOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules dexketoprofen in its Anatomical Therapeutic Chemical (ATC) Classification. DEXKETOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexketoprofen under HS 29183000 and SITC 51395. As of Q4 2014, DEXKETOPROFEN remains the US FDA Preferred Term for this commodity. Dexketoprofen bears US NLM identifiers UMLS ID C0772505 and NCI Concept Code C87321. SMILES: OC(=O)C(C1CC(CCC1)C(=O)C1CCCCC1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O3.C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N674F7L21E, chemically known as benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), (.alpha.s)-, but more generally known as dexketoprofen trometamol, which bears US NIH Compound Identifier 177976. European Medicines Agency schedules dexketoprofen trometamol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07034MIG. Most nations, for tariff purposes, schedule dexketoprofen trometamol under HS 29183000. SMILES: C[C@@H](C1CCCC(C1)C(=O)C2CCCCC2)C(=O)O.C(C(CO)(CO)N)O.
This classification denotes a proton pump inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UYE4T5I70X. European Medicines Agency schedules Dexlansoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31929. Dexlansoprazole generally arises in the molecular formula C16H14F3N3O2S. The term DEXLANSOPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55.) DEXLANSOPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexlansoprazole under HS 29333999 and SITC 51574. As of Q4 2014, DEXLANSOPRAZOLE remains the US FDA Preferred Term for this commodity. Dexlansoprazole bears US NLM identifiers UMLS ID C2607263 and NCI Concept Code C73192. SMILES: CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H12Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VXJ7Z24RN1, chemically known as ( )-(s)-2-(1-(2,6-dichlorophenoxy)ethyl)-2-imidazoline but generally known as dexlofexidine, which bears US NIH Compound Identifier 208822. European Medicines Agency schedules Dexlofexidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07035MIG. The term DEXLOFEXIDINE is an International Non-Proprietary Name. DEXLOFEXIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexlofexidine under HS 29332990 and SITC 51573. As of Q4 2014, DEXLOFEXIDINE remains the US FDA Preferred Term for this commodity. Dexlofexidine bears US NLM identifiers UMLS ID C2699612 and NCI Concept Code C77296. SMILES: CC(C1=NCCN1)OC2=C(C=CC=C2CL)CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H12Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5SPW497X0Z, chemically known as (-)-(r)-2-(1-(2,6-dichlorophenoxy)ethyl)-2-imidazoline. but generally known as levlofexidine, which bears US NIH Compound Identifier 3038503. European Medicines Agency schedules Levlofexidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08461MIG. The term LEVLOFEXIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). LEVLOFEXIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67VB76HONO, chemically known as 1h-imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-, (r)- but generally known as dexmedetomidine, which bears US NIH Compound Identifier 60612. European Medicines Agency schedules Dexmedetomidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07037MIG. The term DEXMEDETOMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules dexmedetomidine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule dexmedetomidine under HS 29332990 and SITC 51573. As of Q4 2014, DEXMEDETOMIDINE remains the US FDA Preferred Term for this commodity. Dexmedetomidine bears US NLM identifiers UMLS ID C0113293 and NCI Concept Code C47479. SMILES: [NH]1C(C(C2C(C(CCC2)C)C)C)CNC1.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1018WH7F9I, chemically known as 1h-imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-, monohydrochloride, (+-)- but more generally known as dexmedetomidine hydrochloride, which bears US NIH Compound Identifier 68601. European Medicines Agency schedules Dexmedetomidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20317. Most nations, for tariff and trade purposes, schedule dexmedetomidine hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, DEXMEDETOMIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dexmedetomidine hydrochloride bears US NLM identifiers UMLS ID C0876757 and NCI Concept Code C72738. SMILES: CC1CCCC(C1C)[C@H](C)C2C[NH]CN2.CL.
This classification denotes a cns stimulant with the molecular formula C14H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) M32RH9MFGP, chemically known as 2-piperidineacetic acid, alpha-phenyl-, methyl ester, threo- but more generally known as dexmethylphenidate, which bears US NIH Compound Identifier 154101. European Medicines Agency schedules Dexmethylphenidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30294. The term DEXMETHYLPHENIDATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules dexmethylphenidate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule dexmethylphenidate under HS 29333999 and SITC 51574. As of Q4 2014, DEXMETHYLPHENIDATE remains US FDA's Preferred Term for this commodity. Dexmethylphenidate bears US NLM identifiers UMLS ID C1169997 and NCI Concept Code C26642. SMILES: O(C(=O)C(C1NCCCC1)C1CCCCC1)C.
This classification denotes a cns stimulant with the molecular formula C14H19NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1678OK0E08, chemically known as 2-piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (r-(r*,r*))- but more generally known as dexmethylphenidate hydrochloride, which bears US NIH Compound Identifier 154100. European Medicines Agency schedules Dexmethylphenidate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20614. Most nations, for tariff and trade purposes, schedule dexmethylphenidate hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DEXMETHYLPHENIDATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dexmethylphenidate hydrochloride bears US NLM identifiers UMLS ID C1170743 and NCI Concept Code C47480. SMILES: COC(=O)[C@H](C1CCCCC1)[C@H]2CCCCN2.CL.
This classification denotes an antidepressant agent with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 601X8G3PCW, chemically known as 1(2h)-naphthalenone, 3,4-dihydro-2-(2-(dimethylamino)ethyl)-2-phenyl-, (s)- but generally known as dexnafenodone, which bears US NIH Compound Identifier 65834. European Medicines Agency schedules Dexnafenodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07038MIG. The term DEXNAFENODONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). DEXNAFENODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexnafenodone under HS 29223900 and SITC 51463. As of Q4 2014, DEXNAFENODONE remains the US FDA Preferred Term for this commodity. Dexnafenodone bears US NLM identifiers UMLS ID CL386858 and NCI Concept Code C78016. SMILES: O=C1C(CCc2c1cccc2)(CCN(C)C)c1ccccc1.
This classification denotes a metal chelator with the molecular formula C11H16N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 048L81261F, chemically known as 2,6-piperazinedione, 4,4-propylenedi-, (+)- but more generally known as dexrazoxane, which bears US NIH Compound Identifier 71384. European Medicines Agency schedules Dexrazoxane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07046MIG. The term DEXRAZOXANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules dexrazoxane in its Anatomical Therapeutic Chemical (ATC) Classification. DEXRAZOXANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dexrazoxane under HS 29335995 and SITC 51576. As of Q4 2014, DEXRAZOXANE remains US FDA's Preferred Term for this commodity. Dexrazoxane bears US NLM identifiers UMLS ID C0733406 and NCI Concept Code C1333. SMILES: CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.
This classification denotes a metal chelator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5346058Q7S. European Medicines Agency schedules Dexrazoxane hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01631MIG. Dexrazoxane hydrochloride generally arises in the molecular formula C11H16N4O4.CLH. The term 'dexrazoxane hydrochloride' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule dexrazoxane hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, DEXRAZOXANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dexrazoxane hydrochloride bears US NLM identifiers UMLS ID C0982118 and NCI Concept Code C66945. SMILES: C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.CL.
This classification denotes the hydrochloride form of an antispasmotic agent and antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3O6AUX3I0J. European Medicines Agency schedules Dexsecoverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07047MIG. Dexsecoverine generally arises in the molecular formula C22H35NO2. The term DEXSECOVERINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, no. 5, 1985, list 25.) DEXSECOVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dexsecoverine hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, DEXSECOVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dexsecoverine hydrochloride bears US NLM NCI C97977. SMILES: CCN(CCCC(=O)C1CCCCC1)[C@@H](C)CC2CCC(CC2)OC.CL.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C22H35NO2 and C22H35NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 3O6AUX3I0J and B8042DUA17. European Medicines Agency schedules Dexsecoverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07047MIG. The term DEXSECOVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) DEXSECOVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dexsecoverine and its salts under HS 29225000 and SITC 51467. As of Q4 2014, DEXSECOVERINE remains the US FDA Preferred Term for this commodity. Dexsecoverine bears US NLM NCI C73161 and C97977. SMILES: O=C(C1CCCCC1)CCCN(C(CC1CCC(OC)CC1)C)CC (base) or CCN(CCCC(=O)C1CCCCC1)[C@@H](C)CC2CCC(CC2)OC.CL (hydrochloride).
This classification denotes a blood substitute, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7SA290YK68. European Medicines Agency schedules Dextran 70 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01638MIG. Dextran 70 generally arises in the molecular formula C12H22O11(C6H10O5)N. The term DEXTRAN 70 is a United States Adopted Name designation. Most nations schedule dextran under HS 39139000 and SITC 57595. SMILES: C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(C=O)O)O)O)O)O)O)O)O)O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class BL800. This VA Drug Class (BL800) classifies this compound as belonging to the group VOLUME EXPANDERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class BL800. This VA Drug Class (BL800) classifies this compound as belonging to the group VOLUME EXPANDERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class BL800. This VA Drug Class (BL800) classifies this compound as belonging to the group VOLUME EXPANDERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class BL800. This VA Drug Class (BL800) classifies this compound as belonging to the group VOLUME EXPANDERS.
This classification denotes a hydrophilic preparation and cicatrizant with the molecular formula C12H22O11(C6H7O5)n.C3H6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30KXI0TVD3, chemically known as dextran 2,3-dihydroxypropyl 2-hydroxy-1,3-propanediyl ether. European Medicines Agency schedules Dextranomer in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01643MIG. The term DEXTRANOMER is an International Non-Proprietary Name (see see WHO INN reference publication, Volume 29, No. 10 1975, List 1). Most nations schedule Dextranomer under HS 39139000 and SITC 57595. SMILES:. As of Q4 2014, DEXTRANOMER remains the US FDA Preferred Term for this commodity. .
This classification denotes a cns stimulant with the molecular formula C9H13N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TZ47U051FI, chemically known as phenethylamine, alpha-methyl-, d- but more generally known as dexamfetamine, which bears US NIH Compound Identifier 5826. European Medicines Agency schedules Dexamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07019MIG. The term DEXAMFETAMINE is an International Non-Proprietary Name. World Health Organization schedules dexamfetamine in its Anatomical Therapeutic Chemical (ATC) Classification. DEXAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DEXTROAMPHETAMINE remains US FDA's Preferred Term for this commodity. Dextroamphetamine bears US NLM identifiers UMLS ID C0011812 and NCI Concept Code C28981. SMILES: NC(CC1CCCCC1)C.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7355X3ROTS, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but more generally known as dextromethorphan, which bears US NIH Compound Identifier 3008. European Medicines Agency schedules Dextromethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07051MIG. The term DEXTROMETHORPHAN is an International Non-Proprietary Name. World Health Organization schedules dextromethorphan in its Anatomical Therapeutic Chemical (ATC) Classification. DEXTROMETHORPHAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dextromethorphan under HS 29334930 and SITC 51575. As of Q4 2014, DEXTROMETHORPHAN remains US FDA's Preferred Term for this commodity. Dextromethorphan bears US NLM identifiers UMLS ID C0011816 and NCI Concept Code C62022. SMILES: O(C1CC2C34C(C(N(CC3)C)CC2CC1)CCCC4)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE508. This VA Drug Class (RE508) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE513. This VA Drug Class (RE513) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE513. This VA Drug Class (RE513) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE508. This VA Drug Class (RE508) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE512. This VA Drug Class (RE512) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE512. This VA Drug Class (RE512) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE508. This VA Drug Class (RE508) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE507. This VA Drug Class (RE507) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE512. This VA Drug Class (RE512) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9S4S6CIY83, chemically known as pyrrolidine, 1-(3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)-, (s)- but generally known as dextromoramide, which bears US NIH Compound Identifier 9648. European Medicines Agency schedules Dextromoramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07052MIG. The term DEXTROMORAMIDE is an International Non-Proprietary Name. World Health Organization schedules dextromoramide in its Anatomical Therapeutic Chemical (ATC) Classification. DEXTROMORAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dextromoramide under HS 29349100 and SITC 51579. As of Q4 2014, DEXTROMORAMIDE remains the US FDA Preferred Term for this commodity. Dextromoramide bears US NLM identifiers UMLS ID C0011817 and NCI Concept Code C87357. SMILES: O=C(N1CCCC1)C(C(CN1CCOCC1)C)(C1CCCCC1)C1CCCCC1.
This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J778U505W5, chemically known as (+)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine bitartrate, but more generally known as dextromoramide bitartrate, which bears US NIH Compound Identifier 92942. European Medicines Agency schedules dextromoramide bitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07052MIG. Most nations, for tariff purposes, schedule dextromoramide bitartrate under HS 29349100. SMILES: C[C@H](CN1CCOCC1)C(C2CCCCC2)(C3CCCCC3)C(=O)N4CCCC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J778U505W5, chemically known as pyrrolidine, 1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)-, (+)-, tartrate (1:1) but more generally known as dextromoramide tartrate, which bears US NIH Compound Identifier 92942. European Medicines Agency schedules Dextromoramide tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01647MIG. Most nations, for tariff and trade purposes, schedule dextromoramide tartrate under HS 29349100 and SITC 51579. As of Q4 2014, DEXTROMORAMIDE TARTRATE remains US FDA's Preferred Term for this commodity. Dextromoramide tartrate bears US NLM identifiers UMLS ID C0355546 and NCI Concept Code C76838. SMILES: C[C@H](CN1CCOCC1)C(C2CCCCC2)(C3CCCCC3)C(=O)N4CCCC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H29NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CB2TL9PS0T, chemically known as 2-butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), hydrochloride, (+)- but more generally known as dextropropoxyphene hydrochloride, which bears US NIH Compound Identifier 15424. European Medicines Agency schedules Dextropropoxyphene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01649MIG. Most nations, for tariff and trade purposes, schedule dextropropoxyphene hydrochloride under HS 29221400. SMILES: CCC(=O)O[C@](CC1CCCCC1)(C2CCCCC2)[C@H](C)CN(C)C.CL.
This classification denotes an opioid receptor agonist and opioid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38M219L1OJ. European Medicines Agency schedules Dextropropoxyphene napsilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01650MIG. Dextropropoxyphene napsilate generally arises in the molecular formula C22H29NO2.C10H8O3S.H2O. The term 'dextropropoxyphene napsilate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule dextropropoxyphene napsilate under HS 29221400. SMILES: CCC(=O)O[C@](CC1CCCCC1)(C2CCCCC2)[C@H](C)CN(C)C.C1CCC2CC(CCC2C1)S(=O)(=O)O.O.
This classification denotes an opiate with the molecular formula C22H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S2F83W92TK, chemically known as 4-dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane but generally known as dextropropoxyphene, which bears US NIH Compound Identifier 10100. European Medicines Agency schedules Dextropropoxyphene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07053MIG. The term DEXTROPROPOXYPHENE is an International Non-Proprietary Name. World Health Organization schedules dextropropoxyphene in its Anatomical Therapeutic Chemical (ATC) Classification. DEXTROPROPOXYPHENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Dextropropoxyphene or propoxyphene bears US NLM identifiers UMLS ID C0033493 and NCI Concept Code C61912. SMILES: O(C(C(CN(C)C)C)(CC1CCCCC1)C1CCCCC1)C(=O)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AU100. This VA Drug Class (AU100) classifies this compound as belonging to the group SYMPATHOMIMETICS (ADRENERGICS).
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA605. This VA Drug Class (GA605) classifies this compound as belonging to the group ANTIEMETICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class MS300. This VA Drug Class (MS300) classifies this compound as belonging to the group NEUROMUSCULAR BLOCKING AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU600. This VA Drug Class (GU600) classifies this compound as belonging to the group OXYTOCICS.
Dextrose and Sodium Chloride Injection, USP (dextrose and sodium chloride inj) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in single dose containers for intravenous administration. It contains no antimicrobial agents.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE104. This VA Drug Class (RE104) classifies this compound as belonging to the group BRONCHODILATORS, XANTHINE-DERIVATIVE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM113. This VA Drug Class (AM113) classifies this compound as belonging to the group EXTENDED SPECTRUM PENICILLINS.
A substance used to treat low blood sugar (hypoglycemia), insulin shock, or dehydration (fluid loss).
This classification denotes a thyroid agent with the molecular formula C15H11I4NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W9K63FION, chemically known as 3,5,3,5-tetraiodothyronine but generally known as dextrothyroxine, which bears US NIH Compound Identifier 853. European Medicines Agency schedules Dextrothyroxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01651MIG. World Health Organization schedules dextrothyroxine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DEXTROTHYROXINE remains the US FDA Preferred Term for this commodity. Dextrothyroxine bears US NLM identifiers UMLS ID C0011824 and NCI Concept Code C61719. SMILES: Ic1cc(CC(N)C(=O)O)cc(I)c1Oc1cc(I)c(O)c(I)c1.
This classification denotes a thyroid agent with the molecular formula C15H10I4NO4.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H00N2AHSP, chemically known as 3,3,5,5-tetraiodo-d-thyronine, sodium salt but more generally known as dextrothyroxine sodium, which bears US NIH Compound Identifier 8729. European Medicines Agency schedules Dextrothyroxine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07055MIG. Most nations, for tariff and trade purposes, schedule dextrothyroxine sodium under HS 29225000 and SITC 51467. As of Q4 2014, DEXTROTHYROXINE SODIUM remains US FDA's Preferred Term for this commodity. Dextrothyroxine sodium bears US NLM identifiers UMLS NCI C65373. SMILES: C1C(CC(C(C1I)OC2CC(C(C(C2)I)O)I)I)C[C@H](C(=O)[O-])N.O.[NA+].
This classification denotes a purine antagonist with the molecular formula C6H6N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9DRB973HUI, chemically known as 6-aminoimidazo(4,5-c)pyridin-4(5h)-one but generally known as dezaguanine, which bears US NIH Compound Identifier 55710. European Medicines Agency schedules Dezaguanine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07057MIG. The term DEZAGUANINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). DEZAGUANINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dezaguanine under HS 29337900 and SITC 51561. As of Q4 2014, DEZAGUANINE remains the US FDA Preferred Term for this commodity. Dezaguanine bears US NLM identifiers UMLS ID C0047332 and NCI Concept Code C968. SMILES: O=C1[NH]C(N)CC2[NH]CNC12.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VHX8K5SV4X, chemically known as 5,11-methanobenzocyclodecen-3-ol, 13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-, (5alpha,11alpha,13s*)-, (-)- but generally known as dezocine, which bears US NIH Compound Identifier 40841. European Medicines Agency schedules Dezocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07059MIG. The term DEZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules dezocine in its Anatomical Therapeutic Chemical (ATC) Classification. DEZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dezocine under HS 29222900 and SITC 51462. As of Q4 2014, DEZOCINE remains the US FDA Preferred Term for this commodity. Dezocine bears US NLM identifiers UMLS ID C0057626 and NCI Concept Code C65374. SMILES: OC1CC2C3(C(N)C(CC2CC1)CCCCC3)C.
This classification denotes a log with the molecular formula C19H12O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4HU6J11EL5. European Medicines Agency schedules diacerein in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07060MIG. The term DIACEREIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24). DIACEREIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diacerein under HS 29189900 and SITC 51396. As of Q4 2014, DIACEREIN remains the US FDA Preferred Term for this commodity. SMILES: O(C1C2C(C(=O)C3C(C2=O)C(OC(=O)C)CCC3)CC(C1)C(=O)O)C(=O)C.
This classification denotes an opiate with the molecular formula C21H23NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70D95007SX, chemically known as morphine, diacetate (ester), hydrochloride but generally known as diacetylmorphine, which bears US NIH Compound Identifier 3592. European Medicines Agency schedules Diamorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13556MIG. World Health Organization schedules diacetylmorphine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O1C2C34C(C(N(CC3)C)Cc3c4c1c(OC(=O)C)cc3)C=CC2OC(=O)C.
This classification denotes an opioid receptor agonist with the molecular formula C21H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26G7YC77BU, chemically known as propionanilide, n-(2-(methylphenethylamino)propyl)- but generally known as diampromide, which bears US NIH Compound Identifier 62370. European Medicines Agency schedules Diampromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07065MIG. The term DIAMPROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). DIAMPROMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diampromide under HS 29242995 and SITC 51479. As of Q4 2014, DIAMPROMIDE remains the US FDA Preferred Term for this commodity. Diampromide bears US NLM identifiers UMLS ID C2699620 and NCI Concept Code C77286. SMILES: O=C(N(CC(N(CCC1CCCCC1)C)C)C1CCCCC1)CC.
This classification denotes an antifungal agent with the molecular formula C15H23N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2KL01R8ZV1, chemically known as 2-benzothiazolamine, 6-(2-(diethylamino)ethoxy)-n,n-dimethyl- but generally known as diamthazole, which bears US NIH Compound Identifier 8708. European Medicines Agency schedules Dimazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07151MIG. The term DIAMTHAZOLE is an International Non-Proprietary Name. World Health Organization schedules diamthazole in its Anatomical Therapeutic Chemical (ATC) Classification. Diamthazole or dimazole bears US NLM identifiers UMLS ID C0057720 and NCI Concept Code C75201. SMILES: CCN(CC)CCOC1=CC2=C(C=C1)N=C(S2)N(C)C.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IL298686U0. European Medicines Agency schedules Diarbarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07066MIG. Diarbarone generally arises in the molecular formula C16H20N2O4. The term DIARBARONE is an International Non-Proprietary Name or INN. DIARBARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DIARBARONE remains the US FDA Preferred Term for this commodity. Diarbarone bears US NLM identifiers UMLS ID C2699622 and NCI Concept Code C77993. SMILES: O1C2C(C(=O)C(C(=O)NCCN(CC)CC)C1O)CCCC2.
This classification denotes a sulfone anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UK27RQ38IX. European Medicines Agency schedules Diathymosulfone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07067MIG. Diathymosulfone generally arises in the molecular formula C32H34N4O4S. The term DIATHYMOSULFONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 16, no. 3 1962, list 4.) DIATHYMOSULFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(C1CCC(N/N=C2/C=C(C(C)C)C(=O)C=C2C)CC1)C1CCC(N/N=C2\C=C(C(C)C)C(=O)C=C2C)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX102. This VA Drug Class (DX102) classifies this compound as belonging to the group IONIC CONTRAST MEDIA.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX102. This VA Drug Class (DX102) classifies this compound as belonging to the group IONIC CONTRAST MEDIA.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX102. This VA Drug Class (DX102) classifies this compound as belonging to the group IONIC CONTRAST MEDIA.
Contrast medium used for gastroview.
This classification denotes a benzodiazepine with the molecular formula C16H13ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3JTX2Q7TU, chemically known as 7-chloro-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2(1h)-one but generally known as diazepam, which bears US NIH Compound Identifier 3016. European Medicines Agency schedules Diazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07069MIG. The term DIAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules diazepam in its Anatomical Therapeutic Chemical (ATC) Classification. DIAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diazepam under HS 29339190 and SITC 51577. As of Q4 2014, DIAZEPAM remains the US FDA Preferred Term for this commodity. Diazepam bears US NLM identifiers UMLS ID C0012010 and NCI Concept Code C28982. SMILES: CLC1CC2C(N(C(=O)CN=C2C2CCCCC2)C)CC1.
This classification denotes a benzodiazepine with the molecular formula C16H13CLN2O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6JD21U639H. European Medicines Agency schedules diazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32951. Most nations, for tariff and trade purposes, schedule diazepam hydrochloride under HS 29339190. As of Q4 2014, DIAZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diazepam hydrochloride bears US NLM identifiers UMLS ID C3273839 and NCI Concept Code C98133. SMILES: CN1C2CCC(CC2C(=NCC1=O)C3CCCCC3)CL.CL.
This classification denotes an ethylenimine compound with the molecular formula C16H20N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQL5EUP13W, chemically known as 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone but more generally known as diaziquone, which bears US NIH Compound Identifier 42616. European Medicines Agency schedules Diaziquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07070MIG. The term DIAZIQUONE is an International Non-Proprietary Name. DIAZIQUONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule diaziquone under HS 29339990 and SITC 51577. As of Q4 2014, DIAZIQUONE remains US FDA's Preferred Term for this commodity. Diaziquone bears US NLM identifiers UMLS ID C0113600 and NCI Concept Code C1363. SMILES: O=C1C(=C(NC(=O)OCC)C(=O)C(=C1NC(=O)OCC)N1CC1)N1CC1.
This classification denotes a vasodilating agent with the molecular formula C8H7ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O5CB12L4FN, chemically known as 7-chloro-3-methyl-2h-1,2,4-benzothiadiazine 1,1-dioxide but generally known as diazoxide, which bears US NIH Compound Identifier 3019. European Medicines Agency schedules Diazoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07071MIG. The term DIAZOXIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules diazoxide in its Anatomical Therapeutic Chemical (ATC) Classification. DIAZOXIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diazoxide under HS 29349990 and SITC 51579. As of Q4 2014, DIAZOXIDE remains the US FDA Preferred Term for this commodity. Diazoxide bears US NLM identifiers UMLS ID C0012022 and NCI Concept Code C428. SMILES: Clc1cc2S(=O)(=O)N=C(Nc2cc1)C.
This classification denotes a calcium phosphate and calcium supplement with the molecular formula Ca.HO4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L11K75P92J, chemically known as phosphoric acid, calcium salt (1:1) but generally known as calcium phosphate, dibasic, which bears US NIH Compound Identifier 24441. European Medicines Agency schedules Calcium phosphate, dibasic in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13192MIG. SMILES: OP(=O)([O-])[O-].[CA+2].
This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45ZFO9E525, chemically known as 3,4-dideoxykanamycin b but generally known as dibekacin, which bears US NIH Compound Identifier 3021. European Medicines Agency schedules Dibekacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07072MIG. The term DIBEKACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules dibekacin in its Anatomical Therapeutic Chemical (ATC) Classification. DIBEKACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dibekacin under HS 29419000 and SITC 54139. As of Q4 2014, DIBEKACIN remains the US FDA Preferred Term for this commodity. Dibekacin bears US NLM identifiers UMLS ID C0012024 and NCI Concept Code C79114. SMILES: O(C1C(O)C(OC2OC(CCC2N)CN)C(N)CC1N)C1OC(C(O)C(N)C1O)CO.
This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O8.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0869I992Z, chemically known as d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1-4))-2-deoxy-, sulfate (salt) but more generally known as dibekacin sulfate, which bears US NIH Compound Identifier 162862. European Medicines Agency schedules Dibekacin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01657MIG. Most nations, for tariff and trade purposes, schedule dibekacin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, DIBEKACIN SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N)N)N.OS(=O)(=O)O.
This classification denotes a dibenzazepine and tricyclic antidepressive agent with the molecular formula C18H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 510SJZ1Y6L, chemically known as 5,10-dihydro-10-(2-(dimethylamino)ethyl)-5-methyl-11h-dibenzo(b,e)(1,4)diazepin-11-one but generally known as dibenzepin, which bears US NIH Compound Identifier 9419. European Medicines Agency schedules Dibenzepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07074MIG. World Health Organization schedules dibenzepin in its Anatomical Therapeutic Chemical (ATC) Classification. DIBENZEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dibenzepin under HS 29339940 and SITC 51577. As of Q4 2014, DIBENZEPIN remains the US FDA Preferred Term for this commodity. SMILES: O=C1N(CCN(C)C)C2C(N(C3C1CCCC3)C)CCCC2.
This classification denotes the hydrochloride form of a dibenzazepine and tricyclic antidepressive agent with the molecular formula C18H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 510SJZ1Y6L, chemically known as 5,10-dihydro-10-(2-(dimethylamino)ethyl)-5-methyl-11h-dibenzo(b,e)(1,4)diazepin-11-one but more generally known as dibenzepin, which bears US NIH Compound Identifier 9419. European Medicines Agency schedules Dibenzepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07074MIG. World Health Organization schedules dibenzepin in its Anatomical Therapeutic Chemical (ATC) Classification. DIBENZEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dibenzepin hydrochloride under HS 29339940 and SITC 51577. As of Q4 2014, DIBENZEPIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1C2CCCCC2C(=O)N(C3C1CCCC3)CCN(C)C.CL.
This classification denotes a topical anti-infective agent with the molecular formula C17H18Br2N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 269M3QL74S, chemically known as 4,4-(trimethylenedioxy)bis(3-bromobenzamidine) but generally known as dibromopropamidine, which bears US NIH Compound Identifier 11974. European Medicines Agency schedules Dibrompropamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07075MIG. The term DIBROMPROPAMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules dibromopropamidine in its Anatomical Therapeutic Chemical (ATC) Classification. Dibromopropamidine or dibrompropamidine bears US NLM identifiers UMLS ID C0057799 and NCI Concept Code C76261. SMILES: BRC1C(OCCCOC2C(BR)CC(CC2)C(=N)N)CCC(C1)C(=N)N.
This classification denotes a tyrosine analog and non-essential amino acid with the molecular formula C9H9Br2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QD49LEP46E, chemically known as 3,5-dibromotyrosine but generally known as dibromotyrosine, which bears US NIH Compound Identifier 10833. European Medicines Agency schedules Dibromotyrosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13561MIG. World Health Organization schedules dibromotyrosine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIBROMOTYROSINE remains the US FDA Preferred Term for this commodity. SMILES: BRC1CC(CC(N)C(=O)O)CC(BR)C1O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a cough suppressant with the molecular formula C18H24O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZXY319VL5S, chemically known as 1-naphthalenesulfonic acid, 3,6-bis(1,1-dimethylethyl)-, ethyl ester or 2,6-ditert-butylnaphthalene-1-sulfonic acid but more generally known as dibunate, which bears US NIH Compound Identifier 3084737. European Medicines Agency schedules dibunate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10557MIG. The term dibunate is an International Non-Proprietary Name or INN. As of Q4 2014, DIBUNATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)C1=CC2=C(C=C1)C(=C(C=C2)C(C)(C)C)S(=O)(=O)O.
This classification denotes an analgesic and antipyretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T99M8X4T54. European Medicines Agency schedules Dibupyrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07079MIG. Dibupyrone generally arises in the molecular formula C16H22N3O4S.NA. The term DIBUPYRONE is an International Non-Proprietary Name or INN. DIBUPYRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dibupyrone under HS 29331190 and SITC 51571. As of Q4 2014, DIBUPYRONE remains the US FDA Preferred Term for this commodity. Dibupyrone bears US NLM identifiers UMLS ID C2699626 and NCI Concept Code C77319. SMILES: S(=O)(=O)(O)CN(CC(C)C)C1C(N(N(C1=O)C1CCCCC1)C)C.[NA].
This classification denotes an antioxidant and antiarrhythmic agent with the molecular formula C13H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0EA50IJ3V, chemically known as 2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1h-pyrido(4,3-b)indole but generally known as dicarbine, which bears US NIH Compound Identifier 65684. European Medicines Agency schedules Dicarbine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07081MIG. The term DICARBINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). DICARBINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dicarbine under HS 29339990 and SITC 51577. As of Q4 2014, DICARBINE remains the US FDA Preferred Term for this commodity. Dicarbine bears US NLM identifiers UMLS ID C0057820 and NCI Concept Code C77973. SMILES: N1C2C(CN(CC2)C)c2c1ccc(c2)C.
This classification denotes a sedative and hypnotic with the molecular formula C11H12N2O.2C2H3Cl3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YYX637R279, chemically known as 1,2-dihydro-1,5-dimethyl-2-phenyl-3h-pyrazol-3-one, compound with 2,2,2-trichloroethane-1,1-diol (1:2) but generally known as dichloralphenazone, which bears US NIH Compound Identifier 10188. European Medicines Agency schedules Dichloralphenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13563MIG. World Health Organization schedules dichloralphenazone in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DICHLORALPHENAZONE remains the US FDA Preferred Term for this commodity. Dichloralphenazone bears US NLM identifiers UMLS ID C0057831 and NCI Concept Code C87204. SMILES: CC1=CC(=O)N(N1C)C2=CC=CC=C2.C(C(CL)(CL)CL)(O)O.C(C(CL)(CL)CL)(O)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H26CL2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, AMW2MRV3OT chemically known as 9.alpha.,11.beta.-dichloro-17.alpha.,21-dihydroxypregna-1,4-diene-3,20-dione but generally known as dichlorisone, which bears US NIH Compound Identifier 23441. European Medicines Agency schedules Dichlorisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07083MIG. The term DICHLORISONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4. ). Most nations schedule dichlorisone under HS 29372200 and SITC 54153. As of Q4 2014, DICHLORISONE remains the US FDA Preferred Term for this commodity. Dichlorisone bears US NLM identifiers UMLS ID C0544366 and NCI Concept Code C77002. SMILES: CLC12C(C3C(C(O)(CC3)C(=O)CO)(CC1CL)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C23H28Cl2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64FTA4579H, chemically known as 9alpha,11beta-dichloro-17alpha,21-dihydroxypregna-1,4-diene-3,20-dione 21-acetate but more generally known as dichlorisone acetate, which bears US NIH Compound Identifier 6605. Most nations, for tariff and trade purposes, schedule dichlorisone acetate under HS 29372200 and SITC 54153. As of Q4 2014, DICHLORISONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)CL)CL)C)O.
This classification denotes a sedative and hypnotic with the molecular formula C11H11Cl2NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TO4OC41XVI, chemically known as 4-metathiazanone, 2-(3,4-dichlorophenyl)-3-methyl-, 1,1-dioxide but generally known as dichlormezanone, which bears US NIH Compound Identifier 71209. European Medicines Agency schedules Dichlormezanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07084MIG. The term DICHLORMEZANONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). DICHLORMEZANONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dichlormezanone under HS 29349990 and SITC 51579. As of Q4 2014, DICHLORMEZANONE remains the US FDA Preferred Term for this commodity. Dichlormezanone bears US NLM identifiers UMLS ID C2699629 and NCI Concept Code C77250. SMILES: CN1C(S(=O)(=O)CCC1=O)C2=CC(=C(C=C2)CL)CL.
This classification denotes a topical anti-infective agent with the molecular formula C7H6Cl2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1NKX3648J9, chemically known as dichlorobenzyl alcohol, mixed isomers but generally known as dichlorobenzyl alcohol, which bears US NIH Compound Identifier 25493. European Medicines Agency schedules Dichlorobenzyl alcohol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13566MIG. World Health Organization schedules dichlorobenzyl alcohol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DICHLOROBENZYL ALCOHOL remains the US FDA Preferred Term for this commodity. Dichlorobenzyl alcohol bears US NLM identifiers UMLS ID C0057846 and NCI Concept Code C77047. SMILES: C1=CC=C(C=C1)C(O)(Cl)Cl.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes an antihelminthic agent with the molecular formula C13H10Cl2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T1J0JOU64O, chemically known as 5,5-dichloro-2,2-dihydroxydiphenylmethane but generally known as dichlorophen, which bears US NIH Compound Identifier 3037. European Medicines Agency schedules Dichlorophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07085MIG. The term DICHLOROPHEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules dichlorophen in its Anatomical Therapeutic Chemical (ATC) Classification. DICHLOROPHEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dichlorophen under HS 29081900 and SITC 51244. As of Q4 2014, DICHLOROPHEN remains the US FDA Preferred Term for this commodity. Dichlorophen bears US NLM identifiers UMLS ID C0012082 and NCI Concept Code C47485. SMILES: C1=CC(=C(C=C1CL)CC2=C(C=CC(=C2)CL)O)O.
This classification denotes an anti-infective agent with the molecular formula C6H6AsCl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3WD5400T9N, chemically known as phenol, 2-amino-4- (dichloroarsino)-, hydrochloride but more generally known as dichlorophenarsine, which bears US NIH Compound Identifier 68302. European Medicines Agency schedules Dichlorophenarsine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07086MIG. The term DICHLOROPHENARSINE is an International Non-Proprietary Name. DICHLOROPHENARSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [AS](CL)(CL)C1CC(N)C(O)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a cholinergic agonist and carbonic anhydrase inhibitor with the molecular formula C6H6Cl2N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VVJ6673MHY, chemically known as 4,5-dichloro-m-benzenedisulfonamide but generally known as dichlorphenamide, which bears US NIH Compound Identifier 3038. European Medicines Agency schedules Dichlorphenamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07093MIG. The term DICLOFENAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules dichlorphenamide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DICHLORPHENAMIDE remains the US FDA Preferred Term for this commodity. Dichlorphenamide bears US NLM identifiers UMLS ID C0012086 and NCI Concept Code C65376. SMILES: CLC1C(S(=O)(=O)N)CC(S(=O)(=O)N)CC1CL.
This classification denotes a pesticide with the molecular formula C4H7Cl2O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U370BPS14, chemically known as 2,2-dichlorovinyl dimethyl phosphate but generally known as dichlorvos, which bears US NIH Compound Identifier 3039. European Medicines Agency schedules Dichlorvos in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07088MIG. The term DICHLORVOS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). DICHLORVOS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dichlorvos under HS 29199090 and SITC 51631. As of Q4 2014, DICHLORVOS remains the US FDA Preferred Term for this commodity. Dichlorvos bears US NLM identifiers UMLS ID C0012087 and NCI Concept Code C76871. SMILES: CL/C(=C/OP(=O)(OC)OC)CL.
This classification denotes an antiprotozoal agent with the molecular formula C17H9Cl3N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K110K1B1VE, chemically known as r64,433 but generally known as diclazuril, which bears US NIH Compound Identifier 58902. European Medicines Agency schedules Diclazuril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07091MIG. The term DICLAZURIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). Most nations schedule diclazuril under HS 29336980 and SITC 51576. As of Q4 2014, DICLAZURIL remains the US FDA Preferred Term for this commodity. Diclazuril bears US NLM identifiers UMLS ID C0057874 and NCI Concept Code C76418. SMILES: CLC1C(C(C2CCC(CL)CC2)C#N)C(CL)CCC1N1NCC(=O)[NH]C1=O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H11Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 144O8QL0L1, chemically known as 2-((2,6-dichlorophenyl)amino)benzeneacetic acid but generally known as diclofenac, which bears US NIH Compound Identifier 3033. European Medicines Agency schedules Diclofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07092MIG. The term DICLOFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules diclofenac in its Anatomical Therapeutic Chemical (ATC) Classification. DICLOFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diclofenac under HS 29224995 and SITC 51465. As of Q4 2014, DICLOFENAC remains the US FDA Preferred Term for this commodity. Diclofenac bears US NLM identifiers UMLS ID C0012091 and NCI Concept Code C28985. SMILES: CLC1C(NC2C(CC(=O)O)CCCC2)C(CL)CCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11CL2NO2.C4H11N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6TGQ35Z71K. European Medicines Agency schedules diclofenac diethylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01669MIG. The term diclofenac diethylamine is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule diclofenac diethylamine under HS 29224995 and SITC 51465. As of Q4 2014, DICLOFENAC DIETHYLAMINE remains US FDA's Preferred Term for this commodity. Diclofenac diethylamine bears US NLM identifiers UMLS ID C0771369 and NCI Concept Code C87322. SMILES: CCNCC.C1CCC(C(C1)CC(=O)O)NC2C(CCCC2CL)CL.
This classification denotes a cyclooxygenase inhibitor C14H11Cl2NO2.C6H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X5F8EKL9ZG, chemically known as benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, compd. with 1-pyrrolidineethanol (1:1), but more generally known as diclofenac epolamine, which bears US NIH Compound Identifier 114753. European Medicines Agency schedules Diclofenac epolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20558. Most nations, for tariff and trade purposes, schedule diclofenac epolamine under HS 29224995 and SITC 51465. As of Q4 2014, DICLOFENAC EPOLAMINE remains US FDA's Preferred Term for this commodity. Diclofenac epolamine bears US NLM identifiers UMLS ID C0082274 and NCI Concept Code C77355. SMILES: C1CCC(C(C1)CC(=O)O)NC2C(CCCC2CL)CL.C1CCN(C1)CCO.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H11Cl2NO2.C6H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X5F8EKL9ZG, chemically known as benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, compd. with 1-pyrrolidineethanol (1:1), but more generally known as diclofenac hydroxyethylpyrrolidine, which bears US NIH Compound Identifier 114753. European Medicines Agency schedules diclofenac hydroxyethylpyrrolidine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07092MIG. Most nations, for tariff purposes, schedule diclofenac hydroxyethylpyrrolidine under HS 29224995. SMILES: C1CCC(C(C1)CC(=O)O)NC2C(CCCC2CL)CL.C1CCN(C1)CCO.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H10Cl2NO2.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L4D5UA6CB4, chemically known as 2-((2,6-dichlorophenyl)amino)benzeneacetic acid but more generally known as diclofenac potassium, which bears US NIH Compound Identifier 3033. European Medicines Agency schedules Diclofenac potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13568MIG. Most nations, for tariff and trade purposes, schedule diclofenac potassium under HS 29224995 and SITC 51465. As of Q4 2014, DICLOFENAC POTASSIUM remains US FDA's Preferred Term for this commodity. Diclofenac potassium bears US NLM identifiers UMLS ID C0282131 and NCI Concept Code C47983. SMILES: C1CCC(C(C1)CC(=O)[O-])NC2C(CCCC2CL)CL.[K+].
This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H10Cl2NO2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QTG126297Q, chemically known as 2-((2,6-dichlorophenyl)amino)benzeneacetic acid but more generally known as diclofenac sodium, which bears US NIH Compound Identifier 3033. European Medicines Agency schedules Diclofenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01674MIG. Most nations, for tariff and trade purposes, schedule diclofenac sodium under HS 29224995 and SITC 51465. As of Q4 2014, DICLOFENAC SODIUM remains US FDA's Preferred Term for this commodity. Diclofenac sodium bears US NLM identifiers UMLS ID C0700583 and NCI Concept Code C47984. SMILES: C1CCC(C(C1)CC(=O)[O-])NC2C(CCCC2CL)CL.[NA+].
This classification denotes an antidepressant agent with the molecular formula C17H17CL2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 09HKW863J6 chemically known as (+/-)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline but generally known as diclofensine, which bears US NIH Compound Identifier 68871. European Medicines Agency schedules Diclofensine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07094MIG. The term DICLOFENSINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21. ). Most nations schedule diclofensine under HS 29334990 and SITC 51575. As of Q4 2014, DICLOFENSINE remains the US FDA Preferred Term for this commodity. Diclofensine bears US NLM identifiers UMLS ID C0057877 and NCI Concept Code C78017. SMILES: CLC1CC(C2CN(CC3C2CCC(OC)C3)C)CCC1CL.
This classification denotes a calcium channel blocker with the molecular formula C18H22Cl2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D1FP3K444H, chemically known as 2,3-dichloro-4-methoxyphenyl 2-furyl ketone (e)-o-(2-(diethylamino)ethyl)-oxime. but generally known as diclofurime, which bears US NIH Compound Identifier 9577638. European Medicines Agency schedules Diclofurime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07095MIG. The term DICLOFURIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). DICLOFURIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diclofurime under HS 29321900 and SITC 51569. As of Q4 2014, DICLOFURIME remains the US FDA Preferred Term for this commodity. Diclofurime bears US NLM identifiers UMLS ID C0113741 and NCI Concept Code C77824. SMILES: Clc1c(/C(=N\OCCN(CC)CC)c2occc2)ccc(OC)c1Cl.
This classification denotes an antipsychotic agent with the molecular formula C14H20Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05186J17EP, chemically known as 3,5-dichloro-n-(2-(diethylamino)-ethyl)-o-anisamide. but generally known as diclometide, which bears US NIH Compound Identifier 208832. European Medicines Agency schedules Diclometide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07096MIG. The term DICLOMETIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). DICLOMETIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diclometide under HS 29242995 and SITC 51479. As of Q4 2014, DICLOMETIDE remains the US FDA Preferred Term for this commodity. Diclometide bears US NLM identifiers UMLS ID C2699631 and NCI Concept Code C79127. SMILES: CLC1C(OC)C(C(=O)NCCN(CC)CC)CC(CL)C1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H8Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 357591W853, chemically known as 2-(2,3-dichloroanilino)-nicotinic acid. but generally known as diclonixin, which bears US NIH Compound Identifier 208833. European Medicines Agency schedules Diclonixin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07097MIG. The term DICLONIXIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). DICLONIXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diclonixin under HS 29333999 and SITC 51574. As of Q4 2014, DICLONIXIN remains the US FDA Preferred Term for this commodity. Diclonixin bears US NLM identifiers UMLS ID C2699632 and NCI Concept Code C77356. SMILES: CLC1C(NC2NCCCC2C(=O)O)CCCC1CL.
This classification denotes an industrial aid with the molecular formula C5H6Cl6N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J3ZB93FIE, chemically known as 1,3-bis(2,2,2-trichloro-1-hydroxyethyl)urea but more generally known as dicloralurea, which bears US NIH Compound Identifier 8313. European Medicines Agency schedules Dicloralurea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07098MIG. The term DICLORALUREA is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). DICLORALUREA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC(CL)(CL)C(O)NC(=O)NC(O)C(CL)(CL)CL.
This classification denotes a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier COF19H7WBK. European Medicines Agency schedules Dicloxacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07099MIG. Dicloxacillin generally arises in the molecular formula C19H17CL2N3O5S. The term DICLOXACILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) DICLOXACILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dicloxacillin under HS 29411090 and SITC 54131. As of Q4 2014, DICLOXACILLIN remains the US FDA Preferred Term for this commodity. Dicloxacillin bears US NLM identifiers UMLS ID C0012093 and NCI Concept Code C28986. SMILES: CLC1C(C2NOC(C2C(=O)NC2C3SC(C(N3C2=O)C(=O)O)(C)C)C)C(CL)CCC1.
This classification denotes a penicillin antibiotic with the molecular formula C19H16Cl2N3O5S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4HZT2V9KX0, chemically known as monosodium (2s,5r,6r)-6-(3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate monohydrate, but more generally known as dicloxacillin sodium, which bears US NIH Compound Identifier 6098. European Medicines Agency schedules dicloxacillin sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07099MIG. Most nations, for tariff purposes, schedule dicloxacillin sodium under HS 29411090. As of Q4 2014, DICLOXACILLIN SODIUM remains US FDA's Preferred Term for this commodity. Dicloxacillin sodium bears US NLM identifiers UMLS ID C0887422 and NCI Concept Code C47985. SMILES: CC1C(C(NO1)C2C(CCCC2CL)CL)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[NA+].
This classification denotes a penicillin antibiotic with the molecular formula C19H16Cl2N3O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CKS6MOL6Z, chemically known as monosodium (2s,5r,6r)-6-(3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate, but more generally known as dicloxacillin sodium anhydrous, which bears US NIH Compound Identifier 64688. European Medicines Agency schedules dicloxacillin sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07099MIG. Most nations, for tariff purposes, schedule dicloxacillin sodium anhydrous under HS 29411090. SMILES: CC1C(C(NO1)C2C(CCCC2CL)CL)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[NA+].
This classification denotes a penicillin antibiotic with the molecular formula C19H16Cl2N3O5S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4HZT2V9KX0, chemically known as 6-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but more generally known as dicloxacillin sodium, which bears US NIH Compound Identifier 6098. European Medicines Agency schedules Dicloxacillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11900MIG. Most nations, for tariff and trade purposes, schedule dicloxacillin sodium monohydrate under HS 29411090 and SITC 54131. SMILES: CC1C(C(NO1)C2C(CCCC2CL)CL)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[NA+].
This classification denotes a protective agent with the molecular formula C10H12N2O8.2Co, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UKC6GH80QR, chemically known as cobaltate(2-), ((n,n-1,2-ethanediylbis(n-(carboxymethyl)glycinato))(4-)-n,n,o,o,o(sup n), o(sup n))-, cobalt(2+) (1:1), (oc-6-21) but generally known as dicobalt edetate, which bears US NIH Compound Identifier 71942. European Medicines Agency schedules Dicobalt edetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13569MIG. The term DICOBALT EDETATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). Most nations schedule dicobalt edetate under HS 29224995 and SITC 51465. As of Q4 2014, DICOBALT EDETATE remains the US FDA Preferred Term for this commodity. Dicobalt edetate bears US NLM identifiers UMLS ID C0950483 and NCI Concept Code C81167. SMILES: C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Co+2].[Co+2].
This classification denotes a coumarin compound and anticoagulant agent with the molecular formula C19H12O6, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7QID3E7BG7, chemically known as 4,4-dihydroxy-3,3-methylene bis coumarin but more generally known as dicoumarol, which bears US NIH Compound Identifier 653. European Medicines Agency schedules Dicoumarol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07101MIG. The term DICOUMAROL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules dicoumarol in its Anatomical Therapeutic Chemical (ATC) Classification. DICOUMAROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Dicumarol bears US NLM identifiers UMLS ID C0005640 and NCI Concept Code C310. SMILES: O1C(O)C(CC2C(=O)C3C(OC2O)CCCC3)C(=O)C2C1CCCC2.
This classification denotes an antimuscarinic agent with the molecular formula C19H35NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4KV4X8IF6V, chemically known as cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester but more generally known as dicyclomine, which bears US NIH Compound Identifier 3042. European Medicines Agency schedules Dicycloverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07103MIG. The term DICYCLOVERINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules dicyclomine in its Anatomical Therapeutic Chemical (ATC) Classification. Dicyclomine bears US NLM identifiers UMLS ID C0012125 and NCI Concept Code C61720. SMILES: CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3GDH6OH08, chemically known as 2,3-dideoxyinosine & scd4(soluble recombinant protein) but generally known as didanosine, which bears US NIH Compound Identifier 50599. European Medicines Agency schedules Didanosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07104MIG. The term DIDANOSINE is an International Non-Proprietary Name. World Health Organization schedules didanosine in its Anatomical Therapeutic Chemical (ATC) Classification. DIDANOSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule didanosine under HS 29349990 and SITC 51579. As of Q4 2014, DIDANOSINE remains the US FDA Preferred Term for this commodity. Didanosine bears US NLM identifiers UMLS ID C0012133 and NCI Concept Code C431. SMILES: C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2NC=NC3=O.
This classification denotes a quaternary ammonium compound with the molecular formula C22H48N.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JXN40O9Y9B, chemically known as 1-decanaminium, n-decyl-n,n-dimethyl-, chloride but generally known as didecyldimethylammonium chloride, which bears US NIH Compound Identifier 23558. World Health Organization schedules didecyldimethylammonium chloride in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Cl-].
This classification denotes a non-steroidal estrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RRW32X4U1F. European Medicines Agency schedules Dienestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07107MIG. Dienestrol generally arises in the molecular formula C18H18O2. The term DIENESTROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) DIENESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dienestrol under HS 29072900 and SITC 51243. As of Q4 2014, DIENESTROL remains the US FDA Preferred Term for this commodity. Dienestrol bears US NLM identifiers UMLS ID C0012145 and NCI Concept Code C65377. SMILES: Oc1ccc(C(=C\C)/C(=C/C)c2ccc(O)cc2)cc1.
This classification denotes a non-steroidal estrogen with the molecular formula C22H22O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D20D148WPQ, chemically known as phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, diacetate, (e,e)-, but more generally known as dienestrol diacetate, which bears US NIH Compound Identifier 5357580. European Medicines Agency schedules dienestrol diacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07107MIG. Most nations, for tariff purposes, schedule dienestrol diacetate under HS 29072900. SMILES: C/C=C(/C(=C/C)/C1CCC(CC1)OC(=O)C)\C2CCC(CC2)OC(=O)C.
This classification denotes a therapeutic progestin with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46M3EV8HHE, chemically known as 19-norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17-alpha)- but generally known as dienogest, which bears US NIH Compound Identifier 68861. European Medicines Agency schedules Dienogest in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07108MIG. The term DIENOGEST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). DIENOGEST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dienogest under HS 29372300 and SITC 54153. As of Q4 2014, DIENOGEST remains the US FDA Preferred Term for this commodity. Dienogest bears US NLM identifiers UMLS ID C0057916 and NCI Concept Code C87238. SMILES: OC1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)CC2)CC1)C)CC#N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes an anti-inflammatory with the molecular formula C11H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V7PT38BJU, chemically known as 2-carboxyphenolate;diethylazanium but generally known as acetylsalicylic acid, which bears US NIH Compound Identifier 54678495. European Medicines Agency schedules diethylamine salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB43350 and SUB13573MIG. As of Q4 2014, DIETHYLAMINE SALICYLATE remains the US FDA Preferred Term for this commodity. SMILES: CC[NH2+]CC.C1=CC=C(C(=C1)C(=O)O)[O-].
This classification denotes an antihelminthic agent with the molecular formula C10H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V867Q8X3ZD, chemically known as 4-methyl-n,n-bis(4-methylpiperazin-2-yl)-piperazine-1-carboxamide but generally known as diethylcarbamazine, which bears US NIH Compound Identifier 3052. European Medicines Agency schedules Diethylcarbamazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07111MIG. The term DIETHYLCARBAMAZINE is an International Non-Proprietary Name. World Health Organization schedules diethylcarbamazine in its Anatomical Therapeutic Chemical (ATC) Classification. DIETHYLCARBAMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diethylcarbamazine under HS 29335995 and SITC 51576. As of Q4 2014, DIETHYLCARBAMAZINE remains the US FDA Preferred Term for this commodity. Diethylcarbamazine bears US NLM identifiers UMLS ID C0012191 and NCI Concept Code C65378. SMILES: CCN(CC)C(=O)N1CCN(CC1)C.
This classification denotes an antihelminthic agent with the molecular formula C10H21N3O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OS1Z389K8S, chemically known as 4-methyl-n,n-bis(4-methylpiperazin-2-yl)-piperazine-1-carboxamide but more generally known as diethylcarbamazine citrate, which bears US NIH Compound Identifier 3052. European Medicines Agency schedules Diethylcarbamazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01686MIG. Most nations, for tariff and trade purposes, schedule diethylcarbamazine citrate under HS 29335990 and SITC 51576. As of Q4 2014, DIETHYLCARBAMAZINE CITRATE remains US FDA's Preferred Term for this commodity. Diethylcarbamazine citrate bears US NLM identifiers UMLS ID C0700531 and NCI Concept Code C65379. SMILES: CCN(CC)C(=O)N1CCN(CC1)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an inhalation anesthetic and solvent with the molecular formula C4H10O, a compound which US FDA regulates as an active or moiety under Unique Ingredient Identifier 0F5N573A2Y,chemically known as 1,1-oxydiethane but generally known as diethyl ether, and which bears US National Library of Medicine Compound Identifier 3293. European Medicines Agency schedules Diethyl ether in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30482. World Health Organization schedules diethyl ether in its Anatomical Therapeutic Chemical (ATC) Classification. Ethyl ether bears European Inventory of Existing Commercial Chemical Substances number 200-467-2. Under the World Customs Organization Harmonised System, ethyl ether is scheduled in 29091100, and ethyl ether bears US Drug Enforcement Administration Number 6584. The United Nations International Drug Control Programme's Technical Services Branch, in accordance with and support of the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, and Article 12 thereof, in conjunction with scientific findings Clandestine Manufacture of Substances under International Control (ST/NAR/10), has determined that this commodity (ethyl ether) is a precursor in manufacture of Amfetamine, Cocaine, DET (N,N-diethyltryptamine), DMT (N,N-dimethyltryptamine), Fentanyl, Heroin, (+)-Lysergide (LSD), Mecloqualone, Mescaline, Metamfetamine, Methadone, Methaqualone, MPPP (1-methyl-4-phenyl-4-propionoxypiperidine), PEPAP (1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine), Pethidine, Phencyclidine (PCP), Psilocine, or ring-substituted derivatives of Amfetamine and Metamfetamine (See Scientific and Technical Note SCITEC/11). Under EU regulations, ethyl ether is governed by Regulation (EC) No 273/2004 (rules for the monitoring of trade between the Community and third countries in drug precursors) and Official Journal L 022, 26/01/2005 P. 0001-0010. Under US regulations, ethyl ether is governed by Title 21 Code of Federal Regulations, §§ 1309, 1310.02, and 1313. Under Canadian regulations, ethyl ether is governed by Controlled Drugs and Substances Act subsection 55(1) (S.C. 1996, c. 19) and Precursor Control Regulations (SOR/2002-359), P.C. 2002-1615 2002-09-24. Diethyl ether or ether bears US NLM identifiers UMLS ID C0014994 and NCI Concept Code C29819. SMILES: CCOCC.
This classification denotes a cns stimulant and anorexiant with the molecular formula C13H19NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19V2PL39NG, chemically known as 1-propanone, 2-(diethylamino)-1-phenyl- but more generally known as amfepramone hydrochloride, which bears US NIH Compound Identifier 7029. European Medicines Agency schedules Amfepramone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00434MIG. As of Q4 2014, DIETHYLPROPION HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diethylpropion hydrochloride bears US NLM identifiers UMLS ID C0723644 and NCI Concept Code C47486. SMILES: O=C(C(N(CC)CC)C)C1CCCCC1.
This classification denotes a non-steroidal estrogen with the molecular formula C18H20O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 731DCA35BT, chemically known as phenol, 4,4-(1,2-diethyl-1,2-ethenediyl)bis- but generally known as diethylstilbestrol, which bears US NIH Compound Identifier 3054. European Medicines Agency schedules Diethylstilbestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07112MIG. The term DIETHYLSTILBESTROL is an International Non-Proprietary Name. World Health Organization schedules diethylstilbestrol in its Anatomical Therapeutic Chemical (ATC) Classification. DIETHYLSTILBESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diethylstilbestrol under HS 29072900 and SITC 51243. As of Q4 2014, DIETHYLSTILBESTROL remains the US FDA Preferred Term for this commodity. Diethylstilbestrol bears US NLM identifiers UMLS ID C0012203 and NCI Concept Code C433. SMILES: Oc1ccc(C(=C(\CC)c2ccc(O)cc2)/CC)cc1.
This classification denotes a non-steroidal estrogen with the molecular formula C50H80O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86291XW83U, chemically known as hexadecanoic acid, (1,2-diethyl-1,2-ethenediyl)di-4,1-phenylene ester, (e)-, but more generally known as diethylstilbestrol dipalmitate, which bears US NIH Compound Identifier 3032511. European Medicines Agency schedules diethylstilbestrol dipalmitate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07112MIG. Most nations, for tariff purposes, schedule diethylstilbestrol dipalmitate under HS 29072900. SMILES: CCCCCCCCCCCCCCCC(=O)OC1CCC(CC1)/C(=C(\CC)/C2CCC(CC2)OC(=O)CCCCCCCCCCCCCCC)/CC.
This classification denotes a hormonal antineoplastic agent with the molecular formula C18H22O8P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0E0NMA80F, chemically known as 4,4-stilbenediol, .alpha., .alpha.-diethyl-, diphosphate, disodium salt but more generally known as fosfestrol, which bears US NIH Compound Identifier 3032325. European Medicines Agency schedules Fosfestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07795MIG. World Health Organization schedules fosfestrol in its Anatomical Therapeutic Chemical (ATC) Classification. FOSFESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule diethylstilbestrol diphosphate under HS 29072900. SMILES: CC/C(=C(/CC)\C1CCC(CC1)OP(=O)(O)O)/C2CCC(CC2)OP(=O)(O)O.
This classification denotes a non-steroidal estrogen with the molecular formula C24H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y98CK3J0OL, chemically known as 4,4-stilbenediol, alpha,alpha-diethyl-, dipropionate, trans- but more generally known as diethylstilbestrol dipropionate, which bears US NIH Compound Identifier 657220. European Medicines Agency schedules Diethylstilbestrol dipropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32995. Most nations, for tariff and trade purposes, schedule diethylstilbestrol dipropionate under HS 29072900. As of Q4 2014, DIETHYLSTILBESTROL DIPROPIONATE remains US FDA's Preferred Term for this commodity. Diethylstilbestrol dipropionate bears US NLM identifiers UMLS ID C0057965 and NCI Concept Code C74557. SMILES: CC/C(=C(/CC)\C1CCC(CC1)OC(=O)CC)/C2CCC(CC2)OC(=O)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
This classification denotes an opioid receptor agonist with the molecular formula C16H21NS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z91X9052O, chemically known as 3-diethylamino-1,1-dithienylbut-1-ene but generally known as diethylthiambutene, which bears US NIH Compound Identifier 6833. European Medicines Agency schedules Diethylthiambutene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07113MIG. The term DIETHYLTHIAMBUTENE is an International Non-Proprietary Name. DIETHYLTHIAMBUTENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diethylthiambutene under HS 29349990 and SITC 51579. As of Q4 2014, DIETHYLTHIAMBUTENE remains the US FDA Preferred Term for this commodity. Diethylthiambutene bears US NLM identifiers UMLS ID C0663393 and NCI Concept Code C77287. SMILES: CCN(CC)C(C)C=C(C1=CC=CS1)C2=CC=CS2.
This classification denotes an opioid receptor agonist C16H21NS2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L46E90B1X, chemically known as 3-buten-2-amine, n,n-diethyl-4,4-di-2-thienyl-, hydrochloride (1:1), but more generally known as diethylthiambutene hydrochloride, which bears US NIH Compound Identifier 8585. Most nations, for tariff and trade purposes, schedule diethylthiambutene hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, DIETHYLTHIAMBUTENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)C(C)C=C(C1CCCS1)C2CCCS2.CL.
This classification denotes a sedative and hypnotic with the molecular formula C28H42N4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7EE4K616KK, chemically known as 1,3-bis(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid dicarbamate ester but generally known as difebarbamate, which bears US NIH Compound Identifier 71880. European Medicines Agency schedules Difebarbamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07116MIG. The term DIFEBARBAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). DIFEBARBAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule difebarbamate under HS 29335400 and SITC kg. As of Q4 2014, DIFEBARBAMATE remains the US FDA Preferred Term for this commodity. Difebarbamate bears US NLM identifiers UMLS ID C0057977 and NCI Concept Code C77252. SMILES: O=C1N(C(=O)N(C(=O)C1(CC)C1CCCCC1)CC(OC(=O)N)COCCCC)CC(OC(=O)N)COCCCC.
This classification denotes an antimuscarinic agent with the molecular formula C20H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 843C4UPZ2F, chemically known as benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, 2-(dimethylamino)-2-methylpropyl ester but generally known as difemerine, which bears US NIH Compound Identifier 165124. European Medicines Agency schedules Difemerine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07117MIG. The term DIFEMERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules difemerine in its Anatomical Therapeutic Chemical (ATC) Classification. DIFEMERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule difemerine under HS 29221980 and SITC 51461. As of Q4 2014, DIFEMERINE remains the US FDA Preferred Term for this commodity. Difemerine bears US NLM identifiers UMLS ID C0612470 and NCI Concept Code C83670. SMILES: O(CC(N(C)C)(C)C)C(=O)C(O)(C1CCCCC1)C1CCCCC1.
This classification denotes an anorexiant with the molecular formula C20H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) O0417MPF6W, chemically known as 1-piperidineethanol, 2-(diphenylmethyl)- but more generally known as difemetorex, which bears US NIH Compound Identifier 65607. European Medicines Agency schedules Difemetorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07118MIG. The term DIFEMETOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). DIFEMETOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule difemetorex under HS 29333999 and SITC 51574. As of Q4 2014, DIFEMETOREX remains US FDA's Preferred Term for this commodity. Difemetorex bears US NLM identifiers UMLS ID C2699771 and NCI Concept Code C77328. SMILES: OCCN1C(CCCC1)C(C1CCCCC1)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H22N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24MR6YLL3W, chemically known as 1,3-diphenyl-5-(2-dimethylaminopropionamido)pyrazole but generally known as difenamizole, which bears US NIH Compound Identifier 65695. European Medicines Agency schedules Difenamizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07119MIG. The term DIFENAMIZOLE is an International Non-Proprietary Name. DIFENAMIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule difenamizole under HS 29331990 and SITC 51571. As of Q4 2014, DIFENAMIZOLE remains the US FDA Preferred Term for this commodity. Difenamizole bears US NLM identifiers UMLS ID C0057979 and NCI Concept Code C77357. SMILES: O=C(NC1N(NC(C1)C1CCCCC1)C1CCCCC1)C(N(C)C)C.
This classification denotes an antiemetic agent with the molecular formula C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQO8R319LY, chemically known as 1,1-diphenyl-4-(1-piperidyl)butan-1-ol but generally known as difenidol, which bears US NIH Compound Identifier 3055. European Medicines Agency schedules Difenidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07121MIG. The term DIFENIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). DIFENIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Difenidol or diphenidol bears US NLM identifiers UMLS ID C0058371 and NCI Concept Code C65421. SMILES: C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O.
This classification denotes an antispasmotic agent with the molecular formula C32H31N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6GEY4W769K, chemically known as 1-piperidinebutanenitrile, 4-(((2,5-dioxo-1-pyrrolidinyl)oxy)carbonyl)-alpha,alpha,4-triphenyl-, monohydrochloride but more generally known as difenoximide hydrochloride, which bears US NIH Compound Identifier 71431. Most nations, for tariff and trade purposes, schedule difenoximide hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DIFENOXIMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Difenoximide hydrochloride bears US NLM NCI C77288. SMILES: C1CCC(CC1)C2(CCN(CC2)CCC(C#N)(C3CCCCC3)C4CCCCC4)C(=O)ON5C(=O)CCC5=O.CL.
This classification denotes an antispasmotic agent with the molecular formulas C32H31N3O4 and C32H31N3O4.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 8UG1323C03 and 6GEY4W769K, the base compound being chemically known as 4-(((2,5-dioxo-1-pyrrolidinyl)oxy)carbonyl)-alpha,alpha,4-triphenyl-1-piperidinebutanenitrile but generally known as difenoximide, which bears US NIH Compound Identifier 39481. European Medicines Agency schedules Difenoximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07122MIG. The term DIFENOXIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). DIFENOXIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule difenoximide and its salts under HS 29333999 and SITC 51574. As of Q4 2014, DIFENOXIMIDE remains the US FDA Preferred Term for this commodity. Difenoximide bears US NLM NCI C73162 and C77288. SMILES: O(N1C(=O)CCC1=O)C(=O)C1(CCN(CC1)CCC(C1CCCCC1)(C1CCCCC1)C#N)C1CCCCC1 (base) or C1CCC(CC1)C2(CCN(CC2)CCC(C#N)(C3CCCCC3)C4CCCCC4)C(=O)ON5C(=O)CCC5=O.CL.
This classification denotes an antidiarrheal agent with the molecular formula C28H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3ZZ5BJ9F2Q, chemically known as 4-piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl- but generally known as difenoxin, which bears US NIH Compound Identifier 34328. European Medicines Agency schedules Difenoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07123MIG. The term DIFENOXIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules difenoxin in its Anatomical Therapeutic Chemical (ATC) Classification. DIFENOXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule difenoxin under HS 29333300 and SITC 51574. As of Q4 2014, DIFENOXIN remains the US FDA Preferred Term for this commodity. Difenoxin bears US NLM identifiers UMLS ID C0057981 and NCI Concept Code C65381. SMILES: OC(=O)C1(CCN(CC1)CCC(C1CCCCC1)(C1CCCCC1)C#N)C1CCCCC1.
This classification denotes an antidiarrheal agent with the molecular formula C28H28N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VQZ63K01IW, chemically known as 4-piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, monohydrochloride but more generally known as difenoxin hydrochloride, which bears US NIH Compound Identifier 37193. European Medicines Agency schedules Difenoxin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01691MIG. Most nations, for tariff and trade purposes, schedule difenoxin hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, DIFENOXIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Difenoxin hydrochloride bears US NLM identifiers UMLS ID C0770333 and NCI Concept Code C47487. SMILES: C1CCC(CC1)C2(CCN(CC2)CCC(C#N)(C3CCCCC3)C4CCCCC4)C(=O)O.CL.
This classification denotes a non-steroidal anti-inflammatory agent and acetamide with the molecular formula C19H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q6U5F6E1QL, chemically known as n-pyridin-2-yl(1,1-biphenyl)-4-acetamide but generally known as difenpiramide, which bears US NIH Compound Identifier 100472. World Health Organization schedules difenpiramide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIFENPIRAMIDE remains the US FDA Preferred Term for this commodity. SMILES: C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)NC3=CC=CC=N3.
This classification denotes an antiprotozoal agent with the molecular formula C14H18As2N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4G9J3Q65W, chemically known as n,n-ethylenediarsanilic acid but generally known as difetarsone, which bears US NIH Compound Identifier 68199. European Medicines Agency schedules Difetarsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07124MIG. The term DIFETARSONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules difetarsone in its Anatomical Therapeutic Chemical (ATC) Classification. DIFETARSONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DIFETARSONE remains the US FDA Preferred Term for this commodity. Difetarsone bears US NLM identifiers UMLS ID C1322006 and NCI Concept Code C78101. SMILES: [AS](=O)(O)(O)C1CCC(NCCNC2CCC([AS](=O)(O)O)CC2)CC1.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A2P950OCL0. European Medicines Agency schedules Difeterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07125MIG. Difeterol generally arises in the molecular formula C25H29NO2. The term DIFETEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) DIFETEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule difeterol under HS 29221980 and SITC 51461. As of Q4 2014, DIFETEROL remains the US FDA Preferred Term for this commodity. Difeterol bears US NLM identifiers UMLS ID C2699775 and NCI Concept Code C77436. SMILES: O(CCN(C(C(O)C1CCCCC1)C)C)C(C1CCCCC1)C1CCCCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C25H29NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H9ZL6T9U7J, chemically known as benzenemethanol, .alpha.-(1-((2-(diphenylmethoxy)ethyl)methylamino)ethyl)-, hydrochloride (1:1), but more generally known as difeterol hydrochloride, which bears US NIH Compound Identifier 444032. European Medicines Agency schedules difeterol hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07125MIG. Most nations, for tariff purposes, schedule difeterol hydrochloride under HS 29221980. SMILES: CC(C(C1CCCCC1)O)N(C)CCOC(C2CCCCC2)C3CCCCC3.CL.
This classification denotes a camptothecin analogue with the molecular formula C21H16F2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QKT1LC4J1P, chemically known as 3h,15h-oxepino(3,4:6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-, (5r)- but generally known as diflomotecan, which bears US NIH Compound Identifier 219023. The term DIFLOMOTECAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule diflomotecan under HS 29399900 and SITC 54149. As of Q4 2014, DIFLOMOTECAN remains the US FDA Preferred Term for this commodity. Diflomotecan bears US NLM identifiers UMLS ID C1541796 and NCI Concept Code C90824. SMILES: CC[C@]1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2DHJ9645W, chemically known as 6alpha-fluorobetamethasone-17,21 diacetate but generally known as diflorasone, which bears US NIH Compound Identifier 71414. European Medicines Agency schedules Diflorasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07126MIG. World Health Organization schedules diflorasone in its Anatomical Therapeutic Chemical (ATC) Classification. DIFLORASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diflorasone under HS 29372200 and SITC 54153. As of Q4 2014, DIFLORASONE remains the US FDA Preferred Term for this commodity. Diflorasone bears US NLM identifiers UMLS ID C0304612 and NCI Concept Code C61722. SMILES: FC12C(C3C(C(OC(=O)C)(C(C3)C)C(=O)COC(=O)C)(CC1O)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H32F2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7W2J09SCWX, chemically known as pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.beta.)- but more generally known as diflorasone diacetate, which bears US NIH Compound Identifier 3056. European Medicines Agency schedules Diflorasone diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01693MIG. Most nations, for tariff and trade purposes, schedule diflorasone diacetate under HS 29372200 and SITC 54153. As of Q4 2014, DIFLORASONE DIACETATE remains US FDA's Preferred Term for this commodity. Diflorasone diacetate bears US NLM identifiers UMLS ID C0720464 and NCI Concept Code C47488. SMILES: C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F.
This classification denotes a quinolone antibiotic with the molecular formula C21H19F2N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z7OO9FNFD, chemically known as 6-fluoro-1-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid but generally known as difloxacin, which bears US NIH Compound Identifier 56206. The term DIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). DIFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule difloxacin under HS 29335995 and SITC 51576. As of Q4 2014, DIFLOXACIN remains the US FDA Preferred Term for this commodity. Difloxacin bears US NLM identifiers UMLS ID C0057993 and NCI Concept Code C65382. SMILES: CN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28F2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K253365DXI, chemically known as 6alpha,9-difluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione but generally known as diflucortolone, which bears US NIH Compound Identifier 17455. European Medicines Agency schedules Diflucortolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07128MIG. The term DIFLUCORTOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules diflucortolone in its Anatomical Therapeutic Chemical (ATC) Classification. DIFLUCORTOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diflucortolone under HS 29372200 and SITC 54153. As of Q4 2014, DIFLUCORTOLONE remains the US FDA Preferred Term for this commodity. Diflucortolone bears US NLM identifiers UMLS ID C0012227 and NCI Concept Code C87231. SMILES: FC12C(C3C(C(C(C3)C)C(=O)CO)(CC1O)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid C27H36F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZR05N78276, chemically known as pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as diflucortolone pivalate, which bears US NIH Compound Identifier 66381. Most nations, for tariff and trade purposes, schedule diflucortolone pivalate under HS 29372200 and SITC 54153. As of Q4 2014, DIFLUCORTOLONE PIVALATE remains US FDA's Preferred Term for this commodity. Diflucortolone pivalate bears US NLM identifiers UMLS ID C0770953 and NCI Concept Code C65383. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C(C)(C)C)C)O)F)C)F.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H36F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1A63Z067C8, chemically known as 6-alpha,9-difluoro-11-beta-hydroxy-21-valeryloxy-16-alpha-methyl-1,4-pregnadiene-3,20-dione but more generally known as diflucortolone valerate, which bears US NIH Compound Identifier 91670. European Medicines Agency schedules Diflucortolone valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01694MIG. Most nations, for tariff and trade purposes, schedule diflucortolone valerate under HS 29372200 and SITC 54153. As of Q4 2014, DIFLUCORTOLONE VALERATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC(=O)OCC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11F2NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E96467495S chemically known as 3'-benzoyl-1,1-difluoromethanesulfonanilide but generally known as diflumidone, which bears US NIH Compound Identifier 31501. European Medicines Agency schedules Diflumidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07129MIG. The term DIFLUMIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9). Most nations schedule diflumidone under HS 29350090 and SITC 51580. As of Q4 2014, DIFLUMIDONE remains the US FDA Preferred Term for this commodity. Diflumidone bears US NLM identifiers UMLS ID C0057995 and NCI Concept Code C65384. SMILES: C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)NS(=O)(=O)C(F)F.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H10F2NO3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2NLB7019Y0, chemically known as 3-benzoyl-1,1-difluoromethanesulfonanilide sodium salt but more generally known as diflumidone sodium, which bears US NIH Compound Identifier 31500. Most nations, for tariff and trade purposes, schedule diflumidone sodium under HS 29350090 and SITC 51580. As of Q4 2014, DIFLUMIDONE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(=O)C2CCCC(C2)[N-]S(=O)(=O)C(F)F.[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H8F2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C546U4DEN, chemically known as 5-(2,4-difluorophenyl)salicylic acid but generally known as diflunisal, which bears US NIH Compound Identifier 3059. European Medicines Agency schedules Diflunisal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07130MIG. The term DIFLUNISAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules diflunisal in its Anatomical Therapeutic Chemical (ATC) Classification. DIFLUNISAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diflunisal under HS 29182980 and SITC 51394. As of Q4 2014, DIFLUNISAL remains the US FDA Preferred Term for this commodity. Diflunisal bears US NLM identifiers UMLS ID C0012228 and NCI Concept Code C47489. SMILES: FC1C(C2CC(C(O)CC2)C(=O)O)CCC(F)C1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H34F2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8A06QG2QE, chemically known as 21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione (6alpha,11beta)- but generally known as difluprednate, which bears US NIH Compound Identifier 32037. European Medicines Agency schedules Difluprednate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07131MIG. The term DIFLUPREDNATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules difluprednate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule difluprednate under HS 29372200 and SITC 54153. As of Q4 2014, DIFLUPREDNATE remains the US FDA Preferred Term for this commodity. Difluprednate bears US NLM identifiers UMLS ID C0058004 and NCI Concept Code C80259. SMILES: FC12C(C3C(C(OC(=O)CCC)(CC3)C(=O)COC(=O)C)(CC1O)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes an enzyme inhibitor and cardiotonic agent with the molecular formula C41H64O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E90NZP2L9U, chemically known as purodigin, crystalline but more generally known as digitoxin, which bears US NIH Compound Identifier 3061. European Medicines Agency schedules Digitoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07133MIG. The term DIGITOXIN is an International Non-Proprietary Name. World Health Organization schedules digitoxin in its Anatomical Therapeutic Chemical (ATC) Classification. DIGITOXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule digitoxin under HS 29389010 and SITC 54161. As of Q4 2014, DIGITOXIN remains US FDA's Preferred Term for this commodity. Digitoxin bears US NLM identifiers UMLS ID C0012258 and NCI Concept Code C2634. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(O)C(O)C6)C)C(O)C5)C)C(O)C3)C)CC4)C)CCC1(C(CC2)C1=CC(=O)OC1)C.
This classification denotes a saponin and cardiotonic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 73K4184T59. European Medicines Agency schedules Digoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07135MIG. Digoxin generally arises in the molecular formula C41H64O14. The term DIGOXIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, list 3.) DIGOXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule digoxin under HS 29389010 and SITC 54161. As of Q4 2014, DIGOXIN remains US FDA's Preferred Term for this commodity. Digoxin bears US NLM identifiers UMLS ID C0012265 and NCI Concept Code C28990. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(O)C(O)C6)C)C(O)C5)C)C(O)C3)C)CC4)C)CC(O)C1(C(CC2)C1=CC(=O)OC1)C.
This classification denotes an antitdote for digitalis overdose with the molecular formula C6394H9908N1698O2011S58, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YB12NQZ1YN.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C20H35NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2FQ66RU9W, chemically known as 2-piperidinoethyl (1,1-bicyclohexyl)-1-carboxylate but generally known as dihexyverine, which bears US NIH Compound Identifier 21788. European Medicines Agency schedules dihexyverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07136MIG. Most nations schedule dihexyverine under HS 29333999 and SITC 51574. As of Q4 2014, DIHEXYVERINE remains the US FDA Preferred Term for this commodity. Dihexyverine bears US NLM identifiers UMLS ID C0771461 and NCI Concept Code C97978. SMILES: C1CCC(CC1)C2(CCCCC2)C(=O)OCCN3CCCCC3.
This classification denotes an antihypertensive agent and hydrazine with the molecular formula C8H10N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PCU411F5L6, chemically known as 2,3-dihydro-1,4-phthalazinedione dihydrazone but generally known as dihydralazine, which bears US NIH Compound Identifier 10230. European Medicines Agency schedules Dihydralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07137MIG. World Health Organization schedules dihydralazine in its Anatomical Therapeutic Chemical (ATC) Classification. DIHYDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dihydralazine under HS 29339990 and SITC 51577. As of Q4 2014, DIHYDRALAZINE remains the US FDA Preferred Term for this commodity. Dihydralazine bears US NLM identifiers UMLS ID C0012271 and NCI Concept Code C97307. SMILES: n1nc(NN)c2c(c1NN)cccc2.
This classification denotes an antihypertensive agent with the molecular formula C8H10N6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OVG1TP7A10, chemically known as 2,3-dihydrophthalazine-1,4-dione dihydrazone monohydrochloride but more generally known as dihydralazine hydrochloride, which bears US NIH Compound Identifier 198456. European Medicines Agency schedules Dihydralazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01701MIG. Most nations, for tariff and trade purposes, schedule dihydralazine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, DIHYDRALAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dihydralazine hydrochloride bears US NLM identifiers UMLS ID C3273349 and NCI Concept Code C97308. SMILES: C1CCC2C(C1)C(NNC2NN)NN.CL.
This classification denotes an antihypertensive agent with the molecular formula C8H10N6.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V8BVP5X5E. European Medicines Agency schedules dihydralazine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20331. Most nations, for tariff and trade purposes, schedule dihydralazine mesilate under HS 29339990 and SITC 51577. SMILES: CS(=O)(=O)O.C1CCC2C(C1)C(NNC2NN)NN.
This classification denotes an antihypertensive agent with the molecular formula C8H10N6.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1C2B1W91NK, chemically known as 1,4-dihydrazinophthalazine sulfate but more generally known as dihydralazine sulfate, which bears US NIH Compound Identifier 81764. European Medicines Agency schedules Dihydralazine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01702MIG. Most nations, for tariff and trade purposes, schedule dihydralazine sulfate under HS 29339990 and SITC 51577. As of Q4 2014, DIHYDRALAZINE SULFATE remains US FDA's Preferred Term for this commodity. Dihydralazine sulfate bears US NLM identifiers UMLS ID C0011569 and NCI Concept Code C81520. SMILES: C1CCC2C(C1)C(NNC2NN)NN.OS(=O)(=O)O.
This classification denotes an antihypertensive agent and hydrazine C8H10N6.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J9CB6K1N70, chemically known as 1,4-phthalazinedione, 2,3-dihydro-, dihydrazone, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more generally known as dihydralazine tartrate, which bears US NIH Compound Identifier 56842459. European Medicines Agency schedules Dihydralazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01703MIG. Most nations, for tariff and trade purposes, schedule dihydralazine tartrate under HS 29339990 and SITC 51577. As of Q4 2014, DIHYDRALAZINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)C(NNC2NN)NN.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9I9HDB855, chemically known as 7, 8-dihydrocodeine but generally known as dihydrocodeine, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07138MIG. The term DIHYDROCODEINE is an International Non-Proprietary Name. World Health Organization schedules dihydrocodeine in its Anatomical Therapeutic Chemical (ATC) Classification. DIHYDROCODEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dihydrocodeine under HS 29391100 and SITC 54141. As of Q4 2014, DIHYDROCODEINE remains the US FDA Preferred Term for this commodity. Dihydrocodeine bears US NLM identifiers UMLS ID C0058056 and NCI Concept Code C84508. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)CCC2O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H23NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8LXS95BSA9, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine bitartrate, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01704MIG. Most nations, for tariff and trade purposes, schedule dihydrocodeine bitartrate under HS 29391100 and SITC 54141. As of Q4 2014, DIHYDROCODEINE BITARTRATE remains US FDA's Preferred Term for this commodity. Dihydrocodeine bitartrate bears US NLM identifiers UMLS ID C0355564 and NCI Concept Code C47490. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes the phosphate form of an opioid receptor agonist and opioid with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9I9HDB855, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07138MIG. The term DIHYDROCODEINE is an International Non-Proprietary Name. World Health Organization schedules dihydrocodeine in its Anatomical Therapeutic Chemical (ATC) Classification. DIHYDROCODEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dihydrocodeine phosphate under HS 29391100 and SITC 54141. As of Q4 2014, DIHYDROCODEINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC.OP(=O)(O)O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H23NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8LXS95BSA9, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine bitartrate, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01704MIG. Most nations, for tariff and trade purposes, schedule dihydrocodeine tartrate under HS 29391100. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an opioid receptor agonist and opioid C18H23NO3.CHNS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 442C0H2H3P, chemically known as morphinan-6-ol, 4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-, thiocyanate (salt), but more generally known as dihydrocodeine thiocyanate, which bears US NIH Compound Identifier 46174078. European Medicines Agency schedules Dihydrocodeine thiocyanate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01707MIG. Most nations, for tariff and trade purposes, schedule dihydrocodeine thiocyanate under HS 29391100 and SITC 54141. As of Q4 2014, DIHYDROCODEINE THIOCYANATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC.C(=N)=S.
This classification denotes a dopamine agonist and alpha-adrenergic blocking agent with the molecular formula C35H41N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05D48LUM4Z, chemically known as ergocristine, dihydro- but generally known as dihydroergocristine, which bears US NIH Compound Identifier 3065. European Medicines Agency schedules Dihydroergocristine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13586MIG. World Health Organization schedules dihydroergocristine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIHYDROERGOCRISTINE remains the US FDA Preferred Term for this commodity. Dihydroergocristine bears US NLM identifiers UMLS ID C0012289 and NCI Concept Code C75938. SMILES: O1C2(O)N(C(C(=O)N3C2CCC3)Cc2ccccc2)C(=O)C1(NC(=O)C1CC2C(N(C1)C)Cc1c3c2cccc3[nH]c1)C(C)C.
This classification denotes an antiparkinson drug with the molecular formula C32H43N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67V3FSL2GL, chemically known as ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, but generally known as Dihydroergocryptine, which bears US NIH Compound Identifier 114948. European Medicines Agency schedules Dihydroergocryptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13588MIG. World Health Organization schedules amantadine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIHYDROERGOCRYPTINE remains the US FDA Preferred Term for this commodity. SMILES: CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.
This classification denotes a nonnarcotic analgesic and dopamine agonist with the molecular formula C33H37N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 436O5HM03C, chemically known as ergotaman-3,6,18-trione, 9,10-dihydro-12-hydroxy-2-methyl-5-(phenylmethyl)-, (5.alpha.,10.alpha.)-, monomethanesulfonate but generally known as dihydroergotamine, which bears US NIH Compound Identifier 3066. European Medicines Agency schedules Dihydroergotamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07139MIG. The term DIHYDROERGOTAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules dihydroergotamine in its Anatomical Therapeutic Chemical (ATC) Classification. DIHYDROERGOTAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dihydroergotamine under HS 29396900 and SITC 54146. As of Q4 2014, DIHYDROERGOTAMINE remains the US FDA Preferred Term for this commodity. Dihydroergotamine bears US NLM identifiers UMLS ID C0012291 and NCI Concept Code C65387. SMILES: O1C2(O)N(C(C(=O)N3C2CCC3)CC2CCCCC2)C(=O)C1(NC(=O)C1CC2C(N(C1)C)CC1C3C2CCCC3[NH]C1)C.
This classification denotes a nonnarcotic analgesic and dopamine agonist with the molecular formula C33H37N5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81AXN7R2QT, chemically known as ergotoman-3',6',18-trione,9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'.alpha.)-, monomethanesulfonate (salt), but more generally known as dihydroergotamine mesylate, which bears US NIH Compound Identifier 3066. European Medicines Agency schedules dihydroergotamine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07139MIG. Most nations, for tariff purposes, schedule dihydroergotamine mesylate under HS 29396900. As of Q4 2014, DIHYDROERGOTAMINE MESYLATE remains US FDA's Preferred Term for this commodity. Dihydroergotamine mesylate bears US NLM identifiers UMLS ID C0700532 and NCI Concept Code C47491. SMILES: C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4CCCCC4)NC(=O)[C@@H]5C[C@@H]6C7CCCC8C7C(C[NH]8)C[C@H]6N(C5)C.CS(=O)(=O)O.
This classification denotes a nonnarcotic analgesic and dopamine agonist with the molecular formula C33H37N5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81AXN7R2QT, chemically known as ergotoman-3',6',18-trione,9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'.alpha.)-, monomethanesulfonate (salt), but more generally known as dihydroergotamine methanesulfonate, which bears US NIH Compound Identifier 10531. European Medicines Agency schedules dihydroergotamine methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07139MIG. Most nations, for tariff purposes, schedule dihydroergotamine methanesulfonate under HS 29396900. SMILES: C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4CCCCC4)NC(=O)[C@@H]5C[C@@H]6C7CCCC8C7C(C[NH]8)C[C@H]6N(C5)C.CS(=O)(=O)O.
This classification denotes an aminoglycoside antibiotic with the molecular formula C21H41N7O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P2I6R8W6UA, chemically known as streptomycin, dihydro- but generally known as dihydrostreptomycin, which bears US NIH Compound Identifier 31406. European Medicines Agency schedules Dihydrostreptomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07140MIG. World Health Organization schedules dihydrostreptomycin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIHYDROSTREPTOMYCIN remains the US FDA Preferred Term for this commodity. Dihydrostreptomycin bears US NLM identifiers UMLS ID C0262967 and NCI Concept Code C61724. SMILES: O(C1OC(C(O)(C1OC1OC(C(O)C(O)C1NC)CO)CO)C)C1C(/N=C(/N)N)C(O)C(/N=C(/N)N)C(O)C1O.
This classification denotes a vitamin d analog with the molecular formula C28H46O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5LM3H112R, chemically known as 9,10-secoergosta-5,7,22-trien-3-ol, (3beta,5e,7e,10alpha,22e)- but generally known as dihydrotachysterol, which bears US NIH Compound Identifier 5281010. European Medicines Agency schedules Dihydrotachysterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07141MIG. The term DIHYDROTACHYSTEROL is an International Non-Proprietary Name. World Health Organization schedules dihydrotachysterol in its Anatomical Therapeutic Chemical (ATC) Classification. DIHYDROTACHYSTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dihydrotachysterol under HS 29061900 and SITC 51231. As of Q4 2014, DIHYDROTACHYSTEROL remains the US FDA Preferred Term for this commodity. Dihydrotachysterol bears US NLM identifiers UMLS ID C0012319 and NCI Concept Code C87290. SMILES: OC1CC(=C\C=C2\C3C(C(CC3)C(C)/C=C/C(C(C)C)C)(CCC2)C)\C(CC1)C.
This classification denotes an anti-ulcer agent with the molecular formula CO3.AL.NA.2HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84H8Z9550J. European Medicines Agency schedules dihydroxyaluminum sodium carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13596MIG. As of Q4 2014, DIHYDROXYALUMINUM SODIUM CARBONATE remains the US FDA Preferred Term for this commodity. Dihydroxyaluminum sodium carbonate bears US NLM identifiers UMLS ID C0058135 and NCI Concept Code C76484. SMILES: C(=O)([O-])O[Al].O.O.[Na+].
This classification denotes a thyroid hormone with the molecular formula C9H9I2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6L57Q44ZWW, chemically known as 3,5-l-diiodotyrosine but generally known as diiodotyrosine, which bears US NIH Compound Identifier 6181. European Medicines Agency schedules Diiodotyrosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13599MIG. World Health Organization schedules diiodotyrosine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIIODOTYROSINE remains the US FDA Preferred Term for this commodity. SMILES: IC1CC(CC(N)C(=O)O)CC(I)C1O.
This classification denotes an antispasmotic agent with the molecular formula C21H29N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E8EN393AL, chemically known as n,n-diisopropyl-3,3-diphenylpropylamine hydrochloride but more generally known as diisopromine hydrochloride, which bears US NIH Compound Identifier 71910. European Medicines Agency schedules Diisopromine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01730MIG. Most nations, for tariff and trade purposes, schedule diisopromine hydrochloride under HS 29214980. As of Q4 2014, DIISOPROMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diisopromine hydrochloride bears US NLM identifiers UMLS ID C1880325 and NCI Concept Code C65388. SMILES: CC(C)N(CCC(C1CCCCC1)C2CCCCC2)C(C)C.CL.
This classification denotes a muscle relaxant with the molecular formula C21H29N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2825S6AW9U, chemically known as benzenepropanamine, n,n-bis(1-methylethyl)-.gamma.-phenyl- but generally known as diisopromine, which bears US NIH Compound Identifier 22262. European Medicines Agency schedules Diisopromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07143MIG. The term DIISOPROMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules diisopromine in its Anatomical Therapeutic Chemical (ATC) Classification. DIISOPROMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Diisopromine or disoprominum bears US NLM identifiers UMLS ID C0771458 and NCI Concept Code C80978. SMILES: N(CCC(c1ccccc1)c1ccccc1)(C(C)C)C(C)C.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C6H14FO3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12UHW9R67N, chemically known as phosphorofluoridic acid, diisopropyl ester but generally known as dyflos, which bears US NIH Compound Identifier 5936. European Medicines Agency schedules Isoflurophate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14274MIG. SMILES: CC(C)OP(=O)(OC(C)C)F. SMILES: CC(C)OP(=O)(OC(C)C)F.
This classification denotes an alpha-adrenergic agonist with the molecular formula C31H44N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8KLC2BD5Z, chemically known as tetrahydro-1h-1,4-diazepine-1,4(5h)-dipropanol 3,4,5-trimethoxybenzoate (diester) but generally known as dilazep, which bears US NIH Compound Identifier 3074. European Medicines Agency schedules Dilazep in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07144MIG. The term DILAZEP is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules dilazep in its Anatomical Therapeutic Chemical (ATC) Classification. DILAZEP is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dilazep under HS 29339990 and SITC 51577. As of Q4 2014, DILAZEP remains the US FDA Preferred Term for this commodity. Dilazep bears US NLM identifiers UMLS ID C0012367 and NCI Concept Code C65389. SMILES: O(CCCN1CCN(CCC1)CCCOC(=O)C1CC(OC)C(OC)C(OC)C1)C(=O)C1CC(OC)C(OC)C(OC)C1.
This classification denotes an alpha-adrenergic agonist C31H44N2O10.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LV48LW10EO, chemically known as 1,4-bis(3-(3,4,5-trimethoxybenzoyloxy)propyl)homopiperazine dihydrochloride, but more generally known as dilazep dihydrochloride, which bears US NIH Compound Identifier 3074. European Medicines Agency schedules Dilazep dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01733MIG. Most nations, for tariff and trade purposes, schedule dilazep dihydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, DILAZEP DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CC(CC(C1OC)OC)C(=O)OCCCN2CCCN(CC2)CCCOC(=O)C3CC(C(C(C3)OC)OC)OC.CL.CL.
This classification denotes a vasodilating agent and adrenergic antagonist with the molecular formula C19H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P6629XE33T, chemically known as (r,r)-labetalol but generally known as dilevalol, which bears US NIH Compound Identifier 134044. European Medicines Agency schedules Dilevalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07145MIG. The term DILEVALOL is an International Non-Proprietary Name. DILEVALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dilevalol under HS 29242995 and SITC 51479. As of Q4 2014, DILEVALOL remains the US FDA Preferred Term for this commodity. Dilevalol bears US NLM identifiers UMLS ID C0012368 and NCI Concept Code C65390. SMILES: OC(CNC(CCc1ccccc1)C)c1cc(c(O)cc1)C(=O)N.
This classification denotes a vasodilating agent and adrenergic antagonist with the molecular structure C19H24N2O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, O5OBT75D2C chemically known as benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-, monohydrochloride, (r-(r*,r*))-, but more commonly known as dilevalol hydrochloride, which bears US NIH Compound Identifier 636407. European Medicines Agency schedules Dilevalol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01734MIG. Most nations, for tariff and trade purposes, schedule dilevalol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, DILEVALOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CCC1CCCCC1)NC[C@@H](C2CCC(C(C2)C(=O)N)O)O.CL.
This classification denotes an antiparasitic agent with the molecular formula C9H9Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89134SCM7M, chemically known as 2,2-dichloro-4-hydroxy-n-methylacetanilide but generally known as diloxanide, which bears US NIH Compound Identifier 11367. European Medicines Agency schedules Diloxanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07147MIG. The term DILOXANIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules diloxanide in its Anatomical Therapeutic Chemical (ATC) Classification. DILOXANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diloxanide furoate under HS 29242995 and SITC 51479. As of Q4 2014, DILOXANIDE FUROATE remains the US FDA Preferred Term for this commodity. SMILES: CLC(CL)C(=O)N(C1CCC(O)CC1)C.
This classification denotes a calcium channel blocker with the molecular formula C22H26N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EE92BBP03H, chemically known as 3-acetoxy-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one but generally known as diltiazem, which bears US NIH Compound Identifier 3076. European Medicines Agency schedules Diltiazem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07148MIG. The term DILTIAZEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules diltiazem in its Anatomical Therapeutic Chemical (ATC) Classification. DILTIAZEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diltiazem under HS 29349990 and SITC 51579. As of Q4 2014, DILTIAZEM remains the US FDA Preferred Term for this commodity. Diltiazem bears US NLM identifiers UMLS ID C0012373 and NCI Concept Code C61725. SMILES: S1C(C(OC(=O)C)C(=O)N(CCN(C)C)c2c1cccc2)c1ccc(OC)cc1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a calcium channel blocker with the molecular formula C22H26N2O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OLH94387TE, chemically known as 1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride, (+)-cis- but more generally known as diltiazem hydrochloride, which bears US NIH Compound Identifier 62920. European Medicines Agency schedules Diltiazem hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13602MIG. Most nations, for tariff and trade purposes, schedule diltiazem hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, DILTIAZEM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diltiazem hydrochloride bears US NLM identifiers UMLS ID C0700940 and NCI Concept Code C398. SMILES: CC(=O)O[C@@H]1[C@@H](SC2CCCCC2N(C1=O)CCN(C)C)C3CCC(CC3)OC.CL.
This classification denotes a calcium channel blocker with the molecular formula C22H26N2O4S.C4H6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 14Y6444DRP, chemically known as 1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-5-(2-(di-methylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-(2s-cis)-, (s)-hydoxybutanedioate (1:1) but more generally known as diltiazem malate, which bears US NIH Compound Identifier 3037122. European Medicines Agency schedules Diltiazem malate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20629. Most nations, for tariff and trade purposes, schedule diltiazem malate under HS 29349990 and SITC 51579. As of Q4 2014, DILTIAZEM MALATE remains US FDA's Preferred Term for this commodity. Diltiazem malate bears US NLM identifiers UMLS ID C1165286 and NCI Concept Code C47493. SMILES: CC(=O)O[C@@H]1[C@@H](SC2CCCCC2N(C1=O)CCN(C)C)C3CCC(CC3)OC.C([C@@H](C(=O)O)O)C(=O)O.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C16H19N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6V4Z7SX7S, chemically known as 7-(p-dimethylaminobenzyl)-1,3-dimethylxanthine but generally known as dimabefylline, which bears US NIH Compound Identifier 71646. European Medicines Agency schedules Dimabefylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07149MIG. The term DIMABEFYLLINE is an International Non-Proprietary Name. DIMABEFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimabefylline under HS 29395900 and SITC 54145. As of Q4 2014, DIMABEFYLLINE remains the US FDA Preferred Term for this commodity. Dimabefylline bears US NLM identifiers UMLS ID C1880329 and NCI Concept Code C65392. SMILES: O=C1N(C(=O)N(C2NCN(C12)CC1CCC(N(C)C)CC1)C)C.
This classification denotes a cns stimulant with the molecular formula C20H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9WII5M0DU3, chemically known as 4h-1-benzopyran-4-one, 8-((dimethylamino)methyl)-7-methoxy-3-methyl-2-phenyl- (9ci) but generally known as dimefline, which bears US NIH Compound Identifier 3078. European Medicines Agency schedules Dimefline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07156MIG. The term DIMEFLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules dimefline in its Anatomical Therapeutic Chemical (ATC) Classification. DIMEFLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimefline under HS 29329985 and SITC 51569. As of Q4 2014, DIMEFLINE remains the US FDA Preferred Term for this commodity. Dimefline bears US NLM identifiers UMLS ID C0058192 and NCI Concept Code C65396. SMILES: O1C2C(CN(C)C)C(OC)CCC2C(=O)C(C1C1CCCCC1)C.
This classification denotes a cns stimulant with the molecular formula C20H21NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H0XB4R74ID, chemically known as 4h-1-benzopyran-4-one, 8-((dimethylamino)methyl)-7-methoxy-3-methyl-2-phenyl- (9ci) but more generally known as dimefline hydrochloride, which bears US NIH Compound Identifier 3078. European Medicines Agency schedules Dimefline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01738MIG. Most nations, for tariff and trade purposes, schedule dimefline hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, DIMEFLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dimefline hydrochloride bears US NLM identifiers UMLS ID C0952747 and NCI Concept Code C65397. SMILES: CC1C(=O)C2CCC(C(C2OC1C3CCCCC3)CN(C)C)OC.CL.
This classification denotes an antitussive agent and anticonvulsant agent with the molecular formula C18H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 623OAC38YU, chemically known as morphinan, 3,17-dimethyl-, (9alpha,13alpha,14alpha)- but more generally known as dimemorfan, which bears US NIH Compound Identifier 3037918. European Medicines Agency schedules Dimemorfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07158MIG. The term DIMEMORFAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21, No. 3, 2007, List 58). World Health Organization schedules dimemorfan in its Anatomical Therapeutic Chemical (ATC) Classification. DIMEMORFAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dimemorfan under HS 29334990 and SITC 51575. As of Q4 2014, DIMEMORFAN remains US FDA's Preferred Term for this commodity. Dimemorfan bears US NLM identifiers UMLS ID C0058193 and NCI Concept Code C65399. SMILES: N1(C2C3C(CC1)(CCCC3)C1C(C2)CCC(C1)C)C.
This classification denotes an antitussive agent and anticonvulsant agent with the molecular formula C18H25N.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S203Y5Y1QP, chemically known as 3,17-dimethyl-9-alpha,13-alpha,14-alpha-morphinan phosphate but more generally known as dimemorfan phosphate, which bears US NIH Compound Identifier 5492722. European Medicines Agency schedules Dimemorfan phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01739MIG. Most nations, for tariff and trade purposes, schedule dimemorfan phosphate under HS 29334990 and SITC 51575. As of Q4 2014, DIMEMORFAN PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC2C(C1)[C@]34CCCC[C@@H]3[C@H](C2)N(CC4)C.OP(=O)(O)O.
This classification denotes an antimuscarinic agent and antiemetic agent with the molecular formula C17H21NO.C7H7ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JB937PER5C, chemically known as 8-chlorotheophylline, compound with 2-(diphenylmethoxy)-n,n-dimethylethylamine (1:1) but generally known as dimenhydrinate, which bears US NIH Compound Identifier 10660. European Medicines Agency schedules Dimenhydrinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07159MIG. The term DIMENHYDRINATE is an International Non-Proprietary Name. DIMENHYDRINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimenhydrinate under HS 29395900 and SITC 54145. As of Q4 2014, DIMENHYDRINATE remains the US FDA Preferred Term for this commodity. Dimenhydrinate bears US NLM identifiers UMLS ID C0012381 and NCI Concept Code C28992. SMILES: CLC1[NH]C2C(N(C(=O)N(C2=O)C)C)N1.O(C(C1CCCCC1)C1CCCCC1)CCN(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN550. This VA Drug Class (CN550) classifies this compound as belonging to the group ANTIVERTIGO AGENTS.
This classification denotes an analgesic agent with the molecular formula C20H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4D65PBX0VK, chemically known as 2-dimethylaminoethyl 1-ethoxy-1,1-diphenylacetate but generally known as dimenoxadol, which bears US NIH Compound Identifier 17036. European Medicines Agency schedules Dimenoxadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07160MIG. The term DIMENOXADOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). DIMENOXADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimenoxadol under HS 29221980 and SITC 51461. As of Q4 2014, DIMENOXADOL remains the US FDA Preferred Term for this commodity. Dimenoxadol bears US NLM identifiers UMLS ID C0058194 and NCI Concept Code C65400. SMILES: O(C(C1CCCCC1)(C1CCCCC1)C(=O)OCCN(C)C)CC.
This classification denotes an opioid receptor agonist with the molecular formula C21H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NNB4I01PA7, chemically known as 6-dimethylamino-4,4-diphenyl-3-heptanol, hydrochloride but generally known as dimepheptanol, which bears US NIH Compound Identifier 28397. European Medicines Agency schedules Dimepheptanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07161MIG. The term DIMEPHEPTANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). DIMEPHEPTANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC.
This classification denotes a therapeutic progestin with the molecular formula C23H36O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X08N6BOT8Y, chemically known as 3beta-hydroxy-6alpha,16alpha-di-methylpregn-4-en-20-one. but generally known as dimepregnen, which bears US NIH Compound Identifier 208839. European Medicines Agency schedules Dimepregnen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07163MIG. The term DIMEPREGNEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). DIMEPREGNEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimepregnen under HS 29144090 and SITC 51629. As of Q4 2014, DIMEPREGNEN remains the US FDA Preferred Term for this commodity. Dimepregnen bears US NLM identifiers UMLS ID C1880333 and NCI Concept Code C65401. SMILES: O=C(C1C2(C(C3C(C4(C(=CC(O)CC4)C(C3)C)C)CC2)CC1C)C)C.
This classification denotes a metal chelator with the molecular formula C3H8OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0CPP32S55X, chemically known as 2,3-mercaptopropanol but generally known as dimercaprol, which bears US NIH Compound Identifier 3080. European Medicines Agency schedules Dimercaprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07165MIG. The term DIMERCAPROL is an International Non-Proprietary Name. World Health Organization schedules dimercaprol in its Anatomical Therapeutic Chemical (ATC) Classification. DIMERCAPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimercaprol under HS 29309085 and SITC 51549. As of Q4 2014, DIMERCAPROL remains the US FDA Preferred Term for this commodity. Dimercaprol bears US NLM identifiers UMLS ID C0012383 and NCI Concept Code C47494. SMILES: SC(CS)CO.
This classification denotes a metal chelator with the molecular formula C4H6O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DX1U2629QE, chemically known as 2,3-dithio-meso-tartaric acid but generally known as succimer, which bears US NIH Compound Identifier 9354. European Medicines Agency schedules Succimer in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10663MIG. The term SUCCIMER is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). SUCCIMER is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Dimercaptosuccinic acid or succimer bears US NLM identifiers UMLS ID C0012384 and NCI Concept Code C61953. SMILES: C(C(C(=O)O)S)(C(=O)O)S.
This classification denotes an antidepressant agent with the molecular formula C20H26N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O341NY501N, chemically known as 9,9-dimethyl-10-(3-(dimethylamino)propyl)acridan but generally known as dimetacrine, which bears US NIH Compound Identifier 94280. European Medicines Agency schedules Dimetacrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07168MIG. The term DIMETACRINE is an International Non-Proprietary Name. World Health Organization schedules dimetacrine in its Anatomical Therapeutic Chemical (ATC) Classification. DIMETACRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimetacrine under HS 29339990 and SITC 51577. As of Q4 2014, DIMETACRINE remains the US FDA Preferred Term for this commodity. Dimetacrine bears US NLM identifiers UMLS ID C0058199 and NCI Concept Code C81490. SMILES: N1(c2c(C(c3c1cccc3)(C)C)cccc2)CCCN(C)C.
This classification denotes an antidepressant agent with the molecular formula C20H26N2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DVH164X0IF, chemically known as acridan, 10-(3-(dimethylamino)propyl)-9,9-dimethyl-, tartrate (1:1), but more generally known as dimetacrine bitartrate, which bears US NIH Compound Identifier 94279. European Medicines Agency schedules dimetacrine bitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07168MIG. Most nations, for tariff purposes, schedule dimetacrine bitartrate under HS 29339990. SMILES: CC1(C2CCCCC2N(C3C1CCCC3)CCCN(C)C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an antiflatulent agent with the molecular formula C4H12Si(C2H6OSi)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92RU3N3Y1O, chemically known as silane, oxybis(trimethyl)- but generally known as dimethicone, which bears US NIH Compound Identifier 24764. European Medicines Agency schedules Dimethicone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01753MIG. As of Q4 2014, DIMETHICONE remains the US FDA Preferred Term for this commodity. Dimethicone bears US NLM identifiers UMLS ID C1113707 and NCI Concept Code C83673. SMILES: C[SI](C)(C)O[SI](C)(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
Prevention of postoperative nausea and vomiting or chemotherapy
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a histamine h1 antagonist, antipruritic, and anti-allergic agent with the molecular formula C20H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 661FH77Z3P, chemically known as 1h-indene-2-ethanamine, n,n-dimethyl-3-(1-(2-pyridinyl)ethyl)- (9ci) but generally known as dimetindene, which bears US NIH Compound Identifier 21855. European Medicines Agency schedules Dimetindene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07179MIG. World Health Organization schedules dimetindene in its Anatomical Therapeutic Chemical (ATC) Classification. DIMETINDENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Dimethindene or dimetindene bears US NLM identifiers UMLS ID C0012390 and NCI Concept Code C83675. SMILES: N(CCC1=C(C(C)C2NCCCC2)C2C(C1)CCCC2)(C)C.
This classification denotes a therapeutic progestin with the molecular formula C23H32O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4MZ02M175, chemically known as 17-alpha-pregn-4-en-20-yn-3-one, 6-alpha,21-dimethyl-17-hydroxy- but generally known as dimethisterone, which bears US NIH Compound Identifier 6607. European Medicines Agency schedules Dimethisterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07173MIG. DIMETHISTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimethisterone under HS 29372300 and SITC 54153. As of Q4 2014, DIMETHISTERONE remains the US FDA Preferred Term for this commodity. Dimethisterone bears US NLM identifiers UMLS ID C0012391 and NCI Concept Code C65404. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)C(C3)C)C)CC2)CC1)C)C#CC.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6U9W3DMYT. European Medicines Agency schedules Dimetholizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07174MIG. Dimetholizine generally arises in the molecular formula C15H24N2O2. The term DIMETHOLIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) DIMETHOLIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimetholizine under HS 29335995 and SITC 51576. As of Q4 2014, DIMETHOLIZINE remains the US FDA Preferred Term for this commodity. Dimetholizine bears US NLM identifiers UMLS ID C1880334 and NCI Concept Code C65405. SMILES: O(CCCN1CCN(CC1)C1C(OC)CCCC1)C.
This classification denotes a histamine-1 receptor antagonist C15H24N2O2.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8VNU0OD47W, chemically known as piperazine, 1-(2-methoxyphenyl)-4-(3-methoxypropyl)-, phosphate, but more generally known as dimetholizine phosphate, which bears US NIH Compound Identifier 71586971. Most nations, for tariff and trade purposes, schedule dimetholizine phosphate under HS 29335995 and SITC 51576. As of Q4 2014, DIMETHOLIZINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: COCCCN1CCN(CC1)C2CCCCC2OC.OP(=O)(O)O.
This classification denotes an antitussive agent with the molecular formula C19H22N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1E3KG5FWDB, chemically known as 10h-phenothiazine-10-carboxylic acid, 2-(2-(dimethylamino)ethoxy)ethyl ester but more generally known as dimethoxanate, which bears US NIH Compound Identifier 10610. European Medicines Agency schedules Dimethoxanate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07175MIG. The term DIMETHOXANATE is an International Non-Proprietary Name. World Health Organization schedules dimethoxanate in its Anatomical Therapeutic Chemical (ATC) Classification. DIMETHOXANATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dimethoxanate under HS 29343090 and SITC 51578. As of Q4 2014, DIMETHOXANATE remains US FDA's Preferred Term for this commodity. Dimethoxanate bears US NLM identifiers UMLS ID C0392426 and NCI Concept Code C80896. SMILES: S1C2C(N(C3C1CCCC3)C(=O)OCCOCCN(C)C)CCCC2.
This classification denotes a cns stimulant with the molecular formula C11H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92M4C245D1, chemically known as (s)-n,n,alpha-trimethylphenethylamine but more generally known as dimetamfetamine, which bears US NIH Compound Identifier 65682. European Medicines Agency schedules Dimetamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07169MIG. The term DIMETAMFETAMINE is an International Non-Proprietary Name. DIMETAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(CC1=CC=CC=C1)N(C)C.
This classification denotes an anti-psoriatic agent with the molecular formula C6H8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FO2303MNI2, chemically known as 2-butenedioic acid (e)-, dimethyl ester but generally known as dimethyl fumarate, which bears US NIH Compound Identifier 637568. European Medicines Agency schedules Dimethyl fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13608MIG. As of Q4 2014, DIMETHYL FUMARATE remains the US FDA Preferred Term for this commodity. Dimethyl fumarate bears US NLM identifiers UMLS ID C0058218 and NCI Concept Code C63670. SMILES: COC(=O)C=CC(=O)OC.
This classification denotes a sulfur compound with the molecular formula C2H6OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YOW8V9698H, chemically known as sulfoxide, dimethyl but generally known as dimethyl sulfoxide, which bears US NIH Compound Identifier 679. European Medicines Agency schedules Dimethyl sulfoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07176MIG. The term DIMETHYL SULFOXIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules dimethyl sulfoxide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule dimethyl sulfoxide under HS 29309085 and SITC 51549. As of Q4 2014, DIMETHYL SULFOXIDE remains the US FDA Preferred Term for this commodity. Dimethyl sulfoxide bears US NLM identifiers UMLS ID C0012403 and NCI Concept Code C437. SMILES: S(=O)(C)C.
This classification denotes a muscle relaxant with the molecular formula C40H48N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V0M92G2U26. As of Q4 2014, METOCURINE remains the US FDA Preferred Term for this commodity. Metocurine bears US NLM identifiers UMLS ID C0066465 and NCI Concept Code C76069. SMILES: C[N+]1(CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H24N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6LL60J9E0O, chemically known as 1h-indene-2-ethanamine, n,n-dimethyl-3-(1-(2-pyridinyl)ethyl)-, (z)-2-butenedioate (1:1) but more generally known as dimethindene maleate, which bears US NIH Compound Identifier 5282414. European Medicines Agency schedules Dimetindene maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01754MIG. Most nations, for tariff and trade purposes, schedule dimetindene maleate under HS 29333999. SMILES: CC(C1CCCCN1)C2=C(CC3C2CCCC3)CCN(C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H17NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BOM1J10QQM, chemically known as 4-hydroxy-3,5-dimethoxy-alpha-((methylamino)methyl)benzyl alcohol but generally known as dimetofrine, which bears US NIH Compound Identifier 31513. European Medicines Agency schedules Dimetofrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07181MIG. The term DIMETOFRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules dimetofrine in its Anatomical Therapeutic Chemical (ATC) Classification. DIMETOFRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimetofrine under HS 29225000 and SITC 51467. As of Q4 2014, DIMETOFRINE remains the US FDA Preferred Term for this commodity. Dimetofrine bears US NLM identifiers UMLS ID C0058204 and NCI Concept Code C65408. SMILES: CNCC(C1=CC(=C(C(=C1)OC)O)OC)O.
This classification denotes a histamine h1 antagonist and phenothiazine with the molecular formula C19H25N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1FTA475ZDB, chemically known as 10-(2-(dimethylamino)propyl)-n,n-dimethylphenothiazine-2-sulfonamide but generally known as dimetotiazine, which bears US NIH Compound Identifier 3089. European Medicines Agency schedules Dimetotiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07182MIG. World Health Organization schedules dimetotiazine in its Anatomical Therapeutic Chemical (ATC) Classification. DIMETOTIAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimetotiazine under HS 29350090 and SITC 51580. SMILES: CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)S(=O)(=O)N(C)C)N(C)C.
This classification denotes a serotonin antagonist with the molecular formula C19H25N3O2S2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B28V86NGNK, chemically known as 10h-phenothiazine-2-sulfonamide, 10-(2-(dimethylamino)propyl)-n,n-dimethyl-, monomethanesulfonate but more generally known as dimetotiazine mesilate, which bears US NIH Compound Identifier 25715. European Medicines Agency schedules Dimetotiazine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01755MIG. Most nations, for tariff and trade purposes, schedule dimetotiazine mesilate under HS 29350090 and SITC 51580. SMILES: CC(CN1C2CCCCC2SC3C1CC(CC3)S(=O)(=O)N(C)C)N(C)C.CS(=O)(=O)O.
This classification denotes an antiprotozoal agent with the molecular formula C5H7N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K59P7XNB8X, chemically known as 1,2-dimethyl-5-nitroimidazole but generally known as dimetridazole, which bears US NIH Compound Identifier 3090. European Medicines Agency schedules Dimetridazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07183MIG. The term DIMETRIDAZOLE is an International Non-Proprietary Name. DIMETRIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dimetridazole under HS 29332990 and SITC 51573. As of Q4 2014, DIMETRIDAZOLE remains the US FDA Preferred Term for this commodity. Dimetridazole bears US NLM identifiers UMLS ID C0012444 and NCI Concept Code C76419. SMILES: O[N](=O)C1N(C(NC1)C)C.
This classification denotes a neuroprotective agent with the molecular formula C6H8N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 4AW7F70MZO chemically known as (+/-)-dihydro-1h-pyrrolo(1,2-a)imidazole-2,5(3h,6h)-dione but generally known as dimiracetam, which bears US NIH Compound Identifier 65955. European Medicines Agency schedules Dimiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07186MIG. The term DIMIRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33). Most nations schedule dimiracetam under HS 29337900 and SITC 51561. As of Q4 2014, DIMIRACETAM remains the US FDA Preferred Term for this commodity. Dimiracetam bears US NLM identifiers UMLS ID C0250359 and NCI Concept Code C79121. SMILES: C1CC(=O)N2C1NC(=O)C2.
This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 411OG24QOU. European Medicines Agency schedules Dinazafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07191MIG. Dinazafone generally arises in the molecular formula C20H21CLN2O2. The term DINAZAFONE is an International Non-Proprietary Name or INN. DINAZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dinazafone under HS 29242995 and SITC 51479. As of Q4 2014, DINAZAFONE remains the US FDA Preferred Term for this commodity. Dinazafone bears US NLM identifiers UMLS ID C1880337 and NCI Concept Code C65411. SMILES: CLC1CC(C(N(C(=O)CNCC(=C)C)C)CC1)C(=O)C1CCCCC1.
This classification denotes a pesticide with the molecular formula C8H7N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AOX68RY4TV, chemically known as 3,5-dinitro-o-toluamide solution but generally known as dinitolmide, which bears US NIH Compound Identifier 3092. European Medicines Agency schedules Dinitolmide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07193MIG. The term DINITOLMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). DINITOLMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dinitolmide under HS 29242995 and SITC 51479. As of Q4 2014, DINITOLMIDE remains the US FDA Preferred Term for this commodity. Dinitolmide bears US NLM identifiers UMLS ID C0012458 and NCI Concept Code C79128. SMILES: O=C(N)C1C(C([N](=O)O)CC([N](=O)O)C1)C.
This classification denotes a prostaglandin analogue with the molecular formula C20H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B7IN85G1HY, chemically known as (5z,13e)-(15s)-9-alpha,11-alpha,15-trihydroxyprosta-5,13-dienoate but generally known as dinoprost, which bears US NIH Compound Identifier 160. European Medicines Agency schedules Dinoprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07194MIG. The term DINOPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules dinoprost in its Anatomical Therapeutic Chemical (ATC) Classification. DINOPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dinoprost under HS 29375000 and SITC 54156. As of Q4 2014, DINOPROST remains the US FDA Preferred Term for this commodity. Dinoprost bears US NLM identifiers UMLS ID C0012471 and NCI Concept Code C65413. SMILES: OC1C(C(C(O)C1)/C=C/C(O)CCCCC)C/C=C/CCCC(=O)O.
This classification denotes a prostaglandin analogue with the molecular formula C20H32O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7Q1JQR04M, chemically known as u,12, 062 but generally known as dinoprostone, which bears US NIH Compound Identifier 158. European Medicines Agency schedules Dinoprostone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07195MIG. The term DINOPROSTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules dinoprostone in its Anatomical Therapeutic Chemical (ATC) Classification. DINOPROSTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dinoprostone under HS 29375000 and SITC 54156. As of Q4 2014, DINOPROSTONE remains the US FDA Preferred Term for this commodity. Dinoprostone bears US NLM identifiers UMLS ID C0012472 and NCI Concept Code C61727. SMILES: OC1C(C(C(=O)C1)C/C=C/CCCC(=O)O)/C=C/C(O)CCCCC.
This classification denotes a prostaglandin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CT6BBQ5A68. European Medicines Agency schedules Dinoprost trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01758MIG. Dinoprost trometamol generally arises in the molecular formula C20H34O5.C4H11NO3. The term 'dinoprost trometamol' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule dinoprost trometamol under HS 29375000 and SITC 54156. SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O.
This classification denotes a prostaglandin analogue with the molecular formula C20H34O5.C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CT6BBQ5A68, chemically known as (e,z)-(1r,2r,3r,5s)-7-(3,5-dihydroxy-2-((3s)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), but more generally known as dinoprost tromethamine, which bears US NIH Compound Identifier 5282415. European Medicines Agency schedules dinoprost tromethamine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07194MIG. Most nations, for tariff purposes, schedule dinoprost tromethamine under HS 29375000. As of Q4 2014, DINOPROST TROMETHAMINE remains US FDA's Preferred Term for this commodity. Dinoprost tromethamine bears US NLM identifiers UMLS ID C0058310 and NCI Concept Code C1074. SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O.
A GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
This classification denotes a dicarboxylic acid and succinate and an aural preparation with tthe molecular formula C20H38NaO7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F05Q2T2JA0. European Medicines Agency schedules Dioctyl Sodium Sulphosuccinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB41674 and SUB06348MIG. SMILES: CCCCCCCCOC(=O)CC(C(=O)OCCCCCCCC)S(=O)(=O)O.[Na+].
This classification denotes an iodinated contrast dye with the molecular formula C7H5I2NO3.C4H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTK4026YJ5, chemically known as 3,5-diiodo-4-pyridone-n-acetic acid, diethanolamine salt but more generally known as diodone, which bears U.S. National Institutes of Health Compound Identifier 9303. The European Medicines Agency schedules Diodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07197MIG. The term DIODONE is an International Non-Proprietary Name. The World Health Organization schedules diodone in its Anatomical Therapeutic Chemical (ATC) Classification. DIODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1CN(CC(=O)O)CC(I)C1=O.OCC[NH2]CCO. Most nations schedule Diodone or iodopyracet under HS 29333999.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G25Z4785LV, chemically known as (- )-1-(1,4-benzodioxan-2-ylmethoxy)-3-(tert-butylamino)-2-propanol. but generally known as dioxadilol, which bears US NIH Compound Identifier 208844. European Medicines Agency schedules Dioxadilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07199MIG. The term DIOXADILOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). DIOXADILOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dioxadilol under HS 29329985 and SITC 51569. As of Q4 2014, DIOXADILOL remains the US FDA Preferred Term for this commodity. Dioxadilol bears US NLM identifiers UMLS ID C1880338 and NCI Concept Code C65414. SMILES: O(CC(O)CNC(C)(C)C)CC1OC2C(OC1)CCCC2.
This classification denotes an opioid receptor agonist and opioid and analgesic agent with the molecular formula C22H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G751H98FY4, chemically known as 4-morpholinebutyric acid, alpha,alpha-diphenyl-, ethyl ester but generally known as dioxaphetyl butyrate, which bears US NIH Compound Identifier 48194. European Medicines Agency schedules Dioxaphetyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07202MIG. The term DIOXAPHETYL is an International Non-Proprietary Name. SMILES: CCOC(=O)C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3.
This classification denotes an opioid receptor agonist and opioid and analgesic agent with the molecular formula C22H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G751H98FY4, chemically known as 4-morpholinebutyric acid, alpha,alpha-diphenyl-, ethyl ester but more generally known as dioxaphetyl butyrate, which bears US NIH Compound Identifier 48194. European Medicines Agency schedules Dioxaphetyl butyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07202MIG. The term DIOXAPHETYL BUTYRATE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule dioxaphetyl butyrate under HS 29349990 and SITC 51579. As of Q4 2014, DIOXAPHETYL BUTYRATE remains US FDA's Preferred Term for this commodity. Dioxaphetyl butyrate bears US NLM identifiers UMLS ID C1880340 and NCI Concept Code C65416. SMILES: CCOC(=O)C(CCN1CCOCC1)(C2CCCCC2)C3CCCCC3.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a vasodilating agent with the molecular formula C22H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GRE0P19C3Z, chemically known as 6,7-dimethoxy-1-(4-ethoxy-3-methoxybenzyl)-3-methylisoquinoline but generally known as dioxyline, which bears US NIH Compound Identifier 23140. SMILES: CCOC1=C(C=C(C=C1)CC2=[NH+]C(=CC3=CC(=C(C=C32)OC)OC)C)OC.OP(=O)(O)[O-].
This classification denotes an anesthetic agent with the molecular formula C22H27N3O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2456GO94TR, chemically known as 1,2-propanediol, 3-piperidino-, dicarbanilate (ester), monohydrochloride but generally known as diperodon, which bears US NIH Compound Identifier 10831. European Medicines Agency schedules Diperodon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07207MIG. DIPERODON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diperodon under HS 29333999 and SITC 51574. As of Q4 2014, DIPERODON remains the US FDA Preferred Term for this commodity. Diperodon bears US NLM identifiers UMLS ID C0163518 and NCI Concept Code C75090. SMILES: O(C(CN1CCCCC1)COC(=O)NC1CCCCC1)C(=O)NC1CCCCC1.
This classification denotes an anesthetic agent with the molecular formula C22H27N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UIN4PYP84R, chemically known as 1,2-propanediol, 3-(1-piperidinyl)-, 1,2-bis(n-phenylcarbamate), but more generally known as diperodon anhydrous, which bears US NIH Compound Identifier 10831. European Medicines Agency schedules diperodon anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07207MIG. Most nations, for tariff purposes, schedule diperodon anhydrous under HS 29333999. SMILES: C1CCC(CC1)NC(=O)OCC(CN2CCCCC2)OC(=O)NC3CCCCC3.
This classification denotes an anesthetic agent with the molecular formula C22H27N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5YZ5R8I73Y, chemically known as 1,2-propanediol, 3-piperidino-, dicarbanilate, hydrochloride but more generally known as diperodon hydrochloride, which bears US NIH Compound Identifier 10830. European Medicines Agency schedules Diperodon hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13620MIG. Most nations, for tariff and trade purposes, schedule diperodon hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DIPERODON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diperodon hydrochloride bears US NLM identifiers UMLS ID C0521935 and NCI Concept Code C75091. SMILES: C1CCC(CC1)NC(=O)OCC(CN2CCCCC2)OC(=O)NC3CCCCC3.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an anticoagulant agent with the molecular formula C23H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 54CA01C6JX, chemically known as 1,3-indandione, 2-(diphenylacetyl)- (8ci) but generally known as diphacinone, which bears US NIH Compound Identifier 6719. European Medicines Agency schedules Diphenadione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07209MIG. The term DIPHACINONE is an International Non-Proprietary Name. World Health Organization schedules diphacinone in its Anatomical Therapeutic Chemical (ATC) Classification. Diphacinone or diphenadione bears US NLM identifiers UMLS ID C0058366 and NCI Concept Code C75156. SMILES: C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)C3C(=O)C4=CC=CC=C4C3=O.
This classification denotes an antimuscarinic agent with the molecular formula C20H24N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q26TX1UD0W, chemically known as 4-(diphenylmethylene)-1,1-dimethylpiperidinium methylsulfate but generally known as diphemanil, which bears US NIH Compound Identifier 6126. World Health Organization schedules diphemanil in its Anatomical Therapeutic Chemical (ATC) Classification. DIPHEMANIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DIPHEMANIL remains the US FDA Preferred Term for this commodity. Diphemanil bears US NLM identifiers UMLS ID C0301371 and NCI Concept Code C78071. SMILES: C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C.COS(=O)(=O)[O-]. .
This classification denotes an antihelminthic agent with the molecular formula C14H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U129BBY8DB, chemically known as 4-(phenylmethyl)phenol, carbamate but generally known as diphenan, which bears US NIH Compound Identifier 7572. European Medicines Agency schedules Diphenan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07210MIG. The term DIPHENAN is an International Non-Proprietary Name. DIPHENAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diphenan under HS 29242995 and SITC 51479. As of Q4 2014, DIPHENAN remains the US FDA Preferred Term for this commodity. Diphenan bears US NLM identifiers UMLS ID C1880342 and NCI Concept Code C65420. SMILES: O(C1CCC(CC2CCCCC2)CC1)C(=O)N.
This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8GTS82S83M, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but generally known as diphenhydramine, which bears US NIH Compound Identifier 3100. European Medicines Agency schedules Diphenhydramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG. The term DIPHENHYDRAMINE is an International Non-Proprietary Name. World Health Organization schedules diphenhydramine in its Anatomical Therapeutic Chemical (ATC) Classification. DIPHENHYDRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diphenhydramine under HS 29221980 and SITC 51461. As of Q4 2014, DIPHENHYDRAMINE remains the US FDA Preferred Term for this commodity. Diphenhydramine bears US NLM identifiers UMLS ID C0012522 and NCI Concept Code C61728. SMILES: O(C(C1CCCCC1)C1CCCCC1)CCN(C)C.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4OD433S209. European Medicines Agency schedules Diphenhydramine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01768MIG. Diphenhydramine citrate generally arises in the molecular formula C17H21NO.C6H8O7. The term 'diphenhydramine citrate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule diphenhydramine citrate under HS 29221980 and SITC 51461. As of Q4 2014, DIPHENHYDRAMINE CITRATE remains US FDA's Preferred Term for this commodity. Diphenhydramine citrate bears US NLM identifiers UMLS ID C0282144 and NCI Concept Code C82274. SMILES: CN(C)CCOC(C1CCCCC1)C2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TC2D6JAD40, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but more generally known as diphenhydramine hcl, which bears US NIH Compound Identifier 3100. European Medicines Agency schedules Diphenhydramine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01769MIG. Most nations, for tariff and trade purposes, schedule diphenhydramine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, DIPHENHYDRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diphenhydramine hydrochloride bears US NLM identifiers UMLS ID C0004963 and NCI Concept Code C300. SMILES: CN(C)CCOC(C1CCCCC1)C2CCCCC2.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO.C12H26O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3E2CN035LB, chemically known as ethanamine, 2-(diphenylmethoxy)-n,n-dimethyl-, dodecyl sulfate, but more generally known as diphenhydramine laurylsulfate, which bears US NIH Compound Identifier 9892949. European Medicines Agency schedules diphenhydramine laurylsulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG. Most nations, for tariff purposes, schedule diphenhydramine laurylsulfate under HS 29221980. SMILES: CCCCCCCCCCCCOS(=O)(=O)O.CN(C)CCOC(C1CCCCC1)C2CCCCC2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM700. This VA Drug Class (AM700) classifies this compound as belonging to the group ANTIFUNGALS.
This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C18H24NO.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CTN47N39PR, chemically known as ammonium, (2-(diphenylmethoxy)ethyl)trimethyl-, iodide, but more generally known as diphenhydramine methiodide, which bears US NIH Compound Identifier 26535. European Medicines Agency schedules diphenhydramine methiodide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG. Most nations, for tariff purposes, schedule diphenhydramine methiodide under HS 29221980. SMILES: C[N+](C)(C)CCOC(C1CCCCC1)C2CCCCC2.[I-].
This classification denotes a histamine h1 antagonist, antiemetic, antitussive, and hypnotic with the molecular formula C18H24NO.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJO67AO8YI, chemically known as ethylamine, n,n-dimethyl-2-(diphenylmethoxy)-, methylbromide but more generally known as diphenhydramine methylbromide, which bears US NIH Compound Identifier 35726. European Medicines Agency schedules Diphenhydramine methylbromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01771MIG. World Health Organization schedules diphenhydramine methylbromide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule diphenhydramine methylbromide under HS 29221980 and SITC 51461. Diphenhydramine methylbromide bears US NLM identifiers UMLS ID C3273576 and NCI Concept Code C97698. SMILES: C[N+](C)(C)CCOC(C1CCCCC1)C2CCCCC2.[BR-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO.C7H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 707L3YC54L, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but more generally known as diphenhydramine salicylate, which bears US NIH Compound Identifier 3100. European Medicines Agency schedules Diphenhydramine salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01774MIG. Most nations, for tariff and trade purposes, schedule diphenhydramine salicylate under HS 29221980 and SITC 51461. As of Q4 2014, DIPHENHYDRAMINE SALICYLATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCOC(C1CCCCC1)C2CCCCC2.C1CCC(C(C1)C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C76H52O46.C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OPI52249ZG. European Medicines Agency schedules diphenhydramine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01775MIG. Most nations, for tariff and trade purposes, schedule diphenhydramine tannate under HS 29221980 and SITC 51461. SMILES: As of Q4 2014, DIPHENHYDRAMINE TANNATE remains US FDA's Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an antidiarrheal agent with the molecular formula C30H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73312P173G, chemically known as 2,2-diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile but generally known as diphenoxylate, which bears US NIH Compound Identifier 13505. European Medicines Agency schedules Diphenoxylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07212MIG. World Health Organization schedules diphenoxylate in its Anatomical Therapeutic Chemical (ATC) Classification. DIPHENOXYLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diphenoxylate under HS 29333300 and SITC 51574. As of Q4 2014, DIPHENOXYLATE remains the US FDA Preferred Term for this commodity. Diphenoxylate bears US NLM identifiers UMLS ID C0012525 and NCI Concept Code C62024. SMILES: O(C(=O)C1(CCN(CC1)CCC(C1CCCCC1)(C1CCCCC1)C#N)C1CCCCC1)CC.
This classification denotes an opioid analgesic and antidiarrheal with the molecular formula C30H32N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W24OD7YW48, chemically known as 2,2-diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile but more generally known as diphenoxylate hydrochloride, which bears US NIH Compound Identifier 13505. European Medicines Agency schedules Diphenoxylate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01776MIG. Most nations, for tariff and trade purposes, schedule diphenoxylate hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, DIPHENOXYLATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diphenoxylate hydrochloride bears US NLM identifiers UMLS ID C0282145 and NCI Concept Code C28995. SMILES: CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2CCCCC2)C3CCCCC3)C4CCCCC4.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33361OE3AV, chemically known as piperidine, 4- (diphenylmethoxy)-1-methyl-, hydrochloride but generally known as diphenylpyraline, which bears US NIH Compound Identifier 3103. European Medicines Agency schedules Diphenylpyraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07213MIG. The term DIPHENYLPYRALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules diphenylpyraline in its Anatomical Therapeutic Chemical (ATC) Classification. DIPHENYLPYRALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diphenylpyraline under HS 29333999 and SITC 51574. As of Q4 2014, DIPHENYLPYRALINE remains the US FDA Preferred Term for this commodity. Diphenylpyraline bears US NLM identifiers UMLS ID C0058389 and NCI Concept Code C65423. SMILES: O(C1CCN(CC1)C)C(C1CCCCC1)C1CCCCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G9FU7F1E87, chemically known as piperidine, 4- (diphenylmethoxy)-1-methyl-, hydrochloride but more generally known as diphenylpyraline hydrochloride, which bears US NIH Compound Identifier 3103. European Medicines Agency schedules Diphenylpyraline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01778MIG. Most nations, for tariff and trade purposes, schedule diphenylpyraline hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DIPHENYLPYRALINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diphenylpyraline hydrochloride bears US NLM identifiers UMLS ID C0700485 and NCI Concept Code C65424. SMILES: CN1CCC(CC1)OC(C2CCCCC2)C3CCCCC3.CL.
This classification denotes a vaccine for a localized infection of mucous membranes or skin caused by toxigenic strains of corynebacterium diphtheriae. It is characterized by the presence of a pseudomembrane at the site of infection. diphtheria toxin, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects.
This clasification denotes a compound preparation. The first component of this preparation addresses a localized infection of mucous membranes or skin caused by toxigenic strains of corynebacterium diphtheriae characterized by the presence of a pseudomembrane at the site of infection. diphtheria toxin, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects. The second component of this preparation addresses a disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class IM100. This VA Drug Class (IM100) classifies this compound as belonging to the group VACCINES.
This classification denotes an opioid receptor agonist and opioid and analgesic agent with the molecular formula C24H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X188638Y2V, chemically known as 4,4-diphenyl-6-piperidino-3-heptanone but generally known as dipipanone, which bears US NIH Compound Identifier 13331. European Medicines Agency schedules Dipipanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07215MIG. The term DIPIPANONE is an International Non-Proprietary Name. DIPIPANONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dipipanone under HS 29333300 and SITC 51574. As of Q4 2014, DIPIPANONE remains the US FDA Preferred Term for this commodity. Dipipanone bears US NLM identifiers UMLS ID C0058410 and NCI Concept Code C65426. SMILES: O=C(C(CC(N1CCCCC1)C)(C1CCCCC1)C1CCCCC1)CC.
This classification denotes an opioid receptor agonist with the molecular formula C24H31NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8VY00AJ0RL, chemically known as 4,4-diphenyl-6-piperidino-3-heptanone hydrochloride but more generally known as dipipanone hydrochloride, which bears US NIH Compound Identifier 13330. European Medicines Agency schedules Dipipanone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01788MIG. Most nations, for tariff and trade purposes, schedule dipipanone hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, DIPIPANONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dipipanone hydrochloride bears US NLM identifiers UMLS ID C0770934 and NCI Concept Code C76839. SMILES: CCC(=O)C(CC(C)N1CCCCC1)(C2CCCCC2)C3CCCCC3.CL.
This classification denotes an anti-glaucoma agent with the molecular formula C19H29NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Q1PVL543G, chemically known as 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat but generally known as dipivefrin, which bears US NIH Compound Identifier 3105. European Medicines Agency schedules Dipivefrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07217MIG. The term DIPIVEFRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules dipivefrin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIPIVEFRIN remains the US FDA Preferred Term for this commodity. Dipivefrin bears US NLM identifiers UMLS ID C0058415 and NCI Concept Code C61729. SMILES: CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C.
This classification denotes an antiarrhythmic agent with the molecular formula C23H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1P35MD5C1F, chemically known as 1-propanone, 1-(2-(3-((1,1-dimethylpropyl)amino)-2-hydroxypropoxy)phenyl)-3-phenyl- but more generally known as diprafenone, which bears US NIH Compound Identifier 71249. European Medicines Agency schedules Diprafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07219MIG. The term DIPRAFENONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). DIPRAFENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule diprafenone under HS 29221980 and SITC 51461. As of Q4 2014, DIPRAFENONE remains US FDA's Preferred Term for this commodity. Diprafenone bears US NLM identifiers UMLS ID C0058420 and NCI Concept Code C65429. SMILES: OC(CNC(CC)(C)C)COC1C(C(=O)CCC2CCCCC2)CCCC1.
This classification denotes an antiparkinsonian agent with the molecular formula C10H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XE7IWD0JX, chemically known as 1,1-dipropylbutylamine but generally known as diprobutine, which bears US NIH Compound Identifier 41701. European Medicines Agency schedules Diprobutine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07221MIG. The term DIPROBUTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). DIPROBUTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diprobutine under HS 29211980 and SITC 51451. As of Q4 2014, DIPROBUTINE remains the US FDA Preferred Term for this commodity. Diprobutine bears US NLM identifiers UMLS ID C0058421 and NCI Concept Code C65430. SMILES: CCCC(CCC)(CCC)N.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C10H14N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 263T0E9RR9, chemically known as 1,3-dimethyl-7-(2,3-dihydroxypropyl)xanthine but generally known as diprophylline, which bears US NIH Compound Identifier 3182. European Medicines Agency schedules Diprophylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07225MIG. The term DIPROPHYLLINE is an International Non-Proprietary Name. World Health Organization schedules diprophylline in its Anatomical Therapeutic Chemical (ATC) Classification. DIPROPHYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Diprophylline or dyphylline bears US NLM identifiers UMLS ID C0721457 and NCI Concept Code C47504. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O.
This classification denotes an antispasmotic agent with the molecular formula C13H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U0K8WHL37U, chemically known as 1,2-propanediol, 3-(4-phenyl-1-piperazinyl)-, (r,s)- but more generally known as dropropizine, which bears US NIH Compound Identifier 3169. European Medicines Agency schedules Dropropizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06412MIG. The term DROPROPIZINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules dropropizine in its Anatomical Therapeutic Chemical (ATC) Classification. DROPROPIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Dipropizine or dropropizine bears US NLM identifiers UMLS ID C0058425 and NCI Concept Code C73179. SMILES: OC(CN1CCN(CC1)C1CCCCC1)CO.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a calcium channel blocker with the molecular formula C26H35NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A5OIA91GT, chemically known as 1-(3,4-diethoxybenzyl)-3,4-dihydro-6,7-diisopropoxyisoquinoline but generally known as diproteverine, which bears US NIH Compound Identifier 50463. European Medicines Agency schedules Diproteverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07227MIG. The term DIPROTEVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). DIPROTEVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule diproteverine under HS 29391900 and SITC 54141. As of Q4 2014, DIPROTEVERINE remains the US FDA Preferred Term for this commodity. Diproteverine bears US NLM identifiers UMLS ID C0114311 and NCI Concept Code C73025. SMILES: O(c1cc2c(C(=NCC2)Cc2cc(OCC)c(OCC)cc2)cc1OC(C)C)C(C)C.
This classification denotes a calcium channel blocker with the molecular formula C26H35NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T587ZFV6UM, chemically known as 1-(3,4-diethoxybenzyl)-3,4-dihydro-6,7-diisopropoxyisoquinoline but more generally known as diproteverine hydrochloride, which bears US NIH Compound Identifier 50463. Most nations, for tariff and trade purposes, schedule diproteverine hydrochloride under HS 29391900. As of Q4 2014, DIPROTEVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diproteverine hydrochloride bears US NLM identifiers UMLS ID C0107185 and NCI Concept Code C97979. SMILES: CCOC1CCC(CC1OCC)CC2=NCCC3C2CC(C(C3)OC(C)C)OC(C)C.CL.
This clasification denotes a compound preparation. The first component of this preparation addresses a localized infection of mucous membranes or skin caused by toxigenic strains of corynebacterium diphtheriae characterized by the presence of a pseudomembrane at the site of infection. diphtheria toxin, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects. The second component of this preparation addresses a disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. The third component of this compound preparation consists of a suspension of killed Bordetella pertussis organisms, used for immunization against pertussis or whooping cough.
This clasification denotes a compound preparation. The first component of this preparation addresses a localized infection of mucous membranes or skin caused by toxigenic strains of corynebacterium diphtheriae characterized by the presence of a pseudomembrane at the site of infection. diphtheria toxin, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects. The second component of this preparation addresses a disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. The third component of this compound preparation consists of a suspension of killed Bordetella pertussis organisms, used for immunization against pertussis or whooping cough.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C24H40N8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64ALC7F90C, chemically known as 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine but generally known as dipyridamole, which bears US NIH Compound Identifier 3108. European Medicines Agency schedules Dipyridamole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07229MIG. The term DIPYRIDAMOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules dipyridamole in its Anatomical Therapeutic Chemical (ATC) Classification. DIPYRIDAMOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dipyridamole under HS 29335995 and SITC 51576. As of Q4 2014, DIPYRIDAMOLE remains the US FDA Preferred Term for this commodity. Dipyridamole bears US NLM identifiers UMLS ID C0012582 and NCI Concept Code C445. SMILES: OCCN(C1NC(N2CCCCC2)C2NC(NC(N3CCCCC3)C2N1)N(CCO)CCO)CCO.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H10O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EF5UVE254C, chemically known as 2,3-dihydroxybenzoic acid diacetate but generally known as dipyrocetyl, which bears US NIH Compound Identifier 68093. European Medicines Agency schedules Dipyrocetyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07231MIG. The term DIPYROCETYL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules dipyrocetyl in its Anatomical Therapeutic Chemical (ATC) Classification. DIPYROCETYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dipyrocetyl under HS 29182980 and SITC 51394. As of Q4 2014, DIPYROCETYL remains the US FDA Preferred Term for this commodity. Dipyrocetyl bears US NLM identifiers UMLS ID C2825247 and NCI Concept Code C80542. SMILES: CC(=O)OC1=CC=CC(=C1OC(=O)C)C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H16N3O4S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6429L0L52Y, chemically known as 4-methylamino-1,5-dimethyl-2-phenyl-3-pyrazolone sodium methanesulfonate but generally known as dipyrone, which bears US NIH Compound Identifier 6236. European Medicines Agency schedules Dipyrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08810MIG. SMILES: S(=O)(=O)(O)CN(C1C(N(N(C1=O)C1CCCCC1)C)C)C.[NA].
This classification denotes a macrolide antibiotic with the molecular formula C42H78N2O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1801D76STL, chemically known as erythromycin, 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethylidene)oxy)-, (9s(r))- but generally known as dirithromycin, which bears US NIH Compound Identifier 5464388. European Medicines Agency schedules Dirithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07232MIG. The term DIRITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules dirithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. DIRITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dirithromycin under HS 29415000 and SITC 54139. As of Q4 2014, DIRITHROMYCIN remains the US FDA Preferred Term for this commodity. Dirithromycin bears US NLM identifiers UMLS ID C0058445 and NCI Concept Code C47496. SMILES: O1C2C(C(NC1COCCOC)C(CC(O)(C(OC1OC(CC(N(C)C)C1O)C)C(C(OC1OC(C(O)C(OC)(C1)C)C)C(C(=O)OC(C2(O)C)CC)C)C)C)C)C.
This classification denotes an anorexiant with the molecular formula C40H33F3N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 578H0RMP25, chemically known as 1h-indole-2-carboxamide, 1-methyl-n-((1s)-2-(methyl(phenylmethyl)amino)-2-oxo-1-phenylethyl)-5-(((4-(trifluoromethyl)(1,1-biphenyl)-2-yl)carbonyl)amino)- but generally known as dirlotapide, which bears US NIH Compound Identifier 6433125. The term DIRLOTAPIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). Most nations schedule dirlotapide under HS 29339990 and SITC 51577. As of Q4 2014, DIRLOTAPIDE remains the US FDA Preferred Term for this commodity. Dirlotapide bears US NLM identifiers UMLS ID C1958588 and NCI Concept Code C77329. SMILES: CN1C2=C(C=C(C=C2)NC(=O)C3=CC=CC=C3C4=CC=C(C=C4)C(F)(F)F)C=C1C(=O)NC(C5=CC=CC=C5)C(=O)N(C)CC6=CC=CC=C6.
This classification denotes a topical anti-infective agent with the molecular formula C27H60NO3Si.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6G4NNS4CW4, chemically known as 1-decanaminium, n-decyl-n-methyl-n-(3-(trimethoxysilyl)propyl)-, chloride but generally known as disiquonium chloride, which bears US NIH Compound Identifier 62253. European Medicines Agency schedules Disiquonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07233MIG. The term DISIQUONIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). As of Q4 2014, DISIQUONIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Disiquonium chloride bears US NLM identifiers UMLS ID C1880358 and NCI Concept Code C65438. SMILES: Cl.[Si](OC)(OC)(OC)CCC[N](CCCCCCCCCC)(CCCCCCCCCC)C.
This classification denotes an antiarrhythmic agent with the molecular formula C23H38ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4IZG3M7XVP, chemically known as 1-piperidinebutanamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-(2-chlorophenyl)- but more generally known as disobutamide, which bears US NIH Compound Identifier 68566. European Medicines Agency schedules Disobutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07234MIG. The term DISOBUTAMIDE is an International Non-Proprietary Name. DISOBUTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule disobutamide under HS 29333999 and SITC 51574. As of Q4 2014, DISOBUTAMIDE remains US FDA's Preferred Term for this commodity. Disobutamide bears US NLM identifiers UMLS ID C0058462 and NCI Concept Code C81427. SMILES: CLC1C(C(CCN2CCCCC2)(CCN(C(C)C)C(C)C)C(=O)N)CCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX202. This VA Drug Class (DX202) classifies this compound as belonging to the group NON-IMAGING AGENTS RADIOPHARMACEUTICALS.
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KI671F2NS. European Medicines Agency schedules Disogluside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07236MIG. Disogluside generally arises in the molecular formula C33H52O8. The term DISOGLUSIDE is an International Non-Proprietary Name or INN. DISOGLUSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule disogluside under HS 29389090 and SITC 54161. As of Q4 2014, DISOGLUSIDE remains the US FDA Preferred Term for this commodity. Disogluside bears US NLM identifiers UMLS ID C2699784 and NCI Concept Code C78057. SMILES: O1C2C(C3(C(C4C(CC3)C3(C(=CC4)CC(OC4OC(C(O)C(O)C4O)CO)CC3)C)C2)C)C(C21OCC(CC2)C)C.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C21H29N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) GFO928U8MQ, chemically known as 2-pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl- but more generally known as disopyramide, which bears US NIH Compound Identifier 3114. European Medicines Agency schedules Disopyramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07237MIG. The term DISOPYRAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules disopyramide in its Anatomical Therapeutic Chemical (ATC) Classification. DISOPYRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule disopyramide under HS 29333999 and SITC 51574. As of Q4 2014, DISOPYRAMIDE remains US FDA's Preferred Term for this commodity. Disopyramide bears US NLM identifiers UMLS ID C0012702 and NCI Concept Code C61730. SMILES: O=C(N)C(CCN(C(C)C)C(C)C)(C1CCCCC1)C1NCCCC1.
This classification denotes an antiviral agent with the molecular formula C20H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FX8Q9PI4VP, chemically known as 5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole but generally known as disoxaril, which bears US NIH Compound Identifier 55717. European Medicines Agency schedules Disoxaril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06322MIG. The term DISOXARIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). DISOXARIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule disoxaril under HS 29349990 and SITC 51579. As of Q4 2014, DISOXARIL remains the US FDA Preferred Term for this commodity. Disoxaril bears US NLM identifiers UMLS ID C0058467 and NCI Concept Code C81607. SMILES: O(CCCCCCCC1ONC(C1)C)C1CCC(C2=NCCO2)CC1.
This classification denotes a distamycin antibiotic and dna minor groove binding agent with the molecular formula C22H27N9O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80O63P88IS, chemically known as distamycin a, hydrochloride but generally known as distamycin a, which bears US NIH Compound Identifier 3115. European Medicines Agency schedules Stallimycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10640MIG. The term DISTAMYCIN A is an International Non-Proprietary Name. Distamycin a or stallimycin bears US NLM identifiers UMLS ID C0244119 and NCI Concept Code C1517. SMILES: O=C(NC1CC(N(C1)C)C(=O)NCCC(=N)N)C1N(CC(NC(=O)C2N(CC(NC=O)C2)C)C1)C.
This classification denotes a cholinesterase inhibitor with the molecular formula C22H32N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T940307O7B, chemically known as 3,3-(1,6-hexanediylbis((methylimino)carbonyl)oxy)bis(1-methylpyridinium) dibromide but generally known as distigmine, which bears US NIH Compound Identifier 27522. European Medicines Agency schedules Distigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01797MIG. World Health Organization schedules distigmine in its Anatomical Therapeutic Chemical (ATC) Classification. DISTIGMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DISTIGMINE remains the US FDA Preferred Term for this commodity. SMILES: BR.BR.O(C(=O)N(CCCCCCN(C)C(=O)OC1C[N](CCC1)C)C)C1C[N](CCC1)C. .
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C22H32N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 750F36OP6J, chemically known as 3,3-(1,6-hexanediylbis((methylimino)carbonyl)oxy)bis(1-methylpyridinium) dibromide but more generally known as distigmine bromide, which bears US NIH Compound Identifier 27522. European Medicines Agency schedules Distigmine bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06323MIG. The term DISTIGMINE BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). Most nations, for tariff and trade purposes, schedule distigmine bromide under HS 29333999 and SITC 51574. As of Q4 2014, DISTIGMINE BROMIDE remains US FDA's Preferred Term for this commodity. Distigmine bromide bears US NLM identifiers UMLS ID C0012757 and NCI Concept Code C87487. SMILES: C[N+]1CCCC(C1)OC(=O)N(C)CCCCCCN(C)C(=O)OC2CCC[N+](C2)C.[BR-].[BR-].
This classification denotes a multidrug resistance modulator and angiogenesis inhibitor with the molecular formula C10H20N2S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TR3MLJ1UAI, chemically known as 1,1-dithiobis(n,n-diethylthioformamide) but generally known as disulfiram, which bears US NIH Compound Identifier 3117. European Medicines Agency schedules Disulfiram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06326MIG. The term DISULFIRAM is an International Non-Proprietary Name. World Health Organization schedules disulfiram in its Anatomical Therapeutic Chemical (ATC) Classification. DISULFIRAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule disulfiram under HS 29303000 and SITC 51543. As of Q4 2014, DISULFIRAM remains the US FDA Preferred Term for this commodity. Disulfiram bears US NLM identifiers UMLS ID C0012772 and NCI Concept Code C447. SMILES: CCN(CC)C(=S)SSC(=S)N(CC)CC.
This classification denotes a proton pump inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V81J4OO2OT. European Medicines Agency schedules Disuprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06327MIG. Disuprazole generally arises in the molecular formula C16H17N3OS2. The term DISUPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) DISUPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule disuprazole under HS 29333999 and SITC 51574. As of Q4 2014, DISUPRAZOLE remains the US FDA Preferred Term for this commodity. Disuprazole bears US NLM identifiers UMLS ID C1880366 and NCI Concept Code C65441. SMILES: S(=O)(CC1NCCC(SCC)C1C)C1[NH]C2C(N1)CCCC2.
This classification denotes an antiplatelet agent with the molecular formula C19H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H2BQI5Z8FT, chemically known as 4,5-diphenyl-2-bis(2-hydroxyethyl)-aminoxazol but generally known as ditazol, which bears US NIH Compound Identifier 29088. European Medicines Agency schedules Ditazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06328MIG. The term DITAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules ditazol in its Anatomical Therapeutic Chemical (ATC) Classification. Ditazol or ditazole bears US NLM identifiers UMLS ID C0012777 and NCI Concept Code C65442. SMILES: C1=CC=C(C=C1)C2=C(OC(=N2)N(CCO)CCO)C3=CC=CC=C3.
This classification denotes an antihypertensive agent with the molecular formula C50H75N9O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5355S3W1IS, chemically known as tert-butyl (2s)-2-(((alphas)-alpha-(((1s)-1-(((1s,2s,4s)-2-hydroxy-1-isobutyl-5-methyl-4-(((1s,2s)-2-methyl-1-((2-pyridylmethyl)carbamoyl)butyl)carbamoyl)hexyl)carbamoyl)-2-imidazol-4-ylethyl)methylcarbamoyl)phenethyl)carbamoyl)-1-pyrrolidinecarboxylate but generally known as ditekiren, which bears US NIH Compound Identifier 5464201. European Medicines Agency schedules Ditekiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06329MIG. The term DITEKIREN is an International Non-Proprietary Name. DITEKIREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ditekiren under HS 29333999 and SITC 51574. As of Q4 2014, DITEKIREN remains the US FDA Preferred Term for this commodity. Ditekiren bears US NLM identifiers UMLS ID C0077636 and NCI Concept Code C95291. SMILES: OC(C(NC(=O)C(N(C(=O)C(NC(=O)C1N(CCC1)C(=O)OC(C)(C)C)Cc1ccccc1)C)Cc1[nH]cnc1)CC(C)C)CC(C(C)C)C(=O)NC(C(CC)C)C(=O)NCc1ncccc1.
This classification denotes a nitrosourea compound with the molecular formula C10H18Cl2N6O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 810O95170J, chemically known as 5,6-dithia-2,9,11-triazatridecanamide, 13-chloro-n-(2-chloroethyl)-n,11-dinitroso-10-oxo- but more generally known as ditiomustine, which bears US NIH Compound Identifier 127547. European Medicines Agency schedules Ditiomustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06334MIG. The term DITIOMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). DITIOMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ditiomustine under HS 29309085 and SITC 51549. As of Q4 2014, DITIOMUSTINE remains US FDA's Preferred Term for this commodity. Ditiomustine bears US NLM identifiers UMLS ID C1880367 and NCI Concept Code C65443. SMILES: C(CSSCCNC(=O)N(CCCL)N=O)NC(=O)N(CCCL)N=O.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C13H21NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AL8499KM94, chemically known as 4-methyl-n,n-dipropyl-benzenesulfonamide but more generally known as ditolamide, which bears US NIH Compound Identifier 208847. European Medicines Agency schedules Ditolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06335MIG. The term DITOLAMIDE is an International Non-Proprietary Name. DITOLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(N(CCC)CCC)C1CCC(CC1)C.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40SR2754GL. European Medicines Agency schedules Ditophal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06336MIG. Ditophal generally arises in the molecular formula C12H14O2S2. The term DITOPHAL is an International Non-Proprietary Name or INN. DITOPHAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ditophal under HS 29309085 and SITC 51549. As of Q4 2014, DITOPHAL remains the US FDA Preferred Term for this commodity. Ditophal bears US NLM identifiers UMLS ID C1880369 and NCI Concept Code C65445. SMILES: CCSC(=O)C1=CC(=CC=C1)C(=O)SCC.
This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BVG9H4U2ZB. European Medicines Agency schedules Divabuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06337MIG. Divabuterol generally arises in the molecular formula C22H35NO5. The term DIVABUTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 1, 2000, list 43.) DIVABUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule divabuterol under HS 29225000 and SITC 51467. As of Q4 2014, DIVABUTEROL remains the US FDA Preferred Term for this commodity. Divabuterol bears US NLM identifiers UMLS ID C1880370 and NCI Concept Code C65446. SMILES: OC(CNC(C)(C)C)C1CC(OC(=O)C(C)(C)C)CC(OC(=O)C(C)(C)C)C1.
This classification denotes an anticonvulsant agent with the molecular formula 2C8H15O2.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 644VL95AO6, chemically known as pentanoic acid, 2-propyl-, sodium salt (2:1) but generally known as divalproex sodium, which bears US NIH Compound Identifier 53519. European Medicines Agency schedules Divalproex sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20309. The term VALPROATE SEMISODIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). SMILES: CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[NA+].
This classification denotes a benzodiazepine with the molecular formula C17H17N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AOV43246G, chemically known as 6-ethyl-7-methoxy-5-methylimidazo(1,2-a)pyrimidin-2-yl phenyl ketone but generally known as divaplon, which bears US NIH Compound Identifier 65822. European Medicines Agency schedules Divaplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06338MIG. The term DIVAPLON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). DIVAPLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule divaplon under HS 29335995 and SITC 51576. As of Q4 2014, DIVAPLON remains the US FDA Preferred Term for this commodity. Divaplon bears US NLM identifiers UMLS ID C0209249 and NCI Concept Code C65448. SMILES: O(C1NC2N(C(C1CC)C)CC(N2)C(=O)C1CCCCC1)C.
This classification denotes a pesticide with the molecular formula C6H10O2S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RN4CQ46FDM, chemically known as xanthogen, bis(ethyl- but generally known as dixanthogen, which bears US NIH Compound Identifier 10404. European Medicines Agency schedules Dixanthogen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06339MIG. The term DIXANTHOGEN is an International Non-Proprietary Name. World Health Organization schedules dixanthogen in its Anatomical Therapeutic Chemical (ATC) Classification. DIXANTHOGEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dixanthogen under HS 29309085 and SITC 51549. As of Q4 2014, DIXANTHOGEN remains the US FDA Preferred Term for this commodity. Dixanthogen bears US NLM identifiers UMLS ID C0058517 and NCI Concept Code C80602. SMILES: S(SC(=S)OCC)C(=S)OCC.
This classification denotes a non-narcotic analgesic, antiemetic, and antipsychotic agent with the molecular formula C24H33N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7H368W3AYC, chemically known as ethanol, 2-(2-(4-(2-methyl-3-phenothiazin-10-ylpropyl)-1-piperazinyl)ethoxy)- but generally known as dixyrazine, which bears US NIH Compound Identifier 17182. European Medicines Agency schedules Dixyrazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13640MIG. World Health Organization schedules dixyrazine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIXYRAZINE remains the US FDA Preferred Term for this commodity. SMILES: S1C2C(N(CC(CN3CCN(CC3)CCOCCO)C)C3C1CCCC3)CCCC2. .
This classification denotes a hepatoprotective agent with the molecular formula C5H11NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73JWT2K6T3. The term d,l-methionine is a United States Adopted Name designation. D,l-methionine or racemethionine bears US NLM identifiers UMLS ID C0034504 and NCI Concept Code C84131. SMILES: CSCCC(C(=O)O)N.
This classification denotes an antipsychotic agent with the molecular formula C20H30ClN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FW0Z2U7O23, chemically known as 4-amino-2-butoxy-5-chloro-n-(1-(1,3-dioxolan-2-ylmethyl)-4-piperidyl)benzamide but generally known as dobupride, which bears US NIH Compound Identifier 65896. European Medicines Agency schedules Dobupride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06342MIG. The term DOBUPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). DOBUPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dobupride under HS 29349990 and SITC 51579. As of Q4 2014, DOBUPRIDE remains the US FDA Preferred Term for this commodity. Dobupride bears US NLM identifiers UMLS ID C0386741 and NCI Concept Code C65451. SMILES: CLC1CC(C(=O)NC2CCN(CC2)CC2OCCO2)C(OCCCC)CC1N.
This classification denotes an adrenergic agent with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3S12J47372, chemically known as 1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+-)- but generally known as dobutamine, which bears US NIH Compound Identifier 36811. European Medicines Agency schedules Dobutamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06343MIG. The term DOBUTAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules dobutamine in its Anatomical Therapeutic Chemical (ATC) Classification. DOBUTAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dobutamine under HS 29222900 and SITC 51462. As of Q4 2014, DOBUTAMINE remains the US FDA Preferred Term for this commodity. Dobutamine bears US NLM identifiers UMLS ID C0012963 and NCI Concept Code C61733. SMILES: OC1CC(CCNC(CCC2CCC(O)CC2)C)CCC1O.
This classification denotes an adrenergic agent with the molecular formula C18H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0WR771DJXV, chemically known as 1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+-)- but more generally known as dobutamine hydrochloride, which bears US NIH Compound Identifier 36811. European Medicines Agency schedules Dobutamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01803MIG. Most nations, for tariff and trade purposes, schedule dobutamine hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, DOBUTAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dobutamine hydrochloride bears US NLM identifiers UMLS ID C0012964 and NCI Concept Code C28997. SMILES: CC(CCC1CCC(CC1)O)NCCC2CCC(C(C2)O)O.CL.
This classification denotes an adrenergic agent with the molecular formula C18H23NO3.C12H22O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CP0YC140T9, chemically known as 1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+/-)-, 4-o-.beta.-d-galactopyranosyl-d-gluconate (salt), but more generally known as dobutamine lactobionate, which bears US NIH Compound Identifier 3038222. European Medicines Agency schedules dobutamine lactobionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06343MIG. Most nations, for tariff purposes, schedule dobutamine lactobionate under HS 29222900. SMILES: CC(CCC1CCC(CC1)O)NCCC2CCC(C(C2)O)O.C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(=O)O)O)O)O)O)O)O.
This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5D1IB9AI6J, chemically known as 1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (- )-, (s-(r*,r*))-2,3-dihydroxybutanedioate (1:1) (salt) but more generally known as dobutamine tartrate, which bears US NIH Compound Identifier 208850. Most nations, for tariff and trade purposes, schedule dobutamine tartrate under HS 29222900 and SITC 51462. As of Q4 2014, DOBUTAMINE TARTRATE remains US FDA's Preferred Term for this commodity. Dobutamine tartrate bears US NLM identifiers UMLS ID C0887392 and NCI Concept Code C65452. SMILES: CC(CCC1CCC(CC1)O)NCCC2CCC(C(C2)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a taxane compound and taxane-site binding agent with the molecular formula C43H53NO14.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15H5577CQD, chemically known as docetaxel, anhydrous but generally known as docetaxel, which bears US NIH Compound Identifier 64780. European Medicines Agency schedules Docetaxel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12492MIG. World Health Organization schedules docetaxel in its Anatomical Therapeutic Chemical (ATC) Classification. DOCETAXEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule docetaxel under HS 29329950 and SITC 51569. As of Q4 2014, DOCETAXEL remains the US FDA Preferred Term for this commodity. Docetaxel bears US NLM identifiers UMLS ID C0246415 and NCI Concept Code C1526. SMILES: O1C2C(OC(=O)C)(C3C(C(O)C2)(C(=O)C(O)C2=C(C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)C4CCCCC4)CC(O)(C3OC(=O)C3CCCCC3)C2(C)C)C)C)C1.
This classification denotes an antifungal agent with the molecular formula C26H22Cl2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VR021VC9TY, chemically known as 1h-imidazole, 1-((4-(((1,1-biphenyl)-4-yloxy)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-2-yl)methyl)-, cis- but generally known as doconazole, which bears US NIH Compound Identifier 65488. European Medicines Agency schedules Doconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06346MIG. The term DOCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). DOCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doconazole under HS 29349990 and SITC 51579. As of Q4 2014, DOCONAZOLE remains the US FDA Preferred Term for this commodity. Doconazole bears US NLM identifiers UMLS ID C1880384 and NCI Concept Code C65454. SMILES: CLC1C(C2(OC(CO2)COC2CCC(CC2)C2CCCCC2)CN2CCNC2)CCC(CL)C1.
This classification denotes a stool softener, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F05Q2T2JA0. European Medicines Agency schedules Docusate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06348MIG. Docusate sodium generally arises in the molecular formula C20H37NAO7S. The term 'docusate sodium' is an International Nomenclature of Cosmetic Ingredients designation. As of Q4 2014, DOCUSATE CALCIUM remains the US FDA Preferred Term for this commodity. Docusate calcium bears US NLM identifiers UMLS ID C0282140 and NCI Concept Code C28999. SMILES: S(=O)(=O)(O)C(CC(=O)OCC(CCCC)CC)C(=O)OCC(CCCC)CC.[NA].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a stool softener with the molecular formula C20H37O7S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CIK9F54ZHR, chemically known as potassium 1,4-bis(2-ethylhexyl) sulfosuccinate but generally known as docusate potassium, which bears US NIH Compound Identifier 24097. European Medicines Agency schedules Docusate potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01807MIG. As of Q4 2014, DOCUSATE POTASSIUM remains the US FDA Preferred Term for this commodity. Docusate potassium bears US NLM identifiers UMLS ID C0282141 and NCI Concept Code C76971. SMILES: CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)[O-].[K+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA204. This VA Drug Class (GA204) classifies this compound as belonging to the group STIMULANT LAXATIVES.
This classification denotes a stool softener, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier F05Q2T2JA0. European Medicines Agency schedules Docusate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06348MIG. Docusate sodium generally arises in the molecular formula C20H37NAO7S. The term 'docusate sodium' is an International Nomenclature of Cosmetic Ingredients designation.
This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XD8BU85ZLK. European Medicines Agency schedules Dodeclonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06349MIG. Dodeclonium bromide generally arises in the molecular formula C22H39CLNO.BR. The term DODECLONIUM BROMIDE is an International Non-Proprietary Name or INN. As of Q4 2014, DODECLONIUM remains the US FDA Preferred Term for this commodity. SMILES: C1=CC=C(C=C1)C(=O)OC2=CC=CC3=C2N=CC=C3.
This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XD8BU85ZLK. European Medicines Agency schedules Dodeclonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06349MIG. Dodeclonium bromide generally arises in the molecular formula C22H39CLNO.BR. The term DODECLONIUM BROMIDE is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule dodeclonium bromide under HS 29239000 and SITC 51481. As of Q4 2014, DODECLONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Dodeclonium bromide bears US NLM identifiers UMLS ID C0771501 and NCI Concept Code C65455. SMILES: CCCCCCCCCCCC[N+](C)(C)CCOC1CCC(CC1)CL.[BR-].
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C19H27N3O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) R4Z9X1N2ND, chemically known as uk 68,798 but more generally known as dofetilide, which bears US NIH Compound Identifier 71329. European Medicines Agency schedules Dofetilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06351MIG. The term DOFETILIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules dofetilide in its Anatomical Therapeutic Chemical (ATC) Classification. DOFETILIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dofetilide under HS 29350090 and SITC 51580. As of Q4 2014, DOFETILIDE remains US FDA's Preferred Term for this commodity. Dofetilide bears US NLM identifiers UMLS ID C0114771 and NCI Concept Code C47499. SMILES: S(=O)(=O)(NC1CCC(CCN(CCOC2CCC(NS(=O)(=O)C)CC2)C)CC1)C.
This classification denotes a 5-ht3 receptor antagonist and antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82WI2L7Q6E. European Medicines Agency schedules Dolasetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06352MIG. Dolasetron generally arises in the molecular formula C19H20N2O3. The term DOLASETRON is an International Non-Proprietary Name or INN. DOLASETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dolasetron under HS 29339990 and SITC 51577. As of Q4 2014, DOLASETRON remains the US FDA Preferred Term for this commodity. Dolasetron bears US NLM identifiers UMLS ID C0209210 and NCI Concept Code C61735. SMILES: O(C1CC2N3C(CC(C2)C(=O)C3)C1)C(=O)C1C2C([NH]C1)CCCC2.
Dolutegravir is used to treat human immunodeficiency virus (HIV) infection.
This classification denotes a combination drug for treatment of HIV. The first component, DOLUTEGRAVIR, has US FDA Unique Ingredient Identifier of DKO1W9H7M1. The second component, EMTRICITABINE, has US FDA Unique Ingredient Identifier of G70B4ETF4S. The third component, TENOFOVIR ALAFENAMIDE, has US FDA Unique Ingredient Identifier of EL9943AG5J.
This classification denotes a combination drug for treatment of HIV. The first component, DOLUTEGRAVIR, has US FDA Unique Ingredient Identifier of DKO1W9H7M1. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.
This classification denotes a mucolytic agent with the molecular formula C5H9IO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C1PXF8V06N, chemically known as 1,3-dioxolane-4-methanol, 2-(iodomethyl)-, (e,z)- but more generally known as domiodol, which bears US NIH Compound Identifier 43814. European Medicines Agency schedules Domiodol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06355MIG. The term DOMIODOL is an International Non-Proprietary Name. World Health Organization schedules domiodol in its Anatomical Therapeutic Chemical (ATC) Classification. DOMIODOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule domiodol under HS 29329970 and SITC 51569. As of Q4 2014, DOMIODOL remains US FDA's Preferred Term for this commodity. Domiodol bears US NLM identifiers UMLS ID C0048365 and NCI Concept Code C65461. SMILES: ICC1OC(CO1)CO.
This classification denotes a surface-active agent with the molecular formula C22H40NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AZL56CU0F. European Medicines Agency schedules domiphen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01814MIG. DOMIPHEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DOMIPHEN remains the US FDA Preferred Term for this commodity. Domiphen bears US NLM identifiers UMLS ID C0058677 and NCI Concept Code C83684. SMILES: CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1.
This classification denotes an antipsychotic agent with the molecular formula C22H24ClN5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5587267Z69, chemically known as 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one but generally known as domperidone, which bears US NIH Compound Identifier 3151. European Medicines Agency schedules Domperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06361MIG. The term DOMPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules domperidone in its Anatomical Therapeutic Chemical (ATC) Classification. DOMPERIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule domperidone under HS 29333999 and SITC 51574. As of Q4 2014, DOMPERIDONE remains the US FDA Preferred Term for this commodity. Domperidone bears US NLM identifiers UMLS ID C0013015 and NCI Concept Code C454. SMILES: CLC1CC2[NH]C(=O)N(C3CCN(CC3)CCCN3C4C([NH]C3=O)CCCC4)C2CC1.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 899U5WF46A. European Medicines Agency schedules Domperidone maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01815MIG. Domperidone maleate generally arises in the molecular formula C22H24CLN5O2.C4H4O4. The term 'domperidone maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule domperidone maleate under HS 29333999 and SITC 51574. As of Q4 2014, DOMPERIDONE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)[NH]C(=O)N2CCCN3CCC(CC3)N4C5CCC(CC5[NH]C4=O)CL.C(=C\C(=O)O)\C(=O)O.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C24H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8SSC91326P, chemically known as 1h-inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)- but generally known as donepezil, which bears US NIH Compound Identifier 3152. European Medicines Agency schedules Donepezil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06362MIG. The term DONEPEZIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). World Health Organization schedules donepezil in its Anatomical Therapeutic Chemical (ATC) Classification. DONEPEZIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule donepezil under HS 29333999 and SITC 51574. As of Q4 2014, DONEPEZIL remains the US FDA Preferred Term for this commodity. Donepezil bears US NLM identifiers UMLS ID C0527316 and NCI Concept Code C66874. SMILES: O=C1C(CC2CCN(CC2)CC2CCCCC2)CC2C1CC(OC)C(OC)C2.
This classification denotes a cholinesterase inhibitor and nootropic agent with the molecular formula C24H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3O2T2PJ89D, chemically known as 1h-inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, hydrochloride but more generally known as donepezil hydrochloride, which bears US NIH Compound Identifier 5741. European Medicines Agency schedules Donepezil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13647MIG. Most nations, for tariff and trade purposes, schedule donepezil hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DONEPEZIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Donepezil hydrochloride bears US NLM identifiers UMLS ID C0771848 and NCI Concept Code C2603. SMILES: COC1CC2C(CC1OC)C(=O)C(C2)CC3CCN(CC3)CC4CCCCC4.CL.
This classification denotes an acetylcholinesterase inhibitor C24H29NO3.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLF7M28SI5, chemically known as 1h-inden-1-one, 2,3-dihydro-5,6-dimethoxyl-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, ethanedoioate (1:1), but more generally known as donepezil oxalate, which bears US NIH Compound Identifier 11397232. Most nations, for tariff and trade purposes, schedule donepezil oxalate under HS 29333999 and SITC 51574. As of Q4 2014, DONEPEZIL OXALATE remains US FDA's Preferred Term for this commodity. Donepezil oxalate bears US NLM identifiers UMLS ID C2828323 and NCI Concept Code C87489. SMILES: COC1CC2C(CC1OC)C(=O)C(C2)CC3CCN(CC3)CC4CCCCC4.C(=O)(C(=O)O)O.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C20H25N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E9730RXS4H, chemically known as 5-((1,2-dihydro-2-oxo-4-pyridyl)methyl)-2-((2-((5-((dimethylamino)methyl)furfuryl)thio)ethyl)amino)-4(1h)-pyrimidinone but generally known as donetidine, which bears US NIH Compound Identifier 57484. European Medicines Agency schedules Donetidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06363MIG. The term DONETIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). DONETIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule donetidine under HS 29349990 and SITC 51579. As of Q4 2014, DONETIDINE remains the US FDA Preferred Term for this commodity. Donetidine bears US NLM identifiers UMLS ID C0074641 and NCI Concept Code C77439. SMILES: S(CC1OC(CN(C)C)CC1)CCNC1[NH]C(=O)C(CC2C(=O)[NH]CCC2)CN1.
This classification denotes a serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70968BVH2J. European Medicines Agency schedules Donitriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01817MIG. Donitriptan generally arises in the molecular formula C23H25N5O2. The term DONITRIPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule donitriptan under HS 29335995 and SITC 51576. As of Q4 2014, DONITRIPTAN remains the US FDA Preferred Term for this commodity. Donitriptan bears US NLM identifiers UMLS ID C0769585 and NCI Concept Code C65466. SMILES: O(CC(=O)N1CCN(CC1)C1CCC(CC1)C#N)C1CC2C(CCN)C[NH]C2CC1.
This classification denotes a serotonin agonist with the molecular formula C23H25N5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XTD13T14MR, chemically known as benzonitrile, 4-(4-(2-((3-(2-aminoethyl)-1h-indol-5-yl)oxy)acetyl)-1-piperazinyl)-, hydrochloride (1:1), but more generally known as donitriptan hydrochloride, which bears US NIH Compound Identifier 197705. European Medicines Agency schedules donitriptan hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01817MIG. Most nations, for tariff purposes, schedule donitriptan hydrochloride under HS 29335995. SMILES: C1CC(CCC1C#N)N2CCN(CC2)C(=O)COC3CCC4C(C3)C(C[NH]4)CCN.CL.
This classification denotes a catecholamine with the molecular formula C8H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VTD58H1Z2X, chemically known as 3,4-dihydroxyphenylethylamine but generally known as dopamine, which bears US NIH Compound Identifier 681. European Medicines Agency schedules Dopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06365MIG. The term DOPAMINE is an International Non-Proprietary Name. World Health Organization schedules dopamine in its Anatomical Therapeutic Chemical (ATC) Classification. DOPAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dopamine under HS 29222900 and SITC 51462. As of Q4 2014, DOPAMINE remains the US FDA Preferred Term for this commodity. Dopamine bears US NLM identifiers UMLS ID C0013030 and NCI Concept Code C62025. SMILES: OC1CC(CCN)CCC1O.
This classification denotes a catecholamine with the molecular formula C10H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IQF9T435OP, chemically known as 2-(3,4-dimethoxyphenyl)ethylamine, but more generally known as dopamine dimethyl ether, which bears US NIH Compound Identifier 8421. European Medicines Agency schedules dopamine dimethyl ether or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06365MIG. Most nations, for tariff purposes, schedule dopamine dimethyl ether under HS 29222900. SMILES: COC1CCC(CC1OC)CCN.
This classification denotes a dopamine agent with the molecular formula C8H11NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7L3E358N9L, chemically known as 3,4-dihydroxyphenylethylamine but more generally known as dopamine hydrochloride, which bears US NIH Compound Identifier 681. European Medicines Agency schedules Dopamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01818MIG. Most nations, for tariff and trade purposes, schedule dopamine hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, DOPAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dopamine hydrochloride bears US NLM identifiers UMLS ID C0282151 and NCI Concept Code C455. SMILES: C1CC(C(CC1CCN)O)O.CL.
This classification denotes a catecholamine with the molecular formula C8H7NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z3OC8499KG, chemically known as indole-5,6-diol, but more generally known as dopamine lutine, which bears US NIH Compound Identifier 114683. European Medicines Agency schedules dopamine lutine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06365MIG. Most nations, for tariff purposes, schedule dopamine lutine under HS 29222900. SMILES: C1C[NH]C2C1CC(C(C2)O)O.
This classification denotes a dopamine agonist and alpha-adrenergic agonist with the molecular formula C22H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 398E7Z7JB5, chemically known as 1,2-benzenediol, 4-(2-((6-((2-phenylethyl)amino)hexyl)amino)ethyl)- but generally known as dopexamine, which bears US NIH Compound Identifier 55483. European Medicines Agency schedules Dopexamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06366MIG. The term DOPEXAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules dopexamine in its Anatomical Therapeutic Chemical (ATC) Classification. DOPEXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dopexamine under HS 29222900 and SITC 51462. As of Q4 2014, DOPEXAMINE remains the US FDA Preferred Term for this commodity. Dopexamine bears US NLM identifiers UMLS ID C0058702 and NCI Concept Code C75039. SMILES: OC1CC(CCNCCCCCCNCCC2CCCCC2)CCC1O.
This classification denotes a dopamine agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VN909S60Y. European Medicines Agency schedules Dopexamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01819MIG. Dopexamine dihydrochloride generally arises in the molecular formula C22H32N2O2.2CLH. The term 'dopexamine dihydrochloride' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule dopexamine dihydrochloride under HS 29222900. SMILES: C1CCC(CC1)CCNCCCCCCNCCC2CCC(C(C2)O)O.CL.CL.
This classification denotes a dopamine agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VN909S60Y. European Medicines Agency schedules Dopexamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01819MIG. Dopexamine hydrochloride generally arises in the molecular formula C22H32N2O2.2CLH. The term 'dopexamine hydrochloride' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule dopexamine hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, DOPEXAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dopexamine hydrochloride bears US NLM identifiers UMLS ID C0770936 and NCI Concept Code C76650. SMILES: C1CCC(CC1)CCNCCCCCCNCCC2CCC(C(C2)O)O.CL.CL.
This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KGD7A54H5P. European Medicines Agency schedules Doramectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06369MIG. Doramectin generally arises in the molecular formula C50H74O14. The term DORAMECTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) DORAMECTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doramectin under HS 29419000 and SITC 54139. As of Q4 2014, DORAMECTIN remains the US FDA Preferred Term for this commodity. Doramectin bears US NLM identifiers UMLS ID C0248572 and NCI Concept Code C81559. SMILES: O1C(C2CCCCC2)C(C=CC21OC1CC(OC(=O)C3C4(O)C(OCC4=CC=CC(C(OC4OC(C(OC5OC(C(O)C(OC)C5)C)C(OC)C4)C)C(=CC1)C)C)C(O)C(=C3)C)C2)C.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3087NKH40A. European Medicines Agency schedules Dorastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06370MIG. Dorastine generally arises in the molecular formula C20H22CLN3. The term DORASTINE is an International Non-Proprietary Name or INN. DORASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dorastine under HS 29333999 and SITC 51574. As of Q4 2014, DORASTINE remains the US FDA Preferred Term for this commodity. Dorastine bears US NLM identifiers UMLS ID C2699801 and NCI Concept Code C76061. SMILES: CLC1CC2C3C(N(C2CC1)CCC1CCC(NC1)C)CCN(C3)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22CLN3.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M52541M8X. The term dorastine hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule dorastine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DORASTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dorastine hydrochloride bears US NLM identifiers UMLS ID C2699802 and NCI Concept Code C76062. SMILES: CC1CCC(CN1)CCN2C3CCC(CC3C4C2CCN(C4)C)CL.CL.CL.
Definition: This classifications denotes a non-nucleoside reverse transcriptase inhibitor, with US FDA active ingredient Unique Ingredient Identifier 913P6LK81M. The term DORAVIRINE is an International Non-Proprietary Name or INN.
This classification denotes an antiparkinsonian agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51K3U6Q5ZN. European Medicines Agency schedules Doreptide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06371MIG. Doreptide generally arises in the molecular formula C17H24N4O3. The term DOREPTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) DOREPTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doreptide under HS 29339990 and SITC 51577. As of Q4 2014, DOREPTIDE remains the US FDA Preferred Term for this commodity. Doreptide bears US NLM identifiers UMLS ID C2699803 and NCI Concept Code C76393. SMILES: O=C(NC(CC)(C1CCCCC1)C(=O)NCC(=O)N)C1NCCC1.
This classification denotes a beta-lactam antibiotic with the molecular formula C15H24N4O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BHV525JOBH, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- but generally known as doripenem, which bears US NIH Compound Identifier 73303. European Medicines Agency schedules Doripenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22196. The term DORIPENEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules doripenem in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule doripenem under HS 29419000 and SITC 54139. As of Q4 2014, DORIPENEM remains the US FDA Preferred Term for this commodity. Doripenem bears US NLM identifiers UMLS ID C0389169 and NCI Concept Code C65470. SMILES: S(C1=C(N2C(C(C2=O)C(O)C)C1C)C(=O)O)C1CC(NC1)CNS(=O)(=O)N.
This classification denotes a beta-lactam antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B035T6NKT. European Medicines Agency schedules Doripenem hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26847. Doripenem hydrate generally arises in the molecular formula C15H24N4O6S2.H2O. The term 'doripenem hydrate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule doripenem hydrate under HS 29419000. SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O.O.
This classification denotes a beta-lactam antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B035T6NKT. European Medicines Agency schedules Doripenem hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26847. Doripenem monohydrate generally arises in the molecular formula C15H24N4O6S2.H2O. The term 'doripenem monohydrate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule doripenem monohydrate under HS 29419000 and SITC 54139. As of Q4 2014, DORIPENEM MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O.O.
This classification denotes a carbonic anhydrase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9JDX055TW1. European Medicines Agency schedules Dorzolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06374MIG. Dorzolamide generally arises in the molecular formula C10H16N2O4S3. The term DORZOLAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33.) DORZOLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dorzolamide under HS 29350090 and SITC 51580. As of Q4 2014, DORZOLAMIDE remains the US FDA Preferred Term for this commodity. Dorzolamide bears US NLM identifiers UMLS ID C0165590 and NCI Concept Code C62026. SMILES: CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C.
This classification denotes a carbonic anhydrase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QZO5366EW7. European Medicines Agency schedules Dorzolamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01820MIG. Dorzolamide hydrochloride generally arises in the molecular formula C10H16N2O4S3.CLH. The term 'dorzolamide hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule dorzolamide hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, DORZOLAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dorzolamide hydrochloride bears US NLM identifiers UMLS ID C0771293 and NCI Concept Code C29003. SMILES: CCN[C@H]1C[C@@H](S(=O)(=O)C2C1CC(S2)S(=O)(=O)N)C.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP105. This VA Drug Class (OP105) classifies this compound as belonging to the group ANTIGLAUCOMA COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes an anxiolytic with the molecular formula C19H21NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W13O82Z7HL, chemically known as 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepine hydrochloride but generally known as dosulepin, which bears US NIH Compound Identifier 5282425. European Medicines Agency schedules Dosulepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06377MIG. World Health Organization schedules dosulepin in its Anatomical Therapeutic Chemical (ATC) Classification. DOSULEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dosulepin under HS 29349990 and SITC 51579. SMILES: Cl.S1Cc2c(/C(=C/CC[NH](C)C)c3c1cccc3)cccc2.
This classification denotes an antidepressant agent with the molecular formula C19H21NS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3H0042311V, chemically known as 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepine hydrochloride but more generally known as dosulepin hydrochloride, which bears US NIH Compound Identifier 5282425. European Medicines Agency schedules Dosulepin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01821MIG. Most nations, for tariff and trade purposes, schedule dosulepin hydrochloride under HS 29349990 and SITC 51579. SMILES: CN(C)CC/C=C/1\C2CCCCC2CSC3C1CCCC3.CL.
This classification denotes a serotonin antagonist and calcium channel blocker with the molecular formula C29H34N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IO7663S6D3, chemically known as 1-(diphenylmethyl)-4-(3-(2-phenyl-1,3-dioxolan-2-yl)propyl)piperazine but generally known as dotarizine, which bears US NIH Compound Identifier 55285. European Medicines Agency schedules Dotarizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06378MIG. The term DOTARIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). DOTARIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dotarizine under HS 29349990 and SITC 51579. As of Q4 2014, DOTARIZINE remains the US FDA Preferred Term for this commodity. Dotarizine bears US NLM identifiers UMLS ID C0248284 and NCI Concept Code C77827. SMILES: O1C(OCC1)(CCCN1CCN(CC1)C(C1CCCCC1)C1CCCCC1)C1CCCCC1.
This classification denotes a muscle relaxant with the molecular formula C20H27N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F41A22A3KV, chemically known as pyrrolidinium, 1-methyl-1-(2-(n-methyl-alpha-2-thienylmandelamido)ethyl)- but generally known as dotefonium, which bears US NIH Compound Identifier 71913. European Medicines Agency schedules Dotefonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06379MIG. The term DOTEFONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). As of Q4 2014, DOTEFONIUM remains the US FDA Preferred Term for this commodity. Dotefonium bears US NLM identifiers UMLS ID C2828324 and NCI Concept Code C87490. SMILES: CN(CC[N+]1(CCCC1)C)C(=O)C(C2=CC=CC=C2)(C3=CC=CS3)O.
This classification denotes a muscle relaxant with the molecular formula C20H27N2O2S.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D762286A5N, chemically known as pyrrolidinium, 1-methyl-1-(2-(n-methyl-alpha-2-thienylmandelamido)ethyl)-, bromide but more generally known as dotefonium bromide, which bears US NIH Compound Identifier 71913. European Medicines Agency schedules Dotefonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06379MIG. The term DOTEFONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). Most nations, for tariff and trade purposes, schedule dotefonium bromide under HS 29349990 and SITC 51579. As of Q4 2014, DOTEFONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Dotefonium bromide bears US NLM identifiers UMLS ID C1880401 and NCI Concept Code C65471. SMILES: CN(CC[N+]1(CCCC1)C)C(=O)C(C2CCCCC2)(C3CCCS3)O.[BR-].
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M78TVM3G5Z. European Medicines Agency schedules Doxacurium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06380MIG. Doxacurium chloride generally arises in the molecular formula C56H78CL2N2O16. The term DOXACURIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) As of Q4 2014, DOXACURIUM remains the US FDA Preferred Term for this commodity. Doxacurium bears US NLM identifiers UMLS ID C0058716 and NCI Concept Code C81000. SMILES: C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C.[CL-].[CL-].
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M78TVM3G5Z. European Medicines Agency schedules Doxacurium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06380MIG. Doxacurium chloride generally arises in the molecular formula C56H78CL2N2O16. The term DOXACURIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 2, no. 3, 1988, list 28.) Most nations, for tariff and trade purposes, schedule doxacurium chloride under HS 29334990 and SITC 51575. Doxacurium chloride bears US NLM identifiers UMLS ID C0114872 and NCI Concept Code C65472. SMILES: As of Q4 2014, DOXACURIUM CHLORIDE remains US FDA's Preferred Term for this commodity.
This classification denotes a beta-adrenergic agonist with the molecular formula C26H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1RZ4ML637I, chemically known as 6,11-dihydro-n-(2-hydroxy-3-phenoxypropyl)-n-methyldibenz(b,e)oxepin-11-ethylamine but generally known as doxaminol, which bears US NIH Compound Identifier 68721. European Medicines Agency schedules Doxaminol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06381MIG. The term DOXAMINOL is an International Non-Proprietary Name. DOXAMINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxaminol under HS 29329985 and SITC 51569. As of Q4 2014, DOXAMINOL remains the US FDA Preferred Term for this commodity. Doxaminol bears US NLM identifiers UMLS ID C0058717 and NCI Concept Code C65473. SMILES: O1C2C(C(CCN(CC(O)COC3CCCCC3)C)C3C(C1)CCCC3)CCCC2.
This classification denotes a cns stimulant with the molecular formula C24H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94F3830Q73, chemically known as 2-pyrrolidinone, 1-ethyl-4- (2-morpholinoethyl)-3,3-diphenyl-, monohydrochloride but generally known as doxapram, which bears US NIH Compound Identifier 3156. European Medicines Agency schedules Doxapram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06382MIG. The term DOXAPRAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules doxapram in its Anatomical Therapeutic Chemical (ATC) Classification. DOXAPRAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxapram under HS 29349990 and SITC 51579. As of Q4 2014, DOXAPRAM remains the US FDA Preferred Term for this commodity. Doxapram bears US NLM identifiers UMLS ID C0013084 and NCI Concept Code C61736. SMILES: O=C1N(CC(C1(C1CCCCC1)C1CCCCC1)CCN1CCOCC1)CC.
This classification denotes a cns stimulant with the molecular formula C24H30N2O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P5RU6UOQ5Y, chemically known as 2-pyrrolidinone, 1-ethyl-4- (2-morpholinoethyl)-3,3-diphenyl-, monohydrochloride but more generally known as doxapram hydrochloride, which bears US NIH Compound Identifier 3156. European Medicines Agency schedules Doxapram hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01823MIG. Most nations, for tariff and trade purposes, schedule doxapram hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, DOXAPRAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Doxapram hydrochloride bears US NLM identifiers UMLS ID C0699979 and NCI Concept Code C47500. SMILES: CCN1CC(C(C1=O)(C2CCCCC2)C3CCCCC3)CCN4CCOCC4.O.CL.
This classification denotes a cns stimulant C24H30N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FB8713U6DM, chemically known as (+/-)-1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride, but more generally known as doxapram hydrochloride anhydrous, which bears US NIH Compound Identifier 64647. Most nations, for tariff and trade purposes, schedule doxapram hydrochloride anhydrous under HS 29349990 and SITC 51579. As of Q4 2014, DOXAPRAM HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. SMILES: CCN1CC(C(C1=O)(C2CCCCC2)C3CCCCC3)CCN4CCOCC4.CL.
This classification denotes a cns stimulant with the molecular formula C24H30N2O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P5RU6UOQ5Y, chemically known as 2-pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-, monohydrochloride, monohydrate, (+/-)-, but more generally known as doxapram hydrochloride hydrate, which bears US NIH Compound Identifier 64648. European Medicines Agency schedules doxapram hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06382MIG. Most nations, for tariff purposes, schedule doxapram hydrochloride hydrate under HS 29349990. SMILES: CCN1CC(C(C1=O)(C2CCCCC2)C3CCCCC3)CCN4CCOCC4.O.CL.
This classification denotes a prostaglandin analogue with the molecular formula C21H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W3G873MK03, chemically known as prost-13-en-1-oic acid, 15-hydroxy-15-methyl-9-oxo-, (13e) but generally known as doxaprost, which bears US NIH Compound Identifier 6441612. European Medicines Agency schedules Doxaprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06383MIG. The term DOXAPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). DOXAPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxaprost under HS 29375000 and SITC 54156. As of Q4 2014, DOXAPROST remains the US FDA Preferred Term for this commodity. Doxaprost bears US NLM identifiers UMLS ID C2699807 and NCI Concept Code C74370. SMILES: O=C1C(C(CC1)/C=C/C(O)(CCCCC)C)CCCCCCC(=O)O.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C23H25N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NW1291F1W8, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin but generally known as doxazosin, which bears US NIH Compound Identifier 3157. European Medicines Agency schedules Doxazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06384MIG. The term DOXAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules doxazosin in its Anatomical Therapeutic Chemical (ATC) Classification. DOXAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxazosin under HS 29349990 and SITC 51579. As of Q4 2014, DOXAZOSIN remains the US FDA Preferred Term for this commodity. Doxazosin bears US NLM identifiers UMLS ID C0114873 and NCI Concept Code C61737. SMILES: O1C(C(=O)N2CCN(CC2)C2NC3C(C(N2)N)CC(OC)C(OC)C3)COC2C1CCCC2.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C23H25N5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86P6PQK0MU, chemically known as piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-, monomethanesulfonate, but more generally known as doxazosin mesylate, which bears US NIH Compound Identifier 3157. European Medicines Agency schedules doxazosin mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06384MIG. Most nations, for tariff purposes, schedule doxazosin mesylate under HS 29349990. As of Q4 2014, DOXAZOSIN MESYLATE remains US FDA's Preferred Term for this commodity. Doxazosin mesylate bears US NLM identifiers UMLS ID C0678136 and NCI Concept Code C29005. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4COC5CCCCC5O4.CS(=O)(=O)O.
This classification denotes a benzodiazepine with the molecular formula C17H14ClFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 231RV72C8L, chemically known as 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-3-hydroxy-1-(2-hydroxyethyl)-2h-1,4-benzodiazepin-2-one but generally known as doxefazepam, which bears US NIH Compound Identifier 38668. European Medicines Agency schedules Doxefazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06385MIG. The term DOXEFAZEPAM is an International Non-Proprietary Name. World Health Organization schedules doxefazepam in its Anatomical Therapeutic Chemical (ATC) Classification. DOXEFAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxefazepam under HS 29339940 and SITC 51577. As of Q4 2014, DOXEFAZEPAM remains the US FDA Preferred Term for this commodity. Doxefazepam bears US NLM identifiers UMLS ID C0114875 and NCI Concept Code C65474. SMILES: CLC1CC2C(N(CCO)C(=O)C(O)N=C2C2C(F)CCCC2)CC1.
This classification denotes a tricyclic antidepressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ASJ6HUZ7D. European Medicines Agency schedules Doxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06387MIG. Doxepin generally arises in the molecular formula C19H21NO. The term DOXEPIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) DOXEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxepin under HS 29329985 and SITC 51569. As of Q4 2014, DOXEPIN remains the US FDA Preferred Term for this commodity. Doxepin bears US NLM identifiers UMLS ID C0013085 and NCI Concept Code C65475. SMILES: CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31.
This classification denotes a tricyclic antidepressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3U9A0FE9N5. European Medicines Agency schedules Doxepin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01825MIG. Doxepin hydrochloride generally arises in the molecular formula C19H21NO.CLH. The term 'doxepin hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule doxepin hydrochloride under HS 29329985 and SITC 51569. Doxepin hydrochloride bears US NLM identifiers UMLS ID C0700535 and NCI Concept Code C29006. SMILES: As of Q4 2014, DOXEPIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.
This classification denotes a pyrimidine antagonist with the molecular formula C9H11FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1JK16Y2JP, chemically known as 1-((4s,2r,3r,5r)-3,4-dihydroxy-5-methyloxolan-2-yl)-5-fluoro-1,3-dihydropyrimidine-2,4-dione but generally known as doxifluridine, which bears US NIH Compound Identifier 18343. European Medicines Agency schedules Doxifluridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06389MIG. The term DOXIFLURIDINE is an International Non-Proprietary Name. DOXIFLURIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxifluridine under HS 29349990 and SITC 51579. As of Q4 2014, DOXIFLURIDINE remains the US FDA Preferred Term for this commodity. Doxifluridine bears US NLM identifiers UMLS ID C0048808 and NCI Concept Code C978. SMILES: FC1CN(C2OC(C(O)C2O)C)C(=O)[NH]C1=O.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C11H14N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MPM23GMO7Z, chemically known as 7-(1,3-dioxolon-2-ylmethyl)-1,2,3,6-tetrahydro-1,3-dimethyl-2,6-purindion but generally known as doxofylline, which bears US NIH Compound Identifier 50942. European Medicines Agency schedules Doxofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06390MIG. The term DOXOFYLLINE is an International Non-Proprietary Name. World Health Organization schedules doxofylline in its Anatomical Therapeutic Chemical (ATC) Classification. DOXOFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxofylline under HS 29395900 and SITC 54145. As of Q4 2014, DOXOFYLLINE remains the US FDA Preferred Term for this commodity. Doxofylline bears US NLM identifiers UMLS ID C0058721 and NCI Concept Code C76317. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3.
This classification denotes a doxorubicin preparation with the molecular formula C27H29NO11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80168379AG, chemically known as 3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside but generally known as doxorubicin, which bears US NIH Compound Identifier 1691. European Medicines Agency schedules Doxorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06391MIG. The term DOXORUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules doxorubicin in its Anatomical Therapeutic Chemical (ATC) Classification. DOXORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxorubicin under HS 29419000 and SITC 54139. As of Q4 2014, DOXORUBICIN remains the US FDA Preferred Term for this commodity. Doxorubicin bears US NLM identifiers UMLS ID C0013089 and NCI Concept Code C456. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)CO)C1OC(C(O)C(N)C1)C.
This classification denotes a doxorubicin preparation with the molecular formula C21H18O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X023T6C35L, chemically known as 5,12-naphthacenedione, 7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8s,10s)-, but more generally known as doxorubicin aglycone, which bears US NIH Compound Identifier 72401. European Medicines Agency schedules doxorubicin aglycone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06391MIG. Most nations, for tariff purposes, schedule doxorubicin aglycone under HS 29419000. SMILES: COC1CCCC2C1C(=O)C3C(C(C4C(C3O)[C@H](C[C@@](C4)(C(=O)CO)O)O)O)C2=O.
This classification denotes a doxorubicin preparation with the molecular formula C27H29NO11.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82F2G7BL4E, chemically known as 3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside but more generally known as doxorubicin hydrochloride, which bears US NIH Compound Identifier 1691. European Medicines Agency schedules Doxorubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01827MIG. Most nations, for tariff and trade purposes, schedule doxorubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, DOXORUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Doxorubicin hydrochloride bears US NLM identifiers UMLS ID C0085752 and NCI Concept Code C1326. SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3C2C(C4C(C3O)C(=O)C5CCCC(C5C4=O)OC)O)(C(=O)CO)O)N)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN200. This VA Drug Class (AN200) classifies this compound as belonging to the group ANTINEOPLASTIC ANTIBIOTICS.
This classification denotes an analgesic agent with the molecular formula C12H18N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9821373UA1, chemically known as 1-(1,3-dioxan-5-yl)-N,N-dimethyl-1-pyridin-3-ylmethanamine but generally known as doxpicomine, which bears US NIH Compound Identifier 71979. European Medicines Agency schedules doxpicomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06392MIG. Most nations schedule doxpicomine under HS 29349990 and SITC 51579. As of Q4 2014, DOXPICOMINE remains the US FDA Preferred Term for this commodity. Doxpicomine bears US NLM identifiers UMLS ID C0058730 and NCI Concept Code C65477. SMILES: CN(C)C(C1COCOC1)C2=CN=CC=C2.Cl.
This classification denotes an analgesic agent with the molecular formula C12H18N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27DYG0QPCR, chemically known as 3-pyridinemethylamine, alpha-1,3-dioxan-5-yl-n,n-dimethyl-, monohydrochloride, (-)- but more generally known as doxpicomine hydrochloride, which bears US NIH Compound Identifier 71979. Most nations, for tariff and trade purposes, schedule doxpicomine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, DOXPICOMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)[C@@H](C1CCCNC1)C2COCOC2.CL.
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O8.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N12000U13O chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.6.alpha.,12a.alpha.))-, monohydrate but generally known as doxycycline, which bears US NIH Compound Identifier 5281011. European Medicines Agency schedules Doxycycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06393MIG. The term DOXYCYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8. ). Most nations schedule doxycycline under HS 29413000 and SITC 54133. As of Q4 2014, DOXYCYCLINE remains the US FDA Preferred Term for this commodity. Doxycycline bears US NLM identifiers UMLS ID C0013090 and NCI Concept Code C457. SMILES: OC1C2C(O)(C(=O)C3=C(O)C4C(C(C13)C)CCCC4O)C(=O)/C(=C(\O)N)C(=O)C2N(C)C.
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 334895S862, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,6.alpha.,12a.alpha.))-, but more generally known as doxycycline anhydrous, which bears US NIH Compound Identifier 5281011. European Medicines Agency schedules doxycycline anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06393MIG. Most nations, for tariff purposes, schedule doxycycline anhydrous under HS 29413000. Doxycycline anhydrous bears US NLM identifiers UMLS ID C2699808 and NCI Concept Code C76990. SMILES: C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.
This classification denotes a tetracycline antibiotic C22H24N2O8.2Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ZL07I20SB, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4a,4aa,5a,5aa,6a,12aa))-, calcium salt (2:1), but more generally known as doxycycline calcium, which bears US NIH Compound Identifier 62305. European Medicines Agency schedules Doxycycline calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01828MIG. Most nations, for tariff and trade purposes, schedule doxycycline calcium under HS 29413000 and SITC 54133. As of Q4 2014, DOXYCYCLINE CALCIUM remains US FDA's Preferred Term for this commodity. Doxycycline calcium bears US NLM identifiers UMLS ID C0282155 and NCI Concept Code C29008. SMILES: C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.[CA+2].[CA+2].
This classification denotes a tetracycline antibiotic with the molecular formula 3C22H24N2O8.Na.O3P.3HO3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2IQ26U2DZQ, chemically known as (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, compound with sodium trihydrogen metaphosphate (h(sub 3)nap(sub 4)o(sub 12)) (3:1), but more generally known as doxycycline fosfatex, which bears US NIH Compound Identifier 6441613. European Medicines Agency schedules doxycycline fosfatex or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06393MIG. Most nations, for tariff purposes, schedule doxycycline fosfatex under HS 29413000. SMILES:. Doxycycline fosfatex bears US NLM identifiers UMLS ID C3468030 and NCI Concept Code C98040.
This classification denotes a tetracycline antibiotic with the molecular formula 2C22H24N2O8.C2H6O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19XTS3T51U, chemically known as 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy- 6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrate but more generally known as doxycycline hyclate, which bears US NIH Compound Identifier 5281011. European Medicines Agency schedules Doxycycline hyclate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01830MIG. Most nations, for tariff and trade purposes, schedule doxycycline hyclate under HS 29413000 and SITC 54133. As of Q4 2014, DOXYCYCLINE HYCLATE remains US FDA's Preferred Term for this commodity. Doxycycline hyclate bears US NLM identifiers UMLS ID C0058731 and NCI Concept Code C29007. SMILES: CCO.C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.O.CL.CL.
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O8.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4182Z6T2ET. European Medicines Agency schedules doxycycline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01831MIG. Most nations, for tariff and trade purposes, schedule doxycycline hydrochloride under HS 29413000 and SITC 54133. As of Q4 2014, DOXYCYCLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Doxycycline hydrochloride bears US NLM identifiers UMLS ID C0771947 and NCI Concept Code C29010. SMILES: C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.CL.
This classification denotes a tetracycline antibiotic with the molecular formula 2C22H24N2O8.C2H6O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19XTS3T51U, chemically known as 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate, but more generally known as doxycycline hydrochloride hemiethanolate hemihydrate, which bears US NIH Compound Identifier 5282244. European Medicines Agency schedules doxycycline hydrochloride hemiethanolate hemihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06393MIG. Most nations, for tariff purposes, schedule doxycycline hydrochloride hemiethanolate hemihydrate under HS 29413000. SMILES: CCO.C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.O.CL.CL.
This classification denotes a tetracycline antibiotic with the molecular structure C22H24N2O8.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N12000U13O chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.6.alpha.,12a.alpha.))-, monohydrate, but more commonly known as doxycycline, which bears US NIH Compound Identifier 5281011. European Medicines Agency schedules Doxycycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06393MIG. The term DOXYCYCLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, no. 10, 1968, list 8. ). Most nations, for tariff and trade purposes, schedule doxycycline monohydrate under HS 29413000 and SITC 54133. SMILES: C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.O.
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O8.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QG2V1M96HM. European Medicines Agency schedules doxycycline phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01833MIG. Most nations, for tariff and trade purposes, schedule doxycycline phosphate under HS 29413000 and SITC 54133. As of Q4 2014, DOXYCYCLINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Doxycycline phosphate bears US NLM identifiers UMLS ID CL436807 and NCI Concept Code C102526. SMILES: C[C@H]1C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.OP(=O)(O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95QB77JKPL, chemically known as pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)- but generally known as doxylamine, which bears US NIH Compound Identifier 3162. European Medicines Agency schedules Doxylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06394MIG. The term DOXYLAMINE is an International Non-Proprietary Name. World Health Organization schedules doxylamine in its Anatomical Therapeutic Chemical (ATC) Classification. DOXYLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxylamine under HS 29333999 and SITC 51574. As of Q4 2014, DOXYLAMINE remains the US FDA Preferred Term for this commodity. Doxylamine bears US NLM identifiers UMLS ID C0013092 and NCI Concept Code C61738. SMILES: O(C(C1CCCCC1)(C1NCCCC1)C)CCN(C)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2O.C7H7ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier POI7XGQ1HN, chemically known as 1h-purine-2,6-dione, 8-chloro-3,9-dihydro-1,3-dimethyl-, compd. with n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine (1:1), but more generally known as doxylamine chlorotheophyllinate, which bears US NIH Compound Identifier 31834. European Medicines Agency schedules doxylamine chlorotheophyllinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06394MIG. Most nations, for tariff purposes, schedule doxylamine chlorotheophyllinate under HS 29333999. SMILES: CC(C1CCCCC1)(C2CCCCN2)OCCN(C)C.CN1C2C(C(=O)N(C1=O)C)[NH]C(N2)CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9BI9B5YI2, chemically known as succinic acid, compd. with 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine (1:1) (8ci) but more generally known as doxylamine hydrogen succinate, which bears US NIH Compound Identifier 11224. European Medicines Agency schedules Doxylamine hydrogen succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11925MIG. Most nations, for tariff and trade purposes, schedule doxylamine hydrogen succinate under HS 29333999. SMILES: CC(C1CCCCC1)(C2CCCCN2)OCCN(C)C.C(CC(=O)O)C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9BI9B5YI2, chemically known as succinic acid, compd. with 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine (1:1) (8ci) but more generally known as doxylamine hydrogen succinate, which bears US NIH Compound Identifier 11224. European Medicines Agency schedules Doxylamine hydrogen succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11925MIG. Most nations, for tariff and trade purposes, schedule doxylamine succinate under HS 29333999 and SITC 51574. As of Q4 2014, DOXYLAMINE SUCCINATE remains US FDA's Preferred Term for this commodity. Doxylamine succinate bears US NLM identifiers UMLS ID C0058733 and NCI Concept Code C47501. SMILES: CC(C1CCCCC1)(C2CCCCN2)OCCN(C)C.C(CC(=O)O)C(=O)O.
This classification denotes a cardiotonic agent and antiplatelet agent with the molecular formula C30H33Cl2F2N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Y25DT968Y, chemically known as 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-,(+-)- but generally known as draflazine, which bears US NIH Compound Identifier 60849. European Medicines Agency schedules Draflazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06395MIG. The term DRAFLAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DRAFLAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule draflazine under HS 29335995 and SITC 51576. As of Q4 2014, DRAFLAZINE remains the US FDA Preferred Term for this commodity. Draflazine bears US NLM identifiers UMLS ID C0209869 and NCI Concept Code C76030. SMILES: CLC1C(NC(=O)CN2C(CN(CC2)CCCCC(C2CCC(F)CC2)C2CCC(F)CC2)C(=O)N)C(CL)CC(N)C1.
This classification denotes a vasodilating agent with the molecular formula C20H29N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8PW276HX8U, chemically known as acetone (- )-(6(3-((3,4-dimethoxyphenethyl)amino)-2-hydroxypropoxy)-3-pyridazinyl)hydrazone. but generally known as dramedilol, which bears US NIH Compound Identifier 208896. European Medicines Agency schedules Dramedilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06396MIG. The term DRAMEDILOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). DRAMEDILOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dramedilol under HS 29339990 and SITC 51577. As of Q4 2014, DRAMEDILOL remains the US FDA Preferred Term for this commodity. Dramedilol bears US NLM identifiers UMLS ID C1880407 and NCI Concept Code C65478. SMILES: OC(CNCCc1cc(OC)c(OC)cc1)COc1nnc(N/N=C(/C)C)cc1.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3B3L3Q0GV. European Medicines Agency schedules Draquinolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06397MIG. Draquinolol generally arises in the molecular formula C24H30N2O4. The term DRAQUINOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) DRAQUINOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule draquinolol under HS 29337900 and SITC 51561. As of Q4 2014, DRAQUINOLOL remains the US FDA Preferred Term for this commodity. Draquinolol bears US NLM identifiers UMLS ID C1880408 and NCI Concept Code C65479. SMILES: O(CC(O)CNCCCC)c1ccc(c2n(c(=O)c3c(c2)ccc(OC)c3)C)cc1.
This classification denotes an antibiotic with the molecular formula C10H10N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W193003XW5, chemically known as 3-methyl-2-quinoxalinecarboxylic acid hydrazide 1,4-dioxide. but more generally known as drazidox, which bears US NIH Compound Identifier 208897. European Medicines Agency schedules Drazidox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06398MIG. The term DRAZIDOX is an International Non-Proprietary Name. DRAZIDOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=C(N(C2=CC=CC=C2N1O)O)C(=O)N=N.
This classification denotes an antihelminthic agent with the molecular formula C15H19N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5491IVP21O, chemically known as carbamic acid, (5-(cyclohexylthio)-1h-benzimidazol-2-yl)-,methyl ester but generally known as dribendazole, which bears US NIH Compound Identifier 170311. European Medicines Agency schedules Dribendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06399MIG. The term DRIBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). DRIBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dribendazole under HS 29339990 and SITC 51577. As of Q4 2014, DRIBENDAZOLE remains the US FDA Preferred Term for this commodity. Dribendazole bears US NLM identifiers UMLS ID C1880410 and NCI Concept Code C65481. SMILES: S(C1CCCCC1)C1CC2[NH]C(NC2CC1)NC(=O)OC.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C10H9NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G715G2AW6N, chemically known as 1h-inden-1-one, 2-(aminomethylene)-2,3-dihydro- but generally known as drinidene, which bears US NIH Compound Identifier 3037167. European Medicines Agency schedules Drinidene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06400MIG. The term DRINIDENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). DRINIDENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule drinidene under HS 29223900 and SITC 51463. As of Q4 2014, DRINIDENE remains the US FDA Preferred Term for this commodity. Drinidene bears US NLM identifiers UMLS ID C2825248 and NCI Concept Code C80543. SMILES: C\1C2=CC=CC=C2C(=O)/C1=C/N.
This classification denotes an antiarrhythmic agent with the molecular formula C19H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6LLN8EQ6TA, chemically known as benzenepropanol, alpha-(((1-methylethyl)amino)methyl)-gamma-phenyl-, (+-)- but more generally known as drobuline, which bears US NIH Compound Identifier 60890. European Medicines Agency schedules Drobuline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06401MIG. The term DROBULINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). DROBULINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule drobuline under HS 29221980 and SITC 51461. As of Q4 2014, DROBULINE remains US FDA's Preferred Term for this commodity. Drobuline bears US NLM identifiers UMLS ID C0607421 and NCI Concept Code C65482. SMILES: OC(CC(C1CCCCC1)C1CCCCC1)CNC(C)C.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C20H31NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MVB31OPW05, chemically known as cyclohexaneacetic acid, alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride but more generally known as drofenine hydrochloride, which bears US NIH Compound Identifier 92806. European Medicines Agency schedules Drofenine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01838MIG. Most nations, for tariff and trade purposes, schedule drofenine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, DROFENINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)C2CCCCC2.CL.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C20H31NO2 and C20H31NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 4QWV355536 and MVB31OPW05, the base compound being chemically known as cyclohexaneacetic acid, .alpha.-phenyl-, 2- (diethylamino)ethyl ester but generally known as drofenine, which bears US NIH Compound Identifier 3166. European Medicines Agency schedules Drofenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB06404MIG and SUB01838MIG. The term DROFENINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). DROFENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule drofenine under HS 29221980 and SITC 51461. As of Q4 2014, DROFENINE remains the US FDA Preferred Term for this commodity. Drofenine bears US NLM NCI C65484. SMILES: O(C(=O)C(C1CCCCC1)C1CCCCC1)CCN(CC)CC (base) or CCN(CC)CCOC(=O)C(C1CCCCC1)C2CCCCC2.CL (hydrochloride).
This classification denotes a selective estrogen receptor modulator with the molecular formula C26H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M67U6Z98F, chemically known as phenol, 3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-, (e)- but more generally known as droloxifene, which bears US NIH Compound Identifier 3033767. European Medicines Agency schedules Droloxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06405MIG. The term DROLOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). DROLOXIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule droloxifene under HS 29221980 and SITC 51461. As of Q4 2014, DROLOXIFENE remains US FDA's Preferred Term for this commodity. Droloxifene bears US NLM identifiers UMLS ID C0047498 and NCI Concept Code C969. SMILES: O(C1CCC(/C(=C(/CC)C2CCCCC2)C2CC(O)CCC2)CC1)CCN(C)C.
This classification denotes a therapeutic androgen with the molecular formula C20H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7DR7H00HDT, chemically known as (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one but generally known as dromostanolone, which bears US NIH Compound Identifier 6011. SMILES:CC1CC2(C(CCC3C2CCC4(C3CCC4O)C)CC1=O)C. Dromostanolone or drostanolone bears US NLM identifiers UMLS ID C0058753 and NCI Concept Code C1076.
This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7J8897W37S. European Medicines Agency schedules Dronabinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06407MIG. Dronabinol generally arises in the molecular formula C21H30O2. The term DRONABINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) DRONABINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dronabinol under HS 29329985 and SITC 51569. As of Q4 2014, DRONABINOL remains the US FDA Preferred Term for this commodity. Dronabinol bears US NLM identifiers UMLS ID C0039663 and NCI Concept Code C867. SMILES: O1C(C2C(C3C1CC(CC3O)CCCCC)C=C(CC2)C)(C)C.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) JQZ1L091Y2. European Medicines Agency schedules Dronedarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06408MIG. Dronedarone generally arises in the molecular formula C31H44N2O5S. The term DRONEDARONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 11997, list 37.) Most nations, for tariff and trade purposes, schedule dronedarone under HS 29350090 and SITC 51580. As of Q4 2014, DRONEDARONE remains US FDA's Preferred Term for this commodity. Dronedarone bears US NLM identifiers UMLS ID C0766326 and NCI Concept Code C65485. SMILES: S(=O)(=O)(NC1CC2C(C(OC2CC1)CCCC)C(=O)C1CCC(OCCCN(CCCC)CCCC)CC1)C.
This classification denotes a butyrophenone with the molecular formula C22H22FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O9U0F09D5X, chemically known as 2h-benzimidazol-2-one, 1-(1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro- but generally known as droperidol, which bears US NIH Compound Identifier 3168. European Medicines Agency schedules Droperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06410MIG. The term DROPERIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules droperidol in its Anatomical Therapeutic Chemical (ATC) Classification. DROPERIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule droperidol under HS 29333999 and SITC 51574. As of Q4 2014, DROPERIDOL remains the US FDA Preferred Term for this commodity. Droperidol bears US NLM identifiers UMLS ID C0013136 and NCI Concept Code C458. SMILES: FC1CCC(C(=O)CCCN2CCC(=CC2)N2C3C([NH]C2=O)CCCC3)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a vasodilating agent with the molecular formula C24H33N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31IPX0ZD7R, chemically known as (+-)-n-(3,3-diphenylpropyl)-alpha-methylcyclohexaneethylamine but generally known as droprenilamine, which bears US NIH Compound Identifier 65470. European Medicines Agency schedules Droprenilamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06411MIG. The term DROPRENILAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). DROPRENILAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule droprenilamine under HS 29214980 and SITC 51454. As of Q4 2014, DROPRENILAMINE remains the US FDA Preferred Term for this commodity. Droprenilamine bears US NLM identifiers UMLS ID C1880414 and NCI Concept Code C65488. SMILES: N(C(CC1CCCCC1)C)CCC(c1ccccc1)c1ccccc1.
This classification denotes a vasodilating agent C24H33N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OG73JS161X, chemically known as benzenepropanamine, n-(2-cyclohexyl-1-methylethyl)-.gamma.-phenyl-, hydrochloride (1:1), but more generally known as droprenilamine hydrochloride, which bears US NIH Compound Identifier 65471. Most nations, for tariff and trade purposes, schedule droprenilamine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, DROPRENILAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCCC1)NCCC(C2CCCCC2)C3CCCCC3.CL.
This classification denotes a therapeutic progestin with the molecular formula C24H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N295J34A25, chemically known as 1,2-dihydrospirorenone but generally known as drospirenone, which bears US NIH Compound Identifier 68873. European Medicines Agency schedules Drospirenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06413MIG. The term DROSPIRENONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). DROSPIRENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule drospirenone under HS 29372900 and SITC 54153. As of Q4 2014, DROSPIRENONE remains the US FDA Preferred Term for this commodity. Drospirenone bears US NLM identifiers UMLS ID C0043822 and NCI Concept Code C47502. SMILES: O1C2(C3C(C4C2(CCC2C4C4C(C4)C4=CC(=O)CCC24C)C)C3)CCC1=O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes an antispasmotic agent with the molecular formula C24H31NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24ZVH4C669, chemically known as 1-benzyl-3,4,6,7-tetraethoxy-1,2,3,4-tetrahydroisoquinoline but more generally known as drotaverine hydrochloride, which bears US NIH Compound Identifier 1712095. European Medicines Agency schedules Drotaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01843MIG. Most nations, for tariff and trade purposes, schedule drotaverine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, DROTAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Drotaverine hydrochloride bears US NLM NCI C97980. SMILES: CCOC1CCC(CC1OCC)/C=C\2/C3CC(C(CC3CCN2)OCC)OCC.CL.
This classification denotes an antispasmotic agent with the molecular formulas C24H31NO4 and C24H31NO4.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 98QS4N58TW and 24ZVH4C669. European Medicines Agency schedules Drotaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB06415MIG and SUB01843MIG. The term DROTAVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) DROTAVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule drotaverine under HS 29334990 and SITC 51575. As of Q4 2014, DROTAVERINE remains the US FDA Preferred Term for this commodity. Drotaverine bears US NLM NCI C65489 and C97980. SMILES: CCOC1=C(C=C(C=C1)C=C2C3=CC(=C(C=C3CCN2)OCC)OCC)OCC (base) or CCOC1CCC(CC1OCC)/C=C\2/C3CC(C(CC3CCN2)OCC)OCC.CL (hydrochloride).
This classification denotes an anticoagulant agent with the molecular formula C1786H2779N509O519S29, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGH8MYC891, chemically known as recombinant human activated protein c but generally known as Drotrecogin alfa. European Medicines Agency schedules Drotrecogin alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20025. The term Drotrecogin alfa is an International Non-Proprietary Name or INN ( see WHO INN reference publication, Volume 16., No. 1.2002, List 47). Most nations schedule Drotrecogin alfa under HS 30021095 and SITC 54163. SMILES:.
This classification denotes an antiarrhythmic agent with the molecular formula C16H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) J6W196LMV3, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-n-(2-hydroxyethyl)-, monohydrochloride, (+-)- but more generally known as droxicainide, which bears US NIH Compound Identifier 135791. European Medicines Agency schedules Droxicainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06418MIG. The term DROXICAINIDE is an International Non-Proprietary Name. DROXICAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule droxicainide under HS 29333999 and SITC 51574. As of Q4 2014, DROXICAINIDE remains US FDA's Preferred Term for this commodity. Droxicainide bears US NLM identifiers UMLS ID C0058764 and NCI Concept Code C72579. SMILES: CL.O=C(N(C1C(CCCC1C)C)CCO)C1NCCCC1.
This classification denotes an antiarrhythmic agent with the molecular formula C16H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91801A0812, chemically known as droxicainide hydrochloride, (+/-)-, but more generally known as droxicainide hydrochloride, which bears US NIH Compound Identifier 3060807. European Medicines Agency schedules droxicainide hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06418MIG. Most nations, for tariff purposes, schedule droxicainide hydrochloride under HS 29333999. SMILES: CC1CCCC(C1NC(=O)C2CCCCN2CCO)C.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H11N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F24ADO1E2D, chemically known as 5-methyl-3-(2-pyridyl)-2h,5h-1,3-oxazino(5,6-c)(1,2)benzothiazine-2,4(3h)-dione 6,6-dioxide but generally known as droxicam, which bears US NIH Compound Identifier 65679. European Medicines Agency schedules Droxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06419MIG. The term DROXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules droxicam in its Anatomical Therapeutic Chemical (ATC) Classification. DROXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule droxicam under HS 29349990 and SITC 51579. As of Q4 2014, DROXICAM remains the US FDA Preferred Term for this commodity. Droxicam bears US NLM identifiers UMLS ID C0058765 and NCI Concept Code C65492. SMILES: S1(=O)(=O)N(C2C(OC(=O)N(C2=O)C2NCCCC2)C2C1CCCC2)C.
This classification denotes an antiparkinsonian agent with the molecular formula C9H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J7A92W69L7, chemically known as (-)-threo-3-(3,4-dihydroxyphenyl)-l-serine but generally known as droxidopa, which bears US NIH Compound Identifier 3171. European Medicines Agency schedules Droxidopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06420MIG. The term DROXIDOPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). DROXIDOPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule droxidopa under HS 29225000 and SITC 51467. As of Q4 2014, DROXIDOPA remains the US FDA Preferred Term for this commodity. Droxidopa bears US NLM identifiers UMLS ID C0000378 and NCI Concept Code C73266. SMILES: OC(C(N)C(=O)O)C1CC(O)C(O)CC1.
This classification denotes an antitussive agent and analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 94J1SMK20X. European Medicines Agency schedules Droxypropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06422MIG. Droxypropine generally arises in the molecular formula C18H27NO3. The term DROXYPROPINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, list 5.) DROXYPROPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule droxypropine under HS 29333999 and SITC 51574. As of Q4 2014, DROXYPROPINE remains US FDA's Preferred Term for this commodity. Droxypropine bears US NLM identifiers UMLS ID C1880419 and NCI Concept Code C65493. SMILES: O=C(C1(CCN(CC1)CCOCCO)C1CCCCC1)CC.
This classification denotes an antidepressant agent with the molecular formula C18H19NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O5TNM5N07U, chemically known as 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one but generally known as duloxetine, which bears US NIH Compound Identifier 3151. European Medicines Agency schedules Duloxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06424MIG. The term DULOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules duloxetine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule duloxetine under HS 29349990 and SITC 51579. As of Q4 2014, DULOXETINE remains the US FDA Preferred Term for this commodity. Duloxetine bears US NLM identifiers UMLS ID C0245561 and NCI Concept Code C65495. SMILES: CLC1CC2[NH]C(=O)N(C3CCN(CC3)CCCN3C4C([NH]C3=O)CCCC4)C2CC1.
This classification denotes an antidepressant agent with the molecular formula C18H19NOS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9044SC542W, chemically known as 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one but more generally known as duloxetine hydrochloride, which bears US NIH Compound Identifier 3151. European Medicines Agency schedules Duloxetine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20026. Most nations, for tariff and trade purposes, schedule duloxetine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, DULOXETINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Duloxetine hydrochloride bears US NLM identifiers UMLS ID C1505021 and NCI Concept Code C65496. SMILES: CNCC[C@@H](C1CCCS1)OC2CCCC3C2CCCC3.CL.
This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BK2633656Q. European Medicines Agency schedules Dulozafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06425MIG. Dulozafone generally arises in the molecular formula C20H22CL2N2O4. The term DULOZAFONE is an International Non-Proprietary Name or INN. DULOZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dulozafone under HS 29242995 and SITC 51479. As of Q4 2014, DULOZAFONE remains the US FDA Preferred Term for this commodity. Dulozafone bears US NLM identifiers UMLS ID C0642769 and NCI Concept Code C65497. SMILES: CLC1CC(C(N(C(=O)CN(CCO)CCO)C)CC1)C(=O)C1C(CL)CCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H19NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L5WVJ201KN, chemically known as 1h-indole-1-acetic acid, 6-methoxy-3-(4-methoxybenzoyl)-2-methyl- but generally known as duometacin, which bears US NIH Compound Identifier 71912. European Medicines Agency schedules Duometacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06427MIG. The term DUOMETACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). DUOMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule duometacin under HS 29339990 and SITC 51577. As of Q4 2014, DUOMETACIN remains the US FDA Preferred Term for this commodity. Duometacin bears US NLM identifiers UMLS ID C1880428 and NCI Concept Code C65498. SMILES: O(C1CC2N(C(C(C2CC1)C(=O)C1CCC(OC)CC1)C)CC(=O)O)C.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C28H26F4N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E84FJ4KW3B chemically known as methanone, (4-fluorophenyl)(1-(3-(2-(trifluoromethyl)-10h-phenothiazin-10-yl)ropyl)-piperidinyl) but generally known as duoperone, which bears US NIH Compound Identifier 43876. European Medicines Agency schedules Duoperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06428MIG. The term DUOPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26. ). Most nations schedule duoperone under HS 29343090 and SITC 51578. As of Q4 2014, DUOPERONE remains the US FDA Preferred Term for this commodity. Duoperone bears US NLM identifiers UMLS ID C0058805 and NCI Concept Code C65499. SMILES: C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(F)(F)F.
This classification denotes a phenothiazine and antipsychotic agent C28H26F4N2OS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7MM186D7U, chemically known as methanone, (4-fluorophenyl)(1-(3-(2-(trifluoromethyl)-10h-phenothiazin-10-yl)propyl)-4-piperidinyl)-, (e)-2-butenedioate (1:1), but more generally known as duoperone fumarate, which bears US NIH Compound Identifier 43876. Most nations, for tariff and trade purposes, schedule duoperone fumarate under HS 29343090 and SITC 51578. As of Q4 2014, DUOPERONE FUMARATE remains US FDA's Preferred Term for this commodity. Duoperone fumarate bears US NLM identifiers UMLS ID C0115127 and NCI Concept Code C74170. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCC(CC4)C(=O)C5CCC(CC5)F.C(=C/C(=O)O)\C(=O)O.
Durvalumab is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[5] It is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
This classification denotes a 5 alpha-reductase inhibitor and anti-androgen with the molecular formula C27H30F6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0J6XJN02I, chemically known as alpha,alpha,alpha,alpha,alpha,alpha-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2,5-xylidide but generally known as dutasteride, which bears US NIH Compound Identifier 152945. European Medicines Agency schedules Dutasteride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06430MIG. The term DUTASTERIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules dutasteride in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule dutasteride under HS 29372900 and SITC 54153. As of Q4 2014, DUTASTERIDE remains the US FDA Preferred Term for this commodity. Dutasteride bears US NLM identifiers UMLS ID C0754659 and NCI Concept Code C47503. SMILES: FC(F)(F)C1C(NC(=O)C2C3(C(C4C(C5(C(NC(=O)C=C5)CC4)C)CC3)CC2)C)CC(CC1)C(F)(F)F.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.
This classification denotes an anesthetic agent with the molecular formula C18H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 078A24Q30O, chemically known as 1-propanone, 1- (4-butoxyphenyl)-3-(1-piperidinyl)-, hydrochloride but generally known as dyclonine, which bears US NIH Compound Identifier 3180. European Medicines Agency schedules Dyclonine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06432MIG. The term DYCLONINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules dyclonine in its Anatomical Therapeutic Chemical (ATC) Classification. DYCLONINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dyclonine under HS 29333999 and SITC 51574. As of Q4 2014, DYCLONINE remains the US FDA Preferred Term for this commodity. Dyclonine bears US NLM identifiers UMLS ID C0058831 and NCI Concept Code C29015. SMILES: O=C(CCN1CCCCC1)C1CCC(OCCCC)CC1.
This classification denotes an anesthetic agent with the molecular formula C18H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZEC193879Q, chemically known as 1-propanone, 1- (4-butoxyphenyl)-3-(1-piperidinyl)-, hydrochloride but more generally known as dyclonine hydrochloride, which bears US NIH Compound Identifier 3180. European Medicines Agency schedules Dyclonine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01848MIG. Most nations, for tariff and trade purposes, schedule dyclonine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DYCLONINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dyclonine hydrochloride bears US NLM identifiers UMLS ID C0304455 and NCI Concept Code C66875. SMILES: CCCCOC1CCC(CC1)C(=O)CCN2CCCCC2.CL.
This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90I02KLE8K, chemically known as 9beta,10alpha-pregna-4,6-diene-3,20-dione but generally known as dydrogesterone, which bears US NIH Compound Identifier 9051. European Medicines Agency schedules Dydrogesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06433MIG. The term DYDROGESTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules dydrogesterone in its Anatomical Therapeutic Chemical (ATC) Classification. DYDROGESTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dydrogesterone under HS 29372300 and SITC 54153. As of Q4 2014, DYDROGESTERONE remains the US FDA Preferred Term for this commodity. Dydrogesterone bears US NLM identifiers UMLS ID C0013340 and NCI Concept Code C65501. SMILES: O=C(C1C2(C(C3C(CC2)C2(C(=CC(=O)CC2)C=C3)C)CC1)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a serotonin agonist and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WV4B56N49H. European Medicines Agency schedules Ebalzotan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06434MIG. Ebalzotan generally arises in the molecular formula C19H30N2O2. The term EBALZOTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.) Most nations schedule ebalzotan under HS 29329985 and SITC 51569. As of Q4 2014, EBALZOTAN remains the US FDA Preferred Term for this commodity. Ebalzotan bears US NLM identifiers UMLS ID C2348371 and NCI Concept Code C72746. SMILES: O1CC(N(C(C)C)CCC)Cc2c1cccc2C(=O)NC(C)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H39NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQD7Q784P1, chemically known as 1-butanone, 1-(4-(1,1-dimethylethyl)phenyl)-4-(4-(diphenylmethoxy)-1-piperidinyl)- but generally known as ebastine, which bears US NIH Compound Identifier 3191. European Medicines Agency schedules Ebastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06435MIG. The term EBASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules ebastine in its Anatomical Therapeutic Chemical (ATC) Classification. EBASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ebastine under HS 29333999 and SITC 51574. As of Q4 2014, EBASTINE remains the US FDA Preferred Term for this commodity. Ebastine bears US NLM identifiers UMLS ID C0058895 and NCI Concept Code C77437. SMILES: O(C1CCN(CC1)CCCC(=O)C1CCC(C(C)(C)C)CC1)C(C1CCCCC1)C1CCCCC1.
This classification denotes an antifungal agent with the molecular formula C18H14Cl2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V7O1U41C9B, chemically known as (+-)-1-(2,4-dichloro-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yl)imidazole but generally known as eberconazole, which bears US NIH Compound Identifier 72051. European Medicines Agency schedules Eberconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06436MIG. The term EBERCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Most nations schedule eberconazole under HS 29332990 and SITC 51573. As of Q4 2014, EBERCONAZOLE remains the US FDA Preferred Term for this commodity. Eberconazole bears US NLM identifiers UMLS ID C0767000 and NCI Concept Code C72961. SMILES: CLC1C2C(N3CCNC3)C3C(CCC2CC(CL)C1)CCCC3.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C14H17BrN6O2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TMZ3IBW2OW, chemically known as benzenesulfonamide, n-(((2-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)ethyl)amino)methylene)-4-bromo-, (e)- but generally known as ebrotidine, which bears US NIH Compound Identifier 65869. European Medicines Agency schedules Ebrotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06438MIG. The term EBROTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). Most nations schedule ebrotidine under HS 29350090 and SITC 51580. As of Q4 2014, EBROTIDINE remains the US FDA Preferred Term for this commodity. Ebrotidine bears US NLM identifiers UMLS ID C0169307 and NCI Concept Code C77440. SMILES: BRC1CCC(S(=O)(=O)N/C=N/CCSCC2NC(SC2)/N=C(/N)N)CC1.
This classification denotes a cyclooxygenase inhibitor and antioxidant with the molecular formula C13H9NOSe, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40X2P7DPGH, chemically known as 1,2-benzisoselenazol-3(2h)-one, 2-phenyl- but generally known as ebselen, which bears US NIH Compound Identifier 3194. European Medicines Agency schedules Ebselen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06439MIG. The term EBSELEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). EBSELEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ebselen under HS 29349990 and SITC 51579. As of Q4 2014, EBSELEN remains the US FDA Preferred Term for this commodity. Ebselen bears US NLM identifiers UMLS ID C0058903 and NCI Concept Code C65503. SMILES: [SE]1N(C(=O)C2C1CCCC2)C1CCCCC1.
This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5Q6TZN2HNM. European Medicines Agency schedules Ecallantide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31283. Ecallantide generally arises in the molecular formula C305H442N88O91S8. The term ECALLANTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 1, 2006, list 55.) Most nations, for tariff and trade purposes, schedule ecallantide under HS 29349990 and SITC 51579. As of Q4 2014, ECALLANTIDE remains US FDA's Preferred Term for this commodity. Ecallantide bears US NLM identifiers UMLS ID C1722685 and NCI Concept Code C65505. SMILES: CCC(C)C1C(=O)NC(C(=O)NCC(=O)NCC(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4CCCC4C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N5CCCC5C(=O)N3)CC(=O)O)CC(=O)O)C)CCCCN)CC6=CC=CC=C6)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C(CCC(=O)O)N)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)O)CCSC)CCCCN)CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC2=O)CCC(=O)O)CC(=O)N)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CC9=CC=CC=C9)CCC(=O)O)CO)CC(C)C)CCC(=O)O)CCC(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CC1=CC=CC=C1)CCC(=O)O)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)C(C)O)CC1=CC=CC=C1)C(C)CC)CC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CCCNC(=N)N)CC1=CN=CN1)C)C)CCCNC(=N)N)CC1=CC=C(C=C1)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C26H33N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EEB95DS30P, chemically known as (- )-4-(3-((3,4-dimethoxy-phenethyl)amino)-2-hydroxypropoxy)-3-(5-isoxazolyl)butyranilide. but generally known as ecastolol, which bears US NIH Compound Identifier 208905. European Medicines Agency schedules Ecastolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06444MIG. The term ECASTOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ECASTOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ecastolol under HS 29349990 and SITC 51579. As of Q4 2014, ECASTOLOL remains the US FDA Preferred Term for this commodity. Ecastolol bears US NLM identifiers UMLS ID C2348372 and NCI Concept Code C72608. SMILES: O(CC(O)CNCCC1CC(OC)C(OC)CC1)C1C(CC(NC(=O)CCC)CC1)C1ONCC1.
This classification denotes a quinolone antibiotic with the molecular formula C19H21FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3613ZY362L, chemically known as 1,8-naphthyridine-3-carboxylic acid, 7-((1r,5s,6s)-6-amino-1-methyl-3-azabicyclo(3.2.0)hept-3-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, rel-( )- but generally known as ecenofloxacin, which bears US NIH Compound Identifier 178066. European Medicines Agency schedules Ecenofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06445MIG. The term ECENOFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). Most nations schedule ecenofloxacin under HS 29339990 and SITC 51577. As of Q4 2014, ECENOFLOXACIN remains the US FDA Preferred Term for this commodity. Ecenofloxacin bears US NLM identifiers UMLS ID C2348374 and NCI Concept Code C72661. SMILES: FC1C(N2CC3(C(C(N)C3)C2)C)NC2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C9H23NO3PS.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BA9QH3P00T, chemically known as s-ester of (2-mercaptoethyl)trimethylammonium iodide with o,o-diethyl phosphorothioate but generally known as echothiophate iodide, which bears US NIH Compound Identifier 10547. European Medicines Agency schedules Ecothiopate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01856MIG. The term ECHOTHIOPHATE IODIDE is an International Non-Proprietary Name. World Health Organization schedules echothiophate iodide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ECHOTHIOPHATE remains the US FDA Preferred Term for this commodity. Echothiophate bears US NLM identifiers UMLS ID C0301366 and NCI Concept Code C76040. SMILES: CCOP(=O)(OCC)SCC[N+](C)(C)C.
This classification denotes an antidepressant agent with the molecular formula C16H22CL2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5Y67H9W4KQ chemically known as propanamide, n-(3,4-dichlorophenyl)-n-(2-(dimethylamino)cyclopentyl)-, trans-(+/-)- but generally known as eclanamine, which bears US NIH Compound Identifier 130380. European Medicines Agency schedules Eclanamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06447MIG. The term ECLANAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26. ). Most nations schedule eclanamine under HS 29242995 and SITC 51479. As of Q4 2014, ECLANAMINE remains the US FDA Preferred Term for this commodity. Eclanamine bears US NLM identifiers UMLS ID C0635054 and NCI Concept Code C81480. SMILES: CCC(=O)N(C1CCCC1N(C)C)C2=CC(=C(C=C2)Cl)Cl.
This classification denotes an antidepressant agent with the molecular formula C16H22CL2N2O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2C169J769. The term eclanamine maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule eclanamine maleate under HS 29242995 and SITC 51479. As of Q4 2014, ECLANAMINE MALEATE remains US FDA's Preferred Term for this commodity. Eclanamine maleate bears US NLM identifiers UMLS ID C0957739 and NCI Concept Code C75171. SMILES: CCC(=O)N(C1CCC(C(C1)CL)CL)[C@@H]2CCC[C@H]2N(C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C12H12ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5ELL4R7VD, chemically known as 2-benzoxazolecarboxylic acid, 5-chloro-, 2-ethoxyethyl ester but generally known as eclazolast, which bears US NIH Compound Identifier 54550. European Medicines Agency schedules Eclazolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06448MIG. The term ECLAZOLAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). ECLAZOLAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eclazolast under HS 29349990 and SITC 51579. As of Q4 2014, ECLAZOLAST remains the US FDA Preferred Term for this commodity. Eclazolast bears US NLM identifiers UMLS ID C0073137 and NCI Concept Code C81140. SMILES: CCOCCOC(=O)C1=NC2=C(O1)C=CC(=C2)CL.
This clasification denotes vaccines or candidate vaccines used to prevent or treat infections from a species of gram-negative, facultatively anaerobic, rod-shaped bacteria (gram-negative facultatively anaerobic rods) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce diarrhea and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins ( enterotoxigenic escherichia coli), etc.
This classification denotes a nitrosourea compound with the molecular formula C10H18ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7369R4J7S2, chemically known as methyl 3-(3-(2-chloroethyl)-3-nitrosoureido)-2,3-dideoxy-alpha-d-arabino-hexopyranoside but more generally known as ecomustine, which bears US NIH Compound Identifier 65855. European Medicines Agency schedules Ecomustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06449MIG. The term ECOMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). ECOMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ecomustine under HS 29329970 and SITC 51569. As of Q4 2014, ECOMUSTINE remains US FDA's Preferred Term for this commodity. Ecomustine bears US NLM identifiers UMLS ID C0056637 and NCI Concept Code C77371. SMILES: COC1CC(C(C(O1)CO)O)NC(=O)N(CCCL)N=O.
This classification denotes an antifungal agent with the molecular formula C18H15Cl3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Z1Y2V4A7M, chemically known as 1-(2,4-dichloro-beta-((p-chlorobenzyl)oxy)phenethyl)imidazole but generally known as econazole, which bears US NIH Compound Identifier 3198. European Medicines Agency schedules Econazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06450MIG. The term ECONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules econazole in its Anatomical Therapeutic Chemical (ATC) Classification. ECONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule econazole under HS 29332990 and SITC 51573. As of Q4 2014, ECONAZOLE remains the US FDA Preferred Term for this commodity. Econazole bears US NLM identifiers UMLS ID C0013547 and NCI Concept Code C61740. SMILES: CLC1C(C(OCC2CCC(CL)CC2)CN2CCNC2)CCC(CL)C1.
This classification denotes an antifungal agent with the molecular formula C18H15Cl3N2O.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H438WYN10E, chemically known as 1-(2,4-dichloro-beta-((p-chlorobenzyl)oxy)phenethyl)imidazole but more generally known as econazole nitrate, which bears US NIH Compound Identifier 3198. European Medicines Agency schedules Econazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01855MIG. Most nations, for tariff and trade purposes, schedule econazole nitrate under HS 29332990 and SITC 51573. As of Q4 2014, ECONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Econazole nitrate bears US NLM identifiers UMLS ID C0546862 and NCI Concept Code C47506. SMILES: C1CC(CCC1COC(CN2CCNC2)C3CCC(CC3CL)CL)CL.[N+](=O)(O)[O-].
This classification denotes an antiplatelet agent with the molecular formula C28H48O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2XM6VR8DO, chemically known as prosta-8,13-dien-1-oic acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11 alpha, 13e,15s)- but generally known as ecraprost, which bears US NIH Compound Identifier 6441614. The term ECRAPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). Most nations schedule ecraprost under HS 29375000 and SITC 54156. As of Q4 2014, ECRAPROST remains the US FDA Preferred Term for this commodity. Ecraprost bears US NLM identifiers UMLS ID C0671097 and NCI Concept Code C76397. SMILES: CCCCCC(C=CC1C(CC(=C1CCCCCCC(=O)OCCCC)OC(=O)CCC)O)O.
This classification denotes a sedative and hypnotic with the molecular formula C7H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1U73ZZU4JK, chemically known as 2-butenamide, n- (aminocarbonyl)-2-ethyl-, (z)- but generally known as ectylurea, which bears US NIH Compound Identifier 7214. European Medicines Agency schedules Ectylurea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06452MIG. The term ECTYLUREA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). ECTYLUREA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ectylurea under HS 29241900 and SITC 51471. As of Q4 2014, ECTYLUREA remains the US FDA Preferred Term for this commodity. Ectylurea bears US NLM identifiers UMLS ID C0167583 and NCI Concept Code C76939. SMILES: O=C(NC(=O)N)C(=C\C)\CC.
This classification denotes an immunomodulator, an immunosuppressant, and monoclonal antibody, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A3ULP0F556. Most nations, for tariff and trade purposes, schedule Eculizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, ECULIZUMAB remains US FDA's Preferred Term for this commodity. . Eculizumab bears US NLM identifiers UMLS ID C1541483 and NCI Concept Code C48386.
This classification denotes a neuroprotective agent with the molecular structure C10H10N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, S798V6YJRP chemically known as 3h-pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl- but generally known as edaravone, which bears US NIH Compound Identifier 4021. European Medicines Agency schedules Edaravone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06453MIG. The term EDARAVONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36). Edaravone or norphenazone bears US NLM identifiers UMLS ID C0070694 and NCI Concept Code C74323. SMILES: O=C1N(N=C(C1)C)C1CCCCC1.
This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C22H25N7O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JT4X6Z1HRR, chemically known as n-(p-(1-((2,4-diamino-6-pteridinyl)methyl)propyl)benzoyl)-l-glutamic acid but generally known as edatrexate, which bears US NIH Compound Identifier 54586. European Medicines Agency schedules Edatrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06454MIG. The term EDATREXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). EDATREXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule edatrexate under HS 29335995 and SITC 51576. As of Q4 2014, EDATREXATE remains the US FDA Preferred Term for this commodity. Edatrexate bears US NLM identifiers UMLS ID C0044667 and NCI Concept Code C958. SMILES: O=C(NC(CCC(=O)O)C(=O)O)C1CCC(C(CC2NC3C(NC2)NC(NC3N)N)CC)CC1.
This classification denotes a chelating agent with the molecular formula C10H12N2O8.CA.2NA.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25IH6R4SGF. The term calcium disodium edetate hydrate is a Japanese Accepted Name designation. As of Q4 2014, EDETATE CALCIUM DISODIUM remains the US FDA Preferred Term for this commodity. Edetate calcium disodium bears US NLM identifiers UMLS ID C0006692 and NCI Concept Code C334. SMILES: C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+].
This classification denotes a chelating agent with the molecular formula C10H12N2O8.2H+.2Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FLD91C86K, chemically known as 3,6-diazaoctanedioic acid, 3,6-bis(carboxymethyl)- but generally known as disodium edetate, which bears US NIH Compound Identifier 6049. European Medicines Agency schedules Disodium edetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11914MIG. As of Q4 2014, EDETATE DISODIUM remains the US FDA Preferred Term for this commodity. Edetate disodium bears US NLM identifiers UMLS ID C0012695 and NCI Concept Code C61741. SMILES: OC(=O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a therapeutic progestin with the molecular formula C26H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9014UFK50C, chemically known as 17-hydroxy-6-methylpregn-5-ene-3,20-dione cyclic 3-(ethylene acetal) acetate but generally known as edogestrone, which bears US NIH Compound Identifier 101860. European Medicines Agency schedules Edogestrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06459MIG. The term EDOGESTRONE is an International Non-Proprietary Name. EDOGESTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule edogestrone under HS 29372300 and SITC 54153. As of Q4 2014, EDOGESTRONE remains the US FDA Preferred Term for this commodity. Edogestrone bears US NLM identifiers UMLS ID C0603207 and NCI Concept Code C74368. SMILES: O(C1(C2(C(C3C(C4(C(=C(C3)C)CC3(OCCO3)CC4)C)CC2)CC1)C)C(=O)C)C(=O)C.
This classification denotes an antiviral agent with the molecular formula C11H16N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15ZQM81Y3R, chemically known as uridine, 2-deoxy-5-ethyl- but generally known as edoxudine, which bears US NIH Compound Identifier 1814. European Medicines Agency schedules Edoxudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06460MIG. The term EDOXUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules edoxudine in its Anatomical Therapeutic Chemical (ATC) Classification. EDOXUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule edoxudine under HS 29349990 and SITC 51579. As of Q4 2014, EDOXUDINE remains the US FDA Preferred Term for this commodity. Edoxudine bears US NLM identifiers UMLS ID C0115510 and NCI Concept Code C87662. SMILES: CCC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C10H16NO.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QO611KSM5P, chemically known as benzenaminium, n-ethyl-3-hydroxy-n,n-dimethyl- but generally known as edrophonium chloride, which bears US NIH Compound Identifier 3202. European Medicines Agency schedules Edrophonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06461MIG. The term EDROPHONIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations schedule edrophonium chloride under HS 29239000 and SITC 51481. As of Q4 2014, EDROPHONIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Edrophonium chloride bears US NLM identifiers UMLS ID C0013617 and NCI Concept Code C47507. SMILES: CC[N+](C)(C)C1=CC(=CC=C1)O.[CL-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes an immunomodulator, an immunosuppressant, and monoclonal antibody, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XX2MN88N5D. Most nations schedule Efalizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, EFALIZUMAB remains the US FDA Preferred Term for this commodity. . Efalizumab bears US NLM identifiers UMLS ID C1320125 and NCI Concept Code C68831.
This classification denotes a radiosensitizing agent with the molecular formula C20H23NO4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier J81E81G364, chemically known as 2-(4-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2 methylpropanic acid but more generally known as efaproxiral, which bears U.S. NIH Compound Identifier 122335. European Medicines Agency schedules Efaproxiral in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21811. The term EFAPROXIRAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3, 2002, List 48). World Health Organization schedules efaproxiral in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C13H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G00490L21H, chemically known as (+-)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline but generally known as efaroxan, which bears US NIH Compound Identifier 72016. European Medicines Agency schedules Efaroxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06462MIG. The term EFAROXAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). EFAROXAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule efaroxan under HS 29349990 and SITC 51579. As of Q4 2014, EFAROXAN remains the US FDA Preferred Term for this commodity. Efaroxan bears US NLM identifiers UMLS ID C0058957 and NCI Concept Code C72923. SMILES: O1C(CC2C1CCCC2)(CC)C1=NCCN1.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C14H9ClF3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JE6H2O27P8, chemically known as 2h-3,1-benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4s)- but generally known as efavirenz, which bears US NIH Compound Identifier 64139. European Medicines Agency schedules Efavirenz in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06463MIG. The term EFAVIRENZ is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules efavirenz in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule efavirenz under HS 29349990 and SITC 51579. As of Q4 2014, EFAVIRENZ remains the US FDA Preferred Term for this commodity. Efavirenz bears US NLM identifiers UMLS ID C0674428 and NCI Concept Code C29027. SMILES: Clc1cc2C(OC(=O)Nc2cc1)(C#CC1CC1)C(F)(F)F.
This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, EFAVIRENZ, has US FDA Unique Ingredient Identifier of JE6H2O27P8. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.
This classification denotes a combination drug for treatment of HIV. The first component, EFAVIRENZ, has US FDA Unique Ingredient Identifier of JE6H2O27P8. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.
This classification denotes a protease inhibitor and anticoagulant agent with the molecular formula C21H32N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, VT0VK2474K chemically known as l-prolinamide, n-methyl-d-phenylalanyl-n-(4-((aminoiminomethyl)amino)-1-formylbutyl)-, (s)- but generally known as efegatran, which bears US NIH Compound Identifier 122267. European Medicines Agency schedules Efegatran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06464MIG. The term EFEGATRAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35). Most nations schedule efegatran under HS 29339990 and SITC 51577. As of Q4 2014, EFEGATRAN remains the US FDA Preferred Term for this commodity. Efegatran bears US NLM identifiers UMLS ID C0286590 and NCI Concept Code C72749. SMILES: CNC(CC1=CC=CC=C1)C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C=O.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MPI4B0COZ7. European Medicines Agency schedules Efetozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06466MIG. Efetozole generally arises in the molecular formula C12H14N2. The term EFETOZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) EFETOZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule efetozole under HS 29332990 and SITC 51573. As of Q4 2014, EFETOZOLE remains the US FDA Preferred Term for this commodity. Efetozole bears US NLM identifiers UMLS ID C2348381 and NCI Concept Code C72750. SMILES: CC1=NC=CN1C(C)C2=CC=CC=C2.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6C301298G. European Medicines Agency schedules Efletirizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06467MIG. Efletirizine generally arises in the molecular formula C21H24F2N2O3. The term EFLETIRIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.) EFLETIRIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule efletirizine under HS 29335995 and SITC 51576. As of Q4 2014, EFLETIRIZINE remains the US FDA Preferred Term for this commodity. Efletirizine bears US NLM identifiers UMLS ID C0893504 and NCI Concept Code C73048. SMILES: FC1CCC(C(N2CCN(CC2)CCOCC(=O)O)C2CCC(F)CC2)CC1.
This classification denotes a histamine-1 receptor antagonist C21H24F2N2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JQ7ZT5MRA0, chemically known as (2-(4-bis(p-fluorophenyl)methyl)-1-piperazinyl)ethoxy)acetic acid, dihydrochloride, but more generally known as efletirizine dihydrochloride, which bears US NIH Compound Identifier 156659. Most nations, for tariff and trade purposes, schedule efletirizine dihydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, EFLETIRIZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Efletirizine dihydrochloride bears US NLM identifiers UMLS ID C2348383 and NCI Concept Code C72751. SMILES: C1CC(CCC1C(C2CCC(CC2)F)N3CCN(CC3)CCOCC(=O)O)F.CL.CL.
This classification denotes an ornithine decarboxylase inhibitor with the molecular formula C6H12F2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZQN1G5V6SR, chemically known as 2,5-diamino-2-(difluoromethyl)pentanoic acid but generally known as eflornithine, which bears US NIH Compound Identifier 3009. European Medicines Agency schedules Eflornithine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06468MIG. The term EFLORNITHINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules eflornithine in its Anatomical Therapeutic Chemical (ATC) Classification. EFLORNITHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eflornithine under HS 29224995 and SITC 51465. As of Q4 2014, EFLORNITHINE remains the US FDA Preferred Term for this commodity. Eflornithine bears US NLM identifiers UMLS ID C0086156 and NCI Concept Code C226. SMILES: FC(F)C(N)(CCCN)C(=O)O.
This classification denotes a vasodilating agent with the molecular formula C19H16O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CZU6V3902K, chemically known as acetic acid, ((4-oxo-2-phenyl-4h-1-benzopyran-7-yl)oxy)-, ethyl ester but generally known as efloxate, which bears US NIH Compound Identifier 8395. European Medicines Agency schedules Efloxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06469MIG. The term EFLOXATE is an International Non-Proprietary Name. World Health Organization schedules efloxate in its Anatomical Therapeutic Chemical (ATC) Classification. EFLOXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule efloxate under HS 29329985 and SITC 51569. As of Q4 2014, EFLOXATE remains the US FDA Preferred Term for this commodity. Efloxate bears US NLM identifiers UMLS ID C0058961 and NCI Concept Code C74416. SMILES: o1c2c(c(=O)cc1c1ccccc1)ccc(OCC(=O)OCC)c2.
This classification denotes an anti-lipidemic agent with the molecular formula C29H43NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DK1X2C37M, chemically known as (s)-2,3,5-trimethyl-4-hydroxy-alpha-dodecylthioacetanilide but generally known as eflucimibe, which bears US NIH Compound Identifier 3025954. The term EFLUCIMIBE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule eflucimibe under HS 29309085 and SITC 51549. As of Q4 2014, EFLUCIMIBE remains the US FDA Preferred Term for this commodity. Eflucimibe bears US NLM identifiers UMLS ID C0963171 and NCI Concept Code C75995. SMILES: CCCCCCCCCCCCCC(=S)NC1=C(C(=C(C(=C1)C)O)C)C.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3CIG2V70UB. European Medicines Agency schedules Eflumast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06470MIG. Eflumast generally arises in the molecular formula C10H8FN5O3. The term EFLUMAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) EFLUMAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eflumast under HS 29339990 and SITC 51577. As of Q4 2014, EFLUMAST remains the US FDA Preferred Term for this commodity. Eflumast bears US NLM identifiers UMLS ID C0654074 and NCI Concept Code C73049. SMILES: CC(=O)C1=CC(=CC(=NC(=O)C2=NNNN2)C1=O)F.
This classification denotes a calcium channel blocker with the molecular formula C34H38N3O7P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40ZTP2T37Q, chemically known as 2-(n-benzylanilino)ethyl (- )-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-5-phosphononicotinate, cyclic 2,2-dimethyltrimethylene ester. but generally known as efonidipine, which bears US NIH Compound Identifier 119171. European Medicines Agency schedules Efonidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06471MIG. The term EFONIDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). EFONIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule efonidipine under HS 29349990 and SITC 51579. As of Q4 2014, EFONIDIPINE remains the US FDA Preferred Term for this commodity. Efonidipine bears US NLM identifiers UMLS ID C0286819 and NCI Concept Code C73026. SMILES: P1(=O)(OCC(CO1)(C)C)C1=C(NC(=C(C1c1cc([N](=O)O)ccc1)C(=O)OCCN(Cc1ccccc1)c1ccccc1)C)C.
This classification denotes a calcium channel blocker with the molecular formula C34H38N3O7P.C2H6O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84HJ0Q6TMN, chemically known as (+/-)-efonidipine hydrochloride ethanolate, but more generally known as efonidipine hydrochloride ethanolate, which bears US NIH Compound Identifier 163838. European Medicines Agency schedules efonidipine hydrochloride ethanolate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06471MIG. Most nations, for tariff purposes, schedule efonidipine hydrochloride ethanolate under HS 29349990. SMILES: CCO.CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3CCCC(C3)[N+](=O)[O-])C(=O)OCCN(CC4CCCCC4)C5CCCCC5.CL.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ZZ84GCW8B. European Medicines Agency schedules Formoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07788MIG. Formoterol generally arises in the molecular formula C19H24N2O4. The term FORMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) FORMOTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Eformoterol or formoterol bears US NLM identifiers UMLS ID C0060657 and NCI Concept Code C65754. SMILES: OC(CNC(CC1CCC(OC)CC1)C)C1CC(NC=O)C(O)CC1.
This classification denotes an antibiotic with the molecular formula C59H88N2O20, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5BPJ82Q45X, chemically known as mocimycin, 31-o-(6-deoxy-4-o-(6-deoxy-2,4-di-o-methyl-alpha-l-mannopyranosyl)-3-o-methyl-beta-d-allopyranosyl)-1-methyl- but more generally known as efrotomycin, which bears US NIH Compound Identifier 6436033. European Medicines Agency schedules Efrotomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06472MIG. The term EFROTOMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). EFROTOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1C(O)(C(O)C(OC2OC(C(OC3OC(C(OC)C(O)C3OC)C)C(OC)C2O)C)C(C1/C=C/C=C/C)(C)C)C(CC)C(=O)NC/C=C/C=C(/C(OC)C(C1OC(C(O)C1O)/C=C/C=C/C=C(\C)C(=O)C1C(O)N(CCC1=O)C)C)C.
This classification denotes a growth hormone-releasing hormone analogue with the molecular formula C221H366N72O67S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MQG94M5EEO, chemically known as (3e)-hex-3-enoylsomatoliberin, which bears US NIH Compound Identifier 16137828. European Medicines Agency schedules tesamorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32399. Egrifta or tesamorelin bears US NLM identifiers UMLS ID C1876200 and NCI Concept Code C77425. SMILES: CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N.
This classification denotes an eicosapentaenoic acid with the molecular formula C20H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AAN7QOV9EA, chemically known as icosa-5,8,11,14,17-pentaenoic acid but generally known as eicosapentaenoic acid, which bears US NIH Compound Identifier 3209. European Medicines Agency schedules Eicosapentaenoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13664MIG. The term ICOSAPENT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). Eicosapentaenoic acid bears US NLM identifiers UMLS ID C0000545 and NCI Concept Code C67080. SMILES: OC(=O)CCC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CC.
This classification denotes an anticholinergic agent with the molecular formula C20H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MV4FO7V23V, chemically known as rmi 80,029 but generally known as elantrine, which bears US NIH Compound Identifier 5383521. European Medicines Agency schedules Elantrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06476MIG. The term ELANTRINE is an International Non-Proprietary Name. ELANTRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elantrine under HS 29339930 and SITC 51577. As of Q4 2014, ELANTRINE remains the US FDA Preferred Term for this commodity. Elantrine bears US NLM identifiers UMLS ID C2825643 and NCI Concept Code C81459. SMILES: N1(CC2C(/C(=C\CCN(C)C)C3C1CCCC3)CCCC2)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H31N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S39YD087F9, chemically known as 1-(2-((2,6-dimethyl-3-nitro-4-pyridyl)amino)ethyl)-4-(diphenylmethyl)piperazine. but generally known as elbanizine, which bears US NIH Compound Identifier 208913. European Medicines Agency schedules Elbanizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06478MIG. The term ELBANIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). ELBANIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elbanizine under HS 29335995 and SITC 51576. As of Q4 2014, ELBANIZINE remains the US FDA Preferred Term for this commodity. Elbanizine bears US NLM identifiers UMLS ID C2348394 and NCI Concept Code C73050. SMILES: O[N](=O)C1C(NCCN2CCN(CC2)C(C2CCCCC2)C2CCCCC2)CC(NC1C)C.
This classification denotes an antithyroid agent with the molecular formula C148H244N42O47, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W0CMS474JK, chemically known as1,7-Dicarbacalcitonin, 1-butanoic acid-26-L-aspartic acid-27-L-valine-29-L-alanine- but generally known as Elcatonin, which bears US NIH Compound Identifier 16129700. European Medicines Agency schedules Methylthiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06479MIG. Elcatonin is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elcatonin under HS 29371900 and SITC 54154. As of Q4 2014, ELCATONIN remains the US FDA Preferred Term for this commodity. Elcatonin bears US NLM identifiers UMLS ID C0115656 and NCI Concept Code C96281. SMILES: CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CCCCCC(=O)OCC(C(=O)NC(C(=O)N1)CC(=O)N)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO.
This classification denotes a serotonin agonist with the molecular formula C22H26N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22QOO9B8KI, chemically known as 1h-indole, 3-(((2r)-1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)ethyl)- but generally known as eletriptan, which bears US NIH Compound Identifier 77993. European Medicines Agency schedules Eletriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06482MIG. The term ELETRIPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules eletriptan in its Anatomical Therapeutic Chemical (ATC) Classification. ELETRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eletriptan under HS 29339990 and SITC 51577. As of Q4 2014, ELETRIPTAN remains the US FDA Preferred Term for this commodity. Eletriptan bears US NLM identifiers UMLS ID C0759933 and NCI Concept Code C65509. SMILES: S(=O)(=O)(CCC1CC2C(CC3N(CCC3)C)C[NH]C2CC1)C1CCCCC1.
This classification denotes a serotonin agonist with the molecular formula C22H26N2O2S.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M41W832TA3, chemically known as 1h-indole, 3-(((2r)-1-methyl-2-pyrrolidinyl))methyl)-5-(2-(phenylsulfonyl)ethyl)-, monohydrobromide but more generally known as eletriptan hydrobromide, which bears US NIH Compound Identifier 156849. European Medicines Agency schedules Eletriptan hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26382. Most nations, for tariff and trade purposes, schedule eletriptan hydrobromide under HS 29339990 and SITC 51577. As of Q4 2014, ELETRIPTAN HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Eletriptan hydrobromide bears US NLM identifiers UMLS ID C1178489 and NCI Concept Code C47508. SMILES: CN1CCC[C@@H]1CC2C[NH]C3C2CC(CC3)CCS(=O)(=O)C4CCCCC4.BR.
This classification denotes an anxiolytic with the molecular formula C19H18ClFN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RM53R5R2BL, chemically known as 7-chloro-1-(2-(ethylsulfonyl)ethyl)-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as elfazepam, which bears US NIH Compound Identifier 65445. European Medicines Agency schedules Elfazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06483MIG. The term ELFAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). ELFAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elfazepam under HS 29339940 and SITC 51577. As of Q4 2014, ELFAZEPAM remains the US FDA Preferred Term for this commodity. Elfazepam bears US NLM identifiers UMLS ID C0059029 and NCI Concept Code C74184. SMILES: CLC1CC2C(N(CCS(=O)(=O)CC)C(=O)CN=C2C2C(F)CCCC2)CC1.
This classification denotes a calcium channel blocker with the molecular formula C29H33FN2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3JI11Z5REF, chemically known as 3,5-pyridinedicarboxylic acid, 4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-, 2-(((4-fluorophenyl)methyl)methylamino)ethyl 1-methylethyl ester, (+-)- but generally known as elgodipine, which bears US NIH Compound Identifier 60701. European Medicines Agency schedules Elgodipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06484MIG. The term ELGODIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). ELGODIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elgodipine under HS 29349990 and SITC 51579. As of Q4 2014, ELGODIPINE remains the US FDA Preferred Term for this commodity. Elgodipine bears US NLM identifiers UMLS ID C0082382 and NCI Concept Code C76579. SMILES: Fc1ccc(CN(CCOC(=O)C2=C(NC(=C(C2c2c3OCOc3ccc2)C(=O)OC(C)C)C)C)C)cc1.
This classification denotes a calcium channel blocker with the molecular formula C29H33FN2O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MIR106H7SI, chemically known as 2-((p-fluorobenzyl)methylamino)ethyl isopropyl (+/-)- 1,4-dihydro-2,6-dimethyl-4-(2,3-(methylenedioxy)phenyl)-3,5-pyridinedicarboxylate hydrochloride, but more generally known as elgodipine hydrochloride, which bears US NIH Compound Identifier 60701. European Medicines Agency schedules elgodipine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06484MIG. Most nations, for tariff purposes, schedule elgodipine hydrochloride under HS 29349990. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2CCCC3C2OCO3)C(=O)OCCN(C)CC4CCC(CC4)F.CL.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C27H29ClN6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WCC8Z95027, chemically known as 1h-imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)-, 1-((ethoxycarbonyl)oxy)ethyl ester but generally known as elisartan, which bears US NIH Compound Identifier 183766. European Medicines Agency schedules Elisartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06487MIG. The term ELISARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ELISARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elisartan under HS 29332990 and SITC 51573. As of Q4 2014, ELISARTAN remains the US FDA Preferred Term for this commodity. Elisartan bears US NLM identifiers UMLS ID C2348398 and NCI Concept Code C72933. SMILES: Clc1nc(n(Cc2ccc(cc2)c2c(cccc2)c2n[nH]nn2)c1C(=O)OC(OC(=O)OCC)C)CCCC.
Elosulfase alfa is a drug for the treatment of Morquio syndrome which is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Elosulfase alfa is a synthetic version of this enzyme.
This classification denotes a topoisomerase-ii inhibitor and miscellaneous antineoplastic antibiotic with the molecular formula C33H35NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTV0FOB6NU, chemically known as 2-amino-2,6-dideoxy-3-o-methyl-d-galactose but generally known as elsamitrucin, which bears US NIH Compound Identifier 5362259. European Medicines Agency schedules Elsamitrucin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06493MIG. The term ELSAMITRUCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). ELSAMITRUCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Elsamicin a or elsamitrucin bears US NLM identifiers UMLS ID C0059041 and NCI Concept Code C1080. SMILES: O(C1C(O)(C(O)C(OC1OC1C2C(C(O)C3C4C2OC(=O)C2C4C(OC3=O)CCC2C)CCC1)C)C)C1OC(C(O)C(OC)C1N)C.
This classification denotes an anesthetic agent with the molecular formula C21H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BXO86P3XXW, chemically known as 5beta-pregnan-20-one, 3alpha-hydroxy- (8ci) but generally known as eltanolone, which bears US NIH Compound Identifier 31402. European Medicines Agency schedules Eltanolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06494MIG. The term ELTANOLONE is an International Non-Proprietary Name. ELTANOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eltanolone under HS 29144090 and SITC 51629. As of Q4 2014, ELTANOLONE remains the US FDA Preferred Term for this commodity. Eltanolone bears US NLM identifiers UMLS ID C0033008 and NCI Concept Code C81407. SMILES: CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H9Cl2NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A153L3JA99, chemically known as 4-(2,6-dichloroanilino)-3-thiopheneacetic acid but generally known as eltenac, which bears US NIH Compound Identifier 51717. European Medicines Agency schedules Eltenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06495MIG. The term ELTENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). ELTENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eltenac under HS 29349990 and SITC 51579. As of Q4 2014, ELTENAC remains the US FDA Preferred Term for this commodity. Eltenac bears US NLM identifiers UMLS ID C0648171 and NCI Concept Code C77358. SMILES: CLC1C(NC2C(CC(=O)O)CSC2)C(CL)CCC1.
This classification denotes a serotonin agonist with the molecular formula C12H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 510M006KO6, chemically known as 1-(1,4-benzodioxan-5-yl)piperazine but generally known as eltoprazine, which bears US NIH Compound Identifier 65853. European Medicines Agency schedules Eltoprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06496MIG. The term ELTOPRAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ELTOPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eltoprazine under HS 29349990 and SITC 51579. As of Q4 2014, ELTOPRAZINE remains the US FDA Preferred Term for this commodity. Eltoprazine bears US NLM identifiers UMLS ID C0082384 and NCI Concept Code C73286. SMILES: C1CN(CCN1)C2=C3C(=CC=C2)OCCO3.
This classification denotes a serotonin agonist with the molecular formula C12H16N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5275JY4PKD, chemically known as piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-, hydrochloride (1:1), but more generally known as eltoprazine hydrochloride, which bears US NIH Compound Identifier 3025067. European Medicines Agency schedules eltoprazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06496MIG. Most nations, for tariff purposes, schedule eltoprazine hydrochloride under HS 29349990. SMILES: C1CC(C2C(C1)OCCO2)N3CCNCC3.CL.
This classification denotes an agent affecting blood and body fluid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S56D65XJ9G. European Medicines Agency schedules Eltrombopag in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30140. Eltrombopag generally arises in the molecular formula C25H22N4O4. The term ELTROMBOPAG is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56.) Most nations schedule eltrombopag under HS 29331900 and SITC 51571. As of Q4 2014, ELTROMBOPAG remains the US FDA Preferred Term for this commodity. Eltrombopag bears US NLM identifiers UMLS ID C1831905 and NCI Concept Code C71634. SMILES: O=C1N([NH]C(C1N/N=C1/C(=O)C(=CC=C1)C1CC(CCC1)C(=O)O)C)C1CC(C(CC1)C)C.
This classification denotes an agent affecting blood and body fluid C25H22N4O4.2C2H7NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4U07F515LG, chemically known as (1,1'-biphenyl)-3-carboxylic acid, 3'-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-, compound with 2-aminoethanol (1:2), but more generally known as eltrombopag olamine, which bears US NIH Compound Identifier 9915926. European Medicines Agency schedules Eltrombopag olamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30141. Most nations, for tariff and trade purposes, schedule eltrombopag olamine under HS 29331900 and SITC 51571. As of Q4 2014, ELTROMBOPAG OLAMINE remains US FDA's Preferred Term for this commodity. Eltrombopag olamine bears US NLM identifiers UMLS ID C1880492 and NCI Concept Code C62501. SMILES: CC1CCC(CC1C)N2C(=O)/C(=N\NC3CCCC(C3O)C4CCCC(C4)C(=O)O)/C(=N2)C.C(CO)N.C(CO)N.
A mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowelsyndrome with diarrhea.
A type of human immunodeficiency virus type 1 (HIV-1) integrasestrand transfer inhibitor used in combination with an HIV proteaseinhibitor coadministered with ritonavir and with other antiretroviraldrug(s) indicated for the treatment of HIV-1 infection in antiretroviraltreatment-experienced adults.
A multi-drug combination indicated as a complete regimen for the treatment of HIV-1.
This classification denotes an antispasmotic agent with the molecular formula C32H37N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1I2BO46745, chemically known as 6,7-dimethoxy-4-((4-(o-methoxyphenyl)-1-piperazinyl)methyl)-1-veratrylisoquinoline but generally known as elziverine, which bears US NIH Compound Identifier 65839. European Medicines Agency schedules Elziverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06498MIG. The term ELZIVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ELZIVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elziverine under HS 29335995 and SITC 51576. As of Q4 2014, ELZIVERINE remains the US FDA Preferred Term for this commodity. Elziverine bears US NLM identifiers UMLS ID C2348435 and NCI Concept Code C73163. SMILES: O(C1C(N2CCN(CC2)CC2C3C(C(NC2)CC2CC(OC)C(OC)CC2)CC(OC)C(OC)C3)CCCC1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H22BrNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HH0KD7Z416, chemically known as 2-(p-bromo-alpha-methyl-alpha-phenylbenzyloxy)-n,n-dimethylethyl amine but generally known as embramine, which bears US NIH Compound Identifier 19105. European Medicines Agency schedules Embramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06500MIG. The term EMBRAMINE is an International Non-Proprietary Name. EMBRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule embramine under HS 29221980 and SITC 51461. As of Q4 2014, EMBRAMINE remains the US FDA Preferred Term for this commodity. Embramine bears US NLM identifiers UMLS ID C0059053 and NCI Concept Code C81150. SMILES: BRC1CCC(C(OCCN(C)C)(C2CCCCC2)C)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular structure C18H22BRNO.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 7BJ3V657VC chemically known as 2-((p-bromo-.alpha.-methyl-.alpha.-phenylbenzyl)oxy)-n,n-dimethylethylamine hydrochloride, but more commonly known as embramine hydrochloride, which bears US NIH Compound Identifier 26365. European Medicines Agency schedules Embramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01870MIG. Most nations, for tariff and trade purposes, schedule embramine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, EMBRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Embramine hydrochloride bears US NLM identifiers UMLS ID C0127383 and NCI Concept Code C81132. SMILES: CC(C1CCCCC1)(C2CCC(CC2)BR)OCCN(C)C.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H26N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J1H7Y9OJV, chemically known as 1-methyl-4-(1-(2-ethoxyethyl)-1h-benzimidazo)-2-yl)(1,4)diazepane but generally known as emedastine, which bears US NIH Compound Identifier 3219. European Medicines Agency schedules Emedastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06503MIG. The term EMEDASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules emedastine in its Anatomical Therapeutic Chemical (ATC) Classification. EMEDASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule emedastine under HS 29339940 and SITC 51577. As of Q4 2014, EMEDASTINE remains the US FDA Preferred Term for this commodity. Emedastine bears US NLM identifiers UMLS ID C0064263 and NCI Concept Code C61743. SMILES: O(CCN1C(N2CCCN(CC2)C)NC2C1CCCC2)CC.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H26N4O.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42MB94QOSM, chemically known as 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1h-1,4-diazepin-1-yl)benzimidazole fumarate (1:2), but more generally known as emedastine difumarate, which bears US NIH Compound Identifier 5282485. European Medicines Agency schedules emedastine difumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06503MIG. Most nations, for tariff purposes, schedule emedastine difumarate under HS 29339940. As of Q4 2014, EMEDASTINE DIFUMARATE remains US FDA's Preferred Term for this commodity. Emedastine difumarate bears US NLM identifiers UMLS ID C0724578 and NCI Concept Code C61744. SMILES: CCOCCN1C(NC2C1CCCC2)N3CCN(CCC3)C.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H26N4O.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42MB94QOSM. European Medicines Agency schedules emedastine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01874MIG. Most nations, for tariff and trade purposes, schedule emedastine fumarate under HS 29339940 and SITC 51577. SMILES: CCOCCN1C(NC2C1CCCC2)N3CCN(CCC3)C.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a muscarinic antagonist and parasympatholytic with the molecular formula C20H28N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04QQ8SWA4U, chemically known as benzenepropanaminium, n-ethyl-n,n,alpha-trimethyl-gamma-phenyl- but generally known as emepronium, which bears US NIH Compound Identifier 34055. European Medicines Agency schedules Emepronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01875MIG. World Health Organization schedules emepronium in its Anatomical Therapeutic Chemical (ATC) Classification. EMEPRONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, EMEPRONIUM remains the US FDA Preferred Term for this commodity. SMILES: [N](C(CC(C1CCCCC1)C1CCCCC1)C)(CC)(C)C.
This classification denotes an antiprotozoal agent with the molecular formula C29H40N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X8D5EPO80M, chemically known as 2h-benzo(a)quinolizine, 3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolyl)methyl)- but generally known as emetine, which bears US NIH Compound Identifier 9426. European Medicines Agency schedules Emetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01877MIG. World Health Organization schedules emetine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule emetine under HS 29399990 and SITC 54149. As of Q4 2014, EMETINE remains the US FDA Preferred Term for this commodity. Emetine bears US NLM identifiers UMLS ID C0013974 and NCI Concept Code C81578. SMILES: O(C1CC2C3N(CC(C(C3)CC3NCCC4C3CC(OC)C(OC)C4)CC)CCC2CC1OC)C.
A hemophilia A treatment approved for people with hemophilia A with or without factor VIII inhibitors.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) CIQ9QG91PY. European Medicines Agency schedules Emilium tosilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06507MIG. Emilium tosilate generally arises in the molecular formula C12H20NO.C7H7O3S. The term EMILIUM TOSILATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, no10, 1977, list 17.) Most nations, for tariff and trade purposes, schedule emilium tosilate under HS 29239000 and SITC 51481. SMILES: CC[N+](C)(C)CC1=CC(=CC=C1)OC.CC1=CC=C(C=C1)S(=O)(=O)[O-].
This classification denotes a pyrimidine antagonist with the molecular formula C28H19FN4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I50NF4AQ2, chemically known as m-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)benzoic acid, 2-ester with 2,6-dihydroxynicotinonitrile, benzoate but generally known as emitefur, which bears US NIH Compound Identifier 65910. European Medicines Agency schedules Emitefur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06508MIG. The term EMITEFUR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). EMITEFUR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule emitefur under HS 29335995 and SITC 51576. As of Q4 2014, EMITEFUR remains the US FDA Preferred Term for this commodity. Emitefur bears US NLM identifiers UMLS ID C0053902 and NCI Concept Code C1022. SMILES: FC1CN(C(=O)N(C(=O)C2CC(CCC2)C(=O)OC2NC(OC(=O)C3CCCCC3)CCC2C#N)C1=O)COCC.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C17H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X87G8IX72O, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)- but generally known as emivirine, which bears US NIH Compound Identifier 65013. European Medicines Agency schedules Emivirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01880MIG. The term EMIVIRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule emivirine under HS 29335995 and SITC 51576. As of Q4 2014, EMIVIRINE remains the US FDA Preferred Term for this commodity. Emivirine bears US NLM identifiers UMLS ID C0248121 and NCI Concept Code C73147. SMILES: O(Cn1c(c(C(C)C)c(=O)[nH]c1=O)Cc1ccccc1)CC.
This classification denotes an antihelminthic agent with the molecular formula C60H90N6O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YZ647Y5GC9. The term EMODEPSIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46. ). Most nations schedule emodepside under HS 29349990 and SITC 51579. As of Q4 2014, EMODEPSIDE remains the US FDA Preferred Term for this commodity. Emodepside bears US NLM identifiers UMLS ID C1172566 and NCI Concept Code C90726. SMILES: CC1C(=O)N(C(C(=O)OC(C(=O)N(C(C(=O)OC(C(=O)N(C(C(=O)OC(C(=O)N(C(C(=O)O1)CC(C)C)C)CC2=CC=C(C=C2)N3CCOCC3)CC(C)C)C)C)CC(C)C)C)CC4=CC=C(C=C4)N5CCOCC5)CC(C)C)C.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M514041RF7. European Medicines Agency schedules Emopamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06510MIG. Emopamil generally arises in the molecular formula C23H30N2. The term EMOPAMIL is an International Non-Proprietary Name or INN. EMOPAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule emopamil under HS 29269095 and SITC 51484. As of Q4 2014, EMOPAMIL remains the US FDA Preferred Term for this commodity. Emopamil bears US NLM identifiers UMLS ID C0059080 and NCI Concept Code C74417. SMILES: N(CCCC(C(C)C)(c1ccccc1)C#N)(CCc1ccccc1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H17N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V93U9DH62C, chemically known as 3(2h)-pyridazinone, 4-ethoxy-2-methyl-5-morpholino- but generally known as emorfazone, which bears US NIH Compound Identifier 3221. European Medicines Agency schedules Emorfazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06511MIG. The term EMORFAZONE is an International Non-Proprietary Name. EMORFAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule emorfazone under HS 29349990 and SITC 51579. As of Q4 2014, EMORFAZONE remains the US FDA Preferred Term for this commodity. Emorfazone bears US NLM identifiers UMLS ID C0059081 and NCI Concept Code C73085. SMILES: CCOC1=C(C=NN(C1=O)C)N2CCOCC2.
Empagliflozin is a medication used together with diet and exercise to treat type 2 diabetes. It can be prescribed instead of metformin and has benefits over sulfonylureas.
This classification denotes a reverse transcriptase inhibitor and pyrimidine antagonist with the molecular formula C8H10FN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G70B4ETF4S, chemically known as 5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine but generally known as emtricitabine, which bears US NIH Compound Identifier 60877. European Medicines Agency schedules Emtricitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01882MIG. The term EMTRICITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules emtricitabine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule emtricitabine under HS 29349990 and SITC 51579. As of Q4 2014, EMTRICITABINE remains the US FDA Preferred Term for this commodity. Emtricitabine bears US NLM identifiers UMLS ID C0909839 and NCI Concept Code C47509. SMILES: S1CC(OC1CO)n1cc(F)c(nc1=O)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.
Bictegravir/emtricitabine/tenofovir alafenamide, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.
This classification denotes an anxiolytic with the molecular formula C7H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KCJ747D3R4, chemically known as 3-pentanol, 3-methyl-, carbamate (8ci)(9ci) but generally known as emylcamate, which bears US NIH Compound Identifier 6526. European Medicines Agency schedules Emylcamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06512MIG. The term EMYLCAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules emylcamate in its Anatomical Therapeutic Chemical (ATC) Classification. EMYLCAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule emylcamate under HS 29241900 and SITC 51471. As of Q4 2014, EMYLCAMATE remains the US FDA Preferred Term for this commodity. Emylcamate bears US NLM identifiers UMLS ID C0175159 and NCI Concept Code C76506. SMILES: O(C(CC)(CC)C)C(=O)N.
This classification denotes an opioid receptor agonist with the molecular formula C24H32N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KJL283326C, chemically known as 4-benzofuranacetamide, n-methyl-n-(7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-, (5r-(5alpha,7alpha,8beta))- but generally known as enadoline, which bears US NIH Compound Identifier 60768. European Medicines Agency schedules Enadoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06513MIG. The term ENADOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). ENADOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enadoline under HS 29349990 and SITC 51579. As of Q4 2014, ENADOLINE remains the US FDA Preferred Term for this commodity. Enadoline bears US NLM identifiers UMLS ID C0209582 and NCI Concept Code C80576. SMILES: O1C2(CC(N3CCCC3)C(N(C)C(=O)CC3C4C(OCC4)CCC3)CC2)CCC1.
This classification denotes an opioid receptor agonist C24H32N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 086I9HO04E, chemically known as n-methyl-n-((5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-4-benzofuranacetamide monohydrochloride, but more generally known as enadoline hydrochloride, which bears US NIH Compound Identifier 60767. Most nations, for tariff and trade purposes, schedule enadoline hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ENADOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Enadoline hydrochloride bears US NLM identifiers UMLS ID C2825260 and NCI Concept Code C80577. SMILES: CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4CCCC5C4CCO5.CL.
This classification denotes an ace inhibitor with the molecular formula C20H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69PN84IO1A, chemically known as l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl- but generally known as enalapril, which bears US NIH Compound Identifier 5362032. European Medicines Agency schedules Enalapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06514MIG. The term ENALAPRIL is an International Non-Proprietary Name. World Health Organization schedules enalapril in its Anatomical Therapeutic Chemical (ATC) Classification. ENALAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enalapril under HS 29339990 and SITC 51577. As of Q4 2014, ENALAPRIL remains the US FDA Preferred Term for this commodity. Enalapril bears US NLM identifiers UMLS ID C0014025 and NCI Concept Code C62027. SMILES: O=C(N1C(CCC1)C(=O)O)C(NC(CCc1ccccc1)C(=O)OCC)C.
This classification denotes an ace inhibitor with the molecular formula C18H24N2O5.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GV0O7ES0R3, chemically known as l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl- but generally known as enalaprilat, which bears US NIH Compound Identifier 5362032. European Medicines Agency schedules Enalaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06515MIG. ENALAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enalaprilat under HS 29339990 and SITC 51577. As of Q4 2014, ENALAPRILAT remains the US FDA Preferred Term for this commodity. Enalaprilat bears US NLM identifiers UMLS ID C0014027 and NCI Concept Code C47510. SMILES: O=C(N1C(CCC1)C(=O)O)C(NC(CCC1CCCCC1)C(=O)OCC)C.
This classification denotes an ace inhibitor with the molecular formula C18H24N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q508Q118JM, chemically known as l-proline, 1-(n-(1-carboxy-3-phenylpropyl)-l-alanyl)-, (s)-, but more generally known as enalaprilat anhydrous, which bears US NIH Compound Identifier 5362033. European Medicines Agency schedules enalaprilat anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06515MIG. Most nations, for tariff purposes, schedule enalaprilat anhydrous under HS 29339990. Enalaprilat anhydrous bears US NLM identifiers UMLS ID C0886809 and NCI Concept Code C76135. SMILES: C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2CCCCC2)C(=O)O.
This classification denotes an ace inhibitor with the molecular formula C18H24N2O5.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GV0O7ES0R3, chemically known as l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl- but more generally known as enalaprilat, which bears US NIH Compound Identifier 5362032. European Medicines Agency schedules Enalaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06515MIG. ENALAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule enalaprilat dihydrate under HS 29339990. SMILES: C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2CCCCC2)C(=O)O.O.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an ace inhibitor with the molecular formula C20H28N2O5.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9O25354EPJ, chemically known as l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl- but more generally known as enalapril maleate, which bears US NIH Compound Identifier 5362032. European Medicines Agency schedules Enalapril maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01884MIG. Most nations, for tariff and trade purposes, schedule enalapril maleate under HS 29339990 and SITC 51577. As of Q4 2014, ENALAPRIL MALEATE remains US FDA's Preferred Term for this commodity. Enalapril maleate bears US NLM identifiers UMLS ID C0600128 and NCI Concept Code C468. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antihypertensive agent with the molecular formula C35H56N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0U7YZ42Z47, chemically known as l-histidinamide, n-(3-amino-3-methyl-1-oxobutyl)-o-methyl-l-tyrosyl-n-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-, (1s-(1r*,2s*,3r*))- but generally known as enalkiren, which bears US NIH Compound Identifier 60594. European Medicines Agency schedules Enalkiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06516MIG. The term ENALKIREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). ENALKIREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enalkiren under HS 29332990 and SITC 51573. As of Q4 2014, ENALKIREN remains the US FDA Preferred Term for this commodity. Enalkiren bears US NLM identifiers UMLS ID C0059089 and NCI Concept Code C87729. SMILES: OC(C(NC(=O)C(NC(=O)C(NC(=O)CC(N)(C)C)Cc1ccc(OC)cc1)Cc1[nH]cnc1)CC1CCCCC1)C(O)CC(C)C.
This classification denotes an antihypertensive agent with the molecular formula C20H28N2O5.C4H4O4 , a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9O25354EPJ, chemically known as (Z)-but-2-enedioicacid;(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid, which bears US NIH Compound Identifier 5388961. SMILES: CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O.C(=CC(=O)O)C(=O)O.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C22H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) SY3J0147NB, chemically known as benzamide, 4-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, (+-)- but more generally known as encainide, which bears US NIH Compound Identifier 48033. European Medicines Agency schedules Encainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06519MIG. The term ENCAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules encainide in its Anatomical Therapeutic Chemical (ATC) Classification. ENCAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule encainide under HS 29333999 and SITC 51574. As of Q4 2014, ENCAINIDE remains US FDA's Preferred Term for this commodity. Encainide bears US NLM identifiers UMLS ID C0085251 and NCI Concept Code C65511. SMILES: O=C(NC1C(C(CN2CCCCC2)C)CCCC1)C1CCC(OC)CC1.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C22H28N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CH7J36N9S, chemically known as benzamide, 4-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, monohydrochloride, (+-)- but more generally known as encainide hydrochloride, which bears US NIH Compound Identifier 48040. European Medicines Agency schedules Encainide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01885MIG. Most nations, for tariff and trade purposes, schedule encainide hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, ENCAINIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Encainide hydrochloride bears US NLM identifiers UMLS ID C0916906 and NCI Concept Code C75131. SMILES: CN1CCCCC1CCC2CCCCC2NC(=O)C3CCC(CC3)OC.CL.
This clasification denotes vaccines to treat inflammation of brain parenchymal tissue as a result of viral infection, typically primary or secondary manifestation of togaviridae infections; herpesviridae infections; adenoviridae infections; flaviviridae infections; bunyaviridae infections; picornaviridae infections; paramyxoviridae infections; orthomyxoviridae infections; retroviridae infections; and arenaviridae infections.
This classification denotes an anxiolytic with the molecular formula C23H32N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, L6X660925G chemically known as (+/-)-1-(3-(3,4,5-trimethoxyphenoxy)-2-hydroxypropyl)-4-(2-methoxyphenyl)piperazine but generally known as enciprazine, which bears US NIH Compound Identifier 50222. European Medicines Agency schedules Enciprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06520MIG. The term ENCIPRAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20. ). Most nations schedule enciprazine under HS 29335995 and SITC 51576. As of Q4 2014, ENCIPRAZINE remains the US FDA Preferred Term for this commodity. Enciprazine bears US NLM identifiers UMLS ID C0059095 and NCI Concept Code C73209. SMILES: COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC(=C(C(=C3)OC)OC)OC)O.
This classification denotes an anxiolytic with the molecular formula C23H32N2O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YTO3CZ93HM, chemically known as 1-piperazineethanol, 4-(2-methoxyphenyl)-.alpha.-((3,4,5-trimethoxyphenoxy)methyl)-, dihydrochloride, (+/-)-, but more generally known as enciprazine dihydrochloride, which bears US NIH Compound Identifier 50221. European Medicines Agency schedules enciprazine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06520MIG. Most nations, for tariff purposes, schedule enciprazine dihydrochloride under HS 29335995. SMILES: COC1CCCCC1N2CCN(CC2)CC(COC3CC(C(C(C3)OC)OC)OC)O.CL.CL.
This classification denotes an anxiolytic with the molecular formula C23H32N2O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YTO3CZ93HM, chemically known as 1-piperazineethanol, 4-(2-methoxyphenyl)-alpha-((3,4,5-trimethoxyphenoxy)methyl)-, dihydrochloride, (+-)- but more generally known as enciprazine hydrochloride, which bears US NIH Compound Identifier 50221. Most nations, for tariff and trade purposes, schedule enciprazine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ENCIPRAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Enciprazine hydrochloride bears US NLM identifiers UMLS ID C0957736 and NCI Concept Code C87666. SMILES: COC1CCCCC1N2CCN(CC2)CC(COC3CC(C(C(C3)OC)OC)OC)O.CL.CL.
This classification denotes an antiestrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6D2UI4FLS. European Medicines Agency schedules Enclomifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06521MIG. Enclomifene generally arises in the molecular formula C26H28CLNO. The term ENCLOMIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) ENCLOMIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enclomifene under HS 29221980 and SITC 51461. SMILES: CL/C(=C(/C1CCC(OCCN(CC)CC)CC1)C1CCCCC1)C1CCCCC1.
This classification denotes an antidepressant agent with the molecular formula C13H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26991ZCA4G, chemically known as cyclopropanecarbamic acid, n-benzyl-, ethyl ester but generally known as encyprate, which bears US NIH Compound Identifier 17298. European Medicines Agency schedules Encyprate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06522MIG. The term ENCYPRATE is an International Non-Proprietary Name. ENCYPRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule encyprate under HS 29242995 and SITC 51479. As of Q4 2014, ENCYPRATE remains the US FDA Preferred Term for this commodity. Encyprate bears US NLM identifiers UMLS ID C2981302 and NCI Concept Code C87612. SMILES: O(C(=O)N(C1CC1)Cc1ccccc1)CC.
This classification denotes a vasodilating agent with the molecular formula C14H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L44741F05P, chemically known as 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido(4,3-c)pyridazin but generally known as endralazine, which bears US NIH Compound Identifier 47608. European Medicines Agency schedules Endralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06525MIG. World Health Organization schedules endralazine in its Anatomical Therapeutic Chemical (ATC) Classification. ENDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule endralazine under HS 29339990 and SITC 51577. As of Q4 2014, ENDRALAZINE remains the US FDA Preferred Term for this commodity. Endralazine bears US NLM identifiers UMLS ID C0116074 and NCI Concept Code C77151. SMILES: O=C(N1CCc2nnc(NN)cc2C1)c1ccccc1.
This classification denotes a vasodilating agent with the molecular formula C14H15N5O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 333M5986I5, chemically known as 6-benzoyl-5,6,7,8-tetrahydropyrido(4,3-c)pyridazin-3(2h)-one hydrazone monomethanesulfonate but more generally known as endralazine mesilate, which bears US NIH Compound Identifier 47607. European Medicines Agency schedules Endralazine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01886MIG. Most nations, for tariff and trade purposes, schedule endralazine mesylate under HS 29339990. As of Q4 2014, ENDRALAZINE MESYLATE remains US FDA's Preferred Term for this commodity. Endralazine mesylate bears US NLM identifiers UMLS ID C2699995 and NCI Concept Code C77075. SMILES: CS(=O)(=O)O.C1CCC(CC1)C(=O)N2CCC3C(C/C(=N/N)/[NH]N3)C2.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JMM46GA2V. European Medicines Agency schedules Enefexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06527MIG. Enefexine generally arises in the molecular formula C13H19N. The term ENEFEXINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) ENEFEXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enefexine under HS 29333999 and SITC 51574. As of Q4 2014, ENEFEXINE remains the US FDA Preferred Term for this commodity. Enefexine bears US NLM identifiers UMLS ID C2348443 and NCI Concept Code C72758. SMILES: N1CCC(CC1)c1ccc(cc1)CC.
This classification denotes an anabolic steroid with the molecular formula C20H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LNS3MVH7NV, chemically known as 4,17beta-dihydroxy-17-methyl-androsta-1,4-dien-3-one, but generally known as enestebol, which bears US NIH Compound Identifier 208919. European Medicines Agency schedules Enestebol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06528MIG. The term ENESTEBOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). ENESTEBOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enestebol under HS 29372900 and SITC 54153. As of Q4 2014, ENESTEBOL remains the US FDA Preferred Term for this commodity. Enestebol bears US NLM identifiers UMLS ID C2825600 and NCI Concept Code C81377. SMILES: OC1(C2(C(C3C(CC2)C2(C(=C(O)C(=O)C=C2)CC3)C)CC1)C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05KO5G76R2, chemically known as benzoic acid, 2-(phenethylamino)- but generally known as enfenamic acid, which bears US NIH Compound Identifier 31635. European Medicines Agency schedules Enfenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06529MIG. The term ENFENAMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). Most nations schedule enfenamic acid under HS 29224995 and SITC 51465. As of Q4 2014, ENFENAMIC ACID remains the US FDA Preferred Term for this commodity. Enfenamic acid bears US NLM identifiers UMLS ID C0116077 and NCI Concept Code C72088. SMILES: C1=CC=C(C=C1)CCNC2=CC=CC=C2C(=O)O.
This classification denotes an anesthetic agent with the molecular formula C3H2ClF5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91I69L5AY5, chemically known as 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane but generally known as enflurane, which bears US NIH Compound Identifier 3226. European Medicines Agency schedules Enflurane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06530MIG. The term ENFLURANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules enflurane in its Anatomical Therapeutic Chemical (ATC) Classification. ENFLURANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enflurane under HS 29091990 and SITC 51616. As of Q4 2014, ENFLURANE remains the US FDA Preferred Term for this commodity. Enflurane bears US NLM identifiers UMLS ID C0014277 and NCI Concept Code C47511. SMILES: CLC(F)C(F)(F)OC(F)F.
This classification denotes an anti-hiv agent with the molecular formula C204H301N51O64, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19OWO1T3ZE, chemically known as l-phenylalaninamide, n-acetyl-l-tyrosyl-l-threonyl-l-seryl-l-leucyl-l-isoleucyl-l-histidyl-l-seryl-l-leucyl-l-isoleucyl-l-alpha-glutamyl-l-alpha-glutamyl-l-seryl-l-glutaminyl-l-asparaginyl-l-glutaminyl-l-glutaminyl-l-alpha-glutamyl-l-lysyl-l-asparaginyl-l-alpha-glutamyl-l-glutaminyl-l-alpha-glutamyl-l-leucyl-l-leucyl-l-alpha-glutamyl-l-leucyl-l-alpha-aspartyl-l-lysyl-l-tryptophyl-l-alanyl-l-seryl-l-leucyl-l-tryptophyl-l-asparaginyl-l-tryptophyl- but generally known as enfuvirtide, which bears US NIH Compound Identifier 16130199. European Medicines Agency schedules Enfuvirtide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12496MIG. The term ENFUVIRTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules enfuvirtide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule enfuvirtide under HS 29332990 and SITC 51573. As of Q4 2014, ENFUVIRTIDE remains the US FDA Preferred Term for this commodity. Enfuvirtide bears US NLM identifiers UMLS ID C0537439 and NCI Concept Code C2105. SMILES: O=C(NC(C(CC)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(C(=O)NC(CCC(=O)N)C(=O)NC(C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(Cc1c2c([nH]c1)cccc2)C(=O)NC(C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(Cc1c2c([nH]c1)cccc2)C(=O)NC(CC(=O)N)C(=O)NC(Cc1c2c([nH]c1)cccc2)C(=O)NC(Cc1ccccc1)C(=O)N)CO)C)CC(=O)O)CCC(=O)O)CCC(=O)N)CCC(=O)O)CC(=O)N)CCC(=O)O)CCC(=O)N)CC(=O)N)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C)Cc1ccc(O)cc1)C(O)C)CO)CC(C)C)C(CC)C)Cc1[nH]cnc1)CO)CC(C)C.
This classification denotes an anti-lipidemic agent with the molecular formula C24H24ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M469UFX48N, chemically known as butanoic acid, 2-(4-((4-chlorophenyl)methyl)phenoxy)-2-methyl-, 3-pyridinylmethyl ester, (+-)- but generally known as eniclobrate, which bears US NIH Compound Identifier 43387. European Medicines Agency schedules Eniclobrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06532MIG. The term ENICLOBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). ENICLOBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eniclobrate under HS 29333999 and SITC 51574. As of Q4 2014, ENICLOBRATE remains the US FDA Preferred Term for this commodity. Eniclobrate bears US NLM identifiers UMLS ID C0059300 and NCI Concept Code C72992. SMILES: Clc1ccc(Cc2ccc(OC(CC)(C)C(=O)OCc3cccnc3)cc2)cc1.
This classification denotes an antifungal agent with the molecular formula C14H14Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K0NOF3XQ6, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-(2-propenyloxy)ethyl)- (9ci) but generally known as enilconazole, which bears US NIH Compound Identifier 37175. European Medicines Agency schedules Enilconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06533MIG. The term ENILCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). ENILCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enilconazole under HS 29332990 and SITC 51573. As of Q4 2014, ENILCONAZOLE remains the US FDA Preferred Term for this commodity. Enilconazole bears US NLM identifiers UMLS ID C0063371 and NCI Concept Code C81505. SMILES: CLC1C(C(OCC=C)CN2CCNC2)CCC(CL)C1.
This classification denotes an antifungal agent with the molecular formula C14H14Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K0NOF3XQ6, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-(2-propenyloxy)ethyl)- (9ci) but more generally known as enilconazole, which bears US NIH Compound Identifier 37175. European Medicines Agency schedules Enilconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06533MIG. The term ENILCONAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). ENILCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule enilconazole for veterinary use under HS 29332990. SMILES: C=CCOC(CN1CCNC1)C2CCC(CC2CL)CL.
This classification denotes an antifungal agent with the molecular formula C14H14Cl2N2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2BD9F4H2H, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-(2-propen-1-yloxy)ethyl)-, sulfate (1:1), but more generally known as enilconazole sulfate, which bears US NIH Compound Identifier 173636. European Medicines Agency schedules enilconazole sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06533MIG. Most nations, for tariff purposes, schedule enilconazole sulfate under HS 29332990. SMILES: C=CCOC(CN1CCNC1)C2CCC(CC2CL)CL.OS(=O)(=O)O.
This classification denotes a pyrimidine antagonist and dihydropyrimidine dehydrogenase inhibitor with the molecular formula C6H4N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2E2W0W5XIU, chemically known as 2,4(1h,3h)-pyrimidinedione, 5-ethynyl- but generally known as eniluracil, which bears US NIH Compound Identifier 43157. European Medicines Agency schedules Eniluracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13674MIG. The term ENILURACIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). ENILURACIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eniluracil under HS 29335995 and SITC 51576. As of Q4 2014, ENILURACIL remains the US FDA Preferred Term for this commodity. Eniluracil bears US NLM identifiers UMLS ID C0098361 and NCI Concept Code C1773. SMILES: O=C1[NH]C(=O)[NH]CC1C#C.
This classification denotes a platinum compound with the molecular formula C7H16N2O.C6H6O4.Pt, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7HT2IO79H, chemically known as platinum, (1,1-cyclobutanedicarboxylato(2-))(tetrahydro-4h-pyran-4,4-dimethanamine-n,n)-, (sp-4-2)- but more generally known as enloplatin, which bears US NIH Compound Identifier 68737. European Medicines Agency schedules Enloplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06536MIG. The term ENLOPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Enoplatin bears NCI CUID C95323 and UMLS ID C0165431. ENLOPLATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cisplatin under HS 28439000 and SITC 52432. SMILES: C1CC(C1)(C(=O)[O-])C(=O)[O-].C1COCCC1(CN)CN.[Pt+2].
This classification denotes a pyrimidine antagonist with the molecular formula C31H55N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9YVR68W306, chemically known as docosanamide,nucleoside deriv but generally known as enocitabine, which bears US NIH Compound Identifier 3228. European Medicines Agency schedules Enocitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06537MIG. The term ENOCITABINE is an International Non-Proprietary Name. ENOCITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enocitabine under HS 29349990 and SITC 51579. As of Q4 2014, ENOCITABINE remains the US FDA Preferred Term for this commodity. Enocitabine bears US NLM identifiers UMLS ID C0059364 and NCI Concept Code C1082. SMILES: O1C(C(O)C(O)C1N1CCC(NC1=O)NC(=O)CCCCCCCCCCCCCCCCCCCCC)CO.
This classification denotes an anti-asthmatic agent with the molecular formula C16H15FO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3T93TS0430, chemically known as 2,6-dimethyl-4-(2-(4-fluorophenyl)ethenyl)phenol but generally known as enofelast, which bears US NIH Compound Identifier 6439222. European Medicines Agency schedules Enofelast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06538MIG. The term ENOFELAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). ENOFELAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enofelast under HS 29081900 and SITC 51244. As of Q4 2014, ENOFELAST remains the US FDA Preferred Term for this commodity. Enofelast bears US NLM identifiers UMLS ID C0091793 and NCI Concept Code C74134. SMILES: FC1CCC(/C=C/C2CC(C(O)C(C2)C)C)CC1.
This classification denotes an anti-infective agent with the molecular formula C15H17FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 325OGW249P, chemically known as 1,8-naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro- 4-oxo-7-piperazinyl but more generally known as enoxacin, which bears US NIH Compound Identifier 3229. European Medicines Agency schedules Enoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06540MIG. The term ENOXACIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 40, No. 6, 1986, List 26). The World Health Organization schedules enoxacin in its Anatomical Therapeutic Chemical (ATC) Classification. ENOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: FC1C(N2CCNCC2)NC2N(CC)CC(C(=O)C2C1)C(=O)O.
This classification denotes an anti-infective agent 2C15H17FN4O3.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I9CD31N8WB, chemically known as 1,8-naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrate (2:3), but more generally known as enoxacin sesquihydrate, which bears US NIH Compound Identifier 3229. European Medicines Agency schedules SUB13675MIGin its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13675MIG. Most nations schedule enoxacin sesquihydrate under HS 29335995 and SITC 51576. As of Q4 2014, ENOXACIN SESQUIHYDRATE remains the US FDA Preferred Term for this commodity. SMILES: CCN1CC(C(=O)C2C1NC(C(C2)F)N3CCNCC3)C(=O)O.CCN1CC(C(=O)C2C1NC(C(C2)F)N3CCNCC3)C(=O)O.O.O.O.
This classification denotes an anti-asthmatic agent with the molecular formula C13H10N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08703R750L, chemically known as (4-(1,4-benzodioxan-6-yl)-2-thiazolyl)oxamic acid. but more generally known as enoxamast, which bears US NIH Compound Identifier 194595. European Medicines Agency schedules Enoxamast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06541MIG. The term ENOXAMAST is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). ENOXAMAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1CC(NC1NC(=O)C(=O)O)C1CC2OCCOC2CC1.
This classification denotes a low molecular weight heparin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E47C0NF7LV. European Medicines Agency schedules Enoxaparin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21316. Enoxaparin generally arises in the molecular formula (C14H18NO11)N.C14H18NO11.C12H17NO12S.(C12H16NO13S)N.C12H15NO13S.NA.H.5HO3S. The term ENOXAPARIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) ENOXAPARIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ENOXAPARIN remains the US FDA Preferred Term for this commodity. Enoxaparin bears US NLM identifiers UMLS ID C0206460 and NCI Concept Code C1452. SMILES: CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H12N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7Z4ITI7L7, chemically known as 1,3-dihydro-4-methyl-5-(4-methylthiobenzoyl)-2h-imidazol-2-one but generally known as enoximone, which bears US NIH Compound Identifier 53708. European Medicines Agency schedules Enoximone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06542MIG. The term ENOXIMONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules enoximone in its Anatomical Therapeutic Chemical (ATC) Classification. ENOXIMONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enoximone under HS 29332990 and SITC 51573. As of Q4 2014, ENOXIMONE remains the US FDA Preferred Term for this commodity. Enoximone bears US NLM identifiers UMLS ID C0116190 and NCI Concept Code C87375. SMILES: CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC.
This classification denotes an anxiolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78G92X9EH7. European Medicines Agency schedules Enpiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06544MIG. Enpiprazole generally arises in the molecular formula C16H21CLN4. The term ENPIPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) ENPIPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enpiprazole under HS 29335995 and SITC 51576. As of Q4 2014, ENPIPRAZOLE remains the US FDA Preferred Term for this commodity. Enpiprazole bears US NLM identifiers UMLS ID C2348449 and NCI Concept Code C73208. SMILES: CLC1C(N2CCN(CC2)CCC2CN(NC2)C)CCCC1.
This classification denotes an anxiolytic C16H21ClN4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9R6Z7M2000, chemically known as piperazine, 1-(2-chlorophenyl)-4-(2-(1-methyl-1h-pyrazol-4-yl)ethyl)-, hydrochloride (1:2), but more generally known as enpiprazole hydrochloride, which bears US NIH Compound Identifier 71586941. European Medicines Agency schedules Enpiprazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01892MIG. Most nations, for tariff and trade purposes, schedule enpiprazole hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ENPIPRAZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC(CN1)CCN2CCN(CC2)C3CCCCC3CL.CL.CL.
This classification denotes an antimalarial agent with the molecular formula C19H18F6N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8M7Y72EP9K chemically known as 4-pyridinemethanol, .alpha.-(2-piperidinyl)-2-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)-, (r*,r*)-(+/-)- but generally known as enpiroline, which bears US NIH Compound Identifier 3033333. European Medicines Agency schedules Enpiroline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06545MIG. The term ENPIROLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25). Most nations schedule enpiroline under HS 29333999 and SITC 51574. As of Q4 2014, ENPIROLINE remains the US FDA Preferred Term for this commodity. Enpiroline bears US NLM identifiers UMLS ID C0059370 and NCI Concept Code C75267. SMILES: C1CCNC(C1)C(C2=CC(=NC(=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)O.
This classification denotes a nitrogen mustard compound with the molecular formula C22H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HBS2850E4H, chemically known as 1,1-diphenyl-2-propynyl-n-cyclohexylcarbamate but more generally known as enpromate, which bears US NIH Compound Identifier 24912. European Medicines Agency schedules Enpromate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06548MIG. The term ENPROMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). ENPROMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule enpromate under HS 29242995 and SITC 51479. As of Q4 2014, ENPROMATE remains US FDA's Preferred Term for this commodity. Enpromate bears US NLM identifiers UMLS ID C0050514 and NCI Concept Code C83689. SMILES: O(C(=O)NC1CCCCC1)C(C1CCCCC1)(C1CCCCC1)C#C.
This classification denotes an anti-ulcer agents and prostaglandins e, synthetic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4IP5Z9DAU. European Medicines Agency schedules Enprostil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06549MIG. Enprostil generally arises in the molecular formula C23H28O6. The term ENPROSTIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) ENPROSTIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enprostil under HS 29375000 and SITC 54156. As of Q4 2014, ENPROSTIL remains the US FDA Preferred Term for this commodity. SMILES: OC1C(C(C(=O)C1)CC=C=CCCC(=O)OC)/C=C/C(O)COC1CCCCC1.
This classification denotes a quinolone antibiotic with the molecular formula C19H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DX3XEK1BN, chemically known as 1,4-dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid but generally known as enrofloxacin, which bears US NIH Compound Identifier 71188. European Medicines Agency schedules Enrofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06550MIG. The term ENROFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ENROFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enrofloxacin under HS 29335995 and SITC 51576. As of Q4 2014, ENROFLOXACIN remains the US FDA Preferred Term for this commodity. Enrofloxacin bears US NLM identifiers UMLS ID C0059374 and NCI Concept Code C72660. SMILES: FC1C(N2CCN(CC2)CC)CC2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes an antiparkinsonian agent with the molecular formula C14H15N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4975G9NM6T, chemically known as 2-propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl- but generally known as entacapone, which bears US NIH Compound Identifier 5281081. European Medicines Agency schedules Entacapone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06552MIG. The term ENTACAPONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules entacapone in its Anatomical Therapeutic Chemical (ATC) Classification. ENTACAPONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule entacapone under HS 29269095 and SITC 51484. As of Q4 2014, ENTACAPONE remains the US FDA Preferred Term for this commodity. Entacapone bears US NLM identifiers UMLS ID C0876730 and NCI Concept Code C61746. SMILES: O=C(N(CC)CC)/C(=C/C1CC([N](=O)O)C(O)C(O)C1)C#N.
This classification denotes an antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5968Y6H45M. European Medicines Agency schedules Entecavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21468. Entecavir generally arises in the molecular formula C12H15N5O3.H2O. The term ENTECAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule entecavir under HS 29335995 and SITC 51576. As of Q4 2014, ENTECAVIR remains the US FDA Preferred Term for this commodity. Entecavir bears US NLM identifiers UMLS ID C0971023 and NCI Concept Code C65513. SMILES: C=C1C(CC(C1CO)O)N2C=NC3=C2NC(=NC3=O)N.
This classification denotes an antiviral agent with the molecular formula C12H15N5O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5968Y6H45M, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-((1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)- monohydrate, but more generally known as entecavir hydrate, which bears US NIH Compound Identifier 170342. European Medicines Agency schedules entecavir hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21468. Most nations, for tariff purposes, schedule entecavir hydrate under HS 29335995. SMILES: C=C1[C@H](C[C@@H]([C@H]1CO)O)N2CNC3C2NC([NH]C3=O)N.O.
Enterotoxemia vaccine produced specifically for goats is available commercially.
This classification denotes an antiviral agent with the molecular formula C19H21N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Q79A81839, chemically known as 1h-benzimidazol-2-amine, 1-((1-methylethyl)sulfonyl)-6-(1-phenyl-1-propenyl)-, (e)- but generally known as enviradene, which bears US NIH Compound Identifier 6435398. European Medicines Agency schedules Enviradene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06555MIG. The term ENVIRADENE is an International Non-Proprietary Name. ENVIRADENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enviradene under HS 29339990 and SITC 51577. As of Q4 2014, ENVIRADENE remains the US FDA Preferred Term for this commodity. Enviradene bears US NLM identifiers UMLS ID C0116243 and NCI Concept Code C65514. SMILES: S(=O)(=O)(N1C2C(NC1N)CCC(C2)/C(=C/C)C1CCCCC1)C(C)C.
This classification denotes an antiviral agent with the molecular formula C17H18N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 133013L556, chemically known as 1h-benzimidazol-2-amine, 6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-, (e)- but generally known as enviroxime, which bears US NIH Compound Identifier 5748733. European Medicines Agency schedules Enviroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06556MIG. The term ENVIROXIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). ENVIROXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enviroxime under HS 29350090 and SITC 51580. As of Q4 2014, ENVIROXIME remains the US FDA Preferred Term for this commodity. Enviroxime bears US NLM identifiers UMLS ID C0059396 and NCI Concept Code C83691. SMILES: S(=O)(=O)(N1C2C(NC1N)CCC(C2)/C(=N/O)C1CCCCC1)C(C)C.
An androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
This classification denotes an aldose reductase inhibitor with the molecular formula C15H13NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 424DV0807X, chemically known as 5-((z,e)-beta-methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid but generally known as epalrestat, which bears US NIH Compound Identifier 1549120. European Medicines Agency schedules Epalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06557MIG. The term EPALRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). EPALRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epalrestat under HS 29341000 and SITC 51579. As of Q4 2014, EPALRESTAT remains the US FDA Preferred Term for this commodity. Epalrestat bears US NLM identifiers UMLS ID C0095278 and NCI Concept Code C72762. SMILES: S1/C(=C\C(=C\C2CCCCC2)C)C(=O)N(CC(=O)O)C1=S.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H23N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9KGC55KP6A, chemically known as benzeneacetamide, n-(2-((3-(2-cyanophenoxy)-2-hydroxypropyl)amino)ethyl)-4-hydroxy- but generally known as epanolol, which bears US NIH Compound Identifier 72014. European Medicines Agency schedules Epanolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06558MIG. The term EPANOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules epanolol in its Anatomical Therapeutic Chemical (ATC) Classification. EPANOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epanolol under HS 29269095 and SITC 51484. As of Q4 2014, EPANOLOL remains the US FDA Preferred Term for this commodity. Epanolol bears US NLM identifiers UMLS ID C0116294 and NCI Concept Code C72616. SMILES: OC(CNCCNC(=O)CC1CCC(O)CC1)COC1C(CCCC1)C#N.
This classification denotes an antibiotic with the molecular formula C18H23FN4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C460ZSU1OW, chemically known as acetamide, n-((3-(3-fluoro-4-(4-(hydroxyacetyl)-1-piperazynyl)phenyl)- 2-oxo-5-oxazolidinyl)methyl)-, (s)- but generally known as eperezolid, which bears US NIH Compound Identifier 73214. European Medicines Agency schedules Eperezolid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06559MIG. The term EPEREZOLID is an International Non-Proprietary Name. EPEREZOLID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eperezolid under HS 29349990 and SITC 51579. As of Q4 2014, EPEREZOLID remains the US FDA Preferred Term for this commodity. Eperezolid bears US NLM identifiers UMLS ID C0663242 and NCI Concept Code C81444. SMILES: FC1C(N2CCN(CC2)C(=O)CO)CCC(N2CC(OC2=O)CNC(=O)C)C1.
This classification denotes an anticholinergic agent with the molecular formula C17H25NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U38O8U7P6X, chemically known as 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-, hydrochloride but more generally known as eperisone hydrochloride, which bears US NIH Compound Identifier 123698. European Medicines Agency schedules Eperisone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01900MIG. Most nations, for tariff and trade purposes, schedule eperisone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, EPERISONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Eperisone hydrochloride bears US NLM NCI C83693. SMILES: CCC1CCC(CC1)C(=O)C(C)CN2CCCCC2.CL.
This classification denotes an anticholinergic agent with the molecular formulas C17H25NO and C17H25NO.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 2M2P0551D3 and U38O8U7P6X, the base compound being chemically known as 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)- but generally known as eperisone, which bears US NIH Compound Identifier 3236. European Medicines Agency schedules Eperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB06560MIG and SUB01900MIG. The term EPERISONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules eperisone in its Anatomical Therapeutic Chemical (ATC) Classification. EPERISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eperisone and its salts under HS 29333999 and SITC 51574. As of Q4 2014, EPERISONE remains the US FDA Preferred Term for this commodity. Eperisone bears US NLM NCI C83692 and C83693. SMILES: O=C(C(CN1CCCCC1)C)C1CCC(CC1)CC (base) or CCc1ccc(cc1)C(=O)C(C)CN2CCCCC2.Cl (hydrochloride).
This classification denotes a pyrimidine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3G05PH9FAS. European Medicines Agency schedules Epervudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06561MIG. Epervudine generally arises in the molecular formula C12H18N2O5. The term EPERVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) EPERVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epervudine under HS 29349990 and SITC 51579. As of Q4 2014, EPERVUDINE remains the US FDA Preferred Term for this commodity. Epervudine bears US NLM identifiers UMLS ID C2700002 and NCI Concept Code C76916. SMILES: CC(C)C1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O.
This classification is an herbal drug, a product which US FDA regulates as an active or moiety under Unique Ingredient Identifier 51QBA3IQ91, and which bears Integrated Taxonomic Information System Serial Number 505858. European Medicines Agency schedules Safrole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13682MIG. Under the World Customs Organization Harmonised System, ephedra is scheduled in 13021920. The United Nations International Drug Control Programme's Technical Services Branch, in accordance with and support of the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, and Article 12 thereof, in conjunction with scientific findings Clandestine Manufacture of Substances under International Control, has determined, based on collateral research in Canada, Japan, and the United States, that this commodity (ephedra) is a precursor in manufacture of Amfetamine and Metamfetamine (See Scientific and Technical Note SCITEC/11). For US verification, see US Drug Enforcement Administration's Ephedra's Role as a Precursor in the Clandestine Manufacture of Methamphetamine (DEA Western Laboratory), ISSN 0022-1198 and Federal Register Volume 62, Number 107 (Wednesday, June 4, 1997), Dietary Supplements Containing Ephedrine Alkaloids (Section 1.A, Characteristics of Ephedrine Alkaloids). Also see Health Canada Monograph 268 and restatement of Canada's Precursor Control Regulations (PCR) (JC 2010) and ephedra's relevance thereto. Under EU regulations, ephedra is governed by Regulation (EC) No 273/2004 (rules for the monitoring of trade between the Community and third countries in drug precursors) and Official Journal L 022, 26/01/2005 P. 0001-0010. Under US regulations, ephedra is governed by Title 21 Code of Federal Regulations, §§ 1309, 1310.02, and 1313. Under Canadian regulations, ephedra is governed by Controlled Drugs and Substances Act subsection 55(1) (S.C. 1996, c. 19) and Precursor Control Regulations (SOR/2002-359), P.C. 2002-1615 2002-09-24.
This classification denotes an adrenergic agent with the molecular formula C10H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GN83C131XS, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but generally known as ephedrine, which bears US NIH Compound Identifier 5032. European Medicines Agency schedules Ephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13683MIG. World Health Organization schedules ephedrine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ephedrine under HS 29394100 and SITC 54144. As of Q4 2014, EPHEDRINE remains the US FDA Preferred Term for this commodity. Ephedrine bears US NLM identifiers UMLS ID C0014479 and NCI Concept Code C472. SMILES: CC(C(C1=CC=CC=C1)O)NC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
Antiasthmatic and expectorant
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE102. This VA Drug Class (RE102) classifies this compound as belonging to the group BRONCHODILATORS, SYMPATHOMIMETIC, INHALATION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) DZY7AR1B0U. European Medicines Agency schedules Epicainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06562MIG. Epicainide generally arises in the molecular formula C21H26N2O2. The term EPICAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, list 19.) EPICAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule epicainide under HS 29339990 and SITC 51577. As of Q4 2014, EPICAINIDE remains US FDA's Preferred Term for this commodity. Epicainide bears US NLM identifiers UMLS ID C0638068 and NCI Concept Code C72580. SMILES: OC(C(=O)NCC1N(CCC1)CC)(C1CCCCC1)C1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C16H21N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3LU1L73C8Y, chemically known as 6-(d-2-amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as epicillin, which bears US NIH Compound Identifier 71392. European Medicines Agency schedules Epicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06563MIG. The term EPICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules epicillin in its Anatomical Therapeutic Chemical (ATC) Classification. EPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epicillin under HS 29411090 and SITC 54131. As of Q4 2014, EPICILLIN remains the US FDA Preferred Term for this commodity. Epicillin bears US NLM identifiers UMLS ID C0059424 and NCI Concept Code C80590. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(N)C1=CCC=CC1.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C32H43N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M64643B5U, chemically known as 9,10alpha-dihydro-13-epi-beta-ergocryptine but generally known as epicriptine, which bears US NIH Compound Identifier 65667. European Medicines Agency schedules Epicriptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06564MIG. The term EPICRIPTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). EPICRIPTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epicriptine under HS 29396900 and SITC 54146. As of Q4 2014, EPICRIPTINE remains the US FDA Preferred Term for this commodity. Epicriptine bears US NLM identifiers UMLS ID C0304433 and NCI Concept Code C75934. SMILES: O1C2(O)N(C(C(=O)N3C2CCC3)C(CC)C)C(=O)C1(NC(=O)C1CC2C(N(C1)C)CC1C3C2CCCC3[NH]C1)C(C)C.
This classification denotes a steroidal estrogen with the molecular formula C19H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IVE3SDZ38, chemically known as 3-methoxyestra-1,3,5(10)-triene-16alpha,17alpha-diol but generally known as epimestrol, which bears US NIH Compound Identifier 23434. European Medicines Agency schedules Epimestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06566MIG. The term EPIMESTROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules epimestrol in its Anatomical Therapeutic Chemical (ATC) Classification. EPIMESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epimestrol under HS 29372300 and SITC 54153. As of Q4 2014, EPIMESTROL remains the US FDA Preferred Term for this commodity. Epimestrol bears US NLM identifiers UMLS ID C0014561 and NCI Concept Code C80783. SMILES: OC1C2(C(C3C(CC2)C2C(CC3)CC(OC)CC2)CC1O)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q13WX941EF, chemically known as 3-amino-9,13b-dihydro-1h-dibenz(c,f)imidazo(1,5-a)azepine but generally known as epinastine, which bears US NIH Compound Identifier 3241. European Medicines Agency schedules Epinastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06567MIG. The term EPINASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules epinastine in its Anatomical Therapeutic Chemical (ATC) Classification. EPINASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epinastine under HS 29339930 and SITC 51577. As of Q4 2014, EPINASTINE remains the US FDA Preferred Term for this commodity. Epinastine bears US NLM identifiers UMLS ID C0078442 and NCI Concept Code C65515. SMILES: N12C(C3C(CC4C1CCCC4)CCCC3)CN=C2N.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H15N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GFM415S5XL, chemically known as 9,13b-dihydro-1h-dibenz(c,f)imidazo(1,5-a)azepin-3-amine hydrochloride but more generally known as epinastine hydrochloride, which bears US NIH Compound Identifier 157313. European Medicines Agency schedules Epinastine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01910MIG. Most nations, for tariff and trade purposes, schedule epinastine hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, EPINASTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Epinastine hydrochloride bears US NLM identifiers UMLS ID C1321612 and NCI Concept Code C47512. SMILES: C1CCC2C(C1)CC3CCCCC3N4C2CN=C4N.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP105. This VA Drug Class (OP105) classifies this compound as belonging to the group ANTIGLAUCOMA COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a folate antagonist and antiprotozoal agent with the molecular structure C19H23N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9G69D95443 chemically known as 2,4-diamino-5-(3,5-diethoxy-4-pyrrol-1-ylbenzyl)pyrimidine, but more commonly known as epiroprim, which bears US NIH Compound Identifier 68916. European Medicines Agency schedules Epiroprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06570MIG. The term EPIROPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, no. 5 1981, list 21).
This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Z8479ZZ5X, chemically known as 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-l-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8s-cis)- but generally known as epirubicin, which bears US NIH Compound Identifier 41867. European Medicines Agency schedules Epirubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06571MIG. The term EPIRUBICIN is an International Non-Proprietary Name. World Health Organization schedules epirubicin in its Anatomical Therapeutic Chemical (ATC) Classification. EPIRUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epirubicin under HS 29419000 and SITC 54139. As of Q4 2014, EPIRUBICIN remains the US FDA Preferred Term for this commodity. Epirubicin bears US NLM identifiers UMLS ID C0014582 and NCI Concept Code C62028. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)CO)C1OC(C(O)C(N)C1)C.
This classification denotes an antineoplastic antibiotic with the molecular formula C27H29NO11.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22966TX7J5, chemically known as 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, hydrochloride (8s-cis)- but more generally known as epirubicin hydrochloride, which bears US NIH Compound Identifier 32874. European Medicines Agency schedules Epirubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01915MIG. Most nations, for tariff and trade purposes, schedule epirubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, EPIRUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Epirubicin hydrochloride bears US NLM identifiers UMLS ID C0701345 and NCI Concept Code C474. SMILES: C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3C2C(C4C(C3O)C(=O)C5CCCC(C5C4=O)OC)O)(C(=O)CO)O)N)O.CL.
This classification denotes a thiazide diuretic with the molecular formula C10H11ClF3N3O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5B266B85J1, chemically known as 6-chloro-3, 4-dihydro-7-sulfamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2h-1,2, 4-benzothiadiazine 1,1-dioxide but generally known as epithiazide, which bears US NIH Compound Identifier 15671. European Medicines Agency schedules Epitizide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06573MIG. The term EPITIZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Epithiazide or epitizide bears US NLM identifiers UMLS ID C2700005 and NCI Concept Code C77141. SMILES: C1=C2C(=CC(=C1CL)S(=O)(=O)N)S(=O)(=O)NC(N2)CSCC(F)(F)F.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C19H30OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YE7586973L, chemically known as 2,3-epithioandrostan-17-ol but generally known as epitiostanol, which bears US NIH Compound Identifier 3243. European Medicines Agency schedules Epitiostanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06572MIG. The term EPITIOSTANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). EPITIOSTANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epitiostanol under HS 29372300 and SITC 54153. As of Q4 2014, EPITIOSTANOL remains the US FDA Preferred Term for this commodity. Epitiostanol bears US NLM identifiers UMLS ID C0059457 and NCI Concept Code C1089. SMILES: S1C2CC3(C4C(C5C(CC4)(C(O)CC5)C)CCC3CC12)C.
This classification denotes a steroid compound and antihypertensive agent with the molecular formula C24H30O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6995V82D0B, chemically known as 9,11alpha-epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic acid, gamma-lactone, methyl ester but generally known as eplerenone, which bears US NIH Compound Identifier 150310. European Medicines Agency schedules Eplerenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06574MIG. The term EPLERENONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). World Health Organization schedules eplerenone in its Anatomical Therapeutic Chemical (ATC) Classification. EPLERENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eplerenone under HS 29372900 and SITC 54153. As of Q4 2014, EPLERENONE remains the US FDA Preferred Term for this commodity. Eplerenone bears US NLM identifiers UMLS ID C0961485 and NCI Concept Code C47513. SMILES: O1C23C(C4C(CC12)(C1(OC(=O)CC1)CC4)C)C(CC1=CC(=O)CCC31C)C(=O)OC.
This classification denotes a chemotherapy regimen used to treat non-hodgkins lymphoma with the molecular formula C809H1301N229O240S5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64FS3BFH5W, more generally known as epoetin alfa. European Medicines Agency schedules epoetin alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06575MIG. The term ERYTHROPOIETIN is an International Non-Proprietary Name or INN. Epoetin alfa bears US NLM identifiers UMLS ID C0357126 and NCI Concept Code C2695.
This classification denotes a prostaglandin analogue and antihypertensive agent with the molecular formula C20H32O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DCR9Z582X0. European Medicines Agency schedules epoprostenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06581MIG. The term EPOPROSTENOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21. ). EPOPROSTENOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Epoprostenol or prostacyclin bears US NLM identifiers UMLS ID C0033567 and NCI Concept Code C61748. SMILES: CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O.
This classification denotes a prostaglandin analogue and antihypertensive agent with the molecular formula C20H31O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4K04IQ1OF4, chemically known as u 53,217a but more generally known as epoprostenol sodium, which bears US NIH Compound Identifier 5282410. European Medicines Agency schedules Epoprostenol sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01918MIG. Most nations, for tariff and trade purposes, schedule epoprostenol sodium under HS 29375000. As of Q4 2014, EPOPROSTENOL SODIUM remains US FDA's Preferred Term for this commodity. Epoprostenol sodium bears US NLM identifiers UMLS ID C0354594 and NCI Concept Code C47514. SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)[O-])/O2)O)O.[NA+].
This classification denotes an anti-progestin with the molecular formula C22H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6375T36951, chemically known as 4,17-dimethyltrilostane but generally known as epostane, which bears US NIH Compound Identifier 51331. European Medicines Agency schedules Epostane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06582MIG. The term EPOSTANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). EPOSTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epostane under HS 29372300 and SITC 54153. As of Q4 2014, EPOSTANE remains the US FDA Preferred Term for this commodity. Epostane bears US NLM identifiers UMLS ID C0059461 and NCI Concept Code C80687. SMILES: O1C23C(C4C(C5C(CC4)(C(O)(CC5)C)C)CC3)(CC(C(=O)C12C)C#N)C.
This classification denotes a mucolytic agent and expectorant with the molecular formula C24H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 883YNL63WU, chemically known as 1-propanone, 3-(4-(2-ethoxy-2-phenylethyl)-1-piperazinyl)-2-methyl-1-phenyl- but more generally known as eprazinone, which bears US NIH Compound Identifier 3245. European Medicines Agency schedules Eprazinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06583MIG. The term EPRAZINONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules eprazinone in its Anatomical Therapeutic Chemical (ATC) Classification. EPRAZINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule eprazinone under HS 29335995 and SITC 51576. As of Q4 2014, EPRAZINONE remains US FDA's Preferred Term for this commodity. Eprazinone bears US NLM identifiers UMLS ID C0059469 and NCI Concept Code C65518. SMILES: O(C(CN1CCN(CC1)CC(C)C(=O)C1CCCCC1)C1CCCCC1)CC.
This classification denotes an antiparasitic agent with the molecular formula C49H73NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75KP30FD8O. The term Eprinomectin is an International Non-Proprietary Name or INN (see WHO INN reference publication, see WHO INN reference publication, Volume 10, No. 3, 1996, List 36.). Most nations schedule eprinomectin under HS 29419000 and SITC 54139. As of Q4 2014, EPRINOMECTIN remains the US FDA Preferred Term for this commodity. Eprinomectin bears US NLM identifiers UMLS ID C0529813 and NCI Concept Code C83694. SMILES: CC1C=CC=C2COC3C2(C(C=C(C3O)C)C(=O)OC4CC(CC=C(C1OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)NC(=O)C)OC)OC)C)OC7(C4)C=CC(C(O7)C(C)C)C)O.
This classification denotes an antidepressant agent and antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier URX5F7RDER. European Medicines Agency schedules Eprobemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06585MIG. Eprobemide generally arises in the molecular formula C14H19CLN2O2. The term EPROBEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) EPROBEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eprobemide under HS 29349990 and SITC 51579. As of Q4 2014, EPROBEMIDE remains the US FDA Preferred Term for this commodity. Eprobemide bears US NLM identifiers UMLS ID C1880541 and NCI Concept Code C65519. SMILES: Clc1ccc(C(=O)NCCCN2CCOCC2)cc1.
This classification denotes an angiotensin ii receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2KH13Z0S0Y. European Medicines Agency schedules Eprosartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06586MIG. Eprosartan generally arises in the molecular formula C23H24N2O4S. The term EPROSARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.) EPROSARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eprosartan under HS 29349990 and SITC 51579. As of Q4 2014, EPROSARTAN remains the US FDA Preferred Term for this commodity. Eprosartan bears US NLM identifiers UMLS ID C0287041 and NCI Concept Code C61749. SMILES: s1c(C/C(=C/c2n(c(nc2)CCCC)Cc2ccc(cc2)C(=O)O)C(=O)O)ccc1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C23H24N2O4S.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8N2L1NX8S3, chemically known as (e)-2-butyl-1-(p-carboxybenzyl)-.alpha.-2-thenylimidazole-5-acrylic acid, monomethanesulfonate, but more generally known as eprosartan mesylate, which bears US NIH Compound Identifier 5282474. European Medicines Agency schedules eprosartan mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06586MIG. Most nations, for tariff purposes, schedule eprosartan mesylate under HS 29349990. As of Q4 2014, EPROSARTAN MESYLATE remains US FDA's Preferred Term for this commodity. Eprosartan mesylate bears US NLM identifiers UMLS ID C0772203 and NCI Concept Code C47515. SMILES: CCCCC1NCC(N1CC2CCC(CC2)C(=O)O)/C=C(\CC3CCCS3)/C(=O)O.CS(=O)(=O)O.
This classification denotes a lipooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4C9310B127. European Medicines Agency schedules Eprovafen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06587MIG. Eprovafen generally arises in the molecular formula C18H22O2S. The term EPROVAFEN is an International Non-Proprietary Name or INN. EPROVAFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eprovafen under HS 29349990 and SITC 51579. As of Q4 2014, EPROVAFEN remains the US FDA Preferred Term for this commodity. Eprovafen bears US NLM identifiers UMLS ID C1880543 and NCI Concept Code C65521. SMILES: s1c(CCCCC(=O)O)ccc1CCCc1ccccc1.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E229K2HE7F. European Medicines Agency schedules Eproxindine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06588MIG. Eproxindine generally arises in the molecular formula C23H29N3O3. The term EPROXINDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, list 23.) EPROXINDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule eproxindine under HS 29339990 and SITC 51577. As of Q4 2014, EPROXINDINE remains US FDA's Preferred Term for this commodity. Eproxindine bears US NLM identifiers UMLS ID C0059470 and NCI Concept Code C81429. SMILES: OC(CN(CC)CC)CNC(=O)C1N(C2C(C1OC)CCCC2)C1CCCCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IJ21AK8IVJ, chemically known as 1-piperazinepropanol, 4-(beta-methoxyphenethyl)-alpha-phenyl- but generally known as eprozinol, which bears US NIH Compound Identifier 122553. European Medicines Agency schedules Eprozinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06589MIG. The term EPROZINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules eprozinol in its Anatomical Therapeutic Chemical (ATC) Classification. EPROZINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eprozinol under HS 29335995 and SITC 51576. As of Q4 2014, EPROZINOL remains the US FDA Preferred Term for this commodity. Eprozinol bears US NLM identifiers UMLS ID C0059471 and NCI Concept Code C65522. SMILES: O(C(CN1CCN(CC1)CCC(O)C1CCCCC1)C1CCCCC1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9AMI360PI, chemically known as 1-piperazinepropanol, 4-(2-methoxy-2-phenylethyl)-.alpha.-phenyl-, hydrochloride (1:2), but more generally known as eprozinol dihydrochloride, which bears US NIH Compound Identifier 161574. European Medicines Agency schedules eprozinol dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06589MIG. Most nations, for tariff purposes, schedule eprozinol dihydrochloride under HS 29335995. SMILES: COC(CN1CCN(CC1)CCC(C2CCCCC2)O)C3CCCCC3.CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30N2O2.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9AMI360PI. European Medicines Agency schedules eprozinol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01921MIG. The term eprozinol hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule eprozinol hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, EPROZINOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC(CN1CCN(CC1)CCC(C2CCCCC2)O)C3CCCCC3.CL.CL.
This classification denotes an antihelminthic agent with the molecular formula C20H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C1SPQ0FSR, chemically known as 2-(cyclohexylcarbonyl)-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino(2,1-a)(2)benzazepine but generally known as epsiprantel, which bears US NIH Compound Identifier 72026. European Medicines Agency schedules Epsiprantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06590MIG. The term EPSIPRANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). EPSIPRANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epsiprantel under HS 29335995 and SITC 51576. As of Q4 2014, EPSIPRANTEL remains the US FDA Preferred Term for this commodity. Epsiprantel bears US NLM identifiers UMLS ID C0059483 and NCI Concept Code C75217. SMILES: O=C(N1CC2N(CCCC3C2CCCC3)C(=O)C1)C1CCCCC1.
This classification denotes a medication that is used to prevent seizures and treat low levels of magnesium in a patient's blood.
This classification denotes an analgesic agent with the molecular formula C15H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2208ZLI77S, chemically known as 1,6-methano-1h-4-benzazonin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, (1s)- but generally known as eptazocine, which bears US NIH Compound Identifier 3246. European Medicines Agency schedules Eptazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06594MIG. The term EPTAZOCINE is an International Non-Proprietary Name. EPTAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eptazocine under HS 29339930 and SITC 51577. As of Q4 2014, EPTAZOCINE remains the US FDA Preferred Term for this commodity. Eptazocine bears US NLM identifiers UMLS ID C0059489 and NCI Concept Code C72115. SMILES: OC1CC2C3(CC(CC2CC1)CN(CC3)C)C.
This classification denotes an analgesic agent with the molecular structure C15H21NO.BRH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 865626Y4ON chemically known as 1,6-methano-1h-4-benzazonin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, hbr (1:1), (1s,6s)-, but more commonly known as eptazocine hydrobromide, which bears US NIH Compound Identifier 155705. European Medicines Agency schedules Eptazocine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01924MIG. Most nations, for tariff and trade purposes, schedule eptazocine hydrobromide under HS 29339930 and SITC 51577. As of Q4 2014, EPTAZOCINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Eptazocine hydrobromide bears US NLM identifiers UMLS ID C0124847 and NCI Concept Code C96732. SMILES: C[C@@]12CCN(C[C@@H](C1)CC3C2CC(CC3)O)C.BR.
This classification denotes an antiplatelet agent with the molecular formula C35H49N11O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NA8320J834, chemically known as 1,2,3-trihydroxypropanol but generally known as eptifibatide, which bears US NIH Compound Identifier 753. European Medicines Agency schedules Eptifibatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12498MIG. The term EPTIFIBATIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules eptifibatide in its Anatomical Therapeutic Chemical (ATC) Classification. EPTIFIBATIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eptifibatide under HS 29349990 and SITC 51579. As of Q4 2014, EPTIFIBATIDE remains the US FDA Preferred Term for this commodity. Eptifibatide bears US NLM identifiers UMLS ID C0253563 and NCI Concept Code C47516. SMILES: OC(CO)CO.
The AAEP core vaccination list consists of rabies, Eastern and Western equine encephalomyelitis (EEE/WEE), tetanus, and West Nile virus (WNV).
This classification denotes a tubulin binding agent with the molecular formula C24H27N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78XGN2K5RX, chemically known as ethyl (+-)-cis-p-(((2-(imidazol-1-ylmethyl)-2-(p-methoxyphenyl)-1,3-dioxolan-4-yl)methyl)thio)carbanilate but generally known as erbulozole, which bears US NIH Compound Identifier 71347. The term ERBULOZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). As of Q4 2014, ERBULOZOLE remains the US FDA Preferred Term for this commodity. Erbulozole bears US NLM identifiers UMLS ID C0059504 and NCI Concept Code C73258. SMILES: CCOC(=O)NC1=CC=C(C=C1)SCC2CO[C@](O2)(CN3C=CN=C3)C4=CC=C(C=C4)OC. .
This classification denotes a mucolytic agent with the molecular formula C8H11NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 76J0853EKA, chemically known as acetic acid, ((2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl)thio)- but more generally known as erdosteine, which bears US NIH Compound Identifier 65632. European Medicines Agency schedules Erdosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06595MIG. The term ERDOSTEINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules erdosteine in its Anatomical Therapeutic Chemical (ATC) Classification. ERDOSTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule erdosteine under HS 29349990 and SITC 51579. As of Q4 2014, ERDOSTEINE remains US FDA's Preferred Term for this commodity. Erdosteine bears US NLM identifiers UMLS ID C0059506 and NCI Concept Code C61750. SMILES: S1CCC(NC(=O)CSCC(=O)O)C1=O.
This classification denotes a serotonin antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YMH3D0ZJWV. European Medicines Agency schedules Ergometrine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01931MIG. Ergonovine maleate generally arises in the molecular formula C23H27N3O6. The term 'ergonovine maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule ergometrine maleate under HS 29396100. SMILES: C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3C[NH]C4C3C(CCC4)C2=C1)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes a serotonin antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YMH3D0ZJWV. European Medicines Agency schedules Ergometrine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01931MIG. Ergonovine maleate generally arises in the molecular formula C23H27N3O6. The term 'ergonovine maleate' is a European Pharmacopoeia designation. Ergometrine or ergonovine bears US NLM identifiers UMLS ID C0014704 and NCI Concept Code C75040. SMILES: O=C(NC(C)C)C1CN(C2C(=C1)C1C3C(C2)C[NH]C3CCC1)C.OC(=O)/C=C\C(=O)O.
This classification denotes a serotonin agonist with the molecular formula C33H35N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PR834Q503T, chemically known as 5-benzyl-12-hydroxy-2-methyl-3,6,18-trioxoergotaman but generally known as ergotamine, which bears US NIH Compound Identifier 3251. European Medicines Agency schedules Ergotamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06598MIG. The term ERGOTAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules ergotamine in its Anatomical Therapeutic Chemical (ATC) Classification. ERGOTAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ergotamine under HS 29396200 and SITC 54146. As of Q4 2014, ERGOTAMINE remains the US FDA Preferred Term for this commodity. Ergotamine bears US NLM identifiers UMLS ID C0014710 and NCI Concept Code C61751. SMILES: O1C2(O)N(C(C(=O)N3C2CCC3)CC2CCCCC2)C(=O)C1(NC(=O)C1CN(C2C(=C1)C1C3C(C2)C[NH]C3CCC1)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.
This classification denotes a serotonin agonist and alpha-adrenergic agonist with the molecular formula 2C33H35N5O5.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MRU5XH3B48, chemically known as ergotamine, tartrate (2:1) (salt) (8ci) but more generally known as ergotamine tartrate, which bears US NIH Compound Identifier 9787. European Medicines Agency schedules Ergotamine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01934MIG. Most nations, for tariff and trade purposes, schedule ergotamine tartrate under HS 29396200 and SITC 54146. As of Q4 2014, ERGOTAMINE TARTRATE remains US FDA's Preferred Term for this commodity. Ergotamine tartrate bears US NLM identifiers UMLS ID C2936189 and NCI Concept Code C47517. SMILES: C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4CCCCC4)NC(=O)[C@H]5CN([C@@H]6CC7C[NH]C8C7C(CCC8)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4CCCCC4)NC(=O)[C@H]5CN([C@@H]6CC7C[NH]C8C7C(CCC8)C6=C5)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a ketones and halichondrin b derivative and antimitotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LR24G6354G. European Medicines Agency schedules Eribulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31134. Eribulin generally arises in the molecular formula C40H59NO11. The term ERIBULIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 1, 2008, list 59.) As of Q4 2014, ERIBULIN remains the US FDA Preferred Term for this commodity. Eribulin bears US NLM identifiers UMLS ID C2350866 and NCI Concept Code C96748. SMILES: CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38R2P4PIEI. European Medicines Agency schedules Ericolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06599MIG. Ericolol generally arises in the molecular formula C18H24CLNO3. The term ERICOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) ERICOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ericolol under HS 29221980 and SITC 51461. As of Q4 2014, ERICOLOL remains the US FDA Preferred Term for this commodity. Ericolol bears US NLM identifiers UMLS ID C1880546 and NCI Concept Code C65527. SMILES: CLC1CC(OCC(O)CNC(C)(C)C)C(C2=CC(=O)CC2)CC1.
This classification denotes a vasodilating agent with the molecular formula C4H6N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35X333P19D, chemically known as 1,2,3,4-butanetetrol, tetranitrate, (r*,s*)- but generally known as eritrityl tetranitrate, which bears US NIH Compound Identifier 23723. European Medicines Agency schedules Eritrityl tetranitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06600MIG. The term ERITRITYL TETRANITRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules eritrityl tetranitrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule eritrityl tetranitrate under HS 29209085 and SITC 51639. SMILES: O([N](=O)O)C(C(O[N](=O)O)CO[N](=O)O)CO[N](=O)O
This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C22H23N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4T82NDH7E, chemically known as 4-quinazolinamine, n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, but generally known as erlotinib, which bears US NIH Compound Identifier 176870. European Medicines Agency schedules Erlotinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16423MIG. The term ERLOTINIB is an International Non-Proprietary Name. World Health Organization schedules erlotinib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule erlotinib under HS 29335995 and SITC 51576. As of Q4 2014, ERLOTINIB remains the US FDA Preferred Term for this commodity. Erlotinib bears US NLM identifiers UMLS ID C1135135 and NCI Concept Code C65530. SMILES: O(C1C(OCCOC)CC2NCNC(NC3CC(CCC3)C#C)C2C1)CCOC.
This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C22H23N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DA87705X9K, chemically known as 4-quinazolinamine, n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride but more generally known as erlotinib hydrochloride, which bears US NIH Compound Identifier 176871. European Medicines Agency schedules Erlotinib hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21050. As of Q4 2014, ERLOTINIB HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Erlotinib hydrochloride bears US NLM identifiers UMLS ID C0910101 and NCI Concept Code C2693. Most nations, for tariff and trade purposes, schedule erlotinib hydrochloride under HS 29335995 and SITC 51576. SMILES: COCCOC1CC2C(CC1OCCOC)NCNC2NC3CCCC(C3)C#C.CL.
This classification denotes a beta-lactam antibiotic with the molecular formula C22H25N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G32F6EID2H, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- but generally known as ertapenem, which bears US NIH Compound Identifier 150610. European Medicines Agency schedules Ertapenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25388. The term ERTAPENEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). World Health Organization schedules ertapenem in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ertapenem under HS 29419000 and SITC 54139. As of Q4 2014, ERTAPENEM remains the US FDA Preferred Term for this commodity. Ertapenem bears US NLM identifiers UMLS ID C1120106 and NCI Concept Code C61752. SMILES: S(C1=C(N2C(C(C2=O)C(O)C)C1C)C(=O)O)C1CC(NC1)C(=O)NC1CC(CCC1)C(=O)O.
This classification denotes a beta-lactam antibiotic C22H23N3O7S.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P5HEA33D9R, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3s,5s)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, sodium salt (1:2), (4r,5s,6s)-, but more generally known as ertapenem disodium, which bears US NIH Compound Identifier 150611. Most nations, for tariff and trade purposes, schedule ertapenem disodium under HS 29419000 and SITC 54139. As of Q4 2014, ERTAPENEM DISODIUM remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)NC4CCCC(C4)C(=O)[O-])C(=O)[O-])[C@@H](C)O.[NA+].[NA+].
This classification denotes a beta-lactam antibiotic with the molecular formula C22H23N3O7S.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2T90KE67L0, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, disodium salt, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- but more generally known as ertapenem sodium, which bears US NIH Compound Identifier 150611. European Medicines Agency schedules Ertapenem sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16424MIG. Most nations, for tariff and trade purposes, schedule ertapenem sodium under HS 29419000 and SITC 54139. Ertapenem sodium bears US NLM identifiers UMLS ID C1170745 and NCI Concept Code C61753. SMILES: As of Q4 2014, ERTAPENEM SODIUM remains US FDA's Preferred Term for this commodity.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63937KV33D, chemically known as sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin but generally known as erythromycin, which bears US NIH Compound Identifier 3255. European Medicines Agency schedules Erythromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG. The term ERYTHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules erythromycin in its Anatomical Therapeutic Chemical (ATC) Classification. ERYTHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule erythromycin under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN remains the US FDA Preferred Term for this commodity. Erythromycin bears US NLM identifiers UMLS ID C0014806 and NCI Concept Code C476. SMILES: O(C1C(C(OC2OC(C(O)C(OC)(C2)C)C)C(C(=O)OC(C(O)(C(O)C(C(=O)C(CC1(O)C)C)C)C)CC)C)C)C1OC(CC(N(C)C)C1O)C.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63937KV33D, chemically known as erythromycin estolate impurity, free erythromycin-, but more generally known as erythromycin a, which bears US NIH Compound Identifier 3255. European Medicines Agency schedules erythromycin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG. Most nations, for tariff purposes, schedule erythromycin a under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C4H7NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DA04YX38DA, chemically known as aspartic acid, l-, compd. with erythromycin (1:1), but more generally known as erythromycin aspartate, which bears US NIH Compound Identifier 83953. European Medicines Agency schedules erythromycin aspartate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG. Most nations, for tariff purposes, schedule erythromycin aspartate under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.C([C@@H](C(=O)O)N)C(=O)O.
This classification denotes a macrolide antibiotic with the molecular formula C37H65NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39V2DI8XOX, chemically known as erythromycin, 1'',16-epoxy-, but more generally known as erythromycin e, which bears US NIH Compound Identifier 5462331. European Medicines Agency schedules erythromycin e or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG. Most nations, for tariff purposes, schedule erythromycin e under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@H]2[C@@H](CO[C@]3(O2)C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C(=O)O1)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C37H65NO12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32B40I7V7B, chemically known as erythromycin, 8,9-didehydro-9-deoxo-6-deoxy-6,9-epoxy-, but more generally known as erythromycin enol ether, which bears US NIH Compound Identifier 6426642. European Medicines Agency schedules erythromycin enol ether or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG. Most nations, for tariff purposes, schedule erythromycin enol ether under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)C)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C40H71NO14.C12H26O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XRJ2P631HP, chemically known as erythromycin, n-demethyl-n-(methyl-11c)- but more generally known as erythromycin estolate, which bears US NIH Compound Identifier 12560. European Medicines Agency schedules Erythromycin estolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01941MIG. Most nations, for tariff and trade purposes, schedule erythromycin estolate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN ESTOLATE remains US FDA's Preferred Term for this commodity. Erythromycin estolate bears US NLM identifiers UMLS ID C0014809 and NCI Concept Code C47986. SMILES: CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2JUE6GD5A. Most nations schedule erythromycin ethylcarbonate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN ETHYLCARBONATE remains the US FDA Preferred Term for this commodity. Erythromycin ethylcarbonate bears US NLM identifiers UMLS ID C2700011 and NCI Concept Code C76762. SMILES: CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)OC(=O)OCC)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1014KSJ86F. European Medicines Agency schedules Erythromycin ethyl succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01942MIG. Erythromycin ethyl succinate generally arises in the molecular formula C43H75NO16. The term 'erythromycin ethyl succinate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule erythromycin ethyl succinate under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NM325T380N, chemically known as erythromycin, 16-hydroxy-, but more generally known as erythromycin f, which bears US NIH Compound Identifier 6426644. European Medicines Agency schedules erythromycin f or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG. Most nations, for tariff purposes, schedule erythromycin f under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)CO)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2AY21R0U64. European Medicines Agency schedules Erythromycin gluceptate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01943MIG. Erythromycin glucoheptonate generally arises in the molecular formula C37H67NO13.C7H14O8. The term 'erythromycin glucoheptonate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule erythromycin gluceptate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN GLUCEPTATE remains US FDA's Preferred Term for this commodity. Erythromycin gluceptate bears US NLM identifiers UMLS ID C0059561 and NCI Concept Code C65533. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.C([C@H]([C@H]([C@@H]([C@H]([C@H](C(=O)O)O)O)O)O)O)O.
This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2AY21R0U64. European Medicines Agency schedules Erythromycin gluceptate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01943MIG. Erythromycin glucoheptonate generally arises in the molecular formula C37H67NO13.C7H14O8. The term 'erythromycin glucoheptonate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule erythromycin glucoheptonate under HS 29415000 and SITC 54139. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.C([C@H]([C@H]([C@@H]([C@H]([C@H](C(=O)O)O)O)O)O)O)O.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C12H22O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33H58I7GLQ, chemically known as erythromycin, n-demethyl-n-(methyl-11c)- but more generally known as erythromycin lactobionate, which bears US NIH Compound Identifier 12560. European Medicines Agency schedules Erythromycin lactobionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01944MIG. Most nations, for tariff and trade purposes, schedule erythromycin lactobionate under HS 29415000 and SITC 54139. Erythromycin lactobionate bears US NLM identifiers UMLS ID C0059562 and NCI Concept Code C47988. SMILES: As of Q4 2014, ERYTHROMYCIN LACTOBIONATE remains US FDA's Preferred Term for this commodity.
This classification denotes a macrolide antibiotic C37H68N2O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10W452CMTZ, chemically known as erythromycin, 9-oxime, but more generally known as erythromycin oxime, which bears US NIH Compound Identifier 6537896. Most nations, for tariff and trade purposes, schedule erythromycin oxime under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN OXIME remains US FDA's Preferred Term for this commodity. Erythromycin oxime bears US NLM identifiers UMLS ID C0207096 and NCI Concept Code C87758. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=NO)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I8T8KU14X7, chemically known as erythromycin, phosphate but more generally known as erythromycin phosphate, which bears US NIH Compound Identifier 83935. Most nations, for tariff and trade purposes, schedule erythromycin phosphate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN PHOSPHATE remains US FDA's Preferred Term for this commodity. Erythromycin phosphate bears US NLM identifiers UMLS ID C0014813 and NCI Concept Code C87759. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.OP(=O)(O)O.
This classification denotes a macrolide antibiotic with the molecular formula C40H71NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HB75CIT999, chemically known as erythromycin, 2-propionate but more generally known as erythromycin propionate, which bears US NIH Compound Identifier 3258. European Medicines Agency schedules Erythromycin propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01945MIG. Most nations, for tariff and trade purposes, schedule erythromycin propionate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN PROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C12H13NO5S.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VMA8F29A76, chemically known as erythromycin, compound with n-acetyl-l-cysteine 2-hydroxybenzoate (ester) (1:1), dihydrate, but more generally known as erythromycin salnacedin, which bears US NIH Compound Identifier 60940. European Medicines Agency schedules erythromycin salnacedin or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG. Most nations, for tariff purposes, schedule erythromycin salnacedin under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.CC(=O)N[C@@H](CSC(=O)C1CCCCC1O)C(=O)O.O.O.
This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C18H36O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LXW024X05M, chemically known as stearic acid, compd. with erythromycin (1:1) but more generally known as erythromycin stearate, which bears US NIH Compound Identifier 12559. European Medicines Agency schedules Erythromycin stearate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01946MIG. Most nations, for tariff and trade purposes, schedule erythromycin stearate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN STEARATE remains US FDA's Preferred Term for this commodity. Erythromycin stearate bears US NLM identifiers UMLS ID C0059566 and NCI Concept Code C47989. SMILES: CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.
This classification denotes a macrolide antibiotic with the molecular formula C41H71NO16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 831SF5M65L. Most nations, for tariff and trade purposes, schedule erythromycin succinate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN SUCCINATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)O)(C)O)C)C)O)(C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.
This classification denotes a macrolide antibiotic C37H67NO13.CHNS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7A95YRI88, chemically known as thiocyanic acid, compd. with erythromycin (1:1), but more generally known as erythromycin thiocyanate, which bears US NIH Compound Identifier 83938. Most nations, for tariff and trade purposes, schedule erythromycin thiocyanate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN THIOCYANATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.C(#N)S.
This classification denotes a chemotherapy regimen used to treat non-hodgkins lymphoma with the molecular formula C809H1301N229O240S5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64FS3BFH5W, more generally known as erythropoietin. European Medicines Agency schedules erythropoietin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06575MIG. The term ERYTHROPOIETIN is an International Non-Proprietary Name or INN. As of Q4 2014, ERYTHROPOIETIN remains the US FDA Preferred Term for this commodity. Erythropoietin bears US NLM identifiers UMLS ID C0014822 and NCI Concept Code C20429. SMILES: NONE.
This classification denotes a quinolone antibiotic with the molecular formula C15H17FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A6NT0I9X0K, chemically known as 1,8-naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- but more generally known as esafloxacin, which bears US NIH Compound Identifier 208933. European Medicines Agency schedules Esafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06606MIG. The term ESAFLOXACIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). ESAFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: FC1C(N2CC(N)CC2)NC2N(CC)CC(C(=O)C2C1)C(=O)O.
This classification denotes an anti-ulcer agent with the molecular formula C12H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38QSU0IB5L, chemically known as 1-piperazineacetamide, n-cyclohexyl- but generally known as esaprazole, which bears US NIH Compound Identifier 68835. European Medicines Agency schedules Esaprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06607MIG. The term ESAPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). ESAPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule esaprazole under HS 29335995 and SITC 51576. As of Q4 2014, ESAPRAZOLE remains the US FDA Preferred Term for this commodity. Esaprazole bears US NLM identifiers UMLS ID C0059583 and NCI Concept Code C65535. SMILES: O=C(NC1CCCCC1)CN1CCNCC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DPF757BOSR, chemically known as 2-[4-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide but generally known as s-atenolol or esatenolol, which bears US NIH Compound Identifier 175540. European Medicines Agency schedules s-atenolol or esatenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06608MIG. The term ESATENOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38.). World Health Organization schedules esatenolol in its Anatomical Therapeutic Chemical (ATC) Classification. Esatenolol or s-atenolol bears US NLM identifiers UMLS ID C2825715 and NCI Concept Code C81661. SMILES: CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O4S742ANY, chemically known as 5-isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1s)- but generally known as escitalopram, which bears US NIH Compound Identifier 146570. European Medicines Agency schedules Escitalopram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16425MIG. World Health Organization schedules escitalopram in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule escitalopram under HS 29329970 and SITC 51569. As of Q4 2014, ESCITALOPRAM remains the US FDA Preferred Term for this commodity. Escitalopram bears US NLM identifiers UMLS ID C1099456 and NCI Concept Code C61754. SMILES: Fc1ccc(C2(OCc3c2ccc(c3)C#N)CCCN(C)C)cc1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5U85DBW7LO, chemically known as 5-isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1s)- but more generally known as escitalopram oxalate, which bears US NIH Compound Identifier 146570. European Medicines Agency schedules Escitalopram oxalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16426MIG. Most nations, for tariff and trade purposes, schedule escitalopram oxalate under HS 29329970 and SITC 51569. As of Q4 2014, ESCITALOPRAM OXALATE remains US FDA's Preferred Term for this commodity. Escitalopram oxalate bears US NLM identifiers UMLS ID C1170746 and NCI Concept Code C47518. SMILES: CN(C)CCC[C@@]1(C2CCC(CC2CO1)C#N)C3CCC(CC3)F.C(=O)(C(=O)O)O.
This classification denotes an anesthetic agent with the molecular formula C13H16ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50LFG02TXD, chemically known as cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8ci) but generally known as esketamine, which bears US NIH Compound Identifier 3821. European Medicines Agency schedules Esketamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25825. The term ESKETAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules esketamine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule esketamine under HS 29223900 and SITC 51463. As of Q4 2014, ESKETAMINE remains the US FDA Preferred Term for this commodity. Esketamine bears US NLM identifiers UMLS ID C2825616 and NCI Concept Code C81400. SMILES: CLC1C(C2(NC)CCCCC2=O)CCCC1.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L8P1H35P2Z. European Medicines Agency schedules Esketamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25811. Esketamine hydrochloride generally arises in the molecular formula C13H16CLNO.CLH. The term 'esketamine hydrochloride' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule esketamine hydrochloride under HS 29223900 and SITC 51463. As of Q4 2014, ESKETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN[C@@]1(CCCCC1=O)C2CCCCC2CL.CL.
This classification denotes an anesthetic agent with the molecular formula C13H16ClNO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 690G0D6V8H, chemically known as cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8ci) but more generally known as ketamine, which bears U.S. National Institutes of Health Compound Identifier 3821. The European Medicines Agency schedules Ketamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08365MIG. The term KETAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). The World Health Organization schedules ketamine in its Anatomical Therapeutic Chemical (ATC) Classification. KETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1C(C2(NC)CCCCC2=O)CCCC1.
This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5VXA428R4. European Medicines Agency schedules Eslicarbazepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27751. Eslicarbazepine generally arises in the molecular formula C15H14N2O2. The term ESLICARBAZEPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53.) Most nations schedule Eslicarbazepine under HS 29339930 and SITC 51577. As of Q4 2014, ESLICARBAZEPINE remains the US FDA Preferred Term for this commodity. Eslicarbazepine bears US NLM identifiers UMLS ID C2725260 and NCI Concept Code C81473. SMILES: C1CCC2C(C1)C[C@@H](C3CCCCC3N2C(=O)N)O.
This classification denotes an anticonvulsant agent C17H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BEA68ZVB2K, chemically known as (10s)-5-carbamoyl-10,11-dihydro-5h-dibenzo(b,f)azepin-10-yl acetate, but more generally known as eslicarbazepine acetate, which bears US NIH Compound Identifier 179344. European Medicines Agency schedules Eslicarbazepine acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30424. Most nations, for tariff and trade purposes, schedule eslicarbazepine acetate under HS 29339930 and SITC 51577. As of Q4 2014, ESLICARBAZEPINE ACETATE remains US FDA's Preferred Term for this commodity. Eslicarbazepine acetate bears US NLM identifiers UMLS ID C2725262 and NCI Concept Code C83697. SMILES: CC(=O)O[C@H]1CC2CCCCC2N(C3C1CCCC3)C(=O)N.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MDY902UXSR, chemically known as benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester but generally known as esmolol, which bears US NIH Compound Identifier 59768. European Medicines Agency schedules Esmolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13718MIG. The term ESMOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules esmolol in its Anatomical Therapeutic Chemical (ATC) Classification. ESMOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule esmolol under HS 29221980 and SITC 51461. As of Q4 2014, ESMOLOL remains the US FDA Preferred Term for this commodity. Esmolol bears US NLM identifiers UMLS ID C0116569 and NCI Concept Code C72617. SMILES: O(CC(O)CNC(C)C)C1CCC(CCC(=O)OC)CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H25NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V05260LC8D, chemically known as benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester but more generally known as esmolol hydrochloride, which bears US NIH Compound Identifier 59768. European Medicines Agency schedules Esmolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01959MIG. Most nations, for tariff and trade purposes, schedule esmolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, ESMOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Esmolol hydrochloride bears US NLM identifiers UMLS ID C0700606 and NCI Concept Code C47519. SMILES: CC(C)NCC(COC1CCC(CC1)CCC(=O)OC)O.CL.
This classification denotes a proton pump inhibitor with the molecular formula C17H19N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KG60484QX9, chemically known as 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole but generally known as omeprazole, which bears US NIH Compound Identifier 4594. European Medicines Agency schedules Omeprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09439MIG. The term OMEPRAZOLE is an International Non-Proprietary Name. World Health Organization schedules omeprazole in its Anatomical Therapeutic Chemical (ATC) Classification. OMEPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Esomeprazole or omeprazole bears US NLM identifiers UMLS ID C0028978 and NCI Concept Code C716. SMILES: S(=O)(CC1NCC(C(OC)C1C)C)C1[NH]C2C(N1)CCC(OC)C2.
This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, RMC41L2WQ3 chemically known as 5,12-naphthacenedione, 10-((4-aminotetrahydro-6-methyl-2h-pyran-2-yl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (2s-(2.alpha,(8r*,10r*),4.beta.,6.beta))- but generally known as esorubicin, which bears US NIH Compound Identifier 44554. European Medicines Agency schedules Esorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12442MIG. The term ESORUBICIN is an International Non-Proprietary Name or INN. Most nations schedule esorubicin under HS 29419000 and SITC 54139. As of Q4 2014, ESORUBICIN remains the US FDA Preferred Term for this commodity. Esorubicin bears US NLM identifiers UMLS ID C0047760 and NCI Concept Code C972. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)CO)C1OC(CC(N)C1)C.
This classification denotes an anthracycline antibiotic C27H29NO10.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2UB1JJT82D, chemically known as (8s,10s)-10-(((2s,4r,6s)-4-aminotetrahydro-6-methyl-2h-pyran-2-yl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride, but more generally known as esorubicin hydrochloride, which bears US NIH Compound Identifier 152035. Most nations, for tariff and trade purposes, schedule esorubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, ESORUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Esorubicin hydrochloride bears US NLM identifiers UMLS ID C2700018 and NCI Concept Code C74943. SMILES: C[C@H]1C[C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3C2C(C4C(C3O)C(=O)C5CCCC(C5C4=O)OC)O)(C(=O)CO)O)N.CL.
This classification denotes a benzodiazepine with the molecular formula C16H11ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36S3EQV54C, chemically known as 8-chloro-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine (iupac) but generally known as estazolam, which bears US NIH Compound Identifier 3261. European Medicines Agency schedules Estazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07241MIG. The term ESTAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules estazolam in its Anatomical Therapeutic Chemical (ATC) Classification. ESTAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule estazolam under HS 29339190 and SITC 51577. As of Q4 2014, ESTAZOLAM remains the US FDA Preferred Term for this commodity. Estazolam bears US NLM identifiers UMLS ID C0014892 and NCI Concept Code C47520. SMILES: CLC1CC2C(N3C(NNC3)CN=C2C2CCCCC2)CC1.
This classification denotes a cholinergic agonist with the molecular formula C8H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4ALN5933BH, chemically known as 1,2,5,6-tetrahydro-1-methylnicotinic acid, methyl ester but generally known as arecoline, which bears US NIH Compound Identifier 2230. arecoline most often comes in base, bromide, hydrobromide, hydrochloride, iodomethylate, methiodide, and p-stibonobenzoic acid forms. SMILES: CN1CCC=C(C1)C(=O)OC.
This classification denotes an estrogen with the molecular formula C18H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4TI98Z838E, chemically known as estra-1,3,5(10)-triene-3,17-diol (17.beta.)- but generally known as esterified estrogens, which bears US NIH Compound Identifier 450. European Medicines Agency schedules esterified estrogens in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13723MIG. The term ESTRADIOL is an International Non-Proprietary Name. World Health Organization schedules esterified estrogens in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: OC1C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C.
This classification denotes an estrogen C20H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5R97F5H93P, chemically known as estra-1,3,5(10)-triene-3,17-diol, (17.beta.)-, 3-acetate, but more generally known as estradiol acetate, which bears US NIH Compound Identifier 157050. European Medicines Agency schedules Estradiol acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27089. Most nations, for tariff and trade purposes, schedule estradiol acetate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRADIOL ACETATE remains US FDA's Preferred Term for this commodity. Estradiol acetate bears US NLM identifiers UMLS ID C1330622 and NCI Concept Code C47990. SMILES: CC(=O)OC1CCC2C(C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C.
This classification denotes a combination contraceptive drug. The first component of this drug is estradiol, an estrogen with the molecular formula C18H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4TI98Z838E, chemically known as estra-1,3,5(10)-triene-3,17-diol (17.beta.)- but generally known as estradiol, which bears US NIH Compound Identifier 450. European Medicines Agency schedules Estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07242MIG. The term ESTRADIOL is an International Non-Proprietary Name. World Health Organization schedules estradiol in its Anatomical Therapeutic Chemical (ATC) Classification. ESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C. The second component of this drug is norethisterone acetate, a therapeutic progestin with the molecular formula C20H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T18F433X4S, chemically known as 19-nortestosterone, 17-ethynyl- but generally known as norethindrone, which bears US NIH Compound Identifier 4536. European Medicines Agency schedules Norethindrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09362MIG. World Health Organization schedules norethindrone in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)C)C#C.
This classification denotes a therapeutic estradiol with the molecular formula C25H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1S4CJB5ZGN, chemically known as estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-benzoate but more generally known as estradiol benzoate, which bears US NIH Compound Identifier 3262. European Medicines Agency schedules Estradiol benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07243MIG. The term ESTRADIOL BENZOATE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule estradiol benzoate under HS 29372300. As of Q4 2014, ESTRADIOL BENZOATE remains US FDA's Preferred Term for this commodity. Estradiol benzoate bears US NLM identifiers UMLS ID C0167626 and NCI Concept Code C29769. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CC[C@@H]2O)OC(=O)C5CCCCC5.
This classification denotes a therapeutic estradiol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E1DV054LO. European Medicines Agency schedules Estradiol cipionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01965MIG. Estradiol cypionate generally arises in the molecular formula C26H36O3. The term 'estradiol cypionate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule estradiol cypionate under HS 29372300. As of Q4 2014, ESTRADIOL CYPIONATE remains US FDA's Preferred Term for this commodity. Estradiol cypionate bears US NLM identifiers UMLS ID C0059610 and NCI Concept Code C47991. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)CCC5CCCC5)O.
Estradiol cypionate/medroxyprogesterone acetate (EC/MPA) is a form of combined injectable birth control.[2] It contains estradiol cypionate (EC), estrogen, and medroxyprogesterone acetate (MPA), a progestin.
This classification denotes a therapeutic estradiol with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NIG5418BXB, chemically known as 3,17beta-dihydroxy-1,3,5(10)-estratriene 3,17-dipropionate but more generally known as estradiol dipropionate, which bears US NIH Compound Identifier 3265. European Medicines Agency schedules Estradiol dipropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22244. Most nations, for tariff and trade purposes, schedule estradiol dipropionate under HS 29372300. As of Q4 2014, ESTRADIOL DIPROPIONATE remains US FDA's Preferred Term for this commodity. Estradiol dipropionate bears US NLM identifiers UMLS ID C0059618 and NCI Concept Code C29770. SMILES: CCC(=O)OC1CCC2C(C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4OC(=O)CC)C.
This classification denotes a therapeutic estradiol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CXY7B3Q98Z. European Medicines Agency schedules Estradiol hemihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11941MIG. Estradiol hemihydrate generally arises in the molecular formula 2C18H24O2.H2O. The term 'estradiol hemihydrate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule estradiol hemihydrate under HS 29372300. As of Q4 2014, ESTRADIOL HEMIHYDRATE remains US FDA's Preferred Term for this commodity. Estradiol hemihydrate bears US NLM identifiers UMLS ID C1320235 and NCI Concept Code C47992. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CC[C@@H]2O)O.C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CC[C@@H]2O)O.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS300. This VA Drug Class (HS300) classifies this compound as belonging to the group ESTROGENS.
This classification denotes an estrogen C34H54O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q5Y448XT0, chemically known as estra-1,3,5(10)-triene-3,17-.beta.-diol 17-palmitate, but more generally known as estradiol monopalmitate, which bears US NIH Compound Identifier 111095. Most nations, for tariff and trade purposes, schedule estradiol monopalmitate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRADIOL MONOPALMITATE remains US FDA's Preferred Term for this commodity. Estradiol monopalmitate bears US NLM identifiers UMLS ID C2700019 and NCI Concept Code C76110. SMILES: CCCCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4C3CCC(C4)O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
This classification denotes an estrogen with the molecular formula C18H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4TI98Z838E, chemically known as estra-1,3,5(10)-triene-3,17-diol (17.beta.)- but generally known as estradiol, which bears US NIH Compound Identifier 450. European Medicines Agency schedules Estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07242MIG. The term ESTRADIOL is an International Non-Proprietary Name. World Health Organization schedules estradiol in its Anatomical Therapeutic Chemical (ATC) Classification. ESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Estradiol or oestradiol bears US NLM identifiers UMLS ID C0014912 and NCI Concept Code C2295. SMILES: OC1C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
Estradiol/trimegestone is a combination producto of hormonal steroids 17-? estradiol and trimegestone for the treatment of menopausal syndrome and in the prevention of postmenopausal osteoporosis.
This classification denotes an estrogen C29H44O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H3N3A8MFJC, chemically known as estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 17-undecanoate, but more generally known as estradiol undecylate, which bears US NIH Compound Identifier 19135. European Medicines Agency schedules Estradiol undecylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07244MIG. Most nations, for tariff and trade purposes, schedule estradiol undecylate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRADIOL UNDECYLATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4C3CCC(C4)O)C.
This classification denotes a therapeutic estradiol with the molecular formula C23H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKG364O896, chemically known as 3,17-epidihydroxyoestratriene but more generally known as estradiol valerate, which bears US NIH Compound Identifier 5757. European Medicines Agency schedules Estradiol valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07245MIG. The term ESTRADIOL VALERATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). Most nations, for tariff and trade purposes, schedule estradiol valerate under HS 29372300. As of Q4 2014, ESTRADIOL VALERATE remains US FDA's Preferred Term for this commodity. Estradiol valerate bears US NLM identifiers UMLS ID C0059623 and NCI Concept Code C1090. SMILES: CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4C3CCC(C4)O)C.
This classification denotes a tubulin binding agent and nitrogen mustard compound with the molecular formula C23H31Cl2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35LT29625A, chemically known as 17-hydroxyestra-1,3,5(10)-trien-3-yl bis(2-chloroethyl)carbamate but generally known as estramustine, which bears US NIH Compound Identifier 18140. European Medicines Agency schedules Estramustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07246MIG. The term ESTRAMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules estramustine in its Anatomical Therapeutic Chemical (ATC) Classification. ESTRAMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule estramustine under HS 29372300 and SITC 54153. As of Q4 2014, ESTRAMUSTINE remains the US FDA Preferred Term for this commodity. Estramustine bears US NLM identifiers UMLS ID C0014921 and NCI Concept Code C479. SMILES: CLCCN(C(=O)OC1CC2C(C3C(C4C(C(O)CC4)(CC3)C)CC2)CC1)CCCL.
This classification denotes a selective estrogen receptor modulator with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9KLU2E3573. The term ESTRAZINOL ACETONIDE is an International Non-Proprietary Name or INN. European Medicines Agency schedules estrazinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07248MIG. Most nations schedule estrazinol under HS 29372300 and SITC 54153. As of Q4 2014, ESTRAZINOL remains the US FDA Preferred Term for this commodity. Estrazinol bears US NLM identifiers UMLS ID C2348469 and NCI Concept Code C72767. SMILES: CC12CCC3C4=C(CCN3C1CCC2(C#C)O)C=C(C=C4)OC.
This classification denotes a selective estrogen receptor modulator with the molecular formula C20H25NO2.BRH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P1NC244SOF. The term estrazinol hydrobromide is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule estrazinol hydrobromide under HS 29372300 and SITC 54153. As of Q4 2014, ESTRAZINOL HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Estrazinol hydrobromide bears US NLM identifiers UMLS ID C2700020 and NCI Concept Code C74403. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CCN3[C@@H]1CC[C@]2(C#C)O)OC.BR.
This classification denotes a steroidal estrogen with the molecular formula C18H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FB33469R8E, chemically known as 3,16beta,17beta-trihydroxy-1,3,5(10)-estratriene but generally known as estriol, which bears US NIH Compound Identifier 3269. European Medicines Agency schedules Estriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01971MIG. World Health Organization schedules estriol in its Anatomical Therapeutic Chemical (ATC) Classification. ESTRIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ESTRIOL remains the US FDA Preferred Term for this commodity. Estriol bears US NLM identifiers UMLS ID C0014927 and NCI Concept Code C80154. SMILES: OC1C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1O)C.
This classification denotes a steroidal estrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AS13K2DY03. European Medicines Agency schedules Estriol succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07249MIG. Estriol succinate generally arises in the molecular formula C26H32O9. The term ESTRIOL SUCCINATE is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule estriol succinate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRIOL SUCCINATE remains US FDA's Preferred Term for this commodity. Estriol succinate bears US NLM identifiers UMLS ID C0059648 and NCI Concept Code C80784. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1C[C@H]([C@@H]2OC(=O)CCC(=O)O)OC(=O)CCC(=O)O)O.
This classification denotes a steroidal estrogen with the molecular formula C24H26O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0CDE7T54KW, chemically known as 21,23-epoxy-19,24-dinor-17alpha-chola-1,3,5(10),7,20,22-hexaene-3,17-diol 3-acetate but generally known as estrofurate, which bears US NIH Compound Identifier 66360. European Medicines Agency schedules Estrofurate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07250MIG. The term ESTROFURATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). ESTROFURATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule estrofurate under HS 29372300 and SITC 54153. As of Q4 2014, ESTROFURATE remains the US FDA Preferred Term for this commodity. Estrofurate bears US NLM identifiers UMLS ID C1880558 and NCI Concept Code C65543. SMILES: OC1(C2(C(CC1)C1=CCc3c(C1CC2)ccc(OC(=O)C)c3)C)c1ccoc1.
This classification denotes a therapeutic progestin with the molecular formula C18H21NaO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IU5QR144QX but generally known as conjugated estrogens, which bears US NIH Compound Identifier 45357473. European Medicines Agency schedules trioxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB36355. SMILES: CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS300. This VA Drug Class (HS300) classifies this compound as belonging to the group ESTROGENS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS300. This VA Drug Class (HS300) classifies this compound as belonging to the group ESTROGENS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
This classification denotes an estrogen with the molecular formula C18H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2DI9HA706A, chemically known as 1,3,5(10)-estratrien-3-ol-17-one but generally known as estrone, which bears US NIH Compound Identifier 698. European Medicines Agency schedules Estrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07251MIG. The term ESTRONE is an International Non-Proprietary Name. World Health Organization schedules estrone in its Anatomical Therapeutic Chemical (ATC) Classification. ESTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule estrone under HS 29372300 and SITC 54153. As of Q4 2014, ESTRONE remains the US FDA Preferred Term for this commodity. Estrone bears US NLM identifiers UMLS ID CL448831 and NCI Concept Code C2294. SMILES: O=C1C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C.
This classification denotes an estrogen C20H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4L6USG266B, chemically known as estra-1,3,5(10)-trien-17-one, 3-(acetyloxy)-, but more generally known as estrone acetate, which bears US NIH Compound Identifier 3273. Most nations, for tariff and trade purposes, schedule estrone acetate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OC1CCC2C(C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C.
This classification denotes an estrogen with the molecular formula C25H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O636LYL5W8, chemically known as estra-1,3,5(10)-trien-17-one, 3-(benzoyloxy)-, but more generally known as estrone benzoate, which bears US NIH Compound Identifier 16963. European Medicines Agency schedules estrone benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07251MIG. Most nations, for tariff purposes, schedule estrone benzoate under HS 29372300. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)OC(=O)C5CCCCC5.
This classification denotes an estrogen with the molecular formula C24H30O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 933Q277TO2, chemically known as .beta.-d-glucopyranosiduronic acid, 17-oxoestra-1,3,5(10)-trien-3-yl, but more generally known as estrone glucuronide, which bears US NIH Compound Identifier 115255. European Medicines Agency schedules estrone glucuronide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07251MIG. Most nations, for tariff purposes, schedule estrone glucuronide under HS 29372300. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O.
This classification denotes an estrogen with the molecular formula C18H22O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QTL48N278K, chemically known as estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, but more generally known as estrone hydrogen sulfate, which bears US NIH Compound Identifier 699. European Medicines Agency schedules estrone hydrogen sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07251MIG. Most nations, for tariff purposes, schedule estrone hydrogen sulfate under HS 29372300. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)OS(=O)(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
This classification denotes an estrogen C18H21O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K6FDA543A, chemically known as estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt, but more generally known as estrone sodium sulfate, which bears US NIH Compound Identifier 23667301. European Medicines Agency schedules Estrone sodium sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01976MIG. Most nations, for tariff and trade purposes, schedule estrone sodium sulfate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRONE SODIUM SULFATE remains US FDA's Preferred Term for this commodity. Estrone sodium sulfate bears US NLM identifiers UMLS ID C0304783 and NCI Concept Code C61942. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)OS(=O)(=O)[O-].[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
This classification denotes a steroidal estrogen with the molecular formula C18H22O5S.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SVI38UY019, chemically known as 3-(sulfooxy)estra-1,3,5(10)-trien-17-one, w/pip* but generally known as estropipate, which bears US NIH Compound Identifier 23703. European Medicines Agency schedules Estropipate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13724MIG. As of Q4 2014, ESTROPIPATE remains the US FDA Preferred Term for this commodity. Estropipate bears US NLM identifiers UMLS ID C0071108 and NCI Concept Code C47521. SMILES: S(=O)(=O)(Oc1cc2c(C3C(C4C(CC3)(C(=O)CC4)C)CC2)cc1)O.N1CCNCC1.
This classification denotes a sedative and hypnotic with the molecular formula C17H17ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UZX80K71OE, chemically known as 4-methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5h-pyrrolo(3,4-b)pyrazin-5-one but generally known as eszopiclone, which bears US NIH Compound Identifier 5735. European Medicines Agency schedules Eszopiclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21373. The term ESZOPICLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 2, 2003, List 49). World Health Organization schedules eszopiclone in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule eszopiclone under HS 29337900 and SITC 51561. As of Q4 2014, ESZOPICLONE remains the US FDA Preferred Term for this commodity. Eszopiclone bears US NLM identifiers UMLS ID C1436328 and NCI Concept Code C65545. SMILES: CLC1CCC(N2C(OC(=O)N3CCN(CC3)C)C3NCCNC3C2=O)NC1.
This classification denotes an anticoagulant agent with the molecular formula C23H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DA25635W9D, chemically known as methanone, (4-(2-(diethylamino)ethoxy)phenyl)(2-ethyl-3-benzofuranyl)- (9ci) but generally known as etabenzarone, which bears US NIH Compound Identifier 27444. European Medicines Agency schedules Etabenzarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07253MIG. The term ETABENZARONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). ETABENZARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etabenzarone under HS 29329985 and SITC 51569. As of Q4 2014, ETABENZARONE remains the US FDA Preferred Term for this commodity. Etabenzarone bears US NLM identifiers UMLS ID C1880559 and NCI Concept Code C65546. SMILES: O1C(C(C2C1CCCC2)C(=O)C1CCC(OCCN(CC)CC)CC1)CC.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 199HW12728. European Medicines Agency schedules Etacepride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07254MIG. Etacepride generally arises in the molecular formula C17H24N2O3. The term ETACEPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) ETACEPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etacepride under HS 29339990 and SITC 51577. As of Q4 2014, ETACEPRIDE remains the US FDA Preferred Term for this commodity. Etacepride bears US NLM identifiers UMLS ID C1880560 and NCI Concept Code C65547. SMILES: O=C(NCC1N(CCC1)CC)c1c(OC)ccc(c1)C(=O)C.
This classification denotes a loop diuretic with the molecular formula C13H12Cl2O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier M5DP350VZV, chemically known as 2,3-dichloro-4-(2-methylenebutyryl)phenoxy acetic acid but more generally known as etacrynic acid, which bears US NIH Compound Identifier 3278. European Medicines Agency schedules Etacrynic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07255MIG. The term ETACRYNIC ACID is an International Non-Proprietary Name World Health Organization schedules etacrynic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Ethacrynic acid bears US NLM identifiers UMLS ID C0014963 and NCI Concept Code C485. SMILES: CLC1C(C(=O)C(=C)CC)CCC(OCC(=O)O)C1CL.
This classification denotes a beta-adrenergic agonist with the molecular formula C12H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Y6VQU63E8, chemically known as benzyl alcohol, alpha-(1-(ethylmethylamino)ethyl)- but generally known as etafedrine, which bears US NIH Compound Identifier 10734. European Medicines Agency schedules Etafedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07256MIG. The term ETAFEDRINE is an International Non-Proprietary Name. ETAFEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etafedrine under HS 29394900 and SITC 54144. As of Q4 2014, ETAFEDRINE remains the US FDA Preferred Term for this commodity. Etafedrine bears US NLM identifiers UMLS ID C0059676 and NCI Concept Code C76539. SMILES: CCN(C)C(C)C(C1=CC=CC=C1)O.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0I14K589E7. European Medicines Agency schedules Etafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07257MIG. Etafenone generally arises in the molecular formula C21H27NO2. The term ETAFENONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) ETAFENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etafenone under HS 29221980 and SITC 51461. As of Q4 2014, ETAFENONE remains the US FDA Preferred Term for this commodity. Etafenone bears US NLM identifiers UMLS ID C0059677 and NCI Concept Code C65548. SMILES: O(CCN(CC)CC)c1c(c2cc(ccc2)C(=O)CC)cccc1.
This classification denotes a beta-adrenergic agonist with the molecular formula C21H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NTS160XKGC, chemically known as l.g.11,457 but more generally known as etafenone hydrochloride, which bears US NIH Compound Identifier 3275. European Medicines Agency schedules Etafenone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01980MIG. Most nations, for tariff and trade purposes, schedule etafenone hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, ETAFENONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etafenone hydrochloride bears US NLM identifiers UMLS ID C0105278 and NCI Concept Code C95811. SMILES: CCN(CC)CCOC1CCCCC1C(=O)CCC2CCCCC2.CL.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C13H21N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 221A91BQ2S, chemically known as 1,3-dimethyl-7-(2-(diethylamino)ethyl)xanthine but generally known as etamiphyllin, which bears US NIH Compound Identifier 28329. European Medicines Agency schedules Etamiphyllin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13725MIG. The term ETAMIPHYLLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules etamiphyllin in its Anatomical Therapeutic Chemical (ATC) Classification. Etamiphyllin or etamiphylline bears US NLM identifiers UMLS ID C0059680 and NCI Concept Code C65551. SMILES: O=C1N(C(=O)N(C2NCN(CCN(CC)CC)C12)C)C.
This classification denotes a cns stimulant with the molecular formula C12H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M44O63YPV9, chemically known as vanillic acid n,n-diethylamide but more generally known as etamivan, which bears US NIH Compound Identifier 9363. European Medicines Agency schedules Etamivan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07259MIG. The term ETAMIVAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules etamivan in its Anatomical Therapeutic Chemical (ATC) Classification. ETAMIVAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Etamivan or ethamivan bears US NLM identifiers UMLS ID C0059692 and NCI Concept Code C76623. SMILES: CCN(CC)C(=O)C1=CC(=C(C=C1)O)OC.
This classification denotes a tetracycline antibiotic with the molecular formula C50H60N6O16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 96D1L38S9Q chemically known as n,n,-(ethylenebis((methylimino)methylene))bis-(4'-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide) but generally known as etamocycline, which bears US NIH Compound Identifier 5464330. European Medicines Agency schedules Etamocycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07260MIG. The term ETAMOCYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8. ). Most nations schedule etamocycline under HS 29413000 and SITC 54133. As of Q4 2014, ETAMOCYCLINE remains the US FDA Preferred Term for this commodity. Etamocycline bears US NLM identifiers UMLS ID C0601392 and NCI Concept Code C65552. SMILES: CC1(C2CC3C(C(=O)C(=C(NCN(C)CCN(C)CNC(=C4C(=O)C(C5CC6C(=C(C7=C(C6(C)O)C=CC=C7O)O)C(=O)C5(C4=O)O)N(C)C)O)O)C(=O)C3(C(=O)C2=C(C8=C1C=CC=C8O)O)O)N(C)C)O.
This classification denotes a hemostatic and benzenesulfonate with the molecular formula C6H6O5S.C4H11N, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 24YL531VOH, chemically known as 2,5-dihydroxybenzenesulfonic acid compound with diethylamine (1:1) but more generally known as etamsylate, which bears US NIH Compound Identifier 17506. European Medicines Agency schedules Etamsylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11943MIG World Health Organization schedules etamsylate in its Anatomical Therapeutic Chemical (ATC) Classification. ETAMSYLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(O)C1C(O)CCC(O)C1.N(CC)CC.
This classification denotes an immunosuppressant with the molecular formula C2224H3475N621O698S36, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OP401G7OJC, more generally known as etanercept. European Medicines Agency schedules etanercept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01984MIG. The term ETANERCEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, list 43. Most nations, for tariff and trade purposes, schedule Etanercept under HS 30021095 and SITC 54163. SMILES:. As of Q4 2014, ETANERCEPT remains US FDA's Preferred Term for this commodity. . Etanercept bears US NLM identifiers UMLS ID C0717758 and NCI Concept Code C2381.
This classification denotes a radiosensitizing agent with the molecular formula C7H10N4O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 30DKA3Q1HL, chemically known as 2-nitroimidazole-1-acetamide, n-(2-hydroxyethyl)- but more generally known as etanidazole, which bears U.S. National Institutes of Health Compound Identifier 3276. The European Medicines Agency schedules Etanidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07261MIG. The term ETANIDAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). ETANIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C(NCCO)CN1C(NCC1)[N](=O)O.
This classification denotes a bronchodilator with the molecular formula C18H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1597304395, chemically known as 5-amino-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)-m-xylene-alpha,alpha-diol but generally known as etanterol, which bears US NIH Compound Identifier 208937. European Medicines Agency schedules Etanterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07262MIG. The term ETANTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). ETANTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etanterol under HS 29225000 and SITC 51467. As of Q4 2014, ETANTEROL remains the US FDA Preferred Term for this commodity. Etanterol bears US NLM identifiers UMLS ID C1880563 and NCI Concept Code C65553. SMILES: OC(CNC(CC1CCC(O)CC1)C)C1CC(CC(N)C1)CO.
This classification denotes a sedative and hypnotic with the molecular formula C17H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HFS3HB32J7, chemically known as 4(3h)-quinazolinone, 3-(o-ethylphenyl)-2-methyl- but generally known as etaqualone, which bears US NIH Compound Identifier 23914. European Medicines Agency schedules Etaqualone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07263MIG. The term ETAQUALONE is an International Non-Proprietary Name. ETAQUALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etaqualone under HS 29335995 and SITC 51576. As of Q4 2014, ETAQUALONE remains the US FDA Preferred Term for this commodity. Etaqualone bears US NLM identifiers UMLS ID C1880564 and NCI Concept Code C65554. SMILES: O=C1N(C2C(CC)CCCC2)C(NC2C1CCCC2)C.
This classification denotes an anxiolytic with the molecular formula C14H19N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I89Y79062L, chemically known as 1h-pyrazolo(3,4-b)pyridine-5-carboxylic acid, 1-ethyl-4-((1-methylethylidene)hydrazino)-, ethyl ester but generally known as etazolate, which bears US NIH Compound Identifier 3277. European Medicines Agency schedules Etazolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07267MIG. The term ETAZOLATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). ETAZOLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etazolate under HS 29339990 and SITC 51577. As of Q4 2014, ETAZOLATE remains the US FDA Preferred Term for this commodity. Etazolate bears US NLM identifiers UMLS ID C0014958 and NCI Concept Code C73334. SMILES: O(C(=O)C1C(N/N=C(/C)C)C2C(N(NC2)CC)NC1)CC.
This classification denotes an anxiolytic with the molecular formula C14H19N5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7YO3254Y6B, chemically known as 1h-pyrazolo(3,4-b)pyridine-5-carboxylic acid, 1-ethyl-4-((1-methylethylidene)hydrazino)-, ethyl ester but more generally known as etazolate hydrochloride, which bears US NIH Compound Identifier 3277. Most nations, for tariff and trade purposes, schedule etazolate hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, ETAZOLATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etazolate hydrochloride bears US NLM identifiers UMLS ID C0917853 and NCI Concept Code C72768. SMILES: CCN1C2C(CN1)C(C(CN2)C(=O)OCC)NN=C(C)C.CL.
This classification denotes a barbiturate with the molecular formula C16H20N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 432SI047GA, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-1,3-bis(methoxymethyl)-5-phenyl- but generally known as eterobarb, which bears US NIH Compound Identifier 33925. European Medicines Agency schedules Eterobarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07269MIG. The term ETEROBARB is an International Non-Proprietary Name. ETEROBARB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eterobarb under HS 29335400 and SITC kg. As of Q4 2014, ETEROBARB remains the US FDA Preferred Term for this commodity. Eterobarb bears US NLM identifiers UMLS ID C0059686 and NCI Concept Code C77629. SMILES: O=C1N(C(=O)N(C(=O)C1(CC)C1CCCCC1)COC)COC.
This classification denotes a local anti-infective agent with the molecular formula C15H15N3O.C3H6O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V5IL571C1T, chemically known as 6,9-diamino-2-ethoxyacridine lactate but generally known as ethacridine lactate, which bears US NIH Compound Identifier 15789. European Medicines Agency schedules Ethacridine lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01985MIG. World Health Organization schedules ethacridine lactate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ethacridine lactate under HS 29339990 and SITC 51577. As of Q4 2014, ETHACRIDINE LACTATE remains the US FDA Preferred Term for this commodity. SMILES: CCOC1=CC2=C(C3=C(C=C(C=C3)N)N=C2C=C1)N.CC(C(=O)O)O.
This classification denotes a loop diuretic with the molecular formula C13H11Cl2O4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K41MYV7MPM, chemically known as sodium (2,3-dichloro-4-(2-methylenebutyryl)phenoxy)acetate but generally known as ethacrynate sodium, which bears US NIH Compound Identifier 23003. As of Q4 2014, ETHACRYNATE SODIUM remains the US FDA Preferred Term for this commodity. Ethacrynate sodium bears US NLM identifiers UMLS ID C0014962 and NCI Concept Code C47993. SMILES: CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])CL)CL.[NA+].
This classification denotes an oxazole with the molecular formula C7H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0F8O700BB, chemically known as 2,4-oxazolidinedione, 3-ethyl-5,5-dimethyl- (8ci)(9ci) but generally known as ethadione, which bears US NIH Compound Identifier 10630. European Medicines Agency schedules Ethadione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13728MIG. World Health Organization schedules ethadione in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ETHADIONE remains the US FDA Preferred Term for this commodity. SMILES: O1C(C(=O)N(CC)C1=O)(C)C.
This classification denotes an antitubercular agent with the molecular formula C10H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8G167061QZ, chemically known as 2,2-(1,2-ethylenediimino)-di-1-butanol but generally known as ethambutol, which bears US NIH Compound Identifier 3279. European Medicines Agency schedules Ethambutol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07271MIG. The term ETHAMBUTOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules ethambutol in its Anatomical Therapeutic Chemical (ATC) Classification. ETHAMBUTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethambutol under HS 29221980 and SITC 51461. As of Q4 2014, ETHAMBUTOL remains the US FDA Preferred Term for this commodity. Ethambutol bears US NLM identifiers UMLS ID C0014964 and NCI Concept Code C61755. SMILES: CCC(CO)NCCNC(CC)CO.
This classification denotes an antitubercular agent with the molecular formula C10H24N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QE4VW5FO07, chemically known as 1-butanol, 2,2'(1,2-ethanediyldiimino)bis-, dihydrochloride, (-(r*,r*)), but more generally known as ethambutol dihydrochloride, which bears US NIH Compound Identifier 3279. European Medicines Agency schedules ethambutol dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07271MIG. Most nations, for tariff purposes, schedule ethambutol dihydrochloride under HS 29221980. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO.CL.CL.
This classification denotes an antitubercular agent with the molecular formula C10H24N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QE4VW5FO07, chemically known as 2,2-(1,2-ethylenediimino)-di-1-butanol but more generally known as ethambutol hydrochloride, which bears US NIH Compound Identifier 3279. European Medicines Agency schedules Ethambutol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11945MIG. Most nations, for tariff and trade purposes, schedule ethambutol hydrochloride under HS 29221980. As of Q4 2014, ETHAMBUTOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ethambutol hydrochloride bears US NLM identifiers UMLS ID C0026895 and NCI Concept Code C29033. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO.CL.CL.
Definition: This classification is for a combination medication for TB treatment. The first component, ETHAMBUTOL, has US FDA Unique Ingredient Identifier of 8G167061QZ. ETHAMBUTOL is an International Non-Proprietary Name or INN. The second component, ISONIAZID, has US FDA Unique Ingredient Identifier of V83O1VOZ8L. ISONIAZID is an International Non-Proprietary Name or INN. The third component, PYRAZINAMIDE, has US FDA Unique Ingredient Identifier of 2KNI5N06TI. PYRAZINAMIDE is an International Non-Proprietary Name or INN. The fourth component, RIFAMPICIN, has US FDA Unique Ingredient Identifier of VJT6J7R4TR. RIFAMPICIN is an International Non-Proprietary Name or INN.
Definition: This classification is for a combination medication for TB treatment. The first component, ETHAMBUTOL, has US FDA Unique Ingredient Identifier of 8G167061QZ. ETHAMBUTOL is an International Non-Proprietary Name or INN. The second component, ISONIAZID, has US FDA Unique Ingredient Identifier of V83O1VOZ8L. ISONIAZID is an International Non-Proprietary Name or INN. The third component, RIFAMPICIN, has US FDA Unique Ingredient Identifier of VJT6J7R4TR. RIFAMPICIN is an International Non-Proprietary Name or INN.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5KV86114PT. European Medicines Agency schedules Ethanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01990MIG. Ethanolamine generally arises in the molecular formula C2H7NO. The term 'ethanolamine' is a Hazardous Substances Data Bank designation. SMILES: CCCCCCCCC=CCCCCCCCC(=O)O.C(CO)N.
This classification denotes a calcium channel blocker and antispasmotic agent with the molecular formula C24H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H2HC19DYZ, chemically known as 6,7-diethoxy-1-(3, 4-diethoxybenzyl)isoquinoline hydrochloride but generally known as ethaverine, which bears US NIH Compound Identifier 3280. European Medicines Agency schedules Ethaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07272MIG. The term ETHAVERINE is an International Non-Proprietary Name. ETHAVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethaverine under HS 29334990 and SITC 51575. As of Q4 2014, ETHAVERINE remains the US FDA Preferred Term for this commodity. Ethaverine bears US NLM identifiers UMLS ID C0059703 and NCI Concept Code C73332. SMILES: O(c1cc2c(nccc2cc1OCC)Cc1cc(OCC)c(OCC)cc1)CC.
This classification denotes a monoamine oxidase inhibitor and calcium channel blocker with the molecular formula C24H29NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Z6T599E49, chemically known as 6,7-diethoxy-1-(3, 4-diethoxybenzyl)isoquinoline hydrochloride but more generally known as ethaverine hydrochloride, which bears US NIH Compound Identifier 3280. European Medicines Agency schedules Ethaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01996MIG. Most nations, for tariff and trade purposes, schedule ethaverine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, ETHAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ethaverine hydrochloride bears US NLM identifiers UMLS ID C0770146 and NCI Concept Code C72769. SMILES: CCOC1CCC(CC1OCC)CC2C3CC(C(CC3CCN2)OCC)OCC.CL.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6EIM3851UZ. European Medicines Agency schedules Ethchlorvynol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07273MIG. Ethchlorvynol generally arises in the molecular formula C7H9CLO. The term ETHCHLORVYNOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) ETHCHLORVYNOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethchlorvynol under HS 29055100 and SITC 51229. As of Q4 2014, ETHCHLORVYNOL remains the US FDA Preferred Term for this commodity. Ethchlorvynol bears US NLM identifiers UMLS ID C0014987 and NCI Concept Code C61758. SMILES: CL/C=C/C(O)(CC)C#C.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L929ZCK4BF. European Medicines Agency schedules Ethenzamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07274MIG. Ethenzamide generally arises in the molecular formula C9H11NO2. The term ETHENZAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) ETHENZAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethenzamide under HS 29242995 and SITC 51479. As of Q4 2014, ETHENZAMIDE remains the US FDA Preferred Term for this commodity. Ethenzamide bears US NLM identifiers UMLS ID C0059708 and NCI Concept Code C87323. SMILES: O(C1C(CCCC1)C(=O)N)CC.
This classification denotes a thiazide diuretic with the molecular formula C9H12ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EK9LSW731R, chemically known as 6-chloro-3-ethyl-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as ethiazide, which bears US NIH Compound Identifier 15763. European Medicines Agency schedules Ethiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07275MIG. The term ETHIAZIDE is an International Non-Proprietary Name. ETHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethiazide under HS 29350090 and SITC 51580. As of Q4 2014, ETHIAZIDE remains the US FDA Preferred Term for this commodity. Ethiazide bears US NLM identifiers UMLS ID C0873164 and NCI Concept Code C80840. SMILES: CLC1CC2NC(NS(=O)(=O)C2CC1S(=O)(=O)N)CC.
This classification denotes a sedative and hypnotic with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IAN371PP48, chemically known as cyclohexanol, 1-ethynyl-, carbamate but generally known as ethinamate, which bears US NIH Compound Identifier 3284. European Medicines Agency schedules Ethinamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07276MIG. The term ETHINAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). ETHINAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethinamate under HS 29242400 and SITC 51479. As of Q4 2014, ETHINAMATE remains the US FDA Preferred Term for this commodity. Ethinamate bears US NLM identifiers UMLS ID C0059714 and NCI Concept Code C65559. SMILES: O(C1(CCCCC1)C#C)C(=O)N.
This classification denotes a combination contraceptive drug. The first component of this drug is ethinyl estradiol, a therapeutic estradiol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 423D2T571U. European Medicines Agency schedules Ethinyl estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07277MIG. Ethinylestradiol generally arises in the molecular formula C20H24O2. The term 'ethinylestradiol' is a European Medicines Agency European Public Assessment Report System designation. ETHINYLESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1(C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C)C#C. The second component of this drug is ethynodiol diacetate, a therapeutic progestin with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62H10A1236, chemically known as 19-norpregn-4-en-20-yne-3,17-diol, diacetate, (3.beta.,17.alpha.)- but generally known as ethynodiol diacetate, which bears US NIH Compound Identifier 3304. European Medicines Agency schedules Etynodiol diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02051MIG. SMILES: CC(=O)OC1CCC2C3CCC4(C(C3CCC2=C1)CCC4(C#C)OC(=O)C)C.
Ethinylestradiol/cyproterone acetate (EE/CPA), also known as co-cyprindiol is a combination of ethinylestradiol (EE), an estrogen, and cyproterone acetate (CPA), a progestin and antiandrogen, which is used as a birth control pill to prevent pregnancy in women.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a therapeutic estradiol, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 423D2T571U. European Medicines Agency schedules Ethinyl estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07277MIG. Ethinylestradiol generally arises in the molecular formula C20H24O2. The term 'ethinylestradiol' is a European Medicines Agency European Public Assessment Report System designation. ETHINYLESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ethinyl estradiol bears US NLM identifiers UMLS ID C0015011 and NCI Concept Code C486. SMILES: OC1(C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C)C#C.
This classification denotes an ethyl ester of iodinated fatty acid of poppyseed oil. It contains 37% organically bound iodine and has been used as a diagnostic aid (radiopaque medium) and as an antineoplastic agent when part of the iodine is 131-I, a preparation with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KZW0R0686Q, chemically known as (3S,8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol, but more generally known as ethiodized oil or ethinodiol or etynodiol, which bears U.S. National Institutes of Health Compound Identifier 14687. The European Medicines Agency schedules Ethiodized Oil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13737MIG. The term ETHIODIZED OIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). ETYNODIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(CCC34)O. Most nations schedule Ethiodized oil or ethiodol or or lipiodol under HS 28444030.
This classification denotes an antitubercular agent with the molecular formula C8H10N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OAY8ORS3CQ, chemically known as cyclohexanol, 1-ethynyl-, carbamate but generally known as ethionamide, which bears US NIH Compound Identifier 3284. European Medicines Agency schedules Ethionamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07278MIG. The term ETHIONAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules ethionamide in its Anatomical Therapeutic Chemical (ATC) Classification. ETHIONAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethionamide under HS 29333999 and SITC 51574. As of Q4 2014, ETHIONAMIDE remains the US FDA Preferred Term for this commodity. Ethionamide bears US NLM identifiers UMLS ID C0733402 and NCI Concept Code C47522. SMILES: O(C1(CCCCC1)C#C)C(=O)N.
This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P201BVY1MJ, chemically known as 17.alpha.-pregn-4-en-20-yn-3-one, 17-hydroxy- but generally known as ethisterone, which bears US NIH Compound Identifier 3288. European Medicines Agency schedules Ethisterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07279MIG. The term ETHISTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules ethisterone in its Anatomical Therapeutic Chemical (ATC) Classification. ETHISTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethisterone under HS 29372300 and SITC 54153. As of Q4 2014, ETHISTERONE remains the US FDA Preferred Term for this commodity. Ethisterone bears US NLM identifiers UMLS ID C0015025 and NCI Concept Code C77012. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)C#C.
This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3A4G3A848U, chemically known as 1H-Azepine-4-carboxylic acid, hexahydro-1-methyl-4-phenyl-, ethyl ester but generally known as ethoheptazine, which bears US NIH Compound Identifier 6469. European Medicines Agency schedules ethoheptazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07280MIG. Most nations schedule ethoheptazine under HS 29339930 and SITC 51577. As of Q4 2014, ETHOHEPTAZINE remains the US FDA Preferred Term for this commodity. Ethoheptazine bears US NLM identifiers UMLS ID C0059725 and NCI Concept Code C76840. SMILES: CCOC(=O)C1(CCCN(CC1)C)C2=CC=CC=C2.
This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LXK8EE245D, chemically known as ethyl hexahydro-1-methyl-4-phenyl-1h-azepine-4-carboxylate, compound with citric acid (1:1) but more generally known as ethoheptazine citrate, which bears US NIH Compound Identifier 23165. European Medicines Agency schedules Ethoheptazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02001MIG. Most nations, for tariff and trade purposes, schedule ethoheptazine citrate under HS 29339930 and SITC 51577. As of Q4 2014, ETHOHEPTAZINE CITRATE remains US FDA's Preferred Term for this commodity. Ethoheptazine citrate bears US NLM identifiers UMLS ID C0770435 and NCI Concept Code C76841. SMILES: CCOC(=O)C1(CCCN(CC1)C)C2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KYO8O8JNO, chemically known as 1h-azepine-4-carboxylic acid, hexahydro-1-methyl-4-phenyl-, ethyl ester, hydrochloride (1:1), but more generally known as ethoheptazine hydrochloride, which bears US NIH Compound Identifier 6469. European Medicines Agency schedules ethoheptazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07280MIG. Most nations, for tariff purposes, schedule ethoheptazine hydrochloride under HS 29339930. SMILES: CCOC(=O)C1(CCCN(CC1)C)C2CCCCC2.CL.
This classification denotes an antiparkinsonian agent with the molecular formula C19H24N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7WI4P02YN1, chemically known as 10h-phenothiazine-10-ethanamine, n,n-diethyl-.alpha.-methyl-, monohydrochloride but generally known as ethopropazine, which bears US NIH Compound Identifier 3290. European Medicines Agency schedules Profenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10071MIG. The term ETHOPROPAZINE is an International Non-Proprietary Name. World Health Organization schedules ethopropazine in its Anatomical Therapeutic Chemical (ATC) Classification. Ethopropazine or profenamine bears US NLM identifiers UMLS ID C0015042 and NCI Concept Code C73333. SMILES: CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31.
This classification denotes an anticonvulsant agent with the molecular formula C7H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5SEH9X1D1D, chemically known as 2,5-pyrrolidinedione, 3-ethyl-3-methyl- but generally known as ethosuximide, which bears US NIH Compound Identifier 3291. European Medicines Agency schedules Ethosuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07282MIG. The term ETHOSUXIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules ethosuximide in its Anatomical Therapeutic Chemical (ATC) Classification. ETHOSUXIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethosuximide under HS 29251995 and SITC 51482. As of Q4 2014, ETHOSUXIMIDE remains the US FDA Preferred Term for this commodity. Ethosuximide bears US NLM identifiers UMLS ID C0015043 and NCI Concept Code C47523. SMILES: O=C1NC(=O)CC1(CC)C.
This classification denotes an anticonvulsant agent with the molecular formula C11H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46QG38NC4U, chemically known as 2,4-imidazolidinedione, 3-ethyl-5-phenyl- but generally known as ethotoin, which bears US NIH Compound Identifier 3292. European Medicines Agency schedules Ethotoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07283MIG. The term ETHOTOIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules ethotoin in its Anatomical Therapeutic Chemical (ATC) Classification. ETHOTOIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethotoin under HS 29332100 and SITC 51572. As of Q4 2014, ETHOTOIN remains the US FDA Preferred Term for this commodity. Ethotoin bears US NLM identifiers UMLS ID C0015046 and NCI Concept Code C47524. SMILES: CCN1C(=O)C(NC1=O)C2=CC=CC=C2.
This classification denotes an anticholinergic agent with the molecular formula C22H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1X2X9N95N, chemically known as 8-azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-ethyl-, endo- but generally known as ethybenztropine, which bears US NIH Compound Identifier 71637. European Medicines Agency schedules Etybenzatropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07348MIG. The term ETYBENZATROPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules ethybenztropine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.
A type of alcohol-based antiseptic that kills microorganisms by dissolving their membrane lipid bilayer and denaturing their proteins, and is effective against most bacteria and fungi and viruses. A solution of 70% ethanol is more effective than pure ethanol because ethanol relies on wsater molecules for optimal antimicrobial activity.
This classification denotes an anticoagulant agent with the molecular formula C22H16O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08KL644731, chemically known as 3,3-(carboxymethylene)bis(4-hydroxycoumarin) ethyl ester but generally known as ethyl biscoumacetate, which bears US NIH Compound Identifier 11047. European Medicines Agency schedules Ethyl biscoumacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07285MIG. The term ETHYL BISCOUMACETATE is an International Non-Proprietary Name. World Health Organization schedules ethyl biscoumacetate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ETHYL BISCOUMACETATE remains the US FDA Preferred Term for this commodity. Ethyl biscoumacetate bears US NLM identifiers UMLS ID C0015056 and NCI Concept Code C75157. SMILES: o1c(O)c(C(c2c(=O)c3c(oc2O)cccc3)C(=O)OCC)c(=O)c2c1cccc2.
This classification denotes a benzodiazepine with the molecular formula C20H17ClFN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36M73UIK01, chemically known as 1h-1,4-benzodiazepine-3-carboxylic acid, 2,3-dihydro-7-chloro-5-(2-fluorophenyl)-1-((methylamino)carbonyl)-2-oxo-, ethyl ester but generally known as ethyl carfluzepate, which bears US NIH Compound Identifier 68856. European Medicines Agency schedules Ethyl carfluzepate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07286MIG. The term ETHYL CARFLUZEPATE is an International Non-Proprietary Name. Most nations schedule ethyl carfluzepate under HS 29339940 and SITC 51577. As of Q4 2014, ETHYL CARFLUZEPATE remains the US FDA Preferred Term for this commodity. Ethyl carfluzepate bears US NLM identifiers UMLS ID C1880572 and NCI Concept Code C65563. SMILES: CCOC(=O)C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)C(=O)NC.
This classification denotes an analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46U771ERWK. European Medicines Agency schedules Ethyl chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13740MIG. Ethyl chloride generally arises in the molecular formula C2H5CL. The term ETHYL CHLORIDE is a U.S. Pharmacopeial Convention designation. Most nations schedule ethyl chloride under HS 29031190 and SITC 51136. As of Q4 2014, ETHYL CHLORIDE remains the US FDA Preferred Term for this commodity. Ethyl chloride bears US NLM identifiers UMLS ID C0015058 and NCI Concept Code C75067. SMILES: CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])CL)CL.[NA+].
This classification denotes a benzodiazepine with the molecular formula C18H14Cl2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74FAA305EW, chemically known as ethyl 7-chloro-5-(o-chlorophenyl)-2,3-dihydro-2-oxo-1h-1,4-benzodiazepine-3-carboxylate. but generally known as ethyl dirazepate, which bears US NIH Compound Identifier 208941. European Medicines Agency schedules Ethyl dirazepate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07289MIG. The term ETHYL DIRAZEPATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). Most nations schedule ethyl dirazepate under HS 29339940 and SITC 51577. As of Q4 2014, ETHYL DIRAZEPATE remains the US FDA Preferred Term for this commodity. Ethyl dirazepate bears US NLM identifiers UMLS ID C1880574 and NCI Concept Code C65565. SMILES: CCOC(=O)C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3Cl.
This classification denotes a chelating agent and anticoagulant agent with the molecular formula C10H16N2O8, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 9G34HU7RV0. The European Medicines Agency schedules edta in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16095MIG. The term EDETIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 13, no. 12, 1959, list 3. ). SMILES: OC(=O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.
This classification denotes an anabolic steroid with the molecular formula C20H32O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ADC79EK5Q8, chemically known as 19-norpregn-4-en-17-ol, (17.alpha.)- but generally known as ethylestrenol, which bears US NIH Compound Identifier 3302. European Medicines Agency schedules Ethylestrenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07291MIG. The term ETHYLESTRENOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules ethylestrenol in its Anatomical Therapeutic Chemical (ATC) Classification. ETHYLESTRENOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethylestrenol under HS 29372300 and SITC 54153. As of Q4 2014, ETHYLESTRENOL remains the US FDA Preferred Term for this commodity. Ethylestrenol bears US NLM identifiers UMLS ID C0015099 and NCI Concept Code C65568. SMILES: OC1(C2(C(C3C(CC2)C2C(=CCCC2)CC3)CC1)C)CC.
This classification denotes a benzodiazepine with the molecular formula C18H14ClFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJB5FW9W9J, chemically known as 1h-1,4-benzodiazepine-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro but generally known as ethyl loflazepate, which bears US NIH Compound Identifier 3299. European Medicines Agency schedules Ethyl loflazepate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07290MIG. The term ETHYL LOFLAZEPATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules ethyl loflazepate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ethyl loflazepate under HS 29339190 and SITC 51577. As of Q4 2014, ETHYL LOFLAZEPATE remains the US FDA Preferred Term for this commodity. Ethyl loflazepate bears US NLM identifiers UMLS ID C0059772 and NCI Concept Code C65566. SMILES: CCOC(=O)C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F.
This classification denotes an opioid receptor agonist with the molecular formula C15H19NS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 722BFZ899Q, chemically known asN-ethyl-N-methyl-4,4-dithiophen-2-ylbut-3-en-2-amine but generally known as Ethylmethylthiambutene, which bears US NIH Compound Identifier 46424. European Medicines Agency schedules Ethylmethylthiambutene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07292MIG. ETHYLMETHYLTHIAMBUTENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethylmethylthiambutene under HS 29349990 and SITC 51579. As of Q4 2014, ETHYLMETHYLTHIAMBUTENE remains the US FDA Preferred Term for this commodity. Ethylmethylthiambutene bears US NLM identifiers UMLS ID C1880576 and NCI Concept Code C65569. SMILES: CCN(C)C(C)C=C(C1=CC=CS1)C2=CC=CS2.
This classification denotes an opioid receptor agonist with the molecular structure C19H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, RWO67D87EU chemically known as (5.alpha.,6.alpha.)-7,8-didehydro-4,5-epoxy-3-ethoxy-17-methylmorphinan-6-ol but generally known as ethylmorphine, which bears US NIH Compound Identifier 5359271. European Medicines Agency schedules Ethylmorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13765MIG. As of Q4 2014, ETHYLMORPHINE remains the US FDA Preferred Term for this commodity. Ethylmorphine bears US NLM identifiers UMLS ID C0015109 and NCI Concept Code C83704. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OCC)CC3)C=CC2O.
This classification denotes an opioid receptor agonist with the molecular formula C19H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MFM5450P3T, chemically known as morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-ethoxy-17-methyl-, hydrochloride but more generally known as ethylmorphine hydrochloride, which bears US NIH Compound Identifier 5360692. European Medicines Agency schedules Ethylmorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13767MIG. Most nations, for tariff and trade purposes, schedule ethylmorphine hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, ETHYLMORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ethylmorphine hydrochloride bears US NLM identifiers UMLS ID C0770954 and NCI Concept Code C76842. SMILES: CCOC1CCC2C3C1O[C@@H]4[C@]35CCN([C@H](C2)[C@@H]5C=C[C@@H]4O)C.CL.
This classification denotes an anticonvulsant agent with the molecular formula C11H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 878CEJ4HGX, chemically known as urea, (2-phenylbutyryl)- but generally known as ethylphenacemide, which bears US NIH Compound Identifier 72060. European Medicines Agency schedules Pheneturide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09760MIG. The term PHENETURIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules ethylphenacemide in its Anatomical Therapeutic Chemical (ATC) Classification. Ethylphenacemide or pheneturide bears US NLM identifiers UMLS ID C0059837 and NCI Concept Code C72826. SMILES: CCC(C1=CC=CC=C1)C(=O)NC(=O)N.
This classification denotes a therapeutic progestin with the molecular formula C20H23ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CKM4S0R7LX, chemically known as 21-chloro-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-20-yn-3-one but generally known as ethynerone, which bears US NIH Compound Identifier 18403. European Medicines Agency schedules Ethynerone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07293MIG. The term ETHYNERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). ETHYNERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethynerone under HS 29372300 and SITC 54153. As of Q4 2014, ETHYNERONE remains the US FDA Preferred Term for this commodity. Ethynerone bears US NLM identifiers UMLS ID C0059848 and NCI Concept Code C74366. SMILES: ClC#CC1(O)C2(C(C3C(=C4C(=CC(=O)CC4)CC3)CC2)CC1)C.
This classification denotes a therapeutic progestin with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62H10A1236, chemically known as 19-norpregn-4-en-20-yne-3,17-diol, diacetate, (3.beta.,17.alpha.)- but generally known as ethynodiol diacetate, which bears US NIH Compound Identifier 3304. European Medicines Agency schedules Etynodiol diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02051MIG. As of Q4 2014, ETHYNODIOL DIACETATE remains the US FDA Preferred Term for this commodity. Ethynodiol diacetate bears US NLM identifiers UMLS ID C0015117 and NCI Concept Code C47525. SMILES: CC(=O)OC1CCC2C3CCC4(C(C3CCC2=C1)CCC4(C#C)OC(=O)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a sedative and hypnotic with the molecular formula C10H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2PO3M8FE7C, chemically known as 3,3-diethyl-5-methyl-2,4(1h,3h)-pyridinedione but generally known as ethypicone, which bears US NIH Compound Identifier 68842. European Medicines Agency schedules Ethypicone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07294MIG. The term ETHYPICONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). ETHYPICONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ethypicone under HS 29337900 and SITC 51561. As of Q4 2014, ETHYPICONE remains the US FDA Preferred Term for this commodity. Ethypicone bears US NLM identifiers UMLS ID C1880577 and NCI Concept Code C65570. SMILES: CCC1(C(=O)C(=CNC1=O)C)CC.
This classification denotes an antihelminthic agent with the molecular formula C18H16FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XU086MM3H, chemically known as r 34,803 but generally known as etibendazole, which bears US NIH Compound Identifier 71745. European Medicines Agency schedules Etibendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07295MIG. The term ETIBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). ETIBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etibendazole under HS 29349990 and SITC 51579. As of Q4 2014, ETIBENDAZOLE remains the US FDA Preferred Term for this commodity. Etibendazole bears US NLM identifiers UMLS ID C1880578 and NCI Concept Code C65571. SMILES: FC1CCC(C2(OCCO2)C2CC3[NH]C(NC3CC2)NC(=O)OC)CC1.
This classification denotes an anesthetic agent with the molecular formula C14H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O8I1LL6A89, chemically known as cyclohexylamine, n-ethyl-1-phenyl- (8ci) but generally known as eticyclidine, which bears US NIH Compound Identifier 16622. European Medicines Agency schedules Eticyclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07297MIG. The term ETICYCLIDINE is an International Non-Proprietary Name. ETICYCLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule eticyclidine under HS 29214980 and SITC 51454. As of Q4 2014, ETICYCLIDINE remains the US FDA Preferred Term for this commodity. Eticyclidine bears US NLM identifiers UMLS ID C1880579 and NCI Concept Code C65573. SMILES: N(C1(CCCCC1)C1CCCCC1)CC.
This classification denotes an anesthetic agent with the molecular formula C17H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I6CQM0F31V, chemically known as 2-(ethylpropylamino)-2,6-butyroxylidide but generally known as etidocaine, which bears US NIH Compound Identifier 37497. European Medicines Agency schedules Etidocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07298MIG. The term ETIDOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules etidocaine in its Anatomical Therapeutic Chemical (ATC) Classification. ETIDOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etidocaine under HS 29242995 and SITC 51479. As of Q4 2014, ETIDOCAINE remains the US FDA Preferred Term for this commodity. Etidocaine bears US NLM identifiers UMLS ID C0015120 and NCI Concept Code C65574. SMILES: O=C(NC1C(CCCC1C)C)C(N(CCC)CC)CC.
This classification denotes an anesthetic agent with the molecular formula C17H28N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6N3B3U8E6, chemically known as 2,6-butyroxylidide, 2-(n-ethylpropylamino)-, hydrochloride, (+-)- but more generally known as etidocaine hydrochloride, which bears US NIH Compound Identifier 37498. European Medicines Agency schedules Etidocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02037MIG. Most nations, for tariff and trade purposes, schedule etidocaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, ETIDOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etidocaine hydrochloride bears US NLM identifiers UMLS ID C0733377 and NCI Concept Code C77325. SMILES: CCCN(CC)C(CC)C(=O)NC1C(CCCC1C)C.CL.
This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C2H6O7P2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M16PXG993G, chemically known as 1,1,1-ethanetriol diphosphonate but generally known as etidronate disodium, which bears US NIH Compound Identifier 3305. European Medicines Agency schedules Etidronate disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13771MIG. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)C.
This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C2H8O7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M2F465ROXU, chemically known as 1,1,1-ethanetriol diphosphonate but generally known as etidronic acid, which bears US NIH Compound Identifier 3305. European Medicines Agency schedules Etidronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07299MIG. The term ETIDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules etidronic acid in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ETIDRONIC ACID remains the US FDA Preferred Term for this commodity. Etidronic acid bears US NLM identifiers UMLS ID C0015121 and NCI Concept Code C1332. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)C.
This classification denotes an anxiolytic with the molecular formula C17H17ClN2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier X24X82MX4X, chemically known as 6-chloro-2-ethylamino-4-methyl-4-phenyl-4h-3,1-benzoxazine but more generally known as etifoxine, which bears U.S. National Institutes of Health Compound Identifier 30768. European Medicines Agency schedules Etifoxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07302MIG. The term ETIFOXINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules etifoxine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. ETIFOXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a cns stimulant with the molecular formula C11H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 022YON1XMX, chemically known as phenethylamine, n-ethyl-.alpha.-methyl-, hydrochloride but more generally known as etilamfetamine, which bears US NIH Compound Identifier 9982. European Medicines Agency schedules Etilamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12434MIG. The term ETILAMFETAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules etilamfetamine in its Anatomical Therapeutic Chemical (ATC) Classification. ETILAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCNC(C)CC1=CC=CC=C1.
This classification denotes an adrenergic agent with the molecular formula C10H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZB6F8MY53V, chemically known as benzyl alcohol, alpha-((ethylamino)methyl)-m-hydroxy- but generally known as etilefrin, which bears US NIH Compound Identifier 3306. European Medicines Agency schedules Etilefrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07303MIG. The term ETILEFRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules etilefrin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule etilefrine under HS 29225000 and SITC 51467. As of Q4 2014, ETILEFRINE remains the US FDA Preferred Term for this commodity. Etilefrine bears US NLM identifiers UMLS ID C0015116 and NCI Concept Code C65576. SMILES: CCNCC(C1=CC(=CC=C1)O)O.
This classification denotes an antiparkinsonian agent with the molecular formula C11H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 895X917GYE, chemically known as (-)-3,4-dihydroxy-l-phenylalanine, ethyl ester but generally known as etilevodopa, which bears US NIH Compound Identifier 170345. European Medicines Agency schedules Etilevodopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02042MIG. The term ETILEVODOPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule etilevodopa under HS 29225000 and SITC 51467. As of Q4 2014, ETILEVODOPA remains the US FDA Preferred Term for this commodity. Etilevodopa bears US NLM identifiers UMLS ID C1434556 and NCI Concept Code C81562. SMILES: CCOC(=O)C(CC1=CC(=C(C=C1)O)O)N.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C12H16N6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, A60Z457SSF chemically known as guanidine, n''-cyano-n-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)-n'-2-propynyl- but generally known as etintidine, which bears US NIH Compound Identifier 150172. European Medicines Agency schedules Etintidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07305MIG. The term ETINTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21). Most nations schedule etintidine under HS 29332990 and SITC 51573. As of Q4 2014, ETINTIDINE remains the US FDA Preferred Term for this commodity. Etintidine bears US NLM identifiers UMLS ID C0059856 and NCI Concept Code C81154. SMILES: CC1=C(N=CN1)CSCCNC(=NCC#C)NC#N.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C12H16N6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T20BD719DD, chemically known as guanidine, n-cyano-n-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)-n-2-propynyl-, monohydrochloride but more generally known as etintidine hydrochloride, which bears US NIH Compound Identifier 150171. Most nations, for tariff and trade purposes, schedule etintidine hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, ETINTIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etintidine hydrochloride bears US NLM identifiers UMLS ID C0955885 and NCI Concept Code C81155. SMILES: CC1C(NC[NH]1)CSCCNC(=NC#N)NCC#C.CL.
This classification denotes an anticonvulsant agent with the molecular formula C8H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 230447L0GL, chemically known as 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-, (s)- but generally known as etiracetam, which bears US NIH Compound Identifier 59708. European Medicines Agency schedules Etiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07308MIG. The term ETIRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). ETIRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etiracetam under HS 29337900 and SITC 51561. As of Q4 2014, ETIRACETAM remains the US FDA Preferred Term for this commodity. Etiracetam bears US NLM identifiers UMLS ID C0059859 and NCI Concept Code C78002. SMILES: O=C1N(CCC1)C(CC)C(=O)N.
This classification denotes an antibiotic with the molecular formula C20H39N5O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0BZK9FE5DE, chemically known as o-3-deoxy-3-(ethylamino)-4-c-methyl-beta-l-arabinopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1->6))-2-deoxy-l-streptamine. but more generally known as etisomicin, which bears US NIH Compound Identifier 216268. European Medicines Agency schedules Etisomicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07311MIG. The term ETISOMICIN is an International Non-Proprietary Name. ETISOMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(O)C(OC2OC(=CCC2N)CN)C(N)CC1N)C1OCC(O)(C(NCC)C1O)C.
This classification denotes a benzodiazepine with the molecular formula C17H15ClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A76XI0HL37, chemically known as 8-ethyl-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine but generally known as etizolam, which bears US NIH Compound Identifier 3307. European Medicines Agency schedules Etizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07313MIG. The term ETIZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules etizolam in its Anatomical Therapeutic Chemical (ATC) Classification. ETIZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etizolam under HS 29349990 and SITC 51579. As of Q4 2014, ETIZOLAM remains the US FDA Preferred Term for this commodity. Etizolam bears US NLM identifiers UMLS ID C0059862 and NCI Concept Code C65583. SMILES: CLC1C(C2=NCC3N(C4SC(CC24)CC)C(NN3)C)CCCC1.
This classification denotes an antitubercular agent with the molecular formula C17H20N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46V3V5EQAM, chemically known as 4,4-diethoxythiocarbanilide but more generally known as etocarlide, which bears US NIH Compound Identifier 667483. European Medicines Agency schedules Etocarlide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07314MIG. The term ETOCARLIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). ETOCARLIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S=C(NC1CCC(OCC)CC1)NC1CCC(OCC)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M36281008, chemically known as 1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid but generally known as etodolac, which bears US NIH Compound Identifier 3308. European Medicines Agency schedules Etodolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07316MIG. The term ETODOLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules etodolac in its Anatomical Therapeutic Chemical (ATC) Classification. ETODOLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etodolac under HS 29349990 and SITC 51579. As of Q4 2014, ETODOLAC remains the US FDA Preferred Term for this commodity. Etodolac bears US NLM identifiers UMLS ID C0059865 and NCI Concept Code C47526. SMILES: O1C(C2[NH]C3C(C2CC1)CCCC3CC)(CC)CC(=O)O.
This classification denotes a sedative and hypnotic with the molecular formula C23H31ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CI1S3XAK7O, chemically known as 3,6-dioxaoctanol, 8-(4-(4-chlorophenylphenylmethyl)piperazinyl)- but generally known as etodroxizine, which bears US NIH Compound Identifier 63345. European Medicines Agency schedules Etodroxizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07317MIG. The term ETODROXIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). ETODROXIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etodroxizine under HS 29335995 and SITC 51576. As of Q4 2014, ETODROXIZINE remains the US FDA Preferred Term for this commodity. Etodroxizine bears US NLM identifiers UMLS ID C0059866 and NCI Concept Code C65585. SMILES: CLC1CCC(C(N2CCN(CC2)CCOCCOCCO)C2CCCCC2)CC1.
This classification denotes a sedative and hypnotic C23H31ClN2O3.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O9NQM95R01, chemically known as ethanol, 2-(2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethoxy)-, (2z)-2-butenedioate (1:2) (salt), but more generally known as etodroxizine dimaleate, which bears US NIH Compound Identifier 6446285. Most nations, for tariff and trade purposes, schedule etodroxizine dimaleate under HS 29335995 and SITC 51576. As of Q4 2014, ETODROXIZINE DIMALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(N2CCN(CC2)CCOCCOCCO)C3CCC(CC3)CL.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes a sedative and hypnotic with the molecular formula C23H31CLN2O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7P7N107PNA. European Medicines Agency schedules etodroxizine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02044MIG. Most nations, for tariff and trade purposes, schedule etodroxizine maleate under HS 29335995 and SITC 51576. As of Q4 2014, ETODROXIZINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(C2CCC(CC2)CL)N3CCN(CC3)CCOCCOCCO.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antiprotozoal agent with the molecular formula C19H20Cl2N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03F36JH21U, chemically known as 2,2-dichloro-n-(2-ethoxyethyl)-n-(p-(p-nitrophenoxy)benzyl)acetamide but generally known as etofamide, which bears US NIH Compound Identifier 65718. European Medicines Agency schedules Etofamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07318MIG. The term ETOFAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules etofamide in its Anatomical Therapeutic Chemical (ATC) Classification. ETOFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etofamide under HS 29242995 and SITC 51479. As of Q4 2014, ETOFAMIDE remains the US FDA Preferred Term for this commodity. Etofamide bears US NLM identifiers UMLS ID C0059867 and NCI Concept Code C65586. SMILES: CLC(CL)C(=O)N(CC1CCC(OC2CCC([N](=O)O)CC2)CC1)CCOCC.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H18F3NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KZF0XM66JC, chemically known as 2-(2-hydroxyethoxy)ethyl-n-(alpha,alpha,alpha-trifluoro-m-tolyl)anthranilate but generally known as etofenamate, which bears US NIH Compound Identifier 35375. European Medicines Agency schedules Etofenamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07319MIG. The term ETOFENAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules etofenamate in its Anatomical Therapeutic Chemical (ATC) Classification. ETOFENAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etofenamate under HS 29224995 and SITC 51465. As of Q4 2014, ETOFENAMATE remains the US FDA Preferred Term for this commodity. Etofenamate bears US NLM identifiers UMLS ID C0059868 and NCI Concept Code C80545. SMILES: FC(F)(F)C1CC(NC2C(CCCC2)C(=O)OCCOCCO)CCC1.
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23TF67G79M. European Medicines Agency schedules Etofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07321MIG. Etofibrate generally arises in the molecular formula C18H18CLNO5. The term ETOFIBRATE is an International Non-Proprietary Name or INN. ETOFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etofibrate under HS 29333999 and SITC 51574. As of Q4 2014, ETOFIBRATE remains the US FDA Preferred Term for this commodity. Etofibrate bears US NLM identifiers UMLS ID C0059869 and NCI Concept Code C65588. SMILES: Clc1ccc(OC(C)(C)C(=O)OCCOC(=O)c2cccnc2)cc1.
This classification denotes an anti-diabetic agent with the molecular formula C8H19N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 630F8M4Q1D, chemically known as 1-butyl-2-ethylbiguanide but more generally known as etoformin, which bears US NIH Compound Identifier 170347. European Medicines Agency schedules etoformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07322MIG. Most nations, for tariff and trade purposes, schedule etoformin under HS 29252900 and SITC 51482. As of Q4 2014, ETOFORMIN remains US FDA's Preferred Term for this commodity. Etoformin bears US NLM identifiers UMLS ID C1880583 and NCI Concept Code C65589. SMILES: CCCCN=C(NCC)N=C(N)N.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C9H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L164909TBI, chemically known as 3,7-dihydro-7-(2-hydroxyethyl)-1,3-dimethyl-1h-purine-2,6-dione (9ci) but generally known as etofylline, which bears US NIH Compound Identifier 1892. European Medicines Agency schedules Etofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07324MIG. The term ETOFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). ETOFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etofylline under HS 29395900 and SITC 54145. As of Q4 2014, ETOFYLLINE remains the US FDA Preferred Term for this commodity. Etofylline bears US NLM identifiers UMLS ID C0059871 and NCI Concept Code C80611. SMILES: O=C1N(C(=O)N(C2NCN(C12)CCO)C)C.
This classification denotes a vasodilating agent with the molecular formula C15H15N5O4, chemically known as 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl pyridine-3-carboxylate but generally known as Etofylline nicotinate, which bears US NIH Compound Identifier 83435. European Medicines Agency schedules Etofylline nicotinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07324MIG. World Health Organization schedules regadenoson in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule etofylline nicotinate under HS 29395900 and SITC 54145. As of Q4 2014, ETOFYLLINE NICOTINATE remains the US FDA Preferred Term for this commodity. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCOC(=O)C3=CN=CC=C3.
This classification denotes an antineoplastic alkylating agent with the molecular formula C12H22O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F9KUA0T4D, chemically known as 4,7,10,13-tetraoxahexadecane, 1,2:15,16-diepoxy- (8ci) but more generally known as etoglucid, which bears US NIH Compound Identifier 16058. European Medicines Agency schedules Etoglucid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07326MIG. The term ETOGLUCID is an International Non-Proprietary Name. World Health Organization schedules etoglucid in its Anatomical Therapeutic Chemical (ATC) Classification. ETOGLUCID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule etoglucid under HS 29109000 and SITC 51615. As of Q4 2014, ETOGLUCID remains US FDA's Preferred Term for this commodity. Etoglucid bears US NLM identifiers UMLS ID C0015039 and NCI Concept Code C489. SMILES: O1C(C1)COCCOCCOCCOCC1OC1.
This classification denotes an anorexiant with the molecular formula C12H18ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 449NCX1P03, chemically known as 2-((p-chloro-alpha,alpha-dimethyl-phenethyl)amino)ethanol but more generally known as etolorex, which bears US NIH Compound Identifier 208943. European Medicines Agency schedules Etolorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07327MIG. The term ETOLOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). ETOLOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule etolorex under HS 29221980 and SITC 51461. As of Q4 2014, ETOLOREX remains US FDA's Preferred Term for this commodity. Etolorex bears US NLM identifiers UMLS ID C1880586 and NCI Concept Code C65592. SMILES: CC(C)(CC1=CC=C(C=C1)CL)NCCO.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C24H29NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U64HJ4AK57, chemically known as 4,9-dihydro-4-(1-(2-(-2(2-hydroxyethoxy)ethoxy)ethyl)-4-piperidylidene)-10h-ben-zo(4,5)cyclohepta(1,2-b)thiophen-10-one. but generally known as etolotifen, which bears US NIH Compound Identifier 208944. European Medicines Agency schedules Etolotifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07328MIG. The term ETOLOTIFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). ETOLOTIFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etolotifen under HS 29349990 and SITC 51579. As of Q4 2014, ETOLOTIFEN remains the US FDA Preferred Term for this commodity. Etolotifen bears US NLM identifiers UMLS ID C1880587 and NCI Concept Code C65593. SMILES: S1C2C(C(=C3\CCN(CC3)CCOCCOCCO)\C3C(CC2=O)CCCC3)CC1.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NEZ417265P. European Medicines Agency schedules Etoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07329MIG. Etoloxamine generally arises in the molecular formula C19H25NO. The term ETOLOXAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) ETOLOXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etoloxamine under HS 29221980 and SITC 51461. As of Q4 2014, ETOLOXAMINE remains the US FDA Preferred Term for this commodity. Etoloxamine bears US NLM identifiers UMLS ID C0659884 and NCI Concept Code C65594. SMILES: O(CCN(CC)CC)C1C(CC2CCCCC2)CCCC1.
This classification denotes an anesthetic agent with the molecular formula C14H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z22628B598, chemically known as 1h-imidazole-5-carboxylic acid, 1-((1r)-1-phenylethyl)-, ethyl ester but generally known as etomidate, which bears US NIH Compound Identifier 36339. European Medicines Agency schedules Etomidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07330MIG. The term ETOMIDATE is an International Non-Proprietary Name. World Health Organization schedules etomidate in its Anatomical Therapeutic Chemical (ATC) Classification. ETOMIDATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etomidate under HS 29332990 and SITC 51573. As of Q4 2014, ETOMIDATE remains the US FDA Preferred Term for this commodity. Etomidate bears US NLM identifiers UMLS ID C0015131 and NCI Concept Code C47527. SMILES: O(C(=O)C1N(C(C2CCCCC2)C)CNC1)CC.
This classification denotes an anesthetic agent with the molecular formula C14H16N2O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZUM3W5027S. European Medicines Agency schedules etomidate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02046MIG. Most nations, for tariff and trade purposes, schedule etomidate hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, ETOMIDATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)C1CNCN1[C@H](C)C2CCCCC2.CL.
This classification denotes an anesthetic agent with the molecular formula C14H16N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y26131IQZI, chemically known as 1h-imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (r)- sulfate (1:1) but more generally known as etomidate sulfate, which bears US NIH Compound Identifier 3084993. European Medicines Agency schedules Etomidate sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02047MIG. Most nations, for tariff and trade purposes, schedule etomidate sulfate under HS 29332990 and SITC 51573. As of Q4 2014, ETOMIDATE SULFATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)C1CNCN1[C@H](C)C2CCCCC2.OS(=O)(=O)O.
This classification denotes an enzyme inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MSB3DD2XP6. European Medicines Agency schedules Etomoxir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07332MIG. Etomoxir generally arises in the molecular formula C17H23CLO4. The term ETOMOXIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) Most nations schedule etomoxir under HS 29189900 and SITC 51396. As of Q4 2014, ETOMOXIR remains the US FDA Preferred Term for this commodity. Etomoxir bears US NLM identifiers UMLS ID C0059872 and NCI Concept Code C81111. SMILES: CLC1CCC(OCCCCCCC2(OC2)C(=O)OCC)CC1.
This classification denotes an analgesic agent with the molecular formula C22H28N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9U3GT3353T, chemically known as 1h-benzimidazole-1-ethanamine, 2-((4-ethoxyphenyl)methyl)-n,n-diethyl-5-nitro- (9ci) but generally known as etonitazene, which bears US NIH Compound Identifier 13493. European Medicines Agency schedules Etonitazene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07334MIG. The term ETONITAZENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). ETONITAZENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etonitazene under HS 29339990 and SITC 51577. As of Q4 2014, ETONITAZENE remains the US FDA Preferred Term for this commodity. Etonitazene bears US NLM identifiers UMLS ID C0015132 and NCI Concept Code C65596. SMILES: O(C1CCC(CC2N(CCN(CC)CC)C3C(N2)CC([N](=O)O)CC3)CC1)CC.
This classification denotes an analgesic agent with the molecular formula C22H28N4O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LD057W8P8B, chemically known as benzimidazole, 1-(2-(diethylamino)ethyl)-2-(p-ethoxybenzyl)-5-nitro-, hydrochloride, but more generally known as etonitazene hydrochloride, which bears US NIH Compound Identifier 16334. European Medicines Agency schedules etonitazene hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07334MIG. Most nations, for tariff purposes, schedule etonitazene hydrochloride under HS 29339990. SMILES: CCN(CC)CCN1C2CCC(CC2NC1CC3CCC(CC3)OCC)[N+](=O)[O-].CL.
This classification denotes a therapeutic progestin with the molecular formula C22H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 304GTH6RNH, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- but generally known as etonogestrel, which bears US NIH Compound Identifier 40976. European Medicines Agency schedules Etonogestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07335MIG. The term ETONOGESTREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules etonogestrel in its Anatomical Therapeutic Chemical (ATC) Classification. ETONOGESTREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etonogestrel under HS 29372300 and SITC 54153. As of Q4 2014, ETONOGESTREL remains the US FDA Preferred Term for this commodity. Etonogestrel bears US NLM identifiers UMLS ID C0047683 and NCI Concept Code C47528. SMILES: OC1(C2(C(C3C(C4C(=CC(=O)CC4)CC3)C(=C)C2)CC1)CC)C#C.
This classification denotes a combination contraceptive drug. The first component of this drug is etonogestrel, a therapeutic progestin with the molecular formula C22H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 304GTH6RNH, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- but generally known as etonogestrel, which bears US NIH Compound Identifier 40976. European Medicines Agency schedules Etonogestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07335MIG. The term ETONOGESTREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules etonogestrel in its Anatomical Therapeutic Chemical (ATC) Classification. ETONOGESTREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1(C2(C(C3C(C4C(=CC(=O)CC4)CC3)C(=C)C2)CC1)CC)C#C. The second component of this drug is ethinyl estradiol, a therapeutic estradiol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 423D2T571U. European Medicines Agency schedules Ethinyl estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07277MIG. Ethinylestradiol generally arises in the molecular formula C20H24O2. The term 'ethinylestradiol' is a European Medicines Agency European Public Assessment Report System designation. ETHINYLESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1(C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C)C#C.
This classification denotes an antiemetic agent with the molecular formula C19H28ClN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KAI6MVO39Z, chemically known as 1,2,4-triazol-3-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-4,5-diethyl-2,4-dihydro- but generally known as etoperidone, which bears US NIH Compound Identifier 40589. European Medicines Agency schedules Etoperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07336MIG. The term ETOPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules etoperidone in its Anatomical Therapeutic Chemical (ATC) Classification. ETOPERIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etoperidone under HS 29335995 and SITC 51576. As of Q4 2014, ETOPERIDONE remains the US FDA Preferred Term for this commodity. Etoperidone bears US NLM identifiers UMLS ID C0059873 and NCI Concept Code C65597. SMILES: Clc1cc(N2CCN(CC2)CCCn2nc(n(c2=O)CC)CC)ccc1.
This classification denotes an antiemetic agent with the molecular formula C19H28ClN5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2FSU2FR80J, chemically known as 1,2,4-triazol-3-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-4,5-diethyl-2,4-dihydro- but more generally known as etoperidone hydrochloride, which bears US NIH Compound Identifier 40589. Most nations, for tariff and trade purposes, schedule etoperidone hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ETOPERIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etoperidone hydrochloride bears US NLM identifiers UMLS ID C1880588 and NCI Concept Code C63783. SMILES: CCC1NN(C(=O)N1CC)CCCN2CCN(CC2)C3CCCC(C3)CL.CL.
This classification denotes an epipodophyllotoxin compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6PLQ3CP4P3. European Medicines Agency schedules Etoposide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07337MIG. Etoposide generally arises in the molecular formula C29H32O13. The term ETOPOSIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) ETOPOSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etoposide under HS 29389090 and SITC 54161. As of Q4 2014, ETOPOSIDE remains the US FDA Preferred Term for this commodity. Etoposide bears US NLM identifiers UMLS ID C0015133 and NCI Concept Code C491. SMILES: O(C1C2C(C(C3C1CC1OCOC1C3)C1CC(OC)C(O)C(OC)C1)C(=O)OC2)C1OC2C(OC(OC2)C)C(O)C1O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H15ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRX4NFY03R, chemically known as 2,3-bipyridine, 5-chloro-6-methyl-3-(4-(methylsulfonyl)phenyl)- but generally known as etoricoxib, which bears US NIH Compound Identifier 123619. European Medicines Agency schedules Etoricoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16429MIG. The term ETORICOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). World Health Organization schedules etoricoxib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule etoricoxib under HS 29333999 and SITC 51574. As of Q4 2014, ETORICOXIB remains the US FDA Preferred Term for this commodity. Etoricoxib bears US NLM identifiers UMLS ID C0972314 and NCI Concept Code C52188. SMILES: CLC1CC(C2CCC(S(=O)(=O)C)CC2)C(NC1)C1CCC(NC1)C.
This classification denotes an opioid receptor agonist with the molecular formula C25H33NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42M2Y6NU9O, chemically known as 6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine but generally known as etorphine, which bears US NIH Compound Identifier 26721. European Medicines Agency schedules Etorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07339MIG. The term ETORPHINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). ETORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etorphine under HS 29391100 and SITC 54141. As of Q4 2014, ETORPHINE remains the US FDA Preferred Term for this commodity. Etorphine bears US NLM identifiers UMLS ID C0015134 and NCI Concept Code C80578. SMILES: O1C2C34C5(C(N(CC3)C)CC3C4C1C(O)CC3)CC(C2(OC)C=C5)C(O)(CCC)C.
This classification denotes an opioid receptor agonist with the molecular formula C25H33NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8CBE01N748, chemically known as 6,14-endo-ethenotetrahydrooripavine, 7-alpha-(1-(r)-hydroxy-1-methylbutyl)-, hydrochloride but more generally known as etorphine hydrochloride, which bears US NIH Compound Identifier 61677. Most nations, for tariff and trade purposes, schedule etorphine hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, ETORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etorphine hydrochloride bears US NLM identifiers UMLS ID C0521927 and NCI Concept Code C83705. SMILES: CCC[C@](C)([C@H]1C[C@@]23C=C[C@]1([C@H]4[C@@]25CCN([C@@H]3CC6C5C(C(CC6)O)O4)C)OC)O.CL.
This classification denotes an anesthetic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SIQ2UWR01K, chemically known as piperidine, 2-(2-ethyl-2-phenyl-1,3-dioxolan-4-yl)- (9ci) but generally known as etoxadrol, which bears US NIH Compound Identifier 19324. European Medicines Agency schedules Etoxadrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07341MIG. The term ETOXADROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). ETOXADROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etoxadrol under HS 29349990 and SITC 51579. As of Q4 2014, ETOXADROL remains the US FDA Preferred Term for this commodity. Etoxadrol bears US NLM identifiers UMLS ID C0015135 and NCI Concept Code C81415. SMILES: O1C(C2NCCCC2)COC1(CC)C1CCCCC1.
This classification denotes an anesthetic agent with the molecular formula C16H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OB67QC801N, chemically known as piperidine, 2-(2-ethyl-2-phenyl-1,3-dioxolan-4-yl),hydrochloride but more generally known as etoxadrol hydrochloride, which bears US NIH Compound Identifier 170363. Most nations, for tariff and trade purposes, schedule etoxadrol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ETOXADROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etoxadrol hydrochloride bears US NLM identifiers UMLS ID C2825621 and NCI Concept Code C81412. SMILES: CC[C@@]1(OC[C@@H](O1)[C@@H]2CCCCN2)C3CCCCC3.CL.
This classification denotes a loop diuretic and antihypertensive agent with the molecular formula C13H20N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UEO8UW9V1Z, chemically known as 3-methyl-4-oxo-5-piperidino-.delta.(sup2,a)-thiazolidineacetic acid ethyl ester but generally known as etozolin, which bears US NIH Compound Identifier 5384145. European Medicines Agency schedules Etozolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07344MIG. The term ETOZOLIN is an International Non-Proprietary Name. World Health Organization schedules etozolin in its Anatomical Therapeutic Chemical (ATC) Classification. ETOZOLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etozolin under HS 29341000 and SITC 51579. As of Q4 2014, ETOZOLIN remains the US FDA Preferred Term for this commodity. Etozolin bears US NLM identifiers UMLS ID C0059877 and NCI Concept Code C65600. SMILES: S1C(N2CCCCC2)C(=O)N(C\1=C/C(=O)OCC)C.
This classification denotes a dopamine antagonist with the molecular formula C8H12N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V55R69267Q, chemically known as 4,5,6,7-tetrahydro-6-(methylamino)benzothiazole but generally known as etrabamine, which bears US NIH Compound Identifier 68895. European Medicines Agency schedules Etrabamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07345MIG. The term ETRABAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). ETRABAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etrabamine under HS 29341000 and SITC 51579. As of Q4 2014, ETRABAMINE remains the US FDA Preferred Term for this commodity. Etrabamine bears US NLM identifiers UMLS ID C1880591 and NCI Concept Code C65601. SMILES: s1c2CC(NC)CCc2nc1.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C20H15BrN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C50HW4FO1, chemically known as benzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl- but generally known as etravirine, which bears US NIH Compound Identifier 193962. European Medicines Agency schedules Etravirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25650. The term ETRAVIRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules etravirine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule etravirine under HS 29335995 and SITC 51576. As of Q4 2014, ETRAVIRINE remains the US FDA Preferred Term for this commodity. Etravirine bears US NLM identifiers UMLS ID C1456409 and NCI Concept Code C73195. SMILES: Brc1c(Oc2c(cc(cc2C)C#N)C)nc(Nc2ccc(cc2)C#N)nc1N.
This classification denotes a retinoic acid agent with the molecular formula C23H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65M2UDR9AG, chemically known as ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoate but generally known as etretinate, which bears US NIH Compound Identifier 3312. European Medicines Agency schedules Etretinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07346MIG. The term ETRETINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules etretinate in its Anatomical Therapeutic Chemical (ATC) Classification. ETRETINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etretinate under HS 29189900 and SITC 51396. As of Q4 2014, ETRETINATE remains the US FDA Preferred Term for this commodity. Etretinate bears US NLM identifiers UMLS ID C0015137 and NCI Concept Code C29036. SMILES: O(C1C(C(C(C(C1)C)/C=C/C(=C/C=C/C(=C/C(=O)OCC)C)C)C)C)C.
This classification denotes an ethynodiol analog, synthetic progestational hormone, and oral contraceptive with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E01C36A9S, chemically known as 19-norpregn-4-en-20-yne-3,17-diol, diacetate, (3beta,17alpha)- but generally known as etynodiol, which bears US NIH Compound Identifier 9270. European Medicines Agency schedules Etynodiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07350MIG. World Health Organization schedules etynodiol in its Anatomical Therapeutic Chemical (ATC) Classification. ETYNODIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etynodiol under HS 29372300 and SITC 54153. SMILES: O(C1(C2(C(C3C(CC2)C2C(=CC(OC(=O)C)CC2)CC3)CC1)C)C#C)C(=O)C.
This classification denotes a therapeutic progestin with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62H10A1236, chemically known as 19-norpregn-4-en-20-yne-3,17-diol, diacetate, (3.beta.,17.alpha.)- but more generally known as ethynodiol diacetate, which bears US NIH Compound Identifier 3304. European Medicines Agency schedules Etynodiol diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02051MIG. Most nations, for tariff and trade purposes, schedule etynodiol diacetate under HS 29372300 and SITC 54153. SMILES: CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2R04ONI662, the source of which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S546YLW6E6, the source of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 27189 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Myrtales, Family Myrtaceae (myrtles, myrtacees), Genus Eucalyptus, Species Eucalyptus globulus Labill., commonly known as BLUEGUM EUCALYPTUS, TASMANIAN BLUEGUM, or as here, EUCALYPTUS GLOBULUS. Eucalyptus globulus bears the USDA PLANTS Database Identifier EUGLG. European Medicines Agency schedules eucalyptus globulus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB30093, SUB31258, SUB40650, SUB40651, SUB46069, SUB46070, SUB46071, and SUB46072. This classification concerns the chemically-neutral viscous substance extracted from organs of eucalyptus globulus, which is to say, the oil extracted from eucalyptus globulus leaves. Eucalyptol or eucalyptus oil bears US NLM identifiers UMLS ID C0055738 and NCI Concept Code C76772.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a local anti-infective agents, fluorescent dye, and intercalating agent with the molecular formula C14H14N3.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1TW3Q60E36, chemically known as 3,6-diamino-10-methylacridinium chloride hydrochloride but generally known as euflavine, which bears US NIH Compound Identifier 91561. World Health Organization schedules euflavine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N. SMILES: C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.
This classification denotes an anesthetic agent with the molecular formula C10H12O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3T8H1794QW, chemically known as 1,3,4-eugenol but generally known as eugenol, which bears US NIH Compound Identifier 3314. European Medicines Agency schedules Eugenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13776MIG. As of Q4 2014, EUGENOL remains the US FDA Preferred Term for this commodity. Eugenol bears US NLM identifiers UMLS ID C0015153 and NCI Concept Code C75095. SMILES: COC1=C(C=CC(=C1)CC=C)O.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers DG4F8T839X and M9VVZ08EKQ (leaf and root), and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 35980 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Asterales, Family Asteraceae, Genus Eupatorium L. (thoroughwort), Species Eupatorium perfoliatum L., more commonly known as EUPATORIUM. Eupatorium bears the USDA PLANTS Database Identifiers EUPE3, EUPEC, and EUPEP. European Medicines Agency schedules eupatorium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13779MIG, SUB34756, SUB40652, SUB40653, SUB46075, SUB55050, and SUB63369.
This classification denotes an anesthetic agent with the molecular formula C24H34N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KRZ086R2VC, chemically known as 10,11-dihydro-6-(3-methylbutoxy)cinchonan-9-ol but generally known as euprocin, which bears US NIH Compound Identifier 14764. European Medicines Agency schedules Euprocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07352MIG. The term EUPROCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). EUPROCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule euprocin under HS 29392000 and SITC 54142. As of Q4 2014, EUPROCIN remains the US FDA Preferred Term for this commodity. Euprocin bears US NLM identifiers UMLS ID C0770363 and NCI Concept Code C81410. SMILES: OC(C1N2CC(C(C1)CC2)CC)C1C2C(NCC1)CCC(OCCC(C)C)C2.
This classification denotes an anesthetic agent C24H34N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EVA0339N2N, chemically known as cinchonan-9-ol, 10,11-dihydro-6'-(3-methylbutoxy)-, dihydrochloride, (8.alpha.,9r)-, but more generally known as euprocin hydrochloride, which bears US NIH Compound Identifier 68544. Most nations, for tariff and trade purposes, schedule euprocin hydrochloride under HS 29392000 and SITC 54142. As of Q4 2014, EUPROCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Euprocin hydrochloride bears US NLM identifiers UMLS ID C2700027 and NCI Concept Code C75096. SMILES: CC[C@H]1C[N@@]2CC[C@H]1C[C@H]2[C@@H](C3CCNC4C3CC(CC4)OCCC(C)C)O.CL.CL.
This classification denotes an anesthetic combination drug with the molecular formula C27H42N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 046O35D44R-98PI200987, chemically known as 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;N-(2-methylphenyl)-2-(propylamino)propanamide but generally known as emla or eutectic mixture of local anesthetics, which bears US NIH Compound Identifier 9911821. SMILES:CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C=CC=C1C)C. Eutectic mixture of local anesthetics bears US NLM identifiers UMLS ID C0059079 and NCI Concept Code C1081.
This classification denotes a lipooxygenase inhibitor with the molecular formula C11H16N4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZG2L2878MD, chemically known as (- )-2-(3-amino-5-methyl-2-pyrazolin-1-yl)-4,5,6,7-tetrahydrobenzothiazole. but generally known as evandamine, which bears US NIH Compound Identifier 3038554. European Medicines Agency schedules Evandamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07353MIG. The term EVANDAMINE is an International Non-Proprietary Name. EVANDAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule evandamine under HS 29341000 and SITC 51579. As of Q4 2014, EVANDAMINE remains the US FDA Preferred Term for this commodity. Evandamine bears US NLM identifiers UMLS ID C1880595 and NCI Concept Code C65604. SMILES: CC1CC(=NN1C2=NC3=C(S2)CCCC3)N.
This classification denotes a mtor inhibitor and immunosuppressant with the molecular formula C53H83NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9HW64Q8G6G, chemically known as rapamycin, 42-o-(2-hydroxyethyl)- but more generally known as everolimus, which bears US NIH Compound Identifier 6442177. European Medicines Agency schedules Everolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02065MIG. The term EVEROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). World Health Organization schedules everolimus in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule everolimus under HS 29349990 and SITC 51579. As of Q4 2014, EVEROLIMUS remains US FDA's Preferred Term for this commodity. Everolimus bears US NLM identifiers UMLS ID C0541315 and NCI Concept Code C48387. SMILES: O(C1C(OC)CC(CC1)CC(C1OC(=O)C2N(CCCC2)C(=O)C(=O)C2(OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(OC)C(O)C(=CC(C(=O)C1)C)C)C)C)C)O)C)CCO.
Evolocumab is a monoclonal antibody medication designed for the treatment of hyperlipidemia.
This classification denotes an antifungal agent with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JEC65JCG2, chemically known as benzamide, o-hexyloxy- but generally known as exalamide, which bears US NIH Compound Identifier 3316. European Medicines Agency schedules Exalamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07354MIG. The term EXALAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). EXALAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule exalamide under HS 29242995 and SITC 51479. As of Q4 2014, EXALAMIDE remains the US FDA Preferred Term for this commodity. Exalamide bears US NLM identifiers UMLS ID C0046146 and NCI Concept Code C65607. SMILES: O(CCCCCC)C1C(CCCC1)C(=O)N.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, Q4XX54I93R chemically known as 2-propanol, 1-(2-cyclohexylphenoxy)-3-((1-methylethyl)amino)-,(+/-)- but generally known as exaprolol, which bears US NIH Compound Identifier 65485. European Medicines Agency schedules Exaprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07491MIG. The term EXAPROLOL is an International Non-Proprietary Name or INN. Most nations schedule exaprolol under HS 29221980 and SITC 51461. As of Q4 2014, EXAPROLOL remains the US FDA Preferred Term for this commodity. Exaprolol bears US NLM identifiers UMLS ID C0059928 and NCI Concept Code C65609. SMILES: CC(C)NCC(COC1=CC=CC=C1C2CCCCC2)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FGT82HNC7L, chemically known as 2-propanol, 1-(2-cyclohexylphenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (+-)- but more generally known as exaprolol hydrochloride, which bears US NIH Compound Identifier 65484. Most nations, for tariff and trade purposes, schedule exaprolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, EXAPROLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Exaprolol hydrochloride bears US NLM identifiers UMLS ID C0952592 and NCI Concept Code C65610. SMILES: CC(C)NCC(COC1CCCCC1C2CCCCC2)O.CL.
This classification denotes a camptothecin analogue with the molecular formula C24H22FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OC71PP0F89, chemically known as 10h,13h-benzo(de)pyrano(3,4:6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1s-trans)- but generally known as exatecan, which bears US NIH Compound Identifier 151115. The term EXATECAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). Most nations schedule exatecan under HS 29399900 and SITC 54149. As of Q4 2014, EXATECAN remains the US FDA Preferred Term for this commodity. Exatecan bears US NLM identifiers UMLS ID C0965941 and NCI Concept Code C66720. SMILES: CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O.
This classification denotes a steroidal aromatase inhibitor with the molecular formula C20H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NY22HMQ4BX, chemically known as 6-methyleneandrosta-1,4-diene-3,17-dione but generally known as exemestane, which bears US NIH Compound Identifier 60198. European Medicines Agency schedules Exemestane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07492MIG. The term EXEMESTANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules exemestane in its Anatomical Therapeutic Chemical (ATC) Classification. EXEMESTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule exemestane under HS 29372900 and SITC 54153. As of Q4 2014, EXEMESTANE remains the US FDA Preferred Term for this commodity. Exemestane bears US NLM identifiers UMLS ID C0851344 and NCI Concept Code C1097. SMILES: O=C1C2(C(C3C(CC2)C2(C(=CC(=O)C=C2)C(=C)C3)C)CC1)C.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9P1872D4OL. European Medicines Agency schedules Exenatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21818. Exenatide generally arises in the molecular formula C184H282N50O60S. The term EXENATIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 18, no. 1, 2004, list 51.) Most nations, for tariff and trade purposes, schedule exenatide under HS 29332990 and SITC 51573. As of Q4 2014, EXENATIDE remains US FDA's Preferred Term for this commodity. Exenatide bears US NLM identifiers UMLS ID C0167117 and NCI Concept Code C65611. SMILES: NONE.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P1872D4OL. European Medicines Agency schedules Exenatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21818. Exenatide synthetic generally arises in the molecular formula C184H282N50O60S. The term 'exenatide synthetic' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule exenatide synthetic under HS 29332990. SMILES:.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C20H17FO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K619IIG2R9, chemically known as 1h-indene-3-acetic acid, 5-fluoro-2-methy l-1-((4-(methylsulfonyl)phenyl)methylene)- but generally known as exisulind, which bears US NIH Compound Identifier 5472495. The term EXISULIND is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule exisulind under HS 29309085 and SITC 51549. As of Q4 2014, EXISULIND remains the US FDA Preferred Term for this commodity. Exisulind bears US NLM identifiers UMLS ID C0075616 and NCI Concept Code C1239. SMILES: CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O.
This classification denotes an enzyme with the molecular formula C31H38N4O7S, chemically known as 4-[[1-[[1-[2-[(1-benzylsulfanyl-1-oxo-3-phenylpropan-2-yl)carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid but generally known as exopeptidase g2, which bears US NIH Compound Identifier 3289209. SMILES: CC(C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(CC2=CC=CC=C2)C(=O)SCC3=CC=CC=C3)NC(=O)CCC(=O)O.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C9642I91WL, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 502558 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Lamiales, Family Orobanchaceae, Genus Euphrasia L. (eyebright), Species Euphrasia stricta, commonly known as DRUG EYEBRIGHT, EYEBRIGHT, or as here, EUPHRASIA. Euphrasia bears the USDA PLANTS Database Identifier EUST7. European Medicines Agency schedules euphrasia in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB45067 and SUB13783MIG. SMILES: NONE.
This classification denotes an anti-lipidemic agent with the molecular formula C24H21F2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EOR26LQQ24, chemically known as 2-azetidinone, 1-(4-fluorophenyl)-3-((3s)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3r,4s)- but generally known as ezetimibe, which bears US NIH Compound Identifier 150311. European Medicines Agency schedules Ezetimibe in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16430MIG. The term EZETIMIBE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules ezetimibe in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ezetimibe under HS 29337900 and SITC 51561. As of Q4 2014, EZETIMIBE remains the US FDA Preferred Term for this commodity. Ezetimibe bears US NLM identifiers UMLS ID C1142985 and NCI Concept Code C47529. SMILES: Fc1ccc(N2C(C(CCC(O)c3ccc(F)cc3)C2=O)c2ccc(O)cc2)cc1.
Ezetimibe and atorvastatin combination is used together with a proper diet to treat high cholesterol and triglyceride (fats) levels in the blood.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV350. This VA Drug Class (CV350) classifies this compound as belonging to the group ANTILIPEMIC AGENTS.
This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12G01I6BBU. European Medicines Agency schedules Retigabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10291MIG. Ezogabine generally arises in the molecular formula C16H18FN3O2. The term 'ezogabine' is a European Medicines Agency European Public Assessment Report System designation. Ezogabine or retigabine bears US NLM identifiers UMLS ID C0530684 and NCI Concept Code C72839. SMILES: FC1CCC(CNC2CC(N)C(NC(=O)OCC)CC2)CC1.
This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C14H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H3988M64PU, chemically known as benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)- but generally known as fadrozole, which bears US NIH Compound Identifier 59693. European Medicines Agency schedules Fadrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07497MIG. The term FADROZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). FADROZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fadrozole under HS 29339990 and SITC 51577. As of Q4 2014, FADROZOLE remains the US FDA Preferred Term for this commodity. Fadrozole bears US NLM identifiers UMLS ID C0117234 and NCI Concept Code C79911. SMILES: N12C(CCCC1CNC2)C1CCC(CC1)C#N.
This classification denotes a calcium channel blocker with the molecular formula C24H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N6A93ZMN7U, chemically known as 2-(3-((3,4-dimethoxyphenetyl)methylamino)propyl)-5,6-dimethoxyphthalimidine but generally known as falipamil, which bears US NIH Compound Identifier 71222. European Medicines Agency schedules Falipamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07500MIG. The term FALIPAMIL is an International Non-Proprietary Name. FALIPAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule falipamil under HS 29337900 and SITC 51561. As of Q4 2014, FALIPAMIL remains the US FDA Preferred Term for this commodity. Falipamil bears US NLM identifiers UMLS ID C0117251 and NCI Concept Code C65614. SMILES: O=C1N(CCCN(CCc2cc(OC)c(OC)cc2)C)Cc2c1cc(OC)c(OC)c2.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C14H19N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QIC03ANI02, chemically known as 1,3-propanediol, 2-(2-(2-amino-9h-purin-9-yl)ethyl)-, diacetate (ester) but generally known as famciclovir, which bears US NIH Compound Identifier 3324. European Medicines Agency schedules Famciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07501MIG. The term FAMCICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules famciclovir in its Anatomical Therapeutic Chemical (ATC) Classification. FAMCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule famciclovir under HS 29335995 and SITC 51576. As of Q4 2014, FAMCICLOVIR remains the US FDA Preferred Term for this commodity. Famciclovir bears US NLM identifiers UMLS ID C0209227 and NCI Concept Code C29044. SMILES: O(CC(CCN1C2NC(NCC2NC1)N)COC(=O)C)C(=O)C.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C8H15N7O2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5QZO15J2Z8, chemically known as propanimidamide, n-(aminosulfonyl)-3-(((2-((diaminomethylene)amino)-4-thiazoly)methyl)thio)- but generally known as famotidine, which bears US NIH Compound Identifier 3325. European Medicines Agency schedules Famotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07503MIG. The term FAMOTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules famotidine in its Anatomical Therapeutic Chemical (ATC) Classification. FAMOTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule famotidine under HS 29341000 and SITC 51579. As of Q4 2014, FAMOTIDINE remains the US FDA Preferred Term for this commodity. Famotidine bears US NLM identifiers UMLS ID C0015620 and NCI Concept Code C29045. SMILES: S(CCC(=N\S(=O)(=O)N)\N)CC1NC(SC1)/N=C(/N)N.
This classification denotes a serotonin antagonist with the molecular formula C23H24FN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38QJ762ET6, chemically known as 2h-naphth(1,8-cd)isothiazole, 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-, 1,1-dioxide but generally known as fananserin, which bears US NIH Compound Identifier 60785. European Medicines Agency schedules Fananserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07507MIG. The term FANANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). FANANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fananserin under HS 29349990 and SITC 51579. As of Q4 2014, FANANSERIN remains the US FDA Preferred Term for this commodity. Fananserin bears US NLM identifiers UMLS ID C0526908 and NCI Concept Code C80768. SMILES: S1(=O)(=O)N(CCCN2CCN(CC2)C2CCC(F)CC2)C2C3C1CCCC3CCC2.
This classification denotes a quinolone antibiotic with the molecular formula C20H18F2N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, I6406OC637 chemically known as 6-fluoro-1-(5-fluoro-2-pyridyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid but generally known as fandofloxacin, which bears US NIH Compound Identifier 178087. European Medicines Agency schedules Fandofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07508MIG. The term FANDOFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40. ). Most nations schedule fandofloxacin under HS 29335995 and SITC 51576. As of Q4 2014, FANDOFLOXACIN remains the US FDA Preferred Term for this commodity. Fandofloxacin bears US NLM identifiers UMLS ID C1880732 and NCI Concept Code C65618. SMILES: FC1C(N2CCN(CC2)C)CC2N(CC(C(=O)C2C1)C(=O)O)C1NCC(F)CC1.
This classification denotes an enzyme inhibitor and calcium channel blocker with the molecular formula C31H38N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KU213XYO69, chemically known as 3,4-dimethoxy-n-methyl-n-(3-(4-((2-(1-methylethyl)-1-indolizinyl)sulfonyl)phenoxy)propyl)benzeneethanmine but generally known as fantofarone, which bears US NIH Compound Identifier 119349. European Medicines Agency schedules Fantofarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07510MIG. The term FANTOFARONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). FANTOFARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fantofarone under HS 29339990 and SITC 51577. As of Q4 2014, FANTOFARONE remains the US FDA Preferred Term for this commodity. Fantofarone bears US NLM identifiers UMLS ID C0245720 and NCI Concept Code C73029. SMILES: S(=O)(=O)(C1C(C(C)C)CN2C1CCCC2)C1CCC(OCCCN(CCC2CC(OC)C(OC)CC2)C)CC1.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5M8L6357X. European Medicines Agency schedules Fantridone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07511MIG. Fantridone generally arises in the molecular formula C18H20N2O. The term FANTRIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) FANTRIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fantridone under HS 29337900 and SITC 51561. As of Q4 2014, FANTRIDONE remains the US FDA Preferred Term for this commodity. Fantridone bears US NLM identifiers UMLS ID C2827154 and NCI Concept Code C83711. SMILES: O=c1n(CCCN(C)C)c2c(c3c1cccc3)cccc2.
This classification denotes an antidepressant agent with the molecular formula C18H20N2O.CLH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DU65LYP662. The term fantridone hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule fantridone hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, FANTRIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fantridone hydrochloride bears US NLM identifiers UMLS ID C1880733 and NCI Concept Code C65619. SMILES: CN(C)CCCN1C2CCCCC2C3CCCCC3C1=O.O.CL.
This classification denotes an anti-diabetic agent with the molecular formula C34H30N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3433GY7132, chemically known as l-tyrosine, n-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl) but more generally known as farglitazar, which bears US NIH Compound Identifier 170364. The term FARGLITAZAR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations, for tariff and trade purposes, schedule farglitazar under HS 29349990 and SITC 51579. As of Q4 2014, FARGLITAZAR remains US FDA's Preferred Term for this commodity. Farglitazar bears US NLM identifiers UMLS ID C1447907 and NCI Concept Code C81693. SMILES: CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC(C(=O)O)NC4=CC=CC=C4C(=O)C5=CC=CC=C5.
This classification denotes a beta-lactam antibiotic with the molecular formula C12H15NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, F52Y83BGH3 chemically known as 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydro-2-furanyl)-,(5r,6s) but generally known as faropenem, which bears US NIH Compound Identifier 3333. European Medicines Agency schedules Faropenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07512MIG. The term FAROPENEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35. ). Most nations schedule faropenem under HS 29419000 and SITC 54139. As of Q4 2014, FAROPENEM remains the US FDA Preferred Term for this commodity. Faropenem bears US NLM identifiers UMLS ID C0541153 and NCI Concept Code C72776. SMILES: CLC1C(C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OCC)CCCC1CL.
This classification denotes a beta-lactam antibiotic with the molecular formula C17H19NO8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OK523O4FU, chemically known as 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydro-2-furanyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5r,6s), but more generally known as faropenem daloxate, which bears US NIH Compound Identifier 6918218. European Medicines Agency schedules faropenem daloxate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07512MIG. Most nations, for tariff purposes, schedule faropenem daloxate under HS 29419000. SMILES: CC1C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4.
This classification denotes a beta-lactam antibiotic C17H19NO8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OK523O4FU, chemically known as (5-methyl-2-oxo-1,3-dioxoren-4-yl)methyl(5r,6s)-6-((r)-1-hydroxyethyl)-7-oxo-3-((r)-2-tetrahydrofuryl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate, but more generally known as faropenem medoxomil, which bears US NIH Compound Identifier 6918218. Most nations, for tariff and trade purposes, schedule faropenem medoxomil under HS 29419000 and SITC 54139. As of Q4 2014, FAROPENEM MEDOXOMIL remains US FDA's Preferred Term for this commodity. Faropenem medoxomil bears US NLM identifiers UMLS ID C1880735 and NCI Concept Code C65621. SMILES: CC1C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4.
This classification denotes a beta-lactam antibiotic with the molecular formula C12H14NO5S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7O46G914RQ. European Medicines Agency schedules faropenem sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16432MIG. The term faropenem sodium is a U.S. FDA designation. Most nations schedule faropenem sodium under HS 29419000 and SITC 54139. As of Q4 2014, FAROPENEM SODIUM remains the US FDA Preferred Term for this commodity. SMILES: CC(C1C2N(C1=O)C(=C(S2)C3CCCO3)C(=O)[O-])O.[NA+].
This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C13H15N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XCA050IPGB, chemically known as 6-ethyl-7-methoxy-5-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo(1,2-a)pyrimidine. but generally known as fasiplon, which bears US NIH Compound Identifier 208954. European Medicines Agency schedules Fasiplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07514MIG. The term FASIPLON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). FASIPLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fasiplon under HS 29349990 and SITC 51579. As of Q4 2014, FASIPLON remains the US FDA Preferred Term for this commodity. Fasiplon bears US NLM identifiers UMLS ID C1880736 and NCI Concept Code C65622. SMILES: O(C1NC2N(C(C1CC)C)CC(N2)C1NC(ON1)C)C.
This classification denotes a nutritional supplement and neuroprotective agent with the molecular formula C10H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42O8UF5CJB, chemically known as piperidine, 1-((5-oxo-2-pyrrolidinyl)carbonyl)-, (r)- but generally known as fasoracetam, which bears US NIH Compound Identifier 198695. The term FASORACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). FASORACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fasoracetam under HS 29337900 and SITC 51561. As of Q4 2014, FASORACETAM remains the US FDA Preferred Term for this commodity. Fasoracetam bears US NLM identifiers UMLS ID C1880737 and NCI Concept Code C65623. SMILES: C1CCN(CC1)C(=O)C2CCC(=O)N2.
This classification denotes a protein kinase inhibitor with the molecular formula C14H17N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q0CH43PGXS, chemically known as 5-(1,4-diazepan-1-sulfonyl)isoquinoline but generally known as fasudil, which bears US NIH Compound Identifier 3547. European Medicines Agency schedules Fasudil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07515MIG. The term FASUDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules fasudil in its Anatomical Therapeutic Chemical (ATC) Classification. FASUDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fasudil under HS 29350090 and SITC 51580. As of Q4 2014, FASUDIL remains the US FDA Preferred Term for this commodity. Fasudil bears US NLM identifiers UMLS ID C0062068 and NCI Concept Code C65624. SMILES: S(=O)(=O)(N1CCCNCC1)c1c2c(ccc1)cncc2.
This classification denotes a protein kinase inhibitor with the molecular formula C14H17N3O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SQ04N8S7BR, chemically known as 5-(1,4-diazepan-1-sulfonyl)isoquinoline but more generally known as fasudil hydrochloride, which bears US NIH Compound Identifier 3547. European Medicines Agency schedules Fasudil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21642. Most nations, for tariff and trade purposes, schedule fasudil hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, FASUDIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC2CNCCC2C(C1)S(=O)(=O)N3CCCNCC3.CL.
This classification denotes a protein kinase inhibitor with the molecular formula 2C14H17N3O2S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LI4L0R5Y7T, chemically known as isoquinoline, 5-((hexahydro-1h-1,4-diazepin-1-yl)sulfonyl)-, hydrochloride, hydrate (2:2:1), but more generally known as fasudil hydrochloride hydrate, which bears US NIH Compound Identifier 11954307. European Medicines Agency schedules fasudil hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07515MIG. Most nations, for tariff purposes, schedule fasudil hydrochloride hydrate under HS 29350090. SMILES: C1CC2CNCCC2C(C1)S(=O)(=O)N3CCCNCC3.C1CC2CNCCC2C(C1)S(=O)(=O)N3CCCNCC3.O.CL.CL.
This classification denotes a nicotinic antagonist with the molecular formula C28H24N6.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8WV5538LFK, chemically known as 1,1-azobis(3-methyl-2-phenylimidazo(1,2-a)pyridinium) dibromide but generally known as fazadinium bromide, which bears US NIH Compound Identifier 5489112. European Medicines Agency schedules Fazadinium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07516MIG. The term FAZADINIUM BROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules fazadinium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule fazadinium bromide under HS 29339990 and SITC 51577. As of Q4 2014, FAZADINIUM BROMIDE remains the US FDA Preferred Term for this commodity. Fazadinium bromide bears US NLM identifiers UMLS ID C0015707 and NCI Concept Code C80530. SMILES: Br.Br.N1(/N=N/n2c(C3CCCCC3)c([n]3c2cccc3)C)C(C2CCCCC2)C([n]2c1cccc2)C.
This classification denotes a pyrimidine antagonist with the molecular formula C8H12N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V71D8JOKK, chemically known as 1,3,5-triazin-2 (1h)-one, 4-amino-1-.beta.-d-ribofuranosyl- but generally known as fazarabine, which bears US NIH Compound Identifier 1805. European Medicines Agency schedules Fazarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07517MIG. The term FAZARABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). FAZARABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fazarabine under HS 29349990 and SITC 51579. As of Q4 2014, FAZARABINE remains the US FDA Preferred Term for this commodity. Fazarabine bears US NLM identifiers UMLS ID C0060103 and NCI Concept Code C1096. SMILES: O1C(C(O)C(O)C1N1C(=O)NC(NC1)N)CO.
This classification denotes an antihelminthic agent with the molecular formula C20H22N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S75C401OS1, chemically known as n-(2-(2,3-bis-(methoxycarbonyl)-guanidino)-5-(phenylthio)-phenyl)-2-methoxyacetamide but generally known as febantel, which bears US NIH Compound Identifier 9570638. European Medicines Agency schedules Febantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07518MIG. The term FEBANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). FEBANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule febantel under HS 29309085 and SITC 51549. As of Q4 2014, FEBANTEL remains the US FDA Preferred Term for this commodity. Febantel bears US NLM identifiers UMLS ID C0060128 and NCI Concept Code C65625. SMILES: S(C1CC(NC(=O)COC)C(N/C(=N\C(=O)OC)NC(=O)OC)CC1)C1CCCCC1.
This classification denotes an antihelminthic agent with the molecular formula C20H22N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S75C401OS1, chemically known as n-(2-(2,3-bis-(methoxycarbonyl)-guanidino)-5-(phenylthio)-phenyl)-2-methoxyacetamide but more generally known as febantel, which bears US NIH Compound Identifier 9570638. European Medicines Agency schedules Febantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07518MIG. The term FEBANTEL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). FEBANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule febantel for veterinary use under HS 29309085. SMILES: COCC(=O)NC1CC(CCC1N=C(NC(=O)OC)NC(=O)OC)SC2CCCCC2.
This classification denotes an anticonvulsant agent with the molecular formula C20H27N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z48ONN38P, chemically known as 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid, carbamate ester but generally known as febarbamate, which bears US NIH Compound Identifier 25803. European Medicines Agency schedules Febarbamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07519MIG. The term FEBARBAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules febarbamate in its Anatomical Therapeutic Chemical (ATC) Classification. FEBARBAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule febarbamate under HS 29335400 and SITC kg. As of Q4 2014, FEBARBAMATE remains the US FDA Preferred Term for this commodity. Febarbamate bears US NLM identifiers UMLS ID C0060130 and NCI Concept Code C65626. SMILES: O=C1N(CC(OC(=O)N)COCCCC)C(=O)NC(=O)C1(CC)c1ccccc1.
This classification denotes a cholagogue or choleretic agent with the molecular formula C13H20O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B5RKR9Y63Y, chemically known as 2-propanol, 1-n-butoxy-3-phenoxy- but generally known as febuprol, which bears US NIH Compound Identifier 71119. European Medicines Agency schedules Febuprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07520MIG. The term FEBUPROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). FEBUPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule febuprol under HS 29094990 and SITC 51617. As of Q4 2014, FEBUPROL remains the US FDA Preferred Term for this commodity. Febuprol bears US NLM identifiers UMLS ID C0060132 and NCI Concept Code C65627. SMILES: O(CC(O)COC1CCCCC1)CCCC.
This classification denotes a xanthine oxidase inhibitor and uricosuric agent with the molecular formula C16H16N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 101V0R1N2E, chemically known as 5-thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl- but generally known as febuxostat, which bears US NIH Compound Identifier 134018. European Medicines Agency schedules Febuxostat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25382. The term FEBUXOSTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules febuxostat in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule febuxostat under HS 29341000 and SITC 51579. As of Q4 2014, FEBUXOSTAT remains the US FDA Preferred Term for this commodity. Febuxostat bears US NLM identifiers UMLS ID C2683462 and NCI Concept Code C65629. SMILES: S1C(NC(C1C(=O)O)C)C1CC(C(OCC(C)C)CC1)C#N.
Fecal microbiota transplant involves restoration of the colon microflora by introducing healthy bacterial flora through infusion of stool, e.g by colonoscopy, enema, orogastric tube, or by mouthin the form of a capsule containing freeze-dried material.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C27H25ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6889JIL5D, chemically known as 4-chlorbenzoesaeure ester mil 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidindion but generally known as feclobuzone, which bears US NIH Compound Identifier 176165. European Medicines Agency schedules Feclobuzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07523MIG. The term FECLOBUZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). FECLOBUZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule feclobuzone under HS 29331990 and SITC 51571. As of Q4 2014, FECLOBUZONE remains the US FDA Preferred Term for this commodity. Feclobuzone bears US NLM identifiers UMLS ID C1880740 and NCI Concept Code C65631. SMILES: CLC1CCC(C(=O)OCC2(CCCC)C(=O)N(N(C2=O)C2CCCCC2)C2CCCCC2)CC1.
This classification denotes an antitussive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) NT86R8M7J5. European Medicines Agency schedules Fedrilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07525MIG. Fedrilate generally arises in the molecular formula C20H29NO4. The term FEDRILATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, no. 10 1969, list 9.) FEDRILATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fedrilate under HS 29349990 and SITC 51579. As of Q4 2014, FEDRILATE remains US FDA's Preferred Term for this commodity. Fedrilate bears US NLM identifiers UMLS ID C0771169 and NCI Concept Code C81597. SMILES: O1CCC(CC1)(C1CCCCC1)C(=O)OC(CCN1CCOCC1)C.
This classification denotes an antitussive agent C20H29NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7UF5M66EUR, chemically known as 2h-pyran-4-carboxylic acid, tetrahydro-4-phenyl-, 1-methyl-3-(4-morpholinyl)propyl ester, (2z)-2-butenedioate (1:1), but more generally known as fedrilate maleate, which bears US NIH Compound Identifier 71587508. European Medicines Agency schedules Fedrilate maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02105MIG. Most nations, for tariff and trade purposes, schedule fedrilate maleate under HS 29349990 and SITC 51579. As of Q4 2014, FEDRILATE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CCN1CCOCC1)OC(=O)C2(CCOCC2)C3CCCCC3.C(=C\C(=O)O)\C(=O)O.
This classification denotes an anticonvulsant agent with the molecular formula C11H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X72RBB02N8, chemically known as 1,3-propanediol, 2-phenyl-, dicarbamate but generally known as felbamate, which bears US NIH Compound Identifier 3331. European Medicines Agency schedules Felbamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07526MIG. The term FELBAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules felbamate in its Anatomical Therapeutic Chemical (ATC) Classification. FELBAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule felbamate under HS 29242995 and SITC 51479. As of Q4 2014, FELBAMATE remains the US FDA Preferred Term for this commodity. Felbamate bears US NLM identifiers UMLS ID C0060135 and NCI Concept Code C47530. SMILES: C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H12O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94WNJ5U8L7, chemically known as ljc 10,141 but generally known as felbinac, which bears US NIH Compound Identifier 3332. European Medicines Agency schedules Felbinac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07527MIG. The term FELBINAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules felbinac in its Anatomical Therapeutic Chemical (ATC) Classification. FELBINAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule felbinac under HS 29163900 and SITC 51379. As of Q4 2014, FELBINAC remains the US FDA Preferred Term for this commodity. Felbinac bears US NLM identifiers UMLS ID C0877860 and NCI Concept Code C80546. SMILES: OC(=O)CC1CCC(C2CCCCC2)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H16O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 978ZPS989U, chemically known as acetic acid, (4-biphenylyl)-, ethyl ester, but more generally known as felbinac ethyl, which bears US NIH Compound Identifier 26436. European Medicines Agency schedules felbinac ethyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07527MIG. Most nations, for tariff purposes, schedule felbinac ethyl under HS 29163900. SMILES: CCOC(=O)CC1CCC(CC1)C2CCCCC2.
This classification denotes a nonsteroidal antiinflammatory drug C16H16O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 978ZPS989U, chemically known as (1,1'-biphenyl)-4-acetic acid, ethyl ester, but more generally known as felbinac ethyl ester, which bears US NIH Compound Identifier 26436. Most nations, for tariff and trade purposes, schedule felbinac ethyl ester under HS 29163900 and SITC 51379. As of Q4 2014, FELBINAC ETHYL ESTER remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)CC1CCC(CC1)C2CCCCC2.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D9FU86687U, chemically known as 2-pyrrolidinone, 1-phenyl-3-piperidino- but generally known as felipyrine, which bears US NIH Compound Identifier 71108. European Medicines Agency schedules Felipyrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07528MIG. The term FELIPYRINE is an International Non-Proprietary Name. FELIPYRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule felipyrine under HS 29337900 and SITC 51561. As of Q4 2014, FELIPYRINE remains the US FDA Preferred Term for this commodity. Felipyrine bears US NLM identifiers UMLS ID C1880742 and NCI Concept Code C65632. SMILES: O=C1N(CCC1N1CCCCC1)C1CCCCC1.
This classification denotes a calcium channel blocker with the molecular formula C18H19Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OL961R6O2C, chemically known as 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester but generally known as felodipine, which bears US NIH Compound Identifier 3333. European Medicines Agency schedules Felodipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11963MIG. The term FELODIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules felodipine in its Anatomical Therapeutic Chemical (ATC) Classification. FELODIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule felodipine under HS 29333999 and SITC 51574. As of Q4 2014, FELODIPINE remains the US FDA Preferred Term for this commodity. Felodipine bears US NLM identifiers UMLS ID C0015772 and NCI Concept Code C29046. SMILES: Clc1c(C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OCC)cccc1Cl.
This classification denotes an antidiurectic hormone analogue with the molecular formula C46H65N13O11S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17N2918V6G, chemically known as vasopressin, 2-l-phenylalanine-8-l-lysine- but generally known as felypressin, which bears US NIH Compound Identifier 5956. European Medicines Agency schedules Felypressin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07529MIG. The term FELYPRESSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). FELYPRESSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule felypressin under HS 29371900 and SITC 54154. As of Q4 2014, FELYPRESSIN remains the US FDA Preferred Term for this commodity. Felypressin bears US NLM identifiers UMLS ID C0015777 and NCI Concept Code C81496. SMILES: S1SCC(N)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CCCCN)C(=O)NCC(=O)N)C1)CC(=O)N)CCC(=O)N)CC1CCCCC1)CC1CCCCC1.
Felypressin/prilocaine is a fixed-dose combination of a vasoconstrictor and a local anesthetics used for dental infiltration and dental nerve block.
This classification denotes a serotonin agonist with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y719ZLX8C, chemically known as piperidine, 3-((4-methoxyphenoxy)methyl)-1-methyl-4-phenyl-, (3r-trans)- but generally known as femoxetine, which bears US NIH Compound Identifier 43103. European Medicines Agency schedules Femoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07530MIG. The term FEMOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). FEMOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule femoxetine under HS 29333999 and SITC 51574. As of Q4 2014, FEMOXETINE remains the US FDA Preferred Term for this commodity. Femoxetine bears US NLM identifiers UMLS ID C0060145 and NCI Concept Code C80759. SMILES: O(CC1C(CCN(C1)C)c1ccccc1)c1ccc(OC)cc1.
This classification denotes a serotonin agonist with the molecular formula C20H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2P1X5BE0XG, chemically known as piperidine, 3-((4-methoxyphenoxy)methyl)-1-methyl-4-phenyl-, (3r-trans)- but more generally known as femoxetine hydrochloride, which bears US NIH Compound Identifier 43103. European Medicines Agency schedules Femoxetine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02108MIG. Most nations, for tariff and trade purposes, schedule femoxetine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, FEMOXETINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@@H]([C@H](C1)COC2CCC(CC2)OC)C3CCCCC3.CL.
This classification denotes a sedative and hypnotic with the molecular formula C8H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8YX6HIZ0IP, chemically known as 1,3,4-oxadiazole, 2-(o-hydroxyphenyl)- but generally known as fenadiazole, which bears US NIH Compound Identifier 5359546. The term FENADIAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). FENADIAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenadiazole under HS 29349990 and SITC 51579. As of Q4 2014, FENADIAZOLE remains the US FDA Preferred Term for this commodity. Fenadiazole bears US NLM identifiers UMLS ID C1880747 and NCI Concept Code C65635. SMILES: C1=C/C(=C\2/NN=CO2)/C(=O)C=C1.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1TBQ3A47P8. European Medicines Agency schedules Fenalcomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07536MIG. Fenalcomine generally arises in the molecular formula C20H27NO2. The term FENALCOMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) FENALCOMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenalcomine under HS 29221980 and SITC 51461. As of Q4 2014, FENALCOMINE remains the US FDA Preferred Term for this commodity. Fenalcomine bears US NLM identifiers UMLS ID C0060147 and NCI Concept Code C65636. SMILES: O(CCNC(Cc1ccccc1)C)c1ccc(C(O)CC)cc1.
This classification denotes an antitubercular agent with the molecular formula C13H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52936SIP7V, chemically known as salicylic acid, 4-amino-, phenyl ester (8ci) but more generally known as fenamisal, which bears US NIH Compound Identifier 8609. European Medicines Agency schedules Fenamisal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07538MIG. The term FENAMISAL is an International Non-Proprietary Name. FENAMISAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C(=O)C1C(O)CC(N)CC1)C1CCCCC1.
This classification denotes an anxiolytic with the molecular formula C21H29FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6W7F1R86P, chemically known as 4-(3-(p-fluorobenzoyl)-propyl)-1-piperazinecarboxylic acid, cyclohexyl ester. but generally known as fenaperone, which bears US NIH Compound Identifier 198061. European Medicines Agency schedules Fenaperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07540MIG. The term FENAPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). FENAPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenaperone under HS 29335995 and SITC 51576. As of Q4 2014, FENAPERONE remains the US FDA Preferred Term for this commodity. Fenaperone bears US NLM identifiers UMLS ID C1880749 and NCI Concept Code C65638. SMILES: FC1CCC(C(=O)CCCN2CCN(CC2)C(=O)OC2CCCCC2)CC1.
This classification denotes an antihelminthic agent with the molecular formula C15H13N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 621BVT9M36, chemically known as 2-benzimidazolecarbamic acid, 5-(phenylthio)-, methyl ester but generally known as fenbendazole, which bears US NIH Compound Identifier 3334. European Medicines Agency schedules Fenbendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07541MIG. The term FENBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules fenbendazole in its Anatomical Therapeutic Chemical (ATC) Classification. FENBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenbendazole under HS 29339990 and SITC 51577. As of Q4 2014, FENBENDAZOLE remains the US FDA Preferred Term for this commodity. Fenbendazole bears US NLM identifiers UMLS ID C0015821 and NCI Concept Code C75218. SMILES: S(C1CC2[NH]C(NC2CC1)NC(=O)OC)C1CCCCC1.
This classification denotes an antihelminthic agent with the molecular formula C15H13N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 621BVT9M36, chemically known as 2-benzimidazolecarbamic acid, 5-(phenylthio)-, methyl ester but more generally known as fenbendazole, which bears US NIH Compound Identifier 3334. European Medicines Agency schedules Fenbendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07541MIG. The term FENBENDAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules fenbendazole in its Anatomical Therapeutic Chemical (ATC) Classification. FENBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fenbendazole for veterinary use under HS 29339990. SMILES: COC(=O)NC1[NH]C2CC(CCC2N1)SC3CCCCC3.
This classification denotes a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 641EDA6X6L. European Medicines Agency schedules Fenbenicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07542MIG. Fenbenicillin generally arises in the molecular formula C22H22N2O5S. The term FENBENICILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 19 1975, list 5.) FENBENICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(OC1CCCCC1)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9815R1WR9B, chemically known as propionic acid, 3-(4-biphenylylcarbonyl)- but generally known as fenbufen, which bears US NIH Compound Identifier 3335. European Medicines Agency schedules Fenbufen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07543MIG. The term FENBUFEN is an International Non-Proprietary Name. World Health Organization schedules fenbufen in its Anatomical Therapeutic Chemical (ATC) Classification. FENBUFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenbufen under HS 29183000 and SITC 51395. As of Q4 2014, FENBUFEN remains the US FDA Preferred Term for this commodity. Fenbufen bears US NLM identifiers UMLS ID C0060156 and NCI Concept Code C80548. SMILES: O=C(C1CCC(C2CCCCC2)CC1)CCC(=O)O.
This classification denotes an anorexiant with the molecular formula C23H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) BKY8H56395, chemically known as butyric acid, 2-phenyl-, 2-(3-methyl-2-phenylmorpholino)ethyl ester but more generally known as fenbutrazate, which bears US NIH Compound Identifier 20395. European Medicines Agency schedules Fenbutrazate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07544MIG. The term FENBUTRAZATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). FENBUTRAZATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fenbutrazate under HS 29349990 and SITC 51579. As of Q4 2014, FENBUTRAZATE remains US FDA's Preferred Term for this commodity. Fenbutrazate bears US NLM identifiers UMLS ID C0605193 and NCI Concept Code C65640. SMILES: O1C(C(N(CC1)CCOC(=O)C(CC)C1CCCCC1)C)C1CCCCC1.
This classification denotes a dopamine agonist with the molecular formula C15H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M1J60BWEX, chemically known as 2-norbornanamine, n-ethyl-3-phenyl-, hydrochloride but more generally known as fencamfamin hydrochloride, which bears US NIH Compound Identifier 14584. European Medicines Agency schedules Fencamfamin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02110MIG. Most nations, for tariff and trade purposes, schedule fencamfamin hydrochloride under HS 29214600. As of Q4 2014, FENCAMFAMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fencamfamin hydrochloride bears US NLM identifiers UMLS ID C0140010 and NCI Concept Code C76051. SMILES: CCNC1C2CCC(C2)C1C3CCCCC3.CL.
This classification denotes a cns stimulant with the molecular formula C15H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NME1I5IGBK, chemically known as 2-norbornanamine, n-ethyl-3-phenyl-, hydrochloride but more generally known as fencamfamin, which bears US NIH Compound Identifier 14584. European Medicines Agency schedules Fencamfamin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07545MIG. The term FENCAMFAMIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules fencamfamin in its Anatomical Therapeutic Chemical (ATC) Classification. FENCAMFAMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Fencamfamin or fencamfamine bears US NLM identifiers UMLS ID C0060157 and NCI Concept Code C87695. SMILES: CCNC1C2CCC(C2)C1C3=CC=CC=C3.
This classification denotes a cholagogue or choleretic agent with the molecular formula C16H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H2V165956A, chemically known as cyclohexaneacetic acid, alpha-ethyl-1-hydroxy-4-phenyl-, (+-)- but generally known as fencibutirol, which bears US NIH Compound Identifier 71170. European Medicines Agency schedules Fencibutirol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07547MIG. The term FENCIBUTIROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). FENCIBUTIROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fencibutirol under HS 29181985 and SITC 51392. As of Q4 2014, FENCIBUTIROL remains the US FDA Preferred Term for this commodity. Fencibutirol bears US NLM identifiers UMLS ID C0060160 and NCI Concept Code C65641. SMILES: OC1(CCC(CC1)C1CCCCC1)C(CC)C(=O)O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H16Cl2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5458S22S8I, chemically known as benzeneacetic acid, alpha,3-dichloro-4-cyclohexyl- but generally known as fenclorac, which bears US NIH Compound Identifier 37494. European Medicines Agency schedules Fenclorac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07552MIG. The term FENCLORAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). FENCLORAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenclorac under HS 29163900 and SITC 51379. As of Q4 2014, FENCLORAC remains the US FDA Preferred Term for this commodity. Fenclorac bears US NLM identifiers UMLS ID C0060162 and NCI Concept Code C65644. SMILES: CLC1C(C2CCCCC2)CCC(C1)C(CL)C(=O)O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C11H8ClNO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58SRQ4DV53, chemically known as 4-thiazoleacetic acid, 2-(p-chlorophenyl)- but generally known as fenclozic acid, which bears US NIH Compound Identifier 28858. European Medicines Agency schedules Fenclozic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07553MIG. The term FENCLOZIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). Most nations schedule fenclozic acid under HS 29341000 and SITC 51579. As of Q4 2014, FENCLOZIC ACID remains the US FDA Preferred Term for this commodity. Fenclozic acid bears US NLM identifiers UMLS ID C0060163 and NCI Concept Code C65645. SMILES: C1=CC(=CC=C1C2=NC(=CS2)CC(=O)O)Cl.
This classification denotes a calcium channel blocker with the molecular formula C23H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S253D559A8, chemically known as benzenepropanamine, gamma-phenyl-n-(1-phenylethyl)- but generally known as fendiline, which bears US NIH Compound Identifier 3336. European Medicines Agency schedules Fendiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07554MIG. The term FENDILINE is an International Non-Proprietary Name. World Health Organization schedules fendiline in its Anatomical Therapeutic Chemical (ATC) Classification. FENDILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fendiline under HS 29214980 and SITC 51454. As of Q4 2014, FENDILINE remains the US FDA Preferred Term for this commodity. Fendiline bears US NLM identifiers UMLS ID C0015824 and NCI Concept Code C81686. SMILES: N(CCC(c1ccccc1)c1ccccc1)C(c1ccccc1)C.
This classification denotes a calcium channel blocker with the molecular formula C23H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HEM3Z10IIK, chemically known as n-(3,3-diphenylpropyl)-alpha-methylbenzylamine hydrochloride but more generally known as fendiline hydrochloride, which bears US NIH Compound Identifier 26154. European Medicines Agency schedules Fendiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02113MIG. Most nations, for tariff and trade purposes, schedule fendiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, FENDILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCCCC1)NCCC(C2CCCCC2)C3CCCCC3.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Z709558TZ, chemically known as 5-(4,5-dihydro-2-phenyl-3h-benz(e)indol-3-yl)salicylic acid but generally known as fendosal, which bears US NIH Compound Identifier 40821. European Medicines Agency schedules Fendosal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07555MIG. The term FENDOSAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). FENDOSAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fendosal under HS 29339990 and SITC 51577. As of Q4 2014, FENDOSAL remains the US FDA Preferred Term for this commodity. Fendosal bears US NLM identifiers UMLS ID C0060164 and NCI Concept Code C80549. SMILES: OC1C(CC(N2C3CCC4C(C3CC2C2CCCCC2)CCCC4)CC1)C(=O)O.
This classification denotes a non-steroidal estrogen with the molecular formula C16H20O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LEC4215V9R, chemically known as 3-cyclohexene-1-carboxylic acid, 5-ethyl-6-methyl-4-phenyl- but generally known as fenestrel, which bears US NIH Compound Identifier 24371. European Medicines Agency schedules Fenestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07557MIG. The term FENESTREL is an International Non-Proprietary Name. FENESTREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenestrel under HS 29163900 and SITC 51379. As of Q4 2014, FENESTREL remains the US FDA Preferred Term for this commodity. Fenestrel bears US NLM identifiers UMLS ID C0060165 and NCI Concept Code C80684. SMILES: OC(=O)C1C(C(C(=CC1)c1ccccc1)CC)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H18N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8J97CUZ4HX, chemically known as 10h-phenothiazine-10-ethanamine, n,n-dimethyl-, monohydrochloride but generally known as fenethazine, which bears US NIH Compound Identifier 68223. European Medicines Agency schedules Fenethazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07558MIG. The term FENETHAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). FENETHAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenethazine under HS 29343090 and SITC 51578. As of Q4 2014, FENETHAZINE remains the US FDA Preferred Term for this commodity. Fenethazine bears US NLM identifiers UMLS ID C0060166 and NCI Concept Code C65646. SMILES: S1C2C(N(CCN(C)C)C3C1CCCC3)CCCC2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H18N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 225AVG0161, chemically known as 10h-phenothiazine-10-ethanamine, n,n-dimethyl-, monohydrochloride but more generally known as fenethazine hydrochloride, which bears US NIH Compound Identifier 68223. Most nations, for tariff and trade purposes, schedule fenethazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, FENETHAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCN1C2CCCCC2SC3C1CCCC3.CL.
This classification denotes a cns stimulant with the molecular formula C18H23N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YZ0N7VL5R3, chemically known as theophylline, 7-(2-((alpha-methylphenethyl)amino)ethyl)- but generally known as fenethylline, which bears US NIH Compound Identifier 19527. European Medicines Agency schedules Fenetylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07560MIG. The term FENETYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules fenethylline in its Anatomical Therapeutic Chemical (ATC) Classification. Fenethylline or phenethylline bears US NLM identifiers UMLS ID C0060167 and NCI Concept Code C81051. SMILES: CC(CC1=CC=CC=C1)NCCN2C=NC3=C2C(=O)N(C(=O)N3C)C.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9GXY5Z0873. European Medicines Agency schedules Fenetradil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07559MIG. Fenetradil generally arises in the molecular formula C22H36N2O3. The term FENETRADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, no. 10 1974, list 14.) FENETRADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenetradil under HS 29335995 and SITC 51576. As of Q4 2014, FENETRADIL remains the US FDA Preferred Term for this commodity. Fenetradil bears US NLM identifiers UMLS ID C1880754 and NCI Concept Code C65647. SMILES: O(C(CN1CCN(CC1)C)COCC(C)C)C(=O)C(CC)c1ccccc1.
This classification denotes a cyclooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PD0931191Q. European Medicines Agency schedules Fenflumizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13827MIG. Fenflumizol generally arises in the molecular formula C23H18F2N2O2. The term FENFLUMIZOL is an International Non-Proprietary Name or INN. FENFLUMIZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Fenflumizol or fenflumizole bears US NLM identifiers UMLS ID C0060168 and NCI Concept Code C65648. SMILES: FC1C(C2[NH]C(C(N2)C2CCC(OC)CC2)C2CCC(OC)CC2)CCC(F)C1.
This classification denotes an anorexiant with the molecular formula C12H16F3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2DS058H2CF, chemically known as phenethylamine, n-ethyl-alpha-methyl-m-(trifluoromethyl)-, (s)- but more generally known as fenfluramine, which bears US NIH Compound Identifier 3337. European Medicines Agency schedules Fenfluramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07561MIG. The term FENFLURAMINE is an International Non-Proprietary Name. World Health Organization schedules fenfluramine in its Anatomical Therapeutic Chemical (ATC) Classification. FENFLURAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fenfluramine under HS 29214980 and SITC 51454. As of Q4 2014, FENFLURAMINE remains US FDA's Preferred Term for this commodity. Fenfluramine bears US NLM identifiers UMLS ID C0015827 and NCI Concept Code C81418. SMILES: CCNC(C)CC1=CC(=CC=C1)C(F)(F)F.
This classification denotes an anorexiant with the molecular formula C12H16F3N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3KC089243P, chemically known as phenethylamine, n-ethyl-alpha-methyl-m-(trifluoromethyl)-, (s)- but more generally known as fenfluramine hydrochloride, which bears US NIH Compound Identifier 3337. European Medicines Agency schedules Fenfluramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02115MIG. Most nations, for tariff and trade purposes, schedule fenfluramine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, FENFLURAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenfluramine hydrochloride bears US NLM identifiers UMLS ID C0282179 and NCI Concept Code C75112. SMILES: CCNC(C)CC1CCCC(C1)C(F)(F)F.CL.
This classification denotes an antidepressant agent with the molecular formula C17H17Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YQG0NJI5A7, chemically known as sl 79,229-00 but generally known as fengabine, which bears US NIH Compound Identifier 5362066. European Medicines Agency schedules Fengabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07563MIG. The term FENGABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). FENGABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fengabine under HS 29252900 and SITC 51482. As of Q4 2014, FENGABINE remains the US FDA Preferred Term for this commodity. Fengabine bears US NLM identifiers UMLS ID C0060170 and NCI Concept Code C72778. SMILES: Clc1c(C(=C2\C=C(Cl)C=CC2=O)/NCCCC)cccc1.
This classification denotes an antipsychotic agent with the molecular formula C13H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z48G09KOD, chemically known as 2,5-pyrrolidinedione, 4-ethyl-3-methyl-3-phenyl- but generally known as fenimide, which bears US NIH Compound Identifier 6068. European Medicines Agency schedules Fenimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07565MIG. The term FENIMIDE is an International Non-Proprietary Name. FENIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenimide under HS 29251995 and SITC 51482. As of Q4 2014, FENIMIDE remains the US FDA Preferred Term for this commodity. Fenimide bears US NLM identifiers UMLS ID C2825693 and NCI Concept Code C81583. SMILES: O=C1NC(=O)C(C1(C1CCCCC1)C)CC.
This classification denotes a cholagogue or choleretic agent with the molecular formula C11H16O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X3FZE77O60, chemically known as 1-pentanol, 1-phenyl- but generally known as fenipentol, which bears US NIH Compound Identifier 3338. European Medicines Agency schedules Fenipentol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07567MIG. The term FENIPENTOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). FENIPENTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenipentol under HS 29062900 and SITC 51235. As of Q4 2014, FENIPENTOL remains the US FDA Preferred Term for this commodity. Fenipentol bears US NLM identifiers UMLS ID C0060173 and NCI Concept Code C65652. SMILES: CCCCC(C1=CC=CC=C1)O.
This classification denotes an anorexiant with the molecular formula C16H16FNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C0P8MP2SR5, chemically known as 1h-2-benzopyran-3-methanamine, 7-fluoro-3,4-dihydro-1-phenyl-, cis- but more generally known as fenisorex, which bears US NIH Compound Identifier 36983. European Medicines Agency schedules Fenisorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07569MIG. The term FENISOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 No. 2 1999, List 40). FENISOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fenisorex under HS 29329985 and SITC 51569. As of Q4 2014, FENISOREX remains US FDA's Preferred Term for this commodity. Fenisorex bears US NLM identifiers UMLS ID C0605359 and NCI Concept Code C65654. SMILES: FC1CC2C(OC(NC)CC2CC1)C1CCCCC1.
This classification denotes an antidepressant agent with the molecular formula C10H10Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C15WFN6GMO, chemically known as 1h-imidazole, 2-((3,4-dichlorophenoxy)methyl)-4,5-dihydro- but generally known as fenmetozole, which bears US NIH Compound Identifier 32049. European Medicines Agency schedules Fenmetozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07571MIG. The term FENMETOZOLE is an International Non-Proprietary Name. FENMETOZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenmetozole under HS 29332990 and SITC 51573. As of Q4 2014, FENMETOZOLE remains the US FDA Preferred Term for this commodity. Fenmetozole bears US NLM identifiers UMLS ID C0060175 and NCI Concept Code C81487. SMILES: C1CN=C(N1)COC2=CC(=C(C=C2)Cl)Cl.
This classification denotes an antidepressant agent with the molecular formula C10H10Cl2N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AIW7IL0D0B, chemically known as 2-imidazoline, 2-((3,4-dichlorophenoxy)methyl)-, monohydrochloride but more generally known as fenmetozole hydrochloride, which bears US NIH Compound Identifier 32048. Most nations, for tariff and trade purposes, schedule fenmetozole hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, FENMETOZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenmetozole hydrochloride bears US NLM identifiers UMLS ID C2825656 and NCI Concept Code C81486. SMILES: C1CC(C(CC1OCC2=NCCN2)CL)CL.CL.
This classification denotes an antidepressant agent with the molecular formula C11H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WCH9HW127L, chemically known as 3-morpholinone, 5-methyl-6-phenyl- but generally known as fenmetramide, which bears US NIH Compound Identifier 21789. European Medicines Agency schedules Fenmetramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07572MIG. The term FENMETRAMIDE is an International Non-Proprietary Name. FENMETRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenmetramide under HS 29349990 and SITC 51579. As of Q4 2014, FENMETRAMIDE remains the US FDA Preferred Term for this commodity. Fenmetramide bears US NLM identifiers UMLS ID C2825659 and NCI Concept Code C81492. SMILES: CC1C(OCC(=O)N1)C2=CC=CC=C2.
This classification denotes a sedative and hypnotic with the molecular formula C11H11ClN4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 07O6708M02, chemically known as urea, n-(3-chlorophenyl)-n-(4,5-dihydro-1-methyl-4-oxo-1h-imidazol-2-yl)- but generally known as fenobam, which bears US NIH Compound Identifier 162834. European Medicines Agency schedules Fenobam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07573MIG. FENOBAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenobam under HS 29332990 and SITC 51573. As of Q4 2014, FENOBAM remains the US FDA Preferred Term for this commodity. Fenobam bears US NLM identifiers UMLS ID C0060177 and NCI Concept Code C80666. SMILES: CN1CC(=O)N=C1NC(=O)NC2=CC(=CC=C2)CL.
This classification denotes an anti-ulcer agent with the molecular formula C27H38N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, B45CF873F8 chemically known as 4-(diphenylmethyl)-1-(n-octylformimidoyl)piperidine, hemihydrate but generally known as fenoctimine, which bears US NIH Compound Identifier 50455. European Medicines Agency schedules Fenoctimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07575MIG. The term FENOCTIMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21). Most nations schedule fenoctimine under HS 29333999 and SITC 51574. As of Q4 2014, FENOCTIMINE remains the US FDA Preferred Term for this commodity. Fenoctimine bears US NLM identifiers UMLS ID C0060178 and NCI Concept Code C76485. SMILES: CCCCCCCCN=CN1CCC(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3.
This classification denotes an anti-lipidemic agent with the molecular formula C20H21ClO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U202363UOS, chemically known as propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester but generally known as fenofibrate, which bears US NIH Compound Identifier 3339. European Medicines Agency schedules Fenofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07576MIG. The term FENOFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules fenofibrate in its Anatomical Therapeutic Chemical (ATC) Classification. FENOFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenofibrate under HS 29189900 and SITC 51396. As of Q4 2014, FENOFIBRATE remains the US FDA Preferred Term for this commodity. Fenofibrate bears US NLM identifiers UMLS ID C0033228 and NCI Concept Code C29047. SMILES: Clc1ccc(C(=O)c2ccc(OC(C)(C)C(=O)OC(C)C)cc2)cc1.
This classification denotes a dopamine agonist with the molecular formula C16H16ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier INU8H2KAWG, chemically known as 1h-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)- but generally known as fenoldopam, which bears US NIH Compound Identifier 3341. European Medicines Agency schedules Fenoldopam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07577MIG. The term FENOLDOPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules fenoldopam in its Anatomical Therapeutic Chemical (ATC) Classification. FENOLDOPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenoldopam under HS 29339930 and SITC 51577. As of Q4 2014, FENOLDOPAM remains the US FDA Preferred Term for this commodity. Fenoldopam bears US NLM identifiers UMLS ID C0060180 and NCI Concept Code C61759. SMILES: CLC1C2C(C(CNCC2)C2CCC(O)CC2)CC(O)C1O.
This classification denotes a dopamine agonist with the molecular formula C16H16ClNO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HA3R0MY016, chemically known as 1h-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt), but more generally known as fenoldopam mesylate, which bears US NIH Compound Identifier 3341. European Medicines Agency schedules fenoldopam mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07577MIG. Most nations, for tariff purposes, schedule fenoldopam mesylate under HS 29339930. As of Q4 2014, FENOLDOPAM MESYLATE remains US FDA's Preferred Term for this commodity. Fenoldopam mesylate bears US NLM identifiers UMLS ID C0700481 and NCI Concept Code C47531. SMILES: CS(=O)(=O)O.C1CC(CCC1C2CNCCC3C2CC(C(C3CL)O)O)O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RA33EAC7KY, chemically known as hydratropic acid, m-phenoxy-, (+-)- but generally known as fenoprofen, which bears US NIH Compound Identifier 3342. European Medicines Agency schedules Fenoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07578MIG. The term FENOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules fenoprofen in its Anatomical Therapeutic Chemical (ATC) Classification. FENOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenoprofen under HS 29189900 and SITC 51396. As of Q4 2014, FENOPROFEN remains the US FDA Preferred Term for this commodity. Fenoprofen bears US NLM identifiers UMLS ID C0015837 and NCI Concept Code C61760. SMILES: O(C1CC(C(C)C(=O)O)CCC1)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H13O3.Ca.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0X2CW1QABJ, chemically known as hydratropic acid, m-phenoxy-, (+-)- but more generally known as fenoprofen calcium, which bears US NIH Compound Identifier 3342. European Medicines Agency schedules Fenoprofen calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02120MIG. Most nations, for tariff and trade purposes, schedule fenoprofen calcium under HS 29189900 and SITC 51396. As of Q4 2014, FENOPROFEN CALCIUM remains US FDA's Preferred Term for this commodity. Fenoprofen calcium bears US NLM identifiers UMLS ID C0887323 and NCI Concept Code C61761. SMILES: CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].O.O.[CA+2].
This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C15H13O3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8R95A3O51K, chemically known as benzeneacetic acid, .alpha.-methyl-3-phenoxy-, calcium salt (2:1), but more generally known as fenoprofen calcium anhydrous, which bears US NIH Compound Identifier 64746. European Medicines Agency schedules fenoprofen calcium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07578MIG. Most nations, for tariff purposes, schedule fenoprofen calcium anhydrous under HS 29189900. SMILES: CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].[CA+2].
This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 869607J16Q, chemically known as benzeneacetic acid, .alpha.-methyl-3-phenoxy-, sodium salt (1:1), but more generally known as fenoprofen sodium, which bears US NIH Compound Identifier 60897. European Medicines Agency schedules fenoprofen sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07578MIG. Most nations, for tariff purposes, schedule fenoprofen sodium under HS 29189900. SMILES: CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].[NA+].
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C17H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22M9P70OQ9, chemically known as 3,5-dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol but generally known as fenoterol, which bears US NIH Compound Identifier 3343. European Medicines Agency schedules Fenoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07579MIG. The term FENOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules fenoterol in its Anatomical Therapeutic Chemical (ATC) Classification. FENOTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenoterol under HS 29225000 and SITC 51467. As of Q4 2014, FENOTEROL remains the US FDA Preferred Term for this commodity. Fenoterol bears US NLM identifiers UMLS ID C0015840 and NCI Concept Code C65659. SMILES: OC(CNC(CC1CCC(O)CC1)C)C1CC(O)CC(O)C1.
This classification denotes an antispasmotic agent with the molecular formula C26H25N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N274ZQ6PZJ, chemically known as 10h-phenothiazine, 10-((4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)acetyl)- but generally known as fenoverine, which bears US NIH Compound Identifier 72098. European Medicines Agency schedules Fenoverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07580MIG. The term FENOVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules fenoverine in its Anatomical Therapeutic Chemical (ATC) Classification. FENOVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenoverine under HS 29343090 and SITC 51578. As of Q4 2014, FENOVERINE remains the US FDA Preferred Term for this commodity. Fenoverine bears US NLM identifiers UMLS ID C0060182 and NCI Concept Code C65660. SMILES: S1C2C(N(C(=O)CN3CCN(CC3)CC3CC4OCOC4CC3)C3C1CCCC3)CCCC2.
This classification denotes an alpha-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97JJW1W1R3. European Medicines Agency schedules Fenoxazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07581MIG. Fenoxazoline generally arises in the molecular formula C13H18N2O. The term FENOXAZOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) FENOXAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Fenoxazoline under HS 29332990 and SITC 51573. As of Q4 2014, FENOXAZOLINE remains the US FDA Preferred Term for this commodity. Fenoxazoline bears US NLM identifiers UMLS ID C0060183 and NCI Concept Code C74265. SMILES: CC(C)C1CCCCC1OCC2=NCCN2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C13H18N2O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K28Y098S7. European Medicines Agency schedules fenoxazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02122MIG. The term fenoxazoline hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule fenoxazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, FENOXAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenoxazoline hydrochloride bears US NLM identifiers UMLS ID C0771654 and NCI Concept Code C65661. SMILES: CC(C)C1CCCCC1OCC2=NCCN2.CL.
This classification denotes a vasodilating agent with the molecular formula C28H42N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ABX8234H6M, chemically known as 2-(p-butoxyphenoxy)-n-(2,5-diethoxyphenyl)-n-(2-(diethylamino)ethyl)acetamide but generally known as fenoxedil, which bears US NIH Compound Identifier 71731. European Medicines Agency schedules Fenoxedil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07582MIG. The term FENOXEDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). FENOXEDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenoxedil under HS 29242995 and SITC 51479. As of Q4 2014, FENOXEDIL remains the US FDA Preferred Term for this commodity. Fenoxedil bears US NLM identifiers UMLS ID C0060184 and NCI Concept Code C65662. SMILES: O(c1c(N(CCN(CC)CC)C(=O)COc2ccc(OCCCC)cc2)cc(OCC)cc1)CC.
This classification denotes a vasodilating agent with the molecular formula C28H42N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1056JI5L58, chemically known as acetamide, 2-(4-butoxyphenoxy)-n-(2,5-diethoxyphenyl)-n-(2-(diethylamino)ethyl)-, hydrochloride (1:1), but more generally known as fenoxedil hydrochloride, which bears US NIH Compound Identifier 119645. European Medicines Agency schedules fenoxedil hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07582MIG. Most nations, for tariff purposes, schedule fenoxedil hydrochloride under HS 29242995. SMILES: CCCCOC1CCC(CC1)OCC(=O)N(CCN(CC)CC)C2CC(CCC2OCC)OCC.CL.
This classification denotes a cns stimulant with the molecular formula C11H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1NZI4LMU6G, chemically known as 2-oxazolin-4-one, 2-ethylamino-5-phenyl- but more generally known as fenozolone, which bears US NIH Compound Identifier 71682. European Medicines Agency schedules Fenozolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07584MIG. The term FENOZOLONE is an International Non-Proprietary Name. World Health Organization schedules fenozolone in its Anatomical Therapeutic Chemical (ATC) Classification. FENOZOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fenozolone under HS 29349990 and SITC 51579. As of Q4 2014, FENOZOLONE remains US FDA's Preferred Term for this commodity. Fenozolone bears US NLM identifiers UMLS ID C0060187 and NCI Concept Code C65663. SMILES: CCNC1=NC(=O)C(O1)C2=CC=CC=C2.
This classification denotes an antidepressant agent with the molecular formula C12H17CLO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, BLO7300903 chemically known as 2-(p-chlorophenyl)-4-methyl-2,4-pentanediol but generally known as fenpentadiol, which bears US NIH Compound Identifier 85896. European Medicines Agency schedules Fenpentadiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07585MIG. The term FENPENTADIOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7. ). Most nations schedule fenpentadiol under HS 29062900 and SITC 51235. As of Q4 2014, FENPENTADIOL remains the US FDA Preferred Term for this commodity. Fenpentadiol bears US NLM identifiers UMLS ID C0060188 and NCI Concept Code C65664. SMILES: CC(C)(CC(C)(C1=CC=C(C=C1)Cl)O)O.
This classification denotes an antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1NJ4DG390G. European Medicines Agency schedules Fenperate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07586MIG. Fenperate generally arises in the molecular formula C25H31NO4. The term FENPERATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) FENPERATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenperate under HS 29333999 and SITC 51574. As of Q4 2014, FENPERATE remains the US FDA Preferred Term for this commodity. Fenperate bears US NLM identifiers UMLS ID C1880759 and NCI Concept Code C65665. SMILES: O(CCN1CCCCC1)C(=O)C(OC(=O)C)(Cc1ccccc1)Cc1ccccc1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6TVC31DEDE, chemically known as 5-(2-(3,6-dihydro-4-phenyl-1(2h)-pyridyl)ethyl)-3-methyl-2-oxazolidinone but generally known as fenpipalone, which bears US NIH Compound Identifier 30822. European Medicines Agency schedules Fenpipalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07587MIG. The term FENPIPALONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). FENPIPALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenpipalone under HS 29349990 and SITC 51579. As of Q4 2014, FENPIPALONE remains the US FDA Preferred Term for this commodity. Fenpipalone bears US NLM identifiers UMLS ID C2825251 and NCI Concept Code C80550. SMILES: O1C(CCN2CCC(=CC2)C2CCCCC2)CN(C1=O)C.
This classification denotes an antimuscarinic agent with the molecular formula C21H26N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KJ2V75P034, chemically known as alpha,alpha-diphenylpiperidine-1-butyramide monohydrochloride but more generally known as fenpipramide hydrochloride, which bears US NIH Compound Identifier 166974. European Medicines Agency schedules Fenpipramide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02123MIG. Most nations, for tariff and trade purposes, schedule fenpipramide hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, FENPIPRAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenpipramide hydrochloride bears US NLM NCI C78073. SMILES: C1CCC(CC1)C(CCN2CCCCC2)(C3CCCCC3)C(=O)N.CL.
This classification denotes an antispasmotic agent with the molecular formulas C21H26N2O and C21H26N2O.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 88445508X3 and KJ2V75P034, chemically known as 1-piperidinebutyramide, alpha,alpha-diphenyl- but generally known as fenpipramide, which bears US NIH Compound Identifier 65573. European Medicines Agency schedules Fenpipramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB07588MIG and SUB02123MIG. The term FENPIPRAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). FENPIPRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenpipramide or its salts under HS 29333999 and SITC 51574. As of Q4 2014, FENPIPRAMIDE remains the US FDA Preferred Term for this commodity. Fenpipramide bears US NLM NCI C65666 and C78073. SMILES: O=C(N)C(CCN1CCCCC1)(C1CCCCC1)C1CCCCC1 (base) or C1CCC(CC1)C(CCN2CCCCC2)(C3CCCCC3)C(=O)N.CL (hydrochloride).
This classification denotes an anticholinergic agent with the molecular formula C20H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 684N1BF96B, chemically known as 3-piperidino-1,1-diphenylpropane hydrochloride but more generally known as fenpiprane hydrochloride, which bears US NIH Compound Identifier 197784. Most nations, for tariff and trade purposes, schedule fenpiprane hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, FENPIPRANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenpiprane hydrochloride bears US NLM NCI C65667. SMILES: C1CCC(CC1)C(CCN2CCCCC2)C3CCCCC3.CL.
This classification denotes an antispasmotic agent with the molecular formulas C20H25N and C20H25N.ClH, and preparation that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers S2FVB1RL5X and C20H25N.ClH. European Medicines Agency schedules Fenpiprane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07589MIG. The term FENPIPRANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) FENPIPRANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenpiprane and its salts under HS 29333999 and SITC 51574. As of Q4 2014, FENPIPRANE remains the US FDA Preferred Term for this commodity. Fenpiprane bears US NLM NCI C73174 and C65667. SMILES: C1CCN(CC1)CCC(C2=CC=CC=C2)C3=CC=CC=C3 (base) or C1CCC(CC1)C(CCN2CCCCC2)C3CCCCC3.CL (hydrochloride).
This classification denotes an antimuscarinic agent with the molecular formula C22H29N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KP2L8LC73B. European Medicines Agency schedules fenpiverinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02124MIG. FENPIVERINIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, FENPIVERINIUM remains the US FDA Preferred Term for this commodity. Fenpiverinium bears US NLM identifiers UMLS ID C0060190 and NCI Concept Code C87638. SMILES: C[N+]1(CCCCC1)CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N.
This classification denotes an anorexiant with the molecular formula C12H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W0194S5FOA, chemically known as propionitrile, 3-((alpha-methylphenethyl)amino)-, (+-)- but more generally known as fenproporex, which bears US NIH Compound Identifier 61810. European Medicines Agency schedules Fenproporex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07592MIG. The term FENPROPOREX is an International Non-Proprietary Name. FENPROPOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fenproporex under HS 29263000 and SITC 51484. As of Q4 2014, FENPROPOREX remains US FDA's Preferred Term for this commodity. Fenproporex bears US NLM identifiers UMLS ID C0060194 and NCI Concept Code C65669. SMILES: CC(CC1=CC=CC=C1)NCCC#N.
This classification denotes a thiazide diuretic with the molecular formula C14H12ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LJ1U13R8IK, chemically known as 6-quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-4-oxo-2-phenyl-, (+-)- but generally known as fenquizone, which bears US NIH Compound Identifier 68548. European Medicines Agency schedules Fenquizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07594MIG. The term FENQUIZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules fenquizone in its Anatomical Therapeutic Chemical (ATC) Classification. FENQUIZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenquizone under HS 29350090 and SITC 51580. As of Q4 2014, FENQUIZONE remains the US FDA Preferred Term for this commodity. Fenquizone bears US NLM identifiers UMLS ID C0060196 and NCI Concept Code C65670. SMILES: CLC1C(S(=O)(=O)N)CC2C(NC(NC2=O)C2CCCCC2)C1.
This classification denotes a vasodilating agent with the molecular formula C15H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S983QC7HKM, chemically known as 1-oxa-3,8-diazaspiro(4.5)decan-2-one, 8-phenethyl- but generally known as fenspiride, which bears US NIH Compound Identifier 3344. European Medicines Agency schedules Fenspiride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07596MIG. The term FENSPIRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules fenspiride in its Anatomical Therapeutic Chemical (ATC) Classification. FENSPIRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenspiride under HS 29349990 and SITC 51579. As of Q4 2014, FENSPIRIDE remains the US FDA Preferred Term for this commodity. Fenspiride bears US NLM identifiers UMLS ID C0015843 and NCI Concept Code C80880. SMILES: O1C2(CCN(CC2)CCC2CCCCC2)CNC1=O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 832NBX878V, chemically known as 8-phenethyl-1-oxa-3,8-diazaspiro(4.5)decan-2-one monohydrochloride but more generally known as fenspiride hydrochloride, which bears US NIH Compound Identifier 68626. European Medicines Agency schedules Fenspiride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02128MIG. Most nations, for tariff and trade purposes, schedule fenspiride hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, FENSPIRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenspiride hydrochloride bears US NLM identifiers UMLS ID C0771539 and NCI Concept Code C80551. SMILES: C1CCC(CC1)CCN2CCC3(CC2)CNC(=O)O3.CL.
This classification denotes an opioid receptor agonist with the molecular formula C22H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UF599785JZ, chemically known as propionanilide, n-(1-phenethyl-4-piperidyl)- but generally known as fentanyl, which bears US NIH Compound Identifier 3345. European Medicines Agency schedules Fentanyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07597MIG. The term FENTANYL is an International Non-Proprietary Name. World Health Organization schedules fentanyl in its Anatomical Therapeutic Chemical (ATC) Classification. FENTANYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fentanyl under HS 29333300 and SITC 51574. As of Q4 2014, FENTANYL remains the US FDA Preferred Term for this commodity. Fentanyl bears US NLM identifiers UMLS ID C0591423 and NCI Concept Code C494. SMILES: O=C(N(C1CCN(CC1)CCC1CCCCC1)C1CCCCC1)CC.
This classification denotes an opioid receptor agonist with the molecular formula C22H28N2O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MUN5LYG46H, chemically known as propionanilide, n-(1-phenethyl-4-piperidyl)- but more generally known as fentanyl citrate, which bears US NIH Compound Identifier 3345. European Medicines Agency schedules Fentanyl citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02129MIG. Most nations, for tariff and trade purposes, schedule fentanyl citrate under HS 29333300 and SITC 51574. As of Q4 2014, FENTANYL CITRATE remains US FDA's Preferred Term for this commodity. Fentanyl citrate bears US NLM identifiers UMLS ID C0546864 and NCI Concept Code C47994. SMILES: CCC(=O)N(C1CCCCC1)C2CCN(CC2)CCC3CCCCC3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H28N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59H156XY46, chemically known as propionanilide, n-(1-phenethyl-4-piperidyl)-, hydrochloride but more generally known as fentanyl hydrochloride, which bears US NIH Compound Identifier 83932. European Medicines Agency schedules Fentanyl hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21234. Most nations, for tariff and trade purposes, schedule fentanyl hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, FENTANYL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fentanyl hydrochloride bears US NLM identifiers UMLS ID C1714006 and NCI Concept Code C61762. SMILES: CCC(=O)N(C1CCCCC1)C2CCN(CC2)CCC3CCCCC3.CL.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H12ClNO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0YHF6E6NLS, chemically known as 5-thiazoleacetic acid, 4-(p-chlorophenyl)-2-phenyl- but generally known as fentiazac, which bears US NIH Compound Identifier 28871. European Medicines Agency schedules Fentiazac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07598MIG. The term FENTIAZAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules fentiazac in its Anatomical Therapeutic Chemical (ATC) Classification. FENTIAZAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fentiazac under HS 29341000 and SITC 51579. As of Q4 2014, FENTIAZAC remains the US FDA Preferred Term for this commodity. Fentiazac bears US NLM identifiers UMLS ID C0060201 and NCI Concept Code C81063. SMILES: CLC1CCC(C2NC(SC2CC(=O)O)C2CCCCC2)CC1.
This classification denotes an antifungal agent with the molecular formula C24H20Cl2N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QG05NRB077, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-((4-(phenylthio)phenyl)methoxy)ethyl)- but generally known as fenticonazole, which bears US NIH Compound Identifier 51755. European Medicines Agency schedules Fenticonazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07600MIG. The term FENTICONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules fenticonazole in its Anatomical Therapeutic Chemical (ATC) Classification. FENTICONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenticonazole under HS 29332990 and SITC 51573. As of Q4 2014, FENTICONAZOLE remains the US FDA Preferred Term for this commodity. Fenticonazole bears US NLM identifiers UMLS ID C0060203 and NCI Concept Code C72963. SMILES: CLC1C(C(OCC2CCC(SC3CCCCC3)CC2)CN2CCNC2)CCC(CL)C1.
This classification denotes an antifungal agent with the molecular formula C24H20Cl2N2OS.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8V4JGC8YRF, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-((4-(phenylthio)phenyl)methoxy)ethyl)-, (+/-)-, mononitrate, but more generally known as fenticonazole mononitrate, which bears US NIH Compound Identifier 51754. European Medicines Agency schedules fenticonazole mononitrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07600MIG. Most nations, for tariff purposes, schedule fenticonazole mononitrate under HS 29332990. SMILES: C1CCC(CC1)SC2CCC(CC2)COC(CN3CCNC3)C4CCC(CC4CL)CL.[N+](=O)(O)[O-].
This classification denotes an antifungal agent with the molecular formula C24H20Cl2N2OS.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8V4JGC8YRF, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-((4-(phenylthio)phenyl)methoxy)ethyl)-, (+-)-, mononitrate but more generally known as fenticonazole nitrate, which bears US NIH Compound Identifier 51754. European Medicines Agency schedules Fenticonazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13831MIG. Most nations, for tariff and trade purposes, schedule fenticonazole nitrate under HS 29332990 and SITC 51573. As of Q4 2014, FENTICONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Fenticonazole nitrate bears US NLM identifiers UMLS ID C0771482 and NCI Concept Code C81508. SMILES: C1CCC(CC1)SC2CCC(CC2)COC(CN3CCNC3)C4CCC(CC4CL)CL.[N+](=O)(O)[O-].
This classification denotes an antimuscarinic agent with the molecular formula C31H34NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26BF4S8FO5. European Medicines Agency schedules fentonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02132MIG. FENTONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, FENTONIUM remains the US FDA Preferred Term for this commodity. Fentonium bears US NLM identifiers UMLS ID C0060206 and NCI Concept Code C83712. SMILES: C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)CC(=O)C4=CC=C(C=C4)C5=CC=CC=C5.[Br-].
This classification denotes a muscle relaxant with the molecular formula C13H14N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M574V6XQH7, chemically known as benzyl alcohol, alpha-((2-pyridylamino)methyl)-, monohydrochloride but more generally known as fenyramidol hydrochloride, which bears US NIH Compound Identifier 9469. European Medicines Agency schedules Fenyramidol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02134MIG. Most nations, for tariff and trade purposes, schedule fenyramidol hydrochloride under HS 29333999. SMILES: C1CCC(CC1)C(CNC2CCCCN2)O.CL.
This classification denotes a muscle relaxant with the molecular formula C13H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3V02WL7O3, chemically known as benzyl alcohol, .alpha.-(2-pyridyl-aminomethyl)-, hydrochloride but generally known as fenyramidol, which bears US NIH Compound Identifier 9470. European Medicines Agency schedules Fenyramidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07602MIG. The term FENYRAMIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules fenyramidol in its Anatomical Therapeutic Chemical (ATC) Classification. FENYRAMIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Fenyramidol or phenyramidol bears US NLM identifiers UMLS ID C1510448 and NCI Concept Code C84054. SMILES: C1=CC=C(C=C1)C(CNC2=CC=CC=N2)O.
This classification denotes a muscle relaxant with the molecular formula C12H13N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IL6ZSG07I5, chemically known as benzyl alcohol, .alpha.-(2-pyridyl-aminomethyl)-, hydrochloride but generally known as fenyripol, which bears US NIH Compound Identifier 9470. European Medicines Agency schedules Fenyripol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07603MIG. The term FENYRIPOL is an International Non-Proprietary Name. FENYRIPOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenyripol under HS 29335995 and SITC 51576. As of Q4 2014, FENYRIPOL remains the US FDA Preferred Term for this commodity. Fenyripol bears US NLM identifiers UMLS ID C2825400 and NCI Concept Code C80983. SMILES: C1=CC=C(C=C1)C(CNC2=CC=CC=N2)O.
This classification denotes a muscle relaxant with the molecular formula C12H13N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R4I084C0NO, chemically known as benzyl alcohol, alpha-((2-pyrimidinylamino)methyl)-, monohydrochloride but more generally known as fenyripol hydrochloride, which bears US NIH Compound Identifier 17118. Most nations, for tariff and trade purposes, schedule fenyripol hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, FENYRIPOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenyripol hydrochloride bears US NLM identifiers UMLS ID C2825401 and NCI Concept Code C80984. SMILES: C1CCC(CC1)C(CNC2NCCCN2)O.CL.
This classification denotes a sedative and hypnotic with the molecular formula C15H14N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M9C5T4Q638, chemically known as 1-methyl-3-(3-pyridyl)-5-(2-hydroxymethylphenyl)-1h-1,2,4-triazole but generally known as fepitrizol, which bears US NIH Compound Identifier 68702. European Medicines Agency schedules Fepitrizol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07605MIG. The term FEPITRIZOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). FEPITRIZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fepitrizol under HS 29333999 and SITC 51574. As of Q4 2014, FEPITRIZOL remains the US FDA Preferred Term for this commodity. Fepitrizol bears US NLM identifiers UMLS ID C1880762 and NCI Concept Code C65673. SMILES: OCC1C(C2N(NC(N2)C2CCCNC2)C)CCCC1.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C20H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BVX6J0CGR, chemically known as 3,5-pyrazolidinedione, 4-(3-methyl-2-butenyl)-1,2-diphenyl- but generally known as feprazone, which bears US NIH Compound Identifier 35455. European Medicines Agency schedules Feprazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07607MIG. The term FEPRAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules feprazone in its Anatomical Therapeutic Chemical (ATC) Classification. FEPRAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule feprazone under HS 29331990 and SITC 51571. As of Q4 2014, FEPRAZONE remains the US FDA Preferred Term for this commodity. Feprazone bears US NLM identifiers UMLS ID C0033056 and NCI Concept Code C65675. SMILES: O=C1N(N(C(=O)C1C/C=C(/C)C)C1CCCCC1)C1CCCCC1.
This classification denotes an antidepressant agent with the molecular formula C11H13N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1G4W8NR1PT, chemically known as 3-(1-methyl-2-phenylethyl)sydnone imine, monohydrochloride but generally known as feprosidnine, which bears US NIH Compound Identifier 72088. European Medicines Agency schedules Feprosidnine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07609MIG. The term FEPROSIDNINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). FEPROSIDNINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule feprosidnine under HS 29349990 and SITC 51579. As of Q4 2014, FEPROSIDNINE remains the US FDA Preferred Term for this commodity. Feprosidnine bears US NLM identifiers UMLS ID C1880764 and NCI Concept Code C65677. SMILES: CC(CC1=CC=CC=C1)[N+]2=CC(=N)O[N-]2.
This classification denotes a ferric and quaternary ammonium compound with the molecular formula C6H8O7.Fe.H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVP74NG1C5, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, ammonium iron(3+) salt but generally known as ferric ammonium citrate, which bears US NIH Compound Identifier 14457. European Medicines Agency schedules Ferric ammonium citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13834MIG. World Health Organization schedules ferric ammonium citrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ferric ammonium citrate under HS 28444030 and SITC 52519. As of Q4 2014, FERRIC AMMONIUM CITRATE remains the US FDA Preferred Term for this commodity. SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.N.[Fe+3].
This classification denotes an antihelminthic agent with the molecular formula 3C2H6AsO2.Fe, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZCT01NZ5HD, chemically known as arsinic acid, dimethyl-, iron(3+) salt but generally known as ferric cacodylate, which bears US NIH Compound Identifier 22273. Most nations schedule ferric cacodylate under HS 28444030 and SITC 52519. As of Q4 2014, FERRIC CACODYLATE remains the US FDA Preferred Term for this commodity. Ferric cacodylate bears US NLM identifiers UMLS ID C0991824 and NCI Concept Code C81518. SMILES: C[As](=O)(C)[O-].C[As](=O)(C)[O-].C[As](=O)(C)[O-].[Fe+3].
This classification denotes a hemostatic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3QJ8WS6V8H. European Medicines Agency schedules Ferric subsulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33641. Ferric subsulfate generally arises in the molecular formula 4FE.5O4S.2HO. The term 'ferric subsulfate' is a U.S. Pharmacopeial Convention designation. As of Q4 2014, FERRIC SUBSULFATE remains the US FDA Preferred Term for this commodity.
Ferrous fumarate is a medicine used to treat and prevent iron deficiency anaemias.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
Iron supplement.
This classification denotes a nutritional supplement with the molecular formula FeO4S; a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2IDP3X9OUD; chemically known as vanadium sulfate; vso4 but generally known as ferrous sulfate; which bears US National Institutes of Health Compound Identifier 1118 European Medicines Agency schedules Ferrous sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13877MIG World Health Organization schedules ferrous sulfate in its Anatomical Therapeutic Chemical (ATC) Classification As of Q4 2014, FERROUS SULFATE remains the US FDA Preferred Term for this commodity. Ferrous sulfate bears US NLM identifiers UMLS ID C0060282 and NCI Concept Code C29049. SMILES: S(=O)(=O)(O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
An iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).
This classification denotes an anticholinergic agent C26H37NO3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EOS72165S7, chemically known as propanoic acid,2-methyl ,2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester,(2e)-2-butenedioate (1:1)(salt), but more generally known as fesoterodine fumarate, which bears US NIH Compound Identifier 9849808. Most nations, for tariff and trade purposes, schedule fesoterodine fumarate under HS 29225000 and SITC 51467. As of Q4 2014, FESOTERODINE FUMARATE remains US FDA's Preferred Term for this commodity. Fesoterodine fumarate bears US NLM NCI C72779. SMILES: CC(C)C(=O)OC1CCC(CC1[C@H](CCN(C(C)C)C(C)C)C2CCCCC2)CO.C(=C/C(=O)O)\C(=O)O.
This classification denotes an anticholinergic agent with the molecular formulas C26H37NO3 and C26H37NO3.C4H4O4, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 621G617227 and EOS72165S7. European Medicines Agency schedules Fesoterodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25383. The term FESOTERODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.) Most nations schedule fesoterodine and its salts under HS 29225000 and SITC 51467. As of Q4 2014, FESOTERODINE remains the US FDA Preferred Term for this commodity. Fesoterodine bears US NLM NCI C74138 and C72779. SMILES: CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2 (base) or CC(C)C(=O)OC1CCC(CC1[C@H](CCN(C(C)C)C(C)C)C2CCCCC2)CO.C(=C/C(=O)O)\C(=O)O (fumarate).
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5N2K83R1L2. European Medicines Agency schedules Fexicaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07617MIG. Fexicaine generally arises in the molecular formula C25H34N2O4. The term FEXICAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) FEXICAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fexicaine under HS 29339990 and SITC 51577. As of Q4 2014, FEXICAINE remains the US FDA Preferred Term for this commodity. Fexicaine bears US NLM identifiers UMLS ID C1880766 and NCI Concept Code C65679. SMILES: O=C(N(CCN1CCCC1)C1C(OC)CCCC1)COC1CCC(OCCCC)CC1.
This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 306ERL82IR. European Medicines Agency schedules Fexinidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07618MIG. Fexinidazole generally arises in the molecular formula C12H13N3O3S. The term FEXINIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) FEXINIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fexinidazole under HS 29332990 and SITC 51573. As of Q4 2014, FEXINIDAZOLE remains the US FDA Preferred Term for this commodity. Fexinidazole bears US NLM identifiers UMLS ID C0060304 and NCI Concept Code C65680. SMILES: CN1C(=CN=C1COC2=CC=C(C=C2)SC)[N+](=O)[O-].
This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H39NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E6582LOH6V, chemically known as 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid but generally known as fexofenadine, which bears US NIH Compound Identifier 3348. European Medicines Agency schedules Fexofenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13883MIG. The term FEXOFENADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules fexofenadine in its Anatomical Therapeutic Chemical (ATC) Classification. FEXOFENADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fexofenadine under HS 29333999 and SITC 51574. As of Q4 2014, FEXOFENADINE remains the US FDA Preferred Term for this commodity. Fexofenadine bears US NLM identifiers UMLS ID C0296800 and NCI Concept Code C61764. SMILES: OC(C1CCN(CC1)CCCC(O)C1CCC(C(C)(C)C(=O)O)CC1)(C1CCCCC1)C1CCCCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H39NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S068B75ZU, chemically known as 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester but generally known as fexofenadine hydrochloride, which bears US NIH Compound Identifier 3333. European Medicines Agency schedules Fexofenadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13884MIG. Most nations schedule fexofenadine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, FEXOFENADINE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Fexofenadine hydrochloride bears US NLM identifiers UMLS ID C0771752 and NCI Concept Code C29050. SMILES: CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O.Cl.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T9L2X03N3F. European Medicines Agency schedules Fezatione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07619MIG. Fezatione generally arises in the molecular formula C17H14N2S2. The term FEZATIONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) FEZATIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fezatione under HS 29341000 and SITC 51579. As of Q4 2014, FEZATIONE remains the US FDA Preferred Term for this commodity. Fezatione bears US NLM identifiers UMLS ID C2825665 and NCI Concept Code C81511. SMILES: S1CC(N(/N=C/C2CCC(CC2)C)C1=S)C1CCCCC1.
This classification denotes an antidepressant agent with the molecular formula C20H23N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1133E05F6C chemically known as 1-(3-(dimethylamino)propyl)-3,4-diphenylpyrazole but generally known as fezolamine, which bears US NIH Compound Identifier 54567. European Medicines Agency schedules Fezolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07620MIG. The term FEZOLAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23. ). Most nations schedule fezolamine under HS 29331990 and SITC 51571. As of Q4 2014, FEZOLAMINE remains the US FDA Preferred Term for this commodity. Fezolamine bears US NLM identifiers UMLS ID C0060305 and NCI Concept Code C72780. SMILES: CN(C)CCCN1C=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3.
This classification denotes an antidepressant agent C20H23N3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I1GX0BGV7P, chemically known as win-41,528-2, but more generally known as fezolamine fumarate, which bears US NIH Compound Identifier 6435397. Most nations, for tariff and trade purposes, schedule fezolamine fumarate under HS 29331990 and SITC 51571. As of Q4 2014, FEZOLAMINE FUMARATE remains US FDA's Preferred Term for this commodity. Fezolamine fumarate bears US NLM identifiers UMLS ID C0956920 and NCI Concept Code C72781. SMILES: CN(C)CCCN1CC(C(N1)C2CCCCC2)C3CCCCC3.C(=C/C(=O)O)\C(=O)O.
This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H11FIN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4058H365ZB, chemically known as 2(1h)-pyrimidinone, 4-amino-1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-iodo- but generally known as fiacitabine, which bears US NIH Compound Identifier 50312. European Medicines Agency schedules Fiacitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07621MIG. The term FIACITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). FIACITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fiacitabine under HS 29349990 and SITC 51579. As of Q4 2014, FIACITABINE remains the US FDA Preferred Term for this commodity. Fiacitabine bears US NLM identifiers UMLS ID C0045211 and NCI Concept Code C73202. SMILES: IC1CN(C2OC(C(O)C2F)CO)C(=O)NC1N.
This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H10FIN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53T7IN77LC, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-iodo- but generally known as fialuridine, which bears US NIH Compound Identifier 50313. European Medicines Agency schedules Fialuridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07622MIG. The term FIALURIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). FIALURIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fialuridine under HS 29349990 and SITC 51579. As of Q4 2014, FIALURIDINE remains the US FDA Preferred Term for this commodity. Fialuridine bears US NLM identifiers UMLS ID C0208078 and NCI Concept Code C73197. SMILES: IC1CN(C2OC(C(O)C2F)CO)C(=O)[NH]C1=O.
This classification denotes a plasma glycoprotein clotted by thrombin composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds, and which is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N94833051K. European Medicines Agency schedules Fibrinogen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12502MIG. The term FIBRINOGEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19.) Fibrinogen bears US NLM identifiers UMLS ID C0016006 and NCI Concept Code C25736.
Aprotinin, calcium chloride, fibrinogen, and thrombin combination is used to help control bleeding during surgery when other procedures to close a wound or incision
A two-component fibrin sealant made from pooled human plasma
This classification denotes a cyp11b2 gene with the molecular formula C12H10FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8SH8T1164U, chemically known as spiro(4h-1-benzopyran-4,4-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2,5-dioxo-, (2s-cis)- but generally known as fidarestat, which bears US NIH Compound Identifier 160024. European Medicines Agency schedules Fidarestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07624MIG. The term FIDARESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). FIDARESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fidarestat under HS 29349990 and SITC 51579. As of Q4 2014, FIDARESTAT remains the US FDA Preferred Term for this commodity. Fidarestat bears US NLM identifiers UMLS ID C0905478 and NCI Concept Code C81355. SMILES: C1[C@H](OC2=C([C@]13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N.
This classification denotes a macrolide antibiotic with the molecular formula C52H74Cl2O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5N076G8YQ, chemically known as [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl]3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate but generally known as Fidaxomicin, which bears US NIH Compound Identifier 10034073. European Medicines Agency schedules Fidaxomicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31455. The term FIDAXOMICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Vol 23, No. 3, 2009, List 62.). As of Q4 2014, FIDAXOMICIN remains the US FDA Preferred Term for this commodity. Fidaxomicin bears US NLM identifiers UMLS ID C0065023 and NCI Concept Code C66979. SMILES: CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C30H29N5O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9O92HYT6I, chemically known as 8-phenyl-3-(4-((3ar,9br)-1,3a,4,9b-tetrahydro-9-methoxy(1)benzopyrano(3,4-c)pyrrol-2(3h)-yl)butyl)pyrazino(2,3:4,5)thieno(3,2-d)pyrimidine-2,4(1h,3h)-dione. but generally known as fiduxosin, which bears US NIH Compound Identifier 172307. The term FIDUXOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule fiduxosin under HS 29349990 and SITC 51579. As of Q4 2014, FIDUXOSIN remains the US FDA Preferred Term for this commodity. Fiduxosin bears US NLM identifiers UMLS ID C1120505 and NCI Concept Code C65682. SMILES: COC1=CC=CC2=C1C3CN(CC3CO2)CCCCN4C(=O)C5=C(C6=NC(=CN=C6S5)C7=CC=CC=C7)NC4=O.
This classification denotes an alpha-adrenergic blocking agent C30H29N5O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UYV23L1N89, chemically known as pyrazino(2',3':4,5)thieno(3,2-d)pyrimidine-2,4(1h,3h)-dione, 8-phenyl-3-(4-((3ar,9br)-1,3a,4,9b-tetrahydro-9-methoxy(1)benzopyrano(3,4-c)pyrrol-2(3h)-yl)butyl)-, monohydrochloride, but more generally known as fiduxosin hydrochloride, which bears US NIH Compound Identifier 172306. Most nations, for tariff and trade purposes, schedule fiduxosin hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, FIDUXOSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fiduxosin hydrochloride bears US NLM identifiers UMLS ID C2825597 and NCI Concept Code C81371. SMILES: COC1CCCC2C1[C@@H]3CN(C[C@@H]3CO2)CCCCN4C(=O)C5C(C6C(S5)NCC(N6)C7CCCCC7)[NH]C4=O.CL.
This classification denotes an analgesic agent with the molecular formula C14H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YFT8T83CF9, chemically known as 4-morpholineethanol, beta-1,3-benzodioxol-5-yl-alpha-methyl-, (r*,s*)-(+-)- but generally known as filenadol, which bears US NIH Compound Identifier 71224. European Medicines Agency schedules Filenadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07626MIG. The term FILENADOL is an International Non-Proprietary Name. FILENADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Filantor or filenadol bears US NLM identifiers UMLS ID C0381655 and NCI Concept Code C65683. SMILES: O1CCN(C(C(O)C)C2CC3OCOC3CC2)CC1.
This classification denotes a therapeutic colony stimulating factor with the molecular formula C845H1339N223O243S9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PVI5M0M1GW, more generally known as filgrastim. European Medicines Agency schedules filgrastim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07627MIG. The term FILGRASTIM is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 5, no. 3 1991, list 31. FILGRASTIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule filgrastim under HS 30012090 and SITC 54162. As of Q4 2014, FILGRASTIM remains the US FDA Preferred Term for this commodity. Filgrastim bears US NLM identifiers UMLS ID C0210630 and NCI Concept Code C1474. SMILES: NONE.
This classification denotes a macrolide antibiotic with the molecular formula C35H58O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 87Z59R7D14 chemically known as oxacyclooctacosa-17,19,21,23,25-pentaen-2-one, 4,6,8,10,12,14,16,27-octahydroxy-3-(1-hydroxyhexyl)-17,28-dimethyl- but generally known as filipin, which bears US NIH Compound Identifier 5351457. European Medicines Agency schedules Filipin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07628MIG. The term FILIPIN is an International Non-Proprietary Name or INN. Most nations schedule filipin under HS 29419000 and SITC 54139. As of Q4 2014, FILIPIN remains the US FDA Preferred Term for this commodity. SMILES: OC1C(C(O)CCCCC)C(=O)OC(C(O)C=CC=CC=CC=CC=C(C(O)CC(O)CC(O)CC(O)CC(O)CC(O)C1)C)C.
This classification denotes a macrolide antibiotic with the molecular formula C35H58O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 87Z59R7D14 chemically known as oxacyclooctacosa-17,19,21,23,25-pentaen-2-one, 4,6,8,10,12,14,16,27-octahydroxy-3-(1-hydroxyhexyl)-17,28-dimethyl- but generally known as filipin, which bears US NIH Compound Identifier 5351457. European Medicines Agency schedules Filipin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07628MIG. The term FILIPIN is an International Non-Proprietary Name or INN. Most nations schedule filipin iii under HS 29419000 and SITC 54139. Filipin iii bears US NLM identifiers UMLS ID C0016095 and NCI Concept Code C80959. SMILES: OC1C(C(O)CCCCC)C(=O)OC(C(O)C=CC=CC=CC=CC=C(C(O)CC(O)CC(O)CC(O)CC(O)CC(O)C1)C)C.
This classification denotes a 5 alpha-reductase inhibitor and anti-androgen with the molecular formula C23H36N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57GNO57U7G, chemically known as 4-azaandrost-1-ene-17-carboxamide, n-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- but generally known as finasteride, which bears US NIH Compound Identifier 57363. European Medicines Agency schedules Finasteride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07629MIG. The term FINASTERIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules finasteride in its Anatomical Therapeutic Chemical (ATC) Classification. FINASTERIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule finasteride under HS 29372900 and SITC 54153. As of Q4 2014, FINASTERIDE remains the US FDA Preferred Term for this commodity. Finasteride bears US NLM identifiers UMLS ID C0060389 and NCI Concept Code C1099. SMILES: O=C(NC(C)(C)C)C1C2(C(C3C(C4(C(NC(=O)C=C4)CC3)C)CC2)CC1)C.
This classification denotes a biological response modifier, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3QN8BYN5QF. European Medicines Agency schedules Fingolimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31908. Fingolimod generally arises in the molecular formula C19H33NO2. The term FINGOLIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, list 53.) Most nations, for tariff and trade purposes, schedule fingolimod under HS 29221980 and SITC 51461. As of Q4 2014, FINGOLIMOD remains US FDA's Preferred Term for this commodity. Fingolimod bears US NLM identifiers UMLS ID C1699926 and NCI Concept Code C74202. SMILES: CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) TG44VME01D. European Medicines Agency schedules Fipexide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07630MIG. Fipexide generally arises in the molecular formula C20H21CLN2O4. The term FIPEXIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, no. 10 1969, list 9.) FIPEXIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fipexide under HS 29349990 and SITC 51579. As of Q4 2014, FIPEXIDE remains US FDA's Preferred Term for this commodity. Fipexide bears US NLM identifiers UMLS ID C0060394 and NCI Concept Code C65685. SMILES: CLC1CCC(OCC(=O)N2CCN(CC2)CC2CC3OCOC3CC2)CC1.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H20O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y6V2W4S4WT, chemically known as 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5h)-one but generally known as firocoxib, which bears US NIH Compound Identifier 208910. The term FIROCOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 1, 2004, List 51). As of Q4 2014, FIROCOXIB remains the US FDA Preferred Term for this commodity. Firocoxib bears US NLM identifiers UMLS ID C1453102 and NCI Concept Code C65686. SMILES: CC1(C(=C(C(=O)O1)OCC2CC2)C3=CC=C(C=C3)S(=O)(=O)C)C.
This classification denotes an antihypertensive agent with the molecular formula C21H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, M8FR1KL85J chemically known as 4h-1-benzopyran-4-one, 7-(2-hydroxy-3-(propylamino)propoxy)-2-phenyl-, (+/-)- but generally known as flavodilol, which bears US NIH Compound Identifier 54410. European Medicines Agency schedules Flavodilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07634MIG. The term FLAVODILOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23. ). Most nations schedule flavodilol under HS 29329985 and SITC 51569. As of Q4 2014, FLAVODILOL remains the US FDA Preferred Term for this commodity. Flavodilol bears US NLM identifiers UMLS ID C0060436 and NCI Concept Code C72783. SMILES: CCCNCC(COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)O.
This classification denotes an antihypertensive agent with the molecular formula C21H23NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0DFC0D3Q8, chemically known as 4h-1-benzopyran-4-one, 7-(2-hydroxy-3-(propylamino)propoxy)-2-phenyl-, (+-)-, (z)-2-butenedioate (1:1) (salt) but generally known as flavodilol maleate, which bears US NIH Compound Identifier 6435382. Most nations schedule flavodilol maleate under HS 29329985 and SITC 51569. As of Q4 2014, FLAVODILOL MALEATE remains the US FDA Preferred Term for this commodity. SMILES: CCCNCC(COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)O.C(=CC(=O)O)C(=O)O.
This classification denotes an antimuscarinic agent with the molecular formula C24H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3E74Y80MEY, chemically known as 4h-1-benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-piperidinoethyl ester, hydrochloride but generally known as flavoxate, which bears US NIH Compound Identifier 3354. European Medicines Agency schedules Flavoxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07635MIG. The term FLAVOXATE is an International Non-Proprietary Name. World Health Organization schedules flavoxate in its Anatomical Therapeutic Chemical (ATC) Classification. FLAVOXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flavoxate under HS 29349990 and SITC 51579. As of Q4 2014, FLAVOXATE remains the US FDA Preferred Term for this commodity. Flavoxate bears US NLM identifiers UMLS ID C0016225 and NCI Concept Code C61765. SMILES: O(CCN1CCCCC1)C(=O)C1C2OC(C(C(=O)C2CCC1)C)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5A1Y43ML91. European Medicines Agency schedules Flazalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07636MIG. Flazalone generally arises in the molecular formula C19H19F2NO2. The term FLAZALONE is an International Non-Proprietary Name or INN. FLAZALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flazalone under HS 29333999 and SITC 51574. As of Q4 2014, FLAZALONE remains the US FDA Preferred Term for this commodity. Flazalone bears US NLM identifiers UMLS ID C0060451 and NCI Concept Code C80552. SMILES: FC1CCC(C2(O)C(CN(CC2)C)C(=O)C2CCC(F)CC2)CC1.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C17H20F6N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) K94FTS1806, chemically known as n-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide but more generally known as flecainide, which bears US NIH Compound Identifier 3356. European Medicines Agency schedules Flecainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07637MIG. The term FLECAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules flecainide in its Anatomical Therapeutic Chemical (ATC) Classification. FLECAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule flecainide under HS 29333999 and SITC 51574. As of Q4 2014, FLECAINIDE remains US FDA's Preferred Term for this commodity. Flecainide bears US NLM identifiers UMLS ID C0016229 and NCI Concept Code C62029. SMILES: FC(F)(F)COC1C(C(=O)NCC2NCCCC2)CC(OCC(F)(F)F)CC1.
This classification denotes an anti-arrhythmia agent with the molecular formula C17H20F6N2O3.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M8U465Q1WQ, chemically known as n-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide but more generally known as flecainide acetate, which bears US NIH Compound Identifier 3356. European Medicines Agency schedules Flecainide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13894MIG. Most nations, for tariff and trade purposes, schedule flecainide acetate under HS 29333999 and SITC 51574. As of Q4 2014, FLECAINIDE ACETATE remains US FDA's Preferred Term for this commodity. Flecainide acetate bears US NLM identifiers UMLS ID C0086303 and NCI Concept Code C499. SMILES: CC(=O)O.C1CC(C(CC1OCC(F)(F)F)C(=O)NCC2CCCCN2)OCC(F)(F)F.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C17H20F6N2O3.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M8U465Q1WQ, chemically known as benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate, but more generally known as flecainide monoacetate, which bears US NIH Compound Identifier 41022. European Medicines Agency schedules flecainide monoacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07637MIG. Most nations, for tariff purposes, schedule flecainide monoacetate under HS 29333999. SMILES: CC(=O)O.C1CC(C(CC1OCC(F)(F)F)C(=O)NCC2CCCCN2)OCC(F)(F)F.
This classification denotes a beta-adrenergic agonist and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F05RR5M463. European Medicines Agency schedules Flerobuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07638MIG. Flerobuterol generally arises in the molecular formula C12H18FNO. The term FLEROBUTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) FLEROBUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flerobuterol under HS 29221980 and SITC 51461. As of Q4 2014, FLEROBUTEROL remains the US FDA Preferred Term for this commodity. Flerobuterol bears US NLM identifiers UMLS ID C0117861 and NCI Concept Code C65691. SMILES: CC(C)(C)NCC(C1=CC=CC=C1F)O.
This classification denotes a quinolone antibiotic with the molecular formula C17H18F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N804LDH51K, chemically known as 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid but generally known as fleroxacin, which bears US NIH Compound Identifier 3357. European Medicines Agency schedules Fleroxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07639MIG. The term FLEROXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules fleroxacin in its Anatomical Therapeutic Chemical (ATC) Classification. FLEROXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fleroxacin under HS 29335995 and SITC 51576. As of Q4 2014, FLEROXACIN remains the US FDA Preferred Term for this commodity. Fleroxacin bears US NLM identifiers UMLS ID C0085161 and NCI Concept Code C72657. SMILES: FC1C(N2CCN(CC2)C)C(F)CC2C1N(CCF)CC(C2=O)C(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H22FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LI02075E1W, chemically known as [3-[[1-(carbamoylamino)-2-methylpropan-2-yl]amino]-2-hydroxypropyl]2-fluorobenzoate but generally known as flestolol, which bears US NIH Compound Identifier 55885. European Medicines Agency schedules flestolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07641MIG. Most nations schedule flestolol under HS 29242190 and SITC 51473. As of Q4 2014, FLESTOLOL remains the US FDA Preferred Term for this commodity. Flestolol bears US NLM identifiers UMLS ID C0060455 and NCI Concept Code C72784. SMILES: CC(C)(CNC(=O)N)NCC(COC(=O)C1=CC=CC=C1F)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H22FN3O4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T5MWT8445U, chemically known as o-fluorobenzoic acid, 3-ester with (+-)-(2-((2,3-dihydroxypropyl)amino)-2-methylpropyl)urea, sulfate (1:1) (salt) but more generally known as flestolol sulfate, which bears US NIH Compound Identifier 55884. Most nations, for tariff and trade purposes, schedule flestolol sulfate under HS 29242190 and SITC 51473. As of Q4 2014, FLESTOLOL SULFATE remains US FDA's Preferred Term for this commodity. Flestolol sulfate bears US NLM identifiers UMLS ID C0956983 and NCI Concept Code C73017. SMILES: CC(C)(CNC(=O)N)NCC(COC(=O)C1CCCCC1F)O.OS(=O)(=O)O.
This classification denotes a serotonin antagonist with the molecular formula C20H21F3N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37JK4STR6Z, chemically known as 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2h-benzimidazol-2-one but generally known as flibanserin, which bears US NIH Compound Identifier 127941. European Medicines Agency schedules Flibanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07644MIG. The term FLIBANSERIN is an International Non-Proprietary Name. FLIBANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flibanserin under HS 29335995 and SITC 51576. As of Q4 2014, FLIBANSERIN remains the US FDA Preferred Term for this commodity. Flibanserin bears US NLM identifiers UMLS ID C0754280 and NCI Concept Code C80769. SMILES: FC(F)(F)c1ccc(N2CCN(CC2)CCn2c3c([nH]c2=O)cccc3)cc1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H17F3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O04HVX6A9Q, chemically known as 2,3-dihydroxypropyl n-(8-(trifluoromethyl)-4-quinolyl)anthranilate but generally known as floctafenine, which bears US NIH Compound Identifier 3360. European Medicines Agency schedules Floctafenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07645MIG. The term FLOCTAFENINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules floctafenine in its Anatomical Therapeutic Chemical (ATC) Classification. FLOCTAFENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule floctafenine under HS 29334990 and SITC 51575. As of Q4 2014, FLOCTAFENINE remains the US FDA Preferred Term for this commodity. Floctafenine bears US NLM identifiers UMLS ID C0016245 and NCI Concept Code C80553. SMILES: FC(F)(F)C1C2NCCC(NC3C(CCCC3)C(=O)OCC(O)CO)C2CCC1.
This classification denotes a cephalosporin antibiotic with the molecular formula C15H18F2N6O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9E5U5XF42, chemically known as (-)-(6r,7r)-7-(2-((difluoromethyl)thio)acetamido)-3-(((1-(2-hydroxyethyl)-1h-tetrazol-5-yl)thio)methyl)-7-methoxy-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid but generally known as flomoxef, which bears US NIH Compound Identifier 65864. European Medicines Agency schedules Flomoxef in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07646MIG. The term FLOMOXEF is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). FLOMOXEF is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flomoxef under HS 29419000 and SITC 54139. As of Q4 2014, FLOMOXEF remains the US FDA Preferred Term for this commodity. Flomoxef bears US NLM identifiers UMLS ID C0117881 and NCI Concept Code C65693. SMILES: S(CC1=C(N2C(OC1)C(OC)(NC(=O)CSC(F)F)C2=O)C(=O)O)C1N(NNN1)CCO.
This classification denotes a cephalosporin antibiotic with the molecular structure C15H17F2N6O7S2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 445HIB8XNF chemically known as 5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((difluoromethyl)thio)acetyl)amino)-3-(((1-(2-hydroxyethyl)-1h-tetrazol-5-yl)thio)methyl)-7-methoxy-8-oxo-, sodium salt (1:1), (6r,7r)-, but more commonly known as flomoxef sodium, which bears US NIH Compound Identifier 443982. European Medicines Agency schedules Flomoxef sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02203MIG. Most nations, for tariff and trade purposes, schedule flomoxef sodium under HS 29419000 and SITC 54139. As of Q4 2014, FLOMOXEF SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CO[C@@]1([C@@H]2N(C1=O)C(=C(CO2)CSC3NNNN3CCO)C(=O)[O-])NC(=O)CSC(F)F.[NA+].
This classification denotes an antispasmotic agent with the molecular formula C9H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05V5NVB5Y1, chemically known as 2,4,6-trihydroxypropiophenone but generally known as flopropione, which bears US NIH Compound Identifier 3362. European Medicines Agency schedules Flopropione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07647MIG. The term FLOPROPIONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). FLOPROPIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flopropione under HS 29145000 and SITC 51629. As of Q4 2014, FLOPROPIONE remains the US FDA Preferred Term for this commodity. Flopropione bears US NLM identifiers UMLS ID C0060462 and NCI Concept Code C65694. SMILES: OC1C(C(=O)CC)C(O)CC(O)C1.
This classification denotes a cholagogue or choleretic agent with the molecular formula C20H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UZ5LMI200P, chemically known as 8-fluoranthenebutyric acid, gamma-oxo- but generally known as florantyrone, which bears US NIH Compound Identifier 10617. European Medicines Agency schedules Florantyrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07648MIG. The term FLORANTYRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). FLORANTYRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule florantyrone under HS 29183000 and SITC 51395. As of Q4 2014, FLORANTYRONE remains the US FDA Preferred Term for this commodity. Florantyrone bears US NLM identifiers UMLS ID C0060463 and NCI Concept Code C74233. SMILES: O=C(C1CC2C3C4C(C2CC1)CCCC4CCC3)CCC(=O)O.
This classification denotes a calcium channel blocker with the molecular formula C26H33F3N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8UFI7XI7R, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-1-(2-(4-morpholinyl)ethyl)-4-(2-(trifluoromethyl)phenyl)-, diethyl ester but generally known as flordipine, which bears US NIH Compound Identifier 53699. European Medicines Agency schedules Flordipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07649MIG. The term FLORDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). FLORDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flordipine under HS 29349990 and SITC 51579. As of Q4 2014, FLORDIPINE remains the US FDA Preferred Term for this commodity. Flordipine bears US NLM identifiers UMLS ID C0060464 and NCI Concept Code C81689. SMILES: FC(F)(F)c1c(C2C(=C(N(CCN3CCOCC3)C(=C2C(=O)OCC)C)C)C(=O)OCC)cccc1.
This classification denotes a vasodilating agent with the molecular formula C16H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LHX2B2R19F, chemically known as 4-(2-(3,5-diethoxyphenoxy)ethyl)morpholine. but generally known as floredil, which bears US NIH Compound Identifier 216221. European Medicines Agency schedules Floredil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07650MIG. The term FLOREDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). FLOREDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Floredil under HS 29349990 and SITC 51579. As of Q4 2014, FLOREDIL remains the US FDA Preferred Term for this commodity. Floredil bears US NLM identifiers UMLS ID C1880792 and NCI Concept Code C65695. SMILES: CCOC1CC(CC(C1)OCCN2CCOCC2)OCC.
This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C12H14Cl2FNO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J97307Y1H, chemically known as 2,2-dichloro-n-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)acetamide but generally known as florfenicol, which bears US NIH Compound Identifier 114811. European Medicines Agency schedules Florfenicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07651MIG. The term FLORFENICOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). FLORFENICOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule florfenicol under HS 29414000 and SITC 54139. As of Q4 2014, FLORFENICOL remains the US FDA Preferred Term for this commodity. Florfenicol bears US NLM identifiers UMLS ID C0060466 and NCI Concept Code C75146. SMILES: CS(=O)(=O)C1=CC=C(C=C1)C(C(CF)NC(=O)C(CL)CL)O.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19S89CMO38. European Medicines Agency schedules Flosatidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07653MIG. Flosatidil generally arises in the molecular formula C26H34F3N3O3S. The term FLOSATIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) FLOSATIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flosatidil under HS 29309085 and SITC 51549. As of Q4 2014, FLOSATIDIL remains the US FDA Preferred Term for this commodity. Flosatidil bears US NLM identifiers UMLS ID C1880793 and NCI Concept Code C65697. SMILES: S(c1c(N(Cc2cc(ccc2)C(F)(F)F)C(=O)CN(CCN(C)C)C(=O)OCC(C)C)cccc1)C.
This classification denotes a vasodilating agent with the molecular formula C11H10FNO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6NB119DLU7, chemically known as 4(1h)-quinolinone, 7-fluoro-1-methyl-3-(methylsulfinyl)- but generally known as flosequinan, which bears US NIH Compound Identifier 53516. European Medicines Agency schedules Flosequinan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07654MIG. The term FLOSEQUINAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules flosequinan in its Anatomical Therapeutic Chemical (ATC) Classification. FLOSEQUINAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flosequinan under HS 29334990 and SITC 51575. As of Q4 2014, FLOSEQUINAN remains the US FDA Preferred Term for this commodity. Flosequinan bears US NLM identifiers UMLS ID C0060470 and NCI Concept Code C73109. SMILES: CN1C=C(C(=O)C2=C1C=C(C=C2)F)SOC.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C16H13F2NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GVR41S4ZHJ, chemically known as n-(6-(2,4-difluorophenoxy)-1-oxo-5-indanyl)methanesulfonamide but generally known as flosulide, which bears US NIH Compound Identifier 71246. European Medicines Agency schedules Flosulide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07655MIG. The term FLOSULIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). FLOSULIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flosulide under HS 29350090 and SITC 51580. As of Q4 2014, FLOSULIDE remains the US FDA Preferred Term for this commodity. Flosulide bears US NLM identifiers UMLS ID C0117885 and NCI Concept Code C65698. SMILES: S(=O)(=O)(NC1CC2CCC(=O)C2CC1OC1C(F)CC(F)CC1)C.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A4JO90697G. European Medicines Agency schedules Flotrenizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07656MIG. Flotrenizine generally arises in the molecular formula C31H38F2N2O. The term FLOTRENIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) FLOTRENIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flotrenizine under HS 29335995 and SITC 51576. As of Q4 2014, FLOTRENIZINE remains the US FDA Preferred Term for this commodity. Flotrenizine bears US NLM identifiers UMLS ID C1880795 and NCI Concept Code C65699. SMILES: FC1CCC(C(N2CCN(CC2)CCCC(O)C2CCC(C(C)(C)C)CC2)C2CCC(F)CC2)CC1.
This classification denotes a penicillin antibiotic with the molecular formula C19H17ClFN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43B2M34G2V, chemically known as 6-(3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as floxacillin, which bears US NIH Compound Identifier 21319. European Medicines Agency schedules Floxacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07673MIG. The term FLUCLOXACILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules floxacillin in its Anatomical Therapeutic Chemical (ATC) Classification. Floxacillin or flucloxacillin bears US NLM identifiers UMLS ID C0016267 and NCI Concept Code C80591. SMILES: CLC1C(C2NOC(C2C(=O)NC2C3SC(C(N3C2=O)C(=O)O)(C)C)C)C(F)CCC1.
This classification denotes a pyrimidine antagonist with the molecular formula C9H11FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 039LU44I5M, chemically known as uridine, 2-deoxy-5-fluoro- but generally known as floxuridine, which bears US NIH Compound Identifier 3363. European Medicines Agency schedules Floxuridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07659MIG. The term FLOXURIDINE is an International Non-Proprietary Name. FLOXURIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule floxuridine under HS 29349990 and SITC 51579. As of Q4 2014, FLOXURIDINE remains the US FDA Preferred Term for this commodity. Floxuridine bears US NLM identifiers UMLS ID C0947603 and NCI Concept Code C504. SMILES: FC1CN(C2OC(C(O)C2)CO)C(=O)[NH]C1=O.
This classification denotes an antipsychotic agent with the molecular formula C21H25FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1D0W98U1I4, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-(2-methoxyphenyl)-1-piperazinyl)- (9ci) but generally known as fluanisone, which bears US NIH Compound Identifier 15139. European Medicines Agency schedules Fluanisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07662MIG. The term FLUANISONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules fluanisone in its Anatomical Therapeutic Chemical (ATC) Classification. FLUANISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluanisone under HS 29335995 and SITC 51576. As of Q4 2014, FLUANISONE remains the US FDA Preferred Term for this commodity. Fluanisone bears US NLM identifiers UMLS ID C0060473 and NCI Concept Code C65704. SMILES: FC1CCC(C(=O)CCCN2CCN(CC2)C2C(OC)CCCC2)CC1.
This classification denotes an antihelminthic agent with the molecular formula C16H12FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8M46911LR, chemically known as 2-benzimidazolecarbamic acid, 5-(p-fluorobenzoyl)-, methyl ester but generally known as flubendazole, which bears US NIH Compound Identifier 35802. European Medicines Agency schedules Flubendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07666MIG. The term FLUBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules flubendazole in its Anatomical Therapeutic Chemical (ATC) Classification. FLUBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flubendazole under HS 29339990 and SITC 51577. As of Q4 2014, FLUBENDAZOLE remains the US FDA Preferred Term for this commodity. Flubendazole bears US NLM identifiers UMLS ID C0060477 and NCI Concept Code C75219. SMILES: FC1CCC(C(=O)C2CC3[NH]C(NC3CC2)NC(=O)OC)CC1.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UU4X6T9FT5. European Medicines Agency schedules Flubepride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07667MIG. Flubepride generally arises in the molecular formula C20H24FN3O4S. The term FLUBEPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) FLUBEPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flubepride under HS 29350090 and SITC 51580. As of Q4 2014, FLUBEPRIDE remains the US FDA Preferred Term for this commodity. Flubepride bears US NLM identifiers UMLS ID C1880799 and NCI Concept Code C65706. SMILES: S(=O)(=O)(N)c1cc(C(=O)NCC2N(CCC2)Cc2ccc(F)cc2)c(OC)cc1.
This classification denotes an analgesic agent with the molecular formula C11H8F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XJK6U3H0P, chemically known as carbostyril, n-methyl-6-(trifluoromethyl)- but generally known as flucarbril, which bears US NIH Compound Identifier 16751. European Medicines Agency schedules Flucarbril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07668MIG. The term FLUCARBRIL is an International Non-Proprietary Name. FLUCARBRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flucarbril under HS 29337900 and SITC 51561. As of Q4 2014, FLUCARBRIL remains the US FDA Preferred Term for this commodity. Flucarbril bears US NLM identifiers UMLS ID C2825603 and NCI Concept Code C81382. SMILES: CN1C2=C(C=CC1=O)C=C(C=C2)C(F)(F)F.
This classification denotes an anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 0JJT8MQ49S. European Medicines Agency schedules Flucetorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07669MIG. Flucetorex generally arises in the molecular formula C20H21F3N2O3. The term FLUCETOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, no. 10 1974, list 14.) FLUCETOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule flucetorex under HS 29242995 and SITC 51479. As of Q4 2014, FLUCETOREX remains US FDA's Preferred Term for this commodity. Flucetorex bears US NLM identifiers UMLS ID C2700198 and NCI Concept Code C75964. SMILES: FC(F)(F)C1CC(CC(NC(=O)CC(=O)NC2CCC(OC)CC2)C)CCC1.
This classification denotes an antipsychotic agent with the molecular formula C14H16F2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5CYU0D0S8M, chemically known as 3-(dimethylamino)-6,8-difluoro-1,2,3,4-tetrahydrocarbazole but generally known as flucindole, which bears US NIH Compound Identifier 38531. European Medicines Agency schedules Flucindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07670MIG. The term FLUCINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). FLUCINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flucindole under HS 29339990 and SITC 51577. As of Q4 2014, FLUCINDOLE remains the US FDA Preferred Term for this commodity. Flucindole bears US NLM identifiers UMLS ID C0060479 and NCI Concept Code C81582. SMILES: FC1C2[NH]C3C(CC(N(C)C)CC3)C2CC(F)C1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H25Cl2FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 036B9W83KK, chemically known as 9,11beta-dichloro-6alpha-fluoro-16alpha,17,21-trihydroxypregna-1,4-diene-3,20-dione but generally known as fluclorolone, which bears US NIH Compound Identifier 20054914. European Medicines Agency schedules Fluclorolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07672MIG. The term FLUCLOROLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). As of Q4 2014, FLUCLOROLONE remains the US FDA Preferred Term for this commodity. SMILES: CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)Cl)Cl)C)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H29Cl2FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MG258KTA37, chemically known as 9,11beta-dichloro-6alpha-fluoro-16alpha,17,21-trihydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone but more generally known as fluclorolone acetonide, which bears US NIH Compound Identifier 19406. European Medicines Agency schedules Fluclorolone acetonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07672MIG. The term FLUCLOROLONE ACETONIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). Most nations, for tariff and trade purposes, schedule fluclorolone acetonide under HS 29372200 and SITC 54153. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)CL)CL.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H29Cl2FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MG258KTA37, chemically known as 9,11beta-dichloro-6alpha-fluoro-16alpha,17,21-trihydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone but generally known as fluclorolone acetonide, which bears US NIH Compound Identifier 19406. European Medicines Agency schedules Fluclorolone acetonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07672MIG. The term FLUCLOROLONE ACETONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). As of Q4 2014, FLUCLORONIDE remains the US FDA Preferred Term for this commodity. Flucloronide bears US NLM identifiers UMLS ID C0663344 and NCI Concept Code C80818. SMILES: CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)CL)CL)C)F)C.
This classification denotes a penicillin antibiotic with the molecular structure C19H16CLFN3O5S.NA.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, LMG7C674WJ chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, sodium salt monohydrate (2s(2.alpha.,5.alpha.,6.beta.)), but more commonly known as flucloxacillin sodium, which bears US NIH Compound Identifier 21319. European Medicines Agency schedules Flucloxacillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02207MIG. Most nations, for tariff and trade purposes, schedule flucloxacillin sodium under HS 29411090. SMILES: CC1C(C(NO1)C2C(CCCC2CL)F)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[NA+].
This classification denotes an antifungal agent with the molecular formula C13H12F2N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8VZV102JFY, chemically known as 2,4-difluoro-alpha,alpha-bis(1h-1,2,4-triazol-1-ylmethyl)benzyl alcohol but generally known as fluconazole, which bears US NIH Compound Identifier 3365. European Medicines Agency schedules Fluconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07674MIG. The term FLUCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules fluconazole in its Anatomical Therapeutic Chemical (ATC) Classification. FLUCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluconazole under HS 29339990 and SITC 51577. As of Q4 2014, FLUCONAZOLE remains the US FDA Preferred Term for this commodity. Fluconazole bears US NLM identifiers UMLS ID C0016277 and NCI Concept Code C500. SMILES: FC1C(C(O)(CN2NCNC2)CN2NCNC2)CCC(F)C1.
This classification denotes a pyrimidine antagonist with the molecular formula C4H4FN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D83282DT06, chemically known as 2(1h)-pyrimidinone, 4-amino-5-fluoro- (8ci)(9ci) but generally known as flucytosine, which bears US NIH Compound Identifier 3366. European Medicines Agency schedules Flucytosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07676MIG. The term FLUCYTOSINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules flucytosine in its Anatomical Therapeutic Chemical (ATC) Classification. FLUCYTOSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flucytosine under HS 29335995 and SITC 51576. As of Q4 2014, FLUCYTOSINE remains the US FDA Preferred Term for this commodity. Flucytosine bears US NLM identifiers UMLS ID C0016278 and NCI Concept Code C501. SMILES: FC1C([NH]C(=O)NC1)N.
This classification denotes a ribonucleotide reductase inhibitor and purine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1X9VK9O1SC. The European Medicines Agency schedules Fludarabine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13897MIG. Fludarabine phosphate generally arises in the molecular formula C10H13FN5O7P. Most nations schedule Fludarabine under HS 29349990. The term 'fludarabine phosphate' is a United States Adopted Name designation. SMILES: P(=O)(OCC1OC(N2C3NC(F)NC(N)C3NC2)C(O)C1O)(O)O.
This classification denotes an anti-infective agent with the molecular formula C26H20Cl4FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K23V2Z5820, chemically known as 1h-imidazolium, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-3-(2-(4-fluorophenyl)-2-oxoethyl)- but generally known as fludazonium, which bears US NIH Compound Identifier 216229. European Medicines Agency schedules Fludazonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07679MIG. The term FLUDAZONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). As of Q4 2014, FLUDAZONIUM remains the US FDA Preferred Term for this commodity. Fludazonium bears US NLM identifiers UMLS ID C2828234 and NCI Concept Code C87261. SMILES: C1=CC(=CC=C1C(=O)C[N+]2=CN(C=C2)CC(C3=C(C=C(C=C3)Cl)Cl)OCC4=C(C=C(C=C4)Cl)Cl)F.
This classification denotes an anti-infective agent with the molecular formula C26H20Cl4FN2O2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 039G8U30HE, chemically known as 1h-imidazolium, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-3-(2-(4-fluorophenyl)-2-oxoethyl)-,chloride but more generally known as fludazonium chloride, which bears US NIH Compound Identifier 216228. European Medicines Agency schedules Fludazonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07679MIG. The term FLUDAZONIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). Most nations, for tariff and trade purposes, schedule fludazonium chloride under HS 29332990 and SITC 51573. As of Q4 2014, FLUDAZONIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Fludazonium chloride bears US NLM identifiers UMLS ID C1880802 and NCI Concept Code C65708. SMILES: C1CC(CCC1C(=O)C[N+]2CCN(C2)CC(C3CCC(CC3CL)CL)OCC4CCC(CC4CL)CL)F.[CL-].
This classification denotes a fluorine-based medical imaging agent and tracer, commonly used in Positron Emission Tomography (PET), a preparation which US FDA regulates under Unique Ingredient Identifier 0Z5B2CJX4D. European Medicines Agency schedules Fludeoxyglucose (18f) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07680MIG. The term FLUDEOXYGLUCOSE (18F) is an International Non-Proprietary Name (see WHO INN reference publication, Volume 4, No. 3 1990, List 30.) FLUDEOXYGLUCOSE F-18 remains the US FDA Preferred Term for this commodity. Fludeoxyglucose (18f) bears US NLM identifiers UMLS ID C0046056 and NCI Concept Code C964. Most nations, for tariff and trade purposes, schedule Fludeoxyglucose (18f) under HS 28444000 and SITC 52519. SMILES: C([C@H]([C@H]([C@@H]([C@H](C=O)[18F])O)O)O)O.
This classification denotes a benzodiazepine with the molecular formula C16H12ClFN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7F64A2K16Z, chemically known as 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl-2h-1,4-benzodiazepin-2-one but generally known as fludiazepam, which bears US NIH Compound Identifier 3369. European Medicines Agency schedules Fludiazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07681MIG. The term FLUDIAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules fludiazepam in its Anatomical Therapeutic Chemical (ATC) Classification. FLUDIAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fludiazepam under HS 29339190 and SITC 51577. As of Q4 2014, FLUDIAZEPAM remains the US FDA Preferred Term for this commodity. Fludiazepam bears US NLM identifiers UMLS ID C0060485 and NCI Concept Code C65709. SMILES: CLC1CC2C(N(C(=O)CN=C2C2C(F)CCCC2)C)CC1.
This classification denotes an antiemetic agent and anorexiant with the molecular formula C11H14F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 346FQP00BI, chemically known as benzeneethanamine, beta-methoxy-n-methyl-3-(trifluoromethyl)- but generally known as fludorex, which bears US NIH Compound Identifier 27139. European Medicines Agency schedules Fludorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07682MIG. The term FLUDOREX is an International Non-Proprietary Name. FLUDOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Fludorex under HS 29221980 and SITC 51461. As of Q4 2014, FLUDOREX remains the US FDA Preferred Term for this commodity. Fludorex bears US NLM identifiers UMLS ID C2983802 and NCI Concept Code C90617. SMILES: CNCC(C1CCCC(C1)C(F)(F)F)OC.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H29FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U0476M545B, chemically known as 9-fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione but generally known as fludrocortisone, which bears US NIH Compound Identifier 31378. European Medicines Agency schedules Fludrocortisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07684MIG. The term FLUDROCORTISONE is an International Non-Proprietary Name. World Health Organization schedules fludrocortisone in its Anatomical Therapeutic Chemical (ATC) Classification. FLUDROCORTISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fludrocortisone under HS 29372200 and SITC 54153. As of Q4 2014, FLUDROCORTISONE remains the US FDA Preferred Term for this commodity. Fludrocortisone bears US NLM identifiers UMLS ID C0016280 and NCI Concept Code C71629. SMILES: FC12C(C3C(C(O)(CC3)C(=O)CO)(CC2O)C)CCC2=CC(=O)CCC12C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C23H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V47IF0PVH4, chemically known as 9-fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate but more generally known as fludrocortisone acetate, which bears US NIH Compound Identifier 10572. European Medicines Agency schedules Fludrocortisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02209MIG. Most nations, for tariff and trade purposes, schedule fludrocortisone acetate under HS 29372200 and SITC 54153. As of Q4 2014, FLUDROCORTISONE ACETATE remains US FDA's Preferred Term for this commodity. Fludrocortisone acetate bears US NLM identifiers UMLS ID C0616274 and NCI Concept Code C1103. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H33FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MS1UFS6FAB, chemically known as pregn-4-ene-3,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-, 21-(hydrogen succinate), but more generally known as fludrocortisone hemisuccinate, which bears US NIH Compound Identifier 31871. European Medicines Agency schedules fludrocortisone hemisuccinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07684MIG. Most nations, for tariff purposes, schedule fludrocortisone hemisuccinate under HS 29372200. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)O)O)C)O)F.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H33FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8EUL29XUQT, chemically known as 6alpha-fluoro-16alpha-hydroxyhydrocortisone 16,17-acetonide but generally known as fludroxycortide, which bears US NIH Compound Identifier 15209. European Medicines Agency schedules Fludroxycortide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07685MIG. The term FLUDROXYCORTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules fludroxycortide in its Anatomical Therapeutic Chemical (ATC) Classification. FLUDROXYCORTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Fludroxycortide or flurandrenolide bears US NLM identifiers UMLS ID C0016374 and NCI Concept Code C47537. SMILES: FC1CC2C3C(C4(OC(OC4C3)(C)C)C(=O)CO)(CC(O)C2C2(C1=CC(=O)CC2)C)C.
This classification denotes an anti-inflammatory agent with the molecular formula C14H10F3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60GCX7Y6BH, chemically known as n-(alpha,alpha,alpha-trifluoro-m-tolyl)anthranilic acid but generally known as flufenamic acid, which bears US NIH Compound Identifier 3371. European Medicines Agency schedules Flufenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07686MIG. World Health Organization schedules flufenamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule flufenamic acid under HS 29224995 and SITC 51465. As of Q4 2014, FLUFENAMIC ACID remains the US FDA Preferred Term for this commodity. SMILES: FC(F)(F)C1CC(NC2C(CCCC2)C(=O)O)CCC1.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C21H24FN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O8G173034U, chemically known as 1h-purine-2,6-dione, 7-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-3,7-dihydro-1,3-dimethyl- but generally known as flufylline, which bears US NIH Compound Identifier 71255. European Medicines Agency schedules Flufylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07689MIG. The term FLUFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). FLUFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flufylline under HS 29395900 and SITC 54145. As of Q4 2014, FLUFYLLINE remains the US FDA Preferred Term for this commodity. Flufylline bears US NLM identifiers UMLS ID C0060489 and NCI Concept Code C65712. SMILES: FC1CCC(C(=O)C2CCN(CC2)CCN2C3C(N(C(=O)N(C3=O)C)C)NC2)CC1.
This classification denotes a neuroprotective agent with the molecular formula C15H14FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40P7XK9392, chemically known as 4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester but generally known as flumazenil, which bears US NIH Compound Identifier 3373. European Medicines Agency schedules Flumazenil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07693MIG. The term FLUMAZENIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules flumazenil in its Anatomical Therapeutic Chemical (ATC) Classification. FLUMAZENIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flumazenil under HS 29339940 and SITC 51577. As of Q4 2014, FLUMAZENIL remains the US FDA Preferred Term for this commodity. Flumazenil bears US NLM identifiers UMLS ID C0016293 and NCI Concept Code C47534. SMILES: FC1CC2C(N3C(CN(C2=O)C)C(NC3)C(=O)OCC)CC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29F3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K80185F39X, chemically known as 17-hydroxy-6alpha-(trifluoromethyl)pregn-4-ene-3,20-dione but generally known as flumedroxone, which bears US NIH Compound Identifier 71881. European Medicines Agency schedules Flumedroxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07695MIG. The term FLUMEDROXONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules flumedroxone in its Anatomical Therapeutic Chemical (ATC) Classification. FLUMEDROXONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flumedroxone under HS 29147000 and SITC 51629. As of Q4 2014, FLUMEDROXONE remains the US FDA Preferred Term for this commodity. Flumedroxone bears US NLM identifiers UMLS ID C0060492 and NCI Concept Code C65715. SMILES: FC(F)(F)C1CC2C3C(C(O)(CC3)C(=O)C)(CCC2C2(C1=CC(=O)CC2)C)C.
This classification denotes a quinolone antibiotic with the molecular formula C14H12FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVG8VSP2SJ, chemically known as 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1h,5h-quinolizine-2-carboxylic acid but generally known as flumequine, which bears US NIH Compound Identifier 3374. European Medicines Agency schedules Flumequine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07696MIG. The term FLUMEQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules flumequine in its Anatomical Therapeutic Chemical (ATC) Classification. FLUMEQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flumequine under HS 29339990 and SITC 51577. As of Q4 2014, FLUMEQUINE remains the US FDA Preferred Term for this commodity. Flumequine bears US NLM identifiers UMLS ID C0060493 and NCI Concept Code C80639. SMILES: FC1CC2CCC(N3C2C(C(=O)C(C3)C(=O)O)C1)C.
This classification denotes an antiemetic agent with the molecular formula C22H23ClFN5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZZN46QU1N, chemically known as 2h-benzimidazol-2-one, 1-(3-(4-(5-chloro-2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)-1-piperidinyl)propyl)-5-fluoro-1,3-dihydro- but generally known as flumeridone, which bears US NIH Compound Identifier 71758. European Medicines Agency schedules Flumeridone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07697MIG. The term FLUMERIDONE is an International Non-Proprietary Name. FLUMERIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flumeridone under HS 29333999 and SITC 51574. As of Q4 2014, FLUMERIDONE remains the US FDA Preferred Term for this commodity. Flumeridone bears US NLM identifiers UMLS ID C1880808 and NCI Concept Code C65716. SMILES: CLC1CC2[NH]C(=O)N(C3CCN(CC3)CCCN3C4C([NH]C3=O)CC(F)CC4)C2CC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28F2O5, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier LR3CD8SX89, chemically known as 6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione but more generally known as flumetasone, which bears U.S. NIH Compound Identifier 16490. European Medicines Agency schedules Flumetasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07698MIG. The term FLUMETASONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules flumetasone in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. FLUMETASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an antihelminthic agent and a fat-soluble pyrethroid veterinary acaracide, ectoparasite, and insecticide used in the control of ectoparasites on cattle, sheep, goats, horses, and dogs, with the molecular formula C28H22Cl2FNO3, chemically known as [cyano-(4-fluoro-3-phenoxyphenyl)methyl]3-[2-chloro-2-(4-chlorophenyl)ethenyl]-2,2-dimethylcyclopropane-1-carboxylate but generally known as flumethrin, which bears US NIH Compound Identifier 91702. The European Chemical Bureau schedules flumethrin as a hazardous substance under EINECS/ECC number 274-110-4. As of Q4 2014, FLUMETHRIN remains the US FDA Preferred Term for this commodity. SMILES: CC1(C(C1C(=O)OC(C#N)C2=CC(=C(C=C2)F)OC3=CC=CC=C3)C=C(C4=CC=C(C=C4)Cl)Cl)C.
This classification denotes an anorexiant with the molecular formula C10H9F3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) LUO2Z7954T, chemically known as 2-oxazolamine, 4,5-dihydro-5-(4-(trifluoromethyl)-phenyl)- but more generally known as fluminorex, which bears US NIH Compound Identifier 24100. European Medicines Agency schedules Fluminorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07703MIG. The term FLUMINOREX is an International Non-Proprietary Name. FLUMINOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fluminorex under HS 29349990 and SITC 51579. As of Q4 2014, FLUMINOREX remains US FDA's Preferred Term for this commodity. Fluminorex bears US NLM identifiers UMLS ID C2348685 and NCI Concept Code C72179. SMILES: C1C(OC(=N1)N)C2=CC=C(C=C2)C(F)(F)F.
This classification denotes a nonsteroidal antiinflammatory drug and antiparkinsonian agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IZ1GXE233H. European Medicines Agency schedules Flunamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07706MIG. Flunamine generally arises in the molecular formula C15H15F2NO. The term FLUNAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, no. 10 1974, list 14.) FLUNAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flunamine under HS 29221980 and SITC 51461. As of Q4 2014, FLUNAMINE remains the US FDA Preferred Term for this commodity. Flunamine bears US NLM identifiers UMLS ID C1880810 and NCI Concept Code C65720. SMILES: Fc1ccc(C(OCCN)c2ccc(F)cc2)cc1.
This classification denotes a histamine-1 receptor antagonist and calcium channel blocker with the molecular formula C26H26F2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R7PLA2DM0J, chemically known as piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (e)- but generally known as flunarizine, which bears US NIH Compound Identifier 941361. European Medicines Agency schedules Flunarizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07707MIG. The term FLUNARIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules flunarizine in its Anatomical Therapeutic Chemical (ATC) Classification. FLUNARIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flunarizine under HS 29335995 and SITC 51576. As of Q4 2014, FLUNARIZINE remains the US FDA Preferred Term for this commodity. Flunarizine bears US NLM identifiers UMLS ID C0016295 and NCI Concept Code C83718. SMILES: FC1CCC(C(N2CCN(CC2)C/C=C/C2CCCCC2)C2CCC(F)CC2)CC1.
This classification denotes a calcium channel blocker with the molecular formula C26H26F2N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C11102TO53, chemically known as piperazine, 1-(bis(p-fluorophenyl)methyl)-4-cinnamyl-, dihydrochloride, (e)- but more generally known as flunarizine dihydrochloride, which bears US NIH Compound Identifier 5282407. European Medicines Agency schedules Flunarizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02213MIG. Most nations, for tariff and trade purposes, schedule flunarizine dihydrochloride under HS 29335995 and SITC 51576. SMILES: C1CCC(CC1)/C=C/CN2CCN(CC2)C(C3CCC(CC3)F)C4CCC(CC4)F.CL.CL.
This classification denotes a histamine-1 receptor antagonist and calcium channel blocker with the molecular formula C26H26F2N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C11102TO53, chemically known as (e)-1-(bis-(p-fluorophenyl)methyl)-4-cinnamylpiperazine dihydrochloride, but more generally known as flunarizine hydrochloride, which bears US NIH Compound Identifier 5282407. European Medicines Agency schedules flunarizine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07707MIG. Most nations, for tariff purposes, schedule flunarizine hydrochloride under HS 29335995. As of Q4 2014, FLUNARIZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Flunarizine hydrochloride bears US NLM identifiers UMLS ID C0282181 and NCI Concept Code C81684. SMILES: C1CCC(CC1)/C=C/CN2CCN(CC2)C(C3CCC(CC3)F)C4CCC(CC4)F.CL.CL.
This classification denotes a therapeutic glucocorticoid with the molecular formula 2C24H31FO6.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, QK4DYS664X chemically known as 6.alpha.-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, hemihydrate but generally known as flunisolide, which bears US NIH Compound Identifier 53655. European Medicines Agency schedules Flunisolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07709MIG. Most nations schedule flunisolide under HS 29372200 and SITC 54153. As of Q4 2014, FLUNISOLIDE remains the US FDA Preferred Term for this commodity. Flunisolide bears US NLM identifiers UMLS ID C0060501 and NCI Concept Code C29054. SMILES: FC1CC2C3C(C4(OC(OC4C3)(C)C)C(=O)CO)(CC(O)C2C2(C1=CC(=O)C=C2)C)C.FC1CC2C3C(C4(OC(OC4C3)(C)C)C(=O)CO)(CC(O)C2C2(C1=CC(=O)C=C2)C)C.O.
This classification denotes a therapeutic glucocorticoid C26H33FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N225H64CIH, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as flunisolide acetate, which bears US NIH Compound Identifier 23724908. European Medicines Agency schedules Flunisolide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13898MIG. Most nations, for tariff and trade purposes, schedule flunisolide acetate under HS 29372200 and SITC 54153. As of Q4 2014, FLUNISOLIDE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3C[C@@H](C5=CC(=O)C=C[C@]45C)F)O)C)OC(O2)(C)C.
This classification denotes a benzodiazepine with the molecular formula C16H12FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 620X0222FQ, chemically known as 1,3-dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2h-1,4-benzodiazepin-2-one but generally known as flunitrazepam, which bears US NIH Compound Identifier 3380. European Medicines Agency schedules Flunitrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07710MIG. The term FLUNITRAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules flunitrazepam in its Anatomical Therapeutic Chemical (ATC) Classification. FLUNITRAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flunitrazepam under HS 29339190 and SITC 51577. As of Q4 2014, FLUNITRAZEPAM remains the US FDA Preferred Term for this commodity. Flunitrazepam bears US NLM identifiers UMLS ID C0016296 and NCI Concept Code C87672. SMILES: FC1C(C2=NCC(=O)N(C3C2CC([N](=O)O)CC3)C)CCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 356IB1O400, chemically known as 3-pyridinecarboxylic acid, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)- but generally known as flunixin, which bears US NIH Compound Identifier 38081. European Medicines Agency schedules Flunixin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07711MIG. The term FLUNIXIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). FLUNIXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flunixin under HS 29333999 and SITC 51574. As of Q4 2014, FLUNIXIN remains the US FDA Preferred Term for this commodity. Flunixin bears US NLM identifiers UMLS ID C0060502 and NCI Concept Code C65721. SMILES: FC(F)(F)C1C(C(NC2NCCCC2C(=O)O)CCC1)C.
This classification denotes a nonsteroidal antiinflammatory drug C14H11F3N2O2.C7H17NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y3JK0JW3U, chemically known as 2-(.alpha.(sup 3),.alpha.(sup 3),.alpha.(sup 3)-trifluoro-2,3-xylidino)nicotinic acid compound with 1-deoxy-1-(methylamino)-d-glucitol (1:1), but more generally known as flunixin meglumine, which bears US NIH Compound Identifier 39212. Most nations, for tariff and trade purposes, schedule flunixin meglumine under HS 29333999 and SITC 51574. As of Q4 2014, FLUNIXIN MEGLUMINE remains US FDA's Preferred Term for this commodity. Flunixin meglumine bears US NLM identifiers UMLS ID C0060503 and NCI Concept Code C76804. SMILES: CC1C(CCCC1NC2C(CCCN2)C(=O)O)C(F)(F)F.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H12FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UKU5U19W9M, chemically known as 5-benzoxazoleacetic acid, 2-(4-fluorophenyl)-alpha-methyl-, (s)- but generally known as flunoxaprofen, which bears US NIH Compound Identifier 68869. European Medicines Agency schedules Flunoxaprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07713MIG. The term FLUNOXAPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules flunoxaprofen in its Anatomical Therapeutic Chemical (ATC) Classification. FLUNOXAPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flunoxaprofen under HS 29349990 and SITC 51579. As of Q4 2014, FLUNOXAPROFEN remains the US FDA Preferred Term for this commodity. Flunoxaprofen bears US NLM identifiers UMLS ID C0060504 and NCI Concept Code C65722. SMILES: FC1CCC(C2OC3C(N2)CC(C(C)C(=O)O)CC3)CC1.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0CD5FD6S2M. European Medicines Agency schedules Fluocinolone acetonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07714MIG. Fluocinolone acetonide generally arises in the molecular formula C24H30F2O6. The term FLUOCINOLONE ACETONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) Most nations schedule fluocinolone acetonide under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCINOLONE ACETONIDE remains the US FDA Preferred Term for this commodity. Fluocinolone acetonide bears US NLM identifiers UMLS ID C0016298 and NCI Concept Code C29055. SMILES: FC12C(C3C(C4(OC(OC4C3)(C)C)C(=O)CO)(CC1O)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
Fluocinolone/lidocaine/neomycin/polymyxin is a combination of drugs used for the treatment of external otitis.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H32F2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2W4A77YPAN, chemically known as 6.alpha.,9-difluoro-11.beta.,16.alpha., 17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16, 17-acetal with acetone, 21-acetate but generally known as fluocinonide, which bears US NIH Compound Identifier 3382. European Medicines Agency schedules Fluocinonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07715MIG. The term FLUOCINONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules fluocinonide in its Anatomical Therapeutic Chemical (ATC) Classification. FLUOCINONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluocinonide under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCINONIDE remains the US FDA Preferred Term for this commodity. Fluocinonide bears US NLM identifiers UMLS ID C0016299 and NCI Concept Code C29056. SMILES: FC12C(C3C(C4(OC(OC4C3)(C)C)C(=O)COC(=O)C)(CC1O)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes a dermatologic agent and glucocorticoid with the molecular formula C22H27FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03837V0H1Y, chemically known as pregna-1,4-dien-21-oic acid, 6-fluoro-11-hydroxy-16-methyl-3,20-dioxo-, (6alpha,11beta,16alpha)- but generally known as fluocortin, which bears US NIH Compound Identifier 118029. European Medicines Agency schedules Fluocortin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07716MIG. World Health Organization schedules fluocortin in its Anatomical Therapeutic Chemical (ATC) Classification. FLUOCORTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluocortin under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCORTIN remains the US FDA Preferred Term for this commodity. SMILES: FC1CC2C3C(C(C(C3)C)C(=O)C(=O)O)(CC(O)C2C2(C1=CC(=O)C=C2)C)C.
This classification denotes a dermatologic agent and glucocorticoid C26H35FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6N7OA9MO7O, chemically known as butyl 6.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-methyl-3,20-dioxopregna-1,4-dien-21-oate, but more generally known as fluocortin butyl, which bears US NIH Compound Identifier 15942715. European Medicines Agency schedules Fluocortin butyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13900MIG. Most nations, for tariff and trade purposes, schedule fluocortin butyl under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCORTIN BUTYL remains US FDA's Preferred Term for this commodity. SMILES: CCCCOC(=O)C(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)F)O)C)C.
This classification denotes a dermatologic agent and glucocorticoid with the molecular formula C26H35FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6N7OA9MO7O, chemically known as pregna-1,4-dien-21-oic acid, 6-fluoro-11-hydroxy-16-methyl-3,20-dioxo-, butyl ester (6.alpha.,11.beta.,16.alpha.)-, but more generally known as fluocortin butyl ester, which bears US NIH Compound Identifier 39034. European Medicines Agency schedules fluocortin butyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07716MIG. Most nations, for tariff purposes, schedule fluocortin butyl ester under HS 29372200. SMILES: CCCCOC(=O)C(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)F)O)C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65VXC1MH0J, chemically known as 6-alpha-fluoro-16-alpha-methylpregna-1,4-diene-11-beta,21-diol-3,20-dione but generally known as fluocortolone, which bears US NIH Compound Identifier 9053. European Medicines Agency schedules Fluocortolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07717MIG. The term FLUOCORTOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules fluocortolone in its Anatomical Therapeutic Chemical (ATC) Classification. FLUOCORTOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluocortolone under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCORTOLONE remains the US FDA Preferred Term for this commodity. Fluocortolone bears US NLM identifiers UMLS ID C0016301 and NCI Concept Code C80819. SMILES: FC1CC2C3C(C(C(C3)C)C(=O)CO)(CC(O)C2C2(C1=CC(=O)C=C2)C)C.
This classification denotes a therapeutic glucocorticoid C24H31FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F0KV2P7H3C, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6-fluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as fluocortolone acetate, which bears US NIH Compound Identifier 22798516. European Medicines Agency schedules Fluocortolone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02217MIG. Most nations, for tariff and trade purposes, schedule fluocortolone acetate under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCORTOLONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@H]1C(=O)COC(=O)C)C)O)C)F.
This classification denotes a therapeutic glucocorticoid C28H39FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90893P8662, chemically known as hexanoic acid, 21-ester with 6.alpha.-fluoro-11.beta.,21-dihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione, but more generally known as fluocortolone caproate, which bears US NIH Compound Identifier 20054915. European Medicines Agency schedules Fluocortolone caproate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13901MIG. Most nations, for tariff and trade purposes, schedule fluocortolone caproate under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCORTOLONE CAPROATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCC(=O)OCC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)F)O)C)C.
This classification denotes a contrast agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier TPY09G7XIR. The European Medicines Agency schedules Fluorescein sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13905MIG. Fluorescein generally arises in the molecular formula C20H12O5. The term 'fluorescein' is an International Nomenclature of Cosmetic Ingredients designation. SMILES: O1C2C(C(C3C1CC(=O)CC3)C1C(CCCC1)C(=O)O)CCC(O)C2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes a dietary fluorine with the molecular formula F, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q80VPU408O, chemically known as drinking water,fluoride treated but generally known as fluoride, which bears US NIH Compound Identifier 28179. European Medicines Agency schedules Fluoride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21927. World Health Organization schedules fluoride in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.
This classification denotes a radio tracer used in PET analysis, with a molecular formula of C9H10FNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2C598205QX. The European Medicines Agency schedules Fluorodopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07719MIG. Most nations schedule Fluorodopa under HS 28444030. SMILES: C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SV0CSG527L, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-6-methyl-, (6.alpha.,11.beta.)- but generally known as fluorometholone, which bears US NIH Compound Identifier 3384. European Medicines Agency schedules Fluorometholone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07720MIG. The term FLUOROMETHOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules fluorometholone in its Anatomical Therapeutic Chemical (ATC) Classification. FLUOROMETHOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluorometholone under HS 29372200 and SITC 54153. As of Q4 2014, FLUOROMETHOLONE remains the US FDA Preferred Term for this commodity. Fluorometholone bears US NLM identifiers UMLS ID C0016351 and NCI Concept Code C29058. SMILES: FC12C(C3C(C(O)(CC3)C(=O)C)(CC1O)C)CC(C1=CC(=O)C=CC21C)C.
This classification denotes a therapeutic glucocorticoid C24H31FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I50C3I3OK, chemically known as pregna-1,4-diene-3,20-dione, 17-(acetyloxy)-9-fluoro-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)-, but more generally known as fluorometholone acetate, which bears US NIH Compound Identifier 240767. European Medicines Agency schedules Fluorometholone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13906MIG. Most nations, for tariff and trade purposes, schedule fluorometholone acetate under HS 29372200 and SITC 54153. As of Q4 2014, FLUOROMETHOLONE ACETATE remains US FDA's Preferred Term for this commodity. Fluorometholone acetate bears US NLM identifiers UMLS ID C0720168 and NCI Concept Code C47535. SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)OC(=O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a thymidylate synthase inhibitor and pyrimidine antagonist with the molecular formula C4H3FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3P01618RT, chemically known as 2,4-dioxo-5-fluoropyrimidine but more generally known as fluorouracil, which bears U.S. National Institutes of Health Compound Identifier 3385. The European Medicines Agency schedules Fluorouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07721MIG. The term FLUOROURACIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules fluorouracil in its Anatomical Therapeutic Chemical (ATC) Classification. FLUOROURACIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Fluorouracil under HS 29335995. SMILES: FC1C(=O)[NH]C(=O)[NH]C1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C17H18F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01K63SUP8D, chemically known as (+) or (-)-n-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine but generally known as fluoxetine, which bears US NIH Compound Identifier 3386. European Medicines Agency schedules Fluoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07723MIG. The term FLUOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules fluoxetine in its Anatomical Therapeutic Chemical (ATC) Classification. FLUOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluoxetine under HS 29221980 and SITC 51461. As of Q4 2014, FLUOXETINE remains the US FDA Preferred Term for this commodity. Fluoxetine bears US NLM identifiers UMLS ID C0016365 and NCI Concept Code C506. SMILES: FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C17H18F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01K63SUP8D, chemically known as (+) or (-)-n-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine but generally known as fluoxetine, which bears US NIH Compound Identifier 3386. European Medicines Agency schedules Fluoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07723MIG. The term FLUOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules fluoxetine in its Anatomical Therapeutic Chemical (ATC) Classification. FLUOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluoxetine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, FLUOXETINE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Fluoxetine hydrochloride bears US NLM identifiers UMLS ID C0733380 and NCI Concept Code C2829. SMILES: FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C20H29FO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9JU12S4YFY, chemically known as 11-beta,17-beta-dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one but generally known as fluoxymesterone, which bears US NIH Compound Identifier 6446. European Medicines Agency schedules Fluoxymesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07724MIG. The term FLUOXYMESTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules fluoxymesterone in its Anatomical Therapeutic Chemical (ATC) Classification. FLUOXYMESTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluoxymesterone under HS 29372900 and SITC 54153. As of Q4 2014, FLUOXYMESTERONE remains the US FDA Preferred Term for this commodity. Fluoxymesterone bears US NLM identifiers UMLS ID C0016366 and NCI Concept Code C507. SMILES: FC12C(C3C(C(O)(CC3)C)(CC2O)C)CCC2=CC(=O)CCC12C.
This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FA0UYH6QUO. European Medicines Agency schedules Flupentixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07726MIG. Flupentixol generally arises in the molecular formula C23H25F3N2OS. The term FLUPENTIXOL is an International Non-Proprietary Name or INN. FLUPENTIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flupentixol under HS 29349990 and SITC 51579. As of Q4 2014, FLUPENTIXOL remains the US FDA Preferred Term for this commodity. Flupentixol bears US NLM identifiers UMLS ID C0016367 and NCI Concept Code C73315. SMILES: S1C2C(/C(=C/CCN3CCN(CC3)CCO)C3C1CCCC3)CC(CC2)C(F)(F)F.
This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C23H25F3N2OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96L0Z069N1, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-, (e)- but more generally known as flupentixol dihydrochloride, which bears US NIH Compound Identifier 5281878. European Medicines Agency schedules Flupentixol dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02229MIG. Most nations, for tariff and trade purposes, schedule flupentixol dihydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, FLUPENTIXOL DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)/C(=C/CCN3CCN(CC3)CCO)/C4CC(CCC4S2)C(F)(F)F.CL.CL.
This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C23H25F3N2OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96L0Z069N1, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-, (e)- but more generally known as flupentixol dihydrochloride, which bears US NIH Compound Identifier 5281878. European Medicines Agency schedules Flupentixol dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02229MIG. Most nations, for tariff and trade purposes, schedule flupentixol hydrochloride under HS 29349990. SMILES: C1CCC2C(C1)/C(=C/CCN3CCN(CC3)CCO)/C4CC(CCC4S2)C(F)(F)F.CL.CL.
This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EWG253M961. European Medicines Agency schedules Fluperlapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07728MIG. Fluperlapine generally arises in the molecular formula C19H20FN3. The term FLUPERLAPINE is an International Non-Proprietary Name or INN. FLUPERLAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluperlapine under HS 29335995 and SITC 51576. As of Q4 2014, FLUPERLAPINE remains the US FDA Preferred Term for this commodity. Fluperlapine bears US NLM identifiers UMLS ID C0060579 and NCI Concept Code C73316. SMILES: FC1CC2N=C(N3CCN(CC3)C)C3C(CC2CC1)CCCC3.
This classification denotes a fluprednisolone analog and pregnadienetriol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S33056JLS5. European Medicines Agency schedules Fluperolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07729MIG. Fluperolone generally arises in the molecular formula C22H29FO5. The term FLUPEROLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) FLUPEROLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluperolone under HS 29372200 and SITC 54153. As of Q4 2014, FLUPEROLONE remains the US FDA Preferred Term for this commodity. SMILES: CC(C(=O)C1(CCC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)O)O.
This classification denotes a fluprednisolone analog C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DOL7Q9DPF9, chemically known as androsta-1,4-dien-3-one, 17-(2-(acetyloxy)-1-oxopropyl)-9-fluoro-11,17-dihydroxy-, (11.beta.,17.alpha.,17(s))-, but more generally known as fluperolone acetate, which bears US NIH Compound Identifier 66257. Most nations, for tariff and trade purposes, schedule fluperolone acetate under HS 29372200 and SITC 54153. As of Q4 2014, FLUPEROLONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H](C(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)O)OC(=O)C.
This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S79426A41Z, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but generally known as fluphenazine, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Fluphenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07730MIG. The term FLUPHENAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules fluphenazine in its Anatomical Therapeutic Chemical (ATC) Classification. FLUPHENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluphenazine under HS 29343090 and SITC 51578. As of Q4 2014, FLUPHENAZINE remains the US FDA Preferred Term for this commodity. Fluphenazine bears US NLM identifiers UMLS ID C0016368 and NCI Concept Code C47536. SMILES: S1C2C(N(CCCN3CCN(CC3)CCO)C3C1CCCC3)CC(CC2)C(F)(F)F.
This classification denotes an antipsychotic agent with the molecular formula C32H44F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FMU62K1L3C, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but more generally known as fluphenazine decanoate, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Fluphenazine decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02230MIG. Most nations, for tariff and trade purposes, schedule fluphenazine decanoate under HS 29343000 and SITC 51578. As of Q4 2014, FLUPHENAZINE DECANOATE remains US FDA's Preferred Term for this commodity. Fluphenazine decanoate bears US NLM identifiers UMLS ID C0060580 and NCI Concept Code C47996. SMILES: CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)C(F)(F)F.
This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZOU145W1XL, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but more generally known as fluphenazine dihydrochloride, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Fluphenazine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02232MIG. Most nations, for tariff and trade purposes, schedule fluphenazine dihydrochloride under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCN(CC4)CCO.CL.CL.
This classification denotes an antipsychotic agent with the molecular formula C29H38F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QSB34YF0W9, chemically known as sq 16,114 but more generally known as fluphenazine enantate, which bears US NIH Compound Identifier 3389. European Medicines Agency schedules Fluphenazine enantate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02231MIG. Most nations, for tariff and trade purposes, schedule fluphenazine enanthate under HS 29343090. As of Q4 2014, FLUPHENAZINE ENANTHATE remains US FDA's Preferred Term for this commodity. Fluphenazine enanthate bears US NLM identifiers UMLS ID C0066682 and NCI Concept Code C65726. SMILES: CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)C(F)(F)F.
This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZOU145W1XL, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but more generally known as fluphenazine dihydrochloride, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Fluphenazine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02232MIG. Most nations, for tariff and trade purposes, schedule fluphenazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, FLUPHENAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fluphenazine hydrochloride bears US NLM identifiers UMLS ID C0700567 and NCI Concept Code C47995. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCN(CC4)CCO.CL.CL.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97151695PW. European Medicines Agency schedules Fluphenazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22373. Fluphenazine maleate generally arises in the molecular formula C22H26F3N3OS.C4H4O4. The term 'fluphenazine maleate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule fluphenazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, FLUPHENAZINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7V73CQS9VA, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-10h-phenothiazin-10-yl)propyl)-, s-oxide, but more generally known as fluphenazine sulfoxide, which bears US NIH Compound Identifier 3036919. European Medicines Agency schedules fluphenazine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07730MIG. Most nations, for tariff purposes, schedule fluphenazine sulfoxide under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3[S+]2[O-])C(F)(F)F)CCCN4CCN(CC4)CCO.
This classification denotes an analgesic agent with the molecular formula C15H17FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MOH3ET196H, chemically known as carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester but generally known as flupirtine, which bears US NIH Compound Identifier 53276. European Medicines Agency schedules Flupirtine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07732MIG. The term FLUPIRTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules flupirtine in its Anatomical Therapeutic Chemical (ATC) Classification. FLUPIRTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flupirtine under HS 29333999 and SITC 51574. As of Q4 2014, FLUPIRTINE remains the US FDA Preferred Term for this commodity. Flupirtine bears US NLM identifiers UMLS ID C0060583 and NCI Concept Code C72116. SMILES: FC1CCC(CNC2NC(N)C(NC(=O)OCC)CC2)CC1.
This classification denotes an analgesic agent C15H17FN4O2.C6H12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D7NP6CR89M, chemically known as d-gluconic acid, compd. with ethyl (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)carbamate, but more generally known as flupirtine gluconate, which bears US NIH Compound Identifier 18608234. European Medicines Agency schedules Flupirtine gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02233MIG. Most nations, for tariff and trade purposes, schedule flupirtine gluconate under HS 29333999 and SITC 51574. As of Q4 2014, FLUPIRTINE GLUCONATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)NC1CCC(NC1N)NCC2CCC(CC2)F.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.
This classification denotes an analgesic agent with the molecular structure C15H17FN4O2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 0VCI53PK4A chemically known as carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester, (z)-2-butenedioate (1:1), but more commonly known as flupirtine maleate, which bears US NIH Compound Identifier 6435335. European Medicines Agency schedules Flupirtine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02234MIG. Most nations, for tariff and trade purposes, schedule flupirtine maleate under HS 29333999 and SITC 51574. As of Q4 2014, FLUPIRTINE MALEATE remains US FDA's Preferred Term for this commodity. Flupirtine maleate bears US NLM identifiers UMLS ID C0772084 and NCI Concept Code C72785. SMILES: CCOC(=O)NC1CCC(NC1N)NCC2CCC(CC2)F.C(=C\C(=O)O)\C(=O)O.
This classification denotes a serotonin agonist with the molecular formula C14H19F3N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 713BBL6840, chemically known as urea, (2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)- but generally known as fluprazine, which bears US NIH Compound Identifier 71153. European Medicines Agency schedules Fluprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07734MIG. The term FLUPRAZINE is an International Non-Proprietary Name. FLUPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Fluprazine under HS 29335995 and SITC 51576. As of Q4 2014, FLUPRAZINE remains the US FDA Preferred Term for this commodity. Fluprazine bears US NLM identifiers UMLS ID C0117988 and NCI Concept Code C65729. SMILES: C1CC(CC(C1)N2CCN(CC2)CCNC(=O)N)C(F)(F)F.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FA517NS3N7, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16-methylenepregna-1,4-diene-3,20-dione but generally known as fluprednidene, which bears US NIH Compound Identifier 92921. European Medicines Agency schedules Fluprednidene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07735MIG. The term FLUPREDNIDENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules fluprednidene in its Anatomical Therapeutic Chemical (ATC) Classification. FLUPREDNIDENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluprednidene under HS 29372200 and SITC 54153. As of Q4 2014, FLUPREDNIDENE remains the US FDA Preferred Term for this commodity. Fluprednidene bears US NLM identifiers UMLS ID C0771950 and NCI Concept Code C77421. SMILES: FC12C(C3C(CC1O)(C(O)(C(=C)C3)C(=O)CO)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H27FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9H05937G3X, chemically known as pregna-1,4-diene-3,20-dione, 6-fluoro-11,17,21-trihydroxy-, (6.alpha.,11.beta.)- but generally known as fluprednisolone, which bears US NIH Compound Identifier 3390. European Medicines Agency schedules Fluprednisolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07736MIG. The term FLUPREDNISOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). FLUPREDNISOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluprednisolone under HS 29372200 and SITC 54153. As of Q4 2014, FLUPREDNISOLONE remains the US FDA Preferred Term for this commodity. Fluprednisolone bears US NLM identifiers UMLS ID C0016369 and NCI Concept Code C65730. SMILES: FC1CC2C3C(C(O)(CC3)C(=O)CO)(CC(O)C2C2(C1=CC(=O)C=C2)C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H35FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PH7R4L7SNF, chemically known as 6alpha-fluoro-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17-valerate but more generally known as fluprednisolone valerate, which bears US NIH Compound Identifier 31779. Most nations, for tariff and trade purposes, schedule fluprednisolone valerate under HS 29372200 and SITC 54153. As of Q4 2014, FLUPREDNISOLONE VALERATE remains US FDA's Preferred Term for this commodity. Fluprednisolone valerate bears US NLM identifiers UMLS ID C2825344 and NCI Concept Code C80820. SMILES: CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)F)O)C)C(=O)CO.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P69N9N4Y9Y. European Medicines Agency schedules Fluprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07737MIG. Fluprofen generally arises in the molecular formula C15H13FO2. The term FLUPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) FLUPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluprofen under HS 29163900 and SITC 51379. As of Q4 2014, FLUPROFEN remains the US FDA Preferred Term for this commodity. Fluprofen bears US NLM identifiers UMLS ID C1880819 and NCI Concept Code C65731. SMILES: FC1CC(C2CCC(C(C)C(=O)O)CC2)CCC1.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C22H26FN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Y42K4JRBJ, chemically known as 1h-purine-2,6-dione, 7-(3-(4-(4-fluorobenzoyl)-1-piperidinyl)propyl)-3,7-dihydro-1,3-dimethyl- but generally known as fluprofylline, which bears US NIH Compound Identifier 65636. European Medicines Agency schedules Fluprofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07738MIG. The term FLUPROFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). FLUPROFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluprofylline under HS 29395900 and SITC 54145. As of Q4 2014, FLUPROFYLLINE remains the US FDA Preferred Term for this commodity. Fluprofylline bears US NLM identifiers UMLS ID C1880820 and NCI Concept Code C65732. SMILES: FC1CCC(C(=O)C2CCN(CC2)CCCN2C3C(N(C(=O)N(C3=O)C)C)NC2)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H10ClF3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31YX4A42L4, chemically known as 2(1h)-quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- but generally known as fluquazone, which bears US NIH Compound Identifier 219069. European Medicines Agency schedules Fluquazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07741MIG. The term FLUQUAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). FLUQUAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluquazone under HS 29335995 and SITC 51576. As of Q4 2014, FLUQUAZONE remains the US FDA Preferred Term for this commodity. Fluquazone bears US NLM identifiers UMLS ID C1880821 and NCI Concept Code C65733. SMILES: CLC1CC2C(N(CC(F)(F)F)C(=O)NC2C2CCCCC2)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes an antihelminthic agent with the molecular formula C19H12F6N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q14SL1C0O, chemically known as 2,6-dihydroxy-3-nitro-3,5-bis(trifluoromethyl)benzanilide diacetate (ester). but generally known as flurantel, which bears US NIH Compound Identifier 219070. European Medicines Agency schedules Flurantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07743MIG. The term FLURANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). FLURANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flurantel under HS 29242995 and SITC 51479. As of Q4 2014, FLURANTEL remains the US FDA Preferred Term for this commodity. Flurantel bears US NLM identifiers UMLS ID C1880822 and NCI Concept Code C65734. SMILES: FC(F)(F)C1CC(NC(=O)C2C(OC(=O)C)C([N](=O)O)CCC2OC(=O)C)CC(C1)C(F)(F)F.
This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IHP475989U, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but generally known as flurazepam, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07744MIG. The term FLURAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules flurazepam in its Anatomical Therapeutic Chemical (ATC) Classification. FLURAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flurazepam under HS 29339190 and SITC 51577. As of Q4 2014, FLURAZEPAM remains the US FDA Preferred Term for this commodity. Flurazepam bears US NLM identifiers UMLS ID C0016375 and NCI Concept Code C62030. SMILES: CLC1CC2C(N(CCN(CC)CC)C(=O)CN=C2C2C(F)CCCC2)CC1.
This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 756RDM536M, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but more generally known as flurazepam dihydrochloride, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02238MIG. Most nations, for tariff and trade purposes, schedule flurazepam dihydrochloride under HS 29339190. SMILES: CCN(CC)CCN1C2CCC(CC2C(=NCC1=O)C3CCCCC3F)CL.CL.CL.
This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 756RDM536M, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but more generally known as flurazepam dihydrochloride, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02238MIG. Most nations, for tariff and trade purposes, schedule flurazepam hydrochloride under HS 29339190 and SITC 51577. As of Q4 2014, FLURAZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Flurazepam hydrochloride bears US NLM identifiers UMLS ID C0242293 and NCI Concept Code C29060. SMILES: CCN(CC)CCN1C2CCC(CC2C(=NCC1=O)C3CCCCC3F)CL.CL.CL.
This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C4JH842IJ, chemically known as 2h-1,4-benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1), but more generally known as flurazepam monohydrochloride, which bears US NIH Compound Identifier 37368. European Medicines Agency schedules flurazepam monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07744MIG. Most nations, for tariff purposes, schedule flurazepam monohydrochloride under HS 29339190. Flurazepam monohydrochloride bears US NLM identifiers UMLS ID C0887259 and NCI Concept Code C98134. SMILES: CCN(CC)CCN1C2CCC(CC2C(=NCC1=O)C3CCCCC3F)CL.CL.
This classification denotes a cyclooxygenase inhibitor and carbonic anhydrase inhibitor with the molecular formula C15H13FO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5GRO578KLP, chemically known as 4-biphenylacetic acid, 2-fluoro-alpha-methyl- but generally known as flurbiprofen, which bears US NIH Compound Identifier 3394. European Medicines Agency schedules Flurbiprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07745MIG. The term FLURBIPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules flurbiprofen in its Anatomical Therapeutic Chemical (ATC) Classification. FLURBIPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flurbiprofen under HS 29163900 and SITC 51379. As of Q4 2014, FLURBIPROFEN remains the US FDA Preferred Term for this commodity. Flurbiprofen bears US NLM identifiers UMLS ID C0016377 and NCI Concept Code C508. SMILES: FC1C(CCC(C(C)C(=O)O)C1)C1CCCCC1.
This classification denotes a cyclooxygenase inhibitor and carbonic anhydrase inhibitor C19H19FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0OU31PUI5, chemically known as (1,1'-biphenyl)-4-acetic acid, 2-fluoro-.alpha.-methyl-, 1-(acetyloxy)ethyl ester, but more generally known as flurbiprofen axetil, which bears US NIH Compound Identifier 3395. European Medicines Agency schedules Flurbiprofen axetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02239MIG. Most nations, for tariff and trade purposes, schedule flurbiprofen axetil under HS 29163900 and SITC 51379. As of Q4 2014, FLURBIPROFEN AXETIL remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCC(C(C1)F)C2CCCCC2)C(=O)OC(C)OC(=O)C.
This classification denotes a cyclooxygenase inhibitor and carbonic anhydrase inhibitor with the molecular formula C15H12FO2.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5B97MU9K4, chemically known as 4-biphenylacetic acid, 2-fluoro-alpha-methyl- but more generally known as flurbiprofen sodium, which bears US NIH Compound Identifier 3394. European Medicines Agency schedules Flurbiprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02240MIG. Most nations, for tariff and trade purposes, schedule flurbiprofen sodium under HS 29163900 and SITC 51379. As of Q4 2014, FLURBIPROFEN SODIUM remains US FDA's Preferred Term for this commodity. Flurbiprofen sodium bears US NLM identifiers UMLS ID C0304658 and NCI Concept Code C47997. SMILES: CC(C1CCC(C(C1)F)C2CCCCC2)C(=O)[O-].O.O.[NA+].
This classification denotes a macrolide antibiotic with the molecular formula C37H66FNO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56C9DTE69V, chemically known as erythromycin, 8-fluoro- but generally known as flurithromycin, which bears US NIH Compound Identifier 71260. European Medicines Agency schedules Flurithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07747MIG. The term FLURITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules flurithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. FLURITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flurithromycin under HS 29415000 and SITC 54139. As of Q4 2014, FLURITHROMYCIN remains the US FDA Preferred Term for this commodity. Flurithromycin bears US NLM identifiers UMLS ID C0060591 and NCI Concept Code C65735. SMILES: FC1(CC(O)(C(OC2OC(CC(N(C)C)C2O)C)C(C(OC2OC(C(O)C(OC)(C2)C)C)C(C(=O)OC(C(O)(C(O)C(C1=O)C)C)CC)C)C)C)C.
This classification denotes a cns stimulant with the molecular formula C4H4F6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Z467FG2YK, chemically known as 2,2,2-trifluoroethyl ether but generally known as flurothyl, which bears US NIH Compound Identifier 9528. European Medicines Agency schedules Flurotyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07750MIG. The term FLUROTYL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). As of Q4 2014, FLUROTHYL remains the US FDA Preferred Term for this commodity. Flurothyl bears US NLM identifiers UMLS ID C0016380 and NCI Concept Code C76624. SMILES: C(C(F)(F)F)OCC(F)(F)F.
This classification denotes an anesthetic agent with the molecular formula C4H5F3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FO7JHA3G03, chemically known as 2,2,2-trifluoroethyl vinyl ether but generally known as fluroxene, which bears US NIH Compound Identifier 9844. European Medicines Agency schedules Fluroxene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07751MIG. The term FLUROXENE is an International Non-Proprietary Name. FLUROXENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluroxene under HS 29091990 and SITC 51616. As of Q4 2014, FLUROXENE remains the US FDA Preferred Term for this commodity. Fluroxene bears US NLM identifiers UMLS ID C0016381 and NCI Concept Code C75097. SMILES: FC(F)(F)COC=C.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1GPL60IRCI. European Medicines Agency schedules Flusoxolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07753MIG. Flusoxolol generally arises in the molecular formula C22H30FNO4. The term FLUSOXOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) FLUSOXOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flusoxolol under HS 29221980 and SITC 51461. As of Q4 2014, FLUSOXOLOL remains the US FDA Preferred Term for this commodity. Flusoxolol bears US NLM identifiers UMLS ID C0117994 and NCI Concept Code C73018. SMILES: FC1CCC(CCOCCOC2CCC(OCC(O)CNC(C)C)CC2)CC1.
This classification denotes an antipsychotic agent with the molecular formula C23H25F2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V0Q53N427T, chemically known as r 28,930 but generally known as fluspiperone, which bears US NIH Compound Identifier 166535. European Medicines Agency schedules Fluspiperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07754MIG. The term FLUSPIPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). FLUSPIPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluspiperone under HS 29333999 and SITC 51574. As of Q4 2014, FLUSPIPERONE remains the US FDA Preferred Term for this commodity. Fluspiperone bears US NLM identifiers UMLS ID C1880823 and NCI Concept Code C65736. SMILES: FC1CCC(N2C3(CCN(CC3)CCCC(=O)C3CCC(F)CC3)C(=O)NC2)CC1.
This classification denotes an antipsychotic agent and dopamine antagonist with the molecular formula C29H31F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C5QA4GLR9M, chemically known as 1,3,8-triazaspiro(4.5)decan-4-one, 8-(4,4-bis(4-fluorophenyl)butyl)-1-phenyl- but generally known as fluspirilene, which bears US NIH Compound Identifier 3396. European Medicines Agency schedules Fluspirilene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07755MIG. World Health Organization schedules fluspirilene in its Anatomical Therapeutic Chemical (ATC) Classification. FLUSPIRILENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluspirilene under HS 29333999 and SITC 51574. As of Q4 2014, FLUSPIRILENE remains the US FDA Preferred Term for this commodity. SMILES: FC1CCC(C(CCCN2CCC3(N(CNC3=O)C3CCCCC3)CC2)C2CCC(F)CC2)CC1.
This classification denotes an aromatic compound and anti-androgen with the molecular formula C11H11F3N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76W6J0943E, chemically known as propanamide, 2-methyl-n-(4-nitro-3-(trifluoromethyl)phenyl)- but generally known as flutamide, which bears US NIH Compound Identifier 3397. European Medicines Agency schedules Flutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07756MIG. The term FLUTAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules flutamide in its Anatomical Therapeutic Chemical (ATC) Classification. FLUTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flutamide under HS 29242995 and SITC 51479. As of Q4 2014, FLUTAMIDE remains the US FDA Preferred Term for this commodity. Flutamide bears US NLM identifiers UMLS ID C0016384 and NCI Concept Code C509. SMILES: CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F.
This classification denotes a benzodiazepine with the molecular formula C19H18ClFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5G2K7O5D8S, chemically known as 10-chloro-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)oxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one but generally known as flutazolam, which bears US NIH Compound Identifier 3398. European Medicines Agency schedules Flutazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07757MIG. The term FLUTAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). FLUTAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flutazolam under HS 29349990 and SITC 51579. As of Q4 2014, FLUTAZOLAM remains the US FDA Preferred Term for this commodity. Flutazolam bears US NLM identifiers UMLS ID C0060593 and NCI Concept Code C65737. SMILES: CLC1CC2C3(OCCN3CC(=O)N(C2CC1)CCO)C1C(F)CCCC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27F3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUT2W21N7U, chemically known as s-(fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate but generally known as fluticasone, which bears US NIH Compound Identifier 54580. European Medicines Agency schedules Fluticasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07760MIG. The term FLUTICASONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules fluticasone in its Anatomical Therapeutic Chemical (ATC) Classification. FLUTICASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluticasone under HS 29309085 and SITC 51549. As of Q4 2014, FLUTICASONE remains the US FDA Preferred Term for this commodity. Fluticasone bears US NLM identifiers UMLS ID C0082607 and NCI Concept Code C61767. SMILES: S(C(=O)C1(OC(=O)CC)C2(C(C3C(F)(C(O)C2)C2(C(=CC(=O)C=C2)C(F)C3)C)CC1C)C)CF.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JS86977WNV. European Medicines Agency schedules Fluticasone furoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26593. Fluticasone furoate generally arises in the molecular formula C27H29F3O6S. The term FLUTICASONE FUROATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21, no. 1, 2007, list 57.) Most nations, for tariff and trade purposes, schedule fluticasone furoate under HS 29372200 and SITC 54153. As of Q4 2014, FLUTICASONE FUROATE remains US FDA's Preferred Term for this commodity. Fluticasone furoate bears US NLM identifiers UMLS ID C1948374 and NCI Concept Code C77003. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5CCCO5)C)O)F)C)F.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H31F3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O2GMZ0LF5W, chemically known as s-(fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate but more generally known as fluticasone propionate, which bears US NIH Compound Identifier 54580. European Medicines Agency schedules Fluticasone propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02241MIG. Most nations, for tariff and trade purposes, schedule fluticasone propionate under HS 29309085 and SITC 51549. As of Q4 2014, FLUTICASONE PROPIONATE remains US FDA's Preferred Term for this commodity. Fluticasone propionate bears US NLM identifiers UMLS ID C0117996 and NCI Concept Code C29061. SMILES: CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes an anticonvulsant agent with the molecular formula C19H16ClFN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2GHY1101MM, chemically known as 7-chloro-1-(cyclopropylmethyl)-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as flutoprazepam, which bears US NIH Compound Identifier 3400. European Medicines Agency schedules Flutoprazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07764MIG. The term FLUTOPRAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). FLUTOPRAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flutoprazepam under HS 29339940 and SITC 51577. As of Q4 2014, FLUTOPRAZEPAM remains the US FDA Preferred Term for this commodity. Flutoprazepam bears US NLM identifiers UMLS ID C0117998 and NCI Concept Code C65742. SMILES: CLC1CC2C(N(CC3CC3)C(=O)CN=C2C2C(F)CCCC2)CC1.
This classification denotes an antifungal agent, and clotrimazole analog with the molecular formula C22H16F2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 776S0UP252, chemically known as 1h-imidazole, 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl)- but generally known as flutrimazole, which bears US NIH Compound Identifier 3401. European Medicines Agency schedules Flutrimazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07765MIG. World Health Organization schedules flutrimazole in its Anatomical Therapeutic Chemical (ATC) Classification. FLUTRIMAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule flutrimazole under HS 29332990 and SITC 51573. As of Q4 2014, FLUTRIMAZOLE remains the US FDA Preferred Term for this commodity. SMILES: FC1C(C(N2CCNC2)(C2CCC(F)CC2)C2CCCCC2)CCCC1.
This classification denotes a mast cell stabilizer with the molecular formula C24H29FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TA73FX29II, chemically known as [(1R,5R)-8-(2-fluoroethyl)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl]2-hydroxy-2,2-diphenylacetate but generally known as flutropium, which bears US NIH Compound Identifier 71962. European Medicines Agency schedules Flutropium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02242MIG. The term FLUTROPIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). As of Q4 2014, FLUTROPIUM remains the US FDA Preferred Term for this commodity. Flutropium bears US NLM identifiers UMLS ID C0873172 and NCI Concept Code C87639. SMILES: C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCF.
This classification denotes a mast cell stabilizer with the molecular formula C24H29FNO3.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3V6HB0M57, chemically known as 1-alpha-h,5-alpha-h-tropanium, 8-(2-fluoroethyl)-3-alpha-hydroxy-, bromide, benzilate, (8r)- but more generally known as flutropium bromide, which bears US NIH Compound Identifier 71962. European Medicines Agency schedules Flutropium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07767MIG. The term FLUTROPIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). Most nations, for tariff and trade purposes, schedule flutropium bromide under HS 29399900 and SITC 54149. As of Q4 2014, FLUTROPIUM BROMIDE remains US FDA's Preferred Term for this commodity. Flutropium bromide bears US NLM identifiers UMLS ID C0117999 and NCI Concept Code C80960. SMILES: C[N+]1([C@@H]2CC[C@@H]1CC(C2)OC(=O)C(C3CCCCC3)(C4CCCCC4)O)CCF.[BR-].
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C24H26FNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4L066368AS, chemically known as (3r,5s)-fluvastatin but generally known as fluvastatin, which bears US NIH Compound Identifier 446155. European Medicines Agency schedules Fluvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07768MIG. The term FLUVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules fluvastatin in its Anatomical Therapeutic Chemical (ATC) Classification. FLUVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluvastatin under HS 29339990 and SITC 51577. As of Q4 2014, FLUVASTATIN remains the US FDA Preferred Term for this commodity. Fluvastatin bears US NLM identifiers UMLS ID C0082608 and NCI Concept Code C61768. SMILES: Fc1ccc(c2c(n(C(C)C)c3c2cccc3)/C=C/C(O)CC(O)CC(=O)O)cc1.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C24H25FNO4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PYF7O1FV7F, chemically known as 6-heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3,5-dihydroxy-, monosodium salt, (r*,s*-(e))-(+-)- but more generally known as fluvastatin sodium, which bears US NIH Compound Identifier 5281101. European Medicines Agency schedules Fluvastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02243MIG. Most nations, for tariff and trade purposes, schedule fluvastatin sodium under HS 29339990 and SITC 51577. As of Q4 2014, FLUVASTATIN SODIUM remains US FDA's Preferred Term for this commodity. Fluvastatin sodium bears US NLM identifiers UMLS ID C0246203 and NCI Concept Code C29062. SMILES: CC(C)N1C2CCCCC2C(C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3CCC(CC3)F.[NA+].
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O4L1XPO44W. European Medicines Agency schedules Fluvoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07769MIG. Fluvoxamine generally arises in the molecular formula C15H21F3N2O2. The term FLUVOXAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) FLUVOXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluvoxamine under HS 29280090 and SITC 51486. As of Q4 2014, FLUVOXAMINE remains the US FDA Preferred Term for this commodity. Fluvoxamine bears US NLM identifiers UMLS ID C0085228 and NCI Concept Code C61769. SMILES: FC(F)(F)c1ccc(C(=N\OCCN)\CCCCOC)cc1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5LGN83G74V. European Medicines Agency schedules Fluvoxamine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13908MIG. Fluvoxamine maleate generally arises in the molecular formula C15H21F3N2O2.C4H4O4. The term 'fluvoxamine maleate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule fluvoxamine maleate under HS 29280090 and SITC 51486. As of Q4 2014, FLUVOXAMINE MALEATE remains US FDA's Preferred Term for this commodity. Fluvoxamine maleate bears US NLM identifiers UMLS ID C0086307 and NCI Concept Code C29063. SMILES: COCCCC/C(=N\OCCN)/C1CCC(CC1)C(F)(F)F.C(=C\C(=O)O)\C(=O)O.
This classification denotes a b vitamin with the molecular formula C19H19N7O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 935E97BOY8, chemically known as 4-pteridinol, 2-amino-6-((p-((1, 3-dicarboxypropyl)carbamoyl)anilino)methyl)- but generally known as folic acid, which bears US NIH Compound Identifier 3405. European Medicines Agency schedules Folic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07774MIG. The term FOLIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules folic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule folic acid under HS 29362900 and SITC 54116. As of Q4 2014, FOLIC ACID remains the US FDA Preferred Term for this commodity. Folic acid bears US NLM identifiers UMLS ID C0016410 and NCI Concept Code C510. SMILES: OC(=O)C(NC(=O)C1CCC(NCC2NC3C([NH]C(NC3=O)N)NC2)CC1)CCC(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes a folic acid derivative with the molecular formula C20H23N7O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q573I9DVLP, chemically known as (+)-l-folinic acid, calcium salt but generally known as calcium folinate, which bears US NIH Compound Identifier 143. European Medicines Agency schedules Calcium folinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06052MIG. The term LEUCOVORIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules calcium folinate in its Anatomical Therapeutic Chemical (ATC) Classification. Folinic acid or leucovorin bears US NLM identifiers UMLS ID C0023413 and NCI Concept Code C71631.
This classification denotes a major gonadotropin secreted by the adenohypophysis (pituitary gland, anterior), sometimes also called follicle-stimulating hormone, and which stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS, and which consists of two noncovalently linked subunits, alpha and beta, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 076WHW89TW. European Medicines Agency schedules Follitropin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB12426MIG, SUB12503MIG, and SUB25237. FOLLITROPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, FOLLITROPIN remains the US FDA Preferred Term for this commodity. This classification encompasses follitropin alfa and follitropin beta.
This classification denotes an enzyme inhibitor with the molecular formula C4H6N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83LCM6L2BY, chemically known as 1h-pyrazole, 4-methyl- but generally known as fomepizole, which bears US NIH Compound Identifier 3406. European Medicines Agency schedules Fomepizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07775MIG. The term FOMEPIZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules fomepizole in its Anatomical Therapeutic Chemical (ATC) Classification. FOMEPIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fomepizole under HS 29331990 and SITC 51571. As of Q4 2014, FOMEPIZOLE remains the US FDA Preferred Term for this commodity. Fomepizole bears US NLM identifiers UMLS ID C0048504 and NCI Concept Code C47538. SMILES: [NH]1NCC(C1)C.
This classification denotes an antisense agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Z6W3S36X5. European Medicines Agency schedules Fomivirsen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02253MIG. Fomivirsen sodium generally arises in the molecular formula C204H243N63O114P20S20.20NA. The term FOMIVIRSEN SODIUM is a United States Adopted Name designation. Most nations schedule fomivirsen under HS 29349990 and SITC 51579. As of Q4 2014, FOMIVIRSEN remains the US FDA Preferred Term for this commodity. SMILES: S=P(OC1C(OC(N2CC(C(=O)[NH]C2=O)C)C1)COP(=S)(OC1C(OC(N2CC(C(=O)[NH]C2=O)C)C1)COP(=S)(OC1C(OC(N2CC(C(=O)[NH]C2=O)C)C1)COP(=S)(OC1C(OC(N2C3NC([NH]C(=O)C3NC2)N)C1)COP(=S)(OC1C(OC(N2CCC(NC2=O)N)C1)COP(=S)(OC1CC(OC1CO)N1C2NC([NH]C(=O)C2NC1)N)O)O)O)O)O)(OCC1OC(N2C3NC([NH]C(=O)C3NC2)N)CC1OP(=S)(OCC1OC(N2CCC(NC2=O)N)CC1OP(=S)(OCC1OC(N2CC(C(=O)[NH]C2=O)C)CC1OP(=S)(OCC1OC(N2CCC(NC2=O)N)CC1OP(=S)(OCC1OC(N2CC(C(=O)[NH]C2=O)C)CC1OP(=S)(OCC1OC(N2CC(C(=O)[NH]C2=O)C)CC1OP(=S)(OCC1OC(N2CCC(NC2=O)N)CC1OP(=S)(OCC1OC(N2CC(C(=O)[NH]C2=O)C)CC1OP(=S)(OCC1OC(N2CC(C(=O)[NH]C2=O)C)CC1OP(=S)(OCC1OC(N2CCC(NC2=O)N)CC1OP(=S)(OCC1OC(N2CC(C(=O)[NH]C2=O)C)CC1OP(=S)(OCC1OC(N2CC(C(=O)[NH]C2=O)C)CC1OP(=S)(OCC1OC(N2C3[NH]C(NC(=O)C3NC2)N)CC1OP(=S)(OCC1OC(N2CCC(NC2=O)N)CC1OP(=S)(OCC1OC(N2C3NC([NH]C(=O)C3NC2)N)CC1O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O.
This classification denotes an antisense agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Z6W3S36X5. European Medicines Agency schedules Fomivirsen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02253MIG. Fomivirsen sodium generally arises in the molecular formula C204H243N63O114P20S20.20NA. The term 'fomivirsen sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule fomivirsen sodium under HS 29349990 and SITC 51579. Fomivirsen sodium bears US NLM identifiers UMLS ID C0982166 and NCI Concept Code C61770. SMILES: As of Q4 2014, FOMIVIRSEN SODIUM remains US FDA's Preferred Term for this commodity.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4XO7A09HQM. European Medicines Agency schedules Fomocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07779MIG. Fomocaine generally arises in the molecular formula C20H25NO2. The term FOMOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) FOMOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fomocaine under HS 29349990 and SITC 51579. As of Q4 2014, FOMOCAINE remains the US FDA Preferred Term for this commodity. Fomocaine bears US NLM identifiers UMLS ID C0060629 and NCI Concept Code C65747. SMILES: O1CCN(CCCC2CCC(CC2)COC2CCCCC2)CC1.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J177FOW5JL. European Medicines Agency schedules Fondaparinux in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25907. Fondaparinux generally arises in the molecular formula C31H43N3NA10O49S8. The term 'fondaparinux' is a Hazardous Substances Data Bank designation. As of Q4 2014, FONDAPARINUX remains the US FDA Preferred Term for this commodity. Fondaparinux bears US NLM identifiers UMLS ID C0701492 and NCI Concept Code C73142. SMILES: S(=O)(=O)(O)NC1C(OS(=O)(=O)O)C(OC2OC(C(OC3OC(C(O)C(O)C3NS(=O)(=O)O)COS(=O)(=O)O)C(O)C2O)C(=O)O)C(OC1OC1C(O)C(OS(=O)(=O)O)C(OC1C(=O)O)OC1C(O)C(NS(=O)(=O)O)C(OC1COS(=O)(=O)O)OC)COS(=O)(=O)O.[NA].[NA].[NA].[NA].[NA].[NA].[NA].[NA].[NA].[NA].
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C23H28N8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 065F7WPT0B, chemically known as 5-((3,5-dibutyl-1h-1,2,4-triazol-1-yl)methyl)-2-(2-(1h-tetrazol-5-ylphenyl))pyridine but generally known as forasartan, which bears US NIH Compound Identifier 132706. European Medicines Agency schedules Forasartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07781MIG. The term FORASARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). FORASARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule forasartan under HS 29333999 and SITC 51574. As of Q4 2014, FORASARTAN remains the US FDA Preferred Term for this commodity. Forasartan bears US NLM identifiers UMLS ID C0250070 and NCI Concept Code C65749. SMILES: n1(nc(nc1CCCC)CCCC)Cc1ccc(nc1)c1c(cccc1)c1n[nH]nn1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AS000. This VA Drug Class (AS000) classifies this compound as belonging to the group ANTISEPTICS/DISINFECTANTS.
This classification denotes an anabolic steroid with the molecular formula C21H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z2MMV08KUQ, chemically known as 11alpha,17beta-dihydroxy-17-methyl-3-oxoandrosta-1,4-diene-2-carboxaldehyde but generally known as formebolone, which bears US NIH Compound Identifier 17150. European Medicines Agency schedules Formebolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07783MIG. The term FORMEBOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). FORMEBOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule formebolone under HS 29372900 and SITC 54153. As of Q4 2014, FORMEBOLONE remains the US FDA Preferred Term for this commodity. Formebolone bears US NLM identifiers UMLS ID C0060670 and NCI Concept Code C65751. SMILES: OC1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)C(=C2)C=O)CC3)C)CC1)C)C.
This classification denotes a steroidal aromatase inhibitor with the molecular formula C19H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PUB9T8T355, chemically known as 4-hydroxyandrost-4-ene-3,17-dione but generally known as formestane, which bears US NIH Compound Identifier 11273. European Medicines Agency schedules Formestane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07784MIG. The term FORMESTANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules formestane in its Anatomical Therapeutic Chemical (ATC) Classification. FORMESTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule formestane under HS 29372300 and SITC 54153. As of Q4 2014, FORMESTANE remains the US FDA Preferred Term for this commodity. Formestane bears US NLM identifiers UMLS ID C0048306 and NCI Concept Code C974. SMILES: O=C1C2(C(C3C(C4(C(=C(O)C(=O)CC4)CC3)C)CC2)CC1)C.
This classification denotes an anorexiant with the molecular formula C10H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 30555LM9SQ, chemically known as formamide, n-(alpha-methylphenethyl)- (8ci) but more generally known as formetorex, which bears US NIH Compound Identifier 65614. European Medicines Agency schedules Formetorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07785MIG. The term FORMETOREX is an International Non-Proprietary Name. FORMETOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule formetorex under HS 29242995 and SITC 51479. As of Q4 2014, FORMETOREX remains US FDA's Preferred Term for this commodity. Formetorex bears US NLM identifiers UMLS ID C1880842 and NCI Concept Code C65752. SMILES: CC(CC1=CC=CC=C1)NC=O.
This classification denotes an antiprotozoal agent with the molecular formula C4H3N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GTW8DB3OVN, chemically known as formamide, n- (5-nitro-2-thiazolyl)- but generally known as forminitrazole, which bears US NIH Compound Identifier 219073. European Medicines Agency schedules Forminitrazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07786MIG. The term FORMINITRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). FORMINITRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule forminitrazole under HS 29341000 and SITC 51579. As of Q4 2014, FORMINITRAZOLE remains the US FDA Preferred Term for this commodity. Forminitrazole bears US NLM identifiers UMLS ID C1880843 and NCI Concept Code C65753. SMILES: S1C([N](=O)O)CNC1NC=O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a protease inhibitor with the molecular formula C25H36N3O9PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WOU1621EEG, chemically known as carbamic acid, ((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, c-((3s)-tetrahydro-3-furanyl) ester but generally known as fosamprenavir, which bears US NIH Compound Identifier 131536. European Medicines Agency schedules Fosamprenavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25386. The term FOSAMPRENAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules fosamprenavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule fosamprenavir under HS 29350090 and SITC 51580. As of Q4 2014, FOSAMPRENAVIR remains the US FDA Preferred Term for this commodity. Fosamprenavir bears US NLM identifiers UMLS ID C1176315 and NCI Concept Code C83720. SMILES: S(=O)(=O)(N(CC(OP(=O)(O)O)C(NC(=O)OC1CCOC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1.
This classification denotes a protease inhibitor C25H34N3O9PS.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ID1GU2627N, chemically known as (3s)-tetrahydro-3-furyl ((.alpha.s)-.alpha.-((1r)-1-hydroxy-2-(n1-isobutylsulfanilamido)ethyl)phenethyl)carbamate, calcium phosphate (ester) (1:1), but more generally known as fosamprenavir calcium, which bears US NIH Compound Identifier 131535. European Medicines Agency schedules Fosamprenavir calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20055. Most nations, for tariff and trade purposes, schedule fosamprenavir calcium under HS 29350090 and SITC 51580. As of Q4 2014, FOSAMPRENAVIR CALCIUM remains US FDA's Preferred Term for this commodity. Fosamprenavir calcium bears US NLM identifiers UMLS ID C1320129 and NCI Concept Code C61771. SMILES: CC(C)CN(C[C@H]([C@H](CC1CCCCC1)NC(=O)O[C@H]2CCOC2)OP(=O)([O-])[O-])S(=O)(=O)C3CCC(CC3)N.[CA+2].
This classification denotes an enzyme inhibitor with the molecular formula C25H34N3O9PS.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XSG28FSA0W, chemically known as carbamic acid, ((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, c-((3s)-tetrahydro-3-furanyl) ester, disodium salt but more generally known as fosamprenavir sodium, which bears US NIH Compound Identifier 131537. Most nations, for tariff and trade purposes, schedule fosamprenavir sodium under HS 29350090 and SITC 51580. As of Q4 2014, FOSAMPRENAVIR SODIUM remains US FDA's Preferred Term for this commodity. Fosamprenavir sodium bears US NLM identifiers UMLS ID C1366241 and NCI Concept Code C72786. SMILES: CC(C)CN(C[C@H]([C@H](CC1CCCCC1)NC(=O)O[C@H]2CCOC2)OP(=O)([O-])[O-])S(=O)(=O)C3CCC(CC3)N.[NA+].[NA+].
This classification denotes an antiemetic agent with the molecular formula C23H22F7N4O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6L8OF9XRDC. European Medicines Agency schedules fosaprepitant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25384. The term FOSAPREPITANT is an International Non-Proprietary Name. Fosaprepitant or ivemend bears US NLM identifiers UMLS ID C2349941 and NCI Concept Code C72787. SMILES: CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NC(=O)N(N3)P(=O)(O)O)C4=CC=C(C=C4)F.
This classification denotes a reverse transcriptase inhibitor with the molecular formula CH3O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 364P9RVW4X, chemically known as phosphinecarboxylic acid, dihydroxy-, oxide but generally known as foscarnet, which bears US NIH Compound Identifier 3415. European Medicines Agency schedules Foscarnet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02258MIG. World Health Organization schedules foscarnet in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, FOSCARNET remains the US FDA Preferred Term for this commodity. Foscarnet bears US NLM identifiers UMLS ID C0070895 and NCI Concept Code C71630. SMILES: P(=O)(O)(O)C(=O)O.
This classification denotes an antipsychotic agent and antidepressant with the molecular formula C14H15N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 16C19Z7F4I, chemically known as (diphenylphosphinyl)acetic acid, hydrazide but generally known as fosenazide, which bears US NIH Compound Identifier 27918. European Medicines Agency schedules Fosenazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07794MIG. The term FOSENAZIDE is an International Non-Proprietary Name. FOSENAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, FOSENAZIDE remains the US FDA Preferred Term for this commodity. Fosenazide bears US NLM identifiers UMLS ID C1880846 and NCI Concept Code C65758. SMILES: P(=O)(CC(=O)NN)(C1CCCCC1)C1CCCCC1.
This classification denotes a hormonal antineoplastic agent with the molecular formula C18H22O8P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0E0NMA80F, chemically known as 4,4-stilbenediol, .alpha., .alpha.-diethyl-, diphosphate, disodium salt but generally known as fosfestrol, which bears US NIH Compound Identifier 3032325. European Medicines Agency schedules Fosfestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07795MIG. World Health Organization schedules fosfestrol in its Anatomical Therapeutic Chemical (ATC) Classification. FOSFESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fosfestrol under HS 29199090 and SITC 51631. As of Q4 2014, FOSFESTROL remains the US FDA Preferred Term for this commodity. Fosfestrol bears US NLM identifiers UMLS ID C0060692 and NCI Concept Code C1105. SMILES: P(=O)(OC1CCC(C(=C(\CC)C2CCC(OP(=O)(O)O)CC2)/CC)CC1)(O)O.
This classification denotes an antifungal agent with the molecular formula C13H13F2N6O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3JIJ299EWH, chemically known as 2,4-difluoro-alpha,alpha-bis(1h-1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester) but generally known as fosfluconazole, which bears US NIH Compound Identifier 214356. European Medicines Agency schedules Fosfluconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20639. The term FOSFLUCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). Most nations schedule fosfluconazole under HS 29339990 and SITC 51577. As of Q4 2014, FOSFLUCONAZOLE remains the US FDA Preferred Term for this commodity. Fosfluconazole bears US NLM identifiers UMLS ID C1452382 and NCI Concept Code C81503. SMILES: P(=O)(OC(CN1NCNC1)(CN1NCNC1)C1C(F)CC(F)CC1)(O)O.
This classification denotes a urinary anti-infective agent with the molecular formula C3H7O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2N81MY12TE, chemically known as phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2r-cis)- but more generally known as fosfomycin, which bears US NIH Compound Identifier 3417. European Medicines Agency schedules Fosfomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07797MIG. The term FOSFOMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). The World Health Organization schedules fosfomycin in its Anatomical Therapeutic Chemical (ATC) Classification. FOSFOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: P(=O)(O)(O)C1OC1C.
This classification denotes a urinary anti-infective agent C3H5O4P.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76EIK6888N, chemically known as monocalcium (-)-(1r,2s)-(1,2-epoxypropyl)phosphonate, but more generally known as fosfomycin calcium, which bears US NIH Compound Identifier 93095. European Medicines Agency schedules SUB02261MIGin its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02261MIG. Most nations schedule fosfomycin calcium under HS 29419000 and SITC 54139. As of Q4 2014, FOSFOMYCIN CALCIUM remains the US FDA Preferred Term for this commodity. SMILES: C[C@H]1[C@H](O1)P(=O)([O-])[O-].[CA+2].
This classfication denotes a urinary anti-infective agent with the molecular formula C3H5O4P.Ca.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T330QG2NYS, chemically known as monocalcium (-)-(1r,2s)-(1,2-epoxypropyl)phosphonate monohydrate, but more generally known as fosfomycin calcium monohydrate, which bears US NIH Compound Identifier 11954232. European Medicines Agency schedules fosfomycin calcium monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07797MIG. Most nations, for tariff purposes, schedule fosfomycin calcium monohydrate under HS 29419000. SMILES: C[C@H]1[C@H](O1)P(=O)([O-])[O-].O.[CA+2].
This classfication denotes a urinary anti-infective agent with the molecular formula C3H5O4P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97MMO19FNO, chemically known as disodium (2r,3s)-3-methyloxiran-2-ylphosphonate, but more generally known as fosfomycin disodium, which bears US NIH Compound Identifier 3417. European Medicines Agency schedules fosfomycin disodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07797MIG. Most nations, for tariff purposes, schedule fosfomycin disodium under HS 29419000. SMILES: C[C@H]1[C@H](O1)P(=O)([O-])[O-].[NA+].[NA+].
This classification denotes a urinary anti-infective agent with the molecular formula C3H5O4P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97MMO19FNO, chemically known as phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2r-cis)- but more generally known as fosfomycin sodium, which bears US NIH Compound Identifier 3417. European Medicines Agency schedules Fosfomycin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02262MIG. Most nations schedule fosfomycin sodium under HS 29419000. As of Q4 2014, FOSFOMYCIN SODIUM remains the US FDA Preferred Term for this commodity. SMILES: C[C@H]1[C@H](O1)P(=O)([O-])[O-].[NA+].[NA+].
This classification denotes a urinary anti-infective agent with the molecular formula C4H11NO3.C3H7O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FXW6U30GY, chemically known as phosphonic acid, (3-methyloxiranyl)-, (2r-cis)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) but more generally known as fosfomycin trometamol, which bears US NIH Compound Identifier 54331. European Medicines Agency schedules Fosfomycin trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02263MIG. Most nations schedule fosfomycin trometamol under HS 29419000. SMILES: C[C@H]1[C@H](O1)P(=O)(O)O.C(C(CO)(CO)N)O.
This classification denotes a urinary anti-infective agent with the molecular formula C4H11NO3.C3H7O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FXW6U30GY, chemically known as phosphonic acid, (3-methyloxiranyl)-, (2r-cis)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) but more generally known as fosfomycin trometamol, which bears US NIH Compound Identifier 54331. European Medicines Agency schedules Fosfomycin trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02263MIG. Most nations schedule fosfomycin tromethamine under HS 29419000. As of Q4 2014, FOSFOMYCIN TROMETHAMINE remains the US FDA Preferred Term for this commodity. Fosfomycin tromethamine bears US NLM identifiers UMLS ID C0543454 and NCI Concept Code C47541. SMILES: C[C@H]1[C@H](O1)P(=O)(O)O.C(C(CO)(CO)N)O.
This classification denotes a reverse transcriptase inhibitor and antiviral agent with the molecular formula C2H5O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N919E46723, chemically known as phosphonoacetic acid, disodium salt, monohydrate but generally known as fosfonet, which bears US NIH Compound Identifier 546. World Health Organization schedules fosfonet in its Anatomical Therapeutic Chemical (ATC) Classification. FOSFONET is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C(C(=O)O)P(=O)(O)O.
This classification denotes an ace inhibitor with the molecular formula C30H46NO7P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R43D2573WO, chemically known as l-proline, 4-cyclohexyl-1-(((2-methyl-1-(1-oxopropoxy)propoxy)(4-phenylbutyl)phosphinyl)acetyl)-, (2alpha,4beta)- but generally known as fosinopril, which bears US NIH Compound Identifier 55891. European Medicines Agency schedules Fosinopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13918MIG. The term FOSINOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules fosinopril in its Anatomical Therapeutic Chemical (ATC) Classification. FOSINOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fosinopril under HS 29339990 and SITC 51577. As of Q4 2014, FOSINOPRIL remains the US FDA Preferred Term for this commodity. Fosinopril bears US NLM identifiers UMLS ID C0118168 and NCI Concept Code C65761. SMILES: P(=O)(OC(OC(=O)CC)C(C)C)(CC(=O)N1CC(C2CCCCC2)CC1C(=O)O)CCCCc1ccccc1.
This classification denotes an ace inhibitor with the molecular formula C23H34NO5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S312EY6ZT8, chemically known as sq 27,519 but generally known as fosinoprilat, which bears US NIH Compound Identifier 62956. European Medicines Agency schedules Fosinoprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07800MIG. The term FOSINOPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). FOSINOPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fosinoprilat under HS 29339990 and SITC 51577. As of Q4 2014, FOSINOPRILAT remains the US FDA Preferred Term for this commodity. Fosinoprilat bears US NLM identifiers UMLS ID C0075061 and NCI Concept Code C65762. SMILES: P(=O)(O)(CC(=O)N1CC(C2CCCCC2)CC1C(=O)O)CCCCc1ccccc1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an ace inhibitor with the molecular formula C30H45NO7P.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NW2RTH6T2N, chemically known as l-proline, 4-cyclohexyl-1-(((2-methyl-1-(1-oxopropoxy)propoxy)(4-phenylbutyl)phosphinyl)acetyl)-, sodium salt, (1(s*(r*)),2alpha,4beta)- but more generally known as fosinopril sodium, which bears US NIH Compound Identifier 55890. European Medicines Agency schedules Fosinopril sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02265MIG. Most nations, for tariff and trade purposes, schedule fosinopril sodium under HS 29339990 and SITC 51577. As of Q4 2014, FOSINOPRIL SODIUM remains US FDA's Preferred Term for this commodity. Fosinopril sodium bears US NLM identifiers UMLS ID C0733440 and NCI Concept Code C47542. SMILES: CCC(=O)O[C@H](C(C)C)O[P@@](=O)(CCCCC1CCCCC1)CC(=O)N2C[C@@H](C[C@H]2C(=O)[O-])C3CCCCC3.[NA+].
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VD27I23138, chemically known as [cyclohex-3-en-1-yl(hydroxy)methyl]-hydroxy-oxo-phosphonium, which bears US NIH Compound Identifier 6338284, but generally known as fosmenic acid. European Medicines Agency schedules Fosmenic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07801MIG. Fosmenic acid generally arises in the molecular formula C7H13O3P. The term FOSMENIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) As of Q4 2014, FOSMENIC ACID remains the US FDA Preferred Term for this commodity. Fosmenic acid bears US NLM identifiers UMLS ID C1880847 and NCI Concept Code C65763. SMILES: P(=O)(O)C(O)C1CCC=CC1.
This classification denotes an antibiotic with the molecular formula C4H10NO5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5829E3D9I9, chemically known as (3-(formylhydroxyamino)propyl)phosphonic acid, monosodium salt but more generally known as fosmidomycin, which bears US NIH Compound Identifier 572. European Medicines Agency schedules Fosmidomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07802MIG. The term FOSMIDOMYCIN is an International Non-Proprietary Name. FOSMIDOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: P(=O)(O)(O)CCCN(O)C=O.
This classification denotes an anticonvulsant agent with the molecular formula C16H13N2O6P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7VLR55452Z, chemically known as 2,4-imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, disodium salt but generally known as fosphenytoin sodium, which bears US NIH Compound Identifier 56338. European Medicines Agency schedules Fosphenytoin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13919MIG. Most nations schedule fosphenytoin under HS 29332100 and SITC 51572. As of Q4 2014, FOSPHENYTOIN remains the US FDA Preferred Term for this commodity. Fosphenytoin bears US NLM identifiers UMLS ID C0244656 and NCI Concept Code C65766. SMILES: P(=O)(OCN1C(=O)C(NC1=O)(C1CCCCC1)C1CCCCC1)(O)O.[NA].[NA].
This classification denotes an anticonvulsant agent with the molecular formula C16H13N2O6P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7VLR55452Z, chemically known as 2,4-imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, disodium salt but more generally known as fosphenytoin sodium, which bears US NIH Compound Identifier 56338. European Medicines Agency schedules Fosphenytoin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13919MIG. Most nations, for tariff and trade purposes, schedule fosphenytoin sodium under HS 29332100 and SITC 51572. As of Q4 2014, FOSPHENYTOIN SODIUM remains US FDA's Preferred Term for this commodity. Fosphenytoin sodium bears US NLM identifiers UMLS ID C0284906 and NCI Concept Code C47543. SMILES: C1CCC(CC1)C2(C(=O)N(C(=O)N2)COP(=O)([O-])[O-])C3CCCCC3.[NA+].[NA+].
This classification denotes an anesthetic agent with the molecular formula C13H19O5P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LZ257RZP7K, chemically known as methanol, (2,6-bis(1-methylethyl)phenoxy)-, dihydrogen phosphate but generally known as fospropofol, which bears US NIH Compound Identifier 3038497. European Medicines Agency schedules Fospropofol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32986. Most nations schedule fospropofol under HS 29199000 and SITC 51631. As of Q4 2014, FOSPROPOFOL remains the US FDA Preferred Term for this commodity. Fospropofol bears US NLM identifiers UMLS ID C2370726 and NCI Concept Code C76954. SMILES: CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)(O)O.
This classification denotes an anesthetic agent with the molecular formula C13H19O5P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30868AY0IF, chemically known as methanol, (2,6-bis(1-methylethyl)phenoxy)-, dihydrogen phosphate, disodium salt but more generally known as fospropofol disodium, which bears US NIH Compound Identifier 3038497. European Medicines Agency schedules Fospropofol disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32986. Most nations, for tariff and trade purposes, schedule fospropofol sodium under HS 29199000 and SITC 51631. SMILES: CC(C)C1CCCC(C1OCOP(=O)([O-])[O-])C(C)C.[NA+].[NA+].
This classification denotes a nitrosourea compound with the molecular formula C9H19ClN3O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GQ7JL9P5I2, chemically known as phosphonic acid, (1-((((2-chloroethyl)nitrosoamino)carbonyl)amino)ethyl)-, diethyl ester but more generally known as fotemustine, which bears US NIH Compound Identifier 104799. European Medicines Agency schedules Fotemustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07809MIG. The term FOTEMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules fotemustine in its Anatomical Therapeutic Chemical (ATC) Classification. FOTEMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, FOTEMUSTINE remains US FDA's Preferred Term for this commodity. Fotemustine bears US NLM identifiers UMLS ID C0060696 and NCI Concept Code C1106. SMILES: CLCCN(N=O)C(=O)NC(P(=O)(OCC)OCC)C.
Fowl Pox Vaccine is a chicken embryo propagated, freeze-dried, live virus vaccine for wing web administration in chickens.
This classification denotes an anticoagulant agent with the molecular formula C20H21N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQ0H2B8YKN, chemically known as (3s,5s)-5-(((4-amidino-4-biphenylyl)oxy)methyl)-2-oxo-3-pyrrolidineacetic acid but generally known as fradafiban, which bears US NIH Compound Identifier 66000. European Medicines Agency schedules Fradafiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07813MIG. The term FRADAFIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). FRADAFIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fradafiban under HS 29337900 and SITC 51561. As of Q4 2014, FRADAFIBAN remains the US FDA Preferred Term for this commodity. Fradafiban bears US NLM identifiers UMLS ID C0665276 and NCI Concept Code C65769. SMILES: O(CC1NC(=O)C(C1)CC(=O)O)C1CCC(CC1)C1CCC(CC1)C(=N)N.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H46N6O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4BOC774388, chemically known as d-streptamine, o-2,6-diamino-2,6-dideoxy-alpha-d-glucopyranosyl-(1-4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-beta-d-ribofuranosyl-(1-5))-2-deoxy- but generally known as framycetin, which bears US NIH Compound Identifier 8378. European Medicines Agency schedules Framycetin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07814MIG. The term FRAMYCETIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules framycetin in its Anatomical Therapeutic Chemical (ATC) Classification. FRAMYCETIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule framycetin under HS 29419000 and SITC 54139. As of Q4 2014, FRAMYCETIN remains the US FDA Preferred Term for this commodity. Framycetin bears US NLM identifiers UMLS ID C0016673 and NCI Concept Code C65770. SMILES: O(C1C(OC2OC(C(O)C(O)C2N)CN)C(N)CC(N)C1O)C1OC(C(OC2OC(C(O)C(O)C2N)CN)C1O)CO.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H46N6O13.3H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3720KZ4TQ, chemically known as neomycin b, sulfate (salt) but more generally known as framycetin sulfate, which bears US NIH Compound Identifier 197162. European Medicines Agency schedules Framycetin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02269MIG. Most nations, for tariff and trade purposes, schedule framycetin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, FRAMYCETIN SULFATE remains US FDA's Preferred Term for this commodity. Framycetin sulfate bears US NLM identifiers UMLS ID C0770899 and NCI Concept Code C75943. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94JPL25DUK. European Medicines Agency schedules Fronepidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07816MIG. Fronepidil generally arises in the molecular formula C21H31NO2. The term FRONEPIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) FRONEPIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fronepidil under HS 29339990 and SITC 51577. As of Q4 2014, FRONEPIDIL remains the US FDA Preferred Term for this commodity. Fronepidil bears US NLM identifiers UMLS ID C1880854 and NCI Concept Code C65771. SMILES: O(CC(N1CCCC1)COCC(C)C)C(c1ccccc1)(C)C#C.
This classification denotes a serotonin agonist with the molecular formula C14H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H82Q2D5WA7, chemically known as 6-methylamino-6,7,8,9-tetrahydro-5h-carbazole-3-carboxamide but generally known as frovatriptan, which bears US NIH Compound Identifier 77992. European Medicines Agency schedules Frovatriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07817MIG. The term FROVATRIPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules frovatriptan in its Anatomical Therapeutic Chemical (ATC) Classification. FROVATRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule frovatriptan under HS 29339990 and SITC 51577. As of Q4 2014, FROVATRIPTAN remains the US FDA Preferred Term for this commodity. Frovatriptan bears US NLM identifiers UMLS ID C0754647 and NCI Concept Code C65772. SMILES: O=C(N)C1CC2C3CC(NC)CCC3[NH]C2CC1.
This classification denotes a serotonin agonist with the molecular formula C14H17N3O.C4H6O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D28J6W18HY, chemically known as 1h-carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (r)-, butanedioate (1:1) but more generally known as frovatriptan succinate, which bears US NIH Compound Identifier 152944. European Medicines Agency schedules Frovatriptan succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22174. Most nations, for tariff and trade purposes, schedule frovatriptan succinate under HS 29339990. As of Q4 2014, FROVATRIPTAN SUCCINATE remains US FDA's Preferred Term for this commodity. Frovatriptan succinate bears US NLM identifiers UMLS ID C1099777 and NCI Concept Code C47544. SMILES: CN[C@@H]1CCC2C(C3CC(CCC3[NH]2)C(=O)N)C1.C(CC(=O)O)C(=O)O.O.
This classification denotes a serotonin agonist with the molecular formula C14H17N3O.C4H6O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D28J6W18HY, chemically known as butanedioic acid, compd. with (r)-2,3,4,9-tetrahydro-3-(methylamino)-1h-carbazole-6-carboxamide (1:1), monohydrate, but more generally known as frovatriptan succinate hydrate, which bears US NIH Compound Identifier 152943. European Medicines Agency schedules frovatriptan succinate hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07817MIG. Most nations, for tariff purposes, schedule frovatriptan succinate hydrate under HS 29339990. SMILES: CN[C@@H]1CCC2C(C3CC(CCC3[NH]2)C(=O)N)C1.C(CC(=O)O)C(=O)O.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA605. This VA Drug Class (GA605) classifies this compound as belonging to the group ANTIEMETICS.
This classification denotes a loop diuretic with the molecular formula C12H11ClN2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LXU5N7ZO5, chemically known as benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- but generally known as furosemide, which bears US NIH Compound Identifier 3440. European Medicines Agency schedules Furosemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07849MIG. The term FUROSEMIDE is an International Non-Proprietary Name. World Health Organization schedules furosemide in its Anatomical Therapeutic Chemical (ATC) Classification. FUROSEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Frusemide or furosemide bears US NLM identifiers UMLS ID C0016860 and NCI Concept Code C515. SMILES: C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)CL.
This classification denotes an antihelminthic agent with the molecular formula C14H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TA9XO4D05J, chemically known as 1,2-benzenedicarboxylic acid, mono (1-ethyl-1-methyl-2-propynyl) ester, sodium salt but generally known as ftalofyne, which bears US NIH Compound Identifier 8573. European Medicines Agency schedules Ftalofyne in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07819MIG. The term FTALOFYNE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). FTALOFYNE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ftalofyne or phthalofyne bears US NLM identifiers UMLS ID C0521915 and NCI Concept Code C75230. SMILES: CCC(C)(C#C)OC(=O)C1=CC=CC=C1C(=O)O.
This classification denotes an antitubercular agent with the molecular formula C14H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40Q4C3O4V0, chemically known as isonicotinic acid, vanillylidenehydrazide but more generally known as ftivazide, which bears US NIH Compound Identifier 5355297. European Medicines Agency schedules Ftivazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07821MIG. The term FTIVAZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). FTIVAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1=C/C(=C/NNC(=O)C2CCNCC2)C=CC1=O)C.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P441EE1PH. European Medicines Agency schedules Ftormetazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07822MIG. Ftormetazine generally arises in the molecular formula C21H22F3N3OS. The term FTORMETAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) FTORMETAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ftormetazine under HS 29343090 and SITC 51578. As of Q4 2014, FTORMETAZINE remains the US FDA Preferred Term for this commodity. Ftormetazine bears US NLM identifiers UMLS ID C1880856 and NCI Concept Code C65774. SMILES: S1c2c(N(C(=O)CCN3CCN(CC3)C)c3c1cccc3)cc(cc2)C(F)(F)F.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU0X85F735. European Medicines Agency schedules Ftorpropazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07823MIG. Ftorpropazine generally arises in the molecular formula C22H24F3N3O2S. The term FTORPROPAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) FTORPROPAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ftorpropazine under HS 29343090 and SITC 51578. As of Q4 2014, FTORPROPAZINE remains the US FDA Preferred Term for this commodity. Ftorpropazine bears US NLM identifiers UMLS ID C1880857 and NCI Concept Code C65775. SMILES: S1c2c(N(C(=O)CCN3CCN(CC3)CCO)c3c1cccc3)cc(cc2)C(F)(F)F.
This classification denotes a mucolytic agent with the molecular formula C6H13NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) UR9VPI71PT, chemically known as l-cysteine, s-(3-hydroxypropyl)- but more generally known as fudosteine, which bears US NIH Compound Identifier 134669. European Medicines Agency schedules Fudosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07825MIG. The term FUDOSTEINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 No. 1 1998, List 39). FUDOSTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule fudosteine under HS 29309016 and SITC 51549. As of Q4 2014, FUDOSTEINE remains US FDA's Preferred Term for this commodity. Fudosteine bears US NLM identifiers UMLS ID C0756016 and NCI Concept Code C65777. SMILES: S(CC(N)C(=O)O)CCCO.
This classification denotes a selective estrogen receptor modulator with the molecular formula C32H47F5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22X328QOC4, chemically known as 7alpha-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol but generally known as fulvestrant, which bears US NIH Compound Identifier 104741. European Medicines Agency schedules Fulvestrant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13933MIG. The term FULVESTRANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules fulvestrant in its Anatomical Therapeutic Chemical (ATC) Classification. FULVESTRANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fulvestrant under HS 29372300 and SITC 54153. As of Q4 2014, FULVESTRANT remains the US FDA Preferred Term for this commodity. Fulvestrant bears US NLM identifiers UMLS ID C0935916 and NCI Concept Code C1379. SMILES: S(=O)(CCCCCCCCCC1C2C3C(CCC2C2C(C1)CC(O)CC2)(C(O)CC3)C)CCCC(F)(F)C(F)(F)F.
This classification denotes an antineoplastic antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7OW73204U1. European Medicines Agency schedules Fumagillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23269. Fumagillin generally arises in the molecular formula C26H34O7. The term FUMAGILLIN is an International Non-Proprietary Name or INN. FUMAGILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fumagillin under HS 29419000 and SITC 54139. As of Q4 2014, FUMAGILLIN remains the US FDA Preferred Term for this commodity. Fumagillin bears US NLM identifiers UMLS ID C0060819 and NCI Concept Code C75963. SMILES: O1C(C2C3(OC3)CCC(OC(=O)/C=C/C=C/C=C/C=C/C(=O)O)C2OC)(C1C/C=C(/C)C)C.
This classification denotes a penicillin antibiotic with the molecular formula C21H21N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7H9M9492J, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((((2-furanylmethylene)amino)(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as fumoxicillin, which bears US NIH Compound Identifier 72000. European Medicines Agency schedules Fumoxicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07826MIG. The term FUMOXICILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). FUMOXICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(/N=C/C1OCCC1)C1CCC(O)CC1.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C12H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2087G0XX3, chemically known as 3-furfuryl-1,8-dimethylxanthine but generally known as furafylline, which bears US NIH Compound Identifier 3433. European Medicines Agency schedules Furafylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07829MIG. The term FURAFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). FURAFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule furafylline under HS 29395900 and SITC 54145. As of Q4 2014, FURAFYLLINE remains the US FDA Preferred Term for this commodity. Furafylline bears US NLM identifiers UMLS ID C0060848 and NCI Concept Code C65779. SMILES: CC1=NC2=C(N1)C(=O)N(C(=O)N2CC3=CC=CO3)C.
This classification denotes an anti-infective agent with the molecular formula C9H7N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2133JVQ6VE, chemically known as 1,2,4-triazin-3-amine, 6-(2-(5-nitro-2-furanyl)ethenyl)- (9ci) but more generally known as furalazine, which bears US NIH Compound Identifier 6436102. European Medicines Agency schedules Furalazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07830MIG. The term FURALAZINE is an International Non-Proprietary Name. FURALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule furalazine under HS 29349990 and SITC 51579. As of Q4 2014, FURALAZINE remains the US FDA Preferred Term for this commodity. Furalazine bears US NLM identifiers UMLS ID C0603287 and NCI Concept Code C65780. SMILES: O1C(CCC1[N](=O)O)/C=C/C1NNC(NC1)N.
This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5X4V82ZN30. European Medicines Agency schedules Furaltadone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07831MIG. Furaltadone generally arises in the molecular formula C13H16N4O6. The term FURALTADONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 no. 12 1967, list 7.) FURALTADONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule furaltadone under HS 29349990 and SITC 51579. As of Q4 2014, FURALTADONE remains the US FDA Preferred Term for this commodity. Furaltadone bears US NLM identifiers UMLS ID C0060849 and NCI Concept Code C75249. SMILES: O1C(CN2CCOCC2)CN(/N=C/C2OC([N](=O)O)CC2)C1=O.
This classification denotes an anti-infective agent with the molecular formula C13H16N4O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37Q02H7JT2, chemically known as 2-oxazolidinone, 5-(morpholinomethyl)-3-((5-nitrofurfurylidene)amino)-, monohydrochloride but more generally known as furaltadone hydrochloride, which bears US NIH Compound Identifier 92968. European Medicines Agency schedules Furaltadone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02285MIG. Most nations schedule furaltadone hydrochloride under HS 29349990. As of Q4 2014, FURALTADONE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. SMILES: C1CC(OC1/C=N/N2CC(OC2=O)CN3CCOCC3)[N+](=O)[O-].CL.
This classification denotes an anabolic steroid with the molecular formula C20H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2W07HSP5PX, chemically known as 17-methyl-5alpha-androstano(2,3-c)furazan-17beta-ol but generally known as furazabol, which bears US NIH Compound Identifier 14708. European Medicines Agency schedules Furazabol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07833MIG. The term FURAZABOL is an International Non-Proprietary Name. FURAZABOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule furazabol under HS 29349990 and SITC 51579. As of Q4 2014, FURAZABOL remains the US FDA Preferred Term for this commodity. Furazabol bears US NLM identifiers UMLS ID C0060855 and NCI Concept Code C65782. SMILES: OC1(C2(C(C3C(C4(C(CC3)CC3NONC3C4)C)CC2)CC1)C)C.
This classification denotes an anti-infective agent with the molecular formula C8H7N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5J9CPU3RE0, chemically known as 2-furanmethanimine, 5-nitro-n-(2-oxo-3-oxazolidinyl)- but more generally known as furazolidone, which bears US NIH Compound Identifier 3435. European Medicines Agency schedules Furazolidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07834MIG. The term FURAZOLIDONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules furazolidone in its Anatomical Therapeutic Chemical (ATC) Classification. FURAZOLIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule furazolidone under HS 29349920 and SITC 51579. As of Q4 2014, FURAZOLIDONE remains US FDA's Preferred Term for this commodity. Furazolidone bears US NLM identifiers UMLS ID C0016855 and NCI Concept Code C65783. SMILES: O1CCN(/N=C/C2OC([N](=O)O)CC2)C1=O.
This classification denotes a penicillin antibiotic with the molecular formula C19H24N2O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 104NHK678E, chemically known as 6-((r)-2-hydroxy-4-methylvaleramido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 2-furoate (ester). but more generally known as furbucillin, which bears US NIH Compound Identifier 216269. European Medicines Agency schedules Furbucillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07836MIG. The term FURBUCILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). FURBUCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(OC(=O)C1OCCC1)CC(C)C.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V52IY042L9. European Medicines Agency schedules Furcloprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07837MIG. Furcloprofen generally arises in the molecular formula C15H11CLO3. The term FURCLOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) FURCLOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule furcloprofen under HS 29329985 and SITC 51569. As of Q4 2014, FURCLOPROFEN remains the US FDA Preferred Term for this commodity. Furcloprofen bears US NLM identifiers UMLS ID C1880871 and NCI Concept Code C65784. SMILES: CLC1CC2C3C(OC2CC1)CC(C(C)C(=O)O)CC3.
This classification denotes an anorexiant with the molecular formula C15H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) X83CZ0Y5TF, chemically known as 2-furanmethanamine, n-methyl-n-(1-methyl-2-phenylethyl)-, (+)- (9ci) but more generally known as furfenorex, which bears US NIH Compound Identifier 26762. European Medicines Agency schedules Furfenorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07840MIG. The term FURFENOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). FURFENOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule furfenorex under HS 29321900 and SITC 51569. As of Q4 2014, FURFENOREX remains US FDA's Preferred Term for this commodity. Furfenorex bears US NLM identifiers UMLS ID C0060861 and NCI Concept Code C75113. SMILES: O1C(CN(C(CC2CCCCC2)C)C)CCC1.
This classification denotes an antihelminthic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9745E7HEBG. European Medicines Agency schedules Furodazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07845MIG. Furodazole generally arises in the molecular formula C15H11N3O2. The term FURODAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) FURODAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Furodazole under HS 29349990 and SITC 51579. As of Q4 2014, FURODAZOLE remains the US FDA Preferred Term for this commodity. Furodazole bears US NLM identifiers UMLS ID C2348718 and NCI Concept Code C72146. SMILES: CC1CC(C2C(N1)CCC3C2[NH]C(N3)C4CCCO4)O.O.
This classification denotes a loop diuretic with the molecular formula C12H10CLN2O5S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 101EM454S7. European Medicines Agency schedules furosemide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02287MIG. Most nations, for tariff and trade purposes, schedule furosemide sodium under HS 29350090. As of Q4 2014, FUROSEMIDE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CC(OC1)CNC2CC(C(CC2C(=O)[O-])S(=O)(=O)N)CL.[NA+].
This classification denotes a loop diuretic C13H21N5O4.C12H11ClN2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y1P3P1MD0G, chemically known as benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)-, compd. with 3,7-dihydro-7-(2-hydroxy-3-((2-hydroxyethyl)methylamino)propyl)-1,3-dimethyl-1h-purine-2,6-dione (1:1), but more generally known as furosemide xantinol, which bears US NIH Compound Identifier 71587213. European Medicines Agency schedules Furosemide xantinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02288MIG. Most nations, for tariff and trade purposes, schedule furosemide xantinol under HS 29350090 and SITC 51580. As of Q4 2014, FUROSEMIDE XANTINOL remains US FDA's Preferred Term for this commodity. SMILES: CN1C2C(C(=O)N(C1=O)C)N(CN2)CC(CN(C)CCO)O.C1CC(OC1)CNC2CC(C(CC2C(=O)O)S(=O)(=O)N)CL.
This classification denotes a diuretic with the molecular formula C10H9N7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TY1X1WG26A, chemically known as 2,4,7-triamino-6-(2-furyl)pteridine but generally known as furterene, which bears US NIH Compound Identifier 71852. European Medicines Agency schedules Furterene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07853MIG. The term FURTERENE is an International Non-Proprietary Name. FURTERENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule furterene under HS 29349990 and SITC 51579. As of Q4 2014, FURTERENE remains the US FDA Preferred Term for this commodity. Furterene bears US NLM identifiers UMLS ID C1880876 and NCI Concept Code C65791. SMILES: C1=COC(=C1)C2=NC3=C(N=C2N)N=C(N=C3N)N.
This classification denotes a cholinergic agonist with the molecular formula C8H14NO.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1D064NLD7G, chemically known as 2-furanmethanaminium, n,n,n-trimethyl-, iodide (9ci) but generally known as furtrethonium iodide, which bears US NIH Compound Identifier 10937. European Medicines Agency schedules Furtrethonium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07854MIG. The term FURTRETHONIUM IODIDE is an International Non-Proprietary Name. Most nations schedule furtrethonium iodide under HS 29321900 and SITC 51569. As of Q4 2014, FURTRETHONIUM IODIDE remains the US FDA Preferred Term for this commodity. Furtrethonium iodide bears US NLM identifiers UMLS ID C0118398 and NCI Concept Code C76041. SMILES: I.o1c(C[N](C)(C)C)ccc1.
This classification denotes a protein synthesis inhibitor and antimicrobial solution with the molecular formula C31H48O6, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 59XE10C19C, chemically known as 29-nordammara-17 (20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha., 9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17z)- but more generally known as fusidic acid, which bears U.S. National Institutes of Health Compound Identifier 3000226. The European Medicines Agency schedules Fusidic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02292MIG. The term FUSIDIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules fusidic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CC1C2CCC3(C(C2(CCC1O)C)C(CC4C3(CC(C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)O)C.
This classification denotes a penicillin antibiotic with the molecular formula C25H26N6O8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J6UQP7JHOT, chemically known as (2s,5r,6r)-6-((2r)-2-(3-((e)-furfurylideneamino)-2-oxo-1-imidazolidinecarboxamido)-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as fuzlocillin, which bears US NIH Compound Identifier 9571079. European Medicines Agency schedules Fuzlocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07855MIG. The term FUZLOCILLIN is an International Non-Proprietary Name. FUZLOCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fuzlocillin under HS 29411090 and SITC 54131. As of Q4 2014, FUZLOCILLIN remains the US FDA Preferred Term for this commodity. Fuzlocillin bears US NLM identifiers UMLS ID C0060856 and NCI Concept Code C65794. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(NC(=O)N1CCN(/N=C/C2OCCC2)C1=O)C1CCC(O)CC1.
This classification denotes a sedative and hypnotic with the molecular formula C9H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6CW7F3G59X, chemically known as cyclohexaneacetic acid, 1-(aminomethyl)- but generally known as gabapentin, which bears US NIH Compound Identifier 3446. European Medicines Agency schedules Gabapentin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07857MIG. The term GABAPENTIN is an International Non-Proprietary Name. World Health Organization schedules gabapentin in its Anatomical Therapeutic Chemical (ATC) Classification. GABAPENTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gabapentin under HS 29224995 and SITC 51465. As of Q4 2014, GABAPENTIN remains the US FDA Preferred Term for this commodity. Gabapentin bears US NLM identifiers UMLS ID C0060926 and NCI Concept Code C1108. SMILES: OC(=O)CC1(CCCCC1)CN.
This classification denotes a sedative and hypnotic with the molecular formula C16H27NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 75OCL1SPBQ chemically known as cyclohexaneacetic acid, 1-((((1-(2-methyl-1-oxopropoxy)ethoxy)carbonyl)amino)methyl)- but generally known as gabapentin enacarbil, which bears US NIH Compound Identifier 9883933. European Medicines Agency schedules Gabapentin enacarbil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35115. The term GABAPENTIN ENACARBIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. ). Most nations schedule gabapentin enacarbil under HS 29242990 and SITC 51479. As of Q4 2014, GABAPENTIN ENACARBIL remains the US FDA Preferred Term for this commodity. Gabapentin enacarbil bears US NLM identifiers UMLS ID C1528993 and NCI Concept Code C79579. SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O.
This classification denotes a protease inhibitor and anticoagulant agent with the molecular formula C16H23N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4V7M9137X9, chemically known as benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester but generally known as gabexate, which bears US NIH Compound Identifier 3447. European Medicines Agency schedules Gabexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07858MIG. The term GABEXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). GABEXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gabexate under HS 29252900 and SITC 51482. As of Q4 2014, GABEXATE remains the US FDA Preferred Term for this commodity. Gabexate bears US NLM identifiers UMLS ID C0085231 and NCI Concept Code C76960. SMILES: O(C(=O)CCCCC/N=C(/N)N)C1CCC(CC1)C(=O)OCC.
This classification denotes a gadolinium-chelate with the molecular formula C22H26N3O11.Gd.2H, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15G12L5X8K, chemically known as gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-n5,n8,n11,o4,o5,o8,o11,o13)-, dihydrogen but more generally known as gadobenic acid, which bears U.S. National Institutes of Health Compound Identifier 105124. The European Medicines Agency schedules Gadobenic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07860MIG. The World Health Organization schedules gadobenic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Gadobenic acid under HS 28469000. SMILES: [Gd]12[N](CC[N]1(C(COCc1ccccc1)C(=O)O)CC(=O)O)(CC[N]2(CC(=O)O)CC(=O)O)CC(=O)O.[H].[H].
This classification denotes a gadolinium-chelate with the molecular formula C18H31N4O9.Gd, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1BJ477IO2L, chemically known as gadolinium, (10-(2,3-dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-n1,n4,n7,n10,o1,o4,o7)- but more generally known as gadobutrol, which bears U.S. National Institutes of Health Compound Identifier 72057. The European Medicines Agency schedules Gadobutrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07861MIG. The term GADOBUTROL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). The World Health Organization schedules gadobutrol in its Anatomical Therapeutic Chemical (ATC) Classification. GADOBUTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Gadobutrol under HS 28469000. SMILES: [GAH3].OC(C(N1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)CO)CO.
This classification denotes a gadolinium-chelate with the molecular formula C16H26GdN5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84F6U3J2R6, chemically known as gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate but more generally known as gadodiamide, which bears U.S. National Institutes of Health Compound Identifier 60754. The European Medicines Agency schedules Gadodiamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07862MIG. The term GADODIAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, List 31). The World Health Organization schedules gadodiamide in its Anatomical Therapeutic Chemical (ATC) Classification. GADODIAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [GD].OC(=O)CN(CCN(CC(=O)NC)CC(=O)O)CCN(CC(=O)NC)CC(=O)O.O. Most nations schedule Gadodiamide under HS 28469000.
This classfication denotes a gadolinium-chelate with the molecular formula C16H26N5O8.Gd.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0RPE15QPL0, chemically known as aqua(n-n'-bis(2-((carboxymethyl)((methylcarbamoyl)methyl)amino)ethyl)glycinato(3-))gadolinium hydrate, but more generally known as gadodiamide hydrate, which bears U.S. National Institutes of Health Compound Identifier 60754. European Medicines Agency schedules gadodiamide hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07862MIG. Most nations, for tariff purposes, schedule gadodiamide hydrate under HS 28469000. SMILES: CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.O.O.[GD+3].
This classification denotes a gadolinium-chelate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E65RW73PHS. The European Medicines Agency schedules Gadofosveset in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25385. Gadofosveset generally arises in the molecular formula C33H38N3O14P.3H+.GD. The term GADOFOSVESET is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule Gadofosveset under HS 28469000.
This classification denotes a gadolinium-chelate with the molecular formula C33H38N3O14P.Gd.3Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XM33Q67UVH, chemically known as gadolinate(3-), (((4r)-4-(bis((carboxy-kappao)methyl)amino-kappan)-6,9-bis((carboxy-kappao)methyl)-1-((4,4-diphenylcyclohexyl)oxy)-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-oic acid-kappan6,kappan9,kappao11) 1-oxidato(6-))-, trisodium but more generally known as gadofosveset trisodium, which bears U.S. National Institutes of Health Compound Identifier 158440. European Medicines Agency schedules Gadofosveset trisodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21051. Most nations schedule gadofosveset trisodium under HS 28469000 and SITC 52595. As of Q4 2014, GADOFOSVESET TRISODIUM remains the US FDA Preferred Term for this commodity. Gadofosveset trisodium bears US NLM identifiers UMLS ID C1433439 and NCI Concept Code C81057. SMILES: C1CCC(CC1)C2(CCC(CC2)OP(=O)([O-])OC[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-])C3CCCCC3.O.[NA+].[NA+].[NA+].[GD+3].
This classificaiton denotes a nonionic structural analog used as a paramagnetic contrast medium in magnetic resonance imaging. Brand Name Omniscan Most nations schedule Gadolinium under HS 28053000.
This classification denotes a gadolinium-chelate with the molecular formula C22H34N5O10.Gd, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VC7M3XD17L, chemically known as (n,n-bis(2-((carboxymethyl)((morpholinocarbonyl)methyl)amino)ethyl)glycinato(3-))gadolinium but more generally known as gadopenamide, which bears US NIH Compound Identifier 3034033. European Medicines Agency schedules Gadopenamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07863MIG. The term GADOPENAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). GADOPENAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [GD].O1CCN(CC1)C(=O)CN(CCN(CCN(CC(=O)N1CCOCC1)CC(=O)O)CC(=O)O)CC(=O)O.
This classification denotes a gadolinium-chelate with the molecular formula C14H18N3O10.2H+.Gd, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2I13DR72L, chemically known as gadolinate(2-), (n,n-bis(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))-, dihydrogen but more generally known as gadopentetic acid, which bears U.S. National Institutes of Health Compound Identifier 157429. The European Medicines Agency schedules Gadopentetic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07864MIG. The World Health Organization schedules gadopentetic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: [Gd].OC(=O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O.[H].[H]. Most nations schedule Gadopentetic acid under HS 28469000.
A gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
This classification denotes a gadolinium contrast media with the molecular formula C16H24N4O8.H+.Gd, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QVF9Y6955W, chemically known as hydrogen (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-))gadolinate(1-). but more generally known as gadoteric acid, which bears U.S. National Institutes of Health Compound Identifier 3085828. The European Medicines Agency schedules Gadoteric acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07865MIG. The World Health Organization schedules gadoteric acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: [Gd].OC(=O)CN1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O. Most nations schedule Gadoteric acid under HS 28469000.
This classification denotes a gadolinium-chelate with the molecular formula C17H29GdN4O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0199MV609F, chemically known as 1,4,7,10-tetraazacyclododecan-1,4,7-triacetic acid, 10-(2-hydroxypropyl)-, gadolinium complex but more generally known as gadoteridol, which bears U.S. National Institutes of Health Compound Identifier 60714. The European Medicines Agency schedules Gadoteridol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07866MIG. The term GADOTERIDOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, List 31). The World Health Organization schedules gadoteridol in its Anatomical Therapeutic Chemical (ATC) Classification. GADOTERIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [GD].OC(CN1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)C. Most nations schedule Gadoteridol under HS 28469000.
This classification denotes a gadolinium-chelate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RLM74T3Z9D. The European Medicines Agency schedules Gadoversetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07867MIG. Gadoversetamide generally arises in the molecular formula C20H34GDN5O10. The term GADOVERSETAMIDE is an International Non-Proprietary Name or INN. GADOVERSETAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [GD].OC(=O)CN(CCN(CC(=O)NCCOC)CC(=O)O)CCN(CC(=O)NCCOC)CC(=O)O. Most nations schedule Gadoversetamide under HS 28469000.
This classification denotes a gadolinium-chelate and contrast agent (especially deployed liver CT studies), a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3QJA87N40S. The European Medicines Agency schedules Gadoxetic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07868MIG. Gadoxetic acid generally arises in the molecular formula C23H30GDN3O11. The term GADOXETIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 9, no. 3, 1995, list 35.) SMILES: [Gd]12[N](CC([N]1(CC(=O)O)CC(=O)O)Cc1ccc(OCC)cc1)(CC[N]2(CC(=O)O)CC(=O)O)CC(=O)O.[H].[H]. Most nations schedule Gadoxetic acid under HS 28469000.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA202. This VA Drug Class (GA202) classifies this compound as belonging to the group HYPEROSMOTIC LAXATIVES.
This classification denotes a nitrogen mustard compound with the molecular formula C10H19Cl2NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P771FDQ1WJ, chemically known as d-galactopyranose, 6-(bis(2-chloroethyl)amino)-6-deoxy- but more generally known as galamustine, which bears US NIH Compound Identifier 65891. European Medicines Agency schedules Galamustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07869MIG. The term GALAMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). GALAMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule galamustine under HS 29329970 and SITC 51569. As of Q4 2014, GALAMUSTINE remains US FDA's Preferred Term for this commodity. Galamustine bears US NLM identifiers UMLS ID C2700228 and NCI Concept Code C76791. SMILES: C(CCL)N(CCCL)CC1C(C(C(C(O1)O)O)O)O.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C17H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0D3Q044KCA, chemically known as 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4as-(4a.alpha.,6.beta.,8ar*))- but generally known as galantamine, which bears US NIH Compound Identifier 3449. European Medicines Agency schedules Galantamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07870MIG. The term GALANTAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules galantamine in its Anatomical Therapeutic Chemical (ATC) Classification. GALANTAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule galantamine under HS 29399900 and SITC 54149. As of Q4 2014, GALANTAMINE remains the US FDA Preferred Term for this commodity. Galantamine bears US NLM identifiers UMLS ID C0016967 and NCI Concept Code C65797. SMILES: O1C2C3(C4C1C(OC)CCC4CN(CC3)C)C=CC(O)C2.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C17H21NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MJ4PTD2VVW, chemically known as 1,2,3,4,6,7,7a,11c-octahydro-9-methoxy-2-methyl-benzofuro(4,3,2-efg)(2)benzazocin-6-ol hbr but more generally known as galantamine hydrobromide, which bears US NIH Compound Identifier 121587. European Medicines Agency schedules Galantamine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02301MIG. Most nations, for tariff and trade purposes, schedule galantamine hydrobromide under HS 29399900 and SITC 54149. As of Q4 2014, GALANTAMINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Galantamine hydrobromide bears US NLM identifiers UMLS ID C0949312 and NCI Concept Code C47546. SMILES: CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4C3C(CCC4OC)C1)O.BR.
This classification denotes an anthracycline antibiotic with the molecular formula C30H32FNO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6F39648E92, chemically known as (8s,10s)-10-((2.6-dideoxy-2-fluoro-alpha-l-talopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione 8(2)-ester with beta-alanine. but generally known as galarubicin, which bears US NIH Compound Identifier 219086. European Medicines Agency schedules Galarubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02302MIG. The term GALARUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule galarubicin under HS 29419000 and SITC 54139. As of Q4 2014, GALARUBICIN remains the US FDA Preferred Term for this commodity. Galarubicin bears US NLM identifiers UMLS ID C2825624 and NCI Concept Code C81422. SMILES: FC1C(OC2CC(O)(CC3C2C(O)C2C(C3O)C(=O)C3C(C2=O)C(OC)CCC3)C(=O)COC(=O)CCN)OC(C(O)C1O)C.
This classification denotes an anticholinergic agent with the molecular formula C24H45N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1146X1WTNM, chemically known as 1,2,3-trihydroxybenzene but generally known as gallamine, which bears US NIH Compound Identifier 1057. European Medicines Agency schedules Gallamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02305MIG. World Health Organization schedules gallamine in its Anatomical Therapeutic Chemical (ATC) Classification. GALLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, GALLAMINE remains the US FDA Preferred Term for this commodity. Gallamine bears US NLM identifiers UMLS ID C0016971 and NCI Concept Code C87604. SMILES: OC1C(O)CCCC1O. .
This classification denotes a malignancy-associated hypercalcemia inhibitor with the molecular formula Ga.3NO3.9H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VRA0C6810N, chemically known as nitric acid, terbium(3+) salt but more generally known as gallium nitrate, which bears US NIH Compound Identifier 944. European Medicines Agency schedules Gallium nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13944MIG. As of Q4 2014, GALLIUM NITRATE remains US FDA's Preferred Term for this commodity. Gallium nitrate bears US NLM identifiers UMLS ID C0061008 and NCI Concept Code C1109. SMILES: O[N](=O)O.
This classification denotes a calcium channel blocker with the molecular formula C28H40N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39WPC8JHR8, chemically known as 5-((3,4-dimethoxyphenethyl)methylamino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile but generally known as gallopamil, which bears US NIH Compound Identifier 1234. European Medicines Agency schedules Gallopamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07874MIG. The term GALLOPAMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules gallopamil in its Anatomical Therapeutic Chemical (ATC) Classification. GALLOPAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gallopamil under HS 29269095 and SITC 51484. As of Q4 2014, GALLOPAMIL remains the US FDA Preferred Term for this commodity. Gallopamil bears US NLM identifiers UMLS ID C0016986 and NCI Concept Code C83725. SMILES: O(c1cc(C(C(C)C)(CCCN(CCc2cc(OC)c(OC)cc2)C)C#N)cc(OC)c1OC)C.
This classification denotes a calcium channel blocker with the molecular formula C28H40N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VT4VR32A0T, chemically known as 5-((3,4-dimethoxyphenethyl)methylamino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile but more generally known as gallopamil hydrochloride, which bears US NIH Compound Identifier 1234. European Medicines Agency schedules Gallopamil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02309MIG. Most nations, for tariff and trade purposes, schedule gallopamil hydrochloride under HS 29269095 and SITC 51484. As of Q4 2014, GALLOPAMIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Gallopamil hydrochloride bears US NLM identifiers UMLS ID C1369325 and NCI Concept Code C83726. SMILES: CC(C)C(CCCN(C)CCC1CCC(C(C1)OC)OC)(C#N)C2CC(C(C(C2)OC)OC)OC.CL.
This classification denotes a pyrimidine antagonist with the molecular formula C19H22FN3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9788XI79O, chemically known as 5-deoxy-5-fluoro-n-(3,4,5-trimethoxybenzoyl)cytidine but generally known as galocitabine, which bears US NIH Compound Identifier 65950. European Medicines Agency schedules Galocitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07875MIG. The term GALOCITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). GALOCITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule galocitabine under HS 29349990 and SITC 51579. As of Q4 2014, GALOCITABINE remains the US FDA Preferred Term for this commodity. Galocitabine bears US NLM identifiers UMLS ID C0084382 and NCI Concept Code C73254. SMILES: FC1CN(C2OC(C(O)C2O)C)C(=O)NC1NC(=O)C1CC(OC)C(OC)C(OC)C1.
This classification denotes an enzyme replacement preparation with the molecular formula C2529H3843N689O716S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59UA429E5G, more generally known as galsulfase. European Medicines Agency schedules galsulfase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21229. The term GALSULFASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 19, no. 3, 2005, list 54. Most nations schedule galsulfase under HS 35079090 and SITC 51691. As of Q4 2014, GALSULFASE remains the US FDA Preferred Term for this commodity. Galsulfase bears US NLM identifiers UMLS ID C1615657 and NCI Concept Code C74207. SMILES: NONE.
This classification denotes gamma-chain antibodies.
This classification denotes an antidepressant agent with the molecular formula C22H36O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98WI44OHIQ, chemically known as pregnan-20-one, 3-hydroxy-3-methyl-, (3alpha,5alpha)- but generally known as ganaxolone, which bears US NIH Compound Identifier 38022. European Medicines Agency schedules Ganaxolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07880MIG. The term GANAXOLONE is an International Non-Proprietary Name. GANAXOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ganaxolone under HS 29144090 and SITC 51629. As of Q4 2014, GANAXOLONE remains the US FDA Preferred Term for this commodity. Ganaxolone bears US NLM identifiers UMLS ID C0537150 and NCI Concept Code C72793. SMILES: OC1(CC2C(C3C(C4C(CC3)(C(CC4)C(=O)C)C)CC2)(CC1)C)C.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C9H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P9G3CKZ4P5, chemically known as 9-(1,3-dihydroxy-propoxymethane)guanine but generally known as ganciclovir, which bears US NIH Compound Identifier 3454. European Medicines Agency schedules Ganciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07881MIG. The term GANCICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules ganciclovir in its Anatomical Therapeutic Chemical (ATC) Classification. GANCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ganciclovir under HS 29335995 and SITC 51576. As of Q4 2014, GANCICLOVIR remains the US FDA Preferred Term for this commodity. Ganciclovir bears US NLM identifiers UMLS ID C0017066 and NCI Concept Code C517. SMILES: O(C(CO)CO)CN1C2[NH]C(NC(=O)C2NC1)N.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C9H12N5O4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02L083W284, chemically known as 9-(1,3-dihydroxy-propoxymethane)guanine but more generally known as ganciclovir sodium, which bears US NIH Compound Identifier 3454. European Medicines Agency schedules Ganciclovir sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02312MIG. Most nations, for tariff and trade purposes, schedule ganciclovir sodium under HS 29335995 and SITC 51576. As of Q4 2014, GANCICLOVIR SODIUM remains US FDA's Preferred Term for this commodity. Ganciclovir sodium bears US NLM identifiers UMLS ID C0282399 and NCI Concept Code C1588. SMILES: C1NC2C(=O)[N-]C(NC2N1COC(CO)CO)N.[NA+].
This classification denotes a gonadotropin releasing hormone inhibitor with the molecular formula C80H113ClN18O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IX503L9WN0, chemically known as d-alaninamide, n-acetyl-3-(1-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(bis(ethylamino)methylene)-d-lysyl-l-leucyl-n6-(bis(ethylamino)methylene)-l-lysyl-l-prolyl- but generally known as ganirelix, which bears US NIH Compound Identifier 16130966. European Medicines Agency schedules Ganirelix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07883MIG. The term GANIRELIX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules ganirelix in its Anatomical Therapeutic Chemical (ATC) Classification. GANIRELIX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ganirelix under HS 29371900 and SITC 54154. As of Q4 2014, GANIRELIX remains the US FDA Preferred Term for this commodity. Ganirelix bears US NLM identifiers UMLS ID C0073629 and NCI Concept Code C77423. SMILES: CLC1CCC(CC(NC(=O)C(NC(=O)C)CC2CC3C(CC2)CCCC3)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(C)C(=O)N)CCCC/N=C(/NCC)NCC)CC(C)C)CCCC/N=C(/NCC)NCC)CC2CCC(O)CC2)CO)CC2CCCNC2)CC1.
This classification denotes a gonadotropin releasing hormone inhibitor with the molecular formula C80H113CLN18O13.2C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56U7906FQW. European Medicines Agency schedules ganirelix acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25637. The term ganirelix acetate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule ganirelix acetate under HS 29371900 and SITC 54154. Ganirelix acetate bears US NLM identifiers UMLS ID C0872894 and NCI Concept Code C61774. SMILES: As of Q4 2014, GANIRELIX ACETATE remains US FDA's Preferred Term for this commodity.
This classification denotes a thrombolytic agent with the molecular formula C21H29N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MRG9KH7HF6, chemically known as 4-(((5r)-3-(p-(carboxyamidino)phenyl)-2-oxo-5-oxazolidinyl)methyl)-1-piperazineacetic acid, 1-ethyl methyl ester. but generally known as gantofiban, which bears US NIH Compound Identifier 9578736. The term GANTOFIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule gantofiban under HS 29349990 and SITC 51579. As of Q4 2014, GANTOFIBAN remains the US FDA Preferred Term for this commodity. Gantofiban bears US NLM identifiers UMLS ID C1120900 and NCI Concept Code C73227. SMILES: CCCOC(=O)CN1CCN(CC1)CC2CN(C(=O)O2)C3=CC=C(C=C3)C(=NC(=O)O)N.
This classification denotes a vasodilating agent with the molecular formula C12H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WWW0P95393, chemically known as 4,4-(iminodimethylene)dipyridine but generally known as gapicomine, which bears US NIH Compound Identifier 68955. European Medicines Agency schedules Gapicomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07884MIG. The term GAPICOMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). GAPICOMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gapicomine under HS 29333999 and SITC 51574. As of Q4 2014, GAPICOMINE remains the US FDA Preferred Term for this commodity. Gapicomine bears US NLM identifiers UMLS ID C1565778 and NCI Concept Code C72117. SMILES: C1=CN=CC=C1CNCC2=CC=NC=C2.
This classification denotes a quinolone antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V72H9867WB. European Medicines Agency schedules Garenoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25475. Garenoxacin generally arises in the molecular formula C23H20F2N2O4. The term GARENOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule garenoxacin under HS 29334990 and SITC 51575. As of Q4 2014, GARENOXACIN remains the US FDA Preferred Term for this commodity. Garenoxacin bears US NLM identifiers UMLS ID C1507354 and NCI Concept Code C65800. SMILES: FC(F)OC1C2N(C3CC3)CC(C(=O)C2CCC1C1CC2C(C(NC2)C)CC1)C(=O)O.
This classification denotes derivations of a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1V998DC17 and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 42652 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Lilianae, Order Aspargales, Family Amaryllidaceae, Genus Allium L., and Species Allium sativum L., more commonly known as GARLIC. Garlic bears the USDA PLANTS Database identifier ALSA2. European Medicines Agency schedules allium sativum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB30040, SUB30041, SUB34031, SUB35833, and SUB40574. The United Nations Common Coding System (UNCCS) codifies the source product under UNCCS 015451. As of Q4 2014, GARLIC remains the US FDA Preferred Term for this commodity. Garlic bears US NLM identifiers UMLS ID C0993630 and NCI Concept Code C38706. SMILES: NONE.
This classification denotes a quinolone antibiotic with the molecular formula 2C19H22FN3O4.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, L4618BD7KJ chemically known as (+/-)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, sesquihydrate but generally known as gatifloxacin, which bears US NIH Compound Identifier 5379. European Medicines Agency schedules Gatifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13952MIG. The term GATIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36. ). Most nations schedule gatifloxacin under HS 29335995 and SITC 51576. As of Q4 2014, GATIFLOXACIN remains the US FDA Preferred Term for this commodity. Gatifloxacin bears US NLM identifiers UMLS ID C1258065 and NCI Concept Code C29070. SMILES: FC1C(N2CC(NCC2)C)C(OC)C2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes an anxiolytic with the molecular formula C23H21ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BWP53NPW3F, chemically known as isopropyl 5-(p-chlorophenoxy)-4-(methoxymethyl)-9h-pyrido(3,4-b)indole-3-carboxylate. but generally known as gedocarnil, which bears US NIH Compound Identifier 219095. European Medicines Agency schedules Gedocarnil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07888MIG. The term GEDOCARNIL is an International Non-Proprietary Name. World Health Organization schedules gedocarnil in its Anatomical Therapeutic Chemical (ATC) Classification. GEDOCARNIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gedocarnil under HS 29339990 and SITC 51577. As of Q4 2014, GEDOCARNIL remains the US FDA Preferred Term for this commodity. Gedocarnil bears US NLM identifiers UMLS ID C2348738 and NCI Concept Code C74183. SMILES: CLC1CCC(OC2C3C4C([NH]C3CCC2)CNC(C4COC)C(=O)OC(C)C)CC1.
This classification denotes an antispasmotic agent with the molecular formula C27H44O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1ISE2Y6ULA, chemically known as 5,9,13-trimethyl-4,8,12-tetradecatrienoic acid 3,7-dimethyl-2,6-octadienyl ester but generally known as gefarnate, which bears US NIH Compound Identifier 5282182. European Medicines Agency schedules Gefarnate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07889MIG. The term GEFARNATE is an International Non-Proprietary Name. World Health Organization schedules gefarnate in its Anatomical Therapeutic Chemical (ATC) Classification. GEFARNATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gefarnate under HS 29161970 and SITC 51379. As of Q4 2014, GEFARNATE remains the US FDA Preferred Term for this commodity. Gefarnate bears US NLM identifiers UMLS ID C0017226 and NCI Concept Code C73187. SMILES: O(C(=O)CC/C=C(/CC/C=C(/CC/C=C(/C)C)C)C)C/C=C(/CC/C=C(/C)C)C.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H24ClFN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S65743JHBS, chemically known as 4-quinazolinamine, n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)- but generally known as gefitinib, which bears US NIH Compound Identifier 123631. European Medicines Agency schedules Gefitinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20637. The term GEFITINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules gefitinib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule gefitinib under HS 29349990 and SITC 51579. As of Q4 2014, GEFITINIB remains the US FDA Preferred Term for this commodity. Gefitinib bears US NLM identifiers UMLS ID C1122962 and NCI Concept Code C1855. SMILES: CLC1CC(NC2NCNC3C2CC(OCCCN2CCOCC2)C(OC)C3)CCC1F.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes derivations of a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 639KR60Q1Q, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29929 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Gentianales, Family Gelsemiaceae, Genus Gelsemium Juss. (trumpetflower), commonly known as TRUMPETFLOWER or as here, GELSEMIUM. Gelsemium bears the USDA PLANTS Database identifier GELSE. European Medicines Agency schedules gelsemium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13956MIG, SUB13957MIG, SUB34788, SUB40657, SUB46533, SUB47364, SUB47365, SUB47366, SUB47367, SUB47368, SUB47369, and SUB47370.
This classification denotes a ribonucleotide reductase inhibitor and pyrimidine antagonist with the molecular formula C9H11F2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B76N6SBZ8R, chemically known as 2-deoxy-.beta.-d-2,2-difluorocytidine but generally known as gemcitabine, which bears US NIH Compound Identifier 60750. European Medicines Agency schedules Gemcitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07892MIG. The term GEMCITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules gemcitabine in its Anatomical Therapeutic Chemical (ATC) Classification. GEMCITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gemcitabine under HS 29349990 and SITC 51579. As of Q4 2014, GEMCITABINE remains the US FDA Preferred Term for this commodity. Gemcitabine bears US NLM identifiers UMLS ID C0045093 and NCI Concept Code C66876. SMILES: FC1(F)C(O)C(OC1N1CCC(NC1=O)N)CO.
This classification denotes a prostaglandin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45KZB1FOLS. European Medicines Agency schedules Gemeprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07893MIG. Gemeprost generally arises in the molecular formula C23H38O5. The term GEMEPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) GEMEPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gemeprost under HS 29375000 and SITC 54156. As of Q4 2014, GEMEPROST remains the US FDA Preferred Term for this commodity. Gemeprost bears US NLM identifiers UMLS ID C0044923 and NCI Concept Code C87382. SMILES: OC1C(C(CCCC/C=C/C(=O)OC)C(=O)C1)/C=C/C(O)C(CCCC)(C)C.
This classification denotes an anti-lipidemic agent with the molecular formula C15H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q8X02027X3, chemically known as 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid but generally known as gemfibrozil, which bears US NIH Compound Identifier 3463. European Medicines Agency schedules Gemfibrozil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07894MIG. The term GEMFIBROZIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules gemfibrozil in its Anatomical Therapeutic Chemical (ATC) Classification. GEMFIBROZIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, GEMFIBROZIL remains the US FDA Preferred Term for this commodity. Gemfibrozil bears US NLM identifiers UMLS ID C0017245 and NCI Concept Code C29071. SMILES: O(CCCC(C)(C)C(=O)O)c1c(ccc(c1)C)C.
This classification denotes a quinolone antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKR68Y0E4T. European Medicines Agency schedules Gemifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27752. Gemifloxacin generally arises in the molecular formula C18H20FN5O4. The term GEMIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 1, 2000, list 43.) Most nations schedule gemifloxacin under HS 29339990 and SITC 51577. As of Q4 2014, GEMIFLOXACIN remains the US FDA Preferred Term for this commodity. Gemifloxacin bears US NLM identifiers UMLS ID C0533545 and NCI Concept Code C61775. SMILES: FC1C(N2CC(/C(=N\OC)C2)CN)NC2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes an anti-cd33 immunotoxin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8GZG754X6M. European Medicines Agency schedules Gemtuzumab ozogamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20794. Gemtuzumab generally arises in the molecular formula C73H96IN6O25S3. The term GEMTUZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule Gemtuzumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, GEMTUZUMAB remains the US FDA Preferred Term for this commodity. .
This classification denotes an aminoglycoside antibiotic with the molecular formula C21H43N5O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T6Z9V48IKG, more generally known as gentamicin. European Medicines Agency schedules gentamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02326MIG. The term GENTAMICIN is an International Non-Proprietary Name or INN. GENTAMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gentamicin under HS 29419000 and SITC 54139. As of Q4 2014, GENTAMICIN remains the US FDA Preferred Term for this commodity. Gentamicin bears US NLM identifiers UMLS ID C0017436 and NCI Concept Code C519. SMILES: CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC.*.
This classification denotes an aminoglycoside antibiotic with the molecular formula C18H36N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W8R3URS2H, chemically known as d-streptamine, o-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-3-(methylamino)-.alpha.-d-xylopyranosyl-(1->6))-2-deoxy-, but more generally known as gentamicin a, which bears US NIH Compound Identifier 86474. European Medicines Agency schedules gentamicin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02326MIG. Most nations, for tariff purposes, schedule gentamicin a under HS 29419000. SMILES: CN[C@H]1[C@H](CO[C@@H]([C@@H]1O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)N)N)N)O.
This classification denotes an aminoglycoside antibiotic C19H39N5O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AV4A72IATD, chemically known as d-streptamine, o-3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-.alpha.-d-erythro-hexopyranosyl-(1->4))-2-deoxy-, but more generally known as gentamicin c1a, which bears US NIH Compound Identifier 72396. Most nations, for tariff and trade purposes, schedule gentamicin c1a under HS 29419000 and SITC 54139. As of Q4 2014, GENTAMICIN C1A remains US FDA's Preferred Term for this commodity. Gentamicin c1a bears US NLM identifiers UMLS ID C1563655 and NCI Concept Code C76149. SMILES: C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X7386QRLV. European Medicines Agency schedules Gentamicin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02327MIG. Gentamicin sulfate generally arises in the molecular formula C21H45N5O11S. The term 'gentamicin sulfate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule gentamicin sulfate under HS 29419000 and SITC 54139. Gentamicin sulfate bears US NLM identifiers UMLS ID C0546866 and NCI Concept Code C65803. SMILES: As of Q4 2014, GENTAMICIN SULFATE remains US FDA's Preferred Term for this commodity.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V51RRX51VH, chemically known as phenol, m-(2-aminopropyl)- but generally known as gepefrine, which bears US NIH Compound Identifier 102551. European Medicines Agency schedules Gepefrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07896MIG. World Health Organization schedules gepefrine in its Anatomical Therapeutic Chemical (ATC) Classification. GEPEFRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gepefrine under HS 29222900 and SITC 51462. As of Q4 2014, GEPEFRINE remains the US FDA Preferred Term for this commodity. Gepefrine bears US NLM identifiers UMLS ID C0082689 and NCI Concept Code C72920. SMILES: OC1CC(CC(N)C)CCC1.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y64EJ7HA03, chemically known as phenol, 3-(2-aminopropyl)-, (s)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1) (salt), but more generally known as gepefrine tartrate, which bears US NIH Compound Identifier 6454022. European Medicines Agency schedules gepefrine tartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07896MIG. Most nations, for tariff purposes, schedule gepefrine tartrate under HS 29222900. SMILES: C[C@@H](CC1CCCC(C1)O)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a serotonin agonist and anxiolytic with the molecular formula C19H29N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JW5Y7B8Z18, chemically known as 3,3-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride but generally known as gepirone, which bears US NIH Compound Identifier 55190. European Medicines Agency schedules Gepirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07897MIG. The term GEPIRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules gepirone in its Anatomical Therapeutic Chemical (ATC) Classification. GEPIRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gepirone under HS 29335995 and SITC 51576. As of Q4 2014, GEPIRONE remains the US FDA Preferred Term for this commodity. Gepirone bears US NLM identifiers UMLS ID C0066624 and NCI Concept Code C74193. SMILES: Cl.O=C1N(CCCCN2CCN(CC2)c2ncccn2)C(=O)CC(C1)(C)C.
This classification denotes a serotonin agonist and anxiolytic with the molecular formula C19H29N5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80C9L8EP6V, chemically known as 3,3-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride but more generally known as gepirone hydrochloride, which bears US NIH Compound Identifier 55190. Most nations, for tariff and trade purposes, schedule gepirone hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, GEPIRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Gepirone hydrochloride bears US NLM identifiers UMLS ID C2348751 and NCI Concept Code C72795. SMILES: CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3NCCCN3)C.CL.
This classification denotes an anti-ulcer agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8S8451A4O. European Medicines Agency schedules Teprenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15486MIG. Teprenone generally arises in the molecular formula C23H38O. The term TEPRENONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) TEPRENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Geranylgeranylacetone or teprenone bears US NLM identifiers UMLS ID C0061231 and NCI Concept Code C66587. SMILES: CC(=CCC/C(=C/CC/C(=C/CC/C(=C/CCC(=O)C)/C)/C)/C)C.
This classification denotes a quinolone antibiotic and antineoplastic antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4155989DN5. European Medicines Agency schedules Geroquinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07898MIG. Geroquinol generally arises in the molecular formula C16H22O2. The term GEROQUINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) GEROQUINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Geranylhydroquinone or geroquinol bears US NLM identifiers UMLS ID C0061232 and NCI Concept Code C72639. SMILES: CC(=CCC/C(=C/CC1=C(C=CC(=C1)O)O)/C)C.
This classification denotes a therapeutic progestin with the molecular formula C21H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1664P6E6MI, chemically known as 18,19-dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)- but generally known as gestodene, which bears US NIH Compound Identifier 43249. European Medicines Agency schedules Gestodene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07901MIG. The term GESTODENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). GESTODENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gestodene under HS 29372300 and SITC 54153. As of Q4 2014, GESTODENE remains the US FDA Preferred Term for this commodity. Gestodene bears US NLM identifiers UMLS ID C0061246 and NCI Concept Code C87240. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)C=C1)CC)C#C.
This classification denotes a therapeutic progestin with the molecular formula C20H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H4G605B7VP, chemically known as 19-norpregn-4-ene-3,20-dione, 17-hydroxy- but generally known as gestonorone, which bears US NIH Compound Identifier 102210. European Medicines Agency schedules Gestonorone caproate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07902MIG. The term GESTONORONE CAPROATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules gestonorone in its Anatomical Therapeutic Chemical (ATC) Classification. GESTONORONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, GESTONORONE remains the US FDA Preferred Term for this commodity. SMILES: CC(=O)C1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)O.
This classification denotes a therapeutic progestin with the molecular formula C20H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H4G605B7VP, chemically known as 19-norpregn-4-ene-3,20-dione, 17-hydroxy- but more generally known as gestonorone, which bears US NIH Compound Identifier 102210. European Medicines Agency schedules Gestonorone caproate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07902MIG. The term GESTONORONE CAPROATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules gestonorone in its Anatomical Therapeutic Chemical (ATC) Classification. GESTONORONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule gestonorone caproate under HS 29372300 and SITC 54153. As of Q4 2014, GESTONORONE CAPROATE remains US FDA's Preferred Term for this commodity. Gestonorone caproate bears US NLM identifiers UMLS ID C0017505 and NCI Concept Code C74365. SMILES: CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C(=O)C.
This classification denotes a therapeutic progestin with the molecular formula C21H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1421533RCM, chemically known as 18,19-dinorpregna-4,9,11-trien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)- (9ci) but generally known as gestrinone, which bears US NIH Compound Identifier 27812. European Medicines Agency schedules Gestrinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13963MIG. The term GESTRINONE is an International Non-Proprietary Name. World Health Organization schedules gestrinone in its Anatomical Therapeutic Chemical (ATC) Classification. GESTRINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gestrinone under HS 29372300 and SITC 54153. As of Q4 2014, GESTRINONE remains the US FDA Preferred Term for this commodity. Gestrinone bears US NLM identifiers UMLS ID C0017507 and NCI Concept Code C87241. SMILES: OC1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)CC)C#C.
This classification denotes derivations of a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19FUJ2C58T, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 183269 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Gymnospermae, Class Ginkgoopsida (ginkgo), Order Ginkgoales, Family Ginkgoaceae, Genus Ginkgo L. (ginkgo), Species Ginkgo biloba L., commonly known as MAIDENHAIR TREE, COMMON GINKGO, GINKO BILOBA, or as here, GINKGO. Ginkgo bears the USDA PLANTS Database identifier GIBI2. European Medicines Agency schedules ginkgo in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13965MIG, SUB13966MIG, SUB16390MIG, SUB32484, SUB33195, SUB33659, SUB43262, SUB47670, and SUB61335. Ginkgo biloba bears US NLM identifiers UMLS ID C0330206 and NCI Concept Code C93305. SMILES: NONE.
This classification denotes derivations of a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUQ3A77YXI, but varieties of which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers E35T4MOI3E, E7XOU43ESD, EP0RRQ7J9A, GD1Z9GY1FW, GQX1C1175U, IQC2WQS369, J337CNM3CW, KYV09BQ2YN, P9T4K47OM0, RS4X1U56YO, V038D626IF, YL6KN21IL2, ZQH6VH092Z, ZUR2T81ETV, ZX5Z2LW23O, 0DAF87OMMD, 0G05EWL44O, 0P067WOA1X, 02VJ3CEY9G, 2E0DVE4XPS, 2HZ95R7082, 3K198YD54P, 3V5S2B524J, 5DWS84R85M, 8W75VCV53Q, 9L5JEP7MES, 76AI4Q0335, 80K66AHT6U, and 99C8CDD94H, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29371 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Araliaceae (ginseng), commonly known as GINSENG, of which there are many children, including Aralia, Cheirodendron, Dendropanax, Eleutherococcus, Fatsia, Hedera, Hydrocotyle, Kalopanax, Meryta, Neopanax, Oplopanax, Osmoxylon, Panax, Polyscias, Pseudopanax, Schefflera, and Tetrapanax. Ginseng bears the USDA PLANTS Database identifier PANAX. European Medicines Agency schedules ginseng in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13799MIG, SUB13967MIG, SUB14303MIG, SUB14747MIG, SUB15167MIG, SUB33900, SUB33921, SUB36574, SUB47460, SUB47461, SUB47462, SUB47463, SUB47465, SUB53926, and SUB69003. The United Nations Common Coding System (UNCCS) codifies ginseng under UNCCS 019320. Ginseng bears US NLM identifiers UMLS ID C0086767 and NCI Concept Code C91401.
This classification denotes an anxiolytic with the molecular formula C18H17ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2LP301A921, chemically known as 5h-2,3-benzodiazepine, 1-(3-chlorophenyl)-7,8-dimethoxy-4-methyl- but generally known as girisopam, which bears US NIH Compound Identifier 71257. European Medicines Agency schedules Girisopam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07907MIG. The term GIRISOPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). GIRISOPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule girisopam under HS 29339940 and SITC 51577. As of Q4 2014, GIRISOPAM remains the US FDA Preferred Term for this commodity. Girisopam bears US NLM identifiers UMLS ID C0164299 and NCI Concept Code C74182. SMILES: CLC1CC(C2=NN=C(CC3C2CC(OC)C(OC)C3)C)CCC1.
This classification denotes a digitalis glycoside and digoxin analog with the molecular formula C46H64O19, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B69U29O7J9, chemically known as gitoxin, pentaformate but generally known as gitoformate, which bears US NIH Compound Identifier 65598. European Medicines Agency schedules Gitoformate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13968MIG. World Health Organization schedules gitoformate in its Anatomical Therapeutic Chemical (ATC) Classification. GITOFORMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(OC=O)C(OC=O)C6)C)C(OC=O)C5)C)C(OC=O)C3)C)CC4)C)CCC1(C(C(OC=O)C2)C1=CC(=O)OC1)C.
This classification denotes an analgesic agent with the molecular formula C19H17ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46HL4I09AH, chemically known as 2,3-dihydroxypropyl n-(7-chloro-4-quinolyl) anthranilate but generally known as glafenine, which bears US NIH Compound Identifier 3474. European Medicines Agency schedules Glafenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07909MIG. The term GLAFENINE is an International Non-Proprietary Name. World Health Organization schedules glafenine in its Anatomical Therapeutic Chemical (ATC) Classification. GLAFENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glafenine under HS 29334990 and SITC 51575. As of Q4 2014, GLAFENINE remains the US FDA Preferred Term for this commodity. Glafenine bears US NLM identifiers UMLS ID C0017592 and NCI Concept Code C72119. SMILES: CLC1CC2NCCC(NC3C(C(=O)OCC(O)CO)CCCC3)C2CC1.
This classification denotes an analgesic agent C19H17ClN2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MS23T96ZZP, chemically known as benzoic acid, 2-((7-chloro-4-quinolinyl)amino)-, 2,3-dihydroxypropyl ester, hydrochloride (1:1), but more generally known as glafenine hydrochloride, which bears US NIH Compound Identifier 3085326. European Medicines Agency schedules Glafenine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02339MIG. Most nations, for tariff and trade purposes, schedule glafenine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, GLAFENINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(C(C1)C(=O)OCC(CO)O)NC2CCNC3C2CCC(C3)CL.CL.
This classification denotes a biological response modifier with the molecular formula (C9H9NO2)n.(C6H12N2O)n.(C5H7NO3)n.(C3H5NO)n.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M691HL4BO, chemically known as l-glutamic acid polymer with l-alanine, l-lysine and l-tyrosine, acetate (salt) but generally known as glatiramer acetate, which bears US NIH Compound Identifier 3081884. European Medicines Agency schedules Glatiramer acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13971MIG. World Health Organization schedules glatiramer acetate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, GLATIRAMER ACETATE remains the US FDA Preferred Term for this commodity. Glatiramer acetate bears US NLM identifiers UMLS ID C0289884 and NCI Concept Code C65805. SMILES: CC(C(=O)O)N.CC(=O)O.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N.
This classification denotes an anti-ulcer agent with the molecular formula C18H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KE7J8A65P6, chemically known as spiro(2,5-cyclohexadiene-1,7(1h)-cyclopent(ij)isoquinolin)-4-one, 2,3,8,8a-tetrahydro-6-hydroxy-5-methoxy-1-methyl-, (+-)- (9ci) but generally known as glaziovine, which bears US NIH Compound Identifier 65631. European Medicines Agency schedules Glaziovine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07911MIG. The term GLAZIOVINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). GLAZIOVINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glaziovine under HS 29399900 and SITC 54149. As of Q4 2014, GLAZIOVINE remains the US FDA Preferred Term for this commodity. Glaziovine bears US NLM identifiers UMLS ID C0061303 and NCI Concept Code C73193. SMILES: OC1C2C3(CC4N(CCC(C24)CC1OC)C)C=CC(=O)C=C3.
Glecaprevir/pibrentasvir (G/P)is a fixed-dose combination medication used to treat hepatitis C.
This classification denotes an anti-diabetic agent with the molecular formula C23H33N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTY52EM5B2, chemically known as 3-pyridinecarboxamide, n-(2-(1-(((((bicyclo(2.2.1)-hept-5-en-2-ylmethyl)amino)carbonyl)amino)sulfonyl)-4-piperidinyl)ethyl)-2-methoxy-, endo but generally known as gliamilide, which bears US NIH Compound Identifier 3037231. European Medicines Agency schedules Gliamilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07915MIG. The term GLIAMILIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). GLIAMILIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gliamilide under HS 29350090 and SITC 51580. As of Q4 2014, GLIAMILIDE remains the US FDA Preferred Term for this commodity. Gliamilide bears US NLM identifiers UMLS ID C2983990 and NCI Concept Code C91020. SMILES: S(=O)(=O)(N1CCC(CC1)CCNC(=O)C1C(OC)NCCC1)NC(=O)NCC1C2CC(C1)C=C2.
This classification denotes a cation channel blocker and anti-diabetic agent with the molecular formula C23H28ClN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SX6K58TVWC, chemically known as urea, 1-((p-(2-(chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl- but more generally known as glibenclamide, which bears US NIH Compound Identifier 3488. European Medicines Agency schedules Glibenclamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07916MIG WHO schedules glibenclamide in its Anatomical Therapeutic Chemical (ATC) Classification. GLIBENCLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Glibenclamide or glyburide bears US NLM identifiers UMLS ID C0017628 and NCI Concept Code C29076. SMILES: CLC1CC(C(=O)NCCC2CCC(S(=O)(=O)NC(=O)NC3CCCCC3)CC2)C(OC)CC1.
This classification denotes a hypoglycemic agent with the molecular formula C18H26N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) VP83E7434R, chemically known as urea, 1-(2-hydroxy-3-bornyl)-3-(p-tolylsulfonyl)-, (1r,2r,3s,4s)- but more generally known as glibornuride, which bears US NIH Compound Identifier 33649. European Medicines Agency schedules Glibornuride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07917MIG WHO schedules glibornuride in its Anatomical Therapeutic Chemical (ATC) Classification. GLIBORNURIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glibornuride under HS 29350090 and SITC 51580. As of Q4 2014, GLIBORNURIDE remains US FDA's Preferred Term for this commodity. SMILES: S(=O)(=O)(NC(=O)NC1C2C(C(C1O)(CC2)C)(C)C)C1CCC(CC1)C.
This classification denotes an anti-diabetic agent with the molecular formula C30H42N6O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) UK5SR22C8Q, chemically known as 1-cyclohexyl-3-((p-(2-(1-ethyl-4-(isopentyloxy)-3-methyl-1h-pyrazolo(3,4-b)pyridine-5-carboxamido)ethyl)phenyl)sulfonyl)urea but more generally known as glicaramide, which bears US NIH Compound Identifier 65799. European Medicines Agency schedules Glicaramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07919MIG. The term GLICARAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). GLICARAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glicaramide under HS 29350090 and SITC 51580. As of Q4 2014, GLICARAMIDE remains US FDA's Preferred Term for this commodity. Glicaramide bears US NLM identifiers UMLS ID C0603303 and NCI Concept Code C72945. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CCC(CCNC(=O)C2C(OCCC(C)C)C3C(N(NC3C)CC)NC2)CC1.
This classification denotes an anti-diabetic agent with the molecular formula C15H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G4PX8C4HKV, chemically known as urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)- but more generally known as gliclazide, which bears US NIH Compound Identifier 3475. European Medicines Agency schedules Gliclazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07921MIG. The term GLICLAZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11) WHO schedules gliclazide in its Anatomical Therapeutic Chemical (ATC) Classification. GLICLAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule gliclazide under HS 29350090 and SITC 51580. As of Q4 2014, GLICLAZIDE remains US FDA's Preferred Term for this commodity. Gliclazide bears US NLM identifiers UMLS ID C0017631 and NCI Concept Code C87618. SMILES: S(=O)(=O)(NC(=O)NN1CC2C(CCC2)C1)C1CCC(CC1)C.
This classification denotes an anti-diabetic agent with the molecular formula C25H29FN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) USE67B01YN, chemically known as benzeneacetamide, n-((1s)-1-(5-fluoro-2-methoxyphenyl)ethyl)-4-(((5-(2-methylpropyl)-2-pyrimidinyl)amino)sulfonyl)- but more generally known as gliflumide, which bears US NIH Compound Identifier 197722. European Medicines Agency schedules Gliflumide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07924MIG. The term GLIFLUMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). GLIFLUMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule gliflumide under HS 29350090 and SITC 51580. As of Q4 2014, GLIFLUMIDE remains US FDA's Preferred Term for this commodity. Gliflumide bears US NLM identifiers UMLS ID C0061322 and NCI Concept Code C72947. SMILES: S(=O)(=O)(NC1NCC(CC(C)C)CN1)C1CCC(CC(=O)NC(C2C(OC)CCC(F)C2)C)CC1.
This classification denotes an anti-diabetic agent with the molecular formula C24H34N4O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6KY687524K, chemically known as 3-ethyl-n,n-bis(3-ethyl-4-methyl-2-oxo-5h-pyrrol-2-yl)-4-methyl-2-oxo-5h-pyrrole-1-carboxamide but more generally known as glimepiride, which bears US NIH Compound Identifier 3476. European Medicines Agency schedules Glimepiride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07925MIG. The term GLIMEPIRIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules glimepiride in its Anatomical Therapeutic Chemical (ATC) Classification. GLIMEPIRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glimepiride under HS 29350090 and SITC 51580. As of Q4 2014, GLIMEPIRIDE remains US FDA's Preferred Term for this commodity. Glimepiride bears US NLM identifiers UMLS ID C0061323 and NCI Concept Code C29073. SMILES: S(=O)(=O)(NC(=O)NC1CCC(CC1)C)C1CCC(CCNC(=O)N2CC(=C(C2=O)CC)C)CC1.
Glimepiride/metformin is a fixed-dose combination therapy of an agent of the biguanide class and a sulfonylurea used to treat high blood sugar levels caused by type 2 diabetes.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes an anti-diabetic agent with the molecular formula C12H15N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W7J490CUHM, chemically known as 4,5-dihydro-5-methyl-n-((4-methylphenyl)sulfonyl)-1h-pyrazole-1-carboxamide but more generally known as glipalamide, which bears US NIH Compound Identifier 65802. European Medicines Agency schedules Glipalamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07926MIG. The term GLIPALAMIDE is an International Non-Proprietary Name. GLIPALAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glipalamide under HS 29350090 and SITC 51580. As of Q4 2014, GLIPALAMIDE remains US FDA's Preferred Term for this commodity. Glipalamide bears US NLM identifiers UMLS ID C0243356 and NCI Concept Code C72797. SMILES: CC1CC=NN1C(=O)NS(=O)(=O)C2=CC=C(C=C2)C.
This classification denotes an anti-diabetic agent with the molecular formula C21H27N5O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) X7WDT95N5C, chemically known as urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)- but more generally known as glipizide, which bears US NIH Compound Identifier 3478. European Medicines Agency schedules Glipizide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07927MIG. The term GLIPIZIDE is an International Non-Proprietary Name WHO schedules glipizide in its Anatomical Therapeutic Chemical (ATC) Classification. GLIPIZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glipizide under HS 29350090 and SITC 51580. As of Q4 2014, GLIPIZIDE remains US FDA's Preferred Term for this commodity. Glipizide bears US NLM identifiers UMLS ID C0017642 and NCI Concept Code C29074. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CCC(CCNC(=O)C2NCC(NC2)C)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes an anti-diabetic agent with the molecular formula C27H33N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C7C2QDD75P, chemically known as 1-cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2h,4h)-isoquinolinedione-2-yl)phenethyl)sulfonylurea but more generally known as gliquidone, which bears US NIH Compound Identifier 91610. European Medicines Agency schedules Gliquidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07928MIG. The term GLIQUIDONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13) WHO schedules gliquidone in its Anatomical Therapeutic Chemical (ATC) Classification. GLIQUIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule gliquidone under HS 29350090 and SITC 51580. As of Q4 2014, GLIQUIDONE remains US FDA's Preferred Term for this commodity. Gliquidone bears US NLM identifiers UMLS ID C0061328 and NCI Concept Code C72798. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CCC(CCN2C(=O)C(C3C(C2=O)CC(OC)CC3)(C)C)CC1.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4C1IE36L0. European Medicines Agency schedules Glisamuride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07929MIG. Glisamuride generally arises in the molecular formula C23H31N5O4S. The term GLISAMURIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) GLISAMURIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glisamuride under HS 29350090 and SITC 51580. As of Q4 2014, GLISAMURIDE remains the US FDA Preferred Term for this commodity. Glisamuride bears US NLM identifiers UMLS ID C2348865 and NCI Concept Code C72948. SMILES: S(=O)(=O)(NC(=O)NC1CCC(CC1)C)C1CCC(CCNC(=O)N(C2NCCCC2)C)CC1.
This classification denotes an anti-diabetic agent with the molecular formula C20H26N4O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F83U6T74XR, chemically known as 3-isozazolecarboxamide, n-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl- but more generally known as glisolamide, which bears US NIH Compound Identifier 65713. European Medicines Agency schedules Glisolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07932MIG. The term GLISOLAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 34, No. 10 1980, List 20). GLISOLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glisolamide under HS 29350090 and SITC 51580. As of Q4 2014, GLISOLAMIDE remains US FDA's Preferred Term for this commodity. Glisolamide bears US NLM identifiers UMLS ID C0061329 and NCI Concept Code C72800. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CCC(CCNC(=O)C2NOC(C2)C)CC1.
This classification denotes an anti-diabetic agent with the molecular formula C20H27N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H7SC0I332I, chemically known as 3-isoxazolecarboxamide, n-(2-(4-(((((hexahydro-1h-azepin-1-yl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl- but more generally known as glisoxepid, which bears US NIH Compound Identifier 32778. European Medicines Agency schedules Glisoxepide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07933MIG. The term GLISOXEPIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11) WHO schedules glisoxepid in its Anatomical Therapeutic Chemical (ATC) Classification. Glisoxepid or glisoxepide bears US NLM identifiers UMLS ID C0061330 and NCI Concept Code C72801. SMILES: CC1=CC(=NO1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NN3CCCCCC3.
This classification denotes a peptide hormone, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 76LA80IG2G. European Medicines Agency schedules Glucagon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02347MIG. Glucagon generally arises in the molecular formula C153H225N43O49S. The term GLUCAGON is a European Pharmacopoeia designation. GLUCAGON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glucagon under HS 29371900 and SITC 54154. As of Q4 2014, GLUCAGON remains US FDA's Preferred Term for this commodity. Glucagon bears US NLM identifiers UMLS ID C0017687 and NCI Concept Code C2268. SMILES: S(CCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(N)CC1NC[NH]C1)CO)CCC(=O)N)C(O)C)CC1CCCCC1).
This classification denotes a therapeutic hormone, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1H87NVF4DB. European Medicines Agency schedules Glucagon hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02349MIG. Glucagon hydrochloride generally arises in the molecular formula C153H225N43O49S.CLH. The term 'glucagon hydrochloride' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule glucagon hydrochloride under HS 29371900 and SITC 54154. Glucagon hydrochloride bears US NLM identifiers UMLS ID C0795614 and NCI Concept Code C87236. SMILES: As of Q4 2014, GLUCAGON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H27ClN2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N1EXE5EHAN, chemically known as d-glucose, 2-(((1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl)acetyl)amino)-2-deoxy-, hydrate but generally known as glucametacin, which bears US NIH Compound Identifier 3033980. European Medicines Agency schedules Glucametacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07936MIG. The term GLUCAMETACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). GLUCAMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glucametacin under HS 29339990 and SITC 51577. As of Q4 2014, GLUCAMETACIN remains the US FDA Preferred Term for this commodity. Glucametacin bears US NLM identifiers UMLS ID C0061377 and NCI Concept Code C80554. SMILES: CLC1CCC(C(=O)N2C(C(C3C2CCC(OC)C3)CC(=O)NC(C(O)C(O)C(O)CO)C=O)C)CC1.
This classification denotes an enzyme replacement preparation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2GFP9BJD79. European Medicines Agency schedules Glucarpidase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25203. Glucarpidase generally arises in the molecular formula 4ZN. The term GLUCARPIDASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations schedule glucarpidase under HS 35079090 and SITC 51691. As of Q4 2014, GLUCARPIDASE remains the US FDA Preferred Term for this commodity. Glucarpidase bears US NLM identifiers UMLS ID C0007072 and NCI Concept Code C346. SMILES: none.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX202. This VA Drug Class (DX202) classifies this compound as belonging to the group NON-IMAGING AGENTS RADIOPHARMACEUTICALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX202. This VA Drug Class (DX202) classifies this compound as belonging to the group NON-IMAGING AGENTS RADIOPHARMACEUTICALS.
This classification denotes a nutritional supplement with the molecular formula C6H13NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N08U5BOQ1K, chemically known as mannopyranose, 2-amoino-2-deoxy-, d- (8ci) but generally known as glucosamine, which bears US NIH Compound Identifier 739. European Medicines Agency schedules Glucosamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07937MIG. The term GLUCOSAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules glucosamine in its Anatomical Therapeutic Chemical (ATC) Classification. GLUCOSAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glucosamine under HS 29329970 and SITC 51569. As of Q4 2014, GLUCOSAMINE remains the US FDA Preferred Term for this commodity. Glucosamine bears US NLM identifiers UMLS ID C0017718 and NCI Concept Code C83731. SMILES: O1C(C(O)C(O)C(N)C1O)CO.
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 750W5330FY. European Medicines Agency schedules Glucosamine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02354MIG. Glucosamine hcl generally arises in the molecular formula C6H13NO5.CLH. The term 'glucosamine hcl' is an International Nomenclature of Cosmetic Ingredients designation. SMILES: Cl.OC(C(O)C(N)C=O)C(O)CO.
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 750W5330FY. European Medicines Agency schedules Glucosamine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02354MIG. Glucosamine hydrochloride generally arises in the molecular formula C6H13NO5.CLH. The term 'glucosamine hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation. Most nations, for tariff and trade purposes, schedule glucosamine hydrochloride under HS 29329970 and SITC 51569. As of Q4 2014, GLUCOSAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Glucosamine hydrochloride bears US NLM identifiers UMLS ID C0771903 and NCI Concept Code C83732. SMILES: C([C@H]([C@H]([C@@H]([C@H](C=O)N)O)O)O)O.CL.
This classification denotes a nutritional supplement with the molecular formula 2C6H13NO5.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1FW7WLR731, chemically known as d-glucose, 2-amino-2-deoxy-, sulfate (salt) but more generally known as glucosamine sulfate, which bears US NIH Compound Identifier 115046. European Medicines Agency schedules Glucosamine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02356MIG. Most nations, for tariff and trade purposes, schedule glucosamine sulfate under HS 29329970 and SITC 51569. As of Q4 2014, GLUCOSAMINE SULFATE remains US FDA's Preferred Term for this commodity. Glucosamine sulfate bears US NLM identifiers UMLS ID C0017720 and NCI Concept Code C29075. SMILES: C([C@H]([C@H]([C@@H]([C@H](C=O)N)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C=O)N)O)O)O)O.OS(=O)(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
Treatment of respiratory depression: Intoxication by depressants of S.N.C. (anesthetics, alcohol, etc), resuscitation of drowning, suffocation of newborns. Circulatory collapse, hypotension.
This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X40L29981F. European Medicines Agency schedules Glucosulfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07938MIG. Glucosulfamide generally arises in the molecular formula C13H21N2O11S2.NA. The term GLUCOSULFAMIDE is an International Non-Proprietary Name or INN. GLUCOSULFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(O)C(NC1CCC(S(=O)(=O)NCO)CC1)C(O)C(O)C(O)C(O)CO.[NA].
This classification denotes a sulfone anti-infective agent with the molecular formula C24H34N2O18S3.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I6RLN7D44F, chemically known as sodium glucosulfone, injection but more generally known as glucosulfone, which bears US NIH Compound Identifier 3481. European Medicines Agency schedules Glucosulfone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07939MIG. The term GLUCOSULFONE is an International Non-Proprietary Name. GLUCOSULFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(O)C(NC1CCC(S(=O)(=O)C2CCC(NC(S(=O)(=O)O)C(O)C(O)C(O)C(O)CO)CC2)CC1)C(O)C(O)C(O)C(O)CO.
This classification denotes a sulfone anti-infective agent with the molecular formula C24H34N2O18S3.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I6RLN7D44F, chemically known as sodium glucosulfone, injection but more generally known as glucosulfone, which bears US NIH Compound Identifier 3481. European Medicines Agency schedules Glucosulfone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07939MIG. The term GLUCOSULFONE is an International Non-Proprietary Name. GLUCOSULFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glucosulfone sodium under HS 29309085. As of Q4 2014, GLUCOSULFONE SODIUM remains the US FDA Preferred Term for this commodity. Glucosulfone sodium bears US NLM identifiers UMLS ID C0301338 and NCI Concept Code C87219. SMILES: C1CC(CCC1NC([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)S(=O)(=O)[O-])S(=O)(=O)C2CCC(CC2)NC([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)S(=O)(=O)[O-].[NA+].[NA+].
This classification denotes an anti-lipidemic agent with the molecular formula C36H28N6O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C62ZH19B0L, chemically known as 2-deoxy-2-nicotinamido-beta-d-glucopyranose 1,3,4,6-tetranicotinate but generally known as glunicate, which bears US NIH Compound Identifier 71243. European Medicines Agency schedules Glunicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07942MIG. The term GLUNICATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). GLUNICATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glunicate under HS 29349990 and SITC 51579. As of Q4 2014, GLUNICATE remains the US FDA Preferred Term for this commodity. Glunicate bears US NLM identifiers UMLS ID C0061453 and NCI Concept Code C87632. SMILES: O1C(C(OC(=O)c2cccnc2)C(OC(=O)c2cccnc2)C(NC(=O)c2cccnc2)C1OC(=O)c1cccnc1)COC(=O)c1cccnc1.
This classification denotes an industrial aid with the molecular formula C5H8O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3C89M417N, chemically known as 1,5-pentanedione but generally known as glutaral, which bears US NIH Compound Identifier 3485. European Medicines Agency schedules Glutaral in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07943MIG. The term GLUTARAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). GLUTARAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glutaral under HS 29121990 and SITC 51621. As of Q4 2014, GLUTARAL remains the US FDA Preferred Term for this commodity. Glutaral bears US NLM identifiers UMLS ID C0017814 and NCI Concept Code C80930. SMILES: C(CC=O)CC=O.
This classification denotes an industrial aid with the molecular formula C5H8O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3C89M417N, chemically known as 1,5-pentanedione but generally known as glutaral, which bears US NIH Compound Identifier 3485. European Medicines Agency schedules Glutaral in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07943MIG. The term GLUTARAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). GLUTARAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C(CC=O)CC=O.
This classification denotes an antioxidant with the molecular formula C10H17N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GAN16C9B8O, chemically known as glycine, n-(n-l-gamma-glutamyl-l-cysteinyl)- but generally known as glutathione, which bears US NIH Compound Identifier 745. European Medicines Agency schedules Glutathione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13990MIG. World Health Organization schedules glutathione in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, GLUTATHIONE remains the US FDA Preferred Term for this commodity. Glutathione bears US NLM identifiers UMLS ID C0017817 and NCI Concept Code C523. SMILES: C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N.
This classification denotes a sedative and hypnotic with the molecular formula C13H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8I4BVN78E, chemically known as 2,6-piperidinedione, 3-(4-aminophenyl)-3-ethyl- but generally known as glutethimide, which bears US NIH Compound Identifier 2145. European Medicines Agency schedules Glutethimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07945MIG. The term GLUTETHIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules glutethimide in its Anatomical Therapeutic Chemical (ATC) Classification. GLUTETHIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glutethimide under HS 29251200 and SITC 51482. As of Q4 2014, GLUTETHIMIDE remains the US FDA Preferred Term for this commodity. Glutethimide bears US NLM identifiers UMLS ID C0017845 and NCI Concept Code C65807. SMILES: O=C1NC(=O)CCC1(CC)C1CCC(N)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes an anti-diabetic agent with the molecular formula C12H16N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 35421N8E8W, chemically known as sulfanilamide, n(sup 1)-(5-tert-butyl-1,3,4-thiadiazol-2-yl)- but more generally known as glybuthiazol, which bears US NIH Compound Identifier 10811. European Medicines Agency schedules Glybuthiazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07946MIG. The term GLYBUTHIAZOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). GLYBUTHIAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glybuthiazol under HS 29350090 and SITC 51580. As of Q4 2014, GLYBUTHIAZOL remains US FDA's Preferred Term for this commodity. Glybuthiazol bears US NLM identifiers UMLS ID C2348868 and NCI Concept Code C72803. SMILES: CC(C)(C)C1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a laxative with the molecular formula C3H8O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PDC6A3C0OX, chemically known as 1,2,3-trihydroxypropanol but generally known as glycerine, which bears US NIH Compound Identifier 753. European Medicines Agency schedules Glycerine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22395. SMILES: OC(CO)CO.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN503. This VA Drug Class (TN503) classifies this compound as belonging to the group AMINO ACIDS/PROTEINS, ORAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT900. This VA Drug Class (NT900) classifies this compound as belonging to the group NASAL AND THROAT, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G59M7S0WS3. European Medicines Agency schedules Glonoinum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB49804. Nitroglycerin generally arises in the molecular formula C3H5N3O9. The term 'nitroglycerin' is a United States Homeopathic Pharmacopoeia Name designation. SMILES: O([N](=O)O)C(CO[N](=O)O)CO[N](=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes an antiprotozoal agent with the molecular formula C8H9AsNO5.Bi.O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E3U8347QWJ, chemically known as bismuth, (hydrogen n-glycoloylarsanilato)oxo- (8ci) but generally known as glycobiarsol, which bears US NIH Compound Identifier 16682839. European Medicines Agency schedules Glycobiarsol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07950MIG. The term GLYCOBIARSOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules glycobiarsol in its Anatomical Therapeutic Chemical (ATC) Classification. GLYCOBIARSOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, GLYCOBIARSOL remains the US FDA Preferred Term for this commodity. Glycobiarsol bears US NLM identifiers UMLS ID C0301343 and NCI Concept Code C76421. SMILES: [BI](=O)O[AS](=O)(O)C1CCC(NC(=O)CO)CC1.
This classification denotes an antimuscarinic agent with the molecular formula C19H28NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A14FB57V1D, chemically known as 3-hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate but generally known as glycopyrrolate, which bears US NIH Compound Identifier 3494. European Medicines Agency schedules Glycopyrronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02381MIG. The term GLYCOPYRRONIUM BROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules glycopyrrolate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, GLYCOPYRROLATE remains the US FDA Preferred Term for this commodity. Glycopyrrolate bears US NLM identifiers UMLS ID C0017970 and NCI Concept Code C29078. SMILES: C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.
This classification denotes an antimuscarinic agent with the molecular formula C19H28NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier A14FB57V1D, chemically known as 3-hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate but more generally known as glycopyrrolate, which bears U.S. National Institutes of Health Compound Identifier 3494. The European Medicines Agency schedules Glycopyrronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02381MIG. The term GLYCOPYRRONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules glycopyrrolate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.
This classification denotes an anti-diabetic agent with the molecular formula C13H14N3O4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QPY3C057X1, chemically known as benzenesulfonamide, n-(5-(2-methoxyethoxy)-2-pyrimidinyl)-, sodium salt but more generally known as glymidine sodium, which bears US NIH Compound Identifier 18956. European Medicines Agency schedules Glymidine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07954MIG. The term GLYMIDINE SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). Most nations, for tariff and trade purposes, schedule glymidine sodium under HS 29350090. As of Q4 2014, GLYMIDINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: COCCOC1CNC(NC1)[N-]S(=O)(=O)C2CCCCC2.[NA+].
This classification denotes an anti-diabetic agent with the molecular formula C13H18ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) ORE084U8IP, chemically known as urea, 1-((p-chlorophenyl)sulfonyl)-3-(hexahydro-1h-azepin-1-yl)- but more generally known as glypinamide, which bears US NIH Compound Identifier 219111. European Medicines Agency schedules Glypinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07956MIG. The term GLYPINAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). GLYPINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glypinamide under HS 29350090 and SITC 51580. As of Q4 2014, GLYPINAMIDE remains US FDA's Preferred Term for this commodity. Glypinamide bears US NLM identifiers UMLS ID C1880993 and NCI Concept Code C65811. SMILES: CLC1CCC(S(=O)(=O)NC(=O)NN2CCCCCC2)CC1.
This classification denotes an anti-diabetic agent with the molecular formula C11H14N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1804FJN4MO, chemically known as 4-amino-n-(5-(1-methylethyl)-1,3,4-thiadiazol-2-yl)benzenesulfonamide but more generally known as glyprothiazol, which bears US NIH Compound Identifier 66458. European Medicines Agency schedules Glyprothiazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07957MIG. The term GLYPROTHIAZOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). GLYPROTHIAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glyprothiazol under HS 29350090 and SITC 51580. As of Q4 2014, GLYPROTHIAZOL remains US FDA's Preferred Term for this commodity. Glyprothiazol bears US NLM identifiers UMLS ID C1880994 and NCI Concept Code C65812. SMILES: CC(C)C1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N.
A tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients.
This classification denotes a gnrh1 gene with the molecular formula C55H75N17O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9O7312W37G, chemically known as gonadotropin, luteinizing hormone-releasing hormone, synthetic but generally known as gonadorelin, which bears US NIH Compound Identifier 36523. European Medicines Agency schedules Gonadorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07960MIG. The term GONADORELIN is an International Non-Proprietary Name. World Health Organization schedules gonadorelin in its Anatomical Therapeutic Chemical (ATC) Classification. GONADORELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gonadorelin under HS 29371900 and SITC 54154. As of Q4 2014, GONADORELIN remains the US FDA Preferred Term for this commodity. SMILES: O=C(N1C(CCC1)C(=O)NCC(=O)N)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1[NH]CNC1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)CC(C)C)CCC/N=C(/N)N.
This classification denotes a gonadotropin-releasing hormone analog with the molecular formula C59H84N18O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0F65R8P09N, chemically known as luteinizing hormone-releasing factor (pig), 6-(o-(1,1-dimethylethyl)-d-serine)-10-deglycinamide-, 2-(aminocarbonyl)hydrazide but generally known as goserelin, which bears US NIH Compound Identifier 47725. European Medicines Agency schedules Goserelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07962MIG. The term GOSERELIN is an International Non-Proprietary Name. World Health Organization schedules goserelin in its Anatomical Therapeutic Chemical (ATC) Classification. GOSERELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule goserelin under HS 29371900 and SITC 54154. As of Q4 2014, GOSERELIN remains the US FDA Preferred Term for this commodity. Goserelin bears US NLM identifiers UMLS ID C0120107 and NCI Concept Code C1374. SMILES: O=C(N1C(CCC1)C(=O)NNC(=O)N)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1[NH]CNC1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)COC(C)(C)C)CC(C)C)CCC/N=C(/N)N.
Goserelin is a medication which is used to suppress production of the sex hormones, particularly in the treatment of breast and prostate cancer.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7M867G6T1U, although the US FDA Substance Registration System (SRS) identifies several varieties and preparations under UNIIs J02K2IV2PB, 8MXU1P42J0, and 6810070TYD, the source product of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29612 Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Apiaceae, Genus Centella L., Species Centella asiatica, more commonly known as GOTU KOLA. Gotu kola bears the USDA PLANTS Database Identifiers CEAS and CEER2. European Medicines Agency schedules gotu kola in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13285MIG, SUB13286MIG, SUB34889, SUB44727, SUB44728, SUB44729, and SUB44730. SMILES: NONE.
This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5IE62321P4. European Medicines Agency schedules Gramicidin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02403MIG. Gramicidin generally arises in the molecular formula C60H92N12O10. The term GRAMICIDIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 26, no. 10 1972, list 12.) GRAMICIDIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(C)CC(C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CC(C)C)C(=O)NC(CC7=CNC8=CC=CC=C87)C(=O)NCCO)NC(=O)C(C)NC(=O)CNC(=O)C(C(C)C)NC=O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP219. This VA Drug Class (OP219) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL OPHTHALMIC, OTHER.
This classification denotes a 5-ht3 receptor antagonist with the molecular formula C18H24N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WZG3J2MCOL, chemically known as 1h-indazole-3-carboxamide, 1-methyl-n-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo- but generally known as granisetron, which bears US NIH Compound Identifier 3510. European Medicines Agency schedules Granisetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07964MIG. The term GRANISETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules granisetron in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule granisetron under HS 29399900 and SITC 54149. As of Q4 2014, GRANISETRON remains the US FDA Preferred Term for this commodity. Granisetron bears US NLM identifiers UMLS ID C0061863 and NCI Concept Code C62031. SMILES: O=C(NC1CC2N(C(C1)CCC2)C)C1NN(C2C1CCCC2)C.
This classification denotes a quinolone antibiotic with the molecular formula C19H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L1M1U2HC31, chemically known as 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo- but generally known as grepafloxacin, which bears US NIH Compound Identifier 72474. European Medicines Agency schedules Grepafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07965MIG. The term GREPAFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules grepafloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule grepafloxacin under HS 29335995 and SITC 51576. As of Q4 2014, GREPAFLOXACIN remains the US FDA Preferred Term for this commodity. Grepafloxacin bears US NLM identifiers UMLS ID C0287721 and NCI Concept Code C65817. SMILES: FC1C(N2CC(NCC2)C)CC2N(C3CC3)CC(C(=O)C2C1C)C(=O)O.
This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32HRV3E3D5. European Medicines Agency schedules Griseofulvin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07966MIG. Griseofulvin generally arises in the molecular formula C17H17CLO6. The term GRISEOFULVIN is an International Non-Proprietary Name or INN. GRISEOFULVIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule griseofulvin under HS 29419000 and SITC 54139. As of Q4 2014, GRISEOFULVIN remains the US FDA Preferred Term for this commodity. Griseofulvin bears US NLM identifiers UMLS ID C0018242 and NCI Concept Code C65819. SMILES: CLC1C2OC3(C(CC(=O)C=C3OC)C)C(=O)C2C(OC)CC1OC.
This classification denotes a cardiotonic agent and enzyme inhibitor with the molecular formula C29H44O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ACL011P69, chemically known as 3-((6-deoxyhexopyranosyl)oxy)-1,5,11,14,19-pentahydroxycard-20(22)-enolide but generally known as g-strophanthin, which bears US NIH Compound Identifier 4605. World Health Organization schedules g-strophanthin in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CC1C(C(C(C(O1)OC2CC(C3(C4C(CCC3(C2)O)C5(CCC(C5(CC4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O.
This classification denotes an antihypertensive agent with the molecular formula C10H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SAW16W26X6, chemically known as (1,4-benzodioxan-6-ylmethyl)guanidine but generally known as guabenxan, which bears US NIH Compound Identifier 28563. European Medicines Agency schedules Guabenxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07967MIG. The term GUABENXAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). GUABENXAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guabenxan under HS 29329985 and SITC 51569. As of Q4 2014, GUABENXAN remains the US FDA Preferred Term for this commodity. Guabenxan bears US NLM identifiers UMLS ID C0617438 and NCI Concept Code C65820. SMILES: C1COC2=C(O1)C=CC(=C2)CN=C(N)N.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T6EKB9V2O2, chemically known as benzoic acid, 2-(acetyloxy)-, 2-methoxyphenyl ester but generally known as guacetisal, which bears US NIH Compound Identifier 68749. European Medicines Agency schedules Guacetisal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07968MIG. The term GUACETISAL is an International Non-Proprietary Name. World Health Organization schedules guacetisal in its Anatomical Therapeutic Chemical (ATC) Classification. GUACETISAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guacetisal under HS 29182200 and SITC 51393. As of Q4 2014, GUACETISAL remains the US FDA Preferred Term for this commodity. Guacetisal bears US NLM identifiers UMLS ID C0120436 and NCI Concept Code C65821. SMILES: O(C1C(OC)CCCC1)C(=O)C1C(OC(=O)C)CCCC1.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L68QKU1H9U. European Medicines Agency schedules Guafecainol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07969MIG. Guafecainol generally arises in the molecular formula C16H27NO4. The term GUAFECAINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, no 10 1978, list 18.) GUAFECAINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule guafecainol under HS 29221980 and SITC 51461. As of Q4 2014, GUAFECAINOL remains US FDA's Preferred Term for this commodity. Guafecainol bears US NLM identifiers UMLS ID C2827163 and NCI Concept Code C83738. SMILES: O(CCN(CC)CC)CC(O)COC1C(OC)CCCC1.
This classification denotes an anti-infective agent and expectorant with the molecular formula C7H8O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6JKA7MAH9C, chemically known as phenol, o-methoxy- but more generally known as guaiacol, which bears US NIH Compound Identifier 460. European Medicines Agency schedules Guaiacol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14027MIG. Most nations, for tariff and trade purposes, schedule guaiacol under HS 29095000 and SITC 51617. As of Q4 2014, GUAIACOL remains US FDA's Preferred Term for this commodity. Guaiacol bears US NLM identifiers UMLS ID C0018304 and NCI Concept Code C76663. SMILES: O(C1C(O)CCCC1)C.
This classification denotes a topical anti-infective agent and expectorant with the molecular formula C9H10O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5YN7743HC, chemically known as phenol, 2-methoxy-, 1-acetate, but more generally known as guaiacol acetate, which bears US NIH Compound Identifier 61155. European Medicines Agency schedules guaiacol acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14027MIG. Most nations, for tariff purposes, schedule guaiacol acetate under HS 29095000. SMILES: CC(=O)OC1CCCCC1OC.
This classification denotes a topical anti-infective agent and expectorant with the molecular formula C14H12O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ODW913ZA6P, chemically known as phenol, 2-methoxy-, 1-benzoate, but more generally known as guaiacol benzoate, which bears US NIH Compound Identifier 68272. European Medicines Agency schedules guaiacol benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14027MIG. Most nations, for tariff purposes, schedule guaiacol benzoate under HS 29095000. SMILES: COC1CCCCC1OC(=O)C2CCCCC2.
This classification denotes a topical anti-infective agent and expectorant with the molecular formula C11H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48936E6FTM, chemically known as butanoic acid, 2-methoxyphenyl ester but more generally known as guaiacol butyrate, which bears US NIH Compound Identifier 77756. Most nations, for tariff and trade purposes, schedule guaiacol butyrate under HS 29095000. As of Q4 2014, GUAIACOL BUTYRATE remains US FDA's Preferred Term for this commodity. SMILES: CCCC(=O)OC1CCCCC1OC.
This classification denotes an expectorant with the molecular formula C15H14O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q71XPQ6R29, chemically known as phenol, 2-methoxy-, carbonate (2:1) (9ci) but more generally known as guaiacol carbonate, which bears US NIH Compound Identifier 11104. European Medicines Agency schedules Guaiacol carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14028MIG. Most nations, for tariff and trade purposes, schedule guaiacol carbonate under HS 29095000 and SITC 51617. As of Q4 2014, GUAIACOL CARBONATE remains US FDA's Preferred Term for this commodity. Guaiacol carbonate bears US NLM identifiers UMLS ID C0771805 and NCI Concept Code C76056. SMILES: COC1CCCCC1OC(=O)OC2CCCCC2OC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a topical anti-infective agent and expectorant with the molecular formula C13H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NL78157RR. Most nations, for tariff and trade purposes, schedule guaiacol nicotinate under HS 29095000 and SITC 51617. As of Q4 2014, GUAIACOL NICOTINATE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCCCC1OC(=O)C2CCCNC2.
This classification denotes a topical anti-infective agent and expectorant with the molecular formula C15H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LLO759386W, chemically known as acetic acid, phenyl-, o-methoxyphenyl ester, but more generally known as guaiacol phenylacetate, which bears US NIH Compound Identifier 61331. European Medicines Agency schedules guaiacol phenylacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14027MIG. Most nations, for tariff purposes, schedule guaiacol phenylacetate under HS 29095000. SMILES: COC1CCCCC1OC(=O)CC2CCCCC2.
This classification denotes a topical anti-infective agent and expectorant with the molecular formula C21H21O7P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56492O1F0U, chemically known as phenol, 2-methoxy-, phosphate (3:1), but more generally known as guaiacol phosphate, which bears US NIH Compound Identifier 68420. European Medicines Agency schedules guaiacol phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14027MIG. Most nations, for tariff purposes, schedule guaiacol phosphate under HS 29095000. SMILES: COC1CCCCC1OP(=O)(OC2CCCCC2OC)OC3CCCCC3OC.
This classification denotes a topical anti-infective agent and expectorant with the molecular formula C10H12O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z7SCO70Q61. Most nations, for tariff and trade purposes, schedule guaiacol propionate under HS 29095000. As of Q4 2014, GUAIACOL PROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)OC1CCCCC1OC.
This classification denotes an antitussive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 713AJ00NPG. European Medicines Agency schedules Sulfogaiacol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10740MIG. Sulfogaiacol generally arises in the molecular formula C7H8O5S.K. The term SULFOGAIACOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, no. 3 1962, list 4.) SULFOGAIACOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C1=CC=C(C(=C1)OCO)S(=O)(=O)[O-].[K+].
This classification denotes an expectorant with the molecular formula C11H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G9J54386JH, chemically known as 1,2-propanediol, 3-(o-ethoxyphenoxy)- but more generally known as guaietolin, which bears US NIH Compound Identifier 68825. European Medicines Agency schedules Guaietolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07972MIG. The term GUAIETOLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). GUAIETOLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule guaietolin under HS 29094990 and SITC 51617. As of Q4 2014, GUAIETOLIN remains US FDA's Preferred Term for this commodity. Guaietolin bears US NLM identifiers UMLS ID C0771575 and NCI Concept Code C83739. SMILES: CCOC1=CC=CC=C1OCC(CO)O.
This classification denotes an expectorant with the molecular formula C10H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears US NIH Compound Identifier 3516. European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG. The term GUAIFENESIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules guaifenesin in its Anatomical Therapeutic Chemical (ATC) Classification. GUAIFENESIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule guaifenesin under HS 29094990 and SITC 51617. As of Q4 2014, GUAIFENESIN remains US FDA's Preferred Term for this commodity. Guaifenesin bears US NLM identifiers UMLS ID C0018305 and NCI Concept Code C29081. SMILES: COC1=CC=CC=C1OCC(CO)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a tetracycline antibiotic with the molecular formula C29H38N8O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 4NQR4R6G3S chemically known as n-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide but generally known as guamecycline, which bears US NIH Compound Identifier 5464311. European Medicines Agency schedules Guamecycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07977MIG. The term GUAMECYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10. ). Most nations schedule guamecycline under HS 29413000 and SITC 54133. As of Q4 2014, GUAMECYCLINE remains the US FDA Preferred Term for this commodity. Guamecycline bears US NLM identifiers UMLS ID C0061935 and NCI Concept Code C90947. SMILES: CC1(C2CC3C(C(=O)/C(=C(\NCN4CCN(CC4)C(=N)N=C(N)N)/O)/C(=O)C3(C(=O)C2=C(C5=C1C=CC=C5O)O)O)N(C)C)O.
This classification denotes a tetracycline antibiotic with the molecular formula C29H38N8O8.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DL609MM5I8, chemically known as 2-naphthacenecarboxamide, n-((4-(((aminoiminomethyl)amino)iminomethyl)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride (1:2), (4s,4as,5as,6s,12as)-, but more generally known as guamecycline dihydrochloride, which bears US NIH Compound Identifier 5464418. European Medicines Agency schedules guamecycline dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07977MIG. Most nations, for tariff purposes, schedule guamecycline dihydrochloride under HS 29413000. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)NCN5CCN(CC5)C(=N)NC(=N)N)O)N(C)C)O)O)O)O.CL.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H8Cl2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GGD30112WC, chemically known as (2,6-dichlorophenyl)methylideneaminoiminomethanediamine but generally known as guanabenz, which bears US NIH Compound Identifier 3517. European Medicines Agency schedules Guanabenz in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07978MIG. GUANABENZ is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanabenz under HS 29280090 and SITC 51486. As of Q4 2014, GUANABENZ remains the US FDA Preferred Term for this commodity. Guanabenz bears US NLM identifiers UMLS ID C0018312 and NCI Concept Code C83740. SMILES: Clc1c(c(Cl)ccc1)/C=N/N=C(/N)N.
This classification denotes an antihypertensive agent with the molecular formula C8H8Cl2N4.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 443O19GK1A, chemically known as (2,6-dichlorophenyl)methylideneaminoiminomethanediamine but more generally known as guanabenz acetate, which bears US NIH Compound Identifier 3517. European Medicines Agency schedules Guanabenz acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02423MIG. Most nations, for tariff and trade purposes, schedule guanabenz acetate under HS 29280090 and SITC 51486. As of Q4 2014, GUANABENZ ACETATE remains US FDA's Preferred Term for this commodity. Guanabenz acetate bears US NLM identifiers UMLS ID C0733381 and NCI Concept Code C65826. SMILES: CC(=O)O.C1CC(C(C(C1)CL)/C=N/NC(=N)N)CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H8Cl2N4.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 443O19GK1A, chemically known as hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)-, monoacetate, but more generally known as guanabenz monoacetate, which bears US NIH Compound Identifier 9570374. European Medicines Agency schedules guanabenz monoacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07978MIG. Most nations, for tariff purposes, schedule guanabenz monoacetate under HS 29280090. SMILES: CC(=O)O.C1CC(C(C(C1)CL)/C=N/NC(=N)N)CL.
This classification denotes an antihypertensive agent with the molecular formula C10H19N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 765C9332T4, chemically known as (1,4-dioxaspiro(4.5)dec-2-ylmethyl)guanidine but generally known as guanadrel, which bears US NIH Compound Identifier 38521. European Medicines Agency schedules Guanadrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07980MIG. The term GUANADREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). GUANADREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanadrel under HS 29329970 and SITC 51569. As of Q4 2014, GUANADREL remains the US FDA Preferred Term for this commodity. Guanadrel bears US NLM identifiers UMLS ID C0061938 and NCI Concept Code C65827. SMILES: C1CCC2(CC1)OCC(O2)CN=C(N)N.
This classification denotes an antihypertensive agent with the molecular formula 2C10H19N3O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MT147RMO91, chemically known as (1,4-dioxaspiro(4.5)dec-2-ylmethyl)guanidine but more generally known as guanadrel sulfate, which bears US NIH Compound Identifier 38521. European Medicines Agency schedules Guanadrel sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02424MIG. Most nations, for tariff and trade purposes, schedule guanadrel sulfate under HS 29329970 and SITC 51569. As of Q4 2014, GUANADREL SULFATE remains US FDA's Preferred Term for this commodity. Guanadrel sulfate bears US NLM identifiers UMLS ID C0304525 and NCI Concept Code C65828. SMILES: C1CCC2(CC1)OCC(O2)CNC(=N)N.C1CCC2(CC1)OCC(O2)CNC(=N)N.OS(=O)(=O)O.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C9H20N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7N05KQ38YI, chemically known as guanidine, ((octahydro-2-azocinyl)methyl)- (8ci,9ci) but generally known as guanazodine, which bears US NIH Compound Identifier 36054. European Medicines Agency schedules Guanazodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07981MIG. The term GUANAZODINE is an International Non-Proprietary Name. World Health Organization schedules guanazodine in its Anatomical Therapeutic Chemical (ATC) Classification. GUANAZODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanazodine under HS 29339990 and SITC 51577. As of Q4 2014, GUANAZODINE remains the US FDA Preferred Term for this commodity. Guanazodine bears US NLM identifiers UMLS ID C0061940 and NCI Concept Code C83741. SMILES: N1C(CCCCCC1)C/N=C(/N)N.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H20N4.H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UKI3DAO4S6. The term guanazodine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule guanazodine sulfate under HS 29339990 and SITC 51577. SMILES: C1CCCNC(CC1)CNC(=N)N.OS(=O)(=O)O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H20N4.H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UKI3DAO4S6. The term guanazodine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule guanazodine sulfate monohydrate under HS 29339990. As of Q4 2014, GUANAZODINE SULFATE MONOHYDRATE remains US FDA's Preferred Term for this commodity. Guanazodine sulfate monohydrate bears US NLM identifiers UMLS ID C2827164 and NCI Concept Code C83742. SMILES: C1CCCNC(CC1)CNC(=N)N.O.OS(=O)(=O)O.
This classification denotes an antihypertensive agent with the molecular formula C9H12CL2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9D89762N7C chemically known as (2-(2,6-dichloroanilino)ethyl)guanidine but generally known as guanclofine, which bears US NIH Compound Identifier 68754. European Medicines Agency schedules Guanclofine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07983MIG. The term GUANCLOFINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16. ). Most nations schedule guanclofine under HS 29252900 and SITC 51482. As of Q4 2014, GUANCLOFINE remains the US FDA Preferred Term for this commodity. Guanclofine bears US NLM identifiers UMLS ID C0061941 and NCI Concept Code C65829. SMILES: C1=CC(=C(C(=C1)Cl)NCCN=C(N)N)Cl.
This classification denotes an antihypertensive agent with the molecular formula C10H22N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTI6C33Q2Q, chemically known as 2-(1-n,n-heptamethyleneimino)ethylguanidine but generally known as guanethidine, which bears US NIH Compound Identifier 3518. European Medicines Agency schedules Guanethidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07984MIG. The term GUANETHIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules guanethidine in its Anatomical Therapeutic Chemical (ATC) Classification. GUANETHIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanethidine under HS 29339990 and SITC 51577. As of Q4 2014, GUANETHIDINE remains the US FDA Preferred Term for this commodity. Guanethidine bears US NLM identifiers UMLS ID C0018318 and NCI Concept Code C65830. SMILES: C1CCCN(CCC1)CCN=C(N)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an antihypertensive agent with the molecular structure C10H22N4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5UBY8Y002G chemically known as guanidine, (2-(hexahydro-1(2h)-azocinyl)ethyl)-, sulfate (1:1), but more commonly known as guanethidine monosulfate, which bears US NIH Compound Identifier 3518. European Medicines Agency schedules Guanethidine monosulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14033MIG. Most nations, for tariff and trade purposes, schedule guanethidine monosulfate under HS 29339990 and SITC 51577. As of Q4 2014, GUANETHIDINE MONOSULFATE remains US FDA's Preferred Term for this commodity. Guanethidine monosulfate bears US NLM identifiers UMLS ID C0282190 and NCI Concept Code C65831. SMILES: C1CCCN(CCC1)CCNC(=N)N.OS(=O)(=O)O.
This classification denotes an antihypertensive agent with the molecular formula 2C10H22N4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8AQ60474G9, chemically known as 2-(1-n,n-heptamethyleneimino)ethylguanidine but more generally known as guanethidine sulfate, which bears US NIH Compound Identifier 3518. European Medicines Agency schedules Guanethidine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02426MIG. Most nations, for tariff and trade purposes, schedule guanethidine sulfate under HS 29339990 and SITC 51577. As of Q4 2014, GUANETHIDINE SULFATE remains US FDA's Preferred Term for this commodity. Guanethidine sulfate bears US NLM identifiers UMLS ID C0700538 and NCI Concept Code C80000. SMILES: C1CCCN(CCC1)CCNC(=N)N.C1CCCN(CCC1)CCNC(=N)N.OS(=O)(=O)O.
This classification denotes an antihypertensive agent and alpha-adrenergic agonist with the molecular formula C9H9Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30OMY4G3MK, chemically known as n-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide but generally known as guanfacine, which bears US NIH Compound Identifier 3519. European Medicines Agency schedules Guanfacine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07985MIG. The term GUANFACINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules guanfacine in its Anatomical Therapeutic Chemical (ATC) Classification. GUANFACINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanfacine under HS 29252900 and SITC 51482. As of Q4 2014, GUANFACINE remains the US FDA Preferred Term for this commodity. Guanfacine bears US NLM identifiers UMLS ID C0079466 and NCI Concept Code C61779. SMILES: CLC1C(CC(=O)/N=C(/N)N)C(CL)CCC1.
This classification denotes an antihypertensive agent and alpha-adrenergic agonist with the molecular formula C9H9Cl2N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PML56A160O, chemically known as n-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide but more generally known as guanfacine hydrochloride, which bears US NIH Compound Identifier 3519. European Medicines Agency schedules Guanfacine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02427MIG. Most nations, for tariff and trade purposes, schedule guanfacine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, GUANFACINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Guanfacine hydrochloride bears US NLM identifiers UMLS ID C0700472 and NCI Concept Code C47550. SMILES: C1CC(C(C(C1)CL)CC(=O)NC(=N)N)CL.CL.
This classification denotes a natural amine with the molecular formula CH5N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JU58VJ6Y3B, chemically known as 594-14-9 (sulfate, 2:1) but generally known as guanidine, which bears US NIH Compound Identifier 3520. European Medicines Agency schedules Guanidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14034MIG. Most nations schedule guanidine under HS 29252900 and SITC 51482. As of Q4 2014, GUANIDINE remains the US FDA Preferred Term for this commodity. Guanidine bears US NLM identifiers UMLS ID C0120446 and NCI Concept Code C77851. SMILES: NC(=N)N.
This classification denotes an antihypertensive agent with the molecular formula C9H12Cl2N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4HBT852YO, chemically known as 2-(2,6-dichlorophenoxy)ethylaminoguanidine sulfate but generally known as guanoclor, which bears US NIH Compound Identifier 71835. European Medicines Agency schedules Guanoclor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07987MIG. World Health Organization schedules guanoclor in its Anatomical Therapeutic Chemical (ATC) Classification. GUANOCLOR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanoclor under HS 29280090 and SITC 51486. As of Q4 2014, GUANOCLOR remains the US FDA Preferred Term for this commodity. Guanoclor bears US NLM identifiers UMLS ID C0061964 and NCI Concept Code C65833. SMILES: Clc1c(OCCN/N=C(/N)N)c(Cl)ccc1.
This classification denotes an antihypertensive agent with the molecular formula 2C9H12Cl2N4O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q1U97XK18R, chemically known as 2-(2,6-dichlorophenoxy)ethylaminoguanidine sulfate but more generally known as guanoclor sulfate, which bears US NIH Compound Identifier 71835. European Medicines Agency schedules Guanoclor sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14036MIG. Most nations, for tariff and trade purposes, schedule guanoclor sulfate under HS 29280090 and SITC 51486. As of Q4 2014, GUANOCLOR SULFATE remains US FDA's Preferred Term for this commodity. Guanoclor sulfate bears US NLM identifiers UMLS ID C1881016 and NCI Concept Code C65834. SMILES: C1CC(C(C(C1)CL)OCCNNC(=N)N)CL.C1CC(C(C(C1)CL)OCCNNC(=N)N)CL.OS(=O)(=O)O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H8Cl2N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P9HIK5V7WK, chemically known as 1-((2,6-dichlorobenzylidene)amino)-3-hydroxyguanidine but generally known as guanoxabenz, which bears US NIH Compound Identifier 9567831. European Medicines Agency schedules Guanoxabenz in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14038MIG. The term GUANOXABENZ is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules guanoxabenz in its Anatomical Therapeutic Chemical (ATC) Classification. GUANOXABENZ is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanoxabenz under HS 29280090 and SITC 51486. As of Q4 2014, GUANOXABENZ remains the US FDA Preferred Term for this commodity. Guanoxabenz bears US NLM identifiers UMLS ID C0061990 and NCI Concept Code C77298. SMILES: CLC1C(C(CL)CCC1)/C=N/N=C(/NO)N.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H8Cl2N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ASL1V61E48, chemically known as hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)-n-hydroxy-, hydrochloride (1:1), but more generally known as guanoxabenz hydrochloride, which bears US NIH Compound Identifier 17750940. European Medicines Agency schedules guanoxabenz hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14038MIG. Most nations, for tariff purposes, schedule guanoxabenz hydrochloride under HS 29280090. SMILES: C1CC(C(C(C1)CL)/C=N/NC(=N)NO)CL.CL.
This classification denotes a guanidine and antihypertensive agent with the molecular formula C10H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V0MRL0R5Y, chemically known as guanidine, ((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)- (9ci) but generally known as guanoxan, which bears US NIH Compound Identifier 16564. European Medicines Agency schedules Guanoxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07989MIG. World Health Organization schedules guanoxan in its Anatomical Therapeutic Chemical (ATC) Classification. GUANOXAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanoxan under HS 29329985 and SITC 51569. As of Q4 2014, GUANOXAN remains the US FDA Preferred Term for this commodity. SMILES: C1C(OC2=CC=CC=C2O1)CN=C(N)N.
This classification denotes a guanidine and antihypertensive agent 2C10H13N3O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N6IT80R85G, chemically known as (1,4-benzodioxan-2-yl-methyl)guanidine sulfate (2:1), but more generally known as guanoxan sulfate, which bears US NIH Compound Identifier 21942. European Medicines Agency schedules Guanoxan sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02432MIG. Most nations, for tariff and trade purposes, schedule guanoxan sulfate under HS 29329985 and SITC 51569. As of Q4 2014, GUANOXAN SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)OCC(O2)CNC(=N)N.C1CCC2C(C1)OCC(O2)CNC(=N)N.OS(=O)(=O)O.
This classification denotes an antihypertensive agent with the molecular formula C10H15N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 03HN50ZAF0 chemically known as cn-34,799-5a but generally known as guanoxyfen, which bears US NIH Compound Identifier 6332517. European Medicines Agency schedules Guanoxyfen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07990MIG. The term GUANOXYFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7. ). Most nations schedule guanoxyfen under HS 29252900 and SITC 51482. As of Q4 2014, GUANOXYFEN remains the US FDA Preferred Term for this commodity. Guanoxyfen bears US NLM identifiers UMLS ID C1881017 and NCI Concept Code C65835. SMILES: C1=CC=C(C=C1)OCCCN=C(N)N.[N+](=O)(O)O.
This classification denotes an antihypertensive agent with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34969JX79R, chemically known as (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione, which bears US NIH Compound Identifier 6439929. As of Q4 2014, GUGGULSTERONE remains the US FDA Preferred Term for this commodity. SMILES: CC=C1C(=O)CC2C1(CCC3C2CCC4=CC(=O)CCC34C)C.
This clasification denotes vaccines or candidate vaccines used to prevent or treat infection a species of avibirnavirus causing severe inflammation of the bursa of Fabricius in chickens and other fowl, sometimes called infectious bursal disease virus. Transmission is thought to be through contaminated feed or water.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers C08B09D8UJ (whole) and AOK8NJ16UX (leaf), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 37451 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Asterales, Family Asteraceae (sunflowers, tournesols), Genus Grindelia Willd., commonly known as GUMWEED or as here, GUMPLANT. Grindelia hirsutula bears the USDA PLANTS Database Identifier GRHI. European Medicines Agency schedules grindelia in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14025MIG. SMILES: NONE.
This classification denotes an immunosuppressant with the molecular formula C17H37N7O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJ0ZJ76DO9, chemically known as spergualin, 15-deoxy but generally known as gusperimus, which bears US NIH Compound Identifier 55362. European Medicines Agency schedules Gusperimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07991MIG. World Health Organization schedules gusperimus in its Anatomical Therapeutic Chemical (ATC) Classification. GUSPERIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gusperimus under HS 29252900 and SITC 51482. As of Q4 2014, GUSPERIMUS remains the US FDA Preferred Term for this commodity. SMILES: OC(NC(=O)CCCCCC/N=C(/N)N)C(=O)NCCCCNCCCN.
This classification denotes a vaccine for a species of haemophilus found on the mucous membranes of humans and a variety of animals, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LUY6P8763W. The US Centers for Disease Control recognizes this preparation under Concept Code 51 and CDC Code System OID 2.16.840.1.113883.12.292.
This classification denotes a vaccine for a) a species of haemophilus found on the mucous membranes of humans and a variety of animals; b) A localized infection of mucous membranes or skin caused by toxigenic strains of corynebacterium diphtheriae; A disease caused by tetanospasmin, a powerful protein toxin produced by clostridium tetani; and d) A respiratory infection caused by bordetella pertussis.
This classification denotes a vaccine for a) a species of haemophilus found on the mucous membranes of humans and a variety of animals; b) A localized infection of mucous membranes or skin caused by toxigenic strains of corynebacterium diphtheriae; A disease caused by tetanospasmin, a powerful protein toxin produced by clostridium tetani; and d) A respiratory infection caused by bordetella pertussis.
This classification denotes a benzodiazepine with the molecular formula C17H12ClF3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 320YC168LF, chemically known as 7-chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2h-1,4-benzodiazepin-2-one but generally known as halazepam, which bears US NIH Compound Identifier 31640. European Medicines Agency schedules Halazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07992MIG. The term HALAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules halazepam in its Anatomical Therapeutic Chemical (ATC) Classification. HALAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halazepam under HS 29339190 and SITC 51577. As of Q4 2014, HALAZEPAM remains the US FDA Preferred Term for this commodity. Halazepam bears US NLM identifiers UMLS ID C0062092 and NCI Concept Code C61780. SMILES: CLC1CC2C(N(CC(F)(F)F)C(=O)CN=C2C2CCCCC2)CC1.
This classification denotes an anti-infective agent with the molecular formula C7H5Cl2NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G359OL82VB, chemically known as 4-(n,n-dichlorosulfamoyl)benzoic acid but generally known as halazone, which bears US NIH Compound Identifier 3552. European Medicines Agency schedules Halazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07993MIG. The term HALAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). HALAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halazone under HS 29350090 and SITC 51580. As of Q4 2014, HALAZONE remains the US FDA Preferred Term for this commodity. Halazone bears US NLM identifiers UMLS ID C0164814 and NCI Concept Code C73153. SMILES: CLN(CL)S(=O)(=O)C1CCC(CC1)C(=O)O.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SI86V6QNEG. European Medicines Agency schedules Halcinonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07994MIG. Halcinonide generally arises in the molecular formula C24H32CLFO5. The term HALCINONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) HALCINONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halcinonide under HS 29372200 and SITC 54153. As of Q4 2014, HALCINONIDE remains the US FDA Preferred Term for this commodity. Halcinonide bears US NLM identifiers UMLS ID C0733757 and NCI Concept Code C47552. SMILES: CLCC(=O)C12OC(OC2CC2C1(CC(O)C1(F)C2CCC2=CC(=O)CCC12C)C)(C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27ClF2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P6159HM7T, chemically known as 21-chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate but generally known as halobetasol, which bears US NIH Compound Identifier 48175. European Medicines Agency schedules Halobetasol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11379MIG. World Health Organization schedules halobetasol in its Anatomical Therapeutic Chemical (ATC) Classification. Halobetasol or ulobetasol bears US NLM identifiers UMLS ID C0082787 and NCI Concept Code C61781. SMILES: CLCC(=O)C1(OC(=O)CC)C2(C(C3C(F)(C(O)C2)C2(C(=CC(=O)C=C2)C(F)C3)C)CC1C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27ClF2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z9TL048W82, chemically known as 9-chloro-6alpha,11beta-difluoro-21-hydroxy-16alpha-methylpregna-1,4-diene-3,20-dione but generally known as halocortolone, which bears US NIH Compound Identifier 214342. European Medicines Agency schedules Halocortolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07997MIG. The term HALOCORTOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). HALOCORTOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halocortolone under HS 29372200 and SITC 54153. As of Q4 2014, HALOCORTOLONE remains the US FDA Preferred Term for this commodity. Halocortolone bears US NLM identifiers UMLS ID C2828224 and NCI Concept Code C87232. SMILES: CLC12C(C3C(C(C(C3)C)C(=O)CO)(CC1F)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes an antimalarial agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2OS4303HZ. European Medicines Agency schedules Halofantrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07998MIG. Halofantrine generally arises in the molecular formula C26H30CL2F3NO. The term HALOFANTRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) HALOFANTRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halofantrine under HS 29221980 and SITC 51461. As of Q4 2014, HALOFANTRINE remains the US FDA Preferred Term for this commodity. Halofantrine bears US NLM identifiers UMLS ID C0120726 and NCI Concept Code C65838. SMILES: CLC1C2CC(C(O)CCN(CCCC)CCCC)C3C(C2CC(CL)C1)CC(CC3)C(F)(F)F.
This classification denotes a uricosuric agent and anti-lipidemic agent with the molecular formula C19H17ClF3NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9TZK4MNO6, chemically known as (p-chlorophenyl)((alpha,alpha,alpha-trifluoro-m-tolyl)oxy)acetic acid ester with n-(2-hydroxyethyl)acetamide but generally known as halofenate, which bears US NIH Compound Identifier 33584. European Medicines Agency schedules Halofenate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07999MIG. The term HALOFENATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). HALOFENATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halofenate under HS 29242995 and SITC 51479. As of Q4 2014, HALOFENATE remains the US FDA Preferred Term for this commodity. Halofenate bears US NLM identifiers UMLS ID C0018541 and NCI Concept Code C83805. SMILES: CLC1CCC(C(OC2CC(CCC2)C(F)(F)F)C(=O)OCCNC(=O)C)CC1.
This classification denotes an angiogenesis activator inhibitor and alkaloid with the molecular formula C16H17BrClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L31MM1385E, chemically known as 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, trans- but generally known as halofuginone, which bears US NIH Compound Identifier 62891. European Medicines Agency schedules Halofuginone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08000MIG. The term HALOFUGINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). HALOFUGINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halofuginone under HS 29335995 and SITC 51576. As of Q4 2014, HALOFUGINONE remains the US FDA Preferred Term for this commodity. Halofuginone bears US NLM identifiers UMLS ID C0062095 and NCI Concept Code C1120. SMILES: BRC1CC2NCN(CC(=O)CC3NCCCC3O)C(=O)C2CC1CL.
This classification denotes a betamethasone analog, anti-asthmatic agent, anti-inflammatory agent, and glucocorticoid with the molecular formula C22H27ClF2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J69Z9UU41Z, chemically known as 2-chloro-6alpha,9-difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione but generally known as halometasone, which bears US NIH Compound Identifier 39745. European Medicines Agency schedules Halometasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08001MIG. World Health Organization schedules halometasone in its Anatomical Therapeutic Chemical (ATC) Classification. HALOMETASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halometasone under HS 29372200 and SITC 54153. As of Q4 2014, HALOMETASONE remains the US FDA Preferred Term for this commodity. SMILES: CLC1=CC2(C3(F)C(C4C(C(O)(C(C4)C)C(=O)CO)(CC3O)C)CC(F)C2=CC1=O)C.
This classification denotes a betamethasone analog C22H27ClF2O5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PJ4SNG9CS, chemically known as pregna-1,4-diene-3,20-dione, 2-chloro-6,9-difluoro-11,17,21-trihydroxy-16-methyl-, hydrate (1:1), (6.alpha.,11.beta.,16.alpha.)-, but more generally known as halometasone monohydrate, which bears US NIH Compound Identifier 9846332. Most nations, for tariff and trade purposes, schedule halometasone monohydrate under HS 29372200 and SITC 54153. As of Q4 2014, HALOMETASONE MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C(=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)CL)F.O.
This classification denotes an antipsychotic agent with the molecular formula C21H22ClFN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65Q28TV0ZY, chemically known as r 34,301 but generally known as halopemide, which bears US NIH Compound Identifier 65490. European Medicines Agency schedules Halopemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08003MIG. The term HALOPEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). HALOPEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halopemide under HS 29333999 and SITC 51574. As of Q4 2014, HALOPEMIDE remains the US FDA Preferred Term for this commodity. Halopemide bears US NLM identifiers UMLS ID C0062101 and NCI Concept Code C65840. SMILES: CLC1CC2[NH]C(=O)N(C3CCN(CC3)CCNC(=O)C3CCC(F)CC3)C2CC1.
This classification denotes a butyrophenone with the molecular formula C21H23ClFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J6292F8L3D, chemically known as 1-butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as haloperidol, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules Haloperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08005MIG. The term HALOPERIDOL is an International Non-Proprietary Name. World Health Organization schedules haloperidol in its Anatomical Therapeutic Chemical (ATC) Classification. HALOPERIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule haloperidol under HS 29333999 and SITC 51574. As of Q4 2014, HALOPERIDOL remains the US FDA Preferred Term for this commodity. Haloperidol bears US NLM identifiers UMLS ID C0018546 and NCI Concept Code C537. SMILES: CLC1CCC(C2(O)CCN(CC2)CCCC(=O)C2CCC(F)CC2)CC1.
This classification denotes a butyrophenone with the molecular formula C31H41ClFNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AC20PJ4101, chemically known as 1-butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but more generally known as haloperidol decanoate, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules Haloperidol decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02452MIG. Most nations, for tariff and trade purposes, schedule haloperidol decanoate under HS 29333999 and SITC 51574. As of Q4 2014, HALOPERIDOL DECANOATE remains US FDA's Preferred Term for this commodity. Haloperidol decanoate bears US NLM identifiers UMLS ID C0062103 and NCI Concept Code C47998. SMILES: CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2CCC(CC2)F)C3CCC(CC3)CL.
This classification denotes a butyrophenone with the molecular formula C21H23ClFNO2.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6387S86PK3, chemically known as (+/-)-haloperidol lactate, but more generally known as haloperidol intensol, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules haloperidol intensol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08005MIG. Most nations, for tariff purposes, schedule haloperidol intensol under HS 29333999. SMILES: CC(C(=O)O)O.C1CC(CCC1C(=O)CCCN2CCC(CC2)(C3CCC(CC3)CL)O)F.
This classification denotes a dopamine antagonist with the molecular formula C21H23ClFNO2.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6387S86PK3, chemically known as 1-butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but more generally known as haloperidol lactate, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules Haloperidol lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02453MIG. Most nations, for tariff and trade purposes, schedule haloperidol lactate under HS 29333999 and SITC 51574. As of Q4 2014, HALOPERIDOL LACTATE remains US FDA's Preferred Term for this commodity. Haloperidol lactate bears US NLM identifiers UMLS ID C0720809 and NCI Concept Code C78110. SMILES: CC(C(=O)O)O.C1CC(CCC1C(=O)CCCN2CCC(CC2)(C3CCC(CC3)CL)O)F.
This classification denotes a therapeutic progestin with the molecular formula C21H28BrFO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 803BIX5JG5, chemically known as 17-bromo-6alpha-fluoropregn-4-ene-3,20-dione but generally known as haloprogesterone, which bears US NIH Compound Identifier 19056. European Medicines Agency schedules Haloprogesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08007MIG. The term HALOPROGESTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). HALOPROGESTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule haloprogesterone under HS 29372300 and SITC 54153. As of Q4 2014, HALOPROGESTERONE remains the US FDA Preferred Term for this commodity. Haloprogesterone bears US NLM identifiers UMLS ID C2697562 and NCI Concept Code C74367. SMILES: BrC1(C2(C(C3C(C4(C(=CC(=O)CC4)C(F)C3)C)CC2)CC1)C)C(=O)C.
This classification denotes an anti-infective agent with the molecular formula C9H4Cl3IO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AIU7053OWL, chemically known as 2,4,5-trichlorophenyl iodopropargyl ether but generally known as haloprogin, which bears US NIH Compound Identifier 3561. European Medicines Agency schedules Haloprogin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08008MIG. The term HALOPROGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules haloprogin in its Anatomical Therapeutic Chemical (ATC) Classification. HALOPROGIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule haloprogin under HS 29093090 and SITC 51616. As of Q4 2014, HALOPROGIN remains the US FDA Preferred Term for this commodity. Haloprogin bears US NLM identifiers UMLS ID C0720811 and NCI Concept Code C65842. SMILES: IC#CCOC1C(CL)CC(CL)C(CL)C1.
This classification denotes an anesthetic agent with the molecular formula C2HBrClF3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UQT9G45D1P, chemically known as 2,2,2-trifluoro-1-chloro-1-bromoethane but generally known as halothane, which bears US NIH Compound Identifier 3562. European Medicines Agency schedules Halothane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08009MIG. The term HALOTHANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules halothane in its Anatomical Therapeutic Chemical (ATC) Classification. HALOTHANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, HALOTHANE remains the US FDA Preferred Term for this commodity. Halothane bears US NLM identifiers UMLS ID C0018549 and NCI Concept Code C47554. SMILES: BRC(CL)C(F)(F)F.
This classification denotes a benzodiazepine with the molecular formula C17H14BrFN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M448L2V8XP, chemically known as 10-bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one but generally known as haloxazolam, which bears US NIH Compound Identifier 3563. European Medicines Agency schedules Haloxazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08010MIG. The term HALOXAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). HALOXAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule haloxazolam under HS 29349100 and SITC 51579. As of Q4 2014, HALOXAZOLAM remains the US FDA Preferred Term for this commodity. Haloxazolam bears US NLM identifiers UMLS ID C0120735 and NCI Concept Code C83744. SMILES: BRC1CC2C3(OCCN3CC(=O)NC2CC1)C1C(F)CCCC1.
This classification denotes an antihelminthic agent with the molecular formula C14H14Cl3O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T8KXA37068, chemically known as phosphorsaeure-o,o-di-(2-chlorethyl)-o-(3-chlor-4-mehyl-cumarin-7-yl)ester but generally known as haloxon, which bears US NIH Compound Identifier 9454. European Medicines Agency schedules Haloxon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08011MIG. The term HALOXON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). HALOXON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, HALOXON remains the US FDA Preferred Term for this commodity. Haloxon bears US NLM identifiers UMLS ID C0062110 and NCI Concept Code C75220. SMILES: CLC1C(C2C(OC1=O)CC(OP(=O)(OCCCL)OCCCL)CC2)C.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers UDA30A2JJY, IH3063S9MY, NT00Y05A2V, T07U1161SV, T7S323PKJS, V663Q8TEFU, 8FP93ED6H2, and 101I4J0U34, the source of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 19033 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Saxifraganae, Order Saxifragales, Family Hamamelidaceae, Genus Hamamelis L., Species Hamamelis virginiana L., commonly known as WITCH-HAZEL, WITCHHAZEL, AMERICAN WITCHHAZEL, or as here, WITCH HAZEL. Witchhazel bears the USDA PLANTS Database Identifier HAMAM. European Medicines Agency schedules witchhazel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB14059MIG, SUB35391, SUB42157, SUB42158, SUB46553, SUB46554, SUB46555, SUB46556, SUB46557, SUB46558, and SUB47383.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers 3D10KUA6BM (base) and ZP9XFG71A7 (leaf), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29393 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Araliaceae, Genus Hedera L. (ivy). Species Hedera helix L., commonly known as ENGLISH IVY or, as here, HEDERA HELIX. Hedera helix bears the USDA PLANTS Database Identifier HEHE. European Medicines Agency schedules hedera helix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB14067MIG, SUB30390, SUB46559, and SUB55052. Hedera helix bears US NLM identifiers UMLS ID C0331030 and NCI Concept Code C74489. SMILES: NONE.
This classification denotes an antibiotic with the molecular formula C22H16O6, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 7N3A092A5X, chemically known as 2h-benzo(cd)pyrene-2,6(1h)-dione, 3,5,7,10-tetrahydroxy-1,1,9-trimethyl- but more generally known as heliomycin, which bears U.S. National Institutes of Health Compound Identifier 5282060. The European Medicines Agency schedules Heliomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08013MIG. The term HELIOMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). HELIOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C1C(C2C3C4C1C(O)CC(O)C4C(=O)C1C3C(C(O)C2)C(CC1O)C)(C)C.
This classification denotes an iron supplement which generally arises in the molecular form C34H32N4O4.Fe.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0WP180G15G. SMILES: CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C)C)CCC(=O)O)CCC(=O)O.O.[Fe+2].
This classification denotes an iron supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31VDO12CJY. As of Q4 2014, HEME IRON POLYPEPTIDE remains the US FDA Preferred Term for this commodity.
This classification denotes a vaccine for a species of haemophilus found on the mucous membranes of humans and a variety of animals, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2495X8VZXG.
Haemorrhagic septicaemia (HS) vaccine is used for prophylactic measures to control haemorrhagic septicaemia disease caused by Pasteurella multocida infections in cattle, buffaloes, sheep and goats.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS202. This VA Drug Class (RS202) classifies this compound as belonging to the group HEMORRHOIDAL PREPARATIONS WITH STEROID.
This classification denotes a low molecular weight heparin with the molecular formula (C14H18NO11)N.2(C12H16NO13S)N.3HO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7UQ7X4Y489. European Medicines Agency schedules heparin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02475MIG. The term heparin is a U.S. FDA designation. HEPARIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule heparin under HS 30019000 and SITC 54162. As of Q4 2014, HEPARIN remains the US FDA Preferred Term for this commodity. Heparin bears US NLM identifiers UMLS ID C0019134 and NCI Concept Code C539. SMILES: CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class BL110. This VA Drug Class (BL110) classifies this compound as belonging to the group ANTICOAGULANTS.
This classification denotes a vaccine for inflammation of the liver in humans caused by a member of the hepatovirus genus, human hepatitis a virus, and which can be transmitted through fecal contamination of food or water.
This classification denotes a vaccine for inflammation of the liver in humans caused by a member of the orthohepadnavirus genus, hepatitis b virus, which transmits (generally) by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
This classification denotes a barbiturate with the molecular formula C13H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V10R70ML23, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl- (9ci) but generally known as heptabarb, which bears US NIH Compound Identifier 10518. European Medicines Agency schedules Heptabarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08015MIG. The term HEPTABARB is an International Non-Proprietary Name. World Health Organization schedules heptabarb in its Anatomical Therapeutic Chemical (ATC) Classification. HEPTABARB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2.
This classification denotes an antispasmotic agent with the molecular formula C18H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0035H8M4YL, chemically known as n,n-dimethyl-n-(3-(8,9,10-trinorbornan-2-yliden)-3-phenylpropyl)amin but generally known as heptaverine, which bears US NIH Compound Identifier 3038460. European Medicines Agency schedules Heptaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08017MIG. The term HEPTAVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). HEPTAVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule heptaverine under HS 29214980 and SITC 51454. As of Q4 2014, HEPTAVERINE remains the US FDA Preferred Term for this commodity. Heptaverine bears US NLM identifiers UMLS ID C2348955 and NCI Concept Code C73166. SMILES: N(CC/C(=C1/C2CC(CC2)C1)C1CCCCC1)(C)C.
This classification denotes an antidepressant agent with the molecular formula C21H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72FH6333M6, chemically known as 4-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yloxy)-1-methylpiperidine but generally known as hepzidine, which bears US NIH Compound Identifier 70593. European Medicines Agency schedules Hepzidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08019MIG. The term HEPZIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). HEPZIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hepzidine under HS 29333999 and SITC 51574. As of Q4 2014, HEPZIDINE remains the US FDA Preferred Term for this commodity. Hepzidine bears US NLM identifiers UMLS ID C1881039 and NCI Concept Code C65844. SMILES: O(C1CCN(CC1)C)C1c2c(CCc3c1cccc3)cccc2.
This classification denotes a penicillin antibiotic with the molecular formula C19H23N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TN4JSC48CV, chemically known as 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillansaeure but generally known as hetacillin, which bears US NIH Compound Identifier 3596. European Medicines Agency schedules Hetacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08020MIG. The term HETACILLIN is an International Non-Proprietary Name. World Health Organization schedules hetacillin in its Anatomical Therapeutic Chemical (ATC) Classification. HETACILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hetacillin under HS 29411090 and SITC 54131. As of Q4 2014, HETACILLIN remains the US FDA Preferred Term for this commodity. Hetacillin bears US NLM identifiers UMLS ID C0062587 and NCI Concept Code C47555. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2N1C(NC(C1=O)C1CCCCC1)(C)C.
This classification denotes a penicillin antibiotic C19H22N3O4S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95PFX5932Y, chemically known as potassium 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate, but more generally known as hetacillin potassium, which bears US NIH Compound Identifier 23677959. European Medicines Agency schedules Hetacillin potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02502MIG. Most nations, for tariff and trade purposes, schedule hetacillin potassium under HS 29411090 and SITC 54131. As of Q4 2014, HETACILLIN POTASSIUM remains US FDA's Preferred Term for this commodity. Hetacillin potassium bears US NLM identifiers UMLS ID C0812398 and NCI Concept Code C65845. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)C4CCCCC4)C(=O)[O-])C.[K+].
This classification denotes a blood substitute, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 875Y4127EA. European Medicines Agency schedules Hetastarch in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14097MIG. Hetastarch generally arises in the molecular formula (C6H7O5)N.C2H5O.H. The term 'hetastarch' is an FDA designation. As of Q4 2014, HETASTARCH remains the US FDA Preferred Term for this commodity. Hetastarch bears US NLM identifiers UMLS ID C0020352 and NCI Concept Code C559. SMILES: CC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)OC)O)O)OC4C(C(C(C(O4)CO)OC)O)OCCO)O)O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class BL800. This VA Drug Class (BL800) classifies this compound as belonging to the group VOLUME EXPANDERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class BL800. This VA Drug Class (BL800) classifies this compound as belonging to the group VOLUME EXPANDERS.
This classification denotes an anti-infective agent with the molecular formula C13H6Cl6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IWW5FV6NK2, chemically known as 2,2-methylenebis (3,5, 6-trichlorophenol) but generally known as hexachlorophene, which bears US NIH Compound Identifier 3598. European Medicines Agency schedules Hexachlorophene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08023MIG. The term HEXACHLOROPHENE is an International Non-Proprietary Name. World Health Organization schedules hexachlorophene in its Anatomical Therapeutic Chemical (ATC) Classification. HEXACHLOROPHENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hexachlorophene under HS 29081900 and SITC 51244. As of Q4 2014, HEXACHLOROPHENE remains the US FDA Preferred Term for this commodity. Hexachlorophene bears US NLM identifiers UMLS ID C0308205 and NCI Concept Code C47556. SMILES: CLC1C(CC2C(O)C(CL)CC(CL)C2CL)C(O)C(CL)CC1CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a cns stimulant with the molecular formula C9H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2K0FP9UB6A, chemically known as 2-[1-(hydroxymethyl)cyclohexyl]acetate but more generally known as hexacyclonate, which bears US NIH Compound Identifier 23675742. European Medicines Agency schedules hexacyclonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10564MIG. The term HEXACYCLONATE is an International Non-Proprietary Name. SMILES: C1CCC(CC1)(CC(=O)[O-])CO.
This classification denotes a vasodilating agent with the molecular formula C19H33N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5T8Q3G88U, chemically known as 2-(2,2-dicyclohexylvinyl)piperidine but generally known as hexadiline, which bears US NIH Compound Identifier 219119. European Medicines Agency schedules Hexadiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08025MIG. The term HEXADILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). HEXADILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hexadiline under HS 29333999 and SITC 51574. As of Q4 2014, HEXADILINE remains the US FDA Preferred Term for this commodity. Hexadiline bears US NLM identifiers UMLS ID C2827169 and NCI Concept Code C83749. SMILES: N1C(/C=C(/C2CCCCC2)C2CCCCC2)CCCC1.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C36H42N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 55W5L6G81R, chemically known as 1,6-hexanediaminium, n, n-di-9h-fluoren-9-yl-n,n,n,n-tetramethyl-, dibromide but generally known as hexafluorenium, which bears US NIH Compound Identifier 3601. Hexafluorenium or hexafluronium bears US NLM identifiers UMLS ID C0062619 and NCI Concept Code C76138. SMILES: C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.
This classification denotes an antispasmotic agent with the molecular formula C36H42N2.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B64NJG83K2, chemically known as 1,6-hexanediaminium, n, n-di-9h-fluoren-9-yl-n,n,n,n-tetramethyl-, dibromide but more generally known as hexafluorenium bromide, which bears US NIH Compound Identifier 3601. European Medicines Agency schedules Hexafluronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14099MIG. The term HEXAFLURONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules hexafluorenium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule hexafluronium bromide under HS 29239000. SMILES: C[N+](C)(CCCCCC[N+](C)(C)C1C2CCCCC2-C3C1CCCC3)C4C5CCCCC5-C6C4CCCC6.[BR-].[BR-].
This classification denotes a nicotinic antagonist with the molecular formula C12H30N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3C9PSP36Z2, chemically known as ammonium, hexamethylenebis(trimethyl- or trimethyl-[6-(trimethylazaniumyl)hexyl]azanium but generally known as hexamethonium, which bears US NIH Compound Identifier 3604. European Medicines Agency schedules Hexamethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02506MIG. The term HEXAMETHONIUM is an International Non-Proprietary Name. As of Q4 2014, HEXAMETHONIUM remains the US FDA Preferred Term for this commodity. Hexamethonium bears US NLM identifiers UMLS ID C0062637 and NCI Concept Code C75979. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.
This classification denotes a nicotinic antagonist with the molecular formula C12H30N2.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8J77X3S603, chemically known as 1,6-hexanediaminium, n,n,n,n,n,n-hexamethyl-, dichloride but more generally known as hexamethonium bromide, which bears US NIH Compound Identifier 3604. European Medicines Agency schedules Hexamethonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08028MIG. The term HEXAMETHONIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule hexamethonium bromide under HS 29239000 and SITC 51481. As of Q4 2014, HEXAMETHONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Hexamethonium bromide bears US NLM identifiers UMLS ID C0121631 and NCI Concept Code C80001. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.[BR-].[BR-].
This classification denotes a urinary anti-infective agent with the molecular formula C9H9NO3.C6H12N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M329791L57, chemically known as n-benzoylglycine, compound with 1,3,5,7-tetraazatricyclo(3.3.1.13,7)decane (1:1) but more generally known as methenamine hippurate, which bears US NIH Compound Identifier 21945. European Medicines Agency schedules Methenamine hippurate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14537MIG. SMILES: O=C(NCC(=O)O)C1CCCCC1.N12CN3CN(CN(C3)C2)C1.
This classification denotes an antibiotic with the molecular formula C20H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3483C2H13H, chemically known as 4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-phenyl- but more generally known as hexamidine, which bears US NIH Compound Identifier 4909. European Medicines Agency schedules Hexamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08029MIG. The term HEXAMIDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules hexamidine in its Anatomical Therapeutic Chemical (ATC) Classification. HEXAMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C1NCNC(=O)C1(CC)C1CCCCC1.
This classfication denotes an antibiotic with the molecular formula C20H26N4O2.2C2H6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 023XA5Z50L, chemically known as 4,4'-(hexamethylenedioxy)dibenzamidine bis(2-hydroxyethanesulphonate), but more generally known as hexamidine diisethionate, which bears US NIH Compound Identifier 3080571. European Medicines Agency schedules hexamidine diisethionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08029MIG. Most nations, for tariff purposes, schedule hexamidine diisethionate under HS 29252900. SMILES: C1CC(CCC1C(=N)N)OCCCCCCOC2CCC(CC2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O.
This classification denotes a urinary anti-infective agent with the molecular formula C8H8O3.C6H12N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 695N30CINR, chemically known as 1,3,5,7-tetraazatricyclo(3.3.1.1(3,7))decane, mono(alpha-hydroxybenzeneacetate) but more generally known as hexamine mandelate, which bears US NIH Compound Identifier 11478. European Medicines Agency schedules Methenamine mandelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03216MIG. Most nations schedule hexamine mandelate under HS 29339990. SMILES: C1CCC(CC1)C(C(=O)O)O.C1N2CN3CN1CN(C2)C3.
This classification denotes a urinary anti-infective agent with the molecular formula C6H12N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J50OIX95QV, chemically known as 1,3,5,7-tetraazatricyclo(3.3.1.1(sup 37))decane but more generally known as hexamine, which bears US NIH Compound Identifier 4101. European Medicines Agency schedules Methenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08845MIG. The term HEXAMINE is an International Non-Proprietary Name. The World Health Organization schedules hexamine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1N2CN3CN1CN(C2)C3.
This classification denotes a sedative and hypnotic with the molecular formula C10H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0J9RN2PRJ7, chemically known as cyclohexanol, 1-(2-propynyl)-, carbamate but generally known as hexapropymate, which bears US NIH Compound Identifier 9661. European Medicines Agency schedules Hexapropymate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08032MIG. The term HEXAPROPYMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules hexapropymate in its Anatomical Therapeutic Chemical (ATC) Classification. HEXAPROPYMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hexapropymate under HS 29242995 and SITC 51479. As of Q4 2014, HEXAPROPYMATE remains the US FDA Preferred Term for this commodity. Hexapropymate bears US NLM identifiers UMLS ID C0062664 and NCI Concept Code C83752. SMILES: C#CCC1(CCCCC1)OC(=O)N.
This classification denotes a muscle relaxant with the molecular formula C18H40N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NM87THP11P, chemically known as n,n,n,n,n,n-hexamethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecamethylendiammonium dibromid but generally known as hexcarbacholine bromide, which bears US NIH Compound Identifier 71495. European Medicines Agency schedules Hexcarbacholine bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08034MIG. The term HEXCARBACHOLINE BROMIDE is an International Non-Proprietary Name. As of Q4 2014, HEXCARBACHOLINE remains the US FDA Preferred Term for this commodity. Hexcarbacholine bears US NLM identifiers UMLS ID C2828259 and NCI Concept Code C87312. SMILES: Br.Br.O(CC[N](C)(C)C)C(=O)NCCCCCCNC(=O)OCC[N](C)(C)C.
This classification denotes a muscle relaxant with the molecular formula C18H40N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NM87THP11P, chemically known as n,n,n,n,n,n-hexamethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecamethylendiammonium dibromid but more generally known as hexcarbacholine bromide, which bears US NIH Compound Identifier 71495. European Medicines Agency schedules Hexcarbacholine bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08034MIG. The term HEXCARBACHOLINE BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule hexcarbacholine bromide under HS 29241900 and SITC 51471. As of Q4 2014, HEXCARBACHOLINE BROMIDE remains US FDA's Preferred Term for this commodity. Hexcarbacholine bromide bears US NLM identifiers UMLS ID C2825403 and NCI Concept Code C80986. SMILES: C[N+](C)(C)CCOC(=O)NCCCCCCNC(=O)OCC[N+](C)(C)C.[BR-].[BR-].
This classification denotes a topical anti-infective agent with the molecular formula C22H45N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LRE2528Y9E, chemically known as 2,6-bis(2-ethylhexyl)-hexahydro-7a-methyl-1h-imidazo(1,5-c)imidazole but more generally known as hexedine, which bears US NIH Compound Identifier 22291. European Medicines Agency schedules Hexedine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08035MIG. The term HEXEDINE is an International Non-Proprietary Name. HEXEDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: N12C(CN(C1)CC(CCCC)CC)(CN(C2)CC(CCCC)CC)C.
This classification denotes a non-steroidal estrogen with the molecular formula C18H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10BI795R7D, chemically known as 4,4′-(1,2-diethylethylene)diphenol but generally known as hexestrol, which bears US NIH Compound Identifier 3606. European Medicines Agency schedules Hexestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08036MIG. The term HEXESTROL is an International Non-Proprietary Name. HEXESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hexestrol under HS 29072900 and SITC 51243. As of Q4 2014, HEXESTROL remains the US FDA Preferred Term for this commodity. Hexestrol bears US NLM identifiers UMLS ID C0019467 and NCI Concept Code C545. SMILES: Oc1ccc(C(C(CC)c2ccc(O)cc2)CC)cc1.
This classification denotes a non-steroidal estrogen C22H26O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0432698UA0, chemically known as phenol,4,4'-((1r,2s)-1,2-diethyl-1,2-ethanediyl)bis-, diacetate, rel-, but more generally known as hexestrol diacetate, which bears US NIH Compound Identifier 656653. European Medicines Agency schedules Hexestrol diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02511MIG. Most nations, for tariff and trade purposes, schedule hexestrol diacetate under HS 29072900 and SITC 51243. As of Q4 2014, HEXESTROL DIACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@H](C1CCC(CC1)OC(=O)C)[C@@H](CC)C2CCC(CC2)OC(=O)C.
This classification denotes a non-steroidal estrogen C18H24O8P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30L14W008X, chemically known as hexestrol 4,4'-diphosphoric ester, but more generally known as hexestrol diphosphate, which bears US NIH Compound Identifier 193055. Most nations, for tariff and trade purposes, schedule hexestrol diphosphate under HS 29072900 and SITC 51243. As of Q4 2014, HEXESTROL DIPHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@H](C1CCC(CC1)OP(=O)(O)O)[C@@H](CC)C2CCC(CC2)OP(=O)(O)O.
This classification denotes a non-steroidal estrogen with the molecular formula C18H20O8P2.4Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VK60X9E36E, chemically known as phenol, 4,4'-((1r,2s)-1,2-diethyl-1,2-ethanediyl)bis-, bis(dihydrogen phosphate), tetrasodium salt, rel-, but more generally known as hexestrol diphosphate sodium, which bears US NIH Compound Identifier 3064060. European Medicines Agency schedules hexestrol diphosphate sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08036MIG. Most nations, for tariff purposes, schedule hexestrol diphosphate sodium under HS 29072900. SMILES: CC[C@H](C1CCC(CC1)OP(=O)([O-])[O-])[C@@H](CC)C2CCC(CC2)OP(=O)([O-])[O-].[NA+].[NA+].[NA+].[NA+].
This classification denotes a non-steroidal estrogen C24H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87WC4ICV8O, chemically known as phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-, 1,1'-dipropanoate, but more generally known as hexestrol dipropionate, which bears US NIH Compound Identifier 107342. Most nations, for tariff and trade purposes, schedule hexestrol dipropionate under HS 29072900 and SITC 51243. As of Q4 2014, HEXESTROL DIPROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@H](C1CCC(CC1)OC(=O)CC)[C@@H](CC)C2CCC(CC2)OC(=O)CC.
This classification denotes a non-steroidal estrogen with the molecular formula C19H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B1LXH6RPPM, chemically known as phenol, 4-(1-ethyl-2-(4-methoxyphenyl)butyl)-, (r*,s*)-, but more generally known as hexestrol monomethyl ether, which bears US NIH Compound Identifier 11954178. European Medicines Agency schedules hexestrol monomethyl ether or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08036MIG. Most nations, for tariff purposes, schedule hexestrol monomethyl ether under HS 29072900. SMILES: CC[C@@H](C1CCC(CC1)O)[C@H](CC)C2CCC(CC2)OC.
This classification denotes an anti-infective agent with the molecular formula C21H45N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 852A84Y8LS, chemically known as 1,3-bis(2-ethylhexyl)hexahydro-5-methyl-5-pyrimidiamine but generally known as hexetidine, which bears US NIH Compound Identifier 3607. European Medicines Agency schedules Hexetidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08037MIG. The term HEXETIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules hexetidine in its Anatomical Therapeutic Chemical (ATC) Classification. HEXETIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hexetidine under HS 29335995 and SITC 51576. As of Q4 2014, HEXETIDINE remains the US FDA Preferred Term for this commodity. Hexetidine bears US NLM identifiers UMLS ID C0019468 and NCI Concept Code C77049. SMILES: N1(CC(N)(CN(C1)CC(CCCC)CC)C)CC(CCCC)CC.
This classification denotes a barbiturate with the molecular formula C12H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AL8Z8K3P6S, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, monosodium salt but generally known as hexobarbital, which bears US NIH Compound Identifier 3608. European Medicines Agency schedules Hexobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08038MIG. The term HEXOBARBITAL is an International Non-Proprietary Name. World Health Organization schedules hexobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. HEXOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Hexobarbital or hexobarbitone bears US NLM identifiers UMLS ID C0019469 and NCI Concept Code C77630. SMILES: CC1(C(=O)NC(=O)N(C1=O)C)C2=CCCCC2.
This classification denotes a barbiturate with the molecular formula C12H15N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I788X867K7, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, monosodium salt but more generally known as hexobarbital sodium, which bears US NIH Compound Identifier 3608. European Medicines Agency schedules Hexobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02514MIG. Most nations, for tariff and trade purposes, schedule hexobarbital sodium under HS 29335400. As of Q4 2014, HEXOBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Hexobarbital sodium bears US NLM identifiers UMLS ID C0037514 and NCI Concept Code C72808. SMILES: CC1(C(=O)[N-]C(=O)N(C1=O)C)C2=CCCCC2.[NA+].
This classification denotes a vasodilating agent with the molecular formula C30H44N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6X4SYR93B, chemically known as 3,4,5-trimethoxybenzoic acid, diester with 3,3-(ethylenebis(methylimino))di-1-propanol but generally known as hexobendine, which bears US NIH Compound Identifier 5777. European Medicines Agency schedules Hexobendine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08039MIG. The term HEXOBENDINE is an International Non-Proprietary Name. World Health Organization schedules hexobendine in its Anatomical Therapeutic Chemical (ATC) Classification. HEXOBENDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hexobendine under HS 29221980 and SITC 51461. As of Q4 2014, HEXOBENDINE remains the US FDA Preferred Term for this commodity. Hexobendine bears US NLM identifiers UMLS ID C0019471 and NCI Concept Code C83755. SMILES: O(CCCN(CCN(CCCOC(=O)c1cc(OC)c(OC)c(OC)c1)C)C)C(=O)c1cc(OC)c(OC)c(OC)c1.
This classification denotes an antimuscarinic agent with the molecular formula C20H33N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LL3147PI1T. European Medicines Agency schedules hexocyclium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02515MIG. HEXOCYCLIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, HEXOCYCLIUM remains the US FDA Preferred Term for this commodity. Hexocyclium bears US NLM identifiers UMLS ID C0062674 and NCI Concept Code C78074. SMILES: OC(C1CCCCC1)(CN1CC[N](CC1)(C)C)C1CCCCC1. .
This classification denotes an adrenergic beta-2 receptor agonist, bronchodilator agent, and tocolytic agent with the molecular formula C22H32N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G9L6B3W684, chemically known as 1,12-bis(3,4-dihydroxyphenyl)-3,10-diaza-1,12-dodecandiol but generally known as hexoprenaline, which bears US NIH Compound Identifier 3609. European Medicines Agency schedules Hexoprenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08041MIG. World Health Organization schedules hexoprenaline in its Anatomical Therapeutic Chemical (ATC) Classification. HEXOPRENALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hexoprenaline under HS 29225000 and SITC 51467. As of Q4 2014, HEXOPRENALINE remains the US FDA Preferred Term for this commodity. SMILES: OC(CNCCCCCCNCC(O)C1CC(O)C(O)CC1)C1CC(O)C(O)CC1.
This classification denotes an adrenergic beta-2 receptor agonist, bronchodilator agent, and tocolytic agent with the molecular formula C22H32N2O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97TDI0239I, chemically known as benzyl alcohol, .alpha.,.alpha.'-(hexamethylenebis(iminomethylene))bis(3,4-dihydroxy-, dihydrochloride, but more generally known as hexoprenaline dihydrochloride, which bears US NIH Compound Identifier 20321. European Medicines Agency schedules hexoprenaline dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08041MIG. Most nations, for tariff purposes, schedule hexoprenaline dihydrochloride under HS 29225000. SMILES: C1CC(C(CC1C(CNCCCCCCNCC(C2CCC(C(C2)O)O)O)O)O)O.CL.CL.
This classification denotes a beta-adrenergic agonist with the molecular formula C22H32N2O6.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U851S9102C, chemically known as 4,4-(hexane-1,6-diylbis(iminio(1-hydroxyethylene)))dipyrocatecholsulphate but more generally known as hexoprenaline sulfate, which bears US NIH Compound Identifier 36094. European Medicines Agency schedules Hexoprenaline sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02516MIG. Most nations, for tariff and trade purposes, schedule hexoprenaline sulfate under HS 29225000 and SITC 51467. As of Q4 2014, HEXOPRENALINE SULFATE remains US FDA's Preferred Term for this commodity. Hexoprenaline sulfate bears US NLM identifiers UMLS ID C0813200 and NCI Concept Code C83756. SMILES: C1CC(C(CC1C(CNCCCCCCNCC(C2CCC(C(C2)O)O)O)O)O)O.OS(=O)(=O)O.
This classification denotes an anesthetic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 511IU0826Z, chemically known as 2-propanol, 1-(cyclohexylamino)-, benzoate (ester) but generally known as hexylcaine, which bears US NIH Compound Identifier 10770. European Medicines Agency schedules Hexylcaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08043MIG. The term HEXYLCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). HEXYLCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hexylcaine under HS 29221980 and SITC 51461. As of Q4 2014, HEXYLCAINE remains the US FDA Preferred Term for this commodity. Hexylcaine bears US NLM identifiers UMLS ID C0062686 and NCI Concept Code C65852. SMILES: O(C(CNC1CCCCC1)C)C(=O)C1CCCCC1.
This classification denotes an anesthetic agent with the molecular formula C16H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V00NQ7SDYI, chemically known as 2-propanol, 1-(cyclohexylamino)-, benzoate (ester) but more generally known as hexylcaine hydrochloride, which bears US NIH Compound Identifier 10770. European Medicines Agency schedules Hexylcaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02518MIG. Most nations, for tariff and trade purposes, schedule hexylcaine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, HEXYLCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Hexylcaine hydrochloride bears US NLM identifiers UMLS ID C0770371 and NCI Concept Code C65853. SMILES: CC(CNC1CCCCC1)OC(=O)C2CCCCC2.CL.
This classification denotes a topical anti-infective agent with the molecular formula C12H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9QTB5E82N, chemically known as 1,3-dihydroxy-4-n-hexylbenzene but generally known as 4-hexylresorcinol, which bears US NIH Compound Identifier 3610. European Medicines Agency schedules Hexylresorcinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14103MIG. World Health Organization schedules 4-hexylresorcinol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, HEXYLRESORCINOL remains the US FDA Preferred Term for this commodity. Hexylresorcinol bears US NLM identifiers UMLS ID C0019497 and NCI Concept Code C29092. SMILES: CCCCCCC1=C(C=C(C=C1)O)O.
Used in benign prostatic hyperplasia
This classification denotes an immunostimulant with the molecular formula C5H9N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 820484N8I3, chemically known as 4-imidazoleethylamine but generally known as histamine, which bears US NIH Compound Identifier 774. European Medicines Agency schedules Histamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14107MIG. World Health Organization schedules histamine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, HISTAMINE remains the US FDA Preferred Term for this commodity. Histamine bears US NLM identifiers UMLS ID C0019588 and NCI Concept Code C73238. SMILES: C1=C(NC=N1)CCN.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0FYM61NG4D. European Medicines Agency schedules Histapyrrodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08044MIG. Histapyrrodine generally arises in the molecular formula C19H24N2. The term HISTAPYRRODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) HISTAPYRRODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule histapyrrodine under HS 29339990 and SITC 51577. As of Q4 2014, HISTAPYRRODINE remains the US FDA Preferred Term for this commodity. Histapyrrodine bears US NLM identifiers UMLS ID C0628458 and NCI Concept Code C65855. SMILES: N1(CCCC1)CCN(CC1CCCCC1)C1CCCCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1W1AQ870ZC, chemically known as 1-pyrrolidineethanamine, n-phenyl-n-(phenylmethyl)-, monohydrochloride but more generally known as histapyrrodine hydrochloride, which bears US NIH Compound Identifier 160809. European Medicines Agency schedules Histapyrrodine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02526MIG. Most nations, for tariff and trade purposes, schedule histapyrrodine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, HISTAPYRRODINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Histapyrrodine hydrochloride bears US NLM identifiers UMLS ID C1314666 and NCI Concept Code C97699. SMILES: C1CCC(CC1)CN(CCN2CCCC2)C3CCCCC3.CL.
This classification denotes a gonadotropin-releasing hormone analog, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H50H3S3W74. European Medicines Agency schedules Histrelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08046MIG. Histrelin generally arises in the molecular formula C66H86N18O12. The term HISTRELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) HISTRELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule histrelin under HS 29371900 and SITC 54154. As of Q4 2014, HISTRELIN remains the US FDA Preferred Term for this commodity. Histrelin bears US NLM identifiers UMLS ID C0121902 and NCI Concept Code C74270. SMILES: O=C(N1C(CCC1)C(=O)NCC)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1NC[NH]C1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)CC1NCN(C1)CC1CCCCC1)CC(C)C)CCCNC(=N)N.
Hog cholera virus grown in PK 15 cells has been concentrated, inactivated with glyceraldehyde, and then mixed with an oil adjuvant; and inoculation of 5 ml of this vaccine has induced a solid and long-lasting immunity.
This classification denotes an antimuscarinic agent with the molecular formula C17H24NO3.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68JRS2HC1C, chemically known as 8-azoniabicyclo(3.2.1)octane, 3-((hydroxyphenylacetyl)oxy)-8,8-dimethyl-, bromide, endo- but generally known as homatropine methylbromide, which bears US NIH Compound Identifier 6646. European Medicines Agency schedules Homatropine methylbromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08048MIG. The term HOMATROPINE METHYLBROMIDE is an International Non-Proprietary Name. Most nations schedule homatropine under HS 29399990 and SITC 54149. As of Q4 2014, HOMATROPINE remains the US FDA Preferred Term for this commodity. Homatropine bears US NLM identifiers UMLS ID C0062922 and NCI Concept Code C61783. SMILES: Br.O(C1CC2[N](C(CC2)C1)(C)C)C(=O)C(O)c1ccccc1.
This classification denotes an antimuscarinic agent with the molecular formula C16H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8QS6WCL55Z, chemically known as 1-alpha-h,5-alpha-h-tropan-3-alpha-ol, mandelate (ester) but generally known as homatropine, which bears US NIH Compound Identifier 3623. European Medicines Agency schedules Homatropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02529MIG. World Health Organization schedules homatropine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule homatropine hydrobromide under HS 29399990 and SITC 54149. As of Q4 2014, HOMATROPINE HYDROBROMIDE remains the US FDA Preferred Term for this commodity. Homatropine hydrobromide bears US NLM identifiers UMLS ID C0770458 and NCI Concept Code C29093. SMILES: O(C1CC2N(C(CC2)C1)C)C(=O)C(O)C1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N5MVC31W2N, chemically known as 1-(p-chloro-.alpha.-phenylbenzyl)hexahydro-4-methyl-1h-1, 4-diazepine, dihydrochloride but generally known as homochlorcyclizine, which bears US NIH Compound Identifier 3627. European Medicines Agency schedules Homochlorcyclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08050MIG. The term HOMOCHLORCYCLIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). HOMOCHLORCYCLIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule homochlorcyclizine under HS 29339940 and SITC 51577. As of Q4 2014, HOMOCHLORCYCLIZINE remains the US FDA Preferred Term for this commodity. Homochlorcyclizine bears US NLM identifiers UMLS ID C0163772 and NCI Concept Code C81142. SMILES: CLC1CCC(C(N2CCCN(CC2)C)C2CCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M1YE3TK8NA, chemically known as (+/-)-homochlorcyclizine dihydrochloride, but more generally known as homochlorcyclizine dihydrochloride, which bears US NIH Compound Identifier 16114. European Medicines Agency schedules homochlorcyclizine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08050MIG. Most nations, for tariff purposes, schedule homochlorcyclizine dihydrochloride under HS 29339940. SMILES: CN1CCCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M1YE3TK8NA, chemically known as (+/-)-homochlorcyclizine dihydrochloride, but more generally known as homochlorcyclizine hydrochloride, which bears US NIH Compound Identifier 32313. European Medicines Agency schedules homochlorcyclizine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08050MIG. Most nations, for tariff purposes, schedule homochlorcyclizine hydrochloride under HS 29339940. SMILES: CN1CCCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.CL.
This classification denotes a sedative and hypnotic with the molecular formula C23H28F3N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PEL7G6VRZ2, chemically known as 2-trifluoroethyl-10-(3-(4-(beta-hydroxyethyl-1-hexahydro-1,4-diazepinyl)propyl)phenothiazine but generally known as homofenazine, which bears US NIH Compound Identifier 19687. European Medicines Agency schedules Homofenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08051MIG. The term HOMOFENAZINE is an International Non-Proprietary Name. HOMOFENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule homofenazine under HS 29343090 and SITC 51578. As of Q4 2014, HOMOFENAZINE remains the US FDA Preferred Term for this commodity. Homofenazine bears US NLM identifiers UMLS ID C2825301 and NCI Concept Code C80674. SMILES: S1C2C(N(CCCN3CCCN(CC3)CCO)C3C1CCCC3)CC(CC2)C(F)(F)F.
This classification denotes a sedative and hypnotic with the molecular formula C23H28F3N3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L5JN11UQL, chemically known as 2-trifluoroethyl-10-(3-(4-(beta-hydroxyethyl-1-hexahydro-1,4-diazepinyl)propyl)phenothiazine but more generally known as homofenazine dihydrochloride, which bears US NIH Compound Identifier 19687. European Medicines Agency schedules Homofenazine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02537MIG. Most nations, for tariff and trade purposes, schedule homofenazine dihydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, HOMOFENAZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCCN(CC4)CCO.CL.CL.
This classification denotes a sedative and hypnotic with the molecular formula C23H28F3N3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L5JN11UQL, chemically known as 2-trifluoroethyl-10-(3-(4-(beta-hydroxyethyl-1-hexahydro-1,4-diazepinyl)propyl)phenothiazine but more generally known as homofenazine dihydrochloride, which bears US NIH Compound Identifier 19687. European Medicines Agency schedules Homofenazine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02537MIG. Most nations, for tariff and trade purposes, schedule homofenazine hydrochloride under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCCN(CC4)CCO.CL.CL.
This classification denotes an antidepressant agent with the molecular formula C24H31N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 09YNW8E5CT, chemically known as 4-(3-(5h-dibenz(b,f)azepin-5-yl)propyl)hexahydro-1h-1,4-diazepine-1-ethanol but generally known as homopipramol, which bears US NIH Compound Identifier 216247. European Medicines Agency schedules Homopipramol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08052MIG. The term HOMOPIPRAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). HOMOPIPRAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule homopipramol under HS 29339940 and SITC 51577. As of Q4 2014, HOMOPIPRAMOL remains the US FDA Preferred Term for this commodity. Homopipramol bears US NLM identifiers UMLS ID C1881066 and NCI Concept Code C65858. SMILES: OCCN1CC=CN(CCCN2c3c(C=Cc4c2cccc4)cccc3)C=C1.
This classification denotes an opioid receptor agonist with the molecular formula C28H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SH57250J2D, chemically known as 22-cyclopropyl-7alpha-((r)-1-hydroxy-1-methylpropyl)-6,14-endo-ethenotetrahydrothebaine but generally known as homprenorphine, which bears US NIH Compound Identifier 3084250. European Medicines Agency schedules Homprenorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08054MIG. The term HOMPRENORPHINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). HOMPRENORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule homprenorphine under HS 29391900 and SITC 54141. As of Q4 2014, HOMPRENORPHINE remains the US FDA Preferred Term for this commodity. Homprenorphine bears US NLM identifiers UMLS ID C2983997 and NCI Concept Code C91042. SMILES: O1C2C34C5(C(N(CC3)CC3CC3)CC3C4C1C(OC)CC3)CC(C2(OC)C=C5)C(O)(CC)C.
This classification denotes a protein-based fluid (sometimes also called simulated body fluid) or that residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 839MOZ74GK. European Medicines Agency schedules Human Blood Plasma in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB51727.
This classification denotes a pituitary agent with the molecular formula C990H1528N262O300S7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQX9KB6PCL, more generally known as somatropin. European Medicines Agency schedules somatropin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10584MIG. The term SOMATROPIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 1, no. 4, 1987, list 27. SOMATROPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: NONE.
This clasification denotes vaccines or candidate vaccines used to prevent or treat a genus of the family paramyxoviridae (subfamily paramyxovirinae) where the virions of most members have hemagglutinin but not neuraminidase activity. All members produce both cytoplasmic and intranuclear inclusion bodies. Human papilloma virus vaccine bears US NLM identifiers UMLS ID C1512511 and NCI Concept Code C1951.
This classification denotes a protein-based fluid (sometimes also called simulated body fluid) or that residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation, and proteins extracted therefrom, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6D53G0FD0Z. European Medicines Agency schedules Human Plasma Protein Fraction in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB51727 and SUB22285 and SUB32334.
This classification denotes a glycosaminoglycan, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S270N0TRQY. European Medicines Agency schedules Hyaluronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14126MIG. Hyaluronic acid generally arises in the molecular formula C14H23NO12(C14H21NO11)N. The term 'hyaluronic acid' is a Hazardous Substances Data Bank designation. SMILES: CC(=O)NC1C(C(C(OC1O)CO)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)NC(=O)C)O)O.
This classification denotes an adjuvant with the molecular formula C2327H3553N589O667S20, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KOG53Z5EM, more generally known as hyaluronidase. European Medicines Agency schedules hyaluronidase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02552MIG. The term HYALURONIDASE is an International Non-Proprietary Name or INN. HYALURONIDASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hyaluronidase under HS 35079090 and SITC 51691. As of Q4 2014, HYALURONIDASE remains the US FDA Preferred Term for this commodity. Hyaluronidase bears US NLM identifiers UMLS ID C0020197 and NCI Concept Code C87576. SMILES: NONE.
This classification denotes an antihelminthic agent with the molecular formula C20H24N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BXX5EVN2A, chemically known as 9h-thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-(hydroxymethyl)- but generally known as hycanthone, which bears US NIH Compound Identifier 3634. European Medicines Agency schedules Hycanthone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08057MIG. The term HYCANTHONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). HYCANTHONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hycanthone under HS 29349990 and SITC 51579. As of Q4 2014, HYCANTHONE remains the US FDA Preferred Term for this commodity. Hycanthone bears US NLM identifiers UMLS ID C0020207 and NCI Concept Code C550. SMILES: S1C2C(C(NCCN(CC)CC)CCC2CO)C(=O)C2C1CCCC2.
This classification denotes an antihelminthic agent with the molecular formula C20H24N2O2S.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48830NW22A, chemically known as 9h-thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-(hydroxymethyl)-, methanesulfonate (1:1), but more generally known as hycanthone mesylate, which bears US NIH Compound Identifier 3634. European Medicines Agency schedules hycanthone mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08057MIG. Most nations, for tariff purposes, schedule hycanthone mesylate under HS 29349990. SMILES: CCN(CC)CCNC1CCC(C2C1C(=O)C3CCCCC3S2)CO.CS(=O)(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C20H24N2O2S.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48830NW22A, chemically known as 9h-thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-(hydroxymethyl)-, methanesulfonate (1:1), but more generally known as hycanthone methanesulfonate, which bears US NIH Compound Identifier 31764. European Medicines Agency schedules hycanthone methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08057MIG. Most nations, for tariff purposes, schedule hycanthone methanesulfonate under HS 29349990. SMILES: CCN(CC)CCNC1CCC(C2C1C(=O)C3CCCCC3S2)CO.CS(=O)(=O)O.
This classification denotes an antihypertensive agent with the molecular formula C8H8N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26NAK24LS8, chemically known as 1 (2h)-phthalazinone, hydrazone, monohydrochloride but generally known as hydralazine, which bears US NIH Compound Identifier 3637. European Medicines Agency schedules Hydralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08059MIG. The term HYDRALAZINE is an International Non-Proprietary Name. World Health Organization schedules hydralazine in its Anatomical Therapeutic Chemical (ATC) Classification. HYDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydralazine under HS 29339990 and SITC 51577. As of Q4 2014, HYDRALAZINE remains the US FDA Preferred Term for this commodity. Hydralazine bears US NLM identifiers UMLS ID C0020223 and NCI Concept Code C62032. SMILES: N(N)c1nncc2c1cccc2.
This classification denotes an antihypertensive agent with the molecular formula C8H8N4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FD171B778Y, chemically known as 1 (2h)-phthalazinone, hydrazone, monohydrochloride but more generally known as hydralazine hydrochloride, which bears US NIH Compound Identifier 3637. European Medicines Agency schedules Hydralazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02553MIG. Most nations, for tariff and trade purposes, schedule hydralazine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, HYDRALAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Hydralazine hydrochloride bears US NLM identifiers UMLS ID C0699178 and NCI Concept Code C551. SMILES: C1CCC2C(C1)CNNC2NN.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers ZW3Z11D0JV (root) and R763EBH88T (whole), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 18781 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Ranunculanae, Order Ranunculales, Family Ranunculaceae, Genus Hydrastis L., Species Hydrastis canadensis L., commonly known as GOLDENSEAL or, as here, HYDRASTIS (canadensis). Hydrastis bears the USDA PLANTS Database Identifier HYCA. European Medicines Agency schedules hydrastis in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB14129MIG, SUB40666, SUB46607, SUB46608, and SUB46609. SMILES: NONE. .
This classification denotes a thiazide diuretic with the molecular formula C7H8ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0J48LPH2TH, chemically known as 6-chloro-7-sulfamoyl-2h-1,2,4-benzothiadiazine 1,1-dioxide but generally known as hydrochlorothiazide, which bears US NIH Compound Identifier 2720. European Medicines Agency schedules Hydrochlorothiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08062MIG. The term HYDROCHLOROTHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules hydrochlorothiazide in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROCHLOROTHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydrochlorothiazide under HS 29350090 and SITC 51580. As of Q4 2014, HYDROCHLOROTHIAZIDE remains the US FDA Preferred Term for this commodity. Hydrochlorothiazide bears US NLM identifiers UMLS ID C0020261 and NCI Concept Code C29098. SMILES: CLC1C(S(=O)(=O)N)CC2S(=O)(=O)N=CNC2C1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV704. This VA Drug Class (CV704) classifies this compound as belonging to the group POTASSIUM SPARING/COMBINATIONS DIURETICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV704. This VA Drug Class (CV704) classifies this compound as belonging to the group POTASSIUM SPARING/COMBINATIONS DIURETICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an opioid receptor agonist and antitussive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NO70W886KK. European Medicines Agency schedules Hydrocodone bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02559MIG. Hydrocodone bitartrate generally arises in the molecular formula 2C18H21NO3.2C4H6O6.5H2O. The term 'hydrocodone bitartrate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule hydrocodone bitartrate under HS 29391100. As of Q4 2014, HYDROCODONE BITARTRATE remains US FDA's Preferred Term for this commodity. Hydrocodone bitartrate bears US NLM identifiers UMLS ID C0546868 and NCI Concept Code C29099. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@H]3[C@H]1C5)OC.CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@H]3[C@H]1C5)OC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.O.O.O.O.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QKZ0920OV3. European Medicines Agency schedules hydrocodone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14131MIG. The term hydrocodone hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule hydrocodone hydrochloride under HS 29391100. As of Q4 2014, HYDROCODONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@H]3[C@H]1C5)OC.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6YKS4Y3WQ7, chemically known as 4,5-epoxy-3-methoxy-17-methylmorphinan-6-one but generally known as hydrocodone, which bears US NIH Compound Identifier 5284569. European Medicines Agency schedules Hydrocodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08063MIG. The term HYDROCODONE is an International Non-Proprietary Name. World Health Organization schedules hydrocodone in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROCODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Hydrocodone or dihydrocodeinone bears US NLM identifiers UMLS ID C0020264 and NCI Concept Code C62033. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)CCC2=O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes an opioid receptor agonist and opioid and antitussive agent with the molecular formula C76H52O46.C18H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68T7388F5H. Most nations, for tariff and trade purposes, schedule hydrocodone tannate under HS 29391100. SMILES:. As of Q4 2014, HYDROCODONE TANNATE remains US FDA's Preferred Term for this commodity.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H41NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3N00BK5WK, chemically known as 17-hydroxycorticosterone, 21-(diethylamino)acetate but generally known as hydrocortamate, which bears US NIH Compound Identifier 84088. European Medicines Agency schedules Hydrocortamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08064MIG. The term HYDROCORTAMATE is an International Non-Proprietary Name. HYDROCORTAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydrocortamate under HS 29372900 and SITC 54153. As of Q4 2014, HYDROCORTAMATE remains the US FDA Preferred Term for this commodity. Hydrocortamate bears US NLM identifiers UMLS ID C0544368 and NCI Concept Code C65862. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)C(O)C2)CC1)C)C(=O)COC(=O)CN(CC)CC.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H41NO6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9QM8U7R83W, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate hydrochloride but more generally known as hydrocortamate hydrochloride, which bears US NIH Compound Identifier 31312. Most nations, for tariff and trade purposes, schedule hydrocortamate hydrochloride under HS 29372900 and SITC 54153. As of Q4 2014, HYDROCORTAMATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Hydrocortamate hydrochloride bears US NLM identifiers UMLS ID C1445700 and NCI Concept Code C65863. SMILES: CCN(CC)CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O.CL.
This classification denotes an anti-inflammatory agent with the molecular formula C21H30O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WI4X0X7BPJ, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione but generally known as hydrocortisone, which bears US NIH Compound Identifier 5754. European Medicines Agency schedules Hydrocortisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08065MIG. The term HYDROCORTISONE is an International Non-Proprietary Name. World Health Organization schedules hydrocortisone in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROCORTISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydrocortisone under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE remains the US FDA Preferred Term for this commodity. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)C(O)C2)CC1)C)C(=O)CO.
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H36O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2340UP1L2G, chemically known as 11beta,17,21-trihydroxy pregn-4-ene-3,20-dione 21-acetate 17-propionate but more generally known as hydrocortisone aceponate, which bears US NIH Compound Identifier 68921. European Medicines Agency schedules Hydrocortisone aceponate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08066MIG. The term HYDROCORTISONE ACEPONATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules hydrocortisone aceponate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule hydrocortisone aceponate under HS 29372900 and SITC 54153. As of Q4 2014, HYDROCORTISONE ACEPONATE remains US FDA's Preferred Term for this commodity. Hydrocortisone aceponate bears US NLM identifiers UMLS ID C0082944 and NCI Concept Code C90952. SMILES: CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)COC(=O)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C23H32O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X7931PO74, chemically known as pregn-4-ene-3,20-dione,11beta,17alpha,21-trihydroxy-,21 acetate but more generally known as hydrocortisone acetate, which bears US NIH Compound Identifier 3641. European Medicines Agency schedules Hydrocortisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02562MIG. Most nations, for tariff and trade purposes, schedule hydrocortisone acetate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE ACETATE remains US FDA's Preferred Term for this commodity. Hydrocortisone acetate bears US NLM identifiers UMLS ID C0063077 and NCI Concept Code C61785. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H40O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6550D6K3A. The term hydrocortisone buteprate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule hydrocortisone buteprate under HS 29372100. SMILES: CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)COC(=O)CC.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H36O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05RMF7YPWN, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione but generally known as hydrocortisone butyrate, which bears US NIH Compound Identifier 5754. European Medicines Agency schedules Hydrocortisone butyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02563MIG. World Health Organization schedules hydrocortisone butyrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule hydrocortisone butyrate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE BUTYRATE remains the US FDA Preferred Term for this commodity. Hydrocortisone butyrate bears US NLM identifiers UMLS ID C0352536 and NCI Concept Code C48022. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)C(O)C2)CC1)C)C(=O)CO.
This classification denotes an anti-inflammatory agent with the molecular formula C28H40O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6550D6K3A, chemically known as 11.beta.-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)pregn-4-ene-3,20-dione, but more generally known as hydrocortisone butyrate propionate, which bears US NIH Compound Identifier 51627. European Medicines Agency schedules hydrocortisone butyrate propionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08065MIG. Most nations, for tariff purposes, schedule hydrocortisone butyrate propionate under HS 29372100. SMILES: CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)COC(=O)CC.
This classification denotes an anti-inflammatory agent C27H40O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SAE475O6E4, chemically known as cortisol, 21-hexanoate, but more generally known as hydrocortisone caproate, which bears US NIH Compound Identifier 107423. Most nations, for tariff and trade purposes, schedule hydrocortisone caproate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE CAPROATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O.
This classification denotes an anti-inflammatory agent with the molecular formula C29H42O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4XDY25L70B, chemically known as pregn-4-ene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11,17-dihydroxy-, (11.beta.)-, but more generally known as hydrocortisone cypionate, which bears US NIH Compound Identifier 10508. European Medicines Agency schedules hydrocortisone cypionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08065MIG. Most nations, for tariff purposes, schedule hydrocortisone cypionate under HS 29372100. Hydrocortisone cypionate bears US NLM identifiers UMLS ID C0612688 and NCI Concept Code C65864. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC5CCCC5)O)C)O.
This classification denotes an anti-inflammatory agent with the molecular formula C25H34O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IHV1VP592V, chemically known as cortisol 21-(hydrogen succinate), but more generally known as hydrocortisone hemisuccinate anhydrous, which bears US NIH Compound Identifier 16623. European Medicines Agency schedules hydrocortisone hemisuccinate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08065MIG. Most nations, for tariff purposes, schedule hydrocortisone hemisuccinate anhydrous under HS 29372100. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)O)O)C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a therapeutic hydrocortisone with the molecular formula C21H31O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Y87E22X71, chemically known as pregn-4-ene-3,20-dione, 11, 17-dihydroxy-21- (phosphonooxy)-, (11.beta.)- but more generally known as hydrocortisone phosphate, which bears US NIH Compound Identifier 3645. Most nations, for tariff and trade purposes, schedule hydrocortisone phosphate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE PHOSPHATE remains US FDA's Preferred Term for this commodity. Hydrocortisone phosphate bears US NLM identifiers UMLS ID C0056383 and NCI Concept Code C83763. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COP(=O)(O)O)O)C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes an anti-inflammatory agent with the molecular formula C28H40O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6550D6K3A, chemically known as 11.beta.-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)pregn-4-ene-3,20-dione, but more generally known as hydrocortisone probutate, which bears US NIH Compound Identifier 636398. European Medicines Agency schedules hydrocortisone probutate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08065MIG. Most nations, for tariff purposes, schedule hydrocortisone probutate under HS 29372100. As of Q4 2014, HYDROCORTISONE PROBUTATE remains US FDA's Preferred Term for this commodity. Hydrocortisone probutate bears US NLM identifiers UMLS ID C0063076 and NCI Concept Code C48023. SMILES: CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)COC(=O)CC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a therapeutic hydrocortisone with the molecular formula C21H29O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0388G963HY, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione but more generally known as hydrocortisone sodium phosphate, which bears US NIH Compound Identifier 5754. European Medicines Agency schedules Hydrocortisone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02568MIG. Most nations, for tariff and trade purposes, schedule hydrocortisone sodium phosphate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE SODIUM PHOSPHATE remains US FDA's Preferred Term for this commodity. Hydrocortisone sodium phosphate bears US NLM identifiers UMLS ID C0770559 and NCI Concept Code C65865. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COP(=O)([O-])[O-])O)C)O.[NA+].[NA+].
This classification denotes a therapeutic hydrocortisone with the molecular formula C25H33O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50LQB69S1Z, chemically known as 1,4-butanedioic acid (succinic acid) but more generally known as hydrocortisone sodium succinate, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Hydrocortisone sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02569MIG. Most nations, for tariff and trade purposes, schedule hydrocortisone sodium succinate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE SODIUM SUCCINATE remains US FDA's Preferred Term for this commodity. Hydrocortisone sodium succinate bears US NLM identifiers UMLS ID C0770560 and NCI Concept Code C1819. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)[O-])O)C)O.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes an anti-inflammatory agent C27H40O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FXJ67LWZ4S, chemically known as cortisol, 21-(3,3-dimethylbutyrate), but more generally known as hydrocortisone tebutate, which bears US NIH Compound Identifier 23424017. Most nations, for tariff and trade purposes, schedule hydrocortisone tebutate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE TEBUTATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CC(C)(C)C)O)C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H38O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68717P8FUZ, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione but more generally known as hydrocortisone valerate, which bears US NIH Compound Identifier 5754. European Medicines Agency schedules Hydrocortisone valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02570MIG. Most nations, for tariff and trade purposes, schedule hydrocortisone valerate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE VALERATE remains US FDA's Preferred Term for this commodity. Hydrocortisone valerate bears US NLM identifiers UMLS ID C0063079 and NCI Concept Code C48024. SMILES: CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO.
This classification denotes a thiazide diuretic with the molecular formula C8H8F3N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 501CFL162R, chemically known as benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- but generally known as hydroflumethiazide, which bears US NIH Compound Identifier 3440. European Medicines Agency schedules Hydroflumethiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08067MIG. The term HYDROFLUMETHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules hydroflumethiazide in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROFLUMETHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydroflumethiazide under HS 29350090 and SITC 51580. As of Q4 2014, HYDROFLUMETHIAZIDE remains the US FDA Preferred Term for this commodity. Hydroflumethiazide bears US NLM identifiers UMLS ID C0020273 and NCI Concept Code C47557. SMILES: CLC1C(S(=O)(=O)N)CC(C(NCC2OCCC2)C1)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.
Galenic product used for therapeutic use in humans. Used as a disinfectant for external use in cleaning wounds or ulcers of the skin or mucous membranes and local infections. As a mouthwash, it should be used diluted for the relief of certain oropharyngeal infections. In irrigation, in pictures of vaginitis.
This classification denotes an opioid receptor agonist with the molecular formula C17H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1O00P9X5C1, chemically known as morphinan-3,6,14-triol, 4,5-epoxy-17-methyl-, (5.alpha.,6.beta.)- but generally known as hydromorphinol, which bears US NIH Compound Identifier 627484. European Medicines Agency schedules Hydromorphinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08069MIG. The term HYDROMORPHINOL is an International Non-Proprietary Name. HYDROMORPHINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydromorphinol under HS 29391900 and SITC 54141. As of Q4 2014, HYDROMORPHINOL remains the US FDA Preferred Term for this commodity. Hydromorphinol bears US NLM identifiers UMLS ID C2983998 and NCI Concept Code C91043. SMILES: O1C2C34C(O)(C(N(CC3)C)CC3C4C1C(O)CC3)CCC2O.
This classification denotes an opiate with the molecular formula C17H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q812464R06, chemically known as morphinone, dihydro-, hydrochloride but generally known as hydromorphone, which bears US NIH Compound Identifier 3648. European Medicines Agency schedules Hydromorphone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08070MIG. The term HYDROMORPHONE is an International Non-Proprietary Name. World Health Organization schedules hydromorphone in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROMORPHONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydromorphone under HS 29391100 and SITC 54141. As of Q4 2014, HYDROMORPHONE remains the US FDA Preferred Term for this commodity. Hydromorphone bears US NLM identifiers UMLS ID C0012306 and NCI Concept Code C62034. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(O)CC3)CCC2=O.
This classification denotes an opiate with the molecular formula C17H19NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L960UP2KRW, chemically known as morphinone, dihydro-, hydrochloride but more generally known as hydromorphone hydrochloride, which bears US NIH Compound Identifier 3648. European Medicines Agency schedules Hydromorphone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02573MIG. Most nations, for tariff and trade purposes, schedule hydromorphone hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, HYDROMORPHONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Hydromorphone hydrochloride bears US NLM identifiers UMLS ID C0700533 and NCI Concept Code C436. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@H]3[C@H]1C5)O.CL.
This classification denotes an anti-arrhythmia agent and parasympatholytic with the molecular formula C20H26N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6BR4G8VAHM, chemically known as hydroquinine, hydrochloride but more generally known as hydroquinidine hydrochloride, which bears US NIH Compound Identifier 102134. European Medicines Agency schedules Hydroquinidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14137MIG. As of Q4 2014, HYDROQUINIDINE remains US FDA's Preferred Term for this commodity. SMILES: CCC1CN2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)OC)O.CL.
This classification denotes an organic carcinogen with the molecular formula C6H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XV74C1N1AE, chemically known as 1,4-hydroxybenzene but generally known as hydroquinone, which bears US NIH Compound Identifier 785. European Medicines Agency schedules Hydroquinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14140MIG. World Health Organization schedules hydroquinone in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, HYDROQUINONE remains the US FDA Preferred Term for this commodity. Hydroquinone bears US NLM identifiers UMLS ID C0020306 and NCI Concept Code C29823. SMILES: OC1CCC(O)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes an antacid preparation with the molecular formula CH7AlMgO10-4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17432CG1KU, chemically known as aluminum;magnesium;carbonate;heptahydroxide but generally known as hydrotalcite, which bears US NIH Compound Identifier 24838866. European Medicines Agency schedules Hydrotalcite in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08071MIG. World Health Organization schedules hydrotalcite in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROTALCITE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydrotalcite under HS 28429080 and SITC 52389. As of Q4 2014, HYDROTALCITE remains the US FDA Preferred Term for this commodity. SMILES: C(=O)([O-])[O-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3].
This classification denotes a diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U8687J667P. European Medicines Agency schedules Hydroxindasate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08072MIG. Hydroxindasate generally arises in the molecular formula C21H24N2O3. The term HYDROXINDASATE is an International Non-Proprietary Name or INN. HYDROXINDASATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydroxindasate under HS 29339990 and SITC 51577. As of Q4 2014, HYDROXINDASATE remains the US FDA Preferred Term for this commodity. Hydroxindasate bears US NLM identifiers UMLS ID C1881075 and NCI Concept Code C65866. SMILES: O(C1CC2C(C(N(C2CC1)CC1CCC(OC)CC1)C)CCN)C(=O)C.
Hydroxocobalamin, also known as vitamin B₁₂ₐ and hydroxycobalamin, is a vitamin found in food and used as a dietary supplement. As a supplement, it is used to treat vitamin B12 deficiency including pernicious anemia. Other uses include treatment for cyanide poisoning, Leber's optic atrophy, and toxic amblyopia.
This classification denotes an adrenergic agent with the molecular formula C9H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQR280JW2N, chemically known as phenol, 4-(2-aminopropyl)- but generally known as hydroxyamfetamine, which bears US NIH Compound Identifier 644000. European Medicines Agency schedules Hydroxyamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08075MIG. The term HYDROXYAMFETAMINE is an International Non-Proprietary Name. HYDROXYAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, HYDROXYAMPHETAMINE remains the US FDA Preferred Term for this commodity. Hydroxyamphetamine bears US NLM identifiers UMLS ID C0030140 and NCI Concept Code C61787. SMILES: OC1CCC(CC(N)C)CC1.
This classification denotes an adrenergic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59IG47SZ0E. European Medicines Agency schedules Hydroxyamfetamine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02581MIG. Hydroxyamphetamine hydrobromide generally arises in the molecular formula C9H13NO.BRH. The term 'hydroxyamphetamine hydrobromide' is a U.S. Pharmacopeial Convention designation. As of Q4 2014, HYDROXYAMPHETAMINE HYDROBROMIDE remains the US FDA Preferred Term for this commodity. Hydroxyamphetamine hydrobromide bears US NLM identifiers UMLS ID C0282278 and NCI Concept Code C47558. SMILES: OC1CCC(CC(N)C)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP600. This VA Drug Class (OP600) classifies this compound as belonging to the group MYDRIATICS/CYCLOPLEGICS, TOPICAL OPHTHALMIC.
This classification denotes a ribonucleotide reductase inhibitor and miscellaneous antimetabolite with the molecular formula CH4N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X6Q56QN5QC, chemically known as urea, n-hydroxy- but generally known as hydroxycarbamide, which bears US NIH Compound Identifier 3657. European Medicines Agency schedules Hydroxycarbamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08076MIG. The term HYDROXYCARBAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules hydroxycarbamide in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROXYCARBAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, HYDROXYUREA remains the US FDA Preferred Term for this commodity. Hydroxyurea bears US NLM identifiers UMLS ID C0020402 and NCI Concept Code C560. SMILES: ONC(=O)N.
This classification denotes an antimalarial agent with the molecular formula C18H26ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4QWG6N8QKH, chemically known as ethanol, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)- but generally known as hydroxychloroquine, which bears US NIH Compound Identifier 3652. European Medicines Agency schedules Hydroxychloroquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08077MIG. The term HYDROXYCHLOROQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules hydroxychloroquine in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROXYCHLOROQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydroxychloroquine under HS 29334990 and SITC 51575. As of Q4 2014, HYDROXYCHLOROQUINE remains the US FDA Preferred Term for this commodity. Hydroxychloroquine bears US NLM identifiers UMLS ID C0020336 and NCI Concept Code C557. SMILES: CLC1CC2NCCC(NC(CCCN(CCO)CC)C)C2CC1.
This classification denotes an antioxidant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HB6PN45W4J. European Medicines Agency schedules Idebenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08114MIG. Idebenone generally arises in the molecular formula C19H30O5. The term 'idebenone' is an International Nomenclature of Cosmetic Ingredients designation. IDEBENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Hydroxydecyl ubiquinone or idebenone bears US NLM identifiers UMLS ID C0123163 and NCI Concept Code C74158.
This classification denotes an anesthetic agent with the molecular formula C25H35O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53J8I8O5EW, chemically known as 4-[2-[(5R,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoate but generally known as hydroxydione, which bears US NIH Compound Identifier 23689389. European Medicines Agency schedules Hydroxydione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08078MIG. The term HYDROXYDIONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). As of Q4 2014, HYDROXYDIONE remains the US FDA Preferred Term for this commodity. SMILES: CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4C(=O)COC(=O)CCC(=O)[O-])C.
This classification denotes an anesthetic agent with the molecular formula C25H35O6.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53J8I8O5EW, chemically known as 21-hydroxypregnane-3,20-dione sodium hemisuccinate but more generally known as hydroxydione sodium, which bears US NIH Compound Identifier 5868. European Medicines Agency schedules Hydroxydione sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08078MIG. The term HYDROXYDIONE SODIUM SUCCINATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). Most nations, for tariff and trade purposes, schedule hydroxydione sodium succinate under HS 29171990 and SITC 51389. As of Q4 2014, HYDROXYDIONE SODIUM SUCCINATE remains US FDA's Preferred Term for this commodity. Hydroxydione sodium succinate bears US NLM identifiers UMLS ID C0042621 and NCI Concept Code C75960. SMILES: C[C@]12CCC(=O)C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)COC(=O)CCC(=O)[O-])C.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes an opioid receptor agonist with the molecular formula C15H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W1J43H2B3K, chemically known as 4-piperidinecarboxylic acid, 4-(m-hydroxyphenyl)-1-methyl-, ethyl ester but generally known as hydroxypethidine, which bears US NIH Compound Identifier 61120. European Medicines Agency schedules Hydroxypethidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08079MIG. The term HYDROXYPETHIDINE is an International Non-Proprietary Name. HYDROXYPETHIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydroxypethidine under HS 29333999 and SITC 51574. As of Q4 2014, HYDROXYPETHIDINE remains the US FDA Preferred Term for this commodity. Hydroxypethidine bears US NLM identifiers UMLS ID C2825263 and NCI Concept Code C80582. SMILES: O(C(=O)C1(CCN(CC1)C)C1CC(O)CCC1)CC.
This classification denotes a therapeutic progestin with the molecular formula C21H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21807M87J2, chemically known as 17-hydroxypregn-4-ene-3,20-dione but generally known as 17alpha-hydroxyprogesterone, which bears US NIH Compound Identifier 6238. European Medicines Agency schedules Hydroxyprogesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08081MIG. The term 17ALPHA-HYDROXYPROGESTERONE is an International Non-Proprietary Name. World Health Organization schedules 17alpha-hydroxyprogesterone in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule hydroxyprogesterone under HS 29372300 and SITC 54153. As of Q4 2014, HYDROXYPROGESTERONE remains the US FDA Preferred Term for this commodity. Hydroxyprogesterone bears US NLM identifiers UMLS ID C0045010 and NCI Concept Code C87242. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)C(=O)C.
This classification denotes a therapeutic progestin C23H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L124O66YSI, chemically known as 17.alpha.-hydroxy-4-pregnene-3,20-dione acetate, but more generally known as hydroxyprogesterone acetate, which bears US NIH Compound Identifier 9325. European Medicines Agency schedules Hydroxyprogesterone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16436MIG. Most nations, for tariff and trade purposes, schedule hydroxyprogesterone acetate under HS 29372300 and SITC 54153. As of Q4 2014, HYDROXYPROGESTERONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)OC(=O)C.
This classification denotes a therapeutic progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 276F2O42F5. European Medicines Agency schedules Hydroxyprogesterone caproate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08082MIG. Hydroxyprogesterone caproate generally arises in the molecular formula C27H40O4. The term HYDROXYPROGESTERONE CAPROATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) Most nations schedule hydroxyprogesterone caproate under HS 29372300 and SITC 54153. As of Q4 2014, HYDROXYPROGESTERONE CAPROATE remains the US FDA Preferred Term for this commodity. Hydroxyprogesterone caproate bears US NLM identifiers UMLS ID C0044971 and NCI Concept Code C960. SMILES: O(C1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)C(=O)C)C(=O)CCCCC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes an anesthetic agent with the molecular formula C15H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A96H4311N, chemically known as 4-(butylamino)-2-hydroxy-benzoic acid, 2-(dimethylino)ethyl ester (9ci) but generally known as hydroxytetracaine, which bears US NIH Compound Identifier 71630. European Medicines Agency schedules Hydroxytetracaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08086MIG. The term HYDROXYTETRACAINE is an International Non-Proprietary Name. HYDROXYTETRACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydroxytetracaine under HS 29225000 and SITC 51467. As of Q4 2014, HYDROXYTETRACAINE remains the US FDA Preferred Term for this commodity. Hydroxytetracaine bears US NLM identifiers UMLS ID C1881079 and NCI Concept Code C65872. SMILES: O(CCN(C)C)C(=O)C1C(O)CC(NCCCC)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H27ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30S50YM8OG, chemically known as ethanol, 2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)- but generally known as hydroxyzine, which bears US NIH Compound Identifier 3658. European Medicines Agency schedules Hydroxyzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08088MIG. The term HYDROXYZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules hydroxyzine in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROXYZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydroxyzine under HS 29335995 and SITC 51576. As of Q4 2014, HYDROXYZINE remains the US FDA Preferred Term for this commodity. Hydroxyzine bears US NLM identifiers UMLS ID C0020404 and NCI Concept Code C29103. SMILES: CLC1CCC(C(N2CCN(CC2)CCOCCO)C2CCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H27ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30S50YM8OG, chemically known as ethanol, 2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)- but generally known as hydroxyzine, which bears US NIH Compound Identifier 3658. European Medicines Agency schedules Hydroxyzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08088MIG. The term HYDROXYZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules hydroxyzine in its Anatomical Therapeutic Chemical (ATC) Classification. HYDROXYZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule hydroxyzine embonate under HS 29335995 and SITC 51576. SMILES: CLC1CCC(C(N2CCN(CC2)CCOCCO)C2CCCCC2)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.
This classification denotes an indicator, reagent, and coumarin with the molecular formula C10H8O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3T5NG4Q468, chemically known as 2h-1-benzopyren-2-one, 7-hydroxy-4-methyl- but generally known as hymecromone, which bears US NIH Compound Identifier 5280567. European Medicines Agency schedules Hymecromone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08089MIG. World Health Organization schedules hymecromone in its Anatomical Therapeutic Chemical (ATC) Classification. HYMECROMONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, HYMECROMONE remains the US FDA Preferred Term for this commodity. SMILES: CC1=CC(=O)OC2=C1C=CC(=C2)O.
This classification denotes a mydriatic agent and antimuscarinic agent with the molecular formula C17H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DL48G20X8X, chemically known as 1.alpha.h, 5.alpha.h-tropan-3.alpha.-ol, 6.beta.,7.beta.-epoxy-, (-)-tropate (ester), hydrobromide but generally known as hyoscine, which bears US NIH Compound Identifier 5184. European Medicines Agency schedules Hyoscine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14152MIG. World Health Organization schedules hyoscine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O1C2C1C1N(C2CC(OC(=O)C(CO)C2CCCCC2)C1)C.
This classification denotes an antimuscarinic agent with the molecular formula C17H23NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier PX44XO846X, chemically known as 1alphah,5alphah-tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate but more generally known as hyoscyamine, which bears U.S. National Institutes of Health Compound Identifier 3661. European Medicines Agency schedules Hyoscyamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14160MIG. World Health Organization schedules hyoscyamine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN301. This VA Drug Class (CN301) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers XK4IUX8MNB (base) and A6V4CUE7PV (flower), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 21454 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Malpighiales, Family Hypericaceae, Genus Hypericum L. (St. Johnswort), Species Hypericum perforatum L., commonly known as ST. JOHN'S WORT, KLAMATHWEED, KLAMATH WEED, or as here, HYPERICUM (perforatum). Hypericum bears the USDA PLANTS Database Identifier HYPE. European Medicines Agency schedules hypericum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB14170MIG, SUB30226, SUB30227, SUB35011, SUB40669, SUB40670, SUB47674, SUB47892, SUB47893, SUB47894, SUB47895, SUB47896, SUB48202, SUB61338, and SUB63700. SMILES: CC1=CC(=C2C3=C1C4=C5C(=C(C=C4C)O)C(=O)C6=C(C=C(C7=C6C5=C3C8=C7C(=CC(=C8C2=O)O)O)O)O)O.
This classification denotes a cholagogue, choleretic, histamine h1 antagonist, and phthalic anhydride with the molecular formula C26H32N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4MW5166YH, chemically known as 4,5,6-triethoxy-7-amino-3-(8-methoxy-2-methyl-6,7-methylenedioxy-1,2,3,4-tetrahydro-1-isochinolinyl)phthalid but generally known as tritoqualine, which bears US NIH Compound Identifier 72145. European Medicines Agency schedules Tritoqualine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11326MIG. World Health Organization schedules tritoqualine in its Anatomical Therapeutic Chemical (ATC) Classification. TRITOQUALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Hypostamine or tritoqualine bears US NLM identifiers UMLS ID C0077316 and NCI Concept Code C97409. SMILES: O1C(C2N(CCC3C2C(OC)C2OCOC2C3)C)C2C(C1=O)C(N)C(OCC)C(OCC)C2OCC.
This classification denotes a synthetic polymer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3NXW29V3WO. European Medicines Agency schedules Hypromellose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02622MIG. Hypromellose generally arises in the molecular formula (C9H14O6)N.CH3.H. The term 'hypromellose' is a European Pharmacopoeia designation. SMILES: CC(COCC1C(C(C(C(O1)OC)OCC(C)O)OCC(C)O)OC2C(C(C(C(O2)COC)OC3C(C(C(C(O3)CO)OC)O)O)OC)OC)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.
This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H12IN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3EK8532DZV, chemically known as cytidine, 2-deoxy-5-iodo- (8ci)(9ci) but generally known as ibacitabine, which bears US NIH Compound Identifier 65050. European Medicines Agency schedules Ibacitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08090MIG. The term IBACITABINE is an International Non-Proprietary Name. World Health Organization schedules ibacitabine in its Anatomical Therapeutic Chemical (ATC) Classification. IBACITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ibacitabine under HS 29349990 and SITC 51579. As of Q4 2014, IBACITABINE remains the US FDA Preferred Term for this commodity. Ibacitabine bears US NLM identifiers UMLS ID C0049263 and NCI Concept Code C83771. SMILES: IC1CN(C2OC(C(O)C2)CO)C(=O)NC1N.
This classification denotes a quinolone antibiotic with the molecular formula C15H14FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53VPK9R0T5, chemically known as 9-fluoro-6,7-dihydro-5,8-dimethyl-1-oxo-1h,5h-benzo(ij)quinolizine-2-carboxylic acid but generally known as ibafloxacin, which bears US NIH Compound Identifier 71186. European Medicines Agency schedules Ibafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08091MIG. The term IBAFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). IBAFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ibafloxacin under HS 29339990 and SITC 51577. As of Q4 2014, IBAFLOXACIN remains the US FDA Preferred Term for this commodity. Ibafloxacin bears US NLM identifiers UMLS ID C0098834 and NCI Concept Code C83772. SMILES: FC1C(C2CCC(N3C2C(C(=O)C(C3)C(=O)O)C1)C)C.
This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C9H23NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UMD7G2653W, chemically known as phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis- but generally known as ibandronic acid, which bears US NIH Compound Identifier 60852. European Medicines Agency schedules Ibandronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08092MIG. The term IBANDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules ibandronic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Ibandronate or ibandronic acid bears US NLM identifiers UMLS ID C0379200 and NCI Concept Code C65874. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CCN(CCCCC)C.
This classification denotes a vasodilating agent with the molecular formula C17H25NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VXW2HU8GS, chemically known as propanoic acid, 2-methyl-, 4-(2-(methylamino)ethyl)-1,2-phenylene ester but generally known as ibopamine, which bears US NIH Compound Identifier 68555. European Medicines Agency schedules Ibopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08094MIG. The term IBOPAMINE HYDROCHLORIDE is an International Non-Proprietary Name. World Health Organization schedules ibopamine in its Anatomical Therapeutic Chemical (ATC) Classification. IBOPAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ibopamine under HS 29222900 and SITC 51462. As of Q4 2014, IBOPAMINE remains the US FDA Preferred Term for this commodity. Ibopamine bears US NLM identifiers UMLS ID C0123043 and NCI Concept Code C65875. SMILES: O(C1CC(CCNC)CCC1OC(=O)C(C)C)C(=O)C(C)C.
This classification denotes a vasodilating agent with the molecular formula C17H25NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VXW2HU8GS, chemically known as propanoic acid, 2-methyl-, 4-(2-(methylamino)ethyl)-1,2-phenylene ester but more generally known as ibopamine, which bears US NIH Compound Identifier 68555. European Medicines Agency schedules Ibopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08094MIG. The term IBOPAMINE HYDROCHLORIDE is an International Non-Proprietary Name. World Health Organization schedules ibopamine in its Anatomical Therapeutic Chemical (ATC) Classification. IBOPAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ibopamine hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, IBOPAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C(=O)OC1CCC(CC1OC(=O)C(C)C)CCNC.CL.
This classification denotes an immunoconjugate, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4Q52C550XK. The European Medicines Agency schedules Ibritumomab tiuxetan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20031. Ibritumomab tiuxetan generally arises in the molecular formula C23H32N5O10S. The term IBRITUMOMAB TIUXETAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 14, no. 1, 2000, list 43.) SMILES: none.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 09C8B34RDF. European Medicines Agency schedules Ibrotamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08095MIG. Ibrotamide generally arises in the molecular formula C7H14BRNO. The term IBROTAMIDE is an International Non-Proprietary Name or INN. IBROTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ibrotamide under HS 29241900 and SITC 51471. As of Q4 2014, IBROTAMIDE remains the US FDA Preferred Term for this commodity. Ibrotamide bears US NLM identifiers UMLS ID C2827189 and NCI Concept Code C83773. SMILES: BRC(C(C)C)(CC)C(=O)N.
A type of kinase inhibitor
This classification denotes a vasodilating agent and antiplatelet agent with the molecular formula C14H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M0TTH61XC5, chemically known as 3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine but generally known as ibudilast, which bears US NIH Compound Identifier 3671. European Medicines Agency schedules Ibudilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08096MIG. The term IBUDILAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules ibudilast in its Anatomical Therapeutic Chemical (ATC) Classification. IBUDILAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ibudilast under HS 29339990 and SITC 51577. As of Q4 2014, IBUDILAST remains the US FDA Preferred Term for this commodity. Ibudilast bears US NLM identifiers UMLS ID C0123047 and NCI Concept Code C65876. SMILES: O=C(c1c(nn2c1cccc2)C(C)C)C(C)C.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WK2XYI10QM, chemically known as u-18,573 but generally known as ibuprofen, which bears US NIH Compound Identifier 3672. European Medicines Agency schedules Ibuprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08098MIG. The term IBUPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules ibuprofen in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ibuprofen under HS 29163990 and SITC 51379. As of Q4 2014, IBUPROFEN remains the US FDA Preferred Term for this commodity. Ibuprofen bears US NLM identifiers UMLS ID C0593507 and NCI Concept Code C561. SMILES: OC(=O)C(C1CCC(CC(C)C)CC1)C.
This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C13H17O2.Al.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0YGZ1VO1B, chemically known as aluminium, hydroxybis(.alpha.-methyl-4-(2-methylpropyl)benzeneacetato-.kappa.o)-, but more generally known as ibuprofen aluminum, which bears US NIH Compound Identifier 16683040. European Medicines Agency schedules ibuprofen aluminum or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08098MIG. Most nations, for tariff purposes, schedule ibuprofen aluminum under HS 29163990. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)[O-].CC(C)CC1CCC(CC1)C(C)C(=O)[O-].[OH-].[AL+3].
This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H18O2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N01ORX9D6S, chemically known as l-lysine, .alpha.-methyl-4-(2-methylpropyl)benzeneacetate (1:1), but more generally known as ibuprofen lysinate, which bears US NIH Compound Identifier 42368. European Medicines Agency schedules ibuprofen lysinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08098MIG. Most nations, for tariff purposes, schedule ibuprofen lysinate under HS 29163990. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)O.C(CCN)C[C@@H](C(=O)O)N.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B0F91K5U4N, chemically known as propionic acid, 2-(p-isobutylphenyl)-, 2-pyridylmethyl ester but more generally known as ibuprofen piconol, which bears US NIH Compound Identifier 3673. European Medicines Agency schedules Ibuprofen piconol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14175MIG. Most nations, for tariff and trade purposes, schedule ibuprofen piconol under HS 29163990 and SITC 51379. As of Q4 2014, IBUPROFEN PICONOL remains US FDA's Preferred Term for this commodity. Ibuprofen piconol bears US NLM identifiers UMLS ID C0071068 and NCI Concept Code C80556. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)OCC2CCCCN2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H17O2.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RM1CE97Z4N, chemically known as hydratropic acid, p-isobutyl-, sodium salt but more generally known as ibuprofen sodium, which bears US NIH Compound Identifier 161696. European Medicines Agency schedules Ibuprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21665. Most nations, for tariff and trade purposes, schedule ibuprofen sodium under HS 29163990 and SITC 51379. As of Q4 2014, IBUPROFEN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)[O-].O.O.[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3LD16O96Z, chemically known as propionohydroxamic acid, 2-(p-isobutylphenyl)-, d,l- but generally known as ibuproxam, which bears US NIH Compound Identifier 68704. European Medicines Agency schedules Ibuproxam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08099MIG. The term IBUPROXAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules ibuproxam in its Anatomical Therapeutic Chemical (ATC) Classification. IBUPROXAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ibuproxam under HS 29280090 and SITC 51486. As of Q4 2014, IBUPROXAM remains the US FDA Preferred Term for this commodity. Ibuproxam bears US NLM identifiers UMLS ID C0063268 and NCI Concept Code C83774. SMILES: O=C(NO)C(C1CCC(CC(C)C)CC1)C.
This classification denotes a cation channel blocker and antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2436VX1U9B. European Medicines Agency schedules Ibutilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08102MIG. Ibutilide generally arises in the molecular formula C20H36N2O3S. The term IBUTILIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, list 31.) IBUTILIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ibutilide under HS 29350090 and SITC 51580. As of Q4 2014, IBUTILIDE remains US FDA's Preferred Term for this commodity. Ibutilide bears US NLM identifiers UMLS ID C0082966 and NCI Concept Code C72581. SMILES: S(=O)(=O)(NC1CCC(C(O)CCCN(CCCCCCC)CC)CC1)C.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula 2C20H36N2O3S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9L5X4M5L6I. European Medicines Agency schedules ibutilide fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14176MIG. Most nations, for tariff and trade purposes, schedule ibutilide fumarate under HS 29350090 and SITC 51580. As of Q4 2014, IBUTILIDE FUMARATE remains US FDA's Preferred Term for this commodity. Ibutilide fumarate bears US NLM identifiers UMLS ID C0644117 and NCI Concept Code C47561. SMILES: CCCCCCCN(CC)CCCC(C1CCC(CC1)NS(=O)(=O)C)O.CCCCCCCN(CC)CCCC(C1CCC(CC1)NS(=O)(=O)C)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes an adrenergic beta-antagonist, non-steroidal anti-inflammatory agent, and antiasthmatic agent with the molecular formula C59H89N19O13S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7PG89G35Q7, chemically known as l-arginine, d-arginyl-l-arginyl-l-prolyl-trans-4-hydroxy-l-prolylglycyl-3-(2-thienyl)-l-alanyl-l-seryl-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2alpha,3abeta,7abeta)-octahydro-1h-indole-2-carbonyl- but generally known as icatibant, which bears US NIH Compound Identifier 71364. European Medicines Agency schedules Icatibant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08104MIG. World Health Organization schedules icatibant in its Anatomical Therapeutic Chemical (ATC) Classification. ICATIBANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule icatibant under HS 29349990 and SITC 51579. As of Q4 2014, ICATIBANT remains the US FDA Preferred Term for this commodity. Icatibant bears US NLM identifiers UMLS ID C0246269 and NCI Concept Code C98883. SMILES: S1C(CC(NC(=O)CNC(=O)C2N(CC(O)C2)C(=O)C2N(CCC2)C(=O)C(NC(=O)C(N)CCC/N=C(/N)N)CCC/N=C(/N)N)C(=O)NC(C(=O)N2C(C(=O)N3C4C(CC3C(=O)NC(CCC/N=C(/N)N)C(=O)O)CCCC4)CC3C(C2)CCCC3)CO)CCC1.
This classification denotes an adrenergic beta-antagonist C59H89N19O13S.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 325O8467XK, chemically known as l-arginine, d-arginyl-l-arginyl-l-prolyl-trans-4-hydroxy-l-prolylglycyl-3-(2-thienyl)-l-alanyl-l-seryl-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2.alpha.,3a.beta.,7a.beta.)-octahydro-1h-indole-2-carbonyl-, acetate (salt), but more generally known as icatibant acetate, which bears US NIH Compound Identifier 6918172. European Medicines Agency schedules Icatibant acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29718. Most nations, for tariff and trade purposes, schedule icatibant acetate under HS 29349990 and SITC 51579. As of Q4 2014, ICATIBANT ACETATE remains US FDA's Preferred Term for this commodity. Icatibant acetate bears US NLM identifiers UMLS ID C0082926 and NCI Concept Code C98884. SMILES: CC(=O)O.C1CCC2C(C1)C[C@@H](N(C2)C(=O)[C@H](CO)NC(=O)[C@H](CC3CCCS3)NC(=O)CNC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O)C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(=N)N)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE101. This VA Drug Class (DE101) classifies this compound as belonging to the group ANTIBACTERIAL, TOPICAL.
This classification denotes an antibiotic with the molecular formula C19H22N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42445HUU0O, chemically known as 5-((2rs)-2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-ylmethyl)pyrimidine-2,4-diamine but more generally known as iclaprim, which bears US NIH Compound Identifier 213043. European Medicines Agency schedules Iclaprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32201. The term ICLAPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 17, No. 4, 2003, List 50). The World Health Organization schedules iclaprim in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O1C(C2CC2)C=CC2C1C(OC)C(OC)CC2CC1C(NC(NC1)N)N.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U972CJ5AT. European Medicines Agency schedules Iclaprim mesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB28993. Iclaprim mesilate generally arises in the molecular formula C19H22N4O3.CH4O3S. The term 'iclaprim mesilate' is a United States Adopted Name designation.
This classification denotes a benzodiazepine with the molecular formula C21H21ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FL061Q6NMC, chemically known as 7-chloro-1-(2-(cyclopropylmethoxy)ethyl)-1,3-dihydro-5-phenyl-2h-1,4-benzodiazepin-2-one but generally known as iclazepam, which bears US NIH Compound Identifier 68777. European Medicines Agency schedules Iclazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08105MIG. The term ICLAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). ICLAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iclazepam under HS 29339940 and SITC 51577. As of Q4 2014, ICLAZEPAM remains the US FDA Preferred Term for this commodity. Iclazepam bears US NLM identifiers UMLS ID C1881125 and NCI Concept Code C65878. SMILES: CLC1CC2C(N(CCOCC3CC3)C(=O)CN=C2C2CCCCC2)CC1.
This classification denotes an anthracycline antibiotic with the molecular formula C26H27NO9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZRP63D75JW, chemically known as 5,12-naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7s-cis)- but generally known as idarubicin, which bears US NIH Compound Identifier 42890. European Medicines Agency schedules Idarubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08111MIG. The term IDARUBICIN is an International Non-Proprietary Name. World Health Organization schedules idarubicin in its Anatomical Therapeutic Chemical (ATC) Classification. IDARUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule idarubicin under HS 29419000 and SITC 54139. As of Q4 2014, IDARUBICIN remains the US FDA Preferred Term for this commodity. Idarubicin bears US NLM identifiers UMLS ID C0020789 and NCI Concept Code C562. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)CCCC2)C(=O)C)C1OC(C(O)C(N)C1)C.
This classification denotes an anthracycline antibiotic with the molecular formula C26H27NO9.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VV3MDU5IE, chemically known as daunomycin, 4-demethoxy-, hydrochloride but more generally known as idarubicin hydrochloride, which bears US NIH Compound Identifier 3685. European Medicines Agency schedules Idarubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02635MIG. Most nations, for tariff and trade purposes, schedule idarubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, IDARUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Idarubicin hydrochloride bears US NLM identifiers UMLS ID C0086450 and NCI Concept Code C1587. SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3C2C(C4C(C3O)C(=O)C5CCCCC5C4=O)O)(C(=O)C)O)N)O.CL.
The monoclonal antibody used as reversal anti-coagulant effects of dabigatran.
This classification denotes an antioxidant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HB6PN45W4J. European Medicines Agency schedules Idebenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08114MIG. Idebenone generally arises in the molecular formula C19H30O5. The term IDEBENONE is an International Nomenclature of Cosmetic Ingredients designation. IDEBENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule idebenone under HS 29146990 and SITC 51629. As of Q4 2014, IDEBENONE remains the US FDA Preferred Term for this commodity. Idebenone bears US NLM identifiers UMLS ID C0123163 and NCI Concept Code C74158. SMILES: OCCCCCCCCCCC1=C(C(=O)C(=C(OC)C1=O)OC)C.
A type of kinase Inhibitor
This classification denotes a selective estrogen receptor modulator with the molecular formula C28H30INO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 456UXE9867, chemically known as pyrrolidine, 1-(2-(4-(1-(4-iodophenyl)-2-phenyl-1-butenyl)phenoxy)ethyl)-, (e)- but more generally known as idoxifene, which bears US NIH Compound Identifier 3034011. European Medicines Agency schedules Idoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08116MIG. The term IDOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). IDOXIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule idoxifene under HS 29339990 and SITC 51577. As of Q4 2014, IDOXIFENE remains US FDA's Preferred Term for this commodity. Idoxifene bears US NLM identifiers UMLS ID C0139560 and NCI Concept Code C1406. SMILES: IC1CCC(C(=C(\CC)C2CCCCC2)/C2CCC(OCCN3CCCC3)CC2)CC1.
This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H11IN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LGP81V5245, chemically known as uridine, 5-iodo-2-deoxy- but generally known as idoxuridine, which bears US NIH Compound Identifier 3687. European Medicines Agency schedules Idoxuridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08117MIG. The term IDOXURIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules idoxuridine in its Anatomical Therapeutic Chemical (ATC) Classification. IDOXURIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule idoxuridine under HS 29349990 and SITC 51579. As of Q4 2014, IDOXURIDINE remains the US FDA Preferred Term for this commodity. Idoxuridine bears US NLM identifiers UMLS ID C0020811 and NCI Concept Code C563. SMILES: IC1CN(C2OC(C(O)C2)CO)C(=O)[NH]C1=O.
This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H11IN2O5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E78KL7PVW, chemically known as uridine, 2'-deoxy-5-iodo-, monohydrate, but more generally known as idoxuridine monohydrate, which bears US NIH Compound Identifier 28330. European Medicines Agency schedules idoxuridine monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08117MIG. Most nations, for tariff purposes, schedule idoxuridine monohydrate under HS 29349990. SMILES: C1C(C(=O)[NH]C(=O)N1[C@H]2C[C@@H]([C@H](O2)CO)O)I.O.
This classification denotes an alpha-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E2U4W02TMR. European Medicines Agency schedules Idralfidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08118MIG. Idralfidine generally arises in the molecular formula C11H14N4O. The term IDRALFIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) IDRALFIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule idralfidine under HS 29332990 and SITC 51573. As of Q4 2014, IDRALFIDINE remains the US FDA Preferred Term for this commodity. Idralfidine bears US NLM identifiers UMLS ID C2827191 and NCI Concept Code C83779. SMILES: CC\1=CC(=O)C=C/C1=C\NNC2=NCCN2.CL.
This classification denotes a muscle relaxant with the molecular formula C11H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6C816LUB1O, chemically known as 2-propenamide, n-(2-hydroxyethyl)-3-phenyl- but generally known as idrocilamide, which bears US NIH Compound Identifier 1550874. European Medicines Agency schedules Idrocilamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08121MIG. The term IDROCILAMIDE is an International Non-Proprietary Name. World Health Organization schedules idrocilamide in its Anatomical Therapeutic Chemical (ATC) Classification. IDROCILAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule idrocilamide under HS 29242995 and SITC 51479. As of Q4 2014, IDROCILAMIDE remains the US FDA Preferred Term for this commodity. Idrocilamide bears US NLM identifiers UMLS ID C0054086 and NCI Concept Code C74280. SMILES: C1=CC=C(C=C1)/C=C/C(=O)NCCO.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5U6118QYHK, chemically known as 1-((5,6-dihydro-1-naphthyl)oxy)-3-(isopropylamino)-2-propanol but generally known as idropranolol, which bears US NIH Compound Identifier 163314. European Medicines Agency schedules Idropranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08122MIG. The term IDROPRANOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). IDROPRANOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule idropranolol under HS 29221980 and SITC 51461. As of Q4 2014, IDROPRANOLOL remains the US FDA Preferred Term for this commodity. Idropranolol bears US NLM identifiers UMLS ID C2827192 and NCI Concept Code C83781. SMILES: O(CC(O)CNC(C)C)C1C2C(CCC=C2)CCC1.
Iduronidase is an enzyme with the systematic name glycosaminoglycan alpha-L-iduronohydrolase.This enzyme catalyses the hydrolysis of unsulfated alpha-L-iduronosidic linkages in dermatan sulfate and is indicated for people with Mucopolysaccharidosis type 1 (MPS 1).
Idursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme is used to treat some of the symptoms of a genetic condition called Hunter's syndrome, also called mucopolysaccharidosis.
This classification denotes a platelet aggregation inhibitor, antiparkinson agent, and anticonvulsant with the molecular formula 2C21H27NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89CTB4XUF7, chemically known as 4-benzyl-1-(beta,4-dihydroxy-alpha-methylphenethyl)piperidinium hydrogen tartrate but generally known as ifenprodil tartrate, which bears US NIH Compound Identifier 134832. European Medicines Agency schedules Ifenprodil tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02636MIG. Most nations schedule ifenprodil under HS 29333999 and SITC 51574. As of Q4 2014, IFENPRODIL remains the US FDA Preferred Term for this commodity. Ifenprodil bears US NLM identifiers UMLS ID C0063340 and NCI Concept Code C83782. SMILES: CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3.C(C(C(=O)O)O)(C(=O)O)O.
This classification denotes a platelet aggregation inhibitor, antiparkinson agent, and anticonvulsant with the molecular formula 2C21H27NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89CTB4XUF7, chemically known as 4-benzyl-1-(beta,4-dihydroxy-alpha-methylphenethyl)piperidinium hydrogen tartrate but more generally known as ifenprodil tartrate, which bears US NIH Compound Identifier 134832. European Medicines Agency schedules Ifenprodil tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02636MIG. Most nations, for tariff and trade purposes, schedule ifenprodil tartrate under HS 29333999 and SITC 51574. As of Q4 2014, IFENPRODIL TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C(C1CCC(CC1)O)O)N2CCC(CC2)CC3CCCCC3.CC(C(C1CCC(CC1)O)O)N2CCC(CC2)CC3CCCCC3.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an antiplatelet agent with the molecular formula C25H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E833KT807K, chemically known as benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, (1s-(exo,exo))- but generally known as ifetroban, which bears US NIH Compound Identifier 64924. European Medicines Agency schedules Ifetroban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08124MIG. The term IFETROBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). IFETROBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ifetroban under HS 29349990 and SITC 51579. As of Q4 2014, IFETROBAN remains the US FDA Preferred Term for this commodity. Ifetroban bears US NLM identifiers UMLS ID C0287939 and NCI Concept Code C81570. SMILES: O1C2C(C(C1CC2)C1OCC(N1)C(=O)NCCCCC)CC1C(CCC(=O)O)CCCC1.
This classification denotes an antiplatelet agent C25H31N2O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48IJA0E92C, chemically known as benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, monosodium salt, (1s-(exo,exo))-, but more generally known as ifetroban sodium, which bears US NIH Compound Identifier 23663994. Most nations, for tariff and trade purposes, schedule ifetroban sodium under HS 29349990 and SITC 51579. As of Q4 2014, IFETROBAN SODIUM remains US FDA's Preferred Term for this commodity. Ifetroban sodium bears US NLM identifiers UMLS ID C2825686 and NCI Concept Code C81569. SMILES: CCCCCNC(=O)C1COC(N1)[C@@H]2[C@H]3CC[C@@H]([C@@H]2CC4CCCCC4CCC(=O)[O-])O3.[NA+].
This classification denotes a nitrogen mustard compound with the molecular formula C7H15Cl2N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UM20QQM95Y, chemically known as 1,3,2-oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide but more generally known as ifosfamide, which bears US NIH Compound Identifier 3690. European Medicines Agency schedules Ifosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08125MIG. The term IFOSFAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules ifosfamide in its Anatomical Therapeutic Chemical (ATC) Classification. IFOSFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ifosfamide under HS 29349990 and SITC 51579. As of Q4 2014, IFOSFAMIDE remains US FDA's Preferred Term for this commodity. Ifosfamide bears US NLM identifiers UMLS ID C0020823 and NCI Concept Code C564. SMILES: CLCCN1P(=O)(OCCC1)NCCCL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN100. This VA Drug Class (AN100) classifies this compound as belonging to the group ANTINEOPLASTICS, ALKYLATING AGENTS.
This classification denotes an antidepressant agent with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LHH887104B, chemically known as 3-piperidinol, 4-(2,3-dimethylphenoxy)-, cis- but generally known as ifoxetine, which bears US NIH Compound Identifier 71971. European Medicines Agency schedules Ifoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08126MIG. The term IFOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). IFOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ifoxetine under HS 29333999 and SITC 51574. As of Q4 2014, IFOXETINE remains the US FDA Preferred Term for this commodity. Ifoxetine bears US NLM identifiers UMLS ID C0123216 and NCI Concept Code C65884. SMILES: O(C1C(O)CNCC1)c1c(c(ccc1)C)C.
This classification denotes an anticonvulsant agent with the molecular formula C15H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ML58O200F, chemically known as 1-(3-(1,3-benzodioxol-5-yl)-1-oxo-2-propenyl)piperidine but generally known as ilepcimide, which bears US NIH Compound Identifier 54930. European Medicines Agency schedules Ilepcimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08130MIG. The term ILEPCIMIDE is an International Non-Proprietary Name. ILEPCIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ilepcimide under HS 29349990 and SITC 51579. As of Q4 2014, ILEPCIMIDE remains the US FDA Preferred Term for this commodity. Ilepcimide bears US NLM identifiers UMLS ID C0284581 and NCI Concept Code C72810. SMILES: O=C(N1CCCCC1)/C=C/C1CC2OCOC2CC1.
This classification denotes a thrombolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 753UJ7AGLA. European Medicines Agency schedules Iliparcil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08131MIG. Iliparcil generally arises in the molecular formula C15H15CLO6S. The term ILIPARCIL is an International Non-Proprietary Name or INN. ILIPARCIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iliparcil under HS 29349990 and SITC 51579. As of Q4 2014, ILIPARCIL remains the US FDA Preferred Term for this commodity. Iliparcil bears US NLM identifiers UMLS ID C0909750 and NCI Concept Code C83783. SMILES: S1C(OC2CC3OC(=O)CC(C3CC2)CC)C(O)C(O)C(O)C1.
This classification denotes an antipsychotic agent with the molecular formula C24H27FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VPO7KJ050N, chemically known as 4-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3-methoxyacetophenone but generally known as iloperidone, which bears US NIH Compound Identifier 71360. European Medicines Agency schedules Iloperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08135MIG. The term ILOPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). ILOPERIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iloperidone under HS 29349990 and SITC 51579. As of Q4 2014, ILOPERIDONE remains the US FDA Preferred Term for this commodity. Iloperidone bears US NLM identifiers UMLS ID C0247194 and NCI Concept Code C83784. SMILES: FC1CC2ONC(C3CCN(CC3)CCCOC3C(OC)CC(CC3)C(=O)C)C2CC1.
This classification denotes a prostaglandin analogue and chemopreventive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JED5K35YGL. European Medicines Agency schedules Iloprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08136MIG. Iloprost generally arises in the molecular formula C22H32O4. The term ILOPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) ILOPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iloprost under HS 29375000 and SITC 54156. As of Q4 2014, ILOPROST remains the US FDA Preferred Term for this commodity. Iloprost bears US NLM identifiers UMLS ID C0079594 and NCI Concept Code C48397. SMILES: CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C29H31N7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BKJ8M8G5HI, chemically known as benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)- but generally known as imatinib, which bears US NIH Compound Identifier 5291. European Medicines Agency schedules Imatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25387. The term IMATINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). World Health Organization schedules imatinib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule imatinib under HS 29335995 and SITC 51576. As of Q4 2014, IMATINIB remains the US FDA Preferred Term for this commodity. Imatinib bears US NLM identifiers UMLS ID C0935989 and NCI Concept Code C62035. SMILES: O=C(NC1CC(NC2NC(C3CCCNC3)CCN2)C(CC1)C)C1CCC(CN2CCN(CC2)C)CC1.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C29H31N7O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A1O1M485B, chemically known as benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)aminophenyl)-, methanesulfonate salt, but more generally known as imatinib mesylate, which bears US NIH Compound Identifier 5291. European Medicines Agency schedules imatinib mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25387. As of Q4 2014, IMATINIB MESYLATE remains US FDA's Preferred Term for this commodity. Imatinib mesylate bears US NLM identifiers UMLS ID C0939537 and NCI Concept Code C1687. Most nations, for tariff purposes, schedule imatinib mesylate under HS 29335995. SMILES: CC1CCC(CC1NC2NCCC(N2)C3CCCNC3)NC(=O)C4CCC(CC4)CN5CCN(CC5)C.CS(=O)(=O)O.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H12N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 6PVQ5VQW24 chemically known as 3(2h)-pyridazinone, 4,5-dihydro-6-(4-(1h-imidazol-1-yl)phenyl) but generally known as imazodan, which bears US NIH Compound Identifier 55918. European Medicines Agency schedules Imazodan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08139MIG. The term IMAZODAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26). Most nations schedule imazodan under HS 29332990 and SITC 51573. As of Q4 2014, IMAZODAN remains the US FDA Preferred Term for this commodity. Imazodan bears US NLM identifiers UMLS ID C0055686 and NCI Concept Code C83787. SMILES: C1CC(=O)NN=C1C2=CC=C(C=C2)N3C=CN=C3.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H12N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5EP74J9Q34, chemically known as 4,5-dihydro-6-(p-imidazol-1-ylphenyl)-3(2h)-pyridazinone monohydrochloride but more generally known as imazodan hydrochloride, which bears US NIH Compound Identifier 55917. Most nations, for tariff and trade purposes, schedule imazodan hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, IMAZODAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Imazodan hydrochloride bears US NLM identifiers UMLS ID C0956497 and NCI Concept Code C72811. SMILES: C1CC(CCC1C2=NNC(=O)CC2)N3CCNC3.CL.
This classification denotes an antiparasitic agent with the molecular formula C17H30N4O7P2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21H450VP7K, chemically known as tetraethyl (2-methoxy-1,4-phenylen)bis(3-thioureidophosphonat) but generally known as imcarbofos, which bears US NIH Compound Identifier 3038394. European Medicines Agency schedules Imcarbofos in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08140MIG. The term IMCARBOFOS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). IMCARBOFOS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imcarbofos under HS 29309085 and SITC 51549. As of Q4 2014, IMCARBOFOS remains the US FDA Preferred Term for this commodity. Imcarbofos bears US NLM identifiers UMLS ID C1881137 and NCI Concept Code C65891. SMILES: S=C(NC1C(OC)CC(NC(=S)NP(=O)(OCC)OCC)CC1)NP(=O)(OCC)OCC.
This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BW7H1TJS22. European Medicines Agency schedules Imidapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08143MIG. Imidapril generally arises in the molecular formula C20H27N3O6. The term IMIDAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) IMIDAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imidapril under HS 29332990 and SITC 51573. As of Q4 2014, IMIDAPRIL remains the US FDA Preferred Term for this commodity. Imidapril bears US NLM identifiers UMLS ID C0165703 and NCI Concept Code C72908. SMILES: O=C(N1C(CN(C1=O)C)C(=O)O)C(NC(CCc1ccccc1)C(=O)OCC)C.
This classification denotes an ace inhibitor with the molecular formula C18H23N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WUU07Y30IA, chemically known as 4-imidazolidinecarboxylic acid, 3-((2s)-2-(((1s)-1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-1-methyl-2-oxo-, (4s)- but generally known as imidaprilat, which bears US NIH Compound Identifier 5464344. European Medicines Agency schedules Imidaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08144MIG. The term IMIDAPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). IMIDAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imidaprilat under HS 29332990 and SITC 51573. As of Q4 2014, IMIDAPRILAT remains the US FDA Preferred Term for this commodity. Imidaprilat bears US NLM identifiers UMLS ID C0246977 and NCI Concept Code C65893. SMILES: O=C(N1C(CN(C1=O)C)C(=O)O)C(NC(CCc1ccccc1)C(=O)O)C.
This classification denotes an ace inhibitor with the molecular formula C20H27N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NSF9GG1NU, chemically known as 4-imidazolidinecarboxylic acid, 3-((2s)-2-(((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1-methyl-2-oxo-, monohydrochloride, (4s)- but more generally known as imidapril hydrochloride, which bears US NIH Compound Identifier 5485193. European Medicines Agency schedules Imidapril hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02642MIG. Most nations, for tariff and trade purposes, schedule imidapril hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, IMIDAPRIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Imidapril hydrochloride bears US NLM identifiers UMLS ID C0872994 and NCI Concept Code C99550. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O.CL.
This classification denotes an ace inhibitor with the molecular formula C20H27N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NSF9GG1NU, chemically known as 3-((2s)-2-((1s)-n-(1-ethoxycarbonyl-3-phenylpropyl)amino)-propionyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid, hydrochloride-, 4s-, but more generally known as imidapril monohydrochloride, which bears US NIH Compound Identifier 5485193. European Medicines Agency schedules imidapril monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08143MIG. Most nations, for tariff purposes, schedule imidapril monohydrochloride under HS 29332990. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H6O3.C3H4N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4JVD4X01MJ, chemically known as salicylic acid, compound with imidazole (1:1) but generally known as imidazole salicylate, which bears US NIH Compound Identifier 37425. European Medicines Agency schedules Imidazole salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08145MIG. The term IMIDAZOLE SALICYLATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules imidazole salicylate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule imidazole salicylate under HS 29332990 and SITC 51573. As of Q4 2014, IMIDAZOLE SALICYLATE remains the US FDA Preferred Term for this commodity. Imidazole salicylate bears US NLM identifiers UMLS ID C0063384 and NCI Concept Code C65894. SMILES: C1=CC=C(C(=C1)C(=O)O)O.C1=CN=CN1.
This classification denotes an antiprotozoal agent with the molecular formula C19H20N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8USS3K0VDH, chemically known as 3,3-di-2-imidazolin-2-ylcarbanilide dihydrochloride but generally known as imidocarb, which bears US NIH Compound Identifier 21389. European Medicines Agency schedules Imidocarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08146MIG. The term IMIDOCARB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). IMIDOCARB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imidocarb under HS 29332990 and SITC 51573. As of Q4 2014, IMIDOCARB remains the US FDA Preferred Term for this commodity. Imidocarb bears US NLM identifiers UMLS ID C0020928 and NCI Concept Code C83790. SMILES: O=C(NC1CC(C2=NCCN2)CCC1)NC1CC(C2=NCCN2)CCC1.
This classification denotes an enzyme replacement preparation with the molecular formula C2532H3843N671O711S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q6U6J48BWY, more generally known as imiglucerase. European Medicines Agency schedules imiglucerase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08148MIG. The term IMIGLUCERASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35. IMIGLUCERASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Imiglucerase under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, IMIGLUCERASE remains the US FDA Preferred Term for this commodity. . Imiglucerase bears US NLM identifiers UMLS ID C0291139 and NCI Concept Code C65896.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZJ56PS1DWK, chemically known as 1h-imidazole, 2-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-1-ethyl-, (7r-(7alpha,8beta,10beta))- but generally known as imiloxan, which bears US NIH Compound Identifier 133621. European Medicines Agency schedules Imiloxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08149MIG. The term IMILOXAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). IMILOXAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imiloxan under HS 29349990 and SITC 51579. As of Q4 2014, IMILOXAN remains the US FDA Preferred Term for this commodity. Imiloxan bears US NLM identifiers UMLS ID C0063395 and NCI Concept Code C83792. SMILES: O1C(CC2N(CC)CCN2)COC2C1CCCC2.
This classification denotes an alpha-adrenergic blocking agent C14H16N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X72FO6ZLZY, chemically known as (+/-)-2-(1,4-benzodioxan-2-ylmethyl)-1-ethylimidazole monohydrochloride, but more generally known as imiloxan hydrochloride, which bears US NIH Compound Identifier 172975. Most nations, for tariff and trade purposes, schedule imiloxan hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, IMILOXAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Imiloxan hydrochloride bears US NLM identifiers UMLS ID C2827196 and NCI Concept Code C83793. SMILES: CCN1CCNC1CC2COC3CCCCC3O2.CL.
This classification denotes a sedative and hypnotic with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H0X939RX9W, chemically known as 3-ethyl-3-phenyl-2,6-piperazindion but generally known as iminophenimide, which bears US NIH Compound Identifier 163317. European Medicines Agency schedules Iminophenimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08150MIG. The term IMINOPHENIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). IMINOPHENIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iminophenimide under HS 29335995 and SITC 51576. As of Q4 2014, IMINOPHENIMIDE remains the US FDA Preferred Term for this commodity. Iminophenimide bears US NLM identifiers UMLS ID C2826568 and NCI Concept Code C82923. SMILES: CCC1(C(=O)NC(=O)CN1)C2=CC=CC=C2.
This classification denotes a beta-lactam antibiotic with the molecular formula C12H17N3O4S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71OTZ9ZE0A, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5r-(5-alpha,6-alpha(r*)))- but generally known as imipenem, which bears US NIH Compound Identifier 47317. European Medicines Agency schedules Imipenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08151MIG. IMIPENEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imipenem under HS 29419000 and SITC 54139. As of Q4 2014, IMIPENEM remains the US FDA Preferred Term for this commodity. Imipenem bears US NLM identifiers UMLS ID C0020933 and NCI Concept Code C570. SMILES: CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O.
This classification denotes a beta-lactam antibiotic with the molecular formula C12H17N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q20IM7HE75, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5r-(5.alpha.,6.alpha.(r*)))-, but more generally known as imipenem anhydrous, which bears US NIH Compound Identifier 47317. European Medicines Agency schedules imipenem anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08151MIG. Most nations, for tariff purposes, schedule imipenem anhydrous under HS 29419000. SMILES: C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCNC=N)O.
This classification denotes a tricyclic antidepressant with the molecular formula C23H16O6.2C19H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MC34P30298. European Medicines Agency schedules imipramine embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02643MIG. The term imipramine embonate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule imipramine embonate under HS 29339990. SMILES: CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes a tricyclic antidepressant with the molecular formula C19H24N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BKE5Q1J60U, chemically known as 5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine but more generally known as imipramine hydrochloride, which bears US NIH Compound Identifier 3696. European Medicines Agency schedules Imipramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02644MIG. Most nations, for tariff and trade purposes, schedule imipramine hydrochloride under HS 29339990. As of Q4 2014, IMIPRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Imipramine hydrochloride bears US NLM identifiers UMLS ID C0589978 and NCI Concept Code C29116. SMILES: CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.CL.
This classification denotes a tricyclic antidepressant with the molecular formula C19H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OGG85SX4E4, chemically known as 5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine but generally known as imipramine, which bears US NIH Compound Identifier 3696. European Medicines Agency schedules Imipramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08152MIG. The term IMIPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules imipramine in its Anatomical Therapeutic Chemical (ATC) Classification. IMIPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: N1(CCCN(C)C)c2c(CCc3c1cccc3)cccc2.
This classification denotes a tricyclic antidepressant with the molecular formula C23H16O6.2C19H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MC34P30298. European Medicines Agency schedules imipramine pamoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02643MIG. The term imipramine embonate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule imipramine pamoate under HS 29339990. As of Q4 2014, IMIPRAMINE PAMOATE remains US FDA's Preferred Term for this commodity. Imipramine pamoate bears US NLM identifiers UMLS ID C0304368 and NCI Concept Code C61788. SMILES: CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes a biological response modifier with the molecular formula C14H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P1QW714R7M, chemically known as 4-amino-1-isobutyl-1h-imidazo(4,5-c)quinoline but generally known as imiquimod, which bears US NIH Compound Identifier 57469. European Medicines Agency schedules Imiquimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12453MIG. The term IMIQUIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules imiquimod in its Anatomical Therapeutic Chemical (ATC) Classification. IMIQUIMOD is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imiquimod under HS 29339990 and SITC 51577. As of Q4 2014, IMIQUIMOD remains the US FDA Preferred Term for this commodity. Imiquimod bears US NLM identifiers UMLS ID C0165032 and NCI Concept Code C1431. SMILES: N1(CC(C)C)C2C3C(NC(N)C2NC1)CCCC3.
This classification denotes an aldose reductase inhibitor with the molecular formula C15H8F2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PM69S95UQ, chemically known as 2,7-difluorospiro(fluorene-9,4-imidazolidine)-2,5-dione but generally known as imirestat, which bears US NIH Compound Identifier 65673. European Medicines Agency schedules Imirestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08154MIG. The term IMIRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). IMIRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imirestat under HS 29332100 and SITC 51572. As of Q4 2014, IMIRESTAT remains the US FDA Preferred Term for this commodity. Imirestat bears US NLM identifiers UMLS ID C0063406 and NCI Concept Code C96290. SMILES: FC1CC2C3(NC(=O)NC3=O)C3C(C2CC1)CCC(F)C3.
This classification denotes a vasodilating agent with the molecular formula C14H20N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5F4RU5VQJ, chemically known as 4-(2-(diethylamino)ethyl)-5-imino-3-phenyl-delta(sup 2)-1,2,4-oxadiazoline but generally known as imolamine, which bears US NIH Compound Identifier 27501. European Medicines Agency schedules Imolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08156MIG. The term IMOLAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules imolamine in its Anatomical Therapeutic Chemical (ATC) Classification. IMOLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imolamine under HS 29349990 and SITC 51579. As of Q4 2014, IMOLAMINE remains the US FDA Preferred Term for this commodity. Imolamine bears US NLM identifiers UMLS ID C0063433 and NCI Concept Code C65899. SMILES: o1nc(n(CCN(CC)CC)c1=N)c1ccccc1.
This classification denotes a vasodilating agent C14H20N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJ3KV70R41, chemically known as .delta.2-1,2,4-oxadiazoline, 4-(2-(diethylamino)ethyl)-5-imino-3-phenyl-, monohydrochloride, but more generally known as imolamine hydrochloride, which bears US NIH Compound Identifier 27500. Most nations, for tariff and trade purposes, schedule imolamine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, IMOLAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCN1C(NOC1=N)C2CCCCC2.CL.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR4924C6G2. European Medicines Agency schedules Imoxiterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08157MIG. Imoxiterol generally arises in the molecular formula C20H25N3O3. The term IMOXITEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) IMOXITEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Imoxiterol under HS 29339990 and SITC 51577. As of Q4 2014, IMOXITEROL remains the US FDA Preferred Term for this commodity. Imoxiterol bears US NLM identifiers UMLS ID C2827197 and NCI Concept Code C83794. SMILES: CC(CCN1CNC2C1CCCC2)NCC(C3CCC(C(C3)OC)O)O.
This classification denotes an anti-lipidemic agent with the molecular formula C35H37N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q70OH404HR, chemically known as (alphas)-alpha-(alpha-(2,4-dimethyl-9h-pyrido(2,3-b)indol-9-yl)-p-tolyl)-n-((alphar)-alpha-(hydroxymethyl)benzyl)cyclopentaneacetamide. but generally known as implitapide, which bears US NIH Compound Identifier 5745206. The term IMPLITAPIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule implitapide under HS 29339990 and SITC 51577. As of Q4 2014, IMPLITAPIDE remains the US FDA Preferred Term for this commodity. Implitapide bears US NLM identifiers UMLS ID C1100413 and NCI Concept Code C65901. SMILES: CC1=CC(=NC2=C1C3=CC=CC=C3N2CC4=CC(=CC=C4)C(C5CCCC5)C(=O)NC(CO)C6=CC=CC=C6)C.
This classification denotes an anti-lipidemic agent with the molecular formula C14H23N7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 931L4X5WMM, chemically known as guanidine, n-(3-(1h-imidazol-4-yl)propyl)-n-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)- but generally known as impromidine, which bears US NIH Compound Identifier 41376. European Medicines Agency schedules Impromidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08159MIG. The term IMPROMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). IMPROMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule impromidine under HS 29332990 and SITC 51573. As of Q4 2014, IMPROMIDINE remains the US FDA Preferred Term for this commodity. Impromidine bears US NLM identifiers UMLS ID C0063440 and NCI Concept Code C65902. SMILES: S(CCN/C(=N/CCCC1[NH]CNC1)N)CC1NC[NH]C1C.
This classification denotes an anti-lipidemic agent with the molecular formula C14H23N7S.3ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E57WP5Y41J, chemically known as guanidine, n-(3-(1h-imidazol-4-yl)propyl)-n'-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)-, trihydrochloride, but more generally known as impromidine hydrochloride, which bears US NIH Compound Identifier 163318. European Medicines Agency schedules impromidine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08159MIG. Most nations, for tariff purposes, schedule impromidine hydrochloride under HS 29332990. Impromidine hydrochloride bears US NLM identifiers UMLS ID C0886650 and NCI Concept Code C65903. SMILES: CC1C(NC[NH]1)CSCCNC(=N)NCCCC2C[NH]CN2.CL.CL.CL.
This classification denotes an alkylsulfonate compound with the molecular formula C8H19NO6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32Y1F7N1ZD, chemically known as 3,3-iminodi-1-propanol dimethanesulfonate (ester) but more generally known as improsulfan, which bears US NIH Compound Identifier 18949. European Medicines Agency schedules Improsulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08160MIG. The term IMPROSULFAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). IMPROSULFAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule improsulfan under HS 29221980 and SITC 51461. As of Q4 2014, IMPROSULFAN remains US FDA's Preferred Term for this commodity. Improsulfan bears US NLM identifiers UMLS ID C1512683 and NCI Concept Code C2308. SMILES: S(=O)(=O)(OCCCNCCCOS(=O)(=O)C)C.
This classification denotes an alkylsulfonate compound C8H19NO6S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GHX2MNT176, chemically known as 1-propanol, 3,3'-iminobis-, dimethanesulfonate (ester), hydrochloride, but more generally known as improsulfan hydrochloride, which bears US NIH Compound Identifier 18948. Most nations, for tariff and trade purposes, schedule improsulfan hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, IMPROSULFAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CS(=O)(=O)OCCCNCCCOS(=O)(=O)C.CL.
This classification denotes an alkylsulfonate compound with the molecular formula C8H19NO6S2.C7H8O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V878J97JFF, chemically known as bis(3-methylsulfonyloxypropyl)amine p-toluenesulfonate, but more generally known as improsulfan tosilate, which bears US NIH Compound Identifier 153709. European Medicines Agency schedules improsulfan tosilate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08160MIG. Most nations, for tariff purposes, schedule improsulfan tosilate under HS 29221980. SMILES: CC1CCC(CC1)S(=O)(=O)O.CS(=O)(=O)OCCCNCCCOS(=O)(=O)C.
This classification denotes a neuroprotective agent with the molecular formula C11H18N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 972FNV35ZM, chemically known as 1,3-bis((2-oxo-1-pyrrolidinyl)methyl)harnstoff but generally known as imuracetam, which bears US NIH Compound Identifier 163319. European Medicines Agency schedules Imuracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08161MIG. The term IMURACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). IMURACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imuracetam under HS 29337900 and SITC 51561. As of Q4 2014, IMURACETAM remains the US FDA Preferred Term for this commodity. Imuracetam bears US NLM identifiers UMLS ID C1881153 and NCI Concept Code C65904. SMILES: C1CC(=O)N(C1)CNC(=O)NCN2CCCC2=O.
This classification denotes a muscle relaxant with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0QAC3P785O, chemically known as 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pyrrolidinyl)-, but generally known as inaperisone, which bears US NIH Compound Identifier 65860. European Medicines Agency schedules Inaperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08162MIG. The term INAPERISONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). INAPERISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule inaperisone under HS 29339990 and SITC 51577. As of Q4 2014, INAPERISONE remains the US FDA Preferred Term for this commodity. Inaperisone bears US NLM identifiers UMLS ID C0062996 and NCI Concept Code C65905. SMILES: O=C(C(CN1CCCC1)C)C1CCC(CC1)CC.
This classification denotes a muscle relaxant with the molecular formula C16H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67D70I271P, chemically known as inaperisone hydrochloride, (+/-)-, but more generally known as inaperisone hydrochloride, which bears US NIH Compound Identifier 147524. European Medicines Agency schedules inaperisone hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08162MIG. Most nations, for tariff purposes, schedule inaperisone hydrochloride under HS 29339990. SMILES: CCC1CCC(CC1)C(=O)C(C)CN2CCCC2.CL.
This classification denotes a beta-adrenergic agonist with the molecular formula C24H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8OR09251MQ, chemically known as 5-{(1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl}-8-hydroxyquinolin-2(1h)-one but generally known as indacaterol, which bears US NIH Compound Identifier 6433117. European Medicines Agency schedules Indacaterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30138. The term INDACATEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). World Health Organization schedules indacaterol in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule indacaterol under HS 29337900 and SITC 51561. As of Q4 2014, INDACATEROL remains the US FDA Preferred Term for this commodity. Indacaterol bears US NLM identifiers UMLS ID C1722260 and NCI Concept Code C81644. SMILES: OC(CNC1CC2C(C1)CC(C(C2)CC)CC)C1C2C([NH]C(=O)CC2)C(O)CC1.
Indacaterol/glycopyrronium bromide is a fixed-dose combination medication for inhalation consisting of the following two active ingredients: Indacaterol maleate, an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA); Glycopyrronium bromide (glycopyrrolate), a muscarinic anticholinergic.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JEC1ITX7R. European Medicines Agency schedules Indacaterol maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30300. Indacaterol maleate generally arises in the molecular formula C24H28N2O3.C4H4O4. The term 'indacaterol maleate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule indacaterol maleate under HS 29337900 and SITC 51561. As of Q4 2014, INDACATEROL MALEATE remains US FDA's Preferred Term for this commodity. Indacaterol maleate bears US NLM identifiers UMLS ID C2920417 and NCI Concept Code C81640. SMILES: CCC1CC2C(CC1CC)CC(C2)NC[C@@H](C3CCC(C4C3CCC(=O)[NH]4)O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0U38EHD86, chemically known as 1h-imidazol-2-amine, n-(2,3-dihydro-1h-inden-4-yl)-4,5-dihydro- but generally known as indanazoline, which bears US NIH Compound Identifier 65979. European Medicines Agency schedules Indanazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08166MIG. The term INDANAZOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). INDANAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Indanazoline under HS 29332990 and SITC 51573. As of Q4 2014, INDANAZOLINE remains the US FDA Preferred Term for this commodity. Indanazoline bears US NLM identifiers UMLS ID C0063449 and NCI Concept Code C65908. SMILES: C1CC2C(C(C1)NC3=NCCN3)CCC2.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H15N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z364A90IV8, chemically known as 2-imidazoline, 2-(4-indanylamino)-, hydrochloride but more generally known as indanazoline hydrochloride, which bears US NIH Compound Identifier 162014. European Medicines Agency schedules Indanazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02661MIG. Most nations, for tariff and trade purposes, schedule indanazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, INDANAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Indanazoline hydrochloride bears US NLM identifiers UMLS ID C1609361 and NCI Concept Code C97700. SMILES: C1CC2C(C(C1)NC3=NCCN3)CCC2.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H13N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MP564IFE34, chemically known as 2h-indazol-4-amine, n-(4,5-dihydro-1h-imidazol-2-yl)-2-methyl-, hydrochloride but generally known as indanidine, which bears US NIH Compound Identifier 121924. European Medicines Agency schedules Indanidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08167MIG. The term INDANIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). INDANIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Indanidine under HS 29332990 and SITC 51573. As of Q4 2014, INDANIDINE remains the US FDA Preferred Term for this commodity. Indanidine bears US NLM identifiers UMLS ID C0244275 and NCI Concept Code C65909. SMILES: CN1CC2C(N1)CCCC2NC3=NCCN3.
This classification denotes an anorexiant with the molecular formula C12H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 982LOO7DEE, chemically known as 1h-inden-2-ol, 2-(1-aminopropyl)-2,3-dihydro- but more generally known as indanorex, which bears US NIH Compound Identifier 65623. European Medicines Agency schedules Indanorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08168MIG. The term INDANOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). INDANOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule indanorex under HS 29221980 and SITC 51461. As of Q4 2014, INDANOREX remains US FDA's Preferred Term for this commodity. Indanorex bears US NLM identifiers UMLS ID C2827198 and NCI Concept Code C83795. SMILES: CCC(C1(CC2=CC=CC=C2C1)O)N.
This classification denotes a thiazide diuretic with the molecular formula C16H16ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F089I0511L, chemically known as 4-chloro-n-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoyl-benzamide but generally known as indapamide, which bears US NIH Compound Identifier 3702. European Medicines Agency schedules Indapamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08169MIG. The term INDAPAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules indapamide in its Anatomical Therapeutic Chemical (ATC) Classification. INDAPAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule indapamide under HS 29350090 and SITC 51580. As of Q4 2014, INDAPAMIDE remains the US FDA Preferred Term for this commodity. Indapamide bears US NLM identifiers UMLS ID C0021186 and NCI Concept Code C29119. SMILES: CLC1C(S(=O)(=O)N)CC(C(=O)NN2C(CC3C2CCCC3)C)CC1.
It is an antihypertensive and is used in the treatment of high blood pressure (hypertension).
Perindopril works by inhibiting the formation of hormones that raise blood pressure (ACE inhibitor), while indapamide increases the elimination of salt and water through the kidneys.
This classification denotes an antidepressant agent with the molecular formula C16H15Cl2N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4U40Y96J1Z, chemically known as 3-(3,4-dichlorophenyl)-n-methyl-1-indanamine hcl but generally known as indatraline, which bears US NIH Compound Identifier 126280. European Medicines Agency schedules Indatraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08170MIG. The term INDATRALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). INDATRALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule indatraline under HS 29214980 and SITC 51454. As of Q4 2014, INDATRALINE remains the US FDA Preferred Term for this commodity. Indatraline bears US NLM identifiers UMLS ID C0065216 and NCI Concept Code C83797. SMILES: Clc1cc(C2CC(NC)c3c2cccc3)ccc1Cl.
This classification denotes an antiarrhythmic agent with the molecular formula C20H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 3AZF20DM1T chemically known as 9h-fluorene-9-carboxamide, 9-(3-((1-methylethyl)amino)propyl)-, but more commonly known as indecainide, which bears US NIH Compound Identifier 52195. European Medicines Agency schedules Indecainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08171MIG. The term INDECAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, list 23). Most nations, for tariff and trade purposes, schedule indecainide under HS 29242995 and SITC 51479. As of Q4 2014, INDECAINIDE remains US FDA's Preferred Term for this commodity. Indecainide bears US NLM identifiers UMLS ID C0063455 and NCI Concept Code C65910. SMILES: CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N.
This classification denotes an antidepressant agent with the molecular formula C14H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 834M09R1KM, chemically known as (r,s)-2-(7-indenyloxymethyl)morpholin but generally known as indeloxazine, which bears US NIH Compound Identifier 3704. European Medicines Agency schedules Indeloxazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08172MIG. The term INDELOXAZINE is an International Non-Proprietary Name. INDELOXAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule indeloxazine under HS 29349990 and SITC 51579. As of Q4 2014, INDELOXAZINE remains the US FDA Preferred Term for this commodity. Indeloxazine bears US NLM identifiers UMLS ID C0063456 and NCI Concept Code C81484. SMILES: O1C(CNCC1)COc1c2CC=Cc2ccc1.
This classification denotes an antidepressant agent with the molecular structure C14H17NO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 15QZ6NE84E chemically known as morpholine, 2-((1h-inden-7-yloxy)methyl)-, hydrochloride, (+/-)-, but more commonly known as indeloxazine hydrochloride, which bears US NIH Compound Identifier 47517. European Medicines Agency schedules Indeloxazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02663MIG. Most nations, for tariff and trade purposes, schedule indeloxazine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, INDELOXAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Indeloxazine hydrochloride bears US NLM identifiers UMLS ID C0953067 and NCI Concept Code C81478. SMILES: C1CC2C(C(C1)OCC3CNCCO3)CC=C2.CL.
This classification denotes a dye with the molecular formula C16H8N2O8S2.2Na, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier D3741U8K7L, chemically known as 2-(1,3-dihydro-3-oxo-5-sulfo-2h-indol-2-ylidene)-2,3-dihydro-3-oxo-1h-indole-5-sulfonic acid, disodium salt but more generally known as acid blue 74, which bears US NIH Compound Identifier 5282429. European Medicines Agency schedules Indigo carmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12518MIG World Health Organization schedules acid blue 74 in its Anatomical Therapeutic Chemical (ATC) Classification. Indigotindisulfonate sodium bears US NLM identifiers UMLS ID C0021219 and NCI Concept Code C83799. SMILES: S(=O)(=O)(O)C1CC2C(N/C(=C3/NC4C(C3=O)CC(S(=O)(=O)O)CC4)C2=O)CC1.[NA].[NA].
This classification denotes a protease inhibitor and anti-hiv agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W6YA9PKKH. European Medicines Agency schedules Indinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08174MIG. Indinavir generally arises in the molecular formula C36H47N5O4. The term INDINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36.) INDINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Indinavir under HS 29335995 and SITC 51576. As of Q4 2014, INDINAVIR remains the US FDA Preferred Term for this commodity. Indinavir bears US NLM identifiers UMLS ID C0376637 and NCI Concept Code C66877. SMILES: CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2CCCCC2)C(=O)N[C@H]3C4CCCCC4C[C@H]3O)O)CC5CCCNC5.O.
This classification denotes a protease inhibitor and anti-hiv agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W6YA9PKKH. European Medicines Agency schedules Indinavir sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02666MIG. Indinavir sulfate generally arises in the molecular formula C36H47N5O4.H2O4S. The term 'indinavir sulfate' is a European Medicines Agency European Public Assessment Report System designation. Most nations, for tariff and trade purposes, schedule indinavir sulfate under HS 29335995 and SITC 51576. As of Q4 2014, INDINAVIR SULFATE remains US FDA's Preferred Term for this commodity. Indinavir sulfate bears US NLM identifiers UMLS ID C0700483 and NCI Concept Code C1662. SMILES: CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2CCCCC2)C(=O)N[C@H]3C4CCCCC4C[C@H]3O)O)CC5CCCNC5.OS(=O)(=O)O.
This classification denotes an immunoconjugate with the molecular formula C32H43N7O14.2H+.In, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03MZ53X1YS. The term Indium 111 capromab pendetide is an International Non-Proprietary Name or INN (See World Health Organization INN reference publication, Volume 13 No. 1, 1999, List 41.).
This classification denotes a radioconjugate, a preparation that World Health Organization schedules in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a radioconjugate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LGX9OL562T. European Medicines Agency schedules Indium in 111 oxyquinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14205MIG. Indium in 111 oxyquinoline generally arises in the molecular formula 3C9H6NO.IN. The term 'indium in 111 oxyquinoline' is a United States Adopted Name designation. SMILES: C1=CC2=C(C(=C1)[O-])N=CC=C2.C1=CC2=C(C(=C1)[O-])N=CC=C2.C1=CC2=C(C(=C1)[O-])N=CC=C2.[In+3].\.
This classification denotes a radioconjugate with the molecular formula C14H18N3O10.2H, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5K3UP561AX, a preparation that World Health Organization schedules in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a radioconjugate with the molecular formula C63H83N13O19S2.H+.IN (a diethylenetriaminopentaacetic (DTPA) conjugate of the human hormone somatostatin peptide analogue [octreotide]), a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M312JJ6Z32, a preparation that World Health Organization schedules in its Anatomical Therapeutic Chemical (ATC) Classification. Indium in 111 satumomab pendetide bears US NLM NCI C1672.
This classification denotes a radioconjugate with the molecular formula C32H43N7O14.2H+.IN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7V9926378A, a preparation that World Health Organization schedules in its Anatomical Therapeutic Chemical (ATC) Classification. Indium in 111 satumomab pendetide bears US NLM NCI C1469.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T9949G4LZ, chemically known as 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethylbenzeneacetic acid but generally known as indobufen, which bears US NIH Compound Identifier 107641. European Medicines Agency schedules Indobufen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08176MIG. The term INDOBUFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules indobufen in its Anatomical Therapeutic Chemical (ATC) Classification. INDOBUFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule indobufen under HS 29337900 and SITC 51561. As of Q4 2014, INDOBUFEN remains the US FDA Preferred Term for this commodity. Indobufen bears US NLM identifiers UMLS ID C0063479 and NCI Concept Code C83800. SMILES: O=C1N(CC2C1CCCC2)C1CCC(C(CC)C(=O)O)CC1.
Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of Indocyanine Green with no more than 5% sodium iodide. It is packaged with Sterile Water for Injection, USP used to dissolve the Indocyanine Green. Indocyanine Green for Injection USP is to be administered intravenously. Indocyanine Green for Injection USP is indicated for Determining Cardiac Output, Hepatic Function and Liver Blood Flow and for ophthalmic angiography.
This classification denotes an indole compound and cyclooxygenase inhibitor with the molecular formula C19H16ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XXE1CET956, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9ci) but generally known as indometacin, which bears US NIH Compound Identifier 3715. European Medicines Agency schedules Indometacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08180MIG. The term INDOMETACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules indometacin in its Anatomical Therapeutic Chemical (ATC) Classification. INDOMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Indometacin or indomethacin bears US NLM identifiers UMLS ID C0021246 and NCI Concept Code C576.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C19H15ClNO4.Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0IMX38M2GG, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, sodium salt, trihydrate but more generally known as indometacin sodium, which bears US NIH Compound Identifier 156283. Most nations, for tariff and trade purposes, schedule indomethacin sodium under HS 29339990. As of Q4 2014, INDOMETHACIN SODIUM remains US FDA's Preferred Term for this commodity. Indomethacin sodium bears US NLM identifiers UMLS ID C0982211 and NCI Concept Code C47999. SMILES: CC1C(C2CC(CCC2N1C(=O)C3CCC(CC3)CL)OC)CC(=O)[O-].O.O.O.[NA+].
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JQ3661CAD. European Medicines Agency schedules Indopanolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08181MIG. Indopanolol generally arises in the molecular formula C20H23CLN2O3. The term INDOPANOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) INDOPANOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule indopanolol under HS 29339990 and SITC 51577. As of Q4 2014, INDOPANOLOL remains the US FDA Preferred Term for this commodity. Indopanolol bears US NLM identifiers UMLS ID C1881198 and NCI Concept Code C65914. SMILES: CLC1(C2C(OCC(O)CNCCOC3CCCCC3)CCCC2N=C1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CPE46ZU14N, chemically known as 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-methylbenzeneacetic acid but generally known as indoprofen, which bears US NIH Compound Identifier 3718. European Medicines Agency schedules Indoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08183MIG. The term INDOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules indoprofen in its Anatomical Therapeutic Chemical (ATC) Classification. INDOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule indoprofen under HS 29337900 and SITC 51561. As of Q4 2014, INDOPROFEN remains the US FDA Preferred Term for this commodity. Indoprofen bears US NLM identifiers UMLS ID C0021251 and NCI Concept Code C83801. SMILES: O=C1N(CC2C1CCCC2)C1CCC(C(C)C(=O)O)CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Z802HMY7H, chemically known as benzamide, n-(1-(2-indol-3-ylethyl)-4-piperidyl)- but generally known as indoramin, which bears US NIH Compound Identifier 33625. European Medicines Agency schedules Indoramin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08184MIG. The term INDORAMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules indoramin in its Anatomical Therapeutic Chemical (ATC) Classification. INDORAMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule indoramin under HS 29333999 and SITC 51574. As of Q4 2014, INDORAMIN remains the US FDA Preferred Term for this commodity. Indoramin bears US NLM identifiers UMLS ID C0021252 and NCI Concept Code C65916. SMILES: O=C(NC1CCN(CC1)CCC1C2C([NH]C1)CCCC2)C1CCCCC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQ0Z3K8W92, chemically known as benzamide, n-(1-(2-(1h-indol-3-yl)ethyl)-4-piperidinyl)-, monohydrochloride but more generally known as indoramin hydrochloride, which bears US NIH Compound Identifier 38102. European Medicines Agency schedules Indoramin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02679MIG. Most nations, for tariff and trade purposes, schedule indoramin hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, INDORAMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(=O)NC2CCN(CC2)CCC3C[NH]C4C3CCCC4.CL.
This classification denotes a monoclonal antibody with the molecular formula C6428H9912N1694O1987S46, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) B72HH48FLU, more generally known as infliximab. European Medicines Agency schedules infliximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02681MIG. The term INFLIXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 1 1998, list 39. Most nations, for tariff and trade purposes, schedule infliximab under HS 30021091 and SITC 54163. As of Q4 2014, INFLIXIMAB remains US FDA's Preferred Term for this commodity. Infliximab bears US NLM identifiers UMLS ID C0666743 and NCI Concept Code C1789. SMILES: none.
This classification denotes a vaccine for an acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the nasal mucosa; the pharynx; and conjunctiva, and by headache and severe, often generalized, myalgia.
This classification denotes an anti-diabetic agent with the molecular formula C23H24ClN3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) UII7156WLU, chemically known as 1h-indole-2-carboxamide, 5-chloro-n-((1s,2r)-3-((3r,4s)-3,4-dihydroxy-1-pyrrolidinyl)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl)- but more generally known as ingliforib, which bears US NIH Compound Identifier 6451325. The term INGLIFORIB is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16., No. 1.2002, List 47). Most nations, for tariff and trade purposes, schedule ingliforib under HS 29339990 and SITC 51577. As of Q4 2014, INGLIFORIB remains US FDA's Preferred Term for this commodity. Ingliforib bears US NLM identifiers UMLS ID C1436456 and NCI Concept Code C75982. SMILES: C1C(C(CN1C(=O)C(C(CC2=CC=CC=C2)NC(=O)C3=CC4=C(N3)C=CC(=C4)CL)O)O)O.
This classification denotes an anti-androgen with the molecular formula C18H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ONU02D116S, chemically known as (3S,3aS,9aS,9bS)-6-ethyl-3-hydroxy-3a-methyl-2,3,4,5,8,9,9a,9b-octahydro-1H-cyclopenta[a]naphthalen-7-one but generally known as inocoterone, which bears US NIH Compound Identifier 11776794. European Medicines Agency schedules inocoteronein its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08189MIG. Most nations schedule inocoterone under HS 29379000 and SITC 54155. As of Q4 2014, INOCOTERONE remains the US FDA Preferred Term for this commodity. SMILES: CCC1=C2CCC3(C(C2CCC1=O)CCC3O)C.
This classification denotes an immunostimulant with the molecular formula C10H12N4O5.3C9H9NO3.3C5H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W1SO0V223F, chemically known as p-acetamidobenzoic salt of n,n-dimethylamino-2-propanol & inosine (3:1) np 113 but generally known as inosine pranobex, which bears US NIH Compound Identifier 37510. European Medicines Agency schedules Inosine pranobex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14214MIG. World Health Organization schedules inosine pranobex in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule inosine pranobex under HS 29349990 and SITC 51579. As of Q4 2014, INOSINE PRANOBEX remains the US FDA Preferred Term for this commodity. Inosine pranobex bears US NLM identifiers UMLS ID C0022230 and NCI Concept Code C601. SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-].CC(CN(C)C)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.C1=NC(=O)C2=C(N1)N(C=N2)C3C(C(C(O3)CO)O)O.
This classification denotes an intracellular second messenger with the molecular formula C6H12O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4L6452S749, chemically known as 1,2,3,4,5,6-hexahydroxy-cyclohexane but generally known as inositol, which bears US NIH Compound Identifier 892. European Medicines Agency schedules Inositol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02688MIG. World Health Organization schedules inositol in its Anatomical Therapeutic Chemical (ATC) Classification. INOSITOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule inositol under HS 29061300 and SITC 51231. As of Q4 2014, INOSITOL remains the US FDA Preferred Term for this commodity. Inositol bears US NLM identifiers UMLS ID C0021547 and NCI Concept Code C28163. SMILES: OC1C(O)C(O)C(O)C(O)C1O.
This classification denotes an anti-lipidemic agent with the molecular formula C42H30N6O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A99MK953KZ, chemically known as 1,2,3,54,6 cyclohexanehexol hexanicotinate but more generally known as inositol hexanicotinate, which bears US NIH Compound Identifier 3720. European Medicines Agency schedules Inositol nicotinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08192MIG. The term INOSITOL NICOTINATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules inositol hexanicotinate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule inositol hexanicotinate under HS 29061300. SMILES: C1CNCC(C1)C(=O)O[C@H]2[C@@H]([C@@H]([C@@H]([C@H]([C@@H]2OC(=O)C3CNCCC3)OC(=O)C4CNCCC4)OC(=O)C5CNCCC5)OC(=O)C6CNCCC6)OC(=O)C7CNCCC7.
This classification denotes an intracellular second messenger with the molecular formula C6H6N6O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 686T63H73D, chemically known as inositol, hexanitrate, but more generally known as inositol hexanitrate, which bears US NIH Compound Identifier 23746. European Medicines Agency schedules inositol hexanitrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02688MIG. Most nations, for tariff purposes, schedule inositol hexanitrate under HS 29061300. SMILES: [C@@H]1([C@@H]([C@@H]([C@@H]([C@H]([C@@H]1O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-].
This classification denotes an anti-lipidemic agent with the molecular formula C42H30N6O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A99MK953KZ, chemically known as 1,2,3,54,6 cyclohexanehexol hexanicotinate but more generally known as inositol hexanicotinate, which bears US NIH Compound Identifier 3720. European Medicines Agency schedules Inositol nicotinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08192MIG. The term INOSITOL NICOTINATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules inositol hexanicotinate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule inositol niacinate under HS 29061300. As of Q4 2014, INOSITOL NIACINATE remains US FDA's Preferred Term for this commodity. Inositol niacinate bears US NLM identifiers UMLS ID C0063584 and NCI Concept Code C75996. SMILES: C1CNCC(C1)C(=O)O[C@H]2[C@@H]([C@@H]([C@@H]([C@H]([C@@H]2OC(=O)C3CNCCC3)OC(=O)C4CNCCC4)OC(=O)C5CNCCC5)OC(=O)C6CNCCC6)OC(=O)C7CNCCC7.
This classification denotes a therapeutic insulin with the molecular formula C256H381N65O79S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D933668QVX, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN ASPART is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 3 1997, List 38) WHO schedules insulin in its Anatomical Therapeutic Chemical (ATC) Classification. INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule insulin under HS 29371200 and SITC 54154. Insulin bears US NLM identifiers UMLS ID CL026873 and NCI Concept Code C2271. SMILES: SCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC1CCCCC1)C(C)C)CC(=O)N)CCC(=O)N)CC1[NH]CNC1)CC(C)C)CS)CO)CC1[NH]CNC1)CC(C)C)C(C)C)CCC(=O)O)C)CC(C)C)CC1CCC(O)CC1)CC(C)C)C(C)C)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC1CCCCC1)C(=O)NC(CC1CCCCC1)C(=O)NC(CC1CCC(O)CC1)C(=O)NC(C(O)C)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)O)CC(=O)O.SCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CN)C(CC)C)C(C)C)CCC(=O)O)CCC(=O)N)CS)CS)C(O)C)CO)C(CC)C)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CC1CCC(O)CC1)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)NC(CC1CCC(O)CC1)C(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)O)CCC(=O)N)CO.
This classification denotes a peptide hormone , a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 785P1QWQ1N, chemically known as insulin (human), 30ba-l-arginine-30bb-l-arginine-, but more generally known as insulin argine, which bears US NIH Compound Identifier 16132322. European Medicines Agency schedules Insulin argine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08194MIG. Most nations, for tariff and trade purposes, schedule insulin argine under HS 29371200 and SITC 54154. SMILES: As of Q4 2014, INSULIN ARGINE remains US FDA's Preferred Term for this commodity.
This classification denotes a therapeutic insulin with the molecular formula C256H381N65O79S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D933668QVX, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN ASPART is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 3 1997, List 38) WHO schedules insulin in its Anatomical Therapeutic Chemical (ATC) Classification. INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule insulin aspart under HS 29371900 and SITC 54154. As of Q4 2014, INSULIN ASPART remains US FDA's Preferred Term for this commodity. Insulin aspart bears US NLM identifiers UMLS ID C0123677 and NCI Concept Code C47563. SMILES: SCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC1CCCCC1)C(C)C)CC(=O)N)CCC(=O)N)CC1[NH]CNC1)CC(C)C)CS)CO)CC1[NH]CNC1)CC(C)C)C(C)C)CCC(=O)O)C)CC(C)C)CC1CCC(O)CC1)CC(C)C)C(C)C)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC1CCCCC1)C(=O)NC(CC1CCCCC1)C(=O)NC(CC1CCC(O)CC1)C(=O)NC(C(O)C)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)O)CC(=O)O.SCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CN)C(CC)C)C(C)C)CCC(=O)O)CCC(=O)N)CS)CS)C(O)C)CO)C(CC)C)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CC1CCC(O)CC1)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)NC(CC1CCC(O)CC1)C(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)O)CCC(=O)N)CO.
Insulin aspart protamine and insulin aspart is a combination of a fast-acting insulin and an intermediate-acting type of human insulin.
This classification denotes a peptide hormone with the molecular formula C254H377N65O75S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 576O9IZ534, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN is an International Non-Proprietary Name. INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, INSULIN BEEF remains US FDA's Preferred Term for this commodity.
Insulin degludec is an ultra long-acting basal insulin analog used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.
This classification denotes a therapeutic insulin with the molecular formula C267H402N64O76S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4FT78T86XV, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN DETEMIR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13 No. 3, 1999, List 42) WHO schedules insulin in its Anatomical Therapeutic Chemical (ATC) Classification. INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule insulin detemir under HS 29349990 and SITC 51579. Insulin detemir bears US NLM identifiers UMLS ID C0537270 and NCI Concept Code C65920. SMILES: As of Q4 2014, INSULIN DETEMIR remains US FDA's Preferred Term for this commodity.
This classification denotes a therapeutic insulin with the molecular formula C267H404N72O78S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2ZM8CX04RZ, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN GLARGINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 3 1997, List 38) WHO schedules insulin in its Anatomical Therapeutic Chemical (ATC) Classification. INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule Insulin glargine under HS 29371900 and SITC 54154. SMILES:. As of Q4 2014, INSULIN GLARGINE remains US FDA's Preferred Term for this commodity. . Insulin glargine bears US NLM identifiers UMLS ID C0907402 and NCI Concept Code C47564.
This classification denotes a therapeutic insulin with the molecular formula C258H384N64O78S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7XIY785AZD, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN GLULISINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 15 No. 3-4, 2001, List 46) WHO schedules insulin in its Anatomical Therapeutic Chemical (ATC) Classification. INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule Insulin glulisine under HS 29371900 and SITC 54154. SMILES:. As of Q4 2014, INSULIN GLULISINE remains US FDA's Preferred Term for this commodity. . Insulin glulisine bears US NLM identifiers UMLS ID C1313386 and NCI Concept Code C65921.
This classification denotes a therapeutic insulin with the molecular formula C257H383N65O77S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1Y17CTI5SR, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN HUMAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule insulin human under HS 29371200 and SITC 54154. As of Q4 2014, INSULIN HUMAN remains US FDA's Preferred Term for this commodity. Insulin human bears US NLM identifiers UMLS ID C0795635 and NCI Concept Code C65922. SMILES: CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN=CN2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN.
This classification denotes a therapeutic insulin with the molecular formula C257H383N65O77S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GFX7QIS1II, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN is an International Non-Proprietary Name WHO schedules insulin in its Anatomical Therapeutic Chemical (ATC) Classification. INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule insulin lispro under HS 29349990 and SITC 51579. Insulin lispro bears US NLM identifiers UMLS ID C0293359 and NCI Concept Code C29123. SMILES: As of Q4 2014, INSULIN LISPRO remains US FDA's Preferred Term for this commodity.
This classification denotes a peptide hormone C8H16N2O4(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Y83I5F10I, chemically known as poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-methoxy-, 28b-ester with 28b-(n6-carboxy-l-lysine)-29b-l-prolineinsulin (human), but more generally known as insulin peglispro, which bears US NIH Compound Identifier 71301236. Most nations, for tariff and trade purposes, schedule insulin peglispro under HS 29371200 and SITC 54154. SMILES: As of Q4 2014, INSULIN PEGLISPRO remains US FDA's Preferred Term for this commodity.
This classification denotes a therapeutic insulin with the molecular formula C256H381N65O76S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AVT680JB39, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-, but more generally known as insulin porcine, which bears US NIH Compound Identifier 16131098. European Medicines Agency schedules insulin porcine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. Most nations, for tariff purposes, schedule insulin porcine under HS 29371200. SMILES:.
This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47RRR83SK7. European Medicines Agency schedules Interferon alfa-2a in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12447MIG. As of Q4 2014, INTERFERON ALFA-2A remains the US FDA Preferred Term for this commodity. SMILES: NONE.
This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43K1W2T1M6, also known as human leucocyte clone pm21 protein moiety reduced. European Medicines Agency schedules Interferon alfa-2a in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12521MIG. As of Q4 2014, INTERFERON ALFA-2B remains the US FDA Preferred Term for this commodity. SMILES: NONE.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.
This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56588OP40D. European Medicines Agency schedules Interferon alfa-2a in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08199MIG. As of Q4 2014, INTERFERON ALFACON-1 remains the US FDA Preferred Term for this commodity. Interferon alfacon-1 bears US NLM identifiers UMLS ID C0164613 and NCI Concept Code C1766. SMILES: NONE.
This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47BPR3V3MP. European Medicines Agency schedules Interferon alfa-n1 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20625. As of Q4 2014, INTERFERON ALFA-N1 remains the US FDA Preferred Term for this commodity. Interferon alfa-n1 bears US NLM identifiers UMLS ID C0699817 and NCI Concept Code C2220. SMILES: NONE.
This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XRO4566Q4R. European Medicines Agency schedules Interferon alfa-n1 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12440MIG. As of Q4 2014, INTERFERON BETA-1A remains the US FDA Preferred Term for this commodity. Interferon beta-1a bears US NLM identifiers UMLS ID C0982234 and NCI Concept Code C1823. SMILES: NONE.
This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TTD90R31WZ. European Medicines Agency schedules Interferon alfa-n1 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12432MIG. As of Q4 2014, INTERFERON BETA-1B remains the US FDA Preferred Term for this commodity. Interferon beta-1b bears US NLM identifiers UMLS ID C0244714 and NCI Concept Code C2221. SMILES: NONE.
This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21K6M2I7AG. European Medicines Agency schedules Interferon alfa-n1 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12076MIG. As of Q4 2014, INTERFERON GAMMA-1B remains the US FDA Preferred Term for this commodity. Interferon gamma-1b bears US NLM identifiers UMLS ID C1579322 and NCI Concept Code C100089. SMILES: NONE.
This classification denotes a cariogenic agents and fructose, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier ED959S6ACY. European Medicines Agency schedules Invert sugar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14234MIG. Invert sugar generally arises in the molecular formula 2C6H12O6. The term 'invert sugar' is a U.S. FDA designation.
This classification denotes an iodinated contrast dye with the molecular formula C8H10IN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35MRW7B4AD, chemically known as guanidine, ((3-iodophenyl)methyl)- but more generally known as iobenguane, which bears U.S. National Institutes of Health Compound Identifier 60860. The European Medicines Agency schedules Iobenguane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32630. IOBENGUANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1CC(C/N=C(/N)N)CCC1. SMILES: IC1CC(C/N=C(/N)N)CCC1. Most nations schedule Iobenguane under HS 28444030.
This classfication denotes an iodinated contrast dye with the molecular formula 2C8H10IN3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8I0922465, chemically known as guanidine, n-((3-iodophenyl)methyl)-, sulfate (2:1), but more generally known as iobenguane sulfate, which bears U.S. National Institutes of Health Compound Identifier 2759362. European Medicines Agency schedules iobenguane sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32630. Most nations, for tariff purposes, schedule iobenguane sulfate under HS 28444030. SMILES: C1CC(CC(C1)I)CNC(=N)N.C1CC(CC(C1)I)CNC(=N)N.OS(=O)(=O)O.
This classification denotes a triiodobenzoic acid with the molecular formula C16H13I3N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F72UWG2SWK, chemically known as 3-((3-amino-2,4,6-triiodobenzoyl)phenylamino)propionic acid but more generally known as iobenzamic acid, which bears U.S. National Institutes of Health Compound Identifier 18377. The European Medicines Agency schedules Iobenzamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08204MIG. The World Health Organization schedules iobenzamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: IC1C(C(=O)N(CCC(=O)O)C2CCCCC2)C(I)CC(I)C1N. Most nations schedule Iobenzamic acid under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C20H28I3N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 182ECH14UH, chemically known as 1,3-benzenedicarboxamide, n,n-bis(2,3-dihydroxypropyl)-5-((5-hydroxy-2-(hydroxymethyl)-1-oxopropyl)amino)-2,4,6-triiodo-n,n-dimethyl- but more generally known as iobitridol, which bears U.S. National Institutes of Health Compound Identifier 65985. The European Medicines Agency schedules Iobitridol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08205MIG. The term IOBITRIDOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 7, No3, 1993, List 33). The World Health Organization schedules iobitridol in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: IC1C(C(=O)N(CC(O)CO)C)C(I)C(NC(=O)C(CO)CO)C(I)C1C(=O)N(CC(O)CO)C. Most nations schedule Iobitridol under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C24H20I6N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82PB24K6TZ, chemically known as 5,5-(tetramethylenebis(carbonylimino))bis(n-methyl-2,4,6-triiodoisophthalamic acid) but more generally known as iocarmic acid, which bears U.S. National Institutes of Health Compound Identifier 25229. The European Medicines Agency schedules Iocarmic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08208MIG. The term IOCARMIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). The World Health Organization schedules iocarmic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(c(I)c(c2I)C(=O)O)C(=O)NC)c(I)c(c(I)c1C(=O)NC)C(=O)O. Most nations schedule Iocarmate or iocarmic acid or iocarmate meglumine under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C24H20I6N4O8, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 82PB24K6TZ, chemically known as 5,5-(tetramethylenebis(carbonylimino))bis(n-methyl-2,4,6-triiodoisophthalamic acid) but more generally known as iocarmic acid, which bears U.S. National Institutes of Health Compound Identifier 25229. The European Medicines Agency schedules Iocarmic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08208MIG. The term IOCARMIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). The World Health Organization schedules iocarmic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(c(I)c(c2I)C(=O)O)C(=O)NC)c(I)c(c(I)c1C(=O)NC)C(=O)O.
This classification denotes an iodinated contrast dye with the molecular formula C12H13I3N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FA675Q0E3E, chemically known as 3-(acetyl-(3-amino-2,4,6-triiodophenyl)amino)-2-methylpropanoic acid but more generally known as iocetamic acid, which bears U.S. National Institutes of Health Compound Identifier 27648. The European Medicines Agency schedules Iocetamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08209MIG. The term IOCETAMIC ACID is an International Non-Proprietary Name. The World Health Organization schedules iocetamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Iocetamic acid under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C12H11I3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4RII332O0R, chemically known as 3-acetylaminomethyl-5-acetylamino-2,4,6-triiodobenzoic acid but more generally known as iodamide, which bears U.S. National Institutes of Health Compound Identifier 3723. The European Medicines Agency schedules Iodamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08210MIG. The World Health Organization schedules iodamide in its Anatomical Therapeutic Chemical (ATC) Classification. IODAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(=O)NCC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I. Most nations schedule Iodamide or iodamide meglumine under HS 29242995.
This classification denotes a biological-based radiopharmaceutical diagnostic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68WQQ3N9TI. SMILES: none. Most nations schedule Iodinated i-125 human serum albumin or jeanatope under HS 28444030.
This classification denotes a dietary mineral with the molecular formula I2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9679TC07X4, chemically known as jod (german, polish) but generally known as iodine, which bears US NIH Compound Identifier 807. European Medicines Agency schedules Iodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14239MIG. World Health Organization schedules iodine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule iodine under HS 28012000 and SITC 52225. As of Q4 2014, IODINE remains the US FDA Preferred Term for this commodity. Iodine bears US NLM identifiers UMLS ID C0021968 and NCI Concept Code C594. SMILES: II.
This classification denotes a pharmaceutical.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE101. This VA Drug Class (DE101) classifies this compound as belonging to the group ANTIBACTERIAL, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE101. This VA Drug Class (DE101) classifies this compound as belonging to the group ANTIBACTERIAL, TOPICAL.
This classification denotes a dimeric, sterile, pyrogen-free, colorless to pale yellow solution isosmolar, nonionic, water-soluble, radiographic contrast medium that practitioners often deploy in X-Ray and/or Computed Tomography (CT) liver studies (especially iodixanol liposomes). bears US NLM identifiers UMLS ID C0063757 and NCI Concept Code C65931. Most nations schedule Iodixanol under HS 29242995.
This classification denotes an anti-infective agent with the molecular formula CHI3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KXI2J76489, chemically known as methane, triiodo- but generally known as iodoform, which bears US NIH Compound Identifier 6374. European Medicines Agency schedules Iodoform in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14246MIG. World Health Organization schedules iodoform in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule iodoform under HS 29033900 and SITC 51137. As of Q4 2014, IODOFORM remains the US FDA Preferred Term for this commodity. Iodoform bears US NLM identifiers UMLS ID C0063779 and NCI Concept Code C77050. SMILES: IC(I)I.
This classification denotes an antiprotozoal agent with the molecular formula C9H5I2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63W7IE88K8, chemically known as 5,7-diodo-8-quinolinol but generally known as diiodohydroxyquinoline, which bears US NIH Compound Identifier 3728. European Medicines Agency schedules Diiodohydroxyquinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07142MIG. The term DIIODOHYDROXYQUINOLINE is an International Non-Proprietary Name. World Health Organization schedules diiodohydroxyquinoline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, IODOQUINOL remains the US FDA Preferred Term for this commodity. Iodoquinol bears US NLM identifiers UMLS ID C0012341 and NCI Concept Code C76008. SMILES: IC1C2C(NCCC2)C(O)C(I)C1.
This classification denotes an iodinated contrast dye with the molecular formula C26H26I6N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NS1Y283HW4, chemically known as 4,7,10,13-tetraoxahexadecane-1,16-dioyl-bis(3-carboxytriiodoanilide) but more generally known as iodoxamic acid, which bears U.S. National Institutes of Health Compound Identifier 35740. The European Medicines Agency schedules Iodoxamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08218MIG. The term IODOXAMIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). The World Health Organization schedules iodoxamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: Ic1c(NC(=O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(c(I)cc2I)C(=O)O)c(I)cc(I)c1C(=O)O. Most nations schedule Iodoxamate or iodoxamate meglumine or iodoxamic acid under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C26H26I6N2O10, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier NS1Y283HW4, chemically known as 4,7,10,13-tetraoxahexadecane-1,16-dioyl-bis(3-carboxytriiodoanilide) but more generally known as iodoxamic acid, which bears U.S. National Institutes of Health Compound Identifier 35740. The European Medicines Agency schedules Iodoxamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08218MIG. The term IODOXAMIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). The World Health Organization schedules iodoxamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: Ic1c(NC(=O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(c(I)cc2I)C(=O)O)c(I)cc(I)c1C(=O)O.
This classification denotes an iodinated contrast dye, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2990I809YH. The European Medicines Agency schedules Iofendylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08219MIG. Iofendylate generally arises in the molecular formula C19H29IO2. The term IOFENDYLATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, list 5.) IOFENDYLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCOC(=O)CCCCCCCCC(C)C1=CC=C(C=C1)I. Most nations schedule Iofendylate or iophendylate under HS 29163900.
This classification denotes a contrast media with the molecular formula C12H18IN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) LV23B78IJC, chemically known as 1-(4-iodanylphenyl)-N-propan-2-ylpropan-2-amine but more generally known as Iofetamine i-123, which bears U.S. National Institutes of Health Compound Identifier 156375. The term Iofetamine i-123 is an International Non-Proprietary Name or INN (See World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24.) European Medicines Agency schedules Iofetamine i-123 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08220MIG. World Health Organization schedules Iofetamine i-123 in its Anatomical Therapeutic Chemical (ATC) Classification. Iofetamine i-123 is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iofetamine i-123 under HS 28444030 and SITC 52519. As of Q4 2014, IOFETAMINE I-123 remains the US FDA Preferred Term for this commodity. SMILES: CC(C)NC(C)CC1=CC=C(C=C1)I.
This classification denotes a radiopharmaceutical compound with the molecular formula C18H23FINO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3MM99T8R5Q, more generally known as ioflupane (123i). European Medicines Agency schedules ioflupane (123i) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08221MIG. The term IOFLUPANE (123I) is an International Non-Proprietary Name or INN.
This classification denotes an iodinated contrast dye with the molecular formula C13H12I3N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3LGR5S8101, chemically known as 5-acetamido-2,4,6-triiodo-n-((methylcarbamoyl)methyl)isophthalamic acid but more generally known as ioglicic acid, which bears U.S. National Institutes of Health Compound Identifier 65437. The European Medicines Agency schedules Ioglicic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08223MIG. The term IOGLICIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). The World Health Organization schedules ioglicic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: Ic1c(c(I)c(c(I)c1NC(=O)C)C(=O)O)C(=O)NCC(=O)NC. Most nations schedule Ioglicic acid under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C18H10I6N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ET36GPP4T7, chemically known as 3,3-(diglycoloyldiimino)bis(2,4,6-triiodobenzoic acid) but more generally known as ioglycamic acid, which bears U.S. National Institutes of Health Compound Identifier 17477. The European Medicines Agency schedules Ioglycamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08227MIG. The term IOGLYCAMIC ACID is an International Non-Proprietary Name. The World Health Organization schedules ioglycamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: Ic1c(NC(=O)COCC(=O)Nc2c(I)c(c(I)cc2I)C(=O)O)c(I)cc(I)c1C(=O)O. Most nations schedule Ioglycamic acid under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C19H26I3N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4419T9MX03, chemically known as 1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo but more generally known as iohexol, which bears U.S. National Institutes of Health Compound Identifier 3730. The European Medicines Agency schedules Iohexol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08228MIG. The term IOHEXOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 34, No. 10 1980, List 20). The World Health Organization schedules iohexol in its Anatomical Therapeutic Chemical (ATC) Classification. IOHEXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1C(N(CC(O)CO)C(=O)C)C(I)C(C(I)C1C(=O)NCC(O)CO)C(=O)NCC(O)CO. Most nations schedule Iohexol under HS 29242995.
This classification denotes an iopamidol analog and contrast media with the molecular formula C17H22I3N3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17E17JBP8L, chemically known as 1,3-benzenedicarboxamide, n,n-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)methylamino)-2,4,6-triiodo- but more generally known as iomeprol, which bears U.S. National Institutes of Health Compound Identifier 3731. The European Medicines Agency schedules Iomeprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08234MIG. The World Health Organization schedules iomeprol in its Anatomical Therapeutic Chemical (ATC) Classification. IOMEPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1C(N(C)C(=O)CO)C(I)C(C(I)C1C(=O)NCC(O)CO)C(=O)NCC(O)CO. Most nations schedule Iomeprol under HS 29242995.
This classification denotes an iodinated contrast dye, which practitioners deploy in Magnetic Resonance Imaging (MRI) and/or Magnetic Resonance Spectroscopy (MRS), with the molecular formula C17H22I3N3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JR13W81H44, chemically known as 1,3-benzenedicarboxamide, n,n-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo- but more generally known as iopamidol, which bears U.S. National Institutes of Health Compound Identifier 3734. The European Medicines Agency schedules Iopamidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08239MIG. The term IOPAMIDOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). The World Health Organization schedules iopamidol in its Anatomical Therapeutic Chemical (ATC) Classification. IOPAMIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1C(C(I)C(NC(=O)C(O)C)C(I)C1C(=O)NC(CO)CO)C(=O)NC(CO)CO. Most nations schedule Iopamidol under HS 29242995.
This classification denotes an iodinated contrast dye, which practitioners use, as one example, in x-ray and/or computed tomography (CT) brain studies, with the molecular formula C11H12I3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FE9794P71J, chemically known as 3-amino-alpha-ethyl-2,4,6-triiodohydrocinnamic acid but more generally known as iopanoic acid, which bears U.S. National Institutes of Health Compound Identifier 3735. The European Medicines Agency schedules Iopanoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08240MIG. The term IOPANOIC ACID is an International Non-Proprietary Name. The World Health Organization schedules iopanoic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Iopanoic acid under HS 29224995.
This classification denotes a triiodobenzoic acid and contrast media with the molecular formula C20H28I3N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D6XWX076T, chemically known as 1,3-benzenedicarboxamide, 5-(acetyl(2-hydroxy-3-methoxypropyl)amino)-n,n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo- but more generally known as iopentol, which bears U.S. National Institutes of Health Compound Identifier 56016. The European Medicines Agency schedules Iopentol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08241MIG. The World Health Organization schedules iopentol in its Anatomical Therapeutic Chemical (ATC) Classification. IOPENTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1C(N(CC(O)COC)C(=O)C)C(I)C(C(I)C1C(=O)NCC(O)CO)C(=O)NCC(O)CO. Most nations schedule Iopentol under HS 29242995.
This classification denotes a contrast agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73TJC7JGUY. The European Medicines Agency schedules Iophenoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08242MIG. Iophenoic acid generally arises in the molecular formula C11H11I3O3. The term IOPHENOIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, no. 12, 1959, list 3.) SMILES: CCC(CC1=C(C(=C(C=C1I)I)O)I)C(=O)O. Most nations schedule Iophenoic acid or ioprocemic acid under HS 29182980.
This classification denotes an iodinated contrast dye with the molecular formula C18H24I3N3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 712BAC33MZ, chemically known as 1,3-benzenedicarboxamide, n,n-bis(2,3-dihydroxypropyl)-5-((methoxyacetyl)amino)-n-methyl-2,4,6-triiodo- but more generally known as iopromide, which bears U.S. National Institutes of Health Compound Identifier 3736. The European Medicines Agency schedules Iopromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08244MIG. The term IOPROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). The World Health Organization schedules iopromide in its Anatomical Therapeutic Chemical (ATC) Classification. IOPROMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1C(C(=O)N(CC(O)CO)C)C(I)C(NC(=O)COC)C(I)C1C(=O)NCC(O)CO. Most nations schedule Iopromide under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C8H9I2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4661K682A, chemically known as 4(1h)-pyridinone, 1-(2,3-dihydroxypropyl)-3,5-diiodo- but more generally known as iopydol, which bears U.S. National Institutes of Health Compound Identifier 21751. The European Medicines Agency schedules Iopydol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08246MIG. The term IOPYDOL is an International Non-Proprietary Name. The World Health Organization schedules iopydol in its Anatomical Therapeutic Chemical (ATC) Classification. IOPYDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1CN(CC(O)CO)CC(I)C1=O. Most nations schedule Iopydol under HS 29333999.
This classification denotes an iodinated contrast dye with the molecular formula C11H9I3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 16CHD79MIX, chemically known as 5-acetamido-2,4,6-triiodo-n-methylisophthalamic acid but more generally known as iotalamic acid, which bears U.S. National Institutes of Health Compound Identifier 3737. The European Medicines Agency schedules Iotalamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08254MIG. The World Health Organization schedules iotalamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I. Most nations schedule Iotalamate or sodium iotalamate under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C37H48I6N6O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 16FL47B687, chemically known as 5,5-(malonylbis(methylimino))bis(n,n-bis(2,3-dihydroxy-1-(hydroxymethyl)propyl)-2,4,6-triiodoisophthalamide) but more generally known as iotrolan, which bears U.S. National Institutes of Health Compound Identifier 3738. The European Medicines Agency schedules Iotrolan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08260MIG. The term IOTROLAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). The World Health Organization schedules iotrolan in its Anatomical Therapeutic Chemical (ATC) Classification. IOTROLAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: IC1C(C(=O)NC(C(O)CO)CO)C(I)C(N(C(=O)CC(=O)N(C2C(I)C(C(=O)NC(C(O)CO)CO)C(I)C(C(=O)NC(C(O)CO)CO)C2I)C)C)C(I)C1C(=O)NC(C(O)CO)CO. Most nations schedule Iotrolan under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C22H18I6N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84C5PTP9X6, chemically known as 3,3-(oxybis(ethyleneoxymethylenecarbonylimino))bis(2,4,6-triiodobenzoic acid) but more generally known as iotroxic acid, which bears U.S. National Institutes of Health Compound Identifier 3740. The European Medicines Agency schedules Iotroxic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08261MIG. The term IOTROXIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). The World Health Organization schedules iotroxic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: Ic1c(NC(=O)COCCOCCOCC(=O)Nc2c(I)c(c(I)cc2I)C(=O)O)c(I)cc(I)c1C(=O)O. Most nations schedule Iotroxic acid under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C18H24I3N3O9, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier N3RIB7X24K, chemically known as 1,3-benzenedicarboxamide, n,n-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo- but more generally known as ioversol, which bears U.S. National Institutes of Health Compound Identifier 3741. European Medicines Agency schedules Ioversol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08262MIG. The term IOVERSOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules ioversol in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. IOVERSOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an iodinated contrast dye with the molecular formula C24H20I6N5O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HQ43CN02U9, chemically known as sodium n-(2-hydroxyethyl)-2,4,6-triiodo-5-(2-(2,4,6-triiodo-3-(n-methylacetamido)-5-(methylcarbamoyl)benzamido)acetamido)isophthalamate but more generally known as ioxaglate sodium, which bears U.S. National Institutes of Health Compound Identifier 50016. The European Medicines Agency schedules Ioxaglate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02757MIG. SMILES: CC(=O)N(C)C1=C(C(=C(C(=C1I)C(=O)NCC(=O)NC2=C(C(=C(C(=C2I)C(=O)[O-])I)C(=O)NCCO)I)I)C(=O)NC)I.[Na+]. Most nations schedule Ioxaglate or ioxaglate meglumine or ioxaglate sodium or sodium ioxaglate under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C24H21I6N5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z40X7EI2AF, chemically known as n-(2-hydroxyethyl)-2,4,6-triiodo-5-(2-(2,4,6-triiodo-3-(n-methylacetamido)-5-(methylcarbamoyl)benzamido)acetamido)isophthalamic acid but more generally known as ioxaglic acid, which bears U.S. National Institutes of Health Compound Identifier 3742. The European Medicines Agency schedules Ioxaglic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08264MIG. The term IOXAGLIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). The World Health Organization schedules ioxaglic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: Ic1c(N(C)C(=O)C)c(I)c(c(I)c1C(=O)NCC(=O)Nc1c(I)c(c(I)c(c1I)C(=O)O)C(=O)NCCO)C(=O)NC. Most nations schedule Ioxaglic acid under HS 29242995.
This classification denotes an iodinated contrast dye with the molecular formula C18H24I3N3O8, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier A4YJ7J11TG, chemically known as 1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n-(2,3-dihydroxypropyl)-n-(2-hydroxyethyl)-2,4,6-triiodo- but more generally known as ioxilan, which bears U.S. NIH Compound Identifier 3743. European Medicines Agency schedules Ioxilan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08265MIG. The term IOXILAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules ioxilan in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. IOXILAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an iodinated contrast dye with the molecular formula C12H11I3N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 967RDI7Z6K, chemically known as 5-acetamido-n-(2-hydroxyethyl)-2,4,6-triiodoisophthalamic acid but more generally known as ioxitalamic acid, which bears U.S. National Institutes of Health Compound Identifier 34536. The European Medicines Agency schedules Ioxitalamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08266MIG. The term IOXITALAMIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). The World Health Organization schedules ioxitalamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Ioxitalamic acid or ioxithalamic acid or ioxithalamate under HS 29242995.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62I3C8233L, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 846063 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Gentianales, Family Rubiaceae, Genus Carapichea, commonly known as IPECACUANHA. European Medicines Agency schedules cinnamomum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB46920, SUB46936, SUB46937, SUB46938, SUB46939, SUB46940, and SUB46941.
This classification denotes an anticholinergic agent with the molecular structure C12H16N2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, CV71VTP0VN chemically known as 9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta(b)quinoline, but more commonly known as ipidacrine, which bears U.S. NIH Compound Identifier 604519. European Medicines Agency schedules Ipidacrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08273MIG. The term IPIDACRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 10, no. 3, 1996, list 36).
This classification denotes a monoclonal antibody with the molecular formula C6472H9972N1732O2004S40, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T8C155666, more generally known as ipilimumab. European Medicines Agency schedules ipilimumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29397. The term IPILIMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. Most nations schedule Ipilimumab under HS 30021020 and SITC 54163. SMILES:. As of Q4 2014, IPILIMUMAB remains the US FDA Preferred Term for this commodity. . Ipilimumab bears US NLM identifiers UMLS ID C1367202 and NCI Concept Code C2654.
This classification denotes a vasodilating agent with the molecular formula C10H16N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZPC9768EH, chemically known as n,n-diisopropyl-3,4-furazandicarboxamide 2-oxide but generally known as ipramidil, which bears US NIH Compound Identifier 71268. European Medicines Agency schedules Ipramidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08275MIG. The term IPRAMIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). IPRAMIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ipramidil under HS 29349990 and SITC 51579. As of Q4 2014, IPRAMIDIL remains the US FDA Preferred Term for this commodity. Ipramidil bears US NLM identifiers UMLS ID C0654557 and NCI Concept Code C74326. SMILES: CC(C)NC(=O)C1=NO[N+](=C1C(=O)NC(C)C)[O-].
This classification denotes a bronchodilator and antimuscarinic agent with the molecular formula C20H30NO3.Br.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J697UZ2A9J, chemically known as 3-alpha-hydroxy-8-isopropyl-1-alpha-h,5-alpha-h-tropanium bromide (+-)-tropate but generally known as ipratropium bromide, which bears US NIH Compound Identifier 31098. European Medicines Agency schedules Ipratropium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08276MIG. World Health Organization schedules ipratropium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ipratropium bromide under HS 29399900 and SITC 54149. As of Q4 2014, IPRATROPIUM BROMIDE remains the US FDA Preferred Term for this commodity. Ipratropium bromide bears US NLM identifiers UMLS ID C0700580 and NCI Concept Code C29128. SMILES: BR.O(C1CC2[N](C(CC2)C1)(C(C)C)C)C(=O)C(CO)C1CCCCC1.
Ipratropium bromide/fenoterol hydrobromide is a fixed combination of an anticholinergic agent and beta2-adrenergic agonist in patients with Asthma and Chronic Obstructive Pulmonary Disease.
This classification denotes a serotonin antagonist with the molecular formula C12H16N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 903A9K181P, chemically known as 5,6-indolinedione, 3-hydroxy-1-isopropyl-, 5-semicarbazone (8ci) but generally known as iprazochrome, which bears US NIH Compound Identifier 6381821. European Medicines Agency schedules Iprazochrome in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08277MIG. The term IPRAZOCHROME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules iprazochrome in its Anatomical Therapeutic Chemical (ATC) Classification. IPRAZOCHROME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iprazochrome under HS 29339990 and SITC 51577. As of Q4 2014, IPRAZOCHROME remains the US FDA Preferred Term for this commodity. Iprazochrome bears US NLM identifiers UMLS ID C0123902 and NCI Concept Code C83834. SMILES: CC(C)N1CC(C2=C/C(=N/NC(=O)N)/C(=O)C=C21)O.
This classification denotes a nutritional supplement and flavonoid with the molecular formula C18H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80BJ7WN25Z, chemically known as 4h-1-benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl- but generally known as ipriflavone, which bears US NIH Compound Identifier 3747. European Medicines Agency schedules Ipriflavone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08278MIG. The term IPRIFLAVONE is an International Non-Proprietary Name. World Health Organization schedules ipriflavone in its Anatomical Therapeutic Chemical (ATC) Classification. IPRIFLAVONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ipriflavone under HS 29329985 and SITC 51569. As of Q4 2014, IPRIFLAVONE remains the US FDA Preferred Term for this commodity. Ipriflavone bears US NLM identifiers UMLS ID C0123903 and NCI Concept Code C63694. SMILES: O(C(C)C)C1CC2OCC(C(=O)C2CC1)C1CCCCC1.
This classification denotes a tricyclic antidepressant with the molecular formula C19H28N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69U0IKR8FP, chemically known as 5h-cyclooct(b)indole-5-propanamine, 6,7,8,9,10,11-hexahydro-n,n-dimethyl- but generally known as iprindole, which bears US NIH Compound Identifier 21722. European Medicines Agency schedules Iprindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08279MIG. World Health Organization schedules iprindole in its Anatomical Therapeutic Chemical (ATC) Classification. IPRINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iprindole under HS 29339990 and SITC 51577. As of Q4 2014, IPRINDOLE remains the US FDA Preferred Term for this commodity. SMILES: n1(c2c(CCCCCC2)c2c1cccc2)CCCN(C)C.
This classification denotes a tricyclic antidepressant C19H28N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z023VDR216, chemically known as 6,7,8,9,10,11-hexahydro-n,n-dimethyl-5h-cyclooct)(b)indole-5-propanamine, hydrochloride, but more generally known as iprindole hydrochloride, which bears US NIH Compound Identifier 159889. European Medicines Agency schedules Iprindole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02768MIG. Most nations, for tariff and trade purposes, schedule iprindole hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, IPRINDOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2C3C1CCCCCC3.CL.
This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C11H15ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1II9D6CB3J, chemically known as acetic acid, (p-chlorophenoxy)-, 2-isopropylhydrazide but generally known as iproclozide, which bears US NIH Compound Identifier 19063. European Medicines Agency schedules Iproclozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08280MIG. The term IPROCLOZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules iproclozide in its Anatomical Therapeutic Chemical (ATC) Classification. IPROCLOZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iproclozide under HS 29280090 and SITC 51486. As of Q4 2014, IPROCLOZIDE remains the US FDA Preferred Term for this commodity. Iproclozide bears US NLM identifiers UMLS ID C0063841 and NCI Concept Code C65955. SMILES: CC(C)NNC(=O)COC1=CC=C(C=C1)Cl.
This classification denotes an antidepressive agent and monoamine oxidase inhibitor with the molecular formula C9H13N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D892HFI3XA, chemically known as 4-pyridinecarboxylic acid, 2-(1-methylethyl)hydrazide but generally known as iproniazid, which bears US NIH Compound Identifier 3748. European Medicines Agency schedules Iproniazid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08283MIG. IPRONIAZID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iproniazid under HS 29333910 and SITC 51574. As of Q4 2014, IPRONIAZID remains the US FDA Preferred Term for this commodity. Iproniazid bears US NLM identifiers UMLS ID C0022059 and NCI Concept Code C97714. SMILES: O=C(NNC(C)C)c1ccncc1.
This classification denotes an antiprotozoal agent with the molecular formula C7H11N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 045BU63E23, chemically known as 1h-imidazole, 2-isopropyl-1-methyl-5-nitro- but generally known as ipronidazole, which bears US NIH Compound Identifier 26951. European Medicines Agency schedules Ipronidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08284MIG. The term IPRONIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). IPRONIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ipronidazole under HS 29332990 and SITC 51573. As of Q4 2014, IPRONIDAZOLE remains the US FDA Preferred Term for this commodity. Ipronidazole bears US NLM identifiers UMLS ID C0022060 and NCI Concept Code C76423. SMILES: O[N](=O)C1N(C(NC1)C(C)C)C.
This classification denotes a calcium channel blocker with the molecular formula C37H49N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VPX99Q2D7, chemically known as ( )-(r)-2-isopropyl-4-methyl-2-(o-(4-(4-(3,4,5-trimethoxyphenethyl)-1-piperazinyl)butoxy)phenyl)-2h-1,4-benzothiazin-3(4h)-one. but generally known as iprotiazem, which bears US NIH Compound Identifier 195131. European Medicines Agency schedules Iprotiazem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08286MIG. The term IPROTIAZEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). IPROTIAZEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iprotiazem under HS 29349990 and SITC 51579. As of Q4 2014, IPROTIAZEM remains the US FDA Preferred Term for this commodity. Iprotiazem bears US NLM identifiers UMLS ID C2825726 and NCI Concept Code C81678. SMILES: S1C(C(C)C)(c2c(OCCCCN3CCN(CC3)CCc3cc(OC)c(OC)c(OC)c3)cccc2)C(=O)N(c2c1cccc2)C.
This classification denotes a vasodilating agent with the molecular formula C18H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier URR853YLZA, chemically known as [4-(2-dimethylaminoethyloxy)-2-methyl-5-propan-2-ylphenyl] propan-2-yl carbonate but generally known as iproxamine, which bears US NIH Compound Identifier 172983. Most nations schedule iproxamine under HS 29221980 and SITC 51461. As of Q4 2014, IPROXAMINE remains the US FDA Preferred Term for this commodity. Iproxamine bears US NLM identifiers UMLS ID C1881263 and NCI Concept Code C65956. SMILES: CC1=CC(=C(C=C1OC(=O)OC(C)C)C(C)C)OCCN(C)C.
This classification denotes a vasodilating agent with the molecular formula C18H29NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83L52U43TX, chemically known as carbonic acid, 4-(2-(dimethylamino)ethoxy)-2-methyl-5-(1-methylethyl)phenyl 1-methylethyl ester, hydrochloride; but more generally known as iproxamine hydrochloride, which bears US NIH Compound Identifier 172982. Most nations, for tariff and trade purposes, schedule iproxamine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, IPROXAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Iproxamine hydrochloride bears US NLM identifiers UMLS ID C1881264 and NCI Concept Code C65957. SMILES: CC1CC(C(CC1OC(=O)OC(C)C)C(C)C)OCCN(C)C.CL.
This classification denotes an antiemetic agent with the molecular formula C13H22ClN5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8WTG4RSP9Y, chemically known as pyrimidine, 4-chloro-2-isopropylamino-6-(4-methylpiperazino)-5-methylthio- but generally known as iprozilamine, which bears US NIH Compound Identifier 68725. European Medicines Agency schedules Iprozilamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08288MIG. The term IPROZILAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). IPROZILAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iprozilamine under HS 29335995 and SITC 51576. As of Q4 2014, IPROZILAMINE remains the US FDA Preferred Term for this commodity. Iprozilamine bears US NLM identifiers UMLS ID C1881265 and NCI Concept Code C65958. SMILES: CLC1NC(NC(N2CCN(CC2)C)C1SC)NC(C)C.
This classification denotes a serotonin agonist and anxiolytic with the molecular formula C19H23N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J9B11MN0K, chemically known as 1,2-benzisothiazol-3(2h)-one, 2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, 1,1-dioxide but generally known as ipsapirone, which bears US NIH Compound Identifier 56971. European Medicines Agency schedules Ipsapirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08290MIG. The term IPSAPIRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). Most nations schedule ipsapirone under HS 29341000 and SITC 51579. As of Q4 2014, IPSAPIRONE remains the US FDA Preferred Term for this commodity. Ipsapirone bears US NLM identifiers UMLS ID C0123905 and NCI Concept Code C74391. SMILES: S1(=O)(=O)N(CCCCN2CCN(CC2)C2NCCCN2)C(=O)C2C1CCCC2.
This classification denotes a serotonin agonist and anxiolytic with the molecular formula C19H23N5O3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08R5U8PYVO, chemically known as 1,2-benzisothiazol-3(2h)-one, 2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, 1,1-dioxide, monohydrochloride but more generally known as ipsapirone hydrochloride, which bears US NIH Compound Identifier 71187. Most nations, for tariff and trade purposes, schedule ipsapirone hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, IPSAPIRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ipsapirone hydrochloride bears US NLM identifiers UMLS ID C2346591 and NCI Concept Code C72812. SMILES: C1CCC2C(C1)C(=O)N(S2(=O)=O)CCCCN3CCN(CC3)C4NCCCN4.CL.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C25H28N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J0E2756Z7N, chemically known as 1,3-diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)- but generally known as irbesartan, which bears US NIH Compound Identifier 3749. European Medicines Agency schedules Irbesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08293MIG. The term IRBESARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules irbesartan in its Anatomical Therapeutic Chemical (ATC) Classification. IRBESARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule irbesartan under HS 29332990 and SITC 51573. As of Q4 2014, IRBESARTAN remains the US FDA Preferred Term for this commodity. Irbesartan bears US NLM identifiers UMLS ID C0595301 and NCI Concept Code C29130. SMILES: O=C1N(C(=NC21CCCC2)CCCC)Cc1ccc(cc1)c1c(cccc1)c1n[nH]nn1.
This classification denotes an angiotensin ii receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3OGC31WUMZ. European Medicines Agency schedules Irbesartan hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29917. Irbesartan hydrochloride generally arises in the molecular formula C25H28N6O.CLH. The term 'irbesartan hydrochloride' is a European Medicines Agency European Public Assessment Report System designation. Most nations, for tariff and trade purposes, schedule irbesartan hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, IRBESARTAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC3CCC(CC3)C4CCCCC4C5[NH]NNN5.CL.
This classification denotes a camptothecin analogue with the molecular formula C33H38N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7673326042, chemically known as irinotecan, cpt-11 but generally known as irinotecan, which bears US NIH Compound Identifier 60838. European Medicines Agency schedules Irinotecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08295MIG. The term IRINOTECAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules irinotecan in its Anatomical Therapeutic Chemical (ATC) Classification. IRINOTECAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule irinotecan under HS 29399900 and SITC 54149. As of Q4 2014, IRINOTECAN remains the US FDA Preferred Term for this commodity. Irinotecan bears US NLM identifiers UMLS ID C0123931 and NCI Concept Code C62040. SMILES: O(C(=O)N1CCC(N2CCCCC2)CC1)C1CC2C(C3CN4C(C3NC2CC1)CC1C(O)(CC)C(=O)OCC1C4=O)CC.
This classification denotes a quinolone antibiotic with the molecular formula C16H13FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36SG77D21B, chemically known as 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1h-pyrrol-1-yl)-3-quinolinecarboxylic acid but generally known as irloxacin, which bears US NIH Compound Identifier 65828. European Medicines Agency schedules Irloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08296MIG. The term IRLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). IRLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule irloxacin under HS 29334990 and SITC 51575. As of Q4 2014, IRLOXACIN remains the US FDA Preferred Term for this commodity. Irloxacin bears US NLM identifiers UMLS ID C0071133 and NCI Concept Code C65961. SMILES: FC1C(N2CCCC2)CC2N(CC)CC(C(=O)C2C1)C(=O)O.
This classification denotes an antineoplastic alkylating agent with the molecular formula C15H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6B799IH05A, chemically known as spiro(cyclopropane-1,5(5h)-inden)-7(6h)-one, 6-hydroxy-3-(hydroxymethyl)-2,4,6-trimethyl-, (r)- but more generally known as irofulven, which bears U.S. National Institutes of Health Compound Identifier 148189. European Medicines Agency schedules Irofulven in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02773MIG. The term IROFULVEN is an International Non-Proprietary Name. Most nations schedule irofulven under HS 29144090 and SITC 51629. As of Q4 2014, IROFULVEN remains the US FDA Preferred Term for this commodity. Irofulven bears US NLM identifiers UMLS ID C0532362 and NCI Concept Code C1717. SMILES: OC1(C2(CC2)C(=C2C(=CC(=C2CO)C)C1=O)C)C.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JS492IR8Z6. European Medicines Agency schedules Irolapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08297MIG. Irolapride generally arises in the molecular formula C19H28N2O3. The term IROLAPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) IROLAPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule irolapride under HS 29339990 and SITC 51577. As of Q4 2014, IROLAPRIDE remains the US FDA Preferred Term for this commodity. Irolapride bears US NLM identifiers UMLS ID C1881269 and NCI Concept Code C65962. SMILES: O=C(NCC1N(CCC1)CC)c1cc(ccc1OC)C(=O)CCC.
Iron Dextran is an injectable low-molecular-weight ferric hydroxide complex indicated for patients with iron deficiency anemia where oral iron therapy is ineffective or poorly tolerated.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes an iron supplement. European Medicines Agency schedules iron polysaccharide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14951MIG. Iron polysaccharide bears US NLM identifiers UMLS ID C0722705 and NCI Concept Code C89826.
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZ7NYF5N8L. European Medicines Agency schedules Iron sucrose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16439MIG. Iron sucrose generally arises in the molecular formula C12H22O11.5FE.2NA.8O.HO.3H2O. The term 'iron sucrose' is a Japanese Accepted Name designation. As of Q4 2014, IRON SUCROSE remains the US FDA Preferred Term for this commodity. Iron sucrose bears US NLM identifiers UMLS ID C0060241 and NCI Concept Code C65963. SMILES: C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)CO)O)O)O)O.[O-2].[O-2].[O-2].[FE+3].[FE+3].
This classification denotes an anti-ulcer agent with the molecular formula C9H7Cl2N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QBX79NZC1D, chemically known as 1,3,5-triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- but generally known as irsogladine, which bears US NIH Compound Identifier 3752. European Medicines Agency schedules Irsogladine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08299MIG. The term IRSOGLADINE is an International Non-Proprietary Name. IRSOGLADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule irsogladine under HS 29336980 and SITC 51576. As of Q4 2014, IRSOGLADINE remains the US FDA Preferred Term for this commodity. Irsogladine bears US NLM identifiers UMLS ID C0063879 and NCI Concept Code C65964. SMILES: CLC1C(C2NC(NC(N2)N)N)CC(CL)CC1.
This classification denotes a uricosuric agent with the molecular formula C18H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AAK27WY74I, chemically known as 1h-benzimidazole, 5-(1h-imidazol-1-ylphenylmethyl)-2-methyl-, (+-)- but generally known as irtemazole, which bears US NIH Compound Identifier 71330. European Medicines Agency schedules Irtemazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08300MIG. The term IRTEMAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). IRTEMAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule irtemazole under HS 29332990 and SITC 51573. As of Q4 2014, IRTEMAZOLE remains the US FDA Preferred Term for this commodity. Irtemazole bears US NLM identifiers UMLS ID C0063880 and NCI Concept Code C65965. SMILES: N1(C(C2CC3[NH]C(NC3CC2)C)C2CCCCC2)CCNC1.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) B51UC955KQ. European Medicines Agency schedules Isaglidole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08301MIG. Isaglidole generally arises in the molecular formula C11H13FN4. The term ISAGLIDOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 4, no. 3 1990, list 30.) ISAGLIDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule isaglidole under HS 29332990 and SITC 51573. As of Q4 2014, ISAGLIDOLE remains US FDA's Preferred Term for this commodity. Isaglidole bears US NLM identifiers UMLS ID C1881270 and NCI Concept Code C65966. SMILES: C1CN=C(N1)NN2CC3=C(C2)C(=CC=C3)F.
This classification denotes a mucolytic agent with the molecular formula C14H15NO6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) K0YPY57FUQ, chemically known as (- )-n-(2-((2-methyl-4-oxo-1,3-benzodioxan-2-yl)thio)propionyl)glycine. but more generally known as isalsteine, which bears US NIH Compound Identifier 3038474. European Medicines Agency schedules Isalsteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08302MIG. The term ISALSTEINE is an International Non-Proprietary Name. ISALSTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule isalsteine under HS 29329970 and SITC 51569. As of Q4 2014, ISALSTEINE remains US FDA's Preferred Term for this commodity. Isalsteine bears US NLM identifiers UMLS ID C1881271 and NCI Concept Code C65967. SMILES: S(C1(OC2C(C(=O)O1)CCCC2)C)C(C)C(=O)NCC(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H23N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XUW8L8PW09, chemically known as 1(6h)-pyridazineacetamide, n-methyl-n-alpha-methylphenethyl-6-oxo-3-phenyl-, l- but generally known as isamfazone, which bears US NIH Compound Identifier 68753. European Medicines Agency schedules Isamfazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08303MIG. The term ISAMFAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). ISAMFAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isamfazone under HS 29339990 and SITC 51577. As of Q4 2014, ISAMFAZONE remains the US FDA Preferred Term for this commodity. Isamfazone bears US NLM identifiers UMLS ID C0063884 and NCI Concept Code C80557. SMILES: O=C(N(C(CC1CCCCC1)C)C)CN1NC(CCC1=O)C1CCCCC1.
This classification denotes an anxiolytic with the molecular formula C16H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2TP37O5J17, chemically known as 2-propanol, 1-((1-methylethyl)amino)-3-(2-(1h-pyrrol-1-yl)phenoxy)- but generally known as isamoltan, which bears US NIH Compound Identifier 127404. European Medicines Agency schedules Isamoltan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08304MIG. The term ISAMOLTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). ISAMOLTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isamoltan under HS 29339990 and SITC 51577. As of Q4 2014, ISAMOLTAN remains the US FDA Preferred Term for this commodity. Isamoltan bears US NLM identifiers UMLS ID C1881272 and NCI Concept Code C65968. SMILES: O(CC(O)CNC(C)C)c1c(n2cccc2)cccc1.
This classification denotes a biological response modifier with the molecular formula C10H12N4O6S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85141ONN7O, chemically known as 5-amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3h,6h)-dione but generally known as isatoribine, which bears US NIH Compound Identifier 72231. Most nations schedule isatoribine under HS 29349990 and SITC 51579. As of Q4 2014, ISATORIBINE remains the US FDA Preferred Term for this commodity. Isatoribine bears US NLM identifiers UMLS ID C1612082 and NCI Concept Code C90811. SMILES: C(C1C(C(C(O1)N2C3=C(C(=O)N=C(N3)N)SC2=O)O)O)O.
An azole antifungal indicated for use in the treatment of Invasive aspergillosis and Invasive mucormycosis.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C11H16N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9C8Z5F38D0, chemically known as 3,7-dihydro-1,3-dimethyl-7-(2-methylpropyl)-1h-purine-2,6-dione but generally known as isbufylline, which bears US NIH Compound Identifier 65681. European Medicines Agency schedules Isbufylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08308MIG. The term ISBUFYLLINE is an International Non-Proprietary Name. ISBUFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isbufylline under HS 29395900 and SITC 54145. As of Q4 2014, ISBUFYLLINE remains the US FDA Preferred Term for this commodity. Isbufylline bears US NLM identifiers UMLS ID C0043937 and NCI Concept Code C65970. SMILES: CC(C)CN1C=NC2=C1C(=O)N(C(=O)N2C)C.
This classification denotes an aminoglycoside antibiotic with the molecular formula C22H43N5O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7K224460P, chemically known as (s)-o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1.4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1.6))-1,3-diamino-n1-(3-aminolactoyl)-1,2,3-trideoxy-d-scyllo-inositol but generally known as isepamicin, which bears US NIH Compound Identifier 3755. European Medicines Agency schedules Isepamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08309MIG. The term ISEPAMICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules isepamicin in its Anatomical Therapeutic Chemical (ATC) Classification. ISEPAMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isepamicin under HS 29419000 and SITC 54139. As of Q4 2014, ISEPAMICIN remains the US FDA Preferred Term for this commodity. Isepamicin bears US NLM identifiers UMLS ID C0124008 and NCI Concept Code C83838. SMILES: O(C1C(NC(=O)C(O)CN)CC(N)C(OC2OC(C(O)C(O)C2O)CN)C1O)C1OCC(O)(C(NC)C1O)C.
This classification denotes an aminoglycoside antibiotic with the molecular formula C22H43N5O12.2H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U606Y00EWE, chemically known as d-streptamine, o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-n(sup 1)-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (s)-, sulfate (salt) but more generally known as isepamicin sulfate, which bears US NIH Compound Identifier 171883. European Medicines Agency schedules Isepamicin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02782MIG. Most nations, for tariff and trade purposes, schedule isepamicin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, ISEPAMICIN SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N)NC(=O)[C@H](CN)O)O.OS(=O)(=O)O.OS(=O)(=O)O.
This classification denotes an antitussive agent with the molecular formula C16H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) R4823W2PQL, chemically known as valeronitrile, 4-(dimethylamino)-2-isopropyl-2-phenyl- but more generally known as isoaminile, which bears US NIH Compound Identifier 6481. European Medicines Agency schedules Isoaminile in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08310MIG. The term ISOAMINILE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules isoaminile in its Anatomical Therapeutic Chemical (ATC) Classification. ISOAMINILE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule isoaminile under HS 29269095 and SITC 51484. As of Q4 2014, ISOAMINILE remains US FDA's Preferred Term for this commodity. Isoaminile bears US NLM identifiers UMLS ID C0063912 and NCI Concept Code C83839. SMILES: N(C(CC(C(C)C)(C1CCCCC1)C#N)C)(C)C.
This classification denotes an antitussive agent with the molecular formula C16H24N2.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27K34XSD46, chemically known as valeronitrile, 4-(dimethylamino)-2-isopropyl-2-phenyl-, citrate but more generally known as isoaminile citrate, which bears US NIH Compound Identifier 161602. European Medicines Agency schedules Isoaminile citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02783MIG. Most nations, for tariff and trade purposes, schedule isoaminile citrate under HS 29269095 and SITC 51484. As of Q4 2014, ISOAMINILE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C(CC(C)N(C)C)(C#N)C1CCCCC1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antitussive agent C16H24N2.C6H13NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4055851484, chemically known as sulfamic acid, n-cyclohexyl-, compd. with .alpha.-(2-(dimethylamino)propyl)-.alpha.-(1-methylethyl)benzeneacetonitrile (1:1), but more generally known as isoaminile cyclamate, which bears US NIH Compound Identifier 112076. Most nations, for tariff and trade purposes, schedule isoaminile cyclamate under HS 29269095 and SITC 51484. As of Q4 2014, ISOAMINILE CYCLAMATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C(CC(C)N(C)C)(C#N)C1CCCCC1.C1CCC(CC1)NS(=O)(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C13H19NO2S, chemically known as (4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl) 2-thiocyanatoacetate but generally known as isobornyl thiocyanoacetate, which bears US NIH Compound Identifier 8267. European Medicines Agency schedules Diethylcarbamazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07111MIG. As of Q4 2014, ISOBORNYL THIOCYANOACETATE remains the US FDA Preferred Term for this commodity. SMILES: CC1(C2CCC1(C(C2)OC(=O)CSC#N)C)C.
This classification denotes a uricosuric agent with the molecular formula C15H9BrO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J1J87P409K, chemically known as 1,3-indandione, 5-bromo-2-phenyl- but generally known as isobromindione, which bears US NIH Compound Identifier 68953. European Medicines Agency schedules Isobromindione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08311MIG. The term ISOBROMINDIONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules isobromindione in its Anatomical Therapeutic Chemical (ATC) Classification. ISOBROMINDIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isobromindione under HS 29147000 and SITC 51629. As of Q4 2014, ISOBROMINDIONE remains the US FDA Preferred Term for this commodity. Isobromindione bears US NLM identifiers UMLS ID C1881274 and NCI Concept Code C65971. SMILES: BRC1CC2C(C(=O)C(C2=O)C2CCCCC2)CC1.
This classification denotes an anesthetic agent with the molecular formula C11H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9566855ULN, chemically known as benzoic acid, p-amino-, isobutyl ester but generally known as isobutamben, which bears US NIH Compound Identifier 7176. European Medicines Agency schedules Isobutamben in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08312MIG. The term ISOBUTAMBEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). ISOBUTAMBEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isobutamben under HS 29224995 and SITC 51465. As of Q4 2014, ISOBUTAMBEN remains the US FDA Preferred Term for this commodity. Isobutamben bears US NLM identifiers UMLS ID C2697820 and NCI Concept Code C75962. SMILES: CC(C)COC(=O)C1=CC=C(C=C1)N.
This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C12H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34237V843T, chemically known as 3-isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide but generally known as isocarboxazid, which bears US NIH Compound Identifier 3759. European Medicines Agency schedules Isocarboxazid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08313MIG. The term ISOCARBOXAZID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules isocarboxazid in its Anatomical Therapeutic Chemical (ATC) Classification. ISOCARBOXAZID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isocarboxazid under HS 29349990 and SITC 51579. As of Q4 2014, ISOCARBOXAZID remains the US FDA Preferred Term for this commodity. Isocarboxazid bears US NLM identifiers UMLS ID C0022154 and NCI Concept Code C47573. SMILES: CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2.
This classification denotes an antifungal agent with the molecular formula C18H14Cl4N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GRI7WFR424, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,6-dichlorophenyl)methoxy)ethyl)- but generally known as isoconazole, which bears US NIH Compound Identifier 3760. European Medicines Agency schedules Isoconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08314MIG. The term ISOCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules isoconazole in its Anatomical Therapeutic Chemical (ATC) Classification. ISOCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoconazole under HS 29332990 and SITC 51573. As of Q4 2014, ISOCONAZOLE remains the US FDA Preferred Term for this commodity. Isoconazole bears US NLM identifiers UMLS ID C0063953 and NCI Concept Code C83841. SMILES: CLC1C(C(OCC2C(CL)CCCC2CL)CN2CCNC2)CCC(CL)C1.
This classification denotes an antifungal agent with the molecular formula C18H14Cl4N2O.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AS8P3N30X, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,6-dichlorophenyl)methoxy)ethyl)-, mononitrate but more generally known as isoconazole nitrate, which bears US NIH Compound Identifier 159968. European Medicines Agency schedules Isoconazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02786MIG. Most nations, for tariff and trade purposes, schedule isoconazole nitrate under HS 29332990 and SITC 51573. As of Q4 2014, ISOCONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Isoconazole nitrate bears US NLM identifiers UMLS ID C0700489 and NCI Concept Code C98015. SMILES: C1CC(C(C(C1)CL)COC(CN2CCNC2)C3CCC(CC3CL)CL)CL.[N+](=O)(O)[O-].
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0L7AR6G18O. European Medicines Agency schedules Isocromil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08315MIG. Isocromil generally arises in the molecular formula C19H16O5. The term ISOCROMIL is an International Non-Proprietary Name or INN. ISOCROMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isocromil under HS 29329985 and SITC 51569. As of Q4 2014, ISOCROMIL remains the US FDA Preferred Term for this commodity. Isocromil bears US NLM identifiers UMLS ID C1881276 and NCI Concept Code C65973. SMILES: O(C(C)C)C1C(OC(=O)C2CC3C(OCCC3=O)CC2)CCCC1.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YV0SN3276Q, chemically known as 3,4-dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol but generally known as isoetarine, which bears US NIH Compound Identifier 3762. European Medicines Agency schedules Isoetarine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08316MIG. The term ISOETARINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules isoetarine in its Anatomical Therapeutic Chemical (ATC) Classification. ISOETARINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Isoetarine or isoetharine bears US NLM identifiers UMLS ID C0022176 and NCI Concept Code C65974. SMILES: CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C13H21NO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DV74WJ5PJB, chemically known as 3,4-dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol methanesulfonate (salt) but more generally known as isoetarine mesilate, which bears U.S. National Institutes of Health Compound Identifier 23702. European Medicines Agency schedules Isoetarine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02788MIG. World Health Organization schedules the base compound, isoetharine (as Isoetarine), in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, US FDA's Preferred Term for this commodity remains ISOETHARINE MESYLATE. Isoetharine mesilate bears US NLM identifiers UMLS ID C0022177 and NCI Concept Code C65976. Most nations, for tariff and trade purposes, schedule Isoetharine mesilate under HS 29225090 and SITC 51467. SMILES: CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C.CS(=O)(=O)O.
This classification denotes an anesthetic agent with the molecular formula C3H2ClF5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CYS9AKD70P, chemically known as 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane but generally known as isoflurane, which bears US NIH Compound Identifier 3763. European Medicines Agency schedules Isoflurane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08319MIG. The term ISOFLURANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules isoflurane in its Anatomical Therapeutic Chemical (ATC) Classification. ISOFLURANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoflurane under HS 29091990 and SITC 51616. As of Q4 2014, ISOFLURANE remains the US FDA Preferred Term for this commodity. Isoflurane bears US NLM identifiers UMLS ID C0022180 and NCI Concept Code C65978. SMILES: CLC(OC(F)F)C(F)(F)F.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN501. This VA Drug Class (TN501) classifies this compound as belonging to the group AMINO ACIDS/PROTEINS, PARENTERAL, WITHOUT ADDED ELECTROLYTES.
This classification denotes an opioid receptor agonist with the molecular formula C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12L95QD6KV, chemically known as 1,1-diphenyl-1-(dimethylaminoisopropyl)butanone-2 but generally known as isomethadone, which bears US NIH Compound Identifier 10072. European Medicines Agency schedules Isomethadone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08323MIG. The term ISOMETHADONE is an International Non-Proprietary Name. ISOMETHADONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isomethadone under HS 29223900 and SITC 51463. As of Q4 2014, ISOMETHADONE remains the US FDA Preferred Term for this commodity. Isomethadone bears US NLM identifiers UMLS ID C0064006 and NCI Concept Code C76085. SMILES: O=C(C(C(CN(C)C)C)(C1CCCCC1)C1CCCCC1)CC.
This classification denotes an adrenergic agent with the molecular formula C9H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7L24THH6T, chemically known as 5-hepten-2-amine, n,6-dimethyl-, hydrochloride but generally known as isometheptene, which bears US NIH Compound Identifier 22297. European Medicines Agency schedules Isometheptene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08324MIG. The term ISOMETHEPTENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules isometheptene in its Anatomical Therapeutic Chemical (ATC) Classification. ISOMETHEPTENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isometheptene under HS 29211980 and SITC 51451. As of Q4 2014, ISOMETHEPTENE remains the US FDA Preferred Term for this commodity. Isometheptene bears US NLM identifiers UMLS ID C0064007 and NCI Concept Code C75929. SMILES: N(C(CC/C=C(/C)C)C)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H19N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4625WF7BM, chemically known as 5-hepten-2-amine, n,6-dimethyl-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1) (9ci) but more generally known as isometheptene bitartrate, which bears US NIH Compound Identifier 22296. Most nations, for tariff and trade purposes, schedule isometheptene bitartrate under HS 29211980 and SITC 51451. As of Q4 2014, ISOMETHEPTENE BITARTRATE remains US FDA's Preferred Term for this commodity. Isometheptene bitartrate bears US NLM identifiers UMLS ID C0770466 and NCI Concept Code C87580. SMILES: CC(CCC=C(C)C)NC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an adrenergic agent with the molecular formula C9H19N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Z4CJC3O5F, chemically known as 5-hepten-2-amine, n,6-dimethyl-, hydrochloride but more generally known as isometheptene hydrochloride, which bears US NIH Compound Identifier 22297. European Medicines Agency schedules Isometheptene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14276MIG. Most nations, for tariff and trade purposes, schedule isometheptene hydrochloride under HS 29211980 and SITC 51451. As of Q4 2014, ISOMETHEPTENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Isometheptene hydrochloride bears US NLM identifiers UMLS ID C2697822 and NCI Concept Code C80003. SMILES: CC(CCC=C(C)C)NC.CL.
This classification denotes an adrenergic agent with the molecular formula 2C9H19N.C6H10O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8O120FDS6P. European Medicines Agency schedules isometheptene mucate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02792MIG. The term isometheptene mucate is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule isometheptene mucate under HS 29211980 and SITC 51451. As of Q4 2014, ISOMETHEPTENE MUCATE remains US FDA's Preferred Term for this commodity. Isometheptene mucate bears US NLM identifiers UMLS ID C0355634 and NCI Concept Code C87577. SMILES: CC(CCC=C(C)C)NC.CC(CCC=C(C)C)NC.[C@@H]([C@@H]([C@H](C(=O)O)O)O)([C@@H](C(=O)O)O)O.
This classification denotes an antitubercular agent with the molecular formula C6H7N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V83O1VOZ8L, chemically known as 4-pyridinecarboxylic acid, hydrazide but generally known as isoniazid, which bears US NIH Compound Identifier 3767. European Medicines Agency schedules Isoniazid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08326MIG. The term ISONIAZID is an International Non-Proprietary Name. World Health Organization schedules isoniazid in its Anatomical Therapeutic Chemical (ATC) Classification. ISONIAZID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoniazid under HS 29333999 and SITC 51574. As of Q4 2014, ISONIAZID remains the US FDA Preferred Term for this commodity. Isoniazid bears US NLM identifiers UMLS ID C0022209 and NCI Concept Code C600. SMILES: O=C(NN)C1CCNCC1.
This classification denotes an antitubercular agent with the molecular formula 2C9H8N3O3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4Q640072Z, chemically known as isonicotinic acid, (1-carboxyethylidene)hydrazide calcium salt (2:1), but more generally known as isoniazid calcium pyruvate, which bears US NIH Compound Identifier 9568684. European Medicines Agency schedules isoniazid calcium pyruvate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08326MIG. Most nations, for tariff purposes, schedule isoniazid calcium pyruvate under HS 29333999. SMILES: CC(=NNC(=O)C1CCNCC1)C(=O)[O-].CC(=NNC(=O)C1CCNCC1)C(=O)[O-].[CA+2].
This classification denotes an antitubercular agent with the molecular formula C7H9N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GN8S7ZES0F, chemically known as isonicotinic acid 2-(sulfomethyl)hydrazine, but more generally known as isoniazid methanesulfonate, which bears US NIH Compound Identifier 3769. European Medicines Agency schedules isoniazid methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08326MIG. Most nations, for tariff purposes, schedule isoniazid methanesulfonate under HS 29333999. SMILES: C1CNCCC1C(=O)NNCS(=O)(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM500. This VA Drug Class (AM500) classifies this compound as belonging to the group ANTITUBERCULARS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM500. This VA Drug Class (AM500) classifies this compound as belonging to the group ANTITUBERCULARS.
This classification is for a combination therapy used for prophylaxis against multiple opportunistic infections in people living with HIV. The first component, ISONIAZID, has US FDA Unique Ingredient Identifier of V83O1VOZ8L. ISONIAZIDis an International Non-Proprietary Name or INN. The second component, PYRIDOXINE, has US FDA Unique Ingredient Identifier of KV2JZ1BI6Z. The third component, SULFAMETHOXAZOLE, has US FDA Unique Ingredient Identifier of JE42381TNV. The fourth component, TRIMETHOPRIM, has US FDA Unique Ingredient Identifier of AN164J8Y0X.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM500. This VA Drug Class (AM500) classifies this compound as belonging to the group ANTITUBERCULARS.
Definition: This classification is for a combination medication for TB treatment. The first component, ISONIAZID, has US FDA Unique Ingredient Identifier of V83O1VOZ8L. ISONIAZID is an International Non-Proprietary Name or INN. The second component, RIFAPENTINE, has US FDA Unique Ingredient Identifier of XJM390A33U. RIFAPENTINE is an International Non-Proprietary Name or INN.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LB0T3NEB48, chemically known as 1-propanone, 1-(4-amino-2-methyl-5-phenylpyrrol-3-yl)-2-methyl- but generally known as isoprazone, which bears US NIH Compound Identifier 71737. European Medicines Agency schedules Isoprazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08328MIG. The term ISOPRAZONE is an International Non-Proprietary Name. ISOPRAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoprazone under HS 29339990 and SITC 51577. As of Q4 2014, ISOPRAZONE remains the US FDA Preferred Term for this commodity. Isoprazone bears US NLM identifiers UMLS ID C0621745 and NCI Concept Code C65981. SMILES: O=C(C1C([NH]C(C1N)C1CCCCC1)C)C(C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G6A72XC0I, chemically known as 11beta,17,21-trihydroxy-16-methylenepregna-4,6-diene-3,20-dione but generally known as isoprednidene, which bears US NIH Compound Identifier 71888. European Medicines Agency schedules Isoprednidene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08329MIG. The term ISOPREDNIDENE is an International Non-Proprietary Name. ISOPREDNIDENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoprednidene under HS 29372900 and SITC 54153. As of Q4 2014, ISOPREDNIDENE remains the US FDA Preferred Term for this commodity. Isoprednidene bears US NLM identifiers UMLS ID C2827217 and NCI Concept Code C83844. SMILES: OC1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)CC2)C=C3)C)CC1=C)C)C(=O)CO.
This classification denotes a bronchodilator with the molecular formula C11H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L628TT009W, chemically known as 3,4-dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol but generally known as isoprenaline, which bears US NIH Compound Identifier 3779. European Medicines Agency schedules Isoprenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08330MIG. The term ISOPRENALINE is an International Non-Proprietary Name. World Health Organization schedules isoprenaline in its Anatomical Therapeutic Chemical (ATC) Classification. ISOPRENALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Isoprenaline under HS 29225000 and SITC 51467. SMILES: CC(C)NCC(C1CCC(C(C1)O)O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H20O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18751GAD0P, chemically known as 2,3-dihydro-alpha-methyl-2-(1-methylethyl)-1h-indene-5-acetic acid but generally known as isoprofen, which bears US NIH Compound Identifier 68769. European Medicines Agency schedules Isoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08331MIG. The term ISOPROFEN is an International Non-Proprietary Name. ISOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoprofen under HS 29163900 and SITC 51379. As of Q4 2014, ISOPROFEN remains the US FDA Preferred Term for this commodity. Isoprofen bears US NLM identifiers UMLS ID C2827218 and NCI Concept Code C83845. SMILES: OC(=O)C(C1CC2CC(CC2CC1)C(C)C)C.
This classification denotes an anticholinergic agent with the molecular formula C23H33N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8B9I31H724, chemically known as 4-(diisopropylamino)-2,2-diphenylbutyramide methiodide but generally known as isopropamide, which bears US NIH Compound Identifier 3775. European Medicines Agency schedules Isopropamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02799MIG. World Health Organization schedules isopropamide in its Anatomical Therapeutic Chemical (ATC) Classification. ISOPROPAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ISOPROPAMIDE remains the US FDA Preferred Term for this commodity. Isopropamide bears US NLM identifiers UMLS ID C0301373 and NCI Concept Code C73139. SMILES: O=C(N)C(CC[N](C(C)C)(C(C)C)C)(C1CCCCC1)C1CCCCC1. .
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes an alcohol with the molecular formula C3H8O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier ND2M416302, chemically known as 2-propanol, titanium (4+) salt but more generally known as isopropyl alcohol, which bears US NIH Compound Identifier 3776. European Medicines Agency schedules Isopropyl alcohol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12085MIG. Isopropyl alcohol bears US NLM identifiers UMLS ID C0022237 and NCI Concept Code C602. SMILES: OC(C)C.
This classification denotes a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05T9139TJW. European Medicines Agency schedules Isopropicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08333MIG. Isopropicillin generally arises in the molecular formula C18H22N2O5S. The term ISOPROPICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) ISOPROPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isopropicillin under HS 29411090 and SITC 54131. As of Q4 2014, ISOPROPICILLIN remains the US FDA Preferred Term for this commodity. Isopropicillin bears US NLM identifiers UMLS ID C2827219 and NCI Concept Code C83846. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(OC1CCCCC1)(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes an industrial aid with the molecular formula C17H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0RE8K4LNJS, chemically known as 1-tridecanecarboxylic acid, isopropyl ester but generally known as isopropyl myristate, which bears US NIH Compound Identifier 8042. European Medicines Agency schedules Isopropyl myristate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14281MIG. As of Q4 2014, ISOPROPYL MYRISTATE remains the US FDA Preferred Term for this commodity. Isopropyl myristate bears US NLM identifiers UMLS ID C0064056 and NCI Concept Code C76717. SMILES: CCCCCCCCCCCCCC(=O)OC(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE102. This VA Drug Class (RE102) classifies this compound as belonging to the group BRONCHODILATORS, SYMPATHOMIMETIC, INHALATION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AU100. This VA Drug Class (AU100) classifies this compound as belonging to the group SYMPATHOMIMETICS (ADRENERGICS).
This classification denotes a vasodilating agent with the molecular formula C6H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WXR179L51S, chemically known as 1,4-dianhydrosorbitol but generally known as isosorbide, which bears US NIH Compound Identifier 12597. European Medicines Agency schedules Isosorbide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08334MIG. The term ISOSORBIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). ISOSORBIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isosorbide under HS 29329985 and SITC 51569. As of Q4 2014, ISOSORBIDE remains the US FDA Preferred Term for this commodity. Isosorbide bears US NLM identifiers UMLS ID C0022251 and NCI Concept Code C60773. SMILES: O1C2C(OCC2O)C(O)C1.
This classification denotes a vasodilating agent with the molecular formula C6H8N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IA7306519N, chemically known as 1,4:3,6-dianhydrosorbitol 2, 5-dinitrate but generally known as isosorbide dinitrate, which bears US NIH Compound Identifier 3780. European Medicines Agency schedules Isosorbide dinitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08335MIG. The term ISOSORBIDE DINITRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules isosorbide dinitrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule isosorbide dinitrate under HS 29329985 and SITC 51569. As of Q4 2014, ISOSORBIDE DINITRATE remains the US FDA Preferred Term for this commodity. Isosorbide dinitrate bears US NLM identifiers UMLS ID C0022252 and NCI Concept Code C29134. SMILES: O1C2C(OCC2O[N](=O)O)C(O[N](=O)O)C1.
This classification denotes a vasodilating agent with the molecular formula C6H9NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LX1OH63030, chemically known as 1,4:3,6-dianhydro-d-glucitol 5-nitrate but generally known as isosorbide mononitrate, which bears US NIH Compound Identifier 27661. European Medicines Agency schedules Isosorbide mononitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08336MIG. The term ISOSORBIDE MONONITRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules isosorbide mononitrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule isosorbide mononitrate under HS 29329985 and SITC 51569. As of Q4 2014, ISOSORBIDE MONONITRATE remains the US FDA Preferred Term for this commodity. Isosorbide mononitrate bears US NLM identifiers UMLS ID C0064079 and NCI Concept Code C47575. SMILES: O1C2C(OCC2O)C(O[N](=O)O)C1.
It is a broad spectrum antiallergic and treats the allergic eye diseases without corticotherapy risks.
This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BRT31Y0N0K. European Medicines Agency schedules Isosulpride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08338MIG. Isosulpride generally arises in the molecular formula C15H23N3O4S. The term ISOSULPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) ISOSULPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isosulpride under HS 29350090 and SITC 51580. As of Q4 2014, ISOSULPRIDE remains the US FDA Preferred Term for this commodity. Isosulpride bears US NLM identifiers UMLS ID C2827220 and NCI Concept Code C83848. SMILES: S(=O)(=O)(N)C1CC(NC(=O)CC2N(CCC2)CC)C(OC)CC1.
This classification denotes a histamine antagonist with the molecular formula C16H19N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WVZ7K9P0JY, chemically known as 10h-pyrido(3,2-b)(1,4)benzothiazine-10-ethanamine, n,n,alpha-trimethyl- but generally known as isothipendyl, which bears US NIH Compound Identifier 3781. European Medicines Agency schedules Isothipendyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08339MIG. World Health Organization schedules isothipendyl in its Anatomical Therapeutic Chemical (ATC) Classification. ISOTHIPENDYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isothipendyl under HS 29349990 and SITC 51579. As of Q4 2014, ISOTHIPENDYL remains the US FDA Preferred Term for this commodity. SMILES: S1C2C(N(CC(N(C)C)C)C3NCCCC13)CCCC2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19N3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 953AP1LBV8, chemically known as 10h-pyrido(3,2-b)(1,4)benzothiazine-10-ethanamine, n,n,alpha-trimethyl- but more generally known as isothipendyl hydrochloride, which bears US NIH Compound Identifier 3781. European Medicines Agency schedules Isothipendyl hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02807MIG. Most nations, for tariff and trade purposes, schedule isothipendyl hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ISOTHIPENDYL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Isothipendyl hydrochloride bears US NLM identifiers UMLS ID C2079449 and NCI Concept Code C76063. SMILES: CC(CN1C2CCCCC2SC3C1NCCC3)N(C)C.CL.
This classification denotes an anti-ulcer agent with the molecular formula C11H14N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EX1ND80X1I, chemically known as 8-quinolinecarbothioamide, 5,6,7,8-tetrahydro-4-methyl-,( -); but generally known as isotiquimide, which bears US NIH Compound Identifier 3037235. European Medicines Agency schedules Isotiquimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08340MIG. The term ISOTIQUIMIDE is an International Non-Proprietary Name. ISOTIQUIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isotiquimide under HS 29334990 and SITC 51575. As of Q4 2014, ISOTIQUIMIDE remains the US FDA Preferred Term for this commodity. Isotiquimide bears US NLM identifiers UMLS ID C1881281 and NCI Concept Code C65984. SMILES: CC1=C2CCCC(C2=NC=C1)C(=S)N.
This classification denotes a retinoic acid agent with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EH28UP18IF, chemically known as 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-nona-2,4,6,8-tetraenoic acid but generally known as isotretinoin, which bears US NIH Compound Identifier 5538. European Medicines Agency schedules Isotretinoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08341MIG. The term ISOTRETINOIN is an International Non-Proprietary Name. World Health Organization schedules isotretinoin in its Anatomical Therapeutic Chemical (ATC) Classification. ISOTRETINOIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isotretinoin under HS 29362100 and SITC 54112. As of Q4 2014, ISOTRETINOIN remains the US FDA Preferred Term for this commodity. Isotretinoin bears US NLM identifiers UMLS ID C1331177 and NCI Concept Code C603. SMILES: OC(=O)/C=C(/C=C/C=C(/C=C/C1=C(CCCC1(C)C)C)C)C.
This classification denotes a retinoic acid agent with the molecular formula C29H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 922SI67369, chemically known as retinoic acid, 1-2-(4-methoxyphenyl)-2-oxoethyl ester, 13-cis-, but more generally known as isotretinoin anisatil, which bears US NIH Compound Identifier 6441814. European Medicines Agency schedules isotretinoin anisatil or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08341MIG. Most nations, for tariff purposes, schedule isotretinoin anisatil under HS 29362100. SMILES: CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)OCC(=O)C2CCC(CC2)OC)/C)/C.
This classification denotes a bronchodilator and beta-adrenergic blocking agent with the molecular formula C19H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Y84EU1HAA, chemically known as 2-propanol, 1-((1,1-dimethylethyl)amino)-3-(2-(2-(3-methyl-5-isoxazolyl)ethenyl)phenoxy)- but generally known as isoxaprolol, which bears US NIH Compound Identifier 6443854. European Medicines Agency schedules Isoxaprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08342MIG. The term ISOXAPROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). ISOXAPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoxaprolol under HS 29349990 and SITC 51579. As of Q4 2014, ISOXAPROLOL remains the US FDA Preferred Term for this commodity. Isoxaprolol bears US NLM identifiers UMLS ID C1881282 and NCI Concept Code C65985. SMILES: OC(CNC(C)(C)C)COC1C(CCCC1)/C=C/C1ONC(C1)C.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8XU734C4NG. European Medicines Agency schedules Isoxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08344MIG. Isoxicam generally arises in the molecular formula C14H13N3O5S. The term ISOXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, no. 10 1974, list 14.) ISOXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoxicam under HS 29349990 and SITC 51579. As of Q4 2014, ISOXICAM remains the US FDA Preferred Term for this commodity. Isoxicam bears US NLM identifiers UMLS ID C0064104 and NCI Concept Code C80558. SMILES: S1(=O)(=O)N(/C(=C(/O)NC2NOC(C2)C)C(=O)C2C1CCCC2)C.
This classification denotes a vasodilating agent and beta-adrenergic agonist with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R15UI3245N, chemically known as benzyl alcohol, p-hydroxy-alpha-(1-((1-methyl-2-phenoxyethyl)amino)ethyl)- but generally known as isoxsuprine, which bears US NIH Compound Identifier 3783. European Medicines Agency schedules Isoxsuprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08345MIG. The term ISOXSUPRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules isoxsuprine in its Anatomical Therapeutic Chemical (ATC) Classification. ISOXSUPRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isoxsuprine under HS 29225000 and SITC 51467. As of Q4 2014, ISOXSUPRINE remains the US FDA Preferred Term for this commodity. Isoxsuprine bears US NLM identifiers UMLS ID C0022267 and NCI Concept Code C61795. SMILES: OC(C(NC(COC1CCCCC1)C)C)C1CCC(O)CC1.
This classification denotes a calcium channel blocker with the molecular formula C19H21N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YO1UK1S598, chemically known as 2,1,3-benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv. but generally known as isradipine, which bears US NIH Compound Identifier 3784. European Medicines Agency schedules Isradipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08346MIG. The term ISRADIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules isradipine in its Anatomical Therapeutic Chemical (ATC) Classification. ISRADIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule isradipine under HS 29349990 and SITC 51579. As of Q4 2014, ISRADIPINE remains the US FDA Preferred Term for this commodity. Isradipine bears US NLM identifiers UMLS ID C0071304 and NCI Concept Code C47577. SMILES: O(C(=O)C1=C(NC(=C(C1c1c2nonc2ccc1)C(=O)OC)C)C)C(C)C.
This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C16H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00S0D0OEKR, chemically known as 2-oxo-n-1alphah,5alphah-tropan-3alpha-yl-1-benzimidazolinecarboxamide but generally known as itasetron, which bears US NIH Compound Identifier 60761. European Medicines Agency schedules Itasetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08350MIG. The term ITASETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). ITASETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule itasetron under HS 29399900 and SITC 54149. As of Q4 2014, ITASETRON remains the US FDA Preferred Term for this commodity. Itasetron bears US NLM identifiers UMLS ID C0526892 and NCI Concept Code C65990. SMILES: O=C(NC1CC2N(C(CC2)C1)C)n1c2c([nH]c1=O)cccc2.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81BMQ80QRL. European Medicines Agency schedules Itopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08352MIG. Itopride generally arises in the molecular formula C20H26N2O4. The term ITOPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) ITOPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule itopride under HS 29242995 and SITC 51479. As of Q4 2014, ITOPRIDE remains the US FDA Preferred Term for this commodity. Itopride bears US NLM identifiers UMLS ID C0531483 and NCI Concept Code C65991. SMILES: O(CCN(C)C)c1ccc(CNC(=O)c2cc(OC)c(OC)cc2)cc1.
This classification denotes an antidepressant agent with the molecular formula C20H26N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H9NV66W0I, chemically known as n-((4-(2-(dimethylamino)ethoxy)phenyl)methyl)-3,4-dimethoxybenzamide monohydrochloride but more generally known as itopride hydrochloride, which bears US NIH Compound Identifier 129791. European Medicines Agency schedules Itopride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16440MIG. Most nations, for tariff and trade purposes, schedule itopride hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, ITOPRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Itopride hydrochloride bears US NLM identifiers UMLS ID C0082935 and NCI Concept Code C99563. SMILES: CN(C)CCOC1CCC(CC1)CNC(=O)C2CCC(C(C2)OC)OC.CL.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 304NUG5GF4. European Medicines Agency schedules Itraconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08353MIG. Itraconazole generally arises in the molecular formula C35H38CL2N8O4. The term ITRACONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) ITRACONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule itraconazole under HS 29349990 and SITC 51579. As of Q4 2014, ITRACONAZOLE remains the US FDA Preferred Term for this commodity. Itraconazole bears US NLM identifiers UMLS ID C0064113 and NCI Concept Code C1138. SMILES: CLC1C(C2(OC(CO2)COC2CCC(N3CCN(CC3)C3CCC(N4C(=O)N(NC4)C(CC)C)CC3)CC2)CN2NCNC2)CCC(CL)C1.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9H0R50KY0. European Medicines Agency schedules Itramin tosilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08354MIG. Itramin tosylate generally arises in the molecular formula C7H8O3S.C2H6N2O3. The term ITRAMIN TOSYLATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) Itramin tosilate or itramin tosylate bears US NLM identifiers UMLS ID C0064114 and NCI Concept Code C83850. SMILES: CC1=CC=C(C=C1)S(=O)(=O)O.C(CO[N+](=O)[O-])N.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 79EDP2VHY8. European Medicines Agency schedules Itrocainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08355MIG. Itrocainide generally arises in the molecular formula C23H27N3O. The term ITROCAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, list 25.) ITROCAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule itrocainide under HS 29334990 and SITC 51575. As of Q4 2014, ITROCAINIDE remains US FDA's Preferred Term for this commodity. Itrocainide bears US NLM identifiers UMLS ID C1881286 and NCI Concept Code C65993. SMILES: O=C(NCCN(CC)CC)C1C2C(C(NC1)C1C(CCCC1)C)CCCC2.
This classification denotes an antiarrhythmic agent with the molecular formula C27H36N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3H48L0LPZQ, chemically known as 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one but more generally known as ivabradine, which bears US NIH Compound Identifier 132999. European Medicines Agency schedules Ivabradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08357MIG. The term IVABRADINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 11997, List 37). World Health Organization schedules ivabradine in its Anatomical Therapeutic Chemical (ATC) Classification. IVABRADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ivabradine under HS 29337900 and SITC 51561. As of Q4 2014, IVABRADINE remains US FDA's Preferred Term for this commodity. Ivabradine bears US NLM identifiers UMLS ID C0257190 and NCI Concept Code C65995. SMILES: O(C1CC2C(CC2CC1OC)CN(CCCN1CCC2C(CC1=O)CC(OC)C(OC)C2)C)C.
This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8883YP2R6D. European Medicines Agency schedules Ivermectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12089MIG. Ivermectin generally arises in the molecular formula C48H74O14. The term IVERMECTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) IVERMECTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ivermectin under HS 29419000 and SITC 54139. As of Q4 2014, IVERMECTIN remains the US FDA Preferred Term for this commodity. Ivermectin bears US NLM identifiers UMLS ID C0022322 and NCI Concept Code C61796. SMILES: CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C.
This classification denotes an antidepressant agent with the molecular formula C20H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W0K2QLU43U, chemically known as 6-methoxy-4-(3-((3s,4r)-3-vinyl-4-piperidyl)propyl)quinoline. but generally known as ivoqualine, which bears US NIH Compound Identifier 3038482. European Medicines Agency schedules Ivoqualine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08359MIG. The term IVOQUALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). IVOQUALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ivoqualine under HS 29334990 and SITC 51575. As of Q4 2014, IVOQUALINE remains the US FDA Preferred Term for this commodity. Ivoqualine bears US NLM identifiers UMLS ID C1881288 and NCI Concept Code C65996. SMILES: O(c1cc2c(CCCC3C(CNCC3)C=C)ccnc2cc1)C.
This classification denotes an epothilone b analogue with the molecular formula C27H42N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K27005NP0A, chemically known as 17-oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (1s,3s,7s,10r,11s,12s,16r)- but generally known as ixabepilone, which bears US NIH Compound Identifier 6445540. European Medicines Agency schedules Ixabepilone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16422MIG. The term IXABEPILONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 1, 2004, List 51). World Health Organization schedules ixabepilone in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ixabepilone under HS 29419000 and SITC 54139. As of Q4 2014, IXABEPILONE remains the US FDA Preferred Term for this commodity. Ixabepilone bears US NLM identifiers UMLS ID C1135132 and NCI Concept Code C37452. SMILES: S1CC(NC1C)/C=C(/C1NC(=O)CC(O)C(C(=O)C(C(O)C(CCCC2(OC2C1)C)C)C)(C)C)C.
Injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation
This classification denotes a macrolide antibiotic with the molecular formula C42H69NO15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HV13HFS217, chemically known as stereoisomer of 7-(formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranoside 4-acetate 4-isovalerate but generally known as josamycin, which bears US NIH Compound Identifier 5282165. European Medicines Agency schedules Josamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12091MIG. The term JOSAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules josamycin in its Anatomical Therapeutic Chemical (ATC) Classification. JOSAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule josamycin under HS 29419000 and SITC 54139. As of Q4 2014, JOSAMYCIN remains the US FDA Preferred Term for this commodity. Josamycin bears US NLM identifiers UMLS ID C0022419 and NCI Concept Code C83851. SMILES: O(C1C(N(C)C)C(O)C(OC1C)OC1C(CC(C(O)C=CC=CCC(OC(=O)CC(OC(=O)C)C1OC)C)C)CC=O)C1OC(C(OC(=O)CC(C)C)C(O)(C1)C)C.
This classification denotes a macrolide antibiotic with the molecular formula C45H73NO16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 053VA4B06Y, chemically known as leucomycin v, 3-acetate 4b-(3-methylbutanoate) 9-propanoate but more generally known as josamycin propionate, which bears US NIH Compound Identifier 5353696. European Medicines Agency schedules Josamycin propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02814MIG. Most nations, for tariff and trade purposes, schedule josamycin propionate under HS 29419000 and SITC 54139. As of Q4 2014, JOSAMYCIN PROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@H]1/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]([C@H]([C@H](C[C@H]1C)CC=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)OC)OC(=O)C)C.
This classification denotes a macrolide antibiotic with the molecular formula C42H69NO15.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PH728K04HS, chemically known as leucomycin v, 3-acetate 4b-(3-methylbutanoate), (2r,3r)-2,3-dihydroxybutanedioate (1:1) (salt), but more generally known as josamycin tartrate, which bears US NIH Compound Identifier 6445955. European Medicines Agency schedules josamycin tartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12091MIG. Most nations, for tariff purposes, schedule josamycin tartrate under HS 29419000. SMILES: C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an antihelminthic agent with the molecular formula C10H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SIV03811UC, chemically known as 3-pyrrolidineacetic acid, 2-carboxy-4- (1-methylethenyl)- but generally known as kainic acid, which bears US NIH Compound Identifier 3816. European Medicines Agency schedules Kainic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08360MIG. The term KAINIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Most nations schedule kainic acid under HS 29339990 and SITC 51577. As of Q4 2014, KAINIC ACID remains the US FDA Preferred Term for this commodity. Kainic acid bears US NLM identifiers UMLS ID C0022471 and NCI Concept Code C79132. SMILES: CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O.
This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RUC37XUP2P. European Medicines Agency schedules Kanamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08362MIG. Kanamycin generally arises in the molecular formula C18H36N4O11. The term KANAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) KANAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule kanamycin under HS 29419000 and SITC 54139. As of Q4 2014, KANAMYCIN remains the US FDA Preferred Term for this commodity. Kanamycin bears US NLM identifiers UMLS ID C0022487 and NCI Concept Code C65997. SMILES: C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N.
This classification denotes an aminoglycoside antibiotic with the molecular formula C18H36N4O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EQK9Q303C5, chemically known as d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-(6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxy-, but more generally known as kanamycin a, which bears US NIH Compound Identifier 6032. European Medicines Agency schedules kanamycin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08362MIG. Most nations, for tariff purposes, schedule kanamycin a under HS 29419000. Kanamycin a bears US NLM identifiers UMLS ID C0022489 and NCI Concept Code C76151. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N.
This classification denotes an aminoglycoside antibiotic with the molecular formula C18H36N4O11.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J80EX28SMQ, chemically known as d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl(1->6)-o-(6-amino-6-deoxy-.alpha.-d-glucopyranosyl(1->4))-2-deoxy-, sulfate (1:1) (salt), but more generally known as kanamycin a sulfate, which bears US NIH Compound Identifier 32943. European Medicines Agency schedules kanamycin a sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08362MIG. Most nations, for tariff purposes, schedule kanamycin a sulfate under HS 29419000. Kanamycin a sulfate bears US NLM identifiers UMLS ID C2697837 and NCI Concept Code C76152. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N.OS(=O)(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BOW48C81XP, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 18313 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Magnolianae, Order Piperales, Family Piperaceae, Genus Piper L. (pepper), Species Piper methysticum G. Forst. (kava), commonly known as KAVA. Kava bears the USDA PLANTS Database Identifier PIME. European Medicines Agency schedules karaya gum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB14881MIG and SUB33469. Most nations schedule Kava under HS 12129990 and SITC 05489. SMILES:.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VD83UL6Y6, chemically known as 3,5-pyrazolidinedione, 1,2-diphenyl-4-(3-oxobutyl)- but generally known as kebuzone, which bears US NIH Compound Identifier 3824. European Medicines Agency schedules Kebuzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08363MIG. The term KEBUZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules kebuzone in its Anatomical Therapeutic Chemical (ATC) Classification. KEBUZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Kebuzone or ketophenylbutazone bears US NLM identifiers UMLS ID C0064324 and NCI Concept Code C79126. SMILES: CC(=O)CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3.
This classification denotes an anesthetic agent with the molecular formula C13H16ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O18YUO0I83, chemically known as cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8ci) but more generally known as ketamine hydrochloride, which bears US NIH Compound Identifier 3821. European Medicines Agency schedules Ketamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02830MIG. Most nations, for tariff and trade purposes, schedule ketamine hydrochloride under HS 29223900. As of Q4 2014, KETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ketamine hydrochloride bears US NLM identifiers UMLS ID C0700541 and NCI Concept Code C29142. SMILES: CNC1(CCCCC1=O)C2CCCCC2CL.CL.
This classification denotes a serotonin antagonist with the molecular formula C22H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97F9DE4CT4, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)- but generally known as ketanserin, which bears US NIH Compound Identifier 3822. European Medicines Agency schedules Ketanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08366MIG. The term KETANSERIN is an International Non-Proprietary Name. World Health Organization schedules ketanserin in its Anatomical Therapeutic Chemical (ATC) Classification. KETANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketanserin under HS 29335995 and SITC 51576. As of Q4 2014, KETANSERIN remains the US FDA Preferred Term for this commodity. Ketanserin bears US NLM identifiers UMLS ID C0022616 and NCI Concept Code C604. SMILES: Fc1ccc(C(=O)C2CCN(CC2)CCn2c(=O)c3c([nH]c2=O)cccc3)cc1.
This classification denotes a serotonin antagonist with the molecular formula C22H22FN3O3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 645498QK7H, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1) but more generally known as ketanserin tartrate, which bears US NIH Compound Identifier 135348. European Medicines Agency schedules Ketanserin tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02831MIG. Most nations, for tariff and trade purposes, schedule ketanserin tartrate under HS 29335995 and SITC 51576. As of Q4 2014, KETANSERIN TARTRATE remains US FDA's Preferred Term for this commodity. Ketanserin tartrate bears US NLM identifiers UMLS ID C1517662 and NCI Concept Code C2036. SMILES: C1CCC2C(C1)C(=O)N(C(=O)[NH]2)CCN3CCC(CC3)C(=O)C4CCC(CC4)F.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an opioid receptor agonist with the molecular formula C18H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6IO4IG518S, chemically known as 2,6-methano-3-benzazocin-1(2h)-one, 3-(cyclopropylmethyl)-3,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-, (2alpha,6alpha,11s*)- but generally known as ketazocine, which bears US NIH Compound Identifier 71426. European Medicines Agency schedules Ketazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08367MIG. The term KETAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). KETAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketazocine under HS 29333999 and SITC 51574. As of Q4 2014, KETAZOCINE remains the US FDA Preferred Term for this commodity. Ketazocine bears US NLM identifiers UMLS ID C0064303 and NCI Concept Code C83853. SMILES: O=C1C2N(CC3CC3)CCC(C2C)(C2C1CCC(O)C2)C.
This classification denotes a benzodiazepine with the molecular formula C20H17ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92A214MD7Y, chemically known as 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-dione but generally known as ketazolam, which bears US NIH Compound Identifier 33746. European Medicines Agency schedules Ketazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08368MIG. The term KETAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules ketazolam in its Anatomical Therapeutic Chemical (ATC) Classification. KETAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketazolam under HS 29349100 and SITC 51579. As of Q4 2014, KETAZOLAM remains the US FDA Preferred Term for this commodity. Ketazolam bears US NLM identifiers UMLS ID C0064304 and NCI Concept Code C83854. SMILES: CLC1CC2C3(OC(=CC(=O)N3CC(=O)N(C2CC1)C)C)C1CCCCC1.
This classification denotes an antiviral agent with the molecular formula C6H12O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E00MDP82S4, chemically known as 3-ethoxy-1,1-dihydroxy-2-butanone but generally known as kethoxal, which bears US NIH Compound Identifier 34006. European Medicines Agency schedules Ketoxal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08379MIG. The term KETOXAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). Kethoxal or ketoxal bears US NLM identifiers UMLS ID C0064305 and NCI Concept Code C83855. SMILES: CCOC(C)C(=O)C(O)O.
This classification denotes an opioid receptor agonist with the molecular formula C15H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PQS1L514CF, chemically known as 1-propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8ci) but generally known as ketobemidone, which bears US NIH Compound Identifier 10101. European Medicines Agency schedules Ketobemidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08370MIG. The term KETOBEMIDONE is an International Non-Proprietary Name. World Health Organization schedules ketobemidone in its Anatomical Therapeutic Chemical (ATC) Classification. KETOBEMIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketobemidone under HS 29333300 and SITC 51574. As of Q4 2014, KETOBEMIDONE remains the US FDA Preferred Term for this commodity. Ketobemidone bears US NLM identifiers UMLS ID C0064311 and NCI Concept Code C80583. SMILES: O=C(C1(CCN(CC1)C)C1CC(O)CCC1)CC.
This classification denotes an opioid receptor agonist with the molecular formula C15H21NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U9U6LTV80K, chemically known as 1-propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride but more generally known as ketobemidone hydrochloride, which bears US NIH Compound Identifier 80069. European Medicines Agency schedules Ketobemidone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02832MIG. Most nations, for tariff and trade purposes, schedule ketobemidone hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, KETOBEMIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ketobemidone hydrochloride bears US NLM identifiers UMLS ID C0952503 and NCI Concept Code C101535. SMILES: CCC(=O)C1(CCN(CC1)C)C2CCCC(C2)O.CL.
This classification denotes a non-steroidal aromatase inhibitor and multidrug resistance modulator with the molecular formula C26H28Cl2N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9400W927I, chemically known as piperazine, 1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1h- imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-, cis- but generally known as ketoconazole, which bears US NIH Compound Identifier 3823. European Medicines Agency schedules Ketoconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08373MIG. The term KETOCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules ketoconazole in its Anatomical Therapeutic Chemical (ATC) Classification. KETOCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketoconazole under HS 29349990 and SITC 51579. As of Q4 2014, KETOCONAZOLE remains the US FDA Preferred Term for this commodity. Ketoconazole bears US NLM identifiers UMLS ID C0022625 and NCI Concept Code C605. SMILES: CLC1C(C2(OC(CO2)COC2CCC(N3CCN(CC3)C(=O)C)CC2)CN2CCNC2)CCC(CL)C1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90Y4QC304K, chemically known as propionic acid, 2-(3-benzoylphenyl)- but generally known as ketoprofen, which bears US NIH Compound Identifier 3825. European Medicines Agency schedules Ketoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08374MIG. The term KETOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules ketoprofen in its Anatomical Therapeutic Chemical (ATC) Classification. KETOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketoprofen under HS 29183000 and SITC 51395. As of Q4 2014, KETOPROFEN remains the US FDA Preferred Term for this commodity. Ketoprofen bears US NLM identifiers UMLS ID C0022635 and NCI Concept Code C47578. SMILES: OC(=O)C(C1CC(CCC1)C(=O)C1CCCCC1)C.
This classification denotes a nonsteroidal antiinflammatory drug C16H14O3.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5WD00E3D4C, chemically known as l-lysine, 3-benzoyl-.alpha.-methylbenzeneacetate (1:1), but more generally known as ketoprofen lysine, which bears US NIH Compound Identifier 119285. European Medicines Agency schedules Ketoprofen lysine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02834MIG. Most nations, for tariff and trade purposes, schedule ketoprofen lysine under HS 29183000 and SITC 51395. As of Q4 2014, KETOPROFEN LYSINE remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCCC(C1)C(=O)C2CCCCC2)C(=O)O.C(CCN)C[C@@H](C(=O)O)N.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5R10M39KS7, chemically known as benzeneacetic acid, 3-benzoyl-alpha-methyl-, sodium salt but more generally known as ketoprofen sodium, which bears US NIH Compound Identifier 42390. European Medicines Agency schedules Ketoprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26651. Most nations, for tariff and trade purposes, schedule ketoprofen sodium under HS 29183000 and SITC 51395. As of Q4 2014, KETOPROFEN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCCC(C1)C(=O)C2CCCCC2)C(=O)[O-].[NA+].
This classification denotes an opioid with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Z0ZXE70XL, chemically known as morphinan-6-one, 17-(cyclopropylmethyl)-4-hydroxy-; but generally known as ketorfanol, which bears US NIH Compound Identifier 5490677. European Medicines Agency schedules Ketorfanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08375MIG. The term KETORFANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). KETORFANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketorfanol under HS 29334990 and SITC 51575. As of Q4 2014, KETORFANOL remains the US FDA Preferred Term for this commodity. Ketorfanol bears US NLM identifiers UMLS ID C1881307 and NCI Concept Code C66000. SMILES: O=C1CC23C(C(N(CC2)CC2CC2)CC2C3C(O)CCC2)CC1.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YZI5105V0L, chemically known as 5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid but generally known as ketorolac, which bears US NIH Compound Identifier 3826. European Medicines Agency schedules Ketorolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08376MIG. The term KETOROLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules ketorolac in its Anatomical Therapeutic Chemical (ATC) Classification. KETOROLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketorolac under HS 29339990 and SITC 51577. As of Q4 2014, KETOROLAC remains the US FDA Preferred Term for this commodity. Ketorolac bears US NLM identifiers UMLS ID C0073631 and NCI Concept Code C1219. SMILES: OC(=O)C1CCN2C1CCC2C(=O)C1CCCCC1.
Treatment of pain and as antispasmodic: Containing Ketorolac and Homatropine Methylbromide is indicated for the short-term management of colic and spasms accompanied by severe to moderate pain present in cases of: Colic and spasms of gastrointestinal motility: intestinal and gastrointestinal colic , irritable bowel and spastic diarrhea. Colic and spasms of the biliary tract: vesicular gallstones, cholelithiasis, choledocholithiasis and cholecystitis. Colic and spasms of the urinary tract: Kidney colic, cystitis, tenesmus, dysmenorrhea, premenstrual tension.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13NO3.C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4EVE5946BQ, chemically known as 1h-pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, (+-)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) but more generally known as ketorolac trometamol, which bears US NIH Compound Identifier 84003. European Medicines Agency schedules Ketorolac trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02835MIG. Most nations, for tariff and trade purposes, schedule ketorolac trometamol under HS 29339990. SMILES: C1CCC(CC1)C(=O)C2CCC3N2CCC3C(=O)O.C(C(CO)(CO)N)O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13NO3.C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4EVE5946BQ, chemically known as 1h-pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, (+-)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) but more generally known as ketorolac trometamol, which bears US NIH Compound Identifier 84003. European Medicines Agency schedules Ketorolac trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02835MIG. Most nations, for tariff and trade purposes, schedule ketorolac tromethamine under HS 29339990 and SITC 51577. As of Q4 2014, KETOROLAC TROMETHAMINE remains US FDA's Preferred Term for this commodity. Ketorolac tromethamine bears US NLM identifiers UMLS ID C0146226 and NCI Concept Code C61798. SMILES: C1CCC(CC1)C(=O)C2CCC3N2CCC3C(=O)O.C(C(CO)(CO)N)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X49220T18G, chemically known as 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one but generally known as ketotifen, which bears US NIH Compound Identifier 3827. European Medicines Agency schedules Ketotifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08377MIG. The term KETOTIFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules ketotifen in its Anatomical Therapeutic Chemical (ATC) Classification. KETOTIFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketotifen under HS 29349990 and SITC 51579. As of Q4 2014, KETOTIFEN remains the US FDA Preferred Term for this commodity. Ketotifen bears US NLM identifiers UMLS ID C0022642 and NCI Concept Code C61799. SMILES: S1C2C(C(=C3\CCN(CC3)C)/C3C(CC2=O)CCCC3)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NOS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HBD503WORO, chemically known as 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one but more generally known as ketotifen fumarate, which bears US NIH Compound Identifier 3827. European Medicines Agency schedules Ketotifen fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02836MIG. Most nations, for tariff and trade purposes, schedule ketotifen fumarate under HS 29349990 and SITC 51579. As of Q4 2014, KETOTIFEN FUMARATE remains US FDA's Preferred Term for this commodity. Ketotifen fumarate bears US NLM identifiers UMLS ID C0043443 and NCI Concept Code C47579. SMILES: CN1CCC(=C2C3CCCCC3CC(=O)C4C2CCS4)CC1.C(=C/C(=O)O)\C(=O)O.
This classification denotes a folate antagonist with the molecular formula C21H27N7O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 504RN634MM, chemically known as n-(p-((2-(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)ethyl)amino)benzoyl)-l-glutamic acid but generally known as ketotrexate, which bears US NIH Compound Identifier 68691. European Medicines Agency schedules Ketotrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08378MIG. The term KETOTREXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). KETOTREXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketotrexate under HS 29335995 and SITC 51576. As of Q4 2014, KETOTREXATE remains the US FDA Preferred Term for this commodity. Ketotrexate bears US NLM identifiers UMLS ID C2697842 and NCI Concept Code C77403. SMILES: O=C1NC([NH]C2NCC(N(C12)C)CCNC1CCC(CC1)C(=O)NC(CCC(=O)O)C(=O)O)N.
This classification denotes an adrenergic antagonist with the molecular formula C19H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5H8897N95, chemically known as benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)- but generally known as labetalol, which bears US NIH Compound Identifier 3869. European Medicines Agency schedules Labetalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08382MIG. The term LABETALOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules labetalol in its Anatomical Therapeutic Chemical (ATC) Classification. LABETALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule labetalol under HS 29242995 and SITC 51479. As of Q4 2014, LABETALOL remains the US FDA Preferred Term for this commodity. Labetalol bears US NLM identifiers UMLS ID C0022860 and NCI Concept Code C29146. SMILES: OC(CNC(CCC1CCCCC1)C)C1CC(C(O)CC1)C(=O)N.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H24N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1GEV3BAW9J, chemically known as benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)- but more generally known as labetalol hydrochloride, which bears US NIH Compound Identifier 3869. European Medicines Agency schedules Labetalol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02844MIG. Most nations, for tariff and trade purposes, schedule labetalol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, LABETALOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Labetalol hydrochloride bears US NLM identifiers UMLS ID C0699440 and NCI Concept Code C63578. SMILES: CC(CCC1CCCCC1)NCC(C2CCC(C(C2)C(=O)N)O)O.CL.
This classification denotes a calcium channel blocker with the molecular formula C26H33NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 260080034N, chemically known as 1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2-(1h-tetrazol-5-yl)(1,1- biphenyl)-4-yl)methyl)- but generally known as lacidipine, which bears US NIH Compound Identifier 3961. European Medicines Agency schedules Lacidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08383MIG. The term LACIDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules lacidipine in its Anatomical Therapeutic Chemical (ATC) Classification. LACIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lacidipine under HS 29333999 and SITC 51574. As of Q4 2014, LACIDIPINE remains the US FDA Preferred Term for this commodity. Lacidipine bears US NLM identifiers UMLS ID C0064568 and NCI Concept Code C80881. SMILES: Clc1nc(n(Cc2ccc(cc2)c2c(cccc2)c2n[nH]nn2)c1CO)CCCC.
This classification denotes an anticonvulsant agent with the molecular formula C13H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 563KS2PQY5, chemically known as 2-(acetylamino)-3-methoxy-n-(phenylmethyl)propanamide, (2r)- but generally known as lacosamide, which bears US NIH Compound Identifier 219078. European Medicines Agency schedules Lacosamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25407. The term LACOSAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, List 52). World Health Organization schedules lacosamide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lacosamide under HS 29242995 and SITC 51479. As of Q4 2014, LACOSAMIDE remains the US FDA Preferred Term for this commodity. Lacosamide bears US NLM identifiers UMLS ID C1311230 and NCI Concept Code C83859. SMILES: O(CC(NC(=O)C)C(=O)NCC1CCCCC1)C.
This classification denotes an isotonic solution with the molecular formula C3H9CaCl2KNa2O6, chemicaly known as calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride; dihydroxide;hydrate but generally known as lactated ringer's solution or Ringer lactate solution, which bears US NIH Compound Identifier European Medicines Agency schedules Lactated ringer's solution in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices 56841910. SUB32409, SUB33298, and SUB33359. SMILES: CC(C(=O)[O-])O.O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].
This classification denotes an industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33X04XA5AT. European Medicines Agency schedules Lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB41225. Lactic acid generally arises in the molecular formula C3H6O3. The term 'lactic acid' is an FDA designation. As of Q4 2014, LACTIC ACID remains the US FDA Preferred Term for this commodity. Lactic acid bears US NLM identifiers UMLS ID C0064582 and NCI Concept Code C76926. SMILES: CC(C(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes an artificial sweetener with the molecular formula C12H24O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L2B0WJF7ZY, chemically known as d-glucitol, 4-o-beta-d-galactopyranosyl- but generally known as lactitol, which bears US NIH Compound Identifier 91476. European Medicines Agency schedules Lactitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08385MIG. The term LACTITOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules lactitol in its Anatomical Therapeutic Chemical (ATC) Classification. LACTITOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lactitol under HS 29400000 and SITC 51692. As of Q4 2014, LACTITOL remains the US FDA Preferred Term for this commodity. Lactitol bears US NLM identifiers UMLS ID C0064585 and NCI Concept Code C81025. SMILES: O1C(OC(C(O)C(O)CO)C(O)CO)C(O)C(O)C(O)C1CO.
This classification denotes an artificial sweetener with the molecular formula C12H24O11.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1F5S85F60B, chemically known as d-glucitol, 4-o-.beta.-d-galactopyranosyl-, dihydrate, but more generally known as lactitol dihydrate, which bears US NIH Compound Identifier 157354. European Medicines Agency schedules lactitol dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08385MIG. Most nations, for tariff purposes, schedule lactitol dihydrate under HS 29400000. SMILES: C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O.O.O.
This classification denotes an artificial sweetener C12H24O11.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UH2K6W1Y64, chemically known as d-glucitol, 4-o-.beta.-d-galactopyranosyl-, monohydrate, but more generally known as lactitol monohydrate, which bears US NIH Compound Identifier 3067270. European Medicines Agency schedules Lactitol monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12097MIG. Most nations, for tariff and trade purposes, schedule lactitol monohydrate under HS 29400000 and SITC 51692. As of Q4 2014, LACTITOL MONOHYDRATE remains US FDA's Preferred Term for this commodity. Lactitol monohydrate bears US NLM identifiers UMLS ID C2697878 and NCI Concept Code C77137. SMILES: C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O.O.
This classification denotes a laxative and disaccharide, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9U7D5QH5AE. European Medicines Agency schedules Lactulose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08386MIG. Lactulose generally arises in the molecular formula C12H22O11. The term LACTULOSE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) LACTULOSE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lactulose under HS 29400000 and SITC 51692. As of Q4 2014, LACTULOSE remains the US FDA Preferred Term for this commodity. Lactulose bears US NLM identifiers UMLS ID C0022957 and NCI Concept Code C29148. SMILES: C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O.
This classification denotes an anthracycline antibiotic with the molecular formula C29H31NO11S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U395ERO49H. The term LADIRUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45. ). Most nations schedule ladirubicin under HS 29419000 and SITC 54139. As of Q4 2014, LADIRUBICIN remains the US FDA Preferred Term for this commodity. Ladirubicin bears US NLM identifiers UMLS ID C2827222 and NCI Concept Code C83861. SMILES: CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N6CC6)OS(=O)(=O)C.
This classification denotes an immunosuppressant with the molecular formula C15H13F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 44EH625IUS, chemically known as (z)alpha-cyano-alpha(sup 4),alpha(sup 4),alpha(sup 4)-trifluoro-beta-hydroxycyclopropaneacrylo-3,4-xylide. but more generally known as laflunimus, which bears US NIH Compound Identifier 5745208. European Medicines Agency schedules Laflunimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08387MIG. The term LAFLUNIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). LAFLUNIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule laflunimus under HS 29269095 and SITC 51484. As of Q4 2014, LAFLUNIMUS remains US FDA's Preferred Term for this commodity. Laflunimus bears US NLM identifiers UMLS ID C2825486 and NCI Concept Code C81163. SMILES: FC(F)(F)C1C(CC(NC(=C(\C(=O)C2CC2)C#N)\O)CC1)C.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C22H29N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49S4O7ADLC, chemically known as acetamide, 2-((2-furanylmethyl)sulfinyl)-n-(4-((4-(1-piperidinylmethyl)-2-pyridinyl)oxy)-2-butenyl)-, (z)- but generally known as lafutidine, which bears US NIH Compound Identifier 5282136. European Medicines Agency schedules Lafutidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08388MIG. The term LAFUTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules lafutidine in its Anatomical Therapeutic Chemical (ATC) Classification. LAFUTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lafutidine under HS 29349990 and SITC 51579. As of Q4 2014, LAFUTIDINE remains the US FDA Preferred Term for this commodity. Lafutidine bears US NLM identifiers UMLS ID C0172827 and NCI Concept Code C79117. SMILES: S(=O)(CC1OCCC1)CC(=O)NC/C=C\COC1NCCC(CN2CCCCC2)C1.
This classification denotes an antiplatelet agent with the molecular formula C24H28N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9XOE28082S, chemically known as acetic acid, ((1-(2-((4-aminoiminomethyl)benzoyl)amino)-3-(4-hydroxyphenyl)-1-oxopropyl)-4-piperidinyl)oxy)-, (s)- but generally known as lamifiban, which bears US NIH Compound Identifier 71453. European Medicines Agency schedules Lamifiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08391MIG. The term LAMIFIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). LAMIFIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lamifiban under HS 29333999 and SITC 51574. As of Q4 2014, LAMIFIBAN remains the US FDA Preferred Term for this commodity. Lamifiban bears US NLM identifiers UMLS ID C0380040 and NCI Concept Code C83862. SMILES: O(C1CCN(CC1)C(=O)C(NC(=O)C1CCC(CC1)C(=N)N)CC1CCC(O)CC1)CC(=O)O.
This classification denotes an antiplatelet agent with the molecular formula C24H28N4O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3UZ1CTQ989, chemically known as (s)-((1-(2-((4-(aminoiminomethyl)benzoyl)amino)-3-(4-hydroxyphenyl)-1-oxopropyl)-4-piperidinyl)oxy)acetic acid monohydrochloride, but more generally known as lamifiban hydrochloride, which bears US NIH Compound Identifier 3038483. European Medicines Agency schedules lamifiban hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08391MIG. Most nations, for tariff purposes, schedule lamifiban hydrochloride under HS 29333999. Lamifiban hydrochloride bears US NLM identifiers UMLS ID C2825685 and NCI Concept Code C81568. SMILES: C1CC(CCC1C[C@@H](C(=O)N2CCC(CC2)OCC(=O)O)NC(=O)C3CCC(CC3)C(=N)N)O.CL.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but generally known as lamivudine, which bears US NIH Compound Identifier 60825. European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG. The term LAMIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules lamivudine in its Anatomical Therapeutic Chemical (ATC) Classification. LAMIVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Lamivudine under HS 29349990 and SITC 51579. As of Q4 2014, LAMIVUDINE remains the US FDA Preferred Term for this commodity. Lamivudine bears US NLM identifiers UMLS ID C0209738 and NCI Concept Code C1471. SMILES: C1CN(C(=O)NC1N)[C@@H]2CS[C@@H](O2)CO.
This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The third component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.
This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, STAVUDINE, has US FDA Unique Ingredient Identifier of BO9LE4QFZF.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H11N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0EH965X85, chemically known as lamivudine sulfoxide, (3rs)-, but more generally known as lamivudine sulfoxide, which bears US NIH Compound Identifier 3081342. European Medicines Agency schedules lamivudine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG. Most nations, for tariff purposes, schedule lamivudine sulfoxide under HS 29349990. SMILES: C1CN(C(=O)NC1N)[C@@H]2C[S+]([C@@H](O2)CO)[O-].
This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.
This classification denotes an anticonvulsant agent with the molecular formula C9H7Cl2N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3H27498KS, chemically known as 1,2,4-triazine-3,5-diamine, 6-(2,3-dichlorophenyl)- but generally known as lamotrigine, which bears US NIH Compound Identifier 3878. European Medicines Agency schedules Lamotrigine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08393MIG. The term LAMOTRIGINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules lamotrigine in its Anatomical Therapeutic Chemical (ATC) Classification. LAMOTRIGINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lamotrigine under HS 29336980 and SITC 51576. As of Q4 2014, LAMOTRIGINE remains the US FDA Preferred Term for this commodity. Lamotrigine bears US NLM identifiers UMLS ID C0678180 and NCI Concept Code C38703. SMILES: CLC1C(C2NNC(NC2N)N)CCCC1CL.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C18H28N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BO55Z3JL5K, chemically known as 1-(m-(3-((3-amino-1-methyl-1h-1,2,4-triazol-5-yl)amino)propoxy)benzyl)piperidine but generally known as lamtidine, which bears US NIH Compound Identifier 71988. European Medicines Agency schedules Lamtidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08394MIG. The term LAMTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). LAMTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lamtidine under HS 29333999 and SITC 51574. As of Q4 2014, LAMTIDINE remains the US FDA Preferred Term for this commodity. Lamtidine bears US NLM identifiers UMLS ID C0064637 and NCI Concept Code C79118. SMILES: O(C1CC(CN2CCCCC2)CCC1)CCCNC1N(NC(N1)N)C.
This classification denotes a lanatoside, digilanide, and cardiac glycoside with the molecular formula C49H76O20, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RR3JFZ771, chemically known as 3-((o beta-d-glucopyranosyl-(1-4)-o-3beta-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12beta,14-dihydroxy-5beta-card-20(22)-enolide but generally known as lanatoside c, which bears US NIH Compound Identifier 3879. European Medicines Agency schedules Lanatoside c in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08395MIG. World Health Organization schedules lanatoside c in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lanatoside c under HS 29389010 and SITC 54161. As of Q4 2014, LANATOSIDE C remains the US FDA Preferred Term for this commodity. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(OC7OC(C(O)C(O)C7O)CO)C(OC(=O)C)C6)C)C(O)C5)C)C(O)C3)C)CC4)C)CC(O)C1(C(CC2)C1=CC(=O)OC1)C.
This classification denotes an antifungal agent with the molecular formula C14H10ClN3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4E7858311F, chemically known as 1h-imidazole-1-acetonitrile, alpha-(4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene)-, (e)-(+-)- but generally known as lanoconazole, which bears US NIH Compound Identifier 3002820. European Medicines Agency schedules Lanoconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08398MIG. The term LANOCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). LANOCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lanoconazole under HS 29349990 and SITC 51579. As of Q4 2014, LANOCONAZOLE remains the US FDA Preferred Term for this commodity. Lanoconazole bears US NLM identifiers UMLS ID C0125333 and NCI Concept Code C81504. SMILES: CLC1C(C2S/C(=C(/N3CCNC3)C#N)SC2)CCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TO2JP2G53H. European Medicines Agency schedules Lanperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08400MIG. Lanperisone generally arises in the molecular formula C15H18F3NO. The term LANPERISONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.) LANPERISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lanperisone under HS 29339990 and SITC 51577. As of Q4 2014, LANPERISONE remains the US FDA Preferred Term for this commodity. Lanperisone bears US NLM identifiers UMLS ID C2697881 and NCI Concept Code C79785. SMILES: FC(F)(F)C1CCC(C(=O)C(CN2CCCC2)C)CC1.
This classification denotes a muscle relaxant with the molecular formula C15H18F3NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JRF22NV56M, chemically known as (-)-lanperisone hydrochloride, but more generally known as lanperisone hydrochloride, which bears US NIH Compound Identifier 198706. European Medicines Agency schedules lanperisone hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08400MIG. Most nations, for tariff purposes, schedule lanperisone hydrochloride under HS 29339990. SMILES: C[C@H](CN1CCCC1)C(=O)C2CCC(CC2)C(F)(F)F.CL.
This classification denotes a somatostatin receptor agonist with the molecular formula C54H69N11O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G3DE8943Y, chemically known as l-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide but generally known as lanreotide, which bears US NIH Compound Identifier 71349. European Medicines Agency schedules Lanreotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08402MIG. World Health Organization schedules lanreotide in its Anatomical Therapeutic Chemical (ATC) Classification. LANREOTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lanreotide under HS 29349990 and SITC 51579. As of Q4 2014, LANREOTIDE remains the US FDA Preferred Term for this commodity. Lanreotide bears US NLM identifiers UMLS ID C0209211 and NCI Concept Code C1523. SMILES: S1SCC(NC(=O)C(N)CC2CC3C(CC2)CCCC3)C(=O)NC(C(=O)NC(CC2C3C([NH]C2)CCCC3)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(C1)C(=O)NC(C(O)C)C(=O)N)CC1CCC(O)CC1.
This classification denotes a proton pump inhibitor with the molecular formula C16H14F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0K5C5T2QPG, chemically known as 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole but generally known as lansoprazole, which bears US NIH Compound Identifier 3883. European Medicines Agency schedules Lansoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08403MIG. The term LANSOPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules lansoprazole in its Anatomical Therapeutic Chemical (ATC) Classification. LANSOPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lansoprazole under HS 29333999 and SITC 51574. As of Q4 2014, LANSOPRAZOLE remains the US FDA Preferred Term for this commodity. Lansoprazole bears US NLM identifiers UMLS ID C0286036 and NCI Concept Code C29150. SMILES: S(=O)(CC1NCCC(OCC(F)(F)F)C1C)C1[NH]C2C(N1)CCCC2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C29H26CLFN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VUA21238F. European Medicines Agency schedules lapatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25379. The term LAPATINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 1, 2004, list 51). Most nations schedule lapatinib under HS 29349990 and SITC 51579. As of Q4 2014, LAPATINIB remains the US FDA Preferred Term for this commodity. Lapatinib bears US NLM identifiers UMLS ID C1506770 and NCI Concept Code C26653. SMILES: CLC1CC(NC2NCNC3C2CC(C2OC(CNCCS(=O)(=O)C)CC2)CC3)CCC1OCC1CC(F)CCC1.
This classification denotes a bronchodilator with the molecular formula C29H36N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F427P36M7J, chemically known as 1-methyl-3-isobutyl-8-(2-ethyl(1-(4-diphenylmethylpiperazinyl)))-3,7-dihydro-(1h)-purine 2,6-dione but generally known as laprafylline, which bears US NIH Compound Identifier 65821. European Medicines Agency schedules Laprafylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08405MIG. The term LAPRAFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). LAPRAFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule laprafylline under HS 29395900 and SITC 54145. As of Q4 2014, LAPRAFYLLINE remains the US FDA Preferred Term for this commodity. Laprafylline bears US NLM identifiers UMLS ID C0073782 and NCI Concept Code C96198. SMILES: O=C1N(C(=O)N(C2NC([NH]C12)CCN1CCN(CC1)C(C1CCCCC1)C1CCCCC1)CC(C)C)C.
This classification denotes an immunosuppressant, a biological preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 908SY76S4G, chemically known as 5-chloro-n-ethyl-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide but more generally known as laquinimod, which bears US NIH Compound Identifier 54677946. European Medicines Agency schedules umirolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25236. Most nations, for tariff and trade purposes, schedule LAQUINIMOD under HS 29337900 amd SITC 51561. SMILES: CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O.
Laronidase is a form of recombinant human alpha-L-iduronidase used to treat Hurler and Hurler-Scheie forms of mucopolysaccharidosis, a genetic deficiency of alpha-L-iduronidase
This classification denotes an antibiotic with the molecular formula C34H54O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W7V2ZZ2FWB, chemically known as 2,3-cresotic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyra but more generally known as lasalocid, which bears US NIH Compound Identifier 3888. European Medicines Agency schedules Lasalocid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08406MIG. The term LASALOCID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). LASALOCID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lasalocid under HS 29419000 and SITC 54139. As of Q4 2014, LASALOCID remains the US FDA Preferred Term for this commodity. Lasalocid bears US NLM identifiers UMLS ID C0023082 and NCI Concept Code C79131. SMILES: O1C(CC(C1C(CC)C(=O)C(C(O)C(CCC1C(C(O)C(CC1)C)C(=O)O)C)C)C)(C1OC(C(O)(CC1)CC)C)CC.
This classification denotes an antibiotic with the molecular formula C34H54O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W7V2ZZ2FWB, chemically known as 2,3-cresotic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyra but more generally known as lasalocid, which bears US NIH Compound Identifier 3888. European Medicines Agency schedules Lasalocid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08406MIG. The term LASALOCID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). LASALOCID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lasalocid a under HS 29419000. SMILES: CC[C@H]([C@@H]1[C@H](C[C@@](O1)(CC)[C@H]2CC[C@@]([C@@H](O2)C)(CC)O)C)C(=O)[C@@H](C)[C@H]([C@H](C)CCC3CCC(C(C3C(=O)O)O)C)O.
This classification denotes an antibiotic with the molecular formula C34H53O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W2S5C71Y3G, chemically known as 2,3-cresotic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyran-2-yl)tetrahydro-3-methyl-2-furyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-, monosodium salt. (-)- but more generally known as lasalocid sodium, which bears US NIH Compound Identifier 33265. Most nations schedule lasalocid sodium under HS 29419000. As of Q4 2014, LASALOCID SODIUM remains the US FDA Preferred Term for this commodity. Lasalocid sodium bears US NLM identifiers UMLS ID C0878439 and NCI Concept Code C79535. SMILES: CC[C@H]([C@@H]1[C@H](C[C@@](O1)(CC)[C@H]2CC[C@@]([C@@H](O2)C)(CC)O)C)C(=O)[C@@H](C)[C@H]([C@H](C)CCC3CCC(C(C3C(=O)[O-])O)C)O.[NA+].
This classification denotes a selective estrogen receptor modulator with the molecular formula C28H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 337G83N988, chemically known as 2-naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5r-cis)- but generally known as lasofoxifene, which bears US NIH Compound Identifier 216416. European Medicines Agency schedules Lasofoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27754. The term LASOFOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules lasofoxifene in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lasofoxifene under HS 29339990 and SITC 51577. As of Q4 2014, LASOFOXIFENE remains the US FDA Preferred Term for this commodity. Lasofoxifene bears US NLM identifiers UMLS ID C0672898 and NCI Concept Code C80679. SMILES: O(CCN1CCCC1)C1CCC(C2C(CCC3C2CCC(O)C3)C2CCCCC2)CC1.
This classification denotes a beta-lactam antibiotic with the molecular formula C20H20N6O9S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VUF6C936Z3, chemically known as 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (6r-(6alpha,7alpha,7(s*)))- but generally known as latamoxef, which bears US NIH Compound Identifier 47499. European Medicines Agency schedules Latamoxef in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08408MIG. The term LATAMOXEF is an International Non-Proprietary Name. World Health Organization schedules latamoxef in its Anatomical Therapeutic Chemical (ATC) Classification. LATAMOXEF is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Latamoxef or moxalactam bears US NLM identifiers UMLS ID C0026651 and NCI Concept Code C670. SMILES: S(CC1=C(N2C(OC1)C(OC)(NC(=O)C(C1CCC(O)CC1)C(=O)O)C2=O)C(=O)O)C1N(NNN1)C.
This classification denotes a prostaglandin analogue and anti-glaucoma agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Z5B6HVF6O. European Medicines Agency schedules Latanoprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08409MIG. Latanoprost generally arises in the molecular formula C26H40O5. The term LATANOPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33.) LATANOPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule latanoprost under HS 29375000 and SITC 54156. As of Q4 2014, LATANOPROST remains the US FDA Preferred Term for this commodity. Latanoprost bears US NLM identifiers UMLS ID C0593887 and NCI Concept Code C29151. SMILES: OC1C(C(C(O)C1)C/C=C/CCCC(=O)OC(C)C)CCC(O)CCC1CCCCC1.
This classification denotes a topical anti-infective agent with the molecular formula C29H44NO2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 07HUP5A29X, chemically known as n,n-dimethyl-n-dodecylbenzenemethanaminium but generally known as lauralkonium, which bears US NIH Compound Identifier 8753. European Medicines Agency schedules Lauralkonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08411MIG. The term LAURALKONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). As of Q4 2014, LAURALKONIUM remains the US FDA Preferred Term for this commodity. SMILES: CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.
This classification denotes an anti-infective agent with the molecular formula C29H44NO2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 07HUP5A29X, chemically known as n,n-dimethyl-n-dodecylbenzenemethanaminium chloride but more generally known as lauralkonium chloride, which bears US NIH Compound Identifier 8753. European Medicines Agency schedules Lauralkonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08411MIG. The term LAURALKONIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations, for tariff and trade purposes, schedule lauralkonium chloride under HS 29239000 and SITC 51481. As of Q4 2014, LAURALKONIUM CHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCC(=O)C1CCC(CC1)OCC[N+](C)(C)CC2CCCCC2.[CL-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes an anti-infective agent with the molecular formula C22H35N2.C2H3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R01EZP92PU, chemically known as quinolinium, 4-amino-1-dodecyl-2-methyl-, acetate (9ci) but generally known as laurolinium acetate, which bears US NIH Compound Identifier 67354. European Medicines Agency schedules Laurolinium acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08416MIG. The term LAUROLINIUM ACETATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Most nations schedule laurolinium acetate under HS 29334990 and SITC 51575. As of Q4 2014, LAUROLINIUM ACETATE remains the US FDA Preferred Term for this commodity. Laurolinium acetate bears US NLM identifiers UMLS ID C2825363 and NCI Concept Code C80858. SMILES: OC(=O)C.[n]1(CCCCCCCCCCCC)c2c(c(N)cc1C)cccc2.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C8H10ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 420HD787N9, chemically known as 2-pyridinecarboxamide, n-(2-aminoethyl)-5-chloro- but generally known as lazabemide, which bears US NIH Compound Identifier 71307. European Medicines Agency schedules Lazabemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08418MIG. The term LAZABEMIDE is an International Non-Proprietary Name. LAZABEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lazabemide under HS 29333999 and SITC 51574. As of Q4 2014, LAZABEMIDE remains the US FDA Preferred Term for this commodity. Lazabemide bears US NLM identifiers UMLS ID C0209106 and NCI Concept Code C80964. SMILES: CLC1CCC(NC1)C(=O)NCCN.
This classification denotes a monoamine oxidase inhibitor C8H10ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PI150J9ZX1, chemically known as 2-pyridinecarboxamide, n-(2-aminoethyl)-5-chloro-, monohydrochloride, but more generally known as lazabemide hydrochloride, which bears US NIH Compound Identifier 163727. Most nations, for tariff and trade purposes, schedule lazabemide hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, LAZABEMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lazabemide hydrochloride bears US NLM identifiers UMLS ID C2825397 and NCI Concept Code C80968. SMILES: C1CC(NCC1CL)C(=O)NCCN.CL.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C8H10ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PI150J9ZX1, chemically known as n-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide hydrochloride, but more generally known as lazabemide monohydrochloride, which bears US NIH Compound Identifier 163727. European Medicines Agency schedules lazabemide monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08418MIG. Most nations, for tariff purposes, schedule lazabemide monohydrochloride under HS 29333999. SMILES: C1CC(NCC1CL)C(=O)NCCN.CL.
This classification denotes a vasodilating agent with the molecular formula C11H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P13OO3FPZB, chemically known as benzenemethanol, 2-hydroxy-3-(1h-imidazol-4-ylmethyl)- but generally known as ledazerol, which bears US NIH Compound Identifier 65932. European Medicines Agency schedules Ledazerol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08420MIG. The term LEDAZEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). LEDAZEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ledazerol under HS 29332990 and SITC 51573. As of Q4 2014, LEDAZEROL remains the US FDA Preferred Term for this commodity. Ledazerol bears US NLM identifiers UMLS ID C2825585 and NCI Concept Code C81348. SMILES: C1=CC(=C(C(=C1)CO)O)CC2=CN=CN2.
This classification denotes an analgesic agent with the molecular formula C16H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4J9726V5Y9, chemically known as 1-dimethylamino-1,2-diphenylethane but generally known as lefetamine, which bears US NIH Compound Identifier 22779. European Medicines Agency schedules Lefetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08423MIG. The term LEFETAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). LEFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lefetamine under HS 29214600 and SITC kg. As of Q4 2014, LEFETAMINE remains the US FDA Preferred Term for this commodity. Lefetamine bears US NLM identifiers UMLS ID C0064766 and NCI Concept Code C81381. SMILES: N(C(CC1CCCCC1)C1CCCCC1)(C)C.
This classification denotes an analgesic agent with the molecular formula C16H19N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XYT5RKF8JA, chemically known as (-)-n,n-dimethyl-1,2-diphenylethylamine hydrochloride, but more generally known as lefetamine hydrochloride, which bears US NIH Compound Identifier 26480. European Medicines Agency schedules lefetamine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08423MIG. Most nations, for tariff purposes, schedule lefetamine hydrochloride under HS 29214600. SMILES: CN(C)[C@H](CC1CCCCC1)C2CCCCC2.CL.
This classification denotes a pyrimidine antagonist and dihydroorotate dehydrogenase inhibitor and angiogenesis activator inhibitor with the molecular formula C12H9F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G162GK9U4W, chemically known as 4-isoxazolecarboxamide, 5-methyl-n-(4-(trifluoromethyl)phenyl but more generally known as leflunomide, which bears US NIH Compound Identifier 3899. European Medicines Agency schedules Leflunomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08424MIG. The term LEFLUNOMIDE is an International Non-Proprietary Name. World Health Organization schedules leflunomide in its Anatomical Therapeutic Chemical (ATC) Classification. LEFLUNOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule leflunomide under HS 29349990 and SITC 51579. As of Q4 2014, LEFLUNOMIDE remains US FDA's Preferred Term for this commodity. Leflunomide bears US NLM identifiers UMLS ID C0718644 and NCI Concept Code C1128. SMILES: FC(F)(F)C1CCC(NC(=O)C2C(ONC2)C)CC1.
This classification denotes an anticholinergic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S1URO6678T. European Medicines Agency schedules Leiopyrrole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08426MIG. Leiopyrrole generally arises in the molecular formula C23H28N2O. The term LEIOPYRROLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) LEIOPYRROLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule leiopyrrole under HS 29339990 and SITC 51577. As of Q4 2014, LEIOPYRROLE remains the US FDA Preferred Term for this commodity. Leiopyrrole bears US NLM identifiers UMLS ID C0603497 and NCI Concept Code C81460. SMILES: O(CCN(CC)CC)C1C(N2C(CCC2C)C2CCCCC2)CCCC1.
This classification denotes a loop diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98C3QM4D0P. European Medicines Agency schedules Lemidosul in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08427MIG. Lemidosul generally arises in the molecular formula C12H19NO3S. The term LEMIDOSUL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) LEMIDOSUL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lemidosul under HS 29309085 and SITC 51549. As of Q4 2014, LEMIDOSUL remains the US FDA Preferred Term for this commodity. Lemidosul bears US NLM identifiers UMLS ID C2825392 and NCI Concept Code C80957. SMILES: S(=O)(=O)(C1CC(C(C)(C)C)CC(C1O)CN)C.
This classification denotes a biological response modifier with the molecular formula C13H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F0P408N6V4, chemically known as 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)- but more generally known as lenalidomide, which bears US NIH Compound Identifier 216326. European Medicines Agency schedules Lenalidomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25389. The term LENALIDOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). World Health Organization schedules lenalidomide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule lenalidomide under HS 29337900 and SITC 51561. As of Q4 2014, LENALIDOMIDE remains US FDA's Preferred Term for this commodity. Lenalidomide bears US NLM identifiers UMLS ID C1144149 and NCI Concept Code C2668. SMILES: O=C1N(C2CCC(=O)NC2=O)CC2C1CCCC2N.
This classification denotes a penicillin antibiotic with the molecular formula C21H23N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8M568DM08K, chemically known as 2,3-dihydroxy-2-butenyl(2s,5r,6r)-6-((r)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate, cyclic carbonate but generally known as lenampicillin, which bears US NIH Compound Identifier 65646. European Medicines Agency schedules Lenampicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08430MIG. The term LENAMPICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). LENAMPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lenampicillin under HS 29411090 and SITC 54131. As of Q4 2014, LENAMPICILLIN remains the US FDA Preferred Term for this commodity. Lenampicillin bears US NLM identifiers UMLS ID C0125457 and NCI Concept Code C90912. SMILES: S1C2N(C(C1(C)C)C(=O)OCC1OC(=O)OC1C)C(=O)C2NC(=O)C(N)C1CCCCC1.
This classification denotes a penicillin antibiotic C21H23N3O7S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6U90E2WB40, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2r)-2-amino-2-phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, hydrochloride (1:1), (2s,5r,6r)-, but more generally known as lenampicillin hydrochloride, which bears US NIH Compound Identifier 6917773. European Medicines Agency schedules Lenampicillin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02887MIG. Most nations, for tariff and trade purposes, schedule lenampicillin hydrochloride under HS 29411090 and SITC 54131. As of Q4 2014, LENAMPICILLIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1C(OC(=O)O1)COC(=O)[C@H]2C(S[C@H]3N2C(=O)[C@H]3NC(=O)[C@@H](C4CCCCC4)N)(C)C.CL.
This classification denotes a recombinant protein and Immunologic adjuvant with the molecular formula C9H14N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WS4C399GB. European Medicines Agency schedules Lenograstim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02888MIG. The term LENOGRASTIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31.). World Health Organization schedules lenograstim in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lenograstim under HS 30012010 and SITC 54162. As of Q4 2014, LENOGRASTIM remains the US FDA Preferred Term for this commodity. Lenograstim bears US NLM identifiers UMLS ID C0218640 and NCI Concept Code C49234. SMILES: N/A.
This classification denotes an antipsychotic agent with the molecular formula C22H23F2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 13P4GX22ES chemically known as 1-butanone, 4-(4-(4-fluorobenzoyl)-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as lenperone, which bears US NIH Compound Identifier 32593. European Medicines Agency schedules Lenperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08434MIG. The term LENPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, no. 10 1972, list 12. ). Most nations schedule lenperone under HS 29333999 and SITC 51574. As of Q4 2014, LENPERONE remains the US FDA Preferred Term for this commodity. Lenperone bears US NLM identifiers UMLS ID C0064748 and NCI Concept Code C73287. SMILES: C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCCC(=O)C3=CC=C(C=C3)F.
This classification denotes an antipsychotic agent C22H23F2NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96Q0TL6O3G, chemically known as 1-butanone, 4-(4-(4-fluorobenzoyl)-1-piperidinyl)-1-(4-fluorophenyl)-, hydrochloride (1:1), but more generally known as lenperone hydrochloride, which bears US NIH Compound Identifier 32592. European Medicines Agency schedules Lenperone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02889MIG. Most nations, for tariff and trade purposes, schedule lenperone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, LENPERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lenperone hydrochloride bears US NLM identifiers UMLS ID C0959966 and NCI Concept Code C77573. SMILES: C1CC(CCC1C(=O)CCCN2CCC(CC2)C(=O)C3CCC(CC3)F)F.CL.
Lenvatinib is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
This classification denotes an anticoagulant agent with the molecular formula C287H440N80O111S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y43GF64R34, chemically known as hirudin (hirudo medicinalis isoform hv1), 63-desulfo- but generally known as lepirudin, which bears US NIH Compound Identifier 16129703. European Medicines Agency schedules Lepirudin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08435MIG. The term LEPIRUDIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules lepirudin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lepirudin under HS 29349990 and SITC 51579. As of Q4 2014, LEPIRUDIN remains the US FDA Preferred Term for this commodity. Lepirudin bears US NLM identifiers UMLS ID C0772394 and NCI Concept Code C1839. SMILES: S1SCC2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C3NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)C(C)C)C(C)C)CC4CCC(O)CC4)C(O)C)CC(=O)O)CSSC3)C(O)C)CCC(=O)O)CO)CCC(=O)N)CC(=O)N)C.
This classification denotes an antihypertensive agent with the molecular formula C12H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5DXM29256P, chemically known as piperidine, 1-(cyclohexylmethyl)- but generally known as leptacline, which bears US NIH Compound Identifier 71660. European Medicines Agency schedules Leptacline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08436MIG. The term LEPTACLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). LEPTACLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule leptacline under HS 29333999 and SITC 51574. As of Q4 2014, LEPTACLINE remains the US FDA Preferred Term for this commodity. Leptacline bears US NLM identifiers UMLS ID C2825667 and NCI Concept Code C81523. SMILES: N1(CC2CCCCC2)CCCCC1.
This classification denotes a calcium channel blocker with the molecular formula C36H41N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V7XTJ4R0BH, chemically known as (+-)-2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate but generally known as lercanidipine, which bears US NIH Compound Identifier 65866. European Medicines Agency schedules Lercanidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08437MIG. The term LERCANIDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules lercanidipine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lercanidipine under HS 29333999 and SITC 51574. As of Q4 2014, LERCANIDIPINE remains the US FDA Preferred Term for this commodity. Lercanidipine bears US NLM identifiers UMLS ID C0526399 and NCI Concept Code C81687. SMILES: O(C(CN(CCC(c1ccccc1)c1ccccc1)C)(C)C)C(=O)C1=C(NC(=C(C1c1cc([N](=O)O)ccc1)C(=O)OC)C)C.
This classification denotes a calcium channel blocker with the molecular formula C36H41N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OA8TFX68PE, chemically known as 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl (4rs)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate monohydrochloride but more generally known as lercanidipine hydrochloride, which bears US NIH Compound Identifier 157917. European Medicines Agency schedules Lercanidipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02894MIG. Most nations, for tariff and trade purposes, schedule lercanidipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, LERCANIDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lercanidipine hydrochloride bears US NLM identifiers UMLS ID C0595331 and NCI Concept Code C87685. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2CCCCC2)C3CCCCC3)C4CCCC(C4)[N+](=O)[O-])C(=O)OC.CL.
A type of URAT1 inhibitor.
This classification denotes a neuroprotective agent with the molecular formula C15H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NBY3IU407M, chemically known as 4-((3-(1,6-dihydro-6-oxo-9h-purin-9-yl)-1-oxopropyl)amino)benzoic acid but generally known as leteprinim, which bears US NIH Compound Identifier 132123. European Medicines Agency schedules Leteprinim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02897MIG. The term LETEPRINIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule leteprinim under HS 29335995 and SITC 51576. As of Q4 2014, LETEPRINIM remains the US FDA Preferred Term for this commodity. Leteprinim bears US NLM identifiers UMLS ID C0252664 and NCI Concept Code C80995. SMILES: O=C(NC1CCC(CC1)C(=O)O)CCN1C2[NH]CNC(=O)C2NC1.
This classification denotes a neuroprotective agent C15H12N5O4.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q06WU8JY4F, chemically known as potassium 4-((3-(1,6-dihydro-6-oxo-9h-purin-9-yl)-1-oxopropyl)amino)benzoate, but more generally known as leteprinim potassium, which bears US NIH Compound Identifier 23663995. Most nations, for tariff and trade purposes, schedule leteprinim potassium under HS 29335995 and SITC 51576. As of Q4 2014, LETEPRINIM POTASSIUM remains US FDA's Preferred Term for this commodity. Leteprinim potassium bears US NLM identifiers UMLS ID C0967722 and NCI Concept Code C80996. SMILES: C1CC(CCC1C(=O)[O-])NC(=O)CCN2CNC3C2NC[NH]C3=O.[K+].
This classification denotes a mucolytic agent with the molecular formula C10H17NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6MVF9U95DW, chemically known as 4-thiazolidinecarboxylic acid, 2-(2-((2-ethoxy-2-oxoethyl)thio)ethyl)- but more generally known as letosteine, which bears US NIH Compound Identifier 68707. European Medicines Agency schedules Letosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08442MIG. The term LETOSTEINE is an International Non-Proprietary Name. World Health Organization schedules letosteine in its Anatomical Therapeutic Chemical (ATC) Classification. LETOSTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule letosteine under HS 29341000 and SITC 51579. As of Q4 2014, LETOSTEINE remains US FDA's Preferred Term for this commodity. Letosteine bears US NLM identifiers UMLS ID C0064777 and NCI Concept Code C80974. SMILES: CCOC(=O)CSCCC1NC(CS1)C(=O)O.
This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LKK855W8I, chemically known as 4,4-(1h-1,2,4-triazol-1-ylmethylene)dibenzonitrile but generally known as letrozole, which bears US NIH Compound Identifier 3902. European Medicines Agency schedules Letrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08444MIG. The term LETROZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules letrozole in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule letrozole under HS 29339990 and SITC 51577. As of Q4 2014, LETROZOLE remains the US FDA Preferred Term for this commodity. Letrozole bears US NLM identifiers UMLS ID C0246421 and NCI Concept Code C1527. SMILES: N1(NCNC1)C(C1CCC(CC1)C#N)C1CCC(CC1)C#N.
This classification denotes an anesthetic agent with the molecular formula C17H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64DXV166PH, chemically known as 1-pentanol, 2-(diethylamino)-4-methyl-, p-aminobenzoate (ester) but generally known as leucinocaine, which bears US NIH Compound Identifier 68648. European Medicines Agency schedules Leucinocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08447MIG. The term LEUCINOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). LEUCINOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule leucinocaine under HS 29224995 and SITC 51465. As of Q4 2014, LEUCINOCAINE remains the US FDA Preferred Term for this commodity. Leucinocaine bears US NLM identifiers UMLS ID C2825617 and NCI Concept Code C81401. SMILES: O(CC(N(CC)CC)CC(C)C)C(=O)C1CCC(N)CC1.
This classification denotes an anesthetic agent with the molecular formula C17H28N2O2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72E501K01E, chemically known as 1-pentanol, 2-(diethylamino)-4-methyl-, 1-(4-aminobenzoate), methanesulfonate (1:1), but more generally known as leucinocaine mesylate, which bears US NIH Compound Identifier 101618. European Medicines Agency schedules leucinocaine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08447MIG. Most nations, for tariff purposes, schedule leucinocaine mesylate under HS 29224995. SMILES: CCN(CC)C(CC(C)C)COC(=O)C1CCC(CC1)N.CS(=O)(=O)O.
This classification denotes a gonadotropin-releasing hormone analog, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EFY6W0M8TG. European Medicines Agency schedules Leuprolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08449MIG. Leuprolide generally arises in the molecular formula C59H84N16O12. The term 'leuprolide' is a European Pharmacopoeia designation. As of Q4 2014, LEUPROLIDE remains the US FDA Preferred Term for this commodity. Leuprolide bears US NLM identifiers UMLS ID C0085272 and NCI Concept Code C62042. SMILES: O=C(N1C(CCC1)C(=O)NCC)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1[NH]CNC1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)CC(C)C)CC(C)C)CCC/N=C(/N)N.
This classification denotes a gonadotropin-releasing hormone analog, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EFY6W0M8TG. European Medicines Agency schedules Leuprolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08449MIG. Leuprolide generally arises in the molecular formula C59H84N16O12. The term 'leuprolide' is a European Pharmacopoeia designation.
This classification denotes an anthracycline antibiotic with the molecular formula C33H40N2O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Z20MGK851, chemically known as (8s,10s)-10-((3-((s)-2-amino-4-methylvaleramido)-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione but generally known as leurubicin, which bears US NIH Compound Identifier 68897. European Medicines Agency schedules Leurubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08450MIG. The term LEURUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). LEURUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule leurubicin under HS 29419000 and SITC 54139. As of Q4 2014, LEURUBICIN remains the US FDA Preferred Term for this commodity. Leurubicin bears US NLM identifiers UMLS ID C2825623 and NCI Concept Code C81421. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)CO)C1OC(C(O)C(NC(=O)C(N)CC(C)C)C1)C.
This classification denotes an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3B637Y991, chemically known as 3-heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3s,6s)-(-)- (8ci) but generally known as levacetylmethadol, which bears US NIH Compound Identifier 15130. European Medicines Agency schedules Levacetylmethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08451MIG. World Health Organization schedules levacetylmethadol in its Anatomical Therapeutic Chemical (ATC) Classification. LEVACETYLMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Levacetylmethadol or levomethadyl acetate bears US NLM identifiers UMLS ID CL414208 and NCI Concept Code C87359. SMILES: O(C(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC)C(=O)C.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EDN2NBH5SS, chemically known as 1,3-benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (-)- but generally known as levalbuterol, which bears US NIH Compound Identifier 123600. European Medicines Agency schedules Levosalbutamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08491MIG. The term LEVOSALBUTAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). Levalbuterol or levosalbutamol bears US NLM identifiers UMLS ID C0772501 and NCI Concept Code C74196. SMILES: CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.
This classification denotes an opiate antagonist with the molecular formula C19H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 353613BU4U, chemically known as morphinan-3-ol, 17-(2-propenyl)- but generally known as levallorphan, which bears US NIH Compound Identifier 3912. European Medicines Agency schedules Levallorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08452MIG. The term LEVALLORPHAN is an International Non-Proprietary Name. LEVALLORPHAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levallorphan under HS 29334990 and SITC 51575. As of Q4 2014, LEVALLORPHAN remains the US FDA Preferred Term for this commodity. Levallorphan bears US NLM identifiers UMLS ID C0023554 and NCI Concept Code C66004. SMILES: OC1CC2C34C(C(N(CC3)CC=C)CC2CC1)CCCC4.
This classification denotes an opiate antagonist with the molecular formula C19H25NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U0VSF7HTN0, chemically known as 2h-10,4a-iminoethanophenanthren-6-ol, 11-allyl-1,3,4,9,10,10a-hexahydro-, tartrate but more generally known as levallorphan tartrate, which bears US NIH Compound Identifier 5464111. European Medicines Agency schedules Levallorphan tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02901MIG. Most nations, for tariff and trade purposes, schedule levallorphan tartrate under HS 29334990 and SITC 51575. As of Q4 2014, LEVALLORPHAN TARTRATE remains US FDA's Preferred Term for this commodity. Levallorphan tartrate bears US NLM identifiers UMLS ID C0770439 and NCI Concept Code C66005. SMILES: C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4C3CC(CC4)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a cns stimulant with the molecular formula C9H13N.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) STC9O9MD79, chemically known as butanedioic acid, compd. with (-)-alpha-methylbenzeneethanamine (1:1) but more generally known as levamfetamine succinate, which bears US NIH Compound Identifier 68638. Most nations, for tariff and trade purposes, schedule levamfetamine under HS 29214600 and SITC kg. As of Q4 2014, LEVAMFETAMINE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1=CC=CC=C1)N.C(CC(=O)O)C(=O)O.
This classification denotes a cns stimulant with the molecular formula C9H13N.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier STC9O9MD79, chemically known as butanedioic acid, compd. with (-)-alpha-methylbenzeneethanamine (1:1) but more generally known as levamfetamine succinate, which bears US NIH Compound Identifier 68638. Most nations, for tariff and trade purposes, schedule levamfetamine succinate under HS 29214900 and SITC 51454. As of Q4 2014, LEVAMFETAMINE SUCCINATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CC1CCCCC1)N.C(CC(=O)O)C(=O)O.
This classification denotes a chemo immunostimulant adjuvant with the molecular formula C11H12N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DL9055K809, chemically known as 2,3,5,6-tetrahydro-6-phenyl-imidazo(2,1-b)thiazole but more generally known as levamisole hydrochloride, which bears US NIH Compound Identifier 3913. European Medicines Agency schedules Levamisole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02902MIG. Most nations, for tariff and trade purposes, schedule levamisole hydrochloride under HS 29349990. As of Q4 2014, LEVAMISOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levamisole hydrochloride bears US NLM identifiers UMLS ID C0733384 and NCI Concept Code C610. SMILES: C1CCC(CC1)[C@H]2CN3CCSC3=N2.CL.
This classification denotes a chemo immunostimulant adjuvant with the molecular formula C11H12N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2880D3468G, chemically known as l-2,3,5,6-tetrahyro-6-phenylimidazo(2,1-b)thiazole but generally known as levamisole, which bears US NIH Compound Identifier 26879. European Medicines Agency schedules Levamisole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08454MIG. The term LEVAMISOLE is an International Non-Proprietary Name. World Health Organization schedules levamisole in its Anatomical Therapeutic Chemical (ATC) Classification. LEVAMISOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Levamisole or tetramisole bears US NLM identifiers UMLS ID C0023556 and NCI Concept Code C61609. SMILES: C1CSC2=NC(CN21)C3=CC=CC=C3.
This classification denotes a biological response modifier and antihelminthic agent with the molecular formula C11H12N2S.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FIG89N8AZY, chemically known as (s)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazoletriylium phosphate but more generally known as levamisole phosphate, which bears US NIH Compound Identifier 198119. Most nations, for tariff and trade purposes, schedule levamisole phosphate under HS 29349990. As of Q4 2014, LEVAMISOLE PHOSPHATE remains US FDA's Preferred Term for this commodity. Levamisole phosphate bears US NLM identifiers UMLS ID C0309393 and NCI Concept Code C77331. SMILES: C1CCC(CC1)[C@H]2CN3CCSC3=N2.OP(=O)(O)O.
This classification denotes a catecholamine with the molecular formula C8H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X4W3ENH1CV, chemically known as 1,2-benzenediol, 4-(2-amino-1-hydroxyethyl)-, (s)- but generally known as noradrenaline, which bears US NIH Compound Identifier 951. European Medicines Agency schedules Noradrenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09360MIG. The term NOREPINEPHRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules noradrenaline in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1=CC(=C(C=C1C(CN)O)O)O.
This classification denotes an enzyme inhibitor with the molecular formula C3H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AK7DRB7FMO, chemically known as 3-isoxazolidinone, 4-amino-, (s)- but more generally known as levcycloserine, which bears US NIH Compound Identifier 401. European Medicines Agency schedules Levcycloserine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08456MIG. The term LEVCYCLOSERINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). LEVCYCLOSERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1NC(=O)C(N)C1.
This classification denotes a neuroprotective agent and anticonvulsant agent with the molecular formula C8H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44YRR34555, chemically known as 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-, (s)- but generally known as levetiracetam, which bears US NIH Compound Identifier 59708. European Medicines Agency schedules Levetiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08459MIG. The term LEVETIRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules levetiracetam in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule levetiracetam under HS 29337900 and SITC 51561. As of Q4 2014, LEVETIRACETAM remains the US FDA Preferred Term for this commodity. Levetiracetam bears US NLM identifiers UMLS ID C0377265 and NCI Concept Code C47581. SMILES: O=C1N(CCC1)C(CC)C(=O)N.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C11H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 588N0603CT, chemically known as 1,2-benzenediol, 4-((1r)-1-hydroxy-2-((1-methylethyl)amino)ethyl)- but generally known as levisoprenaline, which bears US NIH Compound Identifier 5808. European Medicines Agency schedules Levisoprenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08460MIG. The term LEVISOPRENALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). LEVISOPRENALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Levisoprenaline under HS 29225000 and SITC 51467. As of Q4 2014, LEVISOPRENALINE remains the US FDA Preferred Term for this commodity. Levisoprenaline bears US NLM identifiers UMLS ID C2697916 and NCI Concept Code C74197. SMILES: CC(C)NC[C@@H](C1CCC(C(C1)O)O)O.
This classification denotes an adrenergic agent with the molecular formula C10H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y24T9BT2Q2, chemically known as phenethylamine, n,.alpha.-dimethyl-, d- but generally known as levmetamfetamine, which bears US NIH Compound Identifier 36604. The term LEVMETAMFETAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). Levmetamfetamine or levomethamphetamine bears US NLM identifiers UMLS ID C0724614 and NCI Concept Code C75930. SMILES: CC(CC1=CC=CC=C1)NC.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8MR4W4O06J, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (2s)- but more generally known as levobetaxolol hydrochloride, which bears US NIH Compound Identifier 60656. Most nations, for tariff and trade purposes, schedule levobetaxolol hydrochloride under HS 29221980. As of Q4 2014, LEVOBETAXOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levobetaxolol hydrochloride bears US NLM identifiers UMLS ID C0876234 and NCI Concept Code C66007. SMILES: CC(C)NC[C@@H](COC1CCC(CC1)CCOCC2CC2)O.CL.
This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C17H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6317AOI7K, chemically known as 3,4-dihydro-5-(3-(tert-butylamino)-2-hydroxy)propoxy-1(2h)-naphthalenone but generally known as levobunolol, which bears US NIH Compound Identifier 3914. European Medicines Agency schedules Levobunolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08463MIG. The term LEVOBUNOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules levobunolol in its Anatomical Therapeutic Chemical (ATC) Classification. LEVOBUNOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levobunolol under HS 29221980 and SITC 51461. As of Q4 2014, LEVOBUNOLOL remains the US FDA Preferred Term for this commodity. Levobunolol bears US NLM identifiers UMLS ID C0006388 and NCI Concept Code C62043. SMILES: O(C1C2CCCC(=O)C2CCC1)CC(O)CNC(C)(C)C.
This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C17H25NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O90S49LDHH, chemically known as 1(2h)-naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, hydrochloride, (-)- but more generally known as levobunolol hydrochloride, which bears US NIH Compound Identifier 34060. European Medicines Agency schedules Levobunolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14351MIG. Most nations, for tariff and trade purposes, schedule levobunolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, LEVOBUNOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levobunolol hydrochloride bears US NLM identifiers UMLS ID C0591174 and NCI Concept Code C29153. SMILES: CC(C)(C)NC[C@@H](COC1CCCC2C1CCCC2=O)O.CL.
Combination drugs that treat diseases of the eyes Polyvinil alcohol Levobunolol is a beta-adrenergic antagonist used for the reduction of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
This classification denotes an anesthetic agent with the molecular formula C18H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A5H73K9U3W, chemically known as 2,6-pipecoloxylidide, 1-butyl-, l-(-)- but generally known as levobupivacaine, which bears US NIH Compound Identifier 92253. European Medicines Agency schedules Levobupivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08464MIG. The term LEVOBUPIVACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules levobupivacaine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, LEVOBUPIVACAINE remains the US FDA Preferred Term for this commodity. Levobupivacaine bears US NLM identifiers UMLS ID C0873118 and NCI Concept Code C87594. SMILES: O=C(NC1C(CCCC1C)C)C1N(CCCC1)CCCC.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H29FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H68BP06S81, chemically known as 4-piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, (3s-(1(cis),3alpha,4beta))- but generally known as levocabastine, which bears US NIH Compound Identifier 54385. European Medicines Agency schedules Levocabastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08465MIG. The term LEVOCABASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules levocabastine in its Anatomical Therapeutic Chemical (ATC) Classification. LEVOCABASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levocabastine under HS 29333999 and SITC 51574. As of Q4 2014, LEVOCABASTINE remains the US FDA Preferred Term for this commodity. Levocabastine bears US NLM identifiers UMLS ID C0064870 and NCI Concept Code C61806. SMILES: FC1CCC(C2(CCC(N3CC(C(CC3)(C3CCCCC3)C(=O)O)C)CC2)C#N)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H29FN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 124XMA6YEI, chemically known as 4-piperidinecarboxylic acid, 1-(cis-4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, monohydrochloride, (3s,4r)- but more generally known as levocabastine hydrochloride, which bears US NIH Compound Identifier 54384. European Medicines Agency schedules Levocabastine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02905MIG. Most nations, for tariff and trade purposes, schedule levocabastine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, LEVOCABASTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levocabastine hydrochloride bears US NLM identifiers UMLS ID C0244861 and NCI Concept Code C47582. SMILES: C[C@H]1[C@@](CCN(C1)[C@H]2CC[C@@](CC2)(C3CCC(CC3)F)C#N)(C(=O)O)C4CCCCC4.CL.
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G389FZZ9M. European Medicines Agency schedules Carnitine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06134MIG. Carnitine generally arises in the molecular formula C7H15NO3. The term CARNITINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) CARNITINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levocarnitine under HS 29239000 and SITC 51481. As of Q4 2014, LEVOCARNITINE remains the US FDA Preferred Term for this commodity. Levocarnitine bears US NLM identifiers UMLS ID C0087163 and NCI Concept Code C26657. SMILES: CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C.Cl.
This classification denotes a nutritional supplement with the molecular formula C9H17NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DH1W9VH8Q, chemically known as l-(3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide inner salt acetate, but more generally known as levocarnitine acetyl, which bears US NIH Compound Identifier 18230. European Medicines Agency schedules levocarnitine acetyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08466MIG. Most nations, for tariff purposes, schedule levocarnitine acetyl under HS 29239000. SMILES: CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C.
This classification denotes a nutritional supplement with the molecular formula C7H15NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3Y5E6IKS3. European Medicines Agency schedules levocarnitine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02906MIG. The term levocarnitine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule levocarnitine hydrochloride under HS 29239000 and SITC 51481. As of Q4 2014, LEVOCARNITINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[N+](C)(C)C[C@@H](CC(=O)O)O.[CL-].
This classification denotes a nutritional supplement with the molecular formula C10H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0HU2UI27HF. European Medicines Agency schedules levocarnitine propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26424. The term levocarnitine propionate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule levocarnitine propionate under HS 29239000 and SITC 51481. As of Q4 2014, LEVOCARNITINE PROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C.
This classification denotes a nutritional supplement C10H20NO4.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12FW2YBF04, chemically known as (2r)-3-carboxy-n,n,n-trimethyl-2-(propanoyloxy)propan-1-aminium chloride, but more generally known as levocarnitine propionate hydrochloride, which bears US NIH Compound Identifier 157836. European Medicines Agency schedules Levocarnitine propionate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB36026. Most nations, for tariff and trade purposes, schedule levocarnitine propionate hydrochloride under HS 29239000 and SITC 51481. As of Q4 2014, LEVOCARNITINE PROPIONATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@H](CC(=O)O)C[N+](C)(C)C.[CL-].
This classification denotes a nutritional supplement with the molecular formula C7H15NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4D8F2Q45LQ. Most nations, for tariff and trade purposes, schedule levocarnitine tartrate under HS 29239000 and SITC 51481. As of Q4 2014, LEVOCARNITINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C[N+](C)(C)C[C@@H](CC(=O)[O-])O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6U5EA9RT2O, chemically known as acetic acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- but generally known as levocetirizine, which bears US NIH Compound Identifier 1549000. European Medicines Agency schedules Levocetirizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08467MIG. The term LEVOCETIRIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules levocetirizine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule levocetirizine under HS 29335995 and SITC 51576. As of Q4 2014, LEVOCETIRIZINE remains the US FDA Preferred Term for this commodity. Levocetirizine bears US NLM identifiers UMLS ID C1174893 and NCI Concept Code C66008. SMILES: CLC1CCC(C(N2CCN(CC2)CCOCC(=O)O)C2CCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SOD6A38AGA. European Medicines Agency schedules Levocetirizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20474. Levocetirizine dihydrochloride generally arises in the molecular formula C21H25CLN2O3.2CLH. The term 'levocetirizine dihydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule levocetirizine dihydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, LEVOCETIRIZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levocetirizine dihydrochloride bears US NLM identifiers UMLS ID C1311681 and NCI Concept Code C72814. SMILES: C1CCC(CC1)[C@H](C2CCC(CC2)CL)N3CCN(CC3)CCOCC(=O)O.CL.CL.
This classification denotes a dopamine agonist with the molecular formula C9H11NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46627O600J, chemically known as 3,4-dihydroxyphenyl-l-alanine but generally known as levodopa, which bears US NIH Compound Identifier 836. European Medicines Agency schedules Levodopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08468MIG. The term LEVODOPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules levodopa in its Anatomical Therapeutic Chemical (ATC) Classification. LEVODOPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levodopa under HS 29225000 and SITC 51467. As of Q4 2014, LEVODOPA remains the US FDA Preferred Term for this commodity. Levodopa bears US NLM identifiers UMLS ID C0699991 and NCI Concept Code C611. SMILES: OC1CC(CC(N)C(=O)O)CCC1O.
This classification denotes an antitussive agent with the molecular formula C13H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3O31P6T4G3, chemically known as 1,2-propanediol, 3-(4-phenylpiperazin-1-yl)-, s(-)- but more generally known as levodropropizine, which bears US NIH Compound Identifier 65859. European Medicines Agency schedules Levodropropizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12105MIG. The term LEVODROPROPIZINE is an International Non-Proprietary Name. World Health Organization schedules levodropropizine in its Anatomical Therapeutic Chemical (ATC) Classification. LEVODROPROPIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule levodropropizine under HS 29335995 and SITC 51576. As of Q4 2014, LEVODROPROPIZINE remains US FDA's Preferred Term for this commodity. Levodropropizine bears US NLM identifiers UMLS ID C0125654 and NCI Concept Code C81593. SMILES: OC(CN1CCN(CC1)C1CCCCC1)CO.
This classification denotes a cns stimulant with the molecular formula C15H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3SZ9ZII529, chemically known as 2-piperidinemethanol, alpha-phenyl-, acetate (ester), (r*,r*)-(-)- but more generally known as levofacetoperane, which bears US NIH Compound Identifier 65715. European Medicines Agency schedules Levofacetoperane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08469MIG. The term LEVOFACETOPERANE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). LEVOFACETOPERANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Levofacetoperane or levophacetoperane bears US NLM identifiers UMLS ID C0064875 and NCI Concept Code C81053. SMILES: CC(=O)OC(C1CCCCN1)C2=CC=CC=C2.
This classification denotes a quinolone antibiotic with the molecular formula 2C18H20FN3O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6GNT3Y5LMF, chemically known as 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (s)- but generally known as levofloxacin, which bears US NIH Compound Identifier 149096. European Medicines Agency schedules Levofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08471MIG. World Health Organization schedules levofloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule levofloxacin under HS 29349990 and SITC 51579. As of Q4 2014, LEVOFLOXACIN remains the US FDA Preferred Term for this commodity. Levofloxacin bears US NLM identifiers UMLS ID C0282386 and NCI Concept Code C1586. SMILES: CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.
This classification denotes an antimicrobial solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6H66N6UDU. European Medicines Agency schedules Levofuraltadone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08472MIG. Levofuraltadone generally arises in the molecular formula C13H16N4O6. The term LEVOFURALTADONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 21 no. 12 1967, list 7.) LEVOFURALTADONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1C(CN2CCOCC2)CN(/N=C/C2OC([N](=O)O)CC2)C1=O.
This classification denotes an antimicrobial solution C13H16N4O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZIA9BC2JJR, chemically known as furaltadone hydrochloride, l-, but more generally known as levofuraltadone hydrochloride, which bears US NIH Compound Identifier 56840909. Most nations schedule levofuraltadone hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, LEVOFURALTADONE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. SMILES: C1CC(OC1/C=N/N2C[C@@H](OC2=O)CN3CCOCC3)[N+](=O)[O-].CL.
Levoleucovorin injection is a folate indicated for rescue after high-dose methotrexate therapy in osteosarcoma and diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
This classification denotes a cns stimulant with the molecular formula C19H24N2OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42BB1Y2586, chemically known as 10h-phenothiazine-10-propanamine, 2-methoxy-n,n,beta-trimethyl-, monohydrochloride, (r)- (9ci) but more generally known as levomepromazine hydrochloride, which bears US NIH Compound Identifier 102583. European Medicines Agency schedules Levomepromazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02908MIG. Most nations, for tariff and trade purposes, schedule levomepromazine hydrochloride under HS 29343090. As of Q4 2014, LEVOMEPROMAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levomepromazine hydrochloride bears US NLM identifiers UMLS ID CL387309 and NCI Concept Code C78109. SMILES: C[C@@H](CN1C2CCCCC2SC3C1CC(CC3)OC)CN(C)C.CL.
This classification denotes a phenothiazine, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5KN5Y9V01K. European Medicines Agency schedules Levomepromazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02909MIG. Levomepromazine maleate generally arises in the molecular formula C19H24N2OS.C4H4O4. The term 'levomepromazine maleate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule levomepromazine maleate under HS 29343090. As of Q4 2014, LEVOMEPROMAZINE MALEATE remains US FDA's Preferred Term for this commodity. Levomepromazine maleate bears US NLM identifiers UMLS ID C0607673 and NCI Concept Code C66009. SMILES: C[C@@H](CN1C2CCCCC2SC3C1CC(CC3)OC)CN(C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes a phenothiazine with the molecular formula C19H24N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9G0LAW7ATQ, chemically known as 10h-phenothiazine-10-propanamine, 2-methoxy-n,n,beta-trimethyl-, (r)- but generally known as levomepromazine, which bears US NIH Compound Identifier 3916. European Medicines Agency schedules Levomepromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08476MIG. The term LEVOMEPROMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules levomepromazine in its Anatomical Therapeutic Chemical (ATC) Classification. LEVOMEPROMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Levomepromazine or methotrimeprazine bears US NLM identifiers UMLS ID C0025678 and NCI Concept Code C66118. SMILES: S1C2C(N(CC(CN(C)C)C)C3C1CCCC3)CC(OC)CC2.
This classification denotes an opioid receptor agonist with the molecular formula C18H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZZ22K9QE6, chemically known as 2h-10,4a-iminoethanophenanthrene, 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl- but generally known as levomethorphan, which bears US NIH Compound Identifier 3008. European Medicines Agency schedules Levomethorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08478MIG. The term LEVOMETHORPHAN is an International Non-Proprietary Name. LEVOMETHORPHAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levomethorphan under HS 29334990 and SITC 51575. As of Q4 2014, LEVOMETHORPHAN remains the US FDA Preferred Term for this commodity. Levomethorphan bears US NLM identifiers UMLS ID C0023575 and NCI Concept Code C83875. SMILES: O(C1CC2C34C(C(N(CC3)C)CC2CC1)CCCC4)C.
This classification denotes an opioid receptor agonist with the molecular formula C18H25NO.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9YNW43KIJI, chemically known as morphinan, 3-methoxy-17-methyl-, hydrobromide (1:1), but more generally known as levomethorphan hydrobromide, which bears US NIH Compound Identifier 5486607. European Medicines Agency schedules levomethorphan hydrobromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08478MIG. Most nations, for tariff purposes, schedule levomethorphan hydrobromide under HS 29334990. SMILES: CN1CC[C@]23CCCC[C@H]2[C@H]1CC4C3CC(CC4)OC.BR.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4NON6FSON, chemically known as 2-propanol, 1-(2-methoxyphenoxy)-3-((1-methylethyl)amino)-, (s)- but generally known as levomoprolol, which bears US NIH Compound Identifier 3034006. European Medicines Agency schedules Levomoprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08480MIG. The term LEVOMOPROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). LEVOMOPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levomoprolol under HS 29221980 and SITC 51461. As of Q4 2014, LEVOMOPROLOL remains the US FDA Preferred Term for this commodity. Levomoprolol bears US NLM identifiers UMLS ID C0125658 and NCI Concept Code C83877. SMILES: O(CC(O)CNC(C)C)C1C(OC)CCCC1.
This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7M86YFN15D, chemically known as pyrrolidine, 1-(3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)-, (s)- but generally known as levomoramide, which bears US NIH Compound Identifier 9648. European Medicines Agency schedules Levomoramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08481MIG. The term LEVOMORAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). LEVOMORAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levomoramide under HS 29349990 and SITC 51579. As of Q4 2014, LEVOMORAMIDE remains the US FDA Preferred Term for this commodity. Levomoramide bears US NLM identifiers UMLS ID C0608090 and NCI Concept Code C83878. SMILES: O=C(N1CCCC1)C(C(CN1CCOCC1)C)(C1CCCCC1)C1CCCCC1.
This classification denotes an antiemetic agent with the molecular formula C27H35NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03S640ADSK, chemically known as 1,9-phenanthridinediol, 5,6,6a,7,8,9,10,10a-octahydro-6-methyl-3-((1r)-1-methyl-4-phenylbutoxy)-, 1-acetate, (6s,6ar,9r,10ar)- but generally known as levonantradol, which bears US NIH Compound Identifier 5361881. European Medicines Agency schedules Levonantradol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08482MIG. The term LEVONANTRADOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). LEVONANTRADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levonantradol under HS 29339990 and SITC 51577. As of Q4 2014, LEVONANTRADOL remains the US FDA Preferred Term for this commodity. Levonantradol bears US NLM identifiers UMLS ID C0125660 and NCI Concept Code C1385. SMILES: OC1CC2C(CC1)C(NC1C2C(OC(=O)C)CC(OC(CCCC2CCCCC2)C)C1)C.
This classification denotes an adrenergic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V008L6478D. European Medicines Agency schedules Corbadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06805MIG. Corbadrine generally arises in the molecular formula C9H13NO3. The term CORBADRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) CORBADRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, LEVONORDEFRIN remains the US FDA Preferred Term for this commodity. Levonordefrin bears US NLM identifiers UMLS ID C0520472 and NCI Concept Code C47584. SMILES: OC(C(N)C)C1CC(O)C(O)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W7SIA7YZW, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)- but generally known as levonorgestrel, which bears US NIH Compound Identifier 13109. European Medicines Agency schedules Levonorgestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08483MIG. The term LEVONORGESTREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules levonorgestrel in its Anatomical Therapeutic Chemical (ATC) Classification. LEVONORGESTREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levonorgestrel under HS 29372300 and SITC 54153. As of Q4 2014, LEVONORGESTREL remains the US FDA Preferred Term for this commodity. Levonorgestrel bears US NLM identifiers UMLS ID C1145675 and NCI Concept Code C47585. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)CC)C#C.
This classification denotes an opioid receptor agonist with the molecular formula C24H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Q24AL2BR2, chemically known as morphinan-3-ol, 17-(2-oxo-2-phenylethyl)- but generally known as levophenacylmorphan, which bears US NIH Compound Identifier 517743. European Medicines Agency schedules Levophenacylmorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08484MIG. The term LEVOPHENACYLMORPHAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). LEVOPHENACYLMORPHAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levophenacylmorphan under HS 29334990 and SITC 51575. As of Q4 2014, LEVOPHENACYLMORPHAN remains the US FDA Preferred Term for this commodity. Levophenacylmorphan bears US NLM identifiers UMLS ID C2827237 and NCI Concept Code C83880. SMILES: OC1CC2C34C(C(N(CC3)CC(=O)C3CCCCC3)CC2CC1)CCCC4.
This classification denotes an antitussive agent with the molecular formula C22H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U75VZ9PK1J, chemically known as [(2R,3S)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate, but more generally know as levopropoxyphene, which bears US NIH Compound Identifier 200742. The term levopropoxyphene is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule levopropoxyphene under HS 29221980 and SITC 51461. As of Q4 2014, LEVOPROPOXYPHENE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C.
This classification denotes an antitussive agent with the molecular formula C22H29NO2.C10H8O3S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KK9590R73S, chemically known as benzeneethanol, .alpha.-(2-(dimethylamino)-1-methylethyl)-.alpha.-phenyl-, propanoate (ester), (r-(r*,s*))-, compd. with 2-naphthalenesulfonic acid (1:1), monohydrate, but more generally known as levopropoxyphene napsilate, which bears US NIH Compound Identifier 64736. European Medicines Agency schedules levopropoxyphene napsilate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08486MIG. Most nations, for tariff purposes, schedule levopropoxyphene napsilate under HS 29221980. SMILES: CCC(=O)O[C@@](CC1CCCCC1)(C2CCCCC2)[C@@H](C)CN(C)C.C1CCC2CC(CCC2C1)S(=O)(=O)O.O.
This classification denotes an antidepressant agent with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KYX86D468O, chemically known as 1-(9,10-ethanoanthracen-9(10h)-yl)-3-(methylamino)propan-2-ol but generally known as levoprotiline, which bears US NIH Compound Identifier 53511. European Medicines Agency schedules Levoprotiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08488MIG. The term LEVOPROTILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). LEVOPROTILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levoprotiline under HS 29221980 and SITC 51461. As of Q4 2014, LEVOPROTILINE remains the US FDA Preferred Term for this commodity. Levoprotiline bears US NLM identifiers UMLS ID C0125662 and NCI Concept Code C83884. SMILES: OC(CC12CCC(c3c2cccc3)c2c1cccc2)CNC.
This classification denotes an antidepressant agent with the molecular formula C20H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DFI134OU66, chemically known as 9,10-ethanoanthracene-9(10h)-ethanol, alpha-((methylamino)methyl)-, hydrochloride, (r)-, but more generally known as levoprotiline hydrochloride, which bears US NIH Compound Identifier 3033631. European Medicines Agency schedules levoprotiline hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08488MIG. Most nations, for tariff purposes, schedule levoprotiline hydrochloride under HS 29221980. SMILES: CNC[C@@H](CC12CCC(C3C1CCCC3)C4C2CCCC4)O.CL.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27618J1N2X, chemically known as 1,3,4,9,10,10a-hexahydro-6-hydroxy-2h-10,4a-(iminoethano)-11-methylphenanthrene but generally known as levorphanol, which bears US NIH Compound Identifier 5359272. European Medicines Agency schedules Levorphanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08490MIG. The term LEVORPHANOL is an International Non-Proprietary Name. LEVORPHANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levorphanol under HS 29334100 and SITC 51575. As of Q4 2014, LEVORPHANOL remains the US FDA Preferred Term for this commodity. Levorphanol bears US NLM identifiers UMLS ID C0023586 and NCI Concept Code C61810. SMILES: OC1CC2C34C(C(N(CC3)C)CC2CC1)CCCC4.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H23NO.C4H6O6.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04WQU6T9QI, chemically known as morphinan-6-ol, n-methyl-, tartrate (1:1) (salt), stereoisomer but more generally known as levorphanol tartrate, which bears US NIH Compound Identifier 260127. European Medicines Agency schedules Levorphanol tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02914MIG. Most nations, for tariff and trade purposes, schedule levorphanol tartrate under HS 29334100 and SITC 51575. As of Q4 2014, LEVORPHANOL TARTRATE remains US FDA's Preferred Term for this commodity. Levorphanol tartrate bears US NLM identifiers UMLS ID C1450007 and NCI Concept Code C47586. SMILES: CN1CC[C@]23CCCC[C@H]2[C@H]1CC4C3CC(CC4)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.O.O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H23NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WCB1I20F1K, chemically known as morphinan-3-ol, 17-methyl-, [r-(r*,r*)]-2,3-dihydroxybutanedioate (1:1) (salt), but more generally known as levorphanol tartrate anhydrous, which bears US NIH Compound Identifier 5464027. European Medicines Agency schedules levorphanol tartrate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08490MIG. Most nations, for tariff purposes, schedule levorphanol tartrate anhydrous under HS 29334100. SMILES: CN1CC[C@]23CCCC[C@H]2[C@H]1CC4C3CC(CC4)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an anti-arrhythmia agent, cardiotonic agent, and vasodilator agent with the molecular formula C14H12N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C6T4514L4E, chemically known as (r)-((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile but generally known as levosimendan, which bears US NIH Compound Identifier 3033825. European Medicines Agency schedules Levosimendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08493MIG. World Health Organization schedules levosimendan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule levosimendan under HS 29339990 and SITC 51577. As of Q4 2014, LEVOSIMENDAN remains the US FDA Preferred Term for this commodity. SMILES: O=C1NN=C(C(C1)C)c1ccc(N/N=C(/C#N)C#N)cc1.
This classification denotes a dopamine antagonist with the molecular formula C15H23N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7MNE9M8287, chemically known as o-anisamide, n-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-, (s)-(-)- but generally known as sulpiride, which bears US NIH Compound Identifier 5355. European Medicines Agency schedules Sulpiride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10758MIG. The term SULPIRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules sulpiride in its Anatomical Therapeutic Chemical (ATC) Classification. SULPIRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Levosulpiride or sulpiride bears US NLM identifiers UMLS ID C0038803 and NCI Concept Code C87713. SMILES: S(=O)(=O)(N)C1CC(C(=O)NCC2N(CCC2)CC)C(OC)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS851. This VA Drug Class (HS851) classifies this compound as belonging to the group THYROID SUPPLEMENTS.
This classification denotes a generic primary tumor tnm finding with the molecular formula C15H11I4NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q51BO43MG4, chemically known as 3,5,3,5-tetraiodothyronine but generally known as levothyroxine, which bears US NIH Compound Identifier 853. European Medicines Agency schedules Levothyroxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02917MIG. SMILES: C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N.
This classification denotes a thyroid hormone with the molecular formula C15H10I4NO4.Na.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 9J765S329G, chemically known as 3,5,3,5-tetraiodothyronine but more generally known as levothyroxine sodium, which bears U.S. National Institutes of Health Compound Identifier 853. European Medicines Agency schedules Levothyroxine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08495MIG. World Health Organization schedules levothyroxine sodium in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes an analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 811X558HU0. European Medicines Agency schedules Levoxadrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08496MIG. Levoxadrol generally arises in the molecular formula C20H23NO2. The term LEVOXADROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) LEVOXADROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levoxadrol under HS 29349990 and SITC 51579. As of Q4 2014, LEVOXADROL remains the US FDA Preferred Term for this commodity. Levoxadrol bears US NLM identifiers UMLS ID C0125663 and NCI Concept Code C66010. SMILES: O1C(C2(NCCCC2)C)(COC1(C1CCCCC1)C1CCCCC1)C.
This classification denotes an anesthetic agent with the molecular formula C20H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3ARD9VMM81, chemically known as u-22,304a but more generally known as levoxadrol hydrochloride, which bears US NIH Compound Identifier 31785. European Medicines Agency schedules Levoxadrol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21975. Most nations, for tariff and trade purposes, schedule levoxadrol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, LEVOXADROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levoxadrol hydrochloride bears US NLM identifiers UMLS ID C0888632 and NCI Concept Code C87595. SMILES: C1CCC(CC1)C2(OC[C@H](O2)[C@H]3CCCCN3)C4CCCCC4.CL.
This classification denotes a macrolide antibiotic with the molecular formula C38H70N2O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7QKO29734U, chemically known as erythromycin, 9-(o-methyloxime) but generally known as lexithromycin, which bears US NIH Compound Identifier 9570610. European Medicines Agency schedules Lexithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08499MIG. The term LEXITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). LEXITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lexithromycin under HS 29415000 and SITC 54139. As of Q4 2014, LEXITHROMYCIN remains the US FDA Preferred Term for this commodity. Lexithromycin bears US NLM identifiers UMLS ID C2981357 and NCI Concept Code C87760. SMILES: O(C1C(C(OC2OC(C(O)C(OC)(C2)C)C)C(C(=O)OC(C(O)(C(O)C(C(=N\OC)\C(CC1(O)C)C)C)C)CC)C)C)C1OC(CC(N(C)C)C1O)C.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3578QN1B5H. European Medicines Agency schedules Lexofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08500MIG. Lexofenac generally arises in the molecular formula C14H14O3. The term LEXOFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) LEXOFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lexofenac under HS 29183000 and SITC 51395. As of Q4 2014, LEXOFENAC remains the US FDA Preferred Term for this commodity. Lexofenac bears US NLM identifiers UMLS ID C1881374 and NCI Concept Code C66011. SMILES: O=C1CCCC(=C1)C1CCC(CC1)CC(=O)O.
This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H13ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0Q29TGV9Y, chemically known as 1h-benzimidazole, 5-((3-chlorophenyl)-1h-imidazol-1-ylmethyl)- but generally known as liarozole, which bears US NIH Compound Identifier 60652. European Medicines Agency schedules Liarozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14356MIG. The term LIAROZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Most nations schedule liarozole under HS 29332990 and SITC 51573. As of Q4 2014, LIAROZOLE remains the US FDA Preferred Term for this commodity. Liarozole bears US NLM identifiers UMLS ID C0165479 and NCI Concept Code C1433. SMILES: CLC1CC(C(N2CCNC2)C2CC3[NH]CNC3CC2)CCC1.
This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QD8496WWYK. European Medicines Agency schedules Libenzapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08502MIG. Libenzapril generally arises in the molecular formula C18H25N3O5. The term LIBENZAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) LIBENZAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule libenzapril under HS 29337900 and SITC 51561. As of Q4 2014, LIBENZAPRIL remains the US FDA Preferred Term for this commodity. Libenzapril bears US NLM identifiers UMLS ID C0055225 and NCI Concept Code C81335. SMILES: O=C1N(c2c(CCC1NC(CCCCN)C(=O)O)cccc2)CC(=O)O.
This classification denotes a neuroprotective agent with the molecular formula C8H3Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Z3037LJTC, chemically known as 6,7-dichloro-5-nitro-2,3-quinoxalinedione but generally known as licostinel, which bears US NIH Compound Identifier 5486198. European Medicines Agency schedules Licostinel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08503MIG. The term LICOSTINEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). LICOSTINEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule licostinel under HS 29339990 and SITC 51577. As of Q4 2014, LICOSTINEL remains the US FDA Preferred Term for this commodity. Licostinel bears US NLM identifiers UMLS ID C0294340 and NCI Concept Code C73248. SMILES: CLC1C([N](=O)O)C2[NH]C(=O)C(=O)[NH]C2CC1CL.
This classification denotes an antidiarrheal agent with the molecular formula C11H16N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q8X04W8418, chemically known as urea, n-(2,6-dimethylphenyl)-n-(imino(methylamino)methyl)- but generally known as lidamidine, which bears US NIH Compound Identifier 47510. European Medicines Agency schedules Lidamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08504MIG. The term LIDAMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). LIDAMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lidamidine under HS 29252900 and SITC 51482. As of Q4 2014, LIDAMIDINE remains the US FDA Preferred Term for this commodity. Lidamidine bears US NLM identifiers UMLS ID C0064961 and NCI Concept Code C82240. SMILES: CC1=C(C(=CC=C1)C)NC(=O)NC(=NC)N.
This classification denotes an antidiarrheal agent with the molecular formula C11H16N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q1Q4QJV3V, chemically known as 1-(methylamidino)-3-(2,6-xylyl)urea monohydrochloride but more generally known as lidamidine hydrochloride, which bears US NIH Compound Identifier 47509. European Medicines Agency schedules Lidamidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35843. Most nations, for tariff and trade purposes, schedule lidamidine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, LIDAMIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lidamidine hydrochloride bears US NLM identifiers UMLS ID C0771745 and NCI Concept Code C82241. SMILES: CC1CCCC(C1NC(=O)NC(=N)NC)C.CL.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U1E84J0228. European Medicines Agency schedules Lidimycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08506MIG. Lidimycin generally arises in the molecular formula C10H14N2O3S. The term LIDIMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) LIDIMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Lidimycin or lydimycin bears US NLM identifiers UMLS ID C2983836 and NCI Concept Code C90684. SMILES: C1C2C(C(S1)CC/C=C/C(=O)O)NC(=O)N2.
This classification denotes a cation channel blocker and anesthetic agent with the molecular formula C14H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98PI200987, chemically known as 2-diethylamino-n-(2,6-dimethylphenyl)-ethanamide but generally known as lidocaine, which bears US NIH Compound Identifier 3676. European Medicines Agency schedules Lidocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08507MIG. The term LIDOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules lidocaine in its Anatomical Therapeutic Chemical (ATC) Classification. LIDOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lidocaine under HS 29242910 and SITC 51479. As of Q4 2014, LIDOCAINE remains the US FDA Preferred Term for this commodity. Lidocaine bears US NLM identifiers UMLS ID C0023660 and NCI Concept Code C614. SMILES: O=C(NC1C(CCCC1C)C)CN(CC)CC.
This classification denotes a cation channel blocker and anesthetic agent with the molecular formula C21H29N2O.C7H5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M5BA6GAF1O, chemically known as benzenemethanaminium, n-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-n,n-diethyl-, benzoate (1:1), but more generally known as lidocaine benzyl benzoate, which bears US NIH Compound Identifier 19518. European Medicines Agency schedules lidocaine benzyl benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08507MIG. Most nations, for tariff purposes, schedule lidocaine benzyl benzoate under HS 29242910. SMILES: CC[N+](CC)(CC1CCCCC1)CC(=O)NC2C(CCCC2C)C.C1CCC(CC1)C(=O)[O-].
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V13007Z41A. European Medicines Agency schedules Lidocaine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02921MIG. Lidocaine hydrochloride generally arises in the molecular formula C14H22N2O.CLH.H2O. The term 'lidocaine hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation. Most nations, for tariff and trade purposes, schedule lidocaine hydrochloride under HS 29242910 and SITC 51479. As of Q4 2014, LIDOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lidocaine hydrochloride bears US NLM identifiers UMLS ID C0546869 and NCI Concept Code C48000. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C)C.O.CL.
This classification denotes a cation channel blocker and anesthetic agent with the molecular formula C14H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EC2CNF7XFP, chemically known as acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, monohydrochloride, but more generally known as lidocaine hydrochloride anhydrous, which bears US NIH Compound Identifier 6314. European Medicines Agency schedules lidocaine hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08507MIG. Most nations, for tariff purposes, schedule lidocaine hydrochloride anhydrous under HS 29242910. Lidocaine hydrochloride anhydrous bears US NLM identifiers UMLS ID C2756728 and NCI Concept Code C90650. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C)C.CL.
This classification denotes a cation channel blocker and anesthetic agent with the molecular formula C14H22N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V13007Z41A, chemically known as acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate, but more generally known as lidocaine hydrochloride monohydrate, which bears US NIH Compound Identifier 22483. European Medicines Agency schedules lidocaine hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08507MIG. Most nations, for tariff purposes, schedule lidocaine hydrochloride monohydrate under HS 29242910. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C)C.O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a calcium channel blocker with the molecular formula C30H35F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4ZHN3HBTE, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-1-piperazineaceto-2,6-xylidide but generally known as lidoflazine, which bears US NIH Compound Identifier 3926. European Medicines Agency schedules Lidoflazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08509MIG. The term LIDOFLAZINE is an International Non-Proprietary Name. World Health Organization schedules lidoflazine in its Anatomical Therapeutic Chemical (ATC) Classification. LIDOFLAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lidoflazine under HS 29335995 and SITC 51576. As of Q4 2014, LIDOFLAZINE remains the US FDA Preferred Term for this commodity. Lidoflazine bears US NLM identifiers UMLS ID C0023665 and NCI Concept Code C81685. SMILES: Fc1ccc(C(CCCN2CCN(CC2)CC(=O)Nc2c(cccc2C)C)c2ccc(F)cc2)cc1.
This classification denotes an anti-lipidemic agent with the molecular formula C21H26O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6KWX9X0Q5K, chemically known as benzoic acid, 4-(4-(4-(1,1-dimethylethyl)phenyl)-2-hydroxybutoxy)-, (+-)- but generally known as lifibrol, which bears US NIH Compound Identifier 57112. European Medicines Agency schedules Lifibrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08512MIG. The term LIFIBROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). LIFIBROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lifibrol under HS 29189900 and SITC 51396. As of Q4 2014, LIFIBROL remains the US FDA Preferred Term for this commodity. Lifibrol bears US NLM identifiers UMLS ID C0125829 and NCI Concept Code C82244. SMILES: OC(CCc1ccc(C(C)(C)C)cc1)COc1ccc(cc1)C(=O)O.
An oligo-peptide agonist of guanylate cyclase 2C. It was approved by the FDA in August 2012 and by the European Medicines Agency[4] for the treatment in adults of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X29ZEJ4R2. European Medicines Agency schedules Linagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31340. Linagliptin generally arises in the molecular formula C25H28N8O2. The term LINAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, no. 1, 2009, list 61.) As of Q4 2014, LINAGLIPTIN remains US FDA's Preferred Term for this commodity. Linagliptin bears US NLM identifiers UMLS ID C2746078 and NCI Concept Code C83887. SMILES: CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C.
This classification denotes a lincosamide antibiotic with the molecular formula C18H34N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BOD072YW0F, chemically known as lincolnensin, hydrochloride, hemihydrate but generally known as lincomycin, which bears US NIH Compound Identifier 3928. European Medicines Agency schedules Lincomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08517MIG. The term LINCOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules lincomycin in its Anatomical Therapeutic Chemical (ATC) Classification. LINCOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lincomycin under HS 29419000 and SITC 54139. As of Q4 2014, LINCOMYCIN remains the US FDA Preferred Term for this commodity. Lincomycin bears US NLM identifiers UMLS ID C0023726 and NCI Concept Code C61811. SMILES: S(C1OC(C(NC(=O)C2N(CC(C2)CCC)C)C(O)C)C(O)C(O)C1O)C.
This classification denotes a lincosamide antibiotic with the molecular formula C18H34N2O6S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M6T05Z2B68, chemically known as lincolnensin, hydrochloride, hemihydrate but more generally known as lincomycin hydrochloride, which bears US NIH Compound Identifier 3928. European Medicines Agency schedules Lincomycin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02924MIG. Most nations, for tariff and trade purposes, schedule lincomycin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, LINCOMYCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lincomycin hydrochloride bears US NLM identifiers UMLS ID C0282219 and NCI Concept Code C66013. SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O.O.CL.
This classification denotes a lincosamide antibiotic with the molecular formula C18H34N2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCW8Y9936L, chemically known as d-erythro-.alpha.-d-galacto-octopyranoside, methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, monohydrochloride, (2s-trans)-, but more generally known as lincomycin hydrochloride anhydrous, which bears US NIH Compound Identifier 64710. European Medicines Agency schedules lincomycin hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08517MIG. Most nations, for tariff purposes, schedule lincomycin hydrochloride anhydrous under HS 29419000. Lincomycin hydrochloride anhydrous bears US NLM identifiers UMLS ID C2983919 and NCI Concept Code C90876. SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O.CL.
This classification denotes a lincosamide antibiotic with the molecular formula C18H34N2O6S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M6T05Z2B68, chemically known as lincolnensin, hydrochloride, hemihydrate but more generally known as lincomycin hydrochloride, which bears US NIH Compound Identifier 3928. European Medicines Agency schedules Lincomycin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02924MIG. Most nations, for tariff and trade purposes, schedule lincomycin hydrochloride monohydrate under HS 29419000 and SITC 54139. SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O.O.CL.
This classification denotes a chlorinated ring carcinogen with the molecular formula C6H6Cl6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59NEE7PCAB, chemically known as 1,2,3,4,5,6-hexachlorocyclohexane (mixture of isomers) but generally known as lindane, which bears US NIH Compound Identifier 727. European Medicines Agency schedules Lindane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08518MIG. The term LINDANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules lindane in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, LINDANE remains the US FDA Preferred Term for this commodity. Lindane bears US NLM identifiers UMLS ID C0005038 and NCI Concept Code C44397. SMILES: CLC1C(CL)C(CL)C(CL)C(CL)C1CL.
This classification denotes an antibiotic with the molecular formula C16H20FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ISQ9I6J12J, chemically known as acetamide, n-(((5s)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)- but generally known as linezolid, which bears US NIH Compound Identifier 73180. European Medicines Agency schedules Linezolid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08520MIG. The term LINEZOLID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). World Health Organization schedules linezolid in its Anatomical Therapeutic Chemical (ATC) Classification. LINEZOLID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule linezolid under HS 29349990 and SITC 51579. As of Q4 2014, LINEZOLID remains the US FDA Preferred Term for this commodity. Linezolid bears US NLM identifiers UMLS ID C0663241 and NCI Concept Code C29158. SMILES: FC1C(N2CCOCC2)CCC(N2CC(OC2=O)CNC(=O)C)C1.
This classification denotes an anti-diabetic agent with the molecular formula C16H22N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7E521JYJ4X, chemically known as 4-morpholinecarboximidamide, n-(1-methyl-2-pyrrolidinylidene)-n-phenyl- but more generally known as linogliride, which bears US NIH Compound Identifier 6536869. European Medicines Agency schedules Linogliride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08521MIG. The term LINOGLIRIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). LINOGLIRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule linogliride under HS 29349990 and SITC 51579. As of Q4 2014, LINOGLIRIDE remains US FDA's Preferred Term for this commodity. Linogliride bears US NLM identifiers UMLS ID C0065013 and NCI Concept Code C66015. SMILES: O1CCN(CC1)/C(=N\C1CCCCC1)/N=C1/N(CCC1)C.
This classification denotes a cation channel blocker with the molecular formula C26H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I5TB3NZ94T, chemically known as 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2h-indol-2-one but more generally known as linopirdine, which bears US NIH Compound Identifier 3932. European Medicines Agency schedules Linopirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08522MIG. The term LINOPIRDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules linopirdine in its Anatomical Therapeutic Chemical (ATC) Classification. LINOPIRDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule linopirdine under HS 29337900 and SITC 51561. As of Q4 2014, LINOPIRDINE remains US FDA's Preferred Term for this commodity. Linopirdine bears US NLM identifiers UMLS ID C0286263 and NCI Concept Code C82306. SMILES: O=C1N(C2C(C1(CC1CCNCC1)CC1CCNCC1)CCCC2)C1CCCCC1.
This classification denotes a vasodilating agent and nitric oxide-releasing compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5O5U71P6VQ. European Medicines Agency schedules Linsidomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08524MIG. Linsidomine generally arises in the molecular formula C6H10N4O2. The term LINSIDOMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) LINSIDOMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule linsidomine under HS 29349990 and SITC 51579. As of Q4 2014, LINSIDOMINE remains the US FDA Preferred Term for this commodity. Linsidomine bears US NLM identifiers UMLS ID C0525082 and NCI Concept Code C72628. SMILES: O1CCN([n]2[nH]oc(=N)c2)CC1.
This classification denotes a vasodilating agent and nitric oxide-releasing compound with the molecular formula C6H10N4O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0054U597M. European Medicines Agency schedules linsidomine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21667. The term linsidomine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule linsidomine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, LINSIDOMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1C(ON[N+]1N2CCOCC2)N.[CL-].
This classification denotes a serotonin antagonist and antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2R0GEU722. European Medicines Agency schedules Lintopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08526MIG. Lintopride generally arises in the molecular formula C14H19CLN4O2. The term LINTOPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) LINTOPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lintopride under HS 29332990 and SITC 51573. As of Q4 2014, LINTOPRIDE remains the US FDA Preferred Term for this commodity. Lintopride bears US NLM identifiers UMLS ID C0378649 and NCI Concept Code C66018. SMILES: CLC1CC(C(=O)NCC2=NCCN2CC)C(OC)CC1N.
This classification denotes a generic primary tumor tnm finding with the molecular formula C15H12I3NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06LU7C9H1V, chemically known as 3,5,3-triiodothyronine but generally known as liothyronine, which bears US NIH Compound Identifier 861. European Medicines Agency schedules Liothyronine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08527MIG. The term LIOTHYRONINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). LIOTHYRONINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, LIOTHYRONINE remains the US FDA Preferred Term for this commodity. Liothyronine bears US NLM identifiers UMLS ID CL414313 and NCI Concept Code C907. SMILES: IC1CC(CC(N)C(=O)O)CC(I)C1OC1CC(I)C(O)CC1.
This classification denotes a generic primary tumor tnm finding with the molecular formula C15H12I3NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T66DHO0SET, chemically known as alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, hydrochloride, l-, but more generally known as liothyronine hydrochloride, which bears US NIH Compound Identifier 71283. European Medicines Agency schedules liothyronine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08527MIG. Most nations, for tariff purposes, schedule liothyronine hydrochloride under HS 29374000. SMILES: C1CC(C(CC1OC2C(CC(CC2I)C[C@@H](C(=O)O)N)I)I)O.CL.
This classification denotes a generic primary tumor tnm finding with the molecular formula C15H11I3NO4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCA9VV7D2N, chemically known as l-tyrosine, o-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt, but more generally known as liothyronine sodium, which bears US NIH Compound Identifier 5919. European Medicines Agency schedules liothyronine sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08527MIG. Most nations, for tariff purposes, schedule liothyronine sodium under HS 29374000. Liothyronine sodium bears US NLM identifiers UMLS ID C0546882 and NCI Concept Code C2581. SMILES: C1CC(C(CC1OC2C(CC(CC2I)C[C@@H](C(=O)[O-])N)I)I)O.[NA+].
This classification denotes a thyroid hormone and thyroxine-triiodothyronine drug combination with the molecular formula C30H23I7N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YW8HJ0N26X, more generally known as liotrix, chemically known as (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3, 5-diiodophenyl]propanoic acid, but generally known as liotrix. As of Q4 2014, LIOTRIX remains the US FDA Preferred Term for this commodity. Liotrix bears US NLM identifiers UMLS ID C0936106 and NCI Concept Code C87251. SMILES: C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N.
Lipegfilgrastim is a medication used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults. It is given by injection under the skin in the abdomen, upper arm or thigh.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 839I73S42A. European Medicines Agency schedules Liraglutide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25238. Liraglutide generally arises in the molecular formula C172H265N43O51. The term LIRAGLUTIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 17, no. 2uy, 2003, list 49.) Most nations, for tariff and trade purposes, schedule liraglutide under HS 29371900 and SITC 54154. As of Q4 2014, LIRAGLUTIDE remains US FDA's Preferred Term for this commodity. Liraglutide bears US NLM identifiers UMLS ID C1456408 and NCI Concept Code C82239. SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)O)C(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N.
This classification denotes an antifungal agent with the molecular formula C18H20N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5253IGO5X3, chemically known as o-(5,6,7,8,-tetrahydro-2-naphthyl) 6-methoxy-n-methylthio-2-pyridinecarbamate but generally known as liranaftate, which bears US NIH Compound Identifier 3936. European Medicines Agency schedules Liranaftate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08528MIG. The term LIRANAFTATE is an International Non-Proprietary Name. LIRANAFTATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule liranaftate under HS 29333999 and SITC 51574. As of Q4 2014, LIRANAFTATE remains the US FDA Preferred Term for this commodity. Liranaftate bears US NLM identifiers UMLS ID C1173390 and NCI Concept Code C66019. SMILES: S=C(OC1CC2CCCCC2CC1)N(C1NC(OC)CCC1)C.
This classification denotes a sedative and hypnotic with the molecular formula C26H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2VUW1087AD, chemically known as (3s)-1-((10-chloro-6,7-dihydro-4-oxo-3-phenyl-4h-benzo(a)quinolizin-1-yl)carbonyl)-3-ethoxypyrrolidine. but generally known as lirequinil, which bears US NIH Compound Identifier 3045375. European Medicines Agency schedules Lirequinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08529MIG. The term LIREQUINIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). LIREQUINIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lirequinil under HS 29337900 and SITC 51561. As of Q4 2014, LIREQUINIL remains the US FDA Preferred Term for this commodity. Lirequinil bears US NLM identifiers UMLS ID C2825299 and NCI Concept Code C80668. SMILES: CLC1CC2C3N(CCC2CC1)C(=O)C(CC3C(=O)N1CC(OCC)CC1)C1CCCCC1.
This classification denotes an anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H645GUL8KJ. European Medicines Agency schedules Lisdexamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32170. Lisdexamfetamine generally arises in the molecular formula C15H25N3O. The term LISDEXAMFETAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 20, no. 3, 2006, list 56.) Most nations, for tariff and trade purposes, schedule lisdexamfetamine under HS 29242990 and SITC 51479. As of Q4 2014, LISDEXAMFETAMINE remains US FDA's Preferred Term for this commodity. Lisdexamfetamine bears US NLM identifiers UMLS ID C1873633 and NCI Concept Code C75114. SMILES: CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N.
This classification denotes a cns stimulant and anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SJT761GEGS. European Medicines Agency schedules Lisdexamfetamine dimesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32146. Lisdexamfetamine dimesylate generally arises in the molecular formula C15H25N3O.2CH4O3S. The term 'lisdexamfetamine dimesylate' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule lisdexamfetamine dimesylate under HS 29242990. As of Q4 2014, LISDEXAMFETAMINE DIMESYLATE remains US FDA's Preferred Term for this commodity. Lisdexamfetamine dimesylate bears US NLM identifiers UMLS ID C1739826 and NCI Concept Code C76628. SMILES: C[C@@H](CC1CCCCC1)NC(=O)[C@H](CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O.
This classification denotes a cns stimulant and anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SJT761GEGS. European Medicines Agency schedules Lisdexamfetamine dimesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32146. Lisdexamfetamine mesilate generally arises in the molecular formula C15H25N3O.2CH4O3S. The term 'lisdexamfetamine mesilate' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule lisdexamfetamine mesilate under HS 29242990 and SITC 51479. SMILES: C[C@@H](CC1CCCCC1)NC(=O)[C@H](CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O.
This classification denotes an ace inhibitor with the molecular formula C21H31N3O5.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7199S1YWR, chemically known as l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-, dihydrate, (s)- but generally known as lisinopril, which bears US NIH Compound Identifier 5362118. European Medicines Agency schedules Lisinopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08533MIG. World Health Organization schedules lisinopril in its Anatomical Therapeutic Chemical (ATC) Classification. LISINOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lisinopril under HS 29339990 and SITC 51577. As of Q4 2014, LISINOPRIL remains the US FDA Preferred Term for this commodity. Lisinopril bears US NLM identifiers UMLS ID C0065374 and NCI Concept Code C29159. SMILES: O=C(N1C(CCC1)C(=O)O)C(NC(CCc1ccccc1)C(=O)O)CCCCN.O.O.
This classification denotes an ace inhibitor with the molecular formula C21H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Q3P4BS2FD, chemically known as l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-, but more generally known as lisinopril anhydrous, which bears US NIH Compound Identifier 5362119. European Medicines Agency schedules lisinopril anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08533MIG. Most nations, for tariff purposes, schedule lisinopril anhydrous under HS 29339990. Lisinopril anhydrous bears US NLM identifiers UMLS ID C2827257 and NCI Concept Code C83924. SMILES: C1CCC(CC1)CC[C@@H](C(=O)O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)O.
This classification denotes an ace inhibitor with the molecular formula C21H31N3O5.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7199S1YWR, chemically known as l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-, dihydrate, (s)- but more generally known as lisinopril, which bears US NIH Compound Identifier 5362118. European Medicines Agency schedules Lisinopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08533MIG. World Health Organization schedules lisinopril in its Anatomical Therapeutic Chemical (ATC) Classification. LISINOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule lisinopril dihydrate under HS 29339990 and SITC 51577. SMILES: C1CCC(CC1)CC[C@@H](C(=O)O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)O.O.O.
This classification denotes an antiparkinsonian agent with the molecular formula C20H26N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E0QN3D755O, chemically known as 3-(9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea but generally known as lisuride, which bears US NIH Compound Identifier 28864. European Medicines Agency schedules Lisuride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08535MIG. The term LISURIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules lisuride in its Anatomical Therapeutic Chemical (ATC) Classification. LISURIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lisuride under HS 29396900 and SITC 54146. As of Q4 2014, LISURIDE remains the US FDA Preferred Term for this commodity. Lisuride bears US NLM identifiers UMLS ID C0023863 and NCI Concept Code C82247. SMILES: O=C(NC1CN(C2C(=C1)C1C3C(C2)C[NH]C3CCC1)C)N(CC)CC.
This classification denotes an antiparkinsonian agent with the molecular formula C20H26N4O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UV1635N8XW, chemically known as 3-(9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea but more generally known as lisuride maleate, which bears US NIH Compound Identifier 28864. European Medicines Agency schedules Lisuride maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02940MIG. Most nations, for tariff and trade purposes, schedule lisuride maleate under HS 29396900 and SITC 54146. As of Q4 2014, LISURIDE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3C[NH]C4C3C(CCC4)C2=C1)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antipsychotic agent with the molecular formula CO3.2Li, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BMD2GNA4V, chemically known as lithium carbonate, rb2co3 but generally known as lithium carbonate, which bears US NIH Compound Identifier 767. European Medicines Agency schedules Lithium carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14375MIG. Most nations schedule lithium carbonate under HS 28369100 and SITC 52379. As of Q4 2014, LITHIUM CARBONATE remains the US FDA Preferred Term for this commodity. Lithium carbonate bears US NLM identifiers UMLS ID C0085217 and NCI Concept Code C1318. SMILES: OC(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN750. This VA Drug Class (CN750) classifies this compound as belonging to the group LITHIUM SALTS.
This classification denotes an antipsychotic agent with the molecular formula C6H5O7.3Li.4H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z6E9K79YV, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, trilithium salt but generally known as lithium citrate, which bears US NIH Compound Identifier 13520. European Medicines Agency schedules Lithium citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14377MIG. Most nations schedule lithium citrate under HS 29181590 and SITC 51391. As of Q4 2014, LITHIUM CITRATE remains the US FDA Preferred Term for this commodity. Lithium citrate bears US NLM identifiers UMLS ID C0125997 and NCI Concept Code C61812. SMILES: OC(CC(=O)O)(CC(=O)O)C(=O)O.[LI].[LI].[LI].
This classification denotes an antipsychotic agent with the molecular formula C4H4O4.2LI, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MD64P82Y28. European Medicines Agency schedules lithium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14381MIG. The term lithium succinate is a U.S. FDA designation. As of Q4 2014, LITHIUM SUCCINATE remains the US FDA Preferred Term for this commodity. SMILES: OC(=O)CCC(=O)O.[Li].
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9980ST005G. European Medicines Agency schedules Litoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08536MIG. Litoxetine generally arises in the molecular formula C16H19NO. The term LITOXETINE is an International Non-Proprietary Name or INN. LITOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule litoxetine under HS 29333999 and SITC 51574. As of Q4 2014, LITOXETINE remains the US FDA Preferred Term for this commodity. Litoxetine bears US NLM identifiers UMLS ID C0165077 and NCI Concept Code C66021. SMILES: O(C1CCNCC1)Cc1cc2c(cc1)cccc2.
This classification denotes an antidepressant agent with the molecular formula C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B3D399IVR, chemically known as 9-(3-methylaminopropylidene)-10,10-dimethyl-9,10-dihydroanthracene. but generally known as litracen, which bears US NIH Compound Identifier 82730. European Medicines Agency schedules Litracen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08537MIG. The term LITRACEN is an International Non-Proprietary Name. LITRACEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule litracen under HS 29214980 and SITC 51454. As of Q4 2014, LITRACEN remains the US FDA Preferred Term for this commodity. Litracen bears US NLM identifiers UMLS ID C1881414 and NCI Concept Code C66022. SMILES: N(CC/C=C1/c2c(C(c3c1cccc3)(C)C)cccc2)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a nicotinic agonist with the molecular formula C22H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0P25S3P81, chemically known as 8,10-diphenyllobelionol but generally known as lobeline, which bears US NIH Compound Identifier 3945. European Medicines Agency schedules Lobeline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08541MIG. The term LOBELINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). LOBELINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lobeline under HS 29399900 and SITC 54149. As of Q4 2014, LOBELINE remains the US FDA Preferred Term for this commodity. Lobeline bears US NLM identifiers UMLS ID C0023929 and NCI Concept Code C93261. SMILES: OC(CC1N(C(CCC1)CC(=O)C1CCCCC1)C)C1CCCCC1.
This classification denotes a nicotinic agonist with the molecular formula C22H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96J834CB88, chemically known as ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, hydrochloride but more generally known as lobeline hydrochloride, which bears US NIH Compound Identifier 46202. European Medicines Agency schedules Lobeline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14389MIG. Most nations, for tariff and trade purposes, schedule lobeline hydrochloride under HS 29399900 and SITC 54149. As of Q4 2014, LOBELINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1[C@@H](CCC[C@@H]1CC(=O)C2CCCCC2)C[C@@H](C3CCCCC3)O.CL.
This classification denotes a nicotinic agonist with the molecular formula 2C22H27NO2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CJ480V2HP, chemically known as lobeline, sulfate (2:1) (salt) but more generally known as lobeline sulfate, which bears US NIH Compound Identifier 120636. European Medicines Agency schedules Lobeline sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02962MIG. Most nations, for tariff and trade purposes, schedule lobeline sulfate under HS 29399900 and SITC 54149. As of Q4 2014, LOBELINE SULFATE remains US FDA's Preferred Term for this commodity. SMILES: CN1[C@@H](CCC[C@@H]1CC(=O)C2CCCCC2)C[C@@H](C3CCCCC3)O.CN1[C@@H](CCC[C@@H]1CC(=O)C2CCCCC2)C[C@@H](C3CCCCC3)O.OS(=O)(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C10H11N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CMF6Z78SWL, chemically known as 2-benzimidazolecarbamic acid, ethyl ester (8ci) but generally known as lobendazole, which bears US NIH Compound Identifier 22752. European Medicines Agency schedules Lobendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08542MIG. The term LOBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). LOBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lobendazole under HS 29339990 and SITC 51577. As of Q4 2014, LOBENDAZOLE remains the US FDA Preferred Term for this commodity. Lobendazole bears US NLM identifiers UMLS ID C0641229 and NCI Concept Code C66023. SMILES: CCOC(=O)NC1=NC2=CC=CC=C2N1.
This classification denotes an antioxidant with the molecular formula C14H10ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 915EE91P39, chemically known as 4-chlor-2,2-iminodibenzoesaiure but more generally known as lobenzarit, which bears US NIH Compound Identifier 3946. European Medicines Agency schedules Lobenzarit in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08543MIG. The term LOBENZARIT is an International Non-Proprietary Name. LOBENZARIT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule lobenzarit under HS 29224995 and SITC 51465. As of Q4 2014, LOBENZARIT remains US FDA's Preferred Term for this commodity. Lobenzarit bears US NLM identifiers UMLS ID C0065141 and NCI Concept Code C83889. SMILES: CLC1CC(NC2C(CCCC2)C(=O)O)C(CC1)C(=O)O.
This classification denotes an antioxidant with the molecular formula C14H8ClNO4.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z9SP74BXF, chemically known as benzoic acid, 2-((2-carboxyphenyl)amino)-4-chloro-, disodium salt, but more generally known as lobenzarit disodium, which bears US NIH Compound Identifier 47462. European Medicines Agency schedules lobenzarit disodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08543MIG. Most nations, for tariff purposes, schedule lobenzarit disodium under HS 29224995. SMILES: C1CCC(C(C1)C(=O)[O-])NC2CC(CCC2C(=O)[O-])CL.[NA+].[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular structure C14H8CLNO4.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 7Z9SP74BXF chemically known as benzoic acid, 2-((2-carboxyphenyl)amino)-4-chloro-, disodium salt, but more commonly known as lobenzarit sodium, which bears US NIH Compound Identifier 47462. European Medicines Agency schedules Lobenzarit sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02963MIG. Most nations, for tariff and trade purposes, schedule lobenzarit sodium under HS 29224995 and SITC 51465. As of Q4 2014, LOBENZARIT SODIUM remains US FDA's Preferred Term for this commodity. Lobenzarit sodium bears US NLM identifiers UMLS ID C0126105 and NCI Concept Code C72817. SMILES: C1CCC(C(C1)C(=O)[O-])NC2CC(CCC2C(=O)[O-])CL.[NA+].[NA+].
This classification denotes a purine antagonist and antiviral agent with the molecular formula C11H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8U5PYQ1R2E, chemically known as 9-(2,3-bis-(hydroxymethyl)-1-cyclobutyl)guanine but generally known as lobucavir, which bears US NIH Compound Identifier 60786. European Medicines Agency schedules Lobucavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08544MIG. The term LOBUCAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). LOBUCAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lobucavir under HS 29335995 and SITC 51576. As of Q4 2014, LOBUCAVIR remains the US FDA Preferred Term for this commodity. Lobucavir bears US NLM identifiers UMLS ID C0651257 and NCI Concept Code C82253. SMILES: C1C(C(C1N2C=NC3=C2NC(=NC3=O)N)CO)CO.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H33ClN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X2T6O1TUNX, chemically known as propanoic acid, 2-(4-(2-methylpropyl)phenyl)-, 2-(4-(3-chlorophenyl)-1-piperazinyl)ethyl ester, hydrochloride but generally known as lobuprofen, which bears US NIH Compound Identifier 65842. European Medicines Agency schedules Lobuprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08545MIG. The term LOBUPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). LOBUPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lobuprofen under HS 29335995 and SITC 51576. As of Q4 2014, LOBUPROFEN remains the US FDA Preferred Term for this commodity. Lobuprofen bears US NLM identifiers UMLS ID C2825253 and NCI Concept Code C80559. SMILES: CLC1C(N2CCN(CC2)CCOC(=O)C(C2CCC(CC(C)C)CC2)C)CCCC1.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H33ClN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D5BE0IJ3GR, chemically known as benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, 2-(4-(3-chlorophenyl)-1-piperazinyl)ethyl ester, hydrochloride (1:1), but more generally known as lobuprofen hydrochloride, which bears US NIH Compound Identifier 65842. European Medicines Agency schedules lobuprofen hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08545MIG. Most nations, for tariff purposes, schedule lobuprofen hydrochloride under HS 29335995. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)OCCN2CCN(CC2)C3CCCC(C3)CL.CL.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G87210HO7A. European Medicines Agency schedules Locicortolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08546MIG. LThe term LOCICORTOLONE is an International Non-Proprietary Name or INN. As of Q4 2014, LOCICORTOLONE remains the US FDA Preferred Term for this commodity. SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1C(=O)COC(=O)OC(C5CCCCC5)C6CCCCC6)C)Cl)Cl)C.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G87210HO7A. European Medicines Agency schedules Locicortolone dicibate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08546MIG. Locicortolone dicibate generally arises in the molecular formula C36H50CL2O5. The term LOCICORTOLONE DICIBATE is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule locicortolone dicibate under HS 29372200 and SITC 54153. As of Q4 2014, LOCICORTOLONE DICIBATE remains US FDA's Preferred Term for this commodity. Locicortolone dicibate bears US NLM identifiers UMLS ID C2825345 and NCI Concept Code C80821. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)OC(C5CCCCC5)C6CCCCC6)C)CL)CL)C.
This classification denotes an anti-lipidemic agent with the molecular formula C22H24BrClN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4D9016A00, chemically known as 1-(1,1-bis(hydroxymethyl)ethyl)-3-((s)-6-bromo-5-(o-chlorophenyl)-2,3-dihydro-1,3-dimethyl-2-oxo-1h-1,4-benzodiazepin-7-yl)urea but generally known as lodazecar, which bears US NIH Compound Identifier 65657. European Medicines Agency schedules Lodazecar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08548MIG. The term LODAZECAR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). LODAZECAR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lodazecar under HS 29339940 and SITC 51577. As of Q4 2014, LODAZECAR remains the US FDA Preferred Term for this commodity. Lodazecar bears US NLM identifiers UMLS ID C2825677 and NCI Concept Code C81538. SMILES: Brc1c2c(N(C(=O)C(N=C2c2c(Cl)cccc2)C)C)ccc1NC(=O)NC(CO)(CO)C.
This classification denotes an anxiolytic with the molecular formula C21H20Cl2FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T8593BT7B4, chemically known as 5-(2-(4-(3,5-dichlorphenyl)-1-piperazinyl)ethyl)-4-(4-fluorphenyl)-4-oxazolin-2-on but generally known as lodiperone, which bears US NIH Compound Identifier 161849. European Medicines Agency schedules Lodiperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08552MIG. The term LODIPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). LODIPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lodiperone under HS 29349990 and SITC 51579. As of Q4 2014, LODIPERONE remains the US FDA Preferred Term for this commodity. Lodiperone bears US NLM identifiers UMLS ID C1881436 and NCI Concept Code C66025. SMILES: CLC1CC(N2CCN(CC2)CCC2OC(=O)[NH]C2C2CCC(F)CC2)CC(CL)C1.
This classification denotes a mast cell stabilizer with the molecular formula C11H6ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SPU695OD73, chemically known as n,n-(2-chlor-5-cyan-3-phenylen)dioxamsaeure but generally known as lodoxamide, which bears US NIH Compound Identifier 44564. European Medicines Agency schedules Lodoxamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08553MIG. The term LODOXAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules lodoxamide in its Anatomical Therapeutic Chemical (ATC) Classification. LODOXAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lodoxamide under HS 29269095 and SITC 51484. As of Q4 2014, LODOXAMIDE remains the US FDA Preferred Term for this commodity. Lodoxamide bears US NLM identifiers UMLS ID C0126120 and NCI Concept Code C61813. SMILES: C1=C(C=C(C(=C1NC(=O)C(=O)O)CL)NC(=O)C(=O)O)C#N.
This classification denotes a mast cell stabilizer with the molecular formula C15H14ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQY1B8145B, chemically known as acetic acid, 2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)-, bis 2-oxo-, diethyl ester, but more generally known as lodoxamide ethyl, which bears US NIH Compound Identifier 40915. European Medicines Agency schedules lodoxamide ethyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08553MIG. Most nations, for tariff purposes, schedule lodoxamide ethyl under HS 29269095. SMILES: CCOC(=O)C(=O)NC1CC(CC(C1CL)NC(=O)C(=O)OCC)C#N.
This classification denotes a mast cell stabilizer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50LV9A548L. European Medicines Agency schedules Lodoxamide trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02964MIG. Lodoxamide tromethamine generally arises in the molecular formula C11H6CLN3O6.2C4H11NO3. The term 'lodoxamide tromethamine' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule lodoxamide tromethamine under HS 29269095 and SITC 51484. As of Q4 2014, LODOXAMIDE TROMETHAMINE remains US FDA's Preferred Term for this commodity. Lodoxamide tromethamine bears US NLM identifiers UMLS ID C0065148 and NCI Concept Code C29160. SMILES: C1C(CC(C(C1NC(=O)C(=O)O)CL)NC(=O)C(=O)O)C#N.C(C(CO)(CO)N)O.C(C(CO)(CO)N)O.
This classification denotes an antidepressant agent with the molecular formula C26H27ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OCA4JT7PAW, chemically known as 5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine but generally known as lofepramine, which bears US NIH Compound Identifier 3696. European Medicines Agency schedules Lofepramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08557MIG. The term LOFEPRAMINE is an International Non-Proprietary Name. World Health Organization schedules lofepramine in its Anatomical Therapeutic Chemical (ATC) Classification. LOFEPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lofepramine under HS 29339930 and SITC 51577. As of Q4 2014, LOFEPRAMINE remains the US FDA Preferred Term for this commodity. Lofepramine bears US NLM identifiers UMLS ID C0023961 and NCI Concept Code C87615. SMILES: N1(CCCN(C)C)c2c(CCc3c1cccc3)cccc2.
This classification denotes an antidepressant agent with the molecular formula C26H27ClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z24K96F991, chemically known as 5h-dibenz(b,f)azepine, 5-(3-((p-chlorobenzoylmethyl)-n-methylamino)propyl)-, hydrochloride but more generally known as lofepramine hydrochloride, which bears US NIH Compound Identifier 33611. European Medicines Agency schedules Lofepramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02965MIG. Most nations, for tariff and trade purposes, schedule lofepramine hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, LOFEPRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lofepramine hydrochloride bears US NLM identifiers UMLS ID C0023330 and NCI Concept Code C87616. SMILES: CN(CCCN1C2CCCCC2CCC3C1CCCC3)CC(=O)C4CCC(CC4)CL.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H12Cl2N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V47G1SDI1B, chemically known as 2-imidazoline, 2-(1-(2,6-dichlorophenoxy)ethyl)-, monohydrochloride but more generally known as lofexidine hydrochloride, which bears US NIH Compound Identifier 30667. European Medicines Agency schedules Lofexidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02966MIG. Most nations, for tariff and trade purposes, schedule lofexidine hydrochloride under HS 29332990. As of Q4 2014, LOFEXIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lofexidine hydrochloride bears US NLM identifiers UMLS ID C0771049 and NCI Concept Code C87581. SMILES: CC(C1=NCCN1)OC2C(CCCC2CL)CL.CL.
This classification denotes a quinolone antibiotic with the molecular formula C17H19F2N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6BR2WJD8V, chemically known as 1,4-dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid but generally known as lomefloxacin, which bears US NIH Compound Identifier 3948. European Medicines Agency schedules Lomefloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08561MIG. The term LOMEFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules lomefloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. LOMEFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lomefloxacin under HS 29335995 and SITC 51576. As of Q4 2014, LOMEFLOXACIN remains the US FDA Preferred Term for this commodity. Lomefloxacin bears US NLM identifiers UMLS ID C0065162 and NCI Concept Code C61814. SMILES: FC1C(N2CC(NCC2)C)C(F)CC2C1N(CC)CC(C2=O)C(=O)O.
This classification denotes an anticonvulsant agent with the molecular formula C13H18CLNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, V78B234QEY chemically known as 1-naphthalenamine, 8-chloro-1,2,3,4-tetrahydro-5-methoxy-n,n-dimethyl- but generally known as lometraline, which bears US NIH Compound Identifier 34789. European Medicines Agency schedules Lometraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08563MIG. The term LOMETRALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13. ). Most nations schedule lometraline under HS 29222900 and SITC 51462. As of Q4 2014, LOMETRALINE remains the US FDA Preferred Term for this commodity. Lometraline bears US NLM identifiers UMLS ID C0600985 and NCI Concept Code C81474. SMILES: CLC1C2C(N(C)C)CCCC2C(OC)CC1.
This classification denotes an antiparkinsonian agent with the molecular formula C13H18ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2OJ193WGR, chemically known as 8-chloro-1,2,3,4-tetrahydro-5-methoxy-n,n-dimethyl-1-naphthylamine hydrochloride but more generally known as lometraline hydrochloride, which bears US NIH Compound Identifier 34788. Most nations, for tariff and trade purposes, schedule lometraline hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, LOMETRALINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lometraline hydrochloride bears US NLM identifiers UMLS ID C0888036 and NCI Concept Code C81563. SMILES: CN(C)C1CCCC2C1C(CCC2OC)CL.CL.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C13H18N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NA91GV8GDJ, chemically known as 1,2,3,6-tetrahydro-1,3-dimethyl-7-(5-oxohexyl)purin-2,6-dion but generally known as lomifylline, which bears US NIH Compound Identifier 65599. European Medicines Agency schedules Lomifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08566MIG. The term LOMIFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). LOMIFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lomifylline under HS 29395900 and SITC 54145. As of Q4 2014, LOMIFYLLINE remains the US FDA Preferred Term for this commodity. Lomifylline bears US NLM identifiers UMLS ID C0614278 and NCI Concept Code C66030. SMILES: O=C1N(C(=O)N(C2NCN(CCCCC(=O)C)C12)C)C.
This classification denotes a nitrosourea compound with the molecular formula C9H16ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BRF0Z81KG, chemically known as 1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl- but more generally known as lomustine, which bears US NIH Compound Identifier 3950. European Medicines Agency schedules Lomustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08567MIG. The term LOMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules lomustine in its Anatomical Therapeutic Chemical (ATC) Classification. LOMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule lomustine under HS 29242190 and SITC 51473. As of Q4 2014, LOMUSTINE remains US FDA's Preferred Term for this commodity. Lomustine bears US NLM identifiers UMLS ID C0699181 and NCI Concept Code C617. SMILES: CLCCN(N=O)C(=O)NC1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H13ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13097143QI, chemically known as 1h-pyrazole-4-acetic acid, 3-(4-chlorophenyl)-1-phenyl- but generally known as lonazolac, which bears US NIH Compound Identifier 68706. European Medicines Agency schedules Lonazolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08570MIG. The term LONAZOLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules lonazolac in its Anatomical Therapeutic Chemical (ATC) Classification. LONAZOLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lonazolac under HS 29331990 and SITC 51571. As of Q4 2014, LONAZOLAC remains the US FDA Preferred Term for this commodity. Lonazolac bears US NLM identifiers UMLS ID C0065166 and NCI Concept Code C66031. SMILES: CLC1CCC(C2NN(CC2CC(=O)O)C2CCCCC2)CC1.
This classification denotes a nonsteroidal antiinflammatory drug 2C17H12ClN2O2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H73O2AC36, chemically known as 1h-pyrazole-4-acetic acid, 3-(4-chlorophenyl)-1-phenyl-, calcium salt, but more generally known as lonazolac calcium, which bears US NIH Compound Identifier 156369. European Medicines Agency schedules Lonazolac calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02968MIG. Most nations, for tariff and trade purposes, schedule lonazolac calcium under HS 29331990 and SITC 51571. As of Q4 2014, LONAZOLAC CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)N2CC(C(N2)C3CCC(CC3)CL)CC(=O)[O-].C1CCC(CC1)N2CC(C(N2)C3CCC(CC3)CL)CC(=O)[O-].[CA+2].
This classification denotes a radiosensitizing agent and multidrug resistance modulator with the molecular formula C15H10Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U78804BIDR, chemically known as 1h-indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)- (9ci) but generally known as lonidamine, which bears US NIH Compound Identifier 39562. European Medicines Agency schedules Lonidamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08571MIG. The term LONIDAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules lonidamine in its Anatomical Therapeutic Chemical (ATC) Classification. LONIDAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lonidamine under HS 29339990 and SITC 51577. As of Q4 2014, LONIDAMINE remains the US FDA Preferred Term for this commodity. Lonidamine bears US NLM identifiers UMLS ID C0065175 and NCI Concept Code C1146. SMILES: CLC1C(CN2NC(C3C2CCCC3)C(=O)O)CCC(CL)C1.
This classification denotes an opioid and antidiarrheal agent with the molecular formula C29H33ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X9OC3H4II, chemically known as 4-(4-chlorophenyl)-n,n-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide but generally known as loperamide, which bears US NIH Compound Identifier 3955. European Medicines Agency schedules Loperamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08572MIG. The term LOPERAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules loperamide in its Anatomical Therapeutic Chemical (ATC) Classification. LOPERAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loperamide under HS 29333999 and SITC 51574. As of Q4 2014, LOPERAMIDE remains the US FDA Preferred Term for this commodity. Loperamide bears US NLM identifiers UMLS ID C0023992 and NCI Concept Code C618. SMILES: CLC1CCC(C2(O)CCN(CC2)CCC(C2CCCCC2)(C2CCCCC2)C(=O)N(C)C)CC1.
This classification denotes an antidiarrheal agent with the molecular formula C29H33ClN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77TI35393C, chemically known as 4-(p-chlorophenyl)-4-hydroxy-n,n-dimethyl-alpha,alpha-diphenyl-1-piperidinebutyramide monohydrochloride but more generally known as loperamide hydrochloride, which bears US NIH Compound Identifier 71420. European Medicines Agency schedules Loperamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02969MIG. Most nations, for tariff and trade purposes, schedule loperamide hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, LOPERAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Loperamide hydrochloride bears US NLM identifiers UMLS ID C0282221 and NCI Concept Code C1584. SMILES: CN(C)C(=O)C(CCN1CCC(CC1)(C2CCC(CC2)CL)O)(C3CCCCC3)C4CCCCC4.CL.
This classification denotes an opioid and antidiarrheal agent with the molecular formula C29H33ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X9OC3H4II, chemically known as 4-(4-chlorophenyl)-n,n-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide but generally known as loperamide, which bears US NIH Compound Identifier 3955. European Medicines Agency schedules Loperamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08572MIG. The term LOPERAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules loperamide in its Anatomical Therapeutic Chemical (ATC) Classification. LOPERAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loperamide oxide under HS 29333999 and SITC 51574. SMILES: CLC1CCC(C2(O)CCN(CC2)CCC(C2CCCCC2)(C2CCCCC2)C(=O)N(C)C)CC1.
This classification denotes an opioid and antidiarrheal agent with the molecular formula C29H33ClN2O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H3VOT77DE1, chemically known as 1-piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-n,n-dimethyl-alpha,alpha-diphenyl-, 1-oxide, (e)- but more generally known as loperamide oxide, which bears US NIH Compound Identifier 71421. European Medicines Agency schedules Loperamide oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08573MIG. World Health Organization schedules loperamide oxide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule loperamide oxide monohydrate under HS 29333999. As of Q4 2014, LOPERAMIDE OXIDE MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C(=O)C(C1CCCCC1)(C2CCCCC2)CC[N@+]3(CC[C@](CC3)(O)C4CCC(CC4)CL)[O-])C.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.
This classification denotes a protease inhibitor with the molecular formula C37H48N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2494G1JF75, chemically known as 1(2h)-pyrimidineacetamide, n-((1s,3s,4s)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphas)- but generally known as lopinavir, which bears US NIH Compound Identifier 92727. European Medicines Agency schedules Lopinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02970MIG. The term LOPINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules lopinavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lopinavir under HS 29335995 and SITC 51576. As of Q4 2014, LOPINAVIR remains the US FDA Preferred Term for this commodity. Lopinavir bears US NLM identifiers UMLS ID C0674432 and NCI Concept Code C2095. SMILES: OC(CC(NC(=O)C(N1CCCNC1=O)C(C)C)Cc1ccccc1)C(NC(=O)COc1c(cccc1C)C)Cc1ccccc1.
Definition: This classification denotes a combination drug for treatment of HIV. The first component, LOPINAVIR is a protease inhibitor with a US FDA Unique Ingredient Identifier of 2494G1JF75. LOPINAVIR is an International Non-Proprietary Name or INN. The second component, RITONAVIR, is a pharmacokinetic booster with a US FDA Unique Ingredient Identifier of O3J8G9O825. RITONAVIR is an International Non-Proprietary Name or INN.
This classification denotes a benzodiazepine with the molecular formula C23H21ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 759N8462G8, chemically known as 6-(2-chlorophenyl)-2,4-dihydro-2-((4-methyl-1-piperazinyl)methylene)-8-nitro-1h-imidazo(1,2-a) (1,4)benzodiazepin-1-one but generally known as loprazolam, which bears US NIH Compound Identifier 3033860. European Medicines Agency schedules Loprazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08576MIG. The term LOPRAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules loprazolam in its Anatomical Therapeutic Chemical (ATC) Classification. LOPRAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loprazolam under HS 29335500 and SITC 51576. As of Q4 2014, LOPRAZOLAM remains the US FDA Preferred Term for this commodity. Loprazolam bears US NLM identifiers UMLS ID C0077013 and NCI Concept Code C66032. SMILES: CLC1C(C2=NCC3=N/C(=C\N4CCN(CC4)C)C(=O)N3C3C2CC([N](=O)O)CC3)CCCC1.
This classification denotes a benzodiazepine with the molecular formula C23H21ClN6O3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VKF8383J65, chemically known as 1h-imidazo(1,2-a)(1,4)benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-((4-methyl-1-piperazinyl)methylene)-8-nitro-, (2z)-, methanesulfonate (1:1), but more generally known as loprazolam mesylate, which bears US NIH Compound Identifier 6917853. European Medicines Agency schedules loprazolam mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08576MIG. Most nations, for tariff purposes, schedule loprazolam mesylate under HS 29335500. SMILES: CN1CCN(CC1)/C=C\2/C(=O)N3C4CCC(CC4C(=NCC3=N2)C5CCCCC5CL)[N+](=O)[O-].CS(=O)(=O)O.
This classification denotes a benzodiazepine with the molecular formula C23H21ClN6O3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VKF8383J65, chemically known as 1h-imidazo(1,2-a)(1,4)benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-((4-methyl-1-piperazinyl)methylene)-8-nitro-, (2z)-, methanesulfonate (1:1), but more generally known as loprazolam methanesulfonate, which bears US NIH Compound Identifier 3036679. European Medicines Agency schedules loprazolam methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08576MIG. Most nations, for tariff purposes, schedule loprazolam methanesulfonate under HS 29335500. SMILES: CN1CCN(CC1)/C=C\2/C(=O)N3C4CCC(CC4C(=NCC3=N2)C5CCCCC5CL)[N+](=O)[O-].CS(=O)(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H16ClN3O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X11EVM5SU, chemically known as 1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6r-(6alpha,7beta(r*)))- but generally known as loracarbef, which bears US NIH Compound Identifier 3956. European Medicines Agency schedules Loracarbef in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08578MIG. World Health Organization schedules loracarbef in its Anatomical Therapeutic Chemical (ATC) Classification. LORACARBEF is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loracarbef under HS 29419000 and SITC 54139. As of Q4 2014, LORACARBEF remains the US FDA Preferred Term for this commodity. Loracarbef bears US NLM identifiers UMLS ID C0721422 and NCI Concept Code C47588. SMILES: CLC1=C(N2C(C(NC(=O)C(N)C3CCCCC3)C2=O)CC1)C(=O)O.
This classification denotes a cephalosporin antibiotic with the molecular formula C16H16ClN3O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X11EVM5SU, chemically known as 1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, monohydrate, (6r-(6.alpha.,7.beta.(r*)))-, but more generally known as loracarbef monohydrate, which bears US NIH Compound Identifier 60746. European Medicines Agency schedules loracarbef monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08578MIG. Most nations, for tariff purposes, schedule loracarbef monohydrate under HS 29419000. SMILES: C1CCC(CC1)[C@H](C(=O)N[C@H]2[C@H]3CCC(=C(N3C2=O)C(=O)O)CL)N.O.
This classification denotes an anti-arrhythmia agent with the molecular formula C22H27ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F96VX65849, chemically known as ajmalan-17,21-diol, 17-(chloroacetate) but more generally known as lorajmine, which bears US NIH Compound Identifier 92090. European Medicines Agency schedules Lorajmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08579MIG. World Health Organization schedules lorajmine in its Anatomical Therapeutic Chemical (ATC) Classification. LORAJMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule lorajmine under HS 29399900 and SITC 54149. As of Q4 2014, LORAJMINE remains US FDA's Preferred Term for this commodity. SMILES: CLCOC(=O)C1C23C(N(C4C3CCCC4)C)C3N4C(C1C(C3)C(C4O)CC)C2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H23ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7AJO3BO7QN, chemically known as 1-piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11h-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester but generally known as loratadine, which bears US NIH Compound Identifier 3957. European Medicines Agency schedules Loratadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08581MIG. The term LORATADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules loratadine in its Anatomical Therapeutic Chemical (ATC) Classification. LORATADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loratadine under HS 29333999 and SITC 51574. As of Q4 2014, LORATADINE remains the US FDA Preferred Term for this commodity. Loratadine bears US NLM identifiers UMLS ID C0065180 and NCI Concept Code C29162. SMILES: CLC1CC2C(/C(=C3/CCN(CC3)C(=O)OCC)C3NCCCC3CC2)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a benzodiazepine and antiemetic agent with the molecular formula C15H10Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O26FZP769L, chemically known as 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2h-1,4-benzodiazepin-2-one but generally known as lorazepam, which bears US NIH Compound Identifier 3958. European Medicines Agency schedules Lorazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08582MIG. The term LORAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules lorazepam in its Anatomical Therapeutic Chemical (ATC) Classification. LORAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lorazepam under HS 29339190 and SITC 51577. As of Q4 2014, LORAZEPAM remains the US FDA Preferred Term for this commodity. Lorazepam bears US NLM identifiers UMLS ID C0699194 and NCI Concept Code C619. SMILES: CLC1CC2C(=NC(O)C(=O)NC2CC1)C1C(CL)CCCC1.
This classification denotes a benzodiazepine and antiemetic agent with the molecular formula C21H18Cl2N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0G8I56129, chemically known as .beta.-d-glucopyranosiduronic acid, 7-chloro-5-(2-chlorophenyl)-2,3-dihydro-2-oxo-1h-1,4-benzodiazepin-3-yl, but more generally known as lorazepam glucuronide, which bears US NIH Compound Identifier 62966. European Medicines Agency schedules lorazepam glucuronide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08582MIG. Most nations, for tariff purposes, schedule lorazepam glucuronide under HS 29339190. SMILES: C1CCC(C(C1)C2=NC(C(=O)NC3C2CC(CC3)CL)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)CL.
This classification denotes an antiarrhythmic agent with the molecular formula C22H27ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) KGJ2T0N7IQ, chemically known as r 15,889 but more generally known as lorcainide, which bears US NIH Compound Identifier 42884. European Medicines Agency schedules Lorcainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08584MIG. The term LORCAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules lorcainide in its Anatomical Therapeutic Chemical (ATC) Classification. LORCAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule lorcainide under HS 29333999 and SITC 51574. As of Q4 2014, LORCAINIDE remains US FDA's Preferred Term for this commodity. Lorcainide bears US NLM identifiers UMLS ID C0065183 and NCI Concept Code C83894. SMILES: CLC1CCC(N(C2CCN(CC2)C(C)C)C(=O)CC2CCCCC2)CC1.
This classification denotes an antiarrhythmic agent with the molecular formula C22H27ClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1T1S98ONM1, chemically known as benzeneacetamide, n-(4-chlorophenyl)-n-(1-(1-methylethyl)-4-piperidinyl)-, monohydrochloride but more generally known as lorcainide hydrochloride, which bears US NIH Compound Identifier 42883. European Medicines Agency schedules Lorcainide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02973MIG. Most nations, for tariff and trade purposes, schedule lorcainide hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, LORCAINIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lorcainide hydrochloride bears US NLM identifiers UMLS ID C1881445 and NCI Concept Code C66034. SMILES: CC(C)N1CCC(CC1)N(C2CCC(CC2)CL)C(=O)CC3CCCCC3.CL.
This classification denotes an anticonvulsant agent with the molecular formula C10H6Cl3N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DJ32STZ5W, chemically known as 1h-1,2,4-triazole, 1-(2-chloro-2-(2,4-dichlorophenyl)ethenyl)-, (z)- but generally known as loreclezole, which bears US NIH Compound Identifier 3034012. European Medicines Agency schedules Loreclezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08586MIG. The term LORECLEZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). LORECLEZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loreclezole under HS 29339990 and SITC 51577. As of Q4 2014, LORECLEZOLE remains the US FDA Preferred Term for this commodity. Loreclezole bears US NLM identifiers UMLS ID C0083257 and NCI Concept Code C66036. SMILES: C1=CC(=C(C=C1CL)CL)/C(=C/N2C=NC=N2)/CL.
This classification denotes a benzodiazepine with the molecular formula C16H12Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GU56C842ZA, chemically known as 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2h-1,4-benzodiazepin-2-one but generally known as lormetazepam, which bears US NIH Compound Identifier 13314. European Medicines Agency schedules Lormetazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08588MIG. The term LORMETAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules lormetazepam in its Anatomical Therapeutic Chemical (ATC) Classification. LORMETAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lormetazepam under HS 29339190 and SITC 51577. As of Q4 2014, LORMETAZEPAM remains the US FDA Preferred Term for this commodity. Lormetazepam bears US NLM identifiers UMLS ID C0065185 and NCI Concept Code C87673. SMILES: CLC1CC2C(N(C(=O)C(O)N=C2C2C(CL)CCCC2)C)CC1.
L-ornithine-L-aspartate (LOLA) is a salt of two nonessential L-amino acids: ornithine and aspartic acid. It is used as a medicinal product to lower blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H10ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ER09126G7A, chemically known as 6-chloro-4-hydroxy-2-methyl-n-2-pyridyl-2h-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide but generally known as lornoxicam, which bears US NIH Compound Identifier 5282204. European Medicines Agency schedules Lornoxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08589MIG. The term LORNOXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules lornoxicam in its Anatomical Therapeutic Chemical (ATC) Classification. LORNOXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lornoxicam under HS 29349990 and SITC 51579. As of Q4 2014, LORNOXICAM remains the US FDA Preferred Term for this commodity. Lornoxicam bears US NLM identifiers UMLS ID C0055477 and NCI Concept Code C72140. SMILES: CLC1SC2C(S(=O)(=O)N(/C(=C(/O)NC3NCCCC3)C2=O)C)C1.
This classification denotes an antipsychotic agent with the molecular formula C21H26F3N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M14O7T47Q, chemically known as (- )-cis-5,5a,6,7,8,8a-hexahydro-3-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)cyclopenta(3,4)pyrrolo(2,1-c)-s-triazole but generally known as lorpiprazole, which bears US NIH Compound Identifier 3045380. European Medicines Agency schedules Lorpiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08590MIG. The term LORPIPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). LORPIPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lorpiprazole under HS 29335995 and SITC 51576. As of Q4 2014, LORPIPRAZOLE remains the US FDA Preferred Term for this commodity. Lorpiprazole bears US NLM identifiers UMLS ID C2825691 and NCI Concept Code C81579. SMILES: FC(F)(F)C1CC(N2CCN(CCC3N4CC5C(CCC5)C4NN3)CC2)CCC1.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C22H23ClN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JMS50MPO89, chemically known as 1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2-(1h-tetrazol-5-yl)(1,1- biphenyl)-4-yl)methyl)- but generally known as losartan, which bears US NIH Compound Identifier 3961. European Medicines Agency schedules Losartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08593MIG. The term LOSARTAN is an International Non-Proprietary Name. World Health Organization schedules losartan in its Anatomical Therapeutic Chemical (ATC) Classification. LOSARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule losartan under HS 29332990 and SITC 51573. As of Q4 2014, LOSARTAN remains the US FDA Preferred Term for this commodity. Losartan bears US NLM identifiers UMLS ID C0126174 and NCI Concept Code C66869. SMILES: Clc1nc(n(Cc2ccc(cc2)c2c(cccc2)c2n[nH]nn2)c1CO)CCCC.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C22H22ClN6O.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3ST302B24A, chemically known as 2-butyl-4-chloro-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)imidazole-5-methanol, monopotassium salt but more generally known as losartan potassium, which bears US NIH Compound Identifier 60771. European Medicines Agency schedules Losartan potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02974MIG. Most nations, for tariff and trade purposes, schedule losartan potassium under HS 29332990 and SITC 51573. As of Q4 2014, LOSARTAN POTASSIUM remains US FDA's Preferred Term for this commodity. Losartan potassium bears US NLM identifiers UMLS ID C0700492 and NCI Concept Code C29165. SMILES: CCCCC1NC(C(N1CC2CCC(CC2)C3CCCCC3C4[N-]NNN4)CO)CL.[K+].
This classification denotes an anticonvulsant agent with the molecular formula C12H11ClO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84R8O3QM2G, chemically known as 2(5h)-furanone, 5-((2-chlorophenyl)hydroxymethyl)-4-methoxy-, (r*,s*)- but generally known as losigamone, which bears US NIH Compound Identifier 60572. European Medicines Agency schedules Losigamone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08594MIG. The term LOSIGAMONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). LOSIGAMONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, LOSIGAMONE remains the US FDA Preferred Term for this commodity. Losigamone bears US NLM identifiers UMLS ID C0083259 and NCI Concept Code C90707. SMILES: COC1=CC(=O)OC1C(C2=CC=CC=C2CL)O.
This classification denotes an antidepressant agent with the molecular formula C19H20ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IX8TM6153H, chemically known as (- )-(3a alpha,4alpha,9a alpha)-6-chloro-3a,4,9,9a-tetrahydro-2-methyl-4-phenylbenz(f)isoindoline. but generally known as losindole, which bears US NIH Compound Identifier 3045392. European Medicines Agency schedules Losindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08595MIG. The term LOSINDOLE is an International Non-Proprietary Name. LOSINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule losindole under HS 29339990 and SITC 51577. As of Q4 2014, LOSINDOLE remains the US FDA Preferred Term for this commodity. Losindole bears US NLM identifiers UMLS ID C2825657 and NCI Concept Code C81489. SMILES: Clc1cc2C(C3C(CN(C3)C)Cc2cc1)c1ccccc1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H15ClO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GRY6X9550R, chemically known as propionic acid, 2-(3-(p-chlorobenzoyl)-o-tolyloxy)- but generally known as losmiprofen, which bears US NIH Compound Identifier 68922. European Medicines Agency schedules Losmiprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08596MIG. The term LOSMIPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). LOSMIPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule losmiprofen under HS 29189900 and SITC 51396. As of Q4 2014, LOSMIPROFEN remains the US FDA Preferred Term for this commodity. Losmiprofen bears US NLM identifiers UMLS ID C2825255 and NCI Concept Code C80562. SMILES: CLC1CCC(C(=O)C2C(C(OC(C)C(=O)O)CCC2)C)CC1.
This classification denotes an anthrapyrazole antibiotic with the molecular formula C22H27N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47KPH00809, chemically known as anthra(1,9-cd)pyrazol-6(2h)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)- but generally known as losoxantrone, which bears US NIH Compound Identifier 72116. European Medicines Agency schedules Losoxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08597MIG. The term LOSOXANTRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). LOSOXANTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule losoxantrone under HS 29339990 and SITC 51577. As of Q4 2014, LOSOXANTRONE remains the US FDA Preferred Term for this commodity. Losoxantrone bears US NLM identifiers UMLS ID C0245032 and NCI Concept Code C1521. SMILES: O=C1C2C3C(N(NC3C3C1C(O)CCC3)CCNCCO)CCC2NCCNCCO.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8CBU6KR16. European Medicines Agency schedules Loteprednol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08599MIG. Loteprednol generally arises in the molecular formula C21H27CLO5. The term LOTEPREDNOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) LOTEPREDNOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loteprednol under HS 29372900 and SITC 54153. As of Q4 2014, LOTEPREDNOL remains the US FDA Preferred Term for this commodity. Loteprednol bears US NLM identifiers UMLS ID C0772364 and NCI Concept Code C72818. SMILES: CC12CC(C3C(C1CCC2(C(=O)OCCL)O)CCC4=CC(=O)C=CC34C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31ClO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YEH1EZ96K6, chemically known as chloromethyl 17a-ethoxycarbonyloxy-11b-hydroxyandrosta-1,4-diene-3-one-17b-carbo but more generally known as loteprednol etabonate, which bears US NIH Compound Identifier 54808. European Medicines Agency schedules Loteprednol etabonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14390MIG. Most nations, for tariff and trade purposes, schedule loteprednol etabonate under HS 29372900 and SITC 54153. As of Q4 2014, LOTEPREDNOL ETABONATE remains US FDA's Preferred Term for this commodity. Loteprednol etabonate bears US NLM identifiers UMLS ID C0126177 and NCI Concept Code C47589. SMILES: CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H9Cl3N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B3TF200TI, chemically known as 2,2,2-trichloroethyl (4-phenyl-2-thiazolyl)carbamate but generally known as lotifazole, which bears US NIH Compound Identifier 68905. European Medicines Agency schedules Lotifazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08600MIG. The term LOTIFAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). LOTIFAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lotifazole under HS 29341000 and SITC 51579. As of Q4 2014, LOTIFAZOLE remains the US FDA Preferred Term for this commodity. Lotifazole bears US NLM identifiers UMLS ID C0164084 and NCI Concept Code C66037. SMILES: CLC(CL)(CL)COC(=O)NC1SCC(N1)C1CCCCC1.
This classification denotes an antiplatelet agent with the molecular formula C23H32N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KLQ306I83X, chemically known as 1h-1,4-benzodiazepine-2-acetic acid, 7-((4,4-bipiperidin)-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-, (2s)- but generally known as lotrafiban, which bears US NIH Compound Identifier 80274. European Medicines Agency schedules Lotrafiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08601MIG. The term LOTRAFIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). LOTRAFIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lotrafiban under HS 29333999 and SITC 51574. As of Q4 2014, LOTRAFIBAN remains the US FDA Preferred Term for this commodity. Lotrafiban bears US NLM identifiers UMLS ID C0960422 and NCI Concept Code C81574. SMILES: O=C(N1CCC(C2CCNCC2)CC1)C1CC2C(NC(C(=O)N(C2)C)CC(=O)O)CC1.
This classification denotes an antiplatelet agent C23H32N4O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GSV7V79C63, chemically known as (s)-2,3,4,5-tetrahydro-4-methyl-3-oxo-7-((4-(4-piperidyl)piperidino)carbonyl)-1h-1,4-benzodiazepine-2-acetic acid, monohydrochloride, but more generally known as lotrafiban hydrochloride, which bears US NIH Compound Identifier 80275. Most nations, for tariff and trade purposes, schedule lotrafiban hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, LOTRAFIBAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lotrafiban hydrochloride bears US NLM identifiers UMLS ID C1259239 and NCI Concept Code C81572. SMILES: CN1CC2CC(CCC2N[C@H](C1=O)CC(=O)O)C(=O)N3CCC(CC3)C4CCNCC4.CL.
This classification denotes a naphthalene compound and hmg-coa reductase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9LHU78OQFD. European Medicines Agency schedules Lovastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08604MIG. Lovastatin generally arises in the molecular formula C24H36O5. The term LOVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) LOVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, LOVASTATIN remains the US FDA Preferred Term for this commodity. Lovastatin bears US NLM identifiers UMLS ID C0024027 and NCI Concept Code C620. SMILES: O(C1C2C(C(C=CC2=CC(C1)C)C)CCC1OC(=O)CC(O)C1)C(=O)C(CC)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV350. This VA Drug Class (CV350) classifies this compound as belonging to the group ANTILIPEMIC AGENTS.
This classification denotes an immunosuppressant with the molecular formula C14H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 746YWK1B07, chemically known as cyclohexanecarboxylic acid, 1-methyl-4-(4-methylpentyl)-, cis- but more generally known as loxanast, which bears US NIH Compound Identifier 68890. European Medicines Agency schedules Loxanast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08606MIG. The term LOXANAST is an International Non-Proprietary Name. LOXANAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule loxanast under HS 29162000 and SITC 51379. As of Q4 2014, LOXANAST remains US FDA's Preferred Term for this commodity. Loxanast bears US NLM identifiers UMLS ID C2825487 and NCI Concept Code C81164. SMILES: OC(=O)C1(CCC(CC1)CCCC(C)C)C.
This classification denotes an antipsychotic agent with the molecular formula C18H18ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LER583670J, chemically known as 1,4-butanedioic acid (succinic acid) but generally known as loxapine, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Loxapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08607MIG. The term LOXAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules loxapine in its Anatomical Therapeutic Chemical (ATC) Classification. LOXAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loxapine under HS 29349990 and SITC 51579. As of Q4 2014, LOXAPINE remains the US FDA Preferred Term for this commodity. Loxapine bears US NLM identifiers UMLS ID C0024056 and NCI Concept Code C61816. SMILES: OC(=O)CCC(=O)O.
This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C18H18ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 376MYL4MAL, chemically known as 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine monohydrochloride but more generally known as loxapine hydrochloride, which bears US NIH Compound Identifier 71400. European Medicines Agency schedules Loxapine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22686. Most nations, for tariff and trade purposes, schedule loxapine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, LOXAPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Loxapine hydrochloride bears US NLM identifiers UMLS ID C0304390 and NCI Concept Code C77574. SMILES: CN1CCN(CC1)C2=NC3CCCCC3OC4C2CC(CC4)CL.CL.
This classification denotes an antipsychotic agent with the molecular formula C18H18ClN3O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X59SG0MRYU, chemically known as 1,4-butanedioic acid (succinic acid) but more generally known as loxapine succinate, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Loxapine succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02977MIG. Most nations, for tariff and trade purposes, schedule loxapine succinate under HS 29349990 and SITC 51579. As of Q4 2014, LOXAPINE SUCCINATE remains US FDA's Preferred Term for this commodity. Loxapine succinate bears US NLM identifiers UMLS ID C0024057 and NCI Concept Code C47590. SMILES: CN1CCN(CC1)C2=NC3CCCCC3OC4C2CC(CC4)CL.C(CC(=O)O)C(=O)O.
This classification denotes a cyclooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3583H0GZAP. European Medicines Agency schedules Loxoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08609MIG. Loxoprofen generally arises in the molecular formula C15H18O3. The term LOXOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) LOXOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loxoprofen under HS 29183000 and SITC 51395. As of Q4 2014, LOXOPROFEN remains the US FDA Preferred Term for this commodity. Loxoprofen bears US NLM identifiers UMLS ID C0065199 and NCI Concept Code C81064. SMILES: O=C1C(CCC1)CC1CCC(CC1)C(C)C(=O)O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H17O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NDC2M7399S, chemically known as benzeneacetic acid, alpha-methyl-4-((2-oxocyclopentyl)methyl)-, sodium salt, dihydrate but more generally known as loxoprofen sodium, which bears US NIH Compound Identifier 157322. European Medicines Agency schedules Loxoprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02978MIG. Most nations, for tariff and trade purposes, schedule loxoprofen sodium under HS 29183000 and SITC 51395. As of Q4 2014, LOXOPROFEN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCC(CC1)CC2CCCC2=O)C(=O)[O-].[NA+].
This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H17O3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z2DR42L11Y, chemically known as benzeneacetic acid, .alpha.-methyl-4-((2-oxocyclopentyl)methyl)-, sodium salt, hydrate (1:1:2), but more generally known as loxoprofen sodium dihydrate, which bears US NIH Compound Identifier 157322. European Medicines Agency schedules loxoprofen sodium dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08609MIG. Most nations, for tariff purposes, schedule loxoprofen sodium dihydrate under HS 29183000. SMILES: CC(C1CCC(CC1)CC2CCCC2=O)C(=O)[O-].O.O.[NA+].
This classification denotes an anti-ulcer agent with the molecular formula C10H13ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 677AYV0R9N, chemically known as urea, n-(m-chlorobenzyl)-n-ethyl- but generally known as lozilurea, which bears US NIH Compound Identifier 68907. European Medicines Agency schedules Lozilurea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08611MIG. The term LOZILUREA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). LOZILUREA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lozilurea under HS 29242190 and SITC 51473. As of Q4 2014, LOZILUREA remains the US FDA Preferred Term for this commodity. Lozilurea bears US NLM identifiers UMLS ID C0620245 and NCI Concept Code C66039. SMILES: CCNC(=O)NCC1=CC(=CC=C1)CL.
This classification denotes a prostaglandin analogue with the molecular formula C20H32F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7662KG2R6K, chemically known as prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)- but generally known as lubiprostone, which bears US NIH Compound Identifier 157920. European Medicines Agency schedules Lubiprostone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32077. The term LUBIPROSTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 2, 2003, List 49). World Health Organization schedules lubiprostone in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lubiprostone under HS 29375000 and SITC 54156. As of Q4 2014, LUBIPROSTONE remains the US FDA Preferred Term for this commodity. Lubiprostone bears US NLM identifiers UMLS ID C1684405 and NCI Concept Code C66040. SMILES: FC(F)(C1(OC2C(C(C(=O)C2)CCCCCCC(=O)O)CC1)O)CCCC.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H20FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GS8D070P7W, chemically known as (- )-n-((8-fluoro-2,3-dihydro-1-methyl-5-phenyl-1h-1,4-benzodiazepin-2-yl)-methyl)-3-furamide. but generally known as lufuradom, which bears US NIH Compound Identifier 3045400. European Medicines Agency schedules Lufuradom in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08617MIG. The term LUFURADOM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). LUFURADOM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lufuradom under HS 29349990 and SITC 51579. As of Q4 2014, LUFURADOM remains the US FDA Preferred Term for this commodity. Lufuradom bears US NLM identifiers UMLS ID C2825256 and NCI Concept Code C80563. SMILES: FC1CC2N(C(CN=C(C2CC1)C1CCCCC1)CNC(=O)C1CCOC1)C.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13ClFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V91T9204HU, chemically known as benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl- but generally known as lumiracoxib, which bears US NIH Compound Identifier 151166. European Medicines Agency schedules Lumiracoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21406. The term LUMIRACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 2, 2003, List 49). World Health Organization schedules lumiracoxib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lumiracoxib under HS 29224995 and SITC 51465. As of Q4 2014, LUMIRACOXIB remains the US FDA Preferred Term for this commodity. Lumiracoxib bears US NLM identifiers UMLS ID C1176415 and NCI Concept Code C66041. SMILES: CLC1C(NC2C(CC(CC2)C)CC(=O)O)C(F)CCC1.
This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C28H36N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22IC88528T, chemically known as (3ar,4s,7r,7as)-2-((1r,2r)-2-(4-(1,2-benzothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2h-isoindole-1,3-dione but generally known as lurasidone, which bears US NIH Compound Identifier 213046. European Medicines Agency schedules Lurasidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32185. The term LURASIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). Most nations schedule lurasidone under HS 29341000 and SITC 51579. As of Q4 2014, LURASIDONE remains the US FDA Preferred Term for this commodity. Lurasidone bears US NLM identifiers UMLS ID C2003424 and NCI Concept Code C77575. SMILES: S1NC(N2CCN(CC3C(CN4C(=O)C5C6CC(C5C4=O)CC6)CCCC3)CC2)C2C1CCCC2.
This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0P4I5851I. European Medicines Agency schedules Lurasidone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34204. Lurasidone hydrochloride generally arises in the molecular formula C28H36N4O2S.CLH. The term 'lurasidone hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule lurasidone hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, LURASIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lurasidone hydrochloride bears US NLM identifiers UMLS ID C2003425 and NCI Concept Code C77576. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)C[C@@H]4CCCC[C@H]4CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O.CL.
This classification denotes an antipsychotic agent with the molecular formula C22H21N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5KTD2O86CB, chemically known as 3-(2-(3,4-dihydrobenzofuro(3,2-c)pyridin-2(1h)-yl)ethyl)-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one. but generally known as lusaperidone, which bears US NIH Compound Identifier 3045401. The term LUSAPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule lusaperidone under HS 29349990 and SITC 51579. As of Q4 2014, LUSAPERIDONE remains the US FDA Preferred Term for this commodity. Lusaperidone bears US NLM identifiers UMLS ID C2983866 and NCI Concept Code C90760. SMILES: CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC4=C(C3)C5=CC=CC=C5O4.
Lutropin alfa is a recombinant human luteinizing hormone for the treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency.
Lutropin (LH)/Follitropin (FSH) is indicated for the stimulation of follicular development in women with severe deficiency of LH and FSH.
This classification denotes a tetracycline antibiotic with the molecular formula C29H38N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D6EM3S13P, chemically known as 2-(amino-hydroxy-methylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione but generally known as lymecycline, which bears US NIH Compound Identifier 5280963. European Medicines Agency schedules Lymecycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08625MIG. The term LYMECYCLINE is an International Non-Proprietary Name. World Health Organization schedules lymecycline in its Anatomical Therapeutic Chemical (ATC) Classification. LYMECYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lymecycline under HS 29413000 and SITC 54133. As of Q4 2014, LYMECYCLINE remains the US FDA Preferred Term for this commodity. Lymecycline bears US NLM identifiers UMLS ID C0024200 and NCI Concept Code C76991. SMILES: CLC1C2C(O)(C3CC4C(O)(C(=O)C3=C(O)C2C(O)CC1)C(=O)/C(=C(\O)N)C(=O)C4N(C)C)C.
This classification denotes vaccines for an infectious disease caused by a spirochete, borrelia burgdorferi, which is transmitted chiefly by Ixodes dammini and pacificus ticks in the United States and Ixodes ricinis in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. This disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut.
This classification denotes an a synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive which the molecular formula C20H28O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N2Z8ALG4U5, chemically known as (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol but more commonly known as lynoestrenol, which bears US NIH Compound Identifier 5857. SMILES: CC12CCC3C(C1CCC2(C#C)O)CCC4=CCCCC34.
This classification denotes an antidiurectic hormone analogue with the molecular formula C46H65N13O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7CZF3L922Y, chemically known as vasopressin, 8-l-lysine- but generally known as lypressin, which bears US NIH Compound Identifier 5772. European Medicines Agency schedules Lypressin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08627MIG. The term LYPRESSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules lypressin in its Anatomical Therapeutic Chemical (ATC) Classification. LYPRESSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lypressin under HS 29371900 and SITC 54154. As of Q4 2014, LYPRESSIN remains the US FDA Preferred Term for this commodity. Lypressin bears US NLM identifiers UMLS ID C0024328 and NCI Concept Code C66044. SMILES: S1SCC(N)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CCCCN)C(=O)NCC(=O)N)C1)CC(=O)N)CCC(=O)N)CC1CCCCC1)CC1CCC(O)CC1.
This classification denotes a serotonin antagonist and serotonin agonist with the molecular formula C20H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NA5SWF92O, chemically known as d-lysergic acid n,n-diethylamide but generally known as lysergide, which bears US NIH Compound Identifier 3981. European Medicines Agency schedules Lysergide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08628MIG. The term LYSERGIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). LYSERGIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lysergide under HS 29396900 and SITC 54146. As of Q4 2014, LYSERGIDE remains the US FDA Preferred Term for this commodity. Lysergide bears US NLM identifiers UMLS ID C0024334 and NCI Concept Code C76104. SMILES: O=C(N(CC)CC)C1CN(C2C(=C1)c1c3c(C2)c[nH]c3ccc1)C.
This classification denotes a non-morphinic analgesic with the molecular formula C13H11ClN2O2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06PW4M190R, chemically known as 3-pyridinecarboxylic acid, 2-((3-chloro-2-methylphenyl)amino)-, compd. with l-lysine (1:1) but generally known as lysine clonixinate, which bears US NIH Compound Identifier 3080836. European Medicines Agency schedules Lysine clonixinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01363MIG. SMILES: CC1=C(C=CC=C1Cl)NC2=C(C=CC=N2)C(=O)O.C(CCN)CC(C(=O)O)N.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02B8S6J90B, chemically known as benzeneacetamide, n-(2-hydroxyethyl)-alpha-methyl-4-(2-methylpropyl)- but generally known as mabuprofen, which bears US NIH Compound Identifier 71261. European Medicines Agency schedules Mabuprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08630MIG. The term MABUPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). MABUPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mabuprofen under HS 29242995 and SITC 51479. As of Q4 2014, MABUPROFEN remains the US FDA Preferred Term for this commodity. Mabuprofen bears US NLM identifiers UMLS ID C1881504 and NCI Concept Code C66046. SMILES: O=C(NCCO)C(C1CCC(CC(C)C)CC1)C.
This classification denotes a beta-adrenergic agonist with the molecular formula C13H18ClF3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R4K19W6S7Q, chemically known as benzenemethanol, 4-amino-3-chloro-alpha-(((1,1-dimethylethyl)amino)methyl)-5-(trifluoromethyl)- but generally known as mabuterol, which bears US NIH Compound Identifier 3995. European Medicines Agency schedules Mabuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08631MIG. The term MABUTEROL is an International Non-Proprietary Name. MABUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mabuterol under HS 29221980 and SITC 51461. As of Q4 2014, MABUTEROL remains the US FDA Preferred Term for this commodity. Mabuterol bears US NLM identifiers UMLS ID C0065464 and NCI Concept Code C81647. SMILES: CLC1CC(C(O)CNC(C)(C)C)CC(C1N)C(F)(F)F.
Macitentan is an endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension.
This classification denotes a synthetic polymer with the molecular formula C2H6O2(C2H4O)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B697894SGQ. European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. The term polyethylene glycol 400 is an International Nomenclature of Cosmetic Ingredients designation. European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. Macrogol or polyethylene glycol bears US NLM identifiers UMLS ID C0032483 and NCI Concept Code C762. SMILES: COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO.
This classification denotes an anti-infective agent with the molecular formula C7H10N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58447S8P4L, chemically known as p-toluenesulfonamide, .alpha.-amino-, monohydrochloride but generally known as mafenide, which bears US NIH Compound Identifier 3998. European Medicines Agency schedules Mafenide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08633MIG. The term MAFENIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules mafenide in its Anatomical Therapeutic Chemical (ATC) Classification. MAFENIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mafenide under HS 29350090 and SITC 51580. As of Q4 2014, MAFENIDE remains the US FDA Preferred Term for this commodity. Mafenide bears US NLM identifiers UMLS ID C0024452 and NCI Concept Code C61819. SMILES: S(=O)(=O)(N)C1CCC(CC1)CN.
This classification denotes a topical anti-infective agent with the molecular formula C7H10N2O2S.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RQ6LP6Z0WY, chemically known as p-toluenesulfonamide, alpha-amino-, monoacetate but more generally known as mafenide acetate, which bears US NIH Compound Identifier 25590. European Medicines Agency schedules Mafenide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02998MIG. Most nations, for tariff and trade purposes, schedule mafenide acetate under HS 29350090 and SITC 51580. As of Q4 2014, MAFENIDE ACETATE remains US FDA's Preferred Term for this commodity. Mafenide acetate bears US NLM identifiers UMLS ID C0809894 and NCI Concept Code C47591. SMILES: CC(=O)O.C1CC(CCC1CN)S(=O)(=O)N.
This classification denotes a carbonic anhydrase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J751V0284. European Medicines Agency schedules Mafenide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02999MIG. Mafenide hydrochloride generally arises in the molecular formula C7H10N2O2S.CLH. The term 'mafenide hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation. Most nations, for tariff and trade purposes, schedule mafenide hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, MAFENIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mafenide hydrochloride bears US NLM identifiers UMLS ID C2698002 and NCI Concept Code C76107. SMILES: C1CC(CCC1CN)S(=O)(=O)N.CL.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D7UUO54C6N. European Medicines Agency schedules Mafoprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08634MIG. Mafoprazine generally arises in the molecular formula C22H28FN3O3. The term MAFOPRAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) MAFOPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mafoprazine under HS 29335995 and SITC 51576. As of Q4 2014, MAFOPRAZINE remains the US FDA Preferred Term for this commodity. Mafoprazine bears US NLM identifiers UMLS ID C0065505 and NCI Concept Code C66047. SMILES: FC1C(N2CCN(CC2)CCCOC2C(OC)CC(NC(=O)C)CC2)CCCC1.
This classification denotes a nitrogen mustard compound with the molecular formula C9H19Cl2N2O5PS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5970HH9923, chemically known as ethanesulfonic acid, 2-(((2r,4r)-2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl)thio)-, rel- but more generally known as mafosfamide, which bears US NIH Compound Identifier 104746. European Medicines Agency schedules Mafosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08635MIG. The term MAFOSFAMIDE is an International Non-Proprietary Name. MAFOSFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mafosfamide under HS 29349990 and SITC 51579. As of Q4 2014, MAFOSFAMIDE remains US FDA's Preferred Term for this commodity. Mafosfamide bears US NLM identifiers UMLS ID C0065506 and NCI Concept Code C1150. SMILES: CLCCN(P1(=O)OCCC(SCCS(=O)(=O)O)N1)CCCL.
This classification denotes a nitrogen mustard compound with the molecular formula C9H19Cl2N2O5PS2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HAC3DQ8PMS, chemically known as cis-2-((2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl)thio)ethane sulfonate p-oxide l-lysine, but more generally known as mafosfamide lysine, which bears US NIH Compound Identifier 5362268. European Medicines Agency schedules mafosfamide lysine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08635MIG. Most nations, for tariff purposes, schedule mafosfamide lysine under HS 29349990. SMILES: C1CO[P@@](=O)(N[C@H]1SCCS(=O)(=O)O)N(CCCL)CCCL.C(CCN)C[C@@H](C(=O)O)N.
This classification denotes an anti-ulcer agent with the molecular formula 5Al.10Mg.2O4S.31HO.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6V88E24N5T, chemically known as aluminum magnesium hydroxide sulfate, hydrate but generally known as magaldrate, which bears US NIH Compound Identifier 3086011. European Medicines Agency schedules Magaldrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08636MIG. The term MAGALDRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules magaldrate in its Anatomical Therapeutic Chemical (ATC) Classification. MAGALDRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule magaldrate under HS 28429080 and SITC 52389. As of Q4 2014, MAGALDRATE remains the US FDA Preferred Term for this commodity. Magaldrate bears US NLM identifiers UMLS ID C0065512 and NCI Concept Code C95958. SMILES: [OH-].[O-]S(=O)(=O)[O-].[MG+2].[AL].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA199. This VA Drug Class (GA199) classifies this compound as belonging to the group ANTACIDS, OTHER.
This classification denotes an electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0E53J927NA. European Medicines Agency schedules Magnesia carbonica in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34276. Magnesium carbonate generally arises in the molecular formula CO3.MG.H2O. The term 'magnesium carbonate' is a United States Homeopathic Pharmacopoeia Name designation. As of Q4 2014, MAGNESIUM CARBONATE remains the US FDA Preferred Term for this commodity. Magnesium carbonate bears US NLM identifiers UMLS ID C0065517 and NCI Concept Code C66048. SMILES: OC(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN460. This VA Drug Class (TN460) classifies this compound as belonging to the group MAGNESIUM.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a nutritional supplement with the molecular formula 2C6H11O7.Mg.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T42NAD2KHC, chemically known as gluconic acid, magnesium salt (2:1), d- but more generally known as magnesium gluconate, which bears US NIH Compound Identifier 19261. European Medicines Agency schedules Magnesium gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14425MIG. World Health Organization schedules magnesium gluconate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, MAGNESIUM GLUCONATE remains US FDA's Preferred Term for this commodity. Magnesium gluconate bears US NLM identifiers UMLS ID C0126777 and NCI Concept Code C76081. SMILES: C(C(C(C(C(C(=O)[O-])O)O)O)O)O.C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[Mg+2].
Magnesium hydroxide is an inorganic compound and naturally occurring mineral. It can be used as an antacid or a laxative.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a nutritional supplement and laxative, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3A3U0GI71G, chemically known as oxomagnesium, but generally known as magnesium oxide, which bears US NIH Compound Identifier 14792. European Medicines Agency schedules Magnesium oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14436MIG. Magnesium oxide generally arises in the molecular formula MGO. The term MAGNESIUM OXIDE is a United States Homeopathic Pharmacopoeia Name designation. As of Q4 2014, MAGNESIUM OXIDE remains the US FDA Preferred Term for this commodity. Magnesium oxide bears US NLM identifiers UMLS ID C0024477 and NCI Concept Code C29242. SMILES: O=[Mg].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT802. This VA Drug Class (VT802) classifies this compound as belonging to the group MULTIVITAMINS WITH MINERALS.
This classification denotes an iron supplement which generally arises in the molecular formula C10H12MgN2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V5PC588N7G, chemically known as magnesium;(2S)-5-oxopyrrolidine-2-carboxylate but generally known as magnesium pidolate, which bears US NIH Compound Identifier 18601084. European Medicines Agency schedules magnesium pidolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03045MIG. As of Q4 2014, MAGNESIUM PIDOLATE remains the US FDA Preferred Term for this commodity. SMILES: C1CC(=O)NC1C(=O)[O-].C1CC(=O)NC1C(=O)[O-].[Mg+2].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C7H5O3.Mg.4H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41728CY7UX, chemically known as magnesium, bis(2-(hydroxy-kappao)benzoato-kappao)-, (t-4)- but generally known as magnesium salicylate, which bears US NIH Compound Identifier 64738. European Medicines Agency schedules Magnesium salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14444MIG. As of Q4 2014, MAGNESIUM SALICYLATE remains the US FDA Preferred Term for this commodity. Magnesium salicylate bears US NLM identifiers UMLS ID C0126789 and NCI Concept Code C66050. SMILES: C1=CC=C(C(=C1)C(=O)O)[O-].C1=CC=C(C(=C1)C(=O)O)[O-].[MG+2].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA202. This VA Drug Class (GA202) classifies this compound as belonging to the group HYPEROSMOTIC LAXATIVES.
This classification denotes an antacid preparation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2E1CI501T. European Medicines Agency schedules Magnesium trisilicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14451MIG. Magnesium trisilicate generally arises in the molecular formula 2MG.O8SI3.H2O. The term 'magnesium trisilicate' is a European Pharmacopoeia designation. As of Q4 2014, MAGNESIUM TRISILICATE remains the US FDA Preferred Term for this commodity. Magnesium trisilicate bears US NLM identifiers UMLS ID C0065533 and NCI Concept Code C66052. SMILES: [O-][SI](=O)O[SI]([O-])([O-])O[SI](=O)[O-].[MG+2].[MG+2].
This classification denotes a pediculocide with the molecular formula C10H19O6PS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U5N7SU872W, chemically known as 1, 2-di(ethoxycarbonyl)ethyl o,o-dimethyl phosphordithioates but generally known as malathion, which bears US NIH Compound Identifier 4004. European Medicines Agency schedules Malathion in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14453MIG. World Health Organization schedules malathion in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule malathion topical antiparasitic under HS 29309000 and SITC 51549. SMILES: CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC.
This classification denotes a urinary anti-infective agent with the molecular formula C8H8O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NH496X0UJX, chemically known as glycolic acid, phenyl- but generally known as mandelic acid, which bears US NIH Compound Identifier 1292. European Medicines Agency schedules Mandelic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14462MIG. World Health Organization schedules mandelic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule mandelic acid under HS 29181900 and SITC 51392. As of Q4 2014, MANDELIC ACID remains the US FDA Preferred Term for this commodity. Mandelic acid bears US NLM identifiers UMLS ID C0065636 and NCI Concept Code C61822. SMILES: OC(c1ccccc1)C(=O)O.
This classification denotes a contrast media C22H26N4O14P2.H+.Mn.3Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 129FW80TG4, chemically known as mangafodipir trisodium, anhydrous, but more generally known as mangafodipir trisodium, which bears U.S. National Institutes of Health Compound Identifier 160036. European Medicines Agency schedules SUB12529MIGin its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12529MIG. Most nations schedule mangafodipir trisodium under HS 29333999 and SITC 51574. Mangafodipir trisodium bears US NLM identifiers UMLS ID C0067297 and NCI Concept Code C66053. SMILES: As of Q4 2014, MANGAFODIPIR TRISODIUM remains the US FDA Preferred Term for this commodity.
This classification denotes a calcium channel blocker with the molecular formula C35H38N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6O4754US88, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl ester but generally known as manidipine, which bears US NIH Compound Identifier 4008. European Medicines Agency schedules Manidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08641MIG. World Health Organization schedules manidipine in its Anatomical Therapeutic Chemical (ATC) Classification. MANIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule manidipine under HS 29335995 and SITC 51576. As of Q4 2014, MANIDIPINE remains the US FDA Preferred Term for this commodity. Manidipine bears US NLM identifiers UMLS ID C0065656 and NCI Concept Code C81682. SMILES: O(CCN1CCN(CC1)C(c1ccccc1)c1ccccc1)C(=O)C1=C(NC(=C(C1c1cc([N](=O)O)ccc1)C(=O)OC)C)C.
This classification denotes a calcium channel blocker with the molecular formula C35H38N4O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZL507UZ6QL, chemically known as 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl (+/-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinecarboxylate dihydrochloride, but more generally known as manidipine dihydrochloride, which bears US NIH Compound Identifier 150762. European Medicines Agency schedules manidipine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08641MIG. Most nations, for tariff purposes, schedule manidipine dihydrochloride under HS 29335995. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3CCCCC3)C4CCCCC4)C5CCCC(C5)[N+](=O)[O-])C(=O)OC.CL.CL.
This classification denotes a calcium channel blocker with the molecular structure C35H38N4O6.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, ZL507UZ6QL chemically known as 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl (+/-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinecarboxylate dihydrochloride, but more commonly known as manidipine hydrochloride, which bears US NIH Compound Identifier 150762. European Medicines Agency schedules Manidipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03085MIG. Most nations, for tariff and trade purposes, schedule manidipine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, MANIDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3CCCCC3)C4CCCCC4)C5CCCC(C5)[N+](=O)[O-])C(=O)OC.CL.CL.
This classification denotes an osmotic diuretic with the molecular formula C6H14O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3OWL53L36A, chemically known as 1,2,3,4,5,6-hexanehexol but generally known as mannitol, which bears US NIH Compound Identifier 453. European Medicines Agency schedules Mannitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03087MIG. World Health Organization schedules mannitol in its Anatomical Therapeutic Chemical (ATC) Classification. MANNITOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mannitol under HS 29054300 and SITC 51224. As of Q4 2014, MANNITOL remains the US FDA Preferred Term for this commodity. Mannitol bears US NLM identifiers UMLS ID C0024730 and NCI Concept Code C625. SMILES: OC(C(O)C(O)CO)C(O)CO.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99AU28W1G9. European Medicines Agency schedules Mannitol hexanitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08642MIG. Mannitol hexanitrate generally arises in the molecular formula C6H8N6O18. The term MANNITOL HEXANITRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) Most nations schedule mannitol hexanitrate under HS 29209085 and SITC 51639. As of Q4 2014, MANNITOL HEXANITRATE remains the US FDA Preferred Term for this commodity. Mannitol hexanitrate bears US NLM identifiers UMLS ID C0301383 and NCI Concept Code C83902. SMILES: C(C(C(C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.
This classification denotes an osmotic diuretic with the molecular formula C8H18O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6STO1P091F, chemically known as cb-2511, but more generally known as mannitol myleran, which bears US NIH Compound Identifier 14464. European Medicines Agency schedules mannitol myleran or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03087MIG. Most nations, for tariff purposes, schedule mannitol myleran under HS 29054300. SMILES: CS(=O)(=O)OC[C@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)C)O)O)O)O.
This classification denotes a nitrogen mustard compound with the molecular formula C10H22Cl2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E60VWA40D2, chemically known as 1,6-bis(chloroethylamino)-1,6-dideoxy-d-mannite but more generally known as mannomustine, which bears US NIH Compound Identifier 11337. European Medicines Agency schedules Mannomustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08643MIG. The term MANNOMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). MANNOMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mannomustine under HS 29221980 and SITC 51461. As of Q4 2014, MANNOMUSTINE remains US FDA's Preferred Term for this commodity. Mannomustine bears US NLM identifiers UMLS ID C0024738 and NCI Concept Code C2070. SMILES: C(CCL)NCC(C(C(C(CNCCCL)O)O)O)O.
This classification denotes a nitrogen mustard compound with the molecular formula C10H22Cl2N2O4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UOZ2JJZ3I5, chemically known as d-mannitol, 1,6-bis((2-chloroethyl)amino)-1,6-dideoxy-, dihydrochloride, but more generally known as mannomustine dihydrochloride, which bears US NIH Compound Identifier 11337. European Medicines Agency schedules mannomustine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08643MIG. Most nations, for tariff purposes, schedule mannomustine dihydrochloride under HS 29221980. SMILES: C(CCL)NC[C@H]([C@H]([C@@H]([C@@H](CNCCCL)O)O)O)O.CL.CL.
This classification denotes a nitrogen mustard compound C10H22Cl2N2O4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UOZ2JJZ3I5, chemically known as d-mannitol, 1,6-bis((2-chloroethyl)amino)-1,6-dideoxy-, dihydrochloride, but more generally known as mannomustine hydrochloride, which bears US NIH Compound Identifier 9884430. Most nations, for tariff and trade purposes, schedule mannomustine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, MANNOMUSTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C(CCL)NC[C@H]([C@H]([C@@H]([C@@H](CNCCCL)O)O)O)O.CL.CL.
This classification denotes an alkylsulfonate compound with the molecular formula C10H22O14S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 135FQ40L36, chemically known as 1,2,5,6-tetramethanesulphonyl-d-mannite but more generally known as mannosulfan, which bears US NIH Compound Identifier 24140. European Medicines Agency schedules Mannosulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08644MIG. The term MANNOSULFAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules mannosulfan in its Anatomical Therapeutic Chemical (ATC) Classification. MANNOSULFAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mannosulfan under HS 29054980 and SITC 51229. As of Q4 2014, MANNOSULFAN remains US FDA's Preferred Term for this commodity. Mannosulfan bears US NLM identifiers UMLS ID C0065696 and NCI Concept Code C83904. SMILES: CS(=O)(=O)OCC(C(C(C(COS(=O)(=O)C)OS(=O)(=O)C)O)O)OS(=O)(=O)C.
This classification denotes a vasodilating agent with the molecular formula C10H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GZM2484VQ4, chemically known as 4,5,6,7-tetrahydro-2-methyl-5-((methylamino)methyl)benzothiazole but generally known as manozodil, which bears US NIH Compound Identifier 72110. European Medicines Agency schedules Manozodil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08645MIG. The term MANOZODIL is an International Non-Proprietary Name. MANOZODIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule manozodil under HS 29341000 and SITC 51579. As of Q4 2014, MANOZODIL remains the US FDA Preferred Term for this commodity. Manozodil bears US NLM identifiers UMLS ID C2698013 and NCI Concept Code C74415. SMILES: CC1=NC2=C(S1)CCC(C2)CNC.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62LN840SFZ. European Medicines Agency schedules Mapinastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08646MIG. Mapinastine generally arises in the molecular formula C23H34N6O. The term MAPINASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.) MAPINASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mapinastine under HS 29335995 and SITC 51576. As of Q4 2014, MAPINASTINE remains the US FDA Preferred Term for this commodity. Mapinastine bears US NLM identifiers UMLS ID C1881605 and NCI Concept Code C66055. SMILES: O(CCN1C(NC2C1CCCC2)CN1CCN(CC1)CCCCN1NCCC1)CC.
This classification denotes an antidepressant agent with the molecular formula C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2U1W68TROF, chemically known as 9,10-ethanoanthracene-9(10h)-propylamine, n-methyl- but generally known as maprotiline, which bears US NIH Compound Identifier 4011. European Medicines Agency schedules Maprotiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08647MIG. The term MAPROTILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules maprotiline in its Anatomical Therapeutic Chemical (ATC) Classification. MAPROTILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule maprotiline under HS 29214980 and SITC 51454. As of Q4 2014, MAPROTILINE remains the US FDA Preferred Term for this commodity. Maprotiline bears US NLM identifiers UMLS ID C0024778 and NCI Concept Code C61824. SMILES: N(CCCC12CCC(c3c1cccc3)c1c2cccc1)C.
This classification denotes a tricyclic antidepressant with the molecular formula C20H23N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C8J54PVFI, chemically known as 9,10-ethanoanthracene-9(10h)-propylamine, n-methyl-, hydrochloride but more generally known as maprotiline hydrochloride, which bears US NIH Compound Identifier 71478. European Medicines Agency schedules Maprotiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03088MIG. Most nations, for tariff and trade purposes, schedule maprotiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, MAPROTILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Maprotiline hydrochloride bears US NLM identifiers UMLS ID C0024080 and NCI Concept Code C47594. SMILES: CNCCCC12CCC(C3C1CCCC3)C4C2CCCC4.CL.
This classification denotes an antidepressant agent with the molecular formula C20H23N.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22P65W41V0. European Medicines Agency schedules maprotiline mesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03089MIG. Most nations, for tariff and trade purposes, schedule maprotiline mesylate under HS 29214980. As of Q4 2014, MAPROTILINE MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: CNCCCC12CCC(C3C1CCCC3)C4C2CCCC4.CS(=O)(=O)O.
This classification denotes a chemokine receptor antagonist and anti-hiv agent with the molecular formula C29H41F2N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MD6P741W8A, chemically known as uk-427,857 but generally known as maraviroc, which bears US NIH Compound Identifier 3002977. European Medicines Agency schedules Maraviroc in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25224. The term MARAVIROC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). World Health Organization schedules maraviroc in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule maraviroc under HS 29333999 and SITC 51574. As of Q4 2014, MARAVIROC remains the US FDA Preferred Term for this commodity. Maraviroc bears US NLM identifiers UMLS ID C1667052 and NCI Concept Code C73144. SMILES: FC1(F)CCC(C(=O)NC(CCN2C3CC(n4c(nnc4C)C(C)C)CC2CC3)c2ccccc2)CC1.
This classification denotes a quinolone antibiotic with the molecular formula C17H19FN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X09WU898T, chemically known as 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid but generally known as marbofloxacin, which bears US NIH Compound Identifier 60651. European Medicines Agency schedules Marbofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08648MIG. The term MARBOFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). MARBOFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule marbofloxacin under HS 29349990 and SITC 51579. As of Q4 2014, MARBOFLOXACIN remains the US FDA Preferred Term for this commodity. Marbofloxacin bears US NLM identifiers UMLS ID C0214439 and NCI Concept Code C80640. SMILES: FC1C(N2CCN(CC2)C)C2OCN(N3C2C(C1)C(=O)C(C3)C(=O)O)C.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C15H19Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PTB4X93HE1, chemically known as 5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-1h-benzimidazol-2-amine but generally known as maribavir, which bears US NIH Compound Identifier 122872. European Medicines Agency schedules Maribavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03090MIG. The term MARIBAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules maribavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule maribavir under HS 29349990 and SITC 51579. As of Q4 2014, MARIBAVIR remains the US FDA Preferred Term for this commodity. Maribavir bears US NLM identifiers UMLS ID C1508759 and NCI Concept Code C82254. SMILES: Clc1cc2n(C3OC(C(O)C3O)CO)c(NC(C)C)nc2cc1Cl.
This classification denotes an antiemetic agent with the molecular formula C32H40N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4XE2T9H4DH, chemically known as (2S,3S)-2-benzhydryl-N-[(5-tert-butyl-2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine but generally known as maropitant, which bears US NIH Compound Identifier 204108. The term MAROPITANT is an International Non-Proprietary Name or INN. Most nations schedule maropitant under HS 29333999 and SITC 51574. As of Q4 2014, MAROPITANT remains the US FDA Preferred Term for this commodity. Maropitant bears US NLM identifiers UMLS ID C1871004 and NCI Concept Code C81500. SMILES: CC(C)(C)C1=CC(=C(C=C1)OC)CNC2C3CCN(C2C(C4=CC=CC=C4)C5=CC=CC=C5)CC3.
This classification denotes an antidepressant agent with the molecular formula C19H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XG4094G0OY, chemically known as 2,3,4,5-tetrahydro-3-methyl-1h-dibenz(2,3:6,7)oxepino(4,5-d)azepine but generally known as maroxepin, which bears US NIH Compound Identifier 68858. European Medicines Agency schedules Maroxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08651MIG. The term MAROXEPIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). MAROXEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule maroxepin under HS 29349990 and SITC 51579. As of Q4 2014, MAROXEPIN remains the US FDA Preferred Term for this commodity. Maroxepin bears US NLM identifiers UMLS ID C0127034 and NCI Concept Code C66056. SMILES: O1c2c(C3=C(CCN(CC3)C)c3c1cccc3)cccc2.
This classification denotes a lipooxygenase inhibitor and antioxidant with the molecular formula C18H22O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BO8G1BYQU, chemically known as 1,2-benzenediol, 4,4-(2,3-dimethyl-1,4-butanediyl)bis-, (r*,s*)- but generally known as masoprocol, which bears US NIH Compound Identifier 71398. European Medicines Agency schedules Masoprocol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08652MIG. The term MASOPROCOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules masoprocol in its Anatomical Therapeutic Chemical (ATC) Classification. MASOPROCOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule masoprocol under HS 29072900 and SITC 51243. As of Q4 2014, MASOPROCOL remains the US FDA Preferred Term for this commodity. Masoprocol bears US NLM identifiers UMLS ID C0733397 and NCI Concept Code C701. SMILES: OC1CC(CC(C(CC2CC(O)C(O)CC2)C)C)CCC1O.
This classification denotes an anticholinergic agent with the molecular formula C20H25NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I6X824OGWZ, chemically known as 6,6,9-trimethyl-9-azabicyclo(3.3.1)non-3beta-yl di-2-thienylglycolate but generally known as mazaticol, which bears US NIH Compound Identifier 68667. European Medicines Agency schedules Mazaticol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08655MIG. The term MAZATICOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules mazaticol in its Anatomical Therapeutic Chemical (ATC) Classification. MAZATICOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mazaticol under HS 29349990 and SITC 51579. As of Q4 2014, MAZATICOL remains the US FDA Preferred Term for this commodity. Mazaticol bears US NLM identifiers UMLS ID C0065760 and NCI Concept Code C82233. SMILES: S1C(C(O)(C(=O)OC2CC3N(C(CCC3(C)C)C2)C)C2SCCC2)CCC1.
This classification denotes an anticholinergic agent with the molecular formula C20H25NO3S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44WQI5180Q, chemically known as 6,6,9-trimethyl-9-azabicyclo(3.3.1)non-3beta-yl-alpha,alpha-di-(2-thienyl)glycolate hydrochloride but more generally known as mazaticol hydrochloride, which bears US NIH Compound Identifier 135004. European Medicines Agency schedules Mazaticol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03096MIG. Most nations, for tariff and trade purposes, schedule mazaticol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, MAZATICOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1(CCC2CC(CC1N2C)OC(=O)C(C3CCCS3)(C4CCCS4)O)C.CL.
This classification denotes a cns stimulant with the molecular formula C16H13ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C56709M5NH, chemically known as 5-(p-chlorophenyl)-2,5-dihydro-3h-imidazo(2,1-a)isoindol-5-ol but more generally known as mazindol, which bears US NIH Compound Identifier 4020. European Medicines Agency schedules Mazindol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08656MIG. The term MAZINDOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules mazindol in its Anatomical Therapeutic Chemical (ATC) Classification. MAZINDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mazindol under HS 29339190 and SITC 51577. As of Q4 2014, MAZINDOL remains US FDA's Preferred Term for this commodity. Mazindol bears US NLM identifiers UMLS ID C0024977 and NCI Concept Code C66057. SMILES: CLC1CCC(C2(O)N3C(=NCC3)C3C2CCCC3)CC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H38N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QN0W2YSW63, chemically known as 11beta,17-dihydroxy-21-(4-methyl-1-piperazinyl)pregna-1,4-diene-3,20-dione. but generally known as mazipredone, which bears US NIH Compound Identifier 6064. European Medicines Agency schedules Mazipredone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08657MIG. The term MAZIPREDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). MAZIPREDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mazipredone under HS 29372900 and SITC 54153. As of Q4 2014, MAZIPREDONE remains the US FDA Preferred Term for this commodity. Mazipredone bears US NLM identifiers UMLS ID C0650228 and NCI Concept Code C87233. SMILES: OC1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)C=C2)CC3)C)CC1)C)C(=O)CN1CCN(CC1)C.
This classification denotes a therapeutic glucocorticoid C26H38N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HOX0WI4U1F, chemically known as (11.beta.)-11,17-dihydroxy-21-(4-methyl-1-piperazinyl)pregna-1,4-diene-3,20-dione hydrochloride, but more generally known as mazipredone hydrochloride, which bears US NIH Compound Identifier 6063. European Medicines Agency schedules Mazipredone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14485MIG. Most nations, for tariff and trade purposes, schedule mazipredone hydrochloride under HS 29372900 and SITC 54153. As of Q4 2014, MAZIPREDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CN4CCN(CC4)C)O)CCC5=CC(=O)C=C[C@]35C)O.CL.
This classification denotes an antihypertensive agent with the molecular formula C23H28N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3N608EC7L, chemically known as ethyl 5-((3s,4r)-4-((1,6-dihydro-6-oxo-3-pyridazinyl)oxy)-3-hydroxy-2,2,3-trimethyl-6-chromanyl)-1h-tetrazole-1-butyrate. but generally known as mazokalim, which bears US NIH Compound Identifier 3045404. European Medicines Agency schedules Mazokalim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08658MIG. The term MAZOKALIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). MAZOKALIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mazokalim under HS 29349990 and SITC 51579. As of Q4 2014, MAZOKALIM remains the US FDA Preferred Term for this commodity. Mazokalim bears US NLM identifiers UMLS ID C2827250 and NCI Concept Code C83907. SMILES: O1C(C(O)(C(Oc2n[nH]c(=O)cc2)c2c1ccc(c2)c1n(nnn1)CCCC(=O)OCC)C)(C)C.
This clasification denotes a compound vaccine. The first disease that this compound vaccine prevents is a highly contagious infectious disease caused by morbillivirus, called measles, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the mononuclear phagocyte system. The second disease this compound vaccine prevents is an acute infectious disease caused by rubulavirus, called mumps, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. The third disease this compound vaccine prevents An acute infectious disease caused by the rubella virus, commonly called rubella, and which enters the respiratory tract via airborne droplet and spreads to the lymphatic system.
This clasification denotes a compound vaccine. The first disease that this compound vaccine prevents is a highly contagious infectious disease caused by morbillivirus, called measles, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the mononuclear phagocyte system. The second disease this compound vaccine prevents is an acute infectious disease caused by the rubella virus, commonly called rubella, and which enters the respiratory tract via airborne droplet and spreads to the lymphatic system.
This classification denotes a vaccine for a highly contagious infectious disease caused by morbillivirus, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the mononuclear phagocyte system.
This classification denotes an antihelminthic agent with the molecular formula C16H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81G6I5V05I, chemically known as 5-benzoyl-2-benzimidazolecarbamic acid, methyl ester but generally known as mebendazole, which bears US NIH Compound Identifier 4030. European Medicines Agency schedules Mebendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08660MIG. The term MEBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules mebendazole in its Anatomical Therapeutic Chemical (ATC) Classification. MEBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mebendazole under HS 29339990 and SITC 51577. As of Q4 2014, MEBENDAZOLE remains the US FDA Preferred Term for this commodity. Mebendazole bears US NLM identifiers UMLS ID C0025023 and NCI Concept Code C47595. SMILES: O=C(C1CC2[NH]C(NC2CC1)NC(=O)OC)C1CCCCC1.
This classification denotes an anticholinergic agent with the molecular formula C25H35NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7F80CC3NNV, chemically known as 4-(ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl 3,4-dimethoxybenzoate but generally known as mebeverine, which bears US NIH Compound Identifier 4031. European Medicines Agency schedules Mebeverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08662MIG. The term MEBEVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 1, 1999, List 41). World Health Organization schedules mebeverine in its Anatomical Therapeutic Chemical (ATC) Classification. MEBEVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mebeverine under HS 29225000 and SITC 51467. As of Q4 2014, MEBEVERINE remains the US FDA Preferred Term for this commodity. Mebeverine bears US NLM identifiers UMLS ID C0065832 and NCI Concept Code C83909. SMILES: O(CCCCN(C(CC1CCC(OC)CC1)C)CC)C(=O)C1CC(OC)C(OC)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9SUK9B7XVY, chemically known as 5-benzyl-1,3,4,5-tetrahydro-2-methyl-2h-pyrido(4,3-b)indole but generally known as mebhydrolin, which bears US NIH Compound Identifier 22530. European Medicines Agency schedules Mebhydrolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08664MIG. The term MEBHYDROLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules mebhydrolin in its Anatomical Therapeutic Chemical (ATC) Classification. MEBHYDROLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Mebhydrolin or mebhydroline bears US NLM identifiers UMLS ID C0065834 and NCI Concept Code C66059. SMILES: CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=CC=C4.
This classification denotes an antidiarrheal agent with the molecular formula C10H10BiNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DBE10Q8QF6, chemically known as quinoline, 8-((dihydroxybismuthino)oxy)-6-methyl- but generally known as mebiquine, which bears US NIH Compound Identifier 16683098. European Medicines Agency schedules Mebiquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08665MIG. The term MEBIQUINE is an International Non-Proprietary Name. MEBIQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mebiquine under HS 29334990 and SITC 51575. As of Q4 2014, MEBIQUINE remains the US FDA Preferred Term for this commodity. Mebiquine bears US NLM identifiers UMLS ID C1881637 and NCI Concept Code C66060. SMILES: CC1=CC(=C2C(=C1)C=CC=N2)O[BI].O.O.
This classification denotes an anabolic steroid with the molecular formula C42H68N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69C642I19V, chemically known as 17beta-hydroxy-2alpha,17-dimethyl-5alpha-androstan-3-one azine but generally known as mebolazine, which bears US NIH Compound Identifier 9571069. European Medicines Agency schedules Mebolazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08666MIG. The term MEBOLAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). MEBOLAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mebolazine under HS 29372900 and SITC 54153. As of Q4 2014, MEBOLAZINE remains the US FDA Preferred Term for this commodity. Mebolazine bears US NLM identifiers UMLS ID C0604275 and NCI Concept Code C90641. SMILES: OC1(C2(C(C3C(C4(C(CC3)C/C(=N/N=C3/CC5C(C6C(C7C(C(O)(CC7)C)(CC6)C)CC5)(CC3C)C)C(C4)C)C)CC2)CC1)C)C.
This classification denotes an antipsychotic agent with the molecular formula C10H20N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5H8F175RER, chemically known as 2,2-dicarbamyloxymethyl-3-methylpentane but generally known as mebutamate, which bears US NIH Compound Identifier 6151. European Medicines Agency schedules Mebutamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08668MIG. The term MEBUTAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules mebutamate in its Anatomical Therapeutic Chemical (ATC) Classification. MEBUTAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mebutamate under HS 29241900 and SITC 51471. As of Q4 2014, MEBUTAMATE remains the US FDA Preferred Term for this commodity. Mebutamate bears US NLM identifiers UMLS ID C0301379 and NCI Concept Code C66062. SMILES: CCC(C)C(C)(COC(=O)N)COC(=O)N.
This classification denotes a thiazide diuretic with the molecular formula C13H20ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7738AS8324, chemically known as 6-chloro-3,4-dihydro-3-(1,2-dimethylbutyl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as mebutizide, which bears US NIH Compound Identifier 71652. European Medicines Agency schedules Mebutizide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08669MIG. The term MEBUTIZIDE is an International Non-Proprietary Name. World Health Organization schedules mebutizide in its Anatomical Therapeutic Chemical (ATC) Classification. MEBUTIZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mebutizide under HS 29350090 and SITC 51580. As of Q4 2014, MEBUTIZIDE remains the US FDA Preferred Term for this commodity. Mebutizide bears US NLM identifiers UMLS ID C0603520 and NCI Concept Code C83910. SMILES: CLC1CC2NC(NS(=O)(=O)C2CC1S(=O)(=O)N)C(C(CC)C)C.
This classification denotes a nicotinic antagonist with the molecular formula C11H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6EE945D3OK, chemically known as 3-beta-methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane but generally known as mecamylamine, which bears US NIH Compound Identifier 4032. European Medicines Agency schedules Mecamylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08670MIG. The term MECAMYLAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules mecamylamine in its Anatomical Therapeutic Chemical (ATC) Classification. MECAMYLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mecamylamine under HS 29213099 and SITC 51453. As of Q4 2014, MECAMYLAMINE remains the US FDA Preferred Term for this commodity. Mecamylamine bears US NLM identifiers UMLS ID C0025029 and NCI Concept Code C66063. SMILES: CC1(C2CCC(C2)C1(C)NC)C.
This classification denotes a nicotinic antagonist with the molecular formula C11H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4956DJR58O, chemically known as 3-beta-methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane but more generally known as mecamylamine hydrochloride, which bears US NIH Compound Identifier 4032. European Medicines Agency schedules Mecamylamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03104MIG. Most nations, for tariff and trade purposes, schedule mecamylamine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, MECAMYLAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mecamylamine hydrochloride bears US NLM identifiers UMLS ID C0304526 and NCI Concept Code C66064. SMILES: CC1(C2CCC(C2)C1(C)NC)C.CL.
This classification denotes an antihypertensive agent with the molecular formula C13H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z927X3UJ2W, chemically known as 1,2-dimethyl-3-carbethoxy- 5-hydroxyindole but generally known as mecarbinate, which bears US NIH Compound Identifier 616236. European Medicines Agency schedules Mecarbinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08671MIG. The term MECARBINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). MECARBINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mecarbinate under HS 29339990 and SITC 51577. As of Q4 2014, MECARBINATE remains the US FDA Preferred Term for this commodity. Mecarbinate bears US NLM identifiers UMLS ID C0065838 and NCI Concept Code C66065. SMILES: O(C(=O)c1c2c(n(c1C)C)ccc(O)c2)CC.
This classification denotes a therapeutic insulin-like growth factor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7GR9I2683O. European Medicines Agency schedules Mecasermin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08672MIG. Mecasermin generally arises in the molecular formula C331H512N94O101S7. The term MECASERMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) MECASERMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Mecasermin under HS 29371900 and SITC 54154. SMILES:. As of Q4 2014, MECASERMIN remains the US FDA Preferred Term for this commodity. . Mecasermin bears US NLM identifiers UMLS ID C0904505 and NCI Concept Code C2262.
This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C25H27ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L5TQ84570, chemically known as piperazine, 1- (p-chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)-, dihydrochloride but generally known as meclizine, which bears US NIH Compound Identifier 4034. European Medicines Agency schedules Meclozine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08685MIG. The term MECLIZINE is an International Non-Proprietary Name. World Health Organization schedules meclizine in its Anatomical Therapeutic Chemical (ATC) Classification. Meclizine or meclozine bears US NLM identifiers UMLS ID C0025039 and NCI Concept Code C61610. SMILES: CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)CL.
This classification denotes a tetracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23Q8M2HE6S. European Medicines Agency schedules Meclocycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08677MIG. Meclocycline generally arises in the molecular formula C22H21CLN2O8. The term MECLOCYCLINE is an International Non-Proprietary Name or INN. MECLOCYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meclocycline under HS 29413000 and SITC 54133. As of Q4 2014, MECLOCYCLINE remains the US FDA Preferred Term for this commodity. Meclocycline bears US NLM identifiers UMLS ID C0065841 and NCI Concept Code C61825. SMILES: CLC1C2C(=C)C3C(O)C4C(O)(C(=O)C3=C(O)C2C(O)CC1)C(=O)/C(=C(\O)N)C(=O)C4N(C)C.
This classification denotes a tetracycline antibiotic with the molecular structure C22H21CLN2O8.C7H6O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 46VZA7RX2B chemically known as 2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,12a.alpha.))-, mono(2-hydroxy-5-sulfobenzoate) (salt), but more commonly known as meclocycline sulfosalicylate, which bears US NIH Compound Identifier 5282520. European Medicines Agency schedules Meclocycline sulfosalicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03105MIG. Most nations, for tariff and trade purposes, schedule meclocycline sulfosalicylate under HS 29413000 and SITC 54133. As of Q4 2014, MECLOCYCLINE SULFOSALICYLATE remains US FDA's Preferred Term for this commodity. Meclocycline sulfosalicylate bears US NLM identifiers UMLS ID C0700494 and NCI Concept Code C47596. SMILES: CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4C(CCC(C4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)O)CL)O.C1CC(C(CC1S(=O)(=O)O)C(=O)O)O.
This classification denotes a cyclooxygenase inhibitor and veterinary nonsteroidal anti inflammatory drug with the molecular formula C14H11Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48I5LU4ZWD, chemically known as 2-(2, 6-dichloro-3-methylphenyl)aminobenzoic acid but generally known as meclofenamic acid, which bears US NIH Compound Identifier 4037. European Medicines Agency schedules Meclofenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08678MIG. The term MECLOFENAMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules meclofenamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule meclofenamic acid under HS 29224995 and SITC 51465. As of Q4 2014, MECLOFENAMIC ACID remains the US FDA Preferred Term for this commodity. Meclofenamic acid bears US NLM identifiers UMLS ID C0025042 and NCI Concept Code C61826. SMILES: CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl.
This classification denotes a benzodiazepine with the molecular formula C16H12ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RN43209SMA, chemically known as 5-(2-chlorophenyl)-1,3-dihydro-3-methyl-7-nitro-2h-1,4-benzodiazepin-2-one but generally known as meclonazepam, which bears US NIH Compound Identifier 93364. European Medicines Agency schedules Meclonazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08680MIG. The term MECLONAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). MECLONAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meclonazepam under HS 29339940 and SITC 51577. As of Q4 2014, MECLONAZEPAM remains the US FDA Preferred Term for this commodity. Meclonazepam bears US NLM identifiers UMLS ID C0065842 and NCI Concept Code C83911. SMILES: CLC1C(C2=NC(C(=O)NC3C2CC([N](=O)O)CC3)C)CCCC1.
This classification denotes a mucolytic agent with the molecular formula C4H9NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) RQ6L463N3B, chemically known as methyl cysteine, hydrochloride but more generally known as mecysteine, which bears US NIH Compound Identifier 4040. European Medicines Agency schedules Mecysteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08688MIG. The term MECYSTEINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). MECYSTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mecysteine under HS 29309016 and SITC 51549. As of Q4 2014, MECYSTEINE remains US FDA's Preferred Term for this commodity. Mecysteine bears US NLM identifiers UMLS ID C0065850 and NCI Concept Code C66067. SMILES: SCC(N)C(=O)OC.
This classification denotes a benzodiazepine with the molecular formula C16H15ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0J3387W3S, chemically known as 2,3-dihydro-7-chloro-1-methyl-5-phenyl-1h-1,4-benzodiazepine but generally known as medazepam, which bears US NIH Compound Identifier 4041. European Medicines Agency schedules Medazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08689MIG. The term MEDAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules medazepam in its Anatomical Therapeutic Chemical (ATC) Classification. MEDAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule medazepam under HS 29339190 and SITC 51577. As of Q4 2014, MEDAZEPAM remains the US FDA Preferred Term for this commodity. Medazepam bears US NLM identifiers UMLS ID C0025051 and NCI Concept Code C66068. SMILES: CLC1CC2C(N(CCN=C2C2CCCCC2)C)CC1.
This classification denotes a benzodiazepine with the molecular formula C16H15ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ETM878JC9K, chemically known as 2,3-dihydro-7-chloro-1-methyl-5-phenyl-1h-1,4-benzodiazepine but more generally known as medazepam hydrochloride, which bears US NIH Compound Identifier 4041. European Medicines Agency schedules Medazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35638. Most nations, for tariff and trade purposes, schedule medazepam hydrochloride under HS 29339190 and SITC 51577. As of Q4 2014, MEDAZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Medazepam hydrochloride bears US NLM identifiers UMLS ID C0035766 and NCI Concept Code C66069. SMILES: CN1CCN=C(C2C1CCC(C2)CL)C3CCCCC3.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MR15E85MQM, chemically known as 1h-imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)- but generally known as medetomidine, which bears US NIH Compound Identifier 68602. European Medicines Agency schedules Medetomidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08691MIG. The term MEDETOMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). MEDETOMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule medetomidine under HS 29332990 and SITC 51573. As of Q4 2014, MEDETOMIDINE remains the US FDA Preferred Term for this commodity. Medetomidine bears US NLM identifiers UMLS ID C0125656 and NCI Concept Code C81367. SMILES: CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BH210P244U, chemically known as 1h-imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-, monohydrochloride, (+-)- but more generally known as medetomidine hydrochloride, which bears US NIH Compound Identifier 68601. Most nations, for tariff and trade purposes, schedule medetomidine hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, MEDETOMIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Medetomidine hydrochloride bears US NLM identifiers UMLS ID C0065852 and NCI Concept Code C81368. SMILES: CC1CCCC(C1C)C(C)C2C[NH]CN2.CL.
This classification denotes a natural product which US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifiers 2A64U81OQ3, BBO1IJ3ZIW, NX974IRT8E, and M0G28FH9K1, the sources of which Integrated Taxonomic Information System classifies under Taxonomic Serial Numbers 28827, 35682, 27228, and 28811. European Medicines Agency schedules tree pollen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB55247.
This classification denotes a serotonin agonist and dopamine agonist with the molecular formula C16H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KWU7C2A1NT, chemically known as n,n-dimethyl-2,2-diphenoxyethylamine but generally known as medifoxamine, which bears US NIH Compound Identifier 36109. European Medicines Agency schedules Medifoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08693MIG. The term MEDIFOXAMINE is an International Non-Proprietary Name. World Health Organization schedules medifoxamine in its Anatomical Therapeutic Chemical (ATC) Classification. MEDIFOXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule medifoxamine under HS 29225000 and SITC 51467. As of Q4 2014, MEDIFOXAMINE remains the US FDA Preferred Term for this commodity. Medifoxamine bears US NLM identifiers UMLS ID C0065858 and NCI Concept Code C83914. SMILES: O(C(Oc1ccccc1)CN(C)C)c1ccccc1.
This classification denotes a serotonin agonist and dopamine agonist C16H19NO2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OAG6T7TVU2, chemically known as acetaldehyde, (dimethylamino)-, diphenyl acetal, fumarate (1:1), but more generally known as medifoxamine fumarate, which bears US NIH Compound Identifier 6450232. Most nations, for tariff and trade purposes, schedule medifoxamine fumarate under HS 29225000 and SITC 51467. As of Q4 2014, MEDIFOXAMINE FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CC(OC1CCCCC1)OC2CCCCC2.C(=C/C(=O)O)\C(=O)O.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C9H8N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80X61Y4X0B, chemically known as 1,6-naphthyridin-2(1h)-one, 5-methyl- but generally known as medorinone, which bears US NIH Compound Identifier 5362132. European Medicines Agency schedules Medorinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08694MIG. The term MEDORINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). MEDORINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule medorinone under HS 29337900 and SITC 51561. As of Q4 2014, MEDORINONE remains the US FDA Preferred Term for this commodity. Medorinone bears US NLM identifiers UMLS ID C0641935 and NCI Concept Code C74352. SMILES: O=C1[NH]C2C(C(NCC2)C)CC1.
This classification denotes an anthracycline antibiotic with the molecular formula C26H27NO10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NU158DGH9E, chemically known as 5,12-naphthacenedione, 7,8,9,10-tetrahydro-7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-9-(hydroxyacetyl)-6,9,11-trihydroxy-, (7s-cis)- but generally known as medorubicin, which bears US NIH Compound Identifier 68837. European Medicines Agency schedules Medorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08695MIG. The term MEDORUBICIN is an International Non-Proprietary Name. MEDORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule medorubicin under HS 29419000 and SITC 54139. As of Q4 2014, MEDORUBICIN remains the US FDA Preferred Term for this commodity. Medorubicin bears US NLM identifiers UMLS ID C0048224 and NCI Concept Code C87599. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)CCCC2)C(=O)CO)C1OC(C(O)C(N)C1)C.
This classification denotes a therapeutic progestin with the molecular formula C23H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 077DN93G5B, chemically known as 6,17-dimethylpregna-4,6-diene-3,20-dione but generally known as medrogestone, which bears US NIH Compound Identifier 13790. European Medicines Agency schedules Medrogestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08696MIG. The term MEDROGESTONE is an International Non-Proprietary Name. World Health Organization schedules medrogestone in its Anatomical Therapeutic Chemical (ATC) Classification. MEDROGESTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule medrogestone under HS 29372300 and SITC 54153. As of Q4 2014, MEDROGESTONE remains the US FDA Preferred Term for this commodity. Medrogestone bears US NLM identifiers UMLS ID C0025145 and NCI Concept Code C90970. SMILES: O=C(C1(C2(C(C3C(CC2)C2(C(=CC(=O)CC2)C(=C3)C)C)CC1)C)C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX202. This VA Drug Class (DX202) classifies this compound as belonging to the group NON-IMAGING AGENTS RADIOPHARMACEUTICALS.
This classification denotes a therapeutic progestin with the molecular formula C22H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HSU1C9YRES, chemically known as 17-hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione but generally known as medroxyprogesterone, which bears US NIH Compound Identifier 10631. European Medicines Agency schedules Medroxyprogesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08699MIG. World Health Organization schedules medroxyprogesterone in its Anatomical Therapeutic Chemical (ATC) Classification. MEDROXYPROGESTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule medroxyprogesterone under HS 29372300 and SITC 54153. As of Q4 2014, MEDROXYPROGESTERONE remains the US FDA Preferred Term for this commodity. Medroxyprogesterone bears US NLM identifiers UMLS ID C0025147 and NCI Concept Code C629. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)C(C3)C)C)CC2)CC1)C)C(=O)C.
This classification denotes a contraceptive and synthetic progestational hormone with the molecular formula C24H34O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2QI4IOI2G, chemically known as pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6.alpha.)- but generally known as medroxyprogesterone acetate, which bears US NIH Compound Identifier 4042. European Medicines Agency schedules Medroxyprogesterone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03114MIG. Most nations schedule medroxyprogesterone acetate under HS 29372300 and SITC 54153. As of Q4 2014, MEDROXYPROGESTERONE ACETATE remains the US FDA Preferred Term for this commodity. Medroxyprogesterone acetate bears US NLM identifiers UMLS ID C0065864 and NCI Concept Code C1155. SMILES: O(C1(C2(C(C3C(C4(C(=CC(=O)CC4)C(C3)C)C)CC2)CC1)C)C(=O)C)C(=O)C.
This classification denotes a therapeutic progestin with the molecular formula C28H42O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GNC5BCM98A, chemically known as pregn-4-ene-3,20-dione, 6-methyl-17-((1-oxohexyl)oxy)-, (6.alpha.)-, but more generally known as medroxyprogesterone caproate, which bears US NIH Compound Identifier 62997. European Medicines Agency schedules medroxyprogesterone caproate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08699MIG. Most nations, for tariff purposes, schedule medroxyprogesterone caproate under HS 29372300. SMILES: CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C)C)C(=O)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2UFC189XF, chemically known as 11beta-hydroxy-6alpha-methylpregn-4-ene-3,20-dione but generally known as medrysone, which bears US NIH Compound Identifier 4043. European Medicines Agency schedules Medrysone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08701MIG. The term MEDRYSONE is an International Non-Proprietary Name. World Health Organization schedules medrysone in its Anatomical Therapeutic Chemical (ATC) Classification. MEDRYSONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule medrysone under HS 29372900 and SITC 54153. As of Q4 2014, MEDRYSONE remains the US FDA Preferred Term for this commodity. Medrysone bears US NLM identifiers UMLS ID C0720803 and NCI Concept Code C47598. SMILES: OC1C2C(C3C(C1)(C(CC3)C(=O)C)C)CC(C1=CC(=O)CCC21C)C.
This classification denotes a sedative and hypnotic with the molecular formula C20H25ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IM840F32VV, chemically known as 1-o-chlorophenyl-4-(3,4-dimethoxyphenethyl)piperazine but generally known as mefeclorazine, which bears US NIH Compound Identifier 71066. European Medicines Agency schedules Mefeclorazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08702MIG. The term MEFECLORAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). MEFECLORAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mefeclorazine under HS 29335995 and SITC 51576. As of Q4 2014, MEFECLORAZINE remains the US FDA Preferred Term for this commodity. Mefeclorazine bears US NLM identifiers UMLS ID C2698039 and NCI Concept Code C76941. SMILES: CLC1CC(N2CCN(CC2)CCC2CC(OC)C(OC)CC2)CCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 367589PJ2C, chemically known as 2-diphenylaminecarboxylic acid, 2,3-dimethyl- but generally known as mefenamic acid, which bears US NIH Compound Identifier 4044. European Medicines Agency schedules Mefenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08703MIG. The term MEFENAMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules mefenamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule mefenamic acid under HS 29224995 and SITC 51465. As of Q4 2014, MEFENAMIC ACID remains the US FDA Preferred Term for this commodity. Mefenamic acid bears US NLM identifiers UMLS ID C0025152 and NCI Concept Code C47599. SMILES: OC(=O)C1C(NC2C(C(CCC2)C)C)CCCC1.
This classification denotes a vasodilating agent with the molecular formula C12H11N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74WY8560J7, chemically known as 1h-imidazole-4-acetonitrile, 5-methyl-2-phenyl- but generally known as mefenidil, which bears US NIH Compound Identifier 65475. European Medicines Agency schedules Mefenidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08704MIG. The term MEFENIDIL is an International Non-Proprietary Name. MEFENIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mefenidil under HS 29332990 and SITC 51573. As of Q4 2014, MEFENIDIL remains the US FDA Preferred Term for this commodity. Mefenidil bears US NLM identifiers UMLS ID C0065869 and NCI Concept Code C66072. SMILES: CC1=C(N=C(N1)C2=CC=CC=C2)CC#N.
This classification denotes a vasodilating agent C12H11N3.C4H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5QH19BF6YG, chemically known as 1h-imidazole-4-acetonitrile, 5-methyl-2-phenyl-, (e)-2-butanedioate (1:1), but more generally known as mefenidil fumarate, which bears US NIH Compound Identifier 18177393. Most nations, for tariff and trade purposes, schedule mefenidil fumarate under HS 29332990 and SITC 51573. As of Q4 2014, MEFENIDIL FUMARATE remains US FDA's Preferred Term for this commodity. Mefenidil fumarate bears US NLM identifiers UMLS ID C1881763 and NCI Concept Code C66073. SMILES: CC1C(NC([NH]1)C2CCCCC2)CC#N.C(=C/C(=O)[O-])\C(=O)[O-].
This classification denotes an anorexiant with the molecular formula C12H18ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) K98M4N387W, chemically known as phenethylamine, n- (3-chloropropyl)-.alpha.-methyl-, hydrochloride but more generally known as mefenorex, which bears US NIH Compound Identifier 21777. European Medicines Agency schedules Mefenorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08706MIG. The term MEFENOREX is an International Non-Proprietary Name. World Health Organization schedules mefenorex in its Anatomical Therapeutic Chemical (ATC) Classification. MEFENOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mefenorex under HS 29214600 and SITC kg. As of Q4 2014, MEFENOREX remains US FDA's Preferred Term for this commodity. Mefenorex bears US NLM identifiers UMLS ID C0065870 and NCI Concept Code C83915. SMILES: CC(CC1=CC=CC=C1)NCCCCL.
This classification denotes an antihypertensive agent with the molecular formula C32H38N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42EL4L295A, chemically known as 3beta,20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-, methyl ester, (p-methoxyphenoxy)acetate (ester) but generally known as mefeserpine, which bears US NIH Compound Identifier 3045407. European Medicines Agency schedules Mefeserpine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08707MIG. The term MEFESERPINE is an International Non-Proprietary Name. MEFESERPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mefeserpine under HS 29399900 and SITC 54149. As of Q4 2014, MEFESERPINE remains the US FDA Preferred Term for this commodity. Mefeserpine bears US NLM identifiers UMLS ID C2981312 and NCI Concept Code C87628. SMILES: O(C1C(C2C(CN3C(C2)c2[nH]c4c(c2CC3)ccc(OC)c4)CC1OC(=O)COc1ccc(OC)cc1)C(=O)OC)C.
This classification denotes an antimalarial agent with the molecular formula C17H16F6N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TML814419R, chemically known as 4-quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (r*,s*)-(.+/-.)- but generally known as mefloquine, which bears US NIH Compound Identifier 4046. European Medicines Agency schedules Mefloquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08709MIG. The term MEFLOQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules mefloquine in its Anatomical Therapeutic Chemical (ATC) Classification. MEFLOQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mefloquine under HS 29334990 and SITC 51575. As of Q4 2014, MEFLOQUINE remains the US FDA Preferred Term for this commodity. Mefloquine bears US NLM identifiers UMLS ID C0025153 and NCI Concept Code C61827. SMILES: FC(F)(F)C1NC2C(C(C(O)C3NCCCC3)C1)CCCC2C(F)(F)F.
This classification denotes a diuretic with the molecular formula C13H19ClN2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1NS9SNS92, chemically known as 1,3-benzenedisulfonamide, 4-chloro-n(sup 1)-methyl-n(sup 1)-((tetrahydro-2-methyl-2-furanyl)methyl)- but generally known as mefruside, which bears US NIH Compound Identifier 4047. European Medicines Agency schedules Mefruside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08710MIG. World Health Organization schedules mefruside in its Anatomical Therapeutic Chemical (ATC) Classification. MEFRUSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mefruside under HS 29350090 and SITC 51580. As of Q4 2014, MEFRUSIDE remains the US FDA Preferred Term for this commodity. SMILES: CLC1C(S(=O)(=O)N)CC(S(=O)(=O)N(CC2(OCCC2)C)C)CC1.
This classification denotes a therapeutic progestin with the molecular formula C22H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EA6LD1M70M, chemically known as 17-hydroxy-6-methylpregna-4,6-diene-3,20-dione but generally known as megestrol, which bears US NIH Compound Identifier 19090. European Medicines Agency schedules Megestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08712MIG. World Health Organization schedules megestrol in its Anatomical Therapeutic Chemical (ATC) Classification. MEGESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule megestrol under HS 29372300 and SITC 54153. As of Q4 2014, MEGESTROL remains the US FDA Preferred Term for this commodity. Megestrol bears US NLM identifiers UMLS ID C0025175 and NCI Concept Code C630. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)C(=C3)C)C)CC2)CC1)C)C(=O)C.
This classification denotes a therapeutic progestin with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TJ2M0FR8ES, chemically known as pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- but generally known as megestrol acetate, which bears US NIH Compound Identifier 4048. European Medicines Agency schedules Megestrol acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03117MIG. Most nations schedule megestrol acetate under HS 29372300 and SITC 54153. As of Q4 2014, MEGESTROL ACETATE remains the US FDA Preferred Term for this commodity. Megestrol acetate bears US NLM identifiers UMLS ID C0065879 and NCI Concept Code C1156. SMILES: O(C1(C2(C(C3C(CC2)C2(C(=CC(=O)CC2)C(=C3)C)C)CC1)C)C(=O)C)C(=O)C.
This classification denotes an anti-diabetic agent with the molecular formula C17H16ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8V6OK1I088, chemically known as benzoic acid, 4-(2-((5-chloro-2-methoxybenzoyl)amino)ethyl)- but more generally known as meglitinide, which bears US NIH Compound Identifier 41214. European Medicines Agency schedules Meglitinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08713MIG. The term MEGLITINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). MEGLITINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule meglitinide under HS 29242995 and SITC 51479. As of Q4 2014, MEGLITINIDE remains US FDA's Preferred Term for this commodity. Meglitinide bears US NLM identifiers UMLS ID C0065880 and NCI Concept Code C66075. SMILES: CLC1CC(C(=O)NCCC2CCC(CC2)C(=O)O)C(OC)CC1.
This classification denotes an antihelminthic agent with the molecular formula C7H18NO8Sb, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75G4TW236W, chemically known as hydroxy(dioxo)-?5-stibane;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol but generally known as meglumine antimonate, which bears US NIH Compound Identifier 64953. European Medicines Agency schedules Meglumine Antimonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12915MIG. World Health Organization schedules meglumine antimonate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule meglumine antimonate under HS 29221980 and SITC 51461. SMILES: CNCC(C(C(C(CO)O)O)O)O.O[Sb](=O)=O.
This classification denotes an anticholesteremic agent, enzyme inhibitor, hydroxymethylglutaryl-coa reductase inhibitor, and hypolipidemic agent with the molecular formula C6H10O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CLA99KCD53, chemically known as pentanedioic acid, 3-hydroxy-3-methyl- but generally known as meglutol, which bears US NIH Compound Identifier 1662. European Medicines Agency schedules Meglutol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08716MIG. World Health Organization schedules meglutol in its Anatomical Therapeutic Chemical (ATC) Classification. MEGLUTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meglutol under HS 29181985 and SITC 51392. As of Q4 2014, MEGLUTOL remains the US FDA Preferred Term for this commodity. SMILES: OC(CC(=O)O)(CC(=O)O)C.
This classification denotes an antispasmotic agent with the molecular formulas C11H23N7 and C11H23N7.C4H6O6, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 2V6Z0JG2X0 and 7F3DYQ3H7H, the base compound being chemically known as 1,3,5-triazin-2(1h)-one, 4,6-bis(diethylamino)-, hydrazone (9ci) but generally known as meladrazine, which bears US NIH Compound Identifier 71679. European Medicines Agency schedules Meladrazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB08717MIG and SUB03125MIG. The term MELADRAZINE is an International Non-Proprietary Name. World Health Organization schedules meladrazine in its Anatomical Therapeutic Chemical (ATC) Classification. MELADRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meladrazine and its salts under HS 29336980 and SITC 51576. As of Q4 2014, MELADRAZINE remains the US FDA Preferred Term for this commodity. Meladrazine bears US NLM NCI C66076. SMILES: CCN(CC)C1=NC(=NC(=N1)NN)N(CC)CC (base) or CCN(CC)C1[NH]/C(=N\N)/NC(N1)N(CC)CC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O (tartrate).
This classification denotes an antispasmotic agent with the molecular formula C11H23N7.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7F3DYQ3H7H. European Medicines Agency schedules meladrazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03125MIG. Most nations, for tariff and trade purposes, schedule meladrazine tartrate under HS 29336980 and SITC 51576. As of Q4 2014, MELADRAZINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)C1[NH]/C(=N\N)/NC(N1)N(CC)CC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an anticoagulant agent with the molecular formula C22H31N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2A9QP32MD4, chemically known as glycine, n-(2-(2-((((4-(aminoiminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-1-cyclohexyl-2-oxoethyl)-, (s-(r*,s*))- but generally known as melagatran, which bears US NIH Compound Identifier 183797. European Medicines Agency schedules Melagatran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08718MIG. The term MELAGATRAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules melagatran in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule melagatran under HS 29339990 and SITC 51577. As of Q4 2014, MELAGATRAN remains the US FDA Preferred Term for this commodity. Melagatran bears US NLM identifiers UMLS ID C0668961 and NCI Concept Code C66077. SMILES: O=C(N1C(CC1)C(=O)NCC1CCC(CC1)C(=N)N)C(NCC(=O)O)C1CCCCC1.
This classification denotes an antihelminthic agent with the molecular formula C13H21AsN8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 374GJ0S41A, chemically known as bis(2-aminoethyl) p-((4,6-diamino-s-triazin-2-yl)amino)dithiobenzenearsonite but generally known as melarsomine, which bears US NIH Compound Identifier 65962. European Medicines Agency schedules Melarsomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08719MIG. The term MELARSOMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Most nations schedule melarsomine under HS 29336980 and SITC 51576. As of Q4 2014, MELARSOMINE remains the US FDA Preferred Term for this commodity. Melarsomine bears US NLM identifiers UMLS ID C0171462 and NCI Concept Code C66078. SMILES: [AS](SCCN)(SCCN)C1CCC(NC2NC(NC(N2)N)N)CC1.
This classification denotes a trypanocidal agent and arsenical with the molecular formula C12H15AsN6OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZF3786Q2E8, chemically known as 1,3,2-dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)- but generally known as melarsoprol, which bears US NIH Compound Identifier 10311. European Medicines Agency schedules Melarsoprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08721MIG. World Health Organization schedules melarsoprol in its Anatomical Therapeutic Chemical (ATC) Classification. MELARSOPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule melarsoprol under HS 29349990 and SITC 51579. As of Q4 2014, MELARSOPROL remains the US FDA Preferred Term for this commodity. SMILES: C1C(S[AS](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO.
This classification denotes a therapeutic progestin with the molecular formula C23H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, BX98J4T6JU chemically known as 17-hydroxy-6-methyl-16-methylenepregna-4,6-diene-3,20-dione but generally known as melengestrol, which bears US NIH Compound Identifier 21848. European Medicines Agency schedules Melengestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08722MIG. The term MELENGESTROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5. ). Most nations schedule melengestrol under HS 29372300 and SITC 54153. As of Q4 2014, MELENGESTROL remains the US FDA Preferred Term for this commodity. Melengestrol bears US NLM identifiers UMLS ID C0376337 and NCI Concept Code C1659. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)C(=C3)C)C)CC2)CC1=C)C)C(=O)C.
This classification denotes a therapeutic progestin with the molecular formula C25H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W5HDS3936, chemically known as 17-hydroxy-6-methyl-16-methylenepregna-4,6-diene-3,20-dione acetate but more generally known as melengestrol acetate, which bears US NIH Compound Identifier 18020. Most nations, for tariff and trade purposes, schedule melengestrol acetate under HS 29372300 and SITC 54153. As of Q4 2014, MELENGESTROL ACETATE remains US FDA's Preferred Term for this commodity. Melengestrol acetate bears US NLM identifiers UMLS ID C0025223 and NCI Concept Code C74577. SMILES: CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC(=C)[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C.
This classification denotes a dopamine agonist with the molecular formula C10H13NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M30686U4X4, chemically known as l-tyrosine, 3-hydroxy-, methyl ester (9ci) but generally known as melevodopa, which bears US NIH Compound Identifier 23497. European Medicines Agency schedules Melevodopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32447. The term MELEVODOPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules melevodopa in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule melevodopa under HS 29225000 and SITC 51467. As of Q4 2014, MELEVODOPA remains the US FDA Preferred Term for this commodity. Melevodopa bears US NLM identifiers UMLS ID C0064871 and NCI Concept Code C83927. SMILES: COC(=O)C(CC1=CC(=C(C=C1)O)O)N.
This classification denotes a dopamine agonist with the molecular formula C10H13NO4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JFU1A8866V. European Medicines Agency schedules melevodopa hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33439. Most nations, for tariff and trade purposes, schedule melevodopa hydrochloride under HS 29225000. As of Q4 2014, MELEVODOPA HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC(=O)[C@H](CC1CCC(C(C1)O)O)N.CL.
This classification denotes an enzyme inhibitor with the molecular formula C26H41NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JJ07049A84, chemically known as 9,12-octadecadienamide, n-(1-phenylethyl)-, (z,z)- (9ci) but generally known as melinamide, which bears US NIH Compound Identifier 5282142. European Medicines Agency schedules Melinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08724MIG. The term MELINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). MELINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule melinamide under HS 29242995 and SITC 51479. As of Q4 2014, MELINAMIDE remains the US FDA Preferred Term for this commodity. Melinamide bears US NLM identifiers UMLS ID C0067477 and NCI Concept Code C87732. SMILES: O=C(NC(c1ccccc1)C)CCCCCCC/C=C/C/C=C/CCCCC.
This classification denotes an anthracene and tricyclic antidepressive agent with the molecular formula C21H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q7T0Y1109Z, chemically known as 3-(10,10-dimethyl-9(10h)-anthracenylidene)-n,n-dimethyl-1-propanamine but generally known as melitracen, which bears US NIH Compound Identifier 25382. European Medicines Agency schedules Melitracen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08725MIG. World Health Organization schedules melitracen in its Anatomical Therapeutic Chemical (ATC) Classification. MELITRACEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule melitracen under HS 29214980 and SITC 51454. As of Q4 2014, MELITRACEN remains the US FDA Preferred Term for this commodity. SMILES: N(CC/C=C1/c2c(C(c3c1cccc3)(C)C)cccc2)(C)C.
This classification denotes an antidepressant agent with the molecular formula C21H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3448GKP5W, chemically known as 9-(3-dimethylaminopropylidene)-10,10-dimethyl-9,10-dihydroanthracene hydrochloride but more generally known as melitracen hydrochloride, which bears US NIH Compound Identifier 25381. European Medicines Agency schedules Melitracen hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03134MIG. Most nations, for tariff and trade purposes, schedule melitracen hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, MELITRACEN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Melitracen hydrochloride bears US NLM identifiers UMLS ID C2983846 and NCI Concept Code C90710. SMILES: CC1(C2CCCCC2C(=CCCN(C)C)C3C1CCCC3)C.CL.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H13N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VG2QF83CGL, chemically known as 4-hydroxy-2-methyl-n-(5-methyl-2-thiazoyl)-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide but generally known as meloxicam, which bears US NIH Compound Identifier 5281106. European Medicines Agency schedules Meloxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08726MIG. The term MELOXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules meloxicam in its Anatomical Therapeutic Chemical (ATC) Classification. MELOXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meloxicam under HS 29341000 and SITC 51579. As of Q4 2014, MELOXICAM remains the US FDA Preferred Term for this commodity. Meloxicam bears US NLM identifiers UMLS ID C0083381 and NCI Concept Code C61439. SMILES: S1(=O)(=O)N(/C(=C(/O)NC2SC(CN2)C)C(=O)C2C1CCCC2)C.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J8WA3K39B7. European Medicines Agency schedules Melperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08727MIG. Melperone generally arises in the molecular formula C16H22FNO. The term MELPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) MELPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule melperone under HS 29333999 and SITC 51574. As of Q4 2014, MELPERONE remains the US FDA Preferred Term for this commodity. Melperone bears US NLM identifiers UMLS ID C0066477 and NCI Concept Code C73293. SMILES: FC1CCC(C(=O)CCCN2CCC(CC2)C)CC1.
This classification denotes an antipsychotic agent with the molecular formula C16H22FNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88G640374K, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-, hydrochloride but more generally known as melperone hydrochloride, which bears US NIH Compound Identifier 15386. European Medicines Agency schedules Melperone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14503MIG. Most nations, for tariff and trade purposes, schedule melperone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, MELPERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCN(CC1)CCCC(=O)C2CCC(CC2)F.CL.
This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q41OR9510P, chemically known as l-phenylalanine, 4-(bis(2-chloroethyl)amino)- but more generally known as melphalan, which bears US NIH Compound Identifier 4053. European Medicines Agency schedules Melphalan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08728MIG. The term MELPHALAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules melphalan in its Anatomical Therapeutic Chemical (ATC) Classification. MELPHALAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule melphalan under HS 29224995 and SITC 51465. As of Q4 2014, MELPHALAN remains US FDA's Preferred Term for this commodity. Melphalan bears US NLM identifiers UMLS ID C0025241 and NCI Concept Code C633. SMILES: CLCCN(C1CCC(CC(N)C(=O)O)CC1)CCCL.
This classification denotes a nitrogen mustard compound C24H30Cl2FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F70C5K4786, chemically known as l-phenylalanine, 4-(bis(2-chloroethyl)amino)-l-phenylalanyl-4-fluoro-, ethyl ester, but more generally known as melphalan flufenamide, which bears US NIH Compound Identifier 9935639. Most nations, for tariff and trade purposes, schedule melphalan flufenamide under HS 29224995 and SITC 51465. As of Q4 2014, MELPHALAN FLUFENAMIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)[C@H](CC1CCC(CC1)F)NC(=O)[C@H](CC2CCC(CC2)N(CCCL)CCCL)N.
This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1VXP4V453T, chemically known as l-phenylalanine, 4-(bis(2-chloroethyl)amino)- but more generally known as melphalan hydrochloride, which bears US NIH Compound Identifier 4053. Most nations, for tariff and trade purposes, schedule melphalan hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, MELPHALAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Melphalan hydrochloride bears US NLM identifiers UMLS ID C0771055 and NCI Concept Code C48002. SMILES: C1CC(CCC1C[C@@H](C(=O)O)N)N(CCCL)CCCL.CL.
This classification denotes an anti-asthmatic agent with the molecular formula C15H16N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0RO0SEU9AY, chemically known as ethyl 6-ethyl-5,6-dihydro-9-methyl-5-oxo-s-triazolo(1,5-c)quinazoline-2-carboxylate. but generally known as melquinast, which bears US NIH Compound Identifier 3045413. European Medicines Agency schedules Melquinast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08729MIG. The term MELQUINAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). MELQUINAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule melquinast under HS 29335995 and SITC 51576. As of Q4 2014, MELQUINAST remains the US FDA Preferred Term for this commodity. Melquinast bears US NLM identifiers UMLS ID C1881774 and NCI Concept Code C66082. SMILES: O=C1N(C2C(C3N1NC(N3)C(=O)OCC)CC(CC2)C)CC.
This classification denotes a bronchodilator and beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FYC8314117. European Medicines Agency schedules Meluadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08730MIG. Meluadrine generally arises in the molecular formula C12H18CLNO2. The term MELUADRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) Most nations schedule meluadrine under HS 29225000 and SITC 51467. As of Q4 2014, MELUADRINE remains the US FDA Preferred Term for this commodity. Meluadrine bears US NLM identifiers UMLS ID C1881776 and NCI Concept Code C66083. SMILES: CC(C)(C)NCC(C1=C(C=C(C=C1)O)CL)O.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C12H18ClNO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P0KL436YB, chemically known as benzenemethanol, 2-chloro-.alpha.-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (.alpha.r)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1) (salt), but more generally known as meluadrine tartrate, which bears US NIH Compound Identifier 636384. European Medicines Agency schedules meluadrine tartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08730MIG. Most nations, for tariff purposes, schedule meluadrine tartrate under HS 29225000. SMILES: CC(C)(C)NC[C@@H](C1CCC(CC1CL)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a neuroprotective agent and antiparkinsonian agent with the molecular formula C12H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8O17SJF3T, chemically known as 3,5-dimethyltricyclo(3.3.1.1(3,7))decan-1-amine but generally known as memantine, which bears US NIH Compound Identifier 4054. European Medicines Agency schedules Memantine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08731MIG. The term MEMANTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules memantine in its Anatomical Therapeutic Chemical (ATC) Classification. MEMANTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule memantine under HS 29213099 and SITC 51453. As of Q4 2014, MEMANTINE remains the US FDA Preferred Term for this commodity. Memantine bears US NLM identifiers UMLS ID C0025242 and NCI Concept Code C73269. SMILES: NC12CC3(CC(C1)(CC(C3)C2)C)C.
This classification denotes an antiparkinsonian agent with the molecular formula C12H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JY0WD0UA60, chemically known as 3,5-dimethyltricyclo(3.3.1.1(3,7))decan-1-amine but more generally known as memantine hydrochloride, which bears US NIH Compound Identifier 4054. European Medicines Agency schedules Memantine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03137MIG. Most nations, for tariff and trade purposes, schedule memantine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, MEMANTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Memantine hydrochloride bears US NLM identifiers UMLS ID C0771988 and NCI Concept Code C47601. SMILES: C[C@@]12CC3C[C@@](C1)(C[C@](C3)(C2)N)C.CL.
This classification denotes an antiviral agent with the molecular formula C17H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42BHH3WP14, chemically known as 1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline but generally known as memotine, which bears US NIH Compound Identifier 25350. Most nations schedule memotine under HS 29334990 and SITC 51575. As of Q4 2014, MEMOTINE remains the US FDA Preferred Term for this commodity. Memotine bears US NLM identifiers UMLS ID C2981324 and NCI Concept Code C87664. SMILES: COC1=CC=C(C=C1)OCC2=NCCC3=CC=CC=C32.
This classification denotes an antiviral agent with the molecular formula C17H17NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZP0HNU59MM, chemically known as isoquinoline, 3,4-dihydro-1-(4-methoxyphenoxy)methyl]-, hydrochloride but more generally known as memotine hydrochloride, which bears US NIH Compound Identifier 25350. Most nations, for tariff and trade purposes, schedule memotine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, MEMOTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Memotine hydrochloride bears US NLM identifiers UMLS ID C2981325 and NCI Concept Code C87665. SMILES: COC1CCC(CC1)OCC2=NCCC3C2CCCC3.CL.
This clasification denotes vaccines or candidate vaccines used to prevent infection with neisseria meningitidis. Meningococcal vaccine bears US NLM identifiers UMLS ID C0700144 and NCI Concept Code C96397.
This classification denotes a benzodiazepine with the molecular formula C16H17N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1243654WZK, chemically known as 2h-1,4-benzodiazepin-2-one, 5-(1-cyclohexen-1-yl)-1,3-dihydro-1-methyl-7-nitro- but generally known as menitrazepam, which bears US NIH Compound Identifier 189875. European Medicines Agency schedules Menitrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08740MIG. The term MENITRAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). MENITRAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule menitrazepam under HS 29339940 and SITC 51577. As of Q4 2014, MENITRAZEPAM remains the US FDA Preferred Term for this commodity. Menitrazepam bears US NLM identifiers UMLS ID C1881782 and NCI Concept Code C66088. SMILES: O=C1N(C2C(C(=NC1)C1=CCCCC1)CC([N](=O)O)CC2)C.
This classification denotes an antimalarial agent with the molecular formula C24H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QP1A5BD6K9, chemically known as 1,4-naphthoquinone, 2-(8-cyclohexyloctyl)-3-hydroxy- (8ci) but generally known as menoctone, which bears US NIH Compound Identifier 26738. European Medicines Agency schedules Menoctone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08741MIG. The term MENOCTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). MENOCTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule menoctone under HS 29146990 and SITC 51629. As of Q4 2014, MENOCTONE remains the US FDA Preferred Term for this commodity. Menoctone bears US NLM identifiers UMLS ID C0065946 and NCI Concept Code C81543. SMILES: OC1=C(CCCCCCCCC2CCCCC2)C(=O)C(=O)C2C1CCCC2.
This classification denotes an anthracycline antibiotic with the molecular formula C28H31NO10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8JSV4O30HQ, chemically known as 2,6-epoxy-2h-naphthaceno(1,2-b)oxocin-9,16-dione, 4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-, (2r-(2alpha,3beta,4alpha,5beta,6alpha,11alpha,13alpha))- but generally known as menogaril, which bears US NIH Compound Identifier 51370. European Medicines Agency schedules Menogaril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08742MIG. The term MENOGARIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). MENOGARIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule menogaril under HS 29419000 and SITC 54139. As of Q4 2014, MENOGARIL remains the US FDA Preferred Term for this commodity. Menogaril bears US NLM identifiers UMLS ID C0127527 and NCI Concept Code C1389. SMILES: O1C2(C(O)C(N(C)C)C(O)C1OC1C2CC(O)C2C1C(=O)C1C(C2=O)C(O)C2C(OC)CC(O)(CC2C1)C)C.
This classification denotes extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, follicle stimulating hormone and luteinizing hormone, and which are used to treat infertility, preparations that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Y9QQM372Q, and generally arise in the molecular formula C42H65N11O12S2, chemically known as 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide, but generally known as menotropins, and sometimes also called urofollitropin, and which bear US NIH Compound Identifier 62819. The term UROFOLLITROPIN, the synonym for this commodity, is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27.) SMILES: CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O.
This classification denotes a terpene compound and anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L7T10EIP3A. European Medicines Agency schedules Menthol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12531MIG. Menthol generally arises in the molecular formula C10H20O. The term MENTHOL is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule menthol under HS 29061100 and SITC 51231. As of Q4 2014, MENTHOL remains the US FDA Preferred Term for this commodity. Menthol bears US NLM identifiers UMLS ID C0025368 and NCI Concept Code C80301. SMILES: CC1CCC(C(C1)O)C(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an antiarrhythmic agent with the molecular formula C11H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) T91E239Z1V, chemically known as 1-[(4-methoxyphenyl)methyl]-2,3-dimethylguanidine but more generally known as meobentine, which bears US NIH Compound Identifier 42765. European Medicines Agency schedules meobentine its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08743MIG. Most nations, for tariff and trade purposes, schedule meobentine under HS 29252900 and SITC 51482. As of Q4 2014, MEOBENTINE remains US FDA's Preferred Term for this commodity. SMILES: CNC(=NC)NCC1=CC=C(C=C1)OC.
This classification denotes an antiarrhythmic agent with the molecular formula 2C11H17N3O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D6BKO039M0, chemically known as 1-(p-methoxybenzyl)-2,3-dimethylguanidine sulfate (2:1) but more generally known as meobentine sulfate, which bears US NIH Compound Identifier 42764. Most nations, for tariff and trade purposes, schedule meobentine sulfate under HS 29252900 and SITC 51482. As of Q4 2014, MEOBENTINE SULFATE remains US FDA's Preferred Term for this commodity. Meobentine sulfate bears US NLM identifiers UMLS ID C0127535 and NCI Concept Code C90664. SMILES: CNC(=NC)NCC1CCC(CC1)OC.CNC(=NC)NCC1CCC(CC1)OC.OS(=O)(=O)O.
This classification denotes an antiprotozoal agent and antineoplastic with the molecular formula C23H30ClN3O.2ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6242H2NAA, chemically known as 1,4-pentanediamine, n4- (6-chloro-2-methoxy-9-acridinyl)-n1,n1-diethyl-, dihydrochloride but generally known as mepacrine hydrochloride, which bears US NIH Compound Identifier 237. European Medicines Agency schedules Mepacrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03152MIG. Most nations schedule mepacrine under HS 29339990 and SITC 51577. SMILES: Clc1cc2nc3c(c(NC(CCCN(CC)CC)C)c2cc1)cc(OC)cc3.
This classification denotes an antiprotozoal agent with the molecular formula C23H30ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H0C805XYDE, chemically known as 1,4-pentanediamine, n4- (6-chloro-2-methoxy-9-acridinyl)-n1,n1-diethyl-, dihydrochloride but generally known as mepacrine, which bears US NIH Compound Identifier 237. European Medicines Agency schedules Mepacrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08744MIG. The term MEPACRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules mepacrine in its Anatomical Therapeutic Chemical (ATC) Classification. MEPACRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Mepacrine or quinacrine bears US NLM identifiers UMLS ID C0034403 and NCI Concept Code C87656. SMILES: CLC1CC2NC3C(C(NC(CCCN(CC)CC)C)C2CC1)CC(OC)CC3.
This classification denotes a sedative and hypnotic with the molecular formula C6H10O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B017BC5B1N, chemically known as 2-butanol, 2-ethynyl- but generally known as meparfynol, which bears US NIH Compound Identifier 6494. European Medicines Agency schedules Methylpentynol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08869MIG. The term METHYLPENTYNOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules meparfynol in its Anatomical Therapeutic Chemical (ATC) Classification. Meparfynol or methylpentynol bears US NLM identifiers UMLS ID C0066418 and NCI Concept Code C76098. SMILES: CCC(C)(C#C)O.
This classification denotes a macrolide antibiotic with the molecular formula C60H88N2O19, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B7FBW3Y74G, chemically known as (4E,6E,8E,10Z,12Z,14E,16E)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-23,27,29,31,33,35,37-heptahydroxy-19-[5-hydroxy-7-[4-(methylamino)phenyl]-7-oxoheptan-2-yl]-18-methyl-21,25-dioxo-20,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylate but generally known as Mepartricin, which bears US NIH Compound Identifier 6479653. European Medicines Agency schedules Mepartricin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03153MIG. The term MEPARTRICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 1). World Health Organization schedules azithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. MEPARTRICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mepartricin under HS 29419000 and SITC 54139. As of Q4 2014, MEPARTRICIN remains the US FDA Preferred Term for this commodity. SMILES: CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(CC(CC(CC(=O)CC(CC(=O)OC1C(C)CCC(CC(=O)C3=CC=C(C=C3)NC)O)O)O)O)O)O)O)O)C(=O)OC)OC4C(C(C(C(O4)C)O)N)O.
This classification denotes a macrolide antibiotic with the molecular formula C60H88N2O19, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L13V8793FQ, chemically known as candicidin d, 40-demethyl-3,7-dideoxo-3,7-dihydroxy-n47-methyl-5-oxo-, methyl ester, cyclic 15,19-hemiacetal, but more generally known as mepartricin a, which bears US NIH Compound Identifier 3009010. European Medicines Agency schedules mepartricin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03153MIG. Most nations, for tariff purposes, schedule mepartricin a under HS 29419000. SMILES: C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)OC\2CC3C(C(CC(O3)(CC(CC(CC(CC(CC(=O)CC(CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CCC(CC(=O)C4CCC(CC4)NC)O)O)O)O)O)O)O)O)C(=O)OC)O)N)O.
This classification denotes a macrolide antibiotic with the molecular formula C59H86N2O19, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21G4VMN6C9, chemically known as candicidin d, 40-demethyl-3,7-dideoxo-3,7-dihydroxy-5-oxo-, methyl ester, cyclic 15,19-hemiacetal, but more generally known as mepartricin b, which bears US NIH Compound Identifier 6450330. European Medicines Agency schedules mepartricin b or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03153MIG. Most nations, for tariff purposes, schedule mepartricin b under HS 29419000. SMILES: C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)OC\2CC3C(C(CC(O3)(CC(CC(CC(CC(CC(=O)CC(CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CCC(CC(=O)C4CCC(CC4)N)O)O)O)O)O)O)O)O)C(=O)OC)O)N)O.
This classification denotes a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U42703EIIO. European Medicines Agency schedules Pecazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09642MIG. Pecazine generally arises in the molecular formula C19H22N2S. The term PECAZINE is an International Non-Proprietary Name or INN. PECAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Mepazine or pecazine bears US NLM identifiers UMLS ID C0065954 and NCI Concept Code C76052. SMILES: S1C2C(N(CC3CCCN(C3)C)C3C1CCCC3)CCCC2.
This classification denotes an antimuscarinic agent with the molecular formula C21H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ONW3LB39P7, chemically known as 3-hydroxy-1, 1-dimethylpiperidinium bromide benzilate but generally known as mepenzolate, which bears US NIH Compound Identifier 4057. European Medicines Agency schedules Mepenzolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14513MIG. World Health Organization schedules mepenzolate in its Anatomical Therapeutic Chemical (ATC) Classification. MEPENZOLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, MEPENZOLATE remains the US FDA Preferred Term for this commodity. Mepenzolate bears US NLM identifiers UMLS ID C0360172 and NCI Concept Code C61830. SMILES: O(C1C[N](CCC1)(C)C)C(=O)C(O)(C1CCCCC1)C1CCCCC1.
This classification denotes an opioid receptor agonist with the molecular formula C15H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E338QE28F, chemically known as 4-piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester, hydrochloride but generally known as meperidine, which bears US NIH Compound Identifier 4058. European Medicines Agency schedules Pethidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09738MIG. The term MEPERIDINE is an International Non-Proprietary Name. World Health Organization schedules meperidine in its Anatomical Therapeutic Chemical (ATC) Classification. Meperidine or pethidine bears US NLM identifiers UMLS ID C0025376 and NCI Concept Code C71632. SMILES: CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes a muscle relaxant with the molecular formula C10H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7B8PIR2954, chemically known as 1,2-propanediol, 3-(o-tolyloxy)- but generally known as mephenesin, which bears US NIH Compound Identifier 4059. European Medicines Agency schedules Mephenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08746MIG. The term MEPHENESIN is an International Non-Proprietary Name. World Health Organization schedules mephenesin in its Anatomical Therapeutic Chemical (ATC) Classification. MEPHENESIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mephenesin under HS 29094990 and SITC 51617. As of Q4 2014, MEPHENESIN remains the US FDA Preferred Term for this commodity. Mephenesin bears US NLM identifiers UMLS ID C0025379 and NCI Concept Code C76773. SMILES: CC1=CC=CC=C1OCC(CO)O.
This classification denotes a muscle relaxant with the molecular formula C11H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PAD6SXB23N, chemically known as 1,2-propanediol, 3-(o-tolyloxy)-, 1-carbamate (8ci) but more generally known as mephenesin carbamate, which bears US NIH Compound Identifier 10775. Most nations, for tariff and trade purposes, schedule mephenesin carbamate under HS 29094990 and SITC 51617. As of Q4 2014, MEPHENESIN CARBAMATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCCCC1OCC(COC(=O)N)O.
This classification denotes a muscle relaxant with the molecular formula C16H17NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9490C46O95. Most nations schedule mephenesin nicotinate under HS 29094990 and SITC 51617. As of Q4 2014, MEPHENESIN NICOTINATE remains the US FDA Preferred Term for this commodity. SMILES: CC1=CC=CC=C1OCC(COC(=O)N)O.
This classification denotes a muscle relaxant with the molecular formula C11H13NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CZ87T54W8W, chemically known as 2-oxazolidinone, 5-((o-methoxyphenoxy)methyl)- but generally known as mephenoxalone, which bears US NIH Compound Identifier 6257. European Medicines Agency schedules Mephenoxalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08747MIG. The term MEPHENOXALONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules mephenoxalone in its Anatomical Therapeutic Chemical (ATC) Classification. MEPHENOXALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mephenoxalone under HS 29349990 and SITC 51579. As of Q4 2014, MEPHENOXALONE remains the US FDA Preferred Term for this commodity. Mephenoxalone bears US NLM identifiers UMLS ID C0065959 and NCI Concept Code C83930. SMILES: COC1=CC=CC=C1OCC2CNC(=O)O2.
This classification denotes a cns stimulant with the molecular formula C11H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TEZ91L71V4, chemically known as phenethylamine, n,alpha,alpha-trimethyl- but generally known as mephentermine, which bears US NIH Compound Identifier 3677. European Medicines Agency schedules Mephentermine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08748MIG. The term MEPHENTERMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules mephentermine in its Anatomical Therapeutic Chemical (ATC) Classification. MEPHENTERMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mephentermine under HS 29214980 and SITC 51454. As of Q4 2014, MEPHENTERMINE remains the US FDA Preferred Term for this commodity. Mephentermine bears US NLM identifiers UMLS ID C0025380 and NCI Concept Code C66089. SMILES: CC(C)(CC1=CC=CC=C1)NC.
This classification denotes a cns stimulant with the molecular formula 2C11H17N.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 580655Z8RR, chemically known as phenethylamine, n,alpha,alpha-trimethyl-, sulfate (2:1) but more generally known as mephentermine sulfate, which bears US NIH Compound Identifier 71611. European Medicines Agency schedules Mephentermine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03156MIG. Most nations, for tariff and trade purposes, schedule mephentermine sulfate under HS 29214980 and SITC 51454. As of Q4 2014, MEPHENTERMINE SULFATE remains US FDA's Preferred Term for this commodity. Mephentermine sulfate bears US NLM identifiers UMLS ID C0282231 and NCI Concept Code C66090. SMILES: CC(C)(CC1CCCCC1)NC.CC(C)(CC1CCCCC1)NC.OS(=O)(=O)O.
This classification denotes an anticonvulsant agent with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R420KW629U, chemically known as 2,4-imidazolidinedione, 5-ethyl-3-methyl-5-phenyl- but generally known as mephenytoin, which bears US NIH Compound Identifier 4060. European Medicines Agency schedules Mephenytoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08749MIG. The term MEPHENYTOIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules mephenytoin in its Anatomical Therapeutic Chemical (ATC) Classification. MEPHENYTOIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mephenytoin under HS 29332100 and SITC 51572. As of Q4 2014, MEPHENYTOIN remains the US FDA Preferred Term for this commodity. Mephenytoin bears US NLM identifiers UMLS ID C0025381 and NCI Concept Code C66091. SMILES: CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2.
This classification denotes a barbiturate with the molecular formula C13H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5NC67NU76B, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-1-methyl-5-phenyl- but generally known as mephobarbital, which bears US NIH Compound Identifier 8271. European Medicines Agency schedules Mephobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08871MIG. The term MEPHOBARBITAL is an International Non-Proprietary Name. World Health Organization schedules mephobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. Mephobarbital or methylphenobarbital bears US NLM identifiers UMLS ID C0025382 and NCI Concept Code C76528. SMILES: O=C1N(C(=O)NC(=O)C1(CC)C1CCCCC1)C.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00Q31ER368. European Medicines Agency schedules Mepindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08750MIG. Mepindolol generally arises in the molecular formula C15H22N2O2. The term MEPINDOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) MEPINDOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mepindolol under HS 29339990 and SITC 51577. As of Q4 2014, MEPINDOLOL remains the US FDA Preferred Term for this commodity. Mepindolol bears US NLM identifiers UMLS ID C0065961 and NCI Concept Code C84659. SMILES: O(CC(O)CNC(C)C)C1C2C([NH]C(C2)C)CCC1.
This classification denotes a beta-adrenergic blocking agent 2C15H22N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63523X4FBA, chemically known as 2-propanol, 1-((1-methylethyl)amino)-3-((2-methyl-1h-indol-4-yl)oxy)-, sulfate (2:1), but more generally known as mepindolol sulfate, which bears US NIH Compound Identifier 6917859. European Medicines Agency schedules Mepindolol sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03157MIG. Most nations, for tariff and trade purposes, schedule mepindolol sulfate under HS 29339990 and SITC 51577. As of Q4 2014, MEPINDOLOL SULFATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C([NH]1)CCCC2OCC(CNC(C)C)O.CC1CC2C([NH]1)CCCC2OCC(CNC(C)C)O.OS(=O)(=O)O.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 977BAL0NR7. European Medicines Agency schedules Mepiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08751MIG. Mepiprazole generally arises in the molecular formula C16H21CLN4. The term MEPIPRAZOLE is an International Non-Proprietary Name or INN. MEPIPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mepiprazole under HS 29335995 and SITC 51576. As of Q4 2014, MEPIPRAZOLE remains the US FDA Preferred Term for this commodity. Mepiprazole bears US NLM identifiers UMLS ID C0065963 and NCI Concept Code C66092. SMILES: Clc1cc(N2CCN(CC2)CCc2n[nH]c(c2)C)ccc1.
This classification denotes an antidepressant agent with the molecular formula C16H21ClN4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TN5WJ92YGP, chemically known as piperazine, 1-(3-chlorophenyl)-4-(2-(5-methyl-1h-pyrazol-3-yl)ethyl)-, hydrochloride (1:2), but more generally known as mepiprazole dihydrochloride, which bears US NIH Compound Identifier 209757. European Medicines Agency schedules mepiprazole dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08751MIG. Most nations, for tariff purposes, schedule mepiprazole dihydrochloride under HS 29335995. SMILES: CC1CC(N[NH]1)CCN2CCN(CC2)C3CCCC(C3)CL.CL.CL.
This classification denotes an antiestrogen with the molecular formula C25H40O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O00404969K, chemically known as 5-alpha-androstane, 2-alpha,3-alpha-epithio-17-beta-(1-methoxycyclopentyloxy)- but generally known as mepitiostane, which bears US NIH Compound Identifier 30605. European Medicines Agency schedules Mepitiostane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08753MIG. The term MEPITIOSTANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). MEPITIOSTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mepitiostane under HS 29372900 and SITC 54153. As of Q4 2014, MEPITIOSTANE remains the US FDA Preferred Term for this commodity. Mepitiostane bears US NLM identifiers UMLS ID C0065964 and NCI Concept Code C1158. SMILES: S1C2CC3(C4C(C5C(CC4)(C(OC4(OC)CCCC4)CC5)C)CCC3CC12)C.
This classification denotes an anesthetic agent with the molecular formula C15H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6E06QE59J, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-methyl- but generally known as mepivacaine, which bears US NIH Compound Identifier 4062. European Medicines Agency schedules Mepivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14514MIG. The term MEPIVACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules mepivacaine in its Anatomical Therapeutic Chemical (ATC) Classification. MEPIVACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mepivacaine under HS 29333999 and SITC 51574. As of Q4 2014, MEPIVACAINE remains the US FDA Preferred Term for this commodity. Mepivacaine bears US NLM identifiers UMLS ID C0025384 and NCI Concept Code C61831. SMILES: O=C(NC1C(CCCC1C)C)C1N(CCCC1)C.
This classification denotes an anesthetic agent with the molecular formula C15H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VFX2L7EM5, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-methyl- but more generally known as mepivacaine hydrochloride, which bears US NIH Compound Identifier 4062. European Medicines Agency schedules Mepivacaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03158MIG. Most nations, for tariff and trade purposes, schedule mepivacaine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, MEPIVACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mepivacaine hydrochloride bears US NLM identifiers UMLS ID C0700542 and NCI Concept Code C47602. SMILES: CC1CCCC(C1NC(=O)C2CCCCN2C)C.CL.
This classification denotes an anti-asthmatic agent with the molecular formula C20H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7419T4YQQW, chemically known as 9h-xanthen-9-one, 3-methoxy-4-(1-piperidinylmethyl)- but generally known as mepixanox, which bears US NIH Compound Identifier 65687. European Medicines Agency schedules Mepixanox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08754MIG. The term MEPIXANOX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules mepixanox in its Anatomical Therapeutic Chemical (ATC) Classification. MEPIXANOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mepixanox under HS 29349990 and SITC 51579. As of Q4 2014, MEPIXANOX remains the US FDA Preferred Term for this commodity. Mepixanox bears US NLM identifiers UMLS ID C0071070 and NCI Concept Code C66094. SMILES: O1C2C(CN3CCCCC3)C(OC)CCC2C(=O)C2C1CCCC2.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67U96J8P35, chemically known as 17, 21-dihydroxy-16.beta.-methylpregna-1,4-diene-3,11,20-trione but generally known as meprednisone, which bears US NIH Compound Identifier 4063. European Medicines Agency schedules Meprednisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08756MIG. The term MEPREDNISONE is an International Non-Proprietary Name. World Health Organization schedules meprednisone in its Anatomical Therapeutic Chemical (ATC) Classification. MEPREDNISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meprednisone under HS 29372900 and SITC 54153. As of Q4 2014, MEPREDNISONE remains the US FDA Preferred Term for this commodity. Meprednisone bears US NLM identifiers UMLS ID C0065967 and NCI Concept Code C66096. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)C=C4)CC3)C)C(=O)C2)CC1C)C)C(=O)CO.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W80C977F6O, chemically known as pregna-1,4-diene-3,11,20-trione, 17-hydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (16.beta.)-, but more generally known as meprednisone disodium phosphate, which bears US NIH Compound Identifier 31051. European Medicines Agency schedules meprednisone disodium phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08756MIG. Most nations, for tariff purposes, schedule meprednisone disodium phosphate under HS 29372900. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)C.[NA+].[NA+].
This classification denotes a sedative, hypnotic, and anticonvulsant agent with the molecular formula C9H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I7LNY769Q, chemically known as 1,3-propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate (ester) but generally known as meprobamate, which bears US NIH Compound Identifier 2576. European Medicines Agency schedules Meprobamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08757MIG. The term MEPROBAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules meprobamate in its Anatomical Therapeutic Chemical (ATC) Classification. MEPROBAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meprobamate under HS 29241100 and SITC 51471. As of Q4 2014, MEPROBAMATE remains the US FDA Preferred Term for this commodity. Meprobamate bears US NLM identifiers UMLS ID C0025386 and NCI Concept Code C47603. SMILES: O(CC(CCC)(COC(=O)N)C)C(=O)NC(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.
This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1177I648L1. European Medicines Agency schedules Alphameprodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05364MIG. Alphameprodine generally arises in the molecular formula C17H25NO2. The term ALPHAMEPRODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) ALPHAMEPRODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1(C(CN(CC1)C)CC)C1CCCCC1)C(=O)CC.
This classification denotes an antitussive agent with the molecular formula C19H23NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2JXZ154Z0Q, chemically known as 9h-thioxanthen-9-ol, 9-(3-(dimethylamino)propyl)-2-methoxy- but more generally known as meprotixol, which bears US NIH Compound Identifier 71195. European Medicines Agency schedules Meprotixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08759MIG. The term MEPROTIXOL is an International Non-Proprietary Name. World Health Organization schedules meprotixol in its Anatomical Therapeutic Chemical (ATC) Classification. MEPROTIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule meprotixol under HS 29349990 and SITC 51579. As of Q4 2014, MEPROTIXOL remains US FDA's Preferred Term for this commodity. Meprotixol bears US NLM identifiers UMLS ID C2981321 and NCI Concept Code C87660. SMILES: S1C2C(C(O)(CCCN(C)C)C3C1CCCC3)CC(OC)CC2.
This classification denotes an anesthetic agent with the molecular formula C14H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82YT7WU9PW, chemically known as 1-propanol, 2-methyl-2-(propylamino)-, benzoate (ester) but generally known as meprylcaine, which bears US NIH Compound Identifier 4065. European Medicines Agency schedules Meprylcaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08760MIG. The term MEPRYLCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). MEPRYLCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meprylcaine under HS 29221980 and SITC 51461. As of Q4 2014, MEPRYLCAINE remains the US FDA Preferred Term for this commodity. Meprylcaine bears US NLM identifiers UMLS ID C0301288 and NCI Concept Code C83931. SMILES: O(CC(NCCC)(C)C)C(=O)C1CCCCC1.
This classification denotes an anesthetic agent with the molecular structure C14H21NO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, VR843X5GXG chemically known as 1-propanol-2-methyl-2-(propylamino)-, benzoate (ester), hydrochloride, but more commonly known as meprylcaine hydrochloride, which bears US NIH Compound Identifier 101925. European Medicines Agency schedules Meprylcaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03160MIG. Most nations, for tariff and trade purposes, schedule meprylcaine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, MEPRYLCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Meprylcaine hydrochloride bears US NLM identifiers UMLS ID C2347107 and NCI Concept Code C72819. SMILES: CCCNC(C)(C)COC(=O)C1CCCCC1.CL.
This classification denotes an opioid receptor agonist with the molecular formula C15H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18Y7S5JKZD, chemically known as phenol, 3-(3-ethylhexahydro-1-methyl-1h-azepin-3-yl)- but generally known as meptazinol, which bears US NIH Compound Identifier 41049. European Medicines Agency schedules Meptazinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08761MIG. The term MEPTAZINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules meptazinol in its Anatomical Therapeutic Chemical (ATC) Classification. MEPTAZINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meptazinol under HS 29339930 and SITC 51577. As of Q4 2014, MEPTAZINOL remains the US FDA Preferred Term for this commodity. Meptazinol bears US NLM identifiers UMLS ID C0025387 and NCI Concept Code C87360. SMILES: OC1CC(C2(CCCCN(C2)C)CC)CCC1.
This classification denotes an opioid receptor agonist with the molecular formula C15H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T62FQ4ZCPA, chemically known as phenol, 3-(3-ethylhexahydro-1-methyl-1h-azepin-3-yl)- but more generally known as meptazinol hydrochloride, which bears US NIH Compound Identifier 41049. European Medicines Agency schedules Meptazinol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03161MIG. Most nations, for tariff and trade purposes, schedule meptazinol hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, MEPTAZINOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Meptazinol hydrochloride bears US NLM identifiers UMLS ID C0043281 and NCI Concept Code C87361. SMILES: CCC1(CCCCN(C1)C)C2CCCC(C2)O.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular structure C17H23N3O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5T3R4P0I14 chemically known as 1,2-ethanediamine, n1-((4-methoxyphenyl)methyl)-n2,n2-dimethyl-n1-2-pyridinyl-, hydrochloride (1:1), but more commonly known as mepyramine hydrochloride, which bears US NIH Compound Identifier 80139. European Medicines Agency schedules Mepyramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14515MIG. Most nations, for tariff and trade purposes, schedule mepyramine hydrochloride under HS 29333999. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2CCCCN2.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H23N3O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R35D29L3ZA, chemically known as n-(p-methoxybenzyl)-n, n-dimethyl-n-.alpha.-pyridylethylenediamine maleate but more generally known as mepyramine maleate, which bears US NIH Compound Identifier 5284451. European Medicines Agency schedules Mepyramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14516MIG. Most nations, for tariff and trade purposes, schedule mepyramine maleate under HS 29333999. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as 1,2-ethanediamine, n-((4-methoxyphenyl)methyl)-n,n-dimethyl-n-2-pyridinyl- (9ci) but generally known as mepyramine, which bears US NIH Compound Identifier 4992. European Medicines Agency schedules Mepyramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08762MIG. The term MEPYRAMINE is an International Non-Proprietary Name. World Health Organization schedules mepyramine in its Anatomical Therapeutic Chemical (ATC) Classification. MEPYRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Mepyramine or pyrilamine bears US NLM identifiers UMLS ID C0034282 and NCI Concept Code C76676. SMILES: CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C76H52O46.C17H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A9310LW34B. European Medicines Agency schedules mepyramine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03164MIG. Most nations, for tariff and trade purposes, schedule mepyramine tannate under HS 29333999. SMILES:.
This classification denotes a topical anti-infective agent with the molecular formula C10H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4UV6363I81, chemically known as 3-methyl-2-quinoxalinylmethanol n(sup1),n(sup4)-dioxide but more generally known as mequidox, which bears US NIH Compound Identifier 28143. European Medicines Agency schedules Mequidox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08763MIG. The term MEQUIDOX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). MEQUIDOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=C([N+](=O)C2=CC=CC=C2N1[O-])CO.
This classification denotes an agent affecting integumentary system with the molecular formula C7H8O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6HT8U7K3AM, chemically known as 4-hydroxyphenol, polymer-bound but generally known as mequinol, which bears US NIH Compound Identifier 9015. European Medicines Agency schedules Mequinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08764MIG. The term MEQUINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules mequinol in its Anatomical Therapeutic Chemical (ATC) Classification. MEQUINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mequinol under HS 29095090 and SITC 51617. As of Q4 2014, MEQUINOL remains the US FDA Preferred Term for this commodity. Mequinol bears US NLM identifiers UMLS ID C0048318 and NCI Concept Code C47604. SMILES: O(C1CCC(O)CC1)C.
This classification denotes a histamine-1 receptor antagonist and antimuscarinic agent with the molecular formula C21H25N2S.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50D69ZKZ7M, chemically known as 1-azoniabicyclo(2.2.2)octane, 1-methyl-3-(10h-phenothiazin-10-ylmethyl)-, iodide but generally known as mequitamium iodide, which bears US NIH Compound Identifier 72028. European Medicines Agency schedules Mequitamium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08765MIG. The term MEQUITAMIUM IODIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). Most nations schedule mequitamium iodide under HS 29343090 and SITC 51578. As of Q4 2014, MEQUITAMIUM IODIDE remains the US FDA Preferred Term for this commodity. Mequitamium iodide bears US NLM identifiers UMLS ID C0064889 and NCI Concept Code C83919. SMILES: C[N+]12CCC(CC1)C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53.[I-].
This classification denotes an anti-allergic agent and bronchodilator with the molecular formula C20H22N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y463242LY2, chemically known as 10h-phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)- (9ci) but generally known as mequitazine, which bears US NIH Compound Identifier 4066. European Medicines Agency schedules Mequitazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08766MIG. World Health Organization schedules mequitazine in its Anatomical Therapeutic Chemical (ATC) Classification. MEQUITAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mequitazine under HS 29343090 and SITC 51578. As of Q4 2014, MEQUITAZINE remains the US FDA Preferred Term for this commodity. SMILES: S1C2C(N(CC3C4CCN(C3)CC4)C3C1CCCC3)CCCC2.
This classification denotes a quinolone antibiotic with the molecular formula C19H23F2N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6U51T1K77, chemically known as 3-quinolinecarboxylic acid, 1-ethyl-7-(3-((ethylamino)methyl)-1-pyrrolidinyl)-6,8-difluoro-1,4-dihydro-4-oxo- but generally known as merafloxacin, which bears US NIH Compound Identifier 121833. European Medicines Agency schedules Merafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08767MIG. The term MERAFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). MERAFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule merafloxacin under HS 29334910 and SITC 51575. As of Q4 2014, MERAFLOXACIN remains the US FDA Preferred Term for this commodity. Merafloxacin bears US NLM identifiers UMLS ID C0089342 and NCI Concept Code C83932. SMILES: FC1C(N2CC(CC2)CNCC)C(F)CC2C1N(CC)CC(C2=O)C(=O)O.
This classification denotes an anti-infective agent with the molecular formula C19H8HgI2O6S.Na.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77CVD9244H, chemically known as spiro(3h-2,1-benzoxathiole-3,9-(9h)xanthene)-3,6-diol, 2,7-diiodo-, 1,1-dioxide, mercury complex but generally known as meralein sodium, which bears US NIH Compound Identifier 20408. European Medicines Agency schedules Meralein sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08768MIG. The term MERALEIN SODIUM is an International Non-Proprietary Name. Most nations schedule meralein sodium under HS 29329985 and SITC 51569. As of Q4 2014, MERALEIN SODIUM remains the US FDA Preferred Term for this commodity. Meralein sodium bears US NLM identifiers UMLS ID C0301307 and NCI Concept Code C83934. SMILES: [Hg]([OH2])c1c2oc3c(c(c2cc(I)c1O)c1c(S(=O)(=O)O)cccc1)cc(I)c(=O)c3.[Na].
This classification denotes an anti-infective agent with the molecular formula C20H7Br2HgO5.2Na.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M0T18YH28D, chemically known as 2,7-dibromo-4-hydroxymercurifluoresceine disodium salt but generally known as merbromin, which bears US NIH Compound Identifier 8505. European Medicines Agency schedules Merbromin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08769MIG. The term MERBROMIN is an International Non-Proprietary Name. World Health Organization schedules merbromin in its Anatomical Therapeutic Chemical (ATC) Classification. MERBROMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule merbromin under HS 29329985 and SITC 51569. As of Q4 2014, MERBROMIN remains the US FDA Preferred Term for this commodity. Merbromin bears US NLM identifiers UMLS ID C0025397 and NCI Concept Code C82319. SMILES: [HG]([OH2])C1C2OC3C(C4(OC(=O)C5C4CCCC5)C2CC(BR)C1O)CC(BR)C(O)C3.[NA].[NA].
This classification denotes a purine antagonist and immunosuppressant with the molecular formula C5H4N4S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E7WED276I5, chemically known as 1,7-dihydro-6h-purine-6-thione but more generally known as 6-mercaptopurine monohydrate, which bears US NIH Compound Identifier 667490. European Medicines Agency schedules Mercaptopurine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12149MIG. World Health Organization schedules 6-mercaptopurine monohydrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule mercaptopurine under HS 29335995 and SITC 51576. As of Q4 2014, MERCAPTOPURINE remains US FDA's Preferred Term for this commodity. Mercaptopurine bears US NLM identifiers UMLS ID C0000618 and NCI Concept Code C195. SMILES: C1=NC2=C(N1)C(=S)N=CN2.
This classification denotes a purine antagonist and immunosuppressant C5H4N4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PKK6MUZ20G, chemically known as 1,9-dihydro-6h-purine-6-thione, but more generally known as mercaptopurine anhydrous, which bears US NIH Compound Identifier 667490. Most nations, for tariff and trade purposes, schedule mercaptopurine anhydrous under HS 29335995 and SITC 51576. As of Q4 2014, MERCAPTOPURINE ANHYDROUS remains US FDA's Preferred Term for this commodity. Mercaptopurine anhydrous bears US NLM identifiers UMLS ID C1881785 and NCI Concept Code C61832. SMILES: C1[NH]C2C(N1)C(=S)[NH]CN2.
This classification denotes a purine antagonist and immunosuppressant with the molecular formula C10H12N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46S541971T, chemically known as 9h-purine-6(1h)-thione, 9-.beta.-d-ribofuranosyl-, but more generally known as mercaptopurine ribonucleoside, which bears US NIH Compound Identifier 676166. European Medicines Agency schedules mercaptopurine ribonucleoside or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12149MIG. Most nations, for tariff purposes, schedule mercaptopurine ribonucleoside under HS 29335995. SMILES: C1NC2C(C(N1)S)NCN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O.
This classification denotes a cardiotonic agent with the molecular formula C15H14N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4WYD7I9GF4, chemically known as 4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2h)-pyridazinone but generally known as meribendan, which bears US NIH Compound Identifier 5464106. European Medicines Agency schedules Meribendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08776MIG. The term MERIBENDAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). MERIBENDAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meribendan under HS 29331990 and SITC 51571. As of Q4 2014, MERIBENDAN remains the US FDA Preferred Term for this commodity. Meribendan bears US NLM identifiers UMLS ID C0381415 and NCI Concept Code C83936. SMILES: O=C1NN=C(C(C1)C)C1CC2=N/C(=C3/[NH][NH]CC3)N=C2CC1.
This classification denotes a beta-lactam antibiotic with the molecular formula C17H25N3O5S.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FV9J3JU8B1, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, trihydrate, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- but generally known as meropenem, which bears US NIH Compound Identifier 60706. European Medicines Agency schedules Meropenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08778MIG. World Health Organization schedules meropenem in its Anatomical Therapeutic Chemical (ATC) Classification. MEROPENEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meropenem under HS 29419000 and SITC 54139. As of Q4 2014, MEROPENEM remains the US FDA Preferred Term for this commodity. Meropenem bears US NLM identifiers UMLS ID C0066005 and NCI Concept Code C1160. SMILES: S(C1=C(N2C(C(C2=O)C(O)C)C1C)C(=O)O)C1CC(NC1)C(=O)N(C)C.O.O.O.
This classification denotes a beta-lactam antibiotic with the molecular formula C17H25N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YOP6PX0BAO, chemically known as (4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, but more generally known as meropenem anhydrous, which bears US NIH Compound Identifier 64778. European Medicines Agency schedules meropenem anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08778MIG. Most nations, for tariff purposes, schedule meropenem anhydrous under HS 29419000. Meropenem anhydrous bears US NLM identifiers UMLS ID C1881787 and NCI Concept Code C61833. SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O.
This classification denotes a beta-lactam antibiotic with the molecular formula C17H25N3O5S.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FV9J3JU8B1, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, trihydrate, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- but more generally known as meropenem, which bears US NIH Compound Identifier 60706. European Medicines Agency schedules Meropenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08778MIG. World Health Organization schedules meropenem in its Anatomical Therapeutic Chemical (ATC) Classification. MEROPENEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule meropenem trihydrate under HS 29419000 and SITC 54139. SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O.O.O.O.
This classification denotes a diuretic with the molecular formula C13H15HgNO5.Na.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5X1IO031V8, chemically known as mercury, 3-(alpha-carboxy-o-anisamido)-2-methoxypropyl hydroxy-, monosodium salt but generally known as mersalyl, which bears US NIH Compound Identifier 10293. European Medicines Agency schedules Mersalyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08779MIG. The term MERSALYL is an International Non-Proprietary Name. World Health Organization schedules mersalyl in its Anatomical Therapeutic Chemical (ATC) Classification. MERSALYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, MERSALYL remains the US FDA Preferred Term for this commodity. Mersalyl bears US NLM identifiers UMLS ID C0025446 and NCI Concept Code C77560. SMILES: [HG]([OH2])CC(OC)CNC(=O)C1C(OCC(=O)O)CCCC1.[NA].
This classification denotes a diuretic with the molecular formula C13H15HgNO5.Na.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5X1IO031V8, chemically known as mercury, 3-(alpha-carboxy-o-anisamido)-2-methoxypropyl hydroxy-, monosodium salt but more generally known as mersalyl, which bears US NIH Compound Identifier 10293. European Medicines Agency schedules Mersalyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08779MIG. The term MERSALYL is an International Non-Proprietary Name. World Health Organization schedules mersalyl in its Anatomical Therapeutic Chemical (ATC) Classification. MERSALYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mersalyl sodium under HS 29310095. SMILES: COC(CNC(=O)C1CCCCC1OCC(=O)[O-])C[HG+].[OH-].[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H7NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4Q81I59GXC, chemically known as salicylic acid, 5-amino- but more generally known as mesalamine, which bears US NIH Compound Identifier 4075. European Medicines Agency schedules Mesalamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08782MIG. The term MESALAZINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules mesalamine in its Anatomical Therapeutic Chemical (ATC) Classification. Mesalamine bears US NLM identifiers UMLS ID C0127615 and NCI Concept Code C29249. SMILES: OC1C(CC(N)CC1)C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H10ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51KFT71THG, chemically known as 7-chloro-3,3a-dihydro-2-methyl-2h,9h-isoxazolo(3,2-b)(1,3)benzoxazin-9-one but generally known as meseclazone, which bears US NIH Compound Identifier 34445. European Medicines Agency schedules Meseclazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08783MIG. The term MESECLAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). MESECLAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meseclazone under HS 29349990 and SITC 51579. As of Q4 2014, MESECLAZONE remains the US FDA Preferred Term for this commodity. Meseclazone bears US NLM identifiers UMLS ID C0066015 and NCI Concept Code C73088. SMILES: CC1CC2N(O1)C(=O)C3=C(O2)C=CC(=C3)CL.
This classification denotes a uroprotective agent with the molecular formula C2H5O3S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NR7O1405Q9, chemically known as ethanesulfonic acid, 2-mercapto-, monosodium salt but generally known as mesna, which bears US NIH Compound Identifier 598. European Medicines Agency schedules Mesna in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08784MIG. The term MESNA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules mesna in its Anatomical Therapeutic Chemical (ATC) Classification. MESNA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mesna under HS 29309085 and SITC 51549. As of Q4 2014, MESNA remains the US FDA Preferred Term for this commodity. Mesna bears US NLM identifiers UMLS ID C0000294 and NCI Concept Code C192. SMILES: S(=O)(=O)(O)CCS.
This classification denotes a dopamine agonist with the molecular formula C18H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) UMT8MP2NDU, chemically known as sydnone imine, 3-(alpha-methylphenethyl)-n-(phenylcarbamoyl)- but more generally known as mesocarb, which bears US NIH Compound Identifier 71932. European Medicines Agency schedules Mesocarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08785MIG. The term MESOCARB is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). MESOCARB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mesocarb under HS 29349100 and SITC 51579. As of Q4 2014, MESOCARB remains US FDA's Preferred Term for this commodity. Mesocarb bears US NLM identifiers UMLS ID C0074500 and NCI Concept Code C83937. SMILES: O1N[N](C(CC2CCCCC2)C)CC1/N=C(\O)NC1CCCCC1.
This classification denotes a dopamine antagonist and antipsychotic agent with the molecular formula C21H26N2OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XE4NWM740, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)- but generally known as mesoridazine, which bears US NIH Compound Identifier 4078. European Medicines Agency schedules Mesoridazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08786MIG. The term MESORIDAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules mesoridazine in its Anatomical Therapeutic Chemical (ATC) Classification. MESORIDAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mesoridazine under HS 29343090 and SITC 51578. As of Q4 2014, MESORIDAZINE remains the US FDA Preferred Term for this commodity. Mesoridazine bears US NLM identifiers UMLS ID C0025497 and NCI Concept Code C66100. SMILES: S1C2C(N(CCC3N(CCCC3)C)C3C1CCCC3)CC(S(=O)C)CC2.
This classification denotes a dopamine antagonist and antipsychotic agent with the molecular formula C21H26N2OS2.C6H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4G2I958J2, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-, (+/-)-, monobenzenesulfonate, but more generally known as mesoridazine benzenesulfonate, which bears US NIH Compound Identifier 36207. European Medicines Agency schedules mesoridazine benzenesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08786MIG. Most nations, for tariff purposes, schedule mesoridazine benzenesulfonate under HS 29343090. SMILES: CN1CCCCC1CCN2C3CCCCC3SC4C2CC(CC4)[S+](C)[O-].C1CCC(CC1)S(=O)(=O)O.
This classification denotes a dopamine antagonist and antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4G2I958J2. European Medicines Agency schedules Mesoridazine besilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03180MIG. Mesoridazine besylate generally arises in the molecular formula C21H26N2OS2.C6H6O3S. The term 'mesoridazine besylate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule mesoridazine besylate under HS 29343090. As of Q4 2014, MESORIDAZINE BESYLATE remains US FDA's Preferred Term for this commodity. Mesoridazine besylate bears US NLM identifiers UMLS ID C0700543 and NCI Concept Code C66101. SMILES: CN1CCCCC1CCN2C3CCCCC3SC4C2CC(CC4)[S+](C)[O-].C1CCC(CC1)S(=O)(=O)O.
This classification denotes a therapeutic androgen with the molecular formula C20H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0SRQ75X9I9, chemically known as 5alpha-androstan-3-one, 17beta-hydroxy-1alpha-methyl- but generally known as mesterolone, which bears US NIH Compound Identifier 15020. European Medicines Agency schedules Mesterolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08790MIG. The term MESTEROLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules mesterolone in its Anatomical Therapeutic Chemical (ATC) Classification. MESTEROLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mesterolone under HS 29372900 and SITC 54153. As of Q4 2014, MESTEROLONE remains the US FDA Preferred Term for this commodity. Mesterolone bears US NLM identifiers UMLS ID C0025503 and NCI Concept Code C87227. SMILES: OC1C2(C(C3C(C4(C(CC3)CC(=O)CC4C)C)CC2)CC1)C.
This classification denotes a therapeutic estradiol with the molecular formula C21H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B2V233XGE7, chemically known as 19-norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-, (17.alpha.)- but generally known as mestranol, which bears US NIH Compound Identifier 4080. European Medicines Agency schedules Mestranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08791MIG. The term MESTRANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). MESTRANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mestranol under HS 29372300 and SITC 54153. As of Q4 2014, MESTRANOL remains the US FDA Preferred Term for this commodity. Mestranol bears US NLM identifiers UMLS ID C0025506 and NCI Concept Code C636. SMILES: OC1(C2(C(C3C(CC2)c2c(CC3)cc(OC)cc2)CC1)C)C#C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y19VNL22L0. European Medicines Agency schedules Mesulfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08794MIG. Mesulfamide generally arises in the molecular formula C7H10N2O5S2. The term MESULFAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 33, no. 10 1979, list 19.) MESULFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(N)C1CCC(NCS(=O)(=O)O)CC1.
This classification denotes an immunosuppressant with the molecular formula C14H12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EG6V6W7WDD, chemically known as 2,7-dimethylthianthrene but generally known as mesulfen, which bears US NIH Compound Identifier 67272. European Medicines Agency schedules Mesulfen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08795MIG. The term MESULFEN is an International Non-Proprietary Name. World Health Organization schedules mesulfen in its Anatomical Therapeutic Chemical (ATC) Classification. MESULFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Mesulfen or mesulphen bears US NLM identifiers UMLS ID C0066033 and NCI Concept Code C66104. SMILES: CC1=CC2=C(C=C1)SC3=C(S2)C=C(C=C3)C.
This classification denotes an anticonvulsant agent with the molecular formula C12H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 0G76K8X6C0, chemically known as 2,5-pyrrolidinedione,1,3-dimethyl-3-phenyl- but more generally known as mesuximide, which bears US NIH Compound Identifier 6476. European Medicines Agency schedules Mesuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08797MIG. The term MESUXIMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules mesuximide in its Anatomical Therapeutic Chemical (ATC) Classification. Methsuximide bears US NLM identifiers UMLS ID C0109002 and NCI Concept Code C47613. MESUXIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PSJ9VIF3RV, chemically known as ethanol, 2- (isobutylamino)-, m-aminobenzoate (ester), monohydrochloride but generally known as metabutethamine, which bears US NIH Compound Identifier 11115. World Health Organization schedules metabutethamine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, METABUTETHAMINE remains the US FDA Preferred Term for this commodity. Metabutethamine bears US NLM identifiers UMLS ID C0301289 and NCI Concept Code C81413. SMILES: CC(C)CNCCOC(=O)C1=CC(=CC=C1)N.
This classification denotes a benzodiazepine with the molecular formula C18H18BrClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2N2B1303L, chemically known as 7-bromo-5-(o-chlorophenyl)-2,3-dihydro-2-(methoxymethyl)-1-methyl-1h-1,4-benzodiazepine but generally known as metaclazepam, which bears US NIH Compound Identifier 71272. European Medicines Agency schedules Metaclazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08800MIG. The term METACLAZEPAM is an International Non-Proprietary Name. METACLAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metaclazepam under HS 29339940 and SITC 51577. As of Q4 2014, METACLAZEPAM remains the US FDA Preferred Term for this commodity. Metaclazepam bears US NLM identifiers UMLS ID C1619621 and NCI Concept Code C83941. SMILES: BRC1CC2C(N(C(CN=C2C2C(CL)CCCC2)COC)C)CC1.
This classification denotes a benzodiazepine with the molecular formula C18H18BrClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P21PFK193T, chemically known as 2,3-dihydro-7-bromo-5-(2-chlorophenyl)-2-(methoxymethyl)-1-methyl-1h-1,4-benzodiazepine hcl but more generally known as metaclazepam hydrochloride, which bears US NIH Compound Identifier 162950. European Medicines Agency schedules Metaclazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03181MIG. Most nations, for tariff and trade purposes, schedule metaclazepam hydrochloride under HS 29339940 and SITC 51577. As of Q4 2014, METACLAZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metaclazepam hydrochloride bears US NLM identifiers UMLS ID C0066040 and NCI Concept Code C83942. SMILES: CN1C2CCC(CC2C(=NCC1COC)C3CCCCC3CL)BR.CL.
This classification denotes a macrolide antibiotic with the molecular formula C22H22N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IR235I7C5P, chemically known as 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide but generally known as metacycline, which bears US NIH Compound Identifier 5281054. European Medicines Agency schedules Metacycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08801MIG. The term METACYCLINE is an International Non-Proprietary Name. World Health Organization schedules metacycline in its Anatomical Therapeutic Chemical (ATC) Classification. METACYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Metacycline or methacycline bears US NLM identifiers UMLS ID C0025603 and NCI Concept Code C61839. SMILES: OC12C(C(O)C3C(=C(O)c4c(C3=C)cccc4O)C1=O)C(N(C)C)C(=O)C(=C(\O)N)\C2=O.
This classification denotes an anti-diabetic agent with the molecular formula C14H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) T3U6F5D722, chemically known as 1,3,5-triazine-2,4-diamine, 6-chloro-n,n,n,n-tetraethyl- but more generally known as metahexamide, which bears US NIH Compound Identifier 11259. European Medicines Agency schedules Metahexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08803MIG. The term METAHEXAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4) WHO schedules metahexamide in its Anatomical Therapeutic Chemical (ATC) Classification. METAHEXAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule metahexamide under HS 29350090 and SITC 51580. As of Q4 2014, METAHEXAMIDE remains US FDA's Preferred Term for this commodity. Metahexamide bears US NLM identifiers UMLS ID C0663351 and NCI Concept Code C91022. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CC(N)C(CC1)C.
This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3B30XBE7S2, chemically known as l-phenylalanine, 3-(bis(2-chloroethyl)amino)- (9ci) but more generally known as metamelfalan, which bears US NIH Compound Identifier 14152. European Medicines Agency schedules Metamelfalan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08806MIG. The term METAMELFALAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). METAMELFALAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule metamelfalan under HS 29224995 and SITC 51465. As of Q4 2014, METAMELFALAN remains US FDA's Preferred Term for this commodity. Metamelfalan bears US NLM identifiers UMLS ID C0127767 and NCI Concept Code C83946. SMILES: CLCCN(C1CC(CC(N)C(=O)O)CCC1)CCCL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H11N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q0YU79408, chemically known as 3(2h)-pyridazinon, 4-amino-6-methyl-2-phenyl- but generally known as metamfazone, which bears US NIH Compound Identifier 176887. European Medicines Agency schedules Metamfazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08807MIG. The term METAMFAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). METAMFAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metamfazone under HS 29339990 and SITC 51577. As of Q4 2014, METAMFAZONE remains the US FDA Preferred Term for this commodity. Metamfazone bears US NLM identifiers UMLS ID C1881797 and NCI Concept Code C66105. SMILES: CC1=NN(C(=O)C(=C1)N)C2=CC=CC=C2.
This classification denotes a cns stimulant with the molecular formula C10H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44RAL3456C, chemically known as (s)-(+)-n,alpha,dimethylphenethylamine but more generally known as metamfetamine, which bears US NIH Compound Identifier 10836. European Medicines Agency schedules Metamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08809MIG. The term METAMFETAMINE is an International Non-Proprietary Name. World Health Organization schedules metamfetamine in its Anatomical Therapeutic Chemical (ATC) Classification. METAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Metamfetamine or methamphetamine bears US NLM identifiers UMLS ID C0025611 and NCI Concept Code C61840. SMILES: CC(CC1=CC=CC=C1)NC.
This classification denotes an anti-inflammatory agents, non-steroidal, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VSU62Z74ON. European Medicines Agency schedules Metamizole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08810MIG. Metamizole sodium generally arises in the molecular formula C13H16N3O4S.NA. The term METAMIZOLE SODIUM is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule metamizole sodium under HS 29331190. As of Q4 2014, METAMIZOLE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1C(C(=O)N(N1C)C2CCCCC2)N(C)CS(=O)(=O)[O-].[NA+].
This classification denotes an anti-inflammatory agents, non-steroidal, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VSU62Z74ON. European Medicines Agency schedules Metamizole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08810MIG. Metamizole sodium generally arises in the molecular formula C13H16N3O4S.NA. The term METAMIZOLE SODIUM is an International Non-Proprietary Name or INN. SMILES: CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)O.
This classification denotes a penicillin antibiotic with the molecular formula C17H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G0H6U7VSTK, chemically known as 3,3-dimethyl-6-(2-(methyleneamino)-2-phenylacetamidol-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as metampicillin, which bears US NIH Compound Identifier 4084. European Medicines Agency schedules Metampicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08811MIG. The term METAMPICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules metampicillin in its Anatomical Therapeutic Chemical (ATC) Classification. METAMPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metampicillin under HS 29411020 and SITC 54131. As of Q4 2014, METAMPICILLIN remains the US FDA Preferred Term for this commodity. Metampicillin bears US NLM identifiers UMLS ID C0066082 and NCI Concept Code C87368. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(N=C)C1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C17H18N3O4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HE2T55NH5, chemically known as sodium (6r)-6-(d-2-methyleneamino-2-phenylacetamido)penicillanate, but more generally known as metampicillin sodium, which bears US NIH Compound Identifier 5702187. European Medicines Agency schedules metampicillin sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08811MIG. Most nations, for tariff purposes, schedule metampicillin sodium under HS 29411020. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N=C)C(=O)[O-])C.[NA+].
This classification denotes an anabolic steroid with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier COZ1R7EOCC, chemically known as 17-beta-hydroxy-17-methyl-androsta-1,4-dien-3-one (9ci) but generally known as metandienone, which bears US NIH Compound Identifier 6300. European Medicines Agency schedules Metandienone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08812MIG. The term METANDIENONE is an International Non-Proprietary Name. World Health Organization schedules metandienone in its Anatomical Therapeutic Chemical (ATC) Classification. METANDIENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1(C2(C(C3C(CC2)C2(C(=CC(=O)C=C2)CC3)C)CC1)C)C.
This classification denotes a serotonin agonist with the molecular structure C21H29N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 190230I669 chemically known as (1r*,2s*,3r*,4s*)-n-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-2,3-norbornanedicarboximide but generally known as tandospirone, which bears US NIH Compound Identifier 60558. European Medicines Agency schedules Tandospirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10829MIG. The term TANDOSPIRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29. ). Metanopirone or tandospirone bears US NLM identifiers UMLS ID C0074676 and NCI Concept Code C87208. SMILES: C1CC2CC1C3C2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antidepressant agent with the molecular formula C16H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 303954M7YF, chemically known as 10,11-dihydro-5-methyl-10-(methylamino)-5h-dibenz(b,f)azepine but generally known as metapramine, which bears US NIH Compound Identifier 65700. European Medicines Agency schedules Metapramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08814MIG. The term METAPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). METAPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metapramine under HS 29339930 and SITC 51577. As of Q4 2014, METAPRAMINE remains the US FDA Preferred Term for this commodity. Metapramine bears US NLM identifiers UMLS ID C0066057 and NCI Concept Code C87617. SMILES: N1(c2c(C(NC)Cc3c1cccc3)cccc2)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 818U2PZ2EH, chemically known as benzyl alcohol, alpha-(1-aminoethyl)-m-hydroxy-, (-)- but generally known as metaraminol, which bears US NIH Compound Identifier 5906. European Medicines Agency schedules Metaraminol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08815MIG. The term METARAMINOL is an International Non-Proprietary Name. World Health Organization schedules metaraminol in its Anatomical Therapeutic Chemical (ATC) Classification. METARAMINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metaraminol under HS 29399900 and SITC 54149. As of Q4 2014, METARAMINOL remains the US FDA Preferred Term for this commodity. Metaraminol bears US NLM identifiers UMLS ID C0025575 and NCI Concept Code C61835. SMILES: OC(C(N)C)C1CC(O)CCC1.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZC4202M9P3, chemically known as (-)-.alpha.-(1-aminoethyl)-m-hydroxybenzyl alcohol tartrate (1:1) (salt), but more generally known as metaraminol bitartrate, which bears US NIH Compound Identifier 5906. European Medicines Agency schedules metaraminol bitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08815MIG. Most nations, for tariff purposes, schedule metaraminol bitartrate under HS 29399900. As of Q4 2014, METARAMINOL BITARTRATE remains US FDA's Preferred Term for this commodity. Metaraminol bitartrate bears US NLM identifiers UMLS ID C0025576 and NCI Concept Code C61836. SMILES: C[C@@H]([C@@H](C1CCCC(C1)O)O)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an alpha-adrenergic agonist C9H13NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90698QK27F, chemically known as benzenemethanol, .alpha.-((1s)-1-aminoethyl)-3-hydroxy-, hydrochloride (1:1), (.alpha.r)-, but more generally known as metaraminol hydrochloride, which bears US NIH Compound Identifier 22265. Most nations, for tariff and trade purposes, schedule metaraminol hydrochloride under HS 29399900 and SITC 54149. As of Q4 2014, METARAMINOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@@H](C1CCCC(C1)O)O)N.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZC4202M9P3, chemically known as benzyl alcohol, alpha-(1-aminoethyl)-m-hydroxy-, (-)- but more generally known as metaraminol bitartrate, which bears US NIH Compound Identifier 5906. European Medicines Agency schedules Metaraminol bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03194MIG. Most nations, for tariff and trade purposes, schedule metaraminol tartrate under HS 29399900 and SITC 54149. SMILES: C[C@@H]([C@@H](C1CCCC(C1)O)O)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a muscle relaxant with the molecular formula C12H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1NMA9J598Y, chemically known as 5-((3,5-xylyloxy)methyl)-2-oxazolidinone but generally known as metaxalone, which bears US NIH Compound Identifier 15459. European Medicines Agency schedules Metaxalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08817MIG. The term METAXALONE is an International Non-Proprietary Name. METAXALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metaxalone under HS 29349990 and SITC 51579. As of Q4 2014, METAXALONE remains the US FDA Preferred Term for this commodity. Metaxalone bears US NLM identifiers UMLS ID C0163055 and NCI Concept Code C47606. SMILES: CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8AE88M5N5V, chemically known as propionic acid, 3-(4-biphenylylcarbonyl)-2-methyl- but generally known as metbufen, which bears US NIH Compound Identifier 68823. European Medicines Agency schedules Metbufen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08821MIG. The term METBUFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). METBUFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metbufen under HS 29183000 and SITC 51395. As of Q4 2014, METBUFEN remains the US FDA Preferred Term for this commodity. Metbufen bears US NLM identifiers UMLS ID C0066064 and NCI Concept Code C90903. SMILES: O=C(CC(C)C(=O)O)C1CCC(CC1)C1CCCCC1.
This classification denotes a prostaglandin analogue with the molecular formula C23H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 269EB4R1TV, chemically known as 9-methylene-11r,15s-dihydroxy-16,16-dimethyl-5z,13e-prostadienoic acid but generally known as meteneprost, which bears US NIH Compound Identifier 5283060. European Medicines Agency schedules Meteneprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08822MIG. The term METENEPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). METENEPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meteneprost under HS 29375000 and SITC 54156. As of Q4 2014, METENEPROST remains the US FDA Preferred Term for this commodity. Meteneprost bears US NLM identifiers UMLS ID C0127783 and NCI Concept Code C90926. SMILES: OC1C(C(C(=C)C1)C/C=C\CCCC(=O)O)/C=C/C(O)C(CCCC)(C)C.
This classification denotes an anabolic agent with the molecular formula C20H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9062ZT8Q5C, chemically known as androst-1-en-3-one, 17-hydroxy-1-methyl-, (5alpha,17beta)- but generally known as metenolone, which bears US NIH Compound Identifier 9054. European Medicines Agency schedules Metenolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08823MIG. World Health Organization schedules metenolone in its Anatomical Therapeutic Chemical (ATC) Classification. METENOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metenolone under HS 29372900 and SITC 54153. SMILES: OC1C2(C(C3C(C4(C(CC3)CC(=O)C=C4C)C)CC2)CC1)C.
This classification denotes an anabolic agent with the molecular formula C22H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W75590VPKQ, chemically known as androst-1-en-3-one, 17-(acetyloxy)-1-methyl-, (5.alpha.,17.beta.)-, but more generally known as metenolone acetate, which bears US NIH Compound Identifier 4088. European Medicines Agency schedules metenolone acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08823MIG. Most nations, for tariff purposes, schedule metenolone acetate under HS 29372900. SMILES: CC1=CC(=O)C[C@H]2[C@]1([C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4OC(=O)C)C)C.
This classification denotes an anabolic agent with the molecular formula C27H42O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0SPD480WFH, chemically known as androst-1-en-3-one, 1-methyl-17-((1-oxoheptyl)oxy)-, (5.alpha.,17.beta.)-, but more generally known as metenolone enantate, which bears US NIH Compound Identifier 4089. European Medicines Agency schedules metenolone enantate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08823MIG. Most nations, for tariff purposes, schedule metenolone enantate under HS 29372900. SMILES: CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C(=CC(=O)C4)C)C)C.
This classification denotes a chemotherapy regimen in current use with the molecular formula C25H29N3O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1501393LY5, chemically known as 1,6-dimethyl-8-beta-carbobenzyloxaminomethyl-10-alpha-ergoline but more generally known as metergoline, which bears U.S. NIH Compound Identifier 28693. European Medicines Agency schedules Metergoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08824MIG. The term METERGOLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules metergoline in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. METERGOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an opioid receptor agonist with the molecular formula C17H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S36J5ZY2TH, chemically known as 1,3-dimethyl-4-carbethoxy-4-phenylhexamethylenimin but generally known as metethoheptazine, which bears US NIH Compound Identifier 176888. European Medicines Agency schedules Metethoheptazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08829MIG. The term METETHOHEPTAZINE is an International Non-Proprietary Name. METETHOHEPTAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metethoheptazine under HS 29339930 and SITC 51577. As of Q4 2014, METETHOHEPTAZINE remains the US FDA Preferred Term for this commodity. Metethoheptazine bears US NLM identifiers UMLS ID C2983999 and NCI Concept Code C91044. SMILES: O(C(=O)C1(C(CN(CCC1)C)C)C1CCCCC1)CC.
This classification denotes an anti-diabetic agent with the molecular formula C4H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9100L32L2N, chemically known as 1,1-dimethylbiguanide but more generally known as metformin, which bears US NIH Compound Identifier 4091. European Medicines Agency schedules Metformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08831MIG. The term METFORMIN is an International Non-Proprietary Name WHO schedules metformin in its Anatomical Therapeutic Chemical (ATC) Classification. METFORMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule metformin under HS 29252900 and SITC 51482. As of Q4 2014, METFORMIN remains US FDA's Preferred Term for this commodity. Metformin bears US NLM identifiers UMLS ID C0025598 and NCI Concept Code C61612. SMILES: N(C)(C)C(=N)/N=C(/N)N.
This classification denotes an anti-diabetic agent with the molecular formula C23H16O6.2C4H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9AZJ7GJZ1, chemically known as 2-naphthalenecarboxylic acid, 4,4'-methylenebis(3-hydroxy-, compd. with n,n-dimethylimidodicarbonimidic diamide (1:2), but more generally known as metformin embonate, which bears US NIH Compound Identifier 62987. European Medicines Agency schedules metformin embonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08831MIG. Most nations, for tariff purposes, schedule metformin embonate under HS 29252900. SMILES: CN(C)C(=N)NC(=N)N.CN(C)C(=N)NC(=N)N.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an anti-diabetic agent C4H11N5.C2H5NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YEI21W005Y, chemically known as glycine, compd. with n,n-dimethylimidodicarbonimidic diamide (1:1), but more generally known as metformin glycinate, which bears US NIH Compound Identifier 44520175. Most nations, for tariff and trade purposes, schedule metformin glycinate under HS 29252900 and SITC 51482. As of Q4 2014, METFORMIN GLYCINATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)C(=N)NC(=N)N.C(C(=O)O)N.
This classification denotes an anti-diabetic agent with the molecular formula C4H11N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 786Z46389E, chemically known as 1,1-dimethylbiguanide but more generally known as metformin hydrochloride, which bears US NIH Compound Identifier 4091. European Medicines Agency schedules Metformin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03200MIG. Most nations, for tariff and trade purposes, schedule metformin hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, METFORMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metformin hydrochloride bears US NLM identifiers UMLS ID C0770893 and NCI Concept Code C29251. SMILES: CN(C)C(=N)NC(=N)N.CL.
Metformin/linagliptin is a combination of an agent of the biguanide class and a DPP-4 inhibitor used to treat high blood sugar levels caused by type 2 diabetes.
This classification denotes an anti-diabetic agent with the molecular formula C5H4N2O4.C4H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KE1D8AP3J5, chemically known as 4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, compd. with n,n-dimethylimidodicarbonimidic diamide (1:1), but more generally known as metformin orotate, which bears US NIH Compound Identifier 124097. European Medicines Agency schedules metformin orotate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08831MIG. Most nations, for tariff purposes, schedule metformin orotate under HS 29252900. SMILES: CN(C)C(=N)NC(=N)N.C1C([NH]C(=O)[NH]C1=O)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.
This classification denotes a diagnostic reagent with the molecular formula C8H18NO2.Cl, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 0W5ETF9M2K, chemically known as 1-propanaminium, 2-(acetyloxy)-n,n,n-trimethyl-, chloride but more generally known as methacholine chloride, which bears U.S. National Institutes of Health Compound Identifier 6114. The European Medicines Agency schedules Methacholine chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08832MIG. The term METHACHOLINE CHLORIDE is an International Non-Proprietary Name. SMILES: CC(C[N+](C)(C)C)OC(=O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a tetracycline antibiotic with the molecular formula C22H22N2O8.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9GJ0N7ZAP0, chemically known as 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride but more generally known as methacycline hydrochloride, which bears US NIH Compound Identifier 5281092. Most nations, for tariff and trade purposes, schedule methacycline hydrochloride under HS 29413000. As of Q4 2014, METHACYCLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methacycline hydrochloride bears US NLM identifiers UMLS ID C0770655 and NCI Concept Code C47608. SMILES: CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4CCCC(C4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)O)O.CL.
This classification denotes an opiate with the molecular formula C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UC6VBE7V1Z, chemically known as 6-dimethylamino-4,4-diphenyl-heptan-3-one but generally known as methadone, which bears US NIH Compound Identifier 4095. European Medicines Agency schedules Methadone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08833MIG. The term METHADONE is an International Non-Proprietary Name. World Health Organization schedules methadone in its Anatomical Therapeutic Chemical (ATC) Classification. METHADONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methadone under HS 29223100 and SITC 51463. As of Q4 2014, METHADONE remains the US FDA Preferred Term for this commodity. Methadone bears US NLM identifiers UMLS ID C0025605 and NCI Concept Code C62044. SMILES: O=C(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC.
This classification denotes a synthetic opioid, opiate substitution treatment, analgesics, and antitussive agent with the molecular formula C21H27NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 229809935B, chemically known as 6-dimethylamino-4,4-diphenyl-heptan-3-one but more generally known as methadone hydrochloride, which bears US NIH Compound Identifier 4095. European Medicines Agency schedules Methadone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03203MIG. Most nations, for tariff and trade purposes, schedule methadone hydrochloride under HS 29223100 and SITC 51463. As of Q4 2014, METHADONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methadone hydrochloride bears US NLM identifiers UMLS ID C0592779 and NCI Concept Code C638. SMILES: CCC(=O)C(CC(C)N(C)C)(C1CCCCC1)C2CCCCC2.CL.
This classification denotes a non-steroidal estrogen with the molecular formula C18H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XL025389JS, chemically known as 3-(6-methoxy-2-naphthyl)-3-ethyl-2,2-dimethylpropionsaeure but generally known as methallenestril, which bears US NIH Compound Identifier 10599. European Medicines Agency schedules Methallenestril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08834MIG. The term METHALLENESTRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules methallenestril in its Anatomical Therapeutic Chemical (ATC) Classification. METHALLENESTRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, METHALLENESTRIL remains the US FDA Preferred Term for this commodity. Methallenestril bears US NLM identifiers UMLS ID C0066078 and NCI Concept Code C80685. SMILES: OC(=O)C(C(CC)c1cc2c(cc1)cc(OC)cc2)(C)C.
This classification denotes an anabolic steroid with the molecular formula C20H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5730Z864KG, chemically known as 17-methylandrost-5-ene-3-beta,17-beta-diol but generally known as methandriol, which bears US NIH Compound Identifier 10632. European Medicines Agency schedules Methandriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08835MIG. The term METHANDRIOL is an International Non-Proprietary Name. METHANDRIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methandriol under HS 29372900 and SITC 54153. As of Q4 2014, METHANDRIOL remains the US FDA Preferred Term for this commodity. Methandriol bears US NLM identifiers UMLS ID C0025615 and NCI Concept Code C83950. SMILES: OC1(C2(C(C3C(C4(C(=CC3)CC(O)CC4)C)CC2)CC1)C)C.
This classification denotes an anabolic steroid with the molecular formula C24H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z142SX9228, chemically known as androst-5-ene-3,17-diol, 17-methyl-, 3,17-diacetate, (3.beta.,17.beta.)-, but more generally known as methandriol diacetate, which bears US NIH Compound Identifier 102203. European Medicines Agency schedules methandriol diacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08835MIG. Most nations, for tariff purposes, schedule methandriol diacetate under HS 29372900. SMILES: CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@]4(C)OC(=O)C)C)C.
This classification denotes an anabolic steroid with the molecular formula C26H40O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8XIW70Q5I3. Most nations, for tariff and trade purposes, schedule methandriol dipropionate under HS 29372900 and SITC 54153. As of Q4 2014, METHANDRIOL DIPROPIONATE remains US FDA's Preferred Term for this commodity. Methandriol dipropionate bears US NLM identifiers UMLS ID C0770345 and NCI Concept Code C95962. SMILES: CCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@]4(C)OC(=O)CC)C)C.
This classification denotes an antimuscarinic agent with the molecular formula C21H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36EI79TX7I, chemically known as xanthene-9-carboxylic acid, ester with diethyl(2-hydroxyethyl)methylammonium bromide but generally known as methantheline, which bears US NIH Compound Identifier 4097. World Health Organization schedules methantheline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, METHANTHELINE remains the US FDA Preferred Term for this commodity. Methantheline bears US NLM identifiers UMLS ID C0025624 and NCI Concept Code C83951. SMILES: CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13. .
This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H19N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A01LX40298, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-2-pyridinyl-n-(2-thienylmethyl)- but generally known as methapyrilene, which bears US NIH Compound Identifier 4098. European Medicines Agency schedules Methapyrilene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08839MIG. The term METHAPYRILENE is an International Non-Proprietary Name. World Health Organization schedules methapyrilene in its Anatomical Therapeutic Chemical (ATC) Classification. METHAPYRILENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methapyrilene under HS 29349990 and SITC 51579. As of Q4 2014, METHAPYRILENE remains the US FDA Preferred Term for this commodity. Methapyrilene bears US NLM identifiers UMLS ID C0025625 and NCI Concept Code C81143. SMILES: S1C(CN(CCN(C)C)C2NCCCC2)CCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular structure 2C14H19N3S.3C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, KJ5I25TXYL chemically known as 1,2-ethanediamine, n,n-dimethyl-n'-2-pyridinyl-n'-(2-thienylmethyl)-, (e)-2-butenedioate (2:3), but more commonly known as methapyrilene fumarate, which bears US NIH Compound Identifier 6436730. European Medicines Agency schedules Methapyrilene fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14535MIG. Most nations, for tariff and trade purposes, schedule methapyrilene fumarate under HS 29349990 and SITC 51579. As of Q4 2014, METHAPYRILENE FUMARATE remains US FDA's Preferred Term for this commodity. Methapyrilene fumarate bears US NLM identifiers UMLS ID C2064778 and NCI Concept Code C83953. SMILES: CN(CCN(C1NCCCC1)CC2SCCC2)C.CN(CCN(C1NCCCC1)CC2SCCC2)C.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H19N3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00S42N58OM, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-2-pyridinyl-n-(2-thienylmethyl)-, monohydrochloride but more generally known as methapyrilene hydrochloride, which bears US NIH Compound Identifier 8667. European Medicines Agency schedules Methapyrilene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03211MIG. Most nations, for tariff and trade purposes, schedule methapyrilene hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, METHAPYRILENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methapyrilene hydrochloride bears US NLM identifiers UMLS ID C0770858 and NCI Concept Code C81134. SMILES: CN(C)CCN(CC1CCCS1)C2CCCCN2.CL.
This classification denotes a sedative and hypnotic with the molecular formula C16H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZKH8MQW6T, chemically known as 3,4-dihydro-2-methyl-4-oxo-3-o-tolylquinazoline but generally known as methaqualone, which bears US NIH Compound Identifier 6292. European Medicines Agency schedules Methaqualone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08840MIG. The term METHAQUALONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methaqualone in its Anatomical Therapeutic Chemical (ATC) Classification. METHAQUALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methaqualone under HS 29335500 and SITC 51576. As of Q4 2014, METHAQUALONE remains the US FDA Preferred Term for this commodity. Methaqualone bears US NLM identifiers UMLS ID C0025627 and NCI Concept Code C640. SMILES: O=C1N(C2C(CCCC2)C)C(NC2C1CCCC2)C.
This classification denotes an anxiolytic with the molecular formula C16H14N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RJQ4G25ZRH, chemically known as 3,4-dihydro-2-methyl-4-oxo-3-o-tolylquinazoline but more generally known as methaqualone hydrochloride, which bears US NIH Compound Identifier 6292. European Medicines Agency schedules Methaqualone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03212MIG. Most nations, for tariff and trade purposes, schedule methaqualone hydrochloride under HS 29335500 and SITC 51576. As of Q4 2014, METHAQUALONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methaqualone hydrochloride bears US NLM identifiers UMLS ID C1522632 and NCI Concept Code C2484. SMILES: CC1CCCCC1N2C(NC3CCCCC3C2=O)C.CL.
This classification denotes a barbiturate with the molecular formula C9H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02OS7K758T, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl-1-methyl- but generally known as metharbital, which bears US NIH Compound Identifier 4099. European Medicines Agency schedules Metharbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08841MIG. The term METHARBITAL is an International Non-Proprietary Name. World Health Organization schedules metharbital in its Anatomical Therapeutic Chemical (ATC) Classification. METHARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metharbital under HS 29335400 and SITC kg. As of Q4 2014, METHARBITAL remains the US FDA Preferred Term for this commodity. Metharbital bears US NLM identifiers UMLS ID C0025629 and NCI Concept Code C66113. SMILES: O=C1N(C(=O)NC(=O)C1(CC)CC)C.
This classification denotes a diuretic and carbonic anhydrase inhibitor with the molecular formula C5H8N4O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W733B0S9SD, chemically known as 5-acetylimino-4-methyl-delta(sup 2)-1,3,4-thiadiazoline-2-sulfonamide but generally known as methazolamide, which bears US NIH Compound Identifier 4100. European Medicines Agency schedules Methazolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08843MIG. The term METHAZOLAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methazolamide in its Anatomical Therapeutic Chemical (ATC) Classification. METHAZOLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methazolamide under HS 29350090 and SITC 51580. As of Q4 2014, METHAZOLAMIDE remains the US FDA Preferred Term for this commodity. Methazolamide bears US NLM identifiers UMLS ID C0025631 and NCI Concept Code C61318. SMILES: S(=O)(=O)(N)C1S/C(=N\C(=O)C)N(N1)C.
This classification denotes a vasodilating agent with the molecular formula C18H20N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4Q13LY9Z8X, chemically known as 10h-phenothiazine, 10-((1-methyl-3-pyrrolidinyl)methyl)- but generally known as methdilazine, which bears US NIH Compound Identifier 14677. European Medicines Agency schedules Methdilazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08844MIG. The term METHDILAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methdilazine in its Anatomical Therapeutic Chemical (ATC) Classification. METHDILAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methdilazine under HS 29343090 and SITC 51578. As of Q4 2014, METHDILAZINE remains the US FDA Preferred Term for this commodity. Methdilazine bears US NLM identifiers UMLS ID C0066101 and NCI Concept Code C66114. SMILES: S1C2C(N(CC3CCN(C3)C)C3C1CCCC3)CCCC2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H20N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T0GSO02UEZ, chemically known as 10h-phenothiazine, 10-((1-methyl-3-pyrrolidinyl)methyl)-, monohydrochloride but more generally known as methdilazine hydrochloride, which bears US NIH Compound Identifier 14676. European Medicines Agency schedules Methdilazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03213MIG. Most nations, for tariff and trade purposes, schedule methdilazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, METHDILAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methdilazine hydrochloride bears US NLM identifiers UMLS ID C0304371 and NCI Concept Code C63950. SMILES: CN1CCC(C1)CN2C3CCCCC3SC4C2CCCC4.CL.
This classification denotes an adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L7HY239I58. European Medicines Agency schedules Methoxyphedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08859MIG. Methoxyphedrine generally arises in the molecular formula C11H15NO2. The term METHOXYPHEDRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) METHOXYPHEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Methedrone or methoxyphedrine bears US NLM identifiers UMLS ID C2983810 and NCI Concept Code C90631. SMILES: CC(C(=O)C1=CC=C(C=C1)OC)NC.
This classification denotes a urinary anti-infective agent with the molecular formula C8H8O3.C6H12N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 695N30CINR, chemically known as 1,3,5,7-tetraazatricyclo(3.3.1.1(3,7))decane, mono(alpha-hydroxybenzeneacetate) but more generally known as methenamine mandelate, which bears US NIH Compound Identifier 11478. European Medicines Agency schedules Methenamine mandelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03216MIG. SMILES: OC(C1CCCCC1)C(=O)O.N12CN3CN(CN(C3)C2)C1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM550. This VA Drug Class (AM550) classifies this compound as belonging to the group METHENAMINE SALTS ANTIMICROBIALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM550. This VA Drug Class (AM550) classifies this compound as belonging to the group METHENAMINE SALTS ANTIMICROBIALS.
This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 93X4R66P5A, chemically known as methyl 1,2-dimethyl-4-phenyl-4-azepanylcarboxylat but generally known as metheptazine, which bears US NIH Compound Identifier 3047717. European Medicines Agency schedules Metheptazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08846MIG. The term METHEPTAZINE is an International Non-Proprietary Name. METHEPTAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metheptazine under HS 29339930 and SITC 51577. As of Q4 2014, METHEPTAZINE remains the US FDA Preferred Term for this commodity. Metheptazine bears US NLM identifiers UMLS ID C2984000 and NCI Concept Code C91046. SMILES: O(C(=O)C1(CC(N(CCC1)C)C)C1CCCCC1)C.
This classification denotes a therapeutic estrogen with the molecular formula C20H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 199O25Z2BQ, chemically known as 4,4-(1,2-diethylethylene)di-o-cresol but generally known as methestrol, which bears US NIH Compound Identifier 71620. European Medicines Agency schedules Methestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08847MIG. The term METHESTROL is an International Non-Proprietary Name. METHESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methestrol under HS 29072900 and SITC 51243. As of Q4 2014, METHESTROL remains the US FDA Preferred Term for this commodity. Methestrol bears US NLM identifiers UMLS ID C0602259 and NCI Concept Code C90948. SMILES: Oc1c(cc(C(C(CC)c2cc(c(O)cc2)C)CC)cc1)C.
This classification denotes a penicillin antibiotic with the molecular formula C17H20N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q91FH1328A, chemically known as 6-(2,6-dimethoxybenzamido)penicillanic acid but generally known as methicillin, which bears US NIH Compound Identifier 6087. European Medicines Agency schedules Meticillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08885MIG. The term METICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules methicillin in its Anatomical Therapeutic Chemical (ATC) Classification. Methicillin or meticillin bears US NLM identifiers UMLS ID C0025643 and NCI Concept Code C61842. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C.
This classification denotes an antithyroid agent with the molecular formula C4H6N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 554Z48XN5E, chemically known as 1,3-dihydro-1-methyl-2h-imidazole-2-thione but generally known as methimazole, which bears US NIH Compound Identifier 1349907. European Medicines Agency schedules Thiamazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10967MIG. The term THIAMAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methimazole in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, METHIMAZOLE remains the US FDA Preferred Term for this commodity. Methimazole bears US NLM identifiers UMLS ID C0025644 and NCI Concept Code C641. SMILES: S=C1N(CC[NH]1)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM550. This VA Drug Class (AM550) classifies this compound as belonging to the group METHENAMINE SALTS ANTIMICROBIALS.
This classification denotes an iodinated contrast dye with the molecular formula CH2IO3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3880P18UBM, chemically known as monoiodomethanesulfonic acid, sodium salt but more generally known as methiodal, which bears U.S. National Institutes of Health Compound Identifier 31345. The European Medicines Agency schedules Methiodal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03220MIG. The term METHIODAL is an International Non-Proprietary Name. The World Health Organization schedules methiodal in its Anatomical Therapeutic Chemical (ATC) Classification. METHIODAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Methiodal under HS 29049020. SMILES: ICS(=O)(=O)O.[Na].
This classification denotes an iodinated contrast dye with the molecular formula CH2IO3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3880P18UBM, chemically known as monoiodomethanesulfonic acid, sodium salt but more generally known as methiodal, which bears U.S. National Institutes of Health Compound Identifier 31345. European Medicines Agency schedules Methiodal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03220MIG. The term METHIODAL is an International Non-Proprietary Name. World Health Organization schedules methiodal in its Anatomical Therapeutic Chemical (ATC) Classification. METHIODAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methiodal sodium under HS 29049020 and SITC 51140. As of Q4 2014, METHIODAL SODIUM remains the US FDA Preferred Term for this commodity. Methiodal sodium bears US NLM identifiers UMLS ID C0142867 and NCI Concept Code C83954. SMILES: C(S(=O)(=O)[O-])I.[NA+].
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X2R9QTF0OL, chemically known as 10h-phenothiazine-10-propanamine, n,n, .beta.-trimethyl-2- (methylthio)-, monohydrochloride but generally known as methiomeprazine, which bears US NIH Compound Identifier 26430. European Medicines Agency schedules Methiomeprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08849MIG. The term METHIOMEPRAZINE is an International Non-Proprietary Name. METHIOMEPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methiomeprazine under HS 29343090 and SITC 51578. As of Q4 2014, METHIOMEPRAZINE remains the US FDA Preferred Term for this commodity. Methiomeprazine bears US NLM identifiers UMLS ID C0603501 and NCI Concept Code C83955. SMILES: S1C2C(N(CC(CN(C)C)C)C3C1CCCC3)CC(SC)CC2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P3V14N8PKW, chemically known as 10h-phenothiazine-10-propanamine, n,n,beta-trimethyl-2-(methylthio)-, monohydrochloride (9ci) but more generally known as methiomeprazine hydrochloride, which bears US NIH Compound Identifier 26429. Most nations, for tariff and trade purposes, schedule methiomeprazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, METHIOMEPRAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methiomeprazine hydrochloride bears US NLM identifiers UMLS ID C2825473 and NCI Concept Code C81144. SMILES: CC(CN1C2CCCCC2SC3C1CC(CC3)SC)CN(C)C.CL.
This classification denotes a dietary amino acid with the molecular formula C5H11NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AE28F7PNPL, chemically known as methionine which bears US NIH Compound Identifier 876. European Medicines Agency schedules methionine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21984. The term METHIONINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules l-methionine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule methionine under HS 29304010 and SITC 51544. As of Q4 2014, METHIONINE remains the US FDA Preferred Term for this commodity. Methionine bears US NLM identifiers UMLS ID C0025646 and NCI Concept Code C29600. SMILES: S(CCC(N)C(=O)O)C.
This classification denotes a dietary amino acid with the molecular formula C27H35N5O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9JEZ9OD3AS, chemically known as enkephalin-(5-l-methionine), but more generally known as methionine enkephalin, which bears US NIH Compound Identifier 42785. European Medicines Agency schedules methionine enkephalin or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08850MIG. Most nations, for tariff purposes, schedule methionine enkephalin under HS 29304010. SMILES: CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2CCC(CC2)O)N.
This classification denotes a dietary amino acid with the molecular formula C6H13NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BN630929UL, chemically known as (+)-l-methionine methyl ester, but more generally known as methionine methyl ester, which bears US NIH Compound Identifier 64684. European Medicines Agency schedules methionine methyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08850MIG. Most nations, for tariff purposes, schedule methionine methyl ester under HS 29304010. SMILES: COC(=O)[C@H](CCSC)N.
This classification denotes a dietary amino acid with the molecular formula C5H11NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XN1XVI4B2C, chemically known as butanoic acid, 2-amino-4-(methylsulfinyl)-, (2s)-, but more generally known as methionine sulfoxide, which bears US NIH Compound Identifier 847. European Medicines Agency schedules methionine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08850MIG. Most nations, for tariff purposes, schedule methionine sulfoxide under HS 29304010. SMILES: C[S+](CC[C@@H](C(=O)O)N)[O-].
This classification denotes an antiviral agent with the molecular formula C10H10N4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3QML4J07E, chemically known as 1-methylindole-2,3-dione 3-(thiosemicarbazone) but generally known as methisazone, which bears US NIH Compound Identifier 6861563. European Medicines Agency schedules Metisazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08895MIG. The term METHISAZONE is an International Non-Proprietary Name. World Health Organization schedules methisazone in its Anatomical Therapeutic Chemical (ATC) Classification. Methisazone or metisazone bears US NLM identifiers UMLS ID C0025656 and NCI Concept Code C77928. SMILES: CN1C2=CC=CC=C2C(=NNC(=S)N)C1=O.
This classification denotes a barbiturate with the molecular formula C12H20N2O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DZQ457UJ3Y, chemically known as 4,6-(1h,5h)-pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-(methylthio)ethyl)-2-thioxo- but generally known as methitural, which bears US NIH Compound Identifier 3032307. European Medicines Agency schedules Methitural in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08851MIG. The term METHITURAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). METHITURAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methitural under HS 29335400 and SITC kg. As of Q4 2014, METHITURAL remains the US FDA Preferred Term for this commodity. Methitural bears US NLM identifiers UMLS ID C0066138 and NCI Concept Code C83956. SMILES: S(CCC1(C(CCC)C)C(=O)NC(=S)NC1=O)C.
This classification denotes a barbiturate with the molecular formula C12H19N2O2S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 054NQ722GD, chemically known as 4,6(1h,5h)-pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-(methylthio)ethyl)-2-thioxo-, sodium salt (1:1), but more generally known as methitural sodium, which bears US NIH Compound Identifier 3034668. European Medicines Agency schedules methitural sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08851MIG. Most nations, for tariff purposes, schedule methitural sodium under HS 29335400. SMILES: CCCC(C)C1(C(=O)NC(=S)[N-]C1=O)CCSC.[NA+].
This classification denotes an antiparkinsonian agent with the molecular formula C20H23NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32VY6L26ZW, chemically known as 1-pipecoline, 3-(thioxanthen-9-yl)methyl-, hydrochloride but generally known as methixene, which bears US NIH Compound Identifier 4167. European Medicines Agency schedules Metixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08897MIG. The term METHIXENE is an International Non-Proprietary Name. World Health Organization schedules methixene in its Anatomical Therapeutic Chemical (ATC) Classification. Methixene or metixene bears US NLM identifiers UMLS ID C0066139 and NCI Concept Code C74162. SMILES: CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24.
This classification denotes a muscle relaxant with the molecular formula C11H15NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 125OD7737X, chemically known as 1,2-propanediol, 3-(o-methoxyphenoxy)-, 1-carbamate but generally known as methocarbamol, which bears US NIH Compound Identifier 4107. European Medicines Agency schedules Methocarbamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08852MIG. The term METHOCARBAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methocarbamol in its Anatomical Therapeutic Chemical (ATC) Classification. METHOCARBAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methocarbamol under HS 29242995 and SITC 51479. As of Q4 2014, METHOCARBAMOL remains the US FDA Preferred Term for this commodity. Methocarbamol bears US NLM identifiers UMLS ID C0025659 and NCI Concept Code C29252. SMILES: COC1=CC=CC=C1OCC(COC(=O)N)O.
This classification denotes a barbiturate with the molecular formula C14H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E5B8ND5IPE, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+-)- but generally known as methohexital, which bears US NIH Compound Identifier 9034. European Medicines Agency schedules Methohexital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14540MIG. The term METHOHEXITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methohexital in its Anatomical Therapeutic Chemical (ATC) Classification. METHOHEXITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Methohexital or methohexitone bears US NLM identifiers UMLS ID C0025668 and NCI Concept Code C66116. SMILES: O=C1N(C(=O)NC(=O)C1(C(C)C#CCC)CC=C)C.
This classification denotes a barbiturate with the molecular formula C14H17N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60200PNZ7Q, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+-)-, monosodium salt but more generally known as methohexital sodium, which bears US NIH Compound Identifier 9391. European Medicines Agency schedules Methohexital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03223MIG. Most nations, for tariff and trade purposes, schedule methohexital sodium under HS 29335400. As of Q4 2014, METHOHEXITAL SODIUM remains US FDA's Preferred Term for this commodity. Methohexital sodium bears US NLM identifiers UMLS ID C0304448 and NCI Concept Code C66117. SMILES: CCC#CC(C)C1(C(=O)[N-]C(=O)N(C1=O)C)CC=C.[NA+].
This classification denotes an antiadrenergic agent with the molecular formula C33H40N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8F8C1JQH53, chemically known as (-)-10-METHOXYDESERPIDINE but generally known as methoserpidine, which bears US NIH Compound Identifier 297930. The term methoserpidine is an International Non-Proprietary Name or INN. European Medicines Agency schedules methoserpidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08855MIG. Most nations schedule methoserpidine under HS 29399900 and SITC 54149. As of Q4 2014, METHOSERPIDINE remains the US FDA Preferred Term for this commodity. SMILES: COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=C(C=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC.
This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C20H22N8O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YL5FZ2Y5U1, chemically known as poly(imino((1s)-1-carboxy-4-oxo-1,4-butanediyl)), alpha-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-omega-hydroxy- but generally known as methotrexate, which bears US NIH Compound Identifier 4112. European Medicines Agency schedules Methotrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08856MIG. The term METHOTREXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methotrexate in its Anatomical Therapeutic Chemical (ATC) Classification. METHOTREXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methotrexate under HS 29335995 and SITC 51576. As of Q4 2014, METHOTREXATE remains the US FDA Preferred Term for this commodity. Methotrexate bears US NLM identifiers UMLS ID C0025677 and NCI Concept Code C642. SMILES: OC(=O)C(NC(=O)C1CCC(N(CC2NC3C(NC2)NC(NC3N)N)C)CC1)CCC(=O)O.
This classification denotes an antineoplastic antimetabolite, immunosuppressant, folic acid antagonist, and nucleic acid synthesis inhibitor with the molecular formula C20H20N8O5.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3IG1E710ZN, chemically known as glutamic acid, n-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, disodium salt, l-(+)- but more generally known as methotrexate sodium, which bears US NIH Compound Identifier 23893. European Medicines Agency schedules Methotrexate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03225MIG. Most nations, for tariff and trade purposes, schedule methotrexate sodium under HS 29335995 and SITC 51576. As of Q4 2014, METHOTREXATE SODIUM remains US FDA's Preferred Term for this commodity. Methotrexate sodium bears US NLM identifiers UMLS ID C0949359 and NCI Concept Code C1735. SMILES: CN(CC1CNC2C(N1)C(NC(N2)N)N)C3CCC(CC3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[NA+].[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN300. This VA Drug Class (AN300) classifies this compound as belonging to the group ANTINEOPLASTICS, ANTIMETABOLITES.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HUQ1KC1YLI, chemically known as 2-amino-1-(2,5-dimethoxyphenyl)propanol but generally known as methoxamine, which bears US NIH Compound Identifier 6082. European Medicines Agency schedules Methoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08857MIG. The term METHOXAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules methoxamine in its Anatomical Therapeutic Chemical (ATC) Classification. METHOXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methoxamine under HS 29225000 and SITC 51467. As of Q4 2014, METHOXAMINE remains the US FDA Preferred Term for this commodity. Methoxamine bears US NLM identifiers UMLS ID C0025681 and NCI Concept Code C66119. SMILES: CC(C(C1=C(C=CC(=C1)OC)OC)O)N.
This classification denotes a photosensitizing agent and dna crosslinking agent with the molecular formula C12H8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U4VJ29L7BQ, chemically known as 9-methoxyfuro(3,2-g)chromen-7-one but generally known as methoxsalen, which bears US NIH Compound Identifier 4114. European Medicines Agency schedules Methoxsalen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14541MIG. World Health Organization schedules methoxsalen in its Anatomical Therapeutic Chemical (ATC) Classification. Methoxsalen or xanthotoxin bears US NLM identifiers UMLS ID C0025684 and NCI Concept Code C643. SMILES: O1C2C(CC3C(OC(=O)CC3)C2OC)CC1.
This classification denotes an anesthetic agent with the molecular formula C3H4Cl2F2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30905R8O7B, chemically known as 2,2-dichloro-1,1-difluoroethyl methyl ether but generally known as methoxyflurane, which bears US NIH Compound Identifier 4116. European Medicines Agency schedules Methoxyflurane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08858MIG. The term METHOXYFLURANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules methoxyflurane in its Anatomical Therapeutic Chemical (ATC) Classification. METHOXYFLURANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methoxyflurane under HS 29091990 and SITC 51616. As of Q4 2014, METHOXYFLURANE remains the US FDA Preferred Term for this commodity. Methoxyflurane bears US NLM identifiers UMLS ID C0025688 and NCI Concept Code C75098. SMILES: CLC(CL)C(F)(F)OC.
This classification denotes a beta-adrenergic agonist with the molecular formula C11H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3Z5SRI26Z, chemically known as 2-methoxy-n,alpha-dimethylphenethylamin but generally known as methoxyphenamine, which bears US NIH Compound Identifier 4117. European Medicines Agency schedules Methoxyphenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08860MIG. The term METHOXYPHENAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules methoxyphenamine in its Anatomical Therapeutic Chemical (ATC) Classification. METHOXYPHENAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methoxyphenamine under HS 29222900 and SITC 51462. As of Q4 2014, METHOXYPHENAMINE remains the US FDA Preferred Term for this commodity. Methoxyphenamine bears US NLM identifiers UMLS ID C0066165 and NCI Concept Code C83958. SMILES: CC(CC1=CC=CC=C1OC)NC.
This classification denotes a beta-adrenergic agonist with the molecular formula C11H17NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52V8BVV7FX, chemically known as 2-methoxy-n,alpha-dimethylphenethylamin but more generally known as methoxyphenamine hydrochloride, which bears US NIH Compound Identifier 4117. European Medicines Agency schedules Methoxyphenamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03229MIG. Most nations, for tariff and trade purposes, schedule methoxyphenamine hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, METHOXYPHENAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methoxyphenamine hydrochloride bears US NLM identifiers UMLS ID C0770481 and NCI Concept Code C83959. SMILES: CC(CC1CCCCC1OC)NC.CL.
Long-acting erythropoietin receptor activator (CERA) indicated for the treatment of patients with anaemia associated with chronic kidney disease.
This classification denotes an antimuscarinic agent with the molecular formula C18H24NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VDR09VTQ8U, chemically known as scopolammonium, n-methylbromide but generally known as methscopolamine, which bears US NIH Compound Identifier 441342. European Medicines Agency schedules Methscopolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32123. Methscopolamine or methylscopolamine bears US NLM identifiers UMLS ID C0301374 and NCI Concept Code C76001. SMILES: BR.O1C2C3[N](C(C12)CC(OC(=O)C(CO)C1CCCCC1)C3)(C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a thiazide diuretic with the molecular formula C9H11Cl2N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L3H46UAC61, chemically known as 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as methyclothiazide, which bears US NIH Compound Identifier 4121. European Medicines Agency schedules Methyclothiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08861MIG. The term METHYCLOTHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules methyclothiazide in its Anatomical Therapeutic Chemical (ATC) Classification. METHYCLOTHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methyclothiazide under HS 29350090 and SITC 51580. As of Q4 2014, METHYCLOTHIAZIDE remains the US FDA Preferred Term for this commodity. Methyclothiazide bears US NLM identifiers UMLS ID C0025696 and NCI Concept Code C47614. SMILES: CLCC1N(S(=O)(=O)C2C(N1)CC(CL)C(S(=O)(=O)N)C2)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a photosensitizing agent with the molecular formula C6H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 585NM85KYM, chemically known as pentanoic acid, 5-amino-4-oxo-, methyl ester but generally known as methyl aminolevulinate, which bears US NIH Compound Identifier 157922. European Medicines Agency schedules Methyl aminolevulinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22645. World Health Organization schedules methyl aminolevulinate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, METHYL AMINOLEVULINATE remains the US FDA Preferred Term for this commodity. Methyl aminolevulinate bears US NLM identifiers UMLS ID C1134467 and NCI Concept Code C76305. SMILES: O(C(=O)CCC(=O)CN)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a parasympatholytic with the molecular formula C18H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80719I460H, chemically known as 8-azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8,8-dimethyl-, endo-(+-)- but generally known as methylatropine, which bears US NIH Compound Identifier 5861. World Health Organization schedules methylatropine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.
This classification denotes an analgesic.
This classification denotes a laxative with the molecular formula C29H54O16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0GN6F9B2Y, chemically known as (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3, 4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5, 6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane but generally known as methylcellulose, which bears US NIH Compound Identifier 44263857. European Medicines Agency schedules methylcellulose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB45349, SUB45348, SUB45347, SUB43175, SUB45344, SUB60089, and SUB03240MIG.. Most nations schedule methylcellulose under HS 39123980 and SITC 57554. Methylcellulose bears US NLM identifiers UMLS ID C0025729 and NCI Concept Code C29253. SMILES: COCC1C(C(C(C(O1)OC2C(OC(C(C2OC)OC)OC3C(OC(C(C3OC)OC)OC)COC)COC)OC)OC)OC.
This classification denotes an antispasmotic agent with the molecular formula C10H8O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KJ0091KAAH, chemically known as 4h-1-benzopyran-4-one, 3-methyl- but generally known as methylchromone, which bears US NIH Compound Identifier 66569. European Medicines Agency schedules Methylchromone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08864MIG. The term METHYLCHROMONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). METHYLCHROMONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Methylchromone or tricromyl bears US NLM identifiers UMLS ID C1881805 and NCI Concept Code C66121. SMILES: O1C2C(C(=O)C(C1)C)CCCC2.
This classification denotes an opioid receptor agonist with the molecular formula C18H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y460N7W76B, chemically known as morphinan-3-ol, 6,7-didehydro-4,5-epoxy-6,17-dimethyl-, (5.alpha.)- but generally known as methyldesorphine, which bears US NIH Compound Identifier 519207. European Medicines Agency schedules Methyldesorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08865MIG. The term METHYLDESORPHINE is an International Non-Proprietary Name. METHYLDESORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methyldesorphine under HS 29391900 and SITC 54141. As of Q4 2014, METHYLDESORPHINE remains the US FDA Preferred Term for this commodity. Methyldesorphine bears US NLM identifiers UMLS ID C2984001 and NCI Concept Code C91047. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(O)CC3)CC=C2C.
This classification denotes a dopamine agonist and antihypertensive agent with the molecular formula 2C10H13NO4.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56LH93261Y, chemically known as 3,4-dihydroxy-2-methylphenylalanine but generally known as methyldopa, which bears US NIH Compound Identifier 4138. European Medicines Agency schedules Methyldopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08867MIG. World Health Organization schedules methyldopa in its Anatomical Therapeutic Chemical (ATC) Classification. METHYLDOPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methyldopa under HS 29225000 and SITC 51467. As of Q4 2014, METHYLDOPA remains the US FDA Preferred Term for this commodity. Methyldopa bears US NLM identifiers UMLS ID C0025741 and NCI Concept Code C47616. SMILES: CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N.
This classification denotes a dopamine agonist and antihypertensive agent with the molecular formula C10H13NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4R0H12F6M, chemically known as l-3-(3,4-dihydroxyphenyl)-2-methylalanine, but more generally known as methyldopa anhydrous, which bears US NIH Compound Identifier 4138. European Medicines Agency schedules methyldopa anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08867MIG. Most nations, for tariff purposes, schedule methyldopa anhydrous under HS 29225000. SMILES: C[C@](CC1CCC(C(C1)O)O)(C(=O)O)N.
This classification denotes a dopamine agonist and antihypertensive agent with the molecular formula 2C10H13NO4.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56LH93261Y, chemically known as l-3-(3,4-dihydroxyphenyl)-2-methylalanine sesquihydrate, but more generally known as methyldopa sesquihydrate, which bears US NIH Compound Identifier 38852. European Medicines Agency schedules methyldopa sesquihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08867MIG. Most nations, for tariff purposes, schedule methyldopa sesquihydrate under HS 29225000. SMILES: C[C@](CC1CCC(C(C1)O)O)(C(=O)O)N.C[C@](CC1CCC(C(C1)O)O)(C(=O)O)N.O.O.O.
This classification denotes a dye with the molecular formula C16H18N3S.Cl.3H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier T42P99266K, chemically known as 3,7-bis(dimethylamino)phenothiazin-5-ium chloride but more generally known as basic blue 9, which bears US NIH Compound Identifier 6099. European Medicines Agency schedules Methylene blue in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21957. Methylene blue bears US NLM identifiers UMLS ID C0025746 and NCI Concept Code C644. SMILES: S1C2C(NC3C1CC(N(C)C)CC3)CCC(=[N](\C)C)/C2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX201. This VA Drug Class (DX201) classifies this compound as belonging to the group IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS.
This classification denotes a cns stimulant with the molecular formula C20H25N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W53L6FE61V, chemically known as 9,10-didehydro-n-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide but generally known as methylergometrine, which bears US NIH Compound Identifier 8226. European Medicines Agency schedules Methylergometrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08868MIG. The term METHYLERGOMETRINE is an International Non-Proprietary Name. World Health Organization schedules methylergometrine in its Anatomical Therapeutic Chemical (ATC) Classification. METHYLERGOMETRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, METHYLERGONOVINE remains the US FDA Preferred Term for this commodity. Methylergonovine bears US NLM identifiers UMLS ID C0025760 and NCI Concept Code C74105. SMILES: O=C(NC(CC)CO)C1CN(C2C(=C1)C1C3C(C2)C[NH]C3CCC1)C.
This classification denotes a progesterone congener with the molecular formula C19H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 743F1Z557A, chemically known as 17alpha-Methyl-19-nortestosterone but generally known as Methylestrenolone, which bears US NIH Compound Identifier 5284597. European Medicines Agency schedules Methylestrenolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14667MIG. SMILES: CC12CCC3C(C1CCC2(C)O)CCC4=CC(=O)CCC34.
This classification denotes an opiate antagonist with the moleculat formula C21H26NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0RK7M7IABE. European Medicines Agency schedules Methylnaltrexone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33963. The term METHYLNALTREXONE is a European Medicines Agency European Public Assessment Report System designation. As of Q4 2014, METHYLNALTREXONE remains the US FDA Preferred Term for this commodity. Methylnaltrexone bears US NLM identifiers UMLS ID C0066411 and NCI Concept Code C48403. SMILES: C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.
This classification denotes a paraben, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A2I8C7HI9T. European Medicines Agency schedules Methyl hydroxybenzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22117. Methylparaben generally arises in the molecular formula C8H8O3. The term 'methylparaben' is a United States Adopted Name designation. As of Q4 2014, METHYLPARABEN remains the US FDA Preferred Term for this commodity. Methylparaben bears US NLM identifiers UMLS ID C0066415 and NCI Concept Code C76720. SMILES: O(C(=O)C1CCC(O)CC1)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a cns stimulant with the molecular formula C14H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 207ZZ9QZ49, chemically known as 2-piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride but more generally known as methylphenidate, which bears US NIH Compound Identifier 4158. European Medicines Agency schedules Methylphenidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08870MIG. The term METHYLPHENIDATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules methylphenidate in its Anatomical Therapeutic Chemical (ATC) Classification. METHYLPHENIDATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule methylphenidate under HS 29333300 and SITC 51574. As of Q4 2014, METHYLPHENIDATE remains US FDA's Preferred Term for this commodity. Methylphenidate bears US NLM identifiers UMLS ID C0025810 and NCI Concept Code C62045. SMILES: O(C(=O)C(C1NCCCC1)C1CCCCC1)C.
This classification denotes a central nervous system stimulantt and dopamine uptake inhibitor with the molecular formula C14H19NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B3SC438HI, chemically known as 2-piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride but more generally known as methylphenidate hydrochloride, which bears US NIH Compound Identifier 4158. European Medicines Agency schedules Methylphenidate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03254MIG. Most nations, for tariff and trade purposes, schedule methylphenidate hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, METHYLPHENIDATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methylphenidate hydrochloride bears US NLM identifiers UMLS ID C0728759 and NCI Concept Code C646. SMILES: COC(=O)[C@H](C1CCCCC1)[C@H]2CCCCN2.CL.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X4W7ZR7023, chemically known as 1,4-butanedioic acid (succinic acid) but generally known as methylprednisolone, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Methylprednisolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08872MIG. The term METHYLPREDNISOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methylprednisolone in its Anatomical Therapeutic Chemical (ATC) Classification. METHYLPREDNISOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methylprednisolone under HS 29372900 and SITC 54153. As of Q4 2014, METHYLPREDNISOLONE remains the US FDA Preferred Term for this commodity. Methylprednisolone bears US NLM identifiers UMLS ID C0025815 and NCI Concept Code C647. SMILES: OC(=O)CCC(=O)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H36O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ET54W9J4U2, chemically known as 11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione, 21-acetate 17-propionate but more generally known as methylprednisolone aceponate, which bears US NIH Compound Identifier 63019. European Medicines Agency schedules Methylprednisolone aceponate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08873MIG. The term METHYLPREDNISOLONE ACEPONATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules methylprednisolone aceponate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule methylprednisolone aceponate under HS 29372900 and SITC 54153. As of Q4 2014, METHYLPREDNISOLONE ACEPONATE remains US FDA's Preferred Term for this commodity. Methylprednisolone aceponate bears US NLM identifiers UMLS ID C0174938 and NCI Concept Code C90955. SMILES: CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)C)O)C)C(=O)COC(=O)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H32O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43502P7F0P, chemically known as 3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene but more generally known as methylprednisolone acetate, which bears US NIH Compound Identifier 5755. European Medicines Agency schedules Methylprednisolone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03255MIG. Most nations, for tariff and trade purposes, schedule methylprednisolone acetate under HS 29372900 and SITC 54153. As of Q4 2014, METHYLPREDNISOLONE ACETATE remains US FDA's Preferred Term for this commodity. Methylprednisolone acetate bears US NLM identifiers UMLS ID C0600901 and NCI Concept Code C48003. SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes a therapeutic glucocorticoid C22H29O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6089CVN95V, chemically known as pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-(phosphonooxy)-, disodium salt (6.alpha.,11.beta.)-, but more generally known as methylprednisolone sodium phosphate, which bears US NIH Compound Identifier 21115. European Medicines Agency schedules Methylprednisolone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25642. Most nations, for tariff and trade purposes, schedule methylprednisolone sodium phosphate under HS 29372900 and SITC 54153. As of Q4 2014, METHYLPREDNISOLONE SODIUM PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COP(=O)([O-])[O-])O.[NA+].[NA+].
This classification denotes a therapeutic glucocorticoid with the molecular formula C26H33O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LEC9GKY20K, chemically known as 1,4-butanedioic acid (succinic acid) but more generally known as methylprednisolone sodium succinate, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Methylprednisolone sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14562MIG. Most nations, for tariff and trade purposes, schedule methylprednisolone sodium succinate under HS 29372900 and SITC 54153. As of Q4 2014, METHYLPREDNISOLONE SODIUM SUCCINATE remains US FDA's Preferred Term for this commodity. Methylprednisolone sodium succinate bears US NLM identifiers UMLS ID C0700546 and NCI Concept Code C48004. SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)[O-])O.[NA+].
This classification denotes a therapeutic glucocorticoid with the molecular formula C33H48NO10S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6CS53NCVS, chemically known as 7-(methyl(2-sulfoethyl)carbamoyl)heptanoic acid, c-21-ester with 11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione, monosodium salt but more generally known as methylprednisolone suleptanate, which bears US NIH Compound Identifier 56067. European Medicines Agency schedules Methylprednisolone suleptanate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08874MIG. The term METHYLPREDNISOLONE SULEPTANATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). Most nations, for tariff and trade purposes, schedule methylprednisolone suleptanate under HS 29372900 and SITC 54153. As of Q4 2014, METHYLPREDNISOLONE SULEPTANATE remains US FDA's Preferred Term for this commodity. Methylprednisolone suleptanate bears US NLM identifiers UMLS ID C0066429 and NCI Concept Code C77422. SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS(=O)(=O)[O-])O.[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C8H8O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LAV5U5022Y, chemically known as 2-hydroxybenzoic acid, methyl ester but generally known as methyl salicylate, which bears US NIH Compound Identifier 4133. European Medicines Agency schedules Methyl salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14545MIG. Most nations schedule methyl salicylate under HS 29182300 and SITC 51393. As of Q4 2014, METHYL SALICYLATE remains the US FDA Preferred Term for this commodity. Methyl salicylate bears US NLM identifiers UMLS ID C0066282 and NCI Concept Code C80564. SMILES: CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.
This classification denotes a therapeutic androgen with the molecular formula C20H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9EFU16ZIF, chemically known as testosterone, 17-methyl- but generally known as 17-methyltestosterone, which bears US NIH Compound Identifier 6010. European Medicines Agency schedules Methyltestosterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08876MIG. The term METHYLTESTOSTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules 17-methyltestosterone in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule methyltestosterone under HS 29372900 and SITC 54153. As of Q4 2014, METHYLTESTOSTERONE remains the US FDA Preferred Term for this commodity. Methyltestosterone bears US NLM identifiers UMLS ID C0718532 and NCI Concept Code C648. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)C.
This classification denotes an antithyroid agent with the molecular formula C5H6N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QW24888U5F, chemically known as 2,3-dihydro-6-methyl-2-thioxo-4(1h)-pyrimidinone but generally known as methylthiouracil, which bears US NIH Compound Identifier 667493. European Medicines Agency schedules Methylthiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08878MIG. The term METHYLTHIOURACIL is an International Non-Proprietary Name. World Health Organization schedules methylthiouracil in its Anatomical Therapeutic Chemical (ATC) Classification. METHYLTHIOURACIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methylthiouracil under HS 29335995 and SITC 51576. As of Q4 2014, METHYLTHIOURACIL remains the US FDA Preferred Term for this commodity. Methylthiouracil bears US NLM identifiers UMLS ID C0025830 and NCI Concept Code C81590. SMILES: S=C1[NH]C(CC(=O)[NH]1)C.
This classification denotes a sedative and hypnotic with the molecular formula C10H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUT48I42ON, chemically known as 3,3-diethyl-5-methylpiperidine-2,4-dione but generally known as methyprylon, which bears US NIH Compound Identifier 4162. European Medicines Agency schedules Methyprylon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08879MIG. The term METHYPRYLON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules methyprylon in its Anatomical Therapeutic Chemical (ATC) Classification. METHYPRYLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methyprylon under HS 29337200 and SITC 51561. As of Q4 2014, METHYPRYLON remains the US FDA Preferred Term for this commodity. Methyprylon bears US NLM identifiers UMLS ID C0025840 and NCI Concept Code C66122. SMILES: CCC1(C(=O)C(CNC1=O)C)CC.
This classification denotes a serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XZA9HY6Z98. European Medicines Agency schedules Methysergide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08880MIG. Methysergide generally arises in the molecular formula C21H27N3O2. The term METHYSERGIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) METHYSERGIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule methysergide under HS 29396900 and SITC 54146. As of Q4 2014, METHYSERGIDE remains the US FDA Preferred Term for this commodity. Methysergide bears US NLM identifiers UMLS ID C0025842 and NCI Concept Code C66123. SMILES: O=C(NC(CC)CO)C1CN(C2C(=C1)C1C3C(C2)CN(C3CCC1)C)C.
This classification denotes a cns stimulant with the molecular formula C21H27N3O2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2U7H1466GH, chemically known as 9,10-didehydro-n-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide maleate (1:1) (salt) but more generally known as methysergide maleate, which bears US NIH Compound Identifier 5281073. European Medicines Agency schedules Methysergide maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03263MIG. Most nations, for tariff and trade purposes, schedule methysergide maleate under HS 29396900 and SITC 54146. As of Q4 2014, METHYSERGIDE MALEATE remains US FDA's Preferred Term for this commodity. Methysergide maleate bears US NLM identifiers UMLS ID C0036177 and NCI Concept Code C61843. SMILES: CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3CN(C4C3C(CCC4)C2=C1)C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C9H16N4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K7670861M, chemically known as urea, 1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)-2-thio- but generally known as metiamide, which bears US NIH Compound Identifier 1548992. European Medicines Agency schedules Metiamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08881MIG. The term METIAMIDE is an International Non-Proprietary Name. METIAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metiamide under HS 29332990 and SITC 51573. As of Q4 2014, METIAMIDE remains the US FDA Preferred Term for this commodity. Metiamide bears US NLM identifiers UMLS ID C0025845 and NCI Concept Code C90862. SMILES: S(CC1NC[NH]C1C)CCNC(=S)NC.
This classification denotes an antipsychotic agent with the molecular formula C19H21N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 775D6D91J8, chemically known as 2-methyl-11-(4-methyl-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine but generally known as metiapine, which bears US NIH Compound Identifier 22047. European Medicines Agency schedules Metiapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08882MIG. The term METIAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). METIAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metiapine under HS 29349990 and SITC 51579. As of Q4 2014, METIAPINE remains the US FDA Preferred Term for this commodity. Metiapine bears US NLM identifiers UMLS ID C0066451 and NCI Concept Code C90761. SMILES: S1C2C(C(=NC3C1CCCC3)N1CCN(CC1)C)CC(CC2)C.
This classification denotes a penicillin antibiotic with the molecular formula C17H19N2O6S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AO9YF4MN30, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((2,6-dimethoxybenzoyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate, (2s-(2alpha,5alpha,6beta))- but more generally known as methicillin sodium, which bears US NIH Compound Identifier 23675. European Medicines Agency schedules Meticillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03264MIG. Most nations, for tariff and trade purposes, schedule meticillin sodium under HS 29411090. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3C(CCCC3OC)OC)C(=O)[O-])C.[NA+].
This classification denotes a thiazide diuretic with the molecular formula C10H13NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I7EKN1924Q, chemically known as 3,4-dihydro-6-methyl-2h-1-benzothiopyran-7-sulfonamide 1,1-dioxide but generally known as meticrane, which bears US NIH Compound Identifier 4165. European Medicines Agency schedules Meticrane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08886MIG. The term METICRANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules meticrane in its Anatomical Therapeutic Chemical (ATC) Classification. METICRANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meticrane under HS 29350090 and SITC 51580. As of Q4 2014, METICRANE remains the US FDA Preferred Term for this commodity. Meticrane bears US NLM identifiers UMLS ID C0873165 and NCI Concept Code C66125. SMILES: CC1=C(C=C2C(=C1)CCCS2(=O)=O)S(=O)(=O)N.
This classification denotes an anti-arrhythmia agent, cardiotonic agent, and enzyme inhibitor with the molecular formula C42H66O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I7GG1YUC5V, chemically known as digoxin, 4-o-methyl- but more generally known as metildigoxin, which bears US NIH Compound Identifier 35418. European Medicines Agency schedules Metildigoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08887MIG. World Health Organization schedules metildigoxin in its Anatomical Therapeutic Chemical (ATC) Classification. METILDIGOXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule metildigoxin under HS 29389010 and SITC 54161. As of Q4 2014, METILDIGOXIN remains US FDA's Preferred Term for this commodity. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(OC)C(O)C6)C)C(O)C5)C)C(O)C3)C)CC4)C)CC(O)C1(C(CC2)C1=CC(=O)OC1)C.
This classification denotes an antibiotic with the molecular formula C14H18N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K29KWU39J0, chemically known as 2,4-pyrimidinediamine, 5-((3,5-dimethoxy-4-(methylthio)phenyl)methyl)- but more generally known as metioprim, which bears US NIH Compound Identifier 68590. European Medicines Agency schedules Metioprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08889MIG. The term METIOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 34, No. 10 1980, List 20). METIOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(C1C(OC)CC(CC2C(NC(NC2)N)N)CC1OC)C.
This classification denotes an antibiotic with the molecular formula C22H27N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 00V69U1QC7 chemically known as 2-(4-methylpiperidino)ethyl 6-ethyl-2,3,6,9-tetrahydro-3-methyl-2,9-dioxothiazolo(5,4-f)quinoline-8-carboxylate but generally known as metioxate, which bears US NIH Compound Identifier 3047729. European Medicines Agency schedules Metioxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08890MIG. The term METIOXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16. ). Most nations schedule metioxate under HS 29349990 and SITC 51579. As of Q4 2014, METIOXATE remains the US FDA Preferred Term for this commodity. Metioxate bears US NLM identifiers UMLS ID C1881807 and NCI Concept Code C66127. SMILES: CCN1C=C(C(=O)C2=C1C=CC3=C2SC(=O)N3C)C(=O)OCCN4CCC(CC4)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H27NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X39AL81KEB, chemically known as 4-(2-hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate but generally known as metipranolol, which bears US NIH Compound Identifier 31477. European Medicines Agency schedules Metipranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08892MIG. The term METIPRANOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules metipranolol in its Anatomical Therapeutic Chemical (ATC) Classification. METIPRANOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metipranolol under HS 29221980 and SITC 51461. As of Q4 2014, METIPRANOLOL remains the US FDA Preferred Term for this commodity. Metipranolol bears US NLM identifiers UMLS ID C0041030 and NCI Concept Code C61844. SMILES: O(CC(O)CNC(C)C)C1C(C(C(OC(=O)C)C(C1)C)C)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H27NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FBW237ALKD, chemically known as 4-(2-hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate but more generally known as metipranolol hydrochloride, which bears US NIH Compound Identifier 31477. European Medicines Agency schedules Metipranolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03267MIG. Most nations, for tariff and trade purposes, schedule metipranolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, METIPRANOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metipranolol hydrochloride bears US NLM identifiers UMLS ID C0982282 and NCI Concept Code C77946. SMILES: CC1CC(C(C(C1OC(=O)C)C)C)OCC(CNC(C)C)O.CL.
This classification denotes a beta-adrenergic agonist with the molecular formula C12H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1WBF92D66N, chemically known as vanillyl alcohol, alpha-((isopropylamino)methyl)- but generally known as metiprenaline, which bears US NIH Compound Identifier 68951. European Medicines Agency schedules Metiprenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08893MIG. The term METIPRENALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). METIPRENALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metiprenaline under HS 29225000 and SITC 51467. As of Q4 2014, METIPRENALINE remains the US FDA Preferred Term for this commodity. Metiprenaline bears US NLM identifiers UMLS ID C0047657 and NCI Concept Code C87676. SMILES: CC(C)NCC(C1=CC(=C(C=C1)O)OC)O.
This classification denotes a tyrosine hydroxylase inhibitor with the molecular formula C10H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DOQ0J0TPF7, chemically known as l-tyrosine, alpha-methyl-, (-)- but generally known as metirosine, which bears US NIH Compound Identifier 12650. European Medicines Agency schedules Metirosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08894MIG. The term METIROSINE is an International Non-Proprietary Name. World Health Organization schedules metirosine in its Anatomical Therapeutic Chemical (ATC) Classification. METIROSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Metirosine or metyrosine bears US NLM identifiers UMLS ID C0886584 and NCI Concept Code C998. SMILES: C[C@@](CC1=CC=C(C=C1)O)(C(=O)O)N.
This classification denotes an imidazole with the molecular formula C13H14N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z27L8N105U, chemically known as 1h-imidazole, 4,5-dihydro-2-((2-methylbenzo(b)thien-3-yl)methyl)- but generally known as metizoline, which bears US NIH Compound Identifier 28688. European Medicines Agency schedules Metizoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08898MIG. World Health Organization schedules metizoline in its Anatomical Therapeutic Chemical (ATC) Classification. METIZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metizoline under HS 29349990 and SITC 51579. As of Q4 2014, METIZOLINE remains the US FDA Preferred Term for this commodity. Metizoline bears US NLM identifiers UMLS ID C0604284 and NCI Concept Code C99577. SMILES: S1C(C(CC2=NCCN2)C2C1CCCC2)C.
This classification denotes an adrenergic agonist with the molecular formula C13H14N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PU364U720Z, chemically known as 4,5-dihydro-2-((2-methylbenzo(b)thien-3-yl)methyl)-1h-imidazole monohydrochloride but more generally known as metizoline hydrochloride, which bears US NIH Compound Identifier 68629. Most nations, for tariff and trade purposes, schedule metizoline hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, METIZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metizoline hydrochloride bears US NLM identifiers UMLS ID C2983811 and NCI Concept Code C90632. SMILES: CC1C(C2CCCCC2S1)CC3=NCCN3.CL.
This classification denotes an antiemetic agent with the molecular formula C14H22ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L4YEB44I46, chemically known as 2-methoxy-4-amino-5-chloro-n,n-dimethylaminoethyl)benzamide but generally known as metoclopramide, which bears US NIH Compound Identifier 4168. European Medicines Agency schedules Metoclopramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08902MIG. The term METOCLOPRAMIDE is an International Non-Proprietary Name. World Health Organization schedules metoclopramide in its Anatomical Therapeutic Chemical (ATC) Classification. METOCLOPRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metoclopramide under HS 29242995 and SITC 51479. As of Q4 2014, METOCLOPRAMIDE remains the US FDA Preferred Term for this commodity. Metoclopramide bears US NLM identifiers UMLS ID C0025853 and NCI Concept Code C62046. SMILES: CLC1CC(C(=O)NCCN(CC)CC)C(OC)CC1N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AU300. This VA Drug Class (AU300) classifies this compound as belonging to the group PARASYMPATHOMIMETICS (CHOLINERGICS).
This classification denotes a phenothiazine with the molecular formula C31H36ClN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27J5OW8OGT, chemically known as 2-(4-(3-(2-chlorophenothiazin-10-yl)propyl)-1-piperazinyl)ethyl 3,4,5-trimethoxybenzoate but generally known as metofenazate, which bears US NIH Compound Identifier 9800. European Medicines Agency schedules Metofenazate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08903MIG. The term METOFENAZATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). METOFENAZATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metofenazate under HS 29343090 and SITC 51578. As of Q4 2014, METOFENAZATE remains the US FDA Preferred Term for this commodity. Metofenazate bears US NLM identifiers UMLS ID C0066466 and NCI Concept Code C66132. SMILES: CLC1CC2N(CCCN3CCN(CC3)CCOC(=O)C3CC(OC)C(OC)C(OC)C3)C3C(SC2CC1)CCCC3.
This classification denotes a phenothiazine with the molecular formula C31H36ClN3O5S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2A3RCX7T4J, chemically known as benzoic acid, 3,4,5-trimethoxy-, 2-(4-(3-(2-chloro-10h-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester, (2e)-2-butenedioate (1:2), but more generally known as metofenazate difumarate, which bears US NIH Compound Identifier 6433198. European Medicines Agency schedules metofenazate difumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08903MIG. Most nations, for tariff purposes, schedule metofenazate difumarate under HS 29343090. SMILES: COC1C(C(CC(C1)C(=O)OCCN2CCN(CC2)CCCN3C4C(CCC(C4)CL)SC5C3CCCC5)OC)OC.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a thiazide diuretic with the molecular formula C16H16ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TZ7V40X7VX, chemically known as 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide but generally known as metolazone, which bears US NIH Compound Identifier 4170. European Medicines Agency schedules Metolazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08906MIG. The term METOLAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules metolazone in its Anatomical Therapeutic Chemical (ATC) Classification. METOLAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metolazone under HS 29350090 and SITC 51580. As of Q4 2014, METOLAZONE remains the US FDA Preferred Term for this commodity. Metolazone bears US NLM identifiers UMLS ID C0025854 and NCI Concept Code C650. SMILES: CLC1CC2NC(N(C(=O)C2CC1S(=O)(=O)N)C1C(CCCC1)C)C.
This classification denotes a sedative and hypnotic with the molecular formula C13H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z18ZYL8Y51, chemically known as 1h-imidazole-5-carboxylic acid, 1- (1-phenylethyl)-, methyl ester, monohydrochloride but generally known as metomidate, which bears US NIH Compound Identifier 21474. European Medicines Agency schedules Metomidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08907MIG. The term METOMIDATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). METOMIDATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metomidate under HS 29332990 and SITC 51573. As of Q4 2014, METOMIDATE remains the US FDA Preferred Term for this commodity. Metomidate bears US NLM identifiers UMLS ID C0025856 and NCI Concept Code C90941. SMILES: O(C(=O)C1N(C(C2CCCCC2)C)CNC1)C.
This classification denotes a sedative and hypnotic with the molecular formula C13H14N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SKV88232PJ, chemically known as methyl 1-(.alpha.-methylbenzyl)imidazole-5-carboxylate hydrochloride, but more generally known as metomidate hydrochloride, which bears US NIH Compound Identifier 21474. European Medicines Agency schedules metomidate hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08907MIG. Most nations, for tariff purposes, schedule metomidate hydrochloride under HS 29332990. SMILES: CC(C1CCCCC1)N2CNCC2C(=O)OC.CL.
This classification denotes an antiemetic agent with the molecular formula C22H27N3O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 238S75V9AV, chemically known as 4-piperidinecarboxamide, 1-(3-(2-(methylsulfonyl)-10h-phenothiazin-10-yl)propyl)- but generally known as metopimazine, which bears US NIH Compound Identifier 26388. European Medicines Agency schedules Metopimazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08908MIG. The term METOPIMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules metopimazine in its Anatomical Therapeutic Chemical (ATC) Classification. METOPIMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metopimazine under HS 29343090 and SITC 51578. As of Q4 2014, METOPIMAZINE remains the US FDA Preferred Term for this commodity. Metopimazine bears US NLM identifiers UMLS ID C0066469 and NCI Concept Code C81497. SMILES: S1C2C(N(CCCN3CCC(CC3)C(=O)N)C3C1CCCC3)CC(S(=O)(=O)C)CC2.
This classification denotes an opioid receptor agonist with the molecular formula C18H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94XZ1CC69D, chemically known as 4,5-alpha-epoxy-3-hydroxy-5,17-diethylmorphinan-6-one but generally known as metopon, which bears US NIH Compound Identifier 5359353. European Medicines Agency schedules Metopon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08909MIG. The term METOPON is an International Non-Proprietary Name. METOPON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metopon under HS 29391900 and SITC 54141. As of Q4 2014, METOPON remains the US FDA Preferred Term for this commodity. Metopon bears US NLM identifiers UMLS ID C0625593 and NCI Concept Code C83963. SMILES: O1C2(C34C(C(N(CC3)C)CC3C4C1C(O)CC3)CCC2=O)C.
This classification denotes an opioid receptor agonist with the molecular formula C18H21NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6O34Q1K8M6. Most nations, for tariff and trade purposes, schedule metopon hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, METOPON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metopon hydrochloride bears US NLM identifiers UMLS ID C0956898 and NCI Concept Code C83964. SMILES: C[C@]12C(=O)CC[C@@H]3[C@]14CCN([C@@H]3CC5C4C(C(CC5)O)O2)C.CL.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GEB06NHM23, chemically known as 2-propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)- but generally known as metoprolol, which bears US NIH Compound Identifier 4171. European Medicines Agency schedules Metoprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14568MIG. The term METOPROLOL is an International Non-Proprietary Name. World Health Organization schedules metoprolol in its Anatomical Therapeutic Chemical (ATC) Classification. METOPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metoprolol under HS 29221980 and SITC 51461. As of Q4 2014, METOPROLOL remains the US FDA Preferred Term for this commodity. Metoprolol bears US NLM identifiers UMLS ID C0025859 and NCI Concept Code C61845. SMILES: O(CC(O)CNC(C)C)c1ccc(CCOC)cc1.
This classification denotes a beta-adrenergic blocking agent 2C15H25NO3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IO1C09Z674, chemically known as 2-propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-, (+/-)-, (e)-2-butanedioate (2:1) (salt), but more generally known as metoprolol fumarate, which bears US NIH Compound Identifier 6446646. European Medicines Agency schedules Metoprolol fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03273MIG. Most nations, for tariff and trade purposes, schedule metoprolol fumarate under HS 29221980 and SITC 51461. As of Q4 2014, METOPROLOL FUMARATE remains US FDA's Preferred Term for this commodity. Metoprolol fumarate bears US NLM identifiers UMLS ID C0350132 and NCI Concept Code C66133. SMILES: CC(C)NCC(COC1CCC(CC1)CCOC)O.CC(C)NCC(COC1CCC(CC1)CCOC)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C15H25NO3.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TH25PD4CCB, chemically known as 2-propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-, butanedioate (2:1) (salt) but more generally known as metoprolol succinate, which bears US NIH Compound Identifier 62937. European Medicines Agency schedules Metoprolol succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03274MIG. Most nations, for tariff and trade purposes, schedule metoprolol succinate under HS 29221980 and SITC 51461. As of Q4 2014, METOPROLOL SUCCINATE remains US FDA's Preferred Term for this commodity. Metoprolol succinate bears US NLM identifiers UMLS ID C0724633 and NCI Concept Code C29254. SMILES: CC(C)NCC(COC1CCC(CC1)CCOC)O.CC(C)NCC(COC1CCC(CC1)CCOC)O.C(CC(=O)O)C(=O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C15H25NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5S57Y3A5L, chemically known as 2-propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)- but more generally known as metoprolol tartrate, which bears US NIH Compound Identifier 4171. European Medicines Agency schedules Metoprolol tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03275MIG. Most nations, for tariff and trade purposes, schedule metoprolol tartrate under HS 29221980 and SITC 51461. As of Q4 2014, METOPROLOL TARTRATE remains US FDA's Preferred Term for this commodity. Metoprolol tartrate bears US NLM identifiers UMLS ID C0700776 and NCI Concept Code C29255. SMILES: CC(C)NCC(COC1CCC(CC1)CCOC)O.CC(C)NCC(COC1CCC(CC1)CCOC)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a sedative and hypnotic with the molecular formula C24H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X3G4L02XQU, chemically known as 3.beta., 20.alpha.-yohimban-16.beta.-carboxylic acid, 11,17.alpha., 18.alpha.-trimethoxy-, methyl ester, monohydrochloride but generally known as metoserpate, which bears US NIH Compound Identifier 14443. European Medicines Agency schedules Metoserpate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08911MIG. The term METOSERPATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). METOSERPATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metoserpate under HS 29399900 and SITC 54149. As of Q4 2014, METOSERPATE remains the US FDA Preferred Term for this commodity. Metoserpate bears US NLM identifiers UMLS ID C0066470 and NCI Concept Code C76942. SMILES: O(C1C(C2C(CN3C(C2)C2[NH]C4C(C2CC3)CCC(OC)C4)CC1OC)C(=O)OC)C.
This classification denotes a sedative and hypnotic with the molecular formula C24H32N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KBO7409339, chemically known as 3.beta., 20.alpha.-yohimban-16.beta.-carboxylic acid, 11,17.alpha., 18.alpha.-trimethoxy-, methyl ester, monohydrochloride but more generally known as metoserpate hydrochloride, which bears US NIH Compound Identifier 14443. Most nations, for tariff and trade purposes, schedule metoserpate hydrochloride under HS 29399900 and SITC 54149. As of Q4 2014, METOSERPATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metoserpate hydrochloride bears US NLM identifiers UMLS ID C0521930 and NCI Concept Code C76955. SMILES: COC1CCC2C(C1)[NH]C3C2CCN4[C@@H]3C[C@H]5[C@@H](C4)C[C@@H]([C@@H]([C@H]5C(=O)OC)OC)OC.CL.
This classification denotes an antidepressant agent with the molecular formula C20H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8EZK2DSIT, chemically known as 1-(8-methoxydibenz(b,f)oxepin-10-yl)-4-methylpiperazine but generally known as metoxepin, which bears US NIH Compound Identifier 32226. European Medicines Agency schedules Metoxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08913MIG. The term METOXEPIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). METOXEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metoxepin under HS 29349990 and SITC 51579. As of Q4 2014, METOXEPIN remains the US FDA Preferred Term for this commodity. Metoxepin bears US NLM identifiers UMLS ID C1881811 and NCI Concept Code C66135. SMILES: O1c2c(C(=Cc3c1cccc3)N1CCN(CC1)C)cc(OC)cc2.
This classification denotes an antidepressant agent with the molecular formula C15H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2QW3FL6OPA, chemically known as 2,4,5,6-tetrahydro-9-methoxy-4-methyl-1h-3,4,6a-triazafluoranthene but generally known as metralindole, which bears US NIH Compound Identifier 68713. European Medicines Agency schedules Metralindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08915MIG. The term METRALINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). METRALINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metralindole under HS 29335995 and SITC 51576. As of Q4 2014, METRALINDOLE remains the US FDA Preferred Term for this commodity. Metralindole bears US NLM identifiers UMLS ID C0066473 and NCI Concept Code C66137. SMILES: O(c1cc2c3c4n(CCN(C4=NCC3)C)c2cc1)C.
This classification denotes an antidepressant agent with the molecular formula C15H17N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M15TM76Y3L, chemically known as 3-methyl-8-methoxy-3h-1,2,5,6-tetrahydropyrazino(1,2,3-a,b)-.beta.-carboline hydrochloride, but more generally known as metralindole hydrochloride, which bears US NIH Compound Identifier 171296. European Medicines Agency schedules metralindole hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08915MIG. Most nations, for tariff purposes, schedule metralindole hydrochloride under HS 29335995. SMILES: CN1CCN2C3CCC(CC3C4C2C1=NCC4)OC.CL.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C4H8Cl3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DBF2DG4G2K, chemically known as 1-hydroxy-2,2,2-trichloroethylphosphonic acid dimethyl ester but generally known as metrifonate, which bears US NIH Compound Identifier 5853. European Medicines Agency schedules Metrifonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08919MIG. The term METRIFONATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules metrifonate in its Anatomical Therapeutic Chemical (ATC) Classification. METRIFONATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Metrifonate or trichlorfon bears US NLM identifiers UMLS ID C0040898 and NCI Concept Code C84225. SMILES: CLC(CL)(CL)C(P(=O)(OC)OC)O.
This classification denotes a contrast agent with the molecular formula C18H22I3N3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RHH3W8F1CO, chemically known as 3-acetylamino-5-n-methyl-acetylamino-2,4,6-triiodobenzoyl glucosamine but more generally known as metrizamide, which bears U.S. National Institutes of Health Compound Identifier 35734. The European Medicines Agency schedules Metrizamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08921MIG. The term METRIZAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). The World Health Organization schedules metrizamide in its Anatomical Therapeutic Chemical (ATC) Classification. METRIZAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Metrizamide under HS 29329970. SMILES: IC1C(C(=O)NC2C(O)C(O)C(OC2O)CO)C(I)C(NC(=O)C)C(I)C1N(C)C(=O)C.
This classification denotes a contrast agent with the molecular formula C12H11I3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CM1N99QR1M, chemically known as 3-(acetylamino)-5-(acetyl(methyl)amino)-2,4,6-triiodobenzoic acid but more generally known as metrizoic acid, which bears U.S. National Institutes of Health Compound Identifier 2528. The European Medicines Agency schedules Metrizoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03276MIG. The World Health Organization schedules metrizoic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Metrizoic acid under HS 29242995. SMILES: CC(=O)NC1C(C(C(C(C1I)N(C)C(=O)C)I)C(=O)O)I.
This classification denotes a trichomonacide agent and protein synthesis inhibitor with the molecular formula C6H9N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 140QMO216E, chemically known as 1h-imidazole-1-ethanol, 2-methyl-5-nitro- but generally known as metronidazole, which bears US NIH Compound Identifier 4173. European Medicines Agency schedules Metronidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08922MIG. The term METRONIDAZOLE is an International Non-Proprietary Name. World Health Organization schedules metronidazole in its Anatomical Therapeutic Chemical (ATC) Classification. METRONIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule metronidazole under HS 29332990 and SITC 51573. As of Q4 2014, METRONIDAZOLE remains the US FDA Preferred Term for this commodity. Metronidazole bears US NLM identifiers UMLS ID C0025872 and NCI Concept Code C651. SMILES: OCCN1C(NCC1[N](=O)O)C.
This classification denotes a trichomonacide agent and protein synthesis inhibitor with the molecular formula C13H13N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A355C835XC, chemically known as 2-(2-methyl-5-nitroimidazol-1-yl)ethyl benzoate, but more generally known as metronidazole benzoate, which bears US NIH Compound Identifier 4173. European Medicines Agency schedules metronidazole benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08922MIG. Most nations, for tariff purposes, schedule metronidazole benzoate under HS 29332990. Metronidazole benzoate bears US NLM identifiers UMLS ID C0353490 and NCI Concept Code C87387. SMILES: CC1NCC(N1CCOC(=O)C2CCCCC2)[N+](=O)[O-].
This classification denotes a trichomonacide agent and protein synthesis inhibitor with the molecular formula C6H9N3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76JC1633UF, chemically known as 1h-imidazole-1-ethanol, 2-methyl-5-nitro-, hydrochloride but more generally known as metronidazole hydrochloride, which bears US NIH Compound Identifier 68592. European Medicines Agency schedules Metronidazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14570MIG. Most nations, for tariff and trade purposes, schedule metronidazole hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, METRONIDAZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metronidazole hydrochloride bears US NLM identifiers UMLS ID C0282239 and NCI Concept Code C48005. SMILES: CC1NCC(N1CCO)[N+](=O)[O-].CL.
This classification denotes an antiprotozoal agent and antimicrobial with the molecular formula C6H10N3O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L500PR95QA, chemically known as 1h-imidazole-1-ethanol, 2-methyl-5-nitro-, dihydrogen phosphate (ester) but more generally known as metronidazole phosphate, which bears US NIH Compound Identifier 51794. Most nations, for tariff and trade purposes, schedule metronidazole phosphate under HS 29332990 and SITC 51573. As of Q4 2014, METRONIDAZOLE PHOSPHATE remains US FDA's Preferred Term for this commodity. Metronidazole phosphate bears US NLM identifiers UMLS ID C0887130 and NCI Concept Code C90619. SMILES: CC1NCC(N1CCOP(=O)(O)O)[N+](=O)[O-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.
This classification denotes an ethylenimine compound with the molecular formula C11H22N3O3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43255365IF, chemically known as ethyl n-(bis(2,2-dimethylethylenimido)phosphoro)carbamate but more generally known as meturedepa, which bears US NIH Compound Identifier 15456. European Medicines Agency schedules Meturedepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08923MIG. The term METUREDEPA is an International Non-Proprietary Name. METUREDEPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule meturedepa under HS 29339990 and SITC 51577. As of Q4 2014, METUREDEPA remains US FDA's Preferred Term for this commodity. Meturedepa bears US NLM identifiers UMLS ID C0609940 and NCI Concept Code C1760. SMILES: CCOC(=O)NP(=O)(N1CC1(C)C)N2CC2(C)C.
This classification denotes a potassium-sparing diuretic with the molecular formula C14H14N2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier ZS9KD92H6V, chemically known as 1,2-di-3-pyridyl-2-methyl-1-propanone but more generally known as metyrapone, which bears U.S. National Institutes of Health Compound Identifier 4174. The European Medicines Agency schedules Metyrapone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08925MIG. The term METYRAPONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules metyrapone in its Anatomical Therapeutic Chemical (ATC) Classification. METYRAPONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C(C(C1CCCNC1)(C)C)C1CCCNC1.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C23H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UQM1K0W9X, chemically known as 1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone but generally known as mevastatin, which bears US NIH Compound Identifier 53232. European Medicines Agency schedules Mevastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08927MIG. The term MEVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). MEVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, MEVASTATIN remains the US FDA Preferred Term for this commodity. Mevastatin bears US NLM identifiers UMLS ID C0056170 and NCI Concept Code C96285. SMILES: O(C1C2C(C(C=CC2=CC(C1)C)C)CCC1OC(=O)CC(O)C1)C(=O)C(CC)C.
This classification denotes a bronchodilator with the molecular formula C14H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTS2XT15W3, chemically known as 2,6(1h,3h)-purinedione, 3-(3-cyclohexen-1-ylmethyl)-1,8-dimethyl- but generally known as mexafylline, which bears US NIH Compound Identifier 3047743. European Medicines Agency schedules Mexafylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08928MIG. The term MEXAFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). MEXAFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mexafylline under HS 29395900 and SITC 54145. As of Q4 2014, MEXAFYLLINE remains the US FDA Preferred Term for this commodity. Mexafylline bears US NLM identifiers UMLS ID C2981331 and NCI Concept Code C87683. SMILES: O=C1N(CC2CCC=CC2)C2NC([NH]C2C(=O)N1C)C.
This classification denotes a benzodiazepine with the molecular formula C18H16Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5969B6237, chemically known as 10-chloro-11b-(o-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one but generally known as mexazolam, which bears US NIH Compound Identifier 4177. European Medicines Agency schedules Mexazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08929MIG. The term MEXAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). MEXAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mexazolam under HS 29349990 and SITC 51579. As of Q4 2014, MEXAZOLAM remains the US FDA Preferred Term for this commodity. Mexazolam bears US NLM identifiers UMLS ID C0089958 and NCI Concept Code C81637. SMILES: CLC1C(C23OCC(N2CC(=O)NC2C3CC(CL)CC2)C)CCCC1.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C11H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1U511HHV4Z, chemically known as 2-propanamine, 1-(2,6-dimethylphenoxy)- but more generally known as mexiletine, which bears US NIH Compound Identifier 4178. European Medicines Agency schedules Mexiletine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08931MIG. The term MEXILETINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules mexiletine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule mexiletine under HS 29221980 and SITC 51461. As of Q4 2014, MEXILETINE remains US FDA's Preferred Term for this commodity. Mexiletine bears US NLM identifiers UMLS ID C0025887 and NCI Concept Code C62047. SMILES: CC1=C(C(=CC=C1)C)OCC(C)N.
This classification denotes an antiarrhythmic agent with the molecular formula C11H17NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 606D60IS38, chemically known as 2-propanamine, 1-(2,6-dimethylphenoxy)-, hydrochloride but more generally known as mexiletine hydrochloride, which bears US NIH Compound Identifier 21467. European Medicines Agency schedules Mexiletine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03281MIG. Most nations, for tariff and trade purposes, schedule mexiletine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, MEXILETINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mexiletine hydrochloride bears US NLM identifiers UMLS ID C0600129 and NCI Concept Code C652. SMILES: CC1CCCC(C1OCC(C)N)C.CL.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3I63VC13V0. European Medicines Agency schedules Mexoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08933MIG. Mexoprofen generally arises in the molecular formula C16H22O2. The term MEXOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) MEXOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mexoprofen under HS 29163900 and SITC 51379. As of Q4 2014, MEXOPROFEN remains the US FDA Preferred Term for this commodity. Mexoprofen bears US NLM identifiers UMLS ID C2828265 and NCI Concept Code C87324. SMILES: OC(=O)C(C1CCC(C2C(CCCC2)C)CC1)C.
This classification denotes an antipsychotic agent with the molecular formula C11H18ClN5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V243ORA40X, chemically known as 2-pyridinamine, 4-chloro-n-methyl-6-(4-methyl-1-piperazinyl)-5-(methylthio)- but generally known as mezilamine, which bears US NIH Compound Identifier 68678. European Medicines Agency schedules Mezilamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08937MIG. The term MEZILAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). MEZILAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mezilamine under HS 29335995 and SITC 51576. As of Q4 2014, MEZILAMINE remains the US FDA Preferred Term for this commodity. Mezilamine bears US NLM identifiers UMLS ID C0066492 and NCI Concept Code C66144. SMILES: CNC1=NC(=C(C(=N1)Cl)SC)N2CCN(CC2)C.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C21H25N5O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OH2O403D1G, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9ci) but generally known as mezlocillin, which bears US NIH Compound Identifier 3715. European Medicines Agency schedules Mezlocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08938MIG. The term MEZLOCILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules mezlocillin in its Anatomical Therapeutic Chemical (ATC) Classification. MEZLOCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mezlocillin under HS 29411090 and SITC 54131. As of Q4 2014, MEZLOCILLIN remains the US FDA Preferred Term for this commodity. Mezlocillin bears US NLM identifiers UMLS ID C0025893 and NCI Concept Code C653. SMILES: CLC1CCC(C(=O)N2C3C(C(C2C)CC(=O)O)CC(OC)CC3)CC1.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C21H24N5O8S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RX227TP94U, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((((((3-(methylsulfonyl)-2-oxo-1-imidazolidinyl)carbonyl)amino)carbonyl)amino)phenylacetyl)amino)-7-oxo-, monosodium salt, (2s-(2alpha,5alpha,6beta(s*)))- but generally known as mezlocillin sodium, which bears US NIH Compound Identifier 43084. European Medicines Agency schedules Mezlocillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03282MIG. Most nations schedule mezlocillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, MEZLOCILLIN SODIUM remains the US FDA Preferred Term for this commodity. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(NC(=O)N1CCN(S(=O)(=O)C)C1=O)c1ccccc1.[Na].
This classification denotes an extended spectrum penicillin antibiotic C21H24N5O8S2.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3CWW8B5904, chemically known as sodium (2s,5r,6r)-3,3-dimethyl-6-((r)-2-(3-(methylsulfonyl)-2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate, monohydrate, but more generally known as mezlocillin sodium monohydrate, which bears US NIH Compound Identifier 23677831. Most nations, for tariff and trade purposes, schedule mezlocillin sodium monohydrate under HS 29411090 and SITC 54131. As of Q4 2014, MEZLOCILLIN SODIUM MONOHYDRATE remains US FDA's Preferred Term for this commodity. Mezlocillin sodium monohydrate bears US NLM identifiers UMLS ID C2828283 and NCI Concept Code C87369. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)[O-])C.O.[NA+].
This classification denotes a serotonin antagonist and antidepressant agent and adrenergic antagonist with the molecular formula C18H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 250PJI13LM, chemically known as 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine but generally known as mianserin, which bears US NIH Compound Identifier 4184. European Medicines Agency schedules Mianserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08939MIG. The term MIANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules mianserin in its Anatomical Therapeutic Chemical (ATC) Classification. MIANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mianserin under HS 29335995 and SITC 51576. As of Q4 2014, MIANSERIN remains the US FDA Preferred Term for this commodity. Mianserin bears US NLM identifiers UMLS ID C0025912 and NCI Concept Code C87209. SMILES: N12C(CN(CC1)C)c1c(Cc3c2cccc3)cccc1.
This classification denotes a serotonin antagonist and antidepressant agent and adrenergic antagonist with the molecular formula C18H20N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2X03TN217S, chemically known as 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine monohydrochloride but more generally known as mianserin hydrochloride, which bears US NIH Compound Identifier 68551. European Medicines Agency schedules Mianserin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03283MIG. Most nations, for tariff and trade purposes, schedule mianserin hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, MIANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mianserin hydrochloride bears US NLM identifiers UMLS ID C0700456 and NCI Concept Code C87210. SMILES: CN1CCN2C3CCCCC3CC4CCCCC4C2C1.CL.
This classification denotes a calcium channel blocker with the molecular formula C29H38FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27B90X776A, chemically known as acetic acid, methoxy-, 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride, (1s-cis)- but generally known as mibefradil, which bears US NIH Compound Identifier 60662. European Medicines Agency schedules Mibefradil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08940MIG. The term MIBEFRADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules mibefradil in its Anatomical Therapeutic Chemical (ATC) Classification. MIBEFRADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mibefradil under HS 29339990 and SITC 51577. As of Q4 2014, MIBEFRADIL remains the US FDA Preferred Term for this commodity. Mibefradil bears US NLM identifiers UMLS ID C0286185 and NCI Concept Code C87686. SMILES: Cl.Cl.Fc1cc2c(C(C(OC(=O)COC)(CC2)CCN(CCCc2[nH]c3c(n2)cccc3)C)C(C)C)cc1.
This classification denotes a calcium channel blocker with the molecular formula C29H38FN3O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 842TUP3PQ8, chemically known as acetic acid, methoxy-, 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride, (1s-cis)-, but more generally known as mibefradil dihydrochloride, which bears US NIH Compound Identifier 60662. European Medicines Agency schedules mibefradil dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08940MIG. Most nations, for tariff purposes, schedule mibefradil dihydrochloride under HS 29339990. As of Q4 2014, MIBEFRADIL DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mibefradil dihydrochloride bears US NLM identifiers UMLS ID C0286186 and NCI Concept Code C87687. SMILES: CC(C)[C@H]1C2CCC(CC2CC[C@@]1(CCN(C)CCCC3[NH]C4CCCCC4N3)OC(=O)COC)F.CL.CL.
This classification denotes a calcium channel blocker with the molecular formula C29H38FN3O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 842TUP3PQ8, chemically known as acetic acid, methoxy-, 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride, (1s-cis)- but more generally known as mibefradil dihydrochloride, which bears US NIH Compound Identifier 60662. European Medicines Agency schedules Mibefradil dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20668. Most nations, for tariff and trade purposes, schedule mibefradil hydrochloride under HS 29339990 and SITC 51577. SMILES: CC(C)[C@H]1C2CCC(CC2CC[C@@]1(CCN(C)CCCC3[NH]C4CCCCC4N3)OC(=O)COC)F.CL.CL.
This classification denotes a therapeutic androgen with the molecular formula C20H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9OGY4BOR8D, chemically known as 19-nortestosterone, 7alpha,17-dimethyl- but generally known as mibolerone, which bears US NIH Compound Identifier 19454. European Medicines Agency schedules Mibolerone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08941MIG. The term MIBOLERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). MIBOLERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mibolerone under HS 29372900 and SITC 54153. As of Q4 2014, MIBOLERONE remains the US FDA Preferred Term for this commodity. Mibolerone bears US NLM identifiers UMLS ID C0066502 and NCI Concept Code C72100. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3C)CC1)C)C.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R10H71BSWG. European Medicines Agency schedules Micafungin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16444MIG. Micafungin generally arises in the molecular formula C56H71N9O23S. The term MICAFUNGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.) Most nations schedule micafungin under HS 29419000 and SITC 54139. As of Q4 2014, MICAFUNGIN remains the US FDA Preferred Term for this commodity. Micafungin bears US NLM identifiers UMLS ID C1120386 and NCI Concept Code C1850. SMILES: S(=O)(=O)(OC1CC(C(O)C(O)C2NC(=O)C3N(CC(O)C3)C(=O)C(NC(=O)C(NC(=O)C3CCC(CC3)C3NOC(C3)C3CCC(OCCCCC)CC3)CC(O)C(O)NC(=O)C3N(CC(C3O)C)C(=O)C(NC2=O)C(O)CC(=O)N)C(O)C)CCC1O)O.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IS1UP79R56. European Medicines Agency schedules Micafungin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20666. Micafungin sodium generally arises in the molecular formula C56H70N9O23S.NA. The term 'micafungin sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule micafungin sodium under HS 29419000 and SITC 54139. As of Q4 2014, MICAFUNGIN SODIUM remains US FDA's Preferred Term for this commodity. Micafungin sodium bears US NLM identifiers UMLS ID C1576821 and NCI Concept Code C66145. SMILES: CCCCCOC1CCC(CC1)C2CC(NO2)C3CCC(CC3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7CCC(C(C7)OS(=O)(=O)[O-])O)O)O)[C@@H](CC(=O)N)O)C)O)O)O.[NA+].
This classification denotes a vasodilating agent with the molecular formula C23H27NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M87S131A7F, chemically known as nicotinic acid, ester with cis-3,3,5-trimethylcyclohexyl ( -)-mandelate but generally known as micinicate, which bears US NIH Compound Identifier 172291. European Medicines Agency schedules Micinicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08943MIG. The term MICINICATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). MICINICATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule micinicate under HS 29333999 and SITC 51574. As of Q4 2014, MICINICATE remains the US FDA Preferred Term for this commodity. Micinicate bears US NLM identifiers UMLS ID C2983979 and NCI Concept Code C91004. SMILES: O(C1CC(CC(C1)C)(C)C)C(=O)C(OC(=O)c1cccnc1)c1ccccc1.
This classification denotes an antifungal agent with the molecular formula C18H14Cl4N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NNO0D7S5M, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- but generally known as miconazole, which bears US NIH Compound Identifier 4189. European Medicines Agency schedules Miconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08944MIG. The term MICONAZOLE is an International Non-Proprietary Name. World Health Organization schedules miconazole in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule miconazole under HS 29332990 and SITC 51573. As of Q4 2014, MICONAZOLE remains the US FDA Preferred Term for this commodity. Miconazole bears US NLM identifiers UMLS ID C0025942 and NCI Concept Code C62048. SMILES: CLC1C(C(OCC2C(CL)CC(CL)CC2)CN2CCNC2)CCC(CL)C1.
This classification denotes a 14-alpha demethylase inhibitor and antifungal agent with the molecular formula C18H14Cl4N2O.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VW4H1CYW1K, chemically known as 1h-imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- but more generally known as miconazole nitrate, which bears US NIH Compound Identifier 4189. European Medicines Agency schedules Miconazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03285MIG. Most nations, for tariff and trade purposes, schedule miconazole nitrate under HS 29332990 and SITC 51573. As of Q4 2014, MICONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Miconazole nitrate bears US NLM identifiers UMLS ID C0718407 and NCI Concept Code C29257. SMILES: C1CC(C(CC1CL)CL)COC(CN2CCNC2)C3CCC(CC3CL)CL.[N+](=O)(O)[O-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes an aminoglycoside antibiotic with the molecular formula C20H41N5O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9AZ0R40QV, chemically known as o-2-amino-2,3,4,6-tetradeoxy-6-(methylamino)-a-d-erythro-hexopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1->6))-2-deoxy-d-streptamine but generally known as micronomicin, which bears US NIH Compound Identifier 107677. European Medicines Agency schedules Micronomicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08945MIG. The term MICRONOMICIN is an International Non-Proprietary Name. World Health Organization schedules micronomicin in its Anatomical Therapeutic Chemical (ATC) Classification. MICRONOMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule micronomicin under HS 29419000 and SITC 54139. As of Q4 2014, MICRONOMICIN remains the US FDA Preferred Term for this commodity. Micronomicin bears US NLM identifiers UMLS ID C0066520 and NCI Concept Code C90638. SMILES: O(C1C(O)C(OC2OC(CCC2N)CNC)C(N)CC1N)C1OCC(O)(C(NC)C1O)C.
This classification denotes an aminoglycoside antibiotic with the molecular formula 2C20H41N5O7.5H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 09H5UKQ7TZ, chemically known as d-streptamine, o-2-amino-2,3,4,6-tetradeoxy-6-(methylamino)-.alpha.-d-erythro-hexopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1-6))-2-deoxy-, sulfate (salt), but more generally known as micronomicin sulfate, which bears US NIH Compound Identifier 171808. European Medicines Agency schedules micronomicin sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08945MIG. Most nations, for tariff purposes, schedule micronomicin sulfate under HS 29419000. SMILES:.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 840CTL676L. European Medicines Agency schedules Midaflur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08946MIG. Midaflur generally arises in the molecular formula C8H4F12N2. The term MIDAFLUR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) Most nations schedule midaflur under HS 29332990 and SITC 51573. As of Q4 2014, MIDAFLUR remains the US FDA Preferred Term for this commodity. Midaflur bears US NLM identifiers UMLS ID C0066528 and NCI Concept Code C90942. SMILES: FC(F)(F)C1(NC(C=C1N)(C(F)(F)F)C(F)(F)F)C(F)(F)F.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C16H25N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A937Z0MS6C, chemically known as 8-(1-aminocyclopentyl)-1,3-dipropylxanthine but generally known as midaxifylline, which bears US NIH Compound Identifier 3047747. European Medicines Agency schedules Midaxifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03288MIG. The term MIDAXIFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 1, 1999, List 41). Most nations schedule midaxifylline under HS 29395900 and SITC 54145. As of Q4 2014, MIDAXIFYLLINE remains the US FDA Preferred Term for this commodity. Midaxifylline bears US NLM identifiers UMLS ID C1881825 and NCI Concept Code C66147. SMILES: O=C1N(C(=O)N(C2NC([NH]C12)C1(N)CCCC1)CCC)CCC.
This classification denotes an antiplatelet agent with the molecular formula C18H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04HCK0SD2O, chemically known as 1h-imidazole, 1-(3-(phenylmethoxy)-1-octenyl)-, (e)- but generally known as midazogrel, which bears US NIH Compound Identifier 6436121. European Medicines Agency schedules Midazogrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08949MIG. The term MIDAZOGREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). MIDAZOGREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule midazogrel under HS 29332990 and SITC 51573. As of Q4 2014, MIDAZOGREL remains the US FDA Preferred Term for this commodity. Midazogrel bears US NLM identifiers UMLS ID C1881826 and NCI Concept Code C66148. SMILES: O(C(CCCCC)/C=C/N1CCNC1)CC1CCCCC1.
This classification denotes a benzodiazepine with the molecular formula C18H13ClFN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R60L0SM5BC, chemically known as 8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine but generally known as midazolam, which bears US NIH Compound Identifier 4192. European Medicines Agency schedules Midazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08950MIG. The term MIDAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules midazolam in its Anatomical Therapeutic Chemical (ATC) Classification. MIDAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule midazolam under HS 29339190 and SITC 51577. As of Q4 2014, MIDAZOLAM remains the US FDA Preferred Term for this commodity. Midazolam bears US NLM identifiers UMLS ID C0026056 and NCI Concept Code C62049. SMILES: CLC1CC2C(N3C(CN=C2C2C(F)CCCC2)CNC3C)CC1.
This classification denotes an anesthesia adjuvant, anti-anxiety agent, hypnotic, and sedative with the molecular formula C18H13ClFN3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W7TTW573JJ, chemically known as 8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine but more generally known as midazolam hydrochloride, which bears US NIH Compound Identifier 4192. European Medicines Agency schedules Midazolam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03289MIG. Most nations, for tariff and trade purposes, schedule midazolam hydrochloride under HS 29339190 and SITC 51577. As of Q4 2014, MIDAZOLAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Midazolam hydrochloride bears US NLM identifiers UMLS ID C0042553 and NCI Concept Code C654. SMILES: CC1NCC2N1-C3CCC(CC3C(=NC2)C4CCCCC4F)CL.CL.
This classification denotes a benzodiazepine with the molecular formula C18H13ClFN3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77520S18SE, chemically known as 8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine maleate (1:1) but more generally known as midazolam maleate, which bears US NIH Compound Identifier 5384200. European Medicines Agency schedules Midazolam maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14573MIG. Most nations, for tariff and trade purposes, schedule midazolam maleate under HS 29339100 and SITC 51577. As of Q4 2014, MIDAZOLAM MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CC1NCC2N1-C3CCC(CC3C(=NC2)C4CCCCC4F)CL.C(=C\C(=O)O)\C(=O)O.
This classification denotes a leucomycin and macrolides with the molecular formula C41H67NO15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N34Z0Y5UH7, chemically known as leucomycin v, 3,4b-dipropanoate but generally known as midecamycin, which bears US NIH Compound Identifier 5382853. European Medicines Agency schedules midecamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08951MIG. The term MIDECAMYCIN is an International Non-Proprietary Name or INN. Most nations schedule midecamycin under HS 29419000 and SITC 54139. As of Q4 2014, MIDECAMYCIN remains the US FDA Preferred Term for this commodity. SMILES: CCC(=O)OC1CC(=O)OC(CC=CC=CC(C(CC(C(C1OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)OC(=O)CC)(C)O)N(C)C)O)CC=O)C)O)C.
This classification denotes a leucomycin and macrolides with the molecular formula C45H71NO17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3T48CPS7U2, chemically known as leucomycin v, 3b,9-diacetate 3,4b-dipropanoate, but more generally known as midecamycin acetate, which bears US NIH Compound Identifier 5282188. European Medicines Agency schedules midecamycin acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08951MIG. Most nations, for tariff purposes, schedule midecamycin acetate under HS 29419000. SMILES: CCC(=O)O[C@@H]1CC(=O)O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]1OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC)(C)OC(=O)C)N(C)C)O)CC=O)C)OC(=O)C)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6YE7PBM15H, chemically known as 2-amino-n-(2,5-dimethoxy-beta-hydroxyphenethylacetamide but generally known as midodrine, which bears US NIH Compound Identifier 4195. European Medicines Agency schedules Midodrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08954MIG. The term MIDODRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules midodrine in its Anatomical Therapeutic Chemical (ATC) Classification. MIDODRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule midodrine under HS 29242995 and SITC 51479. As of Q4 2014, MIDODRINE remains the US FDA Preferred Term for this commodity. Midodrine bears US NLM identifiers UMLS ID C0026078 and NCI Concept Code C61846. SMILES: COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O.
Midostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.
This classification denotes an immunostimulant with the molecular formula C59H108N6O19P.NA.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1LM890Q4FY. European Medicines Agency schedules mifamurtide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25179. The term MIFAMURTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, no. 1, 2007, list 57). Most nations schedule mifamurtide under HS 29329990 and SITC 51569. As of Q4 2014, MIFAMURTIDE remains the US FDA Preferred Term for this commodity. Mifamurtide bears US NLM identifiers UMLS ID C0129341 and NCI Concept Code C1394. SMILES: P(=O)(OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC)(OCCNC(=O)C(NC(=O)CCC(NC(=O)C(NC(=O)C(OC1C(NC(=O)C)C(OC(C1O)CO)O)C)C)C(=O)N)C)O.[NA].O.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2F70KF5S0K. European Medicines Agency schedules Mifentidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08955MIG. Mifentidine generally arises in the molecular formula C13H16N4. The term MIFENTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) MIFENTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mifentidine under HS 29332990 and SITC 51573. As of Q4 2014, MIFENTIDINE remains the US FDA Preferred Term for this commodity. Mifentidine bears US NLM identifiers UMLS ID C0128486 and NCI Concept Code C66149. SMILES: N(C1CCC(C2[NH]CNC2)CC1)/C=N/C(C)C.
This classification denotes an anti-progestin with the molecular formula C29H35NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 320T6RNW1F, chemically known as 17-beta-hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one but generally known as mifepristone, which bears US NIH Compound Identifier 55245. European Medicines Agency schedules Mifepristone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08956MIG. The term MIFEPRISTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules mifepristone in its Anatomical Therapeutic Chemical (ATC) Classification. MIFEPRISTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mifepristone under HS 29372900 and SITC 54153. As of Q4 2014, MIFEPRISTONE remains the US FDA Preferred Term for this commodity. Mifepristone bears US NLM identifiers UMLS ID C0026088 and NCI Concept Code C655. SMILES: OC1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)C(C2)c2ccc(N(C)C)cc2)CC1)C)C#CC.
This classification denotes a glucosidase inhibitor with the molecular formula C8H17NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 0V5436JAQW, chemically known as 3,4,5-piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2r-(2alpha,3beta,4alpha,5beta))- but more generally known as miglitol, which bears US NIH Compound Identifier 51577. European Medicines Agency schedules Miglitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08958MIG. The term MIGLITOL is an International Non-Proprietary Name WHO schedules miglitol in its Anatomical Therapeutic Chemical (ATC) Classification. MIGLITOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule miglitol under HS 29333999 and SITC 51574. As of Q4 2014, MIGLITOL remains US FDA's Preferred Term for this commodity. Miglitol bears US NLM identifiers UMLS ID C0066535 and NCI Concept Code C61847. SMILES: OC1C(N(CC(O)C1O)CCO)CO.
This classification denotes a glucosidase inhibitor with the molecular formula C10H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ADN3S497AZ, chemically known as 3,4,5-piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2r,3r,4r,5s)- but generally known as miglustat, which bears US NIH Compound Identifier 51634. European Medicines Agency schedules Miglustat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20049. The term MIGLUSTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules miglustat in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Miglustat under HS 29333999 and SITC 51574. As of Q4 2014, MIGLUSTAT remains the US FDA Preferred Term for this commodity. Miglustat bears US NLM identifiers UMLS ID C1321596 and NCI Concept Code C1222. SMILES: CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O.
This classification denotes an anticonvulsant agent with the molecular formula C7H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0HXT24RECU, chemically known as acetamide, 2-(pentylamino)- but generally known as milacemide, which bears US NIH Compound Identifier 53569. European Medicines Agency schedules Milacemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08960MIG. The term MILACEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). MILACEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule milacemide under HS 29241900 and SITC 51471. As of Q4 2014, MILACEMIDE remains the US FDA Preferred Term for this commodity. Milacemide bears US NLM identifiers UMLS ID C0066545 and NCI Concept Code C81467. SMILES: O=C(N)CNCCCCC.
This classification denotes an anticonvulsant agent with the molecular formula C7H16N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6XK4G40F6W, chemically known as acetamide, 2-(pentylamino)-, monohydrochloride but more generally known as milacemide hydrochloride, which bears US NIH Compound Identifier 53568. Most nations, for tariff and trade purposes, schedule milacemide hydrochloride under HS 29241900 and SITC 51471. As of Q4 2014, MILACEMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Milacemide hydrochloride bears US NLM identifiers UMLS ID C2825649 and NCI Concept Code C81470. SMILES: CCCCCNCC(=O)N.CL.
This classification denotes an anxiolytic with the molecular formula C22H23CLFN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9GC5JKP4BD chemically known as 2h-benzimidazol-2-one, 5-chloro-1-(3-(4-(4-fluorobenzoyl)-1-piperidinyl)propyl)-1,3-dihydro- but generally known as milenperone, which bears US NIH Compound Identifier 65489. European Medicines Agency schedules Milenperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08962MIG. The term MILENPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17. ). Most nations schedule milenperone under HS 29333999 and SITC 51574. As of Q4 2014, MILENPERONE remains the US FDA Preferred Term for this commodity. Milenperone bears US NLM identifiers UMLS ID C0066550 and NCI Concept Code C66151. SMILES: C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCCN3C4=C(C=C(C=C4)CL)NC3=O.
This classification denotes a dopamine antagonist with the molecular formula C24H31N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WX1V67H28T, chemically known as 5,6-dimethoxy-3-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-2-methylindole but generally known as milipertine, which bears US NIH Compound Identifier 32345. European Medicines Agency schedules Milipertine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08964MIG. The term MILIPERTINE is an International Non-Proprietary Name. MILIPERTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule milipertine under HS 29335995 and SITC 51576. As of Q4 2014, MILIPERTINE remains the US FDA Preferred Term for this commodity. Milipertine bears US NLM identifiers UMLS ID C0602069 and NCI Concept Code C90841. SMILES: O(C1C(N2CCN(CC2)CCC2C3C([NH]C2C)CC(OC)C(OC)C3)CCCC1)C.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers 49E5S535FG (whole) and 822I9LEJ7S (extract), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 38413 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Asterales, Family Asteraceae, Genus Silybum, Species Silybum marianum, commonly known as BLESSED MILKTHISTLE, BLESSED MILK-THISTLE, SPOTTED THISTLE, VARIEGATED THISTLE, or as here, simply MILK THISTLE. Milk thistle bears the USDA PLANTS Database Identifier SIMA3. European Medicines Agency schedules milk thistle in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB15252MIG, SUB32291, SUB35835, SUB47019, SUB47020, SUB47021, SUB47022, SUB47023, SUB47024, SUB47025, SUB47026, SUB55439, and SUB63378. As of Q4 2014, MILK THISTLE remains the US FDA Preferred Term for this commodity. Milk thistle bears US NLM identifiers UMLS ID C0937640 and NCI Concept Code C29261. SMILES: NONE.
This classification denotes an antidepressant agent and adrenergic agent with the molecular formula C15H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G56VK1HF36, chemically known as cyclopropanecarboxamide, 2-(aminomethyl)-n,n-diethyl-1-phenyl-, cis-(+-)- but generally known as milnacipran, which bears US NIH Compound Identifier 65833. European Medicines Agency schedules Milnacipran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08965MIG. The term MILNACIPRAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules milnacipran in its Anatomical Therapeutic Chemical (ATC) Classification. MILNACIPRAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule milnacipran under HS 29242995 and SITC 51479. As of Q4 2014, MILNACIPRAN remains the US FDA Preferred Term for this commodity. Milnacipran bears US NLM identifiers UMLS ID C1533126 and NCI Concept Code C78021. SMILES: O=C(N(CC)CC)C1(C(C1)CN)c1ccccc1.
This classification denotes an antidepressant agent and adrenergic agent with the molecular formula C15H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RNZ43O5WW5, chemically known as (z)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide hydrochloride but more generally known as milnacipran hydrochloride, which bears US NIH Compound Identifier 55480. European Medicines Agency schedules Milnacipran hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03297MIG. Most nations, for tariff and trade purposes, schedule milnacipran hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, MILNACIPRAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Milnacipran hydrochloride bears US NLM identifiers UMLS ID C0066529 and NCI Concept Code C78022. SMILES: CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2CCCCC2.CL.
This classification denotes an antibiotic with the molecular formula C12H9NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VM4W7043SN, chemically known as 5,8-dihydro-5-methoxy-8-oxo-2h-1,3-dioxolo(4,5-g)quinoline-7-carboxylic acid but generally known as miloxacin, which bears US NIH Compound Identifier 37614. European Medicines Agency schedules Miloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08967MIG. The term MILOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). MILOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule miloxacin under HS 29349990 and SITC 51579. As of Q4 2014, MILOXACIN remains the US FDA Preferred Term for this commodity. Miloxacin bears US NLM identifiers UMLS ID C0066553 and NCI Concept Code C66154. SMILES: O1C2C(OC1)CC1C(N(OC)CC(C1=O)C(=O)O)C2.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H9N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JU9YAX04C7, chemically known as 1,6-dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile but generally known as milrinone, which bears US NIH Compound Identifier 4197. European Medicines Agency schedules Milrinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08968MIG. The term MILRINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules milrinone in its Anatomical Therapeutic Chemical (ATC) Classification. MILRINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule milrinone under HS 29337900 and SITC 51561. As of Q4 2014, MILRINONE remains the US FDA Preferred Term for this commodity. Milrinone bears US NLM identifiers UMLS ID C0128513 and NCI Concept Code C61848. SMILES: O=C1[NH]C(C(C2CCNCC2)CC1C#N)C.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H9N3O.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9K8XR81MO8, chemically known as 1,6-dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile but more generally known as milrinone lactate, which bears US NIH Compound Identifier 4197. European Medicines Agency schedules Milrinone lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14579MIG. Most nations, for tariff and trade purposes, schedule milrinone lactate under HS 29337900 and SITC 51561. As of Q4 2014, MILRINONE LACTATE remains US FDA's Preferred Term for this commodity. Milrinone lactate bears US NLM identifiers UMLS ID C0699132 and NCI Concept Code C29263. SMILES: CC1C(CC(C(=O)[NH]1)C#N)C2CCNCC2.CC(C(=O)O)O.
This classification denotes an alkylphosphocholine compound with the molecular formula C21H46NO4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53EY29W7EC, chemically known as 3,5-dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-, hydroxide, inner salt, 4-oxide but generally known as miltefosine, which bears US NIH Compound Identifier 3599. European Medicines Agency schedules Miltefosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08969MIG. The term MILTEFOSINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules miltefosine in its Anatomical Therapeutic Chemical (ATC) Classification. MILTEFOSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule miltefosine under HS 29239000 and SITC 51481. As of Q4 2014, MILTEFOSINE remains the US FDA Preferred Term for this commodity. Miltefosine bears US NLM identifiers UMLS ID C0068006 and NCI Concept Code C1170. SMILES: P(=O)(OCC[N](C)(C)C)(OCCCCCCCCCCCCCCCC)O.
This classification denotes an antispasmotic agent with the molecular formula C20H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83B517YUVM, chemically known as 4-((3,3-diphenylpropyl)amino)pyridine but generally known as milverine, which bears US NIH Compound Identifier 71139. European Medicines Agency schedules Milverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08970MIG. The term MILVERINE is an International Non-Proprietary Name. MILVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule milverine under HS 29333999 and SITC 51574. As of Q4 2014, MILVERINE remains the US FDA Preferred Term for this commodity. Milverine bears US NLM identifiers UMLS ID C0628924 and NCI Concept Code C66155. SMILES: N(CCC(C1CCCCC1)C1CCCCC1)C1CCNCC1.
This classification denotes an aldose reductase inhibitor with the molecular formula C19H11BrF2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G44PE6QB31, chemically known as 2-((4-bromo-2-fluorophenyl)methyl)-6-fluorospiro(isoquinoline-4(1h),3-pyrrolidine)-1,2,3,5(2h)-tetrone but generally known as minalrestat, which bears US NIH Compound Identifier 190816. European Medicines Agency schedules Minalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08972MIG. The term MINALRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). MINALRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule minalrestat under HS 29251995 and SITC 51482. As of Q4 2014, MINALRESTAT remains the US FDA Preferred Term for this commodity. Minalrestat bears US NLM identifiers UMLS ID C1175807 and NCI Concept Code C72820. SMILES: BRC1CC(F)C(CN2C(=O)C3(CC(=O)NC3=O)C3C(C2=O)CCC(F)C3)CC1.
This classification denotes an antidepressant agent with the molecular formula C17H22N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00U7GX0NLM, chemically known as 4-morpholineethanamine, n- (4-methyl-6-phenyl-3-pyridazinyl)-, dihydrochloride but generally known as minaprine, which bears US NIH Compound Identifier 4199. European Medicines Agency schedules Minaprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08974MIG. The term MINAPRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules minaprine in its Anatomical Therapeutic Chemical (ATC) Classification. MINAPRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule minaprine under HS 29349990 and SITC 51579. As of Q4 2014, MINAPRINE remains the US FDA Preferred Term for this commodity. Minaprine bears US NLM identifiers UMLS ID C0066561 and NCI Concept Code C66158. SMILES: O1CCN(CC1)CCNc1nnc(cc1C)c1ccccc1.
This classification denotes an antidepressant agent with the molecular formula C17H22N4O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82Y7NT6DFT, chemically known as 4-morpholineethanamine, n- (4-methyl-6-phenyl-3-pyridazinyl)-, dihydrochloride but more generally known as minaprine hydrochloride, which bears US NIH Compound Identifier 4199. Most nations, for tariff and trade purposes, schedule minaprine hydrochloride under HS 29349990. As of Q4 2014, MINAPRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Minaprine hydrochloride bears US NLM identifiers UMLS ID C0951496 and NCI Concept Code C80005. SMILES: CC1CC(NNC1NCCN2CCOCC2)C3CCCCC3.CL.CL.
This classification denotes an anesthetic agent with the molecular formula C25H43NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 737SKC73L0, chemically known as pregnan-20-one, 11-(dimethylamino)-2-ethoxy-3-hydroxy-, (2beta,3alpha,5alpha,11alpha)- but generally known as minaxolone, which bears US NIH Compound Identifier 71960. European Medicines Agency schedules Minaxolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08975MIG. The term MINAXOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). MINAXOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule minaxolone under HS 29225000 and SITC 51467. As of Q4 2014, MINAXOLONE remains the US FDA Preferred Term for this commodity. Minaxolone bears US NLM identifiers UMLS ID C0066562 and NCI Concept Code C87596. SMILES: O(C1CC2(C3C(C4C(CC3N(C)C)(C(CC4)C(=O)C)C)CCC2CC1O)C)CC.
This classification denotes a vasodilating agent and antihypertensive agent with the molecular formula C23H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VI1D4HYXC, chemically known as 1-piperidineethanol, alpha-((1h-indol-4-yloxy)methyl)-4-(phenoxymethyl)- but generally known as mindodilol, which bears US NIH Compound Identifier 68892. European Medicines Agency schedules Mindodilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08976MIG. The term MINDODILOL is an International Non-Proprietary Name. MINDODILOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mindodilol under HS 29333999 and SITC 51574. As of Q4 2014, MINDODILOL remains the US FDA Preferred Term for this commodity. Mindodilol bears US NLM identifiers UMLS ID C1881852 and NCI Concept Code C66159. SMILES: O(CC1CCN(CC1)CC(O)COc1c2c([nH]cc2)ccc1)c1ccccc1.
This classification denotes an anxiolytic with the molecular formula C25H29FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 556OP2G5M2, chemically known as butyrophenone, 4-fluoro-4-(4-(6-methoxy-2-methylindol-3-yl)piperidino)- but generally known as mindoperone, which bears US NIH Compound Identifier 172296. European Medicines Agency schedules Mindoperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08977MIG. The term MINDOPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). MINDOPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mindoperone under HS 29333999 and SITC 51574. As of Q4 2014, MINDOPERONE remains the US FDA Preferred Term for this commodity. Mindoperone bears US NLM identifiers UMLS ID C1881853 and NCI Concept Code C66160. SMILES: FC1CCC(C(=O)CCCN2CCC(CC2)C2C3C([NH]C2C)CC(OC)CC3)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H16N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F37A9VKY5Q, chemically known as 6-(methylamino)-4-oxo-10-propyl-4h-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid but generally known as minocromil, which bears US NIH Compound Identifier 71448. European Medicines Agency schedules Minocromil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08979MIG. The term MINOCROMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). MINOCROMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule minocromil under HS 29349990 and SITC 51579. As of Q4 2014, MINOCROMIL remains the US FDA Preferred Term for this commodity. Minocromil bears US NLM identifiers UMLS ID C0066572 and NCI Concept Code C66162. SMILES: O1C2C(CCC)C3NC(CC(NC)C3CC2C(=O)CC1C(=O)O)C(=O)O.
This classification denotes a tetracycline antibiotic with the molecular formula C23H27N3O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FYY3R43WGO, chemically known as 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide but generally known as minocycline, which bears US NIH Compound Identifier 5281021. European Medicines Agency schedules Minocycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08980MIG. The term MINOCYCLINE is an International Non-Proprietary Name. World Health Organization schedules minocycline in its Anatomical Therapeutic Chemical (ATC) Classification. MINOCYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule minocycline under HS 29413000 and SITC 54133. As of Q4 2014, MINOCYCLINE remains the US FDA Preferred Term for this commodity. Minocycline bears US NLM identifiers UMLS ID C0026187 and NCI Concept Code C61849. SMILES: OC12C(CC3C(=C(O)C4C(C3)C(N(C)C)CCC4O)C1=O)C(N(C)C)C(=O)C(=C(\O)N)\C2=O.
This classification denotes a tetracycline antibiotic with the molecular formula C23H27N3O7.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0020414E5U, chemically known as 7-dimethylamino-6-demethyl-6-deoxytetracycline, hcl but more generally known as minocycline hydrochloride, which bears US NIH Compound Identifier 5281093. European Medicines Agency schedules Minocycline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03304MIG. Most nations, for tariff and trade purposes, schedule minocycline hydrochloride under HS 29413000 and SITC 54133. As of Q4 2014, MINOCYCLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Minocycline hydrochloride bears US NLM identifiers UMLS ID C0026186 and NCI Concept Code C47622. SMILES: CN(C)C1CCC(C2C1C[C@H]3C[C@H]4[C@@H](C(=C(C(=O)[C@]4(C(=C3C2=O)O)O)C(=O)N)O)N(C)C)O.CL.
This classification denotes a bone resorption inhibitor with the molecular formula C9H12N2O7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40SGR63TGL, chemically known as 1-hydroxy-2-(imidazo(1,2-a)pyridin-3-yl)ethane-1,1-bisphosphonic acid monohydrate but generally known as minodronic acid, which bears US NIH Compound Identifier 130956. European Medicines Agency schedules Minodronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08981MIG. The term MINODRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). Most nations schedule minodronic acid under HS 29339990 and SITC 51577. As of Q4 2014, MINODRONIC ACID remains the US FDA Preferred Term for this commodity. Minodronic acid bears US NLM identifiers UMLS ID C0256218 and NCI Concept Code C81673. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)Cc1n2c(nc1)cccc2.
This classification denotes a vasodilating agent and antihypertensive agent with the molecular formula C9H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5965120SH1, chemically known as 2,6-diamino-4-piperidinopyrimidin-1-oxid but generally known as minoxidil, which bears US NIH Compound Identifier 4201. European Medicines Agency schedules Minoxidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08982MIG. The term MINOXIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules minoxidil in its Anatomical Therapeutic Chemical (ATC) Classification. MINOXIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule minoxidil under HS 29335995 and SITC 51576. As of Q4 2014, MINOXIDIL remains the US FDA Preferred Term for this commodity. Minoxidil bears US NLM identifiers UMLS ID C0730881 and NCI Concept Code C47623. SMILES: On1c(N)cc(N2CCCCC2)nc1=N.
This classification denotes a vasodilating agent and antihypertensive agent with the molecular formula C9H15N5O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H6K6Y231J, chemically known as 2-pyrimidinamine, 1,6-dihydro-6-imino-4-(1-piperidinyl)-1-(sulfooxy)-, but more generally known as minoxidil sulfate ester, which bears US NIH Compound Identifier 4202. European Medicines Agency schedules minoxidil sulfate ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08982MIG. Most nations, for tariff purposes, schedule minoxidil sulfate ester under HS 29335995. SMILES: C1C([N+](C(NC1N2CCCCC2)N)OS(=O)(=O)[O-])N.
This classification denotes an opioid receptor agonist with the molecular formula C22H24N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2U943H24P, chemically known as N-[1-(2-phenylethyl)piperidin-4-yl]-N-pyrazin-2-ylfuran-2-carboxamide but generally known as mirfentanil, which bears US NIH Compound Identifier 60698. European Medicines Agency schedules mirfentanil its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08988MIG. Most nations schedule mirfentanil under HS 29349990 and SITC 51579. As of Q4 2014, MIRFENTANIL remains the US FDA Preferred Term for this commodity. SMILES: C1CN(CCC1N(C2=NC=CN=C2)C(=O)C3=CC=CO3)CCC4=CC=CC=C4.
This classification denotes an opioid receptor agonist with the molecular formula C22H24N4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4XFQ391SJU, chemically known as 2-furancarboxamide, n-(1-(2-phenylethyl)-4-piperidinyl)-n-pyrazinyl-, monohydrochloride but more generally known as mirfentanil hydrochloride, which bears US NIH Compound Identifier 60697. Most nations, for tariff and trade purposes, schedule mirfentanil hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, MIRFENTANIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mirfentanil hydrochloride bears US NLM identifiers UMLS ID C2984002 and NCI Concept Code C91048. SMILES: C1CCC(CC1)CCN2CCC(CC2)N(C3CNCCN3)C(=O)C4CCCO4.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S00I5XG484, chemically known as 4-imidazo(1,2-a)pyridin-2-yl-alpha-methylbenzeneacetic acid but generally known as miroprofen, which bears US NIH Compound Identifier 68752. European Medicines Agency schedules Miroprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08994MIG. The term MIROPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 1, 1999, List 41). MIROPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule miroprofen under HS 29339990 and SITC 51577. As of Q4 2014, MIROPROFEN remains the US FDA Preferred Term for this commodity. Miroprofen bears US NLM identifiers UMLS ID C0066589 and NCI Concept Code C90910. SMILES: OC(=O)C(C1CCC(C2NC3N(C2)CCCC3)CC1)C.
This classification denotes a macrolide antibiotic with the molecular formula C37H61NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7G02HKM1X, chemically known as 4,17-dioxabicyclo(14.1.0)heptadeca-6,14-diene-5,13-dione, 2-(((6-deoxy-2,3-di-o-methyl-beta-d-allopyranosyl)oxy)methyl)-3-ethyl-2-hydroxy-8,10,12-trimethyl-9-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-, (1r,2s,3r,6e,8s,9s,10s,12r,14e,16s)- but generally known as mirosamicin, which bears US NIH Compound Identifier 6436150. European Medicines Agency schedules Mirosamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08995MIG. The term MIROSAMICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). MIROSAMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mirosamicin under HS 29419000 and SITC 54139. As of Q4 2014, MIROSAMICIN remains the US FDA Preferred Term for this commodity. Mirosamicin bears US NLM identifiers UMLS ID C0245985 and NCI Concept Code C90878. SMILES: O1C2C(O)(C(OC(=O)C=CC(C(OC3OC(CC(N(C)C)C3O)C)C(CC(C(=O)C=CC12)C)C)C)CC)COC1OC(C(O)C(OC)C1OC)C.
This classification denotes an antidepressant agent with the molecular formula C17H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A051Q2099Q, chemically known as 1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine but generally known as mirtazapine, which bears US NIH Compound Identifier 4205. European Medicines Agency schedules Mirtazapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08996MIG. The term MIRTAZAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules mirtazapine in its Anatomical Therapeutic Chemical (ATC) Classification. MIRTAZAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mirtazapine under HS 29335995 and SITC 51576. As of Q4 2014, MIRTAZAPINE remains the US FDA Preferred Term for this commodity. Mirtazapine bears US NLM identifiers UMLS ID C0049506 and NCI Concept Code C29265. SMILES: N12C(CN(CC1)C)c1c(Cc3c2nccc3)cccc1.
This classification denotes a serotonin antagonist with the molecular formula 2C17H19N3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Z5UNK8A61. European Medicines Agency schedules mirtazapine hemihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB48264. Most nations, for tariff and trade purposes, schedule mirtazapine hemihydrate under HS 29335995. As of Q4 2014, MIRTAZAPINE HEMIHYDRATE remains US FDA's Preferred Term for this commodity. Mirtazapine hemihydrate bears US NLM identifiers UMLS ID C2828218 and NCI Concept Code C87211. SMILES: CN1CCN2C3C(CCCN3)CC4CCCCC4C2C1.CN1CCN2C3C(CCCN3)CC4CCCCC4C2C1.O.
This classification denotes a prostaglandin analogue and cytoprotective agent and anti-ulcer agent with the molecular formula C22H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0E43V0BB57, chemically known as prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11alpha,13e)-(+-)- but generally known as misoprostol, which bears US NIH Compound Identifier 5282381. European Medicines Agency schedules Misoprostol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08998MIG. The term MISOPROSTOL is an International Non-Proprietary Name. World Health Organization schedules misoprostol in its Anatomical Therapeutic Chemical (ATC) Classification. MISOPROSTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule misoprostol under HS 29375000 and SITC 54156. As of Q4 2014, MISOPROSTOL remains the US FDA Preferred Term for this commodity. Misoprostol bears US NLM identifiers UMLS ID C0085174 and NCI Concept Code C1313. SMILES: OC1C(C(CCCCCCC(=O)OC)C(=O)C1)/C=C/CC(O)(CCCC)C.
This classification denotes an anti-diabetic agent with the molecular formula C19H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D86I0XLB13, chemically known as (-)-(2s,3a,7a-cis)-alpha-benzylhexahydro-gamma-oxo-2-isoindolinebutyric acid but more generally known as mitiglinide, which bears US NIH Compound Identifier 3047758. European Medicines Agency schedules Mitiglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08999MIG. The term MITIGLINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 No. 2 1999, List 40) WHO schedules mitiglinide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule mitiglinide under HS 29339990 and SITC 51577. As of Q4 2014, MITIGLINIDE remains US FDA's Preferred Term for this commodity. Mitiglinide bears US NLM identifiers UMLS ID C0906166 and NCI Concept Code C81699. SMILES: O=C(N1CC2C(C1)CCCC2)CC(CC1CCCCC1)C(=O)O.
This classification denotes an anti-diabetic agent with the molecular formula 2C19H24NO3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P5WOR98G68, chemically known as (s)-2-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyric acid calcium salt, but more generally known as mitiglinide calcium, which bears US NIH Compound Identifier 5478927. European Medicines Agency schedules mitiglinide calcium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08999MIG. Most nations, for tariff purposes, schedule mitiglinide calcium under HS 29339990. SMILES: C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].[CA+2].
This classification denotes an anti-diabetic agent 2C19H24NO3.Ca.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9651C21W3Z, chemically known as bis((2s)-2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionate) calcium dihydrate, d-, but more generally known as mitiglinide calcium dihydrate, which bears US NIH Compound Identifier 6918235. European Medicines Agency schedules Mitiglinide calcium dihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21788. Most nations, for tariff and trade purposes, schedule mitiglinide calcium dihydrate under HS 29339990 and SITC 51577. As of Q4 2014, MITIGLINIDE CALCIUM DIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].O.O.[CA+2].
This classification denotes an anti-diabetic agent with the molecular formula 2C19H24NO3.Ca.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9651C21W3Z, chemically known as bis((2s)-2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionate) calcium dihydrate, d-, but more generally known as mitiglinide calcium hydrate, which bears US NIH Compound Identifier 6918235. European Medicines Agency schedules mitiglinide calcium hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08999MIG. Most nations, for tariff purposes, schedule mitiglinide calcium hydrate under HS 29339990. SMILES: C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].O.O.[CA+2].
This classification denotes a biomaterial with the molecular formula C6H12Br2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5UP30YED7N, chemically known as 1,2,3,4,5,6-hexanehexol but more generally known as mitobronitol, which bears US NIH Compound Identifier 453. European Medicines Agency schedules Mitobronitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09001MIG. The term MITOBRONITOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules mitobronitol in its Anatomical Therapeutic Chemical (ATC) Classification. MITOBRONITOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mitobronitol under HS 29055999 and SITC 51229. As of Q4 2014, MITOBRONITOL remains US FDA's Preferred Term for this commodity. Mitobronitol bears US NLM identifiers UMLS ID C0026236 and NCI Concept Code C659. SMILES: OC(C(O)C(O)CO)C(O)CO.
This classification denotes a s-adenosyl-methionine decarboxylase inhibitor and polyamine inhibitory agent with the molecular formula C5H12N8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OD5Q0L447W, chemically known as 1,1-((methylethanediylidene)dinitrilo)diguanidine but generally known as mitoguazone, which bears US NIH Compound Identifier 5351154. European Medicines Agency schedules Mitoguazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09004MIG. The term MITOGUAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules mitoguazone in its Anatomical Therapeutic Chemical (ATC) Classification. MITOGUAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mitoguazone under HS 29252900 and SITC 51482. As of Q4 2014, MITOGUAZONE remains the US FDA Preferred Term for this commodity. Mitoguazone bears US NLM identifiers UMLS ID C0026251 and NCI Concept Code C661. SMILES: N(=C(\C)/C=N/N=C(/N)N)\N=C(\N)N.
This classification denotes a radiosensitizing agent and epoxide compound with the molecular formula C6H12Br2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LJ2P1SIK8Y, chemically known as 1,6-dideoy-1,6-dibromo-d-mannitol but more generally known as mitolactol, which bears US NIH Compound Identifier 4208. European Medicines Agency schedules Mitolactol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09005MIG. The term MITOLACTOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). MITOLACTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mitolactol under HS 29055999 and SITC 51229. As of Q4 2014, MITOLACTOL remains US FDA's Preferred Term for this commodity. Mitolactol bears US NLM identifiers UMLS ID C0026252 and NCI Concept Code C662. SMILES: BRCC(O)C(O)C(O)C(O)CBR.
This classification denotes an alkylating agent, antibiotics, antineoplastic, cross-linking reagent, and nucleic acid synthesis inhibitor with the molecular formula C15H18N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50SG953SK6, chemically known as 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino(2,3:3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester) but generally known as mitomycin, which bears US NIH Compound Identifier 5746. European Medicines Agency schedules Mitomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09006MIG. The term MITOMYCIN is an International Non-Proprietary Name. World Health Organization schedules mitomycin in its Anatomical Therapeutic Chemical (ATC) Classification. MITOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mitomycin under HS 29419000 and SITC 54139. As of Q4 2014, MITOMYCIN remains the US FDA Preferred Term for this commodity. Mitomycin bears US NLM identifiers UMLS ID C0002475 and NCI Concept Code C1820. SMILES: O(C12N(CC3NC13)C1=C(C2COC(=O)N)C(=O)C(=C(C1=O)C)N)C.
This classification denotes an intercalating agent with the molecular formula C16H15N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06Q0V17SI9, chemically known as 2-((dimethylamino)ethyl)-2,3-dihydro-5-nitro-2-azaphenalen-1,3-dion but generally known as mitonafide, which bears US NIH Compound Identifier 41202. European Medicines Agency schedules Mitonafide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09007MIG. The term MITONAFIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). MITONAFIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mitonafide under HS 29251995 and SITC 51482. As of Q4 2014, MITONAFIDE remains the US FDA Preferred Term for this commodity. Mitonafide bears US NLM identifiers UMLS ID C0066614 and NCI Concept Code C66165. SMILES: O=C1[NH]C(=O)C2C3C1C(CCN(C)C)CCC3C([N](=O)O)CC2.
This classification denotes an anti-adrenal with the molecular formula C14H10Cl4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78E4J5IB5J, chemically known as 2,4-dichlorophenyldichlorethane but generally known as mitotane, which bears US NIH Compound Identifier 4211. European Medicines Agency schedules Mitotane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09010MIG. The term MITOTANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules mitotane in its Anatomical Therapeutic Chemical (ATC) Classification. MITOTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, MITOTANE remains the US FDA Preferred Term for this commodity. Mitotane bears US NLM identifiers UMLS ID C0026256 and NCI Concept Code C664. SMILES: CLC(CL)C(C1CCC(CL)CC1)C1C(CL)CCCC1.
This classification denotes an anthraquinone compound with the molecular formula C22H28N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BZ114NVM5P, chemically known as 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9ci) but generally known as mitoxantrone, which bears US NIH Compound Identifier 4212. European Medicines Agency schedules Mitoxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09012MIG. The term MITOXANTRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules mitoxantrone in its Anatomical Therapeutic Chemical (ATC) Classification. MITOXANTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mitoxantrone under HS 29225000 and SITC 51467. As of Q4 2014, MITOXANTRONE remains the US FDA Preferred Term for this commodity. Mitoxantrone bears US NLM identifiers UMLS ID C0026259 and NCI Concept Code C62050. SMILES: O=C1C2C(C(NCCNCCO)CCC2NCCNCCO)C(=O)C2C1C(O)CCC2O.
This classification denotes an anthraquinone compound with the molecular formula C22H28N4O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6USW86RD0, chemically known as 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthraquinone dihydrochloride, but more generally known as mitoxantrone dihydrochloride, which bears US NIH Compound Identifier 4212. European Medicines Agency schedules mitoxantrone dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09012MIG. Most nations, for tariff purposes, schedule mitoxantrone dihydrochloride under HS 29225000. SMILES: C1CC(C2C(C1NCCNCCO)C(=O)C3C(CCC(C3C2=O)O)O)NCCNCCO.CL.CL.
This classification denotes an anthracenedione-derived antineoplastic agent, analgesic, and anthraquinone with the molecular formula C22H28N4O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6USW86RD0, chemically known as 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9ci) but more generally known as mitoxantrone hydrochloride, which bears US NIH Compound Identifier 4212. European Medicines Agency schedules Mitoxantrone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03309MIG. Most nations, for tariff and trade purposes, schedule mitoxantrone hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, MITOXANTRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mitoxantrone hydrochloride bears US NLM identifiers UMLS ID C1513359 and NCI Concept Code C665. SMILES: C1CC(C2C(C1NCCNCCO)C(=O)C3C(CCC(C3C2=O)O)O)NCCNCCO.CL.CL.
This classification denotes a muscle relaxant with the molecular formula C58H80N2O14.2Cl, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 600ZG213C3, chemically known as (r)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (e)-4-octenedioate (2:1) but more generally known as mivacurium chloride, which bears U.S. National Institutes of Health Compound Identifier 5281080. European Medicines Agency schedules Mivacurium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09014MIG. The term MIVACURIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules mivacurium chloride in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a muscle relaxant with the molecular formula C58H80N2O14.2Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 600ZG213C3, chemically known as (r)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (e)-4-octenedioate (2:1) but generally known as mivacurium chloride, which bears US NIH Compound Identifier 5281080. European Medicines Agency schedules Mivacurium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09014MIG. The term MIVACURIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules mivacurium chloride in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C11H11N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5P1SSA8KD, chemically known as alpha-imidazol-4-yl-2,3-cresotamide but generally known as mivazerol, which bears US NIH Compound Identifier 60784. European Medicines Agency schedules Mivazerol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09015MIG. The term MIVAZEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Mivazerol or piroximone bears US NLM identifiers UMLS ID C0071150 and NCI Concept Code C90921. SMILES: CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C24H25FN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 244O1F90NA, chemically known as 4(1h)-pyrimidinone, 2-((1-(1-((4-fluorophenyl)methyl)-1h-benzimidazol-2-yl)-4-piperidinyl)methylamino)- but generally known as mizolastine, which bears US NIH Compound Identifier 65906. European Medicines Agency schedules Mizolastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09018MIG. The term MIZOLASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules mizolastine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule mizolastine under HS 29335995 and SITC 51576. As of Q4 2014, MIZOLASTINE remains the US FDA Preferred Term for this commodity. Mizolastine bears US NLM identifiers UMLS ID C0171302 and NCI Concept Code C66171. SMILES: FC1CCC(CN2C(N3CCC(N(C)C4[NH]C(=O)CCN4)CC3)NC3C2CCCC3)CC1.
This classification denotes an immunosuppressant with the molecular formula C9H13N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4JR41A10VP, chemically known as 1h-imidazole-4-carboxamide, 5-hydroxy-1-.beta.-d-ribofuranosyl- but more generally known as mizoribine, which bears US NIH Compound Identifier 4213. European Medicines Agency schedules Mizoribine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09019MIG. The term MIZORIBINE is an International Non-Proprietary Name. MIZORIBINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule mizoribine under HS 29349990 and SITC 51579. As of Q4 2014, MIZORIBINE remains US FDA's Preferred Term for this commodity. Mizoribine bears US NLM identifiers UMLS ID C0128608 and NCI Concept Code C66172. SMILES: O1C(N2C(O)C(NC2)C(=O)N)C(O)C(O)C1CO.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H17ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PJ0Y7AZB63, chemically known as benzamide, 4-chloro-n-(2-(4-morpholinyl)ethyl)- but generally known as moclobemide, which bears US NIH Compound Identifier 4235. European Medicines Agency schedules Moclobemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09024MIG. The term MOCLOBEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules moclobemide in its Anatomical Therapeutic Chemical (ATC) Classification. MOCLOBEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moclobemide under HS 29349990 and SITC 51579. As of Q4 2014, MOCLOBEMIDE remains the US FDA Preferred Term for this commodity. Moclobemide bears US NLM identifiers UMLS ID C0066673 and NCI Concept Code C87772. SMILES: Clc1ccc(C(=O)NCCN2CCOCC2)cc1.
This classification denotes an antidepressant agent with the molecular formula C10H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M6T2W2993, chemically known as 2-methyl-3-piperidin-1-ylpyrazine but generally known as modaline, which bears US NIH Compound Identifier 17859. The term modaline is an International Non-Proprietary Name or INN. European Medicines Agency schedules modaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09027MIG. Most nations schedule modaline under HS 29333999 and SITC 51574. As of Q4 2014, MODALINE remains the US FDA Preferred Term for this commodity. SMILES: CC1=NC=CN=C1N2CCCCC2.
This classification denotes an antidepressant agent with the molecular formula C10H15N3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NH3315AI6E, chemically known as pyrazine, 2-methyl-3-piperidino-, sulfate but more generally known as modaline sulfate, which bears US NIH Compound Identifier 17859. Most nations, for tariff and trade purposes, schedule modaline sulfate under HS 29333999 and SITC 51574. As of Q4 2014, MODALINE SULFATE remains US FDA's Preferred Term for this commodity. Modaline sulfate bears US NLM identifiers UMLS ID C2983847 and NCI Concept Code C90711. SMILES: CC1C(NCCN1)N2CCCCC2.OS(=O)(=O)O.
This classification denotes an antiarrhythmic agent with the molecular formula C22H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) JU27887FWK, chemically known as benzamide, 4-hydroxy-3-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, ( but more generally known as modecainide, which bears US NIH Compound Identifier 54737. European Medicines Agency schedules Modecainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09028MIG. The term MODECAINIDE is an International Non-Proprietary Name. MODECAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule modecainide under HS 29333999 and SITC 51574. As of Q4 2014, MODECAINIDE remains US FDA's Preferred Term for this commodity. Modecainide bears US NLM identifiers UMLS ID C2983824 and NCI Concept Code C90665. SMILES: O=C(NC1C(CCC2N(CCCC2)C)CCCC1)C1CC(OC)C(O)CC1.
This classification denotes an antiplatelet agent with the molecular formula C34H29ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1DMI0E5023, chemically known as ethyl ( )-(r)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-2-(p-(2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)-5-(2-pyridylcarbamoyl)nicotinate. but generally known as modipafant, which bears US NIH Compound Identifier 3047770. European Medicines Agency schedules Modipafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09029MIG. The term MODIPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). Most nations schedule modipafant under HS 29333999 and SITC 51574. As of Q4 2014, MODIPAFANT remains the US FDA Preferred Term for this commodity. Modipafant bears US NLM identifiers UMLS ID C0287533 and NCI Concept Code C90752. SMILES: CLC1C(C2C(=C(NC(=C2C(=O)NC2NCCCC2)C)C2CCC(N3C4C(NC3C)CNCC4)CC2)C(=O)OCC)CCCC1.
This classification denotes an ace inhibitor with the molecular formula C27H34N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WT87C52TJZ, chemically known as (3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester but generally known as moexipril, which bears US NIH Compound Identifier 91270. European Medicines Agency schedules Moexipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09030MIG. The term MOEXIPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules moexipril in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule moexipril under HS 29334990 and SITC 51575. As of Q4 2014, MOEXIPRIL remains the US FDA Preferred Term for this commodity. Moexipril bears US NLM identifiers UMLS ID C0066685 and NCI Concept Code C83967. SMILES: O=C(N1C(Cc2c(C1)cc(OC)c(OC)c2)C(=O)O)C(NC(CCc1ccccc1)C(=O)OCC)C.
This classification denotes an ace inhibitor with the molecular formula C27H34N2O7.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q1UMG3UH45, chemically known as 3-isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-, monohydrochloride, (3s-(2(r*(r*)),3r*))- but more generally known as moexipril hydrochloride, which bears US NIH Compound Identifier 54889. European Medicines Agency schedules Moexipril hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03312MIG. Most nations, for tariff and trade purposes, schedule moexipril hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, MOEXIPRIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Moexipril hydrochloride bears US NLM identifiers UMLS ID C0771294 and NCI Concept Code C29267. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2CC3CC(C(CC3C[C@H]2C(=O)O)OC)OC.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SPW36WUI5Z, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-phenyl- but generally known as mofebutazone, which bears US NIH Compound Identifier 16639. European Medicines Agency schedules Mofebutazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09033MIG. The term MOFEBUTAZONE is an International Non-Proprietary Name. World Health Organization schedules mofebutazone in its Anatomical Therapeutic Chemical (ATC) Classification. MOFEBUTAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mofebutazone under HS 29331990 and SITC 51571. As of Q4 2014, MOFEBUTAZONE remains the US FDA Preferred Term for this commodity. Mofebutazone bears US NLM identifiers UMLS ID C0066774 and NCI Concept Code C73089. SMILES: O=C1N(NC(=O)C1CCCC)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug C13H15N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73X92I1U1W, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-phenyl-, sodium salt (1:1), but more generally known as mofebutazone sodium, which bears US NIH Compound Identifier 16639. European Medicines Agency schedules Mofebutazone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03313MIG. Most nations, for tariff and trade purposes, schedule mofebutazone sodium under HS 29331990 and SITC 51571. As of Q4 2014, MOFEBUTAZONE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC[C-]1C(=O)[NH]N(C1=O)C2CCCCC2.[NA+].
This classification denotes a monoamine oxidase inhibitor with the molecular formula C11H13F2N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1FMJ6D8Y1B, chemically known as benzenebutanamine, 4-fluoro-beta-(fluoromethylene)-, (e)- but generally known as mofegiline, which bears US NIH Compound Identifier 6437850. European Medicines Agency schedules Mofegiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09034MIG. The term MOFEGILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). Most nations schedule mofegiline under HS 29214980 and SITC 51454. As of Q4 2014, MOFEGILINE remains the US FDA Preferred Term for this commodity. Mofegiline bears US NLM identifiers UMLS ID C0208987 and NCI Concept Code C83968. SMILES: C1=CC(=CC=C1CC/C(=C\F)/CN)F.
This classification denotes a monoamine oxidase inhibitor C11H13F2N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08331R10RY, chemically known as benzenebutanamine, 4-fluoro-.beta.-(fluoromethylene)-, hydrochloride, (e)-, but more generally known as mofegiline hydrochloride, which bears US NIH Compound Identifier 3047771. Most nations, for tariff and trade purposes, schedule mofegiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, MOFEGILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mofegiline hydrochloride bears US NLM identifiers UMLS ID C2825395 and NCI Concept Code C80965. SMILES: C1CC(CCC1CC/C(=C\F)/CN)F.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H17NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RVJ0BV3H3Y, chemically known as 3,4-bis(p-methoxyphenyl)-5-isoxazoleacetic acid but generally known as mofezolac, which bears US NIH Compound Identifier 4237. European Medicines Agency schedules Mofezolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09035MIG. The term MOFEZOLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). MOFEZOLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mofezolac under HS 29349990 and SITC 51579. As of Q4 2014, MOFEZOLAC remains the US FDA Preferred Term for this commodity. Mofezolac bears US NLM identifiers UMLS ID C0043597 and NCI Concept Code C66176. SMILES: O1NC(C(C1CC(=O)O)C1CCC(OC)CC1)C1CCC(OC)CC1.
This classification denotes an antispasmotic agent with the molecular formula C16H23NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L1G37N4EBS, chemically known as 2,4,6-trimethoxybenzoic acid 2-morpholinoethyl ester but generally known as mofloverine, which bears US NIH Compound Identifier 172304. European Medicines Agency schedules Mofloverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09036MIG. The term MOFLOVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). MOFLOVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mofloverine under HS 29349990 and SITC 51579. As of Q4 2014, MOFLOVERINE remains the US FDA Preferred Term for this commodity. Mofloverine bears US NLM identifiers UMLS ID C1881880 and NCI Concept Code C66177. SMILES: O1CCN(CC1)CCOC(=O)C1C(OC)CC(OC)CC1OC.
This classification denotes a mucolytic agent with the molecular formula C16H21NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6Y556547YY, chemically known as 3-thiazolidinepropanoic acid, 2-((2-methoxyphenoxy)methyl)-beta-oxo-, ethyl ester, (+-)- but more generally known as moguisteine, which bears US NIH Compound Identifier 65935. European Medicines Agency schedules Moguisteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09038MIG. The term MOGUISTEINE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule moguisteine under HS 29341000 and SITC 51579. As of Q4 2014, MOGUISTEINE remains US FDA's Preferred Term for this commodity. Moguisteine bears US NLM identifiers UMLS ID C0256172 and NCI Concept Code C66178. SMILES: S1C(N(CC1)C(=O)CC(=O)OCC)COC1C(OC)CCCC1.
This classification denotes an anti-ulcer agent with the molecular formula C31H50O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5288I2K01S, chemically known as 3,7,11-trimethyl-2,6,10-dodecatrienyl 4,8,12-trimethyl-3,7,11-tridecatrienoate. but generally known as molfarnate, which bears US NIH Compound Identifier 6446651. European Medicines Agency schedules Molfarnate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09039MIG. The term MOLFARNATE is an International Non-Proprietary Name. MOLFARNATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule molfarnate under HS 29161970 and SITC 51379. As of Q4 2014, MOLFARNATE remains the US FDA Preferred Term for this commodity. Molfarnate bears US NLM identifiers UMLS ID C2825700 and NCI Concept Code C81598. SMILES: O(C/C=C(/CC/C=C(/CC/C=C(/C)C)C)C)C(=O)C/C=C(/CC/C=C(/CC/C=C(/C)C)C)C.
This classification denotes a therapeutic granulocyte-macrophage colony-stimulating factor with the molecular formula C639H1007N171O196S8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B321AL142J, more generally known as molgramostim. European Medicines Agency schedules molgramostim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09040MIG. The term MOLGRAMOSTIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31. MOLGRAMOSTIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Molgramostim under HS 30012090 and SITC 54162. SMILES:. As of Q4 2014, MOLGRAMOSTIM remains the US FDA Preferred Term for this commodity. . Molgramostim bears US NLM identifiers UMLS ID C0218633 and NCI Concept Code C77591.
This classification denotes an antipsychotic agent with the molecular formula C16H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RT3Y3QMF8N, chemically known as 4h-indol-4-one, 3-ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)- but generally known as molindone, which bears US NIH Compound Identifier 23897. European Medicines Agency schedules Molindone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09042MIG. The term MOLINDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules molindone in its Anatomical Therapeutic Chemical (ATC) Classification. MOLINDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule molindone under HS 29349990 and SITC 51579. As of Q4 2014, MOLINDONE remains the US FDA Preferred Term for this commodity. Molindone bears US NLM identifiers UMLS ID C0026388 and NCI Concept Code C61850. SMILES: O1CCN(CC2CCC3[NH]C(C(C3C2=O)CC)C)CC1.
This classification denotes an antipsychotic agent with the molecular formula C16H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1DWS68PNE6, chemically known as 4h-indol-4-one, 3-ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-, monohydrochloride but more generally known as molindone hydrochloride, which bears US NIH Compound Identifier 27421. European Medicines Agency schedules Molindone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14587MIG. Most nations, for tariff and trade purposes, schedule molindone hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, MOLINDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Molindone hydrochloride bears US NLM identifiers UMLS ID C0282249 and NCI Concept Code C47624. SMILES: CCC1C([NH]C2C1C(=O)C(CC2)CN3CCOCC3)C.CL.
This classification denotes a neuroprotective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R47KMF9589. European Medicines Agency schedules Molracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09043MIG. Molracetam generally arises in the molecular formula C18H25N3O4. The term MOLRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) MOLRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule molracetam under HS 29349990 and SITC 51579. As of Q4 2014, MOLRACETAM remains the US FDA Preferred Term for this commodity. Molracetam bears US NLM identifiers UMLS ID C1881887 and NCI Concept Code C66180. SMILES: O1CCN(C(=O)CN2CCN(CC2)C(=O)C2CCC(OC)CC2)CC1.
This classification denotes a nitric oxide donor and vasodilator agent with the molecular formula C9H14N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D46583G77X, chemically known as sydnone imine, n-(ethoxycarbonyl)-3-(4-morpholinyl)- but generally known as molsidomine, which bears US NIH Compound Identifier 4239. European Medicines Agency schedules Molsidomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09044MIG. World Health Organization schedules molsidomine in its Anatomical Therapeutic Chemical (ATC) Classification. MOLSIDOMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule molsidomine under HS 29349990 and SITC 51579. As of Q4 2014, MOLSIDOMINE remains the US FDA Preferred Term for this commodity. SMILES: O1CCN([N]2NOC(NC(=O)OCC)C2)CC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HR4QJ6DW8, chemically known as pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11beta,16alpha)- but generally known as mometasone, which bears US NIH Compound Identifier 123620. European Medicines Agency schedules Mometasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09045MIG. World Health Organization schedules mometasone in its Anatomical Therapeutic Chemical (ATC) Classification. MOMETASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mometasone under HS 29372200 and SITC 54153. As of Q4 2014, MOMETASONE remains the US FDA Preferred Term for this commodity. Mometasone bears US NLM identifiers UMLS ID C0360564 and NCI Concept Code C66181. SMILES: CLC12C(C3C(C(O)(C(C3)C)C(=O)CCL)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H30Cl2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04201GDN4R, chemically known as 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) but more generally known as mometasone furoate, which bears US NIH Compound Identifier 55188. European Medicines Agency schedules Mometasone furoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03318MIG. Most nations, for tariff and trade purposes, schedule mometasone furoate under HS 29372200 and SITC 54153. As of Q4 2014, MOMETASONE FUROATE remains US FDA's Preferred Term for this commodity. Mometasone furoate bears US NLM identifiers UMLS ID C0066700 and NCI Concept Code C29268. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCL)OC(=O)C5CCCO5)C)O)CL)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H30Cl2O6.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MTW0WEG809, chemically known as pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- monohydrate, but more generally known as mometasone furoate hydrate, which bears US NIH Compound Identifier 9893453. European Medicines Agency schedules mometasone furoate hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09045MIG. Most nations, for tariff purposes, schedule mometasone furoate hydrate under HS 29372200. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCL)OC(=O)C5CCCO5)C)O)CL)C.O.
This classification denotes a therapeutic glucocorticoid C27H30Cl2O6.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MTW0WEG809, chemically known as pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- monohydrate, but more generally known as mometasone furoate monohydrate, which bears US NIH Compound Identifier 55188. European Medicines Agency schedules Mometasone furoate monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03318MIG. Most nations, for tariff and trade purposes, schedule mometasone furoate monohydrate under HS 29372200 and SITC 54153. As of Q4 2014, MOMETASONE FUROATE MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCL)OC(=O)C5CCCO5)C)O)CL)C.O.
This classification denotes a calcium channel blocker with the molecular formula C28H30FN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N4MMI0J7PW chemically known as 1-piperazinebutanamide, n-(6,11-dihydrodibenzo(b,e)thiepin-11-yl)-4-(4-fluorophenyl) but generally known as monatepil, which bears US NIH Compound Identifier 5282401. European Medicines Agency schedules Monatepil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09047MIG. The term MONATEPIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33). Most nations schedule monatepil under HS 29349990 and SITC 51579. As of Q4 2014, MONATEPIL remains the US FDA Preferred Term for this commodity. Monatepil bears US NLM identifiers UMLS ID CL412665 and NCI Concept Code C83970. SMILES: C1CN(CCN1CCCC(=O)NC2C3=CC=CC=C3CSC4=CC=CC=C24)C5=CC=C(C=C5)F.C(=C\C(=O)O)\C(=O)O.
This classification denotes a calcium channel blocker with the molecular formula C28H30FN3OS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W456I35SKD. The term monatepil maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule monatepil maleate under HS 29349990 and SITC 51579. As of Q4 2014, MONATEPIL MALEATE remains US FDA's Preferred Term for this commodity. Monatepil maleate bears US NLM identifiers UMLS ID C0246444 and NCI Concept Code C81688. SMILES: C1CCC2C(C1)CSC3CCCCC3C2NC(=O)CCCN4CCN(CC4)C5CCC(CC5)F.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antiprotozoal agent with the molecular formula C36H62O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 906O0YJ6ZP, chemically known as monensin, monosodium salt but generally known as monensin, which bears US NIH Compound Identifier 4243. European Medicines Agency schedules Monensin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09048MIG. The term MONENSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). Most nations schedule monensin under HS 29419000 and SITC 54139. As of Q4 2014, MONENSIN remains the US FDA Preferred Term for this commodity. Monensin bears US NLM identifiers UMLS ID C0026408 and NCI Concept Code C83971. SMILES: O1C(C2OC(CC2C)C2OC(O)(C(CC2C)C)CO)(CCC1C1(OC2(OC(C(C(O)C2)C)C(C(OC)C(C)C(=O)O)C)CC1)C)CC.
This classification denotes a hydrocarbon with the molecular formula C13H12O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9L2KA76MG5, chemically known as phenol, p-(benzyloxy)- but generally known as monobenzone, which bears US NIH Compound Identifier 7638. European Medicines Agency schedules Monobenzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09049MIG. The term MONOBENZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules monobenzone in its Anatomical Therapeutic Chemical (ATC) Classification. MONOBENZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule monobenzone under HS 29095090 and SITC 51617. As of Q4 2014, MONOBENZONE remains the US FDA Preferred Term for this commodity. Monobenzone bears US NLM identifiers UMLS ID C0050962 and NCI Concept Code C992. SMILES: O(CC1CCCCC1)C1CCC(O)CC1.
This classification denotes an antidepressant agent with the molecular formula C19H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 3FDC82890Y chemically known as 9,9-dimethyl-10-(3-(methylamino)propyl)acridan but generally known as monometacrine, which bears US NIH Compound Identifier 145765. European Medicines Agency schedules Monometacrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09051MIG. The term MONOMETACRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8. ). Most nations schedule monometacrine under HS 29339990 and SITC 51577. As of Q4 2014, MONOMETACRINE remains the US FDA Preferred Term for this commodity. Monometacrine bears US NLM identifiers UMLS ID C1881896 and NCI Concept Code C66187. SMILES: CC1(C2=CC=CC=C2N(C3=CC=CC=C31)CCCNC)C.
This classification denotes a flavonoid with the molecular formula C29H34O17, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EKF7043SBU, chemically known as 3,3,4,5-tetrahydroxy-7-(2-hydroxyethoxy)flavone 3-(6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside) but more generally known as monoxerutin, which bears U.S. NIH Compound Identifier 5464100. European Medicines Agency schedules Monoxerutin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09053MIG. The term MONOXERUTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules monoxerutin in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. MONOXERUTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MHM278SD3E. European Medicines Agency schedules Montelukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09054MIG. Montelukast generally arises in the molecular formula C35H36CLNO3S. The term MONTELUKAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36.) MONTELUKAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule montelukast under HS 29334990 and SITC 51575. As of Q4 2014, MONTELUKAST remains the US FDA Preferred Term for this commodity. Montelukast bears US NLM identifiers UMLS ID C0298130 and NCI Concept Code C66189. SMILES: CLC1CC2NC(/C=C/C3CC(C(SCC4(CC4)CC(=O)O)CCC4C(C(O)(C)C)CCCC4)CCC3)CCC2CC1.
This classification denotes an anti-asthmatic agent with the molecular formula C35H35ClNO3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U1O3J18SFL, chemically known as cyclopropaneacetic acid, 1-((((1r)-1-(3-((1e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, monosodium salt but more generally known as montelukast sodium, which bears US NIH Compound Identifier 5281041. European Medicines Agency schedules Montelukast sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03324MIG. Most nations, for tariff and trade purposes, schedule montelukast sodium under HS 29334990 and SITC 51575. As of Q4 2014, MONTELUKAST SODIUM remains US FDA's Preferred Term for this commodity. Montelukast sodium bears US NLM identifiers UMLS ID C0380447 and NCI Concept Code C47625. SMILES: CC(C)(C1CCCCC1CC[C@H](C2CCCC(C2)/C=C/C3CCC4CCC(CC4N3)CL)SCC5(CC5)CC(=O)[O-])O.[NA+].
This classification denotes a thyrotropin-releasing hormone analogue with the molecular formula C17H24N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30MUJ6YYUY, chemically known as (-)-n-(((3r,6s)-6-methyl-5-oxo-3-thiomorpholinyl)carbonyl)-l-histidyl-l-prolinamide but generally known as montirelin, which bears US NIH Compound Identifier 65815. European Medicines Agency schedules Montirelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09056MIG. The term MONTIRELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). MONTIRELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule montirelin under HS 29371900 and SITC 54154. As of Q4 2014, MONTIRELIN remains the US FDA Preferred Term for this commodity. Montirelin bears US NLM identifiers UMLS ID C0377440 and NCI Concept Code C77010. SMILES: S1CC(NC(=O)C1C)C(=O)NC(C(=O)N1C(CCC1)C(=O)N)CC1[NH]CNC1.
This classification denotes an anxiolytic with the molecular formula C22H26FNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OU730881W5, chemically known as 4-fluoro-4-(4-hydroxy-4-p-tolylpiperidino)butyrophenone, hydrochloride but generally known as moperone, which bears US NIH Compound Identifier 4249. European Medicines Agency schedules Moperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09057MIG. The term MOPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules moperone in its Anatomical Therapeutic Chemical (ATC) Classification. MOPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moperone under HS 29333999 and SITC 51574. As of Q4 2014, MOPERONE remains the US FDA Preferred Term for this commodity. Moperone bears US NLM identifiers UMLS ID C0066787 and NCI Concept Code C66190. SMILES: FC1CCC(C(=O)CCCN2CCC(O)(CC2)C2CCC(CC2)C)CC1.
This classification denotes an anxiolytic with the molecular formula C22H26FNO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z2633815T, chemically known as butyrophenone, 4'-fluoro-4-(4-hydroxy-4-p-tolylpiperidino)-, hydrochloride, but more generally known as moperone chlorohydrate, which bears US NIH Compound Identifier 4249. European Medicines Agency schedules moperone chlorohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09057MIG. Most nations, for tariff purposes, schedule moperone chlorohydrate under HS 29333999. SMILES: CC1CCC(CC1)C2(CCN(CC2)CCCC(=O)C3CCC(CC3)F)O.CL.
This classification denotes an anxiolytic C22H26FNO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z2633815T, chemically known as butyrophenone, 4'-fluoro-4-(4-hydroxy-4-p-tolylpiperidino)-, hydrochloride, but more generally known as moperone hydrochloride, which bears US NIH Compound Identifier 19747. European Medicines Agency schedules Moperone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03326MIG. Most nations, for tariff and trade purposes, schedule moperone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, MOPERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC(CC1)C2(CCN(CC2)CCCC(=O)C3CCC(CC3)F)O.CL.
This classification denotes an antihypertensive agent with the molecular formula C14H19N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96600S6GLK, chemically known as 4-(6-((2,5-dimethylpyrrol-1-yl)amino)-3-pyridazinyl)morpholine but generally known as mopidralazine, which bears US NIH Compound Identifier 71143. European Medicines Agency schedules Mopidralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09059MIG. The term MOPIDRALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). MOPIDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mopidralazine under HS 29349990 and SITC 51579. As of Q4 2014, MOPIDRALAZINE remains the US FDA Preferred Term for this commodity. Mopidralazine bears US NLM identifiers UMLS ID C0066788 and NCI Concept Code C66191. SMILES: O1CCN(CC1)c1nnc(Nn2c(ccc2C)C)cc1.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C22H25N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2GT1D0TMX1, chemically known as phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester but more generally known as moracizine, which bears US NIH Compound Identifier 34633. European Medicines Agency schedules Moracizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09062MIG. The term MORACIZINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules moracizine in its Anatomical Therapeutic Chemical (ATC) Classification. MORACIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, MORICIZINE remains US FDA's Preferred Term for this commodity. Moricizine bears US NLM identifiers UMLS ID C0079856 and NCI Concept Code C66196. SMILES: CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4.CL.
This classification denotes an antihelminthic agent with the molecular formula C12H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 7NJ031HAX5 chemically known as (e)-1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)pyrimidine but generally known as morantel, which bears US NIH Compound Identifier 5353792. European Medicines Agency schedules Morantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09063MIG. The term MORANTEL is an International Non-Proprietary Name or INN. Most nations schedule morantel under HS 29349990 and SITC 51579. As of Q4 2014, MORANTEL remains the US FDA Preferred Term for this commodity. Morantel bears US NLM identifiers UMLS ID C0026534 and NCI Concept Code C75221. SMILES: CC1=C(SC=C1)/C=C/C2=NCCCN2C.
This classification denotes an antihelminthic agent with the molecular formula C12H16N2S.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VC8Z4SS5QX, chemically known as pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-((1e)-2-(3-methyl-2-thienyl)ethenyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1), but more generally known as morantel citrate, which bears US NIH Compound Identifier 5702276. European Medicines Agency schedules morantel citrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09063MIG. Most nations, for tariff purposes, schedule morantel citrate under HS 29349990. SMILES: CC1CCSC1/C=C/C2=NCCCN2C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antihelminthic agent with the molecular formula C23H16O6.C12H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J33H52K3OO, chemically known as pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, 4,4'-methylenebis(3-hydroxy-2-naphthoate, (e)-, but more generally known as morantel pamoate, which bears US NIH Compound Identifier 6435816. European Medicines Agency schedules morantel pamoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09063MIG. Most nations, for tariff purposes, schedule morantel pamoate under HS 29349990. SMILES: CC1CCSC1/C=C/C2=NCCCN2C.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C12H16N2S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5WF7E9QC3F. The term morantel tartrate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule morantel tartrate under HS 29349990 and SITC 51579. As of Q4 2014, MORANTEL TARTRATE remains US FDA's Preferred Term for this commodity. Morantel tartrate bears US NLM identifiers UMLS ID C0026535 and NCI Concept Code C75222. SMILES: CC1CCSC1/C=C/C2=NCCCN2C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C23H27N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 870Q5BL2FN, chemically known as 1,2-dihydro-1,5-dimethyl-4-((3-methyl-2-phenyl-4-morpholinyl)methyl)-2-phenyl-3h-pyrazol-3-one but generally known as morazone, which bears US NIH Compound Identifier 39609. European Medicines Agency schedules Morazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09064MIG. The term MORAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). MORAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule morazone under HS 29349990 and SITC 51579. As of Q4 2014, MORAZONE remains the US FDA Preferred Term for this commodity. Morazone bears US NLM identifiers UMLS ID C0066795 and NCI Concept Code C66193. SMILES: O1C(C(N(CC1)CC1C(N(N(C1=O)C1CCCCC1)C)C)C)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C23H27N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EFJ5QS2AU5, chemically known as antipyrine, 4-(4-(3-methyl-2-phenylmorpholino)methyl)-, hydrochloride but more generally known as morazone hydrochloride, which bears US NIH Compound Identifier 39608. European Medicines Agency schedules Morazone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03329MIG. Most nations, for tariff and trade purposes, schedule morazone hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, MORAZONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1C(C(=O)N(N1C)C2CCCCC2)CN3CCOC(C3C)C4CCCCC4.CL.
This classification denotes an antitussive agent with the molecular formula C21H24ClNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) VY62TIB872, chemically known as 4-chloro-3,5-dimethoxy-4-(2-morpholinoethoxy)benzophenone but more generally known as morclofone, which bears US NIH Compound Identifier 35949. European Medicines Agency schedules Morclofone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09065MIG. The term MORCLOFONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules morclofone in its Anatomical Therapeutic Chemical (ATC) Classification. MORCLOFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule morclofone under HS 29349990 and SITC 51579. As of Q4 2014, MORCLOFONE remains US FDA's Preferred Term for this commodity. Morclofone bears US NLM identifiers UMLS ID C0066796 and NCI Concept Code C66194. SMILES: CLC1CCC(C(=O)C2CC(OC)C(OCCN3CCOCC3)C(OC)C2)CC1.
This classification denotes an anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) O9J6ITY8UX. European Medicines Agency schedules Morforex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09066MIG. Morforex generally arises in the molecular formula C15H24N2O. The term MORFOREX is an International Non-Proprietary Name or INN. MORFOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule morforex under HS 29349990 and SITC 51579. As of Q4 2014, MORFOREX remains US FDA's Preferred Term for this commodity. Morforex bears US NLM identifiers UMLS ID C1881900 and NCI Concept Code C66195. SMILES: O1CCN(CCNC(CC2CCCCC2)C)CC1.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C22H25N3O4S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 2GT1D0TMX1, chemically known as phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester but more generally known as moracizine, which bears U.S. National Institutes of Health Compound Identifier 34633. The European Medicines Agency schedules Moracizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09062MIG. The term MORACIZINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11). The World Health Organization schedules moracizine in its Anatomical Therapeutic Chemical (ATC) Classification. MORACIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4.CL.
This classification denotes an antitubercular agent C10H14N4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2F6F46T9YC, chemically known as 2-pyrazinecarboxamide, n-(4-morpholinylmethyl)-, hydrochloride (1:1), but more generally known as morinamide hydrochloride, which bears US NIH Compound Identifier 164837. European Medicines Agency schedules Morinamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03330MIG. Most nations, for tariff and trade purposes, schedule morinamide hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, MORINAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CNC(CN1)C(=O)NCN2CCOCC2.CL.
This classification denotes an antitubercular agent with the molecular formula C10H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8CFL28PA3W, chemically known as pyrazinecarboxamide, n-(morpholinomethyl)- but generally known as morinamide, which bears US NIH Compound Identifier 70374. European Medicines Agency schedules Morinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09067MIG. The term MORINAMIDE is an International Non-Proprietary Name. World Health Organization schedules morinamide in its Anatomical Therapeutic Chemical (ATC) Classification. MORINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C1COCCN1CNC(=O)C2=NC=CN=C2.
This classification denotes an anti-infective agent with the molecular formula C19H20F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R133MWH7X1, chemically known as 3-pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)-, 2-(4-morpholinylethyl) ester but generally known as morniflumate, which bears US NIH Compound Identifier 72106. European Medicines Agency schedules Morniflumate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09068MIG. The term MORNIFLUMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules morniflumate in its Anatomical Therapeutic Chemical (ATC) Classification. MORNIFLUMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule morniflumate under HS 29349990 and SITC 51579. As of Q4 2014, MORNIFLUMATE remains the US FDA Preferred Term for this commodity. Morniflumate bears US NLM identifiers UMLS ID C0066803 and NCI Concept Code C66198. SMILES: FC(F)(F)C1CC(NC2NCCCC2C(=O)OCCN2CCOCC2)CCC1.
This classification denotes a hemostatic agent with the molecular formula C3953H6020N1040O1158S29/C3553H5412N956O1028S33, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 113E3Z3CJJ, more generally known as moroctocog alfa. European Medicines Agency schedules moroctocog alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16445MIG. The term MOROCTOCOG ALFA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.
This classification denotes an anti-infective agent with the molecular formula C6H13N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O611591WAH, chemically known as 4-morpholinecarboximidamide, n- (aminoiminomethyl)-, monohydrochloride but generally known as moroxydine, which bears US NIH Compound Identifier 71655. European Medicines Agency schedules Moroxydine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09070MIG. The term MOROXYDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules moroxydine in its Anatomical Therapeutic Chemical (ATC) Classification. MOROXYDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moroxydine under HS 29349990 and SITC 51579. As of Q4 2014, MOROXYDINE remains the US FDA Preferred Term for this commodity. Moroxydine bears US NLM identifiers UMLS ID C0066805 and NCI Concept Code C66200. SMILES: O1CCN(CC1)C(=N)/N=C(/N)N.
This classification denotes an opiate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76I7G6D29C. European Medicines Agency schedules Morphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG. Morphine generally arises in the molecular formula C17H19NO3. The term MORPHINE is a Hazardous Substances Data Bank designation. Most nations schedule morphine under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE remains the US FDA Preferred Term for this commodity. Morphine bears US NLM identifiers UMLS ID C0026549 and NCI Concept Code C62051. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(O)CC3)C=CC2O.
This classification denotes an opiate with the molecular formula C29H25N3O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7A91YL2XT2, chemically known as morphinan-3,6.alpha.-diol, 7,8-didehydro-4,5.alpha.-epoxy-17-methyl-, dinicotinate (ester), hydrochloride, but more generally known as morphine dinicotinate hydrochloride, which bears US NIH Compound Identifier 166031. European Medicines Agency schedules morphine dinicotinate hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG. Most nations, for tariff purposes, schedule morphine dinicotinate hydrochloride under HS 29391100. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)OC(=O)C6CCCNC6)OC(=O)C7CCCNC7.CL.
This classification denotes an opioid receptor agonist with the molecular formula C17H19NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J28GE0ROVX, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, hydrochloride, (5-alpha,6-alpha)- but more generally known as morphine hydrochloride, which bears US NIH Compound Identifier 5464110. European Medicines Agency schedules Morphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14596MIG. Most nations, for tariff and trade purposes, schedule morphine hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Morphine hydrochloride bears US NLM identifiers UMLS ID C0770901 and NCI Concept Code C83973. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CL.
This classification denotes an opiate C17H19NO3.ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q5F3AS69LF, chemically known as morphinan-3,6.alpha.-diol, 7,8-didehydro-4,5.alpha.-epoxy-17-methyl-, hydrochloride, trihydrate, but more generally known as morphine hydrochloride trihydrate, which bears US NIH Compound Identifier 5492889. European Medicines Agency schedules Morphine hydrochloride trihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27294. Most nations, for tariff and trade purposes, schedule morphine hydrochloride trihydrate under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE HYDROCHLORIDE TRIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.O.O.O.CL.
This classification denotes an opiate C18H22NO3.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1A51P5NGGU, chemically known as morphinanium, 7,8-didehydro-4,5-epoxy-3,6-dihydroxy-17,17-dimethyl-, bromide, (5.alpha.,6.alpha.)-, but more generally known as morphine methylbromide, which bears US NIH Compound Identifier 5362445. Most nations, for tariff and trade purposes, schedule morphine methylbromide under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE METHYLBROMIDE remains US FDA's Preferred Term for this commodity. SMILES: C[N+]1(CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O)C.[BR-].
This classification denotes an opiate C17H19NO3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41TQ665R1X, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5-.alpha.,6-.alpha.)-, monohydrate, but more generally known as morphine monohydrate, which bears US NIH Compound Identifier 110750. Most nations, for tariff and trade purposes, schedule morphine monohydrate under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE MONOHYDRATE remains US FDA's Preferred Term for this commodity. Morphine monohydrate bears US NLM identifiers UMLS ID C2828280 and NCI Concept Code C87362. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes an opiate with the molecular formula C17H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E77NL2Y9I, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5.alpha.,6.alpha.)-, 17-oxide, but more generally known as morphine oxide, which bears US NIH Compound Identifier 5362459. European Medicines Agency schedules morphine oxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG. Most nations, for tariff purposes, schedule morphine oxide under HS 29391100. SMILES: C[N+]1(CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O)[O-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.
This classification denotes an opioid analgesic with the molecular formula 2C17H19NO3.5H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X3P646A2J0, chemically known as 7,8-didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol but more generally known as morphine sulfate, which bears US NIH Compound Identifier 5288826. European Medicines Agency schedules Morphine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14597MIG. Most nations, for tariff and trade purposes, schedule morphine sulfate under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE SULFATE remains US FDA's Preferred Term for this commodity. Morphine sulfate bears US NLM identifiers UMLS ID C0066814 and NCI Concept Code C669. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.O.O.O.O.O.OS(=O)(=O)O.
This classification denotes an opiate with the molecular formula 2C17H19NO3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DY70C97N30, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl, (5.alpha.,6.alpha.)-, sulfate (2:1) (salt), but more generally known as morphine sulfate anhydrous, which bears US NIH Compound Identifier 5359250. European Medicines Agency schedules morphine sulfate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG. Most nations, for tariff purposes, schedule morphine sulfate anhydrous under HS 29391100. Morphine sulfate anhydrous bears US NLM identifiers UMLS ID C2984003 and NCI Concept Code C91049. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.OS(=O)(=O)O.
This classification denotes an opiate with the molecular formula 2C17H19NO3.5H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X3P646A2J0, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl, (5.alpha.,6.alpha.)-, sulfate (2:1) (salt), pentahydrate, but more generally known as morphine sulfate pentahydrate, which bears US NIH Compound Identifier 6436139. European Medicines Agency schedules morphine sulfate pentahydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG. Most nations, for tariff purposes, schedule morphine sulfate pentahydrate under HS 29391100. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.O.O.O.O.O.OS(=O)(=O)O.
This classification denotes an opioid receptor agonist with the molecular formula 2C17H19NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3NSU23LHD. European Medicines Agency schedules morphine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14598MIG. The term morphine tartrate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule morphine tartrate under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an anticonvulsant agent with the molecular formula C16H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57G776P4EJ, chemically known as 2,5-pyrrolidinedione, 3-methyl-1-(4-morpholinylmethyl)-3-phenyl- (9ci) but generally known as morsuximide, which bears US NIH Compound Identifier 71165. European Medicines Agency schedules Morsuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09072MIG. The term MORSUXIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). MORSUXIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule morsuximide under HS 29349990 and SITC 51579. As of Q4 2014, MORSUXIMIDE remains the US FDA Preferred Term for this commodity. Morsuximide bears US NLM identifiers UMLS ID C1881904 and NCI Concept Code C66202. SMILES: O1CCN(CN2C(=O)C(CC2=O)(C2CCCCC2)C)CC1.
This classification denotes an antidepressant agent with the molecular formula C28H35ClN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04UZQ7O9SJ, chemically known as (- )-1-(3-(3-chloro-10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)hexahydrospiro(imidazo(1,2-a)pyridine-3(2h),4-piperidin)-2-one. but generally known as mosapramine, which bears US NIH Compound Identifier 4257. European Medicines Agency schedules Mosapramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09073MIG. The term MOSAPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules mosapramine in its Anatomical Therapeutic Chemical (ATC) Classification. MOSAPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mosapramine under HS 29333999 and SITC 51574. As of Q4 2014, MOSAPRAMINE remains the US FDA Preferred Term for this commodity. Mosapramine bears US NLM identifiers UMLS ID C0208216 and NCI Concept Code C66203. SMILES: Clc1cc2N(CCCN3CCC4(N5C(NC4=O)CCCC5)CC3)c3c(CCc2cc1)cccc3.
This classification denotes an antidepressant agent with the molecular formula C28H35ClN4O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M1W6HZL1X, chemically known as spiro(imidazo(1,2-a)pyridine-3(2h),4'-piperidin)-2-one, 1'-(3-(3-chloro-10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)hexahydro-, hydrochloride (1:2), but more generally known as mosapramine dihydrochloride, which bears US NIH Compound Identifier 656595. European Medicines Agency schedules mosapramine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09073MIG. Most nations, for tariff purposes, schedule mosapramine dihydrochloride under HS 29333999. SMILES: C1CCC2C(C1)CCC3CCC(CC3N2CCCN4CCC5(CC4)C(=O)NC6N5CCCC6)CL.CL.CL.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I8MFJ1C0BY. European Medicines Agency schedules Mosapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09074MIG. Mosapride generally arises in the molecular formula C21H25CLFN3O3. The term MOSAPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) MOSAPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mosapride under HS 29349990 and SITC 51579. As of Q4 2014, MOSAPRIDE remains the US FDA Preferred Term for this commodity. Mosapride bears US NLM identifiers UMLS ID C0526501 and NCI Concept Code C66204. SMILES: Clc1cc(C(=O)NCC2OCCN(C2)Cc2ccc(F)cc2)c(OCC)cc1N.
This classification denotes an antidepressant agent with the molecular formula C21H25ClFN3O3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MF497J489P, chemically known as (+/-)-4-amino-5-chloro-2-ethoxy-n-((4-(p-fluorobenzyl)-2-morpholinyl)methyl)benzamide citrate, but more generally known as mosapride citrate, which bears US NIH Compound Identifier 119583. European Medicines Agency schedules mosapride citrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09074MIG. Most nations, for tariff purposes, schedule mosapride citrate under HS 29349990. SMILES: CCOC1CC(C(CC1C(=O)NCC2CN(CCO2)CC3CCC(CC3)F)CL)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H12N4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4A61P8A37, chemically known as 3(2h)-pyridazinone, 4,5-dihydro-6-(4-imidazol-1-yl-2-thienyl)-5-methyl- but generally known as motapizone, which bears US NIH Compound Identifier 65819. European Medicines Agency schedules Motapizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09075MIG. The term MOTAPIZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). MOTAPIZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule motapizone under HS 29349990 and SITC 51579. As of Q4 2014, MOTAPIZONE remains the US FDA Preferred Term for this commodity. Motapizone bears US NLM identifiers UMLS ID C0066826 and NCI Concept Code C66205. SMILES: CC1CC(=O)NN=C1C2=CC(=CS2)N3C=CN=C3.
This classification denotes an anxiolytic with the molecular formula C17H15N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36YG4ZMR69, chemically known as 2,3-dihydro-1-(methoxymethyl)-7-nitro-5-phenyl-1h-1,4-benzodiazepin-2-on but generally known as motrazepam, which bears US NIH Compound Identifier 65764. European Medicines Agency schedules Motrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09076MIG. The term MOTRAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). MOTRAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule motrazepam under HS 29339940 and SITC 51577. As of Q4 2014, MOTRAZEPAM remains the US FDA Preferred Term for this commodity. Motrazepam bears US NLM identifiers UMLS ID C0073449 and NCI Concept Code C66206. SMILES: O(CN1C2C(C(=NCC1=O)C1CCCCC1)CC([N](=O)O)CC2)C.
This classification denotes a retinoic acid agent with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W786807KL1, chemically known as 2,4,6,8-nonatetraenamide, n-ethyl-9- (4-methoxy-2,3, 6-trimethylphenyl)-3,7-dimethyl-, (all-e)- but generally known as motretinide, which bears US NIH Compound Identifier 41827. European Medicines Agency schedules Motretinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09077MIG. The term MOTRETINIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules motretinide in its Anatomical Therapeutic Chemical (ATC) Classification. MOTRETINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule motretinide under HS 29242995 and SITC 51479. As of Q4 2014, MOTRETINIDE remains the US FDA Preferred Term for this commodity. Motretinide bears US NLM identifiers UMLS ID C0129022 and NCI Concept Code C90940. SMILES: O(C1C(C(C(C(C1)C)/C=C/C(=C/C=C/C(=C/C(=O)NCC)C)C)C)C)C.
This classification denotes an ace inhibitor with the molecular formula C19H30N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LQI0441316, chemically known as (-)-1-((2s)-3-mercapto-2-methylpropionyl)-l-proline, ester with n-(cyclohexyl-carbonyl)thio-d-alanine. but generally known as moveltipril, which bears US NIH Compound Identifier 5745793. European Medicines Agency schedules Moveltipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09078MIG. The term MOVELTIPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). MOVELTIPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moveltipril under HS 29339990 and SITC 51577. As of Q4 2014, MOVELTIPRIL remains the US FDA Preferred Term for this commodity. Moveltipril bears US NLM identifiers UMLS ID C2981287 and NCI Concept Code C87574. SMILES: S(CC(C(=O)N1C(CCC1)C(=O)O)C)C(=O)C(NC(=O)C1CCCCC1)C.
This classification denotes an ace inhibitor with the molecular formula 2C19H29N2O5S.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SB44S25HE5, chemically known as l-proline, n-(cyclohexylcarbonyl)-d-alanyl-(2s)-3-mercapto-2-methylpropanoyl-, calcium salt (2:1), but more generally known as moveltipril calcium, which bears US NIH Compound Identifier 6336573. European Medicines Agency schedules moveltipril calcium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09078MIG. Most nations, for tariff purposes, schedule moveltipril calcium under HS 29339990. SMILES: C[C@H](CSC(=O)[C@@H](C)NC(=O)C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)[O-].C[C@H](CSC(=O)[C@@H](C)NC(=O)C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)[O-].[CA+2].
This classification denotes a beta-lactam antibiotic with the molecular structure C20H18N6O9S.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5APW73W3QZ chemically known as 5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, disodium salt, but more commonly known as moxalactam disodium, which bears US NIH Compound Identifier 47500. European Medicines Agency schedules Moxalactam disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02867MIG. Most nations, for tariff and trade purposes, schedule moxalactam disodium under HS 29419000. As of Q4 2014, MOXALACTAM DISODIUM remains US FDA's Preferred Term for this commodity. Moxalactam disodium bears US NLM identifiers UMLS ID C0813197 and NCI Concept Code C66207. SMILES: CN1C(NNN1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4CCC(CC4)O)C(=O)[O-])OC)OC2)C(=O)[O-].[NA+].[NA+].
This classification denotes an antispasmotic agent C20H21NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6R0I0E99CN, chemically known as 1-benzyl-6,7-dimethoxy-3-ethylisoquinoline hydrochloride, but more generally known as moxaverine hydrochloride, which bears US NIH Compound Identifier 70881. European Medicines Agency schedules Moxaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03341MIG. Most nations, for tariff and trade purposes, schedule moxaverine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, MOXAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCC1CC2CC(C(CC2C(N1)CC3CCCCC3)OC)OC.CL.
This classification denotes an antispasmotic agent with the molecular formulas C20H21NO2 and C20H21NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers P3P08Y1XJ4, chemically known as 3-ethyl-1-benzyl-6,7-dimethoxyisoquinoline but generally known as moxaverine, which bears US NIH Compound Identifier 70882. European Medicines Agency schedules Moxaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB09082MIG and SUB03341MIG. The term MOXAVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules moxaverine in its Anatomical Therapeutic Chemical (ATC) Classification. MOXAVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxaverine and its salts under HS 29334990 and SITC 51575. As of Q4 2014, MOXAVERINE remains the US FDA Preferred Term for this commodity. Moxaverine bears US NLM NCI C66209. SMILES: O(C1CC2C(NC(CC2CC1OC)CC)CC1CCCCC1)C (base) and CCC1CC2CC(C(CC2C(N1)CC3CCCCC3)OC)OC.CL (hydrochloride).
This classification denotes an analgesic agent with the molecular formula C18H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BNB57S7DWT, chemically known as 2,6-methano-3-benzazocin-8-ol, 3-(cyclopropyl-methyl)-1,2,3,4,5,6-hexahydro-11-methoxy-6-methyl-,(2r-(2 alpha, 6 alpha, 11r*))-; but generally known as moxazocine, which bears US NIH Compound Identifier 3047776. European Medicines Agency schedules Moxazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09083MIG. The term MOXAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). MOXAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxazocine under HS 29333999 and SITC 51574. As of Q4 2014, MOXAZOCINE remains the US FDA Preferred Term for this commodity. Moxazocine bears US NLM identifiers UMLS ID C2983815 and NCI Concept Code C90644. SMILES: O(C1C2(CCN(C1CC1C2CC(O)CC1)CC1CC1)C)C.
This classification denotes a therapeutic estrogen with the molecular formula C21H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6923NT44OW, chemically known as 19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 11-methoxy-, (11-beta,17-alpha)- (9ci) but generally known as moxestrol, which bears US NIH Compound Identifier 71714. European Medicines Agency schedules Moxestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14601MIG. The term MOXESTROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules moxestrol in its Anatomical Therapeutic Chemical (ATC) Classification. MOXESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxestrol under HS 29372300 and SITC 54153. As of Q4 2014, MOXESTROL remains the US FDA Preferred Term for this commodity. Moxestrol bears US NLM identifiers UMLS ID C0066834 and NCI Concept Code C87229. SMILES: OC1(C2(C(C3C(C(OC)C2)c2c(CC3)cc(O)cc2)CC1)C)C#C.
This classification denotes an anticoagulant agent with the molecular formula C22H30N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IG2442S013, chemically known as 4-methyl-5,7-bis(2-morpholinoethylethoxy)coumarin but generally known as moxicoumone, which bears US NIH Compound Identifier 65686. European Medicines Agency schedules Moxicoumone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09084MIG. The term MOXICOUMONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). MOXICOUMONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxicoumone under HS 29349990 and SITC 51579. As of Q4 2014, MOXICOUMONE remains the US FDA Preferred Term for this commodity. Moxicoumone bears US NLM identifiers UMLS ID C0066835 and NCI Concept Code C66210. SMILES: O1CCN(CC1)CCOC1C2C(OC(=O)CC2C)CC(OCCN2CCOCC2)C1.
This classification denotes an antiparasitic agent with the molecular formula C37H53NO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NGU5H31YO9, chemically known as milbemycin b, 5-o-demethyl-28-deoxy-25-((1e)-1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-, (6r,23e,25s)- but generally known as moxidectin, which bears US NIH Compound Identifier 9571036. European Medicines Agency schedules Moxidectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09085MIG. The term MOXIDECTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). MOXIDECTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, MOXIDECTIN remains the US FDA Preferred Term for this commodity. Moxidectin bears US NLM identifiers UMLS ID C0163557 and NCI Concept Code C73264. SMILES: O1C2(OC(C(C(=N\OC)\C2)C)/C(=C/C(C)C)C)CC2OC(=O)C3C4(O)C(OCC4=CC=CC(CC(=CCC1C2)C)C)C(O)C(=C3)C.
This classification denotes a quinolone antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U188XYD42P. European Medicines Agency schedules Moxifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09086MIG. Moxifloxacin generally arises in the molecular formula C21H24FN3O4. The term MOXIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) MOXIFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxifloxacin under HS 29334910 and SITC 51575. As of Q4 2014, MOXIFLOXACIN remains the US FDA Preferred Term for this commodity. Moxifloxacin bears US NLM identifiers UMLS ID C0536495 and NCI Concept Code C62052. SMILES: FC1C(N2CC3C(NCCC3)C2)C(OC)C2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes an antimalarial agent with the molecular formula C24H38N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GP95SEQ1AQ, chemically known as 1-piperazinepropanol, 4-(6-((6-methoxy-8-quinolyl)amino)hexyl)-alpha-methyl- but generally known as moxipraquine, which bears US NIH Compound Identifier 72091. European Medicines Agency schedules Moxipraquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09088MIG. The term MOXIPRAQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). MOXIPRAQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxipraquine under HS 29335995 and SITC 51576. As of Q4 2014, MOXIPRAQUINE remains the US FDA Preferred Term for this commodity. Moxipraquine bears US NLM identifiers UMLS ID C0611649 and NCI Concept Code C87633. SMILES: OC(CCN1CCN(CC1)CCCCCCNC1C2NCCCC2CC(OC)C1)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C16H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PW8QYA7KI0, chemically known as phenol, 4-(2-(dimethylamino)ethoxy)-2-methyl-5-(1-methylethyl)-, acetate (ester) but generally known as moxisylyte, which bears US NIH Compound Identifier 4260. European Medicines Agency schedules Moxisylyte in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09090MIG. The term MOXISYLYTE is an International Non-Proprietary Name. World Health Organization schedules moxisylyte in its Anatomical Therapeutic Chemical (ATC) Classification. MOXISYLYTE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxisylyte under HS 29221980 and SITC 51461. As of Q4 2014, MOXISYLYTE remains the US FDA Preferred Term for this commodity. Moxisylyte bears US NLM identifiers UMLS ID C0040108 and NCI Concept Code C87584. SMILES: O(C1C(C(C)C)CC(OC(=O)C)C(C1)C)CCN(C)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C16H25NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WK2KZM9V6X, chemically known as phenol, 4-(2-(dimethylamino)ethoxy)-2-methyl-5-(1-methylethyl)-, acetate (ester) but more generally known as moxisylyte hydrochloride, which bears US NIH Compound Identifier 4260. European Medicines Agency schedules Moxisylyte hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03343MIG. Most nations, for tariff and trade purposes, schedule moxisylyte hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, MOXISYLYTE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Moxisylyte hydrochloride bears US NLM identifiers UMLS ID C1563915 and NCI Concept Code C87585. SMILES: CC1CC(C(CC1OC(=O)C)C(C)C)OCCN(C)C.CL.
This classification denotes an antiprotozoal agent with the molecular formula C13H18N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J21260BCQ, chemically known as 2-oxazolidinone, 3-(((1-methyl-5-nitro-1h-imidazol-2-yl)methylene)amino)-5-(4-morpholinylmethyl)- but generally known as moxnidazole, which bears US NIH Compound Identifier 9571039. European Medicines Agency schedules Moxnidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09091MIG. The term MOXNIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). MOXNIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxnidazole under HS 29349990 and SITC 51579. As of Q4 2014, MOXNIDAZOLE remains the US FDA Preferred Term for this commodity. Moxnidazole bears US NLM identifiers UMLS ID C0066836 and NCI Concept Code C90756. SMILES: O1C(CN2CCOCC2)CN(/N=C/C2N(C([N](=O)O)CN2)C)C1=O.
This classification denotes an antihypertensive agent with the molecular formula C9H12ClN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CC6X0L40GW, chemically known as 5-pyrimidinamine, 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl- (9ci) but generally known as moxonidine, which bears US NIH Compound Identifier 4810. European Medicines Agency schedules Moxonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09092MIG. The term MOXONIDINE is an International Non-Proprietary Name. World Health Organization schedules moxonidine in its Anatomical Therapeutic Chemical (ATC) Classification. MOXONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxonidine under HS 29335995 and SITC 51576. As of Q4 2014, MOXONIDINE remains the US FDA Preferred Term for this commodity. Moxonidine bears US NLM identifiers UMLS ID C0066837 and NCI Concept Code C87629. SMILES: Clc1nc(nc(OC)c1NC1=NCCN1)C.
This classification denotes an antihypertensive agent with the molecular formula C9H12ClN5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RYW07SK5E, chemically known as 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine hydrochloride, but more generally known as moxonidine hydrochloride, which bears US NIH Compound Identifier 156339. European Medicines Agency schedules moxonidine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09092MIG. Most nations, for tariff purposes, schedule moxonidine hydrochloride under HS 29335995. SMILES: CC1NC(C(C(N1)CL)NC2=NCCN2)OC.CL.
This classification denotes a protease inhibitor with the molecular formula C33H36N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64OO8946ER. The term MOZENAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46. ). Most nations schedule mozenavir under HS 29339940 and SITC 51577. As of Q4 2014, MOZENAVIR remains the US FDA Preferred Term for this commodity. Mozenavir bears US NLM identifiers UMLS ID C0390428 and NCI Concept Code C77390. SMILES: C1=CC=C(C=C1)CC2C(C(C(N(C(=O)N2CC3=CC(=CC=C3)N)CC4=CC(=CC=C4)N)CC5=CC=CC=C5)O)O.
This classification denotes alkalinizing agents composed of mixtures of substances that dissociate into two or more ions, to some extent, in water.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.
This classification denotes a vaccine for an acute infectious disease caused by rubulavirus, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected.
This classification denotes a topical anti-infective agent with the molecular formula C26H44O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0GX863OA5, chemically known as 8-carboxyoctyl (e)-4-(2s,3r,4r,5s)-5-((2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2h-pyran-2-yl)-3-methylcrotonat but more generally known as mupirocin, which bears US NIH Compound Identifier 446596. European Medicines Agency schedules Mupirocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09093MIG. The term MUPIROCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). The World Health Organization schedules mupirocin in its Anatomical Therapeutic Chemical (ATC) Classification. MUPIROCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1C(C1C(C(O)C)C)CC1C(O)C(O)C(OC1)C/C(=C/C(=O)OCCCCCCCCC(=O)O)C.
This classification denotes a topical anti-infective agent with the molecular structure 2C26H43O9.CA.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, RG38I2P540 chemically known as (.alpha.e,2s,3r,4r,5s)-5-((2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl)tetrahydro-3,4-dihydroxy-.beta.-methyl-2h-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate, but more commonly known as mupirocin calcium, which bears US NIH Compound Identifier 5282317. European Medicines Agency schedules Mupirocin calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14612MIG.
This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6460H9946N1720O2043S56, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGA39ICE2V, more generally known as muromonab cd3. European Medicines Agency schedules muromonab cd3 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03355MIG. The term MUROMONAB CD3 is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 3, no. 3, 1989, list 29. SMILES: NONE.
This classification denotes an antihypertensive agent and diuretic with the molecular formula C11H11Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 07Z36289ZX, chemically known as 5-amino-2-(1-(3,4-dichlorophenyl)-ethyl)-2,4-dihydro-3h-pyrazol-3-one but generally known as muzolimine, which bears US NIH Compound Identifier 41386. European Medicines Agency schedules Muzolimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09097MIG. World Health Organization schedules muzolimine in its Anatomical Therapeutic Chemical (ATC) Classification. MUZOLIMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule muzolimine under HS 29331990 and SITC 51571. As of Q4 2014, MUZOLIMINE remains the US FDA Preferred Term for this commodity. SMILES: CC(C1=CC(=C(C=C1)Cl)Cl)N2C(=O)CC(=N2)N.
This classification denotes an inosine monophosphate dehydrogenase inhibitor and immunosuppressant, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 9242ECW6R0. European Medicines Agency schedules Mycophenolate mofetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03360MIG. Mycophenolate mofetil generally arises in the molecular formula C23H31NO7. The term 'mycophenolate mofetil' is a United States Adopted Name designation. Mycophenolate mofetil bears US NLM identifiers UMLS ID C0209368 and NCI Concept Code C1468. Most nations, for tariff and trade purposes, schedule mycophenolate mofetil under 29419000 and SITC 54139. SMILES: CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC.
This classification denotes an inosine monophosphate dehydrogenase inhibitor and immunosuppressant with the molecular formula C23H31NO7.ClH, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier UXH81S8ZVB, chemically known as 4-hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, hydrochloride, (e)- but more generally known as mycophenolate mofetil hydrochloride, which bears US NIH Compound Identifier 6441022. European Medicines Agency schedules Mycophenolate mofetil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32913. Mycophenolate mofetil hydrochloride bears US NLM identifiers UMLS ID C0772450 and NCI Concept Code C61852. Most nations, for tariff and trade purposes, schedule mycophenolate mofetil hydrochloride under 29419000 and SITC 54139. SMILES: CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC.Cl.
This classification denotes an inosine monophosphate dehydrogenase inhibitor and immunosuppressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9242ECW6R0. European Medicines Agency schedules Mycophenolate mofetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03360MIG. Mycophenolate mofetil generally arises in the molecular formula C23H31NO7. Mycophenolate or mycophenolic acid bears US NLM identifiers UMLS ID C0883242 and NCI Concept Code C29272. Most nations, for tariff and trade purposes, schedule this comodity under HS 29419000 and SITC 54139. SMILES: O1CCN(CC1)CCOC(=O)CC/C(=C/CC1C(OC)C(C2C(C1O)C(=O)OC2)C)C.
This classification denotes an anesthetic agent with the molecular formula C17H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9902116282, chemically known as 2-(2-(6,6-dimethylbicyclo(3.1.1)hept-2-en-2-yl)ethoxy)-n,n-diethylethanamine but generally known as myrtecaine, which bears US NIH Compound Identifier 71851. European Medicines Agency schedules Myrtecaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09102MIG. The term MYRTECAINE is an International Non-Proprietary Name. MYRTECAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule myrtecaine under HS 29221980 and SITC 51461. As of Q4 2014, MYRTECAINE remains the US FDA Preferred Term for this commodity. Myrtecaine bears US NLM identifiers UMLS ID C0163061 and NCI Concept Code C90653. SMILES: O(CCC1=CCC2C(C1C2)(C)C)CCN(CC)CC.
This classification denotes an antiemetic agent with the molecular formula C24H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2N4O9L084N, chemically known as 9h-dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, trans-(.+/-.)- but generally known as nabilone, which bears US NIH Compound Identifier 39860. European Medicines Agency schedules Nabilone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09104MIG. The term NABILONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules nabilone in its Anatomical Therapeutic Chemical (ATC) Classification. NABILONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nabilone under HS 29329985 and SITC 51569. As of Q4 2014, NABILONE remains the US FDA Preferred Term for this commodity. Nabilone bears US NLM identifiers UMLS ID C1263104 and NCI Concept Code C1171. SMILES: O1C(C2C(CC(=O)CC2)C2C1CC(C(CCCCCC)(C)C)CC2O)(C)C.
This classification denotes a nonsteroidal antiinflammatory drug and naphthalene compound with the molecular formula C15H16O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LW0TIW155Z, chemically known as 2-butanone, 4-(6-methoxy-2-naphthalenyl)- but generally known as nabumetone, which bears US NIH Compound Identifier 4409. European Medicines Agency schedules Nabumetone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09107MIG. The term NABUMETONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules nabumetone in its Anatomical Therapeutic Chemical (ATC) Classification. NABUMETONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nabumetone under HS 29145000 and SITC 51629. As of Q4 2014, NABUMETONE remains the US FDA Preferred Term for this commodity. Nabumetone bears US NLM identifiers UMLS ID C0701331 and NCI Concept Code C47627. SMILES: O(C1CC2C(CC(CCC(=O)C)CC2)CC1)C.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FEN504330V. European Medicines Agency schedules Nadolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09111MIG. Nadolol generally arises in the molecular formula C17H27NO4. The term NADOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) NADOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nadolol under HS 29221980 and SITC 51461. As of Q4 2014, NADOLOL remains the US FDA Preferred Term for this commodity. Nadolol bears US NLM identifiers UMLS ID C0027302 and NCI Concept Code C29280. SMILES: CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O.
This classification denotes a low molecular weight heparin with the molecular formula (C14H18NO11)N.2(C12H16NO13S)N.3HO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K5KDI46KZ. European Medicines Agency schedules nadroparin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03371MIG. As of Q4 2014, NADROPARIN remains the US FDA Preferred Term for this commodity. SMILES: C(C1C(C(C(C(O1)O)NS(=O)(=O)[O-])O)OC2C(C(C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-].
This classification denotes a gonadotropin-releasing hormone analog with the molecular formula C66H83N17O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1X0094V6JV, chemically known as luteinizing hormone-releasing factor (pig), 6-(3-(2-naphthalenyl)-d-alanine)- but generally known as nafarelin, which bears US NIH Compound Identifier 16129618. European Medicines Agency schedules Nafarelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09115MIG. The term NAFARELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules nafarelin in its Anatomical Therapeutic Chemical (ATC) Classification. NAFARELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nafarelin under HS 29371900 and SITC 54154. As of Q4 2014, NAFARELIN remains the US FDA Preferred Term for this commodity. Nafarelin bears US NLM identifiers UMLS ID C0064906 and NCI Concept Code C61613. SMILES: O=C(N1C(CCC1)C(=O)NCC(=O)N)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1NC[NH]C1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)CC1CC2C(CC1)CCCC2)CC(C)C)CCCNC(=N)N.
This classification denotes a beta-lactam antibiotic with the molecular formula C21H22N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CNZ27M7RV, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo- but generally known as nafcillin, which bears US NIH Compound Identifier 8982. European Medicines Agency schedules Nafcillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09118MIG. The term NAFCILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). NAFCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nafcillin under HS 29411090 and SITC 54131. As of Q4 2014, NAFCILLIN remains the US FDA Preferred Term for this commodity. Nafcillin bears US NLM identifiers UMLS ID C0027324 and NCI Concept Code C62053. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C1C2C(CCC1OCC)CCCC2.
This classification denotes an anti-bacterial agent with the molecular formula C21H21N2O5S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49G3001BCK, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo- but more generally known as nafcillin sodium, which bears US NIH Compound Identifier 8982. European Medicines Agency schedules Nafcillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03375MIG. Most nations, for tariff and trade purposes, schedule nafcillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, NAFCILLIN SODIUM remains US FDA's Preferred Term for this commodity. Nafcillin sodium bears US NLM identifiers UMLS ID C0037531 and NCI Concept Code C29281. SMILES: CCOC1CCC2CCCCC2C1C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[NA+].
This classification denotes a beta-lactam antibiotic with the molecular formula C21H21N2O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SY07234TTS, chemically known as sodium 6-(2-ethoxy-1-naphthamido)penicillanate, but more generally known as nafcillin sodium anhydrous, which bears US NIH Compound Identifier 64712. European Medicines Agency schedules nafcillin sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09118MIG. Most nations, for tariff purposes, schedule nafcillin sodium anhydrous under HS 29411090. Nafcillin sodium anhydrous bears US NLM identifiers UMLS ID C2698426 and NCI Concept Code C76224. SMILES: CCOC1CCC2CCCCC2C1C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[NA+].
This classification denotes a beta-lactam antibiotic with the molecular formula C21H21N2O5S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49G3001BCK, chemically known as monosodium (2s,5r,6r)-6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate monohydrate, but more generally known as nafcillin sodium monohydrate, which bears US NIH Compound Identifier 5282391. European Medicines Agency schedules nafcillin sodium monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09118MIG. Most nations, for tariff purposes, schedule nafcillin sodium monohydrate under HS 29411090. SMILES: CCOC1CCC2CCCCC2C1C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[NA+].
This classification denotes an antidepressant agent with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O501R1CSQ, chemically known as 1(2h)-naphthalenone, 3,4-dihydro-2-(2-(dimethylamino)ethyl)-2-phenyl-, (s)- but generally known as nafenodone, which bears US NIH Compound Identifier 65834. European Medicines Agency schedules Nafenodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09119MIG. The term NAFENODONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). NAFENODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nafenodone under HS 29223900 and SITC 51463. As of Q4 2014, NAFENODONE remains the US FDA Preferred Term for this commodity. Nafenodone bears US NLM identifiers UMLS ID C0131796 and NCI Concept Code C72821. SMILES: O=C1C(CCc2c1cccc2)(CCN(C)C)c1ccccc1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C19H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MAL2XF17MP, chemically known as 1,4-ethanonaphthalen-5-ol, 8-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, but generally known as nafetolol, which bears US NIH Compound Identifier 68668. European Medicines Agency schedules Nafetolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09121MIG. The term NAFETOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). NAFETOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nafetolol under HS 29221980 and SITC 51461. As of Q4 2014, NAFETOLOL remains the US FDA Preferred Term for this commodity. Nafetolol bears US NLM identifiers UMLS ID C2983886 and NCI Concept Code C90799. SMILES: O(C1C2C3CCC(CC3)C2C(O)CC1)CC(O)CNC(C)(C)C.
This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HZU3IQ1EWW, chemically known as 2-imidazol-1-yl-1-naphthalen-2-ylethanone but generally known as nafimidone, which bears US NIH Compound Identifier 51200. European Medicines Agency schedules nafimidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09122MIG. The term NAFIMIDONE is an International Non-Proprietary Name or INN. Most nations schedule nafimidone under HS 29332990 and SITC 51573. As of Q4 2014, NAFIMIDONE remains the US FDA Preferred Term for this commodity. SMILES: C1=CC=C2C=C(C=CC2=C1)C(=O)CN3C=CN=C3.
This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LU0A7HD640, chemically known as 2-acetonaphthone, 2-(1-imidazolyl)-, hydrochloride but more generally known as nafimidone hydrochloride, which bears US NIH Compound Identifier 51199. Most nations, for tariff and trade purposes, schedule nafimidone hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, NAFIMIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nafimidone hydrochloride bears US NLM identifiers UMLS ID C2983843 and NCI Concept Code C90708. SMILES: C1CCC2CC(CCC2C1)C(=O)CN3CCNC3.CL.
This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B52439Y33, chemically known as 9-fluoro-1,4-dihydro-11beta,21-dihydroxy-2betah-naphtho(2,3:16,17)pregna-1,4-diene-3,20-dione but generally known as naflocort, which bears US NIH Compound Identifier 64767. European Medicines Agency schedules Naflocort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09124MIG. NAFLOCORT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naflocort under HS 29372200 and SITC 54153. As of Q4 2014, NAFLOCORT remains the US FDA Preferred Term for this commodity. Naflocort bears US NLM identifiers UMLS ID C0625989 and NCI Concept Code C90956. SMILES: FC12C(C3C(C4(C(C3)CC3C(C4)CCCC3)C(=O)CO)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1V2C47TW7H, chemically known as 2'h-naphtho(2',3':16,17)pregna-1,4-diene-3,20-dione, 9-fluoro-1',4'-dihydro-11,21-dihydroxy-, (11.beta.,16.beta.)-, but more generally known as naflocort anhydrous, which bears US NIH Compound Identifier 64767. European Medicines Agency schedules naflocort anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09124MIG. Most nations, for tariff purposes, schedule naflocort anhydrous under HS 29372200. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(CC5CCCCC5C4)C(=O)CO)CCC6=CC(=O)C=C[C@@]63C)F)O.
This classification denotes a vasodilating agent and serotonin antagonist with the molecular formula C24H33NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42H8PQ0NMJ, chemically known as 2-furanpropionic acid, tetrahydro-.alpha.-(1-naphthylmethyl)-, 2-(diethylamino)ethyl esteroxalate (1:1) but generally known as nafronyl, which bears US NIH Compound Identifier 4417. European Medicines Agency schedules Naftidrofuryl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09130MIG. The term NAFTIDROFURYL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules nafronyl in its Anatomical Therapeutic Chemical (ATC) Classification. Nafronyl or naftidrofuryl bears US NLM identifiers UMLS ID C0027329 and NCI Concept Code C87212. SMILES: CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32.
This classification denotes an antihelminthic agent with the molecular formula C16H16NO6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H5IT2P8H5I, chemically known as 1h-benz(de)isoquinoline-1,3(2h)-dione, 2-((diethoxyphosphinyl)oxy)- but generally known as naftalofos, which bears US NIH Compound Identifier 15148. European Medicines Agency schedules Naftalofos in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09128MIG. The term NAFTALOFOS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). NAFTALOFOS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naftalofos under HS 29299000 and SITC 51489. As of Q4 2014, NAFTALOFOS remains the US FDA Preferred Term for this commodity. Naftalofos bears US NLM identifiers UMLS ID C0068365 and NCI Concept Code C90727. SMILES: P(=O)(ON1C(=O)C2C3C(C1=O)CCCC3CCC2)(OCC)OCC.
This classification denotes a vasodilating agent and serotonin antagonist with the molecular formula C24H33NO3.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ADB8D9388, chemically known as 2-furanpropionic acid, tetrahydro-.alpha.-(1-naphthylmethyl)-, 2-(diethylamino)ethyl esteroxalate (1:1) but more generally known as nafronyl oxalate, which bears US NIH Compound Identifier 4417. European Medicines Agency schedules Nafronyl oxalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20719. Most nations, for tariff and trade purposes, schedule naftidrofuryl hydrogen oxalate under HS 29321900. SMILES: CCN(CC)CCOC(=O)C(CC1CCCC2C1CCCC2)CC3CCCO3.C(=O)(C(=O)O)O.
This classification denotes a vasodilating agent and serotonin antagonist with the molecular formula C24H33NO3.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ADB8D9388, chemically known as 2-furanpropionic acid, tetrahydro-.alpha.-(1-naphthylmethyl)-, 2-(diethylamino)ethyl esteroxalate (1:1) but more generally known as nafronyl oxalate, which bears US NIH Compound Identifier 4417. European Medicines Agency schedules Nafronyl oxalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20719. Most nations, for tariff and trade purposes, schedule naftidrofuryl oxalate under HS 29321900. SMILES: CCN(CC)CCOC(=O)C(CC1CCCC2C1CCCC2)CC3CCCO3.C(=O)(C(=O)O)O.
This classification denotes an antifungal agent with the molecular formula C21H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4FB1TON47A, chemically known as 1-naphthalenemethanamine, n-methyl-n-(3-phenyl-2-propenyl)-, (e)- but generally known as naftifine, which bears US NIH Compound Identifier 47641. European Medicines Agency schedules Naftifine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09131MIG. The term NAFTIFINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules naftifine in its Anatomical Therapeutic Chemical (ATC) Classification. NAFTIFINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naftifine under HS 29214980 and SITC 51454. As of Q4 2014, NAFTIFINE remains the US FDA Preferred Term for this commodity. Naftifine bears US NLM identifiers UMLS ID C0068367 and NCI Concept Code C66217. SMILES: N(CC1C2C(CCC1)CCCC2)(C/C=C/C1CCCCC1)C.
This classification denotes an antifungal agent with the molecular formula C21H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25UR9N9041, chemically known as 1-naphthalenemethanamine, n-methyl-n-(3-phenyl-2-propenyl)-, hydrochloride, (e)- but more generally known as naftifine hydrochloride, which bears US NIH Compound Identifier 5281098. European Medicines Agency schedules Naftifine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03377MIG. Most nations, for tariff and trade purposes, schedule naftifine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, NAFTIFINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Naftifine hydrochloride bears US NLM identifiers UMLS ID C0304594 and NCI Concept Code C47628. SMILES: CN(C/C=C/C1CCCCC1)CC2CCCC3C2CCCC3.CL.
This classification denotes an antiplatelet agent and alpha-adrenergic blocking agent with the molecular formula C24H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9PHW59SFN, chemically known as 1-pioerazineethanol, 4-(2-methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)- but generally known as naftopidil, which bears US NIH Compound Identifier 4418. European Medicines Agency schedules Naftopidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09132MIG. The term NAFTOPIDIL is an International Non-Proprietary Name. NAFTOPIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naftopidil under HS 29335995 and SITC 51576. As of Q4 2014, NAFTOPIDIL remains the US FDA Preferred Term for this commodity. Naftopidil bears US NLM identifiers UMLS ID C0083701 and NCI Concept Code C72927. SMILES: OC(CN1CCN(CC1)C1C(OC)CCCC1)COC1C2C(CCC1)CCCC2.
This classification denotes an antiplatelet agent and alpha-adrenergic blocking agent with the molecular formula C24H28N2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6I80E37JBE, chemically known as naftopidil dihydrochloride, (+/-)-, but more generally known as naftopidil dihydrochloride, which bears US NIH Compound Identifier 6603044. European Medicines Agency schedules naftopidil dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09132MIG. Most nations, for tariff purposes, schedule naftopidil dihydrochloride under HS 29335995. SMILES: COC1CCCCC1N2CCN(CC2)CC(COC3CCCC4C3CCCC4)O.CL.CL.
This classification denotes an opioid receptor agonist and opioid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L2T84IQI2K. European Medicines Agency schedules Nalbuphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09137MIG. Nalbuphine generally arises in the molecular formula C21H27NO4. The term NALBUPHINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) NALBUPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nalbuphine under HS 29391900 and SITC 54141. As of Q4 2014, NALBUPHINE remains the US FDA Preferred Term for this commodity. Nalbuphine bears US NLM identifiers UMLS ID C0027348 and NCI Concept Code C61854. SMILES: O1C2C34C(O)(C(N(CC3)CC3CCC3)CC3C4C1C(O)CC3)CCC2O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H27NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZU4275277R, chemically known as 17-(cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride but more generally known as nalbuphine hydrochloride, which bears US NIH Compound Identifier 5360733. European Medicines Agency schedules Nalbuphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14626MIG. Most nations, for tariff and trade purposes, schedule nalbuphine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NALBUPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nalbuphine hydrochloride bears US NLM identifiers UMLS ID C0600099 and NCI Concept Code C47629. SMILES: C1CC(C2C3C1C[C@@H]4[C@]5([C@]3(CCN4CC6CCC6)[C@@H](O2)[C@H](CC5)O)O)O.CL.
This classification denotes an opioid receptor agonist with the molecular formula C28H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XC41AVD567, chemically known as (e)-n-(17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6beta-yl)-3-(furan-3-yl)-n-methylprop-2-enamide but generally known as nalfurafine, which bears US NIH Compound Identifier 6445230. European Medicines Agency schedules Nalfurafine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25222. The term NALFURAFINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 2, 2003, List 49). World Health Organization schedules nalfurafine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule nalfurafine under HS 29391900 and SITC 54141. As of Q4 2014, NALFURAFINE remains the US FDA Preferred Term for this commodity. Nalfurafine bears US NLM identifiers UMLS ID C2825264 and NCI Concept Code C80585. SMILES: O1C2C34C(O)(C(N(CC3)CC3CC3)CC3C4C1C(O)CC3)CCC2N(C)C(=O)/C=C/C1CCOC1.
This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25CC4N0P8J. European Medicines Agency schedules Nalfurafine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32294. Nalfurafine hydrochloride generally arises in the molecular formula C28H32N2O5.CLH. The term 'nalfurafine hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule nalfurafine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NALFURAFINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nalfurafine hydrochloride bears US NLM identifiers UMLS ID C1610428 and NCI Concept Code C80586. SMILES: CN([C@@H]1CC[C@]2([C@H]3CC4CCC(C5C4[C@]2([C@H]1O5)CCN3CC6CC6)O)O)C(=O)/C=C/C7CCOC7.CL.
This classification denotes a urinary anti-infective agent and quinolone antibiotic with the molecular formula C12H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3B91HWA56M, chemically known as 1,8-naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo- but generally known as nalidixic acid, which bears US NIH Compound Identifier 4421. European Medicines Agency schedules Nalidixic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09138MIG. The term NALIDIXIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules nalidixic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule nalidixic acid under HS 29339990 and SITC 51577. As of Q4 2014, NALIDIXIC ACID remains the US FDA Preferred Term for this commodity. Nalidixic acid bears US NLM identifiers UMLS ID C0027353 and NCI Concept Code C47630. SMILES: CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O.
This classification denotes an opiate antagonist with the molecular formula C21H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TOV02TDP9I, chemically known as morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5.alpha.)- but generally known as nalmefene, which bears US NIH Compound Identifier 4422. European Medicines Agency schedules Nalmefene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09139MIG. The term NALMEFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). NALMEFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nalmefene under HS 29391900 and SITC 54141. As of Q4 2014, NALMEFENE remains the US FDA Preferred Term for this commodity. Nalmefene bears US NLM identifiers UMLS ID C0068377 and NCI Concept Code C61855. SMILES: O1C2C34C(O)(C(N(CC3)CC3CC3)CC3C4C1C(O)CC3)CCC2=C.
This classification denotes an opiate antagonist with the molecular formula C21H25NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7K69QC05X, chemically known as 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, , hydrochloride but more generally known as nalmefene hydrochloride, which bears US NIH Compound Identifier 5388881. European Medicines Agency schedules Nalmefene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14628MIG. Most nations, for tariff and trade purposes, schedule nalmefene hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NALMEFENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nalmefene hydrochloride bears US NLM identifiers UMLS ID C0771297 and NCI Concept Code C47631. SMILES: C=C1CC[C@]2([C@H]3CC4CCC(C5C4[C@]2([C@H]1O5)CCN3CC6CC6)O)O.CL.
This classification denotes an opiate antagonist C21H25NO3.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52Z0G7QVJX, chemically known as morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, hydrochloride, hydrate (1:1:2), (5.alpha.)-, but more generally known as nalmefene hydrochloride dihydrate, which bears US NIH Compound Identifier 46209574. Most nations, for tariff and trade purposes, schedule nalmefene hydrochloride dihydrate under HS 29391900 and SITC 54141. As of Q4 2014, NALMEFENE HYDROCHLORIDE DIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C=C1CC[C@]2([C@H]3CC4CCC(C5C4[C@]2([C@H]1O5)CCN3CC6CC6)O)O.O.O.CL.
This classification denotes a narcotic antagonist with the molecular formula C19H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U59WB2WRY2, chemically known as 7,8-didehydro-4,5-epoxy-17-(2-propenyl)morphinan-3,6-diol but generally known as nalorphine, which bears US NIH Compound Identifier 5284595. European Medicines Agency schedules Nalorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09141MIG. World Health Organization schedules nalorphine in its Anatomical Therapeutic Chemical (ATC) Classification. NALORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nalorphine under HS 29391900 and SITC 54141. As of Q4 2014, NALORPHINE remains the US FDA Preferred Term for this commodity. SMILES: O1C2C34C(C(N(CC3)CC=C)CC3C4C1C(O)CC3)C=CC2O.
This classification denotes a narcotic antagonist with the molecular formula C20H23NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1OLB66508A, chemically known as morphinan-3,6-.alpha.-diol, 17-allyl-7,8-didehydro-4,5-.alpha.-epoxy-, hydrobromide, but more generally known as nalorphine bromide, which bears US NIH Compound Identifier 5486631. European Medicines Agency schedules nalorphine bromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09141MIG. Most nations, for tariff purposes, schedule nalorphine bromide under HS 29391900. SMILES: COC1CCC2C3C1O[C@@H]4[C@]35CCN([C@H](C2)[C@@H]5C=C[C@@H]4O)CC=C.BR.
This classification denotes a narcotic antagonist C20H23NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1OLB66508A, chemically known as morphinan-3,6-.alpha.-diol, 17-allyl-7,8-didehydro-4,5-.alpha.-epoxy-, hydrobromide, but more generally known as nalorphine hydrobromide, which bears US NIH Compound Identifier 5486631. Most nations, for tariff and trade purposes, schedule nalorphine hydrobromide under HS 29391900 and SITC 54141. As of Q4 2014, NALORPHINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC2C3C1O[C@@H]4[C@]35CCN([C@H](C2)[C@@H]5C=C[C@@H]4O)CC=C.BR.
This classification denotes an opioid receptor agonist with the molecular formula C19H21NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9FPE56Z2TW, chemically known as 17-allyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol hydrochloride but more generally known as nalorphine hydrochloride, which bears US NIH Compound Identifier 5484366. European Medicines Agency schedules Nalorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03381MIG. Most nations, for tariff and trade purposes, schedule nalorphine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NALORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nalorphine hydrochloride bears US NLM identifiers UMLS ID C0086547 and NCI Concept Code C76849. SMILES: C=CCN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CL.
An opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adultpatients with chronic non-cancer pain
This classification denotes an opiate antagonist with the molecular formula C19H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36B82AMQ7N, chemically known as 17-allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one but generally known as naloxone, which bears US NIH Compound Identifier 5284596. European Medicines Agency schedules Naloxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09142MIG. The term NALOXONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules naloxone in its Anatomical Therapeutic Chemical (ATC) Classification. NALOXONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naloxone under HS 29391900 and SITC 54141. As of Q4 2014, NALOXONE remains the US FDA Preferred Term for this commodity. Naloxone bears US NLM identifiers UMLS ID C0027358 and NCI Concept Code C62054. SMILES: O1C2C34C(O)(C(N(CC3)CC=C)CC3C4C1C(O)CC3)CCC2=O.
This classification denotes a narcotic antagonist with the molecular formula C19H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F850569PQR, chemically known as 17-allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride but more generally known as naloxone hydrochloride, which bears US NIH Compound Identifier 5464092. European Medicines Agency schedules Naloxone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03382MIG. Most nations, for tariff and trade purposes, schedule naloxone hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NALOXONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Naloxone hydrochloride bears US NLM identifiers UMLS ID C0684237 and NCI Concept Code C678. SMILES: C=CCN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O.CL.
This classification denotes an opiate antagonist with the molecular formula C19H21NO4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Q187997EE, chemically known as (-)-n-allyl-14-hydroxynordihydromorphinone hydrochloride dihydrate, but more generally known as naloxone hydrochloride dihydrate, which bears US NIH Compound Identifier 5464092. European Medicines Agency schedules naloxone hydrochloride dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09142MIG. Most nations, for tariff purposes, schedule naloxone hydrochloride dihydrate under HS 29391900. SMILES: C=CCN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O.O.O.CL.
Oxycodone hydrochloride with naloxone hydrochloride dihydrate for the management of moderate to severe pain unresponsive to non-narcotic analgesics.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.
This classification denotes an opiate antagonist with the molecular formula C20H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S6W795CQM, chemically known as morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)- but generally known as naltrexone, which bears US NIH Compound Identifier 4428. European Medicines Agency schedules Naltrexone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09143MIG. The term NALTREXONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules naltrexone in its Anatomical Therapeutic Chemical (ATC) Classification. NALTREXONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naltrexone under HS 29391900 and SITC 54141. As of Q4 2014, NALTREXONE remains the US FDA Preferred Term for this commodity. Naltrexone bears US NLM identifiers UMLS ID C0027360 and NCI Concept Code C62055. SMILES: O1C2C34C(O)(C(N(CC3)CC3CC3)CC3C4C1C(O)CC3)CCC2=O.
This classification denotes an opiate antagonist with the molecular formula C20H23NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z6375YW9SF, chemically known as 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-morphinan-6-one hydrochloride but more generally known as naltrexone hydrochloride, which bears US NIH Compound Identifier 5485201. European Medicines Agency schedules Naltrexone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14629MIG. Most nations, for tariff and trade purposes, schedule naltrexone hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NALTREXONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Naltrexone hydrochloride bears US NLM identifiers UMLS ID C0355800 and NCI Concept Code C679. SMILES: C1CC(C2C3C1C[C@@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)C(=O)CC5)O)O.CL.
This classification denotes an opiate antagonist with the molecular formula C21H26NO4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RFO6IL3D3M, chemically known as morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5.alpha.)-, but more generally known as naltrexone methobromide, which bears US NIH Compound Identifier 5361917. European Medicines Agency schedules naltrexone methobromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09143MIG. Most nations, for tariff purposes, schedule naltrexone methobromide under HS 29391900. SMILES: C[N+]1(CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O)CC6CC6.[BR-].
This classification denotes a beta-adrenergic agonist with the molecular formula C19H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q13LFM3WG, chemically known as 5-amino-alpha-(((p-methoxy-alpha-methylphenethyl)amino)methyl)-m-xylene-alpha,alpha-diol but generally known as naminterol, which bears US NIH Compound Identifier 174101. European Medicines Agency schedules Naminterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09144MIG. The term NAMINTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). NAMINTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naminterol under HS 29225000 and SITC 51467. As of Q4 2014, NAMINTEROL remains the US FDA Preferred Term for this commodity. Naminterol bears US NLM identifiers UMLS ID C2827270 and NCI Concept Code C83980. SMILES: OC(CNC(CC1CCC(OC)CC1)C)C1CC(CC(N)C1)CO.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H18O2.C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38IDB6L05D, chemically known as 4-biphenylacetic acid, alpha-ethyl-, compd. with 2-(dimethylamino)ethanol (1:1) but generally known as namoxyrate, which bears US NIH Compound Identifier 14694. European Medicines Agency schedules Namoxyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09146MIG. The term NAMOXYRATE is an International Non-Proprietary Name. NAMOXYRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule namoxyrate under HS 29221980 and SITC 51461. As of Q4 2014, NAMOXYRATE remains the US FDA Preferred Term for this commodity. Namoxyrate bears US NLM identifiers UMLS ID C2827272 and NCI Concept Code C83982. SMILES: OC(=O)C(CCC1CCC(CC1)C1CCCCC1)C.OCCN(C)C.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C18H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6PG9VR430D, chemically known as estr-4-en-3-one, 17-hydroxy-, (17beta)- (9ci) but generally known as nandrolone, which bears US NIH Compound Identifier 9904. European Medicines Agency schedules Nandrolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG. The term NANDROLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules nandrolone in its Anatomical Therapeutic Chemical (ATC) Classification. NANDROLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nandrolone under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE remains the US FDA Preferred Term for this commodity. Nandrolone bears US NLM identifiers UMLS ID C0027368 and NCI Concept Code C29279. SMILES: OC1C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)C.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C25H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1665A8I95W, chemically known as estr-4-en-3-one, 17-(benzoyloxy)-, (17.beta.)-, but more generally known as nandrolone benzoate, which bears US NIH Compound Identifier 227796. European Medicines Agency schedules nandrolone benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG. Most nations, for tariff purposes, schedule nandrolone benzoate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)C4CCCCC4)CCC5=CC(=O)CC[C@H]35.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C25H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45FAH33FMM, chemically known as estr-4-en-3-one, 17-((cyclohexylcarbonyl)oxy)-, (17.beta.)-, but more generally known as nandrolone cyclohexanecarboxylate, which bears US NIH Compound Identifier 86744. European Medicines Agency schedules nandrolone cyclohexanecarboxylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG. Most nations, for tariff purposes, schedule nandrolone cyclohexanecarboxylate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)C4CCCCC4)CCC5=CC(=O)CC[C@H]35.
This classification denotes a therapeutic androgen and anabolic steroid C27H40O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4NE48GG1Y, chemically known as estr-4-en-3-one, 17-(3-cyclohexyl-1-oxopropoxy)-, (17.beta.)-, but more generally known as nandrolone cyclohexylpropionate, which bears US NIH Compound Identifier 101905. European Medicines Agency schedules Nandrolone cyclohexylpropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23549. Most nations, for tariff and trade purposes, schedule nandrolone cyclohexylpropionate under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE CYCLOHEXYLPROPIONATE remains US FDA's Preferred Term for this commodity. Nandrolone cyclohexylpropionate bears US NLM identifiers UMLS ID C0626162 and NCI Concept Code C95976. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCCC4)CCC5=CC(=O)CC[C@H]35.
This classification denotes a therapeutic androgen and anabolic steroid C28H38O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1MG9GW4ZH8, chemically known as estr-4-en-3-one, 17-(((4-methylbicyclo(2.2.2)oct-2-en-1-yl)carbonyl)oxy)-, (17.beta.)-, but more generally known as nandrolone cyclotate, which bears US NIH Compound Identifier 164526. Most nations, for tariff and trade purposes, schedule nandrolone cyclotate under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE CYCLOTATE remains US FDA's Preferred Term for this commodity. Nandrolone cyclotate bears US NLM identifiers UMLS ID C2828223 and NCI Concept Code C87228. SMILES: C[C@@]12C=C[C@@](CC1)(CC2)C(=O)O[C@@H]3[C@@]4([C@H]([C@H]5[C@@H]([C@@H]6C(=CC(=O)CC6)CC5)CC4)CC3)C.
This classification denotes a therapeutic androgen with the molecular formula C28H44O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H45187T098, chemically known as estr-4-en-3-one, 17-beta-hydroxy-, decanoate but more generally known as nandrolone decanoate, which bears US NIH Compound Identifier 9677. European Medicines Agency schedules Nandrolone decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03384MIG. Most nations, for tariff and trade purposes, schedule nandrolone decanoate under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE DECANOATE remains US FDA's Preferred Term for this commodity. Nandrolone decanoate bears US NLM identifiers UMLS ID C0068395 and NCI Concept Code C1172. SMILES: CCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C25H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W1309SNY8U, chemically known as estr-4-en-3-one, 17-(3-(2-furanyl)-1-oxopropoxy)-, (17.beta.)-, but more generally known as nandrolone furylpropionate, which bears US NIH Compound Identifier 111318. European Medicines Agency schedules nandrolone furylpropionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG. Most nations, for tariff purposes, schedule nandrolone furylpropionate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCO4)CCC5=CC(=O)CC[C@H]35.
This classification denotes a therapeutic androgen with the molecular formula C27H34O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KF7Z9K2T3W, chemically known as 19-nortestosterone, hydrocinnamate but more generally known as nandrolone phenpropionate, which bears US NIH Compound Identifier 4435. European Medicines Agency schedules Nandrolone phenpropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03385MIG. Most nations, for tariff and trade purposes, schedule nandrolone phenpropionate under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE PHENPROPIONATE remains US FDA's Preferred Term for this commodity. Nandrolone phenpropionate bears US NLM identifiers UMLS ID C0068397 and NCI Concept Code C66218. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCCC4)CCC5=CC(=O)CC[C@H]35.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C21H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M86G89RH16, chemically known as estr-4-en-3-one, 17-(1-oxopropoxy)-, (17.beta.)-, but more generally known as nandrolone propionate, which bears US NIH Compound Identifier 111273. European Medicines Agency schedules nandrolone propionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG. Most nations, for tariff purposes, schedule nandrolone propionate under HS 29372900. Nandrolone propionate bears US NLM identifiers UMLS ID C3272467 and NCI Concept Code C95972. SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C.
This classification denotes a therapeutic androgen and anabolic steroid C29H46O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K64MCF1I9Z, chemically known as estr-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17.beta.)-, but more generally known as nandrolone undecylate, which bears US NIH Compound Identifier 94193. European Medicines Agency schedules Nandrolone undecylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03388MIG. Most nations, for tariff and trade purposes, schedule nandrolone undecylate under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE UNDECYLATE remains US FDA's Preferred Term for this commodity. Nandrolone undecylate bears US NLM identifiers UMLS ID C0068398 and NCI Concept Code C95974. SMILES: CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C15H15N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1S169L7KAV, chemically known as 6-(2,4-dimethylimidazol-1-yl)-8-methyl-2-quinolone but generally known as nanterinone, which bears US NIH Compound Identifier 71305. European Medicines Agency schedules Nanterinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09150MIG. The term NANTERINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). NANTERINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nanterinone under HS 29337900 and SITC 51561. As of Q4 2014, NANTERINONE remains the US FDA Preferred Term for this commodity. Nanterinone bears US NLM identifiers UMLS ID C0526440 and NCI Concept Code C76889. SMILES: O=c1[nH]c2c(cc(n3c(nc(c3)C)C)cc2C)cc1.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C15H15N3O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O345A477QI, chemically known as 2(1h)-quinolinone, 6-(2,4-dimethyl-1h-imidazol-1-yl)-8-methyl-, methanesulfonate (1:1), but more generally known as nanterinone mesylate, which bears US NIH Compound Identifier 92089. European Medicines Agency schedules nanterinone mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09150MIG. Most nations, for tariff purposes, schedule nanterinone mesylate under HS 29337900. SMILES: CC1CC(CC2C1[NH]C(=O)CC2)N3CC(NC3C)C.CS(=O)(=O)O.
This classification denotes an analgesic agent with the molecular formula C27H35NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9KB5WI7MQ6, chemically known as 1,9-phenanthridinediol, 5,6,6a,7,8,9,10, 10a-octahydro-6-methyl-3-(1-methyl-4-phenylbutoxy)-, 1-acetate, hydrochloride, (6a,6a.alpha.,9.alpha.,10a.beta.)- but generally known as nantradol, which bears US NIH Compound Identifier 107822. European Medicines Agency schedules Nantradol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09151MIG. The term NANTRADOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). NANTRADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nantradol under HS 29339990 and SITC 51577. As of Q4 2014, NANTRADOL remains the US FDA Preferred Term for this commodity. Nantradol bears US NLM identifiers UMLS ID C0068401 and NCI Concept Code C83983. SMILES: OC1CC2C(CC1)C(NC1C2C(OC(=O)C)CC(OC(CCCC2CCCCC2)C)C1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 571S87U90N, chemically known as 2-naphthaleneethanimidamide, n,n-dimethyl-, monohydrochloride but generally known as napactadine, which bears US NIH Compound Identifier 42152. European Medicines Agency schedules Napactadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09152MIG. The term NAPACTADINE is an International Non-Proprietary Name. NAPACTADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule napactadine under HS 29252900 and SITC 51482. As of Q4 2014, NAPACTADINE remains the US FDA Preferred Term for this commodity. Napactadine bears US NLM identifiers UMLS ID C0625911 and NCI Concept Code C87744. SMILES: Cl.[NH2](/C(=N\C)Cc1cc2c(cc1)cccc2)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H16N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9FB1F1BV0M, chemically known as 2-naphthaleneethanimidamide, n,n-dimethyl-, monohydrochloride but more generally known as napactadine hydrochloride, which bears US NIH Compound Identifier 42152. Most nations, for tariff and trade purposes, schedule napactadine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, NAPACTADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Napactadine hydrochloride bears US NLM identifiers UMLS ID C2827273 and NCI Concept Code C83984. SMILES: CN/C(=N\C)/CC1CCC2CCCCC2C1.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GK4C2D295B, chemically known as 2-((3,4-dihydro-2-naphthyl)methyl)-2-imidazoline but generally known as napamezole, which bears US NIH Compound Identifier 124655. European Medicines Agency schedules Napamezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09153MIG. The term NAPAMEZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). NAPAMEZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule napamezole under HS 29332990 and SITC 51573. As of Q4 2014, NAPAMEZOLE remains the US FDA Preferred Term for this commodity. Napamezole bears US NLM identifiers UMLS ID C0083703 and NCI Concept Code C83985. SMILES: N1CC(=NC1)CC1=CC2C(CC1)CCCC2.
This classification denotes a serotonin agonist and alpha-adrenergic blocking agent with the molecular formula C14H16N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DTN86H1ZWK, chemically known as 2-((3,4-dihydro-2-naphthyl)methyl)-2-imidazoline hydrochloride but more generally known as napamezole hydrochloride, which bears US NIH Compound Identifier 3033727. Most nations, for tariff and trade purposes, schedule napamezole hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, NAPAMEZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Napamezole hydrochloride bears US NLM identifiers UMLS ID C2825583 and NCI Concept Code C81333. SMILES: C1CCC2C(C1)CCC(=C2)CC3=NCCN3.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C14H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H231GF11BV, chemically known as 4,5-dihydro-2-(1-naphthylmethyl)imidazole but more generally known as naphazoline, which bears US NIH Compound Identifier 4436. European Medicines Agency schedules Naphazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09154MIG. The term NAPHAZOLINE is an International Non-Proprietary Name. World Health Organization schedules naphazoline in its Anatomical Therapeutic Chemical (ATC) Classification. NAPHAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule naphazoline under HS 29332990 and SITC 51573. As of Q4 2014, NAPHAZOLINE remains US FDA's Preferred Term for this commodity. Naphazoline bears US NLM identifiers UMLS ID C0027373 and NCI Concept Code C61856. SMILES: N1C(=NCC1)CC1C2C(CCC1)CCCC2.
This classification denotes an alpha-adrenergic agonist with the molecular formula C14H14N2.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SC99GR1T5S, chemically known as 2-imidazoline, 2-(1-naphthylmethyl)-, mononitrate but more generally known as naphazoline nitrate, which bears US NIH Compound Identifier 21225. European Medicines Agency schedules Naphazoline nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03390MIG. Most nations, for tariff and trade purposes, schedule naphazoline nitrate under HS 29332990 and SITC 51573. Naphazoline Nitrate bears US NLM identifiers UMLS ID C0770988 and NCI Concept Code C98243. As of Q4 2014, NAPHAZOLINE NITRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)CCCC2CC3=NCCN3.[N+](=O)(O)[O-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT900. This VA Drug Class (NT900) classifies this compound as belonging to the group NASAL AND THROAT, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.
This classification denotes an immunosuppressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 45081SG6XT. European Medicines Agency schedules Napirimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09156MIG. Napirimus generally arises in the molecular formula C17H13NO3. The term NAPIRIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, list 29.) NAPIRIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule napirimus under HS 29339990 and SITC 51577. As of Q4 2014, NAPIRIMUS remains US FDA's Preferred Term for this commodity. Napirimus bears US NLM identifiers UMLS ID C2698429 and NCI Concept Code C76694. SMILES: O=C(C1C2C(CCC1)CCCC2)C1CN(C(C1)C(=O)O)C.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H21NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, V24GR4LI3I chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 4-(nitrooxy)butyl ester, (.alpha.s)- but generally known as naproxcinod, which bears US NIH Compound Identifier 9884642. European Medicines Agency schedules Naproxcinod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30968. The term NAPROXCINOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, no. 1, 2007, list 57). Most nations schedule naproxcinod under HS 29209090 and SITC 51639. As of Q4 2014, NAPROXCINOD remains the US FDA Preferred Term for this commodity. Naproxcinod bears US NLM identifiers UMLS ID C0915860 and NCI Concept Code C83989. SMILES: O(C(=O)C(C1CC2C(CC1)CC(OC)CC2)C)CCCCO[N](=O)O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57Y76R9ATQ, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (s)- but generally known as naproxen, which bears US NIH Compound Identifier 1302. European Medicines Agency schedules Naproxen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09159MIG. The term NAPROXEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules naproxen in its Anatomical Therapeutic Chemical (ATC) Classification. NAPROXEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naproxen under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN remains the US FDA Preferred Term for this commodity. Naproxen bears US NLM identifiers UMLS ID C0700017 and NCI Concept Code C680. SMILES: O(C1CC2C(CC(C(C)C(=O)O)CC2)CC1)C.
This classification denotes a cyclooxygenase inhibitor C17H20O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 214269U36R, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-(methylsulfonyl)ethyl ester, (.alpha.s)-, but more generally known as naproxen etemesil, which bears US NIH Compound Identifier 25170420. Most nations, for tariff and trade purposes, schedule naproxen etemesil under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN ETEMESIL remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)OCCS(=O)(=O)C.
This classification denotes a cyclooxygenase inhibitor 2C14H14O3.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R2A8B8HIPI, chemically known as (s)-6-methoxy-.alpha.-methylnaphthalene-2-acetic acid, compound with piperazine (2:1), but more generally known as naproxen piperazine, which bears US NIH Compound Identifier 155581. Most nations, for tariff and trade purposes, schedule naproxen piperazine under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN PIPERAZINE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)O.C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)O.C1CNCCN1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H13O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TN87S3A3C, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (s)- but more generally known as naproxen sodium, which bears US NIH Compound Identifier 1302. European Medicines Agency schedules Naproxen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03392MIG. Most nations, for tariff and trade purposes, schedule naproxen sodium under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN SODIUM remains US FDA's Preferred Term for this commodity. Naproxen sodium bears US NLM identifiers UMLS ID C0546873 and NCI Concept Code C48006. SMILES: C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)[O-].[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33S398GAY6. European Medicines Agency schedules Naproxol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09160MIG. Naproxol generally arises in the molecular formula C14H16O2. The term NAPROXOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) NAPROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naproxol under HS 29094990 and SITC 51617. As of Q4 2014, NAPROXOL remains the US FDA Preferred Term for this commodity. Naproxol bears US NLM identifiers UMLS ID C2827277 and NCI Concept Code C83990. SMILES: OCC(C1CC2C(CC1)CC(OC)CC2)C.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VL5IZU8PF8. European Medicines Agency schedules Napsagatran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09161MIG. Napsagatran generally arises in the molecular formula C26H34N6O6S.H2O. The term NAPSAGATRAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.) NAPSAGATRAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule napsagatran under HS 29350090 and SITC 51580. As of Q4 2014, NAPSAGATRAN remains the US FDA Preferred Term for this commodity. Napsagatran bears US NLM identifiers UMLS ID C0380191 and NCI Concept Code C90703. SMILES: S(=O)(=O)(NC(C(=O)N(C1CC1)CC(=O)O)CC(=O)NCC1CCCN(C1)C(=N)N)C1CC2C(CC1)CCCC2.
This classification denotes an antibiotic with the molecular formula C43H72O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DZY9VU539P, chemically known as 2h-pyran-2-acetic acid, alpha-ethyl-6-(5-(2-(5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyran-2-yl)-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro(4.1.5.3)pentadec-13-en-9-yl)-2-hydroxy-1,3-dimethyl-4-oxoheptyl)tetrahydro-3,5-dimethyl- but more generally known as narasin, which bears US NIH Compound Identifier 65452. European Medicines Agency schedules Narasin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09163MIG. The term NARASIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). NARASIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1C(CCC21OC1(OC(C(CC1C)C)C(C(=O)C(C(O)C(C1OC(C(CC1C)C)C(CC)C(=O)O)C)C)CC)C=CC2O)(C1OC(C(O)(CC1)CC)C)C.
This classification denotes a serotonin agonist with the molecular formula C17H25N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QX3KXL1ZA2, chemically known as 1h-indole-5-ethanesulfonamide, n-methyl-3-(1-methyl-4-piperidinyl)- but generally known as naratriptan, which bears US NIH Compound Identifier 4440. European Medicines Agency schedules Naratriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09164MIG. The term NARATRIPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules naratriptan in its Anatomical Therapeutic Chemical (ATC) Classification. NARATRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naratriptan under HS 29350090 and SITC 51580. As of Q4 2014, NARATRIPTAN remains the US FDA Preferred Term for this commodity. Naratriptan bears US NLM identifiers UMLS ID C0540623 and NCI Concept Code C61857. SMILES: S(=O)(=O)(NC)CCC1CC2C(C3CCN(CC3)C)C[NH]C2CC1.
This classification denotes a serotonin agonist with the molecular formula C17H25N3O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10X8X4P12Z, chemically known as 1h-indole-5-ethanesulfonamide, n-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride but more generally known as naratriptan hydrochloride, which bears US NIH Compound Identifier 60875. European Medicines Agency schedules Naratriptan hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14631MIG. Most nations, for tariff and trade purposes, schedule naratriptan hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, NARATRIPTAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Naratriptan hydrochloride bears US NLM identifiers UMLS ID C0594660 and NCI Concept Code C47633. SMILES: CNS(=O)(=O)CCC1CCC2C(C1)C(C[NH]2)C3CCN(CC3)C.CL.
This classification denotes an opioid receptor agonist with the molecular formula C23H27NO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CTT09X2F1M, chemically known as 2,3-dimethoxy-6-((6-(2-dimethylaminoethyl)-2-methoxy-3,4-methylendioxyphenyl)acetyl)benzosaeure but generally known as narceine, which bears US NIH Compound Identifier 8564. European Medicines Agency schedules Narceine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22705. Most nations schedule narceine under HS 29391900 and SITC 54141. As of Q4 2014, NARCEINE remains the US FDA Preferred Term for this commodity. Narceine bears US NLM identifiers UMLS ID C2984004 and NCI Concept Code C91050. SMILES: O1C2C(OC)C(C(CCN(C)C)CC2OC1)CC(=O)C1C(C(OC)C(OC)CC1)C(=O)O.
This classification denotes an opioid receptor agonist with the molecular formula C23H27NO8.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B7W51YUQ3, chemically known as 2,3-dimethoxy-6-((6-(2-dimethylaminoethyl)-2-methoxy-3,4-methylendioxyphenyl)acetyl)benzosaeure hydrochlorid but more generally known as narceine hydrochloride, which bears US NIH Compound Identifier 78617. Most nations, for tariff and trade purposes, schedule narceine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NARCEINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Narceine hydrochloride bears US NLM identifiers UMLS ID C2828281 and NCI Concept Code C87363. SMILES: CN(C)CCC1CC2C(C(C1CC(=O)C3CCC(C(C3C(=O)O)OC)OC)OC)OCO2.CL.
This classification denotes a tubulin binding agent and opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8V32U4AOQU. European Medicines Agency schedules Noscapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09383MIG. Noscapine generally arises in the molecular formula C22H23NO7. The term NOSCAPINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, no 10 1978, list 18.) NOSCAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Narcotinum or noscapine bears US NLM identifiers UMLS ID C0028426 and NCI Concept Code C80589. SMILES: O1C(C2N(CCC3C2C(OC)C2OCOC2C3)C)C2C(C1=O)C(OC)C(OC)CC2.
This classification denotes a beta-adrenergic agonist with the molecular formula C20H24FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70859437W3, chemically known as benzenemethanol, alpha-(((3-(1h-benzimidazol-1-yl)-1,1-dimethylpropyl)amino)methyl)-2-fluoro-4-hydroxy- but generally known as nardeterol, which bears US NIH Compound Identifier 68918. European Medicines Agency schedules Nardeterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09165MIG. The term NARDETEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). NARDETEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nardeterol under HS 29339990 and SITC 51577. As of Q4 2014, NARDETEROL remains the US FDA Preferred Term for this commodity. Nardeterol bears US NLM identifiers UMLS ID C2698430 and NCI Concept Code C76541. SMILES: FC1C(C(O)CNC(CCN2C3C(NC2)CCCC3)(C)C)CCC(O)C1.
This classification denotes a thrombolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 238M5105OY. European Medicines Agency schedules Naroparcil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09166MIG. Naroparcil generally arises in the molecular formula C19H17NO4S2. The term NAROPARCIL is an International Non-Proprietary Name or INN. NAROPARCIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naroparcil under HS 29349990 and SITC 51579. As of Q4 2014, NAROPARCIL remains the US FDA Preferred Term for this commodity. Naroparcil bears US NLM identifiers UMLS ID C0294245 and NCI Concept Code C66219. SMILES: S1C(SC2CCC(CC2)C(=O)C2CCC(CC2)C#N)C(O)C(O)C(O)C1.
This classification denotes an immunosuppressant and antineoplastic monoclonal antibody and multiple sclerosis treatment, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3JB47N2Q2P. The term NATALIZUMAB is an International Non-Proprietary Name or INN. European Medicines Agency schedules natalizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22282. Most nations, for tariff and trade purposes, schedule natalizumab under HS 30021091 and SITC 54163. As of Q4 2014, NATALIZUMAB remains US FDA's Preferred Term for this commodity. Natalizumab bears US NLM identifiers UMLS ID C0665297 and NCI Concept Code C77862. SMILES: none.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8O0C852CPO. European Medicines Agency schedules Natamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09169MIG. Natamycin generally arises in the molecular formula C33H47NO13. The term NATAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) NATAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule natamycin under HS 29419000 and SITC 54139. As of Q4 2014, NATAMYCIN remains the US FDA Preferred Term for this commodity. Natamycin bears US NLM identifiers UMLS ID C0027444 and NCI Concept Code C47634. SMILES: O1C2(O)CC(O)C(C1CC(OC1OC(C(O)C(N)C1O)C)C=CC=CC=CC=CCC(OC(=O)C=CC1OC1CC(O)C2)C)C(=O)O.
This classification denotes an anti-diabetic agent with the molecular formula C19H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 41X3PWK4O2, chemically known as d-phenylalanine, n-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans- but more generally known as nateglinide, which bears US NIH Compound Identifier 60026. European Medicines Agency schedules Nateglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09170MIG. The term NATEGLINIDE is an International Non-Proprietary Name WHO schedules nateglinide in its Anatomical Therapeutic Chemical (ATC) Classification. NATEGLINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nateglinide under HS 29242995 and SITC 51479. As of Q4 2014, NATEGLINIDE remains US FDA's Preferred Term for this commodity. Nateglinide bears US NLM identifiers UMLS ID C1323198 and NCI Concept Code C61858. SMILES: O=C(NC(CC1CCCCC1)C(=O)O)C1CCC(CC1)C(C)C.
This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H11N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PS28W65479. The term NAVURIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46. ). Most nations schedule navuridine under HS 29349990 and SITC 51579. As of Q4 2014, NAVURIDINE remains the US FDA Preferred Term for this commodity. Navuridine bears US NLM identifiers UMLS ID C0046786 and NCI Concept Code C83920. SMILES: C1C(C(OC1N2C=CC(=O)NC2=O)CO)N=[N+]=[N-].
This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25F2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 030Y90569U, chemically known as 2h-1-benzopyran-2-methanol, alpha,alpha-(iminobis(methylene))bis(6-fluoro-3,4-dihydro- but generally known as nebivolol, which bears US NIH Compound Identifier 71301. European Medicines Agency schedules Nebivolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09175MIG. The term NEBIVOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules nebivolol in its Anatomical Therapeutic Chemical (ATC) Classification. NEBIVOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nebivolol under HS 29329985 and SITC 51569. As of Q4 2014, NEBIVOLOL remains the US FDA Preferred Term for this commodity. Nebivolol bears US NLM identifiers UMLS ID C0068475 and NCI Concept Code C66221. SMILES: FC1CC2CCC(OC2CC1)C(O)CNCC(O)C1OC2C(CC1)CC(F)CC2.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGS34J7L9I. European Medicines Agency schedules Nebivolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14632MIG. Nebivolol hydrochloride generally arises in the molecular formula C22H25F2NO4.CLH. The term 'nebivolol hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule nebivolol hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, NEBIVOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nebivolol hydrochloride bears US NLM identifiers UMLS ID C0772208 and NCI Concept Code C81656. SMILES: C1CC2C(CC1F)CC[C@@H](O2)[C@@H](CNC[C@H]([C@@H]3CCC4CC(CCC4O3)F)O)O.CL.
This classification denotes a neuroprotective agent with the molecular formula C12H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T30038QI8N, chemically known as 2-pyrrolidinone, 4-(aminomethyl)-1-(phenylmethyl)- but generally known as nebracetam, which bears US NIH Compound Identifier 65926. European Medicines Agency schedules Nebracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09176MIG. The term NEBRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). NEBRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nebracetam under HS 29337900 and SITC 51561. As of Q4 2014, NEBRACETAM remains the US FDA Preferred Term for this commodity. Nebracetam bears US NLM identifiers UMLS ID C0078459 and NCI Concept Code C66223. SMILES: C1C(CN(C1=O)CC2=CC=CC=C2)CN.
This classification denotes a platinum compound with the molecular structure C2H2O3.PT.2H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8UQ3W6JXAN chemically known as cis-diammine(glycolato-o(sup 1),o(sup 2))platinum, but more commonly known as nedaplatin, which bears US NIH Compound Identifier 72120. European Medicines Agency schedules Nedaplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09178MIG. The term NEDAPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34). bears NCI CUID C61099 and UMLS ID C0093999. Most nations, for tariff and trade purposes, schedule nedaplatin under HS 28439000 and SITC 52432. SMILES: C(C(=O)[O-])[O-].N.N.[Pt+2].
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H17NO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0B535E0BN0, chemically known as 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4h-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid but generally known as nedocromil, which bears US NIH Compound Identifier 50294. European Medicines Agency schedules Nedocromil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09179MIG. The term NEDOCROMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules nedocromil in its Anatomical Therapeutic Chemical (ATC) Classification. NEDOCROMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nedocromil under HS 29349990 and SITC 51579. As of Q4 2014, NEDOCROMIL remains the US FDA Preferred Term for this commodity. Nedocromil bears US NLM identifiers UMLS ID C0068483 and NCI Concept Code C66225. SMILES: O1C2C(C3N(CC)C(CC(=O)C3CC2C(=O)CC1C(=O)O)C(=O)O)CCC.
This classification denotes a histamine-1 receptor antagonist C19H15NO7.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0983W479HH, chemically known as calcium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4h-pyrano(3,2-g)quinoline-2,8-dicarboxylate (1:1), but more generally known as nedocromil calcium, which bears US NIH Compound Identifier 68731. European Medicines Agency schedules Nedocromil calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14633MIG. Most nations, for tariff and trade purposes, schedule nedocromil calcium under HS 29349990 and SITC 51579. As of Q4 2014, NEDOCROMIL CALCIUM remains US FDA's Preferred Term for this commodity. Nedocromil calcium bears US NLM identifiers UMLS ID C0282470 and NCI Concept Code C82647. SMILES: CCCC1C2C(CC3C1OC(CC3=O)C(=O)[O-])C(=O)CC(N2CC)C(=O)[O-].[CA+2].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H15NO7.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ET8IF4KS1T, chemically known as 4h-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-, disodium salt but more generally known as nedocromil sodium, which bears US NIH Compound Identifier 50295. European Medicines Agency schedules Nedocromil sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14634MIG. Most nations, for tariff and trade purposes, schedule nedocromil sodium under HS 29349990 and SITC 51579. As of Q4 2014, NEDOCROMIL SODIUM remains US FDA's Preferred Term for this commodity. Nedocromil sodium bears US NLM identifiers UMLS ID C0886658 and NCI Concept Code C47635. SMILES: CCCC1C2C(CC3C1OC(CC3=O)C(=O)[O-])C(=O)CC(N2CC)C(=O)[O-].[NA+].[NA+].
This classification denotes an antidepressant agent with the molecular formula C25H32ClN5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59H4FCV1TF, chemically known as 3h-1,2,4-triazol-3-one, 2,4-dihydro-2-3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-ethyl-4-(2-phenoxyethyl)- but generally known as nefazodone, which bears US NIH Compound Identifier 4449. European Medicines Agency schedules Nefazodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09180MIG. The term NEFAZODONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules nefazodone in its Anatomical Therapeutic Chemical (ATC) Classification. NEFAZODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nefazodone under HS 29335995 and SITC 51576. As of Q4 2014, NEFAZODONE remains the US FDA Preferred Term for this commodity. Nefazodone bears US NLM identifiers UMLS ID C0068485 and NCI Concept Code C61859. SMILES: Clc1cc(N2CCN(CC2)CCCn2nc(n(c2=O)CCOc2ccccc2)CC)ccc1.
This classification denotes a triazole, analgesic, and second-generation antidepressive agent with the molecular formula C25H32ClN5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27X63J94GR, chemically known as 3h-1,2,4-triazol-3-one, 2,4-dihydro-2-3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-ethyl-4-(2-phenoxyethyl)- but more generally known as nefazodone hydrochloride, which bears US NIH Compound Identifier 4449. European Medicines Agency schedules Nefazodone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03399MIG. Most nations, for tariff and trade purposes, schedule nefazodone hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, NEFAZODONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nefazodone hydrochloride bears US NLM identifiers UMLS ID C0771310 and NCI Concept Code C29283. SMILES: CCC1NN(C(=O)N1CCOC2CCCCC2)CCCN3CCN(CC3)C4CCCC(C4)CL.CL.
This classification denotes a neuroprotective agent with the molecular formula C14H18N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1JK12GX30N, chemically known as 2-oxo-1-pyrrolidineaceto-2,6-xylidide but generally known as nefiracetam, which bears US NIH Compound Identifier 71157. European Medicines Agency schedules Nefiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09181MIG. The term NEFIRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). NEFIRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nefiracetam under HS 29337900 and SITC 51561. As of Q4 2014, NEFIRACETAM remains the US FDA Preferred Term for this commodity. Nefiracetam bears US NLM identifiers UMLS ID C0165264 and NCI Concept Code C74325. SMILES: O=C1N(CCC1)CC(=O)NC1C(CCCC1C)C.
This classification denotes a dopamine antagonist with the molecular formula C22H23FN4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SU2C8RYO3O, chemically known as 1-(1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-piperidyl)-3h-benzimidazol-2(1h)-one hydrochloride but generally known as neflumozide hydrochloride, which bears US NIH Compound Identifier 55463. Most nations schedule neflumozide under HS 29349990 and SITC 51579. As of Q4 2014, NEFLUMOZIDE remains the US FDA Preferred Term for this commodity. Neflumozide bears US NLM identifiers UMLS ID C2827279 and NCI Concept Code C83992. SMILES: C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC4=NOC5=C4C=CC(=C5)F.Cl.
This classification denotes a dopamine antagonist with the molecular formula C22H23FN4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SU2C8RYO3O, chemically known as 1-(1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-piperidyl)-3h-benzimidazol-2(1h)-one hydrochloride but more generally known as neflumozide hydrochloride, which bears US NIH Compound Identifier 55463. Most nations, for tariff and trade purposes, schedule neflumozide hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, NEFLUMOZIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Neflumozide hydrochloride bears US NLM identifiers UMLS ID C2827280 and NCI Concept Code C83993. SMILES: C1CCC2C(C1)[NH]C(=O)N2C3CCN(CC3)CCCC4C5CCC(CC5ON4)F.CL.
This classification denotes a benzodiazepine with the molecular formula C17H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4UP8060B7J, chemically known as 3,4,5,6-tetrahydro-5-methyl-1-phenyl-1h-2,5-benzoxazocin but generally known as nefopam, which bears US NIH Compound Identifier 4450. European Medicines Agency schedules Nefopam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09183MIG. The term NEFOPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules nefopam in its Anatomical Therapeutic Chemical (ATC) Classification. NEFOPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nefopam under HS 29349990 and SITC 51579. As of Q4 2014, NEFOPAM remains the US FDA Preferred Term for this commodity. Nefopam bears US NLM identifiers UMLS ID C0027556 and NCI Concept Code C83994. SMILES: O1C(C2C(CN(CC1)C)CCCC2)C1CCCCC1.
This classification denotes a benzodiazepine with the molecular formula C17H19NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 685J48E13W, chemically known as 3,4,5,6-tetrahydro-5-methyl-1-phenyl-1h-2,5-benzoxazocine hydrochloride but more generally known as nefopam hydrochloride, which bears US NIH Compound Identifier 31872. European Medicines Agency schedules Nefopam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03400MIG. Most nations, for tariff and trade purposes, schedule nefopam hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, NEFOPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nefopam hydrochloride bears US NLM identifiers UMLS ID C0015820 and NCI Concept Code C83995. SMILES: CN1CCOC(C2CCCCC2C1)C3CCCCC3.CL.
This classification denotes a purine antagonist with the molecular formula C11H15N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60158CV180, chemically known as 9h-purin-2-amine, 9beta-d-arabinofuranosyl-6-methyl- but generally known as nelarabine, which bears US NIH Compound Identifier 151121. European Medicines Agency schedules Nelarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09188MIG. World Health Organization schedules nelarabine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, NELARABINE remains the US FDA Preferred Term for this commodity. Nelarabine bears US NLM identifiers UMLS ID C0907349 and NCI Concept Code C1704. SMILES: COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N. .
This classification denotes an antihypertensive agent with the molecular formula C18H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G3E7RO42MB, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(3-hydroxybutyryl)piperazine but generally known as neldazosin, which bears US NIH Compound Identifier 65908. European Medicines Agency schedules Neldazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09184MIG. The term NELDAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). NELDAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule neldazosin under HS 29335995 and SITC 51576. As of Q4 2014, NELDAZOSIN remains the US FDA Preferred Term for this commodity. Neldazosin bears US NLM identifiers UMLS ID C1882042 and NCI Concept Code C66226. SMILES: O=C(N1CCN(CC1)c1nc2c(c(n1)N)cc(OC)c(OC)c2)CC(O)C.
This classification denotes a muscle relaxant with the molecular formula C18H21ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OC19J8O751, chemically known as (3E)-3-(9-chloro-5,6-dihydropyrrolo[1,2-c][3]benzazepin-11-ylidene)-N,N-dimethylpropan-1-amine but generally known as nelezaprine, which bears US NIH Compound Identifier 6436130. European Medicines Agency schedules nelezaprine its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09185MIG. Most nations schedule nelezaprine under HS 29339930 and SITC 51577. As of Q4 2014, NELEZAPRINE remains the US FDA Preferred Term for this commodity. Nelezaprine bears US NLM identifiers UMLS ID C2983927 and NCI Concept Code C90893. SMILES: CN(C)CCC=C1C2=CC=CN2CCC3=C1C=C(C=C3)Cl.
This classification denotes a muscle relaxant with the molecular formula C18H21ClN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q9L107XJB, chemically known as 3-(9-chloro-5,6-dihydro-11-h-pyrrolo(2,1-b))(3)benzazepine-11-ylidine-n,n-dimethyl-1-propanaminebutenedioate but more generally known as nelezaprine maleate, which bears US NIH Compound Identifier 6436129. Most nations, for tariff and trade purposes, schedule nelezaprine maleate under HS 29339930 and SITC 51577. As of Q4 2014, NELEZAPRINE MALEATE remains US FDA's Preferred Term for this commodity. Nelezaprine maleate bears US NLM identifiers UMLS ID C2825399 and NCI Concept Code C80980. SMILES: CN(C)CC/C=C\1/C2CCCN2CCC3C1CC(CC3)CL.C(=C\C(=O)O)\C(=O)O.
This classification denotes a protease inhibitor with the molecular formula C32H45N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HO3OGH5D7I, chemically known as 3-isoquinolinecarboxamide, n-(1,1-dimethylethyl)decahydro-2-((2r,3r)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3s,4as,8as)- but generally known as nelfinavir, which bears US NIH Compound Identifier 64143. European Medicines Agency schedules Nelfinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09186MIG. The term NELFINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). World Health Organization schedules nelfinavir in its Anatomical Therapeutic Chemical (ATC) Classification. NELFINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nelfinavir under HS 29334990 and SITC 51575. As of Q4 2014, NELFINAVIR remains the US FDA Preferred Term for this commodity. Nelfinavir bears US NLM identifiers UMLS ID C0525005 and NCI Concept Code C29285. SMILES: S(CC(NC(=O)c1c(c(O)ccc1)C)C(O)CN1CC2C(CC1C(=O)NC(C)(C)C)CCCC2)c1ccccc1.
This classification denotes a protease inhibitor with the molecular formula C32H45N3O4S.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98D603VP8V, chemically known as (3s,4as,8as)-n-tert-butyl-2-((2r,3r)-3-(3,2-cresotamido)-2-hydroxy-4-(phenylthio)butyl)decahydro-3-isoquinolinecarboxamide monomethanesulfonate (salt), but more generally known as nelfinavir mesylate, which bears US NIH Compound Identifier 64142. European Medicines Agency schedules nelfinavir mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09186MIG. Most nations, for tariff purposes, schedule nelfinavir mesylate under HS 29334990. As of Q4 2014, NELFINAVIR MESYLATE remains US FDA's Preferred Term for this commodity. Nelfinavir mesylate bears US NLM identifiers UMLS ID C0886530 and NCI Concept Code C1624. SMILES: CC1C(CCCC1O)C(=O)N[C@@H](CSC2CCCCC2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O.CS(=O)(=O)O.
This classification denotes a mucolytic agent with the molecular formula C18H20Br2N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U942DGM90X, chemically known as 4,6-dibromo-alpha-((trans-4-hydroxycyclohexyl)amino)-2-thiophene-carboxy-o-toluidide but more generally known as neltenexine, which bears US NIH Compound Identifier 3047787. European Medicines Agency schedules Neltenexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09187MIG. The term NELTENEXINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules neltenexine in its Anatomical Therapeutic Chemical (ATC) Classification. NELTENEXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule neltenexine under HS 29349990 and SITC 51579. As of Q4 2014, NELTENEXINE remains US FDA's Preferred Term for this commodity. Neltenexine bears US NLM identifiers UMLS ID C0382131 and NCI Concept Code C90885. SMILES: BRC1C(NC(=O)C2SCCC2)C(CNC2CCC(O)CC2)CC(BR)C1.
This classification denotes an antiparasitic agent with the molecular formula C36H52O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Y8VJ1G3TY, chemically known as milbemycin b, 5-o-demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-hydroxy-, (6r,23s,25s(e))- but generally known as nemadectin, which bears US NIH Compound Identifier 6436124. European Medicines Agency schedules Nemadectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09189MIG. The term NEMADECTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). NEMADECTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nemadectin under HS 29419000 and SITC 54139. As of Q4 2014, NEMADECTIN remains the US FDA Preferred Term for this commodity. Nemadectin bears US NLM identifiers UMLS ID C0068494 and NCI Concept Code C90750. SMILES: O1C2(OC3CC(OC(=O)C4C5(O)C(OCC5=CC=CC(CC(=CC3)C)C)C(O)C(=C4)C)C2)CC(O)C(C1/C(=C/C(C)C)C)C.
This classification denotes a histamine-1 receptor antagonist and alpha-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QUV3YCP28R. European Medicines Agency schedules Nemazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09190MIG. Nemazoline generally arises in the molecular formula C10H11CL2N3. The term NEMAZOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) NEMAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nemazoline under HS 29332990 and SITC 51573. As of Q4 2014, NEMAZOLINE remains the US FDA Preferred Term for this commodity. Nemazoline bears US NLM identifiers UMLS ID C2827281 and NCI Concept Code C83997. SMILES: C1CN=C(N1)CC2=CC(=C(C(=C2)CL)N)CL.
This classification denotes a histamine-1 receptor antagonist and alpha-adrenergic agonist C10H11Cl2N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EX1KDR36JS, chemically known as benzenamine, 2,6-dichloro-4-((4,5-dihydro-1h-imidazol-2-yl)methyl)-, monohydrochloride, but more generally known as nemazoline hydrochloride, which bears US NIH Compound Identifier 60468. Most nations, for tariff and trade purposes, schedule nemazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, NEMAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nemazoline hydrochloride bears US NLM identifiers UMLS ID C0632201 and NCI Concept Code C83998. SMILES: C1C(CC(C(C1CL)N)CL)CC2=NCCN2.CL.
This classification denotes a dopamine antagonist and antipsychotic agent with the molecular formula C21H26ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q88T5P3444, chemically known as n-(2rs,3rs)-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide but generally known as nemonapride, which bears US NIH Compound Identifier 156333. European Medicines Agency schedules Nemonapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09191MIG. The term NEMONAPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). NEMONAPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nemonapride under HS 29339990 and SITC 51577. As of Q4 2014, NEMONAPRIDE remains the US FDA Preferred Term for this commodity. Nemonapride bears US NLM identifiers UMLS ID C0217937 and NCI Concept Code C73036. SMILES: CLC1CC(C(=O)NC2C(N(CC2)CC2CCCCC2)C)C(OC)CC1NC.
This classification denotes an anthracycline antibiotic with the molecular formula C32H37NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7618O47BQM, chemically known as 5,12-naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-((2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)-alpha-l-lyxo-hexopyranosyl)oxy)-, (8s-cis)- but generally known as nemorubicin, which bears US NIH Compound Identifier 65907. European Medicines Agency schedules Nemorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09192MIG. The term NEMORUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). NEMORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nemorubicin under HS 29419000 and SITC 54139. As of Q4 2014, NEMORUBICIN remains the US FDA Preferred Term for this commodity. Nemorubicin bears US NLM identifiers UMLS ID C2827283 and NCI Concept Code C83999. SMILES: O(C1OC(C(O)C(N2CC(OCC2)OC)C1)C)C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)CO.
This classification denotes an anthracycline antibiotic C32H37NO13.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Q6F8JYX76, chemically known as 5,12-naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-((2,3,6-trideoxy-3-((2s)-2-methoxy-4-morpholinyl)-.alpha.-l-lyxo-hexopyranosyl)oxy)-, hydrochloride, (8s,10s)-, but more generally known as nemorubicin hydrochloride, which bears US NIH Compound Identifier 56840906. Most nations, for tariff and trade purposes, schedule nemorubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, NEMORUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nemorubicin hydrochloride bears US NLM identifiers UMLS ID C2827284 and NCI Concept Code C84000. SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3C2C(C4C(C3O)C(=O)C5CCCC(C5C4=O)OC)O)(C(=O)CO)O)N6CCO[C@@H](C6)OC)O.CL.
This classification denotes a uricosuric agent and analgesic agent with the molecular formula C19H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 539M941Y9O, chemically known as 6-methylcinchophen, ethyl ester but generally known as neocinchophen, which bears US NIH Compound Identifier 68089. European Medicines Agency schedules Neocinchophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09194MIG. The term NEOCINCHOPHEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). NEOCINCHOPHEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule neocinchophen under HS 29334910 and SITC 51575. As of Q4 2014, NEOCINCHOPHEN remains the US FDA Preferred Term for this commodity. Neocinchophen bears US NLM identifiers UMLS ID C0301393 and NCI Concept Code C75068. SMILES: O(C(=O)C1C2C(NC(C1)C1CCCCC1)CCC(C2)C)CC.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H46N6O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I16QD7X297, more generally known as neomycin. European Medicines Agency schedules neomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03406MIG. The term NEOMYCIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 32, no 10 1978, list 18. NEOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule neomycin under HS 29419000 and SITC 54139. As of Q4 2014, NEOMYCIN remains the US FDA Preferred Term for this commodity. Neomycin bears US NLM identifiers UMLS ID C0027603 and NCI Concept Code C683. SMILES: C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H46N6O13.3H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3720KZ4TQ, chemically known as neomycin b, sulfate (salt), but more generally known as neomycin b sulphate, which bears US NIH Compound Identifier 197162. European Medicines Agency schedules neomycin b sulphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03406MIG. Most nations, for tariff purposes, schedule neomycin b sulphate under HS 29419000. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H46N6O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6B1U1NS16Z, chemically known as d-streptamine, o-2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxy-, but more generally known as neomycin c, which bears US NIH Compound Identifier 4454. European Medicines Agency schedules neomycin c or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03406MIG. Most nations, for tariff purposes, schedule neomycin c under HS 29419000. Neomycin c bears US NLM identifiers UMLS ID C0068521 and NCI Concept Code C95127. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CN)O)O)N)O)O)N.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H45N5O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61JJC8N5ZK, chemically known as diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine, but more generally known as neomycin e, which bears US NIH Compound Identifier 24176. European Medicines Agency schedules neomycin e or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03406MIG. Most nations, for tariff purposes, schedule neomycin e under HS 29419000. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 057Y626693. European Medicines Agency schedules Neomycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03409MIG. Neomycin sulfate generally arises in the molecular formula C23H48N6O17S. The term 'neomycin sulfate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule neomycin sulfate under HS 29419000 and SITC 54139. Neomycin sulfate bears US NLM identifiers UMLS ID C0027607 and NCI Concept Code C66227. SMILES: As of Q4 2014, NEOMYCIN SULFATE remains US FDA's Preferred Term for this commodity.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C12H19N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3982TWQ96G, chemically known as 3-trimethylammoniumphenyl n,n-dimethylcarbamate but generally known as neostigmine, which bears US NIH Compound Identifier 4456. European Medicines Agency schedules Neostigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03411MIG. World Health Organization schedules neostigmine in its Anatomical Therapeutic Chemical (ATC) Classification. NEOSTIGMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, NEOSTIGMINE remains the US FDA Preferred Term for this commodity. Neostigmine bears US NLM identifiers UMLS ID C0027679 and NCI Concept Code C75024. SMILES: CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C12H19N2O2.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 005SYP50G5, chemically known as carbamic acid, dimethyl-, ester with (m-hydroxyphenyl)trimethylammonium bromide but more generally known as neostigmine bromide, which bears US NIH Compound Identifier 8246. European Medicines Agency schedules Neostigmine bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09195MIG. The term NEOSTIGMINE BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule neostigmine bromide under HS 29242995 and SITC 51479. As of Q4 2014, NEOSTIGMINE BROMIDE remains US FDA's Preferred Term for this commodity. Neostigmine bromide bears US NLM identifiers UMLS ID C0282261 and NCI Concept Code C76612. SMILES: CN(C)C(=O)OC1CCCC(C1)[N+](C)(C)C.[BR-].
This classification denotes an anti-asthmatic agent with the molecular formula C45H58N10O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XW59TYL1XH, chemically known as men-11,420 but generally known as nepadutant, which bears US NIH Compound Identifier 3086682. European Medicines Agency schedules Nepadutant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09196MIG. The term NEPADUTANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). NEPADUTANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nepadutant under HS 29349990 and SITC 51579. As of Q4 2014, NEPADUTANT remains the US FDA Preferred Term for this commodity. Nepadutant bears US NLM identifiers UMLS ID C0664922 and NCI Concept Code C84001. SMILES: O1C(NC(=O)CC(N)C(=O)NC2CC(=O)NCC(NC(=O)C(NC(=O)C(NC2=O)CC2C3C([NH]C2)CCCC3)CC2CCCCC2)C(=O)NC(CC(C)C)C(=O)O)C(NC(=O)C)C(O)C(O)C1CO.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0J9L7J6V8C, chemically known as benzeneacetamide, 2-amino-3-benzoyl- but generally known as nepafenac, which bears US NIH Compound Identifier 151075. European Medicines Agency schedules Nepafenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09197MIG. The term NEPAFENAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules nepafenac in its Anatomical Therapeutic Chemical (ATC) Classification. NEPAFENAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nepafenac under HS 29242995 and SITC 51479. As of Q4 2014, NEPAFENAC remains the US FDA Preferred Term for this commodity. Nepafenac bears US NLM identifiers UMLS ID C0961209 and NCI Concept Code C66228. SMILES: O=C(C1C(N)C(CC(=O)N)CCC1)C1CCCCC1.
This classification denotes an enzyme inhibitor with the molecular formula C14H15F2N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VPG12K4540, chemically known as 5-(aminomethyl)-1-((s)-5,7-difluoro-1,2,3,4-tetrahydro-2-naphthyl)-4-imidazoline-2-thione but generally known as nepicastat, which bears US NIH Compound Identifier 6367078. European Medicines Agency schedules Nepicastat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09199MIG. The term NEPICASTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). NEPICASTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nepicastat under HS 29332990 and SITC 51573. As of Q4 2014, NEPICASTAT remains the US FDA Preferred Term for this commodity. Nepicastat bears US NLM identifiers UMLS ID C0668779 and NCI Concept Code C84003. SMILES: S=C1[NH](C2CCC3C(C2)CC(F)CC3F)C(=CN1)CN.
This classification denotes an antitussive agent with the molecular formula C18H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L9806LPR7G, chemically known as (- )-3,4-dihydro-1-methyl-1-(2-piperidinoethyl)-2(1h)-naphthalenone. but more generally known as nepinalone, which bears US NIH Compound Identifier 3047788. European Medicines Agency schedules Nepinalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09200MIG. The term NEPINALONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules nepinalone in its Anatomical Therapeutic Chemical (ATC) Classification. NEPINALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nepinalone under HS 29333999 and SITC 51574. As of Q4 2014, NEPINALONE remains US FDA's Preferred Term for this commodity. Nepinalone bears US NLM identifiers UMLS ID C2698448 and NCI Concept Code C76475. SMILES: O=C1C(CCN2CCCCC2)(C2C(CC1)CCCC2)C.
This classification denotes a nitrosourea compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VB67O9FBGM. European Medicines Agency schedules Neptamustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09201MIG. Neptamustine generally arises in the molecular formula C8H16CLN3O2. The term NEPTAMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) NEPTAMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Neptamustine or pentamustine bears US NLM identifiers UMLS ID C1882315 and NCI Concept Code C66341. SMILES: CLCCN(N=O)C(=O)NCC(C)(C)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H5HKR8OEF3, chemically known as (- )-1-(1h-indazol-4-yloxy)-3-((2-(2,6-xylidino)ethyl)amino)-2-propanol but generally known as neraminol, which bears US NIH Compound Identifier 3047789. European Medicines Agency schedules Neraminol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09203MIG. The term NERAMINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). NERAMINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule neraminol under HS 29339990 and SITC 51577. As of Q4 2014, NERAMINOL remains the US FDA Preferred Term for this commodity. Neraminol bears US NLM identifiers UMLS ID C2698450 and NCI Concept Code C76552. SMILES: O(CC(O)CNCCNC1C(CCCC1C)C)C1C2C([NH]NC2)CCC1.
This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C6H17NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8U27U3RIN4, chemically known as 6-amino-1-hydroxyhexane-1,1-diphosphonate but generally known as neridronic acid, which bears US NIH Compound Identifier 71237. European Medicines Agency schedules Neridronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09205MIG. The term NERIDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). As of Q4 2014, NERIDRONIC ACID remains the US FDA Preferred Term for this commodity. Neridronic acid bears US NLM identifiers UMLS ID C1882065 and NCI Concept Code C66230. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CCCCCN.
This classification denotes a vasodilating agent with the molecular formula C23H28N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QRY8KPT3QI, chemically known as (rs)-1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-2-propanol but generally known as nesapidil, which bears US NIH Compound Identifier 175512. European Medicines Agency schedules Nesapidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09207MIG. The term NESAPIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). NESAPIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nesapidil under HS 29349990 and SITC 51579. As of Q4 2014, NESAPIDIL remains the US FDA Preferred Term for this commodity. Nesapidil bears US NLM identifiers UMLS ID C1882067 and NCI Concept Code C66232. SMILES: OC(CN1CCN(CC1)c1c(OC)cccc1)COc1cc(ccc1)c1oc(nn1)C.
This classification denotes a nppb gene, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7WI8UL647. European Medicines Agency schedules Nesiritide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12539MIG. Nesiritide generally arises in the molecular formula C143H244N50O42S4. The term NESIRITIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule nesiritide under HS 29349990 and SITC 51579. As of Q4 2014, NESIRITIDE remains the US FDA Preferred Term for this commodity. Nesiritide bears US NLM identifiers UMLS ID C0054015 and NCI Concept Code C47636. SMILES: CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C3CCCN3C(=O)C(CO)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC4=CN=CN4)C(=O)O)CC(C)C)CO)CO)CO)CO.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a mucolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 445J9K442Z. European Medicines Agency schedules Nesosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09208MIG. Nesosteine generally arises in the molecular formula C11H11NO3S. The term NESOSTEINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, no. 5, 1985, list 25.) NESOSTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nesosteine under HS 29341000 and SITC 51579. As of Q4 2014, NESOSTEINE remains US FDA's Preferred Term for this commodity. Nesosteine bears US NLM identifiers UMLS ID C0068574 and NCI Concept Code C66233. SMILES: C1CSCN1C(=O)C2=CC=CC=C2C(=O)O.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C11H14N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52915ASM3D, chemically known as 3,7-dihydro-1,3-dimethyl-7-(1,3-dithiolan-2-ylmethyl)-1h-purine-2,6-dione but generally known as nestifylline, which bears US NIH Compound Identifier 65931. European Medicines Agency schedules Nestifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09209MIG. The term NESTIFYLLINE is an International Non-Proprietary Name. NESTIFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nestifylline under HS 29395900 and SITC 54145. As of Q4 2014, NESTIFYLLINE remains the US FDA Preferred Term for this commodity. Nestifylline bears US NLM identifiers UMLS ID C1882069 and NCI Concept Code C66234. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3SCCS3.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KVL61ZF9UO. European Medicines Agency schedules Neticonazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14639MIG. Neticonazole generally arises in the molecular formula C17H22N2OS. The term NETICONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) NETICONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule neticonazole under HS 29332990 and SITC 51573. As of Q4 2014, NETICONAZOLE remains the US FDA Preferred Term for this commodity. Neticonazole bears US NLM identifiers UMLS ID C0249830 and NCI Concept Code C66235. SMILES: S(/C=C(/N1CCNC1)C1C(OCCCCC)CCCC1)C.
This classification denotes an antifungal agent with the molecular formula C17H22N2OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PKF582ZH6P, chemically known as 1-((e)-1-(2-amoxyphenyl)-2-(methylthio)vinyl)imidazole hydrochloride, but more generally known as neticonazole hydrochloride, which bears US NIH Compound Identifier 5282432. European Medicines Agency schedules neticonazole hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14639MIG. Most nations, for tariff purposes, schedule neticonazole hydrochloride under HS 29332990. SMILES: CCCCCOC1CCCCC1/C(=C\SC)/N2CCNC2.CL.
This classification denotes an aminoglycoside antibiotic with the molecular formula C21H41N5O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O5J85GJJB, chemically known as o-(2,6-diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-o-(3-desoxy-4-c-methyl-3-methylamino-beta-l-arabinopyranosyl-(1-6)-2-desoxy-n1-ethyl-d-streptamin but generally known as netilmicin, which bears US NIH Compound Identifier 41859. European Medicines Agency schedules Netilmicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09210MIG. The term NETILMICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules netilmicin in its Anatomical Therapeutic Chemical (ATC) Classification. NETILMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule netilmicin under HS 29419000 and SITC 54139. As of Q4 2014, NETILMICIN remains the US FDA Preferred Term for this commodity. Netilmicin bears US NLM identifiers UMLS ID C0027780 and NCI Concept Code C66236. SMILES: O(C1C(NCC)CC(N)C(OC2OC(=CCC2N)CN)C1O)C1OCC(O)(C(NC)C1O)C.
This classification denotes an aminoglycoside antibiotic with the molecular formula 2C21H41N5O7.5H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S741ZJS97U, chemically known as o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1->6))-2-deoxy-n(sup 3)-ethyl-l-streptamine sulfate (2:5) (salt) but more generally known as netilmicin sulfate, which bears US NIH Compound Identifier 62115. European Medicines Agency schedules Netilmicin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03415MIG. Most nations, for tariff and trade purposes, schedule netilmicin sulfate under HS 29419000 and SITC 54139. Netilmicin sulfate bears US NLM identifiers UMLS ID C0700550 and NCI Concept Code C66237. SMILES: As of Q4 2014, NETILMICIN SULFATE remains US FDA's Preferred Term for this commodity.
This classification denotes an antihelminthic agent with the molecular formula C14H20N4O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U30C54N3MU, chemically known as ethanesulfonic acid, 2-((((methoxycarbonyl)amino)((2-nitro-5-(propylthio)phenyl)imino)methyl)amino)- but generally known as netobimin, which bears US NIH Compound Identifier 71449. European Medicines Agency schedules Netobimin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09212MIG. The term NETOBIMIN is an International Non-Proprietary Name. NETOBIMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule netobimin under HS 29309085 and SITC 51549. As of Q4 2014, NETOBIMIN remains the US FDA Preferred Term for this commodity. Netobimin bears US NLM identifiers UMLS ID C0068578 and NCI Concept Code C66238. SMILES: S(=O)(=O)(O)CC/N=C(/NC1C([N](=O)O)CCC(SCCC)C1)NC(=O)OC.
This classification denotes an anti-diabetic agent with the molecular formula C21H16FNO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) QOV2JZ647A, chemically known as 2,4-thiazolidinedione, 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)- but more generally known as netoglitazone, which bears US NIH Compound Identifier 204109. The term NETOGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16., No. 1.2002, List 47). Most nations, for tariff and trade purposes, schedule netoglitazone under HS 29341000 and SITC 51579. As of Q4 2014, NETOGLITAZONE remains US FDA's Preferred Term for this commodity. Netoglitazone bears US NLM identifiers UMLS ID C1721279 and NCI Concept Code C72822. SMILES: C1=CC=C(C(=C1)COC2=CC3=C(C=C2)C=C(C=C3)CC4C(=O)NC(=O)S4)F.
Netupitant/palonosetron is a fixed-dose combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting.
This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99DK7FVK1H. European Medicines Agency schedules Nevirapine, anhydrous in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25191. Nevirapine generally arises in the molecular formula C15H14N4O. The term NEVIRAPINE is a European Pharmacopoeia designation. NEVIRAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nevirapine under HS 29339940 and SITC 51577. As of Q4 2014, NEVIRAPINE remains the US FDA Preferred Term for this commodity. Nevirapine bears US NLM identifiers UMLS ID C0132326 and NCI Concept Code C29277. SMILES: O=C1[NH]C2C(N(C3CC3)C3NCCCC13)NCCC2C.
This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The second component, EMTRICITABINE, has US FDA Unique Ingredient Identifier of G70B4ETF4S. The third component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.
This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.
This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.
This classification denotes a reverse transcriptase inhibitor with the molecular formula 2C15H14N4O.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B7XF2TD73C. European Medicines Agency schedules nevirapine hemihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34149. Most nations, for tariff and trade purposes, schedule nevirapine hemihydrate under HS 29339940 and SITC 51577. As of Q4 2014, NEVIRAPINE HEMIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCNC2C1NC(=O)C3CCCNC3N2C4CC4.CC1CCNC2C1NC(=O)C3CCCNC3N2C4CC4.O.
This clasification denotes vaccines to treat an acute febrile, contagious, viral disease of birds caused by an avulavirus called newcastle disease virus. It is characterized by respiratory and nervous symptoms in fowl and is transmissible to man causing a severe, but transient conjunctivitis.
This classification denotes a b vitamin with the molecular formula C6H6N2O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4D16EOF1QW. Most nations, for tariff and trade purposes, schedule niacinamide hydrochloride under HS 29362900. As of Q4 2014, NIACINAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CNC1)C(=O)N.CL.
This classification denotes a b vitamin with the molecular formula C6H6N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25X51I8RD4, chemically known as pyridine, 3-carbamoyl- but generally known as niacinamide, which bears US NIH Compound Identifier 936. European Medicines Agency schedules Niacinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20661. The term NICOTINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules niacinamide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule niacinamide under HS 29362900 and SITC 54116. As of Q4 2014, NIACINAMIDE remains the US FDA Preferred Term for this commodity. Niacinamide bears US NLM identifiers UMLS ID C0028027 and NCI Concept Code C2327. SMILES: O=C(N)C1CCCNC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT109. This VA Drug Class (VT109) classifies this compound as belonging to the group VITAMIN B, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN550. This VA Drug Class (CN550) classifies this compound as belonging to the group ANTIVERTIGO AGENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT109. This VA Drug Class (VT109) classifies this compound as belonging to the group VITAMIN B, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT900. This VA Drug Class (VT900) classifies this compound as belonging to the group VITAMINS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV350. This VA Drug Class (CV350) classifies this compound as belonging to the group ANTILIPEMIC AGENTS.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C16H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2Q0RYM725, chemically known as 4-pyridinecarboxylic acid, 2-(3-oxo-3-((phenylmethyl)amino)propyl)hydrazide (9ci) but generally known as nialamide, which bears US NIH Compound Identifier 4472. European Medicines Agency schedules Nialamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09217MIG. The term NIALAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules nialamide in its Anatomical Therapeutic Chemical (ATC) Classification. NIALAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nialamide under HS 29333999 and SITC 51574. As of Q4 2014, NIALAMIDE remains the US FDA Preferred Term for this commodity. Nialamide bears US NLM identifiers UMLS ID C0027999 and NCI Concept Code C80970. SMILES: O=C(NCc1ccccc1)CCNNC(=O)c1ccncc1.
This classification denotes a sedative and hypnotic with the molecular formula C20H25FN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R2H3YN6E3L, chemically known as 3-pyridinecarboxamide, n-(3-(4-(4-fluorophenyl)-1-piperazinyl)-1-methylpropyl)- (9ci) but generally known as niaprazine, which bears US NIH Compound Identifier 71919. European Medicines Agency schedules Niaprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09218MIG. The term NIAPRAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules niaprazine in its Anatomical Therapeutic Chemical (ATC) Classification. NIAPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule niaprazine under HS 29335995 and SITC 51576. As of Q4 2014, NIAPRAZINE remains the US FDA Preferred Term for this commodity. Niaprazine bears US NLM identifiers UMLS ID C0068673 and NCI Concept Code C76943. SMILES: FC1CCC(N2CCN(CC2)CCC(NC(=O)C2CCCNC2)C)CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C21H27N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UA960P80H, chemically known as 1,2,3,4-tetrahydro-8-(2-hydroxy-3-(isopropylamino)propoxy)-1-(3-pyridylcarbonyl)quinoline but generally known as nicainoprol, which bears US NIH Compound Identifier 71147. European Medicines Agency schedules Nicainoprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09221MIG. The term NICAINOPROL is an International Non-Proprietary Name. NICAINOPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicainoprol under HS 29334990 and SITC 51575. As of Q4 2014, NICAINOPROL remains the US FDA Preferred Term for this commodity. Nicainoprol bears US NLM identifiers UMLS ID C0068676 and NCI Concept Code C76553. SMILES: O(C1C2N(CCCC2CCC1)C(=O)C1CCCNC1)CC(O)CNC(C)C.
This classification denotes an antioxidant and anti-lipidemic agent with the molecular formula C23H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85DV2PAF78, chemically known as 2,6-di-tert-butyl-4-(3-(3-pyridylmethoxy)propyl)phenol but generally known as nicanartine, which bears US NIH Compound Identifier 66001. European Medicines Agency schedules Nicanartine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09223MIG. The term NICANARTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). NICANARTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicanartine under HS 29333999 and SITC 51574. As of Q4 2014, NICANARTINE remains the US FDA Preferred Term for this commodity. Nicanartine bears US NLM identifiers UMLS ID C0391211 and NCI Concept Code C75298. SMILES: Oc1c(C(C)(C)C)cc(cc1C(C)(C)C)CCCOCc1cccnc1.
This classification denotes a calcium channel blocker with the molecular formula C15H16N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UD8PEV6JBD, chemically known as 1,2-bis(nicotinamido)propane but generally known as nicaraven, which bears US NIH Compound Identifier 71234. European Medicines Agency schedules Nicaraven in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09224MIG. The term NICARAVEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). NICARAVEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicaraven under HS 29333999 and SITC 51574. As of Q4 2014, NICARAVEN remains the US FDA Preferred Term for this commodity. Nicaraven bears US NLM identifiers UMLS ID C0043778 and NCI Concept Code C76580. SMILES: O=C(NC(CNC(=O)c1cccnc1)C)c1cccnc1.
This classification denotes a calcium channel blocker with the molecular formula C26H29N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CZ5312222S, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester but generally known as nicardipine, which bears US NIH Compound Identifier 4474. European Medicines Agency schedules Nicardipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09225MIG. The term NICARDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules nicardipine in its Anatomical Therapeutic Chemical (ATC) Classification. NICARDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicardipine under HS 29333999 and SITC 51574. As of Q4 2014, NICARDIPINE remains the US FDA Preferred Term for this commodity. Nicardipine bears US NLM identifiers UMLS ID C0028005 and NCI Concept Code C66879. SMILES: O(C(=O)C1=C(NC(=C(C1C1CC([N](=O)O)CCC1)C(=O)OC)C)C)CCN(CC1CCCCC1)C.
This classification denotes a calcium channel blockader, antihypertensive agent, and vasodilator agent with the molecular formula C26H29N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5BC5011K3, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester, monohydrochloride but more generally known as nicardipine hydrochloride, which bears US NIH Compound Identifier 41114. European Medicines Agency schedules Nicardipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03420MIG. Most nations, for tariff and trade purposes, schedule nicardipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, NICARDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nicardipine hydrochloride bears US NLM identifiers UMLS ID C0770150 and NCI Concept Code C29840. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2CCCCC2)C3CCCC(C3)[N+](=O)[O-])C(=O)OC.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C24H26BrN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JCV8365FWN, chemically known as 10-methoxy-1,6-dimethylergoline-8.beta.-methanol 5-bromonicotinate ester but generally known as nicergoline, which bears US NIH Compound Identifier 4475. European Medicines Agency schedules Nicergoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09226MIG. The term NICERGOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules nicergoline in its Anatomical Therapeutic Chemical (ATC) Classification. NICERGOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicergoline under HS 29396900 and SITC 54146. As of Q4 2014, NICERGOLINE remains the US FDA Preferred Term for this commodity. Nicergoline bears US NLM identifiers UMLS ID C0028008 and NCI Concept Code C84006. SMILES: BRC1CC(C(=O)OCC2CC3(OC)C(N(C2)C)CC2C4C3CCCC4N(C2)C)CNC1.
This classification denotes an alpha-adrenergic blocking agent C24H26BrN3O3.C6H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J7P36Z4900, chemically known as ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester), (8.beta.)-, (2r,3r)-2,3-dihydroxybutanedioate (salt), but more generally known as nicergoline tartrate, which bears US NIH Compound Identifier 134961. European Medicines Agency schedules Nicergoline tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23254. Most nations, for tariff and trade purposes, schedule nicergoline tartrate under HS 29396900 and SITC 54146. As of Q4 2014, NICERGOLINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H]([C@@H](C)C(=O)O)C(=O)O.CN1CC2C3C1CCCC3[C@]4(C[C@H](CN([C@@H]4C2)C)COC(=O)C5CC(CNC5)BR)OC.
This classification denotes an anti-lipidemic agent with the molecular formula C29H24N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F54EHJ34MV, chemically known as 3-pyridinecarboxylic acid, 2,2-bis(((3-pyridinylcarbonyl)oxy)methyl)-1,3-propanediyl ester but generally known as niceritrol, which bears US NIH Compound Identifier 4476. European Medicines Agency schedules Niceritrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09227MIG. The term NICERITROL is an International Non-Proprietary Name. World Health Organization schedules niceritrol in its Anatomical Therapeutic Chemical (ATC) Classification. NICERITROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule niceritrol under HS 29333999 and SITC 51574. As of Q4 2014, NICERITROL remains the US FDA Preferred Term for this commodity. Niceritrol bears US NLM identifiers UMLS ID C0028009 and NCI Concept Code C75257. SMILES: O(CC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)C(=O)c1cccnc1.
This classification denotes an antihelminthic agent with the molecular formula C13H8Cl2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KK8CQ2K8G, chemically known as 2′,5-dichloro-4′-nitrosalicylanilide but generally known as niclosamide, which bears US NIH Compound Identifier 4477. European Medicines Agency schedules Niclosamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09230MIG. The term NICLOSAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules niclosamide in its Anatomical Therapeutic Chemical (ATC) Classification. NICLOSAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule niclosamide under HS 29242995 and SITC 51479. As of Q4 2014, NICLOSAMIDE remains the US FDA Preferred Term for this commodity. Niclosamide bears US NLM identifiers UMLS ID C0028017 and NCI Concept Code C66240. SMILES: CLC1C(NC(=O)C2C(O)CCC(CL)C2)CCC([N](=O)O)C1.
This classification denotes an antihelminthic agent C13H8Cl2N2O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 20Z25R1145, chemically known as benzamide, 5-chloro-n-(2-chloro-4-nitrophenyl)-2-hydroxy-, hydrate (1:1), but more generally known as niclosamide monohydrate, which bears US NIH Compound Identifier 12296604. European Medicines Agency schedules Niclosamide monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12175MIG. Most nations, for tariff and trade purposes, schedule niclosamide monohydrate under HS 29242995 and SITC 51479. As of Q4 2014, NICLOSAMIDE MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(C(CC1[N+](=O)[O-])CL)NC(=O)C2CC(CCC2O)CL.O.
This classification denotes an analgesic agent with the molecular formula C12H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GSD5B9US0W, chemically known as 3-pyridinecarboxylic acid, butoxyethyl ester but generally known as nicoboxil, which bears US NIH Compound Identifier 14866. European Medicines Agency schedules Nicoboxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09231MIG. The term NICOBOXIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). NICOBOXIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicoboxil under HS 29333999 and SITC 51574. As of Q4 2014, NICOBOXIL remains the US FDA Preferred Term for this commodity. Nicoboxil bears US NLM identifiers UMLS ID C0770962 and NCI Concept Code C84007. SMILES: CCCCOCCOC(=O)C1=CN=CC=C1.
This classification denotes an antitussive agent with the molecular formula C24H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) DYX391P13E, chemically known as morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, 3-pyridinecarboxylate (ester), (5.alpha.,6.alpha.)- but more generally known as nicocodine, which bears US NIH Compound Identifier 520825. European Medicines Agency schedules Nicocodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09233MIG. The term NICOCODINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). NICOCODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nicocodine under HS 29391900 and SITC 54141. As of Q4 2014, NICOCODINE remains US FDA's Preferred Term for this commodity. Nicocodine bears US NLM identifiers UMLS ID C0068697 and NCI Concept Code C84008. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)C=CC2OC(=O)C1CCCNC1.
This classification denotes an antitussive agent with the molecular formula C24H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 04G0T06UGT, chemically known as morphinan-6-ol, 4,5-epoxy-3-methoxy-17-methyl-, 3-pyridinecarboxylate (ester), (5.alpha.,6.alpha.)- but more generally known as nicodicodine, which bears US NIH Compound Identifier 522741. European Medicines Agency schedules Nicodicodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09235MIG. The term NICODICODINE is an International Non-Proprietary Name. NICODICODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nicodicodine under HS 29391900 and SITC 54141. As of Q4 2014, NICODICODINE remains US FDA's Preferred Term for this commodity. Nicodicodine bears US NLM identifiers UMLS ID C2827287 and NCI Concept Code C84010. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)CCC2OC(=O)C1CCCNC1.
This classification denotes a vasodilating agent and anti-lipidemic agent with the molecular formula C30H24N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GF99P6327K, chemically known as 1,3,4,6-tetra-o-nicotinoyl-d-fructofuranose but generally known as nicofuranose, which bears US NIH Compound Identifier 25495. European Medicines Agency schedules Nicofuranose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09237MIG. The term NICOFURANOSE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules nicofuranose in its Anatomical Therapeutic Chemical (ATC) Classification. NICOFURANOSE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicofuranose under HS 29400000 and SITC 51692. As of Q4 2014, NICOFURANOSE remains the US FDA Preferred Term for this commodity. Nicofuranose bears US NLM identifiers UMLS ID C0354652 and NCI Concept Code C83921. SMILES: O1C(O)(C(OC(=O)c2cccnc2)C(OC(=O)c2cccnc2)C1COC(=O)c1cccnc1)COC(=O)c1cccnc1.
This classification denotes an antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DW310SVK6Q. European Medicines Agency schedules Nicogrelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09239MIG. Nicogrelate generally arises in the molecular formula C17H21N3O2. The term NICOGRELATE is an International Non-Proprietary Name or INN. NICOGRELATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicogrelate under HS 29333999 and SITC 51574. As of Q4 2014, NICOGRELATE remains the US FDA Preferred Term for this commodity. Nicogrelate bears US NLM identifiers UMLS ID C2698462 and NCI Concept Code C76399. SMILES: O(C(CCCCC)/C=C/N1CCNC1)C(=O)C1CCCNC1.
This classification denotes a morphine derivative and nicotinic acid with the molecular formula C29H25N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y95FRL95FW, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5.alpha.,6.alpha.)-, di-3-pyridinecarboxylate (ester) but generally known as nicomorphine, which bears US NIH Compound Identifier 571623. European Medicines Agency schedules Nicomorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09241MIG. World Health Organization schedules nicomorphine in its Anatomical Therapeutic Chemical (ATC) Classification. NICOMORPHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicomorphine under HS 29391100 and SITC 54141. As of Q4 2014, NICOMORPHINE remains the US FDA Preferred Term for this commodity. SMILES: CN1CCC23C4C1CC5=C2C(=C(C=C5)OC(=O)C6=CN=CC=C6)OC3C(C=C4)OC(=O)C7=CN=CC=C7.
This classification denotes a morphine derivative and nicotinic acid C29H25N3O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7A91YL2XT2, chemically known as morphinan-3,6.alpha.-diol, 7,8-didehydro-4,5.alpha.-epoxy-17-methyl-, dinicotinate (ester), hydrochloride, but more generally known as nicomorphine hydrochloride, which bears US NIH Compound Identifier 166031. European Medicines Agency schedules Nicomorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22390. Most nations, for tariff and trade purposes, schedule nicomorphine hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, NICOMORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)OC(=O)C6CCCNC6)OC(=O)C7CCCNC7.CL.
This classification denotes a neuroprotective agent with the molecular formula C11H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8U10GC2V6Y, chemically known as 2-pyrrolidinone, 1-((6-methoxy-3-pyridinyl)carbonyl)- but generally known as nicoracetam, which bears US NIH Compound Identifier 3047790. European Medicines Agency schedules Nicoracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09243MIG. The term NICORACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Most nations schedule nicoracetam under HS 29337900 and SITC 51561. As of Q4 2014, NICORACETAM remains the US FDA Preferred Term for this commodity. Nicoracetam bears US NLM identifiers UMLS ID C2698464 and NCI Concept Code C76782. SMILES: COC1=NC=C(C=C1)C(=O)N2CCCC2=O.
This classification denotes a vasodilating agent with the molecular formula C8H9N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 260456HAM0, chemically known as 3-pyridinecarboxamide, n-(2-(nitroxy)ethyl)- but generally known as nicorandil, which bears US NIH Compound Identifier 47528. European Medicines Agency schedules Nicorandil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09244MIG. The term NICORANDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules nicorandil in its Anatomical Therapeutic Chemical (ATC) Classification. NICORANDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicorandil under HS 29333999 and SITC 51574. As of Q4 2014, NICORANDIL remains the US FDA Preferred Term for this commodity. Nicorandil bears US NLM identifiers UMLS ID C0068700 and NCI Concept Code C84012. SMILES: O([N](=O)O)CCNC(=O)C1CCCNC1.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M3C89ZY6R, chemically known as xl all insecti-cide, emo-nib but generally known as nicotine, which bears US NIH Compound Identifier 942. European Medicines Agency schedules Nicotine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14645MIG. World Health Organization schedules nicotine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule nicotine under HS 29399990 and SITC 54149. As of Q4 2014, NICOTINE remains the US FDA Preferred Term for this commodity. Nicotine bears US NLM identifiers UMLS ID C0028040 and NCI Concept Code C691. SMILES: CN1CCCC1C2=CN=CC=C2.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2.2C4H6O6.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R7M676M8YV, chemically known as pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (s)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:2) (9ci) but more generally known as nicotine bitartrate, which bears US NIH Compound Identifier 6174. Most nations, for tariff and trade purposes, schedule nicotine bitartrate under HS 29399990 and SITC 54149. As of Q4 2014, NICOTINE BITARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCC[C@H]1C2CCCNC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.O.O.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I16I55623S, chemically known as nicotine dihydrochloride, (-)-, but more generally known as nicotine dihydrochloride, which bears US NIH Compound Identifier 80115. European Medicines Agency schedules nicotine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14645MIG. Most nations, for tariff purposes, schedule nicotine dihydrochloride under HS 29399990. SMILES: CN1CCC[C@H]1C2CCCNC2.CL.CL.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ELZ2L53YNE, chemically known as nicotine monohydrochloride, (-)-, but more generally known as nicotine hydrochloride, which bears US NIH Compound Identifier 17784. European Medicines Agency schedules nicotine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14645MIG. Most nations, for tariff purposes, schedule nicotine hydrochloride under HS 29399990. SMILES: CN1CCC[C@H]1C2CCCNC2.CL.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2.2C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7892ZN5G41, chemically known as nicotine l-(+)-tartrate (1:2), but more generally known as nicotine hydrogen tartrate, which bears US NIH Compound Identifier 6174. European Medicines Agency schedules nicotine hydrogen tartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14645MIG. Most nations, for tariff purposes, schedule nicotine hydrogen tartrate under HS 29399990. SMILES: CN1CCC[C@H]1C2CCCNC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M3C89ZY6R, chemically known as xl all insecti-cide, emo-nib but more generally known as nicotine, which bears US NIH Compound Identifier 942. European Medicines Agency schedules Nicotine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14645MIG. World Health Organization schedules nicotine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule nicotine polacrilex under HS 29399990 and SITC 54149. SMILES: CN1CCC[C@H]1C2CCCNC2.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2.C7H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 744Q1CL77H. Most nations, for tariff and trade purposes, schedule nicotine salicylate under HS 29399990 and SITC 54149. As of Q4 2014, NICOTINE SALICYLATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCC[C@H]1C2CCCNC2.C1CCC(C(C1)C(=O)O)O.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula 2C10H14N2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UX4GTH155W, chemically known as (s)-3-(1-methyl-2-pyrrolidinyl)-pyridine sulfate, but more generally known as nicotine sulfate, which bears US NIH Compound Identifier 6173. European Medicines Agency schedules nicotine sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14645MIG. Most nations, for tariff purposes, schedule nicotine sulfate under HS 29399990. SMILES: CN1CCC[C@H]1C2CCCNC2.CN1CCC[C@H]1C2CCCNC2.OS(=O)(=O)O.
This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2.2C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7892ZN5G41, chemically known as pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (s)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:2) (9ci) but more generally known as nicotine tartrate, which bears US NIH Compound Identifier 6174. European Medicines Agency schedules Nicotine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22391. Most nations, for tariff and trade purposes, schedule nicotine tartrate under HS 29399990. SMILES: CN1CCC[C@H]1C2CCCNC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TF312056Y. European Medicines Agency schedules Nicotinyl alcohol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14650MIG. Nicotinyl alcohol generally arises in the molecular formula C6H7NO. The term 'nicotinyl alcohol' is a United States Adopted Name designation. SMILES: C1=CC(=CN=C1)CO.
This classification denotes a uricosuric agent with the molecular formula C6H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z3H2D4MF7A, chemically known as 3-pyridinecarboxamide, n-hydroxy- but generally known as nicoxamat, which bears US NIH Compound Identifier 71211. European Medicines Agency schedules Nicoxamat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09249MIG. The term NICOXAMAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). NICOXAMAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nicoxamat under HS 29333999 and SITC 51574. As of Q4 2014, NICOXAMAT remains the US FDA Preferred Term for this commodity. Nicoxamat bears US NLM identifiers UMLS ID C2698465 and NCI Concept Code C77068. SMILES: O=C(NO)C1CCCNC1.
This classification denotes a calcium channel blocker with the molecular formula C17H18N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I9ZF7L6G2L, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-, dimethyl ester (8ci) but generally known as nifedipine, which bears US NIH Compound Identifier 4485. European Medicines Agency schedules Nifedipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09253MIG. The term NIFEDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules nifedipine in its Anatomical Therapeutic Chemical (ATC) Classification. NIFEDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifedipine under HS 29333999 and SITC 51574. As of Q4 2014, NIFEDIPINE remains the US FDA Preferred Term for this commodity. Nifedipine bears US NLM identifiers UMLS ID C0028066 and NCI Concept Code C29290. SMILES: O(C(=O)C1=C(NC(=C(C1C1C([N](=O)O)CCCC1)C(=O)OC)C)C)C.
This classification denotes a calcium channel blocker with the molecular formula C17H18N2O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9626V3KSPM, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester, hydrochloride (1:1), but more generally known as nifedipine hydrochloride, which bears US NIH Compound Identifier 63011. European Medicines Agency schedules nifedipine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09253MIG. Most nations, for tariff purposes, schedule nifedipine hydrochloride under HS 29333999. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC)C2CCCCC2[N+](=O)[O-])C(=O)OC.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H16N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8780F0K71U, chemically known as 2,3-dimethyl-4-nicotinamido-1-phenyl-3-pyrazolin-5-on but generally known as nifenazone, which bears US NIH Compound Identifier 4487. European Medicines Agency schedules Nifenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09256MIG. The term NIFENAZONE is an International Non-Proprietary Name. World Health Organization schedules nifenazone in its Anatomical Therapeutic Chemical (ATC) Classification. NIFENAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifenazone under HS 29333999 and SITC 51574. As of Q4 2014, NIFENAZONE remains the US FDA Preferred Term for this commodity. Nifenazone bears US NLM identifiers UMLS ID C0068738 and NCI Concept Code C76806. SMILES: O=C1N(N(C(C1NC(=O)C1CCCNC1)C)C)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H9F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4U5MP5IUD8, chemically known as 3-pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)- but generally known as niflumic acid, which bears US NIH Compound Identifier 4488. European Medicines Agency schedules Niflumic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09257MIG. The term NIFLUMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules niflumic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule niflumic acid under HS 29333999 and SITC 51574. As of Q4 2014, NIFLUMIC ACID remains the US FDA Preferred Term for this commodity. Niflumic acid bears US NLM identifiers UMLS ID C0028067 and NCI Concept Code C76807. SMILES: C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F.
This classification denotes a topical anti-infective agent with the molecular formula C8H8N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2VX65207DR, chemically known as 2-imidazolidinone, 1-(5-nitrofurfurylideneamino)- but more generally known as nifuradene, which bears US NIH Compound Identifier 11154. European Medicines Agency schedules Nifuradene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09258MIG. The term NIFURADENE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). NIFURADENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. NIFURADENE remains the US FDA Preferred Term for this commodity. Nifuradene bears NCI CUID C84015 and UMLS UID C2827289. Most nations, for tariff and trade purposes, schedule nifuradene under 29349990 and SITC 51579. SMILES: O1C(/C=N/N2CCNC2=O)CCC1[N](=O)O.
This classification denotes an anti-infective agent and antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98SRO07Q7S. European Medicines Agency schedules Nifuralide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09260MIG. Nifuralide generally arises in the molecular formula C14H13N5O4S. The term NIFURALIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, no. 10 1976, list 16.) NIFURALIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifuralide under HS 29341000 and SITC 51579. As of Q4 2014, NIFURALIDE remains the US FDA Preferred Term for this commodity. Nifuralide bears US NLM identifiers UMLS ID C2983803 and NCI Concept Code C90618. SMILES: S1C(NCC=C)NC(C1)C(=O)N/N=C/C=C/C1OC([N](=O)O)CC1.
This classification denotes an antifungal agents and antitrichomonal agents and antiprotozoal, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier U60U6P08SP. European Medicines Agency schedules Nifuratel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09261MIG. Nifuratel generally arises in the molecular formula C10H11N3O5S. The term NIFURATEL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 21 no. 12 1967, list 7.) NIFURATEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 699M5Q0YKN. European Medicines Agency schedules Nifurethazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09264MIG. Nifurethazone generally arises in the molecular formula C10H15N5O4. The term NIFURETHAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, no. 3 1962, list 4.) NIFURETHAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifurethazone under HS 29321900 and SITC 51569. As of Q4 2014, NIFURETHAZONE remains the US FDA Preferred Term for this commodity. Nifurethazone bears US NLM identifiers UMLS ID C2983964 and NCI Concept Code C90978. SMILES: CN(C)CCN(C(=O)N)/N=C/C1=CC=C(O1)[N+](=O)[O-].
This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) NII0A33SQL. European Medicines Agency schedules Nifurimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09266MIG. Nifurimide generally arises in the molecular formula C9H10N4O4. The term NIFURIMIDE is an International Non-Proprietary Name or INN. NIFURIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nifurimide under HS 29349990 and SITC 51579. As of Q4 2014, NIFURIMIDE remains US FDA's Preferred Term for this commodity. Nifurimide bears US NLM identifiers UMLS ID C2983966 and NCI Concept Code C90980. SMILES: O=C1N(/N=C/C2OC([N](=O)O)CC2)C(CN1)C.
This classification denotes an anti-infective agent with the molecular formula C12H13N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 26LO5Z6IHQ, chemically known as 1-imidazolidinecarboxamide, n-methyl-3-((3-(5-nitro-2-furyl)allylidene)amino)-2-oxo- but more generally known as nifurizone, which bears US NIH Compound Identifier 9577579. European Medicines Agency schedules Nifurizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09267MIG. The term NIFURIZONE is an International Non-Proprietary Name. NIFURIZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nifurizone under HS 29349990 and SITC 51579. As of Q4 2014, NIFURIZONE remains US FDA's Preferred Term for this commodity. Nifurizone bears US NLM identifiers UMLS ID C2983967 and NCI Concept Code C90981. SMILES: CNC(=O)N1CCN(C1=O)/N=C/C=C/C2=CC=C(O2)[N+](=O)[O-].
This classification denotes an anti-infective agent with the molecular formula C11H10N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) LOF2A7032C, chemically known as 3-(hydroxymethyl)-1-(3-(5-nitro-2-furyl)allylidenamino)-2,4-imidazolidindion but more generally known as nifurmazole, which bears US NIH Compound Identifier 72086. European Medicines Agency schedules Nifurmazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09268MIG. The term NIFURMAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). NIFURMAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nifurmazole under HS 29349990 and SITC 51579. As of Q4 2014, NIFURMAZOLE remains US FDA's Preferred Term for this commodity. Nifurmazole bears US NLM identifiers UMLS ID C0068740 and NCI Concept Code C84016. SMILES: C1C(=O)N(C(=O)N1/N=C/C=CC2=CC=C(O2)[N+](=O)[O-])CO.
This classification denotes an antifungal agent with the molecular formula C6H4ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F57Y390K2N, chemically known as ketone, chloromethyl 5-nitro-2-furyl but generally known as nifurmerone, which bears US NIH Compound Identifier 21753. European Medicines Agency schedules Nifurmerone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09269MIG. The term NIFURMERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). NIFURMERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifurmerone under HS 29321900 and SITC 51569. As of Q4 2014, NIFURMERONE remains the US FDA Preferred Term for this commodity. Nifurmerone bears US NLM identifiers UMLS ID C2347352 and NCI Concept Code C72592. SMILES: CLCC(=O)C1OC([N](=O)O)CC1.
This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PM5LI0P38J. European Medicines Agency schedules Nifuroxazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09271MIG. Nifuroxazide generally arises in the molecular formula C12H9N3O5. The term NIFUROXAZIDE is an International Non-Proprietary Name or INN. NIFUROXAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifuroxazide under HS 29321900 and SITC 51569. As of Q4 2014, NIFUROXAZIDE remains the US FDA Preferred Term for this commodity. Nifuroxazide bears US NLM identifiers UMLS ID C0068742 and NCI Concept Code C90982. SMILES: O1C(CCC1[N](=O)O)/C=N/NC(=O)C1CCC(O)CC1.
This classification denotes an anti-infective agent with the molecular formula C5H4N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 465N7P5U85, chemically known as 2-furancarboxaldehyde, 5-nitro-, oxime, (z)- but more generally known as nifuroxime, which bears US NIH Compound Identifier 22601. European Medicines Agency schedules Nifuroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09272MIG. The term NIFUROXIME is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). NIFUROXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifuroxime under HS 29321900 and SITC 51569. As of Q4 2014, NIFUROXIME remains the US FDA Preferred Term for this commodity. Nifuroxime bears US NLM identifiers UMLS ID C0028072 and NCI Concept Code C77053. SMILES: O1C(CCC1[N](=O)O)/C=N/O.
This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7O5A98XY8U. European Medicines Agency schedules Nifurpirinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09274MIG. Nifurpirinol generally arises in the molecular formula C12H10N2O4. The term NIFURPIRINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, no. 11 1970, list 10.) NIFURPIRINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifurpirinol under HS 29349990 and SITC 51579. As of Q4 2014, NIFURPIRINOL remains the US FDA Preferred Term for this commodity. Nifurpirinol bears US NLM identifiers UMLS ID C0068743 and NCI Concept Code C90983. SMILES: C1=CC(=NC(=C1)CO)/C=C/C2=CC=C(O2)[N+](=O)[O-].
This classification denotes an antimicrobial with the molecular formula C16H16N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 44E5RRL600, chemically known as 2,2-((2-(5-nitro-2-furyl)-4-quinazolinyl)imino)diethanol but more generally known as nifurquinazol, which bears US NIH Compound Identifier 21139. European Medicines Agency schedules Nifurquinazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09276MIG. The term NIFURQUINAZOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). NIFURQUINAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nifurquinazol under HS 29349990 and SITC 51579. As of Q4 2014, NIFURQUINAZOL remains US FDA's Preferred Term for this commodity. Nifurquinazol bears US NLM identifiers UMLS ID C2983987 and NCI Concept Code C91015. SMILES: OCCN(C1NC(NC2C1CCCC2)C1OC([N](=O)O)CC1)CCO.
This classification denotes an antiprotozoal agent with the molecular formula C10H13N3O5S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier M84I3K7C2O, chemically known as 4-thiomorpholinamine, 3-methyl-n-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide but more generally known as nifurtimox, which bears U.S. National Institutes of Health Compound Identifier 6842999. The European Medicines Agency schedules Nifurtimox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09280MIG. The term NIFURTIMOX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). The World Health Organization schedules nifurtimox in its Anatomical Therapeutic Chemical (ATC) Classification. NIFURTIMOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-].
This classification denotes a urinary anti-infective agent with the molecular formula C9H8N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 980688H13O, chemically known as 2,4-imidazolidinedione, 3-(hydroxymethyl)-1-(((5-nitro-2-furanyl)methylene)amino)- but more generally known as nifurtoinol, which bears US NIH Compound Identifier 9571062. European Medicines Agency schedules Nifurtoinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09281MIG. The term NIFURTOINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules nifurtoinol in its Anatomical Therapeutic Chemical (ATC) Classification. NIFURTOINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nifurtoinol under HS 29349990 and SITC 51579. As of Q4 2014, NIFURTOINOL remains US FDA's Preferred Term for this commodity. Nifurtoinol bears US NLM identifiers UMLS ID C0077875 and NCI Concept Code C90997. SMILES: O=C1N(C(=O)N(/N=C/C2OC([N](=O)O)CC2)C1)CO.
This classification denotes an anti-infective agent with the molecular formula C11H9N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0G95D5K2W, chemically known as 4-pyrimidinol, 2-methyl-6-(2-(5-nitro-2-furyl)vinyl)- but more generally known as nifurvidine, which bears US NIH Compound Identifier 6441378. European Medicines Agency schedules Nifurvidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09282MIG. The term NIFURVIDINE is an International Non-Proprietary Name. NIFURVIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nifurvidine under HS 29349990 and SITC 51579. As of Q4 2014, NIFURVIDINE remains the US FDA Preferred Term for this commodity. Nifurvidine bears US NLM identifiers UMLS ID C2827290 and NCI Concept Code C84017. SMILES: CC1=NC(=O)C=C(N1)/C=C/C2=CC=C(O2)[N+](=O)[O-].
This classification denotes an anti-infective agent with the molecular formula C12H8N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Z35R6K4C26, chemically known as 2-thiophenecarboxylic acid, 5-nitro-, (3-(5-nitro-2-furanyl)-2-propenylidene)hydrazide but more generally known as nifurzide, which bears US NIH Compound Identifier 9571044. European Medicines Agency schedules Nifurzide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09283MIG. The term NIFURZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules nifurzide in its Anatomical Therapeutic Chemical (ATC) Classification. NIFURZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nifurzide under HS 29349990 and SITC 51579. As of Q4 2014, NIFURZIDE remains US FDA's Preferred Term for this commodity. Nifurzide bears US NLM identifiers UMLS ID C0068746 and NCI Concept Code C90985. SMILES: S1C(CCC1[N](=O)O)C(=O)N/N=C/C=C/C1OC([N](=O)O)CC1.
This classification denotes a calcium channel blocker with the molecular formula C36H39N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z81N45O25Z, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(4,4-diphenyl-1-piperidinyl)propyl methyl ester but generally known as niguldipine, which bears US NIH Compound Identifier 1236. European Medicines Agency schedules Niguldipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09284MIG. The term NIGULDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). Most nations schedule niguldipine under HS 29333999 and SITC 51574. As of Q4 2014, NIGULDIPINE remains the US FDA Preferred Term for this commodity. Niguldipine bears US NLM identifiers UMLS ID C0068753 and NCI Concept Code C84018. SMILES: O(CCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C(=O)C1=C(NC(=C(C1c1cc([N](=O)O)ccc1)C(=O)OC)C)C.
This classification denotes a cns stimulant with the molecular formula C10H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 368IVD6M32, chemically known as 3-pyridinecarboxamide, n,n-diethyl- but more generally known as nikethamide, which bears US NIH Compound Identifier 5497. European Medicines Agency schedules Nikethamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09286MIG. The term NIKETHAMIDE is an International Non-Proprietary Name. World Health Organization schedules nikethamide in its Anatomical Therapeutic Chemical (ATC) Classification. NIKETHAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nikethamide under HS 29333999 and SITC 51574. As of Q4 2014, NIKETHAMIDE remains US FDA's Preferred Term for this commodity. Nikethamide bears US NLM identifiers UMLS ID C0028089 and NCI Concept Code C76625. SMILES: CCN(CC)C(=O)C1=CN=CC=C1.
This classification denotes a steroidal estrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JA3B3IALU. European Medicines Agency schedules Nilestriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09288MIG. Nilestriol generally arises in the molecular formula C25H32O3. The term NILESTRIOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) NILESTRIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Nilestriol or nylestriol bears US NLM identifiers UMLS ID C0069173 and NCI Concept Code C80785. SMILES: CC12CCC3C(C1CC(C2(C#C)O)O)CCC4=C3C=CC(=C4)OC5CCCC5.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C28H22F3N7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F41401512X. European Medicines Agency schedules nilotinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25225. The term NILOTINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56). Most nations schedule nilotinib under HS 29335990 and SITC 51576. As of Q4 2014, NILOTINIB remains the US FDA Preferred Term for this commodity. Nilotinib bears US NLM identifiers UMLS ID C1721377 and NCI Concept Code C48375. SMILES: CL.FC(F)(F)C1CC(N2CC(NC2)C)CC(NC(=O)C2CC(NC3NC(C4CCCNC4)CCN3)C(CC2)C)C1.O.
This classification denotes an anti-androgen with the molecular formula C12H10F3N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51G6I8B902, chemically known as 5,5-dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin but generally known as nilutamide, which bears US NIH Compound Identifier 4493. European Medicines Agency schedules Nilutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09291MIG. The term NILUTAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules nilutamide in its Anatomical Therapeutic Chemical (ATC) Classification. NILUTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nilutamide under HS 29332100 and SITC 51572. As of Q4 2014, NILUTAMIDE remains the US FDA Preferred Term for this commodity. Nilutamide bears US NLM identifiers UMLS ID C0722107 and NCI Concept Code C1173. SMILES: CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C.
This classification denotes a calcium channel blocker with the molecular formula C19H19N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0214FUT37J, chemically known as 3,5-pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester but generally known as nilvadipine, which bears US NIH Compound Identifier 4494. European Medicines Agency schedules Nilvadipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09292MIG. The term NILVADIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules nilvadipine in its Anatomical Therapeutic Chemical (ATC) Classification. NILVADIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nilvadipine under HS 29333999 and SITC 51574. As of Q4 2014, NILVADIPINE remains the US FDA Preferred Term for this commodity. Nilvadipine bears US NLM identifiers UMLS ID C0132512 and NCI Concept Code C84019. SMILES: O(C(=O)C1=C(NC(=C(C1c1cc([N](=O)O)ccc1)C(=O)OC)C#N)C)C(C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H9ClN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N71M372MP4, chemically known as 1-imidazolidineacetonitrile, 3-(p-chlorophenyl)-4-imino-2-oxo- but generally known as nimazone, which bears US NIH Compound Identifier 28418. European Medicines Agency schedules Nimazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09293MIG. The term NIMAZONE is an International Non-Proprietary Name. NIMAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nimazone under HS 29332990 and SITC 51573. As of Q4 2014, NIMAZONE remains the US FDA Preferred Term for this commodity. Nimazone bears US NLM identifiers UMLS ID C2347354 and NCI Concept Code C73090. SMILES: C1C(=N)N(C(=O)N1CC#N)C2=CC=C(C=C2)CL.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H12N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V4TKW1454M, chemically known as methanesulfonanilide, 4-nitro-2-phenoxy- but generally known as nimesulide, which bears US NIH Compound Identifier 4495. European Medicines Agency schedules Nimesulide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09294MIG. The term NIMESULIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules nimesulide in its Anatomical Therapeutic Chemical (ATC) Classification. NIMESULIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nimesulide under HS 29350090 and SITC 51580. As of Q4 2014, NIMESULIDE remains the US FDA Preferred Term for this commodity. Nimesulide bears US NLM identifiers UMLS ID C0132515 and NCI Concept Code C29842. SMILES: S(=O)(=O)(NC1C(OC2CCCCC2)CC([N](=O)O)CC1)C.
This classification denotes a benzodiazepine with the molecular formula C16H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4532264KW6, chemically known as 1,3-dihydro-1-methyl-7-nitro-5-phenyl-2h-1,4-benzodiazepin-2-one but generally known as nimetazepam, which bears US NIH Compound Identifier 4496. European Medicines Agency schedules Nimetazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09295MIG. The term NIMETAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). NIMETAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nimetazepam under HS 29339190 and SITC 51577. As of Q4 2014, NIMETAZEPAM remains the US FDA Preferred Term for this commodity. Nimetazepam bears US NLM identifiers UMLS ID C0068774 and NCI Concept Code C76536. SMILES: O=C1N(C2C(C(=NC1)C1CCCCC1)CC([N](=O)O)CC2)C.
This classification denotes a calcium channel blocker with the molecular formula C21H26N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57WA9QZ5WH, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester but generally known as nimodipine, which bears US NIH Compound Identifier 4497. European Medicines Agency schedules Nimodipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09297MIG. The term NIMODIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules nimodipine in its Anatomical Therapeutic Chemical (ATC) Classification. NIMODIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nimodipine under HS 29333999 and SITC 51574. As of Q4 2014, NIMODIPINE remains the US FDA Preferred Term for this commodity. Nimodipine bears US NLM identifiers UMLS ID C0678207 and NCI Concept Code C692. SMILES: O(C(=O)C1=C(NC(=C(C1c1cc([N](=O)O)ccc1)C(=O)OCCOC)C)C)C(C)C.
This classification denotes an antiprotozoal agent with the molecular formula C9H14N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 469ULX0H4G, chemically known as morpholine, 4-(2-(5-nitroimidazol-1-yl)ethyl)- but generally known as nimorazole, which bears US NIH Compound Identifier 23009. European Medicines Agency schedules Nimorazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09298MIG. The term NIMORAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules nimorazole in its Anatomical Therapeutic Chemical (ATC) Classification. NIMORAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nimorazole under HS 29349990 and SITC 51579. As of Q4 2014, NIMORAZOLE remains the US FDA Preferred Term for this commodity. Nimorazole bears US NLM identifiers UMLS ID C0028095 and NCI Concept Code C76425. SMILES: O1CCN(CCN2C([N](=O)O)CNC2)CC1.
This classification denotes a nitrosourea compound with the molecular formula C9H13ClN6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0S726V972K, chemically known as urea, n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(2-chloroethyl)-n-nitroso- but more generally known as nimustine, which bears US NIH Compound Identifier 39214. European Medicines Agency schedules Nimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09299MIG. The term NIMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules nimustine in its Anatomical Therapeutic Chemical (ATC) Classification. NIMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nimustine under HS 29335995 and SITC 51576. As of Q4 2014, NIMUSTINE remains US FDA's Preferred Term for this commodity. Nimustine bears US NLM identifiers UMLS ID C0028096 and NCI Concept Code C693. SMILES: CLCCN(N=O)C(=O)NCC1C(NC(NC1)C)N.
This classification denotes a nitrosourea compound with the molecular formula C9H13ClN6O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DFR965WKBU, chemically known as urea, n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(2-chloroethyl)-n-nitroso- but more generally known as nimustine hydrochloride, which bears US NIH Compound Identifier 39214. European Medicines Agency schedules Nimustine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03435MIG. Most nations, for tariff and trade purposes, schedule nimustine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, NIMUSTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nimustine hydrochloride bears US NLM identifiers UMLS ID C0771987 and NCI Concept Code C95325. SMILES: CC1NCC(C(N1)N)CNC(=O)N(CCCL)N=O.CL.
Nintedanib is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C20H26N4O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12JBD7U72K, chemically known as 1,1-ethenediamine, n-(1,3-benzodioxol-5-ylmethyl)-n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-2-nitro- but generally known as niperotidine, which bears US NIH Compound Identifier 3033952. European Medicines Agency schedules Niperotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09301MIG. The term NIPEROTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules niperotidine in its Anatomical Therapeutic Chemical (ATC) Classification. NIPEROTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule niperotidine under HS 29321900 and SITC 51569. As of Q4 2014, NIPEROTIDINE remains the US FDA Preferred Term for this commodity. Niperotidine bears US NLM identifiers UMLS ID C0650638 and NCI Concept Code C90863. SMILES: S(CC1OC(CN(C)C)CC1)CCNC(=C\[N](=O)O)/NCC1CC2OCOC2CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H22N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FVM336I71Y, chemically known as 3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2h-1-benzopyran but generally known as nipradilol, which bears US NIH Compound Identifier 72006. European Medicines Agency schedules Nipradilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12423MIG. The term NIPRADILOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). NIPRADILOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nipradilol under HS 29329985 and SITC 51569. As of Q4 2014, NIPRADILOL remains the US FDA Preferred Term for this commodity. Nipradilol bears US NLM identifiers UMLS ID C0132531 and NCI Concept Code C76555. SMILES: O1CC(O[N](=O)O)CC2C1C(OCC(O)CNC(C)C)CCC2.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H25N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A995E1KA6, chemically known as 5-pyrazolone, 1-phenyl-2,3-dimethyl-4-(n-nicotinamidomethyl-n-isopropyl)amino- but generally known as niprofazone, which bears US NIH Compound Identifier 65619. European Medicines Agency schedules Niprofazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09302MIG. The term NIPROFAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). NIPROFAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule niprofazone under HS 29333999 and SITC 51574. As of Q4 2014, NIPROFAZONE remains the US FDA Preferred Term for this commodity. Niprofazone bears US NLM identifiers UMLS ID C2698473 and NCI Concept Code C76808. SMILES: O=C1N(N(C(C1N(C(C)C)CNC(=O)C1CCCNC1)C)C)C1CCCCC1.
This classification denotes an antiprotozoal agent with the molecular formula C6H6N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N116U8Y5QQ, chemically known as 2-imidazolidinone, 1-(5-nitro-2-thiazolyl)- but generally known as niridazole, which bears US NIH Compound Identifier 6093. European Medicines Agency schedules Niridazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09304MIG. The term NIRIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules niridazole in its Anatomical Therapeutic Chemical (ATC) Classification. NIRIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule niridazole under HS 29341000 and SITC 51579. As of Q4 2014, NIRIDAZOLE remains the US FDA Preferred Term for this commodity. Niridazole bears US NLM identifiers UMLS ID C0028113 and NCI Concept Code C90757. SMILES: S1C(N2CCNC2=O)NCC1[N](=O)O.
This classification denotes an anti-asthmatic agent with the molecular formula C22H27NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NKL13V61JH, chemically known as [2-acetyloxy-4-[2-(tert-butylamino)-1-hydroxyethyl]phenyl]4-methoxybenzoate but generally known as nisbuterol, which bears US NIH Compound Identifier 3047793. European Medicines Agency schedules nisbuterol its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09305MIG. Most nations schedule nisbuterol under HS 29225000 and SITC 51467. As of Q4 2014, NISBUTEROL remains the US FDA Preferred Term for this commodity. Nisbuterol bears US NLM identifiers UMLS ID C2983896 and NCI Concept Code C90819. SMILES: CC(=O)OC1=C(C=CC(=C1)C(CNC(C)(C)C)O)OC(=O)C2=CC=C(C=C2)OC.
This classification denotes an anti-asthmatic agent with the molecular formula C22H27NO6.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4ZSF6GBG5S, chemically known as benzoic acid, 4-methoxy-, 2-(acetyloxy)-4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)phenyl ester, methanesulfonate (salt) but more generally known as nisbuterol mesylate, which bears US NIH Compound Identifier 3047792. Most nations, for tariff and trade purposes, schedule nisbuterol mesylate under HS 29225000. As of Q4 2014, NISBUTEROL MESYLATE remains US FDA's Preferred Term for this commodity. Nisbuterol mesylate bears US NLM identifiers UMLS ID C2698474 and NCI Concept Code C75139. SMILES: CC(=O)OC1CC(CCC1OC(=O)C2CCC(CC2)OC)C(CNC(C)(C)C)O.CS(=O)(=O)O.
This classification denotes a calcium channel blocker with the molecular formula C20H24N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4I8HAB65SZ, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester but generally known as nisoldipine, which bears US NIH Compound Identifier 4499. European Medicines Agency schedules Nisoldipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09307MIG. The term NISOLDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules nisoldipine in its Anatomical Therapeutic Chemical (ATC) Classification. NISOLDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nisoldipine under HS 29333999 and SITC 51574. As of Q4 2014, NISOLDIPINE remains the US FDA Preferred Term for this commodity. Nisoldipine bears US NLM identifiers UMLS ID C0028116 and NCI Concept Code C29291. SMILES: O(C(=O)C1=C(NC(=C(C1c1c([N](=O)O)cccc1)C(=O)OC)C)C)CC(C)C.
This classification denotes an antidepressant agent with the molecular formula C17H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17NV064B2D, chemically known as benzenepropanamine, gamma-(2-methoxyphenoxy)-n-methyl- but generally known as nisoxetine, which bears US NIH Compound Identifier 4500. European Medicines Agency schedules Nisoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09308MIG. The term NISOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). NISOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nisoxetine under HS 29221980 and SITC 51461. As of Q4 2014, NISOXETINE remains the US FDA Preferred Term for this commodity. Nisoxetine bears US NLM identifiers UMLS ID C0068785 and NCI Concept Code C75172. SMILES: O(C(CCNC)c1ccccc1)c1c(OC)cccc1.
This classification denotes an antiprotozoal agent with the molecular formula C6H6AsNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JP2EN8WORU, chemically known as benzenearsonic acid, p-nitro- but generally known as nitarsone, which bears US NIH Compound Identifier 66826. European Medicines Agency schedules Nitarsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09310MIG. The term NITARSONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). NITARSONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, NITARSONE remains the US FDA Preferred Term for this commodity. Nitarsone bears US NLM identifiers UMLS ID C0068787 and NCI Concept Code C76426. SMILES: [AS](=O)(O)(O)C1CCC([N](=O)O)CC1.
This classification denotes an antiprotozoal agent with the molecular formula C12H9N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SOA12P041N, chemically known as salicylamide, n-(5-nitro-2-thiazolyl)-, acetate (ester) but generally known as nitazoxanide, which bears US NIH Compound Identifier 41684. European Medicines Agency schedules Nitazoxanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09311MIG. The term NITAZOXANIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules nitazoxanide in its Anatomical Therapeutic Chemical (ATC) Classification. NITAZOXANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nitazoxanide under HS 29341000 and SITC 51579. As of Q4 2014, NITAZOXANIDE remains the US FDA Preferred Term for this commodity. Nitazoxanide bears US NLM identifiers UMLS ID C1170029 and NCI Concept Code C47637. SMILES: S1C(NC(=O)C2C(OC(=O)C)CCCC2)NCC1[N](=O)O.
This classification denotes an enzyme inhibitor with the molecular formula C14H10F3NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5BN214699, chemically known as 1,3-cyclohexanedione, 2-(2-nitro-4-(trifluoromethyl)benzoyl)- but generally known as nitisinone, which bears US NIH Compound Identifier 115355. European Medicines Agency schedules Nitisinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09313MIG. World Health Organization schedules nitisinone in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, NITISINONE remains the US FDA Preferred Term for this commodity. Nitisinone bears US NLM identifiers UMLS ID C0173083 and NCI Concept Code C61862. SMILES: FC(F)(F)C1CC([N](=O)O)C(C(=O)C2C(=O)CCCC2=O)CC1.
This classification denotes an intercalating agent with the molecular formula C18H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 712MLZ30SB, chemically known as 1,3-propanediamine, n,n-dimethyl-n-(1-nitro-9-acridinyl)-, dihydrochloride but generally known as nitracrine, which bears US NIH Compound Identifier 20628. European Medicines Agency schedules Nitracrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09314MIG. The term NITRACRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). NITRACRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nitracrine under HS 29339990 and SITC 51577. As of Q4 2014, NITRACRINE remains the US FDA Preferred Term for this commodity. Nitracrine bears US NLM identifiers UMLS ID C0028120 and NCI Concept Code C694. SMILES: O[N](=O)c1c2c(NCCCN(C)C)c3c(nc2ccc1)cccc3.
This classification denotes an intercalating agent with the molecular formula C18H20N4O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T450D0Q71D, chemically known as 9-(3-((dimethylamino)propyl)amino)-1-nitroacridine dihydrochloride, but more generally known as nitracrine dihydrochloride, which bears US NIH Compound Identifier 20628. European Medicines Agency schedules nitracrine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09314MIG. Most nations, for tariff purposes, schedule nitracrine dihydrochloride under HS 29339990. SMILES: CN(C)CCCNC1C2CCCCC2NC3C1C(CCC3)[N+](=O)[O-].CL.CL.
This classification denotes an antidepressant agent with the molecular formula C11H9N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7R3267A08Y, chemically known as 5-(2-nitrophenyl)furan-2-carboximidamide but more commonly known as nitrafudam, which bears US NIH Compound Identifier 163304. The term nitrafudam hydrochloride is a United States Adopted Name designation. European Medicines Agency schedules nitrafudam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09315MIG. Most nations schedule nitrafudam under HS 29321900 and SITC 51569. As of Q4 2014, NITRAFUDAM remains the US FDA Preferred Term for this commodity. Nitrafudam bears US NLM identifiers UMLS ID C2983850 and NCI Concept Code C90714. SMILES: C1=CC=C(C(=C1)C2=CC=C(O2)C(=N)N)[N+](=O)[O-].
This classification denotes an antidepressant agent with the molecular formula C11H9N3O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 555ERF3D9O. The term nitrafudam hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule nitrafudam hydrochloride under HS 29321900 and SITC 51569. As of Q4 2014, NITRAFUDAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nitrafudam hydrochloride bears US NLM identifiers UMLS ID C2347355 and NCI Concept Code C73807. SMILES: C1CCC(C(C1)C2CCC(O2)C(=N)N)[N+](=O)[O-].CL.
This classification denotes an antihelminthic agent with the molecular formula C11H11N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 770KB1W9T8, chemically known as imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-(3-nitrophenyl)-, which bears US NIH Compound Identifier 163306. Most nations schedule nitramisole under HS 29349990 and SITC 51579. As of Q4 2014, NITRAMISOLE remains the US FDA Preferred Term for this commodity. Nitramisole bears US NLM identifiers UMLS ID C0068797 and NCI Concept Code C95056. SMILES: C1CSC2=NC(CN21)C3=CC(=CC=C3)[N+](=O)[O-].
This classification denotes an antihelminthic agent with the molecular formula C11H11N3O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68SZ9299YW, chemically known as imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-(3-nitrophenyl)- but more generally known as nitramisole hydrochloride, which bears US NIH Compound Identifier 163305. Most nations, for tariff and trade purposes, schedule nitramisole hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, NITRAMISOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nitramisole hydrochloride bears US NLM identifiers UMLS ID C0891283 and NCI Concept Code C90728. SMILES: C1CC(CC(C1)[N+](=O)[O-])C2CN3CCSC3=N2.CL.
This classification denotes a benzodiazepine with the molecular formula C15H11N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9CLV70W7HS, chemically known as 2,3-dihydro-7-nitro-5-phenyl-1h-1,4-benzodiazepin-2-on but generally known as nitrazepam, which bears US NIH Compound Identifier 4506. European Medicines Agency schedules Nitrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09318MIG. The term NITRAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules nitrazepam in its Anatomical Therapeutic Chemical (ATC) Classification. NITRAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nitrazepam under HS 29339190 and SITC 51577. As of Q4 2014, NITRAZEPAM remains the US FDA Preferred Term for this commodity. Nitrazepam bears US NLM identifiers UMLS ID C0028126 and NCI Concept Code C87674. SMILES: O=C1NC2C(C(=NC1)C1CCCCC1)CC([N](=O)O)CC2.
This classification denotes a calcium channel blocker with the molecular formula C18H20N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9B627AW319, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester but generally known as nitrendipine, which bears US NIH Compound Identifier 4507. European Medicines Agency schedules Nitrendipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09320MIG. The term NITRENDIPINE is an International Non-Proprietary Name. World Health Organization schedules nitrendipine in its Anatomical Therapeutic Chemical (ATC) Classification. NITRENDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nitrendipine under HS 29333999 and SITC 51574. As of Q4 2014, NITRENDIPINE remains the US FDA Preferred Term for this commodity. Nitrendipine bears US NLM identifiers UMLS ID C0028127 and NCI Concept Code C90821. SMILES: O(C(=O)C1=C(NC(=C(C1C1CC([N](=O)O)CCC1)C(=O)OC)C)C)CC.
This classification denotes an antihelminthic agent with the molecular formula C13H8Cl2N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NT0758136A, chemically known as 4,6-dichloro-4,6-dinitro-2,2-methylenediphenol but generally known as nitroclofene, which bears US NIH Compound Identifier 71718. European Medicines Agency schedules Nitroclofene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09322MIG. The term NITROCLOFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). NITROCLOFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nitroclofene under HS 29089990 and SITC 51244. As of Q4 2014, NITROCLOFENE remains the US FDA Preferred Term for this commodity. Nitroclofene bears US NLM identifiers UMLS ID C0639791 and NCI Concept Code C75224. SMILES: CLC1C(O)C(CC2C(O)C([N](=O)O)CC(CL)C2)CC([N](=O)O)C1.
This classification denotes a tetracycline antibiotic with the molecular formula C21H21N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JH9LR1Y6S, chemically known as 4-(dimethylamino)-1,3,3a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-2-naphthacene-carboxamide but generally known as nitrocycline, which bears US NIH Compound Identifier 5489904. European Medicines Agency schedules Nitrocycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09323MIG. The term NITROCYCLINE is an International Non-Proprietary Name. NITROCYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nitrocycline under HS 29413000 and SITC 54133. As of Q4 2014, NITROCYCLINE remains the US FDA Preferred Term for this commodity. Nitrocycline bears US NLM identifiers UMLS ID C2698476 and NCI Concept Code C76992. SMILES: OC12C(CC3C(=C(O)C4C(C3)C([N](=O)O)CCC4O)C1=O)C(N(C)C)C(=O)C(=C(\O)N)\C2=O.
This classification denotes an antihelminthic agent with the molecular formula C10H8N4O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2STG09LA8F, chemically known as rhodanine, 3-methyl-5-(p-nitrophenylazo)- but generally known as nitrodan, which bears US NIH Compound Identifier 13752. European Medicines Agency schedules Nitrodan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09324MIG. The term NITRODAN is an International Non-Proprietary Name. NITRODAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nitrodan under HS 29341000 and SITC 51579. As of Q4 2014, NITRODAN remains the US FDA Preferred Term for this commodity. Nitrodan bears US NLM identifiers UMLS ID C2698477 and NCI Concept Code C75225. SMILES: CN1C(=O)C(SC1=S)N=NC2=CC=C(C=C2)[N+](=O)[O-].
This classification denotes an antispasmotic agent with the molecular formula C6H6N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X8XI70B5Z6, chemically known as 2-furancarboxaldehyde, 5-nitro-, semicarbazone but generally known as nitrofural, which bears US NIH Compound Identifier 1839. European Medicines Agency schedules Nitrofural in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09325MIG. The term NITROFURAL is an International Non-Proprietary Name. World Health Organization schedules nitrofural in its Anatomical Therapeutic Chemical (ATC) Classification. NITROFURAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, NITROFURAZONE remains the US FDA Preferred Term for this commodity. Nitrofurazone bears US NLM NCI C73150. SMILES: O1C(CCC1[N](=O)O)/C=N/NC(=O)N.
This classification denotes a urinary anti-infective agent with the molecular formula C8H6N4O5, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 927AH8112L, chemically known as hydantoin, 1-(5-nitro-furfurylideneamino)- but more generally known as nitrofurantoin, which bears U.S. National Institutes of Health Compound Identifier 4509. The European Medicines Agency schedules Nitrofurantoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09326MIG. The term NITROFURANTOIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules nitrofurantoin in its Anatomical Therapeutic Chemical (ATC) Classification. NITROFURANTOIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1C(/C=N/N2CC(=O)NC2=O)CCC1[N](=O)O.
This classification denotes a topical anti-infective agent with the molecular formula C7H5HgNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RU6242GP15, chemically known as 7-oxa-8-mercurabicyclo(4.2.0)octa-1,3,5-triene, 5-methyl-2-nitro- but generally known as nitromersol, which bears US NIH Compound Identifier 16682935. European Medicines Agency schedules Nitromersol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14659MIG. As of Q4 2014, NITROMERSOL remains the US FDA Preferred Term for this commodity. Nitromersol bears US NLM identifiers UMLS ID C0301303 and NCI Concept Code C84020. SMILES: [HG]1OC2C1C([N](=O)O)CCC2C. .
This classification denotes an antiestrogen with the molecular formula C27H28N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5FS1NJ6Q8N chemically known as pyrrolidine, 1-(2-(4-(1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl)phenoxy)ethyl)- but generally known as nitromifene, which bears US NIH Compound Identifier 3032557. European Medicines Agency schedules Nitromifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09327MIG. The term NITROMIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15). Most nations schedule nitromifene under HS 29339990 and SITC 51577. As of Q4 2014, NITROMIFENE remains the US FDA Preferred Term for this commodity. Nitromifene bears US NLM identifiers UMLS ID C0028183 and NCI Concept Code C90720. SMILES: O(CCN1CCCC1)C1CCC(/C(=C(\[N](=O)O)C2CCCCC2)C2CCC(OC)CC2)CC1.
This classification denotes an antiestrogen with the molecular formula C27H28N2O4.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TN5UQ266RA, chemically known as 1-(2-(p-(alpha-(p-methoxyphenyl)-beta-nitrostyryl)phenoxy)ethyl)pyrrolidine, monocitrate but more generally known as nitromifene citrate, which bears US NIH Compound Identifier 3032492. Most nations, for tariff and trade purposes, schedule nitromifene citrate under HS 29339990 and SITC 51577. As of Q4 2014, NITROMIFENE CITRATE remains US FDA's Preferred Term for this commodity. Nitromifene citrate bears US NLM identifiers UMLS ID C0919387 and NCI Concept Code C90721. SMILES: COC1CCC(CC1)C(=C(C2CCCCC2)[N+](=O)[O-])C3CCC(CC3)OCCN4CCCC4.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a vasodilating agent and diagnostic reagent with the molecular formula C5FEN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 169D1260KM. European Medicines Agency schedules nitroprusside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14660MIG. As of Q4 2014, NITROPRUSSIDE remains the US FDA Preferred Term for this commodity. Nitroprusside bears US NLM identifiers UMLS ID C0028193 and NCI Concept Code C77153. SMILES: [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Na+].[Na+].[Fe].
This classification denotes an antihelminthic agent with the molecular formula C13H8N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P4IE5B6D6U, chemically known as isothiocyanic acid, p-(p-nitrophenoxy)phenyl ester but generally known as nitroscanate, which bears US NIH Compound Identifier 68547. European Medicines Agency schedules Nitroscanate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09328MIG. The term NITROSCANATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). NITROSCANATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nitroscanate under HS 29309085 and SITC 51549. As of Q4 2014, NITROSCANATE remains the US FDA Preferred Term for this commodity. Nitroscanate bears US NLM identifiers UMLS ID C0068857 and NCI Concept Code C75226. SMILES: S=C=NC1CCC(OC2CCC([N](=O)O)CC2)CC1.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K50XQU1029. European Medicines Agency schedules Nitrous oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03447MIG. Nitrous oxide generally arises in the molecular formula N2O. The term NITROUS OXIDE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule nitrous oxide under HS 28112990 and SITC 52239. As of Q4 2014, NITROUS OXIDE remains the US FDA Preferred Term for this commodity. Nitrous oxide bears US NLM identifiers UMLS ID C0028215 and NCI Concept Code C73617. SMILES: N#[N+][O-].
This classification denotes an antihelminthic agent with the molecular formula C7H3IN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9L0EXQ7125, chemically known as benzonitrile, 4-hydroxy-3-iodo-5-nitro- but generally known as nitroxinil, which bears US NIH Compound Identifier 15532. European Medicines Agency schedules Nitroxinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09330MIG. The term NITROXINIL is an International Non-Proprietary Name. NITROXINIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Nitroxinil or nitroxynil bears US NLM identifiers UMLS ID C0028217 and NCI Concept Code C75227. SMILES: C1=C(C=C(C(=C1[N+](=O)[O-])O)I)C#N.
This classification denotes a quinolone antibiotic with the molecular formula C9H6N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8M33244M6, chemically known as 8-quinolinol, 5-nitro- but more generally known as nitroxoline, which bears US NIH Compound Identifier 19910. European Medicines Agency schedules Nitroxoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09331MIG. The term NITROXOLINE is an International Non-Proprietary Name. The World Health Organization schedules nitroxoline in its Anatomical Therapeutic Chemical (ATC) Classification. NITROXOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1C2NCCCC2C([N](=O)O)CC1.
This classification denotes a mast cell stabilizer with the molecular formula C11H9NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1M887244YI chemically known as 1h-indene-1,3(2h)-dione, 5,6-dimethyl-2-nitro-, ion(1-) but generally known as nivimedone, which bears US NIH Compound Identifier 64753. European Medicines Agency schedules Nivimedone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09333MIG. The term NIVIMEDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17). Most nations schedule nivimedone under HS 29147000 and SITC 51629. As of Q4 2014, NIVIMEDONE remains the US FDA Preferred Term for this commodity. Nivimedone bears US NLM identifiers UMLS ID C0068885 and NCI Concept Code C84021. SMILES: CC1=C(C=C2C(=C1)C(=O)C(C2=O)[N+](=O)[O-])C.
This classification denotes a mast cell stabilizer with the molecular formula C11H8NO4.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4953C873N2, chemically known as 1h-indene-1,3(2h)-dione, 5,6-dimethyl-2-nitro-, ion(1-), sodium, monohydrate but more generally known as nivimedone sodium, which bears US NIH Compound Identifier 43916. Most nations, for tariff and trade purposes, schedule nivimedone sodium under HS 29147000 and SITC 51629. As of Q4 2014, NIVIMEDONE SODIUM remains US FDA's Preferred Term for this commodity. Nivimedone sodium bears US NLM identifiers UMLS ID C0132621 and NCI Concept Code C72941. SMILES: CC1CC2C(CC1C)C(=O)C(=[N+]([O-])[O-])C2=O.O.[NA+].
This classification denotes a mast cell stabilizer with the molecular formula C11H8NO4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50HX07BAJU, chemically known as 1h-indene-1,3(2h)-dione, 5,6-dimethyl-2-nitro-, ion(1-), sodium (1:1), but more generally known as nivimedone sodium anhydrous, which bears US NIH Compound Identifier 64752. European Medicines Agency schedules nivimedone sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09333MIG. Most nations, for tariff purposes, schedule nivimedone sodium anhydrous under HS 29147000. SMILES: CC1CC2C(CC1C)C(=O)C(=[N+]([O-])[O-])C2=O.[NA+].
An injectable human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C12H21N5O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P41PML4GHR, chemically known as 1,1-ethenediamine, n-(2-(((2-((dimethylamino)methyl)-4-thiazoly)methyl)thio)ethyl)-n-methyl-2-nitro- but generally known as nizatidine, which bears US NIH Compound Identifier 3033637. European Medicines Agency schedules Nizatidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09335MIG. The term NIZATIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules nizatidine in its Anatomical Therapeutic Chemical (ATC) Classification. NIZATIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nizatidine under HS 29341000 and SITC 51579. As of Q4 2014, NIZATIDINE remains the US FDA Preferred Term for this commodity. Nizatidine bears US NLM identifiers UMLS ID C0085154 and NCI Concept Code C29295. SMILES: S(CCN/C(=C/[N](=O)O)NC)CC1NC(SC1)CN(C)C.
This classification denotes a neuroprotective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7A2NOC3R88. European Medicines Agency schedules Nizofenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09336MIG. Nizofenone generally arises in the molecular formula C21H21CLN4O3. The term NIZOFENONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, no. 5 1981, list 21.) NIZOFENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nizofenone under HS 29332990 and SITC 51573. As of Q4 2014, NIZOFENONE remains US FDA's Preferred Term for this commodity. Nizofenone bears US NLM identifiers UMLS ID C0068887 and NCI Concept Code C76783. SMILES: CLC1C(C(=O)C2C(N3C(NCC3)CN(CC)CC)CCC([N](=O)O)C2)CCCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9HPD98OUWN, chemically known as 3h-imidazo(4,5-b)pyridin-2-amine, 3-((5-methyl-2-furanyl)methyl)-n-4-piperidinyl- but generally known as noberastine, which bears US NIH Compound Identifier 60531. European Medicines Agency schedules Noberastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09337MIG. The term NOBERASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). NOBERASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule noberastine under HS 29349990 and SITC 51579. As of Q4 2014, NOBERASTINE remains the US FDA Preferred Term for this commodity. Noberastine bears US NLM identifiers UMLS ID C0132719 and NCI Concept Code C74582. SMILES: O1C(CN2C(NC3CCNCC3)NC3C2NCCC3)CCC1C.
This classification denotes an anthracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L059DCD6IP. European Medicines Agency schedules Nogalamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09341MIG. Nogalamycin generally arises in the molecular formula C39H49NO16. The term NOGALAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) NOGALAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nogalamycin under HS 29419000 and SITC 54139. As of Q4 2014, NOGALAMYCIN remains the US FDA Preferred Term for this commodity. Nogalamycin bears US NLM identifiers UMLS ID C0028261 and NCI Concept Code C700. SMILES: O1C2(C(O)C(N(C)C)C(O)C1OC1C2CC(O)C2C1C(=O)C1C(C(O)C3C(OC4OC(C(OC)C(OC)(C4OC)C)C)CC(O)(C(C3C1)C(=O)OC)C)C2=O)C.
This classification denotes a thymidylate synthase inhibitor and folate antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K75ZUN743Q. European Medicines Agency schedules Nolatrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09342MIG. Nolatrexed generally arises in the molecular formula C14H12N4OS. The term NOLATREXED is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) NOLATREXED is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nolatrexed under HS 29335995 and SITC 51576. As of Q4 2014, NOLATREXED remains the US FDA Preferred Term for this commodity. SMILES: S(C1C2C([NH]C(NC2=O)N)CCC1C)C1CCNCC1.
This classification denotes an antiulcerative with the molecular formula C15H11Cl2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N018S592LP, chemically known as 2-(3,4-dichloroanilino)quinolizinium but generally known as nolinium, which bears US NIH Compound Identifier 38666. The term NOLINIUM is an International Non-Proprietary Name or INN. European Medicines Agency schedules nolinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09343MIG. As of Q4 2014, NOLINIUM remains the US FDA Preferred Term for this commodity. SMILES: C1=CC=[N+]2C=CC(=CC2=C1)NC3=CC(=C(C=C3)Cl)Cl.
This classification denotes a therapeutic progestin with the molecular formula C21H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10F89177CO, chemically known as 19-norpregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl- but generally known as nomegestrol, which bears US NIH Compound Identifier 68783. European Medicines Agency schedules Nomegestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09345MIG. World Health Organization schedules nomegestrol in its Anatomical Therapeutic Chemical (ATC) Classification. NOMEGESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nomegestrol under HS 29372300 and SITC 54153. As of Q4 2014, NOMEGESTROL remains the US FDA Preferred Term for this commodity. Nomegestrol bears US NLM identifiers UMLS ID C0068922 and NCI Concept Code C87243. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)C(=C3)C)CC1)C)C(=O)C.
This classification denotes a therapeutic progestin C23H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83J78V5W05, chemically known as 6-methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate, but more generally known as nomegestrol acetate, which bears US NIH Compound Identifier 91668. European Medicines Agency schedules Nomegestrol acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03449MIG. Most nations, for tariff and trade purposes, schedule nomegestrol acetate under HS 29372300 and SITC 54153. As of Q4 2014, NOMEGESTROL ACETATE remains US FDA's Preferred Term for this commodity. Nomegestrol acetate bears US NLM identifiers UMLS ID C0132749 and NCI Concept Code C87244. SMILES: CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FVL27C1DMG. European Medicines Agency schedules Nomelidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09346MIG. Nomelidine generally arises in the molecular formula C15H15BRN2. The term NOMELIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) NOMELIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nomelidine under HS 29333999 and SITC 51574. As of Q4 2014, NOMELIDINE remains the US FDA Preferred Term for this commodity. Nomelidine bears US NLM identifiers UMLS ID C2698483 and NCI Concept Code C75173. SMILES: Brc1ccc(/C(=C/CNC)c2cccnc2)cc1.
This classification denotes an antidepressant agent with the molecular formula C16H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1LGS5JRP31, chemically known as 1,2,3,4-tetrahydro-2-methyl-4-phenyl-8-isoquino* but generally known as nomifensine, which bears US NIH Compound Identifier 4528. European Medicines Agency schedules Nomifensine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09347MIG. The term NOMIFENSINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules nomifensine in its Anatomical Therapeutic Chemical (ATC) Classification. NOMIFENSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nomifensine under HS 29334990 and SITC 51575. As of Q4 2014, NOMIFENSINE remains the US FDA Preferred Term for this commodity. Nomifensine bears US NLM identifiers UMLS ID C0028277 and NCI Concept Code C72824. SMILES: N1(CC(c2c(C1)c(N)ccc2)c1ccccc1)C.
This classification denotes an antidepressant agent with the molecular formula C16H18N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76S8CUH5MR, chemically known as 1,2,3,4-tetrahydro-2-methyl-4-phenyl-8-isoquino* but more generally known as nomifensine maleate, which bears US NIH Compound Identifier 4528. European Medicines Agency schedules Nomifensine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14663MIG. Most nations, for tariff and trade purposes, schedule nomifensine maleate under HS 29334990 and SITC 51575. As of Q4 2014, NOMIFENSINE MALEATE remains US FDA's Preferred Term for this commodity. Nomifensine maleate bears US NLM identifiers UMLS ID C0877847 and NCI Concept Code C73808. SMILES: CN1CC2C(CCCC2N)C(C1)C3CCCCC3.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antiemetic agent and antidepressant agent with the molecular formula C25H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77DUK856J7, chemically known as 7-(1,2-dimethylheptyl)-2,2-dimethyl-4-(4-pyridyl)-2h-1-benzopyran-5-ol but generally known as nonabine, which bears US NIH Compound Identifier 71885. European Medicines Agency schedules Nonabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09348MIG. The term NONABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). NONABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nonabine under HS 29349990 and SITC 51579. As of Q4 2014, NONABINE remains the US FDA Preferred Term for this commodity. Nonabine bears US NLM identifiers UMLS ID C0132764 and NCI Concept Code C72950. SMILES: O1C(C=C(C2C1CC(C(C(CCCCC)C)C)CC2O)C1CCNCC1)(C)C.
This classification denotes an anxiolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JLD8OG7GK0. European Medicines Agency schedules Nonaperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09349MIG. Nonaperone generally arises in the molecular formula C18H24FNO. The term NONAPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) NONAPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nonaperone under HS 29339990 and SITC 51577. As of Q4 2014, NONAPERONE remains the US FDA Preferred Term for this commodity. Nonaperone bears US NLM identifiers UMLS ID C2983883 and NCI Concept Code C90790. SMILES: FC1CCC(C(=O)CCCN2CC3CCC(CC3)C2)CC1.
This classification denotes an anticonvulsant agent with the molecular formula C15H24N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 322D5Y3Q0G, chemically known as 7h-pyrrolo(2,3-d)pyrimidine, 4-(nonylamino)- but generally known as nonapyrimine, which bears US NIH Compound Identifier 3047795. European Medicines Agency schedules Nonapyrimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09350MIG. The term NONAPYRIMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). NONAPYRIMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nonapyrimine under HS 29335995 and SITC 51576. As of Q4 2014, NONAPYRIMINE remains the US FDA Preferred Term for this commodity. Nonapyrimine bears US NLM identifiers UMLS ID C2698489 and NCI Concept Code C75164. SMILES: N(CCCCCCCCC)C1NCNC2[NH]CCC12.
This classification denotes a capsaicin analog, nitric oxide synthase antagonist and inhibitor, and sensory system agent with the molecular formula C17H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S846B891OR, chemically known as nonanamide, n-vanillyl- (8ci) but more generally known as nonivamide, which bears US NIH Compound Identifier 2998. European Medicines Agency schedules Nonivamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09352MIG. NONIVAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule nonivamide under HS 29242995 and SITC 51479. As of Q4 2014, NONIVAMIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCC(=O)NCC1=CC(=C(C=C1)O)OC.
This classification denotes an anabolic steroid with the molecular formula C21H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3BZU2241A, chemically known as 18,19-dinorpregn-4-en-3-one, 13-ethyl-17-hydroxy-, (17-alpha)- (9ci) but generally known as norbolethone, which bears US NIH Compound Identifier 13108. European Medicines Agency schedules Norboletone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09354MIG. The term NORBOLETHONE is an International Non-Proprietary Name. Norboletone or norbolethone bears US NLM identifiers UMLS ID C1142715 and NCI Concept Code C90642. SMILES: CCC12CCC3C(C1CCC2(CC)O)CCC4=CC(=O)CCC34.
This classification denotes a beta-adrenergic agonist with the molecular formula C12H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8P6T83567P, chemically known as 2-cyclobutylamino-1-(3,4-dihydroxyphenyl)ethanol but generally known as norbudrine, which bears US NIH Compound Identifier 166575. European Medicines Agency schedules Norbudrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09355MIG. The term NORBUDRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). NORBUDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norbudrine under HS 29225000 and SITC 51467. As of Q4 2014, NORBUDRINE remains the US FDA Preferred Term for this commodity. Norbudrine bears US NLM identifiers UMLS ID C2698494 and NCI Concept Code C76542. SMILES: C1CC(C1)NCC(C2=CC(=C(C=C2)O)O)O.
This classification denotes an anabolic steroid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VI1001O2DI. European Medicines Agency schedules Norclostebol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09356MIG. Norclostebol generally arises in the molecular formula C18H25CLO2. The term NORCLOSTEBOL is an International Non-Proprietary Name or INN. NORCLOSTEBOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norclostebol under HS 29372900 and SITC 54153. As of Q4 2014, NORCLOSTEBOL remains the US FDA Preferred Term for this commodity. Norclostebol bears US NLM identifiers UMLS ID C2698495 and NCI Concept Code C77307. SMILES: CLC1=C2C(C3C(C4C(CC3)(C(O)CC4)C)CC2)CCC1=O.
This classification denotes a benzodiazepine with the molecular formula C15H11ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67220MCM01, chemically known as 7-chloro-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as nordazepam, which bears US NIH Compound Identifier 2997. European Medicines Agency schedules Nordazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09358MIG. The term NORDAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules nordazepam in its Anatomical Therapeutic Chemical (ATC) Classification. NORDAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nordazepam under HS 29339190 and SITC 51577. As of Q4 2014, NORDAZEPAM remains the US FDA Preferred Term for this commodity. Nordazepam bears US NLM identifiers UMLS ID C0011279 and NCI Concept Code C87675. SMILES: CLC1CC2C(=NCC(=O)NC2CC1)C1CCCCC1.
This classification denotes a therapeutic progestin with the molecular formula C21H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R0TAY3X631, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, oxime, (8-alpha,9-beta,10-alpha,13-alpha,14-beta)- but generally known as norelgestromin, which bears US NIH Compound Identifier 62930. European Medicines Agency schedules Norelgestromin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20476. The term NORELGESTROMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). Most nations schedule norelgestromin under HS 29372900 and SITC 54153. As of Q4 2014, NORELGESTROMIN remains the US FDA Preferred Term for this commodity. Norelgestromin bears US NLM identifiers UMLS ID C1120952 and NCI Concept Code C66243. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=N\O)\CC2)CC3)CC1)CC)C#C.
This classification denotes a therapeutic androgen with the molecular formula C20H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7W01638W6, chemically known as 19-nortestosterone, 17-ethyl- but generally known as norethandrolone, which bears US NIH Compound Identifier 5858. European Medicines Agency schedules Norethandrolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09361MIG. The term NORETHANDROLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules norethandrolone in its Anatomical Therapeutic Chemical (ATC) Classification. NORETHANDROLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norethandrolone under HS 29372900 and SITC 54153. As of Q4 2014, NORETHANDROLONE remains the US FDA Preferred Term for this commodity. Norethandrolone bears US NLM identifiers UMLS ID C0028355 and NCI Concept Code C80802. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)C)CC.
This classification denotes a mast cell stabilizer with the molecular structure C11H9NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1M887244YI chemically known as 1h-indene-1,3(2h)-dione, 5,6-dimethyl-2-nitro-, ion(1-) but generally known as nivimedone, which bears US NIH Compound Identifier 64753. European Medicines Agency schedules Nivimedone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09333MIG. The term NIVIMEDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17). SMILES: CC1=C(C=C2C(=C1)C(=O)C(C2=O)[N+](=O)[O-])C.
This classification denotes a therapeutic progestin with the molecular formula C20H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T18F433X4S, chemically known as 19-nortestosterone, 17-ethynyl- but generally known as norethindrone, which bears US NIH Compound Identifier 4536. European Medicines Agency schedules Norethindrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09362MIG. World Health Organization schedules norethindrone in its Anatomical Therapeutic Chemical (ATC) Classification. Norethindrone or norethisterone bears US NLM identifiers UMLS ID C0028356 and NCI Concept Code C62059. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)C)C#C.
This classification denotes a therapeutic progestin with the molecular formula C20H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88181ACA0M, chemically known as 19-norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- but generally known as norethynodrel, which bears US NIH Compound Identifier 4537. European Medicines Agency schedules Noretynodrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12439MIG. The term NORETYNODREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Norethynodrel or noretynodrel bears US NLM identifiers UMLS ID C0028360 and NCI Concept Code C66244. SMILES: CC12CCC3C(C1CCC2(C#C)O)CCC4=C3CCC(=O)C4.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2P3M6SRN5, chemically known as r,s-norphenylephrine but generally known as norfenefrine, which bears US NIH Compound Identifier 4538. European Medicines Agency schedules Norfenefrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09364MIG. The term NORFENEFRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules norfenefrine in its Anatomical Therapeutic Chemical (ATC) Classification. NORFENEFRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norfenefrine under HS 29225000 and SITC 51467. As of Q4 2014, NORFENEFRINE remains the US FDA Preferred Term for this commodity. Norfenefrine bears US NLM identifiers UMLS ID C0068986 and NCI Concept Code C84022. SMILES: OC(C1CC(O)CCC1)CN.
This classification denotes a quinolone antibiotic with the molecular formula C16H18FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N0F8P22L1P, chemically known as 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid but generally known as norfloxacin, which bears US NIH Compound Identifier 4539. European Medicines Agency schedules Norfloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09365MIG. The term NORFLOXACIN is an International Non-Proprietary Name. World Health Organization schedules norfloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. NORFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norfloxacin under HS 29335995 and SITC 51576. As of Q4 2014, NORFLOXACIN remains the US FDA Preferred Term for this commodity. Norfloxacin bears US NLM identifiers UMLS ID C0028365 and NCI Concept Code C47638. SMILES: FC1C(N2CCNCC2)CC2N(CC)CC(C(=O)C2C1)C(=O)O.
This classification denotes a therapeutic progestin with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YFS274763Y, chemically known as 19-norpregna-5(10),20-dien-3-one, 17-hydroxy-, (17alpha)- (9ci) but generally known as norgesterone, which bears US NIH Compound Identifier 65606. European Medicines Agency schedules Norgesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09368MIG. The term NORGESTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). NORGESTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norgesterone under HS 29372300 and SITC 54153. As of Q4 2014, NORGESTERONE remains the US FDA Preferred Term for this commodity. Norgesterone bears US NLM identifiers UMLS ID C0603673 and NCI Concept Code C90971. SMILES: OC1(C2(C(C3C(CC2)C2=C(CC3)CC(=O)CC2)CC1)C)C=C.
This classification denotes a therapeutic progestin with the molecular formula C23H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C291HFX4DY, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17-alpha)- but generally known as norgestimate, which bears US NIH Compound Identifier 6540478. European Medicines Agency schedules Norgestimate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09369MIG. The term NORGESTIMATE is an International Non-Proprietary Name. NORGESTIMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norgestimate under HS 29372300 and SITC 54153. As of Q4 2014, NORGESTIMATE remains the US FDA Preferred Term for this commodity. Norgestimate bears US NLM identifiers UMLS ID C0068992 and NCI Concept Code C66245. SMILES: O(C1(C2(C(C3C(CC2)C2C(=CC(=N\O)\CC2)CC3)CC1)CC)C#C)C(=O)C.
This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J8Q1747Z2, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-(.+/-.)- but generally known as norgestrel, which bears US NIH Compound Identifier 4542. European Medicines Agency schedules Norgestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09371MIG. The term NORGESTREL is an International Non-Proprietary Name. NORGESTREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norgestrel under HS 29372300 and SITC 54153. As of Q4 2014, NORGESTREL remains the US FDA Preferred Term for this commodity. Norgestrel bears US NLM identifiers UMLS ID C0699169 and NCI Concept Code C703. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)CC)C#C.
This classification denotes a therapeutic estrogen with the molecular formula C20H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89386PYU9O, chemically known as 19-norpregna-4,9,11-trien-20-yn-3-one, 17-hydroxy-, (17-alpha)- (9ci) but generally known as norgestrienone, which bears US NIH Compound Identifier 13313. European Medicines Agency schedules Norgestrienone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09372MIG. The term NORGESTRIENONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules norgestrienone in its Anatomical Therapeutic Chemical (ATC) Classification. NORGESTRIENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norgestrienone under HS 29372300 and SITC 54153. As of Q4 2014, NORGESTRIENONE remains the US FDA Preferred Term for this commodity. Norgestrienone bears US NLM identifiers UMLS ID C0028369 and NCI Concept Code C90949. SMILES: OC1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C)C#C.
This classification denotes an opioid receptor agonist with the molecular formula C20H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) KR2L2A68XL, chemically known as 6-dimethylamino-4,4-diphenyl-3-hexanone but more generally known as normethadone, which bears US NIH Compound Identifier 10090. European Medicines Agency schedules Normethadone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09376MIG. The term NORMETHADONE is an International Non-Proprietary Name. World Health Organization schedules normethadone in its Anatomical Therapeutic Chemical (ATC) Classification. NORMETHADONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule normethadone under HS 29223100 and SITC 51463. As of Q4 2014, NORMETHADONE remains US FDA's Preferred Term for this commodity. Normethadone bears US NLM identifiers UMLS ID C0069008 and NCI Concept Code C76843. SMILES: O=C(C(CCN(C)C)(C1CCCCC1)C1CCCCC1)CC.
This classification denotes a therapeutic progestin with the molecular formula C19H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 743F1Z557A, chemically known as 19-nortestosterone, 17-methyl- but generally known as normethandrone, which bears US NIH Compound Identifier 10576. European Medicines Agency schedules Normethandrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14667MIG. As of Q4 2014, NORMETHANDRONE remains the US FDA Preferred Term for this commodity. Normethandrone bears US NLM identifiers UMLS ID C0650248 and NCI Concept Code C95970. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)C)C. .
This classification denotes an analgesic agent with the molecular formula C23H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 127X8DJ74M, chemically known as 4,4-diphenyl-6-piperidino-3-hexanon but generally known as norpipanone, which bears US NIH Compound Identifier 22391. European Medicines Agency schedules Norpipanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09378MIG. The term NORPIPANONE is an International Non-Proprietary Name. NORPIPANONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norpipanone under HS 29333999 and SITC 51574. As of Q4 2014, NORPIPANONE remains the US FDA Preferred Term for this commodity. Norpipanone bears US NLM identifiers UMLS ID C2698498 and NCI Concept Code C75070. SMILES: O=C(C(CCN1CCCCC1)(C1CCCCC1)C1CCCCC1)CC.
This classification denotes a benzodiazepine with the molecular formula C15H15ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PWL441R6EQ, chemically known as 7-chloro-5-(1-cyclohexen-1-yl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as nortetrazepam, which bears US NIH Compound Identifier 166581. European Medicines Agency schedules Nortetrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09379MIG. The term NORTETRAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). NORTETRAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nortetrazepam under HS 29339940 and SITC 51577. As of Q4 2014, NORTETRAZEPAM remains the US FDA Preferred Term for this commodity. Nortetrazepam bears US NLM identifiers UMLS ID C2698499 and NCI Concept Code C76537. SMILES: CLC1CC2C(=NCC(=O)NC2CC1)C1=CCCCC1.
This classification denotes a tricyclic antidepressant with the molecular formula C19H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BL03SY4LXB, chemically known as 10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine but generally known as nortriptyline, which bears US NIH Compound Identifier 4543. European Medicines Agency schedules Nortriptyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09380MIG. The term NORTRIPTYLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules nortriptyline in its Anatomical Therapeutic Chemical (ATC) Classification. NORTRIPTYLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nortriptyline under HS 29214980 and SITC 51454. As of Q4 2014, NORTRIPTYLINE remains the US FDA Preferred Term for this commodity. Nortriptyline bears US NLM identifiers UMLS ID C0028420 and NCI Concept Code C62060. SMILES: N(CC/C=C1\c2c(CCc3c1cccc3)cccc2)C.
This classification denotes an adrenergic uptake inhibitor and tricyclic antidepressive agent with the molecular formula C19H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00FN6IH15D, chemically known as 10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine but more generally known as nortriptyline hydrochloride, which bears US NIH Compound Identifier 4543. European Medicines Agency schedules Nortriptyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03464MIG. Most nations, for tariff and trade purposes, schedule nortriptyline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, NORTRIPTYLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nortriptyline hydrochloride bears US NLM identifiers UMLS ID C0030256 and NCI Concept Code C704. SMILES: CNCCC=C1C2CCCCC2CCC3C1CCCC3.CL.
This classification denotes a therapeutic progestin with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Q843V12Q0, chemically known as 19-nor-17-alpha-pregna-4,20-dien-3-one, 17-hydroxy- but generally known as norvinisterone, which bears US NIH Compound Identifier 65588. European Medicines Agency schedules Norvinisterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09381MIG. The term NORVINISTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). NORVINISTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule norvinisterone under HS 29372300 and SITC 54153. As of Q4 2014, NORVINISTERONE remains the US FDA Preferred Term for this commodity. Norvinisterone bears US NLM identifiers UMLS ID C2825279 and NCI Concept Code C80623. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)C)C=C.
This classification denotes an antibiotic with the molecular formula C31H36N2O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17EC19951N, chemically known as novobiocin, sodium deriv. but more generally known as novobiocin, which bears US NIH Compound Identifier 4546. European Medicines Agency schedules Novobiocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09385MIG. The term NOVOBIOCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). NOVOBIOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1C(C(OC)C(OC(=O)N)C(O)C1OC1C(C2OC(O)C(NC(=O)C3CC(C/C=C(/C)C)C(O)CC3)C(=O)C2CC1)C)(C)C.
This classification denotes an antibiotic 2C31H35N2O11.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RHW5BU180N, chemically known as benzamide, n-(7-((3-o-(aminocarbonyl)-6-deoxy-5-c-methyl-4-o-methyl-.alpha.-l-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)-, calcium salt (2:1), but more generally known as novobiocin calcium, which bears US NIH Compound Identifier 20297. Most nations schedule novobiocin calcium under HS 29419000 and SITC 54139. As of Q4 2014, NOVOBIOCIN CALCIUM remains the US FDA Preferred Term for this commodity. Novobiocin calcium bears US NLM identifiers UMLS ID C0282264 and NCI Concept Code C81448. SMILES: CC1C(CCC2C1OC(=O)C(C2[O-])NC(=O)C3CCC(C(C3)CC=C(C)C)O)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O.CC1C(CCC2C1OC(=O)C(C2[O-])NC(=O)C3CCC(C(C3)CC=C(C)C)O)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O.[CA+2].
This classification denotes an antidepressant agent with the molecular formula C19H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DF7D3NY7EL, chemically known as 10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-on-o-(2-(dimethylamino)ethyl)oxim but generally known as noxiptiline, which bears US NIH Compound Identifier 21087. European Medicines Agency schedules Noxiptiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09386MIG. The term NOXIPTILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). NOXIPTILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule noxiptiline under HS 29280090 and SITC 51486. As of Q4 2014, NOXIPTILINE remains the US FDA Preferred Term for this commodity. Noxiptiline bears US NLM identifiers UMLS ID C2698505 and NCI Concept Code C75174. SMILES: O(/N=C1/c2c(CCc3c1cccc3)cccc2)CCN(C)C.
This classification denotes an antidepressant agent C19H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PNW59W2B94, chemically known as 5h-dibenzo(a,d)cyclohepten-5-one, 10,11-dihydro-, o-(2-(dimethylamino)ethyl)oxime, monohydrochloride, but more generally known as noxiptiline hydrochloride, which bears US NIH Compound Identifier 21086. European Medicines Agency schedules Noxiptiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03469MIG. Most nations, for tariff and trade purposes, schedule noxiptiline hydrochloride under HS 29280090 and SITC 51486. As of Q4 2014, NOXIPTILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCON=C1C2CCCCC2CCC3C1CCCC3.CL.
This classification denotes a topical anti-infective agent with the molecular formula C3H8N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DN3AF1FU6, chemically known as urea, 1-(hydroxymethyl)-3-methyl-2-thio- but generally known as noxythiolin, which bears US NIH Compound Identifier 27413. European Medicines Agency schedules Noxytiolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09387MIG. The term NOXYTIOLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules noxythiolin in its Anatomical Therapeutic Chemical (ATC) Classification. Noxythiolin or noxytiolin bears US NLM identifiers UMLS ID C0028476 and NCI Concept Code C66248. SMILES: S(#CNCO)NC.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DTQ2MGV34. European Medicines Agency schedules Nuclotixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09389MIG. Nuclotixene generally arises in the molecular formula C21H20CLNS. The term NUCLOTIXENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) NUCLOTIXENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nuclotixene under HS 29349990 and SITC 51579. As of Q4 2014, NUCLOTIXENE remains the US FDA Preferred Term for this commodity. Nuclotixene bears US NLM identifiers UMLS ID C2825653 and NCI Concept Code C81481. SMILES: Clc1cc2/C(=C/C3C4CCN(C3)CC4)c3c(Sc2cc1)cccc3.
This classification denotes an antiplatelet agent with the molecular formula C23H32N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02NKI0ARRJ, chemically known as n-(s)-1-ethoxy-methyl-3-methylbutyl-n-methyl-alpha-(2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)-p-toluenesulfonamide but generally known as nupafant, which bears US NIH Compound Identifier 3047797. European Medicines Agency schedules Nupafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09391MIG. The term NUPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). NUPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nupafant under HS 29350090 and SITC 51580. As of Q4 2014, NUPAFANT remains the US FDA Preferred Term for this commodity. Nupafant bears US NLM identifiers UMLS ID C1741717 and NCI Concept Code C81564. SMILES: S(=O)(=O)(N(COCC)C)C1C(CCC(C)C)CC(CN2C3C(NC2C)CNCC3)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BDF1O1C72E. European Medicines Agency schedules Nystatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03475MIG. Nystatin generally arises in the molecular formula C47H75NO17. The term NYSTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) NYSTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nystatin under HS 29419000 and SITC 54139. As of Q4 2014, NYSTATIN remains the US FDA Preferred Term for this commodity. Nystatin bears US NLM identifiers UMLS ID C0028741 and NCI Concept Code C710. SMILES: CC1C=CC=CCCC=CC=CC=CC=CC(CC(C(C(CC(=O)CC(C(CCC(CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)C(=O)O)O)OC2C(C(C(C(O2)C)O)N)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.
This classification denotes an anticholinergic agent with the molecular formula C14H16N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N6KNE1QA9O, chemically known as 4,4-bis-(hydroxyiminomethyl)-1,1-oxydimethylen-dipyridinium-kation but generally known as obidoxime, which bears US NIH Compound Identifier 5485192. European Medicines Agency schedules Obidoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14676MIG. World Health Organization schedules obidoxime in its Anatomical Therapeutic Chemical (ATC) Classification. OBIDOXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, OBIDOXIME remains the US FDA Preferred Term for this commodity. Obidoxime bears US NLM identifiers UMLS ID C0086728 and NCI Concept Code C84023. SMILES: O(CN1CC/C(=C/[NH]=O)CC1)CN1CC/C(=C/[NH]=O)CC1. .
Obinutuzumab is a humanized anti-CD20 monoclonal antibody as a cancer treatment.
This classification denotes an antipsychotic agent with the molecular formula C24H25FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26HUS7139V, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2,9-dimethyl- but generally known as ocaperidone, which bears US NIH Compound Identifier 71351. European Medicines Agency schedules Ocaperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09395MIG. The term OCAPERIDONE is an International Non-Proprietary Name. OCAPERIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ocaperidone under HS 29349990 and SITC 51579. As of Q4 2014, OCAPERIDONE remains the US FDA Preferred Term for this commodity. Ocaperidone bears US NLM identifiers UMLS ID C0133602 and NCI Concept Code C76441. SMILES: FC1CC2ONC(C3CCN(CC3)CCC3C(NC4N(C3=O)CCCC4C)C)C2CC1.
This classification denotes an opioid receptor agonist with the molecular formula C22H27FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MX52WBC8EV, chemically known as acetamide, n-(2-fluorophenyl)-2-methoxy-n-(1-(2-phenylethyl)-4-piperidinyl)- but generally known as ocfentanil, which bears US NIH Compound Identifier 60575. European Medicines Agency schedules Ocfentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09396MIG. The term OCFENTANIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). OCFENTANIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ocfentanil under HS 29333999 and SITC 51574. As of Q4 2014, OCFENTANIL remains the US FDA Preferred Term for this commodity. Ocfentanil bears US NLM identifiers UMLS ID C0648314 and NCI Concept Code C84024. SMILES: FC1C(N(C2CCN(CC2)CCC2CCCCC2)C(=O)COC)CCCC1.
This classification denotes an opioid receptor agonist with the molecular formula C22H27FN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8T88FVW9V, chemically known as acetamide, n-(2-fluorophenyl)-2-methoxy-n-(1-(2-phenylethyl)-4-piperidinyl)- but more generally known as ocfentanil hydrochloride, which bears US NIH Compound Identifier 60575. Most nations, for tariff and trade purposes, schedule ocfentanil hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, OCFENTANIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ocfentanil hydrochloride bears US NLM identifiers UMLS ID C2698645 and NCI Concept Code C76850. SMILES: COCC(=O)N(C1CCCCC1F)C2CCN(CC2)CCC3CCCCC3.CL.
This classification denotes an anxiolytic with the molecular formula C17H11N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H6KVC5E76, chemically known as 2-pyridinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl)methanone but generally known as ocinaplon, which bears US NIH Compound Identifier 216456. European Medicines Agency schedules Ocinaplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09398MIG. The term OCINAPLON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). OCINAPLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ocinaplon under HS 29335995 and SITC 51576. As of Q4 2014, OCINAPLON remains the US FDA Preferred Term for this commodity. Ocinaplon bears US NLM identifiers UMLS ID C1570833 and NCI Concept Code C81614. SMILES: O=C(C1C2N(NC1)C(C1CCNCC1)CCN2)C1NCCCC1.
Ocrelizumab is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.
This classification denotes an anesthetic agent with the molecular formula C14H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5BZF8S8IL5, chemically known as butyranilide, 3-(diethylamino)- but generally known as octacaine, which bears US NIH Compound Identifier 26329. European Medicines Agency schedules Octacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09401MIG. The term OCTACAINE is an International Non-Proprietary Name. OCTACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule octacaine under HS 29242995 and SITC 51479. As of Q4 2014, OCTACAINE remains the US FDA Preferred Term for this commodity. Octacaine bears US NLM identifiers UMLS ID C0771989 and NCI Concept Code C66251. SMILES: O=C(NC1CCCCC1)CC(N(CC)CC)C.
This classification denotes an anesthetic agent C14H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9HKU5M1CEM, chemically known as butanamide, 3-(diethylamino)-n-phenyl-, hydrochloride (1:1), but more generally known as octacaine hydrochloride, which bears US NIH Compound Identifier 159597. Most nations, for tariff and trade purposes, schedule octacaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, OCTACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)C(C)CC(=O)NC1CCCCC1.CL.
This classification denotes a topical anti-infective agent with the molecular formula C27H42NO.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5SEY06I0DA, chemically known as benzyldiethyl-2-(p-(1,1,3,3-tetramethylbutyl)phenoxy)ethylammonium chloride but more generally known as octafonium chloride, which bears US NIH Compound Identifier 66211. European Medicines Agency schedules Octafonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09402MIG. The term OCTAFONIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). Most nations, for tariff and trade purposes, schedule octafonium chloride under HS 29239000. As of Q4 2014, OCTAFONIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Octafonium chloride bears US NLM identifiers UMLS ID C2983969 and NCI Concept Code C90986. SMILES: CC[N+](CC)(CCOC1CCC(CC1)C(C)(C)CC(C)(C)C)CC2CCCCC2.[CL-].
This classification denotes a topical anti-infective agent with the molecular formula C27H42NO.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5SEY06I0DA, chemically known as benzyldiethyl-2-(p-(1,1,3,3-tetramethylbutyl)phenoxy)ethylammonium chloride but generally known as octafonium chloride, which bears US NIH Compound Identifier 66211. European Medicines Agency schedules Octafonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09402MIG. The term OCTAFONIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). SMILES: CL.O(CC[N](CC1CCCCC1)(CC)CC)C1CCC(C(CC(C)(C)C)(C)C)CC1.
This classification denotes an antimicrobial with the molecular formula C15H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4758KDH62A, chemically known as 1-piperidineethanol, 4-(2-procylpentyl)- but more generally known as octapinol, which bears US NIH Compound Identifier 68906. European Medicines Agency schedules Octapinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09406MIG. The term OCTAPINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 34, No. 10 1980, List 20). OCTAPINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OCCN1CCC(CC(CCC)CCC)CC1.
This classification denotes an anti-infective agent and local anti-infective agent with the molecular formula C36H62N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OZE0372S5A, chemically known as 1,1-decamethylenebis(1,4-dihydro-4-(octylimino)pyridine) but generally known as octenidine, which bears US NIH Compound Identifier 51167. European Medicines Agency schedules Octenidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09411MIG. OCTENIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule octenidine under HS 29333999 and SITC 51574. As of Q4 2014, OCTENIDINE remains the US FDA Preferred Term for this commodity. SMILES: N1(CCCCCCCCCCN2CCC(=N\CCCCCCCC)/CC2)CCC(=N\CCCCCCCC)\CC1.
This classification denotes an anti-infective agent with the molecular formula C36H62N4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U84956NU4B, chemically known as 1-octanamine, n,n'-(1,10-decanediyldi-1(4h)-pyridinyl-4-ylidene)bis-, dihydrochloride, but more generally known as octenidine dihydrochloride, which bears US NIH Compound Identifier 51166. European Medicines Agency schedules octenidine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09411MIG. Most nations, for tariff purposes, schedule octenidine dihydrochloride under HS 29333999. SMILES: CCCCCCCCN=C1CCN(CC1)CCCCCCCCCCN2CCC(=NCCCCCCCC)CC2.CL.CL.
This classification denotes an anti-infective agent with the molecular formula C36H62N4.2C7H5NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R337868TDW, chemically known as 1-octanamine, n,n'-(1,10-decanediyldi-1(4h)-pyridinyl-4-ylidene)bis-, compound with 1,2-benzisothiazol-3(2h)-one 1,1-dioxide (1:2), but more generally known as octenidine saccharin, which bears US NIH Compound Identifier 3047799. European Medicines Agency schedules octenidine saccharin or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09411MIG. Most nations, for tariff purposes, schedule octenidine saccharin under HS 29333999. Octenidine saccharin bears US NLM identifiers UMLS ID C2825364 and NCI Concept Code C80861. SMILES: CCCCCCCCN=C1CCN(CC1)CCCCCCCCCCN2CCC(=NCCCCCCCC)CC2.C1CCC2C(C1)C(=O)NS2(=O)=O.C1CCC2C(C1)C(=O)NS2(=O)=O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3GQ9E911BI, chemically known as 1,5-dimethylhexylamine but generally known as octodrine, which bears US NIH Compound Identifier 10982. European Medicines Agency schedules Octodrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09414MIG. The term OCTODRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). OCTODRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule octodrine under HS 29211980 and SITC 51451. As of Q4 2014, OCTODRINE remains the US FDA Preferred Term for this commodity. Octodrine bears US NLM identifiers UMLS ID C0772192 and NCI Concept Code C74107. SMILES: NC(CCCC(C)C)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 14O50WS8JD, chemically known as benzyl alcohol, .alpha.- (aminomethyl)-p-hydroxy-, hydrochloride, (.+-.)- but generally known as octopamine, which bears US NIH Compound Identifier 4581. European Medicines Agency schedules Octopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09415MIG. The term OCTOPAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules octopamine in its Anatomical Therapeutic Chemical (ATC) Classification. OCTOPAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule octopamine under HS 29379000 and SITC 54155. As of Q4 2014, OCTOPAMINE remains the US FDA Preferred Term for this commodity. Octopamine bears US NLM identifiers UMLS ID C0028403 and NCI Concept Code C75043. SMILES: OC(C1CCC(O)CC1)CN.
This classification denotes a somatostatin receptor agonist with the molecular formula C49H66N10O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RWM8CCW8GP, chemically known as l-cysteinamide, d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (r-(r*,r*))- but generally known as octreotide, which bears US NIH Compound Identifier 383414. European Medicines Agency schedules Octreotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09417MIG. The term OCTREOTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules octreotide in its Anatomical Therapeutic Chemical (ATC) Classification. OCTREOTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule octreotide under HS 29371900 and SITC 54154. As of Q4 2014, OCTREOTIDE remains the US FDA Preferred Term for this commodity. Octreotide bears US NLM identifiers UMLS ID C0028833 and NCI Concept Code C711. SMILES: S1SCC(NC(=O)C(N)CC2CCCCC2)C(=O)NC(C(=O)NC(CC2C3C([NH]C2)CCCC3)C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)NC(C1)C(=O)NC(C(O)C)CO)CC1CCCCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a monoclonal antibody with the molecular formula C6480H10022N1742O2020S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M95KG522R0, more generally known as ofatumumab. European Medicines Agency schedules ofatumumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25221. The term OFATUMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55. OFATUMUMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Ofatumumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, OFATUMUMAB remains the US FDA Preferred Term for this commodity. . Ofatumumab bears US NLM identifiers UMLS ID C1832027 and NCI Concept Code C66952.
This classification denotes a quinolone antibiotic with the molecular formula C18H20FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) A4P49JAZ9H, chemically known as 86393-32-0 (hydrochloride, monohydrate) but more generally known as ofloxacin, which bears U.S. National Institutes of Health Compound Identifier 2764. European Medicines Agency schedules Ofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09422MIG. The term OFLOXACIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules ofloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. OFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ofloxacin under HS 29349990 and SITC 51579. As of Q4 2014, OFLOXACIN remains the US FDA Preferred Term for this commodity. Ofloxacin bears US NLM identifiers UMLS ID C0028902 and NCI Concept Code C712. SMILES: FC1C(N2CCNCC2)CC2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes a quinolone antibiotic with the molecular formula C18H20FN3O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I2UWV315WA. European Medicines Agency schedules ofloxacin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03494MIG. The term ofloxacin hydrochloride is a U.S. FDA designation. Most nations schedule ofloxacin hydrochloride under HS 29349990. As of Q4 2014, OFLOXACIN HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. SMILES: CC1COC2C3N1CC(C(=O)C3CC(C2N4CCN(CC4)C)F)C(=O)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a cariostatic agent with the molecular formula C27H58N2O3.2FH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NY9L8837D, chemically known as 2,2-((3-(2-hydroxyethyl) octadecylamino)propyl) iminodiethanol dihydrofluoride but generally known as olaflur, which bears US NIH Compound Identifier 23257. European Medicines Agency schedules Olaflur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09425MIG. World Health Organization schedules olaflur in its Anatomical Therapeutic Chemical (ATC) Classification. OLAFLUR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule olaflur under HS 29221980 and SITC 51461. As of Q4 2014, OLAFLUR remains the US FDA Preferred Term for this commodity. SMILES: F.F.OCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO.
This classification denotes a quinolone antibiotic with the molecular formula C20H23FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LJG8KL1435, chemically known as 3-quinolinecarboxylic acid, 5-amino-7-(7-amino-5-azaspiro(2,4)hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxo-, (s)- but generally known as olamufloxacin, which bears US NIH Compound Identifier 477670. European Medicines Agency schedules Olamufloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03495MIG. The term OLAMUFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 1, 1999, List 41). Most nations schedule olamufloxacin under HS 29334910 and SITC 51575. As of Q4 2014, OLAMUFLOXACIN remains the US FDA Preferred Term for this commodity. Olamufloxacin bears US NLM identifiers UMLS ID C0965382 and NCI Concept Code C84030. SMILES: FC1C(N2CC3(CC3)C(N)C2)C(C2N(C3CC3)CC(C(=O)C2C1N)C(=O)O)C.
This classification denotes an antipsychotic agent with the molecular formula C17H20N4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N7U69T4SZR, chemically known as 10h-thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- but generally known as olanzapine, which bears US NIH Compound Identifier 4585. European Medicines Agency schedules Olanzapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09426MIG. The term OLANZAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules olanzapine in its Anatomical Therapeutic Chemical (ATC) Classification. OLANZAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule olanzapine under HS 29349990 and SITC 51579. As of Q4 2014, OLANZAPINE remains the US FDA Preferred Term for this commodity. Olanzapine bears US NLM identifiers UMLS ID C0171023 and NCI Concept Code C47639. SMILES: S1C2=NC3C(NC(=C2CC1C)N1CCN(CC1)C)CCCC3.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7S6Q4MHCB. European Medicines Agency schedules Olanzapine embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32279. Olanzapine embonate generally arises in the molecular formula C23H16O6.C17H20N4S.H2O. The term 'olanzapine embonate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule olanzapine embonate under HS 29349990 and SITC 51579. SMILES: CC1CC2C(S1)NC3CCCCC3N=C2N4CCN(CC4)C.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C17H20N4S.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Q8K2L0MC3. Most nations, for tariff and trade purposes, schedule olanzapine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, OLANZAPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C(S1)NC3CCCCC3N=C2N4CCN(CC4)C.CL.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7S6Q4MHCB. European Medicines Agency schedules Olanzapine embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32279. Olanzapine pamoate generally arises in the molecular formula C23H16O6.C17H20N4S.H2O. The term 'olanzapine pamoate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule olanzapine pamoate under HS 29349990. As of Q4 2014, OLANZAPINE PAMOATE remains US FDA's Preferred Term for this commodity. Olanzapine pamoate bears US NLM identifiers UMLS ID C2698647 and NCI Concept Code C76442. SMILES: CC1CC2C(S1)NC3CCCCC3N=C2N4CCN(CC4)C.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.O.
Olaparib is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.
This classification denotes an antimalarial agent with the molecular formula C12H13N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G3LAW9U88T, chemically known as 1,4-dihydroxy-n-(2-hydroxyethyl)-3-methyl-1.lambda.~5~,4.lambda.~5~-quinoxaline-2-carboxamide but more generally known as olaquindox, which bears US NIH Compound Identifier 71905. European Medicines Agency schedules Olaquindox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09427MIG. The term OLAQUINDOX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). OLAQUINDOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=C([N+](=O)C2=CC=CC=C2N1[O-])C(=O)NCCO.
This classification denotes a macrolide antibiotic with the molecular formula C35H61NO12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8ZQ646136, chemically known as 12-((2,6-didesoxy-3-o-methyl-alpha-k-arabino-hexopyranosyl)oxy)-8-hydroxy-5,7,8,11,13,15-hexamethyl-14-((3,4,6-tridesoxy-3-dimethylamino-beta-d-xylo-hexopyranosyl)oxy)-1,9-dioxaspiro(2.13)hexadecan-4,10-dion but generally known as oleandomycin, which bears US NIH Compound Identifier 19822. European Medicines Agency schedules Oleandomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09428MIG. World Health Organization schedules oleandomycin in its Anatomical Therapeutic Chemical (ATC) Classification. OLEANDOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oleandomycin under HS 29419000 and SITC 54139. As of Q4 2014, OLEANDOMYCIN remains the US FDA Preferred Term for this commodity. Oleandomycin bears US NLM identifiers UMLS ID C0028923 and NCI Concept Code C61864. SMILES: O1C2(CC(C(OC3OC(CC(N(C)C)C3O)C)C(C(OC3OC(C(O)C(OC)C3)C)C(C(=O)OC(C(C(O)C(C2=O)C)C)C)C)C)C)C1.
This classification denotes a macrolide antibiotic with the molecular formula C35H61NO12.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8681H0C27P, chemically known as oleandomycin, phosphate (1:1) (salt) but more generally known as oleandomycin phosphate, which bears US NIH Compound Identifier 72492. European Medicines Agency schedules Oleandomycin phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03497MIG. Most nations, for tariff and trade purposes, schedule oleandomycin phosphate under HS 29419000 and SITC 54139. As of Q4 2014, OLEANDOMYCIN PHOSPHATE remains US FDA's Preferred Term for this commodity. Oleandomycin phosphate bears US NLM identifiers UMLS ID C0282269 and NCI Concept Code C61865. SMILES: C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)O)OC)C)C)C)O)C)C)O)N(C)C.OP(=O)(O)O.
This classification denotes a dna minor groove binding agent and antineoplastic antibiotic with the molecular formula C58H84O26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44003517D1, chemically known as olivomycin d, 3(b)-o-(2,6-dideoxy-3-c-methyl-4-o-(2-methyl-1-oxopropyl)-alpha-l-arabino-hexopyranosyl)- but generally known as olivomycin, which bears US NIH Compound Identifier 122806. European Medicines Agency schedules Olivomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03507MIG. The term OLIVOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). OLIVOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule olivomycin under HS 29419000 and SITC 54139. As of Q4 2014, OLIVOMYCIN remains the US FDA Preferred Term for this commodity. Olivomycin bears US NLM identifiers UMLS ID C0028967 and NCI Concept Code C715. SMILES: O(C1CC(OC2CC(OC3C(CC4C(C3=O)C(O)C3C(C4)CC(OC4OC(C(OC(=O)C)C(OC5OC(C(OC)C(O)C5)C)C4)C)CC3O)C(OC)C(=O)C(O)C(O)C)OC(C2O)C)OC(C1O)C)C1OC(C(OC(=O)C(C)C)C(O)(C1)C)C.
This classification denotes a dna minor groove binding agent and antineoplastic antibiotic with the molecular formula C56H80O26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FO0E69826C, chemically known as olivomycin d, 3d-o-(4-o-acetyl-2,6-dideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-, but more generally known as olivomycin b, which bears US NIH Compound Identifier 201840. European Medicines Agency schedules olivomycin b or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03507MIG. Most nations, for tariff purposes, schedule olivomycin b under HS 29419000. SMILES:.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C29H30N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M97XTV3HD, chemically known as 1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1h-tetrazol-5-yl) (1,1-biphenyl)-4-yl)methyl)- but generally known as olmesartan, which bears US NIH Compound Identifier 158781. European Medicines Agency schedules Olmesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20707. The term OLMESARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules olmesartan in its Anatomical Therapeutic Chemical (ATC) Classification. OLMESARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule olmesartan under HS 29332990 and SITC 51573. As of Q4 2014, OLMESARTAN remains the US FDA Preferred Term for this commodity. Olmesartan bears US NLM identifiers UMLS ID C1098320 and NCI Concept Code C66253. SMILES: OC(c1nc(n(c1C(=O)O)Cc1ccc(cc1)c1c(cccc1)c1n[nH]nn1)CCC)(C)C.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C29H30N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M97XTV3HD, chemically known as 1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1h-tetrazol-5-yl) (1,1-biphenyl)-4-yl)methyl)- but more generally known as olmesartan, which bears US NIH Compound Identifier 158781. European Medicines Agency schedules Olmesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20707. The term OLMESARTAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules olmesartan in its Anatomical Therapeutic Chemical (ATC) Classification. OLMESARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule olmesartan medoxomil under HS 29349990 and SITC 51579. As of Q4 2014, OLMESARTAN MEDOXOMIL remains US FDA's Preferred Term for this commodity. Olmesartan medoxomil bears US NLM identifiers UMLS ID C0386393 and NCI Concept Code C47640. SMILES: CCCC1NC(C(N1CC2CCC(CC2)C3CCCCC3C4[NH]NNN4)C(=O)OCC5C(OC(=O)O5)C)C(C)(C)O.
This classification denotes an antihypertensive agent with the molecular formula C9H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0T3B934Y1M, chemically known as 3,4-(methylenedioxy)mandelamidine but generally known as olmidine, which bears US NIH Compound Identifier 31491. European Medicines Agency schedules Olmidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09430MIG. The term OLMIDINE is an International Non-Proprietary Name. OLMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule olmidine under HS 29329970 and SITC 51569. As of Q4 2014, OLMIDINE remains the US FDA Preferred Term for this commodity. Olmidine bears US NLM identifiers UMLS ID C0069453 and NCI Concept Code C90732. SMILES: O1c2c(OC1)ccc(C(O)C(=N)N)c2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D27V6190PM, chemically known as 11-((z)-3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid but generally known as olopatadine, which bears US NIH Compound Identifier 5281071. European Medicines Agency schedules Olopatadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09431MIG. The term OLOPATADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules olopatadine in its Anatomical Therapeutic Chemical (ATC) Classification. OLOPATADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule olopatadine under HS 29329985 and SITC 51569. As of Q4 2014, OLOPATADINE remains the US FDA Preferred Term for this commodity. Olopatadine bears US NLM identifiers UMLS ID C0527189 and NCI Concept Code C61866. SMILES: O1C2C(/C(=C\CCN(C)C)C3C(C1)CCCC3)CC(CC2)CC(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2XG66W44KF, chemically known as 11-((z)-3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid but more generally known as olopatadine hydrochloride, which bears US NIH Compound Identifier 5281071. European Medicines Agency schedules Olopatadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03509MIG. Most nations, for tariff and trade purposes, schedule olopatadine hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, OLOPATADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Olopatadine hydrochloride bears US NLM identifiers UMLS ID C0771892 and NCI Concept Code C61867. SMILES: CN(C)CC/C=C\1/C2CCCCC2COC3C1CC(CC3)CC(=O)O.CL.
This classification denotes a bone resorption inhibitor with the molecular formula C5H15NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 874HHB2V3S, chemically known as phosphonic acid, (3-(dimethylamino)-1-hydroxypropylidene)bis- but generally known as olpadronic acid, which bears US NIH Compound Identifier 198716. European Medicines Agency schedules Olpadronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09432MIG. The term OLPADRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). As of Q4 2014, OLPADRONIC ACID remains the US FDA Preferred Term for this commodity. Olpadronic acid bears US NLM identifiers UMLS ID C0285779 and NCI Concept Code C79878. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CCN(C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H10N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ULS5I8J03O, chemically known as 1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine but generally known as olsalazine, which bears US NIH Compound Identifier 4205. European Medicines Agency schedules Olsalazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09436MIG. The term OLSALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules olsalazine in its Anatomical Therapeutic Chemical (ATC) Classification. OLSALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule olsalazine under HS 32041200 and SITC 53112. As of Q4 2014, OLSALAZINE remains the US FDA Preferred Term for this commodity. Olsalazine bears US NLM identifiers UMLS ID C0069454 and NCI Concept Code C1176. SMILES: N12C(CN(CC1)C)C1C(CC3C2NCCC3)CCCC1.
This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7JEW0XG7I. European Medicines Agency schedules Olsalazine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03510MIG. Olsalazine sodium generally arises in the molecular formula C14H8N2O6.2NA. The term 'olsalazine sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule olsalazine sodium under HS 32041200 and SITC 53112. As of Q4 2014, OLSALAZINE SODIUM remains US FDA's Preferred Term for this commodity. Olsalazine sodium bears US NLM identifiers UMLS ID C0353940 and NCI Concept Code C66254. SMILES: C1CC(C(CC1/N=N/C2CCC(C(C2)C(=O)[O-])O)C(=O)[O-])O.[NA+].[NA+].
This classification denotes an antiviral agent with the molecular formula C10H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C9H909GLI3, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-2-(hydroxymethyl)butyl)- (r)-; but generally known as omaciclovir, which bears US NIH Compound Identifier 3047801. The term OMACICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule omaciclovir under HS 29335995 and SITC 51576. As of Q4 2014, OMACICLOVIR remains the US FDA Preferred Term for this commodity. Omaciclovir bears US NLM identifiers UMLS ID C2983879 and NCI Concept Code C90785. SMILES: C1=NC2=C(N1CC(CCO)CO)NC(=NC2=O)N.
This classification denotes a monoclonal antibody with the molecular formula C6450H9916N1714O2023S38, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2P471X1Z11, more generally known as omalizumab. European Medicines Agency schedules omalizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12543MIG. The term OMALIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46. Most nations, for tariff and trade purposes, schedule Omalizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, OMALIZUMAB remains US FDA's Preferred Term for this commodity. . Omalizumab bears US NLM identifiers UMLS ID C0910794 and NCI Concept Code C29299.
This classification denotes an ace inhibitor with the molecular formula C19H24N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36NLI90E7T, chemically known as 7h-pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-(((2s)-2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo-, (4s,7s,10as)- but generally known as omapatrilat, which bears US NIH Compound Identifier 126046. European Medicines Agency schedules Omapatrilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12450MIG. The term OMAPATRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). OMAPATRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule omapatrilat under HS 29349990 and SITC 51579. As of Q4 2014, OMAPATRILAT remains the US FDA Preferred Term for this commodity. Omapatrilat bears US NLM identifiers UMLS ID C0663645 and NCI Concept Code C1782. SMILES: S1C2N(C(CCC2)C(=O)O)C(=O)C(NC(=O)C(S)Cc2ccccc2)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.
This classification denotes an antidepressant agent with the molecular formula C27H25F2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, H8YI0SSF7B chemically known as 4'-fluoro-2-(trans-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidino)acetophenone but generally known as omiloxetine, which bears US NIH Compound Identifier 3047803. European Medicines Agency schedules Omiloxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09441MIG. The term OMILOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, no. 3 1997, list 38. ). Most nations schedule omiloxetine under HS 29349990 and SITC 51579. As of Q4 2014, OMILOXETINE remains the US FDA Preferred Term for this commodity. Omiloxetine bears US NLM identifiers UMLS ID C2983851 and NCI Concept Code C90715. SMILES: C1CN(CC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4)CC(=O)C5=CC=C(C=C5)F.
This classification denotes an antifungal agent with the molecular formula C20H17Cl3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GQ8ADD54E1, chemically known as 1h-imidazole, 1-(2-(2-(4-chlorophenoxy)ethoxy)-2-(2,4-dichlorophenyl)-1-methylethenyl)-, (z)- but generally known as omoconazole, which bears US NIH Compound Identifier 3033988. European Medicines Agency schedules Omoconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09442MIG. World Health Organization schedules omoconazole in its Anatomical Therapeutic Chemical (ATC) Classification. OMOCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule omoconazole under HS 29332990 and SITC 51573. As of Q4 2014, OMOCONAZOLE remains the US FDA Preferred Term for this commodity. Omoconazole bears US NLM identifiers UMLS ID C0069488 and NCI Concept Code C74599. SMILES: CLC1C(C(=C(\N2CCNC2)C)\OCCOC2CCC(CL)CC2)CCC(CL)C1.
This classification denotes an antifungal agent with the molecular formula C20H17Cl3N2O2.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15LTY5STY6, chemically known as 1h-imidazole, 1-(2-(2-(4-chlorophenoxy)ethoxy)-2-(2,4-dichlorophenyl)-1-methylethenyl)-, (z)-, mononitrate but more generally known as omoconazole nitrate, which bears US NIH Compound Identifier 3036590. European Medicines Agency schedules Omoconazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03516MIG. Most nations, for tariff and trade purposes, schedule omoconazole nitrate under HS 29332990 and SITC 51573. As of Q4 2014, OMOCONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Omoconazole nitrate bears US NLM identifiers UMLS ID C0526119 and NCI Concept Code C75202. SMILES: C/C(=C(\C1CCC(CC1CL)CL)/OCCOC2CCC(CC2)CL)/N3CCNC3.[N+](=O)(O)[O-].
This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C18H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AF302ESOS, chemically known as 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one but generally known as ondansetron, which bears US NIH Compound Identifier 4595. European Medicines Agency schedules Ondansetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09445MIG. The term ONDANSETRON is an International Non-Proprietary Name. World Health Organization schedules ondansetron in its Anatomical Therapeutic Chemical (ATC) Classification. ONDANSETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ondansetron under HS 29332990 and SITC 51573. As of Q4 2014, ONDANSETRON remains the US FDA Preferred Term for this commodity. Ondansetron bears US NLM identifiers UMLS ID C0061851 and NCI Concept Code C1119. SMILES: O=C1C(CCC2N(C3C(C12)CCCC3)C)CN1C(NCC1)C.
This classification denotes an anti-asthmatic agent with the molecular formula C21H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8P8TW6B25I, chemically known as 2-benzoxazolamine, n-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (s)- but generally known as ontazolast, which bears US NIH Compound Identifier 71458. European Medicines Agency schedules Ontazolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09446MIG. The term ONTAZOLAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ONTAZOLAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ontazolast under HS 29349990 and SITC 51579. As of Q4 2014, ONTAZOLAST remains the US FDA Preferred Term for this commodity. Ontazolast bears US NLM identifiers UMLS ID C0663012 and NCI Concept Code C79123. SMILES: O1C(NC(CC2CCCCC2)C2NCCCC2)NC2C1CCC(C2)C.
This classification denotes an antihelminthic agent with the molecular formula C13H12ClNO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CWD6R2J64D, chemically known as 2,6-dioxocyclohexanethiocarboxylic acid 4-chloroanilide but generally known as ontianil, which bears US NIH Compound Identifier 3033959. European Medicines Agency schedules Ontianil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09447MIG. The term ONTIANIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). ONTIANIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ontianil under HS 29309085 and SITC 51549. As of Q4 2014, ONTIANIL remains the US FDA Preferred Term for this commodity. Ontianil bears US NLM identifiers UMLS ID C2983855 and NCI Concept Code C90729. SMILES: CLC1CCC(NC(=S)C2C(=O)CCCC2=O)CC1.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C14H17FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3A8EU2NMU, chemically known as 1(2h)-quinoxalinecarboxylic acid, 2-ethyl-7-fluoro-3,4-dihydro-3-oxo-, 1-methylethyl ester, (2s)- but generally known as opaviraline, which bears US NIH Compound Identifier 154048. The term OPAVIRALINE is an International Non-Proprietary Name. Most nations schedule opaviraline under HS 29339990 and SITC 51577. As of Q4 2014, OPAVIRALINE remains the US FDA Preferred Term for this commodity. Opaviraline bears US NLM identifiers UMLS ID C0910816 and NCI Concept Code C90786. SMILES: CCC1C(=O)NC2=C(N1C(=O)OC(C)C)C=C(C=C2)F.
This classification denotes an antitubercular agent with the molecular formula C16H15N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KD4681N5W4, chemically known as 5,6-dimethoxyphthalaldehydic acid isonicotinoylhydrazone but more generally known as opiniazide, which bears US NIH Compound Identifier 6871212. European Medicines Agency schedules Opiniazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09449MIG. The term OPINIAZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). OPINIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(C(CCC1OC)/C=N/NC(=O)C1CCNCC1)C(=O)O)C.
This classification denotes an anxiolytic and antidepressant agent with the molecular formula C23H29N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D23ZXO613C, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (s)- but generally known as opipramol, which bears US NIH Compound Identifier 1302. European Medicines Agency schedules Opipramol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09450MIG. The term OPIPRAMOL is an International Non-Proprietary Name. World Health Organization schedules opipramol in its Anatomical Therapeutic Chemical (ATC) Classification. OPIPRAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule opipramol under HS 29335995 and SITC 51576. As of Q4 2014, OPIPRAMOL remains the US FDA Preferred Term for this commodity. Opipramol bears US NLM identifiers UMLS ID C0029105 and NCI Concept Code C90612. SMILES: O(c1cc2c(cc(C(C)C(=O)O)cc2)cc1)C.
This classification denotes an anxiolytic and antidepressant agent with the molecular formula C23H29N3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B49OBI656M, chemically known as 1-piperazineethanol, 4-(3-(5h-dibenz(b,f)azepin-5-yl)propyl)-, dihydrochloride, but more generally known as opipramol dihydrochloride, which bears US NIH Compound Identifier 71587. European Medicines Agency schedules opipramol dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09450MIG. Most nations, for tariff purposes, schedule opipramol dihydrochloride under HS 29335995. SMILES: C1CCC2C(C1)C=CC3CCCCC3N2CCCN4CCN(CC4)CCO.CL.CL.
This classification denotes an anxiolytic with the molecular formula C23H29N3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B49OBI656M, chemically known as 5-(gamma-(beta-hydroxyethylpiperazino)propyl)-5h-dibenzo(b,f)azepine dihydrochloride but more generally known as opipramol hydrochloride, which bears US NIH Compound Identifier 71587. European Medicines Agency schedules Opipramol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03520MIG. Most nations, for tariff and trade purposes, schedule opipramol hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, OPIPRAMOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Opipramol hydrochloride bears US NLM identifiers UMLS ID C0282270 and NCI Concept Code C87667. SMILES: C1CCC2C(C1)C=CC3CCCCC3N2CCCN4CCN(CC4)CCO.CL.CL.
This classification denotes a natural product and the source of many narcotic analgesics, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37M3MZ001L. European Medicines Agency schedules Opium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB12190MIG, SUB14698MIG, SUB14699MIG, SUB14700MIG, SUB14701MIG, SUB14702MIG, SUB14703MIG, SUB29028, and SUB61961.. As of Q4 2014, OPIUM remains the US FDA Preferred Term for this commodity. SMILES: O1C2C(OC)C(C(CCN(C)C)CC2OC1)CC(=O)C1C(C(OC)C(OC)CC1)C(=O)O.
This classification denotes a therapeutic interleukin with the molecular formula C854H1411N253O235S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) HM5641GA6F, more generally known as oprelvekin. European Medicines Agency schedules oprelvekin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14704MIG. The term OPRELVEKIN is an International Non-Proprietary Name or INN. see World Health Organization INN reference publication, Volume 11, no. 3 1997, list 38. OPRELVEKIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oprelvekin under HS 30021095 and SITC 54163. As of Q4 2014, OPRELVEKIN remains the US FDA Preferred Term for this commodity. Oprelvekin bears US NLM identifiers UMLS ID C0537670 and NCI Concept Code C1303.
This classification denotes a quinolone antibiotic with the molecular formula C19H20F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 660932TPY6, chemically known as 1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid but generally known as orbifloxacin, which bears US NIH Compound Identifier 60605. European Medicines Agency schedules Orbifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09454MIG. The term ORBIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). ORBIFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule orbifloxacin under HS 29335995 and SITC 51576. As of Q4 2014, ORBIFLOXACIN remains the US FDA Preferred Term for this commodity. Orbifloxacin bears US NLM identifiers UMLS ID C0300903 and NCI Concept Code C72635. SMILES: FC1C2N(C3CC3)CC(C(=O)C2C(F)C(F)C1N1CC(NC(C1)C)C)C(=O)O.
This classification denotes an ace inhibitor with the molecular formula C20H34N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GFJ8659TQP, chemically known as (2s,3as,7as)-1-((s)-n-((s)-1-carboxypentyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester but generally known as orbutopril, which bears US NIH Compound Identifier 5745795. European Medicines Agency schedules Orbutopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09456MIG. The term ORBUTOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ORBUTOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule orbutopril under HS 29339990 and SITC 51577. As of Q4 2014, ORBUTOPRIL remains the US FDA Preferred Term for this commodity. Orbutopril bears US NLM identifiers UMLS ID C2983809 and NCI Concept Code C90629. SMILES: O(C(=O)C1N(C2C(C1)CCCC2)C(=O)C(NC(CCCC)C(=O)O)C)CC.
This classification denotes a bronchodilator with the molecular formula C11H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53QOG569E0, chemically known as 3,5-dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol but generally known as metaproterenol, which bears US NIH Compound Identifier 4086. European Medicines Agency schedules Metaproterenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09457MIG. The term METAPROTERENOL is an International Non-Proprietary Name. World Health Organization schedules metaproterenol in its Anatomical Therapeutic Chemical (ATC) Classification. Orciprenaline or metaproterenol bears US NLM identifiers UMLS ID C0029193 and NCI Concept Code C61834. SMILES: CC(C)NCC(C1=CC(=CC(=C1)O)O)O.
This classification denotes a therapeutic estrogen with the molecular formula C27H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G9VC23W7W0, chemically known as 1,3,5(10)-estratrien-3-ol, 17beta-(1-cyclohexenyloxy)-, propionate but generally known as orestrate, which bears US NIH Compound Identifier 167462. European Medicines Agency schedules Orestrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09459MIG. The term ORESTRATE is an International Non-Proprietary Name. ORESTRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule orestrate under HS 29372300 and SITC 54153. As of Q4 2014, ORESTRATE remains the US FDA Preferred Term for this commodity. Orestrate bears US NLM identifiers UMLS ID C2698657 and NCI Concept Code C76997. SMILES: O(C1C2(C(C3C(CC2)c2c(CC3)cc(OC(=O)CC)cc2)CC1)C)C1=CCCCC1.
A type of lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.
This classification denotes a gastrointestinal lipase inhibitor with the molecular formula C29H53NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95M8R751W8, chemically known as n-formyl-l-leucine, ester with (3s,4s)-3-hexyl-4-((2s)-2-hydroxytridecyl)-2-oxetanone but generally known as orlistat, which bears US NIH Compound Identifier 3034010. European Medicines Agency schedules Orlistat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09460MIG. The term ORLISTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules orlistat in its Anatomical Therapeutic Chemical (ATC) Classification. ORLISTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ORLISTAT remains the US FDA Preferred Term for this commodity. Orlistat bears US NLM identifiers UMLS ID C0732649 and NCI Concept Code C29303. SMILES: O1C(C(CCCCCC)C1=O)CC(OC(=O)C(NC=O)CC(C)C)CCCCCCCCCCC.
This classification denotes an antiestrogen with the molecular formula C30H35NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44AXY5VE90, chemically known as 3,4-trans-2,2-dimethyl-3-phenyl-4-(p-(beta-pyrrolidinoethoxy)phenyl)-7-methoxychroman but generally known as ormeloxifene, which bears US NIH Compound Identifier 35805. European Medicines Agency schedules Ormeloxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09462MIG. The term ORMELOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). ORMELOXIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ormeloxifene or centchroman bears US NLM identifiers UMLS ID C1701687 and NCI Concept Code C90722. SMILES: O1C(C(C(C2C1CC(OC)CC2)C1CCC(OCCN2CCCC2)CC1)C1CCCCC1)(C)C.
This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C14H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M3EFS94984, chemically known as 2,4-pyrimidinediamine, 5-((4,5-dimethoxy-2-methylphenyl)methyl)- but more generally known as ormetoprim, which bears US NIH Compound Identifier 23418. European Medicines Agency schedules Ormetoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09463MIG. The term ORMETOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). ORMETOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1CC(CC2C(NC(NC2)N)N)C(CC1OC)C)C.
This classification denotes an amebicide, antitrichomonal agent, and radiation-sensitizing agent with the molecular formula C7H10ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62XCK0G93T, chemically known as 1h-imidazole-1-ethanol, alpha-(chloromethyl)-2-methyl-5-nitro- but generally known as ornidazole, which bears US NIH Compound Identifier 28061. European Medicines Agency schedules Ornidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09464MIG. World Health Organization schedules ornidazole in its Anatomical Therapeutic Chemical (ATC) Classification. ORNIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ornidazole under HS 29332990 and SITC 51573. As of Q4 2014, ORNIDAZOLE remains the US FDA Preferred Term for this commodity. SMILES: CLCC(O)CN1C(NCC1[N](=O)O)C.
This classification denotes an amino acid and Ketoglutaric Acids with the molecular formula C10H18N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier URK9D85MYO, chemically known as 2-oxopentanedioic acid- d-ornithine(1:1) but generally known as Ornithine oxoglurate, which bears US NIH Compound Identifier 123900. European Medicines Agency schedules Ornithine oxoglurate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03543MIG. World Health Organization schedules bismuth subcitrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ornithine oxoglurate under HS 29224995 and SITC 51465. SMILES: C(CC(C(=O)O)N)CN.C(CC(=O)O)C(=O)C(=O)O.
This classification denotes a muscle relaxant and antimuscarinic agent with the molecular formula C18H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AL805O9OG9, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but generally known as orphenadrine, which bears US NIH Compound Identifier 4601. European Medicines Agency schedules Orphenadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09471MIG. ORPHENADRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule orphenadrine under HS 29221980 and SITC 51461. As of Q4 2014, ORPHENADRINE remains the US FDA Preferred Term for this commodity. Orphenadrine bears US NLM identifiers UMLS ID C0029309 and NCI Concept Code C61868. SMILES: O(C(C1C(CCCC1)C)C1CCCCC1)CCN(C)C.
This classification denotes a muscle relaxant with the molecular formula C18H23NO.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X0A40N8I4S, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but more generally known as orphenadrine citrate, which bears US NIH Compound Identifier 4601. European Medicines Agency schedules Orphenadrine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03546MIG. Most nations, for tariff and trade purposes, schedule orphenadrine citrate under HS 29221990 and SITC 51461. As of Q4 2014, ORPHENADRINE CITRATE remains US FDA's Preferred Term for this commodity. Orphenadrine citrate bears US NLM identifiers UMLS ID C0029310 and NCI Concept Code C47641. SMILES: CC1CCCCC1C(C2CCCCC2)OCCN(C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antimuscarinic agent with the molecular formula C18H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UBY910DUXH, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but more generally known as orphenadrine hydrochloride, which bears US NIH Compound Identifier 4601. European Medicines Agency schedules Orphenadrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03547MIG. Most nations, for tariff and trade purposes, schedule orphenadrine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, ORPHENADRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Orphenadrine hydrochloride bears US NLM identifiers UMLS ID C0699481 and NCI Concept Code C78075. SMILES: CC1CCCCC1C(C2CCCCC2)OCCN(C)C.CL.
This classification denotes an anorexiant with the molecular formula C10H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VF4N11KKKR, chemically known as 1,1-dimethyl-2-phenylethylamine but generally known as ortetamine, which bears US NIH Compound Identifier 4771. European Medicines Agency schedules Ortetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09472MIG. The term ORTETAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). ORTETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ortetamine under HS 29214980 and SITC 51454. As of Q4 2014, ORTETAMINE remains the US FDA Preferred Term for this commodity. Ortetamine bears US NLM identifiers UMLS ID C2698659 and NCI Concept Code C75115. SMILES: CC(C)(CC1=CC=CC=C1)N.
This classification denotes an antiviral agent with the molecular formula C16H28N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 20O93L6F9H, chemically known as 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r,4r,5s)- but generally known as oseltamivir, which bears US NIH Compound Identifier 65028. European Medicines Agency schedules Oseltamivir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03553MIG. The term OSELTAMIVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules oseltamivir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule oseltamivir under HS 29242995 and SITC 51479. As of Q4 2014, OSELTAMIVIR remains the US FDA Preferred Term for this commodity. Oseltamivir bears US NLM identifiers UMLS ID C0874161 and NCI Concept Code C62061. SMILES: O(C1C(NC(=O)C)C(N)CC(=C1)C(=O)OCC)C(CC)CC.
This classification denotes an antiviral agent with the molecular formula C14H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K6106LV5Q8, chemically known as oseltamivir acid, (-)-, but more generally known as oseltamivir carboxylate, which bears US NIH Compound Identifier 449381. European Medicines Agency schedules oseltamivir carboxylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03553MIG. Most nations, for tariff purposes, schedule oseltamivir carboxylate under HS 29242995. SMILES: CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)O.
This classification denotes an antiviral agent with the molecular formula C16H28N2O4.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4A3O49NGEZ, chemically known as 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r,4r,5s)- but more generally known as oseltamivir phosphate, which bears US NIH Compound Identifier 65028. European Medicines Agency schedules Oseltamivir phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12544MIG. Most nations, for tariff and trade purposes, schedule oseltamivir phosphate under HS 29242995 and SITC 51479. As of Q4 2014, OSELTAMIVIR PHOSPHATE remains US FDA's Preferred Term for this commodity. Oseltamivir phosphate bears US NLM identifiers UMLS ID C0872908 and NCI Concept Code C29305. SMILES: CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC.OP(=O)(O)O.
Osimertinib is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
This classification denotes a selective estrogen receptor modulator with the molecular formula C24H23ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B0P231ILBK, chemically known as 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol but more generally known as ospemifene, which bears US NIH Compound Identifier 3036505. European Medicines Agency schedules Ospemifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33020. The term OSPEMIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). Most nations, for tariff and trade purposes, schedule ospemifene under HS 29094990 and SITC 51617. As of Q4 2014, OSPEMIFENE remains US FDA's Preferred Term for this commodity. Ospemifene bears US NLM identifiers UMLS ID C1313616 and NCI Concept Code C76958. SMILES: CLCC/C(=C(/C1CCC(OCCO)CC1)C1CCCCC1)C1CCCCC1.
This classification denotes an antimuscarinic agent with the molecular formula C24H31N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OM7J0XAL0S, chemically known as 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((2-((diethylamino)methyl)-7-piperidinyl)acetyl)- but generally known as otenzepad, which bears US NIH Compound Identifier 107867. European Medicines Agency schedules Otenzepad in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09478MIG. The term OTENZEPAD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). OTENZEPAD is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule otenzepad under HS 29333999 and SITC 51574. As of Q4 2014, OTENZEPAD remains the US FDA Preferred Term for this commodity. Otenzepad bears US NLM identifiers UMLS ID C0090085 and NCI Concept Code C75279. SMILES: O=C(N1C2C(C(=O)[NH]C3C1NCCC3)CCCC2)CN1C(CCCC1)CN(CC)CC.
This classification denotes a pyrimidine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VT6420TIG. European Medicines Agency schedules Oteracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30899. Oteracil generally arises in the molecular formula C4H3N3O4. The term OTERACIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule oteracil under HS 29336980 and SITC 51576. As of Q4 2014, OTERACIL remains the US FDA Preferred Term for this commodity. Oteracil bears US NLM identifiers UMLS ID C0030032 and NCI Concept Code C76917. SMILES: C1(=NC(=O)NC(=O)N1)C(=O)[O-].[K+].
This classification denotes an antimuscarinic agent with the molecular formula C29H43N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21HN3N72PV, chemically known as ethanaminium, n,n-diethyl-n-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-, bromide but generally known as otilonium, which bears US NIH Compound Identifier 72092. European Medicines Agency schedules Otilonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03554MIG. The term OTILONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules otilonium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, OTILONIUM remains the US FDA Preferred Term for this commodity. SMILES: CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.
This classification denotes preparations containing substances with antigenic properties administered to activate veterinary or non-human immune systems, thereby inducing immune responses, preparations called vaccines, of which the current commodities address or prevent an infectious morbillivirus called Ovine rinderpest or Peste des petit ruminants that afflicts goats and sheep, thus the term OVINE RINDERPEST OR PESTE DES PETIT RUMINANTS (PPR) VACCINES.
This classification denotes an anabolic steroid with the molecular formula C26H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51RPF719WE, chemically known as 4-hydroxy-19-nortestosterone but generally known as oxabolone, which bears US NIH Compound Identifier 68952. European Medicines Agency schedules Oxabolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09481MIG. The term OXABOLONE is an International Non-Proprietary Name. World Health Organization schedules oxabolone in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, OXABOLONE remains the US FDA Preferred Term for this commodity. SMILES: CC12CCC3C(C1CCC2O)CCC4=C(C(=O)CCC34)O.
This classification denotes an anabolic steroid with the molecular formula C26H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RXY50Q01N, chemically known as 4,17beta-dihydroxyestr-4-en-3-one 17-cyclopentanepropionate but more generally known as oxabolone cipionate, which bears US NIH Compound Identifier 68952. European Medicines Agency schedules Oxabolone cipionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09481MIG. The term OXABOLONE CIPIONATE is an International Non-Proprietary Name. World Health Organization schedules oxabolone cipionate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule oxabolone cipionate under HS 29372900 and SITC 54153. As of Q4 2014, OXABOLONE CIPIONATE remains US FDA's Preferred Term for this commodity. Oxabolone cipionate bears US NLM identifiers UMLS ID C2825599 and NCI Concept Code C81376. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=C(C(=O)CC[C@H]35)O.
This classification denotes a mucolytic agent and antitussive agent with the molecular formula C18H25Br2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F220MU498K, chemically known as ethyl-((4,6-dibromo-alpha-(cyclohexylmethylamino)-o-tolyl)oxy)acetate but generally known as oxabrexine, which bears US NIH Compound Identifier 167463. European Medicines Agency schedules Oxabrexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09482MIG. The term OXABREXINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). OXABREXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxabrexine under HS 29222900 and SITC 51462. As of Q4 2014, OXABREXINE remains the US FDA Preferred Term for this commodity. Oxabrexine bears US NLM identifiers UMLS ID C2983807 and NCI Concept Code C90624. SMILES: Brc1c(OCC(=O)OCC)c(CN(C2CCCCC2)C)cc(Br)c1.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q0XV76B96L. European Medicines Agency schedules Oxaceprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09483MIG. Oxaceprol generally arises in the molecular formula C7H11NO4. The term OXACEPROL is an International Nomenclature of Cosmetic Ingredients designation. OXACEPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxaceprol under HS 29339990 and SITC 51577. As of Q4 2014, OXACEPROL remains the US FDA Preferred Term for this commodity. Oxaceprol bears US NLM identifiers UMLS ID C0064164 and NCI Concept Code C90905. SMILES: OC1CC(NC1)C(=O)O.
This classification denotes a penicillin antibiotic with the molecular formula C19H19N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UH95VD7V76, chemically known as 5-methyl-3-phenyl-4-isoxazolyl penicillin, sodium but generally known as oxacillin, which bears US NIH Compound Identifier 4608. European Medicines Agency schedules Oxacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09484MIG. The term OXACILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules oxacillin in its Anatomical Therapeutic Chemical (ATC) Classification. OXACILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxacillin under HS 29411090 and SITC 54131. As of Q4 2014, OXACILLIN remains the US FDA Preferred Term for this commodity. Oxacillin bears US NLM identifiers UMLS ID C0029983 and NCI Concept Code C62063. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C1C(NOC1C)C1CCCCC1.
This classification denotes an anti-bacterial agent with the molecular formula C19H18N3O5S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G0V6C994Q5, chemically known as 5-methyl-3-phenyl-4-isoxazolyl penicillin, sodium but more generally known as oxacillin sodium, which bears US NIH Compound Identifier 4608. European Medicines Agency schedules Oxacillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03559MIG. Most nations, for tariff and trade purposes, schedule oxacillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, OXACILLIN SODIUM remains US FDA's Preferred Term for this commodity. Oxacillin sodium bears US NLM identifiers UMLS ID C0037536 and NCI Concept Code C720. SMILES: CC1C(C(NO1)C2CCCCC2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[NA+].
This classification denotes a penicillin antibiotic with the molecular formula C19H18N3O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4TWD2995UP, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, sodium salt (1:1), (2s,5r,6r)-, but more generally known as oxacillin sodium anhydrous, which bears US NIH Compound Identifier 64714. European Medicines Agency schedules oxacillin sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09484MIG. Most nations, for tariff purposes, schedule oxacillin sodium anhydrous under HS 29411090. Oxacillin sodium anhydrous bears US NLM identifiers UMLS ID C2698675 and NCI Concept Code C76225. SMILES: CC1C(C(NO1)C2CCCCC2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[NA+].
This classification denotes an antidepressant agent with the molecular formula C14H18F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V4WLW77V5Q, chemically known as 4-isopropyl-2-(alpha,alpha,alpha-trifluoro-m-tolyl)morpholine but generally known as oxaflozane, which bears US NIH Compound Identifier 71915. European Medicines Agency schedules Oxaflozane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09486MIG. The term OXAFLOZANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules oxaflozane in its Anatomical Therapeutic Chemical (ATC) Classification. OXAFLOZANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxaflozane under HS 29349990 and SITC 51579. As of Q4 2014, OXAFLOZANE remains the US FDA Preferred Term for this commodity. Oxaflozane bears US NLM identifiers UMLS ID C0069709 and NCI Concept Code C75175. SMILES: FC(F)(F)c1ccc(C2OCCN(C2)C(C)C)cc1.
This classification denotes an antidepressant agent with the molecular formula C14H18F3NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E10FW59D1I, chemically known as 4-isopropyl-2-(alpha,alpha,alpha-trifluoro-m-tolyl)morpholine hydrochloride but more generally known as oxaflozane hydrochloride, which bears US NIH Compound Identifier 167466. European Medicines Agency schedules Oxaflozane hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03560MIG. Most nations, for tariff and trade purposes, schedule oxaflozane hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, OXAFLOZANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)N1CCOC(C1)C2CCCC(C2)C(F)(F)F.CL.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0ME957NZRY. European Medicines Agency schedules Oxaflumazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09487MIG. Oxaflumazine generally arises in the molecular formula C26H32F3N3O2S. The term OXAFLUMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) OXAFLUMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxaflumazine under HS 29343090 and SITC 51578. As of Q4 2014, OXAFLUMAZINE remains the US FDA Preferred Term for this commodity. Oxaflumazine bears US NLM identifiers UMLS ID C0069710 and NCI Concept Code C90762. SMILES: S1C2C(N(CCCN3CCN(CC3)CCC3OCCCO3)C3C1CCCC3)CC(CC2)C(F)(F)F.
This classification denotes a platinum compound with the molecular formula C8H14N2O4Pt, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04ZR38536J, chemically known as (sp-4-3-(cis))-(1,2-cyclohexanediamine-n,n)(ethanedioato(2-)-o,o)platinum but more generally known as oxaliplatin, which bears US NIH Compound Identifier 77994. European Medicines Agency schedules Oxaliplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09490MIG. The term OXALIPLATIN is an International Non-Proprietary Name. World Health Organization schedules oxaliplatin in its Anatomical Therapeutic Chemical (ATC) Classification. OXALIPLATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule oxaliplatin under HS 28439090 and SITC 52432. As of Q4 2014, OXALIPLATIN remains US FDA's Preferred Term for this commodity. Oxaliplatin bears US NLM identifiers UMLS ID C0069717 and NCI Concept Code C1181. SMILES: [PT].OC(=O)C(=O)O.NC1C(N)CCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H17ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8G02RSW5CM, chemically known as 1h-indole-3-acetamide, 1-(4-chlorobenzoyl)-n-hydroxy-5-methoxy-2-methyl- (9ci) but generally known as oxametacin, which bears US NIH Compound Identifier 33675. European Medicines Agency schedules Oxametacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09492MIG. The term OXAMETACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules oxametacin in its Anatomical Therapeutic Chemical (ATC) Classification. OXAMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Oxametacin or oxamethacin bears US NLM identifiers UMLS ID C2698676 and NCI Concept Code C76077. SMILES: CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)CL)C=CC(=C2)OC)CC(=O)NO.
This classification denotes an antihelminthic agent with the molecular formula C14H21N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O977R722D, chemically known as 1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol but generally known as oxamniquine, which bears US NIH Compound Identifier 4612. European Medicines Agency schedules Oxamniquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09494MIG. The term OXAMNIQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules oxamniquine in its Anatomical Therapeutic Chemical (ATC) Classification. OXAMNIQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxamniquine under HS 29334990 and SITC 51575. As of Q4 2014, OXAMNIQUINE remains the US FDA Preferred Term for this commodity. Oxamniquine bears US NLM identifiers UMLS ID C0029994 and NCI Concept Code C66258. SMILES: OCC1CC2CCC(NC2CC1[N](=O)O)CNC(C)C.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C19H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7H6TM3CT4L, chemically known as 2-oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)- (9ci) but generally known as oxandrolone, which bears US NIH Compound Identifier 5878. European Medicines Agency schedules Oxandrolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09496MIG. The term OXANDROLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxandrolone in its Anatomical Therapeutic Chemical (ATC) Classification. OXANDROLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxandrolone under HS 29372900 and SITC 54153. As of Q4 2014, OXANDROLONE remains the US FDA Preferred Term for this commodity. Oxandrolone bears US NLM identifiers UMLS ID C0029995 and NCI Concept Code C29306. SMILES: OC1(C2(C(C3C(C4(C(CC3)CC(=O)OC4)C)CC2)CC1)C)C.
This classification denotes a pyrantel analog and antinematodal agent with the molecular formula C13H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94AJJ30D9E, chemically known as phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl)-, (e)- but generally known as oxantel, which bears US NIH Compound Identifier 5281087. European Medicines Agency schedules Oxantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09497MIG. World Health Organization schedules oxantel in its Anatomical Therapeutic Chemical (ATC) Classification. OXANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxantel under HS 29335995 and SITC 51576. As of Q4 2014, OXANTEL remains the US FDA Preferred Term for this commodity. Oxantel bears US NLM identifiers UMLS ID C0069734 and NCI Concept Code C96694. SMILES: OC1CC(/C=C/C2=NCCCN2C)CCC1.
This classification denotes an antihelminthic agent with the molecular formula C23H16O6.C13H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UPY1D732T0, chemically known as 4,4-methylenebis(3-hydroxy-2-naphthoic) acid, compound with (e)-3-(2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl)phenol (1:1) but more generally known as oxantel embonate, which bears US NIH Compound Identifier 5281086. Most nations, for tariff and trade purposes, schedule oxantel embonate under HS 29335995 and SITC 51576. SMILES: CN1CCCN=C1/C=C/C2CCCC(C2)O.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes a pyrantel analog and antinematodal agent with the molecular formula C23H16O6.C13H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UPY1D732T0, chemically known as (e)-m-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)vinyl)phenol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1) (salt), but more generally known as oxantel pamoate, which bears US NIH Compound Identifier 5281086. European Medicines Agency schedules oxantel pamoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09497MIG. Most nations, for tariff purposes, schedule oxantel pamoate under HS 29335995. As of Q4 2014, OXANTEL PAMOATE remains US FDA's Preferred Term for this commodity. Oxantel pamoate bears US NLM identifiers UMLS ID C0163908 and NCI Concept Code C90730. SMILES: CN1CCCN=C1/C=C/C2CCCC(C2)O.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MHJ80W9LRB, chemically known as 4,5-diphenyl-2-oxazolepropionic acid but generally known as oxaprozin, which bears US NIH Compound Identifier 4614. European Medicines Agency schedules Oxaprozin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09502MIG. The term OXAPROZIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules oxaprozin in its Anatomical Therapeutic Chemical (ATC) Classification. OXAPROZIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxaprozin under HS 29349990 and SITC 51579. As of Q4 2014, OXAPROZIN remains the US FDA Preferred Term for this commodity. Oxaprozin bears US NLM identifiers UMLS ID C0603695 and NCI Concept Code C29307. SMILES: O1C(C(NC1CCC(=O)O)C1CCCCC1)C1CCCCC1.
This classification denotes an anti-asthmatic agent with the molecular formula C21H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A34YCH7N8A, chemically known as 9-benzoyl-1,2,3,4-tetrahydro-6-methoxycarbazole-3-carboxylic acid but generally known as oxarbazole, which bears US NIH Compound Identifier 37184. European Medicines Agency schedules Oxarbazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09503MIG. The term OXARBAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). OXARBAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxarbazole under HS 29339990 and SITC 51577. As of Q4 2014, OXARBAZOLE remains the US FDA Preferred Term for this commodity. Oxarbazole bears US NLM identifiers UMLS ID C0069741 and NCI Concept Code C81436. SMILES: OC(=O)C1CC2C(N(C3C2CC(OC)CC3)C(=O)C2CCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C27H30N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J31IL9Z2EE, chemically known as 2h-benzimidazol-2-one, 1,3-dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)- but generally known as oxatomide, which bears US NIH Compound Identifier 4615. European Medicines Agency schedules Oxatomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09504MIG. The term OXATOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules oxatomide in its Anatomical Therapeutic Chemical (ATC) Classification. OXATOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxatomide under HS 29335995 and SITC 51576. As of Q4 2014, OXATOMIDE remains the US FDA Preferred Term for this commodity. Oxatomide bears US NLM identifiers UMLS ID C0134337 and NCI Concept Code C73051. SMILES: O=C1N(CCCN2CCN(CC2)C(C2CCCCC2)C2CCCCC2)C2C([NH]1)CCCC2.
This classification denotes a benzodiazepine with the molecular formula C15H11ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6GOW6DWN2A, chemically known as 1,3-dihydro-7-chloro-3-hydroxy-5-phenyl-3h-1,4-benzodiazepin-2-one but generally known as oxazepam, which bears US NIH Compound Identifier 4616. European Medicines Agency schedules Oxazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09506MIG. The term OXAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxazepam in its Anatomical Therapeutic Chemical (ATC) Classification. OXAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxazepam under HS 29339190 and SITC 51577. As of Q4 2014, OXAZEPAM remains the US FDA Preferred Term for this commodity. Oxazepam bears US NLM identifiers UMLS ID C0029997 and NCI Concept Code C47642. SMILES: CLC1CC2C(=NC(O)C(=O)NC2CC1)C1CCCCC1.
This classification denotes a cholagogue/choleretic agent with the molecular formula C14H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77243B845F. European Medicines Agency schedules oxazorone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09509MIG. The term OXAZORONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11. ). OXAZORONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxazorone under HS 29349990 and SITC 51579. As of Q4 2014, OXAZORONE remains the US FDA Preferred Term for this commodity. Oxazorone bears US NLM identifiers UMLS ID C2825424 and NCI Concept Code C81043. SMILES: O1CCN(CC1)CC1C2C(OC(=O)C1)CC(O)CC2.
This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VZI5B1W380, chemically known as 10,11-dihydro-10-oxo-5h-dibenz(b,f)azepine-5-carboxamide but generally known as oxcarbazepine, which bears US NIH Compound Identifier 34312. European Medicines Agency schedules Oxcarbazepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09510MIG. The term OXCARBAZEPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules oxcarbazepine in its Anatomical Therapeutic Chemical (ATC) Classification. OXCARBAZEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxcarbazepine under HS 29339930 and SITC 51577. As of Q4 2014, OXCARBAZEPINE remains the US FDA Preferred Term for this commodity. Oxcarbazepine bears US NLM identifiers UMLS ID C0876196 and NCI Concept Code C47643. SMILES: O=C1CC2C(N(C3C1CCCC3)C(=O)N)CCCC2.
This classification denotes an adrenergic alpha-agonist, nasal decongestant, sympathomimetic, and vasoconstrictor agent with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PEG5DP7434, chemically known as benzyl alcohol, p-hydroxy-alpha-((methylamino)methyl)- but more generally known as oxedrine, which bears US NIH Compound Identifier 7172. European Medicines Agency schedules Oxedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14726MIG. World Health Organization schedules oxedrine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, OXEDRINE remains US FDA's Preferred Term for this commodity. SMILES: OC(CNC)C1CCC(O)CC1.
This classification denotes an antitussive agent with the molecular formula C20H33NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) SNC1080T5Y, chemically known as 2-(2-diethylaminoethoxy)ethyl alpha,alpha-diethylphenylacetate but more generally known as oxeladin, which bears US NIH Compound Identifier 4619. European Medicines Agency schedules Oxeladin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09513MIG. World Health Organization schedules oxeladin in its Anatomical Therapeutic Chemical (ATC) Classification. OXELADIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule oxeladin under HS 29221980 and SITC 51461. As of Q4 2014, OXELADIN remains US FDA's Preferred Term for this commodity. SMILES: O(C(=O)C(CC)(CC)C1CCCCC1)CCOCCN(CC)CC.
This classification denotes an antitussive agent with the molecular formula C20H33NO3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AEV5C340C, chemically known as benzeneacetic acid, .alpha.,.alpha.-diethyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1), but more generally known as oxeladin citrate, which bears US NIH Compound Identifier 40384. European Medicines Agency schedules oxeladin citrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09513MIG. Most nations, for tariff purposes, schedule oxeladin citrate under HS 29221980. SMILES: CCC(CC)(C1CCCCC1)C(=O)OCCOCCN(CC)CC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H12O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PF3750D8AE, chemically known as 6,11-dihydro-11-oxodibenz(b,e)oxepin-3-acetic acid but generally known as oxepinac, which bears US NIH Compound Identifier 41531. European Medicines Agency schedules Oxepinac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09515MIG. The term OXEPINAC is an International Non-Proprietary Name. OXEPINAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxepinac under HS 29329985 and SITC 51569. As of Q4 2014, OXEPINAC remains the US FDA Preferred Term for this commodity. Oxepinac bears US NLM identifiers UMLS ID C0069754 and NCI Concept Code C66260. SMILES: O1C2C(C(=O)C3C(C1)CCCC3)CCC(C2)CC(=O)O.
This classification denotes an anesthetic agent with the molecular formula C28H41N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IP8QT76V17, chemically known as 2,2-((2-hydroxyethyl)imino)bis(n-(alpha,alpha-dimethylphenethyl)-n-methylacetamide) but generally known as oxetacaine, which bears US NIH Compound Identifier 4621. European Medicines Agency schedules Oxetacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09516MIG. The term OXETACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxetacaine in its Anatomical Therapeutic Chemical (ATC) Classification. OXETACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Oxetacaine or oxethazaine bears US NLM identifiers UMLS ID C0069758 and NCI Concept Code C81409. SMILES: O=C(N(C(CC1CCCCC1)(C)C)C)CN(CC(=O)N(C(CC1CCCCC1)(C)C)C)CCO.
This classification denotes a penicillin antibiotic with the molecular formula C19H23N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47UDJ8GA54, chemically known as (2s,5r,6r)-6-((r)-(4-(p-hydroxyphenyl)-2,2-dimethyl-5-oxo-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but more generally known as oxetacillin, which bears US NIH Compound Identifier 6367080. European Medicines Agency schedules Oxetacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09517MIG. The term OXETACILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). OXETACILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2[NH]1C(NC(C1=O)C1CCC(O)CC1)(C)C.
This classification denotes a serotonin antagonist with the molecular formula C21H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3XOS33TIQ, chemically known as 3-(12h-benzofuro(3,2-c)(1)benzoxepin-6-yliden)-n,n-dimethylpropylamin but generally known as oxetorone, which bears US NIH Compound Identifier 6436540. European Medicines Agency schedules Oxetorone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09518MIG. The term OXETORONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules oxetorone in its Anatomical Therapeutic Chemical (ATC) Classification. OXETORONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxetorone under HS 29329985 and SITC 51569. As of Q4 2014, OXETORONE remains the US FDA Preferred Term for this commodity. Oxetorone bears US NLM identifiers UMLS ID C0069760 and NCI Concept Code C84037. SMILES: O1C2C(C3C1CCCC3)COC1C(C\2=C\CCN(C)C)CCCC1.
This classification denotes an antihelminthic agent with the molecular formula C15H13N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OMP2H17F9E, chemically known as 2-benzimidazolecarbamic acid, 5-(phenylsulfinyl)-, methyl ester but generally known as oxfendazole, which bears US NIH Compound Identifier 40854. European Medicines Agency schedules Oxfendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09519MIG. The term OXFENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). OXFENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxfendazole under HS 29339990 and SITC 51577. As of Q4 2014, OXFENDAZOLE remains the US FDA Preferred Term for this commodity. Oxfendazole bears US NLM identifiers UMLS ID C0069761 and NCI Concept Code C75229. SMILES: S(=O)(C1CC2[NH]C(NC2CC1)NC(=O)OC)C1CCCCC1.
This classification denotes an antihelminthic agent with the molecular formula C15H13N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQM8UA6SPQ, chemically known as carbamic acid, n-(6-(phenylsulfonyl)-1h-benzimidazol-2-yl)-, methyl ester, but more generally known as oxfendazole sulfone, which bears US NIH Compound Identifier 162136. European Medicines Agency schedules oxfendazole sulfone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09519MIG. Most nations, for tariff purposes, schedule oxfendazole sulfone under HS 29339990. SMILES: COC(=O)NC1[NH]C2CCC(CC2N1)S(=O)(=O)C3CCCCC3.
This classification denotes an antihelminthic agent with the molecular formula C12H15N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 022N12KJ0X, chemically known as 2-benzimidazolecarbamic acid, 5-propoxy-, methyl ester but generally known as oxibendazole, which bears US NIH Compound Identifier 4622. European Medicines Agency schedules Oxibendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09521MIG. The term OXIBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). OXIBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxibendazole under HS 29339990 and SITC 51577. As of Q4 2014, OXIBENDAZOLE remains the US FDA Preferred Term for this commodity. Oxibendazole bears US NLM identifiers UMLS ID C0069763 and NCI Concept Code C66262. SMILES: CCCOC1=CC2=C(C=C1)N=C(N2)NC(=O)OC.
This classification denotes an anti-lipidemic agent with the molecular formula C6H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0WVV18VUI, chemically known as n-(2-hydroxyethyl) n,n-dimethylammonioacetat but generally known as oxibetaine, which bears US NIH Compound Identifier 168886. European Medicines Agency schedules Oxibetaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09522MIG. The term OXIBETAINE is an International Non-Proprietary Name. OXIBETAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxibetaine under HS 29239000 and SITC 51481. As of Q4 2014, OXIBETAINE remains the US FDA Preferred Term for this commodity. Oxibetaine bears US NLM identifiers UMLS ID C1882237 and NCI Concept Code C66263. SMILES: OCC[N](CC(=O)O)(C)C.
This classification denotes an antifungal agent with the molecular formula C18H13Cl4N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C668Q9I33J, chemically known as 1h-imidazole, 1-(2-((2-chloro-3-thienyl)methoxy)-2-(2,4-dichlorophenyl)ethyl)- but generally known as oxiconazole, which bears US NIH Compound Identifier 5482. European Medicines Agency schedules Oxiconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09523MIG. The term OXICONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules oxiconazole in its Anatomical Therapeutic Chemical (ATC) Classification. OXICONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxiconazole under HS 29332990 and SITC 51573. As of Q4 2014, OXICONAZOLE remains the US FDA Preferred Term for this commodity. Oxiconazole bears US NLM identifiers UMLS ID C0069765 and NCI Concept Code C61869. SMILES: CLC1C(C(OCC2CCSC2CL)CN2CCNC2)CCC(CL)C1.
This classification denotes an antifungal agent with the molecular formula C18H13Cl4N3O.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RQ8UL4C17S, chemically known as 1h-imidazole, 1-(2-((2-chloro-3-thienyl)methoxy)-2-(2,4-dichlorophenyl)ethyl)- but more generally known as oxiconazole nitrate, which bears US NIH Compound Identifier 5482. European Medicines Agency schedules Oxiconazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03569MIG. Most nations, for tariff and trade purposes, schedule oxiconazole nitrate under HS 29332990 and SITC 51573. As of Q4 2014, OXICONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Oxiconazole nitrate bears US NLM identifiers UMLS ID C0142160 and NCI Concept Code C47644. SMILES: C1CC(C(CC1CL)CL)CO/N=C(\CN2CCNC2)/C3CCC(CC3CL)CL.[N+](=O)(O)[O-].
This classification denotes an antifungal agent with the molecular formula C13H12N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34711907NJ, chemically known as 1,2-dihydro-3-(phenoxymethyl)pyrido(3,4-e)-as-triazin hydrochlorid but generally known as oxifungin hydrochloride, which bears US NIH Compound Identifier 168888. Most nations schedule oxifungin under HS 29339990 and SITC 51577. As of Q4 2014, OXIFUNGIN remains the US FDA Preferred Term for this commodity. Oxifungin bears US NLM identifiers UMLS ID C1882238 and NCI Concept Code C66264. SMILES: C1=CC=C(C=C1)OCC2=NC3=C(C=CN=C3)NN2.Cl.
This classification denotes an antifungal agent with the molecular formula C13H12N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34711907NJ, chemically known as 1,2-dihydro-3-(phenoxymethyl)pyrido(3,4-e)-as-triazin hydrochlorid but more generally known as oxifungin hydrochloride, which bears US NIH Compound Identifier 168888. Most nations, for tariff and trade purposes, schedule oxifungin hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, OXIFUNGIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Oxifungin hydrochloride bears US NLM identifiers UMLS ID C1882239 and NCI Concept Code C66265. SMILES: C1CCC(CC1)OCC2=NC3CNCCC3NN2.CL.
This classification denotes an adrenergic agent with the molecular formula C10H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F49638UBDR, chemically known as (r*,s*)-4-hydroxy-alpha-(1-(methylamino)ethyl)benzyl alcohol but generally known as oxilofrine, which bears US NIH Compound Identifier 9701. European Medicines Agency schedules Oxilofrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09529MIG. The term OXILOFRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). OXILOFRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxilofrine under HS 29399900 and SITC 54149. As of Q4 2014, OXILOFRINE remains the US FDA Preferred Term for this commodity. Oxilofrine bears US NLM identifiers UMLS ID C0069766 and NCI Concept Code C74102. SMILES: CC(C(C1=CC=C(C=C1)O)O)NC.
This classification denotes a beta-lactam antibiotic with the molecular formula C12H15N5O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 482M43SL0K, chemically known as acetic acid, ((3-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-methyl-4-oxo-1-azetidinyl)oxy)-, (2s-(2alpha,3beta(z)))- but generally known as oximonam, which bears US NIH Compound Identifier 9571070. European Medicines Agency schedules Oximonam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09531MIG. The term OXIMONAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). OXIMONAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oximonam under HS 29419000 and SITC 54139. As of Q4 2014, OXIMONAM remains the US FDA Preferred Term for this commodity. Oximonam bears US NLM identifiers UMLS ID C1882240 and NCI Concept Code C66266. SMILES: CC1C(C(=O)N1OCC(=O)O)NC(=O)C(=NOC)C2=CSC(=N2)N.
This classification denotes a beta-lactam antibiotic C12H14N5O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G274R51QFV, chemically known as acetic acid, 2-(((2s,3s)-3-(((2z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl)amino)-2-methyl-4-oxo-1-azetidinyl)oxy)-, sodium salt (1:1), but more generally known as oximonam sodium, which bears US NIH Compound Identifier 23663948. Most nations, for tariff and trade purposes, schedule oximonam sodium under HS 29419000 and SITC 54139. As of Q4 2014, OXIMONAM SODIUM remains US FDA's Preferred Term for this commodity. Oximonam sodium bears US NLM identifiers UMLS ID C1882241 and NCI Concept Code C66267. SMILES: C[C@H]1[C@@H](C(=O)N1OCC(=O)[O-])NC(=O)/C(=N\OC)/C2CSC(N2)N.[NA+].
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZY400R3BNT. European Medicines Agency schedules Oxindanac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09532MIG. Oxindanac generally arises in the molecular formula C17H14O4. The term OXINDANAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) OXINDANAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, OXINDANAC remains the US FDA Preferred Term for this commodity. Oxindanac bears US NLM identifiers UMLS ID C0069768 and NCI Concept Code C66268. SMILES: OC(=O)C1CCC2C1CC(O)C(C2)C(=O)C1CCCCC1.
This classification denotes an antiparkinsonian agent with the molecular formula C20H23N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRO75M6RW2, chemically known as 2h-benzimidazol-2-one, 1,3-dihydro-1-(1-(2-phenoxyethyl)-4-piperidinyl)- but generally known as oxiperomide, which bears US NIH Compound Identifier 68634. European Medicines Agency schedules Oxiperomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09534MIG. The term OXIPEROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). OXIPEROMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxiperomide under HS 29333999 and SITC 51574. As of Q4 2014, OXIPEROMIDE remains the US FDA Preferred Term for this commodity. Oxiperomide bears US NLM identifiers UMLS ID C0069771 and NCI Concept Code C66270. SMILES: O(CCN1CCC(N2C3C([NH]C2=O)CCCC3)CC1)C1CCCCC1.
This classification denotes a xanthine oxidase inhibitor with the molecular formula C5H4N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G97OZE5068, chemically known as 4,6-dihydroxypyrazolo(3,4-d)pyrimidine but generally known as oxipurinol, which bears US NIH Compound Identifier 4644. European Medicines Agency schedules Oxipurinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09535MIG. The term OXIPURINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). OXIPURINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Oxipurinol or oxypurinol bears US NLM identifiers UMLS ID C0030086 and NCI Concept Code C87294. SMILES: O=C1[NH]C(=O)NC2[NH][NH]CC12.
This classification denotes a nutritional supplement and neuroprotective agent with the molecular formula C6H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7U817352G, chemically known as 1-pyrrolidineacetamide, 4-hydroxy-2-oxo-, (s)- but generally known as oxiracetam, which bears US NIH Compound Identifier 4626. European Medicines Agency schedules Oxiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09536MIG. The term OXIRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules oxiracetam in its Anatomical Therapeutic Chemical (ATC) Classification. OXIRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxiracetam under HS 29337900 and SITC 51561. As of Q4 2014, OXIRACETAM remains the US FDA Preferred Term for this commodity. Oxiracetam bears US NLM identifiers UMLS ID C0069772 and NCI Concept Code C66271. SMILES: OC1CN(C(=O)C1)CC(=O)N.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H28O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C39YBM73T, chemically known as 11beta,17,21-trihydroxy-b-homo-a-norpregn-1-ene-3,6,20-trione but generally known as oxisopred, which bears US NIH Compound Identifier 3047809. European Medicines Agency schedules Oxisopred in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09538MIG. The term OXISOPRED is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). OXISOPRED is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxisopred under HS 29372900 and SITC 54153. As of Q4 2014, OXISOPRED remains the US FDA Preferred Term for this commodity. Oxisopred bears US NLM identifiers UMLS ID C1882242 and NCI Concept Code C66272. SMILES: OC1(C2(C(C3C(C(O)C2)C2(C(C(=O)CC3)C(=O)C=C2)C)CC1)C)C(=O)OC.
This classification denotes an amino acid derivative with the molecular formula C11H12N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C1LJO185Q9, chemically known as tryptophan, 5-hydroxy-, l- but more generally known as oxitriptan, which bears U.S. NIH Compound Identifier 144. European Medicines Agency schedules Oxitriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09541MIG. The term OXITRIPTAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules oxitriptan in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. OXITRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an antimuscarinic agent with the molecular structure C19H26NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8G15T83E6I chemically known as (7(s)-(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.))-9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane but generally known as oxitropium, which bears US NIH Compound Identifier 5311335. European Medicines Agency schedules Oxitropium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03574MIG. As of Q4 2014, OXITROPIUM remains the US FDA Preferred Term for this commodity. Oxitropium bears US NLM identifiers UMLS ID C0069776 and NCI Concept Code C87641. SMILES: BR.O1C2C3[N](C(C12)CC(OC(=O)C(CO)C1CCCCC1)C3)(CC)C.
This classification denotes a bronchodilator and antimuscarinic agent with the molecular formula C19H26NO4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SF4NW7NH7C, chemically known as 3-oxa-9-azoniatricyclo(3.3.1.0(sup 2,4))nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, (7(s)-(1-alpha,2-beta,4-beta,5-alpha,7-beta))- but more generally known as oxitropium bromide, which bears US NIH Compound Identifier 34875. European Medicines Agency schedules Oxitropium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09543MIG. The term OXITROPIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules oxitropium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule oxitropium bromide under HS 29399900 and SITC 54149. As of Q4 2014, OXITROPIUM BROMIDE remains US FDA's Preferred Term for this commodity. Oxitropium bromide bears US NLM identifiers UMLS ID C0134499 and NCI Concept Code C74157. SMILES: CC[N+]1([C@@H]2C[C@H](C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4CCCCC4)C.[BR-].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90BEA145GY, chemically known as 1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl- but generally known as oxolamine, which bears US NIH Compound Identifier 13738. European Medicines Agency schedules Oxolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09547MIG. The term OXOLAMINE is an International Non-Proprietary Name. World Health Organization schedules oxolamine in its Anatomical Therapeutic Chemical (ATC) Classification. OXOLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxolamine under HS 29349990 and SITC 51579. As of Q4 2014, OXOLAMINE remains the US FDA Preferred Term for this commodity. Oxolamine bears US NLM identifiers UMLS ID C0069787 and NCI Concept Code C66274. SMILES: O1NC(NC1CCN(CC)CC)C1CCCCC1.
This classification denotes an antitussive agent with the molecular formula C14H19N3O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5X4XBR694, chemically known as 1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-, citrate but more generally known as oxolamine citrate, which bears US NIH Compound Identifier 16045. European Medicines Agency schedules Oxolamine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03576MIG. Most nations, for tariff and trade purposes, schedule oxolamine citrate under HS 29349990 and SITC 51579. As of Q4 2014, OXOLAMINE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCC1NC(NO1)C2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H19N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SHI14LG2ZY, chemically known as 1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-, monohydrochloride, but more generally known as oxolamine hydrochloride, which bears US NIH Compound Identifier 14637. European Medicines Agency schedules oxolamine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09547MIG. Most nations, for tariff purposes, schedule oxolamine hydrochloride under HS 29349990. SMILES: CCN(CC)CCC1NC(NO1)C2CCCCC2.CL.
This classification denotes a nonsteroidal antiinflammatory drug C14H19N3O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DMG78UE3PU, chemically known as 1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-phenyl-, phosphate (1:1), but more generally known as oxolamine phosphate, which bears US NIH Compound Identifier 6431771. European Medicines Agency schedules Oxolamine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03577MIG. Most nations, for tariff and trade purposes, schedule oxolamine phosphate under HS 29349990 and SITC 51579. As of Q4 2014, OXOLAMINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCC1NC(NO1)C2CCCCC2.OP(=O)(O)O.
This classification denotes a quinolone antibiotic with the molecular formula C13H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0A22B22FT, chemically known as 1,3-dioxolo(4,5-g)quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo- but generally known as oxolinic acid, which bears US NIH Compound Identifier 4628. European Medicines Agency schedules Oxolinic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09548MIG. The term OXOLINIC ACID is an International Non-Proprietary Name. World Health Organization schedules oxolinic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule oxolinic acid under HS 29349990 and SITC 51579. As of Q4 2014, OXOLINIC ACID remains the US FDA Preferred Term for this commodity. Oxolinic acid bears US NLM identifiers UMLS ID C0030031 and NCI Concept Code C76921. SMILES: O1c2cc3n(CC)cc(c(=O)c3cc2OC1)C(=O)O.
This classification denotes an antimuscarinic agent with the molecular formula C18H22N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 305MB38V1C, chemically known as 10h-phenothiazine-10-propanamine, n,n,beta-trimethyl- but generally known as oxomemazine, which bears US NIH Compound Identifier 5574. European Medicines Agency schedules Oxomemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09549MIG. The term OXOMEMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxomemazine in its Anatomical Therapeutic Chemical (ATC) Classification. OXOMEMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxomemazine under HS 29343090 and SITC 51578. As of Q4 2014, OXOMEMAZINE remains the US FDA Preferred Term for this commodity. Oxomemazine bears US NLM identifiers UMLS ID C0768401 and NCI Concept Code C73008. SMILES: S1C2C(N(CC(CN(C)C)C)C3C1CCCC3)CCCC2.
This classification denotes an antimuscarinic agent C18H22N2O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6BOK44G9K6, chemically known as phenothiazine, 10-(3-(dimethylamino)-2-methylpropyl)-, 5,5-dioxide, monohydrochloride, but more generally known as oxomemazine hydrochloride, which bears US NIH Compound Identifier 3083870. European Medicines Agency schedules Oxomemazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21934. Most nations, for tariff and trade purposes, schedule oxomemazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, OXOMEMAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(CN1C2CCCCC2S(=O)(=O)C3C1CCCC3)CN(C)C.CL.
This classification denotes an antihypertensive agent with the molecular formula C25H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JGY63UVRO, chemically known as 3-[(7R,8R,9S,10R,13S,14S,17R)-17-hydroxy-10,\13-dimethyl-3-oxo-7-propyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate but generally known as oxprenoate, which bears US NIH Compound Identifier 23677972. European Medicines Agency schedules Oxprenoate potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09554MIG. The term OXPRENOATE is an International Non-Proprietary Name. As of Q4 2014, OXPRENOATE remains the US FDA Preferred Term for this commodity. Oxprenoate bears US NLM identifiers UMLS ID C2981339 and NCI Concept Code C87707. SMILES: CCCC1CC2=CC(=O)CCC2(C3C1C4CCC(C4(CC3)C)(CCC(=O)[O-])O)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 519MXN9YZR, chemically known as 2-propanol, 1-(2-allyloxyphenoxy)-3-(isopropylamino)- but generally known as oxprenolol, which bears US NIH Compound Identifier 4631. European Medicines Agency schedules Oxprenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09555MIG. The term OXPRENOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules oxprenolol in its Anatomical Therapeutic Chemical (ATC) Classification. OXPRENOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxprenolol under HS 29221980 and SITC 51461. As of Q4 2014, OXPRENOLOL remains the US FDA Preferred Term for this commodity. Oxprenolol bears US NLM identifiers UMLS ID C0030040 and NCI Concept Code C66276. SMILES: O(CC(O)CNC(C)C)C1C(OCC=C)CCCC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4XSI7SNIU, chemically known as 2-propanol, 1-(o-allyloxyphenoxy)-3-isopropylamino-, hydrochloride but more generally known as oxprenolol hydrochloride, which bears US NIH Compound Identifier 71172. European Medicines Agency schedules Oxprenolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03578MIG. Most nations, for tariff and trade purposes, schedule oxprenolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, OXPRENOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Oxprenolol hydrochloride bears US NLM identifiers UMLS ID C0700460 and NCI Concept Code C66277. SMILES: CC(C)NCC(COC1CCCCC1OCC=C)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes an anesthetic agent with the molecular formula C17H28N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VE4U49K15, chemically known as benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7ci,8ci,9ci) but more generally known as benoxinate hydrochloride, which bears US NIH Compound Identifier 4633. European Medicines Agency schedules Benoxinate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03580MIG. Most nations, for tariff and trade purposes, schedule oxybuprocaine hydrochloride under HS 29225000. SMILES: CCCCOC1CC(CCC1N)C(=O)OCCN(CC)CC.CL.
This classification denotes an antimuscarinic agent with the molecular formula C22H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9P6MC7092, chemically known as cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester but generally known as oxybutynin, which bears US NIH Compound Identifier 4634. European Medicines Agency schedules Oxybutynin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09558MIG. The term OXYBUTYNIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxybutynin in its Anatomical Therapeutic Chemical (ATC) Classification. OXYBUTYNIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxybutynin under HS 29221980 and SITC 51461. As of Q4 2014, OXYBUTYNIN remains the US FDA Preferred Term for this commodity. Oxybutynin bears US NLM identifiers UMLS ID C0069805 and NCI Concept Code C47647. SMILES: OC(C1CCCCC1)(C1CCCCC1)C(=O)OCC#CCN(CC)CC.
Topical antiseptic.
This classification denotes a uricosuric agent and nonnarcotic analgesic with the molecular formula C16H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) UK6392GD5W, chemically known as 4-quinolinecarboxylic acid, 3-hydroxy-2-phenyl- (9ci) but more generally known as oxycinchophen, which bears US NIH Compound Identifier 10239. European Medicines Agency schedules Oxycinchophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09559MIG. The term OXYCINCHOPHEN is an International Non-Proprietary Name. World Health Organization schedules oxycinchophen in its Anatomical Therapeutic Chemical (ATC) Classification. OXYCINCHOPHEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule oxycinchophen under HS 29334910 and SITC 51575. As of Q4 2014, OXYCINCHOPHEN remains US FDA's Preferred Term for this commodity. Oxycinchophen bears US NLM identifiers UMLS ID C1882245 and NCI Concept Code C66278. SMILES: OC1C(C2C(NC1C1CCCCC1)CCCC2)C(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C13H6Cl5NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1QS9G4876X, chemically known as 3,5,6,3,5-pentachloro-2,2-dihydroxybenzanilide but generally known as oxyclozanide, which bears US NIH Compound Identifier 16779. European Medicines Agency schedules Oxyclozanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09561MIG. The term OXYCLOZANIDE is an International Non-Proprietary Name. OXYCLOZANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Oxyclozanide or zanil bears US NLM identifiers UMLS ID C0030046 and NCI Concept Code C66279. SMILES: C1=C(C=C(C(=C1CL)O)NC(=O)C2=C(C(=CC(=C2CL)CL)CL)O)CL.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CD35PMG570, chemically known as 4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one but generally known as oxycodone, which bears US NIH Compound Identifier 5284603. European Medicines Agency schedules Oxycodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09562MIG. The term OXYCODONE is an International Non-Proprietary Name. World Health Organization schedules oxycodone in its Anatomical Therapeutic Chemical (ATC) Classification. OXYCODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxycodone under HS 29391100 and SITC 54141. As of Q4 2014, OXYCODONE remains the US FDA Preferred Term for this commodity. Oxycodone bears US NLM identifiers UMLS ID C0030049 and NCI Concept Code C29309. SMILES: O1C2C34C(O)(C(N(CC3)C)CC3C4C1C(OC)CC3)CCC2=O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C1ENJ2TE6C, chemically known as 4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one but more generally known as oxycodone hydrochloride, which bears US NIH Compound Identifier 5284603. European Medicines Agency schedules Oxycodone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03583MIG. Most nations, for tariff and trade purposes, schedule oxycodone hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, OXYCODONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Oxycodone hydrochloride bears US NLM identifiers UMLS ID C0722364 and NCI Concept Code C48010. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)OC.CL.
This classification denotes an opioid receptor agonist and opioid with the molecular structure 2C18H21NO4.C8H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, M04XWV43UF chemically known as 4,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one 1,4-benzenedicarboxylate (2:1 salt), but more commonly known as oxycodone terephthalate, which bears US NIH Compound Identifier 5464088. European Medicines Agency schedules Oxycodone terephthalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03585MIG. Most nations, for tariff and trade purposes, schedule oxycodone terephthalate under HS 29391100 and SITC 54141. As of Q4 2014, OXYCODONE TEREPHTHALATE remains US FDA's Preferred Term for this commodity. Oxycodone terephthalate bears US NLM identifiers UMLS ID C0606954 and NCI Concept Code C48009. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)OC.CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)OC.C1CC(CCC1C(=O)O)C(=O)O.
This classification denotes a muscle relaxant with the molecular formula C16H38N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52J3C7381O, chemically known as trimethyl-[5-[5-(trimethylazaniumyl)pentoxy]pentyl]azanium but generally known as oxydipentonium, which bears US NIH Compound Identifier 23560. European Medicines Agency schedules Oxydipentonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09563MIG. The term OXYDIPENTONIUM is an International Non-Proprietary Name. As of Q4 2014, OXYDIPENTONIUM remains the US FDA Preferred Term for this commodity. Oxydipentonium bears US NLM identifiers UMLS ID C2828260 and NCI Concept Code C87313. SMILES: C[N+](C)(C)CCCCCOCCCCC[N+](C)(C)C.[Cl-].
This classification denotes a muscle relaxant with the molecular formula C16H38N2O.2Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VV0B5MP6VI, chemically known as 5,5-bis(trimethylammonium)dipentyl ether dichlorid but more generally known as oxydipentonium chloride, which bears US NIH Compound Identifier 23560. European Medicines Agency schedules Oxydipentonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09563MIG. The term OXYDIPENTONIUM CHLORIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule oxydipentonium chloride under HS 29239000 and SITC 51481. As of Q4 2014, OXYDIPENTONIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Oxydipentonium chloride bears US NLM identifiers UMLS ID C1882246 and NCI Concept Code C66280. SMILES: C[N+](C)(C)CCCCCOCCCCC[N+](C)(C)C.[CL-].[CL-].
This classification denotes a vasodilating agent and beta-adrenergic agonist with the molecular formula C19H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DWL616XF1K, chemically known as 3-(((alphas,betar)-beta-hydroxy-alpha-methylphenethyl)amino)-3-methoxypropiophenone but generally known as oxyfedrine, which bears US NIH Compound Identifier 27454. European Medicines Agency schedules Oxyfedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09564MIG. The term OXYFEDRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules oxyfedrine in its Anatomical Therapeutic Chemical (ATC) Classification. OXYFEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxyfedrine under HS 29225000 and SITC 51467. As of Q4 2014, OXYFEDRINE remains the US FDA Preferred Term for this commodity. Oxyfedrine bears US NLM identifiers UMLS ID C0030053 and NCI Concept Code C74199. SMILES: OC(C(NCCC(=O)c1cc(OC)ccc1)C)c1ccccc1.
This classification denotes a vasodilating agent and beta-adrenergic agonist with the molecular formula C19H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63CF9XK7DA, chemically known as 1-propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, hydrochloride but more generally known as oxyfedrine hydrochloride, which bears US NIH Compound Identifier 27972. European Medicines Agency schedules Oxyfedrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03586MIG. Most nations, for tariff and trade purposes, schedule oxyfedrine hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, OXYFEDRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Oxyfedrine hydrochloride bears US NLM identifiers UMLS ID C2698679 and NCI Concept Code C77154. SMILES: C[C@@H]([C@@H](C1CCCCC1)O)NCCC(=O)C2CCCC(C2)OC.CL.
This classification denotes an antipsychotic agent with the molecular formula C11H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MD0414799X, chemically known as 1,2-butanediol, 2-phenyl-, 1-carbamate but generally known as hydroxyphenamate, which bears US NIH Compound Identifier 5752. European Medicines Agency schedules Oxyfenamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09565MIG. The term OXYFENAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Oxyfenamate or hydroxyphenamate bears US NLM identifiers UMLS ID C0301410 and NCI Concept Code C76011. SMILES: CCC(COC(=O)N)(C1=CC=CC=C1)O.
This classification denotes an anabolic steroid with the molecular formula C20H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4R73K9MRMX, chemically known as 4,17beta-dihydroxy-17-methylandrost-4-en-3-one but generally known as oxymesterone, which bears US NIH Compound Identifier 72061. European Medicines Agency schedules Oxymesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09566MIG. The term OXYMESTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). OXYMESTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxymesterone under HS 29372900 and SITC 54153. As of Q4 2014, OXYMESTERONE remains the US FDA Preferred Term for this commodity. Oxymesterone bears US NLM identifiers UMLS ID C0369772 and NCI Concept Code C74112. SMILES: OC1(C2(C(C3C(C4(C(=C(O)C(=O)CC4)CC3)C)CC2)CC1)C)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C16H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8VLN5B44ZY, chemically known as 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol but more generally known as oxymetazoline, which bears US NIH Compound Identifier 4636. European Medicines Agency schedules Oxymetazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09567MIG. The term OXYMETAZOLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxymetazoline in its Anatomical Therapeutic Chemical (ATC) Classification. OXYMETAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule oxymetazoline under HS 29332990 and SITC 51573. As of Q4 2014, OXYMETAZOLINE remains US FDA's Preferred Term for this commodity. Oxymetazoline bears US NLM identifiers UMLS ID C0030071 and NCI Concept Code C61871. SMILES: OC1C(C(C)(C)C)CC(C(C1C)CC1=NCCN1)C.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C21H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L76T0ZCA8K, chemically known as androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17methyl-, (5.alpha.,17.beta.) but generally known as oxymetholone, which bears US NIH Compound Identifier 9902. European Medicines Agency schedules Oxymetholone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09568MIG. The term OXYMETHOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxymetholone in its Anatomical Therapeutic Chemical (ATC) Classification. OXYMETHOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxymetholone under HS 29372900 and SITC 54153. As of Q4 2014, OXYMETHOLONE remains the US FDA Preferred Term for this commodity. Oxymetholone bears US NLM identifiers UMLS ID C0030072 and NCI Concept Code C723. SMILES: OC1(C2(C(C3C(C4(C(CC3)CC(=O)C(=C\O)/C4)C)CC2)CC1)C)C.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9VXA968E0C, chemically known as 3,14-dihydroxy-4,5-alpha-epoxy-17-methylmorphinan-6-one but generally known as oxymorphone, which bears US NIH Compound Identifier 5284604. European Medicines Agency schedules Oxymorphone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09569MIG. The term OXYMORPHONE is an International Non-Proprietary Name. OXYMORPHONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxymorphone under HS 29391100 and SITC 54141. As of Q4 2014, OXYMORPHONE remains the US FDA Preferred Term for this commodity. Oxymorphone bears US NLM identifiers UMLS ID C0030073 and NCI Concept Code C29314. SMILES: O1C2C34C(O)(C(N(CC3)C)CC3C4C1C(O)CC3)CCC2=O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H19NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Y2EI94NBC, chemically known as 4,5alpha-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one hydrochloride but more generally known as oxymorphone hydrochloride, which bears US NIH Compound Identifier 5359390. European Medicines Agency schedules Oxymorphone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03591MIG. Most nations, for tariff and trade purposes, schedule oxymorphone hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, OXYMORPHONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Oxymorphone hydrochloride bears US NLM identifiers UMLS ID C0733819 and NCI Concept Code C47648. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O.CL.
This classification denotes a dopamine antagonist with the molecular formula C23H29N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5JGL4G25R7, chemically known as 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)indole but generally known as oxypertine, which bears US NIH Compound Identifier 4640. European Medicines Agency schedules Oxypertine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09571MIG. The term OXYPERTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules oxypertine in its Anatomical Therapeutic Chemical (ATC) Classification. OXYPERTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxypertine under HS 29335995 and SITC 51576. As of Q4 2014, OXYPERTINE remains the US FDA Preferred Term for this commodity. Oxypertine bears US NLM identifiers UMLS ID C0030077 and NCI Concept Code C87711. SMILES: O(c1cc2c(CCN3CCN(CC3)c3ccccc3)c([nH]c2cc1OC)C)C.
This classification denotes a dopamine antagonist C23H29N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P131473P6, chemically known as 1h-indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-, hydrochloride (1:1), but more generally known as oxypertine hydrochloride, which bears US NIH Compound Identifier 24194514. European Medicines Agency schedules Oxypertine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03592MIG. Most nations, for tariff and trade purposes, schedule oxypertine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, OXYPERTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1C(C2CC(C(CC2[NH]1)OC)OC)CCN3CCN(CC3)C4CCCCC4.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H806S4B3NS, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl- (van) (8ci) but generally known as oxyphenbutazone, which bears US NIH Compound Identifier 4641. European Medicines Agency schedules Oxyphenbutazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09572MIG. World Health Organization schedules oxyphenbutazone in its Anatomical Therapeutic Chemical (ATC) Classification. OXYPHENBUTAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxyphenbutazone under HS 29331990 and SITC 51571. As of Q4 2014, OXYPHENBUTAZONE remains the US FDA Preferred Term for this commodity. Oxyphenbutazone bears US NLM identifiers UMLS ID C0030078 and NCI Concept Code C66282. SMILES: O=C1N(N(C(=O)C1CCCC)C1CCCCC1)C1CCC(O)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A7D84513GV, chemically known as (+/-)-oxyphenbutazone anhydrous, but more generally known as oxyphenbutazone anhydrous, which bears US NIH Compound Identifier 4641. European Medicines Agency schedules oxyphenbutazone anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09572MIG. Most nations, for tariff purposes, schedule oxyphenbutazone anhydrous under HS 29331990. Oxyphenbutazone anhydrous bears US NLM identifiers UMLS ID C2698680 and NCI Concept Code C74597. SMILES: CCCCC1C(=O)N(N(C1=O)C2CCC(CC2)O)C3CCCCC3.
This classification denotes a nonsteroidal antiinflammatory drug C19H20N2O3.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86B165MRR5, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-, compd. with piperazine (1:1), but more generally known as oxyphenbutazone piperazine, which bears US NIH Compound Identifier 72941570. European Medicines Agency schedules Oxyphenbutazone piperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03593MIG. Most nations, for tariff and trade purposes, schedule oxyphenbutazone piperazine under HS 29331990 and SITC 51571. As of Q4 2014, OXYPHENBUTAZONE PIPERAZINE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC1C(=O)N(N(C1=O)C2CCC(CC2)O)C3CCCCC3.C1CNCCN1.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C20H28N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GWO1432WOU, chemically known as 1,4,5,6-tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat but more generally known as oxyphencyclimine hydrochloride, which bears US NIH Compound Identifier 4642. European Medicines Agency schedules Oxyphencyclimine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03594MIG. Most nations, for tariff and trade purposes, schedule oxyphencyclimine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, OXYPHENCYCLIMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Oxyphencyclimine hydrochloride bears US NLM NCI C66284. SMILES: CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3CCCCC3)O.CL.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C20H28N2O3 and C20H28N2O3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 4V44H1O8XI and GWO1432WOU, the base compound being chemically known as 1,4,5,6-tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat but generally known as oxyphencyclimine, which bears US NIH Compound Identifier 4642. European Medicines Agency schedules Oxyphencyclimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB09573MIG and SUB03594MIG. The term OXYPHENCYCLIMINE is an International Non-Proprietary Name. World Health Organization schedules oxyphencyclimine in its Anatomical Therapeutic Chemical (ATC) Classification. OXYPHENCYCLIMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxyphencyclimine and its salts under HS 29335995 and SITC 51576. As of Q4 2014, OXYPHENCYCLIMINE remains the US FDA Preferred Term for this commodity. Oxyphencyclimine bears US NLM NCI C66283 and C66284. SMILES: OC(C1CCCCC1)(C1CCCCC1)C(=O)OCC1=NCCCN1C (base) or CN1CCCN=C1COC(=O)C(c2ccccc2)(C3CCCCC3)O.Cl (hydrochloride).
This classification denotes a laxative with the molecular formula C20H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3BT0VQG2GQ, chemically known as 4,4-dihydroxydiphenylisatin but generally known as oxyphenisatin, which bears US NIH Compound Identifier 31315. European Medicines Agency schedules Oxyphenisatine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09574MIG. The term OXYPHENISATINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules oxyphenisatin in its Anatomical Therapeutic Chemical (ATC) Classification. Oxyphenisatin or oxyphenisatine bears US NLM identifiers UMLS ID C0031422 and NCI Concept Code C80953. SMILES: C1=CC=C2C(=C1)C(C(=O)N2)(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O.
This classification denotes an antimuscarinic agent with the molecular formula C21H34NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2G5508Y7I, chemically known as ethanaminium, 2-((cyclohexylhydroxyphenylacetyl)oxy)-n,n-diethyl-n-methyl- but generally known as oxyphenonium, which bears US NIH Compound Identifier 5749. European Medicines Agency schedules Oxyphenonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14736MIG. World Health Organization schedules oxyphenonium in its Anatomical Therapeutic Chemical (ATC) Classification. OXYPHENONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, OXYPHENONIUM remains the US FDA Preferred Term for this commodity. Oxyphenonium bears US NLM identifiers UMLS ID C0030082 and NCI Concept Code C78076. SMILES: OC(C1CCCCC1)(C1CCCCC1)C(=O)OCC[N](CC)(CC)C. .
This classification denotes a topical anti-infective agent with the molecular formula C9H7NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5UTX5635HP, chemically known as 8-quinolinol (7ci,8ci,9ci) but generally known as 8-hydroxyquinoline, which bears US NIH Compound Identifier 1923. European Medicines Agency schedules Oxyquinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25866. World Health Organization schedules 8-hydroxyquinoline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, OXYQUINOLINE remains the US FDA Preferred Term for this commodity. Oxyquinoline bears US NLM identifiers UMLS ID C0000665 and NCI Concept Code C80862. SMILES: C1=CC2=C(C(=C1)O)N=CC=C2.
This classification denotes a phenothiazine with the molecular formula C21H26N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OCW5XQQ13I, chemically known as 10h-phenothiazine, 2-methoxy-10-(2-(1-methyl-2-piperidyl)ethyl)- but generally known as oxyridazine, which bears US NIH Compound Identifier 65612. European Medicines Agency schedules Oxyridazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09577MIG. The term OXYRIDAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). OXYRIDAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxyridazine under HS 29343090 and SITC 51578. As of Q4 2014, OXYRIDAZINE remains the US FDA Preferred Term for this commodity. Oxyridazine bears US NLM identifiers UMLS ID C1882248 and NCI Concept Code C66286. SMILES: S1C2C(N(CCC3N(CCCC3)C)C3C1CCCC3)CC(OC)CC2.
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O9.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X20I9EN955, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo- but generally known as oxytetracycline, which bears US NIH Compound Identifier 5280972. European Medicines Agency schedules Oxytetracycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09579MIG. World Health Organization schedules oxytetracycline in its Anatomical Therapeutic Chemical (ATC) Classification. OXYTETRACYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxytetracycline under HS 29413000 and SITC 54133. As of Q4 2014, OXYTETRACYCLINE remains the US FDA Preferred Term for this commodity. Oxytetracycline bears US NLM identifiers UMLS ID C0030092 and NCI Concept Code C61872. SMILES: OC1C2C(O)(C(=O)C3=C(O)C4C(C(O)(C13)C)CCCC4O)C(=O)/C(=C(\O)N)C(=O)C2N(C)C.
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLF0D9077S, chemically known as oxytetracycline (anhydrous) [hsdb], but more generally known as oxytetracycline anhydrous, which bears US NIH Compound Identifier 5280972. European Medicines Agency schedules oxytetracycline anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09579MIG. Most nations, for tariff purposes, schedule oxytetracycline anhydrous under HS 29413000. Oxytetracycline anhydrous bears US NLM identifiers UMLS ID C2698682 and NCI Concept Code C74596. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O.
This classification denotes a tetracycline antibiotic with the molecular formula 2C22H23N2O9.CA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8MRZ07FDV. European Medicines Agency schedules oxytetracycline calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03600MIG. The term oxytetracycline calcium is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule oxytetracycline calcium under HS 29413000 and SITC 54133. As of Q4 2014, OXYTETRACYCLINE CALCIUM remains US FDA's Preferred Term for this commodity. Oxytetracycline calcium bears US NLM identifiers UMLS ID C0282277 and NCI Concept Code C66287. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)[O-])N(C)C)O)O)O)O.C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)[O-])N(C)C)O)O)O)O.[CA+2].
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O9.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X20I9EN955, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo- but more generally known as oxytetracycline, which bears US NIH Compound Identifier 5280972. European Medicines Agency schedules Oxytetracycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09579MIG. World Health Organization schedules oxytetracycline in its Anatomical Therapeutic Chemical (ATC) Classification. OXYTETRACYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule oxytetracycline dihydrate under HS 29413000 and SITC 54133. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O.O.O.
This classification denotes a tetracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4U7K4N52ZM. European Medicines Agency schedules Oxytetracycline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14740MIG. Oxytetracycline hydrochloride generally arises in the molecular formula C22H24N2O9.CLH. The term 'oxytetracycline hydrochloride' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule oxytetracycline hydrochloride under HS 29413000 and SITC 54133. As of Q4 2014, OXYTETRACYCLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Oxytetracycline hydrochloride bears US NLM identifiers UMLS ID C0017449 and NCI Concept Code C47649. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.
This classification denotes a pituitary hormone with the molecular formula C43H66N12O12S2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1JQS135EYN, chemically known as vasopressin, 3-l-isoleucine-8-l-leucine- but more generally known as oxytocin, which bears U.S. National Institutes of Health Compound Identifier 5771. The European Medicines Agency schedules Oxytocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09580MIG. The term OXYTOCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). The World Health Organization schedules oxytocin in its Anatomical Therapeutic Chemical (ATC) Classification. OXYTOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1SCC(N)C(=O)NC(C(=O)NC(C(CC)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(=O)N)C1)CC(=O)N)CCC(=O)N)CC1CCC(O)CC1.
This classification denotes a pituitary hormone C43H66N12O12S2.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1573L6WJ8U, chemically known as oxytocin, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt), but more generally known as oxytocin citrate, which bears US NIH Compound Identifier 72941595. European Medicines Agency schedules Oxytocin citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23136. Most nations, for tariff and trade purposes, schedule oxytocin citrate under HS 29371900 and SITC 54154. As of Q4 2014, OXYTOCIN CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2CCC(CC2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an enzyme inhibitor and antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L256JB984D. European Medicines Agency schedules Ozagrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09581MIG. Ozagrel generally arises in the molecular formula C13H12N2O2. The term OZAGREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) OZAGREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ozagrel under HS 29332990 and SITC 51573. As of Q4 2014, OZAGREL remains the US FDA Preferred Term for this commodity. Ozagrel bears US NLM identifiers UMLS ID C0069392 and NCI Concept Code C66288. SMILES: CL.OC(=O)/C=C/C1CCC(CN2CCNC2)CC1.O.
This classification denotes an enzyme inhibitor and antiplatelet agent with the molecular formula C13H12N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W222U960HS, chemically known as (2e)-3-[4-(1h-imidazol-1-ylmethyl)phenyl]-2-propenoic acid hydrochloride, but more generally known as ozagrel hydrochloride, which bears US NIH Compound Identifier 5282439. European Medicines Agency schedules ozagrel hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09581MIG. Most nations, for tariff purposes, schedule ozagrel hydrochloride under HS 29332990. SMILES: C1CC(CCC1CN2CCNC2)/C=C/C(=O)O.CL.
This classification denotes an enzyme inhibitor and antiplatelet agent with the molecular formula C13H12N2O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C0I3AF4OHV, chemically known as 2-propenoic acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, hydrochloride, hydrate (1:1:1), but more generally known as ozagrel hydrochloride hydrate, which bears US NIH Compound Identifier 6438130. European Medicines Agency schedules ozagrel hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09581MIG. Most nations, for tariff purposes, schedule ozagrel hydrochloride hydrate under HS 29332990. SMILES: C1CC(CCC1CN2CCNC2)/C=C/C(=O)O.O.CL.
This classification denotes an enzyme inhibitor and antiplatelet agent C13H11N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4X5577N3ET, chemically known as 2-propenoic acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, sodium salt (1:1), (2e)-, but more generally known as ozagrel sodium, which bears US NIH Compound Identifier 23663942. European Medicines Agency schedules Ozagrel sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03604MIG. Most nations, for tariff and trade purposes, schedule ozagrel sodium under HS 29332990 and SITC 51573. As of Q4 2014, OZAGREL SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1CN2CCNC2)/C=C/C(=O)[O-].[NA+].
This classification denotes a taxane compound and taxane-site binding agent with the molecular formula C47H51NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P88XT4IS4D, chemically known as 12-benzoate, 9-ester with (2r,3s)-n-benzoyl-3-phenylisoserine but generally known as paclitaxel, which bears US NIH Compound Identifier 36314. European Medicines Agency schedules Paclitaxel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09583MIG. The term PACLITAXEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules paclitaxel in its Anatomical Therapeutic Chemical (ATC) Classification. PACLITAXEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paclitaxel under HS 29329950 and SITC 51569. As of Q4 2014, PACLITAXEL remains the US FDA Preferred Term for this commodity. Paclitaxel bears US NLM identifiers UMLS ID C0144576 and NCI Concept Code C1411. SMILES: O1C2C(OC(=O)C)(C3C(C(O)C2)(C(=O)C(OC(=O)C)C2=C(C(OC(=O)C(O)C(NC(=O)C4CCCCC4)C4CCCCC4)CC(O)(C3OC(=O)C3CCCCC3)C2(C)C)C)C)C1.
This classification denotes a taxane compound and taxane-site binding agent C51H57NO18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B3C86E80A0, chemically known as 7.beta.-((2rs)-2,3-dihydroxypropoxycarbonyloxy)-1-hydroxy-9-oxo-5.beta.,20-epoxytax-11-ene-2.alpha.,4,10.beta.,13.alpha.-tetrayl 4,10-diacetate 2-benzoate 13-((2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoate), but more generally known as paclitaxel ceribate, which bears US NIH Compound Identifier 16760673. As of Q4 2014, PACLITAXEL CERIBATE remains US FDA's Preferred Term for this commodity. Paclitaxel ceribate bears US NLM identifiers UMLS ID C3273125 and NCI Concept Code C96934. Most nations, for tariff and trade purposes, schedule paclitaxel ceribate under HS 29329950 and SITC 51569. SMILES: CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@@H](C5CCCCC5)NC(=O)C6CCCCC6)O)O)OC(=O)C7CCCCC7)(CO4)OC(=O)C)OC(=O)OCC(CO)O)C)OC(=O)C.
This classification denotes a taxane compound and paclitaxel preparation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQ64FZ98ZN. European Medicines Agency schedules Paclitaxel poliglumex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27755. Paclitaxel poliglumex generally arises in the molecular formula C10H16N2O7(C52H56N2O16)N(C5H7NO3)N. The term PACLITAXEL POLIGLUMEX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 3, 2004, list 52.) Most nations schedule paclitaxel poliglumex under HS 39089000 and SITC 57539. As of Q4 2014, PACLITAXEL POLIGLUMEX remains the US FDA Preferred Term for this commodity. Paclitaxel poliglumex bears US NLM identifiers UMLS ID C1702776 and NCI Concept Code C1795. SMILES: CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)OC(=O)CCC(C(=O)NC(CCC(=O)O)C(=O)O)NC(=O)C(CCC(=O)O)N)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C23H28N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CHE211JZXQ, chemically known as (-)-p-(3-((3,4-dimethoxyphenetyl)amino)-2-hydroxypropoxy)-beta-methylcinnamonitrile but generally known as pacrinolol, which bears US NIH Compound Identifier 6436098. European Medicines Agency schedules Pacrinolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09584MIG. The term PACRINOLOL is an International Non-Proprietary Name. PACRINOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pacrinolol under HS 29269095 and SITC 51484. As of Q4 2014, PACRINOLOL remains the US FDA Preferred Term for this commodity. Pacrinolol bears US NLM identifiers UMLS ID C0135043 and NCI Concept Code C90800. SMILES: O(CC(O)CNCCC1CC(OC)C(OC)CC1)C1CCC(CC1)/C(=C/C#N)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AEP5YJ9MZ. European Medicines Agency schedules Pafenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09585MIG. Pafenolol generally arises in the molecular formula C18H31N3O3. The term PAFENOLOL is an International Non-Proprietary Name or INN. PAFENOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pafenolol under HS 29242190 and SITC 51473. As of Q4 2014, PAFENOLOL remains the US FDA Preferred Term for this commodity. Pafenolol bears US NLM identifiers UMLS ID C0069942 and NCI Concept Code C66291. SMILES: O(CC(O)CNC(C)C)C1CCC(CCNC(=O)NC(C)C)CC1.
This classification denotes an anxiolytic with the molecular formula C23H22ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38VAG2SA33, chemically known as 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one but generally known as pagoclone, which bears US NIH Compound Identifier 131664. European Medicines Agency schedules Pagoclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09586MIG. The term PAGOCLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). PAGOCLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pagoclone under HS 29337900 and SITC 51561. As of Q4 2014, PAGOCLONE remains the US FDA Preferred Term for this commodity. Pagoclone bears US NLM identifiers UMLS ID C1120452 and NCI Concept Code C74529. SMILES: CLC1NC2NC(N3C(CC(=O)CCC(C)C)C4C(C3=O)CCCC4)CCC2CC1.
A kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression following endocrine therapy.
This classification denotes a therapeutic fibroblast growth factor with the molecular formula C729H1156N204O207S10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QMS40680K6, more generally known as palifermin. European Medicines Agency schedules palifermin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21058. The term PALIFERMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3, 2002, list 48. Most nations schedule Palifermin under HS 29332990 and SITC 51573. SMILES:. As of Q4 2014, PALIFERMIN remains the US FDA Preferred Term for this commodity. . Palifermin bears US NLM identifiers UMLS ID C0677829 and NCI Concept Code C2455.
This classification denotes a protease inhibitor with the molecular formula C41H52N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 632S1WU9Z2, chemically known as 2-quinolinecarboxamide, n-(1-(((3-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(4-pyridinylmethoxy)-1-piperidinyl)-2-hydroxy-1-(phenylmethyl)propyl)amino)carbonyl)-2-methylpropyl)-, (2s-(1(1r*(r*),2s*),2alpha,4alpha))- but generally known as palinavir, which bears US NIH Compound Identifier 72981. European Medicines Agency schedules Palinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09589MIG. The term PALINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). PALINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule palinavir under HS 29334910 and SITC 51575. As of Q4 2014, PALINAVIR remains the US FDA Preferred Term for this commodity. Palinavir bears US NLM identifiers UMLS ID C0663725 and NCI Concept Code C66292. SMILES: O(C1CC(N(CC1)CC(O)C(NC(=O)C(NC(=O)C1NC2C(CC1)CCCC2)C(C)C)CC1CCCCC1)C(=O)NC(C)(C)C)CC1CCNCC1.
This classification denotes an antipsychotic agent with the molecular formula C23H27FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 838F01T721, chemically known as 4h-pyrido(2,1-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-9-hydroxy-2-methyl- but generally known as paliperidone, which bears US NIH Compound Identifier 115237. European Medicines Agency schedules Paliperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23268. The term PALIPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules paliperidone in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule paliperidone under HS 29349990 and SITC 51579. As of Q4 2014, PALIPERIDONE remains the US FDA Preferred Term for this commodity. Paliperidone bears US NLM identifiers UMLS ID C0753678 and NCI Concept Code C66293. SMILES: FC1CC2ONC(C3CCN(CC3)CCC3C(=O)N4CCCC(O)C4NC3C)C2CC1.
This classification denotes a serotonin antagonist and dopamine antagonist and antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8P8USM8FR. European Medicines Agency schedules Paliperidone palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31687. Paliperidone palmitate generally arises in the molecular formula C39H57FN4O4. The term 'paliperidone palmitate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule paliperidone palmitate under HS 29349990 and SITC 51579. As of Q4 2014, PALIPERIDONE PALMITATE remains US FDA's Preferred Term for this commodity. Paliperidone palmitate bears US NLM identifiers UMLS ID C2719626 and NCI Concept Code C83917. SMILES: CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1NC(C(C2=O)CCN3CCC(CC3)C4C5CCC(CC5ON4)F)C.
A humanized monoclonal antibody (IgG1? ) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).
This classification denotes a calcium channel blocker with the molecular formula C29H34FN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FMS4X67Q96, chemically known as (- )-3-(benzylmethyl-amino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate. but generally known as palonidipine, which bears US NIH Compound Identifier 119154. European Medicines Agency schedules Palonidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09592MIG. The term PALONIDIPINE is an International Non-Proprietary Name. PALONIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule palonidipine under HS 29333999 and SITC 51574. As of Q4 2014, PALONIDIPINE remains the US FDA Preferred Term for this commodity. Palonidipine bears US NLM identifiers UMLS ID C1882274 and NCI Concept Code C66297. SMILES: Fc1c(C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OCC(CN(Cc2ccccc2)C)(C)C)cc([N](=O)O)cc1.
This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C19H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5D06587D6R, chemically known as 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benz(de)isoquinolin-1-one but generally known as palonosetron, which bears US NIH Compound Identifier 148211. European Medicines Agency schedules Palonosetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09593MIG. The term PALONOSETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules palonosetron in its Anatomical Therapeutic Chemical (ATC) Classification. PALONOSETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule palonosetron under HS 29337900 and SITC 51561. As of Q4 2014, PALONOSETRON remains the US FDA Preferred Term for this commodity. Palonosetron bears US NLM identifiers UMLS ID C0220578 and NCI Concept Code C61874. SMILES: O=C1N(C2C3CCN(C2)CC3)CC2C3C1CCCC3CCC2.
This classification denotes a diuretic with the molecular formula C7H7BrN4O2.C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UA8U0KJM72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but generally known as pamabrom, which bears US NIH Compound Identifier 11806. European Medicines Agency schedules Pamabrom in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14745MIG. As of Q4 2014, PAMABROM remains the US FDA Preferred Term for this commodity. Pamabrom bears US NLM identifiers UMLS ID C0135166 and NCI Concept Code C81076. SMILES: BRC1[NH]C2C(N(C(=O)N(C2=O)C)C)N1.OCC(N)(C)C.
This classification denotes an antimalarial agent with the molecular formula C19H29N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99QVL5KPSU, chemically known as 1,4-pentanediamine, n1,n1-diethyl-n4-(6-methoxy-8-quinolinyl)- (9ci) but generally known as pamaquine, which bears US NIH Compound Identifier 10290. European Medicines Agency schedules Pamaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09595MIG. The term PAMAQUINE is an International Non-Proprietary Name. PAMAQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pamaquine under HS 29334990 and SITC 51575. As of Q4 2014, PAMAQUINE remains the US FDA Preferred Term for this commodity. Pamaquine bears US NLM identifiers UMLS ID C0069991 and NCI Concept Code C73003. SMILES: O(C1CC(NC(CCCN(CC)CC)C)C2NCCCC2C1)C.
This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C3H9NO7P2.2Na.5H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8742T8ZQZA, chemically known as 3-amino-1-hydroxypropylidene-1,1-diphosphonate but generally known as pamidronate disodium, which bears US NIH Compound Identifier 4674. European Medicines Agency schedules Pamidronate disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03610MIG. Pamidronate disodium or pamidronic acid bears US NLM identifiers UMLS ID C0043603 and NCI Concept Code C61875. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CCN.
This classification denotes an anxiolytic with the molecular formula C18H17N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V4PW0S7ZP7, chemically known as 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-isopropylimidazo(1,5-a)quinoxalin-4(5h)-one but generally known as panadiplon, which bears US NIH Compound Identifier 3033821. European Medicines Agency schedules Panadiplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09600MIG. The term PANADIPLON is an International Non-Proprietary Name. PANADIPLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule panadiplon under HS 29349990 and SITC 51579. As of Q4 2014, PANADIPLON remains the US FDA Preferred Term for this commodity. Panadiplon bears US NLM identifiers UMLS ID C0287155 and NCI Concept Code C74185. SMILES: O1NC(NC1C1CC1)C1NCN2C1C(=O)N(C(C)C)C1C2CCCC1.
This classification denotes an antipsychotic agent with the molecular formula C23H26N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 023D9E916L chemically known as (5s)-5-((4-hydroxy-4-(3,4-(methylenedioxy)phenyl)piperidino)methyl)-3-(p-methoxyphenyl)-2-oxazolidinone but generally known as panamesine, which bears US NIH Compound Identifier 3047810. European Medicines Agency schedules Panamesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09601MIG. The term PANAMESINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36. ). Most nations schedule panamesine under HS 29349990 and SITC 51579. As of Q4 2014, PANAMESINE remains the US FDA Preferred Term for this commodity. Panamesine bears US NLM identifiers UMLS ID C0663536 and NCI Concept Code C66301. SMILES: COC1=CC=C(C=C1)N2C[C@@H](OC2=O)CN3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O.
This classification denotes a serotonin antagonist with the molecular formula C18H24ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W80HW6Q65O, chemically known as benzamide, 4-amino-n-1-azabicyclo(2.2.2)oct-3-yl-5-chloro-2-(cyclopropylmethoxy)-, (+-)- but generally known as pancopride, which bears US NIH Compound Identifier 71342. European Medicines Agency schedules Pancopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09602MIG. The term PANCOPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). PANCOPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pancopride under HS 29333999 and SITC 51574. As of Q4 2014, PANCOPRIDE remains the US FDA Preferred Term for this commodity. Pancopride bears US NLM identifiers UMLS ID C0210840 and NCI Concept Code C87213. SMILES: CLC1CC(C(=O)NC2C3CCN(C2)CC3)C(OCC2CC2)CC1N.
This classification denotes extracts prepared from pancreatic tissue that may contain the pancreatic enzymes or other specific uncharacterized factors or proteins with specific activities.
This classification denotes a gastrointestinal drug and bile, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQ3DRG0N5K.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.
This classification denotes an adverse event associated with metabolic and laboratory abnormalities with the molecular formula C5850H8902N1606O1739S49, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQ3DRG0N5K, more generally known as pancrelipase. European Medicines Agency schedules pancrelipase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14362MIG. The term PANCRELIPASE is an International Non-Proprietary Name or INN. As of Q4 2014, PANCRELIPASE remains the US FDA Preferred Term for this commodity.
This classification denotes a muscle relaxant with the molecular formula C35H60N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J76UF062FS, chemically known as 5.alpha.-androstan-3.alpha.,17.beta.-diol, 2.beta., 16.beta.-dipipecolinio-, dibromide, diacetate but generally known as pancuronium, which bears US NIH Compound Identifier 4675. European Medicines Agency schedules Pancuronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03618MIG. World Health Organization schedules pancuronium in its Anatomical Therapeutic Chemical (ATC) Classification. PANCURONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PANCURONIUM remains the US FDA Preferred Term for this commodity. Pancuronium bears US NLM identifiers UMLS ID C0030310 and NCI Concept Code C61876. SMILES: O(C1C2(C(C3C(C4(C(CC3)CC(OC(=O)C)C([N]3(CCCCC3)C)C4)C)CC2)CC1[N]1(CCCCC1)C)C)C(=O)C.
This classification denotes a muscle relaxant with the molecular formula C35H60N2O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U9LY9Y75X2, chemically known as 5.alpha.-androstan-3.alpha.,17.beta.-diol, 2.beta., 16.beta.-dipipecolinio-, dibromide, diacetate but more generally known as pancuronium bromide, which bears US NIH Compound Identifier 4675. European Medicines Agency schedules Pancuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09603MIG. The term PANCURONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). Most nations, for tariff and trade purposes, schedule pancuronium bromide under HS 29333999 and SITC 51574. As of Q4 2014, PANCURONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Pancuronium bromide bears US NLM identifiers UMLS ID C0030715 and NCI Concept Code C47651. SMILES: CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[BR-].[BR-].
This classification denotes a beta-lactam antibiotic with the molecular formula C15H21N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9769W09JF, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((1-(1-iminoethyl)-3-pyrrolidinyl)thio)-7-oxo-, (5r-(3(s*),5-alpha,6-alpha(r*)))- but generally known as panipenem, which bears US NIH Compound Identifier 72015. European Medicines Agency schedules Panipenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09605MIG. The term PANIPENEM is an International Non-Proprietary Name. PANIPENEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule panipenem under HS 29419000 and SITC 54139. As of Q4 2014, PANIPENEM remains the US FDA Preferred Term for this commodity. Panipenem bears US NLM identifiers UMLS ID C0207932 and NCI Concept Code C66303. SMILES: S(C1=C(N2C(C(C2=O)C(O)C)C1)C(=O)O)C1CCN(C1)C(=N)C.
This classification denotes a monoclonal antibody with the molecular formula C6398H9878N1694O2016S48, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6A901E312A, more generally known as panitumumab. European Medicines Agency schedules panitumumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25390. The term PANITUMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53. Most nations schedule Panitumumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, PANITUMUMAB remains the US FDA Preferred Term for this commodity. . Panitumumab bears US NLM identifiers UMLS ID C0879427 and NCI Concept Code C1857.
This classification denotes an antiestrogen with the molecular formula C25H24F3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCW5E728OC, chemically known as ethanol, 2-((2-(4-(3,3,3-trifluoro-1,2-diphenyl-1-propenyl)phenoxy)ethyl)amino)-, (e)- but generally known as panomifene, which bears US NIH Compound Identifier 3033654. European Medicines Agency schedules Panomifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09606MIG. The term PANOMIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). PANOMIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule panomifene under HS 29221980 and SITC 51461. As of Q4 2014, PANOMIFENE remains the US FDA Preferred Term for this commodity. Panomifene bears US NLM identifiers UMLS ID C0244902 and NCI Concept Code C66304. SMILES: FC(F)(F)C(=C(\C1CCC(OCCNCCO)CC1)C1CCCCC1)\C1CCCCC1.
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7K81IL792L. European Medicines Agency schedules Pantethine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14755MIG. Pantethine generally arises in the molecular formula C22H42N4O8S2. The term 'pantethine' is an International Nomenclature of Cosmetic Ingredients designation. As of Q4 2014, PANTETHINE remains the US FDA Preferred Term for this commodity. Pantethine bears US NLM identifiers UMLS ID C0070034 and NCI Concept Code C87342. SMILES: S(SCCNC(=O)CCNC(=O)C(O)C(CO)(C)C)CCNC(=O)CCNC(=O)C(O)C(CO)(C)C.
This classification denotes an industrial aid with the molecular formula C9H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WV9CM0O67Z, chemically known as 2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutyramide, d-(+)- but generally known as dl-panthenol, which bears US NIH Compound Identifier 4678. European Medicines Agency schedules Panthenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14756MIG. The term DL-PANTHENOL is an International Non-Proprietary Name. Most nations schedule panthenol under HS 29362200 and SITC 54113. As of Q4 2014, PANTHENOL remains the US FDA Preferred Term for this commodity. Panthenol bears US NLM identifiers UMLS ID C1321598 and NCI Concept Code C82290. SMILES: CC(C)(CO)C(C(=O)NCCCO)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a proton pump inhibitor with the molecular formula C16H15F2N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D8TST4O562, chemically known as 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole but generally known as pantoprazole, which bears US NIH Compound Identifier 4679. European Medicines Agency schedules Pantoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09608MIG. The term PANTOPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules pantoprazole in its Anatomical Therapeutic Chemical (ATC) Classification. PANTOPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pantoprazole under HS 29333999 and SITC 51574. As of Q4 2014, PANTOPRAZOLE remains the US FDA Preferred Term for this commodity. Pantoprazole bears US NLM identifiers UMLS ID C0081876 and NCI Concept Code C29346. SMILES: S(=O)(C1[NH]C2C(N1)CCC(OC(F)F)C2)CC1NCCC(OC)C1OC.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UWS3T8EAB. European Medicines Agency schedules Panuramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09609MIG. Panuramine generally arises in the molecular formula C24H25N3O2. The term PANURAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) PANURAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule panuramine under HS 29333999 and SITC 51574. As of Q4 2014, PANURAMINE remains the US FDA Preferred Term for this commodity. Panuramine bears US NLM identifiers UMLS ID C0070047 and NCI Concept Code C66305. SMILES: O=C(NC1CCN(CC1)Cc1cc2c(cc1)cccc2)NC(=O)c1ccccc1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23473EC6BQ, chemically known as 6,7,3,4-tetramethoxy-1-benzylisoquinoline hydrochloride but more generally known as papaverine hydrochloride, which bears US NIH Compound Identifier 4680. European Medicines Agency schedules Papaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14763MIG. Most nations, for tariff and trade purposes, schedule papaverine hydrochloride under HS 29391900. As of Q4 2014, PAPAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Papaverine hydrochloride bears US NLM identifiers UMLS ID C0700461 and NCI Concept Code C80006. SMILES: COC1CCC(CC1OC)CC2C3CC(C(CC3CCN2)OC)OC.CL.
This classification denotes a vasodilating agent and phosphodiesterase inhibitor C20H21NO4.HNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U8CZ4BHO2Z, chemically known as isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, compd. with nitrous acid (1:1), but more generally known as papaverine nitrite, which bears US NIH Compound Identifier 71586756. Most nations, for tariff and trade purposes, schedule papaverine nitrite under HS 29391900 and SITC 54141. As of Q4 2014, PAPAVERINE NITRITE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC(CC1OC)CC2C3CC(C(CC3CCN2)OC)OC.N(=O)O.
This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DAA13NKG2Q, chemically known as 6,7,3,4-tetramethoxy-1-benzylisoquinoline hydrochloride but generally known as papaverine, which bears US NIH Compound Identifier 4680. European Medicines Agency schedules Papaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14760MIG. World Health Organization schedules papaverine in its Anatomical Therapeutic Chemical (ATC) Classification. Papaverine or papaverinum bears US NLM identifiers UMLS ID C0030350 and NCI Concept Code C726. SMILES: O(c1cc2c(nccc2cc1OC)Cc1cc(OC)c(OC)cc1)C.
This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H21NO4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7A476JZB2T. European Medicines Agency schedules papaverine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14767MIG. Most nations, for tariff and trade purposes, schedule papaverine sulfate under HS 29391900. As of Q4 2014, PAPAVERINE SULFATE remains US FDA's Preferred Term for this commodity. Papaverine sulfate bears US NLM identifiers UMLS ID C3273741 and NCI Concept Code C97985. SMILES: COC1CCC(CC1OC)CC2C3CC(C(CC3CCN2)OC)OC.OS(=O)(=O)O.
Aminosalicylate sodium belongs to the family of medicines called anti-infectives. It is used with other medicines, to help the body overcome tuberculosis (TB). It will not work for colds, flu, or other virus infections.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.
This classification denotes an anticonvulsant, hypnotic, and sedative with the molecular formula C6H12O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S6M3YBG8QA, chemically known as 2,4,6-trimethyl-s-trioxane but generally known as paraldehyde, which bears US NIH Compound Identifier 31264. European Medicines Agency schedules Paraldehyde in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14774MIG. World Health Organization schedules paraldehyde in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PARALDEHYDE remains the US FDA Preferred Term for this commodity. SMILES: O1C(OC(OC1C)C)C.
This classification denotes an anticonvulsant agent with the molecular formula C7H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z615FRW64N, chemically known as 3,5-dimethyl-5-ethyloxazolidine-2,4-dione but generally known as paramethadione, which bears US NIH Compound Identifier 8280. European Medicines Agency schedules Paramethadione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09613MIG. The term PARAMETHADIONE is an International Non-Proprietary Name. World Health Organization schedules paramethadione in its Anatomical Therapeutic Chemical (ATC) Classification. PARAMETHADIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paramethadione under HS 29349990 and SITC 51579. As of Q4 2014, PARAMETHADIONE remains the US FDA Preferred Term for this commodity. Paramethadione bears US NLM identifiers UMLS ID C0070072 and NCI Concept Code C66308. SMILES: O1C(CC)(C(=O)N(C1=O)C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VFC6ZX3584, chemically known as pregna-1,4-diene-3,20-dione, 6-fluoro-11,17,21-trihydroxy-16-methyl-, (6alpha,11beta,16alpha)- but generally known as paramethasone, which bears US NIH Compound Identifier 5875. European Medicines Agency schedules Paramethasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09614MIG. World Health Organization schedules paramethasone in its Anatomical Therapeutic Chemical (ATC) Classification. PARAMETHASONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paramethasone under HS 29372200 and SITC 54153. As of Q4 2014, PARAMETHASONE remains the US FDA Preferred Term for this commodity. Paramethasone bears US NLM identifiers UMLS ID C0030454 and NCI Concept Code C66309. SMILES: FC1CC2C3C(C(O)(C(C3)C)C(=O)CO)(CC(O)C2C2(C1=CC(=O)C=C2)C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X50N88ZDP, chemically known as 6alpha-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-acetate but more generally known as paramethasone acetate, which bears US NIH Compound Identifier 15333. European Medicines Agency schedules Paramethasone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03645MIG. Most nations, for tariff and trade purposes, schedule paramethasone acetate under HS 29372200 and SITC 54153. As of Q4 2014, PARAMETHASONE ACETATE remains US FDA's Preferred Term for this commodity. Paramethasone acetate bears US NLM identifiers UMLS ID C0070073 and NCI Concept Code C66310. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)C)F.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28FO8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41I31208JK, chemically known as pregna-1,4-diene-3,20-dione, 6-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as paramethasone disodium phosphate, which bears US NIH Compound Identifier 16509. European Medicines Agency schedules paramethasone disodium phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09614MIG. Most nations, for tariff purposes, schedule paramethasone disodium phosphate under HS 29372200. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)C)F.[NA+].[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O2ILF29K8B, chemically known as p-toluamidine, .alpha.-fluoren-9-ylidene-, monohydrochloride but generally known as paranyline, which bears US NIH Compound Identifier 160409. European Medicines Agency schedules Renytoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10278MIG. The term RENYTOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Paranyline or renytoline bears US NLM identifiers UMLS ID C1882930 and NCI Concept Code C66514. SMILES: C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CC=C(C=C4)C(=N)N.
This classification denotes an anxiolytic with the molecular formula C10H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H6ON8WA7L, chemically known as 2,3-dihydro-3-oxo-4h-1,4-benzoxazine-4-acetamide. but generally known as paraxazone, which bears US NIH Compound Identifier 3047812. European Medicines Agency schedules Paraxazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09619MIG. The term PARAXAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). PARAXAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paraxazone under HS 29349990 and SITC 51579. As of Q4 2014, PARAXAZONE remains the US FDA Preferred Term for this commodity. Paraxazone bears US NLM identifiers UMLS ID C1882286 and NCI Concept Code C66314. SMILES: C1C(=O)N(C2=CC=CC=C2O1)CC(=O)N.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H15NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3LSZ7869T2, chemically known as acetamide, n-(4-((2-methyl-4-oxo-4h-1,3-benzadioxin-2-yl)oxy)-phenyl)- but generally known as parcetasal, which bears US NIH Compound Identifier 65656. European Medicines Agency schedules Parcetasal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09621MIG. The term PARCETASAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). PARCETASAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule parcetasal under HS 29329985 and SITC 51569. As of Q4 2014, PARCETASAL remains the US FDA Preferred Term for this commodity. Parcetasal bears US NLM identifiers UMLS ID C1882287 and NCI Concept Code C66315. SMILES: O1C(OC(=O)C2C1CCCC2)(OC1CCC(NC(=O)C)CC1)C.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C19H18N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TUW81Y3CE, chemically known as propanamide, n-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)- but generally known as parecoxib, which bears US NIH Compound Identifier 119828. European Medicines Agency schedules Parecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03650MIG. The term PARECOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules parecoxib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule parecoxib under HS 29350090 and SITC 51580. As of Q4 2014, PARECOXIB remains the US FDA Preferred Term for this commodity. Parecoxib bears US NLM identifiers UMLS ID C0915142 and NCI Concept Code C66318. SMILES: S(=O)(=O)(NC(=O)CC)C1CCC(C2C(NOC2C)C2CCCCC2)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H17N2O4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EB87433V6F, chemically known as propanamide, n-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-, sodium salt but more generally known as parecoxib sodium, which bears US NIH Compound Identifier 9576744. European Medicines Agency schedules Parecoxib sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12548MIG. Most nations, for tariff and trade purposes, schedule parecoxib sodium under HS 29350090 and SITC 51580. As of Q4 2014, PARECOXIB SODIUM remains US FDA's Preferred Term for this commodity. Parecoxib sodium bears US NLM identifiers UMLS ID C0915144 and NCI Concept Code C73831. SMILES: CCC(=O)[N-]S(=O)(=O)C1CCC(CC1)C2C(ONC2C3CCCCC3)C.[NA+].
This classification denotes an opioid and antidiarrheal agent.
This classification denotes an anesthetic agent with the molecular formula C15H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68E52E5J67, chemically known as benzoic acid, p-ethoxy-, 2-(diethylamino)ethyl ester but generally known as parethoxycaine, which bears US NIH Compound Identifier 7183. European Medicines Agency schedules Parethoxycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09624MIG. The term PARETHOXYCAINE is an International Non-Proprietary Name. PARETHOXYCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule parethoxycaine under HS 29221980 and SITC 51461. As of Q4 2014, PARETHOXYCAINE remains the US FDA Preferred Term for this commodity. Parethoxycaine bears US NLM identifiers UMLS ID C0771503 and NCI Concept Code C81402. SMILES: O(CCN(CC)CC)C(=O)C1CCC(OCC)CC1.
This classification denotes an anesthetic agent with the molecular formula C15H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 414P5USJ7F, chemically known as benzoic acid, p-ethoxy-, 2-(diethylamino)ethyl ester, hydrochloride but more generally known as parethoxycaine hydrochloride, which bears US NIH Compound Identifier 8694. European Medicines Agency schedules Parethoxycaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14777MIG. Most nations, for tariff and trade purposes, schedule parethoxycaine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PARETHOXYCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Parethoxycaine hydrochloride bears US NLM identifiers UMLS ID C2825614 and NCI Concept Code C81398. SMILES: CCN(CC)CCOC(=O)C1CCC(CC1)OCC.CL.
This classification denotes an antispasmotic agent with the molecular formula C21H23NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XT63P694CJ. European Medicines Agency schedules pargeverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22269. The term pargeverine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule pargeverine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PARGEVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pargeverine hydrochloride bears US NLM NCI C97987. SMILES: CN(C)CCOC(=O)C(C1CCCCC1)(C2CCCCC2)OCC#C.CL.
This classification denotes an antispasmotic agent with the molecular formulas C21H23NO3 and C21H23NO3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers UC61HM8FX0 and XT63P694CJ, the base compound being chemically known as benzeneacetic acid, alpha-phenyl-alpha-(2-propynyloxy)-, 2-(dimethylamino)ethyl ester but generally known as pargeverine, which bears US NIH Compound Identifier 17700. European Medicines Agency schedules Pargeverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB12425MIG and SUB22269. The term PARGEVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). PARGEVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pargeverine and its salts under HS 29221980 and SITC 51461. As of Q4 2014, PARGEVERINE remains the US FDA Preferred Term for this commodity. Pargeverine bears US NLM NCI C66320. SMILES: O(C(C1CCCCC1)(C1CCCCC1)C(=O)OCCN(C)C)CC#C (base) or CN(C)CCOC(=O)C(C1CCCCC1)(C2CCCCC2)OCC#C.CL (hydrochloride).
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OPO851W5L. European Medicines Agency schedules Pargolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09625MIG. Pargolol generally arises in the molecular formula C16H23NO3. The term PARGOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) PARGOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pargolol under HS 29221980 and SITC 51461. As of Q4 2014, PARGOLOL remains the US FDA Preferred Term for this commodity. Pargolol bears US NLM identifiers UMLS ID C0070112 and NCI Concept Code C66321. SMILES: OC(CNC(C)(C)C)COC1C(OCC#C)CCCC1.
This classification denotes a monoamine oxidase inhibitor and antihypertensive agent with the molecular formula C11H13N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9MV14S8G3E, chemically known as 2-propynylamine, n-benzyl-n-methyl-, hydrochloride but generally known as pargyline, which bears US NIH Compound Identifier 4688. European Medicines Agency schedules Pargyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09626MIG. The term PARGYLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules pargyline in its Anatomical Therapeutic Chemical (ATC) Classification. PARGYLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pargyline under HS 29214980 and SITC 51454. As of Q4 2014, PARGYLINE remains the US FDA Preferred Term for this commodity. Pargyline bears US NLM identifiers UMLS ID C0030557 and NCI Concept Code C66322. SMILES: CN(CC#C)CC1=CC=CC=C1.
This classification denotes a monoamine oxidase inhibitor and antihypertensive agent with the molecular formula C11H13N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W70V6I2OMY, chemically known as 2-propynylamine, n-benzyl-n-methyl-, hydrochloride but more generally known as pargyline hydrochloride, which bears US NIH Compound Identifier 4688. European Medicines Agency schedules Pargyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03653MIG. Most nations, for tariff and trade purposes, schedule pargyline hydrochloride under HS 29214900 and SITC 51454. As of Q4 2014, PARGYLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pargyline hydrochloride bears US NLM identifiers UMLS ID C0282289 and NCI Concept Code C66323. SMILES: CN(CC#C)CC1CCCCC1.CL.
This classification denotes an anesthetic agent with the molecular formula C17H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 795182TM5G, chemically known as benzoic acid, p-(butylamino)-, 1-methyl-4-piperidyl ester but generally known as paridocaine, which bears US NIH Compound Identifier 23551. European Medicines Agency schedules Paridocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09628MIG. The term PARIDOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). PARIDOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paridocaine under HS 29333999 and SITC 51574. As of Q4 2014, PARIDOCAINE remains the US FDA Preferred Term for this commodity. Paridocaine bears US NLM identifiers UMLS ID C1882291 and NCI Concept Code C66324. SMILES: O(C1CCN(CC1)C)C(=O)C1CCC(NCCCC)CC1.
This classification denotes a low molecular weight heparin with the molecular formula (C14H18NO11)n.2(C12H16NO13S)n.3HO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M316WT19D8, chemically known as (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate, but generally known as Parnaparin. European Medicines Agency schedules Parnaparin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22270. The term Parnaparin is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). As of Q4 2014, PARNAPARIN remains the US FDA Preferred Term for this commodity. SMILES: C(C1C(C(C(C(O1)O)NS(=O)(=O)[O-])O)OC2C(C(C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-].
This classification denotes a vasodilating agent with the molecular formula C23H27N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Q1O6G98Q8, chemically known as (- )-1-((2-indol-3-yl-1,1-dimethylethyl)amino)-3-(indol-4-yloxy)-2-propanol but generally known as parodilol, which bears US NIH Compound Identifier 3047816. European Medicines Agency schedules Parodilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09629MIG. The term PARODILOL is an International Non-Proprietary Name. PARODILOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule parodilol under HS 29339990 and SITC 51577. As of Q4 2014, PARODILOL remains the US FDA Preferred Term for this commodity. Parodilol bears US NLM identifiers UMLS ID C1882292 and NCI Concept Code C66325. SMILES: OC(CNC(Cc1c2c([nH]c1)cccc2)(C)C)COc1c2c([nH]cc2)ccc1.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H45N5O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61JJC8N5ZK, chemically known as streptamine, o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-o-beta-d-ribofuranosyl-(1-5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1-4))-2-deoxy- but generally known as paromomycin, which bears US NIH Compound Identifier 24176. European Medicines Agency schedules Paromomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09630MIG. The term PAROMOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules paromomycin in its Anatomical Therapeutic Chemical (ATC) Classification. PAROMOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paromomycin under HS 29419000 and SITC 54139. As of Q4 2014, PAROMOMYCIN remains the US FDA Preferred Term for this commodity. Paromomycin bears US NLM identifiers UMLS ID C0030576 and NCI Concept Code C61878. SMILES: O(C1C(OC2OC(C(O)C(O)C2N)CO)C(N)CC(N)C1O)C1OC(C(OC2OC(C(O)C(O)C2N)CN)C1O)CO.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H45N5O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61JJC8N5ZK, chemically known as diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine, but more generally known as paromomycin i, which bears US NIH Compound Identifier 4689. European Medicines Agency schedules paromomycin i or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09630MIG. Most nations, for tariff purposes, schedule paromomycin i under HS 29419000. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.
This classification denotes an aminoglycoside antibiotic with the molecular formula C23H45N5O14.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 845NU6GJPS, chemically known as o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-o-beta-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1->4))-2-deoxystreptamine sulfate (salt) but more generally known as paromomycin sulfate, which bears US NIH Compound Identifier 64144. European Medicines Agency schedules Paromomycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03654MIG. Most nations, for tariff and trade purposes, schedule paromomycin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, PAROMOMYCIN SULFATE remains US FDA's Preferred Term for this commodity. Paromomycin sulfate bears US NLM identifiers UMLS ID C0733821 and NCI Concept Code C47652. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.OS(=O)(=O)O.
This classification denotes a vaccine to treat inflammation of the parotid gland due to Staphylococcus aureus infection.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41VRH5220H. European Medicines Agency schedules Paroxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Paroxetine generally arises in the molecular formula C19H20FNO3. The term PAROXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) PAROXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paroxetine under HS 29349990 and SITC 51579. As of Q4 2014, PAROXETINE remains the US FDA Preferred Term for this commodity. Paroxetine bears US NLM identifiers UMLS ID C0070122 and NCI Concept Code C61879. SMILES: Fc1ccc(C2C(CNCC2)COc2cc3OCOc3cc2)cc1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent C19H20FNO3.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YPO0NTK49O, chemically known as piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, acetate (1:1), (3s,4r)-, but more generally known as paroxetine acetate, which bears US NIH Compound Identifier 9800501. Most nations, for tariff and trade purposes, schedule paroxetine acetate under HS 29349990 and SITC 51579. As of Q4 2014, PAROXETINE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)O.C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41VRH5220H. European Medicines Agency schedules Paroxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Paroxetine generally arises in the molecular formula C19H20FNO3. The term PAROXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) PAROXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paroxetine hydrochloride under HS 29349990 and SITC 51579. Paroxetine hydrochloride bears US NLM identifiers UMLS ID C0771019 and NCI Concept Code C1837. SMILES: Cl.Fc1ccc(C2C(CNCC2)COc2cc3OCOc3cc2)cc1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent 2C19H20FNO3.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X2ELS050D8, chemically known as (-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)-methyl)piperidine hydrochloride hemihydrate, but more generally known as paroxetine hydrochloride hemihydrate, which bears US NIH Compound Identifier 62878. European Medicines Agency schedules Paroxetine hydrochloride hemihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21637. Most nations, for tariff and trade purposes, schedule paroxetine hydrochloride hemihydrate under HS 29349990 and SITC 51579. As of Q4 2014, PAROXETINE HYDROCHLORIDE HEMIHYDRATE remains US FDA's Preferred Term for this commodity. Paroxetine hydrochloride hemihydrate bears US NLM identifiers UMLS ID C0886642 and NCI Concept Code C82238. SMILES: C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.O.CL.CL.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula 2C19H20FNO3.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X2ELS050D8, chemically known as (-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)-methyl)piperidine hydrochloride hemihydrate, but more generally known as paroxetine hydrochloride hydrate, which bears US NIH Compound Identifier 5282487. European Medicines Agency schedules paroxetine hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Most nations, for tariff purposes, schedule paroxetine hydrochloride hydrate under HS 29349990. SMILES: C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.O.CL.CL.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C19H20FNO3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F726G2563Q, chemically known as (3s,4r)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-piperidine maleate, but more generally known as paroxetine maleate, which bears US NIH Compound Identifier 6435921. European Medicines Agency schedules paroxetine maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Most nations, for tariff purposes, schedule paroxetine maleate under HS 29349990. SMILES: C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.C(=C\C(=O)O)\C(=O)O.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C19H20FNO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M711N184JE, chemically known as piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3s,4r)-, methanesulfonate (1:1), but more generally known as paroxetine mesylate, which bears US NIH Compound Identifier 206527. European Medicines Agency schedules paroxetine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Most nations, for tariff purposes, schedule paroxetine mesylate under HS 29349990. As of Q4 2014, PAROXETINE MESYLATE remains US FDA's Preferred Term for this commodity. Paroxetine mesylate bears US NLM identifiers UMLS ID C1365510 and NCI Concept Code C47653. SMILES: CS(=O)(=O)O.C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.
This classification denotes an antimalarial agent with the molecular formula C16H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A2BH18685W, chemically known as 1,4-naphthalenedione, 2-cyclohexyl-3-hydroxy- but generally known as parvaquone, which bears US NIH Compound Identifier 71825. European Medicines Agency schedules Parvaquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09634MIG. The term PARVAQUONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). PARVAQUONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule parvaquone under HS 29146990 and SITC 51629. As of Q4 2014, PARVAQUONE remains the US FDA Preferred Term for this commodity. Parvaquone bears US NLM identifiers UMLS ID C0070129 and NCI Concept Code C66327. SMILES: OC1=C(C2CCCCC2)C(=O)C(=O)C2C1CCCC2.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SY49TH8VUA, the source of which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99B54VQS6L, the source of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 22219 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Malpighiales, Family Passifloraceae, Genus Passiflora L., commonly known as PASSIONFLOWER or as here, PASSION FLOWER. Medically, the two most common passion flower species (and extracts) used are passiflora edulis (UNII SY49TH8VUA) and passiflora incarnata (UNII K8F3G29S6Z). However, there are many other varieties (including Belot, Colville, Mexican, Virgin Island, banana, birdwing, bluecrown, bracted, conch apple, corky, crinkled, cupped, dutchman's , fetid, fringed, goatsfoot, golden bellapple, maypop, perfumed, red, scarlet, slender, tropical, tuberous, twin-flowered, twolobe, white, whiteflower, wingleaf, woodland, and yellow). Passiflora edulis bears the USDA PLANTS Database Identifier PAED, whereas passiflora incarnata bears the USDA PLANTS Database Identifier PAIN6. European Medicines Agency schedules passiflora edulis in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB36101 and schedules passiflora incarnata under Indices SUB14781MIG, SUB30267, SUB34685, SUB35335, SUB42712, SUB46860, SUB46861, and SUB69845.
This classification denotes a tyrosine kinase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7RN5DR86CK. European Medicines Agency schedules Pazopanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29175. Pazopanib generally arises in the molecular formula C21H23N7O2S. The term PAZOPANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56.) As of Q4 2014, PAZOPANIB remains the US FDA Preferred Term for this commodity. Pazopanib bears US NLM identifiers UMLS ID C1831796 and NCI Concept Code C74547. SMILES: CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.
This classification denotes a quinolone antibiotic with the molecular formula C16H15FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CZ1R38NDI, chemically known as 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (s)- but generally known as pazufloxacin, which bears US NIH Compound Identifier 65957. European Medicines Agency schedules Pazufloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09641MIG. The term PAZUFLOXACIN is an International Non-Proprietary Name. World Health Organization schedules pazufloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. PAZUFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pazufloxacin under HS 29349990 and SITC 51579. As of Q4 2014, PAZUFLOXACIN remains the US FDA Preferred Term for this commodity. Pazufloxacin bears US NLM identifiers UMLS ID C0175022 and NCI Concept Code C66331. SMILES: FC1C(C2(N)CC2)C2OCC(N3C2C(C1)C(=O)C(C3)C(=O)O)C.
This classification denotes a dopamine antagonist C19H22N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TIW15Q5R21, chemically known as mepazine hydrochloride, (+/-)-, but more generally known as pecazine hydrochloride, which bears US NIH Compound Identifier 102907. Most nations, for tariff and trade purposes, schedule pecazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, PECAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCCC(C1)CN2C3CCCCC3SC4C2CCCC4.CL.
This classification denotes an antifungal agent with the molecular formula C17H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TSA7W27MF8, chemically known as 2-pyrrolidinone, 1-(8-hydroxy-6-methyl-2,4,6-dodecatrienoyl)-, (e,e,e)-(r)- but generally known as pecilocin, which bears US NIH Compound Identifier 5282176. European Medicines Agency schedules Pecilocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09643MIG. The term PECILOCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules pecilocin in its Anatomical Therapeutic Chemical (ATC) Classification. PECILOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pecilocin or variotin bears US NLM identifiers UMLS ID C0070200 and NCI Concept Code C72593. SMILES: CCCCC(C=C(C)C=CC=CC(=O)N1CCCC1=O)O.
This classification denotes an antibiotic with the molecular formula C29H35N3O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0CG6O25ZC4, chemically known as n-((4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene carboxamido)-methyl)nipecotic acid but more generally known as pecocycline, which bears US NIH Compound Identifier 5745800. European Medicines Agency schedules Pecocycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09644MIG. The term PECOCYCLINE is an International Non-Proprietary Name. PECOCYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC12C(CC3C(O)(C4C(C(=C3C1=O)O)C(O)CCC4)C)C(N(C)C)C(=O)C(=C(\O)NCN1CC(CCC1)C(=O)O)\C2=O.
This classification denotes a quinolone antibiotic with the molecular formula C17H20FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H52Z9F2Q5, chemically known as 3-quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- but generally known as pefloxacin, which bears US NIH Compound Identifier 51081. European Medicines Agency schedules Pefloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09645MIG. The term PEFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules pefloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. PEFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pefloxacin under HS 29335995 and SITC 51576. As of Q4 2014, PEFLOXACIN remains the US FDA Preferred Term for this commodity. Pefloxacin bears US NLM identifiers UMLS ID C0030771 and NCI Concept Code C728. SMILES: FC1C(N2CCN(CC2)C)CC2N(CC)CC(C(=O)C2C1)C(=O)O.
This classification denotes an industrial aid, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HW3H7D91F6. European Medicines Agency schedules Pegademase bovine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30488. Pegademase generally arises in the molecular formula C5H8NO3(C2H4O)N. The term PEGADEMASE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 5, no. 3 1991, list 31.)
This classification denotes an angiogenesis inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H1PA8H1EN. European Medicines Agency schedules Pegaptanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25196. Pegaptanib generally arises in the molecular formula C15H28N3O6(C2H4O)N(C2H4O)N. The term PEGAPTANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule pegaptanib under HS 39072021 and SITC 57419. As of Q4 2014, PEGAPTANIB remains the US FDA Preferred Term for this commodity. Pegaptanib bears US NLM identifiers UMLS ID C1531015 and NCI Concept Code C90657. SMILES: COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC.
This classification denotes an angiogenesis inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3HP012Q0FH. European Medicines Agency schedules Pegaptanib sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21226. Pegaptanib sodium generally arises in the molecular formula C15H28N3O6(C2H4O)N(C2H4O)N.28NA. The term 'pegaptanib sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule pegaptanib sodium under HS 39072021 and SITC 57419. Pegaptanib sodium bears US NLM identifiers UMLS ID C0967532 and NCI Concept Code C95230. SMILES: As of Q4 2014, PEGAPTANIB SODIUM remains US FDA's Preferred Term for this commodity.
This classification denotes a protein synthesis inhibitor with the molecular formula C1377H2208N382O442S17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D96IR0PPM, more generally known as pegaspargase. European Medicines Agency schedules pegaspargase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03666MIG. The term PEGASPARGASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 5, no. 3 1991, list 31. PEGASPARGASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pegaspargase under HS 35079090 and SITC 51691. As of Q4 2014, PEGASPARGASE remains the US FDA Preferred Term for this commodity. Pegaspargase bears US NLM identifiers UMLS ID C0071568 and NCI Concept Code C1200. SMILES: NONE.
This classification denotes a therapeutic colony stimulating factor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3A58010674. European Medicines Agency schedules Pegfilgrastim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16451MIG. Pegfilgrastim generally arises in the molecular formula C3H8NO(C2H4O)N. The term PEGFILGRASTIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations schedule pegfilgrastim under HS 39072021 and SITC 57419. As of Q4 2014, PEGFILGRASTIM remains the US FDA Preferred Term for this commodity. Pegfilgrastim bears US NLM identifiers UMLS ID C1171279 and NCI Concept Code C1854. SMILES: NONE.
Peginterferon alfa-2a is a form of recombinant interferon used alone or with other medicines to treat chronic hepatitis C.
This classification denotes a pegylated interferon alfa with the molecular formula C2H4NO2(C2H4O)N, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier G8RGG88B68. European Medicines Agency schedules peginterferon alfa-2b in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12549MIG. The term PEGINTERFERON ALFA-2B is an International Non-Proprietary Name or INN.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.
This classification denotes an uricase covalently attached to polyethylene glycol and immobilized enzyme with the chemical formula C1549H2430N408O448S8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R581OT55EA, chemically known as des-(1-6)-(7-threonine,46-threonine,291-lysine,301-serine)uricase (ec 1.7.3.3, urate oxidase) but generally known as Pegloticase. European Medicines Agency schedules Pegloticase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32159. The term Pegloticase is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 3, 2008, List 60.) As of Q4 2014, PEGLOTICASE remains the US FDA Preferred Term for this commodity.
This classification denotes a serotonin antagonist with the molecular formula C21H24N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SNR96E409, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(3-(4-phenyl-1-piperazinyl)propyl)- but generally known as pelanserin, which bears US NIH Compound Identifier 65435. European Medicines Agency schedules Pelanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09648MIG. The term PELANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). PELANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Pelanserin under HS 29335995 and SITC 51576. As of Q4 2014, PELANSERIN remains the US FDA Preferred Term for this commodity. Pelanserin bears US NLM identifiers UMLS ID C0070209 and NCI Concept Code C76965. SMILES: C1CCC(CC1)N2CCN(CC2)CCCN3C(=O)C4CCCCC4[NH]C3=O.
This classification denotes a serotonin antagonist C21H24N4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4J8I18ZP0A, chemically known as 3-(3-(4-phenyl-1-piperazinyl)propyl)-2,4(1h,3h)-quinazolinedione monohydrochloride, but more generally known as pelanserin hydrochloride, which bears US NIH Compound Identifier 65436. Most nations, for tariff and trade purposes, schedule pelanserin hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, PELANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pelanserin hydrochloride bears US NLM identifiers UMLS ID C2698754 and NCI Concept Code C76966. SMILES: C1CCC(CC1)N2CCN(CC2)CCCN3C(=O)C4CCCCC4[NH]C3=O.CL.
This classification denotes a purine nucleoside phosphorylase inhibitor with the molecular formula C12H11N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7B646RJ70F, chemically known as 4h-pyrrolo(3,2-d)pyrimidin-4-one, 2-amino-3,5-dihydro-7-(3-pyridinylmethyl)- but generally known as peldesine, which bears US NIH Compound Identifier 60817. European Medicines Agency schedules Peldesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09649MIG. The term PELDESINE is an International Non-Proprietary Name. PELDESINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule peldesine under HS 29335995 and SITC 51576. As of Q4 2014, PELDESINE remains the US FDA Preferred Term for this commodity. Peldesine bears US NLM identifiers UMLS ID C0338278 and NCI Concept Code C1650. SMILES: C1=CC(=CN=C1)CC2=CNC3=C2NC(=NC3=O)N.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H11N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9XK91ZI6I5, chemically known as 2-methyl-4-oxo-6-(pyridin-3-ylmethylamino)-1H-pyrimidine-5-carbonitrile but generally known as pelrinone, which bears US NIH Compound Identifier 55920. European Medicines Agency schedules pelrinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09651MIG. Most nations schedule pelrinone under HS 29335995 and SITC 51576. As of Q4 2014, PELRINONE remains the US FDA Preferred Term for this commodity. SMILES: CC1=NC(=O)C(=C(N1)NCC2=CN=CC=C2)C#N.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H11N5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51K948JB05, chemically known as 1,4-dihydro-2-methyl-4-oxo-6-((3-pyridylmethyl)amino)-5-pyrimidinecarbonitrile monohydrochloride but more generally known as pelrinone hydrochloride, which bears US NIH Compound Identifier 55919. Most nations, for tariff and trade purposes, schedule pelrinone hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, PELRINONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pelrinone hydrochloride bears US NLM identifiers UMLS ID C2983940 and NCI Concept Code C90920. SMILES: CC1[NH]C(C(C(=O)N1)C#N)NCC2CCCNC2.CL.
Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
This classification denotes a thymidylate synthase inhibitor and folate antagonist with the molecular formula C20H21N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04Q9AIZ7NO, chemically known as n-(4-(2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid but generally known as pemetrexed, which bears US NIH Compound Identifier 60843. European Medicines Agency schedules Pemetrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09655MIG. The term PEMETREXED is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules pemetrexed in its Anatomical Therapeutic Chemical (ATC) Classification. PEMETREXED is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pemetrexed under HS 29335995 and SITC 51576. As of Q4 2014, PEMETREXED remains the US FDA Preferred Term for this commodity. Pemetrexed bears US NLM identifiers UMLS ID C0210657 and NCI Concept Code C61614. SMILES: O=C1NC([NH]C2[NH]CC(CCC3CCC(CC3)C(=O)NC(CCC(=O)O)C(=O)O)C12)N.
This classification denotes a mast cell stabilizer with the molecular formula C10H8N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2C09NV773M, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 9-methyl-3-(1h-tetrazol-5-yl)- but generally known as pemirolast, which bears US NIH Compound Identifier 57697. European Medicines Agency schedules Pemirolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09656MIG. The term PEMIROLAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). PEMIROLAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pemirolast under HS 29335995 and SITC 51576. As of Q4 2014, PEMIROLAST remains the US FDA Preferred Term for this commodity. Pemirolast bears US NLM identifiers UMLS ID C0053881 and NCI Concept Code C66334. SMILES: CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3.
This classification denotes a mast cell stabilizer with the molecular formula C10H7N6O.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 497A17OUUE, chemically known as 9-methyl-3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidin-4-one, potassium salt but more generally known as pemirolast potassium, which bears US NIH Compound Identifier 57696. European Medicines Agency schedules Pemirolast potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03670MIG. Most nations, for tariff and trade purposes, schedule pemirolast potassium under HS 29335995 and SITC 51576. As of Q4 2014, PEMIROLAST POTASSIUM remains US FDA's Preferred Term for this commodity. Pemirolast potassium bears US NLM identifiers UMLS ID C0872971 and NCI Concept Code C47654. SMILES: CC1CCCN2C1NCC(C2=O)C3[N-]NNN3.[K+].
This classification denotes a cns stimulant with the molecular formula C9H8N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7GAQ2332NK, chemically known as 4-oxazolidinone, 2-imino-5-phenyl- but more generally known as pemoline, which bears US NIH Compound Identifier 4723. European Medicines Agency schedules Pemoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09657MIG. The term PEMOLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules pemoline in its Anatomical Therapeutic Chemical (ATC) Classification. PEMOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pemoline under HS 29349100 and SITC 51579. As of Q4 2014, PEMOLINE remains US FDA's Preferred Term for this commodity. Pemoline bears US NLM identifiers UMLS ID C0030800 and NCI Concept Code C47655. SMILES: O1C(C2CCCCC2)C(=O)N=C1N.
This classification denotes a nicotinic antagonist and antihypertensive agent with the molecular formula C10H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N5I18JI9D6, chemically known as 1,2,2,6,6-pentamethylpiperidine but generally known as pempidine, which bears US NIH Compound Identifier 6603. European Medicines Agency schedules Pempidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09658MIG. The term PEMPIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). PEMPIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pempidine under HS 29333999 and SITC 51574. As of Q4 2014, PEMPIDINE remains the US FDA Preferred Term for this commodity. Pempidine bears US NLM identifiers UMLS ID C0030810 and NCI Concept Code C66335. SMILES: CC1(CCCC(N1C)(C)C)C.
This classification denotes a nicotinic antagonist and antihypertensive agent C10H21N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier THI82M7N4M, chemically known as 1,2,2,6,6-pentamethylpiperidine tartrate, but more generally known as pempidine tartrate, which bears US NIH Compound Identifier 120729. European Medicines Agency schedules Pempidine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03672MIG. Most nations, for tariff and trade purposes, schedule pempidine tartrate under HS 29333999 and SITC 51574. As of Q4 2014, PEMPIDINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CC1(CCCC(N1C)(C)C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a benzylpenicillin acetoxymethyl ester and penicillin g analog with the molecular formula C19H22N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H0P1YE5581, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-(2s-(2alpha,5alpha,6beta))-, (acetyloxy)methyl ester but generally known as penamecillin, which bears US NIH Compound Identifier 13795. European Medicines Agency schedules Penamecillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09659MIG. World Health Organization schedules penamecillin in its Anatomical Therapeutic Chemical (ATC) Classification. PENAMECILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule penamecillin under HS 29411090 and SITC 54131. As of Q4 2014, PENAMECILLIN remains the US FDA Preferred Term for this commodity. SMILES: S1C2N(C(C1(C)C)C(=O)OCOC(=O)C)C(=O)C2NC(=O)CC1CCCCC1.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78W62V43DY. European Medicines Agency schedules Penbutolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09660MIG. Penbutolol generally arises in the molecular formula C18H29NO2. The term PENBUTOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) PENBUTOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule penbutolol under HS 29221980 and SITC 51461. As of Q4 2014, PENBUTOLOL remains the US FDA Preferred Term for this commodity. Penbutolol bears US NLM identifiers UMLS ID C0030812 and NCI Concept Code C66336. SMILES: O(C1C(C2CCCC2)CCCC1)CC(O)CNC(C)(C)C.
This classification denotes a beta-adrenergic blocking agent and antiarrhythmic agent with the molecular formula 2C18H29NO2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier US71433228, chemically known as 2-propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-, (s)-, sulfate (2:1) (salt) but more generally known as penbutolol sulfate, which bears US NIH Compound Identifier 38010. European Medicines Agency schedules Penbutolol sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03673MIG. Most nations, for tariff and trade purposes, schedule penbutolol sulfate under HS 29221980 and SITC 51461. As of Q4 2014, PENBUTOLOL SULFATE remains US FDA's Preferred Term for this commodity. Penbutolol sulfate bears US NLM identifiers UMLS ID C0282292 and NCI Concept Code C61882. SMILES: CC(C)(C)NC[C@@H](COC1CCCCC1C2CCCC2)O.CC(C)(C)NC[C@@H](COC1CCCCC1C2CCCC2)O.OS(=O)(=O)O.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C10H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 359HUE8FJC, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)- & human interferon-.gamma. but generally known as penciclovir, which bears US NIH Compound Identifier 4725. European Medicines Agency schedules Penciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09661MIG. The term PENCICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules penciclovir in its Anatomical Therapeutic Chemical (ATC) Classification. PENCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule penciclovir under HS 29335995 and SITC 51576. As of Q4 2014, PENCICLOVIR remains the US FDA Preferred Term for this commodity. Penciclovir bears US NLM identifiers UMLS ID C0164815 and NCI Concept Code C66337. SMILES: C1=NC2=C(N1CCC(CO)CO)NC(=NC2=O)N.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C10H14N5O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P06226385L, chemically known as 1,9-dihydro-2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-6h-purin-6-one monosodium salt but more generally known as penciclovir sodium, which bears US NIH Compound Identifier 656702. Most nations, for tariff and trade purposes, schedule penciclovir sodium under HS 29335995 and SITC 51576. As of Q4 2014, PENCICLOVIR SODIUM remains US FDA's Preferred Term for this commodity. Penciclovir sodium bears US NLM identifiers UMLS ID C0719742 and NCI Concept Code C47656. SMILES: C1NC2C(=O)[N-]C(NC2N1CCC(CO)CO)N.[NA+].
This classification denotes a dopamine antagonist with the molecular formula C28H27ClF5NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25TLU22Q8H, chemically known as 4-piperidinol, 4-(4-chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-1-(4,4-bis(p-fluorophenyl)butyl)- but generally known as penfluridol, which bears US NIH Compound Identifier 33630. European Medicines Agency schedules Penfluridol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09664MIG. The term PENFLURIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules penfluridol in its Anatomical Therapeutic Chemical (ATC) Classification. PENFLURIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule penfluridol under HS 29333999 and SITC 51574. As of Q4 2014, PENFLURIDOL remains the US FDA Preferred Term for this commodity. Penfluridol bears US NLM identifiers UMLS ID C0030815 and NCI Concept Code C90843. SMILES: CLC1C(CC(C2(O)CCN(CC2)CCCC(C2CCC(F)CC2)C2CCC(F)CC2)CC1)C(F)(F)F.
This classification denotes an angiogenesis activator inhibitor with the molecular formula C5H11NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) GNN1DV99GX, chemically known as valine, 3-mercapto-, l- but more generally known as penicillamine, which bears US NIH Compound Identifier 4727. European Medicines Agency schedules Penicillamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09667MIG. The term PENICILLAMINE is an International Non-Proprietary Name. World Health Organization schedules penicillamine in its Anatomical Therapeutic Chemical (ATC) Classification. PENICILLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule penicillamine under HS 29309016 and SITC 51549. As of Q4 2014, PENICILLAMINE remains US FDA's Preferred Term for this commodity. Penicillamine bears US NLM identifiers UMLS ID C0030817 and NCI Concept Code C729. SMILES: SC(C(N)C(=O)O)(C)C.
This classification denotes an angiogenesis activator inhibitor with the molecular formula C10H20N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q98FPI4N5P, chemically known as d-valine, 3,3'-dithiobis-, but more generally known as penicillamine disulfide, which bears US NIH Compound Identifier 88724. European Medicines Agency schedules penicillamine disulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09667MIG. Most nations, for tariff purposes, schedule penicillamine disulfide under HS 29309016. SMILES: CC(C)([C@H](C(=O)O)N)SSC(C)(C)[C@H](C(=O)O)N.
This classification denotes an angiogenesis activator inhibitor with the molecular formula C5H11NO2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5N9JK529ZJ, chemically known as valine, 3-mercapto-, hydrochloride, d- but more generally known as penicillamine hydrochloride, which bears US NIH Compound Identifier 92173. European Medicines Agency schedules Penicillamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03676MIG. Most nations, for tariff and trade purposes, schedule penicillamine hydrochloride under HS 29309016 and SITC 51549. As of Q4 2014, PENICILLAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)([C@H](C(=O)O)N)S.CL.
This classification denotes a penicillin antibiotic with the molecular formula C13H18N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6246WH0S1O, chemically known as sodium (2s-(2alpha,5alpha,6beta))-6-((allylthio)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate but generally known as almecillin, which bears US NIH Compound Identifier 23569. European Medicines Agency schedules Almecillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05345MIG. The term ALMECILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). ALMECILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)CSCC=C.[NA].
This classification denotes a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z61I075U2W. European Medicines Agency schedules Penicillin v in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09779MIG. Penicillin v generally arises in the molecular formula C16H18N2O5S. The term 'penicillin v' is a European Pharmacopoeia designation. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)COC1CCCCC1.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BT9Y6D2DR0. European Medicines Agency schedules Penirolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09670MIG. Penirolol generally arises in the molecular formula C15H22N2O2. The term PENIROLOL is an International Non-Proprietary Name or INN. PENIROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule penirolol under HS 29269095 and SITC 51484. As of Q4 2014, PENIROLOL remains the US FDA Preferred Term for this commodity. Penirolol bears US NLM identifiers UMLS ID C1882314 and NCI Concept Code C66339. SMILES: OC(CNC(CC)(C)C)COC1C(CCCC1)C#N.
This classification denotes a topical anti-infective agent with the molecular formula C26H50NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VT390WD2G, chemically known as 2-(2,2-dicyclopentylacetyl)oxyethyl-diethyl-octylazanium but generally known as penoctonium, which bears US NIH Compound Identifier 71690. European Medicines Agency schedules Penoctonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09672MIG. The term PENOCTONIUM is an International Non-Proprietary Name. As of Q4 2014, PENOCTONIUM remains the US FDA Preferred Term for this commodity. Penoctonium bears US NLM identifiers UMLS ID C0604630 and NCI Concept Code C87269. SMILES: CCCCCCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2.
This classification denotes a topical anti-infective agent with the molecular formula C26H50NO2.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HF11NTT6MZ, chemically known as 1-octanaminium, n-(2-((dicyclopentylacetyl)oxy)ethyl)-n,n-diethyl-, bromide (9ci) but more generally known as penoctonium bromide, which bears US NIH Compound Identifier 71690. European Medicines Agency schedules Penoctonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09672MIG. The term PENOCTONIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule penoctonium bromide under HS 29239000 and SITC 51481. As of Q4 2014, PENOCTONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Penoctonium bromide bears US NLM identifiers UMLS ID C2825365 and NCI Concept Code C80863. SMILES: CCCCCCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2.[BR-].
This classification denotes an antipsychotic agent with the molecular formula C8H16N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8871ZB4UGC, chemically known as 1,2,3-trimethyltrimethylenedicarbamate but generally known as pentabamate, which bears US NIH Compound Identifier 3047822. European Medicines Agency schedules Pentabamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09674MIG. The term PENTABAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). PENTABAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pentabamate under HS 29241900 and SITC 51471. As of Q4 2014, PENTABAMATE remains the US FDA Preferred Term for this commodity. Pentabamate bears US NLM identifiers UMLS ID C2347464 and NCI Concept Code C74165. SMILES: O(C(C(C(OC(=O)N)C)C)C)C(=O)N.
This classification denotes a vasodilating agent with the molecular formula C5H8N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10L39TRG1Z, chemically known as 2,2-bis((nitrooxy)methyl)-1,3-propanediol dinitrate (ester) but generally known as pentaerithrityl tetranitrate, which bears US NIH Compound Identifier 6518. European Medicines Agency schedules Pentaerithrityl tetranitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09676MIG. The term PENTAERITHRITYL TETRANITRATE is an International Non-Proprietary Name. World Health Organization schedules pentaerithrityl tetranitrate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O([N](=O)O)CC(CO[N](=O)O)(CO[N](=O)O)CO[N](=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.
This classification denotes a non-steroidal estrogen with the molecular formula C17H15F5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95RFZ48151, chemically known as 4,4-((1r,2s)-1-methyl-2-(2,2,2-trifluoroethyl)ethylene)bis(2-fluorophenol) but generally known as pentafluranol, which bears US NIH Compound Identifier 3047826. European Medicines Agency schedules Pentafluranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09677MIG. The term PENTAFLURANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). PENTAFLURANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pentafluranol under HS 29081900 and SITC 51244. As of Q4 2014, PENTAFLURANOL remains the US FDA Preferred Term for this commodity. Pentafluranol bears US NLM identifiers UMLS ID C2698760 and NCI Concept Code C76825. SMILES: FC(F)(F)CC(C(c1cc(F)c(O)cc1)C)c1cc(F)c(O)cc1.
This classification denotes a diagnostic reagent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EF0NX91490. European Medicines Agency schedules Pentagastrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09678MIG. Pentagastrin generally arises in the molecular formula C37H49N7O9S. The term PENTAGASTRIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 22, no. 10, 1968, list 8.) PENTAGASTRIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a nicotinic antagonist with the molecular formula C11H28N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 521DS2D2HB, chemically known as 1,5-pentanediaminium, n,n,n,n,n,n-hexamethyl-, dibromide (9ci) but generally known as pentamethonium bromide, which bears US NIH Compound Identifier 10919. European Medicines Agency schedules Pentamethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09681MIG. The term PENTAMETHONIUM is an International Non-Proprietary Name. As of Q4 2014, PENTAMETHONIUM remains the US FDA Preferred Term for this commodity. Pentamethonium bears US NLM identifiers UMLS ID C0070299 and NCI Concept Code C84044. SMILES: C[N+](C)(C)CCCCC[N+](C)(C)C.
This classification denotes a nicotinic antagonist with the molecular formula C11H28N2.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0UX03A6JJC, chemically known as 1,5-pentanediaminium, n,n,n,n,n,n-hexamethyl-, dibromide (9ci) but more generally known as pentamethonium bromide, which bears US NIH Compound Identifier 10919. European Medicines Agency schedules Pentamethonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09681MIG. The term PENTAMETHONIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule pentamethonium bromide under HS 29239000 and SITC 51481. As of Q4 2014, PENTAMETHONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Pentamethonium bromide bears US NLM identifiers UMLS ID C0304528 and NCI Concept Code C80532. SMILES: C[N+](C)(C)CCCCC[N+](C)(C)C.[BR-].[BR-].
This classification denotes an antiprotozoal agent and antifungal with the molecular formula C19H24N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 673LC5J4LQ, chemically known as 4,4-(pentamethylenedioxy)dibenzamidine but generally known as pentamidine, which bears US NIH Compound Identifier 4735. European Medicines Agency schedules Pentamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09682MIG. The term PENTAMIDINE is an International Non-Proprietary Name. PENTAMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pentamidine under HS 29252900 and SITC 51482. As of Q4 2014, PENTAMIDINE remains the US FDA Preferred Term for this commodity. Pentamidine bears US NLM identifiers UMLS ID C0030863 and NCI Concept Code C731. SMILES: O(CCCCCOC1CCC(CC1)C(=N)N)C1CCC(CC1)C(=N)N.
This classification denotes an antiprotozoal agent and antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V2P3K60DA2. European Medicines Agency schedules Pentamidine diisetionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12202MIG. Pentamidine isethionate generally arises in the molecular formula C19H24N4O2.2C2H6O4S. The term 'pentamidine isethionate' is a European Pharmacopoeia designation. Most nations schedule pentamidine isethionate under HS 29252900 and SITC 51482. As of Q4 2014, PENTAMIDINE ISETHIONATE remains the US FDA Preferred Term for this commodity. Pentamidine isethionate bears US NLM identifiers UMLS ID C0591959 and NCI Concept Code C29349. SMILES: C1CC(CCC1C(=N)N)OCCCCCOC2CCC(CC2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O.
This classification denotes a carbohydrate, polysaccharide, and glucan, and a derivative of starch used as a plasma substitute in the treatment of hemorrhage, also sometimes called hetastarch, a preparation that typically bears the molecular formula C29H52O21 and which is chemically known as 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol, but generally known as pentastarch, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MOQ3RNM0S, which bears US NIH Compound Identifier 24846132. European Medicines Agency schedules Pentastarch and Hetastarch in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB20665 and SUB14097MIG. As of Q4 2014, PENTASTARCH remains the US FDA Preferred Term for this commodity. SMILES: CC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)OC)O)O)OC4C(C(C(C(O4)CO)OC)O)OCCO)O)O)O)O.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C19H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RP4A60D26L, chemically known as 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol but generally known as pentazocine, which bears US NIH Compound Identifier 4736. European Medicines Agency schedules Pentazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09688MIG. The term PENTAZOCINE is an International Non-Proprietary Name. World Health Organization schedules pentazocine in its Anatomical Therapeutic Chemical (ATC) Classification. PENTAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pentazocine under HS 29333300 and SITC 51574. As of Q4 2014, PENTAZOCINE remains the US FDA Preferred Term for this commodity. Pentazocine bears US NLM identifiers UMLS ID C0030873 and NCI Concept Code C61884. SMILES: OC1CC2C3(C(C(N(CC3)C/C=C(/C)C)CC2CC1)C)C.
This classification denotes an opioid receptor agonist with the molecular formula C19H27NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A36BXO4PPX, chemically known as 2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, hydrochloride, (2r,6r,11r)-rel- but more generally known as pentazocine hydrochloride, which bears US NIH Compound Identifier 107799. European Medicines Agency schedules Pentazocine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03685MIG. Most nations, for tariff and trade purposes, schedule pentazocine hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, PENTAZOCINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pentazocine hydrochloride bears US NLM identifiers UMLS ID C0355587 and NCI Concept Code C47661. SMILES: C[C@H]1[C@H]2CC3CCC(CC3[C@@]1(CCN2CC=C(C)C)C)O.CL.
This classification denotes an opioid receptor agonist with the molecular formula C19H27NO.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P2XIB510O, chemically known as 2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11r*)-, compd. with 2-hydroxypropanoic acid (1:1) but more generally known as pentazocine lactate, which bears US NIH Compound Identifier 66386. European Medicines Agency schedules Pentazocine lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03686MIG. Most nations, for tariff and trade purposes, schedule pentazocine lactate under HS 29333300 and SITC 51574. As of Q4 2014, PENTAZOCINE LACTATE remains US FDA's Preferred Term for this commodity. Pentazocine lactate bears US NLM identifiers UMLS ID C0700554 and NCI Concept Code C76851. SMILES: C[C@H]1[C@H]2CC3CCC(CC3[C@@]1(CCN2CC=C(C)C)C)O.CC(C(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX201. This VA Drug Class (DX201) classifies this compound as belonging to the group IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX201. This VA Drug Class (DX201) classifies this compound as belonging to the group IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS.
This classification denotes a metal chelator with the molecular formula C14H23N3O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7A314HQM0I, chemically known as 1,1,4,7,7-diethylenetriaminepentaacetic acid but generally known as pentetic acid, which bears US NIH Compound Identifier 3053. European Medicines Agency schedules Pentetic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09689MIG. The term PENTETIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Most nations schedule pentetic acid under HS 29224995 and SITC 51465. As of Q4 2014, PENTETIC ACID remains the US FDA Preferred Term for this commodity. Pentetic acid bears US NLM identifiers UMLS ID C0013254 and NCI Concept Code C460. SMILES: OC(=O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O.
This classification denotes a convulsant and gaba antagonist with the molecular formula C6H10N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WM5Z385K7T, chemically known as 7,8,9,10-tetrazabicyclo(5.3.0)-8,10-decadiene but generally known as pentetrazol, which bears US NIH Compound Identifier 5917. European Medicines Agency schedules Pentetrazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09690MIG. World Health Organization schedules pentetrazol in its Anatomical Therapeutic Chemical (ATC) Classification. PENTETRAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pentetrazol under HS 29339990 and SITC 51577. As of Q4 2014, PENTETRAZOL remains the US FDA Preferred Term for this commodity. Pentetrazol bears US NLM identifiers UMLS ID C0030903 and NCI Concept Code C81054. SMILES: C1CCC2=NN=NN2CC1.
This classification denotes a dopamine antagonist with the molecular formula C15H17N5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5P36MQ43L, chemically known as 5-(4-methyl-1-piperazinyl)imidazo(2,1-b)(1,3,5)benzothiadiazepine maleate (1:1) but generally known as pentiapine, which bears US NIH Compound Identifier 54742. Most nations schedule pentiapine under HS 29349990 and SITC 51579. As of Q4 2014, PENTIAPINE remains the US FDA Preferred Term for this commodity. SMILES: CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=NC=CN24.
This classification denotes a dopamine antagonist with the molecular formula C15H17N5S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5P36MQ43L, chemically known as 5-(4-methyl-1-piperazinyl)imidazo(2,1-b)(1,3,5)benzothiadiazepine maleate (1:1) but more generally known as pentiapine maleate, which bears US NIH Compound Identifier 6435401. Most nations, for tariff and trade purposes, schedule pentiapine maleate under HS 29349990 and SITC 51579. As of Q4 2014, PENTIAPINE MALEATE remains US FDA's Preferred Term for this commodity. Pentiapine maleate bears US NLM identifiers UMLS ID C0055211 and NCI Concept Code C90844. SMILES: CN1CCN(CC1)C2=NC3CCCCC3SC4N2CCN4.C(=C\C(=O)O)\C(=O)O.
This classification denotes a phosphodiesterase inhibitor and antiplatelet agent with the molecular formula C13H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MBM1C4K26S, chemically known as 3,7-dimethyl-1-hexyl-1h,3h-purin-2,6-dione but generally known as pentifylline, which bears US NIH Compound Identifier 70569. European Medicines Agency schedules Pentifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09694MIG. The term PENTIFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules pentifylline in its Anatomical Therapeutic Chemical (ATC) Classification. PENTIFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pentifylline under HS 29399900 and SITC 54149. As of Q4 2014, PENTIFYLLINE remains the US FDA Preferred Term for this commodity. Pentifylline bears US NLM identifiers UMLS ID C0070313 and NCI Concept Code C66344. SMILES: O=c1n(CCCCCC)c(=O)n(c2ncn(c12)C)C.
This classification denotes an antiarrhythmic agent with the molecular formula C19H33N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 506T8KTW5Q, chemically known as 2-pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-(2-methylpropyl)-, (+-)- but more generally known as pentisomide, which bears US NIH Compound Identifier 65847. European Medicines Agency schedules Pentisomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09697MIG. The term PENTISOMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). PENTISOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pentisomide under HS 29333999 and SITC 51574. As of Q4 2014, PENTISOMIDE remains US FDA's Preferred Term for this commodity. Pentisomide bears US NLM identifiers UMLS ID C0072206 and NCI Concept Code C90666. SMILES: O=C(N)C(CCN(C(C)C)C(C)C)(CC(C)C)C1NCCCC1.
This classification denotes a barbiturate with the molecular formula C11H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I4744080IR, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-, monosodium salt but generally known as pentobarbital, which bears US NIH Compound Identifier 4737. European Medicines Agency schedules Pentobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09699MIG. The term PENTOBARBITAL is an International Non-Proprietary Name. World Health Organization schedules pentobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. PENTOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pentobarbital or pentobarbitone bears US NLM identifiers UMLS ID C0030883 and NCI Concept Code C61885. SMILES: CCCC(C)C1(C(=O)NC(=O)NC1=O)CC.
This classification denotes a barbiturate with the molecular formula C11H17N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NJJ0475N0S, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-, monosodium salt but more generally known as pentobarbital sodium, which bears US NIH Compound Identifier 4737. European Medicines Agency schedules Pentobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03691MIG. Most nations, for tariff and trade purposes, schedule pentobarbital sodium under HS 29335300. As of Q4 2014, PENTOBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Pentobarbital sodium bears US NLM identifiers UMLS ID C0700349 and NCI Concept Code C47662. SMILES: CCCC(C)C1(C(=O)NC(=O)[N-]C1=O)CC.[NA+].
This classification denotes a nicotinic antagonist with the molecular formula C15H32N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ULL76WPU5X, chemically known as pyrrolidinium, 1,1-(1,5-pentanediyl)bis(1-methyl- but generally known as pentolinium, which bears US NIH Compound Identifier 5850. Pentolinium or pentolonium bears US NLM identifiers UMLS ID C0030885 and NCI Concept Code C77367. SMILES: C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C.
This classification denotes a nicotinic antagonist and antihypertensive agent with the molecular formula C15H32N2.2C4H5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 953357GACY, chemically known as 1,1-pentamethylenebis(1-methylpyrrolidinium tartrate) but more generally known as pentolinium tartrate, which bears US NIH Compound Identifier 5849. European Medicines Agency schedules Pentolonium tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09700MIG. The term PENTOLINIUM TARTRATE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule pentolonium tartrate under HS 29339990. SMILES: C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.
This classification denotes an ace inhibitor with the molecular formula C18H23NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z99269057A, chemically known as 1h-indole-1-pentanoic acid, 2-carboxy-2,3-dihydro-alpha,gamma-dimethyl-delta-oxo-, ethyl ester, (2s-(1(alphas*,gammas*),2r*))- but generally known as pentopril, which bears US NIH Compound Identifier 54938. European Medicines Agency schedules Pentopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09702MIG. The term PENTOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). PENTOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pentopril under HS 29339990 and SITC 51577. As of Q4 2014, PENTOPRIL remains the US FDA Preferred Term for this commodity. Pentopril bears US NLM identifiers UMLS ID C0135946 and NCI Concept Code C72909. SMILES: O=C(N1C(Cc2c1cccc2)C(=O)O)C(CC(C)C(=O)OCC)C.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 914032762Y. European Medicines Agency schedules Pentosan polysulfate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14801MIG. Pentosan polysulfate sodium generally arises in the molecular formula (C5H6NA2O10S2)N. The term PENTOSAN POLYSULFATE SODIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) As of Q4 2014, PENTOSAN POLYSULFATE SODIUM remains the US FDA Preferred Term for this commodity. Pentosan polysulfate sodium bears US NLM identifiers UMLS ID C0524684 and NCI Concept Code C946. SMILES: C1C(C(C(C(O1)OC2COC(C(C2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)O.
This classification denotes a phosphodiesterase inhibitor and antiplatelet agent and alkaloid with the molecular formula C13H18N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SD6QCT3TSU, chemically known as 1,2,3,6-tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion but generally known as pentoxifylline, which bears US NIH Compound Identifier 4740. European Medicines Agency schedules Pentoxifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09705MIG. The term PENTOXIFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules pentoxifylline in its Anatomical Therapeutic Chemical (ATC) Classification. PENTOXIFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pentoxifylline under HS 29395900 and SITC 54145. As of Q4 2014, PENTOXIFYLLINE remains the US FDA Preferred Term for this commodity. Pentoxifylline bears US NLM identifiers UMLS ID C0030899 and NCI Concept Code C733. SMILES: CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C.
This classification denotes a cyclopentane and antitussive agent with the molecular formula C20H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 32C726X12W, chemically known as 2-(2-diethylaminoethoxy)ethyl 1-phenylcyclopentane-1-carboxylate; 2-hydroxypropane-1,2,3-tricarboxylic acid but more generally known as pentoxyverine, which bears US NIH Compound Identifier 2562. European Medicines Agency schedules Pentoxyverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09706MIG. World Health Organization schedules pentoxyverine in its Anatomical Therapeutic Chemical (ATC) Classification. PENTOXYVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pentoxyverine under HS 29221980 and SITC 51461. As of Q4 2014, PENTOXYVERINE remains US FDA's Preferred Term for this commodity. Pentoxyverine bears US NLM identifiers UMLS ID C0054668 and NCI Concept Code C76471. SMILES: CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2.
This classification denotes an antitussive agent with the molecular structure C20H31NO3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 4SH0MFJ5HJ chemically known as cyclopentanecarboxylic acid, 1-phenyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, citrate (1:1), but more commonly known as pentoxyverine citrate, which bears US NIH Compound Identifier 90010. European Medicines Agency schedules Pentoxyverine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03695MIG. Most nations, for tariff and trade purposes, schedule pentoxyverine citrate under HS 29221980 and SITC 51461. As of Q4 2014, PENTOXYVERINE CITRATE remains US FDA's Preferred Term for this commodity. Pentoxyverine citrate bears US NLM identifiers UMLS ID C0937606 and NCI Concept Code C76472. SMILES: CCN(CC)CCOCCOC(=O)C1(CCCC1)C2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antiviral agent with the molecular formula C15H28N4O4.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QW7Y7ZR15U, chemically known as cyclopentanecarboxylic acid, 3-((1s)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1s,2s,3r,4r)- but generally known as peramivir, which bears US NIH Compound Identifier 151164. European Medicines Agency schedules Peramivir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32136. Most nations schedule peramivir under HS 29252900 and SITC 51482. As of Q4 2014, PERAMIVIR remains the US FDA Preferred Term for this commodity. Peramivir bears US NLM identifiers UMLS ID C1675326 and NCI Concept Code C81611. SMILES: OC1C(C(/N=C(/N)N)CC1C(=O)O)C(NC(=O)C)C(CC)CC.
This classification denotes an antihypertensive agent with the molecular formula C23H28N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5726CF21KY, chemically known as 6,7-dimethoxy-2-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-4-(3h)-quinazolinone but generally known as peraquinsin, which bears US NIH Compound Identifier 3047831. European Medicines Agency schedules Peraquinsin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09714MIG. The term PERAQUINSIN is an International Non-Proprietary Name. PERAQUINSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule peraquinsin under HS 29335995 and SITC 51576. As of Q4 2014, PERAQUINSIN remains the US FDA Preferred Term for this commodity. Peraquinsin bears US NLM identifiers UMLS ID C1882322 and NCI Concept Code C66351. SMILES: O(c1c(N2CCN(CC2)CCc2[nH]c3c(c(=O)n2)cc(OC)c(OC)c3)cccc1)C.
This classification denotes a dopamine antagonist with the molecular formula C20H25N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8915147A2B, chemically known as 10h-phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)- but generally known as perazine, which bears US NIH Compound Identifier 4744. European Medicines Agency schedules Perazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14811MIG. World Health Organization schedules perazine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PERAZINE remains the US FDA Preferred Term for this commodity. Perazine bears US NLM identifiers UMLS ID C0030969 and NCI Concept Code C81093. SMILES: S1C2C(N(CCCN3CCN(CC3)C)C3C1CCCC3)CCCC2.
This classification denotes a phosphodiesterase inhibitor and bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M69H5TDQ1K. European Medicines Agency schedules Perbufylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09717MIG. Perbufylline generally arises in the molecular formula C23H28FN5O3. The term PERBUFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) PERBUFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule perbufylline under HS 29395900 and SITC 54145. As of Q4 2014, PERBUFYLLINE remains the US FDA Preferred Term for this commodity. Perbufylline bears US NLM identifiers UMLS ID C1882325 and NCI Concept Code C66354. SMILES: FC1CCC(C(=O)C2CCN(CC2)CCCCN2C3C(N(C(=O)N(C3=O)C)C)NC2)CC1.
This classification denotes a contrast agent, generally used in radiography, with the molecular structure C5F12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 483AU1Y5CZ chemically known as pentane, dodecafluoro-, but more commonly known as dodecafluoropentane, which bears U.S. National Institutes of Health Compound Identifier 12675. The European Medicines Agency schedules Dodecafluoropentane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12493MIG. Most nations schedule Perflenapent or perfluoropentane under HS 29033900. SMILES: FC(F)(C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)F.
This classification denotes a diagnostic reagent with the molecular formula C8BrF17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q1D0Q7R4D9, chemically known as 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane but more generally known as perflubron, which bears U.S. National Institutes of Health Compound Identifier 9873. The European Medicines Agency schedules Perflubron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09721MIG. The term PERFLUBRON is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). The World Health Organization schedules perflubron in its Anatomical Therapeutic Chemical (ATC) Classification. PERFLUBRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Perflubron or perfluorooctyl bromide under HS 29034700. SMILES: BRC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F.
This classification denotes a vasodilating agent with the molecular formula C19H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A8NY1Z12E, chemically known as 4-(3-methyl-1-piperidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone but generally known as perfomedil, which bears US NIH Compound Identifier 65831. European Medicines Agency schedules Perfomedil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09723MIG. The term PERFOMEDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). PERFOMEDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule perfomedil under HS 29333999 and SITC 51574. As of Q4 2014, PERFOMEDIL remains the US FDA Preferred Term for this commodity. Perfomedil bears US NLM identifiers UMLS ID C1882329 and NCI Concept Code C66355. SMILES: O=C(CCCN1CC(CCC1)C)c1c(OC)cc(OC)cc1OC.
This classification denotes a nitrogen mustard compound with the molecular formula C7H15Cl2N2O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U880A4FUDA, chemically known as 2h-1,3,2-oxazophosphorine, 2-(bis(2-chloroethyl)amino)-4-hydroperoxytetrahydro-, 2-oxide but more generally known as perfosfamide, which bears US NIH Compound Identifier 38347. European Medicines Agency schedules Perfosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09724MIG. The term PERFOSFAMIDE is an International Non-Proprietary Name. PERFOSFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule perfosfamide under HS 29349990 and SITC 51579. As of Q4 2014, PERFOSFAMIDE remains US FDA's Preferred Term for this commodity. Perfosfamide bears US NLM identifiers UMLS ID C0163054 and NCI Concept Code C1423. SMILES: CLCCN(P1(=O)OCCC(OO)N1)CCCL.
This classification denotes a dopamine agonist and antiparkinsonian agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24MJ822NZ9. European Medicines Agency schedules Pergolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09725MIG. Pergolide generally arises in the molecular formula C19H26N2S. The term PERGOLIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) PERGOLIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pergolide under HS 29396900 and SITC 54146. As of Q4 2014, PERGOLIDE remains the US FDA Preferred Term for this commodity. Pergolide bears US NLM identifiers UMLS ID C0031007 and NCI Concept Code C61886. SMILES: S(CC1CC2C(N(C1)CCC)CC1C3C2CCCC3[NH]C1)C.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C19H26N2S.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 55B9HQY616, chemically known as ergoline, 8-((methylthio)methyl)-6-propyl-, monomethanesulfonate, (8beta)- but more generally known as pergolide mesilate, which bears US NIH Compound Identifier 47812. European Medicines Agency schedules Pergolide mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03709MIG. Most nations, for tariff and trade purposes, schedule pergolide mesylate under HS 29396900. As of Q4 2014, PERGOLIDE MESYLATE remains US FDA's Preferred Term for this commodity. Pergolide mesylate bears US NLM identifiers UMLS ID C0701027 and NCI Concept Code C47665. SMILES: CCCN1C[C@@H](C[C@H]2[C@H]1CC3C[NH]C4C3C2CCC4)CSC.CS(=O)(=O)O.
This classification denotes a calcium channel blocker, cardiovascular agent, and vasodilator agent with the molecular formula C19H35N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KU65374X44, chemically known as 2-(2,2-dicyclohexylethyl)piperidine but generally known as perhexiline, which bears US NIH Compound Identifier 4746. European Medicines Agency schedules Perhexiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09726MIG. World Health Organization schedules perhexiline in its Anatomical Therapeutic Chemical (ATC) Classification. PERHEXILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule perhexiline under HS 29333999 and SITC 51574. As of Q4 2014, PERHEXILINE remains the US FDA Preferred Term for this commodity. SMILES: N1C(CC(C2CCCCC2)C2CCCCC2)CCCC1.
This classification denotes a calcium channel blocker with the molecular formula C19H35N.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7V8Y90G0H, chemically known as 2-(2,2-dicyclohexylethyl)piperidinium hydrogen maleate but more generally known as perhexiline maleate, which bears US NIH Compound Identifier 5284439. European Medicines Agency schedules Perhexiline maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03710MIG. Most nations, for tariff and trade purposes, schedule perhexiline maleate under HS 29333999 and SITC 51574. As of Q4 2014, PERHEXILINE MALEATE remains US FDA's Preferred Term for this commodity. Perhexiline maleate bears US NLM identifiers UMLS ID C0070413 and NCI Concept Code C90822. SMILES: C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C21H23N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3405M6FD73, chemically known as 4-piperidinol, 1-(3-(2-cyano-10-phenothiazinyl)propyl)- but generally known as periciazine, which bears US NIH Compound Identifier 4747. European Medicines Agency schedules Periciazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09727MIG. The term PERICIAZINE is an International Non-Proprietary Name. World Health Organization schedules periciazine in its Anatomical Therapeutic Chemical (ATC) Classification. PERICIAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule periciazine under HS 29343090 and SITC 51578. As of Q4 2014, PERICIAZINE remains the US FDA Preferred Term for this commodity. Periciazine bears US NLM identifiers UMLS ID C0033459 and NCI Concept Code C81580. SMILES: S1C2C(N(CCCN3CCC(O)CC3)C3C1CCCC3)CC(CC2)C#N.
This classification denotes an ace inhibitor with the molecular formula C19H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y5GMK36KGY, chemically known as 11h-indole-2-carboxylic acid, octahydro-1-(2-((1-ethoxycarbonyl)butyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-beta,7a-beta))- but generally known as perindopril, which bears US NIH Compound Identifier 60184. European Medicines Agency schedules Perindopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09730MIG. The term PERINDOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules perindopril in its Anatomical Therapeutic Chemical (ATC) Classification. PERINDOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule perindopril under HS 29339990 and SITC 51577. As of Q4 2014, PERINDOPRIL remains the US FDA Preferred Term for this commodity. Perindopril bears US NLM identifiers UMLS ID C0136123 and NCI Concept Code C72910. SMILES: O=C(N1C2C(CC1C(=O)O)CCCC2)C(NC(CCC)C(=O)OCC)C.
This classification denotes an ace inhibitor C19H32N2O5.C6H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TFT5IM1KGB, chemically known as l-arginine, (2s,3as,7as)-1-((2s)-2-(((1s)-1-(ethoxycarbonyl)butyl]amino)-1-oxopropyl)octahydro-1h-indole-2-carboxylate (1:1), but more generally known as perindopril arginine, which bears US NIH Compound Identifier 12068809. European Medicines Agency schedules Perindopril arginine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23191. Most nations, for tariff and trade purposes, schedule perindopril arginine under HS 29339990 and SITC 51577. As of Q4 2014, PERINDOPRIL ARGININE remains US FDA's Preferred Term for this commodity. SMILES: CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.C(C[C@@H](C(=O)O)N)CNC(=N)N.
This classification denotes an ace inhibitor with the molecular formula C17H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2UV6ZNQ92K, chemically known as 1h-indole-2-carboxylic acid, octahydro-1-(2-((1-carboxybutyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-beta,7a-beta))- but generally known as perindoprilat, which bears US NIH Compound Identifier 72022. European Medicines Agency schedules Perindoprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09731MIG. The term PERINDOPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). PERINDOPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule perindoprilat under HS 29339990 and SITC 51577. As of Q4 2014, PERINDOPRILAT remains the US FDA Preferred Term for this commodity. Perindoprilat bears US NLM identifiers UMLS ID C0070426 and NCI Concept Code C66357. SMILES: O=C(N1C2C(CC1C(=O)O)CCCC2)C(NC(CCC)C(=O)O)C.
This classification denotes an ace inhibitor with the molecular formula C19H32N2O5.C4H11N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1964X464OJ, chemically known as 1h-indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2alpha,3abeta,7abeta))-, compd. with 2-methyl-2-propanamine (1:1) but more generally known as perindopril erbumine, which bears US NIH Compound Identifier 60183. European Medicines Agency schedules Perindopril erbumine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03711MIG. Most nations, for tariff and trade purposes, schedule perindopril erbumine under HS 29339990 and SITC 51577. As of Q4 2014, PERINDOPRIL ERBUMINE remains US FDA's Preferred Term for this commodity. Perindopril erbumine bears US NLM identifiers UMLS ID C0244718 and NCI Concept Code C47666. SMILES: CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N.
This classification denotes an antihelminthic agent with the molecular formula C21H20Cl2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 509F88P9SZ, chemically known as (3-phenoxyphenyl)methyl3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate, which bears US NIH Compound Identifier 40326. European Medicines Agency schedules permethrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09734MIG. The term PERMETHRIN is an International Non-Proprietary Name. World Health Organization schedules permethrin in its Anatomical Therapeutic Chemical (ATC) Classification. PERMETHRIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule permethrin topical antiparasitic under HS 29162000 and SITC 51379. SMILES: CC1(C(C1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C.
This classification denotes an anxiolytic with the molecular formula C23H30N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N303OK87DT, chemically known as 1h-isoindole-1,3(2h)-dione, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-, cis- but generally known as perospirone, which bears US NIH Compound Identifier 115368. European Medicines Agency schedules Perospirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09735MIG. The term PEROSPIRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). PEROSPIRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule perospirone under HS 29341000 and SITC 51579. As of Q4 2014, PEROSPIRONE remains the US FDA Preferred Term for this commodity. Perospirone bears US NLM identifiers UMLS ID C0084572 and NCI Concept Code C66358. SMILES: S1NC(N2CCN(CCCCN3C(=O)C4C(CCCC4)C3=O)CC2)C2C1CCCC2.
This classification denotes an anxiolytic with the molecular structure C23H30N4O2S.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, T884I76TMN chemically known as cis-n-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide hydrochloride, but more commonly known as perospirone hydrochloride, which bears US NIH Compound Identifier 115367. European Medicines Agency schedules Perospirone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20687. Most nations, for tariff and trade purposes, schedule perospirone hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, PEROSPIRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCCCN4C(=O)[C@@H]5CCCC[C@@H]5C4=O.CL.
This classification denotes an anxiolytic with the molecular formula C23H30N4O2S.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S03S4466IP, chemically known as cis-n-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide hydrochloride dihydrate, but more generally known as perospirone hydrochloride hydrate, which bears US NIH Compound Identifier 5282504. European Medicines Agency schedules perospirone hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09735MIG. Most nations, for tariff purposes, schedule perospirone hydrochloride hydrate under HS 29341000. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCCCN4C(=O)[C@@H]5CCCC[C@@H]5C4=O.O.O.CL.
This classification denotes an antipsychotic agent with the molecular formula C21H26ClN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FTA7XXY4EZ, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but generally known as perphenazine, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Perphenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG. The term PERPHENAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules perphenazine in its Anatomical Therapeutic Chemical (ATC) Classification. PERPHENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule perphenazine under HS 29343090 and SITC 51578. As of Q4 2014, PERPHENAZINE remains the US FDA Preferred Term for this commodity. Perphenazine bears US NLM identifiers UMLS ID C0031184 and NCI Concept Code C29355. SMILES: S1C2C(N(CCCN3CCN(CC3)CCO)C3C1CCCC3)CC(CC2)C(F)(F)F.
This classification denotes an antipsychotic agent C31H44ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RHE0987NHE, chemically known as decanoic acid, 2-(4-(3-(2-chloro-10h-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester, but more generally known as perphenazine decanoate, which bears US NIH Compound Identifier 62873. European Medicines Agency schedules Perphenazine decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03716MIG. Most nations, for tariff and trade purposes, schedule perphenazine decanoate under HS 29343090 and SITC 51578. As of Q4 2014, PERPHENAZINE DECANOATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)CL.
This classification denotes an antipsychotic agent with the molecular formula C28H38ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z6RS3DKN8J, chemically known as 2-(4-(3-(2-chlorophenothiazin-10-yl)propyl)piperazin-1-yl)ethanol, heptanoate, but more generally known as perphenazine enanthate, which bears US NIH Compound Identifier 62871. European Medicines Agency schedules perphenazine enanthate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG. Most nations, for tariff purposes, schedule perphenazine enanthate under HS 29343090. SMILES: CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)CL.
This classification denotes an antipsychotic agent with the molecular formula C21H26ClN3OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 667C5N7677, chemically known as 1-piperazineethanol, 4-(3-(2-chloro-10h-phenothiazin-10-yl)propyl)-, hydrochloride (1:1), but more generally known as perphenazine hydrochloride, which bears US NIH Compound Identifier 76557. European Medicines Agency schedules perphenazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG. Most nations, for tariff purposes, schedule perphenazine hydrochloride under HS 29343090. SMILES: C1CCC2C(C1)N(C3C(CCCC3CL)S2)CCCN4CCN(CC4)CCO.CL.
This classification denotes an antipsychotic agent with the molecular formula C21H26ClN3OS.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7K96LZ09JI, chemically known as 1-piperazineethanol, 4-(3-(2-chloro-10h-phenothiazin-10-yl)propyl)-, (2z)-2-butenedioate (1:2) (salt), but more generally known as perphenazine maleate, which bears US NIH Compound Identifier 6442084. European Medicines Agency schedules perphenazine maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG. Most nations, for tariff purposes, schedule perphenazine maleate under HS 29343090. SMILES: C1CC2C(CC1)SC3C(CC(CC3)CL)N2CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C21H26ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S6Q9MQ62M, chemically known as perphenazine sulfoxide, (+/-)-, but more generally known as perphenazine sulfoxide, which bears US NIH Compound Identifier 82341. European Medicines Agency schedules perphenazine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG. Most nations, for tariff purposes, schedule perphenazine sulfoxide under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3[S+]2[O-])CL)CCCN4CCN(CC4)CCO.
This classification denotes a vaccine for a respiratory infection caused by bordetella pertussis and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.
Pertuzumab is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.
This classification denotes an opioid receptor agonist with the molecular formula C15H21NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N8E7F7Q170, chemically known as 4-piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester, hydrochloride but more generally known as meperidine hydrochloride, which bears US NIH Compound Identifier 4058. European Medicines Agency schedules Meperidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03726MIG. Most nations, for tariff and trade purposes, schedule pethidine hydrochloride under HS 29333300. SMILES: CCOC(=O)C1(CCN(CC1)C)C2CCCCC2.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP300. This VA Drug Class (AP300) classifies this compound as belonging to the group PEDICULICIDES.
This classification denotes an antihelminthic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HOH9HJ2737. European Medicines Agency schedules Pexantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09740MIG. Pexantel generally arises in the molecular formula C12H22N2O. The term PEXANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) PEXANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pexantel under HS 29335995 and SITC 51576. As of Q4 2014, PEXANTEL remains the US FDA Preferred Term for this commodity. Pexantel bears US NLM identifiers UMLS ID C1882353 and NCI Concept Code C66362. SMILES: O=C(N1CCN(CC1)C)C1CCCCC1.
This classification denotes a topical anti-infective agent and antiprotozoal agent with the molecular formula C12H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ID94IS6N8J, chemically known as 4,7-phenanthroline-5,6-quinone but generally known as phanquinone, which bears US NIH Compound Identifier 6764. European Medicines Agency schedules Phanquinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09742MIG. The term PHANQUINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules phanquinone in its Anatomical Therapeutic Chemical (ATC) Classification. PHANQUINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Phanquinone or phanquone bears US NLM identifiers UMLS ID C0070517 and NCI Concept Code C90620. SMILES: C1=CC2=C(C(=O)C(=O)C3=C2C=CC=N3)N=C1.
This classification denotes an anesthetic agent with the molecular formula C18H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V3M4D317W8, chemically known as n,n(sup 2)-bis(p-ethoxyphenyl)acetamidine but generally known as phenacaine, which bears US NIH Compound Identifier 7588. European Medicines Agency schedules Phenacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09743MIG. The term PHENACAINE is an International Non-Proprietary Name. PHENACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenacaine under HS 29252900 and SITC 51482. As of Q4 2014, PHENACAINE remains the US FDA Preferred Term for this commodity. Phenacaine bears US NLM identifiers UMLS ID C0301293 and NCI Concept Code C84046. SMILES: O(C1CCC(N/C(=N/C2CCC(OCC)CC2)C)CC1)CC.
This classification denotes an anesthetic agent with the molecular formula C18H22N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B61HM98KO, chemically known as n,n(sup 2)-bis(p-ethoxyphenyl)acetamidine but more generally known as phenacaine hydrochloride, which bears US NIH Compound Identifier 7588. Most nations, for tariff and trade purposes, schedule phenacaine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, PHENACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phenacaine hydrochloride bears US NLM identifiers UMLS ID C0770375 and NCI Concept Code C75099. SMILES: CCOC1CCC(CC1)N/C(=N/C2CCC(CC2)OCC)/C.O.CL.
This classification denotes an anesthetic agent with the molecular formula C18H22N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B61HM98KO, chemically known as ethanimidamide, n,n'-bis(4-ethoxyphenol)-, monohydrochloride, but more generally known as phenacaine hydrochloride anhydrous, which bears US NIH Compound Identifier 12113. European Medicines Agency schedules phenacaine hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09743MIG. Most nations, for tariff purposes, schedule phenacaine hydrochloride anhydrous under HS 29252900. Phenacaine hydrochloride anhydrous bears US NLM identifiers UMLS ID C2827603 and NCI Concept Code C85245. SMILES: CCOC1CCC(CC1)N/C(=N/C2CCC(CC2)OCC)/C.CL.
This classification denotes an anticonvulsant agent with the molecular formula C9H10N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PAI7J52V09, chemically known as urea, (phenylacetyl)- but generally known as phenacemide, which bears US NIH Compound Identifier 4753. European Medicines Agency schedules Phenacemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09744MIG. The term PHENACEMIDE is an International Non-Proprietary Name. World Health Organization schedules phenacemide in its Anatomical Therapeutic Chemical (ATC) Classification. PHENACEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenacemide under HS 29242995 and SITC 51479. As of Q4 2014, PHENACEMIDE remains the US FDA Preferred Term for this commodity. Phenacemide bears US NLM identifiers UMLS ID C0070525 and NCI Concept Code C66363. SMILES: O=C(NC(=O)N)CC1CCCCC1.
This classification denotes an organo-nitrogen carcinogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ER0CTH01H9. European Medicines Agency schedules Phenacetin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09745MIG. Phenacetin generally arises in the molecular formula C10H13NO2. The term PHENACETIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) PHENACETIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Phenacetin or phenacetinum bears US NLM identifiers UMLS ID C0031364 and NCI Concept Code C44432. SMILES: CCOC1=CC=C(C=C1)NC(=O)C.
This classification denotes a nicotinic antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43P9Q83UFF. European Medicines Agency schedules Phenactropinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09746MIG. Phenactropinium generally arises in the molecular formula C24H28NO4.CL. The term PHENACTROPINIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) As of Q4 2014, PHENACTROPINIUM remains the US FDA Preferred Term for this commodity. SMILES: C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)CC(=O)C4=CC=CC=C4.
This classification denotes a nicotinic antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43P9Q83UFF. European Medicines Agency schedules Phenactropinium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09746MIG. Phenactropinium chloride generally arises in the molecular formula C24H28NO4.CL. The term PHENACTROPINIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, no. 3 1962, list 4.) Most nations, for tariff and trade purposes, schedule phenactropinium chloride under HS 29399900 and SITC 54149. As of Q4 2014, PHENACTROPINIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Phenactropinium chloride bears US NLM identifiers UMLS ID C0604633 and NCI Concept Code C90898. SMILES: C[N+]1(C2CCC1CC(C2)OC(=O)C(C3CCCCC3)O)CC(=O)C4CCCCC4.[CL-].
This classification denotes an opioid receptor agonist and opioid with the molecular formula C23H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 375W3TA42N, chemically known as 4,4-diphenyl-6-morpholino-3-heptanone but generally known as phenadoxone, which bears US NIH Compound Identifier 10089. European Medicines Agency schedules Phenadoxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09747MIG. The term PHENADOXONE is an International Non-Proprietary Name. PHENADOXONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenadoxone under HS 29349990 and SITC 51579. As of Q4 2014, PHENADOXONE remains the US FDA Preferred Term for this commodity. Phenadoxone bears US NLM identifiers UMLS ID C1882360 and NCI Concept Code C66364. SMILES: O1CCN(C(CC(C2CCCCC2)(C2CCCCC2)C(=O)CC)C)CC1.
This classification denotes an opioid with the molecular formula C17H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0600L2M6EZ, chemically known as propionanilide, n-(1-methyl-2-piperidinoethyl)- but generally known as phenampromide, which bears US NIH Compound Identifier 8523. European Medicines Agency schedules Phenampromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09750MIG. The term PHENAMPROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). PHENAMPROMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenampromide under HS 29333999 and SITC 51574. As of Q4 2014, PHENAMPROMIDE remains the US FDA Preferred Term for this commodity. Phenampromide bears US NLM identifiers UMLS ID C1882363 and NCI Concept Code C66367. SMILES: CCC(=O)N(C1=CC=CC=C1)C(C)CN2CCCCC2.
This classification denotes an opioid analgesic and narcotic with the molecular formula C22H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J0ND6N0AQC, chemically known as 1,2,3,4,5,6-hexahydro-8-hydroxy-6,11-dimethyl-3-phenethyl-2,6-methano-3-benzazocine but generally known as phenazocine, which bears US NIH Compound Identifier 14707. European Medicines Agency schedules Phenazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09752MIG. World Health Organization schedules phenazocine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenazocine under HS 29333999 and SITC 51574. As of Q4 2014, PHENAZOCINE remains the US FDA Preferred Term for this commodity. Phenazocine bears US NLM identifiers UMLS ID C0031376 and NCI Concept Code C96728. SMILES: OC1CC2C3(C(C(N(CC3)CCC3CCCCC3)CC2CC1)C)C.
This classification denotes an opioid analgesic and narcotic C22H27NO.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C1749020IH, chemically known as 2'-hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphan, hbr, but more generally known as phenazocine hydrobromide, which bears US NIH Compound Identifier 14706. European Medicines Agency schedules Phenazocine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03734MIG. Most nations, for tariff and trade purposes, schedule phenazocine hydrobromide under HS 29333999 and SITC 51574. As of Q4 2014, PHENAZOCINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Phenazocine hydrobromide bears US NLM identifiers UMLS ID C0600121 and NCI Concept Code C96729. SMILES: C[C@H]1[C@H]2CC3CCC(CC3[C@@]1(CCN2CCC4CCCCC4)C)O.BR.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H12N2O.C7H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F558OJK9JG. European Medicines Agency schedules phenazone salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03735MIG. The term phenazone salicylate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule phenazone salicylate under HS 29331190. SMILES: CC1CC(=O)N(N1C)C2CCCCC2.C1CCC(C(C1)C(=O)O)O.
This classification denotes a nonnarcotic analgesic with the molecular formula C11H11N5, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K2J09EMJ52, chemically known as 2,6-pyridinediamine, 3- (phenylazo)-, monohydrochloride but more generally known as phenazopyridine, which bears U.S. NIH Compound Identifier 4756. European Medicines Agency schedules Phenazopyridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09754MIG. The term PHENAZOPYRIDINE is an International Non-Proprietary Name. World Health Organization schedules phenazopyridine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. PHENAZOPYRIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.
This classification denotes an anesthetic agent with the molecular formula C17H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J1DOI7UV76, chemically known as piperidine, 1- (1-phenylcyclohexyl)-, hydrochloride but generally known as phencyclidine, which bears US NIH Compound Identifier 6468. European Medicines Agency schedules Phencyclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09755MIG. The term PHENCYCLIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). PHENCYCLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phencyclidine under HS 29333300 and SITC 51574. As of Q4 2014, PHENCYCLIDINE remains the US FDA Preferred Term for this commodity. Phencyclidine bears US NLM identifiers UMLS ID C0031381 and NCI Concept Code C738. SMILES: N1(C2(CCCCC2)C2CCCCC2)CCCCC1.
This classification denotes an anesthetic agent with the molecular formula C17H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1JZQ7GDTX, chemically known as piperidine, 1- (1-phenylcyclohexyl)-, hydrochloride but more generally known as phencyclidine hydrochloride, which bears US NIH Compound Identifier 6468. European Medicines Agency schedules Phencyclidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22879. Most nations, for tariff and trade purposes, schedule phencyclidine hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, PHENCYCLIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phencyclidine hydrochloride bears US NLM identifiers UMLS ID C0282301 and NCI Concept Code C75101. SMILES: C1CCC(CC1)C2(CCCCC2)N3CCCCC3.CL.
This classification denotes a cns stimulant and anorexiant with the molecular formula C12H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) AB2794W8KV, chemically known as 3,4-dimethyl-2-phenylmorpholine but more generally known as phendimetrazine, which bears US NIH Compound Identifier 12460. European Medicines Agency schedules Phendimetrazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09756MIG. The term PHENDIMETRAZINE is an International Non-Proprietary Name. PHENDIMETRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule phendimetrazine under HS 29349100 and SITC 51579. As of Q4 2014, PHENDIMETRAZINE remains US FDA's Preferred Term for this commodity. Phendimetrazine bears US NLM identifiers UMLS ID C0070549 and NCI Concept Code C61887. SMILES: CC1C(OCCN1C)C2=CC=CC=C2.
This classification denotes a cns stimulant and anorexiant with the molecular formula C12H17NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6985IP0T80, chemically known as (2s,3s)-3,4-dimethyl-2-phenylmorpholine l-(+)-tartrate, but more generally known as phendimetrazine bitartrate, which bears US NIH Compound Identifier 120608. European Medicines Agency schedules phendimetrazine bitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09756MIG. Most nations, for tariff purposes, schedule phendimetrazine bitartrate under HS 29349100. SMILES: C[C@H]1[C@@H](OCCN1C)C2CCCCC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a cns stimulant and anorexiant with the molecular formula C12H17NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6985IP0T80, chemically known as morpholine, 3,4-dimethyl-2-phenyl-, tartrate, d- but more generally known as phendimetrazine tartrate, which bears US NIH Compound Identifier 120608. European Medicines Agency schedules Phendimetrazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03739MIG. Most nations, for tariff and trade purposes, schedule phendimetrazine tartrate under HS 29349100 and SITC 51579. As of Q4 2014, PHENDIMETRAZINE TARTRATE remains US FDA's Preferred Term for this commodity. Phendimetrazine tartrate bears US NLM identifiers UMLS ID C0148932 and NCI Concept Code C47667. SMILES: C[C@H]1[C@@H](OCCN1C)C2CCCCC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C8H12N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O408N561GF, chemically known as hydrazine, phenethyl-, monohydrochloride but generally known as phenelzine, which bears US NIH Compound Identifier 3675. European Medicines Agency schedules Phenelzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09757MIG. The term PHENELZINE is an International Non-Proprietary Name. World Health Organization schedules phenelzine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENELZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenelzine under HS 29280090 and SITC 51486. As of Q4 2014, PHENELZINE remains the US FDA Preferred Term for this commodity. Phenelzine bears US NLM identifiers UMLS ID C0031392 and NCI Concept Code C61888. SMILES: N(N)CCc1ccccc1.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C8H12N2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2681D7P965, chemically known as hydrazine, phenethyl-, sulfate (1:1) but more generally known as phenelzine sulfate, which bears US NIH Compound Identifier 61100. European Medicines Agency schedules Phenelzine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03740MIG. Most nations, for tariff and trade purposes, schedule phenelzine sulfate under HS 29280090 and SITC 51486. As of Q4 2014, PHENELZINE SULFATE remains US FDA's Preferred Term for this commodity. Phenelzine sulfate bears US NLM identifiers UMLS ID C0701388 and NCI Concept Code C47668. SMILES: C1CCC(CC1)CCNN.OS(=O)(=O)O.
This classification denotes an opioid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2UG271VI0Z. European Medicines Agency schedules Pheneridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09758MIG. Pheneridine generally arises in the molecular formula C22H27NO2. The term PHENERIDINE is an International Non-Proprietary Name or INN. PHENERIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pheneridine under HS 29333999 and SITC 51574. As of Q4 2014, PHENERIDINE remains the US FDA Preferred Term for this commodity. Pheneridine bears US NLM identifiers UMLS ID C1882364 and NCI Concept Code C66370. SMILES: O(C(=O)C1(CCN(CC1)CCC1CCCCC1)C1CCCCC1)CC.
This classification denotes a penicillin v analog and anti-bacterial agent with the molecular formula C17H20N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EFA30X554H, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenoxypropionamido)- but generally known as pheneticillin, which bears US NIH Compound Identifier 4759. European Medicines Agency schedules Pheneticillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09759MIG. World Health Organization schedules pheneticillin in its Anatomical Therapeutic Chemical (ATC) Classification. PHENETICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(OC1CCCCC1)C.
This classification denotes a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70978WUK7C. European Medicines Agency schedules Pheneticillin potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03742MIG. Pheneticillin potassium generally arises in the molecular formula C17H20N2O5S.K. The term 'pheneticillin potassium' is a Hazardous Substances Data Bank designation. Most nations, for tariff and trade purposes, schedule pheneticillin potassium under HS 29411090. SMILES: CC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)[O-])OC3CCCCC3.[K+].
This classification denotes an anti-diabetic agent with the molecular formula C10H15N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) DD5K7529CE, chemically known as imidodicarbonimidic diamide, n- (2-phenylethyl)-, monohydrochloride but more generally known as phenformin, which bears US NIH Compound Identifier 8249. European Medicines Agency schedules Phenformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09761MIG. The term PHENFORMIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4) WHO schedules phenformin in its Anatomical Therapeutic Chemical (ATC) Classification. PHENFORMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule phenformin under HS 29252900 and SITC 51482. As of Q4 2014, PHENFORMIN remains US FDA's Preferred Term for this commodity. Phenformin bears US NLM identifiers UMLS ID C0031404 and NCI Concept Code C81700. SMILES: C1=CC=C(C=C1)CCN=C(N)N=C(N)N.
This classification denotes an anti-diabetic agent with the molecular formula C10H15N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91XC93EU03, chemically known as imidodicarbonimidic diamide, n- (2-phenylethyl)-, monohydrochloride but more generally known as phenformin hydrochloride, which bears US NIH Compound Identifier 8249. European Medicines Agency schedules Phenformin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03743MIG. Most nations, for tariff and trade purposes, schedule phenformin hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, PHENFORMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phenformin hydrochloride bears US NLM identifiers UMLS ID C0770237 and NCI Concept Code C81696. SMILES: C1CCC(CC1)CCNC(=N)NC(=N)N.CL.
This classification denotes an anticholinergic agent with the molecular formula C17H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 679RC9H8TG, chemically known as 2,6-piperidinedione, 3-(2-(diethylamino)ethyl)-3-phenyl- but generally known as phenglutarimide, which bears US NIH Compound Identifier 92870. European Medicines Agency schedules Phenglutarimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09762MIG. The term PHENGLUTARIMIDE is an International Non-Proprietary Name. World Health Organization schedules phenglutarimide in its Anatomical Therapeutic Chemical (ATC) Classification. PHENGLUTARIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenglutarimide under HS 29251995 and SITC 51482. As of Q4 2014, PHENGLUTARIMIDE remains the US FDA Preferred Term for this commodity. Phenglutarimide bears US NLM identifiers UMLS ID C0070561 and NCI Concept Code C90699. SMILES: O=C1NC(=O)CC(C1CCN(CC)CC)C1CCCCC1.
This classification denotes an anticholinergic agent with the molecular formula C17H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B963BYQ21V, chemically known as 2-(2-diethylaminoethyl)-2-phenylglutarimide hydrochloride, but more generally known as phenglutarimide hydrochloride, which bears US NIH Compound Identifier 102668. European Medicines Agency schedules phenglutarimide hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09762MIG. Most nations, for tariff purposes, schedule phenglutarimide hydrochloride under HS 29251995. SMILES: CCN(CC)CCC1(CCC(=O)NC1=O)C2CCCCC2.CL.
This classification denotes an analgesic and antipyretic with the molecular formula C7H9N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1LR2578324, chemically known as 2-phenylhydrazide, carbamic acid but generally known as phenicarbazide, which bears US NIH Compound Identifier 61002. European Medicines Agency schedules Phenicarbazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09763MIG. The term PHENICARBAZIDE is an International Non-Proprietary Name. PHENICARBAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenicarbazide under HS 29280090 and SITC 51486. As of Q4 2014, PHENICARBAZIDE remains the US FDA Preferred Term for this commodity. Phenicarbazide bears US NLM identifiers UMLS ID C0770986 and NCI Concept Code C72931. SMILES: O=C(NNC1CCCCC1)N.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 772BQ8KSST, chemically known as 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lh-indeno(2,1-c)pyridine but generally known as phenindamine, which bears US NIH Compound Identifier 11291. European Medicines Agency schedules Phenindamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09764MIG. The term PHENINDAMINE is an International Non-Proprietary Name. World Health Organization schedules phenindamine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENINDAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenindamine under HS 29339920 and SITC 51577. As of Q4 2014, PHENINDAMINE remains the US FDA Preferred Term for this commodity. Phenindamine bears US NLM identifiers UMLS ID C0070563 and NCI Concept Code C87745. SMILES: N1(CC2=C(CC1)C1C(C2C2CCCCC2)CCCC1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28725X3PV8, chemically known as 2,3,4,9-tetrahydro-2-methyl-9-phenyl-1h-indeno(2,1-c)pyridine tartrate, but more generally known as phenindamine hydrogen tartrate, which bears US NIH Compound Identifier 11290. European Medicines Agency schedules phenindamine hydrogen tartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09764MIG. Most nations, for tariff purposes, schedule phenindamine hydrogen tartrate under HS 29339920. SMILES: CN1CCC2=C(C1)C(C3C2CCCC3)C4CCCCC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28725X3PV8, chemically known as 2,3,4,9-tetrahydro-2-methyl-9-phenyl-1h-indeno(2,1-c)pyridine l-(+)-tartrate (1:1) but more generally known as phenindamine tartrate, which bears US NIH Compound Identifier 11290. European Medicines Agency schedules Phenindamine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03745MIG. Most nations, for tariff and trade purposes, schedule phenindamine tartrate under HS 29339920 and SITC 51577. As of Q4 2014, PHENINDAMINE TARTRATE remains US FDA's Preferred Term for this commodity. Phenindamine tartrate bears US NLM identifiers UMLS ID C0724658 and NCI Concept Code C87746. SMILES: CN1CCC2=C(C1)C(C3C2CCCC3)C4CCCCC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an anticoagulant agent with the molecular formula C15H10O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M7Y6274ZE, chemically known as 1,3-indandione, 2-phenyl- but generally known as phenindione, which bears US NIH Compound Identifier 4760. European Medicines Agency schedules Phenindione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09765MIG. The term PHENINDIONE is an International Non-Proprietary Name. World Health Organization schedules phenindione in its Anatomical Therapeutic Chemical (ATC) Classification. PHENINDIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenindione under HS 29143900 and SITC 51629. As of Q4 2014, PHENINDIONE remains the US FDA Preferred Term for this commodity. Phenindione bears US NLM identifiers UMLS ID C0031406 and NCI Concept Code C66371. SMILES: O=C1C(C(=O)C2C1CCCC2)C1CCCCC1.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C9H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37VKD7067M, chemically known as hydrazine, (.alpha.-methylphenethyl)-, monohydrochloride but generally known as pheniprazine, which bears US NIH Compound Identifier 5929. European Medicines Agency schedules Pheniprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09767MIG. The term PHENIPRAZINE is an International Non-Proprietary Name. PHENIPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pheniprazine under HS 29280090 and SITC 51486. As of Q4 2014, PHENIPRAZINE remains the US FDA Preferred Term for this commodity. Pheniprazine bears US NLM identifiers UMLS ID C0031407 and NCI Concept Code C80967. SMILES: N(N)C(CC1CCCCC1)C.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C9H14N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5B3OM8452C, chemically known as hydrazine, (.alpha.-methylphenethyl)-, monohydrochloride but more generally known as pheniprazine hydrochloride, which bears US NIH Compound Identifier 5929. Most nations, for tariff and trade purposes, schedule pheniprazine hydrochloride under HS 29280090 and SITC 51486. As of Q4 2014, PHENIPRAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pheniprazine hydrochloride bears US NLM identifiers UMLS ID C2347502 and NCI Concept Code C73612. SMILES: CC(CNN)C1CCCCC1.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 134FM9ZZ6M, chemically known as 3-phenyl-3-(2-pyridyl)-n,n-dimethylpropylanine but generally known as pheniramine, which bears US NIH Compound Identifier 4761. European Medicines Agency schedules Pheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09768MIG. The term PHENIRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules pheniramine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENIRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pheniramine under HS 29333999 and SITC 51574. As of Q4 2014, PHENIRAMINE remains the US FDA Preferred Term for this commodity. Pheniramine bears US NLM identifiers UMLS ID C0031408 and NCI Concept Code C61889. SMILES: N(CCC(C1CCCCC1)C1NCCCC1)(C)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20N2.C7H7NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NA6Q9I2PB, chemically known as benzoic acid, 4-amino-2-hydroxy-, compd. with n,n-dimethyl-.gamma.-phenyl-2-pyridinepropanamine (1:1), but more generally known as pheniramine aminosalicylate, which bears US NIH Compound Identifier 92952. European Medicines Agency schedules pheniramine aminosalicylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09768MIG. Most nations, for tariff purposes, schedule pheniramine aminosalicylate under HS 29333999. SMILES: CN(C)CCC(C1CCCCC1)C2CCCCN2.C1CC(C(CC1N)O)C(=O)O.
This classification denotes a histamine-1 receptor antagonist C16H20N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10P41DI6MI, chemically known as n,n-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine hydrochloride, but more generally known as pheniramine hydrochloride, which bears US NIH Compound Identifier 91402. Most nations, for tariff and trade purposes, schedule pheniramine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PHENIRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCC(C1CCCCC1)C2CCCCN2.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NYW905655B, chemically known as n,n-dimethyl-3-phenyl-3-(2-pyridyl)propylamine hydrogen maleate, but more generally known as pheniramine hydrogen maleate, which bears US NIH Compound Identifier 6433160. European Medicines Agency schedules pheniramine hydrogen maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09768MIG. Most nations, for tariff purposes, schedule pheniramine hydrogen maleate under HS 29333999. SMILES: CN(C)CCC(C1CCCCC1)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NYW905655B. European Medicines Agency schedules Pheniramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03747MIG. Pheniramine maleate generally arises in the molecular formula C20H24N2O4. The term 'pheniramine maleate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule pheniramine maleate under HS 29333999 and SITC 51574. As of Q4 2014, PHENIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Pheniramine maleate bears US NLM identifiers UMLS ID C0887016 and NCI Concept Code C29358. SMILES: CN(C)CCC(C1CCCCC1)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT900. This VA Drug Class (NT900) classifies this compound as belonging to the group NASAL AND THROAT, TOPICAL, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AH109. This VA Drug Class (AH109) classifies this compound as belonging to the group ANTIHISTAMINES, OTHER.
This classification denotes a cns stimulant and anorexiant with the molecular formula C11H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) XA501VL3VR, chemically known as 3-methyl-2-phenyltetrahydro-2h-1,4-oxazine but more generally known as phenmetrazine, which bears US NIH Compound Identifier 4762. European Medicines Agency schedules Phenmetrazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09769MIG. The term PHENMETRAZINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). PHENMETRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule phenmetrazine under HS 29349100 and SITC 51579. As of Q4 2014, PHENMETRAZINE remains US FDA's Preferred Term for this commodity. Phenmetrazine bears US NLM identifiers UMLS ID C0031411 and NCI Concept Code C66372. SMILES: CC1C(OCCN1)C2=CC=CC=C2.
This classification denotes a barbiturate and anticonvulsant agent with the molecular formula C12H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YQE403BP4D, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl- but generally known as phenobarbital, which bears US NIH Compound Identifier 4763. European Medicines Agency schedules Phenobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09770MIG. The term PHENOBARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules phenobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. PHENOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenobarbital under HS 29335310 and SITC 51576. As of Q4 2014, PHENOBARBITAL remains the US FDA Preferred Term for this commodity. Phenobarbital bears US NLM identifiers UMLS ID C0031412 and NCI Concept Code C739. SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2.
This classification denotes a barbiturate and anticonvulsant agent C12H12N2O3.C4H11N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RB423CG92E, chemically known as barbituric acid, 5-ethyl-5-phenyl-, compd. with diethylamine (1:1), but more generally known as phenobarbital diethylamine, which bears US NIH Compound Identifier 46174100. Most nations, for tariff and trade purposes, schedule phenobarbital diethylamine under HS 29335310 and SITC 51576. As of Q4 2014, PHENOBARBITAL DIETHYLAMINE remains US FDA's Preferred Term for this commodity. SMILES: CCC1(C(=O)NC(=O)NC1=O)C2CCCCC2.CCNCC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN400. This VA Drug Class (CN400) classifies this compound as belonging to the group ANTICONVULSANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a barbiturate and anticonvulsant agent with the molecular formula C12H11N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SW9M9BB5K3, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl- but more generally known as phenobarbital sodium, which bears US NIH Compound Identifier 4763. European Medicines Agency schedules Phenobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09771MIG. The term PHENOBARBITAL SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations, for tariff and trade purposes, schedule phenobarbital sodium under HS 29335310 and SITC 51576. As of Q4 2014, PHENOBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Phenobarbital sodium bears US NLM identifiers UMLS ID C0282303 and NCI Concept Code C76956. SMILES: CCC1(C(=O)NC(=O)[N-]C1=O)C2CCCCC2.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.
This classification denotes a topical anti-infective agent with the molecular formula C6H5O.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4NC0T56V35, chemically known as 1-ethoxy-2,2,2-trifluoroethanol but generally known as phenolate sodium, which bears US NIH Compound Identifier 8750. European Medicines Agency schedules Phenolate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23138. SMIILES: C1=CC=C(C=C1)[O-].[Na+]. Phenol or phenolate sodium bears US NLM identifiers UMLS ID C0070570 and NCI Concept Code C1191.
This classification denotes an organic carcinogen with the molecular formula C20H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6QK969R2IF, chemically known as 3,3-bis(p-hydroxyphenyl)phthalide but generally known as phenolphthalein, which bears US NIH Compound Identifier 4764. European Medicines Agency schedules Phenolphthalein in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09773MIG. The term PHENOLPHTHALEIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules phenolphthalein in its Anatomical Therapeutic Chemical (ATC) Classification. PHENOLPHTHALEIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PHENOLPHTHALEIN remains the US FDA Preferred Term for this commodity. Phenolphthalein bears US NLM identifiers UMLS ID C0600489 and NCI Concept Code C29359. SMILES: O1C(C2C(C1=O)CCCC2)(C1CCC(O)CC1)C1CCC(O)CC1.
This classification denotes an organic carcinogen with the molecular formula C26H22O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0S390I6642, chemically known as .beta.-d-glucopyranosiduronic acid, 4-(1,3-dihydro-1-(4-hydroxyphenyl)-3-oxo-1-isobenzofuranyl)phenyl, but more generally known as phenolphthalein glucuronide, which bears US NIH Compound Identifier 3032634. European Medicines Agency schedules phenolphthalein glucuronide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09773MIG. Most nations, for tariff purposes, schedule phenolphthalein glucuronide under HS 29322910. SMILES: C1CCC2C(C1)C(=O)OC2(C3CCC(CC3)O)C4CCC(CC4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a diagnostic reagent with the molecular formula C19H14O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I6G9Y0J1OJ, chemically known as 4,4-(3h-2,1-benzoxathiol-3-ylidene)diphenol s,s-dioxide but more generally known as phenolsulfonphthalein, which bears US NIH Compound Identifier 4766. The European Medicines Agency schedules Phenolsulfonphthalein in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14835MIG. The World Health Organization schedules phenolsulfonphthalein in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes an opioid and analgesic agent with the molecular formula C23H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G9BH09J4JW, chemically known as 4-piperidinecarboxylic acid, 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-, ethyl ester but generally known as phenoperidine, which bears US NIH Compound Identifier 11226. European Medicines Agency schedules Phenoperidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09775MIG. The term PHENOPERIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules phenoperidine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENOPERIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenoperidine under HS 29333300 and SITC 51574. As of Q4 2014, PHENOPERIDINE remains the US FDA Preferred Term for this commodity. Phenoperidine bears US NLM identifiers UMLS ID C0031432 and NCI Concept Code C72123. SMILES: O(C(=O)C1(CCN(CC1)CCC(O)C1CCCCC1)C1CCCCC1)CC.
This classification denotes an opioid and analgesic agent C23H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1D9C1OK7KZ, chemically known as isonipecotic acid, 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-, ethyl ester, hydrochloride, but more generally known as phenoperidine hydrochloride, which bears US NIH Compound Identifier 19260. European Medicines Agency schedules Phenoperidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03758MIG. Most nations, for tariff and trade purposes, schedule phenoperidine hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, PHENOPERIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)C1(CCN(CC1)CCC(C2CCCCC2)O)C3CCCCC3.CL.
This classification denotes an antiemetic agent with the molecular formula C12H9NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GS9EX7QNU6, chemically known as 10h-phenothiazine-10-propanamine, 2-chloro-n,n-dimethyl-, radical ion(1+) but generally known as phenothiazine, which bears US NIH Compound Identifier 2726. European Medicines Agency schedules Phenothiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09776MIG. The term PHENOTHIAZINE is an International Non-Proprietary Name. PHENOTHIAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenothiazine under HS 29343090 and SITC 51578. As of Q4 2014, PHENOTHIAZINE remains the US FDA Preferred Term for this commodity. Phenothiazine bears US NLM identifiers UMLS ID C0031436 and NCI Concept Code C740. SMILES: CLC1CC2N(CCCN(C)C)C3C(SC2CC1)CCCC3.
It is used in the treatment of lice, nits, head crabs, body hair and pubic hair.
This classification denotes a carcinogenic aromatic amine and alpha-adrenergic blocking agent with the molecular formula C18H22ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0TTZ664R7Z, chemically known as n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzylamine, hydrochloride but generally known as phenoxybenzamine, which bears US NIH Compound Identifier 4768. European Medicines Agency schedules Phenoxybenzamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09778MIG. The term PHENOXYBENZAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules phenoxybenzamine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENOXYBENZAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenoxybenzamine under HS 29221980 and SITC 51461. As of Q4 2014, PHENOXYBENZAMINE remains the US FDA Preferred Term for this commodity. Phenoxybenzamine bears US NLM identifiers UMLS ID C0031441 and NCI Concept Code C62065. SMILES: CLCCN(C(COC1CCCCC1)C)CC1CCCCC1.
This classification denotes an adrenergic alpha-antagonist, antihypertensive agent, and vasodilator agent with the molecular formula C18H22ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1IEG24OHL, chemically known as n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzylamine, hydrochloride but more generally known as phenoxybenzamine hydrochloride, which bears US NIH Compound Identifier 4768. European Medicines Agency schedules Phenoxybenzamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03761MIG. Most nations, for tariff and trade purposes, schedule phenoxybenzamine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PHENOXYBENZAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phenoxybenzamine hydrochloride bears US NLM identifiers UMLS ID C0701367 and NCI Concept Code C44435. SMILES: CC(COC1CCCCC1)N(CCCL)CC2CCCCC2.CL.
This classification denotes a penicillin antibiotic 2C16H17N2O5S.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3750YH4NM7, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, calcium salt (2:1), (2s,5r,6r)-, but more generally known as phenoxymethylpenicillin calcium, which bears US NIH Compound Identifier 46174101. European Medicines Agency schedules Phenoxymethylpenicillin calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03764MIG. Most nations, for tariff and trade purposes, schedule phenoxymethylpenicillin calcium under HS 29411090 and SITC 54131. As of Q4 2014, PHENOXYMETHYLPENICILLIN CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3CCCCC3)C(=O)[O-])C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3CCCCC3)C(=O)[O-])C.[CA+2].
This classification denotes a penicillin antibiotic with the molecular formula C16H17N2O5S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 146T0TU1JB. European Medicines Agency schedules phenoxymethylpenicillin potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03766MIG. The term penicillin v potassium is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule phenoxymethylpenicillin potassium under HS 29411090. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3CCCCC3)C(=O)[O-])C.[K+].
This classification denotes a carbamate with the molecular formula C10H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJZ473TPS0, chemically known as 1-propanol, 3-phenyl-, carbamate but generally known as phenprobamate, which bears US NIH Compound Identifier 4770. European Medicines Agency schedules Phenprobamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09780MIG. World Health Organization schedules phenprobamate in its Anatomical Therapeutic Chemical (ATC) Classification. PHENPROBAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenprobamate under HS 29242995 and SITC 51479. As of Q4 2014, PHENPROBAMATE remains the US FDA Preferred Term for this commodity. Phenprobamate bears US NLM identifiers UMLS ID C0070591 and NCI Concept Code C98239. SMILES: C1=CC=C(C=C1)CCCOC(=O)N.
This classification denotes an anticoagulant agent with the molecular formula C18H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q08SIO485D, chemically known as 2h-1-benzopyran-2-one, 4-hydroxy-3-(1-phenylpropyl)- but generally known as phenprocoumon, which bears US NIH Compound Identifier 9908. European Medicines Agency schedules Phenprocoumon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09781MIG. The term PHENPROCOUMON is an International Non-Proprietary Name. World Health Organization schedules phenprocoumon in its Anatomical Therapeutic Chemical (ATC) Classification. PHENPROCOUMON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PHENPROCOUMON remains the US FDA Preferred Term for this commodity. Phenprocoumon bears US NLM identifiers UMLS ID C0031444 and NCI Concept Code C66374. SMILES: O1C(O)C(C(CC)C2CCCCC2)C(=O)C2C1CCCC2.
This classification denotes an anticonvulsant agent with the molecular formula C11H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WVL9C355G, chemically known as 2,5-pyrrolidinedione, 1-methyl-3-phenyl- but generally known as phensuximide, which bears US NIH Compound Identifier 6839. European Medicines Agency schedules Phensuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09783MIG. The term PHENSUXIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules phensuximide in its Anatomical Therapeutic Chemical (ATC) Classification. PHENSUXIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phensuximide under HS 29251995 and SITC 51482. As of Q4 2014, PHENSUXIMIDE remains the US FDA Preferred Term for this commodity. Phensuximide bears US NLM identifiers UMLS ID C0070592 and NCI Concept Code C66375. SMILES: CN1C(=O)CC(C1=O)C2=CC=CC=C2.
This classification denotes an anorexiant with the molecular formula C10H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C045TQL4WP, chemically known as 1,1-dimethyl-2-phenylethylamine but more generally known as phentermine, which bears US NIH Compound Identifier 4771. European Medicines Agency schedules Phentermine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09784MIG. The term PHENTERMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules phentermine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENTERMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule phentermine under HS 29214600 and SITC kg. As of Q4 2014, PHENTERMINE remains US FDA's Preferred Term for this commodity. Phentermine bears US NLM identifiers UMLS ID C0031447 and NCI Concept Code C61890. SMILES: CC(C)(CC1=CC=CC=C1)N.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z468598HBV, chemically known as 2-imidazoline, 2-((n-(m-hydroxyphenyl)-p-toluidino)methyl)- but generally known as phentolamine, which bears US NIH Compound Identifier 5775. European Medicines Agency schedules Phentolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09785MIG. The term PHENTOLAMINE is an International Non-Proprietary Name. World Health Organization schedules phentolamine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENTOLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phentolamine under HS 29332910 and SITC 51573. As of Q4 2014, PHENTOLAMINE remains the US FDA Preferred Term for this commodity. Phentolamine bears US NLM identifiers UMLS ID C0031448 and NCI Concept Code C62066. SMILES: OC1CC(N(CC2=NCCN2)C2CCC(CC2)C)CCC1.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H19N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86DRW83R1H, chemically known as 3-(((4,5-dihydro-1h-imidazol-2-yl)methyl)(4-methylphenyl)amino)phenol hydrochloride but more generally known as phentolamine hydrochloride, which bears US NIH Compound Identifier 66147. European Medicines Agency schedules Phentolamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22729. Most nations, for tariff and trade purposes, schedule phentolamine hydrochloride under HS 29332910 and SITC 51573. As of Q4 2014, PHENTOLAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phentolamine hydrochloride bears US NLM identifiers UMLS ID C2698793 and NCI Concept Code C80007. SMILES: CC1CCC(CC1)N(CC2=NCCN2)C3CCCC(C3)O.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H19N3O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7543E5K9T, chemically known as m-(n-(2-imidazolin-2-ylmethyl)-p-toluidino)phenol monomethanesulfonate (salt), but more generally known as phentolamine mesylate, which bears US NIH Compound Identifier 5775. European Medicines Agency schedules phentolamine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09785MIG. Most nations, for tariff purposes, schedule phentolamine mesylate under HS 29332910. As of Q4 2014, PHENTOLAMINE MESYLATE remains US FDA's Preferred Term for this commodity. Phentolamine mesylate bears US NLM identifiers UMLS ID C0733398 and NCI Concept Code C38691. SMILES: CC1CCC(CC1)N(CC2=NCCN2)C3CCCC(C3)O.CS(=O)(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GN5P7K3T8S, chemically known as 3,5-pyrazolidinedione, 4-butyl-1,2-diphenyl- but generally known as phenylbutazone, which bears US NIH Compound Identifier 4781. European Medicines Agency schedules Phenylbutazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09787MIG. The term PHENYLBUTAZONE is an International Non-Proprietary Name. World Health Organization schedules phenylbutazone in its Anatomical Therapeutic Chemical (ATC) Classification. PHENYLBUTAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenylbutazone under HS 29331910 and SITC 51571. As of Q4 2014, PHENYLBUTAZONE remains the US FDA Preferred Term for this commodity. Phenylbutazone bears US NLM identifiers UMLS ID C0031463 and NCI Concept Code C66377. SMILES: O=C1N(N(C(=O)C1CCCC)C1CCCCC1)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug 2C19H19N2O2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RD7H6MM2DL, chemically known as calcium 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione, but more generally known as phenylbutazone calcium, which bears US NIH Compound Identifier 112362. European Medicines Agency schedules Phenylbutazone calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03772MIG. Most nations, for tariff and trade purposes, schedule phenylbutazone calcium under HS 29331910 and SITC 51571. As of Q4 2014, PHENYLBUTAZONE CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC[C-]1C(=O)N(N(C1=O)C2CCCCC2)C3CCCCC3.CCCC[C-]1C(=O)N(N(C1=O)C2CCCCC2)C3CCCCC3.[CA+2].
This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C19H19N2O2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 189M850I32. European Medicines Agency schedules phenylbutazone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03773MIG. The term phenylbutazone sodium is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule phenylbutazone sodium under HS 29331910 and SITC 51571. As of Q4 2014, PHENYLBUTAZONE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC[C-]1C(=O)N(N(C1=O)C2CCCCC2)C3CCCCC3.[NA+].
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but generally known as phenylephrine, which bears US NIH Compound Identifier 6041. European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG. The term PHENYLEPHRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules phenylephrine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENYLEPHRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenylephrine under HS 29225000 and SITC 51467. As of Q4 2014, PHENYLEPHRINE remains the US FDA Preferred Term for this commodity. Phenylephrine bears US NLM identifiers UMLS ID C0031469 and NCI Concept Code C62067. SMILES: OC(CNC)C1CC(O)CCC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE200. This VA Drug Class (RE200) classifies this compound as belonging to the group DECONGESTANTS, SYSTEMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP600. This VA Drug Class (OP600) classifies this compound as belonging to the group MYDRIATICS/CYCLOPLEGICS, TOPICAL OPHTHALMIC.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.
This classification denotes a fungicide with the molecular formula C6H5Hg.NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CG8692ZN14, chemically known as phenylmercuric nitrate, basic but generally known as phenylmercuric nitrate, which bears US NIH Compound Identifier 16682924. European Medicines Agency schedules Phenylmercuric nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03780MIG. World Health Organization schedules phenylmercuric nitrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PHENYLMERCURIC NITRATE remains the US FDA Preferred Term for this commodity. Phenylmercuric nitrate bears US NLM identifiers UMLS ID C0301304 and NCI Concept Code C84052. SMILES: [Hg](O[N](=O)O)c1ccccc1.
This classification denotes an adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33RU150WUN, chemically known as 1r,2s-(-)-norephedrine hydrochloride but generally known as phenylpropanolamine, which bears US NIH Compound Identifier 4786. European Medicines Agency schedules Phenylpropanolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09790MIG. The term PHENYLPROPANOLAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules phenylpropanolamine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENYLPROPANOLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenylpropanolamine under HS 29394900 and SITC 54144. As of Q4 2014, PHENYLPROPANOLAMINE remains the US FDA Preferred Term for this commodity. Phenylpropanolamine bears US NLM identifiers UMLS ID C0031495 and NCI Concept Code C29364. SMILES: OC(C(N)C)C1CCCCC1.
This classification denotes an adrenergic agonist with the molecular formula C9H13NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B48FTC099P, chemically known as (r*,s*)-(+-)-alpha-(1-aminoethyl)benzenemethanol bitartrate but more generally known as phenylpropanolamine bitartrate, which bears US NIH Compound Identifier 62941. European Medicines Agency schedules Phenylpropanolamine bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03781MIG. Most nations, for tariff and trade purposes, schedule phenylpropanolamine bitartrate under HS 29394900 and SITC 54144. As of Q4 2014, PHENYLPROPANOLAMINE BITARTRATE remains US FDA's Preferred Term for this commodity. Phenylpropanolamine bitartrate bears US NLM identifiers UMLS ID C0724661 and NCI Concept Code C84053. SMILES: C[C@@H]([C@@H](C1CCCCC1)O)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an adrenergic agonist with the molecular formula C9H13NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8D5I63UE1Q, chemically known as 1r,2s-(-)-norephedrine hydrochloride but more generally known as phenylpropanolamine hydrochloride, which bears US NIH Compound Identifier 4786. European Medicines Agency schedules Phenylpropanolamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14842MIG. Most nations, for tariff and trade purposes, schedule phenylpropanolamine hydrochloride under HS 29394900 and SITC 54144. As of Q4 2014, PHENYLPROPANOLAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phenylpropanolamine hydrochloride bears US NLM identifiers UMLS ID C0011782 and NCI Concept Code C66379. SMILES: C[C@@H]([C@@H](C1CCCCC1)O)N.CL.
This classification denotes an adrenergic agonist with the molecular formula C9H13NO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86ILV507ZN. Most nations, for tariff and trade purposes, schedule phenylpropanolamine maleate under HS 29394900. As of Q4 2014, PHENYLPROPANOLAMINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@@H](C1CCCCC1)O)N.C(=C\C(=O)O)\C(=O)O.
This classification denotes an adrenergic agonist with the molecular formula 2C9H13NO.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQA3O9M79V. Most nations, for tariff and trade purposes, schedule phenylpropanolamine sulfate under HS 29394900 and SITC 54144. As of Q4 2014, PHENYLPROPANOLAMINE SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@@H](C1CCCCC1)O)N.C[C@@H]([C@@H](C1CCCCC1)O)N.OS(=O)(=O)O.
This classification denotes an analgesic and antipyretic with the molecular formula C13H10O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28A37T47QO, chemically known as 2-hydroxybenzoic acid, phenyl ester but generally known as phenyl salicylate, which bears US NIH Compound Identifier 8361. European Medicines Agency schedules Phenyl salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14839MIG. World Health Organization schedules phenyl salicylate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1=CC=C(C=C1)OC(=O)C2=CC=CC=C2O. SMILES: C1=CC=C(C=C1)OC(=O)C2=CC=CC=C2O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K65LB6598J, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine but generally known as phenyltoloxamine, which bears US NIH Compound Identifier 7077. European Medicines Agency schedules Phenyltoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09791MIG. The term PHENYLTOLOXAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). PHENYLTOLOXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenyltoloxamine under HS 29221980 and SITC 51461. As of Q4 2014, PHENYLTOLOXAMINE remains the US FDA Preferred Term for this commodity. Phenyltoloxamine bears US NLM identifiers UMLS ID C0070709 and NCI Concept Code C47669. SMILES: O(C1C(CC2CCCCC2)CCCC1)CCN(C)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21NO.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8UE48MJH8M, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-toloxy)ethylamine dihydrogen citrate but more generally known as phenyltoloxamine citrate, which bears US NIH Compound Identifier 14440. European Medicines Agency schedules Phenyltoloxamine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03784MIG. Most nations, for tariff and trade purposes, schedule phenyltoloxamine citrate under HS 29221980 and SITC 51461. As of Q4 2014, PHENYLTOLOXAMINE CITRATE remains US FDA's Preferred Term for this commodity. Phenyltoloxamine citrate bears US NLM identifiers UMLS ID C0724662 and NCI Concept Code C82275. SMILES: CN(C)CCOC1CCCCC1CC2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21NO.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8UE48MJH8M, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-toloxy)ethylamine dihydrogen citrate but more generally known as phenyltoloxamine citrate, which bears US NIH Compound Identifier 14440. European Medicines Agency schedules Phenyltoloxamine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03784MIG. Most nations, for tariff and trade purposes, schedule phenyltoloxamine dihydrogen citrate under HS 29221980. SMILES: CN(C)CCOC1CCCCC1CC2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56O4H6ZT2K, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-toloxy)-ethylamine hydrochloride but more generally known as phenyltoloxamine hydrochloride, which bears US NIH Compound Identifier 22528. Most nations, for tariff and trade purposes, schedule phenyltoloxamine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PHENYLTOLOXAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phenyltoloxamine hydrochloride bears US NLM identifiers UMLS ID C0770856 and NCI Concept Code C97702. SMILES: CN(C)CCOC1CCCCC1CC2CCCCC2.CL.
This classification denotes a cation channel blocker and anticonvulsant agent with the molecular formula C15H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6158TKW0C5, chemically known as 5,5-dwufenylohydantoina but generally known as phenytoin, which bears US NIH Compound Identifier 1775. European Medicines Agency schedules Phenytoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12211MIG. The term PHENYTOIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules phenytoin in its Anatomical Therapeutic Chemical (ATC) Classification. PHENYTOIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenytoin under HS 29332100 and SITC 51572. As of Q4 2014, PHENYTOIN remains the US FDA Preferred Term for this commodity. Phenytoin bears US NLM identifiers UMLS ID C0031507 and NCI Concept Code C741. SMILES: O=C1NC(=O)NC1(C1CCCCC1)C1CCCCC1.
This classification denotes a cation channel blocker and anticonvulsant agent with the molecular formula C15H11N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4182431BJH, chemically known as 5,5-diphenylhydantoin sodium salt but more generally known as diphenylhydantoin sodium, which bears US NIH Compound Identifier 12425. European Medicines Agency schedules Phenytoin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03787MIG. Most nations, for tariff and trade purposes, schedule phenytoin sodium under HS 29332100 and SITC 51572. As of Q4 2014, PHENYTOIN SODIUM remains US FDA's Preferred Term for this commodity. Phenytoin sodium bears US NLM identifiers UMLS ID C0237417 and NCI Concept Code C48011. SMILES: C1CCC(CC1)C2(C(=O)[N-]C(=O)N2)C3CCCCC3.[NA+].
This classification denotes an indicator, reagent, antispasmodic, and trinitrobenzene with the molecular formula C6H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DHD7FFG6YS, chemically known as 1,3,5-triol but generally known as phloroglucinol, which bears US NIH Compound Identifier 359. European Medicines Agency schedules Phloroglucinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14845MIG. World Health Organization schedules phloroglucinol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PHLOROGLUCINOL remains the US FDA Preferred Term for this commodity. SMILES: OC1CC(O)CC(O)C1.
This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LPP64AWZ7L. European Medicines Agency schedules Pholcodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09795MIG. Pholcodine generally arises in the molecular formula C23H30N2O4. The term PHOLCODINE is an International Non-Proprietary Name or INN. PHOLCODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pholcodine under HS 29391100 and SITC 54141. As of Q4 2014, PHOLCODINE remains the US FDA Preferred Term for this commodity. Pholcodine bears US NLM identifiers UMLS ID C0070742 and NCI Concept Code C87365. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OCCN1CCOCC1)CC3)C=CC2O.
This classification denotes an adrenergic agent with the molecular formula C10H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AY28O44JGD, chemically known as p-hydroxy-n,alpha-dimethylphenethylamine but generally known as pholedrine, which bears US NIH Compound Identifier 4655. European Medicines Agency schedules Pholedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09796MIG. The term PHOLEDRINE is an International Non-Proprietary Name. PHOLEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pholedrine under HS 29222900 and SITC 51462. As of Q4 2014, PHOLEDRINE remains the US FDA Preferred Term for this commodity. Pholedrine bears US NLM identifiers UMLS ID C0070743 and NCI Concept Code C73067. SMILES: CC(CC1=CC=C(C=C1)O)NC.
This classification denotes an adrenergic agent with the molecular formula 2C10H15NO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WB6LNL73BR, chemically known as propane, 1-(p-hydroxyphenyl)-2-methylamino-, sulfate but more generally known as pholedrine sulfate, which bears US NIH Compound Identifier 93020. European Medicines Agency schedules Pholedrine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03790MIG. Most nations, for tariff and trade purposes, schedule pholedrine sulfate under HS 29222900 and SITC 51462. As of Q4 2014, PHOLEDRINE SULFATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCC(CC1)O)NC.CC(CC1CCC(CC1)O)NC.OS(=O)(=O)O.
This classification denotes an anti-lipidemic agent with the molecular formula C10H20NO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1109Z9J4N, chemically known as [(2R)-2,3-diformyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate, but generally known as phosphatidylcholine, which bears US NIH Compound Identifier 45266626. SMILES: C[N+](C)(C)CCOP(=O)([O-])OCC(COC=O)OC=O.
This classification denotes lipids containing one or more phosphate groups, particularly those derived from either glycerol or sphingosine, polar lipids that are of great importance for the structure and function of cell membranes and the most abundant of membrane lipids, although not stored in large amounts in the system.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C16H14N2O6S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 24PUW23GRX, chemically known as phthalanilic acid, 4-(acetylsulfamoyl)- but more generally known as phthalylsulfacetamide, which bears U.S. National Institutes of Health Compound Identifier 8574. The European Medicines Agency schedules Phthalylsulfacetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35390. SMILES: S(=O)(=O)(NC(=O)C)C1CCC(NC(=O)C2C(CCCC2)C(=O)O)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C17H14N4O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TAY5ZBM0MO, chemically known as 4-((5-methyl-1,3,4-thiadiazol-2-yl)sulfamoyl)phthalanilic acid but more generally known as phthalylsulfamethizole, which bears US NIH Compound Identifier 3047837. European Medicines Agency schedules Phthalylsulfamethizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09798MIG. The term PHTHALYLSULFAMETHIZOLE is an International Non-Proprietary Name. PHTHALYLSULFAMETHIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(NC1SC(NN1)C)C1CCC(NC(=O)C2C(CCCC2)C(=O)O)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C17H13N3O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6875L5852V, chemically known as sulfanilamide, n(sup 4)-(o-carboxybenzoyl)-n-2-thiazolyl- but generally known as phthalylsulfathiazole, which bears US NIH Compound Identifier 4806. European Medicines Agency schedules Phthalylsulfathiazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09799MIG. The term PHTHALYLSULFATHIAZOLE is an International Non-Proprietary Name. World Health Organization schedules phthalylsulfathiazole in its Anatomical Therapeutic Chemical (ATC) Classification. PHTHALYLSULFATHIAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phthalylsulfathiazole under HS 29350090 and SITC 51580. As of Q4 2014, PHTHALYLSULFATHIAZOLE remains the US FDA Preferred Term for this commodity. Phthalylsulfathiazole bears US NLM identifiers UMLS ID C0070975 and NCI Concept Code C80790. SMILES: S(=O)(=O)(NC1SCCN1)C1CCC(NC(=O)C2C(CCCC2)C(=O)O)CC1.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula 2C15H21N3O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G63V2J2N71, chemically known as pyrrolo(2,3-b)indole, 1,2,3,3a,8,8a-hexahydro-5-hydroxy-1,3a,8-trimethyl-, methylcarbamate (ester), (3as-cis)-, sulfate (2:1) but generally known as physostigmine sulfate, which bears US NIH Compound Identifier 6150. European Medicines Agency schedules Physostigmine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14866MIG. As of Q4 2014, PHYSOSTIGMINE remains the US FDA Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP105. This VA Drug Class (OP105) classifies this compound as belonging to the group ANTIGLAUCOMA COMBINATIONS, TOPICAL OPHTHALMIC.
Phytomenadione, also known as vitamin K₁ or phylloquinone, Vitamin K1 is a fat-soluble vitamin used to treat hemorrhagic conditions in infants and coumarin overdoses
This classification denotes an antidepressant agent with the molecular formula C17H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8M09P36809, chemically known as piperazine, 1-(phenylmethyl)-4-(2-pyridinylcarbonyl)- but generally known as piberaline, which bears US NIH Compound Identifier 65975. European Medicines Agency schedules Piberaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09804MIG. The term PIBERALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). PIBERALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piberaline under HS 29335995 and SITC 51576. As of Q4 2014, PIBERALINE remains the US FDA Preferred Term for this commodity. Piberaline bears US NLM identifiers UMLS ID C2347511 and NCI Concept Code C72828. SMILES: O=C(N1CCN(CC1)Cc1ccccc1)c1ncccc1.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C19H24N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4XRL9PL02Y, chemically known as 3-cyclobutene-1,2-dione, 3-amino-4-((4-((4-(1-piperidinylmethyl)-2-pyridinyl)oxy)-2-butenyl)amino)-, (z)- but generally known as pibutidine, which bears US NIH Compound Identifier 5282450. European Medicines Agency schedules Pibutidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09805MIG. The term PIBUTIDINE is an International Non-Proprietary Name. PIBUTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pibutidine under HS 29333999 and SITC 51574. As of Q4 2014, PIBUTIDINE remains the US FDA Preferred Term for this commodity. Pibutidine bears US NLM identifiers UMLS ID C2825480 and NCI Concept Code C81156. SMILES: O(C1NCCC(CN2CCCCC2)C1)C/C=C\CNC1=C(N)C(=O)C1=O.
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12L83YI68T. European Medicines Agency schedules Picafibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09806MIG. Picafibrate generally arises in the molecular formula C18H19CLN2O4. The term PICAFIBRATE is an International Non-Proprietary Name or INN. PICAFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule picafibrate under HS 29333999 and SITC 51574. As of Q4 2014, PICAFIBRATE remains the US FDA Preferred Term for this commodity. Picafibrate bears US NLM identifiers UMLS ID C0071029 and NCI Concept Code C72993. SMILES: Clc1ccc(OC(C)(C)C(=O)OCCNC(=O)c2cccnc2)cc1.
This classification denotes an opioid receptor agonist with the molecular formula C16H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TV3535QWTJ, chemically known as phenol, 3-(1,3-dimethyl-4-propyl-4-piperidinyl)-, trans-(+-)- but generally known as picenadol, which bears US NIH Compound Identifier 53077. European Medicines Agency schedules Picenadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09808MIG. The term PICENADOL is an International Non-Proprietary Name. PICENADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule picenadol under HS 29333999 and SITC 51574. As of Q4 2014, PICENADOL remains the US FDA Preferred Term for this commodity. Picenadol bears US NLM identifiers UMLS ID C0137018 and NCI Concept Code C84057. SMILES: OC1CC(C2(C(CN(CC2)C)C)CCC)CCC1.
This classification denotes an opioid receptor agonist C16H25NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29610N9WR1, chemically known as phenol, 3-(1,3-dimethyl-4-propyl-4-piperidinyl)-, hydrochloride, (+/-)-trans-, but more generally known as picenadol hydrochloride, which bears US NIH Compound Identifier 6917662. Most nations, for tariff and trade purposes, schedule picenadol hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PICENADOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Picenadol hydrochloride bears US NLM identifiers UMLS ID C2698802 and NCI Concept Code C76852. SMILES: CCC[C@]1(CCN(C[C@H]1C)C)C2CCCC(C2)O.CL.
This classification denotes an anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S8K2JDR3NZ. European Medicines Agency schedules Picilorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09809MIG. Picilorex generally arises in the molecular formula C14H18CLN. The term PICILOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, no. 10 1979, list 19.) PICILOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule picilorex under HS 29339990 and SITC 51577. As of Q4 2014, PICILOREX remains US FDA's Preferred Term for this commodity. Picilorex bears US NLM identifiers UMLS ID C2698803 and NCI Concept Code C75116. SMILES: CLC1CCC(C2CC(NC2C)C2CC2)CC1.
This classification denotes an antihypertensive agent with the molecular formula C14H17Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R7P4D56J1Z, chemically known as (+-)-2-(2,6-dichloro-n-(tetrahydro-2h-pyran-2-yl)anilino)-2-imidazoline but generally known as piclonidine, which bears US NIH Compound Identifier 68914. European Medicines Agency schedules Piclonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09811MIG. The term PICLONIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). PICLONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piclonidine under HS 29349990 and SITC 51579. As of Q4 2014, PICLONIDINE remains the US FDA Preferred Term for this commodity. Piclonidine bears US NLM identifiers UMLS ID C1882374 and NCI Concept Code C66381. SMILES: Clc1c(N(C2OCCCC2)C2=NCCN2)c(Cl)ccc1.
This classification denotes a topical anti-infective agent with the molecular formula C20H24Cl2N10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4YC2PY3AEU, chemically known as 1,1-(1,4-piperazinediylbis(imidocarbonyl))bis(3-(p-chlorophenyl)guanidine) but more generally known as picloxydine, which bears US NIH Compound Identifier 5748610. European Medicines Agency schedules Picloxydine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09813MIG. The term PICLOXYDINE is an International Non-Proprietary Name. The World Health Organization schedules picloxydine in its Anatomical Therapeutic Chemical (ATC) Classification. PICLOXYDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1CCC(/N=C(/N=C(\N2CCN(CC2)/C(=N\C(=N\C2CCC(CL)CC2)N)N)N)N)CC1.
This classfication denotes a topical anti-infective agent with the molecular formula C20H24Cl2N10.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WZK4CO345V, chemically known as 1,1'-(1,4-piperazinediylbis(imidocarbonyl))bis(3-(p-chlorophenyl)guanidine) dihydrochloride, but more generally known as picloxydine dihydrochloride, which bears US NIH Compound Identifier 9578346. European Medicines Agency schedules picloxydine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09813MIG. Most nations, for tariff purposes, schedule picloxydine dihydrochloride under HS 29335995. SMILES: C1CC(CCC1NC(=N)NC(=N)N2CCN(CC2)C(=N)NC(=N)NC3CCC(CC3)CL)CL.CL.CL.
This classification denotes an antipsychotic agent with the molecular formula C15H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C46317G8F0, chemically known as 3,5-dimethyl-n-pyridin-4-ylmethyl-benzamide but generally known as picobenzide, which bears US NIH Compound Identifier 40146. European Medicines Agency schedules Picobenzide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09814MIG. The term PICOBENZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). PICOBENZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule picobenzide under HS 29333999 and SITC 51574. As of Q4 2014, PICOBENZIDE remains the US FDA Preferred Term for this commodity. Picobenzide bears US NLM identifiers UMLS ID C0137024 and NCI Concept Code C76443. SMILES: O=C(NCC1CCNCC1)C1CC(CC(C1)C)C.
This classification denotes an antitussive agent with the molecular formula C19H25N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) YK3XA0K1O1, chemically known as 2-pyridinemethanamine, n-phenyl-n-(2-(1-piperidinyl)ethyl)- (9ci) but more generally known as picoperine, which bears US NIH Compound Identifier 65701. European Medicines Agency schedules Picoperine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09818MIG. The term PICOPERINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). PICOPERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule picoperine under HS 29333999 and SITC 51574. As of Q4 2014, PICOPERINE remains US FDA's Preferred Term for this commodity. Picoperine bears US NLM identifiers UMLS ID C2698806 and NCI Concept Code C76476. SMILES: N1(CCCCC1)CCN(CC1NCCCC1)C1CCCCC1.
This classification denotes a platinum compound with the molecular structure C6H7N.2CL.PT.H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, B5TAN0L720 chemically known as platinum, amminedichloro(2-methylpyridine)-, (sp-4-3)-, but more commonly known as picoplatin, which bears US NIH Compound Identifier 177358. European Medicines Agency schedules Picoplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29605. The term PICOPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49). Picoplatin bears US NLM identifiers UMLS ID C0671135 and NCI Concept Code C48416. Most nations, for tariff and trade purposes, schedule picoplatin under HS 28439000 and SITC 52432. SMILES: CC1CCCCN1.N.[CL-].[CL-].[PT+2].
This classification denotes a laxative with the molecular formula C18H13NO8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LR57574HN8, chemically known as 4,4-(2-pyridylmethylene)diphenolbis(hydrogen sulfate) (ester) but generally known as picosulfate, which bears US NIH Compound Identifier 68654. European Medicines Agency schedules Picosulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10569MIG. The term PICOSULFATE is an International Non-Proprietary Name. World Health Organization schedules picosulfate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)[O-])C3=CC=C(C=C3)OS(=O)(=O)[O-].[Na+].[Na+].
This classification denotes an antiplatelet agent with the molecular formula C21H20N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 654G2VCI4Q, chemically known as 1,3-benzenedicarboxamide, n,n-bis(3-pyridinylmethyl)-4-methoxy- but generally known as picotamide, which bears US NIH Compound Identifier 4814. European Medicines Agency schedules Picotamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14868MIG. World Health Organization schedules picotamide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PICOTAMIDE remains the US FDA Preferred Term for this commodity. Picotamide bears US NLM identifiers UMLS ID C0071043 and NCI Concept Code C73157. SMILES: O(C1C(CC(CC1)C(=O)NCC1CCCNC1)C(=O)NCC1CCCNC1)C. .
This classification denotes a beta-adrenergic agonist with the molecular formula C21H29CL2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 86WEQ311WF chemically known as benzenemethanol, 4-amino-3,5-dichloro-.alpha.-(((6-(2-(2-pyridinyl)ethoxy)hexyl)amino)methyl)-, (r)- but generally known as picumeterol, which bears US NIH Compound Identifier 131251. European Medicines Agency schedules Picumeterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09822MIG. The term PICUMETEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31). Most nations schedule picumeterol under HS 29333999 and SITC 51574. As of Q4 2014, PICUMETEROL remains the US FDA Preferred Term for this commodity. Picumeterol bears US NLM identifiers UMLS ID C0385780 and NCI Concept Code C76543. SMILES: C1=CC=NC(=C1)CCOCCCCCCNCC(C2=CC(=C(C(=C2)CL)N)CL)O.
This classification denotes a beta-adrenergic agonist with the molecular formula 2C21H29Cl2N3O2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0SUN4UF93Y, chemically known as benzenemethanol, 4-amino-3,5-dichloro-alpha-(((6-(2-(2-pyridinyl)ethoxy)hexyl)amino)methyl)-, (r)-, (e)-2-butenedioate (2:1) (salt); but more generally known as picumeterol fumarate, which bears US NIH Compound Identifier 6446658. Most nations, for tariff and trade purposes, schedule picumeterol fumarate under HS 29333999 and SITC 51574. As of Q4 2014, PICUMETEROL FUMARATE remains US FDA's Preferred Term for this commodity. Picumeterol fumarate bears US NLM identifiers UMLS ID C0385779 and NCI Concept Code C76544. SMILES: C1CCNC(C1)CCOCCCCCCNC[C@@H](C2CC(C(C(C2)CL)N)CL)O.C1CCNC(C1)CCOCCCCCCNC[C@@H](C2CC(C(C(C2)CL)N)CL)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes an agent affecting integumentary system with the molecular formula C11H11NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7D2GSX1C1, chemically known as 5-oxo-l-proline, p-hydroxyphenyl ester but generally known as pidobenzone, which bears US NIH Compound Identifier 3047843. European Medicines Agency schedules Pidobenzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09823MIG. The term PIDOBENZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). PIDOBENZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pidobenzone under HS 29337900 and SITC 51561. As of Q4 2014, PIDOBENZONE remains the US FDA Preferred Term for this commodity. Pidobenzone bears US NLM identifiers UMLS ID C2604951 and NCI Concept Code C76886. SMILES: C1CC(=O)NC1C(=O)OC2=CC=C(C=C2)O.
This classification denotes an analgesic and antipyretic with the molecular formula C13H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 693SRA99OH, chemically known as 5-oxo-l-proline, ester with 4-hydroxyacetanilide but generally known as pidolacetamol, which bears US NIH Compound Identifier 65920. European Medicines Agency schedules Pidolacetamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09824MIG. The term PIDOLACETAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). PIDOLACETAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pidolacetamol under HS 29337900 and SITC 51561. As of Q4 2014, PIDOLACETAMOL remains the US FDA Preferred Term for this commodity. Pidolacetamol bears US NLM identifiers UMLS ID C2698807 and NCI Concept Code C75080. SMILES: O(C(=O)C1NC(=O)CC1)C1CCC(NC(=O)C)CC1.
This classification denotes an immunostimulant with the molecular formula C9H12N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 785363R681, chemically known as 4-thiazolidinecarboxylic acid, 3-((5-oxo-2-pyrrolidinyl)carbonyl)-, (r-(r*,s*))- but generally known as pidotimod, which bears US NIH Compound Identifier 65944. European Medicines Agency schedules Pidotimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09826MIG. The term PIDOTIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules pidotimod in its Anatomical Therapeutic Chemical (ATC) Classification. PIDOTIMOD is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pidotimod under HS 29341000 and SITC 51579. As of Q4 2014, PIDOTIMOD remains the US FDA Preferred Term for this commodity. Pidotimod bears US NLM identifiers UMLS ID C0081002 and NCI Concept Code C76686. SMILES: S1CC(N(C(=O)C2NC(=O)CC2)C1)C(=O)O.
This classification denotes an anti-ulcer agent with the molecular formula C27H40N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3W85193GZ4, chemically known as 4-farnesyl-1-(3,4-methylenedioxybenzyl)piperazine but generally known as pifarnine, which bears US NIH Compound Identifier 6436032. European Medicines Agency schedules Pifarnine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09827MIG. The term PIFARNINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). PIFARNINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pifarnine under HS 29349990 and SITC 51579. As of Q4 2014, PIFARNINE remains the US FDA Preferred Term for this commodity. Pifarnine bears US NLM identifiers UMLS ID C0071052 and NCI Concept Code C76487. SMILES: O1C2CC(CN3CCN(CC3)C/C=C(/CC/C=C(/CC/C=C(/C)C)C)C)CCC2OC1.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362QBC4NL0. European Medicines Agency schedules Piketoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09832MIG. Piketoprofen generally arises in the molecular formula C22H20N2O2. The term PIKETOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) PIKETOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piketoprofen under HS 29333999 and SITC 51574. As of Q4 2014, PIKETOPROFEN remains the US FDA Preferred Term for this commodity. Piketoprofen bears US NLM identifiers UMLS ID C0285260 and NCI Concept Code C73091. SMILES: O=C(NC1NCCC(C1)C)C(C1CC(CCC1)C(=O)C1CCCCC1)C.
This classification denotes a nonsteroidal antiinflammatory drug C22H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0743PU79JW, chemically known as benzeneacetamide, 3-benzoyl-.alpha.-methyl-n-(4-methyl-2-pyridinyl)-, hydrochloride (1:1), but more generally known as piketoprofen hydrochloride, which bears US NIH Compound Identifier 46174105. European Medicines Agency schedules Piketoprofen hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22652. Most nations, for tariff and trade purposes, schedule piketoprofen hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PIKETOPROFEN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCNC(C1)NC(=O)C(C)C2CCCC(C2)C(=O)C3CCCCC3.CL.
This classification denotes a vasodilating agent with the molecular formula C8H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FU2BGC781U, chemically known as 3(2h)-pyridazinone, 6-((2-hydroxypropyl)methylamino)-, hydrazone but generally known as pildralazine, which bears US NIH Compound Identifier 68829. European Medicines Agency schedules Pildralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09833MIG. The term PILDRALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). PILDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pildralazine under HS 29339990 and SITC 51577. As of Q4 2014, PILDRALAZINE remains the US FDA Preferred Term for this commodity. Pildralazine bears US NLM identifiers UMLS ID C0072178 and NCI Concept Code C66383. SMILES: OC(CN(c1nnc(NN)cc1)C)C.
This classification denotes a cholinergic agonist with the molecular formula C11H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01MI4Q9DI3, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, (3s-cis)- but generally known as pilocarpine, which bears US NIH Compound Identifier 5910. European Medicines Agency schedules Pilocarpine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03818MIG. World Health Organization schedules pilocarpine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule pilocarpine under HS 29399990 and SITC 54149. As of Q4 2014, PILOCARPINE remains the US FDA Preferred Term for this commodity. Pilocarpine bears US NLM identifiers UMLS ID C0031923 and NCI Concept Code C62068. SMILES: CCC1C(COC1=O)CC2=CN=CN2C.
This classification denotes a cholinergic agonist with the molecular formula C11H16N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0WW6D218XJ, chemically known as 3-isopilocarpine, monohydrochloride but more generally known as pilocarpine hydrochloride, which bears US NIH Compound Identifier 4819. European Medicines Agency schedules Pilocarpine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14870MIG. Most nations, for tariff and trade purposes, schedule pilocarpine hydrochloride under HS 29399990 and SITC 54149. As of Q4 2014, PILOCARPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pilocarpine hydrochloride bears US NLM identifiers UMLS ID C0770456 and NCI Concept Code C748. SMILES: CC[C@H]1[C@H](COC1=O)CC2CNCN2C.CL.
This classification denotes a cholinergic agonist with the molecular formula C11H16N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0WW6D218XJ, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, monohydrochloride, (3s,4r)-, but more generally known as pilocarpine monohydrochloride, which bears US NIH Compound Identifier 4819. European Medicines Agency schedules pilocarpine monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03818MIG. Most nations, for tariff purposes, schedule pilocarpine monohydrochloride under HS 29399990. SMILES: CC[C@H]1[C@H](COC1=O)CC2CNCN2C.CL.
This classification denotes a cholinergic agonist with the molecular formula C11H16N2O2.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M20T465H6J, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, (3s-cis)-, mononitrate, but more generally known as pilocarpine mononitrate, which bears US NIH Compound Identifier 83930. European Medicines Agency schedules pilocarpine mononitrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03818MIG. Most nations, for tariff purposes, schedule pilocarpine mononitrate under HS 29399990. SMILES: CC[C@H]1[C@H](COC1=O)CC2CNCN2C.[N+](=O)(O)[O-].
This classification denotes a cholinergic agonist with the molecular formula C11H16N2O2.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M20T465H6J, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, (3s-cis)-, mononitrate but more generally known as pilocarpine nitrate, which bears US NIH Compound Identifier 83930. European Medicines Agency schedules Pilocarpine nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03821MIG. Most nations, for tariff and trade purposes, schedule pilocarpine nitrate under HS 29399990 and SITC 54149. As of Q4 2014, PILOCARPINE NITRATE remains US FDA's Preferred Term for this commodity. Pilocarpine nitrate bears US NLM identifiers UMLS ID C0351975 and NCI Concept Code C91038. SMILES: CC[C@H]1[C@H](COC1=O)CC2CNCN2C.[N+](=O)(O)[O-].
This classification denotes an antiarrhythmic agent with the molecular formula C17H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) AV0X7V6CSE, chemically known as 1h-pyrrolizine-7a(5h)-acetamide, n-(2,6-dimethylphenyl)tetrahydro- but more generally known as pilsicainide, which bears US NIH Compound Identifier 4820. European Medicines Agency schedules Pilsicainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09834MIG. The term PILSICAINIDE is an International Non-Proprietary Name. PILSICAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pilsicainide under HS 29339990 and SITC 51577. As of Q4 2014, PILSICAINIDE remains US FDA's Preferred Term for this commodity. Pilsicainide bears US NLM identifiers UMLS ID C0164155 and NCI Concept Code C72582. SMILES: O=C(NC1C(CCCC1C)C)CC12N(CCC1)CCC2.
This classification denotes an antiarrhythmic agent with the molecular structure C17H24N2O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 03C8I9296V chemically known as 1h-pyrrolizine-7a(5h)-acetamide, n-(2,6-dimethylphenyl)tetrahydro-, hydrochloride (1:1), but more commonly known as pilsicainide hydrochloride, which bears US NIH Compound Identifier 114817. European Medicines Agency schedules Pilsicainide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03822MIG. Most nations, for tariff and trade purposes, schedule pilsicainide hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, PILSICAINIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCCC(C1NC(=O)CC23CCCN2CCC3)C.CL.
This classification denotes an immunosuppressant with the molecular formula C43H68ClNO11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7KYV510875, chemically known as 15,19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-, (3s-(3r*(e(1s*,3s*,4r*)),4s*,5r*,8s*,9e,12r*,14r*,15s*,16r*,18s*,19s*,26ar*))- but more generally known as pimecrolimus, which bears US NIH Compound Identifier 6447131. European Medicines Agency schedules Pimecrolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16457MIG. The term PIMECROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules pimecrolimus in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule pimecrolimus under HS 29349990 and SITC 51579. As of Q4 2014, PIMECROLIMUS remains US FDA's Preferred Term for this commodity. Pimecrolimus bears US NLM identifiers UMLS ID C1099414 and NCI Concept Code C47671. SMILES: CLC1C(OC)CC(CC1)/C=C(/C1OC(=O)C2N(C(=O)C(=O)C3(OC(C(OC)CC3C)C(OC)CC(CC(=CC(C(=O)CC(O)C1C)CC)C)C)O)CCCC2)C.
This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C15H18N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8680B5Y37A, chemically known as 3,7-dihydro-1,3-dimethyl-7-(2-((3-pyridinylmethyl)amino)ethyl)-1h-purine-2,6-dione but generally known as pimefylline, which bears US NIH Compound Identifier 65597. European Medicines Agency schedules Pimefylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09837MIG. The term PIMEFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). PIMEFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pimefylline under HS 29395900 and SITC 54145. As of Q4 2014, PIMEFYLLINE remains the US FDA Preferred Term for this commodity. Pimefylline bears US NLM identifiers UMLS ID C1882379 and NCI Concept Code C66384. SMILES: O=c1n(c(=O)n(c2ncn(c12)CCNCc1cccnc1)C)C.
This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C15H18N6O2.C6H5NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y694512DA, chemically known as nicotinic acid, compd. with 7-(2-((3-pyridylmethyl)amino)ethyl)theophylline (1:1), but more generally known as pimefylline nicotinate, which bears US NIH Compound Identifier 197889. European Medicines Agency schedules pimefylline nicotinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09837MIG. Most nations, for tariff purposes, schedule pimefylline nicotinate under HS 29395900. SMILES: CN1C2C(C(=O)N(C1=O)C)N(CN2)CCNCC3CCCNC3.C1CC(CNC1)C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z6RX3C7B5V. European Medicines Agency schedules Pimetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09839MIG. Pimetacin generally arises in the molecular formula C25H21CLN2O3S. The term PIMETACIN is an International Non-Proprietary Name or INN. PIMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pimetacin under HS 29333999 and SITC 51574. As of Q4 2014, PIMETACIN remains the US FDA Preferred Term for this commodity. Pimetacin bears US NLM identifiers UMLS ID C1882380 and NCI Concept Code C66385. SMILES: CLC1CCC(C(=O)N2C(C(C3C2CCC(OC)C3)CC(=O)SCC2CCCNC2)C)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T46J20J26F, chemically known as piperidine, 1-methyl-4-thioxanthen-9-ylidene- but generally known as pimethixene, which bears US NIH Compound Identifier 4822. European Medicines Agency schedules Pimethixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09840MIG. The term PIMETHIXENE is an International Non-Proprietary Name. World Health Organization schedules pimethixene in its Anatomical Therapeutic Chemical (ATC) Classification. PIMETHIXENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pimethixene under HS 29349990 and SITC 51579. As of Q4 2014, PIMETHIXENE remains the US FDA Preferred Term for this commodity. Pimethixene bears US NLM identifiers UMLS ID C0071069 and NCI Concept Code C82276. SMILES: S1C2C(/C(=C3/CCN(CC3)C)C3C1CCCC3)CCCC2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U22U244M9X, chemically known as thioxanthene, 9-(1-methyl-4-piperidylene)-, maleate but more generally known as pimethixene maleate, which bears US NIH Compound Identifier 5702167. Most nations, for tariff and trade purposes, schedule pimethixene maleate under HS 29349990 and SITC 51579. As of Q4 2014, PIMETHIXENE MALEATE remains US FDA's Preferred Term for this commodity. Pimethixene maleate bears US NLM identifiers UMLS ID C3273580 and NCI Concept Code C97703. SMILES: CN1CCC(=C2C3CCCCC3SC4C2CCCC4)CC1.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antispasmotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VY58MWL7J. European Medicines Agency schedules Pimetremide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09842MIG. Pimetremide generally arises in the molecular formula C16H18N2O2. The term PIMETREMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) PIMETREMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pimetremide under HS 29333999 and SITC 51574. As of Q4 2014, PIMETREMIDE remains the US FDA Preferred Term for this commodity. Pimetremide bears US NLM identifiers UMLS ID C1882381 and NCI Concept Code C66386. SMILES: OCC(C(=O)N(CC1CCCNC1)C)C1CCCCC1.
This classification denotes an opioid receptor agonist with the molecular formula C23H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 3IIX447HWS chemically known as 4-piperidinecarboxylic acid, 4-phenyl-1-(3-(phenylamino)propyl)-, ethyl ester but generally known as piminodine, which bears US NIH Compound Identifier 21950. European Medicines Agency schedules Piminodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09844MIG. The term PIMINODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4). Most nations schedule piminodine under HS 29333999 and SITC 51574. As of Q4 2014, PIMINODINE remains the US FDA Preferred Term for this commodity. Piminodine bears US NLM identifiers UMLS ID C0301398 and NCI Concept Code C84060. SMILES: CCOC(=O)C1(CCN(CC1)CCCNC2=CC=CC=C2)C3=CC=CC=C3.
This classification denotes an opioid receptor agonist with the molecular formula C23H30N2O2.C2H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2C29WCQ951, chemically known as 4-piperidinecarboxylic acid, 4-phenyl-1-(3-(phenylamino)propyl)-, ethyl ester but more generally known as piminodine esylate, which bears US NIH Compound Identifier 21950. Most nations, for tariff and trade purposes, schedule piminodine esylate under HS 29333999 and SITC 51574. As of Q4 2014, PIMINODINE ESYLATE remains US FDA's Preferred Term for this commodity. Piminodine esylate bears US NLM identifiers UMLS ID C1321936 and NCI Concept Code C80987. SMILES: CCOC(=O)C1(CCN(CC1)CCCNC2CCCCC2)C3CCCCC3.CCS(=O)(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C28H29F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HIZ4DL86F, chemically known as 2h-benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- but generally known as pimozide, which bears US NIH Compound Identifier 16362. European Medicines Agency schedules Pimozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09847MIG. The term PIMOZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules pimozide in its Anatomical Therapeutic Chemical (ATC) Classification. PIMOZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pimozide under HS 29333999 and SITC 51574. As of Q4 2014, PIMOZIDE remains the US FDA Preferred Term for this commodity. Pimozide bears US NLM identifiers UMLS ID C0031935 and NCI Concept Code C47672. SMILES: FC1CCC(C(CCCN2CCC(N3C4C([NH]C3=O)CCCC4)CC2)C2CCC(F)CC2)CC1.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Y05905N7G and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29821 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Apiaceae, Genus Pimpinella L. (burnet saxifrage), commonly known as PIMPINELLA SAXIFRAGE. Pimpinella saxifrage bears the USDA PLANTS Database Identifier PIMPI. European Medicines Agency schedules pimpinella saxifrage in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14872MIG. There are also varieties anisum (UNII HO63CL229O), brachycarpa (UNII V6A87V4AML), and major (UNII 8O53J9196C). SMILES: CC=CC1=CC=C(C=C1)OC.CC1C(C(C(C(O1)OCC2C(C(C(C(O2)O)O)O)O)O)O)O.C1=CC=C2C(=C1)C=CC(=O)O2.C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O.
This classification denotes an antihypertensive agent with the molecular formula C13H19N5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7B0ZZH8P2W, chemically known as 2-cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine but generally known as pinacidil, which bears US NIH Compound Identifier 4826. European Medicines Agency schedules Pinacidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09848MIG. World Health Organization schedules pinacidil in its Anatomical Therapeutic Chemical (ATC) Classification. PINACIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pinacidil under HS 29333999 and SITC 51574. As of Q4 2014, PINACIDIL remains the US FDA Preferred Term for this commodity. Pinacidil bears US NLM identifiers UMLS ID C0071074 and NCI Concept Code C66387. SMILES: N(=C(\Nc1ccncc1)NC#N)/C(C(C)(C)C)C.
This classification denotes a gastrointestinal drug with the molecular formula C26H41BrNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U2368VVE7O, chemically known as 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium, and which bears US NIH Compound Identifier 40704. European Medicines Agency schedules PINAVERIUM in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03826MIG. As of Q4 2014, PINAVERIUM remains the US FDA Preferred Term for this commodity. SMILES: CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C.
Non-atropinic antispasmodic which is used for analgesia and correction of the altered gastrointestinal transit. It acts as calcium channel blocker over the muscle fiber of the digestive tract. It dicreases the acid quantity without either modifying the gastric secretion volume or accelerating the gastric evacuation.
This classification denotes a benzodiazepine with the molecular formula C18H13ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5286RBZ882, chemically known as 7-chloro-2,3-dihydro-5-phenyl-1-propargyl-1h-1,4-benzodiazepin-2-one but generally known as pinazepam, which bears US NIH Compound Identifier 40391. European Medicines Agency schedules Pinazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09852MIG. The term PINAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules pinazepam in its Anatomical Therapeutic Chemical (ATC) Classification. PINAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pinazepam under HS 29339190 and SITC 51577. As of Q4 2014, PINAZEPAM remains the US FDA Preferred Term for this commodity. Pinazepam bears US NLM identifiers UMLS ID C0071082 and NCI Concept Code C66388. SMILES: CLC1CC2C(N(C(=O)CN=C2C2CCCCC2)CC#C)CC1.
This classification denotes an antiarrhythmic agent and anesthetic agent with the molecular formula C16H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 66803GMO3G, chemically known as 2,3,4,5,6,7-hexahydro-1h-azepine-1-aceto-2,6-xylidide but more generally known as pincainide, which bears US NIH Compound Identifier 71267. European Medicines Agency schedules Pincainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09853MIG. The term PINCAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). Most nations, for tariff and trade purposes, schedule pincainide under HS 29339930 and SITC 51577. As of Q4 2014, PINCAINIDE remains US FDA's Preferred Term for this commodity. Pincainide bears US NLM identifiers UMLS ID C0137074 and NCI Concept Code C66389. SMILES: O=C(NC1C(CCCC1C)C)CN1CCCCCC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BJ4HF6IU1D, chemically known as 2-propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-, (+-)- but generally known as pindolol, which bears US NIH Compound Identifier 4828. European Medicines Agency schedules Pindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09854MIG. The term PINDOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules pindolol in its Anatomical Therapeutic Chemical (ATC) Classification. PINDOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pindolol under HS 29339990 and SITC 51577. As of Q4 2014, PINDOLOL remains the US FDA Preferred Term for this commodity. Pindolol bears US NLM identifiers UMLS ID C0031937 and NCI Concept Code C47673. SMILES: O(CC(O)CNC(C)C)C1C2C([NH]CC2)CCC1.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YFH4WC535J, a viscous substance obtained from species that Integrated Taxonomic Information System classifies under Taxonomic Serial Number 506603 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Gymnospermae, Class Pinopsida, Order Pinales, Family Pinaceae (pines), Genus Pinus L., commonly known as PINE or PINE TREES. Pine tar is specifically extracted from pinus palustri (ITIS 18038). European Medicines Agency schedules pine tar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14874MIG.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S0U059XF2E. European Medicines Agency schedules Pinolcaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09855MIG. Pinolcaine generally arises in the molecular formula C23H29NO2. The term PINOLCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) PINOLCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pinolcaine under HS 29333999 and SITC 51574. As of Q4 2014, PINOLCAINE remains the US FDA Preferred Term for this commodity. Pinolcaine bears US NLM identifiers UMLS ID C2698813 and NCI Concept Code C75102. SMILES: O(C(C1N(CCCC1)C)(C)C)C(=O)C(C1CCCCC1)C1CCCCC1.
This classification denotes a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3YKO9X8N8. European Medicines Agency schedules Pinoxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09856MIG. Pinoxepin generally arises in the molecular formula C23H27CLN2O2. The term PINOXEPIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) PINOXEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pinoxepin under HS 29349990 and SITC 51579. As of Q4 2014, PINOXEPIN remains the US FDA Preferred Term for this commodity. Pinoxepin bears US NLM identifiers UMLS ID C2827300 and NCI Concept Code C84062. SMILES: CLC1CC2C(=C\CCN3CCN(CC3)CCO)/C3C(COC2CC1)CCCC3.
This classification denotes a dopamine antagonist C23H27ClN2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7KE5R66TSY, chemically known as (z)-4-(3-(2-chlorodibenz(b,e)oxepin-11-(6h)-ylidene)propyl)-1-piperazineethanol dihydrochloride, but more generally known as pinoxepin hydrochloride, which bears US NIH Compound Identifier 6433591. Most nations, for tariff and trade purposes, schedule pinoxepin hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, PINOXEPIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pinoxepin hydrochloride bears US NLM identifiers UMLS ID C2698814 and NCI Concept Code C76653. SMILES: C1CCC\2C(C1)COC3CCC(CC3/C2=C\CCN4CCN(CC4)CCO)CL.CL.CL.
This classification denotes an anti-diabetic agent with the molecular formula C19H20N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) X4OV71U42S, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)- but more generally known as pioglitazone, which bears US NIH Compound Identifier 4829. European Medicines Agency schedules Pioglitazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09857MIG. The term PIOGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29) WHO schedules pioglitazone in its Anatomical Therapeutic Chemical (ATC) Classification. PIOGLITAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pioglitazone under HS 29341000 and SITC 51579. As of Q4 2014, PIOGLITAZONE remains US FDA's Preferred Term for this commodity. Pioglitazone bears US NLM identifiers UMLS ID C0071097 and NCI Concept Code C71633. SMILES: S1C(CC2CCC(OCCC3NCC(CC)CC3)CC2)C(=O)NC1=O.
This classification denotes a hypoglycemic agent with the molecular formula C19H20N2O3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JQT35NPK6C, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)- but more generally known as pioglitazone hydrochloride, which bears US NIH Compound Identifier 4829. European Medicines Agency schedules Pioglitazone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03834MIG. Most nations, for tariff and trade purposes, schedule pioglitazone hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, PIOGLITAZONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pioglitazone hydrochloride bears US NLM identifiers UMLS ID C0872972 and NCI Concept Code C29367. SMILES: CCC1CCC(NC1)CCOC2CCC(CC2)CC3C(=O)NC(=O)S3.CL.
This classification denotes a tetracycline antibiotic with the molecular formula C29H38N4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, PQ3P6082I5 chemically known as 4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-penta-hydroxy-n-((4-(2-hydroxyethyl)-1-piperazinyl)methyl)-6-methyl-1,11-dioxo-2-naphthacenecarboxamide but generally known as pipacycline, which bears US NIH Compound Identifier 5357020. European Medicines Agency schedules Pipacycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09858MIG. The term PIPACYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5. ). Most nations schedule pipacycline under HS 29413000 and SITC 54133. As of Q4 2014, PIPACYCLINE remains the US FDA Preferred Term for this commodity. Pipacycline bears US NLM identifiers UMLS ID C1882382 and NCI Concept Code C66391. SMILES: OC12C(CC3C(O)(C4C(C(=C3C1=O)O)C(O)CCC4)C)C(N(C)C)C(=O)C(=C(\O)NCN1CCN(CC1)CCO)\C2=O.
This classification denotes an antiemetic agent with the molecular formula C21H24ClN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 653552FH1N, chemically known as isonipecotamide, 1-(3-(2-chlorophenothiazin-10-yl)propyl)- but generally known as pipamazine, which bears US NIH Compound Identifier 6761. European Medicines Agency schedules Pipamazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09859MIG. The term PIPAMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). PIPAMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pipamazine under HS 29343090 and SITC 51578. As of Q4 2014, PIPAMAZINE remains the US FDA Preferred Term for this commodity. Pipamazine bears US NLM identifiers UMLS ID C0301468 and NCI Concept Code C81501. SMILES: CLC1CC2N(CCCN3CCC(CC3)C(=O)N)C3C(SC2CC1)CCCC3.
This classification denotes an anxiolytic with the molecular formula C21H30FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5402501F0W, chemically known as 1-(3-(p-fluorobenzoyl)propyl)-(1,4-bipiperidine)-4-carboxamide but generally known as pipamperone, which bears US NIH Compound Identifier 4830. European Medicines Agency schedules Pipamperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09860MIG. The term PIPAMPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules pipamperone in its Anatomical Therapeutic Chemical (ATC) Classification. PIPAMPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pipamperone under HS 29333999 and SITC 51574. As of Q4 2014, PIPAMPERONE remains the US FDA Preferred Term for this commodity. Pipamperone bears US NLM identifiers UMLS ID C0071098 and NCI Concept Code C73297. SMILES: FC1CCC(C(=O)CCCN2CCC(N3CCCCC3)(CC2)C(=O)N)CC1.
This classification denotes an anxiolytic with the molecular formula C21H30FN3O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IT085U64JB, chemically known as 1'-(3-(p-fluorobenzoyl)propyl)-(1,4'-bipiperidine)-4'-carboxamide dihydrochloride, but more generally known as pipamperone dihydrochloride, which bears US NIH Compound Identifier 17139. European Medicines Agency schedules pipamperone dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09860MIG. Most nations, for tariff purposes, schedule pipamperone dihydrochloride under HS 29333999. SMILES: C1CC(CCC1C(=O)CCCN2CCC(CC2)(C(=O)N)N3CCCCC3)F.CL.CL.
This classification denotes an anxiolytic with the molecular formula C21H30FN3O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IT085U64JB, chemically known as 1-(3-(p-fluorobenzoyl)propyl)-(1,4-bipiperidine)-4-carboxamide but more generally known as pipamperone hydrochloride, which bears US NIH Compound Identifier 4830. European Medicines Agency schedules Pipamperone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03835MIG. Most nations, for tariff and trade purposes, schedule pipamperone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PIPAMPERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1C(=O)CCCN2CCC(CC2)(C(=O)N)N3CCCCC3)F.CL.CL.
This classification denotes an antitussive agent with the molecular formula C21H25N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M5EK1T5V2L, chemically known as 10h-pyrido(3,2-b)(1,4)benzothiazine-10-carboxylic acid, 2-(2-piperidinoethoxy)ethyl ester but more generally known as pipazetate, which bears US NIH Compound Identifier 22425. European Medicines Agency schedules Pipazetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09861MIG. The term PIPAZETATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules pipazetate in its Anatomical Therapeutic Chemical (ATC) Classification. PIPAZETATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pipazetate or pipazethate bears US NLM identifiers UMLS ID C0071099 and NCI Concept Code C82252. SMILES: C1CCN(CC1)CCOCCOC(=O)N2C3=CC=CC=C3SC4=C2N=CC=C4.
This classification denotes a muscle relaxant with the molecular formula C35H62N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6ZTY81RE1, chemically known as 4,4-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1,1-dimethylpiperazinium)dibromide, diacetate (ester) but generally known as pipecurium bromide, which bears US NIH Compound Identifier 65332. European Medicines Agency schedules Pipecuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14880MIG. The term PIPECURONIUM BROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules pipecurium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PIPECURONIUM remains the US FDA Preferred Term for this commodity. Pipecuronium bears US NLM identifiers UMLS ID C0071102 and NCI Concept Code C77368. SMILES: CC(=O)OC1CC2CCC3C(C2(CC1N4CC[N+](CC4)(C)C)C)CCC5(C3CC(C5OC(=O)C)N6CC[N+](CC6)(C)C)C.
This classification denotes a muscle relaxant with the molecular formula C35H62N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6ZTY81RE1, chemically known as 4,4-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1,1-dimethylpiperazinium)dibromide, diacetate (ester) but more generally known as pipecurium bromide, which bears US NIH Compound Identifier 65332. European Medicines Agency schedules Pipecuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14880MIG. The term PIPECURONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules pipecurium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule pipecuronium bromide under HS 29335995 and SITC 51576. As of Q4 2014, PIPECURONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Pipecuronium bromide bears US NLM identifiers UMLS ID C0206049 and NCI Concept Code C66393. SMILES: CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C.[BR-].[BR-].
This classification denotes a urinary anti-infective agent and quinolone antibiotic with the molecular formula C14H17N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LT12J5HVR8, chemically known as 5,8-dihydro-8-ethyl-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acid but generally known as pipemidic acid, which bears US NIH Compound Identifier 4831. European Medicines Agency schedules Pipemidic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09863MIG. The term PIPEMIDIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules pipemidic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule pipemidic acid under HS 29335995 and SITC 51576. As of Q4 2014, PIPEMIDIC ACID remains the US FDA Preferred Term for this commodity. Pipemidic acid bears US NLM identifiers UMLS ID C0031953 and NCI Concept Code C66394. SMILES: O=c1c2c(n(CC)cc1C(=O)O)nc(N1CCNCC1)nc2.
This classification denotes a selective estrogen receptor modulator with the molecular formula C29H32N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TPC5Q8496G. The term PIPENDOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46. ). Most nations schedule pipendoxifene under HS 29333999 and SITC 51574. As of Q4 2014, PIPENDOXIFENE remains the US FDA Preferred Term for this commodity. Pipendoxifene bears US NLM identifiers UMLS ID C0935699 and NCI Concept Code C1874. SMILES: CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O.
This classification denotes a piperidine with the molecular formula C22H28NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RS3K5YXV34, chemically known as 1-ethyl-3-hydroxy-1-methyl-piperidinium bromide, benzilic acid ester but generally known as pipenzolate, which bears US NIH Compound Identifier 4832. European Medicines Agency schedules Pipenzolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03838MIG. World Health Organization schedules pipenzolate in its Anatomical Therapeutic Chemical (ATC) Classification. PIPENZOLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PIPENZOLATE remains the US FDA Preferred Term for this commodity. SMILES: O(C1C[N](CCC1)(CC)C)C(=O)C(O)(C1CCCCC1)C1CCCCC1.
This classification denotes an anxiolytic with the molecular formula C22H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3S205V4I2, chemically known as quinoline, 2-phenyl-4-(2-(4-piperidinyl)ethyl)- but generally known as pipequaline, which bears US NIH Compound Identifier 71219. European Medicines Agency schedules Pipequaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09865MIG. The term PIPEQUALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). PIPEQUALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pipequaline under HS 29334990 and SITC 51575. As of Q4 2014, PIPEQUALINE remains the US FDA Preferred Term for this commodity. Pipequaline bears US NLM identifiers UMLS ID C0071104 and NCI Concept Code C66395. SMILES: N1CCC(CC1)CCC1C2C(NC(C1)C1CCCCC1)CCCC2.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C24H30N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KL6248WNW4, chemically known as ketone, 10-(3-(4-(2-hydroxyethyl)piperidino)propyl)phenothiazin-2-yl methyl but generally known as piperacetazine, which bears US NIH Compound Identifier 19675. European Medicines Agency schedules Piperacetazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09866MIG. The term PIPERACETAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). PIPERACETAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piperacetazine under HS 29343090 and SITC 51578. As of Q4 2014, PIPERACETAZINE remains the US FDA Preferred Term for this commodity. Piperacetazine bears US NLM identifiers UMLS ID C0031954 and NCI Concept Code C66396. SMILES: S1C2C(N(CCCN3CCC(CC3)CCO)C3C1CCCC3)CC(CC2)C(=O)C.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C23H27N5O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I628532GX, chemically known as 6-(d-(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid but generally known as piperacillin, which bears US NIH Compound Identifier 43672. European Medicines Agency schedules Piperacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09867MIG. The term PIPERACILLIN ANHYDROUS is an International Non-Proprietary Name. World Health Organization schedules piperacillin in its Anatomical Therapeutic Chemical (ATC) Classification. PIPERACILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piperacillin under HS 29411090 and SITC 54131. As of Q4 2014, PIPERACILLIN remains the US FDA Preferred Term for this commodity. Piperacillin bears US NLM identifiers UMLS ID C0031955 and NCI Concept Code C62069. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(NC(=O)N1CCN(C(=O)C1=O)CC)C1CCCCC1.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C23H27N5O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I628532GX, chemically known as piperacillin, anhydrous, but more generally known as piperacillin anhydrous, which bears US NIH Compound Identifier 43672. European Medicines Agency schedules piperacillin anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09867MIG. Most nations, for tariff purposes, schedule piperacillin anhydrous under HS 29411090. Piperacillin anhydrous bears US NLM identifiers UMLS ID C1882383 and NCI Concept Code C61891. SMILES: CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2CCCCC2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C23H27N5O7S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X00B0D5O0E, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2r)-(((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, monohydrate, (2s,5r,6r)-, but more generally known as piperacillin hydrate, which bears US NIH Compound Identifier 73246. European Medicines Agency schedules piperacillin hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09867MIG. Most nations, for tariff purposes, schedule piperacillin hydrate under HS 29411090. SMILES: CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2CCCCC2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O.O.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C23H26N5O7S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M98T69Q7HP, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as piperacillin sodium, which bears US NIH Compound Identifier 43066. European Medicines Agency schedules Piperacillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03840MIG. Most nations, for tariff and trade purposes, schedule piperacillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, PIPERACILLIN SODIUM remains US FDA's Preferred Term for this commodity. Piperacillin sodium bears US NLM identifiers UMLS ID C0700463 and NCI Concept Code C749. SMILES: CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2CCCCC2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM113. This VA Drug Class (AM113) classifies this compound as belonging to the group EXTENDED SPECTRUM PENICILLINS.
This classification denotes an antihelminthic agent with the molecular formula C17H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83B7UZO20C, chemically known as N-[4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]phenyl]acetamide but generally known as piperamide, which bears US NIH Compound Identifier 14739. Most nations schedule piperamide under HS 29335995 and SITC 51576. As of Q4 2014, PIPERAMIDE remains the US FDA Preferred Term for this commodity. Piperamide bears US NLM identifiers UMLS ID C2698815 and NCI Concept Code C75123. SMILES: CC(=O)NC1=CC=C(C=C1)N2CCN(CC2)CCCN(C)C.
This classification denotes an antihelminthic agent with the molecular formula C17H28N4O.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7T952LZM7T, chemically known as acetanilide, 4-(4-(3-(dimethylamino)propyl)-1-piperazinyl)-, maleate (1:2) but more generally known as piperamide maleate, which bears US NIH Compound Identifier 6433263. Most nations, for tariff and trade purposes, schedule piperamide maleate under HS 29335995 and SITC 51576. As of Q4 2014, PIPERAMIDE MALEATE remains US FDA's Preferred Term for this commodity. Piperamide maleate bears US NLM identifiers UMLS ID C1882385 and NCI Concept Code C66397. SMILES: CC(=O)NC1CCC(CC1)N2CCN(CC2)CCCN(C)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1RTM4PAL0V, chemically known as 1,4-piperazine but generally known as piperazine, which bears US NIH Compound Identifier 4837. European Medicines Agency schedules Piperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03841MIG. World Health Organization schedules piperazine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule piperazine under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE remains the US FDA Preferred Term for this commodity. Piperazine bears US NLM identifiers UMLS ID C0031957 and NCI Concept Code C61892. SMILES: C1CNCCN1.
This classification denotes an antihelminthic agent "C10H12N2O8.C4H10N2.2""H+"".Ca", a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L4QEN8344Z, chemically known as calciate(2-), ((n,n'-1,2-ethanediylbis(n-(carboxymethyl)glycinato))(4-)-n,n',o,o',on,on')-, (oc-6-21)-, dihydrogen, compd. with piperazine (1:1), but more generally known as piperazine calcium edetate, which bears US NIH Compound Identifier 23724991. European Medicines Agency schedules Piperazine calcium edetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09869MIG. Most nations, for tariff and trade purposes, schedule piperazine calcium edetate under HS 29335990 and SITC 51576. SMILES: As of Q4 2014, PIPERAZINE CALCIUM EDETATE remains US FDA's Preferred Term for this commodity.
This classification denotes an antihelminthic agent with the molecular formula 2C6H8O7.3C4H10N2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63KP7FXF2I, chemically known as 1,4-piperazine but more generally known as piperazine citrate, which bears US NIH Compound Identifier 4837. European Medicines Agency schedules Piperazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14884MIG. Most nations, for tariff and trade purposes, schedule piperazine citrate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE CITRATE remains US FDA's Preferred Term for this commodity. Piperazine citrate bears US NLM identifiers UMLS ID C1145666 and NCI Concept Code C47674. SMILES: C1CNCCN1.C1CNCCN1.C1CNCCN1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.O.
This classification denotes an antihelminthic agent with the molecular formula 2C6H8O7.3C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RI85381D5G, chemically known as piperazine, 2-hydroxy-1,2,3-propanetricarboxylate (3:2), but more generally known as piperazine citrate anhydrous, which bears US NIH Compound Identifier 114763. European Medicines Agency schedules piperazine citrate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03841MIG. Most nations, for tariff purposes, schedule piperazine citrate anhydrous under HS 29335990. SMILES: C1CNCCN1.C1CNCCN1.C1CNCCN1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2.2BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AD5RF7D2AU, chemically known as piperazine, hydrobromide (1:2), but more generally known as piperazine dihydrobromide, which bears US NIH Compound Identifier 3017157. European Medicines Agency schedules piperazine dihydrobromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03841MIG. Most nations, for tariff purposes, schedule piperazine dihydrobromide under HS 29335990. SMILES: C1CNCCN1.BR.BR.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17VU4Z4W88, chemically known as piperazine, dihydrochloride but more generally known as piperazine dihydrochloride, which bears US NIH Compound Identifier 8893. European Medicines Agency schedules Piperazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14887MIG. Most nations, for tariff and trade purposes, schedule piperazine dihydrochloride under HS 29335990. As of Q4 2014, PIPERAZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Piperazine dihydrochloride bears US NLM identifiers UMLS ID C0892283 and NCI Concept Code C80008. SMILES: C1CNCCN1.CL.CL.
This classification denotes an antihelminthic agent with the molecular formula C18H22O5S.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SVI38UY019, chemically known as estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1), but more generally known as piperazine estrone sulfate, which bears US NIH Compound Identifier 23703. European Medicines Agency schedules piperazine estrone sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03841MIG. Most nations, for tariff purposes, schedule piperazine estrone sulfate under HS 29335990. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)OS(=O)(=O)O.C1CNCCN1.
This classification denotes an antihelminthic agent C4H10N2.6H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P3M07B8U64, chemically known as piperazine, hydrate (1:6), but more generally known as piperazine hexahydrate, which bears US NIH Compound Identifier 120181. European Medicines Agency schedules Piperazine hexahydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14886MIG. Most nations, for tariff and trade purposes, schedule piperazine hexahydrate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE HEXAHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CNCCN1.O.O.O.O.O.O.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2.6H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P3M07B8U64, chemically known as 1,4-piperazine but more generally known as piperazine hydrate, which bears US NIH Compound Identifier 4837. European Medicines Agency schedules Piperazine hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12218MIG. Most nations, for tariff and trade purposes, schedule piperazine hydrate under HS 29335990. As of Q4 2014, PIPERAZINE HYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CNCCN1.O.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1FWC6DPTK, chemically known as piperazine, hydrobromide (1:1), but more generally known as piperazine hydrobromide, which bears US NIH Compound Identifier 3014804. European Medicines Agency schedules piperazine hydrobromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03841MIG. Most nations, for tariff purposes, schedule piperazine hydrobromide under HS 29335990. SMILES: C1CNCCN1.BR.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17VU4Z4W88, chemically known as piperazine, dihydrochloride but more generally known as piperazine dihydrochloride, which bears US NIH Compound Identifier 8893. European Medicines Agency schedules Piperazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14887MIG. Most nations, for tariff and trade purposes, schedule piperazine hydrochloride under HS 29335990 and SITC 51576. SMILES: C1CNCCN1.CL.CL.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2.H2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8TIF7T48FP, chemically known as piperazine, phosphate but more generally known as piperazine phosphate, which bears US NIH Compound Identifier 64733. European Medicines Agency schedules Piperazine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14888MIG. Most nations, for tariff and trade purposes, schedule piperazine phosphate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Piperazine phosphate bears US NLM identifiers UMLS ID C0137095 and NCI Concept Code C76724. SMILES: C1CNCCN1.O.OP(=O)(O)O.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7S1V82385, chemically known as piperazine, phosphate (1:1), but more generally known as piperazine phosphate anhydrous, which bears US NIH Compound Identifier 64733. European Medicines Agency schedules piperazine phosphate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03841MIG. Most nations, for tariff purposes, schedule piperazine phosphate anhydrous under HS 29335990. SMILES: C1CNCCN1.OP(=O)(O)O.
This classification denotes an antihelminthic agent C10H18O4.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1EUC610UJ, chemically known as decanedioic acid, compd. with piperazine (1:1), but more generally known as piperazine sebacate, which bears US NIH Compound Identifier 3084013. European Medicines Agency schedules Piperazine sebacate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03849MIG. Most nations, for tariff and trade purposes, schedule piperazine sebacate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE SEBACATE remains US FDA's Preferred Term for this commodity. SMILES: C1CNCCN1.C(CCCCC(=O)O)CCCC(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C4H10N2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8493J9B36. The term dipiperazine sulfate is a U.S. FDA Green Book designation. Most nations, for tariff and trade purposes, schedule piperazine sulfate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE SULFATE remains US FDA's Preferred Term for this commodity. Piperazine sulfate bears US NLM identifiers UMLS ID C0892285 and NCI Concept Code C81514. SMILES: C1CNCCN1.OS(=O)(=O)O.
This classification denotes an antihelminthic agent C4H10N2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SM51XZC901, chemically known as piperazine, (2r,3r)-2,3-dihydroxybutanedioate, but more generally known as piperazine tartrate, which bears US NIH Compound Identifier 258091. European Medicines Agency schedules Piperazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14889MIG. Most nations, for tariff and trade purposes, schedule piperazine tartrate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CNCCN1.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a diphenylacetic acid and piperidine with the molecular formula C21H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RJO31255V9, chemically known as 3-piperidinol, 1-ethyl-, diphenylacetate (ester) but generally known as piperidolate, which bears US NIH Compound Identifier 4839. European Medicines Agency schedules Piperidolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09870MIG. World Health Organization schedules piperidolate in its Anatomical Therapeutic Chemical (ATC) Classification. PIPERIDOLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piperidolate under HS 29333999 and SITC 51574. As of Q4 2014, PIPERIDOLATE remains the US FDA Preferred Term for this commodity. SMILES: O(C1CCCN(C1)CC)C(=O)C(C1CCCCC1)C1CCCCC1.
This classification denotes an anesthetic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F66XUI6GZL, chemically known as 2-methyl-1-piperidinopropanol, benzoate but generally known as piperocaine, which bears US NIH Compound Identifier 10782. European Medicines Agency schedules Piperocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09871MIG. The term PIPEROCAINE is an International Non-Proprietary Name. PIPEROCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piperocaine under HS 29333999 and SITC 51574. As of Q4 2014, PIPEROCAINE remains the US FDA Preferred Term for this commodity. Piperocaine bears US NLM identifiers UMLS ID C0071114 and NCI Concept Code C90654. SMILES: O(CCCN1C(CCCC1)C)C(=O)C1CCCCC1.
This classification denotes an anesthetic agent with the molecular formula C16H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2RH0XR1MB, chemically known as 1-piperidinepropanol, 2-methyl-, benzoate (ester), hydrochloride but more generally known as piperocaine hydrochloride, which bears US NIH Compound Identifier 10781. Most nations, for tariff and trade purposes, schedule piperocaine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PIPEROCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Piperocaine hydrochloride bears US NLM identifiers UMLS ID C0770379 and NCI Concept Code C90655. SMILES: CC1CCCCN1CCCOC(=O)C2CCCCC2.CL.
This classification denotes a cyclic ether carcinogen with the molecular formula C19H30O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LWK91TU9AH, chemically known as 4,5-methylenedioxy-2-propylbenzyldiethyleneglycol butyl ether but generally known as piperonyl butoxide, which bears US NIH Compound Identifier 5794. European Medicines Agency schedules Piperonyl butoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14893MIG. SMILES: CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP300. This VA Drug Class (AP300) classifies this compound as belonging to the group PEDICULICIDES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP300. This VA Drug Class (AP300) classifies this compound as belonging to the group PEDICULICIDES.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZCS27634Y, chemically known as 1,4-benzodioxane, 2-(piperidinomethyl)- but generally known as piperoxan, which bears US NIH Compound Identifier 6040. European Medicines Agency schedules Piperoxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09872MIG. The term PIPEROXAN is an International Non-Proprietary Name. PIPEROXAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piperoxan under HS 29349990 and SITC 51579. As of Q4 2014, PIPEROXAN remains the US FDA Preferred Term for this commodity. Piperoxan bears US NLM identifiers UMLS ID C0031963 and NCI Concept Code C66399. SMILES: O1C(CN2CCCCC2)COC2C1CCCC2.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H19NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KS0DZ1UQNW, chemically known as 1,4-benzodioxan, 2-(1-piperidylmethyl)-, hydrochloride but more generally known as piperoxan hydrochloride, which bears US NIH Compound Identifier 101619. Most nations, for tariff and trade purposes, schedule piperoxan hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, PIPEROXAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Piperoxan hydrochloride bears US NLM identifiers UMLS ID C2825596 and NCI Concept Code C81370. SMILES: C1CCC2C(C1)OCC(O2)CN3CCCCC3.CL.
This classification denotes an antineoplastic alkylating agent with the molecular formula C10H16Br2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q99RDT97R, chemically known as 1,4-bis(3-bromopropionyl)piperazine but more generally known as pipobroman, which bears US NIH Compound Identifier 4842. European Medicines Agency schedules Pipobroman in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09875MIG. The term PIPOBROMAN is an International Non-Proprietary Name. World Health Organization schedules pipobroman in its Anatomical Therapeutic Chemical (ATC) Classification. PIPOBROMAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pipobroman under HS 29335995 and SITC 51576. As of Q4 2014, PIPOBROMAN remains US FDA's Preferred Term for this commodity. Pipobroman bears US NLM identifiers UMLS ID C0031965 and NCI Concept Code C750. SMILES: C1CN(CCN1C(=O)CCBR)C(=O)CCBR.
This classification denotes an antidepressant agent with the molecular formula C16H19N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8T739L1FA, chemically known as 5-methyl-3-(4-methyl-1-piperazinyl)-5h-pyridazino(3,4-b)(1,4)benzoxazine but generally known as pipofezine, which bears US NIH Compound Identifier 159977. European Medicines Agency schedules Pipofezine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09877MIG. The term PIPOFEZINE is an International Non-Proprietary Name. PIPOFEZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pipofezine under HS 29349990 and SITC 51579. As of Q4 2014, PIPOFEZINE remains the US FDA Preferred Term for this commodity. Pipofezine bears US NLM identifiers UMLS ID C1882389 and NCI Concept Code C66403. SMILES: O1c2nnc(N3CCN(CC3)C)cc2N(c2c1cccc2)C.
This classification denotes an alkylsulfonate compound with the molecular formula C12H22N2O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VY5DPN1TDU, chemically known as 1,4-dihydracryloylpiperazine dimethanesulfonate (ester) but more generally known as piposulfan, which bears US NIH Compound Identifier 17458. European Medicines Agency schedules Piposulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09878MIG. The term PIPOSULFAN is an International Non-Proprietary Name. PIPOSULFAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule piposulfan under HS 29335995 and SITC 51576. As of Q4 2014, PIPOSULFAN remains US FDA's Preferred Term for this commodity. Piposulfan bears US NLM identifiers UMLS ID C0663942 and NCI Concept Code C1783. SMILES: S(=O)(=O)(OCCC(=O)N1CCN(CC1)C(=O)CCOS(=O)(=O)C)C.
This classification denotes an antipsychotic agent with the molecular formula C24H33N3O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L903J9JPYV, chemically known as 10h-phenothiazine-2-sulfonamide,10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-n,n-dimethyl- but generally known as pipotiazine, which bears US NIH Compound Identifier 62867. European Medicines Agency schedules Pipotiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09879MIG. World Health Organization schedules pipotiazine in its Anatomical Therapeutic Chemical (ATC) Classification. PIPOTIAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pipotiazine under HS 29350090 and SITC 51580. As of Q4 2014, PIPOTIAZINE remains the US FDA Preferred Term for this commodity. Pipotiazine bears US NLM identifiers UMLS ID C0031968 and NCI Concept Code C87657. SMILES: S1C2C(N(CCCN3CCC(CC3)CCO)C3C1CCCC3)CC(S(=O)(=O)N(C)C)CC2.
This classification denotes a dopamine antagonist with the molecular formula C40H63N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4Q3H01QRMI, chemically known as 10-(3-(4-(2-hydroxyethyl)piperidino)propyl)-n,n-dimethylphenothiazine-2-sulfonamide palmitate (ester) but more generally known as pipotiazine palmitate, which bears US NIH Compound Identifier 37767. European Medicines Agency schedules Pipotiazine palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03860MIG. Most nations, for tariff and trade purposes, schedule pipotiazine palmitate under HS 29350090 and SITC 51580. As of Q4 2014, PIPOTIAZINE PALMITATE remains US FDA's Preferred Term for this commodity. Pipotiazine palmitate bears US NLM identifiers UMLS ID C0770895 and NCI Concept Code C87712. SMILES: CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)S(=O)(=O)N(C)C.
This classification denotes an antipsychotic agent C35H51N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XL1XX5J17, chemically known as 10-undecenoic acid,2-(1-(3-(2-((dimethylamino)sulfonyl)-10h-phenothiazin-10-yl)propyl)-4-piperidinyl)ethyl ester, but more generally known as pipotiazine undecylenate, which bears US NIH Compound Identifier 89615. European Medicines Agency schedules Pipotiazine undecylenate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03861MIG. Most nations, for tariff and trade purposes, schedule pipotiazine undecylenate under HS 29350090 and SITC 51580. As of Q4 2014, PIPOTIAZINE UNDECYLENATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)S(=O)(=O)C1CCC2C(C1)N(C3CCCCC3S2)CCCN4CCC(CC4)CCOC(=O)CCCCCCCCC=C.
This classification denotes a piperidine C18H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6E46VR9Y2, chemically known as .alpha.,.alpha.-diphenyl-2-piperidinemethanol hydrochloride, but more generally known as pipradrol hydrochloride, which bears US NIH Compound Identifier 66008. European Medicines Agency schedules Pipradrol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03864MIG. Most nations, for tariff and trade purposes, schedule pipradrol hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, PIPRADROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(C2CCCCC2)(C3CCCCN3)O.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23NO.C7H7ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SI78RFJ7XI, chemically known as theophylline, 8-chloro-, compd. with 4-(diphenylmethoxy)-1-methylpiperidine (1:1) but generally known as piprinhydrinate, which bears US NIH Compound Identifier 71640. European Medicines Agency schedules Piprinhydrinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09886MIG. The term PIPRINHYDRINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). PIPRINHYDRINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piprinhydrinate under HS 29395900 and SITC 54145. As of Q4 2014, PIPRINHYDRINATE remains the US FDA Preferred Term for this commodity. Piprinhydrinate bears US NLM identifiers UMLS ID C0771945 and NCI Concept Code C66408. SMILES: CLC1[NH]C2C(N(C(=O)N(C2=O)C)C)N1.O(C1CCN(CC1)C)C(C1CCCCC1)C1CCCCC1.
This classification denotes a piperidine with the molecular formula C14H22N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7786W0VV8M, chemically known as ethyl 3-ethyl-4-oxo-5-piperidino-.delta.(sup2, .alpha.)-thiazolidineacetate but generally known as piprozolin, which bears US NIH Compound Identifier 28426. European Medicines Agency schedules Piprozolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09889MIG. World Health Organization schedules piprozolin in its Anatomical Therapeutic Chemical (ATC) Classification. PIPROZOLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C(N2CCCCC2)C(=O)N(C\1=C\C(=O)OCC)CC.
This classification denotes a bronchodilator with the molecular formula C19H26N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K46616F1O, chemically known as 4-(6,7-dimethoxyquinazolin-4-yl)piperazine-1-carboxylic acid isobutyl ester but generally known as piquizil, which bears US NIH Compound Identifier 192994. European Medicines Agency schedules piquizil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09891MIG. Most nations schedule piquizil under HS 29335995 and SITC 51576. As of Q4 2014, PIQUIZIL remains the US FDA Preferred Term for this commodity. SMILES: CC(C)COC(=O)N1CCN(CC1)C2=NC=NC3=CC(=C(C=C32)OC)OC.
This classification denotes a bronchodilator with the molecular formula C19H26N4O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4J5215PFO, chemically known as 4-(6,7-dimethoxyquinazolin-4-yl)piperazine-1-carboxylic acid isobutyl ester hydrochloride but more generally known as piquizil hydrochloride, which bears US NIH Compound Identifier 192994. Most nations, for tariff and trade purposes, schedule piquizil hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, PIQUIZIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Piquizil hydrochloride bears US NLM identifiers UMLS ID C1261482 and NCI Concept Code C90820. SMILES: CC(C)COC(=O)N1CCN(CC1)C2C3CC(C(CC3NCN2)OC)OC.CL.
This classification denotes a neuroprotective agent with the molecular formula C6H10N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZH516LNZ10, chemically known as 1-pyrrolidineacetamide, 2-oxo- but generally known as piracetam, which bears US NIH Compound Identifier 4843. European Medicines Agency schedules Piracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09892MIG. The term PIRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules piracetam in its Anatomical Therapeutic Chemical (ATC) Classification. PIRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piracetam under HS 29337900 and SITC 51561. As of Q4 2014, PIRACETAM remains the US FDA Preferred Term for this commodity. Piracetam bears US NLM identifiers UMLS ID C0031977 and NCI Concept Code C66410. SMILES: O=C1N(CCC1)CC(=O)N.
This classification denotes a serotonin agonist with the molecular formula C17H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WC6V8L1Z13, chemically known as 1,3,4,9-tetrahydro-n,n,1-trimethylindeno(1,2-c)-pyran-1,ethylamine hydrochloride but generally known as pirandamine, which bears US NIH Compound Identifier 216376. European Medicines Agency schedules Pirandamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09893MIG. The term PIRANDAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). PIRANDAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirandamine under HS 29329985 and SITC 51569. As of Q4 2014, PIRANDAMINE remains the US FDA Preferred Term for this commodity. Pirandamine bears US NLM identifiers UMLS ID C0071125 and NCI Concept Code C84064. SMILES: O1C(C2=C(Cc3c2cccc3)CC1)(CCN(C)C)C.
This classification denotes an antidepressant agent with the molecular formula C17H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y4F9MIF6M1, chemically known as ay-23,713 but more generally known as pirandamine hydrochloride, which bears US NIH Compound Identifier 431429. Most nations, for tariff and trade purposes, schedule pirandamine hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, PIRANDAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pirandamine hydrochloride bears US NLM identifiers UMLS ID C0088224 and NCI Concept Code C66411. SMILES: CC1(C2=C(CCO1)C3CCCCC3C2)CCN(C)C.CL.
This classification denotes an anthracycline antibiotic, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier D58G680W0G. European Medicines Agency schedules Pirarubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09894MIG. Pirarubicin generally arises in the molecular formula C32H37NO12. The term PIRARUBICIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 3, no. 3, 1989, list 29.) PIRARUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a vasodilating agent with the molecular formula C15H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y1P25NQI7X, chemically known as 3,3,5-trimethylcyclohexyl-2-oxo-1-pyrrolidineacetate. but generally known as piraxelate, which bears US NIH Compound Identifier 3047851. European Medicines Agency schedules Piraxelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09895MIG. The term PIRAXELATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). PIRAXELATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piraxelate under HS 29337900 and SITC 51561. As of Q4 2014, PIRAXELATE remains the US FDA Preferred Term for this commodity. Piraxelate bears US NLM identifiers UMLS ID C1882392 and NCI Concept Code C66412. SMILES: O(C1CC(CC(C1)C)(C)C)C(=O)CN1CCCC1=O.
This classification denotes a pyrimidine antagonist and orotidylate decarboxylase inhibitor with the molecular formula C9H13N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B15044GQZ, chemically known as 1h-pyrazole-5-carboxamide, 4-hydroxy-3-beta-d-ribofuranosyl- but generally known as pirazofurin, which bears US NIH Compound Identifier 5360877. European Medicines Agency schedules Pirazofurin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09897MIG. The term PIRAZOFURIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). PIRAZOFURIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pirazofurin or pyrazofurin bears US NLM identifiers UMLS ID C0072661 and NCI Concept Code C1208. SMILES: C(C1C(C(C(O1)C2=NNC(=C(N)O)C2=O)O)O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H12ClFN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FWY2578LP5, chemically known as 1h-pyrazole-3-acetic acid, 4-(4-chlorophenyl)-1-(4-fluorophenyl)- but generally known as pirazolac, which bears US NIH Compound Identifier 51222. European Medicines Agency schedules Pirazolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09898MIG. The term PIRAZOLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). PIRAZOLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirazolac under HS 29331990 and SITC 51571. As of Q4 2014, PIRAZOLAC remains the US FDA Preferred Term for this commodity. Pirazolac bears US NLM identifiers UMLS ID C0071127 and NCI Concept Code C66413. SMILES: CLC1CCC(C2C(NN(C2)C2CCC(F)CC2)CC(=O)O)CC1.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C12H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OG645J8RVW, chemically known as ethanol, 2-tert-butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)- but generally known as pirbuterol, which bears US NIH Compound Identifier 4845. European Medicines Agency schedules Pirbuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09900MIG. The term PIRBUTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules pirbuterol in its Anatomical Therapeutic Chemical (ATC) Classification. PIRBUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirbuterol under HS 29333999 and SITC 51574. As of Q4 2014, PIRBUTEROL remains the US FDA Preferred Term for this commodity. Pirbuterol bears US NLM identifiers UMLS ID C0071129 and NCI Concept Code C61893. SMILES: OC(CNC(C)(C)C)C1NC(C(O)CC1)CO.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QLE9A8YF1U, chemically known as 1,1-dimethyl-2-(((p-methyl-alpha-phenylbenzyl)oxy)methyl)piperidinium but generally known as pirdonium, which bears US NIH Compound Identifier 3047852. European Medicines Agency schedules Pirdonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09901MIG. The term PIRDONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). As of Q4 2014, PIRDONIUM remains the US FDA Preferred Term for this commodity. Pirdonium bears US NLM identifiers UMLS ID C2981353 and NCI Concept Code C87747. SMILES: CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC3CCCC[N+]3(C)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30NO.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5123Q291S5, chemically known as 1,1-dimethyl-2-(((p-methyl-alpha-phenylbenzyl)oxy)methyl)piperidinium bromide but more generally known as pirdonium bromide, which bears US NIH Compound Identifier 3047852. European Medicines Agency schedules Pirdonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09901MIG. The term PIRDONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). Most nations, for tariff and trade purposes, schedule pirdonium bromide under HS 29333999 and SITC 51574. As of Q4 2014, PIRDONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Pirdonium bromide bears US NLM identifiers UMLS ID C1882393 and NCI Concept Code C66415. SMILES: CC1CCC(CC1)C(C2CCCCC2)OCC3CCCC[N+]3(C)C.[BR-].
This classification denotes an antimuscarinic agent with the molecular formula C19H21N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3G0285N20N, chemically known as 5,11-dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one but generally known as pirenzepine, which bears US NIH Compound Identifier 4848. European Medicines Agency schedules Pirenzepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09904MIG. The term PIRENZEPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules pirenzepine in its Anatomical Therapeutic Chemical (ATC) Classification. PIRENZEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirenzepine under HS 29335995 and SITC 51576. As of Q4 2014, PIRENZEPINE remains the US FDA Preferred Term for this commodity. Pirenzepine bears US NLM identifiers UMLS ID C0031978 and NCI Concept Code C76002. SMILES: O=C(N1C2C(C(=O)[NH]C3C1NCCC3)CCCC2)CN1CCN(CC1)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C21H32N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1J0B4P41O, chemically known as (+-)-6-((2-((3-(p-butoxyphenoxy)-2-hydroxypropyl)amino)ethyl)amino)-1,3-dimethyluracil but generally known as pirepolol, which bears US NIH Compound Identifier 68887. European Medicines Agency schedules Pirepolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09905MIG. The term PIREPOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). PIREPOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirepolol under HS 29335995 and SITC 51576. As of Q4 2014, PIREPOLOL remains the US FDA Preferred Term for this commodity. Pirepolol bears US NLM identifiers UMLS ID C1882394 and NCI Concept Code C66418. SMILES: O(CC(O)CNCCNC1N(C(=O)N(C(=O)C1)C)C)C1CCC(OCCCC)CC1.
This classification denotes a loop diuretic with the molecular formula C17H18N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQ6KK6GV93, chemically known as benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(pyrrolidinyl)- but generally known as piretanide, which bears US NIH Compound Identifier 4849. European Medicines Agency schedules Piretanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09906MIG. The term PIRETANIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules piretanide in its Anatomical Therapeutic Chemical (ATC) Classification. PIRETANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piretanide under HS 29350090 and SITC 51580. As of Q4 2014, PIRETANIDE remains the US FDA Preferred Term for this commodity. Piretanide bears US NLM identifiers UMLS ID C0071132 and NCI Concept Code C66419. SMILES: S(=O)(=O)(N)c1c(Oc2ccccc2)c(N2CCCC2)cc(c1)C(=O)O.
This classification denotes a loop diuretic C17H17N2O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4757J7S0V0, chemically known as benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-, sodium salt (1:1), but more generally known as piretanide sodium, which bears US NIH Compound Identifier 73425479. European Medicines Agency schedules Piretanide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03870MIG. Most nations, for tariff and trade purposes, schedule piretanide sodium under HS 29350090 and SITC 51580. As of Q4 2014, PIRETANIDE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)OC2C(CC(CC2S(=O)(=O)N)C(=O)[O-])N3CCCC3.[NA+].
This classification denotes a radioprotective agent and nonsteroidal antiinflammatory drug with the molecular formula C12H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D7NLD2JX7U, chemically known as 2(1h)-pyridone, 5-methyl-1-phenyl- but more generally known as pirfenidone, which bears US NIH Compound Identifier 40632. European Medicines Agency schedules Pirfenidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09907MIG. The term PIRFENIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). PIRFENIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pirfenidone under HS 29337900 and SITC 51561. As of Q4 2014, PIRFENIDONE remains US FDA's Preferred Term for this commodity. Pirfenidone bears US NLM identifiers UMLS ID C0298067 and NCI Concept Code C2635. SMILES: CC1=CN(C(=O)C=C1)C2=CC=CC=C2.
This classification denotes a dopamine agonist with the molecular formula C16H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DO22K1PRDJ, chemically known as 2-(4-(3,4-methylenedioxybenzyl)piperazino)pyrimidine but generally known as piribedil, which bears US NIH Compound Identifier 4850. European Medicines Agency schedules Piribedil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09908MIG. The term PIRIBEDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules piribedil in its Anatomical Therapeutic Chemical (ATC) Classification. PIRIBEDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piribedil under HS 29349990 and SITC 51579. As of Q4 2014, PIRIBEDIL remains the US FDA Preferred Term for this commodity. Piribedil bears US NLM identifiers UMLS ID C0031979 and NCI Concept Code C81082. SMILES: O1C2CC(CN3CCN(CC3)C3NCCCN3)CCC2OC1.
This classification denotes a dopamine agonist with the molecular formula C16H18N4O2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1U37NGM6KK, chemically known as 2-(4-(1,3-benzodioxol-5-ylmethyl)piperazinyl)pyrimidinium methanesulphonate but more generally known as piribedil mesylate, which bears US NIH Compound Identifier 198284. European Medicines Agency schedules Piribedil mesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21569. Most nations, for tariff and trade purposes, schedule piribedil mesylate under HS 29349990. As of Q4 2014, PIRIBEDIL MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: CS(=O)(=O)O.C1CNC(NC1)N2CCN(CC2)CC3CCC4C(C3)OCO4.
This classification denotes a dopamine agonist with the molecular formula C16H18N4O2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1U37NGM6KK, chemically known as 2-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)pyrimidine, methanesulfonic acid, but more generally known as piribedil monomethanesulfonate, which bears US NIH Compound Identifier 198284. European Medicines Agency schedules piribedil monomethanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09908MIG. Most nations, for tariff purposes, schedule piribedil monomethanesulfonate under HS 29349990. SMILES: CS(=O)(=O)O.C1CNC(NC1)N2CCN(CC2)CC3CCC4C(C3)OCO4.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 488S0H4SQF. European Medicines Agency schedules Piridocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09910MIG. Piridocaine generally arises in the molecular formula C14H20N2O2. The term PIRIDOCAINE is an International Non-Proprietary Name or INN. PIRIDOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piridocaine under HS 29333999 and SITC 51574. As of Q4 2014, PIRIDOCAINE remains the US FDA Preferred Term for this commodity. Piridocaine bears US NLM identifiers UMLS ID C2827301 and NCI Concept Code C84065. SMILES: O(CCC1NCCCC1)C(=O)C1C(N)CCCC1.
This classification denotes an anesthetic agent with the molecular formula C14H20N2O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VG6P406YHV. Most nations, for tariff and trade purposes, schedule piridocaine hydrochloride under HS 29333999. As of Q4 2014, PIRIDOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Piridocaine hydrochloride bears US NLM identifiers UMLS ID C2981293 and NCI Concept Code C87597. SMILES: C1CCC(C(C1)C(=O)OCCC2CCCCN2)N.CL.
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E82B3Z65BN. European Medicines Agency schedules Pirifibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09913MIG. Pirifibrate generally arises in the molecular formula C17H18CLNO4. The term PIRIFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) PIRIFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirifibrate under HS 29333999 and SITC 51574. As of Q4 2014, PIRIFIBRATE remains the US FDA Preferred Term for this commodity. Pirifibrate bears US NLM identifiers UMLS ID C0071136 and NCI Concept Code C66421. SMILES: Clc1ccc(OC(C)(C)C(=O)OCc2nc(ccc2)CO)cc1.
This classification denotes an organic carcinogen with the molecular formula C14H14ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86C4MRT55A, chemically known as 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid but generally known as pirinixic acid, which bears US NIH Compound Identifier 5694. European Medicines Agency schedules Pirinixic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09915MIG. The term PIRINIXIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). Most nations schedule pirinixic acid under HS 29335995 and SITC 51576. As of Q4 2014, PIRINIXIC ACID remains the US FDA Preferred Term for this commodity. Pirinixic acid bears US NLM identifiers UMLS ID C0243266 and NCI Concept Code C29866. SMILES: Clc1nc(SCC(=O)O)nc(Nc2c(c(ccc2)C)C)c1.
This classification denotes an anti-lipidemic agent with the molecular formula C16H19ClN4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 969LVT6GJ2, chemically known as 2-((4-chloro-6-(2,3-xylidino)-2-pyrimidinyl)thio)-n-(2-hydroxyethyl)acetamide but generally known as pirinixil, which bears US NIH Compound Identifier 68851. European Medicines Agency schedules Pirinixil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09916MIG. The term PIRINIXIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). PIRINIXIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirinixil under HS 29335995 and SITC 51576. As of Q4 2014, PIRINIXIL remains the US FDA Preferred Term for this commodity. Pirinixil bears US NLM identifiers UMLS ID C0137120 and NCI Concept Code C66424. SMILES: Clc1nc(SCC(=O)NCCO)nc(Nc2c(c(ccc2)C)C)c1.
This classification denotes a cns stimulant with the molecular formula C16H24N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W618Z2SMVL. European Medicines Agency schedules pirisudanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09919MIG. The term PIRISUDANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21. ). PIRISUDANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pirisudanol or pyrisuccideanol bears US NLM identifiers UMLS ID C0072732 and NCI Concept Code C66427. SMILES: O(Cc1c(c(O)c(nc1)C)CO)C(=O)CCC(=O)OCCN(C)C.
This classification denotes an opioid analgesic, narcotic, and isonipecotic acid with the molecular formula C27H34N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4RP92LYZ2F, chemically known as 2,2-diphenyl-4-(4-piperidino-4-carbamoylpiperidino)butyronitrile but generally known as piritramide, which bears US NIH Compound Identifier 9331. European Medicines Agency schedules Piritramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09920MIG. World Health Organization schedules piritramide in its Anatomical Therapeutic Chemical (ATC) Classification. PIRITRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piritramide under HS 29333300 and SITC 51574. As of Q4 2014, PIRITRAMIDE remains the US FDA Preferred Term for this commodity. SMILES: O=C(N)C1(N2CCCCC2)CCN(CC1)CCC(C1CCCCC1)(C1CCCCC1)C#N.
This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C17H19N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, MK2A783ZUT chemically known as 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine but generally known as piritrexim, which bears US NIH Compound Identifier 54369. European Medicines Agency schedules Piritrexim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09921MIG. The term PIRITREXIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26). Most nations schedule piritrexim under HS 29335995 and SITC 51576. As of Q4 2014, PIRITREXIM remains the US FDA Preferred Term for this commodity. Piritrexim bears US NLM identifiers UMLS ID C0054332 and NCI Concept Code C1031. SMILES: CC1=C2C(=NC(=NC2=NC=C1CC3=C(C=CC(=C3)OC)OC)N)N.
This classification denotes a lincosamide antibiotic with the molecular formula C17H31ClN2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LM19JT6G5K, chemically known as l-threo-alpha-d-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((4-ethyl-2-piperidinyl)carbonyl)amino)-1-thio-, monohydrochloride, (2s-cis)- but generally known as pirlimycin, which bears US NIH Compound Identifier 115329. European Medicines Agency schedules Pirlimycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09922MIG. The term PIRLIMYCIN is an International Non-Proprietary Name. PIRLIMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirlimycin under HS 29419000 and SITC 54139. As of Q4 2014, PIRLIMYCIN remains the US FDA Preferred Term for this commodity. Pirlimycin bears US NLM identifiers UMLS ID C0071142 and NCI Concept Code C84066. SMILES: ClC(C(NC(=O)C1NCCC(C1)CC)C1OC(SC)C(O)C(O)C1O)C.Cl.
This classification denotes a lincosamide antibiotic with the molecular formula C17H31ClN2O5S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8S09O559AQ, chemically known as l-threo-.alpha.-d-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((4-ethyl-2-piperidinyl)carbonyl)amino)-1-thio-, monohydrochloride, monohydrate, (2s-cis)-, but more generally known as pirlimycin hydrochloride, which bears US NIH Compound Identifier 71997. European Medicines Agency schedules pirlimycin hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09922MIG. Most nations, for tariff purposes, schedule pirlimycin hydrochloride under HS 29419000. Pirlimycin hydrochloride bears US NLM identifiers UMLS ID C0521904 and NCI Concept Code C73846. SMILES: CC[C@@H]1CCN[C@@H](C1)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)CL.O.CL.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C15H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V39YPH45FZ, chemically known as 2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino(3,2,1-jk)carbazole but generally known as pirlindole, which bears US NIH Compound Identifier 68802. European Medicines Agency schedules Pirlindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09923MIG. The term PIRLINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). PIRLINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirlindole under HS 29335995 and SITC 51576. As of Q4 2014, PIRLINDOLE remains the US FDA Preferred Term for this commodity. Pirlindole bears US NLM identifiers UMLS ID C0071143 and NCI Concept Code C66428. SMILES: n12c3C(NCC1)CCCc3c1c2ccc(c1)C.
This classification denotes a monoamine oxidase inhibitor C15H18N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q89W8I397C, chemically known as 1h-pyrazino(3,2,1-jk)carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, hydrochloride (1:1), but more generally known as pirlindole hydrochloride, which bears US NIH Compound Identifier 115141. European Medicines Agency schedules Pirlindole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35547. Most nations, for tariff and trade purposes, schedule pirlindole hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, PIRLINDOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC2C(C1)C3C4N2CCNC4CCC3.CL.
This classification denotes an antiarrhythmic agent with the molecular formula C22H30N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) VZ3B6ACV72, chemically known as 2-pyridinemethanol, alpha-(3-(2,6-dimethyl-1-piperidinyl)propyl)-alpha-phenyl-, cis-(+-)- but more generally known as pirmenol, which bears US NIH Compound Identifier 4853. European Medicines Agency schedules Pirmenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09925MIG. The term PIRMENOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 34, No. 10 1980, List 20). PIRMENOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pirmenol under HS 29333999 and SITC 51574. As of Q4 2014, PIRMENOL remains US FDA's Preferred Term for this commodity. Pirmenol bears US NLM identifiers UMLS ID C0071144 and NCI Concept Code C81434. SMILES: OC(CCCN1C(CCCC1C)C)(C1CCCCC1)C1NCCCC1.
This classification denotes an antimuscarinic agent with the molecular formula C22H30N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JA79OMG4QT, chemically known as 2-pyridinemethanol, alpha-(3-(2,6-dimethyl-1-piperidinyl)propyl)-alpha-phenyl-, monohydrochloride, z-(+-)- but more generally known as pirmenol hydrochloride, which bears US NIH Compound Identifier 65501. European Medicines Agency schedules Pirmenol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03874MIG. Most nations, for tariff and trade purposes, schedule pirmenol hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PIRMENOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pirmenol hydrochloride bears US NLM identifiers UMLS ID C2825679 and NCI Concept Code C81547. SMILES: C[C@@H]1CCC[C@@H](N1CCC[C@@](C2CCCCC2)(C3CCCCN3)O)C.CL.
This classification denotes an anti-glaucoma agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S3FHL03F60. European Medicines Agency schedules Pirnabin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09926MIG. Pirnabin generally arises in the molecular formula C19H24O3. The term PIRNABIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) PIRNABIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pirnabin or pirnabine bears US NLM identifiers UMLS ID C3272437 and NCI Concept Code C95917. SMILES: O1C(C2=C(CC(CC2)C)C2C1CC(CC2OC(=O)C)C)(C)C.
This classification denotes an agent affecting integumentary system with the molecular formula C14H23NO2.C2H7NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A4V5C6R9FB, chemically known as 2(1h)-pyridinone, 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-, compound with 2-aminoethanol (1:1) but generally known as piroctone olamine, which bears US NIH Compound Identifier 50258. European Medicines Agency schedules Piroctone olamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23293. SMILES: CC1=CC(=O)N(C(=C1)CC(C)CC(C)(C)C)O.C(CO)N.
This classification denotes an antiparkinsonian agent with the molecular formula C22H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AR6Y753ARL, chemically known as 3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-ethyl-2-methylpyrrolidine but generally known as piroheptine, which bears US NIH Compound Identifier 4854. European Medicines Agency schedules Piroheptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09931MIG. The term PIROHEPTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). PIROHEPTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piroheptine under HS 29339990 and SITC 51577. As of Q4 2014, PIROHEPTINE remains the US FDA Preferred Term for this commodity. Piroheptine bears US NLM identifiers UMLS ID C0071147 and NCI Concept Code C66431. SMILES: N1(C(/C(=C2/C3C(CCC4C2CCCC4)CCCC3)CC1)C)CC.
This classification denotes an antiparkinsonian agent with the molecular structure C22H25N.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 4ZM573199N chemically known as 3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-ethyl-2-methyl, hydrochloride, but more commonly known as piroheptine hydrochloride, which bears US NIH Compound Identifier 27844. European Medicines Agency schedules Piroheptine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32954. Most nations, for tariff and trade purposes, schedule piroheptine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, PIROHEPTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN1CCC(=C2C3CCCCC3CCC4C2CCCC4)C1C.CL.
This classification denotes an anti-asthmatic agent with the molecular formula C16H15N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2LF7L6QD58, chemically known as pyrimido(4,5-b)quinoline-2-carboxylic acid, 1,4-dihydro-7,8-dimethoxy-4-oxo-, ethyl ester but generally known as pirolate, which bears US NIH Compound Identifier 5361200. European Medicines Agency schedules Pirolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09932MIG. The term PIROLATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). PIROLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirolate under HS 29335995 and SITC 51576. As of Q4 2014, PIROLATE remains the US FDA Preferred Term for this commodity. Pirolate bears US NLM identifiers UMLS ID C2826064 and NCI Concept Code C82231. SMILES: O(C1CC2C(NC3[NH]C(NC(=O)C3C2)C(=O)OCC)CC1OC)C.
This classification denotes an antidepressant agent with the molecular formula C23H29N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GQN5BVM24W, chemically known as pyrrolo(1,2-a)pyrazine-2(1h)-butanamide, hexahydro-alpha,alpha-diphenyl- but generally known as pirolazamide, which bears US NIH Compound Identifier 71442. European Medicines Agency schedules Pirolazamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09933MIG. The term PIROLAZAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). PIROLAZAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirolazamide under HS 29335995 and SITC 51576. As of Q4 2014, PIROLAZAMIDE remains the US FDA Preferred Term for this commodity. Pirolazamide bears US NLM identifiers UMLS ID C0606667 and NCI Concept Code C66432. SMILES: O=C(N)C(CCN1CC2N(CCC2)CC1)(c1ccccc1)c1ccccc1.
This classification denotes a urinary anti-infective agent and quinolone antibiotic with the molecular formula C14H16N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3I12WH4EWF, chemically known as 8-ethyl-5-oxo-2-(1-pyrrolidinyl)-5,8-dihydropyrido(2,3-d)pyrimidine-6-carboxylic acid but generally known as piromidic acid, which bears US NIH Compound Identifier 4855. European Medicines Agency schedules Piromidic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09934MIG. The term PIROMIDIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules piromidic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule piromidic acid under HS 29335995 and SITC 51576. As of Q4 2014, PIROMIDIC ACID remains the US FDA Preferred Term for this commodity. Piromidic acid bears US NLM identifiers UMLS ID C0031987 and NCI Concept Code C66433. SMILES: O=c1c2c(n(CC)cc1C(=O)O)nc(N1CCCC1)nc2.
This classification denotes an anthrapyrazole antibiotic with the molecular formula C21H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YL4TY9WH22, chemically known as anthra(1,9-cd)pyrazol-6(2h)-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)- but generally known as piroxantrone, which bears US NIH Compound Identifier 5362372. European Medicines Agency schedules Piroxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09935MIG. The term PIROXANTRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). PIROXANTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piroxantrone under HS 29339990 and SITC 51577. As of Q4 2014, PIROXANTRONE remains the US FDA Preferred Term for this commodity. Piroxantrone bears US NLM identifiers UMLS ID C0069736 and NCI Concept Code C1182. SMILES: OC1C2C3C([NH]N(C3CCC2NCCCN)CCNCCO)C2C1C(=O)C=CC2=O.
This classification denotes a cyclooxygenase inhibitor and aromatic compound with the molecular formula C15H13N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13T4O6VMAM, chemically known as 4-hydroxy-2-methyl-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide but generally known as piroxicam, which bears US NIH Compound Identifier 5280452. European Medicines Agency schedules Piroxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09936MIG. The term PIROXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules piroxicam in its Anatomical Therapeutic Chemical (ATC) Classification. PIROXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piroxicam under HS 29349990 and SITC 51579. As of Q4 2014, PIROXICAM remains the US FDA Preferred Term for this commodity. Piroxicam bears US NLM identifiers UMLS ID C0031990 and NCI Concept Code C751. SMILES: S1(=O)(=O)N(/C(=C(/O)NC2NCCCC2)C(=O)C2C1CCCC2)C.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C24H19N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E8Q32N75N, chemically known as 4-hydroxy-2-methyl-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide, cinnamate (ester) but more generally known as piroxicam cinnamate, which bears US NIH Compound Identifier 6436090. European Medicines Agency schedules Piroxicam cinnamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14900MIG. Most nations, for tariff and trade purposes, schedule piroxicam cinnamate under HS 29349990 and SITC 51579. As of Q4 2014, PIROXICAM CINNAMATE remains US FDA's Preferred Term for this commodity. Piroxicam cinnamate bears US NLM identifiers UMLS ID C0071149 and NCI Concept Code C73032. SMILES: CN1C(=C(C2CCCCC2S1(=O)=O)OC(=O)/C=C/C3CCCCC3)C(=O)NC4CCCCN4.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13N3O4S.C2H7NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4O2MP4507, chemically known as 2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-n-2-pyridinyl-,1,1-dioxide, compd with 2-aminoethanol (1:1) but more generally known as piroxicam olamine, which bears US NIH Compound Identifier 5745802. European Medicines Agency schedules Piroxicam olamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03877MIG. Most nations, for tariff and trade purposes, schedule piroxicam olamine under HS 29349990 and SITC 51579. As of Q4 2014, PIROXICAM OLAMINE remains US FDA's Preferred Term for this commodity. Piroxicam olamine bears US NLM identifiers UMLS ID C1882397 and NCI Concept Code C66434. SMILES: CN1C(=C(C2CCCCC2S1(=O)=O)O)C(=O)NC3CCCCN3.C(CO)N.
This classification denotes a cyclooxygenase inhibitor and aromatic compound with the molecular formula C20H21N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39R048W55L, chemically known as propanoic acid, 2,2-dimethyl-, 2-methyl-1,1-dioxido-3-((2-pyridinylamino)carbonyl)-2h-1,2-benzothiazin-4-yl ester, but more generally known as piroxicam pivalic ester, which bears US NIH Compound Identifier 135836. European Medicines Agency schedules piroxicam pivalic ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09936MIG. Most nations, for tariff purposes, schedule piroxicam pivalic ester under HS 29349990. SMILES: CC(C)(C)C(=O)OC1=C(N(S(=O)(=O)C2C1CCCC2)C)C(=O)NC3CCCCN3.
This classification denotes a penicillin antibiotic with the molecular formula C27H28N8O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HPI5A94GD9, chemically known as (2s,5r,6r)-6-((r)-2-(p-hydroxyphenyl)-2-(3-(4-hydroxy-2-(p-sulfamoylanilino)-5-pyrimidinyl)ureido)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as piroxicillin, which bears US NIH Compound Identifier 3047855. European Medicines Agency schedules Piroxicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09937MIG. The term PIROXICILLIN is an International Non-Proprietary Name. PIROXICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piroxicillin under HS 29411090 and SITC 54131. As of Q4 2014, PIROXICILLIN remains the US FDA Preferred Term for this commodity. Piroxicillin bears US NLM identifiers UMLS ID C2698824 and NCI Concept Code C76857. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(NC(=O)NC1C(=O)[NH]C(NC1)NC1CCC(S(=O)(=O)N)CC1)C1CCC(O)CC1.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C11H11N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2VSD0380YB, chemically known as 2h-imidazol-2-one, 4-ethyl-1,3-dihydro-5-(4-pyridinylcarbonyl)- but generally known as piroximone, which bears US NIH Compound Identifier 55263. European Medicines Agency schedules Piroximone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09938MIG. The term PIROXIMONE is an International Non-Proprietary Name. PIROXIMONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule piroximone under HS 29333999 and SITC 51574. As of Q4 2014, PIROXIMONE remains the US FDA Preferred Term for this commodity. Piroximone bears US NLM identifiers UMLS ID C0071150 and NCI Concept Code C90921. SMILES: CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2.
This classification denotes a phenylpropionate and non-steroidal anti-inflammatory agent with the molecular formula C13H14ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T7KN291890, chemically known as hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)- but generally known as pirprofen, which bears US NIH Compound Identifier 35935. European Medicines Agency schedules Pirprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09940MIG. World Health Organization schedules pirprofen in its Anatomical Therapeutic Chemical (ATC) Classification. PIRPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirprofen under HS 29339990 and SITC 51577. As of Q4 2014, PIRPROFEN remains the US FDA Preferred Term for this commodity. SMILES: CLC1C(N2CC=CC2)CCC(C(C)C(=O)O)C1.
This classification denotes an anti-asthmatic agent with the molecular formula C11H9N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D16HG4V2UC, chemically known as 2-(hydroxymethyl)pyrazolo(1,5-c)quinazolin-5(6h)-one but generally known as pirquinozol, which bears US NIH Compound Identifier 47783. European Medicines Agency schedules Pirquinozol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09941MIG. The term PIRQUINOZOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). PIRQUINOZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirquinozol under HS 29335995 and SITC 51576. As of Q4 2014, PIRQUINOZOL remains the US FDA Preferred Term for this commodity. Pirquinozol bears US NLM identifiers UMLS ID C0071153 and NCI Concept Code C90669. SMILES: C1=CC2=C3C=C(NN3C(=O)N=C2C=C1)CO.
This classification denotes a topical anti-infective agent with the molecular formula C35H72N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T0Y37N2R7O, chemically known as bis[3-(2,5-dimethylpyrrolidin-1-yl)propyl]-hexadecyl-methylazanium but generally known as pirralkonium, which bears US NIH Compound Identifier 3047856. European Medicines Agency schedules Pirralkonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09942MIG. The term PIRRALKONIUM BROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). As of Q4 2014, PIRRALKONIUM remains the US FDA Preferred Term for this commodity. Pirralkonium bears US NLM identifiers UMLS ID C2983971 and NCI Concept Code C90989. SMILES: CCCCCCCCCCCCCCCC[N+](C)(CCCN1C(CCC1C)C)CCCN2C(CCC2C)C.
This classification denotes an anti-infective agent with the molecular formula C35H72N3.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WVM5HPV4T, chemically known as bis(3-(2,5-dimethyl-1-pyrrolidinyl)propyl)hexadecylmethylammonium bromide but more generally known as pirralkonium bromide, which bears US NIH Compound Identifier 3047856. European Medicines Agency schedules Pirralkonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09942MIG. The term PIRRALKONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). Most nations, for tariff and trade purposes, schedule pirralkonium bromide under HS 29339990 and SITC 51577. As of Q4 2014, PIRRALKONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Pirralkonium bromide bears US NLM identifiers UMLS ID C1882398 and NCI Concept Code C66436. SMILES: CCCCCCCCCCCCCCCC[N+](C)(CCCN1C(CCC1C)C)CCCN2C(CCC2C)C.[BR-].
This classification denotes a topical anti-infective agent with the molecular formula C21H38N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S6ON6743TM, chemically known as 1,4-dihydro-1-octyl-4-(octylimino)pyridine but more generally known as pirtenidine, which bears US NIH Compound Identifier 65879. European Medicines Agency schedules Pirtenidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09944MIG. The term PIRTENIDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). PIRTENIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: N1(CCCCCCCC)CC/C(=N/CCCCCCCC)CC1.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C25H24FNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M5681Q5F9P, chemically known as 6-heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))- but generally known as pitavastatin, which bears US NIH Compound Identifier 6366718. European Medicines Agency schedules Pitavastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21363. The term PITAVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules pitavastatin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule pitavastatin under HS 29334990 and SITC 51575. As of Q4 2014, PITAVASTATIN remains the US FDA Preferred Term for this commodity. Pitavastatin bears US NLM identifiers UMLS ID C1101838 and NCI Concept Code C87751. SMILES: Fc1ccc(c2c(c(nc3c2cccc3)C2CC2)/C=C/C(O)CC(O)CC(=O)O)cc1.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZIB93J9J6L. European Medicines Agency schedules Pitenodil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09945MIG. Pitenodil generally arises in the molecular formula C17H27N3O3S. The term PITENODIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) PITENODIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pitenodil under HS 29349990 and SITC 51579. As of Q4 2014, PITENODIL remains the US FDA Preferred Term for this commodity. Pitenodil bears US NLM identifiers UMLS ID C1882400 and NCI Concept Code C66438. SMILES: s1c(C(=O)CCCN2CCN(CC2)CCOC(=O)N(C)C)ccc1.
This classification denotes an antispasmotic agent with the molecular formula C22H25NO4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HE1ZA4ZBEX. European Medicines Agency schedules pitofenone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03880MIG. The term pitofenone hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule pitofenone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PITOFENONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC(=O)C1CCCCC1C(=O)C2CCC(CC2)OCCN3CCCCC3.CL.
This classification denotes an antispasmotic agent with the molecular formulas C22H25NO4 and C22H25NO4.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers M09N8K7YJY and HE1ZA4ZBEX. European Medicines Agency schedules Pitofenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB09946MIG and SUB03880MIG. The term PITOFENONE is an International Non-Proprietary Name or INN. PITOFENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pitofenone and its salts under HS 29333999 and SITC 51574. As of Q4 2014, PITOFENONE remains the US FDA Preferred Term for this commodity. Pitofenone bears US NLM NCI Concept Code C73177. SMILES: O(CCN1CCCCC1)C1CCC(CC1)C(=O)C1C(CCCC1)C(=O)OC (base) or COC(=O)C1CCCCC1C(=O)C2CCC(CC2)OCCN3CCCCC3.CL (hydrochloride).
This classification denotes an anticonvulsant agent with the molecular formula C9H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C53SV0WO4V, chemically known as 4-((2,2-dimethylpropionyl)amino)butyric acid but generally known as pivagabine, which bears US NIH Compound Identifier 68888. European Medicines Agency schedules Pivagabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09948MIG. The term PIVAGABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules pivagabine in its Anatomical Therapeutic Chemical (ATC) Classification. PIVAGABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pivagabine under HS 29241900 and SITC 51471. As of Q4 2014, PIVAGABINE remains the US FDA Preferred Term for this commodity. Pivagabine bears US NLM identifiers UMLS ID C0619323 and NCI Concept Code C66440. SMILES: O=C(NCCCC(=O)O)C(C)(C)C.
This classification denotes a penicillin antibiotic with the molecular formula C22H29N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0HLM346LL7, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (2s-(2alpha,5alpha,6beta(s*)))- but generally known as pivampicillin, which bears US NIH Compound Identifier 33478. European Medicines Agency schedules Pivampicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09949MIG. The term PIVAMPICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules pivampicillin in its Anatomical Therapeutic Chemical (ATC) Classification. PIVAMPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pivampicillin under HS 29411020 and SITC 54131. As of Q4 2014, PIVAMPICILLIN remains the US FDA Preferred Term for this commodity. Pivampicillin bears US NLM identifiers UMLS ID C0032032 and NCI Concept Code C84068. SMILES: S1C2N(C(C1(C)C)C(=O)OCOC(=O)C(C)(C)C)C(=O)C2NC(=O)C(N)C1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C22H29N3O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9HOC53L7L, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as pivampicillin hydrochloride, which bears US NIH Compound Identifier 33477. European Medicines Agency schedules Pivampicillin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03883MIG. Most nations, for tariff and trade purposes, schedule pivampicillin hydrochloride under HS 29411020 and SITC 54131. As of Q4 2014, PIVAMPICILLIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pivampicillin hydrochloride bears US NLM identifiers UMLS ID C0085884 and NCI Concept Code C73834. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)OCOC(=O)C(C)(C)C)C.CL.
This classification denotes a penicillin antibiotic with the molecular formula C23H16O6.2C22H29N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z5TRG74EY, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (2s-((2 alpha, 5 alpha, 6 beta(s*))))-, 4,4-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (2:1) but more generally known as pivampicillin pamoate, which bears US NIH Compound Identifier 3084732. Most nations, for tariff and trade purposes, schedule pivampicillin pamoate under HS 29411020 and SITC 54131. As of Q4 2014, PIVAMPICILLIN PAMOATE remains US FDA's Preferred Term for this commodity. Pivampicillin pamoate bears US NLM identifiers UMLS ID C2347522 and NCI Concept Code C73835. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)OCOC(=O)C(C)(C)C)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)OCOC(=O)C(C)(C)C)C.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an adrenergic agent with the molecular formula C14H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RB4XQ0T71U, chemically known as propanoic acid, 2,2-dimethyl-, 3-(1-hydroxy-2-(methylamino)ethyl)phenyl ester but generally known as pivenfrine, which bears US NIH Compound Identifier 130545. European Medicines Agency schedules Pivenfrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09950MIG. The term PIVENFRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). PIVENFRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pivenfrine under HS 29225000 and SITC 51467. As of Q4 2014, PIVENFRINE remains the US FDA Preferred Term for this commodity. Pivenfrine bears US NLM identifiers UMLS ID C1882403 and NCI Concept Code C66442. SMILES: O(C(=O)C(C)(C)C)C1CC(C(O)CNC)CCC1.
This classification denotes a penicillin antibiotic with the molecular structure C21H33N3O5S.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 48FX7N21H2 chemically known as hydroxymethyl (2s,5r,6r)-6-(((hexahydro-1h-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate pivalate (ester) hydrochloride, but more commonly known as pivmecillinam hydrochloride, which bears US NIH Compound Identifier 115162. European Medicines Agency schedules Pivmecillinam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03884MIG. Most nations, for tariff and trade purposes, schedule pivmecillinam hydrochloride under HS 29419000. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C.CL.
This classification denotes a penicillin antibiotic with the molecular formula C21H33N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1WAM1OQ30B, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((hexahydro-1h-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (2s-(2alpha,5alpha,6beta))- but generally known as amdinocillin pivoxil, which bears US NIH Compound Identifier 36272. European Medicines Agency schedules Amdinocillin pivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB36043. World Health Organization schedules amdinocillin pivoxil in its Anatomical Therapeutic Chemical (ATC) Classification. Pivmecillinam or amdinocillin pivoxil bears US NLM identifiers UMLS ID C0002436 and NCI Concept Code C76216. SMILES: S1C2N(C(C1(C)C)C(=O)OCOC(=O)C(C)(C)C)C(=O)C2/N=C/N1CCCCCC1.
This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3V6I5962EM. European Medicines Agency schedules Pivopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09952MIG. Pivopril generally arises in the molecular formula C16H27NO4S. The term PIVOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) PIVOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pivopril under HS 29309085 and SITC 51549. As of Q4 2014, PIVOPRIL remains the US FDA Preferred Term for this commodity. Pivopril bears US NLM identifiers UMLS ID C1882404 and NCI Concept Code C66443. SMILES: S(CC(C(=O)N(C1CCCC1)CC(=O)O)C)C(=O)C(C)(C)C.
This classification denotes an anxiolytic with the molecular formula C20H19ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4ER8Z6Q3U, chemically known as 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepin-2-one pivalate (ester) but generally known as pivoxazepam, which bears US NIH Compound Identifier 68722. European Medicines Agency schedules Pivoxazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09953MIG. The term PIVOXAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). PIVOXAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pivoxazepam under HS 29339940 and SITC 51577. As of Q4 2014, PIVOXAZEPAM remains the US FDA Preferred Term for this commodity. Pivoxazepam bears US NLM identifiers UMLS ID C0605583 and NCI Concept Code C73207. SMILES: CLC1CC2C(=NC(OC(=O)C(C)(C)C)C(=O)NC2CC1)C1CCCCC1.
This classification denotes an intercalating agent with the molecular formula C17H19N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5SXN2KNMR, chemically known as 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione but generally known as pixantrone, which bears US NIH Compound Identifier 134019. European Medicines Agency schedules Pixantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21304. The term PIXANTRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 1, 2004, List 51). World Health Organization schedules pixantrone in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule pixantrone under HS 29339990 and SITC 51577. As of Q4 2014, PIXANTRONE remains the US FDA Preferred Term for this commodity. Pixantrone bears US NLM identifiers UMLS ID C0253355 and NCI Concept Code C26663. SMILES: O=C1C2C(C(NCCN)CCC2NCCN)C(=O)C2C1CCNC2.
This classification denotes a serotonin antagonist with the molecular formula C19H21NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0BY8440V3N, chemically known as 4-(9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2-b)thien-4-ylidene)-1-methylpiperidine but generally known as pizotifen, which bears US NIH Compound Identifier 27400. European Medicines Agency schedules Pizotifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09954MIG. The term PIZOTIFEN is an International Non-Proprietary Name. World Health Organization schedules pizotifen in its Anatomical Therapeutic Chemical (ATC) Classification. PIZOTIFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pizotifen or pizotyline bears US NLM identifiers UMLS ID C0032036 and NCI Concept Code C87214. SMILES: s1c2c(C(=C3\CCN(CC3)C)/c3c(CC2)cccc3)cc1.
This classification denotes vaccines for an acute infectious disease caused by yersinia pestis that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.
This classification denotes an anti-ulcer agent with the molecular formula C20H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MV715X4634, chemically known as 2,6,10,14-hexadecatetraen-1-ol, 7-(hydroxymethyl)-3,11,15-trimethyl-, (e,z,e)- but generally known as plaunotol, which bears US NIH Compound Identifier 5282197. European Medicines Agency schedules Plaunotol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09956MIG. The term PLAUNOTOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). PLAUNOTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule plaunotol under HS 29053985 and SITC 51229. As of Q4 2014, PLAUNOTOL remains the US FDA Preferred Term for this commodity. Plaunotol bears US NLM identifiers UMLS ID C0071276 and NCI Concept Code C66446. SMILES: OCC(=C\CC/C(=C/CO)C)/CC/C=C(/CC/C=C(/C)C)C.
This classification denotes an anti-infective agent with the molecular formula C18H18F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9H4570Q89D, chemically known as 1,2,4-oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- but generally known as pleconaril, which bears US NIH Compound Identifier 1684. European Medicines Agency schedules Pleconaril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09957MIG. The term PLECONARIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). World Health Organization schedules pleconaril in its Anatomical Therapeutic Chemical (ATC) Classification. PLECONARIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pleconaril under HS 29349990 and SITC 51579. As of Q4 2014, PLECONARIL remains the US FDA Preferred Term for this commodity. Pleconaril bears US NLM identifiers UMLS ID C0759032 and NCI Concept Code C81604. SMILES: FC(F)(F)c1onc(n1)c1cc(c(OCCCc2onc(c2)C)c(c1)C)C.
This classification denotes a chemokine receptor antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S915P5499N. European Medicines Agency schedules Plerixafor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB28849. Plerixafor generally arises in the molecular formula C28H54N8. The term PLERIXAFOR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55.) PLERIXAFOR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule plerixafor under HS 29339990 and SITC 51577. As of Q4 2014, PLERIXAFOR remains the US FDA Preferred Term for this commodity. Plerixafor bears US NLM identifiers UMLS ID C0257001 and NCI Concept Code C1777. SMILES: C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.
This classification denotes an antineoplastic antibiotic and dna minor groove binding agent and bone resorption inhibitor with the molecular formula C52H76O24, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NIJ123W41V, chemically known as 1(2h)-anthracenone, 6-((2,6-dideoxy-3-o-(2,6-dideoxy-beta-d-arabino-hexopyranosyl)-beta-d-arabino-h)-2-((o-2,6-dideoxy-3-c-methyl-beta-d-ribohexopyranosyl-(1,4)-o-2,6-dideoxy-alpha-d-lyxo-hexpyranosyl-(1-3)-2,6-dideoxy-beta-d-arabino-hexpyranosyl)oxy)-3-(3,4-dihydroxy-1-methoxy-2-oxopentyl)-3,4-dihydro-8,9-dihydroxy-7-methyl-, (2s-alpha,3beta(1r*,3r*4s*)))- but generally known as plicamycin, which bears US NIH Compound Identifier 29051. European Medicines Agency schedules Plicamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09959MIG. The term PLICAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules plicamycin in its Anatomical Therapeutic Chemical (ATC) Classification. PLICAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule plicamycin under HS 29419000 and SITC 54139. As of Q4 2014, PLICAMYCIN remains the US FDA Preferred Term for this commodity. Plicamycin bears US NLM identifiers UMLS ID C0026234 and NCI Concept Code C658. SMILES: O(C1CC(OC2C(CC3C(C2=O)C(O)C2C(C3)CC(OC3OC(C(O)C(OC4OC(C(O)C(O)C4)C)C3)C)C(C2O)C)C(OC)C(=O)C(O)C(O)C)OC(C1O)C)C1OC(C(O)C(OC2OC(C(O)C(O)(C2)C)C)C1)C.
This classification denotes vaccines for vaccines or candidate vaccines used to prevent infections with streptococcus pneumoniae.
This classification denotes a vasodilating agent with the molecular formula C18H23N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LI81FMI713, chemically known as 1-(alpha-methyl-3,4-(methylenedioxy)phenethyl)-4-(4-methyl-2-thiazolyl)piperazine. but generally known as podilfen, which bears US NIH Compound Identifier 3050403. European Medicines Agency schedules Podilfen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09962MIG. The term PODILFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). PODILFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule podilfen under HS 29341000 and SITC 51579. As of Q4 2014, PODILFEN remains the US FDA Preferred Term for this commodity. Podilfen bears US NLM identifiers UMLS ID C1882411 and NCI Concept Code C66448. SMILES: s1c(N2CCN(C(Cc3cc4OCOc4cc3)C)CC2)nc(c1)C.
This classification denotes a colchicine-site binding agent with the molecular formula C22H22O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L36H50F353, chemically known as furo(3,4:6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)- but more generally known as podofilox, which bears US NIH Compound Identifier 4865. European Medicines Agency schedules Podofilox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14925MIG. World Health Organization schedules podofilox in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PODOFILOX remains US FDA's Preferred Term for this commodity. Podofilox bears US NLM identifiers UMLS ID C0032334 and NCI Concept Code C29368. SMILES: O1CC2C(C(C3C(C2O)CC2OCOC2C3)C2CC(OC)C(OC)C(OC)C2)C1=O.
This classification denotes a colchicine-site binding agent with the molecular formula C22H22O8, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier L36H50F353, chemically known as furo(3,4:6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)- but more generally known as podofilox, which bears U.S. NIH Compound Identifier 4865. European Medicines Agency schedules Podofilox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14925MIG. World Health Organization schedules podofilox in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 16902YVY2B, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 18849 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Ranunculanae, Order Ranunculales, Family Berberidaceae, Genus Podophyllum L., commonly known as MAYAPPLE. Podophyllinum bears the USDA PLANTS Database Identifier PODOP. European Medicines Agency schedules podophyllinum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB14928MIG, SUB14929MIG, SUB29834, SUB46893, SUB46894, SUB46895, SUB46896, and SUB46897. As of Q4 2014, PODOPHYLLUM RESIN remains the US FDA Preferred Term for this commodity. SMILES: COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O.COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O.COC1=CC(=CC(=C1OC)OC)C2C(C(C(C3=CC4=C(C=C23)OCO4)O)CO)C(=O)O.COC1=CC(=CC(=C1OC)OC)C2C(C(C(C3=CC4=C(C=C23)OCO4)O)CO)C(=O)O.
This classification denotes a tissue adhesive, detergent, and sclerosing solution with the molecular formula C12H26O(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0AWH8BFG9A, chemically known as 3,6,9,12,15,18,21,24,27-nonaoxanonatriacontan-1-ol but generally known as polidocanol, which bears US NIH Compound Identifier 24750. European Medicines Agency schedules Polidocanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03917MIG. World Health Organization schedules polidocanol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, POLIDOCANOL remains the US FDA Preferred Term for this commodity. SMILES: O(CCCCCCCCCCCC)CCO.
This classification denotes a 3.5 per cent colloidal solution containing urea-cross-linked polymerized peptides, with a molecular weight of approximately 35,000, and which manufacturers derive from from gelatin and electrolytes, into a polymeric solution that serves as a plasma expander. European Medicines Agency schedules Polygeline (or Poligeline) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03935MIG.
This classification denotes a biguanide-based antiseptic and disinfectant with the molecular formula (C8H17N5)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 322U039GMF, chemically known as 1-(diaminomethylidene)-2-hexylguanidine but generally known as polihexanide, which bears US NIH Compound Identifier 20977. European Medicines Agency schedules polihexanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09970MIG. Most nations schedule polihexanide under HS 39119099 and SITC 57596. As of Q4 2014, POLIHEXANIDE remains the US FDA Preferred Term for this commodity. SMILES: CCCCCCN=C(N)N=C(N)N.
This classification denotes a vaccine for a species of enterovirus which is the causal agent of poliomyelitis in humans. Three serotypes (strains) exist. Transmission is by the fecal-oral route, pharyngeal secretions, or mechanical vector (flies). Vaccines with both inactivated and live attenuated virus have proven effective in immunizing against the infection.
This classification denotes a therapeutic estradiol with the molecular formula ((C18H22O3P(C18H22O)n)n(C18H23O4P)n)co, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P14877CDX2, chemically known as 17-beta-estra 1,3,5(10)-triene-3,17-diol, 17-dihydrogen phosphate, homopolymer but generally known as polyestradiol phosphate, which bears US NIH Compound Identifier 66435. European Medicines Agency schedules Polyestradiol phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09973MIG. The term POLYESTRADIOL PHOSPHATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules polyestradiol phosphate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule polyestradiol phosphate under HS 29372300 and SITC 54153. As of Q4 2014, POLYESTRADIOL PHOSPHATE remains the US FDA Preferred Term for this commodity. Polyestradiol phosphate bears US NLM identifiers UMLS ID C0071554 and NCI Concept Code C1199. SMILES: CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O.OP(=O)(O)O.
This classification denotes a synthetic polymer with the molecular formula C2H6O2(C2H4O)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B697894SGQ. European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. The term polyethylene glycol 400 is an International Nomenclature of Cosmetic Ingredients designation. European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. Polyethylene glycol bears US NLM identifiers UMLS ID C0032483 and NCI Concept Code C762. SMILES: COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO.
This classification denotes a synthetic polymer with the molecular formula C2H6O2(C2H4O)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B697894SGQ. European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. The term polyethylene glycol 400 is an International Nomenclature of Cosmetic Ingredients designation. As of Q4 2014, POLYETHYLENE GLYCOL 400 remains the US FDA Preferred Term for this commodity.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP600. This VA Drug Class (OP600) classifies this compound as belonging to the group MYDRIATICS/CYCLOPLEGICS, TOPICAL OPHTHALMIC.
Used in the treatment of bronchitis, pharyngitis, laryngitis, asthma, emphysema
This classification denotes a polymyxin antibiotic with the molecular formula C55H95N16O13R, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2VZ07J96K, more generally known as polymyxin b. European Medicines Agency schedules polymyxin b in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03937MIG. The term POLYMYXIN B is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 13, no. 12, 1959, list 3. Most nations schedule polymyxin b under HS 29419000 and SITC 54139. As of Q4 2014, POLYMYXIN B remains the US FDA Preferred Term for this commodity. Polymyxin b bears US NLM identifiers UMLS ID C0032535 and NCI Concept Code C61894. SMILES: CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)C(C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP219. This VA Drug Class (OP219) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL OPHTHALMIC, OTHER.
This classification denotes an antihelminthic agent with the molecular formula C2H6N2O2, chemically known as formaldehyde;urea but generally known as polynoxylin, which bears US NIH Compound Identifier 62705. European Medicines Agency schedules Polynoxylin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03939MIG. The term POLYNOXYLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5.). World Health Organization schedules polynoxylin in its Anatomical Therapeutic Chemical (ATC) Classification. POLYNOXYLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule polynoxylin under HS 39091000 and SITC 57541. SMILES: C=O.C(=O)(N)N.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes an electrolyte replacement agent with the molecular formula C2H6(C8H9O3S)N.(C8H8(C2H3)XL)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70KO0R01RY. SMILES: C=CC1=CC=CC=C1S(=O)(=O)[O-].[CA+2].
This classification denotes a thiazide diuretic with the molecular formula C11H13ClF3N3O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36780APV5N, chemically known as 6-chloro-3,4-dihydro-2-methyl-7-sulphamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2h-benzo-1,2,4-thiadiazine 1,1-dioxide but generally known as polythiazide, which bears US NIH Compound Identifier 4870. European Medicines Agency schedules Polythiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09976MIG. The term POLYTHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules polythiazide in its Anatomical Therapeutic Chemical (ATC) Classification. POLYTHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule polythiazide under HS 29350090 and SITC 51580. As of Q4 2014, POLYTHIAZIDE remains the US FDA Preferred Term for this commodity. Polythiazide bears US NLM identifiers UMLS ID C0032613 and NCI Concept Code C47676. SMILES: CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)CL)CSCC(F)(F)F.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
Used as the embolic agent in a Uterine Fibroid Embolectomy (UFE)
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes an immunosuppressant, a biological preparation with the molecular formula C13H11N3O4 and that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2UX06XLB5, chemically known as 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione or 4-Aminothalidomide but more commonly known as pomalidomide, which bears US NIH Compound Identifier 134780. The term POMALIDOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 1, 2008, List 59). European Medicines Agency schedules pomalidomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33379. SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N.
This classification denotes an aldose reductase inhibitor with the molecular formula C17H12BrFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2CV0A5G64E, chemically known as 3-(4-bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid but generally known as ponalrestat, which bears US NIH Compound Identifier 5278. European Medicines Agency schedules Ponalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09978MIG. The term PONALRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). PONALRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ponalrestat under HS 29339990 and SITC 51577. As of Q4 2014, PONALRESTAT remains the US FDA Preferred Term for this commodity. Ponalrestat bears US NLM identifiers UMLS ID C0071716 and NCI Concept Code C82173. SMILES: BRC1CC(F)C(CN2NC(C3C(C2=O)CCCC3)CC(=O)O)CC1.
This classification denotes an antiprotozoal agent with the molecular formula C18H14F3N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JPW84AS66U, chemically known as 1-methyl-3-(4-(p-((trifluoromethyl)sulfonyl)phenoxy)-m-tolyl)-s-triazine-2,4,6(1h,3h,5h)-trione. but generally known as ponazuril, which bears US NIH Compound Identifier 3050408. The term PONAZURIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule ponazuril under HS 29336980 and SITC 51576. As of Q4 2014, PONAZURIL remains the US FDA Preferred Term for this commodity. Ponazuril bears US NLM identifiers UMLS ID C0961649 and NCI Concept Code C72600. SMILES: CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F.
This classification denotes an anti-lipidemic agent with the molecular formula C18H16Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0ARR2L0V0A, chemically known as 12h-dibenzo(d,g)(1,3)dioxocin-6-carboxylic acid, 2,10-dichloro-12-methyl-, ethyl ester, trans- but generally known as ponfibrate, which bears US NIH Compound Identifier 68701. European Medicines Agency schedules Ponfibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09979MIG. The term PONFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). PONFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ponfibrate under HS 29329970 and SITC 51569. As of Q4 2014, PONFIBRATE remains the US FDA Preferred Term for this commodity. Ponfibrate bears US NLM identifiers UMLS ID C2347628 and NCI Concept Code C72994. SMILES: Clc1cc2C(c3c(OC(Oc2cc1)C(=O)OCC)ccc(Cl)c3)C.
This classification denotes a respiratory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KE3U2023NP. Amiphenazole most often comes in base and hydrochloride forms. European Medicines Agency schedules Poractant Alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22150. As of Q4 2014, PORACTANT ALFA remains the US FDA Preferred Term for this commodity.
This classification denotes a photosensitizing agent with the molecular formula (C34H36N4O5)n.(C34H34N4O4)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M15H03K69B, chemically known as 21h,23h-porphine-2,18-dipropanoic acid, 7-(1-(1-(8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21h,23h-porphin-2-yl)ethoxy)ethyl)-12-(1-hydroxyethyl)-3,8,13,17-tetramethyl- but generally known as porfimer, which bears US NIH Compound Identifier 57166. European Medicines Agency schedules Porfimer in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03954MIG. PORFIMER is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PORFIMER remains the US FDA Preferred Term for this commodity. Porfimer bears US NLM identifiers UMLS ID CL386365 and NCI Concept Code C76306. SMILES: CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)OC(C)C6=C(C7=CC8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)O. .
This classification denotes a photosensitizing agent with the molecular formula (C34H35N4NaO5)n.(C34H33N4NaO4)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3834SIK5F, chemically known as 21h,23h-porphine-2,18-dipropanoic acid, 7-(1-(1-(8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21h,23h-porphin-2-yl)ethoxy)ethyl)-12-(1-hydroxyethyl)-3,8,13,17-tetramethyl- but generally known as porfimer sodium, which bears US NIH Compound Identifier 57166. European Medicines Agency schedules Porfimer sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03955MIG. The term PORFIMER SODIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules porfimer sodium in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule porfimer sodium under HS 38249064 and SITC 59899. As of Q4 2014, PORFIMER SODIUM remains the US FDA Preferred Term for this commodity. Porfimer sodium bears US NLM identifiers UMLS ID C0058031 and NCI Concept Code C1071. SMILES: CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)OC(C)C6=C(C7=CC8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)O.
This classification denotes a mitomycin antibiotic with the molecular formula C16H20N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1WK901OA6, chemically known as 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-1,5-dimethylazirino(2,3:3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester) but more generally known as porfiromycin, which bears US NIH Compound Identifier 13116. European Medicines Agency schedules Porfiromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09980MIG. The term PORFIROMYCIN is an International Non-Proprietary Name. PORFIROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C12N(CC3N(C13)C)C1=C(C2COC(=O)N)C(=O)C(=C(C1=O)C)N)C.
This classification denotes an antifungal agent with the molecular formula C37H42F2N8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6TK1G07BHZ, chemically known as d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1s,2s)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1h-1,2,4-triazol-1-yl)- but generally known as posaconazole, which bears US NIH Compound Identifier 147912. European Medicines Agency schedules Posaconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20322. The term POSACONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). World Health Organization schedules posaconazole in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule posaconazole under HS 29349990 and SITC 51579. As of Q4 2014, POSACONAZOLE remains the US FDA Preferred Term for this commodity. Posaconazole bears US NLM identifiers UMLS ID C0936148 and NCI Concept Code C61500. SMILES: FC1C(C2(OCC(C2)COC2CCC(N3CCN(CC3)C3CCC(N4C(=O)N(NC4)C(C(O)C)CC)CC3)CC2)CN2NCNC2)CCC(F)C1.
This classification denotes an electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M911911U02. European Medicines Agency schedules Potassium acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14962MIG. Potassium acetate generally arises in the molecular formula C2H4O2.K. The term POTASSIUM ACETATE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule potassium acetate under HS 29152900 and SITC 51371. As of Q4 2014, POTASSIUM ACETATE remains the US FDA Preferred Term for this commodity. Potassium acetate bears US NLM identifiers UMLS ID C0137984 and NCI Concept Code C47677. SMILES: CC(=O)[O-].[K+].
Potassium is an essential nutrient found naturally and necessary for many normal functions. It is used to prevent or to treat a potassium deficiency (hypokalemia).
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA110. This VA Drug Class (GA110) classifies this compound as belonging to the group SODIUM BICARBONATE CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS300. This VA Drug Class (RS300) classifies this compound as belonging to the group LAXATIVES, RECTAL.
This classification denotes an industrial aid with the molecular formula BR.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OSD78555ZM. European Medicines Agency schedules potassium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14970MIG. The term potassium bromide is a U.S. Pharmacopeial Convention designation. Most nations schedule potassium bromide under HS 28275100 and SITC 52329. As of Q4 2014, POTASSIUM BROMIDE remains the US FDA Preferred Term for this commodity. Potassium bromide bears US NLM identifiers UMLS ID C0071754 and NCI Concept Code C76725. SMILES: [K+].[Br-].
This classification denotes an electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 660YQ98I10. European Medicines Agency schedules Potassium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12559MIG. Potassium chloride generally arises in the molecular formula CLK. The term 'potassium chloride' is a United States Homeopathic Pharmacopoeia Name designation. As of Q4 2014, POTASSIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Potassium chloride bears US NLM identifiers UMLS ID C0032825 and NCI Concept Code C47679. SMILES: [CL-].[K+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV900. This VA Drug Class (CV900) classifies this compound as belonging to the group CARDIOVASCULAR AGENTS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN102. This VA Drug Class (TN102) classifies this compound as belonging to the group IV SOLUTIONS WITH ELECTROLYTES.
Electrolyte replacement solutions containing potassium chloride, sodium chloride and dextrose.
This product is used to replace fluids and minerals (such as sodium, potassium) lost due to diarrhea and vomiting. It helps prevent or treat the loss of too much body water (dehydration). Having the right amount of fluids and minerals is important for the normal functioning of the body.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class TN900. This VA Drug Class (TN900) classifies this compound as belonging to the group THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYES, OTHER.
Electrolyte replacement solution of potassium chloride in water.
This classification denotes an electrolyte replacement agent with the molecular formula C6H5O7.3K.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EE90ONI6FF, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, tripotassium salt but more generally known as potassium citrate, which bears U.S. NIH Compound Identifier 13344. European Medicines Agency schedules Potassium citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14973MIG. World Health Organization schedules potassium citrate in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.
This classification denotes a radioprotective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1C4QK22F9J. European Medicines Agency schedules Potassium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14985MIG. Potassium iodide generally arises in the molecular formula IK. The term POTASSIUM IODIDE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule potassium iodide under HS 28276000 and SITC 52329. As of Q4 2014, POTASSIUM IODIDE remains the US FDA Preferred Term for this commodity. Potassium iodide bears US NLM identifiers UMLS ID C0032831 and NCI Concept Code C47680. SMILES: [K+].[I-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.
This classification denotes an antithyroid agent with the molecular formula ClO4.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42255P5X4D, chemically known as perchloric acid, potassium salt but generally known as potassium perchlorate, which bears US NIH Compound Identifier 24505. European Medicines Agency schedules Potassium perchlorate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14990MIG. World Health Organization schedules potassium perchlorate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule potassium perchlorate under HS 28299000 and SITC 52339. As of Q4 2014, POTASSIUM PERCHLORATE remains the US FDA Preferred Term for this commodity. Potassium perchlorate bears US NLM identifiers UMLS ID C0071774 and NCI Concept Code C47681. SMILES: [K].[Cl](=O)(=O)(=O)O.
This classification denotes an electrolyte replacement agent with the molecular formula 2K.HO4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CI71S98N1Z, chemically known as potassium phosphate, monobasic (jan/nf) but generally known as potassium phosphate, which bears US NIH Compound Identifier 24506. European Medicines Agency schedules Potassium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21612. Potassium phosphate bears US NLM identifiers UMLS ID C0071778 and NCI Concept Code C29373. SMILES: OP(=O)(O)[O-].[K+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H5O3.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K91YT16P5M, chemically known as benzoic acid, 2-hydroxy-, monopotassium salt but generally known as potassium salicylate, which bears US NIH Compound Identifier 11355. European Medicines Agency schedules Potassium salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14994MIG. World Health Organization schedules potassium salicylate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, POTASSIUM SALICYLATE remains the US FDA Preferred Term for this commodity. Potassium salicylate bears US NLM identifiers UMLS ID C0770438 and NCI Concept Code C84100. SMILES: C1=CC=C(C(=C1)C(=O)[O-])O.[K+].
This classification denotes a laxative with the molecular formula C4H4O6.K.Na.4H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QH257BPV3J, chemically known as 2,3-dihydroxybutanedioic acid, monopotassium monosodium salt but generally known as potassium sodium tartrate, which bears US NIH Compound Identifier 9357. European Medicines Agency schedules Potassium sodium tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12561MIG. As of Q4 2014, POTASSIUM SODIUM TARTRATE remains the US FDA Preferred Term for this commodity. Potassium sodium tartrate bears US NLM identifiers UMLS ID C0770985 and NCI Concept Code C80954. SMILES: [C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O.[Na+].[K+].
This classification denotes a synthetic polymer with the molecular formula (C6H9NO)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZ989GH94E, chemically known as 2-pyrrolidinone, 1-vinyl-, polymers, compd. with aluminum acetate but generally known as povidone, which bears US NIH Compound Identifier 6917. European Medicines Agency schedules Povidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12238MIG. The term POVIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). POVIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule povidone under HS 39059990 and SITC 57592. Povidone bears US NLM identifiers UMLS ID C0032856 and NCI Concept Code C77491. SMILES: C=CN1CCCC1=O.II.
This classification denotes a synthetic polymer with the molecular formula C6H9I2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85H0HZU99M, chemically known as 1-vinyl-2-pyrrolidinone polymer, compound with iodine, but more generally known as povidone iodine, which bears US NIH Compound Identifier 410087. European Medicines Agency schedules povidone iodine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12238MIG. Most nations, for tariff purposes, schedule povidone iodine under HS 39059990. SMILES:.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F1T8QT9U8B (base and leaf), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 33582 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Lamiales, Family Plantaginaceae, Genus Digitalis L. (foxglove), commonly known as foxglove or as here, DIGITALIS. Figitalis bears the USDA PLANTS Database Identifier DIGIT. European Medicines Agency schedules digitalis in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13579MIG (base) and SUB11904MIG (leaf).
This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SUG9176GRW, chemically known as acetanilide, 4-(2-hydroxy-3-(isopropylamino)propoxy)- but generally known as practolol, which bears US NIH Compound Identifier 4883. European Medicines Agency schedules Practolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09986MIG. The term PRACTOLOL is an International Non-Proprietary Name. World Health Organization schedules practolol in its Anatomical Therapeutic Chemical (ATC) Classification. PRACTOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule practolol under HS 29242995 and SITC 51479. As of Q4 2014, PRACTOLOL remains the US FDA Preferred Term for this commodity. Practolol bears US NLM identifiers UMLS ID C0032896 and NCI Concept Code C76556. SMILES: O(CC(O)CNC(C)C)C1CCC(NC(=O)C)CC1.
This classification denotes an anti-arrhythmia agent with the molecular formula C23H33N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75934UD4GJ, chemically known as ajmalanium, 17,21-dihydroxy-4-propyl-, (17r,21-alpha)- but more generally known as prajmaline, which bears US NIH Compound Identifier 37042. World Health Organization schedules prajmaline in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O. SMILES: CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O.
This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C23H23N7O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8Q8I19Q20, more generally known as pralatrexate. European Medicines Agency schedules pralatrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32989. The term PRALATREXATE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 19, no. 3, 2005, list 54. Most nations schedule pralatrexate under HS 29335995 and SITC 51576. As of Q4 2014, PRALATREXATE remains the US FDA Preferred Term for this commodity. Pralatrexate bears US NLM identifiers UMLS ID C0879404 and NCI Concept Code C2250. SMILES: C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.
This classification denotes a cholinergic agonist with the molecular formula C7H9N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7MU9UTP52, chemically known as pyridinium, 2-((hydroxyimino)methyl)-1-methyl-, iodide but generally known as pralidoxime, which bears US NIH Compound Identifier 5353894. European Medicines Agency schedules Pralidoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04002MIG. World Health Organization schedules pralidoxime in its Anatomical Therapeutic Chemical (ATC) Classification. PRALIDOXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PRALIDOXIME remains the US FDA Preferred Term for this commodity. Pralidoxime bears US NLM identifiers UMLS ID C0071808 and NCI Concept Code C78131. SMILES: O=[NH]/C=C1/N(CCCC1)C.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83619PEU5T. European Medicines Agency schedules Pramipexole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09990MIG. Pramipexole generally arises in the molecular formula C10H17N3S. The term PRAMIPEXOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) PRAMIPEXOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pramipexole under HS 29341000 and SITC 51579. As of Q4 2014, PRAMIPEXOLE remains the US FDA Preferred Term for this commodity. Pramipexole bears US NLM identifiers UMLS ID C0074710 and NCI Concept Code C66456. SMILES: CCCNC1CCC2=C(C1)SC(=N2)N.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C10H17N3S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3D867NP06J, chemically known as 2,6-benzothiazolediamine, 4,5,6,7-tetrahydro-n6-propyl-, dihydrochloride, (s)- but more generally known as pramipexole dihydrochloride, which bears US NIH Compound Identifier 119569. European Medicines Agency schedules Pramipexole dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04004MIG. Most nations, for tariff and trade purposes, schedule pramipexole dihydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, PRAMIPEXOLE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pramipexole dihydrochloride bears US NLM identifiers UMLS ID C0721754 and NCI Concept Code C29374. SMILES: CCCN[C@H]1CCC2C(SC(N2)N)C1.O.CL.CL.
This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C10H17N3S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3D867NP06J, chemically known as 2,6-benzothiazolediamine, 4,5,6,7-tetrahydro-n6-propyl-, dihydrochloride, (s)- but more generally known as pramipexole dihydrochloride, which bears US NIH Compound Identifier 119569. European Medicines Agency schedules Pramipexole dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04004MIG. Most nations, for tariff and trade purposes, schedule pramipexole dihydrochloride monohydrate under HS 29341000. SMILES: CCCN[C@H]1CCC2C(SC(N2)N)C1.O.CL.CL.
This classification denotes an antidepressant agent with the molecular formula C10H17N3S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3D867NP06J, chemically known as (s)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate, but more generally known as pramipexole hydrochloride hydrate, which bears US NIH Compound Identifier 166589. European Medicines Agency schedules pramipexole hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09990MIG. Most nations, for tariff purposes, schedule pramipexole hydrochloride hydrate under HS 29341000. SMILES: CCCN[C@H]1CCC2C(SC(N2)N)C1.O.CL.CL.
This classification denotes a neuroprotective agent with the molecular formula C14H27N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4449F8I3LE, chemically known as 2,1,3-benzothiadiazole, 5-chloro-4-(2-imidazolin-2-ylamino)- but more generally known as pramiracetam, which bears US NIH Compound Identifier 5487. European Medicines Agency schedules Pramiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09991MIG. The term PRAMIRACETAM is an International Non-Proprietary Name. World Health Organization schedules pramiracetam in its Anatomical Therapeutic Chemical (ATC) Classification. PRAMIRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pramiracetam under HS 29337900 and SITC 51561. As of Q4 2014, PRAMIRACETAM remains US FDA's Preferred Term for this commodity. Pramiracetam bears US NLM identifiers UMLS ID C0071809 and NCI Concept Code C84171. SMILES: CLC1C(NC2=NCCN2)C2NSNC2CC1.
This classification denotes a neuroprotective agent with the molecular formula C14H27N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WIU553VC0S, chemically known as 1-pyrrolidineacetamide, n-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo-, monohydrochloride; but more generally known as pramiracetam hydrochloride, which bears US NIH Compound Identifier 3050410. European Medicines Agency schedules Pramiracetam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04005MIG. Most nations, for tariff and trade purposes, schedule pramiracetam hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, PRAMIRACETAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pramiracetam hydrochloride bears US NLM identifiers UMLS ID C0956068 and NCI Concept Code C72831. SMILES: CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C.CL.
This classification denotes a neuroprotective agent with the molecular formula C14H27N3O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OP7O7MNS9P, chemically known as 1-pyrrolidineacetamide, n-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo, sulfate (1:1) but more generally known as pramiracetam sulfate, which bears US NIH Compound Identifier 51711. European Medicines Agency schedules Pramiracetam sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04006MIG. Most nations, for tariff and trade purposes, schedule pramiracetam sulfate under HS 29337900 and SITC 51561. As of Q4 2014, PRAMIRACETAM SULFATE remains US FDA's Preferred Term for this commodity. Pramiracetam sulfate bears US NLM identifiers UMLS ID C0956067 and NCI Concept Code C84103. SMILES: CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C.OS(=O)(=O)O.
This classification denotes an antispasmotic agent with the molecular formula C21H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 157NY06G9T, chemically known as 4,4-diphenyl-n-isopropylcyclohexylamine but generally known as pramiverin, which bears US NIH Compound Identifier 71681. European Medicines Agency schedules Pramiverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09992MIG. The term PRAMIVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). Pramiverin or pramiverine bears US NLM identifiers UMLS ID C0663384 and NCI Concept Code C73175. SMILES: CC(C)NC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3.
This classification denotes an anti-diabetic agent with the molecular formula C171H267N51O53S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D3FM8FA78T, chemically known as l-tyrosinamide, l-lysyl-l-cysteinyl-l-asparaginyl-l-threonyl-l-alanyl-l-threonyl-l-cysteinyl-l-alanyl-l-threonyl-l-glutaminyl-l-arginyl-l-leucyl-l-alanyl-l-asparaginyl-l-phenylalanyl-l-leucyl-l-valyl-l-histidyl-l-seryl-l-seryl-l-asparaginyl-l-asparaginyl-l-phenylalanylglycyl-l-prolyl-l-isoleucyl-l-leucyl-l-prolyl-l-prolyl-l-threonyl-l-asparaginyl-l-valylglycyl-l-seryl-l-asparaginyl-l-threonyl-, cyclic (2-7)-disulfide but more generally known as pramlintide, which bears US NIH Compound Identifier 16132446. European Medicines Agency schedules Pramlintide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09993MIG. The term PRAMLINTIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 10, No. 3, 1996, List 36) WHO schedules pramlintide in its Anatomical Therapeutic Chemical (ATC) Classification. PRAMLINTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pramlintide under HS 29349990 and SITC 51579. As of Q4 2014, PRAMLINTIDE remains US FDA's Preferred Term for this commodity. Pramlintide bears US NLM identifiers UMLS ID C0537551 and NCI Concept Code C61901. SMILES: SCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CCCCN)CS)CC(=O)N)C(O)C)C)C(O)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N1C(CCC1)C(=.
This classification denotes an anti-diabetic agent with the molecular formula C171H267N51O53S2.C2H4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 726I6TE06G. European Medicines Agency schedules pramlintide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12564MIG. The term pramlintide acetate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule pramlintide acetate under HS 29349990 and SITC 51579. As of Q4 2014, PRAMLINTIDE ACETATE remains US FDA's Preferred Term for this commodity. Pramlintide acetate bears US NLM identifiers UMLS ID C1174780 and NCI Concept Code C61902. SMILES: CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CN=CN6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(CS)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CS)NC(=O)C(CCCCN)N.
This classification denotes an anesthetic agent with the molecular formula C17H27NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88AYB867L5, chemically known as morpholine, 4-(3-(p-butoxyphenoxy)propyl)-, hydrochloride but more generally known as pramocaine hydrochloride, which bears US NIH Compound Identifier 73957. European Medicines Agency schedules Pramocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15004MIG. Most nations, for tariff and trade purposes, schedule pramocaine hydrochloride under HS 29349990. Pramocaine hydrochloride bears US NLM identifiers UMLS ID C0147008 and NCI Concept Code C47682. SMILES: CCCCOC1CCC(CC1)OCCCN2CCOCC2.CL.
This classification denotes an anesthetic agent with the molecular formula C17H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 068X84E056, chemically known as morpholine, 4-(3-(p-butoxyphenoxy)propyl)- but generally known as pramocaine, which bears US NIH Compound Identifier 4886. European Medicines Agency schedules Pramocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09994MIG. The term PRAMOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules pramocaine in its Anatomical Therapeutic Chemical (ATC) Classification. PRAMOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS201. This VA Drug Class (RS201) classifies this compound as belonging to the group HEMORRHOIDAL PREPARATIONS WITHOUT STEROID.
This classification denotes an anti-asthmatic agent and leukotriene antagonist with the molecular formula C27H23N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TB8Z891092, chemically known as benzamide, n-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)- but generally known as pranlukast, which bears US NIH Compound Identifier 115100. European Medicines Agency schedules Pranlukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09998MIG. World Health Organization schedules pranlukast in its Anatomical Therapeutic Chemical (ATC) Classification. PRANLUKAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pranlukast under HS 29349990 and SITC 51579. As of Q4 2014, PRANLUKAST remains the US FDA Preferred Term for this commodity. Pranlukast bears US NLM identifiers UMLS ID C0526058 and NCI Concept Code C96712. SMILES: O(CCCCC1CCCCC1)C1CCC(CC1)C(=O)NC1CC2OC(CC(=O)C2CC1)C1N[NH]NN1.
This classification denotes an anti-asthmatic agent and leukotriene antagonist with the molecular formula 2C27H23N5O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FR702N558K, chemically known as benzamide, n-(4-oxo-2-(2h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-, hydrate (2:1), but more generally known as pranlukast hydrate, which bears US NIH Compound Identifier 5311184. European Medicines Agency schedules pranlukast hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09998MIG. Most nations, for tariff purposes, schedule pranlukast hydrate under HS 29349990. SMILES: C1CCC(CC1)CCCCOC2CCC(CC2)C(=O)NC3CCCC4C3OC(CC4=O)C5[NH]NNN5.C1CCC(CC1)CCCCOC2CCC(CC2)C(=O)NC3CCCC4C3OC(CC4=O)C5[NH]NNN5.O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2R7O1ET613, chemically known as 5h-(1)benzopyrano(2,3,-b)pyridine-7-acetic acid, alpha-methyl- but generally known as pranoprofen, which bears US NIH Compound Identifier 4888. European Medicines Agency schedules Pranoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10000MIG. The term PRANOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules pranoprofen in its Anatomical Therapeutic Chemical (ATC) Classification. PRANOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pranoprofen under HS 29349990 and SITC 51579. As of Q4 2014, PRANOPROFEN remains the US FDA Preferred Term for this commodity. Pranoprofen bears US NLM identifiers UMLS ID C0072652 and NCI Concept Code C73092. SMILES: O1C2C(CC3C1NCCC3)CC(C(C)C(=O)O)CC2.
This classification denotes a therapeutic androgen with the molecular structure C19H27O5S.NA.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E1CR8487EN chemically known as androst-5-en-17-one, 3.beta.-hydroxy-, hydrogen sulfate, sodium salt, dihydrate, but more commonly known as prasterone sodium sulfate, which bears US NIH Compound Identifier 14193. European Medicines Agency schedules Prasterone sodium sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04010MIG. Most nations, for tariff and trade purposes, schedule prasterone sodium sulfate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)[O-])C.[NA+].
This classification denotes a therapeutic androgen C19H28O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57B09Q7FJR, chemically known as androst-5-en-17-one, 3-(sulfooxy)-, (3.beta.)-, but more generally known as prasterone sulfate, which bears US NIH Compound Identifier 12594. European Medicines Agency schedules Prasterone sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34548. Most nations, for tariff and trade purposes, schedule prasterone sulfate under HS 29372900 and SITC 54153. As of Q4 2014, PRASTERONE SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C.
This classification denotes an antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34K66TBT99. European Medicines Agency schedules Prasugrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30236. Prasugrel generally arises in the molecular formula C20H20FNO3S. The term PRASUGREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53.) Most nations schedule prasugrel under HS 29349990 and SITC 51579. As of Q4 2014, PRASUGREL remains the US FDA Preferred Term for this commodity. Prasugrel bears US NLM identifiers UMLS ID C1620287 and NCI Concept Code C81566. SMILES: S1C2CCN(C(C(=O)C3CC3)C3C(F)CCCC3)CC2CC1OC(=O)C.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C25H26N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66VLQ6E6DL. The term PRATOSARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47. ). Most nations schedule pratosartan under HS 29339990 and SITC 51577. As of Q4 2014, PRATOSARTAN remains the US FDA Preferred Term for this commodity. Pratosartan bears US NLM identifiers UMLS ID C2347659 and NCI Concept Code C72935. SMILES: CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)CCCCC2=O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C23H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P3JW662TWA, chemically known as methanone, (4-methoxyphenyl)(2-methyl-1-(2-(4-morpholinyl)ethyl)-1h-indol-3-yl)- but generally known as pravadoline, which bears US NIH Compound Identifier 56463. European Medicines Agency schedules Pravadoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10003MIG. The term PRAVADOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). PRAVADOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pravadoline under HS 29349990 and SITC 51579. As of Q4 2014, PRAVADOLINE remains the US FDA Preferred Term for this commodity. Pravadoline bears US NLM identifiers UMLS ID C0071815 and NCI Concept Code C84104. SMILES: O1CCN(CCN2C3C(C(C2C)C(=O)C2CCC(OC)CC2)CCCC3)CC1.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C23H26N2O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2DH4X8278M, chemically known as methanone, (4-methoxyphenyl)(2-methyl-1-(2-(4-morpholinyl)ethyl)-1h-indol-3-yl)- but more generally known as pravadoline maleate, which bears US NIH Compound Identifier 56463. Most nations, for tariff and trade purposes, schedule pravadoline maleate under HS 29349990 and SITC 51579. As of Q4 2014, PRAVADOLINE MALEATE remains US FDA's Preferred Term for this commodity. Pravadoline maleate bears US NLM identifiers UMLS ID C0209364 and NCI Concept Code C81065. SMILES: CC1C(C2CCCCC2N1CCN3CCOCC3)C(=O)C4CCC(CC4)OC.C(=C\C(=O)O)\C(=O)O.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C23H36O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KXO2KT9N0G, chemically known as 1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone but generally known as pravastatin, which bears US NIH Compound Identifier 53232. European Medicines Agency schedules Pravastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10004MIG. The term PRAVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules pravastatin in its Anatomical Therapeutic Chemical (ATC) Classification. PRAVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pravastatin under HS 29181985 and SITC 51392. As of Q4 2014, PRAVASTATIN remains the US FDA Preferred Term for this commodity. Pravastatin bears US NLM identifiers UMLS ID C0085542 and NCI Concept Code C62070. SMILES: O(C1C2C(C(C=CC2=CC(C1)C)C)CCC1OC(=O)CC(O)C1)C(=O)C(CC)C.
This classification denotes an antilipemic fungal metabolite, anticholesteremic agent, and hydroxymethylglutaryl-coa reductase inhibitor with the molecular formula C23H35O7.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3M8608UQ61, chemically known as 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1s-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(r*),8aalpha))-1-naphthaleneheptanoic acid but more generally known as pravastatin sodium, which bears US NIH Compound Identifier 54687. European Medicines Agency schedules Pravastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04011MIG. Most nations, for tariff and trade purposes, schedule pravastatin sodium under HS 29181985 and SITC 51392. As of Q4 2014, PRAVASTATIN SODIUM remains US FDA's Preferred Term for this commodity. Pravastatin sodium bears US NLM identifiers UMLS ID C0700763 and NCI Concept Code C29375. SMILES: CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)O.[NA+].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C16H14N2O6S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 24PUW23GRX, chemically known as phthalanilic acid, 4-(acetylsulfamoyl)- but more generally known as phthalylsulfacetamide, which bears U.S. National Institutes of Health Compound Identifier 8574. The European Medicines Agency schedules Phthalylsulfacetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35390. SMILES: S(=O)(=O)(NC(=O)C)C1CCC(NC(=O)C2C(CCCC2)C(=O)O)CC1.
This classification denotes a benzodiazepine with the molecular formula C19H17ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q30VCC064M, chemically known as 7-chloro-1-cyclopropylmethyl-5-phenyl-1h-1,4-benzodiazepin-2(3h)-one but generally known as prazepam, which bears US NIH Compound Identifier 4890. European Medicines Agency schedules Prazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10006MIG. The term PRAZEPAM is an International Non-Proprietary Name. World Health Organization schedules prazepam in its Anatomical Therapeutic Chemical (ATC) Classification. PRAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prazepam under HS 29339190 and SITC 51577. As of Q4 2014, PRAZEPAM remains the US FDA Preferred Term for this commodity. Prazepam bears US NLM identifiers UMLS ID C0032910 and NCI Concept Code C66458. SMILES: CLC1CC2C(N(CC3CC3)C(=O)CN=C2C2CCCCC2)CC1.
This classification denotes an antihelminthic agent with the molecular formula C19H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6490C9U457, chemically known as 4h-pyrazino(2,1-a)isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- but generally known as praziquantel, which bears US NIH Compound Identifier 4891. European Medicines Agency schedules Praziquantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10008MIG. The term PRAZIQUANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules praziquantel in its Anatomical Therapeutic Chemical (ATC) Classification. PRAZIQUANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule praziquantel under HS 29335995 and SITC 51576. As of Q4 2014, PRAZIQUANTEL remains the US FDA Preferred Term for this commodity. Praziquantel bears US NLM identifiers UMLS ID C0032911 and NCI Concept Code C47683. SMILES: O=C(N1CC2N(CCC3C2CCCC3)C(=O)C1)C1CCCCC1.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DZB018428. European Medicines Agency schedules Prazitone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10009MIG. Prazitone generally arises in the molecular formula C16H19N3O3. The term PRAZITONE is an International Non-Proprietary Name or INN. PRAZITONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prazitone under HS 29335400 and SITC kg. As of Q4 2014, PRAZITONE remains the US FDA Preferred Term for this commodity. Prazitone bears US NLM identifiers UMLS ID C1882439 and NCI Concept Code C66460. SMILES: O=C1NC(=O)NC(=O)C1(CC1NCCCC1)c1ccccc1.
This classification denotes an antidepressant agent C16H19N3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1N7P630564, chemically known as barbituric acid, 5-phenyl-5-(2-piperidylmethyl)-, monohydrochloride, but more generally known as prazitone hydrochloride, which bears US NIH Compound Identifier 24845095. European Medicines Agency schedules Prazitone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04012MIG. Most nations, for tariff and trade purposes, schedule prazitone hydrochloride under HS 29335400 and SITC kg. As of Q4 2014, PRAZITONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C2(C(=O)NC(=O)NC2=O)CC3CCCCN3.CL.
This classification denotes a penicillin antibiotic with the molecular formula C19H18Cl2N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IRZ1462XXF, chemically known as 6-(1-(2,6-dichlorophenyl)-4-methylpyrazole-5-carboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as prazocillin, which bears US NIH Compound Identifier 65622. European Medicines Agency schedules Prazocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10010MIG. The term PRAZOCILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). PRAZOCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prazocillin under HS 29411090 and SITC 54131. As of Q4 2014, PRAZOCILLIN remains the US FDA Preferred Term for this commodity. Prazocillin bears US NLM identifiers UMLS ID C0071817 and NCI Concept Code C72832. SMILES: Clc1c(n2ncc(c2C(=O)NC2C3SC(C(N3C2=O)C(=O)O)(C)C)C)c(Cl)ccc1.
This classification denotes an antihypertensive agent and alpha-adrenergic blocking agent with the molecular formula C19H21N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XM03YJ541D, chemically known as 4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone but generally known as prazosin, which bears US NIH Compound Identifier 4893. European Medicines Agency schedules Prazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10011MIG. The term PRAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules prazosin in its Anatomical Therapeutic Chemical (ATC) Classification. PRAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prazosin under HS 29349990 and SITC 51579. As of Q4 2014, PRAZOSIN remains the US FDA Preferred Term for this commodity. Prazosin bears US NLM identifiers UMLS ID C0032912 and NCI Concept Code C767. SMILES: O=C(N1CCN(CC1)C1NC2C(C(N1)N)CC(OC)C(OC)C2)C1OCCC1.
This classification denotes an antihypertensive agent and alpha-adrenergic blocking agent with the molecular formula C19H21N5O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X0Z7454B90, chemically known as 4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone but more generally known as prazosin hydrochloride, which bears US NIH Compound Identifier 4893. European Medicines Agency schedules Prazosin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04013MIG. Most nations, for tariff and trade purposes, schedule prazosin hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, PRAZOSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Prazosin hydrochloride bears US NLM identifiers UMLS ID C0700578 and NCI Concept Code C1507. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4CCCO4.CL.
This classification denotes an antipsychotic agent with the molecular formula C14H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V2O6CRQ6Z, chemically known as 3-[(3S)-1-propylpiperidin-3-yl]phenol but generally known as preclamol, which bears US NIH Compound Identifier 5311189. Most nations schedule preclamol under HS 29333999 and SITC 51574. As of Q4 2014, PRECLAMOL remains the US FDA Preferred Term for this commodity. Preclamol bears US NLM identifiers UMLS ID C0068168 and NCI Concept Code C82251. SMILES: CCCN1CCCC(C1)C2=CC(=CC=C2)O.
This classification denotes an antipsychotic agent with the molecular formula C14H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q8W2T87WWW, chemically known as phenol, 3-(1-propyl-3-piperidinyl)- but more generally known as preclamol hydrochloride, which bears US NIH Compound Identifier 55445. Most nations, for tariff and trade purposes, schedule preclamol hydrochloride under HS 29333999. As of Q4 2014, PRECLAMOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCN1CCC[C@H](C1)C2CCCC(C2)O.CL.
This classification denotes an analgesic and antipyretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71099P640P. European Medicines Agency schedules Prednazate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10013MIG. Prednazate generally arises in the molecular formula C25H32O8.C21H26CLN3OS. The term PREDNAZATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) PREDNAZATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prednazate under HS 29372900 and SITC 54153. As of Q4 2014, PREDNAZATE remains the US FDA Preferred Term for this commodity. Prednazate bears US NLM identifiers UMLS ID C2826062 and NCI Concept Code C82228. SMILES: CLC1CC2N(CCCN3CCN(CC3)CCO)C3C(SC2CC1)CCCC3.OC1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)C=C2)CC3)C)CC1)C)C(=O)COC(=O)CCC(=O)O.
This classification denotes an anti-infective agent and therapeutic glucocorticoid with the molecular formula C27H36O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V901LV1K7D, chemically known as 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17-(ethyl carbonate) 21-propionate but generally known as prednicarbate, which bears US NIH Compound Identifier 52421. European Medicines Agency schedules Prednicarbate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10015MIG. The term PREDNICARBATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules prednicarbate in its Anatomical Therapeutic Chemical (ATC) Classification. PREDNICARBATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prednicarbate under HS 29372900 and SITC 54153. As of Q4 2014, PREDNICARBATE remains the US FDA Preferred Term for this commodity. Prednicarbate bears US NLM identifiers UMLS ID C0071836 and NCI Concept Code C47684. SMILES: O(C1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)C=C2)CC3)C)CC1)C)C(=O)COC(=O)CC)C(=O)OCC.
This classification denotes a nitrogen mustard compound with the molecular formula C35H45Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9403SIO2S8, chemically known as 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate) but more generally known as prednimustine, which bears US NIH Compound Identifier 34457. European Medicines Agency schedules Prednimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10016MIG. The term PREDNIMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules prednimustine in its Anatomical Therapeutic Chemical (ATC) Classification. PREDNIMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule prednimustine under HS 29372900 and SITC 54153. As of Q4 2014, PREDNIMUSTINE remains US FDA's Preferred Term for this commodity. Prednimustine bears US NLM identifiers UMLS ID C0032949 and NCI Concept Code C768. SMILES: CLCCN(C1CCC(CCCC(=O)OCC(=O)C2(O)C3(C(C4C(C(O)C3)C3(C(=CC(=O)C=C3)CC4)C)CC2)C)CC1)CCCL.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9PHQ9Y1OLM, chemically known as 3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene but generally known as prednisolone, which bears US NIH Compound Identifier 5755. European Medicines Agency schedules Prednisolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG. The term PREDNISOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules prednisolone in its Anatomical Therapeutic Chemical (ATC) Classification. PREDNISOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prednisolone under HS 29372100 and SITC 54153. As of Q4 2014, PREDNISOLONE remains the US FDA Preferred Term for this commodity. Prednisolone bears US NLM identifiers UMLS ID C0032950 and NCI Concept Code C769. SMILES: OC1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)C=C2)CC3)C)CC1)C)C(=O)CO.
This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8B2807733D. European Medicines Agency schedules Prednisolone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04014MIG. Prednisolone acetate generally arises in the molecular formula C23H30O6. The term 'prednisolone acetate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule prednisolone acetate under HS 29372100 and SITC 54153. As of Q4 2014, PREDNISOLONE ACETATE remains US FDA's Preferred Term for this commodity. Prednisolone acetate bears US NLM identifiers UMLS ID C0071839 and NCI Concept Code C1202. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)O.
This classification denotes a therapeutic glucocorticoid C25H32O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7080T74ON, chemically known as pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11.beta.)-, but more generally known as prednisolone hemisuccinate, which bears US NIH Compound Identifier 4897. European Medicines Agency schedules Prednisolone hemisuccinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35173. Most nations, for tariff and trade purposes, schedule prednisolone hemisuccinate under HS 29372100 and SITC 54153. As of Q4 2014, PREDNISOLONE HEMISUCCINATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCC(=O)O)O)CCC4=CC(=O)C=C[C@]34C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H29O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 752SY38R6C, chemically known as pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-(phosphonooxy)-, (11.beta.)-, but more generally known as prednisolone phosphate, which bears US NIH Compound Identifier 4896. European Medicines Agency schedules prednisolone phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG. Most nations, for tariff purposes, schedule prednisolone phosphate under HS 29372100. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)(O)O)O)CCC4=CC(=O)C=C[C@]34C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H31O9S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D345THM53T, chemically known as pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-((3-sulfobenzoyl)oxy)-, sodium salt (1:1), (11.beta.)-, but more generally known as prednisolone sodium metasulfobenzoate, which bears US NIH Compound Identifier 12421. European Medicines Agency schedules prednisolone sodium metasulfobenzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG. Most nations, for tariff purposes, schedule prednisolone sodium metasulfobenzoate under HS 29372100. Prednisolone sodium metasulfobenzoate bears US NLM identifiers UMLS ID C0889299 and NCI Concept Code C1862. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)C4CCCC(C4)S(=O)(=O)[O-])O)CCC5=CC(=O)C=C[C@]35C)O.[NA+].
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H27O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IV021NXA9J, chemically known as 3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene but more generally known as prednisolone sodium phosphate, which bears US NIH Compound Identifier 5755. European Medicines Agency schedules Prednisolone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04018MIG. Most nations, for tariff and trade purposes, schedule prednisolone sodium phosphate under HS 29372100 and SITC 54153. As of Q4 2014, PREDNISOLONE SODIUM PHOSPHATE remains US FDA's Preferred Term for this commodity. Prednisolone sodium phosphate bears US NLM identifiers UMLS ID C0138273 and NCI Concept Code C1402. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=C[C@]34C)O.[NA+].[NA+].
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H31O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8223RR9DWF, chemically known as 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-(hydrogen succinate) but more generally known as prednisolone sodium succinate, which bears US NIH Compound Identifier 4897. European Medicines Agency schedules Prednisolone sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04019MIG. Most nations, for tariff and trade purposes, schedule prednisolone sodium succinate under HS 29372100 and SITC 54153. As of Q4 2014, PREDNISOLONE SODIUM SUCCINATE remains US FDA's Preferred Term for this commodity. Prednisolone sodium succinate bears US NLM identifiers UMLS ID C0138274 and NCI Concept Code C1403. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCC(=O)[O-])O)CCC4=CC(=O)C=C[C@]34C)O.[NA+].
This classification denotes a therapeutic glucocorticoid with the molecular formula C41H64O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OZQ2XN817F, chemically known as stearate ester of 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione-21-glycolate but more generally known as prednisolone steaglate, which bears US NIH Compound Identifier 71206. European Medicines Agency schedules Prednisolone steaglate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10019MIG. The term PREDNISOLONE STEAGLATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). Most nations, for tariff and trade purposes, schedule prednisolone steaglate under HS 29372900 and SITC 54153. As of Q4 2014, PREDNISOLONE STEAGLATE remains US FDA's Preferred Term for this commodity. Prednisolone steaglate bears US NLM identifiers UMLS ID C2825346 and NCI Concept Code C80823. SMILES: CCCCCCCCCCCCCCCCCC(=O)OCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H32O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7080T74ON, chemically known as (+)-prednisolone hemisuccinate, but more generally known as prednisolone succinate, which bears US NIH Compound Identifier 4897. European Medicines Agency schedules prednisolone succinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG. Most nations, for tariff purposes, schedule prednisolone succinate under HS 29372100. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCC(=O)O)O)CCC4=CC(=O)C=C[C@]34C)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.
This classification denotes a therapeutic glucocorticoid with the molecular formula C27H38O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1V7A1U282K, chemically known as pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-((3,3-dimethyl-1-oxobutyl)oxy)-, (11.beta.)-, but more generally known as prednisolone tebutate, which bears US NIH Compound Identifier 4898. European Medicines Agency schedules prednisolone tebutate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG. Most nations, for tariff purposes, schedule prednisolone tebutate under HS 29372100. Prednisolone tebutate bears US NLM identifiers UMLS ID C0071844 and NCI Concept Code C66461. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CC(C)(C)C)O)CCC4=CC(=O)C=C[C@]34C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H38O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JB27QJW3D, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-((1-oxopentyl)oxy)-, (11.beta.)-, but more generally known as prednisolone valerate acetate, which bears US NIH Compound Identifier 135307. European Medicines Agency schedules prednisolone valerate acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG. Most nations, for tariff purposes, schedule prednisolone valerate acetate under HS 29372100. Prednisolone valerate acetate bears US NLM identifiers UMLS ID C1882445 and NCI Concept Code C66462. SMILES: CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)COC(=O)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H26O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VB0R961HZT, chemically known as pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- but generally known as prednisone, which bears US NIH Compound Identifier 4900. European Medicines Agency schedules Prednisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10020MIG. The term PREDNISONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules prednisone in its Anatomical Therapeutic Chemical (ATC) Classification. PREDNISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prednisone under HS 29372100 and SITC 54153. As of Q4 2014, PREDNISONE remains the US FDA Preferred Term for this commodity. Prednisone bears US NLM identifiers UMLS ID C0032952 and NCI Concept Code C770. SMILES: OC1(C2(C(C3C(C4(C(=CC(=O)C=C4)CC3)C)C(=O)C2)CC1)C)C(=O)CO.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H26O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VB0R961HZT, chemically known as 17,21-dihydroxypregna-1,4-diene-3,11,20-trione, but more generally known as prednisone intensol, which bears US NIH Compound Identifier 5865. European Medicines Agency schedules prednisone intensol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10020MIG. Most nations, for tariff purposes, schedule prednisone intensol under HS 29372100. SMILES: C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IF8PQP966U, chemically known as 11beta,17,21-trihydroxy-16-methylenepregna-1,4-diene-3,20-dione but generally known as prednylidene, which bears US NIH Compound Identifier 11740. European Medicines Agency schedules Prednylidene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10021MIG. The term PREDNYLIDENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules prednylidene in its Anatomical Therapeutic Chemical (ATC) Classification. PREDNYLIDENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prednylidene under HS 29372900 and SITC 54153. As of Q4 2014, PREDNYLIDENE remains the US FDA Preferred Term for this commodity. Prednylidene bears US NLM identifiers UMLS ID C0044955 and NCI Concept Code C80268. SMILES: OC1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)C=C2)CC3)C)CC1=C)C)C(=O)CO.
A drug indicated for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures, fibromyalgia and neuropathic pain associated with spinal cord injury.
This classification denotes a therapeutic progestin with the molecular formula C21H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73R90F7MQ8, chemically known as 17.alpha.-pregn-5-en-20-one, 3.beta.-hydroxy- but generally known as pregnenolone, which bears US NIH Compound Identifier 1027. European Medicines Agency schedules Pregnenolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10024MIG. The term PREGNENOLONE is an International Non-Proprietary Name. PREGNENOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pregnenolone under HS 29372900 and SITC 54153. As of Q4 2014, PREGNENOLONE remains the US FDA Preferred Term for this commodity. Pregnenolone bears US NLM identifiers UMLS ID C0373704 and NCI Concept Code C82315. SMILES: OC1CC2=CCC3C4C(CCC3C2(CC1)C)(C(CC4)C(=O)C)C.
This classification denotes a therapeutic progestin with the molecular formula C22H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TU767RK7YN, chemically known as pregn-5-en-20-one, 3-methoxy-, (3.beta.)-, but more generally known as pregnenolone methyl ether, which bears US NIH Compound Identifier 233254. European Medicines Agency schedules pregnenolone methyl ether or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10024MIG. Most nations, for tariff purposes, schedule pregnenolone methyl ether under HS 29372900. SMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC)C)C.
This classification denotes a therapeutic progestin with the molecular structure C25H36O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 6LN4W6JJK6 chemically known as pregn-5-en-20-one, 3-(3-carboxy-1-oxopropoxy)-, (3.beta.), but more commonly known as pregnenolone succinate, which bears US NIH Compound Identifier 20728. European Medicines Agency schedules Pregnenolone succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15007MIG. Most nations, for tariff and trade purposes, schedule pregnenolone succinate under HS 29372900 and SITC 54153. As of Q4 2014, PREGNENOLONE SUCCINATE remains US FDA's Preferred Term for this commodity. Pregnenolone succinate bears US NLM identifiers UMLS ID C0771291 and NCI Concept Code C82317. SMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CCC(=O)O)C)C.
This classification denotes a therapeutic progestin with the molecular formula C21H32O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04Y4D91RG0, chemically known as pregn-5-en-20-one, 3-(sulfooxy)-, (3.beta.)-, but more generally known as pregnenolone sulfate, which bears US NIH Compound Identifier 105074. European Medicines Agency schedules pregnenolone sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10024MIG. Most nations, for tariff purposes, schedule pregnenolone sulfate under HS 29372900. SMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C)C.
This classification denotes a quinolone antibiotic with the molecular formula C21H26FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UOM2HMO524, chemically known as 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(1-(methylamino)ethyl)-1-pyrrolidinyl)-4-oxo-, (s-(r*,s*))- but generally known as premafloxacin, which bears US NIH Compound Identifier 71455. European Medicines Agency schedules Premafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10025MIG. The term PREMAFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). Most nations schedule premafloxacin under HS 29334910 and SITC 51575. As of Q4 2014, PREMAFLOXACIN remains the US FDA Preferred Term for this commodity. Premafloxacin bears US NLM identifiers UMLS ID C0537079 and NCI Concept Code C66464. SMILES: FC1C(N2CC(CC2)C(NC)C)C(OC)C2N(C3CC3)CC(C(=O)C2C1)C(=O)O.
This classification denotes a benzodiazepine with the molecular formula C15H15N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OI7443PDLB, chemically known as 3,7-dihydro-6,7-dimethyl-5-phenylpyrrolo(3,4-e)(1,4)diazepin-2(1h)-one but generally known as premazepam, which bears US NIH Compound Identifier 72104. European Medicines Agency schedules Premazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10026MIG. The term PREMAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). PREMAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule premazepam under HS 29339940 and SITC 51577. As of Q4 2014, PREMAZEPAM remains the US FDA Preferred Term for this commodity. Premazepam bears US NLM identifiers UMLS ID C0071879 and NCI Concept Code C66465. SMILES: O=C1NC2C(C(N(C2)C)C)C(=NC1)C1CCCCC1.
This classification denotes an adrenergic beta-1 receptor agonist, cardiotonic agent, and sympathomimetic with the molecular formula C12H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4G34404CX, chemically known as phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, (s)- but generally known as prenalterol, which bears US NIH Compound Identifier 42396. European Medicines Agency schedules Prenalterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10027MIG. World Health Organization schedules prenalterol in its Anatomical Therapeutic Chemical (ATC) Classification. PRENALTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prenalterol under HS 29221980 and SITC 51461. As of Q4 2014, PRENALTEROL remains the US FDA Preferred Term for this commodity. SMILES: CC(C)NCC(COC1=CC=C(C=C1)O)O.
This classification denotes an adrenergic beta-1 receptor agonist C12H19NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6VH18LCQ8, chemically known as phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, hydrochloride, (s)-, but more generally known as prenalterol hydrochloride, which bears US NIH Compound Identifier 43590. European Medicines Agency schedules Prenalterol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04029MIG. Most nations, for tariff and trade purposes, schedule prenalterol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PRENALTEROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NC[C@@H](COC1CCC(CC1)O)O.CL.
This classification denotes a mucolytic agent with the molecular formula C8H15NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 99TA452185, chemically known as l-alanine, 3-((3-methyl-2-butenyl)thio)- but more generally known as prenisteine, which bears US NIH Compound Identifier 21359. European Medicines Agency schedules Prenisteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10028MIG. The term PRENISTEINE is an International Non-Proprietary Name. PRENISTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule prenisteine under HS 29309016 and SITC 51549. As of Q4 2014, PRENISTEINE remains US FDA's Preferred Term for this commodity. Prenisteine bears US NLM identifiers UMLS ID C2347668 and NCI Concept Code C73134. SMILES: S(CC(N)C(=O)O)C/C=C(/C)C.
This classification denotes an antitussive agent with the molecular formula C23H27N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S491HH391H, chemically known as 1-(2-(3-(2,2-diphenylethyl)-1,2,4-oxadiazol-5-yl)ethyl)piperidine. but more generally known as prenoxdiazine, which bears US NIH Compound Identifier 120508. European Medicines Agency schedules Prenoxdiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12421MIG. The term PRENOXDIAZINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules prenoxdiazine in its Anatomical Therapeutic Chemical (ATC) Classification. PRENOXDIAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule prenoxdiazine under HS 29349990 and SITC 51579. As of Q4 2014, PRENOXDIAZINE remains US FDA's Preferred Term for this commodity. Prenoxdiazine bears US NLM identifiers UMLS ID C0138305 and NCI Concept Code C73181. SMILES: O1NC(NC1CCN1CCCCC1)CC(C1CCCCC1)C1CCCCC1.
This classification denotes an adrenergic agent, calcium channel blocker, and vasodilator agent with the molecular formula C24H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2OH82Z000, chemically known as 1-phenyl-2-(1,1-diphenylpropyl-3-amino)propane but generally known as prenylamine, which bears US NIH Compound Identifier 9801. European Medicines Agency schedules Prenylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10030MIG. World Health Organization schedules prenylamine in its Anatomical Therapeutic Chemical (ATC) Classification. PRENYLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prenylamine under HS 29214980 and SITC 51454. As of Q4 2014, PRENYLAMINE remains the US FDA Preferred Term for this commodity. SMILES: N(CCC(C1CCCCC1)C1CCCCC1)C(CC1CCCCC1)C.
This classification denotes an adrenergic agent C24H27N.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J3J6SXI7V, chemically known as benzenepropanamine, n-(1-methyl-2-phenylethyl)-.gamma.-phenyl-, 2-hydroxypropanoate, but more generally known as prenylamine lactate, which bears US NIH Compound Identifier 65557. European Medicines Agency schedules Prenylamine lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04033MIG. Most nations, for tariff and trade purposes, schedule prenylamine lactate under HS 29214980 and SITC 51454. As of Q4 2014, PRENYLAMINE LACTATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCCC1)NCCC(C2CCCCC2)C3CCCCC3.CC(C(=O)O)O.
This classification denotes an antihelminthic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z32Z641H2. European Medicines Agency schedules Pretamazium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10031MIG. Pretamazium iodide generally arises in the molecular formula C29H29N2S.I. The term PRETAMAZIUM IODIDE is an International Non-Proprietary Name or INN. Most nations schedule pretamazium iodide under HS 29341000 and SITC 51579. As of Q4 2014, PRETAMAZIUM IODIDE remains the US FDA Preferred Term for this commodity. Pretamazium iodide bears US NLM identifiers UMLS ID C2347671 and NCI Concept Code C74150. SMILES: I.s1c([n](c(c2ccc(cc2)c2ccccc2)c1)CC)/C=C/c1ccc(N2CCCC2)cc1.
This classification denotes a cns stimulant with the molecular formula C13H24N2O2.C12H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41A1FCW148, chemically known as 2-butenamide, n-(1-((dimethylamino)carbonyl)propyl)-n-ethyl-, mixt. with n-(1-((dimethylamino)carbonyl)propyl)-n-propyl-2-butenamide but generally known as prethcamide, which bears US NIH Compound Identifier 71672. European Medicines Agency schedules Prethcamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35623. World Health Organization schedules prethcamide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PRETHCAMIDE remains the US FDA Preferred Term for this commodity. Prethcamide bears US NLM identifiers UMLS ID C0071957 and NCI Concept Code C76627. SMILES: O=C(N(C)C)C(N(CCC)C(=O)/C=C/C)CC.O=C(N(C)C)C(N(CC)C(=O)/C=C/C)CC.
Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 382TLA8X28. European Medicines Agency schedules Pribecaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10034MIG. Pribecaine generally arises in the molecular formula C16H23NO3. The term PRIBECAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) PRIBECAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pribecaine under HS 29333999 and SITC 51574. As of Q4 2014, PRIBECAINE remains the US FDA Preferred Term for this commodity. Pribecaine bears US NLM identifiers UMLS ID C1882458 and NCI Concept Code C66467. SMILES: O(CCCN1CCCCC1)C(=O)C1CC(OC)CCC1.
This classification denotes an anxiolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78W508SA0Q. European Medicines Agency schedules Prideperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10036MIG. Prideperone generally arises in the molecular formula C23H24FN3O3. The term PRIDEPERONE is an International Non-Proprietary Name or INN. PRIDEPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prideperone under HS 29333999 and SITC 51574. As of Q4 2014, PRIDEPERONE remains the US FDA Preferred Term for this commodity. Prideperone bears US NLM identifiers UMLS ID C2347673 and NCI Concept Code C73288. SMILES: FC1CCC(C(=O)C2CCN(CC2)CCNC(=O)C2C(OC)CCC(C2)C#N)CC1.
This classification denotes an antipsychotic agent with the molecular formula C20H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E75Q6SUUB, chemically known as 1,1-diphenyl-3-piperidino-1-propanol but generally known as pridinol, which bears US NIH Compound Identifier 4904. European Medicines Agency schedules Pridinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10037MIG. The term PRIDINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules pridinol in its Anatomical Therapeutic Chemical (ATC) Classification. PRIDINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pridinol under HS 29333999 and SITC 51574. As of Q4 2014, PRIDINOL remains the US FDA Preferred Term for this commodity. Pridinol bears US NLM identifiers UMLS ID C0071968 and NCI Concept Code C73319. SMILES: OC(CCN1CCCCC1)(C1CCCCC1)C1CCCCC1.
This classification denotes an antipsychotic agent C20H25NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3HI2Q2Y868, chemically known as 1,1-diphenyl-3-(piperidin-1-yl)propan-1-ol hydrochloride, but more generally known as pridinol hydrochloride, which bears US NIH Compound Identifier 71595. European Medicines Agency schedules Pridinol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04035MIG. Most nations, for tariff and trade purposes, schedule pridinol hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PRIDINOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(CCN2CCCCC2)(C3CCCCC3)O.CL.
This classification denotes an antipsychotic agent C20H25NO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AQ4K0AJT6G, chemically known as 1,1-diphenyl-3-piperidinopropan-1-ol methanesulphonate, but more generally known as pridinol mesilate, which bears US NIH Compound Identifier 3041203. European Medicines Agency schedules Pridinol mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04036MIG. Most nations, for tariff and trade purposes, schedule pridinol mesilate under HS 29333999 and SITC 51574. As of Q4 2014, PRIDINOL MESILATE remains US FDA's Preferred Term for this commodity. SMILES: CS(=O)(=O)O.C1CCC(CC1)C(CCN2CCCCC2)(C3CCCCC3)O.
This classification denotes an antipsychotic agent with the molecular formula C20H25NO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AQ4K0AJT6G, chemically known as 1,1-diphenyl-3-piperidinopropan-1-ol methanesulphonate, but more generally known as pridinol methanesulfonate, which bears US NIH Compound Identifier 165542. European Medicines Agency schedules pridinol methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10037MIG. Most nations, for tariff purposes, schedule pridinol methanesulfonate under HS 29333999. SMILES: CS(=O)(=O)O.C1CCC(CC1)C(CCN2CCCCC2)(C3CCCCC3)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H24O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0414BW860U, chemically known as 3,5-di-tert-butyl-4-hydroxyphenyl 2-thienyl ketone but generally known as prifelone, which bears US NIH Compound Identifier 71751. European Medicines Agency schedules Prifelone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10038MIG. The term PRIFELONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). PRIFELONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prifelone under HS 29349990 and SITC 51579. As of Q4 2014, PRIFELONE remains the US FDA Preferred Term for this commodity. Prifelone bears US NLM identifiers UMLS ID C0618049 and NCI Concept Code C80567. SMILES: S1C(C(=O)C2CC(C(C)(C)C)C(O)C(C(C)(C)C)C2)CCC1.
This classification denotes an anticholinergic agent with the molecular structure C22H28N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 3C7TTK1K7K chemically known as 3-(diphenylmethylene)-1,1-diethyl-2-methylpyrrolidinium but generally known as prifinium, which bears US NIH Compound Identifier 4905. European Medicines Agency schedules Prifinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04037MIG. As of Q4 2014, PRIFINIUM remains the US FDA Preferred Term for this commodity. Prifinium bears US NLM identifiers UMLS ID C0771424 and NCI Concept Code C84105. SMILES: [N]1(C(/C(=C(/C2CCCCC2)C2CCCCC2)CC1)C)(CC)CC.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OP2V3XRV2Y. European Medicines Agency schedules Prifuroline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10040MIG. Prifuroline generally arises in the molecular formula C14H16N2O. The term PRIFUROLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) PRIFUROLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prifuroline under HS 29349990 and SITC 51579. As of Q4 2014, PRIFUROLINE remains the US FDA Preferred Term for this commodity. Prifuroline bears US NLM identifiers UMLS ID C0071969 and NCI Concept Code C73245. SMILES: O1C(C2CC(=NC2)N(C)C)CC2C1CCCC2.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 046O35D44R, chemically known as propanamide, n-(2-methylphenyl)-2-(propylamino)-, (s)- but generally known as prilocaine, which bears US NIH Compound Identifier 4906. European Medicines Agency schedules Prilocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10041MIG. The term PRILOCAINE is an International Non-Proprietary Name. World Health Organization schedules prilocaine in its Anatomical Therapeutic Chemical (ATC) Classification. PRILOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prilocaine under HS 29242995 and SITC 51479. As of Q4 2014, PRILOCAINE remains the US FDA Preferred Term for this commodity. Prilocaine bears US NLM identifiers UMLS ID C0033124 and NCI Concept Code C47685. SMILES: O=C(NC1C(CCCC1)C)C(NCCC)C.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MJW015BAPH, chemically known as propanamide, n-(2-methylphenyl)-2-(propylamino)-, monohydrochloride but more generally known as prilocaine hydrochloride, which bears US NIH Compound Identifier 92163. European Medicines Agency schedules Prilocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04038MIG. Most nations, for tariff and trade purposes, schedule prilocaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, PRILOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Prilocaine hydrochloride bears US NLM identifiers UMLS ID C0591261 and NCI Concept Code C48012. SMILES: CCCNC(C)C(=O)NC1CCCCC1C.CL.
This classification denotes an antimalarial agent with the molecular formula C15H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MVR3634GX1, chemically known as 1,4-pentanediamine, n4-(6-methoxy-8-quinolinyl)- (9ci) but generally known as primaquine, which bears US NIH Compound Identifier 4908. European Medicines Agency schedules Primaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10043MIG. The term PRIMAQUINE is an International Non-Proprietary Name. World Health Organization schedules primaquine in its Anatomical Therapeutic Chemical (ATC) Classification. PRIMAQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule primaquine under HS 29334990 and SITC 51575. As of Q4 2014, PRIMAQUINE remains the US FDA Preferred Term for this commodity. Primaquine bears US NLM identifiers UMLS ID C0033126 and NCI Concept Code C62071. SMILES: O(C1CC(NC(CCCN)C)C2NCCCC2C1)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H23N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56QH73D78K, chemically known as 2,4-(1h,3h)-pyrimidinedione, 1-(2-((2-hydroxy-3-(2-methylphenoxy)propyl)amino)ethyl)-5-methyl- but generally known as primidolol, which bears US NIH Compound Identifier 68563. European Medicines Agency schedules Primidolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10044MIG. The term PRIMIDOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). PRIMIDOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule primidolol under HS 29335995 and SITC 51576. As of Q4 2014, PRIMIDOLOL remains the US FDA Preferred Term for this commodity. Primidolol bears US NLM identifiers UMLS ID C0071975 and NCI Concept Code C76557. SMILES: O(CC(O)CNCCN1CC(C(=O)[NH]C1=O)C)C1C(CCCC1)C.
This classification denotes a barbiturate and anticonvulsant agent with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13AFD7670Q, chemically known as 4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-phenyl- but generally known as primidone, which bears US NIH Compound Identifier 4909. European Medicines Agency schedules Primidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10045MIG. The term PRIMIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules primidone in its Anatomical Therapeutic Chemical (ATC) Classification. PRIMIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule primidone under HS 29337900 and SITC 51561. As of Q4 2014, PRIMIDONE remains the US FDA Preferred Term for this commodity. Primidone bears US NLM identifiers UMLS ID C0033148 and NCI Concept Code C47686. SMILES: CCC1(C(=O)NCNC1=O)C2=CC=CC=C2.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers W6LFQ57E4M and TA94NTR55X (root), O2OYX71E94 (leaf), and W5BET37294 (flower), the source of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 24035 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Ericales, Family Primulaceae (primroses), Genus Primula L. (shootingstar, primrose), Species Primula veris L., commonly known as cowslip primrose or as here, primula. Primula (vera) bears the USDA PLANTS Database Identifier PRVE2. European Medicines Agency schedules primula in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB35042 and SUB40726.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W4VMH2E80M, chemically known as 3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2(1h)-quinazolinone but generally known as prinoxodan, which bears US NIH Compound Identifier 5362397. European Medicines Agency schedules Prinoxodan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10048MIG. The term PRINOXODAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Most nations schedule prinoxodan under HS 29335995 and SITC 51576. As of Q4 2014, PRINOXODAN remains the US FDA Preferred Term for this commodity. Prinoxodan bears US NLM identifiers UMLS ID C0165309 and NCI Concept Code C74349. SMILES: O=C1N(CC2C(N1)CCC(C2)C1=NNC(=O)CC1)C.
This classification denotes an antibiotic with the molecular formula C34H50N4O9S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9M4FJE48E, chemically known as virginiamycin m1, 26-((2-(diethylamino)ethyl)sulfonyl)-26,27-dihydro-, (26r,27s)- but generally known as dalfopristin, which bears US NIH Compound Identifier 6323289. European Medicines Agency schedules Dalfopristin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06892MIG. The term DALFOPRISTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DALFOPRISTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(C1C2N(CC1)C(=O)C1NC(OC1)CC(=O)CC(O)C=C(C=CCNC(=O)C=CC(C(OC2=O)C(C)C)C)C)CCN(CC)CC.
This classification denotes a barbiturate with the molecular formula C9H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R87TF75S6O, chemically known as 5-ethyl-5-propan-2-yl-1,3-diazinane-2,4,6-trione but generally known as probarbital, which bears US NIH Compound Identifier 6455. European Medicines Agency schedules Probarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10052MIG. The term PROBARBITAL is an International Non-Proprietary Name. As of Q4 2014, PROBARBITAL remains the US FDA Preferred Term for this commodity. SMILES: CCC1(C(=O)NC(=O)NC1=O)C(C)C.
This classification denotes a barbiturate with the molecular formula C9H13N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YDA0W423G6, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylethyl)-, monosodium salt (9ci) but more generally known as probarbital sodium, which bears US NIH Compound Identifier 67414. European Medicines Agency schedules Probarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10052MIG. The term PROBARBITAL SODIUM is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule probarbital sodium under HS 29335400. As of Q4 2014, PROBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Probarbital sodium bears US NLM identifiers UMLS ID C0770388 and NCI Concept Code C76529. SMILES: CCC1(C(=O)NC(=O)[N-]C1=O)C(C)C.[NA+].
This classification denotes a uricosuric agent with the molecular formula C13H19NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PO572Z7917, chemically known as 4-(n,n-dipropylsulfamoyl)benzoesaeure but generally known as probenecid, which bears US NIH Compound Identifier 4911. European Medicines Agency schedules Probenecid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10053MIG. The term PROBENECID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules probenecid in its Anatomical Therapeutic Chemical (ATC) Classification. PROBENECID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule probenecid under HS 29350090 and SITC 51580. As of Q4 2014, PROBENECID remains the US FDA Preferred Term for this commodity. Probenecid bears US NLM identifiers UMLS ID C0033209 and NCI Concept Code C772. SMILES: S(=O)(=O)(N(CCC)CCC)C1CCC(CC1)C(=O)O.
This classification denotes a uricosuric agent with the molecular formula C13H18NO4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FXB45Q4ZVK, chemically known as sodium 4-((dipropylamino)sulfonyl)benzoate, but more generally known as probenecid sodium, which bears US NIH Compound Identifier 32095. European Medicines Agency schedules probenecid sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10053MIG. Most nations, for tariff purposes, schedule probenecid sodium under HS 29350090. SMILES: CCCN(CCC)S(=O)(=O)C1CCC(CC1)C(=O)[O-].[NA+].
This classification denotes a mast cell stabilizer with the molecular formula C17H10O8.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0U434950BU, chemically known as 4,6-dioxo-10-propyl-4h,6h-benzo(1,2-b:5,4-b)dipyran-2,8-dicarbonsaeure but generally known as probicromil calcium, which bears US NIH Compound Identifier 71950. As of Q4 2014, PROBICROMIL CALCIUM remains the US FDA Preferred Term for this commodity. Probicromil calcium bears US NLM identifiers UMLS ID C1882465 and NCI Concept Code C66469. SMILES: CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)[O-])C(=O)C=C(O2)C(=O)[O-].[Ca+2].
This classification denotes an anti-lipidemic agent with the molecular formula C31H48O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P3CTH044XJ, chemically known as 4,4-(isopropylidenedithio)bis(2,6-di-tert-butylphenol) but generally known as probucol, which bears US NIH Compound Identifier 4912. European Medicines Agency schedules Probucol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10054MIG. The term PROBUCOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules probucol in its Anatomical Therapeutic Chemical (ATC) Classification. PROBUCOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule probucol under HS 29309085 and SITC 51549. As of Q4 2014, PROBUCOL remains the US FDA Preferred Term for this commodity. Probucol bears US NLM identifiers UMLS ID C0033215 and NCI Concept Code C66470. SMILES: S(c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)C(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)(C)C.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C13H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L39WTC366D, chemically known as benzamide, p-amino-n-(2-(diethylamino)ethyl)- but more generally known as procainamide, which bears US NIH Compound Identifier 4913. European Medicines Agency schedules Procainamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10055MIG. The term PROCAINAMIDE is an International Non-Proprietary Name. World Health Organization schedules procainamide in its Anatomical Therapeutic Chemical (ATC) Classification. PROCAINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule procainamide under HS 29242995 and SITC 51479. As of Q4 2014, PROCAINAMIDE remains US FDA's Preferred Term for this commodity. Procainamide bears US NLM identifiers UMLS ID C0033216 and NCI Concept Code C61905. SMILES: O=C(NCCN(CC)CC)C1CCC(N)CC1.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C13H21N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SI4064O0LX, chemically known as benzamide, p-amino-n-(2-(diethylamino)ethyl)-, hydrochloride but more generally known as procainamide hydrochloride, which bears US NIH Compound Identifier 66068. European Medicines Agency schedules Procainamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04045MIG. Most nations, for tariff and trade purposes, schedule procainamide hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, PROCAINAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Procainamide hydrochloride bears US NLM identifiers UMLS ID C0699067 and NCI Concept Code C47687. SMILES: CCN(CC)CCNC(=O)C1CCC(CC1)N.CL.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4Z8Y51M438, chemically known as procaine, base but generally known as procaine, which bears US NIH Compound Identifier 4914. European Medicines Agency schedules Procaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10056MIG. The term PROCAINE is an International Non-Proprietary Name. World Health Organization schedules procaine in its Anatomical Therapeutic Chemical (ATC) Classification. PROCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule procaine under HS 29224995 and SITC 51465. As of Q4 2014, PROCAINE remains the US FDA Preferred Term for this commodity. Procaine bears US NLM identifiers UMLS ID C0033218 and NCI Concept Code C61906. SMILES: O(CCN(CC)CC)C(=O)C1CCC(N)CC1.
This classification denotes a penicillin antibiotic with the molecular formula C16H18N2O4S.C13H20N2O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17R794ESYN. European Medicines Agency schedules procaine benzylpenicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26570. The term penicillin g procaine is a U.S. FDA designation. SMILES: CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.O.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O2.5BHO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B42E10825B, chemically known as 2-(diethylamino)ethyl p-aminobenzoate borate (1:5), but more generally known as procaine borate, which bears US NIH Compound Identifier 67418. European Medicines Agency schedules procaine borate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10056MIG. Most nations, for tariff purposes, schedule procaine borate under HS 29224995. Procaine borate bears US NLM identifiers UMLS ID C3273344 and NCI Concept Code C97301. SMILES: B(=O)O.B(=O)O.B(=O)O.B(=O)O.B(=O)O.CCN(CC)CCOC(=O)C1CCC(CC1)N.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95URV01IDQ, chemically known as procaine, base but more generally known as procaine hydrochloride, which bears US NIH Compound Identifier 4914. European Medicines Agency schedules Procaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04046MIG. Most nations, for tariff and trade purposes, schedule procaine hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, PROCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Procaine hydrochloride bears US NLM identifiers UMLS ID C0358490 and NCI Concept Code C47688. SMILES: CCN(CC)CCOC(=O)C1CCC(CC1)N.CL.
This classification denotes an anesthetic agent with the molecular formula C13H20N2O2.C5H7NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W84930057W, chemically known as benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester, compd. with 5-oxoproline (1:1), but more generally known as procaine pyroglutamate, which bears US NIH Compound Identifier 25097. European Medicines Agency schedules procaine pyroglutamate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10056MIG. Most nations, for tariff purposes, schedule procaine pyroglutamate under HS 29224995. SMILES: CCN(CC)CCOC(=O)C1CCC(CC1)N.C1CC(=O)N[C@@H]1C(=O)O.
This classification denotes a triazene compound with the molecular formula C12H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35S93Y190K, chemically known as p-toluamide, n-isopropyl-.alpha.- (2-methylhydrazino)-, monohydrochloride but more generally known as procarbazine, which bears US NIH Compound Identifier 4915. European Medicines Agency schedules Procarbazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10057MIG. The term PROCARBAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules procarbazine in its Anatomical Therapeutic Chemical (ATC) Classification. PROCARBAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule procarbazine under HS 29280090 and SITC 51486. As of Q4 2014, PROCARBAZINE remains US FDA's Preferred Term for this commodity. Procarbazine bears US NLM identifiers UMLS ID C0033223 and NCI Concept Code C62072. SMILES: CC(C)NC(=O)C1=CC=C(C=C1)CNNC.
This classification denotes an antineoplastic agent with the molecular formula C12H19N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XH0NPH5ZX8, chemically known as p-toluamide, n-isopropyl-.alpha.- (2-methylhydrazino)-, monohydrochloride but more generally known as procarbazine hydrochloride, which bears US NIH Compound Identifier 4915. European Medicines Agency schedules Procarbazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15017MIG. As of Q4 2014, PROCARBAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Procarbazine hydrochloride bears US NLM identifiers UMLS ID C0205909 and NCI Concept Code C773. Most nations, for tariff and trade purposes, schedule procarbazine hydrochloride under HS 29280090 and SITC 51486. SMILES: CC(C)NC(=O)C1CCC(CC1)CNNC.CL.
This classification denotes an adrenergic beta-2 receptor agonist, bronchodilator agent, and sympathomimetic with the molecular formula C16H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7I3EMM5K0, chemically known as 8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1h)-quinolinone (r*,s*)-(+-)- but generally known as procaterol, which bears US NIH Compound Identifier 4916. European Medicines Agency schedules Procaterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10058MIG. World Health Organization schedules procaterol in its Anatomical Therapeutic Chemical (ATC) Classification. PROCATEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule procaterol under HS 29337900 and SITC 51561. As of Q4 2014, PROCATEROL remains the US FDA Preferred Term for this commodity. SMILES: OC(C(NC(C)C)CC)C1C2C([NH]C(=O)CC2)C(O)CC1.
This classification denotes an adrenergic beta-2 receptor agonist C16H22N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VD1BRT7T8, chemically known as 2(1h)-quinolinone, 8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-, monohydrochloride, (r*,s*), (+/-)-, but more generally known as procaterol hydrochloride, which bears US NIH Compound Identifier 43091. European Medicines Agency schedules Procaterol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04050MIG. Most nations, for tariff and trade purposes, schedule procaterol hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, PROCATEROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@H]([C@H](C1CCC(C2C1CCC(=O)[NH]2)O)O)NC(C)C.CL.
This classification denotes an adrenergic beta-2 receptor agonist, bronchodilator agent, and sympathomimetic with the molecular formula 2C16H22N2O3.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8404I5HKFJ, chemically known as 2(1h)-quinolinone, 8-hydroxy-5-((1r,2s)-1-hydroxy-2-((1-methylethyl)amino)butyl)-, hydrochloride, hydrate (2:2:1), rel-, but more generally known as procaterol hydrochloride hemihydrate, which bears US NIH Compound Identifier 6917801. European Medicines Agency schedules procaterol hydrochloride hemihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10058MIG. Most nations, for tariff purposes, schedule procaterol hydrochloride hemihydrate under HS 29337900. SMILES: CC[C@H]([C@H](C1CCC(C2C1CCC(=O)[NH]2)O)O)NC(C)C.CC[C@H]([C@H](C1CCC(C2C1CCC(=O)[NH]2)O)O)NC(C)C.O.CL.CL.
This classification denotes a phenothiazine with the molecular formula C20H24ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YHP6YLT61T, chemically known as 10h-phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)- but generally known as prochlorperazine, which bears US NIH Compound Identifier 4917. European Medicines Agency schedules Prochlorperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10059MIG. The term PROCHLORPERAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules prochlorperazine in its Anatomical Therapeutic Chemical (ATC) Classification. PROCHLORPERAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prochlorperazine under HS 29343090 and SITC 51578. As of Q4 2014, PROCHLORPERAZINE remains the US FDA Preferred Term for this commodity. Prochlorperazine bears US NLM identifiers UMLS ID C0033229 and NCI Concept Code C774. SMILES: CLC1CC2N(CCCN3CCN(CC3)C)C3C(SC2CC1)CCCC3.
This classification denotes a phenothiazine with the molecular formula C20H24ClN3S.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 531SH87H9N, chemically known as piperazine, 1-methyl-4-(3-(2-chloro-phenothiazin-10-yl)propyl)-, hydrogen methanesulfonate but generally known as prochlorperazine mesilate, which bears US NIH Compound Identifier 94252. European Medicines Agency schedules Prochlorperazine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04053MIG. Most nations schedule prochlorperazine mesilate under HS 29343090 and SITC 51578. SMILES: Clc1cc2N(CCCN3CCN(CC3)C)c3c(Sc2cc1)cccc3.S(=O)(=O)(O)C.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLJ0HIL21J. European Medicines Agency schedules Procinolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10060MIG. Procinolol generally arises in the molecular formula C15H23NO2. The term PROCINOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) PROCINOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule procinolol under HS 29221980 and SITC 51461. As of Q4 2014, PROCINOLOL remains the US FDA Preferred Term for this commodity. Procinolol bears US NLM identifiers UMLS ID C0072038 and NCI Concept Code C66471. SMILES: O(C1C(C2CC2)CCCC1)CC(O)CNC(C)C.
This classification denotes a biological response modifier with the molecular formula C10H10N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) SG5IU7FD3R, chemically known as propionic acid, 2-(2-benzimidazolyl)- but more generally known as procodazole, which bears US NIH Compound Identifier 65708. European Medicines Agency schedules Procodazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10063MIG. The term PROCODAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). PROCODAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule procodazole under HS 29339990 and SITC 51577. As of Q4 2014, PROCODAZOLE remains US FDA's Preferred Term for this commodity. Procodazole bears US NLM identifiers UMLS ID C1882468 and NCI Concept Code C66472. SMILES: C1=CC=C2C(=C1)NC(=N2)CCC(=O)O.
This classification denotes a biological response modifier C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 791487L0WH, chemically known as 1h-benzimidazole-2-propanoic acid, ethyl ester, but more generally known as procodazole ethyl ester, which bears US NIH Compound Identifier 228135. Most nations, for tariff and trade purposes, schedule procodazole ethyl ester under HS 29339990 and SITC 51577. As of Q4 2014, PROCODAZOLE ETHYL ESTER remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)CCC1[NH]C2CCCCC2N1.
This classification denotes a biological response modifier C10H9N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9A8201NX4I, chemically known as 1h-benzimidazole-2-propanoic acid, monosodium salt, but more generally known as procodazole sodium, which bears US NIH Compound Identifier 72710717. Most nations, for tariff and trade purposes, schedule procodazole sodium under HS 29339990 and SITC 51577. As of Q4 2014, PROCODAZOLE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)[NH]C(N2)CCC(=O)[O-].[NA+].
This classification denotes an antimuscarinic agent with the molecular formula C19H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C6QE1Q1TKR, chemically known as 1-pyrrolidinepropanol, alpha-cyclohexyl-alpha-phenyl- but generally known as procyclidine, which bears US NIH Compound Identifier 4919. European Medicines Agency schedules Procyclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10064MIG. The term PROCYCLIDINE is an International Non-Proprietary Name. World Health Organization schedules procyclidine in its Anatomical Therapeutic Chemical (ATC) Classification. PROCYCLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule procyclidine under HS 29339990 and SITC 51577. As of Q4 2014, PROCYCLIDINE remains the US FDA Preferred Term for this commodity. Procyclidine bears US NLM identifiers UMLS ID C0033254 and NCI Concept Code C73270. SMILES: OC(C1CCCCC1)(CCN1CCCC1)C1CCCCC1.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 308EUN932K. European Medicines Agency schedules Procymate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10065MIG. Procymate generally arises in the molecular formula C10H19NO2. The term PROCYMATE is an International Non-Proprietary Name or INN. PROCYMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule procymate under HS 29242995 and SITC 51479. As of Q4 2014, PROCYMATE remains the US FDA Preferred Term for this commodity. Procymate bears US NLM identifiers UMLS ID C1882469 and NCI Concept Code C66473. SMILES: CCC(C1CCCCC1)OC(=O)N.
This classification denotes an opioid and analgesic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21J54X4Z4Z, chemically known as 1,3-dimethyl-4-phenyl-4-propionoxypiperidine but generally known as betaprodine, which bears US NIH Compound Identifier 6471. European Medicines Agency schedules Betaprodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05802MIG. The term BETAPRODINE is an International Non-Proprietary Name. BETAPRODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1(C(CN(CC1)C)C)C1CCCCC1)C(=O)CC.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O00T1I1VRN, chemically known as 10h-phenothiazine-10-ethanamine, n,n-diethyl-.alpha.-methyl-, monohydrochloride but more generally known as ethopropazine hydrochloride, which bears US NIH Compound Identifier 3290. European Medicines Agency schedules Profenamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04056MIG. Most nations, for tariff and trade purposes, schedule profenamine hydrochloride under HS 29343090. SMILES: CCN(CC)C(C)CN1C2CCCCC2SC3C1CCCC3.CL.
This classification denotes an anti-infective agent with the molecular formula C13H11N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CY3RNB3K4T, chemically known as 3,7-diamino-5-azaanthracene but generally known as proflavine, which bears US NIH Compound Identifier 7099. European Medicines Agency schedules Proflavine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10073MIG. The term PROFLAVINE is an International Non-Proprietary Name. PROFLAVINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proflavine under HS 29339990 and SITC 51577. As of Q4 2014, PROFLAVINE remains the US FDA Preferred Term for this commodity. Proflavine bears US NLM identifiers UMLS ID C0033294 and NCI Concept Code C77055. SMILES: N1C2C(CC3C1CC(N)CC3)CCC(N)C2.
This classification denotes a topical anti-infective agent C13H11N3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86EZ5R5IR1, chemically known as 3,6-diaminoacridine dihydrochloride, but more generally known as proflavine dihydrochloride, which bears US NIH Compound Identifier 10750. Most nations, for tariff and trade purposes, schedule proflavine dihydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, PROFLAVINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Proflavine dihydrochloride bears US NLM identifiers UMLS ID C2828237 and NCI Concept Code C87270. SMILES: C1CC(CC2C1CC3CCC(CC3N2)N)N.CL.CL.
This classification denotes a topical anti-infective agent with the molecular structure 2C13H11N3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 27V8M747VB chemically known as acridine, 3,6-diamino-, sulfate (2:1), but more commonly known as proflavine hemisulfate, which bears US NIH Compound Identifier 11111. European Medicines Agency schedules Proflavine hemisulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04058MIG. Most nations, for tariff and trade purposes, schedule proflavine hemisulfate under HS 29339990 and SITC 51577. As of Q4 2014, PROFLAVINE HEMISULFATE remains US FDA's Preferred Term for this commodity. Proflavine hemisulfate bears US NLM identifiers UMLS ID C0033295 and NCI Concept Code C84109. SMILES: C1CC(CC2C1CC3CCC(CC3N2)N)N.C1CC(CC2C1CC3CCC(CC3N2)N)N.OS(=O)(=O)O.
This classification denotes a topical anti-infective agent with the molecular formula C13H11N3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86EZ5R5IR1, chemically known as 3,6-diaminoacridine dihydrochloride, but more generally known as proflavine hydrochloride, which bears US NIH Compound Identifier 10750. European Medicines Agency schedules proflavine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10073MIG. Most nations, for tariff purposes, schedule proflavine hydrochloride under HS 29339990. SMILES: C1CC(CC2C1CC3CCC(CC3N2)N)N.CL.CL.
This classification denotes a benzodiazepine with the molecular formula C18H16ClFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 545MN0F125, chemically known as 7-chloro-1-(2,3-dihydroxypropyl)-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as proflazepam, which bears US NIH Compound Identifier 3050433. European Medicines Agency schedules Proflazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10074MIG. The term PROFLAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). PROFLAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proflazepam under HS 29339940 and SITC 51577. As of Q4 2014, PROFLAZEPAM remains the US FDA Preferred Term for this commodity. Proflazepam bears US NLM identifiers UMLS ID C1882473 and NCI Concept Code C66476. SMILES: CLC1CC2C(N(CC(O)CO)C(=O)CN=C2C2C(F)CCCC2)CC1.
This classification denotes an anticonvulsant, antidepressive agent, antiparkinson agent, and gaba agonist with the molecular formula C17H16ClFN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38C836J57Z, chemically known as butyramide, 4-(alpha-(p-chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)- but generally known as progabide, which bears US NIH Compound Identifier 5361323. European Medicines Agency schedules Progabide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10075MIG. World Health Organization schedules progabide in its Anatomical Therapeutic Chemical (ATC) Classification. PROGABIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule progabide under HS 29242995 and SITC 51479. As of Q4 2014, PROGABIDE remains the US FDA Preferred Term for this commodity. SMILES: CLC1CCC(C(=C2\C=C(F)C=CC2=O)\NCCCC(=O)N)CC1.
This classification denotes a progestagen with the molecular formula C21H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G7DS2Q64Y, chemically known as 10.alpha.-pregn-4-ene-3,20-dione but generally known as progesterone, which bears US NIH Compound Identifier 4920. European Medicines Agency schedules Progesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10076MIG. The term PROGESTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules progesterone in its Anatomical Therapeutic Chemical (ATC) Classification. PROGESTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule progesterone under HS 29372300 and SITC 54153. As of Q4 2014, PROGESTERONE remains the US FDA Preferred Term for this commodity. Progesterone bears US NLM identifiers UMLS ID C0033308 and NCI Concept Code C2297. SMILES: O=C(C1C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C)C.
This classification denotes a progestagen with the molecular formula C27H40O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 276F2O42F5, chemically known as pregn-4-ene-3,20-dione, 17-((1-oxohexyl)oxy)-, but more generally known as progesterone caproate, which bears US NIH Compound Identifier 12419. European Medicines Agency schedules progesterone caproate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10076MIG. Most nations, for tariff purposes, schedule progesterone caproate under HS 29372300. SMILES: CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C.
This classification denotes an indoleacetic acid and non-steroidal anti-inflammatory agent with the molecular formula C46H58ClN5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FV919079LU, chemically known as 3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl dl-4-benzamido-n,n-dipropylglutaramate 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetate (ester) but generally known as proglumetacin, which bears US NIH Compound Identifier 4921. European Medicines Agency schedules Proglumetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10077MIG. World Health Organization schedules proglumetacin in its Anatomical Therapeutic Chemical (ATC) Classification. PROGLUMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proglumetacin under HS 29335995 and SITC 51576. As of Q4 2014, PROGLUMETACIN remains the US FDA Preferred Term for this commodity. SMILES: CLC1CCC(C(=O)N2C(C(CC(=O)OCCN3CCN(CC3)CCCOC(=O)CCC(NC(=O)C3CCCCC3)C(=O)N(CCC)CCC)C3C2CCC(OC)C3)C)CC1.
This classification denotes an indoleacetic acid and non-steroidal anti-inflammatory agent with the molecular formula C46H58ClN5O8.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F2PUN24B8C, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethyl ester, (2z)-2-butenedioate (1:2), but more generally known as proglumetacin dimaleate, which bears US NIH Compound Identifier 6437391. European Medicines Agency schedules proglumetacin dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10077MIG. Most nations, for tariff purposes, schedule proglumetacin dimaleate under HS 29335995. SMILES: CCCN(C(=O)C(NC(=O)C1CCCCC1)CCC(=O)OCCCN2CCN(CC2)CCOC(=O)CC3C4C(N(C3C)C(=O)C5CCC(CC5)CL)CCC(C4)OC)CCC.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an indoleacetic acid and non-steroidal anti-inflammatory agent with the molecular formula C46H58ClN5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FV919079LU, chemically known as 3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl dl-4-benzamido-n,n-dipropylglutaramate 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetate (ester) but more generally known as proglumetacin, which bears US NIH Compound Identifier 4921. European Medicines Agency schedules Proglumetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10077MIG. World Health Organization schedules proglumetacin in its Anatomical Therapeutic Chemical (ATC) Classification. PROGLUMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule proglumetacin maleate under HS 29335995 and SITC 51576. As of Q4 2014, PROGLUMETACIN MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CCCN(C(=O)C(NC(=O)C1CCCCC1)CCC(=O)OCCCN2CCN(CC2)CCOC(=O)CC3C4C(N(C3C)C(=O)C5CCC(CC5)CL)CCC(C4)OC)CCC.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an anti-ulcer agent with the molecular formula C18H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EPL8W5565D, chemically known as 2,5-diamino-5-oxopentanoic acid but generally known as proglumide, which bears US NIH Compound Identifier 738. European Medicines Agency schedules Proglumide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10078MIG. The term PROGLUMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules proglumide in its Anatomical Therapeutic Chemical (ATC) Classification. PROGLUMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proglumide under HS 29242995 and SITC 51479. As of Q4 2014, PROGLUMIDE remains the US FDA Preferred Term for this commodity. Proglumide bears US NLM identifiers UMLS ID C0033321 and NCI Concept Code C81916. SMILES: OC(=O)C(N)CCC(=O)N.
This classification denotes a dihydrofolate reductase inhibitor and antimalarial agent with the molecular formula C11H16ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S61K3P7B2V, chemically known as sn 12,837 but generally known as chlorguanide, which bears US NIH Compound Identifier 6178111. European Medicines Agency schedules Proguanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10079MIG. The term PROGUANIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules chlorguanide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule proguanil under HS 29252900 and SITC 51482. As of Q4 2014, PROGUANIL remains the US FDA Preferred Term for this commodity. Proguanil bears US NLM identifiers UMLS ID C0008241 and NCI Concept Code C61907. SMILES: CC(C)N=C(N)/N=C(\N)/NC1=CC=C(C=C1)CL.
This classification denotes an analgesic agent with the molecular formula C17H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S23189WW7E, chemically known as 1,3-dimethyl-4-phenyl-4-propionyloxyazacycloheptane but generally known as proheptazine, which bears US NIH Compound Identifier 60969. European Medicines Agency schedules Proheptazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10080MIG. The term PROHEPTAZINE is an International Non-Proprietary Name. PROHEPTAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proheptazine under HS 29339990 and SITC 51577. As of Q4 2014, PROHEPTAZINE remains the US FDA Preferred Term for this commodity. Proheptazine bears US NLM identifiers UMLS ID C1882476 and NCI Concept Code C66477. SMILES: O(C1(C(CN(CCC1)C)C)C1CCCCC1)C(=O)CC.
This classification denotes a therapeutic progestin with the molecular formula C24H34O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 55772LJ01V, chemically known as 14,17-dihydroxypregn-4-ene-3,20-dione, cyclic acetal with propionaldehyde but generally known as proligestone, which bears US NIH Compound Identifier 71906. European Medicines Agency schedules Proligestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10081MIG. The term PROLIGESTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). PROLIGESTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proligestone under HS 29372300 and SITC 54153. As of Q4 2014, PROLIGESTONE remains the US FDA Preferred Term for this commodity. Proligestone bears US NLM identifiers UMLS ID C0072111 and NCI Concept Code C77016. SMILES: O1C23C(C(OC1CC)(CC3)C(=O)C)(CCC1C2CCC2=CC(=O)CCC12C)C.
This classification denotes a central nervous system stimulant with the molecular formula C15H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) EM4YZW677H, chemically known as pyrrolidine, 1-(.alpha.-propylphenethyl)-, hydrochloride but more generally known as prolintane, which bears US NIH Compound Identifier 14592. European Medicines Agency schedules Prolintane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10083MIG. World Health Organization schedules prolintane in its Anatomical Therapeutic Chemical (ATC) Classification. PROLINTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule prolintane under HS 29339990 and SITC 51577. As of Q4 2014, PROLINTANE remains US FDA's Preferred Term for this commodity. SMILES: N1(C(CCC)CC2CCCCC2)CCCC1.
This classification denotes a central nervous system stimulant C15H23N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YEG124534B, chemically known as pyrrolidine, 1-(1-(phenylmethyl)butyl)-, hydrochloride, but more generally known as prolintane hydrochloride, which bears US NIH Compound Identifier 14591. European Medicines Agency schedules Prolintane hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04064MIG. Most nations, for tariff and trade purposes, schedule prolintane hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, PROLINTANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCC(CC1CCCCC1)N2CCCC2.CL.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H20N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O9M39HTM5W, chemically known as 10h-phenothiazine-10-propanamine, n,n-dimethyl-, monohydrochloride but generally known as promazine, which bears US NIH Compound Identifier 4926. European Medicines Agency schedules Promazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10085MIG. The term PROMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). World Health Organization schedules promazine in its Anatomical Therapeutic Chemical (ATC) Classification. PROMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule promazine under HS 29343090 and SITC 51578. As of Q4 2014, PROMAZINE remains the US FDA Preferred Term for this commodity. Promazine bears US NLM identifiers UMLS ID C0033399 and NCI Concept Code C61908. SMILES: S1C2C(N(CCCN(C)C)C3C1CCCC3)CCCC2.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H20N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U16EOR79U4, chemically known as 10h-phenothiazine-10-propanamine, n,n-dimethyl-, monohydrochloride but more generally known as promazine hydrochloride, which bears US NIH Compound Identifier 4926. European Medicines Agency schedules Promazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04067MIG. Most nations, for tariff and trade purposes, schedule promazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, PROMAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Promazine hydrochloride bears US NLM identifiers UMLS ID C0546875 and NCI Concept Code C47691. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CCCC3.CL.
This classification denotes a phenothiazine and antipsychotic agent C17H20N2S.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4011G9T8I, chemically known as 10h-phenothiazine-10-propanamine, n,n-dimethyl-, phosphate, but more generally known as promazine phosphate, which bears US NIH Compound Identifier 200325. European Medicines Agency schedules Promazine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04068MIG. Most nations, for tariff and trade purposes, schedule promazine phosphate under HS 29343090 and SITC 51578. As of Q4 2014, PROMAZINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CCCC3.OP(=O)(O)O.
This classification denotes an opioid receptor agonist with the molecular formula C17H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1M2IB31DTS, chemically known as 1,2,5-trimethyl-4-phenyl-4-propionyloxypiperidine but generally known as promedol, which bears US NIH Compound Identifier 6148. European Medicines Agency schedules Trimeperidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11303MIG. The term PROMEDOL is an International Non-Proprietary Name. Promedol or trimeperidine bears US NLM identifiers UMLS ID C0041029 and NCI Concept Code C76848. SMILES: CCC(=O)OC1(C[C@@H](N(C[C@H]1C)C)C)C2=CC=CC=C2.
This classification denotes a steroid compound with the molecular formula C22H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9XE0V2SQYX, chemically known as 17alpha-methyl-1,7-propionylestra-4,9-dien-3-one but generally known as promegestone, which bears US NIH Compound Identifier 36709. European Medicines Agency schedules Promegestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10086MIG. The term PROMEGESTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules promegestone in its Anatomical Therapeutic Chemical (ATC) Classification. PROMEGESTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule promegestone under HS 29372300 and SITC 54153. As of Q4 2014, PROMEGESTONE remains the US FDA Preferred Term for this commodity. Promegestone bears US NLM identifiers UMLS ID C0033401 and NCI Concept Code C66478. SMILES: O=C(C1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)CC2)CC1)C)C)CC.
This classification denotes a therapeutic estrogen with the molecular formula C22H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GXM4PER6WZ, chemically known as 17beta-methoxy-3-propoxyestra-1,3,5(10)-triene but generally known as promestriene, which bears US NIH Compound Identifier 71717. European Medicines Agency schedules Promestriene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10087MIG. The term PROMESTRIENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules promestriene in its Anatomical Therapeutic Chemical (ATC) Classification. PROMESTRIENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule promestriene under HS 29372300 and SITC 54153. As of Q4 2014, PROMESTRIENE remains the US FDA Preferred Term for this commodity. Promestriene bears US NLM identifiers UMLS ID C0072151 and NCI Concept Code C76998. SMILES: O(C1C2(C(C3C(CC2)c2c(CC3)cc(OCCC)cc2)CC1)C)C.
This classification denotes a phenothiazine with the molecular formula C17H20N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FF28EJQ494, chemically known as 10h-phenothiazine-10-ethanamine, n,n,alpha-trimethyl-, radical ion(1+) but generally known as promethazine, which bears US NIH Compound Identifier 4927. European Medicines Agency schedules Promethazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10088MIG. The term PROMETHAZINE is an International Non-Proprietary Name. World Health Organization schedules promethazine in its Anatomical Therapeutic Chemical (ATC) Classification. PROMETHAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule promethazine under HS 29343090 and SITC 51578. As of Q4 2014, PROMETHAZINE remains the US FDA Preferred Term for this commodity. Promethazine bears US NLM identifiers UMLS ID C0033405 and NCI Concept Code C779. SMILES: S1C2C(N(CC(N(C)C)C)C3C1CCCC3)CCCC2.
This classification denotes a phenothiazine C17H20N2S.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H7Q13127S, chemically known as 10h-phenothiazine-10-ethanamine, n,n,.alpha.-trimethyl-, hbr (1:1), but more generally known as promethazine hydrobromide, which bears US NIH Compound Identifier 56841706. Most nations, for tariff and trade purposes, schedule promethazine hydrobromide under HS 29343090 and SITC 51578. As of Q4 2014, PROMETHAZINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Promethazine hydrobromide bears US NLM identifiers UMLS ID C0982361 and NCI Concept Code C97704. SMILES: CC(CN1C2CCCCC2SC3C1CCCC3)N(C)C.BR.
This classification denotes a phenothiazine with the molecular formula C17H20N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R61ZEH7I1I, chemically known as 10h-phenothiazine-10-ethanamine, n,n,alpha-trimethyl-, radical ion(1+) but more generally known as promethazine hydrochloride, which bears US NIH Compound Identifier 4927. European Medicines Agency schedules Promethazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04070MIG. Most nations, for tariff and trade purposes, schedule promethazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, PROMETHAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Promethazine hydrochloride bears US NLM identifiers UMLS ID C0591971 and NCI Concept Code C45907. SMILES: CC(CN1C2CCCCC2SC3C1CCCC3)N(C)C.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a phenothiazine with the molecular formula C17H20N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G44A4PX06U, chemically known as n-(2-(dimethylamino)propyl)phenothiazine s-oxide, but more generally known as promethazine sulfoxide, which bears US NIH Compound Identifier 63032. European Medicines Agency schedules promethazine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10088MIG. Most nations, for tariff purposes, schedule promethazine sulfoxide under HS 29343090. SMILES: CC(CN1C2CCCCC2[S+](C3C1CCCC3)[O-])N(C)C.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H20N2S.C7H7ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5PUP23U26, chemically known as 8-chloro-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compd. with n,n,alpha-trimethyl-10h-phenothiazine-10-ethanamine (1:1) but more generally known as promethazine teoclate, which bears US NIH Compound Identifier 63030. European Medicines Agency schedules Promethazine teoclate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10089MIG. The term PROMETHAZINE TEOCLATE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule promethazine teoclate under HS 29395900 and SITC 54145. As of Q4 2014, PROMETHAZINE TEOCLATE remains US FDA's Preferred Term for this commodity. Promethazine teoclate bears US NLM identifiers UMLS ID C0355411 and NCI Concept Code C66479. SMILES: CC(CN1C2CCCCC2SC3C1CCCC3)N(C)C.CN1C2C(C(=O)N(C1=O)C)[NH]C(N2)CL.
This classification denotes a muscle relaxant with the molecular formula C10H20O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JHI9RRY52E, chemically known as 2,2-diisopropyl-4-methanol-1,3-dioxolane but generally known as promoxolane, which bears US NIH Compound Identifier 10105. European Medicines Agency schedules Promoxolane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10091MIG. The term PROMOXOLANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). PROMOXOLANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule promoxolane under HS 29329970 and SITC 51569. As of Q4 2014, PROMOXOLANE remains the US FDA Preferred Term for this commodity. Promoxolane bears US NLM identifiers UMLS ID C0520813 and NCI Concept Code C82296. SMILES: CC(C)C1(OCC(O1)CO)C(C)C.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XBP4RT1IMQ, chemically known as 2-naphthalenemethanol, alpha-((isopropylamino)methyl)- but generally known as pronetalol, which bears US NIH Compound Identifier 4930. European Medicines Agency schedules Pronetalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10092MIG. The term PRONETALOL is an International Non-Proprietary Name. PRONETALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pronetalol or pronethalol bears US NLM identifiers UMLS ID C0033424 and NCI Concept Code C82257. SMILES: CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O.
This classification denotes an analgesic and antipyretic with the molecular formula C14H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5CHW4JMR82, chemically known as n,n-diethylglycine, ester with 4-hydroxyacetanilide but generally known as propacetamol, which bears US NIH Compound Identifier 68865. European Medicines Agency schedules Propacetamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10093MIG. The term PROPACETAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules propacetamol in its Anatomical Therapeutic Chemical (ATC) Classification. PROPACETAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propacetamol under HS 29242995 and SITC 51479. As of Q4 2014, PROPACETAMOL remains the US FDA Preferred Term for this commodity. Propacetamol bears US NLM identifiers UMLS ID C0084186 and NCI Concept Code C75081. SMILES: O(C(=O)CN(CC)CC)C1CCC(NC(=O)C)CC1.
This classification denotes an analgesic and antipyretic with the molecular formula C14H20N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SH41QYH8E5, chemically known as 4-acetamidophenyl n,n-diethylaminoacetate monohydrochloride but more generally known as propacetamol hydrochloride, which bears US NIH Compound Identifier 108082. European Medicines Agency schedules Propacetamol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04076MIG. Most nations, for tariff and trade purposes, schedule propacetamol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, PROPACETAMOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CC(=O)OC1CCC(CC1)NC(=O)C.CL.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C21H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 68IQX3T69U, chemically known as 1-propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl- but more generally known as propafenone, which bears US NIH Compound Identifier 4932. European Medicines Agency schedules Propafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10094MIG. The term PROPAFENONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules propafenone in its Anatomical Therapeutic Chemical (ATC) Classification. PROPAFENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule propafenone under HS 29221980 and SITC 51461. As of Q4 2014, PROPAFENONE remains US FDA's Preferred Term for this commodity. Propafenone bears US NLM identifiers UMLS ID C0033429 and NCI Concept Code C61909. SMILES: O(CC(O)CNCCC)C1C(C(=O)CCC2CCCCC2)CCCC1.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C21H27NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33XCH0HOCD, chemically known as 1-propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl- but more generally known as propafenone hydrochloride, which bears US NIH Compound Identifier 4932. European Medicines Agency schedules Propafenone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04077MIG. Most nations, for tariff and trade purposes, schedule propafenone hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PROPAFENONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Propafenone hydrochloride bears US NLM identifiers UMLS ID C0282316 and NCI Concept Code C47692. SMILES: CCCNCC(COC1CCCCC1C(=O)CCC2CCCCC2)O.CL.
This classification denotes an antiprotozoal agent with the molecular formula C17H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G20G12V769, chemically known as 4,4-(trimethylenedioxy)dibenzamidine but generally known as propamidine, which bears US NIH Compound Identifier 64949. European Medicines Agency schedules Propamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10095MIG. The term PROPAMIDINE is an International Non-Proprietary Name. World Health Organization schedules propamidine in its Anatomical Therapeutic Chemical (ATC) Classification. PROPAMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propamidine under HS 29252900 and SITC 51482. As of Q4 2014, PROPAMIDINE remains the US FDA Preferred Term for this commodity. Propamidine bears US NLM identifiers UMLS ID C0072159 and NCI Concept Code C82250. SMILES: O(CCCOC1CCC(CC1)C(=N)N)C1CCC(CC1)C(=N)N.
This classification denotes an anesthetic agent with the molecular formula C18H27NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AO82L471NS, chemically known as benzeneacetic acid, 4-(2-(diethylamino)-2-oxoethoxy)-3-methoxy-, propyl ester but generally known as propanidid, which bears US NIH Compound Identifier 15004. European Medicines Agency schedules Propanidid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10096MIG. The term PROPANIDID is an International Non-Proprietary Name. World Health Organization schedules propanidid in its Anatomical Therapeutic Chemical (ATC) Classification. PROPANIDID is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propanidid under HS 29242995 and SITC 51479. As of Q4 2014, PROPANIDID remains the US FDA Preferred Term for this commodity. Propanidid bears US NLM identifiers UMLS ID C0033439 and NCI Concept Code C84110. SMILES: O(CC(=O)N(CC)CC)C1C(OC)CC(CC(=O)OCCC)CC1.
This classification denotes a topical anti-infective agent with the molecular formula C3H8O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96F264O9SV, chemically known as propan-1-ol but generally known as propanol or 1-propanol, which bears US NIH Compound Identifier 1031. European Medicines Agency schedules Propanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15024MIG. SMILES: CCCO.
This classification denotes an antimuscarinic agent with the molecular formula C23H30NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1306V2B0Q8, chemically known as 2-propanaminium, n-methyl-n-(1-methylethyl)-n-(2-((9h-xanthen-9-ylcarbonyl)oxy)ethyl)- but generally known as propantheline, which bears US NIH Compound Identifier 4934. European Medicines Agency schedules Propantheline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04081MIG. World Health Organization schedules propantheline in its Anatomical Therapeutic Chemical (ATC) Classification. PROPANTHELINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PROPANTHELINE remains the US FDA Preferred Term for this commodity. Propantheline bears US NLM identifiers UMLS ID C0033447 and NCI Concept Code C78077. SMILES: O(CC[N](C(C)C)(C(C)C)C)C(=O)C1C2C(OC3C1CCCC3)CCCC2.
This classification denotes an anesthetic agent with the molecular formula C16H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B4OB0JHI1X, chemically known as benzoic acid, 3-amino-4-propoxy-, 2-(diethylamino)ethyl ester but generally known as proxymetacaine, which bears US NIH Compound Identifier 4935. European Medicines Agency schedules Proxymetacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10152MIG. The term PROXYMETACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules proparacaine in its Anatomical Therapeutic Chemical (ATC) Classification. Proparacaine or proxymetacaine bears US NLM identifiers UMLS ID C0072510 and NCI Concept Code C61910. SMILES: CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N.
This classification denotes a vasodilating agent with the molecular formula C6H11N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AJT2YN495R, chemically known as 1,3-propanediol, 2-ethyl-2-((nitrooxy)methyl)-, dinitrate (ester) but generally known as propatyl nitrate, which bears US NIH Compound Identifier 66261. European Medicines Agency schedules Propatylnitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10099MIG. The term PROPATYL NITRATE is an International Non-Proprietary Name. World Health Organization schedules propatyl nitrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule propatylnitrate under HS 29209085 and SITC 51639. SMILES: CCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-]
This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F0O89MB7QE. European Medicines Agency schedules Propenidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10101MIG. Propenidazole generally arises in the molecular formula C11H13N3O5. The term PROPENIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) PROPENIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propenidazole under HS 29332990 and SITC 51573. As of Q4 2014, PROPENIDAZOLE remains the US FDA Preferred Term for this commodity. Propenidazole bears US NLM identifiers UMLS ID C1882489 and NCI Concept Code C66480. SMILES: CCOC(=O)/C(=C/C1=NC=C(N1C)[N+](=O)[O-])/C(=O)C.
This classification denotes a neuroprotective agent with the molecular formula C15H22N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5RTA398U4H, chemically known as 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1h-purine-2,6-dione but more generally known as propentofylline, which bears US NIH Compound Identifier 4938. European Medicines Agency schedules Propentofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10102MIG. The term PROPENTOFYLLINE is an International Non-Proprietary Name. World Health Organization schedules propentofylline in its Anatomical Therapeutic Chemical (ATC) Classification. PROPENTOFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule propentofylline under HS 29395900 and SITC 54145. As of Q4 2014, PROPENTOFYLLINE remains US FDA's Preferred Term for this commodity. Propentofylline bears US NLM identifiers UMLS ID C0072171 and NCI Concept Code C81919. SMILES: O=C1N(CCCCC(=O)C)C(=O)N(C2NCN(C12)CCC)C.
This classification denotes an opioid receptor agonist and opioid and analgesic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R1493W1CJ0, chemically known as 4-piperidinecarboxylic acid, 1-methyl-4-phenyl-, 1-methylethyl ester but generally known as properidine, which bears US NIH Compound Identifier 62373. European Medicines Agency schedules Properidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10103MIG. The term PROPERIDINE is an International Non-Proprietary Name. PROPERIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule properidine under HS 29333999 and SITC 51574. As of Q4 2014, PROPERIDINE remains the US FDA Preferred Term for this commodity. Properidine bears US NLM identifiers UMLS ID C1882490 and NCI Concept Code C66481. SMILES: O(C(=O)C1(CCN(CC1)C)C1CCCCC1)C(C)C.
This classification denotes an anabolic steroid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0H1J6311W. European Medicines Agency schedules Propetandrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10105MIG. Propetandrol generally arises in the molecular formula C23H36O3. The term PROPETANDROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) PROPETANDROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propetandrol under HS 29372900 and SITC 54153. As of Q4 2014, PROPETANDROL remains the US FDA Preferred Term for this commodity. Propetandrol bears US NLM identifiers UMLS ID C2826061 and NCI Concept Code C82225. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(OC(=O)CC)CC2)CC3)CC1)C)CC.
This classification denotes a penicillin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X1R260V33. European Medicines Agency schedules Propicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10106MIG. Propicillin generally arises in the molecular formula C18H22N2O5S. The term PROPICILLIN is an International Non-Proprietary Name or INN. PROPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propicillin under HS 29411090 and SITC 54131. As of Q4 2014, PROPICILLIN remains the US FDA Preferred Term for this commodity. Propicillin bears US NLM identifiers UMLS ID C0072176 and NCI Concept Code C66483. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(OC1CCCCC1)CC.
This classification denotes a penicillin antibiotic with the molecular structure C18H21N2O5S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 75RXW2P83Y chemically known as (2s,5r,6r)-3,3-dimethyl-7-oxo-6-((1-oxo-2-phenoxybutyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid potassium salt, but more commonly known as propicillin potassium, which bears US NIH Compound Identifier 92878. European Medicines Agency schedules Propicillin potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04082MIG. Most nations, for tariff and trade purposes, schedule propicillin potassium under HS 29411090 and SITC 54131. As of Q4 2014, PROPICILLIN POTASSIUM remains US FDA's Preferred Term for this commodity. Propicillin potassium bears US NLM identifiers UMLS ID C0771910 and NCI Concept Code C87371. SMILES: CCC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)[O-])OC3CCCCC3.[K+].
This classification denotes an aminoglycoside antibiotic with the molecular formula C21H43N5O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9X6F5H479X, chemically known as uk 31,214 but generally known as propikacin, which bears US NIH Compound Identifier 68557. European Medicines Agency schedules Propikacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10107MIG. The term PROPIKACIN is an International Non-Proprietary Name. PROPIKACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propikacin under HS 29419000 and SITC 54139. As of Q4 2014, PROPIKACIN remains the US FDA Preferred Term for this commodity. Propikacin bears US NLM identifiers UMLS ID C0610191 and NCI Concept Code C75063. SMILES: O(C1C(NC(CO)CO)CC(N)C(OC2OC(C(O)C(O)C2N)CN)C1O)C1OC(C(O)C(N)C1O)CO.
This classification denotes a histamine-2 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70QV580PA4. European Medicines Agency schedules Propinetidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10108MIG. Propinetidine generally arises in the molecular formula C19H25NO2. The term PROPINETIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) Most nations schedule propinetidine under HS 29333999 and SITC 51574. As of Q4 2014, PROPINETIDINE remains the US FDA Preferred Term for this commodity. Propinetidine bears US NLM identifiers UMLS ID C1882491 and NCI Concept Code C66484. SMILES: O(C1(CCN(CC1)CCC1CCCCC1)CC#C)C(=O)CC.
This classification denotes an antipsychotic agent with the molecular formula C20H24N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 242Z0PM79Y, chemically known as 1-propanone, 1-(10-(2-(dimethylamino)propyl)phenothiazin-2-yl)- but generally known as propiomazine, which bears US NIH Compound Identifier 4940. European Medicines Agency schedules Propiomazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10110MIG. The term PROPIOMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules propiomazine in its Anatomical Therapeutic Chemical (ATC) Classification. PROPIOMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propiomazine under HS 29343090 and SITC 51578. As of Q4 2014, PROPIOMAZINE remains the US FDA Preferred Term for this commodity. Propiomazine bears US NLM identifiers UMLS ID C0033473 and NCI Concept Code C66486. SMILES: S1C2C(N(CC(N(C)C)C)C3C1CCCC3)CC(CC2)C(=O)CC.
This classification denotes an antipsychotic agent with the molecular formula C20H24N2OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70BO17YR03, chemically known as 1-propanone, 1-(10-(2-(dimethylamino)propyl)-10h-phenothiazin-2-yl)-, monohydrochloride but more generally known as propiomazine hydrochloride, which bears US NIH Compound Identifier 71802. European Medicines Agency schedules Propiomazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04083MIG. Most nations, for tariff and trade purposes, schedule propiomazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, PROPIOMAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Propiomazine hydrochloride bears US NLM identifiers UMLS ID C0023044 and NCI Concept Code C66487. SMILES: CCC(=O)C1CCC2C(C1)N(C3CCCCC3S2)CC(C)N(C)C.CL.
This classification denotes an antipsychotic agent C20H24N2OS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OEY0ZC43SA, chemically known as 1-propanone, 1-(10-(2-(dimethylamino)propyl)-10h-phenothiazin-2-yl)-, (+/-), (2z)-2-butenedioate (1:1), but more generally known as propiomazine maleate, which bears US NIH Compound Identifier 5702109. European Medicines Agency schedules Propiomazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04084MIG. Most nations, for tariff and trade purposes, schedule propiomazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, PROPIOMAZINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)C1CCC2C(C1)N(C3CCCCC3S2)CC(C)N(C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antispasmotic agent and antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DC4GZD10H3. European Medicines Agency schedules Propiverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04087MIG. Propiverine hydrochloride generally arises in the molecular formula C23H29NO3.CLH. The term 'propiverine hydrochloride' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule propiverine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PROPIVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCOC(C1CCCCC1)(C2CCCCC2)C(=O)OC3CCN(CC3)C.CL.
This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C23H29NO3 and C23H29NO3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 468GE2241L and DC4GZD10H3, the base compound being chemically known as 1-methyl-4-piperidyl 2,2-diphenyl-2-propoxyacetate but generally known as propiverine, which bears US NIH Compound Identifier 4942. European Medicines Agency schedules Propiverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB10114MIG and SUB04087MIG. The term PROPIVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules propiverine in its Anatomical Therapeutic Chemical (ATC) Classification. PROPIVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propiverine and its salts under HS 29333999 and SITC 51574. As of Q4 2014, PROPIVERINE remains the US FDA Preferred Term for this commodity. Propiverine bears US NLM NCI 66491. SMILES: O(C1CCN(CC1)C)C(=O)C(OCCC)(C1CCCCC1)C1CCCCC1 (base) or CCCOC(C1CCCCC1)(C2CCCCC2)C(=O)OC3CCN(CC3)C.CL (hydrochloride).
This classification denotes a sedative and hypnotic with the molecular formula C12H18O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YI7VU623SF, chemically known as 2,6-dipropan-2-ylphenol but generally known as propofol, which bears US NIH Compound Identifier 4943. European Medicines Agency schedules Propofol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10116MIG. The term PROPOFOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules propofol in its Anatomical Therapeutic Chemical (ATC) Classification. PROPOFOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propofol under HS 29071990 and SITC 51243. As of Q4 2014, PROPOFOL remains the US FDA Preferred Term for this commodity. Propofol bears US NLM identifiers UMLS ID C0033487 and NCI Concept Code C29384. SMILES: CC(C)C1=C(C(=CC=C1)C(C)C)O.
This classification denotes an anesthetic agent with the molecular formula C16H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EPD1EH7F53, chemically known as 4-amino-2-propoxybenzoic acid, 2-(diethylamino)ethyl ester but generally known as propoxycaine, which bears US NIH Compound Identifier 6843. European Medicines Agency schedules Propoxycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10118MIG. The term PROPOXYCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). PROPOXYCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propoxycaine under HS 29225000 and SITC 51467. As of Q4 2014, PROPOXYCAINE remains the US FDA Preferred Term for this commodity. Propoxycaine bears US NLM identifiers UMLS ID C0033492 and NCI Concept Code C66492. SMILES: O(CCN(CC)CC)C(=O)C1C(OCCC)CC(N)CC1.
This classification denotes an anesthetic agent with the molecular formula C16H26N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K490D39G46, chemically known as benzoic acid, 4-amino-2-propoxy-, 2-(diethylamino)ethyl ester, monohydrochloride but more generally known as propoxycaine hydrochloride, which bears US NIH Compound Identifier 11078. European Medicines Agency schedules Propoxycaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04089MIG. Most nations, for tariff and trade purposes, schedule propoxycaine hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, PROPOXYCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Propoxycaine hydrochloride bears US NLM identifiers UMLS ID C0282320 and NCI Concept Code C66493. SMILES: CCCOC1CC(CCC1C(=O)OCCN(CC)CC)N.CL.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Y8NXQ24VQ, chemically known as 2-propanol, 1- (isopropylamino)-3-(1-naphthyloxy)-, hydrochloride but generally known as propranolol, which bears US NIH Compound Identifier 4946. European Medicines Agency schedules Propranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10119MIG. The term PROPRANOLOL is an International Non-Proprietary Name. World Health Organization schedules propranolol in its Anatomical Therapeutic Chemical (ATC) Classification. PROPRANOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propranolol under HS 29221980 and SITC 51461. As of Q4 2014, PROPRANOLOL remains the US FDA Preferred Term for this commodity. Propranolol bears US NLM identifiers UMLS ID C0033497 and NCI Concept Code C62073. SMILES: O(CC(O)CNC(C)C)C1C2C(CCC1)CCCC2.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H21NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8A3652H1V, chemically known as 2-propanol, 1- (isopropylamino)-3-(1-naphthyloxy)-, hydrochloride but more generally known as propranolol hydrochloride, which bears US NIH Compound Identifier 4946. European Medicines Agency schedules Propranolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04091MIG. Most nations, for tariff and trade purposes, schedule propranolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PROPRANOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Propranolol hydrochloride bears US NLM identifiers UMLS ID C0282321 and NCI Concept Code C29382. SMILES: CC(C)NCC(COC1CCCC2C1CCCC2)O.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C10H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LQU92IU8LL, chemically known as propylhexedrine, dl- but generally known as propylhexedrine, which bears US NIH Compound Identifier 7558. European Medicines Agency schedules Propylhexedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10121MIG. The term PROPYLHEXEDRINE is an International Non-Proprietary Name. PROPYLHEXEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propylhexedrine under HS 29213099 and SITC 51453. As of Q4 2014, PROPYLHEXEDRINE remains the US FDA Preferred Term for this commodity. Propylhexedrine bears US NLM identifiers UMLS ID C0033508 and NCI Concept Code C47694. SMILES: CC(CC1CCCCC1)NC.
This classification denotes an alpha-adrenergic agonist C10H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 064LUN7NZ5, chemically known as (rs)-n,.alpha.-dimethyl-cyclohexylethylamine hydrochloride, but more generally known as propylhexedrine hydrochloride, which bears US NIH Compound Identifier 102541. Most nations, for tariff and trade purposes, schedule propylhexedrine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, PROPYLHEXEDRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCCC1)NC.CL.
This classification denotes a contrast agent with the molecular formula C10H11I2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5NPJ6BPX36, chemically known as 3,5-diiodo-4-pyridone-n-acetic acid propyl ester but more generally known as propyliodone, which bears U.S. National Institutes of Health Compound Identifier 4949. The European Medicines Agency schedules Propyliodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10122MIG. The term PROPYLIODONE is an International Non-Proprietary Name. The World Health Organization schedules propyliodone in its Anatomical Therapeutic Chemical (ATC) Classification. PROPYLIODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCCOC(=O)CN1C=C(C(=O)C(=C1)I)I. Most nations schedule Propyliodone under HS 29333999.
This classification denotes an antithyroid agent with the molecular formula C7H10N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 721M9407IY, chemically known as 2,3-dihydro-6-propyl-2-thioxo-4(1h)-pyrimidinone but generally known as propylthiouracil, which bears US NIH Compound Identifier 657298. European Medicines Agency schedules Propylthiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10123MIG. The term PROPYLTHIOURACIL is an International Non-Proprietary Name. World Health Organization schedules propylthiouracil in its Anatomical Therapeutic Chemical (ATC) Classification. PROPYLTHIOURACIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propylthiouracil under HS 29335995 and SITC 51576. As of Q4 2014, PROPYLTHIOURACIL remains the US FDA Preferred Term for this commodity. Propylthiouracil bears US NLM identifiers UMLS ID C0033511 and NCI Concept Code C781. SMILES: S=C1[NH]C(CCC)CC(=O)[NH]1.
This classification denotes an anxiolytic with the molecular formula C23H33FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HG22108KQK, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-(1-oxopropyl)(1,4-bipiperidin)-1-yl)- (9ci) but generally known as propyperone, which bears US NIH Compound Identifier 19607. European Medicines Agency schedules Propyperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10124MIG. The term PROPYPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). PROPYPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propyperone under HS 29333999 and SITC 51574. As of Q4 2014, PROPYPERONE remains the US FDA Preferred Term for this commodity. Propyperone bears US NLM identifiers UMLS ID C2347697 and NCI Concept Code C73290. SMILES: FC1CCC(C(=O)CCCN2CCC(N3CCCCC3)(CC2)C(=O)CC)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OED8FV75PY, chemically known as 2,3-dimethyl-4-isopropyl-1-phenyl-3h-pyrazolin-5-one but generally known as propyphenazone, which bears US NIH Compound Identifier 3778. European Medicines Agency schedules Propyphenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10125MIG. The term PROPYPHENAZONE is an International Non-Proprietary Name. World Health Organization schedules propyphenazone in its Anatomical Therapeutic Chemical (ATC) Classification. PROPYPHENAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule propyphenazone under HS 29331110 and SITC 51571. As of Q4 2014, PROPYPHENAZONE remains the US FDA Preferred Term for this commodity. Propyphenazone bears US NLM identifiers UMLS ID C0072245 and NCI Concept Code C72124. SMILES: O=C1N(N(C(C1C(C)C)C)C)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42VPJ2980S, chemically known as 2(1h)-quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- but generally known as proquazone, which bears US NIH Compound Identifier 31508. European Medicines Agency schedules Proquazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10127MIG. The term PROQUAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules proquazone in its Anatomical Therapeutic Chemical (ATC) Classification. PROQUAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proquazone under HS 29335995 and SITC 51576. As of Q4 2014, PROQUAZONE remains the US FDA Preferred Term for this commodity. Proquazone bears US NLM identifiers UMLS ID C0072247 and NCI Concept Code C73093. SMILES: O=C1N(C(C)C)C2C(C(N1)C1CCCCC1)CCC(C2)C.
This classification denotes an antimicrobial with the molecular formula C17H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M91328O79, chemically known as 3-quinolinecarboxylic acid, 4-hydroxy-6,7-diisopropoxy-, methyl ester but more generally known as proquinolate, which bears US NIH Compound Identifier 15547. European Medicines Agency schedules Proquinolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10128MIG. The term PROQUINOLATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). PROQUINOLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(OC(C)C)CC2[NH]CC(C(=O)C2C1)C(=O)OC)C(C)C.
This classification denotes a potassium-sparing diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WET36J3301. European Medicines Agency schedules Prorenoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10129MIG. Prorenoate generally arises in the molecular formula C23H31O4.K. The term PRORENOATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) As of Q4 2014, PRORENOATE remains the US FDA Preferred Term for this commodity. Prorenoate bears US NLM identifiers UMLS ID CL412716 and NCI Concept Code C84117. SMILES: CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4CCC5(CCC(=O)O)O)C.
This classification denotes a potassium-sparing diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2D4XUS623. European Medicines Agency schedules Prorenoate potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10129MIG. Prorenoate potassium generally arises in the molecular formula C23H31O4.K. The term PRORENOATE POTASSIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, no. 10 1975, list 15.) Most nations, for tariff and trade purposes, schedule prorenoate potassium under HS 29372900 and SITC 54153. As of Q4 2014, PRORENOATE POTASSIUM remains US FDA's Preferred Term for this commodity. Prorenoate potassium bears US NLM identifiers UMLS ID C0072213 and NCI Concept Code C84118. SMILES: C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4CC[C@]5(CCC(=O)[O-])O)C.[K+].
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C21H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, T5WT3QN49G chemically known as 1-(1,4-benzodioxan-6-yl)-3-(3-phenyl-1-pyrrolidinyl)-1-propanone but generally known as proroxan, which bears US NIH Compound Identifier 36303. European Medicines Agency schedules Proroxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10130MIG. The term PROROXAN is an International Non-Proprietary Name or INN. Most nations schedule proroxan under HS 29349990 and SITC 51579. As of Q4 2014, PROROXAN remains the US FDA Preferred Term for this commodity. Proroxan bears US NLM identifiers UMLS ID C0072252 and NCI Concept Code C84119. SMILES: C1CN(CC1C2=CC=CC=C2)CCC(=O)C3=CC4=C(C=C3)OCCO4.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C21H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 694Z9P44G4, chemically known as 1,4-benzodioxan, 6-(3-(3-phenylpyrrolidinyl)propionyl)-, hydrochloride but more generally known as proroxan hydrochloride, which bears US NIH Compound Identifier 36302. Most nations, for tariff and trade purposes, schedule proroxan hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, PROROXAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Proroxan hydrochloride bears US NLM identifiers UMLS ID C0951999 and NCI Concept Code C84120. SMILES: C1CCC(CC1)C2CCN(C2)CCC(=O)C3CCC4C(C3)OCCO4.CL.
This classification denotes a cardiotonic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KC6BL281EN. European Medicines Agency schedules Proscillaridin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10131MIG. Proscillaridin generally arises in the molecular formula C30H42O8. The term PROSCILLARIDIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) PROSCILLARIDIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proscillaridin under HS 29389090 and SITC 54161. As of Q4 2014, PROSCILLARIDIN remains the US FDA Preferred Term for this commodity. Proscillaridin bears US NLM identifiers UMLS ID C0033513 and NCI Concept Code C84121. SMILES: OC12C(C(CC2)C2CCC(=O)OC2)(CCC2C1CCC1=CC(OC3OC(C(O)C(O)C3O)C)CCC21C)C.
This classification denotes a protective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0DE9724IHC. European Medicines Agency schedules Protamine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04105MIG. Protamine sulfate generally arises in the molecular formula H2O4S. The term PROTAMINE SULFATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) Most nations schedule protamine sulfate under HS 35040000 and SITC 59225. As of Q4 2014, PROTAMINE SULFATE remains the US FDA Preferred Term for this commodity. Protamine sulfate bears US NLM identifiers UMLS ID C0033602 and NCI Concept Code C84123. SMILES: NONE.
A purified basic protein from pig brain was degraded proteolytically when incubated in an aqueous solution.
This classification denotes a dopamine agonist with the molecular formula C22H32N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10661OD4VE, chemically known as 1,1-diethyl-3-(6-propylergolin-8alpha-yl)urea but generally known as proterguride, which bears US NIH Compound Identifier 71999. European Medicines Agency schedules Proterguride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10136MIG. The term PROTERGURIDE is an International Non-Proprietary Name. PROTERGURIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proterguride under HS 29396900 and SITC 54146. As of Q4 2014, PROTERGURIDE remains the US FDA Preferred Term for this commodity. Proterguride bears US NLM identifiers UMLS ID C0208770 and NCI Concept Code C73309. SMILES: O=C(NC1CC2C(N(C1)CCC)CC1C3C2CCCC3[NH]C1)N(CC)CC.
This classification denotes an antipsychotic agent with the molecular formula C16H19N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5O6VWA87VA, chemically known as 10h-pyrido(3,2-b)(1,4)benzothiazine-10-propanamine, n,n-dimethyl- but generally known as prothipendyl, which bears US NIH Compound Identifier 14670. European Medicines Agency schedules Prothipendyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10138MIG. The term PROTHIPENDYL is an International Non-Proprietary Name. World Health Organization schedules prothipendyl in its Anatomical Therapeutic Chemical (ATC) Classification. PROTHIPENDYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prothipendyl under HS 29349990 and SITC 51579. As of Q4 2014, PROTHIPENDYL remains the US FDA Preferred Term for this commodity. Prothipendyl bears US NLM identifiers UMLS ID C0139007 and NCI Concept Code C84124. SMILES: S1C2C(N(CCCN(C)C)C3NCCCC13)CCCC2.
This classification denotes an antipsychotic agent with the molecular formula C16H19N3S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7610629RVH, chemically known as 10h-pyrido(3,2-b)(1,4)benzothiazine, 10-(3-(dimethylamino)propyl)-, monohydrochloride but more generally known as prothipendyl hydrochloride, which bears US NIH Compound Identifier 14669. European Medicines Agency schedules Prothipendyl hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04111MIG. Most nations, for tariff and trade purposes, schedule prothipendyl hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, PROTHIPENDYL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Prothipendyl hydrochloride bears US NLM identifiers UMLS ID C0772014 and NCI Concept Code C81584. SMILES: CN(C)CCCN1C2CCCCC2SC3C1NCCC3.CL.
This classification denotes a sedative and hypnotic with the molecular formula C18H19NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2HX2OJH78L, chemically known as n,n-dimethylthioxanthene-delta(sup 9,gamma)-propylamine but generally known as prothixene, which bears US NIH Compound Identifier 71115. European Medicines Agency schedules Prothixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10139MIG. The term PROTHIXENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). PROTHIXENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prothixene under HS 29349990 and SITC 51579. As of Q4 2014, PROTHIXENE remains the US FDA Preferred Term for this commodity. Prothixene bears US NLM identifiers UMLS ID C0072428 and NCI Concept Code C73249. SMILES: S1C2C(C(=C\CCN(C)C)/C3C1CCCC3)CCCC2.
This classification denotes an antifungal agent with the molecular formula C12H16O6S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier FIP88CI9Y3, chemically known as 3,4-dihydroxy-2,5-thiophenedicarboxylic acid dipropyl ester but more generally known as protiofate, which bears U.S. NIH Compound Identifier 5464207. European Medicines Agency schedules Protiofate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10140MIG. The term PROTIOFATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules protiofate in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. PROTIOFATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an antitubercular agent with the molecular formula C9H12N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76YOO33643, chemically known as 4-pyridinecarbothioamide, 2-propyl- (9ci) but generally known as protionamide, which bears US NIH Compound Identifier 666418. European Medicines Agency schedules Protionamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10141MIG. The term PROTIONAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules protionamide in its Anatomical Therapeutic Chemical (ATC) Classification. PROTIONAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule protionamide under HS 29333999 and SITC 51574. As of Q4 2014, PROTIONAMIDE remains the US FDA Preferred Term for this commodity. Protionamide bears US NLM identifiers UMLS ID C0033705 and NCI Concept Code C72605. SMILES: S=C(N)C1CC(NCC1)CCC.
This classification denotes a hypothalmic hormone with the molecular structure C16H22N6O4.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, SYW8T997EQ chemically known as l-prolinamide, 5-oxo-l-prolyl-l-histidyl-, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more commonly known as protirelin tartrate, which bears US NIH Compound Identifier 176174. European Medicines Agency schedules Protirelin tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04112MIG. Most nations, for tariff and trade purposes, schedule protirelin tartrate under HS 29371900. As of Q4 2014, PROTIRELIN TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C1C([NH]CN1)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N)NC(=O)[C@@H]3CCC(=O)N3.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C18H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y5Y4EEO2V, chemically known as 1-(3,4-dihydroxyphenyl)-2-(alpha-methyl-3,4-methylendioxyphenethylamino)ethanol but generally known as protokylol, which bears US NIH Compound Identifier 4969. European Medicines Agency schedules Protokylol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10144MIG. The term PROTOKYLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). PROTOKYLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule protokylol under HS 29329970 and SITC 51569. As of Q4 2014, PROTOKYLOL remains the US FDA Preferred Term for this commodity. Protokylol bears US NLM identifiers UMLS ID C0163026 and NCI Concept Code C74198. SMILES: OC(CNC(CC1CC2OCOC2CC1)C)C1CC(O)C(O)CC1.
This classification denotes a beta-adrenergic agonist with the molecular formula C18H21NO5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U7O8Q48IO, chemically known as 1-(3,4-dihydroxyphenyl)-2-(alpha-methyl-3,4-methylendioxyphenethylamino)ethanol but more generally known as protokylol hydrochloride, which bears US NIH Compound Identifier 4969. European Medicines Agency schedules Protokylol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04113MIG. Most nations, for tariff and trade purposes, schedule protokylol hydrochloride under HS 29329970 and SITC 51569. As of Q4 2014, PROTOKYLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Protokylol hydrochloride bears US NLM identifiers UMLS ID C0770472 and NCI Concept Code C66496. SMILES: CC(CC1CCC2C(C1)OCO2)NCC(C3CCC(C(C3)O)O)O.CL.
This classification denotes a tricyclic antidepressant with the molecular formula C19H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4NDU154T12, chemically known as 7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene but generally known as protriptyline, which bears US NIH Compound Identifier 4976. European Medicines Agency schedules Protriptyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10145MIG. The term PROTRIPTYLINE is an International Non-Proprietary Name. World Health Organization schedules protriptyline in its Anatomical Therapeutic Chemical (ATC) Classification. PROTRIPTYLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule protriptyline under HS 29214980 and SITC 51454. As of Q4 2014, PROTRIPTYLINE remains the US FDA Preferred Term for this commodity. Protriptyline bears US NLM identifiers UMLS ID C0033743 and NCI Concept Code C61913. SMILES: N(CCCC1c2c(C=Cc3c1cccc3)cccc2)C.
This classification denotes a tricyclic antidepressant with the molecular formula C19H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44665V00O8, chemically known as 7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene but more generally known as protriptyline hydrochloride, which bears US NIH Compound Identifier 4976. European Medicines Agency schedules Protriptyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04117MIG. Most nations, for tariff and trade purposes, schedule protriptyline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, PROTRIPTYLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Protriptyline hydrochloride bears US NLM identifiers UMLS ID C0042910 and NCI Concept Code C47695. SMILES: CNCCCC1C2CCCCC2C=CC3C1CCCC3.CL.
This classification denotes an antispasmotic agent with the molecular formula C17H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FD72T13M0K, chemically known as 1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, (+)- (9ci) but generally known as proxazole, which bears US NIH Compound Identifier 8590. European Medicines Agency schedules Proxazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10146MIG. The term PROXAZOLE is an International Non-Proprietary Name. World Health Organization schedules proxazole in its Anatomical Therapeutic Chemical (ATC) Classification. PROXAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proxazole under HS 29349990 and SITC 51579. As of Q4 2014, PROXAZOLE remains the US FDA Preferred Term for this commodity. Proxazole bears US NLM identifiers UMLS ID C0072507 and NCI Concept Code C74176. SMILES: O1NC(NC1CCN(CC)CC)C(CC)C1CCCCC1.
This classification denotes a sedative and hypnotic with the molecular formula C10H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F97OMS297F, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propenyl)-, (+-)- (9ci) but generally known as proxibarbal, which bears US NIH Compound Identifier 17336. European Medicines Agency schedules Proxibarbal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10147MIG. The term PROXIBARBAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules proxibarbal in its Anatomical Therapeutic Chemical (ATC) Classification. PROXIBARBAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Proxibarbal or proxibarbital bears US NLM identifiers UMLS ID C0288495 and NCI Concept Code C74375. SMILES: CC(CC1(C(=O)NC(=O)NC1=O)CC=C)O.
This classification denotes an anesthetic agent with the molecular formula C16H26N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U96OL57GOY, chemically known as benzoic acid, 3-amino-4-propoxy-, 2-(diethylamino)ethyl ester, monohydrochloride but more generally known as proparacaine hydrochloride, which bears US NIH Compound Identifier 22169. European Medicines Agency schedules Proparacaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04118MIG. Most nations, for tariff and trade purposes, schedule proxymetacaine hydrochloride under HS 29225000. SMILES: CCCOC1CCC(CC1N)C(=O)OCCN(CC)CC.CL.
This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C10H14N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13G1DMN4P0, chemically known as 3,7-dihydro-7-(2-hydroxypropyl)-1,3-dimethyl-1h-purine-2,6-dione but generally known as proxyphylline, which bears US NIH Compound Identifier 4977. European Medicines Agency schedules Proxyphylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10153MIG. The term PROXYPHYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules proxyphylline in its Anatomical Therapeutic Chemical (ATC) Classification. PROXYPHYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule proxyphylline under HS 29395900 and SITC 54145. As of Q4 2014, PROXYPHYLLINE remains the US FDA Preferred Term for this commodity. Proxyphylline bears US NLM identifiers UMLS ID C0072511 and NCI Concept Code C80339. SMILES: CC(CN1C=NC2=C1C(=O)N(C(=O)N2C)C)O.
This classification denotes an antispasmotic agent with the molecular formula C20H25NO2, chemically known as 1-(3,3-diphenylpropyl)azepane hydrochloride but generally known as prozapine hydrochloride, which bears US NIH Compound Identifier 71127. European Medicines Agency schedules Prozapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10154MIG. Most nations schedule prozapine under HS 29339930 and SITC 51577. As of Q4 2014, PROZAPINE remains the US FDA Preferred Term for this commodity. Prozapine bears US NLM identifiers UMLS ID C0072512 and NCI Concept Code C73167. SMILES: C1CCCN(CC1)CCC(C2=CC=CC=C2)C3=CC=CC=C3.
This classification denotes a serotonin agonist with the molecular formula C18H26ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A09IUW5TP, chemically known as 4-amino-5-chloro-2,3-dihydro-n-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide but generally known as prucalopride, which bears US NIH Compound Identifier 3052762. European Medicines Agency schedules Prucalopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10155MIG. The term PRUCALOPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules prucalopride in its Anatomical Therapeutic Chemical (ATC) Classification. PRUCALOPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prucalopride under HS 29349990 and SITC 51579. As of Q4 2014, PRUCALOPRIDE remains the US FDA Preferred Term for this commodity. Prucalopride bears US NLM identifiers UMLS ID C0913506 and NCI Concept Code C74386. SMILES: CLC1CC(C(=O)NC2CCN(CC2)CCCOC)C2OCCC2C1N.
This classification denotes a serotonin agonist C18H26ClN3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M8IYX9Z79V, chemically known as 4-amino-5-chloro-2,3-dihydro-n-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide hydrochloride, but more generally known as prucalopride hydrochloride, which bears US NIH Compound Identifier 9931054. Most nations, for tariff and trade purposes, schedule prucalopride hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, PRUCALOPRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COCCCN1CCC(CC1)NC(=O)C2CC(C(C3C2OCC3)N)CL.CL.
This classification denotes a serotonin agonist with the molecular formula C18H26CLN3O3.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4V2G75E1CK. European Medicines Agency schedules prucalopride succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB28850. The term prucalopride succinate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule prucalopride succinate under HS 29349990 and SITC 51579. As of Q4 2014, PRUCALOPRIDE SUCCINATE remains US FDA's Preferred Term for this commodity. SMILES: COCCCN1CCC(CC1)NC(=O)C2CC(C(C3C2OCC3)N)CL.C(CC(=O)O)C(=O)O.
This classification denotes a quinolone antibiotic with the molecular formula C21H20FN3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J42298IESW, chemically known as 1h,4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo- but generally known as prulifloxacin, which bears US NIH Compound Identifier 65947. European Medicines Agency schedules Prulifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10156MIG. The term PRULIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules prulifloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. PRULIFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prulifloxacin under HS 29349990 and SITC 51579. As of Q4 2014, PRULIFLOXACIN remains the US FDA Preferred Term for this commodity. Prulifloxacin bears US NLM identifiers UMLS ID C0527129 and NCI Concept Code C72637. SMILES: S1C(N2C3CC(N4CCN(CC4)CC4OC(=O)OC4C)C(F)CC3C(=O)C(C12)C(=O)O)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears US NIH Compound Identifier 5032. European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG. The term PSEUDOEPHEDRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules pseudoephedrine in its Anatomical Therapeutic Chemical (ATC) Classification. PSEUDOEPHEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pseudoephedrine under HS 29394200 and SITC 54144. As of Q4 2014, PSEUDOEPHEDRINE remains US FDA's Preferred Term for this commodity. Pseudoephedrine bears US NLM identifiers UMLS ID C0033798 and NCI Concept Code C61914. SMILES: CC(C(C1=CC=CC=C1)O)NC.
This classification denotes an alpha-adrenergic agonist with the molecular formula 2C10H15NO.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y9DL7QPE6B, chemically known as bis((s-(r*,r*))-(beta-hydroxy-alpha-methylphenethyl)methylammonium) sulphate but more generally known as pseudoephedrine sulfate, which bears US NIH Compound Identifier 62945. European Medicines Agency schedules Pseudoephedrine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15044MIG. Most nations, for tariff and trade purposes, schedule pseudoephedrine sulfate under HS 29394200 and SITC 54144. As of Q4 2014, PSEUDOEPHEDRINE SULFATE remains US FDA's Preferred Term for this commodity. Pseudoephedrine sulfate bears US NLM identifiers UMLS ID C0304431 and NCI Concept Code C47696. SMILES: C[C@@H]([C@H](C1CCCCC1)O)NC.C[C@@H]([C@H](C1CCCCC1)O)NC.OS(=O)(=O)O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C76H52O46.C10H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82W1IJ29AT. European Medicines Agency schedules pseudoephedrine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20399. Most nations, for tariff and trade purposes, schedule pseudoephedrine tannate under HS 29394200 and SITC 54144. As of Q4 2014, PSEUDOEPHEDRINE TANNATE remains US FDA's Preferred Term for this commodity. SMILES: none.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.
This classification denotes a serotonin agonist and alkaloid with the molecular formula C12H17N2O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2RV7212BP0, chemically known as 4-phosphoryloxy-omega-n,n-dimethyltryptamine but generally known as psilocybin, which bears US NIH Compound Identifier 10624. European Medicines Agency schedules Psilocybine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10158MIG. The term PSILOCYBINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). SMILES: CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O.
Psyllium hydrophilic mucilloid (plantago ovata)/senna glycosides or sennosides is a herbal or nutraceutical combination used to treat habitual constipation, hemorrhoids or piles, and bowel regulation for bedridden patient.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UD50RBY30F, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 504438 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Lamiales, Family Plantaginaceae, Genus Plantago L. (Indianwheat, plantain), Species Plantago ovata Forssk., commonly known as DESERT INDIANWHEAT or as here, PSYLLIUM. Plantago bears the USDA PLANTS Database Identifier PLOV. European Medicines Agency schedules psyllium (as Plantago ovata) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB12088MIG, SUB14285MIG, and SUB14286MIG. This classification concerns the outer shell or coating of the plantago, or PSYLLIUM HUSK or PSYLLIUM HUSK. which FDA generically classifies under Unique Ingredient Identifier 9C60Y73166 (base) and UD50RBY30F (ovata). SMILES: NONE.
This classification denotes an antineoplastic alkylating agent with the molecular formula C12H19N8OP, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7AYY495RE0, chemically known as p,p-bis(1-aziridinyl)-n-(2-(dimethylamino)-7-methylpurin-6-yl)phosphinic amide but more generally known as pumitepa, which bears US NIH Compound Identifier 68669. European Medicines Agency schedules Pumitepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10160MIG. The term PUMITEPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). PUMITEPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pumitepa under HS 29335995 and SITC 51576. As of Q4 2014, PUMITEPA remains US FDA's Preferred Term for this commodity. Pumitepa bears US NLM identifiers UMLS ID C0060632 and NCI Concept Code C73239. SMILES: CN1C=NC2=C1C(=NC(=N2)N(C)C)NP(=O)(N3CC3)N4CC4.
This classification denotes an opioid and antidiarrheal agent with the molecular formula C6H10O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89NA02M4RX, chemically known as (2S,3R,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid but generally known as pectin, which bears US NIH Compound Identifier 441476. European Medicines Agency schedules Loperamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14786MIG. World Health Organization schedules pectin in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1(C(C(OC(C1O)O)C(=O)O)O)O.
This classification denotes a protein synthesis inhibitor and miscellaneous antineoplastic antibiotic with the molecular formula C22H29N7O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4A6ZS6Q2CL, chemically known as 3123l, dihydrochloride but generally known as puromycin, which bears US NIH Compound Identifier 4984. European Medicines Agency schedules Puromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10161MIG. The term PUROMYCIN is an International Non-Proprietary Name. PUROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule puromycin under HS 29419000 and SITC 54139. As of Q4 2014, PUROMYCIN remains the US FDA Preferred Term for this commodity. Puromycin bears US NLM identifiers UMLS ID C0034145 and NCI Concept Code C787. SMILES: O1C(C(NC(=O)C(N)CC2CCC(OC)CC2)C(O)C1N1C2NCNC(N(C)C)C2NC1)CO.
This classification denotes a protein synthesis inhibitor and miscellaneous antineoplastic antibiotic with the molecular formula C12H18N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Q580U88V8, chemically known as 6-(dimethylamino)-9-(3-amino-3-deoxy-.beta.-d-ribofuranosyl)purine, but more generally known as puromycin aminonucleoside, which bears US NIH Compound Identifier 1599. European Medicines Agency schedules puromycin aminonucleoside or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10161MIG. Most nations, for tariff purposes, schedule puromycin aminonucleoside under HS 29419000. SMILES: CN(C)C1C2C(NCN1)N(CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 709HYI14M4, the source of which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O05WS7301S, the source of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 837327 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Rosales, Family Rosaceae, Genus Prunus L. (chokecherry, plum), Species Prunus africana, often commonly called RED STINKWOOD or as here, PRUNUS AFRICANA. Prunus L. (Genus) bears the USDA PLANTS Database Identifier PRUNU. European Medicines Agency schedules prunus africana in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB36083 (whole) and SUB36083 (bark).
This classification denotes an antihelminthic agent with the molecular formula C11H14N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4QIH0N49E7, chemically known as pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)-, (e)- but generally known as pyrantel, which bears US NIH Compound Identifier 708857. European Medicines Agency schedules Pyrantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10162MIG. The term PYRANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules pyrantel in its Anatomical Therapeutic Chemical (ATC) Classification. PYRANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pyrantel under HS 29349990 and SITC 51579. As of Q4 2014, PYRANTEL remains the US FDA Preferred Term for this commodity. Pyrantel bears US NLM identifiers UMLS ID C0034235 and NCI Concept Code C75231. SMILES: CN1CCCN=C1C=CC2=CC=CS2.
This classification denotes an antihelminthic agent with the molecular formula C23H16O6.C11H14N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81BK194Z5M, chemically known as 4,4-methylenebis(3-hydroxy-2-naphthoic) acid, compound with (e)-1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine (1:1) but more generally known as pyrantel embonate, which bears US NIH Compound Identifier 5281033. European Medicines Agency schedules Pyrantel embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04132MIG. Most nations, for tariff and trade purposes, schedule pyrantel embonate under HS 29349990 and SITC 51579. SMILES: CN1CCCN=C1/C=C/C2CCCS2.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C23H16O6.C11H14N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81BK194Z5M, chemically known as (e)-1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1), but more generally known as pyrantel pamoate, which bears US NIH Compound Identifier 402. European Medicines Agency schedules pyrantel pamoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10162MIG. Most nations, for tariff purposes, schedule pyrantel pamoate under HS 29349990. As of Q4 2014, PYRANTEL PAMOATE remains US FDA's Preferred Term for this commodity. Pyrantel pamoate bears US NLM identifiers UMLS ID C0034237 and NCI Concept Code C75232. SMILES: CN1CCCN=C1/C=C/C2CCCS2.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.
This classification denotes an antihelminthic agent with the molecular formula C11H14N2S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SC82VF0480. The term pyrantel tartrate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule pyrantel tartrate under HS 29349990 and SITC 51579. As of Q4 2014, PYRANTEL TARTRATE remains US FDA's Preferred Term for this commodity. Pyrantel tartrate bears US NLM identifiers UMLS ID C0034238 and NCI Concept Code C90731. SMILES: CN1CCCN=C1/C=C/C2CCCS2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H20N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X0SMC42Q5O, chemically known as N-(beta-Pyrrolidinoethyl)phenothiazine but generally known as pyrathiazine, which bears US NIH Compound Identifier 10646. SMILES: C1CCN(C1)CCN2C3=CC=CC=C3SC4=CC=CC=C42.Cl.
This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2KNI5N06TI. European Medicines Agency schedules Pyrazinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10163MIG. Pyrazinamide generally arises in the molecular formula C5H5N3O. The term PYRAZINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) PYRAZINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pyrazinamide under HS 29339990 and SITC 51577. As of Q4 2014, PYRAZINAMIDE remains the US FDA Preferred Term for this commodity. Pyrazinamide bears US NLM identifiers UMLS ID C0034239 and NCI Concept Code C29395. SMILES: O=C(N)C1NCCNC1.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C9H13N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19QM69HH21, chemically known as pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester) but generally known as pyridostigmine, which bears US NIH Compound Identifier 4991. European Medicines Agency schedules Pyridostigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15059MIG. World Health Organization schedules pyridostigmine in its Anatomical Therapeutic Chemical (ATC) Classification. PYRIDOSTIGMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PYRIDOSTIGMINE remains the US FDA Preferred Term for this commodity. Pyridostigmine bears US NLM identifiers UMLS ID C0034261 and NCI Concept Code C76139. SMILES: O(C1C[N](CCC1)C)C(=O)N(C)C.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C9H13N2O2.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KVI301NA53, chemically known as pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester) but more generally known as pyridostigmine bromide, which bears US NIH Compound Identifier 4991. European Medicines Agency schedules Pyridostigmine bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10167MIG. The term PYRIDOSTIGMINE BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule pyridostigmine bromide under HS 29333910 and SITC 51574. As of Q4 2014, PYRIDOSTIGMINE BROMIDE remains US FDA's Preferred Term for this commodity. Pyridostigmine bromide bears US NLM identifiers UMLS ID C0034262 and NCI Concept Code C47697. SMILES: C[N+]1CCCC(C1)OC(=O)N(C)C.[BR-].
This classification denotes a cns stimulant with the molecular formula C16H20N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AK5Q5FZH2R, chemically known as 3,3-(dithiodimethylene)bis(5-hydroxy-6-methyl-4-pyridinemethanol) but more generally known as pyrithioxine, which bears US NIH Compound Identifier 14190. European Medicines Agency schedules Pyritinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10175MIG. The term PYRITINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). World Health Organization schedules pyrithioxine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CC1=NC=C(C(=C1O)CO)CSSCC2=CN=C(C(=C2CO)O)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT109. This VA Drug Class (VT109) classifies this compound as belonging to the group VITAMIN B, OTHER.
This classification denotes a dihydrofolate reductase inhibitor and antimalarial agent with the molecular formula C12H13ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z3614QOX8W, chemically known as 2,4-pyrimidinediamine, 5-(p-chlorophenyl)-6-ethyl- but generally known as pyrimethamine, which bears US NIH Compound Identifier 4993. European Medicines Agency schedules Pyrimethamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10169MIG. The term PYRIMETHAMINE is an International Non-Proprietary Name. World Health Organization schedules pyrimethamine in its Anatomical Therapeutic Chemical (ATC) Classification. PYRIMETHAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pyrimethamine under HS 29335995 and SITC 51576. As of Q4 2014, PYRIMETHAMINE remains the US FDA Preferred Term for this commodity. Pyrimethamine bears US NLM identifiers UMLS ID C0034283 and NCI Concept Code C788. SMILES: CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.
This classification denotes an antiarrhythmic agent with the molecular formula C27H20N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 14PEC3LEVH, chemically known as 2-pyridinemethanol, alpha-(3-(di-2-pyridinylmethylene)-1,4-cyclopentadien-1-yl)-alpha-2-pyridinyl but more generally known as pyrinoline, which bears US NIH Compound Identifier 3052765. European Medicines Agency schedules Pyrinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10171MIG. The term PYRINOLINE is an International Non-Proprietary Name. PYRINOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pyrinoline under HS 29333999 and SITC 51574. As of Q4 2014, PYRINOLINE remains US FDA's Preferred Term for this commodity. Pyrinoline bears US NLM identifiers UMLS ID C2347720 and NCI Concept Code C72583. SMILES: OC(C1=C/C(=C(/C2NCCCC2)C2NCCCC2)C=C1)(C1NCCCC1)C1NCCCC1.
This classification denotes an antifungal agent with the molecular formula 2C5H4NOS.Zn, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R953O2RHZ5, chemically known as 2-pyridinethiol-1-oxide, zinc salt but generally known as pyrithione zinc, which bears US NIH Compound Identifier 26041. European Medicines Agency schedules Pyrithione zinc in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10172MIG. The term PYRITHIONE ZINC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules pyrithione zinc in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule pyrithione zinc under HS 29333999 and SITC 51574. As of Q4 2014, PYRITHIONE ZINC remains the US FDA Preferred Term for this commodity. Pyrithione zinc bears US NLM identifiers UMLS ID C0078792 and NCI Concept Code C47698. SMILES: C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[ZN+2].
This classification denotes a sedative and hypnotic with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8AB20823CK, chemically known as 3,3-diethyltetrahydropyridin-2,4-dione but generally known as pyrithyldione, which bears US NIH Compound Identifier 4994. European Medicines Agency schedules Pyrithyldione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10173MIG. The term PYRITHYLDIONE is an International Non-Proprietary Name. World Health Organization schedules pyrithyldione in its Anatomical Therapeutic Chemical (ATC) Classification. PYRITHYLDIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pyrithyldione under HS 29337900 and SITC 51561. As of Q4 2014, PYRITHYLDIONE remains the US FDA Preferred Term for this commodity. Pyrithyldione bears US NLM identifiers UMLS ID C0072736 and NCI Concept Code C80677. SMILES: O=C1NC=CC(=O)C1(CC)CC.
This classification denotes a cns stimulant with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) VOU69C02JP, chemically known as 1-pentanone, 1-(4-methylphenyl)-2-(1-pyrrolidinyl)- but more generally known as pyrovalerone, which bears US NIH Compound Identifier 14373. European Medicines Agency schedules Pyrovalerone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10177MIG. The term PYROVALERONE is an International Non-Proprietary Name. PYROVALERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pyrovalerone under HS 29339190 and SITC 51577. As of Q4 2014, PYROVALERONE remains US FDA's Preferred Term for this commodity. Pyrovalerone bears US NLM identifiers UMLS ID C0072777 and NCI Concept Code C83918. SMILES: O=C(C(N1CCCC1)CCC)C1CCC(CC1)C.
This classification denotes a cns stimulant with the molecular formula C16H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z95Z9C2201, chemically known as 1-pentanone, 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-, hydrochloride but more generally known as pyrovalerone hydrochloride, which bears US NIH Compound Identifier 14372. Most nations, for tariff and trade purposes, schedule pyrovalerone hydrochloride under HS 29339100 and SITC 51577. As of Q4 2014, PYROVALERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pyrovalerone hydrochloride bears US NLM identifiers UMLS ID C0951428 and NCI Concept Code C73830. SMILES: CCCC(C(=O)C1CCC(CC1)C)N2CCCC2.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VE6KP18S8X, chemically known as pyrrolidine, 1-(4-(4-chlorophenyl)-3-phenyl-2-butenyl)- but generally known as pyrrobutamine, which bears US NIH Compound Identifier 5284614. European Medicines Agency schedules Pyrrobutamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15066MIG. World Health Organization schedules pyrrobutamine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PYRROBUTAMINE remains the US FDA Preferred Term for this commodity. Pyrrobutamine bears US NLM identifiers UMLS ID C0163091 and NCI Concept Code C81146. SMILES: CLC1CCC(C/C(=C\CN2CCCC2)C2CCCCC2)CC1.
This classification denotes an anesthetic agent with the molecular formula C14H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9D47L94CPW, chemically known as 1-pyrrolidineaceto-2,6-xylidide but generally known as pyrrocaine, which bears US NIH Compound Identifier 24361. European Medicines Agency schedules Pyrrocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10180MIG. The term PYRROCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). PYRROCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pyrrocaine under HS 29339990 and SITC 51577. As of Q4 2014, PYRROCAINE remains the US FDA Preferred Term for this commodity. Pyrrocaine bears US NLM identifiers UMLS ID C0609331 and NCI Concept Code C81406. SMILES: O=C(NC1C(CCCC1C)C)CN1CCCC1.
This classification denotes an anesthetic agent with the molecular formula C14H20N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9CST8J378F, chemically known as 1-pyrrolidineaceto-2,6-xylidide but more generally known as pyrrocaine hydrochloride, which bears US NIH Compound Identifier 24361. European Medicines Agency schedules Pyrrocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15068MIG. Most nations, for tariff and trade purposes, schedule pyrrocaine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, PYRROCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pyrrocaine hydrochloride bears US NLM identifiers UMLS ID C2825619 and NCI Concept Code C81405. SMILES: CC1CCCC(C1NC(=O)CN2CCCC2)C.CL.
This classification denotes an antifungal agent with the molecular formula C10H6Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N0P24B6EDQ, chemically known as 1h-pyrrole, 3-chloro-4-(3-chloro-2-nitrophenyl)- but generally known as pyrrolnitrin, which bears US NIH Compound Identifier 13916. European Medicines Agency schedules Pyrrolnitrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10182MIG. The term PYRROLNITRIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules pyrrolnitrin in its Anatomical Therapeutic Chemical (ATC) Classification. PYRROLNITRIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pyrrolnitrin under HS 29419000 and SITC 54139. As of Q4 2014, PYRROLNITRIN remains the US FDA Preferred Term for this commodity. Pyrrolnitrin bears US NLM identifiers UMLS ID C0034336 and NCI Concept Code C81509. SMILES: C1=CC(=C(C(=C1)CL)[N+](=O)[O-])C2=CNC=C2CL.
This classification denotes an antiparasitic agent with the molecular formula C26H28N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6B9991FLU3, chemically known as 6-(dimethylamino)-2-(2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)ethenyl)-1-methylquinolinium but generally known as pyrvinium, which bears US NIH Compound Identifier 5281035. European Medicines Agency schedules Pyrvinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04153MIG. World Health Organization schedules pyrvinium in its Anatomical Therapeutic Chemical (ATC) Classification. PYRVINIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PYRVINIUM remains the US FDA Preferred Term for this commodity. Pyrvinium bears US NLM identifiers UMLS ID C0072804 and NCI Concept Code C77330. SMILES: N1(C(C(CC1C)/C=C/C1[N](C2C(CC(N(C)C)CC2)CC1)C)C)C1CCCCC1.
This classification denotes an antihelminthic agent with the molecular structure C26H28N3.CL, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, MT7O310S39 chemically known as 6-dimethylamino-2'-(2-(2,5-dimethyl-1-phenyl-3-pyrrolyl)vinyl)-1-methylquinolinium chloride, but more commonly known as pyrvinium chloride, which bears US NIH Compound Identifier 6436141. European Medicines Agency schedules Pyrvinium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10183MIG. The term PYRVINIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, no. 12, 1959, list 3. ). Most nations, for tariff and trade purposes, schedule pyrvinium chloride under HS 29334990 and SITC 51575. As of Q4 2014, PYRVINIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Pyrvinium chloride bears US NLM identifiers UMLS ID C0301348 and NCI Concept Code C81516. SMILES: CC1CC(C(N1C2CCCCC2)C)/C=C/C3CCC4CC(CCC4[N+]3C)N(C)C.[CL-].
This classification denotes an opioid receptor agonist and opiate antagonist with the molecular formula C25H37NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, X9BMD58553 chemically known as (-)-(2r,6s,11s)-1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-3-pentanone but generally known as quadazocine, which bears US NIH Compound Identifier 115077. European Medicines Agency schedules Quadazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10185MIG. The term QUADAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26). Most nations schedule quadazocine under HS 29333999 and SITC 51574. As of Q4 2014, QUADAZOCINE remains the US FDA Preferred Term for this commodity. Quadazocine bears US NLM identifiers UMLS ID C0139649 and NCI Concept Code C80570. SMILES: CC12CCN(C(C1(C)CCC(=O)CCC3CCCC3)CC4=C2C=C(C=C4)O)C.
This classification denotes an opioid receptor agonist and opiate antagonist with the molecular formula C25H37NO2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 582SS143QX, chemically known as 3-pentanone, 1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-, (2r-(2.alpha.,6.alpha.,11s*))-, methanesulfonate (salt), but more generally known as quadazocine mesylate, which bears US NIH Compound Identifier 3052769. European Medicines Agency schedules quadazocine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10185MIG. Most nations, for tariff purposes, schedule quadazocine mesylate under HS 29333999. Quadazocine mesylate bears US NLM identifiers UMLS ID C2825265 and NCI Concept Code C80587. SMILES: C[C@@]12CCN([C@@H]([C@@]1(C)CCC(=O)CCC3CCCC3)CC4C2CC(CC4)O)C.CS(=O)(=O)O.
This classification denotes an anesthetic agent with the molecular formula C14H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49BR7256ZY, chemically known as propanamide, 2-methyl-n-(2-methylphenyl)-2-(propylamino)- but generally known as quatacaine, which bears US NIH Compound Identifier 65685. European Medicines Agency schedules Quatacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10187MIG. The term QUATACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). QUATACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quatacaine under HS 29242995 and SITC 51479. As of Q4 2014, QUATACAINE remains the US FDA Preferred Term for this commodity. Quatacaine bears US NLM identifiers UMLS ID C0072824 and NCI Concept Code C72164. SMILES: O=C(NC1C(CCCC1)C)C(NCCC)(C)C.
This classification denotes a benzodiazepine with the molecular formula C17H11ClF4N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JF8V0828ZI, chemically known as 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2h-1,4-benzodiazepine-2-thione but generally known as quazepam, which bears US NIH Compound Identifier 4999. European Medicines Agency schedules Quazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10188MIG. The term QUAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules quazepam in its Anatomical Therapeutic Chemical (ATC) Classification. QUAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quazepam under HS 29339940 and SITC 51577. As of Q4 2014, QUAZEPAM remains the US FDA Preferred Term for this commodity. Quazepam bears US NLM identifiers UMLS ID C0072828 and NCI Concept Code C47699. SMILES: CLC1CC2C(N(CC(F)(F)F)C(=S)CN=C2C2C(F)CCCC2)CC1.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C11H10ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D1Q7F6C2FP, chemically known as (r)-6-chloro-1,5-dihydro-3-methylimidazo(2,1-b)quinazolin-2(3h)-one but generally known as quazinone, which bears US NIH Compound Identifier 5000. European Medicines Agency schedules Quazinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10189MIG. The term QUAZINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). QUAZINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quazinone under HS 29335995 and SITC 51576. As of Q4 2014, QUAZINONE remains the US FDA Preferred Term for this commodity. Quazinone bears US NLM identifiers UMLS ID C0072829 and NCI Concept Code C74347. SMILES: CC1C(=O)N=C2N1CC3=C(N2)C=CC=C3CL.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G66N97788I, chemically known as 6,7-dimethoxy-4-ethylquinazoline but generally known as quazodine, which bears US NIH Compound Identifier 19918. European Medicines Agency schedules Quazodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10190MIG. The term QUAZODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). QUAZODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quazodine under HS 29335995 and SITC 51576. As of Q4 2014, QUAZODINE remains the US FDA Preferred Term for this commodity. Quazodine bears US NLM identifiers UMLS ID C0072830 and NCI Concept Code C80615. SMILES: CCC1=NC=NC2=CC(=C(C=C21)OC)OC.
This classification denotes a serotonin antagonist and antipsychotic agent with the molecular formula C21H25N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BGL0JSY5SI, chemically known as 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol fumarate ( but generally known as quetiapine, which bears US NIH Compound Identifier 5002. European Medicines Agency schedules Quetiapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10192MIG. The term QUETIAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules quetiapine in its Anatomical Therapeutic Chemical (ATC) Classification. QUETIAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quetiapine under HS 29349990 and SITC 51579. As of Q4 2014, QUETIAPINE remains the US FDA Preferred Term for this commodity. Quetiapine bears US NLM identifiers UMLS ID C0123091 and NCI Concept Code C61917. SMILES: S1C2C(C(=NC3C1CCCC3)N1CCN(CC1)CCOCCO)CCCC2.
This classification denotes a serotonin antagonist and antipsychotic agent with the molecular formula 2C21H25N3O2S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S3PL1B6UJ, chemically known as 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol fumarate ( but more generally known as quetiapine fumarate, which bears US NIH Compound Identifier 5002. European Medicines Agency schedules Quetiapine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15074MIG. Most nations, for tariff and trade purposes, schedule quetiapine fumarate under HS 29349990 and SITC 51579. As of Q4 2014, QUETIAPINE FUMARATE remains US FDA's Preferred Term for this commodity. Quetiapine fumarate bears US NLM identifiers UMLS ID C0724680 and NCI Concept Code C47700. SMILES: C1CCC2C(C1)C(=NC3CCCCC3S2)N4CCN(CC4)CCOCCO.C1CCC2C(C1)C(=NC3CCCCC3S2)N4CCN(CC4)CCOCCO.C(=C/C(=O)O)\C(=O)O.
This classification denotes a serotonin antagonist and antipsychotic agent with the molecular formula 2C21H25N3O2S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S3PL1B6UJ, chemically known as ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (e)-2-butenedioate (2:1), but more generally known as quetiapine hemifumarate, which bears US NIH Compound Identifier 5002. European Medicines Agency schedules quetiapine hemifumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10192MIG. Most nations, for tariff purposes, schedule quetiapine hemifumarate under HS 29349990. SMILES: C1CCC2C(C1)C(=NC3CCCCC3S2)N4CCN(CC4)CCOCCO.C1CCC2C(C1)C(=NC3CCCCC3S2)N4CCN(CC4)CCOCCO.C(=C/C(=O)O)\C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9A18RJ49B, chemically known as 3-quinuclidinemethanol, alpha,alpha-diphenyl- but generally known as quifenadine, which bears US NIH Compound Identifier 65600. European Medicines Agency schedules Quifenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10193MIG. The term QUIFENADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). QUIFENADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quifenadine under HS 29333999 and SITC 51574. As of Q4 2014, QUIFENADINE remains the US FDA Preferred Term for this commodity. Quifenadine bears US NLM identifiers UMLS ID C0243449 and NCI Concept Code C81147. SMILES: OC(C1C2CCN(C1)CC2)(C1CCCCC1)C1CCCCC1.
This classification denotes an analgesic agent with the molecular formula C21H24ClNO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 8JD13PH39Q, chemically known as 2-(p-chlorophenyl)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2h-benzo(a)quinolizine but more generally known as quillifoline, which bears U.S. National Institutes of Health Compound Identifier 160353. The European Medicines Agency schedules Quillifoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10195MIG. The term QUILLIFOLINE is an International Non-Proprietary Name. QUILLIFOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1CCC(C2CC3N(CC2)CCC2C3CC(OC)C(OC)C2)CC1.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C23H27N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2L1YNO4SQJ, chemically known as 2(1h)-isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3as-cis)- but generally known as quilostigmine, which bears US NIH Compound Identifier 132228. European Medicines Agency schedules Quilostigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10196MIG. The term QUILOSTIGMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). QUILOSTIGMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quilostigmine under HS 29334990 and SITC 51575. As of Q4 2014, QUILOSTIGMINE remains the US FDA Preferred Term for this commodity. Quilostigmine bears US NLM identifiers UMLS ID C0755738 and NCI Concept Code C81922. SMILES: O(C1CC2C3(C(N(CC3)C)N(C2CC1)C)C)C(=O)N1CCC2C(C1)CCCC2.
This classification denotes an antiarrhythmic agent with the molecular formula C21H30N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5OX8977NGO, chemically known as 4-quinolinemethanol, 2-(1,1-dimethylethyl)-alpha-(2-(4-piperidinyl)ethyl)- but more generally known as quinacainol, which bears US NIH Compound Identifier 55464. European Medicines Agency schedules Quinacainol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10197MIG. The term QUINACAINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). QUINACAINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule quinacainol under HS 29334990 and SITC 51575. As of Q4 2014, QUINACAINOL remains US FDA's Preferred Term for this commodity. Quinacainol bears US NLM identifiers UMLS ID C0071172 and NCI Concept Code C82229. SMILES: OC(CCC1CCNCC1)C1CC(NC2C1CCCC2)C(C)(C)C.
This classification denotes an antipsychotic agent with the molecular formula C20H33N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80Q9QWN15M, chemically known as sulfamide, n,n-diethyl-n-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)-, (3-alpha,4a-alpha,10a-beta)-(+-)- but generally known as quinagolide, which bears US NIH Compound Identifier 55645. European Medicines Agency schedules Quinagolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10199MIG. The term QUINAGOLIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules quinagolide in its Anatomical Therapeutic Chemical (ATC) Classification. QUINAGOLIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinagolide under HS 29339990 and SITC 51577. As of Q4 2014, QUINAGOLIDE remains the US FDA Preferred Term for this commodity. Quinagolide bears US NLM identifiers UMLS ID C0256089 and NCI Concept Code C73310. SMILES: S(=O)(=O)(NC1CC2C(N(C1)CCC)CC1C(C2)C(O)CCC1)N(CC)CC.
This classification denotes an antipsychotic agent with the molecular formula C20H33N3O3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33474X943Y, chemically known as sulfamide, n,n-diethyl-n-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)-, monohydrochloride, (3-alpha,4a-alpha,10a-beta)- but more generally known as quinagolide hydrochloride, which bears US NIH Compound Identifier 3086400. European Medicines Agency schedules Quinagolide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04163MIG. Most nations, for tariff and trade purposes, schedule quinagolide hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, QUINAGOLIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCN1C[C@@H](C[C@@H]2[C@@H]1CC3CCCC(C3C2)O)NS(=O)(=O)N(CC)CC.CL.
This classification denotes an ace inhibitor with the molecular formula C25H30N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RJ84Y44811, chemically known as 3-isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, (3s-(2(r*(r*)),3r*))- but generally known as quinapril, which bears US NIH Compound Identifier 54892. European Medicines Agency schedules Quinapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10201MIG. The term QUINAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules quinapril in its Anatomical Therapeutic Chemical (ATC) Classification. QUINAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinapril under HS 29334990 and SITC 51575. As of Q4 2014, QUINAPRIL remains the US FDA Preferred Term for this commodity. Quinapril bears US NLM identifiers UMLS ID C0072857 and NCI Concept Code C62074. SMILES: O=C(N1C(Cc2c(C1)cccc2)C(=O)O)C(NC(CCc1ccccc1)C(=O)OCC)C.
This classification denotes an ace inhibitor with the molecular formula C23H26N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34SSX5LDE5, chemically known as 3-isoquinolinecarboxylic acid, 2-((2s)-2-(((1s)-1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, (3s)- but generally known as quinaprilat, which bears US NIH Compound Identifier 107994. European Medicines Agency schedules Quinaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10202MIG. The term QUINAPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). QUINAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinaprilat under HS 29334990 and SITC 51575. As of Q4 2014, QUINAPRILAT remains the US FDA Preferred Term for this commodity. Quinaprilat bears US NLM identifiers UMLS ID C0072858 and NCI Concept Code C95129. SMILES: O=C(N1C(Cc2c(C1)cccc2)C(=O)O)C(NC(CCc1ccccc1)C(=O)O)C.
This classification denotes a tetrahydroisoquinoline, angiotensin-converting enzyme inhibitor, and antihypertensive agent with the molecular formula C25H30N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33067B3N2M, chemically known as 3-isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, monohydrochloride, (3s-(2(r*(r*)),3r*)) but more generally known as quinapril hydrochloride, which bears US NIH Compound Identifier 54891. European Medicines Agency schedules Quinapril hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04164MIG. Most nations, for tariff and trade purposes, schedule quinapril hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, QUINAPRIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Quinapril hydrochloride bears US NLM identifiers UMLS ID C0770920 and NCI Concept Code C29398. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2CC3CCCCC3C[C@H]2C(=O)O.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H23N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 436XK6QFMR, chemically known as 4-quinazolinamine, 6,7-dimethoxy-2-(4-(2-propenyl)-1-piperazinyl)- but generally known as quinazosin, which bears US NIH Compound Identifier 27486. European Medicines Agency schedules Quinazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10203MIG. The term QUINAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). QUINAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinazosin under HS 29335995 and SITC 51576. As of Q4 2014, QUINAZOSIN remains the US FDA Preferred Term for this commodity. Quinazosin bears US NLM identifiers UMLS ID C2347736 and NCI Concept Code C72924. SMILES: O(C1CC2NC(N3CCN(CC3)CC=C)NC(N)C2CC1OC)C.
This classification denotes an anabolic steroid with the molecular formula C24H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W59598KWLX, chemically known as 17beta-(1-cyclopentenyloxy)-1,4-androstadien-3-on but generally known as quinbolone, which bears US NIH Compound Identifier 17214. European Medicines Agency schedules Quinbolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10204MIG. The term QUINBOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules quinbolone in its Anatomical Therapeutic Chemical (ATC) Classification. QUINBOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinbolone under HS 29372900 and SITC 54153. As of Q4 2014, QUINBOLONE remains the US FDA Preferred Term for this commodity. Quinbolone bears US NLM identifiers UMLS ID C0072862 and NCI Concept Code C82226. SMILES: O(C1C2(C(C3C(CC2)C2(C(=CC(=O)C=C2)CC3)C)CC1)C)C1=CCCC1.
This classification denotes a thiazide diuretic with the molecular formula C17H18ClNO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U40Q9GE876, chemically known as ethyl 10-chloro-3-(ethoxymethyl)-2,3,6,9-tetrahydro-9-oxo-p-dioxino(2,3-g)quinoline-8-carboxylate but generally known as quincarbate, which bears US NIH Compound Identifier 323967. European Medicines Agency schedules Quincarbate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10205MIG. The term QUINCARBATE is an International Non-Proprietary Name. QUINCARBATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quincarbate under HS 29349990 and SITC 51579. As of Q4 2014, QUINCARBATE remains the US FDA Preferred Term for this commodity. Quincarbate bears US NLM identifiers UMLS ID C2698927 and NCI Concept Code C74410. SMILES: CLC1C2OCC(OC2CC2[NH]CC(C(=O)C12)C(=O)OCC)COCC.
This classification denotes a therapeutic estrogen with the molecular formula C23H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 422L8173W8, chemically known as 3-(cyclopentyloxy)estra-1,3,5(10)-triene-16alpha,17beta-diol but generally known as quinestradol, which bears US NIH Compound Identifier 14431. European Medicines Agency schedules Quinestradol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10210MIG. The term QUINESTRADOL is an International Non-Proprietary Name. QUINESTRADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinestradol under HS 29372300 and SITC 54153. As of Q4 2014, QUINESTRADOL remains the US FDA Preferred Term for this commodity. Quinestradol bears US NLM identifiers UMLS ID C0072864 and NCI Concept Code C76999. SMILES: OC1C2(C(C3C(CC2)c2c(CC3)cc(OC3CCCC3)cc2)CC1O)C.
This classification denotes a steroidal estrogen with the molecular formula C25H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JR0N7XD5GZ, chemically known as 19-norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-(cyclopentyloxy)-, (17.alpha.)- but generally known as quinestrol, which bears US NIH Compound Identifier 1451. European Medicines Agency schedules Quinestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10211MIG. The term QUINESTROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). QUINESTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinestrol under HS 29372300 and SITC 54153. As of Q4 2014, QUINESTROL remains the US FDA Preferred Term for this commodity. Quinestrol bears US NLM identifiers UMLS ID C0034410 and NCI Concept Code C66500. SMILES: OC1(C2(C(C3C(CC2)c2c(CC3)cc(OC3CCCC3)cc2)CC1)C)C#C.
This classification denotes a thiazide diuretic with the molecular formula C10H12ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 455E0S048W, chemically known as 7-chloro-2-ethyl-6-sulfamoyl-1,2,3,4-tetrahydro-4-quinazolinone but generally known as quinethazone, which bears US NIH Compound Identifier 6307. European Medicines Agency schedules Quinethazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10213MIG. The term QUINETHAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules quinethazone in its Anatomical Therapeutic Chemical (ATC) Classification. QUINETHAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinethazone under HS 29350090 and SITC 51580. As of Q4 2014, QUINETHAZONE remains the US FDA Preferred Term for this commodity. Quinethazone bears US NLM identifiers UMLS ID C0164608 and NCI Concept Code C66501. SMILES: CCC1NC2=CC(=C(C=C2C(=O)N1)S(=O)(=O)N)CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes an antiprotozoal agent with the molecular formula C16H13Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O1ZB1046R1, chemically known as 2-furoic acid ester with 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol but generally known as quinfamide, which bears US NIH Compound Identifier 71743. European Medicines Agency schedules Quinfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10215MIG. The term QUINFAMIDE is an International Non-Proprietary Name. QUINFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinfamide under HS 29349990 and SITC 51579. As of Q4 2014, QUINFAMIDE remains the US FDA Preferred Term for this commodity. Quinfamide bears US NLM identifiers UMLS ID C0072865 and NCI Concept Code C72156. SMILES: CLC(CL)C(=O)N1CCCC2C1CCC(OC(=O)C1OCCC1)C2.
This classification denotes a norpregnadiene with the molecular formula C25H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1A635076CE, chemically known as 3-cyclopentyloxy-19-nor-3,5-pregnadien-20-in-17beta-ol but generally known as quingestanol, which bears US NIH Compound Identifier 25414. European Medicines Agency schedules Quingestanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10216MIG. World Health Organization schedules quingestanol in its Anatomical Therapeutic Chemical (ATC) Classification. QUINGESTANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quingestanol under HS 29372300 and SITC 54153. As of Q4 2014, QUINGESTANOL remains the US FDA Preferred Term for this commodity. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC3)C=C(OC3CCCC3)CC2)CC1)C)C#C.
This classification denotes a norpregnadiene C27H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M33GGZ63KG, chemically known as 3-(cyclopentyloxy)-19-nor-17.alpha.-pregna-3,5-dien-20-yn-17-ol acetate, but more generally known as quingestanol acetate, which bears US NIH Compound Identifier 18142. European Medicines Agency schedules Quingestanol acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04165MIG. Most nations, for tariff and trade purposes, schedule quingestanol acetate under HS 29372300 and SITC 54153. As of Q4 2014, QUINGESTANOL ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@H]3CCC(=C4)OC5CCCC5)C)C#C.
This classification denotes a cation channel blocker and antimalarial agent with the molecular formula C20H24N2O2.C6H12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) R6875N380F, chemically known as quinidine, d-gluconate (salt) but more generally known as quinidine gluconate, which bears US NIH Compound Identifier 64642. European Medicines Agency schedules Quinidine gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04170MIG. Most nations, for tariff and trade purposes, schedule quinidine under HS 29392000 and SITC 54142. As of Q4 2014, QUINIDINE remains US FDA's Preferred Term for this commodity. Quinidine bears US NLM identifiers UMLS ID C0034414 and NCI Concept Code C793. SMILES: OC(C1N2CC(C(C1)CC2)C=C)C1C2C(NCC1)CCC(OC)C2.OC(C(O)C(O)C(=O)O)C(O)CO.
This classification denotes a cation channel blocker and antimalarial agent with the molecular formula C20H24N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K043Q65TR, chemically known as 8alpha,9r-6-methoxycinchonan-9-ol, sulfate (1:1) salt but more generally known as quinidine bisulfate, which bears US NIH Compound Identifier 11069. European Medicines Agency schedules Quinidine bisulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15078MIG. Most nations, for tariff and trade purposes, schedule quinidine bisulfate under HS 29392000 and SITC 54142. As of Q4 2014, QUINIDINE BISULFATE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC2C(C1)C(CCN2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O.OS(=O)(=O)O.
This classification denotes a cation channel blocker and antimalarial agent with the molecular formula C20H24N2O2.C6H12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6875N380F, chemically known as quinidine, d-gluconate (salt) but more generally known as quinidine gluconate, which bears US NIH Compound Identifier 64642. European Medicines Agency schedules Quinidine gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04170MIG. Most nations, for tariff and trade purposes, schedule quinidine gluconate under HS 29392000 and SITC 54142. As of Q4 2014, QUINIDINE GLUCONATE remains US FDA's Preferred Term for this commodity. Quinidine gluconate bears US NLM identifiers UMLS ID C0072869 and NCI Concept Code C48015. SMILES: COC1CCC2C(C1)C(CCN2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.
This classification denotes a cation channel blocker and antimalarial agent with the molecular formula C20H24N2O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S4P5V5597B, chemically known as quinidine, monohydrochloride but more generally known as quinidine hydrochloride, which bears US NIH Compound Identifier 15474. European Medicines Agency schedules Quinidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15079MIG. Most nations, for tariff and trade purposes, schedule quinidine hydrochloride under HS 29392000 and SITC 54142. As of Q4 2014, QUINIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC2C(C1)C(CCN2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O.CL.
This classification denotes a cation channel blocker and antimalarial agent with the molecular formula 2C20H24N2O2.2H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J13S2394HE, chemically known as quinidine sulfate, (2:1) (salt) but more generally known as quinidine sulfate, which bears US NIH Compound Identifier 5768. European Medicines Agency schedules Quinidine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15082MIG. Most nations, for tariff and trade purposes, schedule quinidine sulfate under HS 29392000 and SITC 54142. As of Q4 2014, QUINIDINE SULFATE remains US FDA's Preferred Term for this commodity. Quinidine sulfate bears US NLM identifiers UMLS ID C1564021 and NCI Concept Code C48014. SMILES: COC1CCC2C(C1)C(CCN2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O.COC1CCC2C(C1)C(CCN2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O.O.O.OS(=O)(=O)O.
This classification denotes an antimalarial agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A7V27PHC7A. European Medicines Agency schedules Quinine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15084MIG. Quinine generally arises in the molecular formula C20H24N2O2. The term QUININE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule quinine under HS 29392000 and SITC 54142. As of Q4 2014, QUININE remains the US FDA Preferred Term for this commodity. Quinine bears US NLM identifiers UMLS ID C0034417 and NCI Concept Code C794. SMILES: OC(C1N2CC(C(C1)CC2)C=C)C1C2C(NCC1)CCC(OC)C2.
This classification denotes an antimalarial agent with the molecular formula C15H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CNG7995Y4B, chemically known as 1,4-pentanediamine, n1-(6-methoxy-8-quinolinyl)- (9ci) but generally known as quinocide, which bears US NIH Compound Identifier 68928. European Medicines Agency schedules Quinocide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10219MIG. The term QUINOCIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). QUINOCIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinocide under HS 29334990 and SITC 51575. As of Q4 2014, QUINOCIDE remains the US FDA Preferred Term for this commodity. Quinocide bears US NLM identifiers UMLS ID C0072873 and NCI Concept Code C73004. SMILES: O(C1CC(NCCCC(N)C)C2NCCCC2C1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H12N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SUC3551A8U, chemically known as 4h-quinolizine-3-carboxamide, 4-oxo-1-phenoxy-n-1h-tetrazol-5-yl but generally known as quinotolast, which bears US NIH Compound Identifier 65871. European Medicines Agency schedules Quinotolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10220MIG. The term QUINOTOLAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). QUINOTOLAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinotolast under HS 29337900 and SITC 51561. As of Q4 2014, QUINOTOLAST remains the US FDA Preferred Term for this commodity. Quinotolast bears US NLM identifiers UMLS ID C0210064 and NCI Concept Code C73052. SMILES: O(C1C2N(C(=O)C(C1)C(=O)NC1N[NH]NN1)CCCC2)C1CCCCC1.
This classification denotes an antihypertensive agent with the molecular formula 2C14H18NO.2Br.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 502H53WMM0, chemically known as 1-methyl-3-oxo-4-phenyl-1-azoniabicyclo(2.2.2)octane, bromide but generally known as quinuclium bromide, which bears US NIH Compound Identifier 47458. European Medicines Agency schedules Quinuclium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10224MIG. Most nations schedule quinuclium bromide under HS 29333999 and SITC 51574. As of Q4 2014, QUINUCLIUM BROMIDE remains the US FDA Preferred Term for this commodity. Quinuclium bromide bears US NLM identifiers UMLS ID C2825666 and NCI Concept Code C81522. SMILES: C[N+]12CCC(CC1)(C(=O)C2)C3=CC=CC=C3.[Br-].
This classification denotes a dibenzazepine and quinuclidine with the molecular formula C21H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29O61HFF4L, chemically known as 10,11-dihydro-5-(3-quinuclidinyl)-5h-dibenz(b,f)azepine but generally known as quinupramine, which bears US NIH Compound Identifier 93154. European Medicines Agency schedules Quinupramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10225MIG. World Health Organization schedules quinupramine in its Anatomical Therapeutic Chemical (ATC) Classification. QUINUPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinupramine under HS 29333999 and SITC 51574. As of Q4 2014, QUINUPRAMINE remains the US FDA Preferred Term for this commodity. SMILES: N12CC(N3C4C(CCC5C3CCCC5)CCCC4)C(CC1)CC2.
This classification denotes an antibiotic with the molecular formula C53H67N9O10S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 23OW28RS7P, chemically known as virginiamycin s1, 4-(4-(dimethylamino)-n-methyl-l-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-l-2-piperidinecarboxylic acid)-, (s)- but more generally known as quinupristin, which bears U.S. National Institutes of Health Compound Identifier 71338. The European Medicines Agency schedules Quinupristin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10226MIG. The term QUINUPRISTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, List 31). QUINUPRISTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(C1C2CCN(C1)CC2)CC1CN2C(CC1=O)C(=O)NC(C1CCCCC1)C(=O)OC(C(NC(=O)C1NCCCC1O)C(=O)NC(C(=O)N1C(CCC1)C(=O)N(C(C2=O)CC1CCC(N(C)C)CC1)C)CC)C.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C21H25N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 60J29WG4Q6 chemically known as 10h-phenothiazine-2-sulfonamide, 10-(1-azabicyclo(2.2.2)oct-3-yl)-n,n-dimethyl- but generally known as quisultazine, which bears US NIH Compound Identifier 68833. European Medicines Agency schedules Quisultazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10228MIG. The term QUISULTAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24. ). Most nations schedule quisultazine under HS 29350090 and SITC 51580. As of Q4 2014, QUISULTAZINE remains the US FDA Preferred Term for this commodity. Quisultazine bears US NLM identifiers UMLS ID C2825481 and NCI Concept Code C81157. SMILES: CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2C4CN5CCC4CC5.
This classification denotes a proton pump inhibitor with the molecular formula C18H21N3O3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 32828355LL, chemically known as 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)- but more generally known as rabeprazole, which bears U.S. NIH Compound Identifier 5029. European Medicines Agency schedules Rabeprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10229MIG. The term RABEPRAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules rabeprazole in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. RABEPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a proton pump inhibitor with the molecular formula C18H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32828355LL, chemically known as 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)- but generally known as rabeprazole, which bears US NIH Compound Identifier 5029. European Medicines Agency schedules Rabeprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10229MIG. The term RABEPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules rabeprazole in its Anatomical Therapeutic Chemical (ATC) Classification. RABEPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rabeprazole sodium under HS 29333999 and SITC 51574. As of Q4 2014, RABEPRAZOLE SODIUM remains the US FDA Preferred Term for this commodity. Rabeprazole sodium bears US NLM identifiers UMLS ID C0732569 and NCI Concept Code C80692. SMILES: S(=O)(CC1NCCC(OCCCOC)C1C)C1[NH]C2C(N1)CCCC2.
This classification denotes a vaccine for an acute viral cns infection affecting mammals, including humans, which is caused by the rabies virus (a type species of lyssavirus) and which usually spreads by contamination with virus-laden saliva of bites of rabid animals, most especially dogs, cats, bats, foxes, raccoons, skunks, and wolves. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
This classification denotes a protease inhibitor and antidiarrheal agent with the molecular formula C21H23NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76K53XP4TO, chemically known as glycine, n-(2-((acetylthio)methyl)-1-oxo-3-phenylpropyl)-, phenylmethyl ester but generally known as racecadotril, which bears US NIH Compound Identifier 107751. European Medicines Agency schedules Racecadotril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12435MIG. The term RACECADOTRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). RACECADOTRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule racecadotril under HS 29309085 and SITC 51549. As of Q4 2014, RACECADOTRIL remains the US FDA Preferred Term for this commodity. Racecadotril bears US NLM identifiers UMLS ID C0050461 and NCI Concept Code C66503. SMILES: S(CC(CC1CCCCC1)C(=O)NCC(=O)OCC1CCCCC1)C(=O)C.
This classification denotes an antibiotic with the molecular formula C12H15Cl2NO5S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 283383NO13, chemically known as (+-)-threo-2,2-dichloro-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)acetamide but more generally known as racefenicol, which bears U.S. National Institutes of Health Compound Identifier 5433. The European Medicines Agency schedules Racefenicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10231MIG. The term RACEFENICOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). RACEFENICOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC(CL)C(=O)NC(C(O)C1CCC(S(=O)(=O)C)CC1)CO.
This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L3J8QT828G, chemically known as pyrrolidine, 1-(3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)-, (s)- but generally known as racemoramide, which bears US NIH Compound Identifier 9648. European Medicines Agency schedules Racemoramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10235MIG. The term RACEMORAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). RACEMORAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule racemoramide under HS 29349990 and SITC 51579. As of Q4 2014, RACEMORAMIDE remains the US FDA Preferred Term for this commodity. Racemoramide bears US NLM identifiers UMLS ID C2698945 and NCI Concept Code C76845. SMILES: O=C(N1CCCC1)C(C(CN1CCOCC1)C)(C1CCCCC1)C1CCCCC1.
This classification denotes an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03VRY66076, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but generally known as racephedrine, which bears US NIH Compound Identifier 5032. European Medicines Agency schedules Racephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10237MIG. The term RACEPHEDRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). RACEPHEDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule racephedrine under HS 29394100 and SITC 54144. As of Q4 2014, RACEPHEDRINE remains the US FDA Preferred Term for this commodity. Racephedrine bears US NLM identifiers UMLS ID C0301359 and NCI Concept Code C81363. SMILES: CC(C(C1=CC=CC=C1)O)NC.
This classification denotes a bronchodilator with the molecular formula C9H13NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 336096P2WE. European Medicines Agency schedules racepinephrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33967. The term racepinephrine hydrochloride is a UNSPSC designation. Racepinefrine or racepinephrine bears US NLM identifiers UMLS ID C0205758 and NCI Concept Code C76546. SMILES: CNCC(C1=CC(=C(C=C1)O)O)O.CL.
This classification denotes a veterinary beta-adrenergic agonist with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57370OZ3P1, chemically known as benzenemethanol, 4-hydroxy-alpha-(((3-(4-hydroxyphenyl)-1-methylpropyl)amino)methyl)- but generally known as ractopamine, which bears US NIH Compound Identifier 56052. European Medicines Agency schedules Ractopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10240MIG. The term RACTOPAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). RACTOPAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ractopamine under HS 29225000 and SITC 51467. As of Q4 2014, RACTOPAMINE remains the US FDA Preferred Term for this commodity. Ractopamine bears US NLM identifiers UMLS ID C0072954 and NCI Concept Code C84132. SMILES: OC(CNC(CCC1CCC(O)CC1)C)C1CCC(O)CC1.
This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 309G9J93TP, chemically known as benzenemethanol, 4-hydroxy-alpha-(((3-(4-hydroxyphenyl)-1-methylpropyl)amino)methyl)- but more generally known as ractopamine hydrochloride, which bears US NIH Compound Identifier 56052. Most nations, for tariff and trade purposes, schedule ractopamine hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, RACTOPAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ractopamine hydrochloride bears US NLM identifiers UMLS ID C0958044 and NCI Concept Code C84133. SMILES: CC(CCC1CCC(CC1)O)NCC(C2CCC(CC2)O)O.CL.
This classification denotes pre-packaged collections of tools indispenable to mixing and administering radioactive chemicals or radionuclide-marked diagnostic antibodies or contrast media.
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223. It is used to treat prostate cancer that has spread to the bones and cannot be treated with surgery and is used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases.
This classification denotes an anti-diabetic agent with the molecular formula C25H25NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Q5ELR5A7Y5, chemically known as benzenepropanoic acid, alpha-ethoxy-4-(2-(10h-phenoxazin-10-yl)ethoxy)-, (alphas)- but more generally known as ragaglitazar, which bears US NIH Compound Identifier 128814. The term RAGAGLITAZAR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16., No. 1.2002, List 47). Most nations, for tariff and trade purposes, schedule ragaglitazar under HS 29349990 and SITC 51579. As of Q4 2014, RAGAGLITAZAR remains US FDA's Preferred Term for this commodity. Ragaglitazar bears US NLM identifiers UMLS ID C1175029 and NCI Concept Code C75192. SMILES: CCOC(CC1=CC=C(C=C1)OCCN2C3=CC=CC=C3OC4=CC=CC=C42)C(=O)O.
This classification denotes an anticonvulsant agent with the molecular formula C13H13ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q4MW9RM93A, chemically known as (z)-6-chloro-3-methyl-4-oxo-delta(sup 2,alpha)-thiazolidineaceto-o-toludide but generally known as ralitoline, which bears US NIH Compound Identifier 6436118. European Medicines Agency schedules Ralitoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10242MIG. The term RALITOLINE is an International Non-Proprietary Name. RALITOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ralitoline under HS 29341000 and SITC 51579. As of Q4 2014, RALITOLINE remains the US FDA Preferred Term for this commodity. Ralitoline bears US NLM identifiers UMLS ID C0072968 and NCI Concept Code C75165. SMILES: CLC1C(NC(=O)/C=C2\SCC(=O)N2C)C(CCC1)C.
This classification denotes a selective estrogen receptor modulator with the molecular formula C28H27NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX9162EO3I, chemically known as methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)- but more generally known as raloxifene, which bears US NIH Compound Identifier 5035. European Medicines Agency schedules Raloxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10243MIG. The term RALOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules raloxifene in its Anatomical Therapeutic Chemical (ATC) Classification. RALOXIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule raloxifene under HS 29349990 and SITC 51579. As of Q4 2014, RALOXIFENE remains US FDA's Preferred Term for this commodity. Raloxifene bears US NLM identifiers UMLS ID C0244404 and NCI Concept Code C1518. SMILES: S1C(C(C2C1CC(O)CC2)C(=O)C1CCC(OCCN2CCCCC2)CC1)C1CCC(O)CC1.
This classification denotes an antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22VKV8053U. European Medicines Agency schedules Raltegravir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25667. Raltegravir generally arises in the molecular formula C20H21FN6O5. The term RALTEGRAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 1, 2008, list 59.) As of Q4 2014, RALTEGRAVIR remains the US FDA Preferred Term for this commodity. Raltegravir bears US NLM identifiers UMLS ID C1871526 and NCI Concept Code C72837. SMILES: CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F.
This classification denotes a thymidylate synthase inhibitor and folate antagonist with the molecular formula C21H22N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FCB9EGG971, chemically known as n-(5-(n-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-n-methylamino)-2-thenoyl)-l-glutamic acid but generally known as raltitrexed, which bears US NIH Compound Identifier 104758. European Medicines Agency schedules Raltitrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10244MIG. The term RALTITREXED is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules raltitrexed in its Anatomical Therapeutic Chemical (ATC) Classification. RALTITREXED is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule raltitrexed under HS 29349990 and SITC 51579. As of Q4 2014, RALTITREXED remains the US FDA Preferred Term for this commodity. Raltitrexed bears US NLM identifiers UMLS ID C0677667 and NCI Concept Code C1804. SMILES: S1C(N(CC2CC3C([NH]C(NC3=O)C)CC2)C)CCC1C(=O)NC(CCC(=O)O)C(=O)O.
This classification denotes a cns stimulant with the molecular formula C16H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 901AS54I69, chemically known as (s)-n-(2-(1,6,7,8-tetrahydro-2h-indeno-(5,4)furan-8-yl)ethyl)propionamide but generally known as ramelteon, which bears US NIH Compound Identifier 208902. European Medicines Agency schedules Ramelteon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21315. The term RAMELTEON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, List 52). World Health Organization schedules ramelteon in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ramelteon under HS 29329970 and SITC 51569. As of Q4 2014, RAMELTEON remains the US FDA Preferred Term for this commodity. Ramelteon bears US NLM identifiers UMLS ID C1565316 and NCI Concept Code C66504. SMILES: O1C2C(C3C(CCC3CC2)CCNC(=O)CC)CC1.
This classification denotes an ace inhibitor with the molecular formula C23H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L35JN3I7SJ, chemically known as cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2alpha,3abeta,6abeta))- but generally known as ramipril, which bears US NIH Compound Identifier 5362129. European Medicines Agency schedules Ramipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10248MIG. The term RAMIPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules ramipril in its Anatomical Therapeutic Chemical (ATC) Classification. RAMIPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ramipril under HS 29339990 and SITC 51577. As of Q4 2014, RAMIPRIL remains the US FDA Preferred Term for this commodity. Ramipril bears US NLM identifiers UMLS ID C0072973 and NCI Concept Code C29411. SMILES: O=C(N1C2C(CC1C(=O)O)CCC2)C(NC(CCc1ccccc1)C(=O)OCC)C.
This classification denotes an ace inhibitor with the molecular formula C21H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6N5U4QFC3G, chemically known as (2s,3as,6as)-1-((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid but generally known as ramiprilat, which bears US NIH Compound Identifier 5464096. European Medicines Agency schedules Ramiprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10249MIG. The term RAMIPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). RAMIPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ramiprilat under HS 29339990 and SITC 51577. As of Q4 2014, RAMIPRILAT remains the US FDA Preferred Term for this commodity. Ramiprilat bears US NLM identifiers UMLS ID C0072970 and NCI Concept Code C72911. SMILES: O=C(N1C2C(CC1C(=O)O)CCC2)C(NC(CCc1ccccc1)C(=O)O)C.
This classification denotes a histamine-2 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 957W618927. European Medicines Agency schedules Ramixotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10250MIG. Ramixotidine generally arises in the molecular formula C16H21N3O3S. The term RAMIXOTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) RAMIXOTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ramixotidine under HS 29349990 and SITC 51579. As of Q4 2014, RAMIXOTIDINE remains the US FDA Preferred Term for this commodity. Ramixotidine bears US NLM identifiers UMLS ID C0139912 and NCI Concept Code C76679. SMILES: S(CC1OC(CN(C)C)CC1)CCNC(=O)C1C[N](O)CCC1.
This classification denotes a cardiotonic agent with the molecular formula C29H44O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8SRY7BR30, chemically known as 14-hydroxy-3beta-((2,3,6-trihydroxy-alpha-l-erythro-hexopyranosyl)oxy)-5beta-card-20(22)-enolide but generally known as ramnodigin, which bears US NIH Compound Identifier 3052773. European Medicines Agency schedules Ramnodigin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10251MIG. The term RAMNODIGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). RAMNODIGIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ramnodigin under HS 29389090 and SITC 54161. As of Q4 2014, RAMNODIGIN remains the US FDA Preferred Term for this commodity. Ramnodigin bears US NLM identifiers UMLS ID C2699004 and NCI Concept Code C76589. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(O)CC3)C)CC4)C)CCC1(C(CC2)C1=CC(=O)OC1)C.
This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C17H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZRO0SC54Y, chemically known as (-)-(r)-1-methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone. but generally known as ramosetron, which bears US NIH Compound Identifier 108000. European Medicines Agency schedules Ramosetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10254MIG. The term RAMOSETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). RAMOSETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ramosetron under HS 29339990 and SITC 51577. As of Q4 2014, RAMOSETRON remains the US FDA Preferred Term for this commodity. Ramosetron bears US NLM identifiers UMLS ID C0526950 and NCI Concept Code C61921. SMILES: O=C(C1CCC2NC[NH]C2C1)C1C2C(N(C1)C)CCCC2.
A human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated for the treatment of Gastric Cancer.
This classification denotes a nitrofuran-based antibacterial and anti-infective agent with the molecular formula C21H24FN5O6, chemically known as Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitrofuran-2-yl)methyl]piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide but more generally known as ranbezolid, which bears U.S. National Institutes of Health Compound Identifier 496993. SMILES: CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)CC4=CC=C(O4)[N+](=O)[O-])F.
This classification denotes an immunoconjugate with the molecular formula C2158H3282N562O681S12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZL1R02VT79, more generally known as ranibizumab. European Medicines Agency schedules ranibizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22314. The term RANIBIZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 18, no. 3, 2004, list 52. Most nations schedule ranibizumab under HS 30021091 and SITC 54163. As of Q4 2014, RANIBIZUMAB remains the US FDA Preferred Term for this commodity. Ranibizumab bears US NLM identifiers UMLS ID C1566537 and NCI Concept Code C67562. SMILES: none.
This classification denotes a nitrosourea compound with the molecular formula C10H18ClN3O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RYH2T97J77, chemically known as glucopyranoside, methyl-6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy-, alpha-d- but more generally known as ranimustine, which bears US NIH Compound Identifier 71741. European Medicines Agency schedules Ranimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10256MIG. The term RANIMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules ranimustine in its Anatomical Therapeutic Chemical (ATC) Classification. RANIMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ranimustine under HS 29329970 and SITC 51569. As of Q4 2014, RANIMUSTINE remains US FDA's Preferred Term for this commodity. Ranimustine bears US NLM identifiers UMLS ID C0243666 and NCI Concept Code C1515. SMILES: COC1C(C(C(C(O1)CNC(=O)N(CCCL)N=O)O)O)O.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C19H27BiN4O10S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7AJ51I17KG, chemically known as bismuth;(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate but generally known as ranitidine bismuth citrate, which bears US NIH Compound Identifier 3033887. European Medicines Agency schedules Ranitidine bismuth citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15106MIG. The term RANITIDINE is an International Non-Proprietary Name. World Health Organization schedules ranitidine in its Anatomical Therapeutic Chemical (ATC) Classification. RANITIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ranitidine under HS 29321900 and SITC 51569. As of Q4 2014, RANITIDINE remains the US FDA Preferred Term for this commodity. Ranitidine bears US NLM identifiers UMLS ID C0034665 and NCI Concept Code C29412. SMILES: CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3].
This classification denotes a histamine-2 receptor antagonist with the molecular formula C13H22N4O3S.C6H5O7.Bi, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7AJ51I17KG, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, bismuth(3(+)) salt (1:1), compd. with n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n-methyl-2-nitro-1,1-ethenediamine (1:1) but more generally known as ranitidine bismuth citrate, which bears US NIH Compound Identifier 3033887. European Medicines Agency schedules Ranitidine bismuth citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15106MIG. World Health Organization schedules ranitidine bismuth citrate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ranitidine bismuth citrate under HS 29321900 and SITC 51569. As of Q4 2014, RANITIDINE BISMUTH CITRATE remains the US FDA Preferred Term for this commodity. Ranitidine bismuth citrate bears US NLM identifiers UMLS ID C0139919 and NCI Concept Code C66505. SMILES: CNC(=C[N+](=O)[O-])NCCSCC1CCC(O1)CN(C)C.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[BI+3].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA301. This VA Drug Class (GA301) classifies this compound as belonging to the group HISTAMINE ANTAGONISTS.
This classification denotes an enzyme inhibitor and cardiotonic agent with the molecular formula C24H33N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A6IEZ5M406, chemically known as 1-piperazineacetamide, n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)- but generally known as ranolazine, which bears US NIH Compound Identifier 56959. European Medicines Agency schedules Ranolazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10259MIG. The term RANOLAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules ranolazine in its Anatomical Therapeutic Chemical (ATC) Classification. RANOLAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ranolazine under HS 29335995 and SITC 51576. As of Q4 2014, RANOLAZINE remains the US FDA Preferred Term for this commodity. Ranolazine bears US NLM identifiers UMLS ID C0073633 and NCI Concept Code C66507. SMILES: OC(CN1CCN(CC1)CC(=O)NC1C(CCCC1C)C)COC1C(OC)CCCC1.
This classification denotes a muscle relaxant with the molecular formula C37H61N2O4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65Q4QDG4KC, chemically known as piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3-(acetyloxy)-17-(1-oxopropoxy)-2-(1-piperidinyl)androstan-16-yl)-1-(2-propenyl)-, bromide but generally known as rapacuronium bromide, which bears US NIH Compound Identifier 177969. European Medicines Agency schedules Rapacuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10260MIG. The term RAPACURONIUM BROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). As of Q4 2014, RAPACURONIUM remains the US FDA Preferred Term for this commodity. SMILES: CCC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)OC(=O)C)N5CCCCC5)C)C)[N+]6(CCCCC6)CC=C.[Br-].
This classification denotes a muscle relaxant with the molecular formula C37H61N2O4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65Q4QDG4KC, chemically known as piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3-(acetyloxy)-17-(1-oxopropoxy)-2-(1-piperidinyl)androstan-16-yl)-1-(2-propenyl)-, bromide but more generally known as rapacuronium bromide, which bears US NIH Compound Identifier 177969. European Medicines Agency schedules Rapacuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10260MIG. The term RAPACURONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 No. 2 1999, List 40). Most nations, for tariff and trade purposes, schedule rapacuronium bromide under HS 29333999 and SITC 51574. As of Q4 2014, RAPACURONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Rapacuronium bromide bears US NLM identifiers UMLS ID C0753790 and NCI Concept Code C66509. SMILES: CCC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)OC(=O)C)N5CCCCC5)C)C)[N+]6(CCCCC6)CC=C.[BR-].
This classification denotes a monoamine oxidase inhibitor and antiparkinsonian agent with the molecular formula C12H13N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 003N66TS6T, chemically known as 2,3-dihydro-n-2-propynyl-1h-inden-1-amine but generally known as rasagiline, which bears US NIH Compound Identifier 122316. European Medicines Agency schedules Rasagiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10261MIG. World Health Organization schedules rasagiline in its Anatomical Therapeutic Chemical (ATC) Classification. RASAGILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rasagiline under HS 29214980 and SITC 51454. As of Q4 2014, RASAGILINE remains the US FDA Preferred Term for this commodity. Rasagiline bears US NLM identifiers UMLS ID C0525678 and NCI Concept Code C66510. SMILES: C#CCNC1CCC2=CC=CC=C12.
This classification denotes a monoamine oxidase inhibitor and antiparkinsonian agent with the molecular formula C12H13N.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LH8C2JI290, chemically known as 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-, methanesulfonate but more generally known as rasagiline mesilate, which bears US NIH Compound Identifier 3052775. European Medicines Agency schedules Rasagiline mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21334. Most nations, for tariff and trade purposes, schedule rasagiline mesylate under HS 29214980 and SITC 51454. As of Q4 2014, RASAGILINE MESYLATE remains US FDA's Preferred Term for this commodity. Rasagiline mesylate bears US NLM identifiers UMLS ID C1615645 and NCI Concept Code C66511. SMILES: CS(=O)(=O)O.C#CCN[C@@H]1CCC2C1CCCC2.
This classification denotes a monoamine oxidase inhibitor and antiparkinsonian agent with the molecular formula C12H13N.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LH8C2JI290, chemically known as (r)-n-2-propynyl-1-indanamine methanesulfonate, but more generally known as rasagiline methanesulfonate, which bears US NIH Compound Identifier 3052775. European Medicines Agency schedules rasagiline methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10261MIG. Most nations, for tariff purposes, schedule rasagiline methanesulfonate under HS 29214980. SMILES: CS(=O)(=O)O.C#CCN[C@@H]1CCC2C1CCCC2.
This classification denotes a uricosuric agent with the molecular formula C1521H2381N417O461S7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08GY9K1EUO, more generally known as rasburicase. European Medicines Agency schedules rasburicase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04204MIG. The term RASBURICASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 1, 2000, list 43. Most nations schedule Rasburicase under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, RASBURICASE remains the US FDA Preferred Term for this commodity. . Rasburicase bears US NLM identifiers UMLS ID C0937932 and NCI Concept Code C2404.
This classification denotes an antifungal agent with the molecular formula C22H17F2N5OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95YH599JWV, chemically known as bms-207,147 but generally known as ravuconazole, which bears US NIH Compound Identifier 467825. The term RAVUCONAZOLE is an International Non-Proprietary Name. Most nations schedule ravuconazole under HS 29341000 and SITC 51579. As of Q4 2014, RAVUCONAZOLE remains the US FDA Preferred Term for this commodity. Ravuconazole bears US NLM identifiers UMLS ID C0535186 and NCI Concept Code C38688. SMILES: CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O.
This classification denotes a vasodilating agent with the molecular formula C27H34N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJ1O5LVT0G, chemically known as 3,4,5-trimethoxybenzoic acid ester with 3-(2-hydroxy-3-morpholinopropyl)-6,7,8-trimethoxy-1,2,3-benzotriazin-4(3h)-one but generally known as razinodil, which bears US NIH Compound Identifier 65771. European Medicines Agency schedules Razinodil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10264MIG. The term RAZINODIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). RAZINODIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule razinodil under HS 29349990 and SITC 51579. As of Q4 2014, RAZINODIL remains the US FDA Preferred Term for this commodity. Razinodil bears US NLM identifiers UMLS ID C0613934 and NCI Concept Code C77078. SMILES: O1CCN(CC(OC(=O)c2cc(OC)c(OC)c(OC)c2)Cn2nnc3c(c2=O)cc(OC)c(OC)c3OC)CC1.
This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C14H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LZ84VWN0U4, chemically known as 4,8-dihydro-3,8-dimethyl-4-phenylpyrazolo(3,4-b)(1,4)diazepine-5,7(1h,6h)-dione but generally known as razobazam, which bears US NIH Compound Identifier 71228. European Medicines Agency schedules Razobazam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10265MIG. The term RAZOBAZAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). RAZOBAZAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule razobazam under HS 29337900 and SITC 51561. As of Q4 2014, RAZOBAZAM remains the US FDA Preferred Term for this commodity. Razobazam bears US NLM identifiers UMLS ID C2347895 and NCI Concept Code C73211. SMILES: O=C1N(C2C(N(C(=O)C1)C)N[NH]C2C)C1CCCCC1.
This classification denotes an anti-ulcer agent with the molecular formula C19H15ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LR583V32ZR, chemically known as 4-quinolinepropanoic acid, 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-, (+-)- but generally known as rebamipide, which bears US NIH Compound Identifier 5042. European Medicines Agency schedules Rebamipide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10267MIG. The term REBAMIPIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). REBAMIPIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rebamipide under HS 29337900 and SITC 51561. As of Q4 2014, REBAMIPIDE remains the US FDA Preferred Term for this commodity. Rebamipide bears US NLM identifiers UMLS ID C0069562 and NCI Concept Code C29852. SMILES: CLC1CCC(C(=O)NC(CC2C3C([NH]C(=O)C2)CCCC3)C(=O)O)CC1.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 947S0YZ36I. European Medicines Agency schedules Reboxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15112MIG. Reboxetine generally arises in the molecular formula C19H23NO3. The term REBOXETINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) REBOXETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule reboxetine under HS 29349990 and SITC 51579. As of Q4 2014, REBOXETINE remains the US FDA Preferred Term for this commodity. Reboxetine bears US NLM identifiers UMLS ID C0168388 and NCI Concept Code C72838. SMILES: O1C(C(Oc2c(OCC)cccc2)c2ccccc2)CNCC1.
This classification denotes an antidepressant agent with the molecular formula C19H23NO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L94J81YNNY, chemically known as (+/-)-(r*,s*)-2-((2-ethoxyphenoxy)phenylmethyl)morpholine methanesulfonate, but more generally known as reboxetine mesylate, which bears US NIH Compound Identifier 127150. European Medicines Agency schedules reboxetine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15112MIG. Most nations, for tariff purposes, schedule reboxetine mesylate under HS 29349990. As of Q4 2014, REBOXETINE MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC1CCCCC1O[C@H](C2CCCCC2)[C@H]3CNCCO3.CS(=O)(=O)O.
This classification denotes an anxiolytic with the molecular formula C18H13Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJL42911RA, chemically known as 4(5h)-oxazolone, 2-(7-chloro-5-(2-chlorophenyl)-2,3-dihydro-1h-1,4-benzodiazepin-1-yl)-; but generally known as reclazepam, which bears US NIH Compound Identifier 3052777. European Medicines Agency schedules Reclazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10269MIG. The term RECLAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). RECLAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule reclazepam under HS 29349990 and SITC 51579. As of Q4 2014, RECLAZEPAM remains the US FDA Preferred Term for this commodity. Reclazepam bears US NLM identifiers UMLS ID C2347902 and NCI Concept Code C74186. SMILES: CLC1CC2C(N(CCN=C2C2C(CL)CCCC2)C2=NC(=O)CO2)CC1.
This classification denotes a vasodilating agent with the molecular formula C15H18N8O5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2XLN4Y044H, chemically known as adenosine, 2-(4-((methylamino)carbonyl)-1h-pyrazol-1-yl)- but generally known as regadenoson, which bears US NIH Compound Identifier 219024. European Medicines Agency schedules Regadenoson in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30494. World Health Organization schedules regadenoson in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule regadenoson under HS 29349990 and SITC 51579. As of Q4 2014, REGADENOSON remains the US FDA Preferred Term for this commodity. Regadenoson bears US NLM identifiers UMLS ID C1698215 and NCI Concept Code C74420. SMILES: O1C(n2c3nc(nc(N)c3nc2)n2ncc(c2)C(=O)NC)C(O)C(O)C1CO.
Regorafenib is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase.
This classification denotes a macrolide antibiotic with the molecular formula C46H79NO17, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier E70CPL81IY. The term RELOMYCIN is an International Non-Proprietary Name or INN. RELOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCC1C(C=C(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CCO)C)C)COC4C(C(C(C(O4)C)O)OC)OC.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C20H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P10582JYYK, chemically known as 1-piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester but generally known as remifentanil, which bears US NIH Compound Identifier 60815. European Medicines Agency schedules Remifentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10272MIG. The term REMIFENTANIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules remifentanil in its Anatomical Therapeutic Chemical (ATC) Classification. REMIFENTANIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule remifentanil under HS 29333999 and SITC 51574. As of Q4 2014, REMIFENTANIL remains the US FDA Preferred Term for this commodity. Remifentanil bears US NLM identifiers UMLS ID C0246631 and NCI Concept Code C66513. SMILES: O(C(=O)C1(N(C2CCCCC2)C(=O)CC)CCN(CC1)CCC(=O)OC)C.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C20H28N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V444H5WIC, chemically known as 4-carboxy-4-(n-phenylpropionamido)-1-piperidine propionic acid, dimethyl ester, monohydrochloride but more generally known as remifentanil hydrochloride, which bears US NIH Compound Identifier 60814. European Medicines Agency schedules Remifentanil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04215MIG. Most nations, for tariff and trade purposes, schedule remifentanil hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, REMIFENTANIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Remifentanil hydrochloride bears US NLM identifiers UMLS ID C0771827 and NCI Concept Code C47702. SMILES: CCC(=O)N(C1CCCCC1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC.CL.
This classification denotes a protease inhibitor and antihypertensive agent with the molecular formula C33H50N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LC7FBL96A4, chemically known as 1h-imidazole-4-propanamide, n-(1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((2-(((1,1-dimethylethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (1s-(1r*(r*(r*)),2s*,3r*))- but generally known as remikiren, which bears US NIH Compound Identifier 5462340. European Medicines Agency schedules Remikiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10273MIG. The term REMIKIREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules remikiren in its Anatomical Therapeutic Chemical (ATC) Classification. REMIKIREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule remikiren under HS 29332990 and SITC 51573. As of Q4 2014, REMIKIREN remains the US FDA Preferred Term for this commodity. Remikiren bears US NLM identifiers UMLS ID C0209499 and NCI Concept Code C73099. SMILES: S(=O)(=O)(CC(C(=O)NC(C(=O)NC(C(O)C(O)C1CC1)CC1CCCCC1)Cc1[nH]cnc1)Cc1ccccc1)C(C)(C)C.
This classification denotes a dopamine antagonist with the molecular formula C16H23BrN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0223RD59PE, chemically known as (-)-(s)-3-bromo-n-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide but generally known as remoxipride, which bears US NIH Compound Identifier 54477. European Medicines Agency schedules Remoxipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10275MIG. The term REMOXIPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules remoxipride in its Anatomical Therapeutic Chemical (ATC) Classification. REMOXIPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule remoxipride under HS 29339990 and SITC 51577. As of Q4 2014, REMOXIPRIDE remains the US FDA Preferred Term for this commodity. Remoxipride bears US NLM identifiers UMLS ID C0073047 and NCI Concept Code C73312. SMILES: BRC1C(OC)C(C(=O)NCC2N(CCC2)CC)C(OC)CC1.
This classification denotes a dopamine antagonist with the molecular formula C16H23BrN2O3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MH4OU8RWCW, chemically known as (-)-(s)-3-bromo-n-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide monohydrochloride, monohydrate but more generally known as remoxipride hydrochloride, which bears US NIH Compound Identifier 60678. Most nations, for tariff and trade purposes, schedule remoxipride hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, REMOXIPRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Remoxipride hydrochloride bears US NLM identifiers UMLS ID C0771022 and NCI Concept Code C73832. SMILES: CCN1CCC[C@H]1CNC(=O)C2C(CCC(C2OC)BR)OC.O.CL.
This classification denotes an ace inhibitor with the molecular formula C13H15NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0TAM1017B, chemically known as 4-thiazolidinecarboxylic acid, 2-(2-hydroxyphenyl)-3-(3-mercapto-1-oxopropyl)-, (2r-cis)- but generally known as rentiapril, which bears US NIH Compound Identifier 71244. European Medicines Agency schedules Rentiapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10277MIG. The term RENTIAPRIL is an International Non-Proprietary Name. RENTIAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rentiapril under HS 29341000 and SITC 51579. As of Q4 2014, RENTIAPRIL remains the US FDA Preferred Term for this commodity. Rentiapril bears US NLM identifiers UMLS ID C0073061 and NCI Concept Code C72912. SMILES: S1C(N(C(C1)C(=O)O)C(=O)CCS)c1c(O)cccc1.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 668Z8C33LU. European Medicines Agency schedules Repaglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10280MIG. Repaglinide generally arises in the molecular formula C27H36N2O4. The term REPAGLINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, no, 3 1992, list 32.) REPAGLINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule repaglinide under HS 29333999 and SITC 51574. As of Q4 2014, REPAGLINIDE remains US FDA's Preferred Term for this commodity. Repaglinide bears US NLM identifiers UMLS ID C0246689 and NCI Concept Code C47703. SMILES: O=C(NC(C1C(N2CCCCC2)CCCC1)CC(C)C)CC1CC(OCC)C(CC1)C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4K8KA8B61G, chemically known as 4h-pyrano(3,2-c)quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, isopentyl ester but generally known as repirinast, which bears US NIH Compound Identifier 5050. European Medicines Agency schedules Repirinast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10281MIG. The term REPIRINAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). REPIRINAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule repirinast under HS 29349990 and SITC 51579. As of Q4 2014, REPIRINAST remains the US FDA Preferred Term for this commodity. Repirinast bears US NLM identifiers UMLS ID C0073071 and NCI Concept Code C73053. SMILES: O1C2C3C([NH]C(=O)C2C(=O)CC1C(=O)OCCC(C)C)C(C(CC3)C)C.
This classification denotes a metaproterenol analog, adrenergic beta-agonists, and bronchodilator agent with the molecular formula C18H23N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11941YC6RN, chemically known as 1,2,3,6-tetrahydro-1,3-dimethyl-7-(3-((beta,3,5-trihydroxyphenethyl)amino)propyl)-2,6-purindion but generally known as reproterol, which bears US NIH Compound Identifier 25654. European Medicines Agency schedules Reproterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10283MIG. World Health Organization schedules reproterol in its Anatomical Therapeutic Chemical (ATC) Classification. REPROTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule reproterol under HS 29395900 and SITC 54145. As of Q4 2014, REPROTEROL remains the US FDA Preferred Term for this commodity. SMILES: OC(CNCCCN1C2C(N(C(=O)N(C2=O)C)C)NC1)C1CC(O)CC(O)C1.
This classification denotes a metaproterenol analog C18H23N5O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y4I1COJ8W8, chemically known as 1h-purine-2,6-dione, 7-(3-((2-(3,5-dihydroxyphenyl)-2-hydroxyethyl)amino)propyl)-3,7-dihydro-1,3-dimethyl-, monohydrochloride, but more generally known as reproterol hydrochloride, which bears US NIH Compound Identifier 3032600. European Medicines Agency schedules Reproterol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04218MIG. Most nations, for tariff and trade purposes, schedule reproterol hydrochloride under HS 29395900 and SITC 54145. As of Q4 2014, REPROTEROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1C2C(C(=O)N(C1=O)C)N(CN2)CCCNCC(C3CC(CC(C3)O)O)O.CL.
This classification denotes an antihypertensive agent with the molecular formula C33H38N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25YF317R6S, chemically known as yohimban-16-carboxylic acid, 18-((3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl)oxy)-11,17-dimethoxy-, methyl ester, (3-beta,16-beta,17-alpha,18-beta,20-alpha)- but generally known as rescimetol, which bears US NIH Compound Identifier 5282209. European Medicines Agency schedules Rescimetol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10284MIG. The term RESCIMETOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). RESCIMETOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rescimetol under HS 29399900 and SITC 54149. As of Q4 2014, RESCIMETOL remains the US FDA Preferred Term for this commodity. Rescimetol bears US NLM identifiers UMLS ID C2347955 and NCI Concept Code C72977. SMILES: O(C1C(C2C(CN3C(C2)c2[nH]c4c(c2CC3)ccc(OC)c4)CC1OC(=O)/C=C/c1cc(OC)c(O)cc1)C(=O)OC)C.
This classification denotes an antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q6W1F7DJ2D. European Medicines Agency schedules Rescinnamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10285MIG. Rescinnamine generally arises in the molecular formula C35H42N2O9. The term RESCINNAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) RESCINNAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rescinnamine under HS 29399900 and SITC 54149. As of Q4 2014, RESCINNAMINE remains the US FDA Preferred Term for this commodity. Rescinnamine bears US NLM identifiers UMLS ID C0035167 and NCI Concept Code C61923. SMILES: O(C1C(C2C(CN3C(C2)c2[nH]c4c(c2CC3)ccc(OC)c4)CC1OC(=O)/C=C/c1cc(OC)c(OC)c(OC)c1)C(=O)OC)C.
This classification denotes a multidrug resistance modulator and adrenergic agent with the molecular formula C33H40N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8B1QWR724A, chemically known as 20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) (8ci) but generally known as reserpine, which bears US NIH Compound Identifier 5052. European Medicines Agency schedules Reserpine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10286MIG. The term RESERPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules reserpine in its Anatomical Therapeutic Chemical (ATC) Classification. RESERPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule reserpine under HS 29399900 and SITC 54149. As of Q4 2014, RESERPINE remains the US FDA Preferred Term for this commodity. Reserpine bears US NLM identifiers UMLS ID C0035179 and NCI Concept Code C803. SMILES: O(C1C(C2C(CN3C(C2)c2[nH]c4c(c2CC3)ccc(OC)c4)CC1OC(=O)c1cc(OC)c(OC)c(OC)c1)C(=O)OC)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.
This classification denotes a biological response modifier with the molecular formula C17H22N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V3DMU7PVXF, chemically known as 1h-imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl- but generally known as resiquimod, which bears US NIH Compound Identifier 159603. The term RESIQUIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule resiquimod under HS 29339990 and SITC 51577. As of Q4 2014, RESIQUIMOD remains the US FDA Preferred Term for this commodity. Resiquimod bears US NLM identifiers UMLS ID C0389573 and NCI Concept Code C63958. SMILES: CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N.
This classification denotes an antihelminthic agent with the molecular formula C13H10BrNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2I8V5Q9A78, chemically known as 4-brom-2,6-dihydroxybenzanilid but generally known as resorantel, which bears US NIH Compound Identifier 65696. European Medicines Agency schedules Resorantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10288MIG. The term RESORANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). RESORANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule resorantel under HS 29242995 and SITC 51479. As of Q4 2014, RESORANTEL remains the US FDA Preferred Term for this commodity. Resorantel bears US NLM identifiers UMLS ID C0073084 and NCI Concept Code C72144. SMILES: BRC1CCC(NC(=O)C2C(O)CCCC2O)CC1.
This classification denotes an anti-infective agent with the molecular formula C8H8O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YL6O37RD1S, chemically known as 1,3-benzenediol, monoacetate but more generally known as resorcinol acetate, which bears US NIH Compound Identifier 5055. European Medicines Agency schedules Resorcinol monoacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15121MIG. Most nations, for tariff and trade purposes, schedule resorcinol acetate under HS 29072100. SMILES: CC(=O)OC1CCCC(C1)O.
This classification denotes an anti-infective agent with the molecular formula C8H8O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YL6O37RD1S, chemically known as 1,3-benzenediol, monoacetate but more generally known as resorcinol acetate, which bears US NIH Compound Identifier 5055. European Medicines Agency schedules Resorcinol monoacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15121MIG. Most nations, for tariff and trade purposes, schedule resorcinol monoacetate under HS 29072100. As of Q4 2014, RESORCINOL MONOACETATE remains US FDA's Preferred Term for this commodity. Resorcinol monoacetate bears US NLM identifiers UMLS ID C0636149 and NCI Concept Code C84136. SMILES: CC(=O)OC1CCCC(C1)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE752. This VA Drug Class (DE752) classifies this compound as belonging to the group ANTIACNE AGENTS, TOPICAL.
This classification denotes a topical anti-infective agent with the molecular formula C6H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YUL4LO94HK, chemically known as 1,3-dihydroxybenzene but generally known as resorcin, which bears US NIH Compound Identifier 5054. European Medicines Agency schedules Resorcinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15120MIG. World Health Organization schedules resorcin in its Anatomical Therapeutic Chemical (ATC) Classification. Resorcin or resorcinol bears US NLM identifiers UMLS ID C0073085 and NCI Concept Code C77056. SMILES: C1=CC(=CC(=C1)O)O.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4MG6O8991R. European Medicines Agency schedules Retapamulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25391. Retapamulin generally arises in the molecular formula C30H47NO4S. The term RETAPAMULIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53.) Most nations schedule retapamulin under HS 29419000 and SITC 54139. As of Q4 2014, RETAPAMULIN remains the US FDA Preferred Term for this commodity. Retapamulin bears US NLM identifiers UMLS ID C1703334 and NCI Concept Code C61924. SMILES: S(C1CC2N(C(C1)CC2)C)CC(=O)OC1C2(C3C(C(C(O)C(C1)(C)C=C)C)(CCC2C)CCC3=O)C.
This classification denotes a plasminogen activator with the molecular formula C1736H2653N499O522S22, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQA630RIE9, more generally known as reteplase. European Medicines Agency schedules reteplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10290MIG. The term RETEPLASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 8 no. 3 1994, list 34. Most nations schedule reteplase under HS 35079090 and SITC 51691. As of Q4 2014, RETEPLASE remains the US FDA Preferred Term for this commodity. Reteplase bears US NLM identifiers UMLS ID C0106660 and NCI Concept Code C90972. SMILES: NONE.
This classification denotes an anxiolytic with the molecular formula C18H21N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X8764TW2J, chemically known as 1,2-benzisothiazol-3(2h)-one, 2-(3-(4-(2-pyrimidinyl)-1-piperazinyl)propyl)-, 1,1-dioxide but generally known as revospirone, which bears US NIH Compound Identifier 72024. European Medicines Agency schedules Revospirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10296MIG. The term REVOSPIRONE is an International Non-Proprietary Name. REVOSPIRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule revospirone under HS 29341000 and SITC 51579. As of Q4 2014, REVOSPIRONE remains the US FDA Preferred Term for this commodity. Revospirone bears US NLM identifiers UMLS ID C2699076 and NCI Concept Code C76509. SMILES: S1(=O)(=O)N(CCCN2CCN(CC2)C2NCCCN2)C(=O)C2C1CCCC2.
This classification denotes bacterial antibodies that prevent Rhesus disease.
This classification denotes an antiviral agent with the molecular formula C8H12N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49717AWG6K, chemically known as 1,2,4-triazole-3-carboxamide, 1-.beta.-d-ribofuranosyl- but generally known as ribavirin, which bears US NIH Compound Identifier 5064. European Medicines Agency schedules Ribavirin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10297MIG. The term RIBAVIRIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules ribavirin in its Anatomical Therapeutic Chemical (ATC) Classification. RIBAVIRIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ribavirin under HS 29349990 and SITC 51579. As of Q4 2014, RIBAVIRIN remains the US FDA Preferred Term for this commodity. Ribavirin bears US NLM identifiers UMLS ID C0035525 and NCI Concept Code C807. SMILES: O1C(C(O)C(O)C1N1NC(NC1)C(=O)N)CO.
Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Q5JOU7T53. European Medicines Agency schedules Ribostamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10300MIG. Ribostamycin generally arises in the molecular formula C17H34N4O10. The term RIBOSTAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, no. 10 1972, list 12.) RIBOSTAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ribostamycin under HS 29419000 and SITC 54139. As of Q4 2014, RIBOSTAMYCIN remains the US FDA Preferred Term for this commodity. Ribostamycin bears US NLM identifiers UMLS ID C0035554 and NCI Concept Code C90639. SMILES: O(C1C(OC2OC(C(O)C2O)CO)C(O)C(N)CC1N)C1OC(C(O)C(O)C1N)CN.
This classification denotes an aminoglycoside antibiotic C17H34N4O10.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QFN1QU7PEN, chemically known as o-2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(.beta-d-ribofuranosyl-(1->5))-2-deoxy-d-streptamine sulfate, but more generally known as ribostamycin sulfate, which bears US NIH Compound Identifier 5702279. European Medicines Agency schedules in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04244MIG. Most nations, for tariff and trade purposes, schedule ribostamycin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, RIBOSTAMYCIN SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O)N.OS(=O)(=O)O.
This classification denotes a 5-ht3 receptor antagonist with the molecular formula C19H27N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R92JB88O88, chemically known as 3,3-dimethyl-n-1alphah,5alphah-tropan-3alpha-yl-1-indolinecarboxamide but generally known as ricasetron, which bears US NIH Compound Identifier 71785. European Medicines Agency schedules Ricasetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10301MIG. The term RICASETRON is an International Non-Proprietary Name. Most nations schedule ricasetron under HS 29399900 and SITC 54149. As of Q4 2014, RICASETRON remains the US FDA Preferred Term for this commodity. Ricasetron bears US NLM identifiers UMLS ID C2699081 and NCI Concept Code C77263. SMILES: O=C(NC1CC2N(C(C1)CC2)C)N1CC(C2C1CCCC2)(C)C.
This classification denotes an immunosuppressant with the molecular formula and that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48Z35KB15K., generally known as pomalidomide, which bears US NIH Compound Identifier 11520894. Most nations, for tariff and trade purposes, schedule ridaforolimus under HS 29349990 and SITC 51579. The term RIDAFOROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 1, 2010 List 63). SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OP(=O)(C)C)C)C)O)OC)C)C)C)OC.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2R4QO1868Y. European Medicines Agency schedules Ridazolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10302MIG. Ridazolol generally arises in the molecular formula C15H18CL2N4O3. The term RIDAZOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) RIDAZOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ridazolol under HS 29339990 and SITC 51577. As of Q4 2014, RIDAZOLOL remains the US FDA Preferred Term for this commodity. Ridazolol bears US NLM identifiers UMLS ID C0073362 and NCI Concept Code C76559. SMILES: CLC1C(NCCNCC(O)COC2C(CL)CCCC2)CN[NH]C1=O.
This classification denotes a heat shock protein inhibitor and antineoplastic antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1W306TDA6S. European Medicines Agency schedules Rifabutin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10304MIG. Rifabutin generally arises in the molecular formula C46H62N4O11. The term RIFABUTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) RIFABUTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifabutin under HS 29419000 and SITC 54139. As of Q4 2014, RIFABUTIN remains the US FDA Preferred Term for this commodity. Rifabutin bears US NLM identifiers UMLS ID C0140575 and NCI Concept Code C1408. SMILES: O(C1C(C(O)C(C(O)C(C)C=CC=C(C(=O)NC2=C3NC4(N=C3C3C(C2=O)C(O)C(C2OC(OC=CC(OC)C1C)(C(=O)C32)C)C)CCN(CC4)CC(C)C)C)C)C)C(=O)C.
This classification denotes an antitubercular agent with the molecular formula C44H60N4O12, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1PUG6262HX, chemically known as rifamycin, 3-(((1-(diethylamino)ethylidene)hydrazono)methyl)- but more generally known as rifametane, which bears U.S. National Institutes of Health Compound Identifier 9571071. The European Medicines Agency schedules Rifametane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10306MIG. The term RIFAMETANE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 4, No. 3 1990, List 30). RIFAMETANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(C(O)C(C(O)C(C)C=CC=C(C(=O)NC2=C(O)C3C(C4C(=O)C(OC=CC(OC)C1C)(OC4C(C3O)C)C)C(=O)/C2=C/N/N=C(\N(CC)CC)C)C)C)C)C(=O)C.
This classification denotes a rna polymerase inhibitor and antitubercular agent with the molecular formula C43H58N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJT6J7R4TR, chemically known as 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(n-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2h)-dione 21-acetate but generally known as rifampicin, which bears US NIH Compound Identifier 5381226. European Medicines Agency schedules Rifampicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10309MIG. The term RIFAMPICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules rifampicin in its Anatomical Therapeutic Chemical (ATC) Classification. RIFAMPICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Rifampicinn or rifampin bears US NLM NCI C811. SMILES: O(C1C(C(O)C(C(O)C(C)C=CC=C(C(=O)NC2=C(O)C3C(C4C(=O)C(OC=CC(OC)C1C)(OC4C(C3O)C)C)C(=O)/C2=C/NN1CCN(CC1)C)C)C)C)C(=O)C.
This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DU69T8ZZPA. European Medicines Agency schedules Rifamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Rifamycin generally arises in the molecular formula C37H47NO12. The term RIFAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) RIFAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifamycin under HS 29419000 and SITC 54139. As of Q4 2014, RIFAMYCIN remains the US FDA Preferred Term for this commodity. Rifamycin bears US NLM identifiers UMLS ID C0035609 and NCI Concept Code C29406. SMILES: O([N](=O)O)C1C(C(O)C(C(O)C(C)C=CC=C(C(=O)CC2C(O)C3C(C4C(OC(OC=CC(OC)C1C)(C4=O)C)C(C3C)C)C(O)C2)C)C)C.
This classification denotes an antitubercular agent with the molecular formula C43H58N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJT6J7R4TR, chemically known as rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-, but more generally known as rifamycin amp, which bears US NIH Compound Identifier 5381226. European Medicines Agency schedules rifamycin amp or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Most nations, for tariff purposes, schedule rifamycin amp under HS 29419000. SMILES: CC1C(C2C3C4C1O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)NC(C2O)C(C3O)C=NN5CCN(CC5)C)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.
This classification denotes an antitubercular agent with the molecular formula C39H49NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8DDB535DJI, chemically known as 4-o-(carboxymethyl)rifamycin, but more generally known as rifamycin b, which bears US NIH Compound Identifier 5459948. European Medicines Agency schedules rifamycin b or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Most nations, for tariff purposes, schedule rifamycin b under HS 29419000. SMILES: CC1C(C2C3C(CC(C2O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](/C=C/O[C@@]4(C(=O)C3C1O4)C)OC)C)OC(=O)C)C)O)C)O)C)/C)OCC(=O)O)O.
This classification denotes an antitubercular agent with the molecular formula C43H58N2O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TS121H7U7E, chemically known as rifamycin, 4-o-(2-(diethylamino)-2-oxoethyl)-, but more generally known as rifamycin b diethylamide, which bears US NIH Compound Identifier 5382104. European Medicines Agency schedules rifamycin b diethylamide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Most nations, for tariff purposes, schedule rifamycin b diethylamide under HS 29419000. SMILES: CCN(CC)C(=O)COC1CC2C(C3C1C4C(C(C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)N2)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.
This classification denotes an antitubercular agent with the molecular formula C39H47NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z67LEM9P1W, chemically known as 4-o-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxorifamycin .gamma.-lactone, but more generally known as rifamycin o, which bears US NIH Compound Identifier 5280468. European Medicines Agency schedules rifamycin o or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Most nations, for tariff purposes, schedule rifamycin o under HS 29419000. SMILES: CC1C(C2C3C4C1O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)NC(=CC35OCC(=O)O5)C2=O)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.
This classification denotes an antitubercular agent with the molecular formula C37H45NO12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PI53N820JV, chemically known as 1,4-dideoxy-1,4-dihydro-1,4-dioxorifamycin, but more generally known as rifamycin s, which bears US NIH Compound Identifier 5475445. European Medicines Agency schedules rifamycin s or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Most nations, for tariff purposes, schedule rifamycin s under HS 29419000. SMILES: CC1C(C2C3C4C1O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)NC(=CC3=O)C2=O)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.
This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32086GS35Z. European Medicines Agency schedules Rifamycin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04246MIG. Rifamycin sodium generally arises in the molecular formula C37H46NO12.NA. The term 'rifamycin sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule rifamycin sodium under HS 29419000 and SITC 54139. As of Q4 2014, RIFAMYCIN SODIUM remains US FDA's Preferred Term for this commodity. Rifamycin sodium bears US NLM identifiers UMLS ID C0771754 and NCI Concept Code C95605. SMILES: CC1C(C2C3C(CC(C2O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](/C=C/O[C@@]4(C(=O)C3C1O4)C)OC)C)OC(=O)C)C)O)C)O)C)/C)[O-])O.[NA+].
This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DU69T8ZZPA. European Medicines Agency schedules Rifamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Rifamycin generally arises in the molecular formula C37H47NO12. The term RIFAMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, list 5.) RIFAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule rifamycin sv under HS 29419000. SMILES: CC1C(C2C3C(CC(C2O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](/C=C/O[C@@]4(C(=O)C3C1O4)C)OC)C)OC(=O)C)C)O)C)O)C)/C)O)O.
This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XJM390A33U. European Medicines Agency schedules Rifapentine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10311MIG. Rifapentine generally arises in the molecular formula C47H64N4O12. The term RIFAPENTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) RIFAPENTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifapentine under HS 29419000 and SITC 54139. As of Q4 2014, RIFAPENTINE remains the US FDA Preferred Term for this commodity. Rifapentine bears US NLM identifiers UMLS ID C0073372 and NCI Concept Code C66516. SMILES: O(C1C(C(O)C(C(O)C(C)C=CC=C(C(=O)NC2=C(O)C3C(C(=O)/C2=C/NN2CCN(C4CCCC4)CC2)C2C(OC(OC=CC(OC)C1C)(C2=O)C)C(C3O)C)C)C)C)C(=O)C.
This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L36O5T016N. European Medicines Agency schedules Rifaximin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10312MIG. Rifaximin generally arises in the molecular formula C43H51N3O11. The term RIFAXIMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) RIFAXIMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifaximin under HS 29419000 and SITC 54139. As of Q4 2014, RIFAXIMIN remains the US FDA Preferred Term for this commodity. Rifaximin bears US NLM identifiers UMLS ID C0073374 and NCI Concept Code C61926. SMILES: O(C1C(C(O)C(C(O)C(C)C=CC=C(C(=O)NC2C3N4C(NC3C3C5C(OC(OC=CC(OC)C1C)(C5=O)C)C(C(O)C3C2O)C)CC(CC4)C)C)C)C)C(=O)C.
This classification denotes an antipsychotic agent with the molecular formula C22H20ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7QCG0RP106, chemically known as (z)-2-chloro-10-(4-methyl-1-piperazinyl)-5h-dibenzo(a,d)cycloheptene-(delta(sup 5,alpha))-acetonitrile but generally known as rilapine, which bears US NIH Compound Identifier 6446980. European Medicines Agency schedules Rilapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10313MIG. The term RILAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). RILAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rilapine under HS 29335995 and SITC 51576. As of Q4 2014, RILAPINE remains the US FDA Preferred Term for this commodity. Rilapine bears US NLM identifiers UMLS ID C2699086 and NCI Concept Code C76445. SMILES: CLC1CC2C=C(N3CCN(CC3)C)C3C(/C(=C/C#N)C2CC1)CCCC3.
This classification denotes an antihypertensive agent with the molecular formula C21H23NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47Y56T6LEI, chemically known as 2-pyrrolidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)-2h-1-benzopyran-4-yl)-, (3s-trans)- but generally known as rilmakalim, which bears US NIH Compound Identifier 65966. European Medicines Agency schedules Rilmakalim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10314MIG. The term RILMAKALIM is an International Non-Proprietary Name. Most nations schedule rilmakalim under HS 29349990 and SITC 51579. As of Q4 2014, RILMAKALIM remains the US FDA Preferred Term for this commodity. Rilmakalim bears US NLM identifiers UMLS ID C0652011 and NCI Concept Code C75239. SMILES: S(=O)(=O)(c1cc2C(N3CCCC3=O)C(O)C(Oc2cc1)(C)C)c1ccccc1.
This classification denotes a sedative and hypnotic with the molecular formula C21H20Cl2N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU3H37T766, chemically known as 5-((2-aminoacetamido)methyl)-1-(4-chloro-2-(o-chlorobenzoyl)phenyl)-n,n-dimethyl-1h-1,2,4-triazole-3-carboxamide but generally known as rilmazafone, which bears US NIH Compound Identifier 5069. European Medicines Agency schedules Rilmazafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10315MIG. The term RILMAZAFONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). RILMAZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rilmazafone under HS 29339990 and SITC 51577. As of Q4 2014, RILMAZAFONE remains the US FDA Preferred Term for this commodity. Rilmazafone bears US NLM identifiers UMLS ID C0073378 and NCI Concept Code C76944. SMILES: CLC1CC(C(N2NC(NC2CNC(=O)CN)C(=O)N(C)C)CC1)C(=O)C1C(CL)CCCC1.
This classification denotes a sedative and hypnotic with the molecular structure C21H20CL2N6O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 25T258X8BV chemically known as 5-(((2-aminoacetyl)amino)methyl)-1-(4-chloro-2-(2-chlorobenzoyl)phenyl)-n,n-dimethyl-1h-1,2,4-triazole-3-carboxamide hydrochloride, but more commonly known as rilmazafone hydrochloride, which bears US NIH Compound Identifier 135366. European Medicines Agency schedules Rilmazafone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22078. Most nations, for tariff and trade purposes, schedule rilmazafone hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, RILMAZAFONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)C(=O)C1NC(N(N1)C2CCC(CC2C(=O)C3CCCCC3CL)CL)CNC(=O)CN.CL.
This classification denotes an antihypertensive agent with the molecular formula C10H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P67IM25ID8, chemically known as 2-oxazolamine, n-(dicyclopropylmethyl)-4,5-dihydro- but generally known as rilmenidine, which bears US NIH Compound Identifier 68712. European Medicines Agency schedules Rilmenidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10316MIG. The term RILMENIDINE is an International Non-Proprietary Name. World Health Organization schedules rilmenidine in its Anatomical Therapeutic Chemical (ATC) Classification. RILMENIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rilmenidine under HS 29349990 and SITC 51579. As of Q4 2014, RILMENIDINE remains the US FDA Preferred Term for this commodity. Rilmenidine bears US NLM identifiers UMLS ID C0140591 and NCI Concept Code C75240. SMILES: C1CC1C(C2CC2)NC3=NCCO3.
This classification denotes an antihypertensive agent with the molecular formula C10H16N2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59QD64Q32M, chemically known as 4,5-dihydro-n-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1) but more generally known as rilmenidine dihydrogen phosphate, which bears US NIH Compound Identifier 198614. European Medicines Agency schedules Rilmenidine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21586. Most nations, for tariff and trade purposes, schedule rilmenidine dihydrogen phosphate under HS 29349990. SMILES: C1CC1C(C2CC2)NC3=NCCO3.OP(=O)(O)O.
This classification denotes an antihypertensive agent with the molecular formula C10H16N2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59QD64Q32M, chemically known as 4,5-dihydro-n-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1) but more generally known as rilmenidine dihydrogen phosphate, which bears US NIH Compound Identifier 198614. European Medicines Agency schedules Rilmenidine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21586. Most nations, for tariff and trade purposes, schedule rilmenidine phosphate under HS 29349990 and SITC 51579. As of Q4 2014, RILMENIDINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: C1CC1C(C2CC2)NC3=NCCO3.OP(=O)(O)O.
This classification denotes a biological response modifier with the molecular formula C9030H13932N2400O2670S74, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8K80YB5GMG, more generally known as rilonacept. European Medicines Agency schedules rilonacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB28994. The term RILONACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, No. 1, 2007, list 57. Most nations, for tariff and trade purposes, schedule Rilonacept under HS 30021020 and SITC 54163. SMILES:. As of Q4 2014, RILONACEPT remains US FDA's Preferred Term for this commodity. . Rilonacept bears US NLM identifiers UMLS ID C2343589 and NCI Concept Code C84137.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 595T4D0KQ3. European Medicines Agency schedules Rilopirox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10317MIG. Rilopirox generally arises in the molecular formula C19H16CLNO4. The term RILOPIROX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) Most nations schedule rilopirox under HS 29333999 and SITC 51574. As of Q4 2014, RILOPIROX remains the US FDA Preferred Term for this commodity. Rilopirox bears US NLM identifiers UMLS ID C0084372 and NCI Concept Code C75204. SMILES: CLC1CCC(OC2CCC(OCC3N(O)C(=O)CC(C3)C)CC2)CC1.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E521I6380L. European Medicines Agency schedules Rilozarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10318MIG. Rilozarone generally arises in the molecular formula C32H36BRCLN2O2. The term RILOZARONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 2, No. 3, 1988, list 28.) RILOZARONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule rilozarone under HS 29339990 and SITC 51577. As of Q4 2014, RILOZARONE remains US FDA's Preferred Term for this commodity. Rilozarone bears US NLM identifiers UMLS ID C2699088 and NCI Concept Code C75134. SMILES: BRC1C(C(N2C1CCCC2)C(=O)C1CC(CL)C(OCCCN(CCCC)CCCC)CC1)C1CCCCC1.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C22H18N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FI96A8X663, chemically known as 4-((4-((4-((1e)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile but generally known as rilpivirine, which bears US NIH Compound Identifier 6451164. European Medicines Agency schedules Rilpivirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31456. The term RILPIVIRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). Most nations schedule rilpivirine under HS 29335995 and SITC 51576. As of Q4 2014, RILPIVIRINE remains the US FDA Preferred Term for this commodity. Rilpivirine bears US NLM identifiers UMLS ID C1566826 and NCI Concept Code C76929. SMILES: N(c1c(cc(cc1C)/C=C/C#N)C)c1nc(Nc2ccc(cc2)C#N)ncc1.
This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 212WAX8KDD. European Medicines Agency schedules Rilpivirine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31460. Rilpivirine hydrochloride generally arises in the molecular formula C22H18N6.CLH. The term 'rilpivirine hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule rilpivirine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, RILPIVIRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC(CC(C1NC2CCNC(N2)NC3CCC(CC3)C#N)C)/C=C/C#N.CL.
This classification denotes an anticonvulsant agent with the molecular formula C8H5F3N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LJ087RS6F, chemically known as 2-benzothiazolamine, 6-(trifluoromethoxy)- but generally known as riluzole, which bears US NIH Compound Identifier 5070. European Medicines Agency schedules Riluzole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10319MIG. The term RILUZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules riluzole in its Anatomical Therapeutic Chemical (ATC) Classification. RILUZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule riluzole under HS 29341000 and SITC 51579. As of Q4 2014, RILUZOLE remains the US FDA Preferred Term for this commodity. Riluzole bears US NLM identifiers UMLS ID C0073379 and NCI Concept Code C47704. SMILES: S1C2C(NC1N)CCC(OC(F)(F)F)C2.
This classification denotes an antiviral agent with the molecular formula C12H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0T2EF4JQTU, chemically known as 1-adamantanemethylamine, .alpha.-methyl-, hydrochloride but generally known as rimantadine, which bears US NIH Compound Identifier 5071. European Medicines Agency schedules Rimantadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10320MIG. The term RIMANTADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules rimantadine in its Anatomical Therapeutic Chemical (ATC) Classification. RIMANTADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rimantadine under HS 29213099 and SITC 51453. As of Q4 2014, RIMANTADINE remains the US FDA Preferred Term for this commodity. Rimantadine bears US NLM identifiers UMLS ID C0035629 and NCI Concept Code C61927. SMILES: NC(C12CC3CC(C2)CC(C1)C3)C.
This classification denotes a pegylated interferon alfa with the molecular formula C10H18N3O5(C2H4O)N(C2H4O)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q46947FE7K. European Medicines Agency schedules peginterferon alfa-2a in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16452MIG. The term peginterferon alfa-2a is a European Medicines Agency European Public Assessment Report System designation. Most nations schedule rimantadine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, RIMANTADINE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Rimantadine hydrochloride bears US NLM identifiers UMLS ID C0733408 and NCI Concept Code C61928. SMILES: NONE.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H19N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 967Y95129A, chemically known as 3-(ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-4h-pyrido(1,2-a)pyrimidinium but generally known as rimazolium, which bears US NIH Compound Identifier 71940. European Medicines Agency schedules Rimazolium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15142MIG. World Health Organization schedules rimazolium in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, RIMAZOLIUM remains the US FDA Preferred Term for this commodity. Rimazolium bears US NLM identifiers UMLS ID C0072022 and NCI Concept Code C84138. SMILES: O=C1N2C(CCCC2[N](CC1C(=O)OCC)C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H34O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O7M2E4264D, chemically known as 11beta-hydroxy-16alpha,17alpha-dimethyl-17-propionylandrosta-1,4-dien-3-one but generally known as rimexolone, which bears US NIH Compound Identifier 39507. European Medicines Agency schedules Rimexolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10323MIG. The term RIMEXOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules rimexolone in its Anatomical Therapeutic Chemical (ATC) Classification. RIMEXOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rimexolone under HS 29372900 and SITC 54153. As of Q4 2014, RIMEXOLONE remains the US FDA Preferred Term for this commodity. Rimexolone bears US NLM identifiers UMLS ID C0140594 and NCI Concept Code C47705. SMILES: OC1C2C(C3C(C(C(C3)C)(C)C(=O)CC)(C1)C)CCC1=CC(=O)C=CC21C.
This classification denotes a beta-adrenergic agonist with the molecular formula C22H32N2O6H2O4S; a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U851S9102C; chemically known as 4;4-(hexane-1;6-diylbis(iminio(1-hydroxyethylene)))dipyrocatecholsulphate but generally known as hexoprenaline sulfate; which bears US National Institutes of Health Compound Identifier 36094 European Medicines Agency schedules Hexoprenaline sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02516MIG Most nations schedule rimiterol under HS 29333999 and SITC 51574. As of Q4 2014, RIMITEROL remains the US FDA Preferred Term for this commodity. Rimiterol bears US NLM identifiers UMLS ID C0035633 and NCI Concept Code C81639. SMILES: S(=O)(=O)(O)OOC(C[NH2]CCCCCC[NH2]CC(O)c1cc(O)c(O)cc1)c1cc(O)c(O)cc1S(=O)(=O)(O)OOC(C[NH2]CCCCCC[NH2]CC(O)c1cc(O)c(O)cc1)c1cc(O)c(O)cc1.
This classification denotes a beta-adrenergic agonist with the molecular formula C12H17NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I29DRR8S3R, chemically known as erythro-.alpha.-(3,4-dihydroxyphenyl)-2-piperidinemethanol hbr, but more generally known as rimiterol hbr, which bears US NIH Compound Identifier 5458580. European Medicines Agency schedules rimiterol hbr or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10324MIG. Most nations, for tariff purposes, schedule rimiterol hbr under HS 29333999. SMILES: C1CC(C(CC1[C@H]([C@@H]2CCCCN2)O)O)O.BR.
This classification denotes a beta-adrenergic agonist with the molecular formula C12H17NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I29DRR8S3R, chemically known as 1,2-benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (r*,s*)- (9ci) but more generally known as rimiterol hydrobromide, which bears US NIH Compound Identifier 71409. European Medicines Agency schedules Rimiterol hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04251MIG. Most nations, for tariff and trade purposes, schedule rimiterol hydrobromide under HS 29333999 and SITC 51574. As of Q4 2014, RIMITEROL HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Rimiterol hydrobromide bears US NLM identifiers UMLS ID C0700493 and NCI Concept Code C81646. SMILES: C1CC(C(CC1[C@H]([C@@H]2CCCCN2)O)O)O.BR.
This classification denotes an anxiolytic with the molecular formula C22H21Cl3N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HL0V2LQZ09, chemically known as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-1h-pyrazole-3-carboxamide monohydrochloride, but more generally known as rimonabant hydrochloride, which bears US NIH Compound Identifier 104849. European Medicines Agency schedules rimonabant hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21719. Most nations, for tariff purposes, schedule rimonabant hydrochloride under HS 29333999. SMILES: CC1C(N(NC1C(=O)NN2CCCCC2)C3CCC(CC3CL)CL)C4CCC(CC4)CL.CL.
Vaccine against contagious bovine pleuropneumonia (CBPP) caused one the three great historic cattle plagues of the world along with foot and mouth disease and Rinderpest.
An inactivated vaccine – a tissue culture rinderpest vaccine, or TCRV – that induced lifelong immunity without major side effects or the risk of further transmission
Riociguat is a stimulator of soluble guanylate cyclase. It is used to treat two forms of pulmonary hypertension: chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.
This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C7H11NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KM2Z91756Z, chemically known as phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis- but generally known as risedronic acid, which bears US NIH Compound Identifier 5245. European Medicines Agency schedules Risedronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10330MIG. The term RISEDRONIC ACID is an International Non-Proprietary Name. World Health Organization schedules risedronic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Risedronate sodium or risedronic acid bears US NLM identifiers UMLS ID C0140610 and NCI Concept Code C66517. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CC1CCCNC1.
This classification denotes an antipsychotic agent with the molecular formula C23H27FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6UH7ZF8HC, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2-methyl- but generally known as risperidone, which bears US NIH Compound Identifier 5073. European Medicines Agency schedules Risperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10335MIG. The term RISPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules risperidone in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule risperidone under HS 29349990 and SITC 51579. As of Q4 2014, RISPERIDONE remains the US FDA Preferred Term for this commodity. Risperidone bears US NLM identifiers UMLS ID C0073393 and NCI Concept Code C29416. SMILES: FC1CC2ONC(C3CCN(CC3)CCC3C(=O)N4CCCCC4NC3C)C2CC1.
This classification denotes an anti-infective agent with the molecular formula C7H10O6S3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier J89LM8QVEE, chemically known as 2,2,2-(methylidynetris(thio))trisacetic acid but more generally known as ritiometan, which bears U.S. National Institutes of Health Compound Identifier 65787. The European Medicines Agency schedules Ritiometan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10338MIG. The term RITIOMETAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). The World Health Organization schedules ritiometan in its Anatomical Therapeutic Chemical (ATC) Classification. RITIOMETAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(C(SCC(=O)O)SCC(=O)O)CC(=O)O.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0Q6O6740J. European Medicines Agency schedules Ritodrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10340MIG. Ritodrine generally arises in the molecular formula C17H21NO3. The term RITODRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) RITODRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ritodrine under HS 29394900 and SITC 54144. As of Q4 2014, RITODRINE remains the US FDA Preferred Term for this commodity. Ritodrine bears US NLM identifiers UMLS ID C0035661 and NCI Concept Code C61929. SMILES: OC(C(NCCC1CCC(O)CC1)C)C1CCC(O)CC1.
This classification denotes an anti-asthmatic agent with the molecular formula C17H13F3N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0E8R4GDE2Q, chemically known as 1,1,1-trifluoro-alpha-2-quinolylmethanesulfon-m-anisidide but generally known as ritolukast, which bears US NIH Compound Identifier 60539. European Medicines Agency schedules Ritolukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10341MIG. The term RITOLUKAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Most nations schedule ritolukast under HS 29350090 and SITC 51580. As of Q4 2014, RITOLUKAST remains the US FDA Preferred Term for this commodity. Ritolukast bears US NLM identifiers UMLS ID C2347965 and NCI Concept Code C74129. SMILES: S(=O)(=O)(NC1CC(OCC2NC3C(CC2)CCCC3)CCC1)C(F)(F)F.
This classification denotes a protease inhibitor with the molecular formula C37H48N6O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3J8G9O825, chemically known as 2,4,7,12-tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5s-(5r*,8r*,10r*,11r*))- but generally known as ritonavir, which bears US NIH Compound Identifier 60954. European Medicines Agency schedules Ritonavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10342MIG. The term RITONAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules ritonavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ritonavir under HS 29341000 and SITC 51579. As of Q4 2014, RITONAVIR remains the US FDA Preferred Term for this commodity. Ritonavir bears US NLM identifiers UMLS ID C0292818 and NCI Concept Code C1609. SMILES: S1C(NC(CN(C(=O)NC(C(C)C)C(=O)NC(CC(O)C(NC(=O)OCC2SCNC2)CC2CCCCC2)CC2CCCCC2)C)C1)C(C)C.
This classification denotes an antineoplastic alkylating agent with the molecular formula C10H24N2O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YIY0662KX9, chemically known as 3,14-dioxa-2,15-dithia-6,11-diazahexadecane-8,9-diol, 2,2,15,15-tetraoxide, (r*,s*)- (9ci) but more generally known as ritrosulfan, which bears US NIH Compound Identifier 20107. European Medicines Agency schedules Ritrosulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10344MIG. The term RITROSULFAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). RITROSULFAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ritrosulfan under HS 29221980 and SITC 51461. As of Q4 2014, RITROSULFAN remains US FDA's Preferred Term for this commodity. Ritrosulfan bears US NLM identifiers UMLS ID C0073401 and NCI Concept Code C75294. SMILES: CS(=O)(=O)OCCNCC(C(CNCCOS(=O)(=O)C)O)O.
This classification denotes a monoclonal antibody with the molecular formula C6416H9874N1688O1987S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F4X42SYQ6, more generally known as rituximab. European Medicines Agency schedules rituximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12570MIG. The term RITUXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 1 1998, list 39. Most nations schedule rituximab under HS 30021091 and SITC 54163. As of Q4 2014, RITUXIMAB remains the US FDA Preferred Term for this commodity. Rituximab bears US NLM identifiers UMLS ID C0732355 and NCI Concept Code C1702. SMILES: CC(=O)NC1C(C(C(OC1N)CO)O)O.
This classification denotes an anticoagulant agent with the molecular formula C19H18ClN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9NDF7JZ4M3, chemically known as 5-chloro-n-(((5s)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide but generally known as rivaroxaban, which bears US NIH Compound Identifier 6433119. European Medicines Agency schedules Rivaroxaban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29263. The term RIVAROXABAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, List 52). World Health Organization schedules rivaroxaban in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule rivaroxaban under HS 29349990 and SITC 51579. As of Q4 2014, RIVAROXABAN remains the US FDA Preferred Term for this commodity. Rivaroxaban bears US NLM identifiers UMLS ID C1739768 and NCI Concept Code C77995. SMILES: CLC1SC(C(=O)NCC2OC(=O)N(C2)C2CCC(N3CCOCC3=O)CC2)CC1.
This classification denotes an acetylcholinesterase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PKI06M3IW0. European Medicines Agency schedules Rivastigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10345MIG. Rivastigmine generally arises in the molecular formula C14H22N2O2. The term RIVASTIGMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 1 1998, list 39.) RIVASTIGMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rivastigmine under HS 29242995 and SITC 51479. As of Q4 2014, RIVASTIGMINE remains the US FDA Preferred Term for this commodity. Rivastigmine bears US NLM identifiers UMLS ID C0649350 and NCI Concept Code C66519. SMILES: O(C1CC(C(N(C)C)C)CCC1)C(=O)N(CC)C.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C14H22N2O2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9IY2357JPE, chemically known as 2,6-dioxo-4-phenyl-piperidine-3-carbonitrile but more generally known as rivastigmine hydrogen tartrate, which bears US NIH Compound Identifier 77991. European Medicines Agency schedules Rivastigmine hydrogen tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04257MIG. Most nations, for tariff and trade purposes, schedule rivastigmine hydrogen tartrate under HS 29242995 and SITC 51479. SMILES: CCN(C)C(=O)OC1CCCC(C1)[C@H](C)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C14H22N2O2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9IY2357JPE, chemically known as carbamic acid, n-ethyl-n-methyl-, 3-((1s)-1-(dimethylamino)ethyl)phenyl ester, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more generally known as rivastigmine hydrogentartrate, which bears US NIH Compound Identifier 77990. European Medicines Agency schedules rivastigmine hydrogentartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10345MIG. Most nations, for tariff purposes, schedule rivastigmine hydrogentartrate under HS 29242995. SMILES: CCN(C)C(=O)OC1CCCC(C1)[C@H](C)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an anti-diabetic agent with the molecular formula C20H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3A3N0634Q6, chemically known as 2,4-thiazolidinedione, 5-((4-((6-methoxy-1-methyl-1h-benzimidazol-2-yl)methoxy)phenyl)methyl)-; but more generally known as rivoglitazone, which bears US NIH Compound Identifier 3055168. The term RIVOGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations, for tariff and trade purposes, schedule rivoglitazone under HS 29341000 and SITC 51579. As of Q4 2014, RIVOGLITAZONE remains US FDA's Preferred Term for this commodity. Rivoglitazone bears US NLM identifiers UMLS ID C1958863 and NCI Concept Code C72841. SMILES: CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4.
This classification denotes an anti-diabetic agent C20H19N3O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60HQU68H8A, chemically known as 2,4-thiazolidinedione, 5-((4-((6-methoxy-1-methyl-1h-benzimidazol-2-yl)methoxy)phenyl)methyl)-, hydrochloride, but more generally known as rivoglitazone hydrochloride, which bears US NIH Compound Identifier 9889104. Most nations, for tariff and trade purposes, schedule rivoglitazone hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, RIVOGLITAZONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1C2CC(CCC2NC1COC3CCC(CC3)CC4C(=O)NC(=O)S4)OC.CL.
An anti-allergy agent.
This classification denotes a serotonin agonist with the molecular formula C15H19N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51086HBW8G, chemically known as 1h-indole-3-ethanamine, n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)- but generally known as rizatriptan, which bears US NIH Compound Identifier 5078. European Medicines Agency schedules Rizatriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10346MIG. World Health Organization schedules rizatriptan in its Anatomical Therapeutic Chemical (ATC) Classification. RIZATRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rizatriptan under HS 29339990 and SITC 51577. As of Q4 2014, RIZATRIPTAN remains the US FDA Preferred Term for this commodity. Rizatriptan bears US NLM identifiers UMLS ID C0297635 and NCI Concept Code C61930. SMILES: [NH]1C2C(C(CCN(C)C)C1)CC(CC2)CN1NCNC1.
This classification denotes a serotonin agonist with the molecular formula C15H19N5.C7H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WR978S7QHH, chemically known as 1h-indole-3-ethanamine, n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)- but more generally known as rizatriptan benzoate, which bears US NIH Compound Identifier 5078. European Medicines Agency schedules Rizatriptan benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04258MIG. Most nations, for tariff and trade purposes, schedule rizatriptan benzoate under HS 29339990 and SITC 51577. As of Q4 2014, RIZATRIPTAN BENZOATE remains US FDA's Preferred Term for this commodity. Rizatriptan benzoate bears US NLM identifiers UMLS ID C0772420 and NCI Concept Code C47708. SMILES: CN(C)CCC1C[NH]C2C1CC(CC2)CN3CNCN3.C1CCC(CC1)C(=O)O.
This classification denotes a serotonin agonist 2C15H19N5.H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13RRH2218G, chemically known as 1h-indole-3-ethanamine, n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-, sulfate (2:1), monohydrate, but more generally known as rizatriptan sulfate, which bears US NIH Compound Identifier 3038519. Most nations, for tariff and trade purposes, schedule rizatriptan sulfate under HS 29339990 and SITC 51577. As of Q4 2014, RIZATRIPTAN SULFATE remains US FDA's Preferred Term for this commodity. Rizatriptan sulfate bears US NLM identifiers UMLS ID C1882957 and NCI Concept Code C66520. SMILES: CN(C)CCC1C[NH]C2C1CC(CC2)CN3CNCN3.CN(C)CCC1C[NH]C2C1CC(CC2)CN3CNCN3.O.OS(=O)(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13F4NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z588009C7C. The term ROBENACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53). Most nations schedule robenacoxib under HS 29224995 and SITC 51465. As of Q4 2014, ROBENACOXIB remains the US FDA Preferred Term for this commodity. Robenacoxib bears US NLM identifiers UMLS ID C2825257 and NCI Concept Code C80565. SMILES: CCC1=CC(=C(C=C1)NC2=C(C(=CC(=C2F)F)F)F)CC(=O)O.
This classification denotes an antiprotozoal agent with the molecular formula C15H13Cl2N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4888ME6C4E, chemically known as 1,3-bis((p-chlorobenzylidene)amino)guanidine but generally known as robenidine, which bears US NIH Compound Identifier 9570438. European Medicines Agency schedules Robenidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10348MIG. The term ROBENIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). ROBENIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule robenidine under HS 29280090 and SITC 51486. As of Q4 2014, ROBENIDINE remains the US FDA Preferred Term for this commodity. Robenidine bears US NLM identifiers UMLS ID C0035780 and NCI Concept Code C76427. SMILES: CLC1CCC(CC1)/C=N/N/C(=N/N=C/C1CCC(CL)CC1)N.
This classification denotes an antiplatelet agent with the molecular formula C26H23ClN6OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4KGX1STY2N, chemically known as 6-(o-chlorophenyl)-7,10-dihydro-1-methylthio-4h-pyrido(4,3:4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8h)-carboxy-p-anisidide but generally known as rocepafant, which bears US NIH Compound Identifier 3033963. European Medicines Agency schedules Rocepafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10350MIG. The term ROCEPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ROCEPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rocepafant under HS 29349990 and SITC 51579. As of Q4 2014, ROCEPAFANT remains the US FDA Preferred Term for this commodity. Rocepafant bears US NLM identifiers UMLS ID C2347968 and NCI Concept Code C73133. SMILES: CLC1C(C2=NCC3N(C4SC5C(CCN(C5)C(=S)NC5CCC(OC)CC5)C24)C(NN3)C)CCCC1.
This classification denotes a purine antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DF29U51Y7. European Medicines Agency schedules Rociclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10351MIG. Rociclovir generally arises in the molecular formula C15H25N5O3. The term ROCICLOVIR is an International Non-Proprietary Name or INN. ROCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rociclovir under HS 29335995 and SITC 51576. As of Q4 2014, ROCICLOVIR remains the US FDA Preferred Term for this commodity. Rociclovir bears US NLM identifiers UMLS ID C0643822 and NCI Concept Code C73204. SMILES: O(C(COC(C)C)COC(C)C)CN1C2NC(NCC2NC1)N.
This classification denotes an antispasmotic agent with the molecular formula C20H37NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VI08KS44V0, chemically known as (1,1-bicyclohexyl)-2-carboxylic acid, 1-hydroxy-, 2-(diethylamino)-1-methylethyl ester but generally known as rociverine, which bears US NIH Compound Identifier 68705. European Medicines Agency schedules Rociverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10352MIG. The term ROCIVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules rociverine in its Anatomical Therapeutic Chemical (ATC) Classification. ROCIVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rociverine under HS 29221980 and SITC 51461. As of Q4 2014, ROCIVERINE remains the US FDA Preferred Term for this commodity. Rociverine bears US NLM identifiers UMLS ID C0073547 and NCI Concept Code C90767. SMILES: OC1(C2CCCCC2)C(CCCC1)C(=O)OC(CN(CC)CC)C.
This classification denotes a nicotinic antagonist with the molecular formula C32H53N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRE554RFEZ. European Medicines Agency schedules rocuronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04260MIG. ROCURONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ROCURONIUM remains the US FDA Preferred Term for this commodity. Rocuronium bears US NLM identifiers UMLS ID C0209337 and NCI Concept Code C80999. SMILES: O(C1C2(C(C3C(C4(C(CC3)CC(O)C(N3CCOCC3)C4)C)CC2)CC1[N]1(CCCC1)CC=C)C)C(=O)C.
This classification denotes a muscle relaxant with the molecular formula C32H53N2O4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I65MW4OFHZ, chemically known as 1-allyl-1-(3alpha,17beta-dihydroxy-2beta-morpholino-5alpha-androstan-16beta-yl)pyrrolidinium bromide, 17-acetate but more generally known as rocuronium bromide, which bears US NIH Compound Identifier 60695. European Medicines Agency schedules Rocuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10353MIG. The term ROCURONIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules rocuronium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule rocuronium bromide under HS 29349990 and SITC 51579. As of Q4 2014, ROCURONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Rocuronium bromide bears US NLM identifiers UMLS ID C0591463 and NCI Concept Code C47709. SMILES: CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[BR-].
This classification denotes an anesthetic agent with the molecular formula C18H25ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9W0Z08C70V, chemically known as 1h-pyrindine-1-propanamide, n-(2-chloro-6-methylphenyl)octahydro- trans- but generally known as rodocaine, which bears US NIH Compound Identifier 71441. European Medicines Agency schedules Rodocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10354MIG. The term RODOCAINE is an International Non-Proprietary Name. RODOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rodocaine under HS 29339990 and SITC 51577. As of Q4 2014, RODOCAINE remains the US FDA Preferred Term for this commodity. Rodocaine bears US NLM identifiers UMLS ID C0603878 and NCI Concept Code C75103. SMILES: CLC1C(NC(=O)CCN2C3C(CCC3)CCC2)C(CCC1)C.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H14O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0QTW8Z7MCR, chemically known as 2(5h)-furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl- but generally known as rofecoxib, which bears US NIH Compound Identifier 5090. European Medicines Agency schedules Rofecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04261MIG. The term ROFECOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules rofecoxib in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ROFECOXIB remains the US FDA Preferred Term for this commodity. Rofecoxib bears US NLM identifiers UMLS ID C0762662 and NCI Concept Code C1832. SMILES: S(=O)(=O)(C1CCC(C2=C(C3CCCCC3)C(=O)OC2)CC1)C.
This classification denotes an antidepressant agent with the molecular formula C13H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 146D7G2I94, chemically known as 2,6,7,8-tetrahydro-7-phenylpyrrolo(1,2-a)pyrimidin-4(3h)-one but generally known as rofelodine, which bears US NIH Compound Identifier 71152. European Medicines Agency schedules Rofelodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10356MIG. The term ROFELODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). ROFELODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rofelodine under HS 29335995 and SITC 51576. As of Q4 2014, ROFELODINE remains the US FDA Preferred Term for this commodity. Rofelodine bears US NLM identifiers UMLS ID C2699092 and NCI Concept Code C75176. SMILES: O=C1N2CC(CC2=NCC1)c1ccccc1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H34F2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9IQ7GVL3E, chemically known as 6 alpha, 9-difluoro-11 beta, 16 alpha, 17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic (r)-16,17-acetal with butyraldehyde. but generally known as rofleponide, which bears US NIH Compound Identifier 3055174. European Medicines Agency schedules Rofleponide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10357MIG. The term ROFLEPONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ROFLEPONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rofleponide under HS 29372900 and SITC 54153. As of Q4 2014, ROFLEPONIDE remains the US FDA Preferred Term for this commodity. Rofleponide bears US NLM identifiers UMLS ID C2699093 and NCI Concept Code C77006. SMILES: FC12C(C3C(C4(OC(OC4C3)CCC)C(=O)CO)(CC1O)C)CC(F)C1=CC(=O)CCC21C.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H14Cl2F2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0P6C6ZOP5U, chemically known as 3-cyclopropylmethoxy-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide but generally known as roflumilast, which bears US NIH Compound Identifier 449193. European Medicines Agency schedules Roflumilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10358MIG. The term ROFLUMILAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). World Health Organization schedules roflumilast in its Anatomical Therapeutic Chemical (ATC) Classification. ROFLUMILAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roflumilast under HS 29333999 and SITC 51574. As of Q4 2014, ROFLUMILAST remains the US FDA Preferred Term for this commodity. Roflumilast bears US NLM identifiers UMLS ID C0965618 and NCI Concept Code C76890. SMILES: CLC1C(NC(=O)C2CC(OCC3CC3)C(OC(F)F)CC2)C(CL)CNC1.
This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 14P4QR28QF, chemically known as 2,6-piperidinedione, 3-ethyl-3-(4-pyridinyl)- but generally known as rogletimide, which bears US NIH Compound Identifier 56487. European Medicines Agency schedules Rogletimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10360MIG. The term ROGLETIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). ROGLETIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rogletimide under HS 29333999 and SITC 51574. As of Q4 2014, ROGLETIMIDE remains the US FDA Preferred Term for this commodity. Rogletimide bears US NLM identifiers UMLS ID C0164550 and NCI Concept Code C1427. SMILES: CCC1(CCC(=O)NC1=O)C2=CC=NC=C2.
This classification denotes a miocamycin analog and leucomycin with the molecular formula C42H69NO15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZPT03UEM0E, chemically known as leucomycin v, 4(sup b)-butanoate 3(sup b)-propanoate but generally known as rokitamycin, which bears US NIH Compound Identifier 5282211. European Medicines Agency schedules Rokitamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10361MIG. World Health Organization schedules rokitamycin in its Anatomical Therapeutic Chemical (ATC) Classification. ROKITAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rokitamycin under HS 29419000 and SITC 54139. As of Q4 2014, ROKITAMYCIN remains the US FDA Preferred Term for this commodity. SMILES: O(C1C(N(C)C)C(O)C(OC1C)OC1C(CC(C(O)C=CC=CCC(OC(=O)CC(O)C1OC)C)C)CC=O)C1OC(C(OC(=O)CCC)C(OC(=O)CC)(C1)C)C.
This classification denotes an antidiarrheal agent with the molecular formula C9H16N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M3NG13839, chemically known as 1h-pyrrole-1-acetamide, n-(aminoiminomethyl)-2,5-dihydro-2,5-dimethyl-, trans but generally known as rolgamidine, which bears US NIH Compound Identifier 3055175. European Medicines Agency schedules Rolgamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10364MIG. The term ROLGAMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). ROLGAMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rolgamidine under HS 29339990 and SITC 51577. As of Q4 2014, ROLGAMIDINE remains the US FDA Preferred Term for this commodity. Rolgamidine bears US NLM identifiers UMLS ID C2699094 and NCI Concept Code C75194. SMILES: O=C(/N=C(/N)N)CN1C(C=CC1C)C.
This classification denotes a sedative and hypnotic with the molecular formula C16H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 183O9O9JE3, chemically known as pyrrolidine, 1-(1-phenylcyclohexyl)- but generally known as rolicyclidine, which bears US NIH Compound Identifier 62436. European Medicines Agency schedules Rolicyclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10365MIG. The term ROLICYCLIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). ROLICYCLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rolicyclidine under HS 29339990 and SITC 51577. As of Q4 2014, ROLICYCLIDINE remains the US FDA Preferred Term for this commodity. Rolicyclidine bears US NLM identifiers UMLS ID C2699095 and NCI Concept Code C74374. SMILES: N1(C2(CCCCC2)C2CCCCC2)CCCC1.
This classification denotes a tetracycline antibiotic with the molecular formula C27H33N3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GH9IW85221, chemically known as tetracycline, n-(pyrrolidinylmethyl)- but generally known as rolitetracycline, which bears US NIH Compound Identifier 5282179. European Medicines Agency schedules Rolitetracycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10368MIG. The term ROLITETRACYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules rolitetracycline in its Anatomical Therapeutic Chemical (ATC) Classification. ROLITETRACYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rolitetracycline under HS 29413000 and SITC 54133. As of Q4 2014, ROLITETRACYCLINE remains the US FDA Preferred Term for this commodity. Rolitetracycline bears US NLM identifiers UMLS ID C0035823 and NCI Concept Code C80801. SMILES: OC12C(CC3C(O)(C4C(C(=C3C1=O)O)C(O)CCC4)C)C(N(C)C)C(=O)C(=C(\O)NCN1CCCC1)\C2=O.
This classification denotes a tetracycline antibiotic with the molecular structure 2C27H33N3O8.2HNO3.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, TG72BS085Y chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-n-(1-pyrrolidinylmethyl)-, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, mononitrate (salt), sesquihydrate, but more commonly known as rolitetracycline nitrate, which bears US NIH Compound Identifier 5282178. European Medicines Agency schedules Rolitetracycline nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04262MIG. Most nations, for tariff and trade purposes, schedule rolitetracycline nitrate under HS 29413000 and SITC 54133. As of Q4 2014, ROLITETRACYCLINE NITRATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)NCN5CCCC5)O)N(C)C)O)O)O)O.C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)NCN5CCCC5)O)N(C)C)O)O)O)O.[N+](=O)(O)[O-].[N+](=O)(O)[O-].O.O.O.
This classification denotes a tetracycline antibiotic with the molecular formula C27H33N3O8.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 496ESB4HTE, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-n-(1-pyrrolidinylmethyl)-, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, mononitrate (salt),, but more generally known as rolitetracycline nitrate anhydrous, which bears US NIH Compound Identifier 5360293. European Medicines Agency schedules rolitetracycline nitrate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10368MIG. Most nations, for tariff purposes, schedule rolitetracycline nitrate anhydrous under HS 29413000. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)NCN5CCCC5)O)N(C)C)O)O)O)O.[N+](=O)(O)[O-].
This classification denotes a neuroprotective agent with the molecular formula C7H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RES9I0LGG5, chemically known as 3,5-dioxopyrrolizidine but generally known as rolziracetam, which bears US NIH Compound Identifier 71893. European Medicines Agency schedules Rolziracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10370MIG. The term ROLZIRACETAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). ROLZIRACETAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rolziracetam under HS 29337900 and SITC 51561. As of Q4 2014, ROLZIRACETAM remains the US FDA Preferred Term for this commodity. Rolziracetam bears US NLM identifiers UMLS ID C0632468 and NCI Concept Code C80998. SMILES: O=C1N2C(CCC2=O)CC1.
This classification denotes an antineoplastic antibiotic and depsipeptide with the molecular formula C24H36N4O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CX3T89XQBK, chemically known as l-valine, n-((3s,4e)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-d-valyl-d-cysteinyl-(2z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide but generally known as romidepsin, which bears US NIH Compound Identifier 5352062. European Medicines Agency schedules Romidepsin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26362. World Health Organization schedules romidepsin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule romidepsin under HS 29349990 and SITC 51579. As of Q4 2014, ROMIDEPSIN remains the US FDA Preferred Term for this commodity. Romidepsin bears US NLM identifiers UMLS ID C1527027 and NCI Concept Code C1544. SMILES: S1SCCC=CC2OC(=O)C(NC(=O)C(=C\C)\NC(=O)C(NC(=O)C(NC(=O)C2)C(C)C)C1)C(C)C.
This classification denotes a serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 876351L05K. European Medicines Agency schedules Romifidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10374MIG. Romifidine generally arises in the molecular formula C9H9BRFN3. The term ROMIFIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) ROMIFIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule romifidine under HS 29332990 and SITC 51573. As of Q4 2014, ROMIFIDINE remains the US FDA Preferred Term for this commodity. Romifidine bears US NLM identifiers UMLS ID C0171473 and NCI Concept Code C74389. SMILES: BRC1C(NC2=NCCN2)C(F)CCC1.
This classification denotes a therapeutic colony stimulating factor with the molecular formula C1317H2043N361O395S9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GN5XU2DXKV, more generally known as romiplostim. European Medicines Agency schedules romiplostim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27756. The term ROMIPLOSTIM is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 22, no. 1, 2008, list 59. As of Q4 2014, ROMIPLOSTIM remains the US FDA Preferred Term for this commodity.
This classification denotes an anti-lipidemic agent with the molecular formula C19H20ClNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W86I18X716, chemically known as 3-pyridinecarboxylic acid, 3-(2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy)propyl ester but generally known as ronifibrate, which bears US NIH Compound Identifier 68671. European Medicines Agency schedules Ronifibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10378MIG. The term RONIFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules ronifibrate in its Anatomical Therapeutic Chemical (ATC) Classification. RONIFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ronifibrate under HS 29333999 and SITC 51574. As of Q4 2014, RONIFIBRATE remains the US FDA Preferred Term for this commodity. Ronifibrate bears US NLM identifiers UMLS ID C2347974 and NCI Concept Code C72995. SMILES: Clc1ccc(OC(C)(C)C(=O)OCCCOC(=O)c2cccnc2)cc1.
This classification denotes an antiparkinsonian agent with the molecular formula C16H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 030PYR8953, chemically known as 4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one but generally known as ropinirole, which bears US NIH Compound Identifier 5095. European Medicines Agency schedules Ropinirole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10380MIG. The term ROPINIROLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules ropinirole in its Anatomical Therapeutic Chemical (ATC) Classification. ROPINIROLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ropinirole under HS 29337900 and SITC 51561. As of Q4 2014, ROPINIROLE remains the US FDA Preferred Term for this commodity. Ropinirole bears US NLM identifiers UMLS ID C0244821 and NCI Concept Code C61931. SMILES: O=C1NC2C(C(CCN(CCC)CCC)CCC2)C1.
This classification denotes an antiparkinsonian agent with the molecular formula C16H24N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D7ZD41RZI9, chemically known as 4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one but more generally known as ropinirole hydrochloride, which bears US NIH Compound Identifier 5095. European Medicines Agency schedules Ropinirole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15144MIG. Most nations, for tariff and trade purposes, schedule ropinirole hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, ROPINIROLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ropinirole hydrochloride bears US NLM identifiers UMLS ID C0771840 and NCI Concept Code C47710. SMILES: CCCN(CCC)CCC1CCCC2C1CC(=O)N2.CL.
This classification denotes an immunosuppressant with the molecular formula C17H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IO5LYA57N, chemically known as n-(2,6-dimethylphenyl)-1-propyl-piperidine-2-carboxamide but generally known as ropivacaine, which bears US NIH Compound Identifier 71273. European Medicines Agency schedules Ropivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10382MIG. The term ROPIVACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules ropivacaine in its Anatomical Therapeutic Chemical (ATC) Classification. ROPIVACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ropivacaine under HS 29333999 and SITC 51574. As of Q4 2014, ROPIVACAINE remains the US FDA Preferred Term for this commodity. Ropivacaine bears US NLM identifiers UMLS ID C0073571 and NCI Concept Code C61932. SMILES: O=C(NC1C(CCCC1C)C)C1N(CCCC1)CCC.
This classification denotes a local anesthetic and amide with the molecular formula C17H26N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V910P86109, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-propyl-, monohydrochloride, (s)- but more generally known as ropivacaine hydrochloride, which bears US NIH Compound Identifier 175804. European Medicines Agency schedules Ropivacaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04264MIG. Most nations, for tariff and trade purposes, schedule ropivacaine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, ROPIVACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ropivacaine hydrochloride bears US NLM identifiers UMLS ID C0771826 and NCI Concept Code C52198. SMILES: CCCN1CCCC[C@H]1C(=O)NC2C(CCCC2C)C.O.CL.
This classification denotes an immunosuppressant with the molecular formula C17H26N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V910P86109, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-propyl-, monohydrochloride, (s)- but more generally known as ropivacaine hydrochloride, which bears US NIH Compound Identifier 175804. European Medicines Agency schedules Ropivacaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04264MIG. Most nations, for tariff and trade purposes, schedule ropivacaine hydrochloride monohydrate under HS 29333999 and SITC 51574. SMILES: CCCN1CCCC[C@H]1C(=O)NC2C(CCCC2C)C.O.CL.
This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q5128GW9D4. European Medicines Agency schedules Ropizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10383MIG. Ropizine generally arises in the molecular formula C24H26N4. The term ROPIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) ROPIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ropizine under HS 29335995 and SITC 51576. As of Q4 2014, ROPIZINE remains the US FDA Preferred Term for this commodity. Ropizine bears US NLM identifiers UMLS ID C0073572 and NCI Concept Code C75166. SMILES: N1(C(C2CCCCC2)C2CCCCC2)CCN(/N=C/C2NC(CCC2)C)CC1.
This classification denotes an immunostimulant and angiogenesis activator inhibitor with the molecular formula C18H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 372T2944C0, chemically known as 1,2-dihydro-4-hydroxy-n,1-dimethyl-2-oxo-3-quinolinecarboxanilide but generally known as roquinimex, which bears US NIH Compound Identifier 55197. European Medicines Agency schedules Roquinimex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10384MIG. The term ROQUINIMEX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules roquinimex in its Anatomical Therapeutic Chemical (ATC) Classification. ROQUINIMEX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roquinimex under HS 29337900 and SITC 51561. As of Q4 2014, ROQUINIMEX remains the US FDA Preferred Term for this commodity. Roquinimex bears US NLM identifiers UMLS ID C0244748 and NCI Concept Code C1519. SMILES: OC1N(C2C(C(=O)C1C(=O)N(C1CCCCC1)C)CCCC2)C.
This classification denotes a dye with the molecular formula C20H2Cl4I4O5.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 956575SN5L, chemically known as 4,5,6,7-tetrachloro-2,4,5,7-tetraiodofluorescein disodium salt but more generally known as rose bengal sodium, which bears U.S. National Institutes of Health Compound Identifier 69438. European Medicines Agency schedules Rose bengal sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15149MIG. World Health Organization schedules rose bengal sodium in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1=C2C(=C3C=C(C(=O)C(=C3OC2=C(C(=C1I)[O-])I)I)I)C4=C(C(=C(C(=C4Cl)Cl)Cl)Cl)C(=O)[O-].[Na+].[Na+].
This classification denotes a differentiation inducer and anti-diabetic agent with the molecular formula C18H19N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 05V02F2KDG, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)- but more generally known as rosiglitazone, which bears US NIH Compound Identifier 77999. European Medicines Agency schedules Rosiglitazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10388MIG. The term ROSIGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 No. 2 1999, List 40) WHO schedules rosiglitazone in its Anatomical Therapeutic Chemical (ATC) Classification. ROSIGLITAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule rosiglitazone under HS 29341000 and SITC 51579. As of Q4 2014, ROSIGLITAZONE remains US FDA's Preferred Term for this commodity. Rosiglitazone bears US NLM identifiers UMLS ID C0289313 and NCI Concept Code C62076. SMILES: S1C(CC2CCC(OCCN(C3NCCCC3)C)CC2)C(=O)NC1=O.
This classification denotes a vasodilator agent, fibrinolytic agent, and hypoglycemic agent with the molecular formula C18H19N3O3S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KX2339DP44, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)- but more generally known as rosiglitazone maleate, which bears US NIH Compound Identifier 77999. European Medicines Agency schedules Rosiglitazone maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04274MIG. Most nations, for tariff and trade purposes, schedule rosiglitazone maleate under HS 29341000 and SITC 51579. As of Q4 2014, ROSIGLITAZONE MALEATE remains US FDA's Preferred Term for this commodity. Rosiglitazone maleate bears US NLM identifiers UMLS ID C0795660 and NCI Concept Code C2583. SMILES: CN(CCOC1CCC(CC1)CC2C(=O)NC(=O)S2)C3CCCCN3.C(=C\C(=O)O)\C(=O)O.
This classification denotes a quinolone antibiotic with the molecular formula C17H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Y1OT3J4NW, chemically known as 3-quinolinecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- but generally known as rosoxacin, which bears US NIH Compound Identifier 287180. European Medicines Agency schedules Rosoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10389MIG. The term ROSOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules rosoxacin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule rosoxacin under HS 29334910 and SITC 51575. As of Q4 2014, ROSOXACIN remains the US FDA Preferred Term for this commodity. Rosoxacin bears US NLM identifiers UMLS ID C0073591 and NCI Concept Code C76232. SMILES: O=C1C2C(N(CC)CC1C(=O)O)CC(CC2)C1CCNCC1.
This classification denotes a therapeutic androgen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L5C5C8ZNG. European Medicines Agency schedules Rosterolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10390MIG. Rosterolone generally arises in the molecular formula C23H38O2. The term ROSTEROLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) ROSTEROLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rosterolone under HS 29372900 and SITC 54153. As of Q4 2014, ROSTEROLONE remains the US FDA Preferred Term for this commodity. Rosterolone bears US NLM identifiers UMLS ID C2347981 and NCI Concept Code C72099. SMILES: OC1(C2(C(C3C(C4(C(CC3)CC(=O)CC4C)C)CC2)CC1)C)CCC.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C22H28FN3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 413KH5ZJ73, chemically known as (3r,5s,6e)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid but generally known as rosuvastatin, which bears US NIH Compound Identifier 446157. European Medicines Agency schedules Rosuvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20634. The term ROSUVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules rosuvastatin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule rosuvastatin under HS 29350090 and SITC 51580. As of Q4 2014, ROSUVASTATIN remains the US FDA Preferred Term for this commodity. Rosuvastatin bears US NLM identifiers UMLS ID C0965129 and NCI Concept Code C66523. SMILES: S(=O)(=O)(N(c1nc(C(C)C)c(c(n1)c1ccc(F)cc1)/C=C/C(O)CC(O)CC(=O)O)C)C.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula 2C22H27FN3O6S.CA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83MVU38M7Q. European Medicines Agency schedules rosuvastatin calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20721. The term rosuvastatin calcium is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule rosuvastatin calcium under HS 29350090 and SITC 51580. As of Q4 2014, ROSUVASTATIN CALCIUM remains US FDA's Preferred Term for this commodity. Rosuvastatin calcium bears US NLM identifiers UMLS ID C1101751 and NCI Concept Code C61933. SMILES: CC(C1NC(NC(C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2CCC(CC2)F)N(S(=O)(=O)C)C)C.CC(C1NC(NC(C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2CCC(CC2)F)N(S(=O)(=O)C)C)C.[CA+2].
This classification denotes a hmg-coa reductase inhibitor 2C22H27FN3O6S.Zn, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70VE4E19Z7, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, zinc salt (2:1), (3r,5s,6e)-, but more generally known as rosuvastatin zinc, which bears US NIH Compound Identifier 56842257. Most nations, for tariff and trade purposes, schedule rosuvastatin zinc under HS 29350090 and SITC 51580. As of Q4 2014, ROSUVASTATIN ZINC remains US FDA's Preferred Term for this commodity. Rosuvastatin zinc bears US NLM identifiers UMLS ID C3272708 and NCI Concept Code C96308. SMILES: CC(C1NC(NC(C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2CCC(CC2)F)N(S(=O)(=O)C)C)C.CC(C1NC(NC(C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2CCC(CC2)F)N(S(=O)(=O)C)C)C.[ZN+2].
This classification denotes a penicillin antibiotic with the molecular formula C28H31N5O5S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier JS13873052, chemically known as (2s,5r,6r)-3,3-dimethyl-7-oxo-6-((r)-2-phenyl-2-(2-(4-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl)acetamido(acetamido-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylic acid but more generally known as rotamicillin, which bears U.S. National Institutes of Health Compound Identifier 3058737. The European Medicines Agency schedules Rotamicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10391MIG. The term ROTAMICILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). ROTAMICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(NC(=O)CC1CCC(C2=NCCCN2)CC1)C1CCCCC1.
This classification denotes a vaccine for a genus of reoviridae, causing acute gastroenteritis in birds and mammals, including humans.
This classification denotes a dopamine agonist with the molecular formula C19H25NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87T4T8BO2E, chemically known as 6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol but generally known as rotigotine, which bears US NIH Compound Identifier 57537. European Medicines Agency schedules Rotigotine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21254. The term ROTIGOTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules rotigotine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule rotigotine under HS 29349990 and SITC 51579. As of Q4 2014, ROTIGOTINE remains the US FDA Preferred Term for this commodity. Rotigotine bears US NLM identifiers UMLS ID C1700683 and NCI Concept Code C77566. SMILES: S1C(CCN(C2CCC3C(C2)CCCC3O)CCC)CCC1.
This classification denotes a dopamine agonist with the molecular formula C19H25NOS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q1W9573L2, chemically known as rotigotine hydrochloride, (-)-, but more generally known as rotigotine hydrochloride, which bears US NIH Compound Identifier 180335. European Medicines Agency schedules rotigotine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21254. Most nations, for tariff purposes, schedule rotigotine hydrochloride under HS 29349990. SMILES: CCCN(CCC1CCCS1)[C@H]2CCC3C(CCCC3O)C2.CL.
This classification denotes an anti-ulcer agent with the molecular formula C17H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KRN50N3Y2T, chemically known as benzenepropanoic acid, 4-((4-(aminomethyl)cyclohexyl)carbonyl)-, trans- but generally known as rotraxate, which bears US NIH Compound Identifier 65829. European Medicines Agency schedules Rotraxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10393MIG. The term ROTRAXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). ROTRAXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rotraxate under HS 29225000 and SITC 51467. As of Q4 2014, ROTRAXATE remains the US FDA Preferred Term for this commodity. Rotraxate bears US NLM identifiers UMLS ID C2699113 and NCI Concept Code C76490. SMILES: O=C(C1CCC(CC1)CN)C1CCC(CC1)CCC(=O)O.
This classification denotes an anti-ulcer agent and histamine h2 antagonist with the molecular formula C17H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IV9VHT3YUM, chemically known as acetamide, 2-hydroxy-n-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)- but generally known as roxatidine, which bears US NIH Compound Identifier 91276. European Medicines Agency schedules Roxatidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10396MIG. World Health Organization schedules roxatidine in its Anatomical Therapeutic Chemical (ATC) Classification. ROXATIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roxatidine under HS 29333999 and SITC 51574. As of Q4 2014, ROXATIDINE remains the US FDA Preferred Term for this commodity. SMILES: O(C1CC(CN2CCCCC2)CCC1)CCCNC(=O)CO.
This classification denotes an anabolic steroid with the molecular formula C21H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3R7NLP419C, chemically known as 11beta,17beta-dihydroxy-17-methyl-3-oxoandrosta-1,4-diene-2-carboxylic acid but generally known as roxibolone, which bears US NIH Compound Identifier 68795. European Medicines Agency schedules Roxibolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10397MIG. The term ROXIBOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). ROXIBOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roxibolone under HS 29372900 and SITC 54153. As of Q4 2014, ROXIBOLONE remains the US FDA Preferred Term for this commodity. Roxibolone bears US NLM identifiers UMLS ID C0073602 and NCI Concept Code C74110. SMILES: OC1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)C(=C2)C(=O)O)CC3)C)CC1)C)C.
This classification denotes a serotonin agonist and dopamine agonist with the molecular formula C23H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43227SMS0O, chemically known as 3-(4-(3,6-dihydro-4-phenyl-1(2h)-pyridinyl)butyl)-1h-indol-5-ol but generally known as roxindole, which bears US NIH Compound Identifier 219050. European Medicines Agency schedules Roxindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10399MIG. The term ROXINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). ROXINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roxindole under HS 29333999 and SITC 51574. As of Q4 2014, ROXINDOLE remains the US FDA Preferred Term for this commodity. Roxindole bears US NLM identifiers UMLS ID C0286106 and NCI Concept Code C90625. SMILES: Oc1cc2c(CCCCN3CCC(=CC3)c3ccccc3)c[nH]c2cc1.
This classification denotes a serotonin agonist and dopamine agonist with the molecular formula C23H26N2O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WCW8374DTW, chemically known as 1h-indol-5-ol, 3-(4-(3,6-dihydro-4-phenyl-1(2h)-pyridinyl)butyl)-, methanesulfonate (1:1), but more generally known as roxindole mesilate, which bears US NIH Compound Identifier 3035894. European Medicines Agency schedules roxindole mesilate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10399MIG. Most nations, for tariff purposes, schedule roxindole mesilate under HS 29333999. SMILES: CS(=O)(=O)O.C1CCC(CC1)C2=CCN(CC2)CCCCC3C[NH]C4C3CC(CC4)O.
This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21KOF230FA. European Medicines Agency schedules Roxithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10400MIG. Roxithromycin generally arises in the molecular formula C41H76N2O15. The term ROXITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) ROXITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roxithromycin under HS 29415000 and SITC 54139. As of Q4 2014, ROXITHROMYCIN remains the US FDA Preferred Term for this commodity. Roxithromycin bears US NLM identifiers UMLS ID C0035891 and NCI Concept Code C818. SMILES: O(C1C(C(OC2OC(C(O)C(OC)(C2)C)C)C(C(=O)OC(C(O)(C(O)C(C(=N\OCOCCOC)/C(CC1(O)C)C)C)C)CC)C)C)C1OC(CC(N(C)C)C1O)C.
This classification denotes an anxiolytic with the molecular formula C19H23FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RS1CY853F, chemically known as 2,8-diazaspiro(4.5)decane-1,3-dione, 8-(4-(4-fluorophenyl)-4-oxobutyl)-2-methyl- (9ci) but generally known as roxoperone, which bears US NIH Compound Identifier 71117. European Medicines Agency schedules Roxoperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10402MIG. The term ROXOPERONE is an International Non-Proprietary Name. ROXOPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roxoperone under HS 29333999 and SITC 51574. As of Q4 2014, ROXOPERONE remains the US FDA Preferred Term for this commodity. Roxoperone bears US NLM identifiers UMLS ID C2699117 and NCI Concept Code C76446. SMILES: FC1CCC(C(=O)CCCN2CCC3(CC2)CC(=O)N(C3=O)C)CC1.
This classification denotes a combination vaccine. The first component of this combination vaccine addresses that acute infectious disease caused by the rubella virus, of type species of rubivirus causing acute infection in humans, primarily children and young adults, and which enters the respiratory tract via airborne droplet and spreads to the lymphatic system. The second component of this combination vaccine addresses an acute infectious disease caused by rubulavirus (a genus of the family paramyxoviridae and subfamily paramyxovirinae, where all the species have hemagglutinin and neuraminidase activities but lack a C protein), which is spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected.
This classification denotes a vaccine that addresses that acute infectious disease caused by the rubella virus, of type species of rubivirus causing acute infection in humans, primarily children and young adults, and which enters the respiratory tract via airborne droplet and spreads to the lymphatic system.
This classification denotes a camptothecin analogue with the molecular formula C20H15N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H19C446XXB, chemically known as 4-ethyl-4-hydroxy-9-nitro-1h-pyrano(3,4:6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione but generally known as rubitecan, which bears US NIH Compound Identifier 123613. European Medicines Agency schedules Rubitecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33089. The term RUBITECAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule rubitecan under HS 29399900 and SITC 54149. As of Q4 2014, RUBITECAN remains the US FDA Preferred Term for this commodity. Rubitecan bears US NLM identifiers UMLS ID C0213800 and NCI Concept Code C1485. SMILES: O1CC2C(C(O)(CC)C1=O)CC1N(CC3C1NC1C(C3)C([N](=O)O)CCC1)C2=O.
This classification denotes an anticonvulsant agent with the molecular formula C10H8F2N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WFW942PR79, chemically known as 1h-1,2,3-triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)- but generally known as rufinamide, which bears US NIH Compound Identifier 129228. European Medicines Agency schedules Rufinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10403MIG. The term RUFINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules rufinamide in its Anatomical Therapeutic Chemical (ATC) Classification. RUFINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rufinamide under HS 29339990 and SITC 51577. As of Q4 2014, RUFINAMIDE remains the US FDA Preferred Term for this commodity. Rufinamide bears US NLM identifiers UMLS ID C0213404 and NCI Concept Code C75167. SMILES: C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F.
This classification denotes a quinolone antibiotic with the molecular formula C17H18FN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y521XM2900, chemically known as 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzothiazine-6-carboxylic acid but generally known as rufloxacin, which bears US NIH Compound Identifier 58258. European Medicines Agency schedules Rufloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10404MIG. The term RUFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules rufloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. RUFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rufloxacin under HS 29349990 and SITC 51579. As of Q4 2014, RUFLOXACIN remains the US FDA Preferred Term for this commodity. Rufloxacin bears US NLM identifiers UMLS ID C0073704 and NCI Concept Code C72638. SMILES: S1C2C(N3CCN(CC3)C)C(F)CC3C2N(CC1)CC(C3=O)C(=O)O.
This classification denotes an antineoplastic antibiotic with the molecular structure C25H22N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 261Q3JB310 chemically known as 2-pyridinecarboxylic acid, 5-amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolinyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl- but generally known as rufocromomycin, which bears US NIH Compound Identifier 5323583. European Medicines Agency schedules Rufocromomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10405MIG. The term RUFOCROMOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15. ). Rufocromomycin or streptonigrin bears US NLM identifiers UMLS ID C0038427 and NCI Concept Code C844. SMILES: O(C1=C(OC)C=CC(=C2\C(C([NH]C(C2N)C2NC3C(CC2)C(=O)C(=C(N)C3=O)OC)C(=O)O)C)\C1=O)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H26ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2AE8M83G3E, chemically known as 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridyl)methyl)-4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine but generally known as rupatadine, which bears US NIH Compound Identifier 133017. European Medicines Agency schedules Rupatadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10406MIG. The term RUPATADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules rupatadine in its Anatomical Therapeutic Chemical (ATC) Classification. RUPATADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rupatadine under HS 29333999 and SITC 51574. As of Q4 2014, RUPATADINE remains the US FDA Preferred Term for this commodity. Rupatadine bears US NLM identifiers UMLS ID C0534301 and NCI Concept Code C73055. SMILES: CLC1CC2C(/C(=C3\CCN(CC3)CC3CC(CNC3)C)C3NCCCC3CC2)CC1.
This classification denotes a histamine-1 receptor antagonist C26H26ClN3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XJ6OT32M93, chemically known as 5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-, (2e)-2-butenedioate (1:1), but more generally known as rupatadine fumarate, which bears US NIH Compound Identifier 6449107. European Medicines Agency schedules Rupatadine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22090. Most nations, for tariff and trade purposes, schedule rupatadine fumarate under HS 29333999 and SITC 51574. As of Q4 2014, RUPATADINE FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC(CNC1)CN2CCC(=C3C4CCC(CC4CCC5C3NCCC5)CL)CC2.C(=C/C(=O)O)\C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O5U67O8927, chemically known as pyruvic acid, o-ethoxybenzoylhydrazone but generally known as ruvazone, which bears US NIH Compound Identifier 9570360. European Medicines Agency schedules Ruvazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10408MIG. The term RUVAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). RUVAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ruvazone under HS 29280090 and SITC 51486. As of Q4 2014, RUVAZONE remains the US FDA Preferred Term for this commodity. Ruvazone bears US NLM identifiers UMLS ID C0073726 and NCI Concept Code C90906. SMILES: CCOC1=CC=CC=C1C(=O)N/N=C(\C)/C(=O)O.
A type of kinase Inhibitor used to treat myelofibrosis.
This classification denotes a natural antidiarrheal agent.
This classification denotes a glycoside hydrolase found primarily in plants and yeasts, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A7F670F2Y, chemically known as .beta.-fructofuranosidase but generally known as Sacrosidase. European Medicines Agency schedules Sacrosidase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB38353. World Health Organization schedules bismuth subcitrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SACROSIDASE remains the US FDA Preferred Term for this commodity.
This classification denotes a calcium channel blocker with the molecular formula C27H31FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 20O65J0B72, chemically known as methyl (5-piperidinomethyl)furfuryl 4-(o-fluorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate. but generally known as sagandipine, which bears US NIH Compound Identifier 3058740. European Medicines Agency schedules Sagandipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10414MIG. The term SAGANDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). SAGANDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sagandipine under HS 29349990 and SITC 51579. As of Q4 2014, SAGANDIPINE remains the US FDA Preferred Term for this commodity. Sagandipine bears US NLM identifiers UMLS ID C2348129 and NCI Concept Code C73028. SMILES: Fc1c(C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OCc2oc(CN3CCCCC3)cc2)cccc1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C9H9NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7G29CRR596, chemically known as salicylamide, n-acetyl- but generally known as salacetamide, which bears US NIH Compound Identifier 10252. European Medicines Agency schedules Salacetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10415MIG. The term SALACETAMIDE is an International Non-Proprietary Name. SALACETAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule salacetamide under HS 29242995 and SITC 51479. As of Q4 2014, SALACETAMIDE remains the US FDA Preferred Term for this commodity. Salacetamide bears US NLM identifiers UMLS ID C2348130 and NCI Concept Code C72126. SMILES: OC1C(CCCC1)C(=O)NC(=O)C.
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HJ57229JPX. European Medicines Agency schedules Salafibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10416MIG. Salafibrate generally arises in the molecular formula C32H32CL2O10. The term SALAFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) SALAFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule salafibrate under HS 29182200 and SITC 51393. As of Q4 2014, SALAFIBRATE remains the US FDA Preferred Term for this commodity. Salafibrate bears US NLM identifiers UMLS ID C2348131 and NCI Concept Code C72996. SMILES: Clc1ccc(OC(C(=O)OCC(OC(=O)c2c(OC(=O)C)cccc2)COC(=O)C(Oc2ccc(Cl)cc2)(C)C)(C)C)cc1.
This classification denotes an antihelminthic agent with the molecular formula C20H11Cl2I2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BIY8B0682Q, chemically known as 3-chloro-4-(p-chlorobenzoyl)-3,5-diiodosalicylanilide but generally known as salantel, which bears US NIH Compound Identifier 185463. European Medicines Agency schedules Salantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10417MIG. The term SALANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). SALANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule salantel under HS 29242995 and SITC 51479. As of Q4 2014, SALANTEL remains the US FDA Preferred Term for this commodity. Salantel bears US NLM identifiers UMLS ID C2348132 and NCI Concept Code C72147. SMILES: IC1C(O)C(C(=O)NC2CC(CL)C(CC2)C(=O)C2CCC(CL)CC2)CC(I)C1.
This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 56PE10F2EA. The European Medicines Agency schedules Salazosulfathiazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10421MIG. Salazosulfathiazole generally arises in the molecular formula C16H12N4O5S2. The term SALAZOSULFATHIAZOLE is an International Non-Proprietary Name or INN. SALAZOSULFATHIAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(NC1SCCN1)C1CCC(N/N=C2/C=C(C(=O)C=C2)C(=O)O)CC1.
This classification denotes an analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4649620TBZ. European Medicines Agency schedules Salicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15176MIG. Salicin generally arises in the molecular formula C13H18O7. The term 'salicin' is an International Nomenclature of Cosmetic Ingredients designation. As of Q4 2014, SALICIN remains the US FDA Preferred Term for this commodity. Salicin bears US NLM identifiers UMLS ID C0073969 and NCI Concept Code C90648. SMILES: O1C(C(O)C(O)C(O)C1OC1CC(CCC1)CO)CO.
This classification denotes an anesthetic agent with the molecular formula C7H8O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FA1N0842KB, chemically known as toluene,alpha,2-dihydroxy but generally known as salicyl alcohol, which bears US NIH Compound Identifier 5146. European Medicines Agency schedules Salicyl alcohol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15177MIG. Most nations schedule salicyl alcohol under HS 29072900 and SITC 51243. As of Q4 2014, SALICYL ALCOHOL remains the US FDA Preferred Term for this commodity. Salicyl alcohol bears US NLM identifiers UMLS ID C0073970 and NCI Concept Code C81408. SMILES: C1=CC=C(C(=C1)CO)O.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EM8BM710ZC. European Medicines Agency schedules Salicylamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Salicylamide generally arises in the molecular formula C7H7NO2. The term SALICYLAMIDE is an International Non-Proprietary Name or INN. SALICYLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule salicylamide under HS 29242995 and SITC 51479. As of Q4 2014, SALICYLAMIDE remains the US FDA Preferred Term for this commodity. Salicylamide bears US NLM identifiers UMLS ID C0036071 and NCI Concept Code C80566. SMILES: OC1C(CCCC1)C(=O)N.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H6NO2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OZV98V4536, chemically known as benzamide, 2-hydroxy-, monosodium salt, but more generally known as salicylamide sodium, which bears US NIH Compound Identifier 17431. European Medicines Agency schedules salicylamide sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10426MIG. Most nations, for tariff purposes, schedule salicylamide sodium under HS 29242995. SMILES: C1CCC(C(C1)C(=O)N)[O-].[NA+].
This classification denotes an anti-infective agent with the molecular formula C7H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O414PZ4LPZ, chemically known as silver salicylate, ag (c7h5o3) but generally known as salicylic acid, which bears US NIH Compound Identifier 338. European Medicines Agency schedules Salicylic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15180MIG. World Health Organization schedules salicylic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule salicylic acid under HS 29182100 and SITC 51393. As of Q4 2014, SALICYLIC ACID remains the US FDA Preferred Term for this commodity. Salicylic acid bears US NLM identifiers UMLS ID C0036079 and NCI Concept Code C61934. SMILES: C1=CC=C(C(=C1)C(=O)O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H10O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9MO595C9I, chemically known as salicylic acid, salicylate but generally known as salsalate, which bears US NIH Compound Identifier 5161. European Medicines Agency schedules Salsalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10434MIG. The term SALSALATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules salsalate in its Anatomical Therapeutic Chemical (ATC) Classification. SALSALATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Salicylsalicylic acid or salsalate bears US NLM identifiers UMLS ID C0073983 and NCI Concept Code C62636. SMILES: C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O.
This classification denotes an antibiotic, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 62UXS86T64. The European Medicines Agency schedules Salinomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10428MIG. Salinomycin generally arises in the molecular formula C42H70O11. The term SALINOMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 31, no10, 1977, list 17.) SALINOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1C(CCC21OC1(OC(C(CC1C)C)C(C(=O)C(C(O)C(C1OC(CCC1C)C(CC)C(=O)O)C)C)CC)C=CC2O)(C1OC(C(O)(CC1)CC)C)C.
This classification denotes preparations designed to lubricate the mouth, or to remedy dryness thereof.
This classification denotes a beta-adrenergic agonist with the molecular formula C19H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q56SEY8X9J, chemically known as 1,3-benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((2-(4-methoxyphenyl)-1-methylethyl)amino)methyl)- but generally known as salmefamol, which bears US NIH Compound Identifier 86805. European Medicines Agency schedules Salmefamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10429MIG. The term SALMEFAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). SALMEFAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule salmefamol under HS 29225000 and SITC 51467. As of Q4 2014, SALMEFAMOL remains the US FDA Preferred Term for this commodity. Salmefamol bears US NLM identifiers UMLS ID C0073991 and NCI Concept Code C76547. SMILES: OC(CNC(CC1CCC(OC)CC1)C)C1CC(C(O)CC1)CO.
This classification denotes a bronchodilator with the molecular formula C25H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2I4BC502BT, chemically known as 1,3-benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)- but generally known as salmeterol, which bears US NIH Compound Identifier 5152. European Medicines Agency schedules Salmeterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10430MIG. The term SALMETEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules salmeterol in its Anatomical Therapeutic Chemical (ATC) Classification. SALMETEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule salmeterol under HS 29225000 and SITC 51467. As of Q4 2014, SALMETEROL remains the US FDA Preferred Term for this commodity. Salmeterol bears US NLM identifiers UMLS ID C0073992 and NCI Concept Code C29443. SMILES: O(CCCCCCNCC(O)C1CC(C(O)CC1)CO)CCCCC1CCCCC1.
This classification denotes an antihelminthic agent with the molecular formula C15H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1VL8J38ERO, chemically known as 11-epiisoeusantona-1,4-dienic acid, 6alpha-hydroxy-3-oxo-, gamma-lactone but generally known as alpha-santonin, which bears US NIH Compound Identifier 10201. European Medicines Agency schedules Santonin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15192MIG. As of Q4 2014, SANTONIN remains the US FDA Preferred Term for this commodity. Santonin bears US NLM identifiers UMLS ID C0036179 and NCI Concept Code C87627. SMILES: CC1C2CCC3(C=CC(=O)C(=C3C2OC1=O)C)C.
This classification denotes an antifungal agent with the molecular formula C35H38F2N8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R2I5PI29CA, chemically known as 3h-1,2,4-triazol-3-one, 4-(4-(4-(4-((2-(2,4-difluorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-2,4-dihydro-2-(1-methylpropyl)- but generally known as saperconazole, which bears US NIH Compound Identifier 60456. European Medicines Agency schedules Saperconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10443MIG. The term SAPERCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). SAPERCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule saperconazole under HS 29349990 and SITC 51579. As of Q4 2014, SAPERCONAZOLE remains the US FDA Preferred Term for this commodity. Saperconazole bears US NLM identifiers UMLS ID C0074037 and NCI Concept Code C1221. SMILES: FC1C(C2(OC(CO2)COC2CCC(N3CCN(CC3)C3CCC(N4C(=O)N(NC4)C(CC)C)CC3)CC2)CN2NCNC2)CCC(F)C1.
This classification denotes an antioxidant with the molecular formula C9H15N5O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EGX657432I, chemically known as 5,6,7,8-tetrahydrobiopterin but more generally known as sapropterin, which bears U.S. NIH Compound Identifier 1125. European Medicines Agency schedules Sapropterin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10445MIG. The term SAPROPTERIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules sapropterin in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. SAPROPTERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a protease inhibitor with the molecular formula C38H50N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L3JE09KZ2F, chemically known as butanediamide, n1-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3alpha,4aalpha,8aalpha))- but generally known as saquinavir, which bears US NIH Compound Identifier 60787. European Medicines Agency schedules Saquinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10446MIG. The term SAQUINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules saquinavir in its Anatomical Therapeutic Chemical (ATC) Classification. SAQUINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule saquinavir under HS 29334910 and SITC 51575. As of Q4 2014, SAQUINAVIR remains the US FDA Preferred Term for this commodity. Saquinavir bears US NLM identifiers UMLS ID C0286738 and NCI Concept Code C29444. SMILES: O=C(NC(C)(C)C)C1N(CC2C(C1)CCCC2)CC(O)C(NC(=O)C(NC(=O)C1NC2C(CC1)CCCC2)CC(=O)N)CC1CCCCC1.
This classification denotes a protease inhibitor with the molecular formula C38H50N6O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UHB9Z3841A, chemically known as butanediamide, n(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3.alpha.,4a.beta.,8a.beta.))-, monomethanesulfonate, but more generally known as saquinavir mesylate, which bears US NIH Compound Identifier 60787. European Medicines Agency schedules saquinavir mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10446MIG. Most nations, for tariff purposes, schedule saquinavir mesylate under HS 29334910. As of Q4 2014, SAQUINAVIR MESYLATE remains US FDA's Preferred Term for this commodity. Saquinavir mesylate bears US NLM identifiers UMLS ID C0286737 and NCI Concept Code C1602. SMILES: CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3CCCCC3)NC(=O)[C@H](CC(=O)N)NC(=O)C4CCC5CCCCC5N4)O.CS(=O)(=O)O.
This classification denotes a quinolone antibiotic with the molecular formula C20H17F2N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RC3WJ907XY, chemically known as 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid but generally known as sarafloxacin, which bears US NIH Compound Identifier 56208. Most nations schedule sarafloxacin under HS 29335995 and SITC 51576. As of Q4 2014, SARAFLOXACIN remains the US FDA Preferred Term for this commodity. Sarafloxacin bears US NLM identifiers UMLS ID C0050308 and NCI Concept Code C84143. SMILES: C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F.
This classification denotes an antihypertensive agent with the molecular formula C42H65N13O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H2AFV2HE66, chemically known as angiotensin ii, 1-(n-methylglycine)-5-l-valine-8-l-alanine- but generally known as saralasin, which bears US NIH Compound Identifier 36736. European Medicines Agency schedules Saralasin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10447MIG. The term SARALASIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). SARALASIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule saralasin under HS 29371900 and SITC 54154. As of Q4 2014, SARALASIN remains the US FDA Preferred Term for this commodity. Saralasin bears US NLM identifiers UMLS ID C0036193 and NCI Concept Code C66527. SMILES: O=C(N1C(CCC1)C(=O)NC(C)C(=O)O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC)CCC/N=C(/N)N)C(C)C)Cc1ccc(O)cc1)C(C)C)Cc1[nH]cnc1.
This classification denotes an antihypertensive agent with the molecular formula C42H65N13O10.C2H4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FO21Z580M4. The term saralasin acetate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule saralasin acetate under HS 29371900 and SITC 54154. As of Q4 2014, SARALASIN ACETATE remains US FDA's Preferred Term for this commodity. Saralasin acetate bears US NLM identifiers UMLS ID C0030114 and NCI Concept Code C66528. SMILES: C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2C[NH]CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3CCC(CC3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC.CC(=O)O.O.
This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A960M0G5TP, chemically known as l-phenylalanine, 4-(bis(2-chloroethyl)amino)- but more generally known as sarcolysin, which bears US NIH Compound Identifier 4053. European Medicines Agency schedules Sarcolysin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10448MIG. The term SARCOLYSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). SARCOLYSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sarcolysin under HS 29224995 and SITC 51465. As of Q4 2014, SARCOLYSIN remains US FDA's Preferred Term for this commodity. Sarcolysin bears US NLM identifiers UMLS ID C0025444 and NCI Concept Code C61936. SMILES: CLCCN(C1CCC(CC(N)C(=O)O)CC1)CCCL.
This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GEG3Q4FC64, chemically known as alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, monohydrochloride, dl-, but more generally known as sarcolysin hydrochloride, which bears US NIH Compound Identifier 4053. European Medicines Agency schedules sarcolysin hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10448MIG. Most nations, for tariff purposes, schedule sarcolysin hydrochloride under HS 29224995. SMILES: C1CC(CCC1CC(C(=O)O)N)N(CCCL)CCCL.CL.
This classification denotes a therapeutic granulocyte-macrophage colony-stimulating factor with the molecular formula C639H1006N168O196S8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5TAA004E22, more generally known as sargramostim. European Medicines Agency schedules sargramostim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10450MIG. The term SARGRAMOSTIM is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 6, no, 3 1992, list 32. SARGRAMOSTIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sargramostim under HS 30012010 and SITC 54162. As of Q4 2014, SARGRAMOSTIM remains the US FDA Preferred Term for this commodity. Sargramostim bears US NLM identifiers UMLS ID C0216231 and NCI Concept Code C1492. SMILES: C1CC(OC1CO)N2C=CC(=NC2=O)N.
This classification denotes an anxiolytic with the molecular formula C15H14ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F84AE7X24P, chemically known as ethyl 7-chloro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo-(1,5-a)(1,4)benzodiazepine-3-carboxylate but generally known as sarmazenil, which bears US NIH Compound Identifier 71231. European Medicines Agency schedules Sarmazenil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10452MIG. The term SARMAZENIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). SARMAZENIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sarmazenil under HS 29339940 and SITC 51577. As of Q4 2014, SARMAZENIL remains the US FDA Preferred Term for this commodity. Sarmazenil bears US NLM identifiers UMLS ID C0532436 and NCI Concept Code C73206. SMILES: CLC1C2C(N3C(CN(C2=O)C)C(NC3)C(=O)OCC)CCC1.
This classification denotes a penicillin antibiotic with the molecular formula C21H27N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R15K9Z4384, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(4-(4-hydroxyphenyl)-2,2-dimethyl-5-oxo-1-imidazolidinyl)-3,3-dimethyl-7-oxo-, methoxymethyl ester, (2s-(2alpha,5alpha,6beta))- but generally known as sarmoxicillin, which bears US NIH Compound Identifier 49808. European Medicines Agency schedules Sarmoxicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10453MIG. The term SARMOXICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). SARMOXICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sarmoxicillin under HS 29411090 and SITC 54131. As of Q4 2014, SARMOXICILLIN remains the US FDA Preferred Term for this commodity. Sarmoxicillin bears US NLM identifiers UMLS ID C0614192 and NCI Concept Code C82302. SMILES: S1C2N(C(C1(C)C)C(=O)OCOC)C(=O)C2N1C(NC(C1=O)C1CCC(O)CC1)(C)C.
This classification denotes a penicillin antibiotic with the molecular formula C21H27N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O70J1GE4YB, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6beta))-, methoxymethyl ester but generally known as sarpicillin, which bears US NIH Compound Identifier 65429. European Medicines Agency schedules Sarpicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10454MIG. The term SARPICILLIN is an International Non-Proprietary Name. SARPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sarpicillin under HS 29411090 and SITC 54131. As of Q4 2014, SARPICILLIN remains the US FDA Preferred Term for this commodity. Sarpicillin bears US NLM identifiers UMLS ID C0074076 and NCI Concept Code C90914. SMILES: S1C2N(C(C1(C)C)C(=O)OCOC)C(=O)C2N1C(NC(C1=O)C1CCCCC1)(C)C.
A sterile aqueous solution of soluble salts of the volatile bases from Sarraceniaceae or Pitcher Plant.
In November 2021, the WHO licensed the vaccines from Pfizer / BioNTech, AstraZeneca / Oxford, Janssen, Moderna, Sinopharm, Sinovac and Bharat. Other vaccines continue to be studied. Additionally, national regulatory agencies (RNAs) have licensed other COVID-19 vaccines in specific countries.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C27H30N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W4P85FO7GS, chemically known as (+-)-1,2-dihydro-5-(p-(2-hydroxy-3-(4-(o-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-6-methyl-2-oxonicotinonitrile but generally known as saterinone, which bears US NIH Compound Identifier 65874. European Medicines Agency schedules Saterinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10457MIG. The term SATERINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). SATERINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule saterinone under HS 29337900 and SITC 51561. As of Q4 2014, SATERINONE remains the US FDA Preferred Term for this commodity. Saterinone bears US NLM identifiers UMLS ID C0074082 and NCI Concept Code C74348. SMILES: OC(CN1CCN(CC1)C1C(OC)CCCC1)COC1CCC(CC1)C1C([NH]C(=O)C(C1)C#N)C.
This classification denotes an antiprotozoal agent with the molecular formula C8H11N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4N7G8A6439, chemically known as 2-imidazolidinone, 1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)- but generally known as satranidazole, which bears US NIH Compound Identifier 41841. European Medicines Agency schedules Satranidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10459MIG. The term SATRANIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). SATRANIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule satranidazole under HS 29350090 and SITC 51580. As of Q4 2014, SATRANIDAZOLE remains the US FDA Preferred Term for this commodity. Satranidazole bears US NLM identifiers UMLS ID C0141597 and NCI Concept Code C72155. SMILES: S(=O)(=O)(N1CCN(C1=O)C1N(C([N](=O)O)CN1)C)C.
This classification denotes a platinum compound with the molecular formula C6H13N.2C2H3O2.2Cl.Pt.H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8D7B37T28G, chemically known as platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)- but more generally known as satraplatin, which bears US NIH Compound Identifier 123974. European Medicines Agency schedules Satraplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04333MIG. The term SATRAPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules satraplatin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SATRAPLATIN remains US FDA's Preferred Term for this commodity. Satraplatin bears US NLM identifiers UMLS ID C1142934 and NCI Concept Code C1493. Most nations, for tariff and trade purposes, schedule satraplatin under HS 28439090 and SITC 52432. SMILES: CC(=O)[O-].CC(=O)[O-].C1CCC(CC1)N.N.[Cl-].[Cl-].[Pt+4].
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J7WWH9M8QS, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 42508 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Lilianae (monocots), Order Arecales, Family Arecaceae, Genus Serenoa Hook. f. (serenoa), Species Serenoa repens, commonly known as SAW PALMETTO. Saw palmetto bears the USDA PLANTS Database Identifier SERE2. European Medicines Agency schedules saw palmetto in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB15228MIG, SUB30163, SUB30858, SUB32068, SUB33320, SUB47013, SUB47014, SUB47015, SUB47016, SUB47017, SUB47018, and SUB47686. As of Q4 2014, SAW PALMETTO remains the US FDA Preferred Term for this commodity. SMILES: NONE.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8I7IO46IVQ. European Medicines Agency schedules Saxagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25220. Saxagliptin generally arises in the molecular formula C18H25N3O2. The term SAXAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations, for tariff and trade purposes, schedule saxagliptin under HS 29339990 and SITC 51577. Saxagliptin bears US NLM identifiers UMLS ID C1611934 and NCI Concept Code C75983. SMILES: OC12C3CC(CC(C1)(CC3)C(N)C(=O)N1C3C(C3)CC1C#N)C2.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8I7IO46IVQ. European Medicines Agency schedules Saxagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25220. Saxagliptin generally arises in the molecular formula C18H25N3O2. The term SAXAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations, for tariff and trade purposes, schedule saxagliptin anhydrous under HS 29339990. As of Q4 2014, SAXAGLIPTIN ANHYDROUS remains US FDA's Preferred Term for this commodity. Saxagliptin anhydrous bears US NLM identifiers UMLS ID C2699273 and NCI Concept Code C75984. SMILES: C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H]([C@]34C[C@@H]5CC(C3)C[C@@](C5)(C4)O)N.
This classification denotes a protease inhibitor and anti-diabetic agent with the molecular formula C18H25N3O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8J84YIX6L. European Medicines Agency schedules saxagliptin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30804. The term saxagliptin hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule saxagliptin hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, SAXAGLIPTIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Saxagliptin hydrochloride bears US NLM identifiers UMLS ID C2719771 and NCI Concept Code C81702. SMILES: C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H]([C@]34C[C@@H]5CC(C3)C[C@@](C5)(C4)O)N.CL.
This classification denotes an anti-diabetic agent C18H25N3O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9GB927LAJW, chemically known as (1s,3s,5s)-2-((2s)-amino(3-hydroxytricyclo(3.3.1.1(sup 3,7))dec-1-yl)acetyl)2-azabicyclo(3.1.0)hexane-3-carbonitrile monohydrate, but more generally known as saxagliptin monohydrate, which bears US NIH Compound Identifier 53297473. Most nations, for tariff and trade purposes, schedule saxagliptin monohydrate under HS 29339990 and SITC 51577. As of Q4 2014, SAXAGLIPTIN MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H]([C@]34C[C@@H]5CC(C3)C[C@@](C5)(C4)O)N.O.
This classification denotes a uricosuric agent with the molecular formula C10H8ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JW3UZ4I1A8, chemically known as 3,3a-dihydro-7-chloro-2h,9h-isoxazolo(3,2-b)(1,3)benzoxazin-9-one but generally known as seclazone, which bears US NIH Compound Identifier 34443. European Medicines Agency schedules Seclazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10466MIG. The term SECLAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). SECLAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule seclazone under HS 29349990 and SITC 51579. As of Q4 2014, SECLAZONE remains the US FDA Preferred Term for this commodity. Seclazone bears US NLM identifiers UMLS ID C0644512 and NCI Concept Code C73105. SMILES: C1CON2C1OC3=C(C2=O)C=C(C=C3)CL.
This classification denotes an antiprotozoal agent with the molecular formula C7H11N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3459K699K, chemically known as imidazole-1-ethanol, alpha,2-dimethyl-5-nitro- but generally known as secnidazole, which bears US NIH Compound Identifier 71815. European Medicines Agency schedules Secnidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10467MIG. The term SECNIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules secnidazole in its Anatomical Therapeutic Chemical (ATC) Classification. SECNIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule secnidazole under HS 29332990 and SITC 51573. As of Q4 2014, SECNIDAZOLE remains the US FDA Preferred Term for this commodity. Secnidazole bears US NLM identifiers UMLS ID C0074246 and NCI Concept Code C66529. SMILES: OC(CN1C(NCC1[N](=O)O)C)C.
This classification denotes a barbiturate with the molecular formula C12H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P7H87IN75, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, monosodium salt but generally known as secobarbital, which bears US NIH Compound Identifier 5193. European Medicines Agency schedules Secobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10468MIG. The term SECOBARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules secobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. SECOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule secobarbital under HS 29335390 and SITC 51576. As of Q4 2014, SECOBARBITAL remains the US FDA Preferred Term for this commodity. Secobarbital bears US NLM identifiers UMLS ID C0036516 and NCI Concept Code C61937. SMILES: CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C.
This classification denotes a barbiturate with the molecular formula C12H17N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XBP604F6UM, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, monosodium salt but more generally known as secobarbital sodium, which bears US NIH Compound Identifier 5193. European Medicines Agency schedules Secobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04344MIG. Most nations, for tariff and trade purposes, schedule secobarbital sodium under HS 29335300 and SITC 51576. As of Q4 2014, SECOBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Secobarbital sodium bears US NLM identifiers UMLS ID C0304359 and NCI Concept Code C66530. SMILES: CCCC(C)C1(C(=O)NC(=O)[N-]C1=O)CC=C.[NA+].
This classification denotes an immunosuppressant that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DLG4EML025, generally known as secukinumab. European Medicines Agency schedules secukinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33242. The term SECUKINUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 1, 2010 List 63). Most nations, for tariff and trade purposes, schedule SECUKINUMAB under HS 29349990 and SITC 51579. SMILES: none.
This classification denotes a macrolide antibiotic with the molecular formula C27H35NO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WLK252Z51F, chemically known as pyruvamide, n-(7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo(13.2.2)nonadeca-3,5,9,11-tetraen-2-yl)-, 13-acetate, (all-e)-(1s,2r,7s,13s,15r,19r)-(-)- but generally known as sedecamycin, which bears US NIH Compound Identifier 5382567. European Medicines Agency schedules Sedecamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10471MIG. The term SEDECAMYCIN is an International Non-Proprietary Name. SEDECAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sedecamycin under HS 29419000 and SITC 54139. As of Q4 2014, SEDECAMYCIN remains the US FDA Preferred Term for this commodity. Sedecamycin bears US NLM identifiers UMLS ID C0074263 and NCI Concept Code C72589. SMILES: O1C2C(C(=O)C(C(NC(=O)C(=O)C)C=C(C)C=CC(O)CC=C(C=CC(OC(=O)C)C2)C)(C1=O)C)C.
This classification denotes a serotonin antagonist with the molecular formula C29H27F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 197HL4EZCC, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-2-methyl-, dihydrochloride but generally known as seganserin, which bears US NIH Compound Identifier 71767. European Medicines Agency schedules Seganserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10472MIG. The term SEGANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). SEGANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule seganserin under HS 29335995 and SITC 51576. As of Q4 2014, SEGANSERIN remains the US FDA Preferred Term for this commodity. Seganserin bears US NLM identifiers UMLS ID C0074270 and NCI Concept Code C76967. SMILES: Fc1ccc(C(=C2\CCN(CC2)CCc2c(nc3n(c2=O)cccc3)C)/c2ccc(F)cc2)cc1.
This classification denotes an antiparasitic agent with the molecular formula C43H63NO11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A2669OWX9N. The term SELAMECTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 1, 2000, list 43. ). As of Q4 2014, SELAMECTIN remains the US FDA Preferred Term for this commodity. Selamectin bears US NLM identifiers UMLS ID C0961275 and NCI Concept Code C75233. SMILES: CC1CCC2(CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)O)OC)C)OC1C7CCCCC7.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H17N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6W731X367Q, chemically known as (-)-(r)-n,alpha-dimethyl-n-2-propynylphenethylamine monohydrochloride but generally known as selegiline hydrochloride, which bears US NIH Compound Identifier 26758. European Medicines Agency schedules Selegiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04347MIG. Most nations schedule selegiline under HS 29214980 and SITC 51454. As of Q4 2014, SELEGILINE remains the US FDA Preferred Term for this commodity. Selegiline bears US NLM identifiers UMLS ID C0036579 and NCI Concept Code C61938. SMILES: CL.N(C(CC1CCCCC1)C)(CC#C)C.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H17N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6W731X367Q, chemically known as (-)-(r)-n,alpha-dimethyl-n-2-propynylphenethylamine monohydrochloride but more generally known as selegiline hydrochloride, which bears US NIH Compound Identifier 26758. European Medicines Agency schedules Selegiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04347MIG. Most nations, for tariff and trade purposes, schedule selegiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, SELEGILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Selegiline hydrochloride bears US NLM identifiers UMLS ID C0700467 and NCI Concept Code C47714. SMILES: C[C@H](CC1CCCCC1)N(C)CC#C.CL.
This classification denotes a topical anti-infective agent and selenium compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z69D9E381Q. European Medicines Agency schedules Selenium sulfide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15211MIG. Selenium sulfide generally arises in the molecular formula S2SE. The term 'selenium sulfide' is a European Pharmacopoeia designation. SMILES: S=[SE]=S.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C15H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71IA9S35AJ, chemically known as 3-((z)-(3,5-dimethylpyrrol-2-yl)methylene)-2-indolinone but generally known as semaxanib, which bears US NIH Compound Identifier 5329098. European Medicines Agency schedules Semaxanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32269. The term SEMAXANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). Most nations schedule semaxanib under HS 29337900 and SITC 51561. As of Q4 2014, SEMAXANIB remains the US FDA Preferred Term for this commodity. Semaxanib bears US NLM identifiers UMLS ID C1135174 and NCI Concept Code C1831. SMILES: O=C1NC2C(/C1=C/C1[NH]C(CC1C)C)CCCC2.
This classification denotes an antiprotozoal agent with the molecular formula C45H76O16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P6VXL377WL, chemically known as uk 61,689 but generally known as semduramicin, which bears US NIH Compound Identifier 71327. European Medicines Agency schedules Semduramicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10479MIG. The term SEMDURAMICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). SEMDURAMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule semduramicin under HS 29419000 and SITC 54139. As of Q4 2014, SEMDURAMICIN remains the US FDA Preferred Term for this commodity. Semduramicin bears US NLM identifiers UMLS ID C0141951 and NCI Concept Code C76009. SMILES: O1C(C2OC(C3OC(CC3OC3OC(C(OC)CC3)C)C3OC(O)(C(CC3C)C)C)(CC2)C)(CCC21OC(C(C(O)C2)C)C(C1OC(O)(C(C(O)C1OC)C)CC(=O)O)C)C.
This classification denotes a calcium channel blocker, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DGN08QZ30G. European Medicines Agency schedules Semotiadil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10481MIG. Semotiadil generally arises in the molecular formula C29H32N2O6S. The term SEMOTIADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) SEMOTIADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule semotiadil under HS 29349990 and SITC 51579. As of Q4 2014, SEMOTIADIL remains the US FDA Preferred Term for this commodity. Semotiadil bears US NLM identifiers UMLS ID C0084530 and NCI Concept Code C72624. SMILES: S1C(c2c(OCCCN(CCOc3cc4OCOc4cc3)C)ccc(OC)c2)C(=O)N(c2c1cccc2)C.
This classification denotes a calcium channel blocker with the molecular formula C29H32N2O6S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48E2Q389VX, chemically known as 2h-1,4-benzothiazin-3(4h)-one, 2-(2-(3-((2-(1,3-benzodioxol-5-yloxy)ethyl)methylamino)propoxy)-5-methoxyphenyl)-4-methyl-, (2r)-, (2e)-2-butenedioate (1:1), but more generally known as semotiadil fumarate, which bears US NIH Compound Identifier 6437846. European Medicines Agency schedules semotiadil fumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10481MIG. Most nations, for tariff purposes, schedule semotiadil fumarate under HS 29349990. SMILES: CN1C2CCCCC2S[C@@H](C1=O)C3CC(CCC3OCCCN(C)CCOC4CCC5C(C4)OCO5)OC.C(=C/C(=O)O)\C(=O)O.
This classification denotes a nitrosourea compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6YY7T1T567. European Medicines Agency schedules Semustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10482MIG. Semustine generally arises in the molecular formula C10H18CLN3O2. The term SEMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, volume 26, no. 10 1972, list 12.) SEMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, SEMUSTINE remains US FDA's Preferred Term for this commodity. Semustine bears US NLM identifiers UMLS ID C0036637 and NCI Concept Code C827. Most nations, for tariff and trade purposes, schedule semustine under HS 29242100 and SITC 51473. SMILES: CC1CCC(CC1)NC(=O)N(CCCl)N=O.
This classification denotes a laxative, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3FYP5M0IJX. European Medicines Agency schedules Sennosides in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB40994. Sennosides generally arises in the molecular formula C42H38O20. The term 'sennosides' is a U.S. Pharmacopeial Convention designation. Senna glycosides or sennosides bears US NLM identifiers UMLS ID C0074332 and NCI Concept Code C29448. SMILES: C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)OC7C(C(C(C(O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O.
This classification denotes a serotonin antagonist and histamine-1 receptor antagonist with the molecular formula C22H27NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C7Q3TBR3FP, chemically known as 3-quinuclidinemethanol, alpha,alpha-di-o-tolyl- but more generally known as sequifenadine, which bears U.S. NIH Compound Identifier 42553. European Medicines Agency schedules Sequifenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10488MIG. The term SEQUIFENADINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). SEQUIFENADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an anti-asthmatic agent with the molecular formula C22H26O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4U58JM421N, chemically known as benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+-)- but generally known as seratrodast, which bears US NIH Compound Identifier 2449. European Medicines Agency schedules Seratrodast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10490MIG. The term SERATRODAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules seratrodast in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule seratrodast under HS 29183000 and SITC 51395. As of Q4 2014, SERATRODAST remains the US FDA Preferred Term for this commodity. Seratrodast bears US NLM identifiers UMLS ID C0050339 and NCI Concept Code C90671. SMILES: O=C1C(=C(C(=O)C(=C1C)C)C)C(CCCCCC(=O)O)C1CCCCC1.
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 910906N64M. European Medicines Agency schedules Serfibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10492MIG. Serfibrate generally arises in the molecular formula C16H20CLNO5S. The term SERFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) SERFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule serfibrate under HS 29309085 and SITC 51549. As of Q4 2014, SERFIBRATE remains the US FDA Preferred Term for this commodity. Serfibrate bears US NLM identifiers UMLS ID C2348187 and NCI Concept Code C72997. SMILES: Clc1ccc(OC(C(=O)SCC(NC(=O)C)CC(=O)O)(C)C)cc1.
This classification denotes a growth hormone-releasing hormone analogue with the molecular formula C149H246N44O42S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89243S03TE, chemically known as somatoliberin (human pancreatic islet), 29-l-argininamide-30-de-l-glutamine-31-de-l-glutamine-32-deglycine-33-de-l-glutamic acid-34-de-l-serine-35-de-l-asparagine-36-de-l-glutamine-37-de-l-glutamic acid-38-de-l-arginine-39-deglycine-40-de-l-alanine-41-de-l-arginine-42-de-l-alanine-43-de-l-argininyl-44-de-l-leucinamide but generally known as sermorelin, which bears US NIH Compound Identifier 16129620. European Medicines Agency schedules Sermorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10496MIG. World Health Organization schedules sermorelin in its Anatomical Therapeutic Chemical (ATC) Classification. SERMORELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sermorelin under HS 29371900 and SITC 54154. As of Q4 2014, SERMORELIN remains the US FDA Preferred Term for this commodity. Sermorelin bears US NLM identifiers UMLS ID C0142046 and NCI Concept Code C62088. SMILES: S(CCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC1CCC(O)CC1)C)CC(=O)O)C)C(CC)C)CC1CCCCC.
This classification denotes a growth hormone-releasing hormone analogue with the molecular formula C149H246N44O42S.C2H4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00IBG87IQW, chemically known as 29-l-argininamide-30-de-l-glutamine-31-de-l-glutamine-32-deglycine-33-de-l-glutamic acid-34-de-l-serine-35-de-l-asparagine-36-de-l-glutamine-37-de-l-glutamic acid-38-de-l-arginine-39-deglycine-40-de-l-alanine-41-de-l-arginine-42-de-l-alanine-43-de-l-arginine-44-de-l-leucinamidegrowth hormone-releasing factor (human pancreatic islet), acetate (salt), hydrate but generally known as sermorelin acetate, which bears US NIH Compound Identifier 16132412. European Medicines Agency schedules Sermorelin acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04370MIG. Most nations schedule sermorelin acetate under HS 29371900 and SITC 54154. As of Q4 2014, SERMORELIN ACETATE remains the US FDA Preferred Term for this commodity. Sermorelin acetate bears US NLM identifiers UMLS ID C0720660 and NCI Concept Code C47715. SMILES: S(CCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC1CCC(O)CC1)C)CC(=O)O)C)C(CC)C)CC1CCCCC1)C(O)C)CC(=O)N)CO)CC1CCC(O)CC1)CCCNC(=N)N)CCCCN)C(C)C)CC(C)C)CCC(=O)N)CC(C)C)CO)C)CCCNC(=N)N)CCCCN)CC(C)C)CC(C)C)CCC(=O)N)CC(=O)O)C(CC)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)N)C.OC(=O)C.
This classification denotes an antifungal agent with the molecular formula C20H15Cl3N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72W71I16EG, chemically known as 7-chloro-3-(1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene but generally known as sertaconazole, which bears US NIH Compound Identifier 65863. European Medicines Agency schedules Sertaconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10497MIG. The term SERTACONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules sertaconazole in its Anatomical Therapeutic Chemical (ATC) Classification. SERTACONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sertaconazole under HS 29349990 and SITC 51579. As of Q4 2014, SERTACONAZOLE remains the US FDA Preferred Term for this commodity. Sertaconazole bears US NLM identifiers UMLS ID C0074391 and NCI Concept Code C75206. SMILES: CLC1C(C(OCC2C3C(SC2)C(CL)CCC3)CN2CCNC2)CCC(CL)C1.
This classification denotes an antifungal agent with the molecular formula C20H15Cl3N2OS.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1DV05410M5, chemically known as 7-chloro-3-(1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene but more generally known as sertaconazole nitrate, which bears US NIH Compound Identifier 65863. European Medicines Agency schedules Sertaconazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04374MIG. Most nations, for tariff and trade purposes, schedule sertaconazole nitrate under HS 29349990 and SITC 51579. As of Q4 2014, SERTACONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Sertaconazole nitrate bears US NLM identifiers UMLS ID C1528751 and NCI Concept Code C47716. SMILES: C1CC2C(CSC2C(C1)CL)COC(CN3CCNC3)C4CCC(CC4CL)CL.[N+](=O)(O)[O-].
This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C24H26ClFN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GVV4Z879SP, chemically known as 2-imidazolidinone, 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1h-indol-3-yl)-1-piperidinyl)ethyl)- but generally known as sertindole, which bears US NIH Compound Identifier 60149. European Medicines Agency schedules Sertindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10498MIG. The term SERTINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules sertindole in its Anatomical Therapeutic Chemical (ATC) Classification. SERTINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sertindole under HS 29333999 and SITC 51574. As of Q4 2014, SERTINDOLE remains the US FDA Preferred Term for this commodity. Sertindole bears US NLM identifiers UMLS ID C0084528 and NCI Concept Code C73295. SMILES: CLC1CC2C(C3CCN(CC3)CCN3CCNC3=O)CN(C2CC1)C1CCC(F)CC1.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C17H17Cl2N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QUC7NX6WMB, chemically known as (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthalenamine but generally known as sertraline, which bears US NIH Compound Identifier 5203. European Medicines Agency schedules Sertraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10499MIG. The term SERTRALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules sertraline in its Anatomical Therapeutic Chemical (ATC) Classification. SERTRALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sertraline under HS 29214500 and SITC 51454. As of Q4 2014, SERTRALINE remains the US FDA Preferred Term for this commodity. Sertraline bears US NLM identifiers UMLS ID C0074393 and NCI Concept Code C61939. SMILES: Clc1cc(C2CCC(NC)c3c2cccc3)ccc1Cl.
This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C17H17Cl2N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UTI8907Y6X, chemically known as 1-naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-, hydrochloride, (1s-cis)- but more generally known as sertraline hydrochloride, which bears US NIH Compound Identifier 63009. European Medicines Agency schedules Sertraline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04375MIG. Most nations, for tariff and trade purposes, schedule sertraline hydrochloride under HS 29214500 and SITC 51454. As of Q4 2014, SERTRALINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Sertraline hydrochloride bears US NLM identifiers UMLS ID C0600526 and NCI Concept Code C29451. SMILES: CN[C@H]1CC[C@H](C2C1CCCC2)C3CCC(C(C3)CL)CL.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H28ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6G3OCF528J, chemically known as 1h-azepine, 1-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)hexahydro- but generally known as setastine, which bears US NIH Compound Identifier 43082. European Medicines Agency schedules Setastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10500MIG. The term SETASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). SETASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule setastine under HS 29339930 and SITC 51577. As of Q4 2014, SETASTINE remains the US FDA Preferred Term for this commodity. Setastine bears US NLM identifiers UMLS ID C0074409 and NCI Concept Code C73056. SMILES: CLC1CCC(C(OCCN2CCCCCC2)(C2CCCCC2)C)CC1.
This classification denotes a histamine-1 receptor antagonist C22H28ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2MB6P84ON, chemically known as setastine hydrochloride, (+/-)-, but more generally known as setastine hydrochloride, which bears US NIH Compound Identifier 43081. European Medicines Agency schedules Setastine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15235MIG. Most nations, for tariff and trade purposes, schedule setastine hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, SETASTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCCCC1)(C2CCC(CC2)CL)OCCN3CCCCCC3.CL.
This classification denotes an anorexiant with the molecular formula C15H16ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92D9H0A3WN, chemically known as alpha-(4-chlorophenyl)-2-((methylamino)methyl)benzenemethanol, hydrochloride but generally known as setazindol, which bears US NIH Compound Identifier 193099. European Medicines Agency schedules Setazindol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10501MIG. The term SETAZINDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). SETAZINDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule setazindol under HS 29221980 and SITC 51461. As of Q4 2014, SETAZINDOL remains the US FDA Preferred Term for this commodity. Setazindol bears US NLM identifiers UMLS ID C2348196 and NCI Concept Code C72846. SMILES: Clc1ccc(C(O)c2c(CNC)cccc2)cc1.
This classification denotes an antiplatelet agent with the molecular formula C26H23ClN6O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UFN2Q54HS6, chemically known as 6-(o-chlorophenyl)-7,10-dihydro-1-methyl-4h-pyrido(4,3:4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8h)-carbox-p-anisidide but generally known as setipafant, which bears US NIH Compound Identifier 65968. European Medicines Agency schedules Setipafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10502MIG. The term SETIPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). SETIPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule setipafant under HS 29349990 and SITC 51579. As of Q4 2014, SETIPAFANT remains the US FDA Preferred Term for this commodity. Setipafant bears US NLM identifiers UMLS ID C2699291 and NCI Concept Code C76402. SMILES: CLC1C(C2=NCC3N(C4SC5C(CCN(C5)C(=O)NC5CCC(OC)CC5)C24)C(NN3)C)CCCC1.
This classification denotes an anxiolytic with the molecular formula C21H24FN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BQ67CS3Q3E, chemically known as 6-(2-(4-(p-fluorobenzoyl)piperidino)ethyl)-2,3-dihydro-7-methyl-5h-thiazolo(3,2-a)pyrimidin-5-one but generally known as setoperone, which bears US NIH Compound Identifier 68604. European Medicines Agency schedules Setoperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10504MIG. The term SETOPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). SETOPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule setoperone under HS 29349990 and SITC 51579. As of Q4 2014, SETOPERONE remains the US FDA Preferred Term for this commodity. Setoperone bears US NLM identifiers UMLS ID C0074411 and NCI Concept Code C73296. SMILES: S1C2N(C(=O)C(CCN3CCC(CC3)C(=O)C3CCC(F)CC3)C(N2)C)CC1.
This classification denotes a polyamine compound with the molecular formula (C9H18N2O)n.(C3H7N)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 941N5DUU5C, chemically known as 2-propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride but generally known as sevelamer, which bears US NIH Compound Identifier 159247. European Medicines Agency schedules Sevelamer in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04381MIG. The term SEVELAMER is an International Non-Proprietary Name. World Health Organization schedules sevelamer in its Anatomical Therapeutic Chemical (ATC) Classification. SEVELAMER is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sevelamer under HS 39119099 and SITC 57596. As of Q4 2014, SEVELAMER remains the US FDA Preferred Term for this commodity. Sevelamer bears US NLM identifiers UMLS ID C0718050 and NCI Concept Code C84172. SMILES: C=CCN.C1C(O1)CCL.CL.
This classification denotes an anesthetic agent with the molecular formula C4H3F7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38LVP0K73A, chemically known as 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane but generally known as sevoflurane, which bears US NIH Compound Identifier 5206. European Medicines Agency schedules Sevoflurane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10506MIG. The term SEVOFLURANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25, No. 10 1971, List 11). World Health Organization schedules sevoflurane in its Anatomical Therapeutic Chemical (ATC) Classification. SEVOFLURANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sevoflurane under HS 29091990 and SITC 51616. As of Q4 2014, SEVOFLURANE remains the US FDA Preferred Term for this commodity. Sevoflurane bears US NLM identifiers UMLS ID C0074414 and NCI Concept Code C47717. SMILES: FC(F)(F)C(OCF)C(F)(F)F.
This classification denotes a muscle relaxant with the molecular formula C29H43N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18USM69UB1, chemically known as benzenepropanamide, alpha-(benzoylamino)-4-(3-(diethylamino)propoxy)-n,n-dipropyl- but generally known as sevopramide, which bears US NIH Compound Identifier 210325. European Medicines Agency schedules Sevopramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10507MIG. The term SEVOPRAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). SEVOPRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sevopramide under HS 29242995 and SITC 51479. As of Q4 2014, SEVOPRAMIDE remains the US FDA Preferred Term for this commodity. Sevopramide bears US NLM identifiers UMLS ID C2699293 and NCI Concept Code C76775. SMILES: O(CCCN(CC)CC)c1ccc(CC(NC(=O)c2ccccc2)C(=O)N(CCC)CCC)cc1.
Sheep Pox Vaccine containing cell cultures derived live attenuated strain of Sheep Pox virus belonging to Kenyan or Romanian strain provides good immunity.
This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H30N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3M7OB98Y7H, chemically known as 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine but generally known as sildenafil, which bears US NIH Compound Identifier 5212. European Medicines Agency schedules Sildenafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10517MIG. The term SILDENAFIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules sildenafil in its Anatomical Therapeutic Chemical (ATC) Classification. SILDENAFIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sildenafil under HS 29350090 and SITC 51580. As of Q4 2014, SILDENAFIL remains the US FDA Preferred Term for this commodity. Sildenafil bears US NLM identifiers UMLS ID C0529793 and NCI Concept Code C61940. SMILES: S(=O)(=O)(N1CCN(CC1)C)C1CC(C2[NH]C3C(NN(C3C(=O)N2)C)CCC)C(OCC)CC1.
This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H30N6O4S.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BW9B0ZE037, chemically known as 1-((3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate (1:1) but more generally known as sildenafil citrate, which bears US NIH Compound Identifier 62853. European Medicines Agency schedules Sildenafil citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04386MIG. Most nations, for tariff and trade purposes, schedule sildenafil citrate under HS 29350090 and SITC 51580. As of Q4 2014, SILDENAFIL CITRATE remains US FDA's Preferred Term for this commodity. Sildenafil citrate bears US NLM identifiers UMLS ID C0724693 and NCI Concept Code C26670. SMILES: CCCC1C2C(C(=O)[NH]C(N2)C3CC(CCC3OCC)S(=O)(=O)N4CCN(CC4)C)N(N1)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an alpha-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUZ39LUY82. European Medicines Agency schedules Silodosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23152. Silodosin generally arises in the molecular formula C25H32F3N3O4. The term SILODOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations schedule silodosin under HS 29339990 and SITC 51577. As of Q4 2014, SILODOSIN remains the US FDA Preferred Term for this commodity. Silodosin bears US NLM identifiers UMLS ID C1870115 and NCI Concept Code C81372. SMILES: FC(F)(F)COC1C(OCCNC(CC2CC3C(N(CC3)CCCO)C(C2)C(=O)N)C)CCCC1.
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R16SK8726X. European Medicines Agency schedules Silperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10521MIG. Silperisone generally arises in the molecular formula C15H24FNSI. The term SILPERISONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) SILPERISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule silperisone under HS 29333999 and SITC 51574. As of Q4 2014, SILPERISONE remains the US FDA Preferred Term for this commodity. Silperisone bears US NLM identifiers UMLS ID C1101150 and NCI Concept Code C74281. SMILES: [SI](CN1CCCCC1)(CC1CCC(F)CC1)(C)C.
An interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
This classification denotes a topical anti-infective agent and sulfonamide anti-infective agent with the molecular formula C10H9N4O2S.Ag, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W46JY43EJR, chemically known as sulfanilamide, n(sup 1)-2-pyrimidinyl-, monosilver(1+) salt but generally known as silver sulfadiazine, which bears US NIH Compound Identifier 31011. European Medicines Agency schedules Silver sulfadiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04622MIG. World Health Organization schedules silver sulfadiazine in its Anatomical Therapeutic Chemical (ATC) Classification. Silvadene or silver sulfadiazine bears US NLM identifiers UMLS ID C0723179 and NCI Concept Code C66567. SMILES: C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+].
This classification denotes an acetate used in smoking cessation treatment, with the molecular formula C2H3O2.Ag, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19PPS85F9H, chemically known as silver;acetate but generally known as silver acetate, which bears US NIH Compound Identifier 11246. The term SPARTEINE is an International Non-Proprietary Name or INN. European Medicines Agency schedules silver acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15244MIG. Most nations schedule silver acetate under HS 28432900 and SITC 52432. As of Q4 2014, SILVER ACETATE remains the US FDA Preferred Term for this commodity. SMILES: CC(=O)[O-].[Ag+].
This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95IT3W8JZE. European Medicines Agency schedules Silver nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15248MIG. Silver nitrate generally arises in the molecular formula AG.HNO3. The term SILVER NITRATE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule silver nitrate under HS 28432100 and SITC 52432. As of Q4 2014, SILVER NITRATE remains the US FDA Preferred Term for this commodity. Silver nitrate bears US NLM identifiers UMLS ID C0037129 and NCI Concept Code C77057. SMILES: [N+](=O)([O-])[O-].[Ag+].
This classification denotes a cardiotonic agent with the molecular formula C14H12N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 349552KRHK, chemically known as propanedinitrile, ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)- but generally known as simendan, which bears US NIH Compound Identifier 60867. European Medicines Agency schedules Simendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10525MIG. The term SIMENDAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). Most nations schedule simendan under HS 29339990 and SITC 51577. As of Q4 2014, SIMENDAN remains the US FDA Preferred Term for this commodity. Simendan bears US NLM identifiers UMLS ID C0287806 and NCI Concept Code C87689. SMILES: O=C1NN=C(C(C1)C)C1CCC(N/N=C(/C#N)C#N)CC1.
This classification denotes an antacid preparation with the molecular formula C6H18O4Si3, chemically known as dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane but generally known as simethicone, which bears US NIH Compound Identifier 6433516. European Medicines Agency schedules Simethicone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB45207 and SUB04403MIG. Simethicone bears US NLM identifiers UMLS ID C0037138 and NCI Concept Code C29453. SMILES: CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O.
This classification denotes an anti-lipidemic agent with the molecular formula C23H26Cl2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L2R75RQX26, chemically known as 1,3-propanediol bis(alpha-(p-chlorophenoxy)isobutyrate) but generally known as simfibrate, which bears US NIH Compound Identifier 5217. European Medicines Agency schedules Simfibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10527MIG. The term SIMFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules simfibrate in its Anatomical Therapeutic Chemical (ATC) Classification. SIMFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule simfibrate under HS 29189900 and SITC 51396. As of Q4 2014, SIMFIBRATE remains the US FDA Preferred Term for this commodity. Simfibrate bears US NLM identifiers UMLS ID C0074551 and NCI Concept Code C72998. SMILES: Clc1ccc(OC(C(=O)OCCCOC(=O)C(Oc2ccc(Cl)cc2)(C)C)(C)C)cc1.
This classification denotes a hmg-coa reductase inhibitor with the molecular formula C25H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AGG2FN16EV, chemically known as 2,2-dimethylbutyric acid, 8-ester with (4r,6r)-6-(2-((1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2h-pyran-2-one but generally known as simvastatin, which bears US NIH Compound Identifier 54454. European Medicines Agency schedules Simvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10529MIG. The term SIMVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules simvastatin in its Anatomical Therapeutic Chemical (ATC) Classification. SIMVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, SIMVASTATIN remains the US FDA Preferred Term for this commodity. Simvastatin bears US NLM identifiers UMLS ID C0074554 and NCI Concept Code C29454. SMILES: O(C1C2C(C(C=CC2=CC(C1)C)C)CCC1OC(=O)CC(O)C1)C(=O)C(CC)(C)C.
Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas.
This classification denotes a bcar2 gene, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W36ZG6FT64. European Medicines Agency schedules Rapamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10537MIG. Sirolimus generally arises in the molecular formula C51H79NO13. The term SIROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) SIROLIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sirolimus under HS 29349990 and SITC 51579. As of Q4 2014, SIROLIMUS remains US FDA's Preferred Term for this commodity. Sirolimus bears US NLM identifiers UMLS ID C0072980 and NCI Concept Code C1212. SMILES: O(C1CC(CCC1O)CC(C1OC(=O)C2N(CCCC2)C(=O)C(=O)C2(OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(OC)C(O)C(=CC(C(=O)C1)C)C)C)C)C)O)C)C.
This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X55XSL74YQ. European Medicines Agency schedules Sisomicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10538MIG. Sisomicin generally arises in the molecular formula C19H37N5O7. The term SISOMICIN is an International Non-Proprietary Name or INN. SISOMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sisomicin under HS 29419000 and SITC 54139. As of Q4 2014, SISOMICIN remains the US FDA Preferred Term for this commodity. Sisomicin bears US NLM identifiers UMLS ID C0037209 and NCI Concept Code C72569. SMILES: O(C1C(O)C(OC2OC(=CCC2N)CN)C(N)CC1N)C1OCC(O)(C(NC)C1O)C.
This classification denotes an aminoglycoside antibiotic with the molecular formula 2C19H37N5O7.5H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K14444371C, chemically known as o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1->6))-2-deoxy-l-streptamine sulfate (2:5) (salt) but more generally known as sisomicin sulfate, which bears US NIH Compound Identifier 65334. European Medicines Agency schedules Sisomicin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04405MIG. Most nations, for tariff and trade purposes, schedule sisomicin sulfate under HS 29419000 and SITC 54139. Sisomicin sulfate bears US NLM identifiers UMLS ID C0037210 and NCI Concept Code C84147. SMILES: As of Q4 2014, SISOMICIN SULFATE remains US FDA's Preferred Term for this commodity.
This classification denotes a quinolone antibiotic with the molecular formula C19H18ClF2N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3GJC60U4Q8, chemically known as 7-((7s)-amino-5-azaspiro(2,4)heptan-5-yl)-8-chloro-6-fluoro-1-((1r,2r)-cis-2-fluoro-1-cyclopropyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid but generally known as sitafloxacin, which bears US NIH Compound Identifier 73011. European Medicines Agency schedules Sitafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10539MIG. The term SITAFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). World Health Organization schedules sitafloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule sitafloxacin under HS 29334910 and SITC 51575. As of Q4 2014, SITAFLOXACIN remains the US FDA Preferred Term for this commodity. Sitafloxacin bears US NLM identifiers UMLS ID C0171447 and NCI Concept Code C76922. SMILES: CLC1C(N2CC3(CC3)C(N)C2)C(F)CC2C1N(C1C(F)C1)CC(C2=O)C(=O)O.
This classification denotes a protease inhibitor with the molecular formula C16H15F6N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) QFP0P1DV7Z, chemically known as 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate but more generally known as sitagliptin, which bears US NIH Compound Identifier 6451150. European Medicines Agency schedules Sitagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25227 WHO schedules sitagliptin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule sitagliptin under HS 29335990 and SITC 51576. As of Q4 2014, SITAGLIPTIN remains US FDA's Preferred Term for this commodity. Sitagliptin bears US NLM identifiers UMLS ID C1565750 and NCI Concept Code C73838. SMILES: P(=O)(O)(O)O.FC(F)(F)C1N2CCN(CC2NN1)C(=O)CC(N)CC1C(F)CC(F)C(F)C1.
This classification denotes a protease inhibitor and anti-diabetic agent with the molecular structure C16H15F6N5O.H2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, TS63EW8X6F chemically known as 1,2,4-triazolo(4,3-a)pyrazine, 7-((3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydro-3-(trifluoromethyl), phosphate (1:1) monohydrate, but more commonly known as sitagliptin phosphate, which bears US NIH Compound Identifier 11591741. European Medicines Agency schedules Sitagliptin phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25200. Most nations, for tariff and trade purposes, schedule sitagliptin phosphate under HS 29335990 and SITC 51576. As of Q4 2014, SITAGLIPTIN PHOSPHATE remains US FDA's Preferred Term for this commodity. Sitagliptin phosphate bears US NLM identifiers UMLS ID C1667080 and NCI Concept Code C73811. SMILES: C1C(C(CC(C1F)F)F)C[C@H](CC(=O)N2CCN3C(NNC3C(F)(F)F)C2)N.O.OP(=O)(O)O.
This classification denotes a protease inhibitor and anti-diabetic agent with the molecular structure C16H15F6N5O.H2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, TS63EW8X6F chemically known as 1,2,4-triazolo(4,3-a)pyrazine, 7-((3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydro-3-(trifluoromethyl), phosphate (1:1) monohydrate, but more commonly known as sitagliptin phosphate, which bears US NIH Compound Identifier 11591741. European Medicines Agency schedules Sitagliptin phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25200. Most nations, for tariff and trade purposes, schedule sitagliptin phosphate hydrate under HS 29335990. SMILES: C1C(C(CC(C1F)F)F)C[C@H](CC(=O)N2CCN3C(NNC3C(F)(F)F)C2)N.O.OP(=O)(O)O.
This classification denotes a diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06H9KWB6IB. European Medicines Agency schedules Sitalidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10540MIG. Sitalidone generally arises in the molecular formula C23H29CLN2O5S. The term SITALIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) Most nations schedule sitalidone under HS 29350090 and SITC 51580. As of Q4 2014, SITALIDONE remains the US FDA Preferred Term for this commodity. Sitalidone bears US NLM identifiers UMLS ID C2699304 and NCI Concept Code C74251. SMILES: CLC1C(S(=O)(=O)NC2CC(C(C)C)C(O)C(C(C)C)C2)CC(C2(O)N(C(=O)CC2)C)CC1.
This classification denotes an antiprotozoal agent with the molecular formula C21H33N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AIJ4TGC6B, chemically known as 1,6-hexanediamine, n,n-diethyl-n-(6-methoxy-4-methyl-8-quinolinyl)- but generally known as sitamaquine, which bears US NIH Compound Identifier 42548. European Medicines Agency schedules Sitamaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37607. The term SITAMAQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule sitamaquine under HS 29334990 and SITC 51575. As of Q4 2014, SITAMAQUINE remains the US FDA Preferred Term for this commodity. Sitamaquine bears US NLM identifiers UMLS ID C1099477 and NCI Concept Code C73010. SMILES: O(C1CC(NCCCCCCN(CC)CC)C2NCCC(C2C1)C)C.
This classification denotes an endothelin-1 protein receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J9QH779MEM. European Medicines Agency schedules Sitaxentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22917. Sitaxentan generally arises in the molecular formula C18H15CLN2O6S2. The term SITAXENTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule sitaxentan under HS 29350090 and SITC 51580. As of Q4 2014, SITAXENTAN remains the US FDA Preferred Term for this commodity. Sitaxentan bears US NLM identifiers UMLS ID C1704271 and NCI Concept Code C73038. SMILES: CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2.
This classification denotes an endothelin-1 protein receptor antagonist C18H14ClN2O6S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6V9JH46E20, chemically known as n-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-(2-(6-methyl-2h-1,3-benzodioxol-5-yl)acetyl)thiophene-3-sulfonamide sodium salt, but more generally known as sitaxentan sodium, which bears US NIH Compound Identifier 11477084. European Medicines Agency schedules Sitaxentan sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22351. Most nations, for tariff and trade purposes, schedule sitaxentan sodium under HS 29350090 and SITC 51580. As of Q4 2014, SITAXENTAN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C(CC1CC(=O)C3C(CCS3)S(=O)(=O)[N-]C4C(C(NO4)C)CL)OCO2.[NA+].
This classification denotes a protease inhibitor with the molecular formula C20H22N2O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DWI62G0P59, chemically known as o-(p-hydroxybenzenesulfonamido)hippuric acid, pivalate (ester) but generally known as sivelestat, which bears US NIH Compound Identifier 107706. European Medicines Agency schedules Sivelestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10543MIG. The term SIVELESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). Most nations schedule sivelestat under HS 29350090 and SITC 51580. As of Q4 2014, SIVELESTAT remains the US FDA Preferred Term for this commodity. Sivelestat bears US NLM identifiers UMLS ID C0130137 and NCI Concept Code C66539. SMILES: S(=O)(=O)(NC1C(CCCC1)C(=O)NCC(=O)O)C1CCC(OC(=O)C(C)(C)C)CC1.
This classification denotes a vaccine an acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers 4V1PP5J0HJ (whole), RI2K1BMA8B (root), and 3988313MM7, the source product of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 20039 Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Caryophyllanae, Order Caryophyllales, Family Caryophyllaceae (pinks), Genus Saponaria L. (soapwort), Species Saponaria officinalis L., commonly known as SOAPWORT, BOUNCINGBET, BOUNCINGBET SOAPWEED, BOUNCING BET, SWEET BETTY, or as here, SAPONARIA. Saponaria bears the USDA PLANTS Database Identifier SAOF4. European Medicines Agency schedules saponaria in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB46975. SMILES: NONE.
This classification denotes a vinca-site binding agent and dolastatin compound with the molecular formula C39H67N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQC51A0WQH, chemically known as n(2)-(n,n-dimethyl-valyl)-n-(2-methoxy-4-(2-(1-methoxy-2-methyl-3-oxo-3-((2-phenylethyl)amino)propyl)-1-pyrrolidinyl)-1-(1-methylpropyl)-4-oxobutyl)-n-methyl-valinamide but generally known as soblidotin, which bears US NIH Compound Identifier 124092. The term SOBLIDOTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule soblidotin under HS 29339990 and SITC 51577. As of Q4 2014, SOBLIDOTIN remains the US FDA Preferred Term for this commodity. Soblidotin bears US NLM identifiers UMLS ID C1328702 and NCI Concept Code C26672. SMILES: CCC(C)C(C(CC(=O)N1CCC(C1)C(C(C)C(=O)NCCC2=CC=CC=C2)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C.
This classification denotes an expectorant with the molecular formula C10H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AI0NX02O35, chemically known as 5-hydroxy-alpha,alpha,4-trimethylcyclohex-3-ene-1-methanol but more generally known as sobrerol, which bears US NIH Compound Identifier 91463. European Medicines Agency schedules Sobrerol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15264MIG. World Health Organization schedules sobrerol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SOBREROL remains US FDA's Preferred Term for this commodity. SMILES: CC1=CCC(CC1O)C(C)(C)O.
This classification denotes an electrolyte replacement agent with the molecular formula C2H3O2.Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4550K0SC9B, chemically known as mercury acetate, hg (oac)2, compd. with 1,4-dihydroanthracene (1:1) but generally known as sodium acetate, which bears US NIH Compound Identifier 176. European Medicines Agency schedules Sodium acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12576MIG. World Health Organization schedules sodium acetate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule sodium acetate under HS 29152900 and SITC 51371. As of Q4 2014, SODIUM ACETATE remains the US FDA Preferred Term for this commodity. Sodium acetate bears US NLM identifiers UMLS ID C0142785 and NCI Concept Code C47720. SMILES: OC(=O)C.
This classification denotes an anticoagulant agent and a alkyl sulfonate, phosphogluconate dehydrogenase antagonists and inhibitor, polyvinyl, polyethylene, and sulfonic acid with the molecular formula C2H3NaO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9461405D9F, chemically known as sodium;ethenesulfonate but generally known as sodium apolate, which bears US NIH Compound Identifier 3270262. European Medicines Agency schedules Sodium Apolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05545MIG. The term SODIUM APOLATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Vol 20 1966, List 6). Most nations schedule sodium apolate under HS 39019090 and SITC 57190. SMILES: C=CS(=O)(=O)[O-].[Na+]
This classification denotes a protein kinase c inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E4768ZY6GM. European Medicines Agency schedules Sodium aurothiomalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10550MIG. Sodium aurothiomalate generally arises in the molecular formula C4H6O4SXNA. The term SODIUM AUROTHIOMALATE is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule sodium aurothiomalate under HS 28433000 and SITC 52432. SMILES: C(C(C(=O)[O-])[S-])C(=O)[O-].[Na+].[Na+].[Au+].
This classification denotes an antirheumatic agent with the molecular formula Au.3Na.2O3S2.2H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier CKS1YQ9W1J, chemically known as aurate(3-), bis(monothiosulfato)-, trisodium but more generally known as sodium aurothiosulfate or gold sodium thiosulfate, which bears US NIH Compound Identifier 27176. SMILES: OS(=O)(=O)[S-].OS(=O)(=O)[S-].[Na+].[Na+].[Na+].[Au].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA110. This VA Drug Class (GA110) classifies this compound as belonging to the group SODIUM BICARBONATE CONTAINING ANTACIDS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX900. This VA Drug Class (DX900) classifies this compound as belonging to the group DIAGNOSTICS, OTHER.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.
This classification denotes a sedative and hypnotic and anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LC1V549NOM. European Medicines Agency schedules Sodium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15275MIG. Sodium bromide generally arises in the molecular formula BRNA. The term SODIUM BROMIDE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule sodium bromide under HS 28275100 and SITC 52329. As of Q4 2014, SODIUM BROMIDE remains the US FDA Preferred Term for this commodity. Sodium bromide bears US NLM identifiers UMLS ID C0074730 and NCI Concept Code C83922. SMILES: [Na+].[Br-].
This classification denotes an antifungal agent with the molecular formula C8H15O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9XTM81VK2B, chemically known as octanoic acid, sodium salt but generally known as sodium caprylate, which bears US NIH Compound Identifier 16123. European Medicines Agency schedules Sodium caprylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12579MIG. As of Q4 2014, SODIUM CAPRYLATE remains the US FDA Preferred Term for this commodity. Sodium caprylate bears US NLM identifiers UMLS ID C0142816 and NCI Concept Code C74148. SMILES: CCCCCCCC(=O)[O-].[Na+].
This classification denotes an electrolyte solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 451W47IQ8X, chemically known as sodium;chloride, more generally known as sodium chloride or saline, US NIH Compound Identifier 5234. European Medicines Agency schedules Sodium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12581MIG. Sodium chloride generally arises in the molecular formula CLNA. The term 'sodium chloride' is an FDA designation, but the term COMPOUND SOLUTION OF SODIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, 1955, 9, 185-194, List 1.) SMILES: [Na+].[Cl-].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD200. This VA Drug Class (AD200) classifies this compound as belonging to the group CYANIDE ANTIDOTES.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN202. This VA Drug Class (CN202) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE ANESTHETICS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV200. This VA Drug Class (CV200) classifies this compound as belonging to the group CALCIUM CHANNEL BLOCKERS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN900. This VA Drug Class (AN900) classifies this compound as belonging to the group ANTINEOPLASTIC, OTHER.
This classification denotes an electrolyte replacement agent and anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q73Q2JULR. European Medicines Agency schedules Sodium citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12582MIG. Sodium citrate generally arises in the molecular formula C6H5NA3O7. The term 'sodium citrate' is a U.S. Pharmacopeial Convention designation. As of Q4 2014, SODIUM CITRATE remains the US FDA Preferred Term for this commodity. Sodium citrate bears US NLM identifiers UMLS ID C0142825 and NCI Concept Code C62075. SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+].[Na+].[Na+].
This classification denotes a chelating agent with the molecular formula C10H12N2O8.4Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MP1J8420LU, chemically known as tetrasodium ethylenediamine-n,n,n,n-tetraacetate but generally known as edetate sodium, which bears US NIH Compound Identifier 6144. European Medicines Agency schedules Edetate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37153. World Health Organization schedules edetate sodium in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule sodium edetate under HS 29224990 and SITC 51465. SMILES: [NA].[NA].[NA].[NA].OC(=O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.
This classification denotes a nutritional supplement with the molecular formula C10H12N2O8.Fe.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 403J23EMFA, chemically known as sodium (n,n,n,n-ethylenediaminetetraacetato)ferrate(1-) but generally known as sodium feredetate, which bears US NIH Compound Identifier 27461. European Medicines Agency schedules Sodium feredetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10560MIG. World Health Organization schedules sodium feredetate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule sodium feredetate under HS 29224995 and SITC 51465. As of Q4 2014, SODIUM FEREDETATE remains the US FDA Preferred Term for this commodity. Sodium feredetate bears US NLM identifiers UMLS ID C0357084 and NCI Concept Code C76827. SMILES: C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Fe+5].
This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CC9149U2QX. European Medicines Agency schedules Sodium ferric gluconate complex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20743. Ferric na gluconate generally arises in the molecular formula C6H11O7.FE.NA. The term 'ferric na gluconate' is a United States Adopted Name designation. SMILES: [FE].[NA].OC(C(O)C(O)C(=O)O)C(O)CO.
This classification denotes a reagent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ZYQ1474W7. The European Medicines Agency schedules Sodium fluoride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15285MIG. Sodium fluoride generally arises in the molecular formula FNA. The term 'sodium fluoride' is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule Sodium fluoride under HS 28261900. SMILES: [F-].[Na+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX202. This VA Drug Class (DX202) classifies this compound as belonging to the group NON-IMAGING AGENTS RADIOPHARMACEUTICALS.
This classification denotes a reagent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier DY38VHM5OD. European Medicines Agency schedules Sodium hypochlorite in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15292MIG. Sodium hypochlorite generally arises in the molecular formula CLHO.NA. The term 'sodium hypochlorite' is a United States Homeopathic Pharmacopoeia Name designation.
This classification denotes a sodium iodide radioactive with the molecular formula I.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29UKX3A616. The term sodium iodide i 123 is a U.S. FDA designation. As of Q4 2014, SODIUM IODIDE I-123 remains the US FDA Preferred Term for this commodity. Sodium iodide i-123 bears US NLM identifiers UMLS ID C0304977 and NCI Concept Code C47724. SMILES: [NA+].[123I-].
This classification denotes a sodium iodide radioactive with the molecular formula NAI, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29VCO8ACHH, more generally known as sodium iodide i-131. European Medicines Agency schedules sodium iodide i-131 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12294MIG. The term SODIUM IODIDE (131I) is an International Non-Proprietary Name or INN. As of Q4 2014, SODIUM IODIDE I-131 remains the US FDA Preferred Term for this commodity. Sodium iodide i-131 bears US NLM identifiers UMLS ID C0304982 and NCI Concept Code C47725. SMILES: [Na+].[I-].
This classification denotes a diagnostic reagent with the molecular formula C12H12I3N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F316LLW9WW, chemically known as 2,4,6-triiodo-3-((dimethylaminomethylene)amino)hydrocinnamic acid but more generally known as ipodate sodium, which bears U.S. National Institutes of Health Compound Identifier 5241. European Medicines Agency schedules Sodium iopodate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12441MIG. The term SODIUM IOPODATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules ipodate sodium in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule sodium iopodate under HS 29252900 and SITC 51482. SMILES: CN(C)C=NC1=C(C=C(C(=C1I)CCC(=O)[O-])I)I.[Na+].
This classification denotes an iodinated contrast dye with the molecular formula C24H20I6N5O8.Na, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier HQ43CN02U9, chemically known as sodium n-(2-hydroxyethyl)-2,4,6-triiodo-5-(2-(2,4,6-triiodo-3-(n-methylacetamido)-5-(methylcarbamoyl)benzamido)acetamido)isophthalamate but more generally known as ioxaglate sodium, which bears U.S. National Institutes of Health Compound Identifier 50016. The European Medicines Agency schedules Ioxaglate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02757MIG. SMILES: CC(=O)N(C)C1=C(C(=C(C(=C1I)C(=O)NCC(=O)NC2=C(C(=C(C(=C2I)C(=O)[O-])I)C(=O)NCCO)I)I)C(=O)NC)I.[Na+].
This classification denotes an electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TU7HW0W0QT. European Medicines Agency schedules Sodium lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15300MIG. Sodium lactate generally arises in the molecular formula C3H6O3.NA. The term SODIUM LACTATE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule sodium lactate under HS 29181100 and SITC 51391. As of Q4 2014, SODIUM LACTATE remains the US FDA Preferred Term for this commodity. Sodium lactate bears US NLM identifiers UMLS ID C0142874 and NCI Concept Code C47726. SMILES: OC(C)C(=O)O.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE400. This VA Drug Class (DE400) classifies this compound as belonging to the group SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS.
This classification denotes an anesthesia adjuvant with the molecular formula C4H7O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7G33012534, chemically known as gamma-hydroxybutyric acid, sodium salt but generally known as sodium oxybate, which bears US NIH Compound Identifier 10412. European Medicines Agency schedules Sodium oxybate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14731MIG. World Health Organization schedules sodium oxybate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SODIUM OXYBATE remains the US FDA Preferred Term for this commodity. Sodium oxybate bears US NLM identifiers UMLS ID C0037537 and NCI Concept Code C61870. SMILES: C(CC(=O)[O-])CO.[Na+].
This classification denotes an industrial aid with the molecular formula BO3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y52BK1W96C, chemically known as perboric acid, sodium salt but generally known as sodium perborate, which bears US NIH Compound Identifier 24270. European Medicines Agency schedules Sodium perborate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15311MIG. World Health Organization schedules sodium perborate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule sodium perborate under HS 28403000 and SITC 52384. As of Q4 2014, SODIUM PERBORATE remains the US FDA Preferred Term for this commodity. Sodium perborate bears US NLM identifiers UMLS ID C0074750 and NCI Concept Code C84164. SMILES: B(=O)O[O-].O.[NA+].
This classification denotes a phenylbutyrate and antineoplastic agent with the molecular formula C10H11O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NT6K61736T, chemically known as benzenebutanoic acid, sodium salt but generally known as sodium phenylbutyrate, which bears US NIH Compound Identifier 15585. European Medicines Agency schedules Sodium phenylbutyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12586MIG. World Health Organization schedules sodium phenylbutyrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SODIUM PHENYLBUTYRATE remains the US FDA Preferred Term for this commodity. Sodium phenylbutyrate bears US NLM identifiers UMLS ID C0718066 and NCI Concept Code C1440. SMILES: C1=CC=C(C=C1)CCCC(=O)[O-].[NA+].
This classification denotes an electrolyte replacement agent with the molecular formula NAH2PO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SE337SVY37, more generally known as sodium phosphate. European Medicines Agency schedules sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12587MIG. The term SODIUM PHOSPHATE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 25 , no. 10 1971, list 11. Most nations schedule sodium phosphate under HS 28444030 and SITC 52519. As of Q4 2014, SODIUM PHOSPHATE remains the US FDA Preferred Term for this commodity. Sodium phosphate bears US NLM identifiers UMLS ID C0074757 and NCI Concept Code C29459. SMILES: [O-]P(=O)([O-])[O-].[NA+].[NA+].[NA+].
The combination salts increase the osmotic pressure in the intestinal lumen promoting the retention of fluid in the colon, it will become fluid and thus release the fecal matter. In addition, there is a physiological increase in peristalsis that makes their elimination practically total.
This classification denotes a laxative with the molecular formula C18H13NO8S2.2Na, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier LR57574HN8, chemically known as 4,4-(2-pyridylmethylene)diphenolbis(hydrogen sulfate) (ester) disodium salt but more generally known as picosulfate sodium, which bears U.S. NIH Compound Identifier 68654. European Medicines Agency schedules Picosulfate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10569MIG. The term PICOSULFATE SODIUM is an International Non-Proprietary Name. World Health Organization schedules picosulfate sodium in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes an electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1699G8679Z. European Medicines Agency schedules Sodium polystyrene sulfonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15321MIG. Sodium polystyrene sulfonate generally arises in the molecular formula (C8H8(C2H3)XL)N.(C8H8O3S)N.NA. The term 'sodium polystyrene sulfonate' is an FDA designation. As of Q4 2014, SODIUM POLYSTYRENE SULFONATE remains the US FDA Preferred Term for this commodity. Sodium polystyrene sulfonate bears US NLM identifiers UMLS ID C0142915 and NCI Concept Code C29461. SMILES: C=CC1=CC=CC=C1S(=O)(=O)[O-].[CA+2].
This classification denotes an industrial aid with the molecular formula C3H5O2.Na.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier DK6Y9P42IN, chemically known as propionic acid, sodium salt but more generally known as sodium propionate, which bears U.S. NIH Compound Identifier 8724. European Medicines Agency schedules Sodium propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15322MIG. World Health Organization schedules sodium propionate in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WIQ1H85SYP. European Medicines Agency schedules Sodium salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12306MIG. Sodium salicylate generally arises in the molecular formula C7H5NAO3. The term 'sodium salicylate' is a United States Homeopathic Pharmacopoeia Name designation. As of Q4 2014, SODIUM SALICYLATE remains the US FDA Preferred Term for this commodity. Sodium salicylate bears US NLM identifiers UMLS ID C0037549 and NCI Concept Code C834. SMILES: C1=CC=C(C(=C1)C(=O)[O-])O.[Na+].
This classification denotes an enzyme inhibitor and antiparasitic agent with the molecular formula C12H18O17Sb2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V083S0159D, chemically known as trinatrium bis(gluconato(3)-o2,o3,o4)hydroxooxido-oxy-bis-antimonat(v) but generally known as sodium stibogluconate, which bears US NIH Compound Identifier 16683012. European Medicines Agency schedules Sodium stibogluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04492MIG. World Health Organization schedules sodium stibogluconate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Sodium stibogluconate under HS 29420000 and SITC 51699. As of Q4 2014, SODIUM STIBOGLUCONATE remains the US FDA Preferred Term for this commodity. Sodium stibogluconate bears US NLM identifiers UMLS ID C0030895 and NCI Concept Code C61083. SMILES: C([C@H]([C@@H]1[C@@H]([C@@H](O[SB](=O)(O1)O[SB]2(=O)O[C@@H]([C@@H]([C@@H](O2)C(=O)[O-])O)[C@@H](CO)O)C(=O)[O-])O)O)O.[NA+].[NA+].
This classification denotes an electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0YPR65R21J. European Medicines Agency schedules Sodium sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15325MIG. Sodium sulfate generally arises in the molecular formula NA2O4S. The term 'sodium sulfate' is a United States Homeopathic Pharmacopoeia Name designation. As of Q4 2014, SODIUM SULFATE remains the US FDA Preferred Term for this commodity. Sodium sulfate bears US NLM identifiers UMLS ID C0074769 and NCI Concept Code C47727. SMILES: S(=O)(=O)(O)O.
An injectable sterile nonpyrogenic solution for intravenous use as a sclerosing agent.
This classification denotes an anesthetic agent with the molecular formula C11H18N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JI8Z5M7NA3, chemically known as 4,6,(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo- (9ci) but generally known as thiopental, which bears US NIH Compound Identifier 3000715. European Medicines Agency schedules Thiopental in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04816MIG. World Health Organization schedules thiopental in its Anatomical Therapeutic Chemical (ATC) Classification. THIOPENTAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCCC(C)C1(C(=O)NC(=S)NC1=O)CC.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H5O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2D9ITW04B, chemically known as 2-mercapto-benzoic acid, monosodium salt but generally known as sodium thiosalicylate, which bears US NIH Compound Identifier 8636. European Medicines Agency schedules Sodium thiosalicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15331MIG. As of Q4 2014, SODIUM THIOSALICYLATE remains the US FDA Preferred Term for this commodity. Sodium thiosalicylate bears US NLM identifiers UMLS ID C0304347 and NCI Concept Code C87326. SMILES: SC1C(CCCC1)C(=O)O.[NA].
This classification denotes a protective agent with the molecular formula 2Na.O3S2.5H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HX1032V43M, chemically known as thiosulfuric acid (h2s2o3), disodium salt but generally known as sodium thiosulfate, which bears US NIH Compound Identifier 24477. European Medicines Agency schedules Sodium thiosulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15332MIG. SMILES: [O-]S(=O)(=S)[O-].[NA+].[NA+].
A medication used as an antidote in cases of cyanide poisoning. Thiosulfate acts as a sulfur donor to produce the conversion of cyanide to thiocyanate, which can then be safely excreted through urine, that conversion is catalyzed by the enzyme rhodamine (rhodanase). It has also been used as a treatment for calciphylaxis in patients undergoing hemodialysis, who have chronic kidney disease. It is also used in the management of extravasation of urine in chemotherapy. Sodium thiosulfate prevents alkylation and tissue destruction, providing a substrate for the alkylating agents that have invaded the subcutaneous tissues. It is also used in foot baths for the prophylaxis of dermatophytosis and as a topical antifungal agent for Pityriasis versicolor.
This classification denotes a contrast media with the molecular formula C15H18I3NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F05V145YR, chemically known as 3-butyramido-alpha-ethyl-2,4,6-triiodohydrocinnamic acid sodium salt but more generally known as tyropanoic acid, which bears U.S. National Institutes of Health Compound Identifier 23676. The European Medicines Agency schedules Tyropanoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05028MIG. The World Health Organization schedules tyropanoic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)[O-])I)I.[Na+]. Most nations schedule Sodium tyropanoate or tyropanoic acid under HS 29242995.
Antiviral for the treatment of Hepatitis C virus infections
Sofosbuvir/velpatasvir is a fixed-dose combination medication for the treatment of hepatitis C in adults.
This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H12JE4313S. European Medicines Agency schedules Solasulfone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10575MIG. Solasulfone generally arises in the molecular formula C30H28N2NA4O14S5. The term SOLASULFONE is an International Non-Proprietary Name or INN. SOLASULFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(O)C(CC(S(=O)(=O)O)NC1CCC(S(=O)(=O)C2CCC(NC(S(=O)(=O)O)CC(S(=O)(=O)O)C3CCCCC3)CC2)CC1)C1CCCCC1.[NA].[NA].[NA].[NA].
This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8910SQJ1U. European Medicines Agency schedules Solifenacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21589. Solifenacin generally arises in the molecular formula C23H26N2O2. The term SOLIFENACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations schedule solifenacin under HS 29334990 and SITC 51575. As of Q4 2014, SOLIFENACIN remains the US FDA Preferred Term for this commodity. Solifenacin bears US NLM identifiers UMLS ID C1099677 and NCI Concept Code C75284. SMILES: O(C1C2CCN(C1)CC2)C(=O)N1C(c2c(CC1)cccc2)c1ccccc1.OC(=O)CCC(=O)O.
This classification denotes an antiviral agent with the molecular formula C14H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 02WMX1FS9Y chemically known as .alpha.,.alpha.-dimethyl-1-adamantaneethylamine but generally known as somantadine, which bears US NIH Compound Identifier 600809. European Medicines Agency schedules Somantadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10580MIG. The term SOMANTADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24. ). Most nations schedule somantadine under HS 29213099 and SITC 51453. As of Q4 2014, SOMANTADINE remains the US FDA Preferred Term for this commodity. Somantadine bears US NLM identifiers UMLS ID C2827334 and NCI Concept Code C84174. SMILES: NCC(C12CC3CC(C2)CC(C1)C3)(C)C.
This classification denotes an antiviral agent with the molecular formula C14H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I505KI9F8Q, chemically known as 2-(1-adamantyl)-1,1-dimethylethylamin hydrochlorid but more generally known as somantadine hydrochloride, which bears US NIH Compound Identifier 3033453. Most nations, for tariff and trade purposes, schedule somantadine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, SOMANTADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Somantadine hydrochloride bears US NLM identifiers UMLS ID C2825701 and NCI Concept Code C81610. SMILES: CC(C)(C[C@]12C[C@@H]3C[C@H](C1)CC(C3)C2)N.CL.
This classification denotes a hypothalmic hormone, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6E20216Q0L. European Medicines Agency schedules Somatostatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12320MIG. Somatostatin generally arises in the molecular formula C76H104N18O19S2. The term SOMATOSTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) SOMATOSTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule somatostatin under HS 29371900 and SITC 54154. As of Q4 2014, SOMATOSTATIN remains the US FDA Preferred Term for this commodity. Somatostatin bears US NLM identifiers UMLS ID C0037659 and NCI Concept Code C28418. SMILES: S1SCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(N)C)C1)CCCCN)CC(=O)N)CC1CCCCC1)CC1CCCCC1)CC1C2C([NH]C1)CCCC2)CCCCN)C(O)C)CC1CCCCC1)C(O)C)CO)C(=O)O.
This classification denotes a pituitary agent with the molecular formula C995H1537N263O301S8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU8D464EDW, more generally known as somatrem. European Medicines Agency schedules somatrem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10583MIG. The term SOMATREM is an International Non-Proprietary Name or INN. SOMATREM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule somatrem under HS 29371100 and SITC 54154. As of Q4 2014, SOMATREM remains the US FDA Preferred Term for this commodity. Somatrem bears US NLM identifiers UMLS ID C0143083 and NCI Concept Code C66556. SMILES: NONE.
This classification denotes a protein kinase inhibitor with the molecular formula C21H16ClF3N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZOQ3TZI87, chemically known as 2-pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-n-methyl- but generally known as sorafenib, which bears US NIH Compound Identifier 216239. European Medicines Agency schedules Sorafenib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23139. The term SORAFENIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules sorafenib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule sorafenib under HS 29333999 and SITC 51574. As of Q4 2014, SORAFENIB remains the US FDA Preferred Term for this commodity. Sorafenib bears US NLM identifiers UMLS ID C1516119 and NCI Concept Code C61948. SMILES: CLC1C(CC(NC(=O)NC2CCC(OC3CC(NCC3)C(=O)NC)CC2)CC1)C(F)(F)F.
This classification denotes a protein kinase inhibitor with the molecular formula C21H16ClF3N4O3.C7H8O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T62Q3B36J, chemically known as 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonate), but more generally known as sorafenib tosylate, which bears US NIH Compound Identifier 216239. European Medicines Agency schedules sorafenib tosylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23139. Sorafenib tosylate bears US NLM identifiers UMLS ID C1676709 and NCI Concept Code C2194. Most nations, for tariff purposes, schedule sorafenib tosylate under HS 29333999. SMILES: CC1CCC(CC1)S(=O)(=O)O.CNC(=O)C1CC(CCN1)OC2CCC(CC2)NC(=O)NC3CCC(C(C3)C(F)(F)F)CL.
This classification denotes a dihydropyrimidine dehydrogenase inhibitor with the molecular formula C11H13BrN2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7VOZ162LV, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-beta-d-arabinofuranosyl-5-(2-bromoethenyl)-, (e)- but generally known as sorivudine, which bears US NIH Compound Identifier 5282192. European Medicines Agency schedules Sorivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10605MIG. The term SORIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). SORIVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sorivudine under HS 29349990 and SITC 51579. As of Q4 2014, SORIVUDINE remains the US FDA Preferred Term for this commodity. Sorivudine bears US NLM identifiers UMLS ID C0207628 and NCI Concept Code C1460. SMILES: C1=C(C(=O)NC(=O)N1C2C(C(C(O2)CO)O)O)C=CBR.
This classification denotes a calcium channel blocker, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z82YP691V7. European Medicines Agency schedules Sornidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10606MIG. Sornidipine generally arises in the molecular formula C22H24N2O9. The term SORNIDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) SORNIDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sornidipine under HS 29349990 and SITC 51579. As of Q4 2014, SORNIDIPINE remains the US FDA Preferred Term for this commodity. Sornidipine bears US NLM identifiers UMLS ID C2699493 and NCI Concept Code C74227. SMILES: O1C2C(OCC2O)C(OC(=O)C2=C(NC(=C(C2c2c([N](=O)O)cccc2)C(=O)OC)C)C)C1.
This classification denotes a cation channel blocker and adrenergic antagonist with the molecular formula C12H20N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) A6D97U294I, chemically known as methanesulfonanilide, 4-(1-hydroxy-2-(isopropylamino)ethyl)- but more generally known as sotalol, which bears US NIH Compound Identifier 5253. European Medicines Agency schedules Sotalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10607MIG. The term SOTALOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules sotalol in its Anatomical Therapeutic Chemical (ATC) Classification. SOTALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sotalol under HS 29350090 and SITC 51580. As of Q4 2014, SOTALOL remains US FDA's Preferred Term for this commodity. Sotalol bears US NLM identifiers UMLS ID C0037707 and NCI Concept Code C61949. SMILES: S(=O)(=O)(NC1CCC(C(O)CNC(C)C)CC1)C.
Soy flour/polyvidone is a combination used in acute and subacute, extensive or localized dermatoses.
Medication that helps against vaginal dryness.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X81L78B3RB. European Medicines Agency schedules Spaglumic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10609MIG. Spaglumic acid generally arises in the molecular formula C11H16N2O8. The term SPAGLUMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) Most nations schedule spaglumic acid under HS 29241900 and SITC 51471. As of Q4 2014, SPAGLUMIC ACID remains the US FDA Preferred Term for this commodity. Spaglumic acid bears US NLM identifiers UMLS ID C2348231 and NCI Concept Code C72084. SMILES: CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O.
This classification denotes a quinolone antibiotic and antitubercular agent with the molecular formula C19H22F2N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q90AGA787L, chemically known as 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, but generally known as sparfloxacin, which bears US NIH Compound Identifier 5257. European Medicines Agency schedules Sparfloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10610MIG. The term SPARFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules sparfloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. SPARFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sparfloxacin under HS 29335995 and SITC 51576. As of Q4 2014, SPARFLOXACIN remains the US FDA Preferred Term for this commodity. Sparfloxacin bears US NLM identifiers UMLS ID C0052585 and NCI Concept Code C61950. SMILES: FC1C2N(C3CC3)CC(C(=O)C2C(N)C(F)C1N1CC(NC(C1)C)C)C(=O)O.
This classification denotes an antiarrhythmic and oxytocic quinolizidine alkaloid with the molecular formula C15H26N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 298897D62S, chemically known as 6-beta,7-alpha,9-alpha,11-alpha-pachycarpinE but more generally known as sparteine, which bears US NIH Compound Identifier 644020. The term SPARTEINE is an International Non-Proprietary Name or INN. European Medicines Agency schedules sparteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10613MIG. Most nations, for tariff and trade purposes, schedule sparteine under HS 29399900 and SITC 54149. As of Q4 2014, SPARTEINE remains US FDA's Preferred Term for this commodity. SMILES: C1CCN2CC3CC(C2C1)CN4C3CCCC4.
This classification denotes an aminoglycoside antibiotic with the molecular formula C14H24N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 93AKI1U6QF, chemically known as 4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- but generally known as spectinomycin, which bears US NIH Compound Identifier 2021. European Medicines Agency schedules Spectinomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10614MIG. The term SPECTINOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules spectinomycin in its Anatomical Therapeutic Chemical (ATC) Classification. SPECTINOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spectinomycin under HS 29419000 and SITC 54139. As of Q4 2014, SPECTINOMYCIN remains the US FDA Preferred Term for this commodity. Spectinomycin bears US NLM identifiers UMLS ID C0001268 and NCI Concept Code C61951. SMILES: O1C2C(OC3OC(CC(=O)C13O)C)C(O)C(NC)C(O)C2NC.
This classification denotes an aminoglycoside antibiotic with the molecular formula C14H24N2O7.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 296JEI210Z, chemically known as 4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, dihydrochloride, but more generally known as spectinomycin dihydrochloride, which bears US NIH Compound Identifier 2021. European Medicines Agency schedules spectinomycin dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10614MIG. Most nations, for tariff purposes, schedule spectinomycin dihydrochloride under HS 29419000. SMILES: C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O.CL.CL.
This classification denotes an aminoglycoside antibiotic with the molecular formula C14H24N2O7.2ClH.5H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HWT06H303Z, chemically known as 4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, dihydrochloride, pentahydrate but more generally known as spectinomycin dihydrochloride pentahydrate, which bears US NIH Compound Identifier 30971. European Medicines Agency schedules Spectinomycin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12327MIG. Most nations, for tariff and trade purposes, schedule spectinomycin dihydrochloride pentahydrate under HS 29419000. SMILES: C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O.O.O.O.O.O.CL.CL.
This classification denotes an aminoglycoside antibiotic with the molecular formula C14H24N2O7.2ClH.5H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HWT06H303Z, chemically known as 4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, dihydrochloride, pentahydrate but more generally known as spectinomycin dihydrochloride pentahydrate, which bears US NIH Compound Identifier 30971. European Medicines Agency schedules Spectinomycin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12327MIG. Most nations, for tariff and trade purposes, schedule spectinomycin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, SPECTINOMYCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Spectinomycin hydrochloride bears US NLM identifiers UMLS ID C0887525 and NCI Concept Code C47728. SMILES: C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O.O.O.O.O.O.CL.CL.
This classification denotes an aminoglycoside antibiotic with the molecular formula C14H24N2O7.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 296JEI210Z, chemically known as 4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, dihydrochloride, but more generally known as spectinomycin hydrochloride anhydrous, which bears US NIH Compound Identifier 3033928. European Medicines Agency schedules spectinomycin hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10614MIG. Most nations, for tariff purposes, schedule spectinomycin hydrochloride anhydrous under HS 29419000. Spectinomycin hydrochloride anhydrous bears US NLM identifiers UMLS ID C2983839 and NCI Concept Code C90690. SMILES: C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O.CL.CL.
This classification denotes an antibiotic with the molecular formula C14H24N2O7.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BZ0H4TLF9X. Most nations, for tariff and trade purposes, schedule spectinomycin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, SPECTINOMYCIN SULFATE remains US FDA's Preferred Term for this commodity. Spectinomycin sulfate bears US NLM identifiers UMLS ID C2983840 and NCI Concept Code C90691. SMILES: C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O.OS(=O)(=O)O.
This classification denotes an aminoglycoside antibiotic C14H24N2O7.4H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YS91P54918, chemically known as (2r-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.))-decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4h-pyrano(2,3-b)(1,4)benzodioxin-4-one sulfate tetrahydrate, but more generally known as spectinomycin sulfate tetrahydrate, which bears US NIH Compound Identifier 64770. Most nations, for tariff and trade purposes, schedule spectinomycin sulfate tetrahydrate under HS 29419000 and SITC 54139. As of Q4 2014, SPECTINOMYCIN SULFATE TETRAHYDRATE remains US FDA's Preferred Term for this commodity. Spectinomycin sulfate tetrahydrate bears US NLM identifiers UMLS ID C2726834 and NCI Concept Code C90692. SMILES: C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O.O.O.O.O.OS(=O)(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C22H26FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 471LF4O004, chemically known as 1,3,8-triazaspiro(4.5)decan-4-one, 8-(3-(4-fluorophenoxy)propyl)-1-phenyl- but generally known as spiramide, which bears US NIH Compound Identifier 68186. European Medicines Agency schedules Spiramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10619MIG. The term SPIRAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). SPIRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spiramide under HS 29333999 and SITC 51574. As of Q4 2014, SPIRAMIDE remains the US FDA Preferred Term for this commodity. Spiramide bears US NLM identifiers UMLS ID C0075006 and NCI Concept Code C66559. SMILES: FC1CCC(OCCCN2CCC3(N(CNC3=O)C3CCCCC3)CC2)CC1.
This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71ODY0V87H. European Medicines Agency schedules Spiramycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04526MIG. Spiramycin generally arises in the molecular formula C43H74N2O14. The term SPIRAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) SPIRAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spiramycin under HS 29419000 and SITC 54139. As of Q4 2014, SPIRAMYCIN remains the US FDA Preferred Term for this commodity. Spiramycin bears US NLM identifiers UMLS ID C0037962 and NCI Concept Code C839. SMILES: CC1C/C=C/C=C/C(C(CC(C(C(C(CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C.
This classification denotes a macrolide antibiotic with the molecular formula C49H84N2O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L9KNT101OK, chemically known as hexanedioic acid, compd. with spiramycin (1:1), but more generally known as spiramycin adipate, which bears US NIH Compound Identifier 6450354. European Medicines Agency schedules spiramycin adipate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04526MIG. Most nations, for tariff purposes, schedule spiramycin adipate under HS 29419000. SMILES:.
This classification denotes a macrolide antibiotic C43H74N2O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 033ECH6IFG, chemically known as leucomycin v, 9-o-((2r,5s,6r)-5-(dimethylamino)tetrahydro-6-methyl-2h-pyran-2-yl)-, but more generally known as spiramycin i, which bears US NIH Compound Identifier 158334. Most nations, for tariff and trade purposes, schedule spiramycin i under HS 29419000 and SITC 54139. As of Q4 2014, SPIRAMYCIN I remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)O[C@H]4CC[C@@H]([C@@H](O4)C)N(C)C.
This classification denotes an ace inhibitor with the molecular formula C22H30N2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96U2K78I3V, chemically known as 1,4-dithia-7-azaspiro(4,4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8s-(7(r*(r*)),8r*))- but generally known as spirapril, which bears US NIH Compound Identifier 91736. European Medicines Agency schedules Spirapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10620MIG. The term SPIRAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules spirapril in its Anatomical Therapeutic Chemical (ATC) Classification. SPIRAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spirapril under HS 29349990 and SITC 51579. As of Q4 2014, SPIRAPRIL remains the US FDA Preferred Term for this commodity. Spirapril bears US NLM identifiers UMLS ID C0075007 and NCI Concept Code C66560. SMILES: S1C2(SCC1)CC(N(C2)C(=O)C(NC(CCc1ccccc1)C(=O)OCC)C)C(=O)O.
This classification denotes an ace inhibitor with the molecular formula C22H30N2O5S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OCC25LM897, chemically known as 1,4-dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, monohydrochloride, (8s-(7(r*(r*)),8r*))- but more generally known as spirapril hydrochloride, which bears US NIH Compound Identifier 71192. European Medicines Agency schedules Spirapril hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04530MIG. Most nations, for tariff and trade purposes, schedule spirapril hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, SPIRAPRIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Spirapril hydrochloride bears US NLM identifiers UMLS ID C1528843 and NCI Concept Code C66561. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3.CL.
This classification denotes an antiparasitic agent with the molecular formula C15H20ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WV516JUV0B, chemically known as 1,3,5-triazaspiro(5.5)undeca-1,3-diene, 2,4-diamino-5-(p-chlorophenyl)-9-methyl- but generally known as spirazine, which bears US NIH Compound Identifier 210321. European Medicines Agency schedules Spirazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10622MIG. The term SPIRAZINE is an International Non-Proprietary Name. SPIRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Spirazine or spirotriazine bears US NLM identifiers UMLS ID C2827337 and NCI Concept Code C84180. SMILES: CLC1CCC(N2C3(N=C(N=C2N)N)CCC(CC3)C)CC1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C21H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96789094BR, chemically known as spiro(cyclohexane-1,2-(2h)inden)-1(3h)-one, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-, (+-)- but generally known as spirendolol, which bears US NIH Compound Identifier 68857. European Medicines Agency schedules Spirendolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10623MIG. The term SPIRENDOLOL is an International Non-Proprietary Name. SPIRENDOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spirendolol under HS 29221980 and SITC 51461. As of Q4 2014, SPIRENDOLOL remains the US FDA Preferred Term for this commodity. Spirendolol bears US NLM identifiers UMLS ID C0629350 and NCI Concept Code C66562. SMILES: O=C1C2(CCCCC2)CC2C1CCCC2OCC(O)CNC(C)(C)C.
This classification denotes a dopamine antagonist with the molecular formula C24H28FN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 672229USCQ, chemically known as 1,3,8-triazaspiro(4.5)decan-4-one, 8-(4-(p-fluorophenyl)-3-penenyl)-1-phenyl- but generally known as spirilene, which bears US NIH Compound Identifier 6436870. European Medicines Agency schedules Spirilene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10625MIG. The term SPIRILENE is an International Non-Proprietary Name. SPIRILENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spirilene under HS 29333999 and SITC 51574. As of Q4 2014, SPIRILENE remains the US FDA Preferred Term for this commodity. Spirilene bears US NLM identifiers UMLS ID C0621228 and NCI Concept Code C90845. SMILES: FC1CCC(/C(=C\CCN2CCC3(N(CNC3=O)C3CCCCC3)CC2)C)CC1.
This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 000F949089. European Medicines Agency schedules Spirofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10627MIG. Spirofylline generally arises in the molecular formula C24H28N6O5. The term SPIROFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) SPIROFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spirofylline under HS 29395900 and SITC 54145. As of Q4 2014, SPIROFYLLINE remains the US FDA Preferred Term for this commodity. Spirofylline bears US NLM identifiers UMLS ID C2699505 and NCI Concept Code C74214. SMILES: O1C2(CCN(CC2)CCC2CCCCC2)CN(C1=O)C(=O)CN1C2C(N(C(=O)N(C2=O)C)C)NC1.
This classification denotes a nitrogen mustard compound with the molecular formula C14H23Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3HB83X76Z, chemically known as 1,3-diazaspiro(4.5)decane-2,4-dione, 3-(2-(bis(2-chloroethyl)amino)ethyl)- but more generally known as spiromustine, which bears US NIH Compound Identifier 41945. European Medicines Agency schedules Spiromustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10630MIG. The term SPIROMUSTINE is an International Non-Proprietary Name. SPIROMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule spiromustine under HS 29332100 and SITC 51572. As of Q4 2014, SPIROMUSTINE remains US FDA's Preferred Term for this commodity. Spiromustine bears US NLM identifiers UMLS ID C0075019 and NCI Concept Code C1233. SMILES: CLCCN(CCN1C(=O)C2(NC1=O)CCCCC2)CCCL.
This classification denotes a potassium-sparing diuretic with the molecular formula C24H32O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27O7W4T232, chemically known as pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, .gamma.-lactone, (7.alpha.,17.alpha.)- but generally known as spironolactone, which bears US NIH Compound Identifier 5267. European Medicines Agency schedules Spironolactone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10631MIG. The term SPIRONOLACTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules spironolactone in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SPIRONOLACTONE remains the US FDA Preferred Term for this commodity. Spironolactone bears US NLM identifiers UMLS ID C0037982 and NCI Concept Code C840. SMILES: S(C1C2C3C(C4(OC(=O)CC4)CC3)(CCC2C2(C(=CC(=O)CC2)C1)C)C)C(=O)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C22H25N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DR0QR50ALL, chemically known as 1,3,8-trianaspiro(4.5)decane-4-one,8-(1,4-benzodioxan-2-ylmethyl)-1-phenyl- but generally known as spiroxatrine, which bears US NIH Compound Identifier 5268. European Medicines Agency schedules Spiroxatrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10635MIG. The term SPIROXATRINE is an International Non-Proprietary Name. SPIROXATRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spiroxatrine under HS 29349990 and SITC 51579. As of Q4 2014, SPIROXATRINE remains the US FDA Preferred Term for this commodity. Spiroxatrine bears US NLM identifiers UMLS ID C0075025 and NCI Concept Code C74108. SMILES: O=C1NCN(C21CCN(CC2)CC1OC2C(OC1)CCCC2)C1CCCCC1.
This classification denotes an anti-ulcer agent with the molecular formula C12H10O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94F21T5G3C, chemically known as 5-acetylspiro(benzofuran-2(3h),1-cyclopropan)-3-one but generally known as spizofurone, which bears US NIH Compound Identifier 71755. European Medicines Agency schedules Spizofurone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10637MIG. The term SPIZOFURONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). SPIZOFURONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spizofurone under HS 29329985 and SITC 51569. As of Q4 2014, SPIZOFURONE remains the US FDA Preferred Term for this commodity. Spizofurone bears US NLM identifiers UMLS ID C0075027 and NCI Concept Code C73190. SMILES: CC(=O)C1=CC2=C(C=C1)OC3(C2=O)CC3.
This classification denotes a distamycin antibiotic and dna minor groove binding agent with the molecular formula C22H27N9O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6010N240F, chemically known as distamycin a, hydrochloride but more generally known as stallimycin hydrochloride, which bears US NIH Compound Identifier 3115. Most nations, for tariff and trade purposes, schedule stallimycin hydrochloride under HS 29419000. As of Q4 2014, STALLIMYCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC(CC1C(=O)NC2CC(N(C2)C)C(=O)NC3CC(N(C3)C)C(=O)NCCC(=N)N)NC=O.CL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX202. This VA Drug Class (DX202) classifies this compound as belonging to the group NON-IMAGING AGENTS RADIOPHARMACEUTICALS.
This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C21H32N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4R1VB9P8V3, chemically known as 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethylcyclopenta(7,8)-phenanthro(2,3-c)pyrazol-1-ol but generally known as stanozolol, which bears US NIH Compound Identifier 25249. European Medicines Agency schedules Stanozolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10641MIG. The term STANOZOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules stanozolol in its Anatomical Therapeutic Chemical (ATC) Classification. STANOZOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule stanozolol under HS 29372900 and SITC 54153. As of Q4 2014, STANOZOLOL remains the US FDA Preferred Term for this commodity. Stanozolol bears US NLM identifiers UMLS ID C0592142 and NCI Concept Code C842. SMILES: OC1(C2(C(C3C(C4(C(CC3)CC3[NH]NCC3C4)C)CC2)CC1)C)C.
This classification denotes a vaccine against staphylococcus aureus, an opportunistic bacterial pathogen, a genus of gram-positive, facultatively anaerobic, coccoid bacteria. Its organisms occur singly, in pairs, and in tetrads and characteristically divide in more than one plane to form irregular clusters.
This classification denotes a combination drug for treatment of HIV. The first component of this combination drug is a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BO9LE4QFZF. European Medicines Agency schedules Stavudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10642MIG. Stavudine generally arises in the molecular formula C10H12N2O4. The term STAVUDINE is an International Non-Proprietary Name or INN. STAVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO. The second component of this drug is a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but generally known as lamivudine, which bears US NIH Compound Identifier 60825. European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG. The term LAMIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules lamivudine in its Anatomical Therapeutic Chemical (ATC) Classification. LAMIVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. The third component of this combination drug is a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99DK7FVK1H. European Medicines Agency schedules Nevirapine, anhydrous in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25191. Nevirapine generally arises in the molecular formula C15H14N4O. The term 'nevirapine' is a European Pharmacopoeia designation. NEVIRAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BO9LE4QFZF. European Medicines Agency schedules Stavudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10642MIG. Stavudine generally arises in the molecular formula C10H12N2O4. The term STAVUDINE is an International Non-Proprietary Name or INN. STAVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Stavudine or stavidine bears US NLM identifiers UMLS ID C0164662 and NCI Concept Code C1428. SMILES: CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO.
This classification denotes a mucolytic agent with the molecular formula C10H11NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 0NOY894QRB, chemically known as glycine, n-(1-oxo-2-((2-thienylcarbonyl)thio)propyl)- but more generally known as stepronin, which bears US NIH Compound Identifier 54120. European Medicines Agency schedules Stepronin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10645MIG. The term STEPRONIN is an International Non-Proprietary Name. World Health Organization schedules stepronin in its Anatomical Therapeutic Chemical (ATC) Classification. STEPRONIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule stepronin under HS 29349990 and SITC 51579. As of Q4 2014, STEPRONIN remains US FDA's Preferred Term for this commodity. Stepronin bears US NLM identifiers UMLS ID C0075227 and NCI Concept Code C74264. SMILES: CC(C(=O)NCC(=O)O)SC(=O)C1=CC=CS1.
This classification denotes a muscle relaxant with the molecular formula C26H43N2.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K1477R7DDR, chemically known as (cona-4,6-dienin-3beta-yl)dimethylethylammonium iodide but generally known as stercuronium iodide, which bears US NIH Compound Identifier 71924. European Medicines Agency schedules Stercuronium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10646MIG. The term STERCURONIUM IODIDE is an International Non-Proprietary Name. As of Q4 2014, STERCURONIUM remains the US FDA Preferred Term for this commodity. SMILES: I.N1(CC23C(C4C(CC3)C3(C(=CC([N](CC)(C)C)CC3)C=C4)C)CCC2C1C)C.
This classification denotes a muscle relaxant with the molecular formula C26H43N2.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K1477R7DDR, chemically known as (cona-4,6-dienin-3beta-yl)dimethylethylammonium iodide but more generally known as stercuronium iodide, which bears US NIH Compound Identifier 71924. European Medicines Agency schedules Stercuronium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10646MIG. The term STERCURONIUM IODIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule stercuronium iodide under HS 29339990 and SITC 51577. As of Q4 2014, STERCURONIUM IODIDE remains US FDA's Preferred Term for this commodity. Stercuronium iodide bears US NLM identifiers UMLS ID C2983929 and NCI Concept Code C90895. SMILES: CC[N+](C)(C)[C@H]1CC[C@@]2([C@H]3CC[C@]45CN([C@H]([C@H]4CC[C@H]5[C@@H]3C=CC2=C1)C)C)C.[I-].
Visualization polymeric agent. The silicone oil replaces the vitreous permanently.
Sterilized water used to supplement nutrition and for g-tube flushes.
Sterilized water used in nebulizers or for nasal rinses.
This classification denotes an electrolyte-active substance, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 059QF0KO0R. European Medicines Agency schedules Water in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15717MIG. Water generally arises in the molecular formula H2O. The term 'water' is a United States Homeopathic Pharmacopoeia Name designation. SMILES: O.
This classification denotes antiseptic drugs made from a clear, odorless, tasteless liquid that is essential for most animal and plant life and is an excellent solvent for many substances. The chemical formula is hydrogen oxide (H2O). SMILES: O.
This classification denotes a vasodilating agent with the molecular formula C27H45NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FW24343731, chemically known as 3beta-(dimethylamino)-5alpha-pregnane-18,20alpha-diol diacetate (ester) but generally known as stevaladil, which bears US NIH Compound Identifier 3083966. European Medicines Agency schedules Stevaladil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10647MIG. The term STEVALADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). STEVALADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule stevaladil under HS 29221980 and SITC 51461. As of Q4 2014, STEVALADIL remains the US FDA Preferred Term for this commodity. Stevaladil bears US NLM identifiers UMLS ID C2983980 and NCI Concept Code C91006. SMILES: O(CC12C(C3C(C4(C(CC3)CC(N(C)C)CC4)C)CC2)CCC1C(OC(=O)C)C)C(=O)C.
This classification denotes an antispasmodic with the molecular formula C22H30NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4L5V8Z34JM, chemically known as ethanaminium, n,n,n-triethyl-2-(4-(2-phenylethenyl)phenoxy)- but generally known as stilonium, which bears US NIH Compound Identifier 5824382. As of Q4 2014, STILONIUM remains the US FDA Preferred Term for this commodity. Stilonium bears US NLM identifiers UMLS ID C2828261 and NCI Concept Code C87314. SMILES: CC[N+](CC)(CC)CCOC1=CC=C(C=C1)C=CC2=CC=CC=C2.
This classification denotes an antispasmotic agent with the molecular formula C22H30NO.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19B3530KQ6, chemically known as n,n,n-triethyl-n-(2-(4-styrylphenoxy)ethyl)ammonium iodide but more generally known as stilonium iodide, which bears US NIH Compound Identifier 6433339. European Medicines Agency schedules Stilonium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10652MIG. The term STILONIUM IODIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). Most nations, for tariff and trade purposes, schedule stilonium iodide under HS 29239000 and SITC 51481. As of Q4 2014, STILONIUM IODIDE remains US FDA's Preferred Term for this commodity. Stilonium iodide bears US NLM identifiers UMLS ID C2348540 and NCI Concept Code C73168. SMILES: CC[N+](CC)(CC)CCOC1CCC(CC1)/C=C/C2CCCCC2.[I-].
This classification denotes an anticonvulsant with the molecular formula C14H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R02XOT8V8I, chemically known as 4,4-dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol but generally known as stiripentol, which bears US NIH Compound Identifier 5311454. European Medicines Agency schedules Stiripentol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10654MIG. World Health Organization schedules stiripentol in its Anatomical Therapeutic Chemical (ATC) Classification. STIRIPENTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule stiripentol under HS 29329970 and SITC 51569. As of Q4 2014, STIRIPENTOL remains the US FDA Preferred Term for this commodity. SMILES: OC(C(C)(C)C)/C=C/C1CC2OCOC2CC1.
This classification denotes an antiarrhythmic agent with the molecular formula C22H34N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) LXD20TIK6Y, chemically known as cycloheptanone, 2-(phenylmethylene)-, o-(2-(bis(1-methylethyl)amino)ethyl)oxime, (e,e)- but more generally known as stirocainide, which bears US NIH Compound Identifier 9570767. European Medicines Agency schedules Stirocainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10655MIG. The term STIROCAINIDE is an International Non-Proprietary Name. STIROCAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule stirocainide under HS 29280090 and SITC 51486. As of Q4 2014, STIROCAINIDE remains US FDA's Preferred Term for this commodity. Stirocainide bears US NLM identifiers UMLS ID C0075263 and NCI Concept Code C72584. SMILES: O(/N=C1\CCCCC\C1=C/C1CCCCC1)CCN(C(C)C)C(C)C.
This classification denotes an aminoglycoside antibiotic, European Medicines Agency schedules Amikacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15402MIG.
This classification denotes an enzyme produced by hemolytic streptococci and which hydrolyzes amide linkages and serves as an activator of plasminogen, and is thus used in thrombolytic therapy, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X1OXL3SNU, chemically known as 4-cyclohexylpyrrolidine-2-carboxylic acid but generally known as streptokinase, which bears US NIH Compound Identifier 9815560. European Medicines Agency schedules Streptokinase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04589MIG. The term STREPTOKINASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3.) Most nations schedule streptokinase under HS 35079090 and SITC 51691. As of Q4 2014, STREPTOKINASE remains the US FDA Preferred Term for this commodity. SMILES: C1CCC(CC1)C2CC(NC2)C(=O)O.
This classification denotes an aminoglycoside antibiotic with the molecular formula C21H39N7O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y45QSO73OB, chemically known as 2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-o-(2-deoxy-2-methylamino-alpha-l-glucopyranosyl)-3-c-formyl-beta-l-lyxopentanofuranoside but generally known as streptomycin, which bears US NIH Compound Identifier 5999. European Medicines Agency schedules Streptomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10656MIG. World Health Organization schedules streptomycin in its Anatomical Therapeutic Chemical (ATC) Classification. STREPTOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule streptomycin under HS 29412080 and SITC 54132. As of Q4 2014, STREPTOMYCIN remains the US FDA Preferred Term for this commodity. Streptomycin bears US NLM identifiers UMLS ID C0038425 and NCI Concept Code C61952. SMILES: O(C1C(/N=C(/N)N)C(O)C(/N=C(/N)N)C(O)C1O)C1OC(C(O)(C1OC1OC(C(O)C(O)C1NC)CO)C=O)C.
This classification denotes an aminoglycoside antibiotic with the molecular formula C27H49N7O17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CJ1467C885, chemically known as d-streptamine, o-.beta.-d-mannopyranosyl-(1->4)-o-2-deoxy-2-(methylamino)-.alpha.-l-glucopyranosyl-(1->2)-o-5-deoxy-3-c-formyl-.alpha.-l-lyxofuranosyl-(1->4)-n1,n3-bis(aminoiminomethyl)-, but more generally known as streptomycin b, which bears US NIH Compound Identifier 121307. European Medicines Agency schedules streptomycin b or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10656MIG. Most nations, for tariff purposes, schedule streptomycin b under HS 29412080. SMILES: C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)NC(=N)N)O)NC(=N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O[C@@H]4[C@H]([C@H]([C@@H]([C@@H](O4)CO)O)O)O)O)NC)(C=O)O.
This classification denotes an aminoglycoside antibiotic with the molecular structure C21H39N7O12.3CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8P331B9592 chemically known as d-streptamine, o-2-deoxy-2-(methylamino)-.alpha.-l-glucopyranosyl-(1->2)-o-5-deoxy-3-c-formyl-.alpha.-l-lyxofuranosyl-(1->4)-n,n'-bis(aminoiminomethyl)-, trihydrochloride, but more commonly known as streptomycin hydrochloride, which bears US NIH Compound Identifier 197844. European Medicines Agency schedules Streptomycin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15404MIG. Most nations, for tariff and trade purposes, schedule streptomycin hydrochloride under HS 29412000 and SITC 54132. As of Q4 2014, STREPTOMYCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)NC(=N)N)O)NC(=N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O.CL.CL.CL.
This classification denotes an aminoglycoside antibiotic with the molecular formula 2C21H39N7O12.3H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CW25IKJ202, chemically known as streptomycin, sulfate (2:3) (salt) but more generally known as streptomycin sulfate, which bears US NIH Compound Identifier 19648. European Medicines Agency schedules Streptomycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04593MIG. Most nations, for tariff and trade purposes, schedule streptomycin sulfate under HS 29412080 and SITC 54132. Streptomycin sulfate bears US NLM identifiers UMLS ID C0038426 and NCI Concept Code C47729. SMILES: As of Q4 2014, STREPTOMYCIN SULFATE remains US FDA's Preferred Term for this commodity.
This classification denotes a nitrosourea compound and antineoplastic antibiotic with the molecular formula C8H15N3O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W494URQ81, chemically known as streptozotocin, pure but generally known as streptozocin, which bears US NIH Compound Identifier 5299. European Medicines Agency schedules Streptozocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10658MIG. The term STREPTOZOCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules streptozocin in its Anatomical Therapeutic Chemical (ATC) Classification. STREPTOZOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule streptozocin under HS 29419000 and SITC 54139. As of Q4 2014, STREPTOZOCIN remains the US FDA Preferred Term for this commodity. Streptozocin bears US NLM identifiers UMLS ID C0038432 and NCI Concept Code C845. SMILES: OC(C(O)C(O)CO)C(NC(=O)N(N=O)C)C=O.
This classification denotes a bone resorption inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04NQ160FRU. European Medicines Agency schedules Strontium ranelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20045. Strontium ranelate generally arises in the molecular formula C12H6N2O8S.2SR. The term 'strontium ranelate' is a European Medicines Agency European Public Assessment Report System designation. As of Q4 2014, STRONTIUM RANELATE remains the US FDA Preferred Term for this commodity. Strontium ranelate bears US NLM identifiers UMLS ID C0936139 and NCI Concept Code C93265. SMILES: [Sr].[Sr].s1c(N(CC(=O)O)CC(=O)O)c(c(c1C(=O)O)CC(=O)O)C#N.
This classification denotes a centrally acting muscle relaxant with the molecular formula C9H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CBK7Y28SP3, chemically known as 2-Hydroxy-2-phenylethyl carbamate, which bears US NIH Compound Identifier 7186. The term STYRAMATE is an International Non-Proprietary Name or INN. European Medicines Agency schedules styramate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10660MIG. Most nations schedule styramate under HS 29242995 and SITC 51479. As of Q4 2014, STYRAMATE remains the US FDA Preferred Term for this commodity. SMILES: C1=CC=C(C=C1)C(COC(=O)N)O.
This classification denotes an antihelminthic agent with the molecular formula C10H5Cl3N4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YT3IDN1WR0, chemically known as 4,5,7-trichloro-2-((3-(methylthio)-1,2,4-thiadiazol-5-yl)thio)benzimidazole but generally known as subendazole, which bears US NIH Compound Identifier 213015. European Medicines Agency schedules Subendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10662MIG. The term SUBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). SUBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule subendazole under HS 29349990 and SITC 51579. As of Q4 2014, SUBENDAZOLE remains the US FDA Preferred Term for this commodity. Subendazole bears US NLM identifiers UMLS ID C2348573 and NCI Concept Code C72150. SMILES: CSC1=NSC(=N1)SC2=NC3=C(N2)C(=C(C=C3CL)CL)CL.
This classification denotes a muscle relaxant with the molecular formula C14H30N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2R869A8YF, chemically known as succinic acid, diester with choline iodide but generally known as succinylcholine, which bears US NIH Compound Identifier 5314. SMILES: C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C. SMILES: C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.
This classification denotes an intestinal antimicrobial agent with the molecular formula C13H13N3O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RSS8647O4S, chemically known as succinanilic acid, 4- (2-thiazolylsulfamoyl)- but generally known as succinylsulfathiazole, which bears US NIH Compound Identifier 5315. European Medicines Agency schedules Succinylsulfathiazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10664MIG. World Health Organization schedules succinylsulfathiazole in its Anatomical Therapeutic Chemical (ATC) Classification. SUCCINYLSULFATHIAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule succinylsulfathiazole under HS 29350090 and SITC 51580. As of Q4 2014, SUCCINYLSULFATHIAZOLE remains the US FDA Preferred Term for this commodity. SMILES: S(=O)(=O)(NC1SCCN1)C1CCC(NC(=O)CCC(=O)O)CC1.
This classification denotes a radioprotective agent and cytoprotective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XX73205DH5. European Medicines Agency schedules Sucralfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04613MIG. Sucralfate generally arises in the molecular formula C12H54AL16O75S8. The term SUCRALFATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) SUCRALFATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sucralfate under HS 29400000 and SITC 51692. As of Q4 2014, SUCRALFATE remains the US FDA Preferred Term for this commodity. Sucralfate bears US NLM identifiers UMLS ID C0038633 and NCI Concept Code C848. SMILES: S(=O)(=O)(OC1C(OC2OC(C(OS(=O)(=O)O)C(OS(=O)(=O)O)C2OS(=O)(=O)O)COS(=O)(=O)O)(OC(OS(=O)(=O)O)C1OS(=O)(=O)O)COS(=O)(=O)O)O.[AL]([OH2])([OH2])[OH2].
This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H30N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AFE2YW0IIZ, chemically known as propanamide, n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-n-phenyl- but generally known as sufentanil, which bears US NIH Compound Identifier 41693. European Medicines Agency schedules Sufentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10671MIG. The term SUFENTANIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules sufentanil in its Anatomical Therapeutic Chemical (ATC) Classification. SUFENTANIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sufentanil under HS 29349100 and SITC 51579. As of Q4 2014, SUFENTANIL remains the US FDA Preferred Term for this commodity. Sufentanil bears US NLM identifiers UMLS ID C0143993 and NCI Concept Code C61956. SMILES: S1C(CCN2CCC(N(C3CCCCC3)C(=O)CC)(CC2)COC)CCC1.
This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H30N2O2S.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9ZFX8403R, chemically known as propanamide, n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-n-phenyl- but more generally known as sufentanil citrate, which bears US NIH Compound Identifier 41693. European Medicines Agency schedules Sufentanil citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04616MIG. Most nations, for tariff and trade purposes, schedule sufentanil citrate under HS 29349100 and SITC 51579. As of Q4 2014, SUFENTANIL CITRATE remains US FDA's Preferred Term for this commodity. Sufentanil citrate bears US NLM identifiers UMLS ID C0733851 and NCI Concept Code C47731. SMILES: CCC(=O)N(C1CCCCC1)C2(CCN(CC2)CCC3CCCS3)COC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an antipsychotic agent with the molecular formula C8H18ClN2O5PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2208Y59985, chemically known as 3-(2-chloroethyl)-2-(2-mesyloxyethylamino)tetrahydro-2h-1,3,2-oxazaphosphorin-2-oxide but more generally known as sufosfamide, which bears US NIH Compound Identifier 65805. European Medicines Agency schedules Sufosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10672MIG. The term SUFOSFAMIDE is an International Non-Proprietary Name. SUFOSFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sufosfamide under HS 29349990 and SITC 51579. As of Q4 2014, SUFOSFAMIDE remains US FDA's Preferred Term for this commodity. Sufosfamide bears US NLM identifiers UMLS ID C0075494 and NCI Concept Code C73260. SMILES: CLCCN1P(=O)(OCCC1)NCCOS(=O)(=O)C.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C20H31N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56B0591Y76, chemically known as 1-(m-(3-((1-methyl-3-((methylsulfonyl)methyl)-1h-1,2,4-triazol-5-yl)amino)propoxy)benzyl)piperidine but generally known as sufotidine, which bears US NIH Compound Identifier 71763. European Medicines Agency schedules Sufotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10673MIG. The term SUFOTIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). SUFOTIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sufotidine under HS 29333999 and SITC 51574. As of Q4 2014, SUFOTIDINE remains the US FDA Preferred Term for this commodity. Sufotidine bears US NLM identifiers UMLS ID C0075495 and NCI Concept Code C73217. SMILES: S(=O)(=O)(CC1NC(NCCCOC2CC(CN3CCCCC3)CCC2)N(N1)C)C.
This classification denotes a protective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 361LPM2T56. European Medicines Agency schedules Sugammadex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26695. Sugammadex generally arises in the molecular formula C72H112O48S8. The term SUGAMMADEX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations schedule sugammadex under HS 29329985 and SITC 51569. As of Q4 2014, SUGAMMADEX remains the US FDA Preferred Term for this commodity. Sugammadex bears US NLM identifiers UMLS ID C1700695 and NCI Concept Code C80629. SMILES: C(CSCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(C(C8O)O)OC9C(OC(O2)C(C9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O.
This classification denotes a protective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ERJ6X2MXV7. European Medicines Agency schedules Sugammadex sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32205. Sugammadex sodium generally arises in the molecular formula C72H104O48S8.8NA. The term 'sugammadex sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule sugammadex sodium under HS 29329985 and SITC 51569. Sugammadex sodium bears US NLM identifiers UMLS ID C2350811 and NCI Concept Code C78123. SMILES: As of Q4 2014, SUGAMMADEX SODIUM remains US FDA's Preferred Term for this commodity.
This classification denotes an anxiolytic with the molecular formula C16H13ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NZ779Q5S0W, chemically known as 7-chloro-2,3-dihydro-1-methyl-5-phenyl-1,4-benzodiazepine-2-thione but generally known as sulazepam, which bears US NIH Compound Identifier 17931. European Medicines Agency schedules Sulazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10674MIG. The term SULAZEPAM is an International Non-Proprietary Name. SULAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulazepam under HS 29339940 and SITC 51577. As of Q4 2014, SULAZEPAM remains the US FDA Preferred Term for this commodity. Sulazepam bears US NLM identifiers UMLS ID C2348591 and NCI Concept Code C73210. SMILES: CLC1CC2C(N(C(=S)CN=C2C2CCCCC2)C)CC1.
This classification denotes an antiprotozoal agent and antihelminthic with the molecular formula C17H15Cl2N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2136B7T7KE, chemically known as 2-(3,5-dichloro-4-(p-(methylsulfonyl)phenoxy)phenyl)dihydro-1-methyl-as-triazine-3,5(2h,4h)-dione but generally known as sulazuril, which bears US NIH Compound Identifier 65904. European Medicines Agency schedules Sulazuril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10675MIG. The term SULAZURIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). SULAZURIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulazuril under HS 29336980 and SITC 51576. As of Q4 2014, SULAZURIL remains the US FDA Preferred Term for this commodity. Sulazuril bears US NLM identifiers UMLS ID C2348592 and NCI Concept Code C72602. SMILES: CLC1CC(N2N(CC(=O)NC2=O)C)CC(CL)C1OC1CCC(S(=O)(=O)C)CC1.
This classification denotes a beta-lactam antibiotic with the molecular formula C8H11NO5S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier S4TF6I2330, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2s-cis)- but more generally known as sulbactam, which bears U.S. National Institutes of Health Compound Identifier 50161. The European Medicines Agency schedules Sulbactam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10676MIG. The term SULBACTAM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). The World Health Organization schedules sulbactam in its Anatomical Therapeutic Chemical (ATC) Classification. SULBACTAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1(=O)(=O)C(C(N2C1CC2=O)C(=O)O)(C)C.
This classification denotes a penicillin antibiotic with the molecular formula C16H18N2O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2VYF0562D, chemically known as 3,3-dimethyl-7-oxo-6-(2-phenyl-2-sulfoacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as sulbenicillin, which bears US NIH Compound Identifier 39031. European Medicines Agency schedules Sulbenicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15423MIG. The term SULBENICILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules sulbenicillin in its Anatomical Therapeutic Chemical (ATC) Classification. SULBENICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulbenicillin under HS 29411090 and SITC 54131. As of Q4 2014, SULBENICILLIN remains the US FDA Preferred Term for this commodity. Sulbenicillin bears US NLM identifiers UMLS ID C0038666 and NCI Concept Code C90915. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(S(=O)(=O)O)C1CCCCC1.
This classification denotes a penicillin antibiotic with the molecular formula C16H16N2O7S2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29SO9LIM1Q, chemically known as d-(-)-.alpha.-sulfobenzylpenicillin sodium salt, but more generally known as sulbenicillin disodium, which bears US NIH Compound Identifier 134931. European Medicines Agency schedules sulbenicillin disodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15423MIG. Most nations, for tariff purposes, schedule sulbenicillin disodium under HS 29411090. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)S(=O)(=O)[O-])C(=O)[O-])C.[NA+].[NA+].
This classification denotes a penicillin antibiotic with the molecular structure C16H16N2O7S2.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 29SO9LIM1Q chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((2-phenyl-2-sulfoacetyl)amino)-, sodium salt (1:2), (2s,5r,6r)-, but more commonly known as sulbenicillin sodium, which bears US NIH Compound Identifier 443984. European Medicines Agency schedules Sulbenicillin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21912. Most nations, for tariff and trade purposes, schedule sulbenicillin sodium under HS 29411090 and SITC 54131. As of Q4 2014, SULBENICILLIN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)S(=O)(=O)[O-])C(=O)[O-])C.[NA+].[NA+].
This classification denotes an antifungal agent with the molecular formula C17H18N2S2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier D0NR12WK9J, chemically known as 3,5-dibenzyltetrahydro-2h-1,3,5-thiadiazine-2-thione but more generally known as dibenzthion, which bears U.S. NIH Compound Identifier 67686. European Medicines Agency schedules Sulbentine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10678MIG. The term SULBENTINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules dibenzthion in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a thiamine analog, glutamatergic, dopaminergic, and neurotropic agent with the molecular formula C32H46N8O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42NCM1BW43, chemically known as thiamine disulfide o,o-diisobutyrate but generally known as sulbutiamine, which bears US NIH Compound Identifier 3002120. European Medicines Agency schedules Sulbutiamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10679MIG. World Health Organization schedules sulbutiamine in its Anatomical Therapeutic Chemical (ATC) Classification. SULBUTIAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulbutiamine under HS 29335995 and SITC 51576. As of Q4 2014, SULBUTIAMINE remains the US FDA Preferred Term for this commodity. SMILES: CC1=NC=C(C(=N1)N)CN(/C(=C(/SS/C(=C(/N(C=O)CC2=CN=C(N=C2N)C)\C)/CCOC(=O)C(C)C)\CCOC(=O)C(C)C)/C)C=O.
This classification denotes an antifungal agent with the molecular formula C18H15Cl3N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5D9HAA5Q5S, chemically known as 1h-imidazole, 1-(2-(((4-chlorophenyl)methyl)thio)-2-(2,4-dichlorophenyl)ethyl)-, (+-)- but generally known as sulconazole, which bears US NIH Compound Identifier 5318. European Medicines Agency schedules Sulconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10681MIG. The term SULCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules sulconazole in its Anatomical Therapeutic Chemical (ATC) Classification. SULCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulconazole under HS 29332990 and SITC 51573. As of Q4 2014, SULCONAZOLE remains the US FDA Preferred Term for this commodity. Sulconazole bears US NLM identifiers UMLS ID C0075503 and NCI Concept Code C61958. SMILES: CLC1C(C(SCC2CCC(CL)CC2)CN2CCNC2)CCC(CL)C1.
This classification denotes an antifungal agent with the molecular formula C18H15Cl3N2S.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1T89100D5U, chemically known as 1h-imidazole, 1-(2-(((4-chlorophenyl)methyl)thio)-2-(2,4-dichlorophenyl)ethyl)-, mononitrate, (+-)- but more generally known as sulconazole nitrate, which bears US NIH Compound Identifier 65495. European Medicines Agency schedules Sulconazole nitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04618MIG. Most nations, for tariff and trade purposes, schedule sulconazole nitrate under HS 29332990 and SITC 51573. As of Q4 2014, SULCONAZOLE NITRATE remains US FDA's Preferred Term for this commodity. Sulconazole nitrate bears US NLM identifiers UMLS ID C0144004 and NCI Concept Code C47733. SMILES: C1CC(CCC1CSC(CN2CCNC2)C3CCC(CC3CL)CL)CL.[N+](=O)(O)[O-].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C13H12N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G58F8OPL4I, chemically known as sulfanilamide, n(sup1)-benzoyl- but generally known as sulfabenzamide, which bears US NIH Compound Identifier 5319. European Medicines Agency schedules Sulfabenzamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10684MIG. The term SULFABENZAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). SULFABENZAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfabenzamide under HS 29350090 and SITC 51580. As of Q4 2014, SULFABENZAMIDE remains the US FDA Preferred Term for this commodity. Sulfabenzamide bears US NLM identifiers UMLS ID C0075504 and NCI Concept Code C87216. SMILES: S(=O)(=O)(NC(=O)C1CCCCC1)C1CCC(N)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C8H10N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4965G3J0F5, chemically known as sulfanilamide, n(sup 1)-acetyl- but generally known as sulfacetamide, which bears US NIH Compound Identifier 5320. European Medicines Agency schedules Sulfacetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10687MIG. World Health Organization schedules sulfacetamide in its Anatomical Therapeutic Chemical (ATC) Classification. SULFACETAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfacetamide under HS 29350090 and SITC 51580. As of Q4 2014, SULFACETAMIDE remains the US FDA Preferred Term for this commodity. Sulfacetamide bears US NLM identifiers UMLS ID C0038670 and NCI Concept Code C62077. SMILES: S(=O)(=O)(NC(=O)C)C1CCC(N)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C8H9N2O3S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4NRT660KJQ, chemically known as sulfanilamide, n(sup 1)-acetyl- but more generally known as sulfacetamide sodium, which bears US NIH Compound Identifier 5320. European Medicines Agency schedules Sulfacetamide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04620MIG. Most nations, for tariff and trade purposes, schedule sulfacetamide sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFACETAMIDE SODIUM remains US FDA's Preferred Term for this commodity. Sulfacetamide sodium bears US NLM identifiers UMLS ID C0282356 and NCI Concept Code C29467. SMILES: CC(=O)[N-]S(=O)(=O)C1CCC(CC1)N.O.[NA+].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C8H9N2O3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30760ZE777, chemically known as acetamide, n-((4-aminophenyl)sulfonyl)-, monosodium salt, but more generally known as sulfacetamide sodium anhydrous, which bears US NIH Compound Identifier 5320. European Medicines Agency schedules sulfacetamide sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10687MIG. Most nations, for tariff purposes, schedule sulfacetamide sodium anhydrous under HS 29350090. SMILES: CC(=O)[N-]S(=O)(=O)C1CCC(CC1)N.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE500. This VA Drug Class (DE500) classifies this compound as belonging to the group KERATOLYTICS/CAUSTICS, TOPICAL.
This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier P78D9P90C0. The European Medicines Agency schedules Sulfachlorpyridazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10688MIG. Sulfachlorpyridazine generally arises in the molecular formula C10H9CLN4O2S. The term SULFACHLORPYRIDAZINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 16, no. 3 1962, list 4.) SULFACHLORPYRIDAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C1=CC(=CC=C1N)S(=O)(=O)NC2=CC(=NN=C2)CL.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C13H13N5O4S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 39O1389K38, chemically known as 4,6-diamino-4-sulfamoylazobenzol-2-carbonsaeure but more generally known as sulfachrysoidine, which bears U.S. National Institutes of Health Compound Identifier 68090. The European Medicines Agency schedules Sulfachrysoidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10689MIG. The term SULFACHRYSOIDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). SULFACHRYSOIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(N)C1CCC(/N=N/C2C(CC(N)CC2N)C(=O)O)CC1.
This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T795873AJP. European Medicines Agency schedules Sulfacitine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10690MIG. Sulfacitine generally arises in the molecular formula C12H14N4O3S. The term SULFACITINE is an International Non-Proprietary Name or INN. SULFACITINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Sulfacitine or sulfacytine bears US NLM identifiers UMLS ID C0262960 and NCI Concept Code C47734. SMILES: CCN1C=CC(=NC1=O)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C12H13ClN4O2S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier AXA8K5U95M, chemically known as 4-amino-n-(5-chloro-2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide but more generally known as sulfaclomide, which bears U.S. National Institutes of Health Compound Identifier 71168. The European Medicines Agency schedules Sulfaclomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10691MIG. The term SULFACLOMIDE is an International Non-Proprietary Name. SULFACLOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=C(C(=NC(=N1)C)NS(=O)(=O)C2=CC=C(C=C2)N)CL.
This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69YP7Z48CW. European Medicines Agency schedules Sulfaclozine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10693MIG. Sulfaclozine generally arises in the molecular formula C10H9CLN4O2S. The term SULFACLOZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) SULFACLOZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Sulfaclozine or sulfachlorpyridazine bears US NLM identifiers UMLS ID C0038672 and NCI Concept Code C76974. SMILES: C1=CC(=CC=C1N)S(=O)(=O)NC2=CN=CC(=N2)CL.
This classification denotes a sulfone anti-infective agent with the molecular formula C14H14N3O5S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQ3M2Y4BU3, chemically known as 4, 4-diaminodiphenylsulfone-2-n-acetylsulfonamide, sodium but more generally known as acetosulfone sodium, which bears US NIH Compound Identifier 31400. European Medicines Agency schedules Sulfadiasulfone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10694MIG. The term SULFADIASULFONE SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). Most nations, for tariff and trade purposes, schedule sulfadiasulfone sodium under HS 29350090. SMILES: CC(=O)[N-]S(=O)(=O)C1CC(CCC1S(=O)(=O)C2CCC(CC2)N)N.[NA+].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C10H10N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0N7609K889, chemically known as trisulfapyrimidine, oral suspension but generally known as sulfadiazine, which bears US NIH Compound Identifier 5215. European Medicines Agency schedules Sulfadiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10695MIG. The term SULFADIAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules sulfadiazine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFADIAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfadiazine under HS 29350090 and SITC 51580. As of Q4 2014, SULFADIAZINE remains the US FDA Preferred Term for this commodity. Sulfadiazine bears US NLM identifiers UMLS ID C0038675 and NCI Concept Code C29468. SMILES: C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a topical anti-infective agent and sulfonamide anti-infective agent with the molecular formula C10H9N4O2S.Ag, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W46JY43EJR, chemically known as sulfanilamide, n(sup 1)-2-pyrimidinyl-, monosilver(1+) salt but more generally known as silver sulfadiazine, which bears US NIH Compound Identifier 31011. European Medicines Agency schedules Silver sulfadiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04622MIG. World Health Organization schedules silver sulfadiazine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule sulfadiazine silver under HS 29350090 and SITC 51580. SMILES: C1CNC(NC1)[N-]S(=O)(=O)C2CCC(CC2)N.[AG+].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C10H9N4O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84CS1P306F, chemically known as trisulfapyrimidine, oral suspension but more generally known as sulfadiazine sodium, which bears US NIH Compound Identifier 5215. European Medicines Agency schedules Sulfadiazine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10696MIG. The term SULFADIAZINE SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations, for tariff and trade purposes, schedule sulfadiazine sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFADIAZINE SODIUM remains US FDA's Preferred Term for this commodity. Sulfadiazine sodium bears US NLM identifiers UMLS ID C0723509 and NCI Concept Code C66566. SMILES: C1CNC(NC1)[N-]S(=O)(=O)C2CCC(CC2)N.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.
This classification denotes a sulfonamide antiinfective with the molecular formula C11H14N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7WZ5EG263C, chemically known as n'-(3,3-dimethylacroyl)sulfanilamide but generally known as sulfadicramide, which bears US NIH Compound Identifier 8281. The term SULFADICRAMIDE is an International Non-Proprietary Name or INN. European Medicines Agency schedules sulfadicramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10697MIG. Most nations schedule sulfadicramide under HS 29350090 and SITC 51580. As of Q4 2014, SULFADICRAMIDE remains the US FDA Preferred Term for this commodity. SMILES: CC(=CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N)C.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C12H14N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48U51W007F, chemically known as 4,6-dimethylsulfadiazine but generally known as sulfadimidine, which bears US NIH Compound Identifier 5327. European Medicines Agency schedules Sulfadimidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10699MIG. World Health Organization schedules sulfadimidine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFADIMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C12H14N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30CPC5LDEX, chemically known as 2,6-dimethoxy-4-sulfanilamidopyrimidine but generally known as sulfadimethoxine, which bears US NIH Compound Identifier 5323. European Medicines Agency schedules Sulfadimethoxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10698MIG. The term SULFADIMETHOXINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules sulfadimethoxine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFADIMETHOXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfadimethoxine under HS 29350090 and SITC 51580. As of Q4 2014, SULFADIMETHOXINE remains the US FDA Preferred Term for this commodity. Sulfadimethoxine bears US NLM identifiers UMLS ID C0038676 and NCI Concept Code C76975. SMILES: COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC.
This classification denotes an antimalarial agent with the molecular formula C12H14N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88463U4SM5, chemically known as 6-(4-aminobenzenesulfonamido)-4,5-dimethoxypyrimidine but generally known as sulfadoxine, which bears US NIH Compound Identifier 17134. European Medicines Agency schedules Sulfadoxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10700MIG. The term SULFADOXINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). SULFADOXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Sulfadoxine or sulphadoxine bears US NLM identifiers UMLS ID C0038679 and NCI Concept Code C47735. SMILES: COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H13N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 740T4C525W, chemically known as 3,4-dimethylisoxazole-5-sulphanilamide but generally known as sulfafurazole, which bears US NIH Compound Identifier 5344. European Medicines Agency schedules Sulfafurazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10702MIG. World Health Organization schedules sulfafurazole in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAFURAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C7H10N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15XQ8043FN, chemically known as sulfanilamide, n(sup1)-amidino- but generally known as sulfaguanidine, which bears US NIH Compound Identifier 5324. European Medicines Agency schedules Sulfaguanidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10703MIG. The term SULFAGUANIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules sulfaguanidine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAGUANIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfaguanidine under HS 29350090 and SITC 51580. As of Q4 2014, SULFAGUANIDINE remains the US FDA Preferred Term for this commodity. Sulfaguanidine bears US NLM identifiers UMLS ID C0038681 and NCI Concept Code C76977. SMILES: S(=O)(=O)(/N=C(/N)N)C1CCC(N)CC1.
This classification denotes an anti-infective agent and sulfanilamide with the molecular formula C12H14N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W03L3ODK6E, chemically known as 4,6-dimethylsulfadiazine but generally known as sulfisomidine, which bears US NIH Compound Identifier 5327. European Medicines Agency schedules Sulfisomidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10739MIG. SULFISOMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T6BL4ZC15G, chemically known as sulfanilamide, n(sup 1)-(3-methoxypyrazinyl)- but generally known as sulfalene, which bears US NIH Compound Identifier 9047. European Medicines Agency schedules Sulfalene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10705MIG. The term SULFALENE is an International Non-Proprietary Name. World Health Organization schedules sulfalene in its Anatomical Therapeutic Chemical (ATC) Classification. SULFALENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Sulfalene or sulfamethopyrazine bears US NLM identifiers UMLS ID C0038683 and NCI Concept Code C80793. SMILES: COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C23H24N6O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D7B8U8VA9J, chemically known as alpha-(4-((6-methoxy-3-pyridazinyl)sulfamoyl)anilino)-2,3-dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-methanesulfonsaeure but generally known as sulfamazone, which bears US NIH Compound Identifier 187764. European Medicines Agency schedules Sulfamazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10707MIG. The term SULFAMAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules sulfamazone in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAMAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfamazone under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMAZONE remains the US FDA Preferred Term for this commodity. Sulfamazone bears US NLM identifiers UMLS ID C2348596 and NCI Concept Code C73102. SMILES: S(=O)(=O)(O)C(NC1CCC(S(=O)(=O)NC2NNC(OC)CC2)CC1)C1C(N(N(C1=O)C1CCCCC1)C)C.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR1SAB295F, chemically known as sulfanilamide, n(sup 1)-(4-methyl-2-pyrimidinyl)- but generally known as sulfamerazine, which bears US NIH Compound Identifier 5325. European Medicines Agency schedules Sulfamerazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10708MIG. The term SULFAMERAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules sulfamerazine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAMERAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfamerazine under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMERAZINE remains the US FDA Preferred Term for this commodity. Sulfamerazine bears US NLM identifiers UMLS ID C0038684 and NCI Concept Code C61959. SMILES: CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H11N4O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JOV4UJY07O, chemically known as sulfanilamide, n(sup 1)-(4-methyl-2-pyrimidinyl)- but more generally known as sulfamerazine sodium, which bears US NIH Compound Identifier 5325. European Medicines Agency schedules Sulfamerazine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10709MIG. The term SULFAMERAZINE SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations, for tariff and trade purposes, schedule sulfamerazine sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMERAZINE SODIUM remains US FDA's Preferred Term for this commodity. Sulfamerazine sodium bears US NLM identifiers UMLS ID C2728211 and NCI Concept Code C80794. SMILES: CC1CCNC(N1)[N-]S(=O)(=O)C2CCC(CC2)N.[NA+].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H10N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25W8454H16, chemically known as 5-methyl-2-sulfanilamido-1,3,4-thiadiazole but generally known as sulfamethizole, which bears US NIH Compound Identifier 5328. European Medicines Agency schedules Sulfamethizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10710MIG. The term SULFAMETHIZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules sulfamethizole in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAMETHIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfamethizole under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMETHIZOLE remains the US FDA Preferred Term for this commodity. Sulfamethizole bears US NLM identifiers UMLS ID C0038687 and NCI Concept Code C47736. SMILES: S(=O)(=O)(NC1SC(NN1)C)C1CCC(N)CC1.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C10H11N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JE42381TNV, chemically known as 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide but generally known as sulfamethoxazole, which bears US NIH Compound Identifier 5329. European Medicines Agency schedules Sulfamethoxazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10711MIG. The term SULFAMETHOXAZOLE is an International Non-Proprietary Name. World Health Organization schedules sulfamethoxazole in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAMETHOXAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfamethoxazole under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMETHOXAZOLE remains the US FDA Preferred Term for this commodity. Sulfamethoxazole bears US NLM identifiers UMLS ID C0038689 and NCI Concept Code C47737. SMILES: CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent C10H10N3O3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PJ0X8H59AI, chemically known as benzenesulfonamide, 4-amino-n-(5-methyl-3-isoxazolyl)-, sodium salt (1:1), but more generally known as sulfamethoxazole sodium, which bears US NIH Compound Identifier 5329. European Medicines Agency schedules Sulfamethoxazole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35068. Most nations, for tariff and trade purposes, schedule sulfamethoxazole sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMETHOXAZOLE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1CC(NO1)[N-]S(=O)(=O)C2CCC(CC2)N.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T034E4NS2Z, chemically known as sulfanilamide, n(sup 1)-(6-methoxy-3-pyridazinyl)- but generally known as sulfamethoxypyridazine, which bears US NIH Compound Identifier 5330. European Medicines Agency schedules Sulfamethoxypyridazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10712MIG. The term SULFAMETHOXYPYRIDAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules sulfamethoxypyridazine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAMETHOXYPYRIDAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfamethoxypyridazine under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMETHOXYPYRIDAZINE remains the US FDA Preferred Term for this commodity. Sulfamethoxypyridazine bears US NLM identifiers UMLS ID C0038693 and NCI Concept Code C80795. SMILES: COC1=NN=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C12H14N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 940ZL3AHKB, chemically known as sulfanilamide, n(sup 1)-(6-methoxy-2-methyl-4-pyrimidinyl)- but generally known as sulfamethomidine, which bears US NIH Compound Identifier 19596. European Medicines Agency schedules Sulfametomidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10713MIG. The term SULFAMETOMIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules sulfamethomidine in its Anatomical Therapeutic Chemical (ATC) Classification. Sulfametomidine or sulfamethomidine bears US NLM identifiers UMLS ID C0075510 and NCI Concept Code C72851. SMILES: CC1=NC(=CC(=N1)OC)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L179F09D6, chemically known as sulfanilamide, n(sup 1)-(5-methoxy-2-pyrimidinyl)- but generally known as sulfameter, which bears US NIH Compound Identifier 5326. European Medicines Agency schedules Sulfametoxydiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10714MIG. The term SULFAMETOXYDIAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules sulfameter in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: COC1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H10N4O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5AK41IPQG, chemically known as 4-amino-n-(5-methoxy-2,1,3-thiadiazol-4-yl)benzolsulfonamid but generally known as sulfametrole, which bears US NIH Compound Identifier 64939. European Medicines Agency schedules Sulfametrole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10715MIG. The term SULFAMETROLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). SULFAMETROLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfametrole under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMETROLE remains the US FDA Preferred Term for this commodity. Sulfametrole bears US NLM identifiers UMLS ID C0075512 and NCI Concept Code C72852. SMILES: S(=O)(=O)(NC1NSNC1OC)C1CCC(N)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier U700P169W2, chemically known as sulfanilamide, n(sup 1)-(6-methoxy-4-pyrimidinyl)- but more generally known as sulfamonomethoxine, which bears U.S. National Institutes of Health Compound Identifier 5332. The European Medicines Agency schedules Sulfamonomethoxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10716MIG. The term SULFAMONOMETHOXINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). SULFAMONOMETHOXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: COC1=NC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes an anti-infective agent and sulfanilamide with the molecular formula C11H13N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HGG82XE020, chemically known as 4,5-dimethyl-2-sulfanilamidooxazole but generally known as sulfamoxole, which bears US NIH Compound Identifier 12894. European Medicines Agency schedules Sulfamoxole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10717MIG. World Health Organization schedules sulfamoxole in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAMOXOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfamoxole under HS 29350090 and SITC 51580. As of Q4 2014, SULFAMOXOLE remains the US FDA Preferred Term for this commodity. SMILES: CC1=C(OC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C.
This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21240MF57M. European Medicines Agency schedules Sulfanilamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10718MIG. Sulfanilamide generally arises in the molecular formula C6H8N2O2S. The term SULFANILAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) SULFANILAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Sulfanilamide or sulphanilamide bears US NLM identifiers UMLS ID C0038702 and NCI Concept Code C47738. SMILES: S(=O)(=O)(N)C1CCC(N)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C14H13N3O5S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier QT35T5T35Q, chemically known as acetanilide, 4-((p-nitrophenyl)sulfamoyl)- (8ci) but more generally known as sulfanitran, which bears U.S. National Institutes of Health Compound Identifier 5334. The European Medicines Agency schedules Sulfanitran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10719MIG. The term SULFANITRAN is an International Non-Proprietary Name. SULFANITRAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(NC1CCC([N](=O)O)CC1)C1CCC(NC(=O)C)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5E840UV9P, chemically known as sulfanilamide, n(sup 1)-(5-methyl-2-pyrimidinyl)- but generally known as sulfaperin, which bears US NIH Compound Identifier 68933. European Medicines Agency schedules Sulfaperin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10720MIG. The term SULFAPERINE is an International Non-Proprietary Name. World Health Organization schedules sulfaperin in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAPERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Sulfaperin or sulfaperine bears US NLM identifiers UMLS ID C0075523 and NCI Concept Code C72854. SMILES: CC1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C15H14N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0J8L4V3F81, chemically known as sulfanilamide, n(sup 1)-(1-phenylpyrazol-5-yl)- (8ci) but generally known as sulfaphenazole, which bears US NIH Compound Identifier 5335. European Medicines Agency schedules Sulfaphenazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10721MIG. The term SULFAPHENAZOLE is an International Non-Proprietary Name. World Health Organization schedules sulfaphenazole in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAPHENAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfaphenazole under HS 29350090 and SITC 51580. As of Q4 2014, SULFAPHENAZOLE remains the US FDA Preferred Term for this commodity. Sulfaphenazole bears US NLM identifiers UMLS ID C0038706 and NCI Concept Code C66569. SMILES: S(=O)(=O)(NC1N(NCC1)C1CCCCC1)C1CCC(N)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C16H18N2O4S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier YR841R53VW, chemically known as benzamide, p-isopropoxy-n-sulfanilyl- (8ci) but more generally known as sulfaproxyline, which bears U.S. National Institutes of Health Compound Identifier 67002. The European Medicines Agency schedules Sulfaproxyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10722MIG. The term SULFAPROXYLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). SULFAPROXYLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(NC(=O)C1CCC(OC(C)C)CC1)C1CCC(N)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H11N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y5V2N1KE8U, chemically known as sulfanilamide, n(sup 1)-2-pyridyl- but generally known as sulfapyridine, which bears US NIH Compound Identifier 5336. European Medicines Agency schedules Sulfapyridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10724MIG. The term SULFAPYRIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules sulfapyridine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFAPYRIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfapyridine under HS 29350090 and SITC 51580. As of Q4 2014, SULFAPYRIDINE remains the US FDA Preferred Term for this commodity. Sulfapyridine bears US NLM identifiers UMLS ID C0038710 and NCI Concept Code C66570. SMILES: C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C14H12N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WNW8115TM9, chemically known as sulfanilamide, n(sup1)-2-quinoxalinyl- but generally known as sulfaquinoxaline, which bears US NIH Compound Identifier 5338. European Medicines Agency schedules Sulfaquinoxaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10725MIG. The term SULFAQUINOXALINE is an International Non-Proprietary Name. SULFAQUINOXALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfaquinoxaline under HS 29350090 and SITC 51580. As of Q4 2014, SULFAQUINOXALINE remains the US FDA Preferred Term for this commodity. Sulfaquinoxaline bears US NLM identifiers UMLS ID C0038711 and NCI Concept Code C76979. SMILES: S(=O)(=O)(NC1NC2C(NC1)CCCC2)C1CCC(N)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C14H11N4O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21223EPJ40, chemically known as n1-(quinoxalin-2-yl)sulphanilamide sodium salt, but more generally known as sulfaquinoxaline sodium, which bears US NIH Compound Identifier 71594. European Medicines Agency schedules sulfaquinoxaline sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10725MIG. Most nations, for tariff purposes, schedule sulfaquinoxaline sodium under HS 29350090. Sulfaquinoxaline sodium bears US NLM identifiers UMLS ID C2728210 and NCI Concept Code C90992. SMILES: C1CCC2C(C1)NCC(N2)[N-]S(=O)(=O)C3CCC(CC3)N.[NA+].
This classification denotes a topical anti-infective agent with the molecular formula C14H14As2N2O8S2.2Na, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier B1GGH4ZUZL, chemically known as 3,3-diamino-4,4-dihydroxyarsenobenzol-n,n-methanesulfonsaeure dinatrium salz but more generally known as sulfarsphenamine, which bears U.S. National Institutes of Health Compound Identifier 71510. The European Medicines Agency schedules Sulfarsphenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10726MIG. The term SULFARSPHENAMINE is an International Non-Proprietary Name. SULFARSPHENAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [ASH](=[ASH]\C1CC(NCS(=O)(=O)O)C(O)CC1)/C1CC(NCS(=O)(=O)O)C(O)CC1.[NA].[NA].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C18H14N4O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3XC8GUZ6CB, chemically known as salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)- but more generally known as sulfasalazine, which bears US NIH Compound Identifier 5353980. European Medicines Agency schedules Sulfasalazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10727MIG. The term SULFASALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules sulfasalazine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFASALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sulfasalazine under HS 29350090 and SITC 51580. As of Q4 2014, SULFASALAZINE remains US FDA's Preferred Term for this commodity. Sulfasalazine bears US NLM identifiers UMLS ID C0036078 and NCI Concept Code C29469. SMILES: S(=O)(=O)(NC1NCCCC1)C1CCC(N/N=C2/C=C(C(=O)C=C2)C(=O)O)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H9N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7FKS2XWQH, chemically known as 4-amino-n-1,3-thiazol-2-ylbenzenesulfonamide but generally known as sulfathiazole, which bears US NIH Compound Identifier 5340. European Medicines Agency schedules Sulfathiazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10731MIG. The term SULFATHIAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules sulfathiazole in its Anatomical Therapeutic Chemical (ATC) Classification. SULFATHIAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfathiazole under HS 29350090 and SITC 51580. As of Q4 2014, SULFATHIAZOLE remains the US FDA Preferred Term for this commodity. Sulfathiazole bears US NLM identifiers UMLS ID C0038722 and NCI Concept Code C66571. SMILES: S(=O)(=O)(NC1SCCN1)C1CCC(N)CC1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H8N3O2S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PV16N742VM, chemically known as sulfanilamide, n(sup 1)-2-thiazolyl-, n(sup 1)-sodium deriv. but more generally known as sulfathiazole sodium, which bears US NIH Compound Identifier 67415. Most nations, for tariff and trade purposes, schedule sulfathiazole sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFATHIAZOLE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1N)S(=O)(=O)[N-]C2NCCS2.[NA+].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H8N3O2S2.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W6NDW4K12P, chemically known as benzenesulfonamide, 4-amino-n-2-thiazolyl-, sodium salt, hydrate (1:1:1), but more generally known as sulfathiazole sodium monohydrate, which bears US NIH Compound Identifier 24975. European Medicines Agency schedules sulfathiazole sodium monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10731MIG. Most nations, for tariff purposes, schedule sulfathiazole sodium monohydrate under HS 29350090. SMILES: C1CC(CCC1N)S(=O)(=O)[N-]C2NCCS2.O.[NA+].
This classification denotes a sulfonamide anti-infective agent with the molecular formula 2C9H8N3O2S2.Zn, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4KCI0QUF9Q, chemically known as benzenesulfonamide, 4-amino-n-2-thiazolyl-, zinc salt, but more generally known as sulfathiazole zinc, which bears US NIH Compound Identifier 21571. European Medicines Agency schedules sulfathiazole zinc or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10731MIG. Most nations, for tariff purposes, schedule sulfathiazole zinc under HS 29350090. SMILES: C1CC(CCC1N)S(=O)(=O)[N-]C2NCCS2.C1CC(CCC1N)S(=O)(=O)[N-]C2NCCS2.[ZN+2].
This classification denotes a sulfonamide anti-infective agent with the molecular formula C7H9N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MXF9G4I1V5, chemically known as urea, 1-sulfanilyl-2-thio- but generally known as sulfathiourea, which bears US NIH Compound Identifier 3000579. European Medicines Agency schedules Sulfathiourea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10732MIG. The term SULFATHIOUREA is an International Non-Proprietary Name. World Health Organization schedules sulfathiourea in its Anatomical Therapeutic Chemical (ATC) Classification. SULFATHIOUREA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfathiourea under HS 29350090 and SITC 51580. As of Q4 2014, SULFATHIOUREA remains the US FDA Preferred Term for this commodity. Sulfathiourea bears US NLM identifiers UMLS ID C0075539 and NCI Concept Code C76982. SMILES: S(=O)(=O)(NC(=S)N)C1CCC(N)CC1.
This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3OLH2HAK9F. European Medicines Agency schedules Sulfatolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10733MIG. Sulfatolamide generally arises in the molecular formula C7H10N2O2S.C7H9N3O2S2. The term SULFATOLAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) SULFATOLAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfatolamide under HS 29350090 and SITC 51580. As of Q4 2014, SULFATOLAMIDE remains the US FDA Preferred Term for this commodity. Sulfatolamide bears US NLM identifiers UMLS ID C0075541 and NCI Concept Code C76983. SMILES: S(=O)(=O)(NC(=S)N)C1CCC(N)CC1.S(=O)(=O)(N)C1CCC(CC1)CN.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C10H12N4O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G91KDP4M35, chemically known as n1-(4-ethoxy-1,2,5-thiadiazol-3-yl)sulfanilamid but generally known as sulfatrozole, which bears US NIH Compound Identifier 216260. European Medicines Agency schedules Sulfatrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10735MIG. The term SULFATROZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). SULFATROZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfatrozole under HS 29350090 and SITC 51580. As of Q4 2014, SULFATROZOLE remains the US FDA Preferred Term for this commodity. Sulfatrozole bears US NLM identifiers UMLS ID C2699719 and NCI Concept Code C76984. SMILES: CCOC1=NSN=C1NS(=O)(=O)C2=CC=C(C=C2)N.
This classification denotes a uricosuric agent with the molecular formula C23H20N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6OFU47K3W, chemically known as 3,5-pyrazolidinedione, 1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)- but generally known as sulfinpyrazone, which bears US NIH Compound Identifier 5342. European Medicines Agency schedules Sulfinpyrazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10737MIG. The term SULFINPYRAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules sulfinpyrazone in its Anatomical Therapeutic Chemical (ATC) Classification. SULFINPYRAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfinpyrazone under HS 29331990 and SITC 51571. As of Q4 2014, SULFINPYRAZONE remains the US FDA Preferred Term for this commodity. Sulfinpyrazone bears US NLM identifiers UMLS ID C0038742 and NCI Concept Code C47739. SMILES: S(=O)(CCC1C(=O)N(N(C1=O)C1CCCCC1)C1CCCCC1)C1CCCCC1.
This classification denotes a fungicide and enzyme inhibitor with the molecular formula C10H20N2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XHL4Q8P7Y, chemically known as thiuram monosulfide, tetraethyl- but generally known as sulfiram, which bears US NIH Compound Identifier 7215. European Medicines Agency schedules Sulfiram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10738MIG. The term SULFIRAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). SULFIRAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfiram under HS 29303000 and SITC 51543. As of Q4 2014, SULFIRAM remains the US FDA Preferred Term for this commodity. Sulfiram bears US NLM identifiers UMLS ID C0066779 and NCI Concept Code C66572. SMILES: CCN(CC)C(=S)SC(=S)N(CC)CC.
This classification denotes an anti-infective agent and sulfanilamide C12H13N4O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 296707F7DU, chemically known as sulfisomidine, sodium, but more generally known as sulfisomidine sodium, which bears US NIH Compound Identifier 5343. Most nations, for tariff and trade purposes, schedule sulfisomidine sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFISOMIDINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1CC(NC(N1)C)[N-]S(=O)(=O)C2CCC(CC2)N.[NA+].
This classification denotes a dye with the molecular formula C20H10Br4O10S2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 0C2P5QKL36, chemically known as 3,3-(4,5,6,7-tetrabromo-3-oxo-1(3h)-isobenzofuranylidene)bis(6-hydroxybenzenesulphonic) acid but more generally known as sulfobromophthalein, which bears U.S. NIH Compound Identifier 5345. World Health Organization schedules sulfobromophthalein in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a dye with the molecular formula C20H8Br4O10S2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62E5JU30OV, chemically known as 4,5,6,7-tetrabromo-3,3-disulfophenolphthalein disodium salt but more generally known as sulfobromophthalein sodium, which bears U.S. National Institutes of Health Compound Identifier 6282.
This classification denotes an antitussive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 713AJ00NPG. European Medicines Agency schedules Sulfogaiacol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10740MIG. Sulfogaiacol generally arises in the molecular formula C7H8O5S.K. The term SULFOGAIACOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, no. 3 1962, list 4.) SULFOGAIACOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sulfogaiacol under HS 29095010 and SITC 51617. Sulfogaiacol bears US NLM identifiers UMLS ID C0061930 and NCI Concept Code C90776. SMILES: C1=CC=C(C(=C1)OCO)S(=O)(=O)[O-].[K+].
This classification denotes a beta-adrenergic agonist with the molecular formula C14H23NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z540ZT2MI6, chemically known as benzenemethanol, alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-3-((methylsulfonyl)methyl)- but generally known as sulfonterol, which bears US NIH Compound Identifier 170373. European Medicines Agency schedules Sulfonterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10741MIG. The term SULFONTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). SULFONTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulfonterol under HS 29309085 and SITC 51549. As of Q4 2014, SULFONTEROL remains the US FDA Preferred Term for this commodity. Sulfonterol bears US NLM identifiers UMLS ID C0075584 and NCI Concept Code C76549. SMILES: S(=O)(=O)(CC1CC(C(O)CNC(C)(C)C)CCC1O)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H6O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L8XED79U3U, chemically known as salicylic acid, sulfo- but generally known as sulfosalicylic acid, which bears US NIH Compound Identifier 7322. As of Q4 2014, SULFOSALICYLIC ACID remains the US FDA Preferred Term for this commodity. Sulfosalicylic acid bears US NLM identifiers UMLS ID C0075593 and NCI Concept Code C84186. SMILES: C1=CC(=C(C=C1S(=O)(=O)O)C(=O)O)O.
This classification denotes a contrast agent with the molecular formula F6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WS7LR3I1D6, chemically known as sulfur fluoride (sf6), (oc-6-11)- but more generally known as sulfur hexafluoride, which bears U.S. National Institutes of Health Compound Identifier 17358. The European Medicines Agency schedules Sulfur hexafluoride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15925MIG. The World Health Organization schedules sulfur hexafluoride in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule Sulfur hexafluoride under HS 28111990. SMILES: S(F)(F)(F)(F)(F)F.
This classification denotes a cyclooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 184SNS8VUH. European Medicines Agency schedules Sulindac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10744MIG. Sulindac generally arises in the molecular formula C20H17FO3S. The term SULINDAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) SULINDAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulindac under HS 29309085 and SITC 51549. As of Q4 2014, SULINDAC remains the US FDA Preferred Term for this commodity. Sulindac bears US NLM identifiers UMLS ID C0038792 and NCI Concept Code C850. SMILES: S(=O)(C1CCC(/C=C2\C(=C(C3C2CCC(F)C3)CC(=O)O)C)CC1)C.
This classification denotes a cyclooxygenase inhibitor C20H16FO3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NJV14I2XPC, chemically known as 1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, sodium salt (1:1), (1z)-, but more generally known as sulindac sodium, which bears US NIH Compound Identifier 23676448. European Medicines Agency schedules Sulindac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04640MIG. Most nations, for tariff and trade purposes, schedule sulindac sodium under HS 29309085 and SITC 51549. As of Q4 2014, SULINDAC SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC\1=C(C2CC(CCC2/C1=C\C3CCC(CC3)[S+](C)[O-])F)CC(=O)[O-].[NA+].
This classification denotes a cyclooxygenase inhibitor with the molecular formula C20H17FO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UVA8S2DEY, chemically known as sulindac sulfide, (z)-, but more generally known as sulindac sulfide, which bears US NIH Compound Identifier 91605. European Medicines Agency schedules sulindac sulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10744MIG. Most nations, for tariff purposes, schedule sulindac sulfide under HS 29309085. Sulindac sulfide bears US NLM identifiers UMLS ID C0075615 and NCI Concept Code C29854. SMILES: CC\1=C(C2CC(CCC2/C1=C\C3CCC(CC3)SC)F)CC(=O)O.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C20H17FO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K619IIG2R9, chemically known as 1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene)-, (1z)-, but more generally known as sulindac sulfone, which bears US NIH Compound Identifier 5472495. European Medicines Agency schedules sulindac sulfone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10744MIG. Most nations, for tariff purposes, schedule sulindac sulfone under HS 29309085. SMILES: CC\1=C(C2CC(CCC2/C1=C\C3CCC(CC3)S(=O)(=O)C)F)CC(=O)O.
This classification denotes a laxative with the molecular formula C21H17NO9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5EOG8KQT0Y, chemically known as 3,3-bis(4-hydroxyphenyl)-7-methyl-2-indolinone, disodium salt of sulfuric acid diester but generally known as sulisatin, which bears US NIH Compound Identifier 41237. European Medicines Agency schedules Sulisatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10745MIG. The term SULISATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). SULISATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulisatin under HS 29337900 and SITC 51561. As of Q4 2014, SULISATIN remains the US FDA Preferred Term for this commodity. Sulisatin bears US NLM identifiers UMLS ID C0075617 and NCI Concept Code C74275. SMILES: S(=O)(=O)(OC1CCC(C2(C3C(NC2=O)C(CCC3)C)C2CCC(OS(=O)(=O)O)CC2)CC1)O.[NA].[NA].
This classification denotes a laxative C21H15NO9S2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7S636L78GU, chemically known as 2h-indol-2-one, 1,3-dihydro-7-methyl-3,3-bis(4-(sulfooxy)phenyl)-, sodium salt (1:2), but more generally known as sulisatin sodium, which bears US NIH Compound Identifier 41237. European Medicines Agency schedules Sulisatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04641MIG. Most nations, for tariff and trade purposes, schedule sulisatin sodium under HS 29337900 and SITC 51561. As of Q4 2014, SULISATIN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1CCCC2C1NC(=O)C2(C3CCC(CC3)OS(=O)(=O)[O-])C4CCC(CC4)OS(=O)(=O)[O-].[NA+].[NA+].
This classification denotes a coumarin compound with the molecular formula C10H8O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73W96524XT, chemically known as 2-(2-methoxy-4-(methylsulfinyl)phenyl)-1h-imidazo(4,5-b)pyridine but generally known as sulmarin, which bears US NIH Compound Identifier 5353. European Medicines Agency schedules Sulmarin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10747MIG. The term SULMARIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). SULMARIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, SULMARIN remains the US FDA Preferred Term for this commodity. Sulmarin bears US NLM identifiers UMLS ID C2699721 and NCI Concept Code C74242. SMILES: COC1=C(C=CC(=C1)S(=O)C)C2=NC3=C(N2)C=CC=N3.
This classification denotes a cardiotonic agent with the molecular formula C14H13N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HK56EH9K44, chemically known as 2-(2-methoxy-4-(methylsulfinyl)phenyl)-1h-imidazo(4,5-b)pyridine but generally known as sulmazole, which bears US NIH Compound Identifier 5353. European Medicines Agency schedules Sulmazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10748MIG. The term SULMAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). SULMAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulmazole under HS 29339990 and SITC 51577. As of Q4 2014, SULMAZOLE remains the US FDA Preferred Term for this commodity. Sulmazole bears US NLM identifiers UMLS ID C0075619 and NCI Concept Code C84188. SMILES: S(=O)(C1CC(OC)C(C2[NH]C3C(N2)NCCC3)CC1)C.
This classification denotes an antiprotozoal agent with the molecular formula C9H14N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 504LR309YV, chemically known as r 26,412 but generally known as sulnidazole, which bears US NIH Compound Identifier 3037172. European Medicines Agency schedules Sulnidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10750MIG. The term SULNIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). SULNIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulnidazole under HS 29332990 and SITC 51573. As of Q4 2014, SULNIDAZOLE remains the US FDA Preferred Term for this commodity. Sulnidazole bears US NLM identifiers UMLS ID C2348602 and NCI Concept Code C73278. SMILES: S=C(OC)NCCN1C(NCC1[N](=O)O)CC.
This classification denotes a vasodilator agent with the molecular formula C20H35NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XV1N1XY17K, chemically known as (r*,s*)-4-(isopropylthio)-alpha-(1-(octylamino)ethyl)benzyl alcohol but generally known as suloctidil, which bears US NIH Compound Identifier 5354. European Medicines Agency schedules Suloctidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10752MIG. World Health Organization schedules suloctidil in its Anatomical Therapeutic Chemical (ATC) Classification. SULOCTIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule suloctidil under HS 29309085 and SITC 51549. As of Q4 2014, SULOCTIDIL remains the US FDA Preferred Term for this commodity. SMILES: S(c1ccc(C(O)C(NCCCCCCCC)C)cc1)C(C)C.
This classification denotes a beta-lactam antibiotic with the molecular formula C12H15NO5S3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier XX514BJ1XW, chemically known as 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-((tetrahydro-3-thienyl)thio)-, s-oxide, (5r-(3(1r*,3s*),5alpha,6alpha(r*)))- but more generally known as sulopenem, which bears U.S. National Institutes of Health Compound Identifier 71341. The European Medicines Agency schedules Sulopenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10754MIG. The term SULOPENEM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 7, No3, 1993, List 33). SULOPENEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(C1C2N(C1=O)C(=C(S2)SC3CCS(=O)C3)C(=O)O)O.
This classification denotes a diuretic with the molecular formula C17H16N2O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CY351D07GJ, chemically known as benzenesulfonic acid, 2-(furfurylamino)-4-phenoxy-5-sulfanoyl- but generally known as sulosemide, which bears US NIH Compound Identifier 213033. European Medicines Agency schedules Sulosemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10755MIG. The term SULOSEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). SULOSEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulosemide under HS 29350090 and SITC 51580. As of Q4 2014, SULOSEMIDE remains the US FDA Preferred Term for this commodity. Sulosemide bears US NLM identifiers UMLS ID C2699723 and NCI Concept Code C74250. SMILES: S(=O)(=O)(N)C1C(OC2CCCCC2)CC(NCC2OCCC2)C(S(=O)(=O)O)C1.
This classification denotes an antiplatelet agent with the molecular formula C16H17NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74574CO5A6, chemically known as acetic acid, (4-(2-((phenylsulfonyl)amino)ethyl)phenoxy)- but generally known as sulotroban, which bears US NIH Compound Identifier 51550. European Medicines Agency schedules Sulotroban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10756MIG. The term SULOTROBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). SULOTROBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulotroban under HS 29350090 and SITC 51580. As of Q4 2014, SULOTROBAN remains the US FDA Preferred Term for this commodity. Sulotroban bears US NLM identifiers UMLS ID C0075621 and NCI Concept Code C84190. SMILES: S(=O)(=O)(NCCC1CCC(OCC(=O)O)CC1)C1CCCCC1.
This classification denotes a bronchodilator with the molecular formula C18H24N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LD18TA6Q06, chemically known as N,N-diethyl-2-[[oxo(diphenyl)-a6-sulfanylidene]amino]ethanamine but generally known as suloxifen, which bears US NIH Compound Identifier 3084445. European Medicines Agency schedules suloxifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10757MIG. Most nations schedule suloxifen under HS 29309085 and SITC 51549. As of Q4 2014, SULOXIFEN remains the US FDA Preferred Term for this commodity. Suloxifen bears US NLM identifiers UMLS ID C2699724 and NCI Concept Code C76575. SMILES: CCN(CC)CCN=S(=O)(C1=CC=CC=C1)C2=CC=CC=C2.
This classification denotes a bronchodilator with the molecular formula C18H24N2OS.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C0HG40P7PY, chemically known as sulfoximine, n-(2-(diethylamino)ethyl)-s,s-diphenyl-, oxalate (1:1) but more generally known as suloxifen oxalate, which bears US NIH Compound Identifier 3084445. Most nations, for tariff and trade purposes, schedule suloxifen oxalate under HS 29309085 and SITC 51549. As of Q4 2014, SULOXIFEN OXALATE remains US FDA's Preferred Term for this commodity. Suloxifen oxalate bears US NLM identifiers UMLS ID C2699725 and NCI Concept Code C74220. SMILES: CCN(CC)CCN=S(=O)(C1CCCCC1)C2CCCCC2.C(=O)(C(=O)O)O.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85LCU5151G. European Medicines Agency schedules Sulprosal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10759MIG. Sulprosal generally arises in the molecular formula C10H12O6S. The term SULPROSAL is an International Non-Proprietary Name or INN. SULPROSAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, SULPROSAL remains the US FDA Preferred Term for this commodity. Sulprosal bears US NLM identifiers UMLS ID C1883217 and NCI Concept Code C66575. SMILES: C1=CC=C(C(=C1)C(=O)OCCCS(=O)(=O)O)O.
This classification denotes a prostaglandin analogue with the molecular formula C23H31NO7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 501Q5EQ1GM, chemically known as 16-phenoxy-omega-17,18,19,20-tetranor prostaglandin e2 methylsulfonylamide but generally known as sulprostone, which bears US NIH Compound Identifier 5312153. European Medicines Agency schedules Sulprostone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10760MIG. The term SULPROSTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules sulprostone in its Anatomical Therapeutic Chemical (ATC) Classification. SULPROSTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulprostone under HS 29375000 and SITC 54156. As of Q4 2014, SULPROSTONE remains the US FDA Preferred Term for this commodity. Sulprostone bears US NLM identifiers UMLS ID C0075628 and NCI Concept Code C84191. SMILES: S(=O)(=O)(NC(=O)CCC/C=C\CC1C(C(O)CC1=O)/C=C/C(O)COC1CCCCC1)C.
This classification denotes an anti-bacterial agent and ampicillin with the molecular formula C25H30N4O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65DT0ML581, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyl)oxy)methyl ester, s,s-dioxide, (2s-(2alpha(2r*,5s*),5alpha,6beta(s*)))- but generally known as sultamicillin, which bears US NIH Compound Identifier 53512. European Medicines Agency schedules Sultamicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10761MIG. World Health Organization schedules sultamicillin in its Anatomical Therapeutic Chemical (ATC) Classification. SULTAMICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sultamicillin under HS 29411090 and SITC 54131. As of Q4 2014, SULTAMICILLIN remains the US FDA Preferred Term for this commodity. SMILES: S1(=O)(=O)C(C(N2C1CC2=O)C(=O)OCOC(=O)C1N2C(SC1(C)C)C(NC(=O)C(N)C1CCCCC1)C2=O)(C)C.
This classification denotes an anticonvulsant and thiazine with the molecular formula C10H14N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I00Q766CZ2, chemically known as 2-(p-sulfamoylphenyl)-tetrahydro-2h-1,2-thiazine 1,1-dioxide but generally known as sultiame, which bears US NIH Compound Identifier 5356. European Medicines Agency schedules Sultiame in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10762MIG. World Health Organization schedules sultiame in its Anatomical Therapeutic Chemical (ATC) Classification. SULTIAME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sultiame under HS 29350090 and SITC 51580. SMILES: C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N.
This classification denotes an antipsychotic agent with the molecular formula C17H26N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AA0G3TW31W, chemically known as o-anisamide, n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)- but generally known as sultopride, which bears US NIH Compound Identifier 5357. European Medicines Agency schedules Sultopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10763MIG. The term SULTOPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules sultopride in its Anatomical Therapeutic Chemical (ATC) Classification. SULTOPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sultopride under HS 29339990 and SITC 51577. As of Q4 2014, SULTOPRIDE remains the US FDA Preferred Term for this commodity. Sultopride bears US NLM identifiers UMLS ID C0075630 and NCI Concept Code C73291. SMILES: S(=O)(=O)(C1CC(C(=O)NCC2N(CCC2)CC)C(OC)CC1)CC.
This classification denotes an antipsychotic agent with the molecular formula C17H26N2O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Q6926T32J, chemically known as n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide hydrochloride, but more generally known as sultopride hydrochloride, which bears US NIH Compound Identifier 41485. European Medicines Agency schedules sultopride hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10763MIG. Most nations, for tariff purposes, schedule sultopride hydrochloride under HS 29339990. SMILES: CCN1CCCC1CNC(=O)C2CC(CCC2OC)S(=O)(=O)CC.CL.
This classification denotes a bronchodilator with the molecular formula C25H36N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M652A5186T, chemically known as 3-(((1r,2e,4z)-1-((alphas)-alpha-hydroxy-m-1h-tetrazol-5-ylbenzyl)-2,4-tetradecadienyl)thio)propionic acid but generally known as sulukast, which bears US NIH Compound Identifier 6436123. European Medicines Agency schedules Sulukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10766MIG. The term SULUKAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). SULUKAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sulukast under HS 29339990 and SITC 51577. As of Q4 2014, SULUKAST remains the US FDA Preferred Term for this commodity. Sulukast bears US NLM identifiers UMLS ID C2699726 and NCI Concept Code C76576. SMILES: S(C(C(O)C1CC(CCC1)C1N[NH]NN1)/C=C/C=C/CCCCCCCCC)CCC(=O)O.
This classification denotes a serotonin agonist with the molecular formula C14H21N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8R78F6L9VO, chemically known as 1h-indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-n-methyl- but generally known as sumatriptan, which bears US NIH Compound Identifier 5358. European Medicines Agency schedules Sumatriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10770MIG. The term SUMATRIPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules sumatriptan in its Anatomical Therapeutic Chemical (ATC) Classification. SUMATRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sumatriptan under HS 29350090 and SITC 51580. As of Q4 2014, SUMATRIPTAN remains the US FDA Preferred Term for this commodity. Sumatriptan bears US NLM identifiers UMLS ID C0075632 and NCI Concept Code C1240. SMILES: S(=O)(=O)(NC)CC1CC2C(CCN(C)C)C[NH]C2CC1.
This classification denotes a serotonin agonist with the molecular formula C14H21N3O2S.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J8BDZ68989, chemically known as 1h-indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-n-methyl- but more generally known as sumatriptan succinate, which bears US NIH Compound Identifier 5358. European Medicines Agency schedules Sumatriptan succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15437MIG. Most nations, for tariff and trade purposes, schedule sumatriptan succinate under HS 29350090 and SITC 51580. As of Q4 2014, SUMATRIPTAN SUCCINATE remains US FDA's Preferred Term for this commodity. Sumatriptan succinate bears US NLM identifiers UMLS ID C0206599 and NCI Concept Code C29470. SMILES: CNS(=O)(=O)CC1CCC2C(C1)C(C[NH]2)CCN(C)C.C(CC(=O)O)C(=O)O.
This classification denotes a tyrosine kinase inhibitor and angiogenesis activator inhibitor with the molecular formula C22H27FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V99T50803M, chemically known as 1h-pyrrole-3-carboxamide, n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl- but generally known as sunitinib, which bears US NIH Compound Identifier 5329102. European Medicines Agency schedules Sunitinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22321. The term SUNITINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 1, 2006, List 55). World Health Organization schedules sunitinib in its Anatomical Therapeutic Chemical (ATC) Classification. SUNITINIB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sunitinib under HS 29337900 and SITC 51561. As of Q4 2014, SUNITINIB remains the US FDA Preferred Term for this commodity. Sunitinib bears US NLM identifiers UMLS ID C1176020 and NCI Concept Code C71622. SMILES: FC1CC2/C(=C/C3[NH]C(C(C3C)C(=O)NCCN(CC)CC)C)C(=O)NC2CC1.
This classification denotes a tyrosine kinase inhibitor and angiogenesis activator inhibitor with the molecular formula C22H27FN4O2.C4H6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LVX8N1UT73. European Medicines Agency schedules sunitinib malate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22366. The term sunitinib malate is a United States Adopted Name designation. As of Q4 2014, SUNITINIB MALATE remains US FDA's Preferred Term for this commodity. Sunitinib malate bears US NLM identifiers UMLS ID C1700685 and NCI Concept Code C26673. Most nations, for tariff and trade purposes, schedule sunitinib malate under HS 29337900 and SITC 51561. SMILES: CCN(CC)CCNC(=O)C1C(C([NH]C1C)/C=C\2/C3CC(CCC3NC2=O)F)C.C([C@@H](C(=O)O)O)C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H12O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 988GU2F9PE, chemically known as r-25,061 but generally known as suprofen, which bears US NIH Compound Identifier 5359. European Medicines Agency schedules Suprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10778MIG. The term SUPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules suprofen in its Anatomical Therapeutic Chemical (ATC) Classification. SUPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule suprofen under HS 29349990 and SITC 51579. As of Q4 2014, SUPROFEN remains the US FDA Preferred Term for this commodity. Suprofen bears US NLM identifiers UMLS ID C0038878 and NCI Concept Code C66576. SMILES: S1C(C(=O)C2CCC(C(C)C(=O)O)CC2)CCC1.
This classification denotes an angiogenesis activator inhibitor with the molecular formula C51H40N6O23S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6032D45BEM, chemically known as 1,3,5-naphthylenetrisulfonic acid, 8,8-(ureylenebis(m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino))di- but generally known as suramin, which bears US NIH Compound Identifier 5361. European Medicines Agency schedules Suramin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04651MIG. SURAMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, SURAMIN remains the US FDA Preferred Term for this commodity. Suramin bears US NLM identifiers UMLS ID C0038880 and NCI Concept Code C853. SMILES: S(=O)(=O)(O)C1C2C(C(S(=O)(=O)O)CCC2NC(=O)C2CC(NC(=O)C3CC(NC(=O)NC4CC(C(=O)NC5CC(C(=O)NC6C7C(C(S(=O)(=O)O)CC6)CC(S(=O)(=O)O)CC7S(=O)(=O)O)CCC5C)CCC4)CCC3)C(CC2)C)CC(S(=O)(=O)O)C1.
This classification denotes a muscle relaxant with the molecular formula C16H34N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MED638SZQB, chemically known as succinic acid, diester with choline iodide but generally known as suxethonium, which bears US NIH Compound Identifier 71732. European Medicines Agency schedules Suxethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15440MIG. The term SUXETHONIUM is an International Non-Proprietary Name. As of Q4 2014, SUXETHONIUM remains the US FDA Preferred Term for this commodity. Suxethonium bears US NLM identifiers UMLS ID C0605824 and NCI Concept Code C87315. SMILES: CC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC.[Cl-].
This classification denotes a muscle relaxant with the molecular formula C16H34N2O4.2Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U5026H7S5S, chemically known as succinic acid, diester with choline iodide but more generally known as suxethonium chloride, which bears US NIH Compound Identifier 5314. European Medicines Agency schedules Suxethonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10788MIG. The term SUXETHONIUM CHLORIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule suxethonium chloride under HS 29239000. As of Q4 2014, SUXETHONIUM CHLORIDE remains US FDA's Preferred Term for this commodity. Suxethonium chloride bears US NLM identifiers UMLS ID C2700609 and NCI Concept Code C74283. SMILES: CC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC.[CL-].[CL-].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C24H26N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86TDZ5WP2B, chemically known as 3,5-pyrazolidinedione, 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-, hydrogen succinate (ester) but generally known as suxibuzone, which bears US NIH Compound Identifier 5362. European Medicines Agency schedules Suxibuzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10789MIG. The term SUXIBUZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules suxibuzone in its Anatomical Therapeutic Chemical (ATC) Classification. SUXIBUZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule suxibuzone under HS 29331990 and SITC 51571. As of Q4 2014, SUXIBUZONE remains the US FDA Preferred Term for this commodity. Suxibuzone bears US NLM identifiers UMLS ID C0075667 and NCI Concept Code C73095. SMILES: O(CC1(CCCC)C(=O)N(N(C1=O)C1CCCCC1)C1CCCCC1)C(=O)CCC(=O)O.
This classification denotes an antiprotozoal agent with the molecular formula C30H48N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UZ8WTY8051, chemically known as 4,4-(ethylenedioxy(bis(n-hexyl-n-methylbenzylamine) but generally known as symetine, which bears US NIH Compound Identifier 214341. European Medicines Agency schedules Symetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10791MIG. The term SYMETINE is an International Non-Proprietary Name. SYMETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule symetine under HS 29222900 and SITC 51462. As of Q4 2014, SYMETINE remains the US FDA Preferred Term for this commodity. Symetine bears US NLM identifiers UMLS ID C2699743 and NCI Concept Code C76431. SMILES: O(C1CCC(CN(CCCCCC)C)CC1)CCOC1CCC(CN(CCCCCC)C)CC1.
This classification denotes a biological response modifier, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) EZ61NB05TG. European Medicines Agency schedules Tabilautide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10793MIG. Tabilautide generally arises in the molecular formula C27H49N5O8. The term TABILAUTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, list 29.) TABILAUTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tabilautide under HS 29241900 and SITC 51471. As of Q4 2014, TABILAUTIDE remains US FDA's Preferred Term for this commodity. Tabilautide bears US NLM identifiers UMLS ID C2699878 and NCI Concept Code C76570. SMILES: O=C(NC(C(=O)NC(CCC(=O)NC(CCCC(N)C(=O)N)C(=O)O)C(=O)O)C)CCCCCCCCCCC.
This classification denotes a vitamin d analog with the molecular formula C27H44O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2W72OJ5ZU, chemically known as 1-alpha,24(r)-dihydroxyvitamin d3 but generally known as tacalcitol, which bears US NIH Compound Identifier 5282177. European Medicines Agency schedules Tacalcitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10794MIG. The term TACALCITOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules tacalcitol in its Anatomical Therapeutic Chemical (ATC) Classification. TACALCITOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tacalcitol under HS 29061900 and SITC 51231. As of Q4 2014, TACALCITOL remains the US FDA Preferred Term for this commodity. Tacalcitol bears US NLM identifiers UMLS ID C0953467 and NCI Concept Code C87292. SMILES: OC(CCC(C1C2(C(CC1)/C(=C/C=C1\CC(O)CC(O)C1=C)CCC2)C)C)C(C)C.
This classification denotes a vitamin d analog C27H44O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B3Q63NVN9R, chemically known as (+)-(5z,7e,24r)-9,10-secocholesta-5,7,10(19)-triene-1.alpha.,3.beta.,24-triol monohydrate, but more generally known as tacalcitol monohydrate, which bears US NIH Compound Identifier 9910819. European Medicines Agency schedules Tacalcitol monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22635. Most nations, for tariff and trade purposes, schedule tacalcitol monohydrate under HS 29061900 and SITC 51231. As of Q4 2014, TACALCITOL MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CC[C@H](C(C)C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C.O.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C13H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VX7YNB537, chemically known as 1,2,3,4-tetrahydro-acridin-9-ylamine but generally known as tacrine, which bears US NIH Compound Identifier 1935. European Medicines Agency schedules Tacrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10796MIG. The term TACRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules tacrine in its Anatomical Therapeutic Chemical (ATC) Classification. TACRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tacrine under HS 29339990 and SITC 51577. As of Q4 2014, TACRINE remains the US FDA Preferred Term for this commodity. Tacrine bears US NLM identifiers UMLS ID C0039245 and NCI Concept Code C61961. SMILES: N1C2C(CCCC2)C(N)C2C1CCCC2.
This classification denotes an acetylcholinesterase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4966RNG0BU. European Medicines Agency schedules Tacrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04665MIG. Tacrine hydrochloride generally arises in the molecular formula C13H15CLN2. The term 'tacrine hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule tacrine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, TACRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tacrine hydrochloride bears US NLM identifiers UMLS ID C0699954 and NCI Concept Code C47742. SMILES: C1CCC2C(C1)C(C3C(N2)CCCC3)N.CL.
This classification denotes a mtor inhibitor and immunosuppressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WM0HAQ4WNM. European Medicines Agency schedules Tacrolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10797MIG. Tacrolimus generally arises in the molecular formula C44H69NO12. The term TACROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) Most nations, for tariff and trade purposes, schedule tacrolimus under HS 29349990 and SITC 51579. As of Q4 2014, TACROLIMUS remains US FDA's Preferred Term for this commodity. Tacrolimus bears US NLM identifiers UMLS ID C0085149 and NCI Concept Code C1311. SMILES: O1C2C(OC)CC(C1(O)C(=O)C(=O)N1C(CCCC1)C(=O)OC(C(C(O)CC(=O)C(C=C(CC(CC2OC)C)C)CC=C)C)/C(=C/C1CC(OC)C(O)CC1)C)C.
This classification denotes a mtor inhibitor and immunosuppressant with the molecular formula C44H69NO12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y5L2157C4J, chemically known as tacrolimus, anhydrous, but more generally known as tacrolimus anhydrous, which bears US NIH Compound Identifier 6436007. European Medicines Agency schedules tacrolimus anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10797MIG. Most nations, for tariff purposes, schedule tacrolimus anhydrous under HS 29349990. Tacrolimus anhydrous bears US NLM identifiers UMLS ID C0771204 and NCI Concept Code C76066. SMILES: C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC.
This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H19N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 742SXX0ICT, chemically known as pyrazino(1,2:1,6)pyrido(3,4-b)indole-1,4-dione,6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6r-trans)- but generally known as tadalafil, which bears US NIH Compound Identifier 110635. European Medicines Agency schedules Tadalafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12602MIG. The term TADALAFIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules tadalafil in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tadalafil under HS 29349990 and SITC 51579. As of Q4 2014, TADALAFIL remains the US FDA Preferred Term for this commodity. Tadalafil bears US NLM identifiers UMLS ID C0967376 and NCI Concept Code C47743. SMILES: O=C1N(CC(=O)N2C1CC1C([NH]C3C1CCCC3)C2C1CC2OCOC2CC1)C.
This classification denotes an antimalarial agent with the molecular formula C24H28F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 262P8GS9L9, chemically known as 1,4-pentanediamine, n4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)- but generally known as tafenoquine, which bears US NIH Compound Identifier 115358. European Medicines Agency schedules Tafenoquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04666MIG. The term TAFENOQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule tafenoquine under HS 29334990 and SITC 51575. As of Q4 2014, TAFENOQUINE remains the US FDA Preferred Term for this commodity. Tafenoquine bears US NLM identifiers UMLS ID C0903411 and NCI Concept Code C73006. SMILES: FC(F)(F)C1CC(OC2C3C(NC(OC)CC3C)C(NC(CCCN)C)CC2OC)CCC1.
This classification denotes a prostaglandin analogue with the molecular formula C25H34F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1O6WQ6T7G3, chemically known as isopropyl (5z)-7-{(1r,2r,3r,5s)-2-((1e)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate but generally known as tafluprost, which bears US NIH Compound Identifier 6433101. European Medicines Agency schedules Tafluprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30776. The term TAFLUPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 1, 2004, List 51). World Health Organization schedules tafluprost in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tafluprost under HS 29375000 and SITC 54156. As of Q4 2014, TAFLUPROST remains the US FDA Preferred Term for this commodity. Tafluprost bears US NLM identifiers UMLS ID C1451502 and NCI Concept Code C87385. SMILES: FC(F)(/C=C/C1C(C(O)CC1O)C/C=C/CCCC(=O)OC(C)C)COC1CCCCC1.
This classification denotes a cns stimulant with the molecular formula C19H19N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CVS43XG1L5, chemically known as 7h-1,3-dioxolo(4,5-h)(2,3)benzodiazepine, 8,9-dihydro-7-acetyl-5-(4-aminophenyl)-8-methyl-, (r)- but generally known as talampanel, which bears US NIH Compound Identifier 164509. The term TALAMPANEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule talampanel under HS 29349990 and SITC 51579. As of Q4 2014, TALAMPANEL remains the US FDA Preferred Term for this commodity. Talampanel bears US NLM identifiers UMLS ID C0250723 and NCI Concept Code C38139. SMILES: CC1CC2=CC3=C(C=C2C(=NN1C(=O)C)C4=CC=C(C=C4)N)OCO3.
This classification denotes an anti-bacterial agent and ampicillin with the molecular formula C24H23N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29OJI73DPC, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester, (2s-(2alpha,5alpha,6beta(s*)))- but generally known as talampicillin, which bears US NIH Compound Identifier 39480. European Medicines Agency schedules Talampicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10800MIG. World Health Organization schedules talampicillin in its Anatomical Therapeutic Chemical (ATC) Classification. TALAMPICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule talampicillin under HS 29411090 and SITC 54131. As of Q4 2014, TALAMPICILLIN remains the US FDA Preferred Term for this commodity. SMILES: S1C2N(C(C1(C)C)C(=O)OC1OC(=O)C3C1CCCC3)C(=O)C2NC(=O)C(N)C1CCCCC1.
This classification denotes an anti-bacterial agent and ampicillin C24H23N3O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4C5O3X072I, chemically known as (2s,5r,6r)-6-((r)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with 3-hydroxyphthalide, monohydrochloride, but more generally known as talampicillin hydrochloride, which bears US NIH Compound Identifier 71446. European Medicines Agency schedules Talampicillin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15449MIG. Most nations, for tariff and trade purposes, schedule talampicillin hydrochloride under HS 29411090 and SITC 54131. As of Q4 2014, TALAMPICILLIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)C(=O)OC4C5CCCCC5C(=O)O4)C.CL.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49AB2PA48B. European Medicines Agency schedules Talastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10801MIG. Talastine generally arises in the molecular formula C19H21N3O. The term TALASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) TALASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule talastine under HS 29339990 and SITC 51577. As of Q4 2014, TALASTINE remains the US FDA Preferred Term for this commodity. Talastine bears US NLM identifiers UMLS ID C0084711 and NCI Concept Code C73057. SMILES: O=C1N(NC(C2C1CCCC2)CC1CCCCC1)CCN(C)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H21N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SBH6TU2VU4, chemically known as 2-(2-(dimethylamino)ethyl)-4-(phenylmethyl)-1(2h)-phthalazinone hydrochloride, but more generally known as talastine hydrochloride, which bears US NIH Compound Identifier 167517. European Medicines Agency schedules talastine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10801MIG. Most nations, for tariff purposes, schedule talastine hydrochloride under HS 29339990. Talastine hydrochloride bears US NLM identifiers UMLS ID C0121937 and NCI Concept Code C95238. SMILES: CN(C)CCN1C(=O)C2CCCCC2C(N1)CC3CCCCC3.CL.
This classification denotes a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4YIR8202AX, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-methypropyl)-5-(2-propenyl)- but generally known as talbutal, which bears US NIH Compound Identifier 8275. European Medicines Agency schedules Talbutal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10802MIG. The term TALBUTAL is an International Non-Proprietary Name. World Health Organization schedules talbutal in its Anatomical Therapeutic Chemical (ATC) Classification. TALBUTAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule talbutal under HS 29335400 and SITC kg. As of Q4 2014, TALBUTAL remains the US FDA Preferred Term for this commodity. Talbutal bears US NLM identifiers UMLS ID C0301407 and NCI Concept Code C66577. SMILES: CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C.
This classification denotes a non-steroidal estrogen with the molecular formula C18H26O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HUN219N434, chemically known as 2,4-dihydroxy-6-(6beta,10-dihydroxyundecyl]benzoic acid mu-lactone but generally known as taleranol, which bears US NIH Compound Identifier 65434. European Medicines Agency schedules Taleranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10803MIG. The term TALERANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). TALERANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, TALERANOL remains the US FDA Preferred Term for this commodity. Taleranol bears US NLM identifiers UMLS ID C0075781 and NCI Concept Code C74260. SMILES: OC1CCCCCc2c(C(=O)OC(CCC1)C)c(O)cc(O)c2.
Taliglucerase alfa is a biopharmaceutical medication developed. The drug is a recombinant glucocerebrosidase used to treat Gaucher's disease.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H33N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3S82268BKG, chemically known as urea, n-cyclohexyl-n-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)- but generally known as talinolol, which bears US NIH Compound Identifier 68770. European Medicines Agency schedules Talinolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10804MIG. The term TALINOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules talinolol in its Anatomical Therapeutic Chemical (ATC) Classification. TALINOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule talinolol under HS 29242190 and SITC 51473. As of Q4 2014, TALINOLOL remains the US FDA Preferred Term for this commodity. Talinolol bears US NLM identifiers UMLS ID C0075783 and NCI Concept Code C73020. SMILES: O=C(NC1CCCCC1)NC1CCC(OCC(O)CNC(C)(C)C)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C27H20ClNO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6FY017I6S7, chemically known as 1,3-dihydro-3-oxo-1-isobenzofuranyl 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indole-3-acetate but generally known as talmetacin, which bears US NIH Compound Identifier 68564. European Medicines Agency schedules Talmetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10808MIG. The term TALMETACIN is an International Non-Proprietary Name. TALMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule talmetacin under HS 29349990 and SITC 51579. As of Q4 2014, TALMETACIN remains the US FDA Preferred Term for this commodity. Talmetacin bears US NLM identifiers UMLS ID C2699883 and NCI Concept Code C76813. SMILES: CLC1CCC(C(=O)N2C(C(C3C2CCC(OC)C3)CC(=O)OC2OC(=O)C3C2CCCC3)C)CC1.
This classification denotes a topical anti-infective agent with the molecular formula C22H20N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X8W4CW0QHK, chemically known as 2-(4-amino-5-((3,4,5-trimethoxyphenyl)methyl)-2-pyrimidinyl)-1h-isoindole-1,3(2h)-dione but more generally known as talmetoprim, which bears US NIH Compound Identifier 163307. European Medicines Agency schedules Talmetoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10809MIG. The term TALMETOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). TALMETOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an antispasmotic agent with the molecular formula C25H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CZ3T9T146K, chemically known as 4-quinolinecarboxamide, 3-hydroxy-2-phenyl-n-(1-phenylpropyl)-, (s)- but generally known as talnetant, which bears US NIH Compound Identifier 133090. European Medicines Agency schedules Talnetant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34015. The term TALNETANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). Most nations schedule talnetant under HS 29334990 and SITC 51575. As of Q4 2014, TALNETANT remains the US FDA Preferred Term for this commodity. Talnetant bears US NLM identifiers UMLS ID C1701942 and NCI Concept Code C76464. SMILES: OC1C(C(=O)NC(CC)C2CCCCC2)C2C(NC1C1CCCCC1)CCCC2.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H13F3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JFK78S0U9S, chemically known as 3-pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester but generally known as talniflumate, which bears US NIH Compound Identifier 48229. European Medicines Agency schedules Talniflumate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10810MIG. The term TALNIFLUMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). TALNIFLUMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule talniflumate under HS 29349990 and SITC 51579. As of Q4 2014, TALNIFLUMATE remains the US FDA Preferred Term for this commodity. Talniflumate bears US NLM identifiers UMLS ID C0772080 and NCI Concept Code C73096. SMILES: FC(F)(F)C1CC(NC2NCCCC2C(=O)OC2OC(=O)C3C2CCCC3)CCC1.
This classification denotes an antidepressant agent and adrenergic agent with the molecular formula C20H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PY881HC79, chemically known as 3,3-dimethyl-1-(3-methylaminopropyl)-1-phenylphthalene but generally known as talopram, which bears US NIH Compound Identifier 23573. European Medicines Agency schedules Talopram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10811MIG. The term TALOPRAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). TALOPRAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule talopram under HS 29329985 and SITC 51569. As of Q4 2014, TALOPRAM remains the US FDA Preferred Term for this commodity. Talopram bears US NLM identifiers UMLS ID C0070963 and NCI Concept Code C84195. SMILES: O1C(c2c(C1(C)C)cccc2)(CCCNC)c1ccccc1.
This classification denotes an antidepressant agent with the molecular formula C20H25NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0X97008FCC, chemically known as 3,3-dimethyl-1-(3-methylaminopropyl)-1-phenylphthalene but more generally known as talopram hydrochloride, which bears US NIH Compound Identifier 23573. Most nations, for tariff and trade purposes, schedule talopram hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, TALOPRAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Talopram hydrochloride bears US NLM identifiers UMLS ID C2348647 and NCI Concept Code C73810. SMILES: CC1(C2CCCCC2C(O1)(CCCNC)C3CCCCC3)C.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H12O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1356SD6O2G, chemically known as salicylic acid acetate, ester with 3-hydroxyphthalide but generally known as talosalate, which bears US NIH Compound Identifier 68558. European Medicines Agency schedules Talosalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10812MIG. The term TALOSALATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). TALOSALATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, TALOSALATE remains the US FDA Preferred Term for this commodity. Talosalate bears US NLM identifiers UMLS ID C2699885 and NCI Concept Code C76814. SMILES: O1C(OC(=O)C2C(OC(=O)C)CCCC2)C2C(C1=O)CCCC2.
This classification denotes an anticonvulsant agent with the molecular formula C13H16N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQ74U9QR5D, chemically known as 2h-isoindole-2-ethanesulfonamide, 1,3-dihydro-n-(1-methylethyl)-1,3-dioxo- but generally known as taltrimide, which bears US NIH Compound Identifier 71248. European Medicines Agency schedules Taltrimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10817MIG. The term TALTRIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). TALTRIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule taltrimide under HS 29350090 and SITC 51580. As of Q4 2014, TALTRIMIDE remains the US FDA Preferred Term for this commodity. Taltrimide bears US NLM identifiers UMLS ID C0075788 and NCI Concept Code C72857. SMILES: S(=O)(=O)(NC(C)C)CCN1C(=O)C2C(C1=O)CCCC2.
This classification denotes a sedative and hypnotic with the molecular formula C22H26N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74ATQ0K1LA, chemically known as 1h-purine-2,6-dione, 3,7-dihydro-7-(2-(4-(1h-indol-3-yl)-1-piperidinyl)ethyl)-1,3-dimethyl- but generally known as tameridone, which bears US NIH Compound Identifier 71304. European Medicines Agency schedules Tameridone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10819MIG. The term TAMERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). TAMERIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tameridone under HS 29395900 and SITC 54145. As of Q4 2014, TAMERIDONE remains the US FDA Preferred Term for this commodity. Tameridone bears US NLM identifiers UMLS ID C2699889 and NCI Concept Code C76946. SMILES: O=C1N(C(=O)N(C2NCN(CCN3CCC(CC3)C3C4C([NH]C3)CCCC4)C12)C)C.
This classification denotes a penicillin antibiotic with the molecular formula C23H33N3O6S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 11MX0V916W, chemically known as 2-(diethylamino)ethyl (2s,5r,6r)-6-(2,6-dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate but more generally known as tameticillin, which bears U.S. National Institutes of Health Compound Identifier 68757. The European Medicines Agency schedules Tameticillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10820MIG. The term TAMETICILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). TAMETICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)OCCN(CC)CC)C(=O)C2NC(=O)C1C(OC)CCCC1OC.
This classification denotes a selective estrogen receptor modulator and protein kinase c inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 094ZI81Y45. European Medicines Agency schedules Tamoxifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10825MIG. Tamoxifen generally arises in the molecular formula C26H29NO. The term TAMOXIFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) TAMOXIFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tamoxifen under HS 29221980 and SITC 51461. As of Q4 2014, TAMOXIFEN remains US FDA's Preferred Term for this commodity. Tamoxifen bears US NLM identifiers UMLS ID C0039286 and NCI Concept Code C62078. SMILES: O(C1CCC(/C(=C(\CC)C2CCCCC2)C2CCCCC2)CC1)CCN(C)C.
This classification denotes a selective estrogen receptor modulator and protein kinase c inhibitor with the molecular formula C26H29NO.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FRV7310N6. European Medicines Agency schedules tamoxifen citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04672MIG. The term tamoxifen citrate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule tamoxifen citrate under HS 29221990 and SITC 51461. As of Q4 2014, TAMOXIFEN CITRATE remains US FDA's Preferred Term for this commodity. Tamoxifen citrate bears US NLM identifiers UMLS ID C0919390 and NCI Concept Code C855. SMILES: CC/C(=C(\C1CCCCC1)/C2CCC(CC2)OCCN(C)C)/C3CCCCC3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H28N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G3P28OML5I, chemically known as benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-, (r)- but generally known as tamsulosin, which bears US NIH Compound Identifier 129211. European Medicines Agency schedules Tamsulosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10827MIG. The term TAMSULOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules tamsulosin in its Anatomical Therapeutic Chemical (ATC) Classification. TAMSULOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tamsulosin under HS 29350090 and SITC 51580. As of Q4 2014, TAMSULOSIN remains the US FDA Preferred Term for this commodity. Tamsulosin bears US NLM identifiers UMLS ID C0257343 and NCI Concept Code C75055. SMILES: S(=O)(=O)(N)C1CC(CC(NCCOC2C(OCC)CCCC2)C)CCC1OC.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H28N2O5S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11SV1951MR, chemically known as benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-, monohydrochloride, (r)- but more generally known as tamsulosin hydrochloride, which bears US NIH Compound Identifier 5362376. European Medicines Agency schedules Tamsulosin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04673MIG. Most nations, for tariff and trade purposes, schedule tamsulosin hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, TAMSULOSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tamsulosin hydrochloride bears US NLM identifiers UMLS ID C0771774 and NCI Concept Code C29486. SMILES: CCOC1CCCCC1OCCN[C@H](C)CC2CCC(C(C2)S(=O)(=O)N)OC.CL.
This classification denotes a serotonin agonist and anxiolytic with the molecular formula C21H29N5O2.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0R8E9BWM4J, chemically known as 4,7-methano-1h-isoindole-1,3(2h)-dione, hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, (3aalpha,4beta,7beta,7aalpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) but more generally known as tandospirone citrate, which bears US NIH Compound Identifier 60558. European Medicines Agency schedules Tandospirone citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04674MIG. Most nations, for tariff and trade purposes, schedule tandospirone citrate under HS 29335995. As of Q4 2014, TANDOSPIRONE CITRATE remains US FDA's Preferred Term for this commodity. Tandospirone citrate bears US NLM identifiers UMLS ID C2699890 and NCI Concept Code C74390. SMILES: C1CNC(NC1)N2CCN(CC2)CCCCN3C(=O)[C@H]4[C@@H]5CC[C@@H](C5)[C@H]4C3=O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKS0I0BBLP. European Medicines Agency schedules Taniplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10830MIG. Taniplon generally arises in the molecular formula C14H15N5O2. The term TANIPLON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) TANIPLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule taniplon under HS 29349990 and SITC 51579. As of Q4 2014, TANIPLON remains the US FDA Preferred Term for this commodity. Taniplon bears US NLM identifiers UMLS ID C2699891 and NCI Concept Code C76947. SMILES: O(C1NC2N(C3CCCCC13)CC(N2)C1NC(ON1)C)C.
This classification denotes a polyphenol and industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28F9E0DJY6. European Medicines Agency schedules Tannic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15451MIG. Tannic acid generally arises in the molecular formula C76H52O46. The term 'tannic acid' is a European Pharmacopoeia designation. As of Q4 2014, TANNIC ACID remains the US FDA Preferred Term for this commodity. Tannic acid bears US NLM identifiers UMLS ID C0039294 and NCI Concept Code C66579. SMILES: C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OCC3C(C(C(C(O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O.
This classification denotes a matrix metalloproteinase inhibitor with the molecular formula C23H19ClO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AM1ZX94EXH, chemically known as (s)-4-chloro-gamma-oxo-alpha-((phenylthio)methyl)(1,1-biphenyl)-4-butanoic acid but generally known as tanomastat, which bears US NIH Compound Identifier 177347. The term TANOMASTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule Tanomastat under HS 29309085 and SITC 51549. As of Q4 2014, TANOMASTAT remains the US FDA Preferred Term for this commodity. Tanomastat bears US NLM identifiers UMLS ID C0393069 and NCI Concept Code C1705. SMILES: C1CCC(CC1)SC[C@@H](CC(=O)C2CCC(CC2)C3CCC(CC3)CL)C(=O)O.
This classification denotes an analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H8A007M585. European Medicines Agency schedules Tapentadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31821. Tapentadol generally arises in the molecular formula C14H23NO. The term TAPENTADOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule tapentadol under HS 29222900 and SITC 51462. As of Q4 2014, TAPENTADOL remains the US FDA Preferred Term for this commodity. Tapentadol bears US NLM identifiers UMLS ID C2001271 and NCI Concept Code C72139. SMILES: C1=CC=C(C=C1)SCC(CC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)Cl)C(=O)O.
This classification denotes an opioid receptor agonist with the molecular formula C14H23NO.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71204KII53. European Medicines Agency schedules tapentadol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32145. The term tapentadol hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule tapentadol hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, TAPENTADOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tapentadol hydrochloride bears US NLM identifiers UMLS ID C2718761 and NCI Concept Code C68922. SMILES: CC[C@@H](C1CCCC(C1)O)[C@@H](C)CN(C)C.CL.
This classification denotes an antiplatelet agent with the molecular formula C24H30O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7MS1HEY2IZ, chemically known as benzoic acid, 3-((4-(3-cyclohexyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2h-cyclopenta(b)furan-2-ylidene)methyl)-, (3ar-(2z,3a-alpha,4-alpha(1e,3s*),5-beta,6a-alpha))- but generally known as taprostene, which bears US NIH Compound Identifier 5311243. European Medicines Agency schedules Taprostene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10831MIG. The term TAPROSTENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). TAPROSTENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule taprostene under HS 29375000 and SITC 54156. As of Q4 2014, TAPROSTENE remains the US FDA Preferred Term for this commodity. Taprostene bears US NLM identifiers UMLS ID C0075812 and NCI Concept Code C76403. SMILES: O1C2C(C(C(O)C2)/C=C/C(O)C2CCCCC2)CC\1=C\C1CC(CCC1)C(=O)O.
This classification denotes an antiplatelet agent with the molecular formula C24H29O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3M078713KZ, chemically known as benzoic acid, 3-((z)-((3ar,4r,5r,6as)-4-((1e,3s)-3-cyclohexyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2h-cyclopenta(b)furan-2-ylidene)methyl)-, monosodium salt, but more generally known as taprostene sodium, which bears US NIH Compound Identifier 6437844. European Medicines Agency schedules taprostene sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10831MIG. Most nations, for tariff purposes, schedule taprostene sodium under HS 29375000. SMILES: C1CC(CC(C1)C(=O)[O-])/C=C\2/C[C@H]3[C@@H](O2)C[C@H]([C@@H]3/C=C/[C@H](C4CCCCC4)O)O.[NA+].
This classification denotes an angiotensin ii type 1 receptor blocker with the molecular formula C23H21N7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48G92V856H, chemically known as 5,8-dihydro-2,4-dimethyl-8-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)pyrido(2,3-d)pyrimidin-7(6h)-one but generally known as tasosartan, which bears US NIH Compound Identifier 60919. European Medicines Agency schedules Tasosartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10834MIG. World Health Organization schedules tasosartan in its Anatomical Therapeutic Chemical (ATC) Classification. TASOSARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tasosartan under HS 29337900 and SITC 51561. As of Q4 2014, TASOSARTAN remains the US FDA Preferred Term for this commodity. SMILES: O=C1N(c2nc(nc(c2CC1)C)C)Cc1ccc(cc1)c1c(cccc1)c1n[nH]nn1.
This classification denotes a mucolytic agent with the molecular formula C10H9N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S4ZCE64Q3O, chemically known as pyrimidine, 2-((3-pyridinylmethyl)thio)- but more generally known as tasuldine, which bears US NIH Compound Identifier 65666. European Medicines Agency schedules Tasuldine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10835MIG. The term TASULDINE is an International Non-Proprietary Name. TASULDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tasuldine under HS 29335995 and SITC 51576. As of Q4 2014, TASULDINE remains US FDA's Preferred Term for this commodity. Tasuldine bears US NLM identifiers UMLS ID C0626803 and NCI Concept Code C74551. SMILES: C1=CC(=CN=C1)CSC2=NC=CC=N2.
This classification denotes an antibiotic with the molecular formula C7H16N4O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8OBZ1M4V3V, chemically known as 4,4-methylenebis(tetrahydro-1,2,4-thiadiazine 1,1-dioxide) but generally known as taurolidine, which bears US NIH Compound Identifier 29566. European Medicines Agency schedules Taurolidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10837MIG. The term TAUROLIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules taurolidine in its Anatomical Therapeutic Chemical (ATC) Classification. TAUROLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule taurolidine under HS 29349990 and SITC 51579. As of Q4 2014, TAUROLIDINE remains the US FDA Preferred Term for this commodity. Taurolidine bears US NLM identifiers UMLS ID C0144567 and NCI Concept Code C2639. SMILES: S1(=O)(=O)NCN(CN2CCS(=O)(=O)NC2)CC1.
This classification denotes a nitrosourea compound with the molecular formula C7H15ClN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 511F69K76Y, chemically known as 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-n,n-dimethylethanesulfonamide but more generally known as tauromustine, which bears US NIH Compound Identifier 55456. European Medicines Agency schedules Tauromustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10838MIG. The term TAUROMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). TAUROMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tauromustine under HS 29350090 and SITC 51580. As of Q4 2014, TAUROMUSTINE remains US FDA's Preferred Term for this commodity. Tauromustine bears US NLM identifiers UMLS ID C0044133 and NCI Concept Code C954. SMILES: CLCCN(N=O)C(=O)NCCS(=O)(=O)N(C)C.
This classification denotes a mucolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 43A07PH183. European Medicines Agency schedules Taurosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10840MIG. Taurosteine generally arises in the molecular formula C7H9NO4S2. The term TAUROSTEINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, no. 3 1991, list 31.) TAUROSTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule taurosteine under HS 29349990 and SITC 51579. As of Q4 2014, TAUROSTEINE remains US FDA's Preferred Term for this commodity. Taurosteine bears US NLM identifiers UMLS ID C2699896 and NCI Concept Code C74549. SMILES: S(=O)(=O)(O)CCNC(=O)C1SCCC1.
This classification denotes a mast cell stabilizer with the molecular formula C13H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T0248823H1, chemically known as acetic acid, oxo((3-(1h-tetrazol-5-yl)phenyl)amino)-, butyl ester but generally known as tazanolast, which bears US NIH Compound Identifier 5380. European Medicines Agency schedules Tazanolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10843MIG. The term TAZANOLAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). TAZANOLAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tazanolast under HS 29339990 and SITC 51577. As of Q4 2014, TAZANOLAST remains the US FDA Preferred Term for this commodity. Tazanolast bears US NLM identifiers UMLS ID C0539675 and NCI Concept Code C76764. SMILES: O(CCCC)C(=O)C(=O)NC1CC(CCC1)C1N[NH]NN1.
This classification denotes a retinoic acid agent with the molecular formula C21H21NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81BDR9Y8PS, chemically known as 3-pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester but generally known as tazarotene, which bears US NIH Compound Identifier 5381. European Medicines Agency schedules Tazarotene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10844MIG. The term TAZAROTENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules tazarotene in its Anatomical Therapeutic Chemical (ATC) Classification. TAZAROTENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tazarotene under HS 29349990 and SITC 51579. As of Q4 2014, TAZAROTENE remains the US FDA Preferred Term for this commodity. Tazarotene bears US NLM identifiers UMLS ID C0288792 and NCI Concept Code C29487. SMILES: S1CCC(C2C1CCC(C2)C#CC1NCC(CC1)C(=O)OCC)(C)C.
This classification denotes an anti-lipidemic agent with the molecular formula C18H17NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SGF1AP698, chemically known as benzeneacetic acid, alpha-(((6-ethoxy-2-benzothiazolyl)thio)methyl)-, (+-)- but generally known as tazasubrate, which bears US NIH Compound Identifier 174749. European Medicines Agency schedules Tazasubrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10845MIG. The term TAZASUBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). TAZASUBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tazasubrate under HS 29341000 and SITC 51579. As of Q4 2014, TAZASUBRATE remains the US FDA Preferred Term for this commodity. Tazasubrate bears US NLM identifiers UMLS ID C0144579 and NCI Concept Code C72999. SMILES: S(C(c1ccccc1)(C)C(=O)O)c1sc2c(n1)ccc(OCC)c2.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S05RV1R3LZ. European Medicines Agency schedules Tazeprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10846MIG. Tazeprofen generally arises in the molecular formula C16H13NO2S. The term TAZEPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) TAZEPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tazeprofen under HS 29341000 and SITC 51579. As of Q4 2014, TAZEPROFEN remains the US FDA Preferred Term for this commodity. Tazeprofen bears US NLM identifiers UMLS ID C2699897 and NCI Concept Code C76815. SMILES: S1C2CC(C(C)C(=O)O)CCC2NC1C1CCCCC1.
This classification denotes a bronchodilator with the molecular formula C23H32N6O3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F45OX6FZWP, chemically known as 7-[2-hydroxy-3-[4-(3-phenylsulfanylpropyl)piperazin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione but generally known as tazifylline, which bears US NIH Compound Identifier 54424. Most nations schedule tazifylline under HS 29395900 and SITC 54145. As of Q4 2014, TAZIFYLLINE remains the US FDA Preferred Term for this commodity. Tazifylline bears US NLM identifiers UMLS ID C0075869 and NCI Concept Code C96196. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CN3CCN(CC3)CCCSC4=CC=CC=C4)O.
This classification denotes a bronchodilator with the molecular formula C23H32N6O3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 409R6U6UEI, chemically known as 1h-purine-2,6-dione, 3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-, dihydrochloride, (+-)- but more generally known as tazifylline hydrochloride, which bears US NIH Compound Identifier 54423. Most nations, for tariff and trade purposes, schedule tazifylline hydrochloride under HS 29395900 and SITC 54145. As of Q4 2014, TAZIFYLLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tazifylline hydrochloride bears US NLM identifiers UMLS ID C0126094 and NCI Concept Code C96197. SMILES: CN1C2C(C(=O)N(C1=O)C)N(CN2)CC(CN3CCN(CC3)CCCSC4CCCCC4)O.CL.CL.
This classification denotes a penicillin antibiotic, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier SE10G96M8W. The European Medicines Agency schedules Tazobactam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10849MIG. Tazobactam generally arises in the molecular formula C10H12N4O5S. The term TAZOBACTAM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 3, no. 3, 1989, list 29.) TAZOBACTAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3.
This classification denotes an immunosuppressant with the molecular formula C18H27NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) VH2I1JN8Q1, chemically known as 4-thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methyl)-, (+-)- but more generally known as tazofelone, which bears US NIH Compound Identifier 68745. European Medicines Agency schedules Tazofelone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10850MIG. The term TAZOFELONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). TAZOFELONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tazofelone under HS 29341000 and SITC 51579. As of Q4 2014, TAZOFELONE remains US FDA's Preferred Term for this commodity. Tazofelone bears US NLM identifiers UMLS ID C0669581 and NCI Concept Code C76695. SMILES: S1C(CC2CC(C(C)(C)C)C(O)C(C(C)(C)C)C2)C(=O)NC1.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17B9PXO2SW. European Medicines Agency schedules Tobuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11135MIG. Tobuterol generally arises in the molecular formula C28H31NO5. The term TOBUTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) TOBUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tazolol under HS 29341000 and SITC 51579. As of Q4 2014, TAZOLOL remains the US FDA Preferred Term for this commodity. Tazolol bears US NLM identifiers UMLS ID C0075871 and NCI Concept Code C81660. SMILES: OC(CNC(C)(C)C)C1CC(OC(=O)C2CCC(CC2)C)CC(OC(=O)C2CCC(CC2)C)C1.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0S37156TW. European Medicines Agency schedules Tebatizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10853MIG. Tebatizole generally arises in the molecular formula C12H21N3S. The term TEBATIZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) TEBATIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tebatizole under HS 29341000 and SITC 51579. As of Q4 2014, TEBATIZOLE remains the US FDA Preferred Term for this commodity. Tebatizole bears US NLM identifiers UMLS ID C2699901 and NCI Concept Code C75181. SMILES: s1c(N2CCN(CC2)C)nc(C(C)(C)C)c1.
This classification denotes an antimalarial agent with the molecular formula C26H25Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 699Q1XT4EN, chemically known as wr 228,258 but generally known as tebuquine, which bears US NIH Compound Identifier 71991. European Medicines Agency schedules Tebuquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10855MIG. The term TEBUQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). TEBUQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tebuquine under HS 29334990 and SITC 51575. As of Q4 2014, TEBUQUINE remains the US FDA Preferred Term for this commodity. Tebuquine bears US NLM identifiers UMLS ID C0144939 and NCI Concept Code C75270. SMILES: CLC1CCC(C2C(O)C(CNC(C)(C)C)CC(NC3C4C(NCC3)CC(CL)CC4)C2)CC1.
This classification denotes a radioconjugate with the molecular formula C51H72N17O19S5.TCO.NA.H, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IV7T84QA4T, more generally known as Technetium Tc 99m apcitide. The European Medicines Agency schedules Technetium Tc 99m apcitide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10860MIG. The term Technetium Tc-99m APCITIDE is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m apcitide or technetium 99mtc apcitide under HS 28444030.
This classification denotes a radioconjugate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 029JF1SCU8, more generally known as Technetium Tc 99m arcitumomab. The European Medicines Agency schedules Technetium Tc 99m arcitumomab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00571MIG. The term Technetium Tc-99m arcitumomab is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m arcitumomab or technetium 99mtc arcitumomab under HS 28444030.
This classification denotes a radioconjugate with the molecular formula C12H21N2O4S2.TCO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H25WJA31XE, more generally known as Technetium Tc 99m bicisate. The European Medicines Agency schedules Technetium Tc 99m bicisate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15462MIG. The term Technetium Tc 99m BICISATE is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m bicisate or technetium 99mtc bicisate under HS 28444030.
This classification denotes a radioconjugate, a contrast agent that practitioners use in cholescintigraphy and ultrasonography, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QTJ2VIW97T. The European Medicines Agency schedules Technetium tc 99m disofenin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15465MIG. Technetium Tc 99m disofenin generally arises in the molecular formula C18H26N2O5.TC. The term 'Technetium Tc 99m disofenin' is a U.S. FDA Orange Book designation. Most nations schedule Technetium Tc-99m disofenin or technetium 99mtc disofenin under HS 28444030.
This classification denotes a radioconjugate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AMF7KOE318, more generally known as Technetium Tc 99m fanolesomab. The European Medicines Agency schedules Technetium Tc 99m fanolesomab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27898. The term Technetium Tc-99m fanolesomab is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m fanolesomab or technetium 99mtc fanolesomab under HS 28444030.
This classification denotes a radioconjugate known as Technetium Tc 99m furifosmin. The European Medicines Agency schedules Technetium Tc 99m furifosmin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10861MIG. The term Technetium Tc-99m furifosmin is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m furifosmin or technetium 99mtc furifosmin under HS 28444030.
This classification denotes a radioconjugate, an contrast medium is study ntracranial lesions, cerebral disorders, and renal disorders, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I853LE095B. The European Medicines Agency schedules Technetium tc 99m gluceptate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15469MIG. Technetium Tc 99m gluceptate generally arises in the molecular formula C7H14O8.TC. The term 'Technetium Tc-99m gluceptate' is a U.S. FDA Orange Book designation. Most nations schedule Technetium Tc-99m gluceptate or technetium 99mtc gluceptate under HS 28444030.
This classification denotes a radioconjugate that World Health Organization schedules in its Anatomical Therapeutic Chemical (ATC) Classification, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6433TZJ6TQ. SMILES: Cc1cccc(c1NC(=O)CN(CC(=O)[O-])CC(=O)[O-])C.[O-2].[Tc+4]
This classification denotes a radioconjugate, a a hepatobiliary imaging agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F2NQ468L52. The European Medicines Agency schedules Technetium tc 99m mebrofenin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15472MIG. Technetium Tc 99m mebrofenin generally arises in the molecular formula C15H19BRN2O5.TC. The term 'Technetium Tc-99m mebrofenin' is a U.S. FDA Orange Book designation. Most nations schedule Technetium Tc-99m mebrofenin or technetium 99mtc mebrofenin under HS 28444030.
This classification denotes a radioconjugate, a bone imaging agent that practitioners use to delineate areas of altered osteogenesis, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X89XV46R07. The European Medicines Agency schedules Technetium tc 99m medronate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15473MIG. Technetium Tc 99m medronate generally arises in the molecular formula CH2O6P2.TC. The term 'Technetium Tc-99m medronate' is a U.S. FDA Orange Book designation. Most nations schedule Technetium Tc-99m medronate or technetium 99mtc medronate under HS 28444030.
This classification denotes a radioconjugate with the molecular formula C8H8N3O5S.2NA.O.TC, often used in study renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36ITO9SKQJ. The term technetium (sup 99m)tc mertiatide is a U.S. FDA designation. Most nations schedule Technetium Tc-99m mertiatide or technetium 99mtc mertiatide under HS 28444030.
This classification denotes a radioconjugate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9UFH75HT7S, more generally known as technetium tc 99m nofetumomab merpentan. Most nations schedule Technetium Tc-99m nofetumomab merpentan or technetium 99mtc nofetumomab merpentan under HS 28444030.
This classification denotes a radioisotope with the molecular structure TC, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, 6EW75241VU chemically known as technetium, tc-99m, but more commonly known as technetium tc 99m, which bears U.S. National Institutes of Health Compound Identifier 6328391. The European Medicines Agency schedules Technetium tc 99m in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15459MIG.
This classification denotes a radioconjugate with the molecular formula C14H18N3O10.Na.Tc, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VW78417PU1, chemically known as technetate(1-)(sup 99 m)tc, (n,n-bis(2-bis(carboxymethyl)amino)ethyl)glycinato(5-))-, sodium but more generally known as technetium tc 99m pentetate, which bears U.S. National Institutes of Health Compound Identifier 6328391. The European Medicines Agency schedules Technetium tc 99m pentetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15476MIG. In general, such compounds consist of one or more radioactive agents linked to a substance, and these in concert providing practitioners the ability to prevent, diagnose, or treat disease, especially cancer. This commodity aids in renal imaging. Most nations schedule Technetium Tc-99m pentetate or technetium 99mtc pentetate under HS 28444030.
This classification denotes a radioconjugate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PPP8783IQ1, more generally known as Technetium Tc 99m pertechnetate. The European Medicines Agency schedules Technetium Tc 99m pertechnetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20433. The term Technetium Tc-99m pertechnetate is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m pertechnetate or technetium 99mtc pertechnetate under HS 28444030.
This classification denotes a radioconjugate that World Health Organization schedules in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a radioconjugate, generally known as Technetium Tc 99m pintumomab. The European Medicines Agency schedules Technetium Tc 99m pintumomab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27896. The term Technetium Tc-99m pintumomab is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m pintumomab or technetium 99mtc pintumomab under HS 28444030.
This classification denotes a radioconjugate, a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5L76I61H2B. The European Medicines Agency schedules Technetium tc 99m pyrophosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25767. Technetium Tc-99m pyrophosphate generally arises in the molecular formula TC.H4O7P2. The term 'Technetium Tc 99m pyrophosphate' is a U.S. FDA Orange Book designation. Most nations schedule Technetium Tc-99m pyrophosphate or technetium 99mtc pyrophosphate under HS 28444030.
This classification denotes a radioconjugate with the molecular formula C36H66N6O6TC, a contrast medium that practitioners use in myocardial perfusion studies, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 971Z4W1S09, more generally known as Technetium Tc-99m sestamibi. The European Medicines Agency schedules Technetium Tc 99m sestamibi in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10857MIG. The term Technetium Tc 99m SESTAMIBI is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m sestamibi or technetium 99mtc sestamibi under HS 28444030.
This classification denotes a radioconjugate with the molecular formula NA.O4TC, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0730CX801. The term sodium pertechnetate (sup 99m)tc is a U.S. FDA designation. Most nations schedule Technetium Tc-99m sodium pertechnetate or technetium 99mtc sodium pertechnetate under HS 28444030.
This classification denotes a radioconjugate with the molecular formula C4H6O4S2.TC, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 494JNQ8L28. The term technetium Tc-99m succimer is a U.S. FDA designation. Most nations schedule Technetium Tc-99m succimer or technetium 99mtc succimer under HS 28444030.
This classification denotes a technetium radioconjugate that practitioners use in bone and soft tissue scans, most especially to isolate prosthetic joint infection (with technetium tc-99m sulesomab or sulesomab and TC-labeled leukocytes). World Health Organization schedules in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a contrast media, commonly used in lymphoscintigraphy (on breast cancer patients, and for liver, spleen and bone marrow imaging and gastric transit studies and gastroesophageal reflux), a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 556Q0P6PB1. The European Medicines Agency schedules Technetium tc 99m sulfur colloid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12345MIG. Technetium Tc 99m sulfur colloid generally arises in the molecular formula S8.TC. The term 'Technetium Tc-99m sulfur colloid' is a Hazardous Substances Data Bank designation. Most nations schedule Technetium Tc-99m sulfur colloid or technetium 99mtc sulfur colloid under HS 28444030.
This classification denotes a radioconjugate with the molecular formula (C6H9N2O2)2./C6H8N2O2.TC,CL,CH3,B, a cardiac imaging contrast medium most often used in myocardial perfusion imaging, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UT0WHJ4951, more generally known as Technetium Tc 99m teboroxime. In general, such compounds consist of one or more radioactive agents linked to a substance, and these in concert providing practitioners the ability to prevent, diagnose, or treat disease, especially cancer. The European Medicines Agency schedules Technetium Tc 99m teboroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04709MIG. The term TECHNETIUM Tc-99m TEBOROXIME is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m teboroxime or technetium 99mtc teboroxime under HS 28444030.
This classification denotes a radioconjugate with the molecular formula (C6H9N2O2)2./C6H8N2O2.TC,CL,CH3,B, a cardiac imaging contrast medium most often used in myocardial perfusion imaging, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UT0WHJ4951, more generally known as Technetium Tc 99m teboroxime. In general, such compounds consist of one or more radioactive agents linked to a substance, and these in concert providing practitioners the ability to prevent, diagnose, or treat disease, especially cancer. The European Medicines Agency schedules Technetium Tc 99m teboroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04709MIG. The term TECHNETIUM Tc-99m TEBOROXIME is an International Non-Proprietary Name or INN. Most nations schedule Technetium Tc-99m tetrofosmin or technetium 99mtc tetrofosmin under HS 28444030.
This classification denotes a radioconjugate, generally known as Technetium Tc 99m tilmanocept. The term Technetium Tc-99m tilmanocept is an International Non-Proprietary Name or INN. In general, such compounds consist of one or more radioactive agents linked to a substance, and these in concert providing practitioners the ability to prevent, diagnose, or treat disease, especially cancer. This commodity aids in lymphatic studies. Most nations schedule Technetium Tc-99m tilmanocept or technetium 99mtc tilmanocept under HS 28444030.
This classification denotes a technetium radioconjugate that World Health Organization schedules in its Anatomical Therapeutic Chemical (ATC) Classification.
This classification denotes a benzylamine and acetamide with the molecular formula C20H28Cl4N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9RIF0COUB, chemically known as 2,2-dichloro-n-(4-(((dichloroacetyl)(2-ethoxyethyl)amino)methyl)benzyl)-n-(2-ethoxyethyl)acetamide but generally known as teclozan, which bears US NIH Compound Identifier 21723. European Medicines Agency schedules Teclozan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10863MIG. World Health Organization schedules teclozan in its Anatomical Therapeutic Chemical (ATC) Classification. TECLOZAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teclozan under HS 29242995 and SITC 51479. As of Q4 2014, TECLOZAN remains the US FDA Preferred Term for this commodity. SMILES: CLC(CL)C(=O)N(CC1CCC(CN(CCOCC)C(=O)C(CL)CL)CC1)CCOCC.
This classification denotes an antiarrhythmic agent with the molecular formula C19H32N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) A5VAY2U3R8, chemically known as 3,7-bis(cyclopropylmethyl)spiro(cyclopentane-1,9-(3,7)diazabicyclo(3.3.1)nonane) but more generally known as tedisamil, which bears US NIH Compound Identifier 65825. European Medicines Agency schedules Tedisamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10864MIG. The term TEDISAMIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules tedisamil in its Anatomical Therapeutic Chemical (ATC) Classification. TEDISAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tedisamil under HS 29333999 and SITC 51574. As of Q4 2014, TEDISAMIL remains US FDA's Preferred Term for this commodity. Tedisamil bears US NLM identifiers UMLS ID C0076034 and NCI Concept Code C72585. SMILES: N1(CC2C3(C(C1)CN(C2)CC1CC1)CCCC3)CC1CC1.
This classification denotes an antiarrhythmic agent with the molecular formula 2C19H32N2.3C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y4HRG433UU, chemically known as bis(3',7'-bis(cyclopropylmethyl)spiro(cyclopentane-1,9'-(3,7)diazabicyclo(3.3.1)nonane))dihydrogen tris((2e-but-2-enedioate), but more generally known as tedisamil sesquifumarate, which bears US NIH Compound Identifier 56841543. European Medicines Agency schedules Tedisamil sesquifumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22754. Most nations, for tariff and trade purposes, schedule tedisamil sesquifumarate under HS 29333999 and SITC 51574. As of Q4 2014, TEDISAMIL SESQUIFUMARATE remains US FDA's Preferred Term for this commodity. Tedisamil sesquifumarate bears US NLM identifiers UMLS ID C2348658 and NCI Concept Code C73802. SMILES: C1CC2(C3CN(CC2CN(C3)CC4CC4)CC5CC5)CC1.C1CC2(C3CN(CC2CN(C3)CC4CC4)CC5CC5)CC1.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.
A type of antibacterial drug indicated for treatment of acute bacterial skin and skin structure infections by susceptible bacteria.
This classification denotes an alpha-adrenergic agonist with the molecular formula C14H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9738II2CCH, chemically known as 2-(5,6,7,8-tetrahydro-1-naphthyl)methyl)-2-imidazolin but generally known as tefazoline, which bears US NIH Compound Identifier 163309. European Medicines Agency schedules Tefazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10865MIG. The term TEFAZOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). TEFAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tefazoline under HS 29332990 and SITC 51573. As of Q4 2014, TEFAZOLINE remains the US FDA Preferred Term for this commodity. Tefazoline bears US NLM identifiers UMLS ID C2699906 and NCI Concept Code C75044. SMILES: N1C(=NCC1)CC1C2CCCCC2CCC1.
This classification denotes an antihypertensive agent with the molecular formula C29H37Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5P145L26T, chemically known as 2-(2,2,6,6-tetramethylpiperidino)ethyl 2-chlor-alpha-(2-chlorbenzyl)-alpha-hydroxyhydrocinnamat acetat but generally known as tefenperate, which bears US NIH Compound Identifier 163310. European Medicines Agency schedules Tefenperate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10866MIG. The term TEFENPERATE is an International Non-Proprietary Name. TEFENPERATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tefenperate under HS 29333999 and SITC 51574. As of Q4 2014, TEFENPERATE remains the US FDA Preferred Term for this commodity. Tefenperate bears US NLM identifiers UMLS ID C2699907 and NCI Concept Code C75241. SMILES: Clc1c(CC(OC(=O)C)(C(=O)OCCN2C(CCCC2(C)C)(C)C)Cc2c(Cl)cccc2)cccc1.
This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C22H24F4N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2XUS19W8FE, chemically known as 1-piperazineethanol, 4-(3-(4-fluorophenyl)-2,3-dihydro-6-(trifluoromethyl)-1h-indel-1-yl)-, trans-(+-)- but generally known as tefludazine, which bears US NIH Compound Identifier 71240. European Medicines Agency schedules Tefludazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10867MIG. The term TEFLUDAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). TEFLUDAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tefludazine under HS 29335995 and SITC 51576. As of Q4 2014, TEFLUDAZINE remains the US FDA Preferred Term for this commodity. Tefludazine bears US NLM identifiers UMLS ID C0245303 and NCI Concept Code C90626. SMILES: FC(F)(F)C1CC2C(N3CCN(CC3)CCO)CC(C2CC1)C1CCC(F)CC1.
This classification denotes a thymidylate synthase inhibitor and pyrimidine antagonist with the molecular formula C8H9FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1548R74NSZ, chemically known as 2,4(1h,3h)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (r)- but generally known as tegafur, which bears US NIH Compound Identifier 5386. European Medicines Agency schedules Tegafur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10870MIG. The term TEGAFUR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules tegafur in its Anatomical Therapeutic Chemical (ATC) Classification. TEGAFUR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tegafur under HS 29349990 and SITC 51579. As of Q4 2014, TEGAFUR remains the US FDA Preferred Term for this commodity. Tegafur bears US NLM identifiers UMLS ID C0016778 and NCI Concept Code C513. SMILES: FC1CN(C2OCCC2)C(=O)[NH]C1=O.
This classification denotes a serotonin antagonist with the molecular formula C16H23N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 458VC51857, chemically known as hydrazinecarboximidamide, 2-((5-methoxy-1h-indol-3-yl)methylene)-n-pentyl- but generally known as tegaserod, which bears US NIH Compound Identifier 5487301. European Medicines Agency schedules Tegaserod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04713MIG. The term TEGASEROD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 1, 1999, List 41). World Health Organization schedules tegaserod in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tegaserod under HS 29339990 and SITC 51577. As of Q4 2014, TEGASEROD remains the US FDA Preferred Term for this commodity. Tegaserod bears US NLM identifiers UMLS ID C0537147 and NCI Concept Code C66583. SMILES: OCC1CC2C(N=CC\2=C/NN/C(=N/CCCCC)N)CC1.
This classification denotes an antibiotic with the molecular formula C58H42CL2N7O18(R1)(R2)(R3), a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4U3D3YY81M, more generally known as teicoplanin. European Medicines Agency schedules teicoplanin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04714MIG. The term TEICOPLANIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 37, no. 6, 1983, list 23. TEICOPLANIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teicoplanin under HS 29419000 and SITC 54139. As of Q4 2014, TEICOPLANIN remains the US FDA Preferred Term for this commodity. Teicoplanin bears US NLM identifiers UMLS ID C0145106 and NCI Concept Code C1412. SMILES: CCCCCC=CCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=CC(=CC(=C7C8=C(C=CC(=C8)C(C(=O)N6)NC(=O)C4NC(=O)C9C1=CC(=CC(=C1)O)OC1=C(C=CC(=C1)C(C(=O)NC(CC1=CC(=C(O3)C=C1)Cl)C(=O)N9)N)O)O)OC1C(C(C(C(O1)CO)O)O)O)O)C(=O)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)O.
This classification denotes an antiviral agent with the molecular formula C36H53N7O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 655M5O3W0U. European Medicines Agency schedules telaprevir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31651. The term TELAPREVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. ). Most nations schedule telaprevir under HS 29339990 and SITC 51577. As of Q4 2014, TELAPREVIR remains the US FDA Preferred Term for this commodity. Telaprevir bears US NLM identifiers UMLS ID C1876229 and NCI Concept Code C81603. SMILES: CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5.
This classification denotes an antibiotic with the molecular formula C80H106Cl2N11O27P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XK134822Z0, chemically known as vancomycin, n3-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)- but generally known as telavancin, which bears US NIH Compound Identifier 3081362. European Medicines Agency schedules Telavancin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26698. The term TELAVANCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). World Health Organization schedules telavancin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule telavancin under HS 29419000 and SITC 54139. As of Q4 2014, TELAVANCIN remains the US FDA Preferred Term for this commodity. Telavancin bears US NLM identifiers UMLS ID C1453642 and NCI Concept Code C87603. SMILES: Clc1c2Oc3c(OC4OC(C(O)C(O)C4OC4OC(C(O)C(NCCNCCCCCCCCCC)(C4)C)C)CO)c4Oc5c(Cl)cc(cc5)C(O)C(NC(=O)C(NC)CC(C)C)C(=O)NC(C(=O)NC(c(c3)c4)C(=O)NC3C(=O)NC(C(O)c(c1)cc2)C(=O)NC(c1c(c2cc3ccc2O)c(O)c(c(O)c1)CNCP(=O)(O)O)C(=O)O)CC(=O)N.
This classification denotes an antimicrobial solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0701472ZG0. European Medicines Agency schedules Telavancin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35005. Telavancin hydrochloride generally arises in the molecular formula C80H106CL2N11O27P.CLH. The term 'telavancin hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule telavancin hydrochloride under HS 29419000 and SITC 54139. Telavancin hydrochloride bears US NLM identifiers UMLS ID C2730005 and NCI Concept Code C87636. SMILES: As of Q4 2014, TELAVANCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H14N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OC4HKD3SF, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-b-l-erythro-pentofuranosyl)-5-methyl- but generally known as telbivudine, which bears US NIH Compound Identifier 159269. European Medicines Agency schedules Telbivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25231. The term TELBIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules telbivudine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule telbivudine under HS 29349990 and SITC 51579. As of Q4 2014, TELBIVUDINE remains the US FDA Preferred Term for this commodity. Telbivudine bears US NLM identifiers UMLS ID C1453933 and NCI Concept Code C66584. SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O.
This classification denotes an antimuscarinic agent with the molecular formula C19H22N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0990EG3K10, chemically known as 4,9-dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-10h-thieno(3,4-b)(1,5)benzodiazepin-10-one but generally known as telenzepine, which bears US NIH Compound Identifier 5387. European Medicines Agency schedules Telenzepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10871MIG. The term TELENZEPINE is an International Non-Proprietary Name. TELENZEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule telenzepine under HS 29349990 and SITC 51579. As of Q4 2014, TELENZEPINE remains the US FDA Preferred Term for this commodity. Telenzepine bears US NLM identifiers UMLS ID C0076066 and NCI Concept Code C75285. SMILES: S1C(C2N(C(=O)CN3CCN(CC3)C)C3C([NH]C(=O)C2C1)CCCC3)C.
This classification denotes a protease inhibitor with the molecular formula C33H44N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IZF55EH3CG, chemically known as butanediamide, n1-(3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (1s-(1r*,(r*),2s*))- but generally known as telinavir, which bears US NIH Compound Identifier 60874. European Medicines Agency schedules Telinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10872MIG. The term TELINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). TELINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule telinavir under HS 29334910 and SITC 51575. As of Q4 2014, TELINAVIR remains the US FDA Preferred Term for this commodity. Telinavir bears US NLM identifiers UMLS ID C2699908 and NCI Concept Code C76911. SMILES: OC(C(NC(=O)C(NC(=O)C1NC2C(CC1)CCCC2)CC(=O)N)CC1CCCCC1)CN(CC(C)C)C(=O)NC(C)(C)C.
This classification denotes a macrolide antibiotic with the molecular formula C43H65N5O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KI8H7H19WL, chemically known as erythromycin, 3-de((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-o-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1h-imidazol-1-yl)butyl)imino))- but generally known as telithromycin, which bears US NIH Compound Identifier 3002190. European Medicines Agency schedules Telithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12606MIG. The term TELITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules telithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule telithromycin under HS 29419000 and SITC 54139. As of Q4 2014, TELITHROMYCIN remains the US FDA Preferred Term for this commodity. Telithromycin bears US NLM identifiers UMLS ID C1452484 and NCI Concept Code C61963. SMILES: O1C2(C(N(C1=O)CCCCN1CC(NC1)C1CCCNC1)C(C(=O)C(CC(OC)(C(OC1OC(CC(N(C)C)C1O)C)C(C(=O)C(C(=O)OC2CC)C)C)C)C)C)C.
This classification denotes a mucolytic agent with the molecular formula C7H11NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 124I3FE35T, chemically known as (-)-3-ethyl hydrogen (r)-3,4-thiazolidinedicarboxylate but more generally known as telmesteine, which bears US NIH Compound Identifier 65946. European Medicines Agency schedules Telmesteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10873MIG. The term TELMESTEINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, List 31). TELMESTEINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule telmesteine under HS 29341000 and SITC 51579. As of Q4 2014, TELMESTEINE remains US FDA's Preferred Term for this commodity. Telmesteine bears US NLM identifiers UMLS ID C0293153 and NCI Concept Code C74550. SMILES: S1CC(N(C1)C(=O)OCC)C(=O)O.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C33H30N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U5SYW473RQ, chemically known as (1,1-biphenyl)-2-carboxylic acid, 4-((1,4-dimethyl-2-propyl(2,6-bi-1h-benzimidazol)-1-yl)methyl)- but generally known as telmisartan, which bears US NIH Compound Identifier 65999. European Medicines Agency schedules Telmisartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10874MIG. The term TELMISARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules telmisartan in its Anatomical Therapeutic Chemical (ATC) Classification. TELMISARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule telmisartan under HS 29339990 and SITC 51577. As of Q4 2014, TELMISARTAN remains the US FDA Preferred Term for this commodity. Telmisartan bears US NLM identifiers UMLS ID C0248719 and NCI Concept Code C47746. SMILES: OC(=O)c1c(c2ccc(Cn3c4c(nc3CCC)c(cc(c4)c3n(c4c(n3)cccc4)C)C)cc2)cccc1.
This classification denotes an anthrapyrazole antibiotic with the molecular formula C21H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96521WL61B, chemically known as anthra(1,9-cd)pyrazol-6(2h)-one, 7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)- but generally known as teloxantrone, which bears US NIH Compound Identifier 5364123. European Medicines Agency schedules Teloxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10875MIG. The term TELOXANTRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). TELOXANTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teloxantrone under HS 29339990 and SITC 51577. As of Q4 2014, TELOXANTRONE remains the US FDA Preferred Term for this commodity. Teloxantrone bears US NLM identifiers UMLS ID C0244823 and NCI Concept Code C1520. SMILES: OC1C2C3C([NH]N(C3CCC2NCCNC)CCNCCO)C2C1C(=O)C=CC2=O.
This classification denotes a calcium channel blocker with the molecular formula C28H38N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z9OJ72BM3O, chemically known as 3,5-pyridinedicarboxylic acid, 2-((dimethylamino)methyl)-4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-6-methyl-, diethyl ester, (e)- but generally known as teludipine, which bears US NIH Compound Identifier 6436165. European Medicines Agency schedules Teludipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10876MIG. The term TELUDIPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). TELUDIPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teludipine under HS 29333999 and SITC 51574. As of Q4 2014, TELUDIPINE remains the US FDA Preferred Term for this commodity. Teludipine bears US NLM identifiers UMLS ID C0292596 and NCI Concept Code C84196. SMILES: O(C(=O)C1=C(NC(=C(C1c1c(cccc1)/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)CN(C)C)CC.
This classification denotes a calcium channel blocker with the molecular formula C28H38N2O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7P6B96QLKN, chemically known as 3,5-pyridinedicarboxylic acid, 2-((dimethylamino)methyl)-4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-6-methyl-, diethyl ester, (e)- but more generally known as teludipine hydrochloride, which bears US NIH Compound Identifier 6436165. Most nations, for tariff and trade purposes, schedule teludipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, TELUDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Teludipine hydrochloride bears US NLM identifiers UMLS ID C0292595 and NCI Concept Code C66585. SMILES: CCOC(=O)C1=C(NC(=C(C1C2CCCCC2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)CN(C)C)C.CL.
This classification denotes a quinolone antibiotic with the molecular formula C21H18F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1WZ12GTT67, chemically known as 3-quinolinecarboxylic acid, 1,4-dihydro-1-(2,4-difluorophenyl)-6-fluoro-7- (3-methyl-1-piperazinyl)-4-oxo- but generally known as temafloxacin, which bears US NIH Compound Identifier 60021. European Medicines Agency schedules Temafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10877MIG. The term TEMAFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules temafloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. TEMAFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule temafloxacin under HS 29335995 and SITC 51576. As of Q4 2014, TEMAFLOXACIN remains the US FDA Preferred Term for this commodity. Temafloxacin bears US NLM identifiers UMLS ID C0076075 and NCI Concept Code C87391. SMILES: FC1C(N2CC(NCC2)C)CC2N(CC(C(=O)C2C1)C(=O)O)C1C(F)CC(F)CC1.
This classification denotes a quinolone antibiotic with the molecular formula C21H18F3N3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OC5IGJ7J6I, chemically known as 3-quinolinecarboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride, (+-)- but generally known as temafloxacin hydrochloride, which bears US NIH Compound Identifier 60020. European Medicines Agency schedules Temafloxacin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04715MIG. Most nations schedule temafloxacin hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, TEMAFLOXACIN HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Temafloxacin hydrochloride bears US NLM identifiers UMLS ID C0957500 and NCI Concept Code C72858. SMILES: Cl.Fc1c(N2CC(NCC2)C)cc2n(cc(c(=O)c2c1)C(=O)O)c1c(F)cc(F)cc1.
This classification denotes an anti-anxiety agent, gaba modulator, hypnotic, and sedative with the molecular formula C16H13ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CHB1QD2QSS, chemically known as 1,3-dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2h-1,4-benzodiazepin-2-one but generally known as temazepam, which bears US NIH Compound Identifier 5391. European Medicines Agency schedules Temazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10880MIG. The term TEMAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules temazepam in its Anatomical Therapeutic Chemical (ATC) Classification. TEMAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule temazepam under HS 29339190 and SITC 51577. As of Q4 2014, TEMAZEPAM remains the US FDA Preferred Term for this commodity. Temazepam bears US NLM identifiers UMLS ID C0039468 and NCI Concept Code C29488. SMILES: CLC1CC2C(N(C(=O)C(O)N=C2C2CCCCC2)C)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H24BrN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BF6IGI53XH, chemically known as 4(1h)-pyrimidinone, 2-((4-(5-bromo-3-methyl-2-pyridinyl)butyl)amino)-5-((6-methyl-3-pyridinyl)methyl)- but generally known as temelastine, which bears US NIH Compound Identifier 55482. European Medicines Agency schedules Temelastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10882MIG. The term TEMELASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). TEMELASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule temelastine under HS 29335995 and SITC 51576. As of Q4 2014, TEMELASTINE remains the US FDA Preferred Term for this commodity. Temelastine bears US NLM identifiers UMLS ID C0076078 and NCI Concept Code C73058. SMILES: BRC1CC(C(NC1)CCCCNC1[NH]C(=O)C(CC2CCC(NC2)C)CN1)C.
This classification denotes an angiotensin-converting enzyme inhibitor and antihypertensive agent with the molecular formula C23H28N2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18IZ008EU6, chemically known as 1,4-thiazepine-4(5h)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, (2s-(2alpha,6beta(r*)))- but generally known as temocapril, which bears US NIH Compound Identifier 71323. European Medicines Agency schedules Temocapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10884MIG. World Health Organization schedules temocapril in its Anatomical Therapeutic Chemical (ATC) Classification. TEMOCAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule temocapril under HS 29349990 and SITC 51579. As of Q4 2014, TEMOCAPRIL remains the US FDA Preferred Term for this commodity. Temocapril bears US NLM identifiers UMLS ID C0753183 and NCI Concept Code C99555. SMILES: S1C(CN(C(=O)C(NC(CCc2ccccc2)C(=O)OCC)C1)CC(=O)O)c1sccc1.
This classification denotes an ace inhibitor with the molecular formula C21H24N2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2D6A12Q12R, chemically known as 1,4-thiazepine-4(5h)-acetic acid, 6-((1-carboxy-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, (2s-(2alpha,6beta(r*)))- but generally known as temocaprilat, which bears US NIH Compound Identifier 71324. European Medicines Agency schedules Temocaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10885MIG. The term TEMOCAPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). TEMOCAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule temocaprilat under HS 29349990 and SITC 51579. As of Q4 2014, TEMOCAPRILAT remains the US FDA Preferred Term for this commodity. Temocaprilat bears US NLM identifiers UMLS ID C0646101 and NCI Concept Code C75023. SMILES: S1C(CN(C(=O)C(NC(CCc2ccccc2)C(=O)O)C1)CC(=O)O)c1sccc1.
This classification denotes an ace inhibitor with the molecular formula C23H28N2O5S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8G820I95VP, chemically known as 1,4-thiazepine-4-(5h)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, monohydrochloride, (2s-(2alpha,6beta(r*)))- but more generally known as temocapril hydrochloride, which bears US NIH Compound Identifier 71322. European Medicines Agency schedules Temocapril hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04716MIG. Most nations, for tariff and trade purposes, schedule temocapril hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TEMOCAPRIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Temocapril hydrochloride bears US NLM identifiers UMLS ID C0208801 and NCI Concept Code C99556. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3CCCS3.CL.
This classification denotes a penicillin antibiotic with the molecular formula C16H18N2O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03QB156W6I, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-6-methoxy-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6alpha))- but generally known as temocillin, which bears US NIH Compound Identifier 171758. European Medicines Agency schedules Temocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10886MIG. The term TEMOCILLIN is an International Non-Proprietary Name. World Health Organization schedules temocillin in its Anatomical Therapeutic Chemical (ATC) Classification. TEMOCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule temocillin under HS 29411090 and SITC 54131. As of Q4 2014, TEMOCILLIN remains the US FDA Preferred Term for this commodity. Temocillin bears US NLM identifiers UMLS ID C0076079 and NCI Concept Code C76858. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2(OC)NC(=O)C(C1CCSC1)C(=O)O.
This classification denotes a penicillin antibiotic with the molecular formula C16H16N2O7S2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96IIP39ODH, chemically known as n-((2s,5r,6s)-2-carboxy-6-methoxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-3-thiophenemalonamic acid disodium salt, but more generally known as temocillin sodium, which bears US NIH Compound Identifier 6917850. European Medicines Agency schedules temocillin sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10886MIG. Most nations, for tariff purposes, schedule temocillin sodium under HS 29411090. SMILES: CC1([C@@H](N2[C@H](S1)[C@@](C2=O)(NC(=O)C(C3CCSC3)C(=O)[O-])OC)C(=O)[O-])C.[NA+].[NA+].
This classification denotes a photosensitizing agent with the molecular formula C44H32N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FU21S769PF, chemically known as 3,3,3,3-(7,8-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol but generally known as temoporfin, which bears US NIH Compound Identifier 60751. European Medicines Agency schedules Temoporfin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10888MIG. The term TEMOPORFIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules temoporfin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TEMOPORFIN remains the US FDA Preferred Term for this commodity. Temoporfin bears US NLM identifiers UMLS ID C0379149 and NCI Concept Code C1669. SMILES: OC1CC(C2=C3[NH]C(=C(C4=NC(=C(C5[NH]C(C(=C6N=C2CC6)C2CC(O)CCC2)CC5)C2CC(O)CCC2)C=C4)C2CC(O)CCC2)CC3)CCC1. .
This classification denotes a triazene compound and gonadotropin releasing hormone inhibitor with the molecular formula C6H6N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YF1K15M17Y, chemically known as 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide but more generally known as temozolomide, which bears US NIH Compound Identifier 5394. European Medicines Agency schedules Temozolomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10889MIG. The term TEMOZOLOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules temozolomide in its Anatomical Therapeutic Chemical (ATC) Classification. TEMOZOLOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule temozolomide under HS 29339990 and SITC 51577. As of Q4 2014, TEMOZOLOMIDE remains US FDA's Preferred Term for this commodity. Temozolomide bears US NLM identifiers UMLS ID C0076080 and NCI Concept Code C1244. SMILES: O=C1N2C(NNN1C)C(NC2)C(=O)N.
This classification denotes a mtor inhibitor with the molecular formula C56H87NO16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 624KN6GM2T, chemically known as rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) but generally known as temsirolimus, which bears US NIH Compound Identifier 6440033. European Medicines Agency schedules Temsirolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21308. The term TEMSIROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 3, 2005, List 54). World Health Organization schedules temsirolimus in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule temsirolimus under HS 29349990 and SITC 51579. As of Q4 2014, TEMSIROLIMUS remains the US FDA Preferred Term for this commodity. Temsirolimus bears US NLM identifiers UMLS ID C1707080 and NCI Concept Code C1844. SMILES: O(C1CC(CCC1OC(=O)C(CO)(CO)C)CC(C1OC(=O)C2N(CCCC2)C(=O)C(=O)C2(OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(OC)C(O)C(=CC(C(=O)C1)C)C)C)C)C)O)C)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6U94N2D00F, chemically known as 4-piperidinamine, 1-methyl-n-phenyl-n-(2-thienylmethyl)- (9ci) but generally known as thenaldine, which bears US NIH Compound Identifier 27901. European Medicines Agency schedules Thenalidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10960MIG. The term THENALIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules thenaldine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CN1CCC(CC1)N(CC2=CC=CS2)C3=CC=CC=C3.
This classification denotes a thrombolytic agent with the molecular formula C2558H3872N738O781S40, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WGD229O42W, more generally known as tenecteplase. European Medicines Agency schedules tenecteplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04718MIG. The term TENECTEPLASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 13 no. 1, 1999, list 41. Most nations schedule tenecteplase under HS 35079090 and SITC 51691. As of Q4 2014, TENECTEPLASE remains the US FDA Preferred Term for this commodity. Tenecteplase bears US NLM identifiers UMLS ID C0872913 and NCI Concept Code C29489. SMILES: NONE.
This classification denotes a non-steroidal anti-inflammatory agent and cyclooxygenase inhibitor with the molecular formula C14H9ClN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9K7CJ74ONH, chemically known as 2,3-dihydro-5-chloro-2-oxo-3-(2-thienylcarbonyl)-1h-indole-1-carboxamide but generally known as tenidap, which bears US NIH Compound Identifier 57946. European Medicines Agency schedules Tenidap in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15484MIG. World Health Organization schedules tenidap in its Anatomical Therapeutic Chemical (ATC) Classification. TENIDAP is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tenidap under HS 29349990 and SITC 51579. As of Q4 2014, TENIDAP remains the US FDA Preferred Term for this commodity. SMILES: CLC1CC2C(C(=O)N(C2CC1)C(=O)N)C(=O)C1SCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular structure C14H8CLN2O3S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, DCV1328NH2 chemically known as 1h-indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, monosodium salt, (z)-, but more commonly known as tenidap sodium, which bears US NIH Compound Identifier 60711. European Medicines Agency schedules Tenidap sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04719MIG. Most nations, for tariff and trade purposes, schedule tenidap sodium under HS 29349990 and SITC 51579. As of Q4 2014, TENIDAP SODIUM remains US FDA's Preferred Term for this commodity. Tenidap sodium bears US NLM identifiers UMLS ID C0145155 and NCI Concept Code C73800. SMILES: C1CC(SC1)/C(=C/2\C3CC(CCC3N(C2=O)C(=O)N)CL)/[O-].[NA+].
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0U312O2BE. European Medicines Agency schedules Tenilapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10892MIG. Tenilapine generally arises in the molecular formula C17H16N4S2. The term TENILAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) TENILAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tenilapine under HS 29349990 and SITC 51579. As of Q4 2014, TENILAPINE remains the US FDA Preferred Term for this commodity. Tenilapine bears US NLM identifiers UMLS ID C2699912 and NCI Concept Code C76448. SMILES: S1CC2C(=NC3C(C(=C\C#N)\C2C1)CSC3)N1CCN(CC1)C.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95Q6WNP25P. European Medicines Agency schedules Teniloxazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10893MIG. Teniloxazine generally arises in the molecular formula C16H19NO2S. The term TENILOXAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) TENILOXAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teniloxazine under HS 29349990 and SITC 51579. As of Q4 2014, TENILOXAZINE remains the US FDA Preferred Term for this commodity. Teniloxazine bears US NLM identifiers UMLS ID C0075496 and NCI Concept Code C75182. SMILES: s1c(Cc2c(OCC3OCCNC3)cccc2)ccc1.
This classification denotes an epipodophyllotoxin compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 957E6438QA. European Medicines Agency schedules Teniposide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10895MIG. Teniposide generally arises in the molecular formula C32H32O13S. The term TENIPOSIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) TENIPOSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teniposide under HS 29389090 and SITC 54161. As of Q4 2014, TENIPOSIDE remains the US FDA Preferred Term for this commodity. Teniposide bears US NLM identifiers UMLS ID C0039512 and NCI Concept Code C857. SMILES: S1C(C2OC3C(O)C(O)C(OC4C5C(C(C6C4CC4OCOC4C6)C4CC(OC)C(O)C(OC)C4)C(=O)OC5)OC3CO2)CCC1.
This classification denotes an ethylenediamine with the molecular formula C10H20N6O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CKB16BAQ3S, chemically known as n,n,n,n-tetrakis(2-hydroxyethyl)ethylenediaminetetranitrate but generally known as tenitramine, which bears US NIH Compound Identifier 168009. European Medicines Agency schedules Tenitramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15485MIG. World Health Organization schedules tenitramine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TENITRAMINE remains the US FDA Preferred Term for this commodity. SMILES: C(CN(CCO[N+](=O)[O-])CCO[N+](=O)[O-])N(CCO[N+](=O)[O-])CCO[N+](=O)[O-].
This classification denotes a reverse transcriptase inhibitor and purine antagonist with the molecular formula C9H14N5O4P.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99YXE507IL, chemically known as phosphonic acid, ((2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, (r)- but generally known as tenofovir, which bears US NIH Compound Identifier 464205. European Medicines Agency schedules Tenofovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04721MIG. Most nations schedule tenofovir under HS 29335995 and SITC 51576. As of Q4 2014, TENOFOVIR remains the US FDA Preferred Term for this commodity. Tenofovir bears US NLM identifiers UMLS ID C0384228 and NCI Concept Code C29490. SMILES: P(=O)(O)(O)COC(Cn1c2ncnc(N)c2nc1)C.
This classification denotes a reverse transcriptase inhibitor and purine antagonist C21H29N6O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EL9943AG5J, chemically known as l-alanine, n-((s)-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester, but more generally known as tenofovir alafenamide, which bears US NIH Compound Identifier 9574768. Most nations, for tariff and trade purposes, schedule tenofovir alafenamide under HS 29335995 and SITC 51576. As of Q4 2014, TENOFOVIR ALAFENAMIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CN1CNC2C1NCNC2N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3CCCCC3.
This classification denotes a reverse transcriptase inhibitor and purine antagonist 2C21H29N6O5P.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FWF6Q91TZO, chemically known as l-alanine, n-((s)-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester, (2e)-2-butenedioate (2:1), but more generally known as tenofovir alafenamide fumarate, which bears US NIH Compound Identifier 71301443. Most nations, for tariff and trade purposes, schedule tenofovir alafenamide fumarate under HS 29335995 and SITC 51576. As of Q4 2014, TENOFOVIR ALAFENAMIDE FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CN1CNC2C1NCNC2N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3CCCCC3.C[C@H](CN1CNC2C1NCNC2N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3CCCCC3.C(=C/C(=O)O)\C(=O)O.
This classification denotes a reverse transcriptase inhibitor and purine antagonist with the molecular formula C19H30N5O10P.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTT9J7900I, chemically known as bis(hydroxymethyl) (((r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phosphonate, bis(isopropyl carbonate) (ester), fumarate (1:1), but more generally known as tenofovir df, which bears US NIH Compound Identifier 6398764. European Medicines Agency schedules tenofovir df or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04721MIG. Most nations, for tariff purposes, schedule tenofovir df under HS 29335995. SMILES: C[C@H](CN1CNC2C1NCNC2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\C(=O)O.
This classification denotes a reverse transcriptase inhibitor and purine antagonist C19H30N5O10P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4YU4LON7I, chemically known as 2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, 1,9-bis(1-methylethyl) ester, 5-oxide, but more generally known as tenofovir disoproxil, which bears US NIH Compound Identifier 5481350. European Medicines Agency schedules Tenofovir disoproxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20643. Most nations, for tariff and trade purposes, schedule tenofovir disoproxil under HS 29335995 and SITC 51576. World Health Organization schedules tenofovir disoproxil in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TENOFOVIR DISOPROXIL remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CN1CNC2C1NCNC2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.
This classification denotes a reverse transcriptase inhibitor with the molecular formula C19H30N5O10P.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTT9J7900I, chemically known as phosphonic acid, ((2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, (r)- but more generally known as tenofovir disoproxil fumarate, which bears US NIH Compound Identifier 464205. European Medicines Agency schedules Tenofovir disoproxil fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12607MIG. Most nations, for tariff and trade purposes, schedule tenofovir disoproxil fumarate under HS 29335995 and SITC 51576. As of Q4 2014, TENOFOVIR DISOPROXIL FUMARATE remains US FDA's Preferred Term for this commodity. Tenofovir disoproxil fumarate bears US NLM identifiers UMLS ID C1099776 and NCI Concept Code C47747. SMILES: C[C@H](CN1CNC2C1NCNC2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\C(=O)O.
This classification denotes an anti-protozoal with the molecular formula C8H5N3O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PBQ7WLE1WP, chemically known as N-(5-nitro-1,3-thiazol-2-yl)thiophene-2-carboxamide but generally known as tenonitrozole, which bears US NIH Compound Identifier 19646. European Medicines Agency schedules tenonitrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10897MIG. Most nations schedule tenonitrozole under HS 29341000 and SITC 51579. As of Q4 2014, TENONITROZOLE remains the US FDA Preferred Term for this commodity. SMILES: C1=CSC(=C1)C(=O)NC2=NC=C(S2)[N+](=O)[O-].
This classification denotes a calcium channel blocker with the molecular formula C12H8O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EEK88K197T, chemically known as 2-thiophenecarboxylic acid, ester with salicylic acid but generally known as tenosal, which bears US NIH Compound Identifier 65838. European Medicines Agency schedules Tenosal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10898MIG. The term TENOSAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). TENOSAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tenosal under HS 29349990 and SITC 51579. As of Q4 2014, TENOSAL remains the US FDA Preferred Term for this commodity. Tenosal bears US NLM identifiers UMLS ID C2699913 and NCI Concept Code C76584. SMILES: s1c(C(=O)Oc2c(cccc2)C(=O)O)ccc1.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3E44064G8N. European Medicines Agency schedules Tenosiprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10899MIG. Tenosiprol generally arises in the molecular formula C10H11NO4S. The term TENOSIPROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) TENOSIPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tenosiprol under HS 29349990 and SITC 51579. As of Q4 2014, TENOSIPROL remains the US FDA Preferred Term for this commodity. Tenosiprol bears US NLM identifiers UMLS ID C2699914 and NCI Concept Code C76816. SMILES: C1C(CNC1C(=O)O)OC(=O)C2=CC=CS2.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z1R9N0A399. European Medicines Agency schedules Tenoxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10900MIG. Tenoxicam generally arises in the molecular formula C13H11N3O4S2. The term TENOXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) TENOXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tenoxicam under HS 29349990 and SITC 51579. As of Q4 2014, TENOXICAM remains the US FDA Preferred Term for this commodity. Tenoxicam bears US NLM identifiers UMLS ID C0076096 and NCI Concept Code C73097. SMILES: S1(=O)(=O)N(/C(=C(/O)NC2NCCCC2)C(=O)C2SCCC12)C.
This classification denotes a vasodilating agent with the molecular formula C16H22N6O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 631R1KON85, chemically known as 1,4:3,6-dianhydro-2-deoxy-2-((3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurin-7-yl)propyl)amino)-l-iditol 5-nitrate but generally known as teopranitol, which bears US NIH Compound Identifier 3034007. European Medicines Agency schedules Teopranitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10902MIG. The term TEOPRANITOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). TEOPRANITOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teopranitol under HS 29395900 and SITC 54145. As of Q4 2014, TEOPRANITOL remains the US FDA Preferred Term for this commodity. Teopranitol bears US NLM identifiers UMLS ID C0076104 and NCI Concept Code C66586. SMILES: O1C2C(OCC2O[N](=O)O)C(NCCCn2c3c(n(c(=O)n(c3=O)C)C)nc2)C1.
This classification denotes a dopamine antagonist with the molecular formula C16H19ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X235XX30GK, chemically known as 5-chloro-3-(1,2,3,6-tetrahydro-1-propyl-4-pyridyl)indole but generally known as tepirindole, which bears US NIH Compound Identifier 68915. European Medicines Agency schedules Tepirindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10904MIG. The term TEPIRINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). TEPIRINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tepirindole under HS 29333999 and SITC 51574. As of Q4 2014, TEPIRINDOLE remains the US FDA Preferred Term for this commodity. Tepirindole bears US NLM identifiers UMLS ID C0084745 and NCI Concept Code C76655. SMILES: CLC1CC2C(C3=CCN(CC3)CCC)C[NH]C2CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H20ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TZ4OX61974, chemically known as 1h-pyrazole-3-propanamide, 5-(4-chlorophenyl)-n-hydroxy-1-(4-methoxyphenyl)-n-methyl- but generally known as tepoxalin, which bears US NIH Compound Identifier 59757. European Medicines Agency schedules Tepoxalin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10905MIG. The term TEPOXALIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). TEPOXALIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tepoxalin under HS 29331990 and SITC 51571. As of Q4 2014, TEPOXALIN remains the US FDA Preferred Term for this commodity. Tepoxalin bears US NLM identifiers UMLS ID C0145162 and NCI Concept Code C76817. SMILES: CLC1CCC(C2N(NC(CCC(=O)N(O)C)C2)C2CCC(OC)CC2)CC1.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8L5014XET7, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but generally known as terazosin, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10907MIG. The term TERAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules terazosin in its Anatomical Therapeutic Chemical (ATC) Classification. TERAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terazosin under HS 29349990 and SITC 51579. As of Q4 2014, TERAZOSIN remains the US FDA Preferred Term for this commodity. Terazosin bears US NLM identifiers UMLS ID C0076107 and NCI Concept Code C61964. SMILES: O1C(CCC1)C(=O)N1CCN(CC1)C1NC2C(C(N1)N)CC(OC)C(OC)C2.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D32S14F082, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but more generally known as terazosin hydrochloride, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04722MIG. Most nations, for tariff and trade purposes, schedule terazosin hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TERAZOSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Terazosin hydrochloride bears US NLM identifiers UMLS ID C0770137 and NCI Concept Code C29491. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4CCCO4.O.O.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8QOP8Z9955. European Medicines Agency schedules terazosin hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04722MIG. Most nations, for tariff and trade purposes, schedule terazosin hydrochloride anhydrous under HS 29349990 and SITC 51579. As of Q4 2014, TERAZOSIN HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. Terazosin hydrochloride anhydrous bears US NLM identifiers UMLS ID C2241271 and NCI Concept Code C75056. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4CCCO4.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D32S14F082, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but more generally known as terazosin hydrochloride dihydrate, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin hydrochloride dihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04722MIG. Most nations, for tariff and trade purposes, schedule terazosin hydrochloride dihydrate under HS 29349990. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4CCCO4.O.O.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D32S14F082, chemically known as methanone, (4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl)(tetrahydro-2-furanyl)-, hydrochloride, hydrate (1:1:2), but more generally known as terazosin monohydrochloride dihydrate, which bears US NIH Compound Identifier 63016. European Medicines Agency schedules terazosin monohydrochloride dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10907MIG. Most nations, for tariff purposes, schedule terazosin monohydrochloride dihydrate under HS 29349990. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4CCCO4.O.O.CL.
This classification denotes an antipsychotic agent with the molecular formula C15H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0DH9WUS03O, chemically known as 1,4-dihydro-1-(methoxymethyl)-4-oxo-n-propyl-3-quinolinecarboxamide but generally known as terbequinil, which bears US NIH Compound Identifier 65916. European Medicines Agency schedules Terbequinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10908MIG. The term TERBEQUINIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). TERBEQUINIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terbequinil under HS 29334990 and SITC 51575. As of Q4 2014, TERBEQUINIL remains the US FDA Preferred Term for this commodity. Terbequinil bears US NLM identifiers UMLS ID C2348661 and NCI Concept Code C73243. SMILES: O(CN1C2C(C(=O)C(C1)C(=O)NCCC)CCCC2)C.
This classification denotes an antifungal agent with the molecular formula C21H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7RIW8S0XP, chemically known as n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine but generally known as terbinafine, which bears US NIH Compound Identifier 5402. European Medicines Agency schedules Terbinafine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10909MIG. The term TERBINAFINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules terbinafine in its Anatomical Therapeutic Chemical (ATC) Classification. TERBINAFINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terbinafine under HS 29214980 and SITC 51454. As of Q4 2014, TERBINAFINE remains the US FDA Preferred Term for this commodity. Terbinafine bears US NLM identifiers UMLS ID C0076110 and NCI Concept Code C48019. SMILES: N(CC1C2C(CCC1)CCCC2)(C/C=C/C#CC(C)(C)C)C.
This classification denotes an antifungal agent with the molecular formula C21H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 012C11ZU6G, chemically known as n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine but more generally known as terbinafine hydrochloride, which bears US NIH Compound Identifier 5402. European Medicines Agency schedules Terbinafine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04723MIG. Most nations, for tariff and trade purposes, schedule terbinafine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, TERBINAFINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Terbinafine hydrochloride bears US NLM identifiers UMLS ID C0771029 and NCI Concept Code C29492. SMILES: CC(C)(C)C#C/C=C/CN(C)CC1CCCC2C1CCCC2.CL.
This classification denotes an anti-lipidemic agent with the molecular formula C20H24O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W41Z308IA3, chemically known as 4-(3-(4-(1,1-dimethylethyl)phenoxy)-2-hydroxypropoxy)benzoic acid but generally known as terbufibrol, which bears US NIH Compound Identifier 41907. European Medicines Agency schedules Terbufibrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10912MIG. The term TERBUFIBROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). TERBUFIBROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, TERBUFIBROL remains the US FDA Preferred Term for this commodity. Terbufibrol bears US NLM identifiers UMLS ID C0076111 and NCI Concept Code C91031. SMILES: O(c1ccc(C(C)(C)C)cc1)CC(O)COc1ccc(cc1)C(=O)O.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C12H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N8ONU3L3PG, chemically known as 1,3-benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9ci) but generally known as terbutaline, which bears US NIH Compound Identifier 5403. European Medicines Agency schedules Terbutaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10915MIG. The term TERBUTALINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules terbutaline in its Anatomical Therapeutic Chemical (ATC) Classification. TERBUTALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terbutaline under HS 29225000 and SITC 51467. As of Q4 2014, TERBUTALINE remains the US FDA Preferred Term for this commodity. Terbutaline bears US NLM identifiers UMLS ID C0039542 and NCI Concept Code C61965. SMILES: CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula 2C12H19NO3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 576PU70Y8E, chemically known as 1,3-benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9ci) but more generally known as terbutaline sulfate, which bears US NIH Compound Identifier 5403. European Medicines Agency schedules Terbutaline sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04724MIG. Most nations, for tariff and trade purposes, schedule terbutaline sulfate under HS 29225000 and SITC 51467. As of Q4 2014, TERBUTALINE SULFATE remains US FDA's Preferred Term for this commodity. Terbutaline sulfate bears US NLM identifiers UMLS ID C0591192 and NCI Concept Code C47748. SMILES: CC(C)(C)NCC(C1CC(CC(C1)O)O)O.CC(C)(C)NCC(C1CC(CC(C1)O)O)O.OS(=O)(=O)O.
This classification denotes an antihypertensive agent with the molecular formula C22H29F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TCE6830H8P, chemically known as (+-)-alpha-(((1-ethynylcyclohexyl)oxy)methyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazineethanol but generally known as terciprazine, which bears US NIH Compound Identifier 68763. European Medicines Agency schedules Terciprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10916MIG. The term TERCIPRAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). TERCIPRAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terciprazine under HS 29335995 and SITC 51576. As of Q4 2014, TERCIPRAZINE remains the US FDA Preferred Term for this commodity. Terciprazine bears US NLM identifiers UMLS ID C0610726 and NCI Concept Code C90734. SMILES: FC(F)(F)c1cc(N2CCN(CC(O)COC3(CCCCC3)C#C)CC2)ccc1.
This classification denotes an antifungal agent with the molecular formula C26H31CL2N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0KJ2VE664U. European Medicines Agency schedules terconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10917MIG. The term TERCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21. ). TERCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terconazole under HS 29349990 and SITC 51579. As of Q4 2014, TERCONAZOLE remains the US FDA Preferred Term for this commodity. Terconazole bears US NLM identifiers UMLS ID C0076115 and NCI Concept Code C29493. SMILES: CLC1C(C2(OC(CO2)COC2CCC(N3CCN(CC3)C(C)C)CC2)CN2NCNC2)CCC(CL)C1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H41NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BA5G9Y06Q, chemically known as 1-piperidinebutanol, alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)- but generally known as terfenadine, which bears US NIH Compound Identifier 5405. European Medicines Agency schedules Terfenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10920MIG. The term TERFENADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules terfenadine in its Anatomical Therapeutic Chemical (ATC) Classification. TERFENADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terfenadine under HS 29333999 and SITC 51574. As of Q4 2014, TERFENADINE remains the US FDA Preferred Term for this commodity. Terfenadine bears US NLM identifiers UMLS ID C0085173 and NCI Concept Code C29494. SMILES: OC(C1CCN(CC1)CCCC(O)C1CCC(C(C)(C)C)CC1)(C1CCCCC1)C1CCCCC1.
This classification denotes an antineoplastic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WUF1DL156G. European Medicines Agency schedules Terfluranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10922MIG. Terfluranol generally arises in the molecular formula C17H17F3O2. The term TERFLURANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) TERFLURANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terfluranol under HS 29081900 and SITC 51244. As of Q4 2014, TERFLURANOL remains the US FDA Preferred Term for this commodity. Terfluranol bears US NLM identifiers UMLS ID C2699917 and NCI Concept Code C75292. SMILES: FC(F)(F)CC(C(C1CCC(O)CC1)C)C1CCC(O)CC1.
This classification denotes a lisuride analog, ergoline, and dopamine agonist with the molecular formula C20H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21OJT43Q88, chemically known as 9,10-alpha-dihydrolisuride but generally known as terguride, which bears US NIH Compound Identifier 37816. European Medicines Agency schedules Terguride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10923MIG. World Health Organization schedules terguride in its Anatomical Therapeutic Chemical (ATC) Classification. TERGURIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terguride under HS 29396900 and SITC 54146. As of Q4 2014, TERGURIDE remains the US FDA Preferred Term for this commodity. SMILES: O=C(NC1CC2C(N(C1)C)CC1C3C2CCCC3[NH]C1)N(CC)CC.
This classification denotes an enzyme inhibitor with the molecular formula C12H9F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1C058IKG3B, chemically known as 2-butenamide, 2-cyano-3-hydroxy-n-(4-(trifluoromethyl)phenyl)- but more generally known as teriflunomide, which bears US NIH Compound Identifier 5479847. European Medicines Agency schedules Teriflunomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25218. The term TERIFLUNOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations, for tariff and trade purposes, schedule teriflunomide under HS 29269095 and SITC 51484. As of Q4 2014, TERIFLUNOMIDE remains US FDA's Preferred Term for this commodity. Teriflunomide bears US NLM identifiers UMLS ID C1718383 and NCI Concept Code C76662. SMILES: FC(F)(F)C1CCC(NC(=C(\C(=O)C)C#N)\O)CC1.
This classification denotes a recombinant parathyroid hormone with the molecular formula C181H291N55O51S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10T9CSU89I, chemically known as l-phenylalanine, l-seryl-l-valyl-l-seryl-l-alpha-glutamyl-l-isoleucyl-l-glutaminyl-l-leucyl-l-methionyl-l-histidyl-l-asparaginyl-l-leucylglycyl-l-lysyl-l-histidyl-l-leucyl-l-asparaginyl-l-seryl-l-methionyl-l-alpha-glutamyl-l-arginyl-l-valyl-l-alpha-glutamyl-l-tryptophyl-l-leucyl-l-arginyl-l-lysyl-l-lysyl-l-leucyl-l-glutaminyl-l-alpha-aspartyl-l-valyl-l-histidyl-l-asparaginyl- but generally known as teriparatide, which bears US NIH Compound Identifier 16129682. European Medicines Agency schedules Teriparatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10925MIG. The term TERIPARATIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules teriparatide in its Anatomical Therapeutic Chemical (ATC) Classification. TERIPARATIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule teriparatide under HS 29371900 and SITC 54154. As of Q4 2014, TERIPARATIDE remains the US FDA Preferred Term for this commodity. Teriparatide bears US NLM identifiers UMLS ID C0070093 and NCI Concept Code C61966. SMILES: S(CCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CO)C(C)C)CO)CCC(=O)O)C(CC)C)CCC(=O)N)CC(C)C)C(=O)NC(CC1NC[NH]C1)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(C)C)C(=O)N.
This classification denotes a recombinant parathyroid hormone with the molecular formula C181H291N55O51S2.C2H4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9959P4V12N. European Medicines Agency schedules teriparatide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04726MIG. The term teriparatide acetate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule teriparatide acetate under HS 29371900 and SITC 54154. As of Q4 2014, TERIPARATIDE ACETATE remains US FDA's Preferred Term for this commodity. Teriparatide acetate bears US NLM identifiers UMLS ID C1170286 and NCI Concept Code C66588. SMILES: CC(=O)O.O.
This classification denotes a recombinant parathyroid hormone with the molecular formula C181H291N55O51S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10T9CSU89I, chemically known as l-phenylalanine, l-seryl-l-valyl-l-seryl-l-alpha-glutamyl-l-isoleucyl-l-glutaminyl-l-leucyl-l-methionyl-l-histidyl-l-asparaginyl-l-leucylglycyl-l-lysyl-l-histidyl-l-leucyl-l-asparaginyl-l-seryl-l-methionyl-l-alpha-glutamyl-l-arginyl-l-valyl-l-alpha-glutamyl-l-tryptophyl-l-leucyl-l-arginyl-l-lysyl-l-lysyl-l-leucyl-l-glutaminyl-l-alpha-aspartyl-l-valyl-l-histidyl-l-asparaginyl- but more generally known as teriparatide, which bears US NIH Compound Identifier 16129682. European Medicines Agency schedules Teriparatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10925MIG. The term TERIPARATIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules teriparatide in its Anatomical Therapeutic Chemical (ATC) Classification. TERIPARATIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule teriparatide recombinant human under HS 29371900. SMILES:.
This classification denotes an antitubercular agent with the molecular formula C14H14N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1199LEX5N8, chemically known as 4,4-(p-phenylenebis(methyleneamino))di-(isoxazolidin-3-one) but generally known as terizidone, which bears US NIH Compound Identifier 65720. European Medicines Agency schedules Terizidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15487MIG. The term TERIZIDONE is an International Non-Proprietary Name. World Health Organization schedules terizidone in its Anatomical Therapeutic Chemical (ATC) Classification. TERIZIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terizidone under HS 29349990 and SITC 51579. As of Q4 2014, TERIZIDONE remains the US FDA Preferred Term for this commodity. Terizidone bears US NLM identifiers UMLS ID C0145184 and NCI Concept Code C90772. SMILES: O1NC(=O)C(/N=C/C2CCC(/C=N/C3CONC3=O)CC2)C1.
This classification denotes an antidiurectic hormone analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z5X49W53P. European Medicines Agency schedules Terlipressin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10927MIG. Terlipressin generally arises in the molecular formula C52H74N16O15S2. The term TERLIPRESSIN is an International Non-Proprietary Name or INN. TERLIPRESSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terlipressin under HS 29371900 and SITC 54154. As of Q4 2014, TERLIPRESSIN remains the US FDA Preferred Term for this commodity. Terlipressin bears US NLM identifiers UMLS ID C0145185 and NCI Concept Code C77387. SMILES: S1SCC(NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CCCCN)C(=O)NCC(=O)N)C1)CC(=O)N)CCC(=O)N)CC1CCCCC1)CC1CCC(O)CC1.
This classification denotes a calcium channel blocker and parasympatholytic with the molecular formula C20H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70KG06964W, chemically known as propylamine, n-tert-butyl-1-methyl-3,3-diphenyl- but generally known as terodiline, which bears US NIH Compound Identifier 23480. European Medicines Agency schedules Terodiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10929MIG. World Health Organization schedules terodiline in its Anatomical Therapeutic Chemical (ATC) Classification. TERODILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terodiline under HS 29214980 and SITC 51454. As of Q4 2014, TERODILINE remains the US FDA Preferred Term for this commodity. SMILES: N(C(CC(c1ccccc1)c1ccccc1)C)C(C)(C)C.
This classification denotes a calcium channel blocker and parasympatholytic C20H27N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2ZA89W43F, chemically known as benzenepropanamine, n-(1,1-dimethylethyl)-.alpha.-methyl-.gamma.-phenyl-, hydrochloride, but more generally known as terodiline hydrochloride, which bears US NIH Compound Identifier 23479. European Medicines Agency schedules Terodiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04728MIG. Most nations, for tariff and trade purposes, schedule terodiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, TERODILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC(C1CCCCC1)C2CCCCC2)NC(C)(C)C.CL.
This classification denotes a menthol analog, insect repellent, and expectorant with the molecular formula C10H20O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S3V868548T, chemically known as 1,8-terpin but more generally known as terpin hydrate, which bears US NIH Compound Identifier 6651. European Medicines Agency schedules Terpin hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15488MIG. As of Q4 2014, TERPIN HYDRATE remains US FDA's Preferred Term for this commodity. SMILES: CC1(CCC(CC1)C(C)(C)O)O.O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H25NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZO341YQXP, chemically known as 2-propanol, 1-((3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)- but generally known as tertatolol, which bears US NIH Compound Identifier 36920. European Medicines Agency schedules Tertatolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10933MIG. The term TERTATOLOL is an International Non-Proprietary Name. World Health Organization schedules tertatolol in its Anatomical Therapeutic Chemical (ATC) Classification. TERTATOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tertatolol under HS 29349990 and SITC 51579. As of Q4 2014, TERTATOLOL remains the US FDA Preferred Term for this commodity. Tertatolol bears US NLM identifiers UMLS ID C0076166 and NCI Concept Code C81654. SMILES: S1C2C(CCC1)CCCC2OCC(O)CNC(C)(C)C.
This classification denotes a beta-adrenergic blocking agent C16H25NO2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9SDH60Z1NO, chemically known as 2-propanol, 1-((3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)-, hydrochloride (1:1), but more generally known as tertatolol hydrochloride, which bears US NIH Compound Identifier 161777. European Medicines Agency schedules Tertatolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32680. Most nations, for tariff and trade purposes, schedule tertatolol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TERTATOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)NCC(COC1CCCC2C1SCCC2)O.CL.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6734037O3L. European Medicines Agency schedules Tesaglitazar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25217. Tesaglitazar generally arises in the molecular formula C20H24O7S. The term TESAGLITAZAR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations, for tariff and trade purposes, schedule tesaglitazar under HS 29189900 and SITC 51396. As of Q4 2014, TESAGLITAZAR remains US FDA's Preferred Term for this commodity. Tesaglitazar bears US NLM identifiers UMLS ID C1570259 and NCI Concept Code C75985. SMILES: S(=O)(=O)(OC1CCC(CCOC2CCC(CC(OCC)C(=O)O)CC2)CC1)C.
This classification denotes a growth hormone-releasing hormone analogue with the molecular formula C221H366N72O67S.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LGW5H38VE3. The term tesamorelin acetate is a United States Adopted Name designation. As of Q4 2014, TESAMORELIN ACETATE remains the US FDA Preferred Term for this commodity. Tesamorelin acetate bears US NLM identifiers UMLS ID C2955463 and NCI Concept Code C90852. SMILES: CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WHO633E898, chemically known as 1,3(2h,4h)-isoquinolinedione, 5,6,7, 8-tetrahydro-4-(phenylmethylene)- but generally known as tesimide, which bears US NIH Compound Identifier 5384729. European Medicines Agency schedules Tesimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10935MIG. The term TESIMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). TESIMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tesimide under HS 29251995 and SITC 51482. As of Q4 2014, TESIMIDE remains the US FDA Preferred Term for this commodity. Tesimide bears US NLM identifiers UMLS ID C2827339 and NCI Concept Code C84197. SMILES: O=C1NC(=O)C(=C\C2CCCCC2)/C2=C1CCCC2.
This classification denotes a steroidal aromatase inhibitor with the molecular formula C19H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J9BLA949Q, chemically known as d-homo-17a-oxaandrosta-1,4-diene-3,17-dione but generally known as testolactone, which bears US NIH Compound Identifier 5407. European Medicines Agency schedules Testolactone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10936MIG. The term TESTOLACTONE is an International Non-Proprietary Name. TESTOLACTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule testolactone under HS 29372900 and SITC 54153. As of Q4 2014, TESTOLACTONE remains the US FDA Preferred Term for this commodity. Testolactone bears US NLM identifiers UMLS ID C0039600 and NCI Concept Code C2301. SMILES: O1C2(C(C3C(C4(C(=CC(=O)C=C4)CC3)C)CC2)CCC1=O)C.
This classification denotes an androgen with the molecular formula C19H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XMK78S47O, chemically known as 10.alpha.-androst-4-en-3-one, 17.beta.-hydroxy- but generally known as testosterone, which bears US NIH Compound Identifier 5408. European Medicines Agency schedules Testosterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10937MIG. The term TESTOSTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules testosterone in its Anatomical Therapeutic Chemical (ATC) Classification. TESTOSTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule testosterone under HS 29372900 and SITC 54153. As of Q4 2014, TESTOSTERONE remains the US FDA Preferred Term for this commodity. Testosterone bears US NLM identifiers UMLS ID CL026906 and NCI Concept Code C2299. SMILES: OC1C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C.
This classification denotes an androgen with the molecular formula C26H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 387187KT3E, chemically known as androst-4-en-3-one, 17-(benzoyloxy)-, (17.beta.)-, but more generally known as testosterone benzoate, which bears US NIH Compound Identifier 101474. European Medicines Agency schedules testosterone benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10937MIG. Most nations, for tariff purposes, schedule testosterone benzoate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)C4CCCCC4)CCC5=CC(=O)CC[C@]35C.
This classification denotes an androgen with the molecular formula C27H40O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M0XW1UBI14, chemically known as androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17.beta.)-, but more generally known as testosterone cyclopentanepropionate, which bears US NIH Compound Identifier 6012. European Medicines Agency schedules testosterone cyclopentanepropionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10937MIG. Most nations, for tariff purposes, schedule testosterone cyclopentanepropionate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=CC(=O)CC[C@]35C.
This classification denotes a therapeutic testosterone, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M0XW1UBI14. European Medicines Agency schedules Testosterone cipionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04734MIG. Testosterone cypionate generally arises in the molecular formula C27H40O3. The term 'testosterone cypionate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule testosterone cypionate under HS 29372900. As of Q4 2014, TESTOSTERONE CYPIONATE remains US FDA's Preferred Term for this commodity. Testosterone cypionate bears US NLM identifiers UMLS ID C0076181 and NCI Concept Code C1246. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=CC(=O)CC[C@]35C.
This classification denotes a therapeutic testosterone with the molecular formula C26H40O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z6522T8N9, chemically known as 17-hydroxyandrost-4-en-3-one, 17-heptanoate but more generally known as testosterone enantate, which bears US NIH Compound Identifier 9416. European Medicines Agency schedules Testosterone enantate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04736MIG. Most nations, for tariff and trade purposes, schedule testosterone enanthate under HS 29372900 and SITC 54153. As of Q4 2014, TESTOSTERONE ENANTHATE remains US FDA's Preferred Term for this commodity. Testosterone enanthate bears US NLM identifiers UMLS ID C0076189 and NCI Concept Code C1247. SMILES: CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.
This classification denotes an androgen with the molecular formula C26H40O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z6522T8N9, chemically known as androst-4-en-3-one, 17-(1-oxoheptyl)oxy-, (17.beta.)-, but more generally known as testosterone heptanoate, which bears US NIH Compound Identifier 9416. European Medicines Agency schedules testosterone heptanoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10937MIG. Most nations, for tariff purposes, schedule testosterone heptanoate under HS 29372900. SMILES: CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.
This classification denotes an androgen with the molecular formula C26H38O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4QOX8847Z, chemically known as androst-4-en-3-one, 17-((cyclohexylcarbonyl)oxy)-, (17.beta.)-, but more generally known as testosterone hexahydrobenzoate, which bears US NIH Compound Identifier 85694. European Medicines Agency schedules testosterone hexahydrobenzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10937MIG. Most nations, for tariff purposes, schedule testosterone hexahydrobenzoate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)C4CCCCC4)CCC5=CC(=O)CC[C@]35C.
This classification denotes a therapeutic testosterone with the molecular formula C27H34O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WAD1QAK81D, chemically known as androst-4-en-3-one, 17-((phenylacetyl)oxy)- but more generally known as testosterone phenylacetate, which bears US NIH Compound Identifier 21925. Most nations, for tariff and trade purposes, schedule testosterone phenylacetate under HS 29372900 and SITC 54153. As of Q4 2014, TESTOSTERONE PHENYLACETATE remains US FDA's Preferred Term for this commodity. Testosterone phenylacetate bears US NLM identifiers UMLS ID C2986926 and NCI Concept Code C95126. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CC4CCCCC4)CCC5=CC(=O)CC[C@]35C.
This classification denotes a therapeutic testosterone with the molecular formula C22H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WI93Z9138A, chemically known as testosterone, propionate but more generally known as testosterone propionate, which bears US NIH Compound Identifier 5995. European Medicines Agency schedules Testosterone propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04743MIG. Most nations, for tariff and trade purposes, schedule testosterone propionate under HS 29372900 and SITC 54153. As of Q4 2014, TESTOSTERONE PROPIONATE remains US FDA's Preferred Term for this commodity. Testosterone propionate bears US NLM identifiers UMLS ID C0039607 and NCI Concept Code C863. SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.
This classification denotes a therapeutic testosterone with the molecular formula C30H48O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H16A5VCT9C, chemically known as 5-alpha-androstan-3-one, 17-beta-hydroxy-, undecanoate but more generally known as testosterone undecanoate, which bears US NIH Compound Identifier 65157. European Medicines Agency schedules Testosterone undecanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04744MIG. Most nations, for tariff and trade purposes, schedule testosterone undecanoate under HS 29372900 and SITC 54153. As of Q4 2014, TESTOSTERONE UNDECANOATE remains US FDA's Preferred Term for this commodity. Testosterone undecanoate bears US NLM identifiers UMLS ID C0076195 and NCI Concept Code C1249. SMILES: CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.
This classification denotes a therapeutic testosterone with the molecular formula C30H48O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H16A5VCT9C, chemically known as 5-alpha-androstan-3-one, 17-beta-hydroxy-, undecanoate but more generally known as testosterone undecanoate, which bears US NIH Compound Identifier 65157. European Medicines Agency schedules Testosterone undecanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04744MIG. Most nations, for tariff and trade purposes, schedule testosterone undecylate under HS 29372900. SMILES: CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.
This classification denotes a vaccine against a disease caused by tetanospasmin, a powerful protein toxin produced by clostridium tetani, a disease commonly called Tetanus. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form.
This classification denotes a dopamine antagonist with the molecular formula C19H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z9O08YRN8O, chemically known as 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2h-benzo(a)quinolizin-2-one but generally known as tetrabenazine, which bears US NIH Compound Identifier 6018. European Medicines Agency schedules Tetrabenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10939MIG. The term TETRABENAZINE is an International Non-Proprietary Name. World Health Organization schedules tetrabenazine in its Anatomical Therapeutic Chemical (ATC) Classification. TETRABENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tetrabenazine under HS 29339990 and SITC 51577. As of Q4 2014, TETRABENAZINE remains the US FDA Preferred Term for this commodity. Tetrabenazine bears US NLM identifiers UMLS ID C0039623 and NCI Concept Code C81095. SMILES: O=C1C(CN2C(C1)C1C(CC2)CC(OC)C(OC)C1)CC(C)C.
This classification denotes an anesthetic agent with the molecular formula C15H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5NF5D4OPCI, chemically known as p-(butylamino)benzoic acid, 2-(dimethylamino)ethyl ester, hydrochloride but more generally known as amethocaine hydrochloride, which bears US NIH Compound Identifier 8695. European Medicines Agency schedules Amethocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04754MIG. Most nations, for tariff and trade purposes, schedule tetracaine hydrochloride under HS 29224995. As of Q4 2014, TETRACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tetracaine hydrochloride bears US NLM identifiers UMLS ID C0304456 and NCI Concept Code C75104. SMILES: CCCCNC1CCC(CC1)C(=O)OCCN(C)C.CL.
This classification denotes a carcinogenic chlorinated hydrocarbon with the molecular formula C2Cl4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TJ904HH8SN, chemically known as 1,1,2,2-tetrachloroethylene but generally known as tetrachloroethylene, which bears US NIH Compound Identifier 31373. As of Q4 2014, TETRACHLOROETHYLENE remains the US FDA Preferred Term for this commodity. Tetrachloroethylene bears US NLM identifiers UMLS ID C0039637 and NCI Concept Code C44451. SMILES: C(=C(CL)CL)(CL)CL.
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8VB5M810T, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s,4as,5as,6s,12as)- but generally known as tetracycline, which bears US NIH Compound Identifier 5280962. European Medicines Agency schedules Tetracycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10942MIG. The term TETRACYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules tetracycline in its Anatomical Therapeutic Chemical (ATC) Classification. TETRACYCLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tetracycline under HS 29413000 and SITC 54133. As of Q4 2014, TETRACYCLINE remains the US FDA Preferred Term for this commodity. Tetracycline bears US NLM identifiers UMLS ID C0039644 and NCI Concept Code C865. SMILES: OC12C(CC3C(O)(C4C(C(=C3C1=O)O)C(O)CCC4)C)C(N(C)C)C(=O)C(=C(\O)N)\C2=O.
This classification denotes a tetracycline antibiotic C22H24N2O8.C7H8O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05T77P89WE, chemically known as 4-hydroxy-3-methoxybenzenesulfonic acid, (2z,4s,4as,5as,6r,12as)-2-(amino(hydroxy)methylidene)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2h,4h,5h)-trione (1:1), but more generally known as tetracycline guaiacolsulfonate, which bears US NIH Compound Identifier 71300435. European Medicines Agency schedules Tetracycline guaiacolsulfonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04759MIG. Most nations, for tariff and trade purposes, schedule tetracycline guaiacolsulfonate under HS 29413000 and SITC 54133. As of Q4 2014, TETRACYCLINE GUAIACOLSULFONATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O.COC1CC(CCC1O)S(=O)(=O)O.
This classification denotes a tetracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P6R62377KV. European Medicines Agency schedules Tetracycline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04760MIG. Tetracycline hydrochloride generally arises in the molecular formula C22H24N2O8.CLH. The term 'tetracycline hydrochloride' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule tetracycline hydrochloride under HS 29413000 and SITC 54133. As of Q4 2014, TETRACYCLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tetracycline hydrochloride bears US NLM identifiers UMLS ID C0546879 and NCI Concept Code C48020. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O.CL.
This classification denotes a tetracycline antibiotic with the molecular structure C22H24N2O8.(NA)MOD.(O3P)MOD, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 6B7BK5H33B chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, phosphate complex, but more commonly known as tetracycline phosphate complex, which bears US NIH Compound Identifier 16131193. European Medicines Agency schedules Tetracycline phosphate complex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04761MIG. Most nations, for tariff and trade purposes, schedule tetracycline metaphosphate under HS 29413000. SMILES:.
This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O8.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NZ662XY5PP. The term tetracycline phosphate is a U.S. FDA Green Book designation. Most nations, for tariff and trade purposes, schedule tetracycline phosphate under HS 29413000. As of Q4 2014, TETRACYCLINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O.OP(=O)(O)O.
This classification denotes a tetracycline antibiotic with the molecular structure C22H24N2O8.(NA)MOD.(O3P)MOD, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 6B7BK5H33B chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, phosphate complex, but more commonly known as tetracycline phosphate complex, which bears US NIH Compound Identifier 16131193. European Medicines Agency schedules Tetracycline phosphate complex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04761MIG. Most nations, for tariff and trade purposes, schedule tetracycline phosphate complex under HS 29413000 and SITC 54133. Tetracycline phosphate complex bears US NLM identifiers UMLS ID C0521901 and NCI Concept Code C87225. SMILES: As of Q4 2014, TETRACYCLINE PHOSPHATE COMPLEX remains US FDA's Preferred Term for this commodity.
This classification denotes a tetracycline antibiotic C22H24N2O8.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 93V6NC52SB, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrate (1:3), (4s,4as,5as,6s,12as)-, but more generally known as tetracycline trihydrate, which bears US NIH Compound Identifier 67858637. Most nations, for tariff and trade purposes, schedule tetracycline trihydrate under HS 29413000 and SITC 54133. As of Q4 2014, TETRACYCLINE TRIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O.O.O.O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier S9U025Y077, chemically known as 4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-1h-imidazole but more generally known as tetrahydrozoline, which bears U.S. National Institutes of Health Compound Identifier 5419. The European Medicines Agency schedules Tetryzoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10955MIG. The term TETRYZOLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). The World Health Organization schedules tetrahydrozoline in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1CC(C2=CC=CC=C2C1)C3=NCCN3.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9U025Y077, chemically known as 4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-1h-imidazole but more generally known as tetrahydrozoline, which bears US NIH Compound Identifier 5419. European Medicines Agency schedules Tetryzoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10955MIG. The term TETRYZOLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules tetrahydrozoline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TETRAHYDROZOLINE remains US FDA's Preferred Term for this commodity. Tetrahydrozoline bears US NLM identifiers UMLS ID C0076286 and NCI Concept Code C61967. SMILES: C1CC(C2=CC=CC=C2C1)C3=NCCN3.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.
This classification denotes a chemo immunostimulant adjuvant C11H12N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NDK265MCV, chemically known as (+/-)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride, but more generally known as tetramisole hydrochloride, which bears US NIH Compound Identifier 68628. Most nations, for tariff and trade purposes, schedule tetramisole hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TETRAMISOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C2CN3CCSC3=N2.CL.
This classification denotes a benzodiazepine with the molecular formula C16H17ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FO92091VP8, chemically known as 7-chloro-5-(cyclohexen-1-yl)-1,3-dihydro-1-methyl-2h-1,4-benzodiazepin-2-one but generally known as tetrazepam, which bears US NIH Compound Identifier 25215. European Medicines Agency schedules Tetrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10946MIG. The term TETRAZEPAM is an International Non-Proprietary Name. World Health Organization schedules tetrazepam in its Anatomical Therapeutic Chemical (ATC) Classification. TETRAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tetrazepam under HS 29339190 and SITC 51577. As of Q4 2014, TETRAZEPAM remains the US FDA Preferred Term for this commodity. Tetrazepam bears US NLM identifiers UMLS ID C0076341 and NCI Concept Code C74282. SMILES: CLC1CC2C(=NCC(=O)N(C2CC1)C)C1=CCCCC1.
This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C16H22N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5R6712AY0K, chemically known as 2,4-pyrimidinediamine, 5-((3,5-dimethoxy-4-(2-methoxyethoxy)phenyl)methyl)- but more generally known as tetroxoprim, which bears US NIH Compound Identifier 65450. European Medicines Agency schedules Tetroxoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10953MIG. The term TETROXOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). TETROXOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a mast cell stabilizer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B562K7K56. European Medicines Agency schedules Texacromil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10957MIG. Texacromil generally arises in the molecular formula C14H14O6S. The term TEXACROMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) TEXACROMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule texacromil under HS 29329985 and SITC 51569. As of Q4 2014, TEXACROMIL remains the US FDA Preferred Term for this commodity. Texacromil bears US NLM identifiers UMLS ID C2699924 and NCI Concept Code C76765. SMILES: S(CC(O)COC1C2C(OC(CC2=O)C(=O)O)CCC1)C.
This classification denotes a ribonucleotide reductase inhibitor and pyrimidine antagonist with the molecular formula C10H12FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7607Y95N9S, chemically known as mdl 101,731 but generally known as tezacitabine, which bears US NIH Compound Identifier 6435808. The term TEZACITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule tezacitabine under HS 29349990 and SITC 51579. As of Q4 2014, TEZACITABINE remains the US FDA Preferred Term for this commodity. Tezacitabine bears US NLM identifiers UMLS ID C0253087 and NCI Concept Code C1539. SMILES: C1=CN(C(=O)N=C1N)C2C(=CF)C(C(O2)CO)O.
This classification denotes a pyrimidine antagonist with the molecular formula C10H11F3N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RMW9V5RW38, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-beta-d-ribofuranosyl)-5-(trifluoromethyl)- but generally known as trifluridine, which bears US NIH Compound Identifier 6256. European Medicines Agency schedules Trifluridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11291MIG. The term TRIFLURIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules trifluridine in its Anatomical Therapeutic Chemical (ATC) Classification. TRIFLURIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O.
This classification denotes an indole compound and immunosuppressant with the molecular formula C13H10N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4Z8R6ORS6L, chemically known as 2,6-dioxo-3-phthalimidopiperidine but generally known as thalidomide, which bears US NIH Compound Identifier 5426. European Medicines Agency schedules Thalidomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10958MIG. The term THALIDOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules thalidomide in its Anatomical Therapeutic Chemical (ATC) Classification. THALIDOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thalidomide under HS 29251995 and SITC 51482. As of Q4 2014, THALIDOMIDE remains the US FDA Preferred Term for this commodity. Thalidomide bears US NLM identifiers UMLS ID C0039736 and NCI Concept Code C870. SMILES: O=C1NC(=O)CCC1N1C(=O)C2C(C1=O)CCCC2.
This classification denotes an opioid receptor agonist with the molecular formula C20H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 520D430GDK, chemically known as thebaine, demethyldihydro-, acetate (ester) but generally known as thebacon, which bears US NIH Compound Identifier 10075. European Medicines Agency schedules Thebacon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10959MIG. The term THEBACON is an International Non-Proprietary Name. World Health Organization schedules thebacon in its Anatomical Therapeutic Chemical (ATC) Classification. THEBACON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thebacon under HS 29391100 and SITC 54141. As of Q4 2014, THEBACON remains the US FDA Preferred Term for this commodity. Thebacon bears US NLM identifiers UMLS ID C2984006 and NCI Concept Code C91052. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)CC=C2OC(=O)C.
This classification denotes an opioid receptor agonist C20H23NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65Y58V95HC, chemically known as .delta.6-codeine, acetate, hydrochloride, but more generally known as thebacon hydrochloride, which bears US NIH Compound Identifier 12443397. European Medicines Agency schedules Thebacon hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04769MIG. Most nations, for tariff and trade purposes, schedule thebacon hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, THEBACON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OC1=CC[C@H]2[C@H]3CC4CCC(C5C4[C@]2([C@H]1O5)CCN3C)OC.CL.
This classification denotes an antihelminthic agent with the molecular formula C15H20NOS.C6H4ClO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TU308VI4JY, chemically known as 2-thiophenemethanaminium, n,n-dimethyl-n-(2-phenoxyethyl)-, salt with 4-chlorobenzenesulfonic acid (1:1) but generally known as thenium closilate, which bears US NIH Compound Identifier 20293. European Medicines Agency schedules Thenium closilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10961MIG. The term THENIUM CLOSILATE is an International Non-Proprietary Name. As of Q4 2014, THENIUM CLOSYLATE remains the US FDA Preferred Term for this commodity. Thenium closylate bears US NLM identifiers UMLS ID C0521914 and NCI Concept Code C84199. SMILES: C[N+](C)(CCOC1=CC=CC=C1)CC2=CC=CS2.C1=CC(=CC=C1S(=O)(=O)[O-])Cl.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H19N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E4U52363JE, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-2-pyridinyl-n-(3-thienylmethyl)- but generally known as thenyldiamine, which bears US NIH Compound Identifier 7066. European Medicines Agency schedules Thenyldiamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10962MIG. The term THENYLDIAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). THENYLDIAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thenyldiamine under HS 29349990 and SITC 51579. As of Q4 2014, THENYLDIAMINE remains the US FDA Preferred Term for this commodity. Thenyldiamine bears US NLM identifiers UMLS ID C0076383 and NCI Concept Code C84200. SMILES: S1CC(CN(CCN(C)C)C2NCCCC2)CC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H19N3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZQC1892H9, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-2-pyridinyl-n-(3-thienylmethyl)-, monohydrochloride but more generally known as thenyldiamine hydrochloride, which bears US NIH Compound Identifier 13734. European Medicines Agency schedules Thenyldiamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15510MIG. Most nations, for tariff and trade purposes, schedule thenyldiamine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, THENYLDIAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Thenyldiamine hydrochloride bears US NLM identifiers UMLS ID C0771290 and NCI Concept Code C84201. SMILES: CN(C)CCN(CC1CCSC1)C2CCCCN2.CL.
This classification denotes a bronchodilator with the molecular formula C7H8N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OBD445WZ5P, chemically known as 3,7-dimethylxanthine but generally known as theobromine, which bears US NIH Compound Identifier 5429. European Medicines Agency schedules Theobromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15511MIG. World Health Organization schedules theobromine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O=C1[NH]C(=O)N(C2NCN(C12)C)C. SMILES: O=C1[NH]C(=O)N(C2NCN(C12)C)C.
This classification denotes a bronchodilator C18H33O2.C7H7N4O2.Mg, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L7IL2RTM6, chemically known as magnesium 3,7-dimethylxanthine oleate, but more generally known as theobromine magnesium oleate, which bears US NIH Compound Identifier 57352542. European Medicines Agency schedules Theobromine magnesium oleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15513MIG. Most nations, for tariff and trade purposes, schedule theobromine magnesium oleate under HS 29399990 and SITC 54149. As of Q4 2014, THEOBROMINE MAGNESIUM OLEATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)[O-].CN1CNC2C1C(=O)[N-]C(=O)N2C.[MG+2].
This classification denotes a bronchodilator with the molecular structure C7H7N4O2.C7H5O3.2NA.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, P6VR6P4A5V chemically known as equimolar mixture of sodium theobromine, sodium salicylate and water, but more commonly known as theobromine sodium salicylate, which bears US NIH Compound Identifier 24700. European Medicines Agency schedules Theobromine sodium salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15514MIG. Most nations, for tariff and trade purposes, schedule theobromine sodium salicylate under HS 29399990. SMILES: CN1CNC2C1C(=O)[NH]C(=O)N2C.C1CCC(C(C1)C(=O)[O-])[O-].O.[NA+].[NA+].
This classification denotes a cardiotonic agent with the molecular formula C17H21N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RW8PD99T8G, chemically known as 7-(2-(2-hydroxy-2-(3,4-dihydroxyphenyl)ethylamino)ethyl)theophylline but generally known as theodrenaline, which bears US NIH Compound Identifier 71857. European Medicines Agency schedules Theodrenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10963MIG. The term THEODRENALINE is an International Non-Proprietary Name. World Health Organization schedules theodrenaline in its Anatomical Therapeutic Chemical (ATC) Classification. THEODRENALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule theodrenaline under HS 29395900 and SITC 54145. As of Q4 2014, THEODRENALINE remains the US FDA Preferred Term for this commodity. Theodrenaline bears US NLM identifiers UMLS ID C0068955 and NCI Concept Code C90826. SMILES: OC(CNCCN1C2C(N(C(=O)N(C2=O)C)C)NC1)C1CC(O)C(O)CC1.
This classification denotes a bronchodilator and alkaloid with the molecular formula C7H8N4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C137DTR5RG, chemically known as 3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione but generally known as theophylline, which bears US NIH Compound Identifier 2153. European Medicines Agency schedules Theophylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15516MIG. World Health Organization schedules theophylline in its Anatomical Therapeutic Chemical (ATC) Classification. THEOPHYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, THEOPHYLLINE remains the US FDA Preferred Term for this commodity. Theophylline bears US NLM identifiers UMLS ID C0039771 and NCI Concept Code C872. SMILES: O=C1N(C(=O)N(C2NC[NH]C12)C)C.
This classification denotes an antihelminthic agent with the molecular formula C10H7N3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier N1Q45E87DT, chemically known as 2-(1,3-thiazol-4-yl)benzimidazole but more generally known as thiabendazole, which bears US NIH Compound Identifier 5430. European Medicines Agency schedules Tiabendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10996MIG. The term THIABENDAZOLE is an International Non-Proprietary Name World Health Organization schedules thiabendazole in its Anatomical Therapeutic Chemical (ATC) Classification. Thiabendazole bears US NLM identifiers UMLS ID C0039832 and NCI Concept Code C873. SMILES: C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3.
This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KW75J7708X. European Medicines Agency schedules Thiacetarsamide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10965MIG. Thiacetarsamide sodium generally arises in the molecular formula C11H10ASNO5S2.2NA. The term THIACETARSAMIDE SODIUM is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule thiacetarsamide sodium under HS 29309085. As of Q4 2014, THIACETARSAMIDE SODIUM remains US FDA's Preferred Term for this commodity. Thiacetarsamide sodium bears US NLM identifiers UMLS ID C0521911 and NCI Concept Code C81557. SMILES: C1CC(CCC1C(=O)N)[AS](SCC(=O)[O-])SCC(=O)[O-].[NA+].[NA+].
This classification denotes a barbiturate with the molecular formula C13H16N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ENV72C33QD, chemically known as 4,6(1h,5h)-pyrimidinedione, 5-(2-cyclohexen-1-yl)dihydro-5-(2-propenyl)-2-thioxo- (9ci) but generally known as thialbarbital, which bears US NIH Compound Identifier 3032306. European Medicines Agency schedules Thialbarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10966MIG. The term THIALBARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). THIALBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thialbarbital under HS 29335400 and SITC kg. As of Q4 2014, THIALBARBITAL remains the US FDA Preferred Term for this commodity. Thialbarbital bears US NLM identifiers UMLS ID C0521929 and NCI Concept Code C77631. SMILES: S=C1NC(=O)C(C2CCCC=C2)(CC=C)C(=O)N1.
This classification denotes an antithyroid agent with the molecular formula C4H6N2S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 554Z48XN5E, chemically known as 1,3-dihydro-1-methyl-2h-imidazole-2-thione but more generally known as methimazole, which bears U.S. National Institutes of Health Compound Identifier 1349907. European Medicines Agency schedules Thiamazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10967MIG. The term THIAMAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methimazole in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.
This classification denotes a b vitamin with the molecular formula C12H17N4OS.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X66NSO3N35, chemically known as 67-03-8 (chloride, hcl) but generally known as thiamine, which bears US NIH Compound Identifier 1130. European Medicines Agency schedules Thiamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. The term THIAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules thiamine in its Anatomical Therapeutic Chemical (ATC) Classification. THIAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thiamine under HS 29362200 and SITC 54113. As of Q4 2014, THIAMINE remains the US FDA Preferred Term for this commodity. Thiamine bears US NLM identifiers UMLS ID C0039840 and NCI Concept Code C874. SMILES: CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.
This classification denotes a b vitamin with the molecular formula C12H17N4OS.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JIJ7B8T57F, chemically known as 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium bromide, but more generally known as thiamine bromide, which bears US NIH Compound Identifier 71284. European Medicines Agency schedules thiamine bromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine bromide under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCO.[BR-].
This classification denotes a b vitamin with the molecular formula C12H17N4OS.Cl.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M572600E5P, chemically known as thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, monohydrochloride, but more generally known as thiamine chloride hydrochloride, which bears US NIH Compound Identifier 1130. European Medicines Agency schedules thiamine chloride hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine chloride hydrochloride under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCO.CL.[CL-].
This classification denotes a b vitamin C24H34N8O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJV8K21YKL, chemically known as n,n'-(dithiobis(2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl))bis(n-((4-amino-2-methyl-5-pyrimidinyl)methyl)formamide), but more generally known as thiamine disulfide, which bears US NIH Compound Identifier 5432. European Medicines Agency schedules Thiamine disulfide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04797MIG. Most nations, for tariff and trade purposes, schedule thiamine disulfide under HS 29362200 and SITC 54113. As of Q4 2014, THIAMINE DISULFIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1NC(C(CN1)CN(/C(=C(\SS/C(=C(\N(C=O)CC2C(NC(NC2)C)N)/C)/CCO)/CCO)/C)C=O)N.
This classification denotes a b vitamin C24H34N8O4S2.2HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Z281VOQ5O, chemically known as formamide, n,n'-(dithiobis(2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl))bis(n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-, (z,z)-, dinitrate (salt), but more generally known as thiamine disulfide nitrate, which bears US NIH Compound Identifier 44630506. Most nations, for tariff and trade purposes, schedule thiamine disulfide nitrate under HS 29362200 and SITC 54113. As of Q4 2014, THIAMINE DISULFIDE NITRATE remains US FDA's Preferred Term for this commodity. SMILES: CC1NC(C(CN1)CN(/C(=C(\SS/C(=C(\N(C=O)CC2C(NC(NC2)C)N)/C)/CCO)/CCO)/C)C=O)N.[N+](=O)([O-])O.[N+](=O)([O-])O.
This classification denotes a b vitamin C24H36N8O10P2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HIX040UVAZ, chemically known as formamide, n,n'-(dithiobis[1-methyl-2-(2-(phosphonooxy)ethyl]-2,1-ethenediyl))bis(n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-, but more generally known as thiamine disulfide phosphate, which bears US NIH Compound Identifier 3034217. European Medicines Agency schedules Thiamine disulfide phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22636. Most nations, for tariff and trade purposes, schedule thiamine disulfide phosphate under HS 29362200 and SITC 54113. As of Q4 2014, THIAMINE DISULFIDE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CC1NC(C(CN1)CN(/C(=C(\SS/C(=C(\N(C=O)CC2C(NC(NC2)C)N)/C)/CCOP(=O)(O)O)/CCOP(=O)(O)O)/C)C=O)N.
This classification denotes a b vitamin with the molecular formula C12H17N4OS.Cl.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M572600E5P, chemically known as 67-03-8 (chloride, hcl) but more generally known as thiamine hcl, which bears US NIH Compound Identifier 1130. European Medicines Agency schedules Thiamine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04798MIG. Most nations, for tariff and trade purposes, schedule thiamine hydrochloride under HS 29362200 and SITC 54113. As of Q4 2014, THIAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Thiamine hydrochloride bears US NLM identifiers UMLS ID C0770309 and NCI Concept Code C48025. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCO.CL.[CL-].
This classification denotes a b vitamin with the molecular formula C12H17N4OS.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X66NSO3N35, chemically known as thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride (1:1), but more generally known as thiamine monochloride, which bears US NIH Compound Identifier 6042. European Medicines Agency schedules thiamine monochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine monochloride under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCO.[CL-].
This classification denotes a b vitamin with the molecular formula C12H17N4OS.NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8K0I04919X, chemically known as 3-(4-amino-2-methylpyrimidyl-5-methyl)-4-methyl-5,beta-hydroxyethylthiazolium nitrate but more generally known as thiamine mononitrate, which bears US NIH Compound Identifier 10762. European Medicines Agency schedules Thiamine mononitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15528MIG. Most nations, for tariff and trade purposes, schedule thiamine mononitrate under HS 29362200 and SITC 54113. As of Q4 2014, THIAMINE MONONITRATE remains US FDA's Preferred Term for this commodity. Thiamine mononitrate bears US NLM identifiers UMLS ID C0039844 and NCI Concept Code C87669. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCO.[N+](=O)([O-])[O-].
This classification denotes a b vitamin with the molecular formula C12H18N4O4PS.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P712T71Q3T, chemically known as thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-4-methyl-5-(2-(phosphonooxy)ethyl)-, chloride (1:1), but more generally known as thiamine monophosphate chloride, which bears US NIH Compound Identifier 10761. European Medicines Agency schedules thiamine monophosphate chloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine monophosphate chloride under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCOP(=O)(O)O.[CL-].
This classification denotes a b vitamin with the molecular formula C24H36N8O10P2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HIX040UVAZ, chemically known as formamide, n,n'-(dithiobis[1-methyl-2-(2-(phosphonooxy)ethyl]-2,1-ethenediyl))bis(n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-, but more generally known as thiamine monophosphate disulfide, which bears US NIH Compound Identifier 3034217. European Medicines Agency schedules thiamine monophosphate disulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine monophosphate disulfide under HS 29362200. SMILES: CC1NC(C(CN1)CN(/C(=C(\SS/C(=C(\N(C=O)CC2C(NC(NC2)C)N)/C)/CCOP(=O)(O)O)/CCOP(=O)(O)O)/C)C=O)N.
This classification denotes a b vitamin with the molecular formula C12H17N4OS.NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8K0I04919X, chemically known as 3-(4-amino-2-methylpyrimidyl-5-methyl)-4-methyl-5,beta-hydroxyethylthiazolium nitrate but more generally known as thiamine mononitrate, which bears US NIH Compound Identifier 10762. European Medicines Agency schedules Thiamine mononitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15528MIG. Most nations, for tariff and trade purposes, schedule thiamine nitrate under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCO.[N+](=O)([O-])[O-].
This classification denotes a b vitamin with the molecular formula C15H24N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UI32MM3XE3, chemically known as n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-1-methyl-2-(propyldithio)-1-butenyl)formamide, but more generally known as thiamine propyl disulfide, which bears US NIH Compound Identifier 4963. European Medicines Agency schedules thiamine propyl disulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine propyl disulfide under HS 29362200. SMILES: CCCSS/C(=C(\C)/N(CC1CNC(NC1N)C)C=O)/CCO.
This classification denotes a b vitamin with the molecular formula C12H19N4O7P2S.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XMK8K8EVIU, chemically known as thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-4-methyl-5-(4,6,6-trihydroxy-4,6-dioxido-3,5-dioxa-4,6-diphosphahex-1-yl)-, chloride (1:1), but more generally known as thiamine pyrophosphate chloride, which bears US NIH Compound Identifier 9068. European Medicines Agency schedules thiamine pyrophosphate chloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine pyrophosphate chloride under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCOP(=O)(O)OP(=O)(O)O.[CL-].
This classification denotes a b vitamin with the molecular formula C17H26N4O3S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3557LWB27, chemically known as n-((4-amino-2-methylpyrimidin-5-yl)methyl)-n-((1e)-4-hydroxy-1-methyl-2-((tetrahydrofuran-2-ylmethyl)disulfanyl)but-1-en-1-yl)formamide hydrochloride, but more generally known as thiamine tetrahydrofurfuryl disulfide hydrochloride, which bears US NIH Compound Identifier 3036228. European Medicines Agency schedules thiamine tetrahydrofurfuryl disulfide hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine tetrahydrofurfuryl disulfide hydrochloride under HS 29362200. SMILES: CC1NCC(C(N1)N)CN(C=O)/C(=C(\CCO)/SSCC2CCCO2)/C.CL.
This classification denotes a b vitamin with the molecular formula C12H19N4O10P3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 464M6AQ7IV, chemically known as thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-4-methyl-5-(4,6,8,8-tetrahydroxy-3,5,7-trioxa-4,6,8-triphosphaoct-1-yl)-, inner salt, p,p',p''-trioxide, but more generally known as thiamine triphosphate, which bears US NIH Compound Identifier 511. European Medicines Agency schedules thiamine triphosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine triphosphate under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCOP(=O)([O-])OP(=O)(O)OP(=O)(O)O.
This classification denotes a b vitamin with the molecular formula C12H19N4O10P3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 464M6AQ7IV, chemically known as thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-4-methyl-5-(4,6,8,8-tetrahydroxy-3,5,7-trioxa-4,6,8-triphosphaoct-1-yl)-, inner salt, p,p',p''-trioxide, but more generally known as thiamine triphosphorate, which bears US NIH Compound Identifier 18989. European Medicines Agency schedules thiamine triphosphorate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine triphosphorate under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCOP(=O)([O-])OP(=O)(O)OP(=O)(O)O.
This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C12H15Cl2NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FLQ7571NPM, chemically known as (+-)-threo-2,2-dichloro-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)acetamide but generally known as thiamphenicol, which bears US NIH Compound Identifier 5433. European Medicines Agency schedules Thiamphenicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10970MIG. The term THIAMPHENICOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules thiamphenicol in its Anatomical Therapeutic Chemical (ATC) Classification. THIAMPHENICOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thiamphenicol under HS 29414000 and SITC 54139. As of Q4 2014, THIAMPHENICOL remains the US FDA Preferred Term for this commodity. Thiamphenicol bears US NLM identifiers UMLS ID C0039854 and NCI Concept Code C61969. SMILES: CS(=O)(=O)C1=CC=C(C=C1)C(C(CO)NC(=O)C(CL)CL)O.
This classification denotes a protein synthesis inhibitor and antibiotic C14H18Cl2N2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88VGC22BWE, chemically known as glycine, (2r,3r)-2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-(methylsulfonyl)phenyl)propyl ester, hydrochloride (1:1), but more generally known as thiamphenicol aminoacetate hydrochloride, which bears US NIH Compound Identifier 3039735. European Medicines Agency schedules Thiamphenicol aminoacetate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04802MIG. Most nations, for tariff and trade purposes, schedule thiamphenicol aminoacetate hydrochloride under HS 29414000 and SITC 54139. As of Q4 2014, THIAMPHENICOL AMINOACETATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CS(=O)(=O)C1CCC(CC1)[C@H]([C@@H](COC(=O)CN)NC(=O)C(CL)CL)O.CL.
This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C14H18Cl2N2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5H94CY6V6, chemically known as glycine, (2r,3r)-2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-(methylsulfonyl)phenyl)propyl ester, but more generally known as thiamphenicol glycinate, which bears US NIH Compound Identifier 115817. European Medicines Agency schedules thiamphenicol glycinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10970MIG. Most nations, for tariff purposes, schedule thiamphenicol glycinate under HS 29414000. SMILES: CS(=O)(=O)C1CCC(CC1)[C@H]([C@@H](COC(=O)CN)NC(=O)C(CL)CL)O.
This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C14H18Cl2N2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88VGC22BWE, chemically known as glycine, (2r,3r)-2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-(methylsulfonyl)phenyl)propyl ester, hydrochloride (1:1), but more generally known as thiamphenicol glycinate hydrochloride, which bears US NIH Compound Identifier 197006. European Medicines Agency schedules thiamphenicol glycinate hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10970MIG. Most nations, for tariff purposes, schedule thiamphenicol glycinate hydrochloride under HS 29414000. SMILES: CS(=O)(=O)C1CCC(CC1)[C@H]([C@@H](COC(=O)CN)NC(=O)C(CL)CL)O.CL.
This classification denotes a barbiturate and anesthetic agent with the molecular formula C12H18N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01T23W89FR, chemically known as 4,6(1h,5h)-pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo- (9ci) but generally known as thiamylal, which bears US NIH Compound Identifier 3032285. European Medicines Agency schedules Thiamylal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15530MIG. As of Q4 2014, THIAMYLAL remains the US FDA Preferred Term for this commodity. Thiamylal bears US NLM identifiers UMLS ID C0039855 and NCI Concept Code C66596. SMILES: CCCC(C)C1(C(=O)NC(=S)NC1=O)CC=C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H23N2S.CH3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IA16WBX317, chemically known as 10h-phenothiazine-10-ethanaminium, n,n,n,alpha-tetramethyl-, methyl sulfate but more generally known as thiazinamium methylsulfate, which bears US NIH Compound Identifier 6015. European Medicines Agency schedules Thiazinamium metilsulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10971MIG. The term THIAZINAMIUM METILSULFATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). Most nations, for tariff and trade purposes, schedule thiazinamium metilsulfate under HS 29343090 and SITC 51578. As of Q4 2014, THIAZINAMIUM METILSULFATE remains US FDA's Preferred Term for this commodity. Thiazinamium metilsulfate bears US NLM identifiers UMLS ID C2825477 and NCI Concept Code C81151. SMILES: CC(CN1C2CCCCC2SC3C1CCCC3)[N+](C)(C)C.COS(=O)(=O)[O-].
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H23N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 666W2P28N2, chemically known as 10h-phenothiazine-10-ethanaminium, n,n,n,alpha-tetramethyl-, methyl sulfate but generally known as thiazinamium, which bears US NIH Compound Identifier 6015. European Medicines Agency schedules Thiazinamium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15532MIG. As of Q4 2014, THIAZINAMIUM remains the US FDA Preferred Term for this commodity. Thiazinamium bears US NLM identifiers UMLS ID C0039857 and NCI Concept Code C84203. SMILES: S1C2C(N(CC([N](C)(C)C)C)C3C1CCCC3)CCCC2.S(=O)(=O)(OC)O.
This classification denotes an antiemetic agent with the molecular formula C22H29N3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ETK1WAF6R, chemically known as 10h-phenothiazine, 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)- but generally known as thiethylperazine, which bears US NIH Compound Identifier 5440. European Medicines Agency schedules Thiethylperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10973MIG. The term THIETHYLPERAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules thiethylperazine in its Anatomical Therapeutic Chemical (ATC) Classification. THIETHYLPERAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thiethylperazine under HS 29343010 and SITC 51578. As of Q4 2014, THIETHYLPERAZINE remains the US FDA Preferred Term for this commodity. Thiethylperazine bears US NLM identifiers UMLS ID C0039865 and NCI Concept Code C62081. SMILES: S1C2C(N(CCCN3CCN(CC3)C)C3C1CCCC3)CC(SCC)CC2.
This classification denotes a topical anti-infective agent and industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2225PI3MOV. European Medicines Agency schedules Thiomersal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10980MIG. Thiomersal generally arises in the molecular formula C9H9HGO2S.NA. The term 'thiomersal' is a European Pharmacopoeia designation. THIOMERSAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Thimerosal or thiomersal bears US NLM identifiers UMLS ID C0039867 and NCI Concept Code C47751. SMILES: CC[HG]SC1=CC=CC=C1C(=O)O.
This classification denotes a barbiturate with the molecular structure C10H16N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 2N0251U7JH chemically known as 5-ethyldihydro-5-(1-methylpropyl)-2-thioxo-4,6(1h,5h)-pyrimidinedione but generally known as thiobutabarbital, which bears US NIH Compound Identifier 3032372. European Medicines Agency schedules Thiobutabarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15533MIG. As of Q4 2014, THIOBUTABARBITAL remains the US FDA Preferred Term for this commodity. Thiobutabarbital bears US NLM identifiers UMLS ID C0076448 and NCI Concept Code C87670. SMILES: CCC(C)C1(C(=O)NC(=S)N=C1[O-])CC.[NA+].
This classification denotes a colchicine analog and hysterosalpingography adjunct with the molecular formula C27H33NO10S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T1X8S697GT, chemically known as colchicoside, 10-thio- (8ci) but generally known as thiocolchicoside, which bears US NIH Compound Identifier 72067. European Medicines Agency schedules Thiocolchicoside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10976MIG. World Health Organization schedules thiocolchicoside in its Anatomical Therapeutic Chemical (ATC) Classification. THIOCOLCHICOSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thiocolchicoside under HS 29399900 and SITC 54149. As of Q4 2014, THIOCOLCHICOSIDE remains the US FDA Preferred Term for this commodity. SMILES: S(C1C(=O)CC2C(NC(=O)C)CCC3C(C2CC1)C(OC)C(OC)C(OC1OC(C(O)C(O)C1O)CO)C3)C.
This classification denotes a purine antagonist and amidophosphoribosyltransferase inhibitor with the molecular formula C5H5N5S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FTK8U1GZNX, chemically known as 6h-purine-6-thione, 2-amino-1,7-dihydro- but generally known as thioguanine, which bears US NIH Compound Identifier 2723601. European Medicines Agency schedules Tioguanine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11084MIG. World Health Organization schedules thioguanine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, THIOGUANINE remains the US FDA Preferred Term for this commodity. Thioguanine bears US NLM identifiers UMLS ID C0039902 and NCI Concept Code C876. SMILES: S=C1NC([NH]C2NC[NH]C12)N.
This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6M8CV4TKXL. European Medicines Agency schedules Thiohexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10979MIG. Thiohexamide generally arises in the molecular formula C14H20N2O3S2. The term THIOHEXAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, list 5.) THIOHEXAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule thiohexamide under HS 29350090 and SITC 51580. As of Q4 2014, THIOHEXAMIDE remains US FDA's Preferred Term for this commodity. Thiohexamide bears US NLM identifiers UMLS ID C2348771 and NCI Concept Code C72861. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CCC(SC)CC1.
This classification denotes a barbiturate and anesthetic agent with the molecular formula C11H17N2O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49Y44QZL70, chemically known as 4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-, monosodium salt but more generally known as thiopental sodium, which bears US NIH Compound Identifier 3000714. European Medicines Agency schedules Thiopental sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10981MIG. The term THIOPENTAL SODIUM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). Most nations, for tariff and trade purposes, schedule thiopental sodium under HS 29335995. As of Q4 2014, THIOPENTAL SODIUM remains US FDA's Preferred Term for this commodity. Thiopental sodium bears US NLM identifiers UMLS ID C0936073 and NCI Concept Code C66599. SMILES: CCCC(C)C1(C(=O)NC(=S)[N-]C1=O)CC.[NA+].
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN202. This VA Drug Class (CN202) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE ANESTHETICS.
This classification denotes a phenothiazine with the molecular formula C23H28ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0JFY081Q2X, chemically known as 1-piperazineethanol, 4-(3-(2-chlorophenothiazin-10-yl)propyl)-, acetate (ester) but generally known as thiopropazate, which bears US NIH Compound Identifier 6762. European Medicines Agency schedules Thiopropazate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10982MIG. World Health Organization schedules thiopropazate in its Anatomical Therapeutic Chemical (ATC) Classification. THIOPROPAZATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thiopropazate under HS 29343090 and SITC 51578. As of Q4 2014, THIOPROPAZATE remains the US FDA Preferred Term for this commodity. SMILES: CLC1CC2N(CCCN3CCN(CC3)CCOC(=O)C)C3C(SC2CC1)CCCC3.
This classification denotes a phenothiazine with the molecular formula C23H28ClN3O2S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2K5E7BGM8X, chemically known as 2-(4-(3-(2-chlorophenothiazin-10-yl)propyl)piperazin-1-yl)ethyl acetate dihydrochloride, but more generally known as thiopropazate dihydrochloride, which bears US NIH Compound Identifier 67416. European Medicines Agency schedules thiopropazate dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10982MIG. Most nations, for tariff purposes, schedule thiopropazate dihydrochloride under HS 29343090. SMILES: CC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)CL.CL.CL.
This classification denotes an antipsychotic agent with the molecular formula C22H30N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJ050AQ56X, chemically known as 10h-phenothiazine-2-sulfonamide, n,n-dimethyl-10-(3-(4-methyl-1-piperazinyl)propyl)- but generally known as thioproperazine, which bears US NIH Compound Identifier 9429. European Medicines Agency schedules Thioproperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10983MIG. The term THIOPROPERAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules thioproperazine in its Anatomical Therapeutic Chemical (ATC) Classification. THIOPROPERAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thioproperazine under HS 29350090 and SITC 51580. As of Q4 2014, THIOPROPERAZINE remains the US FDA Preferred Term for this commodity. Thioproperazine bears US NLM identifiers UMLS ID C0039936 and NCI Concept Code C73292. SMILES: S1C2C(N(CCCN3CCN(CC3)C)C3C1CCCC3)CC(S(=O)(=O)N(C)C)CC2.
This classification denotes an antipsychotic agent with the molecular formula C22H30N4O2S2.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71P630M192, chemically known as n,n-dimethyl-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine-2-sulfonamide, dimethanesulfonate, but more generally known as thioproperazine dimesilate, which bears US NIH Compound Identifier 92178. European Medicines Agency schedules thioproperazine dimesilate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10983MIG. Most nations, for tariff purposes, schedule thioproperazine dimesilate under HS 29350090. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C22H30N4O2S2.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71P630M192, chemically known as phenothiazine-2-sulfonamide, n,n-dimethyl-10-(3-(4-methyl-1-piperazinyl)propyl)-, dimethanesulfonate but more generally known as thioproperazine mesilate, which bears US NIH Compound Identifier 92178. Most nations, for tariff and trade purposes, schedule thioproperazine mesylate under HS 29350090. As of Q4 2014, THIOPROPERAZINE MESYLATE remains US FDA's Preferred Term for this commodity. Thioproperazine mesylate bears US NLM identifiers UMLS ID C0770896 and NCI Concept Code C80010. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O.
This classification denotes a xanthine oxidase inhibitor and uricosuric agent with the molecular formula C5H4N4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 79F9I2R16M, chemically known as 5h-pyrazolo(3,4-d)pyrimidine-4-thione but generally known as tisopurine, which bears US NIH Compound Identifier 667510. European Medicines Agency schedules Tisopurine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11121MIG. The term TISOPURINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules tisopurine in its Anatomical Therapeutic Chemical (ATC) Classification. TISOPURINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Thiopurinol or tisopurine bears US NLM identifiers UMLS ID C0076516 and NCI Concept Code C80872. SMILES: C1=C2C(=NC=NC2=S)NN1.
This classification denotes an antipsychotic agent with the molecular formula C21H26N2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N3D6TG58NI, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)- but generally known as thioridazine, which bears US NIH Compound Identifier 5452. European Medicines Agency schedules Thioridazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10984MIG. The term THIORIDAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules thioridazine in its Anatomical Therapeutic Chemical (ATC) Classification. THIORIDAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thioridazine under HS 29343010 and SITC 51578. As of Q4 2014, THIORIDAZINE remains the US FDA Preferred Term for this commodity. Thioridazine bears US NLM identifiers UMLS ID C0039943 and NCI Concept Code C61971. SMILES: S1C2C(N(CCC3N(CCCC3)C)C3C1CCCC3)CC(SC)CC2.
This classification denotes an antipsychotic agent with the molecular formula C21H26N2S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4WCI67NK8M, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)- but more generally known as thioridazine hydrochloride, which bears US NIH Compound Identifier 5452. European Medicines Agency schedules Thioridazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04821MIG. Most nations, for tariff and trade purposes, schedule thioridazine hydrochloride under HS 29343010 and SITC 51578. As of Q4 2014, THIORIDAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Thioridazine hydrochloride bears US NLM identifiers UMLS ID C0700499 and NCI Concept Code C29498. SMILES: CN1CCCCC1CCN2C3CCCCC3SC4C2CC(CC4)SC.CL.
This classification denotes an ethylenimine compound with the molecular formula C6H12N3PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 905Z5W3GKH, chemically known as 1,1,1-phosphinothioylidynetrisaziridine but more generally known as thiotepa, which bears US NIH Compound Identifier 5453. European Medicines Agency schedules Thiotepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10985MIG. The term THIOTEPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules thiotepa in its Anatomical Therapeutic Chemical (ATC) Classification. THIOTEPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule thiotepa under HS 29339990 and SITC 51577. As of Q4 2014, THIOTEPA remains US FDA's Preferred Term for this commodity. Thiotepa bears US NLM identifiers UMLS ID C0039871 and NCI Concept Code C875. SMILES: S=P(N1CC1)(N1CC1)N1CC1.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P93TO196Z. European Medicines Agency schedules Thiotetrabarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10986MIG. Thiotetrabarbital generally arises in the molecular formula C12H20N2O2S. The term THIOTETRABARBITAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) THIOTETRABARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thiotetrabarbital under HS 29335400 and SITC kg. As of Q4 2014, THIOTETRABARBITAL remains the US FDA Preferred Term for this commodity. Thiotetrabarbital bears US NLM identifiers UMLS ID C2699931 and NCI Concept Code C76099. SMILES: S=C1NC(=O)C(C(CCC)CC)(CC)C(=O)N1.
This classification denotes an antipsychotic agent with the molecular formula C23H29N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7318FJ13YJ, chemically known as cp-12,252-1 base but generally known as thiothixene, which bears US NIH Compound Identifier 5454. European Medicines Agency schedules Tiotixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11094MIG. The term TIOTIXENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules thiothixene in its Anatomical Therapeutic Chemical (ATC) Classification. Thiothixene or tiotixene bears US NLM identifiers UMLS ID C0039955 and NCI Concept Code C47752. SMILES: CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.
This classification denotes a nitric oxide synthetase inhibitor with the molecular formula C4H4N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59X161SCYL, chemically known as 2,3-dihydro-2-thioxo-4(1h)-pyrimidinone but generally known as 2-thiouracil, which bears US NIH Compound Identifier 1269845. European Medicines Agency schedules Thiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15541MIG. Most nations schedule thiouracil under HS 29335990 and SITC 51576. As of Q4 2014, THIOURACIL remains the US FDA Preferred Term for this commodity. Thiouracil bears US NLM identifiers UMLS ID C0039957 and NCI Concept Code C29856. SMILES: S=C1[NH]C(=O)CC[NH]1.
This classification denotes a fungicide with the molecular formula C6H12N2S4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 0D771IS0FH, chemically known as thiuram disulfide, tetramethyl- but more generally known as thiram, which bears U.S. NIH Compound Identifier 5455. European Medicines Agency schedules Thiram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10987MIG. The term THIRAM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13 No. 1, 1999, List 41). World Health Organization schedules thiram in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. THIRAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H22N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R79646H5Z8, chemically known as pyrimidine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)- but generally known as thonzylamine, which bears US NIH Compound Identifier 5457. European Medicines Agency schedules Thonzylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10988MIG. The term THONZYLAMINE is an International Non-Proprietary Name. World Health Organization schedules thonzylamine in its Anatomical Therapeutic Chemical (ATC) Classification. THONZYLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thonzylamine under HS 29335995 and SITC 51576. As of Q4 2014, THONZYLAMINE remains the US FDA Preferred Term for this commodity. Thonzylamine bears US NLM identifiers UMLS ID C0175162 and NCI Concept Code C84204. SMILES: O(C1CCC(CN(CCN(C)C)C2NCCCN2)CC1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H22N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K9YKD48Y4, chemically known as 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)pyrimidine hydrochloride, but more generally known as thonzylamine hydrochloride, which bears US NIH Compound Identifier 6136. European Medicines Agency schedules thonzylamine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10988MIG. Most nations, for tariff purposes, schedule thonzylamine hydrochloride under HS 29335995. Thonzylamine hydrochloride bears US NLM identifiers UMLS ID C1563662 and NCI Concept Code C84205. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2NCCCN2.CL.
This classification denotes an enzyme formed from prothrombin that converts fibrinogen to fibrin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25ADE2236L. European Medicines Agency schedules Thrombin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15544MIG. The term THROMBIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29 and see Volume 22, No. 1, 2008, List 59). As of Q4 2014, THROMBIN remains the US FDA Preferred Term for this commodity.
Used in the treatment of B-cell acute lymphoblastic leukemia [ALL] treatment
This classification denotes a therapeutic hormone with the molecular formula C21H40N8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) M0H0SK3AD5, chemically known as l-valine, n-(n-(n(sup 2)-l-arginyl-l-lysyl)-l-alpha-aspartyl)- but more generally known as thymocartin, which bears US NIH Compound Identifier 3033954. European Medicines Agency schedules Thymocartin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10991MIG. The term THYMOCARTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). THYMOCARTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule thymocartin under HS 29371900 and SITC 54154. As of Q4 2014, THYMOCARTIN remains US FDA's Preferred Term for this commodity. Thymocartin bears US NLM identifiers UMLS ID C0624592 and NCI Concept Code C90959. SMILES: O=C(NC(C(=O)NC(C(C)C)C(=O)O)CC(=O)O)C(NC(=O)C(N)CCC/N=C(/N)N)CCCCN.
This classification denotes a topical anti-infective agent with the molecular formula C20H24I2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A51HJM3XSU, chemically known as 5,5-diisopropyl-2,2-dimethylbiphenyl-4,4-diyl dihypoiodite but generally known as thymol iodide, which bears US NIH Compound Identifier 11088. European Medicines Agency schedules Thymol iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15556MIG. As of Q4 2014, THYMOL IODIDE remains the US FDA Preferred Term for this commodity. Thymol iodide bears US NLM identifiers UMLS ID C0301298 and NCI Concept Code C84206. SMILES: IOC1C(C(C)C)CC(C2CC(C(C)C)C(OI)CC2C)C(C1)C.
This classification denotes an immunostimulant with the molecular formula C30H49N9O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3Y80ZF13F, chemically known as l-tyrosine, n-(n-(n-(n(sup 2)-l-arginyl-l-lysyl)-l-alpha-aspartyl)-l-valyl)- but generally known as thymopentin, which bears US NIH Compound Identifier 50587. European Medicines Agency schedules Thymopentin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10993MIG. The term THYMOPENTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules thymopentin in its Anatomical Therapeutic Chemical (ATC) Classification. THYMOPENTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule thymopentin under HS 29371900 and SITC 54154. As of Q4 2014, THYMOPENTIN remains the US FDA Preferred Term for this commodity. Thymopentin bears US NLM identifiers UMLS ID C0080225 and NCI Concept Code C1294. SMILES: O=C(NC(C(=O)NC(C(C)C)C(=O)NC(CC1CCC(O)CC1)C(=O)O)CC(=O)O)C(NC(=O)C(N)CCC/N=C(/N)N)CCCCN.
This classification denotes a pituitary agent with the molecular formula C975H1513N267O304S26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AVX3D5A4LM, more generally known as thyrotropin alfa. European Medicines Agency schedules thyrotropin alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12610MIG. The term THYROTROPIN ALFA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 2 1999, list 40.
This classification denotes a thyroid agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9MU67I9K5I. European Medicines Agency schedules Tyromedan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11370MIG. Tyromedan generally arises in the molecular formula C21H24I3NO4. The term TYROMEDAN is an International Non-Proprietary Name or INN. TYROMEDAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Thyromedan or tyromedan bears US NLM identifiers UMLS ID C2825356 and NCI Concept Code C80844. SMILES: CCN(CC)CCOC(=O)CC1=CC(=C(C(=C1)I)OC2=CC(=C(C=C2)OC)I)I.Cl.
This classification denotes a hypothalmic hormone with the molecular formula C16H22N6O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 5Y5F15120W, chemically known as l-prolinamide, 5-oxo-l-prolyl-l-histidyl- but more generally known as protirelin, which bears U.S. National Institutes of Health Compound Identifier 32281. The European Medicines Agency schedules Protirelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10142MIG. The term PROTIRELIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). The World Health Organization schedules protirelin in its Anatomical Therapeutic Chemical (ATC) Classification. PROTIRELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C1CC(N(C1)C(=O)C(CC2=CN=CN2)NC(=O)C3CCC(=O)N3)C(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C12H10N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74L3DXN051, chemically known as 2-propenoic acid, 3-(6-(methylthio)-4-oxo-3(4h)-quinazolinyl)-, (e)- but generally known as tiacrilast, which bears US NIH Compound Identifier 6435375. European Medicines Agency schedules Tiacrilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10997MIG. The term TIACRILAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). TIACRILAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiacrilast under HS 29335995 and SITC 51576. As of Q4 2014, TIACRILAST remains the US FDA Preferred Term for this commodity. Tiacrilast bears US NLM identifiers UMLS ID C0145898 and NCI Concept Code C73059. SMILES: CSC1=CC2=C(C=C1)N=CN(C2=O)/C=C/C(=O)O.
This classification denotes a histamine-1 receptor antagonist C12H9N2O3S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4PG8A6UTDX, chemically known as sodium (e)-6-(methylthio)-4-oxo-3(4h)-quinazolineacrylate, monohydrate, but more generally known as tiacrilast sodium, which bears US NIH Compound Identifier 23665632. Most nations, for tariff and trade purposes, schedule tiacrilast sodium under HS 29335995 and SITC 51576. As of Q4 2014, TIACRILAST SODIUM remains US FDA's Preferred Term for this commodity. Tiacrilast sodium bears US NLM identifiers UMLS ID C2348786 and NCI Concept Code C72862. SMILES: CSC1CCC2C(C1)C(=O)N(CN2)/C=C/C(=O)[O-].O.[NA+].
This classification denotes a fatty alcohol and hypolipidemic agent with the molecular formula C14H30O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22251270CX, chemically known as 1,10-bis(hydroxyethylthio)decane but generally known as tiadenol, which bears US NIH Compound Identifier 23403. European Medicines Agency schedules Tiadenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10998MIG. World Health Organization schedules tiadenol in its Anatomical Therapeutic Chemical (ATC) Classification. TIADENOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiadenol under HS 29309085 and SITC 51549. As of Q4 2014, TIADENOL remains the US FDA Preferred Term for this commodity. SMILES: S(CCCCCCCCCCSCCO)CCO.
This classification denotes an anticonvulsant agent with the molecular formula C20H25NO2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z80I64HMNP, chemically known as 3-piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-, (r)- but generally known as tiagabine, which bears US NIH Compound Identifier 60648. European Medicines Agency schedules Tiagabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11000MIG. The term TIAGABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules tiagabine in its Anatomical Therapeutic Chemical (ATC) Classification. TIAGABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiagabine under HS 29349990 and SITC 51579. As of Q4 2014, TIAGABINE remains the US FDA Preferred Term for this commodity. Tiagabine bears US NLM identifiers UMLS ID C0068897 and NCI Concept Code C66602. SMILES: S1C(/C(=C/CCN2CC(CCC2)C(=O)O)C2SCCC2C)C(CC1)C.
This classification denotes an anticonvulsant agent with the molecular formula C20H25NO2S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQH6T6D8OY, chemically known as 3-piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-buten-yl)-, hydrochloride, (r)- but more generally known as tiagabine hydrochloride, which bears US NIH Compound Identifier 91274. European Medicines Agency schedules Tiagabine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15566MIG. Most nations, for tariff and trade purposes, schedule tiagabine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TIAGABINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tiagabine hydrochloride bears US NLM identifiers UMLS ID C0772200 and NCI Concept Code C47755. SMILES: CC1CCSC1C(=CCCN2CCC[C@H](C2)C(=O)O)C3C(CCS3)C.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H10ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 195V08O55G, chemically known as 2-imidazoline, 2-((2-chloro-4-methyl-3-thienyl)amino)-, monohydrochloride but generally known as tiamenidine, which bears US NIH Compound Identifier 39973. European Medicines Agency schedules Tiamenidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11001MIG. The term TIAMENIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). TIAMENIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiamenidine under HS 29349990 and SITC 51579. As of Q4 2014, TIAMENIDINE remains the US FDA Preferred Term for this commodity. Tiamenidine bears US NLM identifiers UMLS ID C0076650 and NCI Concept Code C75046. SMILES: CLC1SCC(C1NC1=NCCN1)C.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C8H10ClN3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9SE2T8DW90, chemically known as 2-imidazoline, 2-((2-chloro-4-methyl-3-thienyl)amino)-, monohydrochloride but more generally known as tiamenidine hydrochloride, which bears US NIH Compound Identifier 39973. European Medicines Agency schedules Tiamenidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04853MIG. Most nations, for tariff and trade purposes, schedule tiamenidine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TIAMENIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tiamenidine hydrochloride bears US NLM identifiers UMLS ID C2699939 and NCI Concept Code C75047. SMILES: CC1CSC(C1NC2=NCCN2)CL.CL.
This classification denotes an antibiotic with the molecular formula C28H47NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E38WZ4U54R chemically known as ((2-(diethylamino)ethyl)thio)-, 6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-yl ester (3as-(3a.alpha.,4.beta.,5.alpha.,6.alpha.,8.beta.,9.alpha.,9a.beta.,10s*))- but generally known as tiamulin, which bears US NIH Compound Identifier 65343. European Medicines Agency schedules Tiamulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11005MIG. The term TIAMULIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16). Most nations schedule tiamulin under HS 29419000 and SITC 54139. As of Q4 2014, TIAMULIN remains the US FDA Preferred Term for this commodity. Tiamulin bears US NLM identifiers UMLS ID C0076651 and NCI Concept Code C84207. SMILES: CCN(CC)CCSCC(=O)OC1CC(C(C(C23CCC(C1(C2C(=O)CC3)C)C)C)O)(C)C=C.
This classification denotes an antibiotic with the molecular formula C28H47NO4S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ION1Q02ZCX, chemically known as acetic acid, ((2-(diethylamino)ethyl)thio)-, 6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3-alpha,9-propano-3-alpha-h-cyclopentacycloocten-8-yl ester, (e)-2-butenedioate (1:1) (salt) but more generally known as tiamulin fumarate, which bears US NIH Compound Identifier 6434500. Most nations, for tariff and trade purposes, schedule tiamulin fumarate under HS 29419000 and SITC 54139. As of Q4 2014, TIAMULIN FUMARATE remains US FDA's Preferred Term for this commodity. Tiamulin fumarate bears US NLM identifiers UMLS ID C0521890 and NCI Concept Code C84208. SMILES: CCN(CC)CCSCC(=O)O[C@@H]1C[C@@]([C@H]([C@@H]([C@@]23CC[C@H]([C@@]1([C@@H]2C(=O)CC3)C)C)C)O)(C)C=C.C(=C/C(=O)O)\C(=O)O.
This classification denotes an antibiotic with the molecular formula C28H47NO4S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ION1Q02ZCX, chemically known as acetic acid, ((2-(diethylamino)ethyl)thio)-, 6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3-alpha,9-propano-3-alpha-h-cyclopentacycloocten-8-yl ester, (e)-2-butenedioate (1:1) (salt) but more generally known as tiamulin fumarate, which bears US NIH Compound Identifier 6434500. Most nations, for tariff and trade purposes, schedule tiamulin hydrogen fumarate under HS 29419000. SMILES: CCN(CC)CCSCC(=O)O[C@@H]1C[C@@]([C@H]([C@@H]([C@@]23CC[C@H]([C@@]1([C@@H]2C(=O)CC3)C)C)C)O)(C)C=C.C(=C/C(=O)O)\C(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H9ClO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0T3ZRK3XV, chemically known as benzo(b)thiophene-2-acetic acid, 5-chloro-3-methyl- but generally known as tianafac, which bears US NIH Compound Identifier 68686. European Medicines Agency schedules Tianafac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11006MIG. The term TIANAFAC is an International Non-Proprietary Name. TIANAFAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tianafac under HS 29349990 and SITC 51579. As of Q4 2014, TIANAFAC remains the US FDA Preferred Term for this commodity. Tianafac bears US NLM identifiers UMLS ID C0602554 and NCI Concept Code C76819. SMILES: CC1=C(SC2=C1C=C(C=C2)CL)CC(=O)O.
This classification denotes a tricyclic antidepressive agent, analgesic, and thiazepine with the molecular formula C21H25ClN2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0T493YFU8O, chemically known as 7-((3-chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid s,s-dioxide but generally known as tianeptine, which bears US NIH Compound Identifier 68870. European Medicines Agency schedules Tianeptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11007MIG. World Health Organization schedules tianeptine in its Anatomical Therapeutic Chemical (ATC) Classification. TIANEPTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tianeptine under HS 29349990 and SITC 51579. As of Q4 2014, TIANEPTINE remains the US FDA Preferred Term for this commodity. SMILES: Clc1cc2S(=O)(=O)N(c3c(C(NCCCCCCC(=O)O)c2cc1)cccc3)C.
This classification denotes a tricyclic antidepressive agent C21H24ClN2O4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YG0E19592I, chemically known as heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, sodium salt (1:1), but more generally known as tianeptine sodium, which bears US NIH Compound Identifier 23663953. European Medicines Agency schedules Tianeptine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21398. Most nations, for tariff and trade purposes, schedule tianeptine sodium under HS 29349990 and SITC 51579. As of Q4 2014, TIANEPTINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CN1C2CCCCC2C(C3CCC(CC3S1(=O)=O)CL)NCCCCCCC(=O)[O-].[NA+].
This classification denotes an anti-dyskinesia agent, antipsychotic agent, and dopamine antagonist with the molecular formula C15H24N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LAH70H9JPH, chemically known as benzamide, n-(2-(diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)- but generally known as tiapride, which bears US NIH Compound Identifier 5467. European Medicines Agency schedules Tiapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11010MIG. World Health Organization schedules tiapride in its Anatomical Therapeutic Chemical (ATC) Classification. TIAPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiapride under HS 29242995 and SITC 51479. As of Q4 2014, TIAPRIDE remains the US FDA Preferred Term for this commodity. SMILES: S(=O)(=O)(C1CC(C(=O)NCCN(CC)CC)C(OC)CC1)C.
This classification denotes an anti-dyskinesia agent C15H24N2O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25N106WEDO, chemically known as benzamide, n-(2-(diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)-, hydrochloride (1:1), but more generally known as tiapride hydrochloride, which bears US NIH Compound Identifier 5702214. European Medicines Agency schedules Tiapride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04854MIG. Most nations, for tariff and trade purposes, schedule tiapride hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, TIAPRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCNC(=O)C1CC(CCC1OC)S(=O)(=O)C.CL.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H12O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1LS1T6R34C, chemically known as 2-thiopheneacetic acid, 5-benzoyl-alpha-methyl- but generally known as tiaprofenic acid, which bears US NIH Compound Identifier 5468. European Medicines Agency schedules Tiaprofenic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11011MIG. The term TIAPROFENIC ACID is an International Non-Proprietary Name. World Health Organization schedules tiaprofenic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tiaprofenic acid under HS 29349990 and SITC 51579. As of Q4 2014, TIAPROFENIC ACID remains the US FDA Preferred Term for this commodity. Tiaprofenic acid bears US NLM identifiers UMLS ID C0076653 and NCI Concept Code C90908. SMILES: S1C(C(C)C(=O)O)CCC1C(=O)C1CCCCC1.
This classification denotes a purine antagonist and inosine monophosphate dehydrogenase inhibitor with the molecular formula C9H12N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ULJ82834RE, chemically known as 4-thiazolecarboxamide, 2-.beta.-d-ribofuranosyl- but generally known as tiazofurin, which bears US NIH Compound Identifier 323701. European Medicines Agency schedules Tiazofurin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27111. The term TIAZOFURINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules tiazofurin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TIAZOFURIN remains the US FDA Preferred Term for this commodity. Tiazofurin bears US NLM identifiers UMLS ID C0076656 and NCI Concept Code C1254. SMILES: S1C(NC(C1)C(=O)N)C1OC(C(O)C1O)CO.
This classification denotes a topical anti-infective agent with the molecular formula C28H32N3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R1D66N3R0Y, chemically known as diethyl-methyl-[2-[[2-(4-phenylsulfanylphenyl)-1H-1,5-benzodiazepin-4-yl]sulfanyl]ethyl]azanium but generally known as tibezonium, which bears US NIH Compound Identifier 41157. European Medicines Agency schedules Tibezonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04856MIG. The term TIBEZONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules tibezonium iodide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TIBEZONIUM remains the US FDA Preferred Term for this commodity. Tibezonium bears US NLM identifiers UMLS ID C0076658 and NCI Concept Code C87273. SMILES: CC[N+](C)(CC)CCSC1=NC2=CC=CC=C2NC(=C1)C3=CC=C(C=C3)SC4=CC=CC=C4.[I-].
This classification denotes an anti-infective agent with the molecular formula C28H32N3S2.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E9P274AJEW, chemically known as 2-(beta-(n-diethylamino)ethylthio)-4-(p-phenylthio)phenyl-3h-1,5-benzodiazepine methiodide but more generally known as tibezonium iodide, which bears US NIH Compound Identifier 41157. European Medicines Agency schedules Tibezonium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11021MIG. The term TIBEZONIUM IODIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules tibezonium iodide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule tibezonium iodide under HS 29339940 and SITC 51577. As of Q4 2014, TIBEZONIUM IODIDE remains US FDA's Preferred Term for this commodity. Tibezonium iodide bears US NLM identifiers UMLS ID C0772481 and NCI Concept Code C72650. SMILES: CC[N+](C)(CC)CCSC1=NC2CCCCC2N=C(C1)C3CCC(CC3)SC4CCCCC4.[I-].
This classification denotes an anabolic steroid with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FF9X0205V2, chemically known as 19-norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7alpha,17alpha)- but generally known as tibolone, which bears US NIH Compound Identifier 21844. European Medicines Agency schedules Tibolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11022MIG. The term TIBOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules tibolone in its Anatomical Therapeutic Chemical (ATC) Classification. TIBOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tibolone under HS 29372300 and SITC 54153. As of Q4 2014, TIBOLONE remains the US FDA Preferred Term for this commodity. Tibolone bears US NLM identifiers UMLS ID C0076660 and NCI Concept Code C66955. SMILES: OC1(C2(C(C3C(CC2)C2=C(CC3C)CC(=O)CC2)CC1)C)C#C.
This classification denotes an antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GLH0314RVC. European Medicines Agency schedules Ticagrelor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30898. Ticagrelor generally arises in the molecular formula C23H28F2N6O4S. The term TICAGRELOR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, no. 1, 2007, list 57.) Most nations schedule ticagrelor under HS 29335990 and SITC 51576. As of Q4 2014, TICAGRELOR remains the US FDA Preferred Term for this commodity. Ticagrelor bears US NLM identifiers UMLS ID C1999375 and NCI Concept Code C76404. SMILES: CCCSC1=NC2=C(C(=N1)NC3CC3C4=CC(=C(C=C4)F)F)N=NN2C5CC(C(C5O)O)OCCO.
This classification denotes an antihelminthic agent with the molecular formula C15H19F3N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4CLF34O60, chemically known as 1-piperidinecarbothioamide, 2,6-dimethyl-n-(3-(trifluoromethyl)phenyl)- but generally known as ticarbodine, which bears US NIH Compound Identifier 3034015. European Medicines Agency schedules Ticarbodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11026MIG. The term TICARBODINE is an International Non-Proprietary Name. TICARBODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ticarbodine under HS 29333999 and SITC 51574. As of Q4 2014, TICARBODINE remains the US FDA Preferred Term for this commodity. Ticarbodine bears US NLM identifiers UMLS ID C0076661 and NCI Concept Code C75234. SMILES: S=C(N1C(CCCC1C)C)NC1CC(CCC1)C(F)(F)F.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C15H16N2O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F93UJX4SWT, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6beta(s*)))- but generally known as ticarcillin, which bears US NIH Compound Identifier 36921. European Medicines Agency schedules Ticarcillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15567MIG. The term TICARCILLIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules ticarcillin in its Anatomical Therapeutic Chemical (ATC) Classification. TICARCILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ticarcillin under HS 29411090 and SITC 54131. As of Q4 2014, TICARCILLIN remains the US FDA Preferred Term for this commodity. Ticarcillin bears US NLM identifiers UMLS ID C0040193 and NCI Concept Code C889. SMILES: S1C2N(C(C1(C)C)C(=O)O)C(=O)C2NC(=O)C(C1CCSC1)C(=O)O.
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C22H21N2O6S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0EVR7Q3336, chemically known as p-tolyl (r)-n-((2s,5r,6r)-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl))-3-thiophenemalonamate sodium salt, but more generally known as ticarcillin cresyl sodium, which bears US NIH Compound Identifier 42946. European Medicines Agency schedules ticarcillin cresyl sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15567MIG. Most nations, for tariff purposes, schedule ticarcillin cresyl sodium under HS 29411090. SMILES: CC1CCC(CC1)OC(=O)[C@H](C2CCSC2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[NA+].
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C15H14N2O6S2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G8TVV6DSYG, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, disodium salt, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as ticarcillin disodium, which bears US NIH Compound Identifier 20823. European Medicines Agency schedules Ticarcillin disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04857MIG. Most nations, for tariff and trade purposes, schedule ticarcillin disodium under HS 29411090 and SITC 54131. As of Q4 2014, TICARCILLIN DISODIUM remains US FDA's Preferred Term for this commodity. Ticarcillin disodium bears US NLM identifiers UMLS ID C0546880 and NCI Concept Code C65205. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCSC3)C(=O)[O-])C(=O)[O-])C.[NA+].[NA+].
This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C15H14N2O6S2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G8TVV6DSYG, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, disodium salt, (2s-(2alpha,5alpha,6beta(s*)))- but more generally known as ticarcillin disodium, which bears US NIH Compound Identifier 20823. European Medicines Agency schedules Ticarcillin disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04857MIG. Most nations, for tariff and trade purposes, schedule ticarcillin sodium under HS 29411090. SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3CCSC3)C(=O)[O-])C(=O)[O-])C.[NA+].[NA+].
This classification denotes a drug therapy and thiazole with the molecular formula C7H4ClNOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BHW384Q9GI, chemically known as 1,2-benzisothiazolin-3-one, 6-chloro- but generally known as ticlatone, which bears US NIH Compound Identifier 6258. European Medicines Agency schedules Ticlatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11027MIG. World Health Organization schedules ticlatone in its Anatomical Therapeutic Chemical (ATC) Classification. TICLATONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ticlatone under HS 29349990 and SITC 51579. As of Q4 2014, TICLATONE remains the US FDA Preferred Term for this commodity. SMILES: CLC1CC2S[NH]C(=O)C2CC1.
This classification denotes a thienopyridine antiplatelet agent with the molecular formula C14H14ClNS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OM90ZUW7M1, chemically known as 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine but generally known as ticlopidine, which bears US NIH Compound Identifier 5472. European Medicines Agency schedules Ticlopidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11028MIG. The term TICLOPIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules ticlopidine in its Anatomical Therapeutic Chemical (ATC) Classification. TICLOPIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ticlopidine under HS 29349990 and SITC 51579. As of Q4 2014, TICLOPIDINE remains the US FDA Preferred Term for this commodity. Ticlopidine bears US NLM identifiers UMLS ID C0040207 and NCI Concept Code C61972. SMILES: CLC1C(CN2CCC3SCCC3C2)CCCC1.
This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Y5LZ9A0KV. European Medicines Agency schedules Tiemonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15570MIG. The term TIEMONIUM is an International Non-Proprietary Name or INN. As of Q4 2014, TIEMONIUM remains the US FDA Preferred Term for this commodity. Tiemonium bears US NLM identifiers UMLS ID C0771438 and NCI Concept Code C84209. SMILES: C[N+]1(CCOCC1)CCC(C2=CC=CC=C2)(C3=CC=CS3)O.
This classification denotes an antimuscarinic agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier FZ2LZ7U304. European Medicines Agency schedules Tiemonium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11031MIG. Tiemonium iodide generally arises in the molecular formula C18H24INO2S. The term TIEMONIUM IODIDE is an International Non-Proprietary Name or INN.
This classification denotes an antipsychotic agent with the molecular formula C15H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B255B0J51N, chemically known as 7,8,9,10-tetrahydro-1,9-dimethyl-6h-pyrido(4,3-b)thieno(3,2-e)indole but generally known as tienocarbine, which bears US NIH Compound Identifier 71140. European Medicines Agency schedules Tienocarbine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11033MIG. The term TIENOCARBINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). TIENOCARBINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tienocarbine under HS 29349990 and SITC 51579. As of Q4 2014, TIENOCARBINE remains the US FDA Preferred Term for this commodity. Tienocarbine bears US NLM identifiers UMLS ID C0076666 and NCI Concept Code C76449. SMILES: S1C2C(C3C4C([NH]C3CC2)CCN(C4)C)C(C1)C.
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36L0QUK8SY. European Medicines Agency schedules Tienopramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11034MIG. Tienopramine generally arises in the molecular formula C17H20N2S. The term TIENOPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) TIENOPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tienopramine under HS 29349990 and SITC 51579. As of Q4 2014, TIENOPRAMINE remains the US FDA Preferred Term for this commodity. Tienopramine bears US NLM identifiers UMLS ID C2699942 and NCI Concept Code C75183. SMILES: s1c2c(N(CCCN(C)C)c3c(C=C2)cccc3)cc1.
This classification denotes an antimuscarinic agent with the molecular formula C20H25NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GX4D5197DT, chemically known as benzeneethanethioic acid, alpha-phenyl-, s-(2-(diethylamino)ethyl) ester but generally known as thiphenamil, which bears US NIH Compound Identifier 11061. European Medicines Agency schedules Tifenamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11038MIG. The term TIFENAMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Most nations schedule tifenamil under HS 29309085 and SITC 51549. SMILES: CCN(CC)CCSC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.
This classification denotes an anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) EG3B69DFQ5. European Medicines Agency schedules Tiflorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11041MIG. Tiflorex generally arises in the molecular formula C12H16F3NS. The term TIFLOREX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, no. 10 1976, list 16.) TIFLOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tiflorex under HS 29309085 and SITC 51549. As of Q4 2014, TIFLOREX remains US FDA's Preferred Term for this commodity. Tiflorex bears US NLM identifiers UMLS ID C0145931 and NCI Concept Code C75117. SMILES: CCNC(C)CC1=CC(=CC=C1)SC(F)(F)F.
This classification denotes a serotonin agonist and antidepressant agent with the molecular formula C16H17FN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M2108NUY0C, chemically known as 9-ethyl-4-fluoro-7,8,9,10-tetrahydro-1-methyl-6h-pyrido(4,3-b)thieno(3,2-e)indole but generally known as tiflucarbine, which bears US NIH Compound Identifier 65677. European Medicines Agency schedules Tiflucarbine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11043MIG. The term TIFLUCARBINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). TIFLUCARBINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiflucarbine under HS 29349990 and SITC 51579. As of Q4 2014, TIFLUCARBINE remains the US FDA Preferred Term for this commodity. Tiflucarbine bears US NLM identifiers UMLS ID C0076671 and NCI Concept Code C72864. SMILES: s1c2c(c3c4c([nH]c3cc2F)CCN(C4)CC)c(c1)C.
This classification denotes an antibiotic with the molecular formula C29H39N5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70JE2N95KR, chemically known as 2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)- but generally known as tigecycline, which bears US NIH Compound Identifier 5282044. European Medicines Agency schedules Tigecycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16467MIG. The term TIGECYCLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3, 2002, List 48). World Health Organization schedules tigecycline in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tigecycline under HS 29413000 and SITC 54133. As of Q4 2014, TIGECYCLINE remains the US FDA Preferred Term for this commodity. Tigecycline bears US NLM identifiers UMLS ID C1260298 and NCI Concept Code C72865. SMILES: OC12C(CC3C(=C(O)C4C(C3)C(N(C)C)CC(NC(=O)CNC(C)(C)C)C4O)C1=O)C(N(C)C)C(=O)C(=C(\O)N)\C2=O.
This classification denotes a quinolone antibiotic, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier P6SB125NHA. The European Medicines Agency schedules Tilbroquinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11049MIG. Tilbroquinol generally arises in the molecular formula C10H8BRNO. The term TILBROQUINOL is an International Non-Proprietary Name or INN. TILBROQUINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=CC(=C(C2=C1C=CC=N2)O)BR.
This classification denotes an anesthetic agent with the molecular formula C12H17NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2YFC543249, chemically known as cyclohexanone, 2- (ethylamino)-2-(2-thienyl)-, hydrochloride but generally known as tiletamine, which bears US NIH Compound Identifier 26533. European Medicines Agency schedules Tiletamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11050MIG. The term TILETAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). TILETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiletamine under HS 29349990 and SITC 51579. As of Q4 2014, TILETAMINE remains the US FDA Preferred Term for this commodity. Tiletamine bears US NLM identifiers UMLS ID C0040217 and NCI Concept Code C84211. SMILES: CCNC1(CCCCC1=O)C2=CC=CS2.
This classification denotes an anesthetic agent with the molecular formula C12H17NOS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99TAQ2QWJI, chemically known as cyclohexanone, 2- (ethylamino)-2-(2-thienyl)-, hydrochloride but more generally known as tiletamine hydrochloride, which bears US NIH Compound Identifier 26533. European Medicines Agency schedules Tiletamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04867MIG. Most nations, for tariff and trade purposes, schedule tiletamine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TILETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tiletamine hydrochloride bears US NLM identifiers UMLS ID C0936267 and NCI Concept Code C84212. SMILES: CCNC1(CCCCC1=O)C2CCCS2.CL.
This classification denotes an opioid analgesic, narcotic, and cyclohexanecarboxylic acid with the molecular formula C17H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GY33N31E9Y, chemically known as 3-cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, trans-(+-)- but generally known as tilidine, which bears US NIH Compound Identifier 30131. European Medicines Agency schedules Tilidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11051MIG. World Health Organization schedules tilidine in its Anatomical Therapeutic Chemical (ATC) Classification. TILIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tilidine under HS 29224400 and SITC 51465. As of Q4 2014, TILIDINE remains the US FDA Preferred Term for this commodity. SMILES: O(C(=O)C1(C(N(C)C)C=CCC1)C1CCCCC1)CC.
This classification denotes an opioid analgesic, narcotic, and cyclohexanecarboxylic acid with the molecular formula C17H23NO2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DXT828600R, chemically known as 3-cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, trans-(+/-)-, (e)-2-butenedioate (1:1), but more generally known as tilidine fumarate, which bears US NIH Compound Identifier 5284464. European Medicines Agency schedules tilidine fumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11051MIG. Most nations, for tariff purposes, schedule tilidine fumarate under HS 29224400. SMILES: CCOC(=O)[C@]1(CCC=C[C@@H]1N(C)C)C2CCCCC2.C(=C/C(=O)O)\C(=O)O.
This classification denotes an opioid analgesic C17H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4YI72J28N9, chemically known as 3-cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride (trans)-(+/-)-, but more generally known as tilidine hydrochloride, which bears US NIH Compound Identifier 32328. European Medicines Agency schedules Tilidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15573MIG. Most nations, for tariff and trade purposes, schedule tilidine hydrochloride under HS 29224400 and SITC 51465. As of Q4 2014, TILIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2CCCCC2.CL.
This classification denotes an opioid analgesic C17H23NO2.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PJ7Z0WL915, chemically known as 3-cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, trans-(+/-)-, phosphate (1:1), but more generally known as tilidine phosphate, which bears US NIH Compound Identifier 71587539. European Medicines Agency schedules Tilidine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20755. Most nations, for tariff and trade purposes, schedule tilidine phosphate under HS 29224400 and SITC 51465. As of Q4 2014, TILIDINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)[C@]1(CCC=C[C@@H]1N(C)C)C2CCCCC2.OP(=O)(O)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QUF41MF56G, chemically known as 1(2h)-isoquinolinone, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-2-methyl- but generally known as tilisolol, which bears US NIH Compound Identifier 5474. European Medicines Agency schedules Tilisolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11053MIG. The term TILISOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). TILISOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tilisolol under HS 29337900 and SITC 51561. As of Q4 2014, TILISOLOL remains the US FDA Preferred Term for this commodity. Tilisolol bears US NLM identifiers UMLS ID C0076678 and NCI Concept Code C76560. SMILES: O(CC(O)CNC(C)(C)C)C1C2C(C(=O)N(C1)C)CCCC2.
This classification denotes a beta-adrenergic blocking agent C17H24N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JW02T8UTIN, chemically known as tilisolol hydrochloride, (+/-)-, but more generally known as tilisolol hydrochloride, which bears US NIH Compound Identifier 44155. European Medicines Agency schedules Tilisolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04871MIG. Most nations, for tariff and trade purposes, schedule tilisolol hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, TILISOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)NCC(COC1CN(C(=O)C2C1CCCC2)C)O.CL.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C16H19FN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6VI5P84SX, chemically known as 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo(4,5)imidazo(1,2a)pyridine-4-n-(2-fluorophenyl)carboxamide but generally known as tilmacoxib, which bears US NIH Compound Identifier 159271. The term TILMACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule tilmacoxib under HS 29350090 and SITC 51580. As of Q4 2014, TILMACOXIB remains the US FDA Preferred Term for this commodity. Tilmacoxib bears US NLM identifiers UMLS ID C2699944 and NCI Concept Code C76640. SMILES: CC1=NC(=C(O1)C2=CC(=C(C=C2)S(=O)(=O)N)F)C3CCCCC3.
This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XL4103X2E3. European Medicines Agency schedules Tilmicosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11054MIG. Tilmicosin generally arises in the molecular formula C46H80N2O13. The term TILMICOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) Most nations schedule tilmicosin under HS 29419000 and SITC 54139. As of Q4 2014, TILMICOSIN remains the US FDA Preferred Term for this commodity. Tilmicosin bears US NLM identifiers UMLS ID C0076681 and NCI Concept Code C84213. SMILES: O(C1C(CCN2CC(CC(C2)C)C)CC(C)C(=O)C=CC(=CC(C(OC(=O)CC(O)C1C)CC)COC1OC(C(O)C(OC)C1OC)C)C)C1OC(C(O)C(N(C)C)C1O)C.
This classification denotes a macrolide antibiotic with the molecular formula C46H80N2O13.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SMH7U1S683. The term tilmicosin phosphate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule tilmicosin phosphate under HS 29419000 and SITC 54139. As of Q4 2014, TILMICOSIN PHOSPHATE remains US FDA's Preferred Term for this commodity. Tilmicosin phosphate bears US NLM identifiers UMLS ID C0521892 and NCI Concept Code C84214. SMILES: CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)CCN3C[C@@H](C[C@@H](C3)C)C)C)\C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC.OP(=O)(O)O.
This classification denotes an antiviral agent with the molecular formula C25H34N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6W7VEW6KS, chemically known as 2,7-bis-deae-fluorenone but generally known as tilorone, which bears US NIH Compound Identifier 5475. European Medicines Agency schedules Tilorone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11057MIG. The term TILORONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). TILORONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tilorone under HS 29221980 and SITC 51461. As of Q4 2014, TILORONE remains the US FDA Preferred Term for this commodity. Tilorone bears US NLM identifiers UMLS ID C0040221 and NCI Concept Code C73335. SMILES: O(C1CC2C(C3C(C2=O)CC(OCCN(CC)CC)CC3)CC1)CCN(CC)CC.
This classification denotes a cholinergic agonist with the molecular formula C25H34N2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BJ507J4LKY, chemically known as 2,7-bis-deae-fluorenone but more generally known as tilorone hydrochloride, which bears US NIH Compound Identifier 5475. Most nations, for tariff and trade purposes, schedule tilorone hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, TILORONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tilorone hydrochloride bears US NLM identifiers UMLS ID C0085800 and NCI Concept Code C72868. SMILES: CCN(CC)CCOC1CCC-2C(C1)C(=O)C3C2CCC(C3)OCCN(CC)CC.CL.CL.
This classification denotes a bone resorption inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6PNS59HP4Y. European Medicines Agency schedules Tiludronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11060MIG. Tiludronic acid generally arises in the molecular formula C7H9CLO6P2S. The term TILUDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) Most nations schedule tiludronic acid under HS 29309085 and SITC 51549. As of Q4 2014, TILUDRONIC ACID remains the US FDA Preferred Term for this commodity. Tiludronic acid bears US NLM identifiers UMLS ID C0043611 and NCI Concept Code C72091. SMILES: Clc1ccc(SC(P(=O)(O)O)P(=O)(O)O)cc1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H23N5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XR74J44UL, chemically known as guanidine, n-cyclohexyl-n-(2-methyl-4-quinolinyl)-n-2-thiazolyl- but generally known as timegadine, which bears US NIH Compound Identifier 68902. European Medicines Agency schedules Timegadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11062MIG. The term TIMEGADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). TIMEGADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule timegadine under HS 29341000 and SITC 51579. As of Q4 2014, TIMEGADINE remains the US FDA Preferred Term for this commodity. Timegadine bears US NLM identifiers UMLS ID C0076684 and NCI Concept Code C90909. SMILES: S1C(NC(=N\C2CCCCC2)/NC2C3C(NC(C2)C)CCCC3)NCC1.
This classification denotes an antipsychotic agent with the molecular formula C17H18FN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 090DE9CRP1, chemically known as 1,2,3,4,4a,5-hexahydro-10-fluoro-3-methyl-7-(2-thienyl)pyrazino(1,2-a)(1,4)benzodiazepine but generally known as timelotem, which bears US NIH Compound Identifier 65844. European Medicines Agency schedules Timelotem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11063MIG. The term TIMELOTEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). TIMELOTEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule timelotem under HS 29349990 and SITC 51579. As of Q4 2014, TIMELOTEM remains the US FDA Preferred Term for this commodity. Timelotem bears US NLM identifiers UMLS ID C0076685 and NCI Concept Code C76450. SMILES: S1C(C2=NCC3N(CCN(C3)C)C3C2CCC(F)C3)CCC1.
This classification denotes an antimuscarinic agent with the molecular formula C17H22NOS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C1WS2XH3K4, chemically known as 3-(dithiophen-2-ylmethylidene)-5-methoxy-1,1-dimethylpiperidin-1-ium but generally known as timepidium, which bears US NIH Compound Identifier 5476. European Medicines Agency schedules Timepidium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04874MIG. The term TIMEPIDIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules timepidium bromide in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TIMEPIDIUM remains the US FDA Preferred Term for this commodity. Timepidium bears US NLM identifiers UMLS ID C1620337 and NCI Concept Code C87647. SMILES: C[N+]1(CC(CC(=C(C2=CC=CS2)C3=CC=CS3)C1)OC)C.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3I3H31VAS6. European Medicines Agency schedules Timirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11066MIG. Timirdine generally arises in the molecular formula C9H10CLN3S. The term TIMIRDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) Most nations schedule timirdine under HS 29341000 and SITC 51579. As of Q4 2014, TIMIRDINE remains the US FDA Preferred Term for this commodity. Timirdine bears US NLM identifiers UMLS ID C2699946 and NCI Concept Code C76452. SMILES: CLC1CC(N)C(N2CCSC2=N)CC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29FO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97TVB2O56G, chemically known as s-methyl 9-fluoro-11beta,17-dihydroxy-16beta-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate but generally known as timobesone acetate, which bears US NIH Compound Identifier 70691439. European Medicines Agency schedules timobesone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11067MIG. Most nations schedule timobesone under HS 29372200 and SITC 54153. As of Q4 2014, TIMOBESONE remains the US FDA Preferred Term for this commodity. SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SC)OC(=O)C)C)O)F)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31FO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LGO8R495QW, chemically known as s-methyl 9-fluoro-11beta,17-dihydroxy-16beta-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-acetate but more generally known as timobesone acetate, which bears US NIH Compound Identifier 3033679. Most nations, for tariff and trade purposes, schedule timobesone acetate under HS 29372200 and SITC 54153. As of Q4 2014, TIMOBESONE ACETATE remains US FDA's Preferred Term for this commodity. Timobesone acetate bears US NLM identifiers UMLS ID C0637015 and NCI Concept Code C90957. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SC)OC(=O)C)C)O)F)C.
This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85P20FW39R. European Medicines Agency schedules Timofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11068MIG. Timofibrate generally arises in the molecular formula C14H16CLNO4S. The term TIMOFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) TIMOFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule timofibrate under HS 29341000 and SITC 51579. As of Q4 2014, TIMOFIBRATE remains the US FDA Preferred Term for this commodity. Timofibrate bears US NLM identifiers UMLS ID C2699947 and NCI Concept Code C75260. SMILES: Clc1ccc(OC(C(=O)N2C(CSC2)C(=O)O)(C)C)cc1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C13H24N4O3S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 817W3C6175, chemically known as 2-propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)-oxy)-, (+-)- but generally known as timolol, which bears US NIH Compound Identifier 5478. European Medicines Agency schedules Timolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11069MIG. World Health Organization schedules timolol in its Anatomical Therapeutic Chemical (ATC) Classification. TIMOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule timolol under HS 29349990 and SITC 51579. As of Q4 2014, TIMOLOL remains the US FDA Preferred Term for this commodity. Timolol bears US NLM identifiers UMLS ID C0040233 and NCI Concept Code C47757. SMILES: CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H24N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5JKY92S7BR. The term TIMOLOL ANHYDROUS is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule timolol anhydrous under HS 29349990. As of Q4 2014, TIMOLOL ANHYDROUS remains US FDA's Preferred Term for this commodity. Timolol anhydrous bears US NLM identifiers UMLS ID C2983887 and NCI Concept Code C90802. SMILES: CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C13H24N4O3S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 817W3C6175, chemically known as (s)-1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)-2-propanol hemihydrate, but more generally known as timolol hemihydrate, which bears US NIH Compound Identifier 62933. European Medicines Agency schedules timolol hemihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11069MIG. Most nations, for tariff purposes, schedule timolol hemihydrate under HS 29349990. SMILES: CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.O.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H24N4O3S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8Y54F701R, chemically known as 2-propanol, 1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)-, (-)-, maleate (1:1) (salt) but more generally known as timolol maleate, which bears US NIH Compound Identifier 5281056. European Medicines Agency schedules Timolol maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04875MIG. Most nations, for tariff and trade purposes, schedule timolol maleate under HS 29349990 and SITC 51579. As of Q4 2014, TIMOLOL MALEATE remains US FDA's Preferred Term for this commodity. Timolol maleate bears US NLM identifiers UMLS ID C0087093 and NCI Concept Code C29501. SMILES: CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes a proton pump inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95H6S1X9CC. European Medicines Agency schedules Timoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11071MIG. Timoprazole generally arises in the molecular formula C13H11N3OS. The term TIMOPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) TIMOPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule timoprazole under HS 29333999 and SITC 51574. As of Q4 2014, TIMOPRAZOLE remains the US FDA Preferred Term for this commodity. Timoprazole bears US NLM identifiers UMLS ID C0076690 and NCI Concept Code C80634. SMILES: S(=O)(C1[NH]C2C(N1)CCCC2)CC1NCCCC1.
This classification denotes an antihypertensive agent with the molecular formula C23H34O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 455Y914AKK, chemically known as 1,2,3,5-tetrahydro-5,5-dimethyl-8-(1,2-dimethylheptyl)thiopyrano(2,3-c)(1)benzopyran-10-ol but generally known as tinabinol, which bears US NIH Compound Identifier 65443. European Medicines Agency schedules Tinabinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11072MIG. The term TINABINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). TINABINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tinabinol under HS 29349990 and SITC 51579. As of Q4 2014, TINABINOL remains the US FDA Preferred Term for this commodity. Tinabinol bears US NLM identifiers UMLS ID C2699948 and NCI Concept Code C75242. SMILES: S1C2=C(c3c(OC2(C)C)cc(C(C(CCCCC)C)C)cc3O)CCC1.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C11H11N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88174AK70T, chemically known as 1h-indole, 3-((4,5-dihydro-1h-imidazol-2-yl)thio)-, monohydrochloride but generally known as tinazoline, which bears US NIH Compound Identifier 68818. European Medicines Agency schedules Tinazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11073MIG. The term TINAZOLINE is an International Non-Proprietary Name. TINAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tinazoline under HS 29332990 and SITC 51573. As of Q4 2014, TINAZOLINE remains the US FDA Preferred Term for this commodity. Tinazoline bears US NLM identifiers UMLS ID C0076698 and NCI Concept Code C75057. SMILES: C1CN=C(N1)SC2=CNC3=CC=CC=C32.
This classification denotes an antiprotozoal agent with the molecular formula C8H13N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 033KF7V46H, chemically known as 1h-imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- but generally known as tinidazole, which bears US NIH Compound Identifier 5479. European Medicines Agency schedules Tinidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11074MIG. The term TINIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). World Health Organization schedules tinidazole in its Anatomical Therapeutic Chemical (ATC) Classification. TINIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tinidazole under HS 29332990 and SITC 51573. As of Q4 2014, TINIDAZOLE remains the US FDA Preferred Term for this commodity. Tinidazole bears US NLM identifiers UMLS ID C0040263 and NCI Concept Code C890. SMILES: S(=O)(=O)(CCN1C(NCC1[N](=O)O)C)CC.
This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 037S03TJ5M. European Medicines Agency schedules Tinisulpride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11075MIG. Tinisulpride generally arises in the molecular formula C20H29N3O4S. The term TINISULPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) TINISULPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tinisulpride under HS 29350090 and SITC 51580. As of Q4 2014, TINISULPRIDE remains the US FDA Preferred Term for this commodity. Tinisulpride bears US NLM identifiers UMLS ID C2699949 and NCI Concept Code C74451. SMILES: S(=O)(=O)(NC(C)(C)C#C)C1CC(C(=O)NCC2N(CCC2)CC)C(OC)CC1.
This classification denotes an antitubercular agent, thiourea isoxyl, and phenylthiourea analog with the molecular formula C23H32N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43M23X81Y2, chemically known as 4,4-diisoamyloxythiocarbanilide but generally known as tiocarlide, which bears US NIH Compound Identifier 3001386. European Medicines Agency schedules Tiocarlide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11078MIG. World Health Organization schedules tiocarlide in its Anatomical Therapeutic Chemical (ATC) Classification. TIOCARLIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiocarlide under HS 29309085 and SITC 51549. As of Q4 2014, TIOCARLIDE remains the US FDA Preferred Term for this commodity. SMILES: S=C(NC1CCC(OCCC(C)C)CC1)NC1CCC(OCCC(C)C)CC1.
This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E5B7C16LFK. European Medicines Agency schedules Tioclomarol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11079MIG. Tioclomarol generally arises in the molecular formula C22H16CL2O4S. The term TIOCLOMAROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, no. 10 1974, list 14.) TIOCLOMAROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tioclomarol under HS 29349990 and SITC 51579. As of Q4 2014, TIOCLOMAROL remains the US FDA Preferred Term for this commodity. Tioclomarol bears US NLM identifiers UMLS ID C0612505 and NCI Concept Code C75159. SMILES: CLC1SC(C(CC(O)C2CCC(CL)CC2)C2C(=O)C3C(OC2O)CCCC3)CC1.
This classification denotes an antifungal agent with the molecular formula C16H13Cl3N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S57Y5X1117, chemically known as 1h-imidazole, 1-(2-((2-chloro-3-thienyl)methoxy)-2-(2,4-dichlorophenyl)ethyl)- but generally known as tioconazole, which bears US NIH Compound Identifier 5482. European Medicines Agency schedules Tioconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11080MIG. The term TIOCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules tioconazole in its Anatomical Therapeutic Chemical (ATC) Classification. TIOCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tioconazole under HS 29349990 and SITC 51579. As of Q4 2014, TIOCONAZOLE remains the US FDA Preferred Term for this commodity. Tioconazole bears US NLM identifiers UMLS ID C0076705 and NCI Concept Code C29500. SMILES: CLC1C(C(OCC2CCSC2CL)CN2CCNC2)CCC(CL)C1.
This classification denotes an agent affecting blood and body fluid with the molecular formula C5H9NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C5W04GO61S, chemically known as glycine, n-(2-mercaptopropionyl)- but more generally known as tiopronin, which bears US NIH Compound Identifier 5483. European Medicines Agency schedules Tiopronin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11089MIG. The term TIOPRONIN is an International Non-Proprietary Name. World Health Organization schedules tiopronin in its Anatomical Therapeutic Chemical (ATC) Classification. TIOPRONIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tiopronin under HS 29309085 and SITC 51549. As of Q4 2014, TIOPRONIN remains US FDA's Preferred Term for this commodity. Tiopronin bears US NLM identifiers UMLS ID C0025405 and NCI Concept Code C47758. SMILES: SC(C(=O)NCC(=O)O)C.
This classification denotes a serotonin agonist and anxiolytic with the molecular formula C24H32N4O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45Q1DF53NN, chemically known as 8-azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-, monohydrochloride but generally known as tiospirone hydrochloride, which bears US NIH Compound Identifier 55751. Most nations schedule tiospirone under HS 29349990 and SITC 51579. As of Q4 2014, TIOSPIRONE remains the US FDA Preferred Term for this commodity. Tiospirone bears US NLM identifiers UMLS ID C0076710 and NCI Concept Code C73303. SMILES: C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54.Cl.
This classification denotes a serotonin agonist and anxiolytic with the molecular formula C24H32N4O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45Q1DF53NN, chemically known as 8-azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-, monohydrochloride but more generally known as tiospirone hydrochloride, which bears US NIH Compound Identifier 55751. Most nations, for tariff and trade purposes, schedule tiospirone hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TIOSPIRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tiospirone hydrochloride bears US NLM identifiers UMLS ID C2348793 and NCI Concept Code C72869. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCCCN4C(=O)CC5(CCCC5)CC4=O.CL.
This classification denotes an antimuscarinic agent with the molecular formula C19H22NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0EB439235F, chemically known as 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide but generally known as tiotropium, which bears US NIH Compound Identifier 5487426. European Medicines Agency schedules Tiotropium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25691. TIOTROPIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, TIOTROPIUM remains the US FDA Preferred Term for this commodity. Tiotropium bears US NLM identifiers UMLS ID C0213771 and NCI Concept Code C76004. SMILES: BR.S1C(C(O)(C(=O)OC2CC3[N](C(C4OC34)C2)(C)C)C2SCCC2)CCC1.
This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L64SXO195N. European Medicines Agency schedules Tiotropium bromide monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21897. Tiotropium bromide generally arises in the molecular formula C19H22NO4S2.BR.H2O. The term 'tiotropium bromide' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule tiotropium bromide under HS 29399900 and SITC 54149. As of Q4 2014, TIOTROPIUM BROMIDE remains US FDA's Preferred Term for this commodity. Tiotropium bromide bears US NLM identifiers UMLS ID CL449040 and NCI Concept Code C84608. SMILES: C[N+]1([C@@H]2C[C@H](C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4CCCS4)(C5CCCS5)O)C.[BR-].
This classification denotes a quinolone antibiotic with the molecular formula C14H12N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0K40CNM74K, chemically known as 6-ethyl-2,3,6,9-tetrahydro-3-methyl-2,9-dioxothiazolo(5,4-f)quinoline-8-carboxylic acid but generally known as tioxacin, which bears US NIH Compound Identifier 65788. European Medicines Agency schedules Tioxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11096MIG. The term TIOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). TIOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tioxacin under HS 29349990 and SITC 51579. As of Q4 2014, TIOXACIN remains the US FDA Preferred Term for this commodity. Tioxacin bears US NLM identifiers UMLS ID C0076712 and NCI Concept Code C76924. SMILES: S1C2C3C(N(CC)CC(C3=O)C(=O)O)CCC2N(C1=O)C.
This classification denotes an astringent with the molecular formula C7H4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S0FAJ1R9CD, chemically known as 1,3-benzoxathiol-2-one, 6-hydroxy- but generally known as tioxolone, which bears US NIH Compound Identifier 72139. European Medicines Agency schedules Tioxolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11100MIG. The term TIOXOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules tioxolone in its Anatomical Therapeutic Chemical (ATC) Classification. TIOXOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tioxolone under HS 29349990 and SITC 51579. As of Q4 2014, TIOXOLONE remains the US FDA Preferred Term for this commodity. Tioxolone bears US NLM identifiers UMLS ID C2699951 and NCI Concept Code C76521. SMILES: S1C2C(OC1=O)CC(O)CC2.
This classification denotes an opioid receptor agonist with the molecular formula C15H17NS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2260ZP67IT, chemically known as piperidine, 3-(di-2-thienylmethylene)-1-methyl- but more generally known as tipepidine, which bears US NIH Compound Identifier 5484. European Medicines Agency schedules Tipepidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11102MIG. The term TIPEPIDINE is an International Non-Proprietary Name. World Health Organization schedules tipepidine in its Anatomical Therapeutic Chemical (ATC) Classification. TIPEPIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tipepidine under HS 29349990 and SITC 51579. As of Q4 2014, TIPEPIDINE remains US FDA's Preferred Term for this commodity. Tipepidine bears US NLM identifiers UMLS ID C0076714 and NCI Concept Code C76847. SMILES: S1C(/C(=C2\CCCN(C2)C)C2SCCC2)CCC1.
This classification denotes a serotonin antagonist with the molecular formula C16H20N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier US65H9WBNH, chemically known as 1,3,4,5-tetrahydrothiopyrano(4,3-b)indole-8-carboxylic acid, 2-(dimethylamino)ethyl ester but generally known as tipindole, which bears US NIH Compound Identifier 65595. European Medicines Agency schedules Tipindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11104MIG. The term TIPINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). TIPINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tipindole under HS 29349990 and SITC 51579. As of Q4 2014, TIPINDOLE remains the US FDA Preferred Term for this commodity. Tipindole bears US NLM identifiers UMLS ID C0076715 and NCI Concept Code C76968. SMILES: S1Cc2c([nH]c3c2cc(cc3)C(=O)OCCN(C)C)CC1.
This classification denotes a protease inhibitor with the molecular formula C31H33F3N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZZT404XD09, chemically known as 2-pyridinesulfonamide, n-(3-((1r)-1-((6r)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2h-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)- but generally known as tipranavir, which bears US NIH Compound Identifier 65027. European Medicines Agency schedules Tipranavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04883MIG. The term TIPRANAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules tipranavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tipranavir under HS 29350090 and SITC 51580. As of Q4 2014, TIPRANAVIR remains the US FDA Preferred Term for this commodity. Tipranavir bears US NLM identifiers UMLS ID C0663733 and NCI Concept Code C66603. SMILES: S(=O)(=O)(Nc1cc(C(C2=C(OC(CC2=O)(CCc2ccccc2)CCC)O)CC)ccc1)c1ncc(cc1)C(F)(F)F.
This classification denotes a vasodilating agent with the molecular formula C20H35NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 007QF56M4D, chemically known as 2-propanol, 1-(4-((1-methylethyl)thio)phenoxy)-3-(octylamino)- but generally known as tipropidil, which bears US NIH Compound Identifier 72176. European Medicines Agency schedules Tipropidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11108MIG. The term TIPROPIDIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). TIPROPIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tipropidil under HS 29309085 and SITC 51549. As of Q4 2014, TIPROPIDIL remains the US FDA Preferred Term for this commodity. Tipropidil bears US NLM identifiers UMLS ID C0076718 and NCI Concept Code C84216. SMILES: S(c1ccc(OCC(O)CNCCCCCCCC)cc1)C(C)C.
This classification denotes a vasodilating agent with the molecular formula C20H35NO2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34K00NS0TZ, chemically known as 2-propanol, 1-(4-((1-methylethyl)thio)phenoxyl)-3-(octylamino)-, hydrochloride but more generally known as tipropidil hydrochloride, which bears US NIH Compound Identifier 72175. Most nations, for tariff and trade purposes, schedule tipropidil hydrochloride under HS 29309085 and SITC 51549. As of Q4 2014, TIPROPIDIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tipropidil hydrochloride bears US NLM identifiers UMLS ID C0145972 and NCI Concept Code C77079. SMILES: CCCCCCCCNCC(COC1CCC(CC1)SC(C)C)O.CL.
This classification denotes an immunostimulant with the molecular formula C10H13NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZ7ZH245CO, chemically known as 5-thiazoleacetic acid, 2-((3-carboxypropyl)thio)-4-methyl- but generally known as tiprotimod, which bears US NIH Compound Identifier 65890. European Medicines Agency schedules Tiprotimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11110MIG. The term TIPROTIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). TIPROTIMOD is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiprotimod under HS 29341000 and SITC 51579. As of Q4 2014, TIPROTIMOD remains the US FDA Preferred Term for this commodity. Tiprotimod bears US NLM identifiers UMLS ID C0076719 and NCI Concept Code C76689. SMILES: CC1=C(SC(=N1)SCCCC(=O)O)CC(=O)O.
This classification denotes an anti-ulcer agent with the molecular formula C11H14N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51O951X8V9, chemically known as 5,6,7,8-tetrahydro-3-methyl-8-quinolinecarbothioamide but generally known as tiquinamide, which bears US NIH Compound Identifier 3003921. European Medicines Agency schedules Tiquinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11112MIG. The term TIQUINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). TIQUINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiquinamide under HS 29334990 and SITC 51575. As of Q4 2014, TIQUINAMIDE remains the US FDA Preferred Term for this commodity. Tiquinamide bears US NLM identifiers UMLS ID C0076720 and NCI Concept Code C90778. SMILES: CC1=CN=C2C(CCCC2=C1)C(=S)N.
This classification denotes an antiarrhythmic agent with the molecular formula C21H25N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9UUO2T61K7, chemically known as ethyl 5-(n,n-dimethylglycyl)-10,11-dihydro-5h-dibenz(b,f)azepine-3-carbamate but generally known as tiracizine, which bears US NIH Compound Identifier 71264. European Medicines Agency schedules Tiracizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11114MIG. The term TIRACIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules tiracizine in its Anatomical Therapeutic Chemical (ATC) Classification. TIRACIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiracizine under HS 29339930 and SITC 51577. As of Q4 2014, TIRACIZINE remains the US FDA Preferred Term for this commodity. Tiracizine bears US NLM identifiers UMLS ID C0145975 and NCI Concept Code C75137. SMILES: O=C(N1c2c(CCc3c1cccc3)ccc(NC(=O)OCC)c2)CN(C)C.
This classification denotes an antiarrhythmic agent with the molecular structure C21H25N3O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, GB5HGM31RA chemically known as carbamic acid, n-(5-(2-(dimethylamino)acetyl)-10,11-dihydro-5h-dibenz(b,f)azepin-3-yl)-, ethyl ester, hydrochloride (1:1), but more commonly known as tiracizine hydrochloride, which bears US NIH Compound Identifier 107750. European Medicines Agency schedules Tiracizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04885MIG. Most nations, for tariff and trade purposes, schedule tiracizine hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, TIRACIZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)NC1CCC2C(C1)N(C3CCCCC3CC2)C(=O)CN(C)C.CL.
This classification denotes a thyroid agent with the molecular formula C14H9I3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29OQ9EU4R1, chemically known as 3,3′,5-triiodothyroacetic acid but generally known as tiratricol, which bears US NIH Compound Identifier 5803. European Medicines Agency schedules Tiratricol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11116MIG. The term TIRATRICOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules tiratricol in its Anatomical Therapeutic Chemical (ATC) Classification. TIRATRICOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiratricol under HS 29189900 and SITC 51396. As of Q4 2014, TIRATRICOL remains the US FDA Preferred Term for this commodity. Tiratricol bears US NLM identifiers UMLS ID C0046882 and NCI Concept Code C66605. SMILES: IC1C(OC2CC(I)C(O)CC2)C(I)CC(CC(=O)O)C1.
This classification denotes an antiplatelet agent with the molecular formula C22H36N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GGX234SI5H, chemically known as l-tyrosine, n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)- but generally known as tirofiban, which bears US NIH Compound Identifier 60947. European Medicines Agency schedules Tirofiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11118MIG. The term TIROFIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules tirofiban in its Anatomical Therapeutic Chemical (ATC) Classification. TIROFIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tirofiban under HS 29350090 and SITC 51580. As of Q4 2014, TIROFIBAN remains the US FDA Preferred Term for this commodity. Tirofiban bears US NLM identifiers UMLS ID C0247025 and NCI Concept Code C76405. SMILES: S(=O)(=O)(NC(Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O)CCCC.
This classification denotes an antiplatelet agent with the molecular formula C22H36N2O5S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6H925F8O5J, chemically known as l-tyrosine, n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-, monohydrochloride, monohydrate but more generally known as tirofiban hydrochloride, which bears US NIH Compound Identifier 60946. European Medicines Agency schedules Tirofiban hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04887MIG. Most nations, for tariff and trade purposes, schedule tirofiban hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, TIROFIBAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tirofiban hydrochloride bears US NLM identifiers UMLS ID C0795668 and NCI Concept Code C47759. SMILES: CCCCS(=O)(=O)N[C@@H](CC1CCC(CC1)OCCCCC2CCNCC2)C(=O)O.O.CL.
This classification denotes an antiplatelet agent with the molecular formula C22H36N2O5S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IKE1P4X57J, chemically known as l-tyrosine, n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-, hydrochloride (1:1), but more generally known as tirofiban hydrochloride anhydrous, which bears US NIH Compound Identifier 64781. European Medicines Agency schedules tirofiban hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11118MIG. Most nations, for tariff purposes, schedule tirofiban hydrochloride anhydrous under HS 29350090. SMILES: CCCCS(=O)(=O)N[C@@H](CC1CCC(CC1)OCCCCC2CCNCC2)C(=O)O.CL.
This classification denotes an antiplatelet agent with the molecular formula C22H36N2O5S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6H925F8O5J, chemically known as l-tyrosine, n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-, hydrochloride, hydrate (1:1:1), but more generally known as tirofiban hydrochloride monohydrate, which bears US NIH Compound Identifier 60946. European Medicines Agency schedules tirofiban hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11118MIG. Most nations, for tariff purposes, schedule tirofiban hydrochloride monohydrate under HS 29350090. SMILES: CCCCS(=O)(=O)N[C@@H](CC1CCC(CC1)OCCCCC2CCNCC2)C(=O)O.O.CL.
This classification denotes a parasympatholytic and tyrosine analog C28H41N3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9523013Y6R, chemically known as benzenepropanamide, alpha-(benzoylamino)-4-(2-(diethylamino)ethoxy)- n,n-dipropyl-, hydrochloride, (+/-)-, but more generally known as tiropramide hydrochloride, which bears US NIH Compound Identifier 134448. European Medicines Agency schedules Tiropramide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15577MIG. Most nations, for tariff and trade purposes, schedule tiropramide hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, TIROPRAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCN(CCC)C(=O)C(CC1CCC(CC1)OCCN(CC)CC)NC(=O)C2CCCCC2.CL.
This classification denotes a parasympatholytic and tyrosine analog with the molecular formulas C28H41N3O3 and C28H41N3O3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers R7S0904CN2 and 9523013Y6R, the base compound being chemically known as dl-alpha-benzamido-para-(2-(diethylamino)ethoxy)-n,n-dipropylhydrocinnamamide but generally known as tiropramide, which bears US NIH Compound Identifier 42262. European Medicines Agency schedules Tiropramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB11119MIG and SUB15577MIG. World Health Organization schedules tiropramide in its Anatomical Therapeutic Chemical (ATC) Classification. TIROPRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tiropramide and its salts under HS 29242995 and SITC 51479. As of Q4 2014, TIROPRAMIDE remains the US FDA Preferred Term for this commodity. SMILES: O=C(N(CCC)CCC)C(NC(=O)C1CCCCC1)CC1CCC(OCCN(CC)CC)CC1 (base) and CCCN(CCC)C(=O)C(CC1CCC(CC1)OCCN(CC)CC)NC(=O)C2CCCCC2.CL (hydrochloride).
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE300. This VA Drug Class (DE300) classifies this compound as belonging to the group SUN PROTECTANTS/SCREENS, TOPICAL.
This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E136TJT00. European Medicines Agency schedules Tivanidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11123MIG. Tivanidazole generally arises in the molecular formula C11H13N5O2S. The term TIVANIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) TIVANIDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tivanidazole under HS 29349990 and SITC 51579. As of Q4 2014, TIVANIDAZOLE remains the US FDA Preferred Term for this commodity. Tivanidazole bears US NLM identifiers UMLS ID C2348794 and NCI Concept Code C73279. SMILES: CCC1=NN=C(S1)/C(=C/C2=NC=C(N2C)[N+](=O)[O-])/C.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F4L1E450W. European Medicines Agency schedules Tixadil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11125MIG. Tixadil generally arises in the molecular formula C24H25NS. The term TIXADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) TIXADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tixadil under HS 29349990 and SITC 51579. As of Q4 2014, TIXADIL remains the US FDA Preferred Term for this commodity. Tixadil bears US NLM identifiers UMLS ID C2699958 and NCI Concept Code C76948. SMILES: S1C2C(C(CCNC(CC3CCCCC3)C)C3C1CCCC3)CCCC2.
This classification denotes a hydrocortisone analog and 21-thiol hydrocortisone derivative with the molecular formula C21H30O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZX3KEK657Z, chemically known as 11beta,17-dihydroxy-21-mercapto-4-pregnen-3,20-dion but generally known as tixocortol, which bears US NIH Compound Identifier 162955. European Medicines Agency schedules Tixocortol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11127MIG. World Health Organization schedules tixocortol in its Anatomical Therapeutic Chemical (ATC) Classification. TIXOCORTOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tixocortol under HS 29372900 and SITC 54153. As of Q4 2014, TIXOCORTOL remains the US FDA Preferred Term for this commodity. SMILES: SCC(=O)C1(O)C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)C(O)C2)CC1)C.
This classification denotes a hydrocortisone analog and 21-thiol hydrocortisone derivative C26H38O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K28E35M3B, chemically known as pregn-4-ene-3,20-dione, 21-((2,2-dimethyl-1-oxopropyl)thio)-11,17-dihydroxy-, (11.beta.)-, but more generally known as tixocortol pivalate, which bears US NIH Compound Identifier 15052414. European Medicines Agency schedules Tixocortol pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04894MIG. Most nations, for tariff and trade purposes, schedule tixocortol pivalate under HS 29372900 and SITC 54153. As of Q4 2014, TIXOCORTOL PIVALATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CSC(=O)C(C)(C)C)O)C)O.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H8ClN5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6AI06C00GW, chemically known as 2,1,3-benzothiadiazole, 5-chloro-4-(2-imidazolin-2-ylamino)- but generally known as tizanidine, which bears US NIH Compound Identifier 5487. European Medicines Agency schedules Tizanidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11129MIG. The term TIZANIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules tizanidine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tizanidine under HS 29349990 and SITC 51579. As of Q4 2014, TIZANIDINE remains the US FDA Preferred Term for this commodity. Tizanidine bears US NLM identifiers UMLS ID C0146011 and NCI Concept Code C61976. SMILES: CLC1C(NC2=NCCN2)C2NSNC2CC1.
This classification denotes an alpha-adrenergic agonist with the molecular formula C9H8ClN5S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B53E3NMY5C, chemically known as 2,1,3-benzothiadiazol-4-amine, 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-, monohydrochloride but more generally known as tizanidine hydrochloride, which bears US NIH Compound Identifier 114869. European Medicines Agency schedules Tizanidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04895MIG. Most nations, for tariff and trade purposes, schedule tizanidine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TIZANIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tizanidine hydrochloride bears US NLM identifiers UMLS ID C0771735 and NCI Concept Code C47760. SMILES: C1CC(C(C2C1NSN2)NC3=NCCN3)CL.CL.
This classification denotes a diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P60K8QK3AA. European Medicines Agency schedules Tizolemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11130MIG. Tizolemide generally arises in the molecular formula C11H14CLN3O3S2. The term TIZOLEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) TIZOLEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tizolemide under HS 29350090 and SITC 51580. As of Q4 2014, TIZOLEMIDE remains the US FDA Preferred Term for this commodity. Tizolemide bears US NLM identifiers UMLS ID C0076749 and NCI Concept Code C90838. SMILES: CN=C1N(C(CS1)(C2=CC(=C(C=C2)CL)S(=O)(=O)N)O)C.
This classification denotes an anti-lipidemic agent with the molecular formula C7H9NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VGT0G37N5M, chemically known as 5-thiazolecarboxylic acid, 2-propyl- but generally known as tizoprolic acid, which bears US NIH Compound Identifier 65773. European Medicines Agency schedules Tizoprolic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11131MIG. The term TIZOPROLIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). Most nations schedule tizoprolic acid under HS 29341000 and SITC 51579. As of Q4 2014, TIZOPROLIC ACID remains the US FDA Preferred Term for this commodity. Tizoprolic acid bears US NLM identifiers UMLS ID C0076750 and NCI Concept Code C75261. SMILES: s1c(ncc1C(=O)O)CCC.
This classification denotes a penicillin antibiotic, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 2P43Z53ESB. The European Medicines Agency schedules Tobicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11132MIG. Tobicillin generally arises in the molecular formula C27H30N2O6S. The term TOBICILLIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 12 no. 2 1999, list 40.) TOBICILLIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S1C2N(C(C1(C)C)C(=O)OC1CC(CCC1)COC(=O)C(C)C)C(=O)C2NC(=O)CC1CCCCC1.
This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VZ8RRZ51VK, chemically known as tobramycin, free base but generally known as tobramycin, which bears US NIH Compound Identifier 5496. European Medicines Agency schedules Tobramycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11134MIG. The term TOBRAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). World Health Organization schedules tobramycin in its Anatomical Therapeutic Chemical (ATC) Classification. TOBRAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tobramycin under HS 29419000 and SITC 54139. As of Q4 2014, TOBRAMYCIN remains the US FDA Preferred Term for this commodity. Tobramycin bears US NLM identifiers UMLS ID C0040341 and NCI Concept Code C62082. SMILES: O(C1C(O)C(OC2OC(C(O)CC2N)CN)C(N)CC1N)C1OC(C(O)C(N)C1O)CO.
This classification denotes an aminoglycoside antibiotic with the molecular formula 2C18H37N5O9.5H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HJT0RXD7JK, chemically known as tobramycin, free base but more generally known as tobramycin sulfate, which bears US NIH Compound Identifier 5496. European Medicines Agency schedules Tobramycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04896MIG. Most nations, for tariff and trade purposes, schedule tobramycin sulfate under HS 29419000 and SITC 54139. Tobramycin sulfate bears US NLM identifiers UMLS ID C0701392 and NCI Concept Code C893. SMILES: As of Q4 2014, TOBRAMYCIN SULFATE remains US FDA's Preferred Term for this commodity.
This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17B9PXO2SW. European Medicines Agency schedules Tobuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11135MIG. Tobuterol generally arises in the molecular formula C28H31NO5. The term TOBUTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) TOBUTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Tobuterol under HS 29225000 and SITC 51467. As of Q4 2014, TOBUTEROL remains the US FDA Preferred Term for this commodity. Tobuterol bears US NLM identifiers UMLS ID C2699960 and NCI Concept Code C76550. SMILES: CC1CCC(CC1)C(=O)OC2CC(CC(C2)OC(=O)C3CCC(CC3)C)C(CNC(C)(C)C)O.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C11H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 27DXO59SAN, chemically known as 2-amino-n-(2,6-dimethylphenyl)propionamid but more generally known as tocainide, which bears US NIH Compound Identifier 38945. European Medicines Agency schedules Tocainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11136MIG. The term TOCAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules tocainide in its Anatomical Therapeutic Chemical (ATC) Classification. TOCAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tocainide under HS 29242995 and SITC 51479. As of Q4 2014, TOCAINIDE remains US FDA's Preferred Term for this commodity. Tocainide bears US NLM identifiers UMLS ID C0085237 and NCI Concept Code C66607. SMILES: CC1=C(C(=CC=C1)C)NC(=O)C(C)N.
This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C11H16N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2K7I38CKN5, chemically known as 2-amino-n-(2,6-dimethylphenyl)propanamide monohydrochloride but more generally known as tocainide hydrochloride, which bears US NIH Compound Identifier 108173. European Medicines Agency schedules Tocainide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04897MIG. Most nations, for tariff and trade purposes, schedule tocainide hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, TOCAINIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tocainide hydrochloride bears US NLM identifiers UMLS ID C0886765 and NCI Concept Code C47761. SMILES: CC1CCCC(C1NC(=O)C(C)N)C.CL.
This classification denotes a purine antagonist and differentiation inducer with the molecular formula C10H11ClN5O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BQ94Z7E5OR, chemically known as 8-chloroadenosine 3,5-monophosphate but generally known as tocladesine, which bears US NIH Compound Identifier 100299. Most nations schedule tocladesine under HS 29349990 and SITC 51579. As of Q4 2014, TOCLADESINE remains the US FDA Preferred Term for this commodity. Tocladesine bears US NLM identifiers UMLS ID C0050063 and NCI Concept Code C2571. SMILES: C1C2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3CL)O)OP(=O)(O1)O.
This classification denotes an antioxidant with the molecular formula C33H54O5(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O03S90U1F2, chemically known as poly(oxy-1,2-ethanediyl), alpha-(4-((3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2h-1-benzopyran-6-yl)oxy)-1,4-dioxobutyl)-omega-hydroxy- but generally known as tocofersolan, which bears US NIH Compound Identifier 71406. European Medicines Agency schedules Tocofersolan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11139MIG. The term TOCOFERSOLAN is an International Non-Proprietary Name. World Health Organization schedules tocofersolan in its Anatomical Therapeutic Chemical (ATC) Classification. TOCOFERSOLAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tocofersolan under HS 29362800 and SITC 54115. SMILES: CC1=C2C(=C(C(=C1C)OC(=O)CCC(=O)OCCO)C)CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C.
This classification denotes a vasodilating agent with the molecular formula C11H12N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WEN3K83YKD, chemically known as hydrazinecarboxylic acid, 2-(1-phthalazinyl)-, ethyl ester (9ci) but generally known as todralazine, which bears US NIH Compound Identifier 5501. European Medicines Agency schedules Todralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11141MIG. The term TODRALAZINE is an International Non-Proprietary Name. TODRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule todralazine under HS 29339990 and SITC 51577. As of Q4 2014, TODRALAZINE remains the US FDA Preferred Term for this commodity. Todralazine bears US NLM identifiers UMLS ID C0040354 and NCI Concept Code C77080. SMILES: CCOC(=O)NNC1=NN=CC2=CC=CC=C21.
This classification denotes a vasodilating agent with the molecular formula C11H12N4O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5998D60YO0, chemically known as ethyl 3-(phthalazin-1-yl)carbazate hydrochloride monohydrate, but more generally known as todralazine hydrochloride, which bears US NIH Compound Identifier 904. European Medicines Agency schedules todralazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11141MIG. Most nations, for tariff purposes, schedule todralazine hydrochloride under HS 29339990. SMILES: CCOC(=O)NNC1C2CCCCC2CNN1.O.CL.
Tofacitinib is an immunosuppressant (a medicine that reduces the activity of the immune system) that works by blocking the action of enzymes known as Janus kinases and used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
This classification denotes an antimuscarinic agent with the molecular formula C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, C4A112M10H chemically known as ethanamine, n-methyl-2-((2-methylphenyl)phenylmethoxy)- but generally known as tofenacin, which bears US NIH Compound Identifier 25315. European Medicines Agency schedules Tofenacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11142MIG. The term TOFENACIN is an International Non-Proprietary Name or INN. Most nations schedule tofenacin under HS 29221980 and SITC 51461. As of Q4 2014, TOFENACIN remains the US FDA Preferred Term for this commodity. Tofenacin bears US NLM identifiers UMLS ID C0076783 and NCI Concept Code C81546. SMILES: CC1=CC=CC=C1C(C2=CC=CC=C2)OCCNC.
This classification denotes an anticholinergic agent with the molecular structure C17H21NO.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 3A10ND4DWR chemically known as ethanamine, n-methyl-2-((2-methylphenyl)phenylmethoxy)-, hydrochloride, but more commonly known as tofenacin hydrochloride, which bears US NIH Compound Identifier 25314. European Medicines Agency schedules Tofenacin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04904MIG. Most nations, for tariff and trade purposes, schedule tofenacin hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, TOFENACIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tofenacin hydrochloride bears US NLM identifiers UMLS ID C2825640 and NCI Concept Code C81452. SMILES: CC1CCCCC1C(C2CCCCC2)OCCNC.CL.
This classification denotes an anxiolytic with the molecular formula C22H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UZC80HAU42, chemically known as 7,8-dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5h-2,3-benzodiazepine but generally known as tofisopam, which bears US NIH Compound Identifier 5502. European Medicines Agency schedules Tofisopam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11144MIG. The term TOFISOPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules tofisopam in its Anatomical Therapeutic Chemical (ATC) Classification. TOFISOPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tofisopam under HS 29339940 and SITC 51577. As of Q4 2014, TOFISOPAM remains the US FDA Preferred Term for this commodity. Tofisopam bears US NLM identifiers UMLS ID C0076784 and NCI Concept Code C90791. SMILES: O(C1CC2C(CC)C(=NN=C(C2CC1OC)C1CC(OC)C(OC)CC1)C)C.
This classification denotes an anti-diabetic agent with the molecular formula C14H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9LT1BRO48Q, chemically known as 4-(p-tolylsulfonyl)-1,1-hexamethylenesemicarbazide but more generally known as tolazamide, which bears US NIH Compound Identifier 5503. European Medicines Agency schedules Tolazamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11147MIG. The term TOLAZAMIDE is an International Non-Proprietary Name WHO schedules tolazamide in its Anatomical Therapeutic Chemical (ATC) Classification. TOLAZAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tolazamide under HS 29350090 and SITC 51580. As of Q4 2014, TOLAZAMIDE remains US FDA's Preferred Term for this commodity. Tolazamide bears US NLM identifiers UMLS ID C0040372 and NCI Concept Code C29502. SMILES: S(=O)(=O)(NC(=O)NN1CCCCCC1)C1CCC(CC1)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C10H12N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CHH9H12AQ3, chemically known as 4,5-dihydro-2-(phenylmethyl)-1h-imidazole but generally known as tolazoline, which bears US NIH Compound Identifier 5504. European Medicines Agency schedules Tolazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11148MIG. The term TOLAZOLINE is an International Non-Proprietary Name. World Health Organization schedules tolazoline in its Anatomical Therapeutic Chemical (ATC) Classification. TOLAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolazoline under HS 29332990 and SITC 51573. As of Q4 2014, TOLAZOLINE remains the US FDA Preferred Term for this commodity. Tolazoline bears US NLM identifiers UMLS ID C0040373 and NCI Concept Code C66608. SMILES: C1CN=C(N1)CC2=CC=CC=C2.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C10H12N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E669Z6S1JG, chemically known as 4,5-dihydro-2-(phenylmethyl)-1h-imidazole monohydrochloride but more generally known as tolazoline hydrochloride, which bears US NIH Compound Identifier 6048. European Medicines Agency schedules Tolazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04906MIG. Most nations, for tariff and trade purposes, schedule tolazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, TOLAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tolazoline hydrochloride bears US NLM identifiers UMLS ID C0770500 and NCI Concept Code C66609. SMILES: C1CCC(CC1)CC2=NCCN2.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H21BO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33P8JV23L7, chemically known as 1,3,2-dioxaborinane, 5-methyl-5-propyl-2-p-tolyl- but generally known as tolboxane, which bears US NIH Compound Identifier 72134. European Medicines Agency schedules Tolboxane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11149MIG. The term TOLBOXANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). TOLBOXANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, TOLBOXANE remains the US FDA Preferred Term for this commodity. Tolboxane bears US NLM identifiers UMLS ID C2699961 and NCI Concept Code C75058. SMILES: O1CC(CCC)(CO[B]1C1CCC(CC1)C)C.
This classification denotes an anti-diabetic agent with the molecular formula C12H18N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 982XCM1FOI, chemically known as urea, 1-butyl-3-(p-tolylsulfonyl)- but more generally known as tolbutamide, which bears US NIH Compound Identifier 5505. European Medicines Agency schedules Tolbutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11150MIG. The term TOLBUTAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3) WHO schedules tolbutamide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule tolbutamide under HS 29350090 and SITC 51580. As of Q4 2014, TOLBUTAMIDE remains US FDA's Preferred Term for this commodity. Tolbutamide bears US NLM identifiers UMLS ID C0040374 and NCI Concept Code C66610. SMILES: CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C.
This classification denotes an antiparkinsonian agent with the molecular formula C14H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CIF6334OLY, chemically known as 3,4-dihydroxy-4-methyl-5-nitrobenzophenone but generally known as tolcapone, which bears US NIH Compound Identifier 4659569. European Medicines Agency schedules Tolcapone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11151MIG. The term TOLCAPONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules tolcapone in its Anatomical Therapeutic Chemical (ATC) Classification. TOLCAPONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolcapone under HS 29147000 and SITC 51629. As of Q4 2014, TOLCAPONE remains the US FDA Preferred Term for this commodity. Tolcapone bears US NLM identifiers UMLS ID C0246330 and NCI Concept Code C47762. SMILES: O=C(C1CC([N](=O)O)C(O)C(O)C1)C1CCC(CC1)C.
This classification denotes a thiocarbamate and antifungal agent with the molecular formula C20H21NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3TZ02X2AZ, chemically known as 1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl n-methyl-n-(m-tolyl)carbamothioate but generally known as tolciclate, which bears US NIH Compound Identifier 5506. European Medicines Agency schedules Tolciclate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11152MIG. World Health Organization schedules tolciclate in its Anatomical Therapeutic Chemical (ATC) Classification. TOLCICLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolciclate under HS 29302000 and SITC 51542. As of Q4 2014, TOLCICLATE remains the US FDA Preferred Term for this commodity. SMILES: S=C(OC1CC2C3CC(CC3)C2CC1)N(C1CC(CCC1)C)C.
This classification denotes an enzyme inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7TJT8X832U. European Medicines Agency schedules Tolfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11154MIG. Tolfamide generally arises in the molecular formula C8H12N3O2P. The term TOLFAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 35, no. 5 1981, list 21.) TOLFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H12ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3G943U18KM, chemically known as benzoic acid, 2-((3-chloro-2-methylphenyl)amino)- (9ci) but generally known as tolfenamic acid, which bears US NIH Compound Identifier 5507. European Medicines Agency schedules Tolfenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11155MIG. The term TOLFENAMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules tolfenamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tolfenamic acid under HS 29224995 and SITC 51465. As of Q4 2014, TOLFENAMIC ACID remains the US FDA Preferred Term for this commodity. Tolfenamic acid bears US NLM identifiers UMLS ID C0076799 and NCI Concept Code C87328. SMILES: CC1=C(C=CC=C1Cl)NC2=CC=CC=C2C(=O)O.
This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0L55QF645F. European Medicines Agency schedules Tolgabide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11156MIG. Tolgabide generally arises in the molecular formula C18H18CL2N2O2. The term TOLGABIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) TOLGABIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolgabide under HS 29252900 and SITC 51482. As of Q4 2014, TOLGABIDE remains the US FDA Preferred Term for this commodity. Tolgabide bears US NLM identifiers UMLS ID C2348800 and NCI Concept Code C72871. SMILES: CLC1=CC(=C(\NCCCC(=O)N)C2CCC(CL)CC2)\C(=O)C(=C1)C.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5236RK32KG. European Medicines Agency schedules Tolindate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11158MIG. Tolindate generally arises in the molecular formula C18H19NOS. The term TOLINDATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) TOLINDATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolindate under HS 29302000 and SITC 51542. As of Q4 2014, TOLINDATE remains the US FDA Preferred Term for this commodity. Tolindate bears US NLM identifiers UMLS ID C2827341 and NCI Concept Code C84218. SMILES: S=C(OC1CC2CCCC2CC1)N(C1CC(CCC1)C)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D8K2JPN18B, chemically known as 1h-pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)- but generally known as tolmetin, which bears US NIH Compound Identifier 5509. European Medicines Agency schedules Tolmetin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11162MIG. The term TOLMETIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules tolmetin in its Anatomical Therapeutic Chemical (ATC) Classification. TOLMETIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolmetin under HS 29339990 and SITC 51577. As of Q4 2014, TOLMETIN remains the US FDA Preferred Term for this commodity. Tolmetin bears US NLM identifiers UMLS ID C0040377 and NCI Concept Code C29503. SMILES: O=C(C1N(C(CC1)CC(=O)O)C)C1CCC(CC1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3RS348SV6U, chemically known as glycine, n-(2-(1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl)acetyl)-, but more generally known as tolmetin glycine amide, which bears US NIH Compound Identifier 135911. European Medicines Agency schedules tolmetin glycine amide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11162MIG. Most nations, for tariff purposes, schedule tolmetin glycine amide under HS 29339990. SMILES: CC1CCC(CC1)C(=O)C2CCC(N2C)CC(=O)NCC(=O)O.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14NO3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02N1TZF99F, chemically known as 1h-pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)- but more generally known as tolmetin sodium, which bears US NIH Compound Identifier 5509. European Medicines Agency schedules Tolmetin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04908MIG. Most nations, for tariff and trade purposes, schedule tolmetin sodium under HS 29339990 and SITC 51577. As of Q4 2014, TOLMETIN SODIUM remains US FDA's Preferred Term for this commodity. Tolmetin sodium bears US NLM identifiers UMLS ID C0087097 and NCI Concept Code C61977. SMILES: CC1CCC(CC1)C(=O)C2CCC(N2C)CC(=O)[O-].O.O.[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14NO3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02N1TZF99F, chemically known as 1h-pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-, sodium salt, dihydrate, but more generally known as tolmetin sodium dihydrate, which bears US NIH Compound Identifier 47400. European Medicines Agency schedules tolmetin sodium dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11162MIG. Most nations, for tariff purposes, schedule tolmetin sodium dihydrate under HS 29339990. SMILES: CC1CCC(CC1)C(=O)C2CCC(N2C)CC(=O)[O-].O.O.[NA+].
This classification denotes an antifungal agent with the molecular formula C19H17NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06KB629TKV, chemically known as o-2-naphthyl n,n-dimethylthiocarbanilate but generally known as tolnaftate, which bears US NIH Compound Identifier 5510. European Medicines Agency schedules Tolnaftate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11163MIG. The term TOLNAFTATE is an International Non-Proprietary Name. World Health Organization schedules tolnaftate in its Anatomical Therapeutic Chemical (ATC) Classification. TOLNAFTATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolnaftate under HS 29309085 and SITC 51549. As of Q4 2014, TOLNAFTATE remains the US FDA Preferred Term for this commodity. Tolnaftate bears US NLM identifiers UMLS ID C0040379 and NCI Concept Code C47763. SMILES: S=C(OC1CC2C(CC1)CCCC2)N(C1CC(CCC1)C)C.
This classification denotes an alpha-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I4O795Q03O. European Medicines Agency schedules Tolonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11167MIG. Tolonidine generally arises in the molecular formula C10H12CLN3. The term TOLONIDINE is an International Non-Proprietary Name or INN. TOLONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolonidine under HS 29332990 and SITC 51573. As of Q4 2014, TOLONIDINE remains the US FDA Preferred Term for this commodity. Tolonidine bears US NLM identifiers UMLS ID C0076803 and NCI Concept Code C75048. SMILES: CC1=CC(=C(C=C1)NC2=NCCN2)CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C10H12ClN3.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75W1B0GTHA, chemically known as 2-(2-chloro-p-toluidino)-2-imidazoline nitrate, but more generally known as tolonidine nitrate, which bears US NIH Compound Identifier 198360. European Medicines Agency schedules tolonidine nitrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11167MIG. Most nations, for tariff purposes, schedule tolonidine nitrate under HS 29332990. SMILES: CC1CCC(C(C1)CL)NC2=NCCN2.[N+](=O)(O)[O-].
This classification denotes an antidepressive agent, monoamine oxidase inhibitor, and oxazolidinone derivative with the molecular formula C11H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T206015T5, chemically known as 2-oxazolidinone, 5-hydroxymethyl-3-(m-tolyl)- but generally known as toloxatone, which bears US NIH Compound Identifier 34521. European Medicines Agency schedules Toloxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11169MIG. World Health Organization schedules toloxatone in its Anatomical Therapeutic Chemical (ATC) Classification. TOLOXATONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule toloxatone under HS 29349990 and SITC 51579. As of Q4 2014, TOLOXATONE remains the US FDA Preferred Term for this commodity. Toloxatone bears US NLM identifiers UMLS ID C0076804 and NCI Concept Code C97715. SMILES: CC1=CC(=CC=C1)N2CC(OC2=O)CO.
This classification denotes a muscle relaxant with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5EOM0LD8E, chemically known as 2,4-dimethyl-3-piperidinopropiophenone but generally known as tolperisone, which bears US NIH Compound Identifier 5511. European Medicines Agency schedules Tolperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11173MIG. The term TOLPERISONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules tolperisone in its Anatomical Therapeutic Chemical (ATC) Classification. TOLPERISONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolperisone under HS 29333999 and SITC 51574. As of Q4 2014, TOLPERISONE remains the US FDA Preferred Term for this commodity. Tolperisone bears US NLM identifiers UMLS ID C0040382 and NCI Concept Code C84219. SMILES: O=C(C(CN1CCCCC1)C)C1CCC(CC1)C.
This classification denotes a muscle relaxant with the molecular structure C16H23NO.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8Z075K2TIG chemically known as 2,4'-dimethyl-3-piperidinopropiophenone hydrochloride, but more commonly known as tolperisone hydrochloride, which bears US NIH Compound Identifier 92965. European Medicines Agency schedules Tolperisone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04912MIG. Most nations, for tariff and trade purposes, schedule tolperisone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, TOLPERISONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tolperisone hydrochloride bears US NLM identifiers UMLS ID C1564420 and NCI Concept Code C84220. SMILES: CC1CCC(CC1)C(=O)C(C)CN2CCCCC2.CL.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8XP74P4HO3. European Medicines Agency schedules Tolpiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11174MIG. Tolpiprazole generally arises in the molecular formula C17H24N4. The term TOLPIPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11.) TOLPIPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolpiprazole under HS 29335995 and SITC 51576. As of Q4 2014, TOLPIPRAZOLE remains the US FDA Preferred Term for this commodity. Tolpiprazole bears US NLM identifiers UMLS ID C2699963 and NCI Concept Code C76453. SMILES: N1(CCN(CC1)C1CC(CCC1)C)CCC1N[NH]C(C1)C.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TBZ8909KFS, chemically known as n,n-dimethyl-3-phenyl-3-p-tolylpropylamine but generally known as tolpropamine, which bears US NIH Compound Identifier 72141. European Medicines Agency schedules Tolpropamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11176MIG. The term TOLPROPAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules tolpropamine in its Anatomical Therapeutic Chemical (ATC) Classification. TOLPROPAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolpropamine under HS 29214980 and SITC 51454. As of Q4 2014, TOLPROPAMINE remains the US FDA Preferred Term for this commodity. Tolpropamine bears US NLM identifiers UMLS ID C0076805 and NCI Concept Code C90861. SMILES: N(CCC(C1CCC(CC1)C)C1CCCCC1)(C)C.
This classification denotes a histamine-1 receptor antagonist with the molecular structure C18H23N.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1P6C450YET chemically known as benzenepropanamine, n,n,4-trimethyl-.gamma.-phenyl-, hydrochloride (1:1), but more commonly known as tolpropamine hydrochloride, which bears US NIH Compound Identifier 102987. European Medicines Agency schedules Tolpropamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04913MIG. Most nations, for tariff and trade purposes, schedule tolpropamine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, TOLPROPAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tolpropamine hydrochloride bears US NLM identifiers UMLS ID C0951394 and NCI Concept Code C97705. SMILES: CC1CCC(CC1)C(CCN(C)C)C2CCCCC2.CL.
This classification denotes an anti-diabetic agent with the molecular formula C12H16N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W68DD2C7VG, chemically known as 1-pyrrolidinecarboxamide, n- (p-tolylsulfonyl)- but more generally known as tolpyrramide, which bears US NIH Compound Identifier 267368. European Medicines Agency schedules Tolpyrramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11177MIG. The term TOLPYRRAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). TOLPYRRAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tolpyrramide under HS 29350090 and SITC 51580. As of Q4 2014, TOLPYRRAMIDE remains US FDA's Preferred Term for this commodity. Tolpyrramide bears US NLM identifiers UMLS ID C2348802 and NCI Concept Code C72872. SMILES: CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCCC2.
This classification denotes an aldose reductase inhibitor with the molecular formula C16H14F3NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 0T93LG5NMK, chemically known as glycine, n-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-n-methyl- but more generally known as tolrestat, which bears US NIH Compound Identifier 53359. European Medicines Agency schedules Tolrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11179MIG. The term TOLRESTAT is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24) WHO schedules tolrestat in its Anatomical Therapeutic Chemical (ATC) Classification. TOLRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tolrestat under HS 29309085 and SITC 51549. As of Q4 2014, TOLRESTAT remains US FDA's Preferred Term for this commodity. Tolrestat bears US NLM identifiers UMLS ID C0076808 and NCI Concept Code C96310. SMILES: S=C(N(CC(=O)O)C)C1C2C(C(C(OC)CC2)C(F)(F)F)CCC1.
This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WHE7A56U7K. European Medicines Agency schedules Tolterodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11180MIG. Tolterodine generally arises in the molecular formula C22H31NO. The term TOLTERODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) TOLTERODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolterodine under HS 29222900 and SITC 51462. As of Q4 2014, TOLTERODINE remains the US FDA Preferred Term for this commodity. Tolterodine bears US NLM identifiers UMLS ID C0388753 and NCI Concept Code C62083. SMILES: OC1C(C(CCN(C(C)C)C(C)C)C2CCCCC2)CC(CC1)C.
This classification denotes an antiprotozoal agent with the molecular formula C18H14F3N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QVZ3IAR3JS, chemically known as 1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1-methyl-3-(3-methyl-4-(4-((trifluoromethyl)thio)phenoxy)phenyl)- but generally known as toltrazuril, which bears US NIH Compound Identifier 68591. European Medicines Agency schedules Toltrazuril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11181MIG. The term TOLTRAZURIL is an International Non-Proprietary Name. TOLTRAZURIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule toltrazuril under HS 29336980 and SITC 51576. As of Q4 2014, TOLTRAZURIL remains the US FDA Preferred Term for this commodity. Toltrazuril bears US NLM identifiers UMLS ID C0146196 and NCI Concept Code C72601. SMILES: S(C1CCC(OC2C(CC(N3C(=O)N(C(=O)[NH]C3=O)C)CC2)C)CC1)C(F)(F)F.
This classification denotes a benzodiazepine with the molecular formula C24H20Cl2N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98SR74X50D, chemically known as 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-1-(2-(p-tolylsulfonyl)ethyl)-2h-1,4-benzodiazepin-2-one but generally known as tolufazepam, which bears US NIH Compound Identifier 65647. European Medicines Agency schedules Tolufazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11182MIG. The term TOLUFAZEPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). TOLUFAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolufazepam under HS 29339940 and SITC 51577. As of Q4 2014, TOLUFAZEPAM remains the US FDA Preferred Term for this commodity. Tolufazepam bears US NLM identifiers UMLS ID C2699964 and NCI Concept Code C76538. SMILES: CLC1CC2C(N(CCS(=O)(=O)C3CCC(CC3)C)C(=O)CN=C2C2C(CL)CCCC2)CC1.
This classification denotes a vasopressin antagonist with the molecular formula C26H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21G72T1950, chemically known as 7-chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1h-1-benzazepine but generally known as tolvaptan, which bears US NIH Compound Identifier 216237. European Medicines Agency schedules Tolvaptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22755. The term TOLVAPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules tolvaptan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tolvaptan under HS 29339930 and SITC 51577. As of Q4 2014, TOLVAPTAN remains the US FDA Preferred Term for this commodity. Tolvaptan bears US NLM identifiers UMLS ID C1176308 and NCI Concept Code C77082. SMILES: CLC1CC2C(O)CCCN(C2CC1)C(=O)C1C(CC(NC(=O)C2C(CCCC2)C)CC1)C.
This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12R8659YM6. European Medicines Agency schedules Tolycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11183MIG. Tolycaine generally arises in the molecular formula C15H22N2O3. The term TOLYCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) TOLYCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tolycaine under HS 29242995 and SITC 51479. As of Q4 2014, TOLYCAINE remains the US FDA Preferred Term for this commodity. Tolycaine bears US NLM identifiers UMLS ID C0538453 and NCI Concept Code C75105. SMILES: O=C(NC1C(CCCC1C(=O)OC)C)CN(CC)CC.
This classification denotes an anesthetic agent with the molecular formula C15H22N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23212OEY8I, chemically known as 2-(2-(diethylamino)acetamido)-m-toluic acid methyl ester monohydrochloride, but more generally known as tolycaine hydrochloride, which bears US NIH Compound Identifier 197869. European Medicines Agency schedules tolycaine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11183MIG. Most nations, for tariff purposes, schedule tolycaine hydrochloride under HS 29242995. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C(=O)OC)C.CL.
This classification denotes an anti-asthmatic agent with the molecular formula C16H22N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59762X5CLS, chemically known as ly-171,883 but generally known as tomelukast, which bears US NIH Compound Identifier 3969. European Medicines Agency schedules Tomelukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11184MIG. The term TOMELUKAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). TOMELUKAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tomelukast under HS 29339990 and SITC 51577. As of Q4 2014, TOMELUKAST remains the US FDA Preferred Term for this commodity. Tomelukast bears US NLM identifiers UMLS ID C2348803 and NCI Concept Code C74135. SMILES: O(CCCCC1N[NH]NN1)C1C(CCC)C(O)C(CC1)C(=O)C.
This classification denotes a cyclooxygenase inhibitor with the molecular formula C21H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EZ948T2878, chemically known as 3-isopropyl-2-(p-methoxyphenyl)-3h-naphth(1,2-d)imidazole but generally known as tomoxiprole, which bears US NIH Compound Identifier 53454. European Medicines Agency schedules Tomoxiprole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11187MIG. The term TOMOXIPROLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). TOMOXIPROLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tomoxiprole under HS 29339990 and SITC 51577. As of Q4 2014, TOMOXIPROLE remains the US FDA Preferred Term for this commodity. Tomoxiprole bears US NLM identifiers UMLS ID C0076824 and NCI Concept Code C66611. SMILES: O(C1CCC(C2[NH]C3C(N2)C(C(C)C)CC2C3CCCC2)CC1)C.
This classification denotes a dermatologic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R533ESO2EC. European Medicines Agency schedules coal tar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB13403MIG, SUB13404MIG, SUB13405MIG, SUB21289, SUB21452, SUB21453, SUB43149, and SUB55279.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C5H0QJ6V7F, the sources of which are any number of species that Integrated Taxonomic Information System classifies under Taxonomic Serial Number 506603 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Gymnospermae, Class Pinopsida, Order Pinales, Family Pinaceae (pines), Genus Pinus L., commonly known as PINE or PINE TREES. Cmmmon pine species from whence this flammable, aromatic, monoterpene-rich resin or liquid comes include pinus halepensis (ITIS SN 506601), pinus massoniana (ITIS SN 822556), pinus merkusii (ITIS SN 506602), pinus palustri (ITIS 18038), pinus ponderosa (ITIS 183365), and pinus taeda (ITIS 18037). European Medicines Agency schedules turpentine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB15638MIG, SUB15691MIG, SUB34008, SUB38777, and SUB56743.
This classification denotes an osmotic diuretic with the molecular formula CH4N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8W8T17847W, chemically known as urea, homopolymer but generally known as carbamide, which bears US NIH Compound Identifier 1176. Carbamide most often comes in base, perhydrate, peroxide, phenylacetate, and resin forms. European Medicines Agency schedules Urea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15662MIG. World Health Organization schedules carbamide in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O=C(N)N.
This classification denotes an anticonvulsant agent with the molecular formula C12H21NO8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H73WJJ391, chemically known as 2,3:4,5-bis-o-isopropylidene-.beta.-d-fructopyranose sulfamate but generally known as topiramate, which bears US NIH Compound Identifier 5514. European Medicines Agency schedules Topiramate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11190MIG. The term TOPIRAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules topiramate in its Anatomical Therapeutic Chemical (ATC) Classification. TOPIRAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule topiramate under HS 29329970 and SITC 51569. As of Q4 2014, TOPIRAMATE remains the US FDA Preferred Term for this commodity. Topiramate bears US NLM identifiers UMLS ID C0076829 and NCI Concept Code C47764. SMILES: S(=O)(=O)(OCC12OCC3OC(OC3C2OC(O1)(C)C)(C)C)N.
This classification denotes a camptothecin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7M7YKX2N15. European Medicines Agency schedules Topotecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11191MIG. Topotecan generally arises in the molecular formula C23H23N3O5. The term TOPOTECAN is an International Non-Proprietary Name or INN. TOPOTECAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule topotecan under HS 29399900 and SITC 54149. As of Q4 2014, TOPOTECAN remains the US FDA Preferred Term for this commodity. Topotecan bears US NLM identifiers UMLS ID C0146224 and NCI Concept Code C1413. SMILES: O1CC2C(C(O)(CC)C1=O)CC1N(CC3C1NC1C(C3)C(CN(C)C)C(O)CC1)C2=O.
This classification denotes a loop diuretic with the molecular formula C16H20N4O3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier W31X2H97FB, chemically known as 3-pyridinesulfonamide, n-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)- but more generally known as torasemide, which bears U.S. National Institutes of Health Compound Identifier 41781. European Medicines Agency schedules Torasemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11195MIG. The term TORASEMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules torasemide in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. TORASEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a selective estrogen receptor modulator with the molecular formula C26H28ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NFE54O27T, chemically known as 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethylamine citrate (1:1) but more generally known as toremifene, which bears US NIH Compound Identifier 3005572. European Medicines Agency schedules Toremifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11197MIG. The term TOREMIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules toremifene in its Anatomical Therapeutic Chemical (ATC) Classification. TOREMIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule toremifene under HS 29221980 and SITC 51461. As of Q4 2014, TOREMIFENE remains US FDA's Preferred Term for this commodity. Toremifene bears US NLM identifiers UMLS ID C0076836 and NCI Concept Code C1256. SMILES: CLCC/C(=C(/C1CCC(OCCN(C)C)CC1)C1CCCCC1)C1CCCCC1.OC(CC(=O)O)(CC(=O)O)C(=O)O.
This classification denotes an anti-progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 711D76P884. European Medicines Agency schedules Toripristone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11198MIG. Toripristone generally arises in the molecular formula C31H39NO2. The term TORIPRISTONE is an International Non-Proprietary Name or INN. TORIPRISTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule toripristone under HS 29372900 and SITC 54153. As of Q4 2014, TORIPRISTONE remains the US FDA Preferred Term for this commodity. Toripristone bears US NLM identifiers UMLS ID C2984007 and NCI Concept Code C91055. SMILES: OC1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)C(C2)c2ccc(N(C(C)C)C)cc2)CC1)C)C#CC.
This classification denotes a quinolone antibiotic with the molecular formula C19H15F3N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GHJ553KQPS, chemically known as 1,8-naphthyridine-3-carboxylic acid, 1,4-dihydro-7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo- but generally known as tosufloxacin, which bears US NIH Compound Identifier 5517. European Medicines Agency schedules Tosufloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11201MIG. The term TOSUFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). TOSUFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tosufloxacin under HS 29339990 and SITC 51577. As of Q4 2014, TOSUFLOXACIN remains the US FDA Preferred Term for this commodity. Tosufloxacin bears US NLM identifiers UMLS ID C0076843 and NCI Concept Code C80642. SMILES: FC1C(N2CC(N)CC2)NC2N(CC(C(=O)C2C1)C(=O)O)C1C(F)CC(F)CC1.
This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I04MF82GW9. European Medicines Agency schedules Tosulur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11202MIG. Tosulur generally arises in the molecular formula C11H15NO5S. The term TOSULUR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) TOSULUR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tosulur under HS 29350090 and SITC 51580. As of Q4 2014, TOSULUR remains the US FDA Preferred Term for this commodity. Tosulur bears US NLM identifiers UMLS ID C2699972 and NCI Concept Code C76434. SMILES: CC1=CC=C(C=C1)S(=O)(=O)NC(=O)OCCOC.
This classification denotes a tosyl compound, chloramine, anti-infective agent, disinfectant, indicator, reagent, and oxidant with the molecular formula C7H7ClNO2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 328AS34YM6, chemically known as p-toluenesulfonamide, n-chloro-, sodium salt but more generally known as tosylchloramide sodium, which bears US NIH Compound Identifier 31387. European Medicines Agency schedules Tosylchloramide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11203MIG. World Health Organization schedules tosylchloramide sodium in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule tosylchloramide sodium under HS 29350090. SMILES: CC1CCC(CC1)S(=O)(=O)[N-]CL.[NA+].
This classification denotes intravenous preparations that deliver minerals and vitamins necessary to proper electrolyte functioning. These typically come in plastic or polymer bags, and attach to a drip, which flushes substances into the patient's bloodstream or system.
This classification denotes a dna minor groove binding agent with the molecular formula C39H43N3O11S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ID0YZQ2TCP, chemically known as spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12h-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1(2h)-isoquinolin)-19-one, 5-(acetyloxy)-3,4,6,6a,7,13,14,16-octahydro-6,8,14-trihydroxy-7,9-dimethoxy-4,10,23-trimethyl-, (1r,6r,6ar,7r,13s,14s,16r)- but generally known as trabectedin, which bears US NIH Compound Identifier 108150. European Medicines Agency schedules Trabectedin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20756. The term TRABECTEDIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3, 2002, List 48). World Health Organization schedules trabectedin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule trabectedin under HS 29349990 and SITC 51579. As of Q4 2014, TRABECTEDIN remains the US FDA Preferred Term for this commodity. Trabectedin bears US NLM identifiers UMLS ID C1311070 and NCI Concept Code C1691. SMILES: S1C2C3N(C(O)C4N(C3C3C(C4)CC(C(OC)C3O)C)C)C(C3C2C(OC(=O)C)C(C2OCOC32)C)COC(=O)C2(NCCC3C2CC(OC)C(O)C3)C1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H28Cl2F2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38ETX8IT42, chemically known as 9,11beta-dichloro-6alpha,21-difluoro-16alpha,17-dihydroxypregna-1,4-diene-3,20-dione cyclic acetal with acetone but generally known as tralonide, which bears US NIH Compound Identifier 30606. European Medicines Agency schedules Tralonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11209MIG. The term TRALONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). TRALONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tralonide under HS 29372200 and SITC 54153. As of Q4 2014, TRALONIDE remains the US FDA Preferred Term for this commodity. Tralonide bears US NLM identifiers UMLS ID C0601865 and NCI Concept Code C90958. SMILES: CLC12C(C3C(C4(OC(OC4C3)(C)C)C(=O)CF)(CC1CL)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes an analgesic agent with the molecular formula C16H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39J1LGJ30J, chemically known as cyclohexanol, 2-((dimethylamino)methyl)-1-(m-methoxyphenyl)- but generally known as tramadol, which bears US NIH Compound Identifier 33741. European Medicines Agency schedules Tramadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11210MIG. The term TRAMADOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules tramadol in its Anatomical Therapeutic Chemical (ATC) Classification. TRAMADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tramadol under HS 29225000 and SITC 51467. As of Q4 2014, TRAMADOL remains the US FDA Preferred Term for this commodity. Tramadol bears US NLM identifiers UMLS ID C0040610 and NCI Concept Code C29507. SMILES: OC1(C(CCCC1)CN(C)C)C1CC(OC)CCC1.
This classification denotes an analgesic agent with the molecular formula C16H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9N7R477WCK, chemically known as cyclohexanol, 2-((dimethylamino)methyl)-1-(m-methoxyphenyl)-, (+,-)-trans- but more generally known as tramadol hydrochloride, which bears US NIH Compound Identifier 5523. European Medicines Agency schedules Tramadol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04927MIG. Most nations, for tariff and trade purposes, schedule tramadol hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, TRAMADOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tramadol hydrochloride bears US NLM identifiers UMLS ID C2350089 and NCI Concept Code C29508. SMILES: CN(C)C[C@H]1CCCC[C@@]1(C2CCCC(C2)OC)O.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H17N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLE31693IV, chemically known as 4,5-dihydro-n-(5,6,7,8-tetrahydro-1-naphthalenyl)-1h-imidazol-2-amine but generally known as tramazoline, which bears US NIH Compound Identifier 5524. European Medicines Agency schedules Tramazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11211MIG. The term TRAMAZOLINE is an International Non-Proprietary Name. World Health Organization schedules tramazoline in its Anatomical Therapeutic Chemical (ATC) Classification. TRAMAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tramazoline under HS 29332990 and SITC 51573. As of Q4 2014, TRAMAZOLINE remains the US FDA Preferred Term for this commodity. Tramazoline bears US NLM identifiers UMLS ID C0076890 and NCI Concept Code C87582. SMILES: N(C1C2CCCCC2CCC1)C1=NCCN1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C13H17N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DG710Q678, chemically known as 4,5-dihydro-n-(5,6,7,8-tetrahydro-1-naphthalenyl)-1h-imidazol-2-amine but more generally known as tramazoline hydrochloride, which bears US NIH Compound Identifier 5524. European Medicines Agency schedules Tramazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04928MIG. Most nations, for tariff and trade purposes, schedule tramazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, TRAMAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tramazoline hydrochloride bears US NLM identifiers UMLS ID C0771031 and NCI Concept Code C87748. SMILES: C1CC2C(C(C1)NC3=NCCN3)CCCC2.CL.
This classification denotes an alpha-adrenergic agonist with the molecular formula C13H17N3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9DF5N42U1U, chemically known as n-(5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1h-imidazol-2-amine hydrochloride monohydrate, but more generally known as tramazoline hydrochloride monohydrate, which bears US NIH Compound Identifier 19472. European Medicines Agency schedules tramazoline hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11211MIG. Most nations, for tariff purposes, schedule tramazoline hydrochloride monohydrate under HS 29332990. SMILES: C1CC2C(C(C1)NC3=NCCN3)CCCC2.O.CL.
A type of kinase Inhibitor
This classification denotes an ace inhibitor with the molecular formula C24H34N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1T0N3G9CRC, chemically known as 1h-indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-alpha,7a-beta))- but generally known as trandolapril, which bears US NIH Compound Identifier 5484727. European Medicines Agency schedules Trandolapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11212MIG. The term TRANDOLAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules trandolapril in its Anatomical Therapeutic Chemical (ATC) Classification. TRANDOLAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trandolapril under HS 29339990 and SITC 51577. As of Q4 2014, TRANDOLAPRIL remains the US FDA Preferred Term for this commodity. Trandolapril bears US NLM identifiers UMLS ID C0076891 and NCI Concept Code C61978. SMILES: O=C(N1C2C(CC1C(=O)O)CCCC2)C(NC(CCc1ccccc1)C(=O)OCC)C.
This classification denotes an ace inhibitor with the molecular formula C22H30N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RR6866VL0O, chemically known as 1h-indol-2-carboxylic acid, 1-(2-((1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)octahydro- but generally known as trandolaprilat, which bears US NIH Compound Identifier 128549. European Medicines Agency schedules Trandolaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11213MIG. The term TRANDOLAPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). TRANDOLAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trandolaprilat under HS 29339990 and SITC 51577. As of Q4 2014, TRANDOLAPRILAT remains the US FDA Preferred Term for this commodity. Trandolaprilat bears US NLM identifiers UMLS ID C0165477 and NCI Concept Code C72913. SMILES: O=C(N1C2C(CC1C(=O)O)CCCC2)C(NC(CCc1ccccc1)C(=O)O)C.
This classification denotes a hemostatic agent with the molecular formula C8H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T84R30KC1, chemically known as rp 18,429 but generally known as tranexamic acid, which bears US NIH Compound Identifier 5526. European Medicines Agency schedules Tranexamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11214MIG. The term TRANEXAMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules tranexamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tranexamic acid under HS 29224995 and SITC 51465. As of Q4 2014, TRANEXAMIC ACID remains the US FDA Preferred Term for this commodity. Tranexamic acid bears US NLM identifiers UMLS ID C0040613 and NCI Concept Code C47765. SMILES: OC(=O)C1CCC(CC1)CN.
This classification denotes an antiarrhythmic agent with the molecular formula C22H35N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5VSP2X37QG, chemically known as 4-piperidinecarboxamide, 4-(dimethylamino)-n-(2,6-dimethylphenyl)-1-(2-hydroxycyclohexyl)-, trans-(+-)- but more generally known as transcainide, which bears US NIH Compound Identifier 68608. European Medicines Agency schedules Transcainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11216MIG. The term TRANSCAINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). TRANSCAINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule transcainide under HS 29333999 and SITC 51574. As of Q4 2014, TRANSCAINIDE remains US FDA's Preferred Term for this commodity. Transcainide bears US NLM identifiers UMLS ID C0076902 and NCI Concept Code C90667. SMILES: OC1C(N2CCC(N(C)C)(CC2)C(=O)NC2C(CCCC2C)C)CCCC1.
This classification denotes a monoamine oxidase inhibitor with the molecular formula C9H11N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3E3V44J4Z9, chemically known as cyclopropylamine, trans-2-phenyl- but generally known as tranylcypromine, which bears US NIH Compound Identifier 5530. European Medicines Agency schedules Tranylcypromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11218MIG. The term TRANYLCYPROMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules tranylcypromine in its Anatomical Therapeutic Chemical (ATC) Classification. TRANYLCYPROMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tranylcypromine under HS 29214980 and SITC 51454. As of Q4 2014, TRANYLCYPROMINE remains the US FDA Preferred Term for this commodity. Tranylcypromine bears US NLM identifiers UMLS ID C0040778 and NCI Concept Code C61979. SMILES: NC1C(C1)c1ccccc1.
This classification denotes a monoamine oxidase inhibitor with the molecular formula 2C9H11N.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZAT6ES870, chemically known as trans,dl-2-phenylcyclopropylamine sulfate but more generally known as tranylcypromine sulfate, which bears US NIH Compound Identifier 26069. European Medicines Agency schedules Tranylcypromine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04930MIG. Most nations, for tariff and trade purposes, schedule tranylcypromine sulfate under HS 29214980 and SITC 51454. As of Q4 2014, TRANYLCYPROMINE SULFATE remains US FDA's Preferred Term for this commodity. Tranylcypromine sulfate bears US NLM identifiers UMLS ID C0304369 and NCI Concept Code C61980. SMILES: C1CCC(CC1)[C@H]2C[C@@H]2N.C1CCC(CC1)[C@H]2C[C@@H]2N.OS(=O)(=O)O.
This classification denotes a phosphodiesterase inhibitor with the molecular formula C10H15N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EYG5Y6355E, chemically known as 7-diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine but generally known as trapidil, which bears US NIH Compound Identifier 5531. European Medicines Agency schedules Trapidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11220MIG. The term TRAPIDIL is an International Non-Proprietary Name. World Health Organization schedules trapidil in its Anatomical Therapeutic Chemical (ATC) Classification. TRAPIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trapidil under HS 29335995 and SITC 51576. As of Q4 2014, TRAPIDIL remains the US FDA Preferred Term for this commodity. Trapidil bears US NLM identifiers UMLS ID C0040779 and NCI Concept Code C66615. SMILES: CCN(CC)C1=CC(=NC2=NC=NN12)C.
This classification denotes a monoclonal antibody with the molecular formula C6470H10012N1726O2013S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P188ANX8CK, more generally known as trastuzumab. European Medicines Agency schedules trastuzumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12612MIG. The term TRASTUZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 2 1999, list 40. TRASTUZUMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trastuzumab under HS 30021091 and SITC 54163. As of Q4 2014, TRASTUZUMAB remains the US FDA Preferred Term for this commodity. Trastuzumab bears US NLM identifiers UMLS ID C0728747 and NCI Concept Code C1647. SMILES: CC(CCC(=O)O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C.
A prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7I6MS3VHQE, chemically known as 1-(9,10-ethanoanthracen-9(10h)-yl)-4-methylpiperazine but generally known as trazitiline, which bears US NIH Compound Identifier 3084449. European Medicines Agency schedules Trazitiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11222MIG. The term TRAZITILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). TRAZITILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trazitiline under HS 29335995 and SITC 51576. As of Q4 2014, TRAZITILINE remains the US FDA Preferred Term for this commodity. Trazitiline bears US NLM identifiers UMLS ID C1883383 and NCI Concept Code C66617. SMILES: N1(C23CCC(c4c2cccc4)c2c3cccc2)CCN(CC1)C.
This classification denotes an antidepressant agent with the molecular formula C17H13ClN3O.C2H5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1PO9LWW5IN, chemically known as 1-(p-chlorophenyl)-1,2-dihydro-1-hydroxy-as-triazino(6,1-a)isoquinolin-5-ium ethanesulfonate but generally known as trazium esilate, which bears US NIH Compound Identifier 72166. European Medicines Agency schedules Trazium esilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11223MIG. The term TRAZIUM ESILATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). Most nations schedule trazium esilate under HS 29339990 and SITC 51577. As of Q4 2014, TRAZIUM ESILATE remains the US FDA Preferred Term for this commodity. Trazium esilate bears US NLM identifiers UMLS ID C2348815 and NCI Concept Code C72873. SMILES: Clc1ccc(C2(O)N=CN[n]3c2c2c(cc3)cccc2)cc1.S(=O)(=O)(O)CC.
This classification denotes an antidepressant agent with the molecular formula C19H22ClN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YBK48BXK30, chemically known as 1,2,4-triazolo(4,3-a)pyridin-3(2h)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)- but generally known as trazodone, which bears US NIH Compound Identifier 5533. European Medicines Agency schedules Trazodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11224MIG. The term TRAZODONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules trazodone in its Anatomical Therapeutic Chemical (ATC) Classification. TRAZODONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trazodone under HS 29335995 and SITC 51576. As of Q4 2014, TRAZODONE remains the US FDA Preferred Term for this commodity. Trazodone bears US NLM identifiers UMLS ID C0040805 and NCI Concept Code C29510. SMILES: Clc1cc(N2CCN(CC2)CCCn2nc3n(c2=O)cccc3)ccc1.
This classification denotes an antidepressant agent with the molecular formula C19H22ClN5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6E8ZO8LRNM, chemically known as 1,2,4-triazolo(4,3-a)pyridin-3(2h)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)- but more generally known as trazodone hydrochloride, which bears US NIH Compound Identifier 5533. European Medicines Agency schedules Trazodone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15596MIG. Most nations, for tariff and trade purposes, schedule trazodone hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, TRAZODONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Trazodone hydrochloride bears US NLM identifiers UMLS ID C0701914 and NCI Concept Code C47767. SMILES: C1CCN2C(C1)NN(C2=O)CCCN3CCN(CC3)C4CCCC(C4)CL.CL.
This classification denotes an anti-lipidemic agent with the molecular formula C16H12Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7YA71JCD50, chemically known as 2,10-dichloro-12h-dibenzo(d,g)(1,3)dioxocin-6-carboxylic acid, methyl ester but generally known as treloxinate, which bears US NIH Compound Identifier 35678. European Medicines Agency schedules Treloxinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11231MIG. The term TRELOXINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). TRELOXINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule treloxinate under HS 29329970 and SITC 51569. As of Q4 2014, TRELOXINATE remains the US FDA Preferred Term for this commodity. Treloxinate bears US NLM identifiers UMLS ID C0076952 and NCI Concept Code C72988. SMILES: Clc1cc2Cc3c(OC(Oc2cc1)C(=O)OC)ccc(Cl)c3.
This classification denotes an anabolic steroid with the molecular formula C18H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, P53R4420TR chemically known as estra-4,9,11-trien-3-one, 17-hydroxy-, (17.beta.)- but generally known as trenbolone, which bears US NIH Compound Identifier 25015. European Medicines Agency schedules Trenbolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11232MIG. The term TRENBOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , no. 10 1971, list 11. ). Most nations schedule trenbolone under HS 29372900 and SITC 54153. As of Q4 2014, TRENBOLONE remains the US FDA Preferred Term for this commodity. Trenbolone bears US NLM identifiers UMLS ID C0040829 and NCI Concept Code C95072. SMILES: OC1C2(C(C3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C.
This classification denotes an anabolic steroid with the molecular formula C20H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RUD5Y4SV0S, chemically known as 17beta-hydroxyestra-4,9,11-trien-3-one, acetate but more generally known as trenbolone acetate, which bears US NIH Compound Identifier 66359. European Medicines Agency schedules Trenbolone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32683. Most nations, for tariff and trade purposes, schedule trenbolone acetate under HS 29372900 and SITC 54153. As of Q4 2014, TRENBOLONE ACETATE remains US FDA's Preferred Term for this commodity. Trenbolone acetate bears US NLM identifiers UMLS ID C0076958 and NCI Concept Code C61982. SMILES: CC(=O)O[C@H]1CC[C@@H]2[C@@]1(C=CC3=C4CCC(=O)C=C4CC[C@@H]23)C.
This classification denotes an anabolic steroid with the molecular formula C26H34O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BNJ7Y3JFF2, chemically known as estra-4,9,11-trien-3-one, 17-(((cyclohexylmethoxy)carbonyl)oxy)-, (17.beta.)-, but more generally known as trenbolone cyclohexylmethylcarbonate, which bears US NIH Compound Identifier 90930. European Medicines Agency schedules trenbolone cyclohexylmethylcarbonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11232MIG. Most nations, for tariff purposes, schedule trenbolone cyclohexylmethylcarbonate under HS 29372900. SMILES: C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)OCC5CCCCC5.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1WPQ720NCK. European Medicines Agency schedules Trenizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11234MIG. Trenizine generally arises in the molecular formula C31H40N2O. The term TRENIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) TRENIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trenizine under HS 29335995 and SITC 51576. As of Q4 2014, TRENIZINE remains the US FDA Preferred Term for this commodity. Trenizine bears US NLM identifiers UMLS ID C1883389 and NCI Concept Code C66622. SMILES: OC(CCCN1CCN(CC1)C(C1CCCCC1)C1CCCCC1)C1CCC(C(C)(C)C)CC1.
This classification denotes an alkylsulfonate compound with the molecular formula C6H14O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CO61ER3EPI, chemically known as 1,2,3,4-butanetetrol, 1,4-dimethanesulfonate, (s-(r*,r*))- (9ci) but more generally known as treosulfan, which bears US NIH Compound Identifier 9296. European Medicines Agency schedules Treosulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11235MIG. The term TREOSULFAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules treosulfan in its Anatomical Therapeutic Chemical (ATC) Classification. TREOSULFAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule treosulfan under HS 29054980 and SITC 51229. As of Q4 2014, TREOSULFAN remains US FDA's Preferred Term for this commodity. Treosulfan bears US NLM identifiers UMLS ID C0076959 and NCI Concept Code C1257. SMILES: S(=O)(=O)(OCC(O)C(O)COS(=O)(=O)C)C.
This classification denotes an antispasmotic agent with the molecular formula C16H22O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1187LU49Q, chemically known as 2,4,5-triethoxy-gamma-oxobenzenebutanoic acid but generally known as trepibutone, which bears US NIH Compound Identifier 5536. European Medicines Agency schedules Trepibutone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11236MIG. The term TREPIBUTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules trepibutone in its Anatomical Therapeutic Chemical (ATC) Classification. TREPIBUTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trepibutone under HS 29189900 and SITC 51396. As of Q4 2014, TREPIBUTONE remains the US FDA Preferred Term for this commodity. Trepibutone bears US NLM identifiers UMLS ID C0094813 and NCI Concept Code C66623. SMILES: O(C1C(CC(OCC)C(OCC)C1)C(=O)CCC(=O)O)CC.
This classification denotes a prostaglandin analogue and antihypertensive agent with the molecular formula C23H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RUM6K67ESG, chemically known as u-62,840 but generally known as treprostinil, which bears US NIH Compound Identifier 54786. European Medicines Agency schedules Treprostinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21168. The term TREPROSTINIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 2, 2003, List 49). World Health Organization schedules treprostinil in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule treprostinil under HS 29375000 and SITC 54156. As of Q4 2014, TREPROSTINIL remains the US FDA Preferred Term for this commodity. Treprostinil bears US NLM identifiers UMLS ID C1145760 and NCI Concept Code C61983. SMILES: OC1C(C2C(C1)Cc1c(C2)cccc1OCC(=O)O)CCC(O)CCCCC.
This classification denotes a prostaglandin analogue and antihypertensive agent with the molecular formula C23H33O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JZ75N2NT6, chemically known as acetic acid, (((1r,2r,3as,9as)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3s)-3-hydroxyoctyl)-1h-benz(f)inden-5-yl)oxy)-, monosodium salt but more generally known as treprostinil sodium, which bears US NIH Compound Identifier 130880. European Medicines Agency schedules Treprostinil sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22911. Most nations, for tariff and trade purposes, schedule treprostinil sodium under HS 29375000 and SITC 54156. As of Q4 2014, TREPROSTINIL SODIUM remains US FDA's Preferred Term for this commodity. Treprostinil sodium bears US NLM identifiers UMLS ID C1101501 and NCI Concept Code C61984. SMILES: CCCCC[C@@H](CC[C@@H]1[C@H]2CC3CCCC(C3C[C@H]2C[C@H]1O)OCC(=O)[O-])O.[NA+].
This classification denotes an antispasmotic agent with the molecular formula C20H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1URW272384, chemically known as ethanamine, n,n-diethyl-2-(phenyltricyclo(2.2.1.02,6)heptylidenemethoxy)-, hydrochloride but generally known as treptilamine, which bears US NIH Compound Identifier 3036965. European Medicines Agency schedules Treptilamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11239MIG. The term TREPTILAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). TREPTILAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule treptilamine under HS 29221980 and SITC 51461. As of Q4 2014, TREPTILAMINE remains the US FDA Preferred Term for this commodity. Treptilamine bears US NLM identifiers UMLS ID C0076961 and NCI Concept Code C66625. SMILES: CL.O(/C(=C1/C2C3C2CC1C3)C1CCCCC1)CCN(CC)CC.
This classification denotes an immunosuppressant with the molecular formula C17H37N7O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 286F595V8H, chemically known as carbamic acid, (4-((3-aminopropyl)amino)butyl)-, 2-((6-((aminoiminomethyl)amino)hexyl)amino)-2-oxoethyl ester but more generally known as tresperimus, which bears US NIH Compound Identifier 3086680. European Medicines Agency schedules Tresperimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11241MIG. The term TRESPERIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). TRESPERIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tresperimus under HS 29252900 and SITC 51482. As of Q4 2014, TRESPERIMUS remains US FDA's Preferred Term for this commodity. Tresperimus bears US NLM identifiers UMLS ID C0528277 and NCI Concept Code C66626. SMILES: O(CC(=O)NCCCCCC/N=C(/N)N)C(=O)NCCCCNCCCN.
This classification denotes an ethylenimine compound with the molecular formula C9H12N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F7IY6HZG9D, chemically known as 2,4,6-tris(ethylenimino)-s-triazine but more generally known as tretamine, which bears US NIH Compound Identifier 5799. European Medicines Agency schedules Tretamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11243MIG. The term TRETAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). TRETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Tretamine or triethylenemelamine bears US NLM identifiers UMLS ID C0040975 and NCI Concept Code C29858. SMILES: N1(CC1)C1NC(N2CC2)NC(N2CC2)N1.
This classification denotes a retinoic acid agent with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5688UTC01R, chemically known as 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-nona-2,4,6,8-tetraenoic acid but generally known as retinoic acid, which bears US NIH Compound Identifier 5538. European Medicines Agency schedules Retinoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20680. The term TRETINOIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules retinoic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule tretinoin under HS 29362100 and SITC 54112. As of Q4 2014, TRETINOIN remains the US FDA Preferred Term for this commodity. Tretinoin bears US NLM identifiers UMLS ID C0040845 and NCI Concept Code C900. SMILES: OC(=O)/C=C(/C=C/C=C(/C=C/C1=C(CCCC1(C)C)C)C)C.
This classification denotes a differentiation inducer with the molecular formula C49H76O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CTD060B1SS, chemically known as (+-)-(2r*)-2,5,7,8-tetramethyl-2-((4r*,8r*)-4,8,12-trimethyltridecyl)-6-chromanyl retinoate but more generally known as tocoretinate, which bears US NIH Compound Identifier 5282180. European Medicines Agency schedules Tretinoin tocoferil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11247MIG. The term TRETINOIN TOCOFERIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). Most nations, for tariff and trade purposes, schedule tretinoin tocoferil under HS 29362800 and SITC 54115. As of Q4 2014, TRETINOIN TOCOFERIL remains US FDA's Preferred Term for this commodity. Tretinoin tocoferil bears US NLM identifiers UMLS ID C0289588 and NCI Concept Code C66628. SMILES: CC1C(C(C(C2C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C3=C(CCCC3(C)C)C)C.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C19H23NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JIO3275WGI, chemically known as 6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-, hydrochloride, (s)- but generally known as tretoquinol, which bears US NIH Compound Identifier 29137. European Medicines Agency schedules Tretoquinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11248MIG. The term TRETOQUINOL is an International Non-Proprietary Name. World Health Organization schedules tretoquinol in its Anatomical Therapeutic Chemical (ATC) Classification. TRETOQUINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tretoquinol under HS 29334990 and SITC 51575. As of Q4 2014, TRETOQUINOL remains the US FDA Preferred Term for this commodity. Tretoquinol bears US NLM identifiers UMLS ID C0040846 and NCI Concept Code C66629. SMILES: CL.OC1CC2C(NCCC2CC1O)CC1CC(OC)C(OC)C(OC)C1.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C19H23NO5.CLH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SS28YGI1ZQ. European Medicines Agency schedules tretoquinol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15598MIG. The term tretoquinol hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule tretoquinol hydrochloride under HS 29334990 and SITC 51575. SMILES: COC1CC(CC(C1OC)OC)C[C@H]2C3CC(C(CC3CCN2)O)O.O.CL.
This classification denotes a macrolide antibiotic with the molecular formula C41H67NO15, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C4DZ64560D, chemically known as oleandomycin, triacetyl- but more generally known as triacetyloleandomycin, which bears U.S. National Institutes of Health Compound Identifier 17675. The European Medicines Agency schedules Troleandomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11333MIG. The term TRIACETYLOLEANDOMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). The World Health Organization schedules triacetyloleandomycin in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C.
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E51A927SNR. European Medicines Agency schedules Triafungin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11250MIG. Triafungin generally arises in the molecular formula C13H10N4. The term TRIAFUNGIN is an International Non-Proprietary Name or INN. TRIAFUNGIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triafungin under HS 29339990 and SITC 51577. As of Q4 2014, TRIAFUNGIN remains the US FDA Preferred Term for this commodity. Triafungin bears US NLM identifiers UMLS ID C2348816 and NCI Concept Code C72965. SMILES: N1C(NNC2C1CNCC2)CC1CCCCC1.
This classification denotes a therapeutic glucocorticoid with the molecular formula C21H27FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1ZK20VI6TY, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)- but generally known as triamcinolone, which bears US NIH Compound Identifier 5544. European Medicines Agency schedules Triamcinolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11251MIG. The term TRIAMCINOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules triamcinolone in its Anatomical Therapeutic Chemical (ATC) Classification. TRIAMCINOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triamcinolone under HS 29372200 and SITC 54153. As of Q4 2014, TRIAMCINOLONE remains the US FDA Preferred Term for this commodity. Triamcinolone bears US NLM identifiers UMLS ID C0040864 and NCI Concept Code C901. SMILES: FC12C(C3C(C(O)(C(O)C3)C(=O)CO)(CC1O)C)CCC1=CC(=O)C=CC21C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F446C597KA, chemically known as 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone but more generally known as triamcinolone acetonide, which bears US NIH Compound Identifier 6436. European Medicines Agency schedules Triamcinolone acetonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04936MIG. Most nations, for tariff and trade purposes, schedule triamcinolone acetonide under HS 29372200 and SITC 54153. As of Q4 2014, TRIAMCINOLONE ACETONIDE remains US FDA's Preferred Term for this commodity. Triamcinolone acetonide bears US NLM identifiers UMLS ID C0040866 and NCI Concept Code C48027. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C28H35FO9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Z83R2HM9L, chemically known as pregna-1,4-diene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11.beta.,16.alpha.)-, but more generally known as triamcinolone acetonide hemisuccinate, which bears US NIH Compound Identifier 3032435. European Medicines Agency schedules triamcinolone acetonide hemisuccinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11251MIG. Most nations, for tariff purposes, schedule triamcinolone acetonide hemisuccinate under HS 29372200. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COC(=O)CCC(=O)O)CCC5=CC(=O)C=C[C@@]53C)F)O.
This classification denotes a therapeutic glucocorticoid C24H30FO9P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R2MZ7K74S8, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-(dihydrogen phosphate), disodium salt, but more generally known as triamcinolone acetonide sodium phosphate, which bears US NIH Compound Identifier 70683053. Most nations, for tariff and trade purposes, schedule triamcinolone acetonide sodium phosphate under HS 29372200 and SITC 54153. As of Q4 2014, TRIAMCINOLONE ACETONIDE SODIUM PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COP(=O)([O-])[O-])CCC5=CC(=O)C=C[C@@]53C)F)O.[NA+].[NA+].
This classification denotes a therapeutic glucocorticoid with the molecular formula C29H39FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H6942ZVG0C, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-21-((1-oxopentyl)oxy)-, (11.beta.,16.alpha.)-, but more generally known as triamcinolone acetonide valerate, which bears US NIH Compound Identifier 60904. European Medicines Agency schedules triamcinolone acetonide valerate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11251MIG. Most nations, for tariff purposes, schedule triamcinolone acetonide valerate under HS 29372200. SMILES: CCCCC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC(O2)(C)C.
This classification denotes a therapeutic glucocorticoid C35H42FNO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9DXL8A82MI, chemically known as 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone 21-ester with n-benzoyl-2-methyl-.beta.-alanine, but more generally known as triamcinolone benetonide, which bears US NIH Compound Identifier 62963. European Medicines Agency schedules Triamcinolone benetonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11252MIG. Most nations, for tariff and trade purposes, schedule triamcinolone benetonide under HS 29372200 and SITC 54153. As of Q4 2014, TRIAMCINOLONE BENETONIDE remains US FDA's Preferred Term for this commodity. Triamcinolone benetonide bears US NLM identifiers UMLS ID C0077002 and NCI Concept Code C98259. SMILES: CC(CNC(=O)C1CCCCC1)C(=O)OCC(=O)[C@@]23[C@@H](C[C@@H]4[C@@]2(C[C@@H]([C@]5([C@H]4CCC6=CC(=O)C=C[C@@]65C)F)O)C)OC(O3)(C)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H31FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A73MM2Q32P, chemically known as 16alpha,21-diacetoxy-9alpha-fluoro-11beta,17alpha-dihydroxy-1,4-pregnadiene-3,20-dione but more generally known as triamcinolone diacetate, which bears US NIH Compound Identifier 6216. European Medicines Agency schedules Triamcinolone diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04938MIG. Most nations, for tariff and trade purposes, schedule triamcinolone diacetate under HS 29372200 and SITC 54153. As of Q4 2014, TRIAMCINOLONE DIACETATE remains US FDA's Preferred Term for this commodity. Triamcinolone diacetate bears US NLM identifiers UMLS ID C0040867 and NCI Concept Code C61985. SMILES: CC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)OC(=O)C)O.
This classification denotes a therapeutic glucocorticoid with the molecular formula C30H41FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I7GT1U99Y9, chemically known as 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone 21-(3,3-dimethylbutyrate) but more generally known as triamcinolone hexacetonide, which bears US NIH Compound Identifier 21826. European Medicines Agency schedules Triamcinolone hexacetonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11254MIG. The term TRIAMCINOLONE HEXACETONIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule triamcinolone hexacetonide under HS 29372200 and SITC 54153. As of Q4 2014, TRIAMCINOLONE HEXACETONIDE remains US FDA's Preferred Term for this commodity. Triamcinolone hexacetonide bears US NLM identifiers UMLS ID C0077004 and NCI Concept Code C48026. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COC(=O)CC(C)(C)C)CCC5=CC(=O)C=C[C@@]53C)F)O.
This classification denotes a potassium-sparing diuretic with the molecular formula C12H11N7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WS821Z52LQ, chemically known as 2,4,7-triamino-6-phenylpteridine but generally known as triamterene, which bears US NIH Compound Identifier 5546. European Medicines Agency schedules Triamterene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11256MIG. The term TRIAMTERENE is an International Non-Proprietary Name. World Health Organization schedules triamterene in its Anatomical Therapeutic Chemical (ATC) Classification. TRIAMTERENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triamterene under HS 29335995 and SITC 51576. As of Q4 2014, TRIAMTERENE remains the US FDA Preferred Term for this commodity. Triamterene bears US NLM identifiers UMLS ID C0040869 and NCI Concept Code C29519. SMILES: C1=CC=C(C=C1)C2=NC3=C(N=C2N)N=C(N=C3N)N.
This classification denotes an ethylenimine compound with the molecular formula C12H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F3D5D9P25I, chemically known as 2,3,5-tris-ethyleniminoquinone-(1,4) but more generally known as triaziquone, which bears US NIH Compound Identifier 6235. European Medicines Agency schedules Triaziquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11257MIG. The term TRIAZIQUONE is an International Non-Proprietary Name. World Health Organization schedules triaziquone in its Anatomical Therapeutic Chemical (ATC) Classification. TRIAZIQUONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule triaziquone under HS 29339990 and SITC 51577. As of Q4 2014, TRIAZIQUONE remains US FDA's Preferred Term for this commodity. Triaziquone bears US NLM identifiers UMLS ID C0040878 and NCI Concept Code C903. SMILES: C1CN1C2=CC(=O)C(=C(C2=O)N3CC3)N4CC4.
This classification denotes a benzodiazepine with the molecular formula C17H12Cl2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HM943223R, chemically known as 8-chloro-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine but generally known as triazolam, which bears US NIH Compound Identifier 5556. European Medicines Agency schedules Triazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11258MIG. The term TRIAZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules triazolam in its Anatomical Therapeutic Chemical (ATC) Classification. TRIAZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triazolam under HS 29339190 and SITC 51577. As of Q4 2014, TRIAZOLAM remains the US FDA Preferred Term for this commodity. Triazolam bears US NLM identifiers UMLS ID C0040879 and NCI Concept Code C29520. SMILES: CLC1CC2C(N3C(NNC3C)CN=C2C2C(CL)CCCC2)CC1.
This classification denotes a form of tricalcium phosphate are used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP), with the molecular formula 5CA.3O4P.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91D9GV0Z28. European Medicines Agency schedules tribasic calcium phosphatein its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34727. The term tribasic calcium phosphate is Homeopathic Pharmacopoeia of the United States designation.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0744Q5ALP. European Medicines Agency schedules Tribendilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11259MIG. Tribendilol generally arises in the molecular formula C18H22N4O4. The term TRIBENDILOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) TRIBENDILOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tribendilol under HS 29339990 and SITC 51577. As of Q4 2014, TRIBENDILOL remains the US FDA Preferred Term for this commodity. Tribendilol bears US NLM identifiers UMLS ID C2700071 and NCI Concept Code C76561. SMILES: O(CC(O)CNCCOC1C(OC)CCCC1)C1C2N[NH]NC2CCC1.
This classification denotes a non-steroidal anti-inflammatory agent with the molecular formula C29H34O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z7N0Y673NU, chemically known as glucofuranoside, ethyl-3,5,6-tri-o-benzyl-, d- but generally known as tribenoside, which bears US NIH Compound Identifier 25145. European Medicines Agency schedules Tribenoside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11260MIG. World Health Organization schedules tribenoside in its Anatomical Therapeutic Chemical (ATC) Classification. TRIBENOSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tribenoside under HS 29400000 and SITC 51692. As of Q4 2014, TRIBENOSIDE remains the US FDA Preferred Term for this commodity. SMILES: O1C(C(OCC2CCCCC2)C(O)C1OCC)C(OCC1CCCCC1)COCC1CCCCC1.
This classification denotes a nitrogen mustard compound with the molecular formula C6H12Cl3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66WBM7N0NM, chemically known as 2,2, 2-trichlorotriethylamine hydrochloride but more generally known as trichlormethine, which bears US NIH Compound Identifier 5561. European Medicines Agency schedules Trichlormethine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11264MIG. The term TRICHLORMETHINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). TRICHLORMETHINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule trichlormethine under HS 29211980 and SITC 51451. As of Q4 2014, TRICHLORMETHINE remains US FDA's Preferred Term for this commodity. Trichlormethine bears US NLM identifiers UMLS ID C0045236 and NCI Concept Code C962. SMILES: CLCCN(CCCL)CCCL.
This classification denotes a carcinogenic chlorinated hydrocarbon with the molecular formula C2HCl3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 290YE8AR51, chemically known as 1,2,2-trichloroethylene but generally known as trichloroethylene, which bears US NIH Compound Identifier 6575. European Medicines Agency schedules Trichloroethylene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11265MIG. The term TRICHLOROETHYLENE is an International Non-Proprietary Name. World Health Organization schedules trichloroethylene in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TRICHLOROETHYLENE remains the US FDA Preferred Term for this commodity. Trichloroethylene bears US NLM identifiers UMLS ID C0040905 and NCI Concept Code C44459. SMILES: CL/C(=C/CL)CL.
This classification denotes a purine antagonist and inosine monophosphate dehydrogenase inhibitor and amidophosphoribosyltransferase inhibitor with the molecular formula C13H16N6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2421HMY9N6, chemically known as 1,4,5,6,8-pentaazaacennaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl- (9ci) but generally known as triciribine, which bears US NIH Compound Identifier 65399. European Medicines Agency schedules Triciribine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11266MIG. The term TRICIRIBINE is an International Non-Proprietary Name. TRICIRIBINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triciribine under HS 29349990 and SITC 51579. As of Q4 2014, TRICIRIBINE remains the US FDA Preferred Term for this commodity. SMILES: O1C(N2C3NCNC4N(NC(N)C(C2)C34)C)C(O)C(O)C1CO.
This classification denotes an antihelminthic agent with the molecular formula C14H9Cl3N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4784C8E03O, chemically known as 6-chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole but generally known as triclabendazole, which bears US NIH Compound Identifier 50248. European Medicines Agency schedules Triclabendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11267MIG. The term TRICLABENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules triclabendazole in its Anatomical Therapeutic Chemical (ATC) Classification. TRICLABENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triclabendazole under HS 29339990 and SITC 51577. As of Q4 2014, TRICLABENDAZOLE remains the US FDA Preferred Term for this commodity. Triclabendazole bears US NLM identifiers UMLS ID C0077071 and NCI Concept Code C75236. SMILES: CLC1C(OC2C(CL)C(CL)CCC2)CC2NC(SC)[NH]C2C1.
This classification denotes an anti-infective agent with the molecular formula C13H9Cl3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BGG1Y1ED0Y, chemically known as 3,4,4-trichlorodiphenylurea but generally known as triclocarban, which bears US NIH Compound Identifier 7547. European Medicines Agency schedules Triclocarban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11271MIG. The term TRICLOCARBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). TRICLOCARBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triclocarban under HS 29242190 and SITC 51473. As of Q4 2014, TRICLOCARBAN remains the US FDA Preferred Term for this commodity. Triclocarban bears US NLM identifiers UMLS ID C0077072 and NCI Concept Code C47770. SMILES: CLC1CC(NC(=O)NC2CCC(CL)CC2)CCC1CL.
This classification denotes a sedative and hypnotic with the molecular formula C2H4Cl3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J712EO9048, chemically known as 2,2,2-trichloroethyl phosphate but generally known as triclofos, which bears US NIH Compound Identifier 5563. European Medicines Agency schedules Triclofos in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11274MIG. The term TRICLOFOS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). World Health Organization schedules triclofos in its Anatomical Therapeutic Chemical (ATC) Classification. TRICLOFOS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triclofos under HS 29199090 and SITC 51631. As of Q4 2014, TRICLOFOS remains the US FDA Preferred Term for this commodity. Triclofos bears US NLM identifiers UMLS ID C0077073 and NCI Concept Code C87206. SMILES: CLC(CL)(CL)COP(=O)(O)O.
This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9F90KA5Q8U. European Medicines Agency schedules Triclofos sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15606MIG. Triclofos sodium generally arises in the molecular formula C2H3CL3O4P.NA. The term 'triclofos sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule triclofos sodium under HS 29199090 and SITC 51631. As of Q4 2014, TRICLOFOS SODIUM remains US FDA's Preferred Term for this commodity. Triclofos sodium bears US NLM identifiers UMLS ID C0355022 and NCI Concept Code C66630. SMILES: C(C(CL)(CL)CL)OP(=O)(O)[O-].[NA+].
This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2T7T4YO42R. European Medicines Agency schedules Triclofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11275MIG. Triclofylline generally arises in the molecular formula C11H13CL3N4O4. The term TRICLOFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, no. 11 1970, list 10.) TRICLOFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triclofylline under HS 29395900 and SITC 54145. As of Q4 2014, TRICLOFYLLINE remains the US FDA Preferred Term for this commodity. Triclofylline bears US NLM identifiers UMLS ID C2700076 and NCI Concept Code C76577. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCOC(C(CL)(CL)CL)O.
This classification denotes a topical corticosteroid with the molecular formula C24H28CL3FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PSM3RT117Z. European Medicines Agency schedules triclonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11276MIG. The term TRICLONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, no. 10 1974, list 14. ). TRICLONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triclonide under HS 29372200 and SITC 54153. As of Q4 2014, TRICLONIDE remains the US FDA Preferred Term for this commodity. Triclonide bears US NLM identifiers UMLS ID C1883394 and NCI Concept Code C66631. SMILES: CLC12C(C3C(C4(OC(OC4C3)(C)C)C(=O)CCL)(CC1CL)C)CC(F)C1=CC(=O)C=CC21C.
This classification denotes an antimuscarinic agent with the molecular formula C21H36NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7HE50A367X, chemically known as benzenepropanaminium, gamma-cyclohexyl-n,n,n-triethyl-gamma-hydroxy-, chloride but generally known as tridihexethyl, which bears US NIH Compound Identifier 20298. European Medicines Agency schedules Tridihexethyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04951MIG. World Health Organization schedules tridihexethyl in its Anatomical Therapeutic Chemical (ATC) Classification. TRIDIHEXETHYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, TRIDIHEXETHYL remains the US FDA Preferred Term for this commodity. Tridihexethyl bears US NLM identifiers UMLS ID C0077081 and NCI Concept Code C78079. SMILES: CL.OC(C1CCCCC1)(CC[N](CC)(CC)CC)C1CCCCC1. .
This classification denotes a metal chelator with the molecular formula C6H18N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SJ76Y07H5F, chemically known as 1,4,7,10-tetraazadecane but generally known as trientine, which bears US NIH Compound Identifier 5565. European Medicines Agency schedules Trientine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11281MIG. The term TRIENTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). TRIENTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trientine under HS 29212900 and SITC 51452. As of Q4 2014, TRIENTINE remains the US FDA Preferred Term for this commodity. Trientine bears US NLM identifiers UMLS ID C0040976 and NCI Concept Code C66633. SMILES: N(CCNCCN)CCN.
This classification denotes a metal chelator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC3NX54582. European Medicines Agency schedules Trientine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04953MIG. Trientine dihydrochloride generally arises in the molecular formula C6H18N4.2CLH. The term TRIENTINE DIHYDROCHLORIDE is a United States Adopted Name designation. Most nations schedule trientine dihydrochloride under HS 29212900 and SITC 51452. SMILES: CL.CL.N(CCNCCN)CCN.
This classification denotes a metal chelator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC3NX54582. European Medicines Agency schedules Trientine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04953MIG. Trientine hydrochloride generally arises in the molecular formula C6H18N4.2CLH. The term 'trientine hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule trientine hydrochloride under HS 29212900. As of Q4 2014, TRIENTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Trientine hydrochloride bears US NLM identifiers UMLS ID C0770325 and NCI Concept Code C61987. SMILES: C(CNCCNCCN)N.CL.CL.
This classification denotes an aural eardrop preparation.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H6O3.C6H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H8O4040BHD, chemically known as 2-hydroxybenzoic acid, compd. with 2,2,2-nitrilotris(ethanol) (1:1) but generally known as tea-salicylate, which bears US NIH Compound Identifier 25213. European Medicines Agency schedules Trolamine salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04990MIG. Most nations schedule triethanolamine salicylate under HS 29221300 and SITC 51461. SMILES: C1=CC=C(C(=C1)C(=O)O)O.C(CO)N(CCO)CCO.
This classification denotes an antiplatelet agent with the molecular formula C25H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59X5ME2O06, chemically known as 2-(o-(2-(dimethylamino)ethoxy)phenyl)-4,5-diphenylimidazole but generally known as trifenagrel, which bears US NIH Compound Identifier 72164. European Medicines Agency schedules Trifenagrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11282MIG. The term TRIFENAGREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). TRIFENAGREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trifenagrel under HS 29332990 and SITC 51573. As of Q4 2014, TRIFENAGREL remains the US FDA Preferred Term for this commodity. Trifenagrel bears US NLM identifiers UMLS ID C0637269 and NCI Concept Code C76406. SMILES: O(C1C(C2[NH]C(C(N2)C2CCCCC2)C2CCCCC2)CCCC1)CCN(C)C.
This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XJ3W180C22. European Medicines Agency schedules Trifezolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11283MIG. Trifezolac generally arises in the molecular formula C23H18N2O2. The term TRIFEZOLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) TRIFEZOLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trifezolac under HS 29331990 and SITC 51571. As of Q4 2014, TRIFEZOLAC remains the US FDA Preferred Term for this commodity. Trifezolac bears US NLM identifiers UMLS ID C2700077 and NCI Concept Code C76824. SMILES: OC(=O)CC1C(N(NC1C1CCCCC1)C1CCCCC1)C1CCCCC1.
This classification denotes a diuretic with the molecular formula C13H9F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S01B3A38SK, chemically known as 4-(alpha,alpha,alpha-trifluoro-m-toluidino)nicotinic acid but generally known as triflocin, which bears US NIH Compound Identifier 25969. European Medicines Agency schedules Triflocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11284MIG. The term TRIFLOCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). TRIFLOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triflocin under HS 29333999 and SITC 51574. As of Q4 2014, TRIFLOCIN remains the US FDA Preferred Term for this commodity. Triflocin bears US NLM identifiers UMLS ID C0244851 and NCI Concept Code C76648. SMILES: FC(F)(F)C1CC(NC2C(CNCC2)C(=O)O)CCC1.
This classification denotes the sodium form of a diuretic with the molecular formula C13H9F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S01B3A38SK, chemically known as 4-(alpha,alpha,alpha-trifluoro-m-toluidino)nicotinic acid but more generally known as triflocin, which bears US NIH Compound Identifier 25969. European Medicines Agency schedules Triflocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11284MIG. The term TRIFLOCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 14, No. 1, 2000, List 43). TRIFLOCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule triflocin sodium under HS 29333999. As of Q4 2014, TRIFLOCIN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CC(C1)NC2CCNCC2C(=O)[O-])C(F)(F)F.[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H14F3NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6G94Z48FK, chemically known as carbanilic acid, m-benzoyl-n-((trifluoromethyl)sulfonyl)-, ethyl ester but generally known as triflumidate, which bears US NIH Compound Identifier 32259. European Medicines Agency schedules Triflumidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11286MIG. The term TRIFLUMIDATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). TRIFLUMIDATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triflumidate under HS 29350090 and SITC 51580. As of Q4 2014, TRIFLUMIDATE remains the US FDA Preferred Term for this commodity. Triflumidate bears US NLM identifiers UMLS ID C0601852 and NCI Concept Code C66634. SMILES: S(=O)(=O)(N(C1CC(CCC1)C(=O)C1CCCCC1)C(=O)OCC)C(F)(F)F.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 214IZI85K3, chemically known as 10h-phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- but generally known as trifluoperazine, which bears US NIH Compound Identifier 5566. European Medicines Agency schedules Trifluoperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11288MIG. The term TRIFLUOPERAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules trifluoperazine in its Anatomical Therapeutic Chemical (ATC) Classification. TRIFLUOPERAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trifluoperazine under HS 29343090 and SITC 51578. As of Q4 2014, TRIFLUOPERAZINE remains the US FDA Preferred Term for this commodity. Trifluoperazine bears US NLM identifiers UMLS ID C0040979 and NCI Concept Code C62084. SMILES: S1C2C(N(CCCN3CCN(CC3)C)C3C1CCCC3)CC(CC2)C(F)(F)F.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P1Y2SNF5V, chemically known as 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine dihydrochloride, but more generally known as trifluoperazine dihydrochloride, which bears US NIH Compound Identifier 5566. European Medicines Agency schedules trifluoperazine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11288MIG. Most nations, for tariff purposes, schedule trifluoperazine dihydrochloride under HS 29343090. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)C(F)(F)F.CL.CL.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AN9ZJ2YUI0, chemically known as phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-, maleate (1:2), but more generally known as trifluoperazine dimaleate, which bears US NIH Compound Identifier 6438223. European Medicines Agency schedules trifluoperazine dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11288MIG. Most nations, for tariff purposes, schedule trifluoperazine dimaleate under HS 29343090. SMILES: CN1CCN(CC1)CCCN2C3C(CCC(C3)C(F)(F)F)SC4C2CCCC4.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P1Y2SNF5V, chemically known as 10h-phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- but more generally known as trifluoperazine hydrochloride, which bears US NIH Compound Identifier 5566. European Medicines Agency schedules Trifluoperazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04956MIG. Most nations, for tariff and trade purposes, schedule trifluoperazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, TRIFLUOPERAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Trifluoperazine hydrochloride bears US NLM identifiers UMLS ID C0304381 and NCI Concept Code C904. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)C(F)(F)F.CL.CL.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AN9ZJ2YUI0, chemically known as phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-, maleate (1:2), but more generally known as trifluoperazine maleate, which bears US NIH Compound Identifier 5282418. European Medicines Agency schedules trifluoperazine maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11288MIG. Most nations, for tariff purposes, schedule trifluoperazine maleate under HS 29343090. SMILES: CN1CCN(CC1)CCCN2C3C(CCC(C3)C(F)(F)F)SC4C2CCCC4.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antipsychotic agent with the molecular formula C22H23F4NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8869Q7R8I, chemically known as 4-fluoro-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)butyrophenone but generally known as trifluperidol, which bears US NIH Compound Identifier 5567. European Medicines Agency schedules Trifluperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11289MIG. The term TRIFLUPERIDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules trifluperidol in its Anatomical Therapeutic Chemical (ATC) Classification. TRIFLUPERIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trifluperidol under HS 29333999 and SITC 51574. As of Q4 2014, TRIFLUPERIDOL remains the US FDA Preferred Term for this commodity. Trifluperidol bears US NLM identifiers UMLS ID C0040988 and NCI Concept Code C76455. SMILES: FC(F)(F)C1CC(C2(O)CCN(CC2)CCCC(=O)C2CCC(F)CC2)CCC1.
This classification denotes an antipsychotic agent with the molecular formula C22H23F4NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UIC8RB6P81, chemically known as 4-fluoro-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)butyrophenone but more generally known as trifluperidol hydrochloride, which bears US NIH Compound Identifier 5567. European Medicines Agency schedules Trifluperidol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04957MIG. Most nations, for tariff and trade purposes, schedule trifluperidol hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, TRIFLUPERIDOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CC(C1)C(F)(F)F)C2(CCN(CC2)CCCC(=O)C3CCC(CC3)F)O.CL.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C18H19F3N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RO16TQF95Y, chemically known as 10h-phenothiazine-10-propanamine, n, n-dimethyl-2- (trifluoromethyl)-, monohydrochloride but generally known as triflupromazine, which bears US NIH Compound Identifier 5568. European Medicines Agency schedules Triflupromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11290MIG. The term TRIFLUPROMAZINE is an International Non-Proprietary Name. World Health Organization schedules triflupromazine in its Anatomical Therapeutic Chemical (ATC) Classification. TRIFLUPROMAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triflupromazine under HS 29343090 and SITC 51578. As of Q4 2014, TRIFLUPROMAZINE remains the US FDA Preferred Term for this commodity. Triflupromazine bears US NLM identifiers UMLS ID C0040989 and NCI Concept Code C66635. SMILES: S1C2C(N(CCCN(C)C)C3C1CCCC3)CC(CC2)C(F)(F)F.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C18H19F3N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E75N4A5HM, chemically known as 10h-phenothiazine-10-propanamine, n, n-dimethyl-2- (trifluoromethyl)-, monohydrochloride but more generally known as triflupromazine hydrochloride, which bears US NIH Compound Identifier 5568. European Medicines Agency schedules Triflupromazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04958MIG. Most nations, for tariff and trade purposes, schedule triflupromazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, TRIFLUPROMAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Triflupromazine hydrochloride bears US NLM identifiers UMLS ID C0304376 and NCI Concept Code C66636. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)C(F)(F)F.CL.
This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C18H19F3N2S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17EKO3WVAY, chemically known as 10h-phenothiazine-10-propanamine, n,n-dimethyl-2-(trifluoromethyl)-, (2z)-2-butenedioate (1:1), but more generally known as triflupromazine maleate, which bears US NIH Compound Identifier 5568. European Medicines Agency schedules triflupromazine maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11290MIG. Most nations, for tariff purposes, schedule triflupromazine maleate under HS 29343090. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)C(F)(F)F.C(=C\C(=O)O)\C(=O)O.
This classification denotes an antiplatelet agent with the molecular formula C10H7F3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Z0YFI05OO, chemically known as 2,4-cresotic acid, alpha,alpha,alpha-trifluoro-, acetate but generally known as triflusal, which bears US NIH Compound Identifier 9458. European Medicines Agency schedules Triflusal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11292MIG. The term TRIFLUSAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules triflusal in its Anatomical Therapeutic Chemical (ATC) Classification. TRIFLUSAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triflusal under HS 29182980 and SITC 51394. As of Q4 2014, TRIFLUSAL remains the US FDA Preferred Term for this commodity. Triflusal bears US NLM identifiers UMLS ID C0077126 and NCI Concept Code C76407. SMILES: CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O.
This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L2D8DE8S32. European Medicines Agency schedules Trigevolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11294MIG. Trigevolol generally arises in the molecular formula C21H28N2O7. The term TRIGEVOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) TRIGEVOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trigevolol under HS 29242995 and SITC 51479. As of Q4 2014, TRIGEVOLOL remains the US FDA Preferred Term for this commodity. Trigevolol bears US NLM identifiers UMLS ID C2825714 and NCI Concept Code C81657. SMILES: O(CC(O)CNCCOC1CC(C(O)CC1)C(=O)N)C1CCC(OCCOC)CC1.
This classification denotes the mesylate form of a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L2D8DE8S32. European Medicines Agency schedules Trigevolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11294MIG. Trigevolol generally arises in the molecular formula C21H28N2O7. The term TRIGEVOLOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, no. 4, 1987, list 27.) TRIGEVOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule trigevolol mesylate under HS 29242995. As of Q4 2014, TRIGEVOLOL MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: COCCOC1CCC(CC1)OCC(CNCCOC2CCC(C(C2)C(=O)N)O)O.CS(=O)(=O)O.
This classification denotes an antiparkinsonian agent and antimuscarinic agent with the molecular formula C20H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6RC5V8B7PO, chemically known as 1-piperidinepropanol, alpha-cyclohexyl-alpha-phenyl- but generally known as trihexyphenidyl, which bears US NIH Compound Identifier 5572. European Medicines Agency schedules Trihexyphenidyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11295MIG. The term TRIHEXYPHENIDYL is an International Non-Proprietary Name. World Health Organization schedules trihexyphenidyl in its Anatomical Therapeutic Chemical (ATC) Classification. TRIHEXYPHENIDYL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trihexyphenidyl under HS 29333999 and SITC 51574. As of Q4 2014, TRIHEXYPHENIDYL remains the US FDA Preferred Term for this commodity. Trihexyphenidyl bears US NLM identifiers UMLS ID C0041009 and NCI Concept Code C61988. SMILES: OC(C1CCCCC1)(CCN1CCCCC1)C1CCCCC1.
This classification denotes a 3-hydroxysteroid dehydrogenase inhibitor and steroidal aromatase inhibitor and anti-adrenal with the molecular formula C20H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0FPV48Q5R, chemically known as 5-alpha-androstane-2-alpha-carbonitrile, 4-alpha,5-epoxy-17-beta-hydroxy-3-oxo- but generally known as trilostane, which bears US NIH Compound Identifier 26163. European Medicines Agency schedules Trilostane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11297MIG. The term TRILOSTANE is an International Non-Proprietary Name. World Health Organization schedules trilostane in its Anatomical Therapeutic Chemical (ATC) Classification. TRILOSTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trilostane under HS 29372900 and SITC 54153. As of Q4 2014, TRILOSTANE remains the US FDA Preferred Term for this commodity. Trilostane bears US NLM identifiers UMLS ID C0077144 and NCI Concept Code C1263. SMILES: O1C23C(C4C(C5C(CC4)(C(O)CC5)C)CC3)(CC(C(=O)C12)C#N)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H29N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31L760807H, chemically known as 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylic acid, 2-hydroxy-2-methylpropyl ester but generally known as trimazosin, which bears US NIH Compound Identifier 37264. European Medicines Agency schedules Trimazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11298MIG. The term TRIMAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules trimazosin in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trimazosin under HS 29335995 and SITC 51576. As of Q4 2014, TRIMAZOSIN remains the US FDA Preferred Term for this commodity. Trimazosin bears US NLM identifiers UMLS ID C0077147 and NCI Concept Code C75059. SMILES: O(C(=O)N1CCN(CC1)C1NC2C(C(N1)N)CC(OC)C(OC)C2OC)CC(O)(C)C.
This classification denotes the hydrochloride form of an alpha-adrenergic blocking agent with the molecular formula C20H29N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31L760807H, chemically known as 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylic acid, 2-hydroxy-2-methylpropyl ester but more generally known as trimazosin, which bears US NIH Compound Identifier 37264. European Medicines Agency schedules Trimazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11298MIG. The term TRIMAZOSIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules trimazosin in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule trimazosin hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, TRIMAZOSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Trimazosin hydrochloride bears US NLM identifiers UMLS ID C0888485 and NCI Concept Code C75060. SMILES: CC(C)(COC(=O)N1CCN(CC1)C2NC3C(CC(C(C3OC)OC)OC)C(N2)N)O.O.CL.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H29N5O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OT29P74170, chemically known as 1-piperazinecarboxylic acid, 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-, 2-hydroxy-2-methylpropyl ester, hydrochloride (1:1), but more generally known as trimazosin hydrochloride anhydrous, which bears US NIH Compound Identifier 64748. European Medicines Agency schedules trimazosin hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11298MIG. Most nations, for tariff purposes, schedule trimazosin hydrochloride anhydrous under HS 29335995. SMILES: CC(C)(COC(=O)N1CCN(CC1)C2NC3C(CC(C(C3OC)OC)OC)C(N2)N)O.CL.
This classification denotes an opioid receptor agonist with the molecular formula C22H29NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QZ1OJ92E5R, chemically known as 3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutyl ester but generally known as trimebutine, which bears US NIH Compound Identifier 5573. European Medicines Agency schedules Trimebutine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11299MIG. The term TRIMEBUTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules trimebutine in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMEBUTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trimebutine under HS 29221980 and SITC 51461. As of Q4 2014, TRIMEBUTINE remains the US FDA Preferred Term for this commodity. Trimebutine bears US NLM identifiers UMLS ID C0041023 and NCI Concept Code C80588. SMILES: O(CC(N(C)C)(CC)C1CCCCC1)C(=O)C1CC(OC)C(OC)C(OC)C1.
This classification denotes an opioid receptor agonist C17H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3696V8BXT, chemically known as propionic acid, 1,2,5-trimethyl-4-phenyl-4-piperidyl ester, hydrochloride, but more generally known as trimeperidine hydrochloride, which bears US NIH Compound Identifier 98519. European Medicines Agency schedules Trimeperidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04968MIG. Most nations, for tariff and trade purposes, schedule trimeperidine hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, TRIMEPERIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@]1(C[C@@H](N(C[C@H]1C)C)C)C2CCCCC2.CL.
This classification denotes a nicotinic antagonist and antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8W556014K9. European Medicines Agency schedules Trimetaphan camsilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11305MIG. Trimetaphan camsilate generally arises in the molecular formula C22H25N2OS.C10H15O4S. The term TRIMETAPHAN CAMSILATE is an International Non-Proprietary Name or INN. Trimetaphan camsilate or trimethaphan camsylate bears US NLM identifiers UMLS ID C0077158 and NCI Concept Code C66639. SMILES: [S]12C(C3N(C(=O)N(C3C1)Cc1ccccc1)Cc1ccccc1)CCC2.S(=O)(=O)(O)CC12C(C(CC1)CC2=O)(C)C.
This classification denotes a nicotinic antagonist and antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8W556014K9. European Medicines Agency schedules Trimetaphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11305MIG. Trimetaphan camsilate generally arises in the molecular formula C22H25N2OS.C10H15O4S. The term TRIMETAPHAN is an International Non-Proprietary Name or INN. Trimetaphan or trimethaphan bears US NLM identifiers UMLS ID C0041040 and NCI Concept Code C77369. SMILES: C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5.
This classification denotes a cardiotonic agent with the molecular formula C14H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9A0A0R9S8, chemically known as 1-(2,3,4-trimethoxybenzyl)piperazine but generally known as trimetazidine, which bears US NIH Compound Identifier 21109. European Medicines Agency schedules Trimetazidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11306MIG. The term TRIMETAZIDINE is an International Non-Proprietary Name. World Health Organization schedules trimetazidine in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMETAZIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trimetazidine under HS 29335995 and SITC 51576. As of Q4 2014, TRIMETAZIDINE remains the US FDA Preferred Term for this commodity. Trimetazidine bears US NLM identifiers UMLS ID C0041037 and NCI Concept Code C76590. SMILES: O(C1C(CN2CCNCC2)CCC(OC)C1OC)C.
This classification denotes a cardiotonic agent with the molecular formula C14H22N2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48V6723Z1P, chemically known as 1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride but more generally known as trimetazidine dihydrochloride, which bears US NIH Compound Identifier 83201. European Medicines Agency schedules Trimetazidine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12374MIG. Most nations, for tariff and trade purposes, schedule trimetazidine dihydrochloride under HS 29335995. As of Q4 2014, TRIMETAZIDINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC(C(C1OC)OC)CN2CCNCC2.CL.CL.
This classification denotes a cardiotonic agent with the molecular formula C14H22N2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48V6723Z1P, chemically known as 1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride but more generally known as trimetazidine dihydrochloride, which bears US NIH Compound Identifier 83201. European Medicines Agency schedules Trimetazidine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12374MIG. Most nations, for tariff and trade purposes, schedule trimetazidine hydrochloride under HS 29335995 and SITC 51576. SMILES: COC1CCC(C(C1OC)OC)CN2CCNCC2.CL.CL.
This classification denotes an anticonvulsant agent with the molecular formula C6H9NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R7GV3H6FQ4, chemically known as 3,5,5,-trimethyloxazolidine-2,4-dione but generally known as trimethadione, which bears US NIH Compound Identifier 5576. European Medicines Agency schedules Trimethadione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11307MIG. The term TRIMETHADIONE is an International Non-Proprietary Name. World Health Organization schedules trimethadione in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMETHADIONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trimethadione under HS 29349990 and SITC 51579. As of Q4 2014, TRIMETHADIONE remains the US FDA Preferred Term for this commodity. Trimethadione bears US NLM identifiers UMLS ID C0041038 and NCI Concept Code C47772. SMILES: O1C(C(=O)N(C1=O)C)(C)C.
This classification denotes an antiemetic agent with the molecular formula C21H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W2X096QY97, chemically known as 4-(2-dimethylaminoethoxy)-n-(3,4,5-trimethoxybenzoyl)benzylamine but generally known as trimethobenzamide, which bears US NIH Compound Identifier 5577. European Medicines Agency schedules Trimethobenzamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11309MIG. The term TRIMETHOBENZAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). TRIMETHOBENZAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trimethobenzamide under HS 29242995 and SITC 51479. As of Q4 2014, TRIMETHOBENZAMIDE remains the US FDA Preferred Term for this commodity. Trimethobenzamide bears US NLM identifiers UMLS ID C0077163 and NCI Concept Code C61989. SMILES: O(CCN(C)C)C1CCC(CNC(=O)C2CC(OC)C(OC)C(OC)C2)CC1.
This classification denotes a urinary anti-infective agent with the molecular formula C14H18N4O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier AN164J8Y0X, chemically known as 2,4-pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- but more generally known as trimethoprim, which bears U.S. National Institutes of Health Compound Identifier 5578. The European Medicines Agency schedules Trimethoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11310MIG. The term TRIMETHOPRIM is an International Non-Proprietary Name. The World Health Organization schedules trimethoprim in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMETHOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1CC(CC2C(NC(NC2)N)N)CC(OC)C1OC)C.
This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C14H18N4O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9XE000OU9B. The term trimethoprim hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule trimethoprim hydrochloride under HS 29335995 and SITC 51576. SMILES: COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N.CL.
This classification denotes the pamoate form of a urinary anti-infective agent with the molecular formula C14H18N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AN164J8Y0X, chemically known as 2,4-pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- but more generally known as trimethoprim, which bears US NIH Compound Identifier 5578. European Medicines Agency schedules Trimethoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11310MIG. The term TRIMETHOPRIM is an International Non-Proprietary Name World Health Organization schedules trimethoprim in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMETHOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule trimethoprim pamoate under HS 29335995 and SITC 51576. SMILES: COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.
This classification denotes a urinary anti-infective agent with the molecular formula 2C14H18N4O3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E377MF8EQ8, chemically known as 2,4-pyrimidinediamine, 5-((3,4-trimethoxyphenyl)methyl)-, sulfate (2:1) but more generally known as trimethoprim sulfate, which bears US NIH Compound Identifier 64936. European Medicines Agency schedules Trimethoprim sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15618MIG. Most nations, for tariff and trade purposes, schedule trimethoprim sulfate under HS 29335995 and SITC 51576. SMILES: COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N.OS(=O)(=O)O.
This classification denotes an anti-psoriatic agent with the molecular formula C14H12O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y6UY8OV51T, chemically known as 4,8,5-trimethylpsoralen but generally known as trioxsalen, which bears US NIH Compound Identifier 5585. European Medicines Agency schedules Trioxysalen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11318MIG. The term TRIOXYSALEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules trioxsalen in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C.
This classification denotes a folate antagonist and dihydrofolate reductase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UPN4ITI8T4. European Medicines Agency schedules Trimetrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11312MIG. Trimetrexate generally arises in the molecular formula C19H23N5O3. The term TRIMETREXATE is an International Non-Proprietary Name or INN. TRIMETREXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trimetrexate under HS 29335995 and SITC 51576. As of Q4 2014, TRIMETREXATE remains the US FDA Preferred Term for this commodity. Trimetrexate bears US NLM identifiers UMLS ID C0085176 and NCI Concept Code C1314. SMILES: O(C1CC(NCC2C(C3C(NC([NH]C3N)N)CC2)C)CC(OC)C1OC)C.
This classification denotes a tricyclic antidepressant with the molecular formula C20H26N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6S082C9NDT, chemically known as 10,11-dihydro-n,n,beta-trimethyl-5h-dibenz(b,f)azepine-5-propanamine but generally known as trimipramine, which bears US NIH Compound Identifier 5584. European Medicines Agency schedules Trimipramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11314MIG. The term TRIMIPRAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules trimipramine in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMIPRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trimipramine under HS 29339930 and SITC 51577. As of Q4 2014, TRIMIPRAMINE remains the US FDA Preferred Term for this commodity. Trimipramine bears US NLM identifiers UMLS ID C0041056 and NCI Concept Code C61990. SMILES: N1(CC(CN(C)C)C)c2c(CCc3c1cccc3)cccc2.
This classification denotes a tricyclic antidepressant with the molecular formula C20H26N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 269K6498LD, chemically known as 5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine but more generally known as trimipramine maleate, which bears US NIH Compound Identifier 3696. European Medicines Agency schedules Trimipramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04977MIG. Most nations, for tariff and trade purposes, schedule trimipramine maleate under HS 29339930 and SITC 51577. As of Q4 2014, TRIMIPRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Trimipramine maleate bears US NLM identifiers UMLS ID C0728956 and NCI Concept Code C47773. SMILES: CC(CN1C2CCCCC2CCC3C1CCCC3)CN(C)C.C(=C\C(=O)O)\C(=O)O.
This classification denotes a selective estrogen receptor modulator with the molecular formula C30H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, R0130F043H chemically known as 3,4-dihydro-2-(p-methoxyphenyl)-1-naphthyl p-(2-(1-pyrrolidinyl)ethoxy)phenyl ketone but generally known as trioxifene, which bears US NIH Compound Identifier 50139. European Medicines Agency schedules Trioxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11317MIG. The term TRIOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19). Most nations schedule trioxifene under HS 29339990 and SITC 51577. As of Q4 2014, TRIOXIFENE remains the US FDA Preferred Term for this commodity. Trioxifene bears US NLM identifiers UMLS ID C0077238 and NCI Concept Code C1266. SMILES: COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3CC2)C(=O)C4=CC=C(C=C4)OCCN5CCCC5.
This classification denotes a selective estrogen receptor modulator with the molecular formula C30H31NO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63ZD22G88L, chemically known as methanone, (3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, methanesulfonate, but more generally known as trioxifene mesylate, which bears US NIH Compound Identifier 50138. European Medicines Agency schedules trioxifene mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11317MIG. Most nations, for tariff purposes, schedule trioxifene mesylate under HS 29339990. Trioxifene mesylate bears US NLM identifiers UMLS ID C0146868 and NCI Concept Code C1414. SMILES: COC1CCC(CC1)C2=C(C3CCCCC3CC2)C(=O)C4CCC(CC4)OCCN5CCCC5.CS(=O)(=O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H21N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3C5ORO99TY, chemically known as 1,2-ethanediamine, n, n-dimethyl-n- (phenylmethyl)-n-2-pyridinyl-, monohydrochloride but generally known as tripelennamine, which bears US NIH Compound Identifier 5587. European Medicines Agency schedules Tripelennamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11322MIG. The term TRIPELENNAMINE is an International Non-Proprietary Name. World Health Organization schedules tripelennamine in its Anatomical Therapeutic Chemical (ATC) Classification. TRIPELENNAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tripelennamine under HS 29333999 and SITC 51574. As of Q4 2014, TRIPELENNAMINE remains the US FDA Preferred Term for this commodity. Tripelennamine bears US NLM identifiers UMLS ID C0041090 and NCI Concept Code C61991. SMILES: N(CCN(C)C)(CC1CCCCC1)C1NCCCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H21N3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30OC46A3J9, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-(phenylmethyl)-n-2-pyridinyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) but more generally known as tripelennamine citrate, which bears US NIH Compound Identifier 197066. European Medicines Agency schedules Tripelennamine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04980MIG. Most nations, for tariff and trade purposes, schedule tripelennamine citrate under HS 29333999 and SITC 51574. As of Q4 2014, TRIPELENNAMINE CITRATE remains US FDA's Preferred Term for this commodity. Tripelennamine citrate bears US NLM identifiers UMLS ID C0242524 and NCI Concept Code C66641. SMILES: CN(C)CCN(CC1CCCCC1)C2CCCCN2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H21N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FWV8GJ56ZN, chemically known as 1,2-ethanediamine, n, n-dimethyl-n- (phenylmethyl)-n-2-pyridinyl-, monohydrochloride but more generally known as tripelennamine hydrochloride, which bears US NIH Compound Identifier 5587. European Medicines Agency schedules Tripelennamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04981MIG. Most nations, for tariff and trade purposes, schedule tripelennamine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, TRIPELENNAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tripelennamine hydrochloride bears US NLM identifiers UMLS ID C0304297 and NCI Concept Code C47774. SMILES: CN(C)CCN(CC1CCCCC1)C2CCCCN2.CL.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2L8T9S52QM. European Medicines Agency schedules Triprolidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11323MIG. Triprolidine generally arises in the molecular formula C19H22N2. The term TRIPROLIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) TRIPROLIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triprolidine under HS 29333999 and SITC 51574. As of Q4 2014, TRIPROLIDINE remains the US FDA Preferred Term for this commodity. Triprolidine bears US NLM identifiers UMLS ID C0041098 and NCI Concept Code C61992. SMILES: N1(CCCC1)C/C=C(/C1CCC(CC1)C)C1NCCCC1.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YAN7R5L890. European Medicines Agency schedules Triprolidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04984MIG. Triprolidine hydrochloride generally arises in the molecular formula C19H22N2.CLH. The term 'triprolidine hydrochloride' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule triprolidine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, TRIPROLIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Triprolidine hydrochloride bears US NLM identifiers UMLS ID C0242525 and NCI Concept Code C61993. SMILES: CC1CCC(CC1)/C(=C\CN2CCCC2)/C3CCCCN3.O.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H22N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NG7A104R3J, chemically known as (e)-2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride, but more generally known as triprolidine hydrochloride anhydrous, which bears US NIH Compound Identifier 5702129. European Medicines Agency schedules triprolidine hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11323MIG. Most nations, for tariff purposes, schedule triprolidine hydrochloride anhydrous under HS 29333999. SMILES: CC1CCC(CC1)/C(=C\CN2CCCC2)/C3CCCCN3.CL.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H22N2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YAN7R5L890, chemically known as (e)-2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride monohydrate, but more generally known as triprolidine hydrochloride monohydrate, which bears US NIH Compound Identifier 6433473. European Medicines Agency schedules triprolidine hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11323MIG. Most nations, for tariff purposes, schedule triprolidine hydrochloride monohydrate under HS 29333999. SMILES: CC1CCC(CC1)/C(=C\CN2CCCC2)/C3CCCCN3.O.CL.
This classification denotes a gonadotropin-releasing hormone analog and anti-androgen with the molecular formula C64H82N18O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9081Y98W2V, chemically known as luteinizing hormone-releasing factor (pig), 6-d-tryptophan but generally known as triptorelin, which bears US NIH Compound Identifier 16129684. European Medicines Agency schedules Triptorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11324MIG. The term TRIPTORELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules triptorelin in its Anatomical Therapeutic Chemical (ATC) Classification. TRIPTORELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triptorelin under HS 29371900 and SITC 54154. As of Q4 2014, TRIPTORELIN remains the US FDA Preferred Term for this commodity. Triptorelin bears US NLM identifiers UMLS ID C0077275 and NCI Concept Code C1267. SMILES: O=C(N1C(CCC1)C(=O)NCC(=O)N)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)CC1NC[NH]C1)CC1C2C([NH]C1)CCCC2)CO)CC1CCC(O)CC1)CC1C2C([NH]C1)CCCC2)CC(C)C)CCCNC(=N)N.
This classification denotes a nitrogen mustard compound with the molecular formula C9H18Cl3N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H64JRU6GJ0, chemically known as 3-(2-chloroethyl)-2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin 2-oxide but more generally known as trofosfamide, which bears US NIH Compound Identifier 65702. European Medicines Agency schedules Trofosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11331MIG. The term TROFOSFAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules trofosfamide in its Anatomical Therapeutic Chemical (ATC) Classification. TROFOSFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule trofosfamide under HS 29349990 and SITC 51579. As of Q4 2014, TROFOSFAMIDE remains US FDA's Preferred Term for this commodity. Trofosfamide bears US NLM identifiers UMLS ID C0077375 and NCI Concept Code C1268. SMILES: CLCCN1P(=O)(OCCC1)N(CCCL)CCCL.
This classification denotes a differentiation inducer and anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I66ZZ0ZN0E. European Medicines Agency schedules Troglitazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11332MIG. Troglitazone generally arises in the molecular formula C24H27NO5S. The term TROGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 7, no3, 1993, list 33.) TROGLITAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule troglitazone under HS 29341000 and SITC 51579. As of Q4 2014, TROGLITAZONE remains US FDA's Preferred Term for this commodity. Troglitazone bears US NLM identifiers UMLS ID C0245514 and NCI Concept Code C1522. SMILES: CC1=C(C(=C2CCC(OC2=C1C)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)O.
This classification denotes a macrolide antibiotic with the molecular formula C41H67NO15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4DZ64560D, chemically known as oleandomycin, triacetyl- but generally known as triacetyloleandomycin, which bears US NIH Compound Identifier 17675. European Medicines Agency schedules Troleandomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11333MIG. The term TRIACETYLOLEANDOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules triacetyloleandomycin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule troleandomycin under HS 29419000 and SITC 54139. As of Q4 2014, TROLEANDOMYCIN remains the US FDA Preferred Term for this commodity. Troleandomycin bears US NLM identifiers UMLS ID C0702222 and NCI Concept Code C66643. SMILES: CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C.
This classification denotes an ethanolamine and nitrate with the molecular formula C6H12N4O9, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier B9M85U075P, chemically known as 2,2,2-nitrilotrisethanol, trinitrate (ester) but more generally known as trolnitrate, which bears U.S. NIH Compound Identifier 11499. European Medicines Agency schedules Trolnitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11334MIG. World Health Organization schedules trolnitrate in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. TROLNITRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an antiviral agent with the molecular formula C16H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H191JFG8WA, chemically known as 2-(2-(dimethylamino)ethoxy)-n-tricyclo(3.3.1.13,7)dec-1-ylacetamide but generally known as tromantadine, which bears US NIH Compound Identifier 64377. European Medicines Agency schedules Tromantadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11335MIG. The term TROMANTADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules tromantadine in its Anatomical Therapeutic Chemical (ATC) Classification. TROMANTADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tromantadine under HS 29242995 and SITC 51479. As of Q4 2014, TROMANTADINE remains the US FDA Preferred Term for this commodity. Tromantadine bears US NLM identifiers UMLS ID C0077379 and NCI Concept Code C81608. SMILES: O=C(NC12CC3CC(C2)CC(C1)C3)COCCN(C)C.
This classification denotes an antiviral agent with the molecular formula C16H28N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H09LUS437B, chemically known as acetamide, n-1-adamantyl-n-(2-(dimethylamino)ethoxy)-, hydrochloride but more generally known as tromantadine hydrochloride, which bears US NIH Compound Identifier 64284. European Medicines Agency schedules Tromantadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04992MIG. Most nations, for tariff and trade purposes, schedule tromantadine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, TROMANTADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tromantadine hydrochloride bears US NLM identifiers UMLS ID C1529464 and NCI Concept Code C96719. SMILES: CN(C)CCOCC(=O)N[C@]12C[C@@H]3C[C@H](C1)CC(C3)C2.CL.
This classification denotes an organic carcinogen with the molecular formula C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 023C2WHX2V, chemically known as 1,1,1-tris(hydroxymethyl)methanamine but generally known as trometamol, which bears US NIH Compound Identifier 6503. European Medicines Agency schedules Trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11336MIG. The term TROMETAMOL is an International Non-Proprietary Name. World Health Organization schedules trometamol in its Anatomical Therapeutic Chemical (ATC) Classification. TROMETAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tromethamine under HS 29221990 and SITC 51461. As of Q4 2014, TROMETHAMINE remains the US FDA Preferred Term for this commodity. Tromethamine bears US NLM identifiers UMLS ID C0041175 and NCI Concept Code C47775. SMILES: OCC(N)(CO)CO.
This classification denotes an organic carcinogen with the molecular formula C4H11NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 383V75M34E. European Medicines Agency schedules tromethamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32380. Most nations, for tariff and trade purposes, schedule tromethamine hydrochloride under HS 29221990. As of Q4 2014, TROMETHAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C(C(CO)(CO)N)O.CL.
This classification denotes an antiparkinsonian agent with the molecular formula C22H25NO2, chemically known as 2-[3-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl]-2-phenylacetic acid but generally known as tropacine, which bears US NIH Compound Identifier 197078. European Medicines Agency schedules Tropacine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15624MIG. As of Q4 2014, TROPACINE remains the US FDA Preferred Term for this commodity. SMILES: CN1C2CCC1CC(C2)C3=CC(=CC=C3)C(C4=CC=CC=C4)C(=O)O.
This classification denotes a serotonin antagonist with the molecular formula C17H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04B48I6VHR, chemically known as tropyl 3,5-dimethylbenzoate but generally known as tropanserin, which bears US NIH Compound Identifier 68600. European Medicines Agency schedules Tropanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11338MIG. The term TROPANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). TROPANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tropanserin under HS 29399900 and SITC 54149. As of Q4 2014, TROPANSERIN remains the US FDA Preferred Term for this commodity. Tropanserin bears US NLM identifiers UMLS ID C2987002 and NCI Concept Code C95218. SMILES: O(C1CC2N(C(CC2)C1)C)C(=O)c1cc(cc(c1)C)C.
This classification denotes a serotonin antagonist with the molecular formula C17H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6R9A98I18O, chemically known as 1alphah,5alphah-tropan-3alpha-yl 3,5-dimethylbenzoate, hydrochloride but more generally known as tropanserin hydrochloride, which bears US NIH Compound Identifier 68599. Most nations, for tariff and trade purposes, schedule tropanserin hydrochloride under HS 29399900 and SITC 54149. As of Q4 2014, TROPANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tropanserin hydrochloride bears US NLM identifiers UMLS ID C2987003 and NCI Concept Code C95219. SMILES: CC1CC(CC(C1)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)C.CL.
This classification denotes a tropane and dibenzothiepin with the molecular formula C22H23NS, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C27HY5RFU5, chemically known as 8-azabicyclo(3.2.1)octane, 3-dibenzo(b,e)thiepin-11(6h)-ylidene-8-methyl- but more generally known as tropatepine, which bears U.S. NIH Compound Identifier 72148. European Medicines Agency schedules Tropatepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11340MIG. World Health Organization schedules tropatepine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. TROPATEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a tropane and dibenzothiepin with the molecular formula C22H23NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C27HY5RFU5, chemically known as 8-azabicyclo(3.2.1)octane, 3-dibenzo(b,e)thiepin-11(6h)-ylidene-8-methyl- but generally known as tropatepine, which bears US NIH Compound Identifier 72148. European Medicines Agency schedules Tropatepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11340MIG. World Health Organization schedules tropatepine in its Anatomical Therapeutic Chemical (ATC) Classification. TROPATEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tropatepine hydrochlorate under HS 29349990 and SITC 51579. SMILES: S1C2C(C(=C3\CC4N(C(CC4)C3)C)/C3C(C1)CCCC3)CCCC2.
This classification denotes a diagnostic reagent and antimuscarinic agent with the molecular formula C17H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N0A3Z5XTC6, chemically known as hydracrylamide, n-ethyl-2-phenyl-n-(4-pyridylmethyl)- but generally known as tropicamide, which bears US NIH Compound Identifier 5593. European Medicines Agency schedules Tropicamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11342MIG. The term TROPICAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules tropicamide in its Anatomical Therapeutic Chemical (ATC) Classification. TROPICAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tropicamide under HS 29333999 and SITC 51574. As of Q4 2014, TROPICAMIDE remains the US FDA Preferred Term for this commodity. Tropicamide bears US NLM identifiers UMLS ID C0041190 and NCI Concept Code C47776. SMILES: O=C(N(CC1CCNCC1)CC)C(C1CCCCC1)CO.
This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C17H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6I819NIK1W, chemically known as 1h-indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo- but generally known as tropisetron, which bears US NIH Compound Identifier 72165. European Medicines Agency schedules Tropisetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11345MIG. The term TROPISETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules tropisetron in its Anatomical Therapeutic Chemical (ATC) Classification. TROPISETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tropisetron under HS 29399900 and SITC 54149. As of Q4 2014, TROPISETRON remains the US FDA Preferred Term for this commodity. Tropisetron bears US NLM identifiers UMLS ID C0063322 and NCI Concept Code C1131. SMILES: O(C1CC2N(C(CC2)C1)C)C(=O)C1C2C([NH]C1)CCCC2.
This classification denotes an antiprotozoal agent with the molecular formula C14H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41X4FOR202, chemically known as 4-morpholinecarboximidamide, n-(3-nitro-4-quinolinyl)- but generally known as troquidazole, which bears US NIH Compound Identifier 65903. European Medicines Agency schedules Troquidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11347MIG. The term TROQUIDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). Most nations schedule troquidazole under HS 29349990 and SITC 51579. As of Q4 2014, TROQUIDAZOLE remains the US FDA Preferred Term for this commodity. Troquidazole bears US NLM identifiers UMLS ID C2700085 and NCI Concept Code C76435. SMILES: O1CCN(CC1)/C(=N/C1C2C(NCC1[N](=O)O)CCCC2)N.
This classification denotes an antimuscarinic agent with the molecular formula C25H30NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4Y8ORK057, chemically known as 6,10-ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate but generally known as trospium, which bears US NIH Compound Identifier 107979. European Medicines Agency schedules Trospium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05000MIG. World Health Organization schedules trospium in its Anatomical Therapeutic Chemical (ATC) Classification. TROSPIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, TROSPIUM remains the US FDA Preferred Term for this commodity. Trospium bears US NLM identifiers UMLS ID C0772089 and NCI Concept Code C78080. SMILES: CL.O(C1CC2[N]3(C(CC2)C1)CCCC3)C(=O)C(O)(C1CCCCC1)C1CCCCC1. .
This classification denotes an antimuscarinic agent with the molecular formula C25H30NO3.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1E6682427E, chemically known as 6,10-ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate but generally known as trospium chloride, which bears US NIH Compound Identifier 107979. European Medicines Agency schedules Trospium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11349MIG. Most nations schedule trospium chloride under HS 29399900 and SITC 54149. As of Q4 2014, TROSPIUM CHLORIDE remains the US FDA Preferred Term for this commodity. Trospium chloride bears US NLM identifiers UMLS ID C0077408 and NCI Concept Code C61995. SMILES: Cl.O(C1CC2[N]3(C(CC2)C1)CCCC3)C(=O)C(O)(c1ccccc1)c1ccccc1.
This classification denotes a quinolone antibiotic with the molecular formula C20H15F3N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9F388J00UK, chemically known as cp-99,219 but generally known as trovafloxacin, which bears US NIH Compound Identifier 62959. European Medicines Agency schedules Trovafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11350MIG. The term TROVAFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules trovafloxacin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule trovafloxacin under HS 29339990 and SITC 51577. As of Q4 2014, TROVAFLOXACIN remains the US FDA Preferred Term for this commodity. Trovafloxacin bears US NLM identifiers UMLS ID C0379881 and NCI Concept Code C66644. SMILES: FC1C(N2CC3C(C3N)C2)NC2N(CC(C(=O)C2C1)C(=O)O)C1C(F)CC(F)CC1.
This classification denotes a pyrimidine antagonist with the molecular formula C8H11N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60KQZ0388Y, chemically known as 2(1h)-pyrimidinone, 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)- but generally known as troxacitabine, which bears US NIH Compound Identifier 151173. European Medicines Agency schedules Troxacitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22612. The term TROXACITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). Most nations schedule troxacitabine under HS 29349990 and SITC 51579. As of Q4 2014, TROXACITABINE remains the US FDA Preferred Term for this commodity. Troxacitabine bears US NLM identifiers UMLS ID C0877874 and NCI Concept Code C1438. SMILES: O1C(N2CCC(NC2=O)N)COC1CO.
This classification denotes a piperidine with the molecular formula C15H22N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W6QJX1Q00Z, chemically known as 3,4,5-trimethoxy-n-(3-piperidyl)benzamide but generally known as troxipide, which bears US NIH Compound Identifier 5597. European Medicines Agency schedules Troxipide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11353MIG. World Health Organization schedules troxipide in its Anatomical Therapeutic Chemical (ATC) Classification. TROXIPIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule troxipide under HS 29333999 and SITC 51574. As of Q4 2014, TROXIPIDE remains the US FDA Preferred Term for this commodity. SMILES: O=C(NC1CCCNC1)C1CC(OC)C(OC)C(OC)C1.
This classification denotes a dietary amino acid with the molecular formula C11H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8DUH1N11BX, chemically known as 1h-indole-3-propanoic acid, a-amino-, (s)- but generally known as l-tryptophan, which bears US NIH Compound Identifier 1148. European Medicines Agency schedules Tryptophan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12377MIG. The term TRYPTOPHAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules l-tryptophan in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TRYPTOPHAN remains the US FDA Preferred Term for this commodity. Tryptophan bears US NLM identifiers UMLS ID C0041249 and NCI Concept Code C29603. SMILES: C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N.
This classification denotes an amine with the molecular formula C7H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z0420GYD84, chemically known as hexylamine, 1-methyl- but generally known as tuaminoheptane, which bears US NIH Compound Identifier 5603. European Medicines Agency schedules Tuaminoheptane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11360MIG. World Health Organization schedules tuaminoheptane in its Anatomical Therapeutic Chemical (ATC) Classification. TUAMINOHEPTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: NC(CCCCC)C.
A type of sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis.
This classification denotes a nicotinic antagonist and neuromuscular nondepolarizing agent with the molecular formula C37H41N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9YXS298BM, chemically known as 13h-4,6:21,24-dietheno-8,12-metheno-1h-pyrido(3,2:14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-, (13ar,25as)- but generally known as tubocurarine, which bears US NIH Compound Identifier 6000. European Medicines Agency schedules Tubocurarine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15635MIG. World Health Organization schedules tubocurarine in its Anatomical Therapeutic Chemical (ATC) Classification. TUBOCURARINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, TUBOCURARINE remains the US FDA Preferred Term for this commodity. SMILES: CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.
This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 900961Z8VR. European Medicines Agency schedules Curare in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB49132. Tubocurarine chloride generally arises in the molecular formula C37H41N2O6.CL.CLH.5H2O. The term 'tubocurarine chloride' is a United States Homeopathic Pharmacopoeia Name designation. Most nations, for tariff and trade purposes, schedule tubocurarine chloride under HS 29399900 and SITC 54149. As of Q4 2014, TUBOCURARINE CHLORIDE remains US FDA's Preferred Term for this commodity. Tubocurarine chloride bears US NLM identifiers UMLS ID C0282372 and NCI Concept Code C47777. SMILES: CN1CCC2CC(C3CC2[C@@H]1CC4CCC(CC4)OC5C6C(CC(C5O)OC)CC[N+]([C@@H]6CC7CCC(C(C7)O3)O)(C)C)OC.O.O.O.O.O.CL.[CL-].
This classification denotes a muscle relaxant with the molecular formula C40H48N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V0M92G2U26. SMILES: C[N+]1(CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C. SMILES: C[N+]1(CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.
This classification denotes an antiplatelet agent with the molecular formula C25H19N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IQ3Q8N1287, chemically known as 1h,3h-pyrrolo(1,2-c)thiazole-7-carboxamide, n-(3-(phenylmethyl)phenyl)-3-(3-pyridinyl)-, (+)- but generally known as tulopafant, which bears US NIH Compound Identifier 65927. European Medicines Agency schedules Tulopafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11366MIG. The term TULOPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). TULOPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tulopafant under HS 29349990 and SITC 51579. As of Q4 2014, TULOPAFANT remains the US FDA Preferred Term for this commodity. Tulopafant bears US NLM identifiers UMLS ID C2825687 and NCI Concept Code C81573. SMILES: S1C(N2C(C1)C(CC2)C(=O)NC1CC(CCC1)C(=O)C1CCCCC1)C1CCCNC1.
This classification denotes a histamine-2 receptor antagonist with the molecular formula C10H17N9O2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TWN203TLYT, chemically known as guanidine, (4-(((2-((5-amino-4-methyl-4h-1,2,4,6-thiatriazin-3-yl)amino)ethyl)thio)methyl)-2-thiazolyl)-, s,s-dioxide but generally known as tuvatidine, which bears US NIH Compound Identifier 65826. European Medicines Agency schedules Tuvatidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11368MIG. The term TUVATIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). TUVATIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tuvatidine under HS 29341000 and SITC 51579. As of Q4 2014, TUVATIDINE remains the US FDA Preferred Term for this commodity. Tuvatidine bears US NLM identifiers UMLS ID C2348828 and NCI Concept Code C73216. SMILES: CN1C(=NS(=O)(=O)N=C1NCCSCC2=CSC(=N2)N=C(N)N)N.
This classification denotes a carbamate anxiolytic with the molecular formula C13H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3875LLL8M8, chemically known as [2-(carbamoyloxymethyl)-2-methylpentyl] N-butylcarbamate but generally known as tybamate, which bears US NIH Compound Identifier 20266. European Medicines Agency schedules tybamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11369MIG. Most nations schedule tybamate under HS 29241900 and SITC 51471. As of Q4 2014, TYBAMATE remains the US FDA Preferred Term for this commodity. Tybamate bears US NLM identifiers UMLS ID C0175163 and NCI Concept Code C98240. SMILES: CCCCNC(=O)OCC(C)(CCC)COC(=O)N.
This classification denotes a macrolide antibiotic with the molecular formula C46H77NO17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YEF4JXN031. The term TYLOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7. ). TYLOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tylosin under HS 29419000 and SITC 54139. As of Q4 2014, TYLOSIN remains the US FDA Preferred Term for this commodity. Tylosin bears US NLM identifiers UMLS ID C0041441 and NCI Concept Code C84234. SMILES: CCC1C(C=C(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)C)COC4C(C(C(C(O4)C)O)OC)OC.
This classification denotes a macrolide antibiotic with the molecular formula C46H77NO17.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NR75X12AFF. The term tylosin phosphate is a U.S. FDA Green Book designation. Most nations, for tariff and trade purposes, schedule tylosin phosphate under HS 29419000. As of Q4 2014, TYLOSIN PHOSPHATE remains US FDA's Preferred Term for this commodity. Tylosin phosphate bears US NLM identifiers UMLS ID C0060065 and NCI Concept Code C84235. SMILES: CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)\C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC.OP(=O)(O)O.
This classification denotes a macrolide antibiotic with the molecular formula C46H77NO17.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5P4625C51T, chemically known as tylosin, tartrate but more generally known as tylosin tartrate, which bears US NIH Compound Identifier 6433274. Most nations, for tariff and trade purposes, schedule tylosin tartrate under HS 29419000 and SITC 54139. Tylosin tartrate bears US NLM identifiers UMLS ID C0041442 and NCI Concept Code C84236. SMILES: As of Q4 2014, TYLOSIN TARTRATE remains US FDA's Preferred Term for this commodity.
This classification denotes a surface-active agent with the molecular formula (C15H22O(C2H4O)n)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y27PUL9H56, chemically known as 4-(1,1,3,3-tetramethylbutyl)phenol, polymer with formaldehyde & oxirane but more generally known as tyloxapol, which bears US NIH Compound Identifier 71388. European Medicines Agency schedules Tyloxapol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05015MIG. World Health Organization schedules tyloxapol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TYLOXAPOL remains US FDA's Preferred Term for this commodity. Tyloxapol bears US NLM identifiers UMLS ID C0077539 and NCI Concept Code C80949. SMILES: CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U993RH5585, chemically known as 1,4,5-dihydro-2-(2-isopropyl-5-methylphenoxymethyl)imidazol but generally known as tymazoline, which bears US NIH Compound Identifier 34154. European Medicines Agency schedules Tymazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15640MIG. World Health Organization schedules tymazoline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TYMAZOLINE remains the US FDA Preferred Term for this commodity. Tymazoline bears US NLM identifiers UMLS ID C0771442 and NCI Concept Code C95309. SMILES: O(C1C(C(C)C)CCC(C1)C)CC1=NCCN1.
This classification denotes vaccines used to prevent typhoid fever (An acute systemic febrile infection caused by salmonella typhi, a serotype of salmonella enterica) and/or paratyphoid fever (a prolonged febrile illness commonly caused by several paratyphi serotypes of salmonella enterica), which are caused by various species of salmonella. Typhoid vaccine bears US NLM identifiers UMLS ID C0041469 and NCI Concept Code C96392.
This classification denotes A polypeptide antibiotic mixture obtained from Bacillus brevis. It consists of a mixture of three tyrocidines (60%) and several gramicidins (20%), with the molecular formula C65H85N11O13, chemically known as 3-[(3R,6S,9S,12S,15S,17S,20S,22R,25S,28S)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11, 14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23, 26-nonazabicyclo[26.3.0]hentriacontan-17-yl]propanoic acid, but generally known as tyrothricin. The term TYROTHRICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, 1955, 9, 185-194, List 1..) TYROTHRICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tyrothricin under HS 29419000 and SITC 54139. SMILES: CC(C)CC1C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)C(NC(=O)C(NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN)C(C)C)CC3=CC=C(C=C3)O)CCC(=O)O)CC(=O)N)CC4=CC=CC=C4)CC5=CC=CC=C5)CC6=CC=CC=C6.
This classification denotes an antiarrhythmic agent with the molecular formula C20H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) FV251T245M, chemically known as 2-(2-(diethylamino)ethyl)-2,3-dihydro-3-phenyl-1h-isoindol-1-one but more generally known as ubisindine, which bears US NIH Compound Identifier 168473. European Medicines Agency schedules Ubisindine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11374MIG. The term UBISINDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, No10, 1977, List 17). UBISINDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ubisindine under HS 29337900 and SITC 51561. As of Q4 2014, UBISINDINE remains US FDA's Preferred Term for this commodity. Ubisindine bears US NLM identifiers UMLS ID C0607222 and NCI Concept Code C74125. SMILES: O=C1N(C(C2C1CCCC2)C1CCCCC1)CCN(CC)CC.
This classification denotes a cgmp phosphodiesterase inhibitor, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier L5IB4XLY36. European Medicines Agency schedules Udenafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32099. Udenafil generally arises in the molecular formula C25H36N6O4S. The term UDENAFIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 20, no. 1, 2006, list 55.) UDENAFIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an anti-progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J5J15Q2X8. European Medicines Agency schedules Ulipristal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30471. Ulipristal generally arises in the molecular formula C28H35NO3. The term ULIPRISTAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, no. 3, 2007, list 58.) As of Q4 2014, ULIPRISTAL remains the US FDA Preferred Term for this commodity. Ulipristal bears US NLM identifiers UMLS ID C0300205 and NCI Concept Code C91056. SMILES: CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O.
This classification denotes an anti-progestin with the molecular formula C30H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YF7V70N02B. European Medicines Agency schedules ulipristal acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30470. The term ulipristal acetate is a United States Adopted Name designation. As of Q4 2014, ULIPRISTAL ACETATE remains the US FDA Preferred Term for this commodity. Ulipristal acetate bears US NLM identifiers UMLS ID C2723461 and NCI Concept Code C91057. SMILES: CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)OC(=O)C.
This classification denotes a therapeutic glucocorticoid with the molecular formula C25H31ClF2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91A0K1TY3Z, chemically known as 21-chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate but more generally known as halobetasol propionate, which bears US NIH Compound Identifier 48175. European Medicines Agency schedules Ulobetasol propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05030MIG. Most nations, for tariff and trade purposes, schedule ulobetasol propionate under HS 29372200. SMILES: CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCL.
A drug administered via oral inhalation for use in adults to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease COPD.
This classification denotes an immunosuppressant with the molecular formula C55H87NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U36PGF65JH, chemically known as rapamycin, 42-o-(2-ethoxyethyl)- but more generally known as umirolimus, which bears US NIH Compound Identifier 11158972. European Medicines Agency schedules umirolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33179. The term UMIROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25, No. 1, 2011, List 64). As of Q4 2014, UMIROLIMUS remains US FDA's Preferred Term for this commodity. Most nations, for tariff and trade purposes, schedule UMIROLIMUS under HS 29349990 and SITC 51579. SMILES: CCOCCOC1CCC(CC1OC)CC(C)C2CC(=O)C(C=C(C(C(C(=O)C(CC(C=CC=CC=C(C(CC3CCC(C(O3)(C(=O)C(=O)N4CCCCC4C(=O)O2)O)C)OC)C)C)C)OC)O)C)C.
This classification denotes an antifungal agent with the molecular formula C11H20O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3D86KJ24N, chemically known as 10-undecenoic acid, zinc salt but generally known as undecenoic acid, which bears US NIH Compound Identifier 5634. European Medicines Agency schedules Undecenoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35139. World Health Organization schedules undecenoic acid in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: OC(=O)CCCCCCCCC=C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE102. This VA Drug Class (DE102) classifies this compound as belonging to the group ANTIFUNGAL, TOPICAL.
This classification denotes a prostaglandin analogue and anti-glaucoma agent with the molecular formula C22H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X4F561V3W, chemically known as 13,14-dihydro-15-keto-20-ethyl pgf2alpha but generally known as unoprostone, which bears US NIH Compound Identifier 5311236. European Medicines Agency schedules Unoprostone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11381MIG. The term UNOPROSTONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules unoprostone in its Anatomical Therapeutic Chemical (ATC) Classification. UNOPROSTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule unoprostone under HS 29375000 and SITC 54156. As of Q4 2014, UNOPROSTONE remains the US FDA Preferred Term for this commodity. Unoprostone bears US NLM identifiers UMLS ID C0772319 and NCI Concept Code C76904. SMILES: OC1C(C(C(O)C1)C/C=C\CCCC(=O)O)CCC(=O)CCCCCCC.
This classification denotes a prostaglandin analogue and anti-glaucoma agent with the molecular formula C25H44O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M161S5O5P, chemically known as isopropyl (5z,9alpha,11alpha)-9,11-dihydroxy-15-oxo-20a,20b-dihomoprost-5-en-1-oate but more generally known as isopropyl unoprostone, which bears US NIH Compound Identifier 5282175. European Medicines Agency schedules Unoprostone isopropyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15658MIG. Most nations, for tariff and trade purposes, schedule unoprostone isopropyl under HS 29375000 and SITC 54156. As of Q4 2014, UNOPROSTONE ISOPROPYL remains US FDA's Preferred Term for this commodity. Unoprostone isopropyl bears US NLM identifiers UMLS ID C0527038 and NCI Concept Code C47778. SMILES: CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O)O.
This classification denotes a prostaglandin analogue and anti-glaucoma agent with the molecular formula C25H44O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M161S5O5P, chemically known as isopropyl z-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)hept-5-enoate, d-, but more generally known as unoprostone isopropyl ester, which bears US NIH Compound Identifier 5282175. European Medicines Agency schedules unoprostone isopropyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11381MIG. Most nations, for tariff purposes, schedule unoprostone isopropyl ester under HS 29375000. SMILES: CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O)O.
This classification denotes a pyrimidine with the molecular formula C4H4N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56HH86ZVCT, chemically known as 2,4-pyrimidinedione but generally known as uracil, which bears US NIH Compound Identifier 1174. European Medicines Agency schedules Uracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20762. Most nations schedule uracil under HS 29335990 and SITC 51576. As of Q4 2014, URACIL remains the US FDA Preferred Term for this commodity. Uracil bears US NLM identifiers UMLS ID C0041917 and NCI Concept Code C917. SMILES: O=C1[NH]C(=O)CC[NH]1.
This classification denotes a nitrogen mustard compound with the molecular formula C8H11Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W7KQ46GJ8U, chemically known as 2,6-dihydroxy-5-bis(2-chloroethyl)aminopyrimidine but more generally known as uracil mustard, which bears US NIH Compound Identifier 6194. European Medicines Agency schedules Uracil mustard in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11383MIG. The term URAMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). SMILES: CLCCN(CCCL)C1C(=O)[NH]C(=O)[NH]C1.
This classification denotes an adrenergic alpha-1 receptor antagonist and antihypertensive agent with the molecular formula C20H29N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A78GF17HJS, chemically known as 2,4(1h,3h)-pyrimidinedione, 6-((3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyl- (9ci) but generally known as urapidil, which bears US NIH Compound Identifier 5639. European Medicines Agency schedules Urapidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11384MIG. World Health Organization schedules urapidil in its Anatomical Therapeutic Chemical (ATC) Classification. URAPIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule urapidil under HS 29335995 and SITC 51576. As of Q4 2014, URAPIDIL remains the US FDA Preferred Term for this commodity. SMILES: O(C1C(N2CCN(CC2)CCCNC2N(C(=O)N(C(=O)C2)C)C)CCCC1)C.
This classification denotes an adrenergic alpha-1 receptor antagonist and antihypertensive agent C20H29N5O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7565ZXN22A, chemically known as 6-((3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)amino)-1,3-dimethylpyrimidine-2,4(1h,3h)-dione (2e)-but-2-enedioate (1:1), but more generally known as urapidil fumarate, which bears US NIH Compound Identifier 9870716. Most nations, for tariff and trade purposes, schedule urapidil fumarate under HS 29335995 and SITC 51576. As of Q4 2014, URAPIDIL FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CN1C(CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3CCCCC3OC.C(=C/C(=O)O)\C(=O)O.
This classification denotes an osmotic diuretic with the molecular formula CH4N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8W8T17847W, chemically known as urea, homopolymer but generally known as carbamide, which bears US NIH Compound Identifier 1176. Carbamide most often comes in base, perhydrate, peroxide, phenylacetate, and resin forms. European Medicines Agency schedules Urea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15662MIG. World Health Organization schedules carbamide in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O=C(N)N.
This classification denotes an ethylenimine compound with the molecular formula C7H14N3O3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V30JZ75AB, chemically known as carbamic acid, (bis(1-aziridinyl)phosphinyl)-, ethyl ester but more generally known as uredepa, which bears US NIH Compound Identifier 9332. European Medicines Agency schedules Uredepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11385MIG. The term UREDEPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). UREDEPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule uredepa under HS 29339990 and SITC 51577. As of Q4 2014, UREDEPA remains US FDA's Preferred Term for this commodity. Uredepa bears US NLM identifiers UMLS ID C1519821 and NCI Concept Code C2072. SMILES: P(=O)(N1CC1)(N1CC1)NC(=O)OCC.
This classification denotes an antihelminthic agent with the molecular formula C19H25N4O6PS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8W25X9B3K, chemically known as rh-32,565 but generally known as uredofos, which bears US NIH Compound Identifier 3033943. European Medicines Agency schedules Uredofos in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11386MIG. The term UREDOFOS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). UREDOFOS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule uredofos under HS 29350090 and SITC 51580. As of Q4 2014, UREDOFOS remains the US FDA Preferred Term for this commodity. Uredofos bears US NLM identifiers UMLS ID C0077868 and NCI Concept Code C72154. SMILES: S(=O)(=O)(NC(=O)NC1C(NC(=S)NP(=O)(OCC)OCC)CCCC1)C1CCC(CC1)C.
This classification denotes a therapeutic follicle stimulating hormone with the molecular formula C975H1513N267O304S26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9BB98U6HP, more generally known as urofollitropin. European Medicines Agency schedules urofollitropin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05053MIG. The term UROFOLLITROPIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 1, no. 4, 1987, list 27. Most nations schedule urofollitropin under HS 29371900 and SITC 54154. As of Q4 2014, UROFOLLITROPIN remains the US FDA Preferred Term for this commodity. Urofollitropin bears US NLM identifiers UMLS ID C0383405 and NCI Concept Code C80805. SMILES: CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O.
This classification denotes a plasminogen activator with the molecular formula C1376H2145N383O406S18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83G67E21XI, more generally known as urokinase. European Medicines Agency schedules urokinase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05055MIG. The term UROKINASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 21 no. 12 1967, list 7. UROKINASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule urokinase under HS 35079090 and SITC 51691. As of Q4 2014, UROKINASE remains the US FDA Preferred Term for this commodity. SMILES: NONE.
This classification denotes a protein kinase c inhibitor and anti-lipidemic agent with the molecular formula C24H40O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 724L30Y2QR, chemically known as cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)- but more generally known as ursodeoxycholic acid, which bears US NIH Compound Identifier 5645. European Medicines Agency schedules Ursodeoxycholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11389MIG. The term URSODEOXYCHOLIC ACID is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules ursodeoxycholic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Ursodiol bears US NLM identifiers UMLS ID C0042105 and NCI Concept Code C1818. SMILES: OC1C2C3C(C(CC3)C(CCC(=O)O)C)(CCC2C2(C(C1)CC(O)CC2)C)C.
This classification denotes a monoclonal antibody with the molecular formula C6482H10004N1712O2016S46, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FU77B4U5Z0, more generally known as ustekinumab. European Medicines Agency schedules ustekinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27761. The term USTEKINUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 1, 2009, list 61. Most nations, for tariff and trade purposes, schedule Ustekinumab under HS 30021020 and SITC 54163. SMILES:. As of Q4 2014, USTEKINUMAB remains US FDA's Preferred Term for this commodity. . Ustekinumab bears US NLM identifiers UMLS ID C1608841 and NCI Concept Code C84237.
This classification denotes an antihypertensive agent with the molecular formula C22H31N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87I5H747BC, chemically known as 1,3,4-thiadiazole-2-carboxylic acid, 5-(1,1-dimethylethyl)-3-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-2,3-dihydro-, (2s-(2r*,3(r*(r*))))- but generally known as utibapril, which bears US NIH Compound Identifier 60359. European Medicines Agency schedules Utibapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11391MIG. The term UTIBAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). UTIBAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule utibapril under HS 29349990 and SITC 51579. As of Q4 2014, UTIBAPRIL remains the US FDA Preferred Term for this commodity. Utibapril bears US NLM identifiers UMLS ID C0082621 and NCI Concept Code C81524. SMILES: S1C(=NN(C1C(=O)O)C(=O)C(NC(CCc1ccccc1)C(=O)OCC)C)C(C)(C)C.
This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KN82541NHV. European Medicines Agency schedules Utibaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00001MIG. Utibaprilat generally arises in the molecular formula C20H27N3O5S. The term UTIBAPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) UTIBAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule utibaprilat under HS 29349990 and SITC 51579. As of Q4 2014, UTIBAPRILAT remains the US FDA Preferred Term for this commodity. Utibaprilat bears US NLM identifiers UMLS ID C0950771 and NCI Concept Code C72914. SMILES: S1C(=NN(C1C(=O)O)C(=O)C(NC(CCc1ccccc1)C(=O)O)C)C(C)(C)C.
This classification denotes an anesthetic agent with the molecular formula C18H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKA45SU1Q4, chemically known as (+-)-6-methoxy-2-methyl-1-piperidinepropiono-2,4-xylidide but generally known as vadocaine, which bears US NIH Compound Identifier 68912. European Medicines Agency schedules Vadocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00002MIG. The term VADOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). VADOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vadocaine under HS 29333999 and SITC 51574. As of Q4 2014, VADOCAINE remains the US FDA Preferred Term for this commodity. Vadocaine bears US NLM identifiers UMLS ID C0084936 and NCI Concept Code C72163. SMILES: O=C(NC1C(CC(CC1OC)C)C)CCN1C(CCCC1)C.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C13H20N6O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier MZ1IW7Q79D, chemically known as valaciclovir, valtrex but more generally known as valaciclovir, which bears U.S. National Institutes of Health Compound Identifier 60773. The European Medicines Agency schedules Valaciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00003MIG. The term VALACICLOVIR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 8 No. 3 1994, List 34). The World Health Organization schedules valaciclovir in its Anatomical Therapeutic Chemical (ATC) Classification. VALACICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(C)C(C(=O)OCCOCN1C=NC2=C1NC(=NC2=O)N)N.CL.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C13H20N6O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G447S0T1VC, chemically known as l-valine, ester with 9-((2-hydroxyethoxy)methyl)guanine, monohydrochloride but generally known as valaciclovir hydrochloride, which bears US NIH Compound Identifier 60772. European Medicines Agency schedules Valaciclovir hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15679MIG. As of Q4 2014, VALACYCLOVIR HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Valacyclovir hydrochloride bears US NLM identifiers UMLS ID C0771309 and NCI Concept Code C29535. SMILES: CL.O(C(=O)C(N)C(C)C)CCOCN1C2[NH]C(NC(=O)C2NC1)N.
This classification denotes an antifungal agent with the molecular formula C16H18Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3EVI8KD2BC, chemically known as (r,s)-2-(2,4-dichlorphenoxy)-1-imidazolyl-4,4-dimethyl-3-pentanon but generally known as valconazole, which bears US NIH Compound Identifier 3016731. European Medicines Agency schedules Valconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00004MIG. The term VALCONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). VALCONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valconazole under HS 29332990 and SITC 51573. As of Q4 2014, VALCONAZOLE remains the US FDA Preferred Term for this commodity. Valconazole bears US NLM identifiers UMLS ID C2349097 and NCI Concept Code C72966. SMILES: CLC1C(OC(C(=O)C(C)(C)C)CN2CCNC2)CCC(CL)C1.
This classification denotes a cyclooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2919279Q3W. European Medicines Agency schedules Valdecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05065MIG. Valdecoxib generally arises in the molecular formula C16H14N2O3S. The term VALDECOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule valdecoxib under HS 29350090 and SITC 51580. As of Q4 2014, VALDECOXIB remains the US FDA Preferred Term for this commodity. Valdecoxib bears US NLM identifiers UMLS ID C0913246 and NCI Concept Code C1869. SMILES: S(=O)(=O)(N)C1CCC(C2C(NOC2C)C2CCCCC2)CC1.
This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JWF5YAW3QW, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 35363 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Dipsacales, Family Valerianaceae, Genus Valeriana L. (valerian), Species Valeriana officinalis L., commonly known as GARDEN HELIOTROPE, GARDEN VALERIAN, or as here, simple VALERIAN. Valerian bears the USDA PLANTS Database Identifier VAOF. European Medicines Agency schedules valerian in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB15683MIG, SUB16050MIG, SUB20767, SUB20768, SUB30201, SUB30368, SUB32487, SUB35338, SUB40760, SUB40761, SUB47682, SUB47967, SUB47968, SUB47969, SUB47970, SUB47971, and SUB63725. As of Q4 2014, VALERIAN remains the US FDA Preferred Term for this commodity. Valerian bears US NLM identifiers UMLS ID C0795675 and NCI Concept Code C38725. SMILES: NONE.
This classification denotes a purine antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCU97FKN3R. European Medicines Agency schedules Valganciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00007MIG. Valganciclovir generally arises in the molecular formula C14H22N6O5. The term VALGANCICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) VALGANCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valganciclovir under HS 29335995 and SITC 51576. As of Q4 2014, VALGANCICLOVIR remains the US FDA Preferred Term for this commodity. Valganciclovir bears US NLM identifiers UMLS ID C0909381 and NCI Concept Code C2629. SMILES: CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1NC(=NC2=O)N)N.
This classification denotes the hydrochloride form of a purine antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCU97FKN3R. European Medicines Agency schedules Valganciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00007MIG. Valganciclovir generally arises in the molecular formula C14H22N6O5. The term VALGANCICLOVIR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 no. 2 1999, list 40.) VALGANCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule valganciclovir hydrochloride under HS 29335995 and SITC 51576. Valganciclovir hydrochloride bears US NLM identifiers UMLS ID C0969586 and NCI Concept Code C66648. SMILES: As of Q4 2014, VALGANCICLOVIR HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.
This classification denotes an antibiotic with the molecular formula C31H52N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2AHC415BQG, chemically known as ((2-((r)-2-amino-3-methylbutyramido)-1,1-dimethylethyl)thio)acetic acid, 8-ester with (3as,4r,5s,6s,8r,9r,9ar,10r)-octahydro-5,8-dihydroxy-4,6,9,10-tetramethyl-6-vinyl-3a,9-propano-3ah-cyclopentacycloocten-1(4h)-one but generally known as valnemulin, which bears US NIH Compound Identifier 127791. European Medicines Agency schedules Valnemulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00009MIG. The term VALNEMULIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). VALNEMULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valnemulin under HS 29419000 and SITC 54139. As of Q4 2014, VALNEMULIN remains the US FDA Preferred Term for this commodity. Valnemulin bears US NLM identifiers UMLS ID C0764565 and NCI Concept Code C75151. SMILES: S(CC(=O)OC1C2(C3C(C(C(O)C(C1)(C)C=C)C)(CCC2C)CCC3=O)C)C(CNC(=O)C(N)C(C)C)(C)C.
This classification denotes an amide with the molecular formula C8H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3O25NRX9YG, chemically known as valeramide, 2-ethyl-3-methyl- but generally known as valnoctamide, which bears US NIH Compound Identifier 20140. European Medicines Agency schedules Valnoctamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00010MIG. World Health Organization schedules valnoctamide in its Anatomical Therapeutic Chemical (ATC) Classification. VALNOCTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valnoctamide under HS 29241900 and SITC 51471. As of Q4 2014, VALNOCTAMIDE remains the US FDA Preferred Term for this commodity. SMILES: O=C(N)C(C(CC)C)CC.
This classification denotes a pyrimidine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I2T0B5G94M. European Medicines Agency schedules Valopicitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35614. Valopicitabine generally arises in the molecular formula C15H24N4O6. The term VALOPICITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55.) VALOPICITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valopicitabine under HS 29349990 and SITC 51579. As of Q4 2014, VALOPICITABINE remains the US FDA Preferred Term for this commodity. Valopicitabine bears US NLM identifiers UMLS ID C1664150 and NCI Concept Code C66649. SMILES: O1C(N2CCC(NC2=O)N)C(O)(C(OC(=O)C(N)C(C)C)C1CO)C.
This classification denotes an anticonvulsant agent with the molecular formula C14H26O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9F5A05A29T, chemically known as hydroxymethyl 2-propylvalerate, pivalate but generally known as valproate pivoxil, which bears US NIH Compound Identifier 71160. European Medicines Agency schedules Valproate pivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00013MIG. The term VALPROATE PIVOXIL is an International Non-Proprietary Name. Most nations schedule valproate pivoxil under HS 29159080 and SITC 51377. As of Q4 2014, VALPROATE PIVOXIL remains the US FDA Preferred Term for this commodity. Valproate pivoxil bears US NLM identifiers UMLS ID C2349103 and NCI Concept Code C72875. SMILES: O(C(=O)C(CCC)CCC)COC(=O)C(C)(C)C.
This classification denotes an anticonvulsant agent with the molecular formula C8H16O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 614OI1Z5WI, chemically known as 4-pentanoic acid, 2-propyl-, (s)- but generally known as valproic acid, which bears US NIH Compound Identifier 3121. European Medicines Agency schedules Valproic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00015MIG. The term VALPROIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules valproic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule valproic acid under HS 29159080 and SITC 51377. As of Q4 2014, VALPROIC ACID remains the US FDA Preferred Term for this commodity. Valproic acid bears US NLM identifiers UMLS ID C0042291 and NCI Concept Code C29536. SMILES: OC(=O)C(CCC)CCC.
This classification denotes an anticonvulsant and valproic acid analog with the molecular formula C8H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RUA6CWU76G, chemically known as valeramide, 2-propyl- but generally known as valpromide, which bears US NIH Compound Identifier 71113. European Medicines Agency schedules Valpromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00016MIG. World Health Organization schedules valpromide in its Anatomical Therapeutic Chemical (ATC) Classification. VALPROMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valpromide under HS 29241900 and SITC 51471. As of Q4 2014, VALPROMIDE remains the US FDA Preferred Term for this commodity. SMILES: O=C(N)C(CCC)CCC.
This classification denotes an anthracycline antibiotic with the molecular formula C34H36F3NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2C6NUM6878, chemically known as pentanoic acid, 2-((2s,4s)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-l-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester but generally known as valrubicin, which bears US NIH Compound Identifier 41744. European Medicines Agency schedules Valrubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05075MIG. The term VALRUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 1, 1999, List 41). World Health Organization schedules valrubicin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule valrubicin under HS 29419000 and SITC 54139. As of Q4 2014, VALRUBICIN remains the US FDA Preferred Term for this commodity. Valrubicin bears US NLM identifiers UMLS ID C0068314 and NCI Concept Code C1340. SMILES: FC(F)(F)C(=O)NC1CC(OC2CC(O)(CC3C2C(O)C2C(C3O)C(=O)C3C(C2=O)C(OC)CCC3)C(=O)COC(=O)CCCC)OC(C1O)C.
This classification denotes an angiotensin ii receptor antagonist with the molecular formula C24H29N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80M03YXJ7I, chemically known as l-valine, n-(1-oxopentyl)-n-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)- but generally known as valsartan, which bears US NIH Compound Identifier 60846. European Medicines Agency schedules Valsartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00017MIG. The term VALSARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules valsartan in its Anatomical Therapeutic Chemical (ATC) Classification. VALSARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valsartan under HS 29339990 and SITC 51577. As of Q4 2014, VALSARTAN remains the US FDA Preferred Term for this commodity. Valsartan bears US NLM identifiers UMLS ID C0216784 and NCI Concept Code C47781. SMILES: OC(=O)C(N(Cc1ccc(cc1)c1c(cccc1)c1n[nH]nn1)C(=O)CCCC)C(C)C.
Sacubitril/valsartan is a drug for chronic heart failure (CHF)
This classification denotes an antimuscarinic agent with the molecular formula C18H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RU10K34QRU, chemically known as 2-pyridineacetamide, alpha-(2-(dimethylamino)propyl)-alpha-phenyl-, (r*,r*)-(+-)- but generally known as vamicamide, which bears US NIH Compound Identifier 65967. European Medicines Agency schedules Vamicamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00020MIG. The term VAMICAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). VAMICAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vamicamide under HS 29333999 and SITC 51574. As of Q4 2014, VAMICAMIDE remains the US FDA Preferred Term for this commodity. Vamicamide bears US NLM identifiers UMLS ID C0247801 and NCI Concept Code C75289. SMILES: O=C(N)C(CC(N(C)C)C)(C1CCCCC1)C1NCCCC1.
This classification denotes an antibiotic with the molecular formula C66H75Cl2N9O24, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q205EH1VU, chemically known as (s(sub a))-(3s,6r,7r,22r,23s,26s,36r,38ar)-44-((2-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-lyxo-hexopyranosyl)-beta-d-glucopyranosyl)oxy)-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-((2r)-4-methyl-2-(methylamino)valeramido)-2,5,24,38,39-pentaoxo-22h-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35- but generally known as vancomycin, which bears US NIH Compound Identifier 14969. European Medicines Agency schedules Vancomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05076MIG. The term VANCOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules vancomycin in its Anatomical Therapeutic Chemical (ATC) Classification. VANCOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vancomycin under HS 29419000 and SITC 54139. As of Q4 2014, VANCOMYCIN remains the US FDA Preferred Term for this commodity. Vancomycin bears US NLM identifiers UMLS ID C0042313 and NCI Concept Code C925. SMILES: CLC1C2OC3C(OC4OC(C(O)C(O)C4OC4OC(C(O)C(N)(C4)C)C)CO)C4OC5C(CL)CC(C(O)C6NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC)CC(C)C)C(O)C(C1)CC2)CC(=O)N)C(C3)C4)C1CC(C2C(C(NC6=O)C(=O)O)CC(O)CC2O)C(O)CC1)CC5.
This classification denotes an antibiotic with the molecular formula C66H75Cl2N9O24.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71WO621TJD, chemically known as vancomycin, monohydrochloride but generally known as vancomycin hydrochloride, which bears US NIH Compound Identifier 14970. European Medicines Agency schedules Vancomycin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05077MIG. Most nations schedule vancomycin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, VANCOMYCIN HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Vancomycin hydrochloride bears US NLM identifiers UMLS ID C0205992 and NCI Concept Code C65207. SMILES: Clc1c2Oc3c(OC4OC(C(O)C(O)C4OC4OC(C(O)C(N)(C4)C)C)CO)c4Oc5c(Cl)cc(C(O)C6NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC)CC(C)C)C(O)c(c1)cc2)CC(=O)N)c(c3)c4)c1cc(c2c(C(NC6=O)C(=O)O)cc(O)cc2O)c(O)cc1)cc5.Cl.
This classification denotes an antibiotic with the molecular formula C66H75Cl2N9O24.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71WO621TJD, chemically known as vancomycin, monohydrochloride, but more generally known as vancomycin monohydrochloride, which bears US NIH Compound Identifier 14970. European Medicines Agency schedules vancomycin monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05076MIG. Most nations, for tariff purposes, schedule vancomycin monohydrochloride under HS 29419000. SMILES:.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H24BrFN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YO460OQ37K, chemically known as 4-quninazolinamine, n-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)- but generally known as vandetanib, which bears US NIH Compound Identifier 3081361. European Medicines Agency schedules Vandetanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29174. The term VANDETANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). World Health Organization schedules vandetanib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule vandetanib under HS 29335995 and SITC 51576. As of Q4 2014, VANDETANIB remains the US FDA Preferred Term for this commodity. Vandetanib bears US NLM identifiers UMLS ID C1384659 and NCI Concept Code C2737. SMILES: BRC1CC(F)C(NC2NCNC3CC(OCC4CCN(CC4)C)C(OC)CC23)CC1.
This classification denotes an antibiotic with the molecular formula C23H28N4O8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M3EKF65MHG, chemically known as ( -)-alpha-(4-amino-5-(3,4,5-trimethoxybenzyl)-2-pyrimidinylamino)-3-ethoxy-4-hydroxy-alpha-toluenesulfonsaeure but more generally known as vaneprim, which bears US NIH Compound Identifier 216266. European Medicines Agency schedules Vaneprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00021MIG. The term VANEPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). VANEPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes a dopamine agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90X28IKH43. European Medicines Agency schedules Vanoxerine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00023MIG. Vanoxerine generally arises in the molecular formula C28H32F2N2O. The term VANOXERINE is an International Non-Proprietary Name or INN. VANOXERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vanoxerine under HS 29335995 and SITC 51576. As of Q4 2014, VANOXERINE remains the US FDA Preferred Term for this commodity. Vanoxerine bears US NLM identifiers UMLS ID C0164200 and NCI Concept Code C81084. SMILES: Fc1ccc(C(OCCN2CCN(CC2)CCCc2ccccc2)c2ccc(F)cc2)cc1.
This classification denotes a sulfonamide anti-infective agent with the molecular formula C20H22N4O6S2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 541ZDL2E7U, chemically known as n4,n4-vanillyldenebis(sulfanilamide) but more generally known as vanyldisulfamide, which bears U.S. National Institutes of Health Compound Identifier 216267. The European Medicines Agency schedules Vanyldisulfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00024MIG. The term VANYLDISULFAMIDE is an International Non-Proprietary Name. VANYLDISULFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(N)C1CCC(NC(NC2CCC(S(=O)(=O)N)CC2)C2CC(OC)C(O)CC2)CC1.
This classification denotes an antiplatelet agent with the molecular formula C30H39NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H84XT1COAU, chemically known as 4-heptenoic acid, 7-(5-((1,1-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, (1r-(1alpha(z),2beta,3beta,5alpha))- but generally known as vapiprost, which bears US NIH Compound Identifier 6436588. European Medicines Agency schedules Vapiprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00025MIG. The term VAPIPROST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). VAPIPROST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vapiprost under HS 29375000 and SITC 54156. As of Q4 2014, VAPIPROST remains the US FDA Preferred Term for this commodity. Vapiprost bears US NLM identifiers UMLS ID C0061849 and NCI Concept Code C76408. SMILES: O(C1C(C(N2CCCCC2)C(O)C1)CC/C=C/CCC(=O)O)CC1CCC(CC1)C1CCCCC1.
This classification denotes a somatostatin receptor agonist with the molecular formula C57H70N12O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2PK59M9GFF, chemically known as l-tryptophanamide, d-phenylalanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2->7)-disulfide but generally known as vapreotide, which bears US NIH Compound Identifier 71306. European Medicines Agency schedules Vapreotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00026MIG. The term VAPREOTIDE is an International Non-Proprietary Name. World Health Organization schedules vapreotide in its Anatomical Therapeutic Chemical (ATC) Classification. VAPREOTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vapreotide under HS 29349990 and SITC 51579. As of Q4 2014, VAPREOTIDE remains the US FDA Preferred Term for this commodity. Vapreotide bears US NLM identifiers UMLS ID C0164678 and NCI Concept Code C1429. SMILES: S1SCC(NC(=O)C(N)CC2CCCCC2)C(=O)NC(C(=O)NC(CC2C3C([NH]C2)CCCC3)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(C1)C(=O)NC(CC1C2C([NH]C1)CCCC2)C(=O)N)CC1CCC(O)CC1.
This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C23H32N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UCE6F4125H, chemically known as 2-(2-ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3h-imidazo(5,1-f)(1,2,4)triazin-4-one but generally known as vardenafil, which bears US NIH Compound Identifier 110634. European Medicines Agency schedules Vardenafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20047. The term VARDENAFIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). World Health Organization schedules vardenafil in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule vardenafil under HS 29350090 and SITC 51580. As of Q4 2014, VARDENAFIL remains the US FDA Preferred Term for this commodity. Vardenafil bears US NLM identifiers UMLS ID C0971579 and NCI Concept Code C66650. SMILES: S(=O)(=O)(N1CCN(CC1)CC)C1CC(C(OCC)CC1)C1[NH]N2C(NC(C2C(=O)N1)C)CCC.
This classification denotes the dihydrochloride form of a cgmp phosphodiesterase inhibitor with the molecular formula C23H32N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UCE6F4125H, chemically known as 2-(2-ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3h-imidazo(5,1-f)(1,2,4)triazin-4-one but more generally known as vardenafil, which bears US NIH Compound Identifier 110634. European Medicines Agency schedules Vardenafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20047. The term VARDENAFIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 14, No. 3, 2000, List 44). World Health Organization schedules vardenafil in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule vardenafil dihydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, VARDENAFIL DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Vardenafil dihydrochloride bears US NLM identifiers UMLS ID C2700155 and NCI Concept Code C76892. SMILES: CCCC1NC(C2N1NC([NH]C2=O)C3CC(CCC3OCC)S(=O)(=O)N4CCN(CC4)CC)C.CL.CL.
This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C23H32N6O4S.ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M8S2CU0TS, chemically known as 2-(2-ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3h-imidazo(5,1-f)(1,2,4)triazin-4-one dihydrochloride but more generally known as vardenafil hydrochloride, which bears US NIH Compound Identifier 147352. European Medicines Agency schedules Vardenafil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20775. Most nations, for tariff and trade purposes, schedule vardenafil hydrochloride under HS 29350090 and SITC 51580. SMILES: CCCC1NC(C2N1[NH]C(NC2=O)C3CC(CCC3OCC)S(=O)(=O)N4CCN(CC4)CC)C.O.O.O.CL.
This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C23H32N6O4S.ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M8S2CU0TS, chemically known as imidazo(5,1-f)(1,2,4)triazin-4(1h)-one, 2-(2-ethoxy-5-((4-ethyl-1-piperazinyl)sulfonyl)phenyl)-5-methyl-7-propyl-, hydrochloride, hydrate (1:1:3), but more generally known as vardenafil hydrochloride hydrate, which bears US NIH Compound Identifier 6918463. European Medicines Agency schedules vardenafil hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20047. Most nations, for tariff purposes, schedule vardenafil hydrochloride hydrate under HS 29350090. SMILES: CCCC1NC(C2N1[NH]C(NC2=O)C3CC(CCC3OCC)S(=O)(=O)N4CCN(CC4)CC)C.O.O.O.CL.
This classification denotes a nicotinic agonist with the molecular formula C13H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W6HS99O8ZO, chemically known as 7,8,9,10-tetrahydro-6,10-methano-6h-pyrazino(2,3-h)(3)benzazepine but generally known as varenicline, which bears US NIH Compound Identifier 170361. European Medicines Agency schedules Varenicline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25195. World Health Organization schedules varenicline in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule varenicline under HS 29333999 and SITC 51574. As of Q4 2014, VARENICLINE remains the US FDA Preferred Term for this commodity. Varenicline bears US NLM identifiers UMLS ID C1569608 and NCI Concept Code C73609. SMILES: N1CC2CC(C3C2CC2NCCNC2C3)C1.
This classification denotes a nicotinic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82269ASB48. European Medicines Agency schedules Varenicline tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22601. Varenicline tartrate generally arises in the molecular formula C13H13N3.C4H6O6. The term 'varenicline tartrate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule varenicline tartrate under HS 29333999 and SITC 51574. As of Q4 2014, VARENICLINE TARTRATE remains US FDA's Preferred Term for this commodity. Varenicline tartrate bears US NLM identifiers UMLS ID C1711887 and NCI Concept Code C61998. SMILES: C1CNC2CC3C(CC2N1)[C@@H]4C[C@H]3CNC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a live, attenuated varicella virus vaccine used for immunization against chickenpox, recommended for children between the ages of 12 months and 13 years.
This classification denotes a tyrosine kinase inhibitor with the molecular formula C20H15ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5DX9U76296, chemically known as 1-phthalazinamine, n-(4-chlorophenyl)-4-(4-pyridinylmethyl)- but generally known as vatalanib, which bears US NIH Compound Identifier 151194. European Medicines Agency schedules Vatalanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26999. The term VATALANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule vatalanib under HS 29333999 and SITC 51574. As of Q4 2014, VATALANIB remains the US FDA Preferred Term for this commodity. Vatalanib bears US NLM identifiers UMLS ID C0912586 and NCI Concept Code C1868. SMILES: CLC1CCC(NC2NNC(C3C2CCCC3)CC2CCNCC2)CC1.
This classification denotes a tyrosine kinase inhibitor with the molecular structure C20H15CLN4.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, V5FUB77031 chemically known as 1-phthalazinamine, n-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1), but more commonly known as vatalanib succinate, which bears US NIH Compound Identifier 151193. European Medicines Agency schedules Vatalanib succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32570. As of Q4 2014, VATALANIB SUCCINATE remains US FDA's Preferred Term for this commodity. Vatalanib succinate bears US NLM identifiers UMLS ID C1524078 and NCI Concept Code C74945. Most nations, for tariff and trade purposes, schedule vatalanib succinate under HS 29333999 and SITC 51574. SMILES: C1CCC2C(C1)C(NNC2NC3CCC(CC3)CL)CC4CCNCC4.C(CC(=O)O)C(=O)O.
This classification denotes a nicotinic antagonist with the molecular formula C34H57N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5438723848, chemically known as 5alpha-androstan-3alpha,17beta-diol, 16beta-pipecolinio-2beta-piperidino-,bromide,diacetate but generally known as vecuronium, which bears US NIH Compound Identifier 39764. European Medicines Agency schedules Vecuronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05084MIG. World Health Organization schedules vecuronium in its Anatomical Therapeutic Chemical (ATC) Classification. VECURONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, VECURONIUM remains the US FDA Preferred Term for this commodity. Vecuronium bears US NLM identifiers UMLS ID C0242531 and NCI Concept Code C87317. SMILES: BR.O(C1C2(C(C3C(C4(C(CC3)CC(OC(=O)C)C(N3CCCCC3)C4)C)CC2)CC1[N]1(CCCCC1)C)C)C(=O)C.
This classification denotes a muscle relaxant with the molecular formula C34H57N2O4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E4PHP5N1D, chemically known as 5alpha-androstan-3alpha,17beta-diol, 16beta-pipecolinio-2beta-piperidino-,bromide,diacetate but more generally known as vecuronium bromide, which bears US NIH Compound Identifier 39764. European Medicines Agency schedules Vecuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00029MIG. The term VECURONIUM BROMIDE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule vecuronium bromide under HS 29333999 and SITC 51574. As of Q4 2014, VECURONIUM BROMIDE remains US FDA's Preferred Term for this commodity. Vecuronium bromide bears US NLM identifiers UMLS ID C0042435 and NCI Concept Code C47782. SMILES: CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[BR-].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKX88EO7OI, chemically known as 1-naphthaleneacetic acid, 4-cyclohexyl-alpha-methyl-, (+-)- but generally known as vedaprofen, which bears US NIH Compound Identifier 72158. European Medicines Agency schedules Vedaprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00031MIG. The term VEDAPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). VEDAPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vedaprofen under HS 29163900 and SITC 51379. As of Q4 2014, VEDAPROFEN remains the US FDA Preferred Term for this commodity. Vedaprofen bears US NLM identifiers UMLS ID C0909493 and NCI Concept Code C66652. SMILES: OC(=O)C(C1C2C(C(C3CCCCC3)CC1)CCCC2)C.
An integrin receptor antagonist.
This classification denotes an enzyme replacement preparation with the molecular formula C2532H3854N672O711S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23HYE36B0I, more generally known as velaglucerase alfa. European Medicines Agency schedules velaglucerase alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31010. The term VELAGLUCERASE ALFA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 3, 2008, list 60. Most nations schedule Velaglucerase alfa under HS 35079000 and SITC 51691. SMILES:. As of Q4 2014, VELAGLUCERASE ALFA remains the US FDA Preferred Term for this commodity. . Velaglucerase alfa bears US NLM identifiers UMLS ID C2919267 and NCI Concept Code C87735.
Venetoclax is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
This classification denotes an antidepressant agent with the molecular formula C17H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GRZ5RCB1QG, chemically known as cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, (+-)- but generally known as venlafaxine, which bears US NIH Compound Identifier 5656. European Medicines Agency schedules Venlafaxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00034MIG. The term VENLAFAXINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules venlafaxine in its Anatomical Therapeutic Chemical (ATC) Classification. VENLAFAXINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule venlafaxine under HS 29225000 and SITC 51467. As of Q4 2014, VENLAFAXINE remains the US FDA Preferred Term for this commodity. Venlafaxine bears US NLM identifiers UMLS ID C0078569 and NCI Concept Code C1278. SMILES: OC1(C(CN(C)C)c2ccc(OC)cc2)CCCCC1.
This classification denotes an antidepressant agent with the molecular formula C17H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D7RX5A8MO, chemically known as wy-45,030 but more generally known as venlafaxine hcl, which bears US NIH Compound Identifier 62923. European Medicines Agency schedules Venlafaxine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05087MIG. Most nations, for tariff and trade purposes, schedule venlafaxine hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, VENLAFAXINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Venlafaxine hydrochloride bears US NLM identifiers UMLS ID C0771200 and NCI Concept Code C29540. SMILES: CN(C)CC(C1CCC(CC1)OC)C2(CCCCC2)O.CL.
This classification denotes an antipsychotic agent with the molecular formula C17H25N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S7064109UD, chemically known as n-((1-allyl-2-pyrrolidinyl)methyl)-2,3-dimethoxy-5-sulfamoylbenzamid but generally known as veralipride, which bears US NIH Compound Identifier 47979. European Medicines Agency schedules Veralipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00037MIG. World Health Organization schedules veralipride in its Anatomical Therapeutic Chemical (ATC) Classification. VERALIPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule veralipride under HS 29350090 and SITC 51580. As of Q4 2014, VERALIPRIDE remains the US FDA Preferred Term for this commodity. SMILES: S(=O)(=O)(N)C1CC(C(=O)NCC2N(CCC2)CC=C)C(OC)C(OC)C1.
This classification denotes a calcium channel blocker with the molecular formula C27H38N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CJ0O37KU29, chemically known as 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile but generally known as verapamil, which bears US NIH Compound Identifier 2520. European Medicines Agency schedules Verapamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00038MIG. The term VERAPAMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules verapamil in its Anatomical Therapeutic Chemical (ATC) Classification. VERAPAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule verapamil under HS 29269000 and SITC 51484. As of Q4 2014, VERAPAMIL remains the US FDA Preferred Term for this commodity. Verapamil bears US NLM identifiers UMLS ID C0042523 and NCI Concept Code C928. SMILES: O(c1cc(C(C(C)C)(CCCN(CCc2cc(OC)c(OC)cc2)C)C#N)ccc1OC)C.
This classification denotes a calcium channel blocker with the molecular formula C27H38N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V3888OEY5R, chemically known as 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile but more generally known as verapamil hydrochloride, which bears US NIH Compound Identifier 2520. European Medicines Agency schedules Verapamil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05088MIG. Most nations, for tariff and trade purposes, schedule verapamil hydrochloride under HS 29269000 and SITC 51484. As of Q4 2014, VERAPAMIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Verapamil hydrochloride bears US NLM identifiers UMLS ID C0700468 and NCI Concept Code C2827. SMILES: CC(C)C(CCCN(C)CCC1CCC(C(C1)OC)OC)(C#N)C2CCC(C(C2)OC)OC.CL.
This classification denotes a natural product which US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifiers 7DEL4FSK0E, 74V0KIG3TK, VB66Y1LB7K, and 197B3Q7T5Q, the soirce of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 42756 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Lilianae, Order Liliales, Family Melanthiaceae, Genus Veratrum L., known commonly as VERATRUM. US FDA classifies various veratrum species, including album, nigrum, and viride. Veratrum bears the USDA PLANTS Database Identifier VERAT, whereas species album, nigrum, and viride bear USDA PLANTS Database Identifiers VEAL3, VENI5, and VEVI, respectively. European Medicines Agency schedules veratrum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB14023MIG, SUB15723MIG, SUB35193, SUB35195, SUB40762, SUB47977, SUB47978, SUB47979, SUB47980, SUB47981, SUB47982, and SUB47983.
This classification denotes an antitubercular agent with the molecular formula C15H15N3O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier XO8D6I4I5L, chemically known as 3,4-dimethoxybenzal isonicotinoylhydrazone but more generally known as verazide, which bears U.S. National Institutes of Health Compound Identifier 162228. The European Medicines Agency schedules Verazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00039MIG. The term VERAZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). VERAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(OC)CCC(C1)/C=N/NC(=O)C1CCNCC1)C.
This classification denotes a mixed ion channel blocker with the molecular formula C20H31NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9G468C8B13, chemically known as (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol but generally known as vernakalant, which bears US NIH Compound Identifier 9930049. Vernakalant most often comes in base and hydrochloride forms. European Medicines Agency schedules Vernakalant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30707. The term VERNAKALANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, No. 3, 2007, List 58). World Health Organization schedules Vernakalant in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, VERNAKALANT remains the US FDA Preferred Term for this commodity. SMILES: COC1=C(C=C(C=C1)CCOC2CCCCC2N3CCC(C3)O)OC.
This classification denotes a bronchodilator with the molecular formula C12H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1J8O1GT31U, chemically known as 3,7-dihydro-1,8-dimethyl-3-(2-methylbutyl)-1h-purine-2,6-dione but generally known as verofylline, which bears US NIH Compound Identifier 47845. European Medicines Agency schedules Verofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00042MIG. The term VEROFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). VEROFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule verofylline under HS 29335995 and SITC 51576. As of Q4 2014, VEROFYLLINE remains the US FDA Preferred Term for this commodity. Verofylline bears US NLM identifiers UMLS ID C0148324 and NCI Concept Code C96193. SMILES: CCC(C)CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C.
This classification denotes a porphyrin and photosensitizing agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0X9PA28K43. European Medicines Agency schedules Verteporfin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00044MIG. Verteporfin generally arises in the molecular formula C41H42N4O8. The term VERTEPORFIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 3, 2004, list 52.) Most nations schedule Verteporfin under HS 29339990 and SITC 51577. SMILES:. As of Q4 2014, VERTEPORFIN remains the US FDA Preferred Term for this commodity. . Verteporfin bears US NLM identifiers UMLS ID C0387288 and NCI Concept Code C1014.
This classification denotes a phosphodiesterase inhibitor and antineoplastic antibiotic with the molecular formula C22H25N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5COW40EV8M, chemically known as 3,4-dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2(1h)-quinolinone but generally known as vesnarinone, which bears US NIH Compound Identifier 5663. European Medicines Agency schedules Vesnarinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00045MIG. The term VESNARINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). VESNARINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Vesnarinone under HS 29337900 and SITC 51561. As of Q4 2014, VESNARINONE remains the US FDA Preferred Term for this commodity. Vesnarinone bears US NLM identifiers UMLS ID C0148345 and NCI Concept Code C1415. SMILES: COC1CCC(CC1OC)C(=O)N2CCN(CC2)C3CCC4C(C3)CCC(=O)N4.
Vestronidase alfa is a therapy intended to replace the deficient lysosomal enzyme beta-glucuronidase to help break down the glycosaminoglycans that accumulate in the tissues of patients with MPS 7.
This classification denotes preparations containing substances with antigenic properties administered to activate veterinary or non-human immune systems, thereby inducing immune responses, preparations called vaccines, of which the current commodities address or prevent infectious Anthrax, a disease caused by the spore-forming bacteria Bacillus anthracis, the same disease that USNLM codifies in MeSH UID D000881 and which afflicts hooved animals such as sheep and goats, thus the term ANTHRAX VACCINES.
This classification denotes preparations containing substances with antigenic properties administered to activate veterinary or non-human immune systems, thereby inducing immune responses, preparations called vaccines, of which the current commodities address or prevent infectious Brucellosis, sometimes also called Bang's disease or Crimean, Gibraltar, Malta, Maltese, or Mediterranean fever, but in common vernacular, Brucella, thus the term BRUCELLA VACCINES.
This classification denotes preparations containing substances with antigenic properties administered to activate veterinary or non-human immune systems, thereby inducing immune responses, preparations called vaccines, of which the current commodities address or prevent infectious aphthae epizooticae, family Picornaviridae, genus Aphthovirus, also called Foot and Mouth Disease or simply, FMD, thus the term FOOT AND MOUTH DISEASE (FMD) VACCINES. This classification concerns all vaccines designed to address or treat FMD Types A, Asia 1, C, O, SAT 1, SAT 2, and SAT 3.
This classification denotes an antispasmotic agent C20H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 54IF66RP20, chemically known as n,n-dimethyl-alpha-(3-phenylpropyl)veratrylamine hydrochloride, but more generally known as vetrabutine hydrochloride, which bears US NIH Compound Identifier 111121. European Medicines Agency schedules Vetrabutine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05093MIG. Most nations, for tariff and trade purposes, schedule vetrabutine hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, VETRABUTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)C(CCCC1CCCCC1)C2CCC(C(C2)OC)OC.CL.
This classification denotes an antispasmotic agent with the molecular formulas C20H27NO2 and C20H27NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers I3E2J32F37 and 54IF66RP20, the base comppound being chemically known as 1-(3,4-dimethoxyphenyl)-1-dimethylamino-4-phenylbutane but generally known as vetrabutine, which bears US NIH Compound Identifier 111122. European Medicines Agency schedules Vetrabutine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB00046MIG and SUB05093MIG. The term VETRABUTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). VETRABUTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vetrabutine and its salts under HS 29222900 and SITC 51462. As of Q4 2014, VETRABUTINE remains the US FDA Preferred Term for this commodity. Vetrabutine bears US NLM NCI C73164. SMILES: O(C1CC(C(N(C)C)CCCC2CCCCC2)CCC1OC)C (base) or CN(C)C(CCCC1CCCCC1)C2CCC(C(C2)OC)OC.CL (hydrochloride).
This classification denotes a purine antagonist and antiviral agent with the molecular formula C10H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XQD2MEW34, chemically known as 9h-purin-6-amine, 9-beta-d-xylofuranosyl- (9ci) but generally known as vidarabine, which bears US NIH Compound Identifier 191. European Medicines Agency schedules Vidarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00047MIG. The term VIDARABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules vidarabine in its Anatomical Therapeutic Chemical (ATC) Classification. VIDARABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vidarabine under HS 29349990 and SITC 51579. As of Q4 2014, VIDARABINE remains the US FDA Preferred Term for this commodity. Vidarabine bears US NLM identifiers UMLS ID C0042646 and NCI Concept Code C929. SMILES: C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CO)O)O.
This classification denotes a purine antagonist and antiviral agent with the molecular formula C10H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XQD2MEW34, chemically known as vidarabine, anhydrous, but more generally known as vidarabine anhydrous, which bears US NIH Compound Identifier 21704. European Medicines Agency schedules vidarabine anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00047MIG. Most nations, for tariff purposes, schedule vidarabine anhydrous under HS 29349990. Vidarabine anhydrous bears US NLM identifiers UMLS ID C2700247 and NCI Concept Code C77393. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N.
This classification denotes the phosphate form of a purine antagonist and antiviral agent with the molecular formula C10H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XQD2MEW34, chemically known as 9h-purin-6-amine, 9-beta-d-xylofuranosyl- (9ci) but more generally known as vidarabine, which bears US NIH Compound Identifier 191. European Medicines Agency schedules Vidarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00047MIG. The term VIDARABINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules vidarabine in its Anatomical Therapeutic Chemical (ATC) Classification. VIDARABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule vidarabine phosphate under HS 29349990 and SITC 51579. As of Q4 2014, VIDARABINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Vidarabine phosphate bears US NLM identifiers UMLS ID C0003674 and NCI Concept Code C90789. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N.
This classification denotes an antiviral agent with the molecular structure C10H12N5O7P.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, ZEC0WCC7UA chemically known as 9-.beta.-d-arabinofuranosyladenine 5'-(dihydrogen phosphate), disodium salt, but more commonly known as vidarabine sodium phosphate, which bears US NIH Compound Identifier 224. European Medicines Agency schedules Vidarabine sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05095MIG. Most nations, for tariff and trade purposes, schedule vidarabine sodium phosphate under HS 29349990 and SITC 51579. As of Q4 2014, VIDARABINE SODIUM PHOSPHATE remains US FDA's Preferred Term for this commodity. Vidarabine sodium phosphate bears US NLM identifiers UMLS ID C0771597 and NCI Concept Code C95911. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)([O-])[O-])O)O)N.[NA+].[NA+].
This classification denotes an anticonvulsant agent with the molecular formula C6H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GR120KRT6K, chemically known as 5-hexenoic acid, 4-amino- but generally known as vigabatrin, which bears US NIH Compound Identifier 5665. European Medicines Agency schedules Vigabatrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00048MIG. The term VIGABATRIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules vigabatrin in its Anatomical Therapeutic Chemical (ATC) Classification. VIGABATRIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vigabatrin under HS 29224995 and SITC 51465. As of Q4 2014, VIGABATRIN remains the US FDA Preferred Term for this commodity. Vigabatrin bears US NLM identifiers UMLS ID C0048044 and NCI Concept Code C87611. SMILES: OC(=O)CCC(N)C=C.
This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema)
This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S239O2OOV3. European Medicines Agency schedules Vilazodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32166. Vilazodone generally arises in the molecular formula C26H27N5O2. The term VILAZODONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule vilazodone under HS 29349990 and SITC 51579. As of Q4 2014, VILAZODONE remains the US FDA Preferred Term for this commodity. Vilazodone bears US NLM identifiers UMLS ID C1530072 and NCI Concept Code C90716. SMILES: C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N.
This classification denotes a serotonin agonist and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U8HTX2GK8J. European Medicines Agency schedules Vilazodone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32288. Vilazodone hydrochloride generally arises in the molecular formula C26H27N5O2.CLH. The term 'vilazodone hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule vilazodone hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, VILAZODONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Vilazodone hydrochloride bears US NLM identifiers UMLS ID C0539286 and NCI Concept Code C90717. SMILES: C1CC2C(CC1C#N)C(C[NH]2)CCCCN3CCN(CC3)C4CCC5C(C4)CC(O5)C(=O)N.CL.
This classification denotes a protease inhibitor and anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I6B4B2U96P. European Medicines Agency schedules Vildagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25199. Vildagliptin generally arises in the molecular formula C17H25N3O2. The term VILDAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 18, no. 3, 2004, list 52.) Most nations, for tariff and trade purposes, schedule vildagliptin under HS 29339990 and SITC 51577. As of Q4 2014, VILDAGLIPTIN remains US FDA's Preferred Term for this commodity. Vildagliptin bears US NLM identifiers UMLS ID C1570906 and NCI Concept Code C66653. SMILES: OC12CC3(NCC(=O)N4C(CCC4)C#N)CC(C1)CC(C3)C2.
This classification denotes an adrenergic uptake inhibitor and second-generation antidepressive agent with the molecular formula C13H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5I5Y2789ZF, chemically known as 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine but generally known as viloxazine, which bears US NIH Compound Identifier 5666. European Medicines Agency schedules Viloxazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00049MIG. World Health Organization schedules viloxazine in its Anatomical Therapeutic Chemical (ATC) Classification. VILOXAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule viloxazine under HS 29349990 and SITC 51579. As of Q4 2014, VILOXAZINE remains the US FDA Preferred Term for this commodity. SMILES: O1C(CNCC1)COC1C(OCC)CCCC1.
This classification denotes the hydrochloride form of an adrenergic uptake inhibitor and second-generation antidepressive agent with the molecular formula C13H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5I5Y2789ZF, chemically known as 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine but more generally known as viloxazine, which bears US NIH Compound Identifier 5666. European Medicines Agency schedules Viloxazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00049MIG. World Health Organization schedules viloxazine in its Anatomical Therapeutic Chemical (ATC) Classification. VILOXAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule viloxazine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, VILOXAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC1CCCCC1OCC2CNCCO2.CL.
This classification denotes an ethanolamine antitussive and analgesic with the molecular formula C21H31ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) TPV54G6XBG, chemically known as 1h-pyrrole-2-methanol, alpha-((bis(1-methylpropyl)amino)methyl)-1-((2-chlorophenyl)methyl)- but more generally known as viminol, which bears US NIH Compound Identifier 65697. European Medicines Agency schedules Viminol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00050MIG. World Health Organization schedules viminol in its Anatomical Therapeutic Chemical (ATC) Classification. VIMINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule viminol under HS 29339990 and SITC 51577. As of Q4 2014, VIMINOL remains US FDA's Preferred Term for this commodity. SMILES: CLC1C(CN2C(C(O)CN(C(CC)C)C(CC)C)CCC2)CCCC1.
This classification denotes a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NZH2C1T6O, chemically known as 2,4,6(1h, 3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methyl-1-butenyl)-, sodium salt but generally known as vinbarbital, which bears US NIH Compound Identifier 5284636. European Medicines Agency schedules Vinbarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00051MIG. The term VINBARBITAL is an International Non-Proprietary Name. World Health Organization schedules vinbarbital in its Anatomical Therapeutic Chemical (ATC) Classification. VINBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinbarbital under HS 29335400 and SITC kg. As of Q4 2014, VINBARBITAL remains the US FDA Preferred Term for this commodity. Vinbarbital bears US NLM identifiers UMLS ID C0301408 and NCI Concept Code C76530. SMILES: CC/C=C(\C)/C1(C(=O)NC(=O)NC1=O)CC.
This classification denotes a barbiturate with the molecular formula C11H15N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BAS6234GZ7, chemically known as sodium 5-ethyl-5-(1-methyl-1-butenyl)barbiturate, but more generally known as vinbarbital sodium, which bears US NIH Compound Identifier 5284636. European Medicines Agency schedules vinbarbital sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00051MIG. Most nations, for tariff purposes, schedule vinbarbital sodium under HS 29335400. Vinbarbital sodium bears US NLM identifiers UMLS ID C2700248 and NCI Concept Code C77632. SMILES: CC/C=C(\C)/C1(C(=O)NC(=O)[N-]C1=O)CC.[NA+].
This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C46H58N4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V9KLZ54CY, chemically known as 1h-indolizino(8,1-cd)carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2h-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, methyl ester, (3ar-(3aalpha,4beta,5beta,5abeta,9(3r*,5s*,7r*,9s*),10br*,13aalpha))- but generally known as vinblastine, which bears US NIH Compound Identifier 13342. European Medicines Agency schedules Vinblastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00052MIG. The term VINBLASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules vinblastine in its Anatomical Therapeutic Chemical (ATC) Classification. VINBLASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinblastine under HS 29399900 and SITC 54149. As of Q4 2014, VINBLASTINE remains the US FDA Preferred Term for this commodity. Vinblastine bears US NLM identifiers UMLS ID C0042670 and NCI Concept Code C930. SMILES: O(C1C2(C3N(CCC43C(N(C3C4CC(C(OC)C3)C3(CC4CC(O)(CN(C4)CCC4C3[NH]C3C4CCCC3)CC)C(=O)OC)C)C1(O)C(=O)OC)CC=C2)CC)C(=O)C.
This classification denotes a vasodilator agent with the molecular formula C19H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G54D0HMY25, chemically known as 14,15-dihydroeburnamenin-14-one but generally known as vinburnine, which bears US NIH Compound Identifier 3195. European Medicines Agency schedules Vinburnine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00053MIG. World Health Organization schedules vinburnine in its Anatomical Therapeutic Chemical (ATC) Classification. VINBURNINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinburnine under HS 29399900 and SITC 54149. As of Q4 2014, VINBURNINE remains the US FDA Preferred Term for this commodity. SMILES: O=C1n2c3C4N(CCCC4(C1)CC)CCc3c1c2cccc1.
This classification denotes a cns stimulant with the molecular formula C21H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 996XVD0JHT, chemically known as methyl (3alpha,14alpha,16alpha)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylate but generally known as vincamine, which bears US NIH Compound Identifier 5668. European Medicines Agency schedules Vincamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00054MIG. The term VINCAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules vincamine in its Anatomical Therapeutic Chemical (ATC) Classification. VINCAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vincamine under HS 29399900 and SITC 54149. As of Q4 2014, VINCAMINE remains the US FDA Preferred Term for this commodity. Vincamine bears US NLM identifiers UMLS ID C0042674 and NCI Concept Code C87697. SMILES: OC1(n2c3C4N(CCCC4(C1)CC)CCc3c1c2cccc1)C(=O)OC.
This classification denotes a cns stimulant C21H26N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9XM85R7QQ, chemically known as (3.alpha.,14.beta.,16.alpha.)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester hydrochloride, but more generally known as vincamine hydrochloride, which bears US NIH Compound Identifier 165895. European Medicines Agency schedules Vincamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05099MIG. Most nations, for tariff and trade purposes, schedule vincamine hydrochloride under HS 29399900 and SITC 54149. As of Q4 2014, VINCAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@@]12CCCN3[C@@H]1C4C(C5CCCCC5N4[C@](C2)(C(=O)OC)O)CC3.CL.
This classification denotes a vasodilating agent with the molecular formula C14H13ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S0KXB0NKWN, chemically known as 10-chloro-1,2,3,3a,4,5-hexahydro-6h-indolo(3,2,1-de)(1,5)naphthyridin-6-one but generally known as vincantril, which bears US NIH Compound Identifier 68854. European Medicines Agency schedules Vincantril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00056MIG. The term VINCANTRIL is an International Non-Proprietary Name. VINCANTRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vincantril under HS 29399900 and SITC 54149. As of Q4 2014, VINCANTRIL remains the US FDA Preferred Term for this commodity. Vincantril bears US NLM identifiers UMLS ID C2700250 and NCI Concept Code C77081. SMILES: Clc1cc2c3c4n(c2cc1)C(=O)CCC4NCC3.
This classification denotes a cholinergic agonist with the molecular formula C18H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 807MP0MJ61, chemically known as 1h-indolo(3,2,1-de)(1,5)naphthyridine-6-carboxylic acid, 3-ethyl-2,3,3a,4-tetrahydro-, methyl ester, (+-)- but generally known as vinconate, which bears US NIH Compound Identifier 68896. European Medicines Agency schedules Vinconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00058MIG. The term VINCONATE is an International Non-Proprietary Name. VINCONATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinconate under HS 29339990 and SITC 51577. As of Q4 2014, VINCONATE remains the US FDA Preferred Term for this commodity. Vinconate bears US NLM identifiers UMLS ID C0078247 and NCI Concept Code C76615. SMILES: O(C(=O)C1=CCC2N(CCC3C2N1C1C3CCCC1)CC)C.
This classification denotes a cholinergic agonist with the molecular formula C18H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H5MM0UO9N8, chemically known as vinconate hydrochloride, (+/-)-, but more generally known as vinconate hydrochloride, which bears US NIH Compound Identifier 147526. European Medicines Agency schedules vinconate hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00058MIG. Most nations, for tariff purposes, schedule vinconate hydrochloride under HS 29339990. SMILES: CCN1CCC2C3CCCCC3N4C2C1CC=C4C(=O)OC.CL.
This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C46H56N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5J49Q6B70F, chemically known as vincaleukoblastine, 22-oxo- but generally known as vincristine, which bears US NIH Compound Identifier 5978. European Medicines Agency schedules Vincristine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00059MIG. The term VINCRISTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules vincristine in its Anatomical Therapeutic Chemical (ATC) Classification. VINCRISTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vincristine under HS 29399900 and SITC 54149. As of Q4 2014, VINCRISTINE remains the US FDA Preferred Term for this commodity. Vincristine bears US NLM identifiers UMLS ID C0042679 and NCI Concept Code C933. SMILES: O(C1C2(C3N(CCC43C(N(C3C4CC(C(OC)C3)C3(CC4CC(O)(CN(C4)CCC4C3[NH]C3C4CCCC3)CC)C(=O)OC)C=O)C1(O)C(=O)OC)CC=C2)CC)C(=O)C.
This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C43H55N5O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RSA8KO39WH, chemically known as vincaleukoblastine, 3-(aminocarbonyl)-o(sup 4)-deacetyl-3-de(methoxycarbonyl)- but generally known as vindesine, which bears US NIH Compound Identifier 40839. European Medicines Agency schedules Vindesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00061MIG. The term VINDESINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules vindesine in its Anatomical Therapeutic Chemical (ATC) Classification. VINDESINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vindesine under HS 29399900 and SITC 54149. As of Q4 2014, VINDESINE remains the US FDA Preferred Term for this commodity. Vindesine bears US NLM identifiers UMLS ID C0042682 and NCI Concept Code C934. SMILES: OC1(C2N(C3C(C42C2N(CC4)CC=CC2(C1O)CC)CC(C(OC)C3)C1(CC2CC(O)(CN(C2)CCC2C1[NH]C1C2CCCC1)CC)C(=O)OC)C)C(=O)N.
This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C46H56N4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, W3375J6V0Y chemically known as vincaleukoblastine, 4'-deoxy-22-oxo-, (4'.alpha.)- but generally known as vinepidine, which bears US NIH Compound Identifier 125688. European Medicines Agency schedules Vinepidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00062MIG. The term VINEPIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24). Most nations schedule vinepidine under HS 29399900 and SITC 54149. As of Q4 2014, VINEPIDINE remains the US FDA Preferred Term for this commodity. Vinepidine bears US NLM identifiers UMLS ID C0078255 and NCI Concept Code C1274. SMILES: CCC1CC2CN(C1)C3C2C(C4=C(C3)C5=CC=CC=C5N4)(C6=C(C=C7C(=C6)C89CCN1C8C(CCC1)(C(C(C9N7C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.
This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C45H54F2N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5BF646324K, chemically known as 4-deoxy-20,20-difluoro-c-norvincaleukoblastine but generally known as vinflunine, which bears US NIH Compound Identifier 157688. European Medicines Agency schedules Vinflunine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00063MIG. The term VINFLUNINE is an International Non-Proprietary Name. World Health Organization schedules vinflunine in its Anatomical Therapeutic Chemical (ATC) Classification. VINFLUNINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinflunine under HS 29399900 and SITC 54149. As of Q4 2014, VINFLUNINE remains the US FDA Preferred Term for this commodity. Vinflunine bears US NLM identifiers UMLS ID C0672663 and NCI Concept Code C61564. SMILES: FC(F)(C1CC2CC(C3CC4C56C7N(CC6)CC=CC7(C(OC(=O)C)C(O)(C5N(C4CC3OC)C)C(=O)OC)CC)(C3[NH]C4C(C3CN(C2)C1)CCCC4)C(=O)OC)C.
This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C51H72N5O10P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AW1UYE6Q9I, chemically known as vincaleukoblastine, o4-deacetyl-3-de(methoxycarbonyl)-3-((((1s)-1-(diethoxyphosphinyl)-2-methylpropyl)amino)carbonyl)- but generally known as vinfosiltine, which bears US NIH Compound Identifier 3086608. European Medicines Agency schedules Vinfosiltine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00065MIG. The term VINFOSILTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). VINFOSILTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinfosiltine under HS 29399900 and SITC 54149. As of Q4 2014, VINFOSILTINE remains the US FDA Preferred Term for this commodity. Vinfosiltine bears US NLM identifiers UMLS ID C0084429 and NCI Concept Code C2378. SMILES: P(=O)(OCC)(OCC)C(NC(=O)C1(O)C2N(C3C(C42C2N(CC4)CC=CC2(C1O)CC)CC(C(OC)C3)C1(CC2CC(O)(CN(C2)CCC2C1[NH]C1C2CCCC1)CC)C(=O)OC)C)C(C)C.
This classification denotes a vinca alkaloid compound with the molecular formula C51H69N5O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MUJ5BW9BWR, chemically known as vincaleukoblastine, o(sup 4)-deacetyl-3-de(methoxycarbonyl)-3-(((1-(ethoxycarbonyl)-2-methylbutyl)amino)carbonyl)-, (3(1s,2s))- but generally known as vinleucinol, which bears US NIH Compound Identifier 72163. European Medicines Agency schedules Vinleucinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00067MIG. The term VINLEUCINOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). VINLEUCINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinleucinol under HS 29399900 and SITC 54149. As of Q4 2014, VINLEUCINOL remains the US FDA Preferred Term for this commodity. Vinleucinol bears US NLM identifiers UMLS ID C0247144 and NCI Concept Code C95239. SMILES: OC1(C2N(C3C(C42C2N(CC4)CC=CC2(C1O)CC)CC(C(OC)C3)C1(CC2CC(O)(CN(C2)CCC2C1[NH]C1C2CCCC1)CC)C(=O)OC)C)C(=O)NC(C(CC)C)C(=O)OCC.
This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C45H54N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q6C979R91Y, chemically known as c-norvincaleukoblastine, 3,4-didehydro-4-deoxy-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:2) (salt) but generally known as vinorelbine, which bears US NIH Compound Identifier 60779. European Medicines Agency schedules Vinorelbine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00069MIG. The term VINORELBINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules vinorelbine in its Anatomical Therapeutic Chemical (ATC) Classification. VINORELBINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinorelbine under HS 29399900 and SITC 54149. As of Q4 2014, VINORELBINE remains the US FDA Preferred Term for this commodity. Vinorelbine bears US NLM identifiers UMLS ID C0078257 and NCI Concept Code C1275. SMILES: O(C1C2(C3N(CCC43C(N(C3C4CC(C(OC)C3)C3(CC4CN(CC5C3[NH]C3C5CCCC3)CC(=C4)CC)C(=O)OC)C)C1(O)C(=O)OC)CC=C2)CC)C(=O)C.OC(C(O)C(=O)O)C(=O)O.OC(C(O)C(=O)O)C(=O)O.
This classification denotes an anticonvulsant, antihypertensive agent, and calcium channel blocker with the molecular formula C22H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 543512OBTC, chemically known as 3-alpha,16-alpha-apovincaminic acid ethyl ester but generally known as vinpocetine, which bears US NIH Compound Identifier 5673. European Medicines Agency schedules Vinpocetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00070MIG. World Health Organization schedules vinpocetine in its Anatomical Therapeutic Chemical (ATC) Classification. VINPOCETINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinpocetine under HS 29399900 and SITC 54149. As of Q4 2014, VINPOCETINE remains the US FDA Preferred Term for this commodity. SMILES: O(C(=O)C1=CC2(C3N(CCC2)CCC2C3N1C1C2CCCC1)CC)CC.
This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8CVR3Q9Y6C. European Medicines Agency schedules Vinpoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00071MIG. Vinpoline generally arises in the molecular formula C23H30N2O3. The term VINPOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, no. 10 1976, list 16.) VINPOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vinpoline under HS 29399900 and SITC 54149. As of Q4 2014, VINPOLINE remains the US FDA Preferred Term for this commodity. Vinpoline bears US NLM identifiers UMLS ID C2827345 and NCI Concept Code C84240. SMILES: O(C(=O)C1n2c3C4N(CCCC4(C1)CC)CCc3c1c2cccc1)CC(O)C.
This classification denotes a calcium channel blocker with the molecular formula C18H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IS7C3GTW01, chemically known as 21-nor-1,14-secoeburnamenin-20-ol, 14,15-dihydro-, (3-alpha,16-alpha)- but generally known as vintoperol, which bears US NIH Compound Identifier 65893. European Medicines Agency schedules Vintoperol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00074MIG. The term VINTOPEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). VINTOPEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vintoperol under HS 29339990 and SITC 51577. As of Q4 2014, VINTOPEROL remains the US FDA Preferred Term for this commodity. Vintoperol bears US NLM identifiers UMLS ID C0084969 and NCI Concept Code C76585. SMILES: OCC1(C2N(CCC1)CCc1c2[nH]c2c1cccc2)CC.
This classification denotes an anesthetic with the molecular formula C4H6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H2T044E11, chemically known as 1,1-oxybisethene but generally known as vinyl ether, which bears US NIH Compound Identifier 8024. European Medicines Agency schedules Vinyl ether in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15697MIG. World Health Organization schedules vinyl ether in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, VINYL ETHER remains the US FDA Preferred Term for this commodity. SMILES: C=COC=C.
This classification denotes a vinca-site binding agent with the molecular formula C48H58ClN5O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 533U947V6Q, chemically known as 2h-3,7-methanoazacycloundecino(5,4-b)indole-9-carboxylic acid, 9-((2beta,3beta,4beta,5alpha,12beta,19alpha)-4-(acetyloxy)-3-(2-chloroethyl)-6,7-didehydro-16-methoxy-1-methyl-2,4-dioxospiro(aspidospermidine-3,5-oxazolidin)-15-yl)-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (3r-(3r*,5s*,7r*,9s*))- but generally known as vinzolidine, which bears US NIH Compound Identifier 49966. Most nations schedule vinzolidine under HS 29399900 and SITC 54149. As of Q4 2014, VINZOLIDINE remains the US FDA Preferred Term for this commodity. Vinzolidine bears US NLM identifiers UMLS ID C0078282 and NCI Concept Code C1276. SMILES: CLCCN1C(=O)C2(OC1=O)C1N(C3C(C41C1N(CC4)CC=CC1(C2OC(=O)C)CC)CC(C(OC)C3)C1(CC2CC(O)(CN(C2)CCC2C1[NH]C1C2CCCC1)CC)C(=O)OC)C.
This classification denotes a sedative and hypnotic with the molecular formula C4H3N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05RFR8AC84, chemically known as 2,4,5,6(1H,3H)-PYRIMIDINETETRONE 5-OXIME but more generally known as Violuric acid, which bears US NIH Compound Identifier 6399005. SMILES: 1(=NO)C(=O)NC(=O)NC1=O.
This classification denotes an antitubercular agent with the molecular formula C25H43N13O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, YVU35998K5 chemically known as glycine, 3-amino-n-((3s)-3,6-diamino-1-oxohexyl)-l-alanyl-l-seryl-l-seryl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-2-((4r,6s)-2-amino-1,4,5,6-tetrahydro-6-hydroxy-4-pyrimidinyl)-, (5->13)-lactam, (2s)- but generally known as viomycin, which bears US NIH Compound Identifier 3032902. European Medicines Agency schedules Viomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00078MIG. The term VIOMYCIN is an International Non-Proprietary Name or INN. Most nations schedule viomycin under HS 29419000 and SITC 54139. As of Q4 2014, VIOMYCIN remains the US FDA Preferred Term for this commodity. Viomycin bears US NLM identifiers UMLS ID C0042697 and NCI Concept Code C66654. SMILES: OC1N=C(NC(C2NC(=O)C(=C\NC(=O)N)\NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CC(N)CCCN)CNC2=O)CO)CO)C1)N.
This classification denotes the hydrochloride form of an antitubercular agent with the molecular structure C25H43N13O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, YVU35998K5 chemically known as glycine, 3-amino-n-((3s)-3,6-diamino-1-oxohexyl)-l-alanyl-l-seryl-l-seryl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-2-((4r,6s)-2-amino-1,4,5,6-tetrahydro-6-hydroxy-4-pyrimidinyl)-, (5->13)-lactam, (2s)-, but more commonly known as viomycin, which bears US NIH Compound Identifier 3032902. European Medicines Agency schedules Viomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00078MIG. The term VIOMYCIN is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule viomycin hydrochloride under HS 29419000. SMILES: C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.CL.CL.CL.
This classification denotes an antitubercular agent with the molecular formula C25H43N13O10.C9H17NO5.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0JTB9X596D, chemically known as .beta.-alanine, n-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (r)-, compd. with viomycin, sulfate (salt) (1:1:1), but more generally known as viomycin pantothenate sulfate, which bears US NIH Compound Identifier 3037980. European Medicines Agency schedules viomycin pantothenate sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00078MIG. Most nations, for tariff purposes, schedule viomycin pantothenate sulfate under HS 29419000. SMILES: CC(C)(CO)[C@H](C(=O)NCCC(=O)O)O.C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.OS(=O)(=O)O.
This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LKO141R05V. European Medicines Agency schedules Viomycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05106MIG. Viomycin sulfate generally arises in the molecular formula C25H43N13O10.H2O4S. The term 'viomycin sulfate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule viomycin sulfate under HS 29419000 and SITC 54139. As of Q4 2014, VIOMYCIN SULFATE remains US FDA's Preferred Term for this commodity. Viomycin sulfate bears US NLM identifiers UMLS ID C1321956 and NCI Concept Code C66655. SMILES: C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.OS(=O)(=O)O.
This classification denotes the trihydrochloride form of an antitubercular agent with the molecular structure C25H43N13O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, YVU35998K5 chemically known as glycine, 3-amino-n-((3s)-3,6-diamino-1-oxohexyl)-l-alanyl-l-seryl-l-seryl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-2-((4r,6s)-2-amino-1,4,5,6-tetrahydro-6-hydroxy-4-pyrimidinyl)-, (5->13)-lactam, (2s)-, but more commonly known as viomycin, which bears US NIH Compound Identifier 3032902. European Medicines Agency schedules Viomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00078MIG. The term VIOMYCIN is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule viomycin trihydrochloride under HS 29419000. As of Q4 2014, VIOMYCIN TRIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.CL.CL.CL.
This classification denotes a quinoline and vasodilator agent with the molecular formula C20H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6FXT2V136, chemically known as 1-propanone, 3-(3-ethenyl-4-piperidinyl)-1-(6-methoxy-4-quinolinyl)-, monohydrochloride, (3r-cis)- but more generally known as viquidil hydrochloride, which bears US NIH Compound Identifier 198279. European Medicines Agency schedules Viquidil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05109MIG. Most nations, for tariff and trade purposes, schedule viquidil hydrochloride under HS 29392000 and SITC 54142. As of Q4 2014, VIQUIDIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC2C(C1)C(CCN2)C(=O)CC[C@@H]3CCNC[C@@H]3C=C.CL.
This classification denotes a quinoline and vasodilator agent with the molecular formulas C20H24N2O2.ClH and C20H24N2O2, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 48T4S8667S and U6FXT2V136, the base compound being chemically known as 1-propanone, 3-(3-ethenyl-4-piperidinyl)-1-(6-methoxy-4-quinolinyl)-(3r-cis)- but generally known as viquidil, which bears US NIH Compound Identifier 198279. European Medicines Agency schedules Viquidil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB00081MIG and SUB05109MIG. Most nations schedule viquidil under HS 29392000 and SITC 54142. As of Q4 2014, VIQUIDIL remains the US FDA Preferred Term for this commodity. SMILES: COC1=CC2=C(C=CN=C2C=C1)C(=O)CCC3CCNCC3C=C (base) or COC1CCC2C(C1)C(CCN2)C(=O)CC[C@@H]3CCNC[C@@H]3C=C.CL (hydrochloride).
This classification denotes a depsipeptide antibiotic with the molecular formula C43H49N7O10, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C49WS9N75L, more generally known as virginiamycin. European Medicines Agency schedules virginiamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05111MIG. The term VIRGINIAMYCIN is an International Non-Proprietary Name or INN. see World Health Organization INN reference publication, volume 22, no. 10, 1968, list 8. VIRGINIAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.
This classification denotes an antiviral agent with the molecular formula (C17H18N4O3S)2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I5V34WG2BE, more generally known as viroxime. European Medicines Agency schedules viroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00082MIG. The term VIROXIME is an International Non-Proprietary Name or INN. VIROXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule viroxime under HS 29350090 and SITC 51580. As of Q4 2014, VIROXIME remains the US FDA Preferred Term for this commodity. SMILES: CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C(=NO)C3=CC=CC=C3)N=C1N.
This classification denotes a vasodilating agent with the molecular formula C21H24O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0RL4V0K263, chemically known as 3,4,5-trihydroxy-2,2-dimethyl-6-chromanacrylic acid delta-lactone 4-acetate 3-(2-methylbutyrate) but generally known as visnadine, which bears US NIH Compound Identifier 10157. European Medicines Agency schedules Visnadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00083MIG. The term VISNADINE is an International Non-Proprietary Name. World Health Organization schedules visnadine in its Anatomical Therapeutic Chemical (ATC) Classification. VISNADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, VISNADINE remains the US FDA Preferred Term for this commodity. Visnadine bears US NLM identifiers UMLS ID C0644519 and NCI Concept Code C87287. SMILES: O1C(C(OC(=O)C(CC)C)C(OC(=O)C)c2c1ccc1c2oc(=O)cc1)(C)C.
This classification denotes a bronchodilator with the molecular formula C18H22NO5.C7H7N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GB901PL1KW, chemically known as (2-((9-methoxy-7-methyl-5-oxo-5h-furo(3,2-g)(1)benzopyran-4-yl)oxy)ethyl)trimethylammonium theophylline derivate but generally known as visnafylline, which bears US NIH Compound Identifier 3084273. European Medicines Agency schedules Visnafylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00084MIG. The term VISNAFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). VISNAFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule visnafylline under HS 29395900 and SITC 54145. As of Q4 2014, VISNAFYLLINE remains the US FDA Preferred Term for this commodity. Visnafylline bears US NLM identifiers UMLS ID C2700253 and NCI Concept Code C74217. SMILES: O(CC[N](C)(C)C)C1C2C(OCC2)C(OC)C2OC(CC(=O)C12)C.O=C1N(C2NCNC2C(O)N1C)C.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT801. This VA Drug Class (VT801) classifies this compound as belonging to the group MULTIVITAMINS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE350. This VA Drug Class (DE350) classifies this compound as belonging to the group EMOLLIENTS.
This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE900. This VA Drug Class (DE900) classifies this compound as belonging to the group DERMATOLOGICALS, TOPICAL OTHER.
This classification denotes an immunosuppressant with the molecular formula C63H111N11O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2PN063X6B1, chemically known as (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone but more generally known as voclosporin, which bears US NIH Compound Identifier 6918486. European Medicines Agency schedules Voclosporin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31127. The term VOCLOSPORIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 1, 2008, List 59). As of Q4 2014, VOCLOSPORIN remains US FDA's Preferred Term for this commodity. SMILES: CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C.
This classification denotes a glucosidase inhibitor and anti-diabetic agent with the molecular formula C10H21NO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S77P977AG8, chemically known as 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-c-(hydroxymethyl)-d-epi-inositol but more generally known as voglibose, which bears US NIH Compound Identifier 5677. European Medicines Agency schedules Voglibose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00085MIG. The term VOGLIBOSE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32) WHO schedules voglibose in its Anatomical Therapeutic Chemical (ATC) Classification. VOGLIBOSE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule voglibose under HS 29221980 and SITC 51461. As of Q4 2014, VOGLIBOSE remains US FDA's Preferred Term for this commodity. Voglibose bears US NLM identifiers UMLS ID C0532578 and NCI Concept Code C95221. SMILES: C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO.
This classification denotes an antibiotic with the molecular formula C28H37N3O7, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 18UAN5144E. The term VOLPRISTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 13 no. 3, 1999, list 42. ). SMILES: CC1C=CC(=O)NCC=CC(=CC(CC(=O)CC2=NC(=CO2)C(=O)N3CCC(C3)C(=O)OC1C(C)C)O)C.
A type of protease-activated receptor-1 (PAR-1) antagonist.
This classification denotes an antifungal agent with the molecular formula C16H14F3N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JFU09I87TR, chemically known as 4-pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1h-1,2,4-triazol-1-ylmethyl)-, (r-(r*,s*))- but generally known as voriconazole, which bears US NIH Compound Identifier 71616. European Medicines Agency schedules Voriconazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00087MIG. The term VORICONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules voriconazole in its Anatomical Therapeutic Chemical (ATC) Classification. VORICONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule voriconazole under HS 29335995 and SITC 51576. As of Q4 2014, VORICONAZOLE remains the US FDA Preferred Term for this commodity. Voriconazole bears US NLM identifiers UMLS ID C0393080 and NCI Concept Code C1707. SMILES: FC1C(C(O)(C(C)C2NCNCC2F)CN2NCNC2)CCC(F)C1.
This classification denotes a histone deacetylase inhibitor with the molecular formula C14H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58IFB293JI, chemically known as saha, suberoylanilide hydroxamic acid but generally known as vorinostat, which bears US NIH Compound Identifier 5311. European Medicines Agency schedules Vorinostat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23356. The term VORINOSTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 3, 2006, List 56). World Health Organization schedules vorinostat in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule vorinostat under HS 29280090 and SITC 51486. As of Q4 2014, VORINOSTAT remains the US FDA Preferred Term for this commodity. Vorinostat bears US NLM identifiers UMLS ID C0672708 and NCI Concept Code C1796. SMILES: O=C(NC1CCCCC1)CCCCCCC(=O)NO.
This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C16H13ClN6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1E2S9YXV2A, chemically known as 6-((4-chlorophenyl)(1h-1,2,4-triazol-1-yl)methyl)-1-methyl-1h-benzotriazole,d- but generally known as vorozole, which bears US NIH Compound Identifier 60796. European Medicines Agency schedules Vorozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00088MIG. The term VOROZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules vorozole in its Anatomical Therapeutic Chemical (ATC) Classification. VOROZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vorozole under HS 29339990 and SITC 51577. As of Q4 2014, VOROZOLE remains the US FDA Preferred Term for this commodity. Vorozole bears US NLM identifiers UMLS ID C0286224 and NCI Concept Code C1601. SMILES: CLC1CCC(C(N2NCNC2)C2CC3N(NNC3CC2)C)CC1.
A drug indicated for the treatment of major depressive disorder.
This classification denotes a coumarin compound and anticoagulant agent with the molecular formula C19H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Q7ZVV76EI, chemically known as 2h-1-benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, & salts, when present at concentrations greater than 0.3% but generally known as warfarin, which bears US NIH Compound Identifier 6691. European Medicines Agency schedules Warfarin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00090MIG. The term WARFARIN is an International Non-Proprietary Name. World Health Organization schedules warfarin in its Anatomical Therapeutic Chemical (ATC) Classification. WARFARIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, WARFARIN remains the US FDA Preferred Term for this commodity. Warfarin bears US NLM identifiers UMLS ID C0043031 and NCI Concept Code C945. SMILES: O1C(O)C(C(CC(=O)C)C2CCCCC2)C(=O)C2C1CCCC2.
This classification denotes a beta-adrenergic agonist with the molecular formula C16H25N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7HE0JQL703, chemically known as 4-morpholinecarboxamide, n-(2-((2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)-, (+-)- but generally known as xamoterol, which bears US NIH Compound Identifier 155774. European Medicines Agency schedules Xamoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00092MIG. The term XAMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules xamoterol in its Anatomical Therapeutic Chemical (ATC) Classification. XAMOTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xamoterol under HS 29349990 and SITC 51579. As of Q4 2014, XAMOTEROL remains the US FDA Preferred Term for this commodity. Xamoterol bears US NLM identifiers UMLS ID C0078595 and NCI Concept Code C81344. SMILES: O1CCN(CC1)C(=O)NCCNCC(O)COC1CCC(O)CC1.
This classification denotes a beta-adrenergic agonist 2C16H25N3O5.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N87007N668, chemically known as ici-118,587 hemifumarate, but more generally known as xamoterol fumarate, which bears US NIH Compound Identifier 6917710. European Medicines Agency schedules Xamoterol fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05144MIG. Most nations, for tariff and trade purposes, schedule xamoterol fumarate under HS 29349990 and SITC 51579. As of Q4 2014, XAMOTEROL FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1O)OCC(CNCCNC(=O)N2CCOCC2)O.C1CC(CCC1O)OCC(CNCCNC(=O)N2CCOCC2)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a beta-adrenergic agonist with the molecular formula 2C16H25N3O5.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N87007N668, chemically known as (+/-)-n-(2-((2-hydroxy-3-(p-hydroxyphenoxy)propyl)amino)ethyl)-4-morpholinecarboxamide fumarate (2:1) (salt), but more generally known as xamoterol hemifumarate, which bears US NIH Compound Identifier 6440459. European Medicines Agency schedules xamoterol hemifumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00092MIG. Most nations, for tariff purposes, schedule xamoterol hemifumarate under HS 29349990. SMILES: C1CC(CCC1O)OCC(CNCCNC(=O)N2CCOCC2)O.C1CC(CCC1O)OCC(CNCCNC(=O)N2CCOCC2)O.C(=C/C(=O)O)\C(=O)O.
This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S6V5I726MH. European Medicines Agency schedules Xanoxic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00094MIG. Xanoxic acid generally arises in the molecular formula C17H14O5. The term XANOXIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) Most nations schedule xanoxic acid under HS 29329985 and SITC 51569. As of Q4 2014, XANOXIC ACID remains the US FDA Preferred Term for this commodity. Xanoxic acid bears US NLM identifiers UMLS ID C2825724 and NCI Concept Code C81676. SMILES: O1C2C(C(=O)C3C1CCC(C3)C(=O)O)CC(OC(C)C)CC2.
This classification denotes an antiviral agent with the molecular formula C23H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KDU8VH09O8, chemically known as benzoic acid, p-(alpha-ethoxy-p-phenylphenacylamino)- but generally known as xenazoic acid, which bears US NIH Compound Identifier 239062. European Medicines Agency schedules Xenazoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00101MIG. The term XENAZOIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Most nations schedule xenazoic acid under HS 29225000 and SITC 51467. As of Q4 2014, XENAZOIC ACID remains the US FDA Preferred Term for this commodity. Xenazoic acid bears US NLM identifiers UMLS ID C1883571 and NCI Concept Code C66662. SMILES: O(C(NC1CCC(CC1)C(=O)O)C(=O)C1CCC(CC1)C1CCCCC1)CC.
This classification denotes an anti-lipidemic agent with the molecular formula C22H29NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PM0Q96HVS, chemically known as 4-biphenylacetic acid, alpha-ethylthio-, s-(2-(diethylamino)ethyl) ester but generally known as xenthiorate, which bears US NIH Compound Identifier 6445348. European Medicines Agency schedules Xenthiorate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00105MIG. The term XENTHIORATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). XENTHIORATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xenthiorate under HS 29309085 and SITC 51549. As of Q4 2014, XENTHIORATE remains the US FDA Preferred Term for this commodity. Xenthiorate bears US NLM identifiers UMLS ID C1883574 and NCI Concept Code C66665. SMILES: S(CCN(CC)CC)C(=O)C(CC)c1ccc(cc1)c1ccccc1.
This classification denotes an antiviral agent and antimicrobial with the molecular formula C16H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3C2T3HG40E, chemically known as 4,4-diphenyldicarboxaldehyde but generally known as xenygloxal, which bears US NIH Compound Identifier 239061. European Medicines Agency schedules Xenygloxal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00106MIG. The term XENYGLOXAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). XENYGLOXAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xenygloxal under HS 29144090 and SITC 51629. As of Q4 2014, XENYGLOXAL remains the US FDA Preferred Term for this commodity. Xenygloxal bears US NLM identifiers UMLS ID C1883575 and NCI Concept Code C66666. SMILES: O=C(C1CCC(C2CCC(CC2)C(=O)C=O)CC1)C=O.
This classification denotes an anti-lipidemic agent with the molecular formula C18H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4293LHY68W, chemically known as 4-hexenoic acid, 2-(4-biphenylyl)- but generally known as xenyhexenic acid, which bears US NIH Compound Identifier 6436176. European Medicines Agency schedules Xenyhexenic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00107MIG. The term XENYHEXENIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Most nations schedule xenyhexenic acid under HS 29163900 and SITC 51379. As of Q4 2014, XENYHEXENIC ACID remains the US FDA Preferred Term for this commodity. Xenyhexenic acid bears US NLM identifiers UMLS ID C1883576 and NCI Concept Code C66667. SMILES: OC(=O)C(c1ccc(cc1)c1ccccc1)C/C=C/C.
This classification denotes a bornane and alcohol with the molecular formula C18H26O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RQ12GMY0FZ, chemically known as 3,4-xylenol, 6-isobornyl- (8ci) but generally known as xibornol, which bears US NIH Compound Identifier 72144. European Medicines Agency schedules Xibornol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00111MIG. World Health Organization schedules xibornol in its Anatomical Therapeutic Chemical (ATC) Classification. XIBORNOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xibornol under HS 29071990 and SITC 51243. As of Q4 2014, XIBORNOL remains the US FDA Preferred Term for this commodity. SMILES: OC1C(C2C3(C(C(C2)CC3)(C)C)C)CC(C(C1)C)C.
This classification denotes an anticoagulant agent with the molecular formula C24H35N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49HFB70472, chemically known as glycine, n-((1r)-1-cyclohexyl-2-((2s)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester but generally known as ximelagatran, which bears US NIH Compound Identifier 9574101. European Medicines Agency schedules Ximelagatran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16473MIG. The term XIMELAGATRAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). World Health Organization schedules ximelagatran in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ximelagatran under HS 29339990 and SITC 51577. As of Q4 2014, XIMELAGATRAN remains the US FDA Preferred Term for this commodity. Ximelagatran bears US NLM identifiers UMLS ID C0966370 and NCI Concept Code C77996. SMILES: O=C(N1C(CC1)C(=O)NCC1CCC(CC1)C(=N\O)\N)C(NCC(=O)OCC)C1CCCCC1.
This classification denotes an anti-lipidemic agent with the molecular formula C5H10N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q22EPG4O8, chemically known as 4,5-dihydro-4,4-dimethyl-2-oxazolamin but generally known as xinomiline, which bears US NIH Compound Identifier 3085023. European Medicines Agency schedules Xinomiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00115MIG. The term XINOMILINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). XINOMILINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xinomiline under HS 29349990 and SITC 51579. As of Q4 2014, XINOMILINE remains the US FDA Preferred Term for this commodity. Xinomiline bears US NLM identifiers UMLS ID C1883579 and NCI Concept Code C66671. SMILES: O1CC(N=C1N)(C)C.
This classification denotes a diuretic with the molecular formula C15H15ClN2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4S9EY0NUEC, chemically known as 4-chloro-5-sulfamoyl-2,6-salicyloxylidide but generally known as xipamide, which bears US NIH Compound Identifier 26618. European Medicines Agency schedules Xipamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00116MIG. The term XIPAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules xipamide in its Anatomical Therapeutic Chemical (ATC) Classification. XIPAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xipamide under HS 29350090 and SITC 51580. As of Q4 2014, XIPAMIDE remains the US FDA Preferred Term for this commodity. Xipamide bears US NLM identifiers UMLS ID C0043355 and NCI Concept Code C87708. SMILES: CLC1C(S(=O)(=O)N)CC(C(=O)NC2C(CCCC2C)C)C(O)C1.
This classification denotes a beta-adrenergic blocking agent with the molecular formula C23H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZJI41P5WMH, chemically known as 2-propanol, 1-(di-2,6-xylylmethoxy)-3-(isopropylamino)- but generally known as xipranolol, which bears US NIH Compound Identifier 65692. European Medicines Agency schedules Xipranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00117MIG. The term XIPRANOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). XIPRANOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xipranolol under HS 29221980 and SITC 51461. As of Q4 2014, XIPRANOLOL remains the US FDA Preferred Term for this commodity. Xipranolol bears US NLM identifiers UMLS ID C0601010 and NCI Concept Code C66672. SMILES: O(C(C1C(CCCC1C)C)C1C(CCCC1C)C)CC(O)CNC(C)C.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2KFG9TP5V8, chemically known as 5,6-dihydro-2-(2,6-xylidino)-4h-1,3-thiazine but generally known as xylazine, which bears US NIH Compound Identifier 5707. European Medicines Agency schedules Xylazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00120MIG. The term XYLAZINE is an International Non-Proprietary Name. XYLAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xylazine under HS 29349990 and SITC 51579. As of Q4 2014, XYLAZINE remains the US FDA Preferred Term for this commodity. Xylazine bears US NLM identifiers UMLS ID C0043366 and NCI Concept Code C75049. SMILES: CC1=C(C(=CC=C1)C)NC2=NCCCS2.
This classification denotes an alpha-adrenergic agonist with the molecular formula C12H16N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NGC3S0882S, chemically known as 4h-1,3-thiazin-2-amine, n-(2,6-dimethylphenyl)-5,6-dihydro-, monohydrochloride, but more generally known as xylazine hydrochloride, which bears US NIH Compound Identifier 68554. European Medicines Agency schedules xylazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00120MIG. Most nations, for tariff purposes, schedule xylazine hydrochloride under HS 29349990. Xylazine hydrochloride bears US NLM identifiers UMLS ID C0242544 and NCI Concept Code C75050. SMILES: CC1CCCC(C1NC2=NCCCS2)C.CL.
This classification denotes a coumarin compound and anticoagulant agent with the molecular formula C17H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J7I598ESCC, chemically known as 4-hydroxy-3-(3,5-xylyl)coumarin but generally known as xylocoumarol, which bears US NIH Compound Identifier 27192. European Medicines Agency schedules Xylocoumarol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00121MIG. The term XYLOCOUMAROL is an International Non-Proprietary Name. XYLOCOUMAROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, XYLOCOUMAROL remains the US FDA Preferred Term for this commodity. Xylocoumarol bears US NLM identifiers UMLS ID C1883580 and NCI Concept Code C66673. SMILES: O1C2C(C(=O)C(C3CC(CC(C3)C)C)C1O)CCCC2.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WPY40FTH8K, chemically known as 2-imidazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)- but more generally known as xylometazoline, which bears US NIH Compound Identifier 5709. European Medicines Agency schedules Xylometazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00122MIG. The term XYLOMETAZOLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules xylometazoline in its Anatomical Therapeutic Chemical (ATC) Classification. XYLOMETAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule xylometazoline under HS 29332990 and SITC 51573. As of Q4 2014, XYLOMETAZOLINE remains US FDA's Preferred Term for this commodity. Xylometazoline bears US NLM identifiers UMLS ID C0078643 and NCI Concept Code C87749. SMILES: N1C(=NCC1)CC1C(CC(C(C)(C)C)CC1C)C.
This classification denotes an antitussive agent with the molecular formula C23H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L95KV83PV9, chemically known as 2-(2-(di-2,6-xylylmethoxy)ethoxy)-n,n-dimethylethylamine but more generally known as xyloxemine, which bears US NIH Compound Identifier 17800. European Medicines Agency schedules Xyloxemine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00123MIG. The term XYLOXEMINE is an International Non-Proprietary Name. XYLOXEMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule xyloxemine under HS 29221980 and SITC 51461. As of Q4 2014, XYLOXEMINE remains US FDA's Preferred Term for this commodity. Xyloxemine bears US NLM identifiers UMLS ID C1883581 and NCI Concept Code C66675. SMILES: O(C(C1C(CCCC1C)C)C1C(CCCC1C)C)CCOCCN(C)C.
This classification denotes a vaccine that addresses an acute infectious disease primarily of the tropics, caused by a virus and transmitted to man by mosquitoes of the genera Aedes and Haemagogus. Yellow fever vaccine bears US NLM identifiers UMLS ID C0301508 and NCI Concept Code C96396.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C21H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Y49VWD90Q, chemically known as 20.alpha.-yohimban-16.beta.-carboxylic acid, 17.alpha.-hydroxy-, methyl ester, monohydrochloride but generally known as yohimbine, which bears US NIH Compound Identifier 2866. European Medicines Agency schedules Yohimbine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15744MIG. World Health Organization schedules yohimbine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule yohimbine under HS 29399990 and SITC 54149. As of Q4 2014, YOHIMBINE remains the US FDA Preferred Term for this commodity. Yohimbine bears US NLM identifiers UMLS ID C0724441 and NCI Concept Code C77304. SMILES: OC1C(C2C(CN3C(C2)C2[NH]C4C(C2CC3)CCCC4)CC1)C(=O)OC.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C21H26N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NB2E1YP49F, chemically known as 20.alpha.-yohimban-16.beta.-carboxylic acid, 17.alpha.-hydroxy-, methyl ester, monohydrochloride but more generally known as yohimbine hydrochloride, which bears US NIH Compound Identifier 2866. European Medicines Agency schedules Yohimbine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15745MIG. Most nations, for tariff and trade purposes, schedule yohimbine hydrochloride under HS 29399990 and SITC 54149. As of Q4 2014, YOHIMBINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Yohimbine hydrochloride bears US NLM identifiers UMLS ID C0521933 and NCI Concept Code C75062. SMILES: COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4C(C5CCCCC5[NH]4)CCN3C2)O.CL.
This classification denotes an ace inhibitor with the molecular formula C23H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 475035SS4C, chemically known as (3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-2-azabicyclo(2.2.2)octane-3-carboxylic acid, 1-ethyl ester but generally known as zabicipril, which bears US NIH Compound Identifier 71262. European Medicines Agency schedules Zabicipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00125MIG. The term ZABICIPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). ZABICIPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zabicipril under HS 29333999 and SITC 51574. As of Q4 2014, ZABICIPRIL remains the US FDA Preferred Term for this commodity. Zabicipril bears US NLM identifiers UMLS ID C0085048 and NCI Concept Code C82218. SMILES: OC(=O)C1N(C2CCC1CC2)C(=O)C(NC(CCc1ccccc1)C(=O)OCC)C.
This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A2D355316. European Medicines Agency schedules Zabiciprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00126MIG. Zabiciprilat generally arises in the molecular formula C21H28N2O5. The term ZABICIPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) ZABICIPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zabiciprilat under HS 29333999 and SITC 51574. As of Q4 2014, ZABICIPRILAT remains the US FDA Preferred Term for this commodity. Zabiciprilat bears US NLM identifiers UMLS ID C0165809 and NCI Concept Code C66678. SMILES: OC(=O)C1N(C2CCC1CC2)C(=O)C(NC(CCc1ccccc1)C(=O)O)C.
This classification denotes an anti-asthmatic agent with the molecular formula C31H33N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XZ629S5L50, chemically known as ici 204,219 but generally known as zafirlukast, which bears US NIH Compound Identifier 5717. European Medicines Agency schedules Zafirlukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00128MIG. The term ZAFIRLUKAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules zafirlukast in its Anatomical Therapeutic Chemical (ATC) Classification. ZAFIRLUKAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zafirlukast under HS 29350090 and SITC 51580. As of Q4 2014, ZAFIRLUKAST remains the US FDA Preferred Term for this commodity. Zafirlukast bears US NLM identifiers UMLS ID C0378466 and NCI Concept Code C47785. SMILES: S(=O)(=O)(NC(=O)C1CC(OC)C(CC2C3C(N(C2)C)CCC(NC(=O)OC2CCCC2)C3)CC1)C1C(CCCC1)C.
This classification denotes a pyrimidine antagonist with the molecular formula C9H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6L3XT8CB3I, chemically known as dideoxycytidine but generally known as zalcitabine, which bears US NIH Compound Identifier 24066. European Medicines Agency schedules Zalcitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00130MIG. The term ZALCITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules zalcitabine in its Anatomical Therapeutic Chemical (ATC) Classification. ZALCITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zalcitabine under HS 29349990 and SITC 51579. As of Q4 2014, ZALCITABINE remains the US FDA Preferred Term for this commodity. Zalcitabine bears US NLM identifiers UMLS ID C0012132 and NCI Concept Code C430. SMILES: O1C(N2CCC(NC2=O)N)CCC1CO.
This classification denotes an antidiarrheal agent with the molecular formula C26H28N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GH66PET6S3, chemically known as (+-)-1-(1-((4-methyl-4h,6h-pyrrolo(1,2-a)(4,1)benzoxazepin-4-yl)methyl)-4-piperidyl)-2-benzimidazolinone but generally known as zaldaride, which bears US NIH Compound Identifier 65909. European Medicines Agency schedules Zaldaride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00131MIG. The term ZALDARIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). ZALDARIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zaldaride under HS 29349990 and SITC 51579. As of Q4 2014, ZALDARIDE remains the US FDA Preferred Term for this commodity. Zaldaride bears US NLM identifiers UMLS ID C1883594 and NCI Concept Code C66680. SMILES: O1C(CN2CCC(N3C4C([NH]C3=O)CCCC4)CC2)(C2N(C3C(C1)CCCC3)CCC2)C.
This classification denotes an antidiarrheal agent with the molecular formula C26H28N4O2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7SG01P7NJ, chemically known as 1,3-dihydro-1-(1-((4-methyl-4h,6h-pyrrolo(1,2-a)(4,1)benzoxazepin-4-yl)methyl)-4-piperidinyl)-2h-benzimidazol-2-one maleate, but more generally known as zaldaride maleate, which bears US NIH Compound Identifier 6450522. European Medicines Agency schedules zaldaride maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00131MIG. Most nations, for tariff purposes, schedule zaldaride maleate under HS 29349990. SMILES: CC1(C2CCCN2-C3CCCCC3CO1)CN4CCC(CC4)N5C6CCCCC6[NH]C5=O.C(=C\C(=O)O)\C(=O)O.
This classification denotes a sedative and hypnotic with the molecular formula C17H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S62U433RMH, chemically known as 3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)-n-ethylacetanilide but generally known as zaleplon, which bears US NIH Compound Identifier 5719. European Medicines Agency schedules Zaleplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00132MIG. The term ZALEPLON is an International Non-Proprietary Name. World Health Organization schedules zaleplon in its Anatomical Therapeutic Chemical (ATC) Classification. ZALEPLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zaleplon under HS 29335995 and SITC 51576. As of Q4 2014, ZALEPLON remains the US FDA Preferred Term for this commodity. Zaleplon bears US NLM identifiers UMLS ID C0251504 and NCI Concept Code C29551. SMILES: O=C(N(C1CC(C2N3NCC(C3NCC2)C#N)CCC1)CC)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H14O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H8635NG3PY, chemically known as 10,11-dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid but generally known as zaltoprofen, which bears US NIH Compound Identifier 5720. European Medicines Agency schedules Zaltoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00135MIG. The term ZALTOPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). ZALTOPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zaltoprofen under HS 29349990 and SITC 51579. As of Q4 2014, ZALTOPROFEN remains the US FDA Preferred Term for this commodity. Zaltoprofen bears US NLM identifiers UMLS ID C2930434 and NCI Concept Code C66681. SMILES: S1C2C(CC(=O)C3C1CCCC3)CC(C(C)C(=O)O)CC2.
This classification denotes an antimuscarinic agent with the molecular formula C27H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y88Q418Y7M, chemically known as piperidine, 1-(2-(1,3-benzodioxol-5-yl)ethyl)-3-(diphenylmethoxy)-, (+-)- but generally known as zamifenacin, which bears US NIH Compound Identifier 124431. European Medicines Agency schedules Zamifenacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00136MIG. The term ZAMIFENACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). ZAMIFENACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zamifenacin under HS 29349990 and SITC 51579. As of Q4 2014, ZAMIFENACIN remains the US FDA Preferred Term for this commodity. Zamifenacin bears US NLM identifiers UMLS ID C0386392 and NCI Concept Code C66682. SMILES: O(C1CN(CCC1)CCC1CC2OCOC2CC1)C(C1CCCCC1)C1CCCCC1.
This classification denotes an antiviral agent with the molecular formula C12H20N4O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6O3XI777I, chemically known as 5-acetamido-4-guanidino-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid but generally known as zanamivir, which bears US NIH Compound Identifier 60855. European Medicines Agency schedules Zanamivir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00137MIG. The term ZANAMIVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 11997, List 37). World Health Organization schedules zanamivir in its Anatomical Therapeutic Chemical (ATC) Classification. ZANAMIVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zanamivir under HS 29329985 and SITC 51569. As of Q4 2014, ZANAMIVIR remains the US FDA Preferred Term for this commodity. Zanamivir bears US NLM identifiers UMLS ID C0216660 and NCI Concept Code C47786. SMILES: O1C(C(NC(=O)C)C(/N=C(/N)N)C=C1C(=O)O)C(O)C(O)CO.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C25H32N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A0800O89N, chemically known as 1-propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)- but generally known as zanapezil, which bears US NIH Compound Identifier 198752. The term ZANAPEZIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). Most nations schedule zanapezil under HS 29333999 and SITC 51574. As of Q4 2014, ZANAPEZIL remains the US FDA Preferred Term for this commodity. Zanapezil bears US NLM identifiers UMLS ID C1883595 and NCI Concept Code C66683. SMILES: C1CCNC2=C(C1)C=CC(=C2)C(=O)CCC3CCN(CC3)CC4=CC=CC=C4.
This classification denotes an antihypertensive agent with the molecular formula C35H55N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I36B16A34Q, chemically known as 4-thiazolepropanamide, n-((1s,2r,3s)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-(((2s)-2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (alphas)- but generally known as zankiren, which bears US NIH Compound Identifier 3036088. European Medicines Agency schedules Zankiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00138MIG. The term ZANKIREN is an International Non-Proprietary Name. ZANKIREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zankiren under HS 29341000 and SITC 51579. As of Q4 2014, ZANKIREN remains the US FDA Preferred Term for this commodity. Zankiren bears US NLM identifiers UMLS ID C2987041 and NCI Concept Code C95290. SMILES: S(=O)(=O)(N1CCN(CC1)C)CC(C(=O)NC(C(=O)NC(CC1CCCCC1)C(O)C(O)CC(C)C)Cc1ncsc1)Cc1ccccc1.
This classification denotes the hydrochloride form of an antihypertensive agent with the molecular formula C35H55N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I36B16A34Q, chemically known as 4-thiazolepropanamide, n-((1s,2r,3s)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-(((2s)-2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (alphas)- but more generally known as zankiren, which bears US NIH Compound Identifier 3036088. European Medicines Agency schedules Zankiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00138MIG. The term ZANKIREN is an International Non-Proprietary Name. ZANKIREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule zankiren hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, ZANKIREN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zankiren hydrochloride bears US NLM identifiers UMLS ID C0936138 and NCI Concept Code C95292. SMILES: CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2CSCN2)NC(=O)[C@H](CC3CCCCC3)CS(=O)(=O)N4CCN(CC4)C)O)O.CL.
This classification denotes an anti-androgen with the molecular formula C23H32N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XQ5V1W49JG, chemically known as 1-(methylsulfonyl)-1h-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol but generally known as zanoterone, which bears US NIH Compound Identifier 60180. European Medicines Agency schedules Zanoterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00139MIG. The term ZANOTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). ZANOTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zanoterone under HS 29372900 and SITC 54153. As of Q4 2014, ZANOTERONE remains the US FDA Preferred Term for this commodity. Zanoterone bears US NLM identifiers UMLS ID C0078493 and NCI Concept Code C74123. SMILES: S(=O)(=O)(N1NC2CC3C(C4C(C5C(CC4)(C(O)(CC5)C#C)C)CC3)(CC2C1)C)C.
This classification denotes a phosphodiesterase inhibitor and bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQ358GWH6Y. European Medicines Agency schedules Zardaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00142MIG. Zardaverine generally arises in the molecular formula C12H10F2N2O3. The term ZARDAVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) ZARDAVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zardaverine under HS 29339990 and SITC 51577. As of Q4 2014, ZARDAVERINE remains the US FDA Preferred Term for this commodity. Zardaverine bears US NLM identifiers UMLS ID C0085049 and NCI Concept Code C66686. SMILES: COC1=C(C=CC(=C1)C2=NNC(=O)C=C2)OC(F)F.
This classification denotes an antiarrhythmic agent with the molecular formula C26H36N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) TV27RY5876, chemically known as 3-(3-((3,4-dimethoxyphenethyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one but more generally known as zatebradine, which bears US NIH Compound Identifier 65637. European Medicines Agency schedules Zatebradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00143MIG. The term ZATEBRADINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 4, No. 3 1990, List 30). ZATEBRADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule zatebradine under HS 29337900 and SITC 51561. As of Q4 2014, ZATEBRADINE remains US FDA's Preferred Term for this commodity. Zatebradine bears US NLM identifiers UMLS ID C0208084 and NCI Concept Code C66687. SMILES: O=C1N(CCC2C(C1)CC(OC)C(OC)C2)CCCN(CCC1CC(OC)C(OC)CC1)C.
This classification denotes a non-steroidal estrogen with the molecular formula C18H26O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76LO2L2V39, chemically known as 1h-2-benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl- but generally known as zeranol, which bears US NIH Compound Identifier 22283. European Medicines Agency schedules Zeranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00148MIG. The term ZERANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). ZERANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Zearalenone or zeranol bears US NLM identifiers UMLS ID C0043465 and NCI Concept Code C76826. SMILES: OC1CCCCCc2c(C(=O)OC(CCC1)C)c(O)cc(O)c2.
This classification denotes an aldose reductase inhibitor with the molecular formula C17H11BrClFN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 180C9PJ8JT, chemically known as 3-(4-bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2h)-quinazolineacetic acid but generally known as zenarestat, which bears US NIH Compound Identifier 5724. European Medicines Agency schedules Zenarestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00145MIG. The term ZENARESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). ZENARESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zenarestat under HS 29335995 and SITC 51576. As of Q4 2014, ZENARESTAT remains the US FDA Preferred Term for this commodity. Zenarestat bears US NLM identifiers UMLS ID C0149322 and NCI Concept Code C72879. SMILES: BRC1CC(F)C(CN2C(=O)N(C3C(C2=O)CCC(CL)C3)CC(=O)O)CC1.
This classification denotes a platinum compound with the molecular formula C6H6O4.C5H14N2O2.Pt, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40ZQ0A17IT, chemically known as platinum, (2,2-bis(aminomethyl)-1,3-propanediol-n,n)(1,1-cyclobutanedicarboxylato(2-))-, (sp-4-2)- but more generally known as zeniplatin, which bears US NIH Compound Identifier 60505. European Medicines Agency schedules Zeniplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00146MIG. The term ZENIPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). ZENIPLATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ZENIPLATIN remains US FDA's Preferred Term for this commodity. Zeniplatin bears US NLM identifiers UMLS ID C0055849 and NCI Concept Code C1053. Most nations, for tariff and trade purposes, schedule zeniplatin under HS 28439090 and SITC 52432. SMILES: C1CC(C1)(C(=O)[O-])C(=O)[O-].C(C(CN)(CO)CO)N.[Pt+2].
This classification denotes an antipsychotic agent with the molecular formula C16H22ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3B5J9TG94X, chemically known as 2-imidazolidinone, 1-(3-chlorophenyl)-3-(2-(3,3-dimethyl-1-azetidinyl)ethyl)- but generally known as zetidoline, which bears US NIH Compound Identifier 72155. European Medicines Agency schedules Zetidoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00149MIG. The term ZETIDOLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). ZETIDOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zetidoline under HS 29332990 and SITC 51573. As of Q4 2014, ZETIDOLINE remains the US FDA Preferred Term for this commodity. Zetidoline bears US NLM identifiers UMLS ID C0078761 and NCI Concept Code C66690. SMILES: CLC1CC(N2CCN(CCN3CC(C3)(C)C)C2=O)CCC1.
This classification denotes a nonnarcotic analgesic with the molecular formula C102H172N36O32S7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7I64C51O16, chemically known as omega-conotoxin m viia (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide) but generally known as ziconotide, which bears US NIH Compound Identifier 16129690. European Medicines Agency schedules Ziconotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00150MIG. The term ZICONOTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules ziconotide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ziconotide under HS 29349990 and SITC 51579. As of Q4 2014, ZICONOTIDE remains the US FDA Preferred Term for this commodity. Ziconotide bears US NLM identifiers UMLS ID C0211011 and NCI Concept Code C1475. SMILES: CC1C(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)NC(C(=O)NCC(=O)NC(C(=O)N3)CO)C(C)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC.
This classification denotes a nonnarcotic analgesic with the molecular formula C102H172N36O32S7.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2I226K69M. European Medicines Agency schedules ziconotide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25201. The term ziconotide acetate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule ziconotide acetate under HS 29349990 and SITC 51579. Ziconotide acetate bears US NLM identifiers UMLS ID C1577317 and NCI Concept Code C95275. SMILES: As of Q4 2014, ZICONOTIDE ACETATE remains US FDA's Preferred Term for this commodity.
This classification denotes a diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F7KU1MIY58. European Medicines Agency schedules Zidapamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00151MIG. Zidapamide generally arises in the molecular formula C16H16CLN3O3S. The term ZIDAPAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) ZIDAPAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zidapamide under HS 29350090 and SITC 51580. As of Q4 2014, ZIDAPAMIDE remains the US FDA Preferred Term for this commodity. Zidapamide bears US NLM identifiers UMLS ID C2826075 and NCI Concept Code C82267. SMILES: CLC1C(S(=O)(=O)N)CC(C(=O)NN2C(C3C(C2)CCCC3)C)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H16N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 446VQG66LC, chemically known as 1h-indole-3-acetic acid, 1-(4-azidobenzoyl)-5-methoxy-2-methyl- but generally known as zidometacin, which bears US NIH Compound Identifier 44179. European Medicines Agency schedules Zidometacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00152MIG. The term ZIDOMETACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). ZIDOMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zidometacin under HS 29339990 and SITC 51577. As of Q4 2014, ZIDOMETACIN remains the US FDA Preferred Term for this commodity. Zidometacin bears US NLM identifiers UMLS ID C0078765 and NCI Concept Code C66691. SMILES: O(C1CC2C(C(N(C2CC1)C(=O)C1CCC(N=[N]=N)CC1)C)CC(=O)O)C.
This classification denotes an acetylcholinesterase inhibitor with the molecular formula C11H13F3OSi, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6275788O83, chemically known as 2,2,2-trifluoro-3-(trimethylsilyl)acetophenone but generally known as zifrosilone, which bears US NIH Compound Identifier 60811. European Medicines Agency schedules Zifrosilone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00154MIG. The term ZIFROSILONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ZIFROSILONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ZIFROSILONE remains the US FDA Preferred Term for this commodity. Zifrosilone bears US NLM identifiers UMLS ID C0288321 and NCI Concept Code C82222. SMILES: C[SI](C)(C)C1=CC=CC(=C1)C(=O)C(F)(F)F.
This classification denotes an antihelminthic agent with the molecular formula C26H38N2O6P2S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I50276Z58E, chemically known as phosphonodithioimidocarbonic acid ethylenedibenyl p,p,p,p-tetraethyl ester but generally known as zilantel, which bears US NIH Compound Identifier 6450244. European Medicines Agency schedules Zilantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00155MIG. The term ZILANTEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). ZILANTEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zilantel under HS 29309085 and SITC 51549. As of Q4 2014, ZILANTEL remains the US FDA Preferred Term for this commodity. Zilantel bears US NLM identifiers UMLS ID C2826067 and NCI Concept Code C82242. SMILES: S(CCS/C(=N\P(=O)(OCC)OCC)SCC1CCCCC1)/C(=N/P(=O)(OCC)OCC)SCC1CCCCC1.
This classification denotes a lipooxygenase inhibitor with the molecular formula C11H12N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1L22WVE2S, chemically known as urea, n-(1-benzo(b)thien-2-ylethyl)-n-hydroxy- but generally known as zileuton, which bears US NIH Compound Identifier 60490. European Medicines Agency schedules Zileuton in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00157MIG. The term ZILEUTON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). ZILEUTON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zileuton under HS 29349990 and SITC 51579. As of Q4 2014, ZILEUTON remains the US FDA Preferred Term for this commodity. Zileuton bears US NLM identifiers UMLS ID C0081408 and NCI Concept Code C26667. SMILES: CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O.
This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S384A1Y12J. European Medicines Agency schedules Zilpaterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00158MIG. Zilpaterol generally arises in the molecular formula C14H19N3O2. The term ZILPATEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) ZILPATEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zilpaterol under HS 29339930 and SITC 51577. As of Q4 2014, ZILPATEROL remains the US FDA Preferred Term for this commodity. Zilpaterol bears US NLM identifiers UMLS ID C1259819 and NCI Concept Code C74221. SMILES: OC1C(NC(C)C)CCN2C3C1CCCC3[NH]C2=O.
This classification denotes a nutritional supplement with the molecular formula 2Cl.Zn, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86Q357L16B, chemically known as zinc muriate, solution but generally known as zinc chloride, which bears US NIH Compound Identifier 5727. European Medicines Agency schedules Zinc chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12622MIG. World Health Organization schedules zinc chloride in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule zinc chloride under HS 28273900 and SITC 52329. As of Q4 2014, ZINC CHLORIDE remains the US FDA Preferred Term for this commodity. Zinc chloride bears US NLM identifiers UMLS ID C0078774 and NCI Concept Code C29865. SMILES: Cl[Zn]Cl.
This classification denotes a topical anti-infective agent with the molecular formula 2C6H5O4S.Zn, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O71YT5YB5, chemically known as zinc-1,4-phenolsulfonate but generally known as zinc phenolsulfonate, which bears US NIH Compound Identifier 31391. European Medicines Agency schedules Zinc phenolsulfonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33888. As of Q4 2014, ZINC PHENOLSULFONATE remains the US FDA Preferred Term for this commodity. Zinc phenolsulfonate bears US NLM identifiers UMLS ID C0301434 and NCI Concept Code C84250. SMILES: [ZN].S(=O)(=O)(O)C1CCC(O)CC1.S(=O)(=O)(O)C1CCC(O)CC1.
This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C11H15N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VQM3328PO0, chemically known as 1,2,4-triazolo(4,3-b)pyridazine, 8-methyl-6-(1-piperidinyl)- but generally known as zindotrine, which bears US NIH Compound Identifier 41856. European Medicines Agency schedules Zindotrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00162MIG. The term ZINDOTRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). ZINDOTRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zindotrine under HS 29333999 and SITC 51574. As of Q4 2014, ZINDOTRINE remains the US FDA Preferred Term for this commodity. Zindotrine bears US NLM identifiers UMLS ID C0078807 and NCI Concept Code C66695. SMILES: CC1=CC(=NN2C1=NN=C2)N3CCCCC3.
This classification denotes a selective estrogen receptor modulator with the molecular formula C21H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1IRS95M8DN, chemically known as 1h-indol-5-ol, 2-(4-(acetyloxy)phenyl)-1-ethyl-3-methyl-, acetate (ester) but generally known as zindoxifene, which bears US NIH Compound Identifier 65645. European Medicines Agency schedules Zindoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00163MIG. The term ZINDOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). ZINDOXIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zindoxifene under HS 29339990 and SITC 51577. As of Q4 2014, ZINDOXIFENE remains the US FDA Preferred Term for this commodity. Zindoxifene bears US NLM identifiers UMLS ID C0078808 and NCI Concept Code C66696. SMILES: O(C1CC2C(N(C(C2C)C2CCC(OC(=O)C)CC2)CC)CC1)C(=O)C.
This classification denotes an antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9SWB3P2O2S. European Medicines Agency schedules Zinviroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00166MIG. Zinviroxime generally arises in the molecular formula C17H18N4O3S. The term ZINVIROXIME is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) ZINVIROXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zinviroxime under HS 29350090 and SITC 51580. As of Q4 2014, ZINVIROXIME remains the US FDA Preferred Term for this commodity. Zinviroxime bears US NLM identifiers UMLS ID C2987040 and NCI Concept Code C95289. SMILES: S(=O)(=O)(N1C2C(NC1N)CCC(C2)/C(=N\O)C1CCCCC1)C(C)C.
This classification denotes an antitussive agent with the molecular formula C23H32N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G5MUV8139H, chemically known as 1-piperazineethanol, alpha-(alpha-methoxybenzyl)-4-(beta-methoxyphenethyl)-, dihydrochloride but more generally known as zipeprol, which bears US NIH Compound Identifier 36909. European Medicines Agency schedules Zipeprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00167MIG. The term ZIPEPROL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 26, No. 10 1972, List 12). World Health Organization schedules zipeprol in its Anatomical Therapeutic Chemical (ATC) Classification. ZIPEPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule zipeprol under HS 29335500 and SITC 51576. As of Q4 2014, ZIPEPROL remains US FDA's Preferred Term for this commodity. Zipeprol bears US NLM identifiers UMLS ID C0078811 and NCI Concept Code C66698. SMILES: CL.CL.OC(CN1CCN(CC1)CC(OC)C1CCCCC1)C(OC)C1CCCCC1.
This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UKA5VEJ6X, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- but generally known as ziprasidone, which bears US NIH Compound Identifier 60854. European Medicines Agency schedules Ziprasidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG. The term ZIPRASIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules ziprasidone in its Anatomical Therapeutic Chemical (ATC) Classification. ZIPRASIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ziprasidone under HS 29341000 and SITC 51579. As of Q4 2014, ZIPRASIDONE remains the US FDA Preferred Term for this commodity. Ziprasidone bears US NLM identifiers UMLS ID C0380393 and NCI Concept Code C47788. SMILES: CLC1C(CCN2CCN(CC2)C2NSC3C2CCCC3)CC2C(NC(=O)C2)C1.
This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 216X081ORU, chemically known as 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-2-indolinone monohydrochloride, monohydrate but more generally known as ziprasidone hydrochloride, which bears US NIH Compound Identifier 60853. European Medicines Agency schedules Ziprasidone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05189MIG. Most nations, for tariff and trade purposes, schedule ziprasidone hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, ZIPRASIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ziprasidone hydrochloride bears US NLM identifiers UMLS ID C0380392 and NCI Concept Code C48031. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.CL.
This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 216X081ORU, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, hydrochloride, hydrate (1:1:1), but more generally known as ziprasidone hydrochloride hydrate, which bears US NIH Compound Identifier 60853. European Medicines Agency schedules ziprasidone hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG. Most nations, for tariff purposes, schedule ziprasidone hydrochloride hydrate under HS 29341000. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.CL.
This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 216X081ORU, chemically known as 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-2-indolinone monohydrochloride, monohydrate but more generally known as ziprasidone hydrochloride, which bears US NIH Compound Identifier 60853. European Medicines Agency schedules Ziprasidone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05189MIG. Most nations, for tariff and trade purposes, schedule ziprasidone hydrochloride monohydrate under HS 29341000. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.CL.
This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.CH4O3S.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X6SAX83JZ, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, methanesulfonate, hydrate (1:1:3), but more generally known as ziprasidone mesylate, which bears US NIH Compound Identifier 154068. European Medicines Agency schedules ziprasidone mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG. Most nations, for tariff purposes, schedule ziprasidone mesylate under HS 29341000. Ziprasidone mesylate bears US NLM identifiers UMLS ID C1170754 and NCI Concept Code C48032. SMILES: CS(=O)(=O)O.C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.O.O.
This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W8U4S4XLWC. European Medicines Agency schedules Zocainone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00169MIG. Zocainone generally arises in the molecular formula C22H27NO3. The term ZOCAINONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, list 19.) ZOCAINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule zocainone under HS 29221980 and SITC 51461. As of Q4 2014, ZOCAINONE remains US FDA's Preferred Term for this commodity. Zocainone bears US NLM identifiers UMLS ID C1883603 and NCI Concept Code C66699. SMILES: O(CCN(CC)CC)C1C(O/C(=C/C2CCCCC2)C(=O)C)CCCC1.
This classification denotes an ace inhibitor with the molecular formula C22H23NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 290ZY759PI chemically known as r-proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-, (1(r*),2.alpha.,4.alpha.)- but generally known as zofenopril, which bears US NIH Compound Identifier 92400. European Medicines Agency schedules Zofenopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00170MIG. The term ZOFENOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24. ). Most nations schedule zofenopril under HS 29339990 and SITC 51577. As of Q4 2014, ZOFENOPRIL remains the US FDA Preferred Term for this commodity. Zofenopril bears US NLM identifiers UMLS ID C0078836 and NCI Concept Code C82219. SMILES: CC(CSC(=O)C1=CC=CC=C1)C(=O)N2CC(CC2C(=O)O)SC3=CC=CC=C3.
This classification denotes an ace inhibitor with the molecular formula C15H19NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G4WDK2YBS, chemically known as (2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylic acid but generally known as zofenoprilat, which bears US NIH Compound Identifier 3034048. European Medicines Agency schedules zofenoprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00171MIG. Most nations schedule zofenoprilat under HS 29339990 and SITC 51577. As of Q4 2014, ZOFENOPRILAT remains the US FDA Preferred Term for this commodity. Zofenoprilat bears US NLM identifiers UMLS ID C0085065 and NCI Concept Code C95293. SMILES: CC(CS)C(=O)N1CC(CC1C(=O)O)SC2=CC=CC=C2.
This classification denotes an ace inhibitor with the molecular formula C15H19NO3S2.C6H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36F26ZSQ0D. The term zofenoprilat arginine is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule zofenoprilat arginine under HS 29339990 and SITC 51577. As of Q4 2014, ZOFENOPRILAT ARGININE remains US FDA's Preferred Term for this commodity. Zofenoprilat arginine bears US NLM identifiers UMLS ID C0646135 and NCI Concept Code C66700. SMILES: C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(=O)O)SC2CCCCC2.C(C[C@@H](C(=O)O)N)CNC(=N)N.
This classification denotes an ace inhibitor with the molecular formula 2C22H22NO4S2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88ZQ329PU2, chemically known as l-proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-, calcium salt, (1(r*),2alpha,4alpha)- but more generally known as zofenopril calcium, which bears US NIH Compound Identifier 3033690. European Medicines Agency schedules Zofenopril calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05191MIG. Most nations, for tariff and trade purposes, schedule zofenopril calcium under HS 29339990 and SITC 51577. As of Q4 2014, ZOFENOPRIL CALCIUM remains US FDA's Preferred Term for this commodity. Zofenopril calcium bears US NLM identifiers UMLS ID C0873162 and NCI Concept Code C82220. SMILES: C[C@H](CSC(=O)C1CCCCC1)C(=O)N2C[C@H](C[C@H]2C(=O)[O-])SC3CCCCC3.C[C@H](CSC(=O)C1CCCCC1)C(=O)N2C[C@H](C[C@H]2C(=O)[O-])SC3CCCCC3.[CA+2].
This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZA518V67A. European Medicines Agency schedules Zoficonazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00172MIG. Zoficonazole generally arises in the molecular formula C20H19CL3N2O2. The term ZOFICONAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) ZOFICONAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zoficonazole under HS 29332990 and SITC 51573. As of Q4 2014, ZOFICONAZOLE remains the US FDA Preferred Term for this commodity. Zoficonazole bears US NLM identifiers UMLS ID C1883605 and NCI Concept Code C66701. SMILES: CLC1C(C(OCCCOC2CCC(CL)CC2)CN2CCNC2)CCC(CL)C1.
This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NXB79TB0N2. European Medicines Agency schedules Zolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00173MIG. Zolamine generally arises in the molecular formula C15H21N3OS. The term ZOLAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) ZOLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zolamine under HS 29341000 and SITC 51579. As of Q4 2014, ZOLAMINE remains the US FDA Preferred Term for this commodity. Zolamine bears US NLM identifiers UMLS ID C0301395 and NCI Concept Code C81148. SMILES: S1C(N(CCN(C)C)CC2CCC(OC)CC2)NCC1.
This classification denotes a histamine-1 receptor antagonist with the molecular formula C15H21N3OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2B9CF1640, chemically known as 1,2-ethanediamine, n-((4-methoxyphenyl)methyl)-n,n-dimethyl-n-2-thiazolyl-, monohydrochloride but more generally known as zolamine hydrochloride, which bears US NIH Compound Identifier 14386. Most nations, for tariff and trade purposes, schedule zolamine hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, ZOLAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zolamine hydrochloride bears US NLM identifiers UMLS ID C2825476 and NCI Concept Code C81149. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2NCCS2.CL.
This classification denotes an angiotensin ii receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6NA6UHB9SW. European Medicines Agency schedules Zolasartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00174MIG. Zolasartan generally arises in the molecular formula C24H20BRCLN6O3. The term ZOLASARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) ZOLASARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zolasartan under HS 29349990 and SITC 51579. As of Q4 2014, ZOLASARTAN remains the US FDA Preferred Term for this commodity. Zolasartan bears US NLM identifiers UMLS ID C0211676 and NCI Concept Code C66702. SMILES: CCCCC1=NC(=C(N1CC2=CC3=C(C=C2)OC(=C3Br)C4=CC=CC=C4C5=NNN=N5)C(=O)O)Cl.
This classification denotes a sedative and hypnotic with the molecular formula C14H13FN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1R474U58U, chemically known as 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)(1,4)diazepin-7(1h)-one but generally known as zolazepam, which bears US NIH Compound Identifier 35775. European Medicines Agency schedules Zolazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00175MIG. The term ZOLAZEPAM is an International Non-Proprietary Name. ZOLAZEPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zolazepam under HS 29339940 and SITC 51577. As of Q4 2014, ZOLAZEPAM remains the US FDA Preferred Term for this commodity. Zolazepam bears US NLM identifiers UMLS ID C0043513 and NCI Concept Code C84252. SMILES: FC1C(C2=NCC(=O)N(C3N(NC(C23)C)C)C)CCCC1.
This classification denotes a sedative and hypnotic with the molecular formula C15H15FN4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45SJ093Q1N, chemically known as 4-(o-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1h)-one monohydrochloride but more generally known as zolazepam hydrochloride, which bears US NIH Compound Identifier 71416. Most nations, for tariff and trade purposes, schedule zolazepam hydrochloride under HS 29339940 and SITC 51577. As of Q4 2014, ZOLAZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zolazepam hydrochloride bears US NLM identifiers UMLS ID C0917859 and NCI Concept Code C76953. SMILES: CC1C2C(N(N1)C)N(C(=O)CN=C2C3CCCCC3F)C.CL.
This classification denotes a bone density conservation agent with the molecular formula C5H10N2O7P2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6XC1PAD3KF, chemically known as phosphonic acid, (1-hydroxy-2-(1h-imidazol-1-yl)ethylidene)bis- but generally known as zoledronic acid, which bears US NIH Compound Identifier 68740. European Medicines Agency schedules Zoledronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00176MIG. World Health Organization schedules zoledronic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule zoledronic acid under HS 29332990 and SITC 51573. As of Q4 2014, ZOLEDRONIC ACID remains the US FDA Preferred Term for this commodity. Zoledronic acid bears US NLM identifiers UMLS ID C0257685 and NCI Concept Code C1699. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CN1CCNC1.
This classification denotes an anti-ulcer agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0XJ4L38Z3. European Medicines Agency schedules Zolenzepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00177MIG. Zolenzepine generally arises in the molecular formula C19H24N6O2. The term ZOLENZEPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) ZOLENZEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zolenzepine under HS 29335995 and SITC 51576. As of Q4 2014, ZOLENZEPINE remains the US FDA Preferred Term for this commodity. Zolenzepine bears US NLM identifiers UMLS ID C1883608 and NCI Concept Code C66704. SMILES: O=C(N1C2C(N(NC2C)C)C(=O)[NH]C2C1CCCC2)CN1CCN(CC1)C.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C13H18N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EMD433OT6A, chemically known as piperazine, 1-phenyl-4-(2-(1h-tetrazol-5-yl)ethyl)- but generally known as zolertine, which bears US NIH Compound Identifier 23669. European Medicines Agency schedules Zolertine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00178MIG. The term ZOLERTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). ZOLERTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zolertine under HS 29335995 and SITC 51576. As of Q4 2014, ZOLERTINE remains the US FDA Preferred Term for this commodity. Zolertine bears US NLM identifiers UMLS ID C0078838 and NCI Concept Code C82223. SMILES: N1(CCN(CC1)C1CCCCC1)CCC1N[NH]NN1.
This classification denotes an alpha-adrenergic blocking agent with the molecular formula C13H18N6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BM71FQZ25G, chemically known as piperazine, 1-phenyl-4-(2-(1h-tetrazol-5-yl)ethyl)- but more generally known as zolertine hydrochloride, which bears US NIH Compound Identifier 23669. Most nations, for tariff and trade purposes, schedule zolertine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ZOLERTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zolertine hydrochloride bears US NLM identifiers UMLS ID C2826060 and NCI Concept Code C82224. SMILES: C1CCC(CC1)N2CCN(CC2)CCC3[NH]NNN3.CL.
This classification denotes an anti-ulcer agent with the molecular formula C14H12N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YCF001N8QB, chemically known as 2-(p-(methylsulfonyl)phenyl)imidazol(1,2-a)pyridine but generally known as zolimidine, which bears US NIH Compound Identifier 14652. European Medicines Agency schedules Zolimidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00179MIG. The term ZOLIMIDINE is an International Non-Proprietary Name. World Health Organization schedules zolimidine in its Anatomical Therapeutic Chemical (ATC) Classification. ZOLIMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zolimidine under HS 29339990 and SITC 51577. As of Q4 2014, ZOLIMIDINE remains the US FDA Preferred Term for this commodity. Zolimidine bears US NLM identifiers UMLS ID C0650163 and NCI Concept Code C66705. SMILES: S(=O)(=O)(C1CCC(C2NC3N(C2)CCCC3)CC1)C.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H11NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2GC047H27, chemically known as propionic acid, 2-(p-((2-thiazolyl)oxy)phenyl)- but generally known as zoliprofen, which bears US NIH Compound Identifier 68758. European Medicines Agency schedules Zoliprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00180MIG. The term ZOLIPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). ZOLIPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zoliprofen under HS 29341000 and SITC 51579. As of Q4 2014, ZOLIPROFEN remains the US FDA Preferred Term for this commodity. Zoliprofen bears US NLM identifiers UMLS ID C1883609 and NCI Concept Code C66706. SMILES: CC(C1=CC=C(C=C1)OC2=NC=CS2)C(=O)O.
This classification denotes a serotonin agonist with the molecular formula C16H21N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2FS66TH3YW, chemically known as 2-oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-, (s)- but generally known as zolmitriptan, which bears US NIH Compound Identifier 60857. European Medicines Agency schedules Zolmitriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00181MIG. The term ZOLMITRIPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules zolmitriptan in its Anatomical Therapeutic Chemical (ATC) Classification. ZOLMITRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zolmitriptan under HS 29349990 and SITC 51579. As of Q4 2014, ZOLMITRIPTAN remains the US FDA Preferred Term for this commodity. Zolmitriptan bears US NLM identifiers UMLS ID C0528166 and NCI Concept Code C47789. SMILES: O1CC(NC1=O)CC1CC2C(CCN(C)C)C[NH]C2CC1.
This classification denotes an anxiolytic with the molecular formula C22H24FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3YU9TET43B, chemically known as 2(3h)-oxazolone, 4-(4-fluorophenyl)-5-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)- but generally known as zoloperone, which bears US NIH Compound Identifier 68696. European Medicines Agency schedules Zoloperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00182MIG. The term ZOLOPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). ZOLOPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zoloperone under HS 29349990 and SITC 51579. As of Q4 2014, ZOLOPERONE remains the US FDA Preferred Term for this commodity. Zoloperone bears US NLM identifiers UMLS ID C1883610 and NCI Concept Code C66707. SMILES: FC1CCC(C2[NH]C(=O)OC2CCN2CCN(CC2)C2C(OC)CCCC2)CC1.
This classification denotes a sedative and hypnotic with the molecular formula C19H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7K383OQI23, chemically known as n,n,6-trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide but generally known as zolpidem, which bears US NIH Compound Identifier 5732. European Medicines Agency schedules Zolpidem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00183MIG. The term ZOLPIDEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules zolpidem in its Anatomical Therapeutic Chemical (ATC) Classification. ZOLPIDEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zolpidem under HS 29339990 and SITC 51577. As of Q4 2014, ZOLPIDEM remains the US FDA Preferred Term for this commodity. Zolpidem bears US NLM identifiers UMLS ID C0078839 and NCI Concept Code C62000. SMILES: O=C(N(C)C)CC1N2C(NC1C1CCC(CC1)C)CCC(C2)C.
This classification denotes a sedative and hypnotic with the molecular formula 2C19H21N3O.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WY6W63843K, chemically known as imidazo(1,2-a)pyridine-3-acetamide, n,n,6-trimethyl-2-(4-methylphenyl)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (2:1), but more generally known as zolpidem hemitartrate, which bears US NIH Compound Identifier 57487. European Medicines Agency schedules zolpidem hemitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00183MIG. Most nations, for tariff purposes, schedule zolpidem hemitartrate under HS 29339990. SMILES: CC1CCC(CC1)C2C(N3CC(CCC3N2)C)CC(=O)N(C)C.CC1CCC(CC1)C2C(N3CC(CCC3N2)C)CC(=O)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes a sedative and hypnotic with the molecular formula 2C19H21N3O.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WY6W63843K, chemically known as n,n,6-trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide but more generally known as zolpidem tartrate, which bears US NIH Compound Identifier 5732. European Medicines Agency schedules Zolpidem tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05192MIG. Most nations, for tariff and trade purposes, schedule zolpidem tartrate under HS 29339990 and SITC 51577. As of Q4 2014, ZOLPIDEM TARTRATE remains US FDA's Preferred Term for this commodity. Zolpidem tartrate bears US NLM identifiers UMLS ID C0724725 and NCI Concept Code C29553. SMILES: CC1CCC(CC1)C2C(N3CC(CCC3N2)C)CC(=O)N(C)C.CC1CCC(CC1)C2C(N3CC(CCC3N2)C)CC(=O)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.
This classification denotes an anxiolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G563Y6G60K. European Medicines Agency schedules Zomebazam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00184MIG. Zomebazam generally arises in the molecular formula C15H16N4O2. The term ZOMEBAZAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) ZOMEBAZAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zomebazam under HS 29337900 and SITC 51561. As of Q4 2014, ZOMEBAZAM remains the US FDA Preferred Term for this commodity. Zomebazam bears US NLM identifiers UMLS ID C1883611 and NCI Concept Code C66708. SMILES: O=C1N(C2C(N(C(=O)C1)C)N(NC2C)C)C1CCCCC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 822G987U9J, chemically known as 5-(4-chlorobenzoyl)-1,4-dimethyl-1h-pyrrole-2-acetic acid but generally known as zomepirac, which bears US NIH Compound Identifier 5733. European Medicines Agency schedules Zomepirac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00185MIG. The term ZOMEPIRAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules zomepirac in its Anatomical Therapeutic Chemical (ATC) Classification. ZOMEPIRAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zomepirac under HS 29339990 and SITC 51577. As of Q4 2014, ZOMEPIRAC remains the US FDA Preferred Term for this commodity. Zomepirac bears US NLM identifiers UMLS ID C0078840 and NCI Concept Code C66709. SMILES: CLC1CCC(C(=O)C2N(C(CC2C)CC(=O)O)C)CC1.
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13ClNO3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0185WZ209, chemically known as 5-(4-chlorobenzoyl)-1,4-dimethyl-1h-pyrrole-2-acetic acid but more generally known as zomepirac sodium, which bears US NIH Compound Identifier 5733. European Medicines Agency schedules Zomepirac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05193MIG. Most nations, for tariff and trade purposes, schedule zomepirac sodium under HS 29339990 and SITC 51577. As of Q4 2014, ZOMEPIRAC SODIUM remains US FDA's Preferred Term for this commodity. Zomepirac sodium bears US NLM identifiers UMLS ID C0149477 and NCI Concept Code C62001. SMILES: CC1CC(N(C1C(=O)C2CCC(CC2)CL)C)CC(=O)[O-].O.O.[NA+].
This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13ClNO3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DA5B6IWF46, chemically known as 1h-pyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethyl-, sodium salt (1:1), but more generally known as zomepirac sodium anhydrous, which bears US NIH Compound Identifier 47290. European Medicines Agency schedules zomepirac sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00185MIG. Most nations, for tariff purposes, schedule zomepirac sodium anhydrous under HS 29339990. SMILES: CC1CC(N(C1C(=O)C2CCC(CC2)CL)C)CC(=O)[O-].[NA+].
This classification denotes an anticonvulsant agent with the molecular formula C12H10ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1C5F0K79E, chemically known as 1,2-benzisoxazole, 5-chloro-3-(1-(1h-imidazol-1-yl)ethyl)- but generally known as zoniclezole, which bears US NIH Compound Identifier 60745. European Medicines Agency schedules Zoniclezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00186MIG. The term ZONICLEZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). ZONICLEZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zoniclezole under HS 29349990 and SITC 51579. As of Q4 2014, ZONICLEZOLE remains the US FDA Preferred Term for this commodity. Zoniclezole bears US NLM identifiers UMLS ID C0656178 and NCI Concept Code C82235. SMILES: CC(C1=NOC2=C1C=C(C=C2)CL)N3C=CN=C3.
This classification denotes an anticonvulsant agent with the molecular formula C12H10ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VM256HNOM, chemically known as 1,2-benzisoxazole, 5-chloro-3-(1-(1h-imidazol-1-yl)ethyl)- but more generally known as zoniclezole hydrochloride, which bears US NIH Compound Identifier 60745. Most nations, for tariff and trade purposes, schedule zoniclezole hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ZONICLEZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zoniclezole hydrochloride bears US NLM identifiers UMLS ID C0959127 and NCI Concept Code C82236. SMILES: CC(C1C2CC(CCC2ON1)CL)N3CCNC3.CL.
This classification denotes an anticonvulsant agent with the molecular formula C8H8N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 459384H98V, chemically known as 1,2-benzisoxazole-3-methanesulfonamide but generally known as zonisamide, which bears US NIH Compound Identifier 5734. European Medicines Agency schedules Zonisamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00187MIG. The term ZONISAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules zonisamide in its Anatomical Therapeutic Chemical (ATC) Classification. ZONISAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zonisamide under HS 29350090 and SITC 51580. As of Q4 2014, ZONISAMIDE remains the US FDA Preferred Term for this commodity. Zonisamide bears US NLM identifiers UMLS ID C0078844 and NCI Concept Code C47790. SMILES: S(=O)(=O)(N)CC1NOC2C1CCCC2.
This classification denotes a sedative and hypnotic with the molecular formula C17H17ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03A5ORL08Q, chemically known as 4-methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5h-pyrrolo(3,4-b)pyrazin-5-one but generally known as zopiclone, which bears US NIH Compound Identifier 5735. European Medicines Agency schedules Zopiclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00188MIG. The term ZOPICLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules zopiclone in its Anatomical Therapeutic Chemical (ATC) Classification. ZOPICLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zopiclone under HS 29337900 and SITC 51561. As of Q4 2014, ZOPICLONE remains the US FDA Preferred Term for this commodity. Zopiclone bears US NLM identifiers UMLS ID C0078847 and NCI Concept Code C80279. SMILES: CLC1CCC(N2C(OC(=O)N3CCN(CC3)C)C3NCCNC3C2=O)NC1.
This classification denotes an aldose reductase inhibitor with the molecular formula C19H12F3N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1PV3S9WP3D, chemically known as 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid but generally known as zopolrestat, which bears US NIH Compound Identifier 1613. European Medicines Agency schedules Zopolrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00189MIG. The term ZOPOLRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). ZOPOLRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zopolrestat under HS 29341000 and SITC 51579. As of Q4 2014, ZOPOLRESTAT remains the US FDA Preferred Term for this commodity. Zopolrestat bears US NLM identifiers UMLS ID C0085066 and NCI Concept Code C82174. SMILES: S1C(NC2C1CCC(C2)C(F)(F)F)CN1NC(C2C(C1=O)CCCC2)CC(=O)O.
This classification denotes an anthracycline antibiotic with the molecular formula C34H35N3O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V25F9362OP, chemically known as rp-22,050 hydrochloride but generally known as zorubicin, which bears US NIH Compound Identifier 6540456. European Medicines Agency schedules Zorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00190MIG. The term ZORUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules zorubicin in its Anatomical Therapeutic Chemical (ATC) Classification. ZORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zorubicin under HS 29419000 and SITC 54139. As of Q4 2014, ZORUBICIN remains the US FDA Preferred Term for this commodity. Zorubicin bears US NLM identifiers UMLS ID CL421815 and NCI Concept Code C91365. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)/C(=N/NC(=O)C1CCCCC1)C)C1OC(C(O)C(N)C1)C.
This classification denotes an anthracycline antibiotic with the molecular formula C34H35N3O10.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WXM8D9M6DE, chemically known as rp-22,050 hydrochloride but more generally known as zorubicin hydrochloride, which bears US NIH Compound Identifier 6540456. European Medicines Agency schedules Zorubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05194MIG. Most nations, for tariff and trade purposes, schedule zorubicin hydrochloride under HS 29419000 and SITC 54139. As of Q4 2014, ZORUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zorubicin hydrochloride bears US NLM identifiers UMLS ID C0206788 and NCI Concept Code C1458. SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3C2C(C4C(C3O)C(=O)C5CCCC(C5C4=O)OC)O)(C(=NNC(=O)C6CCCCC6)C)O)N)O.CL.
A live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older
This classification denotes an immunosuppressant with the molecular formula C52H79N5O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H4GXR80IZE, chemically known as (42s)-42-deoxy-42-(1h-tetrazol-1-yl)-rapamycin but more generally known as zotarolimus, which bears US NIH Compound Identifier 9876378. European Medicines Agency schedules zotarolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32090. The term ZOTAROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 3, 2006, List 56). ZOTAROLIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Zotarolimus bears US NLM identifiers UMLS ID C1700035 and NCI Concept Code C82294. As of Q4 2014, ZOTAROLIMUS remains US FDA's Preferred Term for this commodity. Most nations, for tariff and trade purposes, schedule zotarolimus under HS 29349990 and SITC 51579. SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)N5C=NN=N5)C)C)O)OC)C)C)C)OC.
This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C18H18ClNOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U29O83JAZW, chemically known as 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo(b,f)thiepine but generally known as zotepine, which bears US NIH Compound Identifier 5736. European Medicines Agency schedules Zotepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00191MIG. The term ZOTEPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules zotepine in its Anatomical Therapeutic Chemical (ATC) Classification. ZOTEPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zotepine under HS 29349990 and SITC 51579. As of Q4 2014, ZOTEPINE remains the US FDA Preferred Term for this commodity. Zotepine bears US NLM identifiers UMLS ID C0078849 and NCI Concept Code C81096. SMILES: CLC1CC2C(=CC3C(SC2CC1)CCCC3)OCCN(C)C.
This classification denotes an analgesic agent with the molecular formula C18H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15OX67P384, chemically known as 6-nonenamide, n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (z)- but generally known as zucapsaicin, which bears US NIH Compound Identifier 1548942. European Medicines Agency schedules Zucapsaicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00193MIG. The term ZUCAPSAICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules zucapsaicin in its Anatomical Therapeutic Chemical (ATC) Classification. ZUCAPSAICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zucapsaicin under HS 29399900 and SITC 54149. As of Q4 2014, ZUCAPSAICIN remains the US FDA Preferred Term for this commodity. Zucapsaicin bears US NLM identifiers UMLS ID C0763832 and NCI Concept Code C75078. SMILES: O=C(NCC1CC(OC)C(O)CC1)CCCC/C=C\C(C)C.
This classification denotes an antiestrogen with the molecular formula C26H28ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3JU1DU3652, chemically known as 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine but generally known as zuclomifene, which bears US NIH Compound Identifier 1548955. European Medicines Agency schedules Zuclomifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00194MIG. The term ZUCLOMIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). ZUCLOMIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Zuclomifene or zuclomiphene bears US NLM identifiers UMLS ID C0087182 and NCI Concept Code C66870. SMILES: CL/C(=C(\C1CCC(OCCN(CC)CC)CC1)C1CCCCC1)C1CCCCC1.
This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47ISU063SG. European Medicines Agency schedules Zuclopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00195MIG. Zuclopenthixol generally arises in the molecular formula C22H25CLN2OS. The term ZUCLOPENTHIXOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) ZUCLOPENTHIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zuclopenthixol under HS 29349990 and SITC 51579. As of Q4 2014, ZUCLOPENTHIXOL remains the US FDA Preferred Term for this commodity. Zuclopenthixol bears US NLM identifiers UMLS ID C0376160 and NCI Concept Code C66713. SMILES: CLC1CC2/C(=C\CCN3CCN(CC3)CCO)C3C(SC2CC1)CCCC3.
This classification denotes the acetate form of an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47ISU063SG. European Medicines Agency schedules Zuclopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00195MIG. Zuclopenthixol generally arises in the molecular formula C22H25CLN2OS. The term ZUCLOPENTHIXOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, no. 6, 1984, list 24.) ZUCLOPENTHIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule zuclopenthixol acetate under HS 29349990 and SITC 51579. As of Q4 2014, ZUCLOPENTHIXOL ACETATE remains US FDA's Preferred Term for this commodity. Zuclopenthixol acetate bears US NLM identifiers UMLS ID C0149491 and NCI Concept Code C95835. SMILES: CC(=O)OCCN1CCN(CC1)CC/C=C\2/C3CCCCC3SC4C2CC(CC4)CL.
This classification denotes the hydrochloride form of an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47ISU063SG. European Medicines Agency schedules Zuclopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00195MIG. Zuclopenthixol generally arises in the molecular formula C22H25CLN2OS. The term ZUCLOPENTHIXOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, no. 6, 1984, list 24.) ZUCLOPENTHIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule zuclopenthixol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ZUCLOPENTHIXOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zuclopenthixol hydrochloride bears US NLM identifiers UMLS ID C0350505 and NCI Concept Code C95837. SMILES: C1CCC2C(C1)/C(=C/CCN3CCN(CC3)CCO)/C4CC(CCC4S2)CL.CL.CL.